<SEC-DOCUMENT>0001739940-24-000005.txt : 20240229
<SEC-HEADER>0001739940-24-000005.hdr.sgml : 20240229
<ACCEPTANCE-DATETIME>20240229144805
ACCESSION NUMBER:		0001739940-24-000005
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		197
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240229
DATE AS OF CHANGE:		20240229

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cigna Group
		CENTRAL INDEX KEY:			0001739940
		STANDARD INDUSTRIAL CLASSIFICATION:	HOSPITAL & MEDICAL SERVICE PLANS [6324]
		ORGANIZATION NAME:           	02 Finance
		IRS NUMBER:				824991898
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38769
		FILM NUMBER:		24702887

	BUSINESS ADDRESS:	
		STREET 1:		900 COTTAGE GROVE ROAD
		CITY:			BLOOMFIELD
		STATE:			CT
		ZIP:			06002
		BUSINESS PHONE:		8602266000

	MAIL ADDRESS:	
		STREET 1:		900 COTTAGE GROVE ROAD
		CITY:			BLOOMFIELD
		STATE:			CT
		ZIP:			06002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cigna Corp
		DATE OF NAME CHANGE:	20181221

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Halfmoon Parent, Inc.
		DATE OF NAME CHANGE:	20180508
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ci-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ci="http://www.thecignagroup.com/20231231" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ci-20231231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-1">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-2">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-3">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-4">0001739940</ix:nonNumeric><ix:nonNumeric contextRef="c-8" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="f-237">http://fasb.org/us-gaap/2023#AccountingStandardsUpdate201613Member</ix:nonNumeric><ix:nonNumeric contextRef="c-74" name="us-gaap:DisposalGroupNotDiscontinuedOperationNameOfSegmentExtensibleList" id="f-490">http://www.thecignagroup.com/20231231#CignaHealthcareMember</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="c-80" xsi:nil="true" name="us-gaap:LossContingencyAccrualProvision" id="f-510"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-81" xsi:nil="true" name="us-gaap:LossContingencyAccrualProvision" id="f-511"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-82" xsi:nil="true" name="us-gaap:LossContingencyAccrualProvision" id="f-512"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-80" xsi:nil="true" name="us-gaap:LossContingencyAccrualPayments" id="f-513"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-81" xsi:nil="true" name="us-gaap:LossContingencyAccrualPayments" id="f-514"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-82" xsi:nil="true" name="us-gaap:LossContingencyAccrualPayments" id="f-515"></ix:nonFraction><ix:nonNumeric contextRef="c-13" name="us-gaap:SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration" id="f-550">http://fasb.org/us-gaap/2023#AccountsPayableCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-12" name="us-gaap:SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration" id="f-551">http://fasb.org/us-gaap/2023#AccountsPayableCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-90" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList" id="f-569">http://fasb.org/us-gaap/2023#GainLossOnSaleOfBusiness</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="c-254" xsi:nil="true" name="ci:FairValueMeasurementNonPerformanceRiskAdjustment" id="f-1253"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-255" xsi:nil="true" name="ci:FairValueMeasurementNonPerformanceRiskAdjustment" id="f-1254"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-318" xsi:nil="true" name="ci:FairValueMeasurementNonPerformanceRiskAdjustment" id="f-1255"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-1" xsi:nil="true" name="us-gaap:DerivativeGainLossOnDerivativeNet" id="f-1517"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-7" xsi:nil="true" name="us-gaap:DerivativeGainLossOnDerivativeNet" id="f-1518"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-1" xsi:nil="true" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" id="f-1519"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-7" xsi:nil="true" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" id="f-1520"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-1" xsi:nil="true" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" id="f-1521"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-7" xsi:nil="true" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" id="f-1522"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-513" xsi:nil="true" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" id="f-1755"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-514" xsi:nil="true" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" id="f-1756"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-1" xsi:nil="true" name="ci:RealizedInvestmentLossesCommercialMortgageLoansRealEstateEntitiesCertainEquitySecuritiesWithNoReadilyDeterminableFairValue" id="f-1757"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-7" xsi:nil="true" name="ci:RealizedInvestmentLossesCommercialMortgageLoansRealEstateEntitiesCertainEquitySecuritiesWithNoReadilyDeterminableFairValue" id="f-1758"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-1" xsi:nil="true" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" id="f-1759"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-7" xsi:nil="true" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" id="f-1760"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-522" xsi:nil="true" name="us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount" id="f-1774"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-522" xsi:nil="true" name="us-gaap:NoncontrollingInterestInVariableInterestEntity" id="f-1775"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-626" xsi:nil="true" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" id="f-2066"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-627" xsi:nil="true" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" id="f-2067"></ix:nonFraction><ix:nonNumeric contextRef="c-637" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-2151">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="c-663" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="f-2278">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-673" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-2323">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-675" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-2325">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-677" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" id="f-2327">http://fasb.org/us-gaap/2023#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</ix:nonNumeric><ix:nonNumeric contextRef="c-12" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-2410">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-13" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-2411">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-12" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-2414">http://www.thecignagroup.com/20231231#AccruedExpensesAndOtherLiabilities</ix:nonNumeric><ix:nonNumeric contextRef="c-13" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-2415">http://www.thecignagroup.com/20231231#AccruedExpensesAndOtherLiabilities</ix:nonNumeric><ix:nonNumeric contextRef="c-13" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-2418">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-12" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-2419">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-12" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-2428">http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="c-13" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-2429">http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="c-12" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-2432">http://fasb.org/us-gaap/2023#DebtCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-13" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-2433">http://fasb.org/us-gaap/2023#DebtCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-13" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-2436">http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations</ix:nonNumeric><ix:nonNumeric contextRef="c-12" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-2437">http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="c-712" xsi:nil="true" name="us-gaap:LossContingencyAccrualProvision" id="f-2655"></ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-713" xsi:nil="true" name="us-gaap:LossContingencyAccrualAtCarryingValue" id="f-2656"></ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ci-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ci:MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ci:MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ci:HealthCareServiceCorporationHCSCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:GuaranteesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:PharmacyBenefitsManagementServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:GuaranteesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:PharmacyBenefitsManagementServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:PerformanceGuaranteeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AdministrativeServicesOnlyHealthCareServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:PerformanceGuaranteeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AdministrativeServicesOnlyHealthCareServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:PerformanceGuaranteeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AdministrativeServicesOnlyHealthCareServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ci:MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ci:CHSSJVLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:IndirectGuaranteeOfIndebtednessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ci:InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ci:InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ci:MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ci:MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue202383InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue202383InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2023765InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2023765InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2023FloatingRateInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2023FloatingRateInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20233InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20233InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2023375InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2023375InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2024613InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2024613InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue202435InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue202435InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2025325InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2025325InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20254125InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20254125InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue202645InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue202645InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2026125Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2026125Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20265685Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20265685Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue202734InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue202734InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:DebenturesDue20277875InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:DebenturesDue20277875InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2027305Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2027305Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20284375InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20284375InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue203024InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue203024InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20312375InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20312375InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:StepDownNotesDueJanuary2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:StepDownNotesDueJanuary2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20335400InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20335400InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2036615InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2036615InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue203848InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue203848InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue204032InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue204032InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20415875InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20415875InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20416125InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20416125InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20425375InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20425375InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue204648InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue204648InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20473875Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20473875Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue204849InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue204849InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue205034InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue205034InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue205134InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue205134InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:StepDownNotesDueJanuary2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditAgreementsApril2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:A364DayRevolvingCreditAgreementMaturingApril2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:A364DayRevolvingCreditAgreementMaturingApril2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditAgreementsApril2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="revolvingcreditfacility"><xbrli:measure>ci:revolvingCreditFacility</xbrli:measure></xbrli:unit><xbrli:unit id="position"><xbrli:measure>ci:position</xbrli:measure></xbrli:unit><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditFacilityMaturingApril2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditFacilityMaturingApril2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:A364DayRevolvingCreditAgreementMaturingApril2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:A364DayRevolvingCreditAgreementMaturingApril2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue202435InterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20265685Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20265685Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-07</xbrli:startDate><xbrli:endDate>2023-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20335400InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20335400InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-07</xbrli:startDate><xbrli:endDate>2023-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20265685Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:UsTreasuryUstInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-07</xbrli:startDate><xbrli:endDate>2023-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20335400InterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:UsTreasuryUstInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-07</xbrli:startDate><xbrli:endDate>2023-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-23</xbrli:startDate><xbrli:endDate>2023-03-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-22</xbrli:startDate><xbrli:endDate>2023-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-21</xbrli:startDate><xbrli:endDate>2023-09-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-21</xbrli:startDate><xbrli:endDate>2023-12-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-24</xbrli:startDate><xbrli:endDate>2022-03-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-23</xbrli:startDate><xbrli:endDate>2022-06-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-22</xbrli:startDate><xbrli:endDate>2022-09-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-21</xbrli:startDate><xbrli:endDate>2022-12-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-25</xbrli:startDate><xbrli:endDate>2021-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-23</xbrli:startDate><xbrli:endDate>2021-06-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-23</xbrli:startDate><xbrli:endDate>2021-09-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-22</xbrli:startDate><xbrli:endDate>2021-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-02</xbrli:startDate><xbrli:endDate>2024-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-15</xbrli:startDate><xbrli:endDate>2024-02-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-15</xbrli:startDate><xbrli:endDate>2024-02-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NoncatastrophicEventAxis">ci:CompletionFactorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NoncatastrophicEventAxis">ci:CompletionFactorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NoncatastrophicEventAxis">ci:MedicalCostTrendMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NoncatastrophicEventAxis">ci:MedicalCostTrendMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>ci:claim</xbrli:measure></xbrli:unit><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ci:MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ci:InternationalLifeAccidentSupplementalBenefitsBusinessesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">us-gaap:PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">us-gaap:PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">ci:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">ci:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:EmpowerAnnuityInsuranceCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:EmpowerAnnuityInsuranceCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:EmpowerAnnuityInsuranceCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:EmpowerAnnuityInsuranceCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:PrudentialInsuranceCompanyOfAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:PrudentialInsuranceCompanyOfAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:PrudentialInsuranceCompanyOfAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:PrudentialInsuranceCompanyOfAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:LifeInsuranceCompanyOfNorthAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:LifeInsuranceCompanyOfNorthAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:LifeInsuranceCompanyOfNorthAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:LifeInsuranceCompanyOfNorthAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">us-gaap:OtherReinsurerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">us-gaap:OtherReinsurerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">us-gaap:OtherReinsurerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">us-gaap:OtherReinsurerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:BerkshireHathwayLifeInsuranceCompanyOfNebraskaAndOtherRecoverablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GuaranteedInsuranceContractTypeOfBenefitAxis">us-gaap:GuaranteedMinimumDeathBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:BerkshireHathwayLifeInsuranceCompanyOfNebraskaAndOtherRecoverablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:BerkshireHathwayLifeInsuranceCompanyOfNebraskaAndOtherRecoverablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ci:CededCreditCollateralizationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskSecuredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:SunLifeAssuranceCompanyOfCanadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:SunLifeAssuranceCompanyOfCanadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:LibertyMutualInsuranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:LibertyMutualInsuranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ci:CededCreditCollateralizationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskSecuredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:LibertyMutualInsuranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:SCORSEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:SCORSEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ci:CededCreditCollateralizationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskSecuredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:SCORSEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ShortDurationContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ShortDurationContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ShortDurationContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:LongDurationContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:LongDurationContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:LongDurationContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MortgagesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MortgagesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:PolicyLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:PolicyLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ci:InvestmentsCreditRatingAxis">ci:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ci:InvestmentsCreditRatingAxis">ci:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:InvestmentsCreditRatingAxis">ci:BelowInvestmentGradeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ci:InvestmentsCreditRatingAxis">ci:BelowInvestmentGradeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ci:VillageMDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">us-gaap:HealthcareSectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">ci:EquitySecuritiesFVNIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">ci:LtvLessThan60PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">ci:LtvLessThan60PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">ci:LtvLessThan60PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">ci:LtvLessThan60PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">ci:Ltv60To79PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">ci:Ltv60To79PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">ci:Ltv60To79PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">ci:Ltv60To79PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">us-gaap:Ltv80To100PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">us-gaap:Ltv80To100PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">us-gaap:Ltv80To100PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">us-gaap:Ltv80To100PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RealEstateInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RealEstateInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MortgagesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MortgagesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MortgagesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:PolicyLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:PolicyLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:PolicyLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ci:CashCashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ci:CashCashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ci:CashCashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-436"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-443"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ci:ForwardsSwapsOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-448"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ci:ForwardsSwapsOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-449"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ci:ForwardsSwapsOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-450"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ci:ForwardsSwapsOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-451"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ci:ForwardsSwapsOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ci:ForwardsSwapsOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-453"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ci:ForwardsSwapsOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-454"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ci:ForwardsSwapsOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-455"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:SwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-456"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:SwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-457"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ci:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-458"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ci:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-459"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ci:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-460"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ci:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-461"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ci:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-462"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ci:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-463"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ci:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-464"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ci:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-465"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-466"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-467"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-469"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-470"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-471"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-472"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-473"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-474"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-475"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:DebtAndEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-476"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:DebtAndEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-477"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:DebtAndEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-478"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:DebtAndEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-479"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:DebtAndEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-480"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-481"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-482"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-483"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-484"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-485"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-486"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-487"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-488"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-489"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-490"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-491"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-492"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-493"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RealEstateFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-494"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RealEstateFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-495"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RealEstateFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-496"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RealEstateFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-497"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RealEstateFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-498"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-499"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-500"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="entity"><xbrli:measure>ci:entity</xbrli:measure></xbrli:unit><xbrli:context id="c-516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ci:SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="limitedpartnership"><xbrli:measure>ci:limitedPartnership</xbrli:measure></xbrli:unit><xbrli:context id="c-518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ci:CommitmentToFundPartnershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ci:SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ci:SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-520"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ci:RealEstateJointVenturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ci:AssetBackedAndCorporateSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ci:OtherVariableInterestEntitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ci:OperatingJointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ci:OperatingJointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-525"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ci:OperatingJointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ci:OperatingJointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ci:OperatingJointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ci:OperatingJointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ci:OperatingJointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ci:OperatingJointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ci:OperatingJointVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-532"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-533"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-534"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-535"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-536"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-537"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-538"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-539"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-540"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesGainLossOnSaleOfBusinessParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-541"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesGainLossOnSaleOfBusinessParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-542"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesGainLossOnSaleOfBusinessParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-543"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesRealizedInvestmentGainsLossesParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-544"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesRealizedInvestmentGainsLossesParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-545"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesRealizedInvestmentGainsLossesParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-546"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesSellingGeneralAdministrativeExpenseParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-547"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesSellingGeneralAdministrativeExpenseParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-548"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesSellingGeneralAdministrativeExpenseParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-549"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-550"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-551"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-552"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-553"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-554"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-555"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociLiabilityForFuturePolicyBenefitParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-556"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociLiabilityForFuturePolicyBenefitParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-557"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociLiabilityForFuturePolicyBenefitParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-558"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-559"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-560"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-561"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-562"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-563"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-564"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-565"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-566"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-567"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-568"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-569"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-570"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-571"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-572"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-573"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-574"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-575"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-576"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-577"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-578"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-579"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-580"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-581"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-582"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-583"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-584"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AccumulatedDefinedBenefitPlansAdjustmentGainLossOnSaleOfBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-585"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AccumulatedDefinedBenefitPlansAdjustmentGainLossOnSaleOfBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-586"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AccumulatedDefinedBenefitPlansAdjustmentGainLossOnSaleOfBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-587"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AccumulatedDefinedBenefitPlansAdjustmentSettlementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-588"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AccumulatedDefinedBenefitPlansAdjustmentSettlementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-589"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AccumulatedDefinedBenefitPlansAdjustmentSettlementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-590"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-591"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-592"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-593"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-594"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-595"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-596"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-597"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-598"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-599"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-600"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-605"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">ci:FundInvestmentsAndPooledSeparateAccountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">ci:FundInvestmentsAndPooledSeparateAccountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDebtSecurityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDebtSecurityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-612"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-613"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:RealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:RealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MortgagesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-620"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MortgagesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">ci:GuaranteedDepositAccountContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">ci:GuaranteedDepositAccountContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-623"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">ci:CashAndCashEquivalentsInvestmentTradeReceivablesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-624"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">ci:CashAndCashEquivalentsInvestmentTradeReceivablesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">ci:OtherPlanAssetCategoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-627"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-631"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-632"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-633"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-634"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-635"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-636"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-637"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ci:RestrictedStockGrantsAndUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-638"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ci:RestrictedStockGrantsAndUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-639"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ci:RestrictedStockGrantsAndUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-640"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ci:RestrictedStockGrantsAndUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-641"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ci:RestrictedStockGrantsAndUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-642"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ci:RestrictedStockGrantsAndUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-643"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ci:RestrictedStockGrantsAndUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-644"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ci:RestrictedStockGrantsAndUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-645"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ci:RestrictedStockGrantsAndUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>ci:employee</xbrli:measure></xbrli:unit><xbrli:context id="c-646"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-647"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-648"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-649"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-650"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-651"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-652"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-653"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-654"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-655"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-656"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-657"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-658"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-659"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-660"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-661"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-662"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ci:InternationalLifeAccidentSupplementalBenefitsBusinessesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-663"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-664"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-665"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-666"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-667"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-668"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-669"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-670"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-671"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-672"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-673"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-674"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-675"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-676"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-677"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-678"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-679"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ci:AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-680"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-681"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ci:AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-682"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ci:DepreciationAndAmortizationByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-683"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ci:DepreciationAndAmortizationByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-684"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ci:DepreciationAndAmortizationByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-685"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ci:DepreciationAndAmortizationByTypeAxis">ci:AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-686"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ci:DepreciationAndAmortizationByTypeAxis">ci:AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-687"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ci:DepreciationAndAmortizationByTypeAxis">ci:AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-688"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ci:DepreciationAndAmortizationByTypeAxis">us-gaap:InsuranceContractsAcquiredInBusinessCombinationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-689"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ci:DepreciationAndAmortizationByTypeAxis">us-gaap:InsuranceContractsAcquiredInBusinessCombinationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-690"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ci:DepreciationAndAmortizationByTypeAxis">us-gaap:InsuranceContractsAcquiredInBusinessCombinationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-691"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ci:DepreciationAndAmortizationByTypeAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-692"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ci:DepreciationAndAmortizationByTypeAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-693"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ci:DepreciationAndAmortizationByTypeAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-694"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ci:InternationalLifeAccidentSupplementalBenefitsBusinessesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-695"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ci:InternationalLifeAccidentSupplementalBenefitsBusinessesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-696"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ci:InternationalLifeAccidentSupplementalBenefitsBusinessesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-697"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ci:MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-698"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ci:MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-699"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">ci:IncomeBeforeTaxesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-700"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">ci:IncomeBeforeTaxesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">ci:IncomeBeforeTaxesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:RetirementAndLifeInsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:FinancialGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:RetirementAndLifeInsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:FinancialGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-705"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ci:PricingConcessionsThroughRemainingContractTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ci:ExpressScriptsLitigationWithElevanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ci:PricingConcessionsAfterRemainingTermOfAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ci:ExpressScriptsLitigationWithElevanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-707"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ci:DamagesForServiceIssuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ci:ExpressScriptsLitigationWithElevanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-708"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ci:ExpressScriptsCounterclaimsAgainstElevanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-04-19</xbrli:startDate><xbrli:endDate>2016-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-709"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ci:ExpressScriptsCounterclaimsAgainstElevanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ci:PricingConcessionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ci:ExpressScriptsLitigationWithElevanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-31</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-711"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ci:DamagesForServiceIssuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ci:ExpressScriptsLitigationWithElevanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:InsuranceRelatedAssessmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ci:LitigationMattersAndRegulatoryMattersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-714"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-716"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-717"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-718"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-721"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-722"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">ci:CorporateAndEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-724"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-725"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-728"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">ci:CorporateAndEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-732"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-733"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-734"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-735"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-736"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-737"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-738"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-739"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-740"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-741"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-742"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">ci:CorporateAndEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-743"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:NetworkPharmacyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-744"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:NetworkPharmacyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-745"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:NetworkPharmacyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-746"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:HomeDeliveryAndSpecialtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-747"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:HomeDeliveryAndSpecialtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-748"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:HomeDeliveryAndSpecialtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-749"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OtherPharmacyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-750"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OtherPharmacyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-751"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OtherPharmacyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-752"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-753"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-754"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-755"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:EmployerInsuredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-756"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:EmployerInsuredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-757"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:EmployerInsuredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-758"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-759"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-760"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-761"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:StopLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-762"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:StopLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-763"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:StopLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-764"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:IndividualAndFamilyPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-765"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:IndividualAndFamilyPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-766"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:IndividualAndFamilyPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-767"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OtherHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-768"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OtherHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-769"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OtherHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-770"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-771"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-772"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-773"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:InternationalHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-774"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:InternationalHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-775"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:InternationalHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-776"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:OtherOperationsInternationalBusinessesToBeSoldAndInterestInJointVentureInTurkeyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-777"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:OtherOperationsInternationalBusinessesToBeSoldAndInterestInJointVentureInTurkeyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-778"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:OtherOperationsInternationalBusinessesToBeSoldAndInterestInJointVentureInTurkeyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-779"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:OtherOperationsSegmentOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-780"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:OtherOperationsSegmentOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-781"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:OtherOperationsSegmentOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-782"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-783"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-784"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-785"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-786"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-787"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-788"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-789"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-790"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-791"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-792"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-793"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-794"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-795"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-796"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-797"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ci:SingleForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">ci:RevenuesFromExternalCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-798"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ci:SingleForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">ci:RevenuesFromExternalCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-799"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ci:SingleForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">ci:RevenuesFromExternalCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-800"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-802"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ci:AllOtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-804"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ci:AllOtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ci:AllOtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">ci:RevenuesIncludingNetInvestmentIncomeBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ci:USFederalGovernmentAgenciesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">ci:RevenuesIncludingNetInvestmentIncomeBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ci:USFederalGovernmentAgenciesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-808"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">ci:RevenuesIncludingNetInvestmentIncomeBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ci:USFederalGovernmentAgenciesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-809"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-810"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-811"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-812"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-813"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:SubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:SubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-817"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-818"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:SubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-819"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:SubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-820"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:SubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-822"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditAgreementsApril2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-824"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-826"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-827"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:A364DayRevolvingCreditAgreementMaturingApril2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:A364DayRevolvingCreditAgreementMaturingApril2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-829"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditAgreementsApril2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="bank"><xbrli:measure>ci:bank</xbrli:measure></xbrli:unit><xbrli:context id="c-830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-832"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditFacilityMaturingApril2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-833"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditFacilityMaturingApril2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-834"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:A364DayRevolvingCreditAgreementMaturingApril2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-835"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:A364DayRevolvingCreditAgreementMaturingApril2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-836"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-837"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-838"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue202435InterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-839"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-840"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-841"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-842"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20265685Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-843"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20265685Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-07</xbrli:startDate><xbrli:endDate>2023-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-844"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20335400InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-845"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20335400InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-07</xbrli:startDate><xbrli:endDate>2023-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-846"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20265685Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:UsTreasuryUstInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-07</xbrli:startDate><xbrli:endDate>2023-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-847"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20335400InterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:UsTreasuryUstInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-07</xbrli:startDate><xbrli:endDate>2023-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-848"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ci:EvernorthHealthIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-849"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ci:EvernorthHealthIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-850"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ci:EvernorthHealthIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-851"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ci:ThreeWhollyOwnedSubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-852"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-853"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-854"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-15</xbrli:startDate><xbrli:endDate>2024-02-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-855"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-856"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-857"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-858"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-859"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-860"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-861"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-862"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-863"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-864"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-865"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-866"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-867"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForReinsuranceRecoverableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-868"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForReinsuranceRecoverableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-869"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForReinsuranceRecoverableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-870"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-871"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-872"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-873"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-874"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-875"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-876"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-877"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-878"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForReinsuranceRecoverableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-879"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForReinsuranceRecoverableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-880"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-881"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-882"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-883"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-884"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-885"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-886"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-887"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-888"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForReinsuranceRecoverableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-889"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001739940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForReinsuranceRecoverableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-205" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-205" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-1" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-475" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-1" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-475" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-3" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-476" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-3" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-476" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-1" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-481" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-1" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-481" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-3" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-482" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-1" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-482" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-3" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-439 f-436 f-437 f-430 f-431 f-434 f-433 f-427 f-428 f-425 f-424 f-422 f-219 f-458 f-217 f-452 f-211 f-451 f-215 f-457 f-454 f-213 f-455 f-207 f-449 f-448 f-209 f-440 f-203 f-445 f-446 f-201 f-443 f-191 f-195 f-193 f-199 f-197 f-181 f-185 f-183 f-189 f-187 f-416 f-415 f-418 f-419 f-412 f-413 f-410 f-406 f-403 f-404 f-409 f-407 f-401 f-400 f-39 f-151 f-394 f-391 f-392 f-155 f-397 f-398 f-153 f-395 f-159 f-157 f-382 f-141 f-383 f-380 f-386 f-145 f-143 f-385 f-149 f-388 f-147 f-389 f-58 f-57 f-55 f-54 f-52 f-51 f-173 f-171 f-177 f-175 f-179 f-49 f-48 f-46 f-45 f-43 f-42 f-40 f-163 f-161 f-167 f-165 f-169 f-117 f-359 f-118 f-79 f-78 f-76 f-73 f-72 f-70 f-470 f-111 f-112 f-472 f-473 f-115 f-478 f-358 f-479 f-355 f-114 f-356 f-108 f-109 f-106 f-469 f-69 f-67 f-66 f-64 f-63 f-61 f-60 f-460 f-100 f-221 f-463 f-464 f-461 f-467 f-105 f-102 f-103 f-466 f-139 f-99 f-97 f-96 f-94 f-93 f-371 f-130 f-370 f-133 f-376 f-373 f-132 f-374 f-379 f-138 f-135 f-377 f-136 f-129 f-88 f-87 f-85 f-84 f-82 f-81 f-91 f-90 f-361 f-364 f-485 f-123 f-365 f-120 f-362 f-121 f-484 f-126 f-368 f-127 f-124 f-487 f-367 f-488" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-1" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-204" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-474 f-480" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-3" order="1"></ix:relationship></ix:resources></ix:header></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_925"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span id="i2e38e39de8e04ff2b7c4894a0167653f_668"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Washington, D.C. 20549</span></div><div style="margin-bottom:6pt;text-align:center"><img src="ci-20231231_g1.jpg" alt="cignagroup_logo_color_pos_rgb.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:121px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:115%">FORM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-5">10-K</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.716%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.984%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="f-6">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-7"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-8">December&#160;31</ix:nonNumeric>, 2023</ix:nonNumeric></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">OR</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="f-9">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">For the transition period from ______________ to ______________</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Commission file number</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-10">001-38769</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-11">The Cigna Group</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-12">Delaware</ix:nonNumeric></span></td><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-13">82-4991898</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-14">900 Cottage Grove Road</ix:nonNumeric>,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-15">Bloomfield</ix:nonNumeric>,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-16">Connecticut</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-17">06002</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr><tr><td colspan="6" style="background-color:#d9d9d9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-18">860</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-19">226-6000</ix:nonNumeric></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Registrant's telephone number, including area code</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.929%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="background-color:#bfbfbf;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities registered pursuant to Section 12(b) of the Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-20">Common Stock, Par Value $0.01</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-21">CI</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-22">New York Stock Exchange</ix:nonNumeric>, Inc.</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#bfbfbf;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities registered pursuant to Section 12(g) of the Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">NONE</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:25.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.767%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.767%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.767%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.773%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#bfbfbf;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-23"><ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-24"><ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-25">Yes</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#bfbfbf;border-left:1pt solid #000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-26">No</ix:nonNumeric></span></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:4.49pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:4.49pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:4.49pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:4.49pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div><div style="text-align:center"><span><br/></span></div></td></tr><tr><td colspan="21" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:4.49pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-27">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="f-28">&#9744;</ix:nonNumeric></span></td><td colspan="6" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-29">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:4.49pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:4.49pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="f-30">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:4.49pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-31">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:4.49pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:4.49pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="f-32">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The aggregate market value of the voting stock held by non-affiliates of the registrant as of June 30, 2023 was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-8" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="f-33">82.8</ix:nonFraction> billion.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of January&#160;31, 2024, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-34">292,355,022</ix:nonFraction> shares of the registrant's Common Stock were outstanding.</span></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline">DOCUMENTS INCORPORATED BY REFERENCE</span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-35" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Part III of this Form 10-K incorporates by reference information from the registrant's definitive proxy statement related to the 2024 annual meeting of shareholders.</span></div></ix:nonNumeric><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_928"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center"><span id="i58f83a8d297d4e109becf408ab21476b_31"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">TABLE OF CONTENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.666%"><tr><td style="width:1.0%"/><td style="width:85.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.522%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FREQUENTLY REQUESTED 10-K INFORMATION</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_979">Risk Factors</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_979">30</a></span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_706">Executive Overview</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_706">52</a></span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_745">Key Transactions and Business Developments</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_745">55</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_778">Liquidity and Capital Resources</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_778">56</a></span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_814">Critical Accounting Estimates</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_814">61</a></span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_646">Segment Information</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_646">132</a></span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_673">Revenues by Product Type</a></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_673">136</a></span></div></td></tr></table></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.666%"><tr><td style="width:1.0%"/><td style="width:13.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:75.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_931">Cautionary Statement</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_934">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_937">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_937">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_937">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_940">Overview</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_940">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_949">Evernorth Health Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_949">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_952">Cigna Healthcare</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_952">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_955">Other Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_955">13</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_973">Miscellaneous</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_973">14</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_958">Investment Management</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_958">14</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_961">Strategic Investments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_961">15</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_964">Digital, Data and Technology</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_964">15</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_967">Human Capital Management</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_967">16</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_970">Environmental, Social and Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_970">18</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_976">Regulation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_976">18</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_979">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_979">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_979">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_982">Item 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_982">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_982">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_985">Item 1C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_985">Cybersecurity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_985">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_988">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_988">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_988">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_991">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_991">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_991">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_994">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_994">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_994">47</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_997">Information about our Executive Officers</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_997">48</a></span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.666%"><tr><td style="width:1.0%"/><td style="width:13.002%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:70.694%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.953%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1000">PART II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1003">Item 5.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1003">Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1003">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1012">Item 6.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1012">[Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1012">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_685">Item 7.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_685">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_685">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1015">Item 7A.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1015">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1015">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_16">Item 8.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_16">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_16">73</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1018">Item 9.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1018">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1018">137</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_880">Item 9A.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_880">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_877">137</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1021">Item 9B.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1021">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1021">137</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1024">Item 9C.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1024">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1024">137</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1027">PART III</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1030">Item 10.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1030">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1030">138</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A. Directors of the Registrant</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B. Executive Officers of the Registrant</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C. Code of Ethics and Other Corporate Governance Disclosures</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D. Delinquent Section 16(a) Reports</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1033">Item 11.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1033">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1033">138</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1036">Item 12.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1036">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1036">139</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1039">Item 13.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1039">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1039">139</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1042">Item 14.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1042">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1042">139</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1045">PART IV</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1048">Item 15.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1048">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1048">140</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1054">Item 16.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1054">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1054">147</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1057">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1057">148</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1060">Index to Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1060">FS-1</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_931"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span id="i9c6151cdaffa4a22aef910b7a8c9019d_5977"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Annual Report on Form 10-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on The Cigna Group's current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking statements may include, among others, statements concerning future financial or operating performance, including our ability to improve the health and vitality of those we serve; future growth, business strategy and strategic or operational initiatives; economic, regulatory or competitive environments, particularly with respect to the pace and extent of change in these areas and the impact of developing inflationary and interest rate pressures; financing or capital deployment plans and amounts available for future deployment; our prospects for growth in the coming years; strategic transactions; expectations related to our Medicare Advantage Capitation Rates; and other statements regarding The Cigna Group's future beliefs, expectations, plans, intentions, liquidity, cash flows, financial condition or performance. You may identify forward-looking statements by the use of words such as "believe," "expect," "project," "plan," "intend," "anticipate," "estimate," "predict," "potential," "may," "should," "will" or other words or expressions of similar meaning, although not all forward-looking statements contain such terms.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to achieve our strategic and operational initiatives; our ability to adapt to changes in an evolving and rapidly changing industry; our ability to compete effectively, differentiate our products and services from those of our competitors and maintain or increase market share; price competition, inflation and other pressures that could compress our margins or result in premiums that are insufficient to cover the cost of services delivered to our customers; the potential for actual claims to exceed our estimates related to expected medical claims; our ability to develop and maintain satisfactory relationships with physicians, hospitals, other health service providers and with producers and consultants; our ability to maintain relationships with one or more key pharmaceutical manufacturers or if payments made or discounts provided decline; changes in the pharmacy provider marketplace or pharmacy networks; changes in drug pricing or industry pricing benchmarks; our ability to invest in and properly maintain our information technology and other business systems; our ability to prevent or contain effects of a potential cyberattack or other privacy or data security incident; risks related to our use of artificial intelligence and machine learnings; political, legal, operational, regulatory, economic and other risks that could affect our multinational operations, including currency exchange rates; risks related to strategic transactions and realization of the expected benefits of such transactions, as well as integration or separation difficulties or underperformance relative to expectations; dependence on success of relationships with third parties; risk of significant disruption within our operations or among key suppliers or third parties; potential liability in connection with managing medical practices and operating pharmacies, onsite clinics and other types of medical facilities; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; uncertainties surrounding participation in government-sponsored programs such as Medicare; the outcome of litigation, regulatory audits and investigations; compliance with applicable privacy, security and data laws, regulations and standards; potential failure of our prevention, detection and control systems; unfavorable economic and market conditions, the risk of a recession or other economic downturn and resulting impact on employment metrics, stock market or changes in interest rates and risks related to a downgrade in financial strength ratings of our insurance subsidiaries; the impact of our significant indebtedness and the potential for further indebtedness in the future; credit risk related to our reinsurers; as well as more specific risks and uncertainties discussed in Part I, Item 1A &#8211; Risk Factors and Part II, Item 7 &#8211; Management's Discussion and Analysis of Financial Condition and Results of Operations of this Form 10-K and as described from time to time in our future reports filed with the Securities and Exchange Commission (the "SEC").</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">You should not place undue reliance on forward-looking statements, which speak only as of the date they are made, are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. The Cigna Group undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_934"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">PART I</span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_937"></div><div style="margin-bottom:10pt"><span id="i56a99e989f074387a56b7236a59d589f_20"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Item 1. BUSINESS</span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_940"></div><div style="margin-top:10pt"><span id="ie47c0db33d654e459e69f28fc5782a52_13329"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">OVERVIEW</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Cigna Group, together with its subsidiaries (either individually or collectively referred to as the "Company," "we," "us," or "our"), is a global health company. </span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.318%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Our Purpose and Mission</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Cigna Group is a global health company committed to creating a better future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. Powered by our people and our brands, we advance our mission to improve the health and vitality of those we serve.</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Our Pathways to Growth</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In order to turn the differentiated value we deliver to our customers, patients, clients, communities and investors into attractive, sustained growth, we will continue to cultivate our portfolio of businesses so that it can continue to deliver the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">foundational </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">accelerated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">growth and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> cross-enterprise leverage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> we expect today and in the future.</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:14.5pt">Foundational:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mature, scaled businesses contributing steady, predictable growth.</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:14.5pt">Accelerated: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High-growth businesses in very attractive markets. </span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:14.5pt">Cross-Enterprise Leverage: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working together to create even greater value.</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Core Strengths</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:14.5pt">Deep clinical expertise </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">across pharmacy, medical and behavioral.</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:14.5pt">Robust data and insights </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">supporting care with greater precision and personalization.</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:14.5pt">Focus on developing innovative solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">addressing needs of customers, patients and clients.</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:14.5pt">Partnering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> with others to accelerate innovation and create sustainable impact.</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:14.5pt">Consultative approach </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">driven by an experienced and talented team.</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At The Cigna Group, we relentlessly challenge ourselves to partner and innovate solutions for better health. Our global workforce of approximately 72,500 colleagues work to fulfill our mission to improve the health and vitality of over 164 million customer relationships in more than 30 markets and jurisdictions.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have two growth platforms: Evernorth Health Services and Cigna Healthcare. Evernorth Health Services is our pharmacy benefits, specialty and care solution that is highly attractive to our clients and partners because of the depth of its capabilities and expertise. Evernorth Health Services also enables us to deepen existing relationships across our entire book of business. Cigna Healthcare is the health benefits provider of The Cigna Group, serving customers and clients for our U.S. Healthcare and International Health operating segments, and it allows us to harness our partnership relationship with physicians to deliver affordable and coordinated health care. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our portfolio of offerings solves diverse challenges across the health care system. Our capabilities include: 1) a broad portfolio of solutions and services, some of which can be offered on a stand-alone basis; 2) integrated behavioral, medical and pharmacy management solutions; 3) leading specialty pharmacy, clinical and care management expertise; and 4) advanced analytics that help us engage more meaningfully with those we serve. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Together, Evernorth Health Services and Cigna Healthcare provide a strong and diverse foundation that allows us to capitalize on growth opportunities by leading with our strengths &#8211; pharmacy and medical solutions &#8211; and then expanding those relationships by addressing additional client needs and innovating and delivering new services and solutions. To transform the differentiated value we deliver to our customers, patients, clients, communities and investors into attractive, sustained growth, we continue to cultivate our portfolio of businesses with the goal of consistently delivering the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">foundational growth</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">accelerated growth</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and opportunity for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">cross-enterprise leverage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> we expect today and in the future. When considering our broad portfolio of businesses, we have strong foundational businesses that we expect to continue to grow. These businesses often serve as the key entry point for clients with either a pharmacy relationship, a medical relationship or both. We also have a variety of accelerated growth businesses, both scaled and emerging, which build upon our foundational relationships or provide exposure to adjacent high-growth areas. Our cross-enterprise leverage provides us with an opportunity to unlock even more value as the combined power of the franchise is unleashed. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_946"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Information about Segments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We present the financial results of our businesses in the following segments (see "Executive Overview" section of Management's Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">("MD&amp;A") located in Part II, Item 7 of this Form 10-K for a Financial Summary):</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Evernorth Health Services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">partners with health plans, employers, governmental organizations and health care providers to solve challenges in the areas of pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty distribution, and care delivery and management solutions. Within Evernorth Health Services, pharmacy benefits and home delivery pharmacy are </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">foundational growth</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> businesses and specialty pharmacy, specialty distribution, and care delivery and management solutions are </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">accelerated growth</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> businesses. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cigna Healthcare</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. During the fourth quarter of 2023, the U.S. Commercial and U.S. Government operating segments merged to form the U.S. Healthcare operating segment. U.S. Healthcare provides commercial medical plans and specialty benefits and solutions for insured and self-insured clients (U.S. Employer), Medicare Advantage, Medicare Supplement and Medicare Part D plans for seniors and individual health insurance plans. International Health provides health care solutions in our international markets, as well as health care benefits for globally mobile individuals and employees of multinational organizations. Within Cigna Healthcare, U.S. Employer and International Health are </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">foundational growth </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">businesses.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2024, the Company entered into a definitive agreement to sell the Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits and CareAllies businesses within the U.S. Healthcare operating segment to Health Care Service Corporation ("HCSC") for $3.3 billion cash, subject to applicable regulatory approvals and other customary closing conditions (the "HCSC transaction").</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> comprises the remainder of our business operations, which includes certain ongoing businesses and exited businesses. Our ongoing businesses include our continuing business, corporate-owned life insurance ("COLI"), and our run-off businesses. Our run-off businesses include (i) variable annuity reinsurance business (formerly referred to as guaranteed minimum death benefit ("GMDB") and guaranteed minimum income benefit ("GMIB") business), (ii) settlement annuity business and (iii) individual life insurance and annuity and retirement benefits businesses. Our exited businesses include the international life, accident and supplemental benefits businesses sold in July 2022 (the "Chubb transaction") and our interest in a joint venture in T&#252;rkiye sold in December 2022. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">reflects amounts not allocated to operating segments, including net interest expense (defined as interest on corporate financing less net investment income on investments not supporting segment and other operations), certain litigation matters, expense associated with our frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs and eliminations for products and services sold between segments.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Cross-enterprise Leverage</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cross-enterprise leverage enables us to uniquely use the depth and breadth of our wide-ranging capabilities across the enterprise to create more value, expand our reach and drive growth. We look across our enterprise at our client relationships within both Evernorth Health Services and Cigna Healthcare and seek to deepen them by leveraging our entire suite of capabilities. Cross-enterprise leverage brings teams from across the enterprise together in a quick, efficient and organized manner to move from ideation to solution creation to meet client's evolving needs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Evernorth Health Services offerings, such as the Express Scripts PBM, Accredo Specialty Pharmacy, and Evernorth Care behavioral health solutions, are available within Cigna Healthcare solutions. This broadens Evernorth Health Services&#8217;s presence in the total health care delivery system, and expands the breadth and depth of offerings available to Cigna Healthcare clients and customers while improving affordability, access, quality of care, care innovations and transparency. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A recent product innovation is Pathwell Bone &amp; Joint - a Cigna Healthcare solution powered by Evernorth Health Services. Pathwell Bone &amp; Joint delivers affordability to clients via an enhanced digital customer experience and customized clinical navigation through a care advocate. During 2023, this program was offered to Cigna Healthcare U.S. Employer clients.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Other Information</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The financial information included in this Form 10-K for the fiscal year ended December&#160;31, 2023 is in conformity with accounting principles generally accepted in the United States of America ("GAAP") unless otherwise indicated. In the segment discussions that follow, we use the terms "adjusted revenues" and "pre-tax adjusted income (loss) from operations" to describe segment results. See </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Note 25 to the Consolidated Financial Statements of this Form 10-K for definitions of those terms. Industry rankings and percentages set forth herein are for the year ended December&#160;31, 2023, unless otherwise indicated. In addition, statements set forth in this document concerning our rank or position in an industry or particular line of business have been developed internally based on publicly available information unless otherwise noted.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Cigna Group, through its predecessor companies, was incorporated in Delaware in 1981. Cigna Corporation was renamed The Cigna Group in February 2023.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">You can access our website at http://www.thecignagroup.com to learn more about our company. We make annual, quarterly and current reports and proxy statements and amendments to those reports available, free of charge through our website as soon as reasonably practicable after we electronically file these materials with, or furnish them to, the Securities and Exchange Commission ("SEC"). We also use our website as a means of disclosing material information and for complying with our disclosure obligations under the SEC's Regulation FD (Fair Disclosure). Important information, including news releases, analyst presentations and financial information regarding The Cigna Group is routinely posted on our website. Accordingly, investors should monitor the Investor Relations portion of our website, in addition to following our press releases, SEC filings and public conference calls and webcasts. The information contained on, or that may be accessed through, our website is neither incorporated by reference into nor a part of this report. See also "Code of Ethics and Other Corporate Governance Disclosures" in Part III, Item 10 of this Form 10-K for additional information regarding the availability of our Codes of Ethics on our website.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Intellectual Property Rights</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We hold a variety of trademarks and service marks used throughout our businesses. We also use patents to protect our proprietary technological advances and to differentiate ourselves in the market. The Cigna Group companies hold over 400 United States patents. We are not substantially dependent on any single patent or group of related patents. We are not aware of any facts that could materially impact the continuing use of any of our intellectual property.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_949"></div><div><span id="ie352d24b82f547028f3c75c67b5c7e94_55118"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">EVERNORTH HEALTH SERVICES</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.012%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Evernorth Health Services includes a broad range of independent and coordinated health solutions and capabilities designed to enable the health care system to work better and help people live richer, healthier lives. Health plans, employers, governmental organizations and health care providers partner with Evernorth Health Services to solve their biggest challenges in the areas of pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty distribution, and care delivery and management solutions. In 2023, Evernorth Health Services reported adjusted revenues of $153.5 billion and pre-tax adjusted income from operations of $6.4 billion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since the launch of the Evernorth Health Services brand, we have continued to grow and serve more people. Today, Evernorth Health Services is made up of dozens of businesses across pharmacy benefit, specialty and care services. All products and services below are part of the Evernorth Health Services offering.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.179%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">How We Deliver</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-18.01pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.51pt">Deep clinical expertise </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">when evaluating medicines, digital therapeutics and other health solutions for efficacy and value to assist clients in selecting a cost effective formulary.</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.5pt">Affordable solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">that provide more value and drive risk-sharing and value-based care.</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.5pt">Flexible solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">tailored to client needs, using Evernorth Health Services' combined strengths and capabilities, as well as strategic partnerships, to deliver: better, more efficient care for patients; better experiences for clients, providers and customers; and enhanced choices for clients and customers through our open architecture model.</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.5pt">Talented, experienced and caring people who work as consultative partners </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to solve complex problems across a fragmented health care ecosystem, fueled by data and expertise that drives purposeful innovation.</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following chart depicts a high-level summary of our principal products and services in this segment with definitions on subsequent pages.</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.094%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.955%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Products &amp; Services</span></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Brands/<br/>Subsidiaries</span></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Relationships</span></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Primary Competitors</span></td></tr><tr style="height:119pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pharmacy Benefit Services - Driving Foundational Growth</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pharmacy Benefits</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;Express Scripts PBM, National Preferred Formulary, myMatrixx</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, Express Scripts MedRx Management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, Advanced Utilization Management, Enhanced Fraud, Waste &amp; Abuse, Ascent Health Services, Econdisc Contracting Solutions, Copay Assurance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, Inside Rx</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, Evernorth Wholesale Marketplace</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, Value-Based Programs (Express Scripts SafeGuardRx</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, Express Scripts Patient Assurance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, EncircleRx</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clients, Customers, Health Care Providers, Consultants, Health Plans, Commercial and Government Payors, Self-paying Customers, Pharmacy Providers</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Health Plans, Independent Pharmacy Benefit Managers ("PBMs"), Managed Care PBMs, Third-Party Benefit Administrators, Group Purchasing Organizations, Clinical Solutions and Health Care Data Analytics Companies</span></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Delivery Pharmacy</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Express Scripts Pharmacy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clients, Customers, Health Care Providers</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retail Pharmacies, Home Delivery Pharmacies</span></td></tr><tr style="height:47pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Specialty and Care Services - Driving Accelerated Growth</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Specialty Pharmacy</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accredo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, Freedom Fertility Pharmacy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Resource Center</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clients, Customers, Health Care Providers, Specialty Drug Distributors</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty Pharmacies</span></td></tr><tr style="height:38pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Specialty Distribution</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CuraScript SD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinics, Hospitals, Physicians' Offices, Pharmacies, Alternative Sites of Care</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty Drug Distributors</span></td></tr><tr style="height:84pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Care Delivery and Management Solutions</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">eviCore Healthcare</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, Evernorth Behavioral Health, Evernorth Home-Based Care, MDLIVE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, inMynd</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, Health Connect 360</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, RationalMed</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, Evernorth Digital Health Formulary</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">SM</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clients, Customers, Health Care Providers, VillageMD, Health Plans</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Managed Care Organizations, Care Delivery and Care Management Solutions Providers, Third-Party Benefit Administrators, Health Care Data Analytics Companies</span></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Principal Products &amp; Services</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Pharmacy Benefit Services</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Pharmacy Benefits.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We drive high-quality, cost-effective pharmacy care through a range of services. We adjudicate drug claims from Express Scripts Pharmacy, Accredo and retail network participants, and provide retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management and other services.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Retail Pharmacy Network Administration.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We contract with retail pharmacies to provide prescription drugs to customers of the pharmacy benefit plans our clients offer. We negotiate with pharmacies throughout the United States to discount drug prices and offer national and regional network options responsive to client preferences related to cost containment, convenience of access for customers and network performance. We also manage networks of pharmacies customized for or under direct contract with specific clients and have contracted with pharmacy provider networks to comply with the Center for Medicare and Medicaid Services ("CMS") access requirements for the federal Medicare Part D prescription drug program ("Medicare Part D").</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Drug Formulary Management.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">Formularies are lists of drugs with designations that may be used to determine drug coverage, customer out-of-pocket costs and communicate plan preferences in competitive drug categories. Our formulary management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">services support clients in establishing formularies that assist customers and physicians in choosing clinically-appropriate, cost-effective drugs and prioritize access, safety and affordability. </span></div><div style="padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">We administer specific formularies for our clients, including standard formularies developed by Express Scripts and custom formularies in which we play a more limited role. Many of our clients select standard formularies, governed by our National Pharmacy &amp; Therapeutics Committee ("P&amp;T Committee"), our Therapeutic Assessment Committee ("TAC") and our Value Assessment Committee ("VAC"). These committees work together to develop recommendations for formularies that first consider clinical results independent of price </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:90pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">considerations. Only after these clinical reviews are completed and codified are other factors such as net cost, market share and drug utilization trends considered for the final development of our formularies.</span></div><div style="padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">One of the ways we manage our drug formulary is through negotiating to secure additional affordability for the benefit of our clients based on the utilization of certain prescription drugs and supplies which can be paid to us in the form of a rebate. With respect to our clients' rebate arrangements, most chose to receive the greater of a minimum rebate guarantee or a contractually agreed-upon percentage of rebates. In some rebate arrangements, Express Scripts PBM takes on the risk of securing the rebate value necessary to meet the value guaranteed to its client. The actual amount of value secured by Express Scripts PBM is dependent upon the result of its negotiations for rebates. In 2023, the Express Scripts PBM shared over 95% of the drug formulary management rebates it received with its PBM clients, and two-thirds of its clients received 100% of rebates. </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Benefits Design Consultation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We consult with our clients on how best to structure and leverage the pharmacy benefit to meet plan objectives for affordable access to the prescription medications customers need to stay healthy and to ensure the safe and effective use of those medications.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Drug Utilization Review Program.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> When pharmacies submit claims for prescription drugs to us, we review them electronically in real time for health and safety. We then alert the dispensing pharmacy of any detected issues. Clients may also choose to enroll in programs that result in communications about potential therapy concerns being sent to prescribers after the initial claim submission.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">myMatrixx.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> myMatrixx is a PBM with an exclusive focus on workers' compensation. We combine high-touch customer service with clinical expertise and state-of-the-art business intelligence systems to deliver simplified solutions and positive outcomes.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Medical Drug Management.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We offer a comprehensive range of services and guaranteed savings for managing medically billed specialty drugs. Our solutions apply utilization management, site of care management and claims prepayment review to effectively reduce wasteful spend, while providing services tailored to customers helping ensure safety and healthier outcomes. We also offer Express Scripts MedRx Management, a multifaceted medical drug strategy, developed to provide both clinical and financial value to clients.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Advanced Utilization Management.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> These programs include prior authorization, drug quantity management and step therapy designed to ensure clinically appropriate medication use and avoid unnecessary client pharmacy spend.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Enhanced Fraud, Waste &amp; Abuse.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We help plan sponsors identify customers and prescribers with potentially unusual or excessive utilization patterns. The program is designed to help identify outliers and situations of abnormal use or prescribing patterns by analyzing types of prescriptions, refill patterns and pharmacy utilization.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Administration of Group Purchasing Organizations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We operate various group purchasing organizations that negotiate pricing for the purchase of pharmaceuticals or formulary rebates with pharmaceutical manufacturers on behalf of their participants. These groups also provide various administrative services to their participants including management and reporting.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Inside Rx.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Inside Rx is a prescription medication savings program that offers eligible self-paying customers discounts on many brand and generic medications. This program is not insurance but offers savings at nearly 60,000 participating retail pharmacies (including all major chains) in the United States and Puerto Rico. The program also offers discounts on prescription medications through private label solutions.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Evernorth Wholesale Marketplace.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Evernorth Wholesale Marketplace offers a suite of flexible, private label PBM solutions including but not limited to a Pharmacy Rebate Program, a Retail Network Program, Value-Based Solutions, a Medical Rebate Program and Utilization Management Policies. These offerings are captured under either our drug formulary administrative service arrangements or our formulary processing arrangements.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Value-Based Programs.</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Express Scripts SafeGuardRx.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We offer a solution platform aimed at therapy classes that pose budgetary threats to clients and clinical challenges to customers. Our solutions are designed to help keep our clients ahead of the drug cost curve while providing customers the personalized services and access they need. These solutions are offered throughout our pharmacy benefit management services and include, but are not limited to, care for: cardiovascular, diabetes, hepatitis, HIV, inflammatory conditions, neurological, multiple sclerosis, oncology, pulmonary, rare conditions and weight management. Innovative Express Scripts SafeGuardRx programs may include utilization management, specialized expertise from our Therapeutic Resource Centers and financial savings.</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Express Scripts Copay Assurance and Patient Assurance Programs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Copay Assurance program caps consumer out-of-pocket costs for certain prescription drugs under a client's prescription drug benefit. The Patient Assurance Program addresses affordability challenges for customers managing their diabetes and cardiovascular conditions by providing a lower, fixed, out-of-pocket cost to the customer by negotiating additional discounts to reduce customer out-of-pocket costs, and applies those discounts at the point of service.</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Express Scripts EncircleRx.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> EncircleRx is a data-driven solution that helps clients reduce costs and enhance outcomes for chronic condition categories. EncircleRx focuses on ensuring the right patient population has the correct access, prescriber and pharmacy management parameters in place and provides ongoing patient support in order to track responses to therapy and demonstrate patient outcomes.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Home Delivery Pharmacy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Express Scripts Pharmacy offers free standard shipping of medications nationwide, usually in a 90-day supply, directly to the customer's home and allows for automatic refills on eligible medications and unrestricted telephone access to customer care advocates and specially trained pharmacists to answer customer questions. Our differentiated practice of pharmacy, coupled with our advanced automated dispensing technology, results in safer and more accurate pharmacy operations when compared to retail pharmacies, convenient access to maintenance medications and better coordination with management of our PBM clients' drug costs through operating efficiencies and generic substitutions. The Home Delivery Pharmacy operations consist of thirteen licensed pharmacies, including four fulfillment pharmacies. Our fulfillment pharmacies are located in Arizona, Indiana, Missouri and New Jersey.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Specialty and Care Services</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Specialty Pharmacy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Specialty medications are primarily characterized as high-cost medications for the treatment of complex and rare diseases. These medications broadly include those with frequent dosing adjustments, intensive clinical monitoring, the need for customer training, specialized product administration requirements or medications limited to certain specialty pharmacy networks by manufacturers. The front-end of our pharmacy, anchored by Accredo, is organized into Therapeutic Resource Centers, where pharmacists focus their practice of pharmacy by condition. Accredo is focused on dispensing injectable, infused, oral and inhaled drugs that require a higher level of clinical service and support than traditional pharmacies typically offer. Accredo supports successful outcomes for customers and reduces waste for clients through our specially trained clinicians and network of in-home nursing services, our nationwide footprint, our drug reimbursement services and by helping customers access assistance programs. Drug manufacturers may select Accredo for exclusive dispensing of highly specialized therapies. Freedom Fertility Pharmacy is dedicated exclusively to supporting customers undergoing fertility treatment. Our Specialty Pharmacy operations consist of 31 licensed pharmacies.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Specialty Distribution.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CuraScript SD is a specialty distributor of pharmaceuticals and medical supplies (including injectable and infusible pharmaceuticals and medications to treat specialty and rare or orphan diseases) directly to health care providers, clinics and hospitals in the United States for office or clinic administration. Through this business, we provide distribution services primarily to health care providers who treat customers with chronic diseases and regularly order costly specialty pharmaceuticals. This business operates three distribution centers and ships most products overnight within the United States. It is a contracted supplier with most major group purchasing organizations and leverages its distribution platform to operate as a third-party logistics provider for several pharmaceutical companies.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Care Delivery and Management Solutions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We offer clinical programs to help our clients drive better whole-person health outcomes through our Care Delivery (virtual care, in-home care and physical primary care) and Care Management (eviCore benefits management, behavioral health services and health coaching capabilities) offerings. </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">eviCore Healthcare</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> eviCore Healthcare is a medical benefits management organization that promotes customers' optimal treatment at the right site of care by leveraging our team of medical professionals, evidence-based guidelines and innovative technologies to promote affordable care. eviCore Healthcare provides integrated solutions for key clinical diagnostic areas such as advanced imaging, cardiology and gastroenterology, as well as longitudinal areas such as musculoskeletal, oncology and post-acute care. eviCore Healthcare contracts with health plans to promote the appropriate use of health care services by the customers they serve. In certain instances, this occurs through capitated risk arrangements, when we assume the financial obligation for the cost of health care services provided to eligible customers covered by eviCore healthcare management solutions.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Evernorth Behavioral Health.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Our behavioral health solutions simplify the complicated treatment landscape by assisting members to the right level of care at the right time, in the right place - from start to finish. Our predictive analytics models proactively identify customers who need support so that we can engage them early and provide the appropriate care, leveraging our extensive provider network including in-person providers, virtual providers and digital tools.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Evernorth Home-Based Care.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Our Evernorth Home-Based Care solution is a complete, in-home population health and clinical service business dedicated to serving the diverse needs of members, providers and customers, including in-home primary care, care coordination and enablement services. We address common barriers to care faced by older Americans, including chronic conditions, limited mobility and transportation issues. While most care in this model is home-based, our solution is digitally and virtually enabled for patients and their caregivers.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">MDLIVE.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MDLIVE virtual care services provide flexibility for the customer to access a network of virtual care providers for preventative and routine primary care and wellness, urgent care, dermatology care, behavioral health care needs and chronic condition management.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Pharmacy Solutions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> These programs combine various solutions to coordinate care for customers and include: inMynd, Condition and Disease Management, Navigation, Health Connect 360, RationalMed and Evernorth Digital Health Formulary.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Clients and Customers</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We provide products and services in the Evernorth Health Services segment to clients and customers, as described below. Also described below are our significant clients.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Clients.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We provide services to managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers' compensation plans, government health programs, providers, clinics, hospitals and others. We provide services to a majority of customers in our Cigna Healthcare segment.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Customers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Prescription drugs are dispensed to patients connected to the service offerings we provide to clients. Prescription drugs are dispensed primarily through networks of retail pharmacies under non-exclusive contracts with us and via home delivery from Express Scripts Pharmacy and specialty pharmacies, including Accredo.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Department of Defense ("DoD") TRICARE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Pharmacy Program is the military health care program serving active-duty service customers, National Guard and Reserve customers and retirees, as well as their dependents. We provide online claims adjudication, home delivery services, specialty pharmacy clinical services, enhanced specialty care and care coordination capabilities, claims processing and contact center support and other services critical to managing pharmacy trend. Our seven-year pharmacy program contract is through 2029. Beginning March 1, 2024, the DoD has agreed to expand TRICARE Home Delivery to include specialty pharmacy services through Accredo. Revenues from this contract are significant to the segment.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Express Scripts and Prime Therapeutics LLC ("Prime") have an agreement to deliver improved choice and affordability for Prime's clients and their customers by enhancing retail pharmacy networks and pharmaceutical manufacturer value through 2025. The agreement was expanded to include the option for Prime's plans to access the Accredo specialty pharmacy and Express Scripts home delivery pharmacies through 2025. Revenues from these contracts are significant to the segment.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Effective January 1, 2024, Express Scripts and Centene Corporation ("Centene") have a multi-year agreement to manage pharmacy benefit services for Centene's approximately 20 million customers. Centene customers will also have access to Express Scripts' extensive national network of retail pharmacies. Revenues from these contracts are expected to be significant to the segment.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Competition</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The health care industry has undergone periods of substantial consolidation and may continue to consolidate in the future. Many of the largest managed care organizations now also own health services businesses that compete with Evernorth Health Services in the verticals in which we participate. We believe the primary competitive factors in the industry include the ability to: negotiate with retail pharmacies to ensure our retail pharmacy networks meet the needs of our clients and customers; provide home delivery and specialty pharmacy services; negotiate discounts and rebates on prescription drugs with drug manufacturers; specialize in claim adjudication and benefit administration; navigate the complexities of government-reimbursed business including Medicare, Medicaid and the public exchanges; manage cost and quality of specialty drugs; and use the information we obtain about drug utilization patterns and consumer behavior to reduce costs for our clients and customers and assess the level of service we provide. We believe our focus on improving the health and vitality of those we serve will allow us to further differentiate ourselves from our primary competitors shown in the chart above.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Suppliers</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We maintain an inventory of brand-name and generic pharmaceuticals in our home delivery pharmacies, specialty pharmacies and specialty distributor. Our specialty pharmacies and specialty distributor also carry biopharmaceutical products to meet the needs of our customers, including pharmaceuticals for the treatment of rare or chronic diseases; if a drug is not in our inventory, we can generally obtain it from a supplier within a reasonable amount of time.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We purchase pharmaceuticals either directly from manufacturers or through authorized wholesalers. Evernorth Health Services uses one wholesaler for approximately half of our pharmaceutical purchases, but holds contracts with other wholesalers if needs for an alternate source arise. Generic pharmaceuticals are generally purchased directly from manufacturers.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Growth Strategy</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Evernorth Heath Services' strategy is to continue to create value for our clients by leveraging innovation from across our business and assets to drive affordability, while improving access, service and quality. We relentlessly innovate to make the prediction, prevention and treatment of disease more accessible to millions of people.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our growth platform includes our foundational businesses of Pharmacy Benefits and Home Delivery Pharmacy and our accelerated growth businesses of Specialty Pharmacy, Specialty Distribution and Care Delivery and Management Solutions. As we look to 2024, we will leverage our strong foundation and continue to capitalize on opportunities including: expanding our markets by evolving our </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">service offerings to meet changing customer demands, including focusing on our Care Solutions businesses; increasing transparency and predictability; delivering on biosimilar opportunities; driving improved enterprise affordability initiatives value; investing in our business, infrastructure and people to drive enterprise growth; and continuing to build on our new relationship with Centene.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Cross-enterprise Leverage with Cigna Healthcare</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Evernorth Health Services' offerings continue to be cross-leveraged within Cigna Healthcare solutions, helping broaden our presence in the total health care delivery system, further reducing the total cost of care for clients and customers. See "Cross-enterprise Leverage" section within Item 1. Business - Overview for further information.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Key Transactions and Business Developments</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See the "Executive Overview - Key Transactions and Business Developments" section of our MD&amp;A located in Part II, Item 7 of this Form 10-K for discussion of key developments impacting this segment.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_952"></div><div><span id="i6923600e8c954343a7d87d0c97d6c8bb_52232"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">CIGNA HEALTHCARE</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.012%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cigna Healthcare includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical plan services and coordinated solutions to clients and customers. During the fourth quarter of 2023, the U.S. Commercial and U.S. Government operating segments merged to form the U.S. Healthcare operating segment. Within Cigna Healthcare, U.S. Employer and International Health are foundational growth businesses. In 2023, Cigna Healthcare reported adjusted revenues of $51.2 billion and pre-tax adjusted income from operations of $4.5 billion.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2024, the Company entered into a definitive agreement to sell the Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits and CareAllies businesses within the U.S. Healthcare operating segment to HCSC for $3.3 billion cash, subject to applicable regulatory approvals and other customary closing conditions.</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.318%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">How We Deliver</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.5pt">Clinical programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> to support the highest-quality health outcomes and customer experiences.</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.5pt">Partnership with high-performing providers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, emphasizing value over volume of services.</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.5pt">Differentiated approach </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to understanding clients and responding to evolving workforce needs to improve employee productivity and drive more consistent performance.</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.5pt">Technology and data analytics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> powering actionable insights and promoting solutions to improve health and vitality with greater precision and personalization.</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.5pt">Innovative integrated benefit solutions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> that deliver value for our customers, clients and partners.</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.5pt">Talented, experienced and caring</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> team members who work as consultative partners in aligning client and customer needs to our solutions and putting those we serve at the center of all we do.</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We offer a mix of administrative services only and medical insurance solutions to employers, groups and individuals along with specialty benefits and solutions to improve the quality of care, lower costs and help customers achieve better health outcomes. Many of these solutions are available on a stand-alone basis, but we believe additional value and savings are created when they are integrated with a Cigna Healthcare-administered health plan.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following chart depicts a high-level summary of our principal products and services in this segment, with definitions on subsequent pages.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.927%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.291%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Products &amp; Services</span></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Major Brand(s)</span></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Geography</span></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Funding Solution(s)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Primary Distribution Channel(s)</span></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Primary Competitors</span></td></tr><tr><td colspan="18" style="background-color:#dbdbdb;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">U.S. Healthcare Plans</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employer Medical Plans (including Consumer-Driven Products)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cigna Healthcare</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nationwide</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASO, GC, ER</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brokers, Private Exchanges, Direct</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">National Insurers, Local Healthplans, Third-Party Administrators ("TPAs")</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Individual and Family Plans</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cigna Healthcare</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 states </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GC</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Public Exchanges, Brokers, Direct</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">National Insurers,<br/>Local Healthplans, <br/>Provider-led Plans</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medicare Advantage Plans</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cigna Healthcare</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 states </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> &amp; District of Columbia</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GC</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Direct, Brokers</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">National Insurers,<br/>Local Healthplans,<br/>Provider-led Plans</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medicare Stand-Alone Prescription Drug Plans</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cigna Healthcare, Express Scripts</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nationwide</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASO, GC</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Direct, Brokers</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">National Insurers</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medicare Supplement Plans</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cigna Healthcare</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48 states </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> &amp; District of Columbia</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GC</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brokers, Direct, Private Exchanges</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">National Insurers</span></td></tr><tr><td colspan="18" style="background-color:#dbdbdb;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">U.S. Healthcare Specialty Benefits and Solutions</span></div></td></tr><tr style="height:32pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Behavioral Health</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cigna Healthcare</span></td><td colspan="3" rowspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nationwide</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASO, GC, ER</span></td><td colspan="3" rowspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brokers, Direct</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">National Insurers, <br/>Specialty Companies</span></td></tr><tr style="height:32pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consumer Health Engagement</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cigna Healthcare</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASO, GC, ER</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">National Insurers, <br/>Specialty Companies</span></td></tr><tr style="height:32pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost Containment</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cigna Healthcare</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASO, GC, ER</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">National Insurers, <br/>Specialty Companies</span></td></tr><tr style="height:32pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dental</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cigna Dental Care&#174;</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASO, GC, ER</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dental Insurers, <br/>National Insurers</span></td></tr><tr style="height:32pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pharmacy Management</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cigna Healthcare</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASO, GC, ER</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Independent PBMs, <br/>Managed Care PBMs</span></td></tr><tr style="height:32pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stop-Loss</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cigna Healthcare</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GC</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">National Insurers, <br/>Specialty Companies</span></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt;position:relative;top:-2.8pt;vertical-align:baseline">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Our three funding solutions include administrative services only ("ASO"), insured - guaranteed cost ("GC") and insured - experience-rated ("ER") arrangements.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt;position:relative;top:-2.8pt;vertical-align:baseline">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">AZ, CO, FL, GA, IL, IN, MS, NC, PA, SC, TN, TX, UT &amp; VA.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">AL, AR, AZ, CO, CT, DE, FL, GA, IL, KS, KY, MD, MO, MS, NC, NJ, NM, NY, OH, OK, OR, PA, SC, TN, TX, UT, VA, VT &amp; WA. Effective January 1, 2024, also includes NV.</span></div><div style="margin-bottom:10pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">All states except MA &amp; NY.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.927%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.291%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Products &amp; Services</span></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Major Brand(s)</span></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Geography</span></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Funding Solution(s)</span></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Primary Distribution Channel(s)</span></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Primary Competitors</span></td></tr><tr><td colspan="18" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-right:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">International Health Products and Services</span></td></tr><tr style="height:50pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Global Health Care</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cigna Global Health Benefits, Cigna Global Individual Health</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Worldwide (except as limited by applicable law)</span></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASO, GC, ER</span></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brokers, Direct</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Global insurers</span></td></tr><tr style="height:44pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Local Health Care</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cigna Healthcare, ManipalCigna, CignaCMB</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China, Middle East, Singapore, Hong Kong, Spain, India</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Global insurers and local non-U.S. insurers</span></td></tr></table></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Principal Products &amp; Services</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">U.S. Healthcare Plans</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Employer Medical Plans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> include Health Maintenance Organizations ("HMOs"), LocalPlus&#174;, Network and Open Access Plus, and are offered through our insurance companies, HMOs and TPAs. These plans use cost-sharing incentives to encourage the use of "in-network" rather than "out-of-network" health care providers. In addition, Preferred Provider Organization ("PPO") plan offerings feature broader provider access than the other plans, do not require referrals and typically have a higher cost share if a customer seeks care with an out-of-network provider.</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Consumer-Driven Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> are paired with employer medical plans and offer customers a tax-advantaged way to pay for eligible health care expenses. These products, consisting of health savings accounts, health reimbursement accounts and flexible spending accounts, encourage customers to play an active role in managing their health and health care costs.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Individual and Family Plans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> are Patient Protection and Affordable Care Act ("ACA") compliant exclusive provider organizations ("EPO") or HMO plans marketed to individuals under age 65 who do not have access to health care coverage through an employer or government program such as Medicare or Medicaid. Customers receive comprehensive health care benefits and have access to a local network of health care providers who have been selected with cost and quality in mind.</span></div><div><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;text-decoration:underline">Held for Sale</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Medicare Advantage Plans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> allow Medicare-eligible customers to receive health care benefits, including prescription drugs, through a managed care health plan. Our plans include HMO and PPO plans marketed to individuals and qualified employer groups. A significant portion of our Medicare Advantage customers receive medical care from our value-based models that focus on developing highly-engaged physician networks, aligning payment incentives to improve health outcomes and using timely and transparent data sharing.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Medicare Stand-Alone Prescription Drug ("Part D") Plans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> provide a number of prescription drug plan options, as well as service and information support to Medicare-eligible individuals or individuals through a qualified employer group waiver plan. Our stand-alone plans offer the coverage of Medicare combined with the flexibility to select a product that provides enhanced benefits and a formulary that aligns with the individual's needs. Eligible customers benefit from broad network access and enhanced service intended to promote adherence to treatment plans, wellness and affordability.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Medicare Supplement Plans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> provide Medicare-eligible customers with federally standardized Medigap plans. Customers may select among the various plans to meet their unique needs and may visit any health care provider or facility that accepts Medicare throughout the United States without the need for a referral.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">U.S. Healthcare Specialty Benefits and Solutions</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Behavioral Health</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> solutions consist of a broad national network of behavioral health providers that includes one of the largest virtual networks in the United States, behavioral health specialty case and utilization management, a crisis intervention phone line accessible anytime, employee assistance programs and work/life programs. We integrate our programs and solutions with medical and pharmacy programs to facilitate customized, holistic care as well as to provide resources that increase resiliency and address non-medical factors that affect the overall well-being of our customers.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Consumer Health Engagement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> solutions are offered to customers covered under plans administered by Cigna Healthcare or by third-party administrators and consist of an array of health management, disease management and wellness programs. Our Medical Management programs include case, specialty and utilization management and a 24/7 Health Information phone line which ensures around-the-clock access to a medical professional. Our Health Advocacy program includes early intervention in the treatment of chronic conditions and an array of health and wellness coaching. We administer incentives programs designed to encourage customers to engage in health improvement activities.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Cost Containment Programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> are designed to contain the cost of covered health care services and supplies. These programs reduce out-of-network utilization and costs, protect customers from balance billing and educate customers regarding the availability of lower cost in-network services. In addition, we negotiate discounts with out-of-network providers, review provider bills and recover overpayments. We charge fees for providing or arranging for these services. These programs may be administered by third-party vendors that have contracted with Cigna Healthcare.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Dental</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> solutions include HMO plans, PPO plans, exclusive provider organization plans, traditional indemnity plans and a discount program. Employers and other groups may purchase our products on either an insured or self-insured basis and as stand-alone products or in conjunction with medical products. Additionally, individual customers may purchase insured dental PPO plans as stand-alone products or in conjunction with individual medical policies. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Pharmacy Management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> solutions and benefits may be combined with our medical and behavioral health offerings. We offer a comprehensive suite of pharmacy management products and services to our clients and customers, leveraging the capabilities of Evernorth Health Services.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Stop-Loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> insurance coverage is offered to self-insured clients whose group health plans are administered by Cigna Healthcare. Stop-loss insurance provides reimbursement for claims in excess of a predetermined amount for individuals, the entire group, or both.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">International Health</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Global Health Care</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> offerings include insurance and administrative services for medical, dental, pharmacy, vision and life, accidental death and dismemberment and disability risks. We are a leading provider of products and services that meet the needs of multinational employers, intergovernmental and nongovernmental organizations and globally mobile individuals with a focus on keeping employees healthy and productive.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Local Health Care</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> offerings include medical, dental, pharmacy and vision as well as life coverage. Customers include employers and individuals located in specific countries where the products and services are purchased.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Premiums and Fees</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">ASO.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Plan sponsors (i.e., employers, unions and other groups) create self-funded group health plans to fund all claims, but may purchase stop-loss insurance to limit exposure. We collect fees from ASO clients for providing access to our participating provider networks and for solutions supporting cost-effective benefit management including: claims administration, behavioral health solutions, disease management, utilization management, cost containment, and dental and pharmacy benefit management. Approximately 76% of our U.S. Healthcare medical customers are in ASO arrangements.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Insured.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">GC and ER.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In most states, individual and group insurance premium rates must be approved by the applicable state regulatory agency (typically a department of insurance). State or federal laws may restrict or limit the use of rating methods. Premium rates are established at the beginning of a policy period and, depending on group size, may be based in whole or in part on prior experience of the policyholder or on a pool of similar policyholders. With the exception of ER policies, we generally cannot adjust premium rates to reflect actual claim experience until the next policy period; the policyholder does not participate, or share in, actual claim experience, and we retain any surplus or margin if costs are less than the premium charged (subject to minimum medical loss ratio ("MLR") rebate requirements discussed below). For all insured arrangements, we bear the risk for actual costs in excess of the premium charged. Approximately 24% of our U.S. Healthcare medical customers are in insured arrangements.</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For Medicare Advantage plans, we receive fixed monthly payments from CMS for each plan customer based on customer demographic data and actual customer health risk factors compared to the broader Medicare population. Premiums may be received from customers when our plan premium exceeds the revenue received from CMS. We also may earn additional revenue from CMS related to quality performance measures (known as "Star Ratings"). </span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The ACA subjects individual and small group policy rate increases above an identified threshold to review by the United States Department of Health and Human Services ("HHS"). Our U.S. Healthcare medical plans are subject to minimum MLR requirements. The MLR represents the percentage of premiums used to pay claims and expenses for activities that improve the quality of care. If we do not satisfy the prescribed MLR, statutes require premium refunds to policyholders or to CMS.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="margin-bottom:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See the "Business - Regulation" section of this Form 10-K for additional information about premiums, MLR requirements, Star Ratings and risk adjustment programs of the ACA.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Market Segments</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">U.S. Healthcare</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> comprises the following market segments:</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">National.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Employers with 3,000 or more eligible employees, primarily through ASO funding solutions.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Middle Market.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Employers generally with 500 to 2,999 eligible employees, solutions for third-party payers, Taft-Hartley plans, as well as other groups, through ASO and insured funding solutions.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Select.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Employers generally with 51 to 499 eligible employees, primarily through ASO with stop-loss insurance coverage and insured funding solutions.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Small.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Employers generally with 2 to 50 eligible employees. We offer GC funding solutions in select geographies with our Cigna + Oscar product.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Individual and Family Plans.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Includes GC, medical ACA-compliant plans on and off the public exchanges for individuals primarily under age 65 who do not have access to health care coverage through an employer or government program such as Medicare or Medicaid. We also offer individual dental plans to customers of all ages across various distribution channels.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt;text-decoration:underline">Medicare Advantage.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Includes individuals who are Medicare-eligible customers, as well as employer group sponsored post-65 retirees. We receive Medicare Advantage revenue from CMS based on customer demographic data and health risk factors. Revenues from CMS are significant to the market segment. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">International Health</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">comprises market segments offering international plans to multinational employers and globally mobile individuals, and domestic plans to employers and individuals in specific countries outside of the United States. Employer plans in the International Health segment may be ASO or fully insured plans.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Clients and Customers</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We provide clients and customers with access to a mix of medical and specialty benefits and solutions.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Clients.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Our clients include employers, third-party administrators, union-sponsored benefit plans, government health programs and other groups.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Customers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Our customers include individuals who access our offerings through an employer-sponsored plan, government-sponsored plan, or other insured group.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Primary Distribution Channels</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Brokers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Sales representatives distribute our products and solutions to a broad group of insurance brokers and consultants.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Direct.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Cigna Healthcare sales representatives distribute our products and solutions directly to employers, unions and other groups or individuals. Various products may also be sold directly to insurance companies, HMOs and third-party administrators. Direct distribution may take the form of in-person contact, telephone or group selling venues, or online direct to consumer enrollment platforms.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Private Exchanges.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We partner with select companies that have created private exchanges where individuals and organizations can acquire health insurance. We evaluate private exchange participation opportunities as they emerge in the market and target our participation to those models that best align with our mission and value proposition.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Public Exchanges.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Cigna Healthcare offers individual ACA-compliant policies through public health insurance exchanges in select geographies.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Competition</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The primary competitive factors affecting our business are quality of care and cost effectiveness of service and provider networks, effectiveness of medical care management, products that meet the needs of employers and their employees, total cost management, technology and effectiveness of marketing and sales. Financial strength, as indicated by ratings issued by nationally recognized rating agencies, is also a competitive factor. Our health advocacy capabilities, holistic approach to consumer engagement, breadth of product offerings, clinical care and health management capabilities along with an array of product funding solutions are competitive advantages. We believe our focus on improving the health and vitality of those we serve will allow us to further differentiate ourselves from our primary competitors shown in the chart above.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Growth Strategy</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cigna Healthcare's strategy is to engage customers in their health, partner with providers to help them improve their performance and connect customers and providers through aligned health goals, incentives and actionable information. This enables informed decisions and drives better outcomes. Fueled by advanced insights and predictive analytics, Cigna Healthcare continues to develop targeted, innovative solutions that span the health care delivery system and can be applied to a multitude of providers. 2024 priorities include continued development of integrated, digital-first, data-driven programs and capabilities to drive affordability and improve clinical outcomes by promoting the highest value care choices to our customer base while improving customer experience.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Arrangements enabling Cigna Healthcare to deliver growth and cross-enterprise leverage to the enterprise are described below. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Participating provider network.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We provide our customers with an extensive national network of participating health care providers, hospitals and other facilities, pharmacies and providers of health care services and supplies. In addition, we have strategic alliances with several regional managed care organizations to gain access to their provider networks and discounts.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Provider partnerships.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We enter into a variety of provider partnerships to continuously improve the quality of care for those we serve.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Accountable Care Program.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We have more than 200 collaborative care arrangements with primary care groups and have been a pioneer in the transition from fee-for-service to value-based payment arrangements with providers. Our flagship program is the Cigna Collaborative Accountable Care program ("CAC"). The program rewards providers for improving </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">quality outcomes as well as improving medical cost performance. The quality model also includes elements related to health disparities and social determinants of health.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Specialist Programs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We have more than 100 arrangements with specialist groups in value-based reimbursement arrangements across six different disciplines. Arrangements include incentives for enhanced care coordination and episodes of care reimbursements for meeting cost and quality goals. These programs include prospective bundled payment arrangements beginning with orthopedics.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Hospital Quality Program.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We have contracts with more than 200 hospital systems, involving more than 800 hospitals, with reimbursements tied to quality metrics.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Independent Practice Associations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We have value-based physician engagement models in our Medicare Advantage plans that allow physician groups to share financial outcomes with us. This clinical model also includes outreach to new and at-risk patients to ensure they are accessing their primary care physician.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Site of care optimization.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We encourage the use of clinically appropriate settings to reduce the cost of care through our clinical programs and partnership with eviCore. This results in significant cost savings while ensuring high quality care and service. Additionally, we provide access to MDLIVE virtual care services as a way to reduce the cost of care while supporting the patient/provider relationship, and we provide flexibility for customers to access MDLIVE&#8217;s network of virtual care providers for preventative and routine primary care and wellness, urgent care, dermatology care, behavioral health care needs and chronic condition management.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Cross-enterprise leverage with Evernorth Health Services.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We continue to expand the breadth and depth of the Evernorth Health Services pharmacy benefit services and specialty and care services available to Cigna Healthcare clients and customers to deliver value by improving affordability, access, quality of care, care innovations and transparency. See "Cross-enterprise Leverage" section within Item 1. Business - Overview for further information.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Key Transactions and Business Developments</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See the "Executive Overview - Key Transactions and Business Developments" section of our MD&amp;A located in Part II, Item 7 of this Form 10-K for discussion of key developments impacting this segment.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_955"></div><div><span id="i14ebdeddcc6b4fc08345239257f65694_6445"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">OTHER OPERATIONS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.012%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other Operations comprises the remainder of our business operations, which includes certain ongoing businesses and exited businesses. Our ongoing businesses include our continuing business, COLI, as described below, as well as our run-off businesses. Our run-off businesses include (i) variable annuity reinsurance business (formerly referred to as GMDB and GMIB business) that were effectively exited through reinsurance with Berkshire Hathaway Life Insurance Company of Nebraska in 2013, (ii) settlement annuity business, and (iii) individual life insurance and annuity and retirement benefits businesses which were sold through reinsurance agreements. Our exited businesses include the international life, accident and supplemental benefits businesses sold in July 2022 and our interest in a joint venture in T&#252;rkiye sold in December 2022. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2023, Other Operations reported adjusted revenues of $0.6 billion and pre-tax adjusted income from operations of $96 million. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Ongoing Businesses</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;text-decoration:underline">Continuing Business</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Corporate-Owned Life Insurance</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The principal products of the COLI business are permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations. Permanent life insurance provides coverage that, when adequately funded, does not expire after a term of years. The contracts are primarily non-participating universal life policies. Fees for universal life insurance products consist primarily of mortality and administrative charges assessed against the policyholder's fund balance. Interest credited and mortality charges for universal life and mortality charges on variable universal life may be adjusted prospectively to reflect expected interest and mortality experience. To reduce our exposure to large individual losses, we purchase reinsurance from unaffiliated reinsurers.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;text-decoration:underline">Run-off Businesses</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Settlement Annuity Business</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our settlement annuity business is a closed, run-off block of single premium annuity contracts. These contracts are primarily liability settlements with approximately 13% of the liabilities associated with guaranteed payments not contingent on survivorship. Non-guaranteed payments are contingent on the survival of one or more parties involved in the settlement.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Reinsurance</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our reinsurance operations are an inactive business in run-off. In February 2013, we effectively exited the variable annuity reinsurance business (formerly referred to as GMDB and GMIB business) by reinsuring 100% of our future exposures, net of retrocessional arrangements in place at that time, up to a specified limit. For additional information regarding this reinsurance transaction and the arrangements that secure our reinsurance recoverables, see Note 11 to the Consolidated Financial Statements.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Individual Life Insurance and Annuity and Retirement Benefits Businesses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The individual life insurance and annuity business and the retirement benefits business were sold through reinsurance agreements in 1998 and 2004, respectively. For more information regarding the arrangements that secure our reinsurance recoverables for the retirement benefits business, see Note 11 to the Consolidated Financial Statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exited Businesses</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">International Life Accident and Supplemental Benefits and Our Interest in a Joint Venture in T&#252;rkiye</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We offered life, accident and supplemental benefits insurance products and services in Hong Kong, Indonesia, New Zealand, South Korea, Taiwan and Thailand until completion of the sale of these businesses in July 2022 to Chubb INA Holdings, Inc. ("Chubb"). South Korea represented our single largest geographic market for these businesses. In December 2022, we divested our ownership interest in Cigna Sa&#287;l&#305;k Hayat ve Emeklilik, our joint venture in T&#252;rkiye, to our long-time partner QNB Finansbank.</span></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_973"></div><div><span id="i6e56356b8fca45ccb152091309221429_284"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">MISCELLANEOUS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.012%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Revenues from U.S. Federal Government agencies, under a number of contracts, represented 15% of our consolidated revenues in 2023 and 14% in both 2022 and 2021. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The Company does not rely on business from one or a few brokers or agents. </span></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_958"></div><div><span id="ie7303381559e4a9c9189a5c1ff667459_2970"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">INVESTMENT MANAGEMENT</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.012%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our investment operations provide investment management and related services for our various businesses, including the insurance-related invested assets in our General Account ("General Account Invested Assets"). We acquire or originate, directly or through intermediaries, a broad range of investments, including private placement and public securities, commercial mortgage loans, real estate, mezzanine debt, private equity partnerships and short-term investments. Invested assets also include policy loans that are fully collateralized by insurance policy cash values. We also enter into derivative financial instruments, primarily to minimize the risk of changes in foreign currency exchange rates on our investments and to manage the interest rate exposures of our long-term debt. Invested assets are managed primarily by our subsidiaries and, to a lesser extent, external managers with whom our subsidiaries contract. Net investment income is included as a component of adjusted income from operations for each of our segments and Corporate. Realized investment gains (losses) are reported by segment but excluded from adjusted income from operations. For additional information about invested assets, see the "Investment Assets" section of the MD&amp;A and Notes 12 and 13 to the Consolidated Financial Statements.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We manage our investment portfolios to reflect the underlying characteristics of related insurance and contractholder liabilities and capital requirements, as well as regulatory and tax considerations pertaining to those liabilities and state investment laws. Insurance and contractholder liabilities range from short-duration health care products to longer-term obligations associated with corporate-owned life insurance products and the run-off settlement annuity business. Assets supporting these liabilities are managed in segregated investment portfolios to facilitate matching of asset durations and cash flows to those of corresponding liabilities. Investment results are affected by the amount and timing of cash available for investment, economic and market conditions and asset allocation decisions. We routinely monitor and evaluate the status of our investments, obtaining and analyzing relevant investment-</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">specific information and assessing current economic conditions, trends in capital markets and other factors such as industry sector, geographic and property-specific information.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Separate Accounts</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our subsidiaries or external advisors manage invested assets of separate accounts on behalf of contractholders, including The Cigna Group Pension Plan, variable universal life products sold through our corporate-owned life insurance products and the run-off businesses. These assets are legally segregated from our other businesses and are not included in General Account Invested Assets. Income, gains and losses generally accrue directly to the contractholders.</span></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_961"></div><div><span id="i6a8d41e805c940a1bad00d0ec0b5ed3b_3852"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">STRATEGIC INVESTMENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.012%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The Cigna Group Ventures. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the portfolio investments in our general and separate accounts discussed in the Investment Management section above that support our insurance operations, we make targeted investments within the health care industry, specifically. The Cigna Group has committed $700 million in aggregate since the formation of The Cigna Group Ventures, our strategic corporate venture fund which invests in promising startups and growth-stage companies who, like us, are unlocking new growth possibilities in health care. We invest in companies making groundbreaking progress in three strategic areas: insights and analytics, digital health and experience, and care delivery and enablement. As of December&#160;31, 2023, The Cigna Group Ventures has approximately 10 venture capital partners and 25 existing direct investments. Through these deep partnerships we collaborate, innovate and develop new solutions that address critical challenges of health and vitality impacting the people we serve. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">VillageMD. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2023, we became a minority owner in VillageMD by investing $2.7 billion in VillageMD preferred equity. VillageMD (majority-owned by Walgreens Boots Alliance, Inc.) provides health care services for individuals and communities across the United States, with primary, multi-specialty and urgent care providers serving patients in traditional clinic settings, in patients' homes and online appointments. VillageMD and its subsidiaries operate in 26 markets and are responsible for millions of patients. See Note 12 to the Consolidated Financial Statements for further discussion of this investment. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">CarepathRx Health Systems Solutions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In 2023, we acquired a minority interest in CarepathRx Health Systems Solutions. See Note 5 to the Consolidated Financial Statements for further discussion of this investment.</span></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_964"></div><div><span id="iafed691a75e448f69b474b4d40249d5c_12405"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">DIGITAL, DATA AND TECHNOLOGY</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.012%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Cigna Group's investments in digital, data and technology are focused on cultivating robust digital-first capabilities to better engage with customers and stakeholders. We deliver value for our clients, customers and other stakeholders by creating better health outcomes, improving customer experience and lowering total cost of care.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Innovation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Customer-centric, digital-first, virtual-led vision for health care remains at the forefront of our priorities. The advancement of our internal innovative capabilities and strategic partnerships continues to produce new and more effective ways to engage with our customers to help close gaps in care, optimize treatment and improve outcomes. During 2023, the Technology team continued to deliver value for current business while simultaneously focusing on reducing complexity and cost within our technology ecosystem. As we continue to simplify our technology ecosystem, we expect an increase in digital advancements, customer engagement, loyalty and speed to market. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2023, The Cigna Group continued to invest in our technology capabilities to produce new and more effective ways to operate, as well as meet customers where they are. We intend to lead with digital engagement by creating connections between points of care and guiding customers through the best mechanism to the optimal location and provider. Our modernized data and technology ecosystem will enable us to integrate our assets, gather insights and engage with prospects and customers in new ways. For the year ended December&#160;31, 2023, our capital expenditures for property, equipment and computer software were $1.6 billion. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Cigna Group continued to transform and improve the way health care is delivered through automation, advanced analytics and Artificial Intelligence (&#8220;AI&#8221;) technologies. We utilize these technologies today to analyze data and uncover patterns and insights to help improve outcomes, increase connectivity between the patient and the health care system, speed up administrative processes, and improve the overall member experience. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Cigna Group continued to accelerate the pace of development and innovation through our new AI Center of Enablement ("COE"). Our AI COE focuses on Generative AI ("Gen AI"), and assesses and governs guardrails, systemic controls, and processes to provide oversight to ensure the responsible use of Gen AI practices. These commitments are intended to ensure our Gen AI capabilities and </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">solutions are ethical, defensible, and in compliance with health care privacy and security requirements. With these strict practices and protocols in place, we anticipate rapidly adapting and capitalizing on new opportunities in an increasingly competitive and fast-changing digital landscape. Exploring and implementing new and emerging technology opportunities enables us to improve efficiency via automation, reduce costs and enhance overall decision-making, all while providing real-time, personalized and connected experiences for our customers, patients, clients and provider partners.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Data and Analytics. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our rich, integrated data allows us to provide differentiated outcomes. We conduct timely, rigorous and objective research and analysis that informs evidence-based medical and pharmacy benefit management and evaluates the clinical, economic and individual impact of enhanced benefit designs and programs. The combination of our predictive analytics, as well as our machine and deep learning capabilities create actionable intelligence that informs decision-making of our health care professionals. Our data-driven approach to behavioral health provides personalized and customized care across the entire continuum for the populations we serve. These solutions predict emerging health needs, close gaps in care and drive cost savings - all while empowering whole-person and whole-family health.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During 2023, we continued to leverage both internal and external data to identify and address health disparities and better understand the long-term medical and behavioral complications facing our customers. The data-informed approach allows for delivery of solutions with a digital-first entry point that meet our customers where they are to offer physical and behavioral health support.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Digital. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our digital health focus has shown value across the enterprise by imagining the future of health care and creating engaging experiences that give customers the right information at the right time. We continue to bring new and reusable technology-enabled products and services to the market, expanding on a platform that connects to a given benefit structure in a single personalized environment. This allows for further capitalization on our unique data and enables the design of innovative digital solutions that improve health care experiences and provide more affordable health care for all. Cybersecurity protections continue to be a top priority across The Cigna Group's digital offerings to further strengthen our security posture and grow the trust of those we serve. See Part 1. Item C - Cybersecurity of this Form 10-K for additional information regarding our cybersecurity practices and governance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Technology Operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Technology team, powered by approximately 9,500 employees and several thousand external resources collaborating with our partners, supports the various information systems essential to our operations, including the health benefit claims processing systems and specialty and home delivery pharmacy systems. Uninterrupted point-of-sale electronic retail pharmacy claims processing is a significant operational requirement for our business. We believe we have substantial capacity for growth in our United States pharmacy claims processing facilities. Our pharmacy technology platform allows us to safely, rapidly and accurately adjudicate over one billion adjusted prescriptions annually. Our technology helps retail pharmacies focus on patient care and our real-time safety checks help avoid medication errors. The Cigna Group companies hold over 400 United States patents. We use these patents to protect our proprietary technological advances and to differentiate ourselves in the market.</span></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_967"></div><div><span id="i8fe7d11af2fb4df7ad4b3d13a3366562_10277"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">HUMAN CAPITAL MANAGEMENT</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.012%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Cigna Group's mission is to improve the health and vitality of those we serve. A global healthy and diverse workforce is essential to achieving our mission and our business growth strategies. We are continually investing in our global workforce to support our employees' health and well-being, further drive diversity and inclusion, provide fair and market-competitive pay and foster employee growth and development. As of the end of 2023, we had approximately 72,500 employees, with approximately 93% of our employees based in the United States. Approximately 97% of our employees are full-time.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%">Health, Well-Being and Other Benefits</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tending to our employees' health and vitality is a critical business imperative for our company and one of the most important investments in our enterprise that we make each year. We believe that when we support our employees' health and well-being, they are more productive and engaged in driving our mission and business strategy forward, thereby creating shareholder value. In 2023, The Cigna Group invested approximately 18% of total payroll in health, well-being and other benefits, including life and disability programs, 401(k) contributions and retirement-related benefits for our employees in the United States.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to traditional medical and pharmacy benefits, we provide multi-dimensional wellness programming to support the physical, mental, financial, and social health, as well as overall vitality of employees, including: nutrition and fitness programs, employee assistance program (EAP) benefits that are free to all employees and to all members of their household, and digital tools that provide access to education and therapy to help individuals build greater resilience and cope with stress, anxiety and depression.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%">Diversity, Equity &amp; Inclusion</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At The Cigna Group, we take an expansive view of diversity including race, ethnicity, nationality, gender, veteran status, disability, sexual orientation and gender identity. As of the end of 2023, based on employee self-reporting, approximately 71% of our employees were women, and approximately 41% of our employees in the United States were ethnic minorities (which includes Black / African American, Asian, Hispanic or Latino/a, Pacific Islander and American Indian / Alaskan employees). </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are committed to attracting and recruiting key diverse talent into various leadership development programs and other entry level positions across the business. This success is rooted in strategic relationships with student groups at our partner colleges and universities, as well as our engagement with multiple national, regional and local organizations, which provide us focused recruiting opportunities with women, the LGBTQ+ community, military veterans and underrepresented minority groups. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our compensation practices, rooted in our pay-for-performance philosophy, promote equity in pay through measures such as benchmarking compensation by role, eliminating inquiries regarding applicants' compensation history from the hiring process and monitoring for potential disparities. Our most recent pay equity analysis among our U.S. employees, conducted in 2024, illustrated that female employees of The Cigna Group earn more than 99 cents for every dollar earned by similarly-situated male employees, and employees from underrepresented groups (which includes Black/African American, Hispanic or Latino/a, Pacific Islander and American Indian/Alaskan employees) earn more than 99 cents for every dollar earned by similarly-situated white employees. We also analyzed gender pay on a global basis and found that across the entire Company female employees at The Cigna Group earn more than 99 cents for every dollar earned by similarly-situated male employees.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Talent Acquisition, Development and Retention</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our talent acquisition and rewards strategies are designed to attract and retain skilled employees who are engaged in our mission. Our compensation program is rooted in market competitive base salaries and incentives that reward contributions that advance the Company's strategy and mission. In 2023, the voluntary turnover rate was approximately 11% for all employees, signaling a return to pre-pandemic levels.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our talent acquisition team is both online and on the ground in communities and at colleges and universities to find and recruit the best and brightest talent. Our top ranked external career website allows candidates to learn about The Cigna Group and search for open positions. We also leverage technology and an omnichannel strategy to create awareness and attract candidates through email, text message, social media, a quarterly newsletter, and one-to-one outreach from our recruiters. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recognize the importance of flexibility in the workplace and provide schedules, tools, and support for employees to balance their work responsibilities with their life outside of work. We also empower our employees to volunteer by offering two distinct benefit programs. The first is volunteer time off, referred to as "Use Your 8," for eligible employees to take eight hours of paid leave annually to volunteer with a nonprofit of their choice. The second is our Community Ambassador Fellowship, a program through which employees apply for up to three months of paid leave to support a specific community-based project.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To further engage and reward employees, we have an employee recognition program called Cigna Standout that allows employees to recognize their colleagues for their contributions to our Company and to celebrate both personal and professional milestones. Every employee is empowered to use this system to recognize colleagues for going above and beyond or simply say thank you.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our online learning platform and career development tools, including a career portal and career planning tool, offer a broad range of training, education and development resources to all employees. In 2023, based on internal data, employees on average engaged in 30 hours of learning through these resources. Enterprise leadership development programs are provided to executive, high-potential and new manager audiences to develop and expand leadership capability across the enterprise. We also offer leadership development programs to recent graduates who seek valuable career experience with The Cigna Group, as well as opportunities for college students to join The Cigna Group for a paid summer internship.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Cigna Group offers an education reimbursement program for both full and part-time employees who meet the continuing education criteria. We believe these strategies and programs contribute to employee engagement and retention. </span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_970"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span id="i2a4cf9cdddeb4eb1b4b5c4f361fe37a3_7829"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ENVIRONMENTAL, SOCIAL AND GOVERNANCE</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.012%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Cigna Group's environmental, social and governance ("ESG") framework is structured around four connected pillars that underscore our enterprise mission to improve the health and vitality of those we serve. We drive action through this framework to deliver on our ESG vision: to transform the ecosystem of health into one that is well-functioning, sustainable, accessible and equitable - advancing better health for all. Our commitment to this vision guides us in our multidimensional value-creation strategy as we strive to meet the needs of our many stakeholders. The four pillars of our ESG framework are:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Healthy Society</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We advance better health for all. Building a well-functioning, sustainable, accessible and equitable health care system requires understanding and addressing social determinants of health and improving medical quality and access while lowering health risks, promoting preventive health interventions and coordinating all aspects of care. We drive progress in each of these areas by aligning our products and services with value-based care models, leveraging integrated benefits, managing drug costs through innovation, expanding digital offerings and reviewing coverage policies for health equity. We also help to eliminate barriers to care and address other factors that contribute to health disparities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Healthy Workforce</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that employers play a vital role in the health care system, and we strive to be a model for others by prioritizing the health and vitality of employees within our own company. A healthy and diverse workforce is essential to achieving our mission, and we continually invest in our employees to support their health and vitality, to foster their growth and development and to further cultivate diversity and inclusion. See further discussion of this pillar within Part I, Item 1 "Human Capital Management" section above. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Healthy Environment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that responsible environmental stewardship can improve health and vitality and also makes sound business sense. We strive to identify new efficiencies and make strategic investments that reduce our environmental impacts and our operating costs. In addition, we see an opportunity to positively impact the environment through ways we are advancing our business, including through our continued investment in virtual care.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Healthy Company</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have a deep and long-held commitment to strong governance as well as ethical and resilient business practices. This includes protecting the sensitive data of our clients and customers by ensuring cybersecurity incident response preparedness, as well as supporting a responsible supply chain and committing to increasing our annual diverse supplier spend.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_976"></div><div><span id="idd9c261be2904000b14f12a85b2f9564_90046"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">REGULATION</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.012%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The laws and regulations governing our business continue to increase each year and are subject to frequent change. We are regulated by federal, state and international legislative bodies and agencies, which generally have discretion to issue regulations and interpret and enforce laws and rules. These regulations can vary significantly from jurisdiction to jurisdiction, and the interpretation of existing laws and rules also may change periodically. Domestic and international governments continue to enact and consider various legislative and regulatory proposals, which could materially impact the health care system. We expect continued legislative and regulatory debate of issues related to our businesses. As has become increasingly common with public policy reforms in the health services industry, executive, judicial or legislative intervention could alter, slow or eliminate the impact of any proposal following the related regulation's promulgation.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many aspects of our business are directly regulated by federal and state laws and administrative agencies, such as HHS, CMS, the Internal Revenue Service ("IRS"), the U.S. Departments of Labor ("DOL") and Treasury, the Office of Personnel Management ("OPM"), the Federal Trade Commission ("FTC"), the SEC, the Office of the National Coordinator for Health Information Technology ("ONC"), state departments of insurance and state boards of pharmacy. Our business practices may also be shaped by enforcement actions of federal agencies, such as the Department of Justice ("DOJ"), state agencies, as well as judicial decisions.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, aspects of our business are subject to indirect regulation. The self-funded benefit plans sponsored by our U.S. employer clients are regulated under federal law. These self-funded clients expect us to ensure that our administration of their plans complies with the regulatory requirements applicable to them.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business operations and the books and records of our regulated businesses are routinely subject to examination and audit at regular intervals by state insurance and HMO regulatory agencies, state boards of pharmacy, CMS, DOL, IRS, OPM and comparable international regulators to assess compliance with applicable laws and regulations. Our operations are also subject to non-routine examinations, audits and investigations by various state and federal regulatory agencies, generally as the result of a complaint. In addition, we may be implicated in investigations of our clients whose group benefit plans we administer on their behalf. As a result, we routinely receive subpoenas and other demands or requests for information from various state insurance and HMO regulatory agencies, state attorneys general, the HHS Office of Inspector General ("HHS-OIG"), the DOJ, the DOL and other state, federal and international authorities. We may also be called upon by members of the U.S. Congress to provide information, including testifying before Congressional committees and subcommittees, regarding certain of our business practices. If The Cigna Group is determined to have failed to comply with applicable laws or regulations, these examinations, audits, investigations, reviews, subpoenas and demands may:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">result in fines, penalties, injunctions, consent orders or other settlement agreements such as corporate integrity agreements or loss of licensure;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">suspend or exclude us from participation in government programs or limit our ability to sell or market our products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">require changes in business practices;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">damage relationships with the agencies that regulate us and affect our ability to secure regulatory approvals necessary for the operation of our business; or</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">damage our brand and reputation.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our international subsidiaries are subject to regulations in international jurisdictions, including in certain cases many regulations similar to the federal and state regulations described below, which are complex and where foreign insurers may face more rigorous regulations than their domestic competitors and may also be affected by geopolitical developments or tensions.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The laws and regulations governing our business, as well as the related interpretations, are subject to frequent change and can be inconsistent or in conflict with each other. Changes in our business environment are likely to continue as elected and appointed officials at the national and state levels continue to propose and enact significant modifications to existing laws and regulations. Even where we believe that we are in compliance with the various laws and regulations, any enforcement actions by federal, state or international government officials alleging non-compliance with these rules and regulations could subject us to penalties or restructuring or reorganization of our business. For a discussion of the risks related to our compliance with these laws and regulations see the Risk Factors section located in Part I, Item 1A of this Form 10-K. Management continues to be actively engaged with regulators and policymakers with respect to legislation and rulemaking.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">COVID-19-related Regulatory Actions</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 11, 2023, the COVID-19 Public Health Emergency ("PHE") declared by the Secretary of HHS ended. Some of the legislative and regulatory flexibilities that the U.S. federal and state governments enacted in response to COVID-19 and its variants which were not affected by the end of the PHE were made permanent or were extended. Other legislative and regulatory flexibilities, such as required coverage of COVID-19 tests without cost sharing and certain Medicare and Medicaid waivers for health care providers, ended on May 11 or were set to expire within a certain period of time after the end of the PHE. The Consolidated Appropriations Act, 2023, also provided that states could restart Medicaid eligibility renewals and terminations for ineligible individuals. As a result, states resumed Medicaid redeterminations for the first time since the PHE began; these redeterminations are anticipated to continue through early spring 2024. While state approaches to redeterminations vary, under the redeterminations, many beneficiaries are no longer eligible for Medicaid. As a result, some of the beneficiaries determined to be ineligible for Medicaid sought or will seek alternate coverage in the individual marketplace.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">The Patient Protection and Affordable Care Act</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Patient Protection and Affordable Care Act ("ACA") mandated broad changes to the U.S. health care system that affect insured and self-insured health benefit plans and pharmacy benefit managers. Our business model is impacted by the ACA, including our relationships with current and future producers and health care providers, products, service providers and technologies. The provisions of the ACA imposed, among other things, certain assessments on health insurers, created health insurance exchanges for individuals and small group employers to purchase insurance coverage and implemented minimum MLRs for our Cigna Healthcare business. Certain states have adopted MLR requirements applicable to our employer businesses that are more stringent than those established by the ACA. Other provisions of the ACA in effect include reduced Medicare Advantage payment rates, the requirement to cover preventive services with no enrollee cost-sharing, banning the use of lifetime and annual limits on the dollar amount of essential health benefits, increasing restrictions on rescinding coverage, extending coverage of dependents up to age 26, restrictions on differential pricing, enforcement mechanisms and rules related to health care fraud and abuse enforcement activities and certain pharmacy benefit transparency requirements. The employer mandate requires employers with 50 or more full-time employees to offer affordable health insurance that provides minimum value (each as defined under the ACA) to full-time employees and their dependents, including </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">children up to age 26, or be subject to penalties based on employer size. The ACA also changed certain tax laws to effectively limit tax deductions for certain employee compensation paid by health insurers. In December 2019, the federal government repealed the non-deductible health insurance industry fee effective for 2021, as well as the enacted but never implemented 40% excise tax on certain employer-sponsored coverage (known as the "Cadillac Tax") and the medical device tax. In 2021, in response to the COVID-19 pandemic, the federal government temporarily expanded eligibility for ACA subsidies to higher-income people who did not otherwise qualify, increased ACA subsidies for lower-income people who already qualify for 2021 and 2022, provided subsidies for individuals who receive unemployment benefits in 2021 and prevented taxpayers who misestimated their income in 2020 from having to repay excess premium tax credits. The Inflation Reduction Act, which was signed into law in August 2022, extended the expanded and increased premium tax credits for individuals enrolled in ACA qualified health plans, through December 31, 2025.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Medicare and Medicaid Regulations</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Through our subsidiaries, we offer individual and group Medicare Advantage, Medicare Prescription Drug and Medicare Supplement products. We also provide Medicare Part D-related products and services to other Medicare Part D sponsors, Medicare Advantage Prescription Drug Plans and employers and clients offering Medicare Part D benefits to Medicare Part D eligible beneficiaries, including those dually eligible for Medicare and Medicaid benefits ("dual-eligible"). As part of our Medicare Advantage and Medicare Part D business, we contract with CMS to provide services to Medicare beneficiaries. We offer dual-eligible products and participate in state Medicaid programs directly or indirectly through our clients who are Medicaid managed care contractors. We also perform certain Medicaid subrogation services and certain delegated services for clients, including utilization management, which are regulated by federal and state laws. Our dual-eligible products are regulated by CMS and state Medicaid agencies audit our performance to determine compliance with contracts and regulations. Our ability to obtain payment (and the determination of the amount of such payments), market to, enroll and retain customers and expand into new service areas is subject to compliance with CMS' numerous and complex regulations and requirements that are frequently modified and subject to administrative discretion, review and enforcement. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CMS evaluates Medicare Advantage plans and Part D plans under its "Star Rating" system. The Star Rating system considers various measures adopted by CMS, including, for example, quality of care, preventive services, chronic illness management, coverage determinations and appeals and customer satisfaction. A plan's Star Rating affects its image in the market and plans that perform very well are able to offer enhanced benefits and market more effectively and for longer periods of time than other plans. Medicare Advantage plans' quality-bonus payments are determined by the Star Rating, with plans receiving a rating of four or more stars eligible for such payments. The Star Rating system is subject to change annually by CMS, which may make it more difficult to achieve and maintain four stars or greater. For example, beginning with Star Ratings for payment year 2024, CMS will place more emphasis on patient experience survey-based measures which could reduce Star Ratings predictability year over year. Additionally, as a result of the COVID-19 pandemic's impact on 2020 care patterns and utilization, CMS finalized rules applying relief to Medicare Advantage and Part D Plan Star Ratings for payment year 2023 by utilizing the higher of the payment year 2023 or 2022 measure level Star Ratings.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CMS provides risk-adjusted premium payments for Medicare Advantage plans based on our customer demographics and medical diagnoses, which may change from period to period based on the underlying health of our customers. Under this model, rates paid to Medicare Advantage plans are based on actuarially determined bids, which include a process whereby our prospective payments are based on our estimated cost of providing standard Medicare-covered benefits to an enrollee with a "national average risk profile." That baseline payment amount is adjusted to reflect the health status of our enrolled membership. Under the risk-adjustment methodology, Medicare Advantage plans must collect and submit the necessary diagnosis code information from hospital inpatient, hospital outpatient and physician providers to CMS within prescribed deadlines. We generally rely on providers to appropriately document their claims and other submissions with appropriate diagnoses from which we extract hierarchical condition codes to submit to CMS as the basis for our payments received under the actuarial risk-adjustment model. The CMS risk-adjustment model uses the diagnosis data to calculate the risk-adjusted premium payment to the plans. These adjustments are generally settled semi-annually with CMS. The final adjustment is generally settled with CMS in the year following the contract year. CMS may conduct audits to validate risk-adjustment data submitted by health plans. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 30, 2023, CMS issued the Final Rule titled "Medicare and Medicaid Programs; Policy and Technical Changes to the Medicare Advantage, Medicare Prescription Drug Benefit, Program for All-inclusive Care for the Elderly ("PACE"), Medicaid Fee-For-Service, and Medicaid Managed Care Programs for Years 2020 and 2021," effective April 3, 2023. The Final Rule addresses CMS's audit methodology and related policies for the Risk Adjustment Data Validation ("RADV"). Although CMS did not specify their sampling or extrapolation methodology the rule did codify that CMS will use a statistically valid method for sampling and extrapolation of error rates and the decision not to apply a fee for service adjuster when determining RADV audit findings. CMS will not apply extrapolation to RADV audits until the 2018 payment year with payment recoveries for those RADV audits expected in 2025. Audits for payment years prior to 2018 are not subject to extrapolation. RADV audits for our contract years 2011 through 2015 are currently awaiting CMS finalization. The Company is not currently subject to RADV audits for the 2018 and subsequent payment years. The Final Rule is currently being challenged in federal district court.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Coverage of prescription drugs under Medicare Part D is also regulated by CMS and our contracts with CMS contain provisions for risk sharing and certain payments for prescription drug costs for which we are not at risk. These provisions affect our ultimate payments from CMS. For example, premiums from CMS are subject to risk corridor payments that compare costs targeted in our annual bids with actual prescription costs, limited to actual costs that would have been incurred under the standard coverage as defined by CMS. Variances exceeding certain thresholds may result in CMS making additional payments to us or require us to refund to CMS a portion of the payments we received.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect CMS, HHS-OIG, DOJ and other federal agencies to continue to closely scrutinize each component of the Medicare Advantage program and modify the terms and requirements of the program through rulemaking or enforcement activities. The Company continues to believe that further regulation or changes to existing regulations could result in disruption in the marketplace including the potential for some combination of degraded plan benefits and higher monthly premiums. Noncompliance with these laws and regulations may result in significant consequences, including fines and penalties, enrollment sanctions, exclusion from the Medicare and Medicaid programs, limitations on expansion and criminal penalties.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2024, we entered into a definitive agreement to sell the Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits and CareAllies businesses to HCSC for $3.3 billion cash, subject to applicable regulatory approvals and other customary closing conditions.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">False Claims Act and Anti-Kickback Laws</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our products and services are also subject to the federal False Claims Act (the "False Claims Act"), state false claims acts and federal and state anti-kickback laws. Additionally, the federal government has made investigating and prosecuting health care fraud, waste and abuse a priority. Fraud, waste and abuse prohibitions encompass a wide range of activities, including kickbacks in return for customer referrals, billing for unnecessary medical services, upcoding and improper marketing. The regulations and contractual requirements in this area are complex, frequently modified and subject to administrative discretion and judicial interpretation.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">False Claims Act and Related Criminal Provisions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The False Claims Act imposes civil penalties on any person who knowingly, as defined by the statute, makes, conspires to make, or causes to be made false claims, records, or statements, or fails to return known overpayments, in connection with reimbursement by federal government programs such as Medicare and Medicaid. Private individuals have brought and may bring </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> or "whistleblower" suits under the False Claims Act, which authorizes the payment of a portion of any recovery to the individual bringing suit. The ACA amended the federal anti-kickback laws to state any claim submitted to a federal or state health care program that violates the anti-kickback laws is also a false claim under the False Claims Act. The False Claims Act generally provides for the imposition of civil penalties and for treble damages, creating the possibility of substantial financial liabilities. Criminal statutes similar to the False Claims Act provide that if a corporation is convicted of presenting a claim or making a statement it knows to be false, fictitious or fraudulent to any federal agency, the corporation may be fined. Conviction under these statutes may also result in exclusion from participation in federal and state health care programs. Many states have also enacted laws similar to the False Claims Act, some of which may include criminal penalties, substantial fines and treble damages.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Anti-Kickback and Referral Laws.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Subject to certain exceptions and "safe harbors," the federal anti-kickback statute generally prohibits, among other things, knowingly and willfully paying, receiving or offering any payment or other remuneration to induce a person to purchase, lease, order or arrange for items (including prescription drugs) or services reimbursable in whole or in part under Medicare, Medicaid or another federal health care program. Many states have similar laws, some of which are not limited to items or services paid for with government funds. Sanctions for violating these federal and state anti-kickback laws may include criminal and civil fines and exclusion from participation in federal and state health care programs. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Anti-kickback laws have been cited as a partial basis, along with state consumer protection laws described below, for investigations and multi-state settlements relating to financial incentives provided by drug manufacturers to pharmacies or payors in connection with "product conversion" or promotion programs. Other anti-kickback and referral laws may also be applicable including criminal and civil laws restricting illegal kickbacks and conflicts of interest in connection with plans governed by the Employee Retirement Income Security Act of 1974, as amended ("ERISA"), the federal "Stark Law," and various state anti-kickback restrictions. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020, HHS and HHS-OIG released a final rule that eliminates an anti-kickback regulatory safe harbor protection for price concessions, including rebates, that are offered by pharmaceutical manufacturers to plan sponsors or pharmacy benefit managers under the Medicare Part D program. The final rule creates two new safe harbors: (i) for price reductions by manufacturers to plan sponsors under Medicare Part D and Medicaid managed care organizations that are reflected at the time of dispense and (ii) for fixed-fee service arrangements between manufacturers and pharmacy benefit managers. The effective date of the final rule has been postponed to 2032.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Federal Civil Monetary Penalties Law.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The federal civil monetary penalty statute provides for civil monetary penalties against any person who gives something of value to a Medicare or Medicaid program beneficiary that the person knows or should know is likely to influence the beneficiary's selection of a particular provider for Medicare or Medicaid items or services. Under this law, our wholly-owned home delivery pharmacies, specialty pharmacies and home health providers are restricted from offering certain items of value to influence a Medicare or Medicaid patient's use of services. The ACA also includes several civil monetary provisions, such as penalties for the failure to report and return a known overpayment and failure to grant timely access to the HHS-OIG under certain circumstances.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Federal and State Oversight of Government-Sponsored Health Care Programs</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Participation in government-sponsored health care programs subjects us to a variety of federal and state laws and regulations and risks associated with audits conducted under these programs. These audits may occur years after the provision of services. Risks include potential fines and penalties, restrictions on our ability to participate or expand our presence in certain programs and restrictions on marketing our plans. For example, with respect to our Medicare Advantage business, CMS and the HHS-OIG perform audits to determine a health plan's compliance with federal regulations and contractual obligations, including program audits and RADV audits, which focus on compliance with proper coding practices. Certain of our contracts are currently subject to audits by CMS and the HHS-OIG, including RADV audits. CMS has announced that its goal is to subject all Medicare Advantage contracts to either a comprehensive or a targeted RADV audit for each contract year. The DOJ is also currently conducting industry-wide investigations of the risk adjustment data submission practices and business processes of a number of Medicare Advantage organizations. The Cigna Group was a party to such an investigation, which was settled during the third quarter of 2023. Please see &#8220;&#8212;Medicare and Medicaid Regulations&#8221; for further information related to the settlement and the related CIA.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For our Medicare Part D business, compliance with certain contractual provisions and regulatory requirements is subject to review by Recovery Audit Contractor audits in which third-party contractors conduct post-payment reviews on a contingency fee basis to detect and correct improper payments.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Government Procurement Regulations</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have a contract with the U.S. DoD, which subjects us to applicable Federal Acquisition Regulations ("FAR") and the DoD FAR Supplement, which govern federal government contracts. Further, there are other federal and state laws applicable to our DoD arrangement and our arrangements with other clients that may be subject to government procurement regulations. In addition, certain of our clients participate as contracting carriers in the Federal Employees Health Benefits Program administered by the OPM, which includes various pharmacy benefit management standards.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Employee Retirement Income Security Act</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our domestic subsidiaries sell most of their products and services to sponsors of employee benefit plans that are governed by ERISA. ERISA is a complex set of federal laws and regulations enforced by the IRS and the DOL, as well as the courts. ERISA regulates certain aspects of the relationship between us, the employers that maintain employee welfare benefit plans subject to ERISA and the participants in such plans. Certain of our domestic subsidiaries are also subject to requirements imposed by ERISA affecting claim payment and appeals procedures for individual health insurance and insured and self-insured group health plans and for the insured plans we administer. Certain of our domestic subsidiaries also may contractually agree to comply with these requirements on behalf of the self-insured plans they administer. We believe the conduct of our pharmacy benefit management business is not generally subject to the fiduciary obligations of ERISA. However, there can be no assurances that the DOL may not assert that pharmacy benefit managers are fiduciaries. From time to time, states have considered and, in limited cases, enacted legislation to declare a pharmacy benefit manager or health benefit manager a fiduciary with respect to its clients.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Plans subject to ERISA may also be subject to state laws and the legal question of whether and to what extent ERISA preempts a state law is likely to continue to be a subject for interpretation by the courts for years to come.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Privacy, Security and Data Standards Regulations</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Numerous federal, state and foreign laws and regulations govern the creation, collection, dissemination, receipt, maintenance, protection, use, transmission, disclosure, privacy, confidentiality, security, availability, integrity, processing, and disposal (collectively "Processing") of protected health information ("PHI") and other personally identifiable information ("PII"). Many of our activities involve Processing of PHI and PII. In addition, we use aggregated and/or anonymized data for our own research and analysis purposes and, in some cases, when permitted, provide access to such anonymized data, or analytics created from such data, to third parties. We may also use such information to create analytic models designed to predict, and potentially improve, outcomes and patient care. We are also subject to the Payment Card Industry Data Security Standard, a set of requirements designed to help ensure that entities that Process credit card information maintain a secure environment.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On the federal level we are subject to a number of sector specific regulations. The federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act ("HITECH") and the 21st Century Cures Act, Public Law 116-321, and as implemented by the regulation (collectively "HIPAA") impose requirements on covered entities and business associates that address the privacy and security of PHI. In the conduct of the majority of our business we may be either a covered entity or business associate, and we may also be held liable under HIPAA for violations by our vendors, including downstream services providers, that are business associates. HIPAA imposes contracting requirements and requires breach notifications. HIPAA also regulates permissible uses and disclosures of PHI; for example, HHS has issued guidance regarding tracking technologies that are used to collect and analyze information about how users interact with covered entities&#8217; and business associates&#8217; websites and mobile applications. Violations of HIPAA may result in enforcement actions, civil and criminal penalties and settlement, resolution, and monitoring agreements. Further, state attorneys general may bring civil actions seeking either injunctions or damages in response to violations of HIPAA that threaten the privacy of state residents and may negotiate settlements for related cases on behalf of their respective residents. There can be no assurance that we will not be the subject of an investigation, audit or compliance review regarding our compliance with HIPAA. HIPAA does not preempt more stringent state health privacy laws and regulations, which may protect the health information of certain individuals, such as minors, and certain types of sensitive health information, such as transgender care, HIV/AIDS status, reproductive health information, genetic information, and mental and behavioral health.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other federal and state laws that restrict the use and protect the privacy and security of PII exempt data and/or entities subject to HIPAA, but several states, such as, Nevada, and Connecticut, have recently enacted privacy laws to protect consumer data and require consent for the collection, use, and sharing of consumer health data. These laws may impact our businesses and practices where data collected is outside the reach of HIPAA.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The federal government has also enacted final regulations on interoperability and information blocking to support the seamless and secure access, exchange and use of electronic health information by and between patients, enrollees and entities such as payors and health care providers. These regulations apply to a variety of entities and generally require significant enhancements to information technology and data governance practices. The regulations impact how industry participants, including us, comply with disclosure requirements and share information with individuals and other health care organizations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The federal Gramm-Leach-Bliley Act ("GLBA") and its implementing regulations generally place restrictions on the disclosure of nonpublic information to nonaffiliated third parties, and requires financial institutions, including insurers, to provide customers with notice regarding how their nonpublic personal information is used, including an opportunity to "opt out" of certain disclosures. State departments of insurance and certain federal agencies adopted implementing regulations as required by federal law. In 2023, significant changes to GLBA's "Safeguards Rule" went into effect, substantially raising the GLBA standards for security, which are anticipated to be adopted by some state DOIs (as defined herein).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, under Section 5 of the Federal Trade Commission Act ("FTC Act"), the FTC has jurisdiction over certain privacy and security practices deemed unfair and deceptive acts and practices in or affecting commerce. The FTC has charged companies with violating this act based on failures to appropriately and transparently safeguard personal information, respect consumers' privacy rights, based on disclosures of health and personal information to third parties, the failure to limit third-party use of health information, the failure to implement policies and procedures to prevent the improper or unauthorized disclosure of health information, and the failure to provide notice and obtain consent before the use and disclosure of health information for advertising. In addition to the FTC Act, the FTC also enforces other federal laws relating to consumers' privacy and security. The FTC has also been active with respect to companies' use of big data and AI, specifically ensuring fair and equitable use of these tools, and the FTC has named AI as an area of enforcement focus. State legislatures and regulators are similarly interested in the use of AI, particularly as it is used in modeling, and a handful of states have either passed legislation or issued regulatory guidance concerning AI. Additionally, the National Association of Insurance Commissioners ("NAIC"), an organization of state insurance regulators, recently established the Innovation, Cybersecurity and Technology Committee to provide a forum for regulators to learn, monitor and confer on emerging technology issues, including, among others, cybersecurity and AI. State Departments of Insurance ("DOI") and other state government agencies and legislatures are increasingly aware and active in providing guidance in the AI space.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2023, the SEC approved final rules relating to cybersecurity disclosure obligations on reporting companies and such new disclosures can be found beginning on page </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ibc59a92ac8bc42f794e728f24ce1b626_985">45</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Cybersecurity Information Sharing Act of 2015 ("CISA") encouraged organizations to share cyber threat indicators with the federal government and, among other things, directed HHS to develop a set of voluntary cybersecurity best practices for organizations in the health care industry. States have also begun to issue regulations specifically related to cybersecurity, which may differ or conflict from state to state. In October 2017, the NAIC adopted the Insurance Data Security Model Law that creates rules for insurers and other covered entities addressing data security, investigation and notification of breaches. This includes maintaining an information security program based on ongoing risk assessment, overseeing third-party service providers, investigating data breaches </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and notifying regulators of a cybersecurity event. As the model law is intended to serve as model legislation only, states will need to enact legislation for the model law to become mandatory and enforceable. To date, twenty-one states have enacted some form of the model law.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Over the past several years, the federal government has increasingly focused on the cybersecurity requirements applicable to government contractors, including enhanced guidance and regulation. These include compliance with the Privacy Act of 1974, the Defense Federal Acquisition Regulation Supplement ("DFARS") cybersecurity requirements, the Cybersecurity Maturity Model Certification ("CMMC") (going into effect over the next four years and based on the National Institute of Standards and Technology ("NIST") standards), the Federal Information Security Modernization Act ("FISMA") and the White House's 2021 Executive Order on Improving the Nation's Cybersecurity.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Some local authorities are increasingly focused on protecting individuals from data or identity theft and every state has data security laws and regulations requiring, among other things, certain minimum data security standards and security breach notifications that may apply to us in certain circumstances, as well as certain limitations on access to and use of PII. These laws and regulations include state general data breach laws, which exist in all fifty states and protect PII generally, as well as DOI cybersecurity laws, applicable to various DOI licensees, such as insurers, PBMs and TPAs. Many states also have their own sector-specific laws regarding the Processing of PII which may apply to us as well. In the past few years, fourteen states have adopted their own comprehensive consumer privacy statutes and many more states are considering doing so. Generally, the statutes exempt data and/or entities regulated by GLBA and/or HIPAA but are, in varying respects, applicable to other data we collect, such as PII provided by website visitors, and in California, employees and business partners. Additionally, we anticipate federal and state legislators and regulators will continue to enact legislation related to privacy and cybersecurity.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, international laws, rules and regulations governing the use and disclosure of PII can be more stringent than those in the United States, and they vary from jurisdiction to jurisdiction. The European Union's General Data Protection Regulation ("GDPR"), which became effective May 2018, enhanced or created obligations regarding the handling of PII relating to European residents (such as regarding notices, data protection impact assessments and individual rights) and provides for greater penalties for noncompliance than the previous European Directive or laws. In addition, many countries outside of Europe where we conduct business have implemented or may implement data protection laws and regulations, some of which include requirements modeled after those in the GDPR. Some non-U.S. jurisdictions are also instituting data residency regulations requiring that data be maintained within the respective jurisdiction or otherwise restricting transfer of personal data across borders unless specified regulatory requirements are met.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See Part I, Item 1A, "Risk Factors" for a discussion of the risks related to compliance with privacy and security regulations.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Consumer Protection Laws</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We engage in direct-to-consumer activities and are increasingly offering mobile and web-based solutions to our customers. We are therefore subject to federal and state regulations applicable to electronic communications and other consumer protection laws and regulations, such as the Telephone Consumer Protection Act and the CAN-SPAM Act. With the ever increasing reliance and demand by consumers on using their mobile devices for convenient communications, we face increased risk under these laws. The FTC is also increasingly exercising its enforcement authority in the areas of consumer privacy and data security, with a focus on web-based, mobile data and "big data." Federal consumer protection laws may also apply in some instances to privacy and security practices related to PII.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">State and federal policymakers have taken actions intended to increase transparency and predictability of health care costs for consumers. For example, the Transparency in Coverage rule issued in October 2020 by the HHS, the DOL and the Department of the Treasury now requires most group health plans and health insurance issuers in the individual and group markets to publicly disclose price and cost-sharing information for all items and services to participants and enrollees. Health plans and health insurers must publicly disclose (i) in-network provider negotiated rates, and (ii) historical out-of-network allowed amounts and billed charges. The rule also required public disclosure of in-network negotiated rates and historical net prices for all covered prescription drugs, but the departments announced in August 2021 guidance that they will indefinitely defer enforcement of the rule's requirement that plans and issuers publish machine-readable files relating to prescription drug pricing pending further rulemaking. In 2023, we were required to make available to members personalized cost-sharing information for 500 covered health care items and services. In 2024, this cost-sharing information requirement will expand to all items and services, including prescription drugs. Insurers offering group or individual health insurance coverage may receive credit in their MLR calculations for certain savings they share with enrollees that result from the enrollees shopping for, and receiving care from, lower-cost, higher-value providers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Congress also passed the Consolidated Appropriations Act, 2021 ("CAA"), which included a number of transparency requirements on plans and issuers that are duplicative or overlap with the Transparency in Coverage rule issued by the departments. The indefinite enforcement deferral of the prescription drug pricing file under the Transparency in Coverage rule is, in part, due to the subsequent </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">enactment of the CAA, which requires plans to report information regarding prescription drug spending to federal regulators beginning in 2022. The CAA also included the No Surprises Act, which prohibits health care providers, in certain situations, from balance billing the patient and requires that they work directly with insurers to agree on out-of-network reimbursement, including utilizing an independent dispute resolution ("IDR") process outlined in the act. CMS regulations and guidance implementing the IDR process have been subject to a significant amount of provider-initiated litigation, and CMS has had to temporarily suspend federal IDR functions, including dispute initiation. Many states already have addressed balance billing, or surprise medical bills. These laws and regulations vary in their approach, resulting in different impacts on the health care system as a whole. In 2021, HHS, DOL and the Department of the Treasury, announced interim final rules ("IFR") intended to implement provisions of the No Surprises Act, certain provisions of which were vacated by a Federal district court in February and July 2022. The departments then issued a final rule on August 26, 2022, finalizing disclosure requirements relating to information that group health plans and health insurance issuers offering group or individual health insurance coverage must share about the Qualifying Payment Amount ("QPA"), which the departments have stated is generally based on the median contracted rate for a qualified IDR item or service, and requirements related to the consideration of information when a certified IDR entity makes a payment determination under the federal IDR process. In September and October 2023, the Departments announced proposed rules that outlined fees established for the federal IDR process and that would set forth new requirements relating to the disclosure of information that group health plans and health insurance issuers offering group or individual health insurance coverage must include along with an initial payment or notice of denial for payment for certain items and services subject to the surprise billing protections. The October 2023 proposed rule would also amend requirements related to the open negotiation period before the federal IDR process, the initiation of the federal IDR process, federal IDR dispute eligibility review, and the payment and collection of administrative fees and certified IDR entity fees.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, most states have consumer protection laws that have been the basis for investigations and multi-state settlements relating to financial incentives provided by drug manufacturers to retail pharmacies in connection with product conversion programs. Such statutes have also been cited as the basis for claims or investigations by state attorneys general relative to privacy and data security.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Office of Foreign Assets Control Sanctions and Anti-Money Laundering</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also subject to regulation by the Office of Foreign Assets Control of the U.S. Department of the Treasury, which administers and enforces economic and trade sanctions against targeted foreign jurisdictions and regimes based on U.S. foreign policy and national security goals. Certain of our products are subject to the Department of the Treasury anti-money laundering regulations under the Bank Secrecy Act. In addition, we are subject to similar regulations in non-U.S. jurisdictions in which we operate.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Corporate Practice of Medicine and Other Laws</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many states in which our subsidiaries operate limit the practice of medicine to licensed individuals or professional organizations comprised of licensed individuals, and business corporations generally may not exercise control over the medical decisions of physicians. Statutes and regulations relating to the practice of medicine, fee-splitting between physicians and referral sources and similar issues vary widely from state to state. Under management agreements between certain of our subsidiaries and physician-owned professional groups, these groups retain sole responsibility for all medical decisions, as well as for hiring and managing physicians and other licensed health care providers, developing operating policies and procedures, implementing professional standards and controls and maintaining malpractice insurance. We believe that our health services operations comply with applicable state statutes regarding corporate practice of medicine, fee-splitting and similar issues. However, any enforcement actions by governmental officials alleging noncompliance with these statutes could subject us to penalties or restructuring or reorganization of our business.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Utilization Management Laws </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">State legislatures have begun to propose and enact laws exempting certain providers from pre-authorization requirements of insurers. These exemptions reduce the ability for insurers and medical management entities to review services for medical necessity if the provider meets the law's established thresholds for approval rates in the preceding six months. The inability to apply pre-authorization requirements could lead to increased costs to plan issuers by way of the provision of unnecessary services. States are also standardizing the process for, and restricting the use of, utilization management rules and shortening the time frames within which prescription drug prior authorization determinations must be made. Even where states do not regulate pharmacy benefit or utilization management companies directly, these laws will apply to many of our clients, including managed care organizations and health insurers.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Laws and Legislation Affecting Pharmacy Benefit Plan Design, Administration and Pharmacy Network Access</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Some states have enacted laws that prohibit managed care plan sponsors from implementing certain restrictive benefit plan design features, and many states have laws or have introduced legislation to regulate various aspects of managed care plans, including provisions relating to the pharmacy benefit. For example, some states, under so-called "freedom of choice" legislation, provide that customers of the plan may not be required to use network providers, but must instead be provided with benefits even if they choose to </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">use non-network providers. Some states have also enacted legislation that can negatively impact the use of cost-saving network configurations for plan sponsors, such as limiting the implementation of pharmacy benefit designs and reimbursement structures that leverage affiliate pharmacies to reduce costs. Other states have enacted legislation purporting to prohibit health plans from offering customers financial incentives for use of home delivery pharmacies. Medicare and some states have issued guidance and regulations that limit our ability to fill or refill prescriptions electronically submitted by a physician to our home delivery pharmacy without first obtaining consent from the patient. Such restrictions generate additional costs and limit our ability to maximize efficiencies, which could otherwise be gained through the electronic prescription and automatic refill processes. Legislation has been introduced in some states to prohibit or restrict therapeutic intervention, or to require coverage of all Food and Drug Administration approved drugs. Other states mandate coverage of certain benefits or conditions, and require health plan coverage of specific drugs if deemed medically necessary by the prescribing physician.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, Medicare Part D and a majority of states now have laws, regulations or some form of legislation affecting our ability, or our clients' ability, to limit access to a pharmacy provider network or remove a provider from a network. Such laws, regulations or legislation may require us or our clients to admit any retail pharmacy or provider willing to meet the plan's terms and conditions for network participation ("any willing provider") or may direct that a provider may not be removed from a network except in compliance with certain procedures ("due process").</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain states have laws prohibiting certain pharmacy benefit management clients from imposing additional copayments, deductibles, limitations on benefits, or other conditions on covered individuals utilizing a retail pharmacy when the same conditions are not otherwise imposed on covered individuals utilizing home delivery pharmacies. However, the laws require the retail pharmacy to agree to the same reimbursement amounts and terms and conditions as are imposed on the home delivery pharmacies. An increase in the number of prescriptions filled at retail pharmacies may have a negative impact on the number of prescriptions filled through home delivery.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Pharmacy Benefit Manager and Drug Pricing Regulation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our pharmacy benefit management services are subject to numerous laws and regulations. These laws and regulations govern, and proposed legislation and regulations may govern, critical practices, including: disclosure, receipt and retention of rebates and other payments received from pharmaceutical manufacturers; certain pharmacy contracting practices including disclosure of cost information to customers; the receipt and retention of transmission fees from contracted pharmacies; performance-based price concessions; pharmacy price concessions to drug prices at the point of sale; audits of contracted pharmacies; use of, administration of, or changes to drug formularies, the use and disclosure of maximum allowable cost ("MAC") pricing, or clinical programs; "most favored nation" pricing, which provides that a pharmacy participating in a specific government program must give the program the best price the pharmacy makes available to any third-party plan; disclosure of data to third parties; drug utilization management practices; the level of duty a pharmacy benefit manager owes its clients or customers; configuration of pharmacy networks; the operations of our subsidiary pharmacies; referrals to affiliated pharmacies; disclosure of negotiated provider reimbursement rates; disclosure of negotiated drug rebates, calculation of certain customer cost-share for prescription drug claims; pricing that includes differential or spread (i.e., a difference between the drug price charged to the plan sponsor by a pharmacy benefit manager and the price paid by the manager to the dispensing provider); disclosure of fees associated with administrative service agreements and patient care programs that are attributable to customers' drug utilization; utilization management; and registration or licensing of pharmacy benefit managers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect federal and state governments to continue to prioritize means of addressing out-of-pocket costs for consumers, particularly related to prescription drug costs. Recently enacted legislation, such as the Inflation Reduction Act, which changed Medicare Part B beneficiary coinsurance for certain drugs and imposed caps on out-of-pocket prescription drug costs in Medicare Part D, and other policy proposals and regulations, such as proposed legislation aimed at providing transparency with respect to pharmacy benefit managers, vary broadly in their approaches to achieve that goal. Additionally, proposals at the federal and state levels consider increased regulation of pharmacy benefit managers and health plans as a means to limit consumer out-of-pocket costs, including: proposing to limit the use of various pharmacy benefit management tools; mandating the treatment of fees, discounts or financing mechanisms that otherwise are set in private contractual terms; increasing supply chain transparency; expanding regulatory requirements or definitions of fiduciaries; or 29 mandating plan benefit designs that cap consumer out-of-pocket expense. The NAIC has also proposed laws intended to protect consumer drug benefits and has examined regulatory approaches to pharmacy benefit manager business practices.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Some states have enacted statutes regulating the use of MAC pricing. These statutes, referred to as "MAC Transparency Laws," generally require pharmacy benefit managers to disclose specific information related to MAC pricing to pharmacies and provide certain appeal rights for pharmacies. MAC Transparency Laws also restrict the application of MAC and may require operational changes to maintain compliance with the law. Some states have also enacted laws regulating pharmacy pricing and protecting the profitability of pharmacies for dispensing certain MAC-priced drugs. Some states have enacted laws requiring that the customer cost-share for a prescription drug claim not exceed certain price points, such as the pharmacy's usual and customary charge or its contracted </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">reimbursement for the drug. In a recent Supreme Court decision, the Court found that certain MAC Transparency Laws may be applied by states to ERISA plans in addition to health plans regulated by the applicable state. Following this decision, state legislatures and regulators have sought to extend their oversight authority of self-funded ERISA plans to pharmacy benefit management functions and pharmacy benefit plan designs beyond MAC pricing. </span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Medicaid Drug Rebate Program requires participating drug manufacturers to report certain information and pay rebates on drugs reimbursed through state Medicaid programs, in accordance with applicable law and regulation. We negotiate rebates with drug manufacturers and, in certain circumstances, sell services to drug manufacturers. Investigations are being and have been conducted by certain government entities involving manufacturer calculation and reporting with respect to rebates paid by the manufacturers to the Medicaid programs. Our PBM is not responsible for such calculations, reports or payments. There can be no assurance that our ability to negotiate rebates with, or sell services to, drug manufacturers will not be unfavorably affected by investigations or regulations in the future.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Pharmacy Regulation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our home delivery and specialty pharmacies also subject us to extensive federal, state and local regulation. The practice of pharmacy is generally regulated at the state level by state boards of pharmacy, though our pharmacies are subject to laws described above under the headings "Privacy, Security and Data Standards Regulations" and "Consumer Protection Laws." We are licensed to do business as a pharmacy in the states in which our pharmacies are located and the health care professionals that we employ are also licensed by, and subject to, the laws and regulations of state boards of pharmacy and other governmental authorities. Most of the states into which we deliver pharmaceuticals have laws that require out-of-state home delivery pharmacies to register with, or be licensed by, the board of pharmacy or a similar regulatory body in the state. These states generally permit the pharmacy to follow the laws of the state where the pharmacy is located, although some states require compliance with certain laws in that state as it impacts or relates to drugs distributed or dispensed into that state.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our various pharmacy facilities also provide services under certain Medicare and state Medicaid programs. Participation in these programs requires our pharmacies to comply with the applicable Medicare and Medicaid provider rules and regulations, and exposes the pharmacies to various changes the federal and state governments may impose regarding reimbursement methodologies, the submission of claims and amounts to be paid to participating providers under these programs. In addition, several of our pharmacy facilities are participating providers under Medicare Part D and are required to adhere to certain requirements applicable to Medicare Part D. Additionally, we are subject to CMS rules regarding the administration of our Medicare plans and pricing between our plans and related parties, including our pharmacy business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other statutes and regulations affect our home delivery and specialty pharmacy operations, including the federal and state anti-kickback laws, federal and state false claims acts and the federal civil monetary penalty law described above. Federal and state statutes and regulations govern the labeling, packaging, repackaging, compounding, storing, holding, disposal, distribution, advertising, misbranding, adulteration, transfer, handling and security of prescription drugs and the dispensing of prescription, over-the-counter, hazardous and controlled substances and certain of our pharmacies must register with the U.S. Drug Enforcement Administration, the U.S. Food and Drug Administration and individual state controlled substance authorities. The FTC requires mail order sellers of goods generally to engage in truthful advertising, to stock a reasonable supply of the product to be sold, to fill mail orders within thirty days and to provide clients with refunds when appropriate. The United States Postal Service also has significant statutory authority to restrict the delivery of drugs and medicines through the mail. Violations of pharmacy laws and regulations may result in warning letters, civil and criminal penalties, seizures, suspension, termination or revocation of licenses and registrations, restrictions on facilities or operations, and other enforcement actions.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial Reporting, Internal Control and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Corporate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> Governance</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Regulators closely monitor the financial condition of licensed insurance companies and HMOs. States regulate the form and content of statutory financial statements, the type and concentration of permitted investments and corporate governance over financial reporting. Our insurance and HMO subsidiaries are required to file periodic financial reports and schedules with regulators in most of the jurisdictions in which they do business as well as annual financial statements audited by independent registered public accounting firms. Certain insurance and HMO subsidiaries are required to file an annual report of internal control over financial reporting with most jurisdictions in which they do business. Insurance and HMO subsidiaries' operations and financial statements are subject to examination by regulators. Many states have expanded regulations relating to corporate governance and internal control activities of insurance and HMO subsidiaries as a result of model regulations adopted by the NAIC with elements similar to corporate governance and risk oversight disclosure requirements under federal securities laws.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Guaranty Associations, Indemnity Funds, Risk Pools and Administrative Funds</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Most states and certain non-U.S. jurisdictions require insurance companies to support guaranty associations or indemnity funds that are established to pay claims on behalf of insolvent insurance companies. Some states have similar laws relating to HMOs and other payors, such as consumer operated and oriented plans (co-ops) established under the ACA. In the United States, these associations levy assessments on member insurers licensed in a particular state to pay such claims. Certain states require HMOs to participate in guaranty funds, special risk pools and administrative funds. For additional information about guaranty funds and other assessments, see Note 24 to the Consolidated Financial Statements.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain states continue to require health insurers and HMOs to participate in assigned risk plans, joint underwriting authorities, pools or other residual market mechanisms to cover risks not acceptable under normal underwriting standards, although some states have eliminated these requirements as a result of the ACA.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Solvency and Capital Requirements</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many states have adopted some form of the NAIC model solvency-related laws and risk-based capital ("RBC") rules for life and health insurance companies and HMOs. The RBC rules recommend a minimum level of capital depending on the types and quality of investments held, the types of business written and the types of liabilities incurred. If the ratio of the insurer's adjusted surplus to its RBC falls below statutorily required minimums, the insurer could be subject to regulatory actions ranging from increased scrutiny to conservatorship.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, various non-U.S. jurisdictions prescribe minimum surplus requirements that are based upon solvency, liquidity and reserve coverage measures. Our HMOs and life and health insurance subsidiaries, as well as non-U.S. insurance subsidiaries, are compliant with applicable RBC and non-U.S. surplus rules.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Risk Management and Own Risk and Solvency Assessment Model Act ("ORSA"), adopted by the NAIC, provides requirements and principles for maintaining a group solvency assessment and a risk management framework and reflects a broader approach to U.S. insurance regulation. ORSA includes a requirement to file an annual ORSA Summary Report in the lead state of domicile. To date, an overwhelming majority of the states have adopted the same or similar versions of ORSA. We file our ORSA report annually as required.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Holding Company Laws</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our domestic insurance companies and certain of our HMOs are subject to state laws regulating subsidiaries of insurance holding companies. Under such laws, certain dividends, distributions and other transactions between an insurance company or an HMO subsidiary and its affiliates may require notification to, or approval by, one or more state insurance commissioners. In addition, the holding company acts of states in which our subsidiaries are domiciled restrict the ability of any person to obtain control of an insurance company or HMO subsidiary without prior regulatory approval. State holding company laws and regulations also subject our insurance companies and certain HMO subsidiaries to additional regulatory scrutiny related to their oversight of affiliates performing regulated services on behalf of the insurance company or HMO and require the Company to file an annual Enterprise Risk Report, which summarizes material risks that could pose enterprise risk to the insurance company subsidiaries.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Marketing, Advertising and Products</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In most states, our insurance companies and HMO subsidiaries are required to certify compliance with applicable advertising regulations on an annual basis. Our insurance companies and HMO subsidiaries are also required by most states to file and secure regulatory approval of products prior to the marketing, advertising and sale of such products. Additionally, our Medicare Advantage and Medicare Part D plans must follow certain federal marketing and communications regulations. In April 2023, CMS issued a final rule revising regulations governing marketing by Medicare Advantage and Medicare Part D plans. Among other things, the final rule requires enrollees to be notified of their ability to opt out of phone calls regarding Medicare Advantage and Part D marketing, requires agents to explain the effect of an enrollee&#8217;s enrollment choice on their current coverage, simplifies plan comparisons by requiring medical benefits to be listed in a specific order at the top of a plan&#8217;s Summary of Benefits, requires Medicare Advantage organizations and Part D sponsors to have an oversight plan that monitors activities of agents and brokers and to report noncompliance to CMS, and limits the time a potential enrollee may be contacted about Medicare plan options to 12 months after the enrollee first asked for information.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Licensing and Registration Requirements</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our insurance companies and HMO subsidiaries must be licensed by the jurisdictions in which they conduct business. Additionally, certain subsidiaries contract to provide claim administration, utilization management and other related services for the administration </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of self-insured benefit plans. These subsidiaries may be subject to state third-party administration and other licensing requirements and regulation, as well as third-party accreditation requirements.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have received full accreditation for URAC Pharmacy Benefit Management Standards version 3.1, which includes quality standards for drug utilization management, and select subsidiaries have received full accreditation for URAC Health Utilization Management version 7.4, which includes quality standards for medical utilization management.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain states have adopted pharmacy benefit management registration, licensure or disclosure laws. In addition to registration laws, some states have adopted legislation mandating disclosure of various aspects of our financial practices, including those concerning pharmaceutical company revenue, as well as prescribing processes for prescription switching programs and client and provider audit terms.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our international subsidiaries are often required to be licensed when entering new markets or starting new operations in certain jurisdictions. The licensure requirements for these subsidiaries vary by country and are subject to change.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">International Regulations</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our operations outside of the United States expose us to laws of multiple jurisdictions and the rules and regulations of various governing bodies and regulators, including those related to the provision of insurance, financial and other disclosures, the provision of health care-related services, corporate governance, privacy, data protection, data mining, data transfer, intellectual property, labor and employment, consumer protection, direct-to-consumer communications activities, tax, anti-corruption and anti-money laundering. Foreign laws and rules may include requirements that are different from, or more stringent than, similar requirements in the United States.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our operations in countries outside of the United States:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">are subject to local regulations of the jurisdictions where we operate;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">in some cases, are subject to regulations in the jurisdictions where customers reside; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">in all cases, are subject to the Foreign Corrupt Practices Act ("FCPA").</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Anti-money laundering requirements in countries where we do business also may impose obligations to collect certain information about each customer at time of sale or to risk rank each customer to determine possible future money laundering risk.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FCPA prohibits offering, promising, providing or authorizing others to give anything of value to a foreign government official or employee to obtain or retain business or otherwise secure a business advantage. Outside of the United States, we may interact with government officials in several different capacities: as regulators of our insurance business; as clients or partners who are state-owned or partially state-owned; as health care providers who are employed by the government; as hospitals that are state-owned; and as officials issuing permits in connection with real estate transactions. Violations of the FCPA and other anti-corruption laws may result in severe criminal and civil sanctions as well as other penalties, and the SEC and DOJ have increased their enforcement activities with respect to FCPA. The UK Bribery Act of 2010 applies to all companies with a nexus to the United Kingdom. Other countries in which we do business also have anti-corruption laws to which we are subject. As international regulators often share information, any voluntary disclosures of violations may be shared with authorities in other countries, thus potentially exposing companies to liability and potential penalties in multiple jurisdictions.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_979"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span id="ie03e5e59cde343c9b5a7bd9909a2c16c_113941"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 1A. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">RISK FACTORS</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">As a large global health company operating in a complex industry, we encounter a variety of risks and uncertainties, which could have a material adverse effect on our business, liquidity, results of operations, financial condition or the trading price of our securities. You should carefully consider each of the risks and uncertainties discussed below, together with other information contained in this Form 10-K, including MD&amp;A. These risks and uncertainties are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect us. The following risk factors have been organized by category for ease of use; however many of the risks may have impacts in more than one category. These categories, therefore, should be viewed as a starting point for understanding the significant risks facing us and not as a limitation on the potential impact of the matters discussed. Risk factors are not necessarily listed in order of importance. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Strategic and Operational Risks </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Future performance of our business will depend on our ability to execute our strategic and operational initiatives effectively.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The future performance of our business will depend in large part on our ability to effectively implement and execute our strategic and operational initiatives. Successfully executing on these initiatives depends on a number of factors, including our ability to:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">differentiate our products, services and solutions from those of our competitors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">develop and bring to market new and innovative products, solutions or programs that focus on improving patient outcomes and experiences and assist in controlling costs or in response to government regulation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">develop and create data and analytic solutions to support and improve outcomes for our products, services and solutions, including creating and developing solutions and services through partnerships with other industry participants;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">grow and support our product portfolio, expand our addressable markets and identify and introduce the proper mix, coordination or integration of products that will be accepted by the marketplace;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">evaluate drugs for efficacy, value and price to assist clients in selecting a cost-effective formulary;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">offer cost-effective home delivery pharmacy and specialty services;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">access or continue accessing key drugs and successfully penetrate key treatment categories in our specialty pharmacy business;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">attract and retain sufficient numbers of qualified employees, particularly in a competitive job market;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">attract, develop and maintain collaborative relationships with a sufficient number of qualified partners;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">attract new and maintain existing customer and client relationships;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">leverage purchase volume to deliver discounts to health benefit providers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">transition health care providers from volume-based fee-for-service arrangements to a value-based system;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">improve medical cost competitiveness in our targeted markets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">manage our medical, pharmacy, administrative and other operating costs effectively; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">contract with health care providers, pharmacy providers and pharmaceutical manufacturers on market competitive terms.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For our strategic initiatives to succeed, we must effectively collaborate across our operations, integrate our acquired businesses, actively work to ensure consistency throughout the organization and promote a global mindset along with a focus on individual customers and clients. If we fail to do so, our business may be unable to grow as planned, or the result of expansion may be unsatisfactory. We will be unable to rapidly respond to competitive, economic and regulatory changes if we do not make important strategic and operational decisions quickly, define our appetite for risk, implement new governance, managerial and organizational processes smoothly and communicate roles and responsibilities clearly. If these initiatives fail or are not executed effectively, our consolidated financial position and results of operations could be negatively affected.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We operate in a highly competitive, evolving and rapidly changing industry and our failure to adapt could negatively impact our business.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The health service industry continues to be dynamic and rapidly evolving. Any significant shifts in the structure of the industry could alter industry dynamics and adversely affect our ability to attract or retain clients and customers. Industry shifts could result (and have resulted) from, among other things:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a large intra- or inter-industry merger or industry consolidation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">strategic alliances;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">new or alternative business models or new government options or offerings;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">continuing consolidation among physicians, hospitals and other health care providers, as well as changes in the organizational structures chosen by physicians, hospitals and health care providers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">new market entrants, including those not traditionally in the health service industry;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the ability of larger employers and clients to contract directly with providers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">technological changes and rapid shifts in the use of technology, such as telehealth and AI;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the impact or consequences of legislation or regulatory changes;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">impacts to distribution channels, including changes to the United States Postal Service or the consolidation of shipping carriers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">increased drug acquisition cost or unexpected changes to drug pricing trend;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">changes in the generic/biosimilar drug market or the failure of new generic/biosimilar drugs to come to market; or </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">changes in utilization of health care, prescription drugs or other covered services and items, including under risk-based contracts in the health benefit management market and for those businesses that utilize risk adjustment methodology.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our failure to anticipate or appropriately adapt to changes in the industry could negatively impact our competitive position and adversely affect our business and results of operations.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our failure to compete effectively, to differentiate our products and services from those of our competitors and maintain or increase market share, including maintaining or increasing enrollments in businesses providing health benefits, could materially adversely affect our results of operations, financial position and cash flows.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We operate in a highly competitive environment and an industry subject to significant market pressures brought about by customer and client needs, legislative and regulatory developments and other market factors. In particular markets, our competitors may have greater, better or more established capabilities, resources, market share, reputation or business relationships, or lower profit margin or financial return expectations. Our clients are well informed and organized and can easily move between our competitors and us. Our Express Scripts client contracts generally have three-year terms and may be subject to periodic renegotiation of pricing terms based on market factors. As described in greater detail in the description of our business in Item 1 of this Form 10-K, our key clients in the Evernorth Health Services segment include the DoD, Prime and Centene. If one or more of our large clients terminates or does not renew a contract for any reason, including as a result of being acquired, or if the provisions of a contract with a large client are modified, renewed or otherwise changed with terms less favorable to us, our results of operations could be adversely affected and we could experience a negative reaction in the investment community resulting in decreases in the trading price of our securities or other adverse effects.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our success depends, in part, on our ability to compete effectively in our markets, set prices appropriately in highly competitive markets to keep or increase our market share, increase customers as planned, differentiate our business offerings by innovating and delivering products and services that provide enhanced value to our customers, provide quality and satisfactory levels of service and retain accounts with favorable medical cost experience or more profitable products versus retaining or increasing our customer base in accounts with unfavorable medical cost experience or less profitable products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We must remain competitive to attract new customers, retain existing customers and further integrate additional product and service offerings. To succeed in this highly competitive marketplace, it is imperative that we maintain a strong reputation. Increasingly, our customers, clients and investors consider our efforts on a variety of matters that could impact our stakeholders, including our employees and the communities in which we operate, such as our efforts with respect to the environment and diversity, equity and inclusion. The negative reputational impact of a significant event, including a failure to execute on customer or client contracts or strategic or operational initiatives, failure to comply with applicable laws or regulations, or failure to innovate and deliver products and services that demonstrate greater value to our customers, could affect our ability to grow and retain profitable arrangements, which could have a material adverse effect on our business, results of operations, financial position and cash flows.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We face price competition and other pressures that could compress our margins or result in premiums</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">that are insufficient to cover the cost of services delivered to our customers.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While we compete on the basis of many service and quality-related factors, we expect that price will continue to be a significant basis of competition and we may face pressure to contain premium rates. Our client contracts are subject to negotiation as clients seek to contain their costs, including by reducing benefits offered. Increasingly, our clients seek to negotiate performance guarantees that require us to pay penalties if the guaranteed performance standard is not met. Clients can easily move between our competitors and us. Our clients are well informed and typically have knowledgeable consultants that seek competing bids from our competitors before contract renewal. In addition, as brokers and benefit consultants seek to enhance their revenue streams, they look to take on services that we typically provide. Each of these events could negatively impact our financial results.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Federal and state regulatory agencies may restrict or prevent entirely our ability to implement changes in premium rates. Fiscal or other concerns related to the government-sponsored programs in which we participate, such as Medicare Advantage plans and Medicare Part D plans, may cause decreasing reimbursement rates, delays in premium payments, restrictions on implementing changes in premium rates or insufficient increases in reimbursement rates. Any limitation on our ability to maintain or increase our premium or reimbursement levels, or a significant loss of customers or clients resulting from our need to increase or maintain premium or reimbursement levels, could adversely affect our business, cash flows, financial condition and results of operations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Premiums in the Cigna Healthcare segment are generally set for one-year periods and are priced well in advance of the date on which the contract commences or renews. Our revenue on Medicare Advantage plans, Individual and Family Plans ("IFP") and Medicare Part D plans is based on rates and bids submitted midyear in the year before the contract year. Although we base the premiums we charge and our Medicare Advantage, IFP and Medicare Part D rates and bids on our estimate of future health care costs over the contract period, actual costs may exceed what we estimate in setting premiums. Our participation in health insurance exchanges through our IFP offerings involves uncertainties associated with mix and volume of business and could adversely affect our results of operations, financial position and cash flows. Our health care costs also are affected by external events that we cannot forecast or project and over which we have little or no control, including changes in laws and regulations, as well as pandemics, costly new treatments, new treatment guidelines, provider billing practices, inflation and changes in customers' health care utilization patterns, which may, among other things, impact our ability to appropriately document their health conditions. Our profitability depends, in part, on our ability to accurately predict, price for and effectively manage future health care costs. Relatively small differences between predicted and actual medical costs or utilization rates as a percentage of revenue can result in significant changes in our financial results.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Strong competition within the pharmacy benefit business has also generated greater demand for lower product and service pricing, increased revenue sharing and enhanced product and service offerings. These competitive factors have historically applied pressure on our operating margins and caused many companies, including us, to reduce the prices charged for products and services while sharing with clients a greater portion of the formulary fees and related rebates received from pharmaceutical manufacturers. Our inability to maintain positive trends, or failure to identify and implement new ways to mitigate pricing pressures, could negatively impact our ability to attract or retain clients or sell additional services, which could negatively impact our margins and have a material adverse effect on our business and results of operations. In addition, legislative reforms related to rebates, reporting, and other activities may adversely affect our competitive position, cash flows, financial condition and results of operations.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The reserves we hold for expected medical claims are based on estimates that involve an extensive degree of judgment and are inherently variable. If actual claims exceed our estimates, our operating results could be materially adversely affected, and our ability to take timely corrective actions to contain future costs may be limited.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We maintain and record medical claims reserves in our Consolidated Balance Sheets for estimated future payments. Our estimates of health care costs payable are based on a number of factors, including historical claim experience, but this estimation process requires extensive judgment. Considerable variability is inherent in such estimates, and the accuracy of the estimates is highly sensitive to changes in medical claims submission and processing patterns or procedures, changes in customer base and product mix, changes in the utilization of prescription drugs, medical or other covered items or services, changes in medical cost trends, changes in our health management practices, changes in regulations and the introduction of new benefits and products. If we are not able to accurately and promptly anticipate and detect medical cost trends, our ability to take timely corrective actions to limit future costs and reflect our current benefit cost experience in our pricing process may be limited. Additionally, we must estimate the amount of rebates payable by us under the ACA's and CMS' minimum loss ratio rules and the amounts payable by us to, and receivable by us from, the United States federal government under the ACA's remaining premium stabilization program. Because establishing reserves is an inherently uncertain process involving estimates of future losses, there can be no certainty that ultimate losses will not exceed existing reserves which may adversely affect our results of operations, financial position and cash flows.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we fail to develop and maintain satisfactory relationships with health care payers, physicians, hospitals and other health service providers and with producers and consultants, our business and results of operations may be adversely affected.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We contract with or employ physicians, hospitals and other health service providers and facilities to provide health services to our customers, as well as health care payers (as a service provider to those payers). Our results of operations are substantially dependent on our ability to contract for these services at competitive prices. In any particular market, physicians, hospitals and health service providers may enter into exclusive arrangements with competitors or simply refuse to contract with us, demand higher payments or take other actions that could result in higher medical costs or less desirable products or services for our customers. In some markets, certain providers, particularly hospitals, physician/hospital organizations and multispecialty physician groups, may have significant or controlling market positions that could result in a diminished bargaining position for us. If providers refuse to contract with us, use their market position to negotiate more favorable contracts or place us at a competitive disadvantage, our ability to market products or to be profitable in those areas could be materially adversely affected. Additionally, certain regulations may impact our ability to obtain competitive prices. Establishing collaborative arrangements with physician groups, specialist groups, independent practice associations, hospitals and health care delivery systems is key to our strategic focus to transition from volume-based fee-for-service arrangements to a value-based health care system. If such collaborative arrangements do not result in the lower medical costs that we project or if we fail to attract health care providers to such arrangements, or are less successful at implementing such arrangements </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">than our competitors, our attractiveness to customers may be reduced and our ability to profitably grow our business may be adversely affected.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ability to develop and maintain satisfactory relationships with providers may also be negatively impacted by other factors not associated with us, such as changes in Medicare or Medicaid reimbursement levels, increasing pressure on revenue and other pressures on health care providers and increasing consolidation activity among hospitals, physician groups and providers. Continuing consolidation among physicians, hospitals and other providers, the emergence of accountable care organizations, vertical integration of providers and other entities, changes in the organizational structures chosen by physicians, hospitals and providers, new market entrants, including those not traditionally in the health care industry, and the increased use of virtual care services (including telehealth) may affect the way providers interact with us and may change the competitive landscape in which we operate. In some instances, these organizations may compete directly with us, potentially affecting the way we price our products and services or causing us to incur increased costs if we change our operations to be more competitive.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Out-of-network providers for non-Medicare services are not limited by any agreement with us in the amounts they bill. For Medicare Advantage, out-of-network providers can only receive the same rate that CMS pays for Medicare services. While benefit plans place limits on the amount of charges that will be considered for reimbursement and regulations seek to prescribe payment levels, establish methodologies and dispute resolution processes, providers are increasingly sophisticated and aggressive. As a result, the outcome of disputes where we do not have a provider contract may cause us to pay higher medical or other benefit costs than we projected. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, certain of our products and services are sold in part through non-exclusive producers and consultants for whose services and allegiance we compete. Our sales could be materially adversely affected if we are unable to attract, retain and support such independent producers and consultants or if our sales strategy is not appropriately aligned across distribution channels.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we lose our relationship with one or more key pharmaceutical manufacturers, or if the payments made or discounts provided by pharmaceutical manufacturers decline, our business and results of operations could be adversely affected.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We maintain relationships with numerous pharmaceutical manufacturers, which provide us with, among other things:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">discounts for drugs we purchase to be dispensed from our home delivery and specialty pharmacies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">discounts, in the form of rebates, for drug utilization;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">fees for administering rebate programs, including invoicing, allocating and collecting rebates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">fees for services provided to pharmaceutical manufacturers by our specialty pharmacies; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">access to limited distribution specialty pharmaceuticals by our specialty pharmacies.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our contracts with pharmaceutical manufacturers are typically non-exclusive and terminable on relatively short notice by either party. The consolidation of pharmaceutical manufacturers, the termination or material alteration of our relationships, or our failure to renew contracts on market competitive terms could have a material adverse effect on our business and results of operations. In addition, arrangements between payors and pharmaceutical manufacturers have been the subject of debate in federal and state legislatures and various other public and governmental forums. Adoption of new laws, rules or regulations or changes in, or new interpretations of, existing laws, rules or regulations, relating to any of these programs could materially adversely affect our business and results of operations.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If significant changes occur within the pharmacy provider marketplace, or if other issues arise with respect to our pharmacy networks, including the loss of or adverse change in our relationship with one or more key pharmacy providers, our business and financial results could be adversely affected.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">More than 67,000 pharmacies participated in one or more of our networks as of December&#160;31, 2023. The ten largest retail pharmacy chains represent approximately 60% of the total number of stores in our largest network. In certain geographic areas of the United States, our networks may be comprised of higher concentrations of one or more large pharmacy chains. Contracts with retail pharmacies are generally non-exclusive and are terminable on relatively short notice by either party. If one or more of the larger pharmacy chains terminates its relationship with us, or is able to renegotiate terms substantially less favorable to us, our customers' access to retail pharmacies or our business could be materially adversely affected. The entry of one or more additional large pharmacy chains into the pharmacy benefit management business, the consolidation of existing pharmacy chains or increased leverage or market share by the largest pharmacy providers could increase the likelihood of negative changes in our relationship with such pharmacies. Changes in the overall composition of our pharmacy networks, or reduced pharmacy access under our networks, could have a negative impact on our claims volume or our competitiveness in the marketplace, which could cause us to fall short of certain guarantees in our contracts with clients or otherwise impair our business or results of operations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes in drug pricing or industry pricing benchmarks could materially impact our financial performance.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contracts in the prescription drug industry, including our contracts with retail pharmacy networks and our pharmacy and specialty pharmacy clients, generally use pricing metrics published by third parties as benchmarks to establish pricing for prescription drugs. If these benchmarks are no longer published by third parties, we, or our contractual partners, adopt other pricing benchmarks for establishing prices within the industry, legislation or regulation requires the use of other pricing benchmarks, or future changes in drug prices substantially deviate from our expectations, the short- or long-term impacts may have a material adverse effect on our business and results of operations. Additionally, laws such as the Inflation Reduction Act have granted CMS the ability to negotiate drug prices for certain Part D and Part B drugs, and other federal and state legislative proposals may lead to changes in drug pricing for federal health care programs.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our business depends on our ability to effectively invest in, implement improvements to and properly maintain the uninterrupted operation, availability and data integrity of our information technology and other business systems.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%"> </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business is highly dependent on maintaining effective information systems as well as the integrity and timeliness of the data we use to serve our customers and health care providers and to operate our business. If our data were found to be inaccurate or unreliable due to fraud or other error, or if we, or any of the third-party providers or subcontractors that we or they engage, were to fail to maintain information systems and data integrity effectively, we could experience operational disruptions that may impact our clients, customers and health care providers and hinder our ability to provide or establish appropriate pricing for products and services, retain and attract clients and customers, establish reserves and report financial results timely and accurately and maintain regulatory compliance, among other things.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our information technology strategy and execution are critical to our continued success. We must continue to invest in and maintain long-term solutions that will enable us to anticipate customer needs and expectations, enhance the customer experience, act as a differentiator in the market and protect against cybersecurity risks and threats or other events that could disrupt our information technology systems such as man-made or natural disasters (including those as a result of climate change). Our success is dependent, in large part, on maintaining the effectiveness of existing technology systems and continuing to deliver and enhance technology systems that support our business processes in a cost-efficient and resource-efficient manner. Increasing regulatory and legislative changes will place additional demands on our infrastructure that could have a direct impact on resources available for other projects tied to our strategic initiatives. In addition, recent trends toward greater consumer engagement in health care require new and enhanced technologies, including more sophisticated applications for mobile devices. Connectivity among technologies is becoming increasingly important. We must also develop new systems to meet current market standards and keep pace with continuing changes in information processing technology, evolving industry and regulatory standards and customer needs. Failure to do so may present compliance challenges and impede our ability to deliver services in a competitive manner. Further, because system development projects are long-term in nature, they may be more costly than expected to complete and may not deliver the expected benefits upon completion. Our failure to effectively invest in, implement improvements to and properly maintain the uninterrupted operation, availability and data integrity of our systems could adversely affect our results of operations, financial position and cash flow.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">As a large global health company, we and our vendors are subject to cyberattacks or other privacy or data security incidents. If we are unable to prevent or contain the effects of any such attacks, or fail to ensure vendors do the same, we may suffer exposure to substantial liability, reputational harm, loss of revenue or other damages.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business depends on our clients' and customers' willingness to entrust us with their health-related and other personal information ("PI"), including Protected Health Information ("PHI") that is subject to privacy, security or data breach notification laws. Computer networks or systems may be vulnerable to intrusion, computer viruses or malware, programming errors, attacks by third parties or similar disruptive problems. We have been, and will likely continue to be, the target of computer viruses or other malicious codes, unauthorized access, cyberattacks or other computer-related penetrations. There have been, and will likely continue to be, large scale cyberattacks within the health service industry. Additionally, hardware, software or applications we develop or procure from third parties may contain defects in design, manufacturer defects or other problems that could unexpectedly compromise information technology. Human or technological error has and could in the future result in, for example, unauthorized access to, acquisition, disclosure, modification, misuse, loss, or destruction of company, customer, or other third-party data or systems; theft of sensitive, regulated, or confidential data including PI and intellectual property; the loss of access to critical data or systems through ransomware, destructive attacks or other means; and business delays, service or system disruptions or denials of service.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As we increase the amount of PI that we store and share digitally, our exposure to unauthorized uses and disclosures, and data privacy and related cybersecurity risks increases, including the risk of undetected attacks, damage, loss or unauthorized access or acquisition or misappropriation of proprietary or personal information, and the cost of attempting to protect against these risks also increases. The health care data ecosystem is complex and requires data exchange with vendors, business partners, health care professionals, the government and others. If disruptions, data disclosures, security incidents or breaches are not detected quickly, their effect could be compounded. We have dedicated significant resources to implement privacy and security technologies, processes and procedures to </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">protect PI and provide employee awareness training around phishing, malware and other cyber risks; however, there are no assurances that such measures will be effective against all types of security incidents or breaches. Further, we depend on many vendors to support and assist our business, which requires such vendors to generate, store and use PI. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cybersecurity threats are rapidly evolving and those threats and the means for obtaining access to our proprietary systems are becoming increasingly sophisticated. Cyberattacks can originate from a wide variety of sources including terrorists, nation states, internal actors, or third parties, such as external service providers, and the techniques used change frequently or are often not recognized until after they have been launched. For example, there continues to be an increase in new financial fraud schemes akin to ransomware attacks on large companies whereby a cybercriminal installs a type of malicious software, or malware, that prevents a user or enterprise from accessing computer files, systems or networks and demands payment of a ransom for their return. Those parties may also attempt to fraudulently induce employees, customers or other users of our systems to disclose or inadvertently provide access to systems in order to gain access to our data or that of our customers. In addition, while we have certain standards for all vendors that provide us services, our vendors, and in turn, their own service providers, may become subject to the same types of security breaches. Finally, our offices may be vulnerable to security incidents or security attacks, acts of vandalism or theft, misplaced or lost data, human error or similar events that could negatively affect our systems and our customers' and clients' data. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The costs to eliminate or address security threats and vulnerabilities before or after a cyber-incident could be significant. Our remediation efforts may not be successful and could result in interruptions, delays, or cessation of service and loss of existing or potential customers.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the unauthorized access, acquisition, use, disclosure or dissemination of personal information, proprietary information or confidential information about us, our customers or other third parties could expose our customers' and their private information to the risk of financial or medical identity theft. Unauthorized access, acquisition, use, disclosure or dissemination of confidential and proprietary information about our business and strategy could also negatively affect the achievement of our strategic initiatives. Such events could cause us to breach our contractual obligations and violate applicable laws. These events would negatively affect our ability to compete, our reputation, customer base and revenues and expose us to mandatory disclosure requirements, government investigations, litigation and other enforcement proceedings, material fines, penalties or remediation costs and compensatory, special, punitive and statutory damages, consent orders and other adverse actions, any of which could adversely affect our business, results of operations, financial condition or liquidity.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our use of artificial intelligence and machine learning present regulatory and legal challenges that could negatively affect our business and our reputation.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our use of artificial intelligence (&#8220;AI&#8221;), including machine learning (&#8220;ML&#8221;) technologies, as well as more recent technological advances in AI/ML, pose risks to us and subject us to new and existing laws and regulations. While we are committed to responsible use of AI/ML and following applicable laws and regulations, and while we have made progress developing governance as to use of AI/ML by our organization, any failure to use AI/ML responsibly and to adhere to such laws, regulations and governance could have a material unfavorable effect on our business, results of operations, and financial condition. Depending on how existing laws and regulations are interpreted, and as new laws are passed, we may have to make changes to our business practices to comply with such obligations. These obligations may make it harder for us to conduct our business using AI/ML, lead to regulatory fines or penalties, require us retrain our AI/ML, or prevent or limit our use of AI/ML. Our use of AI/ML technologies could also result in additional compliance costs, regulatory investigations and actions, and consumer or other lawsuits. If we are unable to use AI/ML, or if regulators restrict our ability to use AI/ML for certain purposes, it could make our business less efficient, result in competitive disadvantages, and subject us to potential unfavorable business impacts. To the extent that we rely on or use the output of AI/ML, any inaccuracies, biases or errors could have unfavorable impacts on us, our business and our results of operations or financial condition. The impact of regulatory and legal risks associated with AI/ML is largely unknown.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">As a global company, we face political, legal, operational, regulatory, economic and other risks that present challenges and could negatively affect our multinational operations or our long-term growth.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a global company, our business is increasingly exposed to risks inherent in foreign operations. These risks can vary substantially by market, and include political, legal, operational, regulatory, economic and other risks, including government intervention that we do not face in our U.S. operations. The global nature of our business and operations may present challenges including, but not limited to, those arising from:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">geopolitical business conditions and demands;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">regulation that may discriminate against U.S. companies, favor nationalization or expropriate assets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">price controls or other pricing issues and exchange controls; restrictions that prevent us from transferring funds out of the countries in which we operate; foreign currency exchange rates and fluctuations and restrictions on converting currencies </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">from foreign operations into other currencies; uncertainty with respect to the adoption of new tax laws and the interpretation of tax positions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">reliance on local employees and interpretations of labor laws in foreign jurisdictions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">managing our partner relationships in countries outside of the United States;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">providing data protection on a global basis and sufficient levels of technical support in different locations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the global trend for companies to enact local data residency requirements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">acts of civil unrest, war and terrorism, including the ongoing conflict in the Middle East as well as other political and economic conflicts such as through imposition of economic or political sanctions; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">man-made disasters, natural disasters (including those arising as a result of climate change) and pandemics in locations where we operate; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">general economic and political conditions, including conditions that may become unpredictable during a U.S. presidential election year.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These factors may increase in significance as we continue to expand globally and operating in new foreign markets may require considerable management time before operations generate any significant revenues and earnings. Any one of these challenges could negatively affect our operations or long-term growth.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">International operations also require us to devote significant resources to implement controls and systems in new markets to comply with, and to ensure that our vendors and partners comply with, U.S. and foreign laws prohibiting bribery, corruption and money laundering, in addition to other regulations regarding, among other things, our products, direct-to-consumer communications, customer privacy, data protection and data residency. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or employees, restrictions or outright prohibitions on the conduct of our business and significant reputational harm. Our success depends, in part, on our ability to anticipate these risks and manage these challenges. Our failure to comply with laws and regulations governing our conduct outside of the United States or to establish constructive relations with non-U.S. regulators could have a material adverse effect on our business, results of operations, financial condition, liquidity and long-term growth. Please see "&#8212;Legal and Compliance Risks" below.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Strategic transactions involve risks and we may not realize the expected benefits because of integration or separation difficulties, underperformance relative to our expectations and other challenges.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of our strategy, we regularly consider and enter into strategic transactions, including mergers, acquisitions, joint ventures, licensing arrangements, divestitures and other relationships (collectively referred to as "strategic transactions"). There is significant competition for attractive targets and opportunities and we may be unable to identify and successfully complete strategic transactions in the future. In addition, from time to time, we evaluate alternatives for our businesses that do not meet our strategic, growth or profitability objectives, and we may divest or wind down such businesses. We may be unable to complete any such divestiture on terms favorable to us, within the expected timeframes, or at all. For example, in January 2024 we announced the HCSC transaction, which is subject to regulatory approvals and other closing conditions. We may be unable to satisfy the closing conditions in a timely manner to complete the HCSC transaction, or we may otherwise fail to receive the anticipated benefits from the transaction, even if it is completed. We may have continued financial exposure to divested businesses following the completion of any such transaction, including increased costs due to potential litigation, contingent liabilities and indemnification of the buyer related to, among other things, lawsuits, regulatory matters or tax liabilities. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ability to achieve the anticipated benefits of strategic transactions, including synergies, cost savings, innovation and operational efficiencies, is subject to numerous uncertainties and risks, including our ability to successfully combine or separate business operations, resources and systems, including data security systems and internal financial control standards, in an efficient and effective manner. Integration and separation activities may result in additional and unforeseen expenses, and the anticipated benefits may not be fully realized or may take longer to realize than expected. These activities are complex, costly and time-consuming and may divert management's attention from ongoing business concerns. Delays or issues encountered in these activities could have a material adverse effect on the revenues, expenses, operating results and financial condition of the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, the benefits of strategic transactions and the related timing could be impacted by various factors, including political instability, natural disasters, fluctuations in currency exchange rates, delays in obtaining regulatory approval and changes in regulations. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Strategic transactions could result in increased costs, including facilities and systems consolidation or separation costs and costs to retain key employees, decreases in expected revenues, earnings or cash flows and goodwill or other intangible asset impairment charges. As of December&#160;31, 2023, our goodwill and other intangible assets had a carrying value of approximately $75&#160;billion, representing 49% of our total consolidated assets. The value of our goodwill may be materially and adversely impacted if the businesses we acquire do not perform in a manner consistent with our assumptions. Future evaluations requiring an impairment to goodwill and other intangible assets could materially affect our results of operations and shareholders' equity in the period in which the impairment occurs. A material decrease in shareholders' equity could negatively impact our debt ratings or potentially impact our compliance with existing debt covenants. See Note 20 to the Consolidated Financial Statements for more information on goodwill and </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">intangibles. In addition, the trading price of our securities may decline if, among other things, we are unable to achieve our estimates of earnings growth and operational cost savings, or the transaction costs are greater than expected. The trading price also may decline if we do not achieve the perceived benefits of a transaction as rapidly or to the extent anticipated by financial or industry analysts.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, joint ventures and equity investments present risks that are different from acquisitions, including risks related to: specific operations and finances of the businesses we invest in; selection of appropriate parties; differing objectives of the various parties; competition between and among parties; compliance activities (including compliance with applicable CMS requirements); growing the business in a manner acceptable to all the parties; maintaining positive relationships among the parties, clients and customers; initial and ongoing governance of joint ventures and customer and business disruption that may occur upon a joint venture termination.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, we may finance strategic transactions by issuing common stock for some or all of the purchase price that could dilute the ownership interests of our shareholders, or by incurring additional debt that could increase costs and impact our ability to access capital in the future.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, effective internal controls are necessary to provide reliable and accurate financial reports and to mitigate the risk of fraud. The integration of businesses is likely to cause increasing complexity in our systems and internal controls and make them more difficult to manage. Any difficulties in assimilating businesses into our control system could cause us to fail to meet our financial reporting obligations. We also rely on the internal controls and financial reporting controls of joint venture entities and other entities in which we invest and their failure to maintain effectiveness or comply with applicable standards may materially and adversely affect us. Ineffective internal controls could also cause investors to lose confidence in our reported financial information that could negatively impact the trading price of our securities and our access to capital.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are dependent on the success of our relationships with third parties for various services and functions.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To improve operating costs, productivity and efficiencies, we contract with third parties for the provision of specific services. Our operations may be adversely affected if a third party fails to satisfy its obligations, if the arrangement is terminated in whole or in part or if there is a contractual dispute between us and the third party. Even though contracts are intended to provide certain protections, we have limited control over the actions of third parties. For example, noncompliance with any privacy or security laws and regulations, any security breach involving one of our third-party vendors or a dispute between us and a third-party vendor related to our arrangement could have a material adverse effect on our business, results of operations, financial condition, liquidity and reputation.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Outsourcing also may require us to change our existing operations, adopt new processes for managing these service providers or redistribute responsibilities to realize the potential productivity and operational efficiencies. If there are delays or difficulties in changing business processes or our third-party vendors do not perform as expected, we may not realize, or not realize on a timely basis, the anticipated economic and other benefits of these relationships. This could result in additional costs or regulatory compliance issues or create other operational or financial problems for us. Terminating or transitioning, in whole or in part, arrangements with key vendors could result in additional costs or penalties, risks of operational delays or potential errors and control issues during the termination or transition phase. We may not be able to find an alternative vendor in a timely manner or on acceptable terms. If there is an interruption in business or loss of access to data resulting from a security breach, termination or transition in services, we may not be able to meet the demands of our customers and, in turn, our business and results of operations could be adversely impacted.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">A significant disruption in service within our operations or among our key suppliers or other third parties could materially adversely affect our business and results of operations.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business is highly dependent upon our ability to perform, in an efficient and uninterrupted fashion, necessary business functions, such as claims processing and payment, internet support and customer call centers, data centers and corporate facilities, processing new and renewal business, maintaining appropriate shipment and storage conditions for prescriptions (such as temperature and protection from contamination) and home delivery processing. In some instances, our ability to provide services or products (including processing and dispensing prescriptions) depends on the availability of services and products provided by suppliers, providers, pharmaceutical manufacturers, vendors or shipping carriers. A disruption, or threat of disruption, in our supply chain, including as a result of future pandemics or public health emergencies, or inability to access or deliver products that meet requisite quality safety standards and patient needs in a timely and efficient manner could adversely impact our business. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Increasing natural disasters in connection with climate change could also be a direct threat to us and our third-party vendors, service providers or other stakeholders. Natural disasters, such as wildfires, hurricanes and snow and ice storms, have impacted and may continue to impact our customers and pose a risk to our employees and facilities located in the impacted region. Responses to such scenarios have and may include, among other things, making temporary policy changes, such as waiving various medical requirements, assisting with replacement medications, transferring prescriptions and expanding our help line. In addition, there is a risk that actions taken to respond to climate change could increase the cost of energy, fuel and other commodities, which would increase our operating costs. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also subject to risk as a result of information technology disruptions. Any failure or disruption of our performance of, or our ability to perform, key business functions, including through unavailability or cyberattack of our information technology systems or those of third parties (including cloud service providers), could cause slower response times, decreased levels of service satisfaction and harm to our reputation. Our systems interface with and depend on third-party systems and we could experience service denials if demand for such service exceeds capacity or a third-party system fails or experiences an interruption. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While we have adopted, and continue to enhance, business continuity and disaster recovery plans and strategies, there is no guarantee that such plans and strategies will be effective, which could interrupt the functionality of our information technology systems or those of third parties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our failure to implement adequate business continuity and disaster recovery strategies could significantly reduce our ability to provide products and services to our customers and clients, which could have material adverse effects on our business and results of operations.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">In managing medical practices and operating pharmacies, onsite clinics and other types of medical facilities, we may be subject to additional liability that could result in significant time and expense.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to contracting with physicians and other health care providers for services, we employ physicians, pharmacists, nurses and other health care providers at our home delivery and specialty pharmacies, onsite low acuity and primary care practices and infusion clinics that we manage and operate for our customers, as well as certain clinics for our employees. We also provide in-home care through health care providers that we employ, as well as through third-party contractors. As such, we may be subject to liability for certain acts, omissions, or injuries caused by our employees or agents, or occurring at one of these practices, pharmacies or clinics. The defense of any actions may require diverting personnel and other resources and incurring significant costs that could have a material adverse effect on our business, results of operations, financial condition, liquidity and reputation.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Legal and Compliance Risks</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our business is subject to substantial government regulation, as well as new laws or regulations or changes in existing laws or regulations that could have a material adverse effect on our business, results of operations, financial condition and liquidity.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business is regulated at the federal, state, local and international levels. The laws and rules governing our business and related interpretations are increasing in number and complexity, are subject to frequent change and can be inconsistent or in conflict with each other. Noncompliance with applicable regulations by us or our third-party vendors could have material adverse effects on our business, results of operations, financial condition, liquidity and reputation.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We must identify, assess and respond to new trends in the legislative and regulatory environment, as well as comply with the various existing regulations applicable to our business. There are currently pending, and in the future there will likely be, legislative or regulatory proposals which seek to manage the health services industry, including managing prescription drug costs and health records, as well as regulating drug distribution. Federal and state governments have enacted and we expect federal and state governments to continue to enact and seriously consider many broad-based legislative and regulatory proposals that will or could materially impact various aspects of the health care and related benefits system. In addition, changes to government policies not specifically targeted to the health services industry, such as a change in tax laws and the corporate tax rate or government spending cuts, could have significant impacts on our business, results of operations, financial condition and liquidity. The trading price of our securities may react to the announcement of such proposals. As disclosed in Part II, Item 5 of this Form 10-K, we have an active share repurchase program authorized by our board of directors. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Regulators, customers, investors, employees and other stakeholders are increasingly focusing on ESG matters and related disclosures. These changing rules, regulations and stakeholder expectations have resulted in, and are likely to continue to result in, increased general and administrative expenses and increased management time and attention spent complying with such regulations or meeting such expectations. For example, the European Union's ("EU&#8217;s") Corporate Sustainability Reporting Directive (&#8220;CSRD&#8221;) will require expansive disclosures on various sustainability topics such as climate change, biodiversity, workforce, supply chain, and business ethics by in-scope EU entities and certain non-EU entities with significant cross-border business in EU markets. In addition, California&#8217;s recently-enacted Climate Corporate Data Accountability Act will require annual disclosures of covered companies&#8217; Scope 1, 2 and 3 greenhouse gas emissions. We are assessing our obligations under CSRD and other enhanced reporting requirements, and expect that compliance could require substantial effort in the future. Overall, ESG matters and related stakeholder reaction may impact our reputation and have other business impacts which could adversely affect our business.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Existing or future laws, rules, U.S. Presidential Executive Orders, regulatory interpretations or judgments could force us to change how we conduct our business, affect the products and services we offer and where we offer them, restrict revenue and enrollment growth, increase our costs, including medical, operating, health care technology and administrative costs, and require enhancements to our compliance infrastructure and internal controls environment. For example, health care reforms or the invalidation, modification, repeal or replacement of the ACA or portions thereof could result in material changes to the way we conduct our business, as well as </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the loss of subsidies related to our IFP offerings and could impact the market for our products. We are required to obtain and maintain insurance and other regulatory approvals to, among other things, market many of our products, expand into additional geographic or product markets, increase prices for certain regulated products and consummate some of our acquisitions and dispositions. Delays in obtaining or failure to obtain or maintain these approvals could reduce our revenue or increase our costs. Additionally, we must maintain licenses and registrations in the jurisdictions in which we conduct business, and the suspension, material adverse modification or termination of such license and registrations could adversely affect our operations. Such licensure subjects many of our businesses to state regulation of our operations and products, as well as risks associated with doing business in those jurisdictions. Existing or future laws and rules could also require or lead us to take other actions such as changing our business practices and could increase our liability. Further, failure to effectively implement or adjust our strategic and operational initiatives, such as by reducing operating costs, adjusting premium pricing or benefit design or transforming our business model in response to regulatory changes may have a material adverse effect on our results of operations, financial condition and cash flows.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For more information on regulations affecting our business, see "Business &#8211; Regulation" in Part I, Item 1 of this Form 10-K.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">There are various risks associated with participating in government-sponsored programs, such as Medicare, including dependence upon government funding, compliance with government contracts and increased regulatory oversight and enforcement.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Through our U.S. Healthcare business, we contract with CMS and various state governmental agencies to provide managed health care services including Medicare Advantage plans and Medicare Part D plans. Additionally, our Evernorth Health Services business provides services to government entities and payors participating in government health care programs and our relationships with these government entities is subject to laws and regulations regarding government contracts.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our revenues from government-funded programs, including our Medicare programs and our government clients, are dependent, in whole or in part, upon annual funding from the federal government or applicable state or local governments. Funding for these programs is dependent on many factors outside our control, including general economic conditions, continuing government efforts to contain health care costs, budgetary constraints at the federal or applicable state or local level and general political issues and priorities. These entities generally have the right to not renew or to cancel their contracts with us on short notice without cause or if funds are not available. Unanticipated changes in funding, such as the application of sequestration by the federal or state governments, retroactive rate adjustments, a delay by Congress in raising the federal debt ceiling, or the failure to provide for continued appropriations or regular ongoing scheduled payments to us, could substantially reduce our revenues or profitability or impact our liquidity.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Medicare program has been the subject of regulatory reform initiatives. The premium rates paid to Medicare Advantage plans and Medicare Part D plans are established by contract, although the rates differ depending on a combination of factors, some of which are outside our control. For example, the base premium rate paid differs depending upon a combination of various factors such as defined upper payment limits, a member's health status, age, gender, county or region, benefit mix, member eligibility category and risk scores. Additionally, a portion of each Medicare Advantage plan's reimbursement is tied to the plan's Star Rating, with those plans receiving a rating of four or more stars eligible for quality-based bonus payments. A plan's Star Rating affects its image in the market and plans that perform well are able to offer enhanced benefits, market more effectively and for longer periods of time than other plans. The Star Rating system is subject to change annually by CMS, which may make it more difficult to achieve four stars or greater. Our Medicare Advantage plans' and Medicare Part D plans' operating results, premium revenue and benefit offerings are likely to continue to be significantly determined by their Star Ratings. There can be no assurances that we will be successful in maintaining or improving our Star Ratings in future years. In addition, audits of our performance for past or future periods may result in downgrades to our Star Ratings. If we do not maintain or improve our Star Ratings or if the quality-based bonus payments are reduced or eliminated, we may experience a negative impact on our revenue and the marketability of our plans may be adversely affected. Accordingly, our plans may not be eligible for full level quality bonuses, which could adversely affect the benefits such plans can offer, reduce membership or impact our financial performance. See the "Executive Overview - Key Transactions and Business Developments" section of MD&amp;A in Part II, Item 7 of this Form 10-K for additional information on our Star Ratings.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, if we fail to comply with CMS' contractual requirements, including data submission, enrollment and marketing, provider network adequacy, provider directory accuracy, quality measures, claims payment, continuity of care, timely and accurate processing of appeals and grievances, adverse findings under RADV audits, oversight of first tier downstream and related entities and call center performance, we may be subject to administrative actions, including enrollment sanctions or contract termination, fines or other penalties or enforcement actions that could materially impact our profitability. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We face risks related to litigation, regulatory audits and investigations.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are routinely involved in numerous claims, lawsuits, regulatory audits, investigations and other legal matters arising, for the most part, in the ordinary course of business. These legal matters could include benefit claims, breach of contract actions, tort claims (including claims related to the delivery of health care services, such as medical malpractice by staff at our affiliates' facilities, or by </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">health care practitioners who are employed by us, have contractual relationships with us, or serve as providers to our managed care networks, including as a result of a failure to adhere to applicable clinical, quality and/or patient safety standards), claims arising from consumer protection laws, false claims act laws, claims disputes under federal or state laws and disputes regarding reinsurance arrangements, employment and employment discrimination-related suits, antitrust claims (including as a result of changes in the enforcement of antitrust laws), employee benefit claims, wage and hour claims, tax, privacy, intellectual property and whistleblower claims, shareholder suits and other securities law claims, real estate disputes, claims related to disclosure of certain business practices and claims arising from customer audits and contract performance, including government contracts. In addition, we have incurred and likely will continue to incur liability for practices and claims related to our health care business, such as marketing misconduct, failure to timely or appropriately pay for or provide health care, provider network structure, poor outcomes for care delivered or arranged, provider disputes including disputes over compensation or contractual provisions, ERISA claims, allegations related to calculations of cost sharing and claims related to our administration of self-funded business. We are also routinely involved in legal matters arising from our health services business, including without limitation claims related to the dispensing of pharmaceutical products by our home delivery and specialty pharmacies, pharmacy benefit management services, such as formulary management services, health benefit management services and provider services. Our pharmacy services operations are subject to the clinical quality, patient safety and other risks inherent in the dispensing, packaging and distribution of drugs, including claims related to purported dispensing and other operational errors. There are currently, and may be in the future, attempts to bring class action lawsuits against the Company and other companies in our industry; individual plaintiffs also may bring multiple claims regarding the same subject matter against us and other companies in our industry.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Court decisions and legislative activity may increase our exposure for any of these types of claims. In some cases, substantial noneconomic or punitive damages may be sought. We procure insurance coverage to cover some of these potential liabilities, however we also self-insure a significant portion of our litigation risks. While we maintain some third-party insurance coverage, including excess liability insurance with third-party insurance carriers, certain liabilities or types of damages, such as punitive damages, may not be covered by insurance, insurers may dispute coverage or the amount of insurance may be insufficient to cover the entire damages awarded. Resolving disputes is often expensive and disruptive, regardless of the outcome. Additionally, it is possible that the resolution of current or future legal matters and claims could result in changes to our industry and business practices, losses material to our results of operations, financial condition and liquidity or damage to our reputation.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are frequently the subject of regulatory market conduct and other reviews, audits and investigations by state insurance and health and welfare and pharmacy departments, attorneys general, DOJ, CMS, DOL and the HHS-OIG and comparable authorities in foreign jurisdictions. Additionally, we have in the past been, and may in the future be, subject to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> actions in which the government may or may not intervene. With respect to our Medicare Advantage and Medicare Part D businesses, CMS and HHS-OIG perform audits to determine a health plan's compliance with federal regulations and contractual obligations, including compliance with proper coding practices and fraud and abuse enforcement practices through audits designed to detect and correct improper payments. Certain of our contracts currently have RADV audits by CMS and the HHS-OIG that are awaiting CMS finalization. These audits could result in repayments to the government. There also continues to be heightened review by federal and state regulators of business and reporting practices within the health services industry, including with respect to claims payment and related escheat practices, and increased scrutiny by other federal and state governmental agencies (such as state attorneys general) empowered to bring criminal actions in circumstances that could have previously given rise only to civil or administrative proceedings. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, various government agencies have conducted investigations and audits into certain pharmacy benefit management practices. For example, the FTC is conducting an ongoing study of the pharmacy benefit manager industry and the impact of pharmacy benefit managers on the accessibility and affordability of prescription drugs. In June 2022, the FTC issued an enforcement policy statement indicating the FTC would scrutinize the impact of rebates and fees paid by pharmaceutical manufacturers to pharmacy benefit managers and other intermediaries to determine if laws such as the FTC Act, the Clayton Act, the Robinson-Patman Act and the Sherman Act may have been violated. In July 2023, the FTC voted to issue a statement cautioning against reliance on prior advocacy letters that advocated against proposals to increase regulatory oversight and transparency of pharmacy benefit managers. The FTC previously required three group purchasing organizations to provide information and records on business practices and the six largest pharmacy benefit managers to provide information and records on topics including rebate contracts and ancillary agreements, documents related to strategies, conditions and plans for formulary placement, formulary exclusion, formulary tier assignment, and prior authorization regarding rebated drug products, and annual pharmacy reimbursement data for drugs on specialty drug lists and for rebated drug products.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many investigations and audits have resulted in companies being subject to civil penalties, including the payment of money and entry into corporate integrity agreements. For example, in September 2023, we resolved certain matters related to our Medicare Advantage Business and risk adjustment practices by entering into the Corporate Integrity Agreement (the &#8220;CIA&#8221;) with the HHS-OIG. The CIA imposes various compliance, reporting and governance obligations on us for five years and requires record reviews by an independent review organization. Our failure to meet these obligations could result in monetary penalties and our exclusion from participation in federal healthcare programs (such as Medicare and Medicaid), which could adversely impact our business, cash flows, financial condition, results of operations and reputation. Any failure, or alleged failure, to comply with various state and federal health care laws </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and regulations, including those related to the CIA or otherwise directed at preventing fraud and abuse in government funded programs, has resulted in and could in the future result in investigations or litigation, such as actions under the federal False Claims Act and similar whistleblower statutes under state laws. A successful action or claim against us could subject us to damage awards, including treble damages, fines, penalties or other enforcement actions, restrictions on our ability to market or enroll new customers, limits on expansion, restrictions or exclusions from programs or other agreements with federal or state governmental agencies, which could adversely impact our business, cash flows, financial condition, results of operations and reputation. We cannot predict what effect, if any, such government investigations and audits may ultimately have on us or on the industry in general. However, we will likely continue to experience government scrutiny and audit activity, which has and may in the future result in civil penalties.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Regulatory audits, investigations, litigation or reviews or actions by other government agencies have resulted in and could result in changes to our business practices, retroactive adjustments to certain premiums, significant fines, penalties, civil liabilities, criminal liabilities or other sanctions, including corporate integrity agreements, restrictions on our ability to participate in government programs or exclusion from such programs, market certain products or engage in business-related activities, that could have a material adverse effect on our business, results of operation, financial condition and liquidity. In addition, disclosure of an adverse investigation or audit or the imposition of fines or other sanctions could negatively affect our reputation in certain markets and make it more difficult for us to sell our products and services.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A description of material pending legal actions and other legal and regulatory matters is included in Note 24 to the Consolidated Financial Statements included in this Form 10-K. The outcome of litigation and other legal or regulatory matters is always uncertain.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we fail to comply with applicable privacy, security and data laws, regulations and standards, our business and reputation could be materially adversely affected.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Most of our activities involve the receipt, use, storage or transmission of a substantial amount of individuals' PI, including PHI. We also use aggregated and/or anonymized data for research and analysis purposes, and in some cases, provide access to such anonymized data, or analytics created from such data, to pharmaceutical manufacturers and third-party data aggregators and analysts. We may also use such information to create analytic models designed to predict, and potentially improve, outcomes and patient care. The collection, dissemination, receipt, maintenance, protection, use, transmission, disclosure, privacy, confidentiality, security, availability, integrity, creation, processing, and disposal of PI are regulated at the federal, state, international and industry levels and requirements are imposed on us by contracts with clients. In some cases, such laws, rules, regulations and contractual requirements also apply to our vendors and require us to obtain written assurances of their compliance with such requirements. We are also subject to various other consumer protection laws that regulate our communications with customers, such as the FTC Act and the Telephone Consumer Protection Act. Certain of our businesses are also subject to the Payment Card Industry Data Security Standard, which is designed to protect credit card account data as mandated by payment card industry entities. International laws, rules and regulations governing the use and disclosure of such information, such as the GDPR, can be more stringent than similar laws in the United States, and they vary across jurisdictions. In addition, more jurisdictions are regulating the transfer of data across borders and domestic privacy and data protection laws are generally becoming more onerous.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These laws, rules and contractual requirements are subject to change and the regulatory environment surrounding data security and privacy is increasingly demanding. Compliance with existing or new privacy, security and data laws, regulations and requirements may result in increased operating costs, and may constrain or require us to alter our business model or operations. For more information on privacy regulations to which we are subject, see "Business &#8211; Regulation" in Part I, Item 1 of this Form 10-K.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HIPAA requires covered entities and business associates to comply with the HIPAA privacy, security and breach rules. While we endeavor to provide appropriate protections through our contracts with our third-party service providers and in certain cases assess their security controls, we have limited oversight or control over their actions and practices. Several of our businesses act as business associates to their covered entity clients and, as a result, collect, receive, use, disclose, transmit and maintain PHI in order to provide services to these customers. HHS administers an audit program to assess HIPAA compliance efforts by covered entities and business associates. In addition, HHS continues to exercise its enforcement authority to bring enforcement actions resulting from complaints, compliance reviews, audits and investigations brought on by notification to HHS of a breach or other HIPAA violation. An audit resulting in findings or allegations of noncompliance or the implementation of an enforcement action could have an adverse effect on our results of operations, financial position, cash flows and reputation.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Noncompliance or findings of noncompliance with applicable laws, regulations or requirements, or the occurrence of any privacy or security breach involving the misappropriation, loss or other unauthorized disclosure of PI, whether by us or by one of our third-party service providers, could materially adversely affect our business and reputation, including our results of operations, financial position and cash flows.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Effective prevention, detection and control systems are critical to maintain regulatory compliance and prevent fraud; failure of these systems could adversely affect us.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Federal and state governments have made investigating and prosecuting health care and other insurance fraud and abuse a priority. Fraud and abuse prohibitions encompass a wide range of activities including kickbacks for referral of customers, billing for unnecessary medical services, improper marketing and violations of patient privacy rights. Some of our businesses are also subject to federal and state laws and regulations that may impact our relationships with health care providers and customers, including laws on self-referrals, beneficiary inducements, false claims, fee-splitting, telemedicine, corporate practice of medicine, dispensing, packaging, fulfillment, and distribution of controlled substances, other pharmaceutical products and medical devices, medical malpractice, consumer protection, product liability, narrow networks, provider tiering programs, provider contracts, overpayments, reimbursement of out-of-network claims, and licensure. The regulations and contractual requirements applicable to us are complex and subject to change and may affect our ability to market or provide our products or services. In addition, ongoing vigorous law enforcement, a highly technical regulatory scheme and the Dodd-Frank Act and related regulations enhance regulators' enforcement powers and whistleblower incentives and protections. Our compliance efforts in this area will continue to require significant resources. Failure of our prevention, detection or control systems related to regulatory compliance or the failure of employees to comply with our internal policies, including data systems security or unethical conduct by managers and employees, could adversely affect our reputation and also expose us to litigation and other proceedings, fines and penalties.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, provider or customer fraud that is not prevented or detected could impact our medical costs or those of our self-insured clients. Further, during an economic downturn, we may experience increased fraudulent claims volume that may lead to additional costs due to an increase in disputed claims and litigation.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Economic Risks</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Economic and market conditions affect the value of our financial instruments and the value of particular assets and liabilities, investment income and interest expense.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As an insurer, we have substantial investment assets that support insurance and contractholder deposit liabilities and surplus requirements in our regulated companies. The market values of our investments vary depending on economic and market conditions with no offsetting change in the value of a portion of our liabilities. A substantial portion of our investment assets are in fixed interest-yielding debt securities of varying maturities and commercial mortgage loans. The value of these investment assets can fluctuate significantly with changes in market conditions. In addition, an economic contraction could result in delay in payment of principal or interest by issuers, or defaults by issuers, reducing our investment income and requiring us to write down the value of our investments.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Significant stock market or interest rate declines could result in unfunded pension obligations resulting in the need for additional plan funding by us and increased pension expenses.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We currently have overfunded obligations in our frozen pension plans. A significant decline in the value of the plans' equity and fixed income investments or unfavorable changes in applicable laws or regulations could materially increase our expenses and change the timing and amount of required plan funding. This could reduce the cash available to us, including our subsidiaries. We are also exposed to interest rate and equity risk associated with our pension obligations. Sustained declines in interest rates could have an adverse impact on the funded status of our pension plans and our reinvestment yield on new investments. See Note 18 to the Consolidated Financial Statements for more information on our obligations under the pension plans.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">A downgrade in the financial strength ratings of our insurance subsidiaries could adversely affect new sales and retention of current business, and a downgrade in our debt ratings would increase the cost of borrowed funds and could negatively affect our ability to access capital.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial strength, claims paying ability and debt ratings by recognized rating organizations are each important factors in establishing the competitive position of insurance and health benefits companies. Ratings information by nationally recognized rating agencies is broadly disseminated and generally used throughout the industry. We believe that the claims paying ability and financial strength ratings of our principal insurance subsidiaries are important factors in marketing our products to certain customers. Our debt ratings impact both the cost and availability of future borrowings and, accordingly, our cost of capital. Each of the rating agencies reviews ratings periodically and there can be no assurance that current ratings will be maintained in the future. A downgrade of any of these ratings in the future could make it more difficult to either market our products successfully or raise capital to support business growth.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We maintain significant indebtedness in the ordinary course of business and may incur further indebtedness in the future. Our indebtedness could adversely affect our financial condition, our ability to react to changes in the economy or our industry and could divert our cash flow from operations for debt service costs, leaving us with less cash flow from operations available to fund growth, stock repurchases, dividends and other corporate purposes.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The total indebtedness of The Cigna Group was approximately $30.9 billion as of December&#160;31, 2023. Carrying indebtedness:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">requires us to dedicate a portion of our cash flow from operations to debt payments, thereby reducing the availability of cash flow to fund our operations and growth strategy, including investments, acquisitions and capital expenditures, make stock repurchases, pay dividends and for general corporate purposes;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">increases our vulnerability to general adverse economic and industry conditions, which may require us to dedicate an even greater percentage of our cash flow from operations to the payment of principal and interest on our debt and limit our access to capital markets such that additional capital may not be available or may be available only on unfavorable terms; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">exposes us to increases in interest rates to the extent increased interest expense is not offset by increased income from our investment assets; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">limits our flexibility in planning for, or reacting to, changes in or challenges relating to our business and industry.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The covenants in our debt instruments may have the effect, among other things, of restricting our financial and operating flexibility to respond to significant changes in business and economic conditions. We may incur or assume significantly more debt in the future which may subject us to additional restrictive covenants and increase the risks described above. If our cash flow and capital resources are insufficient to service our debt obligations, we may be forced to seek additional dividends from our subsidiaries, sell assets, seek additional equity or debt capital or restructure our debt.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Unfavorable developments in economic conditions may adversely affect our business, results of operations and financial condition.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many factors, including geopolitical issues, future economic downturns, man-made disasters, natural disasters (including those as a result of climate change) and pandemics, availability and cost of credit and other capital and consumer spending can negatively impact the U.S. and global economies. Our results of operations could be materially adversely affected by the impact of unfavorable economic conditions on our clients and customers (both employers and individuals), health care providers, pharmacy manufacturers, pharmacy providers and third-party vendors. For example:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Employers may take action to reduce their operating costs by modifying, delaying or canceling plans to purchase our products or making changes in the mix of products purchased that are unfavorable to us.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Higher unemployment rates, employee attrition (including challenges filling open positions in light of a competitive job market) and workforce reductions could result in lower enrollment in our employer-based plans (including an increase in the number of employees who opt out of employer-based plans) or our individual plans.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Because of unfavorable economic conditions or the ACA, employers may stop offering health care coverage to employees or elect to offer this coverage on a voluntary, employee-funded basis as a means to reduce their operating costs.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If clients are not successful in generating sufficient funds or are precluded from securing financing, they may not be able to pay, or may delay payment of, accounts receivable that are owed to us.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our clients or potential clients may force us to compete more vigorously on factors such as price and service to retain or obtain their business.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our clients may be acquired, consolidated, or otherwise fail to successfully maintain or grow their business or workforce, which could reduce the number of customers we serve or otherwise result in lower than anticipated utilization of our services.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">A prolonged unfavorable economic environment could adversely impact the financial position of hospitals and other health care providers, potentially increasing our medical costs.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our third-party vendors could significantly and quickly increase their prices or reduce their output to reduce their operating costs. Our business depends on our ability to perform necessary business functions in an efficient and uninterrupted fashion.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Other insurers' financial condition may be weakened, increasing the risk that we will receive significant assessments for obligations of insolvent insurers pursuant to guaranty associations, indemnity funds or other similar laws and regulations.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain of the foregoing events have occurred and may continue to occur, and the occurrence of these events may, individually or in the aggregate, lead to a decrease in our customer base, revenues or margins or an increase in our operating costs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%"> </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, during and following a prolonged unfavorable economic environment, federal and state budgets could be materially adversely affected, resulting in reduced or delayed reimbursements or payments in government programs such as Medicare and Social Security or under contracts with government entities. These budgetary pressures also could cause the government to impose new or a higher level of taxes or assessments on us, such as premium taxes on insurance companies and HMOs and surcharges or fees on select fee-for-service and capitated medical claims. Although we could attempt to mitigate or cover our exposure from such increased costs through, among other things, increases in premiums, there can be no assurance that we will be able to mitigate or cover all of such costs, which may have a material adverse effect on our business, results of operations, financial condition and liquidity.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are subject to the credit risk of our reinsurers.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We enter into reinsurance arrangements with other insurance companies, primarily in connection with acquisition or divestiture transactions when the underwriting company is not being acquired or sold. Under all reinsurance arrangements, reinsurers assume insured losses, subject to certain limitations or exceptions that may include a loss limit. These arrangements also subject us to various obligations, representations and warranties with the reinsurers. Reinsurance does not relieve us of liability as the originating insurer. We remain liable to the underlying policyholders if a reinsurer defaults on obligations under the reinsurance arrangement. Although we regularly evaluate the financial condition of reinsurers to minimize exposure to significant losses from reinsurer insolvencies, reinsurers may become financially unsound. If a reinsurer fails to meet its obligations under the reinsurance contract or if the liabilities exceed any applicable loss limit, we will be forced to cover the claims on the reinsured policies.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The collectability of amounts due from reinsurers is subject to uncertainty arising from a number of factors, including whether the insured losses meet the qualifying conditions of the reinsurance contract, whether reinsurers or their affiliates have the financial capacity and willingness to make payments under the terms of the reinsurance contract and the magnitude and type of collateral supporting our reinsurance recoverable, such as holding sufficient qualifying assets in trusts or letters of credit issued. Although a portion of our reinsurance exposures are secured, the inability to collect a material recovery from a reinsurer could have a material adverse effect on our results of operations, financial condition and liquidity.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">44</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_982"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span id="i5f7e770e193a41dcb7ec2bfc84b6c2f5_46"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 1B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">UNRESOLVED STAFF COMMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">None.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_985"></div><div style="margin-bottom:10pt"><span id="icc8701d4e21f45afb43092365eaa84b2_42355"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 1C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">CYBERSECURITY</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cybersecurity Strategy and Risk Management</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Cigna Group&#8217;s comprehensive cybersecurity program is supported by policies and procedures designed to protect our systems and operations as well as the sensitive personal information and data of our clients and customers from foreseeable cybersecurity threats. This program is an integral component of our enterprise risk management program. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Core to our security model is our defense-in-depth framework, comprising multiple layers of processes and technologies that help prevent, detect, and respond to threats. Our approach to safeguarding against external threats incorporates a suite of preventive technologies, including malicious email blocking, defenses against automated attacks and multifactor authentication. These strategies act to proactively intercept and neutralize cyber threats to help ensure data remains secure within our environment. Event monitoring technologies run continuously, detecting suspected intrusion attempts and alerting our Cybersecurity Incident Response team. The Cigna Group undertakes a number of critical security processes to mitigate and protect against cybersecurity risks, which include but are not limited to:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Identity and Access Management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Employees are provided with the minimum amount of access required to perform their jobs using role-based access control methodology, which defines access to our information systems based on job function. Privileged or elevated access to our systems is subject to supplemental approval requirements, increased authentication processes, and additional logging and monitoring.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Security Awareness and Training</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Events and education activities are hosted throughout the year, such as the Cybersecurity Awareness Month, expos, videos, training programs and frequent phishing simulations. The Cigna Group continuously trains workforce members on the importance of preserving the confidentiality and integrity of customer data. All new hires have mandatory information protection and privacy training as part of their onboarding, and all workforce members complete an annual cybersecurity refresh training. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Security Operations and Monitoring.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Our operational monitoring processes provide valuable insight into the effectiveness of our security program. A centralized system collects security logs and performs event correlation that creates an alert if a trigger occurs. We review any deviations from our established targets and implement corrective actions. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Change Management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Changes to hardware, software, network components, and/or processes introduced into any production environments are managed by a formal change control process. These requests include the submission of required documentation as well as the business justification for the change.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Disaster Recovery / Business Continuity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. These processes are designed to maintain service to our customers, providers and members through a wide range of adverse circumstances. Methods of recovery include rerouting business functions, relocating to an alternative site, independent &#8220;hot sites&#8221;, mobile recovery and work at home.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Intelligence Feeds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. These are used to monitor the security industry for the latest global security threats, exposures and patches to help keep company servers current with the latest security service packs, patches and hot fixes.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Physical Security. Our physical security system is utilized in an effort to properly identify appropriate individuals, authorize entry and define the working areas to which they have access. Additional controls at our data centers includes a combination of guard service, access keys and magnetic card systems.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Third-Party Vendor Security Reviews</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Suppliers that have access to, host, or pass sensitive data are subject to a rigorous vendor security review which includes questionnaires, security controls and maturity assessments, inspection of evidence of compliance and remediation or acceptance of items identified during a Risk Assessment.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Vulnerability Management / Patching</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Any discovered vulnerability is rated by severity and assigned a timeline for remediation. Patching activities are centrally managed with a focus on the identification, remediation, and analysis and closure of vulnerabilities throughout the vulnerability management lifecycle.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Cybersecurity Incident Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Our incident reporting protocol assists prompt and efficient response to cybersecurity threats. This includes links on our internal site listing globally accessible contact numbers for immediate incident reporting, a user-friendly phishing reporting tool in Outlook, and group email boxes that are monitored 24/7 for incident submissions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We routinely manage cybersecurity risks through a defined framework that includes activities aimed at the identification, assessment, treatment and monitoring of risks. Cybersecurity risk assessment results are used by senior management to make informed decisions about where to allocate resources to reduce cybersecurity risks and improve overall security posture. We examine our entire program annually with third-parties and measure the program against generally accepted industry standards and frameworks, such as an internationally recognized security control framework established by the NIST and used by companies to assess and improve their ability to prevent, detect and respond to cyberattacks. Our cybersecurity policies and standards are reviewed annually and are mainly guided by the NIST 800-53 Cybersecurity Framework. In addition to the NIST framework, we leverage the International Organization </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">for Standardization ("ISO") 27001 and 27002 standards. NIST and ISO standards are internationally accepted and provide best practice recommendations for initiating, implementing, and maintaining information security management systems. Cigna's Information Protection policies and standards are informed by NIST 800-53b, moderate level security control baseline requirements. This includes a myriad of NIST controls/control enhancements which are mapped to Cigna Information Protection policies, standards and control library. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To enhance our preparedness and practice our collective cybersecurity response capabilities, we conduct tabletop exercises developed in partnership with external security experts. These events are designed to exercise and engage some of the most critical areas of cybersecurity incident response and preparedness through an interactive/evolving, simulated scenario. This exercise provides an opportunity for us to test our response procedures, escalation and communication protocols, roles and responsibilities, legal/privacy considerations and key decision-making processes, in a safe and controlled environment. The participants in these exercises include leaders, stakeholders, subject matter experts and certain executives. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to these internal measures, the effectiveness of components of our overall cybersecurity program is frequently evaluated by external third parties, exclusive to our independent registered public accounting firm and scope of internal control over financial reporting. This includes work performed over various levels of controls assessments for specific business lines and core processes. These include Health Information Trust Alliance ("HITRUST") for health care data security, Payment Card Industry Data Security Standard (PCI DSS) for payment security, and System Organization Controls (SOC) 2 for information security and related controls. We also perform an annual maturity assessment and benchmark our security controls to identify opportunities to strengthen our cybersecurity program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of our Global Threat Management Program, a dedicated Incident Handling Team, comprising both technical and management personnel, determines the severity of a validated cybersecurity event across the enterprise and is responsible for the development and ongoing maintenance of our comprehensive Global Incident Response Plan ("GIRP"). The GIRP is reviewed quarterly at a minimum but may be updated as needed based on lessons learned, changes in key teams or processes, or other circumstances as warranted. Within the GIRP, incident handling procedures dictate actions during each phase, which include communications, actions to be performed, methods of operation and contingencies for unanticipated outcomes. Using industry best practices and continuous improvement principles, we validate strategies, document business recovery plans, and test these procedures enterprise-wide annually. Upon the discovery of an incident, a broad cross-functional Computer Security Incident Response Team is assembled, which may include but is not limited to experts from key business, technology, legal, privacy and finance sectors, to collaboratively assess the impact and materiality in order to execute a comprehensive and informed response. After an incident is contained, a thorough review is performed to determine if any existing detective or preventative controls were bypassed, or if there was a delay in detection or response. This review, which includes members from our internal audit team, drives the implementation of corrective actions to enhance and strengthen the effectiveness of our prevention, detection, and incident response controls, as applicable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cigna Information Protection ("CIP") maintains a risk register that is used to manage cybersecurity risks associated with its business activities, technology assets, and its interaction with business, Information Technology ("IT"), and security parties; internal and external. Cybersecurity risks are also periodically reviewed by Enterprise Risk Management ("ERM") to ensure appropriate oversight of cybersecurity risk management activities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Suppliers that have access to, host, or transmit The Cigna Group data are contractually required to comply with our Security Policies and Standards. Additionally, suppliers may be subject to periodic security audits or risk assessments, which include security questionnaires, security capabilities and maturity assessments, controls evidence reviews, application vulnerability assessments, public internet presence monitoring, and alignment reviews with service-specific industry standards (e.g., NIST, ISO, HIPAA, and Payment Card Industry standards). Follow-up activities are performed as needed to discuss observations, track issues and ensure remediation plans are completed to maintain compliance. Contracts with suppliers also include critical security requirements including right to audit, technology requirements, key performance metrics and service levels, and hiring practices including background checks for those who have access to The Cigna Group's network. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of the date of this report, we do not believe that any risks from any cybersecurity threats, including as a result of any previous cybersecurity incidents, have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations or financial condition. That said, as discussed more fully under Part 1, Item 1A. "Risk Factors &#8211; Strategic and Operational Risks &#8211; As a large global health company, we and our vendors are subject to cyberattacks or other privacy or data security incidents. If we are unable to prevent or contain the effects of any such attacks, or fail to ensure vendors do the same, we may suffer exposure to substantial liability, reputational harm, loss of revenue or other damages," the sophistication of cybersecurity threats continues to increase, and the preventative actions we take to reduce the risk of cybersecurity incidents and protect our systems and information may become insufficient. Accordingly, no matter how well designed or implemented our controls are, we will not be able to anticipate all attacks of these types, and we may not be able to implement effective preventive measures against such security breaches in a timely manner.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cybersecurity Governance</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Cigna Group&#8217;s Board has ultimate oversight over the Company&#8217;s privacy and cybersecurity programs and strategy and is responsible for ensuring that the Company has risk management policies and processes in place to meet and mitigate evolving risks and threats. Certain members of the Board have cybersecurity expertise, including certifications. The Board executes this oversight directly and through both the Audit Committee, for cybersecurity purposes, and the Compliance Committee, for privacy purposes. In these capacities, these committees are regularly briefed by the Global Chief Information Security Officer ("GCISO") and Chief Privacy Officer on cybersecurity and privacy matters. These briefings are designed to provide visibility about the identification, assessment, and management of critical risks, audit findings, and management&#8217;s risk mitigation strategies. Additionally, these briefings include information about current trends in the environment, incident preparedness, artificial intelligence and various components of the Company&#8217;s cybersecurity and privacy programs. Annually, the full Board reviews the Company&#8217;s cybersecurity program, including the threat landscape and related controls and periodically conducts cybersecurity tabletop exercises.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Cigna Group&#8217;s dedicated cybersecurity team is led by our GCISO. Our current GCISO joined Cigna in October 2023 and works closely with senior management to develop and innovate the cybersecurity strategy and risk management. Prior to joining the team at The Cigna Group, our GCISO held senior information security roles at other global organizations where this individual defined information security strategies, built global information security programs, implemented cybersecurity capabilities that protect consumers, wholesale partners and brand, and oversaw the security of a global payment network, a corporate network and digital assets.</span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_988"></div><div style="margin-bottom:10pt;margin-top:10pt"><span id="ibc833bfbd2ae487e849dd1f8a08eb7b9_4204"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">PROPERTIES</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At the end of 2023, our global real estate portfolio consisted of approximately 9.2 million square feet of owned and leased properties to support the operations of our reporting segments. Our domestic portfolio had approximately 8.3 million square feet in 49 states, the District of Columbia, and the U.S. Virgin Islands. Our international properties contain approximately 934 thousand square feet located throughout the following countries: Australia, Bahrain, Belgium, Canada, Cayman Islands, China, France, Germany, Hong Kong, India, Kenya, Kuwait, Lebanon, Malaysia, Oman, Saudi Arabia, Singapore, Spain, Switzerland, United Arab Emirates, and the United Kingdom.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our principal domestic office locations include the Wilde Building located at 900 Cottage Grove Road in Bloomfield, Connecticut (our corporate headquarters), Evernorth Health Services' corporate offices located at and around One Express Way in St. Louis, Missouri and Two Liberty Place located at 1601 Chestnut Street in Philadelphia, Pennsylvania. The Wilde Building measures approximately 893 thousand square feet and is owned. The St. Louis campus measures approximately 999 thousand square feet of leased space and Two Liberty Place measures approximately 209 thousand square feet of leased space.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The pharmacy operations consist of 13 home delivery pharmacies, 31 specialty pharmacies and four high-volume automated dispensing pharmacies located throughout the United States. Our high-volume automated dispensing pharmacies are located in Arizona, Indiana, Missouri and New Jersey.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the fourth quarter of 2023, we approved a strategic initiative to drive operational improvements and efficiencies. This initiative includes a reduction in the square footage of leased properties and changes how sites are utilized. See Note 17 to the Consolidated Financial Statements of this Form 10-K for additional information.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe our properties are adequate and suitable for our business as presently conducted. The foregoing does not include information on investment properties.</span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_991"></div><div style="margin-bottom:10pt;margin-top:10pt"><span id="ia128ac4feaf7466ebac340d3604d0b48_209"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 3. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">LEGAL PROCEEDINGS</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information contained under "Legal and Regulatory Matters" in Note 24 to the Consolidated Financial Statements of this Form 10-K is incorporated herein by reference.</span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_994"></div><div style="margin-bottom:10pt;margin-top:10pt"><span id="i9141d0168d37406db3bc97e2afc6c880_51"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">MINE SAFETY DISCLOSURES</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">47</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_997"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span id="i3d9a549d334f4e5d9524f2c248266f9a_5929"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Information about our Executive Officers</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The principal occupations and employment histories of our executive officers (as of February&#160;29, 2024) are listed below.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">DAVID BRAILER, 64, Executive Vice President and Chief Health Officer of The Cigna Group beginning September 2022; and Founder and Chairman of Health Evolution beginning in 2011. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">DAVID M. CORDANI, 58, Chairman of the Board of The Cigna Group beginning January 2022; Chief Executive Officer beginning December 2009; Director since October 2009; President beginning June 2008; and Chief Operating Officer from June 2008 until December 2009.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">NOELLE K. EDER, 54, Executive Vice President, Global Chief Information Officer of The Cigna Group beginning September 2020, with responsibility for the Company's technology and operations function beginning September 2023; Executive Vice President, Chief Information and Digital Officer at Hilton Worldwide Holdings from March 2018 until August 2020; Executive Vice President, Chief Card Customer Experience Officer at Capital One Financial Corporation from November 2016 until 2018; and Executive Vice President, Customer Experience and Operations at Capital One Financial Corporation from September 2014 until November 2016.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">BRIAN C. EVANKO, 47, Executive Vice President, Chief Financial Officer of The Cigna Group and President and Chief Executive Officer, Cigna Healthcare beginning January 2024; Executive Vice President and Chief Financial Officer of The Cigna Group from January 2021 to January 2024; President, Government Business from November 2017 to January 2021; and President, U.S. Individual Business from August 2013 to November 2017.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">NICOLE S. JONES, 53, Executive Vice President, Chief Administrative Officer, and General Counsel for The Cigna Group beginning September 2023; Executive Vice President and General Counsel of The Cigna Group beginning June 2011 to September 2023; Senior Vice President and General Counsel of Lincoln Financial Group from May 2010 until June 2011; Vice President and Deputy General Counsel of The Cigna Group from April 2008 until May 2010; and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Corporate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Secretary from September 2006 until April 2010.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ERIC P. PALMER, 47, Executive Vice President, Enterprise Strategy of The Cigna Group and President and Chief Executive Officer, Evernorth Health Services beginning January 2024; President and Chief Executive Officer of Evernorth Health Services beginning January 2022 to January 2024; President and Chief Operating Officer from January 2021 until December 2021; Executive Vice President and Chief Financial Officer of The Cigna Group from June 2017 to January 2021; Deputy Chief Financial Officer from February 2017 until June 2017; Senior Vice President, Chief Business Financial Officer from November 2015 to February 2017; and Vice President, Business Financial Officer, Health Care from April 2012 to November 2015.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">MICHAEL W. TRIPLETT, 62, Special Advisor beginning January 2024; President, U.S. Commercial of Cigna Healthcare beginning February 2017 to January 2024; and Regional Segment Lead from June 2009 to February 2017.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">48</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_1000"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">PART II</span></div><div style="text-align:center"><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_1003"></div><div style="margin-bottom:10pt;margin-top:10pt"><span id="i6b01a8b757944252b1aaeef272863d6b_9"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 5. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES </span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_1006"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the number of shareholders of record was 23,435. The Cigna Group's common stock is listed with, and trades on, the New York Stock Exchange under the symbol "CI".</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, The Cigna Group declared and paid quarterly cash dividends of $1.23 per share of The Cigna Group common stock. The Cigna Group paid quarterly cash dividends of $1.12 per share in 2022 and $1.00 per share in 2021. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;2, 2024, the Board of Directors declared the first quarter cash dividend of $1.40 per share of The Cigna Group common stock to be paid on March&#160;21, 2024 to shareholders of record on March&#160;6, 2024. The Cigna Group currently intends to pay regular quarterly dividends, with future declarations subject to approval by its Board of Directors and the Board's determination that the declaration of dividends remains in the best interests of The Cigna Group and its shareholders. The decision of whether to pay future dividends and the amount of any such dividends will be based on the Company's financial position, results of operations, cash flows, capital requirements, the requirements of applicable law and any other factors the Board may deem relevant. See Note 9 to the Consolidated Financial Statements for further information on dividend payments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For information on securities authorized for issuance under our existing equity compensation plans, see Item 12 under the heading "Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters."</span></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_1009"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Stock Price Performance Graph</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The graph below compares the cumulative total shareholder return on our common stock for the five years ended December 31, 2023 with the cumulative total return of the Standard &amp; Poor's ("S&amp;P") 500 Index and the S&amp;P 500 Health Care Index. The stock performance shown in the graph is not intended to forecast or be indicative of future performance.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><img src="ci-20231231_g2.jpg" alt="Capture.jpg" style="height:457px;margin-bottom:5pt;vertical-align:text-bottom;width:662px"/></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_904"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about The Cigna Group's share repurchase activity for the quarter ended December&#160;31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total # of shares purchased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Average price paid per share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total # of shares purchased as part of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">publicly announced program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approximate dollar value of shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">that may yet be purchased as part</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of publicly announced program </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(in millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 1-31, 2023</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,520,890</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">300.75</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,520,691</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,346</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 1-30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">131,656</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">313.82</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">128,550</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,306</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 1-31, 2023</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,213</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">287.87</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11,306</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,655,759</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">301.76</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,649,241</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes shares tendered by employees under the Company's equity compensation plans as follows: 1) payment of taxes on vesting of restricted stock (grants and units) and strategic performance shares and 2) payment of the exercise price and taxes for certain stock options exercised. Employees tendered 199 shares in October, 3,106 shares in November and 3,213 shares in December 2023.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">Additionally, the Company maintains a share repurchase program authorized by the Board. Under this program, the Company may repurchase shares from time to time, depending on market conditions and alternate uses of capital. The timing and actual number of shares repurchased will depend on a variety of factors, including price, general business and market conditions and alternate uses of capital. The share repurchase program may be effected through Rule 10b5-1 plans, open market purchases, each in compliance with Rule 10b-18 under the Exchange Act, or privately negotiated transactions. The program may be suspended or discontinued at any time and does not have an expiration date. In December 2023, the Board increased repurchasing authority by an additional $10.0 billion. In February 2024, as part of our existing share repurchase program, we entered into accelerated share repurchase agreements ("2024 ASR agreements") to repurchase $3.2 billion of common stock in aggregate. We received an initial delivery of approximately 7.6&#160;million shares of our common stock representing $2.6 billion of the total $3.2 billion remitted. Including the impact of the 2024 ASR agreements, from January&#160;1, 2024 through February&#160;28, 2024, we repurchased 10.1 million shares for approximately $4.0 billion. Share repurchase authority was $7.3 billion as of February&#160;28, 2024. See Note 9 to the Consolidated Financial Statements for further information on our ASR agreements.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Approximate dollar value of shares is as of the last date of the applicable month and excludes the impact of excise tax.</span></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_1012"></div><div style="margin-bottom:10pt"><span id="idebd98cd51944417afa0559681781c10_22"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 6. [Reserved]</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_685"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span id="ibbc01ce00e1b48c5a8e8a143f88184e4_11"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 7. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.567%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PAGE</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_706">Executive Overview</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_706">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_784">Liquidity and Capital Resources</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_784">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_814">Critical Accounting Estimates</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_814">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_826">Segment Reporting</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_826">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_832">Evernorth Health Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_832">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_841">Cigna Healthcare</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_841">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_850">Other Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_850">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_856">Corporate</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_856">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_865">Investment Assets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_865">69</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_694"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&amp;A") is intended to provide information to assist you in better understanding and evaluating The Cigna Group's financial condition as of December&#160;31, 2023 compared with December&#160;31, 2022 and our results of operations for 2023 compared with 2022 and 2021 and is intended to help you understand the ongoing trends in our business. We adopted amended accounting guidance for long-duration insurance contracts effective January 1, 2023. This MD&amp;A has been retrospectively adjusted to conform to the new basis of accounting. The impact of this amended guidance is immaterial. Additionally, during the fourth quarter of 2023, our U.S. Commercial and U.S. Government operating segments were merged to form the U.S. Healthcare operating segment within the Cigna Healthcare reportable segment. For comparisons of our results of operations for 2022 compared with 2021, please refer to the previously filed MD&amp;A included in Part II, Item 7 of our Form 10-K for the year ended December&#160;31, 2022. We encourage you to read this MD&amp;A in conjunction with our Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K ("Form 10-K") and the "Risk Factors" contained in Part I, Item 1A of this Form 10-K. </span></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_697"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Unless otherwise indicated, financial information in this MD&amp;A is presented in accordance with accounting principles generally accepted in the United States of America ("GAAP"). See Note 2 to the Consolidated Financial Statements in this Form 10-K for additional information regarding the Company's significant accounting policies and additional information regarding the adoption of amended accounting guidance for long-duration insurance contracts effective January 1, 2023. In some of our financial tables in this MD&amp;A, we present either percentage changes or "N/M" when those changes are so large as to become not meaningful. Changes in percentages are expressed in basis points ("bps").</span></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_700"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">In this MD&amp;A, our consolidated measures "adjusted income from operations," earnings per share on that same basis and "adjusted revenues" are not determined in accordance with GAAP and should not be viewed as substitutes for the most directly comparable GAAP measures of "shareholders' net income," "earnings per share" and "total revenues." We also use pre-tax adjusted income (loss) from operations and adjusted revenues to measure the results of our segments.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The Company uses "pre-tax adjusted income (loss) from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management believes these metrics best reflect the underlying results of business operations and permit analysis of trends in underlying revenue, expenses and profitability. We define adjusted income from operations as shareholders' net income (or income before income taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding net realized investment results, amortization of acquired intangible assets, and special items. The Cigna Group's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. Consolidated adjusted income (loss) from operations is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders' net income. See the below Financial Highlights section for a reconciliation of consolidated adjusted income from operations to shareholders' net income. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future underlying performance of the business. Adjusted revenues is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, total revenues. See the below Financial Highlights section for a reconciliation of consolidated adjusted revenues to total revenues.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">51</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_706"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span id="ibb2f9413d4d8457bbe54838c0b086b3c_485"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">EXECUTIVE OVERVIEW</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Cigna Group, together with its subsidiaries (either individually or collectively referred to as the "Company," "we," "us" or "our") is a global health company with a mission of helping those we serve improve their health and vitality. Our subsidiaries offer a differentiated set of pharmacy, medical, behavioral, dental and related products and services. For further information on our business and strategy, see Part 1, Item 1, "Business" of this Form 10-K. </span></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_709"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Financial Highlights</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See Note 1 to the Consolidated Financial Statements for a description of our segments. Effective January 1, 2023, we adopted amended accounting guidance for long-duration insurance contracts. Prior period financial highlights and results of operations have been retrospectively adjusted to conform to this new basis of accounting. The impact of this amended guidance is immaterial. See Note 2 to the Consolidated Financial Statements for additional information.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_715"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Summarized below are certain key measures of our performance by segment:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.805%"><tr><td style="width:1.0%"/><td style="width:49.115%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.517%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.952%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.957%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial highlights by segment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td><td colspan="6" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023 vs. 2022</span></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 vs. 2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjusted revenues by segment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Evernorth Health Services</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">153,499</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140,335&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131,912&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cigna Healthcare</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51,205</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Operations</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">596</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,263&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,989&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate, net of eliminations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(9,978)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,991)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,475)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">195,322</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180,644&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174,069&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net realized investment results from certain equity method investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/M</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">195,265</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180,518&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174,069&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders' net income</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,164</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,704&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,370&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjusted income from operations</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,448</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,313&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,982&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Earnings per share (diluted)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shareholders' net income</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17.39</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.41&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.75&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted income from operations</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">25.09</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.36&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.48&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="27" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax adjusted income (loss) from operations by segment</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Evernorth Health Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,442</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cigna Healthcare</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,478</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,099&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,601&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">96</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">903&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate, net of eliminations</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,698)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,466)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,339)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consolidated pre-tax adjusted income from operations</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,318</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,269&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,983&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">146</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net realized investment (losses) gains </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(613)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/M</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,819)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,876)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,998)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Special items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,997)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(451)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/M</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/M</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,513</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,397&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,790&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes the Company's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting.</span></div><div style="text-indent:9pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For further analysis and explanation of each segment's results, see the "Segment Reporting" section of this MD&amp;A.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">52</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_718"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.094%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.716%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.094%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.889%"/><td style="width:0.1%"/></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Results of Operations (GAAP basis)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="12" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td><td colspan="12" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="12" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023 vs. 2022</span></td><td colspan="12" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 vs. 2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmacy revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">137,243</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,566&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121,413&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,677&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,153&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44,237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,238)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fees and other revenues</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,619</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,881&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,953&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,738&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">928&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,166</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(394)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">195,265</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180,518&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174,069&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,747&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,449&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmacy and other service costs</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">133,801</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124,834&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117,553&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,967&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,281&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical costs and other benefit expenses</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">36,287</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,184&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,565&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,103&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,381)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14,822</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,819</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,876&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,998&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total benefits and expenses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">186,729</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172,068&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166,128&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,661&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,940&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,536</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,450&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,941&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,446)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,228)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt extinguishment costs</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/M</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/M</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Loss) gain on sale of businesses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,499)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,161)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/M</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/M</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net realized investment (losses) gains</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(78)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(487)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(685)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/M</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,513</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,397&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,790&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,884)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,607&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total income taxes</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">141</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,615&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,370&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,474)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,372</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,782&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,420&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,410)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,362&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">208</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders' net income</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,164</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,704&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,370&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,540)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,334&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consolidated effective tax rate</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,660)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical customers (in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19,780</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,004&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,081&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,776&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">923&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt"><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_721"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.264%"/><td style="width:0.1%"/></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reconciliation of Shareholders' Net Income (GAAP) to Adjusted Income from Operations</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="24" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">After-tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">After-tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">After-tax</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders' net income</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,164</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,704&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,370&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments to reconcile to adjusted income from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net realized investment losses (gains) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">135</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">114</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,819</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,413</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Special items</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss (gain) on sale of businesses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,499</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,429</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,662)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,332)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charge for organizational efficiency plan</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">252</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">193</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charges (benefits) associated with litigation matters</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">201</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">171</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Integration and transaction-related costs</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax (benefits), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,071)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt extinguishment costs </span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total special items</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,997</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">757</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,533)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,232)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjusted income from operations</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,448</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,313&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,982&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes the Company's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.264%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reconciliation of Shareholders' Net Income (GAAP) to Adjusted Income from Operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="24" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Diluted Earnings Per Share)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">After-tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">After-tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">After-tax</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders' net income</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17.39</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.41&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.75&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments to reconcile to adjusted income from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net realized investment losses (gains) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.45</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.38</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.96&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.59&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.58)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.47)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6.13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4.77</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Special items</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss (gain) on sale of businesses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5.05</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4.81</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charge for organizational efficiency plan</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.85</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.65</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.07&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.49&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.35&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charges (benefits) associated with litigation matters</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.68</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.58</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Integration and transaction-related costs</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.43&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.33&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.50&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax (benefits), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3.61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt extinguishment costs </span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.41&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.32&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total special items</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6.73</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.55</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.90)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.94)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.32&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.82&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjusted income from operations</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">25.09</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.36&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.48&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes the Company's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting.</span></div><div style="margin-bottom:10pt;text-indent:9pt"><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_724"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Commentary: 2023 versus 2022</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The commentary presented below, and in the segment discussions that follow, compare results for the year ended December&#160;31, 2023 with results for the year ended December&#160;31, 2022.</span></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_6064"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Shareholders' net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> decreased 23%, reflecting the estimated loss associated with the sale of our Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits and CareAllies businesses (the "HCSC transaction"), the absence of the gain on the sale of our life, accident and supplemental health benefits business in six countries sold on July 1, 2022 (the "Chubb transaction"), partially offset by foreign deferred tax benefits recorded in the fourth quarter of 2023 as described further under "effective tax rate" below.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Adjusted income from operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> increased 2%, primarily driven by higher earnings in our Cigna Healthcare and Evernorth Health Services segments, largely offset by the absence of earnings reported in the first half of 2022 from the businesses divested in the Chubb transaction and increased interest expense and pension costs.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Medical customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> increased 10%, reflecting growth in fee-based customers as well as in Individual and Family Plans and Medicare Advantage customers. See Part I, Item 1 of this Form 10-K for definitions of Cigna Healthcare's market segments.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Pharmacy revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">increased 7%, reflecting inflation on branded drugs as well as growth in specialty. See the "Segment Reporting - Evernorth Health Services Segment" section of this MD&amp;A for further discussion.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Premiums</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> increased 11% reflecting insured customer growth and higher premium rates in Cigna Healthcare due to anticipated underlying medical cost trend. See the "Segment Reporting - Cigna Healthcare Segment" section of this MD&amp;A for further discussion. These favorable effects were partially offset by a decline in premiums due to the Chubb transaction.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Fees and other revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">increased 16%, primarily reflecting client growth from our continued affordability services within Evernorth Health Services.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Net investment income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> increased 1%, primarily due to growth in average assets, largely offset by the unfavorable impact of the Chubb transaction. See the "Investment Assets" section of this MD&amp;A for further discussion.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Pharmacy and other service costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">increased 7%, reflecting inflation on branded drugs as well as growth in specialty.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Medical costs and other benefit expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">increased 13%, primarily reflecting insured customer growth and medical cost trend in Cigna Healthcare, partially offset by the impact of the Chubb transaction.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">increased 13%, primarily driven by volume-related expenses in Cigna Healthcare due to business growth, as well as increased investments to support the onboarding of new clients and continued advancement of our digital </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">capabilities and care solutions in Evernorth Health Services. Increased expenses were also driven by costs reported in 2023 for an organizational efficiency plan and litigation settlements. These increases were partially offset by the impact of the Chubb transaction.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Interest expense and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> increased 18%, primarily reflecting higher interest rates on our indebtedness and increased pension costs. See the "Segment Reporting - Corporate" section of this MD&amp;A for further discussion. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">(Loss) / gain on sale of businesses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The loss reported in 2023 primarily reflects asset write-downs and estimated costs related to the HCSC transaction. In 2022, the reported gain reflects the impact of the Chubb transaction, which closed on July 1, 2022. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Realized investment results</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> were substantially improved, primarily due to lower mark-to-market losses on investments. See Note 12 to the Consolidated Financial Statements for further discussion.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The effective tax rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> decreased substantially driven by foreign deferred tax benefits. Also contributing to the decrease were favorable results relative to the Company's foreign operations and the release of uncertain tax positions resulting from favorable audit developments. These favorable effects were partially offset by the impact of the valuation allowance recorded resulting from the HCSC transaction. See Note 23 to the Consolidated Financial Statements for additional information. </span></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_730"></div><div><span id="ic864c1e107e4448283d1dcb113c89bc0_19"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Recent Events</span></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_733"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Economic Conditions</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We continue to monitor global economic conditions, including inflation, labor market dynamics and recent geopolitical events. We continue to proactively address impacts to our pricing with third parties (including vendors, health care providers and drug providers), our investment portfolio and our workforce. We are also monitoring the potential impact on client and customer health care needs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our results of operations or cash flows for the year ended December&#160;31, 2023 were not materially impacted by inflation, labor market dynamics, or recent geopolitical events. For further information regarding risks we encounter in our business due to economic conditions, see "Risk Factors" contained in Part I, Item 1A of this Form 10-K.</span></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_736"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Conflict in the Middle East</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Cigna Group serves a limited number of customers and clients in the impacted regions in the Middle East. We have not experienced significant impacts to date on our investment portfolio, financial position or results of operations. For a more complete discussion of the risks we encounter in our business, see "Risk Factors" contained in Part I, Item 1A of this Form 10-K.</span></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_745"></div><div><span id="ibb805cc262ba488ab2d879b237a75d75_8"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Key Transactions and Business Developments</span></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_549755820230"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Sale of Medicare Advantage and Related Businesses</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2024, the Company entered into a definitive agreement to sell the Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits and CareAllies businesses within the U.S. Healthcare operating segment to Health Care Service Corporation ("HCSC") for $3.3 billion cash, subject to applicable regulatory approvals and other customary closing conditions. See Note 6 to the Consolidated Financial Statements for further information.</span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_5996"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Organizational Efficiency Plan</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the fourth quarter of 2023, the Company approved a strategic realignment to drive greater operating effectiveness and efficiency. This plan positions us to be more efficient and focused to deliver differentiated value and services to our clients and customers. The Company recognized a charge in Selling, general and administrative expenses of $252 million, pre-tax ($193 million, after-tax). We expect substantially all of the accrued liability to be paid by the end of 2024. We expect to realize annualized after-tax savings of approximately $280 million. A significant portion of the savings is expected to be recognized in 2024. See Note 17 to the Consolidated Financial Statements for further information.</span></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_748"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CarepathRx Health System Solutions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2023, Evernorth Health, Inc. acquired a minority interest in CarepathRx Health Systems Solutions ("CHSS"). CHSS provides integrated hospital pharmacy solutions to support patients across their complete health care journey. By pairing Evernorth Health Services' diverse specialty and care expertise with CHSS' robust pharmacy and infusion management capabilities, technology solutions and health system relationships, we can further improve, expand and accelerate pharmacy care delivery for the growing </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">number of patients with chronic and complex care needs. See Note 5 to the Consolidated Financial Statements for further discussion of this investment.</span></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_751"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">VillageMD</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2023, the Company became a minority owner in VillageMD by investing $2.7 billion in VillageMD preferred equity. VillageMD (majority-owned by Walgreens Boots Alliance, Inc.) provides health care services for individuals and communities across the United States, with primary, multi-specialty and urgent care providers serving patients in traditional clinic settings, in patients' homes and online appointments. VillageMD and its subsidiaries operate in 26 markets and are responsible for millions of patients. See Note 12 to the Consolidated Financial Statements for further discussion of this investment. </span></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_757"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Centene Corporation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Effective January 1, 2024, Evernorth Health Services and Centene Corporation ("Centene") have a multi-year agreement to manage pharmacy benefit services and make prescription medications more accessible and affordable for Centene's approximately 20 million customers. In addition to greater savings on prescription drugs, Centene customers will also have access to Express Scripts' extensive national network of retail pharmacies.</span></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_766"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Medicare Star Quality Ratings ("Star Ratings")</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Centers for Medicare and Medicaid Services ("CMS") uses a Star Rating system to measure how well Medicare Advantage ("MA") plans perform. Categories of measurement include quality of care and customer service. Star Ratings range from one to five stars. CMS recognizes plans with Star Ratings of four stars or greater with quality bonus payments and the ability to offer enhanced benefits. On October 13, 2023, CMS announced Medicare Star Ratings for bonus payments to be received in 2025. We estimate 67% of our MA customers to be in four star or greater plans for bonus payments to be received in 2024 and 2025 (based upon the current customer mix associated with the announced Star Ratings). See Part I, Item I, "Business - Regulation" section of this Form 10-K for further discussion of Star Ratings.</span></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_769"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Medicare Advantage Rates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 31, 2023, CMS released the final Calendar Year 2024 Medicare Advantage Program and Part D Payment Policies (the "2024 Final Notice"). On January 31, 2024, CMS released the Calendar Year 2025 Advance Notice for Medicare Advantage and Part D Prescription Drug Programs (the "Advance Notice"). CMS will accept comments on the Advance Notice through March 1, 2024, before publishing the final rate announcement by April 1, 2024. The Advance Notice is subject to the required notice and comment period, and we cannot predict when or to what extent CMS will adopt the proposals in the Advance Notice. We are in the process of analyzing the potential implications of the Advance Notice.</span></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_778"></div><div><span id="i74408ef6abac4d29baaf20f3770d5f86_35"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">LIQUIDITY AND CAPITAL RESOURCES</span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_781"></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.043%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Summary</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,822</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,775</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,993&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,545&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28,155</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shareholders' equity</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46,223</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,675&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,958&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_784"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Liquidity</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We maintain liquidity at two levels: the subsidiary level and the parent company level.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash requirements at the subsidiary level generally consist of:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">pharmacy, medical costs and other benefit payments;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">expense requirements, primarily for employee compensation and benefits, information technology and facilities costs; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">income taxes; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">debt service. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our subsidiaries normally meet their liquidity requirements by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">maintaining appropriate levels of cash, cash equivalents and short-term investments;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">using cash flows from operating activities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">matching investment durations to those estimated for the related insurance and contractholder liabilities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">selling investments; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">borrowing from affiliates, subject to applicable regulatory limits.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash requirements at the parent company level generally consist of:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">debt service; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">payment of declared dividends to shareholders;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">lending to subsidiaries as needed; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">pension plan funding.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The parent company normally meets its liquidity requirements by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">maintaining appropriate levels of cash and various types of marketable investments;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">collecting dividends from its subsidiaries;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">using proceeds from issuing debt and common stock; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">borrowing from its subsidiaries, subject to applicable regulatory limits.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividends from our insurance, Health Maintenance Organization ("HMO") and certain foreign subsidiaries are subject to regulatory restrictions. See Note 22 to the Consolidated Financial Statements in this Form 10-K for additional information regarding these restrictions. Most of the Evernorth Health Services segment operations are not subject to regulatory restrictions regarding dividends and therefore provide significant financial flexibility to The Cigna Group.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With respect to our investment portfolio, we support the liquidity needs of our businesses by managing the duration of assets to be consistent with the duration of liabilities. We manage the portfolio to both optimize returns in the current economic environment and meet our liquidity needs.</span></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_790"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash flows were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.043%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11,813</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,656&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,191&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash (used in) provided by investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash proceeds from sales of businesses, net of cash sold</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,835&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(447)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,833)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net investment purchases</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2,835)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(272)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(660)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,573)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,295)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(332)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(170)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net investing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5,174)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,098&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,611)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash (used in) financing activities:</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt (repayments) issuances</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(278)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,559)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock repurchase</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2,284)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,607)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,742)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,384)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,341)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(282)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net financing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4,294)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,240)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,212)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign currency effect on cash</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,361</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,697)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following discussion explains variances in the various categories of cash flows for the year ended December&#160;31, 2023 compared with the same period in 2022. For comparisons of liquidity and capital resources for the year ended December 31, 2022 compared with the year ended December 31, 2021, please refer to the previously filed MD&amp;A included in Part II, Item 7 of our 2022 Form 10-K.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_793"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating activities</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash flows from operating activities consist principally of cash receipts and disbursements for pharmacy revenues and costs, premiums, fees, investment income, taxes, benefit costs and other expenses.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating cash flows increased for the year ended December&#160;31, 2023 due to higher insurance related liabilities, acceleration of cash proceeds from the accounts receivable factoring facility, lower income tax payments and higher CMS Part D annual settlement.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing activities</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company invested $2.7 billion in VillageMD in 2023. This, combined with the absence of the net $4.9 billion proceeds received from the Chubb transaction in 2022, resulted in an increase in cash used in investing activities.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing activities</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company had lower share repurchases and lower net debt outflows in 2023. These factors resulted in a decrease in cash used in financing activities in 2023.</span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_796"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Capital Resources</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our capital resources consist primarily of cash, cash equivalents and investments maintained at regulated subsidiaries required to underwrite insurance risks, cash flows from operating activities, our commercial paper program, credit agreements and the issuance of long-term debt and equity securities. Our businesses generate significant cash flow from operations, some of which is subject to regulatory restrictions relative to the amount and timing of dividend payments to the parent company. Dividends received from U.S. regulated subsidiaries were $1.2 billion for the year ended December&#160;31, 2023 and $1.9 billion for the year ended December&#160;31, 2022. This decrease was due in part to lower statutory earnings in 2022 and additional capital held at subsidiaries to support business growth, which is in line with our capital planning. Non-regulated subsidiaries also generate significant cash flow from operating activities, which is typically available immediately to the parent company for general corporate purposes. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We prioritize our use of capital resources to:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">invest in capital expenditures, primarily related to technology to support innovative solutions for our clients and customers, provide the capital necessary to maintain or improve the financial strength ratings of subsidiaries and to repay debt and fund pension obligations if necessary;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">pay dividends to shareholders;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">consider acquisitions and investments that are strategically and economically advantageous; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">return capital to shareholders through share repurchases.</span></div><div style="margin-bottom:12pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Funds Available</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Commercial Paper Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Cigna Group maintains a commercial paper program and may issue short-term, unsecured commercial paper notes privately placed on a discount basis through certain broker-dealers at any time not to exceed an aggregate amount of $5.0 billion. The net proceeds of issuances have been and are expected to be used for general corporate purposes. The commercial paper program had approximately $1.2 billion outstanding at December 31, 2023.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revolving Credit Agreements. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our revolving credit agreements provide us with the ability to borrow amounts for general corporate purposes, including for the purpose of providing liquidity support if necessary under our commercial paper program discussed above. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, The Cigna Group's revolving credit agreements include: a $4.0 billion five-year revolving credit and letter of credit agreement that expires in April 2028; and a $1.0 billion 364-day revolving credit agreement that expires in April 2024. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, we had $5.0 billion of undrawn committed capacity under our revolving credit agreements (these amounts are available for general corporate purposes, including providing liquidity support for our commercial paper program), $3.8 billion of remaining capacity under our commercial paper program and $8.0 billion in cash and short-term investments, approximately $0.8 billion of which was held by the parent company or certain non-regulated subsidiaries. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See Note 8 to the Consolidated Financial Statements for further information on our credit agreements and commercial paper program. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our debt-to-capitalization ratio was 40.1% at December&#160;31, 2023 and 41.0% at December&#160;31, 2022.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We actively monitor our debt obligations and engage in issuance or redemption activities as needed in accordance with our capital management strategy.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Subsidiary Borrowings. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the sources of liquidity discussed above, the parent company can borrow an additional $2.2 billion from its subsidiaries without further approvals as of December&#160;31, 2023.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;text-decoration:underline">Use of Capital Resources</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Long-term debt. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2023, we repaid $2.9 billion of senior notes at maturity. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Capital expenditures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Capital expenditures for property, equipment and computer software were $1.6 billion in 2023 compared to $1.3 billion in the year ended December&#160;31, 2022. This increase reflects our continued strategic investment in technology for future growth. We expect to deploy approximately $1.5 billion in capital expenditures in 2024. Anticipated capital expenditures will be funded primarily from operating cash flow.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Dividends</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Cigna Group declared and paid quarterly cash dividends of $1.23 per share of its common stock during 2023, compared to quarterly cash dividends of $1.12 per share during 2022. See Note 9 to the Consolidated Financial Statements for further information on our dividend payments. On February&#160;2, 2024, the Board of Directors declared the first quarter cash dividend of $1.40 per share of The Cigna Group common stock to be paid on March&#160;21, 2024 to shareholders of record on March&#160;6, 2024. The Cigna Group currently intends to pay regular quarterly dividends, with future declarations subject to approval by its Board of Directors and the Board's determination that the declaration of dividends remains in the best interests of the Company and its shareholders. The decision of whether to pay future dividends and the amount of any such dividends will be based on the Company's financial position, results of operations, cash flows, capital requirements, the requirements of applicable law and any other factors the Board may deem relevant.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share repurchases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We maintain a share repurchase program authorized by our Board of Directors, under which we may repurchase shares of our common stock from time to time. The timing and actual number of shares repurchased will depend on a variety of factors including price, general business and market conditions and alternate uses of capital. The share repurchase program may be effected through open market purchases in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including through Rule 10b5-1 trading plans or privately negotiated transactions. The program may be suspended or discontinued at any time. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We repurchased 7.8&#160;million shares for approximately $2.3 billion during the year ended December&#160;31, 2023, compared to 27.4 million shares for approximately $7.6 billion during the year ended December&#160;31, 2022. In December 2023, the Board increased repurchase authority by an additional $10.0 billion. We expect to repurchase $5.0 billion of common stock in the first half of 2024. A portion of this repurchase was executed in February 2024 via an Accelerated Share Repurchase ("ASR") as described below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2024, as part of our existing share repurchase program, we entered into separate ASR agreements ("2024 ASR agreements") with Deutsche Bank AG and Bank of America, N.A. (collectively, the "2024 Counterparties") to repurchase $3.2 billion of common stock in aggregate. We remitted $3.2 billion to the 2024 Counterparties and received an initial delivery of approximately 7.6&#160;million shares of our common stock on February 15, 2024 representing $2.6 billion of the total remitted. We expect final settlement under the 2024 ASR agreements to occur in the second quarter of 2024. See Note 9 to the Consolidated Financial Statements for further information on our 2024 ASR agreements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Including the impact of the 2024 ASR agreements, from January&#160;1, 2024 through February&#160;28, 2024, we repurchased 10.1 million shares for approximately $4.0 billion. Share repurchase authority was $7.3 billion as of February&#160;28, 2024. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Strategic investments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2023, we became a minority owner in VillageMD by investing $2.7 billion in VillageMD preferred equity. See Note 12 to the Consolidated Financial Statements for further discussion of this investment. In July 2023, Evernorth Health, Inc. acquired a minority interest in CHSS. See Note 5 to the Consolidated Financial Statements for further discussion of this investment.</span></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_799"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Pension plans. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our pension plans were overfunded by $204 million and $238 million as of December&#160;31, 2023 and December&#160;31, 2022, respectively, and reported in Other assets in our Consolidated Balance Sheets. In 2023, we made immaterial contributions to the qualified pension plans as required under the Pension Protection Act of 2006 and we expect the required contributions for 2024 to be immaterial. See Note 18 to the Consolidated Financial Statements for additional information.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">59</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_802"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;text-decoration:underline">Other Sources of Funds and Uses of Capital Resources</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Divestiture. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2024, we entered into a definitive agreement to sell the Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits and CareAllies businesses within the U.S. Healthcare operating segment to HCSC, subject to applicable regulatory approvals and other customary closing conditions. The transaction is expected to close in the first quarter of 2025 and provide approximately $3.7B in transaction proceeds, which consists primarily of cash proceeds. Following the completion of the sale, we anticipate use of the proceeds in alignment with our capital deployment priorities, with the majority allocated to share repurchases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Debt Issuance and Debt Tender Offers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> On February 5, 2024, we issued $4.5 billion of new senior notes. The proceeds from this debt were used to pay the consideration for the cash tender offers as described below. We intend to use the remaining net proceeds to fund the repayment of our senior notes maturing in March 2024 and for general corporate purposes, which may include repayment of indebtedness and repurchases of shares of our common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Concurrent with the debt issuance, we commenced tender offers to purchase for cash up to $2.25 billion in aggregate principal amount of outstanding notes, which included any and all of the $1.0 billion senior notes due June 2024. Following the early tender results, we increased the tender offers to up to $2.55 billion  aggregate principal amount. On February 22, 2024, we purchased $1.8 billion principal amount of notes at early settlement of the tender offers. The tender offers will expire on March 5, 2024. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;text-decoration:underline">Risks to Liquidity and Capital Resources</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risks to our liquidity and capital resources outlook include cash projections that may not be realized and the demand for funds could exceed available cash if our ongoing businesses experience unexpected shortfalls in earnings or we experience material adverse effects from one or more risks or uncertainties described more fully in the "Risk Factors" section of this Form 10-K. Though we believe we have adequate sources of liquidity, significant disruption or volatility in the capital and credit markets could affect our ability to access those markets for additional borrowings or increase costs.</span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_808"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Guarantees and Contractual Obligations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are contingently liable for various contractual obligations and financial and other guarantees entered into in the ordinary course of business. See Note 24 to the Consolidated Financial Statements for discussion of various guarantees. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company adopted amended accounting guidance for long-duration insurance contracts effective January 1, 2023, which impacted the amounts presented in our Consolidated Balance Sheets. Within our Consolidated Financial Statements, see Note 2 to the Consolidated Financial Statements for a summary of this accounting change and Note 10 to the Consolidated Financial Statements for a summary of the insurance liabilities in our Consolidated Balance Sheets as well as future expected cash flow information. With the adoption of amended accounting guidance for long-duration insurance contracts and enhanced disclosure within Note 10 to the Consolidated Financial Statements, we will no longer present additional information regarding insurance liabilities within this section. </span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_811"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">On balance sheet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt">Long-term debt</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">Total scheduled payments on long-term debt are $44.8&#160;billion, which include scheduled interest payments and maturities of long-term debt. This excludes any impact from our February 2024 debt issuance and debt tender offers transactions as described above.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">We expect $2.8&#160;billion of long-term debt payments (including scheduled interest payments) to be paid within the next twelve months beginning January 1, 2024.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">Finance leases are included in Long-term debt and primarily represent obligations for information technology network storage, servers and equipment. See Note 21 to the Consolidated Financial Statements for information regarding finance leases.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">See Note 8 to the Consolidated Financial Statements for information regarding principal maturities of long-term debt. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt">Other non-current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">These include approximately $335&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of estimated payments (of which we expect $52&#160;million to be paid in the next twelve months beginning January 1, 2024) for other postretirement and postemployment benefit obligations, reinsurance liabilities, supplemental and deferred compensation plans and interest rate and foreign currency swap contracts. </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">In connection with our equity method investment in CarepathRx Health Systems Solutions ("CHSS"), we guaranteed CHSS's credit facilities. See Note 5 to the Consolidated Financial Statements for further information.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">See Note 18 to the Consolidated Financial Statements for further information on pension obligations and funded status.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt">Operating leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">These include operating lease payments of $497&#160;million (of which we expect $110&#160;million of operating lease payments to be due within the next twelve months beginning January 1, 2024). </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">See Note 21 to the Consolidated Financial Statements for additional information.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt">Uncertain tax positions</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">In the event we are unable to sustain all of our $1.4 billion of uncertain tax positions, it could result in future tax payments of approximately $950 million. We are adequately reserved for such positions. As a result, there is minimal direct risk to earnings should we fail to sustain our positions. We cannot reasonably estimate the timing of such future payments.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">See Note 23 to the Consolidated Financial Statements for additional information on uncertain tax positions.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Off-balance sheet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt">Purchase obligations</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">These include agreements to purchase goods or services that are enforceable and legally binding. Purchase obligations exclude contracts that are cancellable without penalty and those that do not contractually require minimum levels of goods or services to be purchased. </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">As of December&#160;31, 2023, purchase obligations consisted of a total of $4.3&#160;billion of estimated payments required under contractual arrangements (of which we expect $1.3&#160;billion of purchase obligations to be paid within the next twelve months beginning January 1, 2024). This includes:</span></div><div style="padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">$2.8&#160;billion of investment commitments (of which we expect $0.7&#160;billion of the committed amounts to be disbursed in 2024).</span></div><div style="padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">$1.5&#160;billion of future service commitments (of which we expect $0.6&#160;billion of the committed amounts to be disbursed in 2024), primarily comprised of contracts for certain outsourced business processes and information technology maintenance and support.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">See Note 12 of the Consolidated Financial Statements for additional information on investment commitments.</span></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_814"></div><div style="margin-bottom:10pt"><span id="i678848a64fdd49329a6df84bdc5ffce0_883"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING ESTIMATES</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect reported amounts and related disclosures in the Consolidated Financial Statements. Management considers an accounting estimate to be critical if:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">it requires assumptions to be made that were uncertain at the time the estimate was made; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">changes in the estimate or different estimates that could have been selected could have a material effect on our consolidated results of operations or financial condition.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Management has discussed how critical accounting estimates are developed and selected with the Audit Committee of our Board of Directors and the Audit Committee has reviewed the disclosures presented in this Form 10-K. We regularly evaluate items that may impact critical accounting estimates.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">61</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_823"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the estimates presented in the following tables, the Notes to the Consolidated Financial Statements describe other estimates that management has made in preparation of the financial statements. Management believes the current assumptions used to estimate amounts reflected in our Consolidated Financial Statements are appropriate. However, if actual experience significantly differs from the assumptions used in estimating amounts reflected in our Consolidated Financial Statements, the resulting changes could have a material adverse effect on our consolidated results of operations and in certain situations, could have a material adverse effect on liquidity and our financial condition. The tables below present the adverse impacts of certain possible changes in assumptions. The effect of assumption changes in the opposite direction would be a positive impact to our consolidated results of operations, liquidity or financial condition, except for assessing impairment of goodwill.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet Caption /<br/>Nature of Critical Accounting Estimate</span></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effect if Different Assumptions Used</span></td></tr><tr><td colspan="6" style="background-color:#dbdbdb;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Goodwill and other intangible assets</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill represents the excess of the cost of businesses acquired over the fair value of their net assets at the acquisition date. Intangible assets primarily reflect the value of customer relationships and other intangibles acquired in business combinations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair values of reporting units are estimated based on discounted cash flow analysis and market approach models using assumptions that we believe a hypothetical market participant would use to determine a current transaction price. The significant assumptions and estimates used in determining fair value primarily include the discount rate and future cash flows. A discount rate is selected to correspond with each reporting unit's weighted average cost of capital, consistent with that used for investment decisions considering the specific and detailed operating plans and strategies within each reporting unit. Projections of future cash flows differ by reporting unit and are consistent with our ongoing strategic projections. Future cash flows for Evernorth Health Services are primarily driven by the forecasted gross margins of the business, as well as operating expenses and long-term growth rates. Future cash flows for our other reporting units are primarily driven by forecasted revenues, benefit expenses, operating expenses and long-term growth rates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The fair value of intangibles and the amortization method were determined using an income approach that relies on projected future cash flows including key assumptions for customer attrition and discount rates. Management revises amortization periods if it believes there has been a change in the length of time that an intangible asset will continue to have value.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:110%">The Company conducts its quantitative evaluation for goodwill impairment at least annually during the third quarter at the reporting unit level and performs qualitative impairment assessments on a quarterly basis to determine if events or changes in circumstances indicate that it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">During the fourth quarter of 2023, following the change in operating segment discussed in Note 1 to the Consolidated Financial Statements, U.S. Government's goodwill was merged with U.S Commercial's goodwill. Certain businesses within the U.S. Healthcare operating segment were designated as held for sale (see Note 6 to the Consolidated Financial Statements).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill and other intangibles as of December 31 were as follows (in millions):</span></div><div><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#183;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023 &#8211; Goodwill $44,259; Other intangible assets $30,863</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#183;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022 &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill $45,811; Other intangible assets $32,492</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">See Note 20 to the Consolidated Financial Statements for additional discussion of our goodwill and other intangible assets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">We completed our normal annual evaluations for impairment of goodwill and intangible assets during the third quarter of 2023, as well as additional qualitative and quantitative tests as required by GAAP. The evaluations support that as of December&#160;31, 2023, the fair value estimates of our reporting units exceed their carrying values by sufficient margins. Changes in assumptions concerning future financial results or other underlying assumptions, including macroeconomic factors, government legislation, changes in the competitive landscape or other market conditions could impact our ability to achieve profitability projections. If we consistently do not achieve our earnings and cash flow projections or our cost of capital rises significantly, the assumptions and estimates underlying the goodwill and intangible asset impairment evaluations could be adversely affected and result in future impairment charges that would negatively impact our operating results and financial position.</span></div><div><span><br/></span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet Caption /<br/>Nature of Critical Accounting Estimate</span></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effect if Different Assumptions Used</span></td></tr><tr><td colspan="6" style="background-color:#dbdbdb;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Income taxes &#8211; uncertain tax positions</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">We evaluate tax positions to determine whether the benefits are more likely than not to be sustained on audit based on their technical merits. The Company establishes a liability if the probability that the position will be sustained is 50% or less. For uncertain positions that management believes are more likely than not to be sustained, the Company recognizes a liability based upon management's estimate of the most likely settlement outcome with the taxing authority. These amounts primarily relate to federal and state uncertain positions of the value and timing of deductions and uncertain positions of attributing taxable income to states.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances that are included in the Consolidated Balance Sheets within Accrued expenses and other liabilities are as follows (in millions):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#183;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023 &#8211; $1,399 </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#183;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022 &#8211; $1,343</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">See Note 23 to the Consolidated Financial Statements for additional discussion around uncertain tax positions and the Liquidity and Capital Resources section of this MD&amp;A for a discussion of their potential impact on liquidity. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The factors that could impact our estimates of uncertain tax positions include the likelihood of being sustained upon audit based on the technical merits of the tax position and related assumed interest and penalties. If our positions are upheld upon audit, our net income would increase.</span></td></tr><tr><td colspan="6" style="background-color:#dbdbdb;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Income taxes - valuation allowance</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes are reflected in the Consolidated Balance Sheets for differences between the financial and income tax reporting bases of the Company's underlying assets and liabilities, and are established based upon enacted tax rates and laws. Deferred income tax assets are recognized when available evidence indicates that realization is more likely than not and a valuation allowance is established to the extent this standard is not met. In 2023, the Company recorded a valuation allowance related to various foreign deferred tax assets in the amount of $772 million as well as a valuation allowance of $584 million related to the tax benefit associated with the sale of the Medicare Advantage and related businesses. It is possible that the realization of deferred tax assets may change due to changes in forecasted future earnings in various foreign jurisdictions or the Company's ability to generate future capital gains.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowances that are included in the Consolidated Balance Sheets within deferred tax liabilities, net are as follows (in millions):</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">&#183;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"> &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$1,498</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">&#183;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"> &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$208</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">See Note 23 to the Consolidated Financial Statements for additional discussion around valuation allowances.</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The factors that could impact our estimates of valuation allowances include changes in forecasted future earnings in foreign jurisdictions and the Company's future ability to generate capital gains. Decreases in our valuation allowance would increase net income, while increases in our valuation allowance would decrease net income.</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet Caption /<br/>Nature of Critical Accounting Estimate</span></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effect if Different Assumptions Used</span></td></tr><tr><td colspan="6" style="background-color:#dbdbdb;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Unpaid claims and claim expenses &#8211; Cigna Healthcare</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unpaid claims and claim expenses reflects estimates of the ultimate cost of claims that have been incurred but not reported, expected development on reported claims, claims that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily comprised of accruals for incentives and other amounts payable to health care professionals and facilities.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unpaid claims and claim expenses in Cigna Healthcare are primarily impacted by assumptions related to completion factors and medical cost trend. Variation of actual results from either assumption could impact the unpaid claims balance as noted below. A large number of factors may cause the medical cost trend to vary from the Company's estimates, including: changes in health management practices, changes in the level and mix of benefits offered and services utilized and changes in medical practices. Completion factors may be affected if actual claims submission rates from providers differ from estimates (that can be influenced by a number of factors, including provider mix and electronic versus manual submissions), or if changes to the Company's internal claims processing patterns occur.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unpaid claims and claim expenses for the Cigna Healthcare segment as of December 31 were as follows (in millions):</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#183;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023 &#8211; gross $5,092; net $4,856</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#183;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022 &#8211; gross $4,176; net $3,955</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">These liabilities are presented above both gross and net of reinsurance and other recoverables.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">See Note 10 to the Consolidated Financial Statements for additional information regarding assumptions and methods used to estimate this liability.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Based on studies of our claim experience, it is reasonably possible that a 100 basis point change in the medical cost trend and a 50 basis point change in completion factors could occur in the near term.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">A 100 basis point increase in the medical cost trend rate would increase this liability by approximately $90 million, resulting in a decrease in net income of approximately $70 million after-tax, and a 50 basis point decrease in completion factors would increase this liability by approximately $180 million, resulting in a decrease in net income of approximately $140 million after-tax.</span></div></td></tr><tr><td colspan="6" style="background-color:#dbdbdb;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Valuation of debt security investments</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Most debt securities are classified as available for sale and are carried at fair value with changes in fair value recorded in Accumulated other comprehensive loss within Shareholders' equity.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value is defined as the price at which an asset could be exchanged in an orderly transaction between market participants at the balance sheet date.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Determining fair value for a financial instrument requires management judgment. The degree of judgment involved generally correlates to the level of pricing readily observable in the markets. Financial instruments with quoted prices in active markets or with market observable inputs to determine fair value, such as public securities, generally require less judgment. Conversely, private placements including more complex securities that are traded infrequently are typically measured using pricing models that require more judgment as to the inputs and assumptions used to estimate fair value. There may be a number of alternative inputs to select based on an understanding of the issuer, the structure of the security and overall market conditions. In addition, these factors are inherently variable in nature as they change frequently in response to market conditions. Approximately 60% of our debt securities are public securities and approximately 40% are private placement securities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Typically, the most significant input in the measurement of fair value is the market interest rate used to discount the estimated future cash flows of the instrument. Such market rates are derived by calculating the appropriate spreads over comparable U.S. Treasury securities, based on the credit quality, industry and structure of the asset.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances that are included in the Consolidated Balance Sheets within Investments and Long-term investments are as follows, inclusive of amounts held for sale as of December 31, 2023 (in millions):</span></div><div><span><br/></span></div><div style="text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#183;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023 - $9,855</span></div><div style="text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#183;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022 - $9,872</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">See Notes 12A. and 13 to the Consolidated Financial Statements for a discussion of our fair value measurements, the procedures performed by management to determine that the amounts represent appropriate estimates and our accounting policy regarding unrealized appreciation on debt securities.</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">If the derived market rates used to calculate fair value increased by 100 basis points, the fair value of the total debt security portfolio of $9.9 billion would decrease by approximately $0.6 billion, resulting in an after-tax decrease to shareholders' equity of approximately $0.5 billion as of December&#160;31, 2023.</span></div></td></tr></table></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">64</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_826"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span id="i50836b10767d4421a8babe114496926c_1512"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SEGMENT REPORTING</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following section of this MD&amp;A discusses the results of each of our segments. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See Note 1 to the Consolidated Financial Statements for further description of our segments.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In segment discussions, we present "adjusted revenues" and "pre-tax adjusted income (loss) from operations," defined as income (loss) before income taxes excluding pre-tax income (loss) attributable to noncontrolling interests, net realized investment results, amortization of acquired intangible assets and special items. The Cigna Group's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. Ratios presented in this segment discussion exclude the same items as adjusted revenues and pre-tax adjusted income (loss) from operations. See Note 25 to the Consolidated Financial Statements for additional discussion of these metrics and a reconciliation of Income before income taxes to pre-tax adjusted income from operations, as well as a reconciliation of Total revenues to adjusted revenues. Note 25 to the Consolidated Financial Statements also explains that segment revenues include both external revenues and sales between segments that are eliminated in Corporate.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In these segment discussions, we also present "pre-tax adjusted margin," defined as pre-tax adjusted income (loss) from operations divided by adjusted revenues.</span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_829"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See the "Executive Overview" section of this MD&amp;A for summarized financial results of each of our segments.</span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_832"></div><div style="margin-bottom:10pt;margin-top:10pt"><span id="ibd5662028ff7494db8161ad801bc4537_3682"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Evernorth Health Services Segment</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Evernorth Health Services partners with health plans, employers, governmental organizations and health care providers to solve challenges in the areas of pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty distribution, and care delivery and management solutions. As described in the introduction to Segment Reporting, Evernorth Health Services' performance is measured using adjusted revenues and pre-tax adjusted income (loss) from operations.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The key factors that impact Evernorth Health Services' Pharmacy revenues, Fees and other revenues and Pharmacy and other service costs are volume, mix of claims and price. These key factors are discussed further below. See Note 2 to the Consolidated Financial Statements included in this Form 10-K for additional information on revenue and cost recognition policies for this segment.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">As our clients' claim volumes increase or decrease, our resulting revenues and cost of revenues correspondingly increase or decrease. Our gross profit, defined as Total revenues less Pharmacy and other service costs, could also increase or decrease as a result of changes in purchasing discounts.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The mix of claims generally considers the type of drug and distribution method used for dispensing and fulfilling. Types of drugs can have an impact on our Pharmacy revenues, Pharmacy and other service costs and gross profit, including amounts payable under certain financial and performance guarantees with our clients. In addition to the types of drugs, the mix of generic claims (i.e., generic fill rate) also impacts our gross profit. Generally, higher generic fill rates reduce revenues, as generic drugs are typically priced lower than the branded drugs they replace. However, as ingredient cost paid to pharmacies on generic drugs is incrementally lower than the price charged to our clients, higher generic fill rates generally have a favorable impact on our gross profit. The home delivery generic fill rate is currently lower than the network generic fill rate as fewer generic substitutions are available among maintenance medications (such as therapies for chronic conditions) commonly dispensed from home delivery pharmacies as compared to acute medications that are primarily dispensed by pharmacies in our retail networks. Furthermore, our gross profit differs among network, home delivery and specialty distribution methods and can impact our profitability.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our client contract pricing is impacted by our ongoing ability to negotiate favorable contracts for pharmacy network, pharmaceutical and wholesaler purchasing and manufacturer rebates on our clients' behalf. Through these affordability services, we seek to improve the effectiveness of our integrated solutions for the benefit of our clients by continuously innovating, improving affordability and implementing drug purchasing contract initiatives. Our revenues, cost of revenues and gross profit could increase or decrease as a result of these affordability services. Pharmaceutical manufacturer inflation also impacts our pricing because most of our contracts provide that we bill clients and pay pharmacies based on a generally recognized price index for pharmaceuticals. Therefore, the rate of inflation for prescription drugs and our efforts to manage this inflation for our clients continues to be a significant driver of our revenues and cost of revenues in the current environment.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In this MD&amp;A, we present revenues and gross profit, as well as adjusted revenues and adjusted gross profit, consistent with our segment reporting metrics, which exclude special items.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">65</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_835"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of Operations</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.177%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.716%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Summary</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="12" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change Favorable<br/>(Unfavorable)</span></td><td colspan="12" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change Favorable<br/>(Unfavorable)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="12" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023 vs. 2022</span></td><td colspan="12" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 vs. 2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">153,499</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140,335&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131,912&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,164&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,423&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">153,499</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140,335&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131,912&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,164&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,423&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmacy and other service costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">143,571</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131,284&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123,504&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,287&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,780&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross profit </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,928</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,051&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,408&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted gross profit </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1),(2)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,928</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,051&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,408&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted income from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,442</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,127&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,818&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted margin</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted expense ratio </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Selected Financial Information</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:29pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="18" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td><td colspan="6" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change Favorable<br/>(Unfavorable)</span></td><td colspan="6" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change Favorable<br/>(Unfavorable)</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(Dollars and adjusted scripts in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023 vs. 2022</span></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 vs. 2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmacy revenue by distribution channel</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted network revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">67,514</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted home delivery and specialty revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">65,732</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61,283&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,391&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other pharmacy revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,047</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total adjusted pharmacy revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">142,293</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132,982&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125,811&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted fees and other revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,965</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">241</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/M</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">153,499</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140,335&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131,912&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pharmacy script volume </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted network scripts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,327</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted home delivery and specialty scripts</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">258</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total adjusted scripts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,585</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,575&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,638&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Generic fill rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Network</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">86.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Home delivery</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">85.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85.1&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85.9&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Overall generic fill rate</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">86.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Total revenues and gross profit were equal to adjusted revenues and adjusted gross profit as there were no special items in the periods presented.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Gross profit and adjusted gross profit are calculated as total revenues or adjusted revenues less pharmacy and other service costs.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Adjusted expense ratio is calculated as selling, general and administrative expenses as a percentage of adjusted revenues.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Non-specialty network scripts filled through 90-day programs and home delivery scripts are multiplied by three. All other network and specialty scripts are counted as one script.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Generic fill rate is defined as the total number of generic scripts divided by the total overall scripts filled.</span></div><div style="text-indent:4.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023 versus 2022</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Adjusted network revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> increased 4%, reflecting inflation on branded drugs and higher claims volume, partially offset by a decrease in claims mix and an increase in the generic fill rate. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Adjusted home delivery and specialty revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">increased 7%, reflecting higher specialty claims volume and inflation on branded drugs, partially offset by lower home delivery claims volume.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other pharmacy revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> increased 34%, reflecting higher volume from our CuraScript Specialty Distribution business, which distributes pharmaceuticals and medical supplies directly to health care providers, clinics and hospitals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Adjusted fees and other revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> increased 51%, reflecting client growth in Care Delivery and Management Solutions, including cross-enterprise leverage, primarily driven by our behavioral health and eviCore Healthcare solutions, and client growth from our continued affordability services.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Adjusted gross profit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> increased 10%,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">pre-tax adjusted income from operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">increased 5%, reflecting continued affordability improvements and growth in Specialty Pharmacy, partially offset by increased strategic investments to support the onboarding of new clients and continued advancement of our digital capabilities and care solutions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">adjusted expense ratio </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">increased 20 bps, reflecting increased strategic investments to support the onboarding of new clients and continued advancement of our digital capabilities and care solutions.</span></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_841"></div><div style="margin-bottom:10pt"><span id="i5f7e23c29fc34ce5a16e3aa3edd9fa90_13079"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Cigna Healthcare Segment</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cigna Healthcare includes the U.S. Healthcare and International Health businesses, which provide comprehensive medical and coordinated solutions to clients and customers. During the fourth quarter of 2023, the U.S. Commercial and U.S. Government operating segments were merged to form the U.S. Healthcare operating segment. As described in the introduction to Segment Reporting, performance of the Cigna Healthcare segment is measured using adjusted revenues and pre-tax adjusted income from operations. Key factors affecting results for this segment include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">customer growth;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">revenue growth;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">percentage of Medicare Advantage customers in plans eligible for quality bonus payments;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">medical costs as a percentage of premiums (medical care ratio or "MCR") for our insured businesses; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">selling, general and administrative expenses as a percentage of adjusted revenues (adjusted expense ratio).</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Effective January 1, 2023, we adopted amended accounting guidance for long-duration insurance contracts. For the Cigna Healthcare segment, prior period results of operations have been retrospectively adjusted to conform to this new basis of accounting. The impact of this amended guidance is immaterial. See Note 2 to the Consolidated Financial Statements for additional information.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2024, we entered into a definitive agreement to sell the Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits and CareAllies businesses within the U.S. Healthcare operating segment to Health Care Service Corporation for $3.3 billion cash, subject to applicable regulatory approvals and other customary closing conditions. See Note 6 to the Consolidated Financial Statements for further information.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.101%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Summary</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:21pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="12" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change Favorable<br/>(Unfavorable)</span></td><td colspan="12" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change Favorable<br/>(Unfavorable)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="12" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023 vs. 2022</span></td><td colspan="12" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 vs. 2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51,205</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,037&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,643&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,168&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted income from operations</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,478</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,099&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,601&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted margin</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical care ratio</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">81.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted expense ratio</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023 versus 2022</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Adjusted revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">increased 14%, primarily reflecting customer growth and higher premium rates due to anticipated underlying medical cost trend.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Pre-tax adjusted income from operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> increased 9%, primarily due to a lower medical care ratio and a lower adjusted expense ratio. The improvement to the medical care ratio and the adjusted expense ratio for the twelve months ended December 31, 2023, as compared to the twelve months ended December 31, 2022, was driven by decreases of 160 bps and 190 bps, respectively, for the three months ended December 31, 2023.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> medical care ratio </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">decreased 40 bps, primarily due to a lower U.S. Healthcare medical care ratio, reflecting improved stop loss results, effective pricing execution and affordability initiatives.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">adjusted expense ratio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> decreased 20 bps for the twelve months ended December 31, 2023, primarily due to revenue growth outpacing volume-related expenses as well as higher technology spend. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">adjusted expense ratio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> decreased 190 bps for the three months ended December 31, 2023, primarily due to revenue growth and timing of investments outpacing volume-related expenses.</span></div><div style="margin-bottom:20pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">67</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_844"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Medical Customers</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A medical customer is defined as a person meeting any one of the following criteria:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">is covered under a medical insurance policy, managed care arrangement or administrative services agreement issued by us;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">has access to our provider network for covered services under their medical plan; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">has medical claims that are administered by us.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.889%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cigna Healthcare Medical Customers</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="12" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change Favorable<br/>(Unfavorable)</span></td><td colspan="12" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change Favorable<br/>(Unfavorable)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="12" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023 vs. 2022</span></td><td colspan="12" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 vs. 2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insured</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,464</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,756&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,757&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">708&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Healthcare</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,280</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,587&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,676&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International Health </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,184</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,169&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Administrative services only</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14,316</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,248&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,324&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,068&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">924&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Healthcare</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13,890</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,619&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,688&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,271&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International Health </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">426</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19,780</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,004&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,081&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,776&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">923&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">International Health excludes medical customers served by less than 100% owned subsidiaries, as well as certain customers served by our third-party administrator. International Health customers as of December&#160;31, 2023 reflect the transition of certain run-off business to Other Operations beginning January 1, 2023.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023 versus 2022</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total medical customers increased 10%, primarily driven by growth in fee-based customers as well as in Individual and Family Plans and Medicare Advantage customers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See Part I, Item 1 of this Form 10-K for definitions of Cigna Healthcare's market segments.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Unpaid Claims and Claim Expenses</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.889%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change Increase (Decrease)</span></td><td colspan="12" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change Increase (Decrease)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="12" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023 vs. 2022</span></td><td colspan="12" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 vs. 2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unpaid claims and claim expenses &#8211; Cigna Healthcare</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,092</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,176&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,261&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">916&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023 versus 2022</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our unpaid claims and claim expenses liability increased 22%, driven by customer growth, primarily within our Individual and Family Plans business.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_850"></div><div style="margin-bottom:10pt"><span id="i89c5125f95bf41638175efbb81ce1f27_2014"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Operations</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other Operations includes corporate owned life insurance ("COLI") and the Company's run-off operations. See Note 1 to the Consolidated Financial Statements for additional information regarding these operations. In the prior periods, Other Operations also included the International businesses sold in July 2022 and our interest in a joint venture in T&#252;rkiye sold in December 2022. As described in the introduction of Segment Reporting, performance of Other Operations is measured using adjusted revenues and pre-tax adjusted income from operations. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Effective January 1, 2023, we adopted amended accounting guidance for long-duration insurance contracts. For the Other Operations segment, prior period results of operations have been retrospectively adjusted to conform to this new basis of accounting. The impact of this amended guidance is immaterial. Prior period results related to long-duration contracts sold in the Chubb transaction and our divested interest in a joint venture in T&#252;rkiye were not adjusted (as permitted by ASU 2022-05). See Note 10 to the Consolidated Financial Statements for additional disclosure of our long-duration insurance contracts and Note 2 to the Consolidated Financial Statements for additional information regarding the adoption of this amended guidance.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.288%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.483%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.377%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Summary</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="18" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td><td colspan="12" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change Favorable<br/>(Unfavorable)</span></td><td colspan="12" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change Favorable<br/>(Unfavorable)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="12" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023 vs. 2022</span></td><td colspan="12" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 vs. 2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">596</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,263&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,989&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,667)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,726)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted income from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">96</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">903&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(413)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(394)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted margin</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.6&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(640)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023 versus 2022</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Adjusted revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> declined reflecting the absence of revenues from the business divested in 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Pre-tax adjusted income from operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> decreased primarily due to the absence of earnings from the businesses divested in the Chubb transaction.</span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_856"></div><div style="margin-bottom:10pt;margin-top:10pt"><span id="i0055b3b5dc784d6b9d65c5a5ca52e299_1037"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Corporate</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Corporate reflects amounts not allocated to operating segments, including net interest expense (defined as interest on corporate financing less net investment income on investments not supporting segment and other operations), certain litigation matters, expense associated with our frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs and eliminations for products and services sold between segments.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.066%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.889%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Summary</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="12" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change Favorable (Unfavorable)</span></td><td colspan="12" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change Favorable (Unfavorable)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="12" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023 vs. 2022</span></td><td colspan="12" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 vs. 2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted loss from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,698)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,466)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,339)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(232)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023 versus 2022</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Pre-tax adjusted loss from operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> increased 16% primarily due to an increase in the weighted average interest rate on our indebtedness and increased pension costs due to lower expected asset returns and a higher discount rate. While our pension expense has increased year-over-year, we continue to expect the required contributions for 2024 to be immaterial.</span></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_865"></div><div style="margin-bottom:10pt"><span id="i2394126b9a13444bafce2656fbdda71e_10173"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INVESTMENT ASSETS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents our investment asset portfolio excluding separate account assets. Additional information regarding our investment assets is included in Notes 12, 13, 14 and 16 to the Consolidated Financial Statements. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.041%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,855</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,872&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,362</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial mortgage loans</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,533</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Policy loans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,211</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term investments</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,181</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,728&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20,348</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,193&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments classified as assets of businesses held for sale </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,438)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments per Consolidated Balance Sheets</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18,910</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,193&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"> Investments related to the HCSC transaction that were held for sale as of December&#160;31, 2023. These investments were primarily comprised of debt securities and commercial mortgage loans, and to a lesser extent, other long term investments.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Investment Outlook</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We continue to actively monitor economic conditions including the impact of inflation, higher interest rates and the potential for a recession on the investment portfolio. Although there has been very limited impact to date on our investment portfolio as a result of 2023 economic and geopolitical events, including banking system stress, we continue to monitor ongoing developments and the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">potential impact of 2023 events on the portfolio. Future realized and unrealized investment results will be driven largely by market conditions and these future conditions are not reasonably predictable. We believe that the vast majority of our investments will continue to perform under their contractual terms. We manage the portfolio for long-term economics and therefore we expect to hold a significant portion of these assets for the long term. The following discussion addresses the strategies and risks associated with our various classes of investment assets. Although future declines in investment fair values remain possible due to interest rate movements and credit deterioration due to both investment-specific uncertainties and global economic uncertainties as discussed below, we do not expect these losses to have a material unfavorable effect on our financial condition or liquidity.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Debt Securities</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Investments in debt securities include publicly traded and privately placed bonds, mortgage and other asset-backed securities and preferred stocks redeemable by the investor. These investments are classified as available for sale and are carried at fair value in our Consolidated Balance Sheets. Additional information regarding valuation methodologies, key inputs and controls is included in Note 13 to the Consolidated Financial Statements. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table reflects our portfolio of debt securities by type of issuer:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.041%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal government and agency</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">267</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State and local government</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">352</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,833</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset-backed</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">365</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,855</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,872&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The carrying value of our debt securities portfolio was flat during the year ended December&#160;31, 2023 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">reflecting net sales activity offset by a valuation increase due to declining market interest rates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Our portfolio remains in a net unrealized depreciation position due to generally increasing interest rates over the last several quarters. More detailed information about debt securities by type of issuer, maturity dates and net unrealized position is included in Note 12 to the Consolidated Financial Statements.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, $8.3&#160;billion, or 84%, of the debt securities in our investment portfolio were investment grade (Baa and above, or equivalent) and the remaining $1.6&#160;billion were below investment grade. The majority of the bonds that are below investment grade were rated at the higher end of the non-investment grade spectrum. These quality characteristics have not materially changed since the prior year and remain consistent with our investment strategy. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Debt securities include private placement assets of $4.0&#160;billion. These investments are generally less marketable than publicly traded bonds; however, yields on these investments tend to be higher than yields on publicly traded bonds with comparable credit risk. We perform a credit analysis of each issuer and require financial and other covenants that allow us to monitor issuers for deteriorating financial strength and pursue remedial actions, if warranted.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Investments in debt securities are diversified by issuer, geography and industry. On an aggregate basis, the debt securities portfolio continues to perform according to original expectations, which includes a long-term economic investment strategy. Elevated global inflation, higher interest rates, continuing supply chain disruptions and potential fallout from the stress in the banking system are the primary risks that many of the issuers in our portfolio are facing. To date, most issuers have been successful in managing the cost escalation and product shortages without undue margin pressure. We continue to monitor the economic environment and its effect on our portfolio and consider the impact of various factors in determining the allowance for credit losses on debt securities, which is discussed in Note 12 to the Consolidated Financial Statements.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Commercial Mortgage Loans</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, our $1.5 billion commercial mortgage loan portfolio consisted of approximately 50 fixed-rate loans, diversified by property type, location and borrower. These loans are carried in our Consolidated Balance Sheets at their unpaid principal balance, net of an allowance for expected credit losses. As a result of increasing market interest rates since the majority of these loans were made, the carrying value exceeds the market value of these loans as of December&#160;31, 2023. See Note 13 to the Consolidated Financial Statements for further details. Given the quality and diversity of the underlying real estate, positive debt service coverage and significant borrower cash invested in the property generally ranging between 30 and 40%, we remain confident that the vast majority of borrowers will continue to perform as expected under their contract terms. For further discussion of the results and changes in key loan metrics, see Note 12 to the Consolidated Financial Statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loans are secured by high quality commercial properties, located in strong institutional markets and are generally made at approximately 65% of the property's value at origination of the loan. Property value, debt service coverage, quality, building tenancy and stability of cash flows are all important financial underwriting considerations. We hold no direct residential mortgage loans and do not originate or service securitized mortgage loans.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We assess the credit quality of our commercial mortgage loan portfolio annually, generally in the second quarter by reviewing each holding's most recent financial statements, rent rolls, budgets and relevant market reports. The review performed in the second quarter of 2023 confirmed ongoing strong overall credit quality in line with the previous year's results. See Note 12 to the Consolidated Financial Statements for further information regarding our key credit quality indicators for commercial mortgage loans.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Office sector fundamentals have been and continue to be weak and values are experiencing stress due to multiple headwinds: expanded work from home flexibility, shorter term leases, elevated tenant improvement allowances and corporate migration to lower cost states. Additionally, the current macroeconomic headwinds are impacting capital markets and reducing investor appetite for capital intensive assets (e.g., offices and regional shopping malls). Our commercial mortgage loan portfolio has no exposure to regional shopping malls and less than 30% exposure to office properties. Although future losses remain possible due to further credit deterioration, we do not expect these losses to have a material unfavorable effect on our financial condition or liquidity.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Other Long-term Investments</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other long-term investments of $4.2 billion as of December&#160;31, 2023 included investments in securities limited partnerships and real estate limited partnerships, direct investments in real estate joint ventures and other deposit activity that is required to support various insurance and health services businesses. Accounting policies for these investments are discussed in Note 12 to the Consolidated Financial Statements. The increase in other long-term investments of $0.5 billion since December 31, 2022 is primarily driven by net additional funding activity. These limited partnership entities typically invest in mezzanine debt or equity of privately-held companies and equity real estate. Given our subordinate position in the capital structure of these underlying entities, we assume a higher level of risk for higher expected returns. To mitigate risk, these investments are diversified across approximately 200 separate partnerships and 100 general partners who manage one or more of these partnerships. Also, the underlying investments are diversified by industry sector or property type and geographic region. No single partnership investment exceeded 4% of our securities and real estate limited partnership portfolio.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income from our limited partnership investments is generally reported on a one quarter lag due to the timing of when financial information is received from the general partner or manager of the investments. We expect continued volatility in private equity and real estate fund performance going forward as fair market valuations are adjusted to reflect market and portfolio transactions. Less than 4% of our other long-term investments are exposed to real estate in the office sector.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We participate in an insurance joint venture in China with a 50% ownership interest. We account for this joint venture under the equity method of accounting and report our share of the net assets of $0.2 billion in Other assets. Our 50% share of the investment portfolio supporting the joint venture's liabilities is approximately $11.7 billion as of December&#160;31, 2023. These investments were comprised of approximately 75% debt securities, including government and corporate debt diversified by issuer, industry and geography; 15% equities, including mutual funds, equity securities and private equity partnerships; and 10% long-term deposits and policy loans. We continuously review the joint venture's investment strategy and its execution. There were no investments with a material unrealized loss as of December&#160;31, 2023.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_871"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">MARKET RISK</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Financial Instruments</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our assets and liabilities include financial instruments subject to the risk of potential losses from adverse changes in market rates and prices. Consistent with disclosure requirements, the following items have been excluded from this consideration of market risk for financial instruments:</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">changes in the fair values of insurance-related assets and liabilities as disclosed in Note 10 to the Consolidated Financial Statements because their primary risks are insurance rather than market risk;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">changes in the fair values of investments recorded using the equity method of accounting and liabilities for pension and other postretirement and postemployment benefit plans (and related assets); and</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">changes in the fair values of other significant assets and liabilities, such as goodwill, deferred policy acquisition costs, taxes and various accrued liabilities. Because they are not financial instruments, their primary risks are other than market risk.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Excluding the items noted in the paragraph above, our primary market risk exposure from financial instruments is our interest-rate risk exposure to fixed-rate, medium-term instruments. Changes in market interest rates affect the value of instruments that promise a fixed </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">return. Following increased investments in equity securities during 2023, primarily as a result of our investment in VillageMD, our exposure to equity price risk has increased. </span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Our Management of Market Risks</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We predominantly rely on two techniques to manage our exposure to market risk:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt">Investment/liability matching.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We generally select investment assets with characteristics (such as duration, yield, currency and liquidity) that correspond to the underlying characteristics of our related insurance and contractholder liabilities so that we can match the investments to our obligations. Shorter-term investments generally support shorter-term life and health liabilities. Medium-term, fixed-rate investments support interest-sensitive and health liabilities. Longer-term investments generally support products with longer payout periods such as annuities.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt">Use of derivatives.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We use derivative financial instruments to reduce our primary market risks. See Note 12 to the Consolidated Financial Statements for additional information about derivative financial instruments.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Effect of Market Fluctuations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We determine the sensitivity of market risk for our fixed income financial instruments, including debt securities and commercial mortgage loans, by estimating the present value of future cash flows using duration modeling and applying a 100 basis point increase in interest rates. The sensitivity of market risk for equity securities is determined by applying a 10% decrease in market prices. The effect of these hypothetical changes in market rates or prices on the fair value of certain financial instruments, subject to the exclusions noted above (particularly insurance liabilities), would have been as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.041%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Market scenario for certain non-insurance financial instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Loss in Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in billions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100 basis point increase in interest rates (excluding the Company's long-term debt)</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10% decrease in market prices for equity securities</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event of a hypothetical 100 basis point increase in interest rates, the fair value of the Company's long-term debt would decrease approximately $1.8 billion at both December&#160;31, 2023 and December&#160;31, 2022. Changes in the fair value of our long-term debt do not impact our financial position or operating results since long-term debt is not required to be recorded at fair value. See Note 8 to the Consolidated Financial Statements for additional information about the Company's debt.</span></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_1015"></div><div style="margin-bottom:10pt"><span id="ib514fe9ed09945b693875866a2729de7_198"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 7A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information contained under the caption "Market Risk" in the MD&amp;A section of this Form 10-K is incorporated by reference.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">72</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_16"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span id="i25246dbe5eee4650a5a3b47d40871fcc_15"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 8. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_19"></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To the</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Board of Directors and Shareholders of The Cigna Group</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have audited the accompanying consolidated balance sheets of The Cigna Group and its subsidiaries (the "Company") as of December&#160;31, 2023 and 2022, and the related consolidated statements of income, comprehensive income, changes in total equity and cash flows for each of the three years in the period ended December&#160;31, 2023, including the related notes and financial statement schedules listed in the index appearing on page FS-1 of this Form 10-K (collectively referred to as the "consolidated financial statements").</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also have audited the Company's internal control over financial reporting as of December&#160;31, 2023, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Internal Control - Integrated Framework</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2013)</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2023 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2023, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Internal Control - Integrated Framework</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2013)</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">issued by the COSO.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Basis for Opinions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management's Annual Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company's consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Critical Audit Matters</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Assessment of Held for Sale and Associated Loss on Sale</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As described in Notes 6 and 20 to the consolidated financial statements, the Company determined that the Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits and CareAllies businesses met the criteria to be classified as held for sale and aggregated and classified the assets and liabilities as held for sale in the Consolidated Balance Sheet as of December 31, 2023. The Company measured the assets and liabilities held for sale at estimated fair value less costs to sell and recognized an estimated loss of $1.5 billion pre-tax that was included within (Loss) gain on sale of businesses in the Consolidated Statement of Income for the year ended December 31, 2023. The estimated loss on sale represents primarily asset write-downs and estimated costs to sell. The fair value of a reporting unit is generally estimated based on discounted cash flow analysis and market approach models using assumptions that management believes a hypothetical market participant would use to determine a current transaction price. Following a change in reporting units or held for sale determination, goodwill is allocated using relative fair value. The significant assumptions and estimates used in determining fair value primarily include the discount rate and future cash flows. Future cash flows are primarily driven by forecasted revenues, benefit expenses, operating expenses and long-term growth rates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The principal considerations for our determination that performing procedures relating to the assessment of held for sale classification and the associated loss on sale is a critical audit matter are (i) the significant judgment by management when determining the held for sale classification and developing the fair value estimate of the reporting unit, including goodwill allocated to businesses held for sale using relative fair value; (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating audit evidence related to (a) management's determination of the held for sale classification, and (b) management&#8217;s significant assumptions used to develop the fair value estimate of the reporting unit, including goodwill allocated to businesses held for sale using relative fair value related to the discount rate, forecasted revenues, benefit expenses, operating expenses and long-term growth rates (collectively referred to as the "significant assumptions"); and (iii) the audit effort involved the use of professionals with specialized skill and knowledge.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to (i) management&#8217;s assessment of held for sale classification and (ii) management&#8217;s estimation of the loss on sale of businesses, including controls over the fair value estimation of the reporting unit, including goodwill allocated to businesses held for sale using relative fair value. These procedures also included, among others, (i) evaluating the reasonableness of management&#8217;s assessment of held for sale classification, which included reading the written agreement in place between the parties related to the sale; (ii) testing management&#8217;s process for estimating the loss on sale of businesses and developing the fair value estimate of the reporting unit, including goodwill allocated to businesses held for sale using relative fair value; (iii) evaluating the appropriateness of the discounted cash flow analysis and market approach used by management; (iv) testing the completeness and accuracy of underlying data used in the discounted cash flow analysis and market approach; and (v) evaluating the reasonableness of the significant assumptions used by management. Evaluating management&#8217;s significant assumptions involved evaluating whether the assumptions used by management were reasonable considering (i) the current and past performance of the reporting unit; (ii) the consistency with external market and industry data; and (iii) whether these assumptions were consistent with evidence obtained in other areas of the audit. Professionals with specialized skill and knowledge were used to assist in evaluating the reasonableness of the discount rate and long-term growth rates significant assumptions. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-36">PricewaterhouseCoopers LLP</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-37">Hartford, Connecticut</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February&#160;29, 2024</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have served as the Company's auditor since 1983. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">74</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_22"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.205%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.097%"/><td style="width:0.1%"/></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span id="id2aa9ecc9a224c2e8905e51ec823eef9_0-0-1-10-866375"></span><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">The Cigna Group</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Statements of Income</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except per share amounts)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmacy revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-38">137,243</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-39">128,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-40">121,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-41">44,237</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-42">39,916</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-43">41,154</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fees and other revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-44">12,619</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-45">10,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-46">9,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:num-dot-decimal" scale="6" id="f-47">1,166</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:num-dot-decimal" scale="6" id="f-48">1,155</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:num-dot-decimal" scale="6" id="f-49">1,549</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TOTAL REVENUES</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-50">195,265</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-51">180,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-52">174,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Benefits and expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmacy and other service costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-53">133,801</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-54">124,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-55">117,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical costs and other benefit expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredNet" format="ixt:num-dot-decimal" scale="6" id="f-56">36,287</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredNet" format="ixt:num-dot-decimal" scale="6" id="f-57">32,184</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredNet" format="ixt:num-dot-decimal" scale="6" id="f-58">33,565</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-59">14,822</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-60">13,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-61">13,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-62">1,819</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-63">1,876</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-64">1,998</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TOTAL BENEFITS AND EXPENSES</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:BenefitsLossesAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-65">186,729</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:BenefitsLossesAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-66">172,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:BenefitsLossesAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-67">166,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-68">8,536</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-69">8,450</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-70">7,941</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense and other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="f-71">1,446</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="f-72">1,228</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="f-73">1,208</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt extinguishment costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="f-74">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="f-75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="f-76">141</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Loss) gain on sale of businesses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="6" id="f-77">1,499</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="6" id="f-78">1,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="6" id="f-79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net realized investment (losses) gains</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="ci:RealizedInvestmentGainLoss" scale="6" id="f-80">78</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="ci:RealizedInvestmentGainLoss" scale="6" id="f-81">487</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:RealizedInvestmentGainLoss" scale="6" id="f-82">198</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income before income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-83">5,513</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-84">8,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-85">6,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TOTAL INCOME TAXES</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-86">141</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-87">1,615</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-88">1,370</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-89">5,372</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-90">6,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-91">5,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-92">208</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-93">78</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-94">50</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SHAREHOLDERS' NET INCOME</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="f-95">5,164</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="f-96">6,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="f-97">5,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders' net income per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-98">17.57</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-99">21.66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-100">15.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-101">17.39</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-102">21.41</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-103">15.75</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:1.43pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts ("LDTI") in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">The accompanying Notes to the Consolidated Financial Statements are an integral part of these statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">75</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_25"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.038%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.098%"/><td style="width:0.1%"/></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span id="icae6bed0297e4f8d8f0f042d64af0791_0-0-1-8-866395"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">The Cigna Group<br/>Consolidated Statements of Comprehensive Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-104">5,372</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-105">6,782</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-106">5,420</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized appreciation (depreciation) on securities and derivatives</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax" scale="6" id="f-107">503</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="ci:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-108">1,598</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="ci:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax" scale="6" id="f-109">302</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net long-duration insurance and contractholder liabilities measurement adjustments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="ci:OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent" scale="6" id="f-110">715</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent" scale="6" id="f-111">509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent" scale="6" id="f-112">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net translation gains (losses) on foreign currencies</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity" scale="6" id="f-113">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity" scale="6" id="f-114">77</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="ci:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity" scale="6" id="f-115">232</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Postretirement benefits liability adjustment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="f-116">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="f-117">420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="f-118">410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="ci:OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity" scale="6" id="f-119">206</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="ci:OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity" scale="6" id="f-120">592</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="ci:OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity" scale="6" id="f-121">57</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total comprehensive income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity" format="ixt:num-dot-decimal" scale="6" id="f-122">5,166</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity" format="ixt:num-dot-decimal" scale="6" id="f-123">6,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity" format="ixt:num-dot-decimal" scale="6" id="f-124">5,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Comprehensive income (loss) attributable to noncontrolling interests</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to redeemable noncontrolling interests</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="6" id="f-125">180</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="6" id="f-126">11</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="6" id="f-127">19</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to other noncontrolling interests</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" scale="6" id="f-128">28</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" scale="6" id="f-129">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" scale="6" id="f-130">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss attributable to redeemable noncontrolling interests</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:TemporaryEquityOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-131">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="ci:TemporaryEquityOtherComprehensiveIncome" scale="6" id="f-132">2</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="ci:TemporaryEquityOtherComprehensiveIncome" scale="6" id="f-133">14</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total comprehensive income attributable to noncontrolling interests</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="f-134">208</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="f-135">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="f-136">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SHAREHOLDERS' COMPREHENSIVE INCOME</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-137">4,958</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-138">6,114</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-139">5,327</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:1.43pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying Notes to the Consolidated Financial Statements are an integral part of these statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">76</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_28"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span id="i2f0fafb7c6394b14a9fca7ac37a912c8_0-0-1-4-866399"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">The Cigna Group<br/>Consolidated Balance Sheets</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-140">7,822</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-141">5,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="f-142">925</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="f-143">905</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-144">17,722</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-145">17,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-146">5,645</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-147">4,777</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-148">2,169</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-149">1,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets of businesses held for sale</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:num-dot-decimal" scale="6" id="f-150">3,068</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:fixed-zero" scale="6" id="f-151">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-152">37,351</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-153">30,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-154">17,985</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-155">16,288</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reinsurance recoverables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:ReinsuranceRecoverablesNonCurrent" format="ixt:num-dot-decimal" scale="6" id="f-156">4,835</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:ReinsuranceRecoverablesNonCurrent" format="ixt:num-dot-decimal" scale="6" id="f-157">5,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-158">3,695</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-159">3,774</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-160">44,259</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-161">45,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-162">30,863</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-163">32,492</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-164">3,421</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-165">2,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separate account assets</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:num-dot-decimal" scale="6" id="f-166">7,430</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:num-dot-decimal" scale="6" id="f-167">7,278</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets of businesses held for sale, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-168">2,922</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="f-169">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TOTAL ASSETS</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-170">152,761</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-171">143,885</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current insurance and contractholder liabilities</span></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:InsuranceAndContractholderLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-172">5,514</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:InsuranceAndContractholderLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-173">5,409</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmacy and other service costs payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:PharmacyAndServiceCostsPayable" format="ixt:num-dot-decimal" scale="6" id="f-174">19,815</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:PharmacyAndServiceCostsPayable" format="ixt:num-dot-decimal" scale="6" id="f-175">17,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-176">8,553</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-177">7,775</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:AccruedExpensesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-178">9,955</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:AccruedExpensesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-179">7,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="f-180">2,775</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="f-181">2,993</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities of businesses held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:num-dot-decimal" scale="6" id="f-182">2,104</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:fixed-zero" scale="6" id="f-183">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-184">48,716</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-185">41,225</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current insurance and contractholder liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:InsuranceAndContractholderLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-186">10,904</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:InsuranceAndContractholderLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-187">11,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="f-188">7,173</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="f-189">7,786</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-190">3,441</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-191">2,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="f-192">28,155</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="f-193">28,100</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separate account liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:SeparateAccountsLiability" format="ixt:num-dot-decimal" scale="6" id="f-194">7,430</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:SeparateAccountsLiability" format="ixt:num-dot-decimal" scale="6" id="f-195">7,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities of businesses held for sale, non-current</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" scale="6" id="f-196">591</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" format="ixt:fixed-zero" scale="6" id="f-197">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TOTAL LIABILITIES</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-198">106,410</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-199">99,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingencies &#8212; Note 24</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-12" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-200"></ix:nonFraction></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-13" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-201"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="f-202">107</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="f-203">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders' equity</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="f-204">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="f-205">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-206">30,669</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-207">30,233</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-208">1,864</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-209">1,658</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-210">41,652</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-211">37,940</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Treasury stock, at cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="f-212">24,238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="f-213">21,844</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TOTAL SHAREHOLDERS' EQUITY</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-214">46,223</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-215">44,675</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="f-216">21</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="f-217">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-218">46,244</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-219">44,688</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-220">152,761</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-221">143,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><ix:footnote id="fn-1" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></ix:footnote></div><div style="margin-bottom:10pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><ix:footnote id="fn-2" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Par value per share, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-222"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-223">0.01</ix:nonFraction></ix:nonFraction>; shares issued, <ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="f-224">400</ix:nonFraction> million as of December&#160;31, 2023 and <ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="f-225">398</ix:nonFraction> million as of December&#160;31, 2022; authorized shares, <ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-226"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-227">600</ix:nonFraction></ix:nonFraction> million.</span></ix:footnote></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">The accompanying Notes to the Consolidated Financial Statements are an integral part of these statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">77</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_37"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.465%"/><td style="width:0.1%"/></tr><tr><td colspan="57" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span id="i774f163b23864928b5017735ae76e96a_0-0-1-19-866410"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">The Cigna Group</span></td></tr><tr><td colspan="57" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Statements of Changes in Total Equity</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-in Capital</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive (Loss)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained Earnings</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders' Equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Non- controlling Interests</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Redeemable Noncontrolling Interests</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020, as previously disclosed</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-228">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-229">28,975</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-230">861</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-231">28,575</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-232">6,372</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-233">50,321</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-234">7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-235">50,328</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="6" id="f-236">58</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-237">Cumulative effect of adopting LDTI (ASU 2018-12)</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-238">164</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-239">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-240">139</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-241">139</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020, as retrospectively restated</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-242">4</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-243">28,975</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-244">1,025</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-245">28,600</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-246">6,372</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-247">50,182</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-248">7</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-249">50,189</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-6" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="6" id="f-250">58</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of issuing stock for employee benefit plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-251">604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-252">93</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-253">511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-254">511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-255">43</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-256">43</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-257">43</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="ci:TemporaryEquityOtherComprehensiveIncome" scale="6" id="f-258">14</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-259">5,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-260">5,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="f-261">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-262">5,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:TemporaryEquityNetIncome" scale="6" id="f-263">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common dividends declared (per share: $<ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-264">4.00</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-265">1,347</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-266">1,347</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-267">1,347</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-268">7,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-269">7,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-270">7,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other transactions impacting noncontrolling interests</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-6" sign="-" name="ci:NoncontrollingInterestOtherChanges" scale="6" id="f-271">5</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-6" sign="-" name="ci:NoncontrollingInterestOtherChanges" scale="6" id="f-272">5</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-6" sign="-" name="ci:NoncontrollingInterestOtherChanges" scale="6" id="f-273">20</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="ci:NoncontrollingInterestOtherChanges" scale="6" id="f-274">25</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="us-gaap:TemporaryEquityOtherChanges" scale="6" id="f-275">9</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021, as retrospectively restated</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-276">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-277">29,574</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-278">1,068</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-279">32,623</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-280">14,175</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-281">46,958</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-282">18</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-283">46,976</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="6" id="f-284">54</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of issuing stock for employee benefit plans</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-285">659</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-286">76</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-287">583</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-288">583</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-289">590</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-290">590</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-291">590</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="ci:TemporaryEquityOtherComprehensiveIncome" scale="6" id="f-292">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-293">6,704</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-294">6,704</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="f-295">67</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-296">6,771</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:TemporaryEquityNetIncome" scale="6" id="f-297">11</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common dividends declared (per share: $<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-298">4.48</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-299">1,387</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-300">1,387</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-301">1,387</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-302">7,593</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-303">7,593</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-304">7,593</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other transactions impacting noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-6" name="ci:NoncontrollingInterestOtherChanges" format="ixt:fixed-zero" scale="6" id="f-305">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-6" name="ci:NoncontrollingInterestOtherChanges" format="ixt:fixed-zero" scale="6" id="f-306">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-6" sign="-" name="ci:NoncontrollingInterestOtherChanges" scale="6" id="f-307">72</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="ci:NoncontrollingInterestOtherChanges" scale="6" id="f-308">72</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:TemporaryEquityOtherChanges" scale="6" id="f-309">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2022, as retrospectively restated</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-310">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-311">30,233</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-312">1,658</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-313">37,940</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-314">21,844</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-315">44,675</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-316">13</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-317">44,688</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="6" id="f-318">66</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of issuing stock for employee benefit plans</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-319">477</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-320">112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-321">365</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-322">365</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-323">206</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-324">206</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-325">206</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:TemporaryEquityOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-326">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-327">5,164</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-328">5,164</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="f-329">28</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-330">5,192</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:TemporaryEquityNetIncome" scale="6" id="f-331">180</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common dividends declared (per share: $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-332">4.92</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-333">1,452</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-334">1,452</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="f-335">1,452</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="f-336">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-337">2,282</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-338">2,282</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-339">2,282</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other transactions impacting noncontrolling interests</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-6" sign="-" name="ci:NoncontrollingInterestOtherChanges" scale="6" id="f-340">41</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-6" sign="-" name="ci:NoncontrollingInterestOtherChanges" scale="6" id="f-341">41</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-6" sign="-" name="ci:NoncontrollingInterestOtherChanges" scale="6" id="f-342">20</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="ci:NoncontrollingInterestOtherChanges" scale="6" id="f-343">61</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:TemporaryEquityOtherChanges" scale="6" id="f-344">139</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-345">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-346">30,669</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-347">1,864</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-348">41,652</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-349">24,238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-350">46,223</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-351">21</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-352">46,244</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="6" id="f-353">107</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">The accompanying Notes to the Consolidated Financial Statements are an integral part of these statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">78</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_40"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div><span id="i4ff480fd43234436b9608efae7eb3f5e_424"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">The Cigna Group</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Consolidated Statements of Cash Flows</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.042%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-354">5,372</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-355">6,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-356">5,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-357">3,035</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-358">2,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-359">2,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Realized investment losses (gains), net</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="ci:RealizedInvestmentGainLoss" scale="6" id="f-360">78</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="ci:RealizedInvestmentGainLoss" scale="6" id="f-361">487</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:RealizedInvestmentGainLoss" scale="6" id="f-362">198</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred income tax benefit</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="6" id="f-363">1,659</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="f-364">472</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="f-365">216</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Loss (gain) on sale of businesses</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="6" id="f-366">1,499</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="6" id="f-367">1,662</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="6" id="f-368">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Debt extinguishment costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="f-369">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="f-370">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="f-371">141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net changes in assets and liabilities, net of non-operating effects:</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" format="ixt:num-dot-decimal" scale="6" id="f-372">1,663</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" format="ixt:num-dot-decimal" scale="6" id="f-373">2,237</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" format="ixt:num-dot-decimal" scale="6" id="f-374">2,843</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-375">868</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="6" id="f-376">1,055</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-377">557</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reinsurance recoverable and Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInReinsuranceRecoverable" scale="6" id="f-378">539</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInReinsuranceRecoverable" scale="6" id="f-379">393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:IncreaseDecreaseInReinsuranceRecoverable" scale="6" id="f-380">655</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Insurance liabilities</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInInsuranceLiabilities" scale="6" id="f-381">584</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInInsuranceLiabilities" scale="6" id="f-382">336</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:IncreaseDecreaseInInsuranceLiabilities" scale="6" id="f-383">805</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pharmacy and other service costs payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:IncreaseDecreaseInPharmacyAndServiceCostsPayable" format="ixt:num-dot-decimal" scale="6" id="f-384">2,030</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:IncreaseDecreaseInPharmacyAndServiceCostsPayable" format="ixt:num-dot-decimal" scale="6" id="f-385">1,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:IncreaseDecreaseInPharmacyAndServiceCostsPayable" format="ixt:num-dot-decimal" scale="6" id="f-386">1,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts payable and Accrued expenses and other liabilities</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-387">3,481</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-388">1,734</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities" scale="6" id="f-389">77</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="f-390">463</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="f-391">325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="f-392">333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NET CASH PROVIDED BY OPERATING ACTIVITIES</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-393">11,813</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-394">8,656</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-395">7,191</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Proceeds from investments sold:</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Debt securities and equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:ProceedsFromSaleOfDebtAndEquitySecurities" format="ixt:num-dot-decimal" scale="6" id="f-396">1,078</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:ProceedsFromSaleOfDebtAndEquitySecurities" format="ixt:num-dot-decimal" scale="6" id="f-397">1,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:ProceedsFromSaleOfDebtAndEquitySecurities" format="ixt:num-dot-decimal" scale="6" id="f-398">2,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Investment maturities and repayments:</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Debt securities and equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities" scale="6" id="f-399">972</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities" format="ixt:num-dot-decimal" scale="6" id="f-400">1,327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities" format="ixt:num-dot-decimal" scale="6" id="f-401">1,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Commercial mortgage loans</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromCollectionOfLoansReceivable" scale="6" id="f-402">186</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ProceedsFromCollectionOfLoansReceivable" scale="6" id="f-403">98</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:ProceedsFromCollectionOfLoansReceivable" scale="6" id="f-404">180</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other sales, maturities and repayments (primarily short-term and other long-term investments)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" scale="6" id="f-405">586</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" format="ixt:num-dot-decimal" scale="6" id="f-406">1,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" format="ixt:num-dot-decimal" scale="6" id="f-407">1,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Investments purchased or originated:</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Debt securities and equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:PaymentsToAcquireDebtAndEquitySecurities" format="ixt:num-dot-decimal" scale="6" id="f-408">4,334</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:PaymentsToAcquireDebtAndEquitySecurities" format="ixt:num-dot-decimal" scale="6" id="f-409">2,756</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:PaymentsToAcquireDebtAndEquitySecurities" format="ixt:num-dot-decimal" scale="6" id="f-410">3,553</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Commercial mortgage loans</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquireMortgageNotesReceivable" scale="6" id="f-411">118</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:PaymentsToAcquireMortgageNotesReceivable" scale="6" id="f-412">161</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:PaymentsToAcquireMortgageNotesReceivable" scale="6" id="f-413">327</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other (primarily short-term and other long-term investments)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:num-dot-decimal" scale="6" id="f-414">1,205</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:num-dot-decimal" scale="6" id="f-415">1,563</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:num-dot-decimal" scale="6" id="f-416">2,554</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Property and equipment purchases, net</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:PaymentsForProceedsFromPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-417">1,573</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:PaymentsForProceedsFromPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-418">1,295</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:PaymentsForProceedsFromPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-419">1,154</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions, net of cash acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="f-420">447</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="f-421">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="f-422">1,833</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Divestitures, net of cash sold</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" scale="6" id="f-423">13</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" format="ixt:num-dot-decimal" scale="6" id="f-424">4,835</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" scale="6" id="f-425">61</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="f-426">332</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="f-427">170</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="f-428">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-429">5,174</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-430">3,098</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-431">3,611</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deposits and interest credited to contractholder deposit funds</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AdditionsToContractHoldersFunds" scale="6" id="f-432">167</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:AdditionsToContractHoldersFunds" scale="6" id="f-433">164</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:AdditionsToContractHoldersFunds" scale="6" id="f-434">153</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Withdrawals and benefit payments from contractholder deposit funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:WithdrawalFromContractHoldersFunds" scale="6" id="f-435">223</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:WithdrawalFromContractHoldersFunds" scale="6" id="f-436">220</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:WithdrawalFromContractHoldersFunds" scale="6" id="f-437">168</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net change in short-term debt</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:ProceedsFromRepaymentsOfOtherShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-438">1,198</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="ci:ProceedsFromRepaymentsOfOtherShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-439">2,059</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:ProceedsFromRepaymentsOfOtherShortTermDebt" scale="6" id="f-440">975</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Payments for debt extinguishment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" format="ixt:fixed-zero" scale="6" id="f-441">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" format="ixt:fixed-zero" scale="6" id="f-442">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" scale="6" id="f-443">136</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Repayment of long-term debt</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-444">2,967</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="f-445">500</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-446">4,578</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net proceeds on issuance of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-447">1,491</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="f-448">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-449">4,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-450">2,284</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-451">7,607</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-452">7,742</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="f-453">187</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="f-454">389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="f-455">326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common stock dividend paid</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-456">1,450</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-457">1,384</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-458">1,341</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="f-459">413</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="f-460">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="f-461">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NET CASH USED IN FINANCING ACTIVITIES</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-462">4,294</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-463">11,240</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-464">8,212</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Effect of foreign currency rate changes on cash, cash equivalents and restricted cash </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="f-465">16</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="f-466">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="f-467">65</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="f-468">2,361</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-469">428</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="f-470">4,697</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash January 1,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-471">5,976</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-472">5,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-473">10,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-474">8,337</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-475">5,976</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="f-476">5,548</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents reclassified to assets of businesses held for sale</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" scale="6" id="f-477">467</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="f-478">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" scale="6" id="f-479">425</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash December 31, per Consolidated Balance Sheets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-480">7,870</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-481">5,976</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-482">5,123</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Supplemental Disclosure of Cash Information:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income taxes paid, net of refunds</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="6" id="f-483">1,471</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="6" id="f-484">1,850</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="6" id="f-485">2,240</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest paid</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="f-486">1,330</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="f-487">1,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="f-488">1,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></div><div style="margin-bottom:10pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><ix:footnote id="fn-3" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Restricted cash and cash equivalents were reported in other long-term investments.</span></ix:footnote></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">The accompanying Notes to the Consolidated Financial Statements are an integral part of these statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">79</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_55"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:20pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE CIGNA GROUP</span></div><div style="margin-bottom:10pt;text-align:center"><span id="id1b20469f0f6458797f28c8dd261dd90_58"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.416%"><tr><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:78.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.754%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Note Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Footnote</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr style="height:14pt"><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">USINESS AND</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">APITAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">TRUCTURE</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_58">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_58">Description of Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_58">81</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_61">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_61">Summary of Significant Accounting Policies</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_61">81</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_91">3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_91">Accounts Receivable, Net</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_91">87</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_118">4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_118">Supplier Finance Program</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_118">88</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_121">5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_121">Mergers, Acquisitions and Divestitures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_121">88</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_157">6</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_157">Assets and Liabilities of Businesses Held for Sale</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_157">89</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_169">7</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_169">Earnings Per Share</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_169">90</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_190">8</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_190">Debt</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_190">91</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_226">9</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_226">Common and Preferred Stock</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_226">93</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NSURANCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NFORMATION</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_241">10</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_241">Insurance and Contractholder Liabilities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_241">95</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_325">11</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_325">Reinsurance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_325">101</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NVESTMENTS</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_373">12</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_373">Investments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_373">104</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_490">13</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_490">Fair Value Measurements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_490">109</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_547">14</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_547">Variable Interest Entities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_547">114</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_559">15</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_559">Collectively Significant Operating Unconsolidated Subsidiaries</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_559">115</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_562">16</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_562">Accumulated Other Comprehensive Income (Loss)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_562">115</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">W</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">ORKFORCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">ANAGEMENT AND</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">OMPENSATION</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_565">17</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_565">Organizational Efficiency Plan</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_565">117</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_571">18</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_571">Pension</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_571">117</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_577">19</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_577">Employee Incentive Plans</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_577">120</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">ROPERTY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">, L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">EASES AND</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> O</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">THER </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">SSET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">ALANCES</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_580">20</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_580">Goodwill, Other Intangibles and Property and Equipment</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_580">123</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_589">21</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_589">Leases</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_589">126</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">OMPLIANCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">, R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">EGULATION AND</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">ONTINGENCIES</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_607">22</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_607">Shareholders' Equity and Dividend Restrictions</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_607">127</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_610">23</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_610">Income Taxes</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_610">128</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_628">24</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_628">Contingencies and Other Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_628">131</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">ESULTS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">ETAILS</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_646">25</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_646">Segment Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_646">132</a></span></div></td></tr></table></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">80</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_58"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NatureOfOperations" id="f-489" escape="true"><div style="margin-bottom:10pt"><span id="ic54f78bd196a45c4afa77338709a7ea1_5265"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1 &#8211; Description of Business</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Cigna Group, together with its subsidiaries (either individually or collectively referred to as the "Company," "we," "us" or "our"), is a global health company committed to creating a better future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. Powered by our people and our brands, we advance our mission to improve the health and vitality of those we serve. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our subsidiaries offer a differentiated set of pharmacy, medical, behavioral, dental and related products and services. The majority of these products and services are offered through employers and other groups such as governmental and non-governmental organizations, unions and associations. Cigna Healthcare also offers commercial health and dental insurance and Medicare products to individuals in the United States and selected international markets. In addition to these operations, The Cigna Group also has certain run-off operations.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A full description of our segments follows:</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Evernorth Health Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> partners with health plans, employers, governmental organizations and health care providers to solve challenges in the areas of pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty distribution, and care delivery and management solutions. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cigna Healthcare</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> includes the U.S. Healthcare and International Health operating segments which provide comprehensive medical and coordinated solutions to clients and customers. During the fourth quarter of 2023, the U.S. Commercial and U.S. Government operating segments merged to form the U.S. Healthcare operating segment. U.S. Healthcare provides commercial medical plans and specialty benefits and solutions for insured and self-insured clients, Medicare Advantage, Medicare Supplement and Medicare Part D plans for seniors and individual health insurance plans. International Health provides health care solutions in our international markets, as well as health care benefits for globally mobile individuals and employees of multinational organizations. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2024, the Company entered into a definitive agreement to sell the Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits and CareAllies businesses within the <span style="-sec-ix-hidden:f-490">U.S. Healthcare</span> operating segment to Health Care Service Corporation ("HCSC") for $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-8" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="9" id="f-491">3.3</ix:nonFraction> billion cash, subject to applicable regulatory approvals and other customary closing conditions (the "HCSC transaction").</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> comprises the remainder of our business operations, which includes ongoing businesses and exited businesses. Our ongoing businesses include continuing business (corporate-owned life insurance ("COLI")), and our run-off businesses. Our run-off businesses include (i) variable annuity reinsurance business (formerly referred to as guaranteed minimum death benefit ("GMDB") and guaranteed minimum income benefit ("GMIB") business) that was effectively exited through reinsurance with Berkshire Hathaway Life Insurance Company of Nebraska ("Berkshire") in 2013, (ii) settlement annuity business, and (iii) individual life insurance and annuity and retirement benefits businesses which were sold through reinsurance agreements. Our exited businesses include the international life, accident and supplemental benefits businesses sold in July 2022 (the "Chubb transaction") and our interest in a joint venture in T&#252;rkiye sold in December 2022.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">reflects amounts not allocated to operating segments, including net interest expense (defined as interest on corporate financing less net investment income on investments not supporting segment and other operations), certain litigation matters, expense associated with our frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs and eliminations for products and services sold between segments.</span></div></ix:nonNumeric><div id="ibc59a92ac8bc42f794e728f24ce1b626_61"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-492" continuedAt="f-492-1" escape="true"><div style="margin-bottom:10pt;margin-top:10pt"><span id="i0260500cfa11442391009e7f8cffe4ab_1054"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2 &#8211; Summary of Significant Accounting Policies&#160;&#160;&#160;&#160;</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-493" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Basis of Presentation</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Consolidated Financial Statements include the accounts of The Cigna Group and its consolidated subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. These Consolidated Financial Statements were prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"). Certain amounts in prior years related to the adoption of Targeted Improvements for the Accounting of Long-Duration Contracts, have been reclassified to conform to the current year presentation. See "Recent Accounting Pronouncements" below.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amounts recorded in the Consolidated Financial Statements necessarily reflect management's estimates and assumptions about medical costs, investment and receivable valuations, interest rates and other factors. Significant estimates are discussed throughout these Notes; however, actual results could differ from those estimates. The impact of a change in estimate is generally included in earnings in the period of adjustment.</span></div></ix:nonNumeric></ix:nonNumeric><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">81</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_67"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-494" continuedAt="f-494-1" escape="true"><ix:continuation id="f-492-1" continuedAt="f-492-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Recent Accounting Pronouncements</span></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div></ix:nonNumeric><div id="ibc59a92ac8bc42f794e728f24ce1b626_6173"></div><ix:continuation id="f-494-1" continuedAt="f-494-2"><ix:continuation id="f-492-2" continuedAt="f-492-3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Targeted Improvements to the Accounting for Long-Duration Contracts, Accounting Standards Update ("ASU") 2018-12 and related amendments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Cigna Group adopted LDTI January 1, 2023, which includes the following key provisions:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Changes to the measurement of the future policy benefits liability for traditional and limited-pay insurance contracts:</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Assumptions used to measure cash flows (such as mortality, morbidity and lapse assumptions) are updated at least annually with the effect of changes in those assumptions remeasured retrospectively and reflected in current period net income. </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Discount rate assumptions are updated quarterly based on market-level yields for low credit risk fixed income instruments ("upper-medium grade fixed income instrument"), with any changes reflected in other comprehensive income. The upper-medium grade fixed income instrument yield is interpreted to mean A-rated.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Deferred policy acquisition costs ("DAC") related to long-duration insurance contracts are amortized on a constant-level basis over the expected term of the related contracts. Other related deferred or capitalized balances (such as unearned revenue liability and value of business acquired) may use this simplified amortization method. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Market risk benefits ("MRB"), defined as protecting the contractholder from other-than-nominal capital market risk and exposing the insurer to that risk, are measured at fair value, with changes in fair value recognized in net income each period, except for the effect of the Company's change in nonperformance risk (own credit risk), which is recognized in other comprehensive income. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Additional disclosures, including disaggregated roll forwards for the liability for future policy benefits, market risk benefits, contractholder deposit funds and DAC, as well as information about significant inputs, judgments, assumptions and methods used in measurement.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The transition methods applied at adoption were:</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The liability for future policy benefits was remeasured using a modified retrospective approach applied to all outstanding contracts as of the beginning of the earliest period presented and was recognized in the opening balance of retained earnings. The impact of remeasuring the future policy benefits liability for the discount rate was recorded through accumulated other comprehensive income. </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">DAC followed the transition method used for future policyholder benefits.</span></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Market risk benefits were remeasured at fair value at the beginning of the earliest period presented. The difference between this fair value and carrying value was recognized in the opening balance of retained earnings, excluding the effect of the Company's change in nonperformance risk (own credit risk), which was recognized in accumulated other comprehensive income. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Effects of adoption:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The new guidance applies to our long-duration insurance products predominantly within the Cigna Healthcare segment and Other Operations.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The cumulative effects of adopting the new standard were immaterial. The impacts were a decrease to January 1, 2021 Shareholders' equity of $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-495">139</ix:nonFraction> million and an increase to Shareholders' net income for the years ended December 31, 2022 and December 31, 2021 of $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="f-496">36</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="f-497">5</ix:nonFraction> million, respectively. The corresponding impact to diluted earnings per share was an increase of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-76" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-498">0.11</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-77" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-499">0.02</ix:nonFraction> for the years ended December 31, 2022 and December 31, 2021, respectively. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The prior periods within our Consolidated Statements of Income, Consolidated Statements of Comprehensive Income, Consolidated Balance Sheets, Consolidated Statements of Changes in Total Equity and Consolidated Statements of Cash Flows were restated to conform to the current presentation. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Prior period balances in the Company's footnote disclosures have been updated to reflect adjustments resulting from the adoption of this standard. Refer to Note 10 to the Consolidated Financial Statements for the Company's updated accounting policies. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">It is possible that our income recognition pattern could change on a prospective basis for several reasons: </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Applying periodic assumption updates, versus the locked-in model, may change our timing of profit or loss recognition. </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">DAC amortization is on a constant level basis over the expected term of the related contracts and no longer tied to the emergence of profit on such contracts. </span></div><div style="text-indent:45pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, in December 2022, the Financial Accounting Standards Board ("FASB") published ASU 2022-05, which simplified the retrospective adoption of LDTI by permitting companies to make an accounting policy election to exclude contracts that are sold and removed from the balance sheet prior to the effective date of the standard from the retrospective adoption of LDTI. The Cigna Group made this policy election for the contracts sold in the Chubb transaction and our divested interest in a joint venture in T&#252;rkiye. </span></div></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">82</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_76"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-494-2"><ix:continuation id="f-492-3" continuedAt="f-492-4"><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Accounting Guidance Not Yet Adopted</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">There are no significant accounting pronouncements not yet adopted as of December&#160;31, 2023.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_79"></div><ix:continuation id="f-492-4" continuedAt="f-492-5"><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Significant Accounting Policies</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's accounting policies are described either in this Note or in the applicable Notes to the Consolidated Financial Statements as listed in the table of contents on page </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ibc59a92ac8bc42f794e728f24ce1b626_55">80</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Cash and Cash Equivalents</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-500" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash and cash equivalents are carried at cost that approximates fair value. Cash equivalents consist of short-term investments with maturities of three months or less from the time of purchase. The Company reclassifies cash overdraft positions to liabilities when the legal right of offset does not exist.</span></div></ix:nonNumeric><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Inventories</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-501" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inventories consist of prescription drugs and medical supplies and are stated at the lower of first-in-first-out cost or net realizable value.</span></div></ix:nonNumeric></ix:continuation><div id="ibc59a92ac8bc42f794e728f24ce1b626_85"></div><div><span><br/></span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">C.</span><ix:continuation id="f-492-5" continuedAt="f-492-6"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Other Assets (Current and Non-Current)</span></ix:continuation></div><ix:continuation id="f-492-6" continuedAt="f-492-7"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="ci:OtherAssetsCurrentAndNoncurrentPolicyPolicyTextBlock" id="f-502" escape="true">Other current assets consist primarily of prepaid expenses, income tax receivables, accrued investment income and the current portion of reinsurance recoverables. Other assets (non-current) consist primarily of the Company's net deferred tax asset associated with foreign tax attributes (see Note 23) and the carrying value of our equity-method investments in business-related joint ventures in China, the U.S. and other foreign jurisdictions. Earnings or losses from these equity-method investments in joint ventures are recorded in Fees and other revenues. See Note 15 for additional information on unconsolidated subsidiaries. Additionally, Other assets (non-current) includes operating lease right-of-use assets, various insurance-related assets and overfunded pension obligations (see Note 18). See Note 21 for the Company's accounting policy related to leases.</ix:nonNumeric> </span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Redeemable Noncontrolling Interests</span></div><ix:nonNumeric contextRef="c-1" name="ci:RedeemableNoncontrollingInterestsPolicyPolicyTextBlock" id="f-503" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Redeemable noncontrolling interests in our Consolidated Balance Sheets represents the noncontrolling shareholders' preferred and common stock interests of the Company's consolidated less than fully owned subsidiaries. Those shareholders may choose to require the Company to purchase their equity interest. For certain entities, we may also have the right to require those shareholders to sell their equity interest to us. As these redeemable noncontrolling interests provide for redemption features not solely within our control, we classify the redeemable noncontrolling interests outside of permanent equity. The noncontrolling interest was initially recorded at fair value. In subsequent reporting periods, the values are adjusted to reflect the earnings, losses and distributions attributable to the noncontrolling interest. When a shareholder's right to require the Company to purchase its equity interest is exercisable, the redeemable noncontrolling interest is recorded at estimated redemption value. When the estimated redemption value for a redeemable noncontrolling interest exceeds its initial carrying value, an adjustment to increase or decrease the redeemable noncontrolling interest is recorded with an offsetting adjustment to Retained earnings or Additional paid-in capital in the absence of Retained earnings. When an adjustment is made to the carrying value of the redeemable noncontrolling interest, the calculation of Shareholders' net income per share will be adjusted if the redemption value exceeds fair value.</span></div></ix:nonNumeric><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">E.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Accrued Expenses and Other Current and Non-Current Liabilities</span></div><ix:nonNumeric contextRef="c-1" name="ci:AccountsPayableAccruedExpensesOtherLiabilitiesPolicyPolicyTextBlock" id="f-504" continuedAt="f-504-1" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued expenses and other liabilities (current) primarily includes financial and performance guarantee liabilities (see section G) and other liabilities arising from pharmacy contracts, management compensation, various insurance-related liabilities, including experience-rated refunds, reinsurance contracts and the risk adjustment and minimum medical loss ratio rebate accruals under The Patient Protection and Affordable Care Act (the "ACA"), and amounts due to financial institutions under the accounts receivable factoring facility (see Note 3). Other non-current liabilities primarily include uncertain tax positions (see Note 23), amounts held for self-funded clients to cover the administration and payment of claims that may emerge post contract termination, lease liabilities (see Note 21) and underfunded pension obligations (see Note 18).</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company accrues for legal and regulatory matters when a loss contingency is both probable and estimable. The estimated loss is generally recorded in Selling, general and administrative expenses and represents the Company's best estimate of the loss contingency. If the loss estimate is a range, the Company accrues the minimum amount in the range if no amount is better than any other estimated amount in the range. Legal costs to defend the Company's litigation and arbitration matters are expensed as incurred in cases that the Company cannot reasonably estimate the ultimate cost to defend. If the Company can reasonably estimate the cost to defend, a liability </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-492-7" continuedAt="f-492-8"><ix:continuation id="f-504-1"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">for these costs is accrued when the claim is reported. Litigation and legal or regulatory matters that the Company has identified with a reasonable possibility of material loss are described in Note 24.</span></div></ix:continuation><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">F.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:9.4pt;text-decoration:underline">Translation of Foreign Currencies</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-505" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company generally conducts its international business through foreign operating entities that maintain assets and liabilities in local currencies that are their functional currencies. The Company uses exchange rates as of the balance sheet date to translate assets and liabilities into U.S. dollars. Translation gains or losses on functional currencies, net of applicable taxes, are recorded in Accumulated other comprehensive loss. The Company uses average monthly exchange rates during the year to translate revenues and expenses into U.S. dollars.</span></div></ix:nonNumeric><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">G.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:7.73pt;text-decoration:underline">Pharmacy Revenues and Costs</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CostOfSalesPolicyTextBlock" id="f-507" continuedAt="f-507-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="f-506" continuedAt="f-506-1" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Pharmacy revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Pharmacy revenues are primarily derived from providing pharmacy benefit management services to clients and customers. Pharmacy revenues are recognized when control of the promised goods or services is transferred to clients and customers, in an amount that reflects the consideration the Company expects to receive for those goods or services.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company provides or makes available various services supporting benefit management and claims administration and is generally obligated to provide prescription drugs to clients' members using multiple distribution methods including retail networks, home delivery and specialty pharmacies. These goods and services are integrated into a single performance obligation to process claims, dispense prescription drugs and provide other services over the contract period (generally three years). This performance obligation is satisfied as the business stands ready to fulfill its obligation.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenues for dispensing prescription drugs through retail pharmacies are reported gross and consist of the prescription price (ingredient cost and dispensing fee) contracted with clients, including the customer copayment and any associated fees for services, because the Company acts as the principal in these arrangements. When a prescription is presented to a retail network pharmacy, the Company is solely responsible for customer eligibility, drug utilization review, drug-to-drug interaction review, any required clinical intervention, plan provision information, payment to the pharmacy and client billing. These revenues are recognized based on the full prescription price when the pharmacy claim is processed and approved for payment. The Company also provides benefit design and formulary consultation services to clients and negotiates separate contractual relationships with clients and network pharmacies. These factors indicate that the Company has control over these transactions until the prescription is processed. Revenues are billed, due and recognized at contract rates either on a periodic basis or as services are provided (such as based on volume of claims processed). This recognition pattern aligns with the benefits from services provided.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Home delivery and specialty pharmacy revenues are due and recognized as each prescription is shipped, net of reserves for discounts and contractual allowances estimated based on historical experience. Any differences between estimates and actual collections are reflected in Pharmacy revenues when payments are received. Historically, adjustments to original estimates and returns have not been material. The Company has elected the practical expedient to account for shipping and handling as a fulfillment activity.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may also provide certain financial and performance guarantees, including a minimum level of discounts a client may receive, generic utilization rates and various service levels. Clients may be entitled to receive compensation if we fail to meet the guarantees. Actual performance is compared to the contractual guarantee for each measure throughout the period and the Company defers revenue for any estimated payouts within Accrued expenses and other liabilities (current). These estimates are adjusted and paid at the end of the annual guarantee period. Historically, adjustments to original estimates have not been material. The liability for these financial and performance guarantees was $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-8" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="9" id="f-508">1.6</ix:nonFraction> billion as of December&#160;31, 2023 and $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-8" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="9" id="f-509">1.3</ix:nonFraction> billion as of December&#160;31, 2022.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company administers programs through which we may receive rebates and other vendor consideration from pharmaceutical manufacturers. The amounts of such rebates or other vendor consideration shared with pharmacy benefit management services clients vary based on the contractual arrangement with the client and in some cases the type of consideration received from the pharmaceutical manufacturer. Rebates and other vendor consideration payable to pharmacy benefit management services clients are recorded as a reduction of Pharmacy revenues. Estimated amounts payable to clients are based on contractual sharing arrangements between the Company and the client and these amounts are adjusted when amounts are collected from pharmaceutical manufacturers in accordance with the contractual arrangement between the Company and the client. Historically, these adjustments have not been material.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In retail, home delivery and specialty transactions, amounts may be collected from third-party payors. These are billed and collected in accordance with the Company's standard accounts receivable collection procedures. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other pharmacy service revenues are earned by distributing specialty pharmaceuticals and medical supplies to providers, clinics and hospitals. These revenues are billed, due and recognized at contracted rates as prescriptions and supplies are shipped and services are provided.</span></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-507-1" continuedAt="f-507-2"><ix:continuation id="f-506-1" continuedAt="f-506-2"><ix:continuation id="f-492-8" continuedAt="f-492-9"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Pharmacy costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Pharmacy costs include the cost of prescriptions sold, network pharmacy claim costs and copayments. Also included are direct costs of dispensing prescriptions including supplies, shipping and handling and direct costs associated with clinical programs, such as drug utilization management and medication adherence counseling. Home delivery and specialty pharmacy costs are recognized when the drug is shipped and retail network costs are recognized when the drug is processed and approved for payment. Rebates and other vendor consideration received when providing pharmacy benefit management services are recorded as a reduction of pharmacy costs. Rebates are recognized as prescriptions are shipped or processed and approved for payment. Historically, the effect of adjustments resulting from the reconciliation of rebates recognized to the amounts billed and collected, net of contractual allowances, has not been material. The Company maintains reimbursement guarantees with certain retail network pharmacies. For each such guarantee, the Company records a pharmacy and other service costs payable or prepaid asset for applicable retail network claims based on our actual performance throughout the period against the contractual reimbursement rate. The Company's contracts with certain retail pharmacies give the Company the right to adjust reimbursement rates during the annual guarantee period.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Incremental costs of obtaining service and pharmacy contracts for short-term arrangements are expensed as incurred.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">H.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:7.73pt;text-decoration:underline">Premiums and Related Expenses</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Premiums for short-duration group health, accident and life insurance and managed care coverages are recognized as revenue on a pro rata basis over the contract period. Benefits and expenses are recognized when incurred and, for our Cigna Healthcare business, are presented net of pharmaceutical manufacturer rebates. For experience-rated contracts, premium revenue includes an adjustment for experience-rated refunds based on contract terms and calculated using the customer's experience (including estimates of incurred but not reported claims).</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Premiums received for the Company's Medicare Advantage plans, Medicare Part D plans and Individual and Family Plans from the Centers for Medicare and Medicaid Services ("CMS") and customers are recognized as revenue ratably over the contract period. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CMS provides risk-adjusted premium payments for Medicare Advantage plans and Medicare Part D plans based on our customer demographics and medical diagnoses, which may change from period to period based on the underlying health of our customers. The Company recognizes changes to risk-adjusted premiums as revenue when the amounts are determinable and collection is reasonably assured. Revenue adjustments are generally settled semi-annually with CMS. The final revenue adjustment is generally settled with CMS in the year following the contract year.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medicare Part D premiums include payments from CMS for risk-sharing adjustments that are estimated quarterly based on claim experience by comparing actual incurred prescription drug costs to the estimated costs submitted in the original contracts. These adjustments may result in more or less revenue from CMS. Final revenue adjustments generally occur in the year following the contract year. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The ACA prescribed a risk-adjustment program to mitigate the risk for participating health insurance companies selling individual coverage on the public exchanges. The risk-adjustment program reallocates funds from insurers with lower risk populations to insurers with higher risk populations based on the relative risk scores of participants. We estimate our receivable or payable based on the risk of our customers compared to the risk of other customers in the same state and market, considering data obtained from industry studies and the United States Department of Health and Human Services ("HHS"). Receivables or payables are recorded as adjustments to premium revenue based on our year-to-date experience when the amounts are reasonably estimable and collection is reasonably assured. Final revenue adjustments are determined by HHS in the year following the policy year.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Premium revenue may also include an adjustment to reflect the estimated effect of rebates due to customers under medical loss ratio provisions of the ACA. These rebate liabilities are settled in the subsequent year.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Premiums for long-duration insurance contracts, including individual life, accident and supplemental health insurance and annuity products, and excluding universal life and investment-related products, are recognized as revenue when due. Cigna Healthcare's long-duration premium revenues are associated with contracts that provide coverage greater than one year or are guaranteed to be renewed at the option of the policyholder beyond one year. Benefits and expenses are matched with premiums. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue for universal life products is recognized as follows:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Investment income on assets supporting universal life products is recognized in Net investment income as earned.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Charges for mortality, administration and policy surrender are recognized in Premiums as earned. Administrative fees are considered earned when services are provided.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Benefits and expenses for universal life products consist of benefit claims in excess of policyholder account balances and income earned by policyholders. Expenses are recognized when claims are incurred and income is credited to policyholders in accordance with contract provisions.</span></div></ix:continuation></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-507-2" continuedAt="f-507-3"><ix:continuation id="f-506-2" continuedAt="f-506-3"><ix:continuation id="f-492-9" continuedAt="f-492-10"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The unrecognized portion of premiums received is recorded as unearned premiums included in Insurance and contractholder liabilities (current and non-current) (see Note 10 to the Consolidated Financial Statements for further information).</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">I.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:11.61pt;text-decoration:underline">Fees and Related Expenses</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The majority of the Company's service fees are derived from administrative services only ("ASO") arrangements, fee-for-service clinical solutions, Wholesale Marketplace Drug Formulary Management services, health benefit management services and administration of services to specialty pharmacy manufacturers.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASO arrangements allow plan sponsors to self-fund claims and assume the risk of medical or other benefit costs. Most of the Company's ASO arrangements are for medical and specialty solutions, including pharmacy benefits. Generally, the Company's ASO arrangements are short-term. Contract modifications typically occur on renewal and are prospective in nature.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In return for fees from these clients, the Company provides access to our participating provider networks and other services supporting benefit management, including claims administration, behavioral health services, disease management, utilization management and cost containment programs. In general, the Company considers these services to be a combined performance obligation to provide cost effective administration of plan benefits over the contract period. Fees are billed, due and recognized monthly at contracted rates based on current membership or utilization. This recognition pattern aligns with the benefits from services provided to clients. These revenues are reported in Fees and other revenues in the Consolidated Statements of Income.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company may also provide performance guarantees that provide potential refunds to clients if certain service standards, clinical outcomes or financial metrics are not met. If these standards, outcomes and metrics are not met, the Company may be financially at risk up to a stated percentage of the contracted fee or a stated dollar amount. The Company defers revenue by recording a liability for estimated payouts associated with these guarantees within Accrued expenses and other liabilities. The amount of revenue deferred is estimated for each type of guarantee using either a most likely amount or expected value method depending on the nature of the guarantee and the information available to estimate refunds. Estimates are refined each reporting period as additional information on the Company's performance becomes available and upon final reconciliation and settlement following the guarantee period. Amounts accrued and paid for these performance guarantees during the reporting periods were not material.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expenses associated with administrative programs and services are recognized as incurred in Selling, general and administrative expenses.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company also earns revenue, as part of its integrated pharmacy benefits performance obligation, by offering fee-for-service clinical solutions to our clients, such as drug utilization management and medication adherence counseling. These clinical programs help clients to drive better health outcomes at a lower cost by identifying and addressing potentially unsafe or wasteful prescribing, dispensing and utilization of prescription drugs and communicating with, or supporting communications with physicians, pharmacies and patients. Fees are billed, due and recognized at contracted rates either on a periodic basis or as services are provided. This recognition pattern aligns with the benefits from services provided. These revenues are reported in Fees and other revenues in the Consolidated Statements of Income. Direct costs associated with these programs are recognized in Pharmacy and other service costs, and other related expenses are recorded as incurred in Selling, general and administrative expenses.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company earns fees from our Wholesale Marketplace Drug Formulary Management services. These services include either our drug formulary administrative service arrangements or our formulary processing arrangements. Drug formulary administrative services may include formulary consultation, administration of rebate contracts, rebate submission, collection from drug manufacturers and the distribution of rebates to clients. Services may also include facilitating audits of data submissions and reporting of rebates to clients. Clients agree to pay administrative fees that are billed, due and recognized at contracted rates as services are performed. These revenues are reported gross in Fees and other revenues and associated costs are reported in Pharmacy and other service costs in the Consolidated Statements of Income. For certain other clients in our formulary processing arrangements, the Company does not control the right to retain rebates before they are transferred to the client for services performed. Clients agree to allow the Company to retain a portion of each rebate collected in exchange for formulary processing services provided. These drug formulary service and administrative fee revenues are reported net in Fees and other revenues in the Consolidated Statements of Income. Revenue is recognized as rebates are processed.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company also earns fees by providing health benefit management solutions that drive cost reductions and improve quality outcomes. Clients are primarily sponsors of health benefit plans and fees may be stated as a per-member-per-month fee or as a per-claim fee. The Company considers the services to be a single performance obligation to stand ready to provide utilization management services over the contract period (generally three years). In certain arrangements, the Company assumes the financial obligation for third-party provider costs for medical services provided to the health plan's customers. Fees are recorded gross in Fees and other revenues in the Consolidated Statements of Income because the Company is acting as a principal in arranging for and controlling the services provided by third-party network providers. Contractual fees vary based on enrollment and provider costs and are billed, due </span></div></ix:continuation></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-507-3"><ix:continuation id="f-506-3"><ix:continuation id="f-492-10"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and recognized monthly. Direct costs associated with these programs are recognized in Pharmacy and other service costs, and other related expenses are recorded in Selling, general and administrative expenses as incurred.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain health benefit management contracts require the Company to share the results of medical cost experience that differ from specified targets. This variable consideration is estimated at contract inception and adjusted through the contract period. The estimated profits and costs are recognized net in Fees and other revenues.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company also earns other service fees related to administrating services to specialty pharmacy manufacturers that are recorded in Fees and other revenues in the Consolidated Statements of Income. These revenues are billed, due and recognized at contracted rates as services are provided.</span></div></ix:continuation></ix:continuation></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_91"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="f-516" continuedAt="f-516-1" escape="true"><div><span id="i320b3e5344194d5b9823c6f2e7007e05_14"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3 &#8211; Accounts Receivable, Net</span></div></ix:nonNumeric><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_94"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="f-517" continuedAt="f-517-1" escape="true"><ix:continuation id="f-516-1" continuedAt="f-516-2"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We bill pharmaceutical manufacturers based on management's interpretation of contractual terms and estimate a contractual allowance based on the best information available at the time a claim is processed. Contractual allowances for certain rebates receivable from pharmaceutical manufacturers are determined by reviewing payment experience and specific known items that could be adjusted under contract terms. The Company's estimation process for contractual allowances for pharmaceutical manufacturer receivables generally results in an allowance for balances outstanding greater than 90 days. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contractual allowances for certain receivables from third-party payors are based on their contractual terms and are estimated based on the Company's best information available at the time revenue is recognized. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Discounts and claims adjustments issued to customers in the form of client credits and other non-credit adjustments are based on the current status of each customer's receivable balance, current economic and market conditions and a variety of other factors, including the length of time the receivables are past due, the financial health of customers and our past experience. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The allowance for expected credit losses for current accounts receivable is based primarily on past collections experience relative to the length of time receivables are past due; however, when available evidence reasonably supports an assumption that counterparty credit risk over the expected payment period will differ from current and historical payment collections, a forecasting adjustment is reflected in the allowance for expected credit losses.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Receivables and any associated allowance are written off only when all collection attempts have failed and such amounts are determined unrecoverable. We regularly review the adequacy of these allowances based on a variety of factors, including age of the outstanding receivable and collection history. When circumstances related to specific collection patterns change, estimates of the recoverability of receivables are adjusted.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's accounts receivable include amounts due from pharmaceutical manufacturers, clients, third-party payors and customers, and are presented net of allowances. These balances include:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt">Pharmaceutical manufacturers receivables - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">amounts due from pharmaceutical manufacturers. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt">Noninsurance customer receivables - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">amounts due from customers for noninsurance services, primarily pharmacy benefit management and ASO contracts.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt">Insurance customer receivables - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">amounts due from customers under insurance and managed care contracts, primarily premiums receivable and amounts due from CMS.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt">Other receivables - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">all other accounts receivable not included in the categories above.</span></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_97"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="f-518" escape="true"><ix:continuation id="f-516-2" continuedAt="f-516-3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following amounts were included within Accounts receivable, net:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.041%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical manufacturers receivables</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:PharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-519">8,169</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:PharmaceuticalManufacturerReceivable" format="ixt:num-dot-decimal" scale="6" id="f-520">7,108</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noninsurance customer receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-521">8,044</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable" format="ixt:num-dot-decimal" scale="6" id="f-522">6,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Insurance customer receivables</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:InsuranceCustomerReceivablesBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-523">2,359</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:InsuranceCustomerReceivables" format="ixt:num-dot-decimal" scale="6" id="f-524">2,963</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:AccountsAndOtherReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-525">272</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="6" id="f-526">248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-527">18,844</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net classified as assets of businesses held for sale</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" format="ixt:num-dot-decimal" scale="6" id="f-528">1,122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-529">17,722</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-530">17,218</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_103"></div><ix:continuation id="f-516-3" continuedAt="f-516-4"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These receivables are reported net of our allowances of $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-8" name="ci:AllowanceForReceivablesCurrent" scale="9" id="f-531">3.7</ix:nonFraction> billion as of December&#160;31, 2023 and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-8" name="ci:AllowanceForReceivablesCurrent" format="ixt:num-dot-decimal" scale="9" id="f-532">1.9</ix:nonFraction> billion as of December&#160;31, 2022 as follows:</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-516-4" continuedAt="f-516-5"><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Included in our Pharmaceutical manufacturers receivables are contractual allowances for certain rebates receivable with pharmaceutical manufacturers of $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-8" name="ci:ContractualAllowancePharmaceuticalManufacturersReceivables" format="ixt:num-dot-decimal" scale="9" id="f-533">3.1</ix:nonFraction> billion as of December&#160;31, 2023 and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:ContractualAllowancePharmaceuticalManufacturersReceivables" format="ixt:num-dot-decimal" scale="9" id="f-534">1.3</ix:nonFraction> billion as of December&#160;31, 2022. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Included in our Noninsurance customer receivables are contractual allowances from third-party payors of $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:ContractualAllowanceNoninsuranceCustomerReceivables" format="ixt:num-dot-decimal" scale="6" id="f-535">386</ix:nonFraction> million as of December&#160;31, 2023 and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:ContractualAllowanceNoninsuranceCustomerReceivables" format="ixt:num-dot-decimal" scale="6" id="f-536">336</ix:nonFraction> million as of December&#160;31, 2022 based upon the contractual payment terms. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The remaining allowances of $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:AllowanceForReceivablesOther" format="ixt:num-dot-decimal" scale="6" id="f-537">219</ix:nonFraction> million as of December&#160;31, 2023 and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:AllowanceForReceivablesOther" format="ixt:num-dot-decimal" scale="6" id="f-538">226</ix:nonFraction> million as of December&#160;31, 2022 include discounts and claims adjustments issued to customers in the form of client credits, an allowance for current expected credit losses and other non-credit adjustments. </span></div></ix:continuation><div style="margin-bottom:10pt"><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_106"></div><ix:continuation id="f-516-5" continuedAt="f-516-6"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's allowance for current expected credit losses was $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-539">90</ix:nonFraction> million as of December&#160;31, 2023 and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-540">86</ix:nonFraction> million as of December&#160;31, 2022.</span></div></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_109"></div><ix:continuation id="f-516-6" continuedAt="f-516-7"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounts Receivable Factoring Facility</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2023, <ix:continuation id="f-517-1" continuedAt="f-517-2">the Company entered into an uncommitted factoring facility (the "Facility") under which certain accounts receivable may be sold on a non-recourse basis to a financial institution</ix:continuation>. The Facility's total capacity is $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-8" name="ci:AccountsReceivableUncommittedFactoringFacilityTotalCapacity" format="ixt:num-dot-decimal" scale="9" id="f-541">1.0</ix:nonFraction> billion with an initial term of <ix:nonNumeric contextRef="c-85" name="ci:AccountsReceivableUncommittedFactoringFacilityInitialTerm" format="ixt-sec:durwordsen" id="f-542">two years</ix:nonNumeric>, followed by automatic <ix:nonNumeric contextRef="c-85" name="ci:AccountsReceivableUncommittedFactoringFacilityAutomaticRenewalTerm" format="ixt-sec:durwordsen" id="f-543">one year</ix:nonNumeric> renewal terms unless terminated by either party. <ix:continuation id="f-517-2" continuedAt="f-517-3">The transactions under the Facility are accounted for as a sale and recorded as a reduction to accounts receivable in the Consolidated Balance Sheets because control of, and risk related to, the accounts receivable are transferred to the financial institution</ix:continuation>. Although the sale is made without recourse, we provide collection services related to the transferred assets. <ix:continuation id="f-517-3" continuedAt="f-517-4">Amounts associated with this Facility are reflected within Net cash provided by operating activities in the Consolidated Statements of Cash Flows. Factoring fees paid under this Facility are reflected in Interest expense and other in the Consolidated Statements of Income.</ix:continuation> </span></div></ix:continuation><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-516-7">For the year ended December&#160;31, 2023, we sold $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-8" name="ci:AccountsReceivableUncommittedFactoringFacilityAmountSold" format="ixt:num-dot-decimal" scale="9" id="f-544">2.1</ix:nonFraction> billion of accounts receivable under the Facility and factoring fees paid were not material. <ix:continuation id="f-517-4">As of December&#160;31, 2023, all sold accounts receivable have been collected from manufacturers, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:AccountsReceivableUncommittedFactoringFacilityAccountsReceivableReceivedButNotRemitted" format="ixt:num-dot-decimal" scale="6" id="f-545">515</ix:nonFraction> million of which have not been remitted to the financial institution. Such amounts are recorded within Accrued expenses and other liabilities in the Consolidated Balance Sheets.</ix:continuation></ix:continuation> </span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_118"></div><div style="margin-bottom:10pt;margin-top:10pt"><span id="ic6dc9f23682647648205466d1cb34682_1521"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="us-gaap:SupplierFinanceProgramTextBlock" id="f-546" continuedAt="f-546-1" escape="true">Note 4 &#8211; Supplier Finance Program</ix:nonNumeric></span></div><ix:continuation id="f-546-1" continuedAt="f-546-2"><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company facilitates a voluntary supplier finance program (the "Program") that provides suppliers the opportunity to sell their accounts receivable due from us (i.e., our payment obligations to the suppliers) to a financial institution, on a non-recourse basis, in order to be paid earlier than our payment terms require. The Cigna Group is not a party to the Program and agrees to commercial terms with its suppliers independently of their participation in the Program. Amounts due to suppliers that participate in the Program are generally paid within <ix:nonNumeric contextRef="c-12" name="us-gaap:SupplierFinanceProgramPaymentTimingPeriod" format="ixt-sec:durwordsen" id="f-547">one month</ix:nonNumeric> following the invoice date. A supplier's participation in the Program has no impact on the Company's payment terms and the Company has no economic interest in a supplier's decision to participate in the Program. The suppliers, at their sole discretion, determine which invoices, if any, to sell to the financial institution. No guarantees or pledged assets are provided by the Company or any of our subsidiaries under the Program. </span></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-546-2">As of December&#160;31, 2023 and December&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-8" name="us-gaap:SupplierFinanceProgramObligationCurrent" format="ixt:num-dot-decimal" scale="9" id="f-548">1.5</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-8" name="us-gaap:SupplierFinanceProgramObligationCurrent" format="ixt:num-dot-decimal" scale="9" id="f-549">1.3</ix:nonFraction>&#160;billion, respectively, of the Company's outstanding payment obligations were confirmed as valid within the Program by the financial institution and are reflected in <span style="-sec-ix-hidden:f-550"><span style="-sec-ix-hidden:f-551">Accounts payable</span></span> in the Consolidated Balance Sheets. The amounts confirmed as valid for both periods are predominately associated with one supplier. As of December&#160;31, 2023, we have been informed by the financial institution that $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold" format="ixt:num-dot-decimal" scale="6" id="f-552">298</ix:nonFraction>&#160;million of the Company's outstanding payment obligations were voluntarily elected by suppliers to be sold to the financial institution under the Program.</ix:continuation> </span></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_121"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> <span id="i988c0ddae1344132bc7d1e8acf24a881_14"></span><ix:nonNumeric contextRef="c-1" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="f-553" continuedAt="f-553-1" escape="true">Note 5 &#8211; Mergers, Acquisitions and Divestitures</ix:nonNumeric></span></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_124"></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">A.</span><ix:continuation id="f-553-1" continuedAt="f-553-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Investment in CarepathRx Health Systems Solutions</span></ix:continuation></div><ix:continuation id="f-553-2" continuedAt="f-553-3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2023, Evernorth Health, Inc. acquired a minority interest in CarepathRx Health Systems Solutions ("CHSS"), a provider of integrated hospital pharmacy solutions to support patients across their complete health care journey. This equity method investment is reported in Other assets and the Company's share of CHSS' net income or loss is reported in Fees and other revenues. The purchase price has been allocated to the acquired tangible and intangible assets, including customer relationships, trade names, internal-use software and goodwill. Amortization of the acquired intangibles is included in Fees and other revenues. The Company's share of CHSS' net loss and amortization of acquired intangibles were immaterial for the year ended December&#160;31, 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company guaranteed $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-6" name="us-gaap:GuaranteeObligationsMaximumExposure" format="ixt:num-dot-decimal" scale="6" id="f-554">125</ix:nonFraction>&#160;million of CHSS' credit facilities through July 2026. The fair value of the guarantee is reflected in other liabilities and is not material. The acquisition also includes separate put and call options to increase our ownership, which </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-553-3" continuedAt="f-553-4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">become exercisable annually beginning as early as April 2025. The net fair value of the options, determined using a Monte Carlo simulation, are not material and are included in Other non-current liabilities and Other assets, respectively.</span></div></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_127"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><ix:continuation id="f-553-4" continuedAt="f-553-5"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt;text-decoration:underline">Divestiture of International Businesses</span></ix:continuation></div><div><span><br/></span></div><ix:continuation id="f-553-5" continuedAt="f-553-6"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2022, the Company completed the sale of its life, accident and supplemental benefits businesses in six countries (Hong Kong, Indonesia, New Zealand, South Korea, Taiwan and Thailand) (the "Chubb transaction") for approximately $<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-8" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="9" id="f-555">5.4</ix:nonFraction> billion in cash and recognized a gain of $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-8" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:num-dot-decimal" scale="9" id="f-556">1.7</ix:nonFraction>&#160;billion pre-tax ($<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-8" name="ci:DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax" format="ixt:num-dot-decimal" scale="9" id="f-557">1.4</ix:nonFraction>&#160;billion after-tax), which included recognition of previously unrealized capital losses on investments sold and translation loss on foreign currencies. In 2023, we recorded immaterial adjustments to the sales price reflecting resolution of certain contractual matters. In December 2022, the Company also divested its ownership interest in a joint venture in T&#252;rkiye. </span></div></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_151"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">C.</span><ix:continuation id="f-553-6" continuedAt="f-553-7"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Integration and Transaction-related Costs</span></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-553-7">As part of our strategic plan, we incurred non-routine costs associated with the disposition and acquisition of certain businesses. In 2023, the Company incurred net costs related to the HCSC and Chubb transactions. In 2022 and 2021, the Company incurred costs related to the Chubb transaction, the sale of the Group Disability and Life business, the acquisition of MDLIVE and the terminated merger with Elevance Health, Inc. ("Elevance"), formerly known as Anthem, Inc. These costs were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:TransactionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="f-558">45</ix:nonFraction> million pre-tax ($<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:TransactionRelatedCostsAfterTax" format="ixt:num-dot-decimal" scale="6" id="f-559">35</ix:nonFraction> million after-tax) for the year ended December&#160;31, 2023, compared with $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:TransactionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="f-560">135</ix:nonFraction> million pre-tax ($<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:TransactionRelatedCostsAfterTax" format="ixt:num-dot-decimal" scale="6" id="f-561">103</ix:nonFraction> million after-tax) for the year ended December&#160;31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:TransactionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="f-562">169</ix:nonFraction> million pre-tax ($<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:TransactionRelatedCostsAfterTax" format="ixt:num-dot-decimal" scale="6" id="f-563">71</ix:nonFraction> million after-tax) for the year ended December&#160;31, 2021. These costs consisted primarily of certain projects to separate or integrate the Company's systems, products and services, fees for legal, advisory and other professional services and certain employment-related costs. After-tax costs for the year ended December 31, 2021 included a tax benefit from the resolution of a tax matter related to the sold Group Disability and Life business.</ix:continuation> </span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_157"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="f-564" continuedAt="f-564-1" escape="true"><div style="margin-top:10pt"><span id="i4615696355794df3b07481211e495cbe_15"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 6 &#8211; Assets and Liabilities of Businesses Held for Sale</span></div></ix:nonNumeric><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_160"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-565" escape="true"><ix:continuation id="f-564-1" continuedAt="f-564-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The Company classifies assets and liabilities as held for sale ("disposal group") when management commits to a plan to sell the disposal group, the sale is probable within one year and the disposal group is available for immediate sale in its present condition. The Company considers various factors, particularly whether actions required to complete the plan indicate it is unlikely that significant changes to the plan will be made or the plan will be withdrawn. Assets held for sale are measured at the lower of carrying value or fair value less costs to sell. Any loss resulting from the measurement is recognized in the period the held-for-sale criteria are met. Conversely, gains are not recognized until the date of the sale. When the disposal group is classified as held for sale, depreciation and amortization for most long-lived assets ceases and the Company tests the assets for impairment. Deferred policy acquisition costs continue to be amortized.</span></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_163"></div><ix:continuation id="f-564-2"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2024, the Company entered into the HCSC transaction for a total purchase price of approximately $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-8" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="9" id="f-566">3.3</ix:nonFraction> billion cash, subject to applicable regulatory approvals and other customary closing conditions. The transaction is expected to close in the first quarter of 2025. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the fourth quarter of 2023, the Company determined that the Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare Supplement and CareAllies businesses met the criteria to be classified as held for sale and aggregated and classified the assets and liabilities as held for sale in our Consolidated Balance Sheet as of December 31, 2023. The Company measured the assets and liabilities held for sale at estimated fair value less costs to sell and recognized an estimated loss of $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-8" sign="-" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:num-dot-decimal" scale="9" id="f-567">1.5</ix:nonFraction> billion pre-tax ($<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-8" sign="-" name="ci:DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax" format="ixt:num-dot-decimal" scale="9" id="f-568">1.4</ix:nonFraction> billion after-tax) that was included within <span style="-sec-ix-hidden:f-569">(Loss) gain on sale of businesses</span> in the Consolidated Statements of Income for the year ended December 31, 2023. The estimated loss on sale represents primarily asset write-downs and estimated costs to sell.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="f-570" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The assets and liabilities of businesses held for sale were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.456%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" scale="6" id="f-571">467</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="ci:DisposalGroupIncludingDiscontinuedOperationInvestments" format="ixt:num-dot-decimal" scale="6" id="f-572">1,438</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" format="ixt:num-dot-decimal" scale="6" id="f-573">1,122</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets, including Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="ci:DisposalGroupIncludingDiscontinuedOperationOtherAssetsGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-574">2,963</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets of businesses held for sale</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:num-dot-decimal" scale="6" id="f-575">5,990</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Insurance and contractholder liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="ci:DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-576">1,636</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">All other liabilities</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="ci:DisposalGroupIncludingDiscontinuedOperationLiabilitiesExcludingInsuranceAndContractholderLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-577">1,059</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities of businesses held for sale</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:num-dot-decimal" scale="6" id="f-578">2,695</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Includes Goodwill of $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1" format="ixt:num-dot-decimal" scale="6" id="f-579">396</ix:nonFraction>&#160;million.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">89</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_169"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-580" continuedAt="f-580-1" escape="true"><div style="margin-top:10pt"><span id="id4b9b7f855c9494fb643b90b2afe1341_14"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7 &#8211; Earnings Per Share</span></div></ix:nonNumeric><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_172"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-581" escape="true"><ix:continuation id="f-580-1" continuedAt="f-580-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company computes basic earnings per share using the weighted-average number of unrestricted common and deferred shares outstanding. Diluted earnings per share also includes the dilutive effect of outstanding employee stock options and restricted stock using the treasury stock method and the effect of strategic performance shares.</span></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_175"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-582" continuedAt="f-582-1" escape="true"><ix:continuation id="f-580-2" continuedAt="f-580-3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic and diluted earnings per share were computed as follows:</span></div></ix:continuation></ix:nonNumeric><div id="ibc59a92ac8bc42f794e728f24ce1b626_181"></div><ix:continuation id="f-582-1"><ix:continuation id="f-580-3" continuedAt="f-580-4"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.241%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="51" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Shares in thousands, dollars in millions, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of<br/>Dilution</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of<br/>Dilution</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of<br/>Dilution</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shareholders' net income</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="f-583">5,164</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="f-584">5,164</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="f-585">6,704</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="f-586">6,704</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="f-587">5,370</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="f-588">5,370</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="f-589">293,892</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="f-590">293,892</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="f-591">309,546</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="f-592">309,546</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="f-593">337,962</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="f-594">337,962</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="f-595">2,990</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="f-596">2,990</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="f-597">3,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="f-598">3,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="f-599">3,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="f-600">3,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total shares</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="f-601">293,892</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="f-602">2,990</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-603">296,882</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="f-604">309,546</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="f-605">3,519</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-606">313,065</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="3" id="f-607">337,962</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="f-608">3,004</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-609">340,966</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Earnings per share</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-610">17.57</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="ci:EarningsPerShareEffectOfDilution" scale="0" id="f-611">0.18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-612">17.39</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-613">21.66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="ci:EarningsPerShareEffectOfDilution" scale="0" id="f-614">0.25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-615">21.41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-616">15.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="2" sign="-" name="ci:EarningsPerShareEffectOfDilution" scale="0" id="f-617">0.14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-618">15.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amounts reflected above for the years ended December&#160;31, 2022 and 2021 have been restated to reflect the impact of adopting amended accounting guidance for long-duration insurance contracts (discussed in Note 2 to the Consolidated Financial Statements).</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_184"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-619" escape="true"><ix:continuation id="f-580-4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following outstanding employee stock options were not included in the computation of diluted earnings per share because their effect was anti-dilutive:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.261%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.041%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Anti-dilutive options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-91" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-620">0.9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-92" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-621">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-93" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-622">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">90</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_190"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-623" continuedAt="f-623-1" escape="true"><div style="margin-bottom:10pt;margin-top:10pt"><span id="ic993c64b84024ee5a62a006b05ea76db_438"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8 &#8211; Debt</span></div><ix:nonNumeric contextRef="c-1" name="ci:ScheduleOfShortTermDebtLongTermDebtTableTextBlock" id="f-624" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The outstanding amounts of debt (net of issuance costs, discounts or premiums) and finance leases were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.041%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term debt</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:CommercialPaper" format="ixt:num-dot-decimal" scale="6" id="f-625">1,237</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="f-626">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-627">17</ix:nonFraction>&#160;million, <ix:nonFraction unitRef="number" contextRef="c-94" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-628">8.300</ix:nonFraction>% Notes due January 2023</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="6" id="f-629">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="f-630">17</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-631">63</ix:nonFraction>&#160;million, <ix:nonFraction unitRef="number" contextRef="c-96" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-632">7.650</ix:nonFraction>% Notes due March 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="6" id="f-633">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="f-634">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-635">700</ix:nonFraction> million, Floating Rate Notes due July 2023</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="6" id="f-636">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="f-637">700</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-638">1,000</ix:nonFraction> million, <ix:nonFraction unitRef="number" contextRef="c-100" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-639">3.000</ix:nonFraction>% Notes due July 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="6" id="f-640">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="f-641">994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-642">1,187</ix:nonFraction> million, <ix:nonFraction unitRef="number" contextRef="c-102" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-643">3.750</ix:nonFraction>% Notes due July 2023</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="6" id="f-644">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="f-645">1,186</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-646">500</ix:nonFraction> million, <ix:nonFraction unitRef="number" contextRef="c-104" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-647">0.613</ix:nonFraction>% Notes due March 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="f-648">500</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="6" id="f-649">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-650">1,000</ix:nonFraction>&#160;million, <ix:nonFraction unitRef="number" contextRef="c-106" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-651">3.500</ix:nonFraction>% Notes due June 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="f-652">996</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="6" id="f-653">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, including finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent" scale="6" id="f-654">42</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent" scale="6" id="f-655">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total short-term debt</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="f-656">2,775</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="f-657">2,993</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-658">500</ix:nonFraction> million, <ix:nonFraction unitRef="number" contextRef="c-104" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-659">0.613</ix:nonFraction>% Notes due March 2024</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="6" id="f-660">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-661">499</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-662">1,000</ix:nonFraction>&#160;million, <ix:nonFraction unitRef="number" contextRef="c-106" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-663">3.500</ix:nonFraction>% Notes due June 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="6" id="f-664">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-665">990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-666">900</ix:nonFraction>&#160;million, <ix:nonFraction unitRef="number" contextRef="c-108" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-667">3.250</ix:nonFraction>% Notes due April 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-668">882</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-669">872</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-670">2,200</ix:nonFraction>&#160;million, <ix:nonFraction unitRef="number" contextRef="c-110" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-671">4.125</ix:nonFraction>% Notes due November 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-672">2,197</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-673">2,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-674">1,500</ix:nonFraction>&#160;million, <ix:nonFraction unitRef="number" contextRef="c-112" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-675">4.500</ix:nonFraction>% Notes due February 2026</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-676">1,502</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-677">1,503</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-678">800</ix:nonFraction> million, <ix:nonFraction unitRef="number" contextRef="c-114" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-679">1.250</ix:nonFraction>% Notes due March 2026 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-680">798</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-681">797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-682">700</ix:nonFraction> million, <ix:nonFraction unitRef="number" contextRef="c-116" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-683">5.685</ix:nonFraction>% Notes due March 2026</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-684">698</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="6" id="f-685">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-686">1,500</ix:nonFraction>&#160;million, <ix:nonFraction unitRef="number" contextRef="c-118" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-687">3.400</ix:nonFraction>% Notes due March 2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-688">1,450</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-689">1,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-690">259</ix:nonFraction>&#160;million, <ix:nonFraction unitRef="number" contextRef="c-120" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-691">7.875</ix:nonFraction>% Debentures due May 2027</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-692">259</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-693">259</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-694">600</ix:nonFraction>&#160;million, <ix:nonFraction unitRef="number" contextRef="c-122" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-695">3.050</ix:nonFraction>% Notes due October 2027 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-696">597</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-697">597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-698">3,800</ix:nonFraction>&#160;million, <ix:nonFraction unitRef="number" contextRef="c-124" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-699">4.375</ix:nonFraction>% Notes due October 2028</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-700">3,787</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-701">3,785</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-702">1,500</ix:nonFraction>&#160;million, <ix:nonFraction unitRef="number" contextRef="c-126" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-703">2.400</ix:nonFraction>% Notes due March 2030 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-704">1,493</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-705">1,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-706">1,500</ix:nonFraction> million, <ix:nonFraction unitRef="number" contextRef="c-128" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-707">2.375</ix:nonFraction>% Notes due March 2031 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-708">1,397</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-709">1,380</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-710">45</ix:nonFraction>&#160;million, <ix:nonFraction unitRef="number" contextRef="c-130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-711">8.080</ix:nonFraction>% Step Down Notes due January 2033 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-712">45</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-713">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-714">800</ix:nonFraction> million, <ix:nonFraction unitRef="number" contextRef="c-132" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-715">5.400</ix:nonFraction>% Notes due March 2033</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-716">794</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="6" id="f-717">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-718">190</ix:nonFraction>&#160;million, <ix:nonFraction unitRef="number" contextRef="c-134" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-719">6.150</ix:nonFraction>% Notes due November 2036</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-720">190</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-721">190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-722">2,200</ix:nonFraction>&#160;million, <ix:nonFraction unitRef="number" contextRef="c-136" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-723">4.800</ix:nonFraction>% Notes due August 2038 </span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-724">2,193</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-725">2,192</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-138" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-726">750</ix:nonFraction>&#160;million, <ix:nonFraction unitRef="number" contextRef="c-138" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-727">3.200</ix:nonFraction>% Notes due March 2040</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-728">744</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-729">743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-730">121</ix:nonFraction>&#160;million, <ix:nonFraction unitRef="number" contextRef="c-140" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-731">5.875</ix:nonFraction>% Notes due March 2041</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-732">119</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-733">119</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-734">448</ix:nonFraction>&#160;million, <ix:nonFraction unitRef="number" contextRef="c-142" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-735">6.125</ix:nonFraction>% Notes due November 2041</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-736">487</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-737">488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-738">317</ix:nonFraction>&#160;million, <ix:nonFraction unitRef="number" contextRef="c-144" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-739">5.375</ix:nonFraction>% Notes due February 2042</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-740">315</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-741">315</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-742">1,500</ix:nonFraction>&#160;million, <ix:nonFraction unitRef="number" contextRef="c-146" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-743">4.800</ix:nonFraction>% Notes due July 2046</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-744">1,467</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-745">1,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-746">1,000</ix:nonFraction>&#160;million, <ix:nonFraction unitRef="number" contextRef="c-148" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-747">3.875</ix:nonFraction>% Notes due October 2047</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-748">989</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-749">989</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-750">3,000</ix:nonFraction>&#160;million, <ix:nonFraction unitRef="number" contextRef="c-150" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-751">4.900</ix:nonFraction>% Notes due December 2048</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-752">2,970</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-753">2,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-754">1,250</ix:nonFraction>&#160;million, <ix:nonFraction unitRef="number" contextRef="c-152" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-755">3.400</ix:nonFraction>% Notes due March 2050</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-756">1,237</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-757">1,236</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-758">1,500</ix:nonFraction> million, <ix:nonFraction unitRef="number" contextRef="c-154" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-759">3.400</ix:nonFraction>% Notes due March 2051</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-760">1,479</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-761">1,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, including finance leases</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:OtherLongTermDebtNoncurrent" scale="6" id="f-762">66</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:OtherLongTermDebtNoncurrent" scale="6" id="f-763">66</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="f-764">28,155</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="f-765">28,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Included in the February 2024 debt tender offers discussed below.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">The Company has entered into interest rate swap contracts hedging a portion of these fixed-rate debt instruments. See Note 12 to the Consolidated Financial Statements for further information about the Company's interest rate risk management and these derivative instruments.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Interest rate step down to <ix:nonFraction unitRef="number" contextRef="c-156" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-766">8.080</ix:nonFraction>% effective January 15, 2023.</span></div></ix:nonNumeric></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_199"></div><ix:continuation id="f-623-1" continuedAt="f-623-2"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Short-term and Credit Facilities Debt</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revolving Credit Agreements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Our revolving credit agreements provide us with the ability to borrow amounts for general corporate purposes, including providing liquidity support if necessary under our commercial paper program discussed below. As of December&#160;31, 2023, there were <ix:nonFraction unitRef="usd" contextRef="c-157" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="0" id="f-767">no</ix:nonFraction> outstanding balances under these revolving credit agreements.</span></div></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">91</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_202"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-623-2" continuedAt="f-623-3"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2023, The Cigna Group entered into the following revolving credit agreements (the "Credit Agreements"):</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a $<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-768">4.0</ix:nonFraction> billion <ix:nonNumeric contextRef="c-159" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-769">five-year</ix:nonNumeric> revolving credit and letter of credit agreement that will mature in April 2028 with an option to extend the maturity date for additional <ix:nonNumeric contextRef="c-159" name="ci:DebtInstrumentExtensionTerm" format="ixt-sec:durwordsen" id="f-770">one-year</ix:nonNumeric> periods, subject to consent of the banks. The Company can borrow up to $<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-771">4.0</ix:nonFraction> billion under the credit agreement for general corporate purposes, with up to $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-772">500</ix:nonFraction> million available for issuance of letters of credit. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-773">1.0</ix:nonFraction> billion <ix:nonNumeric contextRef="c-162" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-774">364-day</ix:nonNumeric> revolving credit agreement that will mature in April 2024. The Company can borrow up to $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-775">1.0</ix:nonFraction> billion under the credit agreement for general corporate purposes. This agreement includes the option to "term out" any revolving loans that are outstanding at maturity by converting them into a term loan maturing on the <ix:nonNumeric contextRef="c-162" name="ci:LineOfCreditFacilityConversionToTermLoanTerm" format="ixt-sec:durwordsen" id="f-776">one-year</ix:nonNumeric> anniversary of conversion.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Each of the Credit Agreements include an option to increase commitments in an aggregate amount of up to $<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="INF" name="ci:LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-777">1.5</ix:nonFraction> billion across both facilities for a maximum total commitment of $<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="INF" name="ci:LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-778">6.5</ix:nonFraction> billion. The Credit Agreements allow for borrowings at either a base rate or an adjusted term Secured Overnight Funding Rate ("SOFR") plus, in each case, an applicable margin based on the Company's senior unsecured credit ratings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Each of the <ix:nonFraction unitRef="revolvingcreditfacility" contextRef="c-163" decimals="INF" name="ci:NumberOfRevolvingCreditFacility" format="ixt-sec:numwordsen" scale="0" id="f-779">two</ix:nonFraction> facilities is diversified among <ix:nonFraction unitRef="position" contextRef="c-163" decimals="INF" name="ci:NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement" scale="0" id="f-780">21</ix:nonFraction> large commercial banks, all of which had an A- equivalent or higher rating by at least one Nationally Recognized Statistical Rating Organization ("NRSRO") as of December&#160;31, 2023. Each facility also contains customary covenants and restrictions, including a financial covenant that the Company's leverage ratio, as defined in the Credit Agreements, may not exceed <ix:nonFraction unitRef="number" contextRef="c-163" decimals="INF" name="ci:LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant" scale="-2" id="f-781">60</ix:nonFraction>% subject to certain exceptions upon the consummation of an acquisition. </span></div></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_205"></div><ix:continuation id="f-623-3" continuedAt="f-623-4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Credit Agreements replaced a prior $<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-782">3.0</ix:nonFraction> billion <ix:nonNumeric contextRef="c-165" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-783">five-year</ix:nonNumeric> revolving credit and letter of credit agreement maturing in April 2027; a $<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-784">1.0</ix:nonFraction> billion <ix:nonNumeric contextRef="c-167" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-785">three-year</ix:nonNumeric> revolving credit agreement maturing in April 2025; and a $<ix:nonFraction unitRef="usd" contextRef="c-168" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-786">1.0</ix:nonFraction> billion <ix:nonNumeric contextRef="c-169" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-787">364-day</ix:nonNumeric> revolving credit agreement maturing in April 2023. </span></div></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_211"></div><ix:continuation id="f-623-4" continuedAt="f-623-5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Commercial Paper. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under our commercial paper program, we may issue short-term, unsecured commercial paper notes privately placed on a discounted basis through certain broker-dealers at any time not to exceed an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-788">5.0</ix:nonFraction> billion. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. The weighted average interest rate of our commercial paper was <ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="srt:CommercialPaperAverageRatePaid" scale="-2" id="f-789">5.63</ix:nonFraction>% at December&#160;31, 2023.</span></div></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_196"></div><ix:continuation id="f-623-5" continuedAt="f-623-6"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Long-term debt</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Debt Issuance and Debt Tender Offers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> On February 5, 2024, we issued $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="f-790">4.5</ix:nonFraction> billion of new senior notes. The proceeds from this debt were used to pay the consideration for the cash tender offers as described below. We intend to use the remaining net proceeds to fund the repayment of our senior notes maturing in March 2024 and for general corporate purposes, which may include repayment of indebtedness and repurchases of shares of our common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Concurrent with the debt issuance, we commenced tender offers to purchase for cash up to $<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-7" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="9" id="f-791">2.25</ix:nonFraction> billion in aggregate principal amount of outstanding notes, which included any and all of the $<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-8" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="9" id="f-792">1.0</ix:nonFraction> billion senior notes due June 2024. Following the early tender results, we increased the tender offers to up to $<ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-7" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="9" id="f-793">2.55</ix:nonFraction> billion aggregate principal amount. On February 22, 2024, we purchased $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-8" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="9" id="f-794">1.8</ix:nonFraction> billion principal amount of notes at early settlement of the tender offers. The tender offers will expire on March 5, 2024.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ci:ScheduleOfIssuancesOfLongTermDebtTableTextBlock" id="f-795" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 7, 2023, the Company issued $<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="f-796">1.5</ix:nonFraction>&#160;billion of new senior notes. The proceeds of this issuance were used for general corporate purposes, and included repayment of outstanding debt securities. Interest on this debt is paid semi-annually.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.486%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Proceeds</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-797">700</ix:nonFraction> million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 15, 2026</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-177" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-798">5.685</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-6" name="ci:ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees" scale="6" id="f-799">698</ix:nonFraction> million</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-800">800</ix:nonFraction> million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 15, 2033</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-179" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-801">5.400</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-6" name="ci:ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees" scale="6" id="f-802">796</ix:nonFraction> million</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Redeemable at any time discounted at the U.S. Treasury rate plus <ix:nonFraction unitRef="number" contextRef="c-181" decimals="4" name="ci:DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate" scale="-4" id="f-803">20</ix:nonFraction> basis points. Redeemable at par on or after March 15, 2024.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Redeemable at any time discounted at the U.S. Treasury rate plus <ix:nonFraction unitRef="number" contextRef="c-182" decimals="4" name="ci:DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate" scale="-4" id="f-804">25</ix:nonFraction> basis points. Redeemable at par on or after December 15, 2032.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">92</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_214"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-623-6" continuedAt="f-623-7"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Debt Maturities. </span><ix:nonNumeric contextRef="c-1" name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock" id="f-805" continuedAt="f-805-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Maturities of outstanding long-term debt as of December&#160;31, 2023 are as follows and exclude the impact of the 2024 debt issuance and debt tender offers described above:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.039%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Scheduled Maturities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="f-806">1,500</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="6" id="f-807">3,100</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="6" id="f-808">3,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="6" id="f-809">2,359</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="6" id="f-810">3,800</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maturities after 2028</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="f-811">16,122</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></ix:nonNumeric></div><div style="margin-bottom:10pt;padding-left:9pt;text-indent:-9pt"><ix:continuation id="f-805-1" continuedAt="f-805-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"><ix:continuation id="f-805-2"> Long-term debt maturity amounts include current maturities of long-term debt. Finance leases are excluded from this table. See Note 21 - Leases for finance lease maturity amounts.</ix:continuation>&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Interest Expense</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest expense on long-term and short-term debt was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="9" id="f-812">1.4</ix:nonFraction> billion in 2023 and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-8" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="9" id="f-813"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-8" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="9" id="f-814">1.3</ix:nonFraction></ix:nonFraction> billion in both 2022 and 2021.</span></div></ix:continuation><div id="ibc59a92ac8bc42f794e728f24ce1b626_217"></div><ix:continuation id="f-623-7"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Debt Covenants</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company was in compliance with its debt covenants as of December&#160;31, 2023.</span></div></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_226"></div><ix:nonNumeric contextRef="c-1" name="ci:ScheduleOfCommonStockByClassScheduleOfPreferredStockByClassTextBlock" id="f-815" continuedAt="f-815-1" escape="true"><div><span id="i8317cb59d11e40858991b6bc9c38bb8b_16"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 9 &#8211; Common and Preferred Stock</span></div></ix:nonNumeric><div style="margin-bottom:10pt"><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_229"></div><ix:continuation id="f-815-1" continuedAt="f-815-2"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Cigna Group has a total of <ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-816">25</ix:nonFraction>&#160;million shares of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-817">1</ix:nonFraction> par value preferred stock authorized for issuance. <ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-818"><ix:nonFraction unitRef="shares" contextRef="c-47" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-819"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-820">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of preferred stock were outstanding at December 31, 2023, 2022 or 2021.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockByClassTextBlock" id="f-821" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the share activity of The Cigna Group:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.042%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Shares in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common: Par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-822"><ix:nonFraction unitRef="usdPerShare" contextRef="c-47" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-823"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-824">0.01</ix:nonFraction></ix:nonFraction></ix:nonFraction>; <ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-825"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-826"><ix:nonFraction unitRef="shares" contextRef="c-47" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-827">600,000</ix:nonFraction></ix:nonFraction></ix:nonFraction> shares authorized</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding- January 1,</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-828">298,676</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-47" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-829">322,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-830">354,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net issued for stock option exercises and other benefit plans</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" format="ixt:num-dot-decimal" scale="3" id="f-831">1,619</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" format="ixt:num-dot-decimal" scale="3" id="f-832">3,173</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" format="ixt:num-dot-decimal" scale="3" id="f-833">3,375</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchased common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="3" id="f-834">7,791</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="3" id="f-835">27,445</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="3" id="f-836">35,198</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding- December 31,</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-837">292,504</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-838">298,676</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-47" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-839">322,948</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="3" id="f-840">107,390</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="3" id="f-841">99,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-47" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="3" id="f-842">71,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issued- December 31,</span></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-843">399,894</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-844">397,819</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-47" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-845">394,194</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:10pt"><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_5939"></div><ix:continuation id="f-815-2" continuedAt="f-815-3"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Dividends</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During 2023, 2022 and 2021, The Cigna Group declared quarterly cash dividends of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-183" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-846"><ix:nonFraction unitRef="usdPerShare" contextRef="c-184" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-847"><ix:nonFraction unitRef="usdPerShare" contextRef="c-185" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-848"><ix:nonFraction unitRef="usdPerShare" contextRef="c-186" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-849">1.23</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-187" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-850"><ix:nonFraction unitRef="usdPerShare" contextRef="c-188" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-851"><ix:nonFraction unitRef="usdPerShare" contextRef="c-189" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-852"><ix:nonFraction unitRef="usdPerShare" contextRef="c-190" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-853">1.12</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-191" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-854"><ix:nonFraction unitRef="usdPerShare" contextRef="c-192" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-855"><ix:nonFraction unitRef="usdPerShare" contextRef="c-193" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-856"><ix:nonFraction unitRef="usdPerShare" contextRef="c-194" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-857">1.00</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> per share of the Company's common stock, respectively.</span></div></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">93</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_5927"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-815-3" continuedAt="f-815-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:DividendsDeclaredTableTextBlock" id="f-858" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides details of the Company's dividend payments:</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Record Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payment Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount per Share</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Amount Paid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"> (in millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 8, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 23, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-195" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="f-859">1.23</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="f-860">368</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 7, 2023</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 22, 2023</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-196" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="f-861">1.23</ix:nonFraction></span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="f-862">362</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 6, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 21, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-197" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="f-863">1.23</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="f-864">362</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 6, 2023</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 21, 2023</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-198" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="f-865">1.23</ix:nonFraction></span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="f-866">358</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 9, 2022</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 24, 2022</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-199" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="f-867">1.12</ix:nonFraction></span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="f-868">357</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 8, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 23, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-200" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="f-869">1.12</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="f-870">352</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2022</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 22, 2022</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-201" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="f-871">1.12</ix:nonFraction></span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="f-872">341</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 6, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 21, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-202" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="f-873">1.12</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="f-874">334</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 10, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 25, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-203" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="f-875">1.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="f-876">345</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 8, 2021</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 23, 2021</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-204" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="f-877">1.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="f-878">342</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 8, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 23, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-205" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="f-879">1.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="f-880">330</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2021</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 22, 2021</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-206" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="f-881">1.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="f-882">324</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February&#160;2, 2024, the Board of Directors declared the first quarter cash dividend of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-207" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-883">1.40</ix:nonFraction> per share of The Cigna Group common stock to be paid on March&#160;21, 2024 to shareholders of record on March&#160;6, 2024. The Company currently intends to pay regular quarterly dividends, with future declarations subject to approval by its Board of Directors and the Board's determination that the declaration of dividends remains in the best interests of The Cigna Group and its shareholders. The decision of whether to pay future dividends and the amount of any such dividends will be based on the Company's financial position, results of operations, cash flows, capital requirements, the requirements of applicable law and any other factors the Board may deem relevant.</span></div></ix:continuation><div id="ibc59a92ac8bc42f794e728f24ce1b626_235"></div><ix:continuation id="f-815-4"><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accelerated Share Repurchase Agreements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2024, as part of our existing share repurchase program, we entered into separate accelerated share repurchase agreements ("2024 ASR agreements") with Deutsche Bank AG and Bank of America, N.A. (collectively, the "2024 Counterparties") to repurchase $<ix:nonFraction unitRef="usd" contextRef="c-208" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="f-884">3.2</ix:nonFraction> billion of common stock in aggregate. We remitted $<ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-8" sign="-" name="us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt" format="ixt:num-dot-decimal" scale="9" id="f-885">3.2</ix:nonFraction> billion to the 2024 Counterparties and received an initial delivery of approximately <ix:nonFraction unitRef="shares" contextRef="c-209" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-886">7.6</ix:nonFraction>&#160;million shares of our common stock on February 15, 2024 representing $<ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-8" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="9" id="f-887">2.6</ix:nonFraction> billion of the total remitted. The final number of shares to be received under the ASR agreements will be determined based on the daily volume-weighted average share price of our common stock over the term of the agreements, less a discount and subject to adjustments pursuant to the terms and conditions of the ASR agreements. We expect final settlement under the ASR agreements to occur in the second quarter of 2024. At final settlement, we may be entitled to receive additional shares of our common stock from the Counterparties or we may be required to make a payment. If we are obligated to make a payment, we may elect to satisfy such obligation in cash or shares of our common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2022, as part of our existing share repurchase program, we entered into separate accelerated share repurchase agreements ("2022 ASR agreements") with Mizuho Markets Americas LLC and Morgan Stanley &amp; Co. LLC (collectively, the "2022 Counterparties") to repurchase $<ix:nonFraction unitRef="usd" contextRef="c-211" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="f-888">3.5</ix:nonFraction> billion of common stock in aggregate. In July 2022, we remitted $<ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-8" sign="-" name="us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt" format="ixt:num-dot-decimal" scale="9" id="f-889">3.5</ix:nonFraction> billion to the 2022 Counterparties and received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="c-213" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-890">10.4</ix:nonFraction>&#160;million shares of our common stock representing $<ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-8" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="9" id="f-891">2.8</ix:nonFraction> billion of the total remitted. Upon final settlement of the 2022 ASR agreements in November 2022, we received an additional <ix:nonFraction unitRef="shares" contextRef="c-215" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-892">1.9</ix:nonFraction> million shares of our common stock for no additional consideration as the value of this stock was held back by the 2022 Counterparties pending final settlement of the agreements. The total number of shares of our common stock repurchased under the 2022 ASR agreements was <ix:nonFraction unitRef="shares" contextRef="c-216" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-893">12.3</ix:nonFraction>&#160;million based on an average daily volume-weighted average share price of our common stock over the term of the agreements, less a discount, of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-216" decimals="2" name="ci:AcceleratedShareRepurchasesVolumeWeightedAverageSharePriceLessDiscount" scale="0" id="f-894">285.10</ix:nonFraction> per share.</span></div></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">94</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_241"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span id="i529f1a5578b94a90871661a1e72c2927_713"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" id="f-895" continuedAt="f-895-1" escape="true">Insurance and Contractholder Liabilities</ix:nonNumeric></span></div><ix:continuation id="f-895-1" continuedAt="f-895-2"><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt;text-decoration:underline">Account Balances &#8211; Insurance and Contractholder Liabilities</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" id="f-896" continuedAt="f-896-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's insurance and contractholder liabilities were comprised of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.288%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.047%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unpaid claims and claim expenses</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cigna Healthcare</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="ci:LiabilityForClaimsAndClaimsAdjustmentExpenseCurrentIncludingDisposalGroups" format="ixt:num-dot-decimal" scale="6" id="f-897">5,017</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="ci:LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrentIncludingDisposalGroups" scale="6" id="f-898">75</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="ci:LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups" format="ixt:num-dot-decimal" scale="6" id="f-899">5,092</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="ci:LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent" format="ixt:num-dot-decimal" scale="6" id="f-900">4,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="ci:LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent" scale="6" id="f-901">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-902">4,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Operations</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-6" name="ci:LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent" scale="6" id="f-903">99</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-6" name="ci:LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent" scale="6" id="f-904">154</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="f-905">253</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-6" name="ci:LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent" scale="6" id="f-906">107</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-6" name="ci:LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent" scale="6" id="f-907">177</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="f-908">284</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Future policy benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cigna Healthcare</span></div></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitsCurrentIncludingDisposalGroups" scale="6" id="f-909">97</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitsNoncurrentIncludingDisposalGroups" scale="6" id="f-910">518</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitsIncludingDisposalGroups" scale="6" id="f-911">615</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent" scale="6" id="f-912">43</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent" scale="6" id="f-913">544</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="us-gaap:LiabilityForFuturePolicyBenefits" scale="6" id="f-914">587</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent" scale="6" id="f-915">163</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-916">3,375</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-6" name="us-gaap:LiabilityForFuturePolicyBenefits" format="ixt:num-dot-decimal" scale="6" id="f-917">3,538</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent" scale="6" id="f-918">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-919">3,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-6" name="us-gaap:LiabilityForFuturePolicyBenefits" format="ixt:num-dot-decimal" scale="6" id="f-920">3,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractholder deposit funds</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cigna Healthcare</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="ci:PolicyholderContractDepositCurrentIncludingDisposalGroups" scale="6" id="f-921">12</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="ci:PolicyholderContractDepositNoncurrentIncludingDisposalGroups" scale="6" id="f-922">133</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="ci:PolicyholderContractDepositsIncludingDisposalGroups" scale="6" id="f-923">145</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="ci:PolicyholderContractDepositCurrent" scale="6" id="f-924">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="ci:PolicyholderContractDepositNoncurrent" scale="6" id="f-925">157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="us-gaap:PolicyholderContractDeposits" scale="6" id="f-926">171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Operations</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-6" name="ci:PolicyholderContractDepositCurrent" scale="6" id="f-927">362</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-6" name="ci:PolicyholderContractDepositNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-928">6,178</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-6" name="us-gaap:PolicyholderContractDeposits" format="ixt:num-dot-decimal" scale="6" id="f-929">6,540</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-6" name="ci:PolicyholderContractDepositCurrent" scale="6" id="f-930">351</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-6" name="ci:PolicyholderContractDepositNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-931">6,358</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-6" name="us-gaap:PolicyholderContractDeposits" format="ixt:num-dot-decimal" scale="6" id="f-932">6,709</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market risk benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:MarketRiskBenefitLiabilityAmountCurrent" scale="6" id="f-933">37</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:MarketRiskBenefitLiabilityAmountNoncurrent" scale="6" id="f-934">966</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:MarketRiskBenefitLiabilityAmount" format="ixt:num-dot-decimal" scale="6" id="f-935">1,003</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:MarketRiskBenefitLiabilityAmountCurrent" scale="6" id="f-936">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:MarketRiskBenefitLiabilityAmountNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-937">1,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:MarketRiskBenefitLiabilityAmount" format="ixt:num-dot-decimal" scale="6" id="f-938">1,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unearned premiums</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:UnearnedPremiumsCurrentIncludingDisposalGroups" scale="6" id="f-939">846</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:UnearnedPremiumsNoncurrentIncludingDisposalGroups" scale="6" id="f-940">22</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:UnearnedPremiumsIncludingDisposalGroups" scale="6" id="f-941">868</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:UnearnedPremiumsCurrent" scale="6" id="f-942">576</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:UnearnedPremiumsNoncurrent" scale="6" id="f-943">22</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:UnearnedPremiums" scale="6" id="f-944">598</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups" format="ixt:num-dot-decimal" scale="6" id="f-945">6,633</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups" format="ixt:num-dot-decimal" scale="6" id="f-946">11,421</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:InsuranceAndContractholderLiabilitiesIncludingDisposalGroups" format="ixt:num-dot-decimal" scale="6" id="f-947">18,054</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Insurance and contractholder liabilities classified as liabilities of businesses held for sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="ci:DisposalGroupIncludingDiscontinuedOperationCurrentInsuranceAndContractholderLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-948">1,119</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="ci:DisposalGroupIncludingDiscontinuedOperationNoncurrentInsuranceAndContractholderLiabilities" scale="6" id="f-949">517</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="ci:DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-950">1,636</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total insurance and contractholder liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:InsuranceAndContractholderLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-951">5,514</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:InsuranceAndContractholderLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-952">10,904</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:InsuranceAndContractholderLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-953">16,418</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:InsuranceAndContractholderLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-954">5,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:InsuranceAndContractholderLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-955">11,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:InsuranceAndContractholderLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-956">17,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Amounts classified as liabilities of businesses held for sale include $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="ci:LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups" format="ixt:num-dot-decimal" scale="6" id="f-957">823</ix:nonFraction>&#160;million of Unpaid claims, $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups" format="ixt:num-dot-decimal" scale="6" id="f-958">429</ix:nonFraction>&#160;million of Future policy benefits, $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="ci:UnearnedPremiumsAttributableToDisposalGroups" format="ixt:num-dot-decimal" scale="6" id="f-959">261</ix:nonFraction>&#160;million of Unearned premiums and $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="ci:PolicyholderContractDepositsAttributableToDisposalGroups" format="ixt:num-dot-decimal" scale="6" id="f-960">123</ix:nonFraction>&#160;million of Contractholder deposit funds as of December&#160;31, 2023. </span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Insurance and contractholder liabilities expected to be paid within one year are classified as current. The Company adopted amended accounting guidance for long-duration insurance contracts on January 1, 2023, discussed further in Note 2 to the Consolidated Financial Statements, which resulted in restatement of prior period amounts. Additionally, see below updated accounting policies and incremental disclosures associated with future policy benefits (Note 10C), contractholder deposit funds (Note 10D), and market risk benefits (Note 10E).</span></div></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_250"></div><ix:continuation id="f-895-2" continuedAt="f-895-3"><ix:nonNumeric contextRef="c-1" name="ci:InsuranceUnearnedPremiumsPolicyTextBlock" id="f-961" continuedAt="f-961-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy - Unearned Premium. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The unrecognized portion of premiums received is recorded as unearned premiums included in Insurance and contractholder liabilities (current and non-current). </span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-961-1">The Company evaluates certain insurance contracts subject to premium deficiency testing and recognizes a premium deficiency loss and corresponding reserve when expected claims costs, claims adjustment expenses, maintenance costs, and unamortized acquisition costs exceed unearned premium. Anticipated investment income is considered in the calculation of premium deficiency.</ix:continuation> </span></div></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_253"></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><ix:continuation id="f-895-3" continuedAt="f-895-4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt;text-decoration:underline">Unpaid Claims and Claim Expenses &#8211; Cigna Healthcare</span></ix:continuation></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy" id="f-962" continuedAt="f-962-1" escape="true"><ix:continuation id="f-895-4" continuedAt="f-895-5"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This liability reflects estimates of the ultimate cost of claims that have been incurred but not reported, expected development on reported claims, claims that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily comprised of accruals for incentives and other amounts payable to health care professionals and facilities. </span></div></ix:continuation></ix:nonNumeric><div id="ibc59a92ac8bc42f794e728f24ce1b626_256"></div><ix:continuation id="f-962-1" continuedAt="f-962-2"><ix:continuation id="f-895-5" continuedAt="f-895-6"><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company compares key assumptions used to establish the medical costs payable to actual experience for each reporting period. The unpaid claims liability is adjusted through current period Shareholders' net income when actual experience differs from these assumptions. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trend. </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The liability is primarily calculated using "completion factors" developed by comparing the claim incurral date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1) electronic (auto-adjudication) versus manual </span></div></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-962-2" continuedAt="f-962-3"><ix:continuation id="f-895-6" continuedAt="f-895-7"><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">claim processing; 2) frequency and timeliness of provider claims submissions; 3) number of customers and 4) the mix of products. The Company uses historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period. </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company relies more heavily on medical cost trend analysis that reflects expected claim payment patterns and other relevant operational considerations for more recent months. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of health benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and deductibles, changes in provider practices and changes in consumer demographics and consumption behavior.</span></div></ix:continuation></ix:continuation><div id="ibc59a92ac8bc42f794e728f24ce1b626_259"></div><ix:continuation id="f-895-7" continuedAt="f-895-8"><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The total of incurred but not reported liabilities plus expected development on reported claims and reported claims in process was $<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-8" name="ci:LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses" format="ixt:num-dot-decimal" scale="9" id="f-963">4.8</ix:nonFraction> billion at December&#160;31, 2023 and $<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-8" name="ci:LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses" format="ixt:num-dot-decimal" scale="9" id="f-964">3.9</ix:nonFraction> billion at December&#160;31, 2022. </span></div><ix:continuation id="f-896-1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Activity, net of intercompany transactions, in the unpaid claims liability for the Cigna Healthcare segment was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.042%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-965">4,176</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-966">4,261</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-967">3,695</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Reinsurance and other amounts recoverable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="f-968">221</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="f-969">261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="f-970">237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance, net</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="f-971">3,955</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="f-972">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="f-973">3,458</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incurred costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-974">35,953</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-975">31,342</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-976">31,755</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="f-977">279</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="f-978">259</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="f-979">219</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total incurred</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="f-980">35,674</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="f-981">31,083</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="f-982">31,536</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Paid costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="f-983">31,322</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="f-984">27,583</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="f-985">27,929</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="6" id="f-986">3,451</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="6" id="f-987">3,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="6" id="f-988">3,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-989">34,773</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-990">31,128</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-991">30,994</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="ci:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups" format="ixt:num-dot-decimal" scale="6" id="f-992">4,856</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="f-993">3,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="f-994">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Add: Reinsurance and other amounts recoverable</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="ci:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups" scale="6" id="f-995">236</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="f-996">221</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="f-997">261</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="ci:LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups" format="ixt:num-dot-decimal" scale="6" id="f-998">5,092</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-999">4,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1000">4,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Includes $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="ci:LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups" format="ixt:num-dot-decimal" scale="6" id="f-1001">823</ix:nonFraction>&#160;million classified as liabilities of businesses held for sale as of December 31, 2023.</span></div></ix:continuation><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="us-gaap:ReinsuranceAccountingPolicy" id="f-1002" continuedAt="f-1002-1" escape="true">Reinsurance and other amounts recoverable reflect amounts due from reinsurers and policyholders to cover incurred but not reported and pending claims of certain business for which the Company administers the plan benefits without any right of offset. See Note 11 to the Consolidated Financial Statements for additional information on reinsurance</ix:nonNumeric>.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock" id="f-1003" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Variances in incurred costs related to prior years' unpaid claims and claim expenses that resulted from the differences between actual experience and the Company's key assumptions were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.889%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="24" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="12" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual completion factors</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="f-1004">70</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-226" decimals="3" name="ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage" scale="-2" id="f-1005">0.2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="f-1006">62</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-227" decimals="3" name="ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage" scale="-2" id="f-1007">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical cost trend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="f-1008">209</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-228" decimals="3" name="ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage" scale="-2" id="f-1009">0.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="f-1010">197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-229" decimals="3" name="ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage" scale="-2" id="f-1011">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total favorable variance</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="f-1012">279</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-223" decimals="3" name="ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage" scale="-2" id="f-1013">0.9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="f-1014">259</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-224" decimals="3" name="ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage" scale="-2" id="f-1015">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Percentage of current year incurred costs as reported for the year ended December&#160;31, 2022.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Percentage of current year incurred costs as reported for the year ended December&#160;31, 2021.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Favorable prior year development in both years reflects lower than expected utilization of medical services as compared to our assumptions.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">96</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_262"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-895-8" continuedAt="f-895-9"><ix:nonNumeric contextRef="c-1" name="us-gaap:ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" id="f-1016" escape="true"><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table depicts the incurred and paid claims development and unpaid claims liability as of December&#160;31, 2023 (net of reinsurance) reported in the Cigna Healthcare segment. The information about incurred and paid claims development for the year ended December&#160;31, 2022 is presented as supplementary information and is unaudited.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.984%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incurred Costs</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incurral Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022<br/>(Unaudited)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unpaid Claims &amp; Claim Expenses</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-6" name="ci:ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1017">30,309</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-6" name="ci:ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1018">30,050</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-6" name="ci:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1019">209</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-6" name="ci:ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1020">34,878</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-6" name="ci:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1021">4,498</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative incurred costs for the periods presented</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="ci:ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1022">64,928</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Costs Paid</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incurral Year</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022<br/>(Unaudited)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-6" name="ci:ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1023">26,687</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-6" name="ci:ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1024">29,841</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-6" name="ci:ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1025">30,380</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative paid costs for the periods presented</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="ci:ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1026">60,221</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding liabilities for the periods presented, net of reinsurance</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="ci:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1027">4,707</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-duration liabilities not included in development table above</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="ci:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseLongDurationNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1028">149</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unpaid claims and claims expenses - Cigna Healthcare</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="ci:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups" format="ixt:num-dot-decimal" scale="6" id="f-1029">4,856</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reinsurance and other amounts recoverable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="ci:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups" scale="6" id="f-1030">236</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unpaid claims and claim expenses - Cigna Healthcare</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="ci:LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups" format="ixt:num-dot-decimal" scale="6" id="f-1031">5,092</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Incurred claims do not typically remain outstanding for multiple years; more than <ix:nonFraction unitRef="number" contextRef="c-217" decimals="2" name="us-gaap:ShortdurationInsuranceContractsHistoricalClaimsDurationYearOne" scale="-2" id="f-1032">95</ix:nonFraction>% of health claims incurred in a year are paid by the end of the following year.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-962-3">There is no single or common claim frequency metric used in the health care industry. The Company believes a relevant metric for its health insurance business is the number of customers for whom an insured medical claim was paid. Customers for whom no insured medical claim was paid are excluded from the calculation. Claims that did not result in a liability are not included in the frequency metric.</ix:continuation> The claim frequency for 2023 and 2022 was approximately <ix:nonFraction unitRef="claim" contextRef="c-223" decimals="-5" name="ci:ShortdurationInsuranceContractsNumberOfPaidClaims" format="ixt:num-dot-decimal" scale="6" id="f-1033">5.5</ix:nonFraction> million and <ix:nonFraction unitRef="claim" contextRef="c-224" decimals="-5" name="ci:ShortdurationInsuranceContractsNumberOfPaidClaims" format="ixt:num-dot-decimal" scale="6" id="f-1034">5.0</ix:nonFraction>&#160;million, respectively.</span></div></ix:continuation><div style="margin-bottom:10pt"><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_277"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">C.</span><ix:continuation id="f-895-9" continuedAt="f-895-10"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Future Policy Benefits</span></ix:continuation></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_6391"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FuturePolicyBenefitsLiabilityPolicy" id="f-1035" escape="true"><ix:continuation id="f-895-10" continuedAt="f-895-11"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting Policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Future policy benefits represent the present value of estimated future obligations, estimated using actuarial methods, for long-duration insurance policies and annuity products currently in force, consisting primarily of reserves for annuity contracts, life insurance benefits, and certain supplemental health products that are guaranteed renewable beyond one year.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contracts are grouped at a level no higher than issue year, based on the original contract issue date, and at lower levels of disaggregation within each issue year for certain businesses to reflect factors including product type, plan type and currency. Management estimates these obligations based on assumptions for premiums, interest rates, mortality or morbidity, future claim adjudication expenses and surrenders. Mortality, morbidity and surrender assumptions are based on the Company's own experience and published actuarial tables, and are updated at least annually, to the extent changes in circumstances require. Interest rate assumptions are based on</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">market-level yields for low credit risk fixed income instruments ("upper-medium grade fixed income instrument"). For interest accretion purposes, interest rates are fixed at the year of the cohort's inception, however for purposes of liability measurement, are updated to the current rate quarterly, with all changes in the interest rate from inception to current period reported through Accumulated other comprehensive loss. For contracts issued domestically, we use observable inputs from a published spot rate curve for terms up to <ix:nonNumeric contextRef="c-1" name="ci:FuturePolicyBenefitsDomesticContractsObservableInputsFromPublishedSpotRateCurveMaximumTerm" format="ixt-sec:duryear" id="f-1036">30</ix:nonNumeric> years and extrapolate for longer terms using a constant forward rate approach. For contracts issued by foreign operating entities with functional currencies other than the U.S. dollar, we use observable inputs to approximate a risk free rate and add a credit spread adjustment to align with a low-credit risk fixed income instrument. For terms beyond the last observable risk free rates, which vary by international market, we extrapolate to the ultimate forward rate assuming a constant credit spread.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the annuity business, the premium paying period is shorter than the benefit coverage period, and a deferred profit liability is reported in future policy benefits representing gross premium received in excess of net premiums. Deferred profit liability is amortized based on expected future benefit payments.</span></div></ix:continuation></ix:nonNumeric><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-895-11" continuedAt="f-895-12"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, approximately <ix:nonFraction unitRef="number" contextRef="c-12" decimals="2" name="ci:LiabilityForFuturePolicyBenefitsPercentSupportedByAssetsHeldInTrust" scale="-2" id="f-1037">34</ix:nonFraction>% of the liability for future policy benefits, excluding amounts held for sale, was supported by assets in trust for the benefit of the ceding company under reinsurance agreements.</span></div></ix:continuation><div style="margin-bottom:10pt"><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_6404"></div><ix:continuation id="f-895-12" continuedAt="f-895-13"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cigna Healthcare</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LiabilityForFuturePolicyBenefitActivityTableTextBlock" id="f-1038" continuedAt="f-1038-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The weighted average interest rates applied and duration for future policy benefits in the Cigna Healthcare segment, consisting primarily of supplemental health products including individual Medicare supplement, limited benefit health products and individual private medical insurance, were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.288%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.430%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest accretion rate </span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-217" decimals="4" name="us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate" scale="-2" id="f-1039">2.54</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-218" decimals="4" name="us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate" scale="-2" id="f-1040">2.58</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current discount rate </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-217" decimals="4" name="us-gaap:LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate" scale="-2" id="f-1041">4.92</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-218" decimals="4" name="us-gaap:LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate" scale="-2" id="f-1042">5.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average duration </span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-217" name="us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageDuration" format="ixt-sec:duryear" id="f-1043">7.9</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-218" name="us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageDuration" format="ixt-sec:duryear" id="f-1044">7.7</ix:nonNumeric> years</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-895-13" continuedAt="f-895-14"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The net liability for future policy benefits for the segment's supplemental health products represents the present value of benefits expected to be paid to policyholders, net of the present value of expected net premiums, which is the portion of expected future gross premium expected to be collected from policyholders that is required to provide for all expected future benefits and expenses. <ix:continuation id="f-1038-1" continuedAt="f-1038-2">The present values of expected net premiums and expected future policy benefits for the Cigna Healthcare segment are as follows: </ix:continuation></span></div><ix:continuation id="f-1038-2" continuedAt="f-1038-3"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.262%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Present value of expected net premiums</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="us-gaap:LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange" format="ixt:num-dot-decimal" scale="6" id="f-1045">8,557</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-6" name="us-gaap:LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange" format="ixt:num-dot-decimal" scale="6" id="f-1046">9,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reversal of effect of beginning of period discount rate assumptions</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" sign="-" name="us-gaap:AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-1047">1,537</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-6" name="us-gaap:AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax" scale="6" id="f-1048">367</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of assumption changes and actual variances from expected experience </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience" scale="6" id="f-1049">314</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience" format="ixt:num-dot-decimal" scale="6" id="f-1050">1,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuances and lapses </span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitExpectedNetPremiumIssuanceAndDerecognition" format="ixt:num-dot-decimal" scale="6" id="f-1051">1,255</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitExpectedNetPremiumIssuanceAndDerecognition" format="ixt:num-dot-decimal" scale="6" id="f-1052">1,067</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net premiums collected</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" name="us-gaap:LiabilityForFuturePolicyBenefitExpectedNetPremiumNetPremiumCollected" format="ixt:num-dot-decimal" scale="6" id="f-1053">1,370</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-6" name="us-gaap:LiabilityForFuturePolicyBenefitExpectedNetPremiumNetPremiumCollected" format="ixt:num-dot-decimal" scale="6" id="f-1054">1,280</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest and other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitExpectedNetPremiumInterestIncomeAndOtherChanges" scale="6" id="f-1055">94</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitExpectedNetPremiumInterestIncomeAndOtherChanges" scale="6" id="f-1056">74</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance at original discount rate</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="us-gaap:LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance" format="ixt:num-dot-decimal" scale="6" id="f-1057">10,387</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="us-gaap:LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance" format="ixt:num-dot-decimal" scale="6" id="f-1058">10,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of end of period discount rate assumptions</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" sign="-" name="us-gaap:AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-1059">1,154</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" sign="-" name="us-gaap:AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-1060">1,537</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (3)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="us-gaap:LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange" format="ixt:num-dot-decimal" scale="6" id="f-1061">9,233</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="us-gaap:LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange" format="ixt:num-dot-decimal" scale="6" id="f-1062">8,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Present value of expected policy benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange" format="ixt:num-dot-decimal" scale="6" id="f-1063">8,945</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-6" name="us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange" format="ixt:num-dot-decimal" scale="6" id="f-1064">9,794</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reversal of effect of discount rate assumptions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="us-gaap:AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-1065">1,611</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-6" sign="-" name="us-gaap:AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax" scale="6" id="f-1066">379</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of assumption changes and actual variances from expected experience </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience" scale="6" id="f-1067">112</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience" format="ixt:num-dot-decimal" scale="6" id="f-1068">1,148</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuances and lapses </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitIssuanceAndDerecognition" format="ixt:num-dot-decimal" scale="6" id="f-1069">1,309</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitIssuanceAndDerecognition" format="ixt:num-dot-decimal" scale="6" id="f-1070">1,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit payments</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" name="us-gaap:LiabilityForFuturePolicyBenefitsPaymentForBenefits" format="ixt:num-dot-decimal" scale="6" id="f-1071">1,374</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-6" name="us-gaap:LiabilityForFuturePolicyBenefitsPaymentForBenefits" format="ixt:num-dot-decimal" scale="6" id="f-1072">1,401</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest and other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitInterestExpenseAndOtherChanges" scale="6" id="f-1073">250</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitInterestExpenseAndOtherChanges" scale="6" id="f-1074">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance at original discount rate</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance" format="ixt:num-dot-decimal" scale="6" id="f-1075">10,853</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance" format="ixt:num-dot-decimal" scale="6" id="f-1076">10,556</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of discount rate assumptions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="us-gaap:AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-1077">1,220</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="us-gaap:AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-1078">1,611</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange" format="ixt:num-dot-decimal" scale="6" id="f-1079">9,633</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange" format="ixt:num-dot-decimal" scale="6" id="f-1080">8,945</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability for future policy benefits </span></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther" scale="6" id="f-1081">400</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther" scale="6" id="f-1082">388</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitOther" scale="6" id="f-1083">215</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitOther" scale="6" id="f-1084">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total liability for future policy benefits </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)(7)</span></div></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1085">615</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="us-gaap:LiabilityForFuturePolicyBenefits" scale="6" id="f-1086">587</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes the effect of actual variances from expectations, which (decreased)/increased the total liability for future policy benefits by $(<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" sign="-" name="ci:LiabilityForFuturePolicyBenefitsCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience" scale="6" id="f-1087">12</ix:nonFraction>) million and $<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitsCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience" format="ixt:num-dot-decimal" scale="6" id="f-1088">46</ix:nonFraction> million, respectively, for the years ended December&#160;31, 2023 and December&#160;31, 2022.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes the foreign exchange rate impact of translating from transactional and functional currency to United States dollar and the impact of flooring the liability at zero. The flooring impact is calculated at the cohort level after discounting the reserves at the current discount rate.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">As of December&#160;31, 2023 and December&#160;31, 2022 undiscounted expected future gross premiums were $<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-8" name="us-gaap:LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumUndiscountedBeforeReinsurance" format="ixt:num-dot-decimal" scale="9" id="f-1089">18.7</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-8" name="us-gaap:LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumUndiscountedBeforeReinsurance" format="ixt:num-dot-decimal" scale="9" id="f-1090">17.5</ix:nonFraction> billion, respectively. As of December&#160;31, 2023 and December&#160;31, 2022 discounted expected future gross premiums were $<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-8" name="us-gaap:LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumDiscountedBeforeReinsurance" format="ixt:num-dot-decimal" scale="9" id="f-1091">13.5</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-8" name="us-gaap:LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumDiscountedBeforeReinsurance" format="ixt:num-dot-decimal" scale="9" id="f-1092">12.2</ix:nonFraction> billion, respectively.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">As of December&#160;31, 2023 and December&#160;31, 2022, undiscounted expected future policy benefits were $<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-8" name="us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance" format="ixt:num-dot-decimal" scale="9" id="f-1093">13.3</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-8" name="us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance" format="ixt:num-dot-decimal" scale="9" id="f-1094">12.7</ix:nonFraction> billion, respectively.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">The liability for future policyholder benefits includes immaterial businesses shown as reconciling items above, most of which are in run-off. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">$<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="us-gaap:LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance" format="ixt:num-dot-decimal" scale="6" id="f-1095">72</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="us-gaap:LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance" format="ixt:num-dot-decimal" scale="6" id="f-1096">155</ix:nonFraction> million reported in Reinsurance recoverables in the Consolidated Balance Sheets as of December&#160;31, 2023 and December&#160;31, 2022, respectively, relate to the liability for future policy benefits. Additionally, $<ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-6" name="ci:ReinsuranceRecoverablesLiabilityForFuturePolicyBenefitsAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1097">79</ix:nonFraction> million of reinsurance recoverables are reported in assets of businesses held for sale in the Consolidated Balance Sheets as of December&#160;31, 2023.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups" format="ixt:num-dot-decimal" scale="6" id="f-1098">429</ix:nonFraction> million of future policy benefits classified as liabilities of businesses held for sale in the Consolidated Balance Sheets as of December&#160;31, 2023.</span></div></ix:continuation></ix:continuation><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_283"></div><ix:continuation id="f-895-14" continuedAt="f-895-15"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other Operations</span></div><ix:continuation id="f-1038-3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The weighted average interest rates applied and duration for future policy benefits in Other Operations, consisting of annuity and life insurance products, were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.288%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.430%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest accretion rate </span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-219" decimals="4" name="us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate" scale="-2" id="f-1099">5.64</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-220" decimals="4" name="us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate" scale="-2" id="f-1100">5.64</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current discount rate </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-219" decimals="4" name="us-gaap:LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate" scale="-2" id="f-1101">4.87</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-220" decimals="4" name="us-gaap:LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate" scale="-2" id="f-1102">5.19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average duration </span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-219" name="us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageDuration" format="ixt-sec:duryear" id="f-1103">11.4</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-220" name="us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageDuration" format="ixt-sec:duryear" id="f-1104">11.5</ix:nonNumeric> years</span></td></tr></table></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Obligations for annuities represent discounted periodic benefits to be paid to an individual or groups of individuals over their remaining lives. Other Operations</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">'</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> traditional insurance contracts, which are in run-off, have no premium remaining to be collected; </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-895-15" continuedAt="f-895-16"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">therefore, future policy benefit reserves represent the present value of expected future policy benefits, discounted using the current discount rate, and the remaining amortizable deferred profit liability.</span></div></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_286"></div><ix:continuation id="f-895-16" continuedAt="f-895-17"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Future policy benefits for Other Operations includes deferred profit liability of $<ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitsDeferredProfitLiability" format="ixt:num-dot-decimal" scale="6" id="f-1105">384</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-6" name="ci:LiabilityForFuturePolicyBenefitsDeferredProfitLiability" format="ixt:num-dot-decimal" scale="6" id="f-1106">390</ix:nonFraction>&#160;million as of December&#160;31, 2023 and December&#160;31, 2022, respectively. Future policy benefits excluding deferred profit liability were $<ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-8" name="ci:LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability" format="ixt:num-dot-decimal" scale="9" id="f-1107"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-8" name="ci:LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability" format="ixt:num-dot-decimal" scale="9" id="f-1108">3.2</ix:nonFraction></ix:nonFraction>&#160;billion as of both December&#160;31, 2023 and December&#160;31, 2022, and $<ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-8" name="ci:LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability" format="ixt:num-dot-decimal" scale="9" id="f-1109">4.3</ix:nonFraction>&#160;billion as of December&#160;31, 2021. These balances exclude amounts classified as liabilities of businesses held for sale of $<ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-8" name="ci:LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups" format="ixt:num-dot-decimal" scale="9" id="f-1110">3.8</ix:nonFraction>&#160;billion as of December&#160;31, 2021. The change in future policy benefits reserves year-to-date was primarily driven by changes in the current discount rate. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Undiscounted expected future policy benefits were $<ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-8" name="us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance" format="ixt:num-dot-decimal" scale="9" id="f-1111">4.5</ix:nonFraction>&#160;billion as of December&#160;31, 2023 and $<ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-8" name="us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance" format="ixt:num-dot-decimal" scale="9" id="f-1112">4.6</ix:nonFraction>&#160;billion as of December&#160;31, 2022. As of December&#160;31, 2023 and December&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-8" name="us-gaap:LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance" format="ixt:num-dot-decimal" scale="9" id="f-1113">1.0</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-8" name="us-gaap:LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance" format="ixt:num-dot-decimal" scale="9" id="f-1114">1.1</ix:nonFraction>&#160;billion, respectively, of the future policy benefit reserve was recoverable through treaties with external reinsurers.</span></div></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_292"></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.</span><ix:continuation id="f-895-17" continuedAt="f-895-18"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt;text-decoration:underline">Contractholder Deposit Funds</span></ix:continuation></div><ix:continuation id="f-895-18" continuedAt="f-895-19"><div><ix:nonNumeric contextRef="c-1" name="ci:ContractholderDepositFundsPolicyPolicyTextBlock" id="f-1115" continuedAt="f-1115-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting Policy. </span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-1115-1">Liabilities for contractholder deposit funds primarily include deposits received from customers for investment-related and universal life products as well as investment earnings on their fund balances in Other Operations. These liabilities are adjusted to reflect administrative charges and, for universal life fund balances, mortality charges. Interest credited on these funds is accrued ratably over the contract period.</ix:continuation> </span></div></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_295"></div><ix:continuation id="f-895-19" continuedAt="f-895-20"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contractholder deposit fund liabilities within Other Operations were $<ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-8" name="us-gaap:PolicyholderContractDeposits" format="ixt:num-dot-decimal" scale="9" id="f-1116">6.5</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-8" name="us-gaap:PolicyholderContractDeposits" format="ixt:num-dot-decimal" scale="9" id="f-1117">6.7</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-8" name="us-gaap:PolicyholderContractDeposits" format="ixt:num-dot-decimal" scale="9" id="f-1118">6.9</ix:nonFraction> billion as of December&#160;31, 2023, December&#160;31, 2022 and December&#160;31, 2021, respectively. Approximately <ix:nonFraction unitRef="number" contextRef="c-12" decimals="2" name="ci:PolicyholderContractBalancePercentReinsuredExternally" scale="-2" id="f-1119">39</ix:nonFraction>% of the balance is reinsured externally as of both December&#160;31, 2023 and December&#160;31, 2022. Activity in these liabilities is presented net of reinsurance in the Consolidated Statements of Cash Flows. The net year-to-date decrease in contractholder deposit fund liabilities generally relates to withdrawals and benefit payments from contractholder deposit funds, partially offset by deposits and interest credited to contractholder deposit funds.</span></div></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_301"></div><ix:continuation id="f-895-20" continuedAt="f-895-21"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, the weighted average crediting rate, net amount at risk and cash surrender value for contractholder deposit fund liabilities not effectively exited through reinsurance were <ix:nonFraction unitRef="number" contextRef="c-219" decimals="4" name="us-gaap:PolicyholderAccountBalanceWeightedAverageCreditingRate" scale="-2" id="f-1120">3.31</ix:nonFraction>%, $<ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-8" name="us-gaap:PolicyholderAccountBalanceNetAmountAtRisk" format="ixt:num-dot-decimal" scale="9" id="f-1121">3.0</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-8" name="us-gaap:CashSurrenderValueDuePolicyholdersAmount" format="ixt:num-dot-decimal" scale="9" id="f-1122">2.8</ix:nonFraction> billion, respectively. The comparative amounts as of December&#160;31, 2022 were <ix:nonFraction unitRef="number" contextRef="c-220" decimals="4" name="us-gaap:PolicyholderAccountBalanceWeightedAverageCreditingRate" scale="-2" id="f-1123">3.08</ix:nonFraction>%, $<ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-8" name="us-gaap:PolicyholderAccountBalanceNetAmountAtRisk" format="ixt:num-dot-decimal" scale="9" id="f-1124">3.0</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-8" name="us-gaap:CashSurrenderValueDuePolicyholdersAmount" format="ixt:num-dot-decimal" scale="9" id="f-1125">2.4</ix:nonFraction> billion, respectively. More than <ix:nonFraction unitRef="number" contextRef="c-236" decimals="2" name="ci:PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage" scale="-2" id="f-1126"><ix:nonFraction unitRef="number" contextRef="c-237" decimals="2" name="ci:PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage" scale="-2" id="f-1127">99</ix:nonFraction></ix:nonFraction>% of the $<ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-8" name="us-gaap:PolicyholderFunds" format="ixt:num-dot-decimal" scale="9" id="f-1128">4.0</ix:nonFraction> billion liability as of December&#160;31, 2023 and the $<ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-8" name="us-gaap:PolicyholderFunds" format="ixt:num-dot-decimal" scale="9" id="f-1129">4.1</ix:nonFraction> billion liability as of December&#160;31, 2022 not reinsured externally is for contracts with guaranteed interest rates of <ix:nonFraction unitRef="number" contextRef="c-238" decimals="2" name="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditRating" scale="-2" id="f-1130"><ix:nonFraction unitRef="number" contextRef="c-239" decimals="2" name="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditRating" scale="-2" id="f-1131">3</ix:nonFraction></ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-240" decimals="2" name="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditRating" scale="-2" id="f-1132"><ix:nonFraction unitRef="number" contextRef="c-241" decimals="2" name="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditRating" scale="-2" id="f-1133">4</ix:nonFraction></ix:nonFraction>%, and approximately $<ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-8" name="us-gaap:PolicyholderFunds" format="ixt:num-dot-decimal" scale="9" id="f-1134"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-8" name="us-gaap:PolicyholderFunds" format="ixt:num-dot-decimal" scale="9" id="f-1135">1.2</ix:nonFraction></ix:nonFraction> billion represented contracts with policies at the guarantee. At both of these same period ends, $<ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-8" name="us-gaap:PolicyholderFunds" format="ixt:num-dot-decimal" scale="9" id="f-1136"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-8" name="us-gaap:PolicyholderFunds" format="ixt:num-dot-decimal" scale="9" id="f-1137">1.2</ix:nonFraction></ix:nonFraction> billion was <ix:nonFraction unitRef="number" contextRef="c-246" decimals="3" name="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate" scale="-4" id="f-1138"><ix:nonFraction unitRef="number" contextRef="c-247" decimals="3" name="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate" scale="-4" id="f-1139">50</ix:nonFraction></ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="c-248" decimals="3" name="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate" scale="-4" id="f-1140"><ix:nonFraction unitRef="number" contextRef="c-249" decimals="3" name="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate" scale="-4" id="f-1141">150</ix:nonFraction></ix:nonFraction> basis points ("bps") above the guarantee and the remaining $<ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-8" name="us-gaap:PolicyholderFunds" format="ixt:num-dot-decimal" scale="9" id="f-1142">1.6</ix:nonFraction> billion as of December&#160;31, 2023 and $<ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-8" name="us-gaap:PolicyholderFunds" format="ixt:num-dot-decimal" scale="9" id="f-1143">1.7</ix:nonFraction> billion as of December&#160;31, 2022 represented contracts above the guarantee that pay the policyholder based on the greater of a guaranteed minimum cash value or the actual cash value. More than <ix:nonFraction unitRef="number" contextRef="c-250" decimals="2" name="ci:PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue" scale="-2" id="f-1144"><ix:nonFraction unitRef="number" contextRef="c-251" decimals="2" name="ci:PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue" scale="-2" id="f-1145">90</ix:nonFraction></ix:nonFraction>% of these contracts have actual cash values of at least 110% of the guaranteed cash value.</span></div></ix:continuation><div id="ibc59a92ac8bc42f794e728f24ce1b626_304"></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E.</span><ix:continuation id="f-895-21" continuedAt="f-895-22"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt;text-decoration:underline">Market Risk Benefits</span></ix:continuation></div><ix:continuation id="f-895-22" continuedAt="f-895-23"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Liabilities for market risk benefits consist of variable annuity reinsurance contracts (formerly referred to as GMDB and GMIB contracts) in Other Operations. These liabilities arise under annuities and riders to annuities written by ceding companies that guarantee the benefit received at death and, for a subset of policies, also provide contractholders the option, within <ix:nonNumeric contextRef="c-1" name="ci:AnnuitizationElectionPeriod" format="ixt-sec:durday" id="f-1146">30</ix:nonNumeric> days of a policy anniversary after the appropriate waiting period, to elect minimum income payments. The Company's capital market risk exposure on variable annuity reinsurance contracts arises when the reinsured guaranteed minimum benefit exceeds the contractholder's account value in the related underlying mutual funds at the time the insurance benefit is payable under the respective contract. The Company receives and pays premium periodically based on the terms of the reinsurance agreements.</span></div></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_307"></div><ix:continuation id="f-895-23" continuedAt="f-895-24"><div><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketRiskBenefitPolicyTextBlock" id="f-1147" continuedAt="f-1147-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting Policy.</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-1147-1"> Variable annuity reinsurance liabilities are measured as MRBs at fair value, net of nonperformance risk, with fluctuations in value gross of reinsurer nonperformance risk reported in benefit expenses, while fluctuations in the Company's own nonperformance risk (own credit risk) are reported in Accumulated other comprehensive loss. Nonperformance risk reflects risk that a party might default and therefore not fulfill its obligations (i.e. nonpayment risk). The nonperformance risk adjustment reflects a market participant's view of nonpayment risk by adding an additional spread to the discount rate in the calculation of both (a) the variable annuity reinsurance liabilities to be paid by the Company and (b) the variable annuity reinsurance assets to be paid by the reinsurers, after considering collateral. The Company classifies variable annuity assets and liabilities in Level 3 of the fair value hierarchy described in Note 13 to the Consolidated Financial Statements because assumptions related to future annuitant behavior are largely unobservable. As discussed further in Note 11 to the Consolidated Financial Statements, due to the reinsurance agreements covering these liabilities, the liabilities do not generally impact net income except for the change in nonperformance risk on the reinsurance recoverable, which is reported in benefit expenses and does not offset the nonperformance risk valuation on the liability. Variable annuity liabilities are established using capital market assumptions and assumptions related to future annuitant behavior (including mortality, lapse and annuity election rates).</ix:continuation> </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_310"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketRiskBenefitActivityTableTextBlock" id="f-1148" continuedAt="f-1148-1" escape="true"><ix:continuation id="f-895-24" continuedAt="f-895-25"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Market risk benefits activity was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.444%"><tr><td style="width:1.0%"/><td style="width:74.877%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.912%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Balance, beginning of year</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk" format="ixt:num-dot-decimal" scale="6" id="f-1149">1,268</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk" format="ixt:num-dot-decimal" scale="6" id="f-1150">1,824</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Balance, beginning of year, before the effect of nonperformance risk (own credit risk)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange" format="ixt:num-dot-decimal" scale="6" id="f-1151">1,379</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange" format="ixt:num-dot-decimal" scale="6" id="f-1152">1,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Changes due to expected run-off</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="ci:MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff" scale="6" id="f-1153">19</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="ci:MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff" scale="6" id="f-1154">54</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Changes due to capital markets versus expected</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="ci:MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange" scale="6" id="f-1155">254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="ci:MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange" scale="6" id="f-1156">567</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Changes due to policyholder behavior versus expected</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected" scale="6" id="f-1157">5</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected" scale="6" id="f-1158">14</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Assumption changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:MarketRiskBenefitIncreaseDecreaseFromOtherAssumption" scale="6" id="f-1159">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:MarketRiskBenefitIncreaseDecreaseFromOtherAssumption" scale="6" id="f-1160">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Balance, end of period, before the effect of changes in nonperformance risk (own credit risk)</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange" format="ixt:num-dot-decimal" scale="6" id="f-1161">1,085</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange" format="ixt:num-dot-decimal" scale="6" id="f-1162">1,379</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Nonperformance risk (own credit risk), end of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax" scale="6" id="f-1163">82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax" scale="6" id="f-1164">111</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Balance, end of period</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk" format="ixt:num-dot-decimal" scale="6" id="f-1165">1,003</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk" format="ixt:num-dot-decimal" scale="6" id="f-1166">1,268</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Reinsured market risk benefit, end of period</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:MarketRiskBenefitReinsuranceRecoverableAfterAllowance" format="ixt:num-dot-decimal" scale="6" id="f-1167">1,081</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:MarketRiskBenefitReinsuranceRecoverableAfterAllowance" format="ixt:num-dot-decimal" scale="6" id="f-1168">1,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_322"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock" id="f-1169" escape="true"><ix:continuation id="f-895-25"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the account value, net amount at risk, average attained age of contractholders (weighted by exposure) and the number of contractholders for guarantees assumed by the Company. The net amount at risk is the amount that the Company would have to pay to contractholders if all deaths or annuitizations occurred as of the earliest possible date in accordance with the insurance contract. As of December&#160;31, 2023, the account value increased primarily due to favorable equity market performance, which resulted in an decrease to the net amount at risk. The Company should be reimbursed in full for these payments unless the Berkshire reinsurance limit is exceeded.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.041%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions, excludes impact of reinsurance ceded)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Account value</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-6" name="us-gaap:NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue" format="ixt:num-dot-decimal" scale="6" id="f-1170">7,736</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-6" name="us-gaap:NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue" format="ixt:num-dot-decimal" scale="6" id="f-1171">7,436</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net amount at risk</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-6" name="us-gaap:NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk" format="ixt:num-dot-decimal" scale="6" id="f-1172">1,609</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-6" name="us-gaap:NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk" format="ixt:num-dot-decimal" scale="6" id="f-1173">2,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Average attained age of contractholders (weighted by exposure)</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-254" name="us-gaap:NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1" format="ixt-sec:duryear" id="f-1174">77.3</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-255" name="us-gaap:NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1" format="ixt-sec:duryear" id="f-1175">74.7</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of contractholders (estimated)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="position" contextRef="c-252" decimals="-4" name="ci:NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated" format="ixt:num-dot-decimal" scale="0" id="f-1176">140,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="c-253" decimals="-4" name="ci:NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated" format="ixt:num-dot-decimal" scale="0" id="f-1177">150,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_325"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ReinsuranceTextBlock" id="f-1178" continuedAt="f-1178-1" escape="true"><div style="margin-bottom:10pt"><span id="i06222830be1a4df2a23a97244932bcc5_626"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 11 &#8211; Reinsurance</span></div><ix:continuation id="f-1002-1" continuedAt="f-1002-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's insurance subsidiaries enter into agreements with other insurance companies to limit losses from large exposures and to permit recovery of a portion of incurred losses. Reinsurance is ceded primarily in acquisition and disposition transactions when the underwriting company is not being acquired. Reinsurance does not relieve the originating insurer of liability. Therefore, reinsured liabilities must continue to be reported along with the related reinsurance recoverables. The Company regularly evaluates the financial condition of its reinsurers and monitors concentrations of its credit risk.</span></div></ix:continuation></ix:nonNumeric><div style="margin-bottom:10pt"><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_328"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><ix:continuation id="f-1178-1" continuedAt="f-1178-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt;text-decoration:underline">Reinsurance Recoverables</span></ix:continuation></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_331"></div><ix:continuation id="f-1178-2" continuedAt="f-1178-3"><ix:continuation id="f-1002-2" continuedAt="f-1002-3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reinsurance recoverables represent amounts due from reinsurers for both paid and unpaid claims of the Company's insurance businesses. The Company bears the risk of loss if its reinsurers and retrocessionaires do not meet or are unable to meet their reinsurance obligations to the Company. Most reinsurance recoverables are classified as non-current assets. The current portion of reinsurance recoverables is reported in Other current assets and consists primarily of recoverables on paid claims expected to be settled within one year. Reinsurance recoverables are presented net of allowances, consisting primarily of an allowance for expected credit losses which is recognized on reinsurance recoverable balances each period and adjusted through Medical costs and other benefit expenses. Estimates of the allowance for expected credit losses are based on internal and external data used to develop expected loss rates over the anticipated duration of the recoverable asset that vary by external credit rating and collateral level. </span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_334"></div><ix:continuation id="f-1178-3" continuedAt="f-1178-4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The majority of the Company's reinsurance recoverables resulted from acquisition and disposition transactions in which the underwriting company was not acquired. <ix:continuation id="f-1002-3" continuedAt="f-1002-4">The Company reviews its reinsurance arrangements and establishes reserves against the recoverables.</ix:continuation></span></div></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_340"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1178-4" continuedAt="f-1178-5"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCededCreditRiskByReinsurerTextBlock" id="f-1179" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's reinsurance recoverables as of December&#160;31, 2023 are presented at amount due by range of external credit rating and collateral level in the following table, with reinsurance recoverables that are market risk benefits separately presented at fair value:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.237%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Fair value of collateral contractually required to meet or exceed carrying value of recoverable</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Collateral provisions exist that may mitigate risk of credit loss </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">No collateral</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ongoing Operations</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">A- equivalent and higher current ratings </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:fixed-zero" scale="6" id="f-1180">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:fixed-zero" scale="6" id="f-1181">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1182">90</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1183">90</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">BBB- to BBB+ equivalent current credit ratings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:fixed-zero" scale="6" id="f-1184">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:fixed-zero" scale="6" id="f-1185">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1186">59</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1187">59</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Not rated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1188">151</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1189">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1190">182</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1191">338</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total recoverables related to ongoing operations</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1192">151</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1193">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1194">331</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1195">487</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition, disposition or run-off activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BBB+ equivalent and higher current ratings </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lincoln National Life and Lincoln Life &amp; Annuity of New York</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:fixed-zero" scale="6" id="f-1196">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1197">2,656</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:fixed-zero" scale="6" id="f-1198">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1199">2,656</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Empower Annuity Insurance Company</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:fixed-zero" scale="6" id="f-1200">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:fixed-zero" scale="6" id="f-1201">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1202">130</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1203">130</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prudential Insurance Company of America</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1204">341</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:fixed-zero" scale="6" id="f-1205">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:fixed-zero" scale="6" id="f-1206">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1207">341</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Life Insurance Company of North America</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:fixed-zero" scale="6" id="f-1208">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1209">356</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:fixed-zero" scale="6" id="f-1210">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1211">356</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1212">166</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1213">19</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1214">14</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1215">199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Not rated</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:fixed-zero" scale="6" id="f-1216">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1217">7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1218">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1219">11</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total recoverables related to acquisition, disposition or run-off activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1220">507</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1221">3,038</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1222">148</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1223">3,693</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reinsurance recoverables before market risk benefits</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1224">658</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1225">3,043</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1226">479</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1227">4,180</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allowance for uncollectible reinsurance</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:ReinsuranceRecoverableAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1228">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market risk benefits </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-6" name="us-gaap:MarketRiskBenefitReinsuranceRecoverableAfterAllowance" format="ixt:num-dot-decimal" scale="6" id="f-1229">1,081</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reinsurance recoverables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1230">5,226</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Certified by a NRSRO.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes collateral provisions requiring the reinsurer to fully collateralize its obligation if its external credit rating is downgraded to a specified level.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Prior to the adoption of LDTI, "acquisition, disposition or run-off activities" in the table above included Berkshire and certain Other recoverables that are related to the Company's variable annuity reinsurance products discussed in section B below. These amounts are now reported at fair market value as MRBs, as further discussed in Note 10 to the Consolidated Financial Statements. At December&#160;31, 2022, we reported $<ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-6" name="us-gaap:MarketRiskBenefitReinsuranceRecoverableAfterAllowance" format="ixt:num-dot-decimal" scale="6" id="f-1231">711</ix:nonFraction> million of recoverables related to the GMDB variable annuity reinsurance product. The restated December&#160;31, 2022 variable annuity reinsurance recoverable balance is $<ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-8" name="us-gaap:MarketRiskBenefitReinsuranceRecoverableAfterAllowance" format="ixt:num-dot-decimal" scale="9" id="f-1232">1.4</ix:nonFraction> billion, which also includes the GMIB variable annuity reinsurance product that was classified in Other assets prior to the adoption of LDTI.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes $<ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-6" name="us-gaap:ReinsuranceRecoverables" format="ixt:num-dot-decimal" scale="6" id="f-1233">183</ix:nonFraction> million of current reinsurance recoverables that are reported in Other current assets and $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="ci:DisposalGroupIncludingDiscontinuedOperationReinsuranceRecoverablesIncludingReinsurancePremiumPaid" format="ixt:num-dot-decimal" scale="6" id="f-1234">208</ix:nonFraction> million of reinsurance recoverables classified as assets of businesses held for sale.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:continuation id="f-1002-4" continuedAt="f-1002-5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Collateral levels are defined internally based on the fair value of the collateral relative to the carrying amount of the reinsurance recoverable, the frequency at which collateral is required to be replenished and the potential for volatility in the collateral's fair value.</span></div></ix:continuation></ix:continuation><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">102</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_346"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">B.</span><ix:continuation id="f-1178-5" continuedAt="f-1178-6"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Effective Exit of Variable Annuity Reinsurance Business</span></ix:continuation></div><ix:continuation id="f-1178-6" continuedAt="f-1178-7"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company entered into an agreement with Berkshire to effectively exit the variable annuity reinsurance business via a reinsurance transaction in 2013. <ix:continuation id="f-1002-5">Variable annuity contracts are accounted for as assumed and ceded reinsurance and categorized as market risk benefits as discussed in Note 10 to the Consolidated Financial Statements.</ix:continuation> Berkshire reinsured <ix:nonFraction unitRef="number" contextRef="c-307" decimals="INF" name="ci:CededReinsuranceAgreementReinsuredRiskPercentage" scale="-2" id="f-1235">100</ix:nonFraction>% of the Company's future cash flows in this business, net of other reinsurance arrangements existing at that time. The reinsurance agreement is subject to an overall limit with approximately $<ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-8" name="ci:CededReinsuranceAgreementCoverageLimitAmountRemaining" scale="9" id="f-1236">3.1</ix:nonFraction> billion remaining at December&#160;31, 2023. As a result of the reinsurance transaction, amounts payable are offset by a corresponding reinsurance recoverable, provided the increased recoverable remains within the overall Berkshire limit.</span></div></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_364"></div><ix:continuation id="f-1178-7" continuedAt="f-1178-8"><ix:continuation id="f-1148-1"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.432%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reinsurer </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Collateral and Other Terms</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">at December&#160;31, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Berkshire</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-6" name="ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances" scale="6" id="f-1237">873</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-6" name="ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances" format="ixt:num-dot-decimal" scale="6" id="f-1238">1,116</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-309" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1239">95</ix:nonFraction>% were secured by assets in a trust.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sun Life Assurance Company of Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-6" name="ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances" scale="6" id="f-1240">92</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-6" name="ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances" scale="6" id="f-1241">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liberty Re (Bermuda) Ltd.</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-6" name="ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances" scale="6" id="f-1242">104</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-6" name="ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances" scale="6" id="f-1243">128</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-314" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1244">100</ix:nonFraction>% were secured by assets in a trust.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SCOR SE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-6" name="ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances" scale="6" id="f-1245">31</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-6" name="ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances" scale="6" id="f-1246">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-317" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1247">80</ix:nonFraction>% were secured by a letter of credit.</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market risk benefits </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-6" name="ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances" format="ixt:num-dot-decimal" scale="6" id="f-1248">1,100</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-6" name="ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances" format="ixt:num-dot-decimal" scale="6" id="f-1249">1,398</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">All reinsurers are rated A- equivalent and higher by an NRSRO.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes IBNR and outstanding claims of $<ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-6" name="us-gaap:ReinsuranceReceivablesIncurredButNotReportedClaims" format="ixt:num-dot-decimal" scale="6" id="f-1250">19</ix:nonFraction> million. These amounts are excluded from market risk benefits at December&#160;31, 2023 in Note 10 and Note 11A to the Consolidated Financial Statements. At December&#160;31, 2022, IBNR and outstanding claims of $<ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-6" name="us-gaap:ReinsuranceReceivablesIncurredButNotReportedClaims" format="ixt:num-dot-decimal" scale="6" id="f-1251">27</ix:nonFraction> million offset by premium due of $<ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-6" name="us-gaap:PremiumsReceivableAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-1252">3</ix:nonFraction> million were excluded from the market risk benefits as restated due to the adoption of LDTI.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The impact of nonperformance risk (i.e., the risk that a counterparty might default) on the variable annuity reinsurance asset was immaterial for the years ended 2023, 2022 and 2021.</span></div></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_343"></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">C.</span><ix:continuation id="f-1178-8" continuedAt="f-1178-9"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Effects of Reinsurance</span></ix:continuation></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EffectsOfReinsuranceTableTextBlock" id="f-1256" escape="true"><ix:continuation id="f-1178-9"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents direct, assumed and ceded earned premiums for both short-duration and long-duration insurance contracts. It also presents reinsurance recoveries that have been netted against Medical costs and other benefit expenses in the Company's Consolidated Statements of Income.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.042%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Premiums</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-duration contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Direct</span></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-6" name="us-gaap:DirectPremiumsEarned" format="ixt:num-dot-decimal" scale="6" id="f-1257">42,266</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-6" name="us-gaap:DirectPremiumsEarned" format="ixt:num-dot-decimal" scale="6" id="f-1258">36,747</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-321" decimals="-6" name="us-gaap:DirectPremiumsEarned" format="ixt:num-dot-decimal" scale="6" id="f-1259">36,513</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-6" name="us-gaap:AssumedPremiumsEarned" scale="6" id="f-1260">303</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-6" name="us-gaap:AssumedPremiumsEarned" scale="6" id="f-1261">416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-321" decimals="-6" name="us-gaap:AssumedPremiumsEarned" scale="6" id="f-1262">335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ceded</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-6" name="us-gaap:CededPremiumsEarned" scale="6" id="f-1263">277</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-6" name="us-gaap:CededPremiumsEarned" scale="6" id="f-1264">265</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-321" decimals="-6" name="us-gaap:CededPremiumsEarned" scale="6" id="f-1265">148</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total short-duration contract premiums</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1266">42,292</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1267">36,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-321" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1268">36,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-duration contracts</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Direct</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-322" decimals="-6" name="us-gaap:DirectPremiumsEarned" format="ixt:num-dot-decimal" scale="6" id="f-1269">2,084</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-323" decimals="-6" name="us-gaap:DirectPremiumsEarned" format="ixt:num-dot-decimal" scale="6" id="f-1270">3,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-6" name="us-gaap:DirectPremiumsEarned" format="ixt:num-dot-decimal" scale="6" id="f-1271">4,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assumed</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-322" decimals="-6" name="us-gaap:AssumedPremiumsEarned" scale="6" id="f-1272">72</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-323" decimals="-6" name="us-gaap:AssumedPremiumsEarned" scale="6" id="f-1273">85</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-6" name="us-gaap:AssumedPremiumsEarned" scale="6" id="f-1274">99</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ceded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-322" decimals="-6" name="us-gaap:CededPremiumsEarned" scale="6" id="f-1275">211</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-323" decimals="-6" name="us-gaap:CededPremiumsEarned" scale="6" id="f-1276">286</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-6" name="us-gaap:CededPremiumsEarned" scale="6" id="f-1277">398</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-duration contract premiums</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-322" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1278">1,945</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-323" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1279">3,018</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1280">4,454</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total premiums</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1281">44,237</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1282">39,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1283">41,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total reinsurance recoveries</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" scale="6" id="f-1284">456</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" scale="6" id="f-1285">702</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" scale="6" id="f-1286">552</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Total short-duration contracts written premiums were $<ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-8" name="us-gaap:PremiumsWrittenNet" format="ixt:num-dot-decimal" scale="9" id="f-1287">41.1</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-8" name="us-gaap:PremiumsWrittenNet" format="ixt:num-dot-decimal" scale="9" id="f-1288">35.0</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-321" decimals="-8" name="us-gaap:PremiumsWrittenNet" format="ixt:num-dot-decimal" scale="9" id="f-1289">35.6</ix:nonFraction> billion for 2023, 2022 and 2021, respectively.</span></div></ix:continuation></ix:nonNumeric><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">103</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_373"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="f-1290" continuedAt="f-1290-1" escape="true"><div><span id="iba773ce036514c4ba5209af3290a59b4_16"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12 &#8211; Investments</span></div></ix:nonNumeric><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_379"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentPolicyTextBlock" id="f-1291" continuedAt="f-1291-1" escape="true"><ix:continuation id="f-1290-1" continuedAt="f-1290-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Cigna Group's investment portfolio consists of a broad range of investments including debt securities, equity securities, commercial mortgage loans, policy loans, other long-term investments, short-term investments and derivative financial instruments. The sections below provide more detail regarding our investment balances and realized investment gains and losses. See Note 13 for information about the valuation of the Company's investment portfolio.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Debt securities, commercial mortgage loans, derivative financial instruments and short-term investments with contractual maturities during the next twelve months are classified on the balance sheet as current investments, unless they are held as statutory deposits or restricted for other purposes and then they are classified in Long-term investments. Equity securities may include funds that are used in our cash management strategy and are classified as current investments. All other investments are classified as Long-term investments.</span></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_382"></div><ix:continuation id="f-1290-2" continuedAt="f-1290-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock" id="f-1292" continuedAt="f-1292-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the Company's investments by category and current or long-term classification:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.212%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-6" name="ci:ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1293">590</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-6" name="ci:LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1294">9,265</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-6" name="ci:InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1295">9,855</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="f-1296">654</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1297">9,218</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-6" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="f-1298">9,872</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-6" name="ci:ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1299">31</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-6" name="ci:LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1300">3,331</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-6" name="ci:InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1301">3,362</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="f-1302">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-6" name="us-gaap:LongTermInvestments" scale="6" id="f-1303">577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-6" name="us-gaap:Investments" scale="6" id="f-1304">622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial mortgage loans</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-6" name="ci:ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1305">182</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-6" name="ci:LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1306">1,351</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-6" name="ci:InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1307">1,533</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-330" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="f-1308">67</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-330" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1309">1,547</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-330" decimals="-6" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="f-1310">1,614</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Policy loans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-331" decimals="-6" name="ci:ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:fixed-zero" scale="6" id="f-1311">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-331" decimals="-6" name="ci:LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1312">1,211</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-331" decimals="-6" name="ci:InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1313">1,211</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-332" decimals="-6" name="us-gaap:ShortTermInvestments" format="ixt:fixed-zero" scale="6" id="f-1314">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-332" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1315">1,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-332" decimals="-6" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="f-1316">1,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term investments</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-333" decimals="-6" name="ci:ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:fixed-zero" scale="6" id="f-1317">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-333" decimals="-6" name="ci:LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1318">4,181</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-333" decimals="-6" name="ci:InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1319">4,181</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-334" decimals="-6" name="us-gaap:ShortTermInvestments" format="ixt:fixed-zero" scale="6" id="f-1320">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-334" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1321">3,728</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-334" decimals="-6" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="f-1322">3,728</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-335" decimals="-6" name="ci:ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1323">206</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-335" decimals="-6" name="ci:LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:fixed-zero" scale="6" id="f-1324">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-335" decimals="-6" name="ci:InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1325">206</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-336" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="f-1326">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-336" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:fixed-zero" scale="6" id="f-1327">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-336" decimals="-6" name="us-gaap:Investments" scale="6" id="f-1328">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1329">1,009</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1330">19,339</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1331">20,348</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments classified as assets of businesses held for sale </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="ci:DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent" scale="6" id="f-1332">84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="ci:DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1333">1,354</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="ci:DisposalGroupIncludingDiscontinuedOperationInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1334">1,438</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments per Consolidated Balance Sheets</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="f-1335">925</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1336">17,985</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="f-1337">18,910</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="f-1338">905</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1339">16,288</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="f-1340">17,193</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="padding-left:9pt;text-indent:-9pt"><ix:continuation id="f-1292-1" continuedAt="f-1292-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"><ix:continuation id="f-1292-2"> Investments related to the HCSC transaction that were held for sale as of December&#160;31, 2023. These investments were primarily comprised of debt securities and commercial mortgage loans, and to a lesser extent, other long term investments.</ix:continuation> </span></div></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_385"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><ix:continuation id="f-1290-3" continuedAt="f-1290-4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt;text-decoration:underline">Investment Portfolio</span></ix:continuation></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_388"></div><ix:continuation id="f-1290-4" continuedAt="f-1290-5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Securities</span></div></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_391"></div><ix:continuation id="f-1291-1" continuedAt="f-1291-2"><ix:continuation id="f-1290-5" continuedAt="f-1290-6"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Debt securities (including bonds, mortgage and other asset-backed securities and preferred stocks redeemable by the investor) are classified as available for sale and are carried at fair value with changes in fair value recorded either in Accumulated other comprehensive loss within Shareholders' equity or in credit loss expense based on fluctuations in the allowance for credit losses, as further discussed below. Prior to the adoption of LDTI on January 1, 2023, net unrealized appreciation on debt securities supporting the Company's run-off settlement annuity business was reported in Non-current insurance and contractholder liabilities rather than Accumulated other comprehensive loss. See Note 16 for impact to Accumulated other comprehensive loss. When the Company intends to sell or determines that it is more likely than not to be required to sell an impaired debt security, the excess of amortized cost over fair value is directly written down with a charge to Net realized investment (losses) gains. Certain asset-backed securities are considered variable interest entities. See Note 14 for additional information. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company reviews declines in fair value from a debt security's amortized cost basis to determine whether a credit loss exists, and when appropriate, recognizes a credit loss allowance with a corresponding charge to credit loss expense, presented in Net realized investment (losses) gains in the Company's Consolidated Statements of Income. The allowance for credit loss represents the excess of amortized cost over the greater of its fair value or the net present value of the debt security's projected future cash flows (based on qualitative and quantitative factors, including the probability of default and the estimated timing and amount of recovery). Each period, the allowance for credit loss is adjusted as needed through credit loss expense.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company does not measure an allowance for credit losses for accrued interest receivables. When interest payments are delinquent based on contractual terms or when certain terms (interest rate or maturity date) of the investment have been restructured, accrued interest, reported in Other current assets, is written off through a charge to Net investment income and interest income is recognized on a cash basis.</span></div></ix:continuation></ix:continuation><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">104</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_397"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1290-6" continuedAt="f-1290-7"><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="f-1341" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The amortized cost and fair value by contractual maturity periods for debt securities were as follows as of December&#160;31, 2023:</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.041%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1342">622</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1343">605</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1344">3,914</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1345">3,761</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1346">3,194</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1347">3,005</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1348">2,251</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1349">2,119</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset-backed securities</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1350">398</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1351">365</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1352">10,379</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1353">9,855</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Actual maturities of these securities could differ from their contractual maturities used in the table above because issuers may have the right to call or prepay obligations, with or without penalties.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="f-1354" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gross unrealized appreciation (depreciation) on debt securities by type of issuer is shown below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.046%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for Credit Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Appreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal government and agency</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-337" decimals="-6" name="ci:AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1355">251</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-337" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:fixed-zero" scale="6" id="f-1356">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-337" decimals="-6" name="ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1357">24</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-337" decimals="-6" name="ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1358">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-337" decimals="-6" name="ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1359">267</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State and local government</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-338" decimals="-6" name="ci:AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1360">37</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-338" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:fixed-zero" scale="6" id="f-1361">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-338" decimals="-6" name="ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1362">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-338" decimals="-6" name="ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1363">1</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-338" decimals="-6" name="ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1364">38</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-6" name="ci:AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1365">355</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:fixed-zero" scale="6" id="f-1366">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-6" name="ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1367">10</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-6" name="ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1368">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-6" name="ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1369">352</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-340" decimals="-6" name="ci:AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1370">9,338</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-340" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1371">33</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-340" decimals="-6" name="ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1372">158</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-340" decimals="-6" name="ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1373">630</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-340" decimals="-6" name="ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1374">8,833</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset-backed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-341" decimals="-6" name="ci:AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1375">398</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-341" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:fixed-zero" scale="6" id="f-1376">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-341" decimals="-6" name="ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1377">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-341" decimals="-6" name="ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1378">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-341" decimals="-6" name="ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1379">365</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1380">10,379</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1381">33</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1382">195</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1383">686</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1384">9,855</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal government and agency</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-342" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" scale="6" id="f-1385">292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-342" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-1386">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-342" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-1387">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-342" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-1388">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-342" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-1389">312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State and local government</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-343" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" scale="6" id="f-1390">43</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-343" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-1391">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-343" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1392">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-343" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-1393">2</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-343" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-1394">41</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" scale="6" id="f-1395">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-1396">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-1397">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-1398">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-1399">365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-345" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="f-1400">9,742</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-345" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" scale="6" id="f-1401">44</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-345" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-1402">89</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-345" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-1403">981</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-345" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-1404">8,806</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset-backed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-346" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" scale="6" id="f-1405">390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-346" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="f-1406">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-346" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-1407">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-346" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-1408">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-346" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="f-1409">348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="f-1410">10,842</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" scale="6" id="f-1411">44</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-1412">133</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-1413">1,059</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-1414">9,872</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="padding-right:36pt"><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_400"></div><ix:continuation id="f-1290-7" continuedAt="f-1290-8"><ix:continuation id="f-1291-2" continuedAt="f-1291-3"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Review of declines in fair value. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Management reviews impaired debt securities to determine whether a credit loss allowance is needed based on criteria that include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">severity of decline;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">financial health and specific prospects of the issuer; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">changes in the regulatory, economic or general market environment of the issuer's industry or geographic region.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="f-1415" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The table below summarizes debt securities with a decline in fair value from amortized cost for which an allowance for credit losses has not been recorded, by investment grade and the length of time these securities have been in an unrealized loss position. Unrealized depreciation on these debt securities is primarily due to declines in fair value resulting from increasing interest rates since these securities were purchased. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of Issues</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of Issues</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">One year or less</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investment grade</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-6" name="ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1416">330</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-6" name="ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1417">338</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-6" name="ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1418">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="position" contextRef="c-347" decimals="INF" name="ci:AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureLessThan12MonthsNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="0" id="f-1419">142</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="f-1420">5,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-1421">6,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-1422">594</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="c-348" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="f-1423">1,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Below investment grade</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-6" name="ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1424">161</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-6" name="ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1425">170</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-6" name="ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1426">9</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="position" contextRef="c-349" decimals="INF" name="ci:AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureLessThan12MonthsNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="0" id="f-1427">135</ix:nonFraction></span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-1428">887</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost" scale="6" id="f-1429">964</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-1430">77</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="c-350" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="f-1431">1,287</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More than one year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investment grade</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-6" name="ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1432">5,441</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-6" name="ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1433">6,036</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-6" name="ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1434">595</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="position" contextRef="c-347" decimals="INF" name="ci:AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureTwelveMonthsOrLongerNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="0" id="f-1435">1,590</ix:nonFraction></span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="f-1436">1,151</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-1437">1,487</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-1438">336</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="c-348" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="f-1439">462</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Below investment grade</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-6" name="ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1440">701</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-6" name="ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1441">775</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-6" name="ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1442">74</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="position" contextRef="c-349" decimals="INF" name="ci:AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureTwelveMonthsOrLongerNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="0" id="f-1443">486</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-1444">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost" scale="6" id="f-1445">382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-1446">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="c-350" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="f-1447">369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1448">6,633</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1449">7,319</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1450">686</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="position" contextRef="c-12" decimals="INF" name="ci:AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="0" id="f-1451">2,353</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="f-1452">7,901</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-1453">8,960</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="6" id="f-1454">1,059</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="c-13" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="f-1455">3,777</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">105</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_412"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1290-8" continuedAt="f-1290-9"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Equity Securities</span></div><ix:continuation id="f-1291-3" continuedAt="f-1291-4"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Equity securities with a readily determinable fair value consist primarily of public equity investments in the health care sector and mutual funds that invest in fixed income debt securities while those without a readily determinable fair value consist of private equity investments. Changes in the fair values of equity securities that have a readily determinable fair value are reported in Net realized investment (losses) gains. Equity securities without a readily determinable fair value are carried at cost minus impairment, if any, plus or minus changes resulting from observable price changes. </span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="ci:EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock" id="f-1456" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides the values of the Company's equity security investments. The amount of impairments or value changes resulting from observable price changes on equity securities with no readily determinable fair value still held was not material to the financial statements as of December&#160;31, 2023 or 2022.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.044%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023 </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="f-1457">656</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="f-1458">51</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="f-1459">673</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="f-1460">138</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities with no readily determinable fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-1461">3,248</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="f-1462">3,311</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost" scale="6" id="f-1463">380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="f-1464">484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-1465">3,904</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-1466">3,362</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-1467">1,053</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount" scale="6" id="f-1468">622</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we became a minority owner in VillageMD by investing $<ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-8" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="9" id="f-1469">2.7</ix:nonFraction>&#160;billion in VillageMD preferred equity. VillageMD is a provider of primary, multi-specialty and urgent care services that is majority-owned by Walgreens Boots Alliance, Inc. These securities are included in Equity securities with no readily determinable fair value in the above table. A compounding dividend of <ix:nonFraction unitRef="number" contextRef="c-351" decimals="3" name="ci:EquitySecuritiesDividend" scale="-2" id="f-1470">5.5</ix:nonFraction>% accrues annually on $<ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-8" name="ci:EquitySecuritiesWithoutReadilyDeterminableFairValueValueOfSharesForAnnualDividendAccrual" format="ixt:num-dot-decimal" scale="9" id="f-1471">2.2</ix:nonFraction>&#160;billion of our cost basis in these shares. Consistent with our strategy to invest in targeted startup and growth-stage companies in the health care industry, approximately <ix:nonFraction unitRef="number" contextRef="c-352" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1472">95</ix:nonFraction>% of our investments in equity securities are in the health care sector.</span></div></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_418"></div><ix:continuation id="f-1290-9" continuedAt="f-1290-10"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Commercial Mortgage Loans</span></div></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_421"></div><ix:continuation id="f-1291-4" continuedAt="f-1291-5"><ix:continuation id="f-1290-10" continuedAt="f-1290-11"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Commercial mortgage loans are carried at unpaid principal balances, net of an allowance for expected credit losses, and classified as either current or long-term investments based on their contractual maturities. Changes in the allowance for expected credit losses are recognized as credit loss expense and presented in Net realized investment (losses) gains in the Company's Consolidated Statements of Income. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Each period, the Company establishes (or adjusts) its allowance for expected credit losses for commercial mortgage loans. The allowance for expected credit losses is based on a credit risk category that is assigned to each loan at origination using key credit quality indicators, including debt service coverage and loan-to-value ratios. Credit risk categories are updated as key credit quality indicators change. An expected loss rate, assigned based on the credit risk category, is applied to each loan's unpaid principal balance to develop the aggregate allowance for expected credit losses. Commercial mortgage loans are considered impaired and written off against the allowance when it is probable that the Company will not collect all amounts due per the terms of the promissory note. In the event of a foreclosure, the allowance for credit losses is based on the excess of the carrying value of the mortgage loan over the fair value of its underlying collateral.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_424"></div><ix:continuation id="f-1291-5" continuedAt="f-1291-6"><ix:continuation id="f-1290-11" continuedAt="f-1290-12"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Mortgage loans held by the Company are made exclusively to commercial borrowers and are diversified by property type, location and borrower. Loans are generally issued at fixed rates of interest and are secured by high quality, primarily completed and substantially leased operating properties.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_427"></div><ix:continuation id="f-1291-6" continuedAt="f-1291-7"><ix:continuation id="f-1290-12" continuedAt="f-1290-13"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Credit quality</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Company regularly evaluates and monitors credit risk, beginning with the initial underwriting of a mortgage loan and continuing throughout the investment holding period. Mortgage origination professionals employ an internal credit quality rating system designed to evaluate the relative risk of the transaction at origination that is then updated each year as part of the annual portfolio loan review. The Company evaluates and monitors credit quality on a consistent and ongoing basis.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Quality ratings are based on our evaluation of a number of key inputs related to the loan, including real estate market-related factors such as rental rates and vacancies, and property-specific inputs such as growth rate assumptions and lease rollover statistics. However, the two most significant contributors to the credit quality rating are the debt service coverage and loan-to-value ratios. The debt service coverage ratio measures the amount of property cash flow available to meet annual interest and principal payments on debt, with a ratio below 1.0 indicating that there is not enough cash flow to cover the required loan payments. The loan-to-value ratio, commonly expressed as a percentage, compares the amount of the loan to the fair value of the underlying property collateralizing the loan.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">106</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_433"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FinancingReceivableCreditQualityIndicatorsTableTextBlock" id="f-1473" escape="true"><ix:continuation id="f-1290-13" continuedAt="f-1290-14"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the credit risk profile of the Company's commercial mortgage loan portfolio:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.890%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Loan-to-Value Ratio</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Debt Service Coverage Ratio</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Loan-to-Value Ratio</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Debt Service Coverage Ratio</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Loan-to-Value Ratio</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Below 60%</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-353" decimals="-6" name="ci:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1474">802</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-354" decimals="2" name="ci:FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="0" id="f-1475">2.13</ix:nonFraction></span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-355" decimals="-6" name="us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-1476">901</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-356" decimals="2" name="ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio" scale="0" id="f-1477">2.12</ix:nonFraction></span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60% to 79%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-357" decimals="-6" name="ci:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1478">574</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-358" decimals="2" name="ci:FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="0" id="f-1479">1.77</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-6" name="us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-1480">564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-360" decimals="2" name="ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio" scale="0" id="f-1481">1.73</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80% to 100%</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-361" decimals="-6" name="ci:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1482">157</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-362" decimals="2" name="ci:FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="0" id="f-1483">0.65</ix:nonFraction></span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-363" decimals="-6" name="us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="f-1484">149</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-364" decimals="2" name="ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio" scale="0" id="f-1485">1.17</ix:nonFraction></span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-6" name="ci:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1486">1,533</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-366" decimals="2" name="ci:FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="0" id="f-1487">1.82</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-366" decimals="2" name="ci:FinancingReceivableCreditQualityLoanToValueRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="-2" id="f-1488">64</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-6" name="us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="f-1489">1,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-368" decimals="2" name="ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio" scale="0" id="f-1490">1.89</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-368" decimals="2" name="ci:FinancingReceivableCreditQualityLoanToValueRatio" scale="-2" id="f-1491">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_436"></div><ix:continuation id="f-1290-14" continuedAt="f-1290-15"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Policy Loans</span></div><ix:continuation id="f-1291-7" continuedAt="f-1291-8"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Policy loans, primarily associated with our corporate-owned life insurance business, are carried at unpaid principal balances plus accumulated interest, the total of which approximates fair value. These loans are collateralized by life insurance policy cash values and therefore have minimal exposure to credit loss. Interest rates are reset annually based on a rolling average of benchmark interest rates.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_442"></div><ix:continuation id="f-1290-15" continuedAt="f-1290-16"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other Long-term Investments</span></div><ix:continuation id="f-1291-8" continuedAt="f-1291-9"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other long-term investments include investments in unconsolidated entities, including certain limited partnerships and limited liability companies holding real estate, securities or loans and health care-related investments. These investments are carried at cost plus the Company's ownership percentage of reporting income or loss, based on the financial statements of the underlying investments that are generally reported at fair value. Income or loss from these investments is reported on a one quarter lag due to the timing of when financial information is received from the general partner or manager of the investments. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other long-term investments also include investment real estate carried at depreciated cost less any impairment write-downs to fair value when cash flows indicate that the carrying value may not be recoverable. Depreciation is generally recorded using the straight-line method based on the estimated useful life of each asset. Investment real estate as of December&#160;31, 2023 and 2022 is expected to be held longer than one year and may include real estate acquired through the foreclosure of commercial mortgage loans.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, foreign currency swaps carried at fair value and certain restricted deposits are reported in the table below as "Other." See discussion below for information on the Company's accounting policies for derivative financial instruments.</span></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-1291-9" continuedAt="f-1291-10">Other long-term investments and related commitments are diversified by issuer, property type and geographic regions. These investments are primarily unconsolidated variable interest entities (see Note 14 for additional information).</ix:continuation> <ix:nonNumeric contextRef="c-1" name="ci:ScheduleOfOtherLongTermInvestmentsTableTextBlock" id="f-1492" continuedAt="f-1492-1" escape="true">The following table provides unfunded commitment and carrying value information for these investments. The Company expects to disburse approximately <ix:nonFraction unitRef="number" contextRef="c-12" decimals="2" name="ci:UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear" scale="-2" id="f-1493">25</ix:nonFraction>% of the committed amounts in 2024. </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-1492-1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-1291-10" continuedAt="f-1291-11">Our limited partnership investments are reduced as the Company receives cash distributions for returns on its investment that were previously recognized in Net investment income. </ix:continuation>The amount of these cash distributions was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="6" id="f-1494">253</ix:nonFraction> million in 2023, $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="6" id="f-1495">487</ix:nonFraction> million in 2022 and $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="6" id="f-1496">568</ix:nonFraction> million in 2021. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.237%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Commitments as of</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value as of December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Real estate investments</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-369" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1497">1,606</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-370" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1498">1,319</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-369" decimals="-6" name="ci:CommitmentsToContributeAdditionalEquityAndCapital" scale="6" id="f-1499">712</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities partnerships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-371" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1500">2,400</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-372" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1501">2,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-371" decimals="-6" name="ci:CommitmentsToContributeAdditionalEquityAndCapital" format="ixt:num-dot-decimal" scale="6" id="f-1502">2,085</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-373" decimals="-6" name="ci:OtherLongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1503">175</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-374" decimals="-6" name="us-gaap:OtherLongTermInvestments" scale="6" id="f-1504">243</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-373" decimals="-6" name="ci:CommitmentsToContributeAdditionalEquityAndCapital" format="ixt:fixed-zero" scale="6" id="f-1505">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:OtherLongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1506">4,181</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1507">3,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:CommitmentsToContributeAdditionalEquityAndCapital" format="ixt:num-dot-decimal" scale="6" id="f-1508">2,797</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_448"></div><ix:continuation id="f-1290-16" continuedAt="f-1290-17"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Short-term Investments and Cash Equivalents</span></div><ix:continuation id="f-1291-11" continuedAt="f-1291-12"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Security investments with maturities of greater than three months to one year from time of purchase are classified as short-term, available for sale and carried at fair value that approximates cost. Cash equivalents consist of short-term investments with maturities of three months or less from the time of purchase and are carried at cost that approximates fair value.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">107</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_454"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">B.</span><ix:continuation id="f-1290-17" continuedAt="f-1290-18"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Derivative Financial Instruments</span></ix:continuation></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativesPolicyTextBlock" id="f-1509" continuedAt="f-1509-1" escape="true"><ix:continuation id="f-1290-18" continuedAt="f-1290-19"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company uses derivative financial instruments to manage the characteristics of investment assets (such as duration, yield, currency and liquidity) to meet the varying demands of the related insurance and contractholder liabilities. The Company also uses derivative financial instruments to hedge the risk of changes in the net assets of certain of its foreign subsidiaries due to changes in foreign currency exchange rates and to hedge the interest rate risk of certain long-term debt.</span></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_457"></div><ix:continuation id="f-1509-1" continuedAt="f-1509-2"><ix:continuation id="f-1290-19" continuedAt="f-1290-20"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Derivatives are recorded in our Consolidated Balance Sheets at fair value and are classified as current or non-current according to their contractual maturities. Further information on our policies for determining fair value are discussed in Note 13. The Company applies hedge accounting when derivatives are designated, qualified and highly effective as hedges. Under hedge accounting, the changes in fair value of the derivative and the hedged risk are generally recognized together and offset each other when reported in Shareholders' net income. Various qualitative or quantitative methods appropriate for each hedge are used to formally assess and document hedge effectiveness at inception and each period throughout the life of a hedge.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's derivative financial instruments are presented as follows:&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Fair value hedges of the foreign exchange-related changes in fair values of certain foreign-denominated bonds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: Swap fair values are reported in Long-term investments or Other non-current liabilities. Offsetting changes in fair values attributable to the foreign exchange risk of the swap contracts and the hedged bonds are reported in Net realized investment (losses) gains. The portion of the swap contracts' changes in fair value excluded from the assessment of hedge effectiveness is recorded in Other comprehensive loss and recognized in Net investment income as swap coupon payments are accrued, offsetting the foreign-denominated coupons received on the designated bonds. Net cash flows are reported in Operating activities, while exchanges of notional principal amounts are reported in Investing activities.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Fair value hedges of the interest rate exposure on the Company's long-term debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: Using fair value hedge accounting, the fair values of the swap contracts are reported in other assets or other liabilities. The critical terms of these swaps match those of the long-term debt being hedged. As a result, the carrying value of the hedged debt is adjusted to reflect changes in its fair value driven by the SOFR. The effects of those adjustments on interest expense are offset by the effects of corresponding changes in the swaps' fair value. The net impact from the hedge reported in Interest expense and other reflects interest expense on the hedged debt at the variable interest rate. Cash flows relating to these contracts are reported in Operating activities.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Net investment hedges of certain foreign subsidiaries that conduct their business principally in currencies other than the U.S. dollar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: The fair values of the foreign currency swap and forward contracts are reported in other assets or other liabilities. The changes in fair values of these instruments are reported in Other comprehensive loss, specifically in translation of foreign currencies. The portion of the change in fair values relating to foreign exchange spot rates will be recognized in earnings upon deconsolidation of the hedged foreign subsidiaries. The remaining changes in fair value of these instruments are excluded from our effectiveness assessment and recognized in Interest expense and other over the term of the instrument. Cash flows relating to these contracts are reported in Investing activities. </span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_463"></div><ix:continuation id="f-1290-20" continuedAt="f-1290-21"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The effects of derivative financial instruments used in our individual hedging strategies were not material to the Consolidated Financial Statements as of December&#160;31, 2023 and December&#160;31, 2022. The gross fair values of our derivative financial instruments are presented in Note 13 to the Consolidated Financial Statements. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDerivativeInstrumentsTextBlock" id="f-1510" continuedAt="f-1510-1" escape="true">The following table summarizes the types and notional quantity of derivative instruments held by the Company: </ix:nonNumeric></span></div><ix:continuation id="f-1510-1"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.177%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.043%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Value as of</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purpose</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Instrument</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><ix:continuation id="f-1509-2" continuedAt="f-1509-3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;text-decoration:underline">Fair value hedge:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> To hedge the foreign exchange-related changes in fair values of certain foreign-denominated bonds. The notional value of these derivatives matches the amortized cost of the hedged bonds. A majority of these instruments are denominated in Euros, with the remaining instruments denominated in British Pounds Sterling and Australian Dollars.</span></div></ix:continuation></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency swap contracts</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-375" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1511">1,026</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-376" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1512">1,083</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><ix:continuation id="f-1509-3" continuedAt="f-1509-4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Fair value hedge:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> To convert a portion of the interest rate exposure on the Company's long-term debt from fixed to variable rates. This more closely aligns the Company's interest expense with the interest income received on its cash equivalent and short-term investment balances. The variable rates are benchmarked to SOFR.</span></div></ix:continuation></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1513">1,500</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-378" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1514">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><ix:continuation id="f-1509-4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;text-decoration:underline">Net investment hedge:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> To reduce the risk of changes in net assets due to changes in foreign currency spot exchange rates for certain foreign subsidiaries that conduct their business principally in currencies other than the U.S. Dollar. The notional value of hedging instruments matches the hedged amount of subsidiary net assets. Foreign currency swap contracts are denominated in Euros.</span></div></ix:continuation></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency swap contracts </span></div></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-379" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="f-1515">415</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-380" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="f-1516">460</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">108</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_469"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1290-21" continuedAt="f-1290-22"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Concentration of Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company did not have a concentration of investments in a single issuer or borrower exceeding 10% of shareholders' equity as of December&#160;31, 2023 or 2022.</span></div></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_472"></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">C.</span><ix:continuation id="f-1290-22" continuedAt="f-1290-23"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Net Investment Income</span></ix:continuation></div><ix:continuation id="f-1290-23" continuedAt="f-1290-24"><ix:continuation id="f-1291-12" continuedAt="f-1291-13"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> When interest and principal payments on investments are current, the Company recognizes interest income when it is earned. The Company recognizes interest income on a cash basis when interest payments are delinquent based on contractual terms or when certain terms (interest rate or maturity date) of the investment have been restructured. For unconsolidated entities that are included in other long-term investments, investment income is generally recognized according to the Company's share of the reported income or loss on the underlying investments. Investment income attributed to the Company's separate accounts is excluded from our earnings because associated gains and losses generally accrue directly to separate account policyholders.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentIncomeTextBlock" id="f-1523" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The components of Net investment income were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.043%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-381" decimals="-6" name="ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" scale="6" id="f-1524">500</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-382" decimals="-6" name="ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" scale="6" id="f-1525">572</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-383" decimals="-6" name="ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" scale="6" id="f-1526">689</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-384" decimals="-6" name="ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" scale="6" id="f-1527">123</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-6" name="ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" scale="6" id="f-1528">14</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-6" name="ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" scale="6" id="f-1529">12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial mortgage loans</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-387" decimals="-6" name="ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" scale="6" id="f-1530">65</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-388" decimals="-6" name="ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" scale="6" id="f-1531">59</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-389" decimals="-6" name="ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" scale="6" id="f-1532">60</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Policy loans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-390" decimals="-6" name="ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" scale="6" id="f-1533">60</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-391" decimals="-6" name="ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" scale="6" id="f-1534">59</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-392" decimals="-6" name="ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" scale="6" id="f-1535">63</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term investments</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-393" decimals="-6" name="ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" scale="6" id="f-1536">123</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-394" decimals="-6" name="ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" scale="6" id="f-1537">390</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-395" decimals="-6" name="ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" scale="6" id="f-1538">758</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments and cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-396" decimals="-6" name="ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" scale="6" id="f-1539">339</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-397" decimals="-6" name="ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" scale="6" id="f-1540">115</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-398" decimals="-6" name="ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" scale="6" id="f-1541">26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total investment income</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1542">1,210</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1543">1,209</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1544">1,608</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less investment expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:InvestmentIncomeInvestmentExpense" scale="6" id="f-1545">44</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:InvestmentIncomeInvestmentExpense" scale="6" id="f-1546">54</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:InvestmentIncomeInvestmentExpense" scale="6" id="f-1547">59</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:num-dot-decimal" scale="6" id="f-1548">1,166</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:num-dot-decimal" scale="6" id="f-1549">1,155</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:num-dot-decimal" scale="6" id="f-1550">1,549</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_475"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.</span><ix:continuation id="f-1290-24" continuedAt="f-1290-25"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt;text-decoration:underline">Realized Investment Gains and Losses</span></ix:continuation></div><div style="margin-bottom:10pt"><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_478"></div><ix:continuation id="f-1290-25" continuedAt="f-1290-26"><div style="margin-bottom:10pt"><ix:continuation id="f-1291-13" continuedAt="f-1291-14"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy. </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-1291-14">Realized investment gains and losses are based on specifically identified assets and result from sales, investment asset write-downs, change in the fair value of certain derivatives and equity securities and changes in allowances for credit losses on debt securities and commercial mortgage loan investments. With the adoption of amended accounting guidance for long-duration insurance contracts on January 1, 2023 (discussed in Note 2 to the Consolidated Financial Statements), realized investment gains and losses no longer exclude amounts that were previously required to adjust future policy benefits for the run-off settlement annuity business. Prior period net realized investment losses have been updated to reflect the impact of adopting LDTI.</ix:continuation> </span></div></ix:continuation><div id="ibc59a92ac8bc42f794e728f24ce1b626_481"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RealizedGainLossOnInvestmentsTableTextBlock" id="f-1551" escape="true"><ix:continuation id="f-1290-26" continuedAt="f-1290-27"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following realized gains and losses on investments exclude realized gains and losses attributed to the Company's separate accounts because those gains and losses generally accrue directly to separate account policyholders:</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.344%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.042%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net realized investment (losses) gains, excluding credit loss expense and asset write-downs</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="ci:RealizedInvestmentGainLossExcludingImpairments" scale="6" id="f-1552">68</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="ci:RealizedInvestmentGainLossExcludingImpairments" scale="6" id="f-1553">451</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:RealizedInvestmentGainLossExcludingImpairments" scale="6" id="f-1554">196</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Credit (loss) / recovery and other investment write-down (losses)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal" scale="6" id="f-1555">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal" scale="6" id="f-1556">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="ci:DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal" scale="6" id="f-1557">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net realized investment (losses) gains, before income taxes</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="ci:RealizedInvestmentGainLoss" scale="6" id="f-1558">78</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="ci:RealizedInvestmentGainLoss" scale="6" id="f-1559">487</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:RealizedInvestmentGainLoss" scale="6" id="f-1560">198</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-1290-27">Net realized investment losses for the years ended December&#160;31, 2023 and December&#160;31, 2022 were primarily due to mark-to-market losses on a strategic health care equity securities investment.</ix:continuation> </span></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_490"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-1561" continuedAt="f-1561-1" escape="true"><div style="margin-bottom:10pt"><span id="i45a6e991e4ac4434bd4db2e67316940b_1591"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13 &#8211; Fair Value Measurements</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-1562" continuedAt="f-1562-1" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company carries certain financial instruments at fair value in the financial statements including debt securities, certain equity securities, short-term investments and derivatives. Other financial instruments are measured at fair value only under certain conditions, such as when impaired or when there are observable price changes for equity securities with no readily determinable fair value.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value is defined as the price at which an asset could be exchanged in an orderly transaction between market participants at the balance sheet date. A liability's fair value is defined as the amount that would be paid to transfer the liability to a market participant, not the amount that would be paid to settle the liability with the creditor.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1562-1" continuedAt="f-1562-2"><ix:continuation id="f-1561-1" continuedAt="f-1561-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's financial assets and liabilities carried at fair value have been classified based upon a hierarchy defined by GAAP. The hierarchy gives the highest ranking to fair values determined using unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest ranking to fair values determined using methodologies and models with unobservable inputs (Level 3). An asset's or a liability's classification is based on the lowest level of input that is significant to its measurement. For example, a financial asset or liability carried at fair value would be classified in Level 3 if unobservable inputs were significant to the instrument's fair value, even though the measurement may be derived using inputs that are both observable (Levels 1 and 2) and unobservable (Level 3).</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_493"></div><ix:continuation id="f-1562-2" continuedAt="f-1562-3"><ix:continuation id="f-1561-2" continuedAt="f-1561-3"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company estimates fair values using prices from third parties or internal pricing methods. Fair value estimates received from third-party pricing services are based on reported trade activity and quoted market prices when available and other market information that a market participant would use to estimate fair value. The internal pricing methods are performed by the Company's investment professionals and generally involve using discounted cash flow analyses, incorporating current market inputs for similar financial instruments with comparable terms and credit quality as well as other qualitative factors. In instances where there is little or no market activity for the same or similar instruments, fair value is estimated using methods, models and assumptions that the Company believes a hypothetical market participant would use to determine a current transaction price. These valuation techniques involve some level of estimation and judgment that becomes significant with increasingly complex instruments or pricing models.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is responsible for determining fair value and for assigning the appropriate level within the fair value hierarchy based on the significance of unobservable inputs. The Company reviews methodologies, processes and controls of third-party pricing services and compares prices on a test basis to those obtained from other external pricing sources or internal estimates. The Company performs ongoing analyses of both prices received from third-party pricing services and those developed internally to determine that they represent appropriate estimates of fair value. The controls executed by the Company include evaluating changes in prices and monitoring for potentially stale valuations. The Company also performs sample testing of sales values to confirm the accuracy of prior fair value estimates. The minimal exceptions identified during these processes indicate that adjustments to prices are infrequent and do not significantly impact valuations. An annual due-diligence review of the most significant pricing service is conducted to review their processes, methodologies and controls. This review includes a walk-through of inputs for a sample of securities held across various asset types to validate the documented pricing process.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_499"></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">A.</span><ix:continuation id="f-1561-3" continuedAt="f-1561-4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Financial Assets and Financial Liabilities Carried at Fair Value</span></ix:continuation></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="f-1563" escape="true"><ix:continuation id="f-1561-4" continuedAt="f-1561-5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides information about the Company's financial assets and liabilities carried at fair value. Further information regarding insurance assets and liabilities carried at fair value is provided in Note 10E to the Consolidated Financial Statements. Separate account assets are also recorded at fair value on the Company's Consolidated Balance Sheets and are reported separately in the Separate Accounts section below as gains and losses related to these assets generally accrue directly to contractholders:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial assets at fair value</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal government and agency</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-399" decimals="-6" name="ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1564">130</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-400" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-1565">147</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-401" decimals="-6" name="ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1566">137</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-402" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-1567">165</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-403" decimals="-6" name="ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:fixed-zero" scale="6" id="f-1568">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-404" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-1569">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-405" decimals="-6" name="ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1570">267</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-406" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-1571">312</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State and local government</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-407" decimals="-6" name="ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:fixed-zero" scale="6" id="f-1572">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-408" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-1573">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-409" decimals="-6" name="ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1574">38</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-410" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-1575">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-411" decimals="-6" name="ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:fixed-zero" scale="6" id="f-1576">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-412" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-1577">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-413" decimals="-6" name="ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1578">38</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-414" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-1579">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-415" decimals="-6" name="ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:fixed-zero" scale="6" id="f-1580">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-416" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-1581">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-417" decimals="-6" name="ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1582">352</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-418" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-1583">365</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-419" decimals="-6" name="ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:fixed-zero" scale="6" id="f-1584">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-420" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-1585">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-421" decimals="-6" name="ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1586">352</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-422" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-1587">365</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-423" decimals="-6" name="ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:fixed-zero" scale="6" id="f-1588">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-424" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-1589">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-425" decimals="-6" name="ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1590">8,432</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-426" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-1591">8,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-427" decimals="-6" name="ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1592">401</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-428" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-1593">412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-429" decimals="-6" name="ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1594">8,833</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-430" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-1595">8,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset-backed</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-431" decimals="-6" name="ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:fixed-zero" scale="6" id="f-1596">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-432" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-1597">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-433" decimals="-6" name="ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1598">319</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-434" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-1599">313</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-435" decimals="-6" name="ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1600">46</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-436" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-1601">35</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-437" decimals="-6" name="ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1602">365</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-438" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-1603">348</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-439" decimals="-6" name="ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1604">130</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-1605">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-6" name="ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1606">9,278</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-1607">9,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-6" name="ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1608">447</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-1609">447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-445" decimals="-6" name="ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1610">9,855</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-446" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-1611">9,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-439" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="f-1612">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="f-1613">6</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="f-1614">47</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="f-1615">132</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="6" id="f-1616">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="6" id="f-1617">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-445" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="f-1618">51</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-446" decimals="-6" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="6" id="f-1619">138</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-439" decimals="-6" name="us-gaap:OtherShortTermInvestments" format="ixt:fixed-zero" scale="6" id="f-1620">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-6" name="us-gaap:OtherShortTermInvestments" format="ixt:fixed-zero" scale="6" id="f-1621">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-6" name="us-gaap:OtherShortTermInvestments" scale="6" id="f-1622">206</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-6" name="us-gaap:OtherShortTermInvestments" scale="6" id="f-1623">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-6" name="us-gaap:OtherShortTermInvestments" format="ixt:fixed-zero" scale="6" id="f-1624">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-6" name="us-gaap:OtherShortTermInvestments" format="ixt:fixed-zero" scale="6" id="f-1625">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-445" decimals="-6" name="us-gaap:OtherShortTermInvestments" scale="6" id="f-1626">206</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-446" decimals="-6" name="us-gaap:OtherShortTermInvestments" scale="6" id="f-1627">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-447" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="f-1628">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-448" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="f-1629">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-449" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="f-1630">131</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-450" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="f-1631">230</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-451" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="f-1632">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-452" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="f-1633">1</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-453" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="f-1634">132</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-454" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="f-1635">231</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial liabilities at fair value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-447" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="f-1636">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-448" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="f-1637">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-449" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="f-1638">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-450" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="f-1639">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-451" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="f-1640">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-452" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="f-1641">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-453" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="f-1642">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-454" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="f-1643">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Excludes certain equity securities that have no readily determinable fair value.</span></div></ix:continuation></ix:nonNumeric><div style="margin-bottom:10pt;padding-left:13.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">110</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_502"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1562-3" continuedAt="f-1562-4"><ix:continuation id="f-1561-5" continuedAt="f-1561-6"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Level 1 Financial Assets</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inputs for instruments classified in Level 1 include unadjusted quoted prices for identical assets in active markets accessible at the measurement date. Active markets provide pricing data for trades occurring at least weekly and include exchanges and dealer markets.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Assets in Level 1 include actively-traded U.S. government bonds and exchange-listed equity securities. A relatively small portion of the Company's investment assets are classified in this category given the narrow definition of Level 1 and the Company's investment asset strategy to maximize investment returns.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Level 2 Financial Assets and Financial Liabilities</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inputs for instruments classified in Level 2 include quoted prices for similar assets or liabilities in active markets, quoted prices from those willing to trade in markets that are not active or other inputs that are market observable or can be corroborated by market data for the term of the instrument. Such other inputs include market interest rates and volatilities, spreads and yield curves. An instrument is classified in Level 2 if the Company determines that unobservable inputs are insignificant.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Debt and equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Approximately <ix:nonFraction unitRef="number" contextRef="c-12" decimals="2" name="ci:DebtAndEquitySecuritiesClassifiedInLevel2PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="-2" id="f-1644">94</ix:nonFraction>% of the Company's investments in debt and equity securities are classified in Level 2 including most public and private corporate debt and equity securities, federal agency and municipal bonds, non-government mortgage-backed securities and preferred stocks. Third-party pricing services and internal methods often use recent trades of securities with similar features and characteristics because many debt securities do not trade daily. Pricing models are used to determine these prices when recent trades are not available. These models calculate fair values by discounting future cash flows at estimated market interest rates. Such market rates are derived by calculating the appropriate spreads over comparable U.S. Treasury securities based on the credit quality, industry and structure of the asset. Typical inputs and assumptions to pricing models include, but are not limited to, a combination of benchmark yields, reported trades, issuer spreads, liquidity, benchmark securities, bids, offers, reference data and industry and economic events. For mortgage-backed securities, inputs and assumptions may also include characteristics of the issuer, collateral attributes, prepayment speeds and credit rating. Nearly all of these instruments are valued using recent trades or pricing models. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Short-term investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> are carried at fair value that approximates cost. The Company compares market prices for these securities to recorded amounts on a regular basis to validate that current carrying amounts approximate exit prices. The short-term nature of the investments and corroboration of the reported amounts over the holding period support their classification in Level 2.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Derivative assets and liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> classified in Level 2 represent over-the-counter instruments such as foreign currency forward and swap contracts. Fair values for these instruments are determined using market observable inputs including forward currency and interest rate curves and widely published market observable indices. Credit risk related to the counterparty and the Company is considered when estimating the fair values of these derivatives. However, the Company is largely protected by collateral arrangements with counterparties and determined that <ix:nonFraction unitRef="usd" contextRef="c-455" decimals="INF" name="us-gaap:DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities" format="ixt:fixed-zero" scale="0" id="f-1645"><ix:nonFraction unitRef="usd" contextRef="c-455" decimals="INF" name="us-gaap:DerivativeCreditRiskValuationAdjustmentDerivativeAssets" format="ixt:fixed-zero" scale="0" id="f-1646"><ix:nonFraction unitRef="usd" contextRef="c-456" decimals="INF" name="us-gaap:DerivativeCreditRiskValuationAdjustmentDerivativeAssets" format="ixt:fixed-zero" scale="0" id="f-1647"><ix:nonFraction unitRef="usd" contextRef="c-456" decimals="INF" name="us-gaap:DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities" format="ixt:fixed-zero" scale="0" id="f-1648">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> adjustments for credit risk were required as of December&#160;31, 2023 or December&#160;31, 2022. The nature and use of these derivative financial instruments are described in Note 12.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_505"></div><ix:continuation id="f-1562-4" continuedAt="f-1562-5"><ix:continuation id="f-1561-6" continuedAt="f-1561-7"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Level 3 Financial Assets and Financial Liabilities</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain inputs for instruments classified in Level 3 are unobservable (supported by little or no market activity) and significant to their resulting fair value measurement. Unobservable inputs reflect the Company's best estimate of what hypothetical market participants would use to determine a transaction price for the asset or liability at the reporting date. Additionally, as discussed in Note 10E to the Consolidated Financial Statements, the Company classifies variable annuity assets and liabilities in Level 3 of the fair value hierarchy.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_508"></div><ix:continuation id="f-1562-5" continuedAt="f-1562-6"><ix:continuation id="f-1561-7" continuedAt="f-1561-8"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company classifies certain newly-issued, privately-placed, complex or illiquid securities in Level 3. Approximately <ix:nonFraction unitRef="number" contextRef="c-12" decimals="2" name="ci:DebtAndEquitySecuritiesClassifiedInLevel3PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="-2" id="f-1649">5</ix:nonFraction>% of debt and equity securities are priced using significant unobservable inputs and classified in this category.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair values of mortgage and other asset-backed securities, as well as corporate and government debt securities, are primarily determined using pricing models that incorporate the specific characteristics of each asset and related assumptions including the investment type and structure, credit quality, industry and maturity date in comparison to current market indices, spreads and liquidity of assets with similar characteristics. Inputs and assumptions for pricing may also include characteristics of the issuer, collateral attributes and prepayment speeds for mortgage and other asset-backed securities. Recent trades in the subject security or similar securities are assessed when available, and the Company may also review published research in its evaluation, as well as the issuer's financial statements.</span></div></ix:continuation></ix:continuation><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">111</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_511"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1561-8" continuedAt="f-1561-9"><ix:continuation id="f-1562-6" continuedAt="f-1562-7"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Quantitative Information about Unobservable Inputs</span></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-1562-7" continuedAt="f-1562-8">The significant unobservable input used to value our corporate and government debt securities and mortgage and other asset-backed securities is an adjustment for liquidity. This adjustment is needed to reflect current market conditions and issuer circumstances when there is limited trading activity for the security.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="f-1650" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the fair value and significant unobservable inputs that were developed directly by the Company and used in pricing these debt securities. The range and weighted average basis point amounts for liquidity reflect the Company's best estimates of the unobservable adjustments a market participant would make to calculate these fair values. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.094%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.101%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value as of</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Adjustment Range (Weighted Average by Quantity) as of</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Fair value in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-457" decimals="-6" name="ci:MarketableSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1651">401</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-458" decimals="-6" name="us-gaap:MarketableSecurities" scale="6" id="f-1652">412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liquidity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-459" decimals="4" name="ci:DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput" scale="-4" id="f-1653">70</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="c-460" decimals="4" name="ci:DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput" scale="-4" id="f-1654">1235</ix:nonFraction> (<ix:nonFraction unitRef="number" contextRef="c-461" decimals="4" name="ci:DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput" scale="-4" id="f-1655">310</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">bps</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-462" decimals="4" name="us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput" scale="-4" id="f-1656">60</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="c-463" decimals="4" name="us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput" scale="-4" id="f-1657">1060</ix:nonFraction> (<ix:nonFraction unitRef="number" contextRef="c-464" decimals="4" name="us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput" scale="-4" id="f-1658">270</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset-backed securities</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-465" decimals="-6" name="ci:MarketableSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1659">46</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-466" decimals="-6" name="us-gaap:MarketableSecurities" scale="6" id="f-1660">35</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liquidity</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-467" decimals="4" name="ci:DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput" scale="-4" id="f-1661">95</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="c-468" decimals="4" name="ci:DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput" scale="-4" id="f-1662">640</ix:nonFraction> (<ix:nonFraction unitRef="number" contextRef="c-469" decimals="4" name="ci:DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput" scale="-4" id="f-1663">310</ix:nonFraction>) </span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">bps</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-470" decimals="4" name="us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput" scale="-4" id="f-1664">105</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="c-471" decimals="4" name="us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput" scale="-4" id="f-1665">520</ix:nonFraction> (<ix:nonFraction unitRef="number" contextRef="c-472" decimals="4" name="us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput" scale="-4" id="f-1666">310</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Level 3 debt securities</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-473" decimals="-6" name="ci:MarketableSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1667">447</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-474" decimals="-6" name="us-gaap:MarketableSecurities" scale="6" id="f-1668">447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">An increase in liquidity spread adjustments would result in a lower fair value measurement, while a decrease would result in a higher fair value measurement.</span></div></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_514"></div><ix:continuation id="f-1561-9" continuedAt="f-1561-10"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value</span></div><ix:nonNumeric contextRef="c-1" name="ci:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" id="f-1669" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the changes in financial assets and financial liabilities classified in Level 3. Gains and losses reported in the table may include net changes in fair value that are attributable to both observable and unobservable inputs.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.066%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.041%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt and Equity Securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-475" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="f-1670">447</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-476" decimals="-6" name="ci:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1671">796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Losses) gains included in Shareholders' net income</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-477" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="6" id="f-1672">2</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-478" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="6" id="f-1673">11</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) included in Other comprehensive loss</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-477" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" scale="6" id="f-1674">8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-478" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" scale="6" id="f-1675">59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchases, sales and settlements</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-477" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" scale="6" id="f-1676">10</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-478" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" scale="6" id="f-1677">158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-477" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" scale="6" id="f-1678">52</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-478" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" scale="6" id="f-1679">207</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total purchases, sales and settlements</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-477" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" scale="6" id="f-1680">42</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-478" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" scale="6" id="f-1681">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Transfers into/(out of) Level 3</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transfers into Level 3</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-477" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" scale="6" id="f-1682">95</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-478" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" scale="6" id="f-1683">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transfers out of Level 3</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-477" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" scale="6" id="f-1684">59</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-478" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" scale="6" id="f-1685">376</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total transfers into/(out of) Level 3</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-477" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" scale="6" id="f-1686">36</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-478" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" scale="6" id="f-1687">252</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-479" decimals="-6" name="ci:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" scale="6" id="f-1688">447</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-475" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="f-1689">447</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total losses included in Shareholders' net income attributable to instruments held at the reporting date</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-477" decimals="-6" sign="-" name="ci:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAttributedToInstrumentsHeldIncludedInEarnings" scale="6" id="f-1690">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-478" decimals="-6" sign="-" name="ci:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAttributedToInstrumentsHeldIncludedInEarnings" scale="6" id="f-1691">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in unrealized gain or (loss) included in Other comprehensive loss for assets held at the end of the reporting period</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss" scale="6" id="f-1692">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="ci:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss" scale="6" id="f-1693">60</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:continuation id="f-1562-8" continuedAt="f-1562-9"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total gains and losses included in Shareholders' net income in the tables above are reflected in the Consolidated Statements of Income as Net realized investment (losses) gains and Net investment income.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gains and losses included in Other comprehensive loss, net of tax in the tables above are reflected in Net unrealized appreciation (depreciation) on securities and derivatives in the Consolidated Statements of Comprehensive Income.</span></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1562-9" continuedAt="f-1562-10">Transfers into or out of the Level 3 category occur when unobservable inputs, such as the Company's best estimate of what a market participant would use to determine a current transaction price, become more or less significant to the fair value measurement. Market activity typically decreases during periods of economic uncertainty and this decrease in activity reduces the availability of market observable data. As a result, the level of unobservable judgment that must be applied to the pricing of certain instruments increases and is typically observed through the widening of liquidity spreads</ix:continuation>. Transfers between Level 2 and Level 3 during 2023 and 2022 primarily reflected changes in liquidity estimates for certain private placement issuers across several sectors. See discussion under Quantitative Information about Unobservable Inputs above for more information.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_520"></div><ix:continuation id="f-1561-10" continuedAt="f-1561-11"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Separate Accounts</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PolicyholderAccountsPolicy" id="f-1694" continuedAt="f-1694-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Separate account assets and liabilities are contractholder funds maintained in accounts with specific investment objectives. The assets of these accounts are legally segregated and are not subject to claims that arise out of any of the Company's other businesses. These separate account assets are carried at fair value with equal amounts recorded for related separate account liabilities. The investment income and fair value gains and losses of separate account assets generally accrue directly to the contractholders and, together with their deposits and withdrawals, are excluded from the Company's Consolidated Statements of Income and Cash Flows. Fees and charges earned for mortality risks, asset management or administrative services are reported in either Premiums or Fees and other revenues. Investments that are measured using the practical expedient of net asset value ("NAV") are excluded from the fair value hierarchy. The separate account activity for the year ended December&#160;31, 2023 and 2022 was primarily driven by changes in the market values of the underlying separate account investments.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_523"></div><ix:nonNumeric contextRef="c-1" name="ci:FairValueOfSeparateAccountAssetsTableTextBlock" id="f-1695" escape="true"><ix:continuation id="f-1561-11" continuedAt="f-1561-12"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair values of Separate account assets were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Guaranteed separate accounts (See Note 24)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-480" decimals="-6" name="ci:GuaranteedSeparateAccountAssets" scale="6" id="f-1696">226</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-481" decimals="-6" name="ci:GuaranteedSeparateAccountAssets" scale="6" id="f-1697">203</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-482" decimals="-6" name="ci:GuaranteedSeparateAccountAssets" scale="6" id="f-1698">352</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-483" decimals="-6" name="ci:GuaranteedSeparateAccountAssets" scale="6" id="f-1699">382</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-484" decimals="-6" name="ci:GuaranteedSeparateAccountAssets" format="ixt:fixed-zero" scale="6" id="f-1700">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-485" decimals="-6" name="ci:GuaranteedSeparateAccountAssets" format="ixt:fixed-zero" scale="6" id="f-1701">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:GuaranteedSeparateAccountAssets" scale="6" id="f-1702">578</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:GuaranteedSeparateAccountAssets" scale="6" id="f-1703">585</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-guaranteed separate accounts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-480" decimals="-6" name="ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy" scale="6" id="f-1704">158</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-481" decimals="-6" name="ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy" scale="6" id="f-1705">211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-482" decimals="-6" name="ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy" format="ixt:num-dot-decimal" scale="6" id="f-1706">5,797</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-483" decimals="-6" name="ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy" format="ixt:num-dot-decimal" scale="6" id="f-1707">5,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-484" decimals="-6" name="ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy" scale="6" id="f-1708">217</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-485" decimals="-6" name="ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy" scale="6" id="f-1709">203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy" format="ixt:num-dot-decimal" scale="6" id="f-1710">6,172</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy" format="ixt:num-dot-decimal" scale="6" id="f-1711">5,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-480" decimals="-6" name="ci:SeparateAccountAssetsClassifiedInFairValueHierarchy" scale="6" id="f-1712">384</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-481" decimals="-6" name="ci:SeparateAccountAssetsClassifiedInFairValueHierarchy" scale="6" id="f-1713">414</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-482" decimals="-6" name="ci:SeparateAccountAssetsClassifiedInFairValueHierarchy" format="ixt:num-dot-decimal" scale="6" id="f-1714">6,149</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-483" decimals="-6" name="ci:SeparateAccountAssetsClassifiedInFairValueHierarchy" format="ixt:num-dot-decimal" scale="6" id="f-1715">5,904</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-484" decimals="-6" name="ci:SeparateAccountAssetsClassifiedInFairValueHierarchy" scale="6" id="f-1716">217</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-485" decimals="-6" name="ci:SeparateAccountAssetsClassifiedInFairValueHierarchy" scale="6" id="f-1717">203</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:SeparateAccountAssetsClassifiedInFairValueHierarchy" format="ixt:num-dot-decimal" scale="6" id="f-1718">6,750</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:SeparateAccountAssetsClassifiedInFairValueHierarchy" format="ixt:num-dot-decimal" scale="6" id="f-1719">6,521</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-guaranteed separate accounts priced at NAV as a practical expedient </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:NonGuaranteedSeparateAccountAssetsPricedAtNetAssetValueAsAPracticalExpedient" scale="6" id="f-1720">680</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:NonGuaranteedSeparateAccountAssetsPricedAtNetAssetValueAsAPracticalExpedient" scale="6" id="f-1721">757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:num-dot-decimal" scale="6" id="f-1722">7,430</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:SeparateAccountAssets" format="ixt:num-dot-decimal" scale="6" id="f-1723">7,278</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Non-guaranteed separate accounts include $<ix:nonFraction unitRef="usd" contextRef="c-486" decimals="-8" name="ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy" format="ixt:num-dot-decimal" scale="9" id="f-1724"><ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-8" name="ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy" format="ixt:num-dot-decimal" scale="9" id="f-1725">4.0</ix:nonFraction></ix:nonFraction> billion as of December&#160;31, 2023 and December&#160;31, 2022 in assets supporting the Company's pension plans, including $<ix:nonFraction unitRef="usd" contextRef="c-488" decimals="-8" name="ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy" format="ixt:num-dot-decimal" scale="9" id="f-1726"><ix:nonFraction unitRef="usd" contextRef="c-489" decimals="-8" name="ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy" format="ixt:num-dot-decimal" scale="9" id="f-1727">0.2</ix:nonFraction></ix:nonFraction> billion classified in Level 3 as of December&#160;31, 2023 and December&#160;31, 2022.</span></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_526"></div><ix:continuation id="f-1694-1" continuedAt="f-1694-2"><ix:continuation id="f-1561-12" continuedAt="f-1561-13"><div style="margin-bottom:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Separate account assets classified as Level 1 primarily include exchange-listed equity securities. Level 2 assets primarily include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">corporate and structured bonds valued using recent trades of similar securities or pricing models that discount future cash flows at estimated market interest rates as described above; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">actively-traded institutional and retail mutual fund investments.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_6456"></div><ix:continuation id="f-1561-13" continuedAt="f-1561-14"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-1694-2" continuedAt="f-1694-3">Separate account assets classified in Level 3 primarily support the Company's pension plans and include certain newly-issued, privately-placed, complex or illiquid securities that are priced using methods discussed above, as well as commercial mortgage loans.</ix:continuation> Activity, including transfers into and out of Level 3, was not material for the years ended December&#160;31, 2023 or 2022. </span></div></ix:continuation><div style="margin-bottom:10pt"><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_529"></div><ix:continuation id="f-1561-14" continuedAt="f-1561-15"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTableTextBlock" id="f-1728" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-1694-3">Separate account investments in securities partnerships, real estate and hedge funds are generally valued based on the separate account's ownership share of the equity of the investee (NAV as a practical expedient), including changes in the fair values of its underlying investments</ix:continuation>. Substantially all of these assets support the Company's pension plans. The following table provides additional information on these investments:</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.322%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value as of</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Commitment as of December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Redemption Frequency<br/>(if currently eligible)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Redemption Notice<br/>Period</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities partnerships</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-490" decimals="-6" name="us-gaap:AlternativeInvestment" scale="6" id="f-1729">419</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-491" decimals="-6" name="us-gaap:AlternativeInvestment" scale="6" id="f-1730">451</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-492" decimals="-6" name="us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" scale="6" id="f-1731">254</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Not applicable</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Not applicable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Real estate funds</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-493" decimals="-6" name="us-gaap:AlternativeInvestment" scale="6" id="f-1732">258</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-494" decimals="-6" name="us-gaap:AlternativeInvestment" scale="6" id="f-1733">302</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-495" decimals="-6" name="us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" format="ixt:fixed-zero" scale="6" id="f-1734">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quarterly</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-496" name="us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1" format="ixt-sec:durday" id="f-1735">30</ix:nonNumeric> - <ix:nonNumeric contextRef="c-497" name="us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1" format="ixt-sec:durday" id="f-1736">90</ix:nonNumeric> days</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-498" decimals="-6" name="us-gaap:AlternativeInvestment" scale="6" id="f-1737">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-499" decimals="-6" name="us-gaap:AlternativeInvestment" scale="6" id="f-1738">4</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-500" decimals="-6" name="us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" format="ixt:fixed-zero" scale="6" id="f-1739">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Up to annually, varying by fund</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-501" name="us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1" format="ixt-sec:durday" id="f-1740">30</ix:nonNumeric> - <ix:nonNumeric contextRef="c-502" name="us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1" format="ixt-sec:durday" id="f-1741">90</ix:nonNumeric> days</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-503" decimals="-6" name="us-gaap:AlternativeInvestment" scale="6" id="f-1742">680</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-504" decimals="-6" name="us-gaap:AlternativeInvestment" scale="6" id="f-1743">757</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-505" decimals="-6" name="us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" scale="6" id="f-1744">254</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, the Company does not have plans to sell any of these assets at less than fair value. These investments are structured to satisfy longer-term investment objectives. Securities partnerships are contractually non-redeemable and the underlying investment assets are expected to be liquidated by the fund managers within <ix:nonNumeric contextRef="c-506" name="ci:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLiquidatingInvestmentPeriodFromInceptionSecuritiesPartnerships" format="ixt-sec:durwordsen" id="f-1745">ten years</ix:nonNumeric> after inception.</span></div></ix:continuation><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">113</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_532"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">B.</span><ix:continuation id="f-1562-10" continuedAt="f-1562-11"><ix:continuation id="f-1561-15" continuedAt="f-1561-16"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Assets and Liabilities Measured at Fair Value under Certain Conditions</span></ix:continuation></ix:continuation></div><ix:continuation id="f-1561-16" continuedAt="f-1561-17"><ix:continuation id="f-1562-11"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Some financial assets and liabilities are not carried at fair value, such as commercial mortgage loans that are carried at unpaid principal, investment real estate that is carried at depreciated cost and equity securities with no readily determinable fair value when there are no observable market transactions. However, these financial assets and liabilities may be measured using fair value under certain conditions, such as when investments become impaired and are written down to their fair value, or when there are observable price changes from orderly market transactions of equity securities that otherwise had no readily determinable fair value.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the years ended December&#160;31, 2023 and 2022, realized investment gains and losses, including those from impairments recognized and observable price changes, were not material. </span></div></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_535"></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">C.</span><ix:continuation id="f-1561-17" continuedAt="f-1561-18"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Fair Value Disclosures for Financial Instruments Not Carried at Fair Value</span></ix:continuation></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="f-1746" escape="true"><ix:continuation id="f-1561-18"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table includes the Company's financial instruments not recorded at fair value but for which fair value disclosure is required. In addition to universal life products and finance leases, financial instruments that are carried in the Company's Consolidated Balance Sheets at amounts that approximate fair value are excluded from the following table:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.045%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification in Fair Value Hierarchy</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial mortgage loans</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-507" decimals="-6" name="ci:MortgageLoansOnRealEstateCommercialAndConsumerNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1747">1,430</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-508" decimals="-6" name="ci:MortgageLoansOnRealEstateCommercialAndConsumerNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-1748">1,533</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-509" decimals="-6" name="us-gaap:MortgageLoansOnRealEstateCommercialAndConsumerNet" format="ixt:num-dot-decimal" scale="6" id="f-1749">1,491</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-510" decimals="-6" name="us-gaap:MortgageLoansOnRealEstateCommercialAndConsumerNet" format="ixt:num-dot-decimal" scale="6" id="f-1750">1,614</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt, including current maturities, excluding finance leases</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-511" decimals="-6" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-1751">28,033</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-508" decimals="-6" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-1752">29,585</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-512" decimals="-6" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-1753">28,653</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-510" decimals="-6" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-1754">30,994</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_547"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="f-1761" continuedAt="f-1761-1" escape="true"><div><span id="ie01e129ab42145fc8bf7e377e885a1a4_13"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14 &#8211; Variable Interest Entities</span></div></ix:nonNumeric><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_553"></div><ix:continuation id="f-1761-1" continuedAt="f-1761-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="f-1762" continuedAt="f-1762-1" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">When the Company becomes involved with a variable interest entity and when there is a change in the Company's involvement with an entity, the Company must determine if it is the primary beneficiary and must consolidate the entity. The Company is considered the primary beneficiary if it has the power to direct the entity's most significant economic activities and has the right to receive benefits or obligation to absorb losses that could be significant to the entity. The Company evaluates the following criteria:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the structure and purpose of the entity;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the risks and rewards created by and shared through the entity; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the Company's ability to direct its activities, receive its benefits and absorb its losses relative to the other parties involved with the entity including its sponsors, equity holders, guarantors, creditors and servicers. </span></div></ix:nonNumeric><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company determined it was <ix:nonFraction unitRef="entity" contextRef="c-515" decimals="0" name="ci:VariableInterestEntitiesNumberOfEntities" format="ixt:fixed-zero" scale="0" id="f-1763"><ix:nonFraction unitRef="entity" contextRef="c-516" decimals="0" name="ci:VariableInterestEntitiesNumberOfEntities" format="ixt:fixed-zero" scale="0" id="f-1764">no</ix:nonFraction></ix:nonFraction>t a primary beneficiary in any material variable interest entity as of December&#160;31, 2023 or 2022. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's involvement in variable interest entities for which it is not the primary beneficiary is described below.</span></div><div><ix:continuation id="f-1762-1" continuedAt="f-1762-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Securities limited partnerships and real estate limited partnerships</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-1762-2" continuedAt="f-1762-3">. The Company owns interests in securities limited partnerships and real estate limited partnerships that are defined as unconsolidated variable interest entities. These partnerships invest in the equity or mezzanine debt of privately-held companies and real estate properties. General partners unaffiliated with the Company control decisions that most significantly impact the partnership's operations and the limited partners do not have substantive kick-out or participating rights. The Company has invested in approximately <ix:nonFraction unitRef="limitedpartnership" contextRef="c-517" decimals="0" name="ci:VariableInterestEntitiesNumberOfEntities" scale="0" id="f-1765">190</ix:nonFraction> limited partnerships that have a carrying value of $<ix:nonFraction unitRef="usd" contextRef="c-517" decimals="-8" name="us-gaap:NoncontrollingInterestInVariableInterestEntity" format="ixt:num-dot-decimal" scale="9" id="f-1766">2.9</ix:nonFraction> billion as of December&#160;31, 2023 reported in other long-term investments.</ix:continuation> As of December&#160;31, 2023, we have commitments to contribute an additional $<ix:nonFraction unitRef="usd" contextRef="c-518" decimals="-8" name="us-gaap:OtherCommitment" format="ixt:num-dot-decimal" scale="9" id="f-1767">2.6</ix:nonFraction> billion to these entities and the Company's maximum exposure to loss from these investments is $<ix:nonFraction unitRef="usd" contextRef="c-517" decimals="-8" name="us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount" format="ixt:num-dot-decimal" scale="9" id="f-1768">5.5</ix:nonFraction> billion, calculated as the sum of our carrying value and the additional funding commitments. Our noncontrolling interest in each of these limited partnerships is generally less than <ix:nonFraction unitRef="number" contextRef="c-519" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-1769">8</ix:nonFraction>% of the partnership ownership interests. See Note 12 for further information on the Company's accounting policy for other long-term investments. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has guaranteed debt payments to mortgage lenders for certain real estate limited partnerships should potential environmental obligations arise. <ix:nonFraction unitRef="usd" contextRef="c-520" decimals="-6" name="us-gaap:GuarantyLiabilities" format="ixt:fixed-zero" scale="6" id="f-1770">No</ix:nonFraction> liability has been incurred related to these guarantees, and the Company's maximum exposure to these guarantees was approximately $<ix:nonFraction unitRef="usd" contextRef="c-520" decimals="-6" name="us-gaap:GuaranteeObligationsMaximumExposure" format="ixt:num-dot-decimal" scale="6" id="f-1771">488</ix:nonFraction> million as of December&#160;31, 2023.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other variable interest entities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The Company is involved in other types of variable interest entities, including certain asset-backed and corporate securities, real estate joint ventures that develop properties for residential and commercial use, independent physician associations ("IPAs") that provide care management services and international health care joint ventures. As of December&#160;31, 2023, the Company's maximum exposure to loss is $<ix:nonFraction unitRef="usd" contextRef="c-521" decimals="-8" name="us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount" format="ixt:num-dot-decimal" scale="9" id="f-1772">0.5</ix:nonFraction> billion from certain asset-backed and corporate securities and $<ix:nonFraction unitRef="usd" contextRef="c-520" decimals="-8" name="us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount" format="ixt:num-dot-decimal" scale="9" id="f-1773">0.9</ix:nonFraction> billion from real estate joint ventures, which represents the sum of our carrying value and the additional funding commitments for these entities. The </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1761-2"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">carrying values and maximum exposures for the remaining unconsolidated variable interest entities were not material as of December&#160;31, 2023.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has not provided, and does not intend to provide, financial support to any of the variable interest entities in excess of its maximum exposure.<ix:continuation id="f-1762-3"> We perform ongoing qualitative analyses of our involvement with these variable interest entities to determine if consolidation is required.</ix:continuation></span></div></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_559"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="f-1776" escape="true"><div style="margin-bottom:10pt"><span id="ie9e3a7152b194e0d81f599bfea9605e2_2394"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 15 &#8211; Collectively Significant Operating Unconsolidated Subsidiaries</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to equity method investments, including certain limited partnerships and limited liability companies holding real estate, securities or loans (as disclosed in Note 12), we maintain a portfolio of operating joint ventures accounted for as equity method investments. Operating joint ventures accounted for under the equity method had a carrying value of $<ix:nonFraction unitRef="usd" contextRef="c-523" decimals="-6" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1777">911</ix:nonFraction> million as of December&#160;31, 2023 and $<ix:nonFraction unitRef="usd" contextRef="c-524" decimals="-6" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1778">734</ix:nonFraction> million as of December&#160;31, 2022, of which $<ix:nonFraction unitRef="usd" contextRef="c-525" decimals="-6" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1779">214</ix:nonFraction> million as of December&#160;31, 2023 and $<ix:nonFraction unitRef="usd" contextRef="c-526" decimals="-6" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1780">602</ix:nonFraction> million as of December&#160;31, 2022 related to our joint venture in China. Total Accumulated Other Comprehensive Income ("AOCI") includes losses of $<ix:nonFraction unitRef="usd" contextRef="c-523" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-1781">510</ix:nonFraction>&#160;million as of December&#160;31, 2023 and $<ix:nonFraction unitRef="usd" contextRef="c-524" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-1782">88</ix:nonFraction>&#160;million as of December&#160;31, 2022 related to the Company's share from unconsolidated entities reported on the equity method primarily driven by the requirement to update discount rate assumptions for certain long-duration liabilities following the adoption of LDTI (discussed in Note 2 to the Consolidated Financial Statements).</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the years ended December 31, 2023, 2022 and 2021, none of our unconsolidated subsidiary investments were individually significant.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy. </span><ix:nonNumeric contextRef="c-1" name="us-gaap:EquityMethodInvestmentsPolicy" id="f-1783" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We record in our Consolidated Statements of Income our proportionate share of net income or loss generated by equity method operating joint ventures within Fees and other revenues. In certain instances, income or loss is reported on a one month lag due to the timing of when financial information is received.</span></ix:nonNumeric></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EquityMethodInvestmentsTextBlock" id="f-1784" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The below summarized results of operations and financial position of the operating joint venture investments accounted for under the equity method reflects the latest available financial information and does not represent the Company's proportionate share of the assets, liabilities or earnings of such entities. Prior period operating joint venture amounts have been retrospectively restated to reflect the adoption of amended accounting guidance for long-duration insurance contracts, as discussed in Note 2 to the Consolidated Financial Statements. </span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-527" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1785">5,962</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-528" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1786">4,665</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-529" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1787">3,750</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-527" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="f-1788">98</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-528" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="f-1789">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-529" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="f-1790">180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.288%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.430%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-530" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-1791">26,681</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-531" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-1792">21,026</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-530" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-1793">25,534</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-531" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-1794">19,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_562"></div><ix:nonNumeric contextRef="c-1" name="ci:AccumulatedOtherComprehensiveIncomeDisclosureTextBlock" id="f-1795" continuedAt="f-1795-1" escape="true"><div style="margin-bottom:10pt"><span id="i28e542229591430e91381eec66292ee8_1746"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 16 &#8211; Accumulated Other Comprehensive Income (Loss)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AOCI includes net unrealized (depreciation) appreciation on securities and derivatives, change in discount rate and instrument specific credit risk for certain long-duration insurance contractholder liabilities (Note 10 to the Consolidated Financial Statements), foreign currency translation and the net postretirement benefits liability adjustment. AOCI includes the Company's share from unconsolidated entities reported on the equity method. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityPolicyTextBlock" id="f-1796" escape="true">Generally, tax effects in AOCI are established at the currently enacted tax rate and reclassified to Shareholders' net income in the same period that the related pre-tax AOCI reclassifications are recognized.</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Shareholders' other comprehensive (loss), net of tax, for the years ended 2023, 2022 and 2021, is primarily driven by the change in discount rates for certain long-duration liabilities, unrealized changes in the market values of securities and derivatives and changes in postretirement benefits liabilities, including the impacts from unconsolidated entities reported on the equity method.</span></div></ix:nonNumeric><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="f-1797" continuedAt="f-1797-1" escape="true"><ix:continuation id="f-1795-1" continuedAt="f-1795-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the components of AOCI, including the restatement for amended accounting guidance for long-duration insurance contracts (discussed in Note 2 to the Consolidated Financial Statements), are as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.205%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Securities and Derivatives</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance, as previously disclosed</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-532" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1798">900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative effect of accounting for Long-duration Insurance Contracts guidance (ASU 2018-12)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-533" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1799">668</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance, as retrospectively restated</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-534" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1800">332</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-535" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1801">1,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-536" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1802">1,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized appreciation (depreciation) on securities and derivatives</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-537" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="f-1803">620</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-538" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-1804">2,274</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-539" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="f-1805">335</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax (expense) benefit</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-537" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="f-1806">146</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-538" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="f-1807">467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-539" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="f-1808">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized appreciation (depreciation) on securities and derivatives</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-537" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1809">474</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-538" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-1810">1,807</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-539" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1811">283</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustment for losses included in Shareholders' net income ((Loss) gain on sale of businesses)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-540" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1812">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-541" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="f-1813">172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-542" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1814">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustment for losses (gains) included in Shareholders' net income (Net realized investment (losses) gains)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="f-1815">38</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-544" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="f-1816">47</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-545" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="f-1817">24</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustment for (gains) included in Shareholders' net income (Selling, general and administrative expenses)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-546" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="f-1818">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-547" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1819">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-548" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1820">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustment for tax (benefit) expense included in Shareholders' net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-537" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="f-1821">8</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-538" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="f-1822">10</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-539" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="f-1823">5</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net losses (gains) reclassified from AOCI to Shareholders' net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-537" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1824">29</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-538" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1825">209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-539" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1826">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-537" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1827">503</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-538" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-1828">1,598</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-539" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1829">302</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1830">171</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-534" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1831">332</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-535" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1832">1,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.205%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net long-duration insurance and contractholder liabilities measurement adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance, as previously disclosed</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-1833">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative effect of accounting for Long-duration Insurance Contracts guidance (ASU 2018-12)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1834">832</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance, as retrospectively restated</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-552" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1835">256</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-553" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1836">765</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-554" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1837">832</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current period change in discount rate for certain long-duration liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-555" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="f-1838">913</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-556" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="f-1839">642</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-557" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="f-1840">59</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-555" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="f-1841">222</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-556" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="f-1842">122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-557" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="f-1843">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period change in discount rate for certain long-duration liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-555" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1844">691</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-556" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1845">520</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-557" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1846">56</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current period change in instrument-specific credit risk for market risk benefits</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-558" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="f-1847">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-559" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="f-1848">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-560" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="f-1849">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-558" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="f-1850">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-559" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="f-1851">3</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-560" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="f-1852">2</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period change in instrument-specific credit risk for market risk benefits</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-558" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1853">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-559" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1854">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-560" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1855">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-561" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1856">715</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-562" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1857">509</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-563" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1858">67</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-564" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1859">971</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-552" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1860">256</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-553" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1861">765</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">Established upon the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.205%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Translation of foreign currencies</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance, as retrospectively restated</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-565" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1862">154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-566" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1863">233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1864">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Translation of foreign currencies</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-6" name="ci:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity" format="ixt:fixed-zero" scale="6" id="f-1865">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" sign="-" name="ci:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity" scale="6" id="f-1866">277</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-6" sign="-" name="ci:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity" scale="6" id="f-1867">213</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-6" sign="-" name="ci:OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity" scale="6" id="f-1868">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" name="ci:OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity" scale="6" id="f-1869">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-6" name="ci:OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity" scale="6" id="f-1870">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net translation of foreign currencies</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-6" name="ci:OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity" scale="6" id="f-1871">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" sign="-" name="ci:OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity" scale="6" id="f-1872">310</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-6" sign="-" name="ci:OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity" scale="6" id="f-1873">232</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustment for losses included in Net income ((Loss) gain on sale of businesses)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1874">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="f-1875">358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1876">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustment for tax expense included in Net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="6" id="f-1877">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="f-1878">29</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="6" id="f-1879">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net translation losses reclassified from AOCI to Net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-1880">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1881">387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-1882">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Translation of foreign currencies</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-6" name="ci:OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity" format="ixt:fixed-zero" scale="6" id="f-1883">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" name="ci:OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity" scale="6" id="f-1884">81</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-6" sign="-" name="ci:OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity" scale="6" id="f-1885">213</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-6" sign="-" name="ci:OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity" scale="6" id="f-1886">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" name="ci:OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity" scale="6" id="f-1887">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-6" name="ci:OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity" scale="6" id="f-1888">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-6" name="ci:OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity" scale="6" id="f-1889">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" name="ci:OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity" scale="6" id="f-1890">77</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-6" sign="-" name="ci:OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity" scale="6" id="f-1891">232</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net translation (loss) on foreign currencies attributable to noncontrolling interests</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-571" decimals="-6" name="ci:TemporaryEquityOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-1892">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-572" decimals="-6" sign="-" name="ci:TemporaryEquityOtherComprehensiveIncome" scale="6" id="f-1893">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-573" decimals="-6" sign="-" name="ci:TemporaryEquityOtherComprehensiveIncome" scale="6" id="f-1894">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shareholders' other comprehensive income (loss), net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-574" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1895">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-575" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1896">79</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-576" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1897">218</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-577" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1898">149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-565" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1899">154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-566" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1900">233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1797-1"><ix:continuation id="f-1795-2"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.205%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Postretirement benefits liability</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-578" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1901">916</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-579" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1902">1,336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-580" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1903">1,746</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustment for amortization of net prior actuarial losses and prior service costs (Interest expense and other)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-581" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="f-1904">46</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-582" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="f-1905">65</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-583" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="f-1906">85</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustment for (gains) included in Shareholders' net income ((Loss) gain on sale of businesses)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-584" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1907">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-585" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="f-1908">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-586" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1909">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustment for settlement (Interest expense and other)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-587" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1910">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-588" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1911">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-589" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="6" id="f-1912">4</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustment for tax (benefit) included in Shareholders' net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-590" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="f-1913">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-591" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="f-1914">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-592" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="f-1915">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net adjustments reclassified from AOCI to Shareholders' net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-590" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1916">35</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-591" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1917">48</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-592" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-1918">68</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation update</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-590" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="f-1919">46</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-591" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="f-1920">487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-592" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" scale="6" id="f-1921">448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-590" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="f-1922">12</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-591" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="f-1923">115</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-592" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="f-1924">106</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change due to valuation update</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-590" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1925">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-591" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1926">372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-592" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-1927">342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-590" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1928">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-591" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1929">420</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-592" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1930">410</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-593" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1931">915</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-578" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1932">916</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-579" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1933">1,336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.205%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Accumulated other comprehensive loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance, as previously disclosed</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1934">861</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative effect of accounting for Long-duration Insurance Contracts guidance (ASU 2018-12)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-1935">164</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance, as retrospectively restated</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1936">1,658</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1937">1,068</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1938">1,025</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shareholders' other comprehensive (loss), net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1939">206</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1940">590</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-1941">43</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1942">1,864</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1943">1,658</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1944">1,068</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_565"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="f-1945" escape="true"><div style="margin-bottom:10pt"><span id="ib4ae12875cf34f83a32bfa168076339d_4120"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 17 &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Organizational Efficiency Plan</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the fourth quarter of 2023, the Company approved a strategic realignment to drive greater operating effectiveness and efficiency. This plan positions us to be more efficient and focused to deliver differentiated value and services to our clients and customers. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recognized a charge in Selling, general and administrative expenses of $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-1946">252</ix:nonFraction> million, pre-tax ($<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-6" name="ci:RestructuringChargesNetOfTaxExpense" format="ixt:num-dot-decimal" scale="6" id="f-1947">193</ix:nonFraction> million, after-tax). This charge included $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-6" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="f-1948">232</ix:nonFraction> million of accrued expenses primarily for severance costs related to headcount reductions, as well as, $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-6" name="us-gaap:BusinessExitCosts1" format="ixt:num-dot-decimal" scale="6" id="f-1949">20</ix:nonFraction> million of one-time expenses related to abandonment of leased assets and impairment of property and equipment. We expect substantially all of the accrued liability to be paid by the end of 2024.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="f-1950" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes a roll forward of the accrued liability recorded in Accrued expenses and other liabilities:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December&#160;31, 2022</span></div></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="f-1951">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fourth quarter 2023 charge</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="f-1952">232</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 payments</span></div></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-1953">30</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December&#160;31, 2023</span></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-1954">202</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_571"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="f-1955" continuedAt="f-1955-1" escape="true"><div style="margin-bottom:10pt"><span id="i99ce20099cc349af960781819814ec06_8144"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 18 &#8211; Pension</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">About Our Plans</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company sponsors U.S. and non-U.S. defined benefit pension plans; future benefit accruals for the domestic plans are frozen.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PensionAndOtherPostretirementPlansPensionsPolicy" id="f-1956" continuedAt="f-1956-1" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Company measures the assets and liabilities of its domestic pension plans as of December 31. Benefit obligations are measured at the present value of estimated future payments based on actuarial assumptions. The Company uses the corridor method to account for changes in the benefit obligation when actual results differ from those assumed, or when assumptions change. These changes are called net unrecognized actuarial gains (losses). Under the corridor method, net unrecognized actuarial gains (losses) are initially recorded in Accumulated other comprehensive loss. When the unrecognized gain (loss) exceeds 10% of the </span></div></ix:nonNumeric></ix:nonNumeric><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1955-1" continuedAt="f-1955-2"><ix:continuation id="f-1956-1" continuedAt="f-1956-2"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">benefit obligation, that excess is amortized to expense over the expected remaining lives of plan participants. The net plan expense is reported in Interest expense and other in the Consolidated Statements of Income.</span></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-1956-2" continuedAt="f-1956-3">For balance sheet purposes, we measure plan assets at fair value. When the actual return differs from the expected return, those differences are reflected in the net unrealized actuarial gain (loss) discussed above. However, to measure pension benefit costs, we use a market-related asset valuation that differs from the actual fair value for domestic pension plan assets invested in non-fixed income investments. The market-related value recognizes the difference between actual and expected long-term returns in the portfolio over five years, a method that reduces the short-term impact of market fluctuations on pension costs.</ix:continuation> The market-related asset value was approximately $<ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-8" name="ci:DefinedBenefitPlanMarketRelatedValueOfPensionPlanAssets" format="ixt:num-dot-decimal" scale="9" id="f-1957">4.0</ix:nonFraction> billion, compared with a fair value of approximately $<ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-8" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="9" id="f-1958">4.1</ix:nonFraction> billion at December&#160;31, 2023. </span></div><div><span><br/></span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Funded Status and Amounts Included in Accumulated Other Comprehensive Loss</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNetFundedStatusTableTextBlock" id="f-1959" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the projected benefit obligations and assets related to our U.S. and non-U.S. pension plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.041%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change in benefit obligation</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit obligation, January 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-486" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1960">3,948</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-594" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1961">5,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-595" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-1962">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-596" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-1963">2</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-595" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="f-1964">204</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-596" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="f-1965">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actuarial losses (gains), net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-595" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="f-1966">93</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-596" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-1967">1,094</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits paid from plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-595" decimals="-6" name="ci:DefinedBenefitPlanBenefitsPaidFromPlanAssets" scale="6" id="f-1968">294</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-596" decimals="-6" name="ci:DefinedBenefitPlanBenefitsPaidFromPlanAssets" scale="6" id="f-1969">296</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-595" decimals="-6" name="ci:DefinedBenefitPlanBenefitsPaidOther" scale="6" id="f-1970">18</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-596" decimals="-6" name="ci:DefinedBenefitPlanBenefitsPaidOther" scale="6" id="f-1971">27</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit obligation, December 31</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1972">3,934</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-486" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="f-1973">3,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change in plan assets</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets, January 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-486" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1974">4,186</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-594" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1975">4,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-595" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="f-1976">246</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-596" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="f-1977">366</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-595" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="f-1978">294</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-596" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="f-1979">296</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-595" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:fixed-zero" scale="6" id="f-1980">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-596" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="f-1981">2</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets, December 31</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1982">4,138</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-486" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-1983">4,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Funded status</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="f-1984">204</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-486" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="f-1985">238</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts presented in Consolidated Balance Sheets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="f-1986">204</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-486" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="f-1987">238</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> 2023 losses reflect a decrease in the discount rate while 2022 gains reflect an increase in the discount rate.</span></div></ix:nonNumeric><div style="text-indent:4.5pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We fund our qualified pension plans at least at the minimum amount required by the Employee Retirement Income Security Act of 1974 and the Pension Protection Act of 2006. The Company made immaterial contributions to the qualified pension plans in 2023. For 2024, contributions to the qualified pension plans are expected to be immaterial. Future years' contributions will ultimately be based on a wide range of factors including but not limited to asset returns, discount rates and funding targets. Non-qualified pension plans are generally funded on a pay-as-you-go basis as there are <ix:nonFraction unitRef="usd" contextRef="c-597" decimals="INF" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="0" id="f-1988">no</ix:nonFraction> plan assets for these plans.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1955-2" continuedAt="f-1955-3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Benefit payments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock" id="f-1989" continuedAt="f-1989-1" escape="true">The following benefit payments are expected to be paid in:</ix:nonNumeric></span><ix:continuation id="f-1989-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.040%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="f-1990">319</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="f-1991">316</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="f-1992">317</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="f-1993">314</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="f-1994">311</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2029 - 2033</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" format="ixt:num-dot-decimal" scale="6" id="f-1995">1,484</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" id="f-1996" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amounts reflected in the pension assets/(liabilities) shown above that have not yet been reported in Net income and, therefore, have been included in Accumulated other comprehensive loss consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.041%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrecognized net (losses)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-1997">1,207</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-486" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-1998">1,208</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrecognized prior service cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="f-1999">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-486" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="f-2000">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Postretirement benefits liability adjustment</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-2001">1,211</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-486" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-2002">1,213</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Cost of Our Plans</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="f-2003" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net pension cost was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.043%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-595" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-2004">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-596" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-2005">2</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-598" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="f-2006">2</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-595" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="f-2007">204</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-596" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="f-2008">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-598" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="f-2009">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected long-term return on plan assets</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-595" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="f-2010">204</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-596" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="f-2011">272</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-598" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="f-2012">269</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization of:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior actuarial losses, net</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-595" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="f-2013">52</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-596" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="f-2014">89</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-598" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="f-2015">78</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlement loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-595" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="f-2016">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-596" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="f-2017">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-598" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="f-2018">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (benefit) cost</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-595" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="f-2019">53</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-596" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="f-2020">41</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-598" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="f-2021">53</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Assumptions Used for Pension</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock" id="f-2022" escape="true"><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.430%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discount rate:</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension benefit obligation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-487" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="f-2023">5.10</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-486" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="f-2024">5.43</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension benefit cost</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-595" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="f-2025">5.43</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-596" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="f-2026">2.82</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expected long-term return on plan assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension benefit cost</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-595" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="f-2027">6.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-596" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="f-2028">6.75</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortality table for pension obligations</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">White Collar mortality table with MP 2021 projection scale</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">White Collar mortality table with MP 2021 projection scale</span></td></tr></table></div></ix:nonNumeric><ix:continuation id="f-1956-3" continuedAt="f-1956-4"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company develops discount rates by applying actual annualized yields for high-quality bonds by duration to the expected pension plan liability cash flows. The bond yields represent a diverse mix of actively traded high quality fixed income securities that have an above average return at each duration as management believes this approach is representative of the yield achieved through plan asset investment strategy.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The expected long-term return on plan assets was developed considering historical long-term actual returns, expected long-term market conditions, plan asset mix and management's plan asset investment strategy.</span></div></ix:continuation><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">E.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Pension Plan Assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, pension assets included $<ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-8" name="ci:DefinedBenefitPlanFairValueOfPlanAssetsInvestedInSeparateAccountsOfSubsidiaries" format="ixt:num-dot-decimal" scale="9" id="f-2029">4.0</ix:nonFraction> billion invested in the separate accounts of Connecticut General Life Insurance Company, a subsidiary of the Company, and an additional $<ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-8" name="ci:DefinedBenefitPlanFairValueOfPlanAssetsInvestedInFundsOfferedByUnaffiliatedEntity" format="ixt:num-dot-decimal" scale="9" id="f-2030">0.1</ix:nonFraction> billion invested in funds of unaffiliated investment managers.</span></div></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1955-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock" id="f-2031" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair values of pension assets by category are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.041%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal government and agency</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-599" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2032">12</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-600" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2033">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-601" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2034">2,780</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-602" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2035">2,349</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-603" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2036">121</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-604" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2037">109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fund investments</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-605" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2038">278</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-606" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2039">478</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-607" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2040">3,191</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-608" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2041">2,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-609" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2042">27</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-610" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2043">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International, including funds and pooled separate accounts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-611" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2044">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-612" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2045">35</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-613" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2046">33</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-614" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2047">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities partnerships</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-615" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2048">419</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2049">452</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Real estate funds, including pooled separate accounts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2050">270</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-618" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2051">315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial mortgage loans</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-619" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2052">46</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2053">63</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Guaranteed deposit account contract</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2054">48</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2055">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents and other current assets, net</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-623" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2056">131</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-624" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="f-2057">235</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total pension assets at fair value</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2058">4,138</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-486" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="f-2059">4,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> A pooled separate account has several participating benefit plans and each owns a share of the total pool of investments.</span></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's current target investment allocation percentages are <ix:nonFraction unitRef="number" contextRef="c-607" decimals="INF" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2060">90</ix:nonFraction>% fixed income and <ix:nonFraction unitRef="number" contextRef="c-625" decimals="INF" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="f-2061">10</ix:nonFraction>% in other investments, including private equity (securities partnerships), public equity securities, and real estate, and are developed by management as guidelines, although the fair values of each asset category are expected to vary as a result of changes in market conditions. The Company will evaluate further allocation changes to equity securities, other investments and fixed income securities as funding levels change.</span></div><div><span><br/></span></div><ix:continuation id="f-1956-4"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See Note 13 for further details regarding how fair value is determined, including the level within the fair value hierarchy and the procedures we use to validate fair value measurements. The Company classifies substantially all debt securities in Level 2 for pension plan assets. These assets are valued using recent trades of similar securities or are fund investments priced using their daily net asset value that is the exit price. All domestic equity securities and international equity funds within pension assets are classified as Level 3.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Securities partnerships, real estate and hedge funds are valued using net asset value as a practical expedient and are excluded from the fair value hierarchy. See Note 13 for additional disclosures related to these assets invested in the separate accounts of the Company's subsidiary. Certain securities as described in Note 13, as well as commercial mortgage loans and guaranteed deposit account contracts, are classified in Level 3 because unobservable inputs used in their valuation are significant.</span></div></ix:continuation><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">F.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:9.4pt;text-decoration:underline">401(k) Plan</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company sponsors a 401(k) plan. All employees are immediately eligible for the plan at hire and the Company matches a portion of employees' contributions to the plan. Participants in the plan may invest in various funds that invest in the Company's common stock, several diversified stock funds, a bond fund or stable value funds. The Company common stock fund under the plan constitutes an "employee stock ownership plan" as defined in the Internal Revenue Code. Dividends from the Company common stock fund are reinvested in a participant's stock fund account unless the participant elects to receive the dividends in cash.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company may elect to increase its matching contributions if the Company's annual performance meets certain targets. <ix:nonNumeric contextRef="c-1" name="us-gaap:DefinedContributionPlanDisclosuresTableTextBlock" id="f-2062" continuedAt="f-2062-1" escape="true">The Company's annual expense for the plan was as follows:</ix:nonNumeric></span><ix:continuation id="f-2062-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.043%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-2063">296</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-2064">274</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-2065">268</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></ix:continuation></div></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_577"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-2068" continuedAt="f-2068-1" escape="true"><div style="margin-bottom:10pt"><span id="ia59fe69ab3a747a18a0ea7f12e4444a7_5726"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 19 &#8211; Employee Incentive Plans</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">About Our Plans</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The People Resources Committee (the "Committee") of the Board of Directors awards stock options, restricted stock grants, restricted stock units, deferred stock and strategic performance shares to certain employees. The Company issues original issue shares for these awards.</span></div></ix:nonNumeric><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-2068-1" continuedAt="f-2068-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-2069" continuedAt="f-2069-1" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company records compensation expense for stock and option awards over their vesting periods primarily based on the estimated fair value at the grant date. Fair value is determined differently for each type of award as discussed below.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="f-2070" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Shares of common stock available for award were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.043%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares available for award</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="f-2071">14.4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="f-2072">16.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-47" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="f-2073">19.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Stock Options</span></div><ix:continuation id="f-2069-1" continuedAt="f-2069-2"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Company awards options to purchase The Cigna Group common stock at the market price of the stock on the grant date. Options vest over periods ranging from <ix:nonNumeric contextRef="c-628" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-2074">one year</ix:nonNumeric> to <ix:nonNumeric contextRef="c-629" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-2075">three years</ix:nonNumeric> and expire no later than <ix:nonNumeric contextRef="c-629" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-2076">10</ix:nonNumeric> years from grant date. Fair value is estimated using the Black-Scholes option-pricing model by applying the assumptions presented below. That fair value is reduced by options expected to be forfeited during the vesting period. The Company estimates forfeitures at the grant date based on our experience and adjusts the expense to reflect actual forfeitures over the vesting period. The fair value of options, net of forfeitures, is recognized in Selling, general and administrative expenses on a straight-line basis over the vesting period.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-2077" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Black-Scholes option-pricing model assumptions and the resulting fair value of options are presented in the following table: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.749%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-2078">1.58</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-631" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-2079">1.98</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-632" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-2080">1.85</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-2081">30.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-631" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-2082">30.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-632" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-2083">30.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-2084">3.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-631" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-2085">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-632" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-2086">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected option life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-2087">4.7</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-631" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-2088">4.5</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-632" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-2089">4.5</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average fair value of options</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-2090">79.66</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-631" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-2091">50.61</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-632" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-2092">44.84</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The dividend yield reflects expected future dividends. The Company intends to continue to pay dividends for the foreseeable future. The expected volatility reflects the past daily stock price volatility of The Cigna Group stock. The Company does not consider volatility implied in the market prices of traded options to be a good indicator of future volatility because remaining traded options will expire within <ix:nonNumeric contextRef="c-630" name="ci:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionReferenceTermOfTradedOptions" format="ixt-sec:durwordsen" id="f-2093">one year</ix:nonNumeric>. The risk-free interest rate is derived using the four-year U.S. Treasury bond yield rate as of the award date for the primary annual grant. Expected option life reflects the Company's historical experience.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock" id="f-2094" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table shows the status of, and changes in, common stock options:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.047%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Options in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding - January 1</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-633" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-2095">6,992</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-633" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-2096">186.54</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-634" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-2097">8,490</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-634" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-2098">169.47</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-635" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-2099">9,742</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-635" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-2100">152.40</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="f-2101">915</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-2102">294.37</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-631" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="f-2103">1,375</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-631" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-2104">226.95</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-632" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="f-2105">1,524</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-632" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-2106">213.81</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-2107">1,080</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-2108">174.66</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-631" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-2109">2,617</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-631" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-2110">149.97</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-632" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-2111">2,584</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-632" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-2112">129.08</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired or canceled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="3" id="f-2113">131</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-2114">246.95</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-631" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="3" id="f-2115">256</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-631" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-2116">211.22</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-632" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="3" id="f-2117">192</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-632" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-2118">199.10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding - December 31</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-636" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-2119">6,696</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-636" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-2120">202.02</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-633" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-2121">6,992</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-633" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-2122">186.54</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-634" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-2123">8,490</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-634" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-2124">169.47</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable at year-end</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-636" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="f-2125">4,616</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-636" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-2126">179.28</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-633" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="f-2127">4,410</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-633" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-2128">168.97</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-634" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="f-2129">5,612</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-634" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-2130">152.92</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Compensation expense of $<ix:nonFraction unitRef="usd" contextRef="c-636" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="f-2131">67</ix:nonFraction> million related to unvested stock options at December&#160;31, 2023 will be recognized over the next <ix:nonNumeric contextRef="c-630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="f-2132">two years</ix:nonNumeric> (weighted average period).</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-2068-2" continuedAt="f-2068-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-2133" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The table below summarizes information for stock options exercised:</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.043%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intrinsic value of options exercised</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-630" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-2134">126</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-631" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-2135">313</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-632" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-2136">268</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash received for options exercised</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-630" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="f-2137">187</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-631" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="f-2138">389</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-632" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="f-2139">326</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax benefit from options exercised</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-630" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="f-2140">17</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-631" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="f-2141">47</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-632" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="f-2142">50</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes information for outstanding common stock options:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.041%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options<br/>Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options<br/>Exercisable</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number (in thousands)</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-636" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-2143">6,696</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-636" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="f-2144">4,616</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intrinsic value (in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-636" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="f-2145">652</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-636" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="f-2146">555</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-636" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-2147">202.02</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-636" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-2148">179.28</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average remaining contractual life</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-2149">5.9</ix:nonNumeric> years</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-2150">4.7</ix:nonNumeric> years</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Restricted Stock</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company awards restricted stock (grants and units) to the Company's employees that vest over periods ranging from <span style="-sec-ix-hidden:f-2151">one</span> to <ix:nonNumeric contextRef="c-638" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-2152">three years</ix:nonNumeric>. Recipients of restricted stock awards accumulate dividends during the vesting period, but generally forfeit their awards and accumulated dividends if their employment terminates before the vesting date.</span></div><ix:continuation id="f-2069-2" continuedAt="f-2069-3"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Fair value of restricted stock awards is equal to the market price of The Cigna Group's common stock on the date of grant. This fair value is reduced by awards that are expected to forfeit. At the grant date, the Company estimates forfeitures based on experience and adjusts the expense to reflect actual forfeitures over the vesting period. This fair value, net of forfeitures, is recognized in Selling, general and administrative expenses over the vesting period on a straight-line basis.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="f-2153" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table shows the status of, and changes in, restricted stock awards:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.047%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Awards in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grants/Units</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Fair Value at Award Date</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grants/Units</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Fair Value at Award Date</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grants/Units</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Fair Value at Award Date</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding - January 1</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-639" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-2154">1,535</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-639" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-2155">219.25</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-640" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-2156">1,524</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-640" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-2157">202.85</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-641" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-2158">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-641" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-2159">186.12</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-642" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-2160">700</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-642" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-2161">294.60</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-643" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-2162">876</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-643" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-2163">229.60</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-644" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-2164">899</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-644" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-2165">213.82</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-642" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="f-2166">759</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-642" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-2167">214.70</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-643" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="f-2168">714</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-643" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-2169">197.83</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-644" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="f-2170">866</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-644" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-2171">184.07</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-642" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="f-2172">72</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-642" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-2173">256.24</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-643" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="f-2174">151</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-643" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-2175">215.02</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-644" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="f-2176">109</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-644" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-2177">197.01</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding - December 31</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-645" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-2178">1,404</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-645" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-2179">257.38</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-639" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-2180">1,535</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-639" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-2181">219.25</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-640" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-2182">1,524</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-640" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-2183">202.85</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of vested restricted stock at the vesting date was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.043%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of vested restricted stock</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-642" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-2184">220</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-643" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-2185">167</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-644" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-2186">183</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Approximately <ix:nonFraction unitRef="employee" contextRef="c-645" decimals="-2" name="ci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfEmployeesHolding" format="ixt:num-dot-decimal" scale="0" id="f-2187">8,900</ix:nonFraction> employees held <ix:nonFraction unitRef="shares" contextRef="c-645" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="6" id="f-2188">1.4</ix:nonFraction> million restricted stock awards at the end of 2023 with $<ix:nonFraction unitRef="usd" contextRef="c-645" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="f-2189">196</ix:nonFraction> million of related compensation expense to be recognized over the next <ix:nonNumeric contextRef="c-642" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="f-2190">two years</ix:nonNumeric> (weighted average period).</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Strategic Performance Shares ("SPS")</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company awards SPSs to executives and certain other key employees generally with a performance period of <ix:nonNumeric contextRef="c-646" name="ci:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" format="ixt-sec:durwordsen" id="f-2191">three years</ix:nonNumeric>. Half of these shares are subject to a market condition (total shareholder return relative to industry peer companies) and half are subject to a performance condition (cumulative adjusted net income). These targets are set by the Committee at the beginning of the performance period. Holders of these awards receive shares of The Cigna Group common stock at the end of the performance period ranging anywhere from <ix:nonFraction unitRef="number" contextRef="c-647" decimals="INF" name="ci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfOriginalGrantAwardedAtEndOfPerformancePeriod" scale="-2" id="f-2192">0</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="c-648" decimals="INF" name="ci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfOriginalGrantAwardedAtEndOfPerformancePeriod" scale="-2" id="f-2193">200</ix:nonFraction>% of the original awards.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-2068-3"><ix:continuation id="f-2069-3"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Compensation expense for SPSs is recorded over the performance period. Fair value is determined at the grant date for "market condition" SPSs using a Monte Carlo simulation model and not subsequently adjusted regardless of the final outcome. Expense is initially accrued for "performance condition" SPSs based on the most likely outcome, but evaluated for adjustment each period for updates in the expected outcome. Expense is adjusted to the actual outcome (number of shares awarded times the share price at the grant date) at the end of the performance period.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" id="f-2194" continuedAt="f-2194-1" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table shows the status of, and changes in, SPSs:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.047%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Awards in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Fair Value at Award Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Fair Value at Award Date</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Fair Value at Award Date</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding - January 1</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-649" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-2195">780</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-649" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-2196">212.68</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-650" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-2197">860</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-650" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-2198">197.07</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-651" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-2199">808</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-651" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-2200">190.02</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-646" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-2201">219</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-646" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-2202">293.85</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-652" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-2203">294</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-652" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-2204">230.69</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-653" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-2205">331</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-653" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-2206">213.90</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-646" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="f-2207">250</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-646" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-2208">191.78</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-652" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="f-2209">261</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-652" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-2210">183.60</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-653" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="f-2211">206</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-653" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-2212">196.29</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-646" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="f-2213">63</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-646" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-2214">237.50</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-652" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="f-2215">113</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-652" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-2216">207.75</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-653" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="f-2217">73</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-653" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-2218">197.38</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding - December 31</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-654" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-2219">686</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-654" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-2220">243.90</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-649" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-2221">780</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-649" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-2222">212.68</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-650" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-2223">860</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-650" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-2224">197.07</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The weighted average fair value per share of SPSs for expense purposes, including the Monte Carlo factor, at the award date for the years ended December&#160;31, 2023, 2022 and 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-646" decimals="2" name="ci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateFairValueIncludingMonteCarloFactor" scale="0" id="f-2225">329.11</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-652" decimals="2" name="ci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateFairValueIncludingMonteCarloFactor" scale="0" id="f-2226">258.37</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-653" decimals="2" name="ci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateFairValueIncludingMonteCarloFactor" scale="0" id="f-2227">239.57</ix:nonFraction>, respectively.</span></div><ix:continuation id="f-2194-1"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of vested SPSs at the vesting date was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.212%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Shares in thousands; $ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares of The Cigna Group common stock distributed upon SPS vesting</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-646" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="f-2228">257</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-646" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-2229">76</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-652" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="f-2230">137</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-652" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-2231">31</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-653" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="f-2232">243</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-653" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-2233">51</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Approximately <ix:nonFraction unitRef="employee" contextRef="c-654" decimals="-2" name="ci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfEmployeesHolding" scale="0" id="f-2234">600</ix:nonFraction> employees held <ix:nonFraction unitRef="shares" contextRef="c-654" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-2235">686,000</ix:nonFraction> SPSs at the end of 2023 and $<ix:nonFraction unitRef="usd" contextRef="c-654" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="f-2236">61</ix:nonFraction>&#160;million of related compensation expense is expected to be recognized over the next <ix:nonNumeric contextRef="c-646" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="f-2237">two years</ix:nonNumeric>. The amount of expense for "performance condition" SPSs will vary based on actual performance in 2024 and 2025.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">E.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-2238" continuedAt="f-2238-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Compensation Cost and Tax Effects of Share-based Compensation</span></ix:nonNumeric></div><ix:continuation id="f-2238-1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company records tax benefits in Shareholders' net income during the vesting period based on the amount of expense being recognized. The difference between tax benefits based on the expense and the actual tax benefit realized are also recorded in income tax expense when stock options are exercised, or when restricted stock and SPSs vest.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.043%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total compensation cost for shared-based awards</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-2239">286</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-2240">264</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-2241">268</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax benefits recognized</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-2242">92</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-2243">80</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-2244">73</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="margin-bottom:10pt"><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_580"></div><ix:nonNumeric contextRef="c-1" name="ci:GoodwillOtherIntangiblesAndPropertyAndEquipmentDisclosureTextBlock" id="f-2245" continuedAt="f-2245-1" escape="true"><div style="margin-bottom:10pt"><span id="id61656c4028645fb94828ae2f199db59_5551"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 20 &#8211; Goodwill, Other Intangibles and Property and Equipment</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Goodwill</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="f-2246" continuedAt="f-2246-1" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Goodwill represents the excess of the cost of businesses acquired over the fair value of their net assets. The resulting goodwill is assigned to those reporting units expected to realize cash flows from the acquisition, based on those reporting units' relative fair values. The Company's reporting units are aligned with its operating segments as described in Note 1.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company conducts its annual quantitative evaluation for goodwill impairment during the third quarter at the reporting unit level and writes it down through Shareholders' net income if impaired. On a quarterly basis, the Company performs a qualitative impairment assessment to determine if events or changes in circumstances indicate that it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value. Fair value of a reporting unit is generally estimated based on discounted cash flow analysis and market approach models using assumptions that the Company believes a hypothetical market participant would use to determine a current transaction price. Following a change in reporting units or held for sale determination, goodwill is allocated using relative fair value. The significant assumptions and estimates used in determining fair value primarily include the discount rate and future cash flows. A discount rate is selected to correspond with each reporting unit's weighted average cost of capital, consistent with </span></div></ix:nonNumeric></ix:nonNumeric><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-2245-1" continuedAt="f-2245-2"><ix:continuation id="f-2246-1"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">that used for investment decisions considering the specific and detailed operating plans and strategies within each reporting unit. Projections of future cash flows differ by reporting unit and are consistent with our ongoing strategic projections. Future cash flows for Evernorth Health Services are primarily driven by the forecasted gross margins of the business, as well as operating expenses and long-term growth rates. Future cash flows for our other reporting units are primarily driven by forecasted revenues, benefit expenses, operating expenses and long-term growth rates.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfGoodwillTextBlock" id="f-2247" continuedAt="f-2247-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Goodwill activity.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Goodwill activity was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Evernorth Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cigna Healthcare</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-655" decimals="-6" name="ci:GoodwillIncludingDisposalGroups" format="ixt:num-dot-decimal" scale="6" id="f-2248">35,128</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-6" name="ci:GoodwillIncludingDisposalGroups" format="ixt:num-dot-decimal" scale="6" id="f-2249">10,683</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-6" name="ci:GoodwillIncludingDisposalGroups" scale="6" id="f-2250">234</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="ci:GoodwillIncludingDisposalGroups" format="ixt:num-dot-decimal" scale="6" id="f-2251">46,045</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill disposed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-656" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="6" id="f-2252">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="6" id="f-2253">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-657" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="f-2254">234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="f-2255">234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impact of foreign currency translation and other adjustments</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-656" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="f-2256">2</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="f-2257">2</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-657" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="f-2258">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="f-2259">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-658" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-2260">35,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-2261">10,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="f-2262">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-2263">45,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill transferred to assets of businesses held for sale</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-659" decimals="-6" name="ci:GoodwillTransfersToAssetsOfBusinessesHeldForSale" format="ixt:fixed-zero" scale="6" id="f-2264">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" name="ci:GoodwillTransfersToAssetsOfBusinessesHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-2265">1,553</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-660" decimals="-6" name="ci:GoodwillTransfersToAssetsOfBusinessesHeldForSale" format="ixt:fixed-zero" scale="6" id="f-2266">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:GoodwillTransfersToAssetsOfBusinessesHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-2267">1,553</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impact of foreign currency translation and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-659" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="f-2268">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="f-2269">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-660" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="f-2270">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="f-2271">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill at December 31, 2023</span></div></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-661" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-2272">35,130</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-2273">9,129</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="f-2274">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-2275">44,259</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><ix:continuation id="f-2247-1"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Includes $<ix:nonFraction unitRef="usd" contextRef="c-662" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1" format="ixt:num-dot-decimal" scale="6" id="f-2276">234</ix:nonFraction> million classified as assets of businesses held for sale, all reported within Other Operations.</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"> </span></div><div><span><br/></span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Other Intangible Assets</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="f-2277" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Company's Other intangible assets primarily include purchased customer and producer relationships, trademarks and provider networks. The fair value of purchased customer relationships and the amortization method were determined as of the dates of purchase using an income approach that relies on projected future net cash flows including key assumptions for customer attrition and discount rates. The Company's definite-lived intangible assets are amortized on an accelerated or straight-line basis, reflecting their pattern of economic benefits, over periods from <span style="-sec-ix-hidden:f-2278">three</span> to <ix:nonNumeric contextRef="c-664" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-2279">30</ix:nonNumeric> years. Management revises amortization periods if it believes there has been a change in the length of time that an intangible asset will continue to have value. Costs incurred to renew or extend the terms of these intangible assets are generally expensed as incurred.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's amortized intangible assets are tested for impairment whenever events or changes in circumstances indicate that the </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">carrying amount may not be recoverable.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> If the total of the expected future undiscounted cash flows generated by the underlying asset group is less than the carrying amount of the asset group, the Company recognizes an impairment charge equal to the difference between the carrying value of the asset group and its estimated fair value. The Company's indefinite-lived intangible assets are reviewed for impairment at least annually by comparing their fair value with their carrying value. If the carrying value exceeds fair value, that excess is recognized as an impairment loss.</span></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Components of other assets, including other intangibles.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="f-2281" continuedAt="f-2281-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="f-2280" continuedAt="f-2280-1" escape="true">Other intangible assets were comprised of the following:</ix:nonNumeric></ix:nonNumeric></span><ix:continuation id="f-2281-1" continuedAt="f-2281-2"><ix:continuation id="f-2280-1" continuedAt="f-2280-2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.043%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-665" decimals="-6" name="ci:FiniteLivedIntangibleAssetsGrossIncludingDisposalGroupsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-2282">29,978</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-665" decimals="-6" name="ci:FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-2283">7,645</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-665" decimals="-6" name="ci:FiniteLivedIntangibleAssetsNetIncludingDisposalGroupsAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-2284">22,333</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade Name - Express Scripts</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-666" decimals="-6" name="ci:IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-2285">8,400</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-666" decimals="-6" name="ci:IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-2286">8,400</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-667" decimals="-6" name="ci:IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale" scale="6" id="f-2287">317</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-667" decimals="-6" name="ci:FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale" scale="6" id="f-2288">110</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-667" decimals="-6" name="ci:IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale" scale="6" id="f-2289">207</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-2290">38,695</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-2291">7,755</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-2292">30,940</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Value of business acquired ("VOBA" reported in Other assets)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:FiniteLivedIntangibleAssetsGrossVOBAIncludingDisposalGroupsAssetHeldForSale" scale="6" id="f-2293">211</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:FiniteLivedIntangibleAssetsAccumulatedAmortizationVOBAIncludingDisposalGroupsAssetsHeldForSale" scale="6" id="f-2294">142</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:FiniteLivedIntangibleAssetsNetVOBAIncludingDisposalGroupsAssetsHeldForSale" scale="6" id="f-2295">69</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups" format="ixt:num-dot-decimal" scale="6" id="f-2296">38,906</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVOBAIncludingDisposalGroups" format="ixt:num-dot-decimal" scale="6" id="f-2297">7,897</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups" format="ixt:num-dot-decimal" scale="6" id="f-2298">31,009</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-668" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-2299">29,974</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-668" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-2300">6,099</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-668" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-2301">23,875</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade Name - Express Scripts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-669" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-2302">8,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-669" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-2303">8,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-670" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="f-2304">348</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-670" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-2305">131</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-670" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="f-2306">217</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-2307">38,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-2308">6,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-2309">32,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Value of business acquired (reported in Other assets)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:FiniteLivedIntangibleAssetsGrossVoba" scale="6" id="f-2310">210</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:FiniteLivedIntangibleAssetsAccumulatedAmortizationVoba" scale="6" id="f-2311">133</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:FiniteLivedIntangibleAssetsNetVoba" scale="6" id="f-2312">77</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:IntangibleAssetsGrossExcludingGoodwillIncludingVoba" format="ixt:num-dot-decimal" scale="6" id="f-2313">38,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVoba" format="ixt:num-dot-decimal" scale="6" id="f-2314">6,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:IntangibleAssetsNetExcludingGoodwillIncludingVoba" format="ixt:num-dot-decimal" scale="6" id="f-2315">32,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation></ix:continuation></div><div style="margin-bottom:10pt"><ix:continuation id="f-2281-2"><ix:continuation id="f-2280-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Includes $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="ci:DisposalGroupIncludingDiscontinuedOperationValueOfBusinessAcquired" format="ixt:num-dot-decimal" scale="6" id="f-2316">69</ix:nonFraction>&#160;million of VOBA and $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-2317">77</ix:nonFraction>&#160;million of Other intangible assets classified as assets of businesses held for sale.</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"> </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has indefinite-lived intangible assets totaling $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-8" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="f-2318"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-8" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="f-2319">8.5</ix:nonFraction></ix:nonFraction> billion at December&#160;31, 2023 and December&#160;31, 2022, largely consisting of the Express Scripts trade name.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-2245-2"><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Property and Equipment</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-2320" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Property and equipment is carried at cost less accumulated depreciation. Cost includes interest, real estate taxes and other costs incurred during construction when applicable. Internal-use software that is acquired, developed or modified solely to meet the Company's internal needs, with no plan to market externally, is also included in this category. Costs directly related to acquiring, developing or modifying internal-use software are capitalized.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company calculates depreciation and amortization principally using the straight-line method generally based on the estimated useful life of each asset as follows: buildings and improvements, <ix:nonNumeric contextRef="c-671" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-2321">10</ix:nonNumeric> to <ix:nonNumeric contextRef="c-672" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-2322">40</ix:nonNumeric> years; purchased and internally developed software, <span style="-sec-ix-hidden:f-2323">three</span> to <ix:nonNumeric contextRef="c-674" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-2324">five years</ix:nonNumeric>; and furniture and equipment (including computer equipment), <span style="-sec-ix-hidden:f-2325">three</span> to <ix:nonNumeric contextRef="c-676" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-2326">10</ix:nonNumeric> years. Improvements to leased facilities are depreciated over <span style="-sec-ix-hidden:f-2327">the lesser of the remaining lease term or the estimated life of the improvement</span>. The Company considers events and circumstances that would indicate the carrying value of property, equipment or capitalized software might not be recoverable. An impairment charge is recorded if the Company determines the carrying value of any of these assets is not recoverable. The Company also reviews and shortens the estimated useful lives of these assets, if necessary.</span></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Components of property and equipment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-2328" continuedAt="f-2328-1" escape="true">Property and equipment was comprised of the following:</ix:nonNumeric></span><ix:continuation id="f-2328-1" continuedAt="f-2328-2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.043%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Internal-use software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-678" decimals="-6" name="ci:PropertyPlantAndEquipmentGrossIncludingDisposalGroups" format="ixt:num-dot-decimal" scale="6" id="f-2329">10,155</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-678" decimals="-6" name="ci:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups" format="ixt:num-dot-decimal" scale="6" id="f-2330">7,161</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-678" decimals="-6" name="ci:PropertyPlantAndEquipmentNetIncludingDisposalGroups" format="ixt:num-dot-decimal" scale="6" id="f-2331">2,994</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other property and equipment</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-679" decimals="-6" name="ci:PropertyPlantAndEquipmentGrossIncludingDisposalGroups" format="ixt:num-dot-decimal" scale="6" id="f-2332">2,282</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-679" decimals="-6" name="ci:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups" format="ixt:num-dot-decimal" scale="6" id="f-2333">1,405</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-679" decimals="-6" name="ci:PropertyPlantAndEquipmentNetIncludingDisposalGroups" scale="6" id="f-2334">877</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:PropertyPlantAndEquipmentGrossIncludingDisposalGroups" format="ixt:num-dot-decimal" scale="6" id="f-2335">12,437</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups" format="ixt:num-dot-decimal" scale="6" id="f-2336">8,566</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:PropertyPlantAndEquipmentNetIncludingDisposalGroups" format="ixt:num-dot-decimal" scale="6" id="f-2337">3,871</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Internal-use software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-680" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="f-2338">8,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-680" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-2339">6,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-680" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-2340">2,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other property and equipment</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-681" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="f-2341">2,256</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-681" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-2342">1,330</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-681" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="f-2343">926</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="f-2344">11,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-2345">7,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-2346">3,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation></div><div style="margin-bottom:10pt"><ix:continuation id="f-2328-2" continuedAt="f-2328-3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"><ix:continuation id="f-2328-3"> Includes $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" format="ixt:num-dot-decimal" scale="6" id="f-2347">176</ix:nonFraction>&#160;million of Property and equipment net carrying value classified as assets of businesses held for sale.</ix:continuation> </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Components of depreciation and amortization.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> <ix:nonNumeric contextRef="c-1" name="ci:ComponentsOfDepreciationAndAmortizationTableTextBlock" id="f-2348" continuedAt="f-2348-1" escape="true">Depreciation and amortization expense was comprised of the following:</ix:nonNumeric></span><ix:continuation id="f-2348-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.043%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Internal-use software</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-682" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-2349">1,216</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-683" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-2350">1,068</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-684" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-2351">1,097</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other property and equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-685" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-2352">260</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-686" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-2353">251</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-687" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-2354">253</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Value of business acquired (reported in Other assets)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-688" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-2355">7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-689" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-2356">12</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-690" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-2357">25</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangibles</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-691" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-2358">1,552</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-692" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-2359">1,606</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-693" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-2360">1,548</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total depreciation and amortization</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-2361">3,035</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-2362">2,937</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-2363">2,923</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-2364" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company estimates annual pre-tax amortization for intangible assets, including internal-use software, over the next five calendar years to be as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.040%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax Amortization</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="f-2365">2,892</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="6" id="f-2366">2,357</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="6" id="f-2367">1,803</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="6" id="f-2368">1,559</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="6" id="f-2369">1,484</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">125</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_589"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeFinanceLeasesTextBlock" id="f-2371" continuedAt="f-2371-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-2370" continuedAt="f-2370-1" escape="true"><div style="margin-top:10pt"><span id="i5991b33a7b8f493f949a254d6e300e2d_1953"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 21 &#8211; Leases</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's leases are primarily for office space and certain computer and other equipment and have terms of up to <ix:nonNumeric contextRef="c-664" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-2372">35</ix:nonNumeric> years.</span></div><div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-2373" continuedAt="f-2373-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-2373-1" continuedAt="f-2373-2"> The Company determines if an arrangement is a lease and its lease classification (operating or finance) at inception. Both operating and finance leases result in (1) a right-of-use ("ROU") asset that represents our right to use the underlying asset for the lease term and (2) a lease liability that represents our obligation to make lease payments arising from the lease.</ix:continuation> <ix:nonNumeric contextRef="c-1" name="ci:AssetsAndLiabilitiesLesseeTableTextBlock" id="f-2374" continuedAt="f-2374-1" escape="true">ROU assets and lease liabilities are reflected in the following lines in the Company's Consolidated Balance Sheets:</ix:nonNumeric></span><ix:continuation id="f-2374-1" continuedAt="f-2374-2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROU Asset</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current Lease Liability</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-Current Lease Liability</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities (current)</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other liabilities (non-current)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt</span></td></tr></table></ix:continuation></div><div><span><br/></span></div><ix:continuation id="f-2373-2"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. Most of the Company's leases do not provide an implicit rate, so the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The ROU asset also includes any lease pre-payments made and excludes lease incentives for operating leases. The Company's expected life of a lease may consider options to extend or terminate a lease when it is reasonably certain that the Company will exercise that option.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has lease agreements with lease and non-lease components that are accounted for as a single lease component. Operating lease ROU assets are amortized on a straight-line basis over the lease term, which is representative of the pattern in which benefit is expected to be derived from the right to use the underlying asset. Variable lease payments are expensed as incurred and represent amounts that are neither fixed in nature, such as maintenance and other services provided by the lessor, nor tied to an index or rate.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-2375" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The components of lease expense were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.288%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.432%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="f-2376">115</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="f-2377">124</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="f-2378">170</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of ROU assets</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="f-2379">41</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="f-2380">33</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="f-2381">22</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="f-2382">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="f-2383">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="f-2384">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total finance lease cost</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:FinanceLeaseCost" scale="6" id="f-2385">45</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:FinanceLeaseCost" scale="6" id="f-2386">35</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:FinanceLeaseCost" scale="6" id="f-2387">24</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:VariableLeaseCost" scale="6" id="f-2388">38</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:VariableLeaseCost" scale="6" id="f-2389">41</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:VariableLeaseCost" scale="6" id="f-2390">39</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:LeaseCost" scale="6" id="f-2391">198</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:LeaseCost" scale="6" id="f-2392">200</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:LeaseCost" scale="6" id="f-2393">233</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ci:CashFlowActivitiesLesseeTableTextBlock" id="f-2394" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Supplemental cash flow information related to leases was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash outflows from operating leases</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="f-2395">132</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="f-2396">148</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="f-2397">167</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash outflows from finance leases</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="f-2398">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="f-2399">2</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="f-2400">2</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing cash outflows from finance leases</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="f-2401">39</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="f-2402">33</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="f-2403">22</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROU assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="f-2404">103</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="f-2405">43</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="f-2406">122</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="f-2407">48</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="f-2408">84</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="f-2409">20</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">126</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_595"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-2371-1" continuedAt="f-2371-2"><ix:continuation id="f-2370-1" continuedAt="f-2370-2"><ix:continuation id="f-2374-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating and finance lease ROU assets and lease liabilities were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.319%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating leases:</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease ROU assets in <span style="-sec-ix-hidden:f-2410"><span style="-sec-ix-hidden:f-2411">Other assets</span></span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-2412">370</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-2413">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2414"><span style="-sec-ix-hidden:f-2415">Accrued expenses and other liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="f-2416">105</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="f-2417">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2418"><span style="-sec-ix-hidden:f-2419">Other non-current liabilities</span></span></span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-2420">340</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-2421">346</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="f-2422">445</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="f-2423">460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance leases:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="6" id="f-2424">177</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="6" id="f-2425">145</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" scale="6" id="f-2426">73</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" scale="6" id="f-2427">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2428"><span style="-sec-ix-hidden:f-2429">Property and equipment, net</span></span></span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="f-2430">104</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="f-2431">97</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2432"><span style="-sec-ix-hidden:f-2433">Short-term debt</span></span></span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="f-2434">42</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="f-2435">33</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2436"><span style="-sec-ix-hidden:f-2437">Long-term debt</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="f-2438">66</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="f-2439">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:FinanceLeaseLiability" scale="6" id="f-2440">108</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:FinanceLeaseLiability" scale="6" id="f-2441">99</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div></ix:continuation></ix:continuation><div id="ibc59a92ac8bc42f794e728f24ce1b626_604"></div><ix:continuation id="f-2371-2"><ix:continuation id="f-2370-2"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2023, the weighted average remaining lease term was <ix:nonNumeric contextRef="c-12" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-2442">6</ix:nonNumeric> years for operating leases and <ix:nonNumeric contextRef="c-12" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-2443">3</ix:nonNumeric> years for finance leases, and the weighted average discount rate was <ix:nonFraction unitRef="number" contextRef="c-12" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-2444">3.45</ix:nonFraction>% for operating leases and <ix:nonFraction unitRef="number" contextRef="c-12" decimals="4" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-2445">4.29</ix:nonFraction>% for finance leases.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="f-2447" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-2446" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Maturities of lease liabilities are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.041%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="f-2448">110</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="f-2449">46</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="f-2450">102</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="6" id="f-2451">38</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="f-2452">83</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="6" id="f-2453">19</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="f-2454">63</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="6" id="f-2455">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="f-2456">41</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" scale="6" id="f-2457">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="f-2458">98</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:fixed-zero" scale="6" id="f-2459">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="f-2460">497</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="6" id="f-2461">115</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="f-2462">52</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="6" id="f-2463">7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="f-2464">445</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:FinanceLeaseLiability" scale="6" id="f-2465">108</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_607"></div><ix:nonNumeric contextRef="c-1" name="ci:StockholdersEquityAndDividendRestrictionsTextBlock" id="f-2466" continuedAt="f-2466-1" escape="true"><div style="margin-bottom:10pt"><span id="i3bcdef59d091463883ab932d4c87d696_1547"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 22 &#8211; Shareholders' Equity and Dividend Restrictions</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">State insurance departments and foreign jurisdictions that regulate certain of the Company's subsidiaries prescribe accounting practices (differing in some respects from GAAP) to determine statutory net income and surplus. The Company's life, accident and health insurance and Health Maintenance Organization ("HMO") subsidiaries are regulated by such statutory requirements. <ix:nonNumeric contextRef="c-1" name="us-gaap:StatutoryAccountingPracticesDisclosureTextBlock" id="f-2467" continuedAt="f-2467-1" escape="true">The statutory net income of the Company's life, accident and health insurance and HMO subsidiaries for the years ended, and their statutory surplus as of December 31 were as follows:</ix:nonNumeric></span><ix:continuation id="f-2467-1" continuedAt="f-2467-2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.043%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In billions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-8" name="us-gaap:StatutoryAccountingPracticesStatutoryNetIncomeAmount" scale="9" id="f-2468">5.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-8" name="us-gaap:StatutoryAccountingPracticesStatutoryNetIncomeAmount" scale="9" id="f-2469">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-8" name="us-gaap:StatutoryAccountingPracticesStatutoryNetIncomeAmount" scale="9" id="f-2470">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surplus</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-8" name="us-gaap:StatutoryCapitalAndSurplusApplyingNationalAssociationOfInsuranceCommissionersNAICPractices" scale="9" id="f-2471">14.9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-8" name="us-gaap:StatutoryCapitalAndSurplusApplyingNationalAssociationOfInsuranceCommissionersNAICPractices" scale="9" id="f-2472">16.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-8" name="us-gaap:StatutoryCapitalAndSurplusApplyingNationalAssociationOfInsuranceCommissionersNAICPractices" scale="9" id="f-2473">13.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></ix:continuation></div></ix:nonNumeric><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-2466-1" continuedAt="f-2466-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's HMO and life, accident and health insurance subsidiaries are also subject to minimum statutory surplus requirements and may be required to maintain investments on deposit with state departments of insurance or other regulatory bodies. Additionally, these subsidiaries may be subject to regulatory restrictions on the amount of annual dividends or other distributions (such as loans or cash advances) that insurance companies may extend to their parent companies without prior approval. <ix:continuation id="f-2467-2" continuedAt="f-2467-3">These amounts, including restricted GAAP net assets of the Company's subsidiaries, were as follows:</ix:continuation></span><ix:continuation id="f-2467-3" continuedAt="f-2467-4"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.040%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In billions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Minimum statutory surplus required by regulators </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-8" name="us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" scale="9" id="f-2474">4.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments on deposit with regulatory bodies</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-8" name="us-gaap:AssetsHeldByInsuranceRegulators" scale="9" id="f-2475">0.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maximum dividend distributions permitted in 2024 without regulatory approval</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-8" name="us-gaap:StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments" scale="9" id="f-2476">2.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maximum loans to the parent company permitted without regulatory approval</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-8" name="ci:StatutoryAccountingPracticesAmountPermittedLendingAuthorityOfLifeInsuranceSubsidiaryToParent" scale="9" id="f-2477">1.4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted GAAP net assets of The Cigna Group's subsidiaries</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-8" name="us-gaap:AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries" scale="9" id="f-2478">12.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation></div><ix:continuation id="f-2467-4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Excludes amounts associated with foreign operated equity method joint ventures.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Permitted practices used by the Company's insurance subsidiaries in 2023 that differed from prescribed regulatory accounting had an immaterial impact on statutory surplus.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-2466-2">Undistributed earnings for equity method investments are $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-8" name="us-gaap:RetainedEarningsUndistributedEarningsFromEquityMethodInvestees" format="ixt:num-dot-decimal" scale="9" id="f-2479">1.0</ix:nonFraction> billion&#160;as of December&#160;31, 2023</ix:continuation>.</span></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_610"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-2480" continuedAt="f-2480-1" escape="true"><div><span id="if56053e95d5e46d0a8e1a2d4abbd865a_14"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 23 &#8211; Income Taxes</span></div></ix:nonNumeric><div id="ibc59a92ac8bc42f794e728f24ce1b626_613"></div><ix:continuation id="f-2480-1" continuedAt="f-2480-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-2481" continuedAt="f-2481-1" escape="true"><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Deferred income taxes are reflected in the Consolidated Balance Sheets for differences between the financial and income tax reporting bases of the Company's underlying assets and liabilities, and are established based upon enacted tax rates and laws. Deferred income tax assets are recognized when available evidence indicates that realization is more likely than not and a valuation allowance is established to the extent this standard is not met. The deferred income tax provision generally represents the net change in deferred income tax assets and liabilities during the reporting period excluding adjustments to Accumulated other comprehensive income (loss) or amounts recorded in connection with a business combination. The current income tax provision generally represents estimated amounts due on income tax returns for the year reported to various jurisdictions plus the effect of any uncertain tax positions. The Company recognizes a liability for uncertain tax positions if management believes the probability that the positions will be sustained is 50% or less. For uncertain positions that management believes are more likely than not to be sustained, the Company recognizes a liability based upon management's estimate of the most likely settlement outcome with the taxing authority. The liabilities for uncertain tax positions are classified as current when the position is expected to be settled within 12 months or the statute of limitation expires within 12 months.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income taxes attributable to the Company's foreign operations are generally provided using the respective foreign jurisdictions' tax rate.</span></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Income Tax Expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-2482" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The components of income taxes were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.043%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current taxes</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. income taxes</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-2483">1,459</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-2484">1,679</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-2485">1,267</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign income taxes</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="f-2486">161</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="f-2487">219</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="f-2488">207</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State income taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="f-2489">180</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="f-2490">189</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="f-2491">112</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current taxes</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-2492">1,800</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-2493">2,087</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-2494">1,586</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deferred taxes (benefits)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. income tax benefits</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="f-2495">533</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="f-2496">275</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="f-2497">163</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign income (tax benefits) taxes</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-2498">1,046</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="f-2499">28</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="f-2500">69</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State income tax benefits</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="f-2501">80</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="f-2502">169</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="f-2503">122</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total deferred tax benefits</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-2504">1,659</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-2505">472</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-2506">216</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total income taxes</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-2507">141</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-2508">1,615</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-2509">1,370</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-2480-2" continuedAt="f-2480-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-2510" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total income taxes were different from the amount computed using the nominal federal income tax rate for the following reasons:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.891%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="36" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax expense at nominal rate</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="6" id="f-2511">1,158</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-2512">21.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="6" id="f-2513">1,763</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-2514">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="6" id="f-2515">1,426</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-2516">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impact of sale of businesses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-694" decimals="-6" name="us-gaap:IncomeTaxReconciliationDispositionOfBusiness" format="ixt:fixed-zero" scale="6" id="f-2517">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-694" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" format="ixt:fixed-zero" scale="-2" id="f-2518">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-695" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationDispositionOfBusiness" scale="6" id="f-2519">37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-695" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" scale="-2" id="f-2520">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-696" decimals="-6" name="us-gaap:IncomeTaxReconciliationDispositionOfBusiness" format="ixt:fixed-zero" scale="6" id="f-2521">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-696" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" format="ixt:fixed-zero" scale="-2" id="f-2522">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impact of businesses held for sale</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationDispositionOfBusiness" scale="6" id="f-2523">213</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-90" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" scale="-2" id="f-2524">3.9</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-697" decimals="-6" name="us-gaap:IncomeTaxReconciliationDispositionOfBusiness" format="ixt:fixed-zero" scale="6" id="f-2525">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-697" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" format="ixt:fixed-zero" scale="-2" id="f-2526">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-698" decimals="-6" name="us-gaap:IncomeTaxReconciliationDispositionOfBusiness" format="ixt:fixed-zero" scale="6" id="f-2527">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-698" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" format="ixt:fixed-zero" scale="-2" id="f-2528">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of foreign earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings" scale="6" id="f-2529">173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="ci:EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings" scale="-2" id="f-2530">3.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings" scale="6" id="f-2531">96</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="ci:EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings" scale="-2" id="f-2532">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings" scale="6" id="f-2533">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-8" decimals="3" name="ci:EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings" scale="-2" id="f-2534">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State income tax (benefit), net of federal income tax benefit</span></div></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="f-2535">39</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-2536">0.7</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="f-2537">16</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-2538">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="f-2539">9</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-8" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-2540">0.1</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss tax attributes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="ci:EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount" format="ixt:num-dot-decimal" scale="6" id="f-2541">1,674</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="ci:EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent" scale="-2" id="f-2542">30.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount" format="ixt:fixed-zero" scale="6" id="f-2543">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="ci:EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent" format="ixt:fixed-zero" scale="-2" id="f-2544">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount" format="ixt:fixed-zero" scale="6" id="f-2545">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="3" name="ci:EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent" format="ixt:fixed-zero" scale="-2" id="f-2546">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other foreign tax attributes</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="ci:EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount" scale="6" id="f-2547">153</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="ci:EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent" scale="-2" id="f-2548">2.8</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount" format="ixt:fixed-zero" scale="6" id="f-2549">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="ci:EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent" format="ixt:fixed-zero" scale="-2" id="f-2550">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount" format="ixt:fixed-zero" scale="6" id="f-2551">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="3" name="ci:EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent" format="ixt:fixed-zero" scale="-2" id="f-2552">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-2553">1,290</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-2554">23.4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:fixed-zero" scale="6" id="f-2555">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:fixed-zero" scale="-2" id="f-2556">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:fixed-zero" scale="6" id="f-2557">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:fixed-zero" scale="-2" id="f-2558">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="6" id="f-2559">55</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="f-2560">0.9</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="6" id="f-2561">31</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="f-2562">0.4</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="6" id="f-2563">14</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-8" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="f-2564">0.2</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total income taxes</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-2565">141</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-2566">2.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-2567">1,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-2568">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-2569">1,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-2570">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Consolidated pre-tax income from the Company's foreign operations was approximately <ix:nonFraction unitRef="number" contextRef="c-699" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-2571">48</ix:nonFraction>% of the Company's pre-tax income in 2023, <ix:nonFraction unitRef="number" contextRef="c-700" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-2572">46</ix:nonFraction>% in 2022 and <ix:nonFraction unitRef="number" contextRef="c-701" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-2573">26</ix:nonFraction>% in 2021. The increase over 2022 is primarily driven by an increase to the Company's international pharmaceutical operations, partially offset by a reduction in earnings from the sold entities. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Foreign Jurisdiction Tax Attributes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Impacting the effective tax rate for the year ended December&#160;31, 2023 was the recording of the Company's net deferred tax asset associated with foreign tax law changes and agreements in certain tax jurisdictions. The Company established deferred tax assets of approximately $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-8" name="ci:DeferredTaxAssetsForeignTaxAttributes" format="ixt:num-dot-decimal" scale="9" id="f-2574">1.8</ix:nonFraction> billion associated with the foreign tax attributes and a related $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DeferredTaxAssetsValuationAllowanceForeignTaxAttributes" format="ixt:num-dot-decimal" scale="6" id="f-2575">772</ix:nonFraction> million valuation allowance against these deferred tax assets based on projections of future earnings and requirements to utilize the assets within certain time periods. It is possible in future periods that the Company may revalue these net deferred tax assets due to modifications in certain assumptions such as forecasted future earnings. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Sale of Medicare Advantage and Related Businesses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-2576"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-2577">584</ix:nonFraction></ix:nonFraction> million of deferred tax benefits and an equal amount of valuation allowance in connection with the HCSC transaction. The valuation allowance has been recorded due to the uncertainty relative to the recovery of the deferred tax benefits as the Company does not currently have capital gain capacity to offset these capital losses. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">129</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-2480-3" continuedAt="f-2480-4"><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Deferred Income Taxes</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-2578" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred income tax assets and liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.041%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deferred tax assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee and retiree benefit plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIncludingDisposalGroupsAssetsHeldForSale" scale="6" id="f-2579">217</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="6" id="f-2580">189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other insurance and contractholder liabilities</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilitiesIncludingDisposalGroupsAssetsHeldForSale" scale="6" id="f-2581">353</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities" scale="6" id="f-2582">278</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DeferredTaxAssetsOperatingLossCarryforwardsIncludingDisposalGroupsAssetsHeldForSale" scale="6" id="f-2583">200</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="f-2584">205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred loss - sale of business</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" scale="6" id="f-2585">584</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" format="ixt:fixed-zero" scale="6" id="f-2586">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOtherIncludingDisposalGroupsAssetsHeldForSale" scale="6" id="f-2587">244</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" scale="6" id="f-2588">265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Policy acquisition expenses</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DeferredTaxAssetsPolicyAcquisitionExpensesIncludingDisposalGroupsAssetsHeldForSale" scale="6" id="f-2589">39</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:DeferredTaxAssetsPolicyAcquisitionExpenses" scale="6" id="f-2590">36</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized depreciation on investments and foreign currency translation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTransactionIncludingDisposalGroupsAssetsHeldForSale" scale="6" id="f-2591">81</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTranslation" scale="6" id="f-2592">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign tax attributes</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DeferredTaxAssetsForeignTaxAttributesIncludingDisposalGroupsAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-2593">1,827</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="ci:DeferredTaxAssetsForeignTaxAttributes" format="ixt:fixed-zero" scale="6" id="f-2594">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DeferredTaxAssetsOtherIncludingDisposalGroupsAssetsHeldForSale" scale="6" id="f-2595">242</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="f-2596">190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets before valuation allowance</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-2597">3,787</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-2598">1,322</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DeferredTaxAssetsValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-2599">1,498</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="f-2600">208</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets, net of valuation allowance</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-2601">2,289</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-2602">1,114</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DeferredTaxLiabilitiesPropertyPlantAndEquipmentIncludingDisposalGroupsAssetsHeldForSale" scale="6" id="f-2603">371</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="f-2604">512</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition-related basis differences</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIncludingDisposalGroupsAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-2605">8,105</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-2606">8,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DeferredTaxLiabilitiesOtherIncludingDisposalGroupsAssetsHeldForSale" format="ixt:fixed-zero" scale="6" id="f-2607">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="f-2608">41</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale" format="ixt:num-dot-decimal" scale="6" id="f-2609">8,476</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-2610">8,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net deferred income tax liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DeferredTaxLiabilitiesNetIncludingDisposalGroup" format="ixt:num-dot-decimal" scale="6" id="f-2611">6,187</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-2612">7,786</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Deferred tax liabilities, net in the Consolidated Balance Sheets as of December&#160;31, 2023, excludes $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DeferredTaxAssetsGrossInOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-2613">1,055</ix:nonFraction>&#160;million reported in Other assets and $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-2614">69</ix:nonFraction>&#160;million reported in liabilities of businesses held for sale.</span></div></ix:nonNumeric><ix:continuation id="f-2481-1" continuedAt="f-2481-2"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Management believes that future results will be sufficient to realize a majority of the Company's gross deferred tax assets. As of December&#160;31, 2023, we had approximately $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DeferredTaxAssetsInvestmentsSubjectToFederalCapitalLossUtilizationRules" format="ixt:num-dot-decimal" scale="6" id="f-2615">218</ix:nonFraction>&#160;million in deferred tax assets ("DTAs") associated with unrealized investment losses that are partially recorded in Accumulated other comprehensive loss. We have determined that a valuation allowance against the DTAs is not currently required based on the Company's ability to carry back losses and our ability and intent to hold certain securities until recovery. We continue to monitor and evaluate the need for any valuation allowance in the future. As of December&#160;31, 2023, we had approximately $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-8" name="ci:DeferredTaxAssetsForeignTaxAttributes" format="ixt:num-dot-decimal" scale="9" id="f-2616">1.8</ix:nonFraction> billion in DTAs associated with the foreign tax attributes as discussed above. We have determined that approximately $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="ci:DeferredTaxAssetsValuationAllowanceForeignTaxAttributes" format="ixt:num-dot-decimal" scale="6" id="f-2617">772</ix:nonFraction> million valuation allowance against these DTAs is required based on the Company's taxable income projections and the requirement to utilize the assets within certain time periods. Additionally, the Company has $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-2618"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-2619">584</ix:nonFraction></ix:nonFraction> million of deferred tax assets and a full valuation allowance associated with the HCSC transaction, as discussed above. Valuation allowances are established against deferred tax assets when it is determined that it is more likely than not that the asset will not be recognized. Valuation allowances have been established against certain federal, state and foreign tax attributes. There are multiple expiration dates associated with these tax attributes.</span></div></ix:continuation><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Uncertain Tax Positions</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-2620" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reconciliations of unrecognized tax benefits were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.043%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1,</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-2621">1,343</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-2622">1,230</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-2623">1,210</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Decrease) / Increase due to prior year positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="f-2624">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="f-2625">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="f-2626">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase due to current year positions</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="f-2627">107</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="f-2628">137</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="f-2629">31</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction related to settlements with taxing authorities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="f-2630">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="f-2631">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="f-2632">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction related to lapse of applicable statute of limitations</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="f-2633">12</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="f-2634">28</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="f-2635">17</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31,</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-2636">1,399</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-2637">1,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-2638">1,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Substantially all unrecognized tax benefits would impact Shareholders' net income if recognized. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-2481-2">The Company classifies net interest expense on uncertain tax positions as a component of income tax expense and in Other non-current liabilities in the Consolidated Balance Sheets.</ix:continuation> In addition to the amounts in the table above, the liability for net interest </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">130</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-2480-4"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">expense on uncertain tax positions was approximately $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" format="ixt:num-dot-decimal" scale="6" id="f-2639">220</ix:nonFraction> million as of December&#160;31, 2023, $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" format="ixt:num-dot-decimal" scale="6" id="f-2640">176</ix:nonFraction> million as of December&#160;31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" format="ixt:num-dot-decimal" scale="6" id="f-2641">148</ix:nonFraction> million as of December&#160;31, 2021.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Other Tax Matters</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The statutes of limitations for The Cigna Group's consolidated federal income tax returns through 2016 have closed. However, The Cigna Group filed amended returns for both the 2015 and 2016 tax years, which are under review by the Internal Revenue Service ("IRS"). Additionally, the IRS is examining The Cigna Group's returns for 2017 and 2018. The statutes of limitations for Express Scripts' consolidated federal income tax returns through 2012 has closed. However, for 2010 through 2012 tax years, there remains a significant disputed matter. The IRS is also examining Express Scripts' consolidated federal income tax returns for 2013 through 2018. The Company has established adequate reserves for these matters.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company conducts business in a number of state and foreign jurisdictions and may be engaged in multiple audit proceedings at any given time. Generally, no further state or foreign audit activity is expected for tax years prior to 2014 for The Cigna Group's entities and 2010 for Express Scripts' entities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Pillar Two. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 15, 2022, the European Union ("EU") Member States formally adopted the EU's Pillar Two Directive, which generally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation and Development ("OECD") Pillar Two Framework that was supported by over 130 countries worldwide. The EU effective dates are January 1, 2024, and January 1, 2025, for different aspects of the directive. A significant number of other countries are also implementing similar legislation, and the OECD continues to release additional guidance on these rules. The Company is within the scope of the OECD Pillar Two model rules and continues to evaluate the potential impact on future periods of the Pillar Two Framework, pending legislative adoption by additional individual countries but expects the impact to not materially change its results from operations.</span></div></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_628"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-2642" continuedAt="f-2642-1" escape="true"><div style="margin-bottom:10pt"><span id="i27908228960e40488ce1e12ef7d7a82d_2913"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 24 &#8211; Contingencies and Other Matters</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company, through its subsidiaries, is contingently liable for various guarantees provided in the ordinary course of business.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">A.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies" id="f-2643" continuedAt="f-2643-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Financial Guarantees: Retiree and Life Insurance Benefits</span></ix:nonNumeric></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-2643-1" continuedAt="f-2643-2">The Company guarantees that separate account assets will be sufficient to pay certain life insurance or retiree benefits. For the majority of these benefits, the sponsoring employers are primarily responsible for ensuring that assets are sufficient to pay these benefits and are required to maintain assets that exceed a certain percentage of benefit obligations. If employers fail to do so, the Company or an affiliate of the buyer of the retirement benefits business has the right to redirect the management of the related assets to provide for benefit payments.</ix:continuation> As of December&#160;31, 2023, employers maintained assets that generally exceeded the benefit obligations under these arrangements of approximately $<ix:nonFraction unitRef="usd" contextRef="c-702" decimals="-7" name="us-gaap:GuaranteeObligationsLiquidationProceeds" format="ixt:num-dot-decimal" scale="6" id="f-2644"><ix:nonFraction unitRef="usd" contextRef="c-703" decimals="-7" name="us-gaap:GuaranteeObligationsMaximumExposure" format="ixt:num-dot-decimal" scale="6" id="f-2645">420</ix:nonFraction></ix:nonFraction> million. <ix:continuation id="f-2643-2" continuedAt="f-2643-3">An additional liability is established if management believes that the Company will be required to make payments under the guarantees;</ix:continuation> there were <ix:nonFraction unitRef="usd" contextRef="c-703" decimals="INF" name="us-gaap:GuaranteeObligationsCurrentCarryingValue" format="ixt:fixed-zero" scale="6" id="f-2646">no</ix:nonFraction> additional liabilities required for these guarantees, net of reinsurance, as of December&#160;31, 2023. <ix:continuation id="f-2643-3" continuedAt="f-2643-4">Separate account assets supporting these guarantees are classified in Levels 1 and 2 of the GAAP fair value hierarchy.</ix:continuation></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company does not expect that these financial guarantees will have a material effect on the Company's consolidated results of operations, liquidity or financial condition.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">B.</span><ix:continuation id="f-2643-4" continuedAt="f-2643-5"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Certain Other Guarantees</span></ix:continuation></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-2643-5" continuedAt="f-2643-6">The Company had indemnification obligations as of December&#160;31, 2023 in connection with acquisition and disposition transactions. These indemnification obligations are triggered by the breach of representations or covenants provided by the Company, such as representations for the presentation of financial statements, filing of tax returns, compliance with laws or regulations or identification of outstanding litigation. These obligations are typically subject to various time limitations, defined by the contract or by operation of law, such as statutes of limitation. In some cases, the maximum potential amount due is subject to contractual limitations based on a stated dollar amount or a percentage of the transaction purchase price, while in other cases limitations are not specified or applicable. The Company does not believe that it is possible to determine the maximum potential amount due under these obligations because not all amounts due under these indemnification obligations are subject to limitation.</ix:continuation> There were <ix:nonFraction unitRef="usd" contextRef="c-704" decimals="INF" name="us-gaap:GuaranteeObligationsCurrentCarryingValue" format="ixt:fixed-zero" scale="0" id="f-2647">no</ix:nonFraction> liabilities for these indemnification obligations as of December&#160;31, 2023.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">C.</span><ix:continuation id="f-2643-6" continuedAt="f-2643-7"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Guaranty Fund Assessments</span></ix:continuation></div><ix:continuation id="f-2643-7"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company operates in a regulatory environment that may require its participation in assessments under state insurance guaranty association laws. The Company's exposure to assessments for certain obligations of insolvent insurance companies to policyholders and claimants is based on its share of business written in the relevant jurisdictions.</span></div></ix:continuation></ix:nonNumeric><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">131</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-2642-1" continuedAt="f-2642-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There were no material charges or credits resulting from existing or new guaranty fund assessments for the year ended December&#160;31, 2023.</span></div></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_631"></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">D.</span><ix:continuation id="f-2642-2" continuedAt="f-2642-3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Legal and Regulatory Matters</span></ix:continuation></div><ix:continuation id="f-2642-3" continuedAt="f-2642-4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is routinely involved in numerous claims, lawsuits, regulatory inquiries and audits, government investigations, including under the federal False Claims Act and state false claims acts initiated by a government investigating body or by a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> relator's filing of a complaint under court seal, and other legal matters arising, for the most part, in the ordinary course of managing a global health company. Additionally, the Company has received and is cooperating with subpoenas or similar processes from various governmental agencies requesting information, all arising in the normal course of its business. Disputed tax matters arising from audits by the Internal Revenue Service or other state and foreign jurisdictions, including those resulting in litigation, are accounted for under GAAP guidance for uncertain tax positions, as described in Note 23.</span></div></ix:continuation><div style="margin-bottom:10pt"><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_637"></div><ix:continuation id="f-2642-4" continuedAt="f-2642-5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pending litigation and legal or regulatory matters that the Company has identified with a reasonably possible material loss and certain other material litigation matters are described below. For those matters that the Company has identified with a reasonably possible material loss, the Company provides disclosure in the aggregate of accruals and range of loss, or a statement that such information cannot be estimated. The Company's accrual for the matter discussed below under "Litigation Matters" is not material. Due to numerous uncertain factors presented in this case, it is not possible to estimate an aggregate range of loss (if any) for this matter at this time. In light of the uncertainties involved in this matter, there is no assurance that its ultimate resolution will not exceed the amount currently accrued by the Company. An adverse outcome in this matter could be material to the Company's results of operations, financial condition or liquidity for any particular period. The outcomes of lawsuits are inherently unpredictable and we may be unsuccessful in this ongoing litigation matter or any future claims or litigation.</span></div></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_640"></div><ix:continuation id="f-2642-5"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Litigation Matters</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Express Scripts Litigation with Elevance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. In March 2016, Elevance filed a lawsuit in the United States District Court for the Southern District of New York alleging various breach of contract claims against Express Scripts relating to the parties' rights and obligations under the periodic pricing review section of the pharmacy benefit management agreement between the parties including allegations that Express Scripts failed to negotiate new pricing concessions in good faith, as well as various alleged service issues. Elevance also requested that the court enter declaratory judgment that Express Scripts is required to provide Elevance competitive benchmark pricing, that Elevance can terminate the agreement and that Express Scripts is required to provide Elevance with post-termination services at competitive benchmark pricing for one year following any termination by Elevance. Elevance claimed it is entitled to $<ix:nonFraction unitRef="usd" contextRef="c-705" decimals="-9" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="9" id="f-2648">13</ix:nonFraction> billion in additional pricing concessions over the remaining term of the agreement, as well as $<ix:nonFraction unitRef="usd" contextRef="c-706" decimals="-8" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="9" id="f-2649">1.8</ix:nonFraction> billion for one year following any contract termination by Elevance and $<ix:nonFraction unitRef="usd" contextRef="c-707" decimals="-6" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="6" id="f-2650">150</ix:nonFraction> million damages for service issues ("Elevance's Allegations"). On April 19, 2016, in response to Elevance's complaint, Express Scripts filed its answer denying Elevance's Allegations in their entirety and asserting affirmative defenses and counterclaims against Elevance. The court subsequently granted Elevance's motion to dismiss <ix:nonFraction unitRef="claim" contextRef="c-708" decimals="INF" name="us-gaap:LossContingencyClaimsDismissedNumber" format="ixt-sec:numwordsen" scale="0" id="f-2651">two</ix:nonFraction> of <ix:nonFraction unitRef="claim" contextRef="c-709" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="f-2652">six</ix:nonFraction> counts of Express Scripts' amended counterclaims. Express Scripts filed its Motion for Summary Judgment on August 27, 2021. Elevance completed filing of its Response to Express Scripts' Motion for Summary Judgment on October 16, 2021. Express Scripts filed its Reply in Support of its Motion for Summary Judgment on November 19, 2021. On March 31, 2022, the court granted summary judgment in favor of Express Scripts on all of Elevance's pricing claims for damages totaling $<ix:nonFraction unitRef="usd" contextRef="c-710" decimals="-8" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="9" id="f-2653">14.8</ix:nonFraction> billion and on most of Elevance's claims relating to service issues. Elevance's only remaining service claims relate to the review or processing of prior authorizations, with alleged damages over $<ix:nonFraction unitRef="usd" contextRef="c-711" decimals="-6" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="6" id="f-2654">100</ix:nonFraction>&#160;million. On November 1, 2023, the parties signed a settlement agreement pursuant to which Express Scripts agreed to resolve the service-related claims. The settlement agreement is not an admission of liability or fault by Express Scripts, the Company or its subsidiaries. Following the settlement, Elevance retains the right to appeal the pricing-related claims that were previously dismissed by the court and Express Scripts retains the ability to reassert its own pricing-related claims in the event any appeal by Elevance is successful. Elevance filed its Notice of Appeal of its pricing-related claims on December 12, 2023. Elevance&#8217;s opening appellate brief is due March 25, 2024.</span></div></ix:continuation><div style="margin-bottom:10pt"><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_646"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-2657" continuedAt="f-2657-1" escape="true"><div style="margin-bottom:10pt"><span id="ia1cd7ace6b8e4804a5b34bf3f9213da6_446"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 25 &#8211; Segment Information</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See Note 1 to the Consolidated Financial Statements for a description of our segments. A description of our basis for reporting segment operating results is outlined below. <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-2658" continuedAt="f-2658-1" escape="true">Intersegment revenues primarily reflect pharmacy and care services transactions between the Evernorth Health Services and Cigna Healthcare segments.</ix:nonNumeric></span></div><ix:continuation id="f-2658-1" continuedAt="f-2658-2"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company uses "pre-tax adjusted income (loss) from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management believes these metrics best reflect the underlying results of business operations and permit analysis of trends in underlying revenue, expenses and profitability. We define pre-tax adjusted income from operations as income before income taxes excluding pre-tax income (loss) attributable to noncontrolling interests, net realized investment results, amortization of acquired intangible assets, and special items. The Cigna Group's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters </span></div></ix:continuation></ix:nonNumeric><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">132</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-2657-1" continuedAt="f-2657-2"><ix:continuation id="f-2658-2" continuedAt="f-2658-3"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">that management believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. </span></div></ix:continuation><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-2658-3">The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future underlying performance of the business.</ix:continuation> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company does not report total assets by segment because this is not a metric used to allocate resources or evaluate segment performance.</span></div></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_649"></div><ix:nonNumeric contextRef="c-1" name="ci:ScheduleOfSpecialItemsTableTextBlock" id="f-2659" escape="true"><ix:continuation id="f-2657-2" continuedAt="f-2657-3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the special items charges (benefits) recorded by the Company, as well as the respective financial statement line items impacted: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.372%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="33" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">After-tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">After-tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">After-tax</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss (gain) on sale of businesses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" format="ixt:num-dot-decimal" scale="6" id="f-2660">1,499</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="ci:SpecialItemGainLossOnSaleOfBusinessNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-2661">1,429</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" format="ixt:num-dot-decimal" scale="6" id="f-2662">1,662</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:SpecialItemGainLossOnSaleOfBusinessNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-2663">1,332</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" format="ixt:fixed-zero" scale="6" id="f-2664">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:SpecialItemGainLossOnSaleOfBusinessNetOfTax" format="ixt:fixed-zero" scale="6" id="f-2665">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charge for organizational efficiency plan<br/>&#160;(Selling, general and administrative expenses)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-2666">252</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:RestructuringChargesNetOfTaxExpense" scale="6" id="f-2667">193</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-2668">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:RestructuringChargesNetOfTaxExpense" scale="6" id="f-2669">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-2670">168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:RestructuringChargesNetOfTaxExpense" scale="6" id="f-2671">119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charges (benefits) associated with litigation matters<br/>&#160;(Selling, general and administrative expenses)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:SpecialItemChargeBenefitBeforeTaxLitigation" scale="6" id="f-2672">201</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:SpecialItemChargeBenefitAfterTaxLitigation" scale="6" id="f-2673">171</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="ci:SpecialItemChargeBenefitBeforeTaxLitigation" scale="6" id="f-2674">28</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="ci:SpecialItemChargeBenefitAfterTaxLitigation" scale="6" id="f-2675">20</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="ci:SpecialItemChargeBenefitBeforeTaxLitigation" scale="6" id="f-2676">27</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="ci:SpecialItemChargeBenefitAfterTaxLitigation" scale="6" id="f-2677">21</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Integration and transaction-related costs<br/>&#160;(Selling, general and administrative expenses)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:TransactionRelatedCosts" scale="6" id="f-2678">45</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:TransactionRelatedCostsAfterTax" scale="6" id="f-2679">35</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:TransactionRelatedCosts" scale="6" id="f-2680">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:TransactionRelatedCostsAfterTax" scale="6" id="f-2681">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:TransactionRelatedCosts" scale="6" id="f-2682">169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:TransactionRelatedCostsAfterTax" scale="6" id="f-2683">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax (benefits), net<br/>&#160;(Income taxes, less amount attributable to noncontrolling interests)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:SpecialItemChargeBenefitTaxMatters" format="ixt:fixed-zero" scale="6" id="f-2684">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="ci:SpecialItemChargeBenefitTaxMattersAfterTax" format="ixt:num-dot-decimal" scale="6" id="f-2685">1,071</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:SpecialItemChargeBenefitTaxMatters" format="ixt:fixed-zero" scale="6" id="f-2686">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:SpecialItemChargeBenefitTaxMattersAfterTax" format="ixt:fixed-zero" scale="6" id="f-2687">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:SpecialItemChargeBenefitTaxMatters" format="ixt:fixed-zero" scale="6" id="f-2688">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:SpecialItemChargeBenefitTaxMattersAfterTax" format="ixt:fixed-zero" scale="6" id="f-2689">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt extinguishment costs </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:SpecialItemChargesDebtExtinguishmentCostsBeforeTax" format="ixt:fixed-zero" scale="6" id="f-2690">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:SpecialItemChargesDebtExtinguishmentCostsNetOfTax" format="ixt:fixed-zero" scale="6" id="f-2691">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:SpecialItemChargesDebtExtinguishmentCostsBeforeTax" format="ixt:fixed-zero" scale="6" id="f-2692">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:SpecialItemChargesDebtExtinguishmentCostsNetOfTax" format="ixt:fixed-zero" scale="6" id="f-2693">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:SpecialItemChargesDebtExtinguishmentCostsBeforeTax" scale="6" id="f-2694">141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:SpecialItemChargesDebtExtinguishmentCostsNetOfTax" scale="6" id="f-2695">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total impact from special items</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="ci:SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity" format="ixt:num-dot-decimal" scale="6" id="f-2696">1,997</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="ci:SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity" scale="6" id="f-2697">757</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity" format="ixt:num-dot-decimal" scale="6" id="f-2698">1,533</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity" format="ixt:num-dot-decimal" scale="6" id="f-2699">1,232</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="ci:SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity" scale="6" id="f-2700">451</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="ci:SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity" scale="6" id="f-2701">279</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">133</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_661"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-2702" continuedAt="f-2702-1" escape="true"><ix:continuation id="f-2657-3" continuedAt="f-2657-4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Effective January 1, 2023, we adopted amended accounting guidance for long-duration insurance contracts. See Note 2 to the Consolidated Financial Statements for further information. Prior period summarized segment information has been retrospectively adjusted to conform to this new basis of accounting. Summarized segment financial information was as follows:</span></div></ix:continuation></ix:nonNumeric><div id="ibc59a92ac8bc42f794e728f24ce1b626_667"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%"> </span><ix:continuation id="f-2702-1" continuedAt="f-2702-2"><ix:continuation id="f-2657-4" continuedAt="f-2657-5"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.349%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Evernorth Health Services</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cigna Healthcare</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Operations</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate and Eliminations</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="33" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from external customers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-659" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-2703">147,588</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-2704">46,219</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-660" decimals="-6" name="ci:NonInvestmentRevenue" scale="6" id="f-2705">291</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-714" decimals="-6" name="ci:NonInvestmentRevenue" scale="6" id="f-2706">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-2707">194,099</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-715" decimals="-6" sign="-" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-2708">5,670</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-716" decimals="-6" sign="-" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-2709">4,332</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-717" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:fixed-zero" scale="6" id="f-2710">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-718" decimals="-6" sign="-" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-2711">10,002</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net investment income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-719" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="f-2712">241</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-720" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="f-2713">597</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-721" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="f-2714">305</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-722" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="f-2715">23</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:num-dot-decimal" scale="6" id="f-2716">1,166</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-719" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-2717">153,499</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-720" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-2718">51,148</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-721" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-2719">596</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-722" decimals="-6" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-2720">9,978</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-2721">195,265</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net realized investment results from certain equity method investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-719" decimals="-6" name="ci:RealizedInvestmentGainsLossesEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-2722">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-720" decimals="-6" sign="-" name="ci:RealizedInvestmentGainsLossesEquityMethodInvestments" scale="6" id="f-2723">57</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-721" decimals="-6" name="ci:RealizedInvestmentGainsLossesEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-2724">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-722" decimals="-6" name="ci:RealizedInvestmentGainsLossesEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-2725">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="ci:RealizedInvestmentGainsLossesEquityMethodInvestments" scale="6" id="f-2726">57</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-719" decimals="-6" name="ci:SegmentRevenues" format="ixt:num-dot-decimal" scale="6" id="f-2727">153,499</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-720" decimals="-6" name="ci:SegmentRevenues" format="ixt:num-dot-decimal" scale="6" id="f-2728">51,205</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-721" decimals="-6" name="ci:SegmentRevenues" scale="6" id="f-2729">596</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-722" decimals="-6" sign="-" name="ci:SegmentRevenues" format="ixt:num-dot-decimal" scale="6" id="f-2730">9,978</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:SegmentRevenues" format="ixt:num-dot-decimal" scale="6" id="f-2731">195,322</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-719" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-2732">2,438</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-720" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-2733">569</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-721" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-2734">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-722" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-2735">25</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-2736">3,035</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-719" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2737">4,768</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-720" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2738">2,664</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-721" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-2739">76</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-722" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2740">1,995</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2741">5,513</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax adjustments to reconcile to adjusted income from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Income) attributable to noncontrolling interests</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-719" decimals="-6" name="ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax" scale="6" id="f-2742">144</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-720" decimals="-6" name="ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax" scale="6" id="f-2743">2</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-721" decimals="-6" name="ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax" format="ixt:fixed-zero" scale="6" id="f-2744">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-714" decimals="-6" name="ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax" format="ixt:fixed-zero" scale="6" id="f-2745">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax" scale="6" id="f-2746">146</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net realized investment losses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-719" decimals="-6" name="ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries" format="ixt:fixed-zero" scale="6" id="f-2747">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-720" decimals="-6" sign="-" name="ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries" scale="6" id="f-2748">133</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-721" decimals="-6" sign="-" name="ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries" scale="6" id="f-2749">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-714" decimals="-6" name="ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries" format="ixt:fixed-zero" scale="6" id="f-2750">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries" scale="6" id="f-2751">135</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-719" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-2752">1,774</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-720" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-2753">45</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-721" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="6" id="f-2754">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-714" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="6" id="f-2755">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-2756">1,819</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Special items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on sale of businesses</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-719" decimals="-6" name="ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" format="ixt:fixed-zero" scale="6" id="f-2757">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-720" decimals="-6" sign="-" name="ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" format="ixt:num-dot-decimal" scale="6" id="f-2758">1,481</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-721" decimals="-6" sign="-" name="ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" scale="6" id="f-2759">18</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-714" decimals="-6" name="ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" format="ixt:fixed-zero" scale="6" id="f-2760">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" format="ixt:num-dot-decimal" scale="6" id="f-2761">1,499</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charge for organizational efficiency plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-719" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-2762">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-720" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-2763">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-721" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-2764">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-714" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-2765">252</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-2766">252</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charges associated with litigation matters</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-719" decimals="-6" name="ci:SpecialItemChargeBenefitBeforeTaxLitigation" scale="6" id="f-2767">44</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-720" decimals="-6" name="ci:SpecialItemChargeBenefitBeforeTaxLitigation" scale="6" id="f-2768">157</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-721" decimals="-6" name="ci:SpecialItemChargeBenefitBeforeTaxLitigation" format="ixt:fixed-zero" scale="6" id="f-2769">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-714" decimals="-6" name="ci:SpecialItemChargeBenefitBeforeTaxLitigation" format="ixt:fixed-zero" scale="6" id="f-2770">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:SpecialItemChargeBenefitBeforeTaxLitigation" scale="6" id="f-2771">201</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Integration and transaction-related costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-719" decimals="-6" name="ci:TransactionRelatedCosts" format="ixt:fixed-zero" scale="6" id="f-2772">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-720" decimals="-6" name="ci:TransactionRelatedCosts" format="ixt:fixed-zero" scale="6" id="f-2773">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-721" decimals="-6" name="ci:TransactionRelatedCosts" format="ixt:fixed-zero" scale="6" id="f-2774">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-714" decimals="-6" name="ci:TransactionRelatedCosts" scale="6" id="f-2775">45</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:TransactionRelatedCosts" scale="6" id="f-2776">45</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted income (loss) from operations</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-719" decimals="-6" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2777">6,442</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-720" decimals="-6" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2778">4,478</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-721" decimals="-6" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-2779">96</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-722" decimals="-6" sign="-" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2780">1,698</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2781">9,318</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Evernorth Health Services</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cigna Healthcare</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Operations</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate and Eliminations</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="33" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from external customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-656" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-2782">135,786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-2783">41,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-657" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-2784">1,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-723" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:fixed-zero" scale="6" id="f-2785">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-2786">179,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-724" decimals="-6" sign="-" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-2787">4,463</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-725" decimals="-6" sign="-" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-2788">2,535</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-726" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:fixed-zero" scale="6" id="f-2789">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-727" decimals="-6" sign="-" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-2790">6,998</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net investment income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-728" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="f-2791">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-729" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="f-2792">638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="f-2793">424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-731" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="f-2794">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:num-dot-decimal" scale="6" id="f-2795">1,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-728" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-2796">140,335</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-729" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-2797">44,911</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-2798">2,263</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-731" decimals="-6" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-2799">6,991</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-2800">180,518</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net realized investment results from certain equity method investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-728" decimals="-6" name="ci:RealizedInvestmentGainsLossesEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-2801">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-729" decimals="-6" sign="-" name="ci:RealizedInvestmentGainsLossesEquityMethodInvestments" scale="6" id="f-2802">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-6" name="ci:RealizedInvestmentGainsLossesEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-2803">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-731" decimals="-6" name="ci:RealizedInvestmentGainsLossesEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-2804">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="ci:RealizedInvestmentGainsLossesEquityMethodInvestments" scale="6" id="f-2805">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-728" decimals="-6" name="ci:SegmentRevenues" format="ixt:num-dot-decimal" scale="6" id="f-2806">140,335</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-729" decimals="-6" name="ci:SegmentRevenues" format="ixt:num-dot-decimal" scale="6" id="f-2807">45,037</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-6" name="ci:SegmentRevenues" format="ixt:num-dot-decimal" scale="6" id="f-2808">2,263</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-731" decimals="-6" sign="-" name="ci:SegmentRevenues" format="ixt:num-dot-decimal" scale="6" id="f-2809">6,991</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:SegmentRevenues" format="ixt:num-dot-decimal" scale="6" id="f-2810">180,644</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-728" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-2811">2,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-729" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-2812">638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-2813">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-731" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-2814">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-2815">2,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-728" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2816">4,421</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-729" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2817">3,470</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2818">2,101</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-731" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2819">1,595</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2820">8,397</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax adjustments to reconcile to adjusted income from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Income) attributable to noncontrolling interests</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-728" decimals="-6" name="ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax" scale="6" id="f-2821">66</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-729" decimals="-6" name="ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax" scale="6" id="f-2822">4</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-6" name="ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax" scale="6" id="f-2823">14</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-723" decimals="-6" name="ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax" format="ixt:fixed-zero" scale="6" id="f-2824">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax" scale="6" id="f-2825">84</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net realized investment losses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-728" decimals="-6" name="ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries" format="ixt:fixed-zero" scale="6" id="f-2826">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-729" decimals="-6" sign="-" name="ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries" scale="6" id="f-2827">530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-6" sign="-" name="ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries" scale="6" id="f-2828">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-723" decimals="-6" name="ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries" format="ixt:fixed-zero" scale="6" id="f-2829">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries" scale="6" id="f-2830">613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-728" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-2831">1,772</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-729" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-2832">103</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-2833">1</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-723" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="6" id="f-2834">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-2835">1,876</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Special items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) on sale of businesses</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-728" decimals="-6" name="ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" format="ixt:fixed-zero" scale="6" id="f-2836">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-729" decimals="-6" name="ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" format="ixt:fixed-zero" scale="6" id="f-2837">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-6" name="ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" format="ixt:num-dot-decimal" scale="6" id="f-2838">1,662</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-723" decimals="-6" name="ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" format="ixt:fixed-zero" scale="6" id="f-2839">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" format="ixt:num-dot-decimal" scale="6" id="f-2840">1,662</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charge for organizational efficiency plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-728" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-2841">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-729" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-2842">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-2843">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-723" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-2844">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-2845">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Benefits) associated with litigation matters</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-728" decimals="-6" name="ci:SpecialItemChargeBenefitBeforeTaxLitigation" format="ixt:fixed-zero" scale="6" id="f-2846">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-729" decimals="-6" name="ci:SpecialItemChargeBenefitBeforeTaxLitigation" format="ixt:fixed-zero" scale="6" id="f-2847">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-6" name="ci:SpecialItemChargeBenefitBeforeTaxLitigation" format="ixt:fixed-zero" scale="6" id="f-2848">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-723" decimals="-6" sign="-" name="ci:SpecialItemChargeBenefitBeforeTaxLitigation" scale="6" id="f-2849">28</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="ci:SpecialItemChargeBenefitBeforeTaxLitigation" scale="6" id="f-2850">28</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Integration and transaction-related costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-728" decimals="-6" name="ci:TransactionRelatedCosts" format="ixt:fixed-zero" scale="6" id="f-2851">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-729" decimals="-6" name="ci:TransactionRelatedCosts" format="ixt:fixed-zero" scale="6" id="f-2852">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-6" name="ci:TransactionRelatedCosts" format="ixt:fixed-zero" scale="6" id="f-2853">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-723" decimals="-6" name="ci:TransactionRelatedCosts" scale="6" id="f-2854">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:TransactionRelatedCosts" scale="6" id="f-2855">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted income (loss) from operations</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-728" decimals="-6" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2856">6,127</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-729" decimals="-6" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2857">4,099</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-6" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-2858">509</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-731" decimals="-6" sign="-" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2859">1,466</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2860">9,269</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation></ix:continuation></div><ix:continuation id="f-2702-2" continuedAt="f-2702-3"><ix:continuation id="f-2657-5" continuedAt="f-2657-6"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes the Company's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div></ix:continuation></ix:continuation><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">134</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_670"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-2657-6" continuedAt="f-2657-7"><ix:continuation id="f-2702-3" continuedAt="f-2702-4"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.046%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Evernorth Health Services</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cigna Healthcare</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate and Eliminations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from external customers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-732" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-2861">127,692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-2862">41,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-733" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-2863">3,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-734" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:fixed-zero" scale="6" id="f-2864">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-2865">172,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-735" decimals="-6" sign="-" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-2866">4,203</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-736" decimals="-6" sign="-" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-2867">2,271</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-737" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:fixed-zero" scale="6" id="f-2868">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-738" decimals="-6" sign="-" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-2869">6,474</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net investment income (loss)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-739" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="f-2870">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-740" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:num-dot-decimal" scale="6" id="f-2871">1,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-741" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="f-2872">530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-742" decimals="-6" sign="-" name="us-gaap:NetInvestmentIncome" scale="6" id="f-2873">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:num-dot-decimal" scale="6" id="f-2874">1,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-739" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-2875">131,912</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-740" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-2876">44,643</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-741" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-2877">3,989</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-742" decimals="-6" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-2878">6,475</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-2879">174,069</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net realized investment results from certain equity method investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-739" decimals="-6" name="ci:RealizedInvestmentGainsLossesEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-2880">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-740" decimals="-6" name="ci:RealizedInvestmentGainsLossesEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-2881">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-741" decimals="-6" name="ci:RealizedInvestmentGainsLossesEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-2882">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-742" decimals="-6" name="ci:RealizedInvestmentGainsLossesEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-2883">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:RealizedInvestmentGainsLossesEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-2884">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-739" decimals="-6" name="ci:SegmentRevenues" format="ixt:num-dot-decimal" scale="6" id="f-2885">131,912</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-740" decimals="-6" name="ci:SegmentRevenues" format="ixt:num-dot-decimal" scale="6" id="f-2886">44,643</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-741" decimals="-6" name="ci:SegmentRevenues" format="ixt:num-dot-decimal" scale="6" id="f-2887">3,989</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-742" decimals="-6" sign="-" name="ci:SegmentRevenues" format="ixt:num-dot-decimal" scale="6" id="f-2888">6,475</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:SegmentRevenues" format="ixt:num-dot-decimal" scale="6" id="f-2889">174,069</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-739" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-2890">2,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-740" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-2891">551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-741" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-2892">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-742" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-2893">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-2894">2,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-739" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2895">3,908</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-740" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2896">3,804</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-741" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-2897">868</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-742" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2898">1,790</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2899">6,790</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax adjustments to reconcile to adjusted income from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Income) attributable to noncontrolling interests</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-739" decimals="-6" name="ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax" scale="6" id="f-2900">31</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-740" decimals="-6" name="ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax" scale="6" id="f-2901">3</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-741" decimals="-6" name="ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax" scale="6" id="f-2902">24</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-734" decimals="-6" name="ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax" format="ixt:fixed-zero" scale="6" id="f-2903">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax" scale="6" id="f-2904">58</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net realized investment losses (gains) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-739" decimals="-6" sign="-" name="ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries" scale="6" id="f-2905">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-740" decimals="-6" name="ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries" scale="6" id="f-2906">247</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-741" decimals="-6" sign="-" name="ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries" scale="6" id="f-2907">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-734" decimals="-6" name="ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries" format="ixt:fixed-zero" scale="6" id="f-2908">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries" scale="6" id="f-2909">198</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-739" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-2910">1,937</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-740" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-2911">47</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-741" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-2912">14</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-734" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="6" id="f-2913">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-2914">1,998</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Special items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charge for organizational efficiency plan</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-739" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-2915">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-740" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-2916">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-741" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-2917">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-734" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-2918">168</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-2919">168</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Benefits) associated with litigation matters</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-739" decimals="-6" name="ci:SpecialItemChargeBenefitBeforeTaxLitigation" format="ixt:fixed-zero" scale="6" id="f-2920">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-740" decimals="-6" name="ci:SpecialItemChargeBenefitBeforeTaxLitigation" format="ixt:fixed-zero" scale="6" id="f-2921">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-741" decimals="-6" name="ci:SpecialItemChargeBenefitBeforeTaxLitigation" format="ixt:fixed-zero" scale="6" id="f-2922">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-734" decimals="-6" sign="-" name="ci:SpecialItemChargeBenefitBeforeTaxLitigation" scale="6" id="f-2923">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="ci:SpecialItemChargeBenefitBeforeTaxLitigation" scale="6" id="f-2924">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Integration and transaction-related costs</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-739" decimals="-6" name="ci:TransactionRelatedCosts" format="ixt:fixed-zero" scale="6" id="f-2925">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-740" decimals="-6" name="ci:TransactionRelatedCosts" format="ixt:fixed-zero" scale="6" id="f-2926">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-741" decimals="-6" name="ci:TransactionRelatedCosts" format="ixt:fixed-zero" scale="6" id="f-2927">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-734" decimals="-6" name="ci:TransactionRelatedCosts" scale="6" id="f-2928">169</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:TransactionRelatedCosts" scale="6" id="f-2929">169</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt extinguishment costs </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-739" decimals="-6" name="ci:SpecialItemChargesDebtExtinguishmentCostsBeforeTax" format="ixt:fixed-zero" scale="6" id="f-2930">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-740" decimals="-6" name="ci:SpecialItemChargesDebtExtinguishmentCostsBeforeTax" format="ixt:fixed-zero" scale="6" id="f-2931">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-741" decimals="-6" name="ci:SpecialItemChargesDebtExtinguishmentCostsBeforeTax" format="ixt:fixed-zero" scale="6" id="f-2932">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-734" decimals="-6" name="ci:SpecialItemChargesDebtExtinguishmentCostsBeforeTax" scale="6" id="f-2933">141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:SpecialItemChargesDebtExtinguishmentCostsBeforeTax" scale="6" id="f-2934">141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted income (loss) from operations</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-739" decimals="-6" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2935">5,818</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-740" decimals="-6" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2936">3,601</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-741" decimals="-6" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-2937">903</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-742" decimals="-6" sign="-" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2938">1,339</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2939">8,983</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:10pt;padding-left:9pt;text-indent:-9pt"><ix:continuation id="f-2702-4" continuedAt="f-2702-5"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"><ix:continuation id="f-2702-5"> Includes the Company's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting.</ix:continuation> </span></div></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">135</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_673"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="f-2940" escape="true"><ix:continuation id="f-2657-7" continuedAt="f-2657-8"><div><span id="i447ccaf65a4944e2ab470d4dcddafa7a_953"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue from external customers includes Pharmacy revenues, Premiums and Fees and other revenues. Prior period amounts have been retrospectively adjusted to reflect adoption of amended accounting guidance for long-duration insurance contracts (as discussed in Note 2 to the Consolidated Financial Statements) and to reflect the merger of the U.S. Commercial and U.S. Government operating segments into the U.S. Healthcare operating segment (as discussed in Note 1 to the Consolidated Financial Statements). The following table presents these revenues by product, premium and service type:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.761%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.042%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Products (Pharmacy revenues) (ASC 606)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Network revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-743" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2941">67,514</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-744" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2942">64,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-745" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2943">64,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Home delivery and specialty revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-746" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2944">65,732</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-747" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2945">61,283</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-748" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2946">54,391</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-749" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2947">9,047</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-750" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2948">6,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-751" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2949">6,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intercompany eliminations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-752" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2950">5,050</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-753" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2951">4,416</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-754" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2952">4,398</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total pharmacy revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2953">137,243</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2954">128,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2955">121,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance premiums (ASC 944)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cigna Healthcare</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">U.S. Healthcare</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employer insured</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-755" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2956">16,490</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-756" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2957">15,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-757" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2958">14,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-758" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2959">8,771</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-759" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2960">7,896</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-760" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2961">8,362</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stop loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-761" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2962">6,143</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-762" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2963">5,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-763" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2964">4,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Individual and Family Plans</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-764" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2965">5,088</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-765" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2966">2,636</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-766" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2967">2,528</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-767" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2968">4,095</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-768" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2969">3,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-769" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2970">5,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Healthcare</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-770" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2971">40,587</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-771" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2972">35,188</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-772" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2973">35,149</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International Health</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-773" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2974">3,295</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-774" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2975">2,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-775" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2976">2,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Cigna Healthcare</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-720" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2977">43,882</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-729" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2978">38,094</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-740" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2979">37,737</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Divested International businesses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-776" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:fixed-zero" scale="6" id="f-2980">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-777" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2981">1,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-778" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2982">3,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-779" decimals="-6" name="us-gaap:PremiumsEarnedNet" scale="6" id="f-2983">281</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-780" decimals="-6" name="us-gaap:PremiumsEarnedNet" scale="6" id="f-2984">225</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-781" decimals="-6" name="us-gaap:PremiumsEarnedNet" scale="6" id="f-2985">221</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intercompany eliminations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-718" decimals="-6" name="us-gaap:PremiumsEarnedNet" scale="6" id="f-2986">74</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-727" decimals="-6" name="us-gaap:PremiumsEarnedNet" scale="6" id="f-2987">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-738" decimals="-6" sign="-" name="us-gaap:PremiumsEarnedNet" scale="6" id="f-2988">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total premiums</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2989">44,237</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2990">39,916</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2991">41,154</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Services (Fees) (ASC 606)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Evernorth Health Services</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-782" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2992">10,866</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-783" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2993">7,234</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-784" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2994">6,070</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cigna Healthcare</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-785" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2995">6,566</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-786" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2996">6,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-787" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2997">5,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Operations</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-788" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2998">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-789" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2999">9</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-790" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-3000">19</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-791" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-3001">210</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-792" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-3002">168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-793" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-3003">188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intercompany eliminations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-794" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-3004">5,026</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-795" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-3005">2,583</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-796" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-3006">2,067</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total fees and other revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-3007">12,619</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-3008">10,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-3009">9,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues from external customers</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-3010">194,099</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-3011">179,363</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-3012">172,520</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_679"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" id="f-3013" escape="true"><ix:continuation id="f-2657-8" continuedAt="f-2657-9"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">U.S. and foreign revenues from external customers are shown below. The Company's foreign revenues are generated by its foreign operating entities. In the periods shown, no single foreign country contributed more than <ix:nonFraction unitRef="number" contextRef="c-797" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-3014"><ix:nonFraction unitRef="number" contextRef="c-798" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-3015"><ix:nonFraction unitRef="number" contextRef="c-799" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-3016">2</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of consolidated revenues from external customers.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.043%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-800" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-3017">189,840</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-801" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-3018">174,540</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-802" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-3019">166,626</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign countries </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-803" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-3020">4,259</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-804" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-3021">4,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-805" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-3022">5,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues from external customers</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-3023">194,099</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-3024">179,363</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="ci:NonInvestmentRevenue" format="ixt:num-dot-decimal" scale="6" id="f-3025">172,520</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> The divested International businesses as described in Note 5 comprised of $<ix:nonFraction unitRef="usd" contextRef="c-804" decimals="-8" name="ci:DisposalGroupIncludingDiscontinuedOperationsNonInvestmentRevenue" format="ixt:num-dot-decimal" scale="9" id="f-3026">1.6</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-805" decimals="-8" name="ci:DisposalGroupIncludingDiscontinuedOperationsNonInvestmentRevenue" format="ixt:num-dot-decimal" scale="9" id="f-3027">3.2</ix:nonFraction> billion in 2022 and 2021, respectively.</span></div></ix:continuation></ix:nonNumeric><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-2657-9">Revenues from U.S. Federal Government agencies, under a number of contracts, were <ix:nonFraction unitRef="number" contextRef="c-806" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-3028"><ix:nonFraction unitRef="number" contextRef="c-807" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-3029">15</ix:nonFraction></ix:nonFraction>% of consolidated revenues in 2023 and <ix:nonFraction unitRef="number" contextRef="c-808" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-3030">14</ix:nonFraction>% in both 2022 and 2021. These amounts were reported in the Evernorth Health Services and Cigna Healthcare segments.</ix:continuation> </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">136</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_1018"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span id="i200a74125c504ac194ee7b7a0ff5f3e1_103"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">None.</span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_5593"></div><div style="margin-bottom:10pt"><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_877"></div><div style="margin-bottom:10pt"><span id="i246e98c7f0374508acf58493233e2a67_30"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 9A. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">CONTROLS AND PROCEDURES</span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_880"></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt">Disclosure Controls and Procedures</span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_883"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on an evaluation of the effectiveness of The Cigna Group's disclosure controls and procedures conducted under the supervision and with the participation of The Cigna Group's management (including The Cigna Group's Chief Executive Officer and Chief Financial Officer), The Cigna Group's Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period covered by this report, The Cigna Group's disclosure controls and procedures are effective to ensure that information required to be disclosed by The Cigna Group in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms and is accumulated and communicated to The Cigna Group's management, including The Cigna Group's Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_886"></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt">Internal Control Over Financial Reporting</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Management's Annual Report on Internal Control over Financial Reporting</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Management of The Cigna Group is responsible for establishing and maintaining adequate internal control over financial reporting. The Company's internal controls were designed to provide reasonable assurance that the Company's consolidated published financial statements for external purposes were prepared in accordance with accounting principles generally accepted in the United States. The Company's internal control over financial reporting includes those policies and procedures that:</span></div><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:17.57pt">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;</span></div><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.8pt">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States and that receipts and expenditures of the Company are being made only in accordance with authorization of management and directors of the Company; and</span></div><div style="margin-bottom:10pt;padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(iii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.03pt">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisitions, use or disposition of the Company's assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Management assessed the effectiveness of the Company's internal control over financial reporting as of December&#160;31, 2023. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO") in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Internal Control-Integrated Framework (2013).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Based on management's assessment and the criteria set forth by COSO, it was determined that the Company's internal control over financial reporting is effective as of December&#160;31, 2023.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's independent registered public accounting firm, PricewaterhouseCoopers LLP, has audited the effectiveness of the Company's internal control over financial reporting, as stated in their report located in Item 8 of this Form 10-K.</span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_889"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Change in Internal Control over Financial Reporting</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There have been no changes in our internal control over financial reporting during the quarter ended December&#160;31, 2023 that have materially affected, or are reasonably likely to materially affect, The Cigna Group's internal control over financial reporting.</span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_1021"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 9B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">OTHER INFORMATION</span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_5903"></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Rule 10b5-1 Plan Elections</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended December&#160;31, 2023, no director or officer of the Company <ix:nonNumeric contextRef="c-185" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-3031"><ix:nonNumeric contextRef="c-185" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-3032">adopted</ix:nonNumeric></ix:nonNumeric>, modified or <ix:nonNumeric contextRef="c-185" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-3033"><ix:nonNumeric contextRef="c-185" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-3034">terminated</ix:nonNumeric></ix:nonNumeric> a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item 408(a) of Regulation S-K.</span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_1024"></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 9C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;Not applicable.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">137</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_1027"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">PART III</span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_1030"></div><div style="margin-bottom:10pt;margin-top:10pt"><span id="i3ae34aab102a4e048575d1bc90168d46_1222"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt">Directors of the Registrant</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information under the captions "Corporate Governance Matters &#8211; Board of Directors' Nominees" and "Corporate Governance Matters &#8211; Board Meetings and Committees" (as it relates to Audit Committee disclosure) in The Cigna Group's definitive proxy statement related to the 2024 annual meeting of shareholders ("the 2024 Proxy Statement") is incorporated herein by reference.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt">Executive Officers of the Registrant</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See Part I &#8211; "Information about our Executive Officers" in this Form 10-K.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt">Code of Ethics and Other Corporate Governance Disclosures</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information under the caption "Corporate Governance Matters &#8211; Codes of Ethics" in the 2024 Proxy Statement is incorporated herein by reference. We intend to promptly disclose on our website, in accordance with applicable rules, any required disclosure of changes to or waivers, if any, of our Code of Ethics or our Director Code of Business Conduct and Ethics.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt">Delinquent Section 16(a) Reports</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information under the caption "Ownership of The Cigna Group Common Stock &#8211; Delinquent Section 16(a) Reports", if included in the 2024 Proxy Statement, is incorporated herein by reference.</span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_1033"></div><div style="margin-bottom:10pt;margin-top:10pt"><span id="i16c8b52a7ea247c0b337b453634cbcfe_475"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">EXECUTIVE COMPENSATION</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information under the captions "Corporate Governance Matters &#8211; Non-Employee Director Compensation," "Certain Transactions &#8211; Compensation Committee Interlocks and Insider Participation," "Compensation Matters &#8211; Compensation Discussion and Analysis," "Compensation Matters &#8211; Report of the People Resources Committee" and "Compensation Matters &#8211; Executive Compensation Tables" in the 2024 Proxy Statement is incorporated herein by reference.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">138</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_1036"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span id="i6aa8915341994d70b4dd934b9903bba0_2140"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents information regarding The Cigna Group's equity compensation plans as of December&#160;31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(b) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(c) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Plan Category</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Securities To Be Issued<br/>Upon Exercise Of<br/>Outstanding Options,<br/>Warrants And Rights</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price Of<br/>Outstanding Options,<br/>Warrants And Rights</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Securities Remaining<br/>Available For Future<br/>Issuance Under Equity<br/>Compensation Plans<br/>(Excluding Securities<br/>Reflected In Column (a))</span></td></tr><tr><td colspan="3" style="background-color:#e5e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity Compensation Plans Approved by Security Holders</span></td><td colspan="3" style="background-color:#e5e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e5e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,161,152</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e5e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e5e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e5e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">202.02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e5e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e5e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14,371,589</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e5e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity Compensation Plans Not Approved by Security Holders</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e5e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e5e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e5e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,161,152</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e5e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e5e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e5e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">202.02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e5e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e5e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14,371,589</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e5e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:7.44pt">Includes, in addition to outstanding stock options:</span></div><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(i) 57,961 restricted stock units, 34,015 deferred shares and 1,372,834 strategic performance shares that are reported at the maximum 200% payout rate granted under the Cigna Long-Term Incentive Plan, the Cigna Corporation Stock Plan and the Cigna Corporation Director Equity Plan; and </span></div><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">(ii) 235,858 shares of common stock underlying stock option awards granted under the Express Scripts Holding Company 2016 Long-Term Incentive Plan, 390,212 shares of common stock underlying stock option awards granted under the Express Scripts, Inc. 2011 Long-Term Incentive Plan, and 182,865 shares of common stock underlying stock option awards granted under the Medco Health Solutions, Inc. 2002 Stock Incentive Plan that were all approved by the applicable company's shareholders before The Cigna Group's acquisition of Express Scripts in December 2018.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:7.44pt">The weighted-average exercise price is based only on outstanding stock options. The outstanding stock options assumed due to The Cigna Group's acquisition of Express Scripts, in aggregate, have a weighted-average exercise price of $154.55. Excluding the assumed options from this acquisition results in a weighted-average exercise price of $208.54.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:7.44pt">Represents 14,371,589 shares of common stock available as of the close of business December&#160;31, 2023 for future issuance under the Cigna Long-Term Incentive Plan. No further grants may be made and no shares remain available for future issuance under any plan other than the Cigna Long-Term Incentive Plan.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information under the captions "Ownership of The Cigna Group Common Stock &#8211; Stock Held by Directors, Nominees and Executive Officers" and "Ownership of The Cigna Group Common Stock &#8211; Stock Held by Certain Beneficial Owners" in the 2024 Proxy Statement is incorporated herein by reference.</span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_1039"></div><div style="margin-bottom:10pt;margin-top:10pt"><span id="i394ffd0e907748fab75992706550bef8_268"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information under the captions "Corporate Governance Matters </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Director Independence" and "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Certain Transactions" in the 2024 Proxy Statement is incorporated herein by reference.</span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_1042"></div><div style="margin-bottom:10pt;margin-top:10pt"><span id="i7490640be8404f53a9acd20b3fbc2d6a_304"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">. PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information under the captions "Audit Matters &#8211; Policy for the Pre-Approval of Audit and Non-Audit Services" and "Audit Matters &#8211; Fees to Independent Registered Public Accounting Firm" in the 2024 Proxy Statement is incorporated herein by reference.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">139</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_1045"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">PART IV</span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_1048"></div><div style="margin-bottom:10pt;margin-top:10pt"><span id="i6f0e1cd4c8e448b1988945876c9b5b8e_1304"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.91pt">(1) The following Financial Statements can be found under Part II Item 8 of this Form 10-K:</span></div><div style="margin-bottom:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Report of Independent Registered Public Accounting Firm. (Public Company Accounting Oversight Board ID: <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-3035">238</ix:nonNumeric>)</span></div><div style="margin-bottom:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Consolidated Statements of Income for the years ended December 31, 2023, 2022 and 2021.</span></div><div style="margin-bottom:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Consolidated Statements of Comprehensive Income for the years ended December 31, 2023, 2022 and 2021.</span></div><div style="margin-bottom:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Consolidated Balance Sheets as of December 31, 2023 and 2022.</span></div><div style="margin-bottom:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Consolidated Statements of Changes in Total Equity for the years ended December 31, 2023, 2022 and 2021.</span></div><div style="margin-bottom:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Consolidated Statements of Cash Flows for the years ended December 31, 2023, 2022 and 2021.</span></div><div style="margin-bottom:10pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notes to the Consolidated Financial Statements.</span></div><div style="margin-bottom:10pt;padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:1.84pt">The financial statement schedules listed in the Index to Financial Statement Schedules on page FS-1 which list is incorporated herein.</span></div><div style="margin-bottom:10pt;padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:1.84pt">Set forth in this Item 15 is a list of exhibits filed or incorporated by reference as part of this Annual Report on Form 10-K. </span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">The exhibits listed in the accompanying "Index to Exhibits" in this Item 15 are filed or incorporated by reference as part of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.91pt">The financial statement schedules listed in the Index to Financial Statement Schedules on page FS-1 are filed as part of this Annual Report on Form 10-K. </span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">140</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_1051"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">INDEX TO EXHIBITS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.456%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Method of Filing</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1(a)</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/701221/000095015918000095/ex2-1.htm">Agreement and Plan of Merger, dated as of March 8, 2018, by and among Cigna Corporation (formerly Halfmoon Parent, Inc.), Express Scripts Holding Company, Cigna Holding Company (formerly Cigna Corporation), Halfmoon I, Inc. and Halfmoon II, Inc.</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by Cigna Holding Company ("CHC") as Exhibit 2.1 to the Current Report on Form 8-K on March 13, 2018 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1(b)</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/701221/000095015918000282/ex2-1.htm">Amendment No. 1, dated as of June 27, 2018, to the Agreement and Plan of Merger, dated as of March 8, 2018, by and among Cigna Corporation, Express Scripts Holding Company, Cigna Holding Company, Halfmoon I, Inc. and Halfmoon II, Inc.</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by CHC as Exhibit 2.1 to the Current Report on Form 8-K on July 2, 2018 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000173994023000016/exhibit31-thecignagroupxre.htm">Restated Certificate of Incorporation of the registrant effective as of April 26, 2023</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by the registrant as Exhibit 3.1 to the Quarterly Report on Form 10-Q for the period ended March 31, 2023 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000095015923000019/ex3-3.htm">Amended and Restated By-Laws of the registrant as last amended February 13, 2023</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by the registrant as Exhibit 3.3 to the Current Report on Form 8-K on February 13, 2023 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1(a)</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/701221/000095015918000403/ex4-1.htm">Indenture, dated as of September 17, 2018, between Cigna Corporation (formerly Halfmoon Parent, Inc.) and U.S. Bank National Association, as trustee</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by CHC as Exhibit 4.1 to the Current Report on Form 8-K on September 21, 2018 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1(b)</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/701221/000095015918000403/ex4-2.htm">Supplemental Indenture, dated as of September 17, 2018, between Cigna Corporation (formerly Halfmoon Parent, Inc.) and U.S. Bank National Association, as trustee</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by CHC as Exhibit 4.2 to the Current Report on Form 8-K on September 21, 2018 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1(c)</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000114036118045479/ex4_7.htm">Second Supplemental Indenture dated as of December 20, 2018, by and among Express Scripts Holding Company, Cigna Holding Company and U.S. Bank National Association, as trustee</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by the registrant as Exhibit 4.7 to the Current Report on Form 8-K on December 20, 2018 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1(d)</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000095015919000178/ex4-1.htm">Third Supplemental Indenture, dated as of October 11, 2019, by and among Cigna Corporation, as the Issuer, Cigna Holding Company and Express Scripts Holding Company, each as guarantors, and U.S. Bank, National Association, as trustee</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by the registrant as Exhibit 4.1 to the Current Report on Form 8-K on October 11, 2019 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1(e)</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000114036120005865/nc10005480x3_ex4-1.htm">Fourth Supplemental Indenture, dated as of March 16, 2020, between Cigna Corporation and U.S. Bank, National Association, as trustee</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Filed by the registrant as Exhibit 4.1 to the Current Report on Form 8-K on March 16, 2020 and incorporated herein by reference.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1(f)</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001739940/000114036121007207/nt10020524x5_ex4-1.htm">Fifth Supplemental Indenture, dated as of March 3, 2021, between Cigna Corporation and U.S. Bank National Association, as trustee</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Filed by the registrant as Exhibit 4.1 to the Current Report on Form 8-K on March 3, 2021 and incorporated herein by reference.</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1 (g)</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000114036123010511/ny20007738x4_ex4-1.htm">Sixth Supplemental Indenture, dated as of March 7, 2023, between Cigna Corporation and U.S. Bank National Association, as trustee</a></span></div><div><span><br/></span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Filed by the registrant as Exhibit 4.1 to the Current Report on Form 8-K on March 7, 2023 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000095015919000178/ex4-2.htm">Registration Rights Agreement, dated as of October 11, 2019, by and among Cigna Corporation, as the Issuer, Cigna Holding Company and Express Scripts Holding Company, each as guarantors, and J.P. Morgan Securities LLC, Deutsche Bank Securities Inc., and Wells Fargo Securities, LLC, each as dealer managers</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by the registrant as Exhibit 4.2 to the Current Report on Form 8-K on October 11, 2019 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3(a)</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/701221/000104746913001925/a2213028zex-4_1a.htm">Senior Indenture dated as of August 16, 2006 between Cigna Holding Company (formerly Cigna Corporation) and U.S. Bank National Association</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by CHC as Exhibit 4.1(a) to the Annual Report on Form 10-K for the year ended December 31, 2012 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3(b)</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/701221/000104746913001925/a2213028zex-4_1b.htm">Supplemental Indenture No. 1 dated as of November 10, 2006 between Cigna Holding Company and U.S. Bank National Association</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by CHC as Exhibit 4.1(b) to the Annual Report on Form 10-K for the year ended December 31, 2012 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3(c)</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/701221/000095015911000748/ex4-1.htm">Supplemental Indenture No. 8 dated as of November 10, 2011 between Cigna Holding Company and U.S. Bank National Association</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by CHC as Exhibit 4.1 to the Current Report on Form 8-K on November 14, 2011 and incorporated herein by reference.</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">141</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.456%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3(d)</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/701221/000110465915023084/a15-7647_1ex4d1.htm">Supplemental Indenture No. 9 dated as of March 20, 2015, between Cigna Holding Company and U.S. Bank National Association, as trustee</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by CHC as Exhibit 4.1 to the Current Report on Form 8-K on March 26, 2015 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3(e)</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/701221/000095015917000216/ex4-1.htm">Supplemental Indenture No. 10 dated as of September 14, 2017 between Cigna Holding Company and U.S. Bank National Association, as trustee</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by CHC as Exhibit 4.1 to the Current Report on Form 8-K filed September 14, 2017 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3(f)</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000114036118045479/ex4_1.htm">Supplemental Indenture No. 11 dated as of December 20, 2018, by and among Cigna Corporation, Cigna Holding Company and U.S. Bank National Association, as trustee</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by the registrant as Exhibit 4.1 to the Current Report on Form 8-K on December 20, 2018 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3(g)</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000095015919000178/ex4-3.htm">Supplemental Indenture No. 12, dated as of October 11, 2019, among Cigna Holding Company, as Issuer, Cigna Corporation, as parent guarantor, and U.S. Bank National Association, as trustee</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by the registrant as Exhibit 4.3 to the Current Report on Form 8-K on October 11, 2019 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4(a)</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/701221/000095012310016612/c96757exv4w2.htm">Indenture dated as of January 1, 1994 between Cigna Holding Company (formerly Cigna Corporation) and Marine Midland Bank</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by CHC as Exhibit 4.2 to the Annual Report on Form 10-K for the year ended December 31, 2009 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4(b)</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000114036118045479/ex4_2.htm">Supplemental Indenture No. 1 dated as of December 20, 2018, by and among Cigna Corporation (formerly Halfmoon Parent, Inc.), Cigna Holding Company and HSBC Bank USA, National Association (as successor to Marine Midland Bank, N.A.), as trustee</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by the registrant as Exhibit 4.2 to the Current Report on Form 8-K on December 20, 2018 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4(c)</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000095015919000178/ex4-4.htm">Supplemental Indenture No. 2, dated as of October 11, 2019, among Cigna Holding Company, as Issuer, Cigna Corporation, as parent guarantor, and HSBC Bank USA, National Association, as trustee</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by the registrant as Exhibit 4.4 to the Current Report on Form 8-K on October 11, 2019 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5(a)</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/701221/000095012310016612/c96757exv4w3.htm">Indenture dated as of June 30, 1988 between Cigna Holding Company (formerly Cigna Corporation) and Bankers Trust Company</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by CHC as Exhibit 4.3 to the Annual Report on Form 10-K for the year ended December 31, 2009 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5(b)</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000114036118045479/ex4_3.htm">Supplemental Indenture No. 1 dated as of December 20, 2018, by and among Cigna Corporation (formerly Halfmoon Parent, Inc.), Cigna Holding Company and Deutsche Bank Trust Company Americas, a New York banking corporation (as successor to Bankers Trust Company), as trustee</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by the registrant as Exhibit 4.3 to the Current Report on Form 8-K on December 20, 2018 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6(a)</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885721/000095012311100363/y93612exv4w1.htm">Indenture, dated as of November 21, 2011, among Express Scripts, Inc., Express Scripts Holding Company (formerly Aristotle Holding, Inc.), the other subsidiaries of Express Scripts Holding Company party thereto and Wells Fargo Bank, National Association, as trustee</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by Express Scripts, Inc. ("ESI") as Exhibit 4.1 to the Current Report on Form 8-K filed November 25, 2011 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6(b)</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885721/000095012311100363/y93612exv4w5.htm">Fourth Supplemental Indenture, dated as of November 21, 2011, among Express Scripts, Inc., Express Scripts Holding Company, the other subsidiaries of Express Scripts Holding Company party thereto and Wells Fargo Bank, National Association, as trustee</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by ESI as Exhibit 4.5 to the Current Report on Form 8-K on November 25, 2011 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6(c)</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1532063/000119312512153615/d330282dex41.htm">Eighth Supplemental Indenture, dated as of April 2, 2012, among Express Scripts, Inc., Express Scripts Holding Company, Medco Health Solutions, Inc., the other subsidiaries of Express Scripts Holding Company party thereto and Wells Fargo Bank, National Association, as trustee</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by Express Scripts Holding Company ("ESRX") as Exhibit 4.1 to the Current Report on Form 8-K on April 6, 2012 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6(d)</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1532063/000119312514227222/d739531dex43.htm">Thirteenth Supplemental Indenture, dated as of June 5, 2014, among Express Scripts Holding Company, the Subsidiary Guarantors party thereto and Wells Fargo Bank, National Association, as trustee</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by ESRX as Exhibit 4.3 to the Current Report on Form 8-K on June 5, 2014 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6(e)</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1532063/000119312516477506/d147797dex42.htm">Seventeenth Supplemental Indenture, dated as of February 25, 2016, among Express Scripts Holding Company, the Subsidiary Guarantors party thereto and Wells Fargo Bank, National Association, as trustee</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by ESRX as Exhibit 4.2 to the Current Report on Form 8-K on February 25, 2016 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6(f)</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1532063/000119312516641222/d222012dex41.htm">Eighteenth Supplemental Indenture, dated as of July 5, 2016, among Express Scripts Holding Company, the Subsidiary Guarantors party thereto and Wells Fargo Bank, National Association, as trustee</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by ESRX as Exhibit 4.1 to the Current Report on Form 8-K on July 5, 2016 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6(g)</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1532063/000119312516641222/d222012dex42.htm">Nineteenth Supplemental Indenture, dated as of July 5, 2016, among Express Scripts Holding Company, the Subsidiary Guarantors party thereto and Wells Fargo Bank, National Association, as trustee</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by ESRX as Exhibit 4.2 to the Current Report on Form 8-K on July 5, 2016 and incorporated herein by reference.</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">142</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.456%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6(h)</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1532063/000119312516641222/d222012dex43.htm">Twentieth Supplemental Indenture, dated as of July 5, 2016, among Express Scripts Holding Company, the Subsidiary Guarantors party thereto and Wells Fargo Bank, National Association, as trustee</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by ESRX as Exhibit 4.3 to the Current Report on Form 8-K on July 5, 2016 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6(i)</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000114036118045479/ex4_4.htm">Twenty-Fifth Supplemental Indenture dated as of December 20, 2018, by and among Cigna Corporation, Express Scripts Holding Company and Wells Fargo Bank, National Association, as trustee</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by the registrant as Exhibit 4.4 to the Current Report on Form 8-K on December 20, 2018 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6(j)</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000095015919000178/ex4-5.htm">Twenty-Sixth Supplemental Indenture, dated as of October 11, 2019, among Express Scripts Holding Company, as Issuer, Cigna Corporation, as parent guarantor, and Wells Fargo Bank, National Association, as trustee</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by the registrant as Exhibit 4.5 to the Current Report on Form 8-K on October 11, 2019 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh_47xdescriptionofsecuri.htm">Description of Securities</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Filed herewith.</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exhibits 10.1 through 10.26 are identified as compensatory plans, management contracts or arrangements pursuant to Item 15 of Form 10-K.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.456%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1(a)</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001739940/000095015921000138/ex10-1.htm">Cigna Long-Term Incentive Plan, amended and restated effective April 28, 2021 (the "Cigna LTIP")</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by the registrant as Exhibit 10.1 to the Current Report on Form 8-K on May 3, 2021 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1(b)</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000173994023000008/exhibit101b-ltip4x28x21and.htm">Amendment No.1 to the Cigna Long-Term Incentive Plan effective December 1, 2022</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by the registrant as Exhibit 10.1(b) to the Annual Report on Form 10-K for the year ended December 31, 2022 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1(c)</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/701221/000110465915032254/a15-7960_1ex10d3.htm">Form of Cigna LTIP: Nonqualified Stock Option Grant Agreement</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by CHC as Exhibit 10.3 to Form 10-Q for the period ended March 31, 2015 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1(d)</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/701221/000110465917030101/a17-8864_1ex10d3.htm">Form of Cigna LTIP: Nonqualified Stock Option Grant Agreement</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by CHC as Exhibit 10.3 to Form 10-Q for the period ended March 31, 2017 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1(e)</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/701221/000110465918030187/a18-8638_1ex10d5.htm">Form of Cigna LTIP: Nonqualified Stock Option Grant Agreement</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by CHC as Exhibit 10.5 to Quarterly Report on Form 10-Q for the period ended March 31, 2018 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1(f)</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000110465919026396/a19-9011_1ex10d2.htm">Form of Cigna LTIP: Nonqualified Stock Option Grant Agreement</a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by the registrant as Exhibit 10.2 to Quarterly Report on Form 10-Q for the period ended March 31, 2019 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1(g)</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000173994020000012/exhibit102-q12020.htm">Form of Cigna LTIP: Nonqualified Stock Option Grant Agreement</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Filed by the registrant as Exhibit 10.2 to Quarterly Report on Form 10-Q for the period ended March 31, 2020 and incorporated herein by reference.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1(h)</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001739940/000173994021000011/exh101grant_agreemntx21sps.htm">Form of Cigna LTIP: Strategic Performance Share Grant Agreement</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Filed by the registrant as Exhibit 10.1 to Quarterly Report on Form 10-Q for the period ended March 31, 2021 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1(i)</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001739940/000173994021000011/exh102grant_agreemntx21nqus.htm">Form of Cigna LTIP: Nonqualified Stock Option Grant Agreement</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Filed by the registrant as Exhibit 10.2 to Quarterly Report on Form 10-Q for the period ended March 31, 2021 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.1(j)</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001739940/000173994021000011/exh103grant_agreemntx21rsg.htm">Form of Cigna LTIP: Restricted Stock Grant Agreement</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Filed by the registrant as Exhibit 10.3 to Quarterly Report on Form 10-Q for the period ended March 31, 2021 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.1(k)</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001739940/000173994021000011/exh104grant_agreemntx21rsu.htm">Form of Cigna Stock Unit Plan: Restricted Stock Unit Grant Agreement</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Filed by the registrant as Exhibit 10.4 to Quarterly Report on Form 10-Q for the period ended March 31, 2021 and incorporated herein by reference.</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">143</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.456%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.1(l)</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000173994021000011/exh101grant_agreemntx21sps.htm">Form of Cigna LTIP: Strategic Performance Share Grant Agreement</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Filed by the registrant as Exhibit 10.1 to Quarterly Report on Form 10-Q for the period ended March 31, 2021 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.1(m)</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001739940/000173994021000011/exh102grant_agreemntx21nqus.htm">Form of Cigna LTIP: Nonqualified Stock Option Grant Agreement</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Filed by the registrant as Exhibit 10.2 to Quarterly Report on Form 10-Q for the period ended March 31, 2021 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.1(n)</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001739940/000173994021000011/exh103grant_agreemntx21rsg.htm">Form of Cigna LTIP: Restricted Stock Grant Agreement</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Filed by the registrant as Exhibit 10.3 to Quarterly Report on Form 10-Q for the period ended March 31, 2021 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.1(o)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001739940/000173994021000011/exh104grant_agreemntx21rsu.htm">Form of Cigna LTIP: Restricted Stock Unit Grant Agreement</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Filed by the registrant as Exhibit 10.4 to Quarterly Report on Form 10-Q for the period ended March 31, 2021 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.1(p)</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000173994020000012/exhibit105-q12020.htm">Form of Cigna LTIP: Covenant Agreement</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Filed by the registrant as Exhibit 10.5 to Quarterly Report on Form 10-Q for the period ended March 31, 2020 and incorporated herein by reference.</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/701221/000095012310016612/c96757exv10w7.htm">Cigna Corporation Stock Plan, as amended through July 2000</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by CHC as Exhibit 10.7 to the Annual Report on Form 10-K for the year ended December 31, 2009 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/701221/000110465917030101/a17-8864_1ex10d5.htm">Cigna Stock Unit Plan, as amended and restated effective February 22, 2017</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by CHC as Exhibit 10.5 to the Quarterly Report on Form 10-Q for the period ended March 31, 2017 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4(a)</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1532063/000119312516511918/d70696ddef14a.htm#toc70696_43">Express Scripts Holding Company 2016 Long-Term Incentive Plan (the "ESRX LTIP")</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by ESRX as Appendix A to ESRX's Definitive Proxy Statement on Schedule 14A for its 2016 Annual Meeting of Stockholders, filed March 21, 2016 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4(b)</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1532063/000119312516577530/d174618dex104.htm">Form of Stock Option Grant Notice for Non-Employee Directors used with respect to grants of stock options by Express Scripts Holding Company to non-employee directors under the ESRX LTIP</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by ESRX as Exhibit 10.4 to the Current Report on Form 8-K on May 4, 2016 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4(c)</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1532063/000119312516577530/d174618dex107.htm">Form of Stock Option Grant Notice used with respect to grants of stock options by Express Scripts Holding Company under the ESRX LTIP</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by ESRX as Exhibit 10.7 to Current Report on Form 8-K on May 4, 2016 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5(a)</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000114036118045513/ex4_10.htm">Express Scripts, Inc. 2011 Long-Term Incentive Plan (as amended and restated effective April 2, 2012) (the "ESI LTIP")</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by the registrant as Exhibit 4.10 to the Registration Statement on Form S-8 (No. 333-228930) on December 20, 2018 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5(b)</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1532063/000119312512340911/d355069dex106.htm">Form of Stock Option Grant Notice for Non-Employee Directors used with respect to grants of stock options by Express Scripts Holding Company under the ESI LTIP</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by ESRX as Exhibit 10.6 to Quarterly Report on Form 10-Q for the quarter ended June 30, 2012 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5(c)</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1532063/000144530513000961/esrx-03312013xex101xesi_op.htm">Form of Stock Option Grant Notice used with respect to grants of stock options by Express Scripts Holding Company under the ESI LTIP</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by ESRX as Exhibit 10.1 to the Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000114036118045513/ex4_11.htm">Medco Health Solutions, Inc. 2002 Stock Incentive Plan (as amended and restated effective April 2, 2012)</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by the registrant as Exhibit 4.11 to the Registration Statement on Form S-8 (No. 333-228930) on December 20, 2018 and incorporated herein by reference.</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">144</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.456%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/701221/000130817912000042/lexhibit_10_1.htm">Deferred Compensation Plan for Directors of Cigna Corporation, as amended and restated January 1, 1997</a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by CHC as Exhibit 10.1 to the Annual Report on Form 10-K for the year ended December 31, 2011 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/701221/000130817912000042/lexhibit_10_14.htm">Cigna Deferred Compensation Plan, as amended and restated October 24, 2001</a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by CHC as Exhibit 10.14 to the Annual Report on Form 10-K for the year ended December 31, 2011 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000114036118045513/ex4_6.htm">Cigna Deferred Compensation Plan of 2005 effective as of January 1, 2005</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by the registrant as Exhibit 4.6 to the Registration Statement on Form S-8 (No. 333-228930) on December 20, 2018 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885721/000088572107000034/execdeferredcompplangrndfthr.htm">Express Scripts, Inc. Amended and Restated Executive Deferred Compensation Plan (effective December 31, 2004 and grandfathered for the purposes of Section 409A of the Code)</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by ESI as Exhibit No. 10.1 to the Current Report on Form 8-K on May 25, 2007 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11(a)</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000114036118045513/ex4_13.htm">Express Scripts, Inc. Executive Deferred Compensation Plan of 2005 (as amended and restated effective December 20, 2018)</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by the registrant as Exhibit 4.13 to the Registration Statement on Form S-8 (No. 333-228930) on December 20, 2018 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11(b)</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000173994020000006/ciexh10d12b.htm">Amendment No. 1 to the Express Scripts, Inc. Executive Deferred Compensation Plan of 2005</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Filed by the registrant as Exhibit 10.12(b) to the Annual Report on Form 10-K for the year ended December 31, 2019 and incorporated herein by reference.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.11(c)</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001739940/000173994021000017/exhibit103-2021_q2.htm">Amendment No. 2 to the Express Scripts, Inc. Executive Deferred Compensation Plan of 2005</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Filed by the registrant as Exhibit 10.3 to Quarterly Report on Form 10-Q for the period ended June 30, 2021 and incorporated herein by reference.</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12(a)</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/701221/000095012310016612/c96757exv10w15wxay.htm">Cigna Supplemental Pension Plan as amended and restated effective August 1, 1998</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by CHC as Exhibit 10.15(a) to the Annual Report on Form 10-K for the year ended December 31, 2009 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12(b)</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/701221/000095012310016612/c96757exv10w15wxby.htm">Amendment No. 1 to the Cigna Supplemental Pension Plan, amended and restated effective as of September 1, 1999</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by CHC as Exhibit 10.15(b) to the Annual Report on Form 10-K for the year ended December 31, 2009 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12(c)</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/701221/000130817912000042/lexhibit_10_16.htm">Amendment No. 2 dated December 6, 2000 to the Cigna Supplemental Pension</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by CHC as Exhibit 10.16(c) to the Annual Report on Form 10-K for the year ended December 31, 2011 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13(a)</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/701221/000095015908000407/ex10-15.htm">Cigna Supplemental Pension Plan of 2005 effective as of January 1, 2005</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by CHC as Exhibit 10.15 to the Annual Report on Form 10-K for the year ended December 31, 2007 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13(b)</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/701221/000095012309027787/c88240exv10w1.htm">Amendment No. 1 to the Cigna Supplemental Pension Plan of 2005</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by CHC as Exhibit 10.1 to the Quarterly Report on Form 10-Q for the period ended June 30, 2009 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14(a)</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000114036118045513/ex4_7.htm">Cigna Supplemental 401(k) Plan effective January 1, 2010</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by the registrant as Exhibit 4.7 to the Registration Statement on Form S-8 (No. 333-228930) on December 20, 2018 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14(b)</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000173994020000006/ciexh10d15b.htm">Amendment No. 1 to the Cigna Supplemental 401(k) Plan</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Filed by the registrant as Exhibit 10.15(b) to the Annual Report on Form 10-K for the year ended December 31, 2019 and incorporated herein by reference.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14(c)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000173994020000006/ciexh10d15c.htm">Amendment No. 2 to the Cigna Supplemental 401(k) Plan</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Filed by the registrant as Exhibit 10.15(c) to the Annual Report on Form 10-K for the year ended December 31, 2019 and incorporated herein by reference.</span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">145</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.456%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14(d)</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000173994020000006/ciexh10d15d.htm">Amendment No. 3 to the Cigna Supplemental 401(k) Plan</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Filed by the registrant as Exhibit 10.15(d) to the Annual Report on Form 10-K for the year ended December 31, 2019 and incorporated herein by reference.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/701221/000110465914033290/a14-9742_1ex10d1.htm">Cigna Corporation Non-Employee Director Compensation Program amended and restated effective February 26, 2014</a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by CHC as Exhibit 10.1 to the Quarterly Report on Form 10-Q for the period ended March 31, 2014 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16(a)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000173994022000007/exh1017adirectorcompensati.htm">Cigna Corporation Non-Employee Director Compensation Program, amended and restated effective January 1, 2022</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by the registrant as Exhibit 10.17(a) to the Annual Report on Form 10-K for the year ended December 31, 2021 and incorporated herein by reference.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16(b)</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000173994022000007/exh1017bdirectorcompensati.htm">Cigna Corporation Non-Employee Director Compensation Program, amended and restated effective April 1, 2022</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by the registrant as Exhibit 10.17(b) to the Annual Report on Form 10-K for the year ended December 31, 2021 and incorporated herein by reference.</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001739940/000173994021000007/exhibit1018-directorsequit.htm">Cigna Corporation Director Equity Plan, as amended December 4, 2020</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Filed by the registrant as Exhibit 10.18 to the Annual Report on Form 10-K for the year ended December 31, 2020 and incorporated herein by reference.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/701221/000104746913001925/a2213028zex-10_4.htm">Cigna Restricted Share Equivalent Plan for Non-Employee Directors as amended and restated effective January 1, 2008</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by CHC as Exhibit 10.4 to the Annual Report on Form 10-K for the year ended December 31, 2012 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000114036118045513/ex4_8.htm">Deferred Compensation Plan of 2005 for Directors of Cigna Corporation, Amended and Restated effective April 28, 2010</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by the registrant as Exhibit 4.8 to the Registration Statement on Form S-8 (No. 333-228930) on December 20, 2018 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1532063/000119312514084479/d689142dex101.htm">Form of Indemnification Agreement with Express Scripts Holding Company's executive officers and former members of the Express Scripts Holding Company's board of directors</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by ESRX as Exhibit 10.1 to the Current Report on Form 8-K on March 5, 2014 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000095015920000231/ex10-1.htm">Cigna Executive Severance Benefits Plan as amended and restated effective December 21, 2020</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Filed by the registrant as Exhibit 10.1 to the Current Report on Form 8-K on October 30, 2020 and incorporated herein by reference.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/701221/000095012310016612/c96757exv10w18.htm">Description of Cigna Corporation Financial Services Program</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by CHC as Exhibit 10.18 to the Annual Report on Form 10-K for the year ended December 31, 2009 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh_1023xpalmerofferletter.htm">Offer Letter for Eric P. Palmer dated January 16, 2024</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000173994023000025/exh_102xnjonesxofferxlet.htm">Offer Letter for Nicole S. Jones dated September 14, 2023</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by the registrant as Exhibit 10.2 to the Quarterly Report on Form 10-Q for the period ended September 30, 2023 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000173994023000025/exh_101xnederxofferxlett.htm">Offer Letter for Noelle K. Eder dated September 14, 2023</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by the registrant as Exhibit 10.1 to the Quarterly Report on Form 10-Q for the period ended September 30, 2023 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh_1026xevankoofferletter.htm">Offer letter for Brian Evanko dated January 16, 2024</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Filed herewith.</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1739940/000095015922000102/ex10-1.htm">Revolving Credit and Letter of Credit Agreement, dated as of April 28, 2022, with the banks named therein, JPMorgan Chase Bank, N.A., as administrative agent, BofA Securities, Inc., Citibank, N.A., Morgan Stanley Senior Funding, Inc., MUFG Bank, LTD and Wells Fargo Securities, LLC, as joint lead arrangers and joint bookrunners</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Filed by the registrant as Exhibit 10.1 to the Current Report on Form 8-K on April 29, 2022 and incorporated herein by reference.</span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">146</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.456%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/701221/000104746913001925/a2213028zex-10_29.htm">Master Transaction Agreement, dated February 4, 2013 among Connecticut General Life Insurance Company, Berkshire Hathaway Life Insurance Company of Nebraska and, solely for purposes of Sections 3.10, 6.1, 6.3, 6.4, 6.6, 6.9 and Articles II, V, VII and VIII, thereof, National Indemnity Company (including the Forms of Retrocession Agreement, the Collateral Trust Agreement, the Security and Control Agreement, the Surety Policy and the ALC Model Purchase Option Agreement as exhibits)</a></span></div><div><span><br/></span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed by CHC as Exhibit 10.29 to the Annual Report on Form 10-K for the year ended December 31, 2012 and incorporated herein by reference.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh_21x10-kx23q4.htm">Subsidiaries of the Registrant</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh_23x10-kx23q4.htm">Consent of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh_311x23q4.htm">Certification of Chief Executive Officer of The Cigna Group pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh_312x23q4.htm">Certification of Chief Financial Officer of The Cigna Group pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh_321x23q4.htm">Certification of Chief Executive Officer of The Cigna Group pursuant to Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. Section 1350</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh_322x23q4.htm">Certification of Chief Financial Officer of The Cigna Group pursuant to Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. Section 1350</a></span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.1</span></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh_971xincentivecompensat.htm">Incentive Compensation Clawback Policy</a></span></div></td><td colspan="3" style="background-color:#e6e0ec;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following materials from The Cigna Group's Annual Report on Form 10-K for the year ended December&#160;31, 2023, formatted in inline XBRL (Extensible Business Reporting Language): (i) the Consolidated Balance Sheets; (ii) the Consolidated Statements of Income; (iii) the Consolidated Statements of Comprehensive Income; (iv) the Consolidated Statements of Cash Flows; (v) the Consolidated Statements of Changes in Total Equity; (vi) the Notes to Consolidated Financial Statements; and (vii) Financial Statement Schedules I and II.</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The agreements and other documents filed as exhibits to this report are not intended to provide factual information or other disclosure other than the terms of the agreements or other documents themselves and you should not rely on them for that purpose. In particular, any representations and warranties made by the Company in these agreements or other documents were made solely within the specific context of the relevant agreement or document and may not describe the actual state of affairs at the date they were made or at any other time.</span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_1054"></div><div style="margin-bottom:10pt;margin-top:10pt"><span id="icbc7279da38f426d948df2c1e9e37bad_36"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">FORM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">10-K SUMMARY</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">None.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">147</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_1057"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center;text-indent:36pt"><span id="i138d2aa548274c5d9b31fa9c2411e946_445"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SIGNATURES</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date: February&#160;29, 2024</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.833%"><tr><td style="width:1.0%"/><td style="width:37.279%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.369%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">THE CIGNA GROUP</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;<br/>&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Brian C. Evanko&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brian C. Evanko</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Financial Officer, The Cigna Group, and President and Chief Executive Officer, Cigna Healthcare</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated as of February&#160;29, 2024.</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:51.262%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David M. Cordani&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David M. Cordani</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Brian C. Evanko&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brian C. Evanko</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Financial Officer, The Cigna Group, and President and Chief Executive Officer, Cigna Healthcare</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mary T. Agoglia Hoeltzel&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mary T. Agoglia Hoeltzel</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Tax and Chief Accounting Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Accounting Officer)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ William J. DeLaney&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William J. DeLaney</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Eric J. Foss&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eric J. Foss</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Elder Granger, M.D.&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elder Granger, M.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Neesha Hathi</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neesha Hathi</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">148</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:51.262%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ George Kurian</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">George Kurian</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kathleen M. Mazzarella</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kathleen M. Mazzarella</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mark B. McClellan, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark B. McClellan, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Philip O. Ozuah, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philip O. Ozuah</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kimberly A. Ross&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kimberly A. Ross</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Eric C. Wiseman&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eric C. Wiseman</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lead Independent Director</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Donna F. Zarcone&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Donna F. Zarcone&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr></table></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">149</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_1060"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center"><span id="iae22a5a92e114d87a8a9977b390f95a9_266"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">THE CIGNA GROUP AND SUBSIDIARIES</span></div><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">INDEX TO FINANCIAL STATEMENT SCHEDULES</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:80.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.540%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">PAGE</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Schedules</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Financial Information of The Cigna Group (Registrant)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1066">FS-2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statements of Income for the Years Ended December 31, 2023, 2022 and 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1066">FS-2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance Sheets as of December 31, 2023 and 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1069">FS-3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statements of Cash Flows for the Years Ended December 31, 2023, 2022 and 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1072">FS-4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Condensed Financial Statements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1075">FS-5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">II</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation and Qualifying Accounts and Reserves for the Years Ended December 31, 2023, 2022 and 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibc59a92ac8bc42f794e728f24ce1b626_1090">FS-7</a></span></div></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Schedules other than those listed above are omitted because they are not required or are not applicable, or the required information is shown in the financial statements or notes thereto.</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FS-1</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_1066"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" id="f-3036" continuedAt="f-3036-1" escape="true"><div style="margin-bottom:10pt;text-align:center"><span id="i04dc17a35c054b6d8e303f8417c40a64_204"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">THE CIGNA GROUP AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">SCHEDULE I</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">CONDENSED FINANCIAL INFORMATION OF THE CIGNA GROUP</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">(REGISTRANT)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">STATEMENTS OF INCOME</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.043%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="f-3037">22</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="f-3038">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" name="us-gaap:NetInvestmentIncome" format="ixt:fixed-zero" scale="6" id="f-3039">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intercompany interest income</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" name="ci:IntercompanyInterestIncome" scale="6" id="f-3040">516</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" name="ci:IntercompanyInterestIncome" scale="6" id="f-3041">478</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" name="ci:IntercompanyInterestIncome" scale="6" id="f-3042">471</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-3043">538</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-3044">483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-3045">471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-3046">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-3047">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-3048">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" name="us-gaap:BenefitsLossesAndExpenses" scale="6" id="f-3049">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" name="us-gaap:BenefitsLossesAndExpenses" scale="6" id="f-3050">2</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" name="us-gaap:BenefitsLossesAndExpenses" scale="6" id="f-3051">8</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income from operations</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-3052">536</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-3053">481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-3054">463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest and other expense</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="f-3055">1,332</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="f-3056">1,215</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="f-3057">1,197</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intercompany interest expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" name="ci:IntercompanyInterestExpense" scale="6" id="f-3058">118</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" name="ci:IntercompanyInterestExpense" scale="6" id="f-3059">147</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" name="ci:IntercompanyInterestExpense" scale="6" id="f-3060">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt extinguishment costs</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="f-3061">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="f-3062">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="f-3063">131</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-3064">914</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-3065">881</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-3066">878</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefits</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-3067">192</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-3068">183</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-3069">180</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Loss of Parent Company</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" sign="-" name="ci:LossOfParentCompany" scale="6" id="f-3070">722</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" sign="-" name="ci:LossOfParentCompany" scale="6" id="f-3071">698</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" sign="-" name="ci:LossOfParentCompany" scale="6" id="f-3072">698</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity in income of subsidiaries</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" name="us-gaap:IncomeLossFromSubsidiariesNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-3073">5,886</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" name="us-gaap:IncomeLossFromSubsidiariesNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-3074">7,402</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" name="us-gaap:IncomeLossFromSubsidiariesNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-3075">6,068</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders' net income</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="f-3076">5,164</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="f-3077">6,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="f-3078">5,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders' other comprehensive income (loss), net of tax</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized appreciation (depreciation) on securities and derivatives</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-3079">503</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="f-3080">1,598</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-3081">302</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net long-duration insurance and contractholder liabilities measurement adjustments</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" sign="-" name="ci:OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent" scale="6" id="f-3082">715</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" name="ci:OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent" scale="6" id="f-3083">509</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" name="ci:OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent" scale="6" id="f-3084">67</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net translation gains (losses) of foreign currencies</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-3085">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-3086">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-3087">218</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Postretirement benefits liability adjustment</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-3088">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-3089">420</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-3090">410</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shareholders' other comprehensive loss, net of tax</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-3091">206</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-3092">590</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-3093">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders' comprehensive income</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-3094">4,958</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-3095">6,114</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-3096">5,327</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 1 to Schedule 1 for further information.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">See Notes to Financial Statements on the following pages.</span></div></ix:nonNumeric><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FS-2</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_1069"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-3036-1" continuedAt="f-3036-2"><div style="margin-bottom:10pt;text-align:center"><span id="i119a375e8e4342d49fe6b4b067c6a227_195"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">THE CIGNA GROUP AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">SCHEDULE I</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">CONDENSED FINANCIAL INFORMATION OF THE CIGNA GROUP</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">(REGISTRANT)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">BALANCE SHEETS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.041%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-812" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-3097">303</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-813" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-3098">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-812" decimals="-6" name="us-gaap:OtherAssetsCurrent" scale="6" id="f-3099">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-813" decimals="-6" name="us-gaap:OtherAssetsCurrent" scale="6" id="f-3100">6</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-812" decimals="-6" name="us-gaap:AssetsCurrent" scale="6" id="f-3101">309</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-813" decimals="-6" name="us-gaap:AssetsCurrent" scale="6" id="f-3102">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments in subsidiaries</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-814" decimals="-6" name="us-gaap:InvestmentsAndOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-3103">69,703</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-815" decimals="-6" name="us-gaap:InvestmentsAndOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-3104">70,679</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intercompany receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-814" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-3105">11,475</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-815" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-3106">10,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-816" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-3107">77</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-817" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-3108">99</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TOTAL ASSETS</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-812" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-3109">81,564</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-813" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-3110">81,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-812" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="f-3111">2,448</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-813" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="f-3112">2,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-812" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-3113">1,854</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-813" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-3114">1,295</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-812" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-3115">4,302</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-813" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-3116">4,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-812" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="f-3117">27,151</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-813" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="f-3118">26,815</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intercompany payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-814" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-3119">3,874</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-815" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-3120">5,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-816" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-3121">14</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-817" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-3122">26</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TOTAL LIABILITIES</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-812" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-3123">35,341</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-813" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-3124">36,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders' Equity</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock (shares issued, <ix:nonFraction unitRef="shares" contextRef="c-812" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-3125">400</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-813" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-3126">398</ix:nonFraction>; authorized, <ix:nonFraction unitRef="shares" contextRef="c-812" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="f-3127"><ix:nonFraction unitRef="shares" contextRef="c-813" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="f-3128">600</ix:nonFraction></ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-812" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="f-3129">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-813" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="f-3130">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-812" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-3131">30,669</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-813" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-3132">30,233</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-812" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-3133">1,864</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-813" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-3134">1,658</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-812" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-3135">41,652</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-813" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-3136">37,940</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less treasury stock, at cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-812" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="f-3137">24,238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-813" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="f-3138">21,844</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TOTAL SHAREHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-812" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-3139">46,223</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-813" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-3140">44,675</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-812" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-3141">81,564</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-813" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-3142">81,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 1 to Schedule 1 for further information.</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">See Notes to Financial Statements on the following pages.</span></div></ix:continuation><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FS-3</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_1072"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-3036-2" continuedAt="f-3036-3"><div style="margin-bottom:10pt;text-align:center"><span id="i328d757352ff45b69e14fe0a6159da0e_253"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">THE CIGNA GROUP AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">SCHEDULE I</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">CONDENSED FINANCIAL INFORMATION OF THE CIGNA GROUP</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">(REGISTRANT)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">STATEMENTS OF CASH FLOWS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.043%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shareholders' net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="f-3143">5,164</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="f-3144">6,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="f-3145">5,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments to reconcile shareholders' net income</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">to net cash provided by operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity in income of subsidiaries</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" name="us-gaap:IncomeLossFromSubsidiariesNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-3146">5,886</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" name="us-gaap:IncomeLossFromSubsidiariesNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-3147">7,402</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" name="us-gaap:IncomeLossFromSubsidiariesNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-3148">6,068</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt extinguishment costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="f-3149">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="6" id="f-3150">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="f-3151">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends received from subsidiaries</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" name="us-gaap:CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="f-3152">1,381</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" name="us-gaap:CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="f-3153">2,056</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" name="us-gaap:CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="f-3154">2,726</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" name="ci:IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities" scale="6" id="f-3155">540</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" name="ci:IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities" scale="6" id="f-3156">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" name="ci:IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities" scale="6" id="f-3157">184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="f-3158">640</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="f-3159">298</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="f-3160">439</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NET CASH PROVIDED BY OPERATING ACTIVITIES</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-3161">1,839</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-3162">1,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-3163">2,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change in amounts due from affiliates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-818" decimals="-6" sign="-" name="ci:IncreaseDecreaseInAmountsDueFromAffiliates" scale="6" id="f-3164">622</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-819" decimals="-6" name="ci:IncreaseDecreaseInAmountsDueFromAffiliates" scale="6" id="f-3165">901</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-820" decimals="-6" name="ci:IncreaseDecreaseInAmountsDueFromAffiliates" format="ixt:num-dot-decimal" scale="6" id="f-3166">1,007</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net proceeds from short-term investments sold (purchased)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:fixed-zero" scale="6" id="f-3167">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" sign="-" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="f-3168">99</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="f-3169">50</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="f-3170">622</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="f-3171">802</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-3172">1,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change in amounts due to affiliates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-818" decimals="-6" name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" format="ixt:num-dot-decimal" scale="6" id="f-3173">1,473</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-819" decimals="-6" name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" format="ixt:num-dot-decimal" scale="6" id="f-3174">10,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-820" decimals="-6" name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" format="ixt:num-dot-decimal" scale="6" id="f-3175">2,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change in commercial paper</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-3176">1,237</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" sign="-" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-3177">2,027</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" scale="6" id="f-3178">997</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments for debt extinguishment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" format="ixt:fixed-zero" scale="6" id="f-3179">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" format="ixt:fixed-zero" scale="6" id="f-3180">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" scale="6" id="f-3181">126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayment of long-term debt</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-3182">2,822</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="f-3183">430</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-3184">4,199</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net proceeds on issuance of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-3185">1,491</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="f-3186">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-3187">4,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="f-3188">187</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="f-3189">389</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="f-3190">326</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common dividends paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-3191">1,450</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-3192">1,384</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-3193">1,341</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-3194">2,284</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-3195">7,607</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-3196">7,742</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax withholding on stock compensation and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="f-3197">110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="f-3198">73</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="f-3199">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NET CASH USED IN FINANCING ACTIVITIES</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-3200">2,278</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-3201">740</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-3202">5,849</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-3203">183</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-3204">119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="f-3205">4,124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of year</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-813" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-3206">152</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-821" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-3207">33</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-822" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-3208">4,157</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of year </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-812" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-3209">335</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-813" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-3210">152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-821" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-3211">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncash Investing and Financing Activities:</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Net amounts due to/(from) affiliates settled through capital transactions</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-818" decimals="-6" name="us-gaap:NotesReduction" format="ixt:num-dot-decimal" scale="6" id="f-3212">5,221</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-819" decimals="-6" name="us-gaap:NotesReduction" format="ixt:num-dot-decimal" scale="6" id="f-3213">5,037</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-820" decimals="-6" name="us-gaap:NotesReduction" format="ixt:num-dot-decimal" scale="6" id="f-3214">8,429</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 1 to Schedule 1 for further information.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Includes restricted cash reported in Other non-current assets as of December&#160;31, 2023 and December 31, 2022.</span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">See Notes to Financial Statements on the following pages.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FS-4</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_1075"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-3036-3" continuedAt="f-3036-4"><div style="margin-bottom:10pt;text-align:center"><span id="i3e615b8bf0cc4c7e95f93f8da300a4b8_1153"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">THE CIGNA GROUP AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SCHEDULE I</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CONDENSED FINANCIAL INFORMATION OF THE CIGNA GROUP</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(REGISTRANT)</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONDENSED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying condensed financial statements should be read in conjunction with the Consolidated Financial Statements and the accompanying notes thereto contained in this Annual Report on Form 10-K ("Form 10-K").</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> - For purposes of these condensed financial statements, The Cigna Group's (the "Company") wholly-owned and majority-owned subsidiaries are recorded using the equity method of accounting. On January 1, 2023, The Cigna Group and its subsidiaries adopted Targeted Improvements to the Accounting for Long-Duration Contracts, Accounting Standards Update ("ASU") 2018-12 and related amendments. See Note 2 - Summary of significant accounting policies included in Part II, Item 8 of this Form 10-K for a description of the key provisions and impacts.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Cigna Group, through its predecessor companies, was incorporated in Delaware in 1981. Cigna Corporation was renamed The Cigna Group in February 2023.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> - See Note 8 &#8211; Debt included in Part II, Item 8 of this Form 10-K for a description of the short-term and long-term debt obligations of The Cigna Group and its subsidiaries.</span></div></ix:continuation><div><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_1081"></div><ix:continuation id="f-3036-4" continuedAt="f-3036-5"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Short-term and Credit Facilities Debt</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revolving Credit Agreements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Our revolving credit agreements provide us with the ability to borrow amounts for general corporate purposes, including for the purpose of providing liquidity support if necessary under our commercial paper program discussed below. As of December&#160;31, 2023, there were <ix:nonFraction unitRef="usd" contextRef="c-823" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="0" id="f-3215">no</ix:nonFraction> outstanding balances under these revolving credit agreements. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2023, The Cigna Group entered into the following revolving credit agreements (the "Credit Agreements"):</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a $<ix:nonFraction unitRef="usd" contextRef="c-824" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-3216">4.0</ix:nonFraction> billion <ix:nonNumeric contextRef="c-825" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-3217">five-year</ix:nonNumeric> revolving credit and letter of credit agreement that will mature in April 2028 with an option to extend the maturity date for additional <ix:nonNumeric contextRef="c-825" name="ci:DebtInstrumentExtensionTerm" format="ixt-sec:durwordsen" id="f-3218">one-year</ix:nonNumeric> periods, subject to consent of the banks. The Company can borrow up to $<ix:nonFraction unitRef="usd" contextRef="c-824" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-3219">4.0</ix:nonFraction> billion under the credit agreement for general corporate purposes, with up to $<ix:nonFraction unitRef="usd" contextRef="c-826" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-3220">500</ix:nonFraction> million available for issuance of letters of credit. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a $<ix:nonFraction unitRef="usd" contextRef="c-827" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-3221">1.0</ix:nonFraction> billion <ix:nonNumeric contextRef="c-828" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-3222">364-day</ix:nonNumeric> revolving credit agreement that will mature in April 2024. The Company can borrow up to $<ix:nonFraction unitRef="usd" contextRef="c-827" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-3223">1.0</ix:nonFraction> billion under the credit agreement for general corporate purposes. This agreement includes the option to "term out" any revolving loans that are outstanding at maturity by converting them into a term loan maturing on the <ix:nonNumeric contextRef="c-828" name="ci:LineOfCreditFacilityConversionToTermLoanTerm" format="ixt-sec:durwordsen" id="f-3224">one-year</ix:nonNumeric> anniversary of conversion.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Each of the Credit Agreements include an option to increase commitments in an aggregate amount of up to $<ix:nonFraction unitRef="usd" contextRef="c-829" decimals="INF" name="ci:LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-3225">1.5</ix:nonFraction> billion across both facilities for a maximum total commitment of $<ix:nonFraction unitRef="usd" contextRef="c-829" decimals="INF" name="ci:LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-3226">6.5</ix:nonFraction> billion. The Credit Agreements allow for borrowings at either a base rate or an adjusted term Secured Overnight Funding Rate ("SOFR") plus, in each case, an applicable margin based on the Company's senior unsecured credit ratings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Each of the two facilities is diversified among <ix:nonFraction unitRef="bank" contextRef="c-829" decimals="INF" name="ci:NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement" scale="0" id="f-3227">21</ix:nonFraction> banks. Each facility also contains customary covenants and restrictions, including a financial covenant that the Company's leverage ratio, as defined in the Credit Agreements, may not exceed <ix:nonFraction unitRef="number" contextRef="c-829" decimals="INF" name="ci:LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant" scale="-2" id="f-3228">60</ix:nonFraction>%, subject to certain exceptions upon the consummation of an acquisition. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Credit Agreements replaced a prior $<ix:nonFraction unitRef="usd" contextRef="c-830" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-3229">3.0</ix:nonFraction> billion <ix:nonNumeric contextRef="c-831" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-3230">five-year</ix:nonNumeric> revolving credit and letter of credit agreement maturing on April 2027, a $<ix:nonFraction unitRef="usd" contextRef="c-832" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-3231">1.0</ix:nonFraction> billion <ix:nonNumeric contextRef="c-833" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-3232">three-year</ix:nonNumeric> revolving credit agreement maturing on April 2025 and a $<ix:nonFraction unitRef="usd" contextRef="c-834" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-3233">1.0</ix:nonFraction> billion <ix:nonNumeric contextRef="c-835" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-3234">364-day</ix:nonNumeric> revolving credit agreement maturing in April 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Commercial Paper. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under our commercial paper program, we may issue short-term, unsecured commercial paper notes privately placed on a discounted basis through certain broker-dealers at any time not to exceed an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="c-836" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-3235">5.0</ix:nonFraction> billion. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. The commercial paper program had approximately</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="c-836" decimals="-8" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="9" id="f-3236">1.2</ix:nonFraction>&#160;billion outstanding at December&#160;31, 2023 and an average interest rate of <ix:nonFraction unitRef="number" contextRef="c-809" decimals="4" name="srt:CommercialPaperAverageRatePaid" scale="-2" id="f-3237">5.63</ix:nonFraction>%.</span></div></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FS-5</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_1078"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-3036-5" continuedAt="f-3036-6"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Long-Term Debt</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Debt Issuance and Debt Tender Offers. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February 5, 2024, we issued $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="f-3238">4.5</ix:nonFraction> billion of new senior notes. The proceeds from this debt were used to pay the consideration for the cash tender offers as described below. We intend to use the remaining net proceeds to fund the repayment of our senior notes maturing in March 2024 and for general corporate purposes, which may include repayment of indebtedness and repurchases of shares of our common stock.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Concurrent with the debt issuance, The Company and its subsidiaries commenced tender offers to purchase for cash up to $<ix:nonFraction unitRef="usd" contextRef="c-837" decimals="-7" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="9" id="f-3239">2.25</ix:nonFraction> billion in aggregate principal amount of outstanding notes, which included any and all of the $<ix:nonFraction unitRef="usd" contextRef="c-838" decimals="-8" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="9" id="f-3240">1.0</ix:nonFraction> billion senior notes due June 2024. Following the early tender results, we increased the tender offers to up to $<ix:nonFraction unitRef="usd" contextRef="c-839" decimals="-7" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="9" id="f-3241">2.55</ix:nonFraction> billion. On February 22, 2024, we purchased $<ix:nonFraction unitRef="usd" contextRef="c-840" decimals="-8" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="9" id="f-3242">1.8</ix:nonFraction> billion principal amount of notes at early settlement of the tender offers. The tender offers will expire on March 5, 2024. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ci:CondensedFinancialInformationOfParentCompanyOnlyScheduleOfIssuancesOfLongTermDebtTableTextBlock" id="f-3243" continuedAt="f-3243-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 7, 2023, the Company issued $<ix:nonFraction unitRef="usd" contextRef="c-841" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="f-3244">1.5</ix:nonFraction>&#160;billion of new senior notes. The proceeds of this issuance were used for general </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">corporate purposes, and included repayment of outstanding debt securities. Interest on this debt is paid semi-annually.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.486%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Proceeds</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-842" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-3245">700</ix:nonFraction> million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 15, 2026</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-842" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-3246">5.685</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-843" decimals="-6" name="ci:ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees" scale="6" id="f-3247">698</ix:nonFraction> million</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-844" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-3248">800</ix:nonFraction> million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 15, 2033</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-844" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-3249">5.400</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-845" decimals="-6" name="ci:ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees" scale="6" id="f-3250">796</ix:nonFraction> million</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Redeemable at any time discounted at the U.S. Treasury rate plus <ix:nonFraction unitRef="number" contextRef="c-846" decimals="4" name="ci:DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate" scale="-4" id="f-3251">20</ix:nonFraction> basis points. Redeemable at par on or after March 15, 2024.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span></div></ix:nonNumeric><div style="padding-left:9pt;text-indent:-9pt"><ix:continuation id="f-3243-1" continuedAt="f-3243-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"><ix:continuation id="f-3243-2"> Redeemable at any time discounted at the U.S. Treasury rate plus <ix:nonFraction unitRef="number" contextRef="c-847" decimals="4" name="ci:DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate" scale="-4" id="f-3252">25</ix:nonFraction> basis points. Redeemable at par on or after December 15, 2032.</ix:continuation> </span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:5pt"><span><br/></span></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_1087"></div><ix:continuation id="f-3036-6" continuedAt="f-3036-7"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Debt Maturities. </span><ix:nonNumeric contextRef="c-1" name="ci:CondensedFinancialInformationOfParentCompanyOnlyScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="f-3253" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Maturities of the Company's long-term debt are as follows and exclude the impacts of the 2024 debt issuance and debt tender offers discussed above. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.040%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-812" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="f-3254">1,214</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-812" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="6" id="f-3255">2,957</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-812" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="6" id="f-3256">2,734</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-812" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="6" id="f-3257">2,056</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-812" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="6" id="f-3258">3,800</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maturities after 2028</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-812" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="f-3259">15,091</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Debt Covenants. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company was in compliance with its debt covenants as of December&#160;31, 2023.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> - The Company's intercompany receivables consist primarily of net intercompany loan amounts due from Evernorth Health, Inc. of $<ix:nonFraction unitRef="usd" contextRef="c-848" decimals="-8" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="9" id="f-3260">8.5</ix:nonFraction>&#160;billion as of December&#160;31, 2023 and $<ix:nonFraction unitRef="usd" contextRef="c-849" decimals="-8" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="9" id="f-3261">8.3</ix:nonFraction>&#160;billion as of December&#160;31, 2022. Interest income on the loan receivable was accrued at an average rate of <ix:nonFraction unitRef="number" contextRef="c-850" decimals="4" name="ci:IntercompanyReceivablesInterestRate" scale="-2" id="f-3262">5.21</ix:nonFraction>% in 2023.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's intercompany payables primarily reflect intercompany balances related to cash pooling arrangements as well as net intercompany loan borrowing from three indirect wholly-owned subsidiaries as of December&#160;31, 2023. Interest expense on the loan payable was accrued at an average rate of <ix:nonFraction unitRef="number" contextRef="c-851" decimals="4" name="ci:AverageInterestRateOnIntercompanyLoan" scale="-2" id="f-3263">3.65</ix:nonFraction>% in 2023.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> - The Company guaranteed approximately $<ix:nonFraction unitRef="usd" contextRef="c-812" decimals="-8" name="us-gaap:GuaranteeObligationsMaximumExposure" format="ixt:num-dot-decimal" scale="9" id="f-3264">2.9</ix:nonFraction> billion primarily related to intercompany indebtedness and financial obligations of certain direct and indirect wholly-owned subsidiaries. There were immaterial liabilities required for these guarantees as of December&#160;31, 2023. Effective January 2024, the amount of such guarantees increased to $<ix:nonFraction unitRef="usd" contextRef="c-852" decimals="-8" name="us-gaap:GuaranteeObligationsMaximumExposure" format="ixt:num-dot-decimal" scale="9" id="f-3265">6.4</ix:nonFraction> billion.</span></div></ix:continuation><div style="margin-bottom:10pt"><ix:continuation id="f-3036-7" continuedAt="f-3036-8"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 5</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-3036-8"> - In February 2024, as part of our existing share repurchase program, we entered into separate ASR agreements ("2024 ASR agreements") with Deutsche Bank AG and Bank of America, N.A. (collectively, the "2024 Counterparties") to repurchase $<ix:nonFraction unitRef="usd" contextRef="c-853" decimals="-8" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="f-3266">3.2</ix:nonFraction> billion of common stock in aggregate. We remitted $<ix:nonFraction unitRef="usd" contextRef="c-853" decimals="-8" sign="-" name="us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt" format="ixt:num-dot-decimal" scale="9" id="f-3267">3.2</ix:nonFraction> billion to the 2024 Counterparties and received an initial delivery of approximately <ix:nonFraction unitRef="shares" contextRef="c-854" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-3268">7.6</ix:nonFraction>&#160;million shares of our common stock on February 15, 2024 representing $<ix:nonFraction unitRef="usd" contextRef="c-854" decimals="-8" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="9" id="f-3269">2.6</ix:nonFraction> billion of the total remitted. We expect final settlement under the 2024 ASR agreements to occur in the second quarter of 2024.</ix:continuation> </span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FS-6</span></div></div></div><div id="ibc59a92ac8bc42f794e728f24ce1b626_1090"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> <span id="i51604efb89d948149b921d2cd42dab5f_576"></span><ix:nonNumeric contextRef="c-1" name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" id="f-3270" continuedAt="f-3270-1" escape="true">THE CIGNA GROUP AND SUBSIDIARIES</ix:nonNumeric></span></div><ix:continuation id="f-3270-1"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SCHEDULE II</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">VALUATION AND QUALIFYING ACCOUNTS AND RESERVES</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.045%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at beginning of year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charged (Credited) to costs and expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charged (Credited) to other accounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at end of year</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investment asset valuation reserves</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-855" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-3271">44</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-856" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="f-3272">11</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-856" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:fixed-zero" scale="6" id="f-3273">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-856" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="f-3274">22</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-857" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-3275">33</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial mortgage loans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-858" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-3276">21</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-859" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="f-3277">10</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-859" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:fixed-zero" scale="6" id="f-3278">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-859" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:fixed-zero" scale="6" id="f-3279">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-860" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-3280">31</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-861" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-3281">160</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-862" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="f-3282">90</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-862" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="f-3283">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-862" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="f-3284">88</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-863" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-3285">163</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax asset valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-864" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-3286">208</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-865" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="6" id="f-3287">1,286</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-865" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="f-3288">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-865" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:fixed-zero" scale="6" id="f-3289">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-866" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="f-3290">1,498</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reinsurance recoverables </span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-867" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-3291">35</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-868" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:fixed-zero" scale="6" id="f-3292">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-868" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:fixed-zero" scale="6" id="f-3293">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-868" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:fixed-zero" scale="6" id="f-3294">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-869" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-3295">35</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investment asset valuation reserves</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-870" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-3296">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-871" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="f-3297">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-871" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:fixed-zero" scale="6" id="f-3298">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-871" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="f-3299">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-855" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-3300">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial mortgage loans</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-872" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-3301">6</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-873" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="f-3302">15</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-873" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:fixed-zero" scale="6" id="f-3303">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-873" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:fixed-zero" scale="6" id="f-3304">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-858" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-3305">21</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-874" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-3306">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-875" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="f-3307">99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-875" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:fixed-zero" scale="6" id="f-3308">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-875" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="f-3309">65</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-861" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-3310">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax asset valuation allowance </span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-876" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-3311">246</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-877" decimals="-6" sign="-" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="f-3312">13</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-877" decimals="-6" sign="-" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="f-3313">25</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-877" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:fixed-zero" scale="6" id="f-3314">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-864" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-3315">208</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reinsurance recoverables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-878" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-3316">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-879" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="f-3317">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-879" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:fixed-zero" scale="6" id="f-3318">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-879" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:fixed-zero" scale="6" id="f-3319">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-867" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-3320">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investment asset valuation reserves</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-880" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-3321">26</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-881" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="f-3322">29</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-881" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:fixed-zero" scale="6" id="f-3323">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-881" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="f-3324">32</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-870" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-3325">23</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial mortgage loans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-882" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-3326">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-883" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:fixed-zero" scale="6" id="f-3327">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-883" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:fixed-zero" scale="6" id="f-3328">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-883" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:fixed-zero" scale="6" id="f-3329">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-872" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-3330">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-884" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-3331">156</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-885" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="f-3332">54</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-885" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:fixed-zero" scale="6" id="f-3333">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-885" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="f-3334">84</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"/><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-874" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-3335">126</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax asset valuation allowance </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-886" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-3336">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-887" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="f-3337">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-887" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="f-3338">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-887" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:fixed-zero" scale="6" id="f-3339">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-876" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-3340">246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reinsurance recoverables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-888" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-3341">30</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-889" decimals="-6" sign="-" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="6" id="f-3342">2</ix:nonFraction>)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-889" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:fixed-zero" scale="6" id="f-3343">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-889" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:fixed-zero" scale="6" id="f-3344">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-878" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-3345">28</ix:nonFraction>&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:700;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts ("LDTI") in 2023. See Note 2 to the Consolidated Financial Statements included in Part II, Item 8 of this Form 10-K for further information.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FS-7</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.7
<SEQUENCE>2
<FILENAME>exh_47xdescriptionofsecuri.htm
<DESCRIPTION>EX-4.7
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i26b55e51969e46e785db3aea5a7eda14_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 4.7</font></div></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES REGISTERED </font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">The following is a summary of the material terms of the Common Stock, par value $0.01 per share of The Cigna Group (&#8220;Cigna&#8221; or the &#8220;Company&#8221;). </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">This summary is not complete and is qualified by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Cigna&#8217;s restated certificate of incorporation, which we refer to as the certificate of incorporation, and Cigna&#8217;s amended and restated bylaws, which we refer to as the bylaws, each of which is incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit is a part, and the applicable provisions of the General Corporation Law of the State of Delaware, which we refer to as the DGCL.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Authorized Capital Stock</font></div><div style="margin-bottom:6pt;padding-right:14.4pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The aggregate number of shares that Cigna has the authority to issue is (1) 600,000,000 shares of Cigna common stock, par value $0.01 per share, and (2) 25,000,000 shares of Cigna preferred stock, par value $1.00 per share. The board of directors is expressly authorized to provide for the issue of all or any shares of the preferred stock, in one or more series, and to fix for each such series such voting powers, full or limited, or no voting powers, and such designations, preferences and relative, participating, optional or other special rights and such qualifications, limitations or restrictions thereof.</font></div><div style="margin-bottom:6pt;padding-right:14.4pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As of the date of the Annual Report of which this Exhibit is a part, no shares of Cigna preferred stock are outstanding.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Common Stock</font></div><div style="margin-bottom:6pt;padding-right:14.4pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Holders of Cigna common stock will be entitled to receive dividends when, as and if declared by Cigna&#8217;s board of directors out of funds legally available for payment. If Cigna issues preferred stock in the future, payment of dividends to holders of Cigna common stock may be subject to the rights of holders of Cigna preferred stock with respect to payment of preferential dividends, if any.</font></div><div style="margin-bottom:6pt;padding-right:3.6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to the rights, if any, of the holders of any series of preferred stock if and when issued and subject to applicable law, each holder of Cigna common stock is entitled to one vote per share and all voting rights are vested in the Cigna common stock. Holders of shares of Cigna common stock have noncumulative voting rights, which means that the holders of more than 50% of the shares voting for the election of directors can elect 100% of the directors and the holders of the remaining shares are not able to elect any directors.</font></div><div style="margin-bottom:6pt;padding-right:3.6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event of a voluntary or involuntary liquidation, dissolution or winding up of Cigna, the holders of Cigna common stock will be entitled to share equally in any of the assets available for distribution after Cigna has paid in full all of its debts and after the holders of all series of outstanding Cigna preferred stock, if any, have received their liquidation preferences in full.</font></div><div style="margin-bottom:6pt;padding-right:3.6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The shares of Cigna common stock outstanding are validly issued, fully paid and nonassessable. Holders of shares of Cigna common stock are not entitled to preemptive rights. Shares of Cigna common stock are not convertible into shares of any other class of capital stock.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Transfer Agent and Registrar </font></div><div style="margin-bottom:6pt;padding-right:25.2pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Computershare Inc. is the transfer agent for the Cigna common stock. Cigna may from time to time engage another transfer agent for its stock as business circumstances warrant.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Listing </font></div><div style="margin-bottom:6pt;padding-right:25.2pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cigna&#8217;s common stock is listed on the New York Stock Exchange (&#8220;NYSE&#8221;) under the symbol &#8220;CI.&#8221; </font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Preferred Stock</font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Under the certificate of incorporation, without further stockholder action, the Cigna board of directors is authorized to provide, by resolution of the Cigna board of directors, for the issuance of all or any shares of Cigna preferred stock in one or more series, and to fix the voting powers, designations, preferences and relative, participating, optional or other special rights and such qualifications, limitations or restrictions of such series including, without limitation, the authority to provide that any such series may be (1) subject </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">to redemption at such time or times and at such price or prices&#59; (2) entitled to receive dividends (which may be cumulative or non-cumulative) at such rates, on such conditions, and at such times, and payable in preference to, or in such relation to, the dividends payable on any other class or any other series&#59; (3) entitled to such rights upon the dissolution of, or upon any distribution of the assets of, Cigna&#59; or (4) convertible into, or exchangeable for, shares of any other class of stock, or of any other series of the same or any other class of stock, of Cigna at such price or prices or at such rates of exchange and with such adjustments.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Number and Election of Directors</font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Cigna board of directors must consist of no less than eight and no more than sixteen directors. The number of directors may be fixed, from time to time, by the affirmative vote of a majority of the entire board of directors. Any decrease in the number of directors will be effective at the time of the next succeeding annual meeting of stockholders unless there will be vacancies in the board of directors, in which case such decrease may become effective at any time prior to the next succeeding annual meeting to the extent of the number of such vacancies.</font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A nominee for director is elected to the board of directors if the votes cast for election exceed the votes cast against&#59; however, if the number of director nominees exceeds the number of directors to be elected, which we refer to as a contested election, directors are elected by a plurality of the votes. Stockholders cannot vote against a nominee in a contested election. A contested election will be deemed to exist at any meeting of stockholders for which (1) the Corporate Secretary of receives a notice that a stockholder has nominated a person for election to the board of directors in compliance with the bylaws and (2) such nomination has not been withdrawn by such stockholder on or prior to the day next preceding the date Cigna first mails its notice of meeting for such meeting to the stockholders.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Vacancies on the Board of Directors and Removal of Directors</font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The bylaws of Cigna provide that, any vacancy in the board of directors may be filled by the majority vote of the directors then in office (even if less than quorum) or by the sole remaining director. Each director so elected will hold office for a term expiring at the next annual meeting of stockholders and will hold office until his or her successor will have been elected and qualified, or until death, or until such director will have resigned, or will have been removed, as provided in the bylaws.</font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any director may be removed, with or without cause, at any time, by a majority of the voting power of the issued and outstanding capital stock of Cigna entitled to vote at an election for directors. Neither the certificate of incorporation nor the bylaws of Cigna authorize the Cigna board of directors to remove any members of the Cigna board of directors.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amendments to Certificates of Incorporation</font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The certificate of incorporation grants Cigna the right to amend, alter, change or repeal any provision in the certificate of incorporation in the manner prescribed by statute. Under Section 242 of the DGCL, unless the certificate of incorporation requires a greater vote, a proposed amendment to the certificate of incorporation must be approved by the affirmative vote of a majority of the voting power of the outstanding stock entitled to vote thereon and a majority of the outstanding stock of each class entitled to vote as a class.</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amendments to Bylaws</font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Cigna bylaws may be adopted, amended or repealed by majority vote of the capital stock of Cigna outstanding and entitled to vote thereon, or by the Cigna board of directors without any vote of the stockholders.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Ability to Call Special Meeting of Stockholders</font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Special meetings of Cigna stockholders, unless otherwise prescribed by statute, may be called at any time by the board of directors or the Chief Executive Officer or may be called by the Corporate Secretary upon the valid request of one or more shareholders that have net long beneficial ownership (as defined in the bylaws) for a period of at least one full year prior to the date of the request, of capital stock of Cigna representing at least 25% of the voting power of the issued and outstanding capital stock of Cigna entitled to vote on the matters to be presented at the special meeting. The right to call a special meeting is subject to specified information, timing and other requirements as set forth in the bylaws. At any special meeting </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">of the stockholders, only such business will be conducted as will have been brought before the meeting by or at the direction of the board of directors or pursuant to valid request by shareholders.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Notice Required for Stockholder Nominations and other Proposals</font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Nominations&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> A stockholder&#8217;s notice must be received by the Corporate Secretary at the principal executive offices of Cigna not less than 90 days nor more than 120 days prior to the first anniversary of the date of the preceding year&#8217;s annual meeting of stockholders&#59; provided, however, that in the event that the annual meeting of stockholders is more than 30 days before or 60 days after such anniversary date or if no such meeting was held in the preceding year, notice by a stockholder will be timely only if received (1) not earlier than 120 days prior to such annual meeting and (2) not less than 90 days before such annual meeting or, if later, within 10 days after the first public announcement of the date of such annual meeting. In no event will any adjournment or postponement of an annual meeting or the announcement thereof commence a new time period (or extend any time period) for the giving of a stockholder&#8217;s notice as described above.</font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Other Proposals&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> A stockholder&#8217;s notice pursuant to this section must be delivered to or mailed and received by the Corporate Secretary at the principal executive offices of Cigna not less than 90 days nor more than 120 days prior to the first anniversary of the date of the preceding year&#8217;s annual meeting of stockholders&#59; provided, however, that in the event that the annual meeting of stockholders is more than 30 days before or 60 days after such anniversary date or if no such meeting was held in the preceding year, notice by a stockholder will be timely only if received (1) not earlier than 120 days prior to such annual meeting and (2) not less than 90 days before such annual meeting or, if later, within 10 days after the first public announcement of the date of such annual meeting. In no event will any adjournment or postponement of an annual meeting or the announcement thereof commence a new time period (or extend any time period) for the giving of a stockholder&#8217;s notice as described above.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Proxy Access</font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The bylaws provide that if the board of directors solicits proxies with respect to the election of directors of Cigna at an annual meeting, a stockholder or a group of up to 20 stockholders owning 3% or more of the aggregate number of shares of Cigna&#8217;s outstanding common stock continuously for at least three years is permitted to nominate and include in Cigna&#8217;s proxy materials director nominees constituting up to the greater of 20% of the board of directors or two individuals, provided the stockholder(s) and the nominee(s) satisfy the requirements specified in the bylaws, including by providing Cigna with advance notice of the nomination.</font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notice must be addressed to and received by the Corporate Secretary not less than 120 days nor more than 150 days prior to the first anniversary of the date on which Cigna&#8217;s definitive proxy statement was released to stockholders in connection with the prior year&#8217;s annual meeting&#59; provided, however, that if the annual meeting is convened more than 30 days prior to or delayed by more than 60 days after the first anniversary of the date of the preceding year&#8217;s annual meeting, the information must be so received not earlier than 120 days prior to such annual meeting and not later than the close of business on the later of (1) the 90th day prior to such annual meeting or (2) the 10th day following the day on which a public announcement of the date of the annual meeting is first made.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">State Anti-Takeover Statutes</font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cigna has elected not to be governed by Section 203 of the DGCL, which provisions generally prohibit &#8220;business combinations,&#8221; including mergers, sales and leases of assets, issuances of securities and similar transactions by a corporation or a subsidiary with an interested stockholder who beneficially owns 15% or more of a corporation&#8217;s voting stock within three years after the person or entity becomes an interested stockholder, unless&#58; (1) the board of directors of the target corporation has approved, before the acquisition time, either the business combination or the transaction that resulted in the person becoming an interested stockholder&#59; (2) upon consummation of the transaction that resulted in the person becoming an interested stockholder, the person owns at least 85% of the corporation&#8217;s voting stock (excluding shares owned by directors who are officers and shares owned by employee stock plans in which participants do not have the right to determine confidentially whether shares will be tendered in a tender or exchange offer)&#59; or (3) after the person or entity becomes an interested stockholder, the business combination is approved by the board of directors and authorized by the vote of at least 66 2&#47;3% of the outstanding voting stock not owned by the interested stockholder at an annual or special meeting.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Transactions Involving Officers or Directors</font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 143 of the DGCL provides that a corporation may lend money to, or guarantee any obligation incurred by, its officers or directors if, in the judgment of the board of directors, the loan or guarantee may reasonably be expected to benefit the corporation. Section 144 of the DGCL provides that any other contract or transaction between the corporation and one or more of its directors or officers is neither void nor voidable solely because the interested director or officer was present, participates or votes at the board of directors or board committee meeting that authorizes the contract or transaction, if either&#58; (1) the director&#8217;s or officer&#8217;s interest is made known to the disinterested directors or the stockholders of the corporation, who thereafter approve the transaction in good faith, or (2) the contract or transaction is fair to the corporation as of the time it is approved or ratified by either the board of directors, a committee thereof, or the stockholders.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exclusive Forum</font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The bylaws provide that, unless Cigna consents in writing to the selection of an alternative forum, the sole and exclusive forum for (1) any derivative action or proceeding brought on behalf of Cigna, (2) any action asserting a claim for or based on a breach of a fiduciary duty owed by any current or former director or officer or other employee of Cigna to Cigna or Cigna&#8217;s stockholders, including a claim alleging the aiding and abetting of such a breach of fiduciary duty, (3) any action asserting a claim against Cigna or any current or former director or officer or other employee of Cigna arising pursuant to any provision of the DGCL or the certificate of incorporation or the bylaws, (4) any action asserting a claim related to or involving Cigna that is governed by the internal affairs doctrine, or (5) any action asserting an &#8220;internal corporate claim&#8221; as that term is defined in Section 115 of the DGCL will be a state court in Delaware (or, if no state court located within Delaware has jurisdiction, the federal district court for the District of Delaware).</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Limitation of Personal Liability of Directors and Officers</font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The DGCL provides that the certificate of incorporation may include provisions which limits or eliminates personal liability of directors and officers to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, as applicable, provided that such liability does not arise from (1) any breach of the director or officer&#8217;s duty of loyalty to Cigna or its stockholders&#59; (2) acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law&#59; (3) in the case of directors, unlawful payments of dividends, certain stock repurchases or redemptions&#59; (4) any transaction from which the director or officer derived an improper personal benefit or (5) in the case of officers, any action by or in the right of Cigna, such as derivative claims. The certificate of incorporation of Cigna limits director and officer liability to the extent permitted by the DGCL.</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnification of Directors and Officers</font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The bylaws provide that Cigna will indemnify each person who was or is made a party or is threatened to be made a party to or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative, which we refer to as a proceeding, because he or she (1) is or was a director or an officer of Cigna or (2) is or was serving at the request of Cigna as a director, officer, employee, agent, partner or trustee of another company or of a partnership, joint venture, trust or other enterprise, including service with respect to an employee benefit plan (we refer to the persons in clauses (1) and (2) hereinafter each as an indemnitee), to the fullest extent permitted by Delaware law, against all expense, liability and loss (including attorneys&#8217; fees, judgments, fines, Employee Retirement Income Security Act of 1974 excise taxes or penalties and amounts paid in settlement) reasonably incurred or suffered by such indemnitee in connection therewith. However, except with respect to proceedings to enforce rights to indemnification, Cigna will indemnify any such indemnitee in connection with a proceeding (or part thereof) initiated by such indemnitee only if such proceeding (or part thereof) was authorized by the Cigna board of directors.</font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cigna may, to the extent authorized from time to time by the Cigna board of directors, grant rights to indemnification and to the advancement of expenses to any employee or agent of Cigna to the fullest extent of indemnification and advancement of expenses of indemnitees of Cigna.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.23
<SEQUENCE>3
<FILENAME>exh_1023xpalmerofferletter.htm
<DESCRIPTION>EX-10.23
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ic71220f9f4694d5384970bc94e8ea3b6_1"></div><div style="min-height:108pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.23</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><img alt="image_2a.jpg" src="image_2a.jpg" style="height:58px;margin-bottom:5pt;vertical-align:text-bottom;width:154px"></div><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:1200%">David M. Cordani</font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:900%">Chairman and CEO</font></div><div><font><br></font></div><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:96px;margin-bottom:5pt;vertical-align:text-bottom;width:201px"></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">January 16, 2024</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Eric Palmer</font></div><div style="padding-right:-36pt"><font><br></font></div><div style="padding-right:-36pt"><font><br></font></div><div style="padding-right:-36pt"><font><br></font></div><div style="padding-right:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dear Eric&#58;</font></div><div style="padding-right:0.9pt"><font><br></font></div><div style="padding-right:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">I am pleased to confirm that the People Resources Committee (PRC) has approved the following changes to your compensation package effective February 5, 2024 in connection with the assumption of your expanded role as EVP, Enterprise Strategy and President &#38; CEO Evernorth&#58; </font></div><div style="padding-right:0.9pt"><font><br></font></div><div style="padding-left:18pt;padding-right:0.9pt;text-indent:-18pt"><font style="font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:12.97pt">Base Salary &#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Your base salary will remain a pre-tax annualized rate of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$1,000,000</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="padding-left:18pt;padding-right:0.9pt"><font><br></font></div><div style="padding-left:18pt;padding-right:0.9pt;text-indent:-18pt"><font style="font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:12.97pt">Annual Incentive &#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Your annual incentive target will increase to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$2,000,000 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">for the 2024 performance year (payable in 2025).  As you are aware, the annual incentive is typically paid in the first quarter of the year following the performance period and is not considered earned until the date paid.</font></div><div style="padding-right:0.9pt"><font><br></font></div><div style="padding-left:18pt;padding-right:-36pt;text-indent:-18pt"><font style="font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:12.97pt">Long-Term Incentive &#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Your annual long-term incentive target will increase to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$6,000,000</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> for the upcoming 2024 annual grant.</font></div><div style="padding-right:0.9pt"><font><br></font></div><div style="padding-right:0.75pt"><font><br></font></div><div style="padding-right:0.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NEW TOTAL ANNUAL COMPENSATION OPPORTUNITY&#58;  $9,000,000</font></div><div style="padding-right:0.75pt"><font><br></font></div><div style="padding-right:0.75pt"><font><br></font></div><div style="padding-right:0.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Your employment will remain as an at-will employee, meaning that you or the Company has the right to terminate your employment relationship at any time for any reason or no reason. The changes above have no impact on previously awarded bonuses, stock options, restricted stock or SPS grants. Your stock ownership guideline will remain six times your base salary.</font><font style="color:#000000;font-family:'Courier New',monospace;font-size:10.5pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As an executive of the company, your compensation will be subject to any future program changes.</font></div><div style="padding-right:-36pt"><font><br></font></div><div style="padding-right:-30.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Eric, congratulations on your expanded role. I look forward to continuing to partner with you.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sincerely,</font></div><div><img alt="image_1a.jpg" src="image_1a.jpg" style="height:54px;margin-bottom:5pt;vertical-align:text-bottom;width:191px"></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">David M. Cordani</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">cc&#58;&#160;&#160;&#160;&#160;K. Stevens</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">       N. Ryan</font></div><div style="height:22.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.26
<SEQUENCE>4
<FILENAME>exh_1026xevankoofferletter.htm
<DESCRIPTION>EX-10.26
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i6262199b8db74751bf46c9865af65f46_1"></div><div style="min-height:108pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.26</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><img alt="image_21a.jpg" src="image_21a.jpg" style="height:58px;margin-bottom:5pt;vertical-align:text-bottom;width:154px"></div></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:1200%">David M. Cordani</font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:900%">Chairman and CEO</font></div><div><font><br></font></div><div><img alt="image_01a.jpg" src="image_01a.jpg" style="height:96px;margin-bottom:5pt;vertical-align:text-bottom;width:201px"></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">January 16, 2024</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Brian Evanko</font></div><div style="padding-right:-36pt"><font><br></font></div><div style="padding-right:-36pt"><font><br></font></div><div style="padding-right:-36pt"><font><br></font></div><div style="padding-right:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dear Brian&#58;</font></div><div style="padding-right:0.9pt"><font><br></font></div><div style="padding-right:0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">I am pleased to confirm that the People Resources Committee (PRC) has approved the following changes to your compensation package effective February 5, 2024 in connection with the assumption of your expanded role as EVP, CFO and President &#38; CEO Cigna Healthcare&#58; </font></div><div style="padding-right:0.9pt"><font><br></font></div><div style="padding-left:18pt;padding-right:0.9pt;text-indent:-18pt"><font style="font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:12.97pt">Base Salary &#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Your base salary will increase to a pre-tax annualized rate of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$1,000,000</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="padding-left:18pt;padding-right:0.9pt"><font><br></font></div><div style="padding-left:18pt;padding-right:0.9pt;text-indent:-18pt"><font style="font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:12.97pt">Annual Incentive &#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Your annual incentive target will increase to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$2,000,000 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">for the 2024 performance year (payable in 2025).  As you are aware, the annual incentive is typically paid in the first quarter of the year following the performance period and is not considered earned until the date paid.</font></div><div style="padding-right:0.9pt"><font><br></font></div><div style="padding-left:18pt;padding-right:-36pt;text-indent:-18pt"><font style="font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:12.97pt">Long-Term Incentive &#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Your annual long-term incentive target will increase to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$6,000,000</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> for the upcoming 2024 annual grant.</font></div><div style="padding-right:0.9pt"><font><br></font></div><div style="padding-right:0.75pt"><font><br></font></div><div style="padding-right:0.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NEW TOTAL ANNUAL COMPENSATION OPPORTUNITY&#58;  $9,000,000</font></div><div style="padding-right:0.75pt"><font><br></font></div><div style="padding-right:0.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The stock ownership guideline for your new position is six times your base salary.&#160;&#160;As you know, each executive has five years from the date they become subject to the stock ownership guidelines to meet the guideline.</font></div><div style="padding-right:0.75pt"><font><br></font></div><div style="padding-right:0.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Your employment will remain as an at-will employee, meaning that you or the Company has the right to terminate your employment relationship at any time for any reason or no reason. The changes above have no impact on previously awarded bonuses, stock options, restricted stock or SPS grants.</font><font style="color:#000000;font-family:'Courier New',monospace;font-size:10.5pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As an executive of the company, your compensation will be subject to any future program changes.</font></div><div style="padding-right:-36pt"><font><br></font></div><div style="padding-right:-30.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Brian, congratulations on your expanded role. I look forward to continuing to partner with you.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sincerely,</font></div><div><img alt="image_11a.jpg" src="image_11a.jpg" style="height:54px;margin-bottom:5pt;vertical-align:text-bottom;width:191px"></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">David M. Cordani</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">cc&#58;&#160;&#160;&#160;&#160;K. Stevens</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">       N. Ryan</font></div><div style="height:22.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>5
<FILENAME>exh_21x10-kx23q4.htm
<DESCRIPTION>EX-21
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i1a5444e0600d46129e847521b7df914f_1"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 21</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21 &#8211; Subsidiaries of the Registrant</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Listed below are subsidiaries of The Cigna Group as of December&#160;31, 2023 with their jurisdictions of organization. Those subsidiaries not listed would not, in the aggregate, constitute a &#8220;significant subsidiary&#8221; of The Cigna Group, as that term is defined in Rule 1-02(w) of Regulation S-X.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:77.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Entity Name</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accredo Health Group, Inc.</font></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accredo Health, Incorporated</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allegiance Life &#38; Health Insurance Company</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Montana</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">American Retirement Life Insurance Company</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohio</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ascent Health Services LLC</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bravo Health Mid-Atlantic, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maryland</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bravo Health Pennsylvania, Inc.</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Care Continuum, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kentucky</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CareCore NJ, LLC</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chiro Alliance Corporation</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna &#38; CMB Life Insurance Company Limited</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna Arbor Life Insurance Company</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Connecticut</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna Dental Health Of California, Inc.</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna Dental Health Of Colorado, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colorado</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna Dental Health Of Delaware, Inc.</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna Dental Health Of Florida, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna Dental Health Of Kansas, Inc.</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kansas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna Dental Health Of Kentucky, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kentucky</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna Dental Health Of Maryland, Inc.</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maryland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna Dental Health Of Missouri, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna Dental Health Of New Jersey, Inc.</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna Dental Health Of North Carolina, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North Carolina</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna Dental Health Of Ohio, Inc.</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohio</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna Dental Health Of Pennsylvania, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna Dental Health Of Texas, Inc.</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna Dental Health Of Virginia, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Virginia</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna Dental Health Plan Of Arizona, Inc.</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna Europe Insurance Company S.A.-N.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna-Evernorth Enterprise Services, Inc.</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna Global Insurance Company Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Guernsey</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna Global Reinsurance Company, Ltd.</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna Health and Life Insurance Company</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Connecticut</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna HealthCare Mid-Atlantic, Inc.</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maryland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna HealthCare of Arizona, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arizona</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna HealthCare of California, Inc.</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna HealthCare of Colorado, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colorado</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna HealthCare of Connecticut, Inc.</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Connecticut</font></td></tr></table></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:77.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna HealthCare of Florida, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna HealthCare of Georgia, Inc.</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna HealthCare of Illinois, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Illinois</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna HealthCare of Indiana, Inc.</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna HealthCare of Massachusetts, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Massachusetts</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna HealthCare of New Hampshire, Inc.</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Hampshire</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna HealthCare of New Jersey, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna HealthCare of North Carolina, Inc.</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North Carolina</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna HealthCare of Pennsylvania, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna HealthCare of South Carolina, Inc.</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Carolina</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna HealthCare of St. Louis, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna HealthCare of Tennessee, Inc.</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna HealthCare of Texas, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna Holding Company</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna Holdings, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna Insurance Company</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohio</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna Insurance Middle East S.A.L.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lebanon</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna Life Insurance Company of Canada</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna Life Insurance Company of Europe S.A.-N.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna National Health Insurance Company</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohio</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna Services Middle East FZE</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dubai</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna Spruce Holdings GmBH</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;<br>Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna Worldwide General Insurance Company Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hong Kong</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigna Worldwide Insurance Company</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Connecticut General Corporation</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Connecticut</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Connecticut General Life Insurance Company</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Connecticut</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CuraScript, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESI Mail Pharmacy Service, Inc.</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evernorth Accountable Care, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evernorth Health, Inc.</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evernorth-VillageMD Care Alliance of NJ, LLC (F&#47;K&#47;A &#34;ENAC of NJ, LLC&#34;)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evernorth Wholesale Distribution, Inc.</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">eviCore Healthcare MSI, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Express Reinsurance Company</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Missouri</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Express Scripts Administrators LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Express Scripts Pharmaceutical Procurement, LLC</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Express Scripts Pharmacy, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Express Scripts Strategic Development, Inc.</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Express Scripts Utilization Management Company</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Express Scripts, Inc.</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HealthSpring Life &#38; Health Insurance Company, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HealthSpring of Florida, Inc.</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inside RX, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:77.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loyal American Life Insurance Company</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohio</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ManipalCigna Health Insurance Company Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matrix Healthcare Services, Inc.</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medco Containment Insurance Company of NY</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medco Containment Life Insurance Company</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medco Health Services, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medco Health Solutions, Inc.</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSI Health Organization of Texas, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provident American Life &#38; Health Insurance Company</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohio</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sterling Life Insurance Company</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Illinois</font></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Temple Insurance Company Limited</font></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</font></td></tr></table></div><div><font><br></font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>6
<FILENAME>exh_23x10-kx23q4.htm
<DESCRIPTION>EX-23
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ibdae42055b434e66b5e7b86c07713fbc_1"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23</font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-268633) and S-8 (Nos. 333-228930, 333-228931 and 333-258507) of The Cigna Group of our report dated February&#160;29, 2024 relating to the financial statements and financial statement schedules, and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; PricewaterhouseCoopers LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hartford, Connecticut</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;29, 2024</font></div><div style="height:50.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>exh_311x23q4.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i33a9f37fb4824faea8b3ce1cd9d09c1d_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, DAVID M. CORDANI, certify that&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of The Cigna Group&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;&#160;&#160;February&#160;29, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David M. Cordani</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman and Chief Executive Officer</font></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>exh_312x23q4.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="if75fec60c24840ff8a11d8adb333335e_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, BRIAN C. EVANKO, certify that&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of The Cigna Group&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.189%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;&#160;&#160;February&#160;29, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Brian C. Evanko</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Financial Officer, The Cigna Group, and President and Chief Executive Officer, Cigna Healthcare</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>exh_321x23q4.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i6db285a0248b437bb9bd7a7f86c30a3e_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certification of Chief Executive Officer of </font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cigna Group pursuant to 18 U.S.C. Section 1350</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I certify that, to the best of my knowledge and belief, the Annual Report on Form 10-K of The Cigna Group for the fiscal period ending December&#160;31, 2023 (the &#8220;Report&#8221;)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of The Cigna Group.</font></div><div style="margin-bottom:12pt;text-align:right;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David M. Cordani</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David M. Cordani</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;29, 2024</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:right"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>exh_322x23q4.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i3c59cded79024c06ad18f21910428bdd_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certification of Chief Financial Officer of</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cigna Group pursuant to 18 U.S.C. Section 1350</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I certify that, to the best of my knowledge and belief, the Annual Report on Form 10-K of The Cigna Group for the fiscal period ending December&#160;31, 2023 (the &#8220;Report&#8221;)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of The Cigna Group.</font></div><div style="margin-bottom:12pt;text-align:right;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:54.967%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Brian C. Evanko</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brian C. Evanko</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Financial Officer, The Cigna Group, and President and Chief Executive Officer, Cigna Healthcare</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;29, 2024</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:right"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>11
<FILENAME>exh_971xincentivecompensat.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i347419c024ae40c182b66fd703b6f100_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 97.1</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">The Cigna Group</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Incentive Compensation <br>Clawback Policy</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(As Adopted on October 25, 2023 Pursuant to NYSE Rule 303A.14)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Overview</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of The Cigna Group (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) has adopted this Incentive Compensation Clawback Policy (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) which requires the recoupment of certain incentive-based compensation in accordance with the terms herein and is intended to comply with Section 303A.14 of The New York Stock Exchange Listed Company Manual, as such section may be amended from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Listing Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Capitalized terms not otherwise defined herein shall have the meanings assigned to such terms under Section 12 of this Policy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Interpretation and Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The People Resources Committee of the Board (the &#8220;Committee&#8221;) shall have full authority to interpret and enforce the Policy&#59; provided, however, that the Policy shall be interpreted in a manner consistent with its intent to meet the requirements of the Listing Rules.  As further set forth in Section 10 below, this Policy is intended to supplement any other clawback policies and procedures that the Company may have in place from time to time pursuant to other applicable law, plans, policies or agreements.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Covered Executives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Policy applies to each current and former Executive Officer of the Company who serves or served as an Executive O&#64259;cer at any time during a performance period in respect of which Incentive Compensation is Received, to the extent that any portion of such Incentive Compensation is (a) Received by the Executive Officer during the last three completed Fiscal Years or any applicable Transition Period preceding the date that the Company is required to prepare a Restatement (regardless of whether any such Restatement is actually filed) and (b) determined to have included Erroneously Awarded Compensation.  For purposes of determining the relevant recovery period referenced in the preceding clause (a), the date that the Company is required to prepare a Restatement under the Policy is the earlier to occur of (i) the date that the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare a Restatement or (ii) the date a court, regulator, or other legally authorized body directs the Company to prepare a Restatement.  Executive Officers subject to this Policy pursuant to this Section 3 are referred to herein as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Covered Executives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Recovery of Erroneously Awarded Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If any Erroneously Awarded Compensation is Received by a Covered Executive, the Company shall reasonably promptly take steps to recover such Erroneously Awarded Compensation in a manner described under Section 5 of this Policy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Forms of Recovery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Committee shall determine, in its sole discretion and in a manner that effectuates the purpose of the Listing Rules, one or more methods for recovering any Erroneously Awarded Compensation hereunder in accordance with Section 4 above, which may include, without limitation&#58; (a) requiring cash reimbursement&#59; (b) seeking recovery or forfeiture of any gain realized on the vesting, exercise, settlement, sale, transfer or other disposition of any equity-based awards&#59; (c) offsetting the amount to be recouped from any compensation otherwise owed by the Company to the Covered Executive&#59; (d) cancelling outstanding vested or unvested equity awards&#59; or (e) taking any other remedial and recovery action permitted by law, as determined by the Committee. To the extent the Covered Executive refuses to pay to the Company an amount equal to the Erroneously Awarded Compensation, the Company shall have the right to sue for repayment and&#47;or enforce the Covered Executive&#8217;s </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">obligation to make payment through the reduction or cancellation of outstanding and future compensation. Any reduction, cancellation or forfeiture of compensation shall be done in compliance with Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">No Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall not indemnify any Covered Executive against the loss of any Erroneously Awarded Compensation for which the Committee has determined to seek recoupment pursuant to this Policy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Exceptions to the Recovery Requirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything in this Policy to the contrary, Erroneously Awarded Compensation need not be recovered pursuant to this Policy if the Committee (or, if the Committee is not composed solely of Independent Directors, a majority of the Independent Directors serving on the Board) determines that recovery would be impracticable as a result of any of the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">the direct expense paid to a third party to assist in enforcing the Policy would exceed the amount to be recovered&#59; provided that, before concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on expense of enforcement, the Company must make a reasonable attempt to recover such Erroneously Awarded Compensation, document such reasonable attempt(s) to recover, and provide that documentation to the Exchange&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and the regulations thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Committee Determination Final</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any determination by the Committee with respect to the Policy shall be final, conclusive and binding on all interested parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Policy may be amended by the Committee from time to time, to the extent permitted under the Listing Rules.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Non-Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Nothing in the Policy shall be viewed as limiting the right of the Company or the Committee to pursue additional remedies or recoupment under or as required by any similar policy adopted by the Company or under the Company&#8217;s compensation plans, award agreements, employment agreements or similar agreements or the applicable provisions of any law, rule or regulation which may require or permit recoupment to a greater degree or with respect to additional compensation as compared to this Policy (but without duplication as to any recoupment already made with respect to Erroneously Awarded Compensation pursuant to this Policy).  This Policy shall be interpreted in all respects to comply with the Listing Rules.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Policy shall be binding and enforceable against all Covered Executives and their beneficiaries, heirs, executors, administrators or other legal representatives.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Covered Executives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 3 of this Policy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Erroneously Awarded Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the amount of Incentive Compensation actually Received that exceeds the amount of Incentive Compensation that otherwise would have been Received had it been determined based on the restated amounts, and computed without regard to any taxes paid. For Incentive Compensation based on stock price or total shareholder return, where the amount of erroneously awarded Incentive Compensation is not subject to mathematical recalculation directly from the information in a Restatement&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.36pt">The calculation of Erroneously Awarded Compensation shall be based on a reasonable estimate of the effect of the Restatement on the stock price or total shareholder return upon which the Incentive Compensation was Received&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.02pt">The Company shall maintain documentation of the determination of that reasonable estimate and provide such documentation to the Exchange.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean The New York Stock Exchange.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Company&#8217;s president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for the Company. Executive officers of the Company&#8217;s parent(s) or subsidiaries shall be deemed executive officers of the Company if they perform such policy-making functions for the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Financial Reporting Measures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements, and any measures that are derived wholly or in part from such measures, including, without limitation, stock price and total shareholder return (in each case, regardless of whether such measures are presented within the Company&#8217;s financial statements or included in a filing with the Securities and Exchange Commission).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Fiscal Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Company&#8217;s fiscal year&#59; provided that a Transition Period between the last day of the Company&#8217;s previous fiscal year end and the first day of its new fiscal year that comprises a period of nine to 12 months will be deemed a completed fiscal year.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Incentive Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any compensation (whether cash or equity-based) that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure, and may include, but shall not be limited to, performance bonuses and long-term incentive awards such as stock options, stock appreciation rights, restricted stock, restricted stock units, performance share units or other equity-based awards.  For the avoidance of doubt, Incentive Compensation does not include awards that vest exclusively upon completion of a specified employment period, without any performance condition, and bonus awards that are discretionary or based on subjective goals or goals unrelated to Financial Reporting Measures. Notwithstanding the foregoing, compensation amounts shall not be considered &#8220;Incentive Compensation&#8221; for purposes of the Policy unless such compensation is Received (1) while the Company has a class of securities listed on a national securities exchange or a national securities association and (2) on or after October 2, 2023, the effective date of the Listing Rules.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Independent Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a director who is determined by the Board to be &#8220;independent&#8221; for Board or Committee membership, as applicable, under the rules of the Exchange, as of any determination date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Listing Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 1 of this Policy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Incentive Compensation shall be deemed &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Received</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; in the Company&#8217;s fiscal period during which the Financial Reporting Measure specified in the Incentive Compensation award is attained, even if the payment or grant of the Incentive Compensation occurs after the end of that period.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Restatement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the Company&#8217;s previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Transition Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any transition period that results from a change in the Company&#8217;s Fiscal Year within or immediately following the three completed Fiscal Years immediately preceding the Company&#8217;s requirement to prepare a Restatement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Adopted on&#58; October 25, 2023</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>ci-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:fd466b51-e399-4368-bda1-c8c0817d4afc,g:199c158e-5fac-4def-904c-2de015f58c08-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ci="http://www.thecignagroup.com/20231231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.thecignagroup.com/20231231">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ci-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ci-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ci-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ci-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.thecignagroup.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.thecignagroup.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofIncome" roleURI="http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome">
        <link:definition>0000003 - Statement - Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>0000004 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.thecignagroup.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000005 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.thecignagroup.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000006 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinTotalEquity" roleURI="http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity">
        <link:definition>0000007 - Statement - Consolidated Statements of Changes in Total Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinTotalEquityParenthetical" roleURI="http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquityParenthetical">
        <link:definition>0000008 - Statement - Consolidated Statements of Changes in Total Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000009 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://www.thecignagroup.com/role/DescriptionofBusiness">
        <link:definition>0000010 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.thecignagroup.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000011 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivableNet" roleURI="http://www.thecignagroup.com/role/AccountsReceivableNet">
        <link:definition>0000012 - Disclosure - Accounts Receivable, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplierFinanceProgram" roleURI="http://www.thecignagroup.com/role/SupplierFinanceProgram">
        <link:definition>0000013 - Disclosure - Supplier Finance Program</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergersAcquisitionsandDivestitures" roleURI="http://www.thecignagroup.com/role/MergersAcquisitionsandDivestitures">
        <link:definition>0000014 - Disclosure - Mergers, Acquisitions and Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandLiabilitiesofBusinessesHeldforSale" roleURI="http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSale">
        <link:definition>0000015 - Disclosure - Assets and Liabilities of Businesses Held for Sale</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.thecignagroup.com/role/EarningsPerShare">
        <link:definition>0000016 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.thecignagroup.com/role/Debt">
        <link:definition>0000017 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonandPreferredStock" roleURI="http://www.thecignagroup.com/role/CommonandPreferredStock">
        <link:definition>0000018 - Disclosure - Common and Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InsuranceandContractholderLiabilities" roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilities">
        <link:definition>0000019 - Disclosure - Insurance and Contractholder Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Reinsurance" roleURI="http://www.thecignagroup.com/role/Reinsurance">
        <link:definition>0000020 - Disclosure - Reinsurance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.thecignagroup.com/role/Investments">
        <link:definition>0000021 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.thecignagroup.com/role/FairValueMeasurements">
        <link:definition>0000022 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntities" roleURI="http://www.thecignagroup.com/role/VariableInterestEntities">
        <link:definition>0000023 - Disclosure - Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollectivelySignificantOperatingUnconsolidatedSubsidiaries" roleURI="http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiaries">
        <link:definition>0000024 - Disclosure - Collectively Significant Operating Unconsolidated Subsidiaries</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLoss" roleURI="http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLoss">
        <link:definition>0000025 - Disclosure - Accumulated Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationalEfficiencyPlan" roleURI="http://www.thecignagroup.com/role/OrganizationalEfficiencyPlan">
        <link:definition>0000026 - Disclosure - Organizational Efficiency Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Pension" roleURI="http://www.thecignagroup.com/role/Pension">
        <link:definition>0000027 - Disclosure - Pension</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeIncentivePlans" roleURI="http://www.thecignagroup.com/role/EmployeeIncentivePlans">
        <link:definition>0000028 - Disclosure - Employee Incentive Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillOtherIntangiblesandPropertyandEquipment" roleURI="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipment">
        <link:definition>0000029 - Disclosure - Goodwill, Other Intangibles and Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.thecignagroup.com/role/Leases">
        <link:definition>0000030 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDividendRestrictions" roleURI="http://www.thecignagroup.com/role/ShareholdersEquityandDividendRestrictions">
        <link:definition>0000031 - Disclosure - Shareholders Equity and Dividend Restrictions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.thecignagroup.com/role/IncomeTaxes">
        <link:definition>0000032 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandOtherMatters" roleURI="http://www.thecignagroup.com/role/ContingenciesandOtherMatters">
        <link:definition>0000033 - Disclosure - Contingencies and Other Matters</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.thecignagroup.com/role/SegmentInformation">
        <link:definition>0000034 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleICondensedFinancialInformationofTheCignaGroup" roleURI="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroup">
        <link:definition>0000035 - Disclosure - Schedule I - Condensed Financial Information of The Cigna Group</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleIIValuationandQualifyingAccountsandReserves" roleURI="http://www.thecignagroup.com/role/ScheduleIIValuationandQualifyingAccountsandReserves">
        <link:definition>0000036 - Disclosure - Schedule II - Valuation and Qualifying Accounts and Reserves</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReceivablesLoansNotesReceivableandOthersPolicies" roleURI="http://www.thecignagroup.com/role/ReceivablesLoansNotesReceivableandOthersPolicies">
        <link:definition>9954472 - Disclosure - Receivables, Loans, Notes Receivable, and Others (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsDebtandEquitySecuritiesPolicies" roleURI="http://www.thecignagroup.com/role/InvestmentsDebtandEquitySecuritiesPolicies">
        <link:definition>9954473 - Disclosure - Investments, Debt and Equity Securities (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivableNetTables" roleURI="http://www.thecignagroup.com/role/AccountsReceivableNetTables">
        <link:definition>9954474 - Disclosure - Accounts Receivable, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandLiabilitiesofBusinessesHeldforSaleTables" roleURI="http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleTables">
        <link:definition>9954475 - Disclosure - Assets and Liabilities of Businesses Held for Sale (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.thecignagroup.com/role/EarningsPerShareTables">
        <link:definition>9954476 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.thecignagroup.com/role/DebtTables">
        <link:definition>9954477 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonandPreferredStockTables" roleURI="http://www.thecignagroup.com/role/CommonandPreferredStockTables">
        <link:definition>9954478 - Disclosure - Common and Preferred Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InsuranceandContractholderLiabilitiesTables" roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesTables">
        <link:definition>9954479 - Disclosure - Insurance and Contractholder Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReinsuranceTables" roleURI="http://www.thecignagroup.com/role/ReinsuranceTables">
        <link:definition>9954480 - Disclosure - Reinsurance (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.thecignagroup.com/role/InvestmentsTables">
        <link:definition>9954481 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsTables">
        <link:definition>9954482 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollectivelySignificantOperatingUnconsolidatedSubsidiariesTables" roleURI="http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiariesTables">
        <link:definition>9954483 - Disclosure - Collectively Significant Operating Unconsolidated Subsidiaries (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossTables">
        <link:definition>9954484 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationalEfficiencyPlanTables" roleURI="http://www.thecignagroup.com/role/OrganizationalEfficiencyPlanTables">
        <link:definition>9954485 - Disclosure - Organizational Efficiency Plan (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionTables" roleURI="http://www.thecignagroup.com/role/PensionTables">
        <link:definition>9954486 - Disclosure - Pension (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeIncentivePlansTables" roleURI="http://www.thecignagroup.com/role/EmployeeIncentivePlansTables">
        <link:definition>9954487 - Disclosure - Employee Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillOtherIntangiblesandPropertyandEquipmentTables" roleURI="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentTables">
        <link:definition>9954488 - Disclosure - Goodwill, Other Intangibles and Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.thecignagroup.com/role/LeasesTables">
        <link:definition>9954489 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDividendRestrictionsTables" roleURI="http://www.thecignagroup.com/role/ShareholdersEquityandDividendRestrictionsTables">
        <link:definition>9954490 - Disclosure - Shareholders Equity and Dividend Restrictions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.thecignagroup.com/role/IncomeTaxesTables">
        <link:definition>9954491 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.thecignagroup.com/role/SegmentInformationTables">
        <link:definition>9954492 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SECScheduleArticle1204CondensedFinancialInformationofRegistrantTables" roleURI="http://www.thecignagroup.com/role/SECScheduleArticle1204CondensedFinancialInformationofRegistrantTables">
        <link:definition>9954493 - Disclosure - SEC Schedule, Article 12-04, Condensed Financial Information of Registrant (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessDetails" roleURI="http://www.thecignagroup.com/role/DescriptionofBusinessDetails">
        <link:definition>9954494 - Disclosure - Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>9954495 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails" roleURI="http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails">
        <link:definition>9954496 - Disclosure - Accounts Receivable, Net - Amounts Included in Accounts Receivable, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails_1" roleURI="http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails_1">
        <link:definition>9954496 - Disclosure - Accounts Receivable, Net - Amounts Included in Accounts Receivable, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivableNetNarrativeDetails" roleURI="http://www.thecignagroup.com/role/AccountsReceivableNetNarrativeDetails">
        <link:definition>9954497 - Disclosure - Accounts Receivable, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplierFinanceProgramDetails" roleURI="http://www.thecignagroup.com/role/SupplierFinanceProgramDetails">
        <link:definition>9954498 - Disclosure - Supplier Finance Program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergersAcquisitionsandDivestituresNarrativeDetails" roleURI="http://www.thecignagroup.com/role/MergersAcquisitionsandDivestituresNarrativeDetails">
        <link:definition>9954499 - Disclosure - Mergers, Acquisitions and Divestitures - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandLiabilitiesofBusinessesHeldforSaleDetails" roleURI="http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails">
        <link:definition>9954500 - Disclosure - Assets and Liabilities of Businesses Held for Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails" roleURI="http://www.thecignagroup.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails">
        <link:definition>9954501 - Disclosure - Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareOutstandingEmployeeStockOptionsNotIncludedintheComputationofDilutedEarningsPerShareDetails" roleURI="http://www.thecignagroup.com/role/EarningsPerShareOutstandingEmployeeStockOptionsNotIncludedintheComputationofDilutedEarningsPerShareDetails">
        <link:definition>9954502 - Disclosure - Earnings Per Share - Outstanding Employee Stock Options Not Included in the Computation of Diluted Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareSharesofCommonStockHeldinTreasuryDetails" roleURI="http://www.thecignagroup.com/role/EarningsPerShareSharesofCommonStockHeldinTreasuryDetails">
        <link:definition>9954503 - Disclosure - Earnings Per Share - Shares of Common Stock Held in Treasury (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtOutstandingAmountsofDebtandFinanceLeasesDetails" roleURI="http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails">
        <link:definition>9954504 - Disclosure - Debt - Outstanding Amounts of Debt and Finance Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtShorttermandCreditFacilitiesDebtDetails" roleURI="http://www.thecignagroup.com/role/DebtShorttermandCreditFacilitiesDebtDetails">
        <link:definition>9954505 - Disclosure - Debt - Short-term and Credit Facilities Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtLongtermDebtDetails" roleURI="http://www.thecignagroup.com/role/DebtLongtermDebtDetails">
        <link:definition>9954506 - Disclosure - Debt - Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtDebtMaturitiesDetails" roleURI="http://www.thecignagroup.com/role/DebtDebtMaturitiesDetails">
        <link:definition>9954507 - Disclosure - Debt - Debt Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtInterestExpenseDetails" roleURI="http://www.thecignagroup.com/role/DebtInterestExpenseDetails">
        <link:definition>9954508 - Disclosure - Debt - Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonandPreferredStockShareActivityDetails" roleURI="http://www.thecignagroup.com/role/CommonandPreferredStockShareActivityDetails">
        <link:definition>9954509 - Disclosure - Common and Preferred Stock - Share Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonandPreferredStockDividendsDetails" roleURI="http://www.thecignagroup.com/role/CommonandPreferredStockDividendsDetails">
        <link:definition>9954510 - Disclosure - Common and Preferred Stock - Dividends (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonandPreferredStockAcceleratedShareRepurchaseAgreementsDetails" roleURI="http://www.thecignagroup.com/role/CommonandPreferredStockAcceleratedShareRepurchaseAgreementsDetails">
        <link:definition>9954511 - Disclosure - Common and Preferred Stock - Accelerated Share Repurchase Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InsuranceandContractholderLiabilitiesAccountBalancesDetails" roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails">
        <link:definition>9954512 - Disclosure - Insurance and Contractholder Liabilities - Account Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InsuranceandContractholderLiabilitiesAccountBalancesDetails_1" roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails_1">
        <link:definition>9954512 - Disclosure - Insurance and Contractholder Liabilities - Account Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InsuranceandContractholderLiabilitiesAccountBalancesDetails_2" roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails_2">
        <link:definition>9954512 - Disclosure - Insurance and Contractholder Liabilities - Account Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails" roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails">
        <link:definition>9954513 - Disclosure - Insurance and Contractholder Liabilities - Unpaid Claims and Claim Expenses - Cigna Healthcare - Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails" roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails">
        <link:definition>9954514 - Disclosure - Insurance and Contractholder Liabilities - Unpaid Claims and Claims Expenses - Cigna Healthcare - Variances in Incurred Costs Related to Prior Years' Unpaid Claims and Claims Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails" roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails">
        <link:definition>9954515 - Disclosure - Insurance and Contractholder Liabilities - Unpaid Claims and Claims Expenses - Cigna Healthcare - Incurred and Paid Claims Development and Unpaid Claims Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InsuranceandContractholderLiabilitiesFuturePolicyBenefitsInterestRatesandDurationDetails" roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsInterestRatesandDurationDetails">
        <link:definition>9954516 - Disclosure - Insurance and Contractholder Liabilities - Future Policy Benefits - Interest Rates and Duration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails" roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails">
        <link:definition>9954517 - Disclosure - Insurance and Contractholder Liabilities - Future Policy Benefits - Present Value of Expected Premiums and Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails" roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails">
        <link:definition>9954518 - Disclosure - Insurance and Contractholder Liabilities - Contractholder Deposit Funds (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InsuranceandContractholderLiabilitiesSummaryofMarketRiskBenefitDetails" roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesSummaryofMarketRiskBenefitDetails">
        <link:definition>9954519 - Disclosure - Insurance and Contractholder Liabilities - Summary of Market Risk Benefit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails" roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails">
        <link:definition>9954520 - Disclosure - Insurance and Contractholder Liabilities - Net Amount of Risk and Average Age of Contractholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReinsuranceReinsuranceRecoverablesDetails" roleURI="http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails">
        <link:definition>9954521 - Disclosure - Reinsurance - Reinsurance Recoverables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReinsuranceEffectsofReinsuranceDetails" roleURI="http://www.thecignagroup.com/role/ReinsuranceEffectsofReinsuranceDetails">
        <link:definition>9954522 - Disclosure - Reinsurance - Effects of Reinsurance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails" roleURI="http://www.thecignagroup.com/role/ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails">
        <link:definition>9954523 - Disclosure - Reinsurance - Effective Exit of Variable Annuity Reinsurance Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInvestmentsbyCategoryDetails" roleURI="http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails">
        <link:definition>9954524 - Disclosure - Investments - Investments by Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInvestmentsbyCategoryDetails_1" roleURI="http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails_1">
        <link:definition>9954524 - Disclosure - Investments - Investments by Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails" roleURI="http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails">
        <link:definition>9954525 - Disclosure - Investments - Debt Securities by Contractual Maturity Periods (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsNarrativeDetails" roleURI="http://www.thecignagroup.com/role/InvestmentsNarrativeDetails">
        <link:definition>9954526 - Disclosure - Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesDetails" roleURI="http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesDetails">
        <link:definition>9954527 - Disclosure - Investments - Gross Unrealized Appreciation (Depreciation) on Debt Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsDebtSecuritieswithaDeclineinFairValueDetails" roleURI="http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails">
        <link:definition>9954528 - Disclosure - Investments - Debt Securities with a Decline in Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsDebtSecuritieswithaDeclineinFairValueDetails_1" roleURI="http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails_1">
        <link:definition>9954528 - Disclosure - Investments - Debt Securities with a Decline in Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsEquitySecurityInvestmentsDetails" roleURI="http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails">
        <link:definition>9954529 - Disclosure - Investments - Equity Security Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsCommercialMortgageLoanPortfolioDetails" roleURI="http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoanPortfolioDetails">
        <link:definition>9954530 - Disclosure - Investments - Commercial Mortgage Loan Portfolio (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsOtherLongTermInvestmentsDetails" roleURI="http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails">
        <link:definition>9954531 - Disclosure - Investments - Other Long-Term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsSummaryofDerivativeInstrumentsDetails" roleURI="http://www.thecignagroup.com/role/InvestmentsSummaryofDerivativeInstrumentsDetails">
        <link:definition>9954532 - Disclosure - Investments - Summary of Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsComponentsofNetInvestmentIncomeDetails" roleURI="http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeDetails">
        <link:definition>9954533 - Disclosure - Investments - Components of Net Investment Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsRealizedGainsandLossesonInvestmentsDetails" roleURI="http://www.thecignagroup.com/role/InvestmentsRealizedGainsandLossesonInvestmentsDetails">
        <link:definition>9954534 - Disclosure - Investments - Realized Gains and Losses on Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsSalesInformationforAvailableforSaleDebtSecuritiesDetails" roleURI="http://www.thecignagroup.com/role/InvestmentsSalesInformationforAvailableforSaleDebtSecuritiesDetails">
        <link:definition>9954535 - Disclosure - Investments - Sales Information for Available-for-Sale Debt Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails" roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails">
        <link:definition>9954536 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>9954537 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails" roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails">
        <link:definition>9954538 - Disclosure - Fair Value Measurements - Quantitative Information About Unobservable Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails" roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails">
        <link:definition>9954539 - Disclosure - Fair Value Measurements - Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValuesofSeparateAccountAssetsDetails" roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsFairValuesofSeparateAccountAssetsDetails">
        <link:definition>9954540 - Disclosure - Fair Value Measurements - Fair Values of Separate Account Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAdditionalInformationonSeparateAccountAssetsPricedatNetAssetValueDetails" roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsAdditionalInformationonSeparateAccountAssetsPricedatNetAssetValueDetails">
        <link:definition>9954541 - Disclosure - Fair Value Measurements - Additional Information on Separate Account Assets Priced at Net Asset Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails" roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails">
        <link:definition>9954542 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value under Certain Conditions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails" roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails">
        <link:definition>9954543 - Disclosure - Fair Value Measurements - Fair Value Disclosures for Financial Instruments Not Carried at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesDetails" roleURI="http://www.thecignagroup.com/role/VariableInterestEntitiesDetails">
        <link:definition>9954544 - Disclosure - Variable Interest Entities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollectivelySignificantOperatingUnconsolidatedSubsidiariesDetails" roleURI="http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiariesDetails">
        <link:definition>9954545 - Disclosure - Collectively Significant Operating Unconsolidated Subsidiaries (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>9954546 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossDetails_1" roleURI="http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails_1">
        <link:definition>9954546 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationalEfficiencyPlanDetails" roleURI="http://www.thecignagroup.com/role/OrganizationalEfficiencyPlanDetails">
        <link:definition>9954547 - Disclosure - Organizational Efficiency Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionNarrativeDetails" roleURI="http://www.thecignagroup.com/role/PensionNarrativeDetails">
        <link:definition>9954548 - Disclosure - Pension - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionProjectedBenefitObligationsandAssetsDetails" roleURI="http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails">
        <link:definition>9954549 - Disclosure - Pension - Projected Benefit Obligations and Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionBenefitPaymentsDetails" roleURI="http://www.thecignagroup.com/role/PensionBenefitPaymentsDetails">
        <link:definition>9954550 - Disclosure - Pension - Benefit Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionAmountsIncludedinAccumulatedOtherComprehensiveIncomeDetails" roleURI="http://www.thecignagroup.com/role/PensionAmountsIncludedinAccumulatedOtherComprehensiveIncomeDetails">
        <link:definition>9954551 - Disclosure - Pension - Amounts Included in Accumulated Other Comprehensive Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionNetPensionCostDetails" roleURI="http://www.thecignagroup.com/role/PensionNetPensionCostDetails">
        <link:definition>9954552 - Disclosure - Pension - Net Pension Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionAssumptionsUsedforPensionDetails" roleURI="http://www.thecignagroup.com/role/PensionAssumptionsUsedforPensionDetails">
        <link:definition>9954553 - Disclosure - Pension - Assumptions Used for Pension (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionPensionPlanAssetsDetails" roleURI="http://www.thecignagroup.com/role/PensionPensionPlanAssetsDetails">
        <link:definition>9954554 - Disclosure - Pension - Pension Plan Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionAnnualExpensefor401kPlansDetails" roleURI="http://www.thecignagroup.com/role/PensionAnnualExpensefor401kPlansDetails">
        <link:definition>9954555 - Disclosure - Pension - Annual Expense for 401(k) Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeIncentivePlansSharesofCommonStockAvailableforAwardDetails" roleURI="http://www.thecignagroup.com/role/EmployeeIncentivePlansSharesofCommonStockAvailableforAwardDetails">
        <link:definition>9954556 - Disclosure - Employee Incentive Plans - Shares of Common Stock Available for Award (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeIncentivePlansNarrativeDetails" roleURI="http://www.thecignagroup.com/role/EmployeeIncentivePlansNarrativeDetails">
        <link:definition>9954557 - Disclosure - Employee Incentive Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeIncentivePlansBlackScholesOptionPricingModelAssumptionsDetails" roleURI="http://www.thecignagroup.com/role/EmployeeIncentivePlansBlackScholesOptionPricingModelAssumptionsDetails">
        <link:definition>9954558 - Disclosure - Employee Incentive Plans - Black-Scholes Option-Pricing Model Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeIncentivePlansStatusofandChangesinCommonStockOptionsDetails" roleURI="http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinCommonStockOptionsDetails">
        <link:definition>9954559 - Disclosure - Employee Incentive Plans - Status of and Changes in Common Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeIncentivePlansSummaryofInformationforStockOptionsExercisedDetails" roleURI="http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsExercisedDetails">
        <link:definition>9954560 - Disclosure - Employee Incentive Plans - Summary of Information for Stock Options Exercised (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeIncentivePlansSummaryofInformationforStockOptionsOutstandingDetails" roleURI="http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsOutstandingDetails">
        <link:definition>9954561 - Disclosure - Employee Incentive Plans - Summary of Information for Stock Options Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeIncentivePlansStatusofandChangesinRestrictedStockAwardsandSPSsDetails" roleURI="http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinRestrictedStockAwardsandSPSsDetails">
        <link:definition>9954562 - Disclosure - Employee Incentive Plans - Status of and Changes in Restricted Stock Awards and SPSs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeIncentivePlansFairValueofVestedRestrictedStockandSPSsDetails" roleURI="http://www.thecignagroup.com/role/EmployeeIncentivePlansFairValueofVestedRestrictedStockandSPSsDetails">
        <link:definition>9954563 - Disclosure - Employee Incentive Plans - Fair Value of Vested Restricted Stock and SPSs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeIncentivePlansCompensationCostandTaxEffectsofSharebasedCompensationDetails" roleURI="http://www.thecignagroup.com/role/EmployeeIncentivePlansCompensationCostandTaxEffectsofSharebasedCompensationDetails">
        <link:definition>9954564 - Disclosure - Employee Incentive Plans - Compensation Cost and Tax Effects of Share-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillOtherIntangiblesandPropertyandEquipmentNarrativeDetails" roleURI="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentNarrativeDetails">
        <link:definition>9954565 - Disclosure - Goodwill, Other Intangibles and Property and Equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillOtherIntangiblesandPropertyandEquipmentGoodwillActivityDetails" roleURI="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentGoodwillActivityDetails">
        <link:definition>9954566 - Disclosure - Goodwill, Other Intangibles, and Property and Equipment - Goodwill Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails" roleURI="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails">
        <link:definition>9954567 - Disclosure - Goodwill, Other Intangibles, and Property and Equipment - Other Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails_1" roleURI="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails_1">
        <link:definition>9954567 - Disclosure - Goodwill, Other Intangibles, and Property and Equipment - Other Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails" roleURI="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails">
        <link:definition>9954568 - Disclosure - Goodwill, Other Intangibles, and Property and Equipment - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails_1" roleURI="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails_1">
        <link:definition>9954568 - Disclosure - Goodwill, Other Intangibles, and Property and Equipment - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillOtherIntangiblesandPropertyandEquipmentComponentsofDepreciationandAmortizationExpenseDetails" roleURI="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentComponentsofDepreciationandAmortizationExpenseDetails">
        <link:definition>9954569 - Disclosure - Goodwill, Other Intangibles, and Property and Equipment - Components of Depreciation and Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillOtherIntangiblesandPropertyandEquipmentEstimatedAnnualPreTaxAmortizationforIntangibleAssetsDetails" roleURI="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentEstimatedAnnualPreTaxAmortizationforIntangibleAssetsDetails">
        <link:definition>9954570 - Disclosure - Goodwill, Other Intangibles, and Property and Equipment - Estimated Annual Pre-Tax Amortization for Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.thecignagroup.com/role/LeasesNarrativeDetails">
        <link:definition>9954571 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseExpenseDetails" roleURI="http://www.thecignagroup.com/role/LeasesComponentsofLeaseExpenseDetails">
        <link:definition>9954572 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalCashFlowInformationRelatedtoLeasesDetails" roleURI="http://www.thecignagroup.com/role/LeasesSupplementalCashFlowInformationRelatedtoLeasesDetails">
        <link:definition>9954573 - Disclosure - Leases - Supplemental Cash Flow Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails" roleURI="http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails">
        <link:definition>9954574 - Disclosure - Leases - Operating and Finance Lease Right of Use ("ROU") Assets and Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofLeaseLiabilitiesDetails" roleURI="http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails">
        <link:definition>9954575 - Disclosure - Leases - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofLeaseLiabilitiesDetails_1" roleURI="http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1">
        <link:definition>9954575 - Disclosure - Leases - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDividendRestrictionsDetails" roleURI="http://www.thecignagroup.com/role/ShareholdersEquityandDividendRestrictionsDetails">
        <link:definition>9954576 - Disclosure - Shareholders Equity and Dividend Restrictions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofIncomeTaxesDetails" roleURI="http://www.thecignagroup.com/role/IncomeTaxesComponentsofIncomeTaxesDetails">
        <link:definition>9954577 - Disclosure - Income Taxes - Components of Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNominalTaxRateReconciliationDetails" roleURI="http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails">
        <link:definition>9954578 - Disclosure - Income Taxes - Nominal Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesPretaxIncomeFromForeignOperationsDetails" roleURI="http://www.thecignagroup.com/role/IncomeTaxesPretaxIncomeFromForeignOperationsDetails">
        <link:definition>9954579 - Disclosure - Income Taxes - Pre-tax Income From Foreign Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesForeignJurisdictionTaxAttributesandSaleofMedicareAdvantageandRelatedBusinessesDetails" roleURI="http://www.thecignagroup.com/role/IncomeTaxesForeignJurisdictionTaxAttributesandSaleofMedicareAdvantageandRelatedBusinessesDetails">
        <link:definition>9954580 - Disclosure - Income Taxes - Foreign Jurisdiction Tax Attributes and Sale of Medicare Advantage and Related Businesses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredIncomeTaxesDetails" roleURI="http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails">
        <link:definition>9954581 - Disclosure - Income Taxes - Deferred Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredIncomeTaxesDetails_1" roleURI="http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails_1">
        <link:definition>9954581 - Disclosure - Income Taxes - Deferred Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesUncertainTaxPositionsDetails" roleURI="http://www.thecignagroup.com/role/IncomeTaxesUncertainTaxPositionsDetails">
        <link:definition>9954582 - Disclosure - Income Taxes - Uncertain Tax Positions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandOtherMattersDetails" roleURI="http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails">
        <link:definition>9954583 - Disclosure - Contingencies and Other Matters (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationSummaryofSpecialItemsDetails" roleURI="http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails">
        <link:definition>9954584 - Disclosure - Segment Information - Summary of Special Items (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationSummarizedSegmentFinancialInformationDetails" roleURI="http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails">
        <link:definition>9954585 - Disclosure - Segment Information - Summarized Segment Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationRevenuefromExternalCustomersDetails" roleURI="http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails">
        <link:definition>9954586 - Disclosure - Segment Information - Revenue from External Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationFinancialandPerformanceGuaranteesDetails" roleURI="http://www.thecignagroup.com/role/SegmentInformationFinancialandPerformanceGuaranteesDetails">
        <link:definition>9954587 - Disclosure - Segment Information - Financial and Performance Guarantees (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationUSandForeignRevenuesfromExternalCustomersDetails" roleURI="http://www.thecignagroup.com/role/SegmentInformationUSandForeignRevenuesfromExternalCustomersDetails">
        <link:definition>9954588 - Disclosure - Segment Information - U.S. and Foreign Revenues from External Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationRevenuesfromUSFederalGovernmentAgenciesDetails" roleURI="http://www.thecignagroup.com/role/SegmentInformationRevenuesfromUSFederalGovernmentAgenciesDetails">
        <link:definition>9954589 - Disclosure - Segment Information - Revenues from U.S. Federal Government Agencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails" roleURI="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails">
        <link:definition>9954590 - Disclosure - Schedule I - Condensed Financial Information of The Cigna Group - Statements of Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails" roleURI="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails">
        <link:definition>9954591 - Disclosure - Schedule I - Condensed Financial Information of The Cigna Group - Balance Sheets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails" roleURI="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails">
        <link:definition>9954592 - Disclosure - Schedule I - Condensed Financial Information of The Cigna Group - Statements of Cash Flows (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails" roleURI="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails">
        <link:definition>9954593 - Disclosure - Schedule I - Condensed Financial Information of The Cigna Group - Short-term and Credit Facilities Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails" roleURI="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails">
        <link:definition>9954594 - Disclosure - Schedule I - Condensed Financial Information of The Cigna Group - Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleICondensedFinancialInformationofTheCignaGroupDebtMaturitiesDetails" roleURI="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupDebtMaturitiesDetails">
        <link:definition>9954595 - Disclosure - Schedule I - Condensed Financial Information of The Cigna Group - Debt Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleICondensedFinancialInformationofTheCignaGroupIntercompanyBalancesDetails" roleURI="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupIntercompanyBalancesDetails">
        <link:definition>9954596 - Disclosure - Schedule I - Condensed Financial Information of The Cigna Group - Intercompany Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleICondensedFinancialInformationofTheCignaGroupGuaranteesDetails" roleURI="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupGuaranteesDetails">
        <link:definition>9954597 - Disclosure - Schedule I - Condensed Financial Information of The Cigna Group - Guarantees (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleICondensedFinancialInformationofTheCignaGroupShareRepurchaseDetails" roleURI="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShareRepurchaseDetails">
        <link:definition>9954598 - Disclosure - Schedule I - Condensed Financial Information of The Cigna Group - Share Repurchase (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleIIValuationandQualifyingAccountsandReservesDetails" roleURI="http://www.thecignagroup.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails">
        <link:definition>9954599 - Disclosure - Schedule II - Valuation and Qualifying Accounts and Reserves (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_LiabilityForFuturePolicyBenefitsIncludingDisposalGroups" abstract="false" name="LiabilityForFuturePolicyBenefitsIncludingDisposalGroups" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_RevenuesIncludingNetInvestmentIncomeBenchmarkMember" abstract="true" name="RevenuesIncludingNetInvestmentIncomeBenchmarkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_DefinedBenefitPlanAssumptionsUsedInCalculationsExpectedLongTermReturnOnPlanAssetsAbstract" abstract="true" name="DefinedBenefitPlanAssumptionsUsedInCalculationsExpectedLongTermReturnOnPlanAssetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost" abstract="false" name="DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_NotesDue202645InterestMember" abstract="true" name="NotesDue202645InterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_EmployerInsuredMember" abstract="true" name="EmployerInsuredMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_CompletionFactorsMember" abstract="true" name="CompletionFactorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_PharmacyBenefitsManagementServicesMember" abstract="true" name="PharmacyBenefitsManagementServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_DisposalGroupIncludingDiscontinuedOperationsNonInvestmentRevenue" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationsNonInvestmentRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale" abstract="false" name="DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_AccumulatedDefinedBenefitPlansAdjustmentSettlementMember" abstract="true" name="AccumulatedDefinedBenefitPlansAdjustmentSettlementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings" abstract="false" name="IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember" abstract="true" name="CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_USGroupDisabilityAndLifeInsuranceBusinessMember" abstract="true" name="USGroupDisabilityAndLifeInsuranceBusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_InsuranceCustomerReceivables" abstract="false" name="InsuranceCustomerReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrentIncludingDisposalGroups" abstract="false" name="LiabilityForClaimsAndClaimsAdjustmentExpenseCurrentIncludingDisposalGroups" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_InternationalHealthMember" abstract="true" name="InternationalHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_AccruedExpensesAndOtherLiabilities" abstract="false" name="AccruedExpensesAndOtherLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract" abstract="true" name="DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_LongTermDebtFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="LongTermDebtFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax" abstract="false" name="IncomeLossAttributableToNoncontrollingInterestBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_AccountsReceivableUncommittedFactoringFacilityAmountSold" abstract="false" name="AccountsReceivableUncommittedFactoringFacilityAmountSold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_LtvGreaterThan100PercentMember" abstract="true" name="LtvGreaterThan100PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVoba" abstract="false" name="FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVoba" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DefinedBenefitPlanBenefitsPaidFromPlanAssets" abstract="false" name="DefinedBenefitPlanBenefitsPaidFromPlanAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate" abstract="false" name="DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTransactionIncludingDisposalGroupsAssetsHeldForSale" abstract="false" name="DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTransactionIncludingDisposalGroupsAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DebtAndEquitySecuritiesClassifiedInLevel3PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="DebtAndEquitySecuritiesClassifiedInLevel3PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ci_ShortdurationInsuranceContractsNumberOfPaidClaims" abstract="false" name="ShortdurationInsuranceContractsNumberOfPaidClaims" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ci_AlternativeInvestmentBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="AlternativeInvestmentBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" abstract="false" name="SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DerivativeLiabilitiesBeforeReclassificationToDisposalGroupLiabilitiesHeldForSale" abstract="false" name="DerivativeLiabilitiesBeforeReclassificationToDisposalGroupLiabilitiesHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_StopLossMember" abstract="true" name="StopLossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_ForwardsSwapsOptionsMember" abstract="true" name="ForwardsSwapsOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_AnthemMember" abstract="true" name="AnthemMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract" abstract="true" name="EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_A364DayRevolvingCreditAgreementMaturingApril2024Member" abstract="true" name="A364DayRevolvingCreditAgreementMaturingApril2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionReferenceTermOfTradedOptions" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionReferenceTermOfTradedOptions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ci_NotesDue2022305InterestMember" abstract="true" name="NotesDue2022305InterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity" abstract="false" name="OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_OperatingLeaseLiabilityCurrentIncludingDisposalGroupsAssetsHeldForSale" abstract="false" name="OperatingLeaseLiabilityCurrentIncludingDisposalGroupsAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DisposalGroupsIncludingDiscontinuedOperationsAmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries" abstract="false" name="DisposalGroupsIncludingDiscontinuedOperationsAmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_EquitySecuritiesFvNiBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="EquitySecuritiesFvNiBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_LiabilityForFuturePolicyBenefitsCurrentIncludingDisposalGroups" abstract="false" name="LiabilityForFuturePolicyBenefitsCurrentIncludingDisposalGroups" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_EquitySecuritiesFVNIMember" abstract="true" name="EquitySecuritiesFVNIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaAndOtherRecoverablesMember" abstract="true" name="BerkshireHathwayLifeInsuranceCompanyOfNebraskaAndOtherRecoverablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_HealthcareMember" abstract="true" name="HealthcareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_AccumulatedDefinedBenefitPlansAdjustmentGainLossOnSaleOfBusinessMember" abstract="true" name="AccumulatedDefinedBenefitPlansAdjustmentGainLossOnSaleOfBusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_AssetBackedAndCorporateSecuritiesMember" abstract="true" name="AssetBackedAndCorporateSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability" abstract="false" name="LiabilityForFuturePolicyBenefitsDeferredProfitLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_NetworkPharmacyMember" abstract="true" name="NetworkPharmacyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups" abstract="false" name="InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_ProceedsFromRepaymentsOfOtherShortTermDebt" abstract="false" name="ProceedsFromRepaymentsOfOtherShortTermDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_CommitmentsToContributeAdditionalEquityAndCapital" abstract="false" name="CommitmentsToContributeAdditionalEquityAndCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member" abstract="true" name="RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_DefinedBenefitPlanGainLossDueToLitigation" abstract="false" name="DefinedBenefitPlanGainLossDueToLitigation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups" abstract="false" name="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_FinanceLeaseLeaseCostAbstract" abstract="true" name="FinanceLeaseLeaseCostAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees" abstract="false" name="ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DisposalGroupIncludingDiscontinuedOperationInvestments" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities" abstract="false" name="IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_StatutoryAccountingPracticesAmountPermittedLendingAuthorityOfLifeInsuranceSubsidiaryToParent" abstract="false" name="StatutoryAccountingPracticesAmountPermittedLendingAuthorityOfLifeInsuranceSubsidiaryToParent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_MedicareAdvantageMember" abstract="true" name="MedicareAdvantageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_InsuranceAndContractholderLiabilitiesAbstract" abstract="true" name="InsuranceAndContractholderLiabilitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_CignaHealthcareMember" abstract="true" name="CignaHealthcareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DeferredTaxAssetsGrossInOtherAssetsNoncurrent" abstract="false" name="DeferredTaxAssetsGrossInOtherAssetsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_NotesDue20254125InterestMember" abstract="true" name="NotesDue20254125InterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_NumberOfRevolvingCreditFacility" abstract="false" name="NumberOfRevolvingCreditFacility" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ci_OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity" abstract="false" name="OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_ContractualAllowanceNoninsuranceCustomerReceivables" abstract="false" name="ContractualAllowanceNoninsuranceCustomerReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_OtherOperationsSegmentOtherMember" abstract="true" name="OtherOperationsSegmentOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember" abstract="true" name="AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember" abstract="true" name="MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_PaymentsToAcquireDebtAndEquitySecurities" abstract="false" name="PaymentsToAcquireDebtAndEquitySecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember" abstract="true" name="AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_ReinsuranceRecoverablesNonCurrent" abstract="false" name="ReinsuranceRecoverablesNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_NotesDue20416125InterestMember" abstract="true" name="NotesDue20416125InterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_IntercompanyInterestIncome" abstract="false" name="IntercompanyInterestIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_ThreeWhollyOwnedSubsidiariesMember" abstract="true" name="ThreeWhollyOwnedSubsidiariesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_VillageMDMember" abstract="true" name="VillageMDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract" abstract="true" name="DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups" abstract="false" name="LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_ServiceFeesMember" abstract="true" name="ServiceFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_LossOfParentCompany" abstract="false" name="LossOfParentCompany" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_AnnuitizationElectionPeriod" abstract="false" name="AnnuitizationElectionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ci_FinanceLeaseCost" abstract="false" name="FinanceLeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DueFromAffiliateNoncurrentNet" abstract="false" name="DueFromAffiliateNoncurrentNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DepreciationAndAmortizationByTypeLineItems" abstract="true" name="DepreciationAndAmortizationByTypeLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant" abstract="false" name="LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ci_DeferredTaxAssetsForeignTaxAttributesIncludingDisposalGroupsAssetsHeldForSale" abstract="false" name="DeferredTaxAssetsForeignTaxAttributesIncludingDisposalGroupsAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_GuaranteedSeparateAccountAssets" abstract="false" name="GuaranteedSeparateAccountAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_ShortDurationContractsMember" abstract="true" name="ShortDurationContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_InsuranceAndContractholderLiabilitiesNoncurrent" abstract="false" name="InsuranceAndContractholderLiabilitiesNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember" abstract="true" name="InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated" abstract="false" name="NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract" abstract="true" name="GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_CommitmentsAndContingenciesNumberOfExpert" abstract="false" name="CommitmentsAndContingenciesNumberOfExpert" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesGainLossOnSaleOfBusinessParentMember" abstract="true" name="AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesGainLossOnSaleOfBusinessParentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax" abstract="false" name="SpecialItemChargesDebtExtinguishmentCostsNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLiquidatingInvestmentPeriodFromInceptionSecuritiesPartnerships" abstract="false" name="FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLiquidatingInvestmentPeriodFromInceptionSecuritiesPartnerships" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups" abstract="false" name="LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_LongDurationContractsMember" abstract="true" name="LongDurationContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_SpecialItemChargeBenefitTaxMatters" abstract="false" name="SpecialItemChargeBenefitTaxMatters" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_EffectiveIncomeTaxRateReconciliationHealthInsuranceIndustryTax" abstract="false" name="EffectiveIncomeTaxRateReconciliationHealthInsuranceIndustryTax" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ci_EvernorthHealthIncorporatedMember" abstract="true" name="EvernorthHealthIncorporatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_RightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract" abstract="true" name="RightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_NotesDue204032InterestMember" abstract="true" name="NotesDue204032InterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateFairValueIncludingMonteCarloFactor" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateFairValueIncludingMonteCarloFactor" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ci_SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity" abstract="false" name="SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilitiesIncludingDisposalGroupsAssetsHeldForSale" abstract="false" name="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilitiesIncludingDisposalGroupsAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember" abstract="true" name="SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity" abstract="false" name="OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_NotesDue2023765InterestMember" abstract="true" name="NotesDue2023765InterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent" abstract="false" name="LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DeferredTaxAssetsPolicyAcquisitionExpenses" abstract="false" name="DeferredTaxAssetsPolicyAcquisitionExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_ScheduleOfDepreciationAndAmortizationTable" abstract="true" name="ScheduleOfDepreciationAndAmortizationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax" abstract="false" name="SpecialItemGainLossOnSaleOfBusinessNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_UnobservableInputsDevelopedByCompanyMember" abstract="true" name="UnobservableInputsDevelopedByCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale" abstract="false" name="FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_ScheduleOfIssuancesOfLongTermDebtTableTextBlock" abstract="false" name="ScheduleOfIssuancesOfLongTermDebtTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ci_OtherShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="OtherShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_MedicalCostTrendMember" abstract="true" name="MedicalCostTrendMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent" abstract="false" name="OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_SunLifeAssuranceCompanyOfCanadaMember" abstract="true" name="SunLifeAssuranceCompanyOfCanadaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock" abstract="false" name="ScheduleOfOtherLongTermInvestmentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ci_IntangibleAssetsGrossExcludingGoodwillIncludingVoba" abstract="false" name="IntangibleAssetsGrossExcludingGoodwillIncludingVoba" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_FundInvestmentsAndPooledSeparateAccountsMember" abstract="true" name="FundInvestmentsAndPooledSeparateAccountsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_NoncontrollingInterestOtherChanges" abstract="false" name="NoncontrollingInterestOtherChanges" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DisposalGroupIncludingDiscontinuedOperationValueOfBusinessAcquired" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationValueOfBusinessAcquired" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_InsuranceAndContractholderLiabilities" abstract="false" name="InsuranceAndContractholderLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_SpecialItemGainLossFromContractAdjustmentBeforeTaxes" abstract="false" name="SpecialItemGainLossFromContractAdjustmentBeforeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_OtherIntangibleAssetsAbstract" abstract="true" name="OtherIntangibleAssetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups" abstract="false" name="LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseLongDurationNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseLongDurationNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_GoodwillTransfersToAssetsOfBusinessesHeldForSale" abstract="false" name="GoodwillTransfersToAssetsOfBusinessesHeldForSale" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups" abstract="false" name="IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange" abstract="false" name="MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract" abstract="true" name="DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost" abstract="false" name="EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups" abstract="false" name="PropertyPlantAndEquipmentNetIncludingDisposalGroups" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIncludingDisposalGroupsAssetsHeldForSale" abstract="false" name="DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIncludingDisposalGroupsAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DebtInstrumentExtensionTerm" abstract="false" name="DebtInstrumentExtensionTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember" abstract="true" name="InternationalLifeAccidentSupplementalBenefitsBusinessesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_OtherVariableInterestEntitiesMember" abstract="true" name="OtherVariableInterestEntitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent" abstract="false" name="LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_VariableInterestEntitiesNumberOfEntities" abstract="false" name="VariableInterestEntitiesNumberOfEntities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ci_NotesDue2023375InterestMember" abstract="true" name="NotesDue2023375InterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_PolicyholderContractDepositNoncurrentIncludingDisposalGroups" abstract="false" name="PolicyholderContractDepositNoncurrentIncludingDisposalGroups" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_CommitmentToFundPartnershipMember" abstract="true" name="CommitmentToFundPartnershipMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_AssetsAndLiabilitiesLesseeOperatingLeasesAbstract" abstract="true" name="AssetsAndLiabilitiesLesseeOperatingLeasesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_SeparateAccountAssetsClassifiedInFairValueHierarchy" abstract="false" name="SeparateAccountAssetsClassifiedInFairValueHierarchy" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_RestructuringChargesNetOfTaxExpense" abstract="false" name="RestructuringChargesNetOfTaxExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_FairValueOfSeparateAccountAssetsTableTextBlock" abstract="false" name="FairValueOfSeparateAccountAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ci_FiniteLivedIntangibleAssetsNetVoba" abstract="false" name="FiniteLivedIntangibleAssetsNetVoba" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_SpecialItemsBeforeTaxAbstract" abstract="true" name="SpecialItemsBeforeTaxAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage" abstract="false" name="PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_HomeDeliveryAndSpecialtyMember" abstract="true" name="HomeDeliveryAndSpecialtyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumIssuanceAndDerecognition" abstract="false" name="LiabilityForFuturePolicyBenefitExpectedNetPremiumIssuanceAndDerecognition" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock" abstract="false" name="AccumulatedOtherComprehensiveIncomeDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis" abstract="true" name="CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ci_SeparateAccountAssetsMember" abstract="true" name="SeparateAccountAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_ScheduleOfCommonStockByClassScheduleOfPreferredStockByClassTextBlock" abstract="false" name="ScheduleOfCommonStockByClassScheduleOfPreferredStockByClassTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses" abstract="false" name="LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain" abstract="true" name="CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_OtherAssetsCurrentAndNoncurrentPolicyPolicyTextBlock" abstract="false" name="OtherAssetsCurrentAndNoncurrentPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember" abstract="true" name="CededCreditRiskSecuredContractuallyRequiredFairValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_OperatingJointVenturesMember" abstract="true" name="OperatingJointVenturesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_AccountsReceivableUncommittedFactoringFacilityAutomaticRenewalTerm" abstract="false" name="AccountsReceivableUncommittedFactoringFacilityAutomaticRenewalTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ci_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilities" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_MortgageLoansOnRealEstateCommercialAndConsumerNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="MortgageLoansOnRealEstateCommercialAndConsumerNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy" abstract="false" name="NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_IncreaseDecreaseInAmountsDueFromAffiliates" abstract="false" name="IncreaseDecreaseInAmountsDueFromAffiliates" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems" abstract="true" name="ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_GuaranteeObligationsPayments" abstract="false" name="GuaranteeObligationsPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_ContractualAllowancePharmaceuticalManufacturersReceivables" abstract="false" name="ContractualAllowancePharmaceuticalManufacturersReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience" abstract="false" name="LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_AssetsAndLiabilitiesLesseeFinanceLeasesAbstract" abstract="true" name="AssetsAndLiabilitiesLesseeFinanceLeasesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_LitigationMattersAndRegulatoryMattersMember" abstract="true" name="LitigationMattersAndRegulatoryMattersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_InvestmentIncomeAndGainsAndLossesAbstract" abstract="true" name="InvestmentIncomeAndGainsAndLossesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale" abstract="false" name="DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_RestrictedStockGrantsAndUnitsMember" abstract="true" name="RestrictedStockGrantsAndUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_ReinsuranceRecoverableAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="ReinsuranceRecoverableAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOtherIncludingDisposalGroupsAssetsHeldForSale" abstract="false" name="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOtherIncludingDisposalGroupsAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_LtvLessThan60PercentMember" abstract="true" name="LtvLessThan60PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_RevolvingCreditAgreementsApril2023Member" abstract="true" name="RevolvingCreditAgreementsApril2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_EquitySecuritiesFvNiCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="EquitySecuritiesFvNiCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_OtherOperationsSegmentMember" abstract="true" name="OtherOperationsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount" abstract="false" name="EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_MaximumPercentLevel2InvestmentsForeignBondsBrokerQuoteBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="MaximumPercentLevel2InvestmentsForeignBondsBrokerQuoteBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ci_RedeemableNoncontrollingInterestsPolicyPolicyTextBlock" abstract="false" name="RedeemableNoncontrollingInterestsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ci_NotesDue202734InterestMember" abstract="true" name="NotesDue202734InterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_IntercompanyReceivablesInterestRate" abstract="false" name="IntercompanyReceivablesInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember" abstract="true" name="AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_DefinedBenefitPlanAssumptionsUsedInCalculationsDiscountRateAbstract" abstract="true" name="DefinedBenefitPlanAssumptionsUsedInCalculationsDiscountRateAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings" abstract="false" name="EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ci_SegmentRevenues" abstract="false" name="SegmentRevenues" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_DisposalGroupIncludingDiscontinuedOperationAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_LibertyMutualInsuranceMember" abstract="true" name="LibertyMutualInsuranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_FinancingReceivableCreditQualityLoanToValueRatio" abstract="false" name="FinancingReceivableCreditQualityLoanToValueRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances" abstract="false" name="MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity" abstract="false" name="OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_CommitmentToPurchaseEquitySecuritiesMember" abstract="true" name="CommitmentToPurchaseEquitySecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="LiabilityForFuturePolicyBenefitBeforeReinsuranceBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ci_AllowanceForReceivablesCurrent" abstract="false" name="AllowanceForReceivablesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_ContractholderDepositFundsPolicyPolicyTextBlock" abstract="false" name="ContractholderDepositFundsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ci_ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity" abstract="false" name="OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_LiabilityForFuturePolicyBenefitsCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience" abstract="false" name="LiabilityForFuturePolicyBenefitsCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_NotesDue20312375InterestMember" abstract="true" name="NotesDue20312375InterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGainsIncludingDisposalGroupsAssetsHeldForSale" abstract="false" name="DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGainsIncludingDisposalGroupsAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGains" abstract="false" name="DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGains" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold" abstract="false" name="SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_VariableInterestEntitiesAbstract" abstract="true" name="VariableInterestEntitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitInterestExpenseAndOtherChanges" abstract="false" name="LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitInterestExpenseAndOtherChanges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_UnearnedPremiumsNoncurrent" abstract="false" name="UnearnedPremiumsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_InterestInJointVentureInTurkeyMember" abstract="true" name="InterestInJointVentureInTurkeyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups" abstract="false" name="InsuranceAndContractholderLiabilitiesIncludingDisposalGroups" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DeferredTaxLiabilitiesNetIncludingDisposalGroup" abstract="false" name="DeferredTaxLiabilitiesNetIncludingDisposalGroup" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ci_RealizedInvestmentGainLossExcludingImpairments" abstract="false" name="RealizedInvestmentGainLossExcludingImpairments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DisposalGroupsIncludingDiscontinuedOperationsAssetsHeldByInsuranceRegulators" abstract="false" name="DisposalGroupsIncludingDiscontinuedOperationsAssetsHeldByInsuranceRegulators" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_LiabilityForFuturePolicyBenefitsPercentSupportedByAssetsHeldInTrust" abstract="false" name="LiabilityForFuturePolicyBenefitsPercentSupportedByAssetsHeldInTrust" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ci_PolicyholderContractBalancePercentReinsuredExternally" abstract="false" name="PolicyholderContractBalancePercentReinsuredExternally" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ci_SCORSEMember" abstract="true" name="SCORSEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract" abstract="true" name="DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitIssuanceAndDerecognition" abstract="false" name="LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitIssuanceAndDerecognition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff" abstract="false" name="MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_CorporateAndEliminationsMember" abstract="true" name="CorporateAndEliminationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_SpecialItemChargeBenefitTaxMattersAfterTax" abstract="false" name="SpecialItemChargeBenefitTaxMattersAfterTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_PaymentsForProceedsFromPropertyPlantAndEquipment" abstract="false" name="PaymentsForProceedsFromPropertyPlantAndEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience" abstract="false" name="LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_SpecialItemsAfterTaxAbstract" abstract="true" name="SpecialItemsAfterTaxAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_NotesDue204648InterestMember" abstract="true" name="NotesDue204648InterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_InsuranceAndContractholderLiabilitiesCurrent" abstract="false" name="InsuranceAndContractholderLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale" abstract="false" name="IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_ComponentsOfDepreciationAndAmortizationTableTextBlock" abstract="false" name="ComponentsOfDepreciationAndAmortizationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ci_NotesDue2027305Member" abstract="true" name="NotesDue2027305Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVOBAIncludingDisposalGroups" abstract="false" name="FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVOBAIncludingDisposalGroups" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity" abstract="false" name="LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DeferredTaxAssetsPolicyAcquisitionExpensesIncludingDisposalGroupsAssetsHeldForSale" abstract="false" name="DeferredTaxAssetsPolicyAcquisitionExpensesIncludingDisposalGroupsAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DisposalGroupIncludingDiscontinuedOperationCurrentInsuranceAndContractholderLiabilities" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationCurrentInsuranceAndContractholderLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups" abstract="false" name="ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureTwelveMonthsOrLongerNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureTwelveMonthsOrLongerNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ci_BalanceSheetAbstract" abstract="true" name="BalanceSheetAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract" abstract="true" name="InsuranceAndContractholderLiabilitiesNoncurrentAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_OtherOperationsInternationalBusinessesToBeSoldMember" abstract="true" name="OtherOperationsInternationalBusinessesToBeSoldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_IntangibleAssetsValueOfBusinessAcquiredAbstract" abstract="true" name="IntangibleAssetsValueOfBusinessAcquiredAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_MeasurementInputLiquidityMember" abstract="true" name="MeasurementInputLiquidityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_CashFlowActivitiesLesseeTableTextBlock" abstract="false" name="CashFlowActivitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ci_InsuranceAndContractholderLiabilitiesTable" abstract="true" name="InsuranceAndContractholderLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ci_TransactionRelatedCosts" abstract="false" name="TransactionRelatedCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_RealizedInvestmentLossesCommercialMortgageLoansRealEstateEntitiesCertainEquitySecuritiesWithNoReadilyDeterminableFairValue" abstract="false" name="RealizedInvestmentLossesCommercialMortgageLoansRealEstateEntitiesCertainEquitySecuritiesWithNoReadilyDeterminableFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ci_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilitiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="DerivativeCreditRiskValuationAdjustmentDerivativeLiabilitiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_PharmaceuticalManufacturerReceivable" abstract="false" name="PharmaceuticalManufacturerReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_MarketRiskBenefitLiabilityAmountNoncurrent" abstract="false" name="MarketRiskBenefitLiabilityAmountNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax" abstract="false" name="DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_AccountsReceivableUncommittedFactoringFacilityAccountsReceivableReceivedButNotRemitted" abstract="false" name="AccountsReceivableUncommittedFactoringFacilityAccountsReceivableReceivedButNotRemitted" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_FiniteLivedIntangibleAssetsNetVOBAIncludingDisposalGroupsAssetsHeldForSale" abstract="false" name="FiniteLivedIntangibleAssetsNetVOBAIncludingDisposalGroupsAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_SingleForeignCountryMember" abstract="true" name="SingleForeignCountryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale" abstract="false" name="DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentDisclosureTextBlock" abstract="false" name="GoodwillOtherIntangiblesAndPropertyAndEquipmentDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInFundsOfferedByUnaffiliatedEntity" abstract="false" name="DefinedBenefitPlanFairValueOfPlanAssetsInvestedInFundsOfferedByUnaffiliatedEntity" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DeferredTaxAssetsForeignTaxAttributes" abstract="false" name="DeferredTaxAssetsForeignTaxAttributes" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_LiabilityForFuturePolicyBenefitOther" abstract="false" name="LiabilityForFuturePolicyBenefitOther" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_CashFlowActivitiesLesseeAbstract" abstract="true" name="CashFlowActivitiesLesseeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_EarningsPerShareEffectOfDilution" abstract="false" name="EarningsPerShareEffectOfDilution" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="ci_FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfEmployeesHolding" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfEmployeesHolding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ci_RevenuesFromExternalCustomersMember" abstract="true" name="RevenuesFromExternalCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember" abstract="true" name="SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_NotesDue2026125Member" abstract="true" name="NotesDue2026125Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_PricingConcessionsAfterRemainingTermOfAgreementMember" abstract="true" name="PricingConcessionsAfterRemainingTermOfAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecreaseIncludingDisposalGroups" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecreaseIncludingDisposalGroups" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_ProceedsFromSaleOfDebtAndEquitySecurities" abstract="false" name="ProceedsFromSaleOfDebtAndEquitySecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_OrganizationalEfficiencyPlanChargesNetOfTax" abstract="false" name="OrganizationalEfficiencyPlanChargesNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_RealizedInvestmentGainLoss" abstract="false" name="RealizedInvestmentGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther" abstract="false" name="LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_EquitySecuritiesWithoutReadilyDeterminableFairValueValueOfSharesForAnnualDividendAccrual" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueValueOfSharesForAnnualDividendAccrual" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_AverageInterestRateOnIntercompanyLoan" abstract="false" name="AverageInterestRateOnIntercompanyLoan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember" abstract="true" name="LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_CededReinsuranceAgreementReinsuredRiskPercentage" abstract="false" name="CededReinsuranceAgreementReinsuredRiskPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ci_LiabilityForFuturePolicyBenefitsNoncurrentIncludingDisposalGroups" abstract="false" name="LiabilityForFuturePolicyBenefitsNoncurrentIncludingDisposalGroups" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost" abstract="false" name="DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_StockholdersEquityAndDividendRestrictionsTextBlock" abstract="false" name="StockholdersEquityAndDividendRestrictionsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ci_EvernorthMember" abstract="true" name="EvernorthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DeferredTaxLiabilitiesOtherIncludingDisposalGroupsAssetsHeldForSale" abstract="false" name="DeferredTaxLiabilitiesOtherIncludingDisposalGroupsAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity" abstract="false" name="LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_USFederalGovernmentAgenciesMember" abstract="true" name="USFederalGovernmentAgenciesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsOutstandingAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsOutstandingAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_NotesDue202435InterestMember" abstract="true" name="NotesDue202435InterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_NotesDue20233InterestMember" abstract="true" name="NotesDue20233InterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_ShareholdersEquityAbstract" abstract="true" name="ShareholdersEquityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax" abstract="false" name="OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ci_IndividualAndFamilyPlansMember" abstract="true" name="IndividualAndFamilyPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTranslation" abstract="false" name="DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTranslation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput" abstract="false" name="DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" abstract="false" name="AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_PolicyholderContractDepositCurrentIncludingDisposalGroups" abstract="false" name="PolicyholderContractDepositCurrentIncludingDisposalGroups" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_InvestmentsCreditRatingDomain" abstract="true" name="InvestmentsCreditRatingDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_DefinedBenefitPlanBenefitsPaidOther" abstract="false" name="DefinedBenefitPlanBenefitsPaidOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_IncomeTaxDisclosureLineItems" abstract="true" name="IncomeTaxDisclosureLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_CorporateAndGovernmentDebtSecuritiesMember" abstract="true" name="CorporateAndGovernmentDebtSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_DepreciationAndAmortizationTypeDomain" abstract="true" name="DepreciationAndAmortizationTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_CashCashEquivalentsAndShortTermInvestmentsMember" abstract="true" name="CashCashEquivalentsAndShortTermInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement" abstract="false" name="NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups" abstract="false" name="InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_PropertyPlantAndEquipmentGrossIncludingDisposalGroups" abstract="false" name="PropertyPlantAndEquipmentGrossIncludingDisposalGroups" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DefinedBenefitPlanMarketRelatedValueOfPensionPlanAssets" abstract="false" name="DefinedBenefitPlanMarketRelatedValueOfPensionPlanAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent" abstract="false" name="LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_RetirementAndLifeInsuranceContractsMember" abstract="true" name="RetirementAndLifeInsuranceContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_DeferredTaxLiabilitiesPropertyPlantAndEquipmentIncludingDisposalGroupsAssetsHeldForSale" abstract="false" name="DeferredTaxLiabilitiesPropertyPlantAndEquipmentIncludingDisposalGroupsAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_NotesDue20335400InterestMember" abstract="true" name="NotesDue20335400InterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_LifeInsuranceCompanyOfNorthAmericaMember" abstract="true" name="LifeInsuranceCompanyOfNorthAmericaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_RealizedInvestmentGainsLossesEquityMethodInvestments" abstract="false" name="RealizedInvestmentGainsLossesEquityMethodInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_IncomeTaxDisclosureTable" abstract="true" name="IncomeTaxDisclosureTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ci_SpecialItemChargeBenefitAfterTaxLitigation" abstract="false" name="SpecialItemChargeBenefitAfterTaxLitigation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_FiniteLivedIntangibleAssetsGrossVOBAIncludingDisposalGroupsAssetHeldForSale" abstract="false" name="FiniteLivedIntangibleAssetsGrossVOBAIncludingDisposalGroupsAssetHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureLessThan12MonthsNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureLessThan12MonthsNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_StepDownNotesDueJanuary2033Member" abstract="true" name="StepDownNotesDueJanuary2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_HealthCareServiceCorporationHCSCMember" abstract="true" name="HealthCareServiceCorporationHCSCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_OngoingOperationsMember" abstract="true" name="OngoingOperationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_PricingConcessionsThroughRemainingContractTermMember" abstract="true" name="PricingConcessionsThroughRemainingContractTermMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_PolicyholderContractDepositNoncurrent" abstract="false" name="PolicyholderContractDepositNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_LineOfCreditFacilityConversionToTermLoanTerm" abstract="false" name="LineOfCreditFacilityConversionToTermLoanTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_InsuranceUnearnedPremiumsPolicyTextBlock" abstract="false" name="InsuranceUnearnedPremiumsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ci_OtherPlanAssetCategoriesMember" abstract="true" name="OtherPlanAssetCategoriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity" abstract="false" name="ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_NotesDue20415875InterestMember" abstract="true" name="NotesDue20415875InterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_MarketRiskBenefitLiabilityAmountCurrent" abstract="false" name="MarketRiskBenefitLiabilityAmountCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_UnearnedPremiumsIncludingDisposalGroups" abstract="false" name="UnearnedPremiumsIncludingDisposalGroups" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_Ltv60To79PercentMember" abstract="true" name="Ltv60To79PercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_InsuranceAndContractholderLiabilitiesCurrentAbstract" abstract="true" name="InsuranceAndContractholderLiabilitiesCurrentAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_RevolvingCreditFacilityMaturingApril2025Member" abstract="true" name="RevolvingCreditFacilityMaturingApril2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_ScheduleOfSpecialItemsTableTextBlock" abstract="false" name="ScheduleOfSpecialItemsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ci_FinancingReceivableCreditQualityLoanToValueRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="FinancingReceivableCreditQualityLoanToValueRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="ci_CommitmentsAndContingenciesNumberOfAdditionalExpert" abstract="false" name="CommitmentsAndContingenciesNumberOfAdditionalExpert" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember" abstract="true" name="NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember" abstract="true" name="BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal" abstract="false" name="DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInSeparateAccountsOfSubsidiaries" abstract="false" name="DefinedBenefitPlanFairValueOfPlanAssetsInvestedInSeparateAccountsOfSubsidiaries" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale" abstract="false" name="IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_FiniteLivedIntangibleAssetsGrossVoba" abstract="false" name="FiniteLivedIntangibleAssetsGrossVoba" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DeferredTaxAssetsValuationAllowanceForeignTaxAttributes" abstract="false" name="DeferredTaxAssetsValuationAllowanceForeignTaxAttributes" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_NotesDue2023FloatingRateInterestMember" abstract="true" name="NotesDue2023FloatingRateInterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost" abstract="false" name="DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax" abstract="false" name="SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsExercisableAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsExercisableAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities" abstract="false" name="ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCostIncludingDisposalGroupsAssetsHeldForSale" abstract="false" name="DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCostIncludingDisposalGroupsAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossInvestmentsAndDerivatives" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossInvestmentsAndDerivatives" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax" abstract="false" name="SpecialItemChargesDebtExtinguishmentCostsBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_AdministrativeServicesOnlyHealthCareServicesMember" abstract="true" name="AdministrativeServicesOnlyHealthCareServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract" abstract="true" name="PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_AccountsReceivableUncommittedFactoringFacilityTotalCapacity" abstract="false" name="AccountsReceivableUncommittedFactoringFacilityTotalCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DefinedBenefitPlanAmortizationAbstract" abstract="true" name="DefinedBenefitPlanAmortizationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_UnearnedPremiumsCurrent" abstract="false" name="UnearnedPremiumsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_InsuranceAndContractholderLiabilitiesLineItems" abstract="true" name="InsuranceAndContractholderLiabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_FuturePolicyBenefitsDomesticContractsObservableInputsFromPublishedSpotRateCurveMaximumTerm" abstract="false" name="FuturePolicyBenefitsDomesticContractsObservableInputsFromPublishedSpotRateCurveMaximumTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ci_ReinsuranceRecoverablesLiabilityForFuturePolicyBenefitsAssetsHeldForSale" abstract="false" name="ReinsuranceRecoverablesLiabilityForFuturePolicyBenefitsAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_NotesDue2025325InterestMember" abstract="true" name="NotesDue2025325InterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_GuaranteedDepositAccountContractMember" abstract="true" name="GuaranteedDepositAccountContractMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_DamagesForServiceIssuesMember" abstract="true" name="DamagesForServiceIssuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_MedicareAdvantageLitigationPrivateIndividualMember" abstract="true" name="MedicareAdvantageLitigationPrivateIndividualMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale" abstract="false" name="IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_NotesDue2024613InterestMember" abstract="true" name="NotesDue2024613InterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_OperatingLeaseLiabilityIncludingDisposalGroupsAssetsHeldForSale" abstract="false" name="OperatingLeaseLiabilityIncludingDisposalGroupsAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_NotesDue205134InterestMember" abstract="true" name="NotesDue205134InterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_AccountsReceivableUncommittedFactoringFacilityInitialTerm" abstract="false" name="AccountsReceivableUncommittedFactoringFacilityInitialTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ci_NotesDue20284375InterestMember" abstract="true" name="NotesDue20284375InterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesRealizedInvestmentGainsLossesParentMember" abstract="true" name="AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesRealizedInvestmentGainsLossesParentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentGrossCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentGrossCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember" abstract="true" name="MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes" abstract="false" name="SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_PolicyholderContractDepositsAttributableToDisposalGroups" abstract="false" name="PolicyholderContractDepositsAttributableToDisposalGroups" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable" abstract="false" name="NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract" abstract="true" name="EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_DerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="DerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DisposalGroupsIncludingDiscontinuedOperationsStatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments" abstract="false" name="DisposalGroupsIncludingDiscontinuedOperationsStatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_FiniteLivedIntangibleAssetsNetIncludingDisposalGroupsAssetsHeldForSale" abstract="false" name="FiniteLivedIntangibleAssetsNetIncludingDisposalGroupsAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_UnobservableInputsNotDevelopedByCompanyMember" abstract="true" name="UnobservableInputsNotDevelopedByCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_PolicyholderContractDepositCurrent" abstract="false" name="PolicyholderContractDepositCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DeferredTaxAssetsOperatingLossCarryforwardsIncludingDisposalGroupsAssetsHeldForSale" abstract="false" name="DeferredTaxAssetsOperatingLossCarryforwardsIncludingDisposalGroupsAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_BelowInvestmentGradeMember" abstract="true" name="BelowInvestmentGradeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_IntercompanyInterestExpense" abstract="false" name="IntercompanyInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_NotesDue2036615InterestMember" abstract="true" name="NotesDue2036615InterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_CededReinsuranceAgreementCoverageLimitAmountRemaining" abstract="false" name="CededReinsuranceAgreementCoverageLimitAmountRemaining" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_NotesDue20425375InterestMember" abstract="true" name="NotesDue20425375InterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" abstract="false" name="InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_MarketableSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="MarketableSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_ExpressScriptsLitigationWithElevanceMember" abstract="true" name="ExpressScriptsLitigationWithElevanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_NonGuaranteedSeparateAccountAssetsPricedAtNetAssetValueAsAPracticalExpedient" abstract="false" name="NonGuaranteedSeparateAccountAssetsPricedAtNetAssetValueAsAPracticalExpedient" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_NotesDue204849InterestMember" abstract="true" name="NotesDue204849InterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_TransactionRelatedCostsAfterTax" abstract="false" name="TransactionRelatedCostsAfterTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_OtherPharmacyMember" abstract="true" name="OtherPharmacyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_EmpowerAnnuityInsuranceCompanyMember" abstract="true" name="EmpowerAnnuityInsuranceCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember" abstract="true" name="SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_NotesDue203848InterestMember" abstract="true" name="NotesDue203848InterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentTable" abstract="true" name="ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ci_FiniteLivedIntangibleAssetsGrossIncludingDisposalGroupsHeldForSale" abstract="false" name="FiniteLivedIntangibleAssetsGrossIncludingDisposalGroupsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_NotesDue20473875Member" abstract="true" name="NotesDue20473875Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember" abstract="true" name="NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIncludingDisposalGroupsAssetsHeldForSale" abstract="false" name="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIncludingDisposalGroupsAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAttributedToInstrumentsHeldIncludedInEarnings" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAttributedToInstrumentsHeldIncludedInEarnings" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_ExpressScriptsCounterclaimsAgainstElevanceMember" abstract="true" name="ExpressScriptsCounterclaimsAgainstElevanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_DebenturesDue20277875InterestMember" abstract="true" name="DebenturesDue20277875InterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInsuranceAndContractholderLiabilities" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationNoncurrentInsuranceAndContractholderLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_FairValueMeasurementNonPerformanceRiskAdjustment" abstract="false" name="FairValueMeasurementNonPerformanceRiskAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DebtAndEquitySecuritiesMember" abstract="true" name="DebtAndEquitySecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries" abstract="false" name="RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_AllOtherCountriesMember" abstract="true" name="AllOtherCountriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DisposalGroupIncludingDiscontinuedOperationReinsuranceRecoverablesIncludingReinsurancePremiumPaid" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationReinsuranceRecoverablesIncludingReinsurancePremiumPaid" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_GainLossOnExtinguishmentOfDebtNetOfTax" abstract="false" name="GainLossOnExtinguishmentOfDebtNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_OtherHealthcareMember" abstract="true" name="OtherHealthcareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_DisposalGroupIncludingDiscontinuedOperationLiabilitiesExcludingInsuranceAndContractholderLiabilities" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationLiabilitiesExcludingInsuranceAndContractholderLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossForeignCurrencyTranslation" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossForeignCurrencyTranslation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DeferredTaxAssetsOtherIncludingDisposalGroupsAssetsHeldForSale" abstract="false" name="DeferredTaxAssetsOtherIncludingDisposalGroupsAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_MedicareAdvantageLitigationDepartmentOfJusticeInvestigationsMember" abstract="true" name="MedicareAdvantageLitigationDepartmentOfJusticeInvestigationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract" abstract="true" name="ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_PropertyPlantAndEquipmentIncludingAssetsHeldForSaleAbstract" abstract="true" name="PropertyPlantAndEquipmentIncludingAssetsHeldForSaleAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_AcquisitionDispositionRunoffActivitiesMember" abstract="true" name="AcquisitionDispositionRunoffActivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_PricingConcessionsMember" abstract="true" name="PricingConcessionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity" abstract="false" name="SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember" abstract="true" name="NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups" abstract="false" name="IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_NotesDue202383InterestMember" abstract="true" name="NotesDue202383InterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_ShortTermAndLongTermInvestmentsAbstract" abstract="true" name="ShortTermAndLongTermInvestmentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ci_ScheduleOfShortTermDebtLongTermDebtTableTextBlock" abstract="false" name="ScheduleOfShortTermDebtLongTermDebtTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVOBAIncludingDisposalGroupsAssetsHeldForSale" abstract="false" name="FiniteLivedIntangibleAssetsAccumulatedAmortizationVOBAIncludingDisposalGroupsAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_GoodwillIncludingDisposalGroups" abstract="false" name="GoodwillIncludingDisposalGroups" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DepreciationAndAmortizationByTypeAxis" abstract="true" name="DepreciationAndAmortizationByTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ci_DisposalGroupIncludingDiscontinuedOperationsStatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationsStatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_OrganizationalEfficiencyPlanCharges" abstract="false" name="OrganizationalEfficiencyPlanCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DerivativeNotionalAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="DerivativeNotionalAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue" abstract="false" name="PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ci_OperatingLeaseLiabilityNoncurrentIncludingDisposalGroupsAssetsHeldForSale" abstract="false" name="OperatingLeaseLiabilityNoncurrentIncludingDisposalGroupsAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DebtAndEquitySecuritiesClassifiedInLevel2PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="DebtAndEquitySecuritiesClassifiedInLevel2PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ci_OtherLongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="OtherLongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_PrudentialInsuranceCompanyOfAmericaMember" abstract="true" name="PrudentialInsuranceCompanyOfAmericaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_PharmacyAndServiceCostsPayable" abstract="false" name="PharmacyAndServiceCostsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_UnitedStatedHealthcareMember" abstract="true" name="UnitedStatedHealthcareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent" abstract="false" name="OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_CededCreditCollateralizationRiskMember" abstract="true" name="CededCreditCollateralizationRiskMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember" abstract="true" name="NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember" abstract="true" name="PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity" abstract="false" name="OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent" abstract="false" name="LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_PharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="PharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DerivativeCreditRiskValuationAdjustmentDerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="DerivativeCreditRiskValuationAdjustmentDerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_NotesDue203024InterestMember" abstract="true" name="NotesDue203024InterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfOriginalGrantAwardedAtEndOfPerformancePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfOriginalGrantAwardedAtEndOfPerformancePeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumInterestIncomeAndOtherChanges" abstract="false" name="LiabilityForFuturePolicyBenefitExpectedNetPremiumInterestIncomeAndOtherChanges" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear" abstract="false" name="UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity" abstract="false" name="OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_AcceleratedShareRepurchasesVolumeWeightedAverageSharePriceLessDiscount" abstract="false" name="AcceleratedShareRepurchasesVolumeWeightedAverageSharePriceLessDiscount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_InsuranceCustomerReceivablesBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="InsuranceCustomerReceivablesBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member" abstract="true" name="RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_IncomeTaxReconciliationHealthInsuranceIndustryTax" abstract="false" name="IncomeTaxReconciliationHealthInsuranceIndustryTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_NonInvestmentRevenue" abstract="false" name="NonInvestmentRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio" abstract="false" name="FinancingReceivableCreditQualityDebtServiceCoverageRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable" abstract="false" name="IncreaseDecreaseInPharmacyAndServiceCostsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability" abstract="false" name="LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups" abstract="false" name="LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfMaturitiesOfLongTermDebtTableTextBlock" abstract="false" name="CondensedFinancialInformationOfParentCompanyOnlyScheduleOfMaturitiesOfLongTermDebtTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ci_AllowanceForReceivablesOther" abstract="false" name="AllowanceForReceivablesOther" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage" abstract="false" name="LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ci_CashAndCashEquivalentsInvestmentTradeReceivablesNetMember" abstract="true" name="CashAndCashEquivalentsInvestmentTradeReceivablesNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_NotesDue20265685Member" abstract="true" name="NotesDue20265685Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_IncomeBeforeTaxesMember" abstract="true" name="IncomeBeforeTaxesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_UnearnedPremiumsCurrentIncludingDisposalGroups" abstract="false" name="UnearnedPremiumsCurrentIncludingDisposalGroups" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_InvestmentGradeMember" abstract="true" name="InvestmentGradeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesSellingGeneralAdministrativeExpenseParentMember" abstract="true" name="AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesSellingGeneralAdministrativeExpenseParentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfIssuancesOfLongTermDebtTableTextBlock" abstract="false" name="CondensedFinancialInformationOfParentCompanyOnlyScheduleOfIssuancesOfLongTermDebtTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member" abstract="true" name="RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_EquitySecuritiesDividend" abstract="false" name="EquitySecuritiesDividend" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrentIncludingDisposalGroups" abstract="false" name="LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrentIncludingDisposalGroups" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_CapitalizationOfDeferredPolicyAcquisitionCostsPolicyPolicyTextBlock" abstract="false" name="CapitalizationOfDeferredPolicyAcquisitionCostsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ci_DepartmentOfDefenseMember" abstract="true" name="DepartmentOfDefenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_UnearnedPremiumsNoncurrentIncludingDisposalGroups" abstract="false" name="UnearnedPremiumsNoncurrentIncludingDisposalGroups" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_AccountsPayableAccruedExpensesOtherLiabilitiesPolicyPolicyTextBlock" abstract="false" name="AccountsPayableAccruedExpensesOtherLiabilitiesPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVoba" abstract="false" name="FiniteLivedIntangibleAssetsAccumulatedAmortizationVoba" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DeferredTaxAssetsValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale" abstract="false" name="DeferredTaxAssetsValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_InvestmentsCreditRatingAxis" abstract="true" name="InvestmentsCreditRatingAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ci_AccountsAndOtherReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="AccountsAndOtherReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" abstract="false" name="FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_A364DayRevolvingCreditAgreementMaturingApril2023Member" abstract="true" name="A364DayRevolvingCreditAgreementMaturingApril2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_EffectiveIncomeTaxRateReconciliationImpactOfBusinessesHeldForSalePercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationImpactOfBusinessesHeldForSalePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ci_SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember" abstract="true" name="SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_SpecialItemGainLossFromContractAdjustmentNetOfTax" abstract="false" name="SpecialItemGainLossFromContractAdjustmentNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_IntangibleAssetsNetExcludingGoodwillIncludingVoba" abstract="false" name="IntangibleAssetsNetExcludingGoodwillIncludingVoba" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_SpecialItemChargeBenefitBeforeTaxLitigation" abstract="false" name="SpecialItemChargeBenefitBeforeTaxLitigation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_DeferredTaxAssetsInvestmentsSubjectToFederalCapitalLossUtilizationRules" abstract="false" name="DeferredTaxAssetsInvestmentsSubjectToFederalCapitalLossUtilizationRules" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_TemporaryEquityOtherComprehensiveIncome" abstract="false" name="TemporaryEquityOtherComprehensiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_OtherOperationsInternationalBusinessesToBeSoldAndInterestInJointVentureInTurkeyMember" abstract="true" name="OtherOperationsInternationalBusinessesToBeSoldAndInterestInJointVentureInTurkeyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_DisposalGroupIncludingDiscontinuedOperationOtherAssetsGoodwill" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationOtherAssetsGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_CHSSJVLLCMember" abstract="true" name="CHSSJVLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock" abstract="false" name="EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_UnearnedPremiumsAttributableToDisposalGroups" abstract="false" name="UnearnedPremiumsAttributableToDisposalGroups" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_RealEstateJointVenturesMember" abstract="true" name="RealEstateJointVenturesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ci_PolicyholderContractDepositsIncludingDisposalGroups" abstract="false" name="PolicyholderContractDepositsIncludingDisposalGroups" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ci_NotesDue205034InterestMember" abstract="true" name="NotesDue205034InterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>ci-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:fd466b51-e399-4368-bda1-c8c0817d4afc,g:199c158e-5fac-4def-904c-2de015f58c08-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="ci-20231231.xsd#ConsolidatedStatementsofIncome"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_cfb81ba5-cc95-4c96-85fa-d4291b9cd65a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_5a843263-c3d3-484d-b3ae-c1d656f1abac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_cfb81ba5-cc95-4c96-85fa-d4291b9cd65a" xlink:to="loc_us-gaap_Revenues_5a843263-c3d3-484d-b3ae-c1d656f1abac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BenefitsLossesAndExpenses_7508618c-8973-4adb-8f4e-63781f5f558d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BenefitsLossesAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_cfb81ba5-cc95-4c96-85fa-d4291b9cd65a" xlink:to="loc_us-gaap_BenefitsLossesAndExpenses_7508618c-8973-4adb-8f4e-63781f5f558d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BenefitsLossesAndExpenses_2210198d-e230-43d1-9f0e-4b5b85909b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BenefitsLossesAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5fbcd6f9-fb20-42bc-9bad-7cbb2893596b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BenefitsLossesAndExpenses_2210198d-e230-43d1-9f0e-4b5b85909b0b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5fbcd6f9-fb20-42bc-9bad-7cbb2893596b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_7f11e5be-f6b5-40ab-89ae-68816a548355" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BenefitsLossesAndExpenses_2210198d-e230-43d1-9f0e-4b5b85909b0b" xlink:to="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_7f11e5be-f6b5-40ab-89ae-68816a548355" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2ce16b4d-d3b9-432a-a07a-51a2ad6c1223" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BenefitsLossesAndExpenses_2210198d-e230-43d1-9f0e-4b5b85909b0b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2ce16b4d-d3b9-432a-a07a-51a2ad6c1223" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_f5fcb7a3-4dc1-40e9-88b2-9b41ea33f079" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BenefitsLossesAndExpenses_2210198d-e230-43d1-9f0e-4b5b85909b0b" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_f5fcb7a3-4dc1-40e9-88b2-9b41ea33f079" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3724efd2-5fb8-425c-ab66-c5bb9d6f661f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_32cc5ef2-5e39-4149-9643-518a8de0ca94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_3724efd2-5fb8-425c-ab66-c5bb9d6f661f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_32cc5ef2-5e39-4149-9643-518a8de0ca94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_898fb7a6-0e81-4688-a9d7-2d8e67314121" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_3724efd2-5fb8-425c-ab66-c5bb9d6f661f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_898fb7a6-0e81-4688-a9d7-2d8e67314121" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b1624b7b-3ac3-4803-9649-ae3499da444f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RealizedInvestmentGainLoss_0f1abc8d-91f1-42f8-9ce5-e92f78f35864" xlink:href="ci-20231231.xsd#ci_RealizedInvestmentGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b1624b7b-3ac3-4803-9649-ae3499da444f" xlink:to="loc_ci_RealizedInvestmentGainLoss_0f1abc8d-91f1-42f8-9ce5-e92f78f35864" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d14753f1-2ad1-49bb-a0fe-aa9c6ace9456" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b1624b7b-3ac3-4803-9649-ae3499da444f" xlink:to="loc_us-gaap_OperatingIncomeLoss_d14753f1-2ad1-49bb-a0fe-aa9c6ace9456" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_44479ef5-4f2d-431e-80ba-a857ab6c64e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b1624b7b-3ac3-4803-9649-ae3499da444f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_44479ef5-4f2d-431e-80ba-a857ab6c64e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_46f6caba-eaf5-4076-9307-6b20be780d45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b1624b7b-3ac3-4803-9649-ae3499da444f" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_46f6caba-eaf5-4076-9307-6b20be780d45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2d9ae700-5f91-4ae7-84e2-c28b6a98fd6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b1624b7b-3ac3-4803-9649-ae3499da444f" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2d9ae700-5f91-4ae7-84e2-c28b6a98fd6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f673690e-b620-4235-bb4f-2052d78098a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d03c61bf-50d8-4ce5-9168-7cbf69e25fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f673690e-b620-4235-bb4f-2052d78098a9" xlink:to="loc_us-gaap_ProfitLoss_d03c61bf-50d8-4ce5-9168-7cbf69e25fe7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_bc412f51-6e36-47ae-a811-a1eb8ec19947" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f673690e-b620-4235-bb4f-2052d78098a9" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_bc412f51-6e36-47ae-a811-a1eb8ec19947" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f4fcae58-58c1-465b-90cc-9c8669a3900e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_11e11d1d-4774-4936-9b2f-2d49013001c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_f4fcae58-58c1-465b-90cc-9c8669a3900e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_11e11d1d-4774-4936-9b2f-2d49013001c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_66d2bb92-3883-4fd8-b3a4-567cef058009" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_f4fcae58-58c1-465b-90cc-9c8669a3900e" xlink:to="loc_us-gaap_PremiumsEarnedNet_66d2bb92-3883-4fd8-b3a4-567cef058009" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_e36f7751-ccd0-4f86-ac05-6fdee3c24f18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_f4fcae58-58c1-465b-90cc-9c8669a3900e" xlink:to="loc_us-gaap_NetInvestmentIncome_e36f7751-ccd0-4f86-ac05-6fdee3c24f18" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="ci-20231231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2d22ab8e-1b9e-4a25-a72e-7338b3f98e60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity_3cb4bbdf-28d7-41ed-866c-16c015b9e62a" xlink:href="ci-20231231.xsd#ci_ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2d22ab8e-1b9e-4a25-a72e-7338b3f98e60" xlink:to="loc_ci_ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity_3cb4bbdf-28d7-41ed-866c-16c015b9e62a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_05f2ac95-fdd9-4adc-ad19-ab71659e9a21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2d22ab8e-1b9e-4a25-a72e-7338b3f98e60" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_05f2ac95-fdd9-4adc-ad19-ab71659e9a21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_530d61ad-ae00-4fb2-97ad-f384e5c9d526" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TemporaryEquityOtherComprehensiveIncome_5a89a6c7-849b-40b2-a6f3-12dd4b174d55" xlink:href="ci-20231231.xsd#ci_TemporaryEquityOtherComprehensiveIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_530d61ad-ae00-4fb2-97ad-f384e5c9d526" xlink:to="loc_ci_TemporaryEquityOtherComprehensiveIncome_5a89a6c7-849b-40b2-a6f3-12dd4b174d55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_75747fe0-4d3b-4283-8f9d-72e5c27ab1c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_530d61ad-ae00-4fb2-97ad-f384e5c9d526" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_75747fe0-4d3b-4283-8f9d-72e5c27ab1c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_7a86bd71-e951-4598-9fd9-f5d8a7c31732" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_530d61ad-ae00-4fb2-97ad-f384e5c9d526" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_7a86bd71-e951-4598-9fd9-f5d8a7c31732" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity_bf97d024-b7c6-4faf-85fd-ba18095e29dc" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent_52d6cffb-3dda-4805-8f45-ec8ebe906d9a" xlink:href="ci-20231231.xsd#ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity_bf97d024-b7c6-4faf-85fd-ba18095e29dc" xlink:to="loc_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent_52d6cffb-3dda-4805-8f45-ec8ebe906d9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax_fd74ff3c-8a15-47bc-9056-16adde130ea2" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity_bf97d024-b7c6-4faf-85fd-ba18095e29dc" xlink:to="loc_ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax_fd74ff3c-8a15-47bc-9056-16adde130ea2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_dcb01b05-ba9e-466c-9d16-c11e7e0b2146" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity_bf97d024-b7c6-4faf-85fd-ba18095e29dc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_dcb01b05-ba9e-466c-9d16-c11e7e0b2146" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity_e4f1c759-74fc-485c-abb2-8802019a3930" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity_bf97d024-b7c6-4faf-85fd-ba18095e29dc" xlink:to="loc_ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity_e4f1c759-74fc-485c-abb2-8802019a3930" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity_6a8c936a-bd28-4acf-9bdf-ef632d1df341" xlink:href="ci-20231231.xsd#ci_ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d734881c-8c85-4823-86fd-14e7d36859fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity_6a8c936a-bd28-4acf-9bdf-ef632d1df341" xlink:to="loc_us-gaap_ProfitLoss_d734881c-8c85-4823-86fd-14e7d36859fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity_4187de06-44c8-43ee-a79f-ab1424a3ad32" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity_6a8c936a-bd28-4acf-9bdf-ef632d1df341" xlink:to="loc_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity_4187de06-44c8-43ee-a79f-ab1424a3ad32" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ci-20231231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9ffc93f5-3ac6-4074-8a6a-b5166591da79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f2867605-2a25-49d7-b978-e73774cf08a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9ffc93f5-3ac6-4074-8a6a-b5166591da79" xlink:to="loc_us-gaap_StockholdersEquity_f2867605-2a25-49d7-b978-e73774cf08a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_a93db4f4-876f-4a23-a322-555feb6b34ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9ffc93f5-3ac6-4074-8a6a-b5166591da79" xlink:to="loc_us-gaap_MinorityInterest_a93db4f4-876f-4a23-a322-555feb6b34ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b7341455-78e0-4a9a-b90d-b1c33b195b25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_48bb1256-3fc9-4de2-9cc4-6362e35443f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b7341455-78e0-4a9a-b90d-b1c33b195b25" xlink:to="loc_us-gaap_LiabilitiesCurrent_48bb1256-3fc9-4de2-9cc4-6362e35443f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent_003dcfe3-b362-47dc-8a8a-e327cfb29a68" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b7341455-78e0-4a9a-b90d-b1c33b195b25" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent_003dcfe3-b362-47dc-8a8a-e327cfb29a68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_15282db1-352d-4ab7-b9fb-8e710d219e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b7341455-78e0-4a9a-b90d-b1c33b195b25" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_15282db1-352d-4ab7-b9fb-8e710d219e2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_9b0c61b8-7238-426f-8fc8-d30624c3d77a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b7341455-78e0-4a9a-b90d-b1c33b195b25" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_9b0c61b8-7238-426f-8fc8-d30624c3d77a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_d3794c22-0e20-40f9-82e6-b47edaabaf9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b7341455-78e0-4a9a-b90d-b1c33b195b25" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_d3794c22-0e20-40f9-82e6-b47edaabaf9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountsLiability_2a57939b-4baf-4a26-afd2-d5703777f835" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeparateAccountsLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b7341455-78e0-4a9a-b90d-b1c33b195b25" xlink:to="loc_us-gaap_SeparateAccountsLiability_2a57939b-4baf-4a26-afd2-d5703777f835" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_68d5bf6e-e27a-4ced-9c10-9b15b8692656" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b7341455-78e0-4a9a-b90d-b1c33b195b25" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_68d5bf6e-e27a-4ced-9c10-9b15b8692656" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0e904dfe-2608-4845-b1d0-4947ddcc0289" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_325382ca-5b97-4d70-8c6a-d893c078e52b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0e904dfe-2608-4845-b1d0-4947ddcc0289" xlink:to="loc_us-gaap_OtherAssetsCurrent_325382ca-5b97-4d70-8c6a-d893c078e52b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a8f20447-512d-4a83-9314-5ac7ced4e4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0e904dfe-2608-4845-b1d0-4947ddcc0289" xlink:to="loc_us-gaap_InventoryNet_a8f20447-512d-4a83-9314-5ac7ced4e4f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_55dfc697-5a88-4bf0-8f65-a9102411757b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0e904dfe-2608-4845-b1d0-4947ddcc0289" xlink:to="loc_us-gaap_ShortTermInvestments_55dfc697-5a88-4bf0-8f65-a9102411757b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_27f39327-9ebd-4401-8e19-be61bf0ddb39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0e904dfe-2608-4845-b1d0-4947ddcc0289" xlink:to="loc_us-gaap_ReceivablesNetCurrent_27f39327-9ebd-4401-8e19-be61bf0ddb39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_101cf955-7eec-4560-a5fc-984d11ef00dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0e904dfe-2608-4845-b1d0-4947ddcc0289" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_101cf955-7eec-4560-a5fc-984d11ef00dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_dfd2c166-b844-43b2-87c7-73e4b87fff04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0e904dfe-2608-4845-b1d0-4947ddcc0289" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_dfd2c166-b844-43b2-87c7-73e4b87fff04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4b37d221-fb50-4f1d-a5f5-f2cdc61d2480" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b06096a3-c092-44cd-9962-b93bd795e9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b37d221-fb50-4f1d-a5f5-f2cdc61d2480" xlink:to="loc_us-gaap_CommonStockValue_b06096a3-c092-44cd-9962-b93bd795e9b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_38da18a4-14ff-4f75-bc3a-a631952c4dea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b37d221-fb50-4f1d-a5f5-f2cdc61d2480" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_38da18a4-14ff-4f75-bc3a-a631952c4dea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3b77a758-8837-4d88-9dbe-e807cc8f7d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b37d221-fb50-4f1d-a5f5-f2cdc61d2480" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3b77a758-8837-4d88-9dbe-e807cc8f7d0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d311d6bd-0f31-4f40-9a15-c6b699504dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b37d221-fb50-4f1d-a5f5-f2cdc61d2480" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d311d6bd-0f31-4f40-9a15-c6b699504dc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_6b51589a-5959-411a-a6b5-b1f2c8462e37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b37d221-fb50-4f1d-a5f5-f2cdc61d2480" xlink:to="loc_us-gaap_TreasuryStockValue_6b51589a-5959-411a-a6b5-b1f2c8462e37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5ddbfa17-ff6c-4e1f-8531-6682a4e0749e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7a53b698-9ec1-4532-bc94-02cb9be0860f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5ddbfa17-ff6c-4e1f-8531-6682a4e0749e" xlink:to="loc_us-gaap_AssetsCurrent_7a53b698-9ec1-4532-bc94-02cb9be0860f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_2f1644d1-16b2-412f-9581-1660790e84de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5ddbfa17-ff6c-4e1f-8531-6682a4e0749e" xlink:to="loc_us-gaap_LongTermInvestments_2f1644d1-16b2-412f-9581-1660790e84de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverablesNonCurrent_c3d47130-5afd-4078-9409-ead76509ca92" xlink:href="ci-20231231.xsd#ci_ReinsuranceRecoverablesNonCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5ddbfa17-ff6c-4e1f-8531-6682a4e0749e" xlink:to="loc_ci_ReinsuranceRecoverablesNonCurrent_c3d47130-5afd-4078-9409-ead76509ca92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_9231b13f-58cb-4716-ba4b-d94773741892" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5ddbfa17-ff6c-4e1f-8531-6682a4e0749e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_9231b13f-58cb-4716-ba4b-d94773741892" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d860c85a-4a1f-4231-9ae3-ff50f4d8a662" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5ddbfa17-ff6c-4e1f-8531-6682a4e0749e" xlink:to="loc_us-gaap_Goodwill_d860c85a-4a1f-4231-9ae3-ff50f4d8a662" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1dc89f10-3b91-48a9-96e5-decc8331380c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5ddbfa17-ff6c-4e1f-8531-6682a4e0749e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1dc89f10-3b91-48a9-96e5-decc8331380c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_89947f4d-8b2f-4028-91ac-21c825a9eb57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5ddbfa17-ff6c-4e1f-8531-6682a4e0749e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_89947f4d-8b2f-4028-91ac-21c825a9eb57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountAssets_900e0019-3b8b-4707-ba1a-7af6e90d1103" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeparateAccountAssets"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5ddbfa17-ff6c-4e1f-8531-6682a4e0749e" xlink:to="loc_us-gaap_SeparateAccountAssets_900e0019-3b8b-4707-ba1a-7af6e90d1103" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_290a7774-2a02-4fca-80af-d869770b7e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5ddbfa17-ff6c-4e1f-8531-6682a4e0749e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_290a7774-2a02-4fca-80af-d869770b7e5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0cab8797-f937-41de-a8df-d73da1090d47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0c0586bb-12ad-498a-87e8-32cfc551190a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0cab8797-f937-41de-a8df-d73da1090d47" xlink:to="loc_us-gaap_AccountsPayableCurrent_0c0586bb-12ad-498a-87e8-32cfc551190a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_c8c0ccd7-b60d-4f68-86ee-ed638d8732d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0cab8797-f937-41de-a8df-d73da1090d47" xlink:to="loc_us-gaap_DebtCurrent_c8c0ccd7-b60d-4f68-86ee-ed638d8732d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesCurrent_d23203bb-3bf5-4a54-9ff5-2aec5d41a142" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0cab8797-f937-41de-a8df-d73da1090d47" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesCurrent_d23203bb-3bf5-4a54-9ff5-2aec5d41a142" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PharmacyAndServiceCostsPayable_5ee2ca54-25d0-4afb-bf9a-8798115a5614" xlink:href="ci-20231231.xsd#ci_PharmacyAndServiceCostsPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0cab8797-f937-41de-a8df-d73da1090d47" xlink:to="loc_ci_PharmacyAndServiceCostsPayable_5ee2ca54-25d0-4afb-bf9a-8798115a5614" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccruedExpensesAndOtherLiabilities_79ee1178-9abf-4ff9-a72f-c0d160251a9c" xlink:href="ci-20231231.xsd#ci_AccruedExpensesAndOtherLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0cab8797-f937-41de-a8df-d73da1090d47" xlink:to="loc_ci_AccruedExpensesAndOtherLiabilities_79ee1178-9abf-4ff9-a72f-c0d160251a9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_b611ab7f-286c-4994-8cc8-a1e3ba163dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0cab8797-f937-41de-a8df-d73da1090d47" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_b611ab7f-286c-4994-8cc8-a1e3ba163dc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9f8059bd-b89b-4386-9812-30f4d95844e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_900cdaac-8469-4457-b7b1-70c18d319a38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9f8059bd-b89b-4386-9812-30f4d95844e7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_900cdaac-8469-4457-b7b1-70c18d319a38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e40da6ba-67fe-4714-b783-02d3a515df72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9f8059bd-b89b-4386-9812-30f4d95844e7" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e40da6ba-67fe-4714-b783-02d3a515df72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_8a874f29-693e-438b-9a67-456e87f4ec1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9f8059bd-b89b-4386-9812-30f4d95844e7" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_8a874f29-693e-438b-9a67-456e87f4ec1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_40e852fd-3f2d-4040-bdba-207862dff6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9f8059bd-b89b-4386-9812-30f4d95844e7" xlink:to="loc_us-gaap_Liabilities_40e852fd-3f2d-4040-bdba-207862dff6b3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ci-20231231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_052a2052-e743-4e83-816a-69af53d5cd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_a25b53c1-91c5-48f0-9ddf-4b86edf0ab60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_052a2052-e743-4e83-816a-69af53d5cd7d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_a25b53c1-91c5-48f0-9ddf-4b86edf0ab60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b3e580ed-041d-44f3-9958-9765ef1c8a30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_052a2052-e743-4e83-816a-69af53d5cd7d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b3e580ed-041d-44f3-9958-9765ef1c8a30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cdf48d46-739d-46f9-9cb6-05ba7ecdb3af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ProceedsFromRepaymentsOfOtherShortTermDebt_a8a31a0a-40e4-431f-ab39-6845b3e28789" xlink:href="ci-20231231.xsd#ci_ProceedsFromRepaymentsOfOtherShortTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cdf48d46-739d-46f9-9cb6-05ba7ecdb3af" xlink:to="loc_ci_ProceedsFromRepaymentsOfOtherShortTermDebt_a8a31a0a-40e4-431f-ab39-6845b3e28789" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_5f95bce8-dcf9-4fad-a78b-4c8836d8e7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cdf48d46-739d-46f9-9cb6-05ba7ecdb3af" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_5f95bce8-dcf9-4fad-a78b-4c8836d8e7c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_43c6c4f8-31bd-412c-a5fe-8b5227fc0ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cdf48d46-739d-46f9-9cb6-05ba7ecdb3af" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_43c6c4f8-31bd-412c-a5fe-8b5227fc0ed4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_1d16ce72-809b-41c4-9d7b-8abdca7d0a05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cdf48d46-739d-46f9-9cb6-05ba7ecdb3af" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_1d16ce72-809b-41c4-9d7b-8abdca7d0a05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WithdrawalFromContractHoldersFunds_9d2f35e0-5820-41b1-b3e5-c67f50fdc423" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WithdrawalFromContractHoldersFunds"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cdf48d46-739d-46f9-9cb6-05ba7ecdb3af" xlink:to="loc_us-gaap_WithdrawalFromContractHoldersFunds_9d2f35e0-5820-41b1-b3e5-c67f50fdc423" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_98d71439-f9ec-4dd6-895b-628ae24f6368" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cdf48d46-739d-46f9-9cb6-05ba7ecdb3af" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_98d71439-f9ec-4dd6-895b-628ae24f6368" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_5d73d521-c616-4483-86ff-6a161f3b92a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cdf48d46-739d-46f9-9cb6-05ba7ecdb3af" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_5d73d521-c616-4483-86ff-6a161f3b92a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8a54249b-b288-4a2a-a433-c98cd453a1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cdf48d46-739d-46f9-9cb6-05ba7ecdb3af" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8a54249b-b288-4a2a-a433-c98cd453a1e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionsToContractHoldersFunds_9416c888-7290-43da-a3e0-f89960c37c85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionsToContractHoldersFunds"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cdf48d46-739d-46f9-9cb6-05ba7ecdb3af" xlink:to="loc_us-gaap_AdditionsToContractHoldersFunds_9416c888-7290-43da-a3e0-f89960c37c85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_85e74bfc-2063-4fc6-98d5-56212c82d28a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cdf48d46-739d-46f9-9cb6-05ba7ecdb3af" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_85e74bfc-2063-4fc6-98d5-56212c82d28a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ddf4a89-9ddb-4a49-aaab-db76b9fa8934" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_de301218-2a40-4c8a-b6cc-c6f87a3ce71f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ddf4a89-9ddb-4a49-aaab-db76b9fa8934" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_de301218-2a40-4c8a-b6cc-c6f87a3ce71f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_0969a16b-ee73-4b6a-b4dc-8a13f164412d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ddf4a89-9ddb-4a49-aaab-db76b9fa8934" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_0969a16b-ee73-4b6a-b4dc-8a13f164412d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities_0149e4ac-0924-4ccc-a415-cb98e3a539aa" xlink:href="ci-20231231.xsd#ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ddf4a89-9ddb-4a49-aaab-db76b9fa8934" xlink:to="loc_ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities_0149e4ac-0924-4ccc-a415-cb98e3a539aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMortgageNotesReceivable_147cb6d6-8bf4-4149-b839-0ffa31dc239b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMortgageNotesReceivable"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ddf4a89-9ddb-4a49-aaab-db76b9fa8934" xlink:to="loc_us-gaap_PaymentsToAcquireMortgageNotesReceivable_147cb6d6-8bf4-4149-b839-0ffa31dc239b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PaymentsForProceedsFromPropertyPlantAndEquipment_cffb579b-cb01-43aa-87e7-24418d573e25" xlink:href="ci-20231231.xsd#ci_PaymentsForProceedsFromPropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ddf4a89-9ddb-4a49-aaab-db76b9fa8934" xlink:to="loc_ci_PaymentsForProceedsFromPropertyPlantAndEquipment_cffb579b-cb01-43aa-87e7-24418d573e25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ProceedsFromSaleOfDebtAndEquitySecurities_649a0734-e62b-4777-a6cc-b9ccf9ae9e4d" xlink:href="ci-20231231.xsd#ci_ProceedsFromSaleOfDebtAndEquitySecurities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ddf4a89-9ddb-4a49-aaab-db76b9fa8934" xlink:to="loc_ci_ProceedsFromSaleOfDebtAndEquitySecurities_649a0734-e62b-4777-a6cc-b9ccf9ae9e4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PaymentsToAcquireDebtAndEquitySecurities_6ff9b378-2661-4523-bd3e-f76da8dc186e" xlink:href="ci-20231231.xsd#ci_PaymentsToAcquireDebtAndEquitySecurities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ddf4a89-9ddb-4a49-aaab-db76b9fa8934" xlink:to="loc_ci_PaymentsToAcquireDebtAndEquitySecurities_6ff9b378-2661-4523-bd3e-f76da8dc186e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfLoansReceivable_6b5fc535-d7d4-498f-97db-514637f48ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollectionOfLoansReceivable"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ddf4a89-9ddb-4a49-aaab-db76b9fa8934" xlink:to="loc_us-gaap_ProceedsFromCollectionOfLoansReceivable_6b5fc535-d7d4-498f-97db-514637f48ab1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9d6f1c38-9e3a-40eb-90b4-ced00ba83978" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ddf4a89-9ddb-4a49-aaab-db76b9fa8934" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9d6f1c38-9e3a-40eb-90b4-ced00ba83978" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_c135371f-7a20-4ed7-b7df-f7d7458deed5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ddf4a89-9ddb-4a49-aaab-db76b9fa8934" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_c135371f-7a20-4ed7-b7df-f7d7458deed5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_f35f4b47-230e-471c-861e-551c4b84d488" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ddf4a89-9ddb-4a49-aaab-db76b9fa8934" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_f35f4b47-230e-471c-861e-551c4b84d488" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2c2edc33-cfb5-4a61-a8a9-2cc38b28c58d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_d01eb391-b5b5-496b-b2b1-5e9e5ff0a496" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2c2edc33-cfb5-4a61-a8a9-2cc38b28c58d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_d01eb391-b5b5-496b-b2b1-5e9e5ff0a496" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities_64c292b2-3b2c-4c62-b470-15fe8b6c5565" xlink:href="ci-20231231.xsd#ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2c2edc33-cfb5-4a61-a8a9-2cc38b28c58d" xlink:to="loc_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities_64c292b2-3b2c-4c62-b470-15fe8b6c5565" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_c63d7cdd-b3f7-4c4e-9ee6-7affc0578bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2c2edc33-cfb5-4a61-a8a9-2cc38b28c58d" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_c63d7cdd-b3f7-4c4e-9ee6-7affc0578bd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8d7195d5-754c-4784-9de1-9f01f25efe5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2c2edc33-cfb5-4a61-a8a9-2cc38b28c58d" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8d7195d5-754c-4784-9de1-9f01f25efe5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_5ff0c1b6-ac9c-41fd-bac0-3d73e2d8da78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2c2edc33-cfb5-4a61-a8a9-2cc38b28c58d" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_5ff0c1b6-ac9c-41fd-bac0-3d73e2d8da78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3cc94c5b-fa12-4405-b208-561a2c99f249" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2c2edc33-cfb5-4a61-a8a9-2cc38b28c58d" xlink:to="loc_us-gaap_ProfitLoss_3cc94c5b-fa12-4405-b208-561a2c99f249" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities_e69d2419-95c9-43e7-82b2-2c405d3f3024" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInsuranceLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2c2edc33-cfb5-4a61-a8a9-2cc38b28c58d" xlink:to="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities_e69d2419-95c9-43e7-82b2-2c405d3f3024" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_a562acb0-6966-4906-afb8-dfd8711650bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2c2edc33-cfb5-4a61-a8a9-2cc38b28c58d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_a562acb0-6966-4906-afb8-dfd8711650bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RealizedInvestmentGainLoss_2a7c4cab-511a-4d47-ad1f-0f51d007e9d5" xlink:href="ci-20231231.xsd#ci_RealizedInvestmentGainLoss"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2c2edc33-cfb5-4a61-a8a9-2cc38b28c58d" xlink:to="loc_ci_RealizedInvestmentGainLoss_2a7c4cab-511a-4d47-ad1f-0f51d007e9d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable_c1a996f0-6e04-45f5-ba6f-2edddda96954" xlink:href="ci-20231231.xsd#ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2c2edc33-cfb5-4a61-a8a9-2cc38b28c58d" xlink:to="loc_ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable_c1a996f0-6e04-45f5-ba6f-2edddda96954" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReinsuranceRecoverable_0820d4eb-1c01-4bbf-b741-5d162bef3d23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInReinsuranceRecoverable"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2c2edc33-cfb5-4a61-a8a9-2cc38b28c58d" xlink:to="loc_us-gaap_IncreaseDecreaseInReinsuranceRecoverable_0820d4eb-1c01-4bbf-b741-5d162bef3d23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_820bd384-34cf-4f40-a8fe-6ee1cdf857bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2c2edc33-cfb5-4a61-a8a9-2cc38b28c58d" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_820bd384-34cf-4f40-a8fe-6ee1cdf857bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_56913fe5-f4b7-4748-8c47-0435d228c712" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2c2edc33-cfb5-4a61-a8a9-2cc38b28c58d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_56913fe5-f4b7-4748-8c47-0435d228c712" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_459029f0-5272-499e-ba40-80fa28d55431" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9670cc17-0233-4561-b80f-02290f13f3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_459029f0-5272-499e-ba40-80fa28d55431" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9670cc17-0233-4561-b80f-02290f13f3a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_36028ecf-003f-443a-ad53-b7a566ad6dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_459029f0-5272-499e-ba40-80fa28d55431" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_36028ecf-003f-443a-ad53-b7a566ad6dc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_813d4179-3dc8-4722-b282-815584046134" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_459029f0-5272-499e-ba40-80fa28d55431" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_813d4179-3dc8-4722-b282-815584046134" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0c928bc9-4d94-443d-bc38-bc513f4d58e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_459029f0-5272-499e-ba40-80fa28d55431" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0c928bc9-4d94-443d-bc38-bc513f4d58e0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale_5561b7f1-e433-4331-a079-e0a085f625e9" xlink:href="ci-20231231.xsd#ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_d43a7100-a362-4012-ba42-5ca8f9bc3d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale_5561b7f1-e433-4331-a079-e0a085f625e9" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_d43a7100-a362-4012-ba42-5ca8f9bc3d5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_95774c1a-9a95-4cdd-ac15-98c66dca8e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale_5561b7f1-e433-4331-a079-e0a085f625e9" xlink:to="loc_us-gaap_ReceivablesNetCurrent_95774c1a-9a95-4cdd-ac15-98c66dca8e4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_f35c7b8c-8a2b-45fb-88a0-e0e1caf836cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceCustomerReceivables_7dc8ff0a-f10a-408c-9177-45116ffa9d4d" xlink:href="ci-20231231.xsd#ci_InsuranceCustomerReceivables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ReceivablesNetCurrent_f35c7b8c-8a2b-45fb-88a0-e0e1caf836cd" xlink:to="loc_ci_InsuranceCustomerReceivables_7dc8ff0a-f10a-408c-9177-45116ffa9d4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PharmaceuticalManufacturerReceivable_1d0808c0-e8c6-4021-b67d-340f409d4e7f" xlink:href="ci-20231231.xsd#ci_PharmaceuticalManufacturerReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ReceivablesNetCurrent_f35c7b8c-8a2b-45fb-88a0-e0e1caf836cd" xlink:to="loc_ci_PharmaceuticalManufacturerReceivable_1d0808c0-e8c6-4021-b67d-340f409d4e7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_96e7ba66-ec29-4f75-8404-ed7baf3158d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ReceivablesNetCurrent_f35c7b8c-8a2b-45fb-88a0-e0e1caf836cd" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_96e7ba66-ec29-4f75-8404-ed7baf3158d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable_1ce07fb7-8056-48b9-95d3-1e23156363ed" xlink:href="ci-20231231.xsd#ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ReceivablesNetCurrent_f35c7b8c-8a2b-45fb-88a0-e0e1caf836cd" xlink:to="loc_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable_1ce07fb7-8056-48b9-95d3-1e23156363ed" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails_1" xlink:type="simple" xlink:href="ci-20231231.xsd#AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails_1"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale_e47a6c2c-0f54-4a16-a461-3bee9fa82fc7" xlink:href="ci-20231231.xsd#ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale_d0f9b918-59cb-4ae7-b3a6-66df81b1bab8" xlink:href="ci-20231231.xsd#ci_PharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale_e47a6c2c-0f54-4a16-a461-3bee9fa82fc7" xlink:to="loc_ci_PharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale_d0f9b918-59cb-4ae7-b3a6-66df81b1bab8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale_63ce9a36-4798-494e-ba52-a3de03090a6a" xlink:href="ci-20231231.xsd#ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale_e47a6c2c-0f54-4a16-a461-3bee9fa82fc7" xlink:to="loc_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale_63ce9a36-4798-494e-ba52-a3de03090a6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceCustomerReceivablesBeforeReclassificationToDisposalGroupAssetsHeldForSale_5d1fb874-f081-4c75-967e-679ae8c3a249" xlink:href="ci-20231231.xsd#ci_InsuranceCustomerReceivablesBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale_e47a6c2c-0f54-4a16-a461-3bee9fa82fc7" xlink:to="loc_ci_InsuranceCustomerReceivablesBeforeReclassificationToDisposalGroupAssetsHeldForSale_5d1fb874-f081-4c75-967e-679ae8c3a249" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccountsAndOtherReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale_b8578ecd-ba4c-4396-98ad-c35f8f10970c" xlink:href="ci-20231231.xsd#ci_AccountsAndOtherReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale_e47a6c2c-0f54-4a16-a461-3bee9fa82fc7" xlink:to="loc_ci_AccountsAndOtherReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale_b8578ecd-ba4c-4396-98ad-c35f8f10970c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#AssetsandLiabilitiesofBusinessesHeldforSaleDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1fe92b28-117b-4565-a054-ed1de5e94f47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationLiabilitiesExcludingInsuranceAndContractholderLiabilities_1c40ae60-83f1-44a2-b809-8e53df8ac16c" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationLiabilitiesExcludingInsuranceAndContractholderLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1fe92b28-117b-4565-a054-ed1de5e94f47" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationLiabilitiesExcludingInsuranceAndContractholderLiabilities_1c40ae60-83f1-44a2-b809-8e53df8ac16c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities_8e023a0f-22b0-44a3-95fa-543c677d1108" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1fe92b28-117b-4565-a054-ed1de5e94f47" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities_8e023a0f-22b0-44a3-95fa-543c677d1108" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_ee92dc28-ae2b-422c-b07f-eed3c9f1a155" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_d2f55680-424b-44f4-b994-80eeaeb6ec35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_ee92dc28-ae2b-422c-b07f-eed3c9f1a155" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_d2f55680-424b-44f4-b994-80eeaeb6ec35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationInvestments_97979377-522a-458d-bc7c-3b5a00705032" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_ee92dc28-ae2b-422c-b07f-eed3c9f1a155" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationInvestments_97979377-522a-458d-bc7c-3b5a00705032" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_0e0e7af9-4de5-498a-b80c-44ed15c3a27c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_ee92dc28-ae2b-422c-b07f-eed3c9f1a155" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_0e0e7af9-4de5-498a-b80c-44ed15c3a27c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationOtherAssetsGoodwill_4da30e88-e426-4e41-9e95-a0b9dba6cc25" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationOtherAssetsGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_ee92dc28-ae2b-422c-b07f-eed3c9f1a155" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationOtherAssetsGoodwill_4da30e88-e426-4e41-9e95-a0b9dba6cc25" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_532b6396-a174-419d-a41b-78c30eae08c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1c31ef61-2d8c-43a8-9f9a-565f68f4d448" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_532b6396-a174-419d-a41b-78c30eae08c9" xlink:to="loc_us-gaap_EarningsPerShareBasic_1c31ef61-2d8c-43a8-9f9a-565f68f4d448" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EarningsPerShareEffectOfDilution_5975eeb5-3c38-4129-b629-bb15b7e2ac50" xlink:href="ci-20231231.xsd#ci_EarningsPerShareEffectOfDilution"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_532b6396-a174-419d-a41b-78c30eae08c9" xlink:to="loc_ci_EarningsPerShareEffectOfDilution_5975eeb5-3c38-4129-b629-bb15b7e2ac50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_426188d5-1a83-4633-b49a-b8dc06a865a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_0fc039b8-2a91-4202-8afd-1b227d0ccced" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_426188d5-1a83-4633-b49a-b8dc06a865a8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_0fc039b8-2a91-4202-8afd-1b227d0ccced" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9791b241-6ae7-4690-8692-94768380cbca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_426188d5-1a83-4633-b49a-b8dc06a865a8" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9791b241-6ae7-4690-8692-94768380cbca" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#DebtOutstandingAmountsofDebtandFinanceLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_30a3c193-4599-453d-887c-52d29f6e6c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_0c8a14fe-c285-4e6d-9b31-ec3656b28433" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_30a3c193-4599-453d-887c-52d29f6e6c8f" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_0c8a14fe-c285-4e6d-9b31-ec3656b28433" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebtNoncurrent_c9c2605d-befd-4a22-a83f-7c7ecc0b147f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_30a3c193-4599-453d-887c-52d29f6e6c8f" xlink:to="loc_us-gaap_OtherLongTermDebtNoncurrent_c9c2605d-befd-4a22-a83f-7c7ecc0b147f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_8eb4498c-b20f-42f3-a01d-a7cddd5fd696" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_461e4807-0bcf-427f-94a5-27e452ed8985" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtCurrent_8eb4498c-b20f-42f3-a01d-a7cddd5fd696" xlink:to="loc_us-gaap_LongTermDebtCurrent_461e4807-0bcf-427f-94a5-27e452ed8985" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_6f89a7a1-e084-405c-b9ba-a39b36c98ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaper"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtCurrent_8eb4498c-b20f-42f3-a01d-a7cddd5fd696" xlink:to="loc_us-gaap_CommercialPaper_6f89a7a1-e084-405c-b9ba-a39b36c98ec3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent_d914d29a-009d-4980-97d1-d7d0fde98f4a" xlink:href="ci-20231231.xsd#ci_OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtCurrent_8eb4498c-b20f-42f3-a01d-a7cddd5fd696" xlink:to="loc_ci_OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent_d914d29a-009d-4980-97d1-d7d0fde98f4a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InsuranceandContractholderLiabilitiesAccountBalancesDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_3adb2394-cdf9-49c1-852a-2069ec1d7989" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent_3869c493-3a53-4600-8206-5633773fc975" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_3adb2394-cdf9-49c1-852a-2069ec1d7989" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent_3869c493-3a53-4600-8206-5633773fc975" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent_4fc41d85-0c68-4c1d-8fbe-e441b1fca874" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_3adb2394-cdf9-49c1-852a-2069ec1d7989" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent_4fc41d85-0c68-4c1d-8fbe-e441b1fca874" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups_200d3dc8-2f68-4f83-b595-50165a51d0d9" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInsuranceAndContractholderLiabilities_41ce8585-8485-4e53-818f-dcdc8816147a" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationCurrentInsuranceAndContractholderLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups_200d3dc8-2f68-4f83-b595-50165a51d0d9" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInsuranceAndContractholderLiabilities_41ce8585-8485-4e53-818f-dcdc8816147a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesCurrent_4f884b01-9fee-46e2-8d4d-511ff852d4e1" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups_200d3dc8-2f68-4f83-b595-50165a51d0d9" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesCurrent_4f884b01-9fee-46e2-8d4d-511ff852d4e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitsIncludingDisposalGroups_f48b2326-c4b1-4a2c-9854-e2abccfc6f90" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitsIncludingDisposalGroups"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitsNoncurrentIncludingDisposalGroups_db68d185-5d54-4ff1-bbfd-f9ae4bb8ce8f" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitsNoncurrentIncludingDisposalGroups"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_LiabilityForFuturePolicyBenefitsIncludingDisposalGroups_f48b2326-c4b1-4a2c-9854-e2abccfc6f90" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitsNoncurrentIncludingDisposalGroups_db68d185-5d54-4ff1-bbfd-f9ae4bb8ce8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitsCurrentIncludingDisposalGroups_3271fca4-c548-46a5-8774-d482f2cbbf15" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitsCurrentIncludingDisposalGroups"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_LiabilityForFuturePolicyBenefitsIncludingDisposalGroups_f48b2326-c4b1-4a2c-9854-e2abccfc6f90" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitsCurrentIncludingDisposalGroups_3271fca4-c548-46a5-8774-d482f2cbbf15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesCurrent_a7e85b1c-db8e-487f-b5c8-7aa44dbad187" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositCurrent_1abca529-6899-4803-8085-4523c1f4e362" xlink:href="ci-20231231.xsd#ci_PolicyholderContractDepositCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrent_a7e85b1c-db8e-487f-b5c8-7aa44dbad187" xlink:to="loc_ci_PolicyholderContractDepositCurrent_1abca529-6899-4803-8085-4523c1f4e362" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitLiabilityAmountCurrent_72cc2672-0833-49ad-b4f7-b51419df3864" xlink:href="ci-20231231.xsd#ci_MarketRiskBenefitLiabilityAmountCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrent_a7e85b1c-db8e-487f-b5c8-7aa44dbad187" xlink:to="loc_ci_MarketRiskBenefitLiabilityAmountCurrent_72cc2672-0833-49ad-b4f7-b51419df3864" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent_99a3febb-4d4c-4855-833a-8ce6c12e4613" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrent_a7e85b1c-db8e-487f-b5c8-7aa44dbad187" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent_99a3febb-4d4c-4855-833a-8ce6c12e4613" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent_dd2b32c1-3886-47c4-ad91-21a8a5fcc466" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrent_a7e85b1c-db8e-487f-b5c8-7aa44dbad187" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent_dd2b32c1-3886-47c4-ad91-21a8a5fcc466" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsCurrent_be21be6d-875c-4ccb-bee4-96ff8c5fa0d3" xlink:href="ci-20231231.xsd#ci_UnearnedPremiumsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrent_a7e85b1c-db8e-487f-b5c8-7aa44dbad187" xlink:to="loc_ci_UnearnedPremiumsCurrent_be21be6d-875c-4ccb-bee4-96ff8c5fa0d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilities_37a15ff1-f9c3-4310-8edb-146deb750085" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitLiabilityAmount_f3cf6f69-006e-4ac0-90c4-c2545d4525b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketRiskBenefitLiabilityAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilities_37a15ff1-f9c3-4310-8edb-146deb750085" xlink:to="loc_us-gaap_MarketRiskBenefitLiabilityAmount_f3cf6f69-006e-4ac0-90c4-c2545d4525b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderContractDeposits_4826681b-58b1-465a-bcb6-9bd43f0928df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderContractDeposits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilities_37a15ff1-f9c3-4310-8edb-146deb750085" xlink:to="loc_us-gaap_PolicyholderContractDeposits_4826681b-58b1-465a-bcb6-9bd43f0928df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_52700f8a-2198-4d77-9e53-636184701aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilities_37a15ff1-f9c3-4310-8edb-146deb750085" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_52700f8a-2198-4d77-9e53-636184701aa3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefits_0e141adb-93a0-4389-9be1-7221210cce62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefits"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilities_37a15ff1-f9c3-4310-8edb-146deb750085" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefits_0e141adb-93a0-4389-9be1-7221210cce62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnearnedPremiums_fb50448b-35c1-4c38-8d0b-3da1a25a905b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnearnedPremiums"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilities_37a15ff1-f9c3-4310-8edb-146deb750085" xlink:to="loc_us-gaap_UnearnedPremiums_fb50448b-35c1-4c38-8d0b-3da1a25a905b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefits_fb0ab861-5912-4ab6-b2bf-9d2a4a0fc37e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefits"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent_3e9a6152-7a3d-488c-a695-66428de0f27b" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefits_fb0ab861-5912-4ab6-b2bf-9d2a4a0fc37e" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent_3e9a6152-7a3d-488c-a695-66428de0f27b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent_892a5c17-4038-4834-a651-758fc2091668" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefits_fb0ab861-5912-4ab6-b2bf-9d2a4a0fc37e" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent_892a5c17-4038-4834-a651-758fc2091668" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups_5105a3db-b897-4c4e-bb8c-a82c9ad35e87" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitsIncludingDisposalGroups_9b56653f-8f5c-488b-9999-0b46ca2d6302" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitsIncludingDisposalGroups"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups_5105a3db-b897-4c4e-bb8c-a82c9ad35e87" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitsIncludingDisposalGroups_9b56653f-8f5c-488b-9999-0b46ca2d6302" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsIncludingDisposalGroups_c151dccb-f6e0-4ff4-86e3-d164fa9a08d9" xlink:href="ci-20231231.xsd#ci_UnearnedPremiumsIncludingDisposalGroups"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups_5105a3db-b897-4c4e-bb8c-a82c9ad35e87" xlink:to="loc_ci_UnearnedPremiumsIncludingDisposalGroups_c151dccb-f6e0-4ff4-86e3-d164fa9a08d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_88d36951-c6ae-4300-ad0d-3e700386a405" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups_5105a3db-b897-4c4e-bb8c-a82c9ad35e87" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_88d36951-c6ae-4300-ad0d-3e700386a405" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitLiabilityAmount_c99d558f-336f-42d8-bfc9-9c7ff32085d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketRiskBenefitLiabilityAmount"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups_5105a3db-b897-4c4e-bb8c-a82c9ad35e87" xlink:to="loc_us-gaap_MarketRiskBenefitLiabilityAmount_c99d558f-336f-42d8-bfc9-9c7ff32085d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositsIncludingDisposalGroups_37594b62-c7bc-428a-82e2-9508d439f8c4" xlink:href="ci-20231231.xsd#ci_PolicyholderContractDepositsIncludingDisposalGroups"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups_5105a3db-b897-4c4e-bb8c-a82c9ad35e87" xlink:to="loc_ci_PolicyholderContractDepositsIncludingDisposalGroups_37594b62-c7bc-428a-82e2-9508d439f8c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent_dff80236-9779-4318-86b5-cf415c5841ba" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitLiabilityAmountNoncurrent_11501716-3a38-4903-9f73-82af67c71598" xlink:href="ci-20231231.xsd#ci_MarketRiskBenefitLiabilityAmountNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent_dff80236-9779-4318-86b5-cf415c5841ba" xlink:to="loc_ci_MarketRiskBenefitLiabilityAmountNoncurrent_11501716-3a38-4903-9f73-82af67c71598" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositNoncurrent_c6e3d97c-b2a1-4c0e-a204-78f26c630621" xlink:href="ci-20231231.xsd#ci_PolicyholderContractDepositNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent_dff80236-9779-4318-86b5-cf415c5841ba" xlink:to="loc_ci_PolicyholderContractDepositNoncurrent_c6e3d97c-b2a1-4c0e-a204-78f26c630621" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent_84d301a0-c826-46e8-b6d7-336bc89bdf98" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent_dff80236-9779-4318-86b5-cf415c5841ba" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent_84d301a0-c826-46e8-b6d7-336bc89bdf98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent_88668c7e-753e-48e6-92cc-43a5847e0c25" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent_dff80236-9779-4318-86b5-cf415c5841ba" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent_88668c7e-753e-48e6-92cc-43a5847e0c25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsNoncurrent_3b80e153-bf47-4e2b-be03-346dd3ecf9d6" xlink:href="ci-20231231.xsd#ci_UnearnedPremiumsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent_dff80236-9779-4318-86b5-cf415c5841ba" xlink:to="loc_ci_UnearnedPremiumsNoncurrent_3b80e153-bf47-4e2b-be03-346dd3ecf9d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities_b1576408-326a-4685-9a35-08dc42da0def" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInsuranceAndContractholderLiabilities_02e2a713-40f2-4af1-be62-9af494225b6d" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInsuranceAndContractholderLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities_b1576408-326a-4685-9a35-08dc42da0def" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInsuranceAndContractholderLiabilities_02e2a713-40f2-4af1-be62-9af494225b6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInsuranceAndContractholderLiabilities_119a961e-b625-4cb3-81cb-d4debc788de4" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationCurrentInsuranceAndContractholderLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities_b1576408-326a-4685-9a35-08dc42da0def" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInsuranceAndContractholderLiabilities_119a961e-b625-4cb3-81cb-d4debc788de4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitLiabilityAmount_6fc8bc20-ad81-4e87-bb31-ce7fb87f9210" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketRiskBenefitLiabilityAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitLiabilityAmountNoncurrent_4b07d15d-6626-4538-a018-53911ea3dbb6" xlink:href="ci-20231231.xsd#ci_MarketRiskBenefitLiabilityAmountNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_MarketRiskBenefitLiabilityAmount_6fc8bc20-ad81-4e87-bb31-ce7fb87f9210" xlink:to="loc_ci_MarketRiskBenefitLiabilityAmountNoncurrent_4b07d15d-6626-4538-a018-53911ea3dbb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitLiabilityAmountCurrent_477879b6-ecb5-4af5-9cf3-5b322edb839e" xlink:href="ci-20231231.xsd#ci_MarketRiskBenefitLiabilityAmountCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_MarketRiskBenefitLiabilityAmount_6fc8bc20-ad81-4e87-bb31-ce7fb87f9210" xlink:to="loc_ci_MarketRiskBenefitLiabilityAmountCurrent_477879b6-ecb5-4af5-9cf3-5b322edb839e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_a31b8cf9-d0aa-4f4e-b869-81c03539da88" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrentIncludingDisposalGroups_c522c471-c5c2-42ba-b565-82aaef302804" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrentIncludingDisposalGroups"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_a31b8cf9-d0aa-4f4e-b869-81c03539da88" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrentIncludingDisposalGroups_c522c471-c5c2-42ba-b565-82aaef302804" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrentIncludingDisposalGroups_5a62cfb4-092d-4654-b24c-0fd3948aa420" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrentIncludingDisposalGroups"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_a31b8cf9-d0aa-4f4e-b869-81c03539da88" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrentIncludingDisposalGroups_5a62cfb4-092d-4654-b24c-0fd3948aa420" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositsIncludingDisposalGroups_aa312514-132d-4ab3-9a6d-2326681523ae" xlink:href="ci-20231231.xsd#ci_PolicyholderContractDepositsIncludingDisposalGroups"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositNoncurrentIncludingDisposalGroups_91675455-f309-46ef-b41c-19f5883c6ba7" xlink:href="ci-20231231.xsd#ci_PolicyholderContractDepositNoncurrentIncludingDisposalGroups"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_PolicyholderContractDepositsIncludingDisposalGroups_aa312514-132d-4ab3-9a6d-2326681523ae" xlink:to="loc_ci_PolicyholderContractDepositNoncurrentIncludingDisposalGroups_91675455-f309-46ef-b41c-19f5883c6ba7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositCurrentIncludingDisposalGroups_d3220995-4a98-48de-b64d-431a94152b74" xlink:href="ci-20231231.xsd#ci_PolicyholderContractDepositCurrentIncludingDisposalGroups"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_PolicyholderContractDepositsIncludingDisposalGroups_aa312514-132d-4ab3-9a6d-2326681523ae" xlink:to="loc_ci_PolicyholderContractDepositCurrentIncludingDisposalGroups_d3220995-4a98-48de-b64d-431a94152b74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderContractDeposits_3ae1dbe4-9be0-4c08-882f-0b5e9de57fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderContractDeposits"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositNoncurrent_4915870f-3e88-4b64-8ff1-ec1778ce0888" xlink:href="ci-20231231.xsd#ci_PolicyholderContractDepositNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PolicyholderContractDeposits_3ae1dbe4-9be0-4c08-882f-0b5e9de57fa5" xlink:to="loc_ci_PolicyholderContractDepositNoncurrent_4915870f-3e88-4b64-8ff1-ec1778ce0888" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositCurrent_cd00c351-3526-4e84-b34d-f6d7bb1d3c9b" xlink:href="ci-20231231.xsd#ci_PolicyholderContractDepositCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PolicyholderContractDeposits_3ae1dbe4-9be0-4c08-882f-0b5e9de57fa5" xlink:to="loc_ci_PolicyholderContractDepositCurrent_cd00c351-3526-4e84-b34d-f6d7bb1d3c9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnearnedPremiums_95cd2851-7de3-431f-9850-c635d9b85b76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnearnedPremiums"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsNoncurrent_cc968a7b-6e04-4522-886e-651879ca96ec" xlink:href="ci-20231231.xsd#ci_UnearnedPremiumsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_UnearnedPremiums_95cd2851-7de3-431f-9850-c635d9b85b76" xlink:to="loc_ci_UnearnedPremiumsNoncurrent_cc968a7b-6e04-4522-886e-651879ca96ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsCurrent_3cddb9f6-ca51-4216-97ab-3d31773469b6" xlink:href="ci-20231231.xsd#ci_UnearnedPremiumsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_UnearnedPremiums_95cd2851-7de3-431f-9850-c635d9b85b76" xlink:to="loc_ci_UnearnedPremiumsCurrent_3cddb9f6-ca51-4216-97ab-3d31773469b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups_e558fff9-7bfd-4a1a-b7d1-ae9bd6bf0622" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrentIncludingDisposalGroups_2c70cc75-986e-45ad-b988-6850d6ddf3a3" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrentIncludingDisposalGroups"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups_e558fff9-7bfd-4a1a-b7d1-ae9bd6bf0622" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrentIncludingDisposalGroups_2c70cc75-986e-45ad-b988-6850d6ddf3a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitsNoncurrentIncludingDisposalGroups_ec65ffdc-9702-42ea-9bb7-cba6134e31b4" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitsNoncurrentIncludingDisposalGroups"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups_e558fff9-7bfd-4a1a-b7d1-ae9bd6bf0622" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitsNoncurrentIncludingDisposalGroups_ec65ffdc-9702-42ea-9bb7-cba6134e31b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositNoncurrentIncludingDisposalGroups_abadb36d-d577-4bb6-8193-da2f23ae071f" xlink:href="ci-20231231.xsd#ci_PolicyholderContractDepositNoncurrentIncludingDisposalGroups"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups_e558fff9-7bfd-4a1a-b7d1-ae9bd6bf0622" xlink:to="loc_ci_PolicyholderContractDepositNoncurrentIncludingDisposalGroups_abadb36d-d577-4bb6-8193-da2f23ae071f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitLiabilityAmountNoncurrent_61a3ca2f-b833-4e63-8bd5-267eaf4b1185" xlink:href="ci-20231231.xsd#ci_MarketRiskBenefitLiabilityAmountNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups_e558fff9-7bfd-4a1a-b7d1-ae9bd6bf0622" xlink:to="loc_ci_MarketRiskBenefitLiabilityAmountNoncurrent_61a3ca2f-b833-4e63-8bd5-267eaf4b1185" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsNoncurrentIncludingDisposalGroups_d1f19765-13d3-4819-aa8d-6879a9321143" xlink:href="ci-20231231.xsd#ci_UnearnedPremiumsNoncurrentIncludingDisposalGroups"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups_e558fff9-7bfd-4a1a-b7d1-ae9bd6bf0622" xlink:to="loc_ci_UnearnedPremiumsNoncurrentIncludingDisposalGroups_d1f19765-13d3-4819-aa8d-6879a9321143" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsIncludingDisposalGroups_8567e64c-85c9-4d28-82d1-44e4e960fbc4" xlink:href="ci-20231231.xsd#ci_UnearnedPremiumsIncludingDisposalGroups"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsNoncurrentIncludingDisposalGroups_b3d18117-d2b1-4f7c-95aa-e00ae3816bd9" xlink:href="ci-20231231.xsd#ci_UnearnedPremiumsNoncurrentIncludingDisposalGroups"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_UnearnedPremiumsIncludingDisposalGroups_8567e64c-85c9-4d28-82d1-44e4e960fbc4" xlink:to="loc_ci_UnearnedPremiumsNoncurrentIncludingDisposalGroups_b3d18117-d2b1-4f7c-95aa-e00ae3816bd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsCurrentIncludingDisposalGroups_72cdb1be-3156-4aff-86da-3bb92c9d7a0c" xlink:href="ci-20231231.xsd#ci_UnearnedPremiumsCurrentIncludingDisposalGroups"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_UnearnedPremiumsIncludingDisposalGroups_8567e64c-85c9-4d28-82d1-44e4e960fbc4" xlink:to="loc_ci_UnearnedPremiumsCurrentIncludingDisposalGroups_72cdb1be-3156-4aff-86da-3bb92c9d7a0c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails_1" xlink:type="simple" xlink:href="ci-20231231.xsd#InsuranceandContractholderLiabilitiesAccountBalancesDetails_1"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilities_efb25f26-6f46-4bfa-9f9b-c9a7e7aba7d6" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent_14b74421-a733-42ec-9a97-d0dc46ced50f" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilities_efb25f26-6f46-4bfa-9f9b-c9a7e7aba7d6" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent_14b74421-a733-42ec-9a97-d0dc46ced50f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesCurrent_cf587999-4929-4eb7-8ff8-ea8d7ec8f368" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilities_efb25f26-6f46-4bfa-9f9b-c9a7e7aba7d6" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesCurrent_cf587999-4929-4eb7-8ff8-ea8d7ec8f368" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups_d8213546-d25d-4af5-af4a-e9b478d208bf" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups_2de4008e-a164-4917-9f94-fc2b002d83f3" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups_d8213546-d25d-4af5-af4a-e9b478d208bf" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups_2de4008e-a164-4917-9f94-fc2b002d83f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups_c4f0aacb-80b7-42f7-a21b-823d738f791a" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups_d8213546-d25d-4af5-af4a-e9b478d208bf" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups_c4f0aacb-80b7-42f7-a21b-823d738f791a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups_a54b6a7e-e4cc-4b27-9a8a-7b3a4e55d69a" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrentIncludingDisposalGroups_775ee9cd-465b-406b-8fee-1f2f93d1e9eb" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrentIncludingDisposalGroups"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups_a54b6a7e-e4cc-4b27-9a8a-7b3a4e55d69a" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrentIncludingDisposalGroups_775ee9cd-465b-406b-8fee-1f2f93d1e9eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitsCurrentIncludingDisposalGroups_82d98db8-cde9-4eb5-a73d-d478a4b3f3a8" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitsCurrentIncludingDisposalGroups"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups_a54b6a7e-e4cc-4b27-9a8a-7b3a4e55d69a" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitsCurrentIncludingDisposalGroups_82d98db8-cde9-4eb5-a73d-d478a4b3f3a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositCurrentIncludingDisposalGroups_ed09cecd-08c3-4ea0-80b9-e93deba5b9c9" xlink:href="ci-20231231.xsd#ci_PolicyholderContractDepositCurrentIncludingDisposalGroups"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups_a54b6a7e-e4cc-4b27-9a8a-7b3a4e55d69a" xlink:to="loc_ci_PolicyholderContractDepositCurrentIncludingDisposalGroups_ed09cecd-08c3-4ea0-80b9-e93deba5b9c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitLiabilityAmountCurrent_82794670-efe6-4924-baf5-de5813290bb3" xlink:href="ci-20231231.xsd#ci_MarketRiskBenefitLiabilityAmountCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups_a54b6a7e-e4cc-4b27-9a8a-7b3a4e55d69a" xlink:to="loc_ci_MarketRiskBenefitLiabilityAmountCurrent_82794670-efe6-4924-baf5-de5813290bb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsCurrentIncludingDisposalGroups_ca1e086f-5ae1-4134-b325-eae71aad46b4" xlink:href="ci-20231231.xsd#ci_UnearnedPremiumsCurrentIncludingDisposalGroups"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups_a54b6a7e-e4cc-4b27-9a8a-7b3a4e55d69a" xlink:to="loc_ci_UnearnedPremiumsCurrentIncludingDisposalGroups_ca1e086f-5ae1-4134-b325-eae71aad46b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups_537391dc-6d47-41c9-9101-07ab71a9b205" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInsuranceAndContractholderLiabilities_2717dd35-a8e6-4b14-99d7-acf7086717ca" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInsuranceAndContractholderLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups_537391dc-6d47-41c9-9101-07ab71a9b205" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInsuranceAndContractholderLiabilities_2717dd35-a8e6-4b14-99d7-acf7086717ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent_cb736e1f-8e8f-4207-ba22-9f44ca9c15fb" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups_537391dc-6d47-41c9-9101-07ab71a9b205" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent_cb736e1f-8e8f-4207-ba22-9f44ca9c15fb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails_2" xlink:type="simple" xlink:href="ci-20231231.xsd#InsuranceandContractholderLiabilitiesAccountBalancesDetails_2"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails_2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups_9193b3f9-ea98-457b-b7d0-ffb050576c3f" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities_bee081da-cd01-4ef1-9581-31a03a2757ee" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups_9193b3f9-ea98-457b-b7d0-ffb050576c3f" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities_bee081da-cd01-4ef1-9581-31a03a2757ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilities_9f58a729-5889-4e3a-a74a-75c047897690" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups_9193b3f9-ea98-457b-b7d0-ffb050576c3f" xlink:to="loc_ci_InsuranceAndContractholderLiabilities_9f58a729-5889-4e3a-a74a-75c047897690" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_390be577-493a-4117-8c7c-ab6fcfe751aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_567d4e08-8002-472b-bf2d-96518d8624df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_390be577-493a-4117-8c7c-ab6fcfe751aa" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_567d4e08-8002-472b-bf2d-96518d8624df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_990f65c3-080a-490c-a881-d9274714c9ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_390be577-493a-4117-8c7c-ab6fcfe751aa" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_990f65c3-080a-490c-a881-d9274714c9ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_2fe06331-007c-44c0-ae0c-198d2ff41c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_7c80000a-caf9-484a-8188-78f9c8f2b9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_2fe06331-007c-44c0-ae0c-198d2ff41c9d" xlink:to="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_7c80000a-caf9-484a-8188-78f9c8f2b9d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_90a8fcf0-7860-4ae3-9406-fe47e8d75d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_2fe06331-007c-44c0-ae0c-198d2ff41c9d" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_90a8fcf0-7860-4ae3-9406-fe47e8d75d8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_ea6acf00-51db-423a-a1a4-d0d976566023" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_210173a5-092b-4df4-86d5-fd928487b872" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_ea6acf00-51db-423a-a1a4-d0d976566023" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_210173a5-092b-4df4-86d5-fd928487b872" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_c3a92718-0b52-4b15-ad87-c0ffa2814545" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_ea6acf00-51db-423a-a1a4-d0d976566023" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_c3a92718-0b52-4b15-ad87-c0ffa2814545" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_3b633512-7ae5-4ca5-9cf3-1ba89bc93dd6" xlink:href="ci-20231231.xsd#ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_93b9335c-3a6f-4614-b602-3b55b78c652f" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_3b633512-7ae5-4ca5-9cf3-1ba89bc93dd6" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_93b9335c-3a6f-4614-b602-3b55b78c652f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups_48ab2b2c-3fcb-4f5e-873a-45339d9add58" xlink:href="ci-20231231.xsd#ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_3b633512-7ae5-4ca5-9cf3-1ba89bc93dd6" xlink:to="loc_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups_48ab2b2c-3fcb-4f5e-873a-45339d9add58" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_5b6878ae-6362-4502-88ec-f68f896f0308" xlink:href="ci-20231231.xsd#ci_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_38195b7f-eeaa-43f2-8532-eec8a6abead9" xlink:href="ci-20231231.xsd#ci_ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_5b6878ae-6362-4502-88ec-f68f896f0308" xlink:to="loc_ci_ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_38195b7f-eeaa-43f2-8532-eec8a6abead9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_4e99e578-025e-4b8c-8155-145398af1bad" xlink:href="ci-20231231.xsd#ci_ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_5b6878ae-6362-4502-88ec-f68f896f0308" xlink:to="loc_ci_ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_4e99e578-025e-4b8c-8155-145398af1bad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_f63cf7e7-9e06-4618-bb65-3d2ad86990b1" xlink:href="ci-20231231.xsd#ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_cbf07a17-5b83-45f9-ba6b-1bb0a852afa9" xlink:href="ci-20231231.xsd#ci_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_f63cf7e7-9e06-4618-bb65-3d2ad86990b1" xlink:to="loc_ci_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_cbf07a17-5b83-45f9-ba6b-1bb0a852afa9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseLongDurationNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_5468eb28-da3c-4e77-8d76-822a52c2a2e5" xlink:href="ci-20231231.xsd#ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseLongDurationNetBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_f63cf7e7-9e06-4618-bb65-3d2ad86990b1" xlink:to="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseLongDurationNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_5468eb28-da3c-4e77-8d76-822a52c2a2e5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance_610211a4-7399-404e-a17f-ab8d85fe6a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax_191f0ee7-b595-4b47-b736-689c837d0972" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance_610211a4-7399-404e-a17f-ab8d85fe6a1a" xlink:to="loc_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax_191f0ee7-b595-4b47-b736-689c837d0972" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange_6088ae70-24e3-49d4-825a-d687eb029b31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance_610211a4-7399-404e-a17f-ab8d85fe6a1a" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange_6088ae70-24e3-49d4-825a-d687eb029b31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther_d6704201-6aca-4d87-ab6b-e24816c94659" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange_9d46a43b-26d6-4379-9836-d3ed1ef5fbb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther_d6704201-6aca-4d87-ab6b-e24816c94659" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange_9d46a43b-26d6-4379-9836-d3ed1ef5fbb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange_e87f2d59-0a26-4e9d-bab7-21394f608e58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther_d6704201-6aca-4d87-ab6b-e24816c94659" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange_e87f2d59-0a26-4e9d-bab7-21394f608e58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceBeforeReclassificationToDisposalGroupAssetsHeldForSale_1c457472-5b14-4696-b13a-07358e42af5b" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther_e648ca9c-3ad8-4dbf-b359-4c4f8999a5cb" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceBeforeReclassificationToDisposalGroupAssetsHeldForSale_1c457472-5b14-4696-b13a-07358e42af5b" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther_e648ca9c-3ad8-4dbf-b359-4c4f8999a5cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitOther_ac47fed7-2d34-4290-9c4c-52a02db9d8cc" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceBeforeReclassificationToDisposalGroupAssetsHeldForSale_1c457472-5b14-4696-b13a-07358e42af5b" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitOther_ac47fed7-2d34-4290-9c4c-52a02db9d8cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance_8583985b-4d1f-4e7d-b73a-229840b89ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange_172a4b16-8218-49ec-8cb5-a6804b72b215" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance_8583985b-4d1f-4e7d-b73a-229840b89ac7" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange_172a4b16-8218-49ec-8cb5-a6804b72b215" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax_ac091009-d589-43c3-89f7-bea8f0857e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance_8583985b-4d1f-4e7d-b73a-229840b89ac7" xlink:to="loc_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax_ac091009-d589-43c3-89f7-bea8f0857e0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefits_df522994-22ba-4bd1-8695-2d17b8fa1fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefits"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitOther_4868a065-93ac-4ede-8980-02bf0a2a538a" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefits_df522994-22ba-4bd1-8695-2d17b8fa1fe7" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitOther_4868a065-93ac-4ede-8980-02bf0a2a538a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther_7bb1adea-7b86-407c-8027-6e090c1a543c" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefits_df522994-22ba-4bd1-8695-2d17b8fa1fe7" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther_7bb1adea-7b86-407c-8027-6e090c1a543c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesSummaryofMarketRiskBenefitDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InsuranceandContractholderLiabilitiesSummaryofMarketRiskBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesSummaryofMarketRiskBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange_242487e2-ee48-42eb-b4a7-a3051d36b76e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax_1302b7ea-00cb-4bd3-9974-52b16416eb81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange_242487e2-ee48-42eb-b4a7-a3051d36b76e" xlink:to="loc_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax_1302b7ea-00cb-4bd3-9974-52b16416eb81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk_e7fff091-720e-449f-820f-c4c2c7580fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange_242487e2-ee48-42eb-b4a7-a3051d36b76e" xlink:to="loc_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk_e7fff091-720e-449f-820f-c4c2c7580fa1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#ReinsuranceReinsuranceRecoverablesDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale_3920ae37-13f8-4d19-9e43-b7240798e5ab" xlink:href="ci-20231231.xsd#ci_ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance_ac13bc52-85e3-466c-a7d2-bbd009ea5bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale_3920ae37-13f8-4d19-9e43-b7240798e5ab" xlink:to="loc_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance_ac13bc52-85e3-466c-a7d2-bbd009ea5bd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale_ba810666-79bc-4f92-99e1-6dfecdebb0fd" xlink:href="ci-20231231.xsd#ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale_3920ae37-13f8-4d19-9e43-b7240798e5ab" xlink:to="loc_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale_ba810666-79bc-4f92-99e1-6dfecdebb0fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverableAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_a0943493-23a6-4661-ac96-55948aad4cdd" xlink:href="ci-20231231.xsd#ci_ReinsuranceRecoverableAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale_3920ae37-13f8-4d19-9e43-b7240798e5ab" xlink:to="loc_ci_ReinsuranceRecoverableAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_a0943493-23a6-4661-ac96-55948aad4cdd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ReinsuranceEffectsofReinsuranceDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#ReinsuranceEffectsofReinsuranceDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/ReinsuranceEffectsofReinsuranceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_43091267-8a1f-4a01-8e24-cbf456eb92c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumedPremiumsEarned_239d4574-cecd-44c2-834f-f56bd889ed95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssumedPremiumsEarned"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PremiumsEarnedNet_43091267-8a1f-4a01-8e24-cbf456eb92c0" xlink:to="loc_us-gaap_AssumedPremiumsEarned_239d4574-cecd-44c2-834f-f56bd889ed95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectPremiumsEarned_4e204726-6356-4add-bdf5-9635579d12e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DirectPremiumsEarned"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PremiumsEarnedNet_43091267-8a1f-4a01-8e24-cbf456eb92c0" xlink:to="loc_us-gaap_DirectPremiumsEarned_4e204726-6356-4add-bdf5-9635579d12e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededPremiumsEarned_3f71b4a7-2dfd-4bdf-9b60-a62c4d89001f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededPremiumsEarned"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PremiumsEarnedNet_43091267-8a1f-4a01-8e24-cbf456eb92c0" xlink:to="loc_us-gaap_CededPremiumsEarned_3f71b4a7-2dfd-4bdf-9b60-a62c4d89001f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InvestmentsInvestmentsbyCategoryDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_864badce-7967-4895-bcec-59a5eac98323" xlink:href="ci-20231231.xsd#ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent_5474430d-305b-46e0-aae2-af14a1641a10" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_864badce-7967-4895-bcec-59a5eac98323" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent_5474430d-305b-46e0-aae2-af14a1641a10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_39b2ad2c-0971-40cb-973b-8fd20af435f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_864badce-7967-4895-bcec-59a5eac98323" xlink:to="loc_us-gaap_LongTermInvestments_39b2ad2c-0971-40cb-973b-8fd20af435f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_87546bb7-b416-403e-b3d2-d72e07fc2d7b" xlink:href="ci-20231231.xsd#ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_2710847f-7788-4549-bd53-71b6389443f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_87546bb7-b416-403e-b3d2-d72e07fc2d7b" xlink:to="loc_us-gaap_Investments_2710847f-7788-4549-bd53-71b6389443f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationInvestments_2038a81c-750a-419d-af74-b1de0d6b2b10" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_87546bb7-b416-403e-b3d2-d72e07fc2d7b" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationInvestments_2038a81c-750a-419d-af74-b1de0d6b2b10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationInvestments_e731922b-21c9-46fa-bf56-879230a6a619" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent_0a13ad53-4ea4-4641-96ee-bf1ffe64ba98" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DisposalGroupIncludingDiscontinuedOperationInvestments_e731922b-21c9-46fa-bf56-879230a6a619" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent_0a13ad53-4ea4-4641-96ee-bf1ffe64ba98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent_54a2cbcb-1135-460c-a0e0-c34116f7c8c3" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DisposalGroupIncludingDiscontinuedOperationInvestments_e731922b-21c9-46fa-bf56-879230a6a619" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent_54a2cbcb-1135-460c-a0e0-c34116f7c8c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_556a2b8b-6bf7-4f84-bda7-24236289df5d" xlink:href="ci-20231231.xsd#ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent_8a5449a1-85cd-4e1d-ad19-c6a64f78a6db" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_556a2b8b-6bf7-4f84-bda7-24236289df5d" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent_8a5449a1-85cd-4e1d-ad19-c6a64f78a6db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_ed8a1d73-0cc8-45cb-b68c-13aaa67a35a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_556a2b8b-6bf7-4f84-bda7-24236289df5d" xlink:to="loc_us-gaap_ShortTermInvestments_ed8a1d73-0cc8-45cb-b68c-13aaa67a35a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_4045aaf6-8129-49b0-b52e-c0617590526c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_567033c2-0314-4e4a-a04f-d5b056c842a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Investments_4045aaf6-8129-49b0-b52e-c0617590526c" xlink:to="loc_us-gaap_ShortTermInvestments_567033c2-0314-4e4a-a04f-d5b056c842a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_d1e257f3-d74b-402a-9120-466537561755" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Investments_4045aaf6-8129-49b0-b52e-c0617590526c" xlink:to="loc_us-gaap_LongTermInvestments_d1e257f3-d74b-402a-9120-466537561755" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails_1" xlink:type="simple" xlink:href="ci-20231231.xsd#InvestmentsInvestmentsbyCategoryDetails_1"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_1be6177d-f7ff-443d-8c27-7109470999e7" xlink:href="ci-20231231.xsd#ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_070f70c3-eca5-41aa-b09e-5d0ade28faf5" xlink:href="ci-20231231.xsd#ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_1be6177d-f7ff-443d-8c27-7109470999e7" xlink:to="loc_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_070f70c3-eca5-41aa-b09e-5d0ade28faf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_a57ff262-3e66-44af-8691-8ea3480ab824" xlink:href="ci-20231231.xsd#ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_1be6177d-f7ff-443d-8c27-7109470999e7" xlink:to="loc_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_a57ff262-3e66-44af-8691-8ea3480ab824" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_d7c3c0f0-0e7b-4697-8a18-0bab70c7c395" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale_c834a920-f770-4870-b574-14000d6fc5e0" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_d7c3c0f0-0e7b-4697-8a18-0bab70c7c395" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale_c834a920-f770-4870-b574-14000d6fc5e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale_5d7a0e1a-7610-486c-b979-8dca99ab975b" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_d7c3c0f0-0e7b-4697-8a18-0bab70c7c395" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale_5d7a0e1a-7610-486c-b979-8dca99ab975b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale_5b284034-4683-4410-894b-51b8d6f7c217" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_d7c3c0f0-0e7b-4697-8a18-0bab70c7c395" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale_5b284034-4683-4410-894b-51b8d6f7c217" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale_af481040-46a4-4958-bb1d-f5d86d6cf3ea" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_d7c3c0f0-0e7b-4697-8a18-0bab70c7c395" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale_af481040-46a4-4958-bb1d-f5d86d6cf3ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_1b3a272a-64f3-4aad-820d-b9c58d5b592a" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_d7c3c0f0-0e7b-4697-8a18-0bab70c7c395" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_1b3a272a-64f3-4aad-820d-b9c58d5b592a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_a2ef7a06-2f4f-485e-a3ca-b8ed933ea5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_5658ff51-4934-430c-9b63-507046f4d2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_a2ef7a06-2f4f-485e-a3ca-b8ed933ea5d5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_5658ff51-4934-430c-9b63-507046f4d2d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_5d3f0563-0756-4053-b704-e046b50f863c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_a2ef7a06-2f4f-485e-a3ca-b8ed933ea5d5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_5d3f0563-0756-4053-b704-e046b50f863c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_075b897b-4e61-415b-8301-d3797b467d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_a2ef7a06-2f4f-485e-a3ca-b8ed933ea5d5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_075b897b-4e61-415b-8301-d3797b467d7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_44bb656c-ad60-477d-ad70-fc3dca71a0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_a2ef7a06-2f4f-485e-a3ca-b8ed933ea5d5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_44bb656c-ad60-477d-ad70-fc3dca71a0b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_9506dcde-1c42-419e-b2b5-6beeed17839c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_a2ef7a06-2f4f-485e-a3ca-b8ed933ea5d5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_9506dcde-1c42-419e-b2b5-6beeed17839c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_80956851-d85f-497b-86d2-994f8dcb8229" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost_19b31983-1955-4cbd-ae91-7029ee79a397" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_80956851-d85f-497b-86d2-994f8dcb8229" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost_19b31983-1955-4cbd-ae91-7029ee79a397" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_1dc10d27-d1e1-4925-8ad2-807b4f083e35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_80956851-d85f-497b-86d2-994f8dcb8229" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_1dc10d27-d1e1-4925-8ad2-807b4f083e35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_56dc1e3f-a098-473c-9032-73113e76229b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_80956851-d85f-497b-86d2-994f8dcb8229" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_56dc1e3f-a098-473c-9032-73113e76229b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_052b54fb-a3c6-439d-92d4-7ff7aaac94bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_80956851-d85f-497b-86d2-994f8dcb8229" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_052b54fb-a3c6-439d-92d4-7ff7aaac94bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_ba9b6848-a40e-4c84-ab32-32f8bb39f534" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_80956851-d85f-497b-86d2-994f8dcb8229" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_ba9b6848-a40e-4c84-ab32-32f8bb39f534" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale_0440259d-bf30-4158-a930-e5b03298ae20" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale_7f88233b-cb99-4bd2-b464-8477212a5c97" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale_0440259d-bf30-4158-a930-e5b03298ae20" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale_7f88233b-cb99-4bd2-b464-8477212a5c97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale_774489d2-8cfe-49d5-b60d-29bff5740284" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale_0440259d-bf30-4158-a930-e5b03298ae20" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale_774489d2-8cfe-49d5-b60d-29bff5740284" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale_1551b52f-251d-494a-aaec-d73eb2f6b7fc" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale_0440259d-bf30-4158-a930-e5b03298ae20" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale_1551b52f-251d-494a-aaec-d73eb2f6b7fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale_d94dd723-b926-4eed-ba4e-3d3b56080c16" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale_0440259d-bf30-4158-a930-e5b03298ae20" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale_d94dd723-b926-4eed-ba4e-3d3b56080c16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_17d28ec7-1f64-4060-8229-31c234126aeb" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale_0440259d-bf30-4158-a930-e5b03298ae20" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_17d28ec7-1f64-4060-8229-31c234126aeb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InvestmentsDebtSecuritieswithaDeclineinFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost_91dcab80-3923-429c-a9a0-6ee6644788ad" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_ec02cc1e-d9af-4997-bc4a-26a257ca969a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost_91dcab80-3923-429c-a9a0-6ee6644788ad" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_ec02cc1e-d9af-4997-bc4a-26a257ca969a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_26f6e298-cb7e-45d4-82a0-815cbab74bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost_91dcab80-3923-429c-a9a0-6ee6644788ad" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_26f6e298-cb7e-45d4-82a0-815cbab74bb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_a5942913-9cf7-4547-b33b-00fb725cfc4c" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_025a2da4-bfc3-4b48-8e33-600967703403" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_a5942913-9cf7-4547-b33b-00fb725cfc4c" xlink:to="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_025a2da4-bfc3-4b48-8e33-600967703403" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_9bf89783-562b-4396-8064-a398b8d86248" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_a5942913-9cf7-4547-b33b-00fb725cfc4c" xlink:to="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_9bf89783-562b-4396-8064-a398b8d86248" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_7472030d-5a6c-4ce6-9ba3-b02c5c57a946" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_9629cbb2-58d2-48b8-b4d0-c94afeffdae1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_7472030d-5a6c-4ce6-9ba3-b02c5c57a946" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_9629cbb2-58d2-48b8-b4d0-c94afeffdae1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_91646c1a-8a78-41ed-9411-1b887020bea6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_7472030d-5a6c-4ce6-9ba3-b02c5c57a946" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_91646c1a-8a78-41ed-9411-1b887020bea6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost_ff2616be-087d-460b-bd1a-3896400d4aaf" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_0eee6b90-e11c-46a0-862c-b23f3d63efb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost_ff2616be-087d-460b-bd1a-3896400d4aaf" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_0eee6b90-e11c-46a0-862c-b23f3d63efb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_b7497405-e37f-4874-9319-ef1f51dad779" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost_ff2616be-087d-460b-bd1a-3896400d4aaf" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_b7497405-e37f-4874-9319-ef1f51dad779" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_419e1495-0894-4bc3-a2cd-af5f73698ba5" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_e92e8b4a-6917-43e2-a8c4-1d5e01a39e02" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_419e1495-0894-4bc3-a2cd-af5f73698ba5" xlink:to="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_e92e8b4a-6917-43e2-a8c4-1d5e01a39e02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_7f78d3ee-d3fc-4afc-a708-760586621c8c" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_419e1495-0894-4bc3-a2cd-af5f73698ba5" xlink:to="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_7f78d3ee-d3fc-4afc-a708-760586621c8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_35e9a34b-58f5-4bed-b81f-07b8edea8159" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_451f9423-c7c7-48f8-8148-a4ab034f0720" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_35e9a34b-58f5-4bed-b81f-07b8edea8159" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_451f9423-c7c7-48f8-8148-a4ab034f0720" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_4d204f24-e2b8-4f85-b1b2-0070477167a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_35e9a34b-58f5-4bed-b81f-07b8edea8159" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_4d204f24-e2b8-4f85-b1b2-0070477167a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale_dbf03247-ced3-459b-9267-2bf00cc7efa5" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_1427a65b-3fff-480d-bdb8-3b24f69c184c" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale_dbf03247-ced3-459b-9267-2bf00cc7efa5" xlink:to="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_1427a65b-3fff-480d-bdb8-3b24f69c184c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_0b3e6a5a-664a-4b59-957e-be9c66d7ad10" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale_dbf03247-ced3-459b-9267-2bf00cc7efa5" xlink:to="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_0b3e6a5a-664a-4b59-957e-be9c66d7ad10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_54377d23-8db2-490c-9685-fd489de1ae00" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_ae631362-e271-4d43-90f4-efbc65022673" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_54377d23-8db2-490c-9685-fd489de1ae00" xlink:to="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_ae631362-e271-4d43-90f4-efbc65022673" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_28c38e91-ce5d-4fe4-9c6d-770f34700c02" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_54377d23-8db2-490c-9685-fd489de1ae00" xlink:to="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_28c38e91-ce5d-4fe4-9c6d-770f34700c02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale_e1e5288f-f30f-496f-b739-23aafc1c3685" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureTwelveMonthsOrLongerNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale_d9255213-1c04-4de1-a17b-d8dec7c49089" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureTwelveMonthsOrLongerNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale_e1e5288f-f30f-496f-b739-23aafc1c3685" xlink:to="loc_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureTwelveMonthsOrLongerNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale_d9255213-1c04-4de1-a17b-d8dec7c49089" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureLessThan12MonthsNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale_86c2f930-99a3-4331-9900-f2153862d829" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureLessThan12MonthsNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale_e1e5288f-f30f-496f-b739-23aafc1c3685" xlink:to="loc_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureLessThan12MonthsNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale_86c2f930-99a3-4331-9900-f2153862d829" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_d119d872-288d-466c-aedb-80840a3276df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_449a8a01-183f-4bbf-971f-100bb122e9b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_d119d872-288d-466c-aedb-80840a3276df" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_449a8a01-183f-4bbf-971f-100bb122e9b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_d4067f2e-38d6-47e1-85a5-2be6fec3c8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_d119d872-288d-466c-aedb-80840a3276df" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_d4067f2e-38d6-47e1-85a5-2be6fec3c8c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost_5481ca12-8736-40fa-bbf8-90c43ef86150" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_27eb8ab8-4bd3-48a6-bb1d-eb820f18bc16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost_5481ca12-8736-40fa-bbf8-90c43ef86150" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_27eb8ab8-4bd3-48a6-bb1d-eb820f18bc16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_d6b407c6-f6cd-497d-9eee-a9b22c88b482" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost_5481ca12-8736-40fa-bbf8-90c43ef86150" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_d6b407c6-f6cd-497d-9eee-a9b22c88b482" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_6966ba95-2d88-46dd-8107-7563cb47a463" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_7224c45a-a345-4454-8288-b802e44cdb81" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_6966ba95-2d88-46dd-8107-7563cb47a463" xlink:to="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_7224c45a-a345-4454-8288-b802e44cdb81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_dca51c68-034c-41de-962d-17da04d56498" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_6966ba95-2d88-46dd-8107-7563cb47a463" xlink:to="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_dca51c68-034c-41de-962d-17da04d56498" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails_1" xlink:type="simple" xlink:href="ci-20231231.xsd#InvestmentsDebtSecuritieswithaDeclineinFairValueDetails_1"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_a0272767-b1e0-46ac-9d6a-e0cb67c0e610" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_099233ab-1566-4410-bd25-10e09ef37fcc" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_a0272767-b1e0-46ac-9d6a-e0cb67c0e610" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_099233ab-1566-4410-bd25-10e09ef37fcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale_afe4229c-9072-44dd-8cce-83c12f946c46" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_a0272767-b1e0-46ac-9d6a-e0cb67c0e610" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale_afe4229c-9072-44dd-8cce-83c12f946c46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost_6798619b-2ef4-4a81-b14d-bf61f0dcce51" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost_97ac7c41-1604-4df0-9ed3-ad51be7f0a4e" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost_6798619b-2ef4-4a81-b14d-bf61f0dcce51" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost_97ac7c41-1604-4df0-9ed3-ad51be7f0a4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost_47720018-5396-4266-859a-0780af0af86c" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost_6798619b-2ef4-4a81-b14d-bf61f0dcce51" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost_47720018-5396-4266-859a-0780af0af86c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InvestmentsEquitySecurityInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount_0b7d7477-552f-417d-b5bc-25f0884c1e88" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_462c304f-9d4e-4ab3-9142-d354b53fbdf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount_0b7d7477-552f-417d-b5bc-25f0884c1e88" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_462c304f-9d4e-4ab3-9142-d354b53fbdf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_f7a08824-ffed-4dac-aea4-88af39196177" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount_0b7d7477-552f-417d-b5bc-25f0884c1e88" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_f7a08824-ffed-4dac-aea4-88af39196177" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_4630c58d-afa4-4ba1-bcb0-46715b54a2f4" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_6cf7f27a-4746-4a22-afd0-df6f30b9ce93" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_4630c58d-afa4-4ba1-bcb0-46715b54a2f4" xlink:to="loc_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_6cf7f27a-4746-4a22-afd0-df6f30b9ce93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFvNiCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_522dfeba-034f-4e55-9cab-c6206799c020" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesFvNiCostBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_4630c58d-afa4-4ba1-bcb0-46715b54a2f4" xlink:to="loc_ci_EquitySecuritiesFvNiCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_522dfeba-034f-4e55-9cab-c6206799c020" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale_ed9d0bae-1538-4a0a-a4e2-4c93970d16a9" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale_c89dc02e-328c-42a0-a284-9fa7622be5aa" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale_ed9d0bae-1538-4a0a-a4e2-4c93970d16a9" xlink:to="loc_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale_c89dc02e-328c-42a0-a284-9fa7622be5aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFvNiBeforeReclassificationToDisposalGroupAssetsHeldForSale_9ba75e4e-1faf-4145-bda7-0726238051f3" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesFvNiBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale_ed9d0bae-1538-4a0a-a4e2-4c93970d16a9" xlink:to="loc_ci_EquitySecuritiesFvNiBeforeReclassificationToDisposalGroupAssetsHeldForSale_9ba75e4e-1faf-4145-bda7-0726238051f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost_988e678a-c340-45f2-8ee4-99a9b2abfed2" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_f36ed726-2b01-4d57-9ca8-5e91ab85bb62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost_988e678a-c340-45f2-8ee4-99a9b2abfed2" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_f36ed726-2b01-4d57-9ca8-5e91ab85bb62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost_4868ca2d-8ab7-42db-8aa4-55ef5cb49af5" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost_988e678a-c340-45f2-8ee4-99a9b2abfed2" xlink:to="loc_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost_4868ca2d-8ab7-42db-8aa4-55ef5cb49af5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InvestmentsComponentsofNetInvestmentIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_7cdfd9f8-7121-426c-8af3-112fffb060f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue_9d88f53c-d7ca-42e1-85f9-f7e8e9dc96af" xlink:href="ci-20231231.xsd#ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetInvestmentIncome_7cdfd9f8-7121-426c-8af3-112fffb060f4" xlink:to="loc_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue_9d88f53c-d7ca-42e1-85f9-f7e8e9dc96af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInvestmentExpense_bd5dced1-1dc3-4179-9c68-dddce1896fff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetInvestmentIncome_7cdfd9f8-7121-426c-8af3-112fffb060f4" xlink:to="loc_us-gaap_InvestmentIncomeInvestmentExpense_bd5dced1-1dc3-4179-9c68-dddce1896fff" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsRealizedGainsandLossesonInvestmentsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InvestmentsRealizedGainsandLossesonInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsRealizedGainsandLossesonInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_RealizedInvestmentGainLoss_05e3452e-a98f-4b30-a3ca-99d3782ee44f" xlink:href="ci-20231231.xsd#ci_RealizedInvestmentGainLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RealizedInvestmentGainLossExcludingImpairments_0b610510-7831-4225-9b7c-27cf295e6950" xlink:href="ci-20231231.xsd#ci_RealizedInvestmentGainLossExcludingImpairments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_RealizedInvestmentGainLoss_05e3452e-a98f-4b30-a3ca-99d3782ee44f" xlink:to="loc_ci_RealizedInvestmentGainLossExcludingImpairments_0b610510-7831-4225-9b7c-27cf295e6950" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal_e8eaefbe-0bed-4671-823b-5b0ec77aa0ee" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_RealizedInvestmentGainLoss_05e3452e-a98f-4b30-a3ca-99d3782ee44f" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal_e8eaefbe-0bed-4671-823b-5b0ec77aa0ee" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_5167ae04-adff-4323-97de-d83d6aef6367" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_4d7f9f2e-6d5b-4138-9431-0417aa983ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_5167ae04-adff-4323-97de-d83d6aef6367" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_4d7f9f2e-6d5b-4138-9431-0417aa983ef3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_900f57a1-b0dc-4b1d-a5e8-8ceb08962ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_5167ae04-adff-4323-97de-d83d6aef6367" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_900f57a1-b0dc-4b1d-a5e8-8ceb08962ba9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements_8d66cc68-cf03-4f96-88bd-a6424e1de865" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_81f7d32d-6b12-4525-b58a-fdc063f4d71f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements_8d66cc68-cf03-4f96-88bd-a6424e1de865" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_81f7d32d-6b12-4525-b58a-fdc063f4d71f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_8e1a7a4c-b98b-4ce4-a9df-18e7f60f5ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements_8d66cc68-cf03-4f96-88bd-a6424e1de865" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_8e1a7a4c-b98b-4ce4-a9df-18e7f60f5ab8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsFairValuesofSeparateAccountAssetsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#FairValueMeasurementsFairValuesofSeparateAccountAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurementsFairValuesofSeparateAccountAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountAssets_15d9acd5-fed1-4653-a03f-de584c49ba34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeparateAccountAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NonGuaranteedSeparateAccountAssetsPricedAtNetAssetValueAsAPracticalExpedient_f13bfc0e-91e2-4924-9b13-99e1b1e98768" xlink:href="ci-20231231.xsd#ci_NonGuaranteedSeparateAccountAssetsPricedAtNetAssetValueAsAPracticalExpedient"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SeparateAccountAssets_15d9acd5-fed1-4653-a03f-de584c49ba34" xlink:to="loc_ci_NonGuaranteedSeparateAccountAssetsPricedAtNetAssetValueAsAPracticalExpedient_f13bfc0e-91e2-4924-9b13-99e1b1e98768" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SeparateAccountAssetsClassifiedInFairValueHierarchy_4296cb7d-0720-4afe-bf56-352f42bdb4c5" xlink:href="ci-20231231.xsd#ci_SeparateAccountAssetsClassifiedInFairValueHierarchy"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SeparateAccountAssets_15d9acd5-fed1-4653-a03f-de584c49ba34" xlink:to="loc_ci_SeparateAccountAssetsClassifiedInFairValueHierarchy_4296cb7d-0720-4afe-bf56-352f42bdb4c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SeparateAccountAssetsClassifiedInFairValueHierarchy_66de0964-93af-49ad-8328-e4ae55e78147" xlink:href="ci-20231231.xsd#ci_SeparateAccountAssetsClassifiedInFairValueHierarchy"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy_9ea381cd-703f-4d44-a66c-508ef6ae9a42" xlink:href="ci-20231231.xsd#ci_NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_SeparateAccountAssetsClassifiedInFairValueHierarchy_66de0964-93af-49ad-8328-e4ae55e78147" xlink:to="loc_ci_NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy_9ea381cd-703f-4d44-a66c-508ef6ae9a42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_GuaranteedSeparateAccountAssets_1e289927-42a4-46e5-b1b4-ab0f84b2fdbb" xlink:href="ci-20231231.xsd#ci_GuaranteedSeparateAccountAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_SeparateAccountAssetsClassifiedInFairValueHierarchy_66de0964-93af-49ad-8328-e4ae55e78147" xlink:to="loc_ci_GuaranteedSeparateAccountAssets_1e289927-42a4-46e5-b1b4-ab0f84b2fdbb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity_c6cffb4d-8d8c-4183-b3b4-8272dc2881ea" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity_d274c651-ef39-4899-9600-c1ba2b85ee0d" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity_c6cffb4d-8d8c-4183-b3b4-8272dc2881ea" xlink:to="loc_ci_OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity_d274c651-ef39-4899-9600-c1ba2b85ee0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity_47d49295-c40a-462a-a85f-8a1a158cb1e9" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity_c6cffb4d-8d8c-4183-b3b4-8272dc2881ea" xlink:to="loc_ci_OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity_47d49295-c40a-462a-a85f-8a1a158cb1e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_b856cc66-3cc4-4b70-b035-a18681918332" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_fca061c4-7697-4066-92e7-c3a2e458aadc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_b856cc66-3cc4-4b70-b035-a18681918332" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_fca061c4-7697-4066-92e7-c3a2e458aadc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_3ce783ef-1a21-4f20-947e-8186f794b974" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_b856cc66-3cc4-4b70-b035-a18681918332" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_3ce783ef-1a21-4f20-947e-8186f794b974" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8711479f-6c71-41f2-a457-9d24488eebc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_132c0563-7a37-42a8-9b21-2238c367ae7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8711479f-6c71-41f2-a457-9d24488eebc3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_132c0563-7a37-42a8-9b21-2238c367ae7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_99dccd59-1c99-473c-8abb-c48e3ab6ab47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8711479f-6c71-41f2-a457-9d24488eebc3" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_99dccd59-1c99-473c-8abb-c48e3ab6ab47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity_257e1203-c24d-434a-9bea-565064a2e89c" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity_dc376923-5762-4293-9867-0fadcab37b57" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity_257e1203-c24d-434a-9bea-565064a2e89c" xlink:to="loc_ci_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity_dc376923-5762-4293-9867-0fadcab37b57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity_83fd8daa-a1a7-4172-91e2-0da47bc9fef4" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity_257e1203-c24d-434a-9bea-565064a2e89c" xlink:to="loc_ci_OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity_83fd8daa-a1a7-4172-91e2-0da47bc9fef4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_b6a456c4-ad16-4a94-a0a3-8a831edc67bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_8ec84020-5fba-4f18-aeef-682457000811" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_b6a456c4-ad16-4a94-a0a3-8a831edc67bf" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_8ec84020-5fba-4f18-aeef-682457000811" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_bf7a2847-2d27-4642-aa7b-3f46fca5f8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_b6a456c4-ad16-4a94-a0a3-8a831edc67bf" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_bf7a2847-2d27-4642-aa7b-3f46fca5f8c7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails_1" xlink:type="simple" xlink:href="ci-20231231.xsd#AccumulatedOtherComprehensiveIncomeLossDetails_1"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_08d53e37-4b2d-4d9f-a166-c9a2aa24c5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity_63e01f16-3239-43a4-a1e2-dc23ab3b9b64" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_08d53e37-4b2d-4d9f-a166-c9a2aa24c5f1" xlink:to="loc_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity_63e01f16-3239-43a4-a1e2-dc23ab3b9b64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TemporaryEquityOtherComprehensiveIncome_4959b667-a207-49ba-ae24-69ec744d463b" xlink:href="ci-20231231.xsd#ci_TemporaryEquityOtherComprehensiveIncome"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_08d53e37-4b2d-4d9f-a166-c9a2aa24c5f1" xlink:to="loc_ci_TemporaryEquityOtherComprehensiveIncome_4959b667-a207-49ba-ae24-69ec744d463b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity_d6e306fa-4ccf-4520-965f-4de0ccb4f718" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity_2b2c32d7-c647-4e3d-907c-848e1fe132d3" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity_d6e306fa-4ccf-4520-965f-4de0ccb4f718" xlink:to="loc_ci_OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity_2b2c32d7-c647-4e3d-907c-848e1fe132d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_9fde7ef8-70d7-4680-aef6-40c99c0c85ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity_d6e306fa-4ccf-4520-965f-4de0ccb4f718" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_9fde7ef8-70d7-4680-aef6-40c99c0c85ff" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/OrganizationalEfficiencyPlanDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#OrganizationalEfficiencyPlanDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/OrganizationalEfficiencyPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_150f7038-8724-47ce-86b3-527bef874ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_3f44bc5c-dead-4fb6-b5ef-99efc033ca0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessExitCosts1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_150f7038-8724-47ce-86b3-527bef874ce0" xlink:to="loc_us-gaap_BusinessExitCosts1_3f44bc5c-dead-4fb6-b5ef-99efc033ca0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_a1253925-5817-47d0-b6fe-b16975754ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_150f7038-8724-47ce-86b3-527bef874ce0" xlink:to="loc_us-gaap_SeveranceCosts1_a1253925-5817-47d0-b6fe-b16975754ab8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#PensionProjectedBenefitObligationsandAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_4dddc706-d1db-46c2-bff9-1e3663a057d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_9c6f07fc-0f79-4f72-96d1-973095f3ad4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_4dddc706-d1db-46c2-bff9-1e3663a057d2" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_9c6f07fc-0f79-4f72-96d1-973095f3ad4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_cfc48773-0dd9-46e4-99cb-9d0c15bb247a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_4dddc706-d1db-46c2-bff9-1e3663a057d2" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_cfc48773-0dd9-46e4-99cb-9d0c15bb247a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/PensionAmountsIncludedinAccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#PensionAmountsIncludedinAccumulatedOtherComprehensiveIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/PensionAmountsIncludedinAccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_3a67f436-e428-4e88-b8bf-4633b086e386" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_0c2534e7-665d-4ae4-b7b7-f66cc18b4446" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_3a67f436-e428-4e88-b8bf-4633b086e386" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_0c2534e7-665d-4ae4-b7b7-f66cc18b4446" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_891029a8-454b-4b4b-990d-39ef5a44c44e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_3a67f436-e428-4e88-b8bf-4633b086e386" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_891029a8-454b-4b4b-990d-39ef5a44c44e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/PensionNetPensionCostDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#PensionNetPensionCostDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/PensionNetPensionCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f21f265b-f2c4-4f4e-bdf6-3e65cf05566c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_9167c744-f961-42c7-8947-8979845614cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f21f265b-f2c4-4f4e-bdf6-3e65cf05566c" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_9167c744-f961-42c7-8947-8979845614cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_93c9d8ba-b5a5-45b5-a625-1c0eb37a9d48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f21f265b-f2c4-4f4e-bdf6-3e65cf05566c" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_93c9d8ba-b5a5-45b5-a625-1c0eb37a9d48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_4c8327a5-d0f1-4493-8c23-cd14dc49bb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f21f265b-f2c4-4f4e-bdf6-3e65cf05566c" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_4c8327a5-d0f1-4493-8c23-cd14dc49bb1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_377e709f-452a-404d-8d01-2795f953ad4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f21f265b-f2c4-4f4e-bdf6-3e65cf05566c" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_377e709f-452a-404d-8d01-2795f953ad4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_e432755b-9b23-4227-837f-a64d98c7b0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f21f265b-f2c4-4f4e-bdf6-3e65cf05566c" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_e432755b-9b23-4227-837f-a64d98c7b0f7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale_942ff48b-552f-4e4f-b283-0dbd22970e62" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsNetIncludingDisposalGroupsAssetsHeldForSale_43e5bbc9-8f8f-4378-8cad-6a343d029a6f" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsNetIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale_942ff48b-552f-4e4f-b283-0dbd22970e62" xlink:to="loc_ci_FiniteLivedIntangibleAssetsNetIncludingDisposalGroupsAssetsHeldForSale_43e5bbc9-8f8f-4378-8cad-6a343d029a6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale_1b997dd3-b10f-4d70-8e05-d41d58346cbc" xlink:href="ci-20231231.xsd#ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale_942ff48b-552f-4e4f-b283-0dbd22970e62" xlink:to="loc_ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale_1b997dd3-b10f-4d70-8e05-d41d58346cbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsNetIncludingDisposalGroupsAssetsHeldForSale_1b4f12f9-755a-4a22-a2bc-300b2e0f0576" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsNetIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale_6e709c08-d924-4137-9e51-e7ad064dc7fb" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_FiniteLivedIntangibleAssetsNetIncludingDisposalGroupsAssetsHeldForSale_1b4f12f9-755a-4a22-a2bc-300b2e0f0576" xlink:to="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale_6e709c08-d924-4137-9e51-e7ad064dc7fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsGrossIncludingDisposalGroupsHeldForSale_a1a788c4-6b17-4e52-9669-9acccab259f8" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsGrossIncludingDisposalGroupsHeldForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_FiniteLivedIntangibleAssetsNetIncludingDisposalGroupsAssetsHeldForSale_1b4f12f9-755a-4a22-a2bc-300b2e0f0576" xlink:to="loc_ci_FiniteLivedIntangibleAssetsGrossIncludingDisposalGroupsHeldForSale_a1a788c4-6b17-4e52-9669-9acccab259f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVOBAIncludingDisposalGroups_bfc7cb6e-4c37-4f83-b5e0-03e1002cad56" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVOBAIncludingDisposalGroups"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVOBAIncludingDisposalGroupsAssetsHeldForSale_f6d2c245-1b2c-4ae9-9a0c-ed9fe87e62bd" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVOBAIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVOBAIncludingDisposalGroups_bfc7cb6e-4c37-4f83-b5e0-03e1002cad56" xlink:to="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVOBAIncludingDisposalGroupsAssetsHeldForSale_f6d2c245-1b2c-4ae9-9a0c-ed9fe87e62bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale_c904ee70-bbe8-437e-aafa-ef04bc521d32" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVOBAIncludingDisposalGroups_bfc7cb6e-4c37-4f83-b5e0-03e1002cad56" xlink:to="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale_c904ee70-bbe8-437e-aafa-ef04bc521d32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_02d5c9dd-694c-42d7-b3da-d422371bd677" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_ffcdb836-de30-4ff1-b774-08089ef039dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_02d5c9dd-694c-42d7-b3da-d422371bd677" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_ffcdb836-de30-4ff1-b774-08089ef039dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4a6c4b5c-c2df-49f3-9fc7-22fb7fca936d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_02d5c9dd-694c-42d7-b3da-d422371bd677" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4a6c4b5c-c2df-49f3-9fc7-22fb7fca936d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsNetVoba_8e0aaacc-6bda-446d-8a43-66990f47fb47" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsNetVoba"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsGrossVoba_73b2d959-8537-4156-b911-151d33057b33" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsGrossVoba"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_FiniteLivedIntangibleAssetsNetVoba_8e0aaacc-6bda-446d-8a43-66990f47fb47" xlink:to="loc_ci_FiniteLivedIntangibleAssetsGrossVoba_73b2d959-8537-4156-b911-151d33057b33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVoba_16818532-bc6e-416a-888b-e4280710416d" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVoba"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_FiniteLivedIntangibleAssetsNetVoba_8e0aaacc-6bda-446d-8a43-66990f47fb47" xlink:to="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVoba_16818532-bc6e-416a-888b-e4280710416d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVoba_edd7ee79-ad73-4c5e-9884-1c27691392c0" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsGrossExcludingGoodwillIncludingVoba"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_df04e832-7229-4953-b22d-9f12502d380f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVoba_edd7ee79-ad73-4c5e-9884-1c27691392c0" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_df04e832-7229-4953-b22d-9f12502d380f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsGrossVoba_cc2b489e-3251-439c-ab6b-b8fbad0ec6ae" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsGrossVoba"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVoba_edd7ee79-ad73-4c5e-9884-1c27691392c0" xlink:to="loc_ci_FiniteLivedIntangibleAssetsGrossVoba_cc2b489e-3251-439c-ab6b-b8fbad0ec6ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale_3f1bf56c-1ebd-4ecf-8ef0-fce5aacf419e" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsGrossIncludingDisposalGroupsHeldForSale_98b2fe23-4996-47f1-9d23-f388276e4c17" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsGrossIncludingDisposalGroupsHeldForSale"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale_3f1bf56c-1ebd-4ecf-8ef0-fce5aacf419e" xlink:to="loc_ci_FiniteLivedIntangibleAssetsGrossIncludingDisposalGroupsHeldForSale_98b2fe23-4996-47f1-9d23-f388276e4c17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale_21be963a-d270-457d-86ac-8e81c5313133" xlink:href="ci-20231231.xsd#ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale_3f1bf56c-1ebd-4ecf-8ef0-fce5aacf419e" xlink:to="loc_ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale_21be963a-d270-457d-86ac-8e81c5313133" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVoba_5958115c-3aa0-468f-9144-3b150298f6f1" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVoba"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4ae14bb1-d3cc-45b1-a2da-b317771179a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVoba_5958115c-3aa0-468f-9144-3b150298f6f1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4ae14bb1-d3cc-45b1-a2da-b317771179a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVoba_979e5910-c317-40fb-8488-f52526cac7b3" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVoba"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVoba_5958115c-3aa0-468f-9144-3b150298f6f1" xlink:to="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVoba_979e5910-c317-40fb-8488-f52526cac7b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups_f0f24f62-ca55-4c7f-b348-d4e899feba4a" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups_96e28fe1-8729-4973-bb76-1e93bb5f6a2c" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups_f0f24f62-ca55-4c7f-b348-d4e899feba4a" xlink:to="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups_96e28fe1-8729-4973-bb76-1e93bb5f6a2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVOBAIncludingDisposalGroups_c049da10-de8f-4c51-86a1-a6f54c998a86" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVOBAIncludingDisposalGroups"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups_f0f24f62-ca55-4c7f-b348-d4e899feba4a" xlink:to="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVOBAIncludingDisposalGroups_c049da10-de8f-4c51-86a1-a6f54c998a86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_398ecea6-15c3-496c-a506-63f4680dded3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0659a493-4814-4744-823e-2e32b67ef30c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_398ecea6-15c3-496c-a506-63f4680dded3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0659a493-4814-4744-823e-2e32b67ef30c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_6fd12737-a122-46cb-bd9a-2e75ac98d4d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_398ecea6-15c3-496c-a506-63f4680dded3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_6fd12737-a122-46cb-bd9a-2e75ac98d4d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingVoba_7fa99996-7ab6-4a0b-a3f8-153622f1a046" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsNetExcludingGoodwillIncludingVoba"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_34fcc391-4b4e-4018-9da6-f5161dc47e80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingVoba_7fa99996-7ab6-4a0b-a3f8-153622f1a046" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_34fcc391-4b4e-4018-9da6-f5161dc47e80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsNetVoba_42c25539-23c6-48fe-ad5a-290c8972e208" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsNetVoba"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingVoba_7fa99996-7ab6-4a0b-a3f8-153622f1a046" xlink:to="loc_ci_FiniteLivedIntangibleAssetsNetVoba_42c25539-23c6-48fe-ad5a-290c8972e208" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_066d7a6b-2b95-4897-849b-8747f78d5320" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f0a6af03-a017-42b4-8752-b4869d3f7cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_066d7a6b-2b95-4897-849b-8747f78d5320" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f0a6af03-a017-42b4-8752-b4869d3f7cdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_858bbfa4-4970-4bff-863a-060455897a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_066d7a6b-2b95-4897-849b-8747f78d5320" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_858bbfa4-4970-4bff-863a-060455897a9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsNetVOBAIncludingDisposalGroupsAssetsHeldForSale_5356d939-ccbd-4d2e-ad55-5e5413028d57" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsNetVOBAIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVOBAIncludingDisposalGroupsAssetsHeldForSale_3e1b71eb-c4b0-45c3-a449-88b021453555" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVOBAIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_FiniteLivedIntangibleAssetsNetVOBAIncludingDisposalGroupsAssetsHeldForSale_5356d939-ccbd-4d2e-ad55-5e5413028d57" xlink:to="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVOBAIncludingDisposalGroupsAssetsHeldForSale_3e1b71eb-c4b0-45c3-a449-88b021453555" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsGrossVOBAIncludingDisposalGroupsAssetHeldForSale_2fa166c6-3740-467f-9cda-04ca96530259" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsGrossVOBAIncludingDisposalGroupsAssetHeldForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_FiniteLivedIntangibleAssetsNetVOBAIncludingDisposalGroupsAssetsHeldForSale_5356d939-ccbd-4d2e-ad55-5e5413028d57" xlink:to="loc_ci_FiniteLivedIntangibleAssetsGrossVOBAIncludingDisposalGroupsAssetHeldForSale_2fa166c6-3740-467f-9cda-04ca96530259" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups_8e50e008-eee0-436f-ba3a-3a403500a789" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale_733606be-8bd2-4c48-a7f7-b30556398cca" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups_8e50e008-eee0-436f-ba3a-3a403500a789" xlink:to="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale_733606be-8bd2-4c48-a7f7-b30556398cca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsGrossVOBAIncludingDisposalGroupsAssetHeldForSale_7c2b5443-9a66-43f6-b5a2-7dab82f04f66" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsGrossVOBAIncludingDisposalGroupsAssetHeldForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups_8e50e008-eee0-436f-ba3a-3a403500a789" xlink:to="loc_ci_FiniteLivedIntangibleAssetsGrossVOBAIncludingDisposalGroupsAssetHeldForSale_7c2b5443-9a66-43f6-b5a2-7dab82f04f66" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="ci-20231231.xsd#GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c8968c34-7e18-4572-b55b-26bfdfe1b29c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5caf83a6-2be3-4013-9204-6041cf4fa5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c8968c34-7e18-4572-b55b-26bfdfe1b29c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5caf83a6-2be3-4013-9204-6041cf4fa5d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4141c0eb-b77d-48c6-8300-42601dafc704" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c8968c34-7e18-4572-b55b-26bfdfe1b29c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4141c0eb-b77d-48c6-8300-42601dafc704" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale_d06c67de-685d-4279-98ae-4993eff37059" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale_0308fcfd-95ae-46bb-ac58-5736c2664e85" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale_d06c67de-685d-4279-98ae-4993eff37059" xlink:to="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale_0308fcfd-95ae-46bb-ac58-5736c2664e85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale_52e711be-c7c2-4e8b-9395-c9235da11e52" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale_d06c67de-685d-4279-98ae-4993eff37059" xlink:to="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale_52e711be-c7c2-4e8b-9395-c9235da11e52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups_7ed7c6ad-f105-4292-b833-27d48e0ced5f" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale_05eff242-ed99-4bc4-a370-0c8c63f0c500" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups_7ed7c6ad-f105-4292-b833-27d48e0ced5f" xlink:to="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale_05eff242-ed99-4bc4-a370-0c8c63f0c500" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsNetVOBAIncludingDisposalGroupsAssetsHeldForSale_300f448a-d2d8-4adb-a3f4-d6588468fa88" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsNetVOBAIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups_7ed7c6ad-f105-4292-b833-27d48e0ced5f" xlink:to="loc_ci_FiniteLivedIntangibleAssetsNetVOBAIncludingDisposalGroupsAssetsHeldForSale_300f448a-d2d8-4adb-a3f4-d6588468fa88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingVoba_91b0097f-9349-4c2d-bb19-96e3623270ce" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsNetExcludingGoodwillIncludingVoba"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVoba_30c8a6fa-839c-49b4-8df1-e15fb44d262a" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVoba"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingVoba_91b0097f-9349-4c2d-bb19-96e3623270ce" xlink:to="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVoba_30c8a6fa-839c-49b4-8df1-e15fb44d262a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVoba_b3436828-a2ae-4901-8816-11e38de10319" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsGrossExcludingGoodwillIncludingVoba"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingVoba_91b0097f-9349-4c2d-bb19-96e3623270ce" xlink:to="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVoba_b3436828-a2ae-4901-8816-11e38de10319" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups_c0869a6d-dbcb-4f7d-b082-e366cdb8fe9f" xlink:href="ci-20231231.xsd#ci_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentCurrent_db3572dd-ef0d-4c60-a3c7-90334e361639" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups_c0869a6d-dbcb-4f7d-b082-e366cdb8fe9f" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentCurrent_db3572dd-ef0d-4c60-a3c7-90334e361639" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_280b4314-1ac0-46e0-9bd4-0a2f1a0baf1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups_c0869a6d-dbcb-4f7d-b082-e366cdb8fe9f" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_280b4314-1ac0-46e0-9bd4-0a2f1a0baf1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups_78f8f3ee-48d2-4df3-9115-e53bdc513243" xlink:href="ci-20231231.xsd#ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_69aae935-74a7-407d-98b9-ff7754e7777f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups_78f8f3ee-48d2-4df3-9115-e53bdc513243" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_69aae935-74a7-407d-98b9-ff7754e7777f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2bbd6caa-4dd6-417a-abe2-25d6cdbebda2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups_78f8f3ee-48d2-4df3-9115-e53bdc513243" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2bbd6caa-4dd6-417a-abe2-25d6cdbebda2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_2268de5b-df3d-459c-bbc1-e1b4af8f66b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentGrossCurrent_b7fef957-cc81-4206-87f1-0072416522ca" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentGrossCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_2268de5b-df3d-459c-bbc1-e1b4af8f66b3" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentGrossCurrent_b7fef957-cc81-4206-87f1-0072416522ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentCurrent_e322239a-3edd-4a4a-85ff-a1c307ecdbfe" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentCurrent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_2268de5b-df3d-459c-bbc1-e1b4af8f66b3" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentCurrent_e322239a-3edd-4a4a-85ff-a1c307ecdbfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a4284fa5-51ee-47f7-ac6b-2f4e591a8a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c2e1e3c2-07e6-4661-b119-469cbd1e91a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_a4284fa5-51ee-47f7-ac6b-2f4e591a8a1e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c2e1e3c2-07e6-4661-b119-469cbd1e91a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d18d999b-5ac1-4348-ada5-876db3ba8aea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_a4284fa5-51ee-47f7-ac6b-2f4e591a8a1e" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d18d999b-5ac1-4348-ada5-876db3ba8aea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PropertyPlantAndEquipmentGrossIncludingDisposalGroups_e762eea4-3204-46e2-bc4a-15efa16db6fb" xlink:href="ci-20231231.xsd#ci_PropertyPlantAndEquipmentGrossIncludingDisposalGroups"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentGrossCurrent_22157c8a-45cf-48c9-b329-111e836b4917" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentGrossCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_PropertyPlantAndEquipmentGrossIncludingDisposalGroups_e762eea4-3204-46e2-bc4a-15efa16db6fb" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentGrossCurrent_22157c8a-45cf-48c9-b329-111e836b4917" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_445ab69b-aa23-4125-bd94-0511c6a3280f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_PropertyPlantAndEquipmentGrossIncludingDisposalGroups_e762eea4-3204-46e2-bc4a-15efa16db6fb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_445ab69b-aa23-4125-bd94-0511c6a3280f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails_1" xlink:type="simple" xlink:href="ci-20231231.xsd#GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails_1"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups_44a1e081-b483-4566-97a2-423fe36d19df" xlink:href="ci-20231231.xsd#ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PropertyPlantAndEquipmentGrossIncludingDisposalGroups_9396dba3-0efa-4111-aac4-fb6d4463dde5" xlink:href="ci-20231231.xsd#ci_PropertyPlantAndEquipmentGrossIncludingDisposalGroups"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups_44a1e081-b483-4566-97a2-423fe36d19df" xlink:to="loc_ci_PropertyPlantAndEquipmentGrossIncludingDisposalGroups_9396dba3-0efa-4111-aac4-fb6d4463dde5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups_2d8bdffb-a9d3-47af-8d70-0a61029c5d71" xlink:href="ci-20231231.xsd#ci_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups_44a1e081-b483-4566-97a2-423fe36d19df" xlink:to="loc_ci_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups_2d8bdffb-a9d3-47af-8d70-0a61029c5d71" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_FinanceLeaseCost_842f174a-4629-4245-95ec-fe2c3de3cbc0" xlink:href="ci-20231231.xsd#ci_FinanceLeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_3e87031d-1ee8-4e64-99e2-b0724aa540d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_FinanceLeaseCost_842f174a-4629-4245-95ec-fe2c3de3cbc0" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_3e87031d-1ee8-4e64-99e2-b0724aa540d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_b71e8053-549d-432e-a67e-667b3326e931" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_FinanceLeaseCost_842f174a-4629-4245-95ec-fe2c3de3cbc0" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_b71e8053-549d-432e-a67e-667b3326e931" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_f07f8480-8111-4dd1-83a3-3db8d2cea694" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_7ef02a84-ac44-4e58-88ef-b4968993c0a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_f07f8480-8111-4dd1-83a3-3db8d2cea694" xlink:to="loc_us-gaap_VariableLeaseCost_7ef02a84-ac44-4e58-88ef-b4968993c0a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FinanceLeaseCost_43ec9585-8a26-45d6-aa05-4d331ae78145" xlink:href="ci-20231231.xsd#ci_FinanceLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_f07f8480-8111-4dd1-83a3-3db8d2cea694" xlink:to="loc_ci_FinanceLeaseCost_43ec9585-8a26-45d6-aa05-4d331ae78145" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_e02a76fb-fdfe-4d87-85c6-44a9c69e4f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_f07f8480-8111-4dd1-83a3-3db8d2cea694" xlink:to="loc_us-gaap_OperatingLeaseCost_e02a76fb-fdfe-4d87-85c6-44a9c69e4f6d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_OperatingLeaseLiabilityIncludingDisposalGroupsAssetsHeldForSale_d46a716a-0ce4-4a01-b913-f42207bc3b41" xlink:href="ci-20231231.xsd#ci_OperatingLeaseLiabilityIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OperatingLeaseLiabilityCurrentIncludingDisposalGroupsAssetsHeldForSale_ce253446-ad72-451d-b93e-f01c3100e208" xlink:href="ci-20231231.xsd#ci_OperatingLeaseLiabilityCurrentIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_OperatingLeaseLiabilityIncludingDisposalGroupsAssetsHeldForSale_d46a716a-0ce4-4a01-b913-f42207bc3b41" xlink:to="loc_ci_OperatingLeaseLiabilityCurrentIncludingDisposalGroupsAssetsHeldForSale_ce253446-ad72-451d-b93e-f01c3100e208" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OperatingLeaseLiabilityNoncurrentIncludingDisposalGroupsAssetsHeldForSale_fe0d69f3-4b65-4cf8-b7fb-aecf9828b73e" xlink:href="ci-20231231.xsd#ci_OperatingLeaseLiabilityNoncurrentIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_OperatingLeaseLiabilityIncludingDisposalGroupsAssetsHeldForSale_d46a716a-0ce4-4a01-b913-f42207bc3b41" xlink:to="loc_ci_OperatingLeaseLiabilityNoncurrentIncludingDisposalGroupsAssetsHeldForSale_fe0d69f3-4b65-4cf8-b7fb-aecf9828b73e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b23ff5ad-00ef-480e-ada7-e7d01bd90cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f30b1d1e-84f8-47a7-8bf0-eb73270769cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_b23ff5ad-00ef-480e-ada7-e7d01bd90cd1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f30b1d1e-84f8-47a7-8bf0-eb73270769cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f38305d6-a3e7-4c8b-961d-2e8d36bfa770" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_b23ff5ad-00ef-480e-ada7-e7d01bd90cd1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f38305d6-a3e7-4c8b-961d-2e8d36bfa770" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_5d61aec6-3393-4349-a8e6-2743231ee6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_64f4383a-3e45-4abb-a5be-fd256676e770" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset_5d61aec6-3393-4349-a8e6-2743231ee6c0" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_64f4383a-3e45-4abb-a5be-fd256676e770" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_60589806-6f80-4405-a4bd-e5939ceba100" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset_5d61aec6-3393-4349-a8e6-2743231ee6c0" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_60589806-6f80-4405-a4bd-e5939ceba100" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_e2417b09-50cf-4ccb-b936-2c5611e00be3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_a1b2def6-40d5-4525-a59f-145a90c20b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_e2417b09-50cf-4ccb-b936-2c5611e00be3" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_a1b2def6-40d5-4525-a59f-145a90c20b8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_d7e1eaf1-e657-44dc-aae1-352f6a5bb201" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_e2417b09-50cf-4ccb-b936-2c5611e00be3" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_d7e1eaf1-e657-44dc-aae1-352f6a5bb201" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_59925a29-6c89-4645-85d0-bae6cfa96e56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f5af5826-41ad-48eb-8fcc-5ce04d0e55bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_59925a29-6c89-4645-85d0-bae6cfa96e56" xlink:to="loc_us-gaap_OperatingLeaseLiability_f5af5826-41ad-48eb-8fcc-5ce04d0e55bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_30d0f1a0-5d32-4d12-ba2b-0345f000cf31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_59925a29-6c89-4645-85d0-bae6cfa96e56" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_30d0f1a0-5d32-4d12-ba2b-0345f000cf31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3dc043b7-5336-4f63-b824-7e1265db5095" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_bded1c81-a54c-4e63-806d-3cf03ead7b47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3dc043b7-5336-4f63-b824-7e1265db5095" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_bded1c81-a54c-4e63-806d-3cf03ead7b47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_d2e635d0-43ef-409b-87da-d69db91862cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3dc043b7-5336-4f63-b824-7e1265db5095" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_d2e635d0-43ef-409b-87da-d69db91862cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_7e241a4e-26f6-4d6a-900f-fe61709c38ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3dc043b7-5336-4f63-b824-7e1265db5095" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_7e241a4e-26f6-4d6a-900f-fe61709c38ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_1f0bdad7-86e4-4114-94c4-ef4f00b6fea9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3dc043b7-5336-4f63-b824-7e1265db5095" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_1f0bdad7-86e4-4114-94c4-ef4f00b6fea9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_f4fe8788-6110-4598-b7c0-ebb342e75581" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3dc043b7-5336-4f63-b824-7e1265db5095" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_f4fe8788-6110-4598-b7c0-ebb342e75581" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_41dbe6d7-5482-4836-af70-f571537880c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3dc043b7-5336-4f63-b824-7e1265db5095" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_41dbe6d7-5482-4836-af70-f571537880c5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="ci-20231231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_808a3210-bb12-45da-ae16-2783631b6743" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_2c4ad1f9-2670-4258-b284-aa5e500df82d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_808a3210-bb12-45da-ae16-2783631b6743" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_2c4ad1f9-2670-4258-b284-aa5e500df82d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_43c1acf0-4b86-4cc1-a9f9-b626c020985e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_808a3210-bb12-45da-ae16-2783631b6743" xlink:to="loc_us-gaap_FinanceLeaseLiability_43c1acf0-4b86-4cc1-a9f9-b626c020985e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ced5e459-dfb5-461b-8a3e-2306dbb2d1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_54ba0a37-6561-4a8d-9042-9bb768608ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ced5e459-dfb5-461b-8a3e-2306dbb2d1c1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_54ba0a37-6561-4a8d-9042-9bb768608ccb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e7dc5a70-7219-4fe5-b6f3-9d902888ba98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ced5e459-dfb5-461b-8a3e-2306dbb2d1c1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e7dc5a70-7219-4fe5-b6f3-9d902888ba98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d37a230d-05ed-4847-9c34-6e1de758b065" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ced5e459-dfb5-461b-8a3e-2306dbb2d1c1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d37a230d-05ed-4847-9c34-6e1de758b065" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b243aafd-f127-4150-8a6a-7514b7403b04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ced5e459-dfb5-461b-8a3e-2306dbb2d1c1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b243aafd-f127-4150-8a6a-7514b7403b04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a0da9e4f-4f63-4e43-b334-52d766de83bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ced5e459-dfb5-461b-8a3e-2306dbb2d1c1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a0da9e4f-4f63-4e43-b334-52d766de83bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_92b42fc4-0c56-400c-aac0-a31298f3c1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ced5e459-dfb5-461b-8a3e-2306dbb2d1c1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_92b42fc4-0c56-400c-aac0-a31298f3c1ca" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/IncomeTaxesComponentsofIncomeTaxesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#IncomeTaxesComponentsofIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/IncomeTaxesComponentsofIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9d646f8f-18b0-4ec9-8b39-fa94650f503b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_4c4c09d2-87d6-4735-8e92-3c65539f29b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9d646f8f-18b0-4ec9-8b39-fa94650f503b" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_4c4c09d2-87d6-4735-8e92-3c65539f29b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_a783301a-1088-4418-99a4-fbc0228e8d00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9d646f8f-18b0-4ec9-8b39-fa94650f503b" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_a783301a-1088-4418-99a4-fbc0228e8d00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_8f9716c5-0b00-4195-a639-4877158ae45b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9d646f8f-18b0-4ec9-8b39-fa94650f503b" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_8f9716c5-0b00-4195-a639-4877158ae45b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5f4f034a-2f46-4165-85df-2eccf8bf7455" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c84352a0-fbcb-4291-8e8b-10b8d8580124" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_5f4f034a-2f46-4165-85df-2eccf8bf7455" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c84352a0-fbcb-4291-8e8b-10b8d8580124" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3e001daa-80cf-41a0-94cf-3dec64dcb3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_5f4f034a-2f46-4165-85df-2eccf8bf7455" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3e001daa-80cf-41a0-94cf-3dec64dcb3b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a31d9269-50b1-4f80-9484-0d426be9caed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_46560d1f-5e9b-43bb-ae12-d2e195234b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a31d9269-50b1-4f80-9484-0d426be9caed" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_46560d1f-5e9b-43bb-ae12-d2e195234b6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_5d6fecce-5a8c-4c52-9da5-21cefa9c3e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a31d9269-50b1-4f80-9484-0d426be9caed" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_5d6fecce-5a8c-4c52-9da5-21cefa9c3e4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_d1a42246-7272-4ecd-8a46-030a5caa1ada" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a31d9269-50b1-4f80-9484-0d426be9caed" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_d1a42246-7272-4ecd-8a46-030a5caa1ada" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#IncomeTaxesNominalTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_694b4a8d-ce75-41ec-bd39-61057f070c31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f15c0272-08f1-42b6-ba8d-f83c4d18e476" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_694b4a8d-ce75-41ec-bd39-61057f070c31" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f15c0272-08f1-42b6-ba8d-f83c4d18e476" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_25b56faf-8b67-41ce-bded-ad7bbe772cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_694b4a8d-ce75-41ec-bd39-61057f070c31" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_25b56faf-8b67-41ce-bded-ad7bbe772cf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EffectiveIncomeTaxRateReconciliationHealthInsuranceIndustryTax_81f787a3-b4ec-4014-bef4-7927a64fb903" xlink:href="ci-20231231.xsd#ci_EffectiveIncomeTaxRateReconciliationHealthInsuranceIndustryTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_694b4a8d-ce75-41ec-bd39-61057f070c31" xlink:to="loc_ci_EffectiveIncomeTaxRateReconciliationHealthInsuranceIndustryTax_81f787a3-b4ec-4014-bef4-7927a64fb903" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_e6ef16ed-933a-4215-933d-39149b2dff03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_694b4a8d-ce75-41ec-bd39-61057f070c31" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_e6ef16ed-933a-4215-933d-39149b2dff03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_831ac0dd-74c0-4dde-bd7e-01193e923e17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_694b4a8d-ce75-41ec-bd39-61057f070c31" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_831ac0dd-74c0-4dde-bd7e-01193e923e17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings_fd459b20-9d08-4564-bb6b-9ac705119463" xlink:href="ci-20231231.xsd#ci_EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_694b4a8d-ce75-41ec-bd39-61057f070c31" xlink:to="loc_ci_EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings_fd459b20-9d08-4564-bb6b-9ac705119463" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EffectiveIncomeTaxRateReconciliationImpactOfBusinessesHeldForSalePercent_8bfbf5fb-848d-4857-b61a-5691a572a81f" xlink:href="ci-20231231.xsd#ci_EffectiveIncomeTaxRateReconciliationImpactOfBusinessesHeldForSalePercent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_694b4a8d-ce75-41ec-bd39-61057f070c31" xlink:to="loc_ci_EffectiveIncomeTaxRateReconciliationImpactOfBusinessesHeldForSalePercent_8bfbf5fb-848d-4857-b61a-5691a572a81f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent_b23bc822-d128-40f2-bfc2-70313d3f2569" xlink:href="ci-20231231.xsd#ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_694b4a8d-ce75-41ec-bd39-61057f070c31" xlink:to="loc_ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent_b23bc822-d128-40f2-bfc2-70313d3f2569" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent_f525d276-d85d-4f38-9d70-d8ebdb18b112" xlink:href="ci-20231231.xsd#ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_694b4a8d-ce75-41ec-bd39-61057f070c31" xlink:to="loc_ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent_f525d276-d85d-4f38-9d70-d8ebdb18b112" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_082e182e-e70f-4e59-9844-274674e47852" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_694b4a8d-ce75-41ec-bd39-61057f070c31" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_082e182e-e70f-4e59-9844-274674e47852" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c0bf285a-3349-4e2e-820d-d232e4d87ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings_d4ab35f0-9ee5-4c5f-a1cb-670824f33292" xlink:href="ci-20231231.xsd#ci_IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_c0bf285a-3349-4e2e-820d-d232e4d87ab4" xlink:to="loc_ci_IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings_d4ab35f0-9ee5-4c5f-a1cb-670824f33292" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_140b7757-b831-4c3d-a130-47f3b1b034a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationDispositionOfBusiness"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_c0bf285a-3349-4e2e-820d-d232e4d87ab4" xlink:to="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_140b7757-b831-4c3d-a130-47f3b1b034a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_e88d9fc7-8eba-45d2-94a9-0ba31d1a9faa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_c0bf285a-3349-4e2e-820d-d232e4d87ab4" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_e88d9fc7-8eba-45d2-94a9-0ba31d1a9faa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_ccc58a80-e2f9-4056-a35b-cf8ebf43d27c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_c0bf285a-3349-4e2e-820d-d232e4d87ab4" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_ccc58a80-e2f9-4056-a35b-cf8ebf43d27c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_5e4d95c3-4c48-417d-95c7-1836ec723dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_c0bf285a-3349-4e2e-820d-d232e4d87ab4" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_5e4d95c3-4c48-417d-95c7-1836ec723dc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncomeTaxReconciliationHealthInsuranceIndustryTax_227ee416-6fba-4d0a-9dd1-dcdc456247f6" xlink:href="ci-20231231.xsd#ci_IncomeTaxReconciliationHealthInsuranceIndustryTax"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_c0bf285a-3349-4e2e-820d-d232e4d87ab4" xlink:to="loc_ci_IncomeTaxReconciliationHealthInsuranceIndustryTax_227ee416-6fba-4d0a-9dd1-dcdc456247f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount_d5070209-3e67-4f06-a445-02b43fb17591" xlink:href="ci-20231231.xsd#ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_c0bf285a-3349-4e2e-820d-d232e4d87ab4" xlink:to="loc_ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount_d5070209-3e67-4f06-a445-02b43fb17591" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount_0434560d-40f6-439b-9a59-48d787cfc7d6" xlink:href="ci-20231231.xsd#ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_c0bf285a-3349-4e2e-820d-d232e4d87ab4" xlink:to="loc_ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount_0434560d-40f6-439b-9a59-48d787cfc7d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_eafa118e-c02b-419d-93ca-ef3cce298530" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_c0bf285a-3349-4e2e-820d-d232e4d87ab4" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_eafa118e-c02b-419d-93ca-ef3cce298530" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#IncomeTaxesDeferredIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale_52c3d76b-8430-4613-9393-21cd44c2c0d4" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsOtherIncludingDisposalGroupsAssetsHeldForSale_0613f076-6689-446a-9a4d-f9246d300f24" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsOtherIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale_52c3d76b-8430-4613-9393-21cd44c2c0d4" xlink:to="loc_ci_DeferredTaxAssetsOtherIncludingDisposalGroupsAssetsHeldForSale_0613f076-6689-446a-9a4d-f9246d300f24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIncludingDisposalGroupsAssetsHeldForSale_ddf6ff74-cda8-4159-909c-d9c9b3f2e3b3" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale_52c3d76b-8430-4613-9393-21cd44c2c0d4" xlink:to="loc_ci_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIncludingDisposalGroupsAssetsHeldForSale_ddf6ff74-cda8-4159-909c-d9c9b3f2e3b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOtherIncludingDisposalGroupsAssetsHeldForSale_e920547b-ade0-4015-a747-b1c42c0ae1f6" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOtherIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale_52c3d76b-8430-4613-9393-21cd44c2c0d4" xlink:to="loc_ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOtherIncludingDisposalGroupsAssetsHeldForSale_e920547b-ade0-4015-a747-b1c42c0ae1f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsOperatingLossCarryforwardsIncludingDisposalGroupsAssetsHeldForSale_02cc509a-d05a-4028-97ac-0b46935091ae" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsOperatingLossCarryforwardsIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale_52c3d76b-8430-4613-9393-21cd44c2c0d4" xlink:to="loc_ci_DeferredTaxAssetsOperatingLossCarryforwardsIncludingDisposalGroupsAssetsHeldForSale_02cc509a-d05a-4028-97ac-0b46935091ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilitiesIncludingDisposalGroupsAssetsHeldForSale_4f793f79-b0a0-48f4-8500-1e3bd0f37ffc" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilitiesIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale_52c3d76b-8430-4613-9393-21cd44c2c0d4" xlink:to="loc_ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilitiesIncludingDisposalGroupsAssetsHeldForSale_4f793f79-b0a0-48f4-8500-1e3bd0f37ffc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsPolicyAcquisitionExpensesIncludingDisposalGroupsAssetsHeldForSale_0ed43f0b-0aec-475a-84cd-d192efed1131" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsPolicyAcquisitionExpensesIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale_52c3d76b-8430-4613-9393-21cd44c2c0d4" xlink:to="loc_ci_DeferredTaxAssetsPolicyAcquisitionExpensesIncludingDisposalGroupsAssetsHeldForSale_0ed43f0b-0aec-475a-84cd-d192efed1131" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTransactionIncludingDisposalGroupsAssetsHeldForSale_48ab4968-f198-4e33-8d7d-921845cbb230" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTransactionIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale_52c3d76b-8430-4613-9393-21cd44c2c0d4" xlink:to="loc_ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTransactionIncludingDisposalGroupsAssetsHeldForSale_48ab4968-f198-4e33-8d7d-921845cbb230" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_bc496730-9cda-4dd9-9771-588c608e7342" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale_52c3d76b-8430-4613-9393-21cd44c2c0d4" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_bc496730-9cda-4dd9-9771-588c608e7342" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsForeignTaxAttributesIncludingDisposalGroupsAssetsHeldForSale_716e5283-32a5-4d5c-9fa2-807df6867c50" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsForeignTaxAttributesIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale_52c3d76b-8430-4613-9393-21cd44c2c0d4" xlink:to="loc_ci_DeferredTaxAssetsForeignTaxAttributesIncludingDisposalGroupsAssetsHeldForSale_716e5283-32a5-4d5c-9fa2-807df6867c50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_ddd00ed6-f01e-4847-aed5-8e96524b2644" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_5ca66af3-8e69-43a8-a867-d85697531986" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_ddd00ed6-f01e-4847-aed5-8e96524b2644" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_5ca66af3-8e69-43a8-a867-d85697531986" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_920ac991-433d-460a-ae2b-6f7239e5090d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_ddd00ed6-f01e-4847-aed5-8e96524b2644" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_920ac991-433d-460a-ae2b-6f7239e5090d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost_6cac7060-b10b-4d8a-b328-f692f541c827" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_ddd00ed6-f01e-4847-aed5-8e96524b2644" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost_6cac7060-b10b-4d8a-b328-f692f541c827" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGains_9928cca9-446c-4a98-a0b6-30bc7cc4a6f4" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGains"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_ddd00ed6-f01e-4847-aed5-8e96524b2644" xlink:to="loc_ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGains_9928cca9-446c-4a98-a0b6-30bc7cc4a6f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_5c7bc6a1-e4fd-49f1-ae46-9e9d84c2c8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_ddd00ed6-f01e-4847-aed5-8e96524b2644" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_5c7bc6a1-e4fd-49f1-ae46-9e9d84c2c8fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_8669f1ab-5632-47c6-a45f-000c9f915953" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_69b032b5-2fc6-4ef6-a748-655c191368e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_8669f1ab-5632-47c6-a45f-000c9f915953" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_69b032b5-2fc6-4ef6-a748-655c191368e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_bb2e01e4-496f-4b98-8bae-e48548e07d08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_8669f1ab-5632-47c6-a45f-000c9f915953" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_bb2e01e4-496f-4b98-8bae-e48548e07d08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_dd7d2ecd-3407-4d35-87fb-0eaedccd7053" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_de5b44c0-f655-4db3-8549-b21752423351" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_dd7d2ecd-3407-4d35-87fb-0eaedccd7053" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_de5b44c0-f655-4db3-8549-b21752423351" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_3e87c6f1-46de-4b4b-87f0-e08d11fd6622" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_dd7d2ecd-3407-4d35-87fb-0eaedccd7053" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_3e87c6f1-46de-4b4b-87f0-e08d11fd6622" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale_f43b31a3-896a-4f70-9ae5-339b05a0c644" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCostIncludingDisposalGroupsAssetsHeldForSale_ca4cd06f-6e25-4531-a50c-329e2ba6c283" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCostIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale_f43b31a3-896a-4f70-9ae5-339b05a0c644" xlink:to="loc_ci_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCostIncludingDisposalGroupsAssetsHeldForSale_ca4cd06f-6e25-4531-a50c-329e2ba6c283" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesOtherIncludingDisposalGroupsAssetsHeldForSale_7ff516a3-20f1-4b6a-83b5-909a54a2d4d7" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesOtherIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale_f43b31a3-896a-4f70-9ae5-339b05a0c644" xlink:to="loc_ci_DeferredTaxLiabilitiesOtherIncludingDisposalGroupsAssetsHeldForSale_7ff516a3-20f1-4b6a-83b5-909a54a2d4d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGainsIncludingDisposalGroupsAssetsHeldForSale_4f6cb98a-cf5b-4546-92ef-f3ebfd0acdcf" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGainsIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale_f43b31a3-896a-4f70-9ae5-339b05a0c644" xlink:to="loc_ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGainsIncludingDisposalGroupsAssetsHeldForSale_4f6cb98a-cf5b-4546-92ef-f3ebfd0acdcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIncludingDisposalGroupsAssetsHeldForSale_864fc250-505c-48d4-9755-b80629d9f6c4" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale_f43b31a3-896a-4f70-9ae5-339b05a0c644" xlink:to="loc_ci_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIncludingDisposalGroupsAssetsHeldForSale_864fc250-505c-48d4-9755-b80629d9f6c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesPropertyPlantAndEquipmentIncludingDisposalGroupsAssetsHeldForSale_ddb4707b-f8f7-45fb-bcf8-c1bfac3f58fc" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesPropertyPlantAndEquipmentIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale_f43b31a3-896a-4f70-9ae5-339b05a0c644" xlink:to="loc_ci_DeferredTaxLiabilitiesPropertyPlantAndEquipmentIncludingDisposalGroupsAssetsHeldForSale_ddb4707b-f8f7-45fb-bcf8-c1bfac3f58fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesNetIncludingDisposalGroup_f627779e-24f3-47a8-a284-c28e787b08d1" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesNetIncludingDisposalGroup"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_30502e84-5405-453d-8100-f0de0ceb6152" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DeferredTaxLiabilitiesNetIncludingDisposalGroup_f627779e-24f3-47a8-a284-c28e787b08d1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_30502e84-5405-453d-8100-f0de0ceb6152" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_1ecf1800-1726-4e5e-9d66-11285b84b0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DeferredTaxLiabilitiesNetIncludingDisposalGroup_f627779e-24f3-47a8-a284-c28e787b08d1" xlink:to="loc_us-gaap_DeferredTaxLiabilities_1ecf1800-1726-4e5e-9d66-11285b84b0c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_01c1c268-d209-4e4e-b21d-55469e91d8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_be23f29f-29cf-470e-865c-3ca4d592b274" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_01c1c268-d209-4e4e-b21d-55469e91d8f0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_be23f29f-29cf-470e-865c-3ca4d592b274" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities_ef4fabac-29ba-47aa-a66b-17558d89c58b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_01c1c268-d209-4e4e-b21d-55469e91d8f0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities_ef4fabac-29ba-47aa-a66b-17558d89c58b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6db73cc8-44bf-4ece-8999-90a07290fe12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_01c1c268-d209-4e4e-b21d-55469e91d8f0" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6db73cc8-44bf-4ece-8999-90a07290fe12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_54b85945-32b2-4cc0-8e4f-abf0fc1154a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_01c1c268-d209-4e4e-b21d-55469e91d8f0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_54b85945-32b2-4cc0-8e4f-abf0fc1154a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_f9df8642-87a4-4b2e-9806-b4949e029d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_01c1c268-d209-4e4e-b21d-55469e91d8f0" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_f9df8642-87a4-4b2e-9806-b4949e029d0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsPolicyAcquisitionExpenses_e2c9c80d-dcb3-4e14-bd6b-99333fe62c2d" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsPolicyAcquisitionExpenses"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_01c1c268-d209-4e4e-b21d-55469e91d8f0" xlink:to="loc_ci_DeferredTaxAssetsPolicyAcquisitionExpenses_e2c9c80d-dcb3-4e14-bd6b-99333fe62c2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTranslation_b1886886-4852-4446-8341-9b687365dd25" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTranslation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_01c1c268-d209-4e4e-b21d-55469e91d8f0" xlink:to="loc_ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTranslation_b1886886-4852-4446-8341-9b687365dd25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_33b3acf3-ebd0-4fd0-a1f4-241053a4c4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_01c1c268-d209-4e4e-b21d-55469e91d8f0" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_33b3acf3-ebd0-4fd0-a1f4-241053a4c4aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsForeignTaxAttributes_b4579185-21b1-4c32-8cde-92c05612fb70" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsForeignTaxAttributes"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_01c1c268-d209-4e4e-b21d-55469e91d8f0" xlink:to="loc_ci_DeferredTaxAssetsForeignTaxAttributes_b4579185-21b1-4c32-8cde-92c05612fb70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale_4cd5aa47-3ed4-4c2d-9de1-2c1ba7c66575" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale_ac3fb385-22ca-4d28-bb69-09493eff47c6" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale_4cd5aa47-3ed4-4c2d-9de1-2c1ba7c66575" xlink:to="loc_ci_DeferredTaxAssetsValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale_ac3fb385-22ca-4d28-bb69-09493eff47c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale_bb541305-a045-46a8-872c-80b4bee30ea2" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale_4cd5aa47-3ed4-4c2d-9de1-2c1ba7c66575" xlink:to="loc_ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale_bb541305-a045-46a8-872c-80b4bee30ea2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails_1" xlink:type="simple" xlink:href="ci-20231231.xsd#IncomeTaxesDeferredIncomeTaxesDetails_1"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesNetIncludingDisposalGroup_96c3f4eb-4297-44f6-aae2-760cd22d5f07" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesNetIncludingDisposalGroup"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale_40d58625-54e4-43c6-9944-9ba9251f5f01" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DeferredTaxLiabilitiesNetIncludingDisposalGroup_96c3f4eb-4297-44f6-aae2-760cd22d5f07" xlink:to="loc_ci_DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale_40d58625-54e4-43c6-9944-9ba9251f5f01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale_fbb4eca1-cf18-4ac7-a67a-8528b0575db6" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_DeferredTaxLiabilitiesNetIncludingDisposalGroup_96c3f4eb-4297-44f6-aae2-760cd22d5f07" xlink:to="loc_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale_fbb4eca1-cf18-4ac7-a67a-8528b0575db6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#SegmentInformationSummaryofSpecialItemsDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity_723a1852-05eb-4518-ab77-4a808406e8de" xlink:href="ci-20231231.xsd#ci_SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TransactionRelatedCostsAfterTax_1c304fd7-d93c-4846-a471-bea76ee0d55e" xlink:href="ci-20231231.xsd#ci_TransactionRelatedCostsAfterTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity_723a1852-05eb-4518-ab77-4a808406e8de" xlink:to="loc_ci_TransactionRelatedCostsAfterTax_1c304fd7-d93c-4846-a471-bea76ee0d55e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RestructuringChargesNetOfTaxExpense_100c3e16-16ca-45dc-bad6-c59f9ed8156a" xlink:href="ci-20231231.xsd#ci_RestructuringChargesNetOfTaxExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity_723a1852-05eb-4518-ab77-4a808406e8de" xlink:to="loc_ci_RestructuringChargesNetOfTaxExpense_100c3e16-16ca-45dc-bad6-c59f9ed8156a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitAfterTaxLitigation_9409461e-4e04-44cc-a3ab-dbec0922038d" xlink:href="ci-20231231.xsd#ci_SpecialItemChargeBenefitAfterTaxLitigation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity_723a1852-05eb-4518-ab77-4a808406e8de" xlink:to="loc_ci_SpecialItemChargeBenefitAfterTaxLitigation_9409461e-4e04-44cc-a3ab-dbec0922038d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax_a109d92f-bf6f-4f4c-b237-c891c4a39529" xlink:href="ci-20231231.xsd#ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity_723a1852-05eb-4518-ab77-4a808406e8de" xlink:to="loc_ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax_a109d92f-bf6f-4f4c-b237-c891c4a39529" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitTaxMattersAfterTax_002caefe-7370-4eb4-9d02-d0041a7bc612" xlink:href="ci-20231231.xsd#ci_SpecialItemChargeBenefitTaxMattersAfterTax"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity_723a1852-05eb-4518-ab77-4a808406e8de" xlink:to="loc_ci_SpecialItemChargeBenefitTaxMattersAfterTax_002caefe-7370-4eb4-9d02-d0041a7bc612" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax_7191141e-db68-4629-bb7c-52fb39da5de1" xlink:href="ci-20231231.xsd#ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity_723a1852-05eb-4518-ab77-4a808406e8de" xlink:to="loc_ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax_7191141e-db68-4629-bb7c-52fb39da5de1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity_f212761a-7323-4bf6-9845-7bad1c345453" xlink:href="ci-20231231.xsd#ci_SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TransactionRelatedCosts_cedd9e6a-ca4e-4c54-aae1-fb9714b88e70" xlink:href="ci-20231231.xsd#ci_TransactionRelatedCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity_f212761a-7323-4bf6-9845-7bad1c345453" xlink:to="loc_ci_TransactionRelatedCosts_cedd9e6a-ca4e-4c54-aae1-fb9714b88e70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_1fab3283-0961-41d9-8017-d1c78d8b04c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity_f212761a-7323-4bf6-9845-7bad1c345453" xlink:to="loc_us-gaap_RestructuringCharges_1fab3283-0961-41d9-8017-d1c78d8b04c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitBeforeTaxLitigation_7a442dfe-4e7f-4c1b-984a-b4e8a34e4f40" xlink:href="ci-20231231.xsd#ci_SpecialItemChargeBenefitBeforeTaxLitigation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity_f212761a-7323-4bf6-9845-7bad1c345453" xlink:to="loc_ci_SpecialItemChargeBenefitBeforeTaxLitigation_7a442dfe-4e7f-4c1b-984a-b4e8a34e4f40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes_14fc9b9d-3f2e-4578-a26f-5984a670bea0" xlink:href="ci-20231231.xsd#ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity_f212761a-7323-4bf6-9845-7bad1c345453" xlink:to="loc_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes_14fc9b9d-3f2e-4578-a26f-5984a670bea0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitTaxMatters_522aba1d-8a17-43a5-a994-ab09ba758702" xlink:href="ci-20231231.xsd#ci_SpecialItemChargeBenefitTaxMatters"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity_f212761a-7323-4bf6-9845-7bad1c345453" xlink:to="loc_ci_SpecialItemChargeBenefitTaxMatters_522aba1d-8a17-43a5-a994-ab09ba758702" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax_5c411255-60f8-4aaa-94ab-cb2716939f14" xlink:href="ci-20231231.xsd#ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity_f212761a-7323-4bf6-9845-7bad1c345453" xlink:to="loc_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax_5c411255-60f8-4aaa-94ab-cb2716939f14" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#SegmentInformationSummarizedSegmentFinancialInformationDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_3d81ac4b-5f2c-4f74-8eaf-8af0f842e89e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NonInvestmentRevenue_21ab32cf-36f0-4c8c-8a33-d8d1b7c407ea" xlink:href="ci-20231231.xsd#ci_NonInvestmentRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_3d81ac4b-5f2c-4f74-8eaf-8af0f842e89e" xlink:to="loc_ci_NonInvestmentRevenue_21ab32cf-36f0-4c8c-8a33-d8d1b7c407ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_74e068bb-9139-48e2-be6a-565f3a5818a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_3d81ac4b-5f2c-4f74-8eaf-8af0f842e89e" xlink:to="loc_us-gaap_NetInvestmentIncome_74e068bb-9139-48e2-be6a-565f3a5818a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SegmentRevenues_26e8bec9-706f-4886-a72a-2e7c865f9ffd" xlink:href="ci-20231231.xsd#ci_SegmentRevenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_65df695e-4277-40cb-93c2-90f1bde51626" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_SegmentRevenues_26e8bec9-706f-4886-a72a-2e7c865f9ffd" xlink:to="loc_us-gaap_Revenues_65df695e-4277-40cb-93c2-90f1bde51626" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RealizedInvestmentGainsLossesEquityMethodInvestments_2315b2e4-bd44-4e5f-8006-2012628dec50" xlink:href="ci-20231231.xsd#ci_RealizedInvestmentGainsLossesEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_SegmentRevenues_26e8bec9-706f-4886-a72a-2e7c865f9ffd" xlink:to="loc_ci_RealizedInvestmentGainsLossesEquityMethodInvestments_2315b2e4-bd44-4e5f-8006-2012628dec50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bcd26da2-8978-47dd-9bb8-8bf40205fdbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c853bd52-128b-49f5-9ee1-cf4be004e427" xlink:href="ci-20231231.xsd#ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bcd26da2-8978-47dd-9bb8-8bf40205fdbc" xlink:to="loc_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c853bd52-128b-49f5-9ee1-cf4be004e427" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries_e48989a1-f2e8-4d51-ba81-c4d9e1e596b9" xlink:href="ci-20231231.xsd#ci_RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bcd26da2-8978-47dd-9bb8-8bf40205fdbc" xlink:to="loc_ci_RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries_e48989a1-f2e8-4d51-ba81-c4d9e1e596b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax_d47f01a9-b0d6-4c73-b7a2-5efa9b178a7d" xlink:href="ci-20231231.xsd#ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bcd26da2-8978-47dd-9bb8-8bf40205fdbc" xlink:to="loc_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax_d47f01a9-b0d6-4c73-b7a2-5efa9b178a7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitBeforeTaxLitigation_e45e3190-2fa9-415f-b57b-05e87dcc27b2" xlink:href="ci-20231231.xsd#ci_SpecialItemChargeBenefitBeforeTaxLitigation"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bcd26da2-8978-47dd-9bb8-8bf40205fdbc" xlink:to="loc_ci_SpecialItemChargeBenefitBeforeTaxLitigation_e45e3190-2fa9-415f-b57b-05e87dcc27b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_3342efd6-42f1-498a-891a-d53ea909b040" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bcd26da2-8978-47dd-9bb8-8bf40205fdbc" xlink:to="loc_us-gaap_RestructuringCharges_3342efd6-42f1-498a-891a-d53ea909b040" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TransactionRelatedCosts_0b23bc80-966a-4050-a3b4-7b8f7b508b65" xlink:href="ci-20231231.xsd#ci_TransactionRelatedCosts"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bcd26da2-8978-47dd-9bb8-8bf40205fdbc" xlink:to="loc_ci_TransactionRelatedCosts_0b23bc80-966a-4050-a3b4-7b8f7b508b65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_c9b323a8-1947-4025-aaed-d6ae7fe8f681" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bcd26da2-8978-47dd-9bb8-8bf40205fdbc" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_c9b323a8-1947-4025-aaed-d6ae7fe8f681" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes_7c3f0851-4aee-4d29-9e49-6ea1345543a5" xlink:href="ci-20231231.xsd#ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bcd26da2-8978-47dd-9bb8-8bf40205fdbc" xlink:to="loc_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes_7c3f0851-4aee-4d29-9e49-6ea1345543a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax_0c2a2e3f-6c03-4a11-aa46-45d0c37d4359" xlink:href="ci-20231231.xsd#ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bcd26da2-8978-47dd-9bb8-8bf40205fdbc" xlink:to="loc_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax_0c2a2e3f-6c03-4a11-aa46-45d0c37d4359" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#SegmentInformationRevenuefromExternalCustomersDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_NonInvestmentRevenue_9c31abf5-d207-44a3-80f9-81c9bd352f8b" xlink:href="ci-20231231.xsd#ci_NonInvestmentRevenue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_6b40469f-245d-482a-aa90-71bfbd7b2739" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_NonInvestmentRevenue_9c31abf5-d207-44a3-80f9-81c9bd352f8b" xlink:to="loc_us-gaap_PremiumsEarnedNet_6b40469f-245d-482a-aa90-71bfbd7b2739" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9bbe5000-aa1f-4ff9-b8d1-5effe6db74f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_NonInvestmentRevenue_9c31abf5-d207-44a3-80f9-81c9bd352f8b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9bbe5000-aa1f-4ff9-b8d1-5effe6db74f5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_LossOfParentCompany_8b8a23b8-6a79-48d7-a460-43cf501c31e2" xlink:href="ci-20231231.xsd#ci_LossOfParentCompany"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1266c2fa-cb17-4293-b569-00315a76e5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_LossOfParentCompany_8b8a23b8-6a79-48d7-a460-43cf501c31e2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1266c2fa-cb17-4293-b569-00315a76e5d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c0a7e18a-a683-408b-bf6b-0781fdfcc487" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ci_LossOfParentCompany_8b8a23b8-6a79-48d7-a460-43cf501c31e2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c0a7e18a-a683-408b-bf6b-0781fdfcc487" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0866bf98-0201-43cf-abb9-303d709756b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_c390c29c-398b-4ffa-9b7d-41d5b07a2b68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0866bf98-0201-43cf-abb9-303d709756b4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_c390c29c-398b-4ffa-9b7d-41d5b07a2b68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_5a327053-10c9-48f9-bd05-bb7ad46938e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0866bf98-0201-43cf-abb9-303d709756b4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_5a327053-10c9-48f9-bd05-bb7ad46938e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_af68bc31-05eb-4a4c-9dfb-fe335e2bb376" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0866bf98-0201-43cf-abb9-303d709756b4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_af68bc31-05eb-4a4c-9dfb-fe335e2bb376" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent_c8229962-5d71-42bf-bc5c-579c3c847edf" xlink:href="ci-20231231.xsd#ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0866bf98-0201-43cf-abb9-303d709756b4" xlink:to="loc_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent_c8229962-5d71-42bf-bc5c-579c3c847edf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_64cd11ac-a564-4016-becd-c10276304ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LossOfParentCompany_a7c744c9-d9d3-46df-91a4-42e5a39c699f" xlink:href="ci-20231231.xsd#ci_LossOfParentCompany"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_64cd11ac-a564-4016-becd-c10276304ae8" xlink:to="loc_ci_LossOfParentCompany_a7c744c9-d9d3-46df-91a4-42e5a39c699f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_63fa5e23-0fc5-4de0-81f2-efc0f9d51694" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromSubsidiariesNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_64cd11ac-a564-4016-becd-c10276304ae8" xlink:to="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_63fa5e23-0fc5-4de0-81f2-efc0f9d51694" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_41865359-ec80-493c-8e7f-05cfd5d28d76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_1916d412-d2a0-4893-9bf8-a86647b7be73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_41865359-ec80-493c-8e7f-05cfd5d28d76" xlink:to="loc_us-gaap_NetInvestmentIncome_1916d412-d2a0-4893-9bf8-a86647b7be73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntercompanyInterestIncome_1f0edbd7-a174-4baa-85a8-b086ec77e3b5" xlink:href="ci-20231231.xsd#ci_IntercompanyInterestIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_41865359-ec80-493c-8e7f-05cfd5d28d76" xlink:to="loc_ci_IntercompanyInterestIncome_1f0edbd7-a174-4baa-85a8-b086ec77e3b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8c1a7289-2fcf-45d7-8656-45423c2f04e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_43146fe1-5c4b-4631-8a8f-7f2b27633b67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8c1a7289-2fcf-45d7-8656-45423c2f04e0" xlink:to="loc_us-gaap_OperatingIncomeLoss_43146fe1-5c4b-4631-8a8f-7f2b27633b67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e10f478d-5c08-458d-a6b3-a6b6afcf0952" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8c1a7289-2fcf-45d7-8656-45423c2f04e0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e10f478d-5c08-458d-a6b3-a6b6afcf0952" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntercompanyInterestExpense_4fb06dae-7d01-445f-94cf-5e52602a1b09" xlink:href="ci-20231231.xsd#ci_IntercompanyInterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8c1a7289-2fcf-45d7-8656-45423c2f04e0" xlink:to="loc_ci_IntercompanyInterestExpense_4fb06dae-7d01-445f-94cf-5e52602a1b09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fc04c10e-33db-4afd-a74c-76868ea02c91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8c1a7289-2fcf-45d7-8656-45423c2f04e0" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fc04c10e-33db-4afd-a74c-76868ea02c91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_7755388b-7972-47f1-a753-96d2ef0d2ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2d630772-96ce-45cd-b137-93799caefbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_7755388b-7972-47f1-a753-96d2ef0d2ba3" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2d630772-96ce-45cd-b137-93799caefbf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_00f55bbf-aeca-4495-9f0d-2e592c3c1940" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_7755388b-7972-47f1-a753-96d2ef0d2ba3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_00f55bbf-aeca-4495-9f0d-2e592c3c1940" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ba446234-bc63-4441-a733-f6d30a12ab75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_cab9eacd-00b7-48be-8d7f-e2956d07a8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ba446234-bc63-4441-a733-f6d30a12ab75" xlink:to="loc_us-gaap_DebtCurrent_cab9eacd-00b7-48be-8d7f-e2956d07a8cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_e700c3b0-3693-4078-a497-149e43d82c48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ba446234-bc63-4441-a733-f6d30a12ab75" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_e700c3b0-3693-4078-a497-149e43d82c48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5e2a3f04-a861-4fe0-8bd5-ab97c943aef3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3da33d12-37ee-4947-a1ed-48d2b8cee573" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5e2a3f04-a861-4fe0-8bd5-ab97c943aef3" xlink:to="loc_us-gaap_AssetsCurrent_3da33d12-37ee-4947-a1ed-48d2b8cee573" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_edef5efa-c178-4752-8949-afc213e3bbb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5e2a3f04-a861-4fe0-8bd5-ab97c943aef3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_edef5efa-c178-4752-8949-afc213e3bbb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndOtherNoncurrentAssets_70ba0ea6-f0d3-46ff-be43-4eeb0e951f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5e2a3f04-a861-4fe0-8bd5-ab97c943aef3" xlink:to="loc_us-gaap_InvestmentsAndOtherNoncurrentAssets_70ba0ea6-f0d3-46ff-be43-4eeb0e951f6c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails"/>
  <link:calculationLink xlink:role="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7017c855-2aae-4b45-be7d-45f6d268813f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfDebt_c889b2a1-e194-4781-8ada-edd066a18566" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7017c855-2aae-4b45-be7d-45f6d268813f" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfDebt_c889b2a1-e194-4781-8ada-edd066a18566" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_941fc081-9b31-4024-9329-26130f2734fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7017c855-2aae-4b45-be7d-45f6d268813f" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_941fc081-9b31-4024-9329-26130f2734fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_d4fa5b9f-1f89-4a21-9266-571724d95f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7017c855-2aae-4b45-be7d-45f6d268813f" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_d4fa5b9f-1f89-4a21-9266-571724d95f0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_da5a1bd5-0abb-41f1-b149-db34ef9a5c85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7017c855-2aae-4b45-be7d-45f6d268813f" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_da5a1bd5-0abb-41f1-b149-db34ef9a5c85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8fbe0fc5-75ab-4f50-9b57-821f07c4849f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7017c855-2aae-4b45-be7d-45f6d268813f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8fbe0fc5-75ab-4f50-9b57-821f07c4849f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b809baf6-a518-4673-b8fd-8af8a2457f55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7017c855-2aae-4b45-be7d-45f6d268813f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b809baf6-a518-4673-b8fd-8af8a2457f55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_5971c781-184e-4895-8b85-bf91eae52f75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7017c855-2aae-4b45-be7d-45f6d268813f" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_5971c781-184e-4895-8b85-bf91eae52f75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_81a148f9-2b98-4311-9554-5198c8c7abe0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7017c855-2aae-4b45-be7d-45f6d268813f" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_81a148f9-2b98-4311-9554-5198c8c7abe0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3da72ccd-61a3-443c-b05c-71aa24bd2245" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7017c855-2aae-4b45-be7d-45f6d268813f" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3da72ccd-61a3-443c-b05c-71aa24bd2245" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_147b1680-16b6-4734-bc3d-6e80ddec7777" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7017c855-2aae-4b45-be7d-45f6d268813f" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_147b1680-16b6-4734-bc3d-6e80ddec7777" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4d41997c-3ee3-4737-8a3c-ace21457efee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncreaseDecreaseInAmountsDueFromAffiliates_19b17f43-5d09-46ba-89b7-8c1e93911e93" xlink:href="ci-20231231.xsd#ci_IncreaseDecreaseInAmountsDueFromAffiliates"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4d41997c-3ee3-4737-8a3c-ace21457efee" xlink:to="loc_ci_IncreaseDecreaseInAmountsDueFromAffiliates_19b17f43-5d09-46ba-89b7-8c1e93911e93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_73e8fa91-610e-4b55-8785-b50aeae98924" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4d41997c-3ee3-4737-8a3c-ace21457efee" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_73e8fa91-610e-4b55-8785-b50aeae98924" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a743d71b-93e3-4d4e-aeef-e788a09c7fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_c7faa9fb-9179-4717-845c-1b5d73cafd64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a743d71b-93e3-4d4e-aeef-e788a09c7fe7" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_c7faa9fb-9179-4717-845c-1b5d73cafd64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_efb9f298-742f-414f-98b4-015c40c33dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromSubsidiariesNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a743d71b-93e3-4d4e-aeef-e788a09c7fe7" xlink:to="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_efb9f298-742f-414f-98b4-015c40c33dc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries_97b0db27-90b0-4af6-89cc-7a97b9ef04b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a743d71b-93e3-4d4e-aeef-e788a09c7fe7" xlink:to="loc_us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries_97b0db27-90b0-4af6-89cc-7a97b9ef04b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities_b594cd5a-00dd-4c15-b522-813dfddc8a09" xlink:href="ci-20231231.xsd#ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a743d71b-93e3-4d4e-aeef-e788a09c7fe7" xlink:to="loc_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities_b594cd5a-00dd-4c15-b522-813dfddc8a09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f73eafe3-fcfb-4085-8965-a4f8c7460522" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a743d71b-93e3-4d4e-aeef-e788a09c7fe7" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f73eafe3-fcfb-4085-8965-a4f8c7460522" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_39a97b49-720c-4d43-94a8-119e3e4fc7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a743d71b-93e3-4d4e-aeef-e788a09c7fe7" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_39a97b49-720c-4d43-94a8-119e3e4fc7c7" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>ci-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:fd466b51-e399-4368-bda1-c8c0817d4afc,g:199c158e-5fac-4def-904c-2de015f58c08-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="ci-20231231.xsd#ConsolidatedStatementsofIncome"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1b04d75a-3365-432c-802a-75103ee2c0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0712072b-e7e3-4fd1-96ca-f1084021dc7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1b04d75a-3365-432c-802a-75103ee2c0a7" xlink:to="loc_us-gaap_StatementTable_0712072b-e7e3-4fd1-96ca-f1084021dc7e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9033a4d1-4a10-4af2-88c9-fbfb151902f9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0712072b-e7e3-4fd1-96ca-f1084021dc7e" xlink:to="loc_srt_ProductOrServiceAxis_9033a4d1-4a10-4af2-88c9-fbfb151902f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9033a4d1-4a10-4af2-88c9-fbfb151902f9_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9033a4d1-4a10-4af2-88c9-fbfb151902f9" xlink:to="loc_srt_ProductsAndServicesDomain_9033a4d1-4a10-4af2-88c9-fbfb151902f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8234b12c-5174-45de-99d4-c29b3d4c681a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9033a4d1-4a10-4af2-88c9-fbfb151902f9" xlink:to="loc_srt_ProductsAndServicesDomain_8234b12c-5174-45de-99d4-c29b3d4c681a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_ba37fac5-eec3-4b75-9470-cd759d786e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8234b12c-5174-45de-99d4-c29b3d4c681a" xlink:to="loc_us-gaap_ProductMember_ba37fac5-eec3-4b75-9470-cd759d786e1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_e9bfbab3-7b4c-4582-afd1-42011f7fb685" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8234b12c-5174-45de-99d4-c29b3d4c681a" xlink:to="loc_us-gaap_ServiceMember_e9bfbab3-7b4c-4582-afd1-42011f7fb685" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_f6bb4d0e-7c30-42e5-ae7a-6c7b540554d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1b04d75a-3365-432c-802a-75103ee2c0a7" xlink:to="loc_us-gaap_RevenuesAbstract_f6bb4d0e-7c30-42e5-ae7a-6c7b540554d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ab5bec7b-0d94-412d-8d5a-7e27405b14cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_f6bb4d0e-7c30-42e5-ae7a-6c7b540554d0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ab5bec7b-0d94-412d-8d5a-7e27405b14cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_91937a04-2bff-4e9d-8c61-9a19935790ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_f6bb4d0e-7c30-42e5-ae7a-6c7b540554d0" xlink:to="loc_us-gaap_PremiumsEarnedNet_91937a04-2bff-4e9d-8c61-9a19935790ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_be2d07c9-98cf-4a3e-8323-e93de8e21f51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_f6bb4d0e-7c30-42e5-ae7a-6c7b540554d0" xlink:to="loc_us-gaap_NetInvestmentIncome_be2d07c9-98cf-4a3e-8323-e93de8e21f51" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_67d51f46-ee02-4f00-bf14-2f18c23df7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_f6bb4d0e-7c30-42e5-ae7a-6c7b540554d0" xlink:to="loc_us-gaap_Revenues_67d51f46-ee02-4f00-bf14-2f18c23df7b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BenefitsLossesAndExpensesAbstract_ab361a9f-df47-45f2-b26d-bf59b3e63fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BenefitsLossesAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1b04d75a-3365-432c-802a-75103ee2c0a7" xlink:to="loc_us-gaap_BenefitsLossesAndExpensesAbstract_ab361a9f-df47-45f2-b26d-bf59b3e63fe2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_e0911b6a-6991-45ca-b0f9-6ac4973b4566" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BenefitsLossesAndExpensesAbstract_ab361a9f-df47-45f2-b26d-bf59b3e63fe2" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_e0911b6a-6991-45ca-b0f9-6ac4973b4566" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_89017d72-6baf-4edf-8fef-a0b88c8edbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BenefitsLossesAndExpensesAbstract_ab361a9f-df47-45f2-b26d-bf59b3e63fe2" xlink:to="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_89017d72-6baf-4edf-8fef-a0b88c8edbf8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3e3e4cd2-804f-4a58-8a82-826563885efb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BenefitsLossesAndExpensesAbstract_ab361a9f-df47-45f2-b26d-bf59b3e63fe2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3e3e4cd2-804f-4a58-8a82-826563885efb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_52a3055b-441d-4371-a36a-4690d369831d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BenefitsLossesAndExpensesAbstract_ab361a9f-df47-45f2-b26d-bf59b3e63fe2" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_52a3055b-441d-4371-a36a-4690d369831d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BenefitsLossesAndExpenses_54103cc3-dad8-4f3d-9311-d1ad212075a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BenefitsLossesAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BenefitsLossesAndExpensesAbstract_ab361a9f-df47-45f2-b26d-bf59b3e63fe2" xlink:to="loc_us-gaap_BenefitsLossesAndExpenses_54103cc3-dad8-4f3d-9311-d1ad212075a5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_39082257-c592-4378-9183-a06180212fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1b04d75a-3365-432c-802a-75103ee2c0a7" xlink:to="loc_us-gaap_OperatingIncomeLoss_39082257-c592-4378-9183-a06180212fd0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_512fce66-1a5b-48a3-931c-c480c51c82b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1b04d75a-3365-432c-802a-75103ee2c0a7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_512fce66-1a5b-48a3-931c-c480c51c82b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a5dd658f-7052-4e78-96b7-1a0fee0a5065" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1b04d75a-3365-432c-802a-75103ee2c0a7" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a5dd658f-7052-4e78-96b7-1a0fee0a5065" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_aa3c45da-6b95-478b-8c0c-dea40b883cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1b04d75a-3365-432c-802a-75103ee2c0a7" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_aa3c45da-6b95-478b-8c0c-dea40b883cf7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RealizedInvestmentGainLoss_b907df40-3d2e-48de-b80b-5976971717d6" xlink:href="ci-20231231.xsd#ci_RealizedInvestmentGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1b04d75a-3365-432c-802a-75103ee2c0a7" xlink:to="loc_ci_RealizedInvestmentGainLoss_b907df40-3d2e-48de-b80b-5976971717d6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9453674e-af54-432a-9f34-0d4675ba749b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1b04d75a-3365-432c-802a-75103ee2c0a7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9453674e-af54-432a-9f34-0d4675ba749b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7a2e1d74-f3a0-4744-b92f-ac94d8b55244" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1b04d75a-3365-432c-802a-75103ee2c0a7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7a2e1d74-f3a0-4744-b92f-ac94d8b55244" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c3749166-3172-4f47-8838-961b53426bde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1b04d75a-3365-432c-802a-75103ee2c0a7" xlink:to="loc_us-gaap_ProfitLoss_c3749166-3172-4f47-8838-961b53426bde" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c483db32-bfef-45f1-a9dc-f49ab383e081" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1b04d75a-3365-432c-802a-75103ee2c0a7" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c483db32-bfef-45f1-a9dc-f49ab383e081" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d6659186-9348-4b31-acde-429cd9a330a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1b04d75a-3365-432c-802a-75103ee2c0a7" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d6659186-9348-4b31-acde-429cd9a330a4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2ce47802-2cd9-43d2-9cb5-7687b02c5f88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1b04d75a-3365-432c-802a-75103ee2c0a7" xlink:to="loc_us-gaap_EarningsPerShareAbstract_2ce47802-2cd9-43d2-9cb5-7687b02c5f88" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b3d12842-3199-42f0-82ec-7457636256bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2ce47802-2cd9-43d2-9cb5-7687b02c5f88" xlink:to="loc_us-gaap_EarningsPerShareBasic_b3d12842-3199-42f0-82ec-7457636256bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_47c8924a-da3b-4c56-8df9-d80026819f64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2ce47802-2cd9-43d2-9cb5-7687b02c5f88" xlink:to="loc_us-gaap_EarningsPerShareDiluted_47c8924a-da3b-4c56-8df9-d80026819f64" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity" xlink:type="simple" xlink:href="ci-20231231.xsd#ConsolidatedStatementsofChangesinTotalEquity"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_84fb7230-9607-4d56-8936-32261bea76bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_14267a74-fbe3-4047-9bef-c0956fdbe795" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_84fb7230-9607-4d56-8936-32261bea76bc" xlink:to="loc_us-gaap_StatementTable_14267a74-fbe3-4047-9bef-c0956fdbe795" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_37fbeaed-08e0-4d78-93a2-ec792cf57210" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_14267a74-fbe3-4047-9bef-c0956fdbe795" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_37fbeaed-08e0-4d78-93a2-ec792cf57210" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_37fbeaed-08e0-4d78-93a2-ec792cf57210_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_37fbeaed-08e0-4d78-93a2-ec792cf57210" xlink:to="loc_us-gaap_EquityComponentDomain_37fbeaed-08e0-4d78-93a2-ec792cf57210_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3d07bfff-4968-4e72-a8e9-2844e646432c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_37fbeaed-08e0-4d78-93a2-ec792cf57210" xlink:to="loc_us-gaap_EquityComponentDomain_3d07bfff-4968-4e72-a8e9-2844e646432c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_c14443dd-40ab-415a-9e75-a9d3d7b465e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3d07bfff-4968-4e72-a8e9-2844e646432c" xlink:to="loc_us-gaap_ParentMember_c14443dd-40ab-415a-9e75-a9d3d7b465e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0539bce5-d0c7-4a98-a8be-91f653d3d047" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_c14443dd-40ab-415a-9e75-a9d3d7b465e6" xlink:to="loc_us-gaap_CommonStockMember_0539bce5-d0c7-4a98-a8be-91f653d3d047" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c220a094-d17f-4921-9ade-614916f710e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_c14443dd-40ab-415a-9e75-a9d3d7b465e6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c220a094-d17f-4921-9ade-614916f710e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fc394785-3d14-465c-bd18-6ef4d968758e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_c14443dd-40ab-415a-9e75-a9d3d7b465e6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fc394785-3d14-465c-bd18-6ef4d968758e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_eaf14480-212a-405c-afec-25d0e7c44bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_c14443dd-40ab-415a-9e75-a9d3d7b465e6" xlink:to="loc_us-gaap_RetainedEarningsMember_eaf14480-212a-405c-afec-25d0e7c44bbe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_917dac81-ceab-4ef1-b3b5-b905299149f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_c14443dd-40ab-415a-9e75-a9d3d7b465e6" xlink:to="loc_us-gaap_TreasuryStockCommonMember_917dac81-ceab-4ef1-b3b5-b905299149f6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_27d6fd77-c932-489d-a7ff-91e6b7dbefab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3d07bfff-4968-4e72-a8e9-2844e646432c" xlink:to="loc_us-gaap_NoncontrollingInterestMember_27d6fd77-c932-489d-a7ff-91e6b7dbefab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_5f7c1e3d-bd83-4ae5-96ba-c817067b22ee" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_14267a74-fbe3-4047-9bef-c0956fdbe795" xlink:to="loc_srt_RestatementAxis_5f7c1e3d-bd83-4ae5-96ba-c817067b22ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_5f7c1e3d-bd83-4ae5-96ba-c817067b22ee_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_5f7c1e3d-bd83-4ae5-96ba-c817067b22ee" xlink:to="loc_srt_RestatementDomain_5f7c1e3d-bd83-4ae5-96ba-c817067b22ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_ba014aee-de58-4c41-9647-f86f30f87f17" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_5f7c1e3d-bd83-4ae5-96ba-c817067b22ee" xlink:to="loc_srt_RestatementDomain_ba014aee-de58-4c41-9647-f86f30f87f17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_53b41195-a443-4179-85a9-28acec3574bf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_ba014aee-de58-4c41-9647-f86f30f87f17" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_53b41195-a443-4179-85a9-28acec3574bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_11e1437c-a93e-46bd-92e7-bddf9a1ca03c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_ba014aee-de58-4c41-9647-f86f30f87f17" xlink:to="loc_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_11e1437c-a93e-46bd-92e7-bddf9a1ca03c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_834a3ca4-b746-401b-a69e-0354b45499b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_84fb7230-9607-4d56-8936-32261bea76bc" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_834a3ca4-b746-401b-a69e-0354b45499b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6dabe4c4-4f42-4ded-b252-809527a0e5db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_834a3ca4-b746-401b-a69e-0354b45499b9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6dabe4c4-4f42-4ded-b252-809527a0e5db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6b6bd6c7-a436-4b31-9301-caef91b2dfbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_834a3ca4-b746-401b-a69e-0354b45499b9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6b6bd6c7-a436-4b31-9301-caef91b2dfbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c9878097-fb51-42a7-af86-3c3b36820209" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_834a3ca4-b746-401b-a69e-0354b45499b9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c9878097-fb51-42a7-af86-3c3b36820209" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_d84ee238-1511-49af-a016-50a714c81e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_834a3ca4-b746-401b-a69e-0354b45499b9" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_d84ee238-1511-49af-a016-50a714c81e4a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_a4609949-f3ca-43cb-8300-e76d15048421" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_834a3ca4-b746-401b-a69e-0354b45499b9" xlink:to="loc_us-gaap_DividendsCommonStockCash_a4609949-f3ca-43cb-8300-e76d15048421" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_ace51d98-bda8-4c20-b6ec-755b86b17d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_834a3ca4-b746-401b-a69e-0354b45499b9" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_ace51d98-bda8-4c20-b6ec-755b86b17d2e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NoncontrollingInterestOtherChanges_c2719ad2-1dbe-4481-9965-1ea9dab74f83" xlink:href="ci-20231231.xsd#ci_NoncontrollingInterestOtherChanges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_834a3ca4-b746-401b-a69e-0354b45499b9" xlink:to="loc_ci_NoncontrollingInterestOtherChanges_c2719ad2-1dbe-4481-9965-1ea9dab74f83" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2f3c6a29-45e4-463e-b7f9-0a29503b5731" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_6078a518-9be4-4612-9670-24bc6a8b3314" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_84fb7230-9607-4d56-8936-32261bea76bc" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_6078a518-9be4-4612-9670-24bc6a8b3314" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_6235d2a8-077d-4c5f-aa02-969a0825843f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_6078a518-9be4-4612-9670-24bc6a8b3314" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_6235d2a8-077d-4c5f-aa02-969a0825843f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TemporaryEquityOtherComprehensiveIncome_02fd3b2b-a868-4d90-9b2c-ced864c3d547" xlink:href="ci-20231231.xsd#ci_TemporaryEquityOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_6078a518-9be4-4612-9670-24bc6a8b3314" xlink:to="loc_ci_TemporaryEquityOtherComprehensiveIncome_02fd3b2b-a868-4d90-9b2c-ced864c3d547" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome_05138657-9235-4030-97fb-0074c2db63ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_6078a518-9be4-4612-9670-24bc6a8b3314" xlink:to="loc_us-gaap_TemporaryEquityNetIncome_05138657-9235-4030-97fb-0074c2db63ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityOtherChanges_6783863e-f7f6-4192-9398-c0c1ec30ef92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityOtherChanges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_6078a518-9be4-4612-9670-24bc6a8b3314" xlink:to="loc_us-gaap_TemporaryEquityOtherChanges_6783863e-f7f6-4192-9398-c0c1ec30ef92" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_653c51a9-c6d1-4f55-99cf-3b959cc72150" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_9871ce2f-1b19-4cf9-9a32-0a3fbadb656f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_84fb7230-9607-4d56-8936-32261bea76bc" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_9871ce2f-1b19-4cf9-9a32-0a3fbadb656f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#DescriptionofBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/DescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_301e469f-c0ac-471a-86bc-21f626726d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d107b796-83e2-4fa1-8066-f7a61e98687d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_301e469f-c0ac-471a-86bc-21f626726d8e" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d107b796-83e2-4fa1-8066-f7a61e98687d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f2fbd874-4ccb-4c26-aac0-7976c0f1b94d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d107b796-83e2-4fa1-8066-f7a61e98687d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f2fbd874-4ccb-4c26-aac0-7976c0f1b94d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f2fbd874-4ccb-4c26-aac0-7976c0f1b94d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f2fbd874-4ccb-4c26-aac0-7976c0f1b94d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f2fbd874-4ccb-4c26-aac0-7976c0f1b94d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f5bf3f86-0da3-4414-a020-37c51b47e082" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f2fbd874-4ccb-4c26-aac0-7976c0f1b94d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f5bf3f86-0da3-4414-a020-37c51b47e082" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_dbcf59ec-0f2b-4b87-86ba-2f1209fbe45d" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f5bf3f86-0da3-4414-a020-37c51b47e082" xlink:to="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_dbcf59ec-0f2b-4b87-86ba-2f1209fbe45d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_63b037f1-eca5-411a-87ab-40a657020818" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d107b796-83e2-4fa1-8066-f7a61e98687d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_63b037f1-eca5-411a-87ab-40a657020818" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_63b037f1-eca5-411a-87ab-40a657020818_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_63b037f1-eca5-411a-87ab-40a657020818" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_63b037f1-eca5-411a-87ab-40a657020818_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_a14ae116-8f84-46d5-9fa0-9ba03e083aef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_63b037f1-eca5-411a-87ab-40a657020818" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_a14ae116-8f84-46d5-9fa0-9ba03e083aef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_b20ba251-5913-407e-b49f-f322ff5c774a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_a14ae116-8f84-46d5-9fa0-9ba03e083aef" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_b20ba251-5913-407e-b49f-f322ff5c774a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_c80a42e6-a684-4fa7-9a27-93c3900c44a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d107b796-83e2-4fa1-8066-f7a61e98687d" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_c80a42e6-a684-4fa7-9a27-93c3900c44a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c80a42e6-a684-4fa7-9a27-93c3900c44a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c80a42e6-a684-4fa7-9a27-93c3900c44a9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c80a42e6-a684-4fa7-9a27-93c3900c44a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_84796b95-ef6b-4968-8256-18f72aae26fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c80a42e6-a684-4fa7-9a27-93c3900c44a9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_84796b95-ef6b-4968-8256-18f72aae26fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_adec772e-4791-470c-834a-5e306707eb92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_84796b95-ef6b-4968-8256-18f72aae26fa" xlink:to="loc_us-gaap_SubsequentEventMember_adec772e-4791-470c-834a-5e306707eb92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d06bc839-e71e-42a2-bd00-5e3652c820a1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d107b796-83e2-4fa1-8066-f7a61e98687d" xlink:to="loc_srt_CounterpartyNameAxis_d06bc839-e71e-42a2-bd00-5e3652c820a1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d06bc839-e71e-42a2-bd00-5e3652c820a1_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d06bc839-e71e-42a2-bd00-5e3652c820a1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d06bc839-e71e-42a2-bd00-5e3652c820a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_424bc2d7-e268-4f4b-8308-d5a486013378" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d06bc839-e71e-42a2-bd00-5e3652c820a1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_424bc2d7-e268-4f4b-8308-d5a486013378" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_HealthCareServiceCorporationHCSCMember_16a3dc9d-a222-4d93-885c-d9280f23b145" xlink:href="ci-20231231.xsd#ci_HealthCareServiceCorporationHCSCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_424bc2d7-e268-4f4b-8308-d5a486013378" xlink:to="loc_ci_HealthCareServiceCorporationHCSCMember_16a3dc9d-a222-4d93-885c-d9280f23b145" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_f3f54084-cf84-49dd-86b2-61e5088f4ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_301e469f-c0ac-471a-86bc-21f626726d8e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_f3f54084-cf84-49dd-86b2-61e5088f4ccb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationNameOfSegmentExtensibleList_145d5a91-aed4-41af-821e-573e59c607c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationNameOfSegmentExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_301e469f-c0ac-471a-86bc-21f626726d8e" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationNameOfSegmentExtensibleList_145d5a91-aed4-41af-821e-573e59c607c6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_97584087-78c5-4dcc-a1c5-f72cacd8dd40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8e72dc53-da78-428d-abc1-b757a4e7bc89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_97584087-78c5-4dcc-a1c5-f72cacd8dd40" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8e72dc53-da78-428d-abc1-b757a4e7bc89" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f490b621-10a5-41e1-bf03-8f7c334cad07" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8e72dc53-da78-428d-abc1-b757a4e7bc89" xlink:to="loc_srt_ProductOrServiceAxis_f490b621-10a5-41e1-bf03-8f7c334cad07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f490b621-10a5-41e1-bf03-8f7c334cad07_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f490b621-10a5-41e1-bf03-8f7c334cad07" xlink:to="loc_srt_ProductsAndServicesDomain_f490b621-10a5-41e1-bf03-8f7c334cad07_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a1c94549-2222-442d-a822-ab25b2cb21ae" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f490b621-10a5-41e1-bf03-8f7c334cad07" xlink:to="loc_srt_ProductsAndServicesDomain_a1c94549-2222-442d-a822-ab25b2cb21ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PharmacyBenefitsManagementServicesMember_cca7b844-79b5-4e0d-abf6-8a51804fc719" xlink:href="ci-20231231.xsd#ci_PharmacyBenefitsManagementServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a1c94549-2222-442d-a822-ab25b2cb21ae" xlink:to="loc_ci_PharmacyBenefitsManagementServicesMember_cca7b844-79b5-4e0d-abf6-8a51804fc719" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AdministrativeServicesOnlyHealthCareServicesMember_d9f03a1a-72e2-4005-a98f-1f75fe976f7f" xlink:href="ci-20231231.xsd#ci_AdministrativeServicesOnlyHealthCareServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a1c94549-2222-442d-a822-ab25b2cb21ae" xlink:to="loc_ci_AdministrativeServicesOnlyHealthCareServicesMember_d9f03a1a-72e2-4005-a98f-1f75fe976f7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_f56ec8b7-94b9-4778-8643-bb6b223db168" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8e72dc53-da78-428d-abc1-b757a4e7bc89" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_f56ec8b7-94b9-4778-8643-bb6b223db168" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_f56ec8b7-94b9-4778-8643-bb6b223db168_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_f56ec8b7-94b9-4778-8643-bb6b223db168" xlink:to="loc_us-gaap_LossContingencyNatureDomain_f56ec8b7-94b9-4778-8643-bb6b223db168_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_1d3d310a-ba23-48cc-97e9-8d1aab192a14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_f56ec8b7-94b9-4778-8643-bb6b223db168" xlink:to="loc_us-gaap_LossContingencyNatureDomain_1d3d310a-ba23-48cc-97e9-8d1aab192a14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceGuaranteeMember_50b26335-e05f-4c40-8062-598ecbeb6063" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceGuaranteeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_1d3d310a-ba23-48cc-97e9-8d1aab192a14" xlink:to="loc_us-gaap_PerformanceGuaranteeMember_50b26335-e05f-4c40-8062-598ecbeb6063" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteesMember_a4dfc594-1ba9-4f2d-af7d-c2d9eddbd6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_1d3d310a-ba23-48cc-97e9-8d1aab192a14" xlink:to="loc_us-gaap_GuaranteesMember_a4dfc594-1ba9-4f2d-af7d-c2d9eddbd6bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_1a435c9f-3d65-4d80-8881-f435cc41b638" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8e72dc53-da78-428d-abc1-b757a4e7bc89" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_1a435c9f-3d65-4d80-8881-f435cc41b638" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_1a435c9f-3d65-4d80-8881-f435cc41b638_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_1a435c9f-3d65-4d80-8881-f435cc41b638" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_1a435c9f-3d65-4d80-8881-f435cc41b638_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8ba89608-b475-41d0-8700-e3ea722e920a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_1a435c9f-3d65-4d80-8881-f435cc41b638" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8ba89608-b475-41d0-8700-e3ea722e920a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_8c0dff9e-c1e6-4796-ad3b-95090c0c5984" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8ba89608-b475-41d0-8700-e3ea722e920a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_8c0dff9e-c1e6-4796-ad3b-95090c0c5984" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_c16c10de-a1c6-4939-808b-9c871474451f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8e72dc53-da78-428d-abc1-b757a4e7bc89" xlink:to="loc_srt_RestatementAxis_c16c10de-a1c6-4939-808b-9c871474451f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_c16c10de-a1c6-4939-808b-9c871474451f_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_c16c10de-a1c6-4939-808b-9c871474451f" xlink:to="loc_srt_RestatementDomain_c16c10de-a1c6-4939-808b-9c871474451f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_3e17293a-6630-42d5-accc-ac429e9f3ea6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_c16c10de-a1c6-4939-808b-9c871474451f" xlink:to="loc_srt_RestatementDomain_3e17293a-6630-42d5-accc-ac429e9f3ea6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_33dad479-495a-4eca-8edf-24ead8c26597" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_3e17293a-6630-42d5-accc-ac429e9f3ea6" xlink:to="loc_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_33dad479-495a-4eca-8edf-24ead8c26597" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3c933e77-fa30-4241-8a6a-d637e8c1cdc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_97584087-78c5-4dcc-a1c5-f72cacd8dd40" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3c933e77-fa30-4241-8a6a-d637e8c1cdc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9afc7947-fbae-46bc-8242-1975f429a0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_97584087-78c5-4dcc-a1c5-f72cacd8dd40" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9afc7947-fbae-46bc-8242-1975f429a0a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d1bf8b36-f2f2-48d8-8973-cda5529ddd4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_97584087-78c5-4dcc-a1c5-f72cacd8dd40" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d1bf8b36-f2f2-48d8-8973-cda5529ddd4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_24547149-db3d-4946-a661-22e4e39675ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_97584087-78c5-4dcc-a1c5-f72cacd8dd40" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_24547149-db3d-4946-a661-22e4e39675ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_b952bc9f-1990-4d77-9186-bd912bb4d81e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_97584087-78c5-4dcc-a1c5-f72cacd8dd40" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_b952bc9f-1990-4d77-9186-bd912bb4d81e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_56afc234-e089-4881-ae92-421cc5a0ed6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_97584087-78c5-4dcc-a1c5-f72cacd8dd40" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_56afc234-e089-4881-ae92-421cc5a0ed6d" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c2693c9-3639-439f-ab34-3ff9aab5c8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6bcd1954-21d5-4f1b-b070-ef3c235305d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c2693c9-3639-439f-ab34-3ff9aab5c8b8" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6bcd1954-21d5-4f1b-b070-ef3c235305d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_ee22d329-df30-47b7-89d3-99714123d26d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6bcd1954-21d5-4f1b-b070-ef3c235305d9" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_ee22d329-df30-47b7-89d3-99714123d26d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ee22d329-df30-47b7-89d3-99714123d26d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_ee22d329-df30-47b7-89d3-99714123d26d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ee22d329-df30-47b7-89d3-99714123d26d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_f27a7d5d-4ee6-481c-8ca3-ae9a46b92e24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_ee22d329-df30-47b7-89d3-99714123d26d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_f27a7d5d-4ee6-481c-8ca3-ae9a46b92e24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_aeee30bc-2080-446d-8158-5c23b6e9deb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_f27a7d5d-4ee6-481c-8ca3-ae9a46b92e24" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_aeee30bc-2080-446d-8158-5c23b6e9deb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f1803428-ff8a-4fab-8404-1c40ab824c12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6bcd1954-21d5-4f1b-b070-ef3c235305d9" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f1803428-ff8a-4fab-8404-1c40ab824c12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f1803428-ff8a-4fab-8404-1c40ab824c12_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f1803428-ff8a-4fab-8404-1c40ab824c12" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f1803428-ff8a-4fab-8404-1c40ab824c12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f90bfa0d-5cc0-4e0a-9436-dc109fc28962" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f1803428-ff8a-4fab-8404-1c40ab824c12" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f90bfa0d-5cc0-4e0a-9436-dc109fc28962" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_88d6a2e5-e2fa-439f-a6ba-b63d65437277" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f90bfa0d-5cc0-4e0a-9436-dc109fc28962" xlink:to="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_88d6a2e5-e2fa-439f-a6ba-b63d65437277" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PharmaceuticalManufacturerReceivable_4f8f69d0-a782-4952-a28d-5d8692ac506a" xlink:href="ci-20231231.xsd#ci_PharmaceuticalManufacturerReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c2693c9-3639-439f-ab34-3ff9aab5c8b8" xlink:to="loc_ci_PharmaceuticalManufacturerReceivable_4f8f69d0-a782-4952-a28d-5d8692ac506a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable_d4299082-b87f-4b03-9573-c764d0639b08" xlink:href="ci-20231231.xsd#ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c2693c9-3639-439f-ab34-3ff9aab5c8b8" xlink:to="loc_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable_d4299082-b87f-4b03-9573-c764d0639b08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceCustomerReceivables_a524e74e-d630-469b-9345-9bee41674159" xlink:href="ci-20231231.xsd#ci_InsuranceCustomerReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c2693c9-3639-439f-ab34-3ff9aab5c8b8" xlink:to="loc_ci_InsuranceCustomerReceivables_a524e74e-d630-469b-9345-9bee41674159" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_538ab548-e345-4324-8a4a-34375c0eef09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c2693c9-3639-439f-ab34-3ff9aab5c8b8" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_538ab548-e345-4324-8a4a-34375c0eef09" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale_6c5f5404-17e9-4b80-a167-8a55d80a8c5d" xlink:href="ci-20231231.xsd#ci_PharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c2693c9-3639-439f-ab34-3ff9aab5c8b8" xlink:to="loc_ci_PharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale_6c5f5404-17e9-4b80-a167-8a55d80a8c5d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale_820eea69-e373-4a43-b4ba-42d92f171762" xlink:href="ci-20231231.xsd#ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c2693c9-3639-439f-ab34-3ff9aab5c8b8" xlink:to="loc_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale_820eea69-e373-4a43-b4ba-42d92f171762" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceCustomerReceivablesBeforeReclassificationToDisposalGroupAssetsHeldForSale_11048432-c591-446d-93c5-8da89ed2b6e7" xlink:href="ci-20231231.xsd#ci_InsuranceCustomerReceivablesBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c2693c9-3639-439f-ab34-3ff9aab5c8b8" xlink:to="loc_ci_InsuranceCustomerReceivablesBeforeReclassificationToDisposalGroupAssetsHeldForSale_11048432-c591-446d-93c5-8da89ed2b6e7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccountsAndOtherReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale_1d44d476-3182-4875-8b54-27579ab5b690" xlink:href="ci-20231231.xsd#ci_AccountsAndOtherReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c2693c9-3639-439f-ab34-3ff9aab5c8b8" xlink:to="loc_ci_AccountsAndOtherReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale_1d44d476-3182-4875-8b54-27579ab5b690" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale_0467ffce-d1e9-44aa-97b1-0b1b1b8bc076" xlink:href="ci-20231231.xsd#ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c2693c9-3639-439f-ab34-3ff9aab5c8b8" xlink:to="loc_ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale_0467ffce-d1e9-44aa-97b1-0b1b1b8bc076" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_f9bc1eb6-41c3-436c-a054-9d57ab27c210" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c2693c9-3639-439f-ab34-3ff9aab5c8b8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_f9bc1eb6-41c3-436c-a054-9d57ab27c210" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_8da34ac0-a5fb-413f-83e3-951dc5b58a48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c2693c9-3639-439f-ab34-3ff9aab5c8b8" xlink:to="loc_us-gaap_ReceivablesNetCurrent_8da34ac0-a5fb-413f-83e3-951dc5b58a48" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/MergersAcquisitionsandDivestituresNarrativeDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#MergersAcquisitionsandDivestituresNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/MergersAcquisitionsandDivestituresNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_466d1bfe-fd12-454e-ad13-8ee07baab186" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_24b06e65-06c7-4267-bfa2-93f30d521799" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_466d1bfe-fd12-454e-ad13-8ee07baab186" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_24b06e65-06c7-4267-bfa2-93f30d521799" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6a51ba1a-4690-42e0-a676-0aaa8cd777c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_24b06e65-06c7-4267-bfa2-93f30d521799" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6a51ba1a-4690-42e0-a676-0aaa8cd777c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6a51ba1a-4690-42e0-a676-0aaa8cd777c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6a51ba1a-4690-42e0-a676-0aaa8cd777c0" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6a51ba1a-4690-42e0-a676-0aaa8cd777c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_13686732-66dc-4c6b-8312-faf0e2616600" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6a51ba1a-4690-42e0-a676-0aaa8cd777c0" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_13686732-66dc-4c6b-8312-faf0e2616600" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_USGroupDisabilityAndLifeInsuranceBusinessMember_f4557c5d-e578-4069-9508-7c210dfb6552" xlink:href="ci-20231231.xsd#ci_USGroupDisabilityAndLifeInsuranceBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_13686732-66dc-4c6b-8312-faf0e2616600" xlink:to="loc_ci_USGroupDisabilityAndLifeInsuranceBusinessMember_f4557c5d-e578-4069-9508-7c210dfb6552" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember_33affdf5-a487-46f6-881a-795acc377d4e" xlink:href="ci-20231231.xsd#ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_13686732-66dc-4c6b-8312-faf0e2616600" xlink:to="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember_33affdf5-a487-46f6-881a-795acc377d4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember_f9e6f9a6-b8f1-47aa-8030-1ded1f315ad1" xlink:href="ci-20231231.xsd#ci_InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember_33affdf5-a487-46f6-881a-795acc377d4e" xlink:to="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember_f9e6f9a6-b8f1-47aa-8030-1ded1f315ad1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_09fb5cb1-9b87-4162-8e78-96bedd0af8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_24b06e65-06c7-4267-bfa2-93f30d521799" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_09fb5cb1-9b87-4162-8e78-96bedd0af8ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_09fb5cb1-9b87-4162-8e78-96bedd0af8ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_09fb5cb1-9b87-4162-8e78-96bedd0af8ad" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_09fb5cb1-9b87-4162-8e78-96bedd0af8ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_53e8e118-2c6e-4a33-b505-8ddafa95fee6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_09fb5cb1-9b87-4162-8e78-96bedd0af8ad" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_53e8e118-2c6e-4a33-b505-8ddafa95fee6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_6025245c-b319-414c-a254-254ef9debd83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_53e8e118-2c6e-4a33-b505-8ddafa95fee6" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_6025245c-b319-414c-a254-254ef9debd83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2284a726-42d2-44c6-8ba0-9a535a0e81b5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_24b06e65-06c7-4267-bfa2-93f30d521799" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2284a726-42d2-44c6-8ba0-9a535a0e81b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_2284a726-42d2-44c6-8ba0-9a535a0e81b5_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2284a726-42d2-44c6-8ba0-9a535a0e81b5" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_2284a726-42d2-44c6-8ba0-9a535a0e81b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_4742df6a-48d0-44b5-88c7-1f641e65955a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2284a726-42d2-44c6-8ba0-9a535a0e81b5" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_4742df6a-48d0-44b5-88c7-1f641e65955a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CHSSJVLLCMember_2f06d015-adde-46f7-8d16-7e992ecb89b0" xlink:href="ci-20231231.xsd#ci_CHSSJVLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_4742df6a-48d0-44b5-88c7-1f641e65955a" xlink:to="loc_ci_CHSSJVLLCMember_2f06d015-adde-46f7-8d16-7e992ecb89b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis_c0ff3576-edcd-4c0e-818a-7a1bf7cffc43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsByNatureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_24b06e65-06c7-4267-bfa2-93f30d521799" xlink:to="loc_us-gaap_GuaranteeObligationsByNatureAxis_c0ff3576-edcd-4c0e-818a-7a1bf7cffc43" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_c0ff3576-edcd-4c0e-818a-7a1bf7cffc43_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_c0ff3576-edcd-4c0e-818a-7a1bf7cffc43" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_c0ff3576-edcd-4c0e-818a-7a1bf7cffc43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_8a705479-a12e-4a8a-89fa-0bc94d142e46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_c0ff3576-edcd-4c0e-818a-7a1bf7cffc43" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_8a705479-a12e-4a8a-89fa-0bc94d142e46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndirectGuaranteeOfIndebtednessMember_97b3e2e0-e293-4898-b900-f8b8759fc915" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndirectGuaranteeOfIndebtednessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain_8a705479-a12e-4a8a-89fa-0bc94d142e46" xlink:to="loc_us-gaap_IndirectGuaranteeOfIndebtednessMember_97b3e2e0-e293-4898-b900-f8b8759fc915" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_366b784b-b253-45c1-8273-89106030c732" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsMaximumExposure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_466d1bfe-fd12-454e-ad13-8ee07baab186" xlink:to="loc_us-gaap_GuaranteeObligationsMaximumExposure_366b784b-b253-45c1-8273-89106030c732" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_bc37d38f-5ea9-474a-8f10-8fec070eadb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_466d1bfe-fd12-454e-ad13-8ee07baab186" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_bc37d38f-5ea9-474a-8f10-8fec070eadb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_212093dc-8050-40cf-8e77-b286fbf4ba10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_466d1bfe-fd12-454e-ad13-8ee07baab186" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_212093dc-8050-40cf-8e77-b286fbf4ba10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax_f826ac61-e0fb-40c5-af9a-62a399c53940" xlink:href="ci-20231231.xsd#ci_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_466d1bfe-fd12-454e-ad13-8ee07baab186" xlink:to="loc_ci_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax_f826ac61-e0fb-40c5-af9a-62a399c53940" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TransactionRelatedCosts_6da464c1-41e5-465a-acf4-edc673361bf4" xlink:href="ci-20231231.xsd#ci_TransactionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_466d1bfe-fd12-454e-ad13-8ee07baab186" xlink:to="loc_ci_TransactionRelatedCosts_6da464c1-41e5-465a-acf4-edc673361bf4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TransactionRelatedCostsAfterTax_316cd410-74df-4305-9eb7-81e05339cbdc" xlink:href="ci-20231231.xsd#ci_TransactionRelatedCostsAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_466d1bfe-fd12-454e-ad13-8ee07baab186" xlink:to="loc_ci_TransactionRelatedCostsAfterTax_316cd410-74df-4305-9eb7-81e05339cbdc" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#AssetsandLiabilitiesofBusinessesHeldforSaleDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be7977e-77e6-4b11-924d-26c138eca95d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2309b2cb-7325-4877-b910-70ab8cf09273" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be7977e-77e6-4b11-924d-26c138eca95d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2309b2cb-7325-4877-b910-70ab8cf09273" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_35e7494b-cca6-4371-9195-b68d254e86e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2309b2cb-7325-4877-b910-70ab8cf09273" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_35e7494b-cca6-4371-9195-b68d254e86e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_35e7494b-cca6-4371-9195-b68d254e86e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_35e7494b-cca6-4371-9195-b68d254e86e0" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_35e7494b-cca6-4371-9195-b68d254e86e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08c137a4-d24c-4ccd-aeee-9c62935be0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_35e7494b-cca6-4371-9195-b68d254e86e0" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08c137a4-d24c-4ccd-aeee-9c62935be0b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_abbb0223-f2d1-460a-bc4a-b8b70b0a8ef7" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08c137a4-d24c-4ccd-aeee-9c62935be0b8" xlink:to="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_abbb0223-f2d1-460a-bc4a-b8b70b0a8ef7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember_9480b36c-616e-4036-9ec5-d842692317e1" xlink:href="ci-20231231.xsd#ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08c137a4-d24c-4ccd-aeee-9c62935be0b8" xlink:to="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember_9480b36c-616e-4036-9ec5-d842692317e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember_565d24f8-6b4f-4d18-9df8-ddf88a2928cc" xlink:href="ci-20231231.xsd#ci_InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember_9480b36c-616e-4036-9ec5-d842692317e1" xlink:to="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember_565d24f8-6b4f-4d18-9df8-ddf88a2928cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_028a776c-3049-4622-82b1-6cdfbdd92a61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2309b2cb-7325-4877-b910-70ab8cf09273" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_028a776c-3049-4622-82b1-6cdfbdd92a61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_028a776c-3049-4622-82b1-6cdfbdd92a61_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_028a776c-3049-4622-82b1-6cdfbdd92a61" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_028a776c-3049-4622-82b1-6cdfbdd92a61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_61844c39-f781-486a-b140-a752feaca7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_028a776c-3049-4622-82b1-6cdfbdd92a61" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_61844c39-f781-486a-b140-a752feaca7e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_f492db42-aaee-4b30-9628-c21c4efd139a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_61844c39-f781-486a-b140-a752feaca7e8" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_f492db42-aaee-4b30-9628-c21c4efd139a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_aea17603-91d4-4c9c-a013-378426eb3683" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_61844c39-f781-486a-b140-a752feaca7e8" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_aea17603-91d4-4c9c-a013-378426eb3683" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_10524b29-87c3-4b3e-97bb-18505f664a20" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2309b2cb-7325-4877-b910-70ab8cf09273" xlink:to="loc_srt_CounterpartyNameAxis_10524b29-87c3-4b3e-97bb-18505f664a20" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_10524b29-87c3-4b3e-97bb-18505f664a20_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_10524b29-87c3-4b3e-97bb-18505f664a20" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_10524b29-87c3-4b3e-97bb-18505f664a20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_454b3e43-fac9-43b0-bf3f-097d3306fcb6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_10524b29-87c3-4b3e-97bb-18505f664a20" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_454b3e43-fac9-43b0-bf3f-097d3306fcb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_HealthCareServiceCorporationHCSCMember_2dcd070a-24ce-48d8-956d-da59c7363ff6" xlink:href="ci-20231231.xsd#ci_HealthCareServiceCorporationHCSCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_454b3e43-fac9-43b0-bf3f-097d3306fcb6" xlink:to="loc_ci_HealthCareServiceCorporationHCSCMember_2dcd070a-24ce-48d8-956d-da59c7363ff6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1c9139a1-e77b-4725-88e7-48d73f1dc5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2309b2cb-7325-4877-b910-70ab8cf09273" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1c9139a1-e77b-4725-88e7-48d73f1dc5ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1c9139a1-e77b-4725-88e7-48d73f1dc5ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1c9139a1-e77b-4725-88e7-48d73f1dc5ac" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1c9139a1-e77b-4725-88e7-48d73f1dc5ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b4997d48-4b5e-41c4-b99f-e4b2b5590466" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1c9139a1-e77b-4725-88e7-48d73f1dc5ac" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b4997d48-4b5e-41c4-b99f-e4b2b5590466" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_88b89a2f-fe5c-4e8b-8970-408c56b22f96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b4997d48-4b5e-41c4-b99f-e4b2b5590466" xlink:to="loc_us-gaap_SubsequentEventMember_88b89a2f-fe5c-4e8b-8970-408c56b22f96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_685172bd-a217-49dc-a330-959ae0d47b29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be7977e-77e6-4b11-924d-26c138eca95d" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_685172bd-a217-49dc-a330-959ae0d47b29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationSegmentThatIncludesDisposalGroup_7ff49ed8-3888-4aee-bc63-dea215652d49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationSegmentThatIncludesDisposalGroup"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be7977e-77e6-4b11-924d-26c138eca95d" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationSegmentThatIncludesDisposalGroup_7ff49ed8-3888-4aee-bc63-dea215652d49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_d7b7fcd3-60cf-484a-b5ef-f85ca24b09a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be7977e-77e6-4b11-924d-26c138eca95d" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_d7b7fcd3-60cf-484a-b5ef-f85ca24b09a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_fb629032-121f-4e43-8553-31d07b4581aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_d7b7fcd3-60cf-484a-b5ef-f85ca24b09a2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_fb629032-121f-4e43-8553-31d07b4581aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationInvestments_94500be5-b262-43f2-bf0f-7bb123681105" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_d7b7fcd3-60cf-484a-b5ef-f85ca24b09a2" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationInvestments_94500be5-b262-43f2-bf0f-7bb123681105" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_225c57c2-8838-4525-b880-fd3496638f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_d7b7fcd3-60cf-484a-b5ef-f85ca24b09a2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_225c57c2-8838-4525-b880-fd3496638f8e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationOtherAssetsGoodwill_8e7e5dda-80de-4d52-822c-6877616838dc" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationOtherAssetsGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_d7b7fcd3-60cf-484a-b5ef-f85ca24b09a2" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationOtherAssetsGoodwill_8e7e5dda-80de-4d52-822c-6877616838dc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_cf6ccb82-ad49-4796-86d8-56ddf200091e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DisposalGroupIncludingDiscontinuedOperationOtherAssetsGoodwill_8e7e5dda-80de-4d52-822c-6877616838dc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_cf6ccb82-ad49-4796-86d8-56ddf200091e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_ab0a7f48-8607-436c-8bd4-a2ab2eadbeb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DisposalGroupIncludingDiscontinuedOperationOtherAssetsGoodwill_8e7e5dda-80de-4d52-822c-6877616838dc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_ab0a7f48-8607-436c-8bd4-a2ab2eadbeb3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_8b581dca-6c02-4db4-856b-a917afd77deb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_d7b7fcd3-60cf-484a-b5ef-f85ca24b09a2" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_8b581dca-6c02-4db4-856b-a917afd77deb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities_58abb551-ffbb-4843-9777-aa4ff70c6f9c" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_d7b7fcd3-60cf-484a-b5ef-f85ca24b09a2" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities_58abb551-ffbb-4843-9777-aa4ff70c6f9c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationLiabilitiesExcludingInsuranceAndContractholderLiabilities_fc5c74f7-a583-4e91-bef0-3ea9f1d851a2" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationLiabilitiesExcludingInsuranceAndContractholderLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_d7b7fcd3-60cf-484a-b5ef-f85ca24b09a2" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationLiabilitiesExcludingInsuranceAndContractholderLiabilities_fc5c74f7-a583-4e91-bef0-3ea9f1d851a2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_9b514e17-337c-48a4-9031-41cb1d98fc63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_d7b7fcd3-60cf-484a-b5ef-f85ca24b09a2" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_9b514e17-337c-48a4-9031-41cb1d98fc63" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossInvestmentsAndDerivatives_63c14ae7-889f-4d12-b609-fe1b9da6cc98" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossInvestmentsAndDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_d7b7fcd3-60cf-484a-b5ef-f85ca24b09a2" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossInvestmentsAndDerivatives_63c14ae7-889f-4d12-b609-fe1b9da6cc98" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossForeignCurrencyTranslation_d494f140-38f9-4e16-8763-a8bcea9dc696" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossForeignCurrencyTranslation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_d7b7fcd3-60cf-484a-b5ef-f85ca24b09a2" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossForeignCurrencyTranslation_d494f140-38f9-4e16-8763-a8bcea9dc696" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxAbstract_6ac6503f-9766-4f80-aea8-0cd1c1b8b8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be7977e-77e6-4b11-924d-26c138eca95d" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxAbstract_6ac6503f-9766-4f80-aea8-0cd1c1b8b8aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_19e14886-0874-40a1-ade4-d70c3bf00851" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxAbstract_6ac6503f-9766-4f80-aea8-0cd1c1b8b8aa" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_19e14886-0874-40a1-ade4-d70c3bf00851" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax_c3a13a14-9ac3-4d26-8075-6b5aa60d642d" xlink:href="ci-20231231.xsd#ci_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxAbstract_6ac6503f-9766-4f80-aea8-0cd1c1b8b8aa" xlink:to="loc_ci_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax_c3a13a14-9ac3-4d26-8075-6b5aa60d642d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList_0c51db2e-d893-4151-9cdd-4e4d734321f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxAbstract_6ac6503f-9766-4f80-aea8-0cd1c1b8b8aa" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList_0c51db2e-d893-4151-9cdd-4e4d734321f9" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EarningsPerShareOutstandingEmployeeStockOptionsNotIncludedintheComputationofDilutedEarningsPerShareDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#EarningsPerShareOutstandingEmployeeStockOptionsNotIncludedintheComputationofDilutedEarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/EarningsPerShareOutstandingEmployeeStockOptionsNotIncludedintheComputationofDilutedEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4c30931c-b81f-4280-b5bd-b36727f6632b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d93374ba-786a-4cf2-b33e-73b2ca8cdbc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4c30931c-b81f-4280-b5bd-b36727f6632b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d93374ba-786a-4cf2-b33e-73b2ca8cdbc6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3a5aaecb-0be7-42b7-a081-e7ca9fac9063" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d93374ba-786a-4cf2-b33e-73b2ca8cdbc6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3a5aaecb-0be7-42b7-a081-e7ca9fac9063" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3a5aaecb-0be7-42b7-a081-e7ca9fac9063_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3a5aaecb-0be7-42b7-a081-e7ca9fac9063" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3a5aaecb-0be7-42b7-a081-e7ca9fac9063_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bb532f1f-4242-4185-a137-2a29b1bdf28d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3a5aaecb-0be7-42b7-a081-e7ca9fac9063" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bb532f1f-4242-4185-a137-2a29b1bdf28d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_47f2761e-f4f0-485e-b380-25df5a56d2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bb532f1f-4242-4185-a137-2a29b1bdf28d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_47f2761e-f4f0-485e-b380-25df5a56d2d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9bc6a32f-421a-4f92-8885-ade4a90e4c96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4c30931c-b81f-4280-b5bd-b36727f6632b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9bc6a32f-421a-4f92-8885-ade4a90e4c96" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#DebtOutstandingAmountsofDebtandFinanceLeasesDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_87cb89b0-3be7-4f1e-92ab-a75065ae7abb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b92bbfdc-7447-43de-a351-7ada1ad802a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_87cb89b0-3be7-4f1e-92ab-a75065ae7abb" xlink:to="loc_us-gaap_DebtInstrumentTable_b92bbfdc-7447-43de-a351-7ada1ad802a8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_13ce7046-1856-4eed-8d33-50864fb496d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b92bbfdc-7447-43de-a351-7ada1ad802a8" xlink:to="loc_us-gaap_DebtInstrumentAxis_13ce7046-1856-4eed-8d33-50864fb496d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_13ce7046-1856-4eed-8d33-50864fb496d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_13ce7046-1856-4eed-8d33-50864fb496d4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_13ce7046-1856-4eed-8d33-50864fb496d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_13ce7046-1856-4eed-8d33-50864fb496d4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue2022305InterestMember_0b4f7cef-c1da-4793-8267-fdea40f15e7b" xlink:href="ci-20231231.xsd#ci_NotesDue2022305InterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue2022305InterestMember_0b4f7cef-c1da-4793-8267-fdea40f15e7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue202383InterestMember_da69f836-d779-4b0a-b0c3-1bfbc41c4d3e" xlink:href="ci-20231231.xsd#ci_NotesDue202383InterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue202383InterestMember_da69f836-d779-4b0a-b0c3-1bfbc41c4d3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue2023765InterestMember_d1f7f934-c42f-4115-986d-1d026e974231" xlink:href="ci-20231231.xsd#ci_NotesDue2023765InterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue2023765InterestMember_d1f7f934-c42f-4115-986d-1d026e974231" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue2023FloatingRateInterestMember_3de6bb36-51fc-4b70-9369-b9bf2fc5e0a7" xlink:href="ci-20231231.xsd#ci_NotesDue2023FloatingRateInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue2023FloatingRateInterestMember_3de6bb36-51fc-4b70-9369-b9bf2fc5e0a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20233InterestMember_9b56e686-aa46-4f95-85aa-35a3bf278974" xlink:href="ci-20231231.xsd#ci_NotesDue20233InterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue20233InterestMember_9b56e686-aa46-4f95-85aa-35a3bf278974" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue2023375InterestMember_4ca36e50-60d4-4a96-8951-f71c697d2a70" xlink:href="ci-20231231.xsd#ci_NotesDue2023375InterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue2023375InterestMember_4ca36e50-60d4-4a96-8951-f71c697d2a70" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue2024613InterestMember_2c696c6e-af28-4558-827b-347f45c247fb" xlink:href="ci-20231231.xsd#ci_NotesDue2024613InterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue2024613InterestMember_2c696c6e-af28-4558-827b-347f45c247fb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue202435InterestMember_0cf626e7-f2b2-4dd9-bc8a-b0dd672ce38e" xlink:href="ci-20231231.xsd#ci_NotesDue202435InterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue202435InterestMember_0cf626e7-f2b2-4dd9-bc8a-b0dd672ce38e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue2025325InterestMember_fc4d3865-8751-4314-adf3-d6e379b431cb" xlink:href="ci-20231231.xsd#ci_NotesDue2025325InterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue2025325InterestMember_fc4d3865-8751-4314-adf3-d6e379b431cb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20254125InterestMember_7a8cecc1-6612-45da-ab21-60680981a313" xlink:href="ci-20231231.xsd#ci_NotesDue20254125InterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue20254125InterestMember_7a8cecc1-6612-45da-ab21-60680981a313" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue202645InterestMember_a1376905-d16b-4bea-a86b-a2a5ac70d27c" xlink:href="ci-20231231.xsd#ci_NotesDue202645InterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue202645InterestMember_a1376905-d16b-4bea-a86b-a2a5ac70d27c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue2026125Member_872f9814-c551-46f7-ac43-ed0d4e7be2ed" xlink:href="ci-20231231.xsd#ci_NotesDue2026125Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue2026125Member_872f9814-c551-46f7-ac43-ed0d4e7be2ed" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20265685Member_974fb48d-4bf5-48ad-ac89-a388df9548d3" xlink:href="ci-20231231.xsd#ci_NotesDue20265685Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue20265685Member_974fb48d-4bf5-48ad-ac89-a388df9548d3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue202734InterestMember_10fdd3c2-f0af-4eb6-a71d-5939201848c3" xlink:href="ci-20231231.xsd#ci_NotesDue202734InterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue202734InterestMember_10fdd3c2-f0af-4eb6-a71d-5939201848c3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebenturesDue20277875InterestMember_4bacb714-295b-48fb-82c4-ac1c44842af4" xlink:href="ci-20231231.xsd#ci_DebenturesDue20277875InterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_DebenturesDue20277875InterestMember_4bacb714-295b-48fb-82c4-ac1c44842af4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue2027305Member_9aaaa792-16b0-4d65-b089-66e9cd1efb4e" xlink:href="ci-20231231.xsd#ci_NotesDue2027305Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue2027305Member_9aaaa792-16b0-4d65-b089-66e9cd1efb4e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20284375InterestMember_f6fc037d-f7b5-4559-9508-03389db47889" xlink:href="ci-20231231.xsd#ci_NotesDue20284375InterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue20284375InterestMember_f6fc037d-f7b5-4559-9508-03389db47889" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue203024InterestMember_ae6c48a0-4523-40ac-9a1a-087e1ff92fcd" xlink:href="ci-20231231.xsd#ci_NotesDue203024InterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue203024InterestMember_ae6c48a0-4523-40ac-9a1a-087e1ff92fcd" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20312375InterestMember_d9f84c65-ffd2-4963-8f05-985987a09506" xlink:href="ci-20231231.xsd#ci_NotesDue20312375InterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue20312375InterestMember_d9f84c65-ffd2-4963-8f05-985987a09506" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_StepDownNotesDueJanuary2033Member_28f34d73-b92a-4a84-a73c-02241f9db473" xlink:href="ci-20231231.xsd#ci_StepDownNotesDueJanuary2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_StepDownNotesDueJanuary2033Member_28f34d73-b92a-4a84-a73c-02241f9db473" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20335400InterestMember_3fd17c2c-95a9-4709-9f4e-12bc43453ed3" xlink:href="ci-20231231.xsd#ci_NotesDue20335400InterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue20335400InterestMember_3fd17c2c-95a9-4709-9f4e-12bc43453ed3" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue2036615InterestMember_8eab6683-19ef-47ca-8678-ac54b7f95a6c" xlink:href="ci-20231231.xsd#ci_NotesDue2036615InterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue2036615InterestMember_8eab6683-19ef-47ca-8678-ac54b7f95a6c" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue203848InterestMember_f245ed76-5ce2-45ff-8b3f-b4ca7ddf4275" xlink:href="ci-20231231.xsd#ci_NotesDue203848InterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue203848InterestMember_f245ed76-5ce2-45ff-8b3f-b4ca7ddf4275" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue204032InterestMember_fbb9de83-e91e-4c66-bd6f-47d4dd55f0a2" xlink:href="ci-20231231.xsd#ci_NotesDue204032InterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue204032InterestMember_fbb9de83-e91e-4c66-bd6f-47d4dd55f0a2" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20415875InterestMember_2f46cf67-25c2-481e-8f06-f570b7c8bdf2" xlink:href="ci-20231231.xsd#ci_NotesDue20415875InterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue20415875InterestMember_2f46cf67-25c2-481e-8f06-f570b7c8bdf2" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20416125InterestMember_9ab259ea-9c53-4a31-baeb-744b893d0739" xlink:href="ci-20231231.xsd#ci_NotesDue20416125InterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue20416125InterestMember_9ab259ea-9c53-4a31-baeb-744b893d0739" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20425375InterestMember_30d6242c-8ead-4b74-bec1-f81cbd9e0135" xlink:href="ci-20231231.xsd#ci_NotesDue20425375InterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue20425375InterestMember_30d6242c-8ead-4b74-bec1-f81cbd9e0135" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue204648InterestMember_14eb3599-ece1-446c-8b3b-3916eb10f5ab" xlink:href="ci-20231231.xsd#ci_NotesDue204648InterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue204648InterestMember_14eb3599-ece1-446c-8b3b-3916eb10f5ab" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20473875Member_0ce71e42-352a-4039-b358-7b815da0f655" xlink:href="ci-20231231.xsd#ci_NotesDue20473875Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue20473875Member_0ce71e42-352a-4039-b358-7b815da0f655" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue204849InterestMember_9ffaeb2e-0e1b-4723-be7a-40ff6ccbed81" xlink:href="ci-20231231.xsd#ci_NotesDue204849InterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue204849InterestMember_9ffaeb2e-0e1b-4723-be7a-40ff6ccbed81" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue205034InterestMember_3996ec7a-492b-4556-a710-41bc8d0b347a" xlink:href="ci-20231231.xsd#ci_NotesDue205034InterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue205034InterestMember_3996ec7a-492b-4556-a710-41bc8d0b347a" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue205134InterestMember_7d424d5c-23ee-41bd-ad37-ccfbf524bff0" xlink:href="ci-20231231.xsd#ci_NotesDue205134InterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue205134InterestMember_7d424d5c-23ee-41bd-ad37-ccfbf524bff0" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrentAbstract_b24ad6f5-1f0f-43b5-a94b-4ecd810d775b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_87cb89b0-3be7-4f1e-92ab-a75065ae7abb" xlink:to="loc_us-gaap_DebtCurrentAbstract_b24ad6f5-1f0f-43b5-a94b-4ecd810d775b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_fb39ec65-47d3-4182-b617-479e3b12b6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaper"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtCurrentAbstract_b24ad6f5-1f0f-43b5-a94b-4ecd810d775b" xlink:to="loc_us-gaap_CommercialPaper_fb39ec65-47d3-4182-b617-479e3b12b6a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_8a157720-651a-4d44-a2ff-2d097368c4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtCurrentAbstract_b24ad6f5-1f0f-43b5-a94b-4ecd810d775b" xlink:to="loc_us-gaap_LongTermDebtCurrent_8a157720-651a-4d44-a2ff-2d097368c4d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent_a28d3802-e99c-46a0-a03f-066f90823b1c" xlink:href="ci-20231231.xsd#ci_OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtCurrentAbstract_b24ad6f5-1f0f-43b5-a94b-4ecd810d775b" xlink:to="loc_ci_OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent_a28d3802-e99c-46a0-a03f-066f90823b1c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_c71b1106-4fb0-413c-a270-9e75428f69f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtCurrentAbstract_b24ad6f5-1f0f-43b5-a94b-4ecd810d775b" xlink:to="loc_us-gaap_DebtCurrent_c71b1106-4fb0-413c-a270-9e75428f69f0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_e3bf7ed4-99f1-4390-88c3-4a62cb8307cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_87cb89b0-3be7-4f1e-92ab-a75065ae7abb" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_e3bf7ed4-99f1-4390-88c3-4a62cb8307cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_8eb49dca-de7e-453f-aac3-9a4f06c94e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_e3bf7ed4-99f1-4390-88c3-4a62cb8307cd" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_8eb49dca-de7e-453f-aac3-9a4f06c94e8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebtNoncurrent_bec5a710-3ff7-4292-853e-98e915c31872" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_e3bf7ed4-99f1-4390-88c3-4a62cb8307cd" xlink:to="loc_us-gaap_OtherLongTermDebtNoncurrent_bec5a710-3ff7-4292-853e-98e915c31872" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_4df93f1c-5251-4d6a-ad55-baf464138f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_e3bf7ed4-99f1-4390-88c3-4a62cb8307cd" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_4df93f1c-5251-4d6a-ad55-baf464138f2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_be45b385-dae5-4fc1-8908-631c3525a3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_87cb89b0-3be7-4f1e-92ab-a75065ae7abb" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_be45b385-dae5-4fc1-8908-631c3525a3f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_da890867-9fef-48ab-b41b-b20e628d6f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_87cb89b0-3be7-4f1e-92ab-a75065ae7abb" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_da890867-9fef-48ab-b41b-b20e628d6f4e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/DebtShorttermandCreditFacilitiesDebtDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#DebtShorttermandCreditFacilitiesDebtDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/DebtShorttermandCreditFacilitiesDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5fc3350f-1e00-4d3f-80df-1b5ab5fefda3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_547f336d-259c-4a7e-bc94-7ecef6dc322c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fc3350f-1e00-4d3f-80df-1b5ab5fefda3" xlink:to="loc_us-gaap_DebtInstrumentTable_547f336d-259c-4a7e-bc94-7ecef6dc322c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_14bfd139-ad28-4200-97c2-edb26bb7ec47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_547f336d-259c-4a7e-bc94-7ecef6dc322c" xlink:to="loc_us-gaap_DebtInstrumentAxis_14bfd139-ad28-4200-97c2-edb26bb7ec47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_14bfd139-ad28-4200-97c2-edb26bb7ec47_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_14bfd139-ad28-4200-97c2-edb26bb7ec47" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_14bfd139-ad28-4200-97c2-edb26bb7ec47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6507db27-fe55-475e-9474-e7adedf6b153" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_14bfd139-ad28-4200-97c2-edb26bb7ec47" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6507db27-fe55-475e-9474-e7adedf6b153" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RevolvingCreditAgreementsApril2023Member_983a43d9-ddfb-49a4-9dd1-a0afbdd5350c" xlink:href="ci-20231231.xsd#ci_RevolvingCreditAgreementsApril2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6507db27-fe55-475e-9474-e7adedf6b153" xlink:to="loc_ci_RevolvingCreditAgreementsApril2023Member_983a43d9-ddfb-49a4-9dd1-a0afbdd5350c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member_df9c889c-b6d7-42c3-8381-3db8eac24fad" xlink:href="ci-20231231.xsd#ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_RevolvingCreditAgreementsApril2023Member_983a43d9-ddfb-49a4-9dd1-a0afbdd5350c" xlink:to="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member_df9c889c-b6d7-42c3-8381-3db8eac24fad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_A364DayRevolvingCreditAgreementMaturingApril2024Member_c13f798b-8769-43c2-8e5c-65e1f59448fe" xlink:href="ci-20231231.xsd#ci_A364DayRevolvingCreditAgreementMaturingApril2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_RevolvingCreditAgreementsApril2023Member_983a43d9-ddfb-49a4-9dd1-a0afbdd5350c" xlink:to="loc_ci_A364DayRevolvingCreditAgreementMaturingApril2024Member_c13f798b-8769-43c2-8e5c-65e1f59448fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member_423fea11-a153-41ec-89c3-2dd023af17c4" xlink:href="ci-20231231.xsd#ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6507db27-fe55-475e-9474-e7adedf6b153" xlink:to="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member_423fea11-a153-41ec-89c3-2dd023af17c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member_8614897e-7893-4673-957a-fa97120e17e5" xlink:href="ci-20231231.xsd#ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member_423fea11-a153-41ec-89c3-2dd023af17c4" xlink:to="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member_8614897e-7893-4673-957a-fa97120e17e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RevolvingCreditFacilityMaturingApril2025Member_8ed67b5a-90df-4b4d-8a07-e752953bdd6e" xlink:href="ci-20231231.xsd#ci_RevolvingCreditFacilityMaturingApril2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member_423fea11-a153-41ec-89c3-2dd023af17c4" xlink:to="loc_ci_RevolvingCreditFacilityMaturingApril2025Member_8ed67b5a-90df-4b4d-8a07-e752953bdd6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_A364DayRevolvingCreditAgreementMaturingApril2023Member_d1c0150d-e05f-49d6-ad34-fb0afab8e298" xlink:href="ci-20231231.xsd#ci_A364DayRevolvingCreditAgreementMaturingApril2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member_423fea11-a153-41ec-89c3-2dd023af17c4" xlink:to="loc_ci_A364DayRevolvingCreditAgreementMaturingApril2023Member_d1c0150d-e05f-49d6-ad34-fb0afab8e298" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_54c50f33-0b69-4627-8602-0fada7d30365" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_547f336d-259c-4a7e-bc94-7ecef6dc322c" xlink:to="loc_us-gaap_CreditFacilityAxis_54c50f33-0b69-4627-8602-0fada7d30365" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_54c50f33-0b69-4627-8602-0fada7d30365_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_54c50f33-0b69-4627-8602-0fada7d30365" xlink:to="loc_us-gaap_CreditFacilityDomain_54c50f33-0b69-4627-8602-0fada7d30365_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_44dd777f-52db-4a2e-a033-25c4dcbd4fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_54c50f33-0b69-4627-8602-0fada7d30365" xlink:to="loc_us-gaap_CreditFacilityDomain_44dd777f-52db-4a2e-a033-25c4dcbd4fd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_7198325d-9e59-485a-86c1-b54cae2c63aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_44dd777f-52db-4a2e-a033-25c4dcbd4fd0" xlink:to="loc_us-gaap_LetterOfCreditMember_7198325d-9e59-485a-86c1-b54cae2c63aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_e895afa3-3088-4e7e-9479-371616ea4791" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_44dd777f-52db-4a2e-a033-25c4dcbd4fd0" xlink:to="loc_us-gaap_CommercialPaperMember_e895afa3-3088-4e7e-9479-371616ea4791" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_0803aa09-f6d2-4a16-b9f5-ef270534f404" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fc3350f-1e00-4d3f-80df-1b5ab5fefda3" xlink:to="loc_us-gaap_LineOfCredit_0803aa09-f6d2-4a16-b9f5-ef270534f404" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8859b231-aac2-4889-9829-02c7e5faf819" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fc3350f-1e00-4d3f-80df-1b5ab5fefda3" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8859b231-aac2-4889-9829-02c7e5faf819" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_f6c1af6c-8371-408d-a423-5b43330c1f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fc3350f-1e00-4d3f-80df-1b5ab5fefda3" xlink:to="loc_us-gaap_DebtInstrumentTerm_f6c1af6c-8371-408d-a423-5b43330c1f2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtInstrumentExtensionTerm_b0175ecd-319d-4c5a-ab48-31bef99acf7d" xlink:href="ci-20231231.xsd#ci_DebtInstrumentExtensionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fc3350f-1e00-4d3f-80df-1b5ab5fefda3" xlink:to="loc_ci_DebtInstrumentExtensionTerm_b0175ecd-319d-4c5a-ab48-31bef99acf7d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LineOfCreditFacilityConversionToTermLoanTerm_c42dc0b4-4278-4c4c-b374-0433e18eabc3" xlink:href="ci-20231231.xsd#ci_LineOfCreditFacilityConversionToTermLoanTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fc3350f-1e00-4d3f-80df-1b5ab5fefda3" xlink:to="loc_ci_LineOfCreditFacilityConversionToTermLoanTerm_c42dc0b4-4278-4c4c-b374-0433e18eabc3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity_4cef702a-aeae-4ac8-98ce-f380bea3121e" xlink:href="ci-20231231.xsd#ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fc3350f-1e00-4d3f-80df-1b5ab5fefda3" xlink:to="loc_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity_4cef702a-aeae-4ac8-98ce-f380bea3121e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity_93a66266-26a7-48dc-a575-9811762291b8" xlink:href="ci-20231231.xsd#ci_LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fc3350f-1e00-4d3f-80df-1b5ab5fefda3" xlink:to="loc_ci_LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity_93a66266-26a7-48dc-a575-9811762291b8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NumberOfRevolvingCreditFacility_673b4e06-1a79-41a6-aed8-7568728604f2" xlink:href="ci-20231231.xsd#ci_NumberOfRevolvingCreditFacility"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fc3350f-1e00-4d3f-80df-1b5ab5fefda3" xlink:to="loc_ci_NumberOfRevolvingCreditFacility_673b4e06-1a79-41a6-aed8-7568728604f2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement_0db2a3b9-0443-4ff5-9c62-8f391266e771" xlink:href="ci-20231231.xsd#ci_NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fc3350f-1e00-4d3f-80df-1b5ab5fefda3" xlink:to="loc_ci_NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement_0db2a3b9-0443-4ff5-9c62-8f391266e771" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant_98617731-8a11-4f59-b0ed-094bb2eb8110" xlink:href="ci-20231231.xsd#ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fc3350f-1e00-4d3f-80df-1b5ab5fefda3" xlink:to="loc_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant_98617731-8a11-4f59-b0ed-094bb2eb8110" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CommercialPaperAverageRatePaid_54fec063-0983-4ca5-9819-6c6e664f065b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CommercialPaperAverageRatePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fc3350f-1e00-4d3f-80df-1b5ab5fefda3" xlink:to="loc_srt_CommercialPaperAverageRatePaid_54fec063-0983-4ca5-9819-6c6e664f065b" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/DebtLongtermDebtDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#DebtLongtermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/DebtLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_91ee2108-8002-4a88-b1e0-63f0ebcb9dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1ae8a697-0d42-4cc3-8185-8b1d796f2ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91ee2108-8002-4a88-b1e0-63f0ebcb9dc6" xlink:to="loc_us-gaap_DebtInstrumentTable_1ae8a697-0d42-4cc3-8185-8b1d796f2ff9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_037fb956-38f0-4971-8ff9-00ae209d15b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1ae8a697-0d42-4cc3-8185-8b1d796f2ff9" xlink:to="loc_us-gaap_DebtInstrumentAxis_037fb956-38f0-4971-8ff9-00ae209d15b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_037fb956-38f0-4971-8ff9-00ae209d15b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_037fb956-38f0-4971-8ff9-00ae209d15b3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_037fb956-38f0-4971-8ff9-00ae209d15b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0e22b25a-33c6-4084-8ee9-d62e6bc32e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_037fb956-38f0-4971-8ff9-00ae209d15b3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0e22b25a-33c6-4084-8ee9-d62e6bc32e5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20265685Member_c3f3cad8-5cff-44dc-a5a1-3fc971e0f0f3" xlink:href="ci-20231231.xsd#ci_NotesDue20265685Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0e22b25a-33c6-4084-8ee9-d62e6bc32e5d" xlink:to="loc_ci_NotesDue20265685Member_c3f3cad8-5cff-44dc-a5a1-3fc971e0f0f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20335400InterestMember_f0f3bfd5-22bf-4145-aa95-612f83854eba" xlink:href="ci-20231231.xsd#ci_NotesDue20335400InterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0e22b25a-33c6-4084-8ee9-d62e6bc32e5d" xlink:to="loc_ci_NotesDue20335400InterestMember_f0f3bfd5-22bf-4145-aa95-612f83854eba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue202435InterestMember_c45438dc-b092-478c-96b1-4b1a570d26d2" xlink:href="ci-20231231.xsd#ci_NotesDue202435InterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0e22b25a-33c6-4084-8ee9-d62e6bc32e5d" xlink:to="loc_ci_NotesDue202435InterestMember_c45438dc-b092-478c-96b1-4b1a570d26d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_83485655-68bd-40ff-b16e-ee96350b815b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1ae8a697-0d42-4cc3-8185-8b1d796f2ff9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_83485655-68bd-40ff-b16e-ee96350b815b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_83485655-68bd-40ff-b16e-ee96350b815b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_83485655-68bd-40ff-b16e-ee96350b815b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_83485655-68bd-40ff-b16e-ee96350b815b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ea182cd8-7797-45f7-9b46-15a68e308920" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_83485655-68bd-40ff-b16e-ee96350b815b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ea182cd8-7797-45f7-9b46-15a68e308920" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_ff01b60e-0bf2-4a8c-9bf0-679bbd727e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ea182cd8-7797-45f7-9b46-15a68e308920" xlink:to="loc_us-gaap_SeniorNotesMember_ff01b60e-0bf2-4a8c-9bf0-679bbd727e2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_bf663c6d-85f6-4a45-b150-630dbf038a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1ae8a697-0d42-4cc3-8185-8b1d796f2ff9" xlink:to="loc_us-gaap_VariableRateAxis_bf663c6d-85f6-4a45-b150-630dbf038a5d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_bf663c6d-85f6-4a45-b150-630dbf038a5d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_bf663c6d-85f6-4a45-b150-630dbf038a5d" xlink:to="loc_us-gaap_VariableRateDomain_bf663c6d-85f6-4a45-b150-630dbf038a5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_420eab64-0102-4118-a9a2-d48e999ac2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_bf663c6d-85f6-4a45-b150-630dbf038a5d" xlink:to="loc_us-gaap_VariableRateDomain_420eab64-0102-4118-a9a2-d48e999ac2eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UsTreasuryUstInterestRateMember_61d534fc-320b-4285-8d37-fe94a29c94aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UsTreasuryUstInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_420eab64-0102-4118-a9a2-d48e999ac2eb" xlink:to="loc_us-gaap_UsTreasuryUstInterestRateMember_61d534fc-320b-4285-8d37-fe94a29c94aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_ee7cfff4-80c5-43ac-8fdb-b0b699dfad8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1ae8a697-0d42-4cc3-8185-8b1d796f2ff9" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_ee7cfff4-80c5-43ac-8fdb-b0b699dfad8e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ee7cfff4-80c5-43ac-8fdb-b0b699dfad8e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ee7cfff4-80c5-43ac-8fdb-b0b699dfad8e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ee7cfff4-80c5-43ac-8fdb-b0b699dfad8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_629aaabf-3801-42a8-a8a6-ed6970cd71ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ee7cfff4-80c5-43ac-8fdb-b0b699dfad8e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_629aaabf-3801-42a8-a8a6-ed6970cd71ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_59205d4c-e2e2-44b2-89d1-6e929e3326e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_629aaabf-3801-42a8-a8a6-ed6970cd71ad" xlink:to="loc_us-gaap_SubsequentEventMember_59205d4c-e2e2-44b2-89d1-6e929e3326e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_fa696c47-d3c6-42db-a4db-a1ac95e2e238" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1ae8a697-0d42-4cc3-8185-8b1d796f2ff9" xlink:to="loc_srt_StatementScenarioAxis_fa696c47-d3c6-42db-a4db-a1ac95e2e238" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_fa696c47-d3c6-42db-a4db-a1ac95e2e238_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_fa696c47-d3c6-42db-a4db-a1ac95e2e238" xlink:to="loc_srt_ScenarioUnspecifiedDomain_fa696c47-d3c6-42db-a4db-a1ac95e2e238_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_10474e20-edb8-4bf5-a810-33d403f8d58d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_fa696c47-d3c6-42db-a4db-a1ac95e2e238" xlink:to="loc_srt_ScenarioUnspecifiedDomain_10474e20-edb8-4bf5-a810-33d403f8d58d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_3bbf3aab-ab55-4baf-b28d-68935e2b5616" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_10474e20-edb8-4bf5-a810-33d403f8d58d" xlink:to="loc_srt_ScenarioForecastMember_3bbf3aab-ab55-4baf-b28d-68935e2b5616" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e9ae7596-68fb-4d3d-9944-108e502fd1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91ee2108-8002-4a88-b1e0-63f0ebcb9dc6" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e9ae7596-68fb-4d3d-9944-108e502fd1b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ace8d909-e6f5-4bf5-826e-88a19f8dd6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91ee2108-8002-4a88-b1e0-63f0ebcb9dc6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ace8d909-e6f5-4bf5-826e-88a19f8dd6f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees_fe6eb714-826d-475c-939b-6ccd7ea5de3d" xlink:href="ci-20231231.xsd#ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91ee2108-8002-4a88-b1e0-63f0ebcb9dc6" xlink:to="loc_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees_fe6eb714-826d-475c-939b-6ccd7ea5de3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate_b47d03d5-3405-40fb-a74c-0c283c5459ba" xlink:href="ci-20231231.xsd#ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91ee2108-8002-4a88-b1e0-63f0ebcb9dc6" xlink:to="loc_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate_b47d03d5-3405-40fb-a74c-0c283c5459ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_133c0dcf-4efa-45e7-a443-32aaf3e93c69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91ee2108-8002-4a88-b1e0-63f0ebcb9dc6" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_133c0dcf-4efa-45e7-a443-32aaf3e93c69" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_22efe96a-a4f2-4e64-981e-9cbdb2028056" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91ee2108-8002-4a88-b1e0-63f0ebcb9dc6" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_22efe96a-a4f2-4e64-981e-9cbdb2028056" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_GainLossOnExtinguishmentOfDebtNetOfTax_bf5b2376-da0e-49cf-893f-8cd609398729" xlink:href="ci-20231231.xsd#ci_GainLossOnExtinguishmentOfDebtNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91ee2108-8002-4a88-b1e0-63f0ebcb9dc6" xlink:to="loc_ci_GainLossOnExtinguishmentOfDebtNetOfTax_bf5b2376-da0e-49cf-893f-8cd609398729" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_511d853d-e035-421b-9c8b-94c45ec07f77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91ee2108-8002-4a88-b1e0-63f0ebcb9dc6" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_511d853d-e035-421b-9c8b-94c45ec07f77" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_b545837e-793d-44ed-9ea6-8f72d8c88133" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91ee2108-8002-4a88-b1e0-63f0ebcb9dc6" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_b545837e-793d-44ed-9ea6-8f72d8c88133" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/CommonandPreferredStockDividendsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#CommonandPreferredStockDividendsDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/CommonandPreferredStockDividendsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_91240d03-cb38-408b-b712-1541717a9cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_729e00d7-7eda-4f1a-821d-cab776e3926f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_91240d03-cb38-408b-b712-1541717a9cdb" xlink:to="loc_us-gaap_SubsequentEventTable_729e00d7-7eda-4f1a-821d-cab776e3926f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a57b2b64-bdca-4c86-84b9-7adc2049b0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_729e00d7-7eda-4f1a-821d-cab776e3926f" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a57b2b64-bdca-4c86-84b9-7adc2049b0f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a57b2b64-bdca-4c86-84b9-7adc2049b0f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a57b2b64-bdca-4c86-84b9-7adc2049b0f5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a57b2b64-bdca-4c86-84b9-7adc2049b0f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_45c94795-a319-4331-8115-917c6eb9552e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a57b2b64-bdca-4c86-84b9-7adc2049b0f5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_45c94795-a319-4331-8115-917c6eb9552e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d1006b10-c5cc-4cff-a517-c510d8f488a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_45c94795-a319-4331-8115-917c6eb9552e" xlink:to="loc_us-gaap_SubsequentEventMember_d1006b10-c5cc-4cff-a517-c510d8f488a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_ef29ff16-b42b-461f-88c2-40fa5ec2de53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_91240d03-cb38-408b-b712-1541717a9cdb" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_ef29ff16-b42b-461f-88c2-40fa5ec2de53" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/CommonandPreferredStockAcceleratedShareRepurchaseAgreementsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#CommonandPreferredStockAcceleratedShareRepurchaseAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/CommonandPreferredStockAcceleratedShareRepurchaseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesLineItems_2e42e2f4-403e-4aa8-a5fc-4e9ac7d902a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesTable_b5a01be6-12e6-45b0-913e-56e057fe1144" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_2e42e2f4-403e-4aa8-a5fc-4e9ac7d902a0" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesTable_b5a01be6-12e6-45b0-913e-56e057fe1144" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3a10647b-487a-4fd2-90f6-fbabe2d778c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesTable_b5a01be6-12e6-45b0-913e-56e057fe1144" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3a10647b-487a-4fd2-90f6-fbabe2d778c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3a10647b-487a-4fd2-90f6-fbabe2d778c1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3a10647b-487a-4fd2-90f6-fbabe2d778c1" xlink:to="loc_us-gaap_EquityComponentDomain_3a10647b-487a-4fd2-90f6-fbabe2d778c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f18d4c6a-3d65-4c6b-9342-69f09859405d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3a10647b-487a-4fd2-90f6-fbabe2d778c1" xlink:to="loc_us-gaap_EquityComponentDomain_f18d4c6a-3d65-4c6b-9342-69f09859405d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_41eaafa8-3c45-42a9-91c9-08faae4ca2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f18d4c6a-3d65-4c6b-9342-69f09859405d" xlink:to="loc_us-gaap_TreasuryStockCommonMember_41eaafa8-3c45-42a9-91c9-08faae4ca2ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7debca7c-0b29-4e22-a55b-6d2c085dbb10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f18d4c6a-3d65-4c6b-9342-69f09859405d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7debca7c-0b29-4e22-a55b-6d2c085dbb10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4865ad6b-01ef-41e4-990a-d070dd014b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesTable_b5a01be6-12e6-45b0-913e-56e057fe1144" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4865ad6b-01ef-41e4-990a-d070dd014b5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4865ad6b-01ef-41e4-990a-d070dd014b5e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4865ad6b-01ef-41e4-990a-d070dd014b5e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4865ad6b-01ef-41e4-990a-d070dd014b5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4a582dcb-51fa-428d-85a9-304359834b44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4865ad6b-01ef-41e4-990a-d070dd014b5e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4a582dcb-51fa-428d-85a9-304359834b44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d1173319-4341-48a1-ba74-cdf38e7077bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4a582dcb-51fa-428d-85a9-304359834b44" xlink:to="loc_us-gaap_SubsequentEventMember_d1173319-4341-48a1-ba74-cdf38e7077bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_304e3a2b-d730-461c-a22a-1508c7c5a075" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_2e42e2f4-403e-4aa8-a5fc-4e9ac7d902a0" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_304e3a2b-d730-461c-a22a-1508c7c5a075" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_6e5de15e-8ac4-4f4e-94ec-0624d679b8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_2e42e2f4-403e-4aa8-a5fc-4e9ac7d902a0" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_6e5de15e-8ac4-4f4e-94ec-0624d679b8a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_b347f6f6-ff1e-4908-9947-a9e405c6adb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_2e42e2f4-403e-4aa8-a5fc-4e9ac7d902a0" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_b347f6f6-ff1e-4908-9947-a9e405c6adb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_fad71771-dc4e-4e42-b99b-6352a8f1a1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_2e42e2f4-403e-4aa8-a5fc-4e9ac7d902a0" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_fad71771-dc4e-4e42-b99b-6352a8f1a1f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AcceleratedShareRepurchasesVolumeWeightedAverageSharePriceLessDiscount_f50c7ef0-6c07-489c-be39-6156e3f67bef" xlink:href="ci-20231231.xsd#ci_AcceleratedShareRepurchasesVolumeWeightedAverageSharePriceLessDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_2e42e2f4-403e-4aa8-a5fc-4e9ac7d902a0" xlink:to="loc_ci_AcceleratedShareRepurchasesVolumeWeightedAverageSharePriceLessDiscount_f50c7ef0-6c07-489c-be39-6156e3f67bef" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InsuranceandContractholderLiabilitiesAccountBalancesDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_df93e24c-edad-4bcb-8a18-5da813ae5778" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesTable_14d779d0-58cf-476b-a88b-43cfe2ebcb04" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_df93e24c-edad-4bcb-8a18-5da813ae5778" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesTable_14d779d0-58cf-476b-a88b-43cfe2ebcb04" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_9cf9d419-0df1-492a-a083-c703995f7c23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesTable_14d779d0-58cf-476b-a88b-43cfe2ebcb04" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_9cf9d419-0df1-492a-a083-c703995f7c23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9cf9d419-0df1-492a-a083-c703995f7c23_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9cf9d419-0df1-492a-a083-c703995f7c23" xlink:to="loc_us-gaap_SegmentDomain_9cf9d419-0df1-492a-a083-c703995f7c23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_38bb23d7-6c70-4d3d-aeab-455aa8b2469d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9cf9d419-0df1-492a-a083-c703995f7c23" xlink:to="loc_us-gaap_SegmentDomain_38bb23d7-6c70-4d3d-aeab-455aa8b2469d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember_1d918370-798e-4ab2-8a1a-d64c2c5cd445" xlink:href="ci-20231231.xsd#ci_CignaHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_38bb23d7-6c70-4d3d-aeab-455aa8b2469d" xlink:to="loc_ci_CignaHealthcareMember_1d918370-798e-4ab2-8a1a-d64c2c5cd445" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherOperationsSegmentMember_a5e81b8b-2270-4c32-a567-4e0261b586d0" xlink:href="ci-20231231.xsd#ci_OtherOperationsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_38bb23d7-6c70-4d3d-aeab-455aa8b2469d" xlink:to="loc_ci_OtherOperationsSegmentMember_a5e81b8b-2270-4c32-a567-4e0261b586d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_faf0b33e-b19b-4d7e-95e9-0dd8e0d346d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesTable_14d779d0-58cf-476b-a88b-43cfe2ebcb04" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_faf0b33e-b19b-4d7e-95e9-0dd8e0d346d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_faf0b33e-b19b-4d7e-95e9-0dd8e0d346d8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_faf0b33e-b19b-4d7e-95e9-0dd8e0d346d8" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_faf0b33e-b19b-4d7e-95e9-0dd8e0d346d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_0934a5a7-a99a-4109-9214-c1c12e7b3d35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_faf0b33e-b19b-4d7e-95e9-0dd8e0d346d8" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_0934a5a7-a99a-4109-9214-c1c12e7b3d35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_e80ac8fd-73b3-47f4-b9db-a4cd56b97c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_0934a5a7-a99a-4109-9214-c1c12e7b3d35" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_e80ac8fd-73b3-47f4-b9db-a4cd56b97c2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b544d375-6a1c-4a89-b358-61b0c166fc2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesTable_14d779d0-58cf-476b-a88b-43cfe2ebcb04" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b544d375-6a1c-4a89-b358-61b0c166fc2b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b544d375-6a1c-4a89-b358-61b0c166fc2b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b544d375-6a1c-4a89-b358-61b0c166fc2b" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b544d375-6a1c-4a89-b358-61b0c166fc2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3e2ac1e6-44fc-452e-a91a-2c6ff0b357ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b544d375-6a1c-4a89-b358-61b0c166fc2b" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3e2ac1e6-44fc-452e-a91a-2c6ff0b357ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_77116709-4ad1-4968-a134-84f4c217453f" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3e2ac1e6-44fc-452e-a91a-2c6ff0b357ce" xlink:to="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_77116709-4ad1-4968-a134-84f4c217453f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_229dddc4-1f2a-493d-98cc-a953e844ed2b" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_df93e24c-edad-4bcb-8a18-5da813ae5778" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_229dddc4-1f2a-493d-98cc-a953e844ed2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent_c33ee336-7aae-432e-8c42-0b5886cc80a7" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_229dddc4-1f2a-493d-98cc-a953e844ed2b" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent_c33ee336-7aae-432e-8c42-0b5886cc80a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrentIncludingDisposalGroups_51af779e-45fa-40f5-bf3b-705dcf962031" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrentIncludingDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_229dddc4-1f2a-493d-98cc-a953e844ed2b" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrentIncludingDisposalGroups_51af779e-45fa-40f5-bf3b-705dcf962031" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent_a6062824-1985-45fd-b683-e33bca8f0e82" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_229dddc4-1f2a-493d-98cc-a953e844ed2b" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent_a6062824-1985-45fd-b683-e33bca8f0e82" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitsCurrentIncludingDisposalGroups_4a36a5d7-cbf7-4540-9020-3b0e78257fe2" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitsCurrentIncludingDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_229dddc4-1f2a-493d-98cc-a953e844ed2b" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitsCurrentIncludingDisposalGroups_4a36a5d7-cbf7-4540-9020-3b0e78257fe2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositCurrent_461927be-2a7a-466a-a883-7ef6bcbc10bc" xlink:href="ci-20231231.xsd#ci_PolicyholderContractDepositCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_229dddc4-1f2a-493d-98cc-a953e844ed2b" xlink:to="loc_ci_PolicyholderContractDepositCurrent_461927be-2a7a-466a-a883-7ef6bcbc10bc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositCurrentIncludingDisposalGroups_a5fafb1b-f192-4402-ba2c-a7faf758baea" xlink:href="ci-20231231.xsd#ci_PolicyholderContractDepositCurrentIncludingDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_229dddc4-1f2a-493d-98cc-a953e844ed2b" xlink:to="loc_ci_PolicyholderContractDepositCurrentIncludingDisposalGroups_a5fafb1b-f192-4402-ba2c-a7faf758baea" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitLiabilityAmountCurrent_f36e9158-6fa5-40b6-9c0f-4154681a0ac2" xlink:href="ci-20231231.xsd#ci_MarketRiskBenefitLiabilityAmountCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_229dddc4-1f2a-493d-98cc-a953e844ed2b" xlink:to="loc_ci_MarketRiskBenefitLiabilityAmountCurrent_f36e9158-6fa5-40b6-9c0f-4154681a0ac2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsCurrent_e4afa7dd-722d-4ba2-ab22-fcbf4259182d" xlink:href="ci-20231231.xsd#ci_UnearnedPremiumsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_229dddc4-1f2a-493d-98cc-a953e844ed2b" xlink:to="loc_ci_UnearnedPremiumsCurrent_e4afa7dd-722d-4ba2-ab22-fcbf4259182d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsCurrentIncludingDisposalGroups_c15d4427-37d0-4eec-93f0-2d516d96ca3d" xlink:href="ci-20231231.xsd#ci_UnearnedPremiumsCurrentIncludingDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_229dddc4-1f2a-493d-98cc-a953e844ed2b" xlink:to="loc_ci_UnearnedPremiumsCurrentIncludingDisposalGroups_c15d4427-37d0-4eec-93f0-2d516d96ca3d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups_6f568bb1-633c-42e6-a2c7-f195ca9dbc6f" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_229dddc4-1f2a-493d-98cc-a953e844ed2b" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups_6f568bb1-633c-42e6-a2c7-f195ca9dbc6f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInsuranceAndContractholderLiabilities_037d49aa-c472-431a-bf7a-087e9401bc66" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationCurrentInsuranceAndContractholderLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_229dddc4-1f2a-493d-98cc-a953e844ed2b" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInsuranceAndContractholderLiabilities_037d49aa-c472-431a-bf7a-087e9401bc66" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesCurrent_3ff77f30-7b8a-4e67-b490-ae44593a1269" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_229dddc4-1f2a-493d-98cc-a953e844ed2b" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesCurrent_3ff77f30-7b8a-4e67-b490-ae44593a1269" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_914a1b11-a07e-4be1-9fcd-ff56addcda0a" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_df93e24c-edad-4bcb-8a18-5da813ae5778" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_914a1b11-a07e-4be1-9fcd-ff56addcda0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent_a2a1dfc6-5770-4389-89f6-93a4be4317e0" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_914a1b11-a07e-4be1-9fcd-ff56addcda0a" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent_a2a1dfc6-5770-4389-89f6-93a4be4317e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrentIncludingDisposalGroups_b372e2cb-ebe1-4676-99a1-59f0461fc5a5" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrentIncludingDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_914a1b11-a07e-4be1-9fcd-ff56addcda0a" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrentIncludingDisposalGroups_b372e2cb-ebe1-4676-99a1-59f0461fc5a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent_c0c6faf4-21d4-497d-be07-94e340653933" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_914a1b11-a07e-4be1-9fcd-ff56addcda0a" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent_c0c6faf4-21d4-497d-be07-94e340653933" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitsNoncurrentIncludingDisposalGroups_3047fc46-ed9f-4c15-863a-6c603f65d920" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitsNoncurrentIncludingDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_914a1b11-a07e-4be1-9fcd-ff56addcda0a" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitsNoncurrentIncludingDisposalGroups_3047fc46-ed9f-4c15-863a-6c603f65d920" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositNoncurrent_d6bb15d0-9839-4379-950e-64eeb84f755d" xlink:href="ci-20231231.xsd#ci_PolicyholderContractDepositNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_914a1b11-a07e-4be1-9fcd-ff56addcda0a" xlink:to="loc_ci_PolicyholderContractDepositNoncurrent_d6bb15d0-9839-4379-950e-64eeb84f755d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositNoncurrentIncludingDisposalGroups_65ee050c-c5b9-468b-ac47-d719a9e83212" xlink:href="ci-20231231.xsd#ci_PolicyholderContractDepositNoncurrentIncludingDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_914a1b11-a07e-4be1-9fcd-ff56addcda0a" xlink:to="loc_ci_PolicyholderContractDepositNoncurrentIncludingDisposalGroups_65ee050c-c5b9-468b-ac47-d719a9e83212" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitLiabilityAmountNoncurrent_8e55709f-ba70-4cc0-b7d1-86da3c562ddc" xlink:href="ci-20231231.xsd#ci_MarketRiskBenefitLiabilityAmountNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_914a1b11-a07e-4be1-9fcd-ff56addcda0a" xlink:to="loc_ci_MarketRiskBenefitLiabilityAmountNoncurrent_8e55709f-ba70-4cc0-b7d1-86da3c562ddc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsNoncurrent_2032c77d-a2a7-4515-8777-466d868cf56c" xlink:href="ci-20231231.xsd#ci_UnearnedPremiumsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_914a1b11-a07e-4be1-9fcd-ff56addcda0a" xlink:to="loc_ci_UnearnedPremiumsNoncurrent_2032c77d-a2a7-4515-8777-466d868cf56c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsNoncurrentIncludingDisposalGroups_a6688c36-7f3d-4483-ad5b-631ca8ff4aba" xlink:href="ci-20231231.xsd#ci_UnearnedPremiumsNoncurrentIncludingDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_914a1b11-a07e-4be1-9fcd-ff56addcda0a" xlink:to="loc_ci_UnearnedPremiumsNoncurrentIncludingDisposalGroups_a6688c36-7f3d-4483-ad5b-631ca8ff4aba" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups_04310084-8a62-43d8-bacc-cd75c4b7be75" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_914a1b11-a07e-4be1-9fcd-ff56addcda0a" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups_04310084-8a62-43d8-bacc-cd75c4b7be75" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInsuranceAndContractholderLiabilities_77b13b28-6c44-4eba-ac9b-731a2b621947" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInsuranceAndContractholderLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_914a1b11-a07e-4be1-9fcd-ff56addcda0a" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInsuranceAndContractholderLiabilities_77b13b28-6c44-4eba-ac9b-731a2b621947" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent_9d09fb84-bacd-4b55-a59a-49a2bccbd0c8" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_914a1b11-a07e-4be1-9fcd-ff56addcda0a" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent_9d09fb84-bacd-4b55-a59a-49a2bccbd0c8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_2b751012-01d4-4bea-83dc-f20f81dff4a3" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_df93e24c-edad-4bcb-8a18-5da813ae5778" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_2b751012-01d4-4bea-83dc-f20f81dff4a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_bd36a74e-3bbb-4e02-805f-26b52403b417" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_2b751012-01d4-4bea-83dc-f20f81dff4a3" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_bd36a74e-3bbb-4e02-805f-26b52403b417" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_6a659029-7370-43ce-a67b-075c7a847047" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_2b751012-01d4-4bea-83dc-f20f81dff4a3" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_6a659029-7370-43ce-a67b-075c7a847047" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefits_78c3976e-140a-4f06-8777-1fa82c4ba13c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_2b751012-01d4-4bea-83dc-f20f81dff4a3" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefits_78c3976e-140a-4f06-8777-1fa82c4ba13c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitsIncludingDisposalGroups_5e1c5d98-b1d1-487b-a144-120710ce738c" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitsIncludingDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_2b751012-01d4-4bea-83dc-f20f81dff4a3" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitsIncludingDisposalGroups_5e1c5d98-b1d1-487b-a144-120710ce738c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderContractDeposits_1260fb6c-1908-4938-a39a-6e4f1ce4bb59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderContractDeposits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_2b751012-01d4-4bea-83dc-f20f81dff4a3" xlink:to="loc_us-gaap_PolicyholderContractDeposits_1260fb6c-1908-4938-a39a-6e4f1ce4bb59" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositsIncludingDisposalGroups_44597fa9-5540-43e7-8c83-549f329d2c02" xlink:href="ci-20231231.xsd#ci_PolicyholderContractDepositsIncludingDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_2b751012-01d4-4bea-83dc-f20f81dff4a3" xlink:to="loc_ci_PolicyholderContractDepositsIncludingDisposalGroups_44597fa9-5540-43e7-8c83-549f329d2c02" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitLiabilityAmount_f77d7b81-3a37-4a95-9f16-304138adb3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketRiskBenefitLiabilityAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_2b751012-01d4-4bea-83dc-f20f81dff4a3" xlink:to="loc_us-gaap_MarketRiskBenefitLiabilityAmount_f77d7b81-3a37-4a95-9f16-304138adb3c5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnearnedPremiums_e637e315-59ad-48f1-bd8f-de223aad538f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnearnedPremiums"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_2b751012-01d4-4bea-83dc-f20f81dff4a3" xlink:to="loc_us-gaap_UnearnedPremiums_e637e315-59ad-48f1-bd8f-de223aad538f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsIncludingDisposalGroups_1dbcdfbb-ea9a-4b5f-a662-cdb1939b65a5" xlink:href="ci-20231231.xsd#ci_UnearnedPremiumsIncludingDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_2b751012-01d4-4bea-83dc-f20f81dff4a3" xlink:to="loc_ci_UnearnedPremiumsIncludingDisposalGroups_1dbcdfbb-ea9a-4b5f-a662-cdb1939b65a5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups_a8e269ea-b046-44f5-8c46-a11b6400fa11" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_2b751012-01d4-4bea-83dc-f20f81dff4a3" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups_a8e269ea-b046-44f5-8c46-a11b6400fa11" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities_a3f98794-e8a7-469b-ad34-a016401b9b2d" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_2b751012-01d4-4bea-83dc-f20f81dff4a3" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities_a3f98794-e8a7-469b-ad34-a016401b9b2d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilities_67c1b32b-5c14-4f35-ba90-a2cda681d025" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_2b751012-01d4-4bea-83dc-f20f81dff4a3" xlink:to="loc_ci_InsuranceAndContractholderLiabilities_67c1b32b-5c14-4f35-ba90-a2cda681d025" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups_8bc86b5b-8164-4c1b-85f6-64a44cc8de22" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_df93e24c-edad-4bcb-8a18-5da813ae5778" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups_8bc86b5b-8164-4c1b-85f6-64a44cc8de22" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups_a58f96bf-d2b0-4e2b-a8ad-0611603bb774" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_df93e24c-edad-4bcb-8a18-5da813ae5778" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups_a58f96bf-d2b0-4e2b-a8ad-0611603bb774" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsAttributableToDisposalGroups_4bff3abb-3aa6-45f6-add1-e9382791edd9" xlink:href="ci-20231231.xsd#ci_UnearnedPremiumsAttributableToDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_df93e24c-edad-4bcb-8a18-5da813ae5778" xlink:to="loc_ci_UnearnedPremiumsAttributableToDisposalGroups_4bff3abb-3aa6-45f6-add1-e9382791edd9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositsAttributableToDisposalGroups_9574bc20-418f-4875-b2ec-09a0e3a5f931" xlink:href="ci-20231231.xsd#ci_PolicyholderContractDepositsAttributableToDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_df93e24c-edad-4bcb-8a18-5da813ae5778" xlink:to="loc_ci_PolicyholderContractDepositsAttributableToDisposalGroups_9574bc20-418f-4875-b2ec-09a0e3a5f931" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_f5e6cd1b-2bb6-49df-8a69-ad28ce6daf40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_943cf325-e91c-4f77-a9ea-393d9f2fc081" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_f5e6cd1b-2bb6-49df-8a69-ad28ce6daf40" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_943cf325-e91c-4f77-a9ea-393d9f2fc081" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1ede6328-852a-4481-9a84-fe7525b1f734" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_943cf325-e91c-4f77-a9ea-393d9f2fc081" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1ede6328-852a-4481-9a84-fe7525b1f734" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1ede6328-852a-4481-9a84-fe7525b1f734_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1ede6328-852a-4481-9a84-fe7525b1f734" xlink:to="loc_us-gaap_SegmentDomain_1ede6328-852a-4481-9a84-fe7525b1f734_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fc28f75b-8fa0-44b8-8f7f-56bbc820650f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1ede6328-852a-4481-9a84-fe7525b1f734" xlink:to="loc_us-gaap_SegmentDomain_fc28f75b-8fa0-44b8-8f7f-56bbc820650f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember_ea7fda5c-5e23-480e-a36a-0f0f2e3674af" xlink:href="ci-20231231.xsd#ci_CignaHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_fc28f75b-8fa0-44b8-8f7f-56bbc820650f" xlink:to="loc_ci_CignaHealthcareMember_ea7fda5c-5e23-480e-a36a-0f0f2e3674af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_f5b498e1-b741-40f2-96e6-944bb4434460" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_943cf325-e91c-4f77-a9ea-393d9f2fc081" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_f5b498e1-b741-40f2-96e6-944bb4434460" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_f5b498e1-b741-40f2-96e6-944bb4434460_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f5b498e1-b741-40f2-96e6-944bb4434460" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_f5b498e1-b741-40f2-96e6-944bb4434460_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_6bd0f982-f8e9-406e-b583-dd17084cf6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f5b498e1-b741-40f2-96e6-944bb4434460" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_6bd0f982-f8e9-406e-b583-dd17084cf6f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_14a91f79-5cfa-4c35-a12b-95a03334a79d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_6bd0f982-f8e9-406e-b583-dd17084cf6f0" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_14a91f79-5cfa-4c35-a12b-95a03334a79d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3fdac428-b093-4800-b6a4-6b840e564d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_943cf325-e91c-4f77-a9ea-393d9f2fc081" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3fdac428-b093-4800-b6a4-6b840e564d9a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3fdac428-b093-4800-b6a4-6b840e564d9a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3fdac428-b093-4800-b6a4-6b840e564d9a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3fdac428-b093-4800-b6a4-6b840e564d9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_64e2c88e-cb6a-47f1-bb8f-bf6eae619254" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3fdac428-b093-4800-b6a4-6b840e564d9a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_64e2c88e-cb6a-47f1-bb8f-bf6eae619254" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_01057672-0f99-41ab-ac4d-d725d13a1b31" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_64e2c88e-cb6a-47f1-bb8f-bf6eae619254" xlink:to="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_01057672-0f99-41ab-ac4d-d725d13a1b31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses_bd214679-959b-45b4-b53e-4c28af5cda13" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_f5e6cd1b-2bb6-49df-8a69-ad28ce6daf40" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses_bd214679-959b-45b4-b53e-4c28af5cda13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_50e54382-f5ac-4b17-a080-4c6552315175" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_f5e6cd1b-2bb6-49df-8a69-ad28ce6daf40" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_50e54382-f5ac-4b17-a080-4c6552315175" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_1e64b94d-eb5c-4286-be2c-ce8f1ac01aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_50e54382-f5ac-4b17-a080-4c6552315175" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_1e64b94d-eb5c-4286-be2c-ce8f1ac01aa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_65368357-e6c8-4a10-87b0-15cbc9cc5dff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_50e54382-f5ac-4b17-a080-4c6552315175" xlink:to="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_65368357-e6c8-4a10-87b0-15cbc9cc5dff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_8aa77910-5a84-4004-86f4-3a61a26427ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_50e54382-f5ac-4b17-a080-4c6552315175" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_8aa77910-5a84-4004-86f4-3a61a26427ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_086b0b21-7804-467b-841a-8948d707daf0" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_50e54382-f5ac-4b17-a080-4c6552315175" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_086b0b21-7804-467b-841a-8948d707daf0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups_0e224b19-9b18-46a5-afb0-362393bdbc13" xlink:href="ci-20231231.xsd#ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_50e54382-f5ac-4b17-a080-4c6552315175" xlink:to="loc_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups_0e224b19-9b18-46a5-afb0-362393bdbc13" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_f4409300-df26-4473-afa8-cecd5c2257c5" xlink:href="ci-20231231.xsd#ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_50e54382-f5ac-4b17-a080-4c6552315175" xlink:to="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_f4409300-df26-4473-afa8-cecd5c2257c5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_bcd75c0d-6357-40f9-b2d1-df2e139691ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_50e54382-f5ac-4b17-a080-4c6552315175" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_bcd75c0d-6357-40f9-b2d1-df2e139691ec" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_8b47d5d4-c059-4a9c-a7d6-644d6137fccc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_bcd75c0d-6357-40f9-b2d1-df2e139691ec" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_8b47d5d4-c059-4a9c-a7d6-644d6137fccc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_8fe1941e-4385-4590-9b1a-291ae4809dce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_bcd75c0d-6357-40f9-b2d1-df2e139691ec" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_8fe1941e-4385-4590-9b1a-291ae4809dce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_eaf98e0c-1ad0-41fd-b104-8c83fd1e940d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_bcd75c0d-6357-40f9-b2d1-df2e139691ec" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_eaf98e0c-1ad0-41fd-b104-8c83fd1e940d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_eed8d682-33f6-4af8-b3d9-5941b5259e94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_50e54382-f5ac-4b17-a080-4c6552315175" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_eed8d682-33f6-4af8-b3d9-5941b5259e94" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_53470baa-6546-40f6-b1dd-e0a4211d9f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_eed8d682-33f6-4af8-b3d9-5941b5259e94" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_53470baa-6546-40f6-b1dd-e0a4211d9f2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_927dbd2b-1be2-41df-9ccb-a20d3a8d3d13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_eed8d682-33f6-4af8-b3d9-5941b5259e94" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_927dbd2b-1be2-41df-9ccb-a20d3a8d3d13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_accdb0cb-64da-4324-8b52-b6c5d9491727" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_eed8d682-33f6-4af8-b3d9-5941b5259e94" xlink:to="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_accdb0cb-64da-4324-8b52-b6c5d9491727" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_3e0c5928-b507-4df9-94ea-b507e2a77edf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_c7b66a3b-2496-4729-94d0-9a4b861cc948" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_9248cd7a-d7bc-447b-922a-887187f7cdfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_361ebc5c-5b1d-448b-afd2-fb4bcd04927f" xlink:href="ci-20231231.xsd#ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups_2dad7600-ea29-4ac8-92a1-2e69fec13538" xlink:href="ci-20231231.xsd#ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_6e5e2092-0951-4afc-942a-78266dd4c527" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups_2bf79a63-c813-479f-be38-430e7a1ef986" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_50e54382-f5ac-4b17-a080-4c6552315175" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups_2bf79a63-c813-479f-be38-430e7a1ef986" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_6ce79b47-38e4-49a6-adb6-d542990d341f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_a5b0df87-ce62-4a9b-8364-e48180186423" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_6ce79b47-38e4-49a6-adb6-d542990d341f" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_a5b0df87-ce62-4a9b-8364-e48180186423" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_6bcaa5d6-f64d-4684-aef4-d75be6c5446a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_a5b0df87-ce62-4a9b-8364-e48180186423" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_6bcaa5d6-f64d-4684-aef4-d75be6c5446a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6bcaa5d6-f64d-4684-aef4-d75be6c5446a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6bcaa5d6-f64d-4684-aef4-d75be6c5446a" xlink:to="loc_us-gaap_SegmentDomain_6bcaa5d6-f64d-4684-aef4-d75be6c5446a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_aa2a178c-a256-4d1e-97fe-bdd6d4b5ad65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6bcaa5d6-f64d-4684-aef4-d75be6c5446a" xlink:to="loc_us-gaap_SegmentDomain_aa2a178c-a256-4d1e-97fe-bdd6d4b5ad65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember_9586e2d6-7ea5-447e-9ea8-0c0d8cfc4e88" xlink:href="ci-20231231.xsd#ci_CignaHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_aa2a178c-a256-4d1e-97fe-bdd6d4b5ad65" xlink:to="loc_ci_CignaHealthcareMember_9586e2d6-7ea5-447e-9ea8-0c0d8cfc4e88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncatastrophicEventAxis_57221361-49b0-4a9b-a11d-e73c19c4316f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncatastrophicEventAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_a5b0df87-ce62-4a9b-8364-e48180186423" xlink:to="loc_us-gaap_NoncatastrophicEventAxis_57221361-49b0-4a9b-a11d-e73c19c4316f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncatastrophicEventDomain_57221361-49b0-4a9b-a11d-e73c19c4316f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncatastrophicEventDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_NoncatastrophicEventAxis_57221361-49b0-4a9b-a11d-e73c19c4316f" xlink:to="loc_us-gaap_NoncatastrophicEventDomain_57221361-49b0-4a9b-a11d-e73c19c4316f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncatastrophicEventDomain_402f0a28-5745-48f5-85bd-150ea037de7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncatastrophicEventDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_NoncatastrophicEventAxis_57221361-49b0-4a9b-a11d-e73c19c4316f" xlink:to="loc_us-gaap_NoncatastrophicEventDomain_402f0a28-5745-48f5-85bd-150ea037de7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CompletionFactorsMember_bea9dc7e-c924-403a-acce-573bb8061ee3" xlink:href="ci-20231231.xsd#ci_CompletionFactorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncatastrophicEventDomain_402f0a28-5745-48f5-85bd-150ea037de7c" xlink:to="loc_ci_CompletionFactorsMember_bea9dc7e-c924-403a-acce-573bb8061ee3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicalCostTrendMember_3e5c06cc-b228-4d9b-a052-c9efc0a9e9c5" xlink:href="ci-20231231.xsd#ci_MedicalCostTrendMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncatastrophicEventDomain_402f0a28-5745-48f5-85bd-150ea037de7c" xlink:to="loc_ci_MedicalCostTrendMember_3e5c06cc-b228-4d9b-a052-c9efc0a9e9c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_1ce676ff-c954-46e8-a6b1-048c84aac9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_6ce79b47-38e4-49a6-adb6-d542990d341f" xlink:to="loc_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_1ce676ff-c954-46e8-a6b1-048c84aac9e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_96373b64-636c-4a2e-a5be-a9e9a40384aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_1ce676ff-c954-46e8-a6b1-048c84aac9e2" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_96373b64-636c-4a2e-a5be-a9e9a40384aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage_c4d18dd2-965e-46f4-8daf-9cd6ed3c29ce" xlink:href="ci-20231231.xsd#ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_1ce676ff-c954-46e8-a6b1-048c84aac9e2" xlink:to="loc_ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage_c4d18dd2-965e-46f4-8daf-9cd6ed3c29ce" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClaimsDevelopmentLineItems_1350537e-166d-465d-a520-03c7665095bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClaimsDevelopmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_320c9398-9776-4f58-ab51-01fb61e82afc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_1350537e-166d-465d-a520-03c7665095bd" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_320c9398-9776-4f58-ab51-01fb61e82afc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_61ba94e1-0a3c-42f6-855e-13f9f1e1354e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_320c9398-9776-4f58-ab51-01fb61e82afc" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_61ba94e1-0a3c-42f6-855e-13f9f1e1354e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_61ba94e1-0a3c-42f6-855e-13f9f1e1354e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_61ba94e1-0a3c-42f6-855e-13f9f1e1354e" xlink:to="loc_us-gaap_SegmentDomain_61ba94e1-0a3c-42f6-855e-13f9f1e1354e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b45527ab-d83f-4dfb-bbb9-3d96655df6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_61ba94e1-0a3c-42f6-855e-13f9f1e1354e" xlink:to="loc_us-gaap_SegmentDomain_b45527ab-d83f-4dfb-bbb9-3d96655df6cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember_2428738f-6a9e-4069-b1a2-154af4f1873a" xlink:href="ci-20231231.xsd#ci_CignaHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b45527ab-d83f-4dfb-bbb9-3d96655df6cd" xlink:to="loc_ci_CignaHealthcareMember_2428738f-6a9e-4069-b1a2-154af4f1873a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_483ebcb1-656d-401f-b72f-8f6ae442c811" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_320c9398-9776-4f58-ab51-01fb61e82afc" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_483ebcb1-656d-401f-b72f-8f6ae442c811" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_483ebcb1-656d-401f-b72f-8f6ae442c811_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_483ebcb1-656d-401f-b72f-8f6ae442c811" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_483ebcb1-656d-401f-b72f-8f6ae442c811_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_c5810afd-b7c1-49ad-b590-121c83d1848b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_483ebcb1-656d-401f-b72f-8f6ae442c811" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_c5810afd-b7c1-49ad-b590-121c83d1848b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member_600f9937-88b5-4454-97b2-5b7b88f275fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_c5810afd-b7c1-49ad-b590-121c83d1848b" xlink:to="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member_600f9937-88b5-4454-97b2-5b7b88f275fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2023Member_b0468eca-271a-4d3c-9b53-c34f0b905cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_c5810afd-b7c1-49ad-b590-121c83d1848b" xlink:to="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2023Member_b0468eca-271a-4d3c-9b53-c34f0b905cdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_8028705b-1d49-4bcf-a8cc-1a48b460e755" xlink:href="ci-20231231.xsd#ci_ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_1350537e-166d-465d-a520-03c7665095bd" xlink:to="loc_ci_ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_8028705b-1d49-4bcf-a8cc-1a48b460e755" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_ec00d6e1-2769-49af-bb54-838f72076c58" xlink:href="ci-20231231.xsd#ci_ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_1350537e-166d-465d-a520-03c7665095bd" xlink:to="loc_ci_ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_ec00d6e1-2769-49af-bb54-838f72076c58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_9ca96bd8-23cb-49ad-8297-1cf73fbcad5c" xlink:href="ci-20231231.xsd#ci_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_1350537e-166d-465d-a520-03c7665095bd" xlink:to="loc_ci_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_9ca96bd8-23cb-49ad-8297-1cf73fbcad5c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseLongDurationNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_c407f65d-fd09-4a92-b4ea-ca2c4eb9cf8b" xlink:href="ci-20231231.xsd#ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseLongDurationNetBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_1350537e-166d-465d-a520-03c7665095bd" xlink:to="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseLongDurationNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_c407f65d-fd09-4a92-b4ea-ca2c4eb9cf8b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_8d799857-c82d-414e-a16c-08df4161aae9" xlink:href="ci-20231231.xsd#ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_1350537e-166d-465d-a520-03c7665095bd" xlink:to="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_8d799857-c82d-414e-a16c-08df4161aae9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups_afdd1317-0504-4861-a2f4-5e04a368f2b7" xlink:href="ci-20231231.xsd#ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_1350537e-166d-465d-a520-03c7665095bd" xlink:to="loc_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups_afdd1317-0504-4861-a2f4-5e04a368f2b7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_de11bf54-fd1e-442b-a6d7-cbbd72a428f3" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_1350537e-166d-465d-a520-03c7665095bd" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_de11bf54-fd1e-442b-a6d7-cbbd72a428f3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsHistoricalClaimsDurationYearOne_7f5881ea-b68d-44e8-95b8-1c1152769449" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsHistoricalClaimsDurationYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_1350537e-166d-465d-a520-03c7665095bd" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsHistoricalClaimsDurationYearOne_7f5881ea-b68d-44e8-95b8-1c1152769449" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortdurationInsuranceContractsNumberOfPaidClaims_39bf2673-e91e-43f6-9f9f-a5363b3ec043" xlink:href="ci-20231231.xsd#ci_ShortdurationInsuranceContractsNumberOfPaidClaims"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_1350537e-166d-465d-a520-03c7665095bd" xlink:to="loc_ci_ShortdurationInsuranceContractsNumberOfPaidClaims_39bf2673-e91e-43f6-9f9f-a5363b3ec043" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsInterestRatesandDurationDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InsuranceandContractholderLiabilitiesFuturePolicyBenefitsInterestRatesandDurationDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsInterestRatesandDurationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3077296d-ef39-4932-b4f1-c4f2405b4e87" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesTable_a7504327-8e88-4ef6-9c0e-b2b3b9a0b4ee" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3077296d-ef39-4932-b4f1-c4f2405b4e87" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesTable_a7504327-8e88-4ef6-9c0e-b2b3b9a0b4ee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_964694ae-43da-4a62-91e0-59dec087d183" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesTable_a7504327-8e88-4ef6-9c0e-b2b3b9a0b4ee" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_964694ae-43da-4a62-91e0-59dec087d183" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_964694ae-43da-4a62-91e0-59dec087d183_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_964694ae-43da-4a62-91e0-59dec087d183" xlink:to="loc_us-gaap_SegmentDomain_964694ae-43da-4a62-91e0-59dec087d183_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0dde4536-854f-4b56-8742-8b2f457ba3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_964694ae-43da-4a62-91e0-59dec087d183" xlink:to="loc_us-gaap_SegmentDomain_0dde4536-854f-4b56-8742-8b2f457ba3b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember_a09dfb53-792d-4c0b-bdf3-85be800bca7e" xlink:href="ci-20231231.xsd#ci_CignaHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0dde4536-854f-4b56-8742-8b2f457ba3b7" xlink:to="loc_ci_CignaHealthcareMember_a09dfb53-792d-4c0b-bdf3-85be800bca7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherOperationsSegmentMember_3dfa8c5d-e39d-44f1-8c19-cbf1e99efbe1" xlink:href="ci-20231231.xsd#ci_OtherOperationsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0dde4536-854f-4b56-8742-8b2f457ba3b7" xlink:to="loc_ci_OtherOperationsSegmentMember_3dfa8c5d-e39d-44f1-8c19-cbf1e99efbe1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate_3a090480-d556-43ae-8e77-d77f5dadfb0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3077296d-ef39-4932-b4f1-c4f2405b4e87" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate_3a090480-d556-43ae-8e77-d77f5dadfb0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate_14c030bd-94fb-491d-b3cc-675504d46a81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3077296d-ef39-4932-b4f1-c4f2405b4e87" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate_14c030bd-94fb-491d-b3cc-675504d46a81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration_534716e3-d853-44bc-848e-652ed113dbaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3077296d-ef39-4932-b4f1-c4f2405b4e87" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration_534716e3-d853-44bc-848e-652ed113dbaf" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesTable_0e635474-8e0d-4339-a995-8b0da9ff4200" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesTable_0e635474-8e0d-4339-a995-8b0da9ff4200" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d43a8536-a105-4117-8e95-c438286102d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesTable_0e635474-8e0d-4339-a995-8b0da9ff4200" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d43a8536-a105-4117-8e95-c438286102d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d43a8536-a105-4117-8e95-c438286102d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d43a8536-a105-4117-8e95-c438286102d5" xlink:to="loc_us-gaap_SegmentDomain_d43a8536-a105-4117-8e95-c438286102d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_883e9428-230c-4d23-9d41-c1ae384cadd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d43a8536-a105-4117-8e95-c438286102d5" xlink:to="loc_us-gaap_SegmentDomain_883e9428-230c-4d23-9d41-c1ae384cadd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember_e9721e9d-23ff-45d4-8375-42829f8bcd05" xlink:href="ci-20231231.xsd#ci_CignaHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_883e9428-230c-4d23-9d41-c1ae384cadd3" xlink:to="loc_ci_CignaHealthcareMember_e9721e9d-23ff-45d4-8375-42829f8bcd05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherOperationsSegmentMember_05afed99-6c12-4cb3-8e60-8f234513c4b2" xlink:href="ci-20231231.xsd#ci_OtherOperationsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_883e9428-230c-4d23-9d41-c1ae384cadd3" xlink:to="loc_ci_OtherOperationsSegmentMember_05afed99-6c12-4cb3-8e60-8f234513c4b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_522c3e85-8c9d-473c-9c47-3089ffdbe821" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesTable_0e635474-8e0d-4339-a995-8b0da9ff4200" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_522c3e85-8c9d-473c-9c47-3089ffdbe821" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_522c3e85-8c9d-473c-9c47-3089ffdbe821_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_522c3e85-8c9d-473c-9c47-3089ffdbe821" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_522c3e85-8c9d-473c-9c47-3089ffdbe821_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ea7967b4-64e8-4f05-8376-b3b3e3c57f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_522c3e85-8c9d-473c-9c47-3089ffdbe821" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ea7967b4-64e8-4f05-8376-b3b3e3c57f0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_f1548435-6f02-49e2-97ce-9781ae3e4982" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_ea7967b4-64e8-4f05-8376-b3b3e3c57f0b" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_f1548435-6f02-49e2-97ce-9781ae3e4982" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_d13cb9f1-0f75-4e35-88df-0f58940f458a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_ea7967b4-64e8-4f05-8376-b3b3e3c57f0b" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_d13cb9f1-0f75-4e35-88df-0f58940f458a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8256806d-6555-4cd4-b829-00e4914072ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesTable_0e635474-8e0d-4339-a995-8b0da9ff4200" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8256806d-6555-4cd4-b829-00e4914072ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8256806d-6555-4cd4-b829-00e4914072ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8256806d-6555-4cd4-b829-00e4914072ca" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8256806d-6555-4cd4-b829-00e4914072ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_af26598a-0c4a-4843-b6e4-5041176d89fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8256806d-6555-4cd4-b829-00e4914072ca" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_af26598a-0c4a-4843-b6e4-5041176d89fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_64ee2106-bfe0-4c13-9807-75c4dcae78a4" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_af26598a-0c4a-4843-b6e4-5041176d89fc" xlink:to="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_64ee2106-bfe0-4c13-9807-75c4dcae78a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember_b8d353c5-606f-4a95-8a84-fe5c483d57e1" xlink:href="ci-20231231.xsd#ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_af26598a-0c4a-4843-b6e4-5041176d89fc" xlink:to="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember_b8d353c5-606f-4a95-8a84-fe5c483d57e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward_ca38ca0e-7ece-4584-94e9-503d29bcd9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward_ca38ca0e-7ece-4584-94e9-503d29bcd9b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange_87b4e1c0-ec7b-48de-8150-f0c754a4b946" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward_ca38ca0e-7ece-4584-94e9-503d29bcd9b7" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange_87b4e1c0-ec7b-48de-8150-f0c754a4b946" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax_a2286de2-a758-450b-a20a-4aa4e4ba4387" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward_ca38ca0e-7ece-4584-94e9-503d29bcd9b7" xlink:to="loc_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax_a2286de2-a758-450b-a20a-4aa4e4ba4387" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience_32348cac-89d4-43c3-a140-f81524992558" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward_ca38ca0e-7ece-4584-94e9-503d29bcd9b7" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience_32348cac-89d4-43c3-a140-f81524992558" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumIssuanceAndDerecognition_e3a01072-8ec0-4731-8f25-5874d148d595" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumIssuanceAndDerecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward_ca38ca0e-7ece-4584-94e9-503d29bcd9b7" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumIssuanceAndDerecognition_e3a01072-8ec0-4731-8f25-5874d148d595" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumNetPremiumCollected_1c24c3f2-7f49-4273-af59-45e9a860291e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumNetPremiumCollected"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward_ca38ca0e-7ece-4584-94e9-503d29bcd9b7" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumNetPremiumCollected_1c24c3f2-7f49-4273-af59-45e9a860291e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumInterestIncomeAndOtherChanges_0c2c07b7-1e51-4bf1-9cf8-2e33411a0d4e" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumInterestIncomeAndOtherChanges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward_ca38ca0e-7ece-4584-94e9-503d29bcd9b7" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumInterestIncomeAndOtherChanges_0c2c07b7-1e51-4bf1-9cf8-2e33411a0d4e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance_155f4714-cde7-46cf-a75a-0a8e7ed834fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward_ca38ca0e-7ece-4584-94e9-503d29bcd9b7" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance_155f4714-cde7-46cf-a75a-0a8e7ed834fe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax_b5aa6642-320d-42db-9c39-50a2150452aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange_80c6d431-d02c-473f-88b5-e00a0920c722" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward_9ae186a1-d9b8-44bf-9b76-7df02cad82cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward_9ae186a1-d9b8-44bf-9b76-7df02cad82cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange_3ad7d162-4fbd-497c-8993-9070c792dd67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward_9ae186a1-d9b8-44bf-9b76-7df02cad82cc" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange_3ad7d162-4fbd-497c-8993-9070c792dd67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax_d330757a-ee9c-4ebc-ae21-4c289a4b3515" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward_9ae186a1-d9b8-44bf-9b76-7df02cad82cc" xlink:to="loc_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax_d330757a-ee9c-4ebc-ae21-4c289a4b3515" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience_ff8d1fb6-109b-44c2-9504-1175c28f269d" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward_9ae186a1-d9b8-44bf-9b76-7df02cad82cc" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience_ff8d1fb6-109b-44c2-9504-1175c28f269d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitIssuanceAndDerecognition_7312e625-2335-43db-b9ef-5f131f991eb0" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitIssuanceAndDerecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward_9ae186a1-d9b8-44bf-9b76-7df02cad82cc" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitIssuanceAndDerecognition_7312e625-2335-43db-b9ef-5f131f991eb0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits_147c40b6-915d-445c-bace-9401950bb722" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward_9ae186a1-d9b8-44bf-9b76-7df02cad82cc" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits_147c40b6-915d-445c-bace-9401950bb722" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitInterestExpenseAndOtherChanges_706cc250-3989-4e05-a364-a14da7503e41" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitInterestExpenseAndOtherChanges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward_9ae186a1-d9b8-44bf-9b76-7df02cad82cc" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitInterestExpenseAndOtherChanges_706cc250-3989-4e05-a364-a14da7503e41" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance_5bb417dc-66a9-4332-a69e-add6e9aa1dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward_9ae186a1-d9b8-44bf-9b76-7df02cad82cc" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance_5bb417dc-66a9-4332-a69e-add6e9aa1dd9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax_457be560-39b4-4931-bed8-65275e89bc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange_c929faf6-8440-456c-88cc-9fda9bfb0673" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther_2c9181ca-5fa7-4328-bc5a-765ee33c8eae" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther_2c9181ca-5fa7-4328-bc5a-765ee33c8eae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitOther_8ed6a004-5c72-4fe0-9b29-1819642eeb9a" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitOther_8ed6a004-5c72-4fe0-9b29-1819642eeb9a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefits_013d8047-7973-456b-af7b-57ce7d9d8e69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefits_013d8047-7973-456b-af7b-57ce7d9d8e69" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceBeforeReclassificationToDisposalGroupAssetsHeldForSale_a8f9175b-d605-4178-b404-6cee4c568043" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceBeforeReclassificationToDisposalGroupAssetsHeldForSale_a8f9175b-d605-4178-b404-6cee4c568043" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitsCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience_744f3f08-c963-4f95-bd1c-708481e83f08" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitsCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitsCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience_744f3f08-c963-4f95-bd1c-708481e83f08" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumUndiscountedBeforeReinsurance_f18c9bd9-181d-459b-85bc-72ba1c882c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumUndiscountedBeforeReinsurance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumUndiscountedBeforeReinsurance_f18c9bd9-181d-459b-85bc-72ba1c882c0a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumDiscountedBeforeReinsurance_091ff56d-c29a-43cd-970a-971c14521c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumDiscountedBeforeReinsurance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumDiscountedBeforeReinsurance_091ff56d-c29a-43cd-970a-971c14521c1e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance_c92da5b8-5843-42dc-aeee-48dc2cb421ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance_c92da5b8-5843-42dc-aeee-48dc2cb421ca" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance_bedfdbcd-5df3-4b1d-bda3-a25607893346" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance_bedfdbcd-5df3-4b1d-bda3-a25607893346" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverablesLiabilityForFuturePolicyBenefitsAssetsHeldForSale_cf2f4580-192c-4047-87cd-3e0c0fa25f1e" xlink:href="ci-20231231.xsd#ci_ReinsuranceRecoverablesLiabilityForFuturePolicyBenefitsAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_ci_ReinsuranceRecoverablesLiabilityForFuturePolicyBenefitsAssetsHeldForSale_cf2f4580-192c-4047-87cd-3e0c0fa25f1e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FuturePolicyBenefitsDomesticContractsObservableInputsFromPublishedSpotRateCurveMaximumTerm_6441beae-5fe0-4107-a238-e5ae65c50052" xlink:href="ci-20231231.xsd#ci_FuturePolicyBenefitsDomesticContractsObservableInputsFromPublishedSpotRateCurveMaximumTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_ci_FuturePolicyBenefitsDomesticContractsObservableInputsFromPublishedSpotRateCurveMaximumTerm_6441beae-5fe0-4107-a238-e5ae65c50052" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability_fc173459-925f-46ee-9ed1-d4360e2fa6a4" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability_fc173459-925f-46ee-9ed1-d4360e2fa6a4" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability_ccb75d59-ff7c-4b36-aa2f-a183ab2a3bd2" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability_ccb75d59-ff7c-4b36-aa2f-a183ab2a3bd2" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups_b6545fb3-8b0a-4c18-ad4b-492abaa15700" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups_b6545fb3-8b0a-4c18-ad4b-492abaa15700" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitsPercentSupportedByAssetsHeldInTrust_578b0297-0026-4abb-b5b9-97c8e2bae490" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitsPercentSupportedByAssetsHeldInTrust"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitsPercentSupportedByAssetsHeldInTrust_578b0297-0026-4abb-b5b9-97c8e2bae490" xlink:type="arc" order="16"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_ae822dd6-3898-4db7-9493-057ffcde4b24" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesTable_bfa7e1a3-c302-478a-b94b-a1b4bd5f69ed" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_ae822dd6-3898-4db7-9493-057ffcde4b24" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesTable_bfa7e1a3-c302-478a-b94b-a1b4bd5f69ed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0cb6dfee-b9be-471c-9e5d-1daadbac437b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesTable_bfa7e1a3-c302-478a-b94b-a1b4bd5f69ed" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0cb6dfee-b9be-471c-9e5d-1daadbac437b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0cb6dfee-b9be-471c-9e5d-1daadbac437b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0cb6dfee-b9be-471c-9e5d-1daadbac437b" xlink:to="loc_us-gaap_SegmentDomain_0cb6dfee-b9be-471c-9e5d-1daadbac437b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f75a328f-aa49-4c13-9e83-5809a4a22eab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0cb6dfee-b9be-471c-9e5d-1daadbac437b" xlink:to="loc_us-gaap_SegmentDomain_f75a328f-aa49-4c13-9e83-5809a4a22eab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember_257d06dd-ac93-4a3f-bc43-a22229cceca9" xlink:href="ci-20231231.xsd#ci_CignaHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f75a328f-aa49-4c13-9e83-5809a4a22eab" xlink:to="loc_ci_CignaHealthcareMember_257d06dd-ac93-4a3f-bc43-a22229cceca9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherOperationsSegmentMember_491dc72b-3123-4a34-b725-0cc0aa6349ca" xlink:href="ci-20231231.xsd#ci_OtherOperationsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f75a328f-aa49-4c13-9e83-5809a4a22eab" xlink:to="loc_ci_OtherOperationsSegmentMember_491dc72b-3123-4a34-b725-0cc0aa6349ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2f4cf21f-d6b6-4685-bcd2-3084e980b3e1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesTable_bfa7e1a3-c302-478a-b94b-a1b4bd5f69ed" xlink:to="loc_srt_RangeAxis_2f4cf21f-d6b6-4685-bcd2-3084e980b3e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2f4cf21f-d6b6-4685-bcd2-3084e980b3e1_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2f4cf21f-d6b6-4685-bcd2-3084e980b3e1" xlink:to="loc_srt_RangeMember_2f4cf21f-d6b6-4685-bcd2-3084e980b3e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cb7dd406-5c85-473b-87e6-e9387327541d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2f4cf21f-d6b6-4685-bcd2-3084e980b3e1" xlink:to="loc_srt_RangeMember_cb7dd406-5c85-473b-87e6-e9387327541d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b3130a62-94ff-4c79-80ea-ff5cbc76fa78" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cb7dd406-5c85-473b-87e6-e9387327541d" xlink:to="loc_srt_MinimumMember_b3130a62-94ff-4c79-80ea-ff5cbc76fa78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f90ab486-1edf-4992-965e-0b63af5f7e16" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cb7dd406-5c85-473b-87e6-e9387327541d" xlink:to="loc_srt_MaximumMember_f90ab486-1edf-4992-965e-0b63af5f7e16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis_824181d3-9c46-4fbc-8332-a0bdb15db02a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesTable_bfa7e1a3-c302-478a-b94b-a1b4bd5f69ed" xlink:to="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis_824181d3-9c46-4fbc-8332-a0bdb15db02a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain_824181d3-9c46-4fbc-8332-a0bdb15db02a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis_824181d3-9c46-4fbc-8332-a0bdb15db02a" xlink:to="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain_824181d3-9c46-4fbc-8332-a0bdb15db02a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain_fa8149ba-1609-4e44-ade7-05a825222023" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis_824181d3-9c46-4fbc-8332-a0bdb15db02a" xlink:to="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain_fa8149ba-1609-4e44-ade7-05a825222023" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member_4f84fe85-3005-4f06-8239-cf1dbd11b6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain_fa8149ba-1609-4e44-ade7-05a825222023" xlink:to="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member_4f84fe85-3005-4f06-8239-cf1dbd11b6dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis_dac932d7-310e-4a87-8d1e-3d361d33dd62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesTable_bfa7e1a3-c302-478a-b94b-a1b4bd5f69ed" xlink:to="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis_dac932d7-310e-4a87-8d1e-3d361d33dd62" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain_dac932d7-310e-4a87-8d1e-3d361d33dd62_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis_dac932d7-310e-4a87-8d1e-3d361d33dd62" xlink:to="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain_dac932d7-310e-4a87-8d1e-3d361d33dd62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain_2a8063a7-0f6b-474f-a6e9-02a18da63ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis_dac932d7-310e-4a87-8d1e-3d361d33dd62" xlink:to="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain_2a8063a7-0f6b-474f-a6e9-02a18da63ad6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember_4240ca54-57af-45a6-bd41-2debdb4441d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain_2a8063a7-0f6b-474f-a6e9-02a18da63ad6" xlink:to="loc_us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember_4240ca54-57af-45a6-bd41-2debdb4441d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member_4ed89537-b50c-4218-91b9-7feb05cad266" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain_2a8063a7-0f6b-474f-a6e9-02a18da63ad6" xlink:to="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member_4ed89537-b50c-4218-91b9-7feb05cad266" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember_fbb3a3cc-0a50-48e9-a220-1bcc462e5a12" xlink:href="ci-20231231.xsd#ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain_2a8063a7-0f6b-474f-a6e9-02a18da63ad6" xlink:to="loc_ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember_fbb3a3cc-0a50-48e9-a220-1bcc462e5a12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderContractDeposits_0987eeef-0e95-4232-8149-de850051e0dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderContractDeposits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_ae822dd6-3898-4db7-9493-057ffcde4b24" xlink:to="loc_us-gaap_PolicyholderContractDeposits_0987eeef-0e95-4232-8149-de850051e0dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractBalancePercentReinsuredExternally_b56bb511-863b-49c7-95f6-c83d386231c7" xlink:href="ci-20231231.xsd#ci_PolicyholderContractBalancePercentReinsuredExternally"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_ae822dd6-3898-4db7-9493-057ffcde4b24" xlink:to="loc_ci_PolicyholderContractBalancePercentReinsuredExternally_b56bb511-863b-49c7-95f6-c83d386231c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate_f65dfa96-d541-4f25-b841-64a92420f565" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_ae822dd6-3898-4db7-9493-057ffcde4b24" xlink:to="loc_us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate_f65dfa96-d541-4f25-b841-64a92420f565" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceNetAmountAtRisk_d040e58a-38f7-4bfc-a3b6-2a6797cea163" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceNetAmountAtRisk"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_ae822dd6-3898-4db7-9493-057ffcde4b24" xlink:to="loc_us-gaap_PolicyholderAccountBalanceNetAmountAtRisk_d040e58a-38f7-4bfc-a3b6-2a6797cea163" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashSurrenderValueDuePolicyholdersAmount_213c7856-36f5-420b-b517-4fede21c2f94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashSurrenderValueDuePolicyholdersAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_ae822dd6-3898-4db7-9493-057ffcde4b24" xlink:to="loc_us-gaap_CashSurrenderValueDuePolicyholdersAmount_213c7856-36f5-420b-b517-4fede21c2f94" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage_857c2e86-be5d-45ba-b2b0-df7c447059cd" xlink:href="ci-20231231.xsd#ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_ae822dd6-3898-4db7-9493-057ffcde4b24" xlink:to="loc_ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage_857c2e86-be5d-45ba-b2b0-df7c447059cd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderFunds_ec2ca56e-70db-40aa-a700-1d5018321e98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderFunds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_ae822dd6-3898-4db7-9493-057ffcde4b24" xlink:to="loc_us-gaap_PolicyholderFunds_ec2ca56e-70db-40aa-a700-1d5018321e98" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate_d0b104ea-0f82-4c4f-906d-d2a9e1d93f18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_ae822dd6-3898-4db7-9493-057ffcde4b24" xlink:to="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate_d0b104ea-0f82-4c4f-906d-d2a9e1d93f18" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating_e3ea5f09-a736-4562-9674-8620a71ea717" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_ae822dd6-3898-4db7-9493-057ffcde4b24" xlink:to="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating_e3ea5f09-a736-4562-9674-8620a71ea717" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue_fa1591a2-323d-4d21-87c1-a830d660a69b" xlink:href="ci-20231231.xsd#ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_ae822dd6-3898-4db7-9493-057ffcde4b24" xlink:to="loc_ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue_fa1591a2-323d-4d21-87c1-a830d660a69b" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems_24c5bc6a-8230-4071-8bd3-9fae346e1f29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeTable_ebc76333-11de-4b64-a3af-70ab75328475" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetAmountAtRiskByProductAndGuaranteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems_24c5bc6a-8230-4071-8bd3-9fae346e1f29" xlink:to="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeTable_ebc76333-11de-4b64-a3af-70ab75328475" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_41b5215c-76d8-4d5e-b789-bb0463fc2a57" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeTable_ebc76333-11de-4b64-a3af-70ab75328475" xlink:to="loc_srt_ProductOrServiceAxis_41b5215c-76d8-4d5e-b789-bb0463fc2a57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_41b5215c-76d8-4d5e-b789-bb0463fc2a57_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_41b5215c-76d8-4d5e-b789-bb0463fc2a57" xlink:to="loc_srt_ProductsAndServicesDomain_41b5215c-76d8-4d5e-b789-bb0463fc2a57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2f4c7b77-cb82-4786-86ba-abb4b9d84c7d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_41b5215c-76d8-4d5e-b789-bb0463fc2a57" xlink:to="loc_srt_ProductsAndServicesDomain_2f4c7b77-cb82-4786-86ba-abb4b9d84c7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableAnnuityMember_913170ee-b8ec-400b-b572-d2abd1b67ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableAnnuityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2f4c7b77-cb82-4786-86ba-abb4b9d84c7d" xlink:to="loc_us-gaap_VariableAnnuityMember_913170ee-b8ec-400b-b572-d2abd1b67ac2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue_88f4b34e-136f-4b20-86f7-e261a29d46ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems_24c5bc6a-8230-4071-8bd3-9fae346e1f29" xlink:to="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue_88f4b34e-136f-4b20-86f7-e261a29d46ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk_5f506865-9ff2-4bd1-8742-793d5a1df79a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems_24c5bc6a-8230-4071-8bd3-9fae346e1f29" xlink:to="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk_5f506865-9ff2-4bd1-8742-793d5a1df79a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1_6d67ef1c-f754-412a-9b96-0eccb5bec320" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems_24c5bc6a-8230-4071-8bd3-9fae346e1f29" xlink:to="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1_6d67ef1c-f754-412a-9b96-0eccb5bec320" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated_1e7e1be4-d3bd-451f-ac50-93f3634d3a82" xlink:href="ci-20231231.xsd#ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems_24c5bc6a-8230-4071-8bd3-9fae346e1f29" xlink:to="loc_ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated_1e7e1be4-d3bd-451f-ac50-93f3634d3a82" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#ReinsuranceReinsuranceRecoverablesDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskLineItems_f0967b3a-d22c-4477-954b-0ec991c8f627" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskTable_cdfbb835-c3c6-45c8-b378-5d649d73cff8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CededCreditRiskLineItems_f0967b3a-d22c-4477-954b-0ec991c8f627" xlink:to="loc_us-gaap_CededCreditRiskTable_cdfbb835-c3c6-45c8-b378-5d649d73cff8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e087c824-ad62-48fc-b3c0-f4990abef8d4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CededCreditRiskTable_cdfbb835-c3c6-45c8-b378-5d649d73cff8" xlink:to="loc_srt_ProductOrServiceAxis_e087c824-ad62-48fc-b3c0-f4990abef8d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e087c824-ad62-48fc-b3c0-f4990abef8d4_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e087c824-ad62-48fc-b3c0-f4990abef8d4" xlink:to="loc_srt_ProductsAndServicesDomain_e087c824-ad62-48fc-b3c0-f4990abef8d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_290c18ca-13d0-4099-b84c-6105ac3f8ac7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e087c824-ad62-48fc-b3c0-f4990abef8d4" xlink:to="loc_srt_ProductsAndServicesDomain_290c18ca-13d0-4099-b84c-6105ac3f8ac7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableAnnuityMember_ed1f18b7-bb97-4e43-8571-8823ad62e3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableAnnuityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_290c18ca-13d0-4099-b84c-6105ac3f8ac7" xlink:to="loc_us-gaap_VariableAnnuityMember_ed1f18b7-bb97-4e43-8571-8823ad62e3ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OngoingOperationsMember_4f59927e-1fcf-4134-86d3-65c3383fbfc4" xlink:href="ci-20231231.xsd#ci_OngoingOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableAnnuityMember_ed1f18b7-bb97-4e43-8571-8823ad62e3ae" xlink:to="loc_ci_OngoingOperationsMember_4f59927e-1fcf-4134-86d3-65c3383fbfc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AcquisitionDispositionRunoffActivitiesMember_b5931976-6ee6-41b0-a26e-67b34e682c91" xlink:href="ci-20231231.xsd#ci_AcquisitionDispositionRunoffActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableAnnuityMember_ed1f18b7-bb97-4e43-8571-8823ad62e3ae" xlink:to="loc_ci_AcquisitionDispositionRunoffActivitiesMember_b5931976-6ee6-41b0-a26e-67b34e682c91" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskCollateralizationAxis_1da7d1fc-9fd0-4e87-a038-5d90a2b4a3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskCollateralizationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CededCreditRiskTable_cdfbb835-c3c6-45c8-b378-5d649d73cff8" xlink:to="loc_us-gaap_CededCreditRiskCollateralizationAxis_1da7d1fc-9fd0-4e87-a038-5d90a2b4a3d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskCollateralizationDomain_1da7d1fc-9fd0-4e87-a038-5d90a2b4a3d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskCollateralizationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CededCreditRiskCollateralizationAxis_1da7d1fc-9fd0-4e87-a038-5d90a2b4a3d0" xlink:to="loc_us-gaap_CededCreditRiskCollateralizationDomain_1da7d1fc-9fd0-4e87-a038-5d90a2b4a3d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskCollateralizationDomain_7c0d3474-c069-4537-9c6d-8f6dbe8c0927" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskCollateralizationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CededCreditRiskCollateralizationAxis_1da7d1fc-9fd0-4e87-a038-5d90a2b4a3d0" xlink:to="loc_us-gaap_CededCreditRiskCollateralizationDomain_7c0d3474-c069-4537-9c6d-8f6dbe8c0927" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskSecuredMember_03a5e257-9204-409b-806f-094f769f61ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskSecuredMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskCollateralizationDomain_7c0d3474-c069-4537-9c6d-8f6dbe8c0927" xlink:to="loc_us-gaap_CededCreditRiskSecuredMember_03a5e257-9204-409b-806f-094f769f61ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember_a4912f64-6762-4826-9c62-81e210d4222b" xlink:href="ci-20231231.xsd#ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskSecuredMember_03a5e257-9204-409b-806f-094f769f61ce" xlink:to="loc_ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember_a4912f64-6762-4826-9c62-81e210d4222b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember_a84a942b-43ad-4848-95f6-2f7f31d77130" xlink:href="ci-20231231.xsd#ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskSecuredMember_03a5e257-9204-409b-806f-094f769f61ce" xlink:to="loc_ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember_a84a942b-43ad-4848-95f6-2f7f31d77130" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskUnsecuredMember_fae971eb-9f9b-4370-b4a3-919ac6327f42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskUnsecuredMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskCollateralizationDomain_7c0d3474-c069-4537-9c6d-8f6dbe8c0927" xlink:to="loc_us-gaap_CededCreditRiskUnsecuredMember_fae971eb-9f9b-4370-b4a3-919ac6327f42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis_f3feb2d0-8087-47c8-90a8-2bfa4feacbd5" xlink:href="ci-20231231.xsd#ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CededCreditRiskTable_cdfbb835-c3c6-45c8-b378-5d649d73cff8" xlink:to="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis_f3feb2d0-8087-47c8-90a8-2bfa4feacbd5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain_f3feb2d0-8087-47c8-90a8-2bfa4feacbd5_default" xlink:href="ci-20231231.xsd#ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis_f3feb2d0-8087-47c8-90a8-2bfa4feacbd5" xlink:to="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain_f3feb2d0-8087-47c8-90a8-2bfa4feacbd5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain_d3a61ac1-2a4c-43af-b3e9-5cdf7c65e081" xlink:href="ci-20231231.xsd#ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis_f3feb2d0-8087-47c8-90a8-2bfa4feacbd5" xlink:to="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain_d3a61ac1-2a4c-43af-b3e9-5cdf7c65e081" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember_98ad4c15-83c7-4493-bee4-3719e73c95d6" xlink:href="ci-20231231.xsd#ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain_d3a61ac1-2a4c-43af-b3e9-5cdf7c65e081" xlink:to="loc_ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember_98ad4c15-83c7-4493-bee4-3719e73c95d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember_e191d18f-c324-4e75-b96e-4438e75436ba" xlink:href="ci-20231231.xsd#ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember_98ad4c15-83c7-4493-bee4-3719e73c95d6" xlink:to="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember_e191d18f-c324-4e75-b96e-4438e75436ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember_0272dc8f-1450-4191-b028-f4190f809d66" xlink:href="ci-20231231.xsd#ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain_d3a61ac1-2a4c-43af-b3e9-5cdf7c65e081" xlink:to="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember_0272dc8f-1450-4191-b028-f4190f809d66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember_63b21643-e33f-4b8c-b07c-773ab0e3a957" xlink:href="ci-20231231.xsd#ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain_d3a61ac1-2a4c-43af-b3e9-5cdf7c65e081" xlink:to="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember_63b21643-e33f-4b8c-b07c-773ab0e3a957" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskAxis_c8e57490-0b90-4cd9-b8c2-9d24eac929bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CededCreditRiskTable_cdfbb835-c3c6-45c8-b378-5d649d73cff8" xlink:to="loc_us-gaap_CededCreditRiskAxis_c8e57490-0b90-4cd9-b8c2-9d24eac929bb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskReinsurerDomain_c8e57490-0b90-4cd9-b8c2-9d24eac929bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskReinsurerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CededCreditRiskAxis_c8e57490-0b90-4cd9-b8c2-9d24eac929bb" xlink:to="loc_us-gaap_CededCreditRiskReinsurerDomain_c8e57490-0b90-4cd9-b8c2-9d24eac929bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskReinsurerDomain_d2f32e8a-170b-4b36-b44a-0ac48336925f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskReinsurerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CededCreditRiskAxis_c8e57490-0b90-4cd9-b8c2-9d24eac929bb" xlink:to="loc_us-gaap_CededCreditRiskReinsurerDomain_d2f32e8a-170b-4b36-b44a-0ac48336925f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember_7bd2da0e-3631-4bf4-bba3-ea1978845499" xlink:href="ci-20231231.xsd#ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain_d2f32e8a-170b-4b36-b44a-0ac48336925f" xlink:to="loc_ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember_7bd2da0e-3631-4bf4-bba3-ea1978845499" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EmpowerAnnuityInsuranceCompanyMember_1da06ff7-2ced-4739-b850-b21cc24ae2be" xlink:href="ci-20231231.xsd#ci_EmpowerAnnuityInsuranceCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain_d2f32e8a-170b-4b36-b44a-0ac48336925f" xlink:to="loc_ci_EmpowerAnnuityInsuranceCompanyMember_1da06ff7-2ced-4739-b850-b21cc24ae2be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PrudentialInsuranceCompanyOfAmericaMember_46ed0501-bf0a-431e-84b3-fe3b84720f6b" xlink:href="ci-20231231.xsd#ci_PrudentialInsuranceCompanyOfAmericaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain_d2f32e8a-170b-4b36-b44a-0ac48336925f" xlink:to="loc_ci_PrudentialInsuranceCompanyOfAmericaMember_46ed0501-bf0a-431e-84b3-fe3b84720f6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LifeInsuranceCompanyOfNorthAmericaMember_dc19cc71-fc10-4296-bd62-2d6b1075e359" xlink:href="ci-20231231.xsd#ci_LifeInsuranceCompanyOfNorthAmericaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain_d2f32e8a-170b-4b36-b44a-0ac48336925f" xlink:to="loc_ci_LifeInsuranceCompanyOfNorthAmericaMember_dc19cc71-fc10-4296-bd62-2d6b1075e359" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReinsurerMember_ec3afb2c-48f6-483c-943e-e73fabeab019" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReinsurerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain_d2f32e8a-170b-4b36-b44a-0ac48336925f" xlink:to="loc_us-gaap_OtherReinsurerMember_ec3afb2c-48f6-483c-943e-e73fabeab019" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaAndOtherRecoverablesMember_df3ecea1-064b-4f6a-b589-02116d05674b" xlink:href="ci-20231231.xsd#ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaAndOtherRecoverablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain_d2f32e8a-170b-4b36-b44a-0ac48336925f" xlink:to="loc_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaAndOtherRecoverablesMember_df3ecea1-064b-4f6a-b589-02116d05674b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f841ea3e-adac-495f-927d-0e20dbca5127" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CededCreditRiskTable_cdfbb835-c3c6-45c8-b378-5d649d73cff8" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f841ea3e-adac-495f-927d-0e20dbca5127" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f841ea3e-adac-495f-927d-0e20dbca5127_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f841ea3e-adac-495f-927d-0e20dbca5127" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f841ea3e-adac-495f-927d-0e20dbca5127_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_976f030c-08b0-408d-97e6-28d704d695e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f841ea3e-adac-495f-927d-0e20dbca5127" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_976f030c-08b0-408d-97e6-28d704d695e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_67a53fb5-eba9-4bb8-8f17-29db061df10a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_976f030c-08b0-408d-97e6-28d704d695e0" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_67a53fb5-eba9-4bb8-8f17-29db061df10a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteedInsuranceContractTypeOfBenefitAxis_6f7aeec3-487f-43dc-befb-0343534d9a45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteedInsuranceContractTypeOfBenefitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CededCreditRiskTable_cdfbb835-c3c6-45c8-b378-5d649d73cff8" xlink:to="loc_us-gaap_GuaranteedInsuranceContractTypeOfBenefitAxis_6f7aeec3-487f-43dc-befb-0343534d9a45" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteedInsuranceContractTypeOfBenefitDomain_6f7aeec3-487f-43dc-befb-0343534d9a45_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteedInsuranceContractTypeOfBenefitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GuaranteedInsuranceContractTypeOfBenefitAxis_6f7aeec3-487f-43dc-befb-0343534d9a45" xlink:to="loc_us-gaap_GuaranteedInsuranceContractTypeOfBenefitDomain_6f7aeec3-487f-43dc-befb-0343534d9a45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteedInsuranceContractTypeOfBenefitDomain_10846e88-747d-45c6-8881-ffa0d2dca126" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteedInsuranceContractTypeOfBenefitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GuaranteedInsuranceContractTypeOfBenefitAxis_6f7aeec3-487f-43dc-befb-0343534d9a45" xlink:to="loc_us-gaap_GuaranteedInsuranceContractTypeOfBenefitDomain_10846e88-747d-45c6-8881-ffa0d2dca126" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteedMinimumDeathBenefitMember_96a8e27c-b9fa-482f-9ae3-aad7aca07337" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteedMinimumDeathBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteedInsuranceContractTypeOfBenefitDomain_10846e88-747d-45c6-8881-ffa0d2dca126" xlink:to="loc_us-gaap_GuaranteedMinimumDeathBenefitMember_96a8e27c-b9fa-482f-9ae3-aad7aca07337" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_a51c6474-c49c-47fb-82fd-37c6d8964f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CededCreditRiskTable_cdfbb835-c3c6-45c8-b378-5d649d73cff8" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_a51c6474-c49c-47fb-82fd-37c6d8964f1d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_a51c6474-c49c-47fb-82fd-37c6d8964f1d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_a51c6474-c49c-47fb-82fd-37c6d8964f1d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_a51c6474-c49c-47fb-82fd-37c6d8964f1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_58e04a65-a2a0-4e31-8359-8bd59c24edb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_a51c6474-c49c-47fb-82fd-37c6d8964f1d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_58e04a65-a2a0-4e31-8359-8bd59c24edb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_d7d7e8ab-db8d-4988-bfa3-9e868752303f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_58e04a65-a2a0-4e31-8359-8bd59c24edb2" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_d7d7e8ab-db8d-4988-bfa3-9e868752303f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c5c5822b-d0e4-4c66-b788-4ac12d709ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CededCreditRiskTable_cdfbb835-c3c6-45c8-b378-5d649d73cff8" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c5c5822b-d0e4-4c66-b788-4ac12d709ed8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c5c5822b-d0e4-4c66-b788-4ac12d709ed8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c5c5822b-d0e4-4c66-b788-4ac12d709ed8" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c5c5822b-d0e4-4c66-b788-4ac12d709ed8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fcea88b1-19c0-4ffa-8c5f-fa104fe57e68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c5c5822b-d0e4-4c66-b788-4ac12d709ed8" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fcea88b1-19c0-4ffa-8c5f-fa104fe57e68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_2781b815-a283-495c-a252-3557a30f086b" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fcea88b1-19c0-4ffa-8c5f-fa104fe57e68" xlink:to="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_2781b815-a283-495c-a252-3557a30f086b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale_42e0d10f-76ea-435c-89d1-3ca6283c1fc4" xlink:href="ci-20231231.xsd#ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskLineItems_f0967b3a-d22c-4477-954b-0ec991c8f627" xlink:to="loc_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale_42e0d10f-76ea-435c-89d1-3ca6283c1fc4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverableAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_d325d884-4977-4138-bde1-67e8afe4217f" xlink:href="ci-20231231.xsd#ci_ReinsuranceRecoverableAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskLineItems_f0967b3a-d22c-4477-954b-0ec991c8f627" xlink:to="loc_ci_ReinsuranceRecoverableAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_d325d884-4977-4138-bde1-67e8afe4217f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance_52d41dc4-7eb6-4f51-ba98-5e8faba974f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskLineItems_f0967b3a-d22c-4477-954b-0ec991c8f627" xlink:to="loc_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance_52d41dc4-7eb6-4f51-ba98-5e8faba974f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale_c18b75a5-159c-4d8d-bdaf-adb52b030906" xlink:href="ci-20231231.xsd#ci_ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskLineItems_f0967b3a-d22c-4477-954b-0ec991c8f627" xlink:to="loc_ci_ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale_c18b75a5-159c-4d8d-bdaf-adb52b030906" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverables_c71dfd18-3e47-47fb-a785-1a6624c46449" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceRecoverables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskLineItems_f0967b3a-d22c-4477-954b-0ec991c8f627" xlink:to="loc_us-gaap_ReinsuranceRecoverables_c71dfd18-3e47-47fb-a785-1a6624c46449" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationReinsuranceRecoverablesIncludingReinsurancePremiumPaid_eb3e8760-0599-4142-af29-c96acf994130" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationReinsuranceRecoverablesIncludingReinsurancePremiumPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskLineItems_f0967b3a-d22c-4477-954b-0ec991c8f627" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationReinsuranceRecoverablesIncludingReinsurancePremiumPaid_eb3e8760-0599-4142-af29-c96acf994130" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ReinsuranceEffectsofReinsuranceDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#ReinsuranceEffectsofReinsuranceDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/ReinsuranceEffectsofReinsuranceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectsOfReinsuranceLineItems_b1adb37d-84a1-4f5e-9536-7ee040675d49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectsOfReinsuranceLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectsOfReinsuranceTable_cf6e2b7a-48c6-4fb6-a480-19629500cca2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectsOfReinsuranceTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EffectsOfReinsuranceLineItems_b1adb37d-84a1-4f5e-9536-7ee040675d49" xlink:to="loc_us-gaap_EffectsOfReinsuranceTable_cf6e2b7a-48c6-4fb6-a480-19629500cca2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8a4174a6-3a49-46a7-aa21-db0666646844" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_EffectsOfReinsuranceTable_cf6e2b7a-48c6-4fb6-a480-19629500cca2" xlink:to="loc_srt_ProductOrServiceAxis_8a4174a6-3a49-46a7-aa21-db0666646844" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8a4174a6-3a49-46a7-aa21-db0666646844_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8a4174a6-3a49-46a7-aa21-db0666646844" xlink:to="loc_srt_ProductsAndServicesDomain_8a4174a6-3a49-46a7-aa21-db0666646844_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dc9985a9-4f2e-422c-9253-0d8fc4fa08db" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8a4174a6-3a49-46a7-aa21-db0666646844" xlink:to="loc_srt_ProductsAndServicesDomain_dc9985a9-4f2e-422c-9253-0d8fc4fa08db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortDurationContractsMember_0f3fca67-f1cf-44b0-ad55-3eb04d97bf9a" xlink:href="ci-20231231.xsd#ci_ShortDurationContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc9985a9-4f2e-422c-9253-0d8fc4fa08db" xlink:to="loc_ci_ShortDurationContractsMember_0f3fca67-f1cf-44b0-ad55-3eb04d97bf9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LongDurationContractsMember_bfb021ee-2583-437b-b4c2-891347118f01" xlink:href="ci-20231231.xsd#ci_LongDurationContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc9985a9-4f2e-422c-9253-0d8fc4fa08db" xlink:to="loc_ci_LongDurationContractsMember_bfb021ee-2583-437b-b4c2-891347118f01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract_7c584db7-0e3f-49ab-b063-04dd5c7bf6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectsOfReinsuranceLineItems_b1adb37d-84a1-4f5e-9536-7ee040675d49" xlink:to="loc_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract_7c584db7-0e3f-49ab-b063-04dd5c7bf6cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectPremiumsEarned_1fa9cac8-52fc-4e52-b55e-85ca85175a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DirectPremiumsEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract_7c584db7-0e3f-49ab-b063-04dd5c7bf6cf" xlink:to="loc_us-gaap_DirectPremiumsEarned_1fa9cac8-52fc-4e52-b55e-85ca85175a3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumedPremiumsEarned_d6f2abf3-59d3-4517-9f46-63a35082e28e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssumedPremiumsEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract_7c584db7-0e3f-49ab-b063-04dd5c7bf6cf" xlink:to="loc_us-gaap_AssumedPremiumsEarned_d6f2abf3-59d3-4517-9f46-63a35082e28e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededPremiumsEarned_f640faa1-ea8f-45a3-9c87-469f814c64f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededPremiumsEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract_7c584db7-0e3f-49ab-b063-04dd5c7bf6cf" xlink:to="loc_us-gaap_CededPremiumsEarned_f640faa1-ea8f-45a3-9c87-469f814c64f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_3f900e35-0534-4ce7-951a-e200d2300c25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract_7c584db7-0e3f-49ab-b063-04dd5c7bf6cf" xlink:to="loc_us-gaap_PremiumsEarnedNet_3f900e35-0534-4ce7-951a-e200d2300c25" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract_d197e451-9ccf-417f-adcf-680d50c90eef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectsOfReinsuranceLineItems_b1adb37d-84a1-4f5e-9536-7ee040675d49" xlink:to="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract_d197e451-9ccf-417f-adcf-680d50c90eef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded_e3f2315d-796e-49c4-af17-2bd3182855d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract_d197e451-9ccf-417f-adcf-680d50c90eef" xlink:to="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded_e3f2315d-796e-49c4-af17-2bd3182855d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsWrittenNet_2cf9e26f-fc24-441f-b99f-c96277478bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PremiumsWrittenNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectsOfReinsuranceLineItems_b1adb37d-84a1-4f5e-9536-7ee040675d49" xlink:to="loc_us-gaap_PremiumsWrittenNet_2cf9e26f-fc24-441f-b99f-c96277478bb8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskLineItems_9daba6c4-2da0-4d45-bc78-3fb1c33bda64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskTable_b559f65c-8f3f-4161-aad0-9c6105511091" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CededCreditRiskLineItems_9daba6c4-2da0-4d45-bc78-3fb1c33bda64" xlink:to="loc_us-gaap_CededCreditRiskTable_b559f65c-8f3f-4161-aad0-9c6105511091" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_79e9e404-d393-4a56-878a-2458b45d7e69" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CededCreditRiskTable_b559f65c-8f3f-4161-aad0-9c6105511091" xlink:to="loc_srt_ProductOrServiceAxis_79e9e404-d393-4a56-878a-2458b45d7e69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_79e9e404-d393-4a56-878a-2458b45d7e69_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_79e9e404-d393-4a56-878a-2458b45d7e69" xlink:to="loc_srt_ProductsAndServicesDomain_79e9e404-d393-4a56-878a-2458b45d7e69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ef607699-df41-461e-b348-b2cf4d65d951" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_79e9e404-d393-4a56-878a-2458b45d7e69" xlink:to="loc_srt_ProductsAndServicesDomain_ef607699-df41-461e-b348-b2cf4d65d951" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableAnnuityMember_afeb7a14-c3a1-49fa-9927-2071a0b89b70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableAnnuityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ef607699-df41-461e-b348-b2cf4d65d951" xlink:to="loc_us-gaap_VariableAnnuityMember_afeb7a14-c3a1-49fa-9927-2071a0b89b70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskAxis_59f4180a-37ea-4479-8a6c-333126ef6976" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CededCreditRiskTable_b559f65c-8f3f-4161-aad0-9c6105511091" xlink:to="loc_us-gaap_CededCreditRiskAxis_59f4180a-37ea-4479-8a6c-333126ef6976" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskReinsurerDomain_59f4180a-37ea-4479-8a6c-333126ef6976_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskReinsurerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CededCreditRiskAxis_59f4180a-37ea-4479-8a6c-333126ef6976" xlink:to="loc_us-gaap_CededCreditRiskReinsurerDomain_59f4180a-37ea-4479-8a6c-333126ef6976_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskReinsurerDomain_2d9f4347-aeb2-47dc-9446-a67282d1633e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskReinsurerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CededCreditRiskAxis_59f4180a-37ea-4479-8a6c-333126ef6976" xlink:to="loc_us-gaap_CededCreditRiskReinsurerDomain_2d9f4347-aeb2-47dc-9446-a67282d1633e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember_4c6d974b-2c8d-4129-9a1f-f177f9667fc6" xlink:href="ci-20231231.xsd#ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain_2d9f4347-aeb2-47dc-9446-a67282d1633e" xlink:to="loc_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember_4c6d974b-2c8d-4129-9a1f-f177f9667fc6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SunLifeAssuranceCompanyOfCanadaMember_7f358959-09d9-43c3-9576-731d3274d1fd" xlink:href="ci-20231231.xsd#ci_SunLifeAssuranceCompanyOfCanadaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain_2d9f4347-aeb2-47dc-9446-a67282d1633e" xlink:to="loc_ci_SunLifeAssuranceCompanyOfCanadaMember_7f358959-09d9-43c3-9576-731d3274d1fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LibertyMutualInsuranceMember_eff4016f-2d79-4c18-b5ab-ce0f72c17392" xlink:href="ci-20231231.xsd#ci_LibertyMutualInsuranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain_2d9f4347-aeb2-47dc-9446-a67282d1633e" xlink:to="loc_ci_LibertyMutualInsuranceMember_eff4016f-2d79-4c18-b5ab-ce0f72c17392" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SCORSEMember_192f62dd-8c71-4213-8884-d2f7ad73deda" xlink:href="ci-20231231.xsd#ci_SCORSEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain_2d9f4347-aeb2-47dc-9446-a67282d1633e" xlink:to="loc_ci_SCORSEMember_192f62dd-8c71-4213-8884-d2f7ad73deda" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskCollateralizationAxis_87529216-d463-4454-8cbb-278f2abf27e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskCollateralizationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CededCreditRiskTable_b559f65c-8f3f-4161-aad0-9c6105511091" xlink:to="loc_us-gaap_CededCreditRiskCollateralizationAxis_87529216-d463-4454-8cbb-278f2abf27e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskCollateralizationDomain_87529216-d463-4454-8cbb-278f2abf27e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskCollateralizationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CededCreditRiskCollateralizationAxis_87529216-d463-4454-8cbb-278f2abf27e4" xlink:to="loc_us-gaap_CededCreditRiskCollateralizationDomain_87529216-d463-4454-8cbb-278f2abf27e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskCollateralizationDomain_b3580836-35f0-4ea2-93ad-496c3f6072ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskCollateralizationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CededCreditRiskCollateralizationAxis_87529216-d463-4454-8cbb-278f2abf27e4" xlink:to="loc_us-gaap_CededCreditRiskCollateralizationDomain_b3580836-35f0-4ea2-93ad-496c3f6072ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskSecuredMember_6ff00671-5eb2-4743-a3e3-c55d609a7de8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskSecuredMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskCollateralizationDomain_b3580836-35f0-4ea2-93ad-496c3f6072ef" xlink:to="loc_us-gaap_CededCreditRiskSecuredMember_6ff00671-5eb2-4743-a3e3-c55d609a7de8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_898c305f-41df-4185-923a-112d04e6b158" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CededCreditRiskTable_b559f65c-8f3f-4161-aad0-9c6105511091" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_898c305f-41df-4185-923a-112d04e6b158" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_898c305f-41df-4185-923a-112d04e6b158_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_898c305f-41df-4185-923a-112d04e6b158" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_898c305f-41df-4185-923a-112d04e6b158_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c47cdc60-f292-4ee8-a21a-43437ac367d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_898c305f-41df-4185-923a-112d04e6b158" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c47cdc60-f292-4ee8-a21a-43437ac367d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember_ae9b493b-f1e0-405f-8e0a-70b668ccb5ff" xlink:href="ci-20231231.xsd#ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c47cdc60-f292-4ee8-a21a-43437ac367d5" xlink:to="loc_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember_ae9b493b-f1e0-405f-8e0a-70b668ccb5ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_60fbd7be-554e-471e-9ee4-b116af40c635" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CededCreditRiskTable_b559f65c-8f3f-4161-aad0-9c6105511091" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_60fbd7be-554e-471e-9ee4-b116af40c635" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_60fbd7be-554e-471e-9ee4-b116af40c635_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_60fbd7be-554e-471e-9ee4-b116af40c635" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_60fbd7be-554e-471e-9ee4-b116af40c635_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6e204d93-745d-43ea-a96f-88f219ce64e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_60fbd7be-554e-471e-9ee4-b116af40c635" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6e204d93-745d-43ea-a96f-88f219ce64e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CededCreditCollateralizationRiskMember_48e00cd1-2256-4559-a6c6-eb71dd269141" xlink:href="ci-20231231.xsd#ci_CededCreditCollateralizationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_6e204d93-745d-43ea-a96f-88f219ce64e7" xlink:to="loc_ci_CededCreditCollateralizationRiskMember_48e00cd1-2256-4559-a6c6-eb71dd269141" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CededReinsuranceAgreementReinsuredRiskPercentage_1d9c3083-9539-4651-8854-42d61d9b4d51" xlink:href="ci-20231231.xsd#ci_CededReinsuranceAgreementReinsuredRiskPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskLineItems_9daba6c4-2da0-4d45-bc78-3fb1c33bda64" xlink:to="loc_ci_CededReinsuranceAgreementReinsuredRiskPercentage_1d9c3083-9539-4651-8854-42d61d9b4d51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CededReinsuranceAgreementCoverageLimitAmountRemaining_622e13fc-e182-47c5-bc4e-9f999fc47a96" xlink:href="ci-20231231.xsd#ci_CededReinsuranceAgreementCoverageLimitAmountRemaining"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskLineItems_9daba6c4-2da0-4d45-bc78-3fb1c33bda64" xlink:to="loc_ci_CededReinsuranceAgreementCoverageLimitAmountRemaining_622e13fc-e182-47c5-bc4e-9f999fc47a96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ae907849-ef32-4854-9973-82553ec2c298" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskLineItems_9daba6c4-2da0-4d45-bc78-3fb1c33bda64" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ae907849-ef32-4854-9973-82553ec2c298" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances_fce623e3-b72a-410b-82e5-e51df1b497ca" xlink:href="ci-20231231.xsd#ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskLineItems_9daba6c4-2da0-4d45-bc78-3fb1c33bda64" xlink:to="loc_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances_fce623e3-b72a-410b-82e5-e51df1b497ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceReceivablesIncurredButNotReportedClaims_81a15277-b8a5-48d2-bbc5-9e172d394725" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceReceivablesIncurredButNotReportedClaims"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskLineItems_9daba6c4-2da0-4d45-bc78-3fb1c33bda64" xlink:to="loc_us-gaap_ReinsuranceReceivablesIncurredButNotReportedClaims_81a15277-b8a5-48d2-bbc5-9e172d394725" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsReceivableAtCarryingValue_acb7a0c1-bdc7-4351-b5ff-8d217a47247a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PremiumsReceivableAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskLineItems_9daba6c4-2da0-4d45-bc78-3fb1c33bda64" xlink:to="loc_us-gaap_PremiumsReceivableAtCarryingValue_acb7a0c1-bdc7-4351-b5ff-8d217a47247a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueMeasurementNonPerformanceRiskAdjustment_0b4c8480-8441-40e7-a3b1-7e2080ce1957" xlink:href="ci-20231231.xsd#ci_FairValueMeasurementNonPerformanceRiskAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CededCreditRiskLineItems_9daba6c4-2da0-4d45-bc78-3fb1c33bda64" xlink:to="loc_ci_FairValueMeasurementNonPerformanceRiskAdjustment_0b4c8480-8441-40e7-a3b1-7e2080ce1957" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InvestmentsInvestmentsbyCategoryDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_da230ba2-1d72-4077-bd84-4fa669d2753f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_075eaddf-70bd-4da3-ba18-caa6e915f6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_da230ba2-1d72-4077-bd84-4fa669d2753f" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_075eaddf-70bd-4da3-ba18-caa6e915f6ed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_5b2a04e9-2ec2-4297-a4b3-7abff9cc9a90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_075eaddf-70bd-4da3-ba18-caa6e915f6ed" xlink:to="loc_us-gaap_InvestmentTypeAxis_5b2a04e9-2ec2-4297-a4b3-7abff9cc9a90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_5b2a04e9-2ec2-4297-a4b3-7abff9cc9a90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_5b2a04e9-2ec2-4297-a4b3-7abff9cc9a90" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_5b2a04e9-2ec2-4297-a4b3-7abff9cc9a90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_2b4171c3-1114-4e09-bab4-0190e51a735a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_5b2a04e9-2ec2-4297-a4b3-7abff9cc9a90" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_2b4171c3-1114-4e09-bab4-0190e51a735a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_66b5eb96-0d2d-4409-80e6-5b49b03366d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2b4171c3-1114-4e09-bab4-0190e51a735a" xlink:to="loc_us-gaap_DebtSecuritiesMember_66b5eb96-0d2d-4409-80e6-5b49b03366d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_f186052f-8dcd-4851-b3b7-bdbb9795f33b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2b4171c3-1114-4e09-bab4-0190e51a735a" xlink:to="loc_us-gaap_EquitySecuritiesMember_f186052f-8dcd-4851-b3b7-bdbb9795f33b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgagesMember_0b5d04fc-06af-4231-b85e-0681c631b0be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgagesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2b4171c3-1114-4e09-bab4-0190e51a735a" xlink:to="loc_us-gaap_MortgagesMember_0b5d04fc-06af-4231-b85e-0681c631b0be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyLoansMember_489d31a6-22c0-42ee-b012-68b882e133a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2b4171c3-1114-4e09-bab4-0190e51a735a" xlink:to="loc_us-gaap_PolicyLoansMember_489d31a6-22c0-42ee-b012-68b882e133a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestmentsMember_18a20092-3dda-4274-a1b5-7d132d1a3296" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2b4171c3-1114-4e09-bab4-0190e51a735a" xlink:to="loc_us-gaap_OtherLongTermInvestmentsMember_18a20092-3dda-4274-a1b5-7d132d1a3296" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_ea02b691-3f65-4729-9638-ff9fd950dde5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2b4171c3-1114-4e09-bab4-0190e51a735a" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_ea02b691-3f65-4729-9638-ff9fd950dde5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_7fbc3be3-54e2-4e09-b721-efb0a417081a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_075eaddf-70bd-4da3-ba18-caa6e915f6ed" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_7fbc3be3-54e2-4e09-b721-efb0a417081a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_7fbc3be3-54e2-4e09-b721-efb0a417081a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_7fbc3be3-54e2-4e09-b721-efb0a417081a" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_7fbc3be3-54e2-4e09-b721-efb0a417081a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_d142f902-8368-4bd5-a4f2-d0ed62ca74e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_7fbc3be3-54e2-4e09-b721-efb0a417081a" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_d142f902-8368-4bd5-a4f2-d0ed62ca74e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_194c20d5-8043-461c-a51e-6836f5c6004b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_d142f902-8368-4bd5-a4f2-d0ed62ca74e8" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_194c20d5-8043-461c-a51e-6836f5c6004b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_45438892-fc51-4b58-ad84-ef875e593712" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_075eaddf-70bd-4da3-ba18-caa6e915f6ed" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_45438892-fc51-4b58-ad84-ef875e593712" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_45438892-fc51-4b58-ad84-ef875e593712_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_45438892-fc51-4b58-ad84-ef875e593712" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_45438892-fc51-4b58-ad84-ef875e593712_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7264ecc3-6447-40ba-803f-61216ec97245" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_45438892-fc51-4b58-ad84-ef875e593712" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7264ecc3-6447-40ba-803f-61216ec97245" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_9eceb8bf-7087-4b6d-833a-e05e22977108" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7264ecc3-6447-40ba-803f-61216ec97245" xlink:to="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_9eceb8bf-7087-4b6d-833a-e05e22977108" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract_c0115f40-5c5b-4757-953d-fb646f89a4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_da230ba2-1d72-4077-bd84-4fa669d2753f" xlink:to="loc_us-gaap_ShortTermInvestmentsAbstract_c0115f40-5c5b-4757-953d-fb646f89a4bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_bb2ae3b6-cbb1-4f5a-b1c1-bdcbdbf6b237" xlink:href="ci-20231231.xsd#ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_c0115f40-5c5b-4757-953d-fb646f89a4bc" xlink:to="loc_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_bb2ae3b6-cbb1-4f5a-b1c1-bdcbdbf6b237" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent_3d76d2d8-a8ba-4851-b1ab-4a604f50a7d9" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_c0115f40-5c5b-4757-953d-fb646f89a4bc" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent_3d76d2d8-a8ba-4851-b1ab-4a604f50a7d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_54855a7e-2308-4893-b8ca-6eaff30ddf34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_c0115f40-5c5b-4757-953d-fb646f89a4bc" xlink:to="loc_us-gaap_ShortTermInvestments_54855a7e-2308-4893-b8ca-6eaff30ddf34" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestmentsAbstract_70f34c23-d71a-4aae-8157-6f017e3ecd74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_da230ba2-1d72-4077-bd84-4fa669d2753f" xlink:to="loc_us-gaap_LongTermInvestmentsAbstract_70f34c23-d71a-4aae-8157-6f017e3ecd74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_c7a6de6c-26ed-498d-b376-3b82400ad7ec" xlink:href="ci-20231231.xsd#ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_70f34c23-d71a-4aae-8157-6f017e3ecd74" xlink:to="loc_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_c7a6de6c-26ed-498d-b376-3b82400ad7ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent_815b597b-d9f0-43bd-bd34-9532e1018b37" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_70f34c23-d71a-4aae-8157-6f017e3ecd74" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent_815b597b-d9f0-43bd-bd34-9532e1018b37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_253f2d23-c78f-44eb-82be-b682c212daaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_70f34c23-d71a-4aae-8157-6f017e3ecd74" xlink:to="loc_us-gaap_LongTermInvestments_253f2d23-c78f-44eb-82be-b682c212daaf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortTermAndLongTermInvestmentsAbstract_ec90f714-c412-4d60-9722-3702b2857adb" xlink:href="ci-20231231.xsd#ci_ShortTermAndLongTermInvestmentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_da230ba2-1d72-4077-bd84-4fa669d2753f" xlink:to="loc_ci_ShortTermAndLongTermInvestmentsAbstract_ec90f714-c412-4d60-9722-3702b2857adb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_db5cdd29-64b2-4aa5-ac65-d0349eb910d4" xlink:href="ci-20231231.xsd#ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ShortTermAndLongTermInvestmentsAbstract_ec90f714-c412-4d60-9722-3702b2857adb" xlink:to="loc_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_db5cdd29-64b2-4aa5-ac65-d0349eb910d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationInvestments_65459a57-5653-4dd8-9e92-975a98068df0" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ShortTermAndLongTermInvestmentsAbstract_ec90f714-c412-4d60-9722-3702b2857adb" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationInvestments_65459a57-5653-4dd8-9e92-975a98068df0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_0753133d-a331-47dc-a365-0dd3bbc855fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ShortTermAndLongTermInvestmentsAbstract_ec90f714-c412-4d60-9722-3702b2857adb" xlink:to="loc_us-gaap_Investments_0753133d-a331-47dc-a365-0dd3bbc855fd" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsNarrativeDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InvestmentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/InvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_b765db54-b8cc-4aa1-8c00-315a4812a204" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_a5b704ca-3fd3-4aba-9955-3f293572b005" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b765db54-b8cc-4aa1-8c00-315a4812a204" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_a5b704ca-3fd3-4aba-9955-3f293572b005" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePortfolioSegmentAxis_1521fe61-a41d-493a-8d13-e2d68a26124d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablePortfolioSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_a5b704ca-3fd3-4aba-9955-3f293572b005" xlink:to="loc_us-gaap_FinancingReceivablePortfolioSegmentAxis_1521fe61-a41d-493a-8d13-e2d68a26124d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePortfolioSegmentDomain_1521fe61-a41d-493a-8d13-e2d68a26124d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablePortfolioSegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancingReceivablePortfolioSegmentAxis_1521fe61-a41d-493a-8d13-e2d68a26124d" xlink:to="loc_us-gaap_FinancingReceivablePortfolioSegmentDomain_1521fe61-a41d-493a-8d13-e2d68a26124d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePortfolioSegmentDomain_f0243570-b719-43e7-b594-222403620c58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablePortfolioSegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancingReceivablePortfolioSegmentAxis_1521fe61-a41d-493a-8d13-e2d68a26124d" xlink:to="loc_us-gaap_FinancingReceivablePortfolioSegmentDomain_f0243570-b719-43e7-b594-222403620c58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPortfolioSegmentMember_b202a505-fc7d-44ee-838d-e3cb458f1337" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPortfolioSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivablePortfolioSegmentDomain_f0243570-b719-43e7-b594-222403620c58" xlink:to="loc_us-gaap_CommercialPortfolioSegmentMember_b202a505-fc7d-44ee-838d-e3cb458f1337" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_1c7e338e-f1ec-4a4f-b5c9-4b5aad893eee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_a5b704ca-3fd3-4aba-9955-3f293572b005" xlink:to="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_1c7e338e-f1ec-4a4f-b5c9-4b5aad893eee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_1c7e338e-f1ec-4a4f-b5c9-4b5aad893eee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_1c7e338e-f1ec-4a4f-b5c9-4b5aad893eee" xlink:to="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_1c7e338e-f1ec-4a4f-b5c9-4b5aad893eee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_51cba97d-ede1-419e-aa75-91a4f5cdb056" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_1c7e338e-f1ec-4a4f-b5c9-4b5aad893eee" xlink:to="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_51cba97d-ede1-419e-aa75-91a4f5cdb056" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateLoanMember_17ccbc8a-155a-4838-99b0-ef11d51d81f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstateLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_51cba97d-ede1-419e-aa75-91a4f5cdb056" xlink:to="loc_us-gaap_RealEstateLoanMember_17ccbc8a-155a-4838-99b0-ef11d51d81f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_20834b32-b1e8-4e47-acae-5e60037ca154" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_a5b704ca-3fd3-4aba-9955-3f293572b005" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_20834b32-b1e8-4e47-acae-5e60037ca154" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_20834b32-b1e8-4e47-acae-5e60037ca154_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_20834b32-b1e8-4e47-acae-5e60037ca154" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_20834b32-b1e8-4e47-acae-5e60037ca154_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_3736ff89-b347-4a36-8d7a-c557639cc139" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_20834b32-b1e8-4e47-acae-5e60037ca154" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_3736ff89-b347-4a36-8d7a-c557639cc139" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_VillageMDMember_5946c46f-3946-4d34-95d3-7041cba47523" xlink:href="ci-20231231.xsd#ci_VillageMDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_3736ff89-b347-4a36-8d7a-c557639cc139" xlink:to="loc_ci_VillageMDMember_5946c46f-3946-4d34-95d3-7041cba47523" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_da2da696-32a2-45fd-868f-3d9ff34e3c55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b765db54-b8cc-4aa1-8c00-315a4812a204" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_da2da696-32a2-45fd-868f-3d9ff34e3c55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_ce4b1032-9d50-4ad8-ac0c-c87b8e87c619" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b765db54-b8cc-4aa1-8c00-315a4812a204" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_ce4b1032-9d50-4ad8-ac0c-c87b8e87c619" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_9a9f1a16-40de-4dfa-94df-3e943c321a14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b765db54-b8cc-4aa1-8c00-315a4812a204" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_9a9f1a16-40de-4dfa-94df-3e943c321a14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_1644a646-8d1b-40ba-867f-bdda404915df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b765db54-b8cc-4aa1-8c00-315a4812a204" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_1644a646-8d1b-40ba-867f-bdda404915df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_4a630eb3-bb24-42a6-8016-c0c706f26833" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b765db54-b8cc-4aa1-8c00-315a4812a204" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_4a630eb3-bb24-42a6-8016-c0c706f26833" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesDividend_2624a642-8142-41bb-81c3-b89b4e8a45ce" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesDividend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b765db54-b8cc-4aa1-8c00-315a4812a204" xlink:to="loc_ci_EquitySecuritiesDividend_2624a642-8142-41bb-81c3-b89b4e8a45ce" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueValueOfSharesForAnnualDividendAccrual_aa4ea593-9375-4273-bcea-8e59cb5fb0b1" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesWithoutReadilyDeterminableFairValueValueOfSharesForAnnualDividendAccrual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b765db54-b8cc-4aa1-8c00-315a4812a204" xlink:to="loc_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueValueOfSharesForAnnualDividendAccrual_aa4ea593-9375-4273-bcea-8e59cb5fb0b1" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88f85a2a-b715-4d94-a5f3-03039fb5ff61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_041ebb23-6c3f-4c99-858c-ee21b5d73f91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88f85a2a-b715-4d94-a5f3-03039fb5ff61" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_041ebb23-6c3f-4c99-858c-ee21b5d73f91" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1f9522c2-a347-408b-8ba8-a58a5141a008" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_041ebb23-6c3f-4c99-858c-ee21b5d73f91" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1f9522c2-a347-408b-8ba8-a58a5141a008" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f9522c2-a347-408b-8ba8-a58a5141a008_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1f9522c2-a347-408b-8ba8-a58a5141a008" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f9522c2-a347-408b-8ba8-a58a5141a008_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bc29f687-dfd2-4991-b9e9-91a73fc3a24b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1f9522c2-a347-408b-8ba8-a58a5141a008" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bc29f687-dfd2-4991-b9e9-91a73fc3a24b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_2b985f3d-cc3a-4a46-bc14-55297903ad8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bc29f687-dfd2-4991-b9e9-91a73fc3a24b" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_2b985f3d-cc3a-4a46-bc14-55297903ad8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_467c2de8-01fa-4561-a25a-ec74bcef3b00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bc29f687-dfd2-4991-b9e9-91a73fc3a24b" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_467c2de8-01fa-4561-a25a-ec74bcef3b00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_a99f4cb4-e934-4bf3-aa2b-ec5d0cff7c52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bc29f687-dfd2-4991-b9e9-91a73fc3a24b" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_a99f4cb4-e934-4bf3-aa2b-ec5d0cff7c52" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_5965133a-4278-449c-b8d9-43cc95947cae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bc29f687-dfd2-4991-b9e9-91a73fc3a24b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_5965133a-4278-449c-b8d9-43cc95947cae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_2daa9ae3-cf2d-4aad-8963-988a1736daf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bc29f687-dfd2-4991-b9e9-91a73fc3a24b" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_2daa9ae3-cf2d-4aad-8963-988a1736daf4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_7f906ce3-58ef-42bc-8124-7d4d421d69b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88f85a2a-b715-4d94-a5f3-03039fb5ff61" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_7f906ce3-58ef-42bc-8124-7d4d421d69b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_904b3336-83c1-494f-b253-5cffd37cabae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88f85a2a-b715-4d94-a5f3-03039fb5ff61" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_904b3336-83c1-494f-b253-5cffd37cabae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7ef6cd39-4e7b-45e4-8d0e-174d3698bdc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88f85a2a-b715-4d94-a5f3-03039fb5ff61" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7ef6cd39-4e7b-45e4-8d0e-174d3698bdc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a7dc5a70-702e-4b89-84ef-d6e9031b554a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88f85a2a-b715-4d94-a5f3-03039fb5ff61" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a7dc5a70-702e-4b89-84ef-d6e9031b554a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_07d404a3-d87f-4542-ab7b-67be61d27cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88f85a2a-b715-4d94-a5f3-03039fb5ff61" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_07d404a3-d87f-4542-ab7b-67be61d27cd7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale_6d579a06-eb5b-4327-b90c-2974d594b433" xlink:href="ci-20231231.xsd#ci_AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88f85a2a-b715-4d94-a5f3-03039fb5ff61" xlink:to="loc_ci_AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale_6d579a06-eb5b-4327-b90c-2974d594b433" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_6c40c2f4-3b05-4595-be65-6e3618e91390" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88f85a2a-b715-4d94-a5f3-03039fb5ff61" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_6c40c2f4-3b05-4595-be65-6e3618e91390" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale_f2cb720a-16d0-4dff-b4b8-26fb16cba5ff" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88f85a2a-b715-4d94-a5f3-03039fb5ff61" xlink:to="loc_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale_f2cb720a-16d0-4dff-b4b8-26fb16cba5ff" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale_91c20150-1795-4050-9eb3-3924e8b117e9" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88f85a2a-b715-4d94-a5f3-03039fb5ff61" xlink:to="loc_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale_91c20150-1795-4050-9eb3-3924e8b117e9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale_98c71293-65ec-420a-88ee-cdef5a6faf3c" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88f85a2a-b715-4d94-a5f3-03039fb5ff61" xlink:to="loc_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale_98c71293-65ec-420a-88ee-cdef5a6faf3c" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InvestmentsDebtSecuritieswithaDeclineinFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f3b3c70-7029-4455-8afb-0af4fc5c073d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7ba9122b-8c3e-4dfd-bcac-06991298d210" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f3b3c70-7029-4455-8afb-0af4fc5c073d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7ba9122b-8c3e-4dfd-bcac-06991298d210" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InvestmentsCreditRatingAxis_78437caa-f65e-427b-bb6b-ddf958a6c5f4" xlink:href="ci-20231231.xsd#ci_InvestmentsCreditRatingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7ba9122b-8c3e-4dfd-bcac-06991298d210" xlink:to="loc_ci_InvestmentsCreditRatingAxis_78437caa-f65e-427b-bb6b-ddf958a6c5f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InvestmentsCreditRatingDomain_78437caa-f65e-427b-bb6b-ddf958a6c5f4_default" xlink:href="ci-20231231.xsd#ci_InvestmentsCreditRatingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ci_InvestmentsCreditRatingAxis_78437caa-f65e-427b-bb6b-ddf958a6c5f4" xlink:to="loc_ci_InvestmentsCreditRatingDomain_78437caa-f65e-427b-bb6b-ddf958a6c5f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InvestmentsCreditRatingDomain_70c6bc53-4288-443e-a3de-37a99c4b0b4e" xlink:href="ci-20231231.xsd#ci_InvestmentsCreditRatingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ci_InvestmentsCreditRatingAxis_78437caa-f65e-427b-bb6b-ddf958a6c5f4" xlink:to="loc_ci_InvestmentsCreditRatingDomain_70c6bc53-4288-443e-a3de-37a99c4b0b4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InvestmentGradeMember_194712f9-249b-4871-810b-604ba3ca6d2c" xlink:href="ci-20231231.xsd#ci_InvestmentGradeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InvestmentsCreditRatingDomain_70c6bc53-4288-443e-a3de-37a99c4b0b4e" xlink:to="loc_ci_InvestmentGradeMember_194712f9-249b-4871-810b-604ba3ca6d2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_BelowInvestmentGradeMember_c2dd934d-0c6c-455d-94c6-160bd6eac2bb" xlink:href="ci-20231231.xsd#ci_BelowInvestmentGradeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_InvestmentsCreditRatingDomain_70c6bc53-4288-443e-a3de-37a99c4b0b4e" xlink:to="loc_ci_BelowInvestmentGradeMember_c2dd934d-0c6c-455d-94c6-160bd6eac2bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b2f7c266-7d8f-43c3-bf92-537cda7dd096" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7ba9122b-8c3e-4dfd-bcac-06991298d210" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b2f7c266-7d8f-43c3-bf92-537cda7dd096" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b2f7c266-7d8f-43c3-bf92-537cda7dd096_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b2f7c266-7d8f-43c3-bf92-537cda7dd096" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b2f7c266-7d8f-43c3-bf92-537cda7dd096_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_584c4302-dd92-4070-b033-120041e75c96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b2f7c266-7d8f-43c3-bf92-537cda7dd096" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_584c4302-dd92-4070-b033-120041e75c96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_f1550952-1dcc-4908-977b-179b0a204810" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_584c4302-dd92-4070-b033-120041e75c96" xlink:to="loc_us-gaap_DebtSecuritiesMember_f1550952-1dcc-4908-977b-179b0a204810" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_92f3cfd5-9564-422d-ac1e-df1993f43e81" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f3b3c70-7029-4455-8afb-0af4fc5c073d" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_92f3cfd5-9564-422d-ac1e-df1993f43e81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_f285bf0b-5226-4305-b1b3-fc6f62b98e47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_92f3cfd5-9564-422d-ac1e-df1993f43e81" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_f285bf0b-5226-4305-b1b3-fc6f62b98e47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost_d51f290b-76c0-48b0-9d05-6b593b571f6b" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_92f3cfd5-9564-422d-ac1e-df1993f43e81" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost_d51f290b-76c0-48b0-9d05-6b593b571f6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_77d83033-978e-4b10-9543-984c630f32ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_92f3cfd5-9564-422d-ac1e-df1993f43e81" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_77d83033-978e-4b10-9543-984c630f32ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_3fc61ee9-dbfa-4d82-9b6c-39ec8c5e1c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_92f3cfd5-9564-422d-ac1e-df1993f43e81" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_3fc61ee9-dbfa-4d82-9b6c-39ec8c5e1c4d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_0bf28d1f-b56a-4aaa-a53b-9de21706ea2e" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_92f3cfd5-9564-422d-ac1e-df1993f43e81" xlink:to="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_0bf28d1f-b56a-4aaa-a53b-9de21706ea2e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_89e04671-8afa-473d-ab76-ef580f9eebe0" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_92f3cfd5-9564-422d-ac1e-df1993f43e81" xlink:to="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_89e04671-8afa-473d-ab76-ef580f9eebe0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_a4a07251-120a-43ba-ad6b-d3e3b3894b71" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_92f3cfd5-9564-422d-ac1e-df1993f43e81" xlink:to="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_a4a07251-120a-43ba-ad6b-d3e3b3894b71" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureLessThan12MonthsNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale_be49e601-f969-43f7-9aaa-2bf689a297bb" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureLessThan12MonthsNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_92f3cfd5-9564-422d-ac1e-df1993f43e81" xlink:to="loc_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureLessThan12MonthsNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale_be49e601-f969-43f7-9aaa-2bf689a297bb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_5b5fc440-c5f0-4e34-acc6-404af043b62f" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f3b3c70-7029-4455-8afb-0af4fc5c073d" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_5b5fc440-c5f0-4e34-acc6-404af043b62f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_e9506309-ac9d-4e59-adbb-fe604e673358" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_5b5fc440-c5f0-4e34-acc6-404af043b62f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_e9506309-ac9d-4e59-adbb-fe604e673358" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost_19c0bec4-096c-4900-a84f-ca53449973b8" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_5b5fc440-c5f0-4e34-acc6-404af043b62f" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost_19c0bec4-096c-4900-a84f-ca53449973b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_6e27f868-3fc9-4b4b-8394-a7e044ab628c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_5b5fc440-c5f0-4e34-acc6-404af043b62f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_6e27f868-3fc9-4b4b-8394-a7e044ab628c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_68c61950-c007-435e-9cea-24b9d5b89c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_5b5fc440-c5f0-4e34-acc6-404af043b62f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_68c61950-c007-435e-9cea-24b9d5b89c9d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_30f5bc28-4318-4735-8645-9c33fb2e1120" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_5b5fc440-c5f0-4e34-acc6-404af043b62f" xlink:to="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_30f5bc28-4318-4735-8645-9c33fb2e1120" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_a9449cce-c484-4415-9acd-b511a1180b87" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_5b5fc440-c5f0-4e34-acc6-404af043b62f" xlink:to="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_a9449cce-c484-4415-9acd-b511a1180b87" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_74cf61f1-c27f-4651-a534-56ce1c0de7de" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_5b5fc440-c5f0-4e34-acc6-404af043b62f" xlink:to="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_74cf61f1-c27f-4651-a534-56ce1c0de7de" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureTwelveMonthsOrLongerNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale_2925c021-1e20-46b5-aa62-7076ab083923" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureTwelveMonthsOrLongerNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_5b5fc440-c5f0-4e34-acc6-404af043b62f" xlink:to="loc_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureTwelveMonthsOrLongerNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale_2925c021-1e20-46b5-aa62-7076ab083923" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_b939beae-103a-4093-bbba-8b4434ad756c" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f3b3c70-7029-4455-8afb-0af4fc5c073d" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_b939beae-103a-4093-bbba-8b4434ad756c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_824f3c31-5da3-4a3a-943e-8d2c8efddd9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_b939beae-103a-4093-bbba-8b4434ad756c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_824f3c31-5da3-4a3a-943e-8d2c8efddd9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost_d05927f2-ba80-4e8a-a6e1-166d9ddb7a6a" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_b939beae-103a-4093-bbba-8b4434ad756c" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost_d05927f2-ba80-4e8a-a6e1-166d9ddb7a6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_fa0ef40b-52fb-4896-9d99-626003515f47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_b939beae-103a-4093-bbba-8b4434ad756c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_fa0ef40b-52fb-4896-9d99-626003515f47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_8222dd49-b790-45a8-bb98-fc62b3a0d381" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_b939beae-103a-4093-bbba-8b4434ad756c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_8222dd49-b790-45a8-bb98-fc62b3a0d381" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale_f3ef991b-83fe-4e7e-9c47-94da96dfe7ef" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_b939beae-103a-4093-bbba-8b4434ad756c" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale_f3ef991b-83fe-4e7e-9c47-94da96dfe7ef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_a7d7b9de-237f-4246-94bd-8b2e932badd5" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_b939beae-103a-4093-bbba-8b4434ad756c" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_a7d7b9de-237f-4246-94bd-8b2e932badd5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_f94789dd-ea77-45f2-a9a5-f1aa0e70e08a" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_b939beae-103a-4093-bbba-8b4434ad756c" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_f94789dd-ea77-45f2-a9a5-f1aa0e70e08a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale_56e5c2a1-0c21-488f-b4c8-5853a4bae7b4" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_b939beae-103a-4093-bbba-8b4434ad756c" xlink:to="loc_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale_56e5c2a1-0c21-488f-b4c8-5853a4bae7b4" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InvestmentsEquitySecurityInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_c0c39de0-76df-4fdf-b29a-a4476afee460" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_5ec6a6c4-bfd9-40fe-b746-7a54471f7b39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c0c39de0-76df-4fdf-b29a-a4476afee460" xlink:to="loc_us-gaap_OtherCommitmentsTable_5ec6a6c4-bfd9-40fe-b746-7a54471f7b39" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_df285630-ec74-49ae-bf70-89fa754a7c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_5ec6a6c4-bfd9-40fe-b746-7a54471f7b39" xlink:to="loc_us-gaap_OtherCommitmentsAxis_df285630-ec74-49ae-bf70-89fa754a7c3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_df285630-ec74-49ae-bf70-89fa754a7c3e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_df285630-ec74-49ae-bf70-89fa754a7c3e" xlink:to="loc_us-gaap_OtherCommitmentsDomain_df285630-ec74-49ae-bf70-89fa754a7c3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_4b0f008a-4887-4cbd-b695-f07b15668030" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_df285630-ec74-49ae-bf70-89fa754a7c3e" xlink:to="loc_us-gaap_OtherCommitmentsDomain_4b0f008a-4887-4cbd-b695-f07b15668030" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CommitmentToPurchaseEquitySecuritiesMember_d781f325-1256-4895-aa16-a721aff87c59" xlink:href="ci-20231231.xsd#ci_CommitmentToPurchaseEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_4b0f008a-4887-4cbd-b695-f07b15668030" xlink:to="loc_ci_CommitmentToPurchaseEquitySecuritiesMember_d781f325-1256-4895-aa16-a721aff87c59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cb50cc2b-e9d2-4b23-8ee1-bb5b02dab875" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_5ec6a6c4-bfd9-40fe-b746-7a54471f7b39" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cb50cc2b-e9d2-4b23-8ee1-bb5b02dab875" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cb50cc2b-e9d2-4b23-8ee1-bb5b02dab875_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cb50cc2b-e9d2-4b23-8ee1-bb5b02dab875" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cb50cc2b-e9d2-4b23-8ee1-bb5b02dab875_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4d04466e-b482-475a-9010-b1bac40ff13d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cb50cc2b-e9d2-4b23-8ee1-bb5b02dab875" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4d04466e-b482-475a-9010-b1bac40ff13d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIMember_ac3bfd8a-34ad-4115-b531-d10eb6aa9f43" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesFVNIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4d04466e-b482-475a-9010-b1bac40ff13d" xlink:to="loc_ci_EquitySecuritiesFVNIMember_ac3bfd8a-34ad-4115-b531-d10eb6aa9f43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_aa72cf31-7346-451d-8b1d-42cbbe3fa184" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_5ec6a6c4-bfd9-40fe-b746-7a54471f7b39" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_aa72cf31-7346-451d-8b1d-42cbbe3fa184" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_aa72cf31-7346-451d-8b1d-42cbbe3fa184_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_aa72cf31-7346-451d-8b1d-42cbbe3fa184" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_aa72cf31-7346-451d-8b1d-42cbbe3fa184_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c2921636-17f0-4503-ad57-382d2144460c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_aa72cf31-7346-451d-8b1d-42cbbe3fa184" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c2921636-17f0-4503-ad57-382d2144460c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_4582970e-6e4f-42d6-9947-91dfaf129a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_c2921636-17f0-4503-ad57-382d2144460c" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_4582970e-6e4f-42d6-9947-91dfaf129a1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesByIndustryAxis_ddce9802-3be7-4f50-9a6d-5d1462b1b49c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesByIndustryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_5ec6a6c4-bfd9-40fe-b746-7a54471f7b39" xlink:to="loc_us-gaap_EquitySecuritiesByIndustryAxis_ddce9802-3be7-4f50-9a6d-5d1462b1b49c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_ddce9802-3be7-4f50-9a6d-5d1462b1b49c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesIndustryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_ddce9802-3be7-4f50-9a6d-5d1462b1b49c" xlink:to="loc_us-gaap_EquitySecuritiesIndustryMember_ddce9802-3be7-4f50-9a6d-5d1462b1b49c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_399fdf47-4ba3-4805-9ad6-1be8d78f3b95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesIndustryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_ddce9802-3be7-4f50-9a6d-5d1462b1b49c" xlink:to="loc_us-gaap_EquitySecuritiesIndustryMember_399fdf47-4ba3-4805-9ad6-1be8d78f3b95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthcareSectorMember_e3bc95e9-0172-4f1c-8440-ba5986abc6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthcareSectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesIndustryMember_399fdf47-4ba3-4805-9ad6-1be8d78f3b95" xlink:to="loc_us-gaap_HealthcareSectorMember_e3bc95e9-0172-4f1c-8440-ba5986abc6fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f2d19029-b8b0-42be-8ba8-466f63af884d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_5ec6a6c4-bfd9-40fe-b746-7a54471f7b39" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f2d19029-b8b0-42be-8ba8-466f63af884d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f2d19029-b8b0-42be-8ba8-466f63af884d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f2d19029-b8b0-42be-8ba8-466f63af884d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f2d19029-b8b0-42be-8ba8-466f63af884d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4d59ea51-fa14-4f1d-b29c-211ad9bcc33e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f2d19029-b8b0-42be-8ba8-466f63af884d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4d59ea51-fa14-4f1d-b29c-211ad9bcc33e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6e1d8f94-3c11-437d-9d2f-1c289c6e5b02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4d59ea51-fa14-4f1d-b29c-211ad9bcc33e" xlink:to="loc_us-gaap_SubsequentEventMember_6e1d8f94-3c11-437d-9d2f-1c289c6e5b02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_079d81be-c56e-4c6f-b1dd-ae371b31eb15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c0c39de0-76df-4fdf-b29a-a4476afee460" xlink:to="loc_us-gaap_OtherCommitment_079d81be-c56e-4c6f-b1dd-ae371b31eb15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PaymentsToAcquireDebtAndEquitySecurities_6eda7e8e-0f8e-4896-b18b-018df43d865e" xlink:href="ci-20231231.xsd#ci_PaymentsToAcquireDebtAndEquitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c0c39de0-76df-4fdf-b29a-a4476afee460" xlink:to="loc_ci_PaymentsToAcquireDebtAndEquitySecurities_6eda7e8e-0f8e-4896-b18b-018df43d865e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_8cb1c69b-14e1-4230-83d2-77ae41c843da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c0c39de0-76df-4fdf-b29a-a4476afee460" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_8cb1c69b-14e1-4230-83d2-77ae41c843da" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoanPortfolioDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InvestmentsCommercialMortgageLoanPortfolioDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoanPortfolioDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_bb1bbdb3-e8be-4d71-967c-37a903596efd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_828a9d02-cfa8-4fb4-b60d-435203f9ef9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_bb1bbdb3-e8be-4d71-967c-37a903596efd" xlink:to="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_828a9d02-cfa8-4fb4-b60d-435203f9ef9f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_6f1298f1-69e2-4ab0-8c87-3b72fcb0b113" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_828a9d02-cfa8-4fb4-b60d-435203f9ef9f" xlink:to="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_6f1298f1-69e2-4ab0-8c87-3b72fcb0b113" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_6f1298f1-69e2-4ab0-8c87-3b72fcb0b113_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_6f1298f1-69e2-4ab0-8c87-3b72fcb0b113" xlink:to="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_6f1298f1-69e2-4ab0-8c87-3b72fcb0b113_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_978b7439-9157-4aec-99b6-8feee37302ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_6f1298f1-69e2-4ab0-8c87-3b72fcb0b113" xlink:to="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_978b7439-9157-4aec-99b6-8feee37302ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateLoanMember_3d9e96dc-61da-410b-b904-5f1a4d3f261c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstateLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_978b7439-9157-4aec-99b6-8feee37302ae" xlink:to="loc_us-gaap_RealEstateLoanMember_3d9e96dc-61da-410b-b904-5f1a4d3f261c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePortfolioSegmentAxis_73d1b16f-7103-4d45-b5f5-e1c8d0d21df8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablePortfolioSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_828a9d02-cfa8-4fb4-b60d-435203f9ef9f" xlink:to="loc_us-gaap_FinancingReceivablePortfolioSegmentAxis_73d1b16f-7103-4d45-b5f5-e1c8d0d21df8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePortfolioSegmentDomain_73d1b16f-7103-4d45-b5f5-e1c8d0d21df8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablePortfolioSegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancingReceivablePortfolioSegmentAxis_73d1b16f-7103-4d45-b5f5-e1c8d0d21df8" xlink:to="loc_us-gaap_FinancingReceivablePortfolioSegmentDomain_73d1b16f-7103-4d45-b5f5-e1c8d0d21df8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePortfolioSegmentDomain_e27d71b7-d0cd-4afe-b164-6563bf836e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablePortfolioSegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancingReceivablePortfolioSegmentAxis_73d1b16f-7103-4d45-b5f5-e1c8d0d21df8" xlink:to="loc_us-gaap_FinancingReceivablePortfolioSegmentDomain_e27d71b7-d0cd-4afe-b164-6563bf836e7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPortfolioSegmentMember_492617d1-68d3-46c1-ba95-24758c116c76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPortfolioSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivablePortfolioSegmentDomain_e27d71b7-d0cd-4afe-b164-6563bf836e7f" xlink:to="loc_us-gaap_CommercialPortfolioSegmentMember_492617d1-68d3-46c1-ba95-24758c116c76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoanToValueAxis_91e758b3-b56c-4a9e-8b17-3ec2a2d2e04b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoanToValueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_828a9d02-cfa8-4fb4-b60d-435203f9ef9f" xlink:to="loc_us-gaap_LoanToValueAxis_91e758b3-b56c-4a9e-8b17-3ec2a2d2e04b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoanToValueDomain_91e758b3-b56c-4a9e-8b17-3ec2a2d2e04b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoanToValueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LoanToValueAxis_91e758b3-b56c-4a9e-8b17-3ec2a2d2e04b" xlink:to="loc_us-gaap_LoanToValueDomain_91e758b3-b56c-4a9e-8b17-3ec2a2d2e04b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoanToValueDomain_21c41a7f-f46e-4e3a-ad23-91c0286862ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoanToValueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LoanToValueAxis_91e758b3-b56c-4a9e-8b17-3ec2a2d2e04b" xlink:to="loc_us-gaap_LoanToValueDomain_21c41a7f-f46e-4e3a-ad23-91c0286862ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LtvLessThan60PercentMember_54213cd3-6022-48c7-9f0d-020dddb234f9" xlink:href="ci-20231231.xsd#ci_LtvLessThan60PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LoanToValueDomain_21c41a7f-f46e-4e3a-ad23-91c0286862ba" xlink:to="loc_ci_LtvLessThan60PercentMember_54213cd3-6022-48c7-9f0d-020dddb234f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_Ltv60To79PercentMember_d5cd4329-71d6-43c5-af27-543959d962af" xlink:href="ci-20231231.xsd#ci_Ltv60To79PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LoanToValueDomain_21c41a7f-f46e-4e3a-ad23-91c0286862ba" xlink:to="loc_ci_Ltv60To79PercentMember_d5cd4329-71d6-43c5-af27-543959d962af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Ltv80To100PercentMember_f326e24f-b0a7-4cc0-b78d-05a0f373dcc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Ltv80To100PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LoanToValueDomain_21c41a7f-f46e-4e3a-ad23-91c0286862ba" xlink:to="loc_us-gaap_Ltv80To100PercentMember_f326e24f-b0a7-4cc0-b78d-05a0f373dcc5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LtvGreaterThan100PercentMember_404dba71-8091-4fd2-89e1-dcb6ee35be92" xlink:href="ci-20231231.xsd#ci_LtvGreaterThan100PercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LoanToValueDomain_21c41a7f-f46e-4e3a-ad23-91c0286862ba" xlink:to="loc_ci_LtvGreaterThan100PercentMember_404dba71-8091-4fd2-89e1-dcb6ee35be92" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9982b693-2f70-4001-a966-36c203608fc9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_828a9d02-cfa8-4fb4-b60d-435203f9ef9f" xlink:to="loc_srt_RangeAxis_9982b693-2f70-4001-a966-36c203608fc9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9982b693-2f70-4001-a966-36c203608fc9_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9982b693-2f70-4001-a966-36c203608fc9" xlink:to="loc_srt_RangeMember_9982b693-2f70-4001-a966-36c203608fc9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ea831426-b003-4057-a13a-09a7c9f47ce1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9982b693-2f70-4001-a966-36c203608fc9" xlink:to="loc_srt_RangeMember_ea831426-b003-4057-a13a-09a7c9f47ce1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_ad0a5a48-7e16-442d-9e2a-4ecc763d4c7c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ea831426-b003-4057-a13a-09a7c9f47ce1" xlink:to="loc_srt_WeightedAverageMember_ad0a5a48-7e16-442d-9e2a-4ecc763d4c7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss_14b56184-8b00-4067-a283-eee36e2d3b68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_bb1bbdb3-e8be-4d71-967c-37a903596efd" xlink:to="loc_us-gaap_FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss_14b56184-8b00-4067-a283-eee36e2d3b68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest_f160420d-e2b5-417d-aa2d-be983f3baf37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_bb1bbdb3-e8be-4d71-967c-37a903596efd" xlink:to="loc_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest_f160420d-e2b5-417d-aa2d-be983f3baf37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss_fe2445f3-39a1-48ff-8b4c-b5763dd4e44e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_bb1bbdb3-e8be-4d71-967c-37a903596efd" xlink:to="loc_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss_fe2445f3-39a1-48ff-8b4c-b5763dd4e44e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio_52df0bed-7176-4e9b-a2ce-2cb355131451" xlink:href="ci-20231231.xsd#ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_bb1bbdb3-e8be-4d71-967c-37a903596efd" xlink:to="loc_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio_52df0bed-7176-4e9b-a2ce-2cb355131451" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FinancingReceivableCreditQualityLoanToValueRatio_f80a2f9f-1420-4206-91e3-0f56065a224b" xlink:href="ci-20231231.xsd#ci_FinancingReceivableCreditQualityLoanToValueRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_bb1bbdb3-e8be-4d71-967c-37a903596efd" xlink:to="loc_ci_FinancingReceivableCreditQualityLoanToValueRatio_f80a2f9f-1420-4206-91e3-0f56065a224b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_cab3639e-97dc-4925-b5d8-6509f8eacd3c" xlink:href="ci-20231231.xsd#ci_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_bb1bbdb3-e8be-4d71-967c-37a903596efd" xlink:to="loc_ci_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_cab3639e-97dc-4925-b5d8-6509f8eacd3c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale_c01dcda3-0bc3-4ef3-975c-a2db4d521bb9" xlink:href="ci-20231231.xsd#ci_FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_bb1bbdb3-e8be-4d71-967c-37a903596efd" xlink:to="loc_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale_c01dcda3-0bc3-4ef3-975c-a2db4d521bb9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FinancingReceivableCreditQualityLoanToValueRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale_9605ae16-4abf-4b8f-b34a-77889dd9e269" xlink:href="ci-20231231.xsd#ci_FinancingReceivableCreditQualityLoanToValueRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_bb1bbdb3-e8be-4d71-967c-37a903596efd" xlink:to="loc_ci_FinancingReceivableCreditQualityLoanToValueRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale_9605ae16-4abf-4b8f-b34a-77889dd9e269" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InvestmentsOtherLongTermInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_9ae15585-ef0c-4c41-9d57-c3dad4dfa53c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_a6bd8653-b039-4c61-9672-55d8fb6d5dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_9ae15585-ef0c-4c41-9d57-c3dad4dfa53c" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_a6bd8653-b039-4c61-9672-55d8fb6d5dcd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_9c02725b-9ad0-4a25-a25c-3a84ea6963d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_a6bd8653-b039-4c61-9672-55d8fb6d5dcd" xlink:to="loc_us-gaap_InvestmentTypeAxis_9c02725b-9ad0-4a25-a25c-3a84ea6963d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_9c02725b-9ad0-4a25-a25c-3a84ea6963d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_9c02725b-9ad0-4a25-a25c-3a84ea6963d6" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_9c02725b-9ad0-4a25-a25c-3a84ea6963d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_442b6cda-a28f-44ef-86d3-7d477f052d33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_9c02725b-9ad0-4a25-a25c-3a84ea6963d6" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_442b6cda-a28f-44ef-86d3-7d477f052d33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateInvestmentMember_fd3672bd-1b30-4e9d-888a-dd5606d61d90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstateInvestmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_442b6cda-a28f-44ef-86d3-7d477f052d33" xlink:to="loc_us-gaap_RealEstateInvestmentMember_fd3672bd-1b30-4e9d-888a-dd5606d61d90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PartnershipInterestMember_6f27dc0c-6bd7-48c1-88a6-9c9497064e76" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PartnershipInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_442b6cda-a28f-44ef-86d3-7d477f052d33" xlink:to="loc_srt_PartnershipInterestMember_6f27dc0c-6bd7-48c1-88a6-9c9497064e76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember_49d7bb80-5798-48f6-b6dd-de0cd5a0c543" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_442b6cda-a28f-44ef-86d3-7d477f052d33" xlink:to="loc_us-gaap_OtherInvestmentsMember_49d7bb80-5798-48f6-b6dd-de0cd5a0c543" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear_66d5f241-9eab-4d2f-900b-08e8addd596a" xlink:href="ci-20231231.xsd#ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_9ae15585-ef0c-4c41-9d57-c3dad4dfa53c" xlink:to="loc_ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear_66d5f241-9eab-4d2f-900b-08e8addd596a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_33671e42-442a-4f69-bb65-e8a1d17629a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_9ae15585-ef0c-4c41-9d57-c3dad4dfa53c" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_33671e42-442a-4f69-bb65-e8a1d17629a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_3bf081a8-aba4-4b31-8751-49a4a1060d50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_9ae15585-ef0c-4c41-9d57-c3dad4dfa53c" xlink:to="loc_us-gaap_OtherLongTermInvestments_3bf081a8-aba4-4b31-8751-49a4a1060d50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherLongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_532839b4-bffc-4aea-9d91-3be542e49ba4" xlink:href="ci-20231231.xsd#ci_OtherLongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_9ae15585-ef0c-4c41-9d57-c3dad4dfa53c" xlink:to="loc_ci_OtherLongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_532839b4-bffc-4aea-9d91-3be542e49ba4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CommitmentsToContributeAdditionalEquityAndCapital_32a97bd7-e758-4db3-bec1-ef91ea015831" xlink:href="ci-20231231.xsd#ci_CommitmentsToContributeAdditionalEquityAndCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_9ae15585-ef0c-4c41-9d57-c3dad4dfa53c" xlink:to="loc_ci_CommitmentsToContributeAdditionalEquityAndCapital_32a97bd7-e758-4db3-bec1-ef91ea015831" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsSummaryofDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InvestmentsSummaryofDerivativeInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/InvestmentsSummaryofDerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_dfcd7be1-2d39-42ec-a2ca-bc970d9608e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_4ab28ae3-d381-44e7-a6bc-38e502e05c18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_dfcd7be1-2d39-42ec-a2ca-bc970d9608e2" xlink:to="loc_us-gaap_DerivativeTable_4ab28ae3-d381-44e7-a6bc-38e502e05c18" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_d4aa312f-dca0-4d5b-a2b7-be0c0ca6d2f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_4ab28ae3-d381-44e7-a6bc-38e502e05c18" xlink:to="loc_us-gaap_HedgingDesignationAxis_d4aa312f-dca0-4d5b-a2b7-be0c0ca6d2f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_d4aa312f-dca0-4d5b-a2b7-be0c0ca6d2f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_d4aa312f-dca0-4d5b-a2b7-be0c0ca6d2f5" xlink:to="loc_us-gaap_HedgingDesignationDomain_d4aa312f-dca0-4d5b-a2b7-be0c0ca6d2f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_615a68c8-d312-475e-b279-723898bc08e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_d4aa312f-dca0-4d5b-a2b7-be0c0ca6d2f5" xlink:to="loc_us-gaap_HedgingDesignationDomain_615a68c8-d312-475e-b279-723898bc08e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_eeaccf21-370f-4a86-8e7e-3b2bc9c0a28d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_615a68c8-d312-475e-b279-723898bc08e9" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_eeaccf21-370f-4a86-8e7e-3b2bc9c0a28d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember_fa7417e6-013f-484f-ae18-0f9d94045a29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_615a68c8-d312-475e-b279-723898bc08e9" xlink:to="loc_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember_fa7417e6-013f-484f-ae18-0f9d94045a29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7721957f-5940-42ff-b1de-d285499755fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_4ab28ae3-d381-44e7-a6bc-38e502e05c18" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7721957f-5940-42ff-b1de-d285499755fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_7721957f-5940-42ff-b1de-d285499755fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7721957f-5940-42ff-b1de-d285499755fb" xlink:to="loc_us-gaap_HedgingRelationshipDomain_7721957f-5940-42ff-b1de-d285499755fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_58289131-f276-413b-998d-0f7f43472870" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7721957f-5940-42ff-b1de-d285499755fb" xlink:to="loc_us-gaap_HedgingRelationshipDomain_58289131-f276-413b-998d-0f7f43472870" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_9741fd83-0ca1-4e6b-a9cb-9711be486a46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_58289131-f276-413b-998d-0f7f43472870" xlink:to="loc_us-gaap_FairValueHedgingMember_9741fd83-0ca1-4e6b-a9cb-9711be486a46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_5628cd51-f692-4f7e-b4c8-38b976ce5cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_58289131-f276-413b-998d-0f7f43472870" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_5628cd51-f692-4f7e-b4c8-38b976ce5cc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_66c1beb9-4f1f-4841-8715-c61583f72dac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_4ab28ae3-d381-44e7-a6bc-38e502e05c18" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_66c1beb9-4f1f-4841-8715-c61583f72dac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_66c1beb9-4f1f-4841-8715-c61583f72dac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_66c1beb9-4f1f-4841-8715-c61583f72dac" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_66c1beb9-4f1f-4841-8715-c61583f72dac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7f95e3b8-be7b-4d55-9169-d32e70350483" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_66c1beb9-4f1f-4841-8715-c61583f72dac" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7f95e3b8-be7b-4d55-9169-d32e70350483" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_9f575094-558a-4b42-9b85-f279b4fe1913" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7f95e3b8-be7b-4d55-9169-d32e70350483" xlink:to="loc_us-gaap_CurrencySwapMember_9f575094-558a-4b42-9b85-f279b4fe1913" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_23b5e799-aa08-45f1-b9f4-1dcceead296e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7f95e3b8-be7b-4d55-9169-d32e70350483" xlink:to="loc_us-gaap_InterestRateSwapMember_23b5e799-aa08-45f1-b9f4-1dcceead296e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_fb025141-9582-4b83-86f3-8ac9705156b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_dfcd7be1-2d39-42ec-a2ca-bc970d9608e2" xlink:to="loc_us-gaap_DerivativeNotionalAmount_fb025141-9582-4b83-86f3-8ac9705156b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DerivativeNotionalAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale_8bb8e11a-6864-47b9-94f8-ca8d79533701" xlink:href="ci-20231231.xsd#ci_DerivativeNotionalAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_dfcd7be1-2d39-42ec-a2ca-bc970d9608e2" xlink:to="loc_ci_DerivativeNotionalAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale_8bb8e11a-6864-47b9-94f8-ca8d79533701" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InvestmentsComponentsofNetInvestmentIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_38e92676-0e59-46b0-8bdc-a6e1aa48b0e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_d9577f30-ec3d-442e-ae4d-b2c8cc55e3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_38e92676-0e59-46b0-8bdc-a6e1aa48b0e5" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_d9577f30-ec3d-442e-ae4d-b2c8cc55e3a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_9f9cef05-a71b-427e-b813-2a0dd5d98509" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_d9577f30-ec3d-442e-ae4d-b2c8cc55e3a4" xlink:to="loc_us-gaap_InvestmentTypeAxis_9f9cef05-a71b-427e-b813-2a0dd5d98509" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_9f9cef05-a71b-427e-b813-2a0dd5d98509_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_9f9cef05-a71b-427e-b813-2a0dd5d98509" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_9f9cef05-a71b-427e-b813-2a0dd5d98509_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_527c1052-b240-47fe-9d55-6c8870b975ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_9f9cef05-a71b-427e-b813-2a0dd5d98509" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_527c1052-b240-47fe-9d55-6c8870b975ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_6526deda-0e8d-4848-9b34-c4772b01a948" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_527c1052-b240-47fe-9d55-6c8870b975ca" xlink:to="loc_us-gaap_DebtSecuritiesMember_6526deda-0e8d-4848-9b34-c4772b01a948" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_b5b76746-b1c6-4740-be36-5ccb877d4ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_527c1052-b240-47fe-9d55-6c8870b975ca" xlink:to="loc_us-gaap_EquitySecuritiesMember_b5b76746-b1c6-4740-be36-5ccb877d4ff8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgagesMember_19ca68dc-440f-4b0d-9e46-c4b93518815a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgagesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_527c1052-b240-47fe-9d55-6c8870b975ca" xlink:to="loc_us-gaap_MortgagesMember_19ca68dc-440f-4b0d-9e46-c4b93518815a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyLoansMember_4af3883a-7791-4a6b-8757-26443efc6b96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_527c1052-b240-47fe-9d55-6c8870b975ca" xlink:to="loc_us-gaap_PolicyLoansMember_4af3883a-7791-4a6b-8757-26443efc6b96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestmentsMember_fc4f2457-bd3f-4aca-8f42-056cc3560a10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_527c1052-b240-47fe-9d55-6c8870b975ca" xlink:to="loc_us-gaap_OtherLongTermInvestmentsMember_fc4f2457-bd3f-4aca-8f42-056cc3560a10" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CashCashEquivalentsAndShortTermInvestmentsMember_8ac06e76-02d3-44cf-b545-d5d1999afa9e" xlink:href="ci-20231231.xsd#ci_CashCashEquivalentsAndShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_527c1052-b240-47fe-9d55-6c8870b975ca" xlink:to="loc_ci_CashCashEquivalentsAndShortTermInvestmentsMember_8ac06e76-02d3-44cf-b545-d5d1999afa9e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue_1d65ee40-d002-49b3-8f6a-71b907c23a1e" xlink:href="ci-20231231.xsd#ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_38e92676-0e59-46b0-8bdc-a6e1aa48b0e5" xlink:to="loc_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue_1d65ee40-d002-49b3-8f6a-71b907c23a1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInvestmentExpense_098a23d4-4b70-4ed8-9489-14ecc2534148" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_38e92676-0e59-46b0-8bdc-a6e1aa48b0e5" xlink:to="loc_us-gaap_InvestmentIncomeInvestmentExpense_098a23d4-4b70-4ed8-9489-14ecc2534148" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_b72c4959-9a6e-44a5-9520-6ab0cff80c29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_38e92676-0e59-46b0-8bdc-a6e1aa48b0e5" xlink:to="loc_us-gaap_NetInvestmentIncome_b72c4959-9a6e-44a5-9520-6ab0cff80c29" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e986a12d-1460-41bf-bcae-f308fa44dc12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64ca39d0-34c7-4fe5-a3a0-f9aac902b7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e986a12d-1460-41bf-bcae-f308fa44dc12" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64ca39d0-34c7-4fe5-a3a0-f9aac902b7cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f83e43d7-5851-4918-8c81-7dc2b648ea19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64ca39d0-34c7-4fe5-a3a0-f9aac902b7cc" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f83e43d7-5851-4918-8c81-7dc2b648ea19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f83e43d7-5851-4918-8c81-7dc2b648ea19_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f83e43d7-5851-4918-8c81-7dc2b648ea19" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f83e43d7-5851-4918-8c81-7dc2b648ea19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d23009ac-4679-4a20-9660-336257aa798d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f83e43d7-5851-4918-8c81-7dc2b648ea19" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d23009ac-4679-4a20-9660-336257aa798d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_baa26582-721a-4e00-bd97-b022632d510c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d23009ac-4679-4a20-9660-336257aa798d" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_baa26582-721a-4e00-bd97-b022632d510c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_078d1916-6edc-4bad-864d-4685f3579945" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d23009ac-4679-4a20-9660-336257aa798d" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_078d1916-6edc-4bad-864d-4685f3579945" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_aaa9d664-65d5-42bd-8909-dc827b55ed75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d23009ac-4679-4a20-9660-336257aa798d" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_aaa9d664-65d5-42bd-8909-dc827b55ed75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1f7a670d-7258-416a-9a51-fbdc622995b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d23009ac-4679-4a20-9660-336257aa798d" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1f7a670d-7258-416a-9a51-fbdc622995b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_aab38264-1646-4ca6-a11b-7914b989222c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d23009ac-4679-4a20-9660-336257aa798d" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_aab38264-1646-4ca6-a11b-7914b989222c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bb6dfb79-a1d0-47ad-a25c-0b0ea08173b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64ca39d0-34c7-4fe5-a3a0-f9aac902b7cc" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bb6dfb79-a1d0-47ad-a25c-0b0ea08173b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bb6dfb79-a1d0-47ad-a25c-0b0ea08173b8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bb6dfb79-a1d0-47ad-a25c-0b0ea08173b8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bb6dfb79-a1d0-47ad-a25c-0b0ea08173b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_952d6370-9667-49b9-8d95-b752e6adb8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bb6dfb79-a1d0-47ad-a25c-0b0ea08173b8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_952d6370-9667-49b9-8d95-b752e6adb8b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f532defa-75df-45e3-8dd3-31b57081854b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_952d6370-9667-49b9-8d95-b752e6adb8b9" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f532defa-75df-45e3-8dd3-31b57081854b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c8ae3e83-8c07-4941-9d2f-d64d71661615" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_952d6370-9667-49b9-8d95-b752e6adb8b9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c8ae3e83-8c07-4941-9d2f-d64d71661615" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9a073dd9-d942-4227-85d5-88d4bb482809" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_952d6370-9667-49b9-8d95-b752e6adb8b9" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9a073dd9-d942-4227-85d5-88d4bb482809" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0e1569f8-3ebf-4cb9-9725-f63d804fc35a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64ca39d0-34c7-4fe5-a3a0-f9aac902b7cc" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0e1569f8-3ebf-4cb9-9725-f63d804fc35a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0e1569f8-3ebf-4cb9-9725-f63d804fc35a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0e1569f8-3ebf-4cb9-9725-f63d804fc35a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0e1569f8-3ebf-4cb9-9725-f63d804fc35a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_47dd7d82-c5d9-47a7-af7c-ab19b8e7def6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0e1569f8-3ebf-4cb9-9725-f63d804fc35a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_47dd7d82-c5d9-47a7-af7c-ab19b8e7def6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d4350623-0ef6-4935-9196-181e8b60785c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_47dd7d82-c5d9-47a7-af7c-ab19b8e7def6" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d4350623-0ef6-4935-9196-181e8b60785c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3d88d160-fc76-4f8e-a4a2-10098e8a7c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64ca39d0-34c7-4fe5-a3a0-f9aac902b7cc" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3d88d160-fc76-4f8e-a4a2-10098e8a7c5a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3d88d160-fc76-4f8e-a4a2-10098e8a7c5a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3d88d160-fc76-4f8e-a4a2-10098e8a7c5a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3d88d160-fc76-4f8e-a4a2-10098e8a7c5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_889ef326-29c7-4053-b964-62c1923c397d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3d88d160-fc76-4f8e-a4a2-10098e8a7c5a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_889ef326-29c7-4053-b964-62c1923c397d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ForwardsSwapsOptionsMember_d71e7b3f-7bd0-4fe8-bae1-0c5daab2b450" xlink:href="ci-20231231.xsd#ci_ForwardsSwapsOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_889ef326-29c7-4053-b964-62c1923c397d" xlink:to="loc_ci_ForwardsSwapsOptionsMember_d71e7b3f-7bd0-4fe8-bae1-0c5daab2b450" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SwapMember_54a542c4-2531-456c-be8c-7a7fc85848a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ForwardsSwapsOptionsMember_d71e7b3f-7bd0-4fe8-bae1-0c5daab2b450" xlink:to="loc_us-gaap_SwapMember_54a542c4-2531-456c-be8c-7a7fc85848a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_61dd1a74-2f56-42a9-959d-d7b94c0cc9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e986a12d-1460-41bf-bcae-f308fa44dc12" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_61dd1a74-2f56-42a9-959d-d7b94c0cc9ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6439b49f-16bc-4c8b-b332-9c94a75312e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_61dd1a74-2f56-42a9-959d-d7b94c0cc9ca" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6439b49f-16bc-4c8b-b332-9c94a75312e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_916a7181-e7fc-4cd9-b6a9-94a91397f59e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_61dd1a74-2f56-42a9-959d-d7b94c0cc9ca" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_916a7181-e7fc-4cd9-b6a9-94a91397f59e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_c285a837-95c7-4e65-9314-2507c91b18e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_61dd1a74-2f56-42a9-959d-d7b94c0cc9ca" xlink:to="loc_us-gaap_OtherShortTermInvestments_c285a837-95c7-4e65-9314-2507c91b18e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_1d34b63a-caca-41a5-9a5e-6116f833f1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_61dd1a74-2f56-42a9-959d-d7b94c0cc9ca" xlink:to="loc_us-gaap_DerivativeAssets_1d34b63a-caca-41a5-9a5e-6116f833f1b0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_54b8fd52-06f3-410d-92fe-f6eadfc5c08d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_61dd1a74-2f56-42a9-959d-d7b94c0cc9ca" xlink:to="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_54b8fd52-06f3-410d-92fe-f6eadfc5c08d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale_d0619554-cbff-41fa-ae06-0a840ab1c11e" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_61dd1a74-2f56-42a9-959d-d7b94c0cc9ca" xlink:to="loc_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale_d0619554-cbff-41fa-ae06-0a840ab1c11e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFvNiBeforeReclassificationToDisposalGroupAssetsHeldForSale_5a09e84d-1056-4d46-aece-50d2d2b9a2a2" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesFvNiBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_61dd1a74-2f56-42a9-959d-d7b94c0cc9ca" xlink:to="loc_ci_EquitySecuritiesFvNiBeforeReclassificationToDisposalGroupAssetsHeldForSale_5a09e84d-1056-4d46-aece-50d2d2b9a2a2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_659b711b-8f8c-4d53-abb0-603702fbe675" xlink:href="ci-20231231.xsd#ci_OtherShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_61dd1a74-2f56-42a9-959d-d7b94c0cc9ca" xlink:to="loc_ci_OtherShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_659b711b-8f8c-4d53-abb0-603702fbe675" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale_64c0f42e-46ae-4b7f-855c-36b60b5d7a21" xlink:href="ci-20231231.xsd#ci_DerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_61dd1a74-2f56-42a9-959d-d7b94c0cc9ca" xlink:to="loc_ci_DerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale_64c0f42e-46ae-4b7f-855c-36b60b5d7a21" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7ee83c96-eef2-4643-b524-512dfd7efde1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e986a12d-1460-41bf-bcae-f308fa44dc12" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7ee83c96-eef2-4643-b524-512dfd7efde1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_dbb12fd5-444c-4780-a17f-18b02065eefb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7ee83c96-eef2-4643-b524-512dfd7efde1" xlink:to="loc_us-gaap_DerivativeLiabilities_dbb12fd5-444c-4780-a17f-18b02065eefb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DerivativeLiabilitiesBeforeReclassificationToDisposalGroupLiabilitiesHeldForSale_8e907ecd-8730-47b0-9cef-bab4397116a4" xlink:href="ci-20231231.xsd#ci_DerivativeLiabilitiesBeforeReclassificationToDisposalGroupLiabilitiesHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7ee83c96-eef2-4643-b524-512dfd7efde1" xlink:to="loc_ci_DerivativeLiabilitiesBeforeReclassificationToDisposalGroupLiabilitiesHeldForSale_8e907ecd-8730-47b0-9cef-bab4397116a4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b564d935-fec3-4907-b1c8-81d5f36b9a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5bb4cc41-24e7-4211-9bc4-e535c7ce4095" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b564d935-fec3-4907-b1c8-81d5f36b9a9c" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5bb4cc41-24e7-4211-9bc4-e535c7ce4095" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2475c8a0-e4f2-47d3-a1cd-dbfccf88ccea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5bb4cc41-24e7-4211-9bc4-e535c7ce4095" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2475c8a0-e4f2-47d3-a1cd-dbfccf88ccea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2475c8a0-e4f2-47d3-a1cd-dbfccf88ccea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2475c8a0-e4f2-47d3-a1cd-dbfccf88ccea" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2475c8a0-e4f2-47d3-a1cd-dbfccf88ccea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dfc7d50f-3b62-41d7-8519-0655df596549" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2475c8a0-e4f2-47d3-a1cd-dbfccf88ccea" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dfc7d50f-3b62-41d7-8519-0655df596549" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2d8f7608-5359-4196-951c-bd76acf7bc6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dfc7d50f-3b62-41d7-8519-0655df596549" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2d8f7608-5359-4196-951c-bd76acf7bc6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_3a4d9c54-58b8-4f61-96ab-1a334fda1ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5bb4cc41-24e7-4211-9bc4-e535c7ce4095" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_3a4d9c54-58b8-4f61-96ab-1a334fda1ed5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3a4d9c54-58b8-4f61-96ab-1a334fda1ed5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_3a4d9c54-58b8-4f61-96ab-1a334fda1ed5" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3a4d9c54-58b8-4f61-96ab-1a334fda1ed5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6334f544-2fdb-4baf-9fd1-ef38b9216e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_3a4d9c54-58b8-4f61-96ab-1a334fda1ed5" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6334f544-2fdb-4baf-9fd1-ef38b9216e7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SeparateAccountAssetsMember_0d2cf362-8fe0-4daf-97fa-c6a11c08b517" xlink:href="ci-20231231.xsd#ci_SeparateAccountAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6334f544-2fdb-4baf-9fd1-ef38b9216e7e" xlink:to="loc_ci_SeparateAccountAssetsMember_0d2cf362-8fe0-4daf-97fa-c6a11c08b517" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c09052d7-bdc9-4258-ac2d-6a77e45d5b95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5bb4cc41-24e7-4211-9bc4-e535c7ce4095" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c09052d7-bdc9-4258-ac2d-6a77e45d5b95" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c09052d7-bdc9-4258-ac2d-6a77e45d5b95_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c09052d7-bdc9-4258-ac2d-6a77e45d5b95" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c09052d7-bdc9-4258-ac2d-6a77e45d5b95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7ebe968a-c16e-4e9e-a5d6-10725aceb3e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c09052d7-bdc9-4258-ac2d-6a77e45d5b95" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7ebe968a-c16e-4e9e-a5d6-10725aceb3e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_83aafadc-3a67-4f5b-8cee-a9208819f290" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7ebe968a-c16e-4e9e-a5d6-10725aceb3e1" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_83aafadc-3a67-4f5b-8cee-a9208819f290" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_6b30f4f4-11e6-4947-89d6-9e271087be29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5bb4cc41-24e7-4211-9bc4-e535c7ce4095" xlink:to="loc_us-gaap_InvestmentTypeAxis_6b30f4f4-11e6-4947-89d6-9e271087be29" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_6b30f4f4-11e6-4947-89d6-9e271087be29_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_6b30f4f4-11e6-4947-89d6-9e271087be29" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_6b30f4f4-11e6-4947-89d6-9e271087be29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_e5841a2c-cc1d-4037-abb8-f7f963447d26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_6b30f4f4-11e6-4947-89d6-9e271087be29" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_e5841a2c-cc1d-4037-abb8-f7f963447d26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PartnershipInterestMember_0fdae4c2-e759-48a7-8c53-8f2bcf54f544" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PartnershipInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_e5841a2c-cc1d-4037-abb8-f7f963447d26" xlink:to="loc_srt_PartnershipInterestMember_0fdae4c2-e759-48a7-8c53-8f2bcf54f544" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_69b5fbaa-0f74-478c-b2ea-3c68bd5e80cd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5bb4cc41-24e7-4211-9bc4-e535c7ce4095" xlink:to="loc_srt_RangeAxis_69b5fbaa-0f74-478c-b2ea-3c68bd5e80cd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_69b5fbaa-0f74-478c-b2ea-3c68bd5e80cd_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_69b5fbaa-0f74-478c-b2ea-3c68bd5e80cd" xlink:to="loc_srt_RangeMember_69b5fbaa-0f74-478c-b2ea-3c68bd5e80cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3b7e3406-801a-4677-bcbb-4dce10aed67d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_69b5fbaa-0f74-478c-b2ea-3c68bd5e80cd" xlink:to="loc_srt_RangeMember_3b7e3406-801a-4677-bcbb-4dce10aed67d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_54863555-dc86-46cc-bd63-2e62dbb11e13" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3b7e3406-801a-4677-bcbb-4dce10aed67d" xlink:to="loc_srt_MaximumMember_54863555-dc86-46cc-bd63-2e62dbb11e13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_8bcbb3fc-9713-4251-9126-24dd422ea770" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5bb4cc41-24e7-4211-9bc4-e535c7ce4095" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_8bcbb3fc-9713-4251-9126-24dd422ea770" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_8bcbb3fc-9713-4251-9126-24dd422ea770_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_8bcbb3fc-9713-4251-9126-24dd422ea770" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_8bcbb3fc-9713-4251-9126-24dd422ea770_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e9fd610f-13ed-43f4-b2e0-bdc09bc8430b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_8bcbb3fc-9713-4251-9126-24dd422ea770" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e9fd610f-13ed-43f4-b2e0-bdc09bc8430b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SwapMember_d64fa164-5a5e-422f-b00d-c36a113a1d02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e9fd610f-13ed-43f4-b2e0-bdc09bc8430b" xlink:to="loc_us-gaap_SwapMember_d64fa164-5a5e-422f-b00d-c36a113a1d02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtAndEquitySecuritiesClassifiedInLevel2PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale_a8cf5f69-78b3-493b-bdd0-63e7e73db986" xlink:href="ci-20231231.xsd#ci_DebtAndEquitySecuritiesClassifiedInLevel2PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b564d935-fec3-4907-b1c8-81d5f36b9a9c" xlink:to="loc_ci_DebtAndEquitySecuritiesClassifiedInLevel2PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale_a8cf5f69-78b3-493b-bdd0-63e7e73db986" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MaximumPercentLevel2InvestmentsForeignBondsBrokerQuoteBeforeReclassificationToDisposalGroupAssetsHeldForSale_4ebbda2d-e716-4b05-89a6-f13b435bc957" xlink:href="ci-20231231.xsd#ci_MaximumPercentLevel2InvestmentsForeignBondsBrokerQuoteBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b564d935-fec3-4907-b1c8-81d5f36b9a9c" xlink:to="loc_ci_MaximumPercentLevel2InvestmentsForeignBondsBrokerQuoteBeforeReclassificationToDisposalGroupAssetsHeldForSale_4ebbda2d-e716-4b05-89a6-f13b435bc957" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DerivativeCreditRiskValuationAdjustmentDerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale_73137cbe-7c41-49cf-b2e2-98026a759dd7" xlink:href="ci-20231231.xsd#ci_DerivativeCreditRiskValuationAdjustmentDerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b564d935-fec3-4907-b1c8-81d5f36b9a9c" xlink:to="loc_ci_DerivativeCreditRiskValuationAdjustmentDerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale_73137cbe-7c41-49cf-b2e2-98026a759dd7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtAndEquitySecuritiesClassifiedInLevel3PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale_31581ec0-0a33-4892-b8ca-18f783576a3a" xlink:href="ci-20231231.xsd#ci_DebtAndEquitySecuritiesClassifiedInLevel3PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b564d935-fec3-4907-b1c8-81d5f36b9a9c" xlink:to="loc_ci_DebtAndEquitySecuritiesClassifiedInLevel3PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale_31581ec0-0a33-4892-b8ca-18f783576a3a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeAssets_c4530221-0b65-4b5a-bfbe-c81f7ecfe260" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b564d935-fec3-4907-b1c8-81d5f36b9a9c" xlink:to="loc_us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeAssets_c4530221-0b65-4b5a-bfbe-c81f7ecfe260" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilitiesBeforeReclassificationToDisposalGroupAssetsHeldForSale_4f58e2b6-9a08-4bc6-b0c4-c5a13ed32cfd" xlink:href="ci-20231231.xsd#ci_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilitiesBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b564d935-fec3-4907-b1c8-81d5f36b9a9c" xlink:to="loc_ci_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilitiesBeforeReclassificationToDisposalGroupAssetsHeldForSale_4f58e2b6-9a08-4bc6-b0c4-c5a13ed32cfd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities_81b6d9d5-c920-4daf-8f7a-04c763f1e829" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b564d935-fec3-4907-b1c8-81d5f36b9a9c" xlink:to="loc_us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities_81b6d9d5-c920-4daf-8f7a-04c763f1e829" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_ff1bf4aa-abaf-4581-99d7-7d41430001f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b564d935-fec3-4907-b1c8-81d5f36b9a9c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_ff1bf4aa-abaf-4581-99d7-7d41430001f4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecreaseIncludingDisposalGroups_121bb2eb-e8f0-4300-8f62-1202c37cdbc5" xlink:href="ci-20231231.xsd#ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecreaseIncludingDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b564d935-fec3-4907-b1c8-81d5f36b9a9c" xlink:to="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecreaseIncludingDisposalGroups_121bb2eb-e8f0-4300-8f62-1202c37cdbc5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLiquidatingInvestmentPeriodFromInceptionSecuritiesPartnerships_99e6eeae-386d-45d5-b960-0823dea5a655" xlink:href="ci-20231231.xsd#ci_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLiquidatingInvestmentPeriodFromInceptionSecuritiesPartnerships"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b564d935-fec3-4907-b1c8-81d5f36b9a9c" xlink:to="loc_ci_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLiquidatingInvestmentPeriodFromInceptionSecuritiesPartnerships_99e6eeae-386d-45d5-b960-0823dea5a655" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_cf129118-d018-4248-9fc6-e8e369e03024" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_785ef25d-ccde-4b35-bbb8-a9c579396651" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_cf129118-d018-4248-9fc6-e8e369e03024" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_785ef25d-ccde-4b35-bbb8-a9c579396651" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_3519acc8-4c1e-4aae-9951-476b5f27dbf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_785ef25d-ccde-4b35-bbb8-a9c579396651" xlink:to="loc_us-gaap_FinancialInstrumentAxis_3519acc8-4c1e-4aae-9951-476b5f27dbf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3519acc8-4c1e-4aae-9951-476b5f27dbf9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3519acc8-4c1e-4aae-9951-476b5f27dbf9" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3519acc8-4c1e-4aae-9951-476b5f27dbf9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3f940319-0867-4fb4-a314-0c45db7acd13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3519acc8-4c1e-4aae-9951-476b5f27dbf9" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3f940319-0867-4fb4-a314-0c45db7acd13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_bd16e019-706a-4ffa-95b5-4d8b0e6ed3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3f940319-0867-4fb4-a314-0c45db7acd13" xlink:to="loc_us-gaap_DebtSecuritiesMember_bd16e019-706a-4ffa-95b5-4d8b0e6ed3c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CorporateAndGovernmentDebtSecuritiesMember_a9242938-808f-4dae-a2d3-024867985929" xlink:href="ci-20231231.xsd#ci_CorporateAndGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesMember_bd16e019-706a-4ffa-95b5-4d8b0e6ed3c5" xlink:to="loc_ci_CorporateAndGovernmentDebtSecuritiesMember_a9242938-808f-4dae-a2d3-024867985929" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_63232a38-c8f0-42c3-a412-e3f7f8f70488" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesMember_bd16e019-706a-4ffa-95b5-4d8b0e6ed3c5" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_63232a38-c8f0-42c3-a412-e3f7f8f70488" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_4ec187bf-6c6c-4243-8887-17b7389d2e33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesMember_bd16e019-706a-4ffa-95b5-4d8b0e6ed3c5" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_4ec187bf-6c6c-4243-8887-17b7389d2e33" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_4ccb9916-f387-4469-94b8-003850fa0ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_785ef25d-ccde-4b35-bbb8-a9c579396651" xlink:to="loc_us-gaap_ValuationTechniqueAxis_4ccb9916-f387-4469-94b8-003850fa0ab8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_4ccb9916-f387-4469-94b8-003850fa0ab8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_4ccb9916-f387-4469-94b8-003850fa0ab8" xlink:to="loc_us-gaap_ValuationTechniqueDomain_4ccb9916-f387-4469-94b8-003850fa0ab8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_618da81e-32fa-42f8-aac8-e31c06eaa18e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_4ccb9916-f387-4469-94b8-003850fa0ab8" xlink:to="loc_us-gaap_ValuationTechniqueDomain_618da81e-32fa-42f8-aac8-e31c06eaa18e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnobservableInputsDevelopedByCompanyMember_303e17c0-2f66-4e9e-a7de-ee9fbe912e0b" xlink:href="ci-20231231.xsd#ci_UnobservableInputsDevelopedByCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_618da81e-32fa-42f8-aac8-e31c06eaa18e" xlink:to="loc_ci_UnobservableInputsDevelopedByCompanyMember_303e17c0-2f66-4e9e-a7de-ee9fbe912e0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnobservableInputsNotDevelopedByCompanyMember_ff6d8d54-843b-433f-8ec8-6fe1596eb18a" xlink:href="ci-20231231.xsd#ci_UnobservableInputsNotDevelopedByCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_618da81e-32fa-42f8-aac8-e31c06eaa18e" xlink:to="loc_ci_UnobservableInputsNotDevelopedByCompanyMember_ff6d8d54-843b-433f-8ec8-6fe1596eb18a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b1a46642-d5da-4129-a47c-e7bfa6414504" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_785ef25d-ccde-4b35-bbb8-a9c579396651" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b1a46642-d5da-4129-a47c-e7bfa6414504" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b1a46642-d5da-4129-a47c-e7bfa6414504_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b1a46642-d5da-4129-a47c-e7bfa6414504" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b1a46642-d5da-4129-a47c-e7bfa6414504_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8352e7ed-f610-4824-aa5e-e6d351ab0bef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b1a46642-d5da-4129-a47c-e7bfa6414504" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8352e7ed-f610-4824-aa5e-e6d351ab0bef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_fa7dac15-5329-4e54-8bef-f3b2a71a457c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_8352e7ed-f610-4824-aa5e-e6d351ab0bef" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_fa7dac15-5329-4e54-8bef-f3b2a71a457c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3cb6bb77-c3cf-4889-9101-7389ac17922f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_785ef25d-ccde-4b35-bbb8-a9c579396651" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3cb6bb77-c3cf-4889-9101-7389ac17922f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3cb6bb77-c3cf-4889-9101-7389ac17922f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3cb6bb77-c3cf-4889-9101-7389ac17922f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3cb6bb77-c3cf-4889-9101-7389ac17922f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fd087ed8-c815-4ccd-94cd-4f81f8d851af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3cb6bb77-c3cf-4889-9101-7389ac17922f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fd087ed8-c815-4ccd-94cd-4f81f8d851af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_893d8ea8-0545-4e3e-abe8-afb8d9511eea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fd087ed8-c815-4ccd-94cd-4f81f8d851af" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_893d8ea8-0545-4e3e-abe8-afb8d9511eea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_12f579c4-1df0-45aa-8463-868040eca092" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_785ef25d-ccde-4b35-bbb8-a9c579396651" xlink:to="loc_srt_RangeAxis_12f579c4-1df0-45aa-8463-868040eca092" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_12f579c4-1df0-45aa-8463-868040eca092_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_12f579c4-1df0-45aa-8463-868040eca092" xlink:to="loc_srt_RangeMember_12f579c4-1df0-45aa-8463-868040eca092_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_356c1bfd-1c90-4be2-ae9a-fc0a7e11d68f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_12f579c4-1df0-45aa-8463-868040eca092" xlink:to="loc_srt_RangeMember_356c1bfd-1c90-4be2-ae9a-fc0a7e11d68f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5e691bc0-1b33-4833-9639-38dbc3b197ae" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_356c1bfd-1c90-4be2-ae9a-fc0a7e11d68f" xlink:to="loc_srt_MinimumMember_5e691bc0-1b33-4833-9639-38dbc3b197ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_23eecbdf-33c6-4fe2-b915-fc6b4938bdfc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_356c1bfd-1c90-4be2-ae9a-fc0a7e11d68f" xlink:to="loc_srt_MaximumMember_23eecbdf-33c6-4fe2-b915-fc6b4938bdfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_4d5e70bb-75ab-4deb-9f41-50cece3e1d66" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_356c1bfd-1c90-4be2-ae9a-fc0a7e11d68f" xlink:to="loc_srt_WeightedAverageMember_4d5e70bb-75ab-4deb-9f41-50cece3e1d66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1d399c59-68ea-4e02-9593-d0b29dafb682" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_785ef25d-ccde-4b35-bbb8-a9c579396651" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1d399c59-68ea-4e02-9593-d0b29dafb682" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1d399c59-68ea-4e02-9593-d0b29dafb682_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1d399c59-68ea-4e02-9593-d0b29dafb682" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1d399c59-68ea-4e02-9593-d0b29dafb682_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_0b8f4b25-9463-4551-89ed-68fc84ebd71a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1d399c59-68ea-4e02-9593-d0b29dafb682" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_0b8f4b25-9463-4551-89ed-68fc84ebd71a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MeasurementInputLiquidityMember_69b18327-69fe-4221-a82c-2a79aa82dadf" xlink:href="ci-20231231.xsd#ci_MeasurementInputLiquidityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0b8f4b25-9463-4551-89ed-68fc84ebd71a" xlink:to="loc_ci_MeasurementInputLiquidityMember_69b18327-69fe-4221-a82c-2a79aa82dadf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_8362a071-005a-402d-8303-b91582c18e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_cf129118-d018-4248-9fc6-e8e369e03024" xlink:to="loc_us-gaap_MarketableSecurities_8362a071-005a-402d-8303-b91582c18e5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketableSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale_c16a86ac-1cae-4857-a0f3-a1ebbbddcdcc" xlink:href="ci-20231231.xsd#ci_MarketableSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_cf129118-d018-4248-9fc6-e8e369e03024" xlink:to="loc_ci_MarketableSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale_c16a86ac-1cae-4857-a0f3-a1ebbbddcdcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput_0bacfb14-3557-4412-9aca-da005e41f5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_cf129118-d018-4248-9fc6-e8e369e03024" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput_0bacfb14-3557-4412-9aca-da005e41f5d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput_1ef687b3-4ea0-419e-9c4f-5bc043e98a11" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_cf129118-d018-4248-9fc6-e8e369e03024" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput_1ef687b3-4ea0-419e-9c4f-5bc043e98a11" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3d8d38f8-a440-45c3-b387-0649af1726e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_48dadf0e-9479-476f-8524-4cc992a2abac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3d8d38f8-a440-45c3-b387-0649af1726e1" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_48dadf0e-9479-476f-8524-4cc992a2abac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_ad12ae11-175c-46ac-afaf-2733a8bf1020" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_48dadf0e-9479-476f-8524-4cc992a2abac" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_ad12ae11-175c-46ac-afaf-2733a8bf1020" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ad12ae11-175c-46ac-afaf-2733a8bf1020_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_ad12ae11-175c-46ac-afaf-2733a8bf1020" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ad12ae11-175c-46ac-afaf-2733a8bf1020_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a645a429-4268-4279-8252-e053873a4829" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_ad12ae11-175c-46ac-afaf-2733a8bf1020" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a645a429-4268-4279-8252-e053873a4829" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtAndEquitySecuritiesMember_bd0c9fa9-1219-420c-8c05-e37ffb4c7489" xlink:href="ci-20231231.xsd#ci_DebtAndEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a645a429-4268-4279-8252-e053873a4829" xlink:to="loc_ci_DebtAndEquitySecuritiesMember_bd0c9fa9-1219-420c-8c05-e37ffb4c7489" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fa229ba4-c18f-4b14-8ba1-596296a58c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_48dadf0e-9479-476f-8524-4cc992a2abac" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fa229ba4-c18f-4b14-8ba1-596296a58c6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fa229ba4-c18f-4b14-8ba1-596296a58c6a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fa229ba4-c18f-4b14-8ba1-596296a58c6a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fa229ba4-c18f-4b14-8ba1-596296a58c6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f780c0d-4651-4050-b1a3-6731014137fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fa229ba4-c18f-4b14-8ba1-596296a58c6a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f780c0d-4651-4050-b1a3-6731014137fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0b4f30e7-3cfc-40e1-a15d-b2d39a768d50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f780c0d-4651-4050-b1a3-6731014137fa" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0b4f30e7-3cfc-40e1-a15d-b2d39a768d50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3eda2431-7afa-4c3c-b240-5d44dbdf13a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3d8d38f8-a440-45c3-b387-0649af1726e1" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3eda2431-7afa-4c3c-b240-5d44dbdf13a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_996b73bf-5480-4de9-a2c0-1123145b9d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3eda2431-7afa-4c3c-b240-5d44dbdf13a1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_996b73bf-5480-4de9-a2c0-1123145b9d9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_8ae6f8ec-c5df-4778-84cf-290a2fe13ee9" xlink:href="ci-20231231.xsd#ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3eda2431-7afa-4c3c-b240-5d44dbdf13a1" xlink:to="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_8ae6f8ec-c5df-4778-84cf-290a2fe13ee9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_d638b7cb-aaaa-46a0-9949-2de0bd0af227" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3eda2431-7afa-4c3c-b240-5d44dbdf13a1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_d638b7cb-aaaa-46a0-9949-2de0bd0af227" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_483f14cd-1d45-4b7c-b2b5-465e5ea3bad1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3eda2431-7afa-4c3c-b240-5d44dbdf13a1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_483f14cd-1d45-4b7c-b2b5-465e5ea3bad1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits_07cb5ea2-f308-4cd3-b105-f07090f3c0bc" xlink:href="ci-20231231.xsd#ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3eda2431-7afa-4c3c-b240-5d44dbdf13a1" xlink:to="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits_07cb5ea2-f308-4cd3-b105-f07090f3c0bc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract_1b652b78-0730-4119-96f3-e2dbf6671523" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3eda2431-7afa-4c3c-b240-5d44dbdf13a1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract_1b652b78-0730-4119-96f3-e2dbf6671523" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_3e5fc4f0-35de-4b0d-a6d2-7aae47c90716" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract_1b652b78-0730-4119-96f3-e2dbf6671523" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_3e5fc4f0-35de-4b0d-a6d2-7aae47c90716" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales_75f45764-6bc2-4296-94c9-3a0210abfdc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract_1b652b78-0730-4119-96f3-e2dbf6671523" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales_75f45764-6bc2-4296-94c9-3a0210abfdc1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_b8431ddc-15d2-4a3b-b25a-8700bcb64b87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract_1b652b78-0730-4119-96f3-e2dbf6671523" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_b8431ddc-15d2-4a3b-b25a-8700bcb64b87" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements_87edd136-4a7d-4a33-89cb-fb05c3efd903" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract_1b652b78-0730-4119-96f3-e2dbf6671523" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements_87edd136-4a7d-4a33-89cb-fb05c3efd903" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_6cd676bf-74bd-41f6-aee0-c7548556ed2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3eda2431-7afa-4c3c-b240-5d44dbdf13a1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_6cd676bf-74bd-41f6-aee0-c7548556ed2b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_8f8d0618-e710-46ca-b512-8885f5cc6946" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_6cd676bf-74bd-41f6-aee0-c7548556ed2b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_8f8d0618-e710-46ca-b512-8885f5cc6946" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_4d229edc-9887-45f7-9331-938c69057f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_6cd676bf-74bd-41f6-aee0-c7548556ed2b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_4d229edc-9887-45f7-9331-938c69057f8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_0893a975-64f9-44c2-a216-503223b6d86e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_6cd676bf-74bd-41f6-aee0-c7548556ed2b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_0893a975-64f9-44c2-a216-503223b6d86e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_17bbfb5c-7641-48bf-b9d1-e5301e2005f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_10e8a4cf-f879-4989-a086-69f7625efed4" xlink:href="ci-20231231.xsd#ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAttributedToInstrumentsHeldIncludedInEarnings_912dbc49-7861-4921-9c0d-c294d8c0f561" xlink:href="ci-20231231.xsd#ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAttributedToInstrumentsHeldIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3d8d38f8-a440-45c3-b387-0649af1726e1" xlink:to="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAttributedToInstrumentsHeldIncludedInEarnings_912dbc49-7861-4921-9c0d-c294d8c0f561" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss_8303508a-f31c-4523-8244-9e7692800586" xlink:href="ci-20231231.xsd#ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3d8d38f8-a440-45c3-b387-0649af1726e1" xlink:to="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss_8303508a-f31c-4523-8244-9e7692800586" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsFairValuesofSeparateAccountAssetsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#FairValueMeasurementsFairValuesofSeparateAccountAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurementsFairValuesofSeparateAccountAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ccfa13e5-bc49-4796-bdc4-6ad977a5b98b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_61380f11-88ab-447e-bbd5-6c8557c92714" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ccfa13e5-bc49-4796-bdc4-6ad977a5b98b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_61380f11-88ab-447e-bbd5-6c8557c92714" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ab44dbe6-a1d7-4c32-ab85-45890f585a94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_61380f11-88ab-447e-bbd5-6c8557c92714" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ab44dbe6-a1d7-4c32-ab85-45890f585a94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ab44dbe6-a1d7-4c32-ab85-45890f585a94_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ab44dbe6-a1d7-4c32-ab85-45890f585a94" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ab44dbe6-a1d7-4c32-ab85-45890f585a94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1fe65bc-5433-45da-bfa4-4dff8f8ade83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ab44dbe6-a1d7-4c32-ab85-45890f585a94" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1fe65bc-5433-45da-bfa4-4dff8f8ade83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_27c3d602-3ee6-4aa5-8551-411c5bcdb010" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1fe65bc-5433-45da-bfa4-4dff8f8ade83" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_27c3d602-3ee6-4aa5-8551-411c5bcdb010" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8f28de40-5379-485c-a6df-faf80c7a4417" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1fe65bc-5433-45da-bfa4-4dff8f8ade83" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8f28de40-5379-485c-a6df-faf80c7a4417" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c0faccba-7b47-4d8b-99e5-5331a89cbcc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1fe65bc-5433-45da-bfa4-4dff8f8ade83" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c0faccba-7b47-4d8b-99e5-5331a89cbcc1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_3de66032-f5ab-43ad-bfa5-cbaeb3f36dce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_61380f11-88ab-447e-bbd5-6c8557c92714" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_3de66032-f5ab-43ad-bfa5-cbaeb3f36dce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_3de66032-f5ab-43ad-bfa5-cbaeb3f36dce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_3de66032-f5ab-43ad-bfa5-cbaeb3f36dce" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_3de66032-f5ab-43ad-bfa5-cbaeb3f36dce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_e1feda87-e375-4be5-be29-508ee75f6295" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_3de66032-f5ab-43ad-bfa5-cbaeb3f36dce" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_e1feda87-e375-4be5-be29-508ee75f6295" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_46a5f8be-8e14-4553-a1f5-39d0e021e914" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_e1feda87-e375-4be5-be29-508ee75f6295" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_46a5f8be-8e14-4553-a1f5-39d0e021e914" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_GuaranteedSeparateAccountAssets_26dffe73-d8fe-4aae-bd6e-af40c285eb09" xlink:href="ci-20231231.xsd#ci_GuaranteedSeparateAccountAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ccfa13e5-bc49-4796-bdc4-6ad977a5b98b" xlink:to="loc_ci_GuaranteedSeparateAccountAssets_26dffe73-d8fe-4aae-bd6e-af40c285eb09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy_d9df8372-52b1-432b-baed-ba183a524d9d" xlink:href="ci-20231231.xsd#ci_NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ccfa13e5-bc49-4796-bdc4-6ad977a5b98b" xlink:to="loc_ci_NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy_d9df8372-52b1-432b-baed-ba183a524d9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SeparateAccountAssetsClassifiedInFairValueHierarchy_ea59f724-6989-4f09-b88b-35f6f4943cf0" xlink:href="ci-20231231.xsd#ci_SeparateAccountAssetsClassifiedInFairValueHierarchy"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ccfa13e5-bc49-4796-bdc4-6ad977a5b98b" xlink:to="loc_ci_SeparateAccountAssetsClassifiedInFairValueHierarchy_ea59f724-6989-4f09-b88b-35f6f4943cf0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NonGuaranteedSeparateAccountAssetsPricedAtNetAssetValueAsAPracticalExpedient_4fbfd118-6aa6-4f9d-9c99-b73b56a0d16f" xlink:href="ci-20231231.xsd#ci_NonGuaranteedSeparateAccountAssetsPricedAtNetAssetValueAsAPracticalExpedient"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ccfa13e5-bc49-4796-bdc4-6ad977a5b98b" xlink:to="loc_ci_NonGuaranteedSeparateAccountAssetsPricedAtNetAssetValueAsAPracticalExpedient_4fbfd118-6aa6-4f9d-9c99-b73b56a0d16f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountAssets_77642e7f-0314-45c4-b3cd-9b7372b290c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeparateAccountAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ccfa13e5-bc49-4796-bdc4-6ad977a5b98b" xlink:to="loc_us-gaap_SeparateAccountAssets_77642e7f-0314-45c4-b3cd-9b7372b290c4" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsAdditionalInformationonSeparateAccountAssetsPricedatNetAssetValueDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#FairValueMeasurementsAdditionalInformationonSeparateAccountAssetsPricedatNetAssetValueDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurementsAdditionalInformationonSeparateAccountAssetsPricedatNetAssetValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems_01c0bfbe-931c-4ebd-b8da-44ef20644e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable_ab791894-c7cf-4bf1-93d2-a364e31858ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems_01c0bfbe-931c-4ebd-b8da-44ef20644e3b" xlink:to="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable_ab791894-c7cf-4bf1-93d2-a364e31858ef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_8057f4c9-d8b9-4eb7-a490-4af21eb66da4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable_ab791894-c7cf-4bf1-93d2-a364e31858ef" xlink:to="loc_us-gaap_InvestmentTypeAxis_8057f4c9-d8b9-4eb7-a490-4af21eb66da4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_8057f4c9-d8b9-4eb7-a490-4af21eb66da4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_8057f4c9-d8b9-4eb7-a490-4af21eb66da4" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_8057f4c9-d8b9-4eb7-a490-4af21eb66da4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_6a0746b5-a2fc-4bbe-bc2b-7cac52c9edad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_8057f4c9-d8b9-4eb7-a490-4af21eb66da4" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_6a0746b5-a2fc-4bbe-bc2b-7cac52c9edad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PartnershipInterestMember_341bca72-6c79-4cb7-a38e-a51190febad7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PartnershipInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6a0746b5-a2fc-4bbe-bc2b-7cac52c9edad" xlink:to="loc_srt_PartnershipInterestMember_341bca72-6c79-4cb7-a38e-a51190febad7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateFundsMember_a74a15a7-51c8-4f40-8166-d53c12bd7287" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstateFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6a0746b5-a2fc-4bbe-bc2b-7cac52c9edad" xlink:to="loc_us-gaap_RealEstateFundsMember_a74a15a7-51c8-4f40-8166-d53c12bd7287" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgeFundsMember_f11eaae8-264a-4868-8291-511582e4a693" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgeFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6a0746b5-a2fc-4bbe-bc2b-7cac52c9edad" xlink:to="loc_us-gaap_HedgeFundsMember_f11eaae8-264a-4868-8291-511582e4a693" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_423ed2ab-c640-4a58-87b8-e7c4f84ae954" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable_ab791894-c7cf-4bf1-93d2-a364e31858ef" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_423ed2ab-c640-4a58-87b8-e7c4f84ae954" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_423ed2ab-c640-4a58-87b8-e7c4f84ae954_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_423ed2ab-c640-4a58-87b8-e7c4f84ae954" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_423ed2ab-c640-4a58-87b8-e7c4f84ae954_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4123351e-8d10-49bc-b81e-a2a4b955d69e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_423ed2ab-c640-4a58-87b8-e7c4f84ae954" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4123351e-8d10-49bc-b81e-a2a4b955d69e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SeparateAccountAssetsMember_006c70b0-0f44-421d-8b47-f75823befcb4" xlink:href="ci-20231231.xsd#ci_SeparateAccountAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4123351e-8d10-49bc-b81e-a2a4b955d69e" xlink:to="loc_ci_SeparateAccountAssetsMember_006c70b0-0f44-421d-8b47-f75823befcb4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_90e4c2e5-c5a0-48d0-be99-db09cd1cb9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable_ab791894-c7cf-4bf1-93d2-a364e31858ef" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_90e4c2e5-c5a0-48d0-be99-db09cd1cb9ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_90e4c2e5-c5a0-48d0-be99-db09cd1cb9ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_90e4c2e5-c5a0-48d0-be99-db09cd1cb9ec" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_90e4c2e5-c5a0-48d0-be99-db09cd1cb9ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9c41257f-f7f4-466b-aa0c-faf75bede922" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_90e4c2e5-c5a0-48d0-be99-db09cd1cb9ec" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9c41257f-f7f4-466b-aa0c-faf75bede922" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_c34f17de-121b-4d7c-9acc-5aa2cfb7d865" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9c41257f-f7f4-466b-aa0c-faf75bede922" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_c34f17de-121b-4d7c-9acc-5aa2cfb7d865" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_59aba48f-3c05-4474-b803-ff7af43a7df7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable_ab791894-c7cf-4bf1-93d2-a364e31858ef" xlink:to="loc_srt_RangeAxis_59aba48f-3c05-4474-b803-ff7af43a7df7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_59aba48f-3c05-4474-b803-ff7af43a7df7_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_59aba48f-3c05-4474-b803-ff7af43a7df7" xlink:to="loc_srt_RangeMember_59aba48f-3c05-4474-b803-ff7af43a7df7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dd8744b2-63d8-42c2-834e-7251d2a66e57" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_59aba48f-3c05-4474-b803-ff7af43a7df7" xlink:to="loc_srt_RangeMember_dd8744b2-63d8-42c2-834e-7251d2a66e57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_faf8c076-06c3-4eb5-8877-34e4503b59ac" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_dd8744b2-63d8-42c2-834e-7251d2a66e57" xlink:to="loc_srt_MinimumMember_faf8c076-06c3-4eb5-8877-34e4503b59ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_594dc836-17ce-47d3-8b07-c51af1a58840" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_dd8744b2-63d8-42c2-834e-7251d2a66e57" xlink:to="loc_srt_MaximumMember_594dc836-17ce-47d3-8b07-c51af1a58840" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_31a222aa-1116-4993-8a7b-79ef2e2e0ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable_ab791894-c7cf-4bf1-93d2-a364e31858ef" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_31a222aa-1116-4993-8a7b-79ef2e2e0ba9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31a222aa-1116-4993-8a7b-79ef2e2e0ba9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_31a222aa-1116-4993-8a7b-79ef2e2e0ba9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31a222aa-1116-4993-8a7b-79ef2e2e0ba9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8bd38ee6-fbff-41b8-977a-505515340caa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_31a222aa-1116-4993-8a7b-79ef2e2e0ba9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8bd38ee6-fbff-41b8-977a-505515340caa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_2aca254e-8c46-44ad-9865-8d84362c7c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8bd38ee6-fbff-41b8-977a-505515340caa" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_2aca254e-8c46-44ad-9865-8d84362c7c1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestment_cd574453-315e-45f4-8d4a-fc7797ca38bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AlternativeInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems_01c0bfbe-931c-4ebd-b8da-44ef20644e3b" xlink:to="loc_us-gaap_AlternativeInvestment_cd574453-315e-45f4-8d4a-fc7797ca38bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AlternativeInvestmentBeforeReclassificationToDisposalGroupAssetsHeldForSale_2f7c838e-6d3c-4e8c-994a-5e5700bcd407" xlink:href="ci-20231231.xsd#ci_AlternativeInvestmentBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems_01c0bfbe-931c-4ebd-b8da-44ef20644e3b" xlink:to="loc_ci_AlternativeInvestmentBeforeReclassificationToDisposalGroupAssetsHeldForSale_2f7c838e-6d3c-4e8c-994a-5e5700bcd407" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_867ffba2-89b0-41f3-9211-26b4fe00ec52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems_01c0bfbe-931c-4ebd-b8da-44ef20644e3b" xlink:to="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_867ffba2-89b0-41f3-9211-26b4fe00ec52" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1_de5501c7-0674-46a3-ae1c-73c22a7a1d41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems_01c0bfbe-931c-4ebd-b8da-44ef20644e3b" xlink:to="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1_de5501c7-0674-46a3-ae1c-73c22a7a1d41" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_87ce2ebd-8df8-4440-b256-70a1f5fae3c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a3fdc0ca-40b3-4aa1-ae33-e02ce2b0d071" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_87ce2ebd-8df8-4440-b256-70a1f5fae3c2" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a3fdc0ca-40b3-4aa1-ae33-e02ce2b0d071" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2c331f80-8257-4cbb-bbaf-614a19d0cc40" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a3fdc0ca-40b3-4aa1-ae33-e02ce2b0d071" xlink:to="loc_srt_RangeAxis_2c331f80-8257-4cbb-bbaf-614a19d0cc40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2c331f80-8257-4cbb-bbaf-614a19d0cc40_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2c331f80-8257-4cbb-bbaf-614a19d0cc40" xlink:to="loc_srt_RangeMember_2c331f80-8257-4cbb-bbaf-614a19d0cc40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_de06fd70-8a11-4f1f-a7d8-98fcb70d1bca" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2c331f80-8257-4cbb-bbaf-614a19d0cc40" xlink:to="loc_srt_RangeMember_de06fd70-8a11-4f1f-a7d8-98fcb70d1bca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f24c4f27-e9e7-483b-81d2-a3315a3fe28c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_de06fd70-8a11-4f1f-a7d8-98fcb70d1bca" xlink:to="loc_srt_MaximumMember_f24c4f27-e9e7-483b-81d2-a3315a3fe28c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RealizedInvestmentLossesCommercialMortgageLoansRealEstateEntitiesCertainEquitySecuritiesWithNoReadilyDeterminableFairValue_24b5da77-68df-4ba2-b3dc-35d6d1206090" xlink:href="ci-20231231.xsd#ci_RealizedInvestmentLossesCommercialMortgageLoansRealEstateEntitiesCertainEquitySecuritiesWithNoReadilyDeterminableFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_87ce2ebd-8df8-4440-b256-70a1f5fae3c2" xlink:to="loc_ci_RealizedInvestmentLossesCommercialMortgageLoansRealEstateEntitiesCertainEquitySecuritiesWithNoReadilyDeterminableFairValue_24b5da77-68df-4ba2-b3dc-35d6d1206090" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_4674c041-90a6-4bf9-8f25-4ea245a5a55b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_87ce2ebd-8df8-4440-b256-70a1f5fae3c2" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_4674c041-90a6-4bf9-8f25-4ea245a5a55b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2056a181-13d3-4908-a774-b1f19a162357" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8d6ce69a-624d-4b6a-97f5-10ce86e27508" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2056a181-13d3-4908-a774-b1f19a162357" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8d6ce69a-624d-4b6a-97f5-10ce86e27508" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_509a76c7-71c6-452b-8e55-4551b70301de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8d6ce69a-624d-4b6a-97f5-10ce86e27508" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_509a76c7-71c6-452b-8e55-4551b70301de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_509a76c7-71c6-452b-8e55-4551b70301de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_509a76c7-71c6-452b-8e55-4551b70301de" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_509a76c7-71c6-452b-8e55-4551b70301de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1a40eb46-02b4-4b17-a77e-10ed00283c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_509a76c7-71c6-452b-8e55-4551b70301de" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1a40eb46-02b4-4b17-a77e-10ed00283c0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_23941799-f011-4cf2-a80e-abe9e78d9566" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1a40eb46-02b4-4b17-a77e-10ed00283c0c" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_23941799-f011-4cf2-a80e-abe9e78d9566" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_bf8e2998-bc22-489f-8e64-17cad09c6a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_23941799-f011-4cf2-a80e-abe9e78d9566" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_bf8e2998-bc22-489f-8e64-17cad09c6a0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_0a3aaee5-69ef-4bdd-8e53-c0d1fbe58be6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_23941799-f011-4cf2-a80e-abe9e78d9566" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_0a3aaee5-69ef-4bdd-8e53-c0d1fbe58be6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_67e364a3-942f-43ab-902e-34eb2ab9c7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8d6ce69a-624d-4b6a-97f5-10ce86e27508" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_67e364a3-942f-43ab-902e-34eb2ab9c7cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67e364a3-942f-43ab-902e-34eb2ab9c7cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_67e364a3-942f-43ab-902e-34eb2ab9c7cf" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67e364a3-942f-43ab-902e-34eb2ab9c7cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dda89ea7-e781-4471-8e95-07d9535aec78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_67e364a3-942f-43ab-902e-34eb2ab9c7cf" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dda89ea7-e781-4471-8e95-07d9535aec78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_11ff43a0-6806-4253-9270-92b984a977f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dda89ea7-e781-4471-8e95-07d9535aec78" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_11ff43a0-6806-4253-9270-92b984a977f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a633b42c-981a-492a-bf44-7cd7266d85d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dda89ea7-e781-4471-8e95-07d9535aec78" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a633b42c-981a-492a-bf44-7cd7266d85d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet_3df14b26-41d9-4c95-ae3b-9d42acae70c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2056a181-13d3-4908-a774-b1f19a162357" xlink:to="loc_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet_3df14b26-41d9-4c95-ae3b-9d42acae70c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_35b409f7-40e7-4c85-a27d-348b2a6b21d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2056a181-13d3-4908-a774-b1f19a162357" xlink:to="loc_us-gaap_LongTermDebtFairValue_35b409f7-40e7-4c85-a27d-348b2a6b21d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MortgageLoansOnRealEstateCommercialAndConsumerNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_fa06396a-f705-436b-973f-66460144510f" xlink:href="ci-20231231.xsd#ci_MortgageLoansOnRealEstateCommercialAndConsumerNetBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2056a181-13d3-4908-a774-b1f19a162357" xlink:to="loc_ci_MortgageLoansOnRealEstateCommercialAndConsumerNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_fa06396a-f705-436b-973f-66460144510f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LongTermDebtFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_21e1813d-9717-4e88-b62a-d8f10f1ec4fd" xlink:href="ci-20231231.xsd#ci_LongTermDebtFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2056a181-13d3-4908-a774-b1f19a162357" xlink:to="loc_ci_LongTermDebtFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_21e1813d-9717-4e88-b62a-d8f10f1ec4fd" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/VariableInterestEntitiesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#VariableInterestEntitiesDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/VariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_bb0d8526-b55d-4e76-a5c2-74a7538954f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_44f94251-50e2-4a7b-9ec1-c5ab753a2cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_bb0d8526-b55d-4e76-a5c2-74a7538954f5" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_44f94251-50e2-4a7b-9ec1-c5ab753a2cc6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_12932d22-c3c3-4949-8dad-7821dad93a74" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_44f94251-50e2-4a7b-9ec1-c5ab753a2cc6" xlink:to="loc_srt_ConsolidatedEntitiesAxis_12932d22-c3c3-4949-8dad-7821dad93a74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_12932d22-c3c3-4949-8dad-7821dad93a74_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_12932d22-c3c3-4949-8dad-7821dad93a74" xlink:to="loc_srt_ConsolidatedEntitiesDomain_12932d22-c3c3-4949-8dad-7821dad93a74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_fdc0dc28-e31d-490e-b402-b1cd9be79e58" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_12932d22-c3c3-4949-8dad-7821dad93a74" xlink:to="loc_srt_ConsolidatedEntitiesDomain_fdc0dc28-e31d-490e-b402-b1cd9be79e58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_f95cfeab-6e55-4a4b-8424-b9433774ceff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_fdc0dc28-e31d-490e-b402-b1cd9be79e58" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_f95cfeab-6e55-4a4b-8424-b9433774ceff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_70383645-6696-4b0e-8048-e9a0eb1b0937" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_fdc0dc28-e31d-490e-b402-b1cd9be79e58" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_70383645-6696-4b0e-8048-e9a0eb1b0937" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_3cfadafa-873c-400c-9f0c-60cfe23e644e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_44f94251-50e2-4a7b-9ec1-c5ab753a2cc6" xlink:to="loc_us-gaap_OtherCommitmentsAxis_3cfadafa-873c-400c-9f0c-60cfe23e644e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_3cfadafa-873c-400c-9f0c-60cfe23e644e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_3cfadafa-873c-400c-9f0c-60cfe23e644e" xlink:to="loc_us-gaap_OtherCommitmentsDomain_3cfadafa-873c-400c-9f0c-60cfe23e644e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_4312b3fa-ae24-4a98-a637-f69e072401aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_3cfadafa-873c-400c-9f0c-60cfe23e644e" xlink:to="loc_us-gaap_OtherCommitmentsDomain_4312b3fa-ae24-4a98-a637-f69e072401aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CommitmentToFundPartnershipMember_b1b49135-1c48-42ac-b6fb-9e82d182e878" xlink:href="ci-20231231.xsd#ci_CommitmentToFundPartnershipMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_4312b3fa-ae24-4a98-a637-f69e072401aa" xlink:to="loc_ci_CommitmentToFundPartnershipMember_b1b49135-1c48-42ac-b6fb-9e82d182e878" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_85d92008-1f05-4e63-88ba-096ba268e17e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_44f94251-50e2-4a7b-9ec1-c5ab753a2cc6" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_85d92008-1f05-4e63-88ba-096ba268e17e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_85d92008-1f05-4e63-88ba-096ba268e17e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_85d92008-1f05-4e63-88ba-096ba268e17e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_85d92008-1f05-4e63-88ba-096ba268e17e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_20f85ce5-e17f-40e9-9ae6-e19e7af85379" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_85d92008-1f05-4e63-88ba-096ba268e17e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_20f85ce5-e17f-40e9-9ae6-e19e7af85379" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember_bfa986b0-9d3a-4eb6-8e90-5e581f17c11e" xlink:href="ci-20231231.xsd#ci_SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_20f85ce5-e17f-40e9-9ae6-e19e7af85379" xlink:to="loc_ci_SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember_bfa986b0-9d3a-4eb6-8e90-5e581f17c11e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_e26a2b25-09e1-4ca1-943d-ae86a56b0cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_44f94251-50e2-4a7b-9ec1-c5ab753a2cc6" xlink:to="loc_us-gaap_InvestmentTypeAxis_e26a2b25-09e1-4ca1-943d-ae86a56b0cfd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_e26a2b25-09e1-4ca1-943d-ae86a56b0cfd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_e26a2b25-09e1-4ca1-943d-ae86a56b0cfd" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_e26a2b25-09e1-4ca1-943d-ae86a56b0cfd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_994efbc5-f302-4369-acb1-a360e51dc492" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_e26a2b25-09e1-4ca1-943d-ae86a56b0cfd" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_994efbc5-f302-4369-acb1-a360e51dc492" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember_b9727130-e0ab-475f-b3cb-fca6b5522d64" xlink:href="ci-20231231.xsd#ci_SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_994efbc5-f302-4369-acb1-a360e51dc492" xlink:to="loc_ci_SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember_b9727130-e0ab-475f-b3cb-fca6b5522d64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RealEstateJointVenturesMember_39036898-f5d2-44e6-868f-af2365abc0b4" xlink:href="ci-20231231.xsd#ci_RealEstateJointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_994efbc5-f302-4369-acb1-a360e51dc492" xlink:to="loc_ci_RealEstateJointVenturesMember_39036898-f5d2-44e6-868f-af2365abc0b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AssetBackedAndCorporateSecuritiesMember_15e165a9-b6f3-44ad-879c-7067e6d216da" xlink:href="ci-20231231.xsd#ci_AssetBackedAndCorporateSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_994efbc5-f302-4369-acb1-a360e51dc492" xlink:to="loc_ci_AssetBackedAndCorporateSecuritiesMember_15e165a9-b6f3-44ad-879c-7067e6d216da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherVariableInterestEntitiesMember_743521b5-a18e-4a06-9d05-aac2274d71ea" xlink:href="ci-20231231.xsd#ci_OtherVariableInterestEntitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_994efbc5-f302-4369-acb1-a360e51dc492" xlink:to="loc_ci_OtherVariableInterestEntitiesMember_743521b5-a18e-4a06-9d05-aac2274d71ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_66d5d966-7b06-4705-9dfd-7cc4188e141f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_44f94251-50e2-4a7b-9ec1-c5ab753a2cc6" xlink:to="loc_srt_RangeAxis_66d5d966-7b06-4705-9dfd-7cc4188e141f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_66d5d966-7b06-4705-9dfd-7cc4188e141f_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_66d5d966-7b06-4705-9dfd-7cc4188e141f" xlink:to="loc_srt_RangeMember_66d5d966-7b06-4705-9dfd-7cc4188e141f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6be5d0bc-5e33-4c60-8048-c260223cb9f1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_66d5d966-7b06-4705-9dfd-7cc4188e141f" xlink:to="loc_srt_RangeMember_6be5d0bc-5e33-4c60-8048-c260223cb9f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9c7c213a-e09b-4b21-b4be-571a4d73c1c0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6be5d0bc-5e33-4c60-8048-c260223cb9f1" xlink:to="loc_srt_MaximumMember_9c7c213a-e09b-4b21-b4be-571a4d73c1c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_VariableInterestEntitiesNumberOfEntities_48c51bc4-4d52-49fd-9d9a-68b74005d744" xlink:href="ci-20231231.xsd#ci_VariableInterestEntitiesNumberOfEntities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_bb0d8526-b55d-4e76-a5c2-74a7538954f5" xlink:to="loc_ci_VariableInterestEntitiesNumberOfEntities_48c51bc4-4d52-49fd-9d9a-68b74005d744" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_49bbd250-07be-4e5f-9d20-71ce36c2a4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestInVariableInterestEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_bb0d8526-b55d-4e76-a5c2-74a7538954f5" xlink:to="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_49bbd250-07be-4e5f-9d20-71ce36c2a4d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_805294f0-a578-413d-b111-8b554c68d6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_bb0d8526-b55d-4e76-a5c2-74a7538954f5" xlink:to="loc_us-gaap_OtherCommitment_805294f0-a578-413d-b111-8b554c68d6ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount_3d62bb41-19aa-4418-ba84-3cd99193fee4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_bb0d8526-b55d-4e76-a5c2-74a7538954f5" xlink:to="loc_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount_3d62bb41-19aa-4418-ba84-3cd99193fee4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_59888027-7918-42cd-b278-6b133e4f58a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_bb0d8526-b55d-4e76-a5c2-74a7538954f5" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_59888027-7918-42cd-b278-6b133e4f58a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuarantyLiabilities_763ffe5e-1264-4b74-ad0f-eb217a6107b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuarantyLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_bb0d8526-b55d-4e76-a5c2-74a7538954f5" xlink:to="loc_us-gaap_GuarantyLiabilities_763ffe5e-1264-4b74-ad0f-eb217a6107b1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_00bf8a02-9afb-4f47-a18d-5d088b47a0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsMaximumExposure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_bb0d8526-b55d-4e76-a5c2-74a7538954f5" xlink:to="loc_us-gaap_GuaranteeObligationsMaximumExposure_00bf8a02-9afb-4f47-a18d-5d088b47a0b4" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiariesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#CollectivelySignificantOperatingUnconsolidatedSubsidiariesDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiariesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_92c3502e-f795-4696-bfa5-086d7c982409" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3e54dddf-7d30-408e-ae37-30effbaafef9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_92c3502e-f795-4696-bfa5-086d7c982409" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3e54dddf-7d30-408e-ae37-30effbaafef9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_758f2d49-0482-4e41-bd51-1e59caab88ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3e54dddf-7d30-408e-ae37-30effbaafef9" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_758f2d49-0482-4e41-bd51-1e59caab88ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_758f2d49-0482-4e41-bd51-1e59caab88ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_758f2d49-0482-4e41-bd51-1e59caab88ca" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_758f2d49-0482-4e41-bd51-1e59caab88ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_4be28edc-5d77-4789-ac27-a7ce8e0d6862" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_758f2d49-0482-4e41-bd51-1e59caab88ca" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_4be28edc-5d77-4789-ac27-a7ce8e0d6862" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OperatingJointVenturesMember_e48823ba-0660-473e-9581-65ed3f240ffc" xlink:href="ci-20231231.xsd#ci_OperatingJointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_4be28edc-5d77-4789-ac27-a7ce8e0d6862" xlink:to="loc_ci_OperatingJointVenturesMember_e48823ba-0660-473e-9581-65ed3f240ffc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b6cf0d3d-2fc5-45e2-873e-6a073e9d83fe" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3e54dddf-7d30-408e-ae37-30effbaafef9" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b6cf0d3d-2fc5-45e2-873e-6a073e9d83fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_b6cf0d3d-2fc5-45e2-873e-6a073e9d83fe_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b6cf0d3d-2fc5-45e2-873e-6a073e9d83fe" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_b6cf0d3d-2fc5-45e2-873e-6a073e9d83fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_654ddc0a-7feb-4a4f-8136-fb2adadf2683" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b6cf0d3d-2fc5-45e2-873e-6a073e9d83fe" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_654ddc0a-7feb-4a4f-8136-fb2adadf2683" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OperatingJointVenturesMember_d226600c-6c7e-4048-af50-5e11afaf1d03" xlink:href="ci-20231231.xsd#ci_OperatingJointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_654ddc0a-7feb-4a4f-8136-fb2adadf2683" xlink:to="loc_ci_OperatingJointVenturesMember_d226600c-6c7e-4048-af50-5e11afaf1d03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d72f7e34-600f-415d-a554-d1c02877dec8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3e54dddf-7d30-408e-ae37-30effbaafef9" xlink:to="loc_srt_StatementGeographicalAxis_d72f7e34-600f-415d-a554-d1c02877dec8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d72f7e34-600f-415d-a554-d1c02877dec8_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_d72f7e34-600f-415d-a554-d1c02877dec8" xlink:to="loc_srt_SegmentGeographicalDomain_d72f7e34-600f-415d-a554-d1c02877dec8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e5cf14f5-817b-43f9-8235-77eaed1caf97" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_d72f7e34-600f-415d-a554-d1c02877dec8" xlink:to="loc_srt_SegmentGeographicalDomain_e5cf14f5-817b-43f9-8235-77eaed1caf97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_6fd2a708-983a-42da-ae85-b1ccd0155fc6" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e5cf14f5-817b-43f9-8235-77eaed1caf97" xlink:to="loc_country_CN_6fd2a708-983a-42da-ae85-b1ccd0155fc6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract_1e509a82-1853-407f-81df-a0f35df2e3da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_92c3502e-f795-4696-bfa5-086d7c982409" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract_1e509a82-1853-407f-81df-a0f35df2e3da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_04a763f6-c819-40b9-be65-70a22aff0d90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract_1e509a82-1853-407f-81df-a0f35df2e3da" xlink:to="loc_us-gaap_EquityMethodInvestments_04a763f6-c819-40b9-be65-70a22aff0d90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f819554b-1888-4c9b-b1e7-74d8501c0798" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract_1e509a82-1853-407f-81df-a0f35df2e3da" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f819554b-1888-4c9b-b1e7-74d8501c0798" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_9c6f4bb3-3f4d-4c7d-bb3c-c66b7de9c396" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract_1e509a82-1853-407f-81df-a0f35df2e3da" xlink:to="loc_us-gaap_IncomeStatementAbstract_9c6f4bb3-3f4d-4c7d-bb3c-c66b7de9c396" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_962a7936-e69b-4c8a-8805-07de43591c38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_9c6f4bb3-3f4d-4c7d-bb3c-c66b7de9c396" xlink:to="loc_us-gaap_Revenues_962a7936-e69b-4c8a-8805-07de43591c38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0f87ba6f-95f6-44a6-8a77-3626e5eb994f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_9c6f4bb3-3f4d-4c7d-bb3c-c66b7de9c396" xlink:to="loc_us-gaap_ProfitLoss_0f87ba6f-95f6-44a6-8a77-3626e5eb994f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_BalanceSheetAbstract_382c0fd3-7776-4b90-84dc-7316333195ab" xlink:href="ci-20231231.xsd#ci_BalanceSheetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract_1e509a82-1853-407f-81df-a0f35df2e3da" xlink:to="loc_ci_BalanceSheetAbstract_382c0fd3-7776-4b90-84dc-7316333195ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2df9050f-99ab-431f-8baf-d5178b52c43e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_BalanceSheetAbstract_382c0fd3-7776-4b90-84dc-7316333195ab" xlink:to="loc_us-gaap_Assets_2df9050f-99ab-431f-8baf-d5178b52c43e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f28eb687-7f87-47ec-afe9-488e8ea1d686" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_BalanceSheetAbstract_382c0fd3-7776-4b90-84dc-7316333195ab" xlink:to="loc_us-gaap_Liabilities_f28eb687-7f87-47ec-afe9-488e8ea1d686" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_bc5dbb46-014f-4f33-ab69-7c17af53b41e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_bc5dbb46-014f-4f33-ab69-7c17af53b41e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_34bdf377-3985-4444-9a75-46743a81ee50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_bc5dbb46-014f-4f33-ab69-7c17af53b41e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_34bdf377-3985-4444-9a75-46743a81ee50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_34bdf377-3985-4444-9a75-46743a81ee50_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_34bdf377-3985-4444-9a75-46743a81ee50" xlink:to="loc_us-gaap_EquityComponentDomain_34bdf377-3985-4444-9a75-46743a81ee50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8a778763-13a1-4829-84b5-ebe9efd735cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_34bdf377-3985-4444-9a75-46743a81ee50" xlink:to="loc_us-gaap_EquityComponentDomain_8a778763-13a1-4829-84b5-ebe9efd735cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_da780c2e-471e-42e3-a704-d5c754ed72cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8a778763-13a1-4829-84b5-ebe9efd735cb" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_da780c2e-471e-42e3-a704-d5c754ed72cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember_a83a5578-6f99-4427-ade0-e01ea5f9dd06" xlink:href="ci-20231231.xsd#ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_da780c2e-471e-42e3-a704-d5c754ed72cb" xlink:to="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember_a83a5578-6f99-4427-ade0-e01ea5f9dd06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesGainLossOnSaleOfBusinessParentMember_c7a492b7-8ce6-49bd-aef1-572469261f32" xlink:href="ci-20231231.xsd#ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesGainLossOnSaleOfBusinessParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember_a83a5578-6f99-4427-ade0-e01ea5f9dd06" xlink:to="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesGainLossOnSaleOfBusinessParentMember_c7a492b7-8ce6-49bd-aef1-572469261f32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesRealizedInvestmentGainsLossesParentMember_c71e69be-9620-40d1-9287-4cf33cb0c2f3" xlink:href="ci-20231231.xsd#ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesRealizedInvestmentGainsLossesParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember_a83a5578-6f99-4427-ade0-e01ea5f9dd06" xlink:to="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesRealizedInvestmentGainsLossesParentMember_c71e69be-9620-40d1-9287-4cf33cb0c2f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesSellingGeneralAdministrativeExpenseParentMember_e0976088-afe9-4c60-9bb6-910751fea746" xlink:href="ci-20231231.xsd#ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesSellingGeneralAdministrativeExpenseParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember_a83a5578-6f99-4427-ade0-e01ea5f9dd06" xlink:to="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesSellingGeneralAdministrativeExpenseParentMember_e0976088-afe9-4c60-9bb6-910751fea746" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember_167e0bee-9972-47ab-9a17-e98c46533425" xlink:href="ci-20231231.xsd#ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_da780c2e-471e-42e3-a704-d5c754ed72cb" xlink:to="loc_ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember_167e0bee-9972-47ab-9a17-e98c46533425" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLiabilityForFuturePolicyBenefitParentMember_80bc23af-8ce3-4ae8-a210-8c5c1cad9a88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociLiabilityForFuturePolicyBenefitParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember_167e0bee-9972-47ab-9a17-e98c46533425" xlink:to="loc_us-gaap_AociLiabilityForFuturePolicyBenefitParentMember_80bc23af-8ce3-4ae8-a210-8c5c1cad9a88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember_74690803-c94b-48ba-9103-027851c03ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember_167e0bee-9972-47ab-9a17-e98c46533425" xlink:to="loc_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember_74690803-c94b-48ba-9103-027851c03ad8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_0e47c035-d18d-43e9-a47a-8e7d150b8284" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_da780c2e-471e-42e3-a704-d5c754ed72cb" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_0e47c035-d18d-43e9-a47a-8e7d150b8284" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_93370329-5a19-4afd-b513-35503190be35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_0e47c035-d18d-43e9-a47a-8e7d150b8284" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_93370329-5a19-4afd-b513-35503190be35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember_6c13c6c2-4964-4aca-bd62-ca3ceb39be85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_0e47c035-d18d-43e9-a47a-8e7d150b8284" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember_6c13c6c2-4964-4aca-bd62-ca3ceb39be85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_08b73290-933e-46d4-88d4-05797bc82a46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_da780c2e-471e-42e3-a704-d5c754ed72cb" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_08b73290-933e-46d4-88d4-05797bc82a46" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_11b4b316-47c0-4a94-8881-e6c331146cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_08b73290-933e-46d4-88d4-05797bc82a46" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_11b4b316-47c0-4a94-8881-e6c331146cb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccumulatedDefinedBenefitPlansAdjustmentGainLossOnSaleOfBusinessMember_b3df4ee4-783b-4805-91df-a398fbd3b078" xlink:href="ci-20231231.xsd#ci_AccumulatedDefinedBenefitPlansAdjustmentGainLossOnSaleOfBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_08b73290-933e-46d4-88d4-05797bc82a46" xlink:to="loc_ci_AccumulatedDefinedBenefitPlansAdjustmentGainLossOnSaleOfBusinessMember_b3df4ee4-783b-4805-91df-a398fbd3b078" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccumulatedDefinedBenefitPlansAdjustmentSettlementMember_8e1a9ad8-09da-492f-b97f-069e55ebbd5e" xlink:href="ci-20231231.xsd#ci_AccumulatedDefinedBenefitPlansAdjustmentSettlementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_08b73290-933e-46d4-88d4-05797bc82a46" xlink:to="loc_ci_AccumulatedDefinedBenefitPlansAdjustmentSettlementMember_8e1a9ad8-09da-492f-b97f-069e55ebbd5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_7910a38d-93e4-49f1-a9d2-967c3a5946b5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_bc5dbb46-014f-4f33-ab69-7c17af53b41e" xlink:to="loc_srt_RestatementAxis_7910a38d-93e4-49f1-a9d2-967c3a5946b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_7910a38d-93e4-49f1-a9d2-967c3a5946b5_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_7910a38d-93e4-49f1-a9d2-967c3a5946b5" xlink:to="loc_srt_RestatementDomain_7910a38d-93e4-49f1-a9d2-967c3a5946b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_e6f3b25a-c96d-461b-9220-b64480b07e64" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_7910a38d-93e4-49f1-a9d2-967c3a5946b5" xlink:to="loc_srt_RestatementDomain_e6f3b25a-c96d-461b-9220-b64480b07e64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_72e12168-ed5f-49a5-913c-f5b61eb880b7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_e6f3b25a-c96d-461b-9220-b64480b07e64" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_72e12168-ed5f-49a5-913c-f5b61eb880b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_9ced25da-76f3-46b7-b32c-272e5fcc7521" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_e6f3b25a-c96d-461b-9220-b64480b07e64" xlink:to="loc_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_9ced25da-76f3-46b7-b32c-272e5fcc7521" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f49ee473-ef10-4d3f-a8a5-1936926dd60c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f49ee473-ef10-4d3f-a8a5-1936926dd60c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_a0fdfa1c-de53-4c02-acb6-1e139d9fb2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_a0fdfa1c-de53-4c02-acb6-1e139d9fb2ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_8d724253-228a-4798-ab72-0dd7a021fff6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_8d724253-228a-4798-ab72-0dd7a021fff6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_b6822e23-ea18-4fec-a32e-01a209b7c246" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_b6822e23-ea18-4fec-a32e-01a209b7c246" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity_9dac0312-2714-4d53-8175-8d16b9d4e6f8" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:to="loc_ci_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity_9dac0312-2714-4d53-8175-8d16b9d4e6f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity_0648d874-02f8-45b7-9572-e9af183bcc8f" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:to="loc_ci_OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity_0648d874-02f8-45b7-9572-e9af183bcc8f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity_e708dda3-df67-4c5e-bbb4-8789ea798065" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:to="loc_ci_OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity_e708dda3-df67-4c5e-bbb4-8789ea798065" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_3f9da1cf-9973-4426-bca6-46b064351cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_3f9da1cf-9973-4426-bca6-46b064351cb1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_e4f34572-d88d-4f5c-adb0-45abc86504cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_e4f34572-d88d-4f5c-adb0-45abc86504cf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_ef264ff6-f884-431d-9c8f-68be0fe46233" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_ef264ff6-f884-431d-9c8f-68be0fe46233" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity_dd781111-98a7-424b-86fa-c1bdade546e4" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:to="loc_ci_OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity_dd781111-98a7-424b-86fa-c1bdade546e4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity_c35211c3-47fc-48c0-97d8-1703a610a8de" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:to="loc_ci_OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity_c35211c3-47fc-48c0-97d8-1703a610a8de" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity_eab2683e-53ae-4a9a-bd3f-cfa93ef500b5" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:to="loc_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity_eab2683e-53ae-4a9a-bd3f-cfa93ef500b5" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TemporaryEquityOtherComprehensiveIncome_dd04cdba-088b-4c31-8dcc-0f503d88fd5f" xlink:href="ci-20231231.xsd#ci_TemporaryEquityOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:to="loc_ci_TemporaryEquityOtherComprehensiveIncome_dd04cdba-088b-4c31-8dcc-0f503d88fd5f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4d5b21d6-0480-4b4b-8ca2-efdef9ca67a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4d5b21d6-0480-4b4b-8ca2-efdef9ca67a5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ff524993-09ae-46dd-85e8-dc5a1b3ae0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/PensionNarrativeDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#PensionNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/PensionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb3ae8b5-fa8f-464a-aacd-1b23d22e259e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9d955988-994d-4d63-9d43-74aac35d5aec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb3ae8b5-fa8f-464a-aacd-1b23d22e259e" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9d955988-994d-4d63-9d43-74aac35d5aec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_2d83e6f4-cd42-4315-adea-258430fb08f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9d955988-994d-4d63-9d43-74aac35d5aec" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_2d83e6f4-cd42-4315-adea-258430fb08f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_2d83e6f4-cd42-4315-adea-258430fb08f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2d83e6f4-cd42-4315-adea-258430fb08f2" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_2d83e6f4-cd42-4315-adea-258430fb08f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_8de01719-8f67-4a62-ad32-e3e6c66d45fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2d83e6f4-cd42-4315-adea-258430fb08f2" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_8de01719-8f67-4a62-ad32-e3e6c66d45fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_dba4885e-1249-4a8b-ac35-c9eb3832eba9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_8de01719-8f67-4a62-ad32-e3e6c66d45fa" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_dba4885e-1249-4a8b-ac35-c9eb3832eba9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_27817705-8133-4c50-981b-a536b6574e96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTaxStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9d955988-994d-4d63-9d43-74aac35d5aec" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_27817705-8133-4c50-981b-a536b6574e96" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_27817705-8133-4c50-981b-a536b6574e96_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTaxStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_27817705-8133-4c50-981b-a536b6574e96" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_27817705-8133-4c50-981b-a536b6574e96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_5aa2fcf8-e5d5-45fb-9393-bf63dd310b84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTaxStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_27817705-8133-4c50-981b-a536b6574e96" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_5aa2fcf8-e5d5-45fb-9393-bf63dd310b84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QualifiedPlanMember_263e8b0d-e708-453c-a7f3-c470425ef022" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_QualifiedPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_5aa2fcf8-e5d5-45fb-9393-bf63dd310b84" xlink:to="loc_us-gaap_QualifiedPlanMember_263e8b0d-e708-453c-a7f3-c470425ef022" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonqualifiedPlanMember_a721e233-b4ce-48ff-a59c-5b0554a4b8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonqualifiedPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_5aa2fcf8-e5d5-45fb-9393-bf63dd310b84" xlink:to="loc_us-gaap_NonqualifiedPlanMember_a721e233-b4ce-48ff-a59c-5b0554a4b8dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DefinedBenefitPlanMarketRelatedValueOfPensionPlanAssets_63211f4d-e971-44fe-8266-746c2d96af02" xlink:href="ci-20231231.xsd#ci_DefinedBenefitPlanMarketRelatedValueOfPensionPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb3ae8b5-fa8f-464a-aacd-1b23d22e259e" xlink:to="loc_ci_DefinedBenefitPlanMarketRelatedValueOfPensionPlanAssets_63211f4d-e971-44fe-8266-746c2d96af02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_f106b842-e782-4cf3-a902-c2462945a2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb3ae8b5-fa8f-464a-aacd-1b23d22e259e" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_f106b842-e782-4cf3-a902-c2462945a2dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_f5d47461-7726-4ba4-ad23-8985447293ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb3ae8b5-fa8f-464a-aacd-1b23d22e259e" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_f5d47461-7726-4ba4-ad23-8985447293ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_fa7efe4f-56b9-457d-b562-5fc7a0851031" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb3ae8b5-fa8f-464a-aacd-1b23d22e259e" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_fa7efe4f-56b9-457d-b562-5fc7a0851031" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DefinedBenefitPlanGainLossDueToLitigation_a5226c28-bbe6-45ae-9a04-cedd4896ebe2" xlink:href="ci-20231231.xsd#ci_DefinedBenefitPlanGainLossDueToLitigation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb3ae8b5-fa8f-464a-aacd-1b23d22e259e" xlink:to="loc_ci_DefinedBenefitPlanGainLossDueToLitigation_a5226c28-bbe6-45ae-9a04-cedd4896ebe2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInSeparateAccountsOfSubsidiaries_5df9fd5c-063f-4f6f-9474-c80fce89aaf3" xlink:href="ci-20231231.xsd#ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInSeparateAccountsOfSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb3ae8b5-fa8f-464a-aacd-1b23d22e259e" xlink:to="loc_ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInSeparateAccountsOfSubsidiaries_5df9fd5c-063f-4f6f-9474-c80fce89aaf3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInFundsOfferedByUnaffiliatedEntity_426c7757-cbd1-4e2f-a16c-5f4b9a227a5f" xlink:href="ci-20231231.xsd#ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInFundsOfferedByUnaffiliatedEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb3ae8b5-fa8f-464a-aacd-1b23d22e259e" xlink:to="loc_ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInFundsOfferedByUnaffiliatedEntity_426c7757-cbd1-4e2f-a16c-5f4b9a227a5f" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#PensionProjectedBenefitObligationsandAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_71e22efc-ee47-4dae-82e2-2a3fe246b0e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_d96502fa-9f1e-4637-b2fd-09fb65ed8137" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_71e22efc-ee47-4dae-82e2-2a3fe246b0e9" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_d96502fa-9f1e-4637-b2fd-09fb65ed8137" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_195f414b-e5d1-48a6-b1e2-6a7b41a5a9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_d96502fa-9f1e-4637-b2fd-09fb65ed8137" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_195f414b-e5d1-48a6-b1e2-6a7b41a5a9e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_195f414b-e5d1-48a6-b1e2-6a7b41a5a9e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_195f414b-e5d1-48a6-b1e2-6a7b41a5a9e5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_195f414b-e5d1-48a6-b1e2-6a7b41a5a9e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_408bd6ff-197c-4b06-ac67-23e9cfde3d42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_195f414b-e5d1-48a6-b1e2-6a7b41a5a9e5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_408bd6ff-197c-4b06-ac67-23e9cfde3d42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_6c0b2c98-7ff2-45b4-93bf-2e1006438fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_408bd6ff-197c-4b06-ac67-23e9cfde3d42" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_6c0b2c98-7ff2-45b4-93bf-2e1006438fe9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_309e5378-2304-49ff-b06d-941b8aa263ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_71e22efc-ee47-4dae-82e2-2a3fe246b0e9" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_309e5378-2304-49ff-b06d-941b8aa263ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_97bede39-48b1-43ad-855b-2076b61592c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_309e5378-2304-49ff-b06d-941b8aa263ea" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_97bede39-48b1-43ad-855b-2076b61592c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_6fb420dd-4388-4c05-bb2f-58c51054ab60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_309e5378-2304-49ff-b06d-941b8aa263ea" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_6fb420dd-4388-4c05-bb2f-58c51054ab60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_8cad5b76-13e7-402a-a6ae-878f631e1296" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_309e5378-2304-49ff-b06d-941b8aa263ea" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_8cad5b76-13e7-402a-a6ae-878f631e1296" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_f397d144-5d7c-41c9-849b-cf6333370c19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_309e5378-2304-49ff-b06d-941b8aa263ea" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_f397d144-5d7c-41c9-849b-cf6333370c19" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DefinedBenefitPlanBenefitsPaidFromPlanAssets_4fa078d7-0e5f-49e9-833a-04dc75cc4c30" xlink:href="ci-20231231.xsd#ci_DefinedBenefitPlanBenefitsPaidFromPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_309e5378-2304-49ff-b06d-941b8aa263ea" xlink:to="loc_ci_DefinedBenefitPlanBenefitsPaidFromPlanAssets_4fa078d7-0e5f-49e9-833a-04dc75cc4c30" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation_24ee2b23-9625-4cf0-bfb6-4660cd39be73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDivestituresBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_309e5378-2304-49ff-b06d-941b8aa263ea" xlink:to="loc_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation_24ee2b23-9625-4cf0-bfb6-4660cd39be73" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DefinedBenefitPlanBenefitsPaidOther_f695bbc1-34d4-48a1-8fcf-05f10a183f5b" xlink:href="ci-20231231.xsd#ci_DefinedBenefitPlanBenefitsPaidOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_309e5378-2304-49ff-b06d-941b8aa263ea" xlink:to="loc_ci_DefinedBenefitPlanBenefitsPaidOther_f695bbc1-34d4-48a1-8fcf-05f10a183f5b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_baf1f9e7-64e8-439a-8d14-63cb412aed1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_995ab554-adc6-462c-86f6-73dd62326001" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_71e22efc-ee47-4dae-82e2-2a3fe246b0e9" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_995ab554-adc6-462c-86f6-73dd62326001" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_fa881269-2d67-47e4-a2a9-cda3a4a815d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_995ab554-adc6-462c-86f6-73dd62326001" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_fa881269-2d67-47e4-a2a9-cda3a4a815d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_2e8a980c-75ad-45ef-8605-da1e6c66faef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_995ab554-adc6-462c-86f6-73dd62326001" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_2e8a980c-75ad-45ef-8605-da1e6c66faef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_e65f29a6-ff01-44d6-bda9-e54d9dc416c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_995ab554-adc6-462c-86f6-73dd62326001" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_e65f29a6-ff01-44d6-bda9-e54d9dc416c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDivestituresPlanAssets_0b47bcd7-d176-4b67-b8b7-fd96f08546ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDivestituresPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_995ab554-adc6-462c-86f6-73dd62326001" xlink:to="loc_us-gaap_DefinedBenefitPlanDivestituresPlanAssets_0b47bcd7-d176-4b67-b8b7-fd96f08546ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_aee5cf5a-1fb2-46c3-bb1c-15da7cea8063" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_995ab554-adc6-462c-86f6-73dd62326001" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_aee5cf5a-1fb2-46c3-bb1c-15da7cea8063" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_97a5ec71-9131-43d9-b1b6-c4fe2669308e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_ebd6b23d-878b-47b7-abe4-81c665a2736b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_995ab554-adc6-462c-86f6-73dd62326001" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_ebd6b23d-878b-47b7-abe4-81c665a2736b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansNoncurrentLiabilitiesAbstract_ade325a2-3cf7-496d-b333-60a731bfd70d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansNoncurrentLiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_71e22efc-ee47-4dae-82e2-2a3fe246b0e9" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansNoncurrentLiabilitiesAbstract_ade325a2-3cf7-496d-b333-60a731bfd70d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_24441121-be4d-4a69-94a4-416ed5bcc34e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansNoncurrentLiabilitiesAbstract_ade325a2-3cf7-496d-b333-60a731bfd70d" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_24441121-be4d-4a69-94a4-416ed5bcc34e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_2eaa3326-5535-4ba1-851d-12ad72e3d0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansNoncurrentLiabilitiesAbstract_ade325a2-3cf7-496d-b333-60a731bfd70d" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_2eaa3326-5535-4ba1-851d-12ad72e3d0f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_33e53f28-ec18-4e52-b4c6-bedf5aaedc29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansNoncurrentLiabilitiesAbstract_ade325a2-3cf7-496d-b333-60a731bfd70d" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_33e53f28-ec18-4e52-b4c6-bedf5aaedc29" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/PensionBenefitPaymentsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#PensionBenefitPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/PensionBenefitPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0367085b-a6e7-4a1a-9e16-aa0bc4d754be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c8395a36-82aa-4c66-8700-2e7cac4cab24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0367085b-a6e7-4a1a-9e16-aa0bc4d754be" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c8395a36-82aa-4c66-8700-2e7cac4cab24" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_9c509351-ca3b-4f2b-b26c-d32c71c61098" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c8395a36-82aa-4c66-8700-2e7cac4cab24" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_9c509351-ca3b-4f2b-b26c-d32c71c61098" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_9c509351-ca3b-4f2b-b26c-d32c71c61098_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_9c509351-ca3b-4f2b-b26c-d32c71c61098" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_9c509351-ca3b-4f2b-b26c-d32c71c61098_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_13d39d96-f382-41e4-af45-6e79ce387ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_9c509351-ca3b-4f2b-b26c-d32c71c61098" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_13d39d96-f382-41e4-af45-6e79ce387ee3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_07388c9a-011e-496b-afa6-ce3cda941b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_13d39d96-f382-41e4-af45-6e79ce387ee3" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_07388c9a-011e-496b-afa6-ce3cda941b8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_9aff012e-75df-43d5-a648-5457af4598ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0367085b-a6e7-4a1a-9e16-aa0bc4d754be" xlink:to="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_9aff012e-75df-43d5-a648-5457af4598ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_c5131c36-7538-483a-abc2-2195388ca29e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_9aff012e-75df-43d5-a648-5457af4598ec" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_c5131c36-7538-483a-abc2-2195388ca29e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_af17df38-9f8b-4d96-8ca5-554b247b21d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_9aff012e-75df-43d5-a648-5457af4598ec" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_af17df38-9f8b-4d96-8ca5-554b247b21d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_f99977f2-5b63-436e-b002-a378c135bf27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_9aff012e-75df-43d5-a648-5457af4598ec" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_f99977f2-5b63-436e-b002-a378c135bf27" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_ea3ced50-e3be-4a2d-a679-45e91f1b3473" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_9aff012e-75df-43d5-a648-5457af4598ec" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_ea3ced50-e3be-4a2d-a679-45e91f1b3473" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_90e4bc7b-6b0a-413f-8849-d4a900d2b99b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_9aff012e-75df-43d5-a648-5457af4598ec" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_90e4bc7b-6b0a-413f-8849-d4a900d2b99b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_77963b0b-76b4-40a7-9164-6a356180c4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_9aff012e-75df-43d5-a648-5457af4598ec" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_77963b0b-76b4-40a7-9164-6a356180c4e4" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/PensionAmountsIncludedinAccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#PensionAmountsIncludedinAccumulatedOtherComprehensiveIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/PensionAmountsIncludedinAccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_36d9ab13-3f8b-4047-aa39-b077bf81a098" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4427acbb-7337-4ee4-b16a-5a86e7a36ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_36d9ab13-3f8b-4047-aa39-b077bf81a098" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4427acbb-7337-4ee4-b16a-5a86e7a36ea2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_31d99f26-8918-4a6f-aaca-04e6bd278c70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4427acbb-7337-4ee4-b16a-5a86e7a36ea2" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_31d99f26-8918-4a6f-aaca-04e6bd278c70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_31d99f26-8918-4a6f-aaca-04e6bd278c70_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_31d99f26-8918-4a6f-aaca-04e6bd278c70" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_31d99f26-8918-4a6f-aaca-04e6bd278c70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_3e59c9f7-cfaa-4d5a-90d4-d49ca1986d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_31d99f26-8918-4a6f-aaca-04e6bd278c70" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_3e59c9f7-cfaa-4d5a-90d4-d49ca1986d0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_3b903f4c-71a8-4b13-9d1d-48ee06bc1c05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3e59c9f7-cfaa-4d5a-90d4-d49ca1986d0a" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_3b903f4c-71a8-4b13-9d1d-48ee06bc1c05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_5222aaf1-e7c8-4680-a7d4-a037da772e23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_36d9ab13-3f8b-4047-aa39-b077bf81a098" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_5222aaf1-e7c8-4680-a7d4-a037da772e23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_d5ae9992-eddb-4971-b676-779c757b9873" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_36d9ab13-3f8b-4047-aa39-b077bf81a098" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_d5ae9992-eddb-4971-b676-779c757b9873" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_f62a59bd-b16d-4a85-8d7a-70bfc3131496" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_36d9ab13-3f8b-4047-aa39-b077bf81a098" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_f62a59bd-b16d-4a85-8d7a-70bfc3131496" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/PensionNetPensionCostDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#PensionNetPensionCostDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/PensionNetPensionCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bbdbfbeb-7a13-47f5-8454-63103d0720db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e2a5459b-33a3-46be-b77a-756c2d0cc5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bbdbfbeb-7a13-47f5-8454-63103d0720db" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e2a5459b-33a3-46be-b77a-756c2d0cc5cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_a749852b-f673-4775-b8c2-f735da88a65e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e2a5459b-33a3-46be-b77a-756c2d0cc5cc" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_a749852b-f673-4775-b8c2-f735da88a65e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_a749852b-f673-4775-b8c2-f735da88a65e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a749852b-f673-4775-b8c2-f735da88a65e" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_a749852b-f673-4775-b8c2-f735da88a65e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_fb40ba40-036a-4cd5-bea3-dcd3dc64bcca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a749852b-f673-4775-b8c2-f735da88a65e" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_fb40ba40-036a-4cd5-bea3-dcd3dc64bcca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_d22a658a-d5ca-4d35-9008-0b2a949aea8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_fb40ba40-036a-4cd5-bea3-dcd3dc64bcca" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_d22a658a-d5ca-4d35-9008-0b2a949aea8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6043ac78-112b-447d-874b-2036f3234291" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bbdbfbeb-7a13-47f5-8454-63103d0720db" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6043ac78-112b-447d-874b-2036f3234291" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_33be0c05-c557-4c91-9706-64eef537af27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6043ac78-112b-447d-874b-2036f3234291" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_33be0c05-c557-4c91-9706-64eef537af27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_90508747-9650-4023-886a-9dac1842cce8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6043ac78-112b-447d-874b-2036f3234291" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_90508747-9650-4023-886a-9dac1842cce8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_5325f7be-1532-45fe-9650-56d2972bcf9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6043ac78-112b-447d-874b-2036f3234291" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_5325f7be-1532-45fe-9650-56d2972bcf9e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DefinedBenefitPlanAmortizationAbstract_c45c7223-a08a-4e9d-a7d7-4861cb3c2b8d" xlink:href="ci-20231231.xsd#ci_DefinedBenefitPlanAmortizationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6043ac78-112b-447d-874b-2036f3234291" xlink:to="loc_ci_DefinedBenefitPlanAmortizationAbstract_c45c7223-a08a-4e9d-a7d7-4861cb3c2b8d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_90a0cfcb-8e0f-4373-8582-ffb0b2829830" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DefinedBenefitPlanAmortizationAbstract_c45c7223-a08a-4e9d-a7d7-4861cb3c2b8d" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_90a0cfcb-8e0f-4373-8582-ffb0b2829830" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DefinedBenefitPlanGainLossDueToLitigation_0c9a6421-b518-422b-af0d-be3d9004438f" xlink:href="ci-20231231.xsd#ci_DefinedBenefitPlanGainLossDueToLitigation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6043ac78-112b-447d-874b-2036f3234291" xlink:to="loc_ci_DefinedBenefitPlanGainLossDueToLitigation_0c9a6421-b518-422b-af0d-be3d9004438f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_1840495e-79dd-46b0-a7de-a1615ac22320" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6043ac78-112b-447d-874b-2036f3234291" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_1840495e-79dd-46b0-a7de-a1615ac22320" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_4405aff1-6ce2-4c04-ba69-7a09c652087d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6043ac78-112b-447d-874b-2036f3234291" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_4405aff1-6ce2-4c04-ba69-7a09c652087d" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/PensionAssumptionsUsedforPensionDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#PensionAssumptionsUsedforPensionDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/PensionAssumptionsUsedforPensionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_63115f65-b1b1-48a3-9c7d-a1007ffaf3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c9ab1c1a-2f95-4506-a54a-8a556d9d5a44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_63115f65-b1b1-48a3-9c7d-a1007ffaf3e7" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c9ab1c1a-2f95-4506-a54a-8a556d9d5a44" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_5cb3b6ad-94e5-4cb6-a745-b89b4897a325" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c9ab1c1a-2f95-4506-a54a-8a556d9d5a44" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_5cb3b6ad-94e5-4cb6-a745-b89b4897a325" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_5cb3b6ad-94e5-4cb6-a745-b89b4897a325_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_5cb3b6ad-94e5-4cb6-a745-b89b4897a325" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_5cb3b6ad-94e5-4cb6-a745-b89b4897a325_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_962f0e2b-45db-464e-ae27-5edee0869f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_5cb3b6ad-94e5-4cb6-a745-b89b4897a325" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_962f0e2b-45db-464e-ae27-5edee0869f6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_77cc1d89-8a8c-45b5-9d46-6bce11eec492" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_962f0e2b-45db-464e-ae27-5edee0869f6c" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_77cc1d89-8a8c-45b5-9d46-6bce11eec492" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsDiscountRateAbstract_f47cd20f-da43-4eb3-98be-bb95bdc800a0" xlink:href="ci-20231231.xsd#ci_DefinedBenefitPlanAssumptionsUsedInCalculationsDiscountRateAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_63115f65-b1b1-48a3-9c7d-a1007ffaf3e7" xlink:to="loc_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsDiscountRateAbstract_f47cd20f-da43-4eb3-98be-bb95bdc800a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_f713fd3c-d431-4db5-989d-dfaa1b308002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsDiscountRateAbstract_f47cd20f-da43-4eb3-98be-bb95bdc800a0" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_f713fd3c-d431-4db5-989d-dfaa1b308002" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_1938fb3b-dd52-4385-b9e4-52dfe9e8baad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsDiscountRateAbstract_f47cd20f-da43-4eb3-98be-bb95bdc800a0" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_1938fb3b-dd52-4385-b9e4-52dfe9e8baad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsExpectedLongTermReturnOnPlanAssetsAbstract_8ac24756-3133-4669-adfc-a02934529dd2" xlink:href="ci-20231231.xsd#ci_DefinedBenefitPlanAssumptionsUsedInCalculationsExpectedLongTermReturnOnPlanAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_63115f65-b1b1-48a3-9c7d-a1007ffaf3e7" xlink:to="loc_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsExpectedLongTermReturnOnPlanAssetsAbstract_8ac24756-3133-4669-adfc-a02934529dd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_31caeee7-c82f-417c-909a-d3ee9f30305a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsExpectedLongTermReturnOnPlanAssetsAbstract_8ac24756-3133-4669-adfc-a02934529dd2" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_31caeee7-c82f-417c-909a-d3ee9f30305a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/PensionPensionPlanAssetsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#PensionPensionPlanAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/PensionPensionPlanAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e4883cee-310e-4f0b-9a5e-116581477f49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_91ded823-7639-4695-9c6b-330d8cc8c0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e4883cee-310e-4f0b-9a5e-116581477f49" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_91ded823-7639-4695-9c6b-330d8cc8c0e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_e65a3f3c-a2aa-4d28-a590-9c6f05b40630" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_91ded823-7639-4695-9c6b-330d8cc8c0e2" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_e65a3f3c-a2aa-4d28-a590-9c6f05b40630" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_e65a3f3c-a2aa-4d28-a590-9c6f05b40630_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_e65a3f3c-a2aa-4d28-a590-9c6f05b40630" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_e65a3f3c-a2aa-4d28-a590-9c6f05b40630_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_33f512da-bc01-4110-a499-b8969875765f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_e65a3f3c-a2aa-4d28-a590-9c6f05b40630" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_33f512da-bc01-4110-a499-b8969875765f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_53e9e8e7-c332-4639-83c2-57e2a50dfdb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_33f512da-bc01-4110-a499-b8969875765f" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_53e9e8e7-c332-4639-83c2-57e2a50dfdb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_da571522-6d88-44e3-a8a7-177e40fab549" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_91ded823-7639-4695-9c6b-330d8cc8c0e2" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_da571522-6d88-44e3-a8a7-177e40fab549" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_da571522-6d88-44e3-a8a7-177e40fab549_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_da571522-6d88-44e3-a8a7-177e40fab549" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_da571522-6d88-44e3-a8a7-177e40fab549_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_8fbb1f9a-90db-4af4-b065-3095f1ac599f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_da571522-6d88-44e3-a8a7-177e40fab549" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_8fbb1f9a-90db-4af4-b065-3095f1ac599f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_38caa2ad-c1b5-40b7-9ab7-ec1056eb6e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDebtSecurityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8fbb1f9a-90db-4af4-b065-3095f1ac599f" xlink:to="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_38caa2ad-c1b5-40b7-9ab7-ec1056eb6e1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_26df8b15-6a73-4734-873c-1d9f467cf305" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_38caa2ad-c1b5-40b7-9ab7-ec1056eb6e1d" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_26df8b15-6a73-4734-873c-1d9f467cf305" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_da5c7972-a813-4991-950e-055ec03fe8c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_38caa2ad-c1b5-40b7-9ab7-ec1056eb6e1d" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_da5c7972-a813-4991-950e-055ec03fe8c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_b2e15ea0-e868-44b9-b82c-d2c81c9354fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_38caa2ad-c1b5-40b7-9ab7-ec1056eb6e1d" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_b2e15ea0-e868-44b9-b82c-d2c81c9354fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FundInvestmentsAndPooledSeparateAccountsMember_ef7ba25a-a973-4dbe-ba06-940e0b97856e" xlink:href="ci-20231231.xsd#ci_FundInvestmentsAndPooledSeparateAccountsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_38caa2ad-c1b5-40b7-9ab7-ec1056eb6e1d" xlink:to="loc_ci_FundInvestmentsAndPooledSeparateAccountsMember_ef7ba25a-a973-4dbe-ba06-940e0b97856e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherPlanAssetCategoriesMember_f536ebd5-e902-44ee-b84d-e52d48cbe9d6" xlink:href="ci-20231231.xsd#ci_OtherPlanAssetCategoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8fbb1f9a-90db-4af4-b065-3095f1ac599f" xlink:to="loc_ci_OtherPlanAssetCategoriesMember_f536ebd5-e902-44ee-b84d-e52d48cbe9d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_b2a1324b-a6ef-4f1b-b7a2-28cead8f458e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_OtherPlanAssetCategoriesMember_f536ebd5-e902-44ee-b84d-e52d48cbe9d6" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_b2a1324b-a6ef-4f1b-b7a2-28cead8f458e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_7174f28d-eba1-48b5-81c9-d4a94a801ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_b2a1324b-a6ef-4f1b-b7a2-28cead8f458e" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_7174f28d-eba1-48b5-81c9-d4a94a801ae0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_8e971e0e-4126-4705-9ddf-1a6858c4e2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_b2a1324b-a6ef-4f1b-b7a2-28cead8f458e" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_8e971e0e-4126-4705-9ddf-1a6858c4e2dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PartnershipInterestMember_172fbe5c-9a9f-42c4-87d9-822f82cabb3c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PartnershipInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_OtherPlanAssetCategoriesMember_f536ebd5-e902-44ee-b84d-e52d48cbe9d6" xlink:to="loc_srt_PartnershipInterestMember_172fbe5c-9a9f-42c4-87d9-822f82cabb3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateMember_e64d7281-f9d5-45bb-8fd8-1826827812e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_OtherPlanAssetCategoriesMember_f536ebd5-e902-44ee-b84d-e52d48cbe9d6" xlink:to="loc_us-gaap_RealEstateMember_e64d7281-f9d5-45bb-8fd8-1826827812e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgagesMember_b55d6c1c-383a-4fae-9258-3a09262b64ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgagesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_OtherPlanAssetCategoriesMember_f536ebd5-e902-44ee-b84d-e52d48cbe9d6" xlink:to="loc_us-gaap_MortgagesMember_b55d6c1c-383a-4fae-9258-3a09262b64ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgeFundsMember_a5ffd74f-ec30-451a-a8ed-bf2d15db78d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgeFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_OtherPlanAssetCategoriesMember_f536ebd5-e902-44ee-b84d-e52d48cbe9d6" xlink:to="loc_us-gaap_HedgeFundsMember_a5ffd74f-ec30-451a-a8ed-bf2d15db78d4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_GuaranteedDepositAccountContractMember_f250285e-f1dc-4eb2-9c3e-e404f4de4586" xlink:href="ci-20231231.xsd#ci_GuaranteedDepositAccountContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_OtherPlanAssetCategoriesMember_f536ebd5-e902-44ee-b84d-e52d48cbe9d6" xlink:to="loc_ci_GuaranteedDepositAccountContractMember_f250285e-f1dc-4eb2-9c3e-e404f4de4586" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CashAndCashEquivalentsInvestmentTradeReceivablesNetMember_065f17f8-38e0-45f4-844a-f449a0262082" xlink:href="ci-20231231.xsd#ci_CashAndCashEquivalentsInvestmentTradeReceivablesNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_OtherPlanAssetCategoriesMember_f536ebd5-e902-44ee-b84d-e52d48cbe9d6" xlink:to="loc_ci_CashAndCashEquivalentsInvestmentTradeReceivablesNetMember_065f17f8-38e0-45f4-844a-f449a0262082" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_ae9c4bb9-f11e-4fa5-beb5-3bd5659923d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e4883cee-310e-4f0b-9a5e-116581477f49" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_ae9c4bb9-f11e-4fa5-beb5-3bd5659923d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_34b03024-7b8f-4b40-a772-e28196462cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e4883cee-310e-4f0b-9a5e-116581477f49" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_34b03024-7b8f-4b40-a772-e28196462cd1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EmployeeIncentivePlansNarrativeDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#EmployeeIncentivePlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/EmployeeIncentivePlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b7b91b4-63c2-4f79-b109-bb2fc9483131" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f21c368-40af-45ac-afb2-6c9879f3e6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b7b91b4-63c2-4f79-b109-bb2fc9483131" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f21c368-40af-45ac-afb2-6c9879f3e6a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f80cf4fc-9eb3-4778-a614-8819793d5dc8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f21c368-40af-45ac-afb2-6c9879f3e6a7" xlink:to="loc_srt_RangeAxis_f80cf4fc-9eb3-4778-a614-8819793d5dc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f80cf4fc-9eb3-4778-a614-8819793d5dc8_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f80cf4fc-9eb3-4778-a614-8819793d5dc8" xlink:to="loc_srt_RangeMember_f80cf4fc-9eb3-4778-a614-8819793d5dc8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_788d29f2-9f34-42f8-8c55-b62b5811ee99" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f80cf4fc-9eb3-4778-a614-8819793d5dc8" xlink:to="loc_srt_RangeMember_788d29f2-9f34-42f8-8c55-b62b5811ee99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c55545e1-4213-46bd-921e-289962631a49" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_788d29f2-9f34-42f8-8c55-b62b5811ee99" xlink:to="loc_srt_MinimumMember_c55545e1-4213-46bd-921e-289962631a49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f22bb035-45f7-48b3-b17b-17762ef19f76" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_788d29f2-9f34-42f8-8c55-b62b5811ee99" xlink:to="loc_srt_MaximumMember_f22bb035-45f7-48b3-b17b-17762ef19f76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_049f33a2-9c15-4dc8-9fa2-6c326c58b96d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f21c368-40af-45ac-afb2-6c9879f3e6a7" xlink:to="loc_us-gaap_AwardTypeAxis_049f33a2-9c15-4dc8-9fa2-6c326c58b96d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_049f33a2-9c15-4dc8-9fa2-6c326c58b96d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_049f33a2-9c15-4dc8-9fa2-6c326c58b96d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_049f33a2-9c15-4dc8-9fa2-6c326c58b96d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ceaca6b-3da9-4334-a3d3-d2ce00940b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_049f33a2-9c15-4dc8-9fa2-6c326c58b96d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ceaca6b-3da9-4334-a3d3-d2ce00940b9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_790a40ea-92ab-4786-80b7-5ee5ead1c0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ceaca6b-3da9-4334-a3d3-d2ce00940b9f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_790a40ea-92ab-4786-80b7-5ee5ead1c0f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RestrictedStockGrantsAndUnitsMember_884aa8b2-0ae7-4800-a840-27dd194b99da" xlink:href="ci-20231231.xsd#ci_RestrictedStockGrantsAndUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ceaca6b-3da9-4334-a3d3-d2ce00940b9f" xlink:to="loc_ci_RestrictedStockGrantsAndUnitsMember_884aa8b2-0ae7-4800-a840-27dd194b99da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_d0e0eb55-85cf-4a3a-b391-fc4596f671f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ceaca6b-3da9-4334-a3d3-d2ce00940b9f" xlink:to="loc_us-gaap_PerformanceSharesMember_d0e0eb55-85cf-4a3a-b391-fc4596f671f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_57c1ff3f-a851-4979-aceb-9ce17bb11896" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b7b91b4-63c2-4f79-b109-bb2fc9483131" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_57c1ff3f-a851-4979-aceb-9ce17bb11896" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_571efb72-669f-48ea-a85d-57e51375c0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b7b91b4-63c2-4f79-b109-bb2fc9483131" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_571efb72-669f-48ea-a85d-57e51375c0b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionReferenceTermOfTradedOptions_d1d11e8f-ab8b-4714-8cda-633dbf045001" xlink:href="ci-20231231.xsd#ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionReferenceTermOfTradedOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b7b91b4-63c2-4f79-b109-bb2fc9483131" xlink:to="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionReferenceTermOfTradedOptions_d1d11e8f-ab8b-4714-8cda-633dbf045001" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d2e6f481-b89d-45f1-a9ff-98e3c6d5f10e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b7b91b4-63c2-4f79-b109-bb2fc9483131" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d2e6f481-b89d-45f1-a9ff-98e3c6d5f10e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_de03b4aa-eb2d-4f93-9574-5a396753b51b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b7b91b4-63c2-4f79-b109-bb2fc9483131" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_de03b4aa-eb2d-4f93-9574-5a396753b51b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateFairValueIncludingMonteCarloFactor_5297dc96-674c-447b-83ea-8380bda1c026" xlink:href="ci-20231231.xsd#ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateFairValueIncludingMonteCarloFactor"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b7b91b4-63c2-4f79-b109-bb2fc9483131" xlink:to="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateFairValueIncludingMonteCarloFactor_5297dc96-674c-447b-83ea-8380bda1c026" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfEmployeesHolding_f1ab0476-f8a5-4753-bb44-a5b3baece8d6" xlink:href="ci-20231231.xsd#ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfEmployeesHolding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b7b91b4-63c2-4f79-b109-bb2fc9483131" xlink:to="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfEmployeesHolding_f1ab0476-f8a5-4753-bb44-a5b3baece8d6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_49dad7ec-f539-49a2-9366-da1ec8299fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b7b91b4-63c2-4f79-b109-bb2fc9483131" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_49dad7ec-f539-49a2-9366-da1ec8299fb0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod_59b88d83-92e3-4bee-b39e-7d88c29302a3" xlink:href="ci-20231231.xsd#ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b7b91b4-63c2-4f79-b109-bb2fc9483131" xlink:to="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod_59b88d83-92e3-4bee-b39e-7d88c29302a3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfOriginalGrantAwardedAtEndOfPerformancePeriod_aea18f61-e6bf-49e2-976b-1b1bb5ffb64d" xlink:href="ci-20231231.xsd#ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfOriginalGrantAwardedAtEndOfPerformancePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b7b91b4-63c2-4f79-b109-bb2fc9483131" xlink:to="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfOriginalGrantAwardedAtEndOfPerformancePeriod_aea18f61-e6bf-49e2-976b-1b1bb5ffb64d" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EmployeeIncentivePlansBlackScholesOptionPricingModelAssumptionsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#EmployeeIncentivePlansBlackScholesOptionPricingModelAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/EmployeeIncentivePlansBlackScholesOptionPricingModelAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06532ef4-5a69-4556-a233-358b60a3adfa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_50899dfb-7063-4cd3-bf0c-45d837ba408e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06532ef4-5a69-4556-a233-358b60a3adfa" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_50899dfb-7063-4cd3-bf0c-45d837ba408e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f95d4fae-a2be-417d-a3d2-dd4b35e856d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_50899dfb-7063-4cd3-bf0c-45d837ba408e" xlink:to="loc_us-gaap_AwardTypeAxis_f95d4fae-a2be-417d-a3d2-dd4b35e856d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f95d4fae-a2be-417d-a3d2-dd4b35e856d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f95d4fae-a2be-417d-a3d2-dd4b35e856d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f95d4fae-a2be-417d-a3d2-dd4b35e856d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33f1d53e-3d12-4374-8bae-f29c9ec44a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f95d4fae-a2be-417d-a3d2-dd4b35e856d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33f1d53e-3d12-4374-8bae-f29c9ec44a0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8d00972d-a1b6-4a0f-b4ee-27029358a9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33f1d53e-3d12-4374-8bae-f29c9ec44a0d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8d00972d-a1b6-4a0f-b4ee-27029358a9c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2ed8ebd6-4258-4a9b-9390-7b655bc11ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06532ef4-5a69-4556-a233-358b60a3adfa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2ed8ebd6-4258-4a9b-9390-7b655bc11ff7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7c963827-add0-48e5-9ad5-ee2e57fdf311" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06532ef4-5a69-4556-a233-358b60a3adfa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7c963827-add0-48e5-9ad5-ee2e57fdf311" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d3dba5ea-3af8-44f5-9b6c-12c5618154b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06532ef4-5a69-4556-a233-358b60a3adfa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d3dba5ea-3af8-44f5-9b6c-12c5618154b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1d76a41e-ffc8-4dd4-aa77-6912e2116148" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06532ef4-5a69-4556-a233-358b60a3adfa" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1d76a41e-ffc8-4dd4-aa77-6912e2116148" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8126eff9-1622-4002-bf56-47317b390c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06532ef4-5a69-4556-a233-358b60a3adfa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8126eff9-1622-4002-bf56-47317b390c5e" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinCommonStockOptionsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#EmployeeIncentivePlansStatusofandChangesinCommonStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinCommonStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3dc4382-5413-4b30-8d82-a56734f6a845" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d7363df-f4b2-4c8d-885f-ae7782d7625a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3dc4382-5413-4b30-8d82-a56734f6a845" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d7363df-f4b2-4c8d-885f-ae7782d7625a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a0cdc1bc-bb73-4c95-be90-cb66f6bf658e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d7363df-f4b2-4c8d-885f-ae7782d7625a" xlink:to="loc_us-gaap_AwardTypeAxis_a0cdc1bc-bb73-4c95-be90-cb66f6bf658e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0cdc1bc-bb73-4c95-be90-cb66f6bf658e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a0cdc1bc-bb73-4c95-be90-cb66f6bf658e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0cdc1bc-bb73-4c95-be90-cb66f6bf658e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f29b58b3-830e-460d-aae4-7d162a78bd1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a0cdc1bc-bb73-4c95-be90-cb66f6bf658e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f29b58b3-830e-460d-aae4-7d162a78bd1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_77532387-9458-4d7c-86ba-900f39bf0a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f29b58b3-830e-460d-aae4-7d162a78bd1a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_77532387-9458-4d7c-86ba-900f39bf0a2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7dd4ebea-4cf5-499d-9d77-7ea3968aadd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3dc4382-5413-4b30-8d82-a56734f6a845" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7dd4ebea-4cf5-499d-9d77-7ea3968aadd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_03fdf5b6-2c28-4093-a75c-28e6264dca9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7dd4ebea-4cf5-499d-9d77-7ea3968aadd5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_03fdf5b6-2c28-4093-a75c-28e6264dca9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d6e908c6-421d-4143-9de7-565fe15e4ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7dd4ebea-4cf5-499d-9d77-7ea3968aadd5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d6e908c6-421d-4143-9de7-565fe15e4ba2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_489e5a9b-9727-4cbb-ae8a-dbedc55a76dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7dd4ebea-4cf5-499d-9d77-7ea3968aadd5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_489e5a9b-9727-4cbb-ae8a-dbedc55a76dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_99a8a8ca-cbb7-4cc0-823b-527bc07adf29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7dd4ebea-4cf5-499d-9d77-7ea3968aadd5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_99a8a8ca-cbb7-4cc0-823b-527bc07adf29" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ab476230-8988-4d6d-9dcf-26f5c088a3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_728b60f1-a610-4889-828e-f1c1bad6d4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3dc4382-5413-4b30-8d82-a56734f6a845" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_728b60f1-a610-4889-828e-f1c1bad6d4d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7308615e-b62f-4710-a7ea-f3c9a35e2ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3dc4382-5413-4b30-8d82-a56734f6a845" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7308615e-b62f-4710-a7ea-f3c9a35e2ff4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b271a280-19de-41d4-aaea-53f11537a8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7308615e-b62f-4710-a7ea-f3c9a35e2ff4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b271a280-19de-41d4-aaea-53f11537a8d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_049e3c8f-87e6-492e-a583-9d62dcb59ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7308615e-b62f-4710-a7ea-f3c9a35e2ff4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_049e3c8f-87e6-492e-a583-9d62dcb59ed8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0b1028ec-4d4b-4526-87e8-04d1288ed300" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7308615e-b62f-4710-a7ea-f3c9a35e2ff4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0b1028ec-4d4b-4526-87e8-04d1288ed300" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_5536be2a-24a2-48a3-afe6-e2c973b02001" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7308615e-b62f-4710-a7ea-f3c9a35e2ff4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_5536be2a-24a2-48a3-afe6-e2c973b02001" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4f438921-0381-434b-bb5a-c2a21e1abf5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d9a462e3-cd5f-402f-8daf-2ab50a1c927b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3dc4382-5413-4b30-8d82-a56734f6a845" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d9a462e3-cd5f-402f-8daf-2ab50a1c927b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsExercisedDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#EmployeeIncentivePlansSummaryofInformationforStockOptionsExercisedDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsExercisedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fbd6b3a7-ceec-4ffe-80d1-21790a846f79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a1755c74-5f67-410e-b220-eb02e4c3c85d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fbd6b3a7-ceec-4ffe-80d1-21790a846f79" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a1755c74-5f67-410e-b220-eb02e4c3c85d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f053b9c5-a667-4d3b-96f3-7767d43e5011" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a1755c74-5f67-410e-b220-eb02e4c3c85d" xlink:to="loc_us-gaap_AwardTypeAxis_f053b9c5-a667-4d3b-96f3-7767d43e5011" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f053b9c5-a667-4d3b-96f3-7767d43e5011_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f053b9c5-a667-4d3b-96f3-7767d43e5011" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f053b9c5-a667-4d3b-96f3-7767d43e5011_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_23d3667f-5eff-4814-bf5d-178c9cb937a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f053b9c5-a667-4d3b-96f3-7767d43e5011" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_23d3667f-5eff-4814-bf5d-178c9cb937a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7a9cd7a8-99d8-4827-9f7d-20668505d994" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_23d3667f-5eff-4814-bf5d-178c9cb937a1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7a9cd7a8-99d8-4827-9f7d-20668505d994" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e337c658-97b2-4060-8190-146f8f88203e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fbd6b3a7-ceec-4ffe-80d1-21790a846f79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e337c658-97b2-4060-8190-146f8f88203e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_98ba89ad-8391-4f45-9e10-1e3edf3fab51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fbd6b3a7-ceec-4ffe-80d1-21790a846f79" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_98ba89ad-8391-4f45-9e10-1e3edf3fab51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_ac776e85-a52e-445a-a985-48b62f702eed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fbd6b3a7-ceec-4ffe-80d1-21790a846f79" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_ac776e85-a52e-445a-a985-48b62f702eed" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsOutstandingDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#EmployeeIncentivePlansSummaryofInformationforStockOptionsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3e7c602-8a1c-4dde-b567-a86f46e54971" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_83e5586d-c045-443b-bbfe-41f01ed4ca74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3e7c602-8a1c-4dde-b567-a86f46e54971" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_83e5586d-c045-443b-bbfe-41f01ed4ca74" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e089dbee-3c48-41b7-bb80-a23696c2b327" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_83e5586d-c045-443b-bbfe-41f01ed4ca74" xlink:to="loc_us-gaap_AwardTypeAxis_e089dbee-3c48-41b7-bb80-a23696c2b327" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e089dbee-3c48-41b7-bb80-a23696c2b327_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e089dbee-3c48-41b7-bb80-a23696c2b327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e089dbee-3c48-41b7-bb80-a23696c2b327_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da84a41e-e8bc-4a72-8875-d37cf4282273" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e089dbee-3c48-41b7-bb80-a23696c2b327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da84a41e-e8bc-4a72-8875-d37cf4282273" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a2f4e19b-2a7b-4006-bed3-52b6389716f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da84a41e-e8bc-4a72-8875-d37cf4282273" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a2f4e19b-2a7b-4006-bed3-52b6389716f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsOutstandingAbstract_173d68be-c5e2-4a1c-a9bf-a66822c06a25" xlink:href="ci-20231231.xsd#ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3e7c602-8a1c-4dde-b567-a86f46e54971" xlink:to="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsOutstandingAbstract_173d68be-c5e2-4a1c-a9bf-a66822c06a25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_31283480-727a-4273-b5ee-a4c5121787ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsOutstandingAbstract_173d68be-c5e2-4a1c-a9bf-a66822c06a25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_31283480-727a-4273-b5ee-a4c5121787ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e1e3de55-e68d-4b8c-a139-7e2d2cac2521" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsOutstandingAbstract_173d68be-c5e2-4a1c-a9bf-a66822c06a25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e1e3de55-e68d-4b8c-a139-7e2d2cac2521" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_23a2dbf8-3124-492d-bbdb-f385d19dafbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsOutstandingAbstract_173d68be-c5e2-4a1c-a9bf-a66822c06a25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_23a2dbf8-3124-492d-bbdb-f385d19dafbb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_cf0c78f5-e99a-4e9e-834d-ac8d826cf38f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsOutstandingAbstract_173d68be-c5e2-4a1c-a9bf-a66822c06a25" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_cf0c78f5-e99a-4e9e-834d-ac8d826cf38f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsExercisableAbstract_c1ae1848-afb6-4906-bb88-a2569f693723" xlink:href="ci-20231231.xsd#ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsExercisableAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3e7c602-8a1c-4dde-b567-a86f46e54971" xlink:to="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsExercisableAbstract_c1ae1848-afb6-4906-bb88-a2569f693723" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ba970a20-ad86-4a7c-8b3e-3bcd7515ad75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsExercisableAbstract_c1ae1848-afb6-4906-bb88-a2569f693723" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ba970a20-ad86-4a7c-8b3e-3bcd7515ad75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a458f80c-5518-49b2-a47d-48354d6f67df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsExercisableAbstract_c1ae1848-afb6-4906-bb88-a2569f693723" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a458f80c-5518-49b2-a47d-48354d6f67df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1c1486e6-1711-495a-839a-9d9c1ffa0b03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsExercisableAbstract_c1ae1848-afb6-4906-bb88-a2569f693723" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1c1486e6-1711-495a-839a-9d9c1ffa0b03" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_89c5cfb7-9f80-409f-ad53-aa64f0966652" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsExercisableAbstract_c1ae1848-afb6-4906-bb88-a2569f693723" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_89c5cfb7-9f80-409f-ad53-aa64f0966652" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinRestrictedStockAwardsandSPSsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#EmployeeIncentivePlansStatusofandChangesinRestrictedStockAwardsandSPSsDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinRestrictedStockAwardsandSPSsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f63835f7-7d5d-439e-ba94-719fcf5e1b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f7f44e11-8eb4-4ae9-ba9c-e36a091a0d42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f63835f7-7d5d-439e-ba94-719fcf5e1b2d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f7f44e11-8eb4-4ae9-ba9c-e36a091a0d42" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ffcb153f-0634-46c1-8c2c-78f94faabe79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f7f44e11-8eb4-4ae9-ba9c-e36a091a0d42" xlink:to="loc_us-gaap_AwardTypeAxis_ffcb153f-0634-46c1-8c2c-78f94faabe79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ffcb153f-0634-46c1-8c2c-78f94faabe79_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ffcb153f-0634-46c1-8c2c-78f94faabe79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ffcb153f-0634-46c1-8c2c-78f94faabe79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_499e61de-9733-48af-b3bc-8759ba21b658" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ffcb153f-0634-46c1-8c2c-78f94faabe79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_499e61de-9733-48af-b3bc-8759ba21b658" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RestrictedStockGrantsAndUnitsMember_e29f22f7-9e93-449e-bc12-b0c7197ecfa1" xlink:href="ci-20231231.xsd#ci_RestrictedStockGrantsAndUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_499e61de-9733-48af-b3bc-8759ba21b658" xlink:to="loc_ci_RestrictedStockGrantsAndUnitsMember_e29f22f7-9e93-449e-bc12-b0c7197ecfa1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ef4c1ffb-3e54-4899-be80-cfef7a36348d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_499e61de-9733-48af-b3bc-8759ba21b658" xlink:to="loc_us-gaap_PerformanceSharesMember_ef4c1ffb-3e54-4899-be80-cfef7a36348d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7d09feec-b7f6-4a11-bb6a-77944a1e42c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f63835f7-7d5d-439e-ba94-719fcf5e1b2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7d09feec-b7f6-4a11-bb6a-77944a1e42c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3d1bc345-c214-47df-b9d1-808286fbc028" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7d09feec-b7f6-4a11-bb6a-77944a1e42c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3d1bc345-c214-47df-b9d1-808286fbc028" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_001f2b82-fe70-40d9-b45c-78e39ceb6990" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7d09feec-b7f6-4a11-bb6a-77944a1e42c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_001f2b82-fe70-40d9-b45c-78e39ceb6990" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7bcffc69-20b6-4503-8280-e99cceb9e227" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7d09feec-b7f6-4a11-bb6a-77944a1e42c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7bcffc69-20b6-4503-8280-e99cceb9e227" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_fb17a29e-dd38-457b-b443-8e5575816fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7d09feec-b7f6-4a11-bb6a-77944a1e42c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_fb17a29e-dd38-457b-b443-8e5575816fe3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_87eef8cb-188c-4ba2-a091-303e7a9751d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e429a90-78f8-49a5-888c-ac3be29c3170" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f63835f7-7d5d-439e-ba94-719fcf5e1b2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e429a90-78f8-49a5-888c-ac3be29c3170" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_26895869-e775-45e2-a642-b515ed85328f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e429a90-78f8-49a5-888c-ac3be29c3170" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_26895869-e775-45e2-a642-b515ed85328f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2bacb9ee-60a1-4e20-8bec-3ee5c1320c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e429a90-78f8-49a5-888c-ac3be29c3170" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2bacb9ee-60a1-4e20-8bec-3ee5c1320c0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9209f8cb-5626-488a-81d3-d8d24fb6f1ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e429a90-78f8-49a5-888c-ac3be29c3170" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9209f8cb-5626-488a-81d3-d8d24fb6f1ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_23d05e17-7761-43cc-be7b-e270afab9acf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e429a90-78f8-49a5-888c-ac3be29c3170" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_23d05e17-7761-43cc-be7b-e270afab9acf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_81615a21-b7ab-48e2-8b93-1a37a0fb63eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EmployeeIncentivePlansFairValueofVestedRestrictedStockandSPSsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#EmployeeIncentivePlansFairValueofVestedRestrictedStockandSPSsDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/EmployeeIncentivePlansFairValueofVestedRestrictedStockandSPSsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c253baea-ef50-4baf-aad9-a553fe5e6109" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85f7364f-eed1-4852-82be-ce3ad7cb98f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c253baea-ef50-4baf-aad9-a553fe5e6109" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85f7364f-eed1-4852-82be-ce3ad7cb98f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_35c9263d-370d-419d-bf0b-480a806c3a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85f7364f-eed1-4852-82be-ce3ad7cb98f3" xlink:to="loc_us-gaap_AwardTypeAxis_35c9263d-370d-419d-bf0b-480a806c3a8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35c9263d-370d-419d-bf0b-480a806c3a8e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_35c9263d-370d-419d-bf0b-480a806c3a8e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35c9263d-370d-419d-bf0b-480a806c3a8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d5d993c-1131-406d-98de-852150c7557c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_35c9263d-370d-419d-bf0b-480a806c3a8e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d5d993c-1131-406d-98de-852150c7557c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RestrictedStockGrantsAndUnitsMember_14c3bb8b-bf08-42c3-85c1-65f84770f231" xlink:href="ci-20231231.xsd#ci_RestrictedStockGrantsAndUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d5d993c-1131-406d-98de-852150c7557c" xlink:to="loc_ci_RestrictedStockGrantsAndUnitsMember_14c3bb8b-bf08-42c3-85c1-65f84770f231" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ad290fb0-5ce3-459a-b6ae-79a4df9cc5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d5d993c-1131-406d-98de-852150c7557c" xlink:to="loc_us-gaap_PerformanceSharesMember_ad290fb0-5ce3-459a-b6ae-79a4df9cc5ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_21ab2800-ca9c-44c1-a4b8-cf762a8ac6f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c253baea-ef50-4baf-aad9-a553fe5e6109" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_21ab2800-ca9c-44c1-a4b8-cf762a8ac6f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_a323651f-88a7-4cc1-a893-0c90c282215a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c253baea-ef50-4baf-aad9-a553fe5e6109" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_a323651f-88a7-4cc1-a893-0c90c282215a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#GoodwillOtherIntangiblesandPropertyandEquipmentNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems_7ccde0df-cbb5-4fa7-a323-d2dfef7f9fb6" xlink:href="ci-20231231.xsd#ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentTable_3bdb0ad4-8136-4b2a-8cce-3c11c888613b" xlink:href="ci-20231231.xsd#ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems_7ccde0df-cbb5-4fa7-a323-d2dfef7f9fb6" xlink:to="loc_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentTable_3bdb0ad4-8136-4b2a-8cce-3c11c888613b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6c53e895-baed-4e49-94bd-14f131cce474" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentTable_3bdb0ad4-8136-4b2a-8cce-3c11c888613b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6c53e895-baed-4e49-94bd-14f131cce474" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6c53e895-baed-4e49-94bd-14f131cce474_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6c53e895-baed-4e49-94bd-14f131cce474" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6c53e895-baed-4e49-94bd-14f131cce474_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_539571a3-c912-426d-aa35-0d963cd2d3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6c53e895-baed-4e49-94bd-14f131cce474" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_539571a3-c912-426d-aa35-0d963cd2d3a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_575fde30-9938-4409-b97d-1aecc2f20aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_539571a3-c912-426d-aa35-0d963cd2d3a0" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_575fde30-9938-4409-b97d-1aecc2f20aa9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_557a99aa-feb0-44b0-8988-3b3baac04037" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_539571a3-c912-426d-aa35-0d963cd2d3a0" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_557a99aa-feb0-44b0-8988-3b3baac04037" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_5b0a2387-cfa6-4240-a9cc-5ad1e3874666" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_539571a3-c912-426d-aa35-0d963cd2d3a0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_5b0a2387-cfa6-4240-a9cc-5ad1e3874666" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_e929ce8d-75e1-4d5e-9a88-11793d50ca94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_539571a3-c912-426d-aa35-0d963cd2d3a0" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_e929ce8d-75e1-4d5e-9a88-11793d50ca94" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_64c38809-c316-42e0-a457-cc4de41c4e07" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentTable_3bdb0ad4-8136-4b2a-8cce-3c11c888613b" xlink:to="loc_srt_RangeAxis_64c38809-c316-42e0-a457-cc4de41c4e07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_64c38809-c316-42e0-a457-cc4de41c4e07_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_64c38809-c316-42e0-a457-cc4de41c4e07" xlink:to="loc_srt_RangeMember_64c38809-c316-42e0-a457-cc4de41c4e07_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_45ac7ed2-72b9-441b-a5ee-a898a6add483" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_64c38809-c316-42e0-a457-cc4de41c4e07" xlink:to="loc_srt_RangeMember_45ac7ed2-72b9-441b-a5ee-a898a6add483" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8e6de656-8eea-400b-94be-7b3f0469caf4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_45ac7ed2-72b9-441b-a5ee-a898a6add483" xlink:to="loc_srt_MinimumMember_8e6de656-8eea-400b-94be-7b3f0469caf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9264e1d5-1e38-4a49-8d6a-29558410d04f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_45ac7ed2-72b9-441b-a5ee-a898a6add483" xlink:to="loc_srt_MaximumMember_9264e1d5-1e38-4a49-8d6a-29558410d04f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_39b9db0c-ea90-4d29-ac2a-3523789c0de2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems_7ccde0df-cbb5-4fa7-a323-d2dfef7f9fb6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_39b9db0c-ea90-4d29-ac2a-3523789c0de2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_9688255c-c597-4ca2-9f7f-ce67ca963ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems_7ccde0df-cbb5-4fa7-a323-d2dfef7f9fb6" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_9688255c-c597-4ca2-9f7f-ce67ca963ffe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c4d0fe2d-e76a-4d73-9964-92155fb33d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems_7ccde0df-cbb5-4fa7-a323-d2dfef7f9fb6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c4d0fe2d-e76a-4d73-9964-92155fb33d0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_44290e35-c7f3-4e1d-996f-0d0b1fa18b95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems_7ccde0df-cbb5-4fa7-a323-d2dfef7f9fb6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_44290e35-c7f3-4e1d-996f-0d0b1fa18b95" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_f4f65563-607e-4c19-a12a-c39d863a0cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems_7ccde0df-cbb5-4fa7-a323-d2dfef7f9fb6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_f4f65563-607e-4c19-a12a-c39d863a0cf1" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentGoodwillActivityDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#GoodwillOtherIntangiblesandPropertyandEquipmentGoodwillActivityDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentGoodwillActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_a3493f3a-4490-46f4-b2fc-f50f2ad8be94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_66517519-7179-422d-a0ec-a77c79f6fc7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_a3493f3a-4490-46f4-b2fc-f50f2ad8be94" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_66517519-7179-422d-a0ec-a77c79f6fc7f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c5d6da25-c2c5-4b9a-b71e-a75d6a2f65ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_66517519-7179-422d-a0ec-a77c79f6fc7f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c5d6da25-c2c5-4b9a-b71e-a75d6a2f65ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c5d6da25-c2c5-4b9a-b71e-a75d6a2f65ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c5d6da25-c2c5-4b9a-b71e-a75d6a2f65ca" xlink:to="loc_us-gaap_SegmentDomain_c5d6da25-c2c5-4b9a-b71e-a75d6a2f65ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2d1c4de5-d233-4aa8-afd5-3224a6ee6b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c5d6da25-c2c5-4b9a-b71e-a75d6a2f65ca" xlink:to="loc_us-gaap_SegmentDomain_2d1c4de5-d233-4aa8-afd5-3224a6ee6b0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EvernorthMember_2af30902-c9e0-4f5e-9998-5cdc447a9cfd" xlink:href="ci-20231231.xsd#ci_EvernorthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2d1c4de5-d233-4aa8-afd5-3224a6ee6b0f" xlink:to="loc_ci_EvernorthMember_2af30902-c9e0-4f5e-9998-5cdc447a9cfd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember_55446462-9136-462f-8020-eec8dcf9ca8b" xlink:href="ci-20231231.xsd#ci_CignaHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2d1c4de5-d233-4aa8-afd5-3224a6ee6b0f" xlink:to="loc_ci_CignaHealthcareMember_55446462-9136-462f-8020-eec8dcf9ca8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherOperationsSegmentMember_6862b985-30d7-47be-8c63-fc371196f262" xlink:href="ci-20231231.xsd#ci_OtherOperationsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2d1c4de5-d233-4aa8-afd5-3224a6ee6b0f" xlink:to="loc_ci_OtherOperationsSegmentMember_6862b985-30d7-47be-8c63-fc371196f262" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_9cb78ec2-15fd-4d6d-a1e2-da594b322052" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_66517519-7179-422d-a0ec-a77c79f6fc7f" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_9cb78ec2-15fd-4d6d-a1e2-da594b322052" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_9cb78ec2-15fd-4d6d-a1e2-da594b322052_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9cb78ec2-15fd-4d6d-a1e2-da594b322052" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_9cb78ec2-15fd-4d6d-a1e2-da594b322052_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_cd48f390-5871-453e-a355-921dd0ca8ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9cb78ec2-15fd-4d6d-a1e2-da594b322052" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_cd48f390-5871-453e-a355-921dd0ca8ba6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_824c4d96-7b5e-4a32-a768-3e2de1ef9927" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_cd48f390-5871-453e-a355-921dd0ca8ba6" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_824c4d96-7b5e-4a32-a768-3e2de1ef9927" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5e859cde-dbb3-45e8-920d-8a81fdb51e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_66517519-7179-422d-a0ec-a77c79f6fc7f" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5e859cde-dbb3-45e8-920d-8a81fdb51e7f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5e859cde-dbb3-45e8-920d-8a81fdb51e7f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5e859cde-dbb3-45e8-920d-8a81fdb51e7f" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5e859cde-dbb3-45e8-920d-8a81fdb51e7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1dab4f32-a04b-4652-a161-65bb14d7c1de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5e859cde-dbb3-45e8-920d-8a81fdb51e7f" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1dab4f32-a04b-4652-a161-65bb14d7c1de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember_2ed40afb-eafd-4912-886c-5ccaeef16522" xlink:href="ci-20231231.xsd#ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1dab4f32-a04b-4652-a161-65bb14d7c1de" xlink:to="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember_2ed40afb-eafd-4912-886c-5ccaeef16522" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_e681ba8a-705a-4c70-91a7-09e851ac8332" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_a3493f3a-4490-46f4-b2fc-f50f2ad8be94" xlink:to="loc_us-gaap_GoodwillRollForward_e681ba8a-705a-4c70-91a7-09e851ac8332" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3e2f9f26-1920-42e0-9bda-0269b5be49b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_e681ba8a-705a-4c70-91a7-09e851ac8332" xlink:to="loc_us-gaap_Goodwill_3e2f9f26-1920-42e0-9bda-0269b5be49b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_GoodwillIncludingDisposalGroups_0b0fb299-0c2e-4431-a8cc-cddd865a0da6" xlink:href="ci-20231231.xsd#ci_GoodwillIncludingDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_e681ba8a-705a-4c70-91a7-09e851ac8332" xlink:to="loc_ci_GoodwillIncludingDisposalGroups_0b0fb299-0c2e-4431-a8cc-cddd865a0da6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_e681da4c-af0f-4002-a21d-3608d52bfcc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_e681ba8a-705a-4c70-91a7-09e851ac8332" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_e681da4c-af0f-4002-a21d-3608d52bfcc3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_faf2f059-3f87-4238-9a03-22754c2dab1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_e681ba8a-705a-4c70-91a7-09e851ac8332" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_faf2f059-3f87-4238-9a03-22754c2dab1c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_GoodwillTransfersToAssetsOfBusinessesHeldForSale_9cb5dbd5-f8c0-4395-98c9-82585f8fa6ec" xlink:href="ci-20231231.xsd#ci_GoodwillTransfersToAssetsOfBusinessesHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_e681ba8a-705a-4c70-91a7-09e851ac8332" xlink:to="loc_ci_GoodwillTransfersToAssetsOfBusinessesHeldForSale_9cb5dbd5-f8c0-4395-98c9-82585f8fa6ec" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_8fde5b82-1501-4bc3-811f-a3feb008157c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_e681ba8a-705a-4c70-91a7-09e851ac8332" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_8fde5b82-1501-4bc3-811f-a3feb008157c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_cf393fb6-ffa4-4ecb-bf5a-6838b1a447d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_GoodwillIncludingDisposalGroups_e754142c-8109-409c-a4f8-84f61000c30a" xlink:href="ci-20231231.xsd#ci_GoodwillIncludingDisposalGroups"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_080615d1-8786-4db7-8343-0b21c9ac5c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_a3493f3a-4490-46f4-b2fc-f50f2ad8be94" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_080615d1-8786-4db7-8343-0b21c9ac5c9e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_78c7aeb9-08ed-46ef-8a39-567e716c18bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_094a1de1-4a64-4df7-96c2-6789bfa2b496" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_78c7aeb9-08ed-46ef-8a39-567e716c18bf" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_094a1de1-4a64-4df7-96c2-6789bfa2b496" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f2be4b97-f856-43f0-9975-35eb86d04cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_094a1de1-4a64-4df7-96c2-6789bfa2b496" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f2be4b97-f856-43f0-9975-35eb86d04cfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2be4b97-f856-43f0-9975-35eb86d04cfd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f2be4b97-f856-43f0-9975-35eb86d04cfd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2be4b97-f856-43f0-9975-35eb86d04cfd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1cde6508-f4da-4a40-b46d-4647e545bdf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f2be4b97-f856-43f0-9975-35eb86d04cfd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1cde6508-f4da-4a40-b46d-4647e545bdf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_b4ad5756-1165-446d-9618-c3b930125f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1cde6508-f4da-4a40-b46d-4647e545bdf3" xlink:to="loc_us-gaap_CustomerRelationshipsMember_b4ad5756-1165-446d-9618-c3b930125f4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_98e234fc-298c-4ee0-9c2b-6b5c9aaf4634" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1cde6508-f4da-4a40-b46d-4647e545bdf3" xlink:to="loc_us-gaap_TradeNamesMember_98e234fc-298c-4ee0-9c2b-6b5c9aaf4634" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_e8ec1a9e-a759-4752-b39a-2f387fdc209d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1cde6508-f4da-4a40-b46d-4647e545bdf3" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_e8ec1a9e-a759-4752-b39a-2f387fdc209d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_8547ab9c-c63c-4521-84db-311a6642c9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_094a1de1-4a64-4df7-96c2-6789bfa2b496" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_8547ab9c-c63c-4521-84db-311a6642c9f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_8547ab9c-c63c-4521-84db-311a6642c9f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_8547ab9c-c63c-4521-84db-311a6642c9f3" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_8547ab9c-c63c-4521-84db-311a6642c9f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_106fba00-6a70-4f39-89f2-1d3ed9b60af9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_8547ab9c-c63c-4521-84db-311a6642c9f3" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_106fba00-6a70-4f39-89f2-1d3ed9b60af9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_02f4eb1f-99c4-4186-a166-307799af338b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_106fba00-6a70-4f39-89f2-1d3ed9b60af9" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_02f4eb1f-99c4-4186-a166-307799af338b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b4bb9ae5-3875-43ac-9ffd-6cc8d6b96a24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_094a1de1-4a64-4df7-96c2-6789bfa2b496" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b4bb9ae5-3875-43ac-9ffd-6cc8d6b96a24" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b4bb9ae5-3875-43ac-9ffd-6cc8d6b96a24_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b4bb9ae5-3875-43ac-9ffd-6cc8d6b96a24" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b4bb9ae5-3875-43ac-9ffd-6cc8d6b96a24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ecaa3a4a-fb41-4d59-b36f-b8c5280630b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b4bb9ae5-3875-43ac-9ffd-6cc8d6b96a24" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ecaa3a4a-fb41-4d59-b36f-b8c5280630b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_f03adbcb-696c-4c97-969d-3c709c0d23fd" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ecaa3a4a-fb41-4d59-b36f-b8c5280630b5" xlink:to="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_f03adbcb-696c-4c97-969d-3c709c0d23fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_863be35a-e096-4317-84ae-4e9c2a16892f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_78c7aeb9-08ed-46ef-8a39-567e716c18bf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_863be35a-e096-4317-84ae-4e9c2a16892f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ac17d755-444c-40fa-9cb9-478f0cd9c674" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_863be35a-e096-4317-84ae-4e9c2a16892f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ac17d755-444c-40fa-9cb9-478f0cd9c674" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ee02cbfe-e54c-4f32-abb1-99059425720c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_863be35a-e096-4317-84ae-4e9c2a16892f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ee02cbfe-e54c-4f32-abb1-99059425720c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9992240b-f17f-4743-8d64-648a60111dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_863be35a-e096-4317-84ae-4e9c2a16892f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9992240b-f17f-4743-8d64-648a60111dd7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsGrossIncludingDisposalGroupsHeldForSale_b52e405a-2ce0-442a-8859-a1f936d10372" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsGrossIncludingDisposalGroupsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_863be35a-e096-4317-84ae-4e9c2a16892f" xlink:to="loc_ci_FiniteLivedIntangibleAssetsGrossIncludingDisposalGroupsHeldForSale_b52e405a-2ce0-442a-8859-a1f936d10372" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale_c235a9b9-fac0-42de-bc88-96b5a1a83e32" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_863be35a-e096-4317-84ae-4e9c2a16892f" xlink:to="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale_c235a9b9-fac0-42de-bc88-96b5a1a83e32" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsNetIncludingDisposalGroupsAssetsHeldForSale_a42ef434-e176-405c-8b05-456e4e9cfae1" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsNetIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_863be35a-e096-4317-84ae-4e9c2a16892f" xlink:to="loc_ci_FiniteLivedIntangibleAssetsNetIncludingDisposalGroupsAssetsHeldForSale_a42ef434-e176-405c-8b05-456e4e9cfae1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_87f2bb77-2568-445f-9cdc-91fc5ff6212b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_78c7aeb9-08ed-46ef-8a39-567e716c18bf" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_87f2bb77-2568-445f-9cdc-91fc5ff6212b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_fbcd1537-1593-4127-8530-2ac1c5dfa565" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_87f2bb77-2568-445f-9cdc-91fc5ff6212b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_fbcd1537-1593-4127-8530-2ac1c5dfa565" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4d7d9399-7892-4648-9580-ac520442d46f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale_bfa41733-05ba-4f7e-9735-01e9998a2bd8" xlink:href="ci-20231231.xsd#ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_87f2bb77-2568-445f-9cdc-91fc5ff6212b" xlink:to="loc_ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale_bfa41733-05ba-4f7e-9735-01e9998a2bd8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale_9d2a92c0-9603-4f51-a7a9-13cf9cdf44d9" xlink:href="ci-20231231.xsd#ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherIntangibleAssetsAbstract_935cf249-3502-465b-909d-dce5a0408f57" xlink:href="ci-20231231.xsd#ci_OtherIntangibleAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_78c7aeb9-08ed-46ef-8a39-567e716c18bf" xlink:to="loc_ci_OtherIntangibleAssetsAbstract_935cf249-3502-465b-909d-dce5a0408f57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_8db285bb-1c47-4be7-97fa-ac7098469348" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_OtherIntangibleAssetsAbstract_935cf249-3502-465b-909d-dce5a0408f57" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_8db285bb-1c47-4be7-97fa-ac7098469348" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_66e30921-1edf-4d96-9188-525ba071a56f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_OtherIntangibleAssetsAbstract_935cf249-3502-465b-909d-dce5a0408f57" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_66e30921-1edf-4d96-9188-525ba071a56f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale_5dee079a-84d0-42fb-9343-2f85c599575e" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_OtherIntangibleAssetsAbstract_935cf249-3502-465b-909d-dce5a0408f57" xlink:to="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale_5dee079a-84d0-42fb-9343-2f85c599575e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale_4b3aba09-4509-4ece-ad3b-8557cb145901" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_OtherIntangibleAssetsAbstract_935cf249-3502-465b-909d-dce5a0408f57" xlink:to="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale_4b3aba09-4509-4ece-ad3b-8557cb145901" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsValueOfBusinessAcquiredAbstract_ffc8acad-86e2-41a9-82b0-50924ee3004a" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsValueOfBusinessAcquiredAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_78c7aeb9-08ed-46ef-8a39-567e716c18bf" xlink:to="loc_ci_IntangibleAssetsValueOfBusinessAcquiredAbstract_ffc8acad-86e2-41a9-82b0-50924ee3004a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsGrossVoba_03ca2525-f0e5-4b3a-8076-5bc2f7be3da7" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsGrossVoba"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_IntangibleAssetsValueOfBusinessAcquiredAbstract_ffc8acad-86e2-41a9-82b0-50924ee3004a" xlink:to="loc_ci_FiniteLivedIntangibleAssetsGrossVoba_03ca2525-f0e5-4b3a-8076-5bc2f7be3da7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVoba_b685940f-1fd5-46df-a9b2-6dd66a325a36" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVoba"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_IntangibleAssetsValueOfBusinessAcquiredAbstract_ffc8acad-86e2-41a9-82b0-50924ee3004a" xlink:to="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVoba_b685940f-1fd5-46df-a9b2-6dd66a325a36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsNetVoba_d9971922-e33b-46f6-9a5b-070a401a334e" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsNetVoba"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_IntangibleAssetsValueOfBusinessAcquiredAbstract_ffc8acad-86e2-41a9-82b0-50924ee3004a" xlink:to="loc_ci_FiniteLivedIntangibleAssetsNetVoba_d9971922-e33b-46f6-9a5b-070a401a334e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsGrossVOBAIncludingDisposalGroupsAssetHeldForSale_cf2e3d63-73ef-4578-b6d3-e7edf7a553fc" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsGrossVOBAIncludingDisposalGroupsAssetHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_IntangibleAssetsValueOfBusinessAcquiredAbstract_ffc8acad-86e2-41a9-82b0-50924ee3004a" xlink:to="loc_ci_FiniteLivedIntangibleAssetsGrossVOBAIncludingDisposalGroupsAssetHeldForSale_cf2e3d63-73ef-4578-b6d3-e7edf7a553fc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVOBAIncludingDisposalGroupsAssetsHeldForSale_077d2cd3-49fc-424e-9cfc-1aa4b0573e7d" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVOBAIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_IntangibleAssetsValueOfBusinessAcquiredAbstract_ffc8acad-86e2-41a9-82b0-50924ee3004a" xlink:to="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVOBAIncludingDisposalGroupsAssetsHeldForSale_077d2cd3-49fc-424e-9cfc-1aa4b0573e7d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsNetVOBAIncludingDisposalGroupsAssetsHeldForSale_f0ce4888-e09a-4873-ac62-10660d8eb8b8" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsNetVOBAIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_IntangibleAssetsValueOfBusinessAcquiredAbstract_ffc8acad-86e2-41a9-82b0-50924ee3004a" xlink:to="loc_ci_FiniteLivedIntangibleAssetsNetVOBAIncludingDisposalGroupsAssetsHeldForSale_f0ce4888-e09a-4873-ac62-10660d8eb8b8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4eb8709b-c248-4c48-a3f7-8e8d78d5a6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_78c7aeb9-08ed-46ef-8a39-567e716c18bf" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4eb8709b-c248-4c48-a3f7-8e8d78d5a6c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVoba_b5dd56a7-148d-4d77-8a5a-79f87a6cdf56" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsGrossExcludingGoodwillIncludingVoba"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4eb8709b-c248-4c48-a3f7-8e8d78d5a6c6" xlink:to="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVoba_b5dd56a7-148d-4d77-8a5a-79f87a6cdf56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVoba_16dc338b-29df-47f8-8ab1-2a413f3ad8d2" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVoba"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4eb8709b-c248-4c48-a3f7-8e8d78d5a6c6" xlink:to="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVoba_16dc338b-29df-47f8-8ab1-2a413f3ad8d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingVoba_33f15c7e-f99c-4b1f-875a-bc900592f30c" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsNetExcludingGoodwillIncludingVoba"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4eb8709b-c248-4c48-a3f7-8e8d78d5a6c6" xlink:to="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingVoba_33f15c7e-f99c-4b1f-875a-bc900592f30c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups_f0f5dc4c-876c-40f4-9c4e-dd4256a93725" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4eb8709b-c248-4c48-a3f7-8e8d78d5a6c6" xlink:to="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups_f0f5dc4c-876c-40f4-9c4e-dd4256a93725" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVOBAIncludingDisposalGroups_e2cef6ec-8772-4583-98dc-5d9ef8abe434" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVOBAIncludingDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4eb8709b-c248-4c48-a3f7-8e8d78d5a6c6" xlink:to="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVOBAIncludingDisposalGroups_e2cef6ec-8772-4583-98dc-5d9ef8abe434" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups_68067fcb-d9e4-4832-931a-0271d9a0ab09" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4eb8709b-c248-4c48-a3f7-8e8d78d5a6c6" xlink:to="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups_68067fcb-d9e4-4832-931a-0271d9a0ab09" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationValueOfBusinessAcquired_7253ddc6-3aba-4863-aa1a-1637f7dfc80c" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationValueOfBusinessAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_78c7aeb9-08ed-46ef-8a39-567e716c18bf" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationValueOfBusinessAcquired_7253ddc6-3aba-4863-aa1a-1637f7dfc80c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_120dfa41-16a7-46e2-b74c-9188848d7e78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_78c7aeb9-08ed-46ef-8a39-567e716c18bf" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_120dfa41-16a7-46e2-b74c-9188848d7e78" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e27b48ec-8f2d-4184-87ee-d2f072ca328f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fd50eb62-73ed-4f16-a9b6-9f770d9b8c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e27b48ec-8f2d-4184-87ee-d2f072ca328f" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fd50eb62-73ed-4f16-a9b6-9f770d9b8c8b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5ce7d595-ecf6-4be0-bcae-66e3d31c79be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fd50eb62-73ed-4f16-a9b6-9f770d9b8c8b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5ce7d595-ecf6-4be0-bcae-66e3d31c79be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5ce7d595-ecf6-4be0-bcae-66e3d31c79be_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5ce7d595-ecf6-4be0-bcae-66e3d31c79be" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5ce7d595-ecf6-4be0-bcae-66e3d31c79be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4e5c4998-4df1-45fb-bf54-d96df35392ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5ce7d595-ecf6-4be0-bcae-66e3d31c79be" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4e5c4998-4df1-45fb-bf54-d96df35392ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_7a2cb7ef-c1fb-4e80-bb9e-14673a0d189f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4e5c4998-4df1-45fb-bf54-d96df35392ba" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_7a2cb7ef-c1fb-4e80-bb9e-14673a0d189f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember_a3be4642-f550-496d-8579-15182509f386" xlink:href="ci-20231231.xsd#ci_AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4e5c4998-4df1-45fb-bf54-d96df35392ba" xlink:to="loc_ci_AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember_a3be4642-f550-496d-8579-15182509f386" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_bb0de3ef-6ee7-461f-914d-b011242ec2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fd50eb62-73ed-4f16-a9b6-9f770d9b8c8b" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_bb0de3ef-6ee7-461f-914d-b011242ec2ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_bb0de3ef-6ee7-461f-914d-b011242ec2ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_bb0de3ef-6ee7-461f-914d-b011242ec2ae" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_bb0de3ef-6ee7-461f-914d-b011242ec2ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_1fd17d67-5d9a-4d40-803f-69446c71ad1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_bb0de3ef-6ee7-461f-914d-b011242ec2ae" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_1fd17d67-5d9a-4d40-803f-69446c71ad1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_a0a9c23a-48e3-4b7c-b7b6-b144484bbcfa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_1fd17d67-5d9a-4d40-803f-69446c71ad1d" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_a0a9c23a-48e3-4b7c-b7b6-b144484bbcfa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_236e008a-42fb-4e12-9fd8-4de25221df87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fd50eb62-73ed-4f16-a9b6-9f770d9b8c8b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_236e008a-42fb-4e12-9fd8-4de25221df87" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_236e008a-42fb-4e12-9fd8-4de25221df87_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_236e008a-42fb-4e12-9fd8-4de25221df87" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_236e008a-42fb-4e12-9fd8-4de25221df87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9c347026-d014-4a67-b44d-cb73a0e671e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_236e008a-42fb-4e12-9fd8-4de25221df87" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9c347026-d014-4a67-b44d-cb73a0e671e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_a8c072e9-cfe0-4ec5-83bd-f95552d7d75e" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9c347026-d014-4a67-b44d-cb73a0e671e3" xlink:to="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_a8c072e9-cfe0-4ec5-83bd-f95552d7d75e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PropertyPlantAndEquipmentIncludingAssetsHeldForSaleAbstract_73ce8ce3-99df-49a0-bc7e-41113697b4bb" xlink:href="ci-20231231.xsd#ci_PropertyPlantAndEquipmentIncludingAssetsHeldForSaleAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e27b48ec-8f2d-4184-87ee-d2f072ca328f" xlink:to="loc_ci_PropertyPlantAndEquipmentIncludingAssetsHeldForSaleAbstract_73ce8ce3-99df-49a0-bc7e-41113697b4bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PropertyPlantAndEquipmentGrossIncludingDisposalGroups_1f9426f4-dd74-492b-a541-8d5e41447285" xlink:href="ci-20231231.xsd#ci_PropertyPlantAndEquipmentGrossIncludingDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_PropertyPlantAndEquipmentIncludingAssetsHeldForSaleAbstract_73ce8ce3-99df-49a0-bc7e-41113697b4bb" xlink:to="loc_ci_PropertyPlantAndEquipmentGrossIncludingDisposalGroups_1f9426f4-dd74-492b-a541-8d5e41447285" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups_469a3016-67ac-482c-a104-d3a46b19d658" xlink:href="ci-20231231.xsd#ci_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_PropertyPlantAndEquipmentIncludingAssetsHeldForSaleAbstract_73ce8ce3-99df-49a0-bc7e-41113697b4bb" xlink:to="loc_ci_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups_469a3016-67ac-482c-a104-d3a46b19d658" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups_56a2cbc2-4e23-439f-bc7e-6e548f9f17a8" xlink:href="ci-20231231.xsd#ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_PropertyPlantAndEquipmentIncludingAssetsHeldForSaleAbstract_73ce8ce3-99df-49a0-bc7e-41113697b4bb" xlink:to="loc_ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups_56a2cbc2-4e23-439f-bc7e-6e548f9f17a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract_37fac2be-da06-4d5e-a23b-f5faf470ef30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e27b48ec-8f2d-4184-87ee-d2f072ca328f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract_37fac2be-da06-4d5e-a23b-f5faf470ef30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentGrossCurrent_0472c4e9-1c0d-40e0-9780-9922c48b483b" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentGrossCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract_37fac2be-da06-4d5e-a23b-f5faf470ef30" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentGrossCurrent_0472c4e9-1c0d-40e0-9780-9922c48b483b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentCurrent_01bfdd00-8a97-4b81-bab4-641fc5395226" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract_37fac2be-da06-4d5e-a23b-f5faf470ef30" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentCurrent_01bfdd00-8a97-4b81-bab4-641fc5395226" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_70a254c0-1fa7-4b2c-9be0-9b7ee1d6c8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract_37fac2be-da06-4d5e-a23b-f5faf470ef30" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_70a254c0-1fa7-4b2c-9be0-9b7ee1d6c8d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_64954884-b7fa-4652-8267-c30dd78001b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e27b48ec-8f2d-4184-87ee-d2f072ca328f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_64954884-b7fa-4652-8267-c30dd78001b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8f7da334-887c-456a-8930-67913bfaa004" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_64954884-b7fa-4652-8267-c30dd78001b1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8f7da334-887c-456a-8930-67913bfaa004" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0488e7b6-ef61-4f4b-b184-9def49e3b9b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_64954884-b7fa-4652-8267-c30dd78001b1" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0488e7b6-ef61-4f4b-b184-9def49e3b9b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9fe247a9-73b8-4307-a07e-37f9a4f05bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_64954884-b7fa-4652-8267-c30dd78001b1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9fe247a9-73b8-4307-a07e-37f9a4f05bd1" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentComponentsofDepreciationandAmortizationExpenseDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#GoodwillOtherIntangiblesandPropertyandEquipmentComponentsofDepreciationandAmortizationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentComponentsofDepreciationandAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_DepreciationAndAmortizationByTypeLineItems_5604167a-4d17-4fab-b245-83239cdc4c89" xlink:href="ci-20231231.xsd#ci_DepreciationAndAmortizationByTypeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ScheduleOfDepreciationAndAmortizationTable_a3d82468-4101-4fc1-a837-b6d074e21849" xlink:href="ci-20231231.xsd#ci_ScheduleOfDepreciationAndAmortizationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ci_DepreciationAndAmortizationByTypeLineItems_5604167a-4d17-4fab-b245-83239cdc4c89" xlink:to="loc_ci_ScheduleOfDepreciationAndAmortizationTable_a3d82468-4101-4fc1-a837-b6d074e21849" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DepreciationAndAmortizationByTypeAxis_64fc2cc9-46ac-4e3a-9540-cdbf1b9a3184" xlink:href="ci-20231231.xsd#ci_DepreciationAndAmortizationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ci_ScheduleOfDepreciationAndAmortizationTable_a3d82468-4101-4fc1-a837-b6d074e21849" xlink:to="loc_ci_DepreciationAndAmortizationByTypeAxis_64fc2cc9-46ac-4e3a-9540-cdbf1b9a3184" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DepreciationAndAmortizationTypeDomain_64fc2cc9-46ac-4e3a-9540-cdbf1b9a3184_default" xlink:href="ci-20231231.xsd#ci_DepreciationAndAmortizationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ci_DepreciationAndAmortizationByTypeAxis_64fc2cc9-46ac-4e3a-9540-cdbf1b9a3184" xlink:to="loc_ci_DepreciationAndAmortizationTypeDomain_64fc2cc9-46ac-4e3a-9540-cdbf1b9a3184_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DepreciationAndAmortizationTypeDomain_6ac0cd3f-222c-4db9-8fe6-7b2eeb1bfa26" xlink:href="ci-20231231.xsd#ci_DepreciationAndAmortizationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ci_DepreciationAndAmortizationByTypeAxis_64fc2cc9-46ac-4e3a-9540-cdbf1b9a3184" xlink:to="loc_ci_DepreciationAndAmortizationTypeDomain_6ac0cd3f-222c-4db9-8fe6-7b2eeb1bfa26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_f0ef052a-ac76-4941-9dc0-f7ead35163c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DepreciationAndAmortizationTypeDomain_6ac0cd3f-222c-4db9-8fe6-7b2eeb1bfa26" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_f0ef052a-ac76-4941-9dc0-f7ead35163c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember_7eb819fc-f8b4-40a2-bab5-c72b7055732e" xlink:href="ci-20231231.xsd#ci_AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DepreciationAndAmortizationTypeDomain_6ac0cd3f-222c-4db9-8fe6-7b2eeb1bfa26" xlink:to="loc_ci_AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember_7eb819fc-f8b4-40a2-bab5-c72b7055732e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceContractsAcquiredInBusinessCombinationMember_178c121b-11cd-4c13-b7ed-d0206ee0339e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceContractsAcquiredInBusinessCombinationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DepreciationAndAmortizationTypeDomain_6ac0cd3f-222c-4db9-8fe6-7b2eeb1bfa26" xlink:to="loc_us-gaap_InsuranceContractsAcquiredInBusinessCombinationMember_178c121b-11cd-4c13-b7ed-d0206ee0339e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_cb9d44be-a228-43ed-940b-0fa29cbc1327" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DepreciationAndAmortizationTypeDomain_6ac0cd3f-222c-4db9-8fe6-7b2eeb1bfa26" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_cb9d44be-a228-43ed-940b-0fa29cbc1327" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_be7710ac-98f1-49c2-a878-f2ac4dd8e2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DepreciationAndAmortizationByTypeLineItems_5604167a-4d17-4fab-b245-83239cdc4c89" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_be7710ac-98f1-49c2-a878-f2ac4dd8e2a7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_bbb45c27-dbf3-42a6-99e0-ae529a35d379" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_f59e4ba9-8071-45e7-9482-686ba4454146" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bbb45c27-dbf3-42a6-99e0-ae529a35d379" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_f59e4ba9-8071-45e7-9482-686ba4454146" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_33c89212-7e3f-4266-befa-438535665556" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f59e4ba9-8071-45e7-9482-686ba4454146" xlink:to="loc_srt_RangeAxis_33c89212-7e3f-4266-befa-438535665556" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_33c89212-7e3f-4266-befa-438535665556_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_33c89212-7e3f-4266-befa-438535665556" xlink:to="loc_srt_RangeMember_33c89212-7e3f-4266-befa-438535665556_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2943c26d-9253-4fb7-a386-58e147a96ebc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_33c89212-7e3f-4266-befa-438535665556" xlink:to="loc_srt_RangeMember_2943c26d-9253-4fb7-a386-58e147a96ebc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_513ed6b0-3240-448c-8a00-74d3f7b84c4c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2943c26d-9253-4fb7-a386-58e147a96ebc" xlink:to="loc_srt_MaximumMember_513ed6b0-3240-448c-8a00-74d3f7b84c4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e7a17ece-9443-4d91-be52-a29921253fde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bbb45c27-dbf3-42a6-99e0-ae529a35d379" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e7a17ece-9443-4d91-be52-a29921253fde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ec7e164a-c973-4454-a6e7-088dcd94df9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bbb45c27-dbf3-42a6-99e0-ae529a35d379" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ec7e164a-c973-4454-a6e7-088dcd94df9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_0ea9ca2c-b573-44a0-ab62-1301ec4624d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bbb45c27-dbf3-42a6-99e0-ae529a35d379" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_0ea9ca2c-b573-44a0-ab62-1301ec4624d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d37be72f-0bcc-4d85-8781-c7e9d6e8737e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bbb45c27-dbf3-42a6-99e0-ae529a35d379" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d37be72f-0bcc-4d85-8781-c7e9d6e8737e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_3bd54559-744a-4865-b78f-12d5706a837d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bbb45c27-dbf3-42a6-99e0-ae529a35d379" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_3bd54559-744a-4865-b78f-12d5706a837d" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#IncomeTaxesNominalTaxRateReconciliationDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncomeTaxDisclosureLineItems_600cd2c8-2589-4e9a-9591-d1e9110cf7d7" xlink:href="ci-20231231.xsd#ci_IncomeTaxDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncomeTaxDisclosureTable_0efea929-4a88-443d-a9a2-2eaca40f9e59" xlink:href="ci-20231231.xsd#ci_IncomeTaxDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ci_IncomeTaxDisclosureLineItems_600cd2c8-2589-4e9a-9591-d1e9110cf7d7" xlink:to="loc_ci_IncomeTaxDisclosureTable_0efea929-4a88-443d-a9a2-2eaca40f9e59" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_3d2ad9ef-0e93-4fc8-9e3e-233e75c74431" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ci_IncomeTaxDisclosureTable_0efea929-4a88-443d-a9a2-2eaca40f9e59" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_3d2ad9ef-0e93-4fc8-9e3e-233e75c74431" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_3d2ad9ef-0e93-4fc8-9e3e-233e75c74431_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_3d2ad9ef-0e93-4fc8-9e3e-233e75c74431" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_3d2ad9ef-0e93-4fc8-9e3e-233e75c74431_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_073c6a40-fe09-4dfd-9ff7-4997f7a72ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_3d2ad9ef-0e93-4fc8-9e3e-233e75c74431" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_073c6a40-fe09-4dfd-9ff7-4997f7a72ebc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_d3dfb467-93fa-40ea-9e06-b3e133bdedbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_073c6a40-fe09-4dfd-9ff7-4997f7a72ebc" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_d3dfb467-93fa-40ea-9e06-b3e133bdedbd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_48ea7e87-d431-491f-92b2-fecc262ecb15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_073c6a40-fe09-4dfd-9ff7-4997f7a72ebc" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_48ea7e87-d431-491f-92b2-fecc262ecb15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2a5d62c9-97b9-4b87-9987-c575e8fb208d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ci_IncomeTaxDisclosureTable_0efea929-4a88-443d-a9a2-2eaca40f9e59" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2a5d62c9-97b9-4b87-9987-c575e8fb208d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2a5d62c9-97b9-4b87-9987-c575e8fb208d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2a5d62c9-97b9-4b87-9987-c575e8fb208d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2a5d62c9-97b9-4b87-9987-c575e8fb208d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cb3eef26-f3a5-4751-be0a-92dd6cba671b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2a5d62c9-97b9-4b87-9987-c575e8fb208d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cb3eef26-f3a5-4751-be0a-92dd6cba671b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_8ee643af-7422-400e-ba93-4ec0d37412f8" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cb3eef26-f3a5-4751-be0a-92dd6cba671b" xlink:to="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_8ee643af-7422-400e-ba93-4ec0d37412f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember_d7bfaafc-266c-457d-86e0-6b0f63996212" xlink:href="ci-20231231.xsd#ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cb3eef26-f3a5-4751-be0a-92dd6cba671b" xlink:to="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember_d7bfaafc-266c-457d-86e0-6b0f63996212" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70c94002-7f91-46d7-832e-a2f2dfb0cae1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_IncomeTaxDisclosureLineItems_600cd2c8-2589-4e9a-9591-d1e9110cf7d7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70c94002-7f91-46d7-832e-a2f2dfb0cae1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_71bb0cd0-81fc-4c82-b6a9-c0009dfefdc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70c94002-7f91-46d7-832e-a2f2dfb0cae1" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_71bb0cd0-81fc-4c82-b6a9-c0009dfefdc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_2cc6309a-17a1-4834-b722-811c2c6cefe8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationDispositionOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70c94002-7f91-46d7-832e-a2f2dfb0cae1" xlink:to="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_2cc6309a-17a1-4834-b722-811c2c6cefe8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings_cff2ad61-b7fd-4b3c-818b-233618f7b621" xlink:href="ci-20231231.xsd#ci_IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70c94002-7f91-46d7-832e-a2f2dfb0cae1" xlink:to="loc_ci_IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings_cff2ad61-b7fd-4b3c-818b-233618f7b621" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncomeTaxReconciliationHealthInsuranceIndustryTax_385dbb6a-48ba-45f7-a6c7-a02bb0a69bea" xlink:href="ci-20231231.xsd#ci_IncomeTaxReconciliationHealthInsuranceIndustryTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70c94002-7f91-46d7-832e-a2f2dfb0cae1" xlink:to="loc_ci_IncomeTaxReconciliationHealthInsuranceIndustryTax_385dbb6a-48ba-45f7-a6c7-a02bb0a69bea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_59c20e55-ca6a-4b94-a626-dfedeffc77c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70c94002-7f91-46d7-832e-a2f2dfb0cae1" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_59c20e55-ca6a-4b94-a626-dfedeffc77c9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount_5ec43ffd-63d6-4f20-9fd9-aa7c23477b1b" xlink:href="ci-20231231.xsd#ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70c94002-7f91-46d7-832e-a2f2dfb0cae1" xlink:to="loc_ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount_5ec43ffd-63d6-4f20-9fd9-aa7c23477b1b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount_2872e8d3-78d6-4fe7-8dfd-8fb49a9c69d5" xlink:href="ci-20231231.xsd#ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70c94002-7f91-46d7-832e-a2f2dfb0cae1" xlink:to="loc_ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount_2872e8d3-78d6-4fe7-8dfd-8fb49a9c69d5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_95f8363a-ca80-44fe-ace3-76d81caaa927" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70c94002-7f91-46d7-832e-a2f2dfb0cae1" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_95f8363a-ca80-44fe-ace3-76d81caaa927" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_370c2ed0-d5e7-4985-96a8-6d85557dcc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70c94002-7f91-46d7-832e-a2f2dfb0cae1" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_370c2ed0-d5e7-4985-96a8-6d85557dcc4d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_63056b4e-57ed-4cc4-946b-31837b4ea666" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70c94002-7f91-46d7-832e-a2f2dfb0cae1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_63056b4e-57ed-4cc4-946b-31837b4ea666" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0074dadf-c389-4b33-bfe3-627ce7cb4978" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_IncomeTaxDisclosureLineItems_600cd2c8-2589-4e9a-9591-d1e9110cf7d7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0074dadf-c389-4b33-bfe3-627ce7cb4978" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7b812808-3bc3-40ac-9cd4-ebdb122f7a92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0074dadf-c389-4b33-bfe3-627ce7cb4978" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7b812808-3bc3-40ac-9cd4-ebdb122f7a92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_37c03290-eb01-4088-a456-535d72992d83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0074dadf-c389-4b33-bfe3-627ce7cb4978" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_37c03290-eb01-4088-a456-535d72992d83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings_ba8ac23e-a5e7-4915-9dc5-30c054d0adb4" xlink:href="ci-20231231.xsd#ci_EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0074dadf-c389-4b33-bfe3-627ce7cb4978" xlink:to="loc_ci_EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings_ba8ac23e-a5e7-4915-9dc5-30c054d0adb4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EffectiveIncomeTaxRateReconciliationHealthInsuranceIndustryTax_cc22b4c1-53af-425d-b844-e4c47855b7ec" xlink:href="ci-20231231.xsd#ci_EffectiveIncomeTaxRateReconciliationHealthInsuranceIndustryTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0074dadf-c389-4b33-bfe3-627ce7cb4978" xlink:to="loc_ci_EffectiveIncomeTaxRateReconciliationHealthInsuranceIndustryTax_cc22b4c1-53af-425d-b844-e4c47855b7ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_b43f2be6-0358-494d-84f5-58fd4dbcf7ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0074dadf-c389-4b33-bfe3-627ce7cb4978" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_b43f2be6-0358-494d-84f5-58fd4dbcf7ee" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent_f417f050-c946-461a-a6fc-cd0e8f772844" xlink:href="ci-20231231.xsd#ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0074dadf-c389-4b33-bfe3-627ce7cb4978" xlink:to="loc_ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent_f417f050-c946-461a-a6fc-cd0e8f772844" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent_e1e31c04-1b7b-4c38-a02e-3488293f6ed2" xlink:href="ci-20231231.xsd#ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0074dadf-c389-4b33-bfe3-627ce7cb4978" xlink:to="loc_ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent_e1e31c04-1b7b-4c38-a02e-3488293f6ed2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_5a8ea0aa-5b64-4d1b-8cf5-98a6cf46f840" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0074dadf-c389-4b33-bfe3-627ce7cb4978" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_5a8ea0aa-5b64-4d1b-8cf5-98a6cf46f840" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_e5860973-8d86-406e-b101-bf49a12702da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0074dadf-c389-4b33-bfe3-627ce7cb4978" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_e5860973-8d86-406e-b101-bf49a12702da" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_fe5eb65e-6ce0-45d1-a015-68c960597c74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0074dadf-c389-4b33-bfe3-627ce7cb4978" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_fe5eb65e-6ce0-45d1-a015-68c960597c74" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/IncomeTaxesPretaxIncomeFromForeignOperationsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#IncomeTaxesPretaxIncomeFromForeignOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/IncomeTaxesPretaxIncomeFromForeignOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_3ee75cfb-d431-429d-9958-c98be7ed8f58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_bf10e7c4-fc60-4bd9-9fed-0d787f1da08d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_3ee75cfb-d431-429d-9958-c98be7ed8f58" xlink:to="loc_us-gaap_ConcentrationRiskTable_bf10e7c4-fc60-4bd9-9fed-0d787f1da08d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_77036fdf-7edc-4512-aadc-e9e706c00e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_bf10e7c4-fc60-4bd9-9fed-0d787f1da08d" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_77036fdf-7edc-4512-aadc-e9e706c00e5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_77036fdf-7edc-4512-aadc-e9e706c00e5c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_77036fdf-7edc-4512-aadc-e9e706c00e5c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_77036fdf-7edc-4512-aadc-e9e706c00e5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fd656535-cf14-4815-a59f-fdb4bda15e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_77036fdf-7edc-4512-aadc-e9e706c00e5c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fd656535-cf14-4815-a59f-fdb4bda15e0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncomeBeforeTaxesMember_48d77d6b-1f85-45cf-a823-8856a90424bc" xlink:href="ci-20231231.xsd#ci_IncomeBeforeTaxesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fd656535-cf14-4815-a59f-fdb4bda15e0c" xlink:to="loc_ci_IncomeBeforeTaxesMember_48d77d6b-1f85-45cf-a823-8856a90424bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_d23c2402-611a-4272-b6e2-7e72834b73bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_bf10e7c4-fc60-4bd9-9fed-0d787f1da08d" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_d23c2402-611a-4272-b6e2-7e72834b73bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_d23c2402-611a-4272-b6e2-7e72834b73bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_d23c2402-611a-4272-b6e2-7e72834b73bd" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_d23c2402-611a-4272-b6e2-7e72834b73bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_00693308-38c6-4cb1-801f-786e192a9d74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_d23c2402-611a-4272-b6e2-7e72834b73bd" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_00693308-38c6-4cb1-801f-786e192a9d74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_c19a6a3c-40a7-480e-afaf-7a554f7866ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_00693308-38c6-4cb1-801f-786e192a9d74" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_c19a6a3c-40a7-480e-afaf-7a554f7866ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionAxis_f52379b5-554e-4d5c-8669-a0e5e23eadec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicDistributionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_bf10e7c4-fc60-4bd9-9fed-0d787f1da08d" xlink:to="loc_us-gaap_GeographicDistributionAxis_f52379b5-554e-4d5c-8669-a0e5e23eadec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionDomain_f52379b5-554e-4d5c-8669-a0e5e23eadec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicDistributionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GeographicDistributionAxis_f52379b5-554e-4d5c-8669-a0e5e23eadec" xlink:to="loc_us-gaap_GeographicDistributionDomain_f52379b5-554e-4d5c-8669-a0e5e23eadec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionDomain_3bb8be2e-364d-4f47-8caa-bb7a0308d79d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicDistributionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GeographicDistributionAxis_f52379b5-554e-4d5c-8669-a0e5e23eadec" xlink:to="loc_us-gaap_GeographicDistributionDomain_3bb8be2e-364d-4f47-8caa-bb7a0308d79d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionForeignMember_bc8cc37f-f40e-47bc-baf4-ba584a0d0a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicDistributionForeignMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GeographicDistributionDomain_3bb8be2e-364d-4f47-8caa-bb7a0308d79d" xlink:to="loc_us-gaap_GeographicDistributionForeignMember_bc8cc37f-f40e-47bc-baf4-ba584a0d0a3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_7948fb1f-a714-4eff-9328-e8fea5b5a88c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_3ee75cfb-d431-429d-9958-c98be7ed8f58" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_7948fb1f-a714-4eff-9328-e8fea5b5a88c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/IncomeTaxesForeignJurisdictionTaxAttributesandSaleofMedicareAdvantageandRelatedBusinessesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#IncomeTaxesForeignJurisdictionTaxAttributesandSaleofMedicareAdvantageandRelatedBusinessesDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/IncomeTaxesForeignJurisdictionTaxAttributesandSaleofMedicareAdvantageandRelatedBusinessesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f82bc7ae-1c5e-4766-8f79-2c487ff3586a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4425785a-a4e0-45c7-a5b8-8457329d9aec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f82bc7ae-1c5e-4766-8f79-2c487ff3586a" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4425785a-a4e0-45c7-a5b8-8457329d9aec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_9153fd1f-80b0-4434-bf2d-2c212c91a62f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4425785a-a4e0-45c7-a5b8-8457329d9aec" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_9153fd1f-80b0-4434-bf2d-2c212c91a62f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_9153fd1f-80b0-4434-bf2d-2c212c91a62f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9153fd1f-80b0-4434-bf2d-2c212c91a62f" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_9153fd1f-80b0-4434-bf2d-2c212c91a62f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ffa05469-a518-4b25-9911-0d912dd10c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9153fd1f-80b0-4434-bf2d-2c212c91a62f" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ffa05469-a518-4b25-9911-0d912dd10c6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_165931e6-a79a-4d25-a695-e5bf3ac4a679" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_ffa05469-a518-4b25-9911-0d912dd10c6d" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_165931e6-a79a-4d25-a695-e5bf3ac4a679" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a236bf07-68cc-4170-ba45-d274e9f1daad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4425785a-a4e0-45c7-a5b8-8457329d9aec" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a236bf07-68cc-4170-ba45-d274e9f1daad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a236bf07-68cc-4170-ba45-d274e9f1daad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a236bf07-68cc-4170-ba45-d274e9f1daad" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a236bf07-68cc-4170-ba45-d274e9f1daad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_22c96bb3-6724-4645-afea-acc0db7e9507" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a236bf07-68cc-4170-ba45-d274e9f1daad" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_22c96bb3-6724-4645-afea-acc0db7e9507" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_a1ba6aec-cfcb-4fc3-bc44-8d717e678b76" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_22c96bb3-6724-4645-afea-acc0db7e9507" xlink:to="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_a1ba6aec-cfcb-4fc3-bc44-8d717e678b76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_ae668793-e91c-4c53-a7a5-da04d7ec5ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f82bc7ae-1c5e-4766-8f79-2c487ff3586a" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_ae668793-e91c-4c53-a7a5-da04d7ec5ef9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_fab27700-70d7-4145-b9fc-3d94db20e602" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f82bc7ae-1c5e-4766-8f79-2c487ff3586a" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_fab27700-70d7-4145-b9fc-3d94db20e602" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#IncomeTaxesDeferredIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncomeTaxDisclosureLineItems_48ccdf2a-28d9-46fc-b64c-bfcd03f4c275" xlink:href="ci-20231231.xsd#ci_IncomeTaxDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncomeTaxDisclosureTable_e62a3e3f-6275-4543-a604-0d2dace787a8" xlink:href="ci-20231231.xsd#ci_IncomeTaxDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ci_IncomeTaxDisclosureLineItems_48ccdf2a-28d9-46fc-b64c-bfcd03f4c275" xlink:to="loc_ci_IncomeTaxDisclosureTable_e62a3e3f-6275-4543-a604-0d2dace787a8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_71e40927-fd0e-4725-ada6-94b22a258eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ci_IncomeTaxDisclosureTable_e62a3e3f-6275-4543-a604-0d2dace787a8" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_71e40927-fd0e-4725-ada6-94b22a258eb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_71e40927-fd0e-4725-ada6-94b22a258eb2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_71e40927-fd0e-4725-ada6-94b22a258eb2" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_71e40927-fd0e-4725-ada6-94b22a258eb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_eb7d0659-4754-4012-bb34-b53011930611" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_71e40927-fd0e-4725-ada6-94b22a258eb2" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_eb7d0659-4754-4012-bb34-b53011930611" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_a68c2433-cf7b-4e12-85a1-0aecbd5ad834" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_eb7d0659-4754-4012-bb34-b53011930611" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_a68c2433-cf7b-4e12-85a1-0aecbd5ad834" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_29f87912-1ff0-4ca4-86b2-0f57f25bd946" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ci_IncomeTaxDisclosureTable_e62a3e3f-6275-4543-a604-0d2dace787a8" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_29f87912-1ff0-4ca4-86b2-0f57f25bd946" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_29f87912-1ff0-4ca4-86b2-0f57f25bd946_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_29f87912-1ff0-4ca4-86b2-0f57f25bd946" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_29f87912-1ff0-4ca4-86b2-0f57f25bd946_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_554bb828-d461-4f07-8702-5bf251f172f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_29f87912-1ff0-4ca4-86b2-0f57f25bd946" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_554bb828-d461-4f07-8702-5bf251f172f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_099193b6-b1b1-4985-8984-6654058e2dfd" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_554bb828-d461-4f07-8702-5bf251f172f8" xlink:to="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_099193b6-b1b1-4985-8984-6654058e2dfd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5e61f79e-40b4-4a09-b5c4-76345b6b585b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_IncomeTaxDisclosureLineItems_48ccdf2a-28d9-46fc-b64c-bfcd03f4c275" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5e61f79e-40b4-4a09-b5c4-76345b6b585b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_e2f58077-721d-4fee-bba1-213d016b7545" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5e61f79e-40b4-4a09-b5c4-76345b6b585b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_e2f58077-721d-4fee-bba1-213d016b7545" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities_85867eaf-99a3-46da-9ad5-e9fa3ca7c2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5e61f79e-40b4-4a09-b5c4-76345b6b585b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities_85867eaf-99a3-46da-9ad5-e9fa3ca7c2e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_28237ccc-adff-4454-bff8-e4c797618c03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5e61f79e-40b4-4a09-b5c4-76345b6b585b" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_28237ccc-adff-4454-bff8-e4c797618c03" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_ff9e0e24-d01e-4382-96cf-1ef15b3a2c20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5e61f79e-40b4-4a09-b5c4-76345b6b585b" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_ff9e0e24-d01e-4382-96cf-1ef15b3a2c20" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_6e85ebb9-c887-401e-8867-8b7dc647c917" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5e61f79e-40b4-4a09-b5c4-76345b6b585b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_6e85ebb9-c887-401e-8867-8b7dc647c917" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsPolicyAcquisitionExpenses_73b9177a-3ee6-4ea9-965c-88d8da5da932" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsPolicyAcquisitionExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5e61f79e-40b4-4a09-b5c4-76345b6b585b" xlink:to="loc_ci_DeferredTaxAssetsPolicyAcquisitionExpenses_73b9177a-3ee6-4ea9-965c-88d8da5da932" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTranslation_cfe6f5c9-e0be-40b5-82b1-849db42769f7" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTranslation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5e61f79e-40b4-4a09-b5c4-76345b6b585b" xlink:to="loc_ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTranslation_cfe6f5c9-e0be-40b5-82b1-849db42769f7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsForeignTaxAttributes_e67e1c05-d64a-4bb6-b2d7-0ce245f749d6" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsForeignTaxAttributes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5e61f79e-40b4-4a09-b5c4-76345b6b585b" xlink:to="loc_ci_DeferredTaxAssetsForeignTaxAttributes_e67e1c05-d64a-4bb6-b2d7-0ce245f749d6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_38bac068-cdec-46c9-b557-a794140369ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5e61f79e-40b4-4a09-b5c4-76345b6b585b" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_38bac068-cdec-46c9-b557-a794140369ee" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_285be239-c373-4390-aed2-0b8a4edcfbde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5e61f79e-40b4-4a09-b5c4-76345b6b585b" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_285be239-c373-4390-aed2-0b8a4edcfbde" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2bf74426-bd79-4810-8fe4-5128cb59a03c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5e61f79e-40b4-4a09-b5c4-76345b6b585b" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2bf74426-bd79-4810-8fe4-5128cb59a03c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_ec338cdf-31e7-470a-b09b-421b66558bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5e61f79e-40b4-4a09-b5c4-76345b6b585b" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_ec338cdf-31e7-470a-b09b-421b66558bf9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract_24b35941-0125-41c1-854e-10cefe11dd00" xlink:href="ci-20231231.xsd#ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_IncomeTaxDisclosureLineItems_48ccdf2a-28d9-46fc-b64c-bfcd03f4c275" xlink:to="loc_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract_24b35941-0125-41c1-854e-10cefe11dd00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIncludingDisposalGroupsAssetsHeldForSale_808b80b7-03bc-4b73-b42a-81ca03038b83" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract_24b35941-0125-41c1-854e-10cefe11dd00" xlink:to="loc_ci_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIncludingDisposalGroupsAssetsHeldForSale_808b80b7-03bc-4b73-b42a-81ca03038b83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilitiesIncludingDisposalGroupsAssetsHeldForSale_eafee7d2-aa2e-4edd-b89f-4dcedec1a923" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilitiesIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract_24b35941-0125-41c1-854e-10cefe11dd00" xlink:to="loc_ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilitiesIncludingDisposalGroupsAssetsHeldForSale_eafee7d2-aa2e-4edd-b89f-4dcedec1a923" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsOperatingLossCarryforwardsIncludingDisposalGroupsAssetsHeldForSale_26aa65f1-8f91-447e-b325-58d8807ee2f5" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsOperatingLossCarryforwardsIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract_24b35941-0125-41c1-854e-10cefe11dd00" xlink:to="loc_ci_DeferredTaxAssetsOperatingLossCarryforwardsIncludingDisposalGroupsAssetsHeldForSale_26aa65f1-8f91-447e-b325-58d8807ee2f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_35e43ea7-e816-4f18-a27e-246937e69e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOtherIncludingDisposalGroupsAssetsHeldForSale_f4d74fa8-1bf4-40b2-a2e1-5b54e9c057cd" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOtherIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract_24b35941-0125-41c1-854e-10cefe11dd00" xlink:to="loc_ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOtherIncludingDisposalGroupsAssetsHeldForSale_f4d74fa8-1bf4-40b2-a2e1-5b54e9c057cd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsPolicyAcquisitionExpensesIncludingDisposalGroupsAssetsHeldForSale_68dc0201-4efd-4680-8adf-ce03518268d4" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsPolicyAcquisitionExpensesIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract_24b35941-0125-41c1-854e-10cefe11dd00" xlink:to="loc_ci_DeferredTaxAssetsPolicyAcquisitionExpensesIncludingDisposalGroupsAssetsHeldForSale_68dc0201-4efd-4680-8adf-ce03518268d4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTransactionIncludingDisposalGroupsAssetsHeldForSale_b07c8a6f-37b2-4a84-a907-8ab6a4c0e835" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTransactionIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract_24b35941-0125-41c1-854e-10cefe11dd00" xlink:to="loc_ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTransactionIncludingDisposalGroupsAssetsHeldForSale_b07c8a6f-37b2-4a84-a907-8ab6a4c0e835" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsForeignTaxAttributesIncludingDisposalGroupsAssetsHeldForSale_92740912-39bd-4545-a1fa-65f6498a463f" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsForeignTaxAttributesIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract_24b35941-0125-41c1-854e-10cefe11dd00" xlink:to="loc_ci_DeferredTaxAssetsForeignTaxAttributesIncludingDisposalGroupsAssetsHeldForSale_92740912-39bd-4545-a1fa-65f6498a463f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsOtherIncludingDisposalGroupsAssetsHeldForSale_3acb3742-83b3-4133-bd98-b3b30c25addf" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsOtherIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract_24b35941-0125-41c1-854e-10cefe11dd00" xlink:to="loc_ci_DeferredTaxAssetsOtherIncludingDisposalGroupsAssetsHeldForSale_3acb3742-83b3-4133-bd98-b3b30c25addf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale_050cad33-79b9-43ee-9327-639cd7534345" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract_24b35941-0125-41c1-854e-10cefe11dd00" xlink:to="loc_ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale_050cad33-79b9-43ee-9327-639cd7534345" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale_eb25f0de-c8e2-4900-91df-67c45ba509ab" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract_24b35941-0125-41c1-854e-10cefe11dd00" xlink:to="loc_ci_DeferredTaxAssetsValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale_eb25f0de-c8e2-4900-91df-67c45ba509ab" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale_0501e8b0-c939-47b3-9616-c0e1b68e0372" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract_24b35941-0125-41c1-854e-10cefe11dd00" xlink:to="loc_ci_DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale_0501e8b0-c939-47b3-9616-c0e1b68e0372" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f7b5aab8-295e-4f2e-a13c-566e22562f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_IncomeTaxDisclosureLineItems_48ccdf2a-28d9-46fc-b64c-bfcd03f4c275" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f7b5aab8-295e-4f2e-a13c-566e22562f1c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_ed9a29e9-d0a7-436c-8617-400df05fb619" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f7b5aab8-295e-4f2e-a13c-566e22562f1c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_ed9a29e9-d0a7-436c-8617-400df05fb619" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_a0b91cec-1a4b-4fae-a11d-5b52b134c94d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f7b5aab8-295e-4f2e-a13c-566e22562f1c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_a0b91cec-1a4b-4fae-a11d-5b52b134c94d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost_76d559dc-e5fb-4e6e-8170-93590aaf0b71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f7b5aab8-295e-4f2e-a13c-566e22562f1c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost_76d559dc-e5fb-4e6e-8170-93590aaf0b71" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGains_a9da800e-db53-4c28-a379-616ff09bd1d0" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGains"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f7b5aab8-295e-4f2e-a13c-566e22562f1c" xlink:to="loc_ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGains_a9da800e-db53-4c28-a379-616ff09bd1d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_8f0c0400-bd1e-4d5e-b968-9dfdbe89b0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f7b5aab8-295e-4f2e-a13c-566e22562f1c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_8f0c0400-bd1e-4d5e-b968-9dfdbe89b0bc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_e70cb22e-f537-43c1-8177-c12cb0ed4edd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f7b5aab8-295e-4f2e-a13c-566e22562f1c" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_e70cb22e-f537-43c1-8177-c12cb0ed4edd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract_83c9f6ce-6f84-4756-813c-fd1d4b42430a" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_IncomeTaxDisclosureLineItems_48ccdf2a-28d9-46fc-b64c-bfcd03f4c275" xlink:to="loc_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract_83c9f6ce-6f84-4756-813c-fd1d4b42430a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesPropertyPlantAndEquipmentIncludingDisposalGroupsAssetsHeldForSale_aba65e5e-685d-4dcb-b8a8-93375df788d6" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesPropertyPlantAndEquipmentIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract_83c9f6ce-6f84-4756-813c-fd1d4b42430a" xlink:to="loc_ci_DeferredTaxLiabilitiesPropertyPlantAndEquipmentIncludingDisposalGroupsAssetsHeldForSale_aba65e5e-685d-4dcb-b8a8-93375df788d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIncludingDisposalGroupsAssetsHeldForSale_74eb4ac5-79f2-4bd4-9edf-5555ae284281" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract_83c9f6ce-6f84-4756-813c-fd1d4b42430a" xlink:to="loc_ci_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIncludingDisposalGroupsAssetsHeldForSale_74eb4ac5-79f2-4bd4-9edf-5555ae284281" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCostIncludingDisposalGroupsAssetsHeldForSale_d0740fa9-92aa-450d-8fc2-d3358da9aa94" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCostIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract_83c9f6ce-6f84-4756-813c-fd1d4b42430a" xlink:to="loc_ci_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCostIncludingDisposalGroupsAssetsHeldForSale_d0740fa9-92aa-450d-8fc2-d3358da9aa94" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGainsIncludingDisposalGroupsAssetsHeldForSale_c1257d86-1660-4881-8097-6ff45a13df84" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGainsIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract_83c9f6ce-6f84-4756-813c-fd1d4b42430a" xlink:to="loc_ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGainsIncludingDisposalGroupsAssetsHeldForSale_c1257d86-1660-4881-8097-6ff45a13df84" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesOtherIncludingDisposalGroupsAssetsHeldForSale_d8adbbc3-185a-4725-af6f-e30a8225349f" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesOtherIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract_83c9f6ce-6f84-4756-813c-fd1d4b42430a" xlink:to="loc_ci_DeferredTaxLiabilitiesOtherIncludingDisposalGroupsAssetsHeldForSale_d8adbbc3-185a-4725-af6f-e30a8225349f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale_c1da6fc9-910f-4ed7-9cf8-14c7460e83cf" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract_83c9f6ce-6f84-4756-813c-fd1d4b42430a" xlink:to="loc_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale_c1da6fc9-910f-4ed7-9cf8-14c7460e83cf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesNetIncludingDisposalGroup_5c302276-7aa4-4f04-8654-f167079301ee" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesNetIncludingDisposalGroup"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_IncomeTaxDisclosureLineItems_48ccdf2a-28d9-46fc-b64c-bfcd03f4c275" xlink:to="loc_ci_DeferredTaxLiabilitiesNetIncludingDisposalGroup_5c302276-7aa4-4f04-8654-f167079301ee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_8b521453-063b-4f88-87fc-c8196079f703" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_IncomeTaxDisclosureLineItems_48ccdf2a-28d9-46fc-b64c-bfcd03f4c275" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_8b521453-063b-4f88-87fc-c8196079f703" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_2c119b5e-480e-4c36-b27c-c8794cffff85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_IncomeTaxDisclosureLineItems_48ccdf2a-28d9-46fc-b64c-bfcd03f4c275" xlink:to="loc_us-gaap_DeferredTaxLiabilities_2c119b5e-480e-4c36-b27c-c8794cffff85" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsGrossInOtherAssetsNoncurrent_99f00a1a-1b04-4b55-b14f-c65be03093db" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsGrossInOtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_IncomeTaxDisclosureLineItems_48ccdf2a-28d9-46fc-b64c-bfcd03f4c275" xlink:to="loc_ci_DeferredTaxAssetsGrossInOtherAssetsNoncurrent_99f00a1a-1b04-4b55-b14f-c65be03093db" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsInvestmentsSubjectToFederalCapitalLossUtilizationRules_621787e6-a7f8-41c0-82e7-7d2e89ebf196" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsInvestmentsSubjectToFederalCapitalLossUtilizationRules"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_IncomeTaxDisclosureLineItems_48ccdf2a-28d9-46fc-b64c-bfcd03f4c275" xlink:to="loc_ci_DeferredTaxAssetsInvestmentsSubjectToFederalCapitalLossUtilizationRules_621787e6-a7f8-41c0-82e7-7d2e89ebf196" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#ContingenciesandOtherMattersDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_CommitmentsAndContingenciesLineItems_4f7de799-ae5c-4205-a5a9-1533b1fdbd86" xlink:href="ci-20231231.xsd#ci_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CommitmentsAndContingenciesTable_06c8151f-4952-4105-90e7-4927c8d4225c" xlink:href="ci-20231231.xsd#ci_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems_4f7de799-ae5c-4205-a5a9-1533b1fdbd86" xlink:to="loc_ci_CommitmentsAndContingenciesTable_06c8151f-4952-4105-90e7-4927c8d4225c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_48868583-ace5-454a-8877-1deb87019a39" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ci_CommitmentsAndContingenciesTable_06c8151f-4952-4105-90e7-4927c8d4225c" xlink:to="loc_srt_ProductOrServiceAxis_48868583-ace5-454a-8877-1deb87019a39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_48868583-ace5-454a-8877-1deb87019a39_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_48868583-ace5-454a-8877-1deb87019a39" xlink:to="loc_srt_ProductsAndServicesDomain_48868583-ace5-454a-8877-1deb87019a39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_449a7a9b-a7ea-4b4f-92a9-2e85e5c0ed75" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_48868583-ace5-454a-8877-1deb87019a39" xlink:to="loc_srt_ProductsAndServicesDomain_449a7a9b-a7ea-4b4f-92a9-2e85e5c0ed75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RetirementAndLifeInsuranceContractsMember_fd25d8a7-35bb-4920-ad17-7bb3cce9eed4" xlink:href="ci-20231231.xsd#ci_RetirementAndLifeInsuranceContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_449a7a9b-a7ea-4b4f-92a9-2e85e5c0ed75" xlink:to="loc_ci_RetirementAndLifeInsuranceContractsMember_fd25d8a7-35bb-4920-ad17-7bb3cce9eed4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis_6e461fd5-b3cd-4ebb-a654-a78e490e218e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsByNatureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ci_CommitmentsAndContingenciesTable_06c8151f-4952-4105-90e7-4927c8d4225c" xlink:to="loc_us-gaap_GuaranteeObligationsByNatureAxis_6e461fd5-b3cd-4ebb-a654-a78e490e218e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_6e461fd5-b3cd-4ebb-a654-a78e490e218e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_6e461fd5-b3cd-4ebb-a654-a78e490e218e" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_6e461fd5-b3cd-4ebb-a654-a78e490e218e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_e4416ac9-3975-492f-b8ec-41a98c808bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_6e461fd5-b3cd-4ebb-a654-a78e490e218e" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_e4416ac9-3975-492f-b8ec-41a98c808bb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialGuaranteeMember_832cb212-fa5b-4d87-8d91-de8cd802c4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialGuaranteeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain_e4416ac9-3975-492f-b8ec-41a98c808bb4" xlink:to="loc_us-gaap_FinancialGuaranteeMember_832cb212-fa5b-4d87-8d91-de8cd802c4c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember_f55038b5-c7ce-4ea0-9e96-e992a9497f95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndemnificationGuaranteeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain_e4416ac9-3975-492f-b8ec-41a98c808bb4" xlink:to="loc_us-gaap_IndemnificationGuaranteeMember_f55038b5-c7ce-4ea0-9e96-e992a9497f95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_d04f5a91-efdf-4805-9428-fc72e2ad0d79" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ci_CommitmentsAndContingenciesTable_06c8151f-4952-4105-90e7-4927c8d4225c" xlink:to="loc_srt_LitigationCaseAxis_d04f5a91-efdf-4805-9428-fc72e2ad0d79" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d04f5a91-efdf-4805-9428-fc72e2ad0d79_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_d04f5a91-efdf-4805-9428-fc72e2ad0d79" xlink:to="loc_srt_LitigationCaseTypeDomain_d04f5a91-efdf-4805-9428-fc72e2ad0d79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_068eaeaf-5905-4542-b3f1-b667d4c1e360" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_d04f5a91-efdf-4805-9428-fc72e2ad0d79" xlink:to="loc_srt_LitigationCaseTypeDomain_068eaeaf-5905-4542-b3f1-b667d4c1e360" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ExpressScriptsLitigationWithElevanceMember_cbd72139-f1f2-4c00-b0f7-06ee425f81d7" xlink:href="ci-20231231.xsd#ci_ExpressScriptsLitigationWithElevanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_068eaeaf-5905-4542-b3f1-b667d4c1e360" xlink:to="loc_ci_ExpressScriptsLitigationWithElevanceMember_cbd72139-f1f2-4c00-b0f7-06ee425f81d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ExpressScriptsCounterclaimsAgainstElevanceMember_b14073d9-70ac-40c8-8812-61239079e544" xlink:href="ci-20231231.xsd#ci_ExpressScriptsCounterclaimsAgainstElevanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ExpressScriptsLitigationWithElevanceMember_cbd72139-f1f2-4c00-b0f7-06ee425f81d7" xlink:to="loc_ci_ExpressScriptsCounterclaimsAgainstElevanceMember_b14073d9-70ac-40c8-8812-61239079e544" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageLitigationPrivateIndividualMember_4038d068-d058-45c7-93fa-afe85e554158" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageLitigationPrivateIndividualMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_068eaeaf-5905-4542-b3f1-b667d4c1e360" xlink:to="loc_ci_MedicareAdvantageLitigationPrivateIndividualMember_4038d068-d058-45c7-93fa-afe85e554158" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageLitigationDepartmentOfJusticeInvestigationsMember_d6b6b7bc-822d-4b74-941c-68245f615aa8" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageLitigationDepartmentOfJusticeInvestigationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_068eaeaf-5905-4542-b3f1-b667d4c1e360" xlink:to="loc_ci_MedicareAdvantageLitigationDepartmentOfJusticeInvestigationsMember_d6b6b7bc-822d-4b74-941c-68245f615aa8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_2294979a-72f1-4b7d-a042-0d8fe6fcc24f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ci_CommitmentsAndContingenciesTable_06c8151f-4952-4105-90e7-4927c8d4225c" xlink:to="loc_us-gaap_LitigationStatusAxis_2294979a-72f1-4b7d-a042-0d8fe6fcc24f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_2294979a-72f1-4b7d-a042-0d8fe6fcc24f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_2294979a-72f1-4b7d-a042-0d8fe6fcc24f" xlink:to="loc_us-gaap_LitigationStatusDomain_2294979a-72f1-4b7d-a042-0d8fe6fcc24f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_431c9ba1-7f94-4417-b2f3-1ef641ff673d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_2294979a-72f1-4b7d-a042-0d8fe6fcc24f" xlink:to="loc_us-gaap_LitigationStatusDomain_431c9ba1-7f94-4417-b2f3-1ef641ff673d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JudicialRulingMember_3ad5cd32-cbae-4e75-a315-21972b58d429" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_JudicialRulingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_431c9ba1-7f94-4417-b2f3-1ef641ff673d" xlink:to="loc_us-gaap_JudicialRulingMember_3ad5cd32-cbae-4e75-a315-21972b58d429" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_9cef1bad-7641-4d41-8dc7-3a4dd505ebbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_431c9ba1-7f94-4417-b2f3-1ef641ff673d" xlink:to="loc_us-gaap_PendingLitigationMember_9cef1bad-7641-4d41-8dc7-3a4dd505ebbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_29d08b5e-6519-45ab-a503-ca081738ae15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_431c9ba1-7f94-4417-b2f3-1ef641ff673d" xlink:to="loc_us-gaap_SettledLitigationMember_29d08b5e-6519-45ab-a503-ca081738ae15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_eab5fe5d-b44e-4668-9e53-dc80f72d1994" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ci_CommitmentsAndContingenciesTable_06c8151f-4952-4105-90e7-4927c8d4225c" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_eab5fe5d-b44e-4668-9e53-dc80f72d1994" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_eab5fe5d-b44e-4668-9e53-dc80f72d1994_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_eab5fe5d-b44e-4668-9e53-dc80f72d1994" xlink:to="loc_us-gaap_LossContingencyNatureDomain_eab5fe5d-b44e-4668-9e53-dc80f72d1994_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_8a7e0618-0252-4c76-a328-fa5065b67fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_eab5fe5d-b44e-4668-9e53-dc80f72d1994" xlink:to="loc_us-gaap_LossContingencyNatureDomain_8a7e0618-0252-4c76-a328-fa5065b67fb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PricingConcessionsMember_1f8b06e2-955d-40b4-ae62-6657a39f11e9" xlink:href="ci-20231231.xsd#ci_PricingConcessionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_8a7e0618-0252-4c76-a328-fa5065b67fb1" xlink:to="loc_ci_PricingConcessionsMember_1f8b06e2-955d-40b4-ae62-6657a39f11e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PricingConcessionsThroughRemainingContractTermMember_7bb7685b-9ee0-4127-986b-0f4a21710224" xlink:href="ci-20231231.xsd#ci_PricingConcessionsThroughRemainingContractTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_PricingConcessionsMember_1f8b06e2-955d-40b4-ae62-6657a39f11e9" xlink:to="loc_ci_PricingConcessionsThroughRemainingContractTermMember_7bb7685b-9ee0-4127-986b-0f4a21710224" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PricingConcessionsAfterRemainingTermOfAgreementMember_9fd0c2dc-862f-4d14-ae84-de538debb059" xlink:href="ci-20231231.xsd#ci_PricingConcessionsAfterRemainingTermOfAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_PricingConcessionsMember_1f8b06e2-955d-40b4-ae62-6657a39f11e9" xlink:to="loc_ci_PricingConcessionsAfterRemainingTermOfAgreementMember_9fd0c2dc-862f-4d14-ae84-de538debb059" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DamagesForServiceIssuesMember_1195eca2-92cd-41b2-911a-392608bd2486" xlink:href="ci-20231231.xsd#ci_DamagesForServiceIssuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_8a7e0618-0252-4c76-a328-fa5065b67fb1" xlink:to="loc_ci_DamagesForServiceIssuesMember_1195eca2-92cd-41b2-911a-392608bd2486" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceRelatedAssessmentsMember_a21b5aa0-7025-4968-9b91-59fdea8714bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceRelatedAssessmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_8a7e0618-0252-4c76-a328-fa5065b67fb1" xlink:to="loc_us-gaap_InsuranceRelatedAssessmentsMember_a21b5aa0-7025-4968-9b91-59fdea8714bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LitigationMattersAndRegulatoryMattersMember_ed036c5e-9f9e-4410-b142-8ecba74485b9" xlink:href="ci-20231231.xsd#ci_LitigationMattersAndRegulatoryMattersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_8a7e0618-0252-4c76-a328-fa5065b67fb1" xlink:to="loc_ci_LitigationMattersAndRegulatoryMattersMember_ed036c5e-9f9e-4410-b142-8ecba74485b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_2c6fcb72-5c62-47f2-91a3-e2acb5f75f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsMaximumExposure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems_4f7de799-ae5c-4205-a5a9-1533b1fdbd86" xlink:to="loc_us-gaap_GuaranteeObligationsMaximumExposure_2c6fcb72-5c62-47f2-91a3-e2acb5f75f7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsLiquidationProceeds_bb7774c3-2a7e-47aa-8dbc-8604f86d73ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsLiquidationProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems_4f7de799-ae5c-4205-a5a9-1533b1fdbd86" xlink:to="loc_us-gaap_GuaranteeObligationsLiquidationProceeds_bb7774c3-2a7e-47aa-8dbc-8604f86d73ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_c75ec347-67a9-49f7-ad1b-fcb43d806578" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems_4f7de799-ae5c-4205-a5a9-1533b1fdbd86" xlink:to="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_c75ec347-67a9-49f7-ad1b-fcb43d806578" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_ccb4a8a8-8999-4b9f-9487-c58e98525b99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems_4f7de799-ae5c-4205-a5a9-1533b1fdbd86" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_ccb4a8a8-8999-4b9f-9487-c58e98525b99" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_ff3d3d16-07b3-48c1-8f80-537e1ba7cade" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems_4f7de799-ae5c-4205-a5a9-1533b1fdbd86" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_ff3d3d16-07b3-48c1-8f80-537e1ba7cade" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_ebf182fb-04d1-4927-9258-f5350e85e80f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems_4f7de799-ae5c-4205-a5a9-1533b1fdbd86" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_ebf182fb-04d1-4927-9258-f5350e85e80f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_0dacb5a5-3234-4829-b40e-8c865162bf7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems_4f7de799-ae5c-4205-a5a9-1533b1fdbd86" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_0dacb5a5-3234-4829-b40e-8c865162bf7d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_153c4ac7-bc37-4f45-8c7a-fc9a57095f68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems_4f7de799-ae5c-4205-a5a9-1533b1fdbd86" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_153c4ac7-bc37-4f45-8c7a-fc9a57095f68" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CommitmentsAndContingenciesNumberOfExpert_2436307e-d976-42f3-b925-39800268f682" xlink:href="ci-20231231.xsd#ci_CommitmentsAndContingenciesNumberOfExpert"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems_4f7de799-ae5c-4205-a5a9-1533b1fdbd86" xlink:to="loc_ci_CommitmentsAndContingenciesNumberOfExpert_2436307e-d976-42f3-b925-39800268f682" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CommitmentsAndContingenciesNumberOfAdditionalExpert_f808dcaa-92a5-4155-8dea-8c0c32433118" xlink:href="ci-20231231.xsd#ci_CommitmentsAndContingenciesNumberOfAdditionalExpert"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems_4f7de799-ae5c-4205-a5a9-1533b1fdbd86" xlink:to="loc_ci_CommitmentsAndContingenciesNumberOfAdditionalExpert_f808dcaa-92a5-4155-8dea-8c0c32433118" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_ceef3895-851f-4a6e-9918-ed1a8586f8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems_4f7de799-ae5c-4205-a5a9-1533b1fdbd86" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_ceef3895-851f-4a6e-9918-ed1a8586f8e7" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#SegmentInformationSummarizedSegmentFinancialInformationDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_25606fa6-a978-4d92-9c81-636119b601c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8fed7dea-4301-46e1-8f9c-ca4be2acc31f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_25606fa6-a978-4d92-9c81-636119b601c7" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8fed7dea-4301-46e1-8f9c-ca4be2acc31f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_beda560a-f2ea-41b9-924d-644896f9cf69" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8fed7dea-4301-46e1-8f9c-ca4be2acc31f" xlink:to="loc_srt_ConsolidationItemsAxis_beda560a-f2ea-41b9-924d-644896f9cf69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_beda560a-f2ea-41b9-924d-644896f9cf69_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_beda560a-f2ea-41b9-924d-644896f9cf69" xlink:to="loc_srt_ConsolidationItemsDomain_beda560a-f2ea-41b9-924d-644896f9cf69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_a55e94f3-ced0-4f10-957b-c08f604f55bd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_beda560a-f2ea-41b9-924d-644896f9cf69" xlink:to="loc_srt_ConsolidationItemsDomain_a55e94f3-ced0-4f10-957b-c08f604f55bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_9d9485e6-ad50-498c-bdc3-09adaaefca51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_a55e94f3-ced0-4f10-957b-c08f604f55bd" xlink:to="loc_us-gaap_OperatingSegmentsMember_9d9485e6-ad50-498c-bdc3-09adaaefca51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CorporateAndEliminationsMember_5d0926eb-1bee-41f2-bda9-03d58d8b8db7" xlink:href="ci-20231231.xsd#ci_CorporateAndEliminationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_a55e94f3-ced0-4f10-957b-c08f604f55bd" xlink:to="loc_ci_CorporateAndEliminationsMember_5d0926eb-1bee-41f2-bda9-03d58d8b8db7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_06ef57c8-5a97-490d-be4b-144cd1fa1644" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_CorporateAndEliminationsMember_5d0926eb-1bee-41f2-bda9-03d58d8b8db7" xlink:to="loc_us-gaap_CorporateNonSegmentMember_06ef57c8-5a97-490d-be4b-144cd1fa1644" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_4e7ebd34-729d-4532-a890-cc5a2501a040" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_CorporateAndEliminationsMember_5d0926eb-1bee-41f2-bda9-03d58d8b8db7" xlink:to="loc_us-gaap_IntersegmentEliminationMember_4e7ebd34-729d-4532-a890-cc5a2501a040" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5fb144f6-dbc4-4165-9d4f-95184cdbf60a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8fed7dea-4301-46e1-8f9c-ca4be2acc31f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5fb144f6-dbc4-4165-9d4f-95184cdbf60a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5fb144f6-dbc4-4165-9d4f-95184cdbf60a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5fb144f6-dbc4-4165-9d4f-95184cdbf60a" xlink:to="loc_us-gaap_SegmentDomain_5fb144f6-dbc4-4165-9d4f-95184cdbf60a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8b416362-bc1b-43f4-b3fc-f04b1877ab89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5fb144f6-dbc4-4165-9d4f-95184cdbf60a" xlink:to="loc_us-gaap_SegmentDomain_8b416362-bc1b-43f4-b3fc-f04b1877ab89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EvernorthMember_685f8617-e185-4e9c-ba71-8d28f753d013" xlink:href="ci-20231231.xsd#ci_EvernorthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8b416362-bc1b-43f4-b3fc-f04b1877ab89" xlink:to="loc_ci_EvernorthMember_685f8617-e185-4e9c-ba71-8d28f753d013" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember_db9fb140-0aa6-4600-acf3-c446080c3772" xlink:href="ci-20231231.xsd#ci_CignaHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8b416362-bc1b-43f4-b3fc-f04b1877ab89" xlink:to="loc_ci_CignaHealthcareMember_db9fb140-0aa6-4600-acf3-c446080c3772" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherOperationsSegmentMember_b22ee93d-6dcc-4079-b4cf-c223c1c3b2dc" xlink:href="ci-20231231.xsd#ci_OtherOperationsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8b416362-bc1b-43f4-b3fc-f04b1877ab89" xlink:to="loc_ci_OtherOperationsSegmentMember_b22ee93d-6dcc-4079-b4cf-c223c1c3b2dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NonInvestmentRevenue_a36c60e4-5a46-45b5-a61e-6896c5997f89" xlink:href="ci-20231231.xsd#ci_NonInvestmentRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_25606fa6-a978-4d92-9c81-636119b601c7" xlink:to="loc_ci_NonInvestmentRevenue_a36c60e4-5a46-45b5-a61e-6896c5997f89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_99ed04cc-59a0-48e1-803f-ba0ae0e51833" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_25606fa6-a978-4d92-9c81-636119b601c7" xlink:to="loc_us-gaap_NetInvestmentIncome_99ed04cc-59a0-48e1-803f-ba0ae0e51833" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1e7c5d73-6903-4152-bc68-fdca804f3019" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_25606fa6-a978-4d92-9c81-636119b601c7" xlink:to="loc_us-gaap_Revenues_1e7c5d73-6903-4152-bc68-fdca804f3019" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RealizedInvestmentGainsLossesEquityMethodInvestments_261b130b-3edd-4288-85ee-56d1e92d328a" xlink:href="ci-20231231.xsd#ci_RealizedInvestmentGainsLossesEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_25606fa6-a978-4d92-9c81-636119b601c7" xlink:to="loc_ci_RealizedInvestmentGainsLossesEquityMethodInvestments_261b130b-3edd-4288-85ee-56d1e92d328a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SegmentRevenues_c38915e0-70a7-4411-a9ae-e9acb617f2c9" xlink:href="ci-20231231.xsd#ci_SegmentRevenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_25606fa6-a978-4d92-9c81-636119b601c7" xlink:to="loc_ci_SegmentRevenues_c38915e0-70a7-4411-a9ae-e9acb617f2c9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5b522171-0a0a-4483-9c3e-8a8380405453" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_25606fa6-a978-4d92-9c81-636119b601c7" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_5b522171-0a0a-4483-9c3e-8a8380405453" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_085e25c3-15f4-4506-96d3-74757ac43ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_25606fa6-a978-4d92-9c81-636119b601c7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_085e25c3-15f4-4506-96d3-74757ac43ddd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract_543bb99c-69a7-4bd1-90f7-226fbd98d9fd" xlink:href="ci-20231231.xsd#ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_25606fa6-a978-4d92-9c81-636119b601c7" xlink:to="loc_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract_543bb99c-69a7-4bd1-90f7-226fbd98d9fd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax_5d021948-c671-4371-9613-6f98dd37ea25" xlink:href="ci-20231231.xsd#ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract_543bb99c-69a7-4bd1-90f7-226fbd98d9fd" xlink:to="loc_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax_5d021948-c671-4371-9613-6f98dd37ea25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries_e5a99102-339c-43c2-97ad-7c4ba8747d2a" xlink:href="ci-20231231.xsd#ci_RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract_543bb99c-69a7-4bd1-90f7-226fbd98d9fd" xlink:to="loc_ci_RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries_e5a99102-339c-43c2-97ad-7c4ba8747d2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_eedc12c3-c493-4d4d-9052-39a02205118e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract_543bb99c-69a7-4bd1-90f7-226fbd98d9fd" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_eedc12c3-c493-4d4d-9052-39a02205118e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemsBeforeTaxAbstract_9ea3b9b9-09c5-4a00-8cb8-ee381b14fa68" xlink:href="ci-20231231.xsd#ci_SpecialItemsBeforeTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract_543bb99c-69a7-4bd1-90f7-226fbd98d9fd" xlink:to="loc_ci_SpecialItemsBeforeTaxAbstract_9ea3b9b9-09c5-4a00-8cb8-ee381b14fa68" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes_33aaa567-92ae-4364-a0e9-f408eba0ffa7" xlink:href="ci-20231231.xsd#ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_9ea3b9b9-09c5-4a00-8cb8-ee381b14fa68" xlink:to="loc_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes_33aaa567-92ae-4364-a0e9-f408eba0ffa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_23356235-1b88-4de4-9f31-1341f1c1b61a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_9ea3b9b9-09c5-4a00-8cb8-ee381b14fa68" xlink:to="loc_us-gaap_RestructuringCharges_23356235-1b88-4de4-9f31-1341f1c1b61a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitBeforeTaxLitigation_6c7181a7-be29-4692-8704-9eb7c1c31e7b" xlink:href="ci-20231231.xsd#ci_SpecialItemChargeBenefitBeforeTaxLitigation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_9ea3b9b9-09c5-4a00-8cb8-ee381b14fa68" xlink:to="loc_ci_SpecialItemChargeBenefitBeforeTaxLitigation_6c7181a7-be29-4692-8704-9eb7c1c31e7b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TransactionRelatedCosts_0fcdb797-6abc-473c-9988-3c9f2317cda4" xlink:href="ci-20231231.xsd#ci_TransactionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_9ea3b9b9-09c5-4a00-8cb8-ee381b14fa68" xlink:to="loc_ci_TransactionRelatedCosts_0fcdb797-6abc-473c-9988-3c9f2317cda4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax_bf2b13d9-cf26-4351-9df5-089e09d72157" xlink:href="ci-20231231.xsd#ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_9ea3b9b9-09c5-4a00-8cb8-ee381b14fa68" xlink:to="loc_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax_bf2b13d9-cf26-4351-9df5-089e09d72157" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OrganizationalEfficiencyPlanCharges_deae12a5-26c6-4d7b-bf48-aa87cd7b5b1c" xlink:href="ci-20231231.xsd#ci_OrganizationalEfficiencyPlanCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_9ea3b9b9-09c5-4a00-8cb8-ee381b14fa68" xlink:to="loc_ci_OrganizationalEfficiencyPlanCharges_deae12a5-26c6-4d7b-bf48-aa87cd7b5b1c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes_c3543720-dbe7-46e0-a614-eb7e18469d56" xlink:href="ci-20231231.xsd#ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_9ea3b9b9-09c5-4a00-8cb8-ee381b14fa68" xlink:to="loc_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes_c3543720-dbe7-46e0-a614-eb7e18469d56" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossFromContractAdjustmentBeforeTaxes_919a7701-8d3e-4fb9-9bba-2c452eeb392e" xlink:href="ci-20231231.xsd#ci_SpecialItemGainLossFromContractAdjustmentBeforeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_9ea3b9b9-09c5-4a00-8cb8-ee381b14fa68" xlink:to="loc_ci_SpecialItemGainLossFromContractAdjustmentBeforeTaxes_919a7701-8d3e-4fb9-9bba-2c452eeb392e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_842a323a-1755-43b1-918d-ecc1076c51f5" xlink:href="ci-20231231.xsd#ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract_543bb99c-69a7-4bd1-90f7-226fbd98d9fd" xlink:to="loc_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_842a323a-1755-43b1-918d-ecc1076c51f5" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#SegmentInformationRevenuefromExternalCustomersDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_6236a2c6-5f72-493c-af99-2fae694cfe11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_d8efcf90-5ce1-4791-908f-d2402326eba3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_6236a2c6-5f72-493c-af99-2fae694cfe11" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_d8efcf90-5ce1-4791-908f-d2402326eba3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_525ae2e8-9a9b-4d21-ba68-bbf48469ba93" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_d8efcf90-5ce1-4791-908f-d2402326eba3" xlink:to="loc_srt_ProductOrServiceAxis_525ae2e8-9a9b-4d21-ba68-bbf48469ba93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_525ae2e8-9a9b-4d21-ba68-bbf48469ba93_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_525ae2e8-9a9b-4d21-ba68-bbf48469ba93" xlink:to="loc_srt_ProductsAndServicesDomain_525ae2e8-9a9b-4d21-ba68-bbf48469ba93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8f5676a3-702c-4805-a859-c4791593eaa0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_525ae2e8-9a9b-4d21-ba68-bbf48469ba93" xlink:to="loc_srt_ProductsAndServicesDomain_8f5676a3-702c-4805-a859-c4791593eaa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_53106612-ec63-4847-a2c3-0a49a6904c05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8f5676a3-702c-4805-a859-c4791593eaa0" xlink:to="loc_us-gaap_ProductMember_53106612-ec63-4847-a2c3-0a49a6904c05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NetworkPharmacyMember_9329420c-5851-4504-9844-052e22ad6e18" xlink:href="ci-20231231.xsd#ci_NetworkPharmacyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_53106612-ec63-4847-a2c3-0a49a6904c05" xlink:to="loc_ci_NetworkPharmacyMember_9329420c-5851-4504-9844-052e22ad6e18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_HomeDeliveryAndSpecialtyMember_adfddf98-2c4c-47a6-9302-a6b47c75d393" xlink:href="ci-20231231.xsd#ci_HomeDeliveryAndSpecialtyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_53106612-ec63-4847-a2c3-0a49a6904c05" xlink:to="loc_ci_HomeDeliveryAndSpecialtyMember_adfddf98-2c4c-47a6-9302-a6b47c75d393" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherPharmacyMember_e4fe1e4a-a6c5-46c6-b5da-d364aaea55f7" xlink:href="ci-20231231.xsd#ci_OtherPharmacyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_53106612-ec63-4847-a2c3-0a49a6904c05" xlink:to="loc_ci_OtherPharmacyMember_e4fe1e4a-a6c5-46c6-b5da-d364aaea55f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_HealthcareMember_202b8f7a-e91e-49ec-84cd-efd561cb25ff" xlink:href="ci-20231231.xsd#ci_HealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8f5676a3-702c-4805-a859-c4791593eaa0" xlink:to="loc_ci_HealthcareMember_202b8f7a-e91e-49ec-84cd-efd561cb25ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EmployerInsuredMember_fadc646a-86a7-473d-bb7c-55bfbb1bd584" xlink:href="ci-20231231.xsd#ci_EmployerInsuredMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_HealthcareMember_202b8f7a-e91e-49ec-84cd-efd561cb25ff" xlink:to="loc_ci_EmployerInsuredMember_fadc646a-86a7-473d-bb7c-55bfbb1bd584" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageMember_8f5c8fbe-5b7a-45d2-90b0-89909b533bde" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_HealthcareMember_202b8f7a-e91e-49ec-84cd-efd561cb25ff" xlink:to="loc_ci_MedicareAdvantageMember_8f5c8fbe-5b7a-45d2-90b0-89909b533bde" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_StopLossMember_cc175733-f410-4354-85ee-86d4b46c89dd" xlink:href="ci-20231231.xsd#ci_StopLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_HealthcareMember_202b8f7a-e91e-49ec-84cd-efd561cb25ff" xlink:to="loc_ci_StopLossMember_cc175733-f410-4354-85ee-86d4b46c89dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IndividualAndFamilyPlansMember_dddce853-ed99-4166-985f-39754cc74bc7" xlink:href="ci-20231231.xsd#ci_IndividualAndFamilyPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_HealthcareMember_202b8f7a-e91e-49ec-84cd-efd561cb25ff" xlink:to="loc_ci_IndividualAndFamilyPlansMember_dddce853-ed99-4166-985f-39754cc74bc7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherHealthcareMember_7e91185a-5ee4-4b37-90e4-f518bc7d6548" xlink:href="ci-20231231.xsd#ci_OtherHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_HealthcareMember_202b8f7a-e91e-49ec-84cd-efd561cb25ff" xlink:to="loc_ci_OtherHealthcareMember_7e91185a-5ee4-4b37-90e4-f518bc7d6548" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_430447f6-63eb-4893-988e-62dc2b337bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8f5676a3-702c-4805-a859-c4791593eaa0" xlink:to="loc_us-gaap_ServiceMember_430447f6-63eb-4893-988e-62dc2b337bd7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ServiceFeesMember_1e16c8df-cdb9-4e4c-9480-4f3b2ebc9977" xlink:href="ci-20231231.xsd#ci_ServiceFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ServiceMember_430447f6-63eb-4893-988e-62dc2b337bd7" xlink:to="loc_ci_ServiceFeesMember_1e16c8df-cdb9-4e4c-9480-4f3b2ebc9977" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceOtherMember_06f45cc3-7a0c-4db2-a2c3-b9a6832fa57e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ServiceMember_430447f6-63eb-4893-988e-62dc2b337bd7" xlink:to="loc_us-gaap_ServiceOtherMember_06f45cc3-7a0c-4db2-a2c3-b9a6832fa57e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3b6fb471-1bf1-4d9c-b45b-54e193d91a76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_d8efcf90-5ce1-4791-908f-d2402326eba3" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3b6fb471-1bf1-4d9c-b45b-54e193d91a76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3b6fb471-1bf1-4d9c-b45b-54e193d91a76_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3b6fb471-1bf1-4d9c-b45b-54e193d91a76" xlink:to="loc_us-gaap_SegmentDomain_3b6fb471-1bf1-4d9c-b45b-54e193d91a76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_96f8d4ea-1d21-45d9-8d98-eaa32a2d26d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3b6fb471-1bf1-4d9c-b45b-54e193d91a76" xlink:to="loc_us-gaap_SegmentDomain_96f8d4ea-1d21-45d9-8d98-eaa32a2d26d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EvernorthMember_61a6aa59-fc40-4a3b-bba4-4ff5dba3e1cd" xlink:href="ci-20231231.xsd#ci_EvernorthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_96f8d4ea-1d21-45d9-8d98-eaa32a2d26d0" xlink:to="loc_ci_EvernorthMember_61a6aa59-fc40-4a3b-bba4-4ff5dba3e1cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember_192b579f-e5d9-4329-90a7-ee555364aca5" xlink:href="ci-20231231.xsd#ci_CignaHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_96f8d4ea-1d21-45d9-8d98-eaa32a2d26d0" xlink:to="loc_ci_CignaHealthcareMember_192b579f-e5d9-4329-90a7-ee555364aca5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherOperationsSegmentMember_fb482638-0e17-427e-bb8f-ee4be4621ab3" xlink:href="ci-20231231.xsd#ci_OtherOperationsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_96f8d4ea-1d21-45d9-8d98-eaa32a2d26d0" xlink:to="loc_ci_OtherOperationsSegmentMember_fb482638-0e17-427e-bb8f-ee4be4621ab3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_3cab96fc-5ef7-4c47-9075-aa8d6e8b6b35" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_d8efcf90-5ce1-4791-908f-d2402326eba3" xlink:to="loc_srt_ConsolidationItemsAxis_3cab96fc-5ef7-4c47-9075-aa8d6e8b6b35" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_3cab96fc-5ef7-4c47-9075-aa8d6e8b6b35_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_3cab96fc-5ef7-4c47-9075-aa8d6e8b6b35" xlink:to="loc_srt_ConsolidationItemsDomain_3cab96fc-5ef7-4c47-9075-aa8d6e8b6b35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_114ecb44-306a-4215-9ed0-44cb5d2d5b4e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_3cab96fc-5ef7-4c47-9075-aa8d6e8b6b35" xlink:to="loc_srt_ConsolidationItemsDomain_114ecb44-306a-4215-9ed0-44cb5d2d5b4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_b563428b-a0c0-4ce7-a6a9-ce28d9c0284c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_114ecb44-306a-4215-9ed0-44cb5d2d5b4e" xlink:to="loc_us-gaap_IntersegmentEliminationMember_b563428b-a0c0-4ce7-a6a9-ce28d9c0284c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_e4c9fa20-0533-4cc3-9f46-adc5efcefeb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_114ecb44-306a-4215-9ed0-44cb5d2d5b4e" xlink:to="loc_us-gaap_OperatingSegmentsMember_e4c9fa20-0533-4cc3-9f46-adc5efcefeb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_595ae2b4-ad8c-4b0f-bf1d-6179f224eca0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_d8efcf90-5ce1-4791-908f-d2402326eba3" xlink:to="loc_us-gaap_SubsegmentsAxis_595ae2b4-ad8c-4b0f-bf1d-6179f224eca0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_595ae2b4-ad8c-4b0f-bf1d-6179f224eca0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_595ae2b4-ad8c-4b0f-bf1d-6179f224eca0" xlink:to="loc_us-gaap_SubsegmentsDomain_595ae2b4-ad8c-4b0f-bf1d-6179f224eca0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_b23ac703-2b2f-453f-97b3-fc203b70a516" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_595ae2b4-ad8c-4b0f-bf1d-6179f224eca0" xlink:to="loc_us-gaap_SubsegmentsDomain_b23ac703-2b2f-453f-97b3-fc203b70a516" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnitedStatedHealthcareMember_811f0170-3449-4668-8ed4-d42868b47fa4" xlink:href="ci-20231231.xsd#ci_UnitedStatedHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_b23ac703-2b2f-453f-97b3-fc203b70a516" xlink:to="loc_ci_UnitedStatedHealthcareMember_811f0170-3449-4668-8ed4-d42868b47fa4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InternationalHealthMember_91744309-705a-4baf-8bdb-2fe20859e046" xlink:href="ci-20231231.xsd#ci_InternationalHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_b23ac703-2b2f-453f-97b3-fc203b70a516" xlink:to="loc_ci_InternationalHealthMember_91744309-705a-4baf-8bdb-2fe20859e046" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherOperationsInternationalBusinessesToBeSoldAndInterestInJointVentureInTurkeyMember_2b9e688d-a99f-47bf-913c-d226bd78349f" xlink:href="ci-20231231.xsd#ci_OtherOperationsInternationalBusinessesToBeSoldAndInterestInJointVentureInTurkeyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_b23ac703-2b2f-453f-97b3-fc203b70a516" xlink:to="loc_ci_OtherOperationsInternationalBusinessesToBeSoldAndInterestInJointVentureInTurkeyMember_2b9e688d-a99f-47bf-913c-d226bd78349f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherOperationsInternationalBusinessesToBeSoldMember_1f8a0964-9be0-48d7-84dd-6cff85f57143" xlink:href="ci-20231231.xsd#ci_OtherOperationsInternationalBusinessesToBeSoldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_OtherOperationsInternationalBusinessesToBeSoldAndInterestInJointVentureInTurkeyMember_2b9e688d-a99f-47bf-913c-d226bd78349f" xlink:to="loc_ci_OtherOperationsInternationalBusinessesToBeSoldMember_1f8a0964-9be0-48d7-84dd-6cff85f57143" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InterestInJointVentureInTurkeyMember_ca45ef86-906d-4751-a708-42dfc336b598" xlink:href="ci-20231231.xsd#ci_InterestInJointVentureInTurkeyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_OtherOperationsInternationalBusinessesToBeSoldAndInterestInJointVentureInTurkeyMember_2b9e688d-a99f-47bf-913c-d226bd78349f" xlink:to="loc_ci_InterestInJointVentureInTurkeyMember_ca45ef86-906d-4751-a708-42dfc336b598" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherOperationsSegmentOtherMember_7f72dd1a-0caf-4d49-89d2-8147abc23c60" xlink:href="ci-20231231.xsd#ci_OtherOperationsSegmentOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_b23ac703-2b2f-453f-97b3-fc203b70a516" xlink:to="loc_ci_OtherOperationsSegmentOtherMember_7f72dd1a-0caf-4d49-89d2-8147abc23c60" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d9173848-03d2-4b78-9d90-111c04c4a539" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_6236a2c6-5f72-493c-af99-2fae694cfe11" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d9173848-03d2-4b78-9d90-111c04c4a539" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_5d6af6d9-a113-4bbe-a440-799924128469" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_6236a2c6-5f72-493c-af99-2fae694cfe11" xlink:to="loc_us-gaap_PremiumsEarnedNet_5d6af6d9-a113-4bbe-a440-799924128469" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NonInvestmentRevenue_3e8d4a16-7c6f-408e-a8a6-54063aff499d" xlink:href="ci-20231231.xsd#ci_NonInvestmentRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_6236a2c6-5f72-493c-af99-2fae694cfe11" xlink:to="loc_ci_NonInvestmentRevenue_3e8d4a16-7c6f-408e-a8a6-54063aff499d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SegmentInformationFinancialandPerformanceGuaranteesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#SegmentInformationFinancialandPerformanceGuaranteesDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/SegmentInformationFinancialandPerformanceGuaranteesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_829b59a7-f992-476b-ad75-8dfcbbf44d98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_7d630b10-e1c7-4fc4-beb4-b25ec9520e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_829b59a7-f992-476b-ad75-8dfcbbf44d98" xlink:to="loc_us-gaap_LossContingenciesTable_7d630b10-e1c7-4fc4-beb4-b25ec9520e4e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8b8cae90-9627-4904-897d-50b8b96929a4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7d630b10-e1c7-4fc4-beb4-b25ec9520e4e" xlink:to="loc_srt_ProductOrServiceAxis_8b8cae90-9627-4904-897d-50b8b96929a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8b8cae90-9627-4904-897d-50b8b96929a4_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8b8cae90-9627-4904-897d-50b8b96929a4" xlink:to="loc_srt_ProductsAndServicesDomain_8b8cae90-9627-4904-897d-50b8b96929a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6def74bd-fda0-4d93-9981-9b65e6c406d7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8b8cae90-9627-4904-897d-50b8b96929a4" xlink:to="loc_srt_ProductsAndServicesDomain_6def74bd-fda0-4d93-9981-9b65e6c406d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PharmacyBenefitsManagementServicesMember_93f44201-c647-421f-a365-c2b8a8aa0ab0" xlink:href="ci-20231231.xsd#ci_PharmacyBenefitsManagementServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6def74bd-fda0-4d93-9981-9b65e6c406d7" xlink:to="loc_ci_PharmacyBenefitsManagementServicesMember_93f44201-c647-421f-a365-c2b8a8aa0ab0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_873cd3ae-01af-4fec-826f-a7bf8182cfc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7d630b10-e1c7-4fc4-beb4-b25ec9520e4e" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_873cd3ae-01af-4fec-826f-a7bf8182cfc5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_873cd3ae-01af-4fec-826f-a7bf8182cfc5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_873cd3ae-01af-4fec-826f-a7bf8182cfc5" xlink:to="loc_us-gaap_LossContingencyNatureDomain_873cd3ae-01af-4fec-826f-a7bf8182cfc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_ba6841d9-862a-4635-99ec-727b8126f74a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_873cd3ae-01af-4fec-826f-a7bf8182cfc5" xlink:to="loc_us-gaap_LossContingencyNatureDomain_ba6841d9-862a-4635-99ec-727b8126f74a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteesMember_a2ee601a-f211-485b-bb5b-9e9c34795b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_ba6841d9-862a-4635-99ec-727b8126f74a" xlink:to="loc_us-gaap_GuaranteesMember_a2ee601a-f211-485b-bb5b-9e9c34795b9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_02824542-440a-4605-8c2e-7b3f000a3ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_829b59a7-f992-476b-ad75-8dfcbbf44d98" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_02824542-440a-4605-8c2e-7b3f000a3ef8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SegmentInformationUSandForeignRevenuesfromExternalCustomersDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#SegmentInformationUSandForeignRevenuesfromExternalCustomersDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/SegmentInformationUSandForeignRevenuesfromExternalCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_b3409ab9-2776-451e-a069-95762099b86d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_c1b45832-dbd8-4c09-9c3e-b71fba583d50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_b3409ab9-2776-451e-a069-95762099b86d" xlink:to="loc_us-gaap_LossContingenciesTable_c1b45832-dbd8-4c09-9c3e-b71fba583d50" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2f0df1bd-3518-416c-b12d-4eb89e8d500c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c1b45832-dbd8-4c09-9c3e-b71fba583d50" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2f0df1bd-3518-416c-b12d-4eb89e8d500c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2f0df1bd-3518-416c-b12d-4eb89e8d500c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2f0df1bd-3518-416c-b12d-4eb89e8d500c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2f0df1bd-3518-416c-b12d-4eb89e8d500c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1eab0b69-7d00-418a-81b1-fb4a23834005" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2f0df1bd-3518-416c-b12d-4eb89e8d500c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1eab0b69-7d00-418a-81b1-fb4a23834005" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RevenuesIncludingNetInvestmentIncomeBenchmarkMember_291f6821-656f-4693-8694-a74d56b6c333" xlink:href="ci-20231231.xsd#ci_RevenuesIncludingNetInvestmentIncomeBenchmarkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1eab0b69-7d00-418a-81b1-fb4a23834005" xlink:to="loc_ci_RevenuesIncludingNetInvestmentIncomeBenchmarkMember_291f6821-656f-4693-8694-a74d56b6c333" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RevenuesFromExternalCustomersMember_9798c967-9411-4f32-b349-982d46b549c0" xlink:href="ci-20231231.xsd#ci_RevenuesFromExternalCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1eab0b69-7d00-418a-81b1-fb4a23834005" xlink:to="loc_ci_RevenuesFromExternalCustomersMember_9798c967-9411-4f32-b349-982d46b549c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_aeb1d721-930c-4aa8-a64b-ad35165773ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c1b45832-dbd8-4c09-9c3e-b71fba583d50" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_aeb1d721-930c-4aa8-a64b-ad35165773ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_aeb1d721-930c-4aa8-a64b-ad35165773ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_aeb1d721-930c-4aa8-a64b-ad35165773ac" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_aeb1d721-930c-4aa8-a64b-ad35165773ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0febb7d6-687d-4011-971e-fe765b28ff08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_aeb1d721-930c-4aa8-a64b-ad35165773ac" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0febb7d6-687d-4011-971e-fe765b28ff08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_83331639-217e-48ba-a5d9-5b4852b4ce55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_0febb7d6-687d-4011-971e-fe765b28ff08" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_83331639-217e-48ba-a5d9-5b4852b4ce55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_19a06b15-bac5-4e65-a884-60c1eadc4347" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_0febb7d6-687d-4011-971e-fe765b28ff08" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_19a06b15-bac5-4e65-a884-60c1eadc4347" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_d76236b9-bc66-410a-aad3-c3872bd86865" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c1b45832-dbd8-4c09-9c3e-b71fba583d50" xlink:to="loc_srt_MajorCustomersAxis_d76236b9-bc66-410a-aad3-c3872bd86865" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_d76236b9-bc66-410a-aad3-c3872bd86865_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_d76236b9-bc66-410a-aad3-c3872bd86865" xlink:to="loc_srt_NameOfMajorCustomerDomain_d76236b9-bc66-410a-aad3-c3872bd86865_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a02e8aff-a448-4ed3-8ee1-9dc5484019d0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_d76236b9-bc66-410a-aad3-c3872bd86865" xlink:to="loc_srt_NameOfMajorCustomerDomain_a02e8aff-a448-4ed3-8ee1-9dc5484019d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_USFederalGovernmentAgenciesMember_4ad6eb8c-ebe1-4e90-9e58-f63bc6adc43d" xlink:href="ci-20231231.xsd#ci_USFederalGovernmentAgenciesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a02e8aff-a448-4ed3-8ee1-9dc5484019d0" xlink:to="loc_ci_USFederalGovernmentAgenciesMember_4ad6eb8c-ebe1-4e90-9e58-f63bc6adc43d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5b4e8133-c55e-45f6-a6f3-30f4bfb4eb6c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c1b45832-dbd8-4c09-9c3e-b71fba583d50" xlink:to="loc_srt_StatementGeographicalAxis_5b4e8133-c55e-45f6-a6f3-30f4bfb4eb6c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5b4e8133-c55e-45f6-a6f3-30f4bfb4eb6c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_5b4e8133-c55e-45f6-a6f3-30f4bfb4eb6c" xlink:to="loc_srt_SegmentGeographicalDomain_5b4e8133-c55e-45f6-a6f3-30f4bfb4eb6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_786cac2a-160e-4735-94eb-2bd6e66df563" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_5b4e8133-c55e-45f6-a6f3-30f4bfb4eb6c" xlink:to="loc_srt_SegmentGeographicalDomain_786cac2a-160e-4735-94eb-2bd6e66df563" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_07cff080-3bf9-4a5a-919e-8b464cedfbbe" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_786cac2a-160e-4735-94eb-2bd6e66df563" xlink:to="loc_country_US_07cff080-3bf9-4a5a-919e-8b464cedfbbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AllOtherCountriesMember_49de1e67-ff09-421e-98b9-00b30b464459" xlink:href="ci-20231231.xsd#ci_AllOtherCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_786cac2a-160e-4735-94eb-2bd6e66df563" xlink:to="loc_ci_AllOtherCountriesMember_49de1e67-ff09-421e-98b9-00b30b464459" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SingleForeignCountryMember_7b6dd258-565b-4454-bf54-5c5c77fa9e2b" xlink:href="ci-20231231.xsd#ci_SingleForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_AllOtherCountriesMember_49de1e67-ff09-421e-98b9-00b30b464459" xlink:to="loc_ci_SingleForeignCountryMember_7b6dd258-565b-4454-bf54-5c5c77fa9e2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NonInvestmentRevenue_3dd0ebcf-77a2-475a-a17e-6e3b5a3f3eef" xlink:href="ci-20231231.xsd#ci_NonInvestmentRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b3409ab9-2776-451e-a069-95762099b86d" xlink:to="loc_ci_NonInvestmentRevenue_3dd0ebcf-77a2-475a-a17e-6e3b5a3f3eef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationsNonInvestmentRevenue_b9bffd43-0d71-4abc-8ecd-7aa3ed79d895" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationsNonInvestmentRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b3409ab9-2776-451e-a069-95762099b86d" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationsNonInvestmentRevenue_b9bffd43-0d71-4abc-8ecd-7aa3ed79d895" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_75e5193a-b039-4657-a4b5-e948c781ed6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b3409ab9-2776-451e-a069-95762099b86d" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_75e5193a-b039-4657-a4b5-e948c781ed6d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SegmentInformationRevenuesfromUSFederalGovernmentAgenciesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#SegmentInformationRevenuesfromUSFederalGovernmentAgenciesDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/SegmentInformationRevenuesfromUSFederalGovernmentAgenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_db86693c-60a8-4db2-b6d8-b8e614627a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_8c729181-43f5-48dc-a4ea-fc543c28b4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_db86693c-60a8-4db2-b6d8-b8e614627a4e" xlink:to="loc_us-gaap_ConcentrationRiskTable_8c729181-43f5-48dc-a4ea-fc543c28b4ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_8dcbff0a-f0b6-435b-bd1b-43c83bad09cc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_8c729181-43f5-48dc-a4ea-fc543c28b4ae" xlink:to="loc_srt_MajorCustomersAxis_8dcbff0a-f0b6-435b-bd1b-43c83bad09cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_8dcbff0a-f0b6-435b-bd1b-43c83bad09cc_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_8dcbff0a-f0b6-435b-bd1b-43c83bad09cc" xlink:to="loc_srt_NameOfMajorCustomerDomain_8dcbff0a-f0b6-435b-bd1b-43c83bad09cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ec0897d7-bb29-4c93-bdc4-0e540655f9d7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_8dcbff0a-f0b6-435b-bd1b-43c83bad09cc" xlink:to="loc_srt_NameOfMajorCustomerDomain_ec0897d7-bb29-4c93-bdc4-0e540655f9d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AnthemMember_c8a9b3d9-b279-4840-83d0-5250a3e123ed" xlink:href="ci-20231231.xsd#ci_AnthemMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ec0897d7-bb29-4c93-bdc4-0e540655f9d7" xlink:to="loc_ci_AnthemMember_c8a9b3d9-b279-4840-83d0-5250a3e123ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DepartmentOfDefenseMember_b311c806-d8e8-4d87-beba-2eb10eb4b40b" xlink:href="ci-20231231.xsd#ci_DepartmentOfDefenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ec0897d7-bb29-4c93-bdc4-0e540655f9d7" xlink:to="loc_ci_DepartmentOfDefenseMember_b311c806-d8e8-4d87-beba-2eb10eb4b40b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2dfa3ddf-fde6-401a-99f8-73142926f77f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_8c729181-43f5-48dc-a4ea-fc543c28b4ae" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2dfa3ddf-fde6-401a-99f8-73142926f77f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2dfa3ddf-fde6-401a-99f8-73142926f77f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2dfa3ddf-fde6-401a-99f8-73142926f77f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2dfa3ddf-fde6-401a-99f8-73142926f77f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0fff1237-ce8a-43e7-9b3b-45a829627c69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2dfa3ddf-fde6-401a-99f8-73142926f77f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0fff1237-ce8a-43e7-9b3b-45a829627c69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_df96b8b2-0fef-4f8d-9f22-17f39805bb88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0fff1237-ce8a-43e7-9b3b-45a829627c69" xlink:to="loc_us-gaap_SalesRevenueNetMember_df96b8b2-0fef-4f8d-9f22-17f39805bb88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_b7289c0e-cf9a-46d1-ae84-a298710f04d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_8c729181-43f5-48dc-a4ea-fc543c28b4ae" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_b7289c0e-cf9a-46d1-ae84-a298710f04d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b7289c0e-cf9a-46d1-ae84-a298710f04d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b7289c0e-cf9a-46d1-ae84-a298710f04d5" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b7289c0e-cf9a-46d1-ae84-a298710f04d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b3c33f50-682a-49d4-a378-1f0532a597b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b7289c0e-cf9a-46d1-ae84-a298710f04d5" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b3c33f50-682a-49d4-a378-1f0532a597b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_fdb1a7cd-6f03-43ab-93f9-700269f8ec77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_b3c33f50-682a-49d4-a378-1f0532a597b3" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_fdb1a7cd-6f03-43ab-93f9-700269f8ec77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_af9ca61e-7ca7-4d19-89bd-9bab0d83be2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_db86693c-60a8-4db2-b6d8-b8e614627a4e" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_af9ca61e-7ca7-4d19-89bd-9bab0d83be2b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ef0d86c5-7e0a-43a7-a125-c21375ae328c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_822e001c-ea68-4a02-9957-a8366455fecf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ef0d86c5-7e0a-43a7-a125-c21375ae328c" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_822e001c-ea68-4a02-9957-a8366455fecf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_6fe75eca-1a8b-40b4-b4e6-34aff379e26b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_822e001c-ea68-4a02-9957-a8366455fecf" xlink:to="loc_srt_ConsolidatedEntitiesAxis_6fe75eca-1a8b-40b4-b4e6-34aff379e26b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_6fe75eca-1a8b-40b4-b4e6-34aff379e26b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_6fe75eca-1a8b-40b4-b4e6-34aff379e26b" xlink:to="loc_srt_ConsolidatedEntitiesDomain_6fe75eca-1a8b-40b4-b4e6-34aff379e26b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_2a1280e7-536a-464d-9209-b1c65e47c3e3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_6fe75eca-1a8b-40b4-b4e6-34aff379e26b" xlink:to="loc_srt_ConsolidatedEntitiesDomain_2a1280e7-536a-464d-9209-b1c65e47c3e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_a8fe39da-3e4b-43f8-b869-c83de79172a3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_2a1280e7-536a-464d-9209-b1c65e47c3e3" xlink:to="loc_srt_ParentCompanyMember_a8fe39da-3e4b-43f8-b869-c83de79172a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_0c122427-9dfd-4d3f-aadd-afbea48079b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ef0d86c5-7e0a-43a7-a125-c21375ae328c" xlink:to="loc_us-gaap_RevenuesAbstract_0c122427-9dfd-4d3f-aadd-afbea48079b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_4a03fe13-307e-4079-b889-3d77b722a55d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_0c122427-9dfd-4d3f-aadd-afbea48079b6" xlink:to="loc_us-gaap_NetInvestmentIncome_4a03fe13-307e-4079-b889-3d77b722a55d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntercompanyInterestIncome_a4a4fe51-092b-4561-a101-7231b919717c" xlink:href="ci-20231231.xsd#ci_IntercompanyInterestIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_0c122427-9dfd-4d3f-aadd-afbea48079b6" xlink:to="loc_ci_IntercompanyInterestIncome_a4a4fe51-092b-4561-a101-7231b919717c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_74ba58a3-ac7e-4e1d-b2bd-5b4025d3c5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_0c122427-9dfd-4d3f-aadd-afbea48079b6" xlink:to="loc_us-gaap_Revenues_74ba58a3-ac7e-4e1d-b2bd-5b4025d3c5d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_eacafdec-ae6c-4c8f-8c1d-5d171b6fa2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ef0d86c5-7e0a-43a7-a125-c21375ae328c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_eacafdec-ae6c-4c8f-8c1d-5d171b6fa2cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b7b0ab56-aad8-4775-8b06-57150fc86969" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_eacafdec-ae6c-4c8f-8c1d-5d171b6fa2cb" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b7b0ab56-aad8-4775-8b06-57150fc86969" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BenefitsLossesAndExpenses_13fd1b80-81f9-4253-8c9e-ef477b7fe630" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BenefitsLossesAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_eacafdec-ae6c-4c8f-8c1d-5d171b6fa2cb" xlink:to="loc_us-gaap_BenefitsLossesAndExpenses_13fd1b80-81f9-4253-8c9e-ef477b7fe630" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4001e067-f825-4a33-b804-c6b2a85fe783" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ef0d86c5-7e0a-43a7-a125-c21375ae328c" xlink:to="loc_us-gaap_OperatingIncomeLoss_4001e067-f825-4a33-b804-c6b2a85fe783" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_50cf0e69-92ee-40df-ab31-fb2f15c22068" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ef0d86c5-7e0a-43a7-a125-c21375ae328c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_50cf0e69-92ee-40df-ab31-fb2f15c22068" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntercompanyInterestExpense_a97d90bb-245a-46b4-867d-6db94553286b" xlink:href="ci-20231231.xsd#ci_IntercompanyInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ef0d86c5-7e0a-43a7-a125-c21375ae328c" xlink:to="loc_ci_IntercompanyInterestExpense_a97d90bb-245a-46b4-867d-6db94553286b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0a26c945-a728-43ee-aada-648726a95542" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ef0d86c5-7e0a-43a7-a125-c21375ae328c" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0a26c945-a728-43ee-aada-648726a95542" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RealizedInvestmentGainLoss_fa5f6487-0be2-4090-98c7-3a2f1caeb07a" xlink:href="ci-20231231.xsd#ci_RealizedInvestmentGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ef0d86c5-7e0a-43a7-a125-c21375ae328c" xlink:to="loc_ci_RealizedInvestmentGainLoss_fa5f6487-0be2-4090-98c7-3a2f1caeb07a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_618932cc-5796-4bb9-b821-9efbcfa54bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ef0d86c5-7e0a-43a7-a125-c21375ae328c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_618932cc-5796-4bb9-b821-9efbcfa54bd7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9680b972-0219-4d59-b07a-ef5f422eb1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ef0d86c5-7e0a-43a7-a125-c21375ae328c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9680b972-0219-4d59-b07a-ef5f422eb1a2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LossOfParentCompany_5d8969d2-c858-4911-a901-5809fa615f7c" xlink:href="ci-20231231.xsd#ci_LossOfParentCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ef0d86c5-7e0a-43a7-a125-c21375ae328c" xlink:to="loc_ci_LossOfParentCompany_5d8969d2-c858-4911-a901-5809fa615f7c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_53ffdc6f-e367-4722-bdb8-ee2e0667250f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromSubsidiariesNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ef0d86c5-7e0a-43a7-a125-c21375ae328c" xlink:to="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_53ffdc6f-e367-4722-bdb8-ee2e0667250f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d46039a2-dcff-44e1-a29b-f185ef0b08e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ef0d86c5-7e0a-43a7-a125-c21375ae328c" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d46039a2-dcff-44e1-a29b-f185ef0b08e6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_984083b9-e3f0-4dce-989f-3e786579434e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ef0d86c5-7e0a-43a7-a125-c21375ae328c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_984083b9-e3f0-4dce-989f-3e786579434e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_0a5fb7f5-25a9-4bf1-85c4-b67f650a7cec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_984083b9-e3f0-4dce-989f-3e786579434e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_0a5fb7f5-25a9-4bf1-85c4-b67f650a7cec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent_e538178a-0545-41e2-a91b-11e11c8fdfc8" xlink:href="ci-20231231.xsd#ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_984083b9-e3f0-4dce-989f-3e786579434e" xlink:to="loc_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent_e538178a-0545-41e2-a91b-11e11c8fdfc8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2202b6af-0148-4a24-8d72-ad71b2c5188d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_984083b9-e3f0-4dce-989f-3e786579434e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2202b6af-0148-4a24-8d72-ad71b2c5188d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_bff9e34a-c640-4927-9845-bf1db0a42272" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_984083b9-e3f0-4dce-989f-3e786579434e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_bff9e34a-c640-4927-9845-bf1db0a42272" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_84828c32-be93-4559-8127-5bb466c85dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_984083b9-e3f0-4dce-989f-3e786579434e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_84828c32-be93-4559-8127-5bb466c85dfd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b43b8743-1e70-4eba-a875-657895983811" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ef0d86c5-7e0a-43a7-a125-c21375ae328c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_b43b8743-1e70-4eba-a875-657895983811" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_9a68d313-64ab-4a39-838e-743fca482800" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_e7aeb4ec-f2ec-4c8b-bc02-7ad53bd3bd75" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_9a68d313-64ab-4a39-838e-743fca482800" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_e7aeb4ec-f2ec-4c8b-bc02-7ad53bd3bd75" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_3884bd5a-0956-4155-a61a-f66e0ab69434" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_e7aeb4ec-f2ec-4c8b-bc02-7ad53bd3bd75" xlink:to="loc_srt_ConsolidatedEntitiesAxis_3884bd5a-0956-4155-a61a-f66e0ab69434" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_3884bd5a-0956-4155-a61a-f66e0ab69434_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_3884bd5a-0956-4155-a61a-f66e0ab69434" xlink:to="loc_srt_ConsolidatedEntitiesDomain_3884bd5a-0956-4155-a61a-f66e0ab69434_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_008988c4-9310-4def-84c2-4ea96f8f780d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_3884bd5a-0956-4155-a61a-f66e0ab69434" xlink:to="loc_srt_ConsolidatedEntitiesDomain_008988c4-9310-4def-84c2-4ea96f8f780d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_daba0927-9609-4a8a-be34-6ffba006d119" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_008988c4-9310-4def-84c2-4ea96f8f780d" xlink:to="loc_srt_ParentCompanyMember_daba0927-9609-4a8a-be34-6ffba006d119" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d984c454-b7b9-46b4-abf9-7540aaf2b9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_e7aeb4ec-f2ec-4c8b-bc02-7ad53bd3bd75" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d984c454-b7b9-46b4-abf9-7540aaf2b9e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d984c454-b7b9-46b4-abf9-7540aaf2b9e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d984c454-b7b9-46b4-abf9-7540aaf2b9e7" xlink:to="loc_us-gaap_RelatedPartyDomain_d984c454-b7b9-46b4-abf9-7540aaf2b9e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_628d1a5a-84f8-40db-ba54-4f0d5c208e90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d984c454-b7b9-46b4-abf9-7540aaf2b9e7" xlink:to="loc_us-gaap_RelatedPartyDomain_628d1a5a-84f8-40db-ba54-4f0d5c208e90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_c24bc482-c300-416a-845d-61b4341b3063" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_628d1a5a-84f8-40db-ba54-4f0d5c208e90" xlink:to="loc_us-gaap_NonrelatedPartyMember_c24bc482-c300-416a-845d-61b4341b3063" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_61abf133-bd23-4f1c-8418-d25cbce2add5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_628d1a5a-84f8-40db-ba54-4f0d5c208e90" xlink:to="loc_us-gaap_RelatedPartyMember_61abf133-bd23-4f1c-8418-d25cbce2add5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SubsidiariesMember_d4ca4c12-faae-454d-aa9d-02dbf3c7c5cc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyMember_61abf133-bd23-4f1c-8418-d25cbce2add5" xlink:to="loc_srt_SubsidiariesMember_d4ca4c12-faae-454d-aa9d-02dbf3c7c5cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_82a1e4ae-ae54-4b11-b88c-7215a6359423" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_9a68d313-64ab-4a39-838e-743fca482800" xlink:to="loc_us-gaap_AssetsAbstract_82a1e4ae-ae54-4b11-b88c-7215a6359423" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f8be9b13-5b26-4ead-9300-81a63e1cc73c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_82a1e4ae-ae54-4b11-b88c-7215a6359423" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f8be9b13-5b26-4ead-9300-81a63e1cc73c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_051b3cd3-58a8-4a50-9217-2a81a2b77d32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_82a1e4ae-ae54-4b11-b88c-7215a6359423" xlink:to="loc_us-gaap_ShortTermInvestments_051b3cd3-58a8-4a50-9217-2a81a2b77d32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_95c81250-72f8-4e8e-b3d4-f7c256e0291b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_82a1e4ae-ae54-4b11-b88c-7215a6359423" xlink:to="loc_us-gaap_OtherAssetsCurrent_95c81250-72f8-4e8e-b3d4-f7c256e0291b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7f712f86-0b38-484f-88bd-a94a85b57051" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_82a1e4ae-ae54-4b11-b88c-7215a6359423" xlink:to="loc_us-gaap_AssetsCurrent_7f712f86-0b38-484f-88bd-a94a85b57051" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndOtherNoncurrentAssets_5db8aa0a-e3fa-48de-a3aa-370091340b45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_82a1e4ae-ae54-4b11-b88c-7215a6359423" xlink:to="loc_us-gaap_InvestmentsAndOtherNoncurrentAssets_5db8aa0a-e3fa-48de-a3aa-370091340b45" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c386fe04-b023-497f-a6fd-d4ce78366834" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_82a1e4ae-ae54-4b11-b88c-7215a6359423" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c386fe04-b023-497f-a6fd-d4ce78366834" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2686154d-2823-42da-85fb-86d3ad17f40c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_82a1e4ae-ae54-4b11-b88c-7215a6359423" xlink:to="loc_us-gaap_Assets_2686154d-2823-42da-85fb-86d3ad17f40c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_2bad65c9-e945-4756-9491-019d33cd7864" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_9a68d313-64ab-4a39-838e-743fca482800" xlink:to="loc_us-gaap_LiabilitiesAbstract_2bad65c9-e945-4756-9491-019d33cd7864" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_15836f3e-f461-4277-abb8-70414ba137d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_2bad65c9-e945-4756-9491-019d33cd7864" xlink:to="loc_us-gaap_DebtCurrent_15836f3e-f461-4277-abb8-70414ba137d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_08ee9cd6-de64-4ef3-9316-09ec6ea52ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_2bad65c9-e945-4756-9491-019d33cd7864" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_08ee9cd6-de64-4ef3-9316-09ec6ea52ef4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3fa526e0-a7a9-46bc-9f35-e033761aa291" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_2bad65c9-e945-4756-9491-019d33cd7864" xlink:to="loc_us-gaap_LiabilitiesCurrent_3fa526e0-a7a9-46bc-9f35-e033761aa291" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b0959a38-fd5f-4802-a132-5c6a965ad2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_2bad65c9-e945-4756-9491-019d33cd7864" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b0959a38-fd5f-4802-a132-5c6a965ad2d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_303f3ab6-fdff-4190-930f-0aa2884199b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_2bad65c9-e945-4756-9491-019d33cd7864" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_303f3ab6-fdff-4190-930f-0aa2884199b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_716ad076-b13d-42d0-806d-e0129fcb5650" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_2bad65c9-e945-4756-9491-019d33cd7864" xlink:to="loc_us-gaap_Liabilities_716ad076-b13d-42d0-806d-e0129fcb5650" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShareholdersEquityAbstract_d6cb56ad-8561-4be9-a6f3-c1d3b2612915" xlink:href="ci-20231231.xsd#ci_ShareholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_9a68d313-64ab-4a39-838e-743fca482800" xlink:to="loc_ci_ShareholdersEquityAbstract_d6cb56ad-8561-4be9-a6f3-c1d3b2612915" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0b0b927e-b119-4531-864f-64db44ed13ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ShareholdersEquityAbstract_d6cb56ad-8561-4be9-a6f3-c1d3b2612915" xlink:to="loc_us-gaap_CommonStockValue_0b0b927e-b119-4531-864f-64db44ed13ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e483a4c8-43c2-4068-8535-ac0d10b7c7eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ShareholdersEquityAbstract_d6cb56ad-8561-4be9-a6f3-c1d3b2612915" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e483a4c8-43c2-4068-8535-ac0d10b7c7eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6bd0a0f2-a9cd-49f3-9629-fe2b68523691" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ShareholdersEquityAbstract_d6cb56ad-8561-4be9-a6f3-c1d3b2612915" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6bd0a0f2-a9cd-49f3-9629-fe2b68523691" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5f4d6a03-9a78-4f3e-b202-9875b61c07e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ShareholdersEquityAbstract_d6cb56ad-8561-4be9-a6f3-c1d3b2612915" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5f4d6a03-9a78-4f3e-b202-9875b61c07e0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_43ce0621-46a7-4d2c-ac86-79e8ca442a69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ShareholdersEquityAbstract_d6cb56ad-8561-4be9-a6f3-c1d3b2612915" xlink:to="loc_us-gaap_TreasuryStockValue_43ce0621-46a7-4d2c-ac86-79e8ca442a69" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8571610c-c6ba-4c85-b00c-36e782285ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_ShareholdersEquityAbstract_d6cb56ad-8561-4be9-a6f3-c1d3b2612915" xlink:to="loc_us-gaap_StockholdersEquity_8571610c-c6ba-4c85-b00c-36e782285ccd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ad82950f-a488-436e-84ab-02e46258e41a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_9a68d313-64ab-4a39-838e-743fca482800" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ad82950f-a488-436e-84ab-02e46258e41a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_6dbf5cf5-1265-44dc-9780-98f3a15e08ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_9a68d313-64ab-4a39-838e-743fca482800" xlink:to="loc_us-gaap_CommonStockSharesIssued_6dbf5cf5-1265-44dc-9780-98f3a15e08ee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ac544a62-b6c9-48a7-a192-f86433ce39d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_9a68d313-64ab-4a39-838e-743fca482800" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ac544a62-b6c9-48a7-a192-f86433ce39d3" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7983508b-6996-48f4-bca4-28296bffdf40" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_9b19d6ad-a64a-44ad-822d-ed064e46b4c2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7983508b-6996-48f4-bca4-28296bffdf40" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_9b19d6ad-a64a-44ad-822d-ed064e46b4c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_e24e475b-f836-4075-b4e2-a7a0fc2d20a5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_9b19d6ad-a64a-44ad-822d-ed064e46b4c2" xlink:to="loc_srt_ConsolidatedEntitiesAxis_e24e475b-f836-4075-b4e2-a7a0fc2d20a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_e24e475b-f836-4075-b4e2-a7a0fc2d20a5_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_e24e475b-f836-4075-b4e2-a7a0fc2d20a5" xlink:to="loc_srt_ConsolidatedEntitiesDomain_e24e475b-f836-4075-b4e2-a7a0fc2d20a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_367d9b81-638d-4267-96fd-4473bdb6ccc6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_e24e475b-f836-4075-b4e2-a7a0fc2d20a5" xlink:to="loc_srt_ConsolidatedEntitiesDomain_367d9b81-638d-4267-96fd-4473bdb6ccc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_a163478c-09f8-426e-b248-5478c3026267" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_367d9b81-638d-4267-96fd-4473bdb6ccc6" xlink:to="loc_srt_ParentCompanyMember_a163478c-09f8-426e-b248-5478c3026267" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6536d45f-4d9a-4d9d-b0d4-a288bcfd52a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_9b19d6ad-a64a-44ad-822d-ed064e46b4c2" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6536d45f-4d9a-4d9d-b0d4-a288bcfd52a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_6536d45f-4d9a-4d9d-b0d4-a288bcfd52a3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6536d45f-4d9a-4d9d-b0d4-a288bcfd52a3" xlink:to="loc_us-gaap_RelatedPartyDomain_6536d45f-4d9a-4d9d-b0d4-a288bcfd52a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e73594bb-c0a7-4d79-95e3-1a69beb752fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6536d45f-4d9a-4d9d-b0d4-a288bcfd52a3" xlink:to="loc_us-gaap_RelatedPartyDomain_e73594bb-c0a7-4d79-95e3-1a69beb752fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_b691af29-9a06-46e6-9a36-94cbd3e10999" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_e73594bb-c0a7-4d79-95e3-1a69beb752fd" xlink:to="loc_us-gaap_NonrelatedPartyMember_b691af29-9a06-46e6-9a36-94cbd3e10999" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_91d22520-0744-425c-9922-24047f7add63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_e73594bb-c0a7-4d79-95e3-1a69beb752fd" xlink:to="loc_us-gaap_RelatedPartyMember_91d22520-0744-425c-9922-24047f7add63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SubsidiariesMember_81113dbb-bdba-45fb-8a9a-31ef04daa1c2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyMember_91d22520-0744-425c-9922-24047f7add63" xlink:to="loc_srt_SubsidiariesMember_81113dbb-bdba-45fb-8a9a-31ef04daa1c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ce11e329-996a-4f80-b8f5-5951671f722b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7983508b-6996-48f4-bca4-28296bffdf40" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ce11e329-996a-4f80-b8f5-5951671f722b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_902b11ed-f0c0-4775-aa8d-28a1cfa51f87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ce11e329-996a-4f80-b8f5-5951671f722b" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_902b11ed-f0c0-4775-aa8d-28a1cfa51f87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d388704f-0ec7-45b8-9375-cddd5fb27742" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ce11e329-996a-4f80-b8f5-5951671f722b" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d388704f-0ec7-45b8-9375-cddd5fb27742" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_796e2501-7717-4f59-811d-fe6ee76cb53f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromSubsidiariesNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d388704f-0ec7-45b8-9375-cddd5fb27742" xlink:to="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_796e2501-7717-4f59-811d-fe6ee76cb53f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_05454add-ba3b-4c3e-b0cb-ac492b99b4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d388704f-0ec7-45b8-9375-cddd5fb27742" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_05454add-ba3b-4c3e-b0cb-ac492b99b4d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries_1674f337-9b78-402b-9c35-d095d4b25ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d388704f-0ec7-45b8-9375-cddd5fb27742" xlink:to="loc_us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries_1674f337-9b78-402b-9c35-d095d4b25ea2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities_19606547-71b9-4a38-adba-f23e9ea60dcd" xlink:href="ci-20231231.xsd#ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d388704f-0ec7-45b8-9375-cddd5fb27742" xlink:to="loc_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities_19606547-71b9-4a38-adba-f23e9ea60dcd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_c47e6371-e6f5-487a-802a-28632b440c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d388704f-0ec7-45b8-9375-cddd5fb27742" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_c47e6371-e6f5-487a-802a-28632b440c5b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a71248a-45e8-4e4b-96a2-b5524e390202" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ce11e329-996a-4f80-b8f5-5951671f722b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a71248a-45e8-4e4b-96a2-b5524e390202" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_397f03c4-e4d4-4917-b251-275fcca95a57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7983508b-6996-48f4-bca4-28296bffdf40" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_397f03c4-e4d4-4917-b251-275fcca95a57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncreaseDecreaseInAmountsDueFromAffiliates_b636c96d-1f5f-4a1c-af6d-84ca8f14baae" xlink:href="ci-20231231.xsd#ci_IncreaseDecreaseInAmountsDueFromAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_397f03c4-e4d4-4917-b251-275fcca95a57" xlink:to="loc_ci_IncreaseDecreaseInAmountsDueFromAffiliates_b636c96d-1f5f-4a1c-af6d-84ca8f14baae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_5c005ee0-a364-41ee-b46e-b6dd4e03ad1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_397f03c4-e4d4-4917-b251-275fcca95a57" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_5c005ee0-a364-41ee-b46e-b6dd4e03ad1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9689a92f-1bc9-4806-b76a-11257c6e4f19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_397f03c4-e4d4-4917-b251-275fcca95a57" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9689a92f-1bc9-4806-b76a-11257c6e4f19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dad29f47-16c3-48ff-9392-07527555cf9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7983508b-6996-48f4-bca4-28296bffdf40" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dad29f47-16c3-48ff-9392-07527555cf9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_1e2fb9f6-12b9-4b33-b347-90bc9468ca76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dad29f47-16c3-48ff-9392-07527555cf9d" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_1e2fb9f6-12b9-4b33-b347-90bc9468ca76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_65dcc118-6c80-48da-bf26-7e3e847d63b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dad29f47-16c3-48ff-9392-07527555cf9d" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_65dcc118-6c80-48da-bf26-7e3e847d63b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_28946d72-62a0-4eb2-a89a-0b5e96a0d855" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dad29f47-16c3-48ff-9392-07527555cf9d" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_28946d72-62a0-4eb2-a89a-0b5e96a0d855" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_b09427b2-2f9d-4e40-bb33-bb80266c1a78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dad29f47-16c3-48ff-9392-07527555cf9d" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_b09427b2-2f9d-4e40-bb33-bb80266c1a78" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_5dcfcc7f-dd22-48d9-afb4-08433564603c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dad29f47-16c3-48ff-9392-07527555cf9d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_5dcfcc7f-dd22-48d9-afb4-08433564603c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ac4b4223-bd03-4726-846a-fc737fc6e38c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dad29f47-16c3-48ff-9392-07527555cf9d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ac4b4223-bd03-4726-846a-fc737fc6e38c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_ba907e22-f47d-4b31-8c19-6bc311a8e235" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dad29f47-16c3-48ff-9392-07527555cf9d" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_ba907e22-f47d-4b31-8c19-6bc311a8e235" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d7efeb5f-68fe-452d-9887-1d6522fff9af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dad29f47-16c3-48ff-9392-07527555cf9d" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d7efeb5f-68fe-452d-9887-1d6522fff9af" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_abca783f-d258-4746-8538-86c33548cfb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dad29f47-16c3-48ff-9392-07527555cf9d" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_abca783f-d258-4746-8538-86c33548cfb0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0db98a0f-4c96-439d-b59b-108552bb886f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dad29f47-16c3-48ff-9392-07527555cf9d" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0db98a0f-4c96-439d-b59b-108552bb886f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_eed66d96-d9b2-4548-b860-120a90e718c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dad29f47-16c3-48ff-9392-07527555cf9d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_eed66d96-d9b2-4548-b860-120a90e718c3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_eb3ff58e-5edd-47fc-a601-0452e0c978c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7983508b-6996-48f4-bca4-28296bffdf40" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_eb3ff58e-5edd-47fc-a601-0452e0c978c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3b749033-fd8c-4087-9fd1-34329217b8b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7983508b-6996-48f4-bca4-28296bffdf40" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3b749033-fd8c-4087-9fd1-34329217b8b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5d34f720-ca07-4ddb-bcb4-6d30872ad51c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReduction_a5b225ee-6db0-4aca-b6a7-c45e0829502e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesReduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7983508b-6996-48f4-bca4-28296bffdf40" xlink:to="loc_us-gaap_NotesReduction_a5b225ee-6db0-4aca-b6a7-c45e0829502e" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_cd4fceb5-8e5c-4e70-9c75-38c1c9ab3666" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_c0984e01-adf3-4cc3-9367-991817129903" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_cd4fceb5-8e5c-4e70-9c75-38c1c9ab3666" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_c0984e01-adf3-4cc3-9367-991817129903" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_e728ac71-a878-48d7-9cb3-2bfa1713ad46" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_c0984e01-adf3-4cc3-9367-991817129903" xlink:to="loc_srt_ConsolidatedEntitiesAxis_e728ac71-a878-48d7-9cb3-2bfa1713ad46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_e728ac71-a878-48d7-9cb3-2bfa1713ad46_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_e728ac71-a878-48d7-9cb3-2bfa1713ad46" xlink:to="loc_srt_ConsolidatedEntitiesDomain_e728ac71-a878-48d7-9cb3-2bfa1713ad46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_90852a49-a395-43d4-8b33-bd96b76d3f75" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_e728ac71-a878-48d7-9cb3-2bfa1713ad46" xlink:to="loc_srt_ConsolidatedEntitiesDomain_90852a49-a395-43d4-8b33-bd96b76d3f75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_f3b64acb-dd21-4bcd-8e48-53bc4a134216" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_90852a49-a395-43d4-8b33-bd96b76d3f75" xlink:to="loc_srt_ParentCompanyMember_f3b64acb-dd21-4bcd-8e48-53bc4a134216" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_dac02865-e8f8-41c9-b0fc-23ae33828bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_c0984e01-adf3-4cc3-9367-991817129903" xlink:to="loc_us-gaap_DebtInstrumentAxis_dac02865-e8f8-41c9-b0fc-23ae33828bcb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_dac02865-e8f8-41c9-b0fc-23ae33828bcb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_dac02865-e8f8-41c9-b0fc-23ae33828bcb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_dac02865-e8f8-41c9-b0fc-23ae33828bcb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f151a95f-9479-4efc-a161-d4ef67378aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_dac02865-e8f8-41c9-b0fc-23ae33828bcb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f151a95f-9479-4efc-a161-d4ef67378aa9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RevolvingCreditAgreementsApril2023Member_d792033f-443c-4033-9807-405341196503" xlink:href="ci-20231231.xsd#ci_RevolvingCreditAgreementsApril2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f151a95f-9479-4efc-a161-d4ef67378aa9" xlink:to="loc_ci_RevolvingCreditAgreementsApril2023Member_d792033f-443c-4033-9807-405341196503" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member_6f8ff458-f6d3-4934-89c3-f097e36c9426" xlink:href="ci-20231231.xsd#ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_RevolvingCreditAgreementsApril2023Member_d792033f-443c-4033-9807-405341196503" xlink:to="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member_6f8ff458-f6d3-4934-89c3-f097e36c9426" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_A364DayRevolvingCreditAgreementMaturingApril2024Member_8212c99e-d8b7-486a-9d42-f8b03cf1cbe3" xlink:href="ci-20231231.xsd#ci_A364DayRevolvingCreditAgreementMaturingApril2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_RevolvingCreditAgreementsApril2023Member_d792033f-443c-4033-9807-405341196503" xlink:to="loc_ci_A364DayRevolvingCreditAgreementMaturingApril2024Member_8212c99e-d8b7-486a-9d42-f8b03cf1cbe3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member_d869a9a0-e9c7-4900-8939-b05c7d7f639d" xlink:href="ci-20231231.xsd#ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f151a95f-9479-4efc-a161-d4ef67378aa9" xlink:to="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member_d869a9a0-e9c7-4900-8939-b05c7d7f639d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member_9489e6dc-d49e-4035-8d68-059a99802581" xlink:href="ci-20231231.xsd#ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member_d869a9a0-e9c7-4900-8939-b05c7d7f639d" xlink:to="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member_9489e6dc-d49e-4035-8d68-059a99802581" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RevolvingCreditFacilityMaturingApril2025Member_18cd1097-db71-43b6-9ef2-43a369d241b2" xlink:href="ci-20231231.xsd#ci_RevolvingCreditFacilityMaturingApril2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member_d869a9a0-e9c7-4900-8939-b05c7d7f639d" xlink:to="loc_ci_RevolvingCreditFacilityMaturingApril2025Member_18cd1097-db71-43b6-9ef2-43a369d241b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_A364DayRevolvingCreditAgreementMaturingApril2023Member_04d297b9-03df-4675-9d18-313d679cfebd" xlink:href="ci-20231231.xsd#ci_A364DayRevolvingCreditAgreementMaturingApril2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member_d869a9a0-e9c7-4900-8939-b05c7d7f639d" xlink:to="loc_ci_A364DayRevolvingCreditAgreementMaturingApril2023Member_04d297b9-03df-4675-9d18-313d679cfebd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_388cdad5-618c-4661-81c3-e8106567cd77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_c0984e01-adf3-4cc3-9367-991817129903" xlink:to="loc_us-gaap_CreditFacilityAxis_388cdad5-618c-4661-81c3-e8106567cd77" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_388cdad5-618c-4661-81c3-e8106567cd77_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_388cdad5-618c-4661-81c3-e8106567cd77" xlink:to="loc_us-gaap_CreditFacilityDomain_388cdad5-618c-4661-81c3-e8106567cd77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_abaeb070-f0d2-4524-bc32-bfa67beba4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_388cdad5-618c-4661-81c3-e8106567cd77" xlink:to="loc_us-gaap_CreditFacilityDomain_abaeb070-f0d2-4524-bc32-bfa67beba4b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_d15b0cab-5bbe-4864-a6d3-11aacebe3d80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_abaeb070-f0d2-4524-bc32-bfa67beba4b5" xlink:to="loc_us-gaap_LetterOfCreditMember_d15b0cab-5bbe-4864-a6d3-11aacebe3d80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_3377a6c2-b9c8-46a8-946a-6d908e52742a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_abaeb070-f0d2-4524-bc32-bfa67beba4b5" xlink:to="loc_us-gaap_CommercialPaperMember_3377a6c2-b9c8-46a8-946a-6d908e52742a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_a5407bc1-214c-4a93-b713-75a74c285585" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_cd4fceb5-8e5c-4e70-9c75-38c1c9ab3666" xlink:to="loc_us-gaap_LineOfCredit_a5407bc1-214c-4a93-b713-75a74c285585" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_900ee688-59e6-414d-9717-60a4fa8e5b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_cd4fceb5-8e5c-4e70-9c75-38c1c9ab3666" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_900ee688-59e6-414d-9717-60a4fa8e5b8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_c9a31589-c526-4e29-9929-ed41c4b86933" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_cd4fceb5-8e5c-4e70-9c75-38c1c9ab3666" xlink:to="loc_us-gaap_DebtInstrumentTerm_c9a31589-c526-4e29-9929-ed41c4b86933" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtInstrumentExtensionTerm_ef4c29b0-8d29-4007-aaf1-c286dc16e76d" xlink:href="ci-20231231.xsd#ci_DebtInstrumentExtensionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_cd4fceb5-8e5c-4e70-9c75-38c1c9ab3666" xlink:to="loc_ci_DebtInstrumentExtensionTerm_ef4c29b0-8d29-4007-aaf1-c286dc16e76d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LineOfCreditFacilityConversionToTermLoanTerm_6b4a2a6f-1bd7-461f-9113-6295eb44f9e7" xlink:href="ci-20231231.xsd#ci_LineOfCreditFacilityConversionToTermLoanTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_cd4fceb5-8e5c-4e70-9c75-38c1c9ab3666" xlink:to="loc_ci_LineOfCreditFacilityConversionToTermLoanTerm_6b4a2a6f-1bd7-461f-9113-6295eb44f9e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity_20e5f11d-ea7d-4f0d-a92b-a2b26eba56cf" xlink:href="ci-20231231.xsd#ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_cd4fceb5-8e5c-4e70-9c75-38c1c9ab3666" xlink:to="loc_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity_20e5f11d-ea7d-4f0d-a92b-a2b26eba56cf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity_95a34650-adc7-4373-9f3f-e35d36034d62" xlink:href="ci-20231231.xsd#ci_LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_cd4fceb5-8e5c-4e70-9c75-38c1c9ab3666" xlink:to="loc_ci_LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity_95a34650-adc7-4373-9f3f-e35d36034d62" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement_79d967a0-ab8e-46bf-8b97-c9344863f5ff" xlink:href="ci-20231231.xsd#ci_NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_cd4fceb5-8e5c-4e70-9c75-38c1c9ab3666" xlink:to="loc_ci_NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement_79d967a0-ab8e-46bf-8b97-c9344863f5ff" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant_1042e0ff-55e6-4ef1-8587-6e4718992f9b" xlink:href="ci-20231231.xsd#ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_cd4fceb5-8e5c-4e70-9c75-38c1c9ab3666" xlink:to="loc_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant_1042e0ff-55e6-4ef1-8587-6e4718992f9b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CommercialPaperAverageRatePaid_5f6b2acc-8c4f-4a16-9ac3-5c040d41210a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CommercialPaperAverageRatePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_cd4fceb5-8e5c-4e70-9c75-38c1c9ab3666" xlink:to="loc_srt_CommercialPaperAverageRatePaid_5f6b2acc-8c4f-4a16-9ac3-5c040d41210a" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4e4cc760-ed20-49b7-8ae3-85dbdd35ecb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6ca32003-39ab-447d-8366-f07c5d687d10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e4cc760-ed20-49b7-8ae3-85dbdd35ecb8" xlink:to="loc_us-gaap_DebtInstrumentTable_6ca32003-39ab-447d-8366-f07c5d687d10" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_92ad50b3-ec9b-4f81-b29c-280375fbda50" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6ca32003-39ab-447d-8366-f07c5d687d10" xlink:to="loc_srt_ConsolidatedEntitiesAxis_92ad50b3-ec9b-4f81-b29c-280375fbda50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_92ad50b3-ec9b-4f81-b29c-280375fbda50_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_92ad50b3-ec9b-4f81-b29c-280375fbda50" xlink:to="loc_srt_ConsolidatedEntitiesDomain_92ad50b3-ec9b-4f81-b29c-280375fbda50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_b8e0cc6c-dfb5-4d22-b357-87fccde5e058" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_92ad50b3-ec9b-4f81-b29c-280375fbda50" xlink:to="loc_srt_ConsolidatedEntitiesDomain_b8e0cc6c-dfb5-4d22-b357-87fccde5e058" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_eb2fab26-637a-4d2d-ab10-a3ddbf7fb6da" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_b8e0cc6c-dfb5-4d22-b357-87fccde5e058" xlink:to="loc_srt_ParentCompanyMember_eb2fab26-637a-4d2d-ab10-a3ddbf7fb6da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c69c4ad0-721d-4fd7-8b97-0a8b15269bce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6ca32003-39ab-447d-8366-f07c5d687d10" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c69c4ad0-721d-4fd7-8b97-0a8b15269bce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c69c4ad0-721d-4fd7-8b97-0a8b15269bce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c69c4ad0-721d-4fd7-8b97-0a8b15269bce" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c69c4ad0-721d-4fd7-8b97-0a8b15269bce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_eb776046-ff0e-4e23-9fb3-ef7954044330" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c69c4ad0-721d-4fd7-8b97-0a8b15269bce" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_eb776046-ff0e-4e23-9fb3-ef7954044330" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_07d6365f-6939-402b-80cd-1398363c0404" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_eb776046-ff0e-4e23-9fb3-ef7954044330" xlink:to="loc_us-gaap_SeniorNotesMember_07d6365f-6939-402b-80cd-1398363c0404" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_39e82ce3-6ded-4bcc-bf3d-4a8c72de158e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6ca32003-39ab-447d-8366-f07c5d687d10" xlink:to="loc_us-gaap_DebtInstrumentAxis_39e82ce3-6ded-4bcc-bf3d-4a8c72de158e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_39e82ce3-6ded-4bcc-bf3d-4a8c72de158e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_39e82ce3-6ded-4bcc-bf3d-4a8c72de158e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_39e82ce3-6ded-4bcc-bf3d-4a8c72de158e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_817cce55-81ad-41a8-9717-8ba62a239c09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_39e82ce3-6ded-4bcc-bf3d-4a8c72de158e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_817cce55-81ad-41a8-9717-8ba62a239c09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20265685Member_bd359382-f69d-4383-a878-b463cf875de0" xlink:href="ci-20231231.xsd#ci_NotesDue20265685Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_817cce55-81ad-41a8-9717-8ba62a239c09" xlink:to="loc_ci_NotesDue20265685Member_bd359382-f69d-4383-a878-b463cf875de0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20335400InterestMember_c5dded23-8d94-4eb2-9a40-27c5d3068be9" xlink:href="ci-20231231.xsd#ci_NotesDue20335400InterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_817cce55-81ad-41a8-9717-8ba62a239c09" xlink:to="loc_ci_NotesDue20335400InterestMember_c5dded23-8d94-4eb2-9a40-27c5d3068be9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue202435InterestMember_53dccdba-f8da-445e-85f7-6755382ef93f" xlink:href="ci-20231231.xsd#ci_NotesDue202435InterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_817cce55-81ad-41a8-9717-8ba62a239c09" xlink:to="loc_ci_NotesDue202435InterestMember_53dccdba-f8da-445e-85f7-6755382ef93f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_7fb39523-c25c-4c46-ac1b-f2f04cc644f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6ca32003-39ab-447d-8366-f07c5d687d10" xlink:to="loc_us-gaap_VariableRateAxis_7fb39523-c25c-4c46-ac1b-f2f04cc644f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_7fb39523-c25c-4c46-ac1b-f2f04cc644f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_7fb39523-c25c-4c46-ac1b-f2f04cc644f6" xlink:to="loc_us-gaap_VariableRateDomain_7fb39523-c25c-4c46-ac1b-f2f04cc644f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_8808cf23-711d-482d-9cc6-6ce75795f467" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_7fb39523-c25c-4c46-ac1b-f2f04cc644f6" xlink:to="loc_us-gaap_VariableRateDomain_8808cf23-711d-482d-9cc6-6ce75795f467" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UsTreasuryUstInterestRateMember_3dae3e84-e6d5-4347-b398-9060f425ac8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UsTreasuryUstInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_8808cf23-711d-482d-9cc6-6ce75795f467" xlink:to="loc_us-gaap_UsTreasuryUstInterestRateMember_3dae3e84-e6d5-4347-b398-9060f425ac8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a45d101c-de46-4c31-9228-bc79241c6146" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6ca32003-39ab-447d-8366-f07c5d687d10" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a45d101c-de46-4c31-9228-bc79241c6146" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a45d101c-de46-4c31-9228-bc79241c6146_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a45d101c-de46-4c31-9228-bc79241c6146" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a45d101c-de46-4c31-9228-bc79241c6146_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_64d2b8a0-4e76-4249-8e0c-dfdf68f64dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a45d101c-de46-4c31-9228-bc79241c6146" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_64d2b8a0-4e76-4249-8e0c-dfdf68f64dd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_4f6bea70-7195-4f64-8270-5ee4de8aceaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_64d2b8a0-4e76-4249-8e0c-dfdf68f64dd8" xlink:to="loc_us-gaap_SubsequentEventMember_4f6bea70-7195-4f64-8270-5ee4de8aceaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_234f645c-20c4-4b5a-9a42-8602f96a5220" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6ca32003-39ab-447d-8366-f07c5d687d10" xlink:to="loc_srt_StatementScenarioAxis_234f645c-20c4-4b5a-9a42-8602f96a5220" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_234f645c-20c4-4b5a-9a42-8602f96a5220_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_234f645c-20c4-4b5a-9a42-8602f96a5220" xlink:to="loc_srt_ScenarioUnspecifiedDomain_234f645c-20c4-4b5a-9a42-8602f96a5220_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_37737e2e-6c3a-4f50-a8f2-e71321555f7f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_234f645c-20c4-4b5a-9a42-8602f96a5220" xlink:to="loc_srt_ScenarioUnspecifiedDomain_37737e2e-6c3a-4f50-a8f2-e71321555f7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_a2ff735c-5d50-48ab-b06f-0541f725bfee" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_37737e2e-6c3a-4f50-a8f2-e71321555f7f" xlink:to="loc_srt_ScenarioForecastMember_a2ff735c-5d50-48ab-b06f-0541f725bfee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_99395926-f663-46b7-9ee8-a1c68ba542bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e4cc760-ed20-49b7-8ae3-85dbdd35ecb8" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_99395926-f663-46b7-9ee8-a1c68ba542bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees_9c83fbba-fc1b-4f17-803c-cf94a8a96a6b" xlink:href="ci-20231231.xsd#ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e4cc760-ed20-49b7-8ae3-85dbdd35ecb8" xlink:to="loc_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees_9c83fbba-fc1b-4f17-803c-cf94a8a96a6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8e9312bd-2a96-4120-940b-ee48a50254a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e4cc760-ed20-49b7-8ae3-85dbdd35ecb8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8e9312bd-2a96-4120-940b-ee48a50254a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate_582fc862-15da-4214-9c72-3465966fa3c7" xlink:href="ci-20231231.xsd#ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e4cc760-ed20-49b7-8ae3-85dbdd35ecb8" xlink:to="loc_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate_582fc862-15da-4214-9c72-3465966fa3c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_4160e017-abc6-437a-ad47-f34111160822" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e4cc760-ed20-49b7-8ae3-85dbdd35ecb8" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_4160e017-abc6-437a-ad47-f34111160822" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6fef36cb-1df1-44e4-9b03-11a524683f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e4cc760-ed20-49b7-8ae3-85dbdd35ecb8" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6fef36cb-1df1-44e4-9b03-11a524683f6b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_GainLossOnExtinguishmentOfDebtNetOfTax_3b01df75-0157-4bc1-971f-b41384060178" xlink:href="ci-20231231.xsd#ci_GainLossOnExtinguishmentOfDebtNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e4cc760-ed20-49b7-8ae3-85dbdd35ecb8" xlink:to="loc_ci_GainLossOnExtinguishmentOfDebtNetOfTax_3b01df75-0157-4bc1-971f-b41384060178" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_95f3d88e-54c3-4e96-bb46-225b8e5c4bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e4cc760-ed20-49b7-8ae3-85dbdd35ecb8" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_95f3d88e-54c3-4e96-bb46-225b8e5c4bb2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_799dc15d-a74f-413f-a85d-e2b152fe8b35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e4cc760-ed20-49b7-8ae3-85dbdd35ecb8" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_799dc15d-a74f-413f-a85d-e2b152fe8b35" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupDebtMaturitiesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#ScheduleICondensedFinancialInformationofTheCignaGroupDebtMaturitiesDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupDebtMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_eca782d3-a6f5-4b0c-b518-eacf99a2156f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a3880b97-9f1f-4a8a-9123-242c3b6e6b02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_eca782d3-a6f5-4b0c-b518-eacf99a2156f" xlink:to="loc_us-gaap_DebtInstrumentTable_a3880b97-9f1f-4a8a-9123-242c3b6e6b02" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_abd4be00-bf83-4b5f-a8f2-16f2ed267240" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a3880b97-9f1f-4a8a-9123-242c3b6e6b02" xlink:to="loc_srt_ConsolidatedEntitiesAxis_abd4be00-bf83-4b5f-a8f2-16f2ed267240" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_abd4be00-bf83-4b5f-a8f2-16f2ed267240_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_abd4be00-bf83-4b5f-a8f2-16f2ed267240" xlink:to="loc_srt_ConsolidatedEntitiesDomain_abd4be00-bf83-4b5f-a8f2-16f2ed267240_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_c069de4d-d2df-43b2-9bcd-529fb856fac1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_abd4be00-bf83-4b5f-a8f2-16f2ed267240" xlink:to="loc_srt_ConsolidatedEntitiesDomain_c069de4d-d2df-43b2-9bcd-529fb856fac1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_5029f2b2-7ef3-4282-9229-c0325e4b621d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_c069de4d-d2df-43b2-9bcd-529fb856fac1" xlink:to="loc_srt_ParentCompanyMember_5029f2b2-7ef3-4282-9229-c0325e4b621d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_30fc31e1-2bf0-4c18-a125-2b7c650568b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_eca782d3-a6f5-4b0c-b518-eacf99a2156f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_30fc31e1-2bf0-4c18-a125-2b7c650568b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_00a5e940-a7d3-4409-900a-323117b0fcc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_eca782d3-a6f5-4b0c-b518-eacf99a2156f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_00a5e940-a7d3-4409-900a-323117b0fcc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_07aa2b3e-97e5-4ff7-835c-f988d2ec3166" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_eca782d3-a6f5-4b0c-b518-eacf99a2156f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_07aa2b3e-97e5-4ff7-835c-f988d2ec3166" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_12cf8241-1712-43eb-ae13-975de2374b36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_eca782d3-a6f5-4b0c-b518-eacf99a2156f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_12cf8241-1712-43eb-ae13-975de2374b36" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_8efae55a-79f8-4d32-b71c-291d04fab503" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_eca782d3-a6f5-4b0c-b518-eacf99a2156f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_8efae55a-79f8-4d32-b71c-291d04fab503" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_ce1a3192-04cd-4f44-9ab9-1cff3111ee2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_eca782d3-a6f5-4b0c-b518-eacf99a2156f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_ce1a3192-04cd-4f44-9ab9-1cff3111ee2a" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupIntercompanyBalancesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#ScheduleICondensedFinancialInformationofTheCignaGroupIntercompanyBalancesDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupIntercompanyBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_cb892534-3baf-427b-bf5b-4c3eadbad43a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_e35d1d5d-a05b-40ca-9017-6fafab8b5f22" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_cb892534-3baf-427b-bf5b-4c3eadbad43a" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_e35d1d5d-a05b-40ca-9017-6fafab8b5f22" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_15ed9696-aed6-422c-92a4-46e55e6e6627" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_e35d1d5d-a05b-40ca-9017-6fafab8b5f22" xlink:to="loc_srt_ConsolidatedEntitiesAxis_15ed9696-aed6-422c-92a4-46e55e6e6627" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_15ed9696-aed6-422c-92a4-46e55e6e6627_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_15ed9696-aed6-422c-92a4-46e55e6e6627" xlink:to="loc_srt_ConsolidatedEntitiesDomain_15ed9696-aed6-422c-92a4-46e55e6e6627_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_7ad3c118-ad09-4822-9568-e38eead40267" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_15ed9696-aed6-422c-92a4-46e55e6e6627" xlink:to="loc_srt_ConsolidatedEntitiesDomain_7ad3c118-ad09-4822-9568-e38eead40267" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_d43082ee-94a5-4189-b5af-0cb3b5efa4b1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_7ad3c118-ad09-4822-9568-e38eead40267" xlink:to="loc_srt_ParentCompanyMember_d43082ee-94a5-4189-b5af-0cb3b5efa4b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_84859e49-31ef-43a4-a9c9-ce9e0572d8e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_e35d1d5d-a05b-40ca-9017-6fafab8b5f22" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_84859e49-31ef-43a4-a9c9-ce9e0572d8e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_84859e49-31ef-43a4-a9c9-ce9e0572d8e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_84859e49-31ef-43a4-a9c9-ce9e0572d8e6" xlink:to="loc_us-gaap_RelatedPartyDomain_84859e49-31ef-43a4-a9c9-ce9e0572d8e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_55b438ff-83aa-4149-b4b5-cb1592291e34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_84859e49-31ef-43a4-a9c9-ce9e0572d8e6" xlink:to="loc_us-gaap_RelatedPartyDomain_55b438ff-83aa-4149-b4b5-cb1592291e34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_6d6abf18-7442-4504-b764-1bc55e0f7321" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_55b438ff-83aa-4149-b4b5-cb1592291e34" xlink:to="loc_us-gaap_NonrelatedPartyMember_6d6abf18-7442-4504-b764-1bc55e0f7321" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_e032240b-cda4-4875-aaa1-10ad83f83a09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_55b438ff-83aa-4149-b4b5-cb1592291e34" xlink:to="loc_us-gaap_RelatedPartyMember_e032240b-cda4-4875-aaa1-10ad83f83a09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SubsidiariesMember_a6c23ba8-8812-40ad-9ee5-e5780a6e36ce" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyMember_e032240b-cda4-4875-aaa1-10ad83f83a09" xlink:to="loc_srt_SubsidiariesMember_a6c23ba8-8812-40ad-9ee5-e5780a6e36ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EvernorthHealthIncorporatedMember_bafafa55-01fb-4500-8543-1fe590bc2239" xlink:href="ci-20231231.xsd#ci_EvernorthHealthIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SubsidiariesMember_a6c23ba8-8812-40ad-9ee5-e5780a6e36ce" xlink:to="loc_ci_EvernorthHealthIncorporatedMember_bafafa55-01fb-4500-8543-1fe590bc2239" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ThreeWhollyOwnedSubsidiariesMember_69269e6f-6717-463f-82c2-5c10aea7183f" xlink:href="ci-20231231.xsd#ci_ThreeWhollyOwnedSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SubsidiariesMember_a6c23ba8-8812-40ad-9ee5-e5780a6e36ce" xlink:to="loc_ci_ThreeWhollyOwnedSubsidiariesMember_69269e6f-6717-463f-82c2-5c10aea7183f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_4863b634-8c04-42c5-a2bb-e3f6f1418b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_cb892534-3baf-427b-bf5b-4c3eadbad43a" xlink:to="loc_us-gaap_OtherAssetsCurrent_4863b634-8c04-42c5-a2bb-e3f6f1418b4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntercompanyReceivablesInterestRate_6f29d92f-78e2-44b3-87e5-d78752153d6d" xlink:href="ci-20231231.xsd#ci_IntercompanyReceivablesInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_cb892534-3baf-427b-bf5b-4c3eadbad43a" xlink:to="loc_ci_IntercompanyReceivablesInterestRate_6f29d92f-78e2-44b3-87e5-d78752153d6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AverageInterestRateOnIntercompanyLoan_d9b75563-b658-4d4f-a870-334965b1938b" xlink:href="ci-20231231.xsd#ci_AverageInterestRateOnIntercompanyLoan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_cb892534-3baf-427b-bf5b-4c3eadbad43a" xlink:to="loc_ci_AverageInterestRateOnIntercompanyLoan_d9b75563-b658-4d4f-a870-334965b1938b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DueFromAffiliateNoncurrentNet_8ea56a33-49e3-41c8-b8aa-283146895093" xlink:href="ci-20231231.xsd#ci_DueFromAffiliateNoncurrentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_cb892534-3baf-427b-bf5b-4c3eadbad43a" xlink:to="loc_ci_DueFromAffiliateNoncurrentNet_8ea56a33-49e3-41c8-b8aa-283146895093" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupGuaranteesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#ScheduleICondensedFinancialInformationofTheCignaGroupGuaranteesDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupGuaranteesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsLineItems_602f70b3-67cc-4553-894c-3d5ce6bae2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_0953086c-4431-4998-8bdf-3d546e5cd721" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGuaranteeObligationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_602f70b3-67cc-4553-894c-3d5ce6bae2fd" xlink:to="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_0953086c-4431-4998-8bdf-3d546e5cd721" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_42f5622f-a48c-48bf-b867-9de82888e419" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_0953086c-4431-4998-8bdf-3d546e5cd721" xlink:to="loc_srt_ConsolidatedEntitiesAxis_42f5622f-a48c-48bf-b867-9de82888e419" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_42f5622f-a48c-48bf-b867-9de82888e419_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_42f5622f-a48c-48bf-b867-9de82888e419" xlink:to="loc_srt_ConsolidatedEntitiesDomain_42f5622f-a48c-48bf-b867-9de82888e419_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_9157f396-cd3f-4e9a-9d2d-cf2f24cf2e76" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_42f5622f-a48c-48bf-b867-9de82888e419" xlink:to="loc_srt_ConsolidatedEntitiesDomain_9157f396-cd3f-4e9a-9d2d-cf2f24cf2e76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_b6290fca-165e-4375-b129-898ac1ddb3ee" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_9157f396-cd3f-4e9a-9d2d-cf2f24cf2e76" xlink:to="loc_srt_ParentCompanyMember_b6290fca-165e-4375-b129-898ac1ddb3ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_52d209a7-a4a5-454b-b2bb-b580f89e195f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_0953086c-4431-4998-8bdf-3d546e5cd721" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_52d209a7-a4a5-454b-b2bb-b580f89e195f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_52d209a7-a4a5-454b-b2bb-b580f89e195f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_52d209a7-a4a5-454b-b2bb-b580f89e195f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_52d209a7-a4a5-454b-b2bb-b580f89e195f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a94ccd1d-c4cc-45fc-b186-fd314044b622" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_52d209a7-a4a5-454b-b2bb-b580f89e195f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a94ccd1d-c4cc-45fc-b186-fd314044b622" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_66b2eedc-e025-40ac-8a4b-7ba72570f382" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a94ccd1d-c4cc-45fc-b186-fd314044b622" xlink:to="loc_us-gaap_SubsequentEventMember_66b2eedc-e025-40ac-8a4b-7ba72570f382" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_c6bb7158-e4ab-4196-adca-e5107621cd41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsMaximumExposure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_602f70b3-67cc-4553-894c-3d5ce6bae2fd" xlink:to="loc_us-gaap_GuaranteeObligationsMaximumExposure_c6bb7158-e4ab-4196-adca-e5107621cd41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_22699da8-f97b-4d7e-88f1-75b141333661" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_602f70b3-67cc-4553-894c-3d5ce6bae2fd" xlink:to="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_22699da8-f97b-4d7e-88f1-75b141333661" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_GuaranteeObligationsPayments_82327bd3-bd70-4c02-bc56-1ae9c6925a69" xlink:href="ci-20231231.xsd#ci_GuaranteeObligationsPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_602f70b3-67cc-4553-894c-3d5ce6bae2fd" xlink:to="loc_ci_GuaranteeObligationsPayments_82327bd3-bd70-4c02-bc56-1ae9c6925a69" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShareRepurchaseDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#ScheduleICondensedFinancialInformationofTheCignaGroupShareRepurchaseDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShareRepurchaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_669aa06b-f8c1-4124-b189-9e072a2e0663" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4da5978-9c2c-478d-bb57-28050f174ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_669aa06b-f8c1-4124-b189-9e072a2e0663" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4da5978-9c2c-478d-bb57-28050f174ba2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_8a0211f6-0c2e-48ab-a728-ce0786afb276" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4da5978-9c2c-478d-bb57-28050f174ba2" xlink:to="loc_srt_ConsolidatedEntitiesAxis_8a0211f6-0c2e-48ab-a728-ce0786afb276" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_8a0211f6-0c2e-48ab-a728-ce0786afb276_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_8a0211f6-0c2e-48ab-a728-ce0786afb276" xlink:to="loc_srt_ConsolidatedEntitiesDomain_8a0211f6-0c2e-48ab-a728-ce0786afb276_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_48e35d29-c796-4665-8550-d974d9ec8eca" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_8a0211f6-0c2e-48ab-a728-ce0786afb276" xlink:to="loc_srt_ConsolidatedEntitiesDomain_48e35d29-c796-4665-8550-d974d9ec8eca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_20985ff3-0b9c-40e2-baea-7dcc761532e2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_48e35d29-c796-4665-8550-d974d9ec8eca" xlink:to="loc_srt_ParentCompanyMember_20985ff3-0b9c-40e2-baea-7dcc761532e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_32eaa36a-0332-4b87-aadd-b42af55f4096" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4da5978-9c2c-478d-bb57-28050f174ba2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_32eaa36a-0332-4b87-aadd-b42af55f4096" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_32eaa36a-0332-4b87-aadd-b42af55f4096_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_32eaa36a-0332-4b87-aadd-b42af55f4096" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_32eaa36a-0332-4b87-aadd-b42af55f4096_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8d38e46c-3e5d-4687-8d52-98cf03cc940c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_32eaa36a-0332-4b87-aadd-b42af55f4096" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8d38e46c-3e5d-4687-8d52-98cf03cc940c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d2a5150e-308c-472c-96af-275f0e3d609a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8d38e46c-3e5d-4687-8d52-98cf03cc940c" xlink:to="loc_us-gaap_SubsequentEventMember_d2a5150e-308c-472c-96af-275f0e3d609a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_9201ff63-5aa2-4dbd-a833-e1356e2a8ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_669aa06b-f8c1-4124-b189-9e072a2e0663" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_9201ff63-5aa2-4dbd-a833-e1356e2a8ad4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_8d030bfd-a5ca-469a-9252-63738b95745d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_669aa06b-f8c1-4124-b189-9e072a2e0663" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_8d030bfd-a5ca-469a-9252-63738b95745d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_d4606d59-1163-4917-b9ff-1bcd2fc26b95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_669aa06b-f8c1-4124-b189-9e072a2e0663" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_d4606d59-1163-4917-b9ff-1bcd2fc26b95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_af34c5f1-b812-4412-a33f-820176bc943e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_669aa06b-f8c1-4124-b189-9e072a2e0663" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_af34c5f1-b812-4412-a33f-820176bc943e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#ScheduleIIValuationandQualifyingAccountsandReservesDetails"/>
  <link:definitionLink xlink:role="http://www.thecignagroup.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_98abb62f-88e3-4a31-a2bb-83e4ecdde4ac" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a2a69560-79f8-4bf2-b850-2dbee6455881" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_98abb62f-88e3-4a31-a2bb-83e4ecdde4ac" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a2a69560-79f8-4bf2-b850-2dbee6455881" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6ae4b692-55a6-4ad6-ba69-0f3e53635287" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a2a69560-79f8-4bf2-b850-2dbee6455881" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6ae4b692-55a6-4ad6-ba69-0f3e53635287" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_6ae4b692-55a6-4ad6-ba69-0f3e53635287_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6ae4b692-55a6-4ad6-ba69-0f3e53635287" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_6ae4b692-55a6-4ad6-ba69-0f3e53635287_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_80e1720e-3e2a-450b-bc70-41a88097ade4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6ae4b692-55a6-4ad6-ba69-0f3e53635287" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_80e1720e-3e2a-450b-bc70-41a88097ade4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember_d9afbc42-2c7e-41eb-8653-38898e1afca2" xlink:href="ci-20231231.xsd#ci_SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_80e1720e-3e2a-450b-bc70-41a88097ade4" xlink:to="loc_ci_SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember_d9afbc42-2c7e-41eb-8653-38898e1afca2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember_14c13719-a528-4b9a-bd8a-9d55f6658f0b" xlink:href="ci-20231231.xsd#ci_SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_80e1720e-3e2a-450b-bc70-41a88097ade4" xlink:to="loc_ci_SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember_14c13719-a528-4b9a-bd8a-9d55f6658f0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember_f50b6a85-a909-4814-b2aa-509702fd1f53" xlink:href="ci-20231231.xsd#ci_SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_80e1720e-3e2a-450b-bc70-41a88097ade4" xlink:to="loc_ci_SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember_f50b6a85-a909-4814-b2aa-509702fd1f53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_aea14131-c1b3-47af-b4e5-ddfb7f7435fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_80e1720e-3e2a-450b-bc70-41a88097ade4" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_aea14131-c1b3-47af-b4e5-ddfb7f7435fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForReinsuranceRecoverableMember_2f09390c-7fbd-4c38-a04b-c1c7ccd9de9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForReinsuranceRecoverableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_80e1720e-3e2a-450b-bc70-41a88097ade4" xlink:to="loc_us-gaap_AllowanceForReinsuranceRecoverableMember_2f09390c-7fbd-4c38-a04b-c1c7ccd9de9d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_034f1d8a-0f9e-4cf9-a020-d66f67f4ee9c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a2a69560-79f8-4bf2-b850-2dbee6455881" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_034f1d8a-0f9e-4cf9-a020-d66f67f4ee9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_034f1d8a-0f9e-4cf9-a020-d66f67f4ee9c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_034f1d8a-0f9e-4cf9-a020-d66f67f4ee9c" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_034f1d8a-0f9e-4cf9-a020-d66f67f4ee9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_77a72fed-8e03-4128-acea-79fc55ad93d5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_034f1d8a-0f9e-4cf9-a020-d66f67f4ee9c" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_77a72fed-8e03-4128-acea-79fc55ad93d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_1a0d75e0-0c3b-4380-9e02-7aecdb9fc186" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_77a72fed-8e03-4128-acea-79fc55ad93d5" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_1a0d75e0-0c3b-4380-9e02-7aecdb9fc186" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_b3c1552a-2f35-4118-b5dc-6241728fce1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_98abb62f-88e3-4a31-a2bb-83e4ecdde4ac" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_b3c1552a-2f35-4118-b5dc-6241728fce1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_678947e1-be01-4a22-9c7c-9bcf83b40686" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_b3c1552a-2f35-4118-b5dc-6241728fce1e" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_678947e1-be01-4a22-9c7c-9bcf83b40686" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_09e92374-6401-47cf-82c1-8e6adabfaf1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_b3c1552a-2f35-4118-b5dc-6241728fce1e" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_09e92374-6401-47cf-82c1-8e6adabfaf1f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_3e9706da-4f08-4614-ba56-4fe3db8a86e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_b3c1552a-2f35-4118-b5dc-6241728fce1e" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_3e9706da-4f08-4614-ba56-4fe3db8a86e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_e2aac5be-a1bd-473c-aee1-9318b00ca85b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_b3c1552a-2f35-4118-b5dc-6241728fce1e" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_e2aac5be-a1bd-473c-aee1-9318b00ca85b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_efad6477-a428-4516-9bff-26a7a74007a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_176f04dc-70fe-4859-85bf-1ad4b05e60b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember_c5255475-7353-4b13-9b04-9869d6482064" xlink:href="ci-20231231.xsd#ci_CignaHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="loc_ci_CignaHealthcareMember_c5255475-7353-4b13-9b04-9869d6482064" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccruedExpensesAndOtherLiabilities_a8d8c75c-3780-4ac2-a2d4-610299d87c04" xlink:href="ci-20231231.xsd#ci_AccruedExpensesAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_ci_AccruedExpensesAndOtherLiabilities_a8d8c75c-3780-4ac2-a2d4-610299d87c04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RestrictedStockGrantsAndUnitsMember_8ff95b9b-43c4-4a5e-8105-d2903c5478fa" xlink:href="ci-20231231.xsd#ci_RestrictedStockGrantsAndUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ci_RestrictedStockGrantsAndUnitsMember_8ff95b9b-43c4-4a5e-8105-d2903c5478fa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_PerformanceSharesMember" xlink:type="arc" order="5"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>ci-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:fd466b51-e399-4368-bda1-c8c0817d4afc,g:199c158e-5fac-4def-904c-2de015f58c08-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_OtherShortTermInvestments_7c8fba3b-6e7f-4a87-87c3-834a0e9d50a4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_OtherShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_OtherShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherShortTermInvestments" xlink:to="lab_us-gaap_OtherShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_82472f89-3fdc-4618-9cbf-f47603f74f4c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax_65edd025-28c5-4eee-8977-88306d2d9e9d_negatedLabel_en-US" xlink:label="lab_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Income) loss attributable to noncontrolling interests</link:label>
    <link:label id="lab_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax_label_en-US" xlink:label="lab_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Loss Attributable To Noncontrolling Interest Before Tax</link:label>
    <link:label id="lab_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax_documentation_en-US" xlink:label="lab_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of pre-tax income (loss) attributable to noncontrolling interest.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax" xlink:href="ci-20231231.xsd#ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax" xlink:to="lab_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost_0106911b-59b3-496f-b313-63653739c422_totalLabel_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost_label_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Amortized Cost</link:label>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost_documentation_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost" xlink:to="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_b30615d7-ed12-4cb7-964b-b63b23962385_terseLabel_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance And Contractholder Liabilities, Noncurrent [Abstract]</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_documentation_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance And Contractholder Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract" xlink:to="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f6b91a46-e07c-4bed-a024-b7ae97b3dffa_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in assets and liabilities, net of non-operating effects:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity_1ed00b2f-bc72-48fb-8555-32b1acc169b8_totalLabel_en-US" xlink:label="lab_ci_ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income</link:label>
    <link:label id="lab_ci_ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity_label_en-US" xlink:label="lab_ci_ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest, Including Temporary Equity</link:label>
    <link:label id="lab_ci_ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity_documentation_en-US" xlink:label="lab_ci_ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest, Including Temporary Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity" xlink:href="ci-20231231.xsd#ci_ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity" xlink:to="lab_ci_ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_a73df9eb-af57-4b18-a7d7-f970a3721649_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e04f79d8-0329-48f6-abef-05078f58028e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_UnobservableInputsDevelopedByCompanyMember_cea6761f-b6d9-4fdb-9b46-1c3e291f845b_terseLabel_en-US" xlink:label="lab_ci_UnobservableInputsDevelopedByCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Priced by the Company</link:label>
    <link:label id="lab_ci_UnobservableInputsDevelopedByCompanyMember_label_en-US" xlink:label="lab_ci_UnobservableInputsDevelopedByCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unobservable Inputs Developed By Company [Member]</link:label>
    <link:label id="lab_ci_UnobservableInputsDevelopedByCompanyMember_documentation_en-US" xlink:label="lab_ci_UnobservableInputsDevelopedByCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant unobservable inputs used in pricing Level 3 securities that were developed directly by the Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnobservableInputsDevelopedByCompanyMember" xlink:href="ci-20231231.xsd#ci_UnobservableInputsDevelopedByCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_UnobservableInputsDevelopedByCompanyMember" xlink:to="lab_ci_UnobservableInputsDevelopedByCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_13fcbf74-2d5c-45d5-94e6-deeb0b233b5c_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairments of other intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OngoingOperationsMember_41e8dc78-ffbe-4ee1-92c6-2eb6356b2a8a_terseLabel_en-US" xlink:label="lab_ci_OngoingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ongoing Operations</link:label>
    <link:label id="lab_ci_OngoingOperationsMember_label_en-US" xlink:label="lab_ci_OngoingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ongoing Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OngoingOperationsMember" xlink:href="ci-20231231.xsd#ci_OngoingOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OngoingOperationsMember" xlink:to="lab_ci_OngoingOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceGuaranteeMember_ecee7445-55ac-46e8-add3-22363ad3dbee_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Guarantee</link:label>
    <link:label id="lab_us-gaap_PerformanceGuaranteeMember_label_en-US" xlink:label="lab_us-gaap_PerformanceGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Guarantee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceGuaranteeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceGuaranteeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceGuaranteeMember" xlink:to="lab_us-gaap_PerformanceGuaranteeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_608f1dfa-f7cf-489c-bb53-ca0baa2fa3a8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term investments</link:label>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_label_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermInvestments" xlink:to="lab_us-gaap_OtherLongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NonInvestmentRevenue_4dbe0051-0a34-409e-9efd-95abcb738495_verboseLabel_en-US" xlink:label="lab_ci_NonInvestmentRevenue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from customers</link:label>
    <link:label id="lab_ci_NonInvestmentRevenue_1d4517f3-8b53-4e61-88fc-24595e3aba23_totalLabel_en-US" xlink:label="lab_ci_NonInvestmentRevenue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues from external customers</link:label>
    <link:label id="lab_ci_NonInvestmentRevenue_caccee9c-3885-4ac9-a4dd-5b3989914963_terseLabel_en-US" xlink:label="lab_ci_NonInvestmentRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from external customers</link:label>
    <link:label id="lab_ci_NonInvestmentRevenue_label_en-US" xlink:label="lab_ci_NonInvestmentRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Investment Revenue</link:label>
    <link:label id="lab_ci_NonInvestmentRevenue_documentation_en-US" xlink:label="lab_ci_NonInvestmentRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue excluding net investment income and realized investment results.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NonInvestmentRevenue" xlink:href="ci-20231231.xsd#ci_NonInvestmentRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NonInvestmentRevenue" xlink:to="lab_ci_NonInvestmentRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_8b2b741f-a3f4-4317-a6db-dd77398ca5ac_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SpecialItemGainLossFromContractAdjustmentBeforeTaxes_5f623efc-d51e-4615-8050-58714533aba2_negatedLabel_en-US" xlink:label="lab_ci_SpecialItemGainLossFromContractAdjustmentBeforeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustment for a former client (Pharmacy revenues)</link:label>
    <link:label id="lab_ci_SpecialItemGainLossFromContractAdjustmentBeforeTaxes_c2706a46-6942-4139-98aa-163e563d604f_negatedTerseLabel_en-US" xlink:label="lab_ci_SpecialItemGainLossFromContractAdjustmentBeforeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustment for a former client</link:label>
    <link:label id="lab_ci_SpecialItemGainLossFromContractAdjustmentBeforeTaxes_label_en-US" xlink:label="lab_ci_SpecialItemGainLossFromContractAdjustmentBeforeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Item, Gain (Loss) From Contract Adjustment, Before Taxes</link:label>
    <link:label id="lab_ci_SpecialItemGainLossFromContractAdjustmentBeforeTaxes_documentation_en-US" xlink:label="lab_ci_SpecialItemGainLossFromContractAdjustmentBeforeTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Item, Gain (Loss) From Contract Adjustment, Before Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossFromContractAdjustmentBeforeTaxes" xlink:href="ci-20231231.xsd#ci_SpecialItemGainLossFromContractAdjustmentBeforeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SpecialItemGainLossFromContractAdjustmentBeforeTaxes" xlink:to="lab_ci_SpecialItemGainLossFromContractAdjustmentBeforeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_BalanceSheetAbstract_920d615d-94bf-419e-8056-0ad1021f9662_terseLabel_en-US" xlink:label="lab_ci_BalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet [Abstract]</link:label>
    <link:label id="lab_ci_BalanceSheetAbstract_label_en-US" xlink:label="lab_ci_BalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet [Abstract]</link:label>
    <link:label id="lab_ci_BalanceSheetAbstract_documentation_en-US" xlink:label="lab_ci_BalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_BalanceSheetAbstract" xlink:href="ci-20231231.xsd#ci_BalanceSheetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_BalanceSheetAbstract" xlink:to="lab_ci_BalanceSheetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_7c795274-f362-4efc-9d95-b1c5594d7ea7_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_10860e95-f561-466a-896b-e109e2994d76_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember_82fac324-9e0d-4951-b7d2-99972ea050f3_terseLabel_en-US" xlink:label="lab_ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BBB+ equivalent and higher current ratings</link:label>
    <link:label id="lab_ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember_label_en-US" xlink:label="lab_ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nationally Recognized Statistical Rating Organizations (NRSRO), BBB+ Or Higher [Member]</link:label>
    <link:label id="lab_ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember_documentation_en-US" xlink:label="lab_ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nationally Recognized Statistical Rating Organizations (NRSRO), BBB+ Or Higher</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember" xlink:href="ci-20231231.xsd#ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember" xlink:to="lab_ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_30f507df-5f57-42d8-9a4f-52e4100f79bc_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Financing Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Financing Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:to="lab_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_55de21a3-f615-4906-9c43-3cf45fa228e7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable at year-end (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e9ba6f35-26b8-454d-82bf-35f9fdabc7c0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_RealizedInvestmentLossesCommercialMortgageLoansRealEstateEntitiesCertainEquitySecuritiesWithNoReadilyDeterminableFairValue_21293305-e2d1-4036-a1ee-a6d9a736180c_terseLabel_en-US" xlink:label="lab_ci_RealizedInvestmentLossesCommercialMortgageLoansRealEstateEntitiesCertainEquitySecuritiesWithNoReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized investment losses on assets measured at fair value under certain conditions, after-tax</link:label>
    <link:label id="lab_ci_RealizedInvestmentLossesCommercialMortgageLoansRealEstateEntitiesCertainEquitySecuritiesWithNoReadilyDeterminableFairValue_label_en-US" xlink:label="lab_ci_RealizedInvestmentLossesCommercialMortgageLoansRealEstateEntitiesCertainEquitySecuritiesWithNoReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Losses Commercial Mortgage Loans And Real Estate Entities With No Readily Determinable Fair Value</link:label>
    <link:label id="lab_ci_RealizedInvestmentLossesCommercialMortgageLoansRealEstateEntitiesCertainEquitySecuritiesWithNoReadilyDeterminableFairValue_documentation_en-US" xlink:label="lab_ci_RealizedInvestmentLossesCommercialMortgageLoansRealEstateEntitiesCertainEquitySecuritiesWithNoReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized investment losses on impaired real estate, partnership entities, commercial mortgage loans and certain equity securities with no readily determinable fair value, after-tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RealizedInvestmentLossesCommercialMortgageLoansRealEstateEntitiesCertainEquitySecuritiesWithNoReadilyDeterminableFairValue" xlink:href="ci-20231231.xsd#ci_RealizedInvestmentLossesCommercialMortgageLoansRealEstateEntitiesCertainEquitySecuritiesWithNoReadilyDeterminableFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_RealizedInvestmentLossesCommercialMortgageLoansRealEstateEntitiesCertainEquitySecuritiesWithNoReadilyDeterminableFairValue" xlink:to="lab_ci_RealizedInvestmentLossesCommercialMortgageLoansRealEstateEntitiesCertainEquitySecuritiesWithNoReadilyDeterminableFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2bfb717c-38da-458b-877c-15b8bf34aa9c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfEmployeesHolding_869d666a-85ed-45ec-9b3b-a3739a9adda5_terseLabel_en-US" xlink:label="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfEmployeesHolding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees holding share-based payment awards</link:label>
    <link:label id="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfEmployeesHolding_label_en-US" xlink:label="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfEmployeesHolding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Number Of Employees Holding</link:label>
    <link:label id="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfEmployeesHolding_documentation_en-US" xlink:label="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfEmployeesHolding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees holding share based payment awards at the reporting date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfEmployeesHolding" xlink:href="ci-20231231.xsd#ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfEmployeesHolding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfEmployeesHolding" xlink:to="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfEmployeesHolding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FuturePolicyBenefitsLiabilityPolicy_10c80d58-5cff-422c-858e-454223f5493e_terseLabel_en-US" xlink:label="lab_us-gaap_FuturePolicyBenefitsLiabilityPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Policy Benefits</link:label>
    <link:label id="lab_us-gaap_FuturePolicyBenefitsLiabilityPolicy_label_en-US" xlink:label="lab_us-gaap_FuturePolicyBenefitsLiabilityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefit [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FuturePolicyBenefitsLiabilityPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FuturePolicyBenefitsLiabilityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FuturePolicyBenefitsLiabilityPolicy" xlink:to="lab_us-gaap_FuturePolicyBenefitsLiabilityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_80aa51aa-6ade-4a1d-96e5-0089cfc1d1dc_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OtherAssetsCurrentAndNoncurrentPolicyPolicyTextBlock_adef10b1-74b9-4e74-bad7-f1808700ee9e_terseLabel_en-US" xlink:label="lab_ci_OtherAssetsCurrentAndNoncurrentPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets (Current and Non-Current)</link:label>
    <link:label id="lab_ci_OtherAssetsCurrentAndNoncurrentPolicyPolicyTextBlock_label_en-US" xlink:label="lab_ci_OtherAssetsCurrentAndNoncurrentPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets Current And Noncurrent Policy [Policy Text Block]</link:label>
    <link:label id="lab_ci_OtherAssetsCurrentAndNoncurrentPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_ci_OtherAssetsCurrentAndNoncurrentPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting policies related to Other Assets, Current and Noncurrent and the items included therein.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherAssetsCurrentAndNoncurrentPolicyPolicyTextBlock" xlink:href="ci-20231231.xsd#ci_OtherAssetsCurrentAndNoncurrentPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OtherAssetsCurrentAndNoncurrentPolicyPolicyTextBlock" xlink:to="lab_ci_OtherAssetsCurrentAndNoncurrentPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OtherLongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_b0640e1f-b138-4d3f-9d4d-9a819c37186d_terseLabel_en-US" xlink:label="lab_ci_OtherLongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long term investments, including held for sale assets</link:label>
    <link:label id="lab_ci_OtherLongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_OtherLongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Investments Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_OtherLongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_OtherLongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Investments Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherLongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_OtherLongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OtherLongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_OtherLongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_c63d8085-e011-4ea6-91af-4ee0368d6350_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c01793a6-5a5b-4d4a-84fe-93c3e87ec82d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NotesDue204648InterestMember_441a5ac3-05fb-4109-b6de-fbaa1abe478e_terseLabel_en-US" xlink:label="lab_ci_NotesDue204648InterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$1,500&#160;million, 4.800% Notes due July 2046</link:label>
    <link:label id="lab_ci_NotesDue204648InterestMember_label_en-US" xlink:label="lab_ci_NotesDue204648InterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2046, 4.8% Interest [Member]</link:label>
    <link:label id="lab_ci_NotesDue204648InterestMember_documentation_en-US" xlink:label="lab_ci_NotesDue204648InterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior notes payable bearing interest at 4.8% due in 2046. Debt assumed acquisition from Express Scripts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue204648InterestMember" xlink:href="ci-20231231.xsd#ci_NotesDue204648InterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NotesDue204648InterestMember" xlink:to="lab_ci_NotesDue204648InterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CommitmentsAndContingenciesLineItems_f4b8076b-9098-48c9-9746-afbc58ea8fc0_terseLabel_en-US" xlink:label="lab_ci_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_ci_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_ci_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_ci_CommitmentsAndContingenciesLineItems_documentation_en-US" xlink:label="lab_ci_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CommitmentsAndContingenciesLineItems" xlink:href="ci-20231231.xsd#ci_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems" xlink:to="lab_ci_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_a94073ce-d462-4b3c-ab7b-edbee4301aa3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. income tax benefits</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_9ff6c8ce-001b-4b5f-8ac6-972735cad753_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_5c3f7051-fd41-4725-881e-8dbdcc74714c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock dividend paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_56f5b88f-59a7-49e1-80ca-f091214b1649_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total amount paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_f8b2160f-5728-4f00-9ddd-1d08628b8cbf_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_4bb53c27-eabf-4133-8a5b-9dbeca681a9f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_c90e7c42-d9d2-4fe4-bfd4-e4c5c0afea7c_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase to diluted earnings per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_b4570c76-1afd-4da0-af3a-f925776fc560_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EPS, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_50bfc8c8-362a-4f48-b7f0-48a3c742db05_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_6d8878f2-bc11-4738-8a35-240eff0432cd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative gain (loss) reclassified from other comprehensive income into shareholders' net income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_23ac22fd-3ede-4d23-9551-625f6ed2b518_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2b7bd38c-8ec8-45a2-a6a9-5302af54f0bb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrentIncludingDisposalGroups_a148707e-eaef-480e-a1e7-2fdab68f84f1_terseLabel_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrentIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid claims and claim expenses, non-current, including held for sale liabilities</link:label>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrentIncludingDisposalGroups_label_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrentIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Claims And Claims Adjustment Expense Noncurrent Including Disposal Groups</link:label>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrentIncludingDisposalGroups_documentation_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrentIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount (expected to be paid after one year) needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrentIncludingDisposalGroups" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrentIncludingDisposalGroups"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrentIncludingDisposalGroups" xlink:to="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrentIncludingDisposalGroups" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AlternativeInvestment_2ec094d0-b102-4052-9487-4508a5805947_terseLabel_en-US" xlink:label="lab_us-gaap_AlternativeInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AlternativeInvestment_label_en-US" xlink:label="lab_us-gaap_AlternativeInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AlternativeInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AlternativeInvestment" xlink:to="lab_us-gaap_AlternativeInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_341a9a77-cf5f-48e0-b653-6bbae8fd028a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_72816e67-48de-4d7f-bdde-67136755c901_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_2fdf8be4-f68b-4742-b398-77623e3ee777_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_56a2da74-e1f5-4cb2-8faa-f0ee9d1121c6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_a63c20ee-4358-4aef-8808-ce6c9feef836_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded Commitments</link:label>
    <link:label id="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_label_en-US" xlink:label="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:to="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3422f0d4-1a4d-439d-9499-b2811840d585_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computation of Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_5ecdf47b-4abf-4bda-84ea-112286078673_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NonGuaranteedSeparateAccountAssetsPricedAtNetAssetValueAsAPracticalExpedient_fdfb9944-1b49-4584-8949-aba5f878004b_terseLabel_en-US" xlink:label="lab_ci_NonGuaranteedSeparateAccountAssetsPricedAtNetAssetValueAsAPracticalExpedient" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-guaranteed separate accounts priced at NAV as a practical expedient</link:label>
    <link:label id="lab_ci_NonGuaranteedSeparateAccountAssetsPricedAtNetAssetValueAsAPracticalExpedient_label_en-US" xlink:label="lab_ci_NonGuaranteedSeparateAccountAssetsPricedAtNetAssetValueAsAPracticalExpedient" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Guaranteed Separate Account Assets Priced At Net Asset Value As A Practical Expedient</link:label>
    <link:label id="lab_ci_NonGuaranteedSeparateAccountAssetsPricedAtNetAssetValueAsAPracticalExpedient_documentation_en-US" xlink:label="lab_ci_NonGuaranteedSeparateAccountAssetsPricedAtNetAssetValueAsAPracticalExpedient" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The fair value of the assets held by the Entity for the benefit of separate account policyholders without guarantees and priced at net asset value as a practical expedient.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NonGuaranteedSeparateAccountAssetsPricedAtNetAssetValueAsAPracticalExpedient" xlink:href="ci-20231231.xsd#ci_NonGuaranteedSeparateAccountAssetsPricedAtNetAssetValueAsAPracticalExpedient"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NonGuaranteedSeparateAccountAssetsPricedAtNetAssetValueAsAPracticalExpedient" xlink:to="lab_ci_NonGuaranteedSeparateAccountAssetsPricedAtNetAssetValueAsAPracticalExpedient" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_6d5e867e-9c1c-4dc3-a557-f202ecd22944_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized prior service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_32b456f5-9617-49df-ba86-35b714749a4d_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_54ce04b0-7f61-4bad-925f-34f89689b480_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NotesDue205034InterestMember_d371e2d2-15bd-414e-9893-0b05fd47bf01_terseLabel_en-US" xlink:label="lab_ci_NotesDue205034InterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$1,250&#160;million, 3.400% Notes due March 2050</link:label>
    <link:label id="lab_ci_NotesDue205034InterestMember_label_en-US" xlink:label="lab_ci_NotesDue205034InterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2050, 3.4% Interest [Member]</link:label>
    <link:label id="lab_ci_NotesDue205034InterestMember_documentation_en-US" xlink:label="lab_ci_NotesDue205034InterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2050, 3.4% Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue205034InterestMember" xlink:href="ci-20231231.xsd#ci_NotesDue205034InterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NotesDue205034InterestMember" xlink:to="lab_ci_NotesDue205034InterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_541725d0-67c5-44e6-af1f-c10a1c11c4d6_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postretirement benefits liability adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_c68481d1-8d70-4300-86ae-f9c9e004f8e8_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Value</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteeObligationsMaximumExposure_87e11a32-29e7-42a3-933f-8b1db910bb64_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsMaximumExposure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum guarantee exposure</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsMaximumExposure_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsMaximumExposure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor Obligations, Maximum Exposure, Undiscounted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsMaximumExposure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsMaximumExposure" xlink:to="lab_us-gaap_GuaranteeObligationsMaximumExposure" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIncludingDisposalGroupsAssetsHeldForSale_af4e5a0c-481c-4159-a666-b50e8763f59f_terseLabel_en-US" xlink:label="lab_ci_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related basis differences</link:label>
    <link:label id="lab_ci_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIncludingDisposalGroupsAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Goodwill and Intangible Assets, Including Disposal Groups Assets Held For Sale</link:label>
    <link:label id="lab_ci_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIncludingDisposalGroupsAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Goodwill and Intangible Assets, Including Disposal Groups Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIncludingDisposalGroupsAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIncludingDisposalGroupsAssetsHeldForSale" xlink:to="lab_ci_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIncludingDisposalGroupsAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_8c9983ce-b29d-4a84-8fe5-ac4be01e1e3a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_babf71b5-915f-4f8a-85b0-65ba0dda644f_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CashFlowActivitiesLesseeAbstract_3fda3913-2be4-4cbc-95f1-0374d9d41ce0_terseLabel_en-US" xlink:label="lab_ci_CashFlowActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_ci_CashFlowActivitiesLesseeAbstract_label_en-US" xlink:label="lab_ci_CashFlowActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Activities, Lessee [Abstract]</link:label>
    <link:label id="lab_ci_CashFlowActivitiesLesseeAbstract_documentation_en-US" xlink:label="lab_ci_CashFlowActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Activities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CashFlowActivitiesLesseeAbstract" xlink:href="ci-20231231.xsd#ci_CashFlowActivitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CashFlowActivitiesLesseeAbstract" xlink:to="lab_ci_CashFlowActivitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_91ae443e-e1b5-4b06-9cab-2f60be5c645d_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PolicyholderContractDepositCurrentIncludingDisposalGroups_80448c05-fb2a-4a2a-a987-11f551e9cad0_terseLabel_en-US" xlink:label="lab_ci_PolicyholderContractDepositCurrentIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractholder deposit funds, current, including held for sale liabilities</link:label>
    <link:label id="lab_ci_PolicyholderContractDepositCurrentIncludingDisposalGroups_label_en-US" xlink:label="lab_ci_PolicyholderContractDepositCurrentIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Contract Deposit, Current Including Disposal Groups</link:label>
    <link:label id="lab_ci_PolicyholderContractDepositCurrentIncludingDisposalGroups_documentation_en-US" xlink:label="lab_ci_PolicyholderContractDepositCurrentIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Contract Deposit, Current Including Disposal Groups</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositCurrentIncludingDisposalGroups" xlink:href="ci-20231231.xsd#ci_PolicyholderContractDepositCurrentIncludingDisposalGroups"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PolicyholderContractDepositCurrentIncludingDisposalGroups" xlink:to="lab_ci_PolicyholderContractDepositCurrentIncludingDisposalGroups" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_82b99106-9afb-4721-8cee-c0f6f9b0fc57_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_309bb8d9-202d-4a7f-8456-ba8fb6124fea_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current year</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest_ce3b277d-531c-42d9-9a17-b6deb4055f58_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest" xlink:to="lab_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_794687f1-e476-411b-8fa5-51f997c37dbb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_98de0aed-2ffa-411c-a5d1-85bbcd1bd194_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AcquisitionDispositionRunoffActivitiesMember_5cc74bc0-10e1-4db9-bbbe-732178afc99c_terseLabel_en-US" xlink:label="lab_ci_AcquisitionDispositionRunoffActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition, disposition or run-off activities</link:label>
    <link:label id="lab_ci_AcquisitionDispositionRunoffActivitiesMember_label_en-US" xlink:label="lab_ci_AcquisitionDispositionRunoffActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Disposition Runoff Activities [Member]</link:label>
    <link:label id="lab_ci_AcquisitionDispositionRunoffActivitiesMember_documentation_en-US" xlink:label="lab_ci_AcquisitionDispositionRunoffActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products related to acquisition, disposition or runoff activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AcquisitionDispositionRunoffActivitiesMember" xlink:href="ci-20231231.xsd#ci_AcquisitionDispositionRunoffActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AcquisitionDispositionRunoffActivitiesMember" xlink:to="lab_ci_AcquisitionDispositionRunoffActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_477101c5-b77f-4cb3-955b-a51a2a95a665_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_b4fbeafe-2d13-4a56-9128-dc8321e080f1_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesTable_eccf7b1d-f80b-45f4-91d4-10eeb839fcab_terseLabel_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance And Contractholder Liabilities [Table]</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesTable_label_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance And Contractholder Liabilities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesTable" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesTable" xlink:to="lab_ci_InsuranceAndContractholderLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationSegmentThatIncludesDisposalGroup_514fd1b4-8a57-429f-ba62-9599612d2554_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationSegmentThatIncludesDisposalGroup" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Segment that Includes Disposal Group</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationSegmentThatIncludesDisposalGroup_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationSegmentThatIncludesDisposalGroup" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Segment that Includes Disposal Group</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationSegmentThatIncludesDisposalGroup" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationSegmentThatIncludesDisposalGroup"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationSegmentThatIncludesDisposalGroup" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationSegmentThatIncludesDisposalGroup" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_eace8160-eaee-453d-b132-bb4feeff8754_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange_6c76dc45-aa90-468c-99d4-f3cc7e288616_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange_18e3971e-6097-42aa-9c4a-0ebb331ac83c_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefit, Expected Future Policy Benefit, before Reinsurance, after Discount Rate Change</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_5564102a-197c-4ab8-8a31-444b74843f7f_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_f4c83fe4-ecfa-4790-b7f3-f4f482e041f2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities of businesses held for sale, non-current</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience_bc429214-e047-4fae-8091-08f7e01ff33e_terseLabel_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of assumption changes and actual variances from expected experience (1)</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience_label_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefit, Expected Net Premium, Cumulative Increase (Decrease) From Cash Flow Change And Actual Variance From Expected Experience</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience_documentation_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefit, Expected Net Premium, Cumulative Increase (Decrease) From Cash Flow Change And Actual Variance From Expected Experience</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience" xlink:to="lab_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrentAbstract_4ce63611-2544-44a6-b2c6-e4937ab5e75d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt</link:label>
    <link:label id="lab_us-gaap_DebtCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_DebtCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrentAbstract" xlink:to="lab_us-gaap_DebtCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_05bc31f3-936f-470b-ae94-f7a60352460a_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumDiscountedBeforeReinsurance_c47e849a-1dbe-4eb5-81ae-241ba5c27d5c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumDiscountedBeforeReinsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted expected future gross premiums</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumDiscountedBeforeReinsurance_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumDiscountedBeforeReinsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefit, Expected Future Gross Premium, Discounted, before Reinsurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumDiscountedBeforeReinsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumDiscountedBeforeReinsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumDiscountedBeforeReinsurance" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumDiscountedBeforeReinsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_64b2e781-b76b-4f66-abeb-6d6096fb2eb7_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsExpectedLongTermReturnOnPlanAssetsAbstract_5e57602a-d187-4bc8-9817-abc491d17be9_terseLabel_en-US" xlink:label="lab_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsExpectedLongTermReturnOnPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected long-term return on plan assets:</link:label>
    <link:label id="lab_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsExpectedLongTermReturnOnPlanAssetsAbstract_label_en-US" xlink:label="lab_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsExpectedLongTermReturnOnPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used in Calculations, Expected Long-Term Return On Plan Assets [Abstract]</link:label>
    <link:label id="lab_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsExpectedLongTermReturnOnPlanAssetsAbstract_documentation_en-US" xlink:label="lab_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsExpectedLongTermReturnOnPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used in Calculations, Expected Long-Term Return On Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsExpectedLongTermReturnOnPlanAssetsAbstract" xlink:href="ci-20231231.xsd#ci_DefinedBenefitPlanAssumptionsUsedInCalculationsExpectedLongTermReturnOnPlanAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsExpectedLongTermReturnOnPlanAssetsAbstract" xlink:to="lab_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsExpectedLongTermReturnOnPlanAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_5b988056-28c8-43a0-a5c8-3d5a2a79658d_terseLabel_en-US" xlink:label="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Outstanding Long-Term Debt</link:label>
    <link:label id="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_label_en-US" xlink:label="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes_d6af597d-b99a-4290-ac36-131118328927_negatedLabel_en-US" xlink:label="lab_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on sale of business</link:label>
    <link:label id="lab_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes_label_en-US" xlink:label="lab_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Item, Gain (Loss) On Sale Of Business, Before Taxes</link:label>
    <link:label id="lab_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes_documentation_en-US" xlink:label="lab_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Item, Gain (Loss) On Sale Of Business, Before Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" xlink:href="ci-20231231.xsd#ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" xlink:to="lab_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_e26737d8-b200-4206-a142-11473508e81a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Joint Venture Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_0c9c9c8e-bb48-499f-9fca-e8ac39e7a848_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense on long-term and short-term debt</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NumberOfRevolvingCreditFacility_0e768c29-a18d-4a16-8a08-abd7ce674356_terseLabel_en-US" xlink:label="lab_ci_NumberOfRevolvingCreditFacility" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of revolving credit facilities</link:label>
    <link:label id="lab_ci_NumberOfRevolvingCreditFacility_label_en-US" xlink:label="lab_ci_NumberOfRevolvingCreditFacility" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Revolving Credit Facility</link:label>
    <link:label id="lab_ci_NumberOfRevolvingCreditFacility_documentation_en-US" xlink:label="lab_ci_NumberOfRevolvingCreditFacility" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Revolving Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NumberOfRevolvingCreditFacility" xlink:href="ci-20231231.xsd#ci_NumberOfRevolvingCreditFacility"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NumberOfRevolvingCreditFacility" xlink:to="lab_ci_NumberOfRevolvingCreditFacility" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating_14030d65-36b6-4974-8e51-8f062d1482eb_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guaranteed minimum credit rating</link:label>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating_label_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Account Balance, Guaranteed Minimum Credit Rating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating" xlink:to="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_6479ad8c-0717-4490-82f9-ab762b60449d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ForwardsSwapsOptionsMember_ca45b3f1-c3e6-4cd5-867e-72d18f3a99bb_terseLabel_en-US" xlink:label="lab_ci_ForwardsSwapsOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forwards, swaps, options</link:label>
    <link:label id="lab_ci_ForwardsSwapsOptionsMember_label_en-US" xlink:label="lab_ci_ForwardsSwapsOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forwards Swaps Options [Member]</link:label>
    <link:label id="lab_ci_ForwardsSwapsOptionsMember_documentation_en-US" xlink:label="lab_ci_ForwardsSwapsOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forwards Swaps Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ForwardsSwapsOptionsMember" xlink:href="ci-20231231.xsd#ci_ForwardsSwapsOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ForwardsSwapsOptionsMember" xlink:to="lab_ci_ForwardsSwapsOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AccountsAndOtherReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale_2b8b9806-38d1-4837-84d6-59cea734cfed_terseLabel_en-US" xlink:label="lab_ci_AccountsAndOtherReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables, including held for sale assets</link:label>
    <link:label id="lab_ci_AccountsAndOtherReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_AccountsAndOtherReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and Other Receivables, Net, Current, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_AccountsAndOtherReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_AccountsAndOtherReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and Other Receivables, Net, Current, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccountsAndOtherReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_AccountsAndOtherReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AccountsAndOtherReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_AccountsAndOtherReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b7f86fcc-9fe3-47ba-8be3-fdd2461d5f8e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive options (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationNameOfSegmentExtensibleList_06c14b7f-099e-4b23-a626-75fed530965a_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationNameOfSegmentExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Name of Segment [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationNameOfSegmentExtensibleList_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationNameOfSegmentExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Name of Segment [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationNameOfSegmentExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationNameOfSegmentExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationNameOfSegmentExtensibleList" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationNameOfSegmentExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PolicyholderContractDepositCurrent_731f5285-a0fe-43ad-84b4-99f732ad7a38_terseLabel_en-US" xlink:label="lab_ci_PolicyholderContractDepositCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractholder deposit funds, current</link:label>
    <link:label id="lab_ci_PolicyholderContractDepositCurrent_label_en-US" xlink:label="lab_ci_PolicyholderContractDepositCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Contract Deposit, Current</link:label>
    <link:label id="lab_ci_PolicyholderContractDepositCurrent_documentation_en-US" xlink:label="lab_ci_PolicyholderContractDepositCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Contract Deposit, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositCurrent" xlink:href="ci-20231231.xsd#ci_PolicyholderContractDepositCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PolicyholderContractDepositCurrent" xlink:to="lab_ci_PolicyholderContractDepositCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedFinancialStatementsCaptionsLineItems_4603bebc-0f53-49f6-a341-b7fe923ceffe_terseLabel_en-US" xlink:label="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements, Captions [Line Items]</link:label>
    <link:label id="lab_srt_CondensedFinancialStatementsCaptionsLineItems_label_en-US" xlink:label="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements, Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2ac1cdbd-0ecc-4084-9597-25eb7a2c99e9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_e333ec1f-0f9b-4868-bc7a-6a67017b3cc5_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_7d1138d7-4ce6-429f-8055-4dc1fec64d78_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_e2a78bb1-d611-4443-b584-35364d83eb9e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_7e9f4465-3dbc-4745-9e28-3cd7bcae1b86_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract_e5727fac-736a-4814-8d77-6d7ec0ed02eb_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums</link:label>
    <link:label id="lab_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract_label_en-US" xlink:label="lab_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Earned, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract" xlink:to="lab_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_3af92393-4bcf-42a5-8502-4f1b1b6a9e5d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions to qualifed pension plans</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_6ab736e9-c732-4ed5-b57a-e8d8ec380983_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NotesDue20265685Member_e5a10570-ceea-4e3b-834e-8615e91c23d5_terseLabel_en-US" xlink:label="lab_ci_NotesDue20265685Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$700 million, 5.685% Notes due March 2026</link:label>
    <link:label id="lab_ci_NotesDue20265685Member_label_en-US" xlink:label="lab_ci_NotesDue20265685Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes due 2026, 5.685% [Member]</link:label>
    <link:label id="lab_ci_NotesDue20265685Member_documentation_en-US" xlink:label="lab_ci_NotesDue20265685Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes due 2026, 5.685%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20265685Member" xlink:href="ci-20231231.xsd#ci_NotesDue20265685Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NotesDue20265685Member" xlink:to="lab_ci_NotesDue20265685Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentGrossCurrent_932d0b34-ce85-4b5e-ae45-6e5d8e082e7d_negatedLabel_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentGrossCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentGrossCurrent_label_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Including Discontinued Operation Property Plant And Equipment Gross Current</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentGrossCurrent_documentation_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale, attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentGrossCurrent" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentGrossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentGrossCurrent" xlink:to="lab_ci_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentGrossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_afee3969-9221-4d3c-9466-3983f2615b9e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net classified as assets of businesses held for sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_5711a13e-2445-45b8-a954-037cb2169c42_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_834cc1cc-92cc-499a-b57a-b185a4bd4b58_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_GoodwillTransfersToAssetsOfBusinessesHeldForSale_803c88c8-8e6e-4d39-ad2b-eac170f05dae_negatedLabel_en-US" xlink:label="lab_ci_GoodwillTransfersToAssetsOfBusinessesHeldForSale" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill transferred to assets of businesses held for sale</link:label>
    <link:label id="lab_ci_GoodwillTransfersToAssetsOfBusinessesHeldForSale_label_en-US" xlink:label="lab_ci_GoodwillTransfersToAssetsOfBusinessesHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Transfers To Assets Of Businesses Held-For-Sale</link:label>
    <link:label id="lab_ci_GoodwillTransfersToAssetsOfBusinessesHeldForSale_documentation_en-US" xlink:label="lab_ci_GoodwillTransfersToAssetsOfBusinessesHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Transfers To Assets Of Businesses Held-For-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_GoodwillTransfersToAssetsOfBusinessesHeldForSale" xlink:href="ci-20231231.xsd#ci_GoodwillTransfersToAssetsOfBusinessesHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_GoodwillTransfersToAssetsOfBusinessesHeldForSale" xlink:to="lab_ci_GoodwillTransfersToAssetsOfBusinessesHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ContractualAllowanceNoninsuranceCustomerReceivables_476ce296-3863-4522-9a7a-ab1ad06783b0_terseLabel_en-US" xlink:label="lab_ci_ContractualAllowanceNoninsuranceCustomerReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noninsurance customer receivables allowance</link:label>
    <link:label id="lab_ci_ContractualAllowanceNoninsuranceCustomerReceivables_label_en-US" xlink:label="lab_ci_ContractualAllowanceNoninsuranceCustomerReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Allowance, Noninsurance Customer Receivables</link:label>
    <link:label id="lab_ci_ContractualAllowanceNoninsuranceCustomerReceivables_documentation_en-US" xlink:label="lab_ci_ContractualAllowanceNoninsuranceCustomerReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of contractual allowances from third-party payors based upon the contractual payment terms.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ContractualAllowanceNoninsuranceCustomerReceivables" xlink:href="ci-20231231.xsd#ci_ContractualAllowanceNoninsuranceCustomerReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ContractualAllowanceNoninsuranceCustomerReceivables" xlink:to="lab_ci_ContractualAllowanceNoninsuranceCustomerReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_165d48a3-98d0-42a1-ad54-f8fe7c788b6e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitsPercentSupportedByAssetsHeldInTrust_ce0fddf6-7dc0-4c95-a919-53036fea3b3b_terseLabel_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitsPercentSupportedByAssetsHeldInTrust" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of the liability for future policy benefits supported by assets held in trust</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitsPercentSupportedByAssetsHeldInTrust_label_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitsPercentSupportedByAssetsHeldInTrust" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefits, Percent Supported By Assets Held In Trust</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitsPercentSupportedByAssetsHeldInTrust_documentation_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitsPercentSupportedByAssetsHeldInTrust" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefits, Percent Supported By Assets Held In Trust</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitsPercentSupportedByAssetsHeldInTrust" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitsPercentSupportedByAssetsHeldInTrust"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForFuturePolicyBenefitsPercentSupportedByAssetsHeldInTrust" xlink:to="lab_ci_LiabilityForFuturePolicyBenefitsPercentSupportedByAssetsHeldInTrust" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnearnedPremiums_5962e4d5-2286-4e51-aa92-7449610d2b62_totalLabel_en-US" xlink:label="lab_us-gaap_UnearnedPremiums" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unearned premiums</link:label>
    <link:label id="lab_us-gaap_UnearnedPremiums_label_en-US" xlink:label="lab_us-gaap_UnearnedPremiums" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unearned Premiums</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnearnedPremiums" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnearnedPremiums"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnearnedPremiums" xlink:to="lab_us-gaap_UnearnedPremiums" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale_f805778c-341b-43d3-aa76-39c300f75dca_totalLabel_en-US" xlink:label="lab_ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_1585d99d-40ba-4d37-93d1-de12277d9859_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis_c0d8ae0b-0d5b-4571-be94-63eee3f0ae03_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Account Balance, Guaranteed Minimum Crediting Rate Range [Axis]</link:label>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis_label_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Account Balance, Guaranteed Minimum Crediting Rate Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis" xlink:to="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_914e206c-68e6-4f27-ba28-d970be9edd6d_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax asset valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:to="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_207be945-c3e2-424f-a6fd-1b6b867e1f57_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected contributions to qualified pension plans in next fiscal year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_TransactionRelatedCosts_f06f050e-a4be-439c-8269-05e4cef81aa6_verboseLabel_en-US" xlink:label="lab_ci_TransactionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Integration and transaction-related costs, pre-tax</link:label>
    <link:label id="lab_ci_TransactionRelatedCosts_342621e4-753b-4721-89fb-63b8a4833b1f_terseLabel_en-US" xlink:label="lab_ci_TransactionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Integration and transaction-related costs</link:label>
    <link:label id="lab_ci_TransactionRelatedCosts_label_en-US" xlink:label="lab_ci_TransactionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Related Costs</link:label>
    <link:label id="lab_ci_TransactionRelatedCosts_documentation_en-US" xlink:label="lab_ci_TransactionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax transaction-related costs primarily consisting of fees for legal, advisory and other professional services, as well as employee costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TransactionRelatedCosts" xlink:href="ci-20231231.xsd#ci_TransactionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_TransactionRelatedCosts" xlink:to="lab_ci_TransactionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_7d91ee93-8b9b-480c-9628-3a1ff9d232da_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CorporateAndEliminationsMember_a393a8f7-bcce-43ad-af70-e1beb00186ec_terseLabel_en-US" xlink:label="lab_ci_CorporateAndEliminationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate and Eliminations</link:label>
    <link:label id="lab_ci_CorporateAndEliminationsMember_label_en-US" xlink:label="lab_ci_CorporateAndEliminationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate And Eliminations [Member]</link:label>
    <link:label id="lab_ci_CorporateAndEliminationsMember_documentation_en-US" xlink:label="lab_ci_CorporateAndEliminationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reflects amounts not allocated to other segments, such as net interest expense (defined as interest on corporate debt less net investment income on investments not supporting segment operations), interest on uncertain tax positions, certain litigation matters, intersegment eliminations, compensation cost for stock options, expense associated with its frozen pension plans, certain corporate project and overhead costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CorporateAndEliminationsMember" xlink:href="ci-20231231.xsd#ci_CorporateAndEliminationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CorporateAndEliminationsMember" xlink:to="lab_ci_CorporateAndEliminationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d987afa7-5a5c-45fb-832c-51a241109881_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5e536b66-9757-45fb-b914-d8c977d92b55_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DeferredTaxLiabilitiesNetIncludingDisposalGroup_8481d519-2824-4598-84f8-07af07114c2f_negatedTotalLabel_en-US" xlink:label="lab_ci_DeferredTaxLiabilitiesNetIncludingDisposalGroup" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net, including amounts reported in Liabilities of businesses held for sale</link:label>
    <link:label id="lab_ci_DeferredTaxLiabilitiesNetIncludingDisposalGroup_label_en-US" xlink:label="lab_ci_DeferredTaxLiabilitiesNetIncludingDisposalGroup" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net, Including Disposal Group</link:label>
    <link:label id="lab_ci_DeferredTaxLiabilitiesNetIncludingDisposalGroup_documentation_en-US" xlink:label="lab_ci_DeferredTaxLiabilitiesNetIncludingDisposalGroup" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net, Including Disposal Group</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesNetIncludingDisposalGroup" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesNetIncludingDisposalGroup"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DeferredTaxLiabilitiesNetIncludingDisposalGroup" xlink:to="lab_ci_DeferredTaxLiabilitiesNetIncludingDisposalGroup" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PharmaceuticalManufacturerReceivable_bb80aa54-8877-42f8-95ef-54dcd5e169f7_terseLabel_en-US" xlink:label="lab_ci_PharmaceuticalManufacturerReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical manufacturer receivables</link:label>
    <link:label id="lab_ci_PharmaceuticalManufacturerReceivable_label_en-US" xlink:label="lab_ci_PharmaceuticalManufacturerReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Manufacturer Receivable</link:label>
    <link:label id="lab_ci_PharmaceuticalManufacturerReceivable_documentation_en-US" xlink:label="lab_ci_PharmaceuticalManufacturerReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables due from pharmaceutical manufacturers related to rebate contracts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PharmaceuticalManufacturerReceivable" xlink:href="ci-20231231.xsd#ci_PharmaceuticalManufacturerReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PharmaceuticalManufacturerReceivable" xlink:to="lab_ci_PharmaceuticalManufacturerReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_9ccd44f5-6d1c-4f05-9d80-b267321e0458_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangible assets, held for sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PropertyPlantAndEquipmentIncludingAssetsHeldForSaleAbstract_37c25888-5e12-4c15-9e62-cf3d2d511607_terseLabel_en-US" xlink:label="lab_ci_PropertyPlantAndEquipmentIncludingAssetsHeldForSaleAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, including held for sale assets</link:label>
    <link:label id="lab_ci_PropertyPlantAndEquipmentIncludingAssetsHeldForSaleAbstract_label_en-US" xlink:label="lab_ci_PropertyPlantAndEquipmentIncludingAssetsHeldForSaleAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant And Equipment, Including Assets Held-For-Sale [Abstract]</link:label>
    <link:label id="lab_ci_PropertyPlantAndEquipmentIncludingAssetsHeldForSaleAbstract_documentation_en-US" xlink:label="lab_ci_PropertyPlantAndEquipmentIncludingAssetsHeldForSaleAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant And Equipment, Including Assets Held-For-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PropertyPlantAndEquipmentIncludingAssetsHeldForSaleAbstract" xlink:href="ci-20231231.xsd#ci_PropertyPlantAndEquipmentIncludingAssetsHeldForSaleAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PropertyPlantAndEquipmentIncludingAssetsHeldForSaleAbstract" xlink:to="lab_ci_PropertyPlantAndEquipmentIncludingAssetsHeldForSaleAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax_80cda7b8-a05d-4703-ad6c-ee4eca814fed_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonperformance risk (own credit risk), end of period</link:label>
    <link:label id="lab_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax_label_en-US" xlink:label="lab_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Market Risk Benefit, Instrument-Specific Credit Risk, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax" xlink:to="lab_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CededCreditRiskReinsurerDomain_0c939a0f-461d-4553-a7a3-6ca55921d3fc_terseLabel_en-US" xlink:label="lab_us-gaap_CededCreditRiskReinsurerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded Credit Risk, Reinsurer [Domain]</link:label>
    <link:label id="lab_us-gaap_CededCreditRiskReinsurerDomain_label_en-US" xlink:label="lab_us-gaap_CededCreditRiskReinsurerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurer, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskReinsurerDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskReinsurerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain" xlink:to="lab_us-gaap_CededCreditRiskReinsurerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy_0b366cc1-7835-4bbb-a805-050da2b59153_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" xlink:to="lab_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_03dad3b5-abc8-4ce5-bdb4-9968fe287787_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Issues</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_16f17991-6f46-46b5-b5ea-9e464c84aa55_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ac5d531a-d7c5-4158-b5e0-0372ec3aa6cd_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e778ce0c-14ae-4154-a64b-fea6dd802e5b_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss related to unconsolidated entities reported on the equity method</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_a7923e05-0617-45d0-a449-b8c411a6d07f_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before reclassifications, after-tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_fbbe116a-c850-4007-ab0f-82c541e1a323_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_cdfd7cd1-f43c-4b7c-b31a-1e008d2f007b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_0419ebb4-59d7-4943-aa9d-ec828baf9d8f_periodStartLabel_en-US" xlink:label="lab_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, net, including held for sale liabilities</link:label>
    <link:label id="lab_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_0376fd1a-16f0-4f36-9386-d796f688f864_periodEndLabel_en-US" xlink:label="lab_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, net, including held for sale liabilities</link:label>
    <link:label id="lab_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_97c17ad7-dbff-49ee-8d54-5ff45a909f58_totalLabel_en-US" xlink:label="lab_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unpaid claims and claims expenses - Cigna Healthcare</link:label>
    <link:label id="lab_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_label_en-US" xlink:label="lab_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Unpaid Claims And Claims Adjustment Expense Net Including Disposal Groups</link:label>
    <link:label id="lab_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_documentation_en-US" xlink:label="lab_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Unpaid Claims And Claims Adjustment Expense Net Including Disposal Groups</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups" xlink:href="ci-20231231.xsd#ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups" xlink:to="lab_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtInstrumentExtensionTerm_36af1c90-93a5-44aa-936d-75740b56909e_terseLabel_en-US" xlink:label="lab_ci_DebtInstrumentExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit agreement extension term</link:label>
    <link:label id="lab_ci_DebtInstrumentExtensionTerm_label_en-US" xlink:label="lab_ci_DebtInstrumentExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Extension Term</link:label>
    <link:label id="lab_ci_DebtInstrumentExtensionTerm_documentation_en-US" xlink:label="lab_ci_DebtInstrumentExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Extension Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtInstrumentExtensionTerm" xlink:href="ci-20231231.xsd#ci_DebtInstrumentExtensionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtInstrumentExtensionTerm" xlink:to="lab_ci_DebtInstrumentExtensionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CapitalizationOfDeferredPolicyAcquisitionCostsPolicyPolicyTextBlock_2532de88-e8b9-4861-9c8c-7167d9b19d32_terseLabel_en-US" xlink:label="lab_ci_CapitalizationOfDeferredPolicyAcquisitionCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Policy Acquisition Costs</link:label>
    <link:label id="lab_ci_CapitalizationOfDeferredPolicyAcquisitionCostsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_ci_CapitalizationOfDeferredPolicyAcquisitionCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalization Of Deferred Policy Acquisition Costs Policy [Policy Text Block]</link:label>
    <link:label id="lab_ci_CapitalizationOfDeferredPolicyAcquisitionCostsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_ci_CapitalizationOfDeferredPolicyAcquisitionCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Describes an insurance entity's accounting policy for deferred policy acquisition costs, including the nature and amount of capitalized costs incurred to write or acquire insurance contracts, and the basis for and methodologies applied in capitalizing and amortizing such costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CapitalizationOfDeferredPolicyAcquisitionCostsPolicyPolicyTextBlock" xlink:href="ci-20231231.xsd#ci_CapitalizationOfDeferredPolicyAcquisitionCostsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CapitalizationOfDeferredPolicyAcquisitionCostsPolicyPolicyTextBlock" xlink:to="lab_ci_CapitalizationOfDeferredPolicyAcquisitionCostsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_3c2390d2-cb72-4aba-befb-3704ea84d777_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_5d0437a1-cc91-4107-a026-54c01f6d44cd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount of outstanding debt securities redeemed</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_394381f1-701a-4c12-b2f5-f1cc0f5d2200_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expense to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience_a48adf5f-de6c-4531-bf17-9f71df1c3739_terseLabel_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of assumption changes and actual variances from expected experience (1)</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience_label_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefit, Expected Future Policy Benefit, Cumulative Increase (Decrease) From Cash Flow Change And Actual Variance From Expected Experience</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience_documentation_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefit, Expected Future Policy Benefit, Cumulative Increase (Decrease) From Cash Flow Change And Actual Variance From Expected Experience</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience" xlink:to="lab_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NotesDue20473875Member_6662bc4e-2d64-4d1c-97ad-cea59e3f6914_terseLabel_en-US" xlink:label="lab_ci_NotesDue20473875Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$1,000&#160;million, 3.875% Notes due October 2047</link:label>
    <link:label id="lab_ci_NotesDue20473875Member_label_en-US" xlink:label="lab_ci_NotesDue20473875Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2047, 3.875% [Member]</link:label>
    <link:label id="lab_ci_NotesDue20473875Member_documentation_en-US" xlink:label="lab_ci_NotesDue20473875Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable bearing interest at 3.875% due October 15, 2047.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20473875Member" xlink:href="ci-20231231.xsd#ci_NotesDue20473875Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NotesDue20473875Member" xlink:to="lab_ci_NotesDue20473875Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_6104fa94-6e26-4bc1-bf38-b23c0c930aa1_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill acquired</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseLongDurationNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_d9c743d9-0a1a-47a0-921d-830b72dbb39a_terseLabel_en-US" xlink:label="lab_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseLongDurationNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-duration liabilities not included in development table above, including assets held for sale</link:label>
    <link:label id="lab_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseLongDurationNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseLongDurationNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Unpaid Claims And Claims Adjustment Expense Long Duration Net, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseLongDurationNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseLongDurationNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Unpaid Claims And Claims Adjustment Expense Long Duration Net, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseLongDurationNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseLongDurationNetBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseLongDurationNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseLongDurationNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesAbstract_b07af3df-3f56-493e-bcac-e5ec4cf3b025_terseLabel_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesAbstract_label_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance And Contractholder Liabilities [Abstract]</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesAbstract_documentation_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance And Contractholder Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesAbstract" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract" xlink:to="lab_ci_InsuranceAndContractholderLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CashFlowActivitiesLesseeTableTextBlock_1bd440ae-f0a4-4108-97b0-31b95fa15469_terseLabel_en-US" xlink:label="lab_ci_CashFlowActivitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information Related to Leases</link:label>
    <link:label id="lab_ci_CashFlowActivitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_ci_CashFlowActivitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Activities Lessee [Table Text Block]</link:label>
    <link:label id="lab_ci_CashFlowActivitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_ci_CashFlowActivitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of lessee cash flows related to finance and operating leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CashFlowActivitiesLesseeTableTextBlock" xlink:href="ci-20231231.xsd#ci_CashFlowActivitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CashFlowActivitiesLesseeTableTextBlock" xlink:to="lab_ci_CashFlowActivitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_d22324bd-2928-4f04-9c51-7d8c79185aa6_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk</link:label>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicConcentrationRiskMember" xlink:to="lab_us-gaap_GeographicConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems_e880df99-c2ca-4dd3-9a9c-56d51a9e8c6d_terseLabel_en-US" xlink:label="lab_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Line Items]</link:label>
    <link:label id="lab_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Line Items]</link:label>
    <link:label id="lab_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems_documentation_en-US" xlink:label="lab_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems" xlink:href="ci-20231231.xsd#ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems" xlink:to="lab_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_4c3f3c0f-5ea5-49ce-8968-074155e270d3_terseLabel_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Gains and Losses on Investments</link:label>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_0391ce41-510a-42f6-9e33-5482137ff855_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. income taxes</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance_3be5a4a9-1425-48fa-81a6-d2d8e956d22e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance at original discount rate</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefit, Expected Future Policy Benefit, Original Discount Rate, before Cash Flow and Reinsurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities_15ea79b5-f91b-45d2-b852-8a35653e4264_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Insurance Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInsuranceLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInInsuranceLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration_97144335-5799-4997-a8c8-395b2c0ec7a6_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average duration</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefit, Weighted-Average Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NotesDue20233InterestMember_fada5ec8-a3ff-4643-b9b7-db458b54c21c_terseLabel_en-US" xlink:label="lab_ci_NotesDue20233InterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$1,000&#160;million, 3% Notes due July 2023</link:label>
    <link:label id="lab_ci_NotesDue20233InterestMember_label_en-US" xlink:label="lab_ci_NotesDue20233InterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2023, 3% Interest [Member]</link:label>
    <link:label id="lab_ci_NotesDue20233InterestMember_documentation_en-US" xlink:label="lab_ci_NotesDue20233InterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior notes payable bearing interest at 3% due in 2023. Debt assumed acquisition from Express Scripts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20233InterestMember" xlink:href="ci-20231231.xsd#ci_NotesDue20233InterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NotesDue20233InterestMember" xlink:to="lab_ci_NotesDue20233InterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BenefitsLossesAndExpensesAbstract_64539592-f141-4fe4-81a5-5c76b049e191_terseLabel_en-US" xlink:label="lab_us-gaap_BenefitsLossesAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits and expenses</link:label>
    <link:label id="lab_us-gaap_BenefitsLossesAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_BenefitsLossesAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits, Losses and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BenefitsLossesAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BenefitsLossesAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BenefitsLossesAndExpensesAbstract" xlink:to="lab_us-gaap_BenefitsLossesAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_6ac6f3f2-e73f-467f-9760-3f12df3e88e8_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NotesDue204032InterestMember_a40571d4-56e5-4b30-9b5f-406e633e614f_terseLabel_en-US" xlink:label="lab_ci_NotesDue204032InterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$750&#160;million, 3.200% Notes due March 2040</link:label>
    <link:label id="lab_ci_NotesDue204032InterestMember_label_en-US" xlink:label="lab_ci_NotesDue204032InterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2040, 3.2% Interest [Member]</link:label>
    <link:label id="lab_ci_NotesDue204032InterestMember_documentation_en-US" xlink:label="lab_ci_NotesDue204032InterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2040, 3.2% Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue204032InterestMember" xlink:href="ci-20231231.xsd#ci_NotesDue204032InterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NotesDue204032InterestMember" xlink:to="lab_ci_NotesDue204032InterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_IncomeTaxDisclosureLineItems_4ed2ede9-5232-432e-b3a7-e079d3664c57_terseLabel_en-US" xlink:label="lab_ci_IncomeTaxDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Line Items]</link:label>
    <link:label id="lab_ci_IncomeTaxDisclosureLineItems_label_en-US" xlink:label="lab_ci_IncomeTaxDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Line Items]</link:label>
    <link:label id="lab_ci_IncomeTaxDisclosureLineItems_documentation_en-US" xlink:label="lab_ci_IncomeTaxDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncomeTaxDisclosureLineItems" xlink:href="ci-20231231.xsd#ci_IncomeTaxDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_IncomeTaxDisclosureLineItems" xlink:to="lab_ci_IncomeTaxDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent_b0f2cb2c-b2cf-471c-b1dd-12838d13f793_terseLabel_en-US" xlink:label="lab_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net long-duration insurance and contractholder liabilities measurement adjustments</link:label>
    <link:label id="lab_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent_label_en-US" xlink:label="lab_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Liability For Future Policy Benefit And Market Risk Benefit, Instrument-Specific Credit Risk, Gain (Loss), After Reclassification Adjustment And Tax, Portion Attributable To Parent</link:label>
    <link:label id="lab_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent_documentation_en-US" xlink:label="lab_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Liability For Future Policy Benefit And Market Risk Benefit, Instrument-Specific Credit Risk, Gain (Loss), After Reclassification Adjustment And Tax, Portion Attributable To Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent" xlink:href="ci-20231231.xsd#ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent" xlink:to="lab_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses_f1c0894e-bfeb-46ae-a851-a30e808d4a35_verboseLabel_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total of incurred but not reported liabilities plus expected claim development on reported claims, including reported claims in process</link:label>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses_label_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Claims And Claims Adjustment Expense Excluding Physician Incentives And Other Expenses</link:label>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses_documentation_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the total liability for incurred but not reported claims plus expected claim development on reported claims, including reported claims in process. Excludes amounts due for physician incentives and other medical care expenses and services payable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses" xlink:to="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentIncome_b682428e-e321-4aa1-bf12-a2ce88aecf5e_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment income</link:label>
    <link:label id="lab_us-gaap_NetInvestmentIncome_f3a274a3-b344-4ee9-bc69-1908a38583fd_totalLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment income</link:label>
    <link:label id="lab_us-gaap_NetInvestmentIncome_de02f28e-37b0-464f-a3cf-9a67941f2cb6_verboseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentIncome" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment income (loss)</link:label>
    <link:label id="lab_us-gaap_NetInvestmentIncome_label_en-US" xlink:label="lab_us-gaap_NetInvestmentIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentIncome" xlink:to="lab_us-gaap_NetInvestmentIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DeferredTaxAssetsValuationAllowanceForeignTaxAttributes_1a426fa0-cee9-42d0-84e9-14712cedb3bd_terseLabel_en-US" xlink:label="lab_ci_DeferredTaxAssetsValuationAllowanceForeignTaxAttributes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance against deferred tax assets associated with foreign tax attributes</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsValuationAllowanceForeignTaxAttributes_label_en-US" xlink:label="lab_ci_DeferredTaxAssetsValuationAllowanceForeignTaxAttributes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance, Foreign Tax Attributes</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsValuationAllowanceForeignTaxAttributes_documentation_en-US" xlink:label="lab_ci_DeferredTaxAssetsValuationAllowanceForeignTaxAttributes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance, Foreign Tax Attributes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsValuationAllowanceForeignTaxAttributes" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsValuationAllowanceForeignTaxAttributes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DeferredTaxAssetsValuationAllowanceForeignTaxAttributes" xlink:to="lab_ci_DeferredTaxAssetsValuationAllowanceForeignTaxAttributes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_5f43096d-7ee2-4534-86c4-1d20e8b9f3f7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial (gains), net</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_338576f4-8991-4f2f-9c9c-0f6572534864_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_553ae938-b1ab-433a-a52e-75a3eb1a83cb_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPortfolioSegmentMember_6a06f30b-71e1-4579-813a-1adccd15acb7_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPortfolioSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Portfolio Segment</link:label>
    <link:label id="lab_us-gaap_CommercialPortfolioSegmentMember_label_en-US" xlink:label="lab_us-gaap_CommercialPortfolioSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Portfolio Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPortfolioSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPortfolioSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPortfolioSegmentMember" xlink:to="lab_us-gaap_CommercialPortfolioSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4007709e-fcf8-4f50-afa6-c4ecc0584a9c_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_5f8abe3e-7df2-478a-9168-ede755b313ca_netLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_96b1563c-ea6c-424b-8dfd-7fbcbe1fa476_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Value</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesTable_2a04d417-f11b-4316-8c01-0a6a7b56fd9a_terseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases [Table]</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesTable_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesTable" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_979ef4ce-0878-4b2c-a8bf-b5ae4b964979_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding - January 1 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6c373900-93ed-4fba-ae4e-642b0bdbbeae_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding - December 31 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_MedicareAdvantageLitigationPrivateIndividualMember_989e271b-329d-42a7-b0d3-50f4c546dc4c_terseLabel_en-US" xlink:label="lab_ci_MedicareAdvantageLitigationPrivateIndividualMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage, Private Individual</link:label>
    <link:label id="lab_ci_MedicareAdvantageLitigationPrivateIndividualMember_label_en-US" xlink:label="lab_ci_MedicareAdvantageLitigationPrivateIndividualMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage Litigation Private Individual [Member]</link:label>
    <link:label id="lab_ci_MedicareAdvantageLitigationPrivateIndividualMember_documentation_en-US" xlink:label="lab_ci_MedicareAdvantageLitigationPrivateIndividualMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A qui tam action filed by a private individual on behalf of the government relating to risk adjustment practices within the Medicare Advantage business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageLitigationPrivateIndividualMember" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageLitigationPrivateIndividualMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_MedicareAdvantageLitigationPrivateIndividualMember" xlink:to="lab_ci_MedicareAdvantageLitigationPrivateIndividualMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_5e631fc1-ba4d-4f05-9e1b-2d726dacb80a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PaymentsToAcquireDebtAndEquitySecurities_397618fe-4ce6-452d-a767-d64a0e2b59db_negatedLabel_en-US" xlink:label="lab_ci_PaymentsToAcquireDebtAndEquitySecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities and equity securities</link:label>
    <link:label id="lab_ci_PaymentsToAcquireDebtAndEquitySecurities_446da498-f3c6-4b34-82b4-d71ca111c8ba_terseLabel_en-US" xlink:label="lab_ci_PaymentsToAcquireDebtAndEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount funded</link:label>
    <link:label id="lab_ci_PaymentsToAcquireDebtAndEquitySecurities_label_en-US" xlink:label="lab_ci_PaymentsToAcquireDebtAndEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Debt And Equity Securities</link:label>
    <link:label id="lab_ci_PaymentsToAcquireDebtAndEquitySecurities_documentation_en-US" xlink:label="lab_ci_PaymentsToAcquireDebtAndEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Debt And Equity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PaymentsToAcquireDebtAndEquitySecurities" xlink:href="ci-20231231.xsd#ci_PaymentsToAcquireDebtAndEquitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PaymentsToAcquireDebtAndEquitySecurities" xlink:to="lab_ci_PaymentsToAcquireDebtAndEquitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_adaf1d24-9a12-4ab9-948f-5977941a4e2c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_29913785-a198-41ba-b5d2-51b6531796af_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_5e711665-6358-4428-bad5-de35d8ef66b9_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract_c1c8d921-bd1a-4b72-a18e-6008828b67da_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment maturities and repayments:</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Held-to-Maturity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_5eecf2c7-7456-4d7a-bd43-ce0b43e2443f_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_1ced1bf9-37fa-49c0-b825-c8fbd43708d1_totalLabel_en-US" xlink:label="lab_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments including held for sale assets</link:label>
    <link:label id="lab_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Investments Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Investments Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_34bd55fb-b40c-48f8-a94e-fd937e5eb27b_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QualifiedPlanMember_0bd03d63-1478-4ab7-a4e5-c823345c106d_terseLabel_en-US" xlink:label="lab_us-gaap_QualifiedPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qualified Plan</link:label>
    <link:label id="lab_us-gaap_QualifiedPlanMember_label_en-US" xlink:label="lab_us-gaap_QualifiedPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qualified Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QualifiedPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_QualifiedPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QualifiedPlanMember" xlink:to="lab_us-gaap_QualifiedPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_BelowInvestmentGradeMember_10421f26-9ec4-4708-8fd6-8ecb735ace44_terseLabel_en-US" xlink:label="lab_ci_BelowInvestmentGradeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Below investment grade</link:label>
    <link:label id="lab_ci_BelowInvestmentGradeMember_label_en-US" xlink:label="lab_ci_BelowInvestmentGradeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Below Investment Grade [Member]</link:label>
    <link:label id="lab_ci_BelowInvestmentGradeMember_documentation_en-US" xlink:label="lab_ci_BelowInvestmentGradeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">External credit-ratings or internal groupings that could be used to describe the current status of the payment and performance risk of debt and securities investments that connote non-investment grade.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_BelowInvestmentGradeMember" xlink:href="ci-20231231.xsd#ci_BelowInvestmentGradeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_BelowInvestmentGradeMember" xlink:to="lab_ci_BelowInvestmentGradeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_2b3ae831-d764-4d91-b6a7-e8720559ca14_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_213d2f20-88b5-4db2-a9bb-4e648ec49ade_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period Of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract_71ea76b3-c647-4149-95ed-808efb190ee7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from investments sold:</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities_b5ffb25f-a62c-4eb8-9b40-24c5c57be16d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment for credit risk on derivatives liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Credit Risk Valuation Adjustment, Derivative Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FairValueOfSeparateAccountAssetsTableTextBlock_c750a19e-fc12-4afb-a8e6-054f989cc0aa_terseLabel_en-US" xlink:label="lab_ci_FairValueOfSeparateAccountAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values of Separate Account Assets</link:label>
    <link:label id="lab_ci_FairValueOfSeparateAccountAssetsTableTextBlock_label_en-US" xlink:label="lab_ci_FairValueOfSeparateAccountAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Separate Account Assets [Table Text Block]</link:label>
    <link:label id="lab_ci_FairValueOfSeparateAccountAssetsTableTextBlock_documentation_en-US" xlink:label="lab_ci_FairValueOfSeparateAccountAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclose the aggregate fair value of separate account assets, by fair value level.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueOfSeparateAccountAssetsTableTextBlock" xlink:href="ci-20231231.xsd#ci_FairValueOfSeparateAccountAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FairValueOfSeparateAccountAssetsTableTextBlock" xlink:to="lab_ci_FairValueOfSeparateAccountAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale_72015df5-c890-44ad-bb65-0c6a6ec1e55d_terseLabel_en-US" xlink:label="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities with no readily determinable fair value, including held for sale assets</link:label>
    <link:label id="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Amount Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Amount Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ScheduleOfIssuancesOfLongTermDebtTableTextBlock_53548a2c-976b-49e5-9f0f-1a98c07eebf6_terseLabel_en-US" xlink:label="lab_ci_ScheduleOfIssuancesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Debt Issuances</link:label>
    <link:label id="lab_ci_ScheduleOfIssuancesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_ci_ScheduleOfIssuancesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Issuances Of Long-Term Debt [Table Text Block]</link:label>
    <link:label id="lab_ci_ScheduleOfIssuancesOfLongTermDebtTableTextBlock_documentation_en-US" xlink:label="lab_ci_ScheduleOfIssuancesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Issuances Of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ScheduleOfIssuancesOfLongTermDebtTableTextBlock" xlink:href="ci-20231231.xsd#ci_ScheduleOfIssuancesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ScheduleOfIssuancesOfLongTermDebtTableTextBlock" xlink:to="lab_ci_ScheduleOfIssuancesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther_61b75765-8016-4b4f-9ac6-26464e524d85_totalLabel_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for future policy benefits</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther_label_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefit, Before Reinsurance And Other</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther_documentation_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefit, Before Reinsurance And Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther" xlink:to="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsDiscountRateAbstract_d6f22ea3-21f4-4867-9636-193ecd109a54_terseLabel_en-US" xlink:label="lab_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate:</link:label>
    <link:label id="lab_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsDiscountRateAbstract_label_en-US" xlink:label="lab_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used in Calculations, Discount Rate [Abstract]</link:label>
    <link:label id="lab_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsDiscountRateAbstract_documentation_en-US" xlink:label="lab_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used in Calculations, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsDiscountRateAbstract" xlink:href="ci-20231231.xsd#ci_DefinedBenefitPlanAssumptionsUsedInCalculationsDiscountRateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsDiscountRateAbstract" xlink:to="lab_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsDiscountRateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_55c45b90-3d44-43da-a163-39c263c3dae0_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestmentsAbstract_d14d77f9-11d2-4e98-9b25-6aad9d85e4ff_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments purchased or originated:</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestmentsAbstract" xlink:to="lab_us-gaap_PaymentsToAcquireInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderContractDeposits_10f84505-c5db-4d0b-afde-321e99271323_totalLabel_en-US" xlink:label="lab_us-gaap_PolicyholderContractDeposits" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractholder deposit funds</link:label>
    <link:label id="lab_us-gaap_PolicyholderContractDeposits_d21299bf-d94f-47ce-b690-c108697489f9_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderContractDeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractholder deposit funds</link:label>
    <link:label id="lab_us-gaap_PolicyholderContractDeposits_label_en-US" xlink:label="lab_us-gaap_PolicyholderContractDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Contract Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderContractDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderContractDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderContractDeposits" xlink:to="lab_us-gaap_PolicyholderContractDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5ef4dc31-cb10-48a0-af0d-47994424b0d3_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax_031fadee-5d47-4ef5-9087-e32dbeb26cac_terseLabel_en-US" xlink:label="lab_ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt extinguishment costs, after-tax</link:label>
    <link:label id="lab_ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax_label_en-US" xlink:label="lab_ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Item Charges Debt Extinguishment Costs Net Of Tax</link:label>
    <link:label id="lab_ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax_documentation_en-US" xlink:label="lab_ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Item Charges Debt Extinguishment Costs Net Of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax" xlink:href="ci-20231231.xsd#ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax" xlink:to="lab_ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DeferredTaxAssetsPolicyAcquisitionExpenses_849779d9-30ca-4e02-87da-d491d7db969c_terseLabel_en-US" xlink:label="lab_ci_DeferredTaxAssetsPolicyAcquisitionExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policy acquisition expenses</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsPolicyAcquisitionExpenses_label_en-US" xlink:label="lab_ci_DeferredTaxAssetsPolicyAcquisitionExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Policy Acquisition Expenses</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsPolicyAcquisitionExpenses_documentation_en-US" xlink:label="lab_ci_DeferredTaxAssetsPolicyAcquisitionExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Policy Acquisition Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsPolicyAcquisitionExpenses" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsPolicyAcquisitionExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DeferredTaxAssetsPolicyAcquisitionExpenses" xlink:to="lab_ci_DeferredTaxAssetsPolicyAcquisitionExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceBeforeReclassificationToDisposalGroupAssetsHeldForSale_f3f59de0-53ea-4e26-8902-4dcbb5702cf1_totalLabel_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liability for future policy benefits, including assets held for sale</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefit, before Reinsurance, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefit, before Reinsurance, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FinancingReceivableCreditQualityLoanToValueRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale_3063b081-9a3f-47f9-bc87-be68c3bdad7c_terseLabel_en-US" xlink:label="lab_ci_FinancingReceivableCreditQualityLoanToValueRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Loan-to-Value Ratio, including assets held for sale</link:label>
    <link:label id="lab_ci_FinancingReceivableCreditQualityLoanToValueRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_FinancingReceivableCreditQualityLoanToValueRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable Credit Quality Loan To Value Ratio, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_FinancingReceivableCreditQualityLoanToValueRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_FinancingReceivableCreditQualityLoanToValueRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable Credit Quality Loan To Value Ratio, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FinancingReceivableCreditQualityLoanToValueRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_FinancingReceivableCreditQualityLoanToValueRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FinancingReceivableCreditQualityLoanToValueRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_FinancingReceivableCreditQualityLoanToValueRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_8e7e4b5d-ef89-4c19-9a6a-4fec2d53eaa0_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NotesDue20415875InterestMember_1d455b60-9f0d-431b-9bae-1398aed8a0e0_terseLabel_en-US" xlink:label="lab_ci_NotesDue20415875InterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$121&#160;million, 5.875% Notes due March 2041</link:label>
    <link:label id="lab_ci_NotesDue20415875InterestMember_label_en-US" xlink:label="lab_ci_NotesDue20415875InterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2041, 5.875% Interest [Member]</link:label>
    <link:label id="lab_ci_NotesDue20415875InterestMember_documentation_en-US" xlink:label="lab_ci_NotesDue20415875InterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable bearing interest at 5.875% due in 2041.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20415875InterestMember" xlink:href="ci-20231231.xsd#ci_NotesDue20415875InterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NotesDue20415875InterestMember" xlink:to="lab_ci_NotesDue20415875InterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_518db60a-0153-464a-85b7-c181421b7886_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_6e78a101-2010-497c-971d-8c2f5947d9b4_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets of businesses held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_93120422-5ecc-4a88-a890-dcdf809a6101_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVoba_3b816a47-5a19-45ee-996e-6cabd344bc86_totalLabel_en-US" xlink:label="lab_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVoba" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVoba_label_en-US" xlink:label="lab_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVoba" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Gross Excluding Goodwill Including VOBA</link:label>
    <link:label id="lab_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVoba_documentation_en-US" xlink:label="lab_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVoba" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before accumulated amortization of intangible assets, excluding goodwill. Inlcudes insurance contracts acquired in a business combination that are reported in deferred policy acquisition costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVoba" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsGrossExcludingGoodwillIncludingVoba"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVoba" xlink:to="lab_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVoba" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_ebe1584a-223d-476a-b919-82c232609546_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract_3466aa46-3ca6-40d8-959d-441eb436f9c9_terseLabel_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract_label_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Amortized Cost [Abstract]</link:label>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract_documentation_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract" xlink:to="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_2da4ca32-c0d3-4616-84bd-44d27ad467cc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash outflows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_545d83fe-164f-4393-b7c9-68fc809c4e88_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration_1bdc8aec-6b83-4e0f-b87c-39f4b26b5872_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_e3f48197-6aba-4f47-af18-e497fa08c71c_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_6a664b42-a99f-483e-9d24-c6000dcb9193_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1b016bb0-36b2-4725-afb6-f9106f054c94_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_32f4bfab-6b87-4fda-9fbb-d4c8f60d5f6c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_587422e5-b345-4cca-9f68-ed56c8acb839_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income tax (benefit), net of federal income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis_e8538f08-b0dc-45ef-812d-bdfc13b48d38_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Account Balance, above Guaranteed Minimum Crediting Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis_label_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Account Balance, above Guaranteed Minimum Crediting Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis" xlink:to="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_83fc8fac-9082-4f07-b550-74ff9632fb61_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CommitmentsToContributeAdditionalEquityAndCapital_6f1afe83-8063-4f30-be52-a8964f3d3b29_terseLabel_en-US" xlink:label="lab_ci_CommitmentsToContributeAdditionalEquityAndCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded commitments</link:label>
    <link:label id="lab_ci_CommitmentsToContributeAdditionalEquityAndCapital_label_en-US" xlink:label="lab_ci_CommitmentsToContributeAdditionalEquityAndCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments To Contribute Additional Equity And Capital</link:label>
    <link:label id="lab_ci_CommitmentsToContributeAdditionalEquityAndCapital_documentation_en-US" xlink:label="lab_ci_CommitmentsToContributeAdditionalEquityAndCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment commitments of estimated payments required under contractual arrangements diversified by issuer, property type and geographic regions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CommitmentsToContributeAdditionalEquityAndCapital" xlink:href="ci-20231231.xsd#ci_CommitmentsToContributeAdditionalEquityAndCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CommitmentsToContributeAdditionalEquityAndCapital" xlink:to="lab_ci_CommitmentsToContributeAdditionalEquityAndCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_MedicareAdvantageMember_8ab7aa48-a5d8-4838-bb5c-2039f5d03f5e_terseLabel_en-US" xlink:label="lab_ci_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage</link:label>
    <link:label id="lab_ci_MedicareAdvantageMember_label_en-US" xlink:label="lab_ci_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageMember" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_MedicareAdvantageMember" xlink:to="lab_ci_MedicareAdvantageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_093fa909-e218-4aa9-b726-b8e56f5c8baf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_VillageMDMember_685c2338-387f-445f-bc7a-801e106ec244_terseLabel_en-US" xlink:label="lab_ci_VillageMDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VillageMD</link:label>
    <link:label id="lab_ci_VillageMDMember_label_en-US" xlink:label="lab_ci_VillageMDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VillageMD [Member]</link:label>
    <link:label id="lab_ci_VillageMDMember_documentation_en-US" xlink:label="lab_ci_VillageMDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VillageMD</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_VillageMDMember" xlink:href="ci-20231231.xsd#ci_VillageMDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_VillageMDMember" xlink:to="lab_ci_VillageMDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_5ba11ccd-0ff0-4c2c-be1c-f28a23cd7dc0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities of businesses held for sale</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_c424fe5f-d4b4-485a-9322-06e88f7d54d7_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_cccd5974-0ea7-44cd-afe0-52711844c2db_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_0ab7cbcd-ec78-49dc-8fb1-11f69053d47f_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL LIABILITIES</link:label>
    <link:label id="lab_us-gaap_Liabilities_4f881e50-90ca-460b-a3a9-855d519c3107_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NotesDue20284375InterestMember_8cc84854-eb49-47bd-923a-d4fa86027d94_terseLabel_en-US" xlink:label="lab_ci_NotesDue20284375InterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$3,800&#160;million, 4.375% Notes due October 2028</link:label>
    <link:label id="lab_ci_NotesDue20284375InterestMember_label_en-US" xlink:label="lab_ci_NotesDue20284375InterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2028, 4.375% Interest [Member]</link:label>
    <link:label id="lab_ci_NotesDue20284375InterestMember_documentation_en-US" xlink:label="lab_ci_NotesDue20284375InterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior notes payable bearing interest at 4.375% due in 2028. Debt issued to finance acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20284375InterestMember" xlink:href="ci-20231231.xsd#ci_NotesDue20284375InterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NotesDue20284375InterestMember" xlink:to="lab_ci_NotesDue20284375InterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrent_41d29e69-23a3-4258-8f30-0ee9111c6328_terseLabel_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current insurance and contractholder liabilities</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrent_63493962-7439-4469-bcec-a9c726a9fe4d_totalLabel_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current insurance and contractholder liabilities</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrent_label_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance And Contractholder Liabilities Noncurrent</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrent_documentation_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The carrying amounts as of the balance sheet date of all current insurance and contractholder liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent" xlink:to="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CommercialPaperAverageRatePaid_7c491a0d-bfa9-4dfc-8f2d-e3bd2bf098e3_terseLabel_en-US" xlink:label="lab_srt_CommercialPaperAverageRatePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper average interest rate</link:label>
    <link:label id="lab_srt_CommercialPaperAverageRatePaid_label_en-US" xlink:label="lab_srt_CommercialPaperAverageRatePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper, Average Rate Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CommercialPaperAverageRatePaid" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CommercialPaperAverageRatePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CommercialPaperAverageRatePaid" xlink:to="lab_srt_CommercialPaperAverageRatePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_67bb2911-121a-40a7-9c0d-b2b467a42fe3_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FuturePolicyBenefitsDomesticContractsObservableInputsFromPublishedSpotRateCurveMaximumTerm_d366b80d-68cb-48ce-8e30-d1682352e765_terseLabel_en-US" xlink:label="lab_ci_FuturePolicyBenefitsDomesticContractsObservableInputsFromPublishedSpotRateCurveMaximumTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Observable inputs from published spot rate curve term (in years)</link:label>
    <link:label id="lab_ci_FuturePolicyBenefitsDomesticContractsObservableInputsFromPublishedSpotRateCurveMaximumTerm_label_en-US" xlink:label="lab_ci_FuturePolicyBenefitsDomesticContractsObservableInputsFromPublishedSpotRateCurveMaximumTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Policy Benefits, Domestic Contracts, Observable Inputs From Published Spot Rate Curve, Maximum Term</link:label>
    <link:label id="lab_ci_FuturePolicyBenefitsDomesticContractsObservableInputsFromPublishedSpotRateCurveMaximumTerm_documentation_en-US" xlink:label="lab_ci_FuturePolicyBenefitsDomesticContractsObservableInputsFromPublishedSpotRateCurveMaximumTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Policy Benefits, Domestic Contracts, Observable Inputs From Published Spot Rate Curve, Maximum Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FuturePolicyBenefitsDomesticContractsObservableInputsFromPublishedSpotRateCurveMaximumTerm" xlink:href="ci-20231231.xsd#ci_FuturePolicyBenefitsDomesticContractsObservableInputsFromPublishedSpotRateCurveMaximumTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FuturePolicyBenefitsDomesticContractsObservableInputsFromPublishedSpotRateCurveMaximumTerm" xlink:to="lab_ci_FuturePolicyBenefitsDomesticContractsObservableInputsFromPublishedSpotRateCurveMaximumTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock_6fe6d613-0e88-4a05-93d7-9178e8f4743a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Account Value, Net Amount at Risk and the Number of Contractholders for Guarantees Assumed in the Event of Death</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Amount of Risk by Product and Guarantee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssumedPremiumsEarned_c08102f1-5f8d-4b27-95b8-2a6d36494e24_terseLabel_en-US" xlink:label="lab_us-gaap_AssumedPremiumsEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed</link:label>
    <link:label id="lab_us-gaap_AssumedPremiumsEarned_label_en-US" xlink:label="lab_us-gaap_AssumedPremiumsEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed Premiums Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumedPremiumsEarned" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssumedPremiumsEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssumedPremiumsEarned" xlink:to="lab_us-gaap_AssumedPremiumsEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio_efddebc8-5208-43da-8283-317e3257c2b5_terseLabel_en-US" xlink:label="lab_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Debt Service Coverage Ratio</link:label>
    <link:label id="lab_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio_label_en-US" xlink:label="lab_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Credit Quality Debt Service Coverage Ratio</link:label>
    <link:label id="lab_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio_documentation_en-US" xlink:label="lab_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Credit Quality Debt Service Coverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio" xlink:href="ci-20231231.xsd#ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio" xlink:to="lab_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_IntercompanyInterestIncome_175d37f5-afbc-41ca-9654-d7c617e9f592_terseLabel_en-US" xlink:label="lab_ci_IntercompanyInterestIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intercompany interest income</link:label>
    <link:label id="lab_ci_IntercompanyInterestIncome_label_en-US" xlink:label="lab_ci_IntercompanyInterestIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intercompany Interest Income</link:label>
    <link:label id="lab_ci_IntercompanyInterestIncome_documentation_en-US" xlink:label="lab_ci_IntercompanyInterestIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense associated with intercompany loan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntercompanyInterestIncome" xlink:href="ci-20231231.xsd#ci_IntercompanyInterestIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_IntercompanyInterestIncome" xlink:to="lab_ci_IntercompanyInterestIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AssetsAndLiabilitiesLesseeOperatingLeasesAbstract_866ad88b-094b-44e4-8329-6241f8a474cb_terseLabel_en-US" xlink:label="lab_ci_AssetsAndLiabilitiesLesseeOperatingLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases:</link:label>
    <link:label id="lab_ci_AssetsAndLiabilitiesLesseeOperatingLeasesAbstract_label_en-US" xlink:label="lab_ci_AssetsAndLiabilitiesLesseeOperatingLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee, Operating Leases [Abstract]</link:label>
    <link:label id="lab_ci_AssetsAndLiabilitiesLesseeOperatingLeasesAbstract_documentation_en-US" xlink:label="lab_ci_AssetsAndLiabilitiesLesseeOperatingLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee, Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AssetsAndLiabilitiesLesseeOperatingLeasesAbstract" xlink:href="ci-20231231.xsd#ci_AssetsAndLiabilitiesLesseeOperatingLeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AssetsAndLiabilitiesLesseeOperatingLeasesAbstract" xlink:to="lab_ci_AssetsAndLiabilitiesLesseeOperatingLeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_RevenuesIncludingNetInvestmentIncomeBenchmarkMember_39cb98e6-8701-4a5f-a254-3bc5b941e24c_terseLabel_en-US" xlink:label="lab_ci_RevenuesIncludingNetInvestmentIncomeBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_ci_RevenuesIncludingNetInvestmentIncomeBenchmarkMember_label_en-US" xlink:label="lab_ci_RevenuesIncludingNetInvestmentIncomeBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, Including Net Investment Income Benchmark [Member]</link:label>
    <link:label id="lab_ci_RevenuesIncludingNetInvestmentIncomeBenchmarkMember_documentation_en-US" xlink:label="lab_ci_RevenuesIncludingNetInvestmentIncomeBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, Including Net Investment Income Benchmark</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RevenuesIncludingNetInvestmentIncomeBenchmarkMember" xlink:href="ci-20231231.xsd#ci_RevenuesIncludingNetInvestmentIncomeBenchmarkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_RevenuesIncludingNetInvestmentIncomeBenchmarkMember" xlink:to="lab_ci_RevenuesIncludingNetInvestmentIncomeBenchmarkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_edefa816-2e03-46c2-b7a4-68d04d92d7e1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_d77e497e-7257-4440-a46f-d4d5601367bc_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">China</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale_4fa38854-010c-4e7e-ace9-316a293417d8_totalLabel_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, including assets held for sale</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_d422c8bb-d981-46ac-a2e2-9961031caab7_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income taxes</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PaymentsForProceedsFromPropertyPlantAndEquipment_9b19cc19-6098-4240-94db-65e6b03556be_negatedLabel_en-US" xlink:label="lab_ci_PaymentsForProceedsFromPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment purchases, net</link:label>
    <link:label id="lab_ci_PaymentsForProceedsFromPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ci_PaymentsForProceedsFromPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Property, Plant, And Equipment</link:label>
    <link:label id="lab_ci_PaymentsForProceedsFromPropertyPlantAndEquipment_documentation_en-US" xlink:label="lab_ci_PaymentsForProceedsFromPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Property, Plant, And Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PaymentsForProceedsFromPropertyPlantAndEquipment" xlink:href="ci-20231231.xsd#ci_PaymentsForProceedsFromPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PaymentsForProceedsFromPropertyPlantAndEquipment" xlink:to="lab_ci_PaymentsForProceedsFromPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_7c3620fd-38fd-429c-ad67-392adad3a6ee_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_ca8570fc-2311-420e-bd29-e024cb7602d9_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosure of Cash Information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock_91d89e74-864e-43a2-93ef-c4baff0cca30_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the Credit Risk Profile of the Commercial Mortgage Loan Portfolio</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable Credit Quality Indicators [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock" xlink:to="lab_us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_c1b51f73-df32-4910-8102-8e4b00f6a8be_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:to="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CededCreditRiskCollateralizationDomain_08f4237d-6a03-43f3-be68-105ba434e080_terseLabel_en-US" xlink:label="lab_us-gaap_CededCreditRiskCollateralizationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded Credit Risk, Collateralization [Domain]</link:label>
    <link:label id="lab_us-gaap_CededCreditRiskCollateralizationDomain_label_en-US" xlink:label="lab_us-gaap_CededCreditRiskCollateralizationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded Credit Risk, Collateralization [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskCollateralizationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskCollateralizationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CededCreditRiskCollateralizationDomain" xlink:to="lab_us-gaap_CededCreditRiskCollateralizationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_a36f816f-8427-4a14-81b0-c5be3239d4b7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchased common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member_f4b74dc0-8684-40f9-8341-248886389c15_terseLabel_en-US" xlink:label="lab_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five-year Revolving Credit Agreement, Maturing April 2028</link:label>
    <link:label id="lab_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member_label_en-US" xlink:label="lab_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit And Letter Of Credit Facility Maturing April 2028 [Member]</link:label>
    <link:label id="lab_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member_documentation_en-US" xlink:label="lab_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit And Letter Of Credit Facility Maturing April 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member" xlink:href="ci-20231231.xsd#ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member" xlink:to="lab_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member_4145038a-1b7f-4c15-a06a-b5aa474680d9_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400</link:label>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member_label_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 to 0399 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member" xlink:to="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member_b6ef5745-5bd9-4de4-bafd-40c0fcb6404e_terseLabel_en-US" xlink:label="lab_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving credit agreements, April 2022</link:label>
    <link:label id="lab_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member_label_en-US" xlink:label="lab_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit And Letter Of Credit Facility Maturing April 2027, Revolving Credit Facility Maturing April 2025, And 364 Day Revolving Credit Agreement, Maturing April 2023 [Member]</link:label>
    <link:label id="lab_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member_documentation_en-US" xlink:label="lab_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit And Letter Of Credit Facility Maturing April 2027, Revolving Credit Facility Maturing April 2025, And 364 Day Revolving Credit Agreement, Maturing April 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member" xlink:href="ci-20231231.xsd#ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member" xlink:to="lab_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_be98ebfe-a827-4b01-8cb5-c20ff22facc7_totalLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total investments</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e3d000f1-8dc6-4e57-ac8f-d9962edd6d17_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_481cca98-038a-45d4-be36-2e7cb6891f89_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_f1bd9b0a-32e4-4122-b255-c21be30f2a89_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOtherIncludingDisposalGroupsAssetsHeldForSale_a8872b60-9ebc-49cb-a787-41828bd71561_terseLabel_en-US" xlink:label="lab_ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOtherIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOtherIncludingDisposalGroupsAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOtherIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other, Including Disposal Groups Assets Held For Sale</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOtherIncludingDisposalGroupsAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOtherIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other, Including Disposal Groups Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOtherIncludingDisposalGroupsAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOtherIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOtherIncludingDisposalGroupsAssetsHeldForSale" xlink:to="lab_ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOtherIncludingDisposalGroupsAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_300f51b8-ea94-4d38-a1c0-c6df74c1574b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Annual Pre-Tax Amortization for Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember_e83e0664-6f95-4ce7-90c9-a73bf840b3e0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translation of foreign currencies attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceContractsAcquiredInBusinessCombinationMember_379b46dc-4310-4b1e-807d-03375240085e_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceContractsAcquiredInBusinessCombinationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of business acquired (reported in Other assets)</link:label>
    <link:label id="lab_us-gaap_InsuranceContractsAcquiredInBusinessCombinationMember_label_en-US" xlink:label="lab_us-gaap_InsuranceContractsAcquiredInBusinessCombinationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Contracts Acquired in Business Combination [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceContractsAcquiredInBusinessCombinationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceContractsAcquiredInBusinessCombinationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceContractsAcquiredInBusinessCombinationMember" xlink:to="lab_us-gaap_InsuranceContractsAcquiredInBusinessCombinationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_1b081d19-0013-47a0-9713-50fa2595512c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_9c9e7feb-e8dc-445b-a9da-9286806be0dd_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale_b5c7fb0e-c703-4f23-9a98-9db31a3656dc_totalLabel_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Number of Issues, including held for sale assets</link:label>
    <link:label id="lab_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities In Unrealized Loss Positions, Qualitative Disclosure, Number Of Positions, Before Reclassification To Disposal Group, Assets Held For Sale</link:label>
    <link:label id="lab_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities In Unrealized Loss Positions, Qualitative Disclosure, Number Of Positions, Before Reclassification To Disposal Group, Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CommitmentsAndContingenciesNumberOfExpert_960d1c75-c476-4297-8659-947aa1c2c224_terseLabel_en-US" xlink:label="lab_ci_CommitmentsAndContingenciesNumberOfExpert" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of experts</link:label>
    <link:label id="lab_ci_CommitmentsAndContingenciesNumberOfExpert_label_en-US" xlink:label="lab_ci_CommitmentsAndContingenciesNumberOfExpert" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies, Number Of Expert</link:label>
    <link:label id="lab_ci_CommitmentsAndContingenciesNumberOfExpert_documentation_en-US" xlink:label="lab_ci_CommitmentsAndContingenciesNumberOfExpert" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies, Number Of Expert</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CommitmentsAndContingenciesNumberOfExpert" xlink:href="ci-20231231.xsd#ci_CommitmentsAndContingenciesNumberOfExpert"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CommitmentsAndContingenciesNumberOfExpert" xlink:to="lab_ci_CommitmentsAndContingenciesNumberOfExpert" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent_e12304ce-fe3c-43ea-81f9-7021a10b292d_terseLabel_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid claims and claim expenses, current</link:label>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent_label_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Claims And Claims Adjustment Expense, Current</link:label>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent_documentation_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Claims And Claims Adjustment Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent" xlink:to="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2023Member_9065384d-9b80-4e87-ad57-883e9ec2b89f_terseLabel_en-US" xlink:label="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurral Year - 2023</link:label>
    <link:label id="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2023Member_label_en-US" xlink:label="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contract, Accident Year 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2023Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2023Member" xlink:to="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_6892c422-e264-4116-9fef-efb90aa6cba4_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationLiabilitiesExcludingInsuranceAndContractholderLiabilities_c117831c-c439-48ab-a193-2d342aa0a150_terseLabel_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationLiabilitiesExcludingInsuranceAndContractholderLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other liabilities</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationLiabilitiesExcludingInsuranceAndContractholderLiabilities_label_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationLiabilitiesExcludingInsuranceAndContractholderLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities Excluding Insurance And Contractholder Liabilities</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationLiabilitiesExcludingInsuranceAndContractholderLiabilities_documentation_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationLiabilitiesExcludingInsuranceAndContractholderLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities Excluding Insurance And Contractholder Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationLiabilitiesExcludingInsuranceAndContractholderLiabilities" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationLiabilitiesExcludingInsuranceAndContractholderLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DisposalGroupIncludingDiscontinuedOperationLiabilitiesExcludingInsuranceAndContractholderLiabilities" xlink:to="lab_ci_DisposalGroupIncludingDiscontinuedOperationLiabilitiesExcludingInsuranceAndContractholderLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f68e65a6-fcdd-41b4-9262-56bf71534865_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivablePortfolioSegmentAxis_b6244c98-dc10-47b4-bdd4-4d1a81297255_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable Portfolio Segment [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancingReceivablePortfolioSegmentAxis_label_en-US" xlink:label="lab_us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable Portfolio Segment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablePortfolioSegmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:to="lab_us-gaap_FinancingReceivablePortfolioSegmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_01499145-3ae9-445d-a555-eea23b904c03_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of counts dismissed</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Dismissed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:to="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_6907af44-b655-471d-8be3-b163b604bf88_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_46c49d34-fe11-439f-b4bc-ce1b1ed709c8_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OperatingLeaseLiabilityCurrentIncludingDisposalGroupsAssetsHeldForSale_31b633ed-b028-4e67-b1b4-97be4c20a812_terseLabel_en-US" xlink:label="lab_ci_OperatingLeaseLiabilityCurrentIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities, including held for sale liabilities</link:label>
    <link:label id="lab_ci_OperatingLeaseLiabilityCurrentIncludingDisposalGroupsAssetsHeldForSale_label_en-US" xlink:label="lab_ci_OperatingLeaseLiabilityCurrentIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability Current Including Disposal Groups Assets Held For Sale</link:label>
    <link:label id="lab_ci_OperatingLeaseLiabilityCurrentIncludingDisposalGroupsAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_OperatingLeaseLiabilityCurrentIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability Current Including Disposal Groups Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OperatingLeaseLiabilityCurrentIncludingDisposalGroupsAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_OperatingLeaseLiabilityCurrentIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OperatingLeaseLiabilityCurrentIncludingDisposalGroupsAssetsHeldForSale" xlink:to="lab_ci_OperatingLeaseLiabilityCurrentIncludingDisposalGroupsAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_28b9de13-24e1-4500-8535-72899c68d57f_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities with no readily determinable fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fc31de71-3bb7-42cf-a4ad-0ad6e09dd327_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale_4a547749-e65f-48a0-a1c9-0158575e3d0d_terseLabel_en-US" xlink:label="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization, including held for sale assets</link:label>
    <link:label id="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale_label_en-US" xlink:label="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets, Accumulated Amortization, Including Disposal Groups Assets Held For Sale</link:label>
    <link:label id="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets, Accumulated Amortization, Including Disposal Groups Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale" xlink:to="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InvestmentsCreditRatingDomain_333dc063-004e-4b42-81dc-cb0ca5105bbe_terseLabel_en-US" xlink:label="lab_ci_InvestmentsCreditRatingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Credit Rating [Domain]</link:label>
    <link:label id="lab_ci_InvestmentsCreditRatingDomain_label_en-US" xlink:label="lab_ci_InvestmentsCreditRatingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Credit Rating [Domain]</link:label>
    <link:label id="lab_ci_InvestmentsCreditRatingDomain_documentation_en-US" xlink:label="lab_ci_InvestmentsCreditRatingDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">External credit-ratings or internal groupings that could be used to describe the current status of the payment and performance risk of debt and securities investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InvestmentsCreditRatingDomain" xlink:href="ci-20231231.xsd#ci_InvestmentsCreditRatingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InvestmentsCreditRatingDomain" xlink:to="lab_ci_InvestmentsCreditRatingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_4e96aad7-156f-4303-96d1-e37f7257374f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_72085825-daad-43c7-8772-f71d2767fdb6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Equity Securities, US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:to="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsHeldByInsuranceRegulators_5d0e1b67-59d7-4ea4-af36-2f5708b20108_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsHeldByInsuranceRegulators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments on deposit with regulatory bodies</link:label>
    <link:label id="lab_us-gaap_AssetsHeldByInsuranceRegulators_label_en-US" xlink:label="lab_us-gaap_AssetsHeldByInsuranceRegulators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held by Insurance Regulators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldByInsuranceRegulators" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldByInsuranceRegulators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldByInsuranceRegulators" xlink:to="lab_us-gaap_AssetsHeldByInsuranceRegulators" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_4c5b2e02-e913-4160-bcbc-e3166b0d5db6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit payments including expected future services [Abstract]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ShortTermAndLongTermInvestmentsAbstract_53c06f64-771b-4e66-857f-fc1e6db4d3b3_terseLabel_en-US" xlink:label="lab_ci_ShortTermAndLongTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ci_ShortTermAndLongTermInvestmentsAbstract_label_en-US" xlink:label="lab_ci_ShortTermAndLongTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term And Long-Term Investments [Abstract]</link:label>
    <link:label id="lab_ci_ShortTermAndLongTermInvestmentsAbstract_documentation_en-US" xlink:label="lab_ci_ShortTermAndLongTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term And Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortTermAndLongTermInvestmentsAbstract" xlink:href="ci-20231231.xsd#ci_ShortTermAndLongTermInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ShortTermAndLongTermInvestmentsAbstract" xlink:to="lab_ci_ShortTermAndLongTermInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AssetsAndLiabilitiesLesseeTableTextBlock_c4faac0c-531b-4916-8f75-aa09288edcd1_terseLabel_en-US" xlink:label="lab_ci_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and Finance Lease Right of Use ("ROU") Assets and Lease Liabilities</link:label>
    <link:label id="lab_ci_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_ci_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_ci_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_ci_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of lessee right-of-use assets and lease liabilities for operating and finance leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="ci-20231231.xsd#ci_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_ci_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_72e696a0-d47b-4011-934e-63bae8c51aa3_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets before valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_5fc743a6-2ab5-4eba-8395-a45f4ff72b26_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charged (Credited) to other accounts</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealEstateFundsMember_b75cfc69-3255-4c27-9829-aa38739b6cec_terseLabel_en-US" xlink:label="lab_us-gaap_RealEstateFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real estate funds</link:label>
    <link:label id="lab_us-gaap_RealEstateFundsMember_label_en-US" xlink:label="lab_us-gaap_RealEstateFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstateFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealEstateFundsMember" xlink:to="lab_us-gaap_RealEstateFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableAnnuityMember_b7543b93-28e6-407b-9c78-90c35eb9071e_terseLabel_en-US" xlink:label="lab_us-gaap_VariableAnnuityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Annuity</link:label>
    <link:label id="lab_us-gaap_VariableAnnuityMember_label_en-US" xlink:label="lab_us-gaap_VariableAnnuityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Annuity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableAnnuityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableAnnuityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableAnnuityMember" xlink:to="lab_us-gaap_VariableAnnuityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceOtherMember_c3bf5a7c-ed44-4b94-a4d4-d28a7e52ae88_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_us-gaap_ServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceOtherMember" xlink:to="lab_us-gaap_ServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ParentCompanyMember_07f50dba-0aad-40d9-8cf6-2db0947abb29_terseLabel_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Cigna Group</link:label>
    <link:label id="lab_srt_ParentCompanyMember_label_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent Company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ParentCompanyMember" xlink:to="lab_srt_ParentCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PharmacyAndServiceCostsPayable_3887ffa3-b816-4a5f-a92b-0b4e84cf1b8b_terseLabel_en-US" xlink:label="lab_ci_PharmacyAndServiceCostsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy and other service costs payable</link:label>
    <link:label id="lab_ci_PharmacyAndServiceCostsPayable_label_en-US" xlink:label="lab_ci_PharmacyAndServiceCostsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy And Service Costs Payable</link:label>
    <link:label id="lab_ci_PharmacyAndServiceCostsPayable_documentation_en-US" xlink:label="lab_ci_PharmacyAndServiceCostsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reflects amounts due to pharmacies for prescriptions filled through our retail network of pharmacies. Also includes amounts due to clients for their portion of rebates that must be contractually shared.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PharmacyAndServiceCostsPayable" xlink:href="ci-20231231.xsd#ci_PharmacyAndServiceCostsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PharmacyAndServiceCostsPayable" xlink:to="lab_ci_PharmacyAndServiceCostsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DerivativeCreditRiskValuationAdjustmentDerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale_a8956335-9b77-4e3c-919c-b7ee45e5976e_terseLabel_en-US" xlink:label="lab_ci_DerivativeCreditRiskValuationAdjustmentDerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment for credit risk on derivatives assets</link:label>
    <link:label id="lab_ci_DerivativeCreditRiskValuationAdjustmentDerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DerivativeCreditRiskValuationAdjustmentDerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Credit Risk Valuation Adjustment, Derivative Assets, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_DerivativeCreditRiskValuationAdjustmentDerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DerivativeCreditRiskValuationAdjustmentDerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Credit Risk Valuation Adjustment, Derivative Assets, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DerivativeCreditRiskValuationAdjustmentDerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DerivativeCreditRiskValuationAdjustmentDerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DerivativeCreditRiskValuationAdjustmentDerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_DerivativeCreditRiskValuationAdjustmentDerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FiniteLivedIntangibleAssetsGrossIncludingDisposalGroupsHeldForSale_6da46f33-e519-4284-96cc-10ac70c0d86e_terseLabel_en-US" xlink:label="lab_ci_FiniteLivedIntangibleAssetsGrossIncludingDisposalGroupsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, including held for sale assets</link:label>
    <link:label id="lab_ci_FiniteLivedIntangibleAssetsGrossIncludingDisposalGroupsHeldForSale_label_en-US" xlink:label="lab_ci_FiniteLivedIntangibleAssetsGrossIncludingDisposalGroupsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets Gross, Including Disposal Groups, Held For Sale</link:label>
    <link:label id="lab_ci_FiniteLivedIntangibleAssetsGrossIncludingDisposalGroupsHeldForSale_documentation_en-US" xlink:label="lab_ci_FiniteLivedIntangibleAssetsGrossIncludingDisposalGroupsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets Gross, Including Disposal Groups, Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsGrossIncludingDisposalGroupsHeldForSale" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsGrossIncludingDisposalGroupsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FiniteLivedIntangibleAssetsGrossIncludingDisposalGroupsHeldForSale" xlink:to="lab_ci_FiniteLivedIntangibleAssetsGrossIncludingDisposalGroupsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a137dc0b-ae72-4c29-a796-b143d31eb4fb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d7782c2c-8427-4abd-9092-485663fef702_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossForeignCurrencyTranslation_872063f6-d2aa-459f-a847-4e1882d45621_negatedTerseLabel_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross translation loss on foreign currencies</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossForeignCurrencyTranslation_label_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Accumulated Gross Unrealized Gain (Loss) Foreign Currency Translation</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossForeignCurrencyTranslation_documentation_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Accumulated Gross Unrealized Gain (Loss) Foreign Currency Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossForeignCurrencyTranslation" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossForeignCurrencyTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossForeignCurrencyTranslation" xlink:to="lab_ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossForeignCurrencyTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits_7f5a6711-2a98-4244-bc58-5d530a3d9acf_terseLabel_en-US" xlink:label="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) required to adjust future policy benefits for settlement annuities</link:label>
    <link:label id="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits_label_en-US" xlink:label="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Required To Adjust Future Policy Benefits</link:label>
    <link:label id="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits_documentation_en-US" xlink:label="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents total gains or losses for the period (realized and unrealized), arising from assets measured at fair value on a recurring basis using unobservable inputs (Level 3), which are included in gains or losses required to adjust future policy benefits for settlement annuities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits" xlink:href="ci-20231231.xsd#ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits" xlink:to="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_6f10003f-f266-4298-ae45-b6c311f0baff_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postretirement benefits liability adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments_63983906-35e2-4f43-9fcb-d8ba07e77576_terseLabel_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum dividend distributions permitted in 2024 without regulatory approval</link:label>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments_label_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Accounting Practices, Statutory Amount Available for Dividend Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments" xlink:to="lab_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilities_440673e5-b1ea-4863-b0ed-b5579e67f50e_terseLabel_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, held for sale</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilities_label_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Lease Liabilities</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilities" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilities" xlink:to="lab_ci_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost_c139ec1e-1e8d-43a6-b5f2-d3e666a2dc40_totalLabel_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost_label_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, 12 Months Or Longer, Amortized Cost</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost_documentation_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, 12 Months Or Longer, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost" xlink:to="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_f6269483-c724-4208-8e3d-d6c56ba98b7e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction related to lapse of applicable statute of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_f7af8bba-8ebe-4a2a-85a6-16704f5ea73f_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_4208354e-9bf1-4a2e-b98a-72b7b95efed6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated stock repurchase, amount remitted</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Settlement (Payment) or Receipt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SpecialItemChargeBenefitBeforeTaxLitigation_90c1f17a-9db4-40c3-9a7b-e0b29b57a576_verboseLabel_en-US" xlink:label="lab_ci_SpecialItemChargeBenefitBeforeTaxLitigation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Benefits) charges associated with litigation matters (Selling, general and administrative expenses)</link:label>
    <link:label id="lab_ci_SpecialItemChargeBenefitBeforeTaxLitigation_143f3f0b-3918-4dac-bfe2-0cfc5e5cf842_terseLabel_en-US" xlink:label="lab_ci_SpecialItemChargeBenefitBeforeTaxLitigation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Benefits) charges associated with litigation matters</link:label>
    <link:label id="lab_ci_SpecialItemChargeBenefitBeforeTaxLitigation_label_en-US" xlink:label="lab_ci_SpecialItemChargeBenefitBeforeTaxLitigation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Item Charge (Benefit) Before Tax Litigation</link:label>
    <link:label id="lab_ci_SpecialItemChargeBenefitBeforeTaxLitigation_documentation_en-US" xlink:label="lab_ci_SpecialItemChargeBenefitBeforeTaxLitigation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After-tax charges associated with litigation matters that are classified as special items, attributable to the parent. Special items reflect amounts that management does not believe are representative of underlying results of operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitBeforeTaxLitigation" xlink:href="ci-20231231.xsd#ci_SpecialItemChargeBenefitBeforeTaxLitigation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SpecialItemChargeBenefitBeforeTaxLitigation" xlink:to="lab_ci_SpecialItemChargeBenefitBeforeTaxLitigation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_129ac856-93a4-4f85-bd74-57d81655f57d_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to other noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAbstract_fc642a6c-1c47-4e30-8fb3-a5e8b74e47f6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f8393f6e-fdcb-4b7e-a554-dbc12507875b_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying value</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_d6c1985a-075d-4251-9125-5bbe4a934fee_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_b28a6945-0f4a-45dc-9a45-7972e5dded5f_totalLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_e15280e9-1753-455d-9309-9998bdbace58_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_453b205c-ad2a-4215-a741-c8aa60402db9_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit obligation, January 1</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_316dbcd5-d4b4-4ba2-8d0a-8979e857f20c_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit obligation, December 31</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_222ee4b8-f0d3-4e87-af49-2324d0a384cc_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translation of foreign currencies including portion attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock_cb8a11d0-9edb-44d0-b943-86229ef6a75b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Recoverables by Range of External Credit Rating and Collateral Level</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded Credit Risk [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock" xlink:to="lab_us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_b698a1dd-a41b-4e0f-b747-93ccd6d8708e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_6585b857-1f44-4130-a1fa-063291db2df6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitsCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience_2071f90d-4a42-4527-aeee-1e7c6d2fc940_terseLabel_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitsCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of actual variances from expectations</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitsCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience_label_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitsCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefits Cumulative Increase Decrease Of Actual Variance From Expected Experience</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitsCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience_documentation_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitsCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefits Cumulative Increase Decrease Of Actual Variance From Expected Experience</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitsCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitsCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForFuturePolicyBenefitsCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience" xlink:to="lab_ci_LiabilityForFuturePolicyBenefitsCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale_05aa8458-fb59-41db-aed3-104142be6ec0_totalLabel_en-US" xlink:label="lab_ci_DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net of valuation allowance</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance, Including Disposal Groups Assets Held For Sale</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance, Including Disposal Groups Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale" xlink:to="lab_ci_DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_c38c104d-0381-40ed-ada9-3f5a78ef4de8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_cc011adb-7a02-4550-ba3c-a707c632b9f7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PolicyholderContractDepositsIncludingDisposalGroups_68b94e83-0873-446f-9c42-e3bafc097cf2_totalLabel_en-US" xlink:label="lab_ci_PolicyholderContractDepositsIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractholder deposit funds, including liabilities held for sale</link:label>
    <link:label id="lab_ci_PolicyholderContractDepositsIncludingDisposalGroups_label_en-US" xlink:label="lab_ci_PolicyholderContractDepositsIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Contract Deposits Including Disposal Groups</link:label>
    <link:label id="lab_ci_PolicyholderContractDepositsIncludingDisposalGroups_documentation_en-US" xlink:label="lab_ci_PolicyholderContractDepositsIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Contract Deposits Including Disposal Groups</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositsIncludingDisposalGroups" xlink:href="ci-20231231.xsd#ci_PolicyholderContractDepositsIncludingDisposalGroups"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PolicyholderContractDepositsIncludingDisposalGroups" xlink:to="lab_ci_PolicyholderContractDepositsIncludingDisposalGroups" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebenturesDue20277875InterestMember_bf706658-41c7-44a8-9c6e-e18e240e6aa4_terseLabel_en-US" xlink:label="lab_ci_DebenturesDue20277875InterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$259&#160;million, 7.875% Debentures due May 2027</link:label>
    <link:label id="lab_ci_DebenturesDue20277875InterestMember_label_en-US" xlink:label="lab_ci_DebenturesDue20277875InterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debentures due 2027 7.875% Interest [Member]</link:label>
    <link:label id="lab_ci_DebenturesDue20277875InterestMember_documentation_en-US" xlink:label="lab_ci_DebenturesDue20277875InterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debentures bearing interest at 7.875% due in 2027.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebenturesDue20277875InterestMember" xlink:href="ci-20231231.xsd#ci_DebenturesDue20277875InterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebenturesDue20277875InterestMember" xlink:to="lab_ci_DebenturesDue20277875InterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DefinedBenefitPlanBenefitsPaidFromPlanAssets_b7fc584f-4ab6-4b37-ba17-b61fc50345c8_negatedTerseLabel_en-US" xlink:label="lab_ci_DefinedBenefitPlanBenefitsPaidFromPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid from plan assets</link:label>
    <link:label id="lab_ci_DefinedBenefitPlanBenefitsPaidFromPlanAssets_label_en-US" xlink:label="lab_ci_DefinedBenefitPlanBenefitsPaidFromPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Benefits Paid From Plan Assets</link:label>
    <link:label id="lab_ci_DefinedBenefitPlanBenefitsPaidFromPlanAssets_documentation_en-US" xlink:label="lab_ci_DefinedBenefitPlanBenefitsPaidFromPlanAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of payments made from plan assets for which participants are entitled under a pension plan, including pension benefits, death benefits, and benefits due on termination of employment. Also includes payments made under a postretirement benefit plan, including prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DefinedBenefitPlanBenefitsPaidFromPlanAssets" xlink:href="ci-20231231.xsd#ci_DefinedBenefitPlanBenefitsPaidFromPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DefinedBenefitPlanBenefitsPaidFromPlanAssets" xlink:to="lab_ci_DefinedBenefitPlanBenefitsPaidFromPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0281ab41-d5b9-4924-a0ae-a73a7705164c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET CASH USED IN FINANCING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_f77a580d-7f8d-4bb1-9c80-342fc7e9e9cf_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4d636f98-138d-4c2b-8b7c-22ad5256e121_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies and Other Matters</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_038ce3da-0107-48ad-afdb-75c76a2062ca_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_b6459baf-8940-487d-9404-13ad71192ead_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers into/(out of) Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_483a094d-6d93-450f-b565-effd82dbf52c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesCurrent_9caac868-9352-4943-a6f4-ef9171d186b6_terseLabel_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current insurance and contractholder liabilities</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesCurrent_5a26b879-689b-4023-90de-ab5f7fd77376_totalLabel_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current insurance and contractholder liabilities</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesCurrent_label_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance And Contractholder Liabilities Current</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesCurrent_documentation_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The carrying amounts as of the balance sheet date of all current insurance and contractholder liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesCurrent" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrent" xlink:to="lab_ci_InsuranceAndContractholderLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AllowanceForReceivablesOther_82692c30-291d-43a1-8174-980f32ad2852_terseLabel_en-US" xlink:label="lab_ci_AllowanceForReceivablesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining allowances</link:label>
    <link:label id="lab_ci_AllowanceForReceivablesOther_label_en-US" xlink:label="lab_ci_AllowanceForReceivablesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Receivables, Other</link:label>
    <link:label id="lab_ci_AllowanceForReceivablesOther_documentation_en-US" xlink:label="lab_ci_AllowanceForReceivablesOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of other allowances classified as current, including allowances, discounts and claims adjustments issued to customers in the form of client credits, allowance for current expected credit losses and other non-credit adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AllowanceForReceivablesOther" xlink:href="ci-20231231.xsd#ci_AllowanceForReceivablesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AllowanceForReceivablesOther" xlink:to="lab_ci_AllowanceForReceivablesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_78e4e612-57bd-4a5f-875b-f8e907bdce10_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_049cc5b5-59b1-4828-933a-eecb75023afc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EPS, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_RedeemableNoncontrollingInterestsPolicyPolicyTextBlock_e012d210-0f52-48fd-93ad-93b9d6b70f49_terseLabel_en-US" xlink:label="lab_ci_RedeemableNoncontrollingInterestsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest</link:label>
    <link:label id="lab_ci_RedeemableNoncontrollingInterestsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_ci_RedeemableNoncontrollingInterestsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interests Policy [Policy Text Block]</link:label>
    <link:label id="lab_ci_RedeemableNoncontrollingInterestsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_ci_RedeemableNoncontrollingInterestsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting policy for noncontrolling shareholders' preferred and common stock interests of consolidated, less than fully owned subsidiaries.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RedeemableNoncontrollingInterestsPolicyPolicyTextBlock" xlink:href="ci-20231231.xsd#ci_RedeemableNoncontrollingInterestsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_RedeemableNoncontrollingInterestsPolicyPolicyTextBlock" xlink:to="lab_ci_RedeemableNoncontrollingInterestsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PricingConcessionsAfterRemainingTermOfAgreementMember_fe2fd755-f983-43f0-a5c7-d76092cb00db_terseLabel_en-US" xlink:label="lab_ci_PricingConcessionsAfterRemainingTermOfAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pricing Concessions After Remaining Term of Agreement</link:label>
    <link:label id="lab_ci_PricingConcessionsAfterRemainingTermOfAgreementMember_label_en-US" xlink:label="lab_ci_PricingConcessionsAfterRemainingTermOfAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pricing Concessions After Remaining Term Of Agreement [Member]</link:label>
    <link:label id="lab_ci_PricingConcessionsAfterRemainingTermOfAgreementMember_documentation_en-US" xlink:label="lab_ci_PricingConcessionsAfterRemainingTermOfAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pricing concessions sought in litigation for one year arfter contract termination.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PricingConcessionsAfterRemainingTermOfAgreementMember" xlink:href="ci-20231231.xsd#ci_PricingConcessionsAfterRemainingTermOfAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PricingConcessionsAfterRemainingTermOfAgreementMember" xlink:to="lab_ci_PricingConcessionsAfterRemainingTermOfAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_58ad2db4-518c-4004-a0bd-8d8e9c9d519a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_MortgageLoansOnRealEstateCommercialAndConsumerNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_4566ab3e-566c-452e-b994-51dba83c4b4e_terseLabel_en-US" xlink:label="lab_ci_MortgageLoansOnRealEstateCommercialAndConsumerNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial mortgage loans, including assets held for sale</link:label>
    <link:label id="lab_ci_MortgageLoansOnRealEstateCommercialAndConsumerNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_MortgageLoansOnRealEstateCommercialAndConsumerNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Loans on Real Estate, Commercial and Consumer, Net, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_MortgageLoansOnRealEstateCommercialAndConsumerNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_MortgageLoansOnRealEstateCommercialAndConsumerNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Loans on Real Estate, Commercial and Consumer, Net, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MortgageLoansOnRealEstateCommercialAndConsumerNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_MortgageLoansOnRealEstateCommercialAndConsumerNetBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_MortgageLoansOnRealEstateCommercialAndConsumerNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_MortgageLoansOnRealEstateCommercialAndConsumerNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealEstateInvestmentMember_efb6bfee-7bdf-4084-a51a-fa1ffdc29869_terseLabel_en-US" xlink:label="lab_us-gaap_RealEstateInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real estate investments</link:label>
    <link:label id="lab_us-gaap_RealEstateInvestmentMember_label_en-US" xlink:label="lab_us-gaap_RealEstateInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Investment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateInvestmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstateInvestmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealEstateInvestmentMember" xlink:to="lab_us-gaap_RealEstateInvestmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_b9a3cedd-3fa7-4231-b7a7-68f2ad4ac875_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of sale of businesses</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Business, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_GuaranteedDepositAccountContractMember_ff6f8b9c-c42e-405c-94e6-25a277676b43_terseLabel_en-US" xlink:label="lab_ci_GuaranteedDepositAccountContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guaranteed deposit account contract</link:label>
    <link:label id="lab_ci_GuaranteedDepositAccountContractMember_label_en-US" xlink:label="lab_ci_GuaranteedDepositAccountContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guaranteed Deposit Account Contract [Member]</link:label>
    <link:label id="lab_ci_GuaranteedDepositAccountContractMember_documentation_en-US" xlink:label="lab_ci_GuaranteedDepositAccountContractMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment account administered by an insurance company that provides a guaranteed fixed rate of return; in which defined benefit plan asset is invested.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_GuaranteedDepositAccountContractMember" xlink:href="ci-20231231.xsd#ci_GuaranteedDepositAccountContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_GuaranteedDepositAccountContractMember" xlink:to="lab_ci_GuaranteedDepositAccountContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale_0c6db092-e827-4875-a137-4277d3750739_totalLabel_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Fair Value, including held for sale assets</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Unrealized Loss Position, Before Reclassification To Disposal Group, Assets Held For Sale</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Unrealized Loss Position, Before Reclassification To Disposal Group, Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity_3c3e06f8-3f50-4f2a-beec-ecf56010185e_negatedTerseLabel_en-US" xlink:label="lab_ci_OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) including temporary equity, before reclassifications, tax</link:label>
    <link:label id="lab_ci_OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity_label_en-US" xlink:label="lab_ci_OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss) before Reclassifications, Tax, Including Temporary Equity</link:label>
    <link:label id="lab_ci_OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity_documentation_en-US" xlink:label="lab_ci_OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss) before Reclassifications, Tax, Including Temporary Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity" xlink:to="lab_ci_OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVOBAIncludingDisposalGroups_64da5f81-7d3e-48ec-a1c7-5b57e99ec02d_totalLabel_en-US" xlink:label="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVOBAIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization, including held for sale assets</link:label>
    <link:label id="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVOBAIncludingDisposalGroups_label_en-US" xlink:label="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVOBAIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets Accumulated Amortization Including VOBA Including Disposal Groups</link:label>
    <link:label id="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVOBAIncludingDisposalGroups_documentation_en-US" xlink:label="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVOBAIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets Accumulated Amortization Including VOBA Including Disposal Groups</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVOBAIncludingDisposalGroups" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVOBAIncludingDisposalGroups"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVOBAIncludingDisposalGroups" xlink:to="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVOBAIncludingDisposalGroups" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTaxStatusDomain_dd197a30-e8b8-4b3f-86e3-436ea7c25984_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTaxStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Tax Status [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTaxStatusDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTaxStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Tax Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTaxStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain" xlink:to="lab_us-gaap_RetirementPlanTaxStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DamagesForServiceIssuesMember_cf6342fd-61bf-43f9-b8cc-c533cec9999e_terseLabel_en-US" xlink:label="lab_ci_DamagesForServiceIssuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages for Service Issues</link:label>
    <link:label id="lab_ci_DamagesForServiceIssuesMember_label_en-US" xlink:label="lab_ci_DamagesForServiceIssuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages For Service Issues [Member]</link:label>
    <link:label id="lab_ci_DamagesForServiceIssuesMember_documentation_en-US" xlink:label="lab_ci_DamagesForServiceIssuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages sought in litigation for service issues.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DamagesForServiceIssuesMember" xlink:href="ci-20231231.xsd#ci_DamagesForServiceIssuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DamagesForServiceIssuesMember" xlink:to="lab_ci_DamagesForServiceIssuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ContractholderDepositFundsPolicyPolicyTextBlock_a4d9415d-f24c-4f52-8812-8cd7e8c23213_terseLabel_en-US" xlink:label="lab_ci_ContractholderDepositFundsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractholder Deposit Funds</link:label>
    <link:label id="lab_ci_ContractholderDepositFundsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_ci_ContractholderDepositFundsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractholder Deposit Funds, Policy [Policy Text Block]</link:label>
    <link:label id="lab_ci_ContractholderDepositFundsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_ci_ContractholderDepositFundsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Describes an entity's accounting policy for contractholder deposit funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ContractholderDepositFundsPolicyPolicyTextBlock" xlink:href="ci-20231231.xsd#ci_ContractholderDepositFundsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ContractholderDepositFundsPolicyPolicyTextBlock" xlink:to="lab_ci_ContractholderDepositFundsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_MarketRiskBenefitLiabilityAmountNoncurrent_470bf12d-7ae9-46e2-9c69-dcf65e0e177c_terseLabel_en-US" xlink:label="lab_ci_MarketRiskBenefitLiabilityAmountNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market risk benefits, non-current</link:label>
    <link:label id="lab_ci_MarketRiskBenefitLiabilityAmountNoncurrent_label_en-US" xlink:label="lab_ci_MarketRiskBenefitLiabilityAmountNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Risk Benefit, Liability, Amount, Noncurrent</link:label>
    <link:label id="lab_ci_MarketRiskBenefitLiabilityAmountNoncurrent_documentation_en-US" xlink:label="lab_ci_MarketRiskBenefitLiabilityAmountNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Risk Benefit, Liability, Amount, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitLiabilityAmountNoncurrent" xlink:href="ci-20231231.xsd#ci_MarketRiskBenefitLiabilityAmountNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_MarketRiskBenefitLiabilityAmountNoncurrent" xlink:to="lab_ci_MarketRiskBenefitLiabilityAmountNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LibertyMutualInsuranceMember_0fc19b22-2a39-464a-8eec-65cf8a013011_verboseLabel_en-US" xlink:label="lab_ci_LibertyMutualInsuranceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liberty Re (Bermuda) Ltd.</link:label>
    <link:label id="lab_ci_LibertyMutualInsuranceMember_label_en-US" xlink:label="lab_ci_LibertyMutualInsuranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liberty Mutual Insurance [Member]</link:label>
    <link:label id="lab_ci_LibertyMutualInsuranceMember_documentation_en-US" xlink:label="lab_ci_LibertyMutualInsuranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liberty Mutual Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LibertyMutualInsuranceMember" xlink:href="ci-20231231.xsd#ci_LibertyMutualInsuranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LibertyMutualInsuranceMember" xlink:to="lab_ci_LibertyMutualInsuranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CommitmentsAndContingenciesTable_5e490f81-95fa-4ee8-a4dc-9c5218d255a9_terseLabel_en-US" xlink:label="lab_ci_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_ci_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_ci_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_ci_CommitmentsAndContingenciesTable_documentation_en-US" xlink:label="lab_ci_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CommitmentsAndContingenciesTable" xlink:href="ci-20231231.xsd#ci_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CommitmentsAndContingenciesTable" xlink:to="lab_ci_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_9e7f14db-6ac9-4ad8-8818-4608767201de_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_09a264f5-2055-4aaf-b831-83e9592d5a46_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SunLifeAssuranceCompanyOfCanadaMember_399e04d9-fd22-4272-8c32-6ef178f64ffb_verboseLabel_en-US" xlink:label="lab_ci_SunLifeAssuranceCompanyOfCanadaMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sun Life Assurance Company of Canada</link:label>
    <link:label id="lab_ci_SunLifeAssuranceCompanyOfCanadaMember_label_en-US" xlink:label="lab_ci_SunLifeAssuranceCompanyOfCanadaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sun Life Assurance Company Of Canada [Member]</link:label>
    <link:label id="lab_ci_SunLifeAssuranceCompanyOfCanadaMember_documentation_en-US" xlink:label="lab_ci_SunLifeAssuranceCompanyOfCanadaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sun Life Assurance Company of Canada</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SunLifeAssuranceCompanyOfCanadaMember" xlink:href="ci-20231231.xsd#ci_SunLifeAssuranceCompanyOfCanadaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SunLifeAssuranceCompanyOfCanadaMember" xlink:to="lab_ci_SunLifeAssuranceCompanyOfCanadaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate_46bb27e5-7be6-478b-bed2-3354b43cba59_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current discount rate</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefit, Current Weighted-Average Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_5e15a08a-6203-4ac1-ae9d-73d265ba4473_periodStartLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Reinsurance and other amounts recoverable</link:label>
    <link:label id="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_462f5418-220d-4d0f-ad1b-6c4bc9879d8c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add: Reinsurance and other amounts recoverable</link:label>
    <link:label id="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_label_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Recoverable for Unpaid Claims and Claims Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:to="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_44c74755-5f54-4184-ae54-52b85f0d1e7c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationsNonInvestmentRevenue_3a9e9109-29fd-4db3-a8b1-5cbd500801a7_terseLabel_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationsNonInvestmentRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, disposal group</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationsNonInvestmentRevenue_label_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationsNonInvestmentRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Non Investment Revenue</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationsNonInvestmentRevenue_documentation_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationsNonInvestmentRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Non Investment Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationsNonInvestmentRevenue" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationsNonInvestmentRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DisposalGroupIncludingDiscontinuedOperationsNonInvestmentRevenue" xlink:to="lab_ci_DisposalGroupIncludingDiscontinuedOperationsNonInvestmentRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_e155892c-45b3-4138-b856-836b06b0566f_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on sale of business, pre-tax</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_0032aba2-ba83-41cf-977b-285a03758755_negatedLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated loss on sale, pre-tax</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_34af0132-984e-41df-9f91-b6dc08394065_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumIssuanceAndDerecognition_f1e40d89-3085-4285-a111-206a91648a24_terseLabel_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumIssuanceAndDerecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances and lapses</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumIssuanceAndDerecognition_label_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumIssuanceAndDerecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefit, Expected Net Premium, Issuance And Derecognition</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumIssuanceAndDerecognition_documentation_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumIssuanceAndDerecognition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefit, Expected Net Premium, Issuance And Derecognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumIssuanceAndDerecognition" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumIssuanceAndDerecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumIssuanceAndDerecognition" xlink:to="lab_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumIssuanceAndDerecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NotesDue203848InterestMember_76b6678a-9b84-4b60-8633-6f6fd9d78bcb_terseLabel_en-US" xlink:label="lab_ci_NotesDue203848InterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$2,200&#160;million, 4.800% Notes due August 2038</link:label>
    <link:label id="lab_ci_NotesDue203848InterestMember_label_en-US" xlink:label="lab_ci_NotesDue203848InterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2038, 4.8% Interest [Member]</link:label>
    <link:label id="lab_ci_NotesDue203848InterestMember_documentation_en-US" xlink:label="lab_ci_NotesDue203848InterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior notes payable bearing interest at 4.8% due in 2038. Debt issued to finance acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue203848InterestMember" xlink:href="ci-20231231.xsd#ci_NotesDue203848InterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NotesDue203848InterestMember" xlink:to="lab_ci_NotesDue203848InterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AuditInformationAbstract_label_en-US" xlink:label="lab_ci_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_ci_AuditInformationAbstract_documentation_en-US" xlink:label="lab_ci_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AuditInformationAbstract" xlink:href="ci-20231231.xsd#ci_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AuditInformationAbstract" xlink:to="lab_ci_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CashCashEquivalentsAndShortTermInvestmentsMember_d4f6d734-4122-4fa7-9276-c6c5a2eb2320_verboseLabel_en-US" xlink:label="lab_ci_CashCashEquivalentsAndShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments and cash</link:label>
    <link:label id="lab_ci_CashCashEquivalentsAndShortTermInvestmentsMember_label_en-US" xlink:label="lab_ci_CashCashEquivalentsAndShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Cash Equivalents And Short Term Investments [Member]</link:label>
    <link:label id="lab_ci_CashCashEquivalentsAndShortTermInvestmentsMember_documentation_en-US" xlink:label="lab_ci_CashCashEquivalentsAndShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate of cash, cash equivalents and short-term investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CashCashEquivalentsAndShortTermInvestmentsMember" xlink:href="ci-20231231.xsd#ci_CashCashEquivalentsAndShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CashCashEquivalentsAndShortTermInvestmentsMember" xlink:to="lab_ci_CashCashEquivalentsAndShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1dd57b10-e31c-49c3-afc5-a55b55d555c5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_e1b4c43b-0624-4b63-8eda-285bdd8ccea2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received for options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember_c023371c-651b-4c97-8ab8-a080d7c78e4a_terseLabel_en-US" xlink:label="lab_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market risk benefits reinsurance recoverable, including IBNR and outstanding claims, less premiums due</link:label>
    <link:label id="lab_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember_label_en-US" xlink:label="lab_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Risk Benefit Reinsurance Recoverable After Allowance And Related Balances [Member]</link:label>
    <link:label id="lab_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember_documentation_en-US" xlink:label="lab_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market risk benefit reinsurance recoverable, including IBNR and outstanding claims, less premiums due.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember" xlink:href="ci-20231231.xsd#ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember" xlink:to="lab_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInsuranceAndContractholderLiabilities_9b098b4e-972a-406f-b5a4-9e2d6d8ff92c_negatedLabel_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInsuranceAndContractholderLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance and contractholder liabilities, non-current, classified as held for sale</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInsuranceAndContractholderLiabilities_label_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInsuranceAndContractholderLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Noncurrent Insurance And Contractholder Liabilities</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInsuranceAndContractholderLiabilities_documentation_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInsuranceAndContractholderLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Noncurrent Insurance And Contractholder Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInsuranceAndContractholderLiabilities" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInsuranceAndContractholderLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInsuranceAndContractholderLiabilities" xlink:to="lab_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInsuranceAndContractholderLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NotesDue205134InterestMember_179f87cb-2647-4482-953f-f4cfaeddd62d_terseLabel_en-US" xlink:label="lab_ci_NotesDue205134InterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$1,500 million, 3.400% Notes due March 2051</link:label>
    <link:label id="lab_ci_NotesDue205134InterestMember_label_en-US" xlink:label="lab_ci_NotesDue205134InterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2051, 3.4% Interest [Member]</link:label>
    <link:label id="lab_ci_NotesDue205134InterestMember_documentation_en-US" xlink:label="lab_ci_NotesDue205134InterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable bearing interest at 3.4% due 2051.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue205134InterestMember" xlink:href="ci-20231231.xsd#ci_NotesDue205134InterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NotesDue205134InterestMember" xlink:to="lab_ci_NotesDue205134InterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale_7e8a18a5-2963-42cf-8b14-c972b7792d5a_totalLabel_en-US" xlink:label="lab_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross, Including Disposal Groups Assets Held For Sale</link:label>
    <link:label id="lab_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross, Including Disposal Groups Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale" xlink:to="lab_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInFundsOfferedByUnaffiliatedEntity_ca51ee2c-85d3-4029-8e5a-d227b95897b3_terseLabel_en-US" xlink:label="lab_ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInFundsOfferedByUnaffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan assets invested in funds offered by an unaffiliated insurance company</link:label>
    <link:label id="lab_ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInFundsOfferedByUnaffiliatedEntity_label_en-US" xlink:label="lab_ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInFundsOfferedByUnaffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Fair Value Of Plan Assets Invested In Funds Offered By Unaffiliated Entity</link:label>
    <link:label id="lab_ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInFundsOfferedByUnaffiliatedEntity_documentation_en-US" xlink:label="lab_ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInFundsOfferedByUnaffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Fair Value Of Plan Assets Invested In Funds Offered By Unaffiliated Entity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInFundsOfferedByUnaffiliatedEntity" xlink:href="ci-20231231.xsd#ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInFundsOfferedByUnaffiliatedEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInFundsOfferedByUnaffiliatedEntity" xlink:to="lab_ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInFundsOfferedByUnaffiliatedEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicDistributionForeignMember_4ffbe020-534a-40cc-b86a-c33d8b317561_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicDistributionForeignMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_GeographicDistributionForeignMember_label_en-US" xlink:label="lab_us-gaap_GeographicDistributionForeignMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Distribution, Foreign [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionForeignMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicDistributionForeignMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicDistributionForeignMember" xlink:to="lab_us-gaap_GeographicDistributionForeignMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_530c78d3-e7ad-4fc6-a033-04804edc8174_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_92d02b4c-0a92-4f61-95b1-b71b076c276a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Operating Joint Ventures</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange_424c13a3-eda0-4cee-aed7-9e391c51ca8c_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange_569cabc9-4ef8-44a2-89aa-d46547072524_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefit, Expected Net Premium, before Reinsurance, after Discount Rate Change</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OtherOperationsInternationalBusinessesToBeSoldAndInterestInJointVentureInTurkeyMember_d6e3c24e-01f3-4588-ac5a-38cfc2453f2c_terseLabel_en-US" xlink:label="lab_ci_OtherOperationsInternationalBusinessesToBeSoldAndInterestInJointVentureInTurkeyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divested International businesses</link:label>
    <link:label id="lab_ci_OtherOperationsInternationalBusinessesToBeSoldAndInterestInJointVentureInTurkeyMember_label_en-US" xlink:label="lab_ci_OtherOperationsInternationalBusinessesToBeSoldAndInterestInJointVentureInTurkeyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operations, International Businesses To Be Sold And Interest In Joint Venture In Turkey [Member]</link:label>
    <link:label id="lab_ci_OtherOperationsInternationalBusinessesToBeSoldAndInterestInJointVentureInTurkeyMember_documentation_en-US" xlink:label="lab_ci_OtherOperationsInternationalBusinessesToBeSoldAndInterestInJointVentureInTurkeyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operations, International Businesses To Be Sold And Interest In Joint Venture In Turkey</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherOperationsInternationalBusinessesToBeSoldAndInterestInJointVentureInTurkeyMember" xlink:href="ci-20231231.xsd#ci_OtherOperationsInternationalBusinessesToBeSoldAndInterestInJointVentureInTurkeyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OtherOperationsInternationalBusinessesToBeSoldAndInterestInJointVentureInTurkeyMember" xlink:to="lab_ci_OtherOperationsInternationalBusinessesToBeSoldAndInterestInJointVentureInTurkeyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits_72342d85-1b15-4dd4-a416-b670dd6a83ba_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit payments</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefit, Expected Future Policy Benefit, Benefit Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_IntercompanyInterestExpense_2b348212-25bc-4407-b698-bd4d4fa1432f_negatedLabel_en-US" xlink:label="lab_ci_IntercompanyInterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intercompany interest expense</link:label>
    <link:label id="lab_ci_IntercompanyInterestExpense_label_en-US" xlink:label="lab_ci_IntercompanyInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intercompany interest</link:label>
    <link:label id="lab_ci_IntercompanyInterestExpense_documentation_en-US" xlink:label="lab_ci_IntercompanyInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense associated with intercompany loan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntercompanyInterestExpense" xlink:href="ci-20231231.xsd#ci_IntercompanyInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_IntercompanyInterestExpense" xlink:to="lab_ci_IntercompanyInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGuaranteeObligationsTable_76204158-fc1e-4d20-b30e-e2fbaad57f63_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGuaranteeObligationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Guarantor Obligations [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGuaranteeObligationsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGuaranteeObligationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Guarantor Obligations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGuaranteeObligationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGuaranteeObligationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable" xlink:to="lab_us-gaap_ScheduleOfGuaranteeObligationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_4cac48db-c677-4a29-839c-841cdcaf0e9f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyLoansMember_9fa89732-94f9-45bc-b8b8-c47826a3e093_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policy loans</link:label>
    <link:label id="lab_us-gaap_PolicyLoansMember_0a3906db-608b-4ded-9682-612da03c9aef_verboseLabel_en-US" xlink:label="lab_us-gaap_PolicyLoansMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policy loans</link:label>
    <link:label id="lab_us-gaap_PolicyLoansMember_label_en-US" xlink:label="lab_us-gaap_PolicyLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policy Loans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyLoansMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyLoansMember" xlink:to="lab_us-gaap_PolicyLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitsNoncurrentIncludingDisposalGroups_3a39cf74-f1bb-4e4a-af54-fcefa89c7a13_terseLabel_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitsNoncurrentIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future policy benefits, non-current, including held for sale liabilities</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitsNoncurrentIncludingDisposalGroups_label_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitsNoncurrentIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefits Noncurrent Including Disposal Groups</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitsNoncurrentIncludingDisposalGroups_documentation_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitsNoncurrentIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of accrued obligation to policyholders that relates to insured events for long-duration contracts, expected to be paid after one year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitsNoncurrentIncludingDisposalGroups" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitsNoncurrentIncludingDisposalGroups"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForFuturePolicyBenefitsNoncurrentIncludingDisposalGroups" xlink:to="lab_ci_LiabilityForFuturePolicyBenefitsNoncurrentIncludingDisposalGroups" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_be25e0dc-3948-4f34-af60-c06c3d4d39fd_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_6f53c161-1ef0-46bf-9bbb-9a9f96f0b248_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_dddbab6a-9f1f-49ad-8d33-b4ec85532789_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_201fc181-c5e9-4674-aaf8-14eda678da29_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_884c57e5-77b0-4140-9a76-e58c806321ae_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_e2c63c02-79ec-4c5b-ac51-24ab566b68cc_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_31853a8b-4f23-4753-a5f4-48edfa1877ed_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale_1ed3cee5-c7c8-4fef-81d8-cbee627ee3e1_terseLabel_en-US" xlink:label="lab_ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, including held for sale assets</link:label>
    <link:label id="lab_ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale_43aed511-675f-4171-a550-bb2e8d45cc5c_verboseLabel_en-US" xlink:label="lab_ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Value, including held for sale assets</link:label>
    <link:label id="lab_ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale_label_en-US" xlink:label="lab_ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite Lived Intangible Assets Excluding Goodwill, Including Disposal Groups Assets Held For Sale</link:label>
    <link:label id="lab_ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite Lived Intangible Assets Excluding Goodwill, Including Disposal Groups Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale" xlink:to="lab_ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_be637da7-2cc3-4f41-8d25-dd21c9ed25c8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_a4753e52-648b-481e-8206-42cc2478b865_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amounts reclassified from AOCI to net income</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_4e713b1f-0564-4bf6-be36-bea79c17a620_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Depreciation</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OperatingJointVenturesMember_139294ac-cf46-4d12-a7e0-3ac3fa66796a_terseLabel_en-US" xlink:label="lab_ci_OperatingJointVenturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating joint ventures</link:label>
    <link:label id="lab_ci_OperatingJointVenturesMember_label_en-US" xlink:label="lab_ci_OperatingJointVenturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Joint Ventures [Member]</link:label>
    <link:label id="lab_ci_OperatingJointVenturesMember_documentation_en-US" xlink:label="lab_ci_OperatingJointVenturesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OperatingJointVenturesMember" xlink:href="ci-20231231.xsd#ci_OperatingJointVenturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OperatingJointVenturesMember" xlink:to="lab_ci_OperatingJointVenturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4a1fd789-704e-45b9-9aba-225478df11e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_MarketableSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale_e4c831a2-f947-4306-9a5c-d0e568520cb8_terseLabel_en-US" xlink:label="lab_ci_MarketableSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, including held for sale assets</link:label>
    <link:label id="lab_ci_MarketableSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_MarketableSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_MarketableSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_MarketableSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketableSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_MarketableSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_MarketableSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_MarketableSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OtherPlanAssetCategoriesMember_f06a8162-b37b-495f-83d2-6e3d06f45979_terseLabel_en-US" xlink:label="lab_ci_OtherPlanAssetCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investments</link:label>
    <link:label id="lab_ci_OtherPlanAssetCategoriesMember_label_en-US" xlink:label="lab_ci_OtherPlanAssetCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Plan Asset Categories [Member]</link:label>
    <link:label id="lab_ci_OtherPlanAssetCategoriesMember_documentation_en-US" xlink:label="lab_ci_OtherPlanAssetCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investments not separately identified, in which defined benefit plan is invested.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherPlanAssetCategoriesMember" xlink:href="ci-20231231.xsd#ci_OtherPlanAssetCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OtherPlanAssetCategoriesMember" xlink:to="lab_ci_OtherPlanAssetCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_b925f25c-4eaa-4d69-8f95-a3c7ed2e1d31_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior actuarial losses, net</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_125c1dda-f99d-4d9b-8cd4-cd971d0f8b02_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Status of and Changes in SPSs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_3090fa11-d5c3-4d64-a7f6-5b824f2447ac_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Depreciation</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1bc8e4c4-fc74-4bfe-a3ed-c82bf5f42b75_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NotesDue2027305Member_08454680-6fc3-4a7b-868d-be1f169f6392_terseLabel_en-US" xlink:label="lab_ci_NotesDue2027305Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$600&#160;million, 3.050% Notes due October 2027 (1)</link:label>
    <link:label id="lab_ci_NotesDue2027305Member_label_en-US" xlink:label="lab_ci_NotesDue2027305Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2027, 3.05% [Member]</link:label>
    <link:label id="lab_ci_NotesDue2027305Member_documentation_en-US" xlink:label="lab_ci_NotesDue2027305Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable bearing interest at 3.05% due October 15, 2027.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue2027305Member" xlink:href="ci-20231231.xsd#ci_NotesDue2027305Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NotesDue2027305Member" xlink:to="lab_ci_NotesDue2027305Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_0801384a-1310-4643-ba02-b23ca50fef12_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life, property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_5a3c80e9-87b6-4be2-af71-c26680ad3f5c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_RevolvingCreditFacilityMaturingApril2025Member_dbbccb02-0318-4566-9205-258bdcc1b426_terseLabel_en-US" xlink:label="lab_ci_RevolvingCreditFacilityMaturingApril2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Maturing April 2025</link:label>
    <link:label id="lab_ci_RevolvingCreditFacilityMaturingApril2025Member_label_en-US" xlink:label="lab_ci_RevolvingCreditFacilityMaturingApril2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Maturing April 2025 [Member]</link:label>
    <link:label id="lab_ci_RevolvingCreditFacilityMaturingApril2025Member_documentation_en-US" xlink:label="lab_ci_RevolvingCreditFacilityMaturingApril2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Maturing April 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RevolvingCreditFacilityMaturingApril2025Member" xlink:href="ci-20231231.xsd#ci_RevolvingCreditFacilityMaturingApril2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_RevolvingCreditFacilityMaturingApril2025Member" xlink:to="lab_ci_RevolvingCreditFacilityMaturingApril2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitment_f11f84a7-2002-461f-94f6-47b0bdd967ca_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_347ef635-928b-48dd-bfa4-442f72c7a6f1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional commitments</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_label_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment" xlink:to="lab_us-gaap_OtherCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_fa042b20-ce38-4d96-9d87-be4ad6cf9287_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_764955ae-5258-4847-818a-5e851be66db0_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_2718c11b-fc17-4d03-8099-5c34850daf3b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Issued, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_1991db80-28b5-4153-99d3-e63b84150bcf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction related to settlements with taxing authorities</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_f8da0836-0e71-4191-a8df-9cecc51bc697_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_f7e3e353-5146-4862-8510-d7c7d9dd091a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_62ef380b-30ab-4485-83ae-bdf88d99a5bb_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis_5d546c11-c723-49c8-a883-0bb4e9814ae0_terseLabel_en-US" xlink:label="lab_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Rating, Nationally Recognized Statistical Rating Organization (NRSRO) [Axis]</link:label>
    <link:label id="lab_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis_label_en-US" xlink:label="lab_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Rating, Nationally Recognized Statistical Rating Organization (NRSRO) [Axis]</link:label>
    <link:label id="lab_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis_documentation_en-US" xlink:label="lab_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Rating, Nationally Recognized Statistical Rating Organization (NRSRO)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis" xlink:href="ci-20231231.xsd#ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis" xlink:to="lab_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_384e5a0b-2905-41e2-be8b-00818429322e_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_06c464dc-974e-4d17-a027-bf6a17b66a1b_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossInvestmentsAndDerivatives_0f6f0f53-cafa-46ee-83e7-667f8fd58a96_terseLabel_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossInvestmentsAndDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized appreciation on securities and derivatives</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossInvestmentsAndDerivatives_label_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossInvestmentsAndDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Accumulated Gross Unrealized Gain (Loss), Investments And Derivatives</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossInvestmentsAndDerivatives_documentation_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossInvestmentsAndDerivatives" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Accumulated Gross Unrealized Gain (Loss), Investments And Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossInvestmentsAndDerivatives" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossInvestmentsAndDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossInvestmentsAndDerivatives" xlink:to="lab_ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossInvestmentsAndDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_116be4fa-2140-4150-b043-6a4827507596_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_5614efdb-e123-4e7b-afd8-f2c83bff9611_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_9b8058e0-02c8-4f0f-aef1-2d0dd1799921_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated_d340ec01-64c6-48f5-ac28-89c6adf47945_terseLabel_en-US" xlink:label="lab_ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guaranteed Minimum Death Benefits Total Contractholders</link:label>
    <link:label id="lab_ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated_label_en-US" xlink:label="lab_ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Amount At Risk By Product And Guarantee, Number Of Contractholders Estimated</link:label>
    <link:label id="lab_ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated_documentation_en-US" xlink:label="lab_ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Amount At Risk By Product And Guarantee, Number Of Contractholders Estimated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated" xlink:href="ci-20231231.xsd#ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated" xlink:to="lab_ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_645856f2-7eb6-44f6-a491-3cff53d8bb89_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_1081ddf8-f0da-42a6-bac5-21158f673dd0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0ef8d014-6cc9-4099-b844-7d2c38fe133c_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_7eae99f4-3d10-4ff7-8db4-7676ead2c9f6_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired or canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_3452087e-e64a-4b6a-97c9-d48924aff231_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_6d1e0710-b959-428e-929a-f2ffb02cddb1_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_1e98208a-d4be-4cb7-8c32-6a60745ead44_netLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_323aa7e5-b764-4695-84b3-14aae52d7370_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember_22ae25ec-90a8-45fe-b251-c70985a59b6f_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Account Balance, at Guaranteed Minimum Crediting Rate</link:label>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember_label_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Account Balance, at Guaranteed Minimum Crediting Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember" xlink:to="lab_us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ProceedsFromSaleOfDebtAndEquitySecurities_9b59a26e-607b-4a19-8f8f-91d5b9d9d887_terseLabel_en-US" xlink:label="lab_ci_ProceedsFromSaleOfDebtAndEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities and equity securities</link:label>
    <link:label id="lab_ci_ProceedsFromSaleOfDebtAndEquitySecurities_label_en-US" xlink:label="lab_ci_ProceedsFromSaleOfDebtAndEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Debt And Equity Securities</link:label>
    <link:label id="lab_ci_ProceedsFromSaleOfDebtAndEquitySecurities_documentation_en-US" xlink:label="lab_ci_ProceedsFromSaleOfDebtAndEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of debt and equity securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ProceedsFromSaleOfDebtAndEquitySecurities" xlink:href="ci-20231231.xsd#ci_ProceedsFromSaleOfDebtAndEquitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ProceedsFromSaleOfDebtAndEquitySecurities" xlink:to="lab_ci_ProceedsFromSaleOfDebtAndEquitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_72295cb1-3264-41f3-99dc-a78eda2012d5_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceDisclosuresAbstract_1cfd0597-5181-442b-96f0-b270556ddf3d_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ReinsuranceDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ReinsuranceDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract" xlink:to="lab_us-gaap_ReinsuranceDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_UnearnedPremiumsIncludingDisposalGroups_2c9d105d-6ae1-4f71-85c9-447c4d236f0c_totalLabel_en-US" xlink:label="lab_ci_UnearnedPremiumsIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unearned premiums, including held for sale liabilities</link:label>
    <link:label id="lab_ci_UnearnedPremiumsIncludingDisposalGroups_label_en-US" xlink:label="lab_ci_UnearnedPremiumsIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unearned Premiums Including Disposal Groups</link:label>
    <link:label id="lab_ci_UnearnedPremiumsIncludingDisposalGroups_documentation_en-US" xlink:label="lab_ci_UnearnedPremiumsIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unearned Premiums Including Disposal Groups</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsIncludingDisposalGroups" xlink:href="ci-20231231.xsd#ci_UnearnedPremiumsIncludingDisposalGroups"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_UnearnedPremiumsIncludingDisposalGroups" xlink:to="lab_ci_UnearnedPremiumsIncludingDisposalGroups" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_bb83c7b7-7537-418e-9a0e-13856ba8954d_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NotesDue202645InterestMember_a4f09b97-ab98-424c-8987-3e8a305efd4d_terseLabel_en-US" xlink:label="lab_ci_NotesDue202645InterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$1,500&#160;million, 4.500% Notes due February 2026 (1)</link:label>
    <link:label id="lab_ci_NotesDue202645InterestMember_label_en-US" xlink:label="lab_ci_NotesDue202645InterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2026, 4.5% Interest [Member]</link:label>
    <link:label id="lab_ci_NotesDue202645InterestMember_documentation_en-US" xlink:label="lab_ci_NotesDue202645InterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior notes payable bearing interest at 4.5% due in 2026. Debt assumed acquisition from Express Scripts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue202645InterestMember" xlink:href="ci-20231231.xsd#ci_NotesDue202645InterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NotesDue202645InterestMember" xlink:to="lab_ci_NotesDue202645InterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount_603afe1c-400d-4dbc-9ef1-5150b610f0a6_terseLabel_en-US" xlink:label="lab_ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other foreign tax attributes</link:label>
    <link:label id="lab_ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount_label_en-US" xlink:label="lab_ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Foreign Tax Attributes, Amount</link:label>
    <link:label id="lab_ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount_documentation_en-US" xlink:label="lab_ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Foreign Tax Attributes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount" xlink:href="ci-20231231.xsd#ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount" xlink:to="lab_ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ShortdurationInsuranceContractsNumberOfPaidClaims_cdd16a17-8169-44fe-9c4c-861ac4482ff0_terseLabel_en-US" xlink:label="lab_ci_ShortdurationInsuranceContractsNumberOfPaidClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claim frequency</link:label>
    <link:label id="lab_ci_ShortdurationInsuranceContractsNumberOfPaidClaims_label_en-US" xlink:label="lab_ci_ShortdurationInsuranceContractsNumberOfPaidClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shortduration Insurance Contracts Number Of Paid Claims</link:label>
    <link:label id="lab_ci_ShortdurationInsuranceContractsNumberOfPaidClaims_documentation_en-US" xlink:label="lab_ci_ShortdurationInsuranceContractsNumberOfPaidClaims" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of customers for whom an insured medical claim was paid. Customers for whom no insured medical claim was paid and claims that did not result in a liability are excluded from the calculation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortdurationInsuranceContractsNumberOfPaidClaims" xlink:href="ci-20231231.xsd#ci_ShortdurationInsuranceContractsNumberOfPaidClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ShortdurationInsuranceContractsNumberOfPaidClaims" xlink:to="lab_ci_ShortdurationInsuranceContractsNumberOfPaidClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract_0a1da39e-d875-4317-a3ab-bdc917d0d8a2_terseLabel_en-US" xlink:label="lab_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax adjustments to reconcile to adjusted income from operations</link:label>
    <link:label id="lab_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract_label_en-US" xlink:label="lab_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pretax Adjustments To Reconcile Adjusted Income From Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract" xlink:href="ci-20231231.xsd#ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract" xlink:to="lab_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_b7b30592-a584-46c0-9fac-5ca4b2d58f98_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability_202c8454-e978-490b-afb7-80ca53f72f2c_terseLabel_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future policy benefit, excluding DPL</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability_label_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefit, Excluding Deferred Profit Liability</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability_documentation_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefit, Excluding Deferred Profit Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability" xlink:to="lab_ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ExpressScriptsCounterclaimsAgainstElevanceMember_9ca34ea5-a4fe-4c4f-a788-bfd20f0493a1_terseLabel_en-US" xlink:label="lab_ci_ExpressScriptsCounterclaimsAgainstElevanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Express Scripts counterclaims against Elevance</link:label>
    <link:label id="lab_ci_ExpressScriptsCounterclaimsAgainstElevanceMember_label_en-US" xlink:label="lab_ci_ExpressScriptsCounterclaimsAgainstElevanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Express Scripts Counterclaims Against Elevance [Member]</link:label>
    <link:label id="lab_ci_ExpressScriptsCounterclaimsAgainstElevanceMember_documentation_en-US" xlink:label="lab_ci_ExpressScriptsCounterclaimsAgainstElevanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Express Scripts Counterclaims Against Elevance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ExpressScriptsCounterclaimsAgainstElevanceMember" xlink:href="ci-20231231.xsd#ci_ExpressScriptsCounterclaimsAgainstElevanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ExpressScriptsCounterclaimsAgainstElevanceMember" xlink:to="lab_ci_ExpressScriptsCounterclaimsAgainstElevanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_9c13779c-5316-45be-827f-006a99a929c8_terseLabel_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum statutory surplus required by regulators</link:label>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_label_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Accounting Practices, Statutory Capital and Surplus Required</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:to="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_3b9e55f2-a25f-479e-a5fe-486cc8b618c2_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CompletionFactorsMember_3de1ee66-72a2-41d2-9182-b291edbdcba2_terseLabel_en-US" xlink:label="lab_ci_CompletionFactorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual completion factors</link:label>
    <link:label id="lab_ci_CompletionFactorsMember_label_en-US" xlink:label="lab_ci_CompletionFactorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Completion Factors [Member]</link:label>
    <link:label id="lab_ci_CompletionFactorsMember_documentation_en-US" xlink:label="lab_ci_CompletionFactorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts relating to actual claims emerging differently from assumptions about claim payment speed used to set reserves.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CompletionFactorsMember" xlink:href="ci-20231231.xsd#ci_CompletionFactorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CompletionFactorsMember" xlink:to="lab_ci_CompletionFactorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_609443b9-90be-460d-aadf-9df401c6842e_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_d896379a-fccc-4b20-af2d-b8956ccd24cf_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding balances</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteeObligationsCurrentCarryingValue_8e7ddca1-402e-4bab-a26f-31a834db7152_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for guarantees</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsCurrentCarryingValue_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor Obligations, Current Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:to="lab_us-gaap_GuaranteeObligationsCurrentCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_USFederalGovernmentAgenciesMember_a9085a6d-411d-4cba-a79d-f10d48c0e2be_terseLabel_en-US" xlink:label="lab_ci_USFederalGovernmentAgenciesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Federal Government Agencies</link:label>
    <link:label id="lab_ci_USFederalGovernmentAgenciesMember_label_en-US" xlink:label="lab_ci_USFederalGovernmentAgenciesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Federal Government Agencies [Member]</link:label>
    <link:label id="lab_ci_USFederalGovernmentAgenciesMember_documentation_en-US" xlink:label="lab_ci_USFederalGovernmentAgenciesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Federal Government Agencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_USFederalGovernmentAgenciesMember" xlink:href="ci-20231231.xsd#ci_USFederalGovernmentAgenciesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_USFederalGovernmentAgenciesMember" xlink:to="lab_ci_USFederalGovernmentAgenciesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_314fe745-9616-4710-be72-4915c78e0f4d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International, including funds and pooled separate accounts</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Equity Securities, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:to="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ReinsuranceRecoverablesLiabilityForFuturePolicyBenefitsAssetsHeldForSale_7752e7e7-1cde-4a46-9878-9be32421e49f_terseLabel_en-US" xlink:label="lab_ci_ReinsuranceRecoverablesLiabilityForFuturePolicyBenefitsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future policy benefits reserve, reinsurance recoverables reported in assets of businesses held for sale</link:label>
    <link:label id="lab_ci_ReinsuranceRecoverablesLiabilityForFuturePolicyBenefitsAssetsHeldForSale_label_en-US" xlink:label="lab_ci_ReinsuranceRecoverablesLiabilityForFuturePolicyBenefitsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Recoverables, Liability For Future Policy Benefits, Assets Held-For-Sale</link:label>
    <link:label id="lab_ci_ReinsuranceRecoverablesLiabilityForFuturePolicyBenefitsAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_ReinsuranceRecoverablesLiabilityForFuturePolicyBenefitsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Recoverables, Liability For Future Policy Benefits, Assets Held-For-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverablesLiabilityForFuturePolicyBenefitsAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_ReinsuranceRecoverablesLiabilityForFuturePolicyBenefitsAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ReinsuranceRecoverablesLiabilityForFuturePolicyBenefitsAssetsHeldForSale" xlink:to="lab_ci_ReinsuranceRecoverablesLiabilityForFuturePolicyBenefitsAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_03a4e05f-524e-43e5-b396-1cba4e320aba_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a5135b70-8235-40cb-8e3b-e2b11d78293b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear_04d5a103-80b4-4b15-9c53-2b60c858a8bb_terseLabel_en-US" xlink:label="lab_ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded commitments, percentage expected to fund in next fiscal year</link:label>
    <link:label id="lab_ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear_label_en-US" xlink:label="lab_ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded Commitments, Percentage Expected To Fund In Next Fiscal Year</link:label>
    <link:label id="lab_ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear_documentation_en-US" xlink:label="lab_ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded Commitments, Percentage Expected To Fund In Next Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear" xlink:href="ci-20231231.xsd#ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear" xlink:to="lab_ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_4e04a514-0a5d-4f4a-aaec-6c5d01fb26a9_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_aa29cde7-dc87-4284-8c87-dad078530c1a_totalLabel_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost, including held for sale assets</link:label>
    <link:label id="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Amortized Cost Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Amortized Cost Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain_367836f6-0b3c-4987-a6d6-59af061e128a_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Account Balance, above Guaranteed Minimum Crediting Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain_label_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Account Balance, above Guaranteed Minimum Crediting Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain" xlink:to="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NotesDue202383InterestMember_8dad7ea3-8665-471f-b930-de74e29d50eb_terseLabel_en-US" xlink:label="lab_ci_NotesDue202383InterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$17&#160;million, 8.3% Notes due January 2023</link:label>
    <link:label id="lab_ci_NotesDue202383InterestMember_label_en-US" xlink:label="lab_ci_NotesDue202383InterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2023, 8.3% Interest [Member]</link:label>
    <link:label id="lab_ci_NotesDue202383InterestMember_documentation_en-US" xlink:label="lab_ci_NotesDue202383InterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable bearing interest at 8.3% due in 2023.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue202383InterestMember" xlink:href="ci-20231231.xsd#ci_NotesDue202383InterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NotesDue202383InterestMember" xlink:to="lab_ci_NotesDue202383InterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OtherPharmacyMember_93e170b8-f6ec-4a6f-b2da-159e911c6bf1_terseLabel_en-US" xlink:label="lab_ci_OtherPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_ci_OtherPharmacyMember_label_en-US" xlink:label="lab_ci_OtherPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Pharmacy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherPharmacyMember" xlink:href="ci-20231231.xsd#ci_OtherPharmacyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OtherPharmacyMember" xlink:to="lab_ci_OtherPharmacyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a086c41b-478c-4778-a1df-f4e76f43ea99_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_24702c44-b9f7-4314-a668-64c6b1761c34_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding - January 1 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f5d09e60-17f9-465c-93ec-dd8527f13d0d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding - December 31 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_9a2ac363-855b-49a2-b503-17ea161451e8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_67207469-9bd6-4de7-8efc-1e3f6da5cd86_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAndOtherNoncurrentAssets_e5746d42-7189-409d-a4ab-7fa7b9b49626_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and Other Noncurrent Assets</link:label>
    <link:label id="lab_us-gaap_InvestmentsAndOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:to="lab_us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_622cfe38-3837-46bd-8581-e759e7298773_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_8e4af13f-4590-49d0-b664-a6014b83349d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f7acfa8d-ba69-48c5-b2d1-d1dfe23f63e0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_78293a12-ee43-4dde-ba83-0d72d326d277_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_d0ff778f-b289-4ca4-99c7-f106a9cc582e_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_3a61f0bb-59c8-4cc2-ac5e-a10baa4aa894_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OrganizationalEfficiencyPlanChargesNetOfTax_bce73caa-a482-420f-a181-bdafdc64660c_terseLabel_en-US" xlink:label="lab_ci_OrganizationalEfficiencyPlanChargesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge for organizational efficiency plan, 2020 (Selling, general and administrative expenses)</link:label>
    <link:label id="lab_ci_OrganizationalEfficiencyPlanChargesNetOfTax_label_en-US" xlink:label="lab_ci_OrganizationalEfficiencyPlanChargesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organizational Efficiency Plan Charges, Net Of Tax</link:label>
    <link:label id="lab_ci_OrganizationalEfficiencyPlanChargesNetOfTax_documentation_en-US" xlink:label="lab_ci_OrganizationalEfficiencyPlanChargesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organizational Efficiency Plan Charges, Net Of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OrganizationalEfficiencyPlanChargesNetOfTax" xlink:href="ci-20231231.xsd#ci_OrganizationalEfficiencyPlanChargesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OrganizationalEfficiencyPlanChargesNetOfTax" xlink:to="lab_ci_OrganizationalEfficiencyPlanChargesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_8c5cfb82-e5d1-4f0f-89a1-677551403e60_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of counts</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_abd37a4d-fe0f-408c-886e-49594a99e90e_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax expense at nominal rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_594038c1-c65c-40b2-8cd8-f95bc226fa85_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies &#8212; Note 24</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d902b198-f4e3-487d-a2ad-6f04d5c90158_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FiniteLivedIntangibleAssetsNetVoba_4d192ef6-2cdd-4136-9912-d1c35592fe40_totalLabel_en-US" xlink:label="lab_ci_FiniteLivedIntangibleAssetsNetVoba" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Value</link:label>
    <link:label id="lab_ci_FiniteLivedIntangibleAssetsNetVoba_label_en-US" xlink:label="lab_ci_FiniteLivedIntangibleAssetsNetVoba" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets Net VOBA</link:label>
    <link:label id="lab_ci_FiniteLivedIntangibleAssetsNetVoba_documentation_en-US" xlink:label="lab_ci_FiniteLivedIntangibleAssetsNetVoba" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount after amortization of insurance contracts acquired in a business combination that are reported in deferred policy acquisition costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsNetVoba" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsNetVoba"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FiniteLivedIntangibleAssetsNetVoba" xlink:to="lab_ci_FiniteLivedIntangibleAssetsNetVoba" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_55f353f5-8ff7-4404-965e-a1ee7e57f1d1_terseLabel_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Previously Reported</link:label>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_label_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Previously Reported [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioPreviouslyReportedMember" xlink:to="lab_srt_ScenarioPreviouslyReportedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_StopLossMember_bdd639f9-6ef6-4802-8b8e-b84f41ae2943_terseLabel_en-US" xlink:label="lab_ci_StopLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stop loss</link:label>
    <link:label id="lab_ci_StopLossMember_label_en-US" xlink:label="lab_ci_StopLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stop Loss [Member]</link:label>
    <link:label id="lab_ci_StopLossMember_documentation_en-US" xlink:label="lab_ci_StopLossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">An insurance product that provides additional coverage on Administrative Services Only plans that provides reimbursement for claims in excess of a predetermined amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_StopLossMember" xlink:href="ci-20231231.xsd#ci_StopLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_StopLossMember" xlink:to="lab_ci_StopLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_bdebe0a4-01c0-4f2b-8280-126a931eabd6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumUndiscountedBeforeReinsurance_097cfb91-5b34-4511-b5d8-cc31f8f7c811_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumUndiscountedBeforeReinsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undiscounted expected future gross premiums</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumUndiscountedBeforeReinsurance_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumUndiscountedBeforeReinsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefit, Expected Future Gross Premium, Undiscounted, before Reinsurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumUndiscountedBeforeReinsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumUndiscountedBeforeReinsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumUndiscountedBeforeReinsurance" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumUndiscountedBeforeReinsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_40cdaab4-f639-4add-bf7d-e1ac5540cabf_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid claims and claim expenses</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_7a9ddc56-ea70-400d-9f6f-727800ba25c6_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_5f03f869-5fbb-4c69-af03-5b24f88057ab_periodEndLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (1)</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVoba_c4befefd-5c20-4f49-90f6-a9e61fa5804a_terseLabel_en-US" xlink:label="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVoba" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVoba_label_en-US" xlink:label="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVoba" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets Accumulated Amortization VOBA</link:label>
    <link:label id="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVoba_documentation_en-US" xlink:label="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVoba" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amount of amortization of insurance contracts acquired in a business combination that are reported in deferred policy acquisition costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVoba" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVoba"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVoba" xlink:to="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVoba" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesIndustryMember_3b4b4c6a-0dba-4732-844c-4688587ec486_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesIndustryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Industry Sector [Domain]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesIndustryMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesIndustryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Industry Sector [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesIndustryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesIndustryMember" xlink:to="lab_us-gaap_EquitySecuritiesIndustryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureTwelveMonthsOrLongerNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale_fe131495-e044-4051-b8c3-9b614e935fdd_terseLabel_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureTwelveMonthsOrLongerNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Issues, including held for sale assets</link:label>
    <link:label id="lab_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureTwelveMonthsOrLongerNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureTwelveMonthsOrLongerNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities In Unrealized Loss Positions, Qualitative Disclosure, Twelve Months Or Longer, Number Of Positions, Before Reclassification To Disposal Group, Assets Held For Sale</link:label>
    <link:label id="lab_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureTwelveMonthsOrLongerNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureTwelveMonthsOrLongerNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities In Unrealized Loss Positions, Qualitative Disclosure, Twelve Months Or Longer, Number Of Positions, Before Reclassification To Disposal Group, Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureTwelveMonthsOrLongerNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureTwelveMonthsOrLongerNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureTwelveMonthsOrLongerNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureTwelveMonthsOrLongerNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_909b1ced-a98c-4cc3-87b7-3b7d3d5c6ee4_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_61ca4abc-bdba-41fc-be13-c0330d5409af_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInsuranceAndContractholderLiabilities_e0541861-23f0-49fa-8b2f-7fbb5785d418_negatedLabel_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInsuranceAndContractholderLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance and contractholder liabilities current, classified as held for sale</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInsuranceAndContractholderLiabilities_label_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInsuranceAndContractholderLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Current Insurance And Contractholder Liabilities</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInsuranceAndContractholderLiabilities_documentation_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInsuranceAndContractholderLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Current Insurance And Contractholder Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInsuranceAndContractholderLiabilities" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationCurrentInsuranceAndContractholderLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInsuranceAndContractholderLiabilities" xlink:to="lab_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInsuranceAndContractholderLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_1aec7dbd-662c-4c14-8359-b1119831a99d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ComponentsOfDepreciationAndAmortizationTableTextBlock_2522903e-dc8f-43e1-9c2a-c57e602a537f_terseLabel_en-US" xlink:label="lab_ci_ComponentsOfDepreciationAndAmortizationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Depreciation and Amortization Expense</link:label>
    <link:label id="lab_ci_ComponentsOfDepreciationAndAmortizationTableTextBlock_label_en-US" xlink:label="lab_ci_ComponentsOfDepreciationAndAmortizationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components Of Depreciation And Amortization [Table Text Block]</link:label>
    <link:label id="lab_ci_ComponentsOfDepreciationAndAmortizationTableTextBlock_documentation_en-US" xlink:label="lab_ci_ComponentsOfDepreciationAndAmortizationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discloses the depreciation and amortization of property and equipment and other intangibles.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ComponentsOfDepreciationAndAmortizationTableTextBlock" xlink:href="ci-20231231.xsd#ci_ComponentsOfDepreciationAndAmortizationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ComponentsOfDepreciationAndAmortizationTableTextBlock" xlink:to="lab_ci_ComponentsOfDepreciationAndAmortizationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_3b2249ff-469f-4b1a-b3a7-4eee79c3bf6e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Pension Assets by Category</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy_f204d04b-2e7e-4358-b9c5-cda4e889d450_terseLabel_en-US" xlink:label="lab_ci_NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-guaranteed separate accounts</link:label>
    <link:label id="lab_ci_NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy_label_en-US" xlink:label="lab_ci_NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Guaranteed Separate Account Assets Classified In Fair Value Hierarchy</link:label>
    <link:label id="lab_ci_NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy_documentation_en-US" xlink:label="lab_ci_NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The fair value of the assets held by the Entity for the benefit of separate account policyholders without guarantees classified in the fair value hierarchy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy" xlink:href="ci-20231231.xsd#ci_NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy" xlink:to="lab_ci_NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_80b247e7-2830-4df4-9411-80564692e4a0_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock held in treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_d61bb3be-c648-40e9-9764-94d2e1912446_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d3bbcf52-e40f-4201-af2d-50c8ee63608d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding - January 1 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_74d8bc67-cb94-435f-9157-ab17c5141e03_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding - December 31 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a475679f-1718-4510-861a-60dedfa145cb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_cad3397e-f798-4fe5-8f7d-86617eb19b52_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and Improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NetworkPharmacyMember_b9ce710a-d6be-47a6-8a3c-1b1e680b5c6a_terseLabel_en-US" xlink:label="lab_ci_NetworkPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network revenues</link:label>
    <link:label id="lab_ci_NetworkPharmacyMember_label_en-US" xlink:label="lab_ci_NetworkPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Pharmacy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NetworkPharmacyMember" xlink:href="ci-20231231.xsd#ci_NetworkPharmacyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NetworkPharmacyMember" xlink:to="lab_ci_NetworkPharmacyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale_87b9585b-d89f-4e32-97ed-a7476a61aa15_totalLabel_en-US" xlink:label="lab_ci_ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total reinsurance recoverables, including assets held for sale</link:label>
    <link:label id="lab_ci_ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Recoverables, Including Reinsurance Premium Paid, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Recoverables, Including Reinsurance Premium Paid, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxAbstract_a4cbc657-34bd-4bff-b055-65b6c79ed00b_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax [Abstract]</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SwapMember_96324ecc-b042-42da-9421-011084ec9af5_terseLabel_en-US" xlink:label="lab_us-gaap_SwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swaps</link:label>
    <link:label id="lab_us-gaap_SwapMember_label_en-US" xlink:label="lab_us-gaap_SwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SwapMember" xlink:to="lab_us-gaap_SwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_6a3bdc17-3545-4e44-9881-8db7545613db_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax_b49825c6-8a05-4f42-ac2d-51c3afffdee7_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of effect of beginning of period discount rate assumptions</link:label>
    <link:label id="lab_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax_a721a036-9915-4256-b3fd-e841eded48f7_periodEndLabel_en-US" xlink:label="lab_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of end of period discount rate assumptions</link:label>
    <link:label id="lab_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax_label_en-US" xlink:label="lab_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Liability for Future Policy Benefit, Expected Net Premium, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax" xlink:to="lab_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_2bb0430e-98a2-40f9-8dc6-77279113d0f0_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0f111827-b99a-4343-ac35-a7bf4e86f21f_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translation of Foreign Currencies</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuarantyLiabilities_af620955-94b4-4ef5-af0e-df1ba18ddf3f_terseLabel_en-US" xlink:label="lab_us-gaap_GuarantyLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guaranty liability</link:label>
    <link:label id="lab_us-gaap_GuarantyLiabilities_label_en-US" xlink:label="lab_us-gaap_GuarantyLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guaranty Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuarantyLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuarantyLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuarantyLiabilities" xlink:to="lab_us-gaap_GuarantyLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaper_5d5626be-95d3-4814-8e56-faa9dba4354d_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaper" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaper_label_en-US" xlink:label="lab_us-gaap_CommercialPaper" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaper"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaper" xlink:to="lab_us-gaap_CommercialPaper" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember_fd97b849-3782-4108-b74e-7bce0d09b7f6_terseLabel_en-US" xlink:label="lab_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International life, accident and supplemental benefits businesses</link:label>
    <link:label id="lab_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember_label_en-US" xlink:label="lab_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Life Accident Supplemental Benefits Businesses [Member]</link:label>
    <link:label id="lab_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember_documentation_en-US" xlink:label="lab_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Life, accident and supplemental benefits businesses in Hong Kong, Indonesia, New Zealand, South Korea, Taiwan, Thailand and interest in a joint venture in Turkey.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember" xlink:href="ci-20231231.xsd#ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember" xlink:to="lab_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes_9575c5be-1824-41cf-b955-2af02bb9dc36_negatedLabel_en-US" xlink:label="lab_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk corridors recovery (Selling, general and administrative expenses)</link:label>
    <link:label id="lab_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes_2501ba11-d1fd-4aed-bf43-bf06ed847383_negatedTerseLabel_en-US" xlink:label="lab_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk corridors recovery</link:label>
    <link:label id="lab_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes_label_en-US" xlink:label="lab_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Item, Gain (Loss) On Risk Corridor Allowance Adjustment, Before Taxes</link:label>
    <link:label id="lab_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes_documentation_en-US" xlink:label="lab_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Item, Gain (Loss) On Risk Corridor Allowance Adjustment, Before Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes" xlink:href="ci-20231231.xsd#ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes" xlink:to="lab_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_6078ba89-5952-40cc-87e3-2c96c18af37b_terseLabel_en-US" xlink:label="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule I - Condensed Financial Information of The Cigna Group</link:label>
    <link:label id="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Information of Parent Company Only Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:to="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_b95c4e0e-3698-4549-ad55-14267c6c7289_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1adb14f5-7f96-4b52-80eb-3c25e5d3f0a3_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AnthemMember_b3f71ee1-e05f-4633-8baa-6814b9ea25ab_terseLabel_en-US" xlink:label="lab_ci_AnthemMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anthem [Member]</link:label>
    <link:label id="lab_ci_AnthemMember_label_en-US" xlink:label="lab_ci_AnthemMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anthem [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AnthemMember" xlink:href="ci-20231231.xsd#ci_AnthemMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AnthemMember" xlink:to="lab_ci_AnthemMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OtherOperationsSegmentMember_7ca076ab-8c73-4449-9674-375f624a9f0c_terseLabel_en-US" xlink:label="lab_ci_OtherOperationsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operations</link:label>
    <link:label id="lab_ci_OtherOperationsSegmentMember_label_en-US" xlink:label="lab_ci_OtherOperationsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operations Segment [Member]</link:label>
    <link:label id="lab_ci_OtherOperationsSegmentMember_documentation_en-US" xlink:label="lab_ci_OtherOperationsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operations Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherOperationsSegmentMember" xlink:href="ci-20231231.xsd#ci_OtherOperationsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OtherOperationsSegmentMember" xlink:to="lab_ci_OtherOperationsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_baee2834-c8ac-44c1-9f91-1f25d6379d39_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_56b31a4a-745e-49f6-b290-b08a58a7c5df_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_95231b5c-f9ea-42e9-95e0-4a0ea530c0c5_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of Common Stock Available for Award</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SpecialItemChargeBenefitTaxMattersAfterTax_45ae2b6e-bfab-4c01-919f-3720daa60f55_terseLabel_en-US" xlink:label="lab_ci_SpecialItemChargeBenefitTaxMattersAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax (benefits), net, after-tax (Income taxes, less amount attributable to noncontrolling interests)</link:label>
    <link:label id="lab_ci_SpecialItemChargeBenefitTaxMattersAfterTax_label_en-US" xlink:label="lab_ci_SpecialItemChargeBenefitTaxMattersAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Item Charge Benefit Tax Matters After Tax</link:label>
    <link:label id="lab_ci_SpecialItemChargeBenefitTaxMattersAfterTax_documentation_en-US" xlink:label="lab_ci_SpecialItemChargeBenefitTaxMattersAfterTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Item Charge Benefit Tax Matters After Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitTaxMattersAfterTax" xlink:href="ci-20231231.xsd#ci_SpecialItemChargeBenefitTaxMattersAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SpecialItemChargeBenefitTaxMattersAfterTax" xlink:to="lab_ci_SpecialItemChargeBenefitTaxMattersAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_ced03a54-f3b0-4bbc-a35c-2b2121439466_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease) / Increase due to prior year positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_43829902-cb7a-40f9-8085-dfdfb4347002_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SeparateAccountAssetsClassifiedInFairValueHierarchy_1379ca7e-23f2-438e-87ac-6ebae7c3a0ad_totalLabel_en-US" xlink:label="lab_ci_SeparateAccountAssetsClassifiedInFairValueHierarchy" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_ci_SeparateAccountAssetsClassifiedInFairValueHierarchy_label_en-US" xlink:label="lab_ci_SeparateAccountAssetsClassifiedInFairValueHierarchy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate Account Assets Classified In Fair Value Hierarchy</link:label>
    <link:label id="lab_ci_SeparateAccountAssetsClassifiedInFairValueHierarchy_documentation_en-US" xlink:label="lab_ci_SeparateAccountAssetsClassifiedInFairValueHierarchy" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The fair value of the assets held by the Entity for the benefit of separate account policyholders classified in the fair value hierarchy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SeparateAccountAssetsClassifiedInFairValueHierarchy" xlink:href="ci-20231231.xsd#ci_SeparateAccountAssetsClassifiedInFairValueHierarchy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SeparateAccountAssetsClassifiedInFairValueHierarchy" xlink:to="lab_ci_SeparateAccountAssetsClassifiedInFairValueHierarchy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_e11f7ff1-9589-4026-9d5d-a18d48503bb7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior years</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_IndividualAndFamilyPlansMember_a2ba7b49-ebf7-4e80-925f-280880a6629b_terseLabel_en-US" xlink:label="lab_ci_IndividualAndFamilyPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual and Family Plans</link:label>
    <link:label id="lab_ci_IndividualAndFamilyPlansMember_label_en-US" xlink:label="lab_ci_IndividualAndFamilyPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual And Family Plans [Member]</link:label>
    <link:label id="lab_ci_IndividualAndFamilyPlansMember_documentation_en-US" xlink:label="lab_ci_IndividualAndFamilyPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IndividualAndFamilyPlansMember" xlink:href="ci-20231231.xsd#ci_IndividualAndFamilyPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_IndividualAndFamilyPlansMember" xlink:to="lab_ci_IndividualAndFamilyPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DepreciationAndAmortizationByTypeAxis_6f7c4256-2a1b-4606-8296-327c833ace57_terseLabel_en-US" xlink:label="lab_ci_DepreciationAndAmortizationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation And Amortization By Type [Axis]</link:label>
    <link:label id="lab_ci_DepreciationAndAmortizationByTypeAxis_label_en-US" xlink:label="lab_ci_DepreciationAndAmortizationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation And Amortization By Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DepreciationAndAmortizationByTypeAxis" xlink:href="ci-20231231.xsd#ci_DepreciationAndAmortizationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DepreciationAndAmortizationByTypeAxis" xlink:to="lab_ci_DepreciationAndAmortizationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities_7d1faea4-520f-47f3-9cf5-869d4173cab2_terseLabel_en-US" xlink:label="lab_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and Accrued expenses and other liabilities</link:label>
    <link:label id="lab_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities_32cf992a-b3d8-41d6-951c-10ba593b9dc5_verboseLabel_en-US" xlink:label="lab_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Accounts Payable Accrued And Other Operating Liabilities</link:label>
    <link:label id="lab_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities_documentation_en-US" xlink:label="lab_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in the aggregate amount of accounts payable, accrued liabilities and other operating obligations not separately disclosed in the statement of cash flows.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities" xlink:href="ci-20231231.xsd#ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities" xlink:to="lab_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SubsidiariesMember_17cd9707-1f34-4e88-b779-2275d5a30ed6_terseLabel_en-US" xlink:label="lab_srt_SubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiaries</link:label>
    <link:label id="lab_srt_SubsidiariesMember_label_en-US" xlink:label="lab_srt_SubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiaries [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SubsidiariesMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SubsidiariesMember" xlink:to="lab_srt_SubsidiariesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_e74b124a-a28e-4e6e-a9b3-5fdea6433509_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common dividends declared (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermDebtNoncurrent_107aa27e-06d4-4948-b3dc-1e5b8e144022_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, including finance leases</link:label>
    <link:label id="lab_us-gaap_OtherLongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-Term Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermDebtNoncurrent" xlink:to="lab_us-gaap_OtherLongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_e0fff6f7-9e4b-4d1f-adbe-e5076bf23317_terseLabel_en-US" xlink:label="lab_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]</link:label>
    <link:label id="lab_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:to="lab_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_c6cf2848-7431-4efe-8b9d-eb41e3896427_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_c055f1b6-eab8-4f58-93c1-831f5012edcb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Income [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_bd47721b-06e4-4ec3-8729-3254e7a80613_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk_905347a1-43b9-46a1-81bc-c76dec2a1fa4_terseLabel_en-US" xlink:label="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amount at risk</link:label>
    <link:label id="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk_label_en-US" xlink:label="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Amount at Risk by Product and Guarantee, Net Amount at Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk" xlink:to="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance_ab07893b-1cae-450e-9aef-d5a31dca6c81_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsured market risk benefit, end of period</link:label>
    <link:label id="lab_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance_e7f81381-e448-4cce-8542-a4cc5cbee401_terseLabel_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market risk benefits</link:label>
    <link:label id="lab_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance_label_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Risk Benefit, Reinsurance Recoverable, after Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance" xlink:to="lab_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_e46614d7-7fcb-47f2-b37e-d5e5d6f725e5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_e94284ff-aab2-4c22-9641-9af195973a23_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_0713c4b7-f3c5-4d6a-bee5-baf2329be50e_negatedLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustment, before tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_06315973-3db0-40f4-b576-beb6c8aa6c3b_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment upon Adoption</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings_eb7e6417-2f30-4d73-ae7a-4b78333364cd_negatedTerseLabel_en-US" xlink:label="lab_ci_EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of foreign earnings</link:label>
    <link:label id="lab_ci_EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings_label_en-US" xlink:label="lab_ci_EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Permanently Reinvested Foreign Earnings</link:label>
    <link:label id="lab_ci_EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings_documentation_en-US" xlink:label="lab_ci_EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to permanently reinvested foreign earnings.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings" xlink:href="ci-20231231.xsd#ci_EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings" xlink:to="lab_ci_EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_26d43404-5440-4b12-b62d-bf77f280455c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued for stock option exercises and other benefit plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_c559d8c2-34ed-456e-baf2-5388269b0c15_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_JudicialRulingMember_d74baa94-5659-442f-8e7b-d418a70371dd_terseLabel_en-US" xlink:label="lab_us-gaap_JudicialRulingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judicial Ruling</link:label>
    <link:label id="lab_us-gaap_JudicialRulingMember_label_en-US" xlink:label="lab_us-gaap_JudicialRulingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judicial Ruling [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JudicialRulingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_JudicialRulingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_JudicialRulingMember" xlink:to="lab_us-gaap_JudicialRulingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NotesDue202734InterestMember_ef325a3b-8a1a-406e-9fa5-e73ec25a3bf1_terseLabel_en-US" xlink:label="lab_ci_NotesDue202734InterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$1,500&#160;million, 3.400% Notes due March 2027</link:label>
    <link:label id="lab_ci_NotesDue202734InterestMember_label_en-US" xlink:label="lab_ci_NotesDue202734InterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2027, 3.4% Interest [Member]</link:label>
    <link:label id="lab_ci_NotesDue202734InterestMember_documentation_en-US" xlink:label="lab_ci_NotesDue202734InterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior notes payable bearing interest at 3.4% due in 2027. Debt assumed acquisition from Express Scripts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue202734InterestMember" xlink:href="ci-20231231.xsd#ci_NotesDue202734InterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NotesDue202734InterestMember" xlink:to="lab_ci_NotesDue202734InterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_6bcff561-718a-4955-b1a4-460ba078b6d9_terseLabel_en-US" xlink:label="lab_ci_ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurred Costs, including assets held for sale</link:label>
    <link:label id="lab_ci_ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NoncontrollingInterestOtherChanges_4cf7764c-9484-4a1d-951f-4e72b93bf800_verboseLabel_en-US" xlink:label="lab_ci_NoncontrollingInterestOtherChanges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other transactions impacting noncontrolling interests</link:label>
    <link:label id="lab_ci_NoncontrollingInterestOtherChanges_label_en-US" xlink:label="lab_ci_NoncontrollingInterestOtherChanges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest Other Changes</link:label>
    <link:label id="lab_ci_NoncontrollingInterestOtherChanges_documentation_en-US" xlink:label="lab_ci_NoncontrollingInterestOtherChanges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other activity associated with noncontrolling interest that is not separately disclosed.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NoncontrollingInterestOtherChanges" xlink:href="ci-20231231.xsd#ci_NoncontrollingInterestOtherChanges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NoncontrollingInterestOtherChanges" xlink:to="lab_ci_NoncontrollingInterestOtherChanges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_27d20ebd-3851-4875-a117-0a886da30867_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_76a1e5f5-21ba-4df9-abed-0b245b04495a_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1_cec698e2-aa02-45b7-a3de-74174e008255_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption Notice Period</link:label>
    <link:label id="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1_label_en-US" xlink:label="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Investment Redemption, Notice Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1" xlink:to="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_a1ba396e-0c03-48df-b43d-a3fa8e114792_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, net</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_0304a4ae-d5db-40e6-80ae-5a92bac0a2a7_periodEndLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, net</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_e7ab3e1f-0dcd-4093-9458-74422bfb5e2c_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Lease Expense</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilities_c365df37-4e81-402a-bf0b-e523ce8952fa_totalLabel_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total insurance and contractholder liabilities</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilities_label_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance And Contractholder Liabilities</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilities_documentation_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance And Contractholder Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilities" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InsuranceAndContractholderLiabilities" xlink:to="lab_ci_InsuranceAndContractholderLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_98bfab37-ecfc-4c8c-b4f1-f13a55b5b872_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceRelatedAssessmentsMember_9d80e997-968c-4930-bc06-35873bbcfe63_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceRelatedAssessmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guaranty Fund Assessments</link:label>
    <link:label id="lab_us-gaap_InsuranceRelatedAssessmentsMember_label_en-US" xlink:label="lab_us-gaap_InsuranceRelatedAssessmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance-related Assessments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceRelatedAssessmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceRelatedAssessmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceRelatedAssessmentsMember" xlink:to="lab_us-gaap_InsuranceRelatedAssessmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_a65d5f48-fcb4-4f16-9e85-aededd06880c_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings_a73aac15-a024-438e-8f2d-43a495b1aae1_negatedLabel_en-US" xlink:label="lab_ci_IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of foreign earnings</link:label>
    <link:label id="lab_ci_IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings_label_en-US" xlink:label="lab_ci_IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Permanently Reinvested Foreign Earnings</link:label>
    <link:label id="lab_ci_IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings_documentation_en-US" xlink:label="lab_ci_IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to permanently reinvested foreign earnings.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings" xlink:href="ci-20231231.xsd#ci_IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings" xlink:to="lab_ci_IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax_b443fb54-9a37-42e3-9d4c-27784b3096e6_terseLabel_en-US" xlink:label="lab_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt extinguishment costs</link:label>
    <link:label id="lab_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax_label_en-US" xlink:label="lab_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Item Charges Debt Extinguishment Costs Before Tax</link:label>
    <link:label id="lab_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax_documentation_en-US" xlink:label="lab_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Item Charges Debt Extinguishment Costs Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax" xlink:href="ci-20231231.xsd#ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax" xlink:to="lab_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_b520fc4a-61e6-449e-af03-895213725c1d_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt extinguishment costs</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_ff56da55-bf17-4937-afb7-2a76c7db6640_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt extinguishment costs</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_9347ef97-9d94-4a89-b50c-112615aebc9b_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on repurchase of debt, pre-tax</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeAssets_ea2c6193-853d-4256-a75a-c07af7243ffa_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment for credit risk on derivatives assets</link:label>
    <link:label id="lab_us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Credit Risk Valuation Adjustment, Derivative Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeAssets" xlink:to="lab_us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_71f6d19d-69a5-430e-ac19-5fe2c9875826_negatedLabel_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Depreciation, including held for sale assets</link:label>
    <link:label id="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Continuous Unrealized Loss Position Less Than 12 Months Accumulated Loss Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Continuous Unrealized Loss Position Less Than 12 Months Accumulated Loss Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold_7ae2f5ee-8c1e-4c73-b54b-15393fa79223_terseLabel_en-US" xlink:label="lab_ci_SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding payment obligations, current, voluntarily elected by suppliers to be sold to the financial institution</link:label>
    <link:label id="lab_ci_SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold_label_en-US" xlink:label="lab_ci_SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Finance Program, Outstanding Payment Obligation, Current, Voluntarily Elected To Be Sold</link:label>
    <link:label id="lab_ci_SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold_documentation_en-US" xlink:label="lab_ci_SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Finance Program, Outstanding Payment Obligation, Current, Voluntarily Elected To Be Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold" xlink:href="ci-20231231.xsd#ci_SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold" xlink:to="lab_ci_SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity_8bd61ffd-3818-42e3-b758-eaac342e9a9b_terseLabel_en-US" xlink:label="lab_ci_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) including temporary equity, before reclassifications, before tax</link:label>
    <link:label id="lab_ci_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity_label_en-US" xlink:label="lab_ci_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, before Tax, Including Temporary Equity</link:label>
    <link:label id="lab_ci_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity_documentation_en-US" xlink:label="lab_ci_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, before Tax, Including Temporary Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity" xlink:to="lab_ci_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_fe904266-d355-485f-9c36-85896fa209fd_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_6a6d3636-8674-43fa-a0a6-ce42ef74bda4_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff_08341366-6a45-4f40-b71d-9d754009ee13_terseLabel_en-US" xlink:label="lab_ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes due to expected run-off</link:label>
    <link:label id="lab_ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff_label_en-US" xlink:label="lab_ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Risk Benefit, Increase (Decrease) Due to Expected Run-Off</link:label>
    <link:label id="lab_ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff_documentation_en-US" xlink:label="lab_ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Risk Benefit, Increase (Decrease) Due to Expected Run-Off</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff" xlink:href="ci-20231231.xsd#ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff" xlink:to="lab_ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_MeasurementInputLiquidityMember_4873d6de-5aa9-40cc-97b0-a64287462105_terseLabel_en-US" xlink:label="lab_ci_MeasurementInputLiquidityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity</link:label>
    <link:label id="lab_ci_MeasurementInputLiquidityMember_label_en-US" xlink:label="lab_ci_MeasurementInputLiquidityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Liquidity [Member]</link:label>
    <link:label id="lab_ci_MeasurementInputLiquidityMember_documentation_en-US" xlink:label="lab_ci_MeasurementInputLiquidityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Liquidity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MeasurementInputLiquidityMember" xlink:href="ci-20231231.xsd#ci_MeasurementInputLiquidityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_MeasurementInputLiquidityMember" xlink:to="lab_ci_MeasurementInputLiquidityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_0f179d4c-bc94-4e6f-a7cf-cea5d344ef82_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net carrying value classified as assets of business held for sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_61ee51b5-41da-4e31-8be0-506ff5a77166_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease) due to prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_7ba936ab-12a6-4903-b8f9-068531768989_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1d9682ea-47fd-4a34-966d-81941cc14923_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash and cash equivalents December 31,</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f576d425-8e7d-49b8-8880-611ee9898ccf_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash and cash equivalents January 1,</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_55b8f08a-c3b5-4d27-977a-39ce8d0f3c1f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of year (2)</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SpecialItemsBeforeTaxAbstract_9c7a5ab4-8b21-4572-b0e9-b25858ab483d_verboseLabel_en-US" xlink:label="lab_ci_SpecialItemsBeforeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax</link:label>
    <link:label id="lab_ci_SpecialItemsBeforeTaxAbstract_9c329ef4-d74c-475f-8015-27e5f2ed6128_terseLabel_en-US" xlink:label="lab_ci_SpecialItemsBeforeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special items</link:label>
    <link:label id="lab_ci_SpecialItemsBeforeTaxAbstract_label_en-US" xlink:label="lab_ci_SpecialItemsBeforeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Items Before Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemsBeforeTaxAbstract" xlink:href="ci-20231231.xsd#ci_SpecialItemsBeforeTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract" xlink:to="lab_ci_SpecialItemsBeforeTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_e1b68cc9-a6e2-4e53-b6eb-71bf9d546704_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_2be114f3-e2a9-45db-b482-551f1dd7ea80_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_da8dfd6b-14da-4d7b-be9b-b0efcc6e2f17_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_3170604b-7d1b-45fd-98e8-40d60c76cec7_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_50b23039-6963-4f80-97bc-0faa32fcd2eb_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Depreciation</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_928fc3d8-be57-4968-aae2-742a88fa8f1b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NotesDue2026125Member_6ce40fc4-18e8-408a-a889-e2cfb0c7c37b_terseLabel_en-US" xlink:label="lab_ci_NotesDue2026125Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$800 million, 1.250% Notes due March 2026 (1)</link:label>
    <link:label id="lab_ci_NotesDue2026125Member_label_en-US" xlink:label="lab_ci_NotesDue2026125Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes due 2026, 1.25% [Member]</link:label>
    <link:label id="lab_ci_NotesDue2026125Member_documentation_en-US" xlink:label="lab_ci_NotesDue2026125Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable bearing interest at 1.25% due in 2026.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue2026125Member" xlink:href="ci-20231231.xsd#ci_NotesDue2026125Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NotesDue2026125Member" xlink:to="lab_ci_NotesDue2026125Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_e67fc446-a78f-4517-bcd2-331ab206f7c1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_d559c6a1-f5a6-416c-a3f6-761bbb46c88c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_330b9fa3-b9ff-4092-840f-fd4c25bf2e75_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems_d3c9a708-9cc8-4abf-9c2b-132119d3602f_terseLabel_en-US" xlink:label="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Amount at Risk by Product and Guarantee [Line Items]</link:label>
    <link:label id="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems_label_en-US" xlink:label="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Amount at Risk by Product and Guarantee [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems" xlink:to="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivablePortfolioSegmentDomain_30742477-8550-48ed-8d49-33ce91a85343_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable Portfolio Segment [Domain]</link:label>
    <link:label id="lab_us-gaap_FinancingReceivablePortfolioSegmentDomain_label_en-US" xlink:label="lab_us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable Portfolio Segment [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablePortfolioSegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:to="lab_us-gaap_FinancingReceivablePortfolioSegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CashAndCashEquivalentsInvestmentTradeReceivablesNetMember_676f3468-0b6b-4081-a7a4-c590270715e4_terseLabel_en-US" xlink:label="lab_ci_CashAndCashEquivalentsInvestmentTradeReceivablesNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and other current assets, net</link:label>
    <link:label id="lab_ci_CashAndCashEquivalentsInvestmentTradeReceivablesNetMember_label_en-US" xlink:label="lab_ci_CashAndCashEquivalentsInvestmentTradeReceivablesNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents Investment Trade Receivables Net [Member]</link:label>
    <link:label id="lab_ci_CashAndCashEquivalentsInvestmentTradeReceivablesNetMember_documentation_en-US" xlink:label="lab_ci_CashAndCashEquivalentsInvestmentTradeReceivablesNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reflects cash, cash equivalents and net receivables for investment sales and purchases. Cash and cash equivalents includes currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CashAndCashEquivalentsInvestmentTradeReceivablesNetMember" xlink:href="ci-20231231.xsd#ci_CashAndCashEquivalentsInvestmentTradeReceivablesNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CashAndCashEquivalentsInvestmentTradeReceivablesNetMember" xlink:to="lab_ci_CashAndCashEquivalentsInvestmentTradeReceivablesNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PricingConcessionsMember_2b7de089-fc42-4501-86df-424ea47b2a37_terseLabel_en-US" xlink:label="lab_ci_PricingConcessionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pricing Concessions</link:label>
    <link:label id="lab_ci_PricingConcessionsMember_label_en-US" xlink:label="lab_ci_PricingConcessionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pricing Concessions [Member]</link:label>
    <link:label id="lab_ci_PricingConcessionsMember_documentation_en-US" xlink:label="lab_ci_PricingConcessionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pricing Concessions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PricingConcessionsMember" xlink:href="ci-20231231.xsd#ci_PricingConcessionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PricingConcessionsMember" xlink:to="lab_ci_PricingConcessionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_98093c68-2be8-4c95-9ca1-b2fa49c13905_totalLabel_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, including held for sale assets</link:label>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Amortized Cost, Before Reclassification To Disposal Group, Assets Held For Sale</link:label>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Amortized Cost, Before Reclassification To Disposal Group, Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PolicyholderContractDepositNoncurrentIncludingDisposalGroups_f6aed3ec-9853-47c0-ad09-13cfa0920105_terseLabel_en-US" xlink:label="lab_ci_PolicyholderContractDepositNoncurrentIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractholder deposit funds, non-current, including liabilities held for sale</link:label>
    <link:label id="lab_ci_PolicyholderContractDepositNoncurrentIncludingDisposalGroups_label_en-US" xlink:label="lab_ci_PolicyholderContractDepositNoncurrentIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Contract Deposit, Noncurrent Including Disposal Groups</link:label>
    <link:label id="lab_ci_PolicyholderContractDepositNoncurrentIncludingDisposalGroups_documentation_en-US" xlink:label="lab_ci_PolicyholderContractDepositNoncurrentIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Contract Deposit, Noncurrent Including Disposal Groups</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositNoncurrentIncludingDisposalGroups" xlink:href="ci-20231231.xsd#ci_PolicyholderContractDepositNoncurrentIncludingDisposalGroups"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PolicyholderContractDepositNoncurrentIncludingDisposalGroups" xlink:to="lab_ci_PolicyholderContractDepositNoncurrentIncludingDisposalGroups" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_GoodwillIncludingDisposalGroups_b7b5f017-12cd-41e3-adf1-38d25e6c5ad7_periodStartLabel_en-US" xlink:label="lab_ci_GoodwillIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at January 1, including held for sale assets</link:label>
    <link:label id="lab_ci_GoodwillIncludingDisposalGroups_ce1095f0-dd94-42e4-98c8-7f24c9e235b7_periodEndLabel_en-US" xlink:label="lab_ci_GoodwillIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31, including held for sale assets</link:label>
    <link:label id="lab_ci_GoodwillIncludingDisposalGroups_label_en-US" xlink:label="lab_ci_GoodwillIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Including Disposal Groups</link:label>
    <link:label id="lab_ci_GoodwillIncludingDisposalGroups_documentation_en-US" xlink:label="lab_ci_GoodwillIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Including Disposal Groups</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_GoodwillIncludingDisposalGroups" xlink:href="ci-20231231.xsd#ci_GoodwillIncludingDisposalGroups"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_GoodwillIncludingDisposalGroups" xlink:to="lab_ci_GoodwillIncludingDisposalGroups" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_IntangibleAssetsValueOfBusinessAcquiredAbstract_6a8ccdb3-8888-4668-86e3-16873b17259c_terseLabel_en-US" xlink:label="lab_ci_IntangibleAssetsValueOfBusinessAcquiredAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of business acquired ("VOBA" reported in Other assets)</link:label>
    <link:label id="lab_ci_IntangibleAssetsValueOfBusinessAcquiredAbstract_label_en-US" xlink:label="lab_ci_IntangibleAssetsValueOfBusinessAcquiredAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Value Of Business Acquired [Abstract]</link:label>
    <link:label id="lab_ci_IntangibleAssetsValueOfBusinessAcquiredAbstract_documentation_en-US" xlink:label="lab_ci_IntangibleAssetsValueOfBusinessAcquiredAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Value Of Business Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsValueOfBusinessAcquiredAbstract" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsValueOfBusinessAcquiredAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_IntangibleAssetsValueOfBusinessAcquiredAbstract" xlink:to="lab_ci_IntangibleAssetsValueOfBusinessAcquiredAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_a25296c5-7120-4cf7-bcde-b346bbcdb574_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bd017118-c4a5-4724-9ca3-51dfd9820abb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_a24198a2-91bc-460c-a1b4-d8179be34bcb_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to redeemable noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Redeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_8f97ea49-4aa7-4a60-849b-143279617fd7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation_7f8dc971-bed8-4f70-ac69-8d1a16dff6cd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded in divestiture</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Divestiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDivestituresBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_d18ec904-ba82-491b-a115-6fdbbfade82f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsAbstract_b4b2f949-4dd5-4a39-93d5-1ff1e1e622fa_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract" xlink:to="lab_us-gaap_ShortTermInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DeferredTaxAssetsOperatingLossCarryforwardsIncludingDisposalGroupsAssetsHeldForSale_699e5ff2-68a1-4992-8092-f3227ac02951_terseLabel_en-US" xlink:label="lab_ci_DeferredTaxAssetsOperatingLossCarryforwardsIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss carryforwards</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsOperatingLossCarryforwardsIncludingDisposalGroupsAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DeferredTaxAssetsOperatingLossCarryforwardsIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Including Disposal Groups Assets Held For Sale</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsOperatingLossCarryforwardsIncludingDisposalGroupsAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DeferredTaxAssetsOperatingLossCarryforwardsIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Including Disposal Groups Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsOperatingLossCarryforwardsIncludingDisposalGroupsAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsOperatingLossCarryforwardsIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DeferredTaxAssetsOperatingLossCarryforwardsIncludingDisposalGroupsAssetsHeldForSale" xlink:to="lab_ci_DeferredTaxAssetsOperatingLossCarryforwardsIncludingDisposalGroupsAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_c1cea678-c3ef-433f-877c-a4576ebd7b13_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_57c9c68e-54b7-4409-af21-3a6bbb943bbe_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), before reclassifications, tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss) before Reclassifications, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_e1d1d6d3-e55e-48eb-95f2-007e1165936f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteedInsuranceContractTypeOfBenefitDomain_be04d6dd-512a-42c3-9c0f-8faefbbc207b_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteedInsuranceContractTypeOfBenefitDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guaranteed Insurance Contract, Type of Benefit [Domain]</link:label>
    <link:label id="lab_us-gaap_GuaranteedInsuranceContractTypeOfBenefitDomain_label_en-US" xlink:label="lab_us-gaap_GuaranteedInsuranceContractTypeOfBenefitDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guaranteed Insurance Contract, Type of Benefit [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteedInsuranceContractTypeOfBenefitDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteedInsuranceContractTypeOfBenefitDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteedInsuranceContractTypeOfBenefitDomain" xlink:to="lab_us-gaap_GuaranteedInsuranceContractTypeOfBenefitDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTaxStatusAxis_08d608e7-cde2-4f7b-a470-787ee7f4fb9e_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTaxStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Tax Status [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTaxStatusAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTaxStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Tax Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTaxStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis" xlink:to="lab_us-gaap_RetirementPlanTaxStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PricingConcessionsThroughRemainingContractTermMember_ec38f99b-6ca6-4383-9f4c-5fe2bd445e62_terseLabel_en-US" xlink:label="lab_ci_PricingConcessionsThroughRemainingContractTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pricing Concessions Through Remaining Contract Term</link:label>
    <link:label id="lab_ci_PricingConcessionsThroughRemainingContractTermMember_label_en-US" xlink:label="lab_ci_PricingConcessionsThroughRemainingContractTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pricing Concessions Through Remaining Contract Term [Member]</link:label>
    <link:label id="lab_ci_PricingConcessionsThroughRemainingContractTermMember_documentation_en-US" xlink:label="lab_ci_PricingConcessionsThroughRemainingContractTermMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pricing concessions sought in litigation for remainder of contract term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PricingConcessionsThroughRemainingContractTermMember" xlink:href="ci-20231231.xsd#ci_PricingConcessionsThroughRemainingContractTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PricingConcessionsThroughRemainingContractTermMember" xlink:to="lab_ci_PricingConcessionsThroughRemainingContractTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesGainLossOnSaleOfBusinessParentMember_d5c27924-b8f3-4580-a18f-b8f6a6cbfcbe_terseLabel_en-US" xlink:label="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesGainLossOnSaleOfBusinessParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-For-Sale And Derivatives, (Gain) Loss On Sale Of Business, Parent</link:label>
    <link:label id="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesGainLossOnSaleOfBusinessParentMember_label_en-US" xlink:label="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesGainLossOnSaleOfBusinessParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-For-Sale And Derivatives, (Gain) Loss On Sale Of Business, Parent [Member]</link:label>
    <link:label id="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesGainLossOnSaleOfBusinessParentMember_documentation_en-US" xlink:label="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesGainLossOnSaleOfBusinessParentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-For-Sale And Derivatives, (Gain) Loss On Sale Of Business, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesGainLossOnSaleOfBusinessParentMember" xlink:href="ci-20231231.xsd#ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesGainLossOnSaleOfBusinessParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesGainLossOnSaleOfBusinessParentMember" xlink:to="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesGainLossOnSaleOfBusinessParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage_82ced612-9b04-46aa-87f0-fc097c2696d2_terseLabel_en-US" xlink:label="lab_ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractholder deposit funds not reinsured externally, percent with guaranteed interest rates of 0300 to 0400</link:label>
    <link:label id="lab_ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage_label_en-US" xlink:label="lab_ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Percentage</link:label>
    <link:label id="lab_ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage_documentation_en-US" xlink:label="lab_ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of policyholder account balance representing contract with guaranteed interest rates of 3%-4%.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage" xlink:href="ci-20231231.xsd#ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage" xlink:to="lab_ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_06610fe5-85e2-4f8d-82e7-ac8f2e82cfe7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_80aed053-ab06-4289-a9ef-4b50fc72c3b8_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Insurance and Contractholder Liabilities, Activity in the Unpaid Claims Liability and Liability Details for Unpaid Claims and Claim Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfOriginalGrantAwardedAtEndOfPerformancePeriod_93816bce-7e4f-4e9b-9a33-a64ea42486e0_terseLabel_en-US" xlink:label="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfOriginalGrantAwardedAtEndOfPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of original shares granted that may be awarded at end of performance period</link:label>
    <link:label id="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfOriginalGrantAwardedAtEndOfPerformancePeriod_label_en-US" xlink:label="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfOriginalGrantAwardedAtEndOfPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Percent Of Original Grant Awarded At End Of Performance Period</link:label>
    <link:label id="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfOriginalGrantAwardedAtEndOfPerformancePeriod_documentation_en-US" xlink:label="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfOriginalGrantAwardedAtEndOfPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percent of the original grant amount that holders of strategic performance shares will be awarded in shares of the Company's common stock at the end of the performance period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfOriginalGrantAwardedAtEndOfPerformancePeriod" xlink:href="ci-20231231.xsd#ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfOriginalGrantAwardedAtEndOfPerformancePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfOriginalGrantAwardedAtEndOfPerformancePeriod" xlink:to="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfOriginalGrantAwardedAtEndOfPerformancePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceTextBlock_c5555cf4-fa7e-4d57-8497-40c6405b7c35_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance</link:label>
    <link:label id="lab_us-gaap_ReinsuranceTextBlock_label_en-US" xlink:label="lab_us-gaap_ReinsuranceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceTextBlock" xlink:to="lab_us-gaap_ReinsuranceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_d77e3353-65f7-4c63-afcd-d01aff464cdd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent_01edfb4c-fa51-4006-ba0a-875213504f4a_terseLabel_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid claims and claim expenses, non-current</link:label>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent_label_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Claims And Claims Adjustment Expense, Noncurrent</link:label>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent_documentation_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Claims And Claims Adjustment Expense, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent" xlink:to="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesByIndustryAxis_f96537da-aaae-4b49-8af4-545dff93f3ed_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesByIndustryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Industry Sector [Axis]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesByIndustryAxis_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesByIndustryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Industry Sector [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesByIndustryAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesByIndustryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis" xlink:to="lab_us-gaap_EquitySecuritiesByIndustryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_c8911a05-7e93-47b4-a147-e5fefa97f187_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities of Business Held for Sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_a76f9acc-866b-424e-95ce-34e698c01ccf_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_4fc9ee36-b3e7-4b95-bc8f-24f2fee93573_terseLabel_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mergers, Acquisitions and Divestitures</link:label>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGains_3f32f737-47fd-4d01-99e7-203ddc28ca3d_terseLabel_en-US" xlink:label="lab_ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGains" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized appreciation on investments and foreign currency translation</link:label>
    <link:label id="lab_ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGains_label_en-US" xlink:label="lab_ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGains" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities Unrealized Gains On Investments And Unrealized Currency Transaction Gains</link:label>
    <link:label id="lab_ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGains_documentation_en-US" xlink:label="lab_ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGains" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on investments and foreign currency translation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGains" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGains"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGains" xlink:to="lab_ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGains" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_df1900a9-a91a-420f-bfd8-24e599f1cdd8_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements_113cb497-8fb5-4e85-b0d7-240fcfd113e7_totalLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total purchases, sales and settlements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_ebe30c6d-0650-43c6-9e49-a7a759a49acd_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_4d12f2a1-3b9f-4b4b-b237-7be20ee2c90a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualProvision_65e5ac7f-3311-42e0-9bd1-89db5d0128f3_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualProvision" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency accrual provision</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualProvision_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualProvision" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualProvision" xlink:to="lab_us-gaap_LossContingencyAccrualProvision" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax_c758d1b6-f923-482f-9d9a-ef4efaf72fbd_negatedTerseLabel_en-US" xlink:label="lab_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk corridors recovery (Selling, general and administrative expenses)</link:label>
    <link:label id="lab_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax_label_en-US" xlink:label="lab_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Item, Gain (Loss) On Risk Corridor Allowance Adjustment, Net Of Tax</link:label>
    <link:label id="lab_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax_documentation_en-US" xlink:label="lab_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Item, Gain (Loss) On Risk Corridor Allowance Adjustment, Net Of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax" xlink:href="ci-20231231.xsd#ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax" xlink:to="lab_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_73043e4b-5989-4fc8-a806-59ce297d6560_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers into Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_db096e15-b7cb-4545-a859-c8f166330eb7_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_faab2205-1072-4749-a34c-7d9f2e03c3b0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_b0fae76a-ca02-4e1d-b089-48d0a21888b0_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Claims Development [Table]</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Claims Development [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_34700124-e648-477d-a50c-d11510724957_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_58a24c67-cdeb-4841-99f8-8f7dccee04b8_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior years</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_637f450c-d7f4-498e-a8f9-6ef77c827d7b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Favorable (unfavorable) variance, amount</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_2ae64ecb-f037-4fce-acd8-57dbe364b26b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_b7317d41-9170-4e01-9c50-aa38332d155c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_cf553388-d22b-4b1e-a636-f35c232ee4ef_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill classified as Assets of businesses held for sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_c87d37cb-0843-4dc5-9590-76e184fcf707_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EquitySecuritiesFvNiCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_34b848d3-c192-4309-b629-330018d3338e_terseLabel_en-US" xlink:label="lab_ci_EquitySecuritiesFvNiCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities with readily determinable fair values, including held for sale assets</link:label>
    <link:label id="lab_ci_EquitySecuritiesFvNiCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_EquitySecuritiesFvNiCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Fv Ni Cost Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_EquitySecuritiesFvNiCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_EquitySecuritiesFvNiCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Fv Ni Cost Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFvNiCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesFvNiCostBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EquitySecuritiesFvNiCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_EquitySecuritiesFvNiCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteeObligationsLineItems_575f8fd1-a662-469d-9dd6-0d7da405b604_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor Obligations [Line Items]</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsLineItems_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor Obligations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems" xlink:to="lab_us-gaap_GuaranteeObligationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitOther_fff953b9-17e4-4a09-b77e-0f450e8c3789_terseLabel_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitOther_label_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefit, Other</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitOther_documentation_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefit, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitOther" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForFuturePolicyBenefitOther" xlink:to="lab_ci_LiabilityForFuturePolicyBenefitOther" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember_4d719ce3-af47-4bd5-89fc-817384852e2b_terseLabel_en-US" xlink:label="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A- equivalent and higher current ratings</link:label>
    <link:label id="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember_label_en-US" xlink:label="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nationally Recognized Statisical Rating Organizations (NRSRO), A- Or Higher [Member]</link:label>
    <link:label id="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember_documentation_en-US" xlink:label="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nationally Recognized Statisical Rating Organizations (NRSRO), A- Or Higher</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember" xlink:href="ci-20231231.xsd#ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember" xlink:to="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AssetBackedAndCorporateSecuritiesMember_2cc1687e-2e0a-41de-8f54-693ed09d83cc_terseLabel_en-US" xlink:label="lab_ci_AssetBackedAndCorporateSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed and corporate securities</link:label>
    <link:label id="lab_ci_AssetBackedAndCorporateSecuritiesMember_label_en-US" xlink:label="lab_ci_AssetBackedAndCorporateSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Backed And Corporate Securities [Member]</link:label>
    <link:label id="lab_ci_AssetBackedAndCorporateSecuritiesMember_documentation_en-US" xlink:label="lab_ci_AssetBackedAndCorporateSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Backed And Corporate Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AssetBackedAndCorporateSecuritiesMember" xlink:href="ci-20231231.xsd#ci_AssetBackedAndCorporateSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AssetBackedAndCorporateSecuritiesMember" xlink:to="lab_ci_AssetBackedAndCorporateSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefits_f3a7f1f2-f926-487a-a8a5-65fc26a57076_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefits" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liability for future policy benefits</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefits_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefit, before Reinsurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefits" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_46eebc53-e6a4-42d0-b17b-a2a729cd258a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Line Items]</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate_e81a94c7-8c0c-424c-b9ab-ed5e432ffe61_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average crediting rate</link:label>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate_label_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Account Balance, Weighted Average Crediting Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate" xlink:to="lab_us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_caca97ce-5037-492a-8b67-0b32a0af3dcc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net translation gains (losses) of foreign currencies</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_7b5bf5ec-33cc-416f-903b-3f0e24b26d62_negatedTerseLabel_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Credit Loss, including held for sale assets</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available For Sale, Allowance For Credit Loss, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available For Sale, Allowance For Credit Loss, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5f8a9504-9be8-4907-a26a-5123ffd8ba0e_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHAREHOLDERS' NET INCOME</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9d681b59-14c3-42ff-bdf1-7c4e42239c1c_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase to shareholders' net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_bf3d1d75-9433-4e20-811e-0dba085b3a96_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ce672343-bd14-4c32-ae5d-fbd26eebf316_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_RealizedInvestmentGainLossExcludingImpairments_c97e92dc-1741-4f2c-b55a-e4d0df1da4fb_verboseLabel_en-US" xlink:label="lab_ci_RealizedInvestmentGainLossExcludingImpairments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net realized investment (losses) gains, excluding credit loss expense and asset write-downs</link:label>
    <link:label id="lab_ci_RealizedInvestmentGainLossExcludingImpairments_label_en-US" xlink:label="lab_ci_RealizedInvestmentGainLossExcludingImpairments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gain Loss Excluding Impairments</link:label>
    <link:label id="lab_ci_RealizedInvestmentGainLossExcludingImpairments_documentation_en-US" xlink:label="lab_ci_RealizedInvestmentGainLossExcludingImpairments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net realized gains or (losses) on investments during the period before impairments, including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RealizedInvestmentGainLossExcludingImpairments" xlink:href="ci-20231231.xsd#ci_RealizedInvestmentGainLossExcludingImpairments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_RealizedInvestmentGainLossExcludingImpairments" xlink:to="lab_ci_RealizedInvestmentGainLossExcludingImpairments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_cea11dae-2689-4694-be06-4822c4f42b53_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_53d66b7e-2c27-46d8-81c5-9d865bc1d427_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_95267981-1941-4587-bfc3-69207e236b3f_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale price</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ScheduleOfCommonStockByClassScheduleOfPreferredStockByClassTextBlock_a6bde057-ec04-42c6-9397-99b95f68492c_terseLabel_en-US" xlink:label="lab_ci_ScheduleOfCommonStockByClassScheduleOfPreferredStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common and Preferred Stock</link:label>
    <link:label id="lab_ci_ScheduleOfCommonStockByClassScheduleOfPreferredStockByClassTextBlock_label_en-US" xlink:label="lab_ci_ScheduleOfCommonStockByClassScheduleOfPreferredStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Common Stock By Class Schedule Of Preferred Stock By Class [Text Block]</link:label>
    <link:label id="lab_ci_ScheduleOfCommonStockByClassScheduleOfPreferredStockByClassTextBlock_documentation_en-US" xlink:label="lab_ci_ScheduleOfCommonStockByClassScheduleOfPreferredStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element may be used to capture the complete disclosure pertaining to an entity's common stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation. B Preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued and outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ScheduleOfCommonStockByClassScheduleOfPreferredStockByClassTextBlock" xlink:href="ci-20231231.xsd#ci_ScheduleOfCommonStockByClassScheduleOfPreferredStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ScheduleOfCommonStockByClassScheduleOfPreferredStockByClassTextBlock" xlink:to="lab_ci_ScheduleOfCommonStockByClassScheduleOfPreferredStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract_b50978f8-b41a-43fe-98fd-ba52a06cf465_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e0e52cf2-868a-4c14-9ea6-75293f16020a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees_9342d835-e5c8-43bf-a96d-9a525153f253_terseLabel_en-US" xlink:label="lab_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds</link:label>
    <link:label id="lab_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees_label_en-US" xlink:label="lab_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Long-term Debt, Net Of Discounts And Underwriting Fees</link:label>
    <link:label id="lab_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees_documentation_en-US" xlink:label="lab_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Long-term Debt, Net Of Discounts And Underwriting Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees" xlink:href="ci-20231231.xsd#ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees" xlink:to="lab_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_f79315df-5917-49f9-ba6c-3d9c3371990f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefits recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bb5dc317-6319-4e4a-846a-75efeed40f34_terseLabel_en-US" xlink:label="lab_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax adjusted income (loss) from operations</link:label>
    <link:label id="lab_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="ci-20231231.xsd#ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale_c5377f13-e4a3-4888-a723-7bff73543914_totalLabel_en-US" xlink:label="lab_ci_IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, including held for sale assets</link:label>
    <link:label id="lab_ci_IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale_label_en-US" xlink:label="lab_ci_IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Gross Excluding Goodwill, Including Disposal Groups Assets Held For Sale</link:label>
    <link:label id="lab_ci_IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Gross Excluding Goodwill, Including Disposal Groups Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale" xlink:to="lab_ci_IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesSellingGeneralAdministrativeExpenseParentMember_6f71f99f-a277-4dcc-937d-002ba0157b86_terseLabel_en-US" xlink:label="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesSellingGeneralAdministrativeExpenseParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustment for (gains) included in Shareholders' net income (Selling, general and administrative expenses)</link:label>
    <link:label id="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesSellingGeneralAdministrativeExpenseParentMember_label_en-US" xlink:label="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesSellingGeneralAdministrativeExpenseParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-For-Sale And Derivatives, Selling General Administrative Expense, Parent [Member]</link:label>
    <link:label id="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesSellingGeneralAdministrativeExpenseParentMember_documentation_en-US" xlink:label="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesSellingGeneralAdministrativeExpenseParentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-For-Sale And Derivatives, Selling General Administrative Expense, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesSellingGeneralAdministrativeExpenseParentMember" xlink:href="ci-20231231.xsd#ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesSellingGeneralAdministrativeExpenseParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesSellingGeneralAdministrativeExpenseParentMember" xlink:to="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesSellingGeneralAdministrativeExpenseParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_def81804-e2e1-4e86-b2a6-0a14126ee5e2_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_cc419d60-d94f-4123-bb0d-1ac9d24a3738_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Credit Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitInterestExpenseAndOtherChanges_88be9c90-530e-4166-92bf-d2b58039a4f6_terseLabel_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitInterestExpenseAndOtherChanges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitInterestExpenseAndOtherChanges_label_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitInterestExpenseAndOtherChanges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefit, Expected Future Policy Benefit, Interest Expense And Other Changes</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitInterestExpenseAndOtherChanges_documentation_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitInterestExpenseAndOtherChanges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefit, Expected Future Policy Benefit, Interest Expense And Other Changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitInterestExpenseAndOtherChanges" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitInterestExpenseAndOtherChanges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitInterestExpenseAndOtherChanges" xlink:to="lab_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitInterestExpenseAndOtherChanges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_18d4cc9a-bf72-4ad0-a77d-4818626c1f12_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AccruedExpensesAndOtherLiabilities_025cc5be-d0f5-4f13-9b6b-a53c1cf6f494_terseLabel_en-US" xlink:label="lab_ci_AccruedExpensesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_ci_AccruedExpensesAndOtherLiabilities_label_en-US" xlink:label="lab_ci_AccruedExpensesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses And Other Liabilities</link:label>
    <link:label id="lab_ci_AccruedExpensesAndOtherLiabilities_documentation_en-US" xlink:label="lab_ci_AccruedExpensesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of other current liabilities and obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccruedExpensesAndOtherLiabilities" xlink:href="ci-20231231.xsd#ci_AccruedExpensesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AccruedExpensesAndOtherLiabilities" xlink:to="lab_ci_AccruedExpensesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_659e6571-807d-4872-901c-2ba540dc747f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance sheet location of non-current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_HomeDeliveryAndSpecialtyMember_17716d9e-5281-4e84-bd77-883152e6d239_terseLabel_en-US" xlink:label="lab_ci_HomeDeliveryAndSpecialtyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home delivery and specialty revenues</link:label>
    <link:label id="lab_ci_HomeDeliveryAndSpecialtyMember_label_en-US" xlink:label="lab_ci_HomeDeliveryAndSpecialtyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Delivery And Specialty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_HomeDeliveryAndSpecialtyMember" xlink:href="ci-20231231.xsd#ci_HomeDeliveryAndSpecialtyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_HomeDeliveryAndSpecialtyMember" xlink:to="lab_ci_HomeDeliveryAndSpecialtyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_6fe877e0-8c33-4373-bbe1-98522e5f8a7b_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_eb9b9c4c-4ce9-4d5b-a778-432273922770_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes (benefits)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_0f42b49c-d24c-49e0-88a5-754792debbb5_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash outflows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c20227ab-7211-4972-9edd-45a5906e1ed3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_0081c5df-5069-498a-9743-f1c10c2e781d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Finance Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_StepDownNotesDueJanuary2033Member_12057ac1-1c48-461c-83e5-f156b5073575_terseLabel_en-US" xlink:label="lab_ci_StepDownNotesDueJanuary2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$45&#160;million, 8.080% Step Down Notes due January 2033 (3)</link:label>
    <link:label id="lab_ci_StepDownNotesDueJanuary2033Member_label_en-US" xlink:label="lab_ci_StepDownNotesDueJanuary2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Step Down Notes Due January 2033 [Member]</link:label>
    <link:label id="lab_ci_StepDownNotesDueJanuary2033Member_documentation_en-US" xlink:label="lab_ci_StepDownNotesDueJanuary2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Step-down debt due in January 2033.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_StepDownNotesDueJanuary2033Member" xlink:href="ci-20231231.xsd#ci_StepDownNotesDueJanuary2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_StepDownNotesDueJanuary2033Member" xlink:to="lab_ci_StepDownNotesDueJanuary2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_0505b245-8377-4dd1-bc85-01cc03ed39a7_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock_fb3e942f-0d87-4e36-ad98-feac9854633c_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Incurred and Paid Claims Development, Claims Frequency Metrics and Incurred but Not Yet Reported Liabilities</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Claims Development [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_0e138830-e5bd-45ef-9a5d-97db291609ed_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember_f5cac9c4-505d-41a4-8e46-fad973654194_terseLabel_en-US" xlink:label="lab_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International life, accident, supplemental benefits businesses sold to Chubb</link:label>
    <link:label id="lab_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember_label_en-US" xlink:label="lab_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Life Accident Supplemental Benefits Businesses Excluding Turkey Joint Venture [Member]</link:label>
    <link:label id="lab_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember_documentation_en-US" xlink:label="lab_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sold life, accident and supplemental benefits businesses in Hong Kong, Indonesia, New Zealand, South Korea, Taiwan and Thailand.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember" xlink:href="ci-20231231.xsd#ci_InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember" xlink:to="lab_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsDomain_d47612e6-1bcd-4704-b201-dbde3ad0e19d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain" xlink:to="lab_us-gaap_SubsegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_781a8da3-9374-4333-ba56-83fc8a77bfc2_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-for-Sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Held-for-Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_76efaa16-d597-4547-996a-bed27e8f694b_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at January 1,</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_f42cac0a-3fe5-4751-b576-dfc1d02d2967_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31,</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_9491ab6a-3873-4463-88ea-3903c77a3a86_totalLabel_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, including assets held for sale</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_c6e343a7-12dd-4fab-9ae5-5d3bcc0e9148_terseLabel_en-US" xlink:label="lab_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Information Disclosure [Abstract]</link:label>
    <link:label id="lab_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_label_en-US" xlink:label="lab_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="lab_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitsIncludingDisposalGroups_da06ffb6-87a0-42cc-9674-d40292806574_totalLabel_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitsIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future policy benefits, including held for sale liabilities</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitsIncludingDisposalGroups_label_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitsIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefits Including Disposal Groups</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitsIncludingDisposalGroups_documentation_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitsIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefits Including Disposal Groups</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitsIncludingDisposalGroups" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitsIncludingDisposalGroups"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForFuturePolicyBenefitsIncludingDisposalGroups" xlink:to="lab_ci_LiabilityForFuturePolicyBenefitsIncludingDisposalGroups" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_5fa8435c-c8c4-4287-ba66-71091b478794_negatedLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other deductions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_ec5f2044-b523-4c02-b6aa-0512acf1dce0_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PremiumsWrittenNet_e585c162-55d6-439b-a478-b27396bb99d5_terseLabel_en-US" xlink:label="lab_us-gaap_PremiumsWrittenNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written premiums</link:label>
    <link:label id="lab_us-gaap_PremiumsWrittenNet_label_en-US" xlink:label="lab_us-gaap_PremiumsWrittenNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Written, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsWrittenNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PremiumsWrittenNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PremiumsWrittenNet" xlink:to="lab_us-gaap_PremiumsWrittenNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent_a5bb19ae-08c1-4c7a-89d9-513459832d99_verboseLabel_en-US" xlink:label="lab_ci_OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, including finance leases</link:label>
    <link:label id="lab_ci_OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent_label_en-US" xlink:label="lab_ci_OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Short-Term Debt, Current Maturities Of Long-Term Debt, And Lease Obligations, Current</link:label>
    <link:label id="lab_ci_OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent_documentation_en-US" xlink:label="lab_ci_OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Short-Term Debt, Current Maturities Of Long-Term Debt, And Lease Obligations, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent" xlink:href="ci-20231231.xsd#ci_OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent" xlink:to="lab_ci_OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_9e83ed32-0aeb-4b88-9a0b-5d3d86b8aef7_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_c80b1191-e463-452c-a44f-ff13e2ab3891_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_40761118-46a0-4bdb-9b1e-b5e2c9b00097_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled value plus interest and attorneys fees</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_914d0e40-146d-4357-bf9d-e303124bbe6b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy_95d6b325-7498-445f-90bc-91dcd863b048_terseLabel_en-US" xlink:label="lab_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid Claims and Claims Expenses</link:label>
    <link:label id="lab_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid Policy Claims and Claims Adjustment Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy" xlink:to="lab_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InsuranceCustomerReceivablesBeforeReclassificationToDisposalGroupAssetsHeldForSale_fd5fcc16-f652-4aac-9451-71c58feffe1e_terseLabel_en-US" xlink:label="lab_ci_InsuranceCustomerReceivablesBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance customer receivables, including held for sale assets</link:label>
    <link:label id="lab_ci_InsuranceCustomerReceivablesBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_InsuranceCustomerReceivablesBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Customer Receivables, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_InsuranceCustomerReceivablesBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_InsuranceCustomerReceivablesBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Customer Receivables, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceCustomerReceivablesBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_InsuranceCustomerReceivablesBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InsuranceCustomerReceivablesBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_InsuranceCustomerReceivablesBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_738ddbde-f3b7-415a-812a-204f35439d41_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_b5399e69-707b-40c9-a7e4-71908a4a5534_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LongTermDebtFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_f35e8090-7a11-4b7c-b58b-e5dabf5f3378_terseLabel_en-US" xlink:label="lab_ci_LongTermDebtFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, including current maturities, excluding finance leases, including assets held for sale</link:label>
    <link:label id="lab_ci_LongTermDebtFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_LongTermDebtFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fair Value, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_LongTermDebtFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_LongTermDebtFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fair Value, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LongTermDebtFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_LongTermDebtFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LongTermDebtFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_LongTermDebtFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_e9a66e7f-22e6-47bd-aab4-69693352ba35_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) gain on sale of businesses</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_4a598090-cbbc-45b3-8103-536634cf5732_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (gain) on sale of businesses</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:to="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_abeb79b5-0727-4146-9578-53b4cafbd590_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL SHAREHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AccountsReceivableUncommittedFactoringFacilityAmountSold_46af372c-020f-4314-8e61-b99212052634_terseLabel_en-US" xlink:label="lab_ci_AccountsReceivableUncommittedFactoringFacilityAmountSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable sold, uncommitted factoring facility</link:label>
    <link:label id="lab_ci_AccountsReceivableUncommittedFactoringFacilityAmountSold_label_en-US" xlink:label="lab_ci_AccountsReceivableUncommittedFactoringFacilityAmountSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Uncommitted Factoring Facility, Amount Sold</link:label>
    <link:label id="lab_ci_AccountsReceivableUncommittedFactoringFacilityAmountSold_documentation_en-US" xlink:label="lab_ci_AccountsReceivableUncommittedFactoringFacilityAmountSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of receivables sold to a financial institution under an uncommitted Accounts receivable factoring facility during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccountsReceivableUncommittedFactoringFacilityAmountSold" xlink:href="ci-20231231.xsd#ci_AccountsReceivableUncommittedFactoringFacilityAmountSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AccountsReceivableUncommittedFactoringFacilityAmountSold" xlink:to="lab_ci_AccountsReceivableUncommittedFactoringFacilityAmountSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bcd16452-c415-476b-9716-9e2fc1032261_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityNetIncome_6081cab2-6d61-4572-985f-ebac6536a094_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityNetIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityNetIncome_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityNetIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Net Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityNetIncome" xlink:to="lab_us-gaap_TemporaryEquityNetIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtAndEquitySecuritiesMember_d9c85371-9853-4114-bbed-f0e750718333_terseLabel_en-US" xlink:label="lab_ci_DebtAndEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Equity Securities</link:label>
    <link:label id="lab_ci_DebtAndEquitySecuritiesMember_label_en-US" xlink:label="lab_ci_DebtAndEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Equity Securities [Member]</link:label>
    <link:label id="lab_ci_DebtAndEquitySecuritiesMember_documentation_en-US" xlink:label="lab_ci_DebtAndEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal of debt and equity securities carried at fair value on the balance sheet.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtAndEquitySecuritiesMember" xlink:href="ci-20231231.xsd#ci_DebtAndEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtAndEquitySecuritiesMember" xlink:to="lab_ci_DebtAndEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1cad4c1f-3236-41fa-a754-30b1470f15eb_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected option life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_ad5bdfad-528e-4d1b-842f-5c3372a16605_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bd6b4a88-9c09-4f2f-b4b6-cee7ceeea24f_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTranslation_2eeaec78-5a87-4d40-a95b-f15f7cbf65eb_terseLabel_en-US" xlink:label="lab_ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized depreciation on investments and foreign currency translation</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTranslation_label_en-US" xlink:label="lab_ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Unrealized Losses On Investments And Foreign Currency Translation</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTranslation_documentation_en-US" xlink:label="lab_ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of deferred tax assets attributable to taxable temporary differences from unrealized losses on investments and foreign currency translation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTranslation" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTranslation" xlink:to="lab_ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicDistributionAxis_fc0d49b4-0ccc-452b-a88a-f5cf5144bb2e_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicDistributionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Distribution [Axis]</link:label>
    <link:label id="lab_us-gaap_GeographicDistributionAxis_label_en-US" xlink:label="lab_us-gaap_GeographicDistributionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Distribution [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicDistributionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicDistributionAxis" xlink:to="lab_us-gaap_GeographicDistributionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ec5bb4fe-e079-4402-a1b9-3bb08c522bbf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_7d847f11-0b7d-4aea-88f4-e7809f303c03_terseLabel_en-US" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local government</link:label>
    <link:label id="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_label_en-US" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US States and Political Subdivisions Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:to="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_4c4dd9f4-24c0-4ced-8999-95a81a8b8e74_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organizational Efficiency Plan</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentTable_69e7bab6-de68-4304-a86e-b4dc36a004a4_terseLabel_en-US" xlink:label="lab_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Table]</link:label>
    <link:label id="lab_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Table]</link:label>
    <link:label id="lab_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentTable_documentation_en-US" xlink:label="lab_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentTable" xlink:href="ci-20231231.xsd#ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentTable" xlink:to="lab_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_155350b8-d120-4f06-a81f-fcb0aafbfb5a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_1e8affb6-8a90-4ffb-9fb3-a5aa7329cb9b_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward_e5d29dbb-6b23-4390-b125-eb958df315f8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AllowanceForReceivablesCurrent_82c92445-b4fb-454f-b4ab-c6fef234c3d9_terseLabel_en-US" xlink:label="lab_ci_AllowanceForReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for receivables, current</link:label>
    <link:label id="lab_ci_AllowanceForReceivablesCurrent_label_en-US" xlink:label="lab_ci_AllowanceForReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Receivables Current</link:label>
    <link:label id="lab_ci_AllowanceForReceivablesCurrent_documentation_en-US" xlink:label="lab_ci_AllowanceForReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of allowance for receivables, classified as current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AllowanceForReceivablesCurrent" xlink:href="ci-20231231.xsd#ci_AllowanceForReceivablesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AllowanceForReceivablesCurrent" xlink:to="lab_ci_AllowanceForReceivablesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ThreeWhollyOwnedSubsidiariesMember_dc8f9f0d-3eb3-4dd3-9f7d-bb25eeaf798d_terseLabel_en-US" xlink:label="lab_ci_ThreeWhollyOwnedSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three wholly-owned subsidiaries</link:label>
    <link:label id="lab_ci_ThreeWhollyOwnedSubsidiariesMember_label_en-US" xlink:label="lab_ci_ThreeWhollyOwnedSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Wholly Owned Subsidiaries [Member]</link:label>
    <link:label id="lab_ci_ThreeWhollyOwnedSubsidiariesMember_documentation_en-US" xlink:label="lab_ci_ThreeWhollyOwnedSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Wholly Owned Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ThreeWhollyOwnedSubsidiariesMember" xlink:href="ci-20231231.xsd#ci_ThreeWhollyOwnedSubsidiariesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ThreeWhollyOwnedSubsidiariesMember" xlink:to="lab_ci_ThreeWhollyOwnedSubsidiariesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_ce22519d-ef05-47c4-9d1e-bc5a80922883_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_RevenuesFromExternalCustomersMember_d29ee941-df4a-4187-b314-75b80fe1f91e_terseLabel_en-US" xlink:label="lab_ci_RevenuesFromExternalCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from external customers</link:label>
    <link:label id="lab_ci_RevenuesFromExternalCustomersMember_label_en-US" xlink:label="lab_ci_RevenuesFromExternalCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues From External Customers [Member]</link:label>
    <link:label id="lab_ci_RevenuesFromExternalCustomersMember_documentation_en-US" xlink:label="lab_ci_RevenuesFromExternalCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues From External Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RevenuesFromExternalCustomersMember" xlink:href="ci-20231231.xsd#ci_RevenuesFromExternalCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_RevenuesFromExternalCustomersMember" xlink:to="lab_ci_RevenuesFromExternalCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_51130aec-71f8-4e6d-8b9f-72d99ad996b9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Total Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_3bf8df8b-0f48-4a74-9a85-e6390a35a3c5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EmployerInsuredMember_41aa2604-3312-4a0c-a726-da7184359372_terseLabel_en-US" xlink:label="lab_ci_EmployerInsuredMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer insured</link:label>
    <link:label id="lab_ci_EmployerInsuredMember_label_en-US" xlink:label="lab_ci_EmployerInsuredMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer Insured [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EmployerInsuredMember" xlink:href="ci-20231231.xsd#ci_EmployerInsuredMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EmployerInsuredMember" xlink:to="lab_ci_EmployerInsuredMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_f88dbff6-fb45-423e-80e9-8f39cdb56eb4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization period, other intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_2f503a25-3d87-4d91-89c5-e170dce2099e_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_869fea1b-3cbf-478f-9d87-19b9556100db_terseLabel_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_label_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Total [Abstract]</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_documentation_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract" xlink:to="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SingleForeignCountryMember_24ffffbc-7911-4713-9e3a-7782f4714529_terseLabel_en-US" xlink:label="lab_ci_SingleForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Single foreign country</link:label>
    <link:label id="lab_ci_SingleForeignCountryMember_label_en-US" xlink:label="lab_ci_SingleForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Single Foreign Country [Member]</link:label>
    <link:label id="lab_ci_SingleForeignCountryMember_documentation_en-US" xlink:label="lab_ci_SingleForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Single Foreign Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SingleForeignCountryMember" xlink:href="ci-20231231.xsd#ci_SingleForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SingleForeignCountryMember" xlink:to="lab_ci_SingleForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_991e5cd1-05db-449f-9009-0e161127cace_terseLabel_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, including held for sale assets</link:label>
    <link:label id="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_ea6ba05e-9ee8-4e65-bdcd-e5ff63b81a74_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderFunds_3573f039-9b96-4a59-b70f-3870855d0d34_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderFunds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractholder deposit funds not reinsured externally</link:label>
    <link:label id="lab_us-gaap_PolicyholderFunds_label_en-US" xlink:label="lab_us-gaap_PolicyholderFunds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Account Balance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderFunds" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderFunds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderFunds" xlink:to="lab_us-gaap_PolicyholderFunds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_eff01ee9-e21c-4a38-9a95-3d8476996361_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term length for operating leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DeferredTaxAssetsGrossInOtherAssetsNoncurrent_be5099c3-cd2c-4d12-a7fd-dad397a5b91e_terseLabel_en-US" xlink:label="lab_ci_DeferredTaxAssetsGrossInOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets reported in Other Assets</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsGrossInOtherAssetsNoncurrent_label_en-US" xlink:label="lab_ci_DeferredTaxAssetsGrossInOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Gross In Other Assets Noncurrent</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsGrossInOtherAssetsNoncurrent_documentation_en-US" xlink:label="lab_ci_DeferredTaxAssetsGrossInOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Gross reported in Other Assets Noncurrent on the Balance Sheet.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsGrossInOtherAssetsNoncurrent" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsGrossInOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DeferredTaxAssetsGrossInOtherAssetsNoncurrent" xlink:to="lab_ci_DeferredTaxAssetsGrossInOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1e92f053-f488-4925-80c1-d235e2c933e7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Information for Stock Options Exercised and Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1b44e3ea-76de-4843-94f2-64490c3db3fc_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_7fdf9059-c601-47ac-9292-f128ef7de70b_negatedLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common dividends declared</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DeferredTaxAssetsForeignTaxAttributes_9f2eae13-dce4-4ebf-b857-bf514040e944_verboseLabel_en-US" xlink:label="lab_ci_DeferredTaxAssetsForeignTaxAttributes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets associated with foreign tax attributes</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsForeignTaxAttributes_dd22dba5-b02a-4b5c-b43b-2e25646f8416_terseLabel_en-US" xlink:label="lab_ci_DeferredTaxAssetsForeignTaxAttributes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign tax attributes</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsForeignTaxAttributes_label_en-US" xlink:label="lab_ci_DeferredTaxAssetsForeignTaxAttributes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Foreign Tax Attributes</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsForeignTaxAttributes_documentation_en-US" xlink:label="lab_ci_DeferredTaxAssetsForeignTaxAttributes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Foreign Tax Attributes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsForeignTaxAttributes" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsForeignTaxAttributes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DeferredTaxAssetsForeignTaxAttributes" xlink:to="lab_ci_DeferredTaxAssetsForeignTaxAttributes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketRiskBenefitLiabilityAmount_d33f0c29-24ce-4302-be5c-a467d314157e_totalLabel_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitLiabilityAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market risk benefits</link:label>
    <link:label id="lab_us-gaap_MarketRiskBenefitLiabilityAmount_label_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitLiabilityAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Risk Benefit, Liability, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitLiabilityAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketRiskBenefitLiabilityAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketRiskBenefitLiabilityAmount" xlink:to="lab_us-gaap_MarketRiskBenefitLiabilityAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketRiskBenefitActivityTableTextBlock_67412225-7cb0-44ce-ac90-ddafc0960903_terseLabel_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Market Risk Benefit</link:label>
    <link:label id="lab_us-gaap_MarketRiskBenefitActivityTableTextBlock_d9c521d4-9748-4f9c-922e-9e8b5ff75195_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Recoverables for Variable Annuity Business</link:label>
    <link:label id="lab_us-gaap_MarketRiskBenefitActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Risk Benefit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketRiskBenefitActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketRiskBenefitActivityTableTextBlock" xlink:to="lab_us-gaap_MarketRiskBenefitActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_297f041d-9e93-4e55-b238-7531e0f842b2_terseLabel_en-US" xlink:label="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities with no readily determinable fair values including held for sale assets</link:label>
    <link:label id="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value, Amortized Cost, Before Reclassification To Disposal Group, Assets Held For Sale</link:label>
    <link:label id="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value, Amortized Cost, Before Reclassification To Disposal Group, Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_e6febb9e-33f6-45e5-80d8-81a7433d2d76_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance sheet location of operating lease ROU assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EmpowerAnnuityInsuranceCompanyMember_deb8b11f-2ffd-48e8-abad-a2bf81ba1ad2_terseLabel_en-US" xlink:label="lab_ci_EmpowerAnnuityInsuranceCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Empower Annuity Insurance Company</link:label>
    <link:label id="lab_ci_EmpowerAnnuityInsuranceCompanyMember_label_en-US" xlink:label="lab_ci_EmpowerAnnuityInsuranceCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Empower Annuity Insurance Company [Member]</link:label>
    <link:label id="lab_ci_EmpowerAnnuityInsuranceCompanyMember_documentation_en-US" xlink:label="lab_ci_EmpowerAnnuityInsuranceCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Empower Annuity Insurance Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EmpowerAnnuityInsuranceCompanyMember" xlink:href="ci-20231231.xsd#ci_EmpowerAnnuityInsuranceCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EmpowerAnnuityInsuranceCompanyMember" xlink:to="lab_ci_EmpowerAnnuityInsuranceCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_b9c3ebf0-556f-4b57-abaa-ae9e68bd1c5d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid, net of refunds</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIncludingDisposalGroupsAssetsHeldForSale_3fc811e1-1c17-4444-8d00-72b119876b0b_terseLabel_en-US" xlink:label="lab_ci_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee and retiree benefit plans</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIncludingDisposalGroupsAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Including Disposal Groups Assets Held For Sale</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIncludingDisposalGroupsAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Including Disposal Groups Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIncludingDisposalGroupsAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIncludingDisposalGroupsAssetsHeldForSale" xlink:to="lab_ci_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIncludingDisposalGroupsAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketRiskBenefitRollForward_feb2d287-f604-474c-8a86-0d9d4b2c7718_terseLabel_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Risk Benefit [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MarketRiskBenefitRollForward_label_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Risk Benefit [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketRiskBenefitRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketRiskBenefitRollForward" xlink:to="lab_us-gaap_MarketRiskBenefitRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_026b2e8d-9d21-44b8-8cd7-ee5ba6ad9a13_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Issues</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_643715b3-6beb-47b4-ae4f-1acc5c43c578_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Cost and Tax Effects of Share-based Compensation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_a1cb9c7b-3efb-41c7-b7d4-1fced58e83a2_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_499efd12-93f8-428a-a948-0fcab86fcfbc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_f5650317-0f89-4c7f-8110-8efee1ba8a79_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_RealizedInvestmentGainLoss_0138f599-5a18-432f-b627-f6cbf69136e6_terseLabel_en-US" xlink:label="lab_ci_RealizedInvestmentGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net realized investment (losses) gains</link:label>
    <link:label id="lab_ci_RealizedInvestmentGainLoss_7a9f0efd-3cc3-4dab-a889-e88383e5ed4e_negatedLabel_en-US" xlink:label="lab_ci_RealizedInvestmentGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized investment losses (gains), net</link:label>
    <link:label id="lab_ci_RealizedInvestmentGainLoss_1706e87e-6020-462d-95c3-f5c611b36750_totalLabel_en-US" xlink:label="lab_ci_RealizedInvestmentGainLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net realized investment (losses) gains, before income taxes</link:label>
    <link:label id="lab_ci_RealizedInvestmentGainLoss_label_en-US" xlink:label="lab_ci_RealizedInvestmentGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gain Loss</link:label>
    <link:label id="lab_ci_RealizedInvestmentGainLoss_documentation_en-US" xlink:label="lab_ci_RealizedInvestmentGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net realized gains or (losses) on investments during the period, including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RealizedInvestmentGainLoss" xlink:href="ci-20231231.xsd#ci_RealizedInvestmentGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_RealizedInvestmentGainLoss" xlink:to="lab_ci_RealizedInvestmentGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_814ef1ec-c1be-4c8d-86dd-ac2d61fc06c8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_88672a93-9893-4d26-8c6c-973c82d25fd6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketRiskBenefitIncreaseDecreaseFromOtherAssumption_628e83dd-9a0b-4c7f-9a24-4db62c08bf5e_terseLabel_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitIncreaseDecreaseFromOtherAssumption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumption changes</link:label>
    <link:label id="lab_us-gaap_MarketRiskBenefitIncreaseDecreaseFromOtherAssumption_label_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitIncreaseDecreaseFromOtherAssumption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Risk Benefit, Increase (Decrease) from Other Assumption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitIncreaseDecreaseFromOtherAssumption" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketRiskBenefitIncreaseDecreaseFromOtherAssumption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketRiskBenefitIncreaseDecreaseFromOtherAssumption" xlink:to="lab_us-gaap_MarketRiskBenefitIncreaseDecreaseFromOtherAssumption" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LtvGreaterThan100PercentMember_110aebb2-705f-4b6a-8f33-47f51d338ef8_terseLabel_en-US" xlink:label="lab_ci_LtvGreaterThan100PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Greater than 100%</link:label>
    <link:label id="lab_ci_LtvGreaterThan100PercentMember_label_en-US" xlink:label="lab_ci_LtvGreaterThan100PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ltv Greater Than 100 Percent [Member]</link:label>
    <link:label id="lab_ci_LtvGreaterThan100PercentMember_documentation_en-US" xlink:label="lab_ci_LtvGreaterThan100PercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt-to-value ratio greater than 100 percent. Element name an standard label in DTV [numeric lower end] to [numeric higher end] Percent [Member] format.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LtvGreaterThan100PercentMember" xlink:href="ci-20231231.xsd#ci_LtvGreaterThan100PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LtvGreaterThan100PercentMember" xlink:to="lab_ci_LtvGreaterThan100PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_390f0c09-4232-446b-859e-3b1e3d0eeb31_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance sheet location of current finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_a209335e-fefd-4a04-b197-f29eafde6168_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReinsuranceRecoverable_1eae8001-179f-4cd5-91f2-7d788dfec2a4_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReinsuranceRecoverable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance recoverable and Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReinsuranceRecoverable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReinsuranceRecoverable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Reinsurance Recoverable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReinsuranceRecoverable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInReinsuranceRecoverable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReinsuranceRecoverable" xlink:to="lab_us-gaap_IncreaseDecreaseInReinsuranceRecoverable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInvestmentExpense_8ed3a3b1-265b-47f8-85ff-51327d3e2d39_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInvestmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less investment expenses</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInvestmentExpense_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInvestmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Investment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInvestmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInvestmentExpense" xlink:to="lab_us-gaap_InvestmentIncomeInvestmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_72a09d9e-c837-451e-b061-2c7d94065c8a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_e8368d89-f567-4f07-83dc-59ef83339b88_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summarized Segment Financial Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DefinedBenefitPlanMarketRelatedValueOfPensionPlanAssets_198e0f5a-93d8-442d-92e3-0dfe37cabed1_terseLabel_en-US" xlink:label="lab_ci_DefinedBenefitPlanMarketRelatedValueOfPensionPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market-related valuation of pension plan assets</link:label>
    <link:label id="lab_ci_DefinedBenefitPlanMarketRelatedValueOfPensionPlanAssets_label_en-US" xlink:label="lab_ci_DefinedBenefitPlanMarketRelatedValueOfPensionPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Market Related Value Of Pension Plan Assets</link:label>
    <link:label id="lab_ci_DefinedBenefitPlanMarketRelatedValueOfPensionPlanAssets_documentation_en-US" xlink:label="lab_ci_DefinedBenefitPlanMarketRelatedValueOfPensionPlanAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The market-related value of plan assets, used to measure pension costs, which differs from the actual fair value for domestic pension plan assets invested in non-fixed income investments. The 'market-related' value recognizes the difference between actual and expected long-term returns in the portfolio over five years, a method that reduces the short-term impact of market fluctuations on pension costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DefinedBenefitPlanMarketRelatedValueOfPensionPlanAssets" xlink:href="ci-20231231.xsd#ci_DefinedBenefitPlanMarketRelatedValueOfPensionPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DefinedBenefitPlanMarketRelatedValueOfPensionPlanAssets" xlink:to="lab_ci_DefinedBenefitPlanMarketRelatedValueOfPensionPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_1079dcdc-8a06-4a5c-be32-5ba96ec416cf_totalLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge for organizational efficiency plan recorded in Selling, general and administrative expenses, pre-tax</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_62d9c556-d304-4e21-a5e0-97b427707ade_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge for organizational efficiency plan (Selling, general and administrative expenses)</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_49cf5706-dc1b-4716-b656-74ce59d7cddc_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge for organizational efficiency plan</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DisposalGroupsIncludingDiscontinuedOperationsAssetsHeldByInsuranceRegulators_fc11d9e6-e1b6-48d3-8326-fb1c519bbfac_terseLabel_en-US" xlink:label="lab_ci_DisposalGroupsIncludingDiscontinuedOperationsAssetsHeldByInsuranceRegulators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments on deposit with regulatory bodies, disposal groups</link:label>
    <link:label id="lab_ci_DisposalGroupsIncludingDiscontinuedOperationsAssetsHeldByInsuranceRegulators_label_en-US" xlink:label="lab_ci_DisposalGroupsIncludingDiscontinuedOperationsAssetsHeldByInsuranceRegulators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Assets Held by Insurance Regulators</link:label>
    <link:label id="lab_ci_DisposalGroupsIncludingDiscontinuedOperationsAssetsHeldByInsuranceRegulators_documentation_en-US" xlink:label="lab_ci_DisposalGroupsIncludingDiscontinuedOperationsAssetsHeldByInsuranceRegulators" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Assets Held by Insurance Regulators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupsIncludingDiscontinuedOperationsAssetsHeldByInsuranceRegulators" xlink:href="ci-20231231.xsd#ci_DisposalGroupsIncludingDiscontinuedOperationsAssetsHeldByInsuranceRegulators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DisposalGroupsIncludingDiscontinuedOperationsAssetsHeldByInsuranceRegulators" xlink:to="lab_ci_DisposalGroupsIncludingDiscontinuedOperationsAssetsHeldByInsuranceRegulators" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_0504aed6-2e76-4293-b9e5-4b9171bb78f9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_IncomeTaxDisclosureTable_c8e5f532-ca1e-4aae-bc43-c3a3a871f875_terseLabel_en-US" xlink:label="lab_ci_IncomeTaxDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Table]</link:label>
    <link:label id="lab_ci_IncomeTaxDisclosureTable_label_en-US" xlink:label="lab_ci_IncomeTaxDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Table]</link:label>
    <link:label id="lab_ci_IncomeTaxDisclosureTable_documentation_en-US" xlink:label="lab_ci_IncomeTaxDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncomeTaxDisclosureTable" xlink:href="ci-20231231.xsd#ci_IncomeTaxDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_IncomeTaxDisclosureTable" xlink:to="lab_ci_IncomeTaxDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateFairValueIncludingMonteCarloFactor_45e429ff-e2cb-47f0-9e33-c1901fc1736c_terseLabel_en-US" xlink:label="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateFairValueIncludingMonteCarloFactor" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value per share for expense purposes, including the Monte Carlo Factor</link:label>
    <link:label id="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateFairValueIncludingMonteCarloFactor_label_en-US" xlink:label="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateFairValueIncludingMonteCarloFactor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Granted, Weighted Average Grant Date Fair Value Including Monte Carlo Factor</link:label>
    <link:label id="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateFairValueIncludingMonteCarloFactor_documentation_en-US" xlink:label="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateFairValueIncludingMonteCarloFactor" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Granted, Weighted Average Grant Date Fair Value Including Monte Carlo Factor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateFairValueIncludingMonteCarloFactor" xlink:href="ci-20231231.xsd#ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateFairValueIncludingMonteCarloFactor"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateFairValueIncludingMonteCarloFactor" xlink:to="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateFairValueIncludingMonteCarloFactor" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LineOfCreditFacilityConversionToTermLoanTerm_706274f5-a9c6-4fd7-bf47-488794f4d115_terseLabel_en-US" xlink:label="lab_ci_LineOfCreditFacilityConversionToTermLoanTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility, conversion to term loan, term</link:label>
    <link:label id="lab_ci_LineOfCreditFacilityConversionToTermLoanTerm_label_en-US" xlink:label="lab_ci_LineOfCreditFacilityConversionToTermLoanTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Conversion To Term Loan, Term</link:label>
    <link:label id="lab_ci_LineOfCreditFacilityConversionToTermLoanTerm_documentation_en-US" xlink:label="lab_ci_LineOfCreditFacilityConversionToTermLoanTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Conversion To Term Loan, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LineOfCreditFacilityConversionToTermLoanTerm" xlink:href="ci-20231231.xsd#ci_LineOfCreditFacilityConversionToTermLoanTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LineOfCreditFacilityConversionToTermLoanTerm" xlink:to="lab_ci_LineOfCreditFacilityConversionToTermLoanTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_f25d36c4-4dc3-4084-9527-778144c5d3e9_totalLabel_en-US" xlink:label="lab_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments including held for sale assets</link:label>
    <link:label id="lab_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Investments Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Investments Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_510fcc47-7530-4c44-9ad4-afece587c9c5_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Appreciation</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_058a6ccf-3ea2-4293-9d98-300dd828d322_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NotesDue204849InterestMember_199744c9-c025-4906-ad0b-695e23e5fe50_terseLabel_en-US" xlink:label="lab_ci_NotesDue204849InterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$3,000&#160;million, 4.900% Notes due December 2048</link:label>
    <link:label id="lab_ci_NotesDue204849InterestMember_label_en-US" xlink:label="lab_ci_NotesDue204849InterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2048, 4.9% Interest [Member]</link:label>
    <link:label id="lab_ci_NotesDue204849InterestMember_documentation_en-US" xlink:label="lab_ci_NotesDue204849InterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior notes payable bearing interest at 4.9% due in 2048. Debt issued to finance acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue204849InterestMember" xlink:href="ci-20231231.xsd#ci_NotesDue204849InterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NotesDue204849InterestMember" xlink:to="lab_ci_NotesDue204849InterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ScheduleOfShortTermDebtLongTermDebtTableTextBlock_77d30d63-6a51-4bad-9de3-b3225955ef2a_terseLabel_en-US" xlink:label="lab_ci_ScheduleOfShortTermDebtLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Amounts of Debt and Finance Leases</link:label>
    <link:label id="lab_ci_ScheduleOfShortTermDebtLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_ci_ScheduleOfShortTermDebtLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Short Term Debt Long Term Debt [Table Text Block]</link:label>
    <link:label id="lab_ci_ScheduleOfShortTermDebtLongTermDebtTableTextBlock_documentation_en-US" xlink:label="lab_ci_ScheduleOfShortTermDebtLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance-sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation. Also, Pertinent information about each long-term debt arrangement including the carrying amount as of the balance sheet date, by type of long-term debt. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ScheduleOfShortTermDebtLongTermDebtTableTextBlock" xlink:href="ci-20231231.xsd#ci_ScheduleOfShortTermDebtLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ScheduleOfShortTermDebtLongTermDebtTableTextBlock" xlink:to="lab_ci_ScheduleOfShortTermDebtLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_1513ca8c-c437-4e49-86f6-5ca06965f383_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCostIncludingDisposalGroupsAssetsHeldForSale_ebbf43e1-0f23-4a33-a40a-7922ac160e00_terseLabel_en-US" xlink:label="lab_ci_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCostIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policy acquisition expenses</link:label>
    <link:label id="lab_ci_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCostIncludingDisposalGroupsAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCostIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense, Deferred Policy Acquisition Cost, Including Disposal Groups Assets Held For Sale</link:label>
    <link:label id="lab_ci_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCostIncludingDisposalGroupsAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCostIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense, Deferred Policy Acquisition Cost, Including Disposal Groups Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCostIncludingDisposalGroupsAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCostIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCostIncludingDisposalGroupsAssetsHeldForSale" xlink:to="lab_ci_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCostIncludingDisposalGroupsAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_92181dc0-215d-4359-bdf1-acd5df5acb84_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments by category and current or long-term classification</link:label>
    <link:label id="lab_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Holdings, Schedule of Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock" xlink:to="lab_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax_89bd715b-3a22-40b0-b823-061122b6a07e_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustment, tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_7f5917cd-5108-4d88-ba28-c67b737bf867_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FinancingReceivableCreditQualityLoanToValueRatio_c5093450-01ef-4808-9fdd-d86d7fe5b921_terseLabel_en-US" xlink:label="lab_ci_FinancingReceivableCreditQualityLoanToValueRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Loan-to-Value Ratio</link:label>
    <link:label id="lab_ci_FinancingReceivableCreditQualityLoanToValueRatio_label_en-US" xlink:label="lab_ci_FinancingReceivableCreditQualityLoanToValueRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable Credit Quality Loan To Value Ratio</link:label>
    <link:label id="lab_ci_FinancingReceivableCreditQualityLoanToValueRatio_documentation_en-US" xlink:label="lab_ci_FinancingReceivableCreditQualityLoanToValueRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable Credit Quality Loan To Value Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FinancingReceivableCreditQualityLoanToValueRatio" xlink:href="ci-20231231.xsd#ci_FinancingReceivableCreditQualityLoanToValueRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FinancingReceivableCreditQualityLoanToValueRatio" xlink:to="lab_ci_FinancingReceivableCreditQualityLoanToValueRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_MaximumPercentLevel2InvestmentsForeignBondsBrokerQuoteBeforeReclassificationToDisposalGroupAssetsHeldForSale_512959e7-58c1-4a28-980d-8bf6347d6a8b_terseLabel_en-US" xlink:label="lab_ci_MaximumPercentLevel2InvestmentsForeignBondsBrokerQuoteBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of investments classified in Level 2 representing foreign bonds priced using unadjusted broker quotes</link:label>
    <link:label id="lab_ci_MaximumPercentLevel2InvestmentsForeignBondsBrokerQuoteBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_MaximumPercentLevel2InvestmentsForeignBondsBrokerQuoteBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Percent Level2 Investments Foreign Bonds Broker Quote Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_MaximumPercentLevel2InvestmentsForeignBondsBrokerQuoteBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_MaximumPercentLevel2InvestmentsForeignBondsBrokerQuoteBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Percent Level2 Investments Foreign Bonds Broker Quote Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MaximumPercentLevel2InvestmentsForeignBondsBrokerQuoteBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_MaximumPercentLevel2InvestmentsForeignBondsBrokerQuoteBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_MaximumPercentLevel2InvestmentsForeignBondsBrokerQuoteBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_MaximumPercentLevel2InvestmentsForeignBondsBrokerQuoteBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_f734e1a2-26bb-4359-bfdc-84780deddc29_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss_d6bfa31c-a6d9-4bd2-a1de-65ee11ec4a48_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value, before allowance for credit loss</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Excluding Accrued Interest, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:to="lab_us-gaap_FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_03ce5878-8ea3-4cc3-9119-9082f717b23f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_c1233d52-e3db-4d1f-9237-0ef5baecff46_totalLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total short-term debt</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_5459e1d9-a741-422d-9302-94d2c484803c_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_824925b7-4f4c-4539-84b3-2a02af6cc336_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WithdrawalFromContractHoldersFunds_a1f7b89e-6dd1-41a7-b47d-3c75a9f0c9c9_negatedLabel_en-US" xlink:label="lab_us-gaap_WithdrawalFromContractHoldersFunds" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Withdrawals and benefit payments from contractholder deposit funds</link:label>
    <link:label id="lab_us-gaap_WithdrawalFromContractHoldersFunds_label_en-US" xlink:label="lab_us-gaap_WithdrawalFromContractHoldersFunds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Withdrawal from Contract Holders Funds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WithdrawalFromContractHoldersFunds" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WithdrawalFromContractHoldersFunds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WithdrawalFromContractHoldersFunds" xlink:to="lab_us-gaap_WithdrawalFromContractHoldersFunds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7c2e9d31-50a5-46cb-8ff0-afadd6666af8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_364d07e2-8e3a-4fdb-b8f2-4f455ead201d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_9542c843-4a44-4f03-bb0c-7021b782d9b7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of The Cigna Group common stock distributed upon SPS vesting (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReinsurerMember_debe9585-5cb6-427d-b149-51ecffba5f33_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReinsurerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherReinsurerMember_label_en-US" xlink:label="lab_us-gaap_OtherReinsurerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurer, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReinsurerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReinsurerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReinsurerMember" xlink:to="lab_us-gaap_OtherReinsurerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_MarketRiskBenefitLiabilityAmountCurrent_63eb350d-be70-496a-a635-a74309b93335_terseLabel_en-US" xlink:label="lab_ci_MarketRiskBenefitLiabilityAmountCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market risk benefits, current</link:label>
    <link:label id="lab_ci_MarketRiskBenefitLiabilityAmountCurrent_label_en-US" xlink:label="lab_ci_MarketRiskBenefitLiabilityAmountCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Risk Benefit, Liability, Amount, Current</link:label>
    <link:label id="lab_ci_MarketRiskBenefitLiabilityAmountCurrent_documentation_en-US" xlink:label="lab_ci_MarketRiskBenefitLiabilityAmountCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Risk Benefit, Liability, Amount, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitLiabilityAmountCurrent" xlink:href="ci-20231231.xsd#ci_MarketRiskBenefitLiabilityAmountCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_MarketRiskBenefitLiabilityAmountCurrent" xlink:to="lab_ci_MarketRiskBenefitLiabilityAmountCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtAndEquitySecuritiesClassifiedInLevel2PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale_b805caf0-232b-468b-8e06-55b535518fbf_terseLabel_en-US" xlink:label="lab_ci_DebtAndEquitySecuritiesClassifiedInLevel2PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of debt and equity securities classified in Level 2, including assets held for sale</link:label>
    <link:label id="lab_ci_DebtAndEquitySecuritiesClassifiedInLevel2PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DebtAndEquitySecuritiesClassifiedInLevel2PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt And Equity Securities Classified In Level2 Percentage Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_DebtAndEquitySecuritiesClassifiedInLevel2PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DebtAndEquitySecuritiesClassifiedInLevel2PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt And Equity Securities Classified In Level2 Percentage Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtAndEquitySecuritiesClassifiedInLevel2PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DebtAndEquitySecuritiesClassifiedInLevel2PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtAndEquitySecuritiesClassifiedInLevel2PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_DebtAndEquitySecuritiesClassifiedInLevel2PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate_cff4fa74-40b2-429d-ae17-37e34172777d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest accretion rate</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefit, Weighted-Average Interest Accretion Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_6dba0b6a-494d-4120-adba-361408cd0168_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_999cada4-9765-44f7-a348-1f680813e624_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fe2fb085-5295-46e4-a10c-48d907a773c6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_00b22f62-2204-486b-a912-71b4646de5af_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_0c137b36-acc5-4475-b103-77c2656c1c63_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups_f4442fbb-867d-4961-8d9d-2cfbd315c86f_terseLabel_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future policy benefits classified as liabilities of business held for sale</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups_label_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefits Attributable To Disposal Groups</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups_documentation_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefits Attributable To Disposal Groups</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups" xlink:to="lab_ci_LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_4eaf21ed-392f-47af-8714-5150aed61788_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_e347d738-5f5d-4f2a-8900-6843204db6a8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FinanceLeaseLeaseCostAbstract_198ce87e-e646-4ec7-ad3e-b576f25f651c_terseLabel_en-US" xlink:label="lab_ci_FinanceLeaseLeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease cost:</link:label>
    <link:label id="lab_ci_FinanceLeaseLeaseCostAbstract_label_en-US" xlink:label="lab_ci_FinanceLeaseLeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Lease Cost [Abstract]</link:label>
    <link:label id="lab_ci_FinanceLeaseLeaseCostAbstract_documentation_en-US" xlink:label="lab_ci_FinanceLeaseLeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Lease Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FinanceLeaseLeaseCostAbstract" xlink:href="ci-20231231.xsd#ci_FinanceLeaseLeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FinanceLeaseLeaseCostAbstract" xlink:to="lab_ci_FinanceLeaseLeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_122d1d3c-96ff-4248-9022-1d2b789ceccb_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total compensation cost for shared-based awards</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EffectiveIncomeTaxRateReconciliationHealthInsuranceIndustryTax_820c677c-1e95-4512-8ed8-f4e820d3c74c_terseLabel_en-US" xlink:label="lab_ci_EffectiveIncomeTaxRateReconciliationHealthInsuranceIndustryTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health insurance industry tax</link:label>
    <link:label id="lab_ci_EffectiveIncomeTaxRateReconciliationHealthInsuranceIndustryTax_label_en-US" xlink:label="lab_ci_EffectiveIncomeTaxRateReconciliationHealthInsuranceIndustryTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Health Insurance Industry Tax</link:label>
    <link:label id="lab_ci_EffectiveIncomeTaxRateReconciliationHealthInsuranceIndustryTax_documentation_en-US" xlink:label="lab_ci_EffectiveIncomeTaxRateReconciliationHealthInsuranceIndustryTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) due to the non-deductibility for federal income tax purposes of the health insurance industry tax assessed under Health Care Reform.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EffectiveIncomeTaxRateReconciliationHealthInsuranceIndustryTax" xlink:href="ci-20231231.xsd#ci_EffectiveIncomeTaxRateReconciliationHealthInsuranceIndustryTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EffectiveIncomeTaxRateReconciliationHealthInsuranceIndustryTax" xlink:to="lab_ci_EffectiveIncomeTaxRateReconciliationHealthInsuranceIndustryTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociLiabilityForFuturePolicyBenefitParentMember_c0b93c28-ab33-477d-9e7d-8e689c4fe0cc_terseLabel_en-US" xlink:label="lab_us-gaap_AociLiabilityForFuturePolicyBenefitParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period change in discount rate for certain long-duration liabilities</link:label>
    <link:label id="lab_us-gaap_AociLiabilityForFuturePolicyBenefitParentMember_label_en-US" xlink:label="lab_us-gaap_AociLiabilityForFuturePolicyBenefitParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Liability for Future Policy Benefit, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLiabilityForFuturePolicyBenefitParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociLiabilityForFuturePolicyBenefitParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociLiabilityForFuturePolicyBenefitParentMember" xlink:to="lab_us-gaap_AociLiabilityForFuturePolicyBenefitParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_dfcbd7c7-f684-4146-9603-4cddffb208a1_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoanToValueAxis_97b3d9ea-3aa1-4dfa-8d34-22cb6d289a5b_terseLabel_en-US" xlink:label="lab_us-gaap_LoanToValueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt-to-Value [Axis]</link:label>
    <link:label id="lab_us-gaap_LoanToValueAxis_label_en-US" xlink:label="lab_us-gaap_LoanToValueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt-to-Value [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoanToValueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoanToValueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoanToValueAxis" xlink:to="lab_us-gaap_LoanToValueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SeparateAccountAssetsMember_e60f615a-fddf-4a5c-a25f-d5b5ddde1277_terseLabel_en-US" xlink:label="lab_ci_SeparateAccountAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate Account Assets</link:label>
    <link:label id="lab_ci_SeparateAccountAssetsMember_label_en-US" xlink:label="lab_ci_SeparateAccountAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate Account Assets [Member]</link:label>
    <link:label id="lab_ci_SeparateAccountAssetsMember_documentation_en-US" xlink:label="lab_ci_SeparateAccountAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A separate investment account established and maintained by an insurance entity under relevant state insurance law to which funds have been allocated for certain contracts of the insurance entity. Funds in a separate account are not commingled with other assets of the insurance entity for investment purposes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SeparateAccountAssetsMember" xlink:href="ci-20231231.xsd#ci_SeparateAccountAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SeparateAccountAssetsMember" xlink:to="lab_ci_SeparateAccountAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e7967cfc-fabe-4123-8b32-5b00a26bb655_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_0c382d20-6896-49e0-abfd-ee8555d5c824_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_1d16b306-57ff-4209-b3b2-31f8dbf9e156_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CignaHealthcareMember_4268358a-2a2e-4ced-ab56-92de9e17cd38_terseLabel_en-US" xlink:label="lab_ci_CignaHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cigna Healthcare</link:label>
    <link:label id="lab_ci_CignaHealthcareMember_label_en-US" xlink:label="lab_ci_CignaHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cigna Healthcare [Member]</link:label>
    <link:label id="lab_ci_CignaHealthcareMember_documentation_en-US" xlink:label="lab_ci_CignaHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cigna Healthcare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember" xlink:href="ci-20231231.xsd#ci_CignaHealthcareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CignaHealthcareMember" xlink:to="lab_ci_CignaHealthcareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities_67397d5c-5800-413c-9dbf-dd97ae1e89da_terseLabel_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance and contractholder liabilities</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities_b43724c4-3d9b-447c-b982-e1cc0857bc23_negatedTotalLabel_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance and contractholder liabilities classified as held for sale</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities_label_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group,Including Discontinued Operation, Insurance And Contractholder Liabilities</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities_documentation_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group,Including Discontinued Operation, Insurance And Contractholder Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities" xlink:to="lab_ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_786f572e-6759-4dd1-9a71-139c4c14e37d_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_657d8fcc-f591-4e49-860a-14f008013d17_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk_81347edf-358c-4e40-b880-b48f853d448e_periodStartLabel_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of year</link:label>
    <link:label id="lab_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk_26f245f8-341b-4aaf-80c7-508c8842f8e9_periodEndLabel_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of period</link:label>
    <link:label id="lab_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk_label_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Risk Benefit, after Increase (Decrease) from Instrument-Specific Credit Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk" xlink:to="lab_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_37ad8239-87ee-41d7-8711-3601c50b56c1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance sheet location of non-current finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_b958484f-2015-4b0b-9fdc-77432aed965d_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_24e8a9ee-30b1-4a86-b9ff-29ae2232e9db_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost_76e7086a-bbfc-4e06-912b-4f7546ee6de9_totalLabel_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost_label_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Less Than 12 Months, Amortized Cost</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost_documentation_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Less Than 12 Months, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost" xlink:to="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_6fe2eca2-b879-4ca2-8990-9b7d0a13f249_negatedTotalLabel_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Unrealized Depreciation, including held for sale assets</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Unrealized Loss Position, Accumulated Loss, Before Reclassification To Disposal Group, Assets Held-For-Sale</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Unrealized Loss Position, Accumulated Loss, Before Reclassification To Disposal Group, Assets Held-For-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue_12177c38-2768-441d-b4ac-3d854b22cb0b_terseLabel_en-US" xlink:label="lab_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income</link:label>
    <link:label id="lab_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue_label_en-US" xlink:label="lab_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest And Dividend Income Operating And Operating Leases Income Statement Lease Revenue</link:label>
    <link:label id="lab_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue_documentation_en-US" xlink:label="lab_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein. Also includes the total amount of revenue recognized for the period from operating leases, including minimum lease revenue, contingent revenue, percentage revenue and sublease revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" xlink:href="ci-20231231.xsd#ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" xlink:to="lab_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OtherHealthcareMember_6e62a1f6-7c6c-4a31-b41e-956d6c54e1f6_terseLabel_en-US" xlink:label="lab_ci_OtherHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ci_OtherHealthcareMember_label_en-US" xlink:label="lab_ci_OtherHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Healthcare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherHealthcareMember" xlink:href="ci-20231231.xsd#ci_OtherHealthcareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OtherHealthcareMember" xlink:to="lab_ci_OtherHealthcareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain_4e8cad59-4ee7-4ba1-8591-d946b866994e_terseLabel_en-US" xlink:label="lab_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Rating, Nationally Recognized Statistical Rating Organization (NRSRO) [Domain]</link:label>
    <link:label id="lab_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain_label_en-US" xlink:label="lab_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Rating, Nationally Recognized Statistical Rating Organization (NRSRO) [Domain]</link:label>
    <link:label id="lab_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain_documentation_en-US" xlink:label="lab_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Rating, Nationally Recognized Statistical Rating Organization (NRSRO)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain" xlink:href="ci-20231231.xsd#ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain" xlink:to="lab_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AdministrativeServicesOnlyHealthCareServicesMember_6a68d56f-42fb-49d3-8176-0e72a4e9274f_terseLabel_en-US" xlink:label="lab_ci_AdministrativeServicesOnlyHealthCareServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Services Only Health Care Services</link:label>
    <link:label id="lab_ci_AdministrativeServicesOnlyHealthCareServicesMember_label_en-US" xlink:label="lab_ci_AdministrativeServicesOnlyHealthCareServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Services Only Health Care Services [Member]</link:label>
    <link:label id="lab_ci_AdministrativeServicesOnlyHealthCareServicesMember_documentation_en-US" xlink:label="lab_ci_AdministrativeServicesOnlyHealthCareServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Services Only Health Care Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AdministrativeServicesOnlyHealthCareServicesMember" xlink:href="ci-20231231.xsd#ci_AdministrativeServicesOnlyHealthCareServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AdministrativeServicesOnlyHealthCareServicesMember" xlink:to="lab_ci_AdministrativeServicesOnlyHealthCareServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity_d6090dbe-70e7-4435-a46d-17f39addb2da_terseLabel_en-US" xlink:label="lab_ci_LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum total commitment</link:label>
    <link:label id="lab_ci_LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity_label_en-US" xlink:label="lab_ci_LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Maximum Borrowing Capacity And Accordion Feature, Incremental Increase In Maximum Borrowing Capacity</link:label>
    <link:label id="lab_ci_LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity_documentation_en-US" xlink:label="lab_ci_LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Maximum Borrowing Capacity And Accordion Feature, Incremental Increase In Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity" xlink:href="ci-20231231.xsd#ci_LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity" xlink:to="lab_ci_LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_StatutoryAccountingPracticesAmountPermittedLendingAuthorityOfLifeInsuranceSubsidiaryToParent_161131fc-1559-4649-8b4d-cd588d58a176_terseLabel_en-US" xlink:label="lab_ci_StatutoryAccountingPracticesAmountPermittedLendingAuthorityOfLifeInsuranceSubsidiaryToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum loans to the parent company permitted without regulatory approval</link:label>
    <link:label id="lab_ci_StatutoryAccountingPracticesAmountPermittedLendingAuthorityOfLifeInsuranceSubsidiaryToParent_label_en-US" xlink:label="lab_ci_StatutoryAccountingPracticesAmountPermittedLendingAuthorityOfLifeInsuranceSubsidiaryToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Accounting Practices Amount Permitted Lending Authority Of Life Insurance Subsidiary To Parent</link:label>
    <link:label id="lab_ci_StatutoryAccountingPracticesAmountPermittedLendingAuthorityOfLifeInsuranceSubsidiaryToParent_documentation_en-US" xlink:label="lab_ci_StatutoryAccountingPracticesAmountPermittedLendingAuthorityOfLifeInsuranceSubsidiaryToParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum permitted amount certain of the Company's life insurance subsidiaries may loan to the parent company without prior approval from the state's Department of Insurance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_StatutoryAccountingPracticesAmountPermittedLendingAuthorityOfLifeInsuranceSubsidiaryToParent" xlink:href="ci-20231231.xsd#ci_StatutoryAccountingPracticesAmountPermittedLendingAuthorityOfLifeInsuranceSubsidiaryToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_StatutoryAccountingPracticesAmountPermittedLendingAuthorityOfLifeInsuranceSubsidiaryToParent" xlink:to="lab_ci_StatutoryAccountingPracticesAmountPermittedLendingAuthorityOfLifeInsuranceSubsidiaryToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfIssuancesOfLongTermDebtTableTextBlock_f6cfe092-9b24-4ff6-a204-a89cf02183b3_terseLabel_en-US" xlink:label="lab_ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfIssuancesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Debt Issuances</link:label>
    <link:label id="lab_ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfIssuancesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfIssuancesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Information Of Parent Company Only, Schedule Of Issuances Of Long-Term Debt [Table Text Block]</link:label>
    <link:label id="lab_ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfIssuancesOfLongTermDebtTableTextBlock_documentation_en-US" xlink:label="lab_ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfIssuancesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Information Of Parent Company Only, Schedule Of Issuances Of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfIssuancesOfLongTermDebtTableTextBlock" xlink:href="ci-20231231.xsd#ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfIssuancesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfIssuancesOfLongTermDebtTableTextBlock" xlink:to="lab_ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfIssuancesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CededPremiumsEarned_50baadca-4627-43fc-aa90-3b7dc581922e_negatedLabel_en-US" xlink:label="lab_us-gaap_CededPremiumsEarned" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded</link:label>
    <link:label id="lab_us-gaap_CededPremiumsEarned_label_en-US" xlink:label="lab_us-gaap_CededPremiumsEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded Premiums Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededPremiumsEarned" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededPremiumsEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CededPremiumsEarned" xlink:to="lab_us-gaap_CededPremiumsEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_TemporaryEquityOtherComprehensiveIncome_435a153f-055b-4841-ad8f-23b05b88ed9b_verboseLabel_en-US" xlink:label="lab_ci_TemporaryEquityOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss attributable to redeemable noncontrolling interests</link:label>
    <link:label id="lab_ci_TemporaryEquityOtherComprehensiveIncome_cdbe4aab-dafa-469c-90ad-f71216c7a02b_netLabel_en-US" xlink:label="lab_ci_TemporaryEquityOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_ci_TemporaryEquityOtherComprehensiveIncome_b92858b5-86dd-4a96-8754-99674e33fe0a_terseLabel_en-US" xlink:label="lab_ci_TemporaryEquityOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net translation (loss) on foreign currencies attributable to noncontrolling interests</link:label>
    <link:label id="lab_ci_TemporaryEquityOtherComprehensiveIncome_label_en-US" xlink:label="lab_ci_TemporaryEquityOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Other Comprehensive Income</link:label>
    <link:label id="lab_ci_TemporaryEquityOtherComprehensiveIncome_documentation_en-US" xlink:label="lab_ci_TemporaryEquityOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The portion of other comprehensive income or(loss) attributable to temporary equity interest.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TemporaryEquityOtherComprehensiveIncome" xlink:href="ci-20231231.xsd#ci_TemporaryEquityOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_TemporaryEquityOtherComprehensiveIncome" xlink:to="lab_ci_TemporaryEquityOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_2fee3408-78a2-49b4-aba3-6abac6af4812_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash outflows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectsOfReinsuranceTableTextBlock_ec0ea1d0-160f-4aaf-80d1-bf0b86156050_terseLabel_en-US" xlink:label="lab_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of Reinsurance</link:label>
    <link:label id="lab_us-gaap_EffectsOfReinsuranceTableTextBlock_label_en-US" xlink:label="lab_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of Reinsurance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectsOfReinsuranceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:to="lab_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_68504955-b8af-4551-aeb5-cf6884052b20_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of sale of businesses</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Business, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationDispositionOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:to="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ScheduleOfDepreciationAndAmortizationTable_6a9dead5-dd12-4ac8-9b4e-16b35fa042f4_terseLabel_en-US" xlink:label="lab_ci_ScheduleOfDepreciationAndAmortizationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Depreciation And Amortization [Table]</link:label>
    <link:label id="lab_ci_ScheduleOfDepreciationAndAmortizationTable_label_en-US" xlink:label="lab_ci_ScheduleOfDepreciationAndAmortizationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Depreciation And Amortization [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ScheduleOfDepreciationAndAmortizationTable" xlink:href="ci-20231231.xsd#ci_ScheduleOfDepreciationAndAmortizationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ScheduleOfDepreciationAndAmortizationTable" xlink:to="lab_ci_ScheduleOfDepreciationAndAmortizationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cfa2a08a-036c-48ed-acf7-5661636a0de9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_3575c765-af3f-4d78-ba31-4ec106ae5eaa_terseLabel_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_label_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain" xlink:to="lab_us-gaap_PlanAssetCategoriesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_MedicalCostTrendMember_a2ceff9a-76cd-4d80-a087-a2042e11c91c_terseLabel_en-US" xlink:label="lab_ci_MedicalCostTrendMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical cost trend</link:label>
    <link:label id="lab_ci_MedicalCostTrendMember_label_en-US" xlink:label="lab_ci_MedicalCostTrendMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Cost Trend [Member]</link:label>
    <link:label id="lab_ci_MedicalCostTrendMember_documentation_en-US" xlink:label="lab_ci_MedicalCostTrendMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts relating to actual claims emerging differently from assumptions about the level of claims per member used to set reserves.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicalCostTrendMember" xlink:href="ci-20231231.xsd#ci_MedicalCostTrendMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_MedicalCostTrendMember" xlink:to="lab_ci_MedicalCostTrendMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups_757241e2-8e88-49fa-b5d8-afa6983ff238_totalLabel_en-US" xlink:label="lab_ci_IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Value, including held for sale assets</link:label>
    <link:label id="lab_ci_IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups_label_en-US" xlink:label="lab_ci_IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Net Excluding Goodwill Including VOBA Including Disposal Groups</link:label>
    <link:label id="lab_ci_IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups_documentation_en-US" xlink:label="lab_ci_IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Net Excluding Goodwill Including VOBA Including Disposal Groups</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups" xlink:to="lab_ci_IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAdditionalDisclosuresAbstract_afcbdb69-b7e7-406c-82c8-ea7519b3ecdf_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts associated with businesses held for sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecurities_6ae07955-654c-4c10-a55a-0c00576a9182_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_label_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecurities" xlink:to="lab_us-gaap_MarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UsTreasuryUstInterestRateMember_c69d2a6a-062e-489c-a52f-d27edd369a37_terseLabel_en-US" xlink:label="lab_us-gaap_UsTreasuryUstInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury rate</link:label>
    <link:label id="lab_us-gaap_UsTreasuryUstInterestRateMember_label_en-US" xlink:label="lab_us-gaap_UsTreasuryUstInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury (UST) Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UsTreasuryUstInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UsTreasuryUstInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UsTreasuryUstInterestRateMember" xlink:to="lab_us-gaap_UsTreasuryUstInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_29079f50-bd0b-42ec-b104-2873de01df2a_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities with readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationValueOfBusinessAcquired_be7d2e28-9114-4c70-9423-173279a03924_terseLabel_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationValueOfBusinessAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VOBA, held for sale</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationValueOfBusinessAcquired_label_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationValueOfBusinessAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Value Of Business Acquired</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationValueOfBusinessAcquired_documentation_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationValueOfBusinessAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Value Of Business Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationValueOfBusinessAcquired" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationValueOfBusinessAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DisposalGroupIncludingDiscontinuedOperationValueOfBusinessAcquired" xlink:to="lab_ci_DisposalGroupIncludingDiscontinuedOperationValueOfBusinessAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthcareSectorMember_a57e9642-1a90-4536-9825-ebc09d714831_terseLabel_en-US" xlink:label="lab_us-gaap_HealthcareSectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Sector</link:label>
    <link:label id="lab_us-gaap_HealthcareSectorMember_label_en-US" xlink:label="lab_us-gaap_HealthcareSectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Sector [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthcareSectorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthcareSectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthcareSectorMember" xlink:to="lab_us-gaap_HealthcareSectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermInvestmentsMember_8c061e0a-2fae-4413-a2a3-c35c049cc858_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term investments</link:label>
    <link:label id="lab_us-gaap_OtherLongTermInvestmentsMember_a1c0c6b8-75d4-4e28-a584-7347a932e2a0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term investments</link:label>
    <link:label id="lab_us-gaap_OtherLongTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-Term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermInvestmentsMember" xlink:to="lab_us-gaap_OtherLongTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumInterestIncomeAndOtherChanges_6c9b5efe-2d5a-4f95-ad51-c0d9ac7e051f_terseLabel_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumInterestIncomeAndOtherChanges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumInterestIncomeAndOtherChanges_label_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumInterestIncomeAndOtherChanges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefit, Expected Net Premium, Interest Income And Other Changes</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumInterestIncomeAndOtherChanges_documentation_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumInterestIncomeAndOtherChanges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefit, Expected Net Premium, Interest Income And Other Changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumInterestIncomeAndOtherChanges" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumInterestIncomeAndOtherChanges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumInterestIncomeAndOtherChanges" xlink:to="lab_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumInterestIncomeAndOtherChanges" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_bae53300-6153-4516-9604-527cb7de6788_terseLabel_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset-backed securities, including assets held for sale</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Amortized Cost, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Amortized Cost, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_fcad5eff-e39a-43af-9618-540bf71ca027_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_662ebca2-1d16-4327-9619-bef848690cf5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FinanceLeaseCost_fb68e392-ede9-4819-84d1-2edf570033ca_totalLabel_en-US" xlink:label="lab_ci_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total finance lease cost</link:label>
    <link:label id="lab_ci_FinanceLeaseCost_label_en-US" xlink:label="lab_ci_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Cost</link:label>
    <link:label id="lab_ci_FinanceLeaseCost_documentation_en-US" xlink:label="lab_ci_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost associated with finance lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FinanceLeaseCost" xlink:href="ci-20231231.xsd#ci_FinanceLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FinanceLeaseCost" xlink:to="lab_ci_FinanceLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitsCurrentIncludingDisposalGroups_39b80258-1e48-4d64-ab5d-7208531c66fa_terseLabel_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitsCurrentIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future policy benefits, current, including held for sale liabilities</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitsCurrentIncludingDisposalGroups_label_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitsCurrentIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefits Current Including Disposal Groups</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitsCurrentIncludingDisposalGroups_documentation_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitsCurrentIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of accrued obligation to policyholders that relates to insured events for long-duration contracts, expected to be paid within one year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitsCurrentIncludingDisposalGroups" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitsCurrentIncludingDisposalGroups"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForFuturePolicyBenefitsCurrentIncludingDisposalGroups" xlink:to="lab_ci_LiabilityForFuturePolicyBenefitsCurrentIncludingDisposalGroups" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_StockholdersEquityAndDividendRestrictionsTextBlock_bf935f02-b080-48cc-800d-68f3a3e80a5a_terseLabel_en-US" xlink:label="lab_ci_StockholdersEquityAndDividendRestrictionsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity And Dividend Restrictions</link:label>
    <link:label id="lab_ci_StockholdersEquityAndDividendRestrictionsTextBlock_label_en-US" xlink:label="lab_ci_StockholdersEquityAndDividendRestrictionsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Equity And Dividend Restrictions [Text Block]</link:label>
    <link:label id="lab_ci_StockholdersEquityAndDividendRestrictionsTextBlock_documentation_en-US" xlink:label="lab_ci_StockholdersEquityAndDividendRestrictionsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Footnote describing statutory requirements by various states for shareholders' equity and dividend restrictions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_StockholdersEquityAndDividendRestrictionsTextBlock" xlink:href="ci-20231231.xsd#ci_StockholdersEquityAndDividendRestrictionsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_StockholdersEquityAndDividendRestrictionsTextBlock" xlink:to="lab_ci_StockholdersEquityAndDividendRestrictionsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_RealizedInvestmentGainsLossesEquityMethodInvestments_59185e41-cd4b-47d3-8a25-1e019e98278d_negatedLabel_en-US" xlink:label="lab_ci_RealizedInvestmentGainsLossesEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net realized investment results from certain equity method investments</link:label>
    <link:label id="lab_ci_RealizedInvestmentGainsLossesEquityMethodInvestments_label_en-US" xlink:label="lab_ci_RealizedInvestmentGainsLossesEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains Losses Equity Method Investments</link:label>
    <link:label id="lab_ci_RealizedInvestmentGainsLossesEquityMethodInvestments_documentation_en-US" xlink:label="lab_ci_RealizedInvestmentGainsLossesEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to exclude net realized gains (losses) from equity method subsidiaries (recorded in Other revenues) from Operating revenues.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RealizedInvestmentGainsLossesEquityMethodInvestments" xlink:href="ci-20231231.xsd#ci_RealizedInvestmentGainsLossesEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_RealizedInvestmentGainsLossesEquityMethodInvestments" xlink:to="lab_ci_RealizedInvestmentGainsLossesEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_UnobservableInputsNotDevelopedByCompanyMember_c22a1f62-c37c-4eb8-9fd3-e5a929843217_terseLabel_en-US" xlink:label="lab_ci_UnobservableInputsNotDevelopedByCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Not Priced by the Company</link:label>
    <link:label id="lab_ci_UnobservableInputsNotDevelopedByCompanyMember_label_en-US" xlink:label="lab_ci_UnobservableInputsNotDevelopedByCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unobservable Inputs Not Developed By Company [Member]</link:label>
    <link:label id="lab_ci_UnobservableInputsNotDevelopedByCompanyMember_documentation_en-US" xlink:label="lab_ci_UnobservableInputsNotDevelopedByCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant unobservable inputs used in pricing Level 3 securities that were not developed directly by the Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnobservableInputsNotDevelopedByCompanyMember" xlink:href="ci-20231231.xsd#ci_UnobservableInputsNotDevelopedByCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_UnobservableInputsNotDevelopedByCompanyMember" xlink:to="lab_ci_UnobservableInputsNotDevelopedByCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain_9e5005b2-224b-4b2a-88c1-01404d69c06d_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Account Balance, Guaranteed Minimum Crediting Rate Range [Domain]</link:label>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain_label_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Account Balance, Guaranteed Minimum Crediting Rate Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain" xlink:to="lab_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PolicyholderContractDepositNoncurrent_8ac7f7d8-d7af-405d-b8aa-1335b48a4ae3_terseLabel_en-US" xlink:label="lab_ci_PolicyholderContractDepositNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractholder deposit funds, non-current</link:label>
    <link:label id="lab_ci_PolicyholderContractDepositNoncurrent_label_en-US" xlink:label="lab_ci_PolicyholderContractDepositNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Contract Deposit, Noncurrent</link:label>
    <link:label id="lab_ci_PolicyholderContractDepositNoncurrent_documentation_en-US" xlink:label="lab_ci_PolicyholderContractDepositNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Contract Deposit, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositNoncurrent" xlink:href="ci-20231231.xsd#ci_PolicyholderContractDepositNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PolicyholderContractDepositNoncurrent" xlink:to="lab_ci_PolicyholderContractDepositNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PolicyholderContractBalancePercentReinsuredExternally_d02c5065-1f0a-445e-ae05-fcd64abbd601_terseLabel_en-US" xlink:label="lab_ci_PolicyholderContractBalancePercentReinsuredExternally" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractholder deposit fund liabilities, approximate percent reinsured externally</link:label>
    <link:label id="lab_ci_PolicyholderContractBalancePercentReinsuredExternally_label_en-US" xlink:label="lab_ci_PolicyholderContractBalancePercentReinsuredExternally" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Contract Balance, Percent Reinsured Externally</link:label>
    <link:label id="lab_ci_PolicyholderContractBalancePercentReinsuredExternally_documentation_en-US" xlink:label="lab_ci_PolicyholderContractBalancePercentReinsuredExternally" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Contract Balance, Percent Reinsured Externally</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractBalancePercentReinsuredExternally" xlink:href="ci-20231231.xsd#ci_PolicyholderContractBalancePercentReinsuredExternally"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PolicyholderContractBalancePercentReinsuredExternally" xlink:to="lab_ci_PolicyholderContractBalancePercentReinsuredExternally" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_8cf94a59-0b54-413b-b258-9a2229e9f0df_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_f33b57d3-bd22-48f6-ad1f-17d032dd0e9e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_ccafa561-1353-49df-b6d4-a6cc4f793f7f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale_97bb693a-3398-409c-bfcd-5dec1697667a_terseLabel_en-US" xlink:label="lab_ci_DerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative assets, including held for sale assets</link:label>
    <link:label id="lab_ci_DerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Assets Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_DerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Assets Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_DerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_UnearnedPremiumsCurrent_bffddbff-d759-42af-b141-39b4525a0059_terseLabel_en-US" xlink:label="lab_ci_UnearnedPremiumsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unearned premiums, current</link:label>
    <link:label id="lab_ci_UnearnedPremiumsCurrent_label_en-US" xlink:label="lab_ci_UnearnedPremiumsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unearned Premiums, Current</link:label>
    <link:label id="lab_ci_UnearnedPremiumsCurrent_documentation_en-US" xlink:label="lab_ci_UnearnedPremiumsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unearned Premiums, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsCurrent" xlink:href="ci-20231231.xsd#ci_UnearnedPremiumsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_UnearnedPremiumsCurrent" xlink:to="lab_ci_UnearnedPremiumsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_e4cd14ea-71d6-4a6b-b875-39b558f2a48d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for net interest expense on uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_3c318baa-2f21-486c-a808-2458626f3427_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Derivative Instruments Held</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_93cf4b17-fa2f-4ea1-8db1-751f4bb7f023_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_87b9af1e-0612-4041-9c89-1f29ea74f5f2_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Non- controlling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InvestmentGradeMember_73914045-f5e3-496a-9c17-722bcfdba0b4_terseLabel_en-US" xlink:label="lab_ci_InvestmentGradeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment grade</link:label>
    <link:label id="lab_ci_InvestmentGradeMember_label_en-US" xlink:label="lab_ci_InvestmentGradeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Grade [Member]</link:label>
    <link:label id="lab_ci_InvestmentGradeMember_documentation_en-US" xlink:label="lab_ci_InvestmentGradeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">External credit-ratings or internal groupings that could be used to describe the current status of the payment and performance risk of debt and securities investments that connote investment grade.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InvestmentGradeMember" xlink:href="ci-20231231.xsd#ci_InvestmentGradeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InvestmentGradeMember" xlink:to="lab_ci_InvestmentGradeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale_16d6c34e-b5e6-4c77-98af-08716f2eac42_terseLabel_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, including held for sale assets</link:label>
    <link:label id="lab_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale_723efc95-cae4-44c9-8d6e-28e5d6efb3e5_verboseLabel_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, including held for sale assets</link:label>
    <link:label id="lab_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Debt Securities Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Debt Securities Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EquitySecuritiesFvNiBeforeReclassificationToDisposalGroupAssetsHeldForSale_db407271-02d9-4544-8a62-a3fbce88008a_terseLabel_en-US" xlink:label="lab_ci_EquitySecuritiesFvNiBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities with readily determinable fair values, including held for sale assets</link:label>
    <link:label id="lab_ci_EquitySecuritiesFvNiBeforeReclassificationToDisposalGroupAssetsHeldForSale_304e0be9-c650-44d9-a47e-9b48b4958f91_verboseLabel_en-US" xlink:label="lab_ci_EquitySecuritiesFvNiBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities, including held for sale assets</link:label>
    <link:label id="lab_ci_EquitySecuritiesFvNiBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_EquitySecuritiesFvNiBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Fv Ni Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_EquitySecuritiesFvNiBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_EquitySecuritiesFvNiBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Fv Ni Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFvNiBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesFvNiBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EquitySecuritiesFvNiBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_EquitySecuritiesFvNiBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrentIncludingDisposalGroups_44a3935a-e861-43bd-8e2a-db4901323fef_terseLabel_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrentIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid claims and claim expenses, current, including held for sale liabilities</link:label>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrentIncludingDisposalGroups_label_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrentIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Claims And Claims Adjustment Expense Current Including Disposal Groups</link:label>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrentIncludingDisposalGroups_documentation_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrentIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount (expected to be paid within one year) needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrentIncludingDisposalGroups" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrentIncludingDisposalGroups"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrentIncludingDisposalGroups" xlink:to="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrentIncludingDisposalGroups" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SpecialItemChargeBenefitTaxMatters_60601d52-dc7d-40f4-805c-c6a79777e84e_terseLabel_en-US" xlink:label="lab_ci_SpecialItemChargeBenefitTaxMatters" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax (benefits), net (Income taxes, less amount attributable to noncontrolling interests)</link:label>
    <link:label id="lab_ci_SpecialItemChargeBenefitTaxMatters_label_en-US" xlink:label="lab_ci_SpecialItemChargeBenefitTaxMatters" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Item Charge Benefit Tax Matters</link:label>
    <link:label id="lab_ci_SpecialItemChargeBenefitTaxMatters_documentation_en-US" xlink:label="lab_ci_SpecialItemChargeBenefitTaxMatters" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Item Charge Benefit Tax Matters</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitTaxMatters" xlink:href="ci-20231231.xsd#ci_SpecialItemChargeBenefitTaxMatters"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SpecialItemChargeBenefitTaxMatters" xlink:to="lab_ci_SpecialItemChargeBenefitTaxMatters" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ddcd9ed5-4642-4f40-bf59-73da6ffa21bb_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_eac973d9-6f11-4156-bc38-3facc55efb46_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LongDurationContractsMember_5a205cc7-a078-4a04-b0e2-ce3e9d9c01f9_terseLabel_en-US" xlink:label="lab_ci_LongDurationContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-duration contracts</link:label>
    <link:label id="lab_ci_LongDurationContractsMember_label_en-US" xlink:label="lab_ci_LongDurationContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Duration Contracts [Member]</link:label>
    <link:label id="lab_ci_LongDurationContractsMember_documentation_en-US" xlink:label="lab_ci_LongDurationContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance contracts, primarily Life and Disability contracts, that are expected to remain in force for an extended period of time, generally one year or longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LongDurationContractsMember" xlink:href="ci-20231231.xsd#ci_LongDurationContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LongDurationContractsMember" xlink:to="lab_ci_LongDurationContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales_7d0c7ad2-d466-4ab6-a17c-63beae09cb58_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax_9ff59cad-c135-4176-b9bf-b4469a4374e1_periodStartLabel_en-US" xlink:label="lab_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of effect of discount rate assumptions</link:label>
    <link:label id="lab_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax_f634877b-30f1-462f-90cc-3540576c74e5_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of discount rate assumptions</link:label>
    <link:label id="lab_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax_label_en-US" xlink:label="lab_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Liability for Future Policy Benefit, Expected Future Policy Benefit, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax" xlink:to="lab_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_USGroupDisabilityAndLifeInsuranceBusinessMember_8f711adb-38cc-43e4-bee7-28979d52304c_terseLabel_en-US" xlink:label="lab_ci_USGroupDisabilityAndLifeInsuranceBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S Group Disability and Life Insurance</link:label>
    <link:label id="lab_ci_USGroupDisabilityAndLifeInsuranceBusinessMember_label_en-US" xlink:label="lab_ci_USGroupDisabilityAndLifeInsuranceBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S Group Disability And Life Insurance Business [Member]</link:label>
    <link:label id="lab_ci_USGroupDisabilityAndLifeInsuranceBusinessMember_documentation_en-US" xlink:label="lab_ci_USGroupDisabilityAndLifeInsuranceBusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S Group Disability And Life Insurance Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_USGroupDisabilityAndLifeInsuranceBusinessMember" xlink:href="ci-20231231.xsd#ci_USGroupDisabilityAndLifeInsuranceBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_USGroupDisabilityAndLifeInsuranceBusinessMember" xlink:to="lab_ci_USGroupDisabilityAndLifeInsuranceBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_d5e162b7-7953-40a4-9776-25ae7a8bc116_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CededCreditCollateralizationRiskMember_60fc5710-b108-4682-93a3-6f538be427f2_terseLabel_en-US" xlink:label="lab_ci_CededCreditCollateralizationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateralization risk</link:label>
    <link:label id="lab_ci_CededCreditCollateralizationRiskMember_label_en-US" xlink:label="lab_ci_CededCreditCollateralizationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded Credit Collateralization Risk [Member]</link:label>
    <link:label id="lab_ci_CededCreditCollateralizationRiskMember_documentation_en-US" xlink:label="lab_ci_CededCreditCollateralizationRiskMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk related to collateralization of a specified benchmark, such as reinsurance recoverables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CededCreditCollateralizationRiskMember" xlink:href="ci-20231231.xsd#ci_CededCreditCollateralizationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CededCreditCollateralizationRiskMember" xlink:to="lab_ci_CededCreditCollateralizationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock_0885c5dc-2f18-49df-9346-e620bf6e1007_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the Projected Benefit Obligations and Assets Related to Pension Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Funded Status [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNetFundedStatusTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups_617a0572-5f3b-472d-8936-84678a0d30da_periodStartLabel_en-US" xlink:label="lab_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Reinsurance, including held for sale liabilities</link:label>
    <link:label id="lab_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups_2e9d5f20-f231-42e3-9c66-7b3d0cd91021_periodEndLabel_en-US" xlink:label="lab_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add: Reinsurance, including held for sale liabilities</link:label>
    <link:label id="lab_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups_ccf3bf7a-49bd-4161-9ba4-874bab918c55_terseLabel_en-US" xlink:label="lab_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance and other amounts recoverable, including assets held for sale</link:label>
    <link:label id="lab_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups_label_en-US" xlink:label="lab_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Recoverable For Unpaid Claims And Claims Adjustments Including Disposal Groups</link:label>
    <link:label id="lab_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups_documentation_en-US" xlink:label="lab_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Recoverable For Unpaid Claims And Claims Adjustments Including Disposal Groups</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups" xlink:href="ci-20231231.xsd#ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups" xlink:to="lab_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_43ef3532-2a94-4aba-a06b-4630fc8096e2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign and U.S. Revenues from External Customers</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NotesDue203024InterestMember_e8805e9c-28ce-4fae-bbbb-9f517125bf02_terseLabel_en-US" xlink:label="lab_ci_NotesDue203024InterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$1,500&#160;million, 2.400% Notes due March 2030 (1)</link:label>
    <link:label id="lab_ci_NotesDue203024InterestMember_label_en-US" xlink:label="lab_ci_NotesDue203024InterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2030, 2.4% Interest [Member]</link:label>
    <link:label id="lab_ci_NotesDue203024InterestMember_documentation_en-US" xlink:label="lab_ci_NotesDue203024InterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2030, 2.4% Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue203024InterestMember" xlink:href="ci-20231231.xsd#ci_NotesDue203024InterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NotesDue203024InterestMember" xlink:to="lab_ci_NotesDue203024InterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AccountsReceivableUncommittedFactoringFacilityTotalCapacity_69fa4edb-c456-4d2f-8abb-1090a57c058c_terseLabel_en-US" xlink:label="lab_ci_AccountsReceivableUncommittedFactoringFacilityTotalCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total capacity, uncommitted factoring facility</link:label>
    <link:label id="lab_ci_AccountsReceivableUncommittedFactoringFacilityTotalCapacity_label_en-US" xlink:label="lab_ci_AccountsReceivableUncommittedFactoringFacilityTotalCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Uncommitted Factoring Facility, Total Capacity</link:label>
    <link:label id="lab_ci_AccountsReceivableUncommittedFactoringFacilityTotalCapacity_documentation_en-US" xlink:label="lab_ci_AccountsReceivableUncommittedFactoringFacilityTotalCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total amount of certain accounts receivable that may be sold on a non-recourse basis to a financial institution under an uncommitted Accounts receivable factoring facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccountsReceivableUncommittedFactoringFacilityTotalCapacity" xlink:href="ci-20231231.xsd#ci_AccountsReceivableUncommittedFactoringFacilityTotalCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AccountsReceivableUncommittedFactoringFacilityTotalCapacity" xlink:to="lab_ci_AccountsReceivableUncommittedFactoringFacilityTotalCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_1ef46665-ecf2-41bb-aeb5-a15589528843_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_06346c25-7d52-4faa-8d0e-44fb9c872788_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumptions Used for Pension</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_2a530ee0-e1e5-4707-9037-3350e979fbd9_terseLabel_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersegment Eliminations</link:label>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_label_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersegment Eliminations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntersegmentEliminationMember" xlink:to="lab_us-gaap_IntersegmentEliminationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CommitmentToPurchaseEquitySecuritiesMember_83ca365b-a210-4c1b-83e7-d43ba5bb48aa_terseLabel_en-US" xlink:label="lab_ci_CommitmentToPurchaseEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment to purchase equity securities</link:label>
    <link:label id="lab_ci_CommitmentToPurchaseEquitySecuritiesMember_label_en-US" xlink:label="lab_ci_CommitmentToPurchaseEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment To Purchase Equity Securities [Member]</link:label>
    <link:label id="lab_ci_CommitmentToPurchaseEquitySecuritiesMember_documentation_en-US" xlink:label="lab_ci_CommitmentToPurchaseEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment To Purchase Equity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CommitmentToPurchaseEquitySecuritiesMember" xlink:href="ci-20231231.xsd#ci_CommitmentToPurchaseEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CommitmentToPurchaseEquitySecuritiesMember" xlink:to="lab_ci_CommitmentToPurchaseEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_GuaranteeObligationsPayments_658c78a3-fd9b-45dc-a13a-361c17173805_terseLabel_en-US" xlink:label="lab_ci_GuaranteeObligationsPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments made on guarantees</link:label>
    <link:label id="lab_ci_GuaranteeObligationsPayments_label_en-US" xlink:label="lab_ci_GuaranteeObligationsPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantee Obligations Payments</link:label>
    <link:label id="lab_ci_GuaranteeObligationsPayments_documentation_en-US" xlink:label="lab_ci_GuaranteeObligationsPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to guarantee obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_GuaranteeObligationsPayments" xlink:href="ci-20231231.xsd#ci_GuaranteeObligationsPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_GuaranteeObligationsPayments" xlink:to="lab_ci_GuaranteeObligationsPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_d04d7be5-12ef-42a5-b11a-3a29e0789f5a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired or canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AccountsReceivableUncommittedFactoringFacilityAccountsReceivableReceivedButNotRemitted_416e7498-f5dd-4409-811e-e3e3374d7717_terseLabel_en-US" xlink:label="lab_ci_AccountsReceivableUncommittedFactoringFacilityAccountsReceivableReceivedButNotRemitted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable received but not remitted, uncommitted factoring facility</link:label>
    <link:label id="lab_ci_AccountsReceivableUncommittedFactoringFacilityAccountsReceivableReceivedButNotRemitted_label_en-US" xlink:label="lab_ci_AccountsReceivableUncommittedFactoringFacilityAccountsReceivableReceivedButNotRemitted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Uncommitted Factoring Facility, Accounts Receivable Received But Not Remitted</link:label>
    <link:label id="lab_ci_AccountsReceivableUncommittedFactoringFacilityAccountsReceivableReceivedButNotRemitted_documentation_en-US" xlink:label="lab_ci_AccountsReceivableUncommittedFactoringFacilityAccountsReceivableReceivedButNotRemitted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of, as of the reporting date, of receivables sold to a financial institution under an uncommitted Accounts receivable factoring facility that have been received from the manufacturers but not yet remitted to the financial institution.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccountsReceivableUncommittedFactoringFacilityAccountsReceivableReceivedButNotRemitted" xlink:href="ci-20231231.xsd#ci_AccountsReceivableUncommittedFactoringFacilityAccountsReceivableReceivedButNotRemitted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AccountsReceivableUncommittedFactoringFacilityAccountsReceivableReceivedButNotRemitted" xlink:to="lab_ci_AccountsReceivableUncommittedFactoringFacilityAccountsReceivableReceivedButNotRemitted" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_8c44cd6f-7753-4c91-83d0-a6736121610c_totalLabel_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Amortized Cost, including held for sale assets</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Unrealized Loss Position, Amortized Cost, Before Reclassification To Disposal Group, Assets Held-For-Sale</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Unrealized Loss Position, Amortized Cost, Before Reclassification To Disposal Group, Assets Held-For-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_243cd128-beb3-427b-bd9d-b728f41fe5c8_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Treasury stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale_ea417b4a-a4bc-470f-830f-d68cd1258e6c_totalLabel_en-US" xlink:label="lab_ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets before valuation allowance</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross, Including Disposal Groups Assets Held For Sale</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross, Including Disposal Groups Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale" xlink:to="lab_ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_ef11d48b-b8df-4ef7-9385-3e5ec3696dbb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_dc775610-4001-4cb8-8683-7245c0282769_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Net Pension Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_486279de-9dd0-472d-a685-f6d67e4f0543_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before reclassifications, before tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeTable_3909ed7f-a854-4656-bea3-6bb7809d8783_terseLabel_en-US" xlink:label="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Amount at Risk, by Product and Guarantee [Table]</link:label>
    <link:label id="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeTable_label_en-US" xlink:label="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Amount at Risk, by Product and Guarantee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetAmountAtRiskByProductAndGuaranteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeTable" xlink:to="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_004fd493-dea7-4ea8-a212-14349b6a57cf_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_47d2e1c1-9928-4984-808e-2815cc680995_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_604b1bc9-f345-4f08-be1d-53a919fedba4_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_f7f2833a-bc1f-4ef7-b98a-4639c32ec347_verboseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LifeInsuranceCompanyOfNorthAmericaMember_d84f01ae-3b25-443c-9fff-ce7a792b1c8c_terseLabel_en-US" xlink:label="lab_ci_LifeInsuranceCompanyOfNorthAmericaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Life Insurance Company of North America</link:label>
    <link:label id="lab_ci_LifeInsuranceCompanyOfNorthAmericaMember_label_en-US" xlink:label="lab_ci_LifeInsuranceCompanyOfNorthAmericaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Life Insurance Company Of North America [Member]</link:label>
    <link:label id="lab_ci_LifeInsuranceCompanyOfNorthAmericaMember_documentation_en-US" xlink:label="lab_ci_LifeInsuranceCompanyOfNorthAmericaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Life Insurance Company Of North America</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LifeInsuranceCompanyOfNorthAmericaMember" xlink:href="ci-20231231.xsd#ci_LifeInsuranceCompanyOfNorthAmericaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LifeInsuranceCompanyOfNorthAmericaMember" xlink:to="lab_ci_LifeInsuranceCompanyOfNorthAmericaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems_22f01951-a628-4ece-9dc2-5f1152166df5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:to="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteeObligationsNatureDomain_67f04c89-19e4-4c78-abcb-8780cdc346f5_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor Obligations, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsNatureDomain_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor Obligations, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain" xlink:to="lab_us-gaap_GuaranteeObligationsNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_905ebe60-461e-46e7-9edb-5c8a7cec79b1_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">%</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_2b7ea848-c137-4358-8463-9990c7b22ca9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember" xlink:to="lab_us-gaap_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_2208dad5-5268-49b9-800b-6ac9402a2b87_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_VariableInterestEntitiesNumberOfEntities_c02e4a31-a955-4ab2-9552-8e533a881f47_terseLabel_en-US" xlink:label="lab_ci_VariableInterestEntitiesNumberOfEntities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of VIEs</link:label>
    <link:label id="lab_ci_VariableInterestEntitiesNumberOfEntities_label_en-US" xlink:label="lab_ci_VariableInterestEntitiesNumberOfEntities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities, Number Of Entities</link:label>
    <link:label id="lab_ci_VariableInterestEntitiesNumberOfEntities_documentation_en-US" xlink:label="lab_ci_VariableInterestEntitiesNumberOfEntities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities, Number Of Entities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_VariableInterestEntitiesNumberOfEntities" xlink:href="ci-20231231.xsd#ci_VariableInterestEntitiesNumberOfEntities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_VariableInterestEntitiesNumberOfEntities" xlink:to="lab_ci_VariableInterestEntitiesNumberOfEntities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c03b811c-b8cf-4763-a7ef-49724b81ce0a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_60f6893f-b083-4319-ae3b-205eab87ba4c_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other sales, maturities and repayments (primarily short-term and other long-term investments)</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_0a9adb94-9664-4f45-bb2c-091112d04f34_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliations of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DefinedBenefitPlanAmortizationAbstract_17104940-7c0d-4cfc-93d0-462b2d9519e8_terseLabel_en-US" xlink:label="lab_ci_DefinedBenefitPlanAmortizationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of:</link:label>
    <link:label id="lab_ci_DefinedBenefitPlanAmortizationAbstract_label_en-US" xlink:label="lab_ci_DefinedBenefitPlanAmortizationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization [Abstract]</link:label>
    <link:label id="lab_ci_DefinedBenefitPlanAmortizationAbstract_documentation_en-US" xlink:label="lab_ci_DefinedBenefitPlanAmortizationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DefinedBenefitPlanAmortizationAbstract" xlink:href="ci-20231231.xsd#ci_DefinedBenefitPlanAmortizationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DefinedBenefitPlanAmortizationAbstract" xlink:to="lab_ci_DefinedBenefitPlanAmortizationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityOtherChanges_900afbc0-72ed-41c7-8c53-f8e1af828a8e_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityOtherChanges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other transactions impacting noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityOtherChanges_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityOtherChanges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Other Changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityOtherChanges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityOtherChanges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityOtherChanges" xlink:to="lab_us-gaap_TemporaryEquityOtherChanges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_f573f787-6fc1-4246-aced-999e8c0ab019_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_12728cb9-6bf0-4bd6-8d48-e6d3e45b761a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangibles</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2ad19662-bec0-4a71-a44f-0af0de9abeef_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of foreign currency rate changes on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6c1be7f8-6937-4fda-8339-bc99ddbc6725_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants/Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput_8c8eb8fd-8208-41c2-b595-a3803cfdbaa9_terseLabel_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unobservable Adjustment, including held for sale assets</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput_label_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Including Disposal Group, Measurement Input</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput_documentation_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Including Disposal Group, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput" xlink:to="lab_ci_DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_9cd1df7a-e10f-419f-ac02-52af93ed7a16_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_8f63f76d-230f-4bd6-a1d1-3f654e2139b5_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net of valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets_25bb544a-f25e-4f39-bb7c-8c45436a3b1b_terseLabel_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease ROU assets, held for sale</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Lease Right Of Use Assets</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Lease Right Of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets" xlink:to="lab_ci_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_d28e2a59-1366-4330-84f0-17fb51fc1ef4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e2e2e3cd-d836-4d8c-96a9-6e4987436cb2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares available for award (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NotesDue2023FloatingRateInterestMember_b6bc2b1d-71db-46cb-9b56-03ceca67fdd6_terseLabel_en-US" xlink:label="lab_ci_NotesDue2023FloatingRateInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$700&#160;million, Floating Rate Notes due July 2023</link:label>
    <link:label id="lab_ci_NotesDue2023FloatingRateInterestMember_label_en-US" xlink:label="lab_ci_NotesDue2023FloatingRateInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2023 Floating Rate Interest [Member]</link:label>
    <link:label id="lab_ci_NotesDue2023FloatingRateInterestMember_documentation_en-US" xlink:label="lab_ci_NotesDue2023FloatingRateInterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior notes payable with floating interest due in 2023. Debt issued to finance acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue2023FloatingRateInterestMember" xlink:href="ci-20231231.xsd#ci_NotesDue2023FloatingRateInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NotesDue2023FloatingRateInterestMember" xlink:to="lab_ci_NotesDue2023FloatingRateInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_dc1d2527-a230-41ce-8f30-9a2070f0756c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_4eb1f340-da82-48d5-82bc-d99c6463b1da_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember_b5aa688b-c754-4d3b-a713-da1c5be4e9c3_terseLabel_en-US" xlink:label="lab_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period change in instrument-specific credit risk for market risk benefits</link:label>
    <link:label id="lab_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember_label_en-US" xlink:label="lab_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Market Risk Benefit, Instrument-Specific Credit Risk, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember" xlink:to="lab_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_b815d11b-88f3-41eb-a354-c84c3eedef08_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional Value</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AcceleratedShareRepurchasesVolumeWeightedAverageSharePriceLessDiscount_011da30d-6679-4088-811f-29124c151d4b_terseLabel_en-US" xlink:label="lab_ci_AcceleratedShareRepurchasesVolumeWeightedAverageSharePriceLessDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated stock repurchase, volume weighted average share price (in dollars per share)</link:label>
    <link:label id="lab_ci_AcceleratedShareRepurchasesVolumeWeightedAverageSharePriceLessDiscount_label_en-US" xlink:label="lab_ci_AcceleratedShareRepurchasesVolumeWeightedAverageSharePriceLessDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Volume Weighted Average Share Price, Less Discount</link:label>
    <link:label id="lab_ci_AcceleratedShareRepurchasesVolumeWeightedAverageSharePriceLessDiscount_documentation_en-US" xlink:label="lab_ci_AcceleratedShareRepurchasesVolumeWeightedAverageSharePriceLessDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Volume Weighted Average Share Price, Less Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AcceleratedShareRepurchasesVolumeWeightedAverageSharePriceLessDiscount" xlink:href="ci-20231231.xsd#ci_AcceleratedShareRepurchasesVolumeWeightedAverageSharePriceLessDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AcceleratedShareRepurchasesVolumeWeightedAverageSharePriceLessDiscount" xlink:to="lab_ci_AcceleratedShareRepurchasesVolumeWeightedAverageSharePriceLessDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_1af2ca0d-d833-4802-a9e6-833961277c3a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CorporateAndGovernmentDebtSecuritiesMember_07e6cd26-2953-4aba-aeac-f3d0d57ee7fa_terseLabel_en-US" xlink:label="lab_ci_CorporateAndGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_ci_CorporateAndGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_ci_CorporateAndGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate And Government Debt Securities [Member]</link:label>
    <link:label id="lab_ci_CorporateAndGovernmentDebtSecuritiesMember_documentation_en-US" xlink:label="lab_ci_CorporateAndGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This category includes information about debt securities that are issued by either a domestic or foreign corporate business entity with a promise of repayment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CorporateAndGovernmentDebtSecuritiesMember" xlink:href="ci-20231231.xsd#ci_CorporateAndGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CorporateAndGovernmentDebtSecuritiesMember" xlink:to="lab_ci_CorporateAndGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NotesDue20312375InterestMember_7f4b7c30-4192-471a-bff4-2838e5584404_terseLabel_en-US" xlink:label="lab_ci_NotesDue20312375InterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$1,500 million, 2.375% Notes due 2031</link:label>
    <link:label id="lab_ci_NotesDue20312375InterestMember_label_en-US" xlink:label="lab_ci_NotesDue20312375InterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2031, 2.375% Interest [Member]</link:label>
    <link:label id="lab_ci_NotesDue20312375InterestMember_documentation_en-US" xlink:label="lab_ci_NotesDue20312375InterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable bearing interest at 2.375% due in 2031.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20312375InterestMember" xlink:href="ci-20231231.xsd#ci_NotesDue20312375InterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NotesDue20312375InterestMember" xlink:to="lab_ci_NotesDue20312375InterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectsOfReinsuranceLineItems_09c342d1-b444-4a63-a51d-4e6149013868_terseLabel_en-US" xlink:label="lab_us-gaap_EffectsOfReinsuranceLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of Reinsurance [Line Items]</link:label>
    <link:label id="lab_us-gaap_EffectsOfReinsuranceLineItems_label_en-US" xlink:label="lab_us-gaap_EffectsOfReinsuranceLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of Reinsurance [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectsOfReinsuranceLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectsOfReinsuranceLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectsOfReinsuranceLineItems" xlink:to="lab_us-gaap_EffectsOfReinsuranceLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ShortDurationContractsMember_69766655-e080-4e8f-b147-9244147fc6e8_terseLabel_en-US" xlink:label="lab_ci_ShortDurationContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration contracts</link:label>
    <link:label id="lab_ci_ShortDurationContractsMember_label_en-US" xlink:label="lab_ci_ShortDurationContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Duration Contracts [Member]</link:label>
    <link:label id="lab_ci_ShortDurationContractsMember_documentation_en-US" xlink:label="lab_ci_ShortDurationContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance contracts, primarily Accident and Health contracts, that are expected to remain in force for a short duration, generally one year or less.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortDurationContractsMember" xlink:href="ci-20231231.xsd#ci_ShortDurationContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ShortDurationContractsMember" xlink:to="lab_ci_ShortDurationContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_84b6c253-0d28-44bf-b662-f89dae4dd0da_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Status of and Changes in Restricted Stock Awards and the Fair Value of Vested Restricted Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_66927907-6353-4fc7-8c03-abba234856ec_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_104f681b-94e3-4c03-9fdf-a6d2f947ace2_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CededCreditRiskAxis_85f625d6-0763-4ccc-b2e4-e11168e1a5ec_terseLabel_en-US" xlink:label="lab_us-gaap_CededCreditRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded Credit Risk, Reinsurer [Axis]</link:label>
    <link:label id="lab_us-gaap_CededCreditRiskAxis_label_en-US" xlink:label="lab_us-gaap_CededCreditRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurer, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CededCreditRiskAxis" xlink:to="lab_us-gaap_CededCreditRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities_e10923a3-fa84-4a09-a265-87f1d3072b38_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other insurance and contractholder liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Policyholder Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsOutstandingAbstract_e888a7ca-e324-4281-a361-fdf7d8ff6780_terseLabel_en-US" xlink:label="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding</link:label>
    <link:label id="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsOutstandingAbstract_label_en-US" xlink:label="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Information About Options Outstanding [Abstract]</link:label>
    <link:label id="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsOutstandingAbstract_documentation_en-US" xlink:label="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Information About Options Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsOutstandingAbstract" xlink:href="ci-20231231.xsd#ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsOutstandingAbstract" xlink:to="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NotesDue2022305InterestMember_3700f1fe-5085-415c-aaef-d716ebc1ce39_terseLabel_en-US" xlink:label="lab_ci_NotesDue2022305InterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2022, 3.05% Interest</link:label>
    <link:label id="lab_ci_NotesDue2022305InterestMember_label_en-US" xlink:label="lab_ci_NotesDue2022305InterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2022, 3.05% Interest [Member]</link:label>
    <link:label id="lab_ci_NotesDue2022305InterestMember_documentation_en-US" xlink:label="lab_ci_NotesDue2022305InterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior notes payable bearing interest at 3.05% due in 2022. Debt assumed acquisition from Express Scripts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue2022305InterestMember" xlink:href="ci-20231231.xsd#ci_NotesDue2022305InterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NotesDue2022305InterestMember" xlink:to="lab_ci_NotesDue2022305InterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_b91bd165-0b79-4ac7-b209-2c4cb1e8315b_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale_4ef6dec1-522d-40c6-9211-6a550dec4598_terseLabel_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years, including assets held for sale</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgagesMember_c8af5fbd-46d5-497c-9143-92a8580d7211_verboseLabel_en-US" xlink:label="lab_us-gaap_MortgagesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial mortgage loans</link:label>
    <link:label id="lab_us-gaap_MortgagesMember_label_en-US" xlink:label="lab_us-gaap_MortgagesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgages [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgagesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgagesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgagesMember" xlink:to="lab_us-gaap_MortgagesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_affccfff-82f8-4dc1-a7be-485eef17074f_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_3d66d20e-7474-4946-adba-0aa8828a7d2e_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL REVENUES</link:label>
    <link:label id="lab_us-gaap_Revenues_43557091-34eb-4908-a0ec-67f4f9b1a5bf_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FairValueMeasurementNonPerformanceRiskAdjustment_b2c93249-05ab-4a5a-a286-333571ea9f95_terseLabel_en-US" xlink:label="lab_ci_FairValueMeasurementNonPerformanceRiskAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of non-performance risk</link:label>
    <link:label id="lab_ci_FairValueMeasurementNonPerformanceRiskAdjustment_label_en-US" xlink:label="lab_ci_FairValueMeasurementNonPerformanceRiskAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Non-Performance Risk Adjustment</link:label>
    <link:label id="lab_ci_FairValueMeasurementNonPerformanceRiskAdjustment_documentation_en-US" xlink:label="lab_ci_FairValueMeasurementNonPerformanceRiskAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Non-Performance Risk Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueMeasurementNonPerformanceRiskAdjustment" xlink:href="ci-20231231.xsd#ci_FairValueMeasurementNonPerformanceRiskAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FairValueMeasurementNonPerformanceRiskAdjustment" xlink:to="lab_ci_FairValueMeasurementNonPerformanceRiskAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_518a5e1d-ae23-41c6-9d69-c253f2c9da19_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Employee Stock Options Not Included in the Computation of Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable_98ad78b2-2aa6-4dad-aff7-ae8c02c21a3f_terseLabel_en-US" xlink:label="lab_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noninsurance customer receivables</link:label>
    <link:label id="lab_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable_label_en-US" xlink:label="lab_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noninsurance Customer Receivables Excluding Pharmaceutical Manufacturers Receivable</link:label>
    <link:label id="lab_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable_documentation_en-US" xlink:label="lab_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables due from customers that are not under insurance contracts. These include pharmacy sales and fees due from employer clients.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable" xlink:href="ci-20231231.xsd#ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable" xlink:to="lab_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_40fc221d-f879-4d10-b733-ca833e2d449b_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Beginning Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_b3ed3cdf-26ce-45d6-a054-0be291a8b59f_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Ending Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_f8f1d08e-9dc0-4c2e-a40a-b6d37654786d_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3e1ac050-4281-4b9e-8142-522d954455af_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilitiesBeforeReclassificationToDisposalGroupAssetsHeldForSale_a0cfbeca-598c-4640-a0f8-afd4acf901af_terseLabel_en-US" xlink:label="lab_ci_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilitiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment for credit risk on derivatives liabilities</link:label>
    <link:label id="lab_ci_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilitiesBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilitiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Credit Risk Valuation Adjustment, Derivative Liabilities, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilitiesBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilitiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Credit Risk Valuation Adjustment, Derivative Liabilities, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilitiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilitiesBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilitiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilitiesBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_79e26f13-be5d-45e8-b0df-e8a5caeb17c7_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_0efb8026-d3eb-4416-898b-b83255bfac49_totalLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total paid</link:label>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:to="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9500925a-1c5c-4405-bb92-3c1ee49957ee_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsDeclaredTableTextBlock_61187b72-e2cf-4148-82dc-7467e9c2a9be_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsDeclaredTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend Payments</link:label>
    <link:label id="lab_us-gaap_DividendsDeclaredTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DividendsDeclaredTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Declared [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsDeclaredTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsDeclaredTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsDeclaredTableTextBlock" xlink:to="lab_us-gaap_DividendsDeclaredTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderAccountsPolicy_f7b95f75-1a8d-4a3f-a2e6-a691f2b87d09_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate Accounts</link:label>
    <link:label id="lab_us-gaap_PolicyholderAccountsPolicy_label_en-US" xlink:label="lab_us-gaap_PolicyholderAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Accounts, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderAccountsPolicy" xlink:to="lab_us-gaap_PolicyholderAccountsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b2dc51b1-8005-43c7-a1e0-20aee6678d96_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_c2617a66-85b9-49fb-b668-686836494049_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_fee0afe7-29a3-419d-8a88-e5e8fa342e83_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected long-term return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_74c406c3-39ef-4bc2-876a-be2649485472_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Income Tax Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected_46d34689-3046-4fb8-8332-8420dd4c29c5_terseLabel_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes due to policyholder behavior versus expected</link:label>
    <link:label id="lab_us-gaap_MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected_label_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Risk Benefit, Increase (Decrease) from Actual Policyholder Behavior Different from Expected</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected" xlink:to="lab_us-gaap_MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance_4aff1a2b-ecbb-4cee-999d-f0860c7df022_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undiscounted expected future policy benefits</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefit, Expected Future Policy Benefit, Undiscounted, before Reinsurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_9d7eed84-1019-416f-839e-99760a66fb31_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member_ad389628-93a6-492f-9876-c06717407c0d_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Account Balance, above Guaranteed Minimum Crediting Rate, Range from 0051 to 0150</link:label>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member_label_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Account Balance, above Guaranteed Minimum Crediting Rate, Range from 0051 to 0150 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member" xlink:to="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent_ba3c9660-6760-44cf-94f6-c3b3fcbe1c48_terseLabel_en-US" xlink:label="lab_ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swiss tax attributes</link:label>
    <link:label id="lab_ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent_label_en-US" xlink:label="lab_ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Swiss Tax Attributes, Percent</link:label>
    <link:label id="lab_ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent_documentation_en-US" xlink:label="lab_ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Swiss Tax Attributes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent" xlink:href="ci-20231231.xsd#ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent" xlink:to="lab_ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_711b58f4-1d47-4ade-a9fa-72370d3f07c1_terseLabel_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance And Contractholder Liabilities, Current [Abstract]</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_documentation_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance And Contractholder Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract" xlink:to="lab_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9fab569b-fc62-4062-9a27-e85273504c97_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_a820f25f-8402-49d6-aaf0-204967f16716_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_363ede46-3dce-4c96-8493-af5ba965724a_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements, Recently Adopted Accounting Guidance and Accounting Guidance Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_255623f8-152d-4742-acec-a4d399091166_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred loss - sale of business</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Capital Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_fb9a2825-63b9-49d8-b299-199b29eb0d0e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee and retiree benefit plans</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ScheduleOfSpecialItemsTableTextBlock_93e4edf4-c14d-464b-b99d-7c9c926a7d57_terseLabel_en-US" xlink:label="lab_ci_ScheduleOfSpecialItemsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Special Items</link:label>
    <link:label id="lab_ci_ScheduleOfSpecialItemsTableTextBlock_label_en-US" xlink:label="lab_ci_ScheduleOfSpecialItemsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Special Items [Table Text Block]</link:label>
    <link:label id="lab_ci_ScheduleOfSpecialItemsTableTextBlock_documentation_en-US" xlink:label="lab_ci_ScheduleOfSpecialItemsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of pre- and after-tax amounts reported as special items, attributable to the parent. Special items are amounts that management does not believe are representative of underlying results of operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ScheduleOfSpecialItemsTableTextBlock" xlink:href="ci-20231231.xsd#ci_ScheduleOfSpecialItemsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ScheduleOfSpecialItemsTableTextBlock" xlink:to="lab_ci_ScheduleOfSpecialItemsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DeferredTaxAssetsPolicyAcquisitionExpensesIncludingDisposalGroupsAssetsHeldForSale_87d0fbe7-af53-4937-b5c6-4b25a01b8f3b_terseLabel_en-US" xlink:label="lab_ci_DeferredTaxAssetsPolicyAcquisitionExpensesIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policy acquisition expenses</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsPolicyAcquisitionExpensesIncludingDisposalGroupsAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DeferredTaxAssetsPolicyAcquisitionExpensesIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Policy Acquisition Expenses, Including Disposal Groups Assets Held For Sale</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsPolicyAcquisitionExpensesIncludingDisposalGroupsAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DeferredTaxAssetsPolicyAcquisitionExpensesIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Policy Acquisition Expenses, Including Disposal Groups Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsPolicyAcquisitionExpensesIncludingDisposalGroupsAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsPolicyAcquisitionExpensesIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DeferredTaxAssetsPolicyAcquisitionExpensesIncludingDisposalGroupsAssetsHeldForSale" xlink:to="lab_ci_DeferredTaxAssetsPolicyAcquisitionExpensesIncludingDisposalGroupsAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceAbstract_label_en-US" xlink:label="lab_us-gaap_InsuranceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceAbstract" xlink:to="lab_us-gaap_InsuranceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_92559c33-a3f9-4aef-b11f-b6363b26d162_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Black-Sholes Option-Pricing Model Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_4bb12fd8-1e20-4de9-8b9d-f0b9c5979e5c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_eb7f0f87-1432-48f5-bfeb-d83a79cd858e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Incentive Plans</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_95bbdfae-c19a-4458-91c9-65ee6247aa76_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecreaseIncludingDisposalGroups_9b758669-962b-4b43-9683-93228af15f1f_terseLabel_en-US" xlink:label="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecreaseIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate accounts assets classified in Level 3, including disposal groups, period increase (decrease), including transfers in and out of Level 3</link:label>
    <link:label id="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecreaseIncludingDisposalGroups_label_en-US" xlink:label="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecreaseIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease), Including Disposal Groups</link:label>
    <link:label id="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecreaseIncludingDisposalGroups_documentation_en-US" xlink:label="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecreaseIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease), Including Disposal Groups</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecreaseIncludingDisposalGroups" xlink:href="ci-20231231.xsd#ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecreaseIncludingDisposalGroups"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecreaseIncludingDisposalGroups" xlink:to="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecreaseIncludingDisposalGroups" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract_label_en-US" xlink:label="lab_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Other Intangibles And Property And Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract" xlink:href="ci-20231231.xsd#ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract" xlink:to="lab_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_ee97f7b6-40b5-42f8-9f81-3fe3929e384d_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AccountsReceivableUncommittedFactoringFacilityAutomaticRenewalTerm_fed48df4-cccf-47fb-bed7-8afa5123c88e_terseLabel_en-US" xlink:label="lab_ci_AccountsReceivableUncommittedFactoringFacilityAutomaticRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Automatic renewal term, uncommitted factoring facility (in years)</link:label>
    <link:label id="lab_ci_AccountsReceivableUncommittedFactoringFacilityAutomaticRenewalTerm_label_en-US" xlink:label="lab_ci_AccountsReceivableUncommittedFactoringFacilityAutomaticRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Uncommitted Factoring Facility, Automatic Renewal Term</link:label>
    <link:label id="lab_ci_AccountsReceivableUncommittedFactoringFacilityAutomaticRenewalTerm_documentation_en-US" xlink:label="lab_ci_AccountsReceivableUncommittedFactoringFacilityAutomaticRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Automatic renewal term for uncommitted Accounts receivable factoring facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccountsReceivableUncommittedFactoringFacilityAutomaticRenewalTerm" xlink:href="ci-20231231.xsd#ci_AccountsReceivableUncommittedFactoringFacilityAutomaticRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AccountsReceivableUncommittedFactoringFacilityAutomaticRenewalTerm" xlink:to="lab_ci_AccountsReceivableUncommittedFactoringFacilityAutomaticRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_6e828e94-ad10-4310-8d34-4820deb3a1eb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_54d197b1-0403-4c74-9702-3f931a8863be_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity_154d4cff-13f1-4283-8092-31681eaecf4c_negatedLabel_en-US" xlink:label="lab_ci_OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax, Including Temporary Equity</link:label>
    <link:label id="lab_ci_OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity_label_en-US" xlink:label="lab_ci_OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax, Including Temporary Equity</link:label>
    <link:label id="lab_ci_OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity_documentation_en-US" xlink:label="lab_ci_OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax, Including Temporary Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity" xlink:to="lab_ci_OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_5ddf4477-defc-40a9-b5f9-e3bcd560224d_negatedLabel_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Depreciation, including held for sale assets</link:label>
    <link:label id="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Continuous Unrealized Loss Position 12 Months Or Longer Accumulated Loss Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Continuous Unrealized Loss Position 12 Months Or Longer Accumulated Loss Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BenefitsLossesAndExpenses_80dac37f-f2d2-4eda-9f7f-fd1fd3180d53_totalLabel_en-US" xlink:label="lab_us-gaap_BenefitsLossesAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL BENEFITS AND EXPENSES</link:label>
    <link:label id="lab_us-gaap_BenefitsLossesAndExpenses_label_en-US" xlink:label="lab_us-gaap_BenefitsLossesAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits, Losses and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BenefitsLossesAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BenefitsLossesAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BenefitsLossesAndExpenses" xlink:to="lab_us-gaap_BenefitsLossesAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_db0a0b5b-d321-44c0-b282-b1f8795c1c93_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustment for amortization of net prior actuarial losses and prior service costs (Interest expense and other)</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrencySwapMember_550355a0-6bdf-4376-b73f-0821792ba931_terseLabel_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency swap contracts</link:label>
    <link:label id="lab_us-gaap_CurrencySwapMember_label_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrencySwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrencySwapMember" xlink:to="lab_us-gaap_CurrencySwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_6430ace9-de7f-4e1e-be16-c4b20ed4238f_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_4b521776-207e-4a11-95c7-4c42c2c1963b_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SegmentRevenues_7dd78f29-cbf1-4367-90d2-d3ee8762baff_totalLabel_en-US" xlink:label="lab_ci_SegmentRevenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted revenues</link:label>
    <link:label id="lab_ci_SegmentRevenues_label_en-US" xlink:label="lab_ci_SegmentRevenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenues</link:label>
    <link:label id="lab_ci_SegmentRevenues_documentation_en-US" xlink:label="lab_ci_SegmentRevenues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues less realized investment gains from equity method subsidiaries, special items and other reconciling items determined by management.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SegmentRevenues" xlink:href="ci-20231231.xsd#ci_SegmentRevenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SegmentRevenues" xlink:to="lab_ci_SegmentRevenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatutoryCapitalAndSurplusApplyingNationalAssociationOfInsuranceCommissionersNAICPractices_10ae1223-cbcf-4c63-8b2e-f2102e36bfc5_terseLabel_en-US" xlink:label="lab_us-gaap_StatutoryCapitalAndSurplusApplyingNationalAssociationOfInsuranceCommissionersNAICPractices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surplus</link:label>
    <link:label id="lab_us-gaap_StatutoryCapitalAndSurplusApplyingNationalAssociationOfInsuranceCommissionersNAICPractices_label_en-US" xlink:label="lab_us-gaap_StatutoryCapitalAndSurplusApplyingNationalAssociationOfInsuranceCommissionersNAICPractices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Capital and Surplus Applying National Association of Insurance Commissioners (NAIC) Practices</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryCapitalAndSurplusApplyingNationalAssociationOfInsuranceCommissionersNAICPractices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatutoryCapitalAndSurplusApplyingNationalAssociationOfInsuranceCommissionersNAICPractices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatutoryCapitalAndSurplusApplyingNationalAssociationOfInsuranceCommissionersNAICPractices" xlink:to="lab_us-gaap_StatutoryCapitalAndSurplusApplyingNationalAssociationOfInsuranceCommissionersNAICPractices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_51b7c024-3db3-4cc2-9e57-f9ecdaca7db3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities after 2028</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_89ec3b18-b147-4d44-a373-00004d3f5351_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount_69b61d02-90f9-4271-9e12-73cba9c6ea3c_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum exposure to loss, variable interest entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount" xlink:to="lab_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_cac77f87-66a9-47e7-ad49-4aed2537b143_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period Of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_3e4d2760-9823-449d-9647-92d99677909a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueValueOfSharesForAnnualDividendAccrual_88dc2f15-7dfe-4dcb-8cc5-0dd48dc7a280_terseLabel_en-US" xlink:label="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueValueOfSharesForAnnualDividendAccrual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares for annual dividend accrual</link:label>
    <link:label id="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueValueOfSharesForAnnualDividendAccrual_label_en-US" xlink:label="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueValueOfSharesForAnnualDividendAccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value, Value Of Shares For Annual Dividend Accrual</link:label>
    <link:label id="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueValueOfSharesForAnnualDividendAccrual_documentation_en-US" xlink:label="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueValueOfSharesForAnnualDividendAccrual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value, Value Of Shares For Annual Dividend Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueValueOfSharesForAnnualDividendAccrual" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesWithoutReadilyDeterminableFairValueValueOfSharesForAnnualDividendAccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueValueOfSharesForAnnualDividendAccrual" xlink:to="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueValueOfSharesForAnnualDividendAccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_871acbb4-4a40-48f2-b7dd-d9436038310f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InterestInJointVentureInTurkeyMember_1dec8fbd-167f-4f68-9900-aca980a66359_terseLabel_en-US" xlink:label="lab_ci_InterestInJointVentureInTurkeyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest in Turkiye Joint Venture</link:label>
    <link:label id="lab_ci_InterestInJointVentureInTurkeyMember_label_en-US" xlink:label="lab_ci_InterestInJointVentureInTurkeyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest In Joint Venture In Turkey [Member]</link:label>
    <link:label id="lab_ci_InterestInJointVentureInTurkeyMember_documentation_en-US" xlink:label="lab_ci_InterestInJointVentureInTurkeyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest In Joint Venture In Turkey</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InterestInJointVentureInTurkeyMember" xlink:href="ci-20231231.xsd#ci_InterestInJointVentureInTurkeyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InterestInJointVentureInTurkeyMember" xlink:to="lab_ci_InterestInJointVentureInTurkeyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8f27798e-da80-4a08-b3ef-0fd559e189bf_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Incentive Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CommitmentsAndContingenciesNumberOfAdditionalExpert_9a0b7714-fa05-4e8e-8fa2-5f1d223cb252_terseLabel_en-US" xlink:label="lab_ci_CommitmentsAndContingenciesNumberOfAdditionalExpert" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional experts</link:label>
    <link:label id="lab_ci_CommitmentsAndContingenciesNumberOfAdditionalExpert_label_en-US" xlink:label="lab_ci_CommitmentsAndContingenciesNumberOfAdditionalExpert" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies, Number Of Additional Expert</link:label>
    <link:label id="lab_ci_CommitmentsAndContingenciesNumberOfAdditionalExpert_documentation_en-US" xlink:label="lab_ci_CommitmentsAndContingenciesNumberOfAdditionalExpert" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies, Number Of Additional Expert</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CommitmentsAndContingenciesNumberOfAdditionalExpert" xlink:href="ci-20231231.xsd#ci_CommitmentsAndContingenciesNumberOfAdditionalExpert"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CommitmentsAndContingenciesNumberOfAdditionalExpert" xlink:to="lab_ci_CommitmentsAndContingenciesNumberOfAdditionalExpert" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_fb1c6676-5661-496a-bcf5-23ae71a62fcc_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierFinanceProgramTextBlock_404a1b12-c014-4d7c-8716-35275b67dacd_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Finance Program</link:label>
    <link:label id="lab_us-gaap_SupplierFinanceProgramTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Finance Program [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierFinanceProgramTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierFinanceProgramTextBlock" xlink:to="lab_us-gaap_SupplierFinanceProgramTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_GuaranteedSeparateAccountAssets_8788a229-8885-4a37-8f66-0ca2e46508bb_terseLabel_en-US" xlink:label="lab_ci_GuaranteedSeparateAccountAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guaranteed separate accounts</link:label>
    <link:label id="lab_ci_GuaranteedSeparateAccountAssets_label_en-US" xlink:label="lab_ci_GuaranteedSeparateAccountAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guaranteed Separate Account Assets</link:label>
    <link:label id="lab_ci_GuaranteedSeparateAccountAssets_documentation_en-US" xlink:label="lab_ci_GuaranteedSeparateAccountAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guaranteed Separate Account Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_GuaranteedSeparateAccountAssets" xlink:href="ci-20231231.xsd#ci_GuaranteedSeparateAccountAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_GuaranteedSeparateAccountAssets" xlink:to="lab_ci_GuaranteedSeparateAccountAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InsuranceUnearnedPremiumsPolicyTextBlock_b1c314c0-6cca-4d99-b5d2-f5db7b49b86f_terseLabel_en-US" xlink:label="lab_ci_InsuranceUnearnedPremiumsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unearned Premium</link:label>
    <link:label id="lab_ci_InsuranceUnearnedPremiumsPolicyTextBlock_label_en-US" xlink:label="lab_ci_InsuranceUnearnedPremiumsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance, Unearned Premiums [Policy Text Block]</link:label>
    <link:label id="lab_ci_InsuranceUnearnedPremiumsPolicyTextBlock_documentation_en-US" xlink:label="lab_ci_InsuranceUnearnedPremiumsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance, Unearned Premiums</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceUnearnedPremiumsPolicyTextBlock" xlink:href="ci-20231231.xsd#ci_InsuranceUnearnedPremiumsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InsuranceUnearnedPremiumsPolicyTextBlock" xlink:to="lab_ci_InsuranceUnearnedPremiumsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_0011e6fa-fb3f-426a-9f90-abe264dd34af_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for current expected credit losses on accounts receivable</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AverageInterestRateOnIntercompanyLoan_631b2140-2b5f-409a-a7b5-5ef34073f125_terseLabel_en-US" xlink:label="lab_ci_AverageInterestRateOnIntercompanyLoan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average interest rate on intercompany loan</link:label>
    <link:label id="lab_ci_AverageInterestRateOnIntercompanyLoan_label_en-US" xlink:label="lab_ci_AverageInterestRateOnIntercompanyLoan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Interest Rate On Intercompany Loan</link:label>
    <link:label id="lab_ci_AverageInterestRateOnIntercompanyLoan_documentation_en-US" xlink:label="lab_ci_AverageInterestRateOnIntercompanyLoan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The average monthly interest on an intercompany loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AverageInterestRateOnIntercompanyLoan" xlink:href="ci-20231231.xsd#ci_AverageInterestRateOnIntercompanyLoan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AverageInterestRateOnIntercompanyLoan" xlink:to="lab_ci_AverageInterestRateOnIntercompanyLoan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_acc85052-03e3-494f-94b7-a54318be3df2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_d52952f2-0b84-4fd6-b575-6dd29c57fa26_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income tax benefits</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity_eaeb25a2-c416-41a5-82d5-82bdced6c246_totalLabel_en-US" xlink:label="lab_ci_OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) including temporary equity, before reclassifications, after-tax</link:label>
    <link:label id="lab_ci_OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity_label_en-US" xlink:label="lab_ci_OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Before Reclassifications, After Tax, Including Temporary Equity</link:label>
    <link:label id="lab_ci_OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity_documentation_en-US" xlink:label="lab_ci_OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Before Reclassifications, After Tax, Including Temporary Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity" xlink:to="lab_ci_OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_a674034a-8d91-4a07-88ab-5c519e887112_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_UnearnedPremiumsNoncurrentIncludingDisposalGroups_b1d577a2-65ce-46ad-affd-a81dfd89e265_terseLabel_en-US" xlink:label="lab_ci_UnearnedPremiumsNoncurrentIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unearned premiums, non-current, including held for sale liabilities</link:label>
    <link:label id="lab_ci_UnearnedPremiumsNoncurrentIncludingDisposalGroups_label_en-US" xlink:label="lab_ci_UnearnedPremiumsNoncurrentIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unearned Premiums Noncurrent Including Disposal Groups</link:label>
    <link:label id="lab_ci_UnearnedPremiumsNoncurrentIncludingDisposalGroups_documentation_en-US" xlink:label="lab_ci_UnearnedPremiumsNoncurrentIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount of premiums written on insurance contracts that have not been earned as of the balance sheet date, expected to be paid after one year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsNoncurrentIncludingDisposalGroups" xlink:href="ci-20231231.xsd#ci_UnearnedPremiumsNoncurrentIncludingDisposalGroups"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_UnearnedPremiumsNoncurrentIncludingDisposalGroups" xlink:to="lab_ci_UnearnedPremiumsNoncurrentIncludingDisposalGroups" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CHSSJVLLCMember_301d4e8b-561e-4c4b-b9ea-328613d05d1f_terseLabel_en-US" xlink:label="lab_ci_CHSSJVLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHSS JV LLC</link:label>
    <link:label id="lab_ci_CHSSJVLLCMember_label_en-US" xlink:label="lab_ci_CHSSJVLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHSS JV LLC [Member]</link:label>
    <link:label id="lab_ci_CHSSJVLLCMember_documentation_en-US" xlink:label="lab_ci_CHSSJVLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHSS JV LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CHSSJVLLCMember" xlink:href="ci-20231231.xsd#ci_CHSSJVLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CHSSJVLLCMember" xlink:to="lab_ci_CHSSJVLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_529019b9-a580-478b-a155-6b49e77fb7c8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life, leasehold improvements</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_3ee4680b-d509-400f-9ba7-7b5f4d622549_verboseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_100793c3-f3a3-4477-b2f9-aadcd9e518e5_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_836bcdb6-01c8-42fc-9ddc-682984a2e7d0_terseLabel_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One year or less</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_label_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less Than 12 Months [Abstract]</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_documentation_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less Than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract" xlink:to="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DeferredTaxLiabilitiesPropertyPlantAndEquipmentIncludingDisposalGroupsAssetsHeldForSale_79965638-1ba6-432f-b941-48dc4044b287_terseLabel_en-US" xlink:label="lab_ci_DeferredTaxLiabilitiesPropertyPlantAndEquipmentIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_ci_DeferredTaxLiabilitiesPropertyPlantAndEquipmentIncludingDisposalGroupsAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DeferredTaxLiabilitiesPropertyPlantAndEquipmentIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment, Including Disposal Groups Assets Held For Sale</link:label>
    <link:label id="lab_ci_DeferredTaxLiabilitiesPropertyPlantAndEquipmentIncludingDisposalGroupsAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DeferredTaxLiabilitiesPropertyPlantAndEquipmentIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment, Including Disposal Groups Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesPropertyPlantAndEquipmentIncludingDisposalGroupsAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesPropertyPlantAndEquipmentIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DeferredTaxLiabilitiesPropertyPlantAndEquipmentIncludingDisposalGroupsAssetsHeldForSale" xlink:to="lab_ci_DeferredTaxLiabilitiesPropertyPlantAndEquipmentIncludingDisposalGroupsAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember_16d21ac2-522c-4214-9e10-eaf3d884a4d6_verboseLabel_en-US" xlink:label="lab_ci_AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other property and equipment</link:label>
    <link:label id="lab_ci_AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember_1476d883-3fea-4392-8be5-d996be672f86_terseLabel_en-US" xlink:label="lab_ci_AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other property and equipment</link:label>
    <link:label id="lab_ci_AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember_label_en-US" xlink:label="lab_ci_AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held Under Capital Leases And Other Capitalized Property Plant And Equipment [Member]</link:label>
    <link:label id="lab_ci_AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember_documentation_en-US" xlink:label="lab_ci_AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long lived property, plant or equipment assets held by a lessee through a captial lease and all other long term captalized assts related to property plant and equipment not otherwise previously categorized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember" xlink:href="ci-20231231.xsd#ci_AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember" xlink:to="lab_ci_AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_869d60a4-caaa-4e9b-bff5-fe0219ef4c97_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_894e3914-66aa-48f3-9116-d64d60b71e62_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of foreign currency translation and other adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member_66e39844-0036-4871-bf85-7c1d1627c9b1_terseLabel_en-US" xlink:label="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurral Year - 2022</link:label>
    <link:label id="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member_label_en-US" xlink:label="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contract, Accident Year 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member" xlink:to="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_9e5dc371-7088-41f3-aebd-8e32b2ce68fc_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_53edbd78-b5d0-439d-9e92-6d5544196f28_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtAndEquitySecuritiesClassifiedInLevel3PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale_24fc2969-e59e-4db4-ba34-c2a50b5d3b04_terseLabel_en-US" xlink:label="lab_ci_DebtAndEquitySecuritiesClassifiedInLevel3PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of debt and equity securities classified in Level 3, including assets held for sale</link:label>
    <link:label id="lab_ci_DebtAndEquitySecuritiesClassifiedInLevel3PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DebtAndEquitySecuritiesClassifiedInLevel3PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt And Equity Securities Classified In Level 3 Percentage Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_DebtAndEquitySecuritiesClassifiedInLevel3PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DebtAndEquitySecuritiesClassifiedInLevel3PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of debt and equity securities classified in Level 3 Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtAndEquitySecuritiesClassifiedInLevel3PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DebtAndEquitySecuritiesClassifiedInLevel3PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtAndEquitySecuritiesClassifiedInLevel3PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_DebtAndEquitySecuritiesClassifiedInLevel3PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_832ac334-f2dd-451c-89ae-cbc2d6f33e14_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf862139-7dc5-40eb-a72b-f71fa751e637_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SCORSEMember_968da409-595e-448d-8bea-5e535d543055_terseLabel_en-US" xlink:label="lab_ci_SCORSEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCOR SE</link:label>
    <link:label id="lab_ci_SCORSEMember_label_en-US" xlink:label="lab_ci_SCORSEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCOR SE [Member]</link:label>
    <link:label id="lab_ci_SCORSEMember_documentation_en-US" xlink:label="lab_ci_SCORSEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCOR SE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SCORSEMember" xlink:href="ci-20231231.xsd#ci_SCORSEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SCORSEMember" xlink:to="lab_ci_SCORSEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncatastrophicEventDomain_43f67159-d49b-441a-9b45-455eff2bd956_terseLabel_en-US" xlink:label="lab_us-gaap_NoncatastrophicEventDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncatastrophic Event [Domain]</link:label>
    <link:label id="lab_us-gaap_NoncatastrophicEventDomain_label_en-US" xlink:label="lab_us-gaap_NoncatastrophicEventDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncatastrophic Event [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncatastrophicEventDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncatastrophicEventDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncatastrophicEventDomain" xlink:to="lab_us-gaap_NoncatastrophicEventDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_088f5312-8c5b-4d10-9e32-b2d6137d2a86_terseLabel_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">More than one year</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_label_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months Or Longer [Abstract]</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_documentation_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months Or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract" xlink:to="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_0148c386-ca96-480c-bff5-35334e7b3c63_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other debt securities</link:label>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Debt Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDebtSecuritiesMember" xlink:to="lab_us-gaap_OtherDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_cea644bf-74db-4f12-a099-5fe3960fc2d3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related basis differences</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue_feac3dd7-f274-42a2-bd29-1c7a8c38d7d5_terseLabel_en-US" xlink:label="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Account value</link:label>
    <link:label id="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue_label_en-US" xlink:label="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Amount at Risk by Product and Guarantee, General Account Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue" xlink:to="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_26ce1dfe-22cf-4ec4-8692-85de6748d3fe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate accounts assets classified in Level 3, period increase (decrease), including transfers in and out of Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_3b71469a-9289-47cd-a192-c8373848342f_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities with readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_f1ba7e04-ec00-45c5-804d-2d2583915a91_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_IncomeTaxReconciliationHealthInsuranceIndustryTax_c9bbec04-cbe9-47d6-b217-a0e8cc9c5cbc_terseLabel_en-US" xlink:label="lab_ci_IncomeTaxReconciliationHealthInsuranceIndustryTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health insurance industry tax</link:label>
    <link:label id="lab_ci_IncomeTaxReconciliationHealthInsuranceIndustryTax_label_en-US" xlink:label="lab_ci_IncomeTaxReconciliationHealthInsuranceIndustryTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Health Insurance Industry Tax</link:label>
    <link:label id="lab_ci_IncomeTaxReconciliationHealthInsuranceIndustryTax_documentation_en-US" xlink:label="lab_ci_IncomeTaxReconciliationHealthInsuranceIndustryTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) due to the non-deductibility for federal income tax purposes of the health insurance industry tax assessed under Health Care Reform.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncomeTaxReconciliationHealthInsuranceIndustryTax" xlink:href="ci-20231231.xsd#ci_IncomeTaxReconciliationHealthInsuranceIndustryTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_IncomeTaxReconciliationHealthInsuranceIndustryTax" xlink:to="lab_ci_IncomeTaxReconciliationHealthInsuranceIndustryTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_e636c81b-dc56-4a70-967e-408355b82371_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_350652cd-816d-41a5-aa9a-35b3d9eaa924_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1c391dff-d62f-4ba1-987d-4c59fc28cb93_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_3f2d1540-1e90-4a7a-a13e-d7aa2e9f125e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding - beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d15c9c88-ab48-4fb2-b287-1a35882903f7_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding - ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NotesDue2025325InterestMember_566b5695-88e0-42ec-a13e-ffd300da10bc_terseLabel_en-US" xlink:label="lab_ci_NotesDue2025325InterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$900&#160;million, 3.250% Notes due April 2025 (2)</link:label>
    <link:label id="lab_ci_NotesDue2025325InterestMember_label_en-US" xlink:label="lab_ci_NotesDue2025325InterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2025 3.25% Interest [Member]</link:label>
    <link:label id="lab_ci_NotesDue2025325InterestMember_documentation_en-US" xlink:label="lab_ci_NotesDue2025325InterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable bearing interest at 3.25% due in 2025.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue2025325InterestMember" xlink:href="ci-20231231.xsd#ci_NotesDue2025325InterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NotesDue2025325InterestMember" xlink:to="lab_ci_NotesDue2025325InterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceRecoverables_3c3b3bc7-01bd-4dc7-bb1d-01259662ab86_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance recoverables</link:label>
    <link:label id="lab_us-gaap_ReinsuranceRecoverables_label_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Recoverables, Including Reinsurance Premium Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceRecoverables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceRecoverables" xlink:to="lab_us-gaap_ReinsuranceRecoverables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndemnificationGuaranteeMember_bd229b02-bba6-4d31-96aa-9ab3d0bcf426_terseLabel_en-US" xlink:label="lab_us-gaap_IndemnificationGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification obligations</link:label>
    <link:label id="lab_us-gaap_IndemnificationGuaranteeMember_label_en-US" xlink:label="lab_us-gaap_IndemnificationGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndemnificationGuaranteeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndemnificationGuaranteeMember" xlink:to="lab_us-gaap_IndemnificationGuaranteeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketRiskBenefitPolicyTextBlock_f4741c3e-bb74-4367-baaa-f47bdd6a8f70_terseLabel_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Risk Benefits</link:label>
    <link:label id="lab_us-gaap_MarketRiskBenefitPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Risk Benefit [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketRiskBenefitPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketRiskBenefitPolicyTextBlock" xlink:to="lab_us-gaap_MarketRiskBenefitPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_d89d998c-ef18-495f-98cc-f043715051ff_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ServiceFeesMember_ea939217-9fc1-44fa-ae03-f9f826789aee_terseLabel_en-US" xlink:label="lab_ci_ServiceFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fees</link:label>
    <link:label id="lab_ci_ServiceFeesMember_label_en-US" xlink:label="lab_ci_ServiceFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service, Fees [Member]</link:label>
    <link:label id="lab_ci_ServiceFeesMember_documentation_en-US" xlink:label="lab_ci_ServiceFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service, Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ServiceFeesMember" xlink:href="ci-20231231.xsd#ci_ServiceFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ServiceFeesMember" xlink:to="lab_ci_ServiceFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_d0bd7e59-70e3-40c2-9cd5-d6b077ff7927_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_78e9a900-8067-47a0-9fab-63f57af4e9c5_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap contracts</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_91f5f0e5-88e1-4dd5-9f9f-a02cb4cf084f_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Issues</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_935e351b-8eda-4de4-b4da-12a3ed88f644_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups_4b812aaf-6ddb-4a77-933b-9c7dc6b93a21_totalLabel_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, current</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups_label_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance And Contractholder Liabilities, Current, Including Disposal Groups</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups_documentation_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance And Contractholder Liabilities, Current, Including Disposal Groups</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups" xlink:to="lab_ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_eff1e2ba-1ce3-494d-82ee-a220764fdde6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansNoncurrentLiabilitiesAbstract_6080bdaf-d25e-4529-b31d-d6f0c162b3e6_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansNoncurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts presented in Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansNoncurrentLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansNoncurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansNoncurrentLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansNoncurrentLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansNoncurrentLiabilitiesAbstract" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansNoncurrentLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_2b4d70b0-4807-4adb-9af5-07bad7d7f643_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember_9e875695-cd93-4d49-896c-d583d3d68585_terseLabel_en-US" xlink:label="lab_ci_SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_ci_SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember_label_en-US" xlink:label="lab_ci_SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Allowance, Credit Loss, Uncollectible Premium Receivables, And Financing Receivables [Member]</link:label>
    <link:label id="lab_ci_SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember_documentation_en-US" xlink:label="lab_ci_SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Allowance, Credit Loss, Uncollectible Premium Receivables, And Financing Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember" xlink:href="ci-20231231.xsd#ci_SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember" xlink:to="lab_ci_SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_08b008da-c933-469c-989e-367949dd36e8_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current taxes</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3151f038-e437-4fb7-932d-b853b77e8768_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DueFromAffiliateNoncurrentNet_778fea29-0939-4c6d-a9c9-a10c2306ada4_terseLabel_en-US" xlink:label="lab_ci_DueFromAffiliateNoncurrentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intercompany receivables, net</link:label>
    <link:label id="lab_ci_DueFromAffiliateNoncurrentNet_label_en-US" xlink:label="lab_ci_DueFromAffiliateNoncurrentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due From Affiliate Noncurrent Net</link:label>
    <link:label id="lab_ci_DueFromAffiliateNoncurrentNet_documentation_en-US" xlink:label="lab_ci_DueFromAffiliateNoncurrentNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of receivables, net of payables, due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership, due after 1 year (or 1 business cycle).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DueFromAffiliateNoncurrentNet" xlink:href="ci-20231231.xsd#ci_DueFromAffiliateNoncurrentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DueFromAffiliateNoncurrentNet" xlink:to="lab_ci_DueFromAffiliateNoncurrentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_209ac3ce-c013-47b2-8a2f-3e05ea7a38e6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_bffdc566-dad8-421c-b4c3-00fb9b7eb15a_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Financing Receivable [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Financing Receivable [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:to="lab_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncatastrophicEventAxis_d8b4d235-c16b-40d7-93a6-891afc2c927a_terseLabel_en-US" xlink:label="lab_us-gaap_NoncatastrophicEventAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncatastrophic Event [Axis]</link:label>
    <link:label id="lab_us-gaap_NoncatastrophicEventAxis_label_en-US" xlink:label="lab_us-gaap_NoncatastrophicEventAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncatastrophic Event [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncatastrophicEventAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncatastrophicEventAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncatastrophicEventAxis" xlink:to="lab_us-gaap_NoncatastrophicEventAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentCurrent_48f4c91c-392e-4c40-a964-78621e16c7a2_negatedLabel_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentCurrent_label_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Including Discontinued Operation Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentCurrent" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DisposalGroupIncludingDiscontinuedOperationAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentCurrent" xlink:to="lab_ci_DisposalGroupIncludingDiscontinuedOperationAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_121ec4dd-f6f9-43f3-9be0-cc91ad944dbc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_1f899cc5-3a4d-41f8-a242-a05f87377514_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposed of by Sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ShareholdersEquityAbstract_fd993dea-b9d5-42e7-93c5-ec50c012dc11_terseLabel_en-US" xlink:label="lab_ci_ShareholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_ci_ShareholdersEquityAbstract_label_en-US" xlink:label="lab_ci_ShareholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShareholdersEquityAbstract" xlink:href="ci-20231231.xsd#ci_ShareholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ShareholdersEquityAbstract" xlink:to="lab_ci_ShareholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_6f3778ec-083c-4086-ba65-55c3ad0984a4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_e87daaaf-7fe1-4c0c-8e8c-eea68366d1a1_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FiniteLivedIntangibleAssetsNetVOBAIncludingDisposalGroupsAssetsHeldForSale_1a2def32-df0e-439b-bab1-b703ab0c9d3e_totalLabel_en-US" xlink:label="lab_ci_FiniteLivedIntangibleAssetsNetVOBAIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Value, including held for sale assets</link:label>
    <link:label id="lab_ci_FiniteLivedIntangibleAssetsNetVOBAIncludingDisposalGroupsAssetsHeldForSale_label_en-US" xlink:label="lab_ci_FiniteLivedIntangibleAssetsNetVOBAIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets Net VOBA Including Disposal Groups Assets Held For Sale</link:label>
    <link:label id="lab_ci_FiniteLivedIntangibleAssetsNetVOBAIncludingDisposalGroupsAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_FiniteLivedIntangibleAssetsNetVOBAIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets Net VOBA Including Disposal Groups Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsNetVOBAIncludingDisposalGroupsAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsNetVOBAIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FiniteLivedIntangibleAssetsNetVOBAIncludingDisposalGroupsAssetsHeldForSale" xlink:to="lab_ci_FiniteLivedIntangibleAssetsNetVOBAIncludingDisposalGroupsAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_83ce0989-e8a2-4883-aeee-b21b8db2db86_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Accident Year [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Accident Year [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_IntercompanyReceivablesInterestRate_2962c88b-e945-4a96-8095-e2a419c3fe13_terseLabel_en-US" xlink:label="lab_ci_IntercompanyReceivablesInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate, intercompany receivables</link:label>
    <link:label id="lab_ci_IntercompanyReceivablesInterestRate_label_en-US" xlink:label="lab_ci_IntercompanyReceivablesInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intercompany Receivables Interest Rate</link:label>
    <link:label id="lab_ci_IntercompanyReceivablesInterestRate_documentation_en-US" xlink:label="lab_ci_IntercompanyReceivablesInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual fixed rate of interest at which interest income on intercompany receivables was accrued.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntercompanyReceivablesInterestRate" xlink:href="ci-20231231.xsd#ci_IntercompanyReceivablesInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_IntercompanyReceivablesInterestRate" xlink:to="lab_ci_IntercompanyReceivablesInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_ca049eed-69a2-4925-8d18-bc7016cf403e_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_24500957-9694-4d68-83d9-2b312659c809_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_2ca93870-70ef-4079-80a7-0763521644ff_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_4e06737b-1cc6-4400-ad57-be4ac6b96a8e_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (benefit) cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesLineItems_4280ba76-c3af-4046-b623-7ff088eb62b9_terseLabel_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance and Contractholder Liabilities [Line Items]</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesLineItems_label_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance and Contractholder Liabilities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesLineItems" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems" xlink:to="lab_ci_InsuranceAndContractholderLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_223b0870-9544-4e1e-8e8a-c392e733d4de_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Status of and Changes in Common Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_28e6134e-9bf2-41e7-9bf4-74a88324537e_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_7ad7b0f7-cd67-422b-b9c6-f1696fbd0b08_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CededCreditRiskLineItems_634cdfe9-1aff-4293-894e-ec0ac56c99ab_terseLabel_en-US" xlink:label="lab_us-gaap_CededCreditRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded Credit Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_CededCreditRiskLineItems_label_en-US" xlink:label="lab_us-gaap_CededCreditRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded Credit Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CededCreditRiskLineItems" xlink:to="lab_us-gaap_CededCreditRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_f33cc4c5-6ddc-43fe-a962-2214746885da_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CededReinsuranceAgreementReinsuredRiskPercentage_7810820f-8c9f-416f-9088-6e3e80a5e958_terseLabel_en-US" xlink:label="lab_ci_CededReinsuranceAgreementReinsuredRiskPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of future claim payments reinsured</link:label>
    <link:label id="lab_ci_CededReinsuranceAgreementReinsuredRiskPercentage_label_en-US" xlink:label="lab_ci_CededReinsuranceAgreementReinsuredRiskPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded Reinsurance Agreement Reinsured Risk Percentage</link:label>
    <link:label id="lab_ci_CededReinsuranceAgreementReinsuredRiskPercentage_documentation_en-US" xlink:label="lab_ci_CededReinsuranceAgreementReinsuredRiskPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of future claim payments reinsured under reinsurance agreement(s), net of existing retrocessional arrangements at the time agreement was made.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CededReinsuranceAgreementReinsuredRiskPercentage" xlink:href="ci-20231231.xsd#ci_CededReinsuranceAgreementReinsuredRiskPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CededReinsuranceAgreementReinsuredRiskPercentage" xlink:to="lab_ci_CededReinsuranceAgreementReinsuredRiskPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_939f82c0-aa0a-47e4-bee5-59b42a0f0d82_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMortgageNotesReceivable_ac153271-7b96-40d6-8790-50b020bcc7e2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMortgageNotesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial mortgage loans</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMortgageNotesReceivable_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMortgageNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Mortgage Notes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMortgageNotesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMortgageNotesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMortgageNotesReceivable" xlink:to="lab_us-gaap_PaymentsToAcquireMortgageNotesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3828d308-5ebf-424c-8b9a-ace39debf6da_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current taxes</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_ab013162-aa1e-47f0-8654-a5d191e0e246_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in the Components of AOCI</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_5f62a752-b0ba-42df-8f63-24ff4bab1802_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income tax (benefit), net of federal income tax benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_d15d378e-4920-43d7-8ced-b05401bd92ea_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_14eb83dc-256c-4b7b-b415-24cacc2e9a62_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_7f08fee4-2711-48ce-886f-e18dbaee14fb_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal government and agency</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_a3d88f4b-db55-495f-a534-4f69be216d57_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal government securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_b8164403-8a5a-4f97-9b6b-988b1d325536_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset-backed</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_d142c1be-0427-4d36-8fe4-ff12f22c0e4d_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesLineItems_b7e30eba-d219-4437-b6af-c28683efdbd8_terseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesLineItems_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb276939-8d24-41eb-a497-5991f0e60e89_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET CASH PROVIDED BY OPERATING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4093e5ed-55ae-46ba-8204-7f1732b38f08_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteesMember_e8ea95f8-123c-4bf8-b530-74b1618afc60_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantees</link:label>
    <link:label id="lab_us-gaap_GuaranteesMember_label_en-US" xlink:label="lab_us-gaap_GuaranteesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteesMember" xlink:to="lab_us-gaap_GuaranteesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_73911ce0-c727-4a4b-9c8d-a8ef56a36a16_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collectively Significant Operating Unconsolidated Subsidiaries</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember_83e75ff2-5e6a-4f1c-b2db-914d10c81538_terseLabel_en-US" xlink:label="lab_ci_SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial mortgage loans</link:label>
    <link:label id="lab_ci_SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember_label_en-US" xlink:label="lab_ci_SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Allowance, Investment Valuation Reserves, Commercial Mortgage Loans [Member]</link:label>
    <link:label id="lab_ci_SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember_documentation_en-US" xlink:label="lab_ci_SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Allowance, Investment Valuation Reserves, Commercial Mortgage Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember" xlink:href="ci-20231231.xsd#ci_SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember" xlink:to="lab_ci_SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale_dc8b67f3-5cf8-4ffb-a14d-9abb5a84215d_terseLabel_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after ten years, including assets held for sale</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_40e25826-fef8-4070-be5e-7e6cdb04c589_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross gains on sales</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_e3525bb9-2079-4a2a-87bb-00d01a1d07b2_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_7cb52c3d-c33b-4384-962e-78dcb6349cd5_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_ad6249d3-46f4-48d5-80a6-4b18ba69a174_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_a6c3fdfe-fd60-4192-ae28-64f2ac515236_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance for deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_b51dfad8-1093-42f2-8aff-4b530fc1e8d4_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsAxis_c51971f5-c2a8-48d3-8d9d-d52ac35e8814_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis" xlink:to="lab_us-gaap_SubsegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_47dc3c16-09e2-4e58-a3a6-b9f6217ff9cc_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FiniteLivedIntangibleAssetsGrossVoba_79cd39cc-bd8c-4293-bbe2-bb49cf889e68_terseLabel_en-US" xlink:label="lab_ci_FiniteLivedIntangibleAssetsGrossVoba" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_ci_FiniteLivedIntangibleAssetsGrossVoba_label_en-US" xlink:label="lab_ci_FiniteLivedIntangibleAssetsGrossVoba" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets Gross VOBA</link:label>
    <link:label id="lab_ci_FiniteLivedIntangibleAssetsGrossVoba_documentation_en-US" xlink:label="lab_ci_FiniteLivedIntangibleAssetsGrossVoba" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before amortization of insurance contracts acquired in a business combination that are reported in deferred policy acquisition costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsGrossVoba" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsGrossVoba"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FiniteLivedIntangibleAssetsGrossVoba" xlink:to="lab_ci_FiniteLivedIntangibleAssetsGrossVoba" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_1f8d20b0-c0b4-4dd4-be26-227f4fad53b0_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsExercisableAbstract_5e530321-d3e9-47f5-bf12-d1808377939c_terseLabel_en-US" xlink:label="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsExercisableAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Exercisable</link:label>
    <link:label id="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsExercisableAbstract_label_en-US" xlink:label="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsExercisableAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Information About Options Exercisable [Abstract]</link:label>
    <link:label id="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsExercisableAbstract_documentation_en-US" xlink:label="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsExercisableAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Information About Options Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsExercisableAbstract" xlink:href="ci-20231231.xsd#ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsExercisableAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsExercisableAbstract" xlink:to="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsExercisableAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfMaturitiesOfLongTermDebtTableTextBlock_b1ea44fd-ab8e-498c-bdfc-5df2265fdc5d_terseLabel_en-US" xlink:label="lab_ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt</link:label>
    <link:label id="lab_ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Information Of Parent Company Only, Schedule Of Maturities Of Long-Term Debt [Table Text Block]</link:label>
    <link:label id="lab_ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfMaturitiesOfLongTermDebtTableTextBlock_documentation_en-US" xlink:label="lab_ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Information Of Parent Company Only, Schedule Of Maturities Of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="ci-20231231.xsd#ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NotesDue2036615InterestMember_013c17e6-7df0-46b3-a7e9-bf3589203d15_terseLabel_en-US" xlink:label="lab_ci_NotesDue2036615InterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$190&#160;million, 6.150% Notes due November 2036</link:label>
    <link:label id="lab_ci_NotesDue2036615InterestMember_label_en-US" xlink:label="lab_ci_NotesDue2036615InterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes due 2036 6.15% Interest [Member]</link:label>
    <link:label id="lab_ci_NotesDue2036615InterestMember_documentation_en-US" xlink:label="lab_ci_NotesDue2036615InterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable bearing interest at 6.15% due in 2036.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue2036615InterestMember" xlink:href="ci-20231231.xsd#ci_NotesDue2036615InterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NotesDue2036615InterestMember" xlink:to="lab_ci_NotesDue2036615InterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_6ccb3ac1-58fc-4560-8b11-c2901adcfa98_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_91b70a6e-d0d5-4f05-8794-0feb76632f82_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_203687b5-97a6-4279-8942-9a3c40b9abdc_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Value</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteedMinimumDeathBenefitMember_97b7af0e-f895-48c4-974c-a75baf126f2d_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteedMinimumDeathBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GMDB</link:label>
    <link:label id="lab_us-gaap_GuaranteedMinimumDeathBenefitMember_label_en-US" xlink:label="lab_us-gaap_GuaranteedMinimumDeathBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guaranteed Minimum Death Benefit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteedMinimumDeathBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteedMinimumDeathBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteedMinimumDeathBenefitMember" xlink:to="lab_us-gaap_GuaranteedMinimumDeathBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_IncreaseDecreaseInAmountsDueFromAffiliates_c477dff6-d23d-430b-a0e5-80c6b3db67d4_negatedTerseLabel_en-US" xlink:label="lab_ci_IncreaseDecreaseInAmountsDueFromAffiliates" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in amounts due from affiliates</link:label>
    <link:label id="lab_ci_IncreaseDecreaseInAmountsDueFromAffiliates_label_en-US" xlink:label="lab_ci_IncreaseDecreaseInAmountsDueFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Amounts Due From Affiliates</link:label>
    <link:label id="lab_ci_IncreaseDecreaseInAmountsDueFromAffiliates_documentation_en-US" xlink:label="lab_ci_IncreaseDecreaseInAmountsDueFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) Decrease In Amounts Due From Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncreaseDecreaseInAmountsDueFromAffiliates" xlink:href="ci-20231231.xsd#ci_IncreaseDecreaseInAmountsDueFromAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_IncreaseDecreaseInAmountsDueFromAffiliates" xlink:to="lab_ci_IncreaseDecreaseInAmountsDueFromAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_fbeeee8b-685b-4364-bd2b-6b641ff8c9c0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_4a48d9a2-54f4-41c3-bc70-548897b1e064_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5d2f4d84-8ca1-4b8c-9c8e-43b039626f72_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract_21a710b7-90d5-40ca-b81e-729979bc6cd8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment classified as Assets of businesses held for sale</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Assets Held-for-Sale Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale_60d459bc-97a6-4074-a8ea-50c5a25bd463_terseLabel_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Appreciation, including held for sale assets</link:label>
    <link:label id="lab_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_33108c3e-bd9c-479b-82c3-51c48b906ef1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance and Contractholder Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_01605e29-6fb3-4bc6-ad8d-82c7d8120ae3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets and Financial Liabilities Carried at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1e1d1101-cc5c-4c28-a375-d0f4331a04a5_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b3ab6d8a-edc1-4a6e-9be7-e458453ef503_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c59976bf-40af-4152-b094-dd19bf24c437_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0c82184d-1695-4ed6-a80c-0d581e873589_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease to shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_3271fece-a4e3-41df-b3f5-669451b858ae_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_21122d5e-b53f-460b-b1a0-1433c9d0654c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income distributions</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:to="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember_a8992134-24bb-4618-995b-e54776de2dc2_terseLabel_en-US" xlink:label="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BBB- to BBB+ equivalent current credit ratings</link:label>
    <link:label id="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember_label_en-US" xlink:label="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nationally Recognized Statisical Rating Organizations (NRSRO), BBB- To BBB+ Rating [Member]</link:label>
    <link:label id="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember_documentation_en-US" xlink:label="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nationally Recognized Statisical Rating Organizations (NRSRO), BBB- To BBB+ Rating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember" xlink:href="ci-20231231.xsd#ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember" xlink:to="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_880f0df4-43fe-4ad8-a847-454d2aefbdac_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in amounts due to affiliates</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Related Party Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_4e351cb8-5827-4f86-a5bd-b1c2ca672d8d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_08f7c5b2-cf82-4a34-9762-dd8a30414914_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_18e46f1e-f364-40ae-ac6e-ba25ce90edfb_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligationCurrent_9c5b7677-94fb-4b47-85ab-c113923b6576_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding payment obligations, current</link:label>
    <link:label id="lab_us-gaap_SupplierFinanceProgramObligationCurrent_label_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramObligationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Finance Program, Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierFinanceProgramObligationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierFinanceProgramObligationCurrent" xlink:to="lab_us-gaap_SupplierFinanceProgramObligationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_811923e5-9a0f-49d4-86ee-45f05de54067_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_09f5ac6d-71b2-4964-b097-496b411d6bae_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total incurred</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_d53a8024-fbaf-45e5-8a73-6ef257a197dd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds on issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CededReinsuranceAgreementCoverageLimitAmountRemaining_96fd3413-85f8-4f43-9e3f-633733ee78ad_terseLabel_en-US" xlink:label="lab_ci_CededReinsuranceAgreementCoverageLimitAmountRemaining" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining overall limit under reinsurance agreement</link:label>
    <link:label id="lab_ci_CededReinsuranceAgreementCoverageLimitAmountRemaining_label_en-US" xlink:label="lab_ci_CededReinsuranceAgreementCoverageLimitAmountRemaining" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded Reinsurance Agreement, Coverage Limit, Amount Remaining</link:label>
    <link:label id="lab_ci_CededReinsuranceAgreementCoverageLimitAmountRemaining_documentation_en-US" xlink:label="lab_ci_CededReinsuranceAgreementCoverageLimitAmountRemaining" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount remaining of overall limit to claims covered under ceded reinsurance agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CededReinsuranceAgreementCoverageLimitAmountRemaining" xlink:href="ci-20231231.xsd#ci_CededReinsuranceAgreementCoverageLimitAmountRemaining"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CededReinsuranceAgreementCoverageLimitAmountRemaining" xlink:to="lab_ci_CededReinsuranceAgreementCoverageLimitAmountRemaining" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_UnearnedPremiumsAttributableToDisposalGroups_79e3c5a0-d10e-497b-a2cd-2eabe7fa9992_terseLabel_en-US" xlink:label="lab_ci_UnearnedPremiumsAttributableToDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unearned premiums classified as liabilities of business held for sale</link:label>
    <link:label id="lab_ci_UnearnedPremiumsAttributableToDisposalGroups_label_en-US" xlink:label="lab_ci_UnearnedPremiumsAttributableToDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unearned Premiums Attributable To Disposal Groups</link:label>
    <link:label id="lab_ci_UnearnedPremiumsAttributableToDisposalGroups_documentation_en-US" xlink:label="lab_ci_UnearnedPremiumsAttributableToDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unearned Premiums Attributable To Disposal Groups</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsAttributableToDisposalGroups" xlink:href="ci-20231231.xsd#ci_UnearnedPremiumsAttributableToDisposalGroups"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_UnearnedPremiumsAttributableToDisposalGroups" xlink:to="lab_ci_UnearnedPremiumsAttributableToDisposalGroups" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_fd4ef4a9-3540-49f3-8ebd-90e8889a5ec0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax withholding on stock compensation and other</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant_91f51020-a081-4795-b661-59bbc8087aec_terseLabel_en-US" xlink:label="lab_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leverage ratio covenant</link:label>
    <link:label id="lab_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant_label_en-US" xlink:label="lab_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility Debt To Adjusted Capital Ratio Covenant</link:label>
    <link:label id="lab_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant_documentation_en-US" xlink:label="lab_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The debt-to adjusted capital ratio which the Company must not exceed in accordance with the terms of the line of credit facility agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant" xlink:href="ci-20231231.xsd#ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant" xlink:to="lab_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_89c02d17-7316-4645-8714-3e6f10f72443_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule II - Valuation and Qualifying Accounts and Reserves</link:label>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_139626bd-1a79-406a-97a2-519048c544d8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVoba_d8b78054-2390-4efd-a79b-885a7cd1fd8c_totalLabel_en-US" xlink:label="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVoba" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVoba_label_en-US" xlink:label="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVoba" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets Accumulated Amortization Including VOBA</link:label>
    <link:label id="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVoba_documentation_en-US" xlink:label="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVoba" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. Includes insurance contracts acquired in a business combination that are reported in deferred policy acquisition costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVoba" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVoba"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVoba" xlink:to="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVoba" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AccumulatedDefinedBenefitPlansAdjustmentGainLossOnSaleOfBusinessMember_2832bf96-4cd9-44a0-bbd6-e75858c0c2e2_terseLabel_en-US" xlink:label="lab_ci_AccumulatedDefinedBenefitPlansAdjustmentGainLossOnSaleOfBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustment for (gains) included in Shareholders' net income ((Loss) gain on sale of businesses)</link:label>
    <link:label id="lab_ci_AccumulatedDefinedBenefitPlansAdjustmentGainLossOnSaleOfBusinessMember_label_en-US" xlink:label="lab_ci_AccumulatedDefinedBenefitPlansAdjustmentGainLossOnSaleOfBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment, Gain (Loss) On Sale Of Business [Member]</link:label>
    <link:label id="lab_ci_AccumulatedDefinedBenefitPlansAdjustmentGainLossOnSaleOfBusinessMember_documentation_en-US" xlink:label="lab_ci_AccumulatedDefinedBenefitPlansAdjustmentGainLossOnSaleOfBusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment, Gain (Loss) On Sale Of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccumulatedDefinedBenefitPlansAdjustmentGainLossOnSaleOfBusinessMember" xlink:href="ci-20231231.xsd#ci_AccumulatedDefinedBenefitPlansAdjustmentGainLossOnSaleOfBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AccumulatedDefinedBenefitPlansAdjustmentGainLossOnSaleOfBusinessMember" xlink:to="lab_ci_AccumulatedDefinedBenefitPlansAdjustmentGainLossOnSaleOfBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups_fc4c135b-1abd-4172-8221-9da47872b8ae_totalLabel_en-US" xlink:label="lab_ci_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_ci_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups_label_en-US" xlink:label="lab_ci_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Including Disposal Groups</link:label>
    <link:label id="lab_ci_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups_documentation_en-US" xlink:label="lab_ci_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount, including disposal groups, of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups" xlink:href="ci-20231231.xsd#ci_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups" xlink:to="lab_ci_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_fa082b5a-af32-4bd3-9952-19172e3bee85_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAttributedToInstrumentsHeldIncludedInEarnings_e6e9c567-d099-41ba-b6f4-1c569aeaa38f_terseLabel_en-US" xlink:label="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAttributedToInstrumentsHeldIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total losses included in Shareholders' net income attributable to instruments held at the reporting date</link:label>
    <link:label id="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAttributedToInstrumentsHeldIncludedInEarnings_label_en-US" xlink:label="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAttributedToInstrumentsHeldIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Attributed To Instruments Held Included In Earnings</link:label>
    <link:label id="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAttributedToInstrumentsHeldIncludedInEarnings_documentation_en-US" xlink:label="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAttributedToInstrumentsHeldIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents total gains or losses for the period (realized and unrealized), arising from assets included in income attributable to instruments held at the reporting date, measured at fair value on a recurring basis using unobservable inputs (Level 3), which are included in earnings or resulted in a change in asset value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAttributedToInstrumentsHeldIncludedInEarnings" xlink:href="ci-20231231.xsd#ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAttributedToInstrumentsHeldIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAttributedToInstrumentsHeldIncludedInEarnings" xlink:to="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAttributedToInstrumentsHeldIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_8894e413-90a6-4bcb-97a1-cc61fec611ad_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember_e0a14221-5577-4093-b5cf-efd26aace01c_terseLabel_en-US" xlink:label="lab_ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net long-duration insurance and contractholder liabilities measurement adjustments (1)</link:label>
    <link:label id="lab_ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember_label_en-US" xlink:label="lab_ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Liability For Future Policy Benefit And Market Risk Benefit, Instrument-Specific Credit Risk, Parent [Member]</link:label>
    <link:label id="lab_ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember_documentation_en-US" xlink:label="lab_ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Liability For Future Policy Benefit And Market Risk Benefit, Instrument-Specific Credit Risk, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember" xlink:href="ci-20231231.xsd#ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember" xlink:to="lab_ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups_609fd021-d99f-44ce-a119-68378e5b247f_totalLabel_en-US" xlink:label="lab_ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Value</link:label>
    <link:label id="lab_ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups_label_en-US" xlink:label="lab_ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Plant And Equipment Net Including Disposal Groups</link:label>
    <link:label id="lab_ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups_documentation_en-US" xlink:label="lab_ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount, including disposal groups, after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups" xlink:href="ci-20231231.xsd#ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups" xlink:to="lab_ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_b5daa231-501f-4549-bea8-e508862a565f_totalLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total transfers into/(out of) Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_a04a03c6-10de-448c-877c-65cb77b06fd8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative gain (loss) recognized in other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationReinsuranceRecoverablesIncludingReinsurancePremiumPaid_2b8c4528-9ac9-4f6e-b0b2-c8fc5c927fb5_terseLabel_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationReinsuranceRecoverablesIncludingReinsurancePremiumPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance recoverable classified as assets of businesses held for sale</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationReinsuranceRecoverablesIncludingReinsurancePremiumPaid_label_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationReinsuranceRecoverablesIncludingReinsurancePremiumPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Reinsurance Recoverables, Including Reinsurance Premium Paid</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationReinsuranceRecoverablesIncludingReinsurancePremiumPaid_documentation_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationReinsuranceRecoverablesIncludingReinsurancePremiumPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Reinsurance Recoverables, Including Reinsurance Premium Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationReinsuranceRecoverablesIncludingReinsurancePremiumPaid" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationReinsuranceRecoverablesIncludingReinsurancePremiumPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DisposalGroupIncludingDiscontinuedOperationReinsuranceRecoverablesIncludingReinsurancePremiumPaid" xlink:to="lab_ci_DisposalGroupIncludingDiscontinuedOperationReinsuranceRecoverablesIncludingReinsurancePremiumPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_1b5a9572-fe17-4aaf-97b9-f582bf6594ed_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_88551e93-caef-4029-a3b1-ce545908688c_terseLabel_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period, Accounting Standards Update, Adjustment</link:label>
    <link:label id="lab_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_label_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period, Accounting Standards Update, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:to="lab_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AssetsAndLiabilitiesLesseeFinanceLeasesAbstract_70dac3d2-8ae0-4b9a-8376-8d93f371bcb4_terseLabel_en-US" xlink:label="lab_ci_AssetsAndLiabilitiesLesseeFinanceLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases:</link:label>
    <link:label id="lab_ci_AssetsAndLiabilitiesLesseeFinanceLeasesAbstract_label_en-US" xlink:label="lab_ci_AssetsAndLiabilitiesLesseeFinanceLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee, Finance Leases [Abstract]</link:label>
    <link:label id="lab_ci_AssetsAndLiabilitiesLesseeFinanceLeasesAbstract_documentation_en-US" xlink:label="lab_ci_AssetsAndLiabilitiesLesseeFinanceLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee, Finance Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AssetsAndLiabilitiesLesseeFinanceLeasesAbstract" xlink:href="ci-20231231.xsd#ci_AssetsAndLiabilitiesLesseeFinanceLeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AssetsAndLiabilitiesLesseeFinanceLeasesAbstract" xlink:to="lab_ci_AssetsAndLiabilitiesLesseeFinanceLeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_5a303efe-6bd6-45fa-8c8b-8bf861f9366c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_d2380917-622c-4326-8cd8-645e27a2226a_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets, January 1</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_4e62e181-3789-4aa9-be78-1192c286aa54_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets, December 31</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_be1883a7-80a4-496c-a9c8-a776d84bea7d_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension assets at fair value</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DeferredTaxAssetsInvestmentsSubjectToFederalCapitalLossUtilizationRules_b38b4572-3655-4d19-af51-216b6212aef2_terseLabel_en-US" xlink:label="lab_ci_DeferredTaxAssetsInvestmentsSubjectToFederalCapitalLossUtilizationRules" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets associated with unrealized investment losses</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsInvestmentsSubjectToFederalCapitalLossUtilizationRules_label_en-US" xlink:label="lab_ci_DeferredTaxAssetsInvestmentsSubjectToFederalCapitalLossUtilizationRules" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Investments Subject To Federal Capital Loss Utilization Rules</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsInvestmentsSubjectToFederalCapitalLossUtilizationRules_documentation_en-US" xlink:label="lab_ci_DeferredTaxAssetsInvestmentsSubjectToFederalCapitalLossUtilizationRules" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets relative to investments subject to Federal capital loss utilization rules. Capital losses can only be utilized to extent there are capital gains in a given year. If capital losses exceed capital gains, the taxpayer can utilize capital losses to the extent there are capital gains in the applicable carryback period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsInvestmentsSubjectToFederalCapitalLossUtilizationRules" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsInvestmentsSubjectToFederalCapitalLossUtilizationRules"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DeferredTaxAssetsInvestmentsSubjectToFederalCapitalLossUtilizationRules" xlink:to="lab_ci_DeferredTaxAssetsInvestmentsSubjectToFederalCapitalLossUtilizationRules" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_79edab04-fcd2-4482-97be-48a1363b4cab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity_b3c6dbca-31d8-4fbf-8329-46cb1a868b73_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIEs, Carrying value</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest in Variable Interest Entity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestInVariableInterestEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:to="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_927f02c0-2799-4883-8c12-09a77355112a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Debt Securities with a Decline in Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract_d24abe10-f475-4597-8b3a-933d1af97711_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total reinsurance recoveries</link:label>
    <link:label id="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract_label_en-US" xlink:label="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Benefits and Claims Incurred, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract" xlink:to="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_47f06f66-53da-4f93-a1e3-850425550529_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_05a7fc0c-a860-4b6e-884f-020239cc2291_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance sheet location of current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PharmacyBenefitsManagementServicesMember_ee09142a-a9cb-488d-afac-a3478757875b_terseLabel_en-US" xlink:label="lab_ci_PharmacyBenefitsManagementServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Benefits Management Services</link:label>
    <link:label id="lab_ci_PharmacyBenefitsManagementServicesMember_label_en-US" xlink:label="lab_ci_PharmacyBenefitsManagementServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Benefits Management Services [Member]</link:label>
    <link:label id="lab_ci_PharmacyBenefitsManagementServicesMember_documentation_en-US" xlink:label="lab_ci_PharmacyBenefitsManagementServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy benefit management services provided to corporate client, other employer groups and their employees. These services include pharmacy home delivery, retail network administration and specialty pharmacy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PharmacyBenefitsManagementServicesMember" xlink:href="ci-20231231.xsd#ci_PharmacyBenefitsManagementServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PharmacyBenefitsManagementServicesMember" xlink:to="lab_ci_PharmacyBenefitsManagementServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_3fe1ce4d-29a9-49d1-af84-7c1e993ac8e6_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_65d6ccad-0954-447a-bc6c-2a68b6cb990c_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LitigationMattersAndRegulatoryMattersMember_04c0cbc1-467c-4818-91fb-8dd5d6f20f5e_terseLabel_en-US" xlink:label="lab_ci_LitigationMattersAndRegulatoryMattersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Matters and Regulatory Matters</link:label>
    <link:label id="lab_ci_LitigationMattersAndRegulatoryMattersMember_label_en-US" xlink:label="lab_ci_LitigationMattersAndRegulatoryMattersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Matters And Regulatory Matters [Member]</link:label>
    <link:label id="lab_ci_LitigationMattersAndRegulatoryMattersMember_documentation_en-US" xlink:label="lab_ci_LitigationMattersAndRegulatoryMattersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Matters And Regulatory Matters</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LitigationMattersAndRegulatoryMattersMember" xlink:href="ci-20231231.xsd#ci_LitigationMattersAndRegulatoryMattersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LitigationMattersAndRegulatoryMattersMember" xlink:to="lab_ci_LitigationMattersAndRegulatoryMattersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_fd6ee5c5-b96c-4b18-963e-5381ee144374_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid costs related to:</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_GainLossOnExtinguishmentOfDebtNetOfTax_e1380474-a049-45a7-8211-58c1dac70d35_negatedTerseLabel_en-US" xlink:label="lab_ci_GainLossOnExtinguishmentOfDebtNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on repurchase of debt, after-tax</link:label>
    <link:label id="lab_ci_GainLossOnExtinguishmentOfDebtNetOfTax_label_en-US" xlink:label="lab_ci_GainLossOnExtinguishmentOfDebtNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Extinguishment Of Debt, Net Of Tax</link:label>
    <link:label id="lab_ci_GainLossOnExtinguishmentOfDebtNetOfTax_documentation_en-US" xlink:label="lab_ci_GainLossOnExtinguishmentOfDebtNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Extinguishment Of Debt, Net Of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_GainLossOnExtinguishmentOfDebtNetOfTax" xlink:href="ci-20231231.xsd#ci_GainLossOnExtinguishmentOfDebtNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_GainLossOnExtinguishmentOfDebtNetOfTax" xlink:to="lab_ci_GainLossOnExtinguishmentOfDebtNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeTextBlock_080c6256-3cff-4195-9dd1-08c59ed25ae5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Net Investment Income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeTextBlock" xlink:to="lab_us-gaap_InvestmentIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DeferredTaxLiabilitiesOtherIncludingDisposalGroupsAssetsHeldForSale_42098edc-b17f-47b8-8a7a-19714683cf5d_terseLabel_en-US" xlink:label="lab_ci_DeferredTaxLiabilitiesOtherIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ci_DeferredTaxLiabilitiesOtherIncludingDisposalGroupsAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DeferredTaxLiabilitiesOtherIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other, Including Disposal Groups Assets Held For Sale</link:label>
    <link:label id="lab_ci_DeferredTaxLiabilitiesOtherIncludingDisposalGroupsAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DeferredTaxLiabilitiesOtherIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other, Including Disposal Groups Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesOtherIncludingDisposalGroupsAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesOtherIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DeferredTaxLiabilitiesOtherIncludingDisposalGroupsAssetsHeldForSale" xlink:to="lab_ci_DeferredTaxLiabilitiesOtherIncludingDisposalGroupsAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_eb4f3176-7a1d-45df-9f02-b09c6524219e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTransactionIncludingDisposalGroupsAssetsHeldForSale_6e7dd4ea-57c3-4e99-9ece-20b034189e69_terseLabel_en-US" xlink:label="lab_ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTransactionIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized depreciation on investments and foreign currency translation</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTransactionIncludingDisposalGroupsAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTransactionIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Unrealized Losses On Investments And Foreign Currency Transaction, Including Disposal Groups Assets Held For Sale</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTransactionIncludingDisposalGroupsAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTransactionIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of deferred tax assets, including held for sale amounts, attributable to taxable temporary differences from unrealized losses on investments and foreign currency translation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTransactionIncludingDisposalGroupsAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTransactionIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTransactionIncludingDisposalGroupsAssetsHeldForSale" xlink:to="lab_ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTransactionIncludingDisposalGroupsAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CededCreditRiskUnsecuredMember_0b65f560-8207-4319-af63-1cfbdcaaa4c8_terseLabel_en-US" xlink:label="lab_us-gaap_CededCreditRiskUnsecuredMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No collateral</link:label>
    <link:label id="lab_us-gaap_CededCreditRiskUnsecuredMember_label_en-US" xlink:label="lab_us-gaap_CededCreditRiskUnsecuredMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded Credit Risk, Unsecured [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskUnsecuredMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskUnsecuredMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CededCreditRiskUnsecuredMember" xlink:to="lab_us-gaap_CededCreditRiskUnsecuredMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_1c63db18-f362-4f0b-911e-455de2c73f8f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaAndOtherRecoverablesMember_a727aac4-5d3e-491a-957f-082a500fb695_terseLabel_en-US" xlink:label="lab_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaAndOtherRecoverablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Berkshire Hathway Life Insurance Company Of Nebraska and Other Recoverables</link:label>
    <link:label id="lab_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaAndOtherRecoverablesMember_label_en-US" xlink:label="lab_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaAndOtherRecoverablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Berkshire Hathway Life Insurance Company Of Nebraska And Other Recoverables [Member]</link:label>
    <link:label id="lab_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaAndOtherRecoverablesMember_documentation_en-US" xlink:label="lab_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaAndOtherRecoverablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Berkshire Hathway Life Insurance Company Of Nebraska And Other Recoverables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaAndOtherRecoverablesMember" xlink:href="ci-20231231.xsd#ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaAndOtherRecoverablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaAndOtherRecoverablesMember" xlink:to="lab_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaAndOtherRecoverablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeparateAccountsLiability_b3920582-a348-4f6c-8173-fd50b8c6cfb6_terseLabel_en-US" xlink:label="lab_us-gaap_SeparateAccountsLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate account liabilities</link:label>
    <link:label id="lab_us-gaap_SeparateAccountsLiability_label_en-US" xlink:label="lab_us-gaap_SeparateAccountsLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate Account, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountsLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeparateAccountsLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeparateAccountsLiability" xlink:to="lab_us-gaap_SeparateAccountsLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f4dbe3e4-21cc-49e6-8e90-9dbc35fec130_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_c27c693a-181c-41d9-80f5-8a1511bc8cc9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_a0282046-ffe5-4927-be87-5b1b43f92864_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax benefits</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceReceivablesIncurredButNotReportedClaims_d3f16ea8-d742-430f-a8fa-b695f99b5655_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceReceivablesIncurredButNotReportedClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurred but not yet paid and outstanding claims</link:label>
    <link:label id="lab_us-gaap_ReinsuranceReceivablesIncurredButNotReportedClaims_label_en-US" xlink:label="lab_us-gaap_ReinsuranceReceivablesIncurredButNotReportedClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Recoverables, Incurred but Not Reported Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceReceivablesIncurredButNotReportedClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceReceivablesIncurredButNotReportedClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceReceivablesIncurredButNotReportedClaims" xlink:to="lab_us-gaap_ReinsuranceReceivablesIncurredButNotReportedClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_HealthCareServiceCorporationHCSCMember_dce6777a-b17f-4a7b-b139-19489198a11e_terseLabel_en-US" xlink:label="lab_ci_HealthCareServiceCorporationHCSCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Service Corporation (HCSC)</link:label>
    <link:label id="lab_ci_HealthCareServiceCorporationHCSCMember_label_en-US" xlink:label="lab_ci_HealthCareServiceCorporationHCSCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Service Corporation (HCSC) [Member]</link:label>
    <link:label id="lab_ci_HealthCareServiceCorporationHCSCMember_documentation_en-US" xlink:label="lab_ci_HealthCareServiceCorporationHCSCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Service Corporation (HCSC)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_HealthCareServiceCorporationHCSCMember" xlink:href="ci-20231231.xsd#ci_HealthCareServiceCorporationHCSCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_HealthCareServiceCorporationHCSCMember" xlink:to="lab_ci_HealthCareServiceCorporationHCSCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_33164b38-10d9-46b8-8cae-fb3dc57187da_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0ae8092a-0084-4ee3-9210-f9c555f38fae_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesDisclosureTextBlock_cc1cca36-e442-40af-8c4b-3d8dd91e22c6_terseLabel_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Net Income and Net Assets of the Company's Subsidiaries</link:label>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Accounting Practices Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatutoryAccountingPracticesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatutoryAccountingPracticesDisclosureTextBlock" xlink:to="lab_us-gaap_StatutoryAccountingPracticesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance_26846456-ca06-4458-9c49-4366ee5135ea_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance at original discount rate</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefit, Expected Net Premium, Original Discount Rate, before Cash Flow and Reinsurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_01e80e49-d23a-462e-b531-04867161afdf_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_d98d6f39-9f0d-4bf9-a969-38b2d0f0ac95_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_9f29d66f-7869-4f34-8508-4aae1c0af500_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InvestmentsCreditRatingAxis_575ae52b-85b0-4396-9d7e-948e0512c25a_terseLabel_en-US" xlink:label="lab_ci_InvestmentsCreditRatingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Credit Rating [Axis]</link:label>
    <link:label id="lab_ci_InvestmentsCreditRatingAxis_label_en-US" xlink:label="lab_ci_InvestmentsCreditRatingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Credit Rating [Axis]</link:label>
    <link:label id="lab_ci_InvestmentsCreditRatingAxis_documentation_en-US" xlink:label="lab_ci_InvestmentsCreditRatingAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information by credit rating of debt and securities investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InvestmentsCreditRatingAxis" xlink:href="ci-20231231.xsd#ci_InvestmentsCreditRatingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InvestmentsCreditRatingAxis" xlink:to="lab_ci_InvestmentsCreditRatingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_beb3a597-c7a0-4219-89fd-20a1f1ba30d6_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_UnearnedPremiumsCurrentIncludingDisposalGroups_55deca03-9c48-44f6-b391-a551d812e253_terseLabel_en-US" xlink:label="lab_ci_UnearnedPremiumsCurrentIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unearned premiums, current, including held for sale liabilities</link:label>
    <link:label id="lab_ci_UnearnedPremiumsCurrentIncludingDisposalGroups_label_en-US" xlink:label="lab_ci_UnearnedPremiumsCurrentIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unearned Premiums Current Including Disposal Groups</link:label>
    <link:label id="lab_ci_UnearnedPremiumsCurrentIncludingDisposalGroups_documentation_en-US" xlink:label="lab_ci_UnearnedPremiumsCurrentIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount of premiums written on insurance contracts that have not been earned as of the balance sheet date, expected to be paid in one year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsCurrentIncludingDisposalGroups" xlink:href="ci-20231231.xsd#ci_UnearnedPremiumsCurrentIncludingDisposalGroups"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_UnearnedPremiumsCurrentIncludingDisposalGroups" xlink:to="lab_ci_UnearnedPremiumsCurrentIncludingDisposalGroups" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0be1a2e6-c85f-48c6-a210-80a2c7d257c4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_631ae874-c725-41a3-a614-9c58ab6f7b26_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock equivalents (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock_8952d544-cdef-4396-95ce-10e7191afb82_terseLabel_en-US" xlink:label="lab_ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock_label_en-US" xlink:label="lab_ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Text Block]</link:label>
    <link:label id="lab_ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock_documentation_en-US" xlink:label="lab_ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclousre of the changes in the componenets of other comprehensive income/loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock" xlink:href="ci-20231231.xsd#ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock" xlink:to="lab_ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_918cf381-63cf-43d5-9c18-647b41fe5a4a_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OtherIntangibleAssetsAbstract_4537ab48-48be-48f5-9458-a1786c829359_terseLabel_en-US" xlink:label="lab_ci_OtherIntangibleAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangible assets</link:label>
    <link:label id="lab_ci_OtherIntangibleAssetsAbstract_label_en-US" xlink:label="lab_ci_OtherIntangibleAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Abstract]</link:label>
    <link:label id="lab_ci_OtherIntangibleAssetsAbstract_documentation_en-US" xlink:label="lab_ci_OtherIntangibleAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherIntangibleAssetsAbstract" xlink:href="ci-20231231.xsd#ci_OtherIntangibleAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OtherIntangibleAssetsAbstract" xlink:to="lab_ci_OtherIntangibleAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumNetPremiumCollected_5da7f994-c305-4813-b065-44619fbac7f9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumNetPremiumCollected" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net premiums collected</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumNetPremiumCollected_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumNetPremiumCollected" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefit, Expected Net Premium, Net Premium Collected</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumNetPremiumCollected" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumNetPremiumCollected"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumNetPremiumCollected" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumNetPremiumCollected" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationOtherAssetsGoodwill_7d0084c9-c3d8-4ad4-a2af-958b621243d1_terseLabel_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationOtherAssetsGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets, including Goodwill</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationOtherAssetsGoodwill_label_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationOtherAssetsGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets Goodwill</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationOtherAssetsGoodwill_documentation_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationOtherAssetsGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and amount classified as other assets attributable to disposal group held for sale or disposed of.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationOtherAssetsGoodwill" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationOtherAssetsGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DisposalGroupIncludingDiscontinuedOperationOtherAssetsGoodwill" xlink:to="lab_ci_DisposalGroupIncludingDiscontinuedOperationOtherAssetsGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_28436004-b000-49eb-9e9f-7a5b90c7ffbe_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate for finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost_4ea95339-9560-43d9-b373-67ec1442105a_terseLabel_en-US" xlink:label="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities with no readily determinable fair value</link:label>
    <link:label id="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost_label_en-US" xlink:label="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value, Amortized Cost</link:label>
    <link:label id="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost_documentation_en-US" xlink:label="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost" xlink:to="lab_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_e36104d0-f315-467b-bdc8-b5c1b62e2118_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance guarantee liability</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_ec28bdf0-4638-453d-9e1b-b483214180bc_verboseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves for litigation matters, pre-tax</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_5155a270-e0bc-4e04-b497-69e01c0649df_netLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantee liability</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_a7638ddb-b135-458f-a939-3db2e16b2426_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EquitySecuritiesFVNIMember_f2d1347f-ae93-4b0d-ad2e-aaad306424a6_terseLabel_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities FV NI</link:label>
    <link:label id="lab_ci_EquitySecuritiesFVNIMember_label_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities FV NI [Member]</link:label>
    <link:label id="lab_ci_EquitySecuritiesFVNIMember_documentation_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities FV NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIMember" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesFVNIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EquitySecuritiesFVNIMember" xlink:to="lab_ci_EquitySecuritiesFVNIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_ea1ba0d9-4a0f-47ec-b4aa-3a42f458e69e_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_dbd48905-ace6-4a47-a189-4fe933e7d50b_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_8c8c3a22-5bb3-4e59-a4b5-35b085b1096c_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable_12dbebe7-e7cc-493a-abdc-f443360cc366_terseLabel_en-US" xlink:label="lab_ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy and other service costs payable</link:label>
    <link:label id="lab_ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable_label_en-US" xlink:label="lab_ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Pharmacy And Service Costs Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable" xlink:href="ci-20231231.xsd#ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable" xlink:to="lab_ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0f70b6bd-9350-45dc-8369-4310359b94c7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term for operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity_a1f00b39-4c79-4cf0-abd9-e298ceecfae6_negatedTotalLabel_en-US" xlink:label="lab_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total impact from special items</link:label>
    <link:label id="lab_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity_label_en-US" xlink:label="lab_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Item Gain Or Loss Before Tax Attributable To Reportng Entity</link:label>
    <link:label id="lab_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity_documentation_en-US" xlink:label="lab_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sum of before-tax tax amounts classified as special items, attributable to the parent. Special items are excluded from the calculation of 'adjusted income (loss) from operations' because management believes they are not representative of the underlying results of operations. This is generally because the nature and size of these matters are not indicative of our ongoing business operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity" xlink:href="ci-20231231.xsd#ci_SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity" xlink:to="lab_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_a8d2dbd1-e02c-40a9-bbfe-aba095e80868_terseLabel_en-US" xlink:label="lab_ci_ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Costs Paid, including assets held for sale</link:label>
    <link:label id="lab_ci_ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_36b42231-904f-4ab8-81ee-74961e52c972_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PropertyPlantAndEquipmentGrossIncludingDisposalGroups_e84ff9ac-51bd-44c1-a59b-4beda727df9e_totalLabel_en-US" xlink:label="lab_ci_PropertyPlantAndEquipmentGrossIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_ci_PropertyPlantAndEquipmentGrossIncludingDisposalGroups_label_en-US" xlink:label="lab_ci_PropertyPlantAndEquipmentGrossIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Plant And Equipment Gross Including Disposal Groups</link:label>
    <link:label id="lab_ci_PropertyPlantAndEquipmentGrossIncludingDisposalGroups_documentation_en-US" xlink:label="lab_ci_PropertyPlantAndEquipmentGrossIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount, including disposal groups, before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PropertyPlantAndEquipmentGrossIncludingDisposalGroups" xlink:href="ci-20231231.xsd#ci_PropertyPlantAndEquipmentGrossIncludingDisposalGroups"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PropertyPlantAndEquipmentGrossIncludingDisposalGroups" xlink:to="lab_ci_PropertyPlantAndEquipmentGrossIncludingDisposalGroups" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AlternativeInvestmentBeforeReclassificationToDisposalGroupAssetsHeldForSale_21d128be-977d-4d5c-b112-6c5a60c3e92f_terseLabel_en-US" xlink:label="lab_ci_AlternativeInvestmentBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, including held for sale assets</link:label>
    <link:label id="lab_ci_AlternativeInvestmentBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_AlternativeInvestmentBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Before Reclassification To Disposal Group, Assets Held For Sale</link:label>
    <link:label id="lab_ci_AlternativeInvestmentBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_AlternativeInvestmentBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Before Reclassification To Disposal Group, Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AlternativeInvestmentBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_AlternativeInvestmentBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AlternativeInvestmentBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_AlternativeInvestmentBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups_bf037caa-b723-44f8-8476-276bb5780015_totalLabel_en-US" xlink:label="lab_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, including held for sale assets</link:label>
    <link:label id="lab_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups_label_en-US" xlink:label="lab_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Gross Excluding Goodwill Including VOBA Including Disposal Groups</link:label>
    <link:label id="lab_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups_documentation_en-US" xlink:label="lab_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Gross Excluding Goodwill Including VOBA Including Disposal Groups</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups" xlink:to="lab_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_c507869e-aa11-46ba-8592-77a7a728ccf0_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_a399213c-f14b-4a35-a5f3-ae6b333a6c51_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_1065ef83-dcb8-49d3-b39b-5213ae892d00_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Credit Quality Indicator [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Credit Quality Indicator [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable" xlink:to="lab_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_7d59a5a4-ec1b-49dc-ae60-fdf897ddb97b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentDisclosureTextBlock_8adc9e93-7fd6-40fb-a9eb-8363c774185b_terseLabel_en-US" xlink:label="lab_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Intangibles, and Property and Equipment</link:label>
    <link:label id="lab_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Other Intangibles And Property And Equipment Disclosure [Text Block]</link:label>
    <link:label id="lab_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentDisclosureTextBlock_documentation_en-US" xlink:label="lab_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discloses the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain or loss on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss. This element may be used as a single block of text to include the entire intangible asset disclosure including data and tables. Disclosure of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, building and production equipment. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures. This element may be used as a single block of text to include the entire PPE disclosure, including data and tables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentDisclosureTextBlock" xlink:href="ci-20231231.xsd#ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentDisclosureTextBlock" xlink:to="lab_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_0a002e71-fb9f-41f8-b1dd-8ad56cb1d91e_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability_d4c2b7d9-a0f5-48f3-be94-b7f95fd07559_terseLabel_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future policy benefits, DPL</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability_label_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefits, Deferred Profit Liability</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability_documentation_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefits, Deferred Profit Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability" xlink:to="lab_ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_906b6aa5-5df3-45cd-8660-f5147811491c_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchased (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_7203bc0d-f8de-4f57-a324-e1d3a034890c_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_3409e7ed-4349-4b0b-9c64-a4dfeb24c9f4_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities of businesses held for sale</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForReinsuranceRecoverableMember_f62161df-0d6e-4f5b-a1d0-1f965bc49fb9_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForReinsuranceRecoverableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance recoverables</link:label>
    <link:label id="lab_us-gaap_AllowanceForReinsuranceRecoverableMember_label_en-US" xlink:label="lab_us-gaap_AllowanceForReinsuranceRecoverableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Allowance, Reinsurance Recoverable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForReinsuranceRecoverableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForReinsuranceRecoverableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForReinsuranceRecoverableMember" xlink:to="lab_us-gaap_AllowanceForReinsuranceRecoverableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_95cfb8fc-7665-44bf-bad2-06b46aced9e7_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages sought by Elevance</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FundInvestmentsAndPooledSeparateAccountsMember_0f51c635-c294-4c90-972e-893b11381dc8_terseLabel_en-US" xlink:label="lab_ci_FundInvestmentsAndPooledSeparateAccountsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fund investments</link:label>
    <link:label id="lab_ci_FundInvestmentsAndPooledSeparateAccountsMember_label_en-US" xlink:label="lab_ci_FundInvestmentsAndPooledSeparateAccountsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fund Investments And Pooled Separate Accounts [Member]</link:label>
    <link:label id="lab_ci_FundInvestmentsAndPooledSeparateAccountsMember_documentation_en-US" xlink:label="lab_ci_FundInvestmentsAndPooledSeparateAccountsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security representing ownership in an investment entity that invests funds in debt instruments for which ownership is represented by either shares or units, in which defined benefit plan asset is invested.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FundInvestmentsAndPooledSeparateAccountsMember" xlink:href="ci-20231231.xsd#ci_FundInvestmentsAndPooledSeparateAccountsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FundInvestmentsAndPooledSeparateAccountsMember" xlink:to="lab_ci_FundInvestmentsAndPooledSeparateAccountsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_df16be12-0d5a-4f9a-8326-3c87f2687f76_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale_3d16bcd2-5b55-4cb1-a8be-e83ca83ff452_terseLabel_en-US" xlink:label="lab_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance recoverables before market risk benefits, including assets held for sale</link:label>
    <link:label id="lab_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Recoverables, Gross, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Recoverables, Gross, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock_cf717a84-7ed7-40fa-be2c-8622c81b24d5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Expense for 401(k) Plans</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:to="lab_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_afa89f47-1b2f-4f38-ac6c-3c476739d71d_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DisposalGroupsIncludingDiscontinuedOperationsStatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments_89537a3a-5298-4b2a-9733-feaf69f3fccc_terseLabel_en-US" xlink:label="lab_ci_DisposalGroupsIncludingDiscontinuedOperationsStatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum dividend distributions permitted in 2022 without regulatory approval, disposal groups</link:label>
    <link:label id="lab_ci_DisposalGroupsIncludingDiscontinuedOperationsStatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments_label_en-US" xlink:label="lab_ci_DisposalGroupsIncludingDiscontinuedOperationsStatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Statutory Accounting Practices, Statutory Amount Available for Dividend Payments</link:label>
    <link:label id="lab_ci_DisposalGroupsIncludingDiscontinuedOperationsStatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments_documentation_en-US" xlink:label="lab_ci_DisposalGroupsIncludingDiscontinuedOperationsStatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Statutory Accounting Practices, Statutory Amount Available for Dividend Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupsIncludingDiscontinuedOperationsStatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments" xlink:href="ci-20231231.xsd#ci_DisposalGroupsIncludingDiscontinuedOperationsStatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DisposalGroupsIncludingDiscontinuedOperationsStatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments" xlink:to="lab_ci_DisposalGroupsIncludingDiscontinuedOperationsStatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract_a67d0201-3c24-4e29-a824-0b60820a03c0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases, sales and settlements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_a5d3a617-b45b-4d9f-9048-77a5e73e5d36_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash January 1, including held for sale assets</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_c3264cc9-1b29-468a-9373-a08c8089e0c2_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash December 31, including held for sale assets</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent_697b379b-5426-4a28-b52c-476830416035_terseLabel_en-US" xlink:label="lab_ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other foreign tax attributes</link:label>
    <link:label id="lab_ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent_label_en-US" xlink:label="lab_ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Foreign Tax Attributes, Percent</link:label>
    <link:label id="lab_ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent_documentation_en-US" xlink:label="lab_ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Foreign Tax Attributes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent" xlink:href="ci-20231231.xsd#ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent" xlink:to="lab_ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_2c5d6337-2c2b-4ddb-ac92-9447c2549ca4_terseLabel_en-US" xlink:label="lab_ci_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value, after allowance for credit loss, including assets held for sale</link:label>
    <link:label id="lab_ci_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Excluding Accrued Interest, after Allowance for Credit Loss, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Excluding Accrued Interest, after Allowance for Credit Loss, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAxis_8764d69d-ff27-4507-a07e-9ff053b6c232_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DirectPremiumsEarned_a8b46712-6cb8-42b0-a9ca-b442209ca298_terseLabel_en-US" xlink:label="lab_us-gaap_DirectPremiumsEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct</link:label>
    <link:label id="lab_us-gaap_DirectPremiumsEarned_label_en-US" xlink:label="lab_us-gaap_DirectPremiumsEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct Premiums Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectPremiumsEarned" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DirectPremiumsEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DirectPremiumsEarned" xlink:to="lab_us-gaap_DirectPremiumsEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PremiumsReceivableAtCarryingValue_89b2e40e-c0fa-4f6b-beb3-0f7da3ab30a1_terseLabel_en-US" xlink:label="lab_us-gaap_PremiumsReceivableAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums due</link:label>
    <link:label id="lab_us-gaap_PremiumsReceivableAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_PremiumsReceivableAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsReceivableAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PremiumsReceivableAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PremiumsReceivableAtCarryingValue" xlink:to="lab_us-gaap_PremiumsReceivableAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AccountsPayableAccruedExpensesOtherLiabilitiesPolicyPolicyTextBlock_a1e44dea-c35f-4b4f-8b41-439dd8337f8b_terseLabel_en-US" xlink:label="lab_ci_AccountsPayableAccruedExpensesOtherLiabilitiesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other Current and Non-Current Liabilities</link:label>
    <link:label id="lab_ci_AccountsPayableAccruedExpensesOtherLiabilitiesPolicyPolicyTextBlock_label_en-US" xlink:label="lab_ci_AccountsPayableAccruedExpensesOtherLiabilitiesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable Accrued Expenses Other Liabilities Policy [Policy Text Block]</link:label>
    <link:label id="lab_ci_AccountsPayableAccruedExpensesOtherLiabilitiesPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_ci_AccountsPayableAccruedExpensesOtherLiabilitiesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Describes an entity's accounting policy for accounts payable, accrued expenses and other liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccountsPayableAccruedExpensesOtherLiabilitiesPolicyPolicyTextBlock" xlink:href="ci-20231231.xsd#ci_AccountsPayableAccruedExpensesOtherLiabilitiesPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AccountsPayableAccruedExpensesOtherLiabilitiesPolicyPolicyTextBlock" xlink:to="lab_ci_AccountsPayableAccruedExpensesOtherLiabilitiesPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_1ff87b73-5b92-4f27-bb9d-3c2703e71c02_terseLabel_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Net</link:label>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DeferredTaxAssetsForeignTaxAttributesIncludingDisposalGroupsAssetsHeldForSale_32dd3634-8290-4cdd-86b2-1e785199d01c_terseLabel_en-US" xlink:label="lab_ci_DeferredTaxAssetsForeignTaxAttributesIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign tax attributes</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsForeignTaxAttributesIncludingDisposalGroupsAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DeferredTaxAssetsForeignTaxAttributesIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Foreign Tax Attributes, Including Disposal Groups Assets Held For Sale</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsForeignTaxAttributesIncludingDisposalGroupsAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DeferredTaxAssetsForeignTaxAttributesIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Foreign Tax Attributes, Including Disposal Groups Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsForeignTaxAttributesIncludingDisposalGroupsAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsForeignTaxAttributesIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DeferredTaxAssetsForeignTaxAttributesIncludingDisposalGroupsAssetsHeldForSale" xlink:to="lab_ci_DeferredTaxAssetsForeignTaxAttributesIncludingDisposalGroupsAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member_88b6cfbc-e169-4cdc-a8eb-1d9f45572fd5_terseLabel_en-US" xlink:label="lab_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit And Letter Of Credit Facility Maturing April 2027</link:label>
    <link:label id="lab_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member_label_en-US" xlink:label="lab_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit And Letter Of Credit Facility Maturing April 2027 [Member]</link:label>
    <link:label id="lab_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member_documentation_en-US" xlink:label="lab_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit And Letter Of Credit Facility Maturing April 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member" xlink:href="ci-20231231.xsd#ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member" xlink:to="lab_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationInvestments_cc4f3a4e-bc59-46f4-bc42-5d0d39a608e6_terseLabel_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationInvestments_05803fca-9b52-4b49-828d-27b10464a186_negatedTotalLabel_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments classified as assets of business held for sale</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationInvestments_label_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Investments</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationInvestments_documentation_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationInvestments" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DisposalGroupIncludingDiscontinuedOperationInvestments" xlink:to="lab_ci_DisposalGroupIncludingDiscontinuedOperationInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent_e8ac8c09-2d6b-4e81-8f9e-2886d718cbe9_terseLabel_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future policy benefits, current</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent_label_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefit, Before Reinsurance, Current</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent_documentation_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefit, Before Reinsurance, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent" xlink:to="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DepreciationAndAmortizationByTypeLineItems_5d8e07da-7e06-4d08-a4d8-0d52226f5d2a_terseLabel_en-US" xlink:label="lab_ci_DepreciationAndAmortizationByTypeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation And Amortization By Type [Line Items]</link:label>
    <link:label id="lab_ci_DepreciationAndAmortizationByTypeLineItems_label_en-US" xlink:label="lab_ci_DepreciationAndAmortizationByTypeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation And Amortization By Type [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DepreciationAndAmortizationByTypeLineItems" xlink:href="ci-20231231.xsd#ci_DepreciationAndAmortizationByTypeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DepreciationAndAmortizationByTypeLineItems" xlink:to="lab_ci_DepreciationAndAmortizationByTypeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries_67521fef-4234-4785-8f0e-375a4c0b1acb_terseLabel_en-US" xlink:label="lab_us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted GAAP net assets of The Cigna Group's subsidiaries</link:label>
    <link:label id="lab_us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries_label_en-US" xlink:label="lab_us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Restricted Net Assets for Consolidated and Unconsolidated Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries" xlink:to="lab_us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_ebc0b588-7e93-47e0-b192-76f0c70745ad_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of ROU assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_c8b4ddab-b3b1-4b44-8a4e-b19a66872b4e_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate_74b542d7-886a-4ee1-a98f-ff0975dfc960_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Above guaranteed minimum crediting rate</link:label>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate_label_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Account Balance, above Guaranteed Minimum Crediting Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate" xlink:to="lab_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_53b0cf91-4821-49e7-bdf1-fffd3822706b_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign government</link:label>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security, Government, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a67082ef-0ebc-41d9-89ed-2de857ae549c_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OperatingLeaseLiabilityIncludingDisposalGroupsAssetsHeldForSale_2753da10-ef89-40f8-afe4-7c2bab5d2811_totalLabel_en-US" xlink:label="lab_ci_OperatingLeaseLiabilityIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities, including held for sale liabilities</link:label>
    <link:label id="lab_ci_OperatingLeaseLiabilityIncludingDisposalGroupsAssetsHeldForSale_label_en-US" xlink:label="lab_ci_OperatingLeaseLiabilityIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability Including Disposal Groups Assets Held For Sale</link:label>
    <link:label id="lab_ci_OperatingLeaseLiabilityIncludingDisposalGroupsAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_OperatingLeaseLiabilityIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability Including Disposal Groups Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OperatingLeaseLiabilityIncludingDisposalGroupsAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_OperatingLeaseLiabilityIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OperatingLeaseLiabilityIncludingDisposalGroupsAssetsHeldForSale" xlink:to="lab_ci_OperatingLeaseLiabilityIncludingDisposalGroupsAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal_71aeb080-16f0-4f20-ab40-69768aa83be2_negatedLabel_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit (loss) / recovery and other investment write-down (losses)</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal_label_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, And Commercial Mortgage Loans, Allowance For Credit Loss, Expense (Recovery) And Impairments On Investments Total</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal_documentation_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, And Commercial Mortgage Loans, Allowance For Credit Loss, Expense (Recovery) And Impairments On Investments Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal" xlink:to="lab_ci_DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_9e87a87d-c738-4411-9c54-fb9c4cc28971_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_d42be172-fa4f-47d5-8669-2d163713cf0c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_fd7dbc5f-2e68-4c6e-8535-e4b844cdbbb9_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_ce52d009-59c7-48f0-ac3d-3a47f516fca5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_39e2b192-b82b-48ee-ae6f-4de7719c20c2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_ee478464-7b40-40d1-bae9-d379d7c25baf_totalLabel_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost, including held for sale assets</link:label>
    <link:label id="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Amortized Cost Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Amortized Cost Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_076cffbb-89db-467b-a88a-cc9cc4b5387d_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesRealizedInvestmentGainsLossesParentMember_eba24504-b971-4975-b2e5-bf208d1bf8ec_terseLabel_en-US" xlink:label="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesRealizedInvestmentGainsLossesParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustment for losses (gains) included in Shareholders' net income (Net realized investment (losses) gains)</link:label>
    <link:label id="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesRealizedInvestmentGainsLossesParentMember_label_en-US" xlink:label="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesRealizedInvestmentGainsLossesParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-For-Sale And Derivatives, Realized Investment (Gains) Losses, Parent [Member]</link:label>
    <link:label id="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesRealizedInvestmentGainsLossesParentMember_documentation_en-US" xlink:label="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesRealizedInvestmentGainsLossesParentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-For-Sale And Derivatives, Realized Investment (Gains) Losses, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesRealizedInvestmentGainsLossesParentMember" xlink:href="ci-20231231.xsd#ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesRealizedInvestmentGainsLossesParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesRealizedInvestmentGainsLossesParentMember" xlink:to="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesRealizedInvestmentGainsLossesParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_affcf315-1897-4e8b-85ee-6b131d166b5a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LtvLessThan60PercentMember_03dca280-ea63-462b-bc52-9aebc29de33a_terseLabel_en-US" xlink:label="lab_ci_LtvLessThan60PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Below 60%</link:label>
    <link:label id="lab_ci_LtvLessThan60PercentMember_label_en-US" xlink:label="lab_ci_LtvLessThan60PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LTV Less Than 60 Percent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LtvLessThan60PercentMember" xlink:href="ci-20231231.xsd#ci_LtvLessThan60PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LtvLessThan60PercentMember" xlink:to="lab_ci_LtvLessThan60PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_267bd395-ce71-434d-8a01-1516f09d4218_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SpecialItemGainLossFromContractAdjustmentNetOfTax_91227623-58a8-47bd-994d-bf0a3051288d_negatedLabel_en-US" xlink:label="lab_ci_SpecialItemGainLossFromContractAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustment for a former client (Pharmacy revenues)</link:label>
    <link:label id="lab_ci_SpecialItemGainLossFromContractAdjustmentNetOfTax_label_en-US" xlink:label="lab_ci_SpecialItemGainLossFromContractAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Item, Gain (Loss) From Contract Adjustment, Net Of Tax</link:label>
    <link:label id="lab_ci_SpecialItemGainLossFromContractAdjustmentNetOfTax_documentation_en-US" xlink:label="lab_ci_SpecialItemGainLossFromContractAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Item, Gain (Loss) From Contract Adjustment, Net Of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossFromContractAdjustmentNetOfTax" xlink:href="ci-20231231.xsd#ci_SpecialItemGainLossFromContractAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SpecialItemGainLossFromContractAdjustmentNetOfTax" xlink:to="lab_ci_SpecialItemGainLossFromContractAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_472df261-3d0b-4f78-821a-4c0c884d91f7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract_29bc8248-dba4-4d95-b70b-50d781251fcb_terseLabel_en-US" xlink:label="lab_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, including held for sale assets</link:label>
    <link:label id="lab_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract_label_en-US" xlink:label="lab_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets Including Disposal Groups [Abstract]</link:label>
    <link:label id="lab_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract_documentation_en-US" xlink:label="lab_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets Including Disposal Groups</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract" xlink:href="ci-20231231.xsd#ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract" xlink:to="lab_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_207d68ff-b2ab-4ec0-b861-afce5b72b39a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember_58fce27a-fa48-45f1-a57e-8ecd7ef51d71_terseLabel_en-US" xlink:label="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities and Derivatives</link:label>
    <link:label id="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember_label_en-US" xlink:label="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-For-Sale And Derivatives, Parent [Member]</link:label>
    <link:label id="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember_documentation_en-US" xlink:label="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-For-Sale And Derivatives, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember" xlink:href="ci-20231231.xsd#ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember" xlink:to="lab_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfLoansReceivable_bbc69646-deef-477e-9985-34341ee23915_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfLoansReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial mortgage loans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfLoansReceivable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfLoansReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collection of Loans Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfLoansReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollectionOfLoansReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollectionOfLoansReceivable" xlink:to="lab_us-gaap_ProceedsFromCollectionOfLoansReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_5f390935-9a7a-416d-8701-d1eea6af4109_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVOBAIncludingDisposalGroupsAssetsHeldForSale_131ae0bc-a9ed-41ce-9bf6-c1baef5f8566_terseLabel_en-US" xlink:label="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVOBAIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization, including held for sale assets</link:label>
    <link:label id="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVOBAIncludingDisposalGroupsAssetsHeldForSale_label_en-US" xlink:label="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVOBAIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets Accumulated Amortization VOBA Including Disposal Groups Assets Held For Sale</link:label>
    <link:label id="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVOBAIncludingDisposalGroupsAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVOBAIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets Accumulated Amortization VOBA Including Disposal Groups Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVOBAIncludingDisposalGroupsAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVOBAIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVOBAIncludingDisposalGroupsAssetsHeldForSale" xlink:to="lab_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVOBAIncludingDisposalGroupsAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NotesDue2023765InterestMember_d2569570-0366-439d-b7e5-2965d557c815_terseLabel_en-US" xlink:label="lab_ci_NotesDue2023765InterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$63&#160;million, 7.65% Notes due March 2023</link:label>
    <link:label id="lab_ci_NotesDue2023765InterestMember_label_en-US" xlink:label="lab_ci_NotesDue2023765InterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes due 2023 7.65% Interest [Member]</link:label>
    <link:label id="lab_ci_NotesDue2023765InterestMember_documentation_en-US" xlink:label="lab_ci_NotesDue2023765InterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable bearing interest at 7.65% due in 2023.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue2023765InterestMember" xlink:href="ci-20231231.xsd#ci_NotesDue2023765InterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NotesDue2023765InterestMember" xlink:to="lab_ci_NotesDue2023765InterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_ee7e4ffd-cb9b-439a-9d5e-156f20e0a407_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_Ltv60To79PercentMember_683e2243-ae61-4aba-9a73-1408cab894ae_terseLabel_en-US" xlink:label="lab_ci_Ltv60To79PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">60% to 79%</link:label>
    <link:label id="lab_ci_Ltv60To79PercentMember_label_en-US" xlink:label="lab_ci_Ltv60To79PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LTV 60 to 79 Percent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_Ltv60To79PercentMember" xlink:href="ci-20231231.xsd#ci_Ltv60To79PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_Ltv60To79PercentMember" xlink:to="lab_ci_Ltv60To79PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement_97fef298-119c-4676-807a-203ba4edb17b_terseLabel_en-US" xlink:label="lab_ci_NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of participating banks</link:label>
    <link:label id="lab_ci_NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement_label_en-US" xlink:label="lab_ci_NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Banks Participating In Revolving Credit And Letter Of Credit Agreement</link:label>
    <link:label id="lab_ci_NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement_documentation_en-US" xlink:label="lab_ci_NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of banks participating in revolving credit and letter of credit agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement" xlink:href="ci-20231231.xsd#ci_NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement" xlink:to="lab_ci_NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashSurrenderValueDuePolicyholdersAmount_3cf0831b-f185-468a-8a2d-0a21c86b1e63_terseLabel_en-US" xlink:label="lab_us-gaap_CashSurrenderValueDuePolicyholdersAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash surrender value</link:label>
    <link:label id="lab_us-gaap_CashSurrenderValueDuePolicyholdersAmount_label_en-US" xlink:label="lab_us-gaap_CashSurrenderValueDuePolicyholdersAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Account Balance, Cash Surrender Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashSurrenderValueDuePolicyholdersAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashSurrenderValueDuePolicyholdersAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashSurrenderValueDuePolicyholdersAmount" xlink:to="lab_us-gaap_CashSurrenderValueDuePolicyholdersAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_8851eb25-19ce-4c91-9944-212c7bfc98d0_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgeFundsMember_9da79f3b-8ca3-4a43-8454-42747bfed940_terseLabel_en-US" xlink:label="lab_us-gaap_HedgeFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedge funds</link:label>
    <link:label id="lab_us-gaap_HedgeFundsMember_label_en-US" xlink:label="lab_us-gaap_HedgeFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedge Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgeFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgeFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgeFundsMember" xlink:to="lab_us-gaap_HedgeFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilitiesIncludingDisposalGroupsAssetsHeldForSale_493bea9e-62ce-4386-9306-676b22cc9fd4_terseLabel_en-US" xlink:label="lab_ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilitiesIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other insurance and contractholder liabilities</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilitiesIncludingDisposalGroupsAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilitiesIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Policyholder Liabilities, Including Disposal Groups Assets Held For Sale</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilitiesIncludingDisposalGroupsAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilitiesIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Policyholder Liabilities, Including Disposal Groups Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilitiesIncludingDisposalGroupsAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilitiesIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilitiesIncludingDisposalGroupsAssetsHeldForSale" xlink:to="lab_ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilitiesIncludingDisposalGroupsAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity_8a853de8-c085-436b-a2dc-697ec71f7a67_negatedTotalLabel_en-US" xlink:label="lab_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total impact from special items</link:label>
    <link:label id="lab_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity_label_en-US" xlink:label="lab_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Item Gain Or Loss Net Of Tax Attributable To Reportng Entity</link:label>
    <link:label id="lab_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity_documentation_en-US" xlink:label="lab_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sum of after-tax amounts classified as special items, attributable to the parent. Special items are excluded from the calculation of 'adjusted income (loss) from operations' because management believes they are not representative of the underlying results of operations. This is generally because the nature and size of these matters are not indicative of our ongoing business operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity" xlink:href="ci-20231231.xsd#ci_SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity" xlink:to="lab_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_7ba10965-4906-48e7-aad1-b6f398fe6bdb_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPSs</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_a3a09e33-9617-49e3-9e4d-89b4476b57a9_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers out of Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NotesDue20254125InterestMember_28ac4109-21ce-480f-bdeb-ac2f2fe62cdd_terseLabel_en-US" xlink:label="lab_ci_NotesDue20254125InterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$2,200&#160;million, 4.125% Notes due November 2025 (1)</link:label>
    <link:label id="lab_ci_NotesDue20254125InterestMember_label_en-US" xlink:label="lab_ci_NotesDue20254125InterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2025, 4.125% Interest [Member]</link:label>
    <link:label id="lab_ci_NotesDue20254125InterestMember_documentation_en-US" xlink:label="lab_ci_NotesDue20254125InterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior notes payable bearing interest at 4.125% due in 2025. Debt issued to finance acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20254125InterestMember" xlink:href="ci-20231231.xsd#ci_NotesDue20254125InterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NotesDue20254125InterestMember" xlink:to="lab_ci_NotesDue20254125InterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDebtSecurityMember_c051419b-51ba-41a5-86dc-322127f07e06_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDebtSecurityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDebtSecurityMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDebtSecurityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Debt Security [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDebtSecurityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember" xlink:to="lab_us-gaap_DefinedBenefitPlanDebtSecurityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_315b8e6d-085e-4c7e-b54e-7deb1f2f5a6c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_dc6ebbcd-329f-41a9-9773-b3b4e1693064_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_a73975eb-ea1c-4a51-a501-ca9c917f0c14_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionsToContractHoldersFunds_f09cad2e-6311-4166-a80b-528293ca7185_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionsToContractHoldersFunds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits and interest credited to contractholder deposit funds</link:label>
    <link:label id="lab_us-gaap_AdditionsToContractHoldersFunds_label_en-US" xlink:label="lab_us-gaap_AdditionsToContractHoldersFunds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to Contract Holders Funds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionsToContractHoldersFunds" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionsToContractHoldersFunds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionsToContractHoldersFunds" xlink:to="lab_us-gaap_AdditionsToContractHoldersFunds" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PolicyholderContractDepositsAttributableToDisposalGroups_e5b520a5-41be-4a61-9862-55046d4ba6b4_terseLabel_en-US" xlink:label="lab_ci_PolicyholderContractDepositsAttributableToDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractholder deposit funds classified as liabilities held for sale</link:label>
    <link:label id="lab_ci_PolicyholderContractDepositsAttributableToDisposalGroups_label_en-US" xlink:label="lab_ci_PolicyholderContractDepositsAttributableToDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Contract Deposits Attributable To Disposal Groups</link:label>
    <link:label id="lab_ci_PolicyholderContractDepositsAttributableToDisposalGroups_documentation_en-US" xlink:label="lab_ci_PolicyholderContractDepositsAttributableToDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Contract Deposits Attributable To Disposal Groups</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositsAttributableToDisposalGroups" xlink:href="ci-20231231.xsd#ci_PolicyholderContractDepositsAttributableToDisposalGroups"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PolicyholderContractDepositsAttributableToDisposalGroups" xlink:to="lab_ci_PolicyholderContractDepositsAttributableToDisposalGroups" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_9a153b03-e387-4657-a5e2-4b7f4372b66f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonqualifiedPlanMember_94456e1d-372a-4e3c-b022-d492a7f8b4b3_terseLabel_en-US" xlink:label="lab_us-gaap_NonqualifiedPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Qualified Plan</link:label>
    <link:label id="lab_us-gaap_NonqualifiedPlanMember_label_en-US" xlink:label="lab_us-gaap_NonqualifiedPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonqualified Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonqualifiedPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonqualifiedPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonqualifiedPlanMember" xlink:to="lab_us-gaap_NonqualifiedPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_285c6041-1e3b-4db6-89d7-058fc8e64629_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract_cbb860cc-8340-4a87-91a0-a534d72c828b_terseLabel_en-US" xlink:label="lab_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, including held for sale liabilities</link:label>
    <link:label id="lab_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract_label_en-US" xlink:label="lab_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross, Including Disposal Groups [Abstract]</link:label>
    <link:label id="lab_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract_documentation_en-US" xlink:label="lab_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross, Including Disposal Groups</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract" xlink:to="lab_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicDistributionDomain_0720471e-adf5-47a7-907f-d5c1450d3fa2_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicDistributionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Distribution [Domain]</link:label>
    <link:label id="lab_us-gaap_GeographicDistributionDomain_label_en-US" xlink:label="lab_us-gaap_GeographicDistributionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Distribution [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicDistributionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicDistributionDomain" xlink:to="lab_us-gaap_GeographicDistributionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange_a54db37e-b79e-4e62-ae33-7508bb184115_periodStartLabel_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of year, before the effect of nonperformance risk (own credit risk)</link:label>
    <link:label id="lab_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange_497417cf-277d-4e36-b0dc-354d99cb31e1_periodEndLabel_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of period, before the effect of changes in nonperformance risk (own credit risk)</link:label>
    <link:label id="lab_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange_label_en-US" xlink:label="lab_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Risk Benefit, before Reinsurance and Cumulative Increase (Decrease) from Instrument-Specific Credit Risk Change</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange" xlink:to="lab_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_bfbcfb9a-33cc-4d0e-9dc6-6e9b9d702019_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Accident Year [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Accident Year [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OperatingLeaseLiabilityNoncurrentIncludingDisposalGroupsAssetsHeldForSale_1b9b5c46-6ead-426a-b36b-7d3fd54bf91f_terseLabel_en-US" xlink:label="lab_ci_OperatingLeaseLiabilityNoncurrentIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities, including held for sale liabilities</link:label>
    <link:label id="lab_ci_OperatingLeaseLiabilityNoncurrentIncludingDisposalGroupsAssetsHeldForSale_label_en-US" xlink:label="lab_ci_OperatingLeaseLiabilityNoncurrentIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability Noncurrent Including Disposal Groups Assets Held For Sale</link:label>
    <link:label id="lab_ci_OperatingLeaseLiabilityNoncurrentIncludingDisposalGroupsAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_OperatingLeaseLiabilityNoncurrentIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability Noncurrent Including Disposal Groups Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OperatingLeaseLiabilityNoncurrentIncludingDisposalGroupsAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_OperatingLeaseLiabilityNoncurrentIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OperatingLeaseLiabilityNoncurrentIncludingDisposalGroupsAssetsHeldForSale" xlink:to="lab_ci_OperatingLeaseLiabilityNoncurrentIncludingDisposalGroupsAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteeObligationsByNatureAxis_b71cfb78-e2d3-4bf6-a276-211411a350a5_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsByNatureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor Obligations, Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsByNatureAxis_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsByNatureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor Obligations, Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsByNatureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis" xlink:to="lab_us-gaap_GuaranteeObligationsByNatureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_22abecdf-81d6-4344-9846-19c401cad51c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_eff0d78b-057c-4eb0-bd97-dc339cb49de4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value of preferred stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_47ba027e-c9a5-45d3-89e7-5a42d13bc55e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Fair Value at Award Date</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale_c4c3beeb-0191-4758-93e1-cede532d0bf5_terseLabel_en-US" xlink:label="lab_ci_PharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical manufacturers receivable, including held for sale assets</link:label>
    <link:label id="lab_ci_PharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_PharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Manufacturers Receivable Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_PharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_PharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Manufacturers Receivable Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_PharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_PharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_33ec3a23-8ccb-4a0d-ac24-628be4d7c563_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss_28eb9199-5521-49d9-ad1a-3a0129f69226_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value, after allowance for credit loss</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Excluding Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SpecialItemsAfterTaxAbstract_4d99fa31-d56c-4e00-aac4-b87a17d86c4e_terseLabel_en-US" xlink:label="lab_ci_SpecialItemsAfterTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After-tax</link:label>
    <link:label id="lab_ci_SpecialItemsAfterTaxAbstract_label_en-US" xlink:label="lab_ci_SpecialItemsAfterTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Items After Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemsAfterTaxAbstract" xlink:href="ci-20231231.xsd#ci_SpecialItemsAfterTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SpecialItemsAfterTaxAbstract" xlink:to="lab_ci_SpecialItemsAfterTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cbac9ec3-07cb-44f4-a356-b822d0718ae6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_2b97d65f-9e42-4e5f-ab36-889ae7d7421b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent_37f0e409-2136-4a0b-84f6-1e21241296b0_negatedLabel_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments classified as assets of business held for sale</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent_label_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Including Discontinued Operation Noncurrent Investments Current</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent_documentation_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Including Discontinued Operation Noncurrent Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent" xlink:to="lab_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PrudentialInsuranceCompanyOfAmericaMember_d8371faa-629e-4a96-b85f-d53aa812be45_terseLabel_en-US" xlink:label="lab_ci_PrudentialInsuranceCompanyOfAmericaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prudential Insurance Company of America</link:label>
    <link:label id="lab_ci_PrudentialInsuranceCompanyOfAmericaMember_label_en-US" xlink:label="lab_ci_PrudentialInsuranceCompanyOfAmericaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prudential Insurance Company Of America [Member]</link:label>
    <link:label id="lab_ci_PrudentialInsuranceCompanyOfAmericaMember_documentation_en-US" xlink:label="lab_ci_PrudentialInsuranceCompanyOfAmericaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prudential Insurance Company Of America</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PrudentialInsuranceCompanyOfAmericaMember" xlink:href="ci-20231231.xsd#ci_PrudentialInsuranceCompanyOfAmericaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PrudentialInsuranceCompanyOfAmericaMember" xlink:to="lab_ci_PrudentialInsuranceCompanyOfAmericaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_fa733485-4dd6-4aae-be05-685d53acf4f2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_807250c6-0545-4728-b61e-076d1082897d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClaimsDevelopmentLineItems_1395ff4b-0836-4f55-ba34-5ec18f7d998b_terseLabel_en-US" xlink:label="lab_us-gaap_ClaimsDevelopmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims Development [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClaimsDevelopmentLineItems_label_en-US" xlink:label="lab_us-gaap_ClaimsDevelopmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims Development [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClaimsDevelopmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClaimsDevelopmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems" xlink:to="lab_us-gaap_ClaimsDevelopmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_3aae3980-1c1f-4d76-b2c7-39f33fb1ab05_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c2ccf6fe-9d98-4fb6-9043-0ae72e60136a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value of options (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_128b015f-4451-4a65-9b0c-fd5753fe431f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, including current maturities, excluding finance leases</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount_b758561a-4cc4-405a-b075-df53d47c1162_terseLabel_en-US" xlink:label="lab_ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swiss tax attributes</link:label>
    <link:label id="lab_ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount_label_en-US" xlink:label="lab_ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Swiss Tax Attributes, Amount</link:label>
    <link:label id="lab_ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount_documentation_en-US" xlink:label="lab_ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Swiss Tax Attributes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount" xlink:href="ci-20231231.xsd#ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount" xlink:to="lab_ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_6e68a5e1-23e7-4fbb-8c3c-47e2b01c5004_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_7eac2d19-ae7f-425f-be75-6526e7aac684_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_211713b2-071f-4fe6-9746-d81975f2c8df_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_TransactionRelatedCostsAfterTax_ee00a3f6-e15b-4b3e-99d3-ce7aff5d3551_verboseLabel_en-US" xlink:label="lab_ci_TransactionRelatedCostsAfterTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Integration and transaction-related costs, after-tax</link:label>
    <link:label id="lab_ci_TransactionRelatedCostsAfterTax_075f1258-348c-47e8-8ba8-c65a4e7025f0_terseLabel_en-US" xlink:label="lab_ci_TransactionRelatedCostsAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Integration and transaction-related costs, after-tax (Selling, general and administrative expenses)</link:label>
    <link:label id="lab_ci_TransactionRelatedCostsAfterTax_label_en-US" xlink:label="lab_ci_TransactionRelatedCostsAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Related Costs After Tax</link:label>
    <link:label id="lab_ci_TransactionRelatedCostsAfterTax_documentation_en-US" xlink:label="lab_ci_TransactionRelatedCostsAfterTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After-tax transaction-related costs including the impact of tax benefits realized from termination of merger agreement. Transaction-related costs consist primarily of fees for legal, advisory and other professional services as well as employee costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TransactionRelatedCostsAfterTax" xlink:href="ci-20231231.xsd#ci_TransactionRelatedCostsAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_TransactionRelatedCostsAfterTax" xlink:to="lab_ci_TransactionRelatedCostsAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_e7109475-0bc7-4c82-b977-75ef738be5fe_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList_e429b8f0-2d20-4484-aa24-d88d08acc8ff_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on sale of businesses, location, Consolidated Statements of Income</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_20e03283-c1fb-46c0-80f9-ed0ebe6ba45d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Depreciation</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EquitySecuritiesDividend_41376056-1943-4819-b53d-e499d9f52f02_terseLabel_en-US" xlink:label="lab_ci_EquitySecuritiesDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend</link:label>
    <link:label id="lab_ci_EquitySecuritiesDividend_label_en-US" xlink:label="lab_ci_EquitySecuritiesDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Dividend</link:label>
    <link:label id="lab_ci_EquitySecuritiesDividend_documentation_en-US" xlink:label="lab_ci_EquitySecuritiesDividend" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesDividend" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EquitySecuritiesDividend" xlink:to="lab_ci_EquitySecuritiesDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_1ad3ec34-b705-4978-b15b-75efa70e154c_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of impairments or value changes resulting from observable price changes on equity securities with no readily available fair value still held</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_d98f131b-da36-47de-a22a-911776f7050a_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy and other service costs</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7745eac0-bc49-4efe-838a-5f3c31ca6177_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLiquidatingInvestmentPeriodFromInceptionSecuritiesPartnerships_3e26c3e6-d429-49fb-9844-7c0f913475ed_terseLabel_en-US" xlink:label="lab_ci_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLiquidatingInvestmentPeriodFromInceptionSecuritiesPartnerships" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected liquidation period after inception</link:label>
    <link:label id="lab_ci_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLiquidatingInvestmentPeriodFromInceptionSecuritiesPartnerships_label_en-US" xlink:label="lab_ci_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLiquidatingInvestmentPeriodFromInceptionSecuritiesPartnerships" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Investments Entities That Calculate Net Asset Value Per Share Liquidating Investment Period From Inception Securities Partnerships</link:label>
    <link:label id="lab_ci_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLiquidatingInvestmentPeriodFromInceptionSecuritiesPartnerships_documentation_en-US" xlink:label="lab_ci_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLiquidatingInvestmentPeriodFromInceptionSecuritiesPartnerships" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected liquidation period after inception of the underlying securities partnership assets measured at net asset value per share or unit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLiquidatingInvestmentPeriodFromInceptionSecuritiesPartnerships" xlink:href="ci-20231231.xsd#ci_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLiquidatingInvestmentPeriodFromInceptionSecuritiesPartnerships"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLiquidatingInvestmentPeriodFromInceptionSecuritiesPartnerships" xlink:to="lab_ci_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLiquidatingInvestmentPeriodFromInceptionSecuritiesPartnerships" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale_5affff12-0f37-4197-863f-7796c7bb7f3a_negatedLabel_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Depreciation, including held for sale assets</link:label>
    <link:label id="lab_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_9c32bc51-0dc3-4d5b-91f8-8b676362fd79_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_ab3a1e6e-1c2b-4c5e-9f7a-559309d8a607_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale_6fc31240-109c-488d-97b0-a316fb92f42a_terseLabel_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less, including assets held for sale</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax_03e0b6d2-706c-483e-b339-f4929590618c_terseLabel_en-US" xlink:label="lab_ci_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on sale of business, after-tax</link:label>
    <link:label id="lab_ci_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax_27e716ea-e73a-4e7e-a796-6a84e6790313_negatedLabel_en-US" xlink:label="lab_ci_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated loss on sale, after-tax</link:label>
    <link:label id="lab_ci_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax_label_en-US" xlink:label="lab_ci_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) On Disposal, Net Of Tax</link:label>
    <link:label id="lab_ci_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax_documentation_en-US" xlink:label="lab_ci_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) On Disposal, Net Of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax" xlink:href="ci-20231231.xsd#ci_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax" xlink:to="lab_ci_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_7718e533-9f18-48bb-b3ce-f7c99a77691f_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_101f770f-93fd-41c5-8c90-80480059d831_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at January 1</link:label>
    <link:label id="lab_us-gaap_Goodwill_b4ba6e6a-95e1-42b6-8df1-2e200d9137a8_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LossOfParentCompany_9fe58945-acf5-49ac-92cc-8fa92b6f166e_totalLabel_en-US" xlink:label="lab_ci_LossOfParentCompany" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss of Parent Company</link:label>
    <link:label id="lab_ci_LossOfParentCompany_label_en-US" xlink:label="lab_ci_LossOfParentCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before equity in earnings of subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LossOfParentCompany" xlink:href="ci-20231231.xsd#ci_LossOfParentCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LossOfParentCompany" xlink:to="lab_ci_LossOfParentCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InsuranceCustomerReceivables_31113696-ae6e-4a6b-a252-64d1f0100c63_terseLabel_en-US" xlink:label="lab_ci_InsuranceCustomerReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance customer receivables</link:label>
    <link:label id="lab_ci_InsuranceCustomerReceivables_label_en-US" xlink:label="lab_ci_InsuranceCustomerReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Customer Receivables</link:label>
    <link:label id="lab_ci_InsuranceCustomerReceivables_documentation_en-US" xlink:label="lab_ci_InsuranceCustomerReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables due from customers under insurance contracts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceCustomerReceivables" xlink:href="ci-20231231.xsd#ci_InsuranceCustomerReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InsuranceCustomerReceivables" xlink:to="lab_ci_InsuranceCustomerReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss_8f4afd27-e08c-48e9-ada5-3df095cc7857_terseLabel_en-US" xlink:label="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in unrealized gain or (loss) included in Other comprehensive loss for assets held at the end of the reporting period</link:label>
    <link:label id="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss_label_en-US" xlink:label="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Unrealized Gain (Loss) Included In Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss_documentation_en-US" xlink:label="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Unrealized Gain (Loss) Included In Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:href="ci-20231231.xsd#ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:to="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_d6f1b417-f158-4f89-b7bf-97a6ef21b239_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale_3ddc64a8-b571-4685-87a8-3a5d86d96e2e_terseLabel_en-US" xlink:label="lab_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Debt Service Coverage Ratio, including assets held for sale</link:label>
    <link:label id="lab_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Credit Quality Debt Service Coverage Ratio, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Credit Quality Debt Service Coverage Ratio, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_MedicareAdvantageLitigationDepartmentOfJusticeInvestigationsMember_b1cb40ed-e837-43f4-b80c-b830fe49da2e_terseLabel_en-US" xlink:label="lab_ci_MedicareAdvantageLitigationDepartmentOfJusticeInvestigationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage, DOJ Investigations</link:label>
    <link:label id="lab_ci_MedicareAdvantageLitigationDepartmentOfJusticeInvestigationsMember_label_en-US" xlink:label="lab_ci_MedicareAdvantageLitigationDepartmentOfJusticeInvestigationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage Litigation Department Of Justice Investigations [Member]</link:label>
    <link:label id="lab_ci_MedicareAdvantageLitigationDepartmentOfJusticeInvestigationsMember_documentation_en-US" xlink:label="lab_ci_MedicareAdvantageLitigationDepartmentOfJusticeInvestigationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation related to the industry-wide investigations by the Department of Justice into the risk adjustment practices of Medicare Advantage organizations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageLitigationDepartmentOfJusticeInvestigationsMember" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageLitigationDepartmentOfJusticeInvestigationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_MedicareAdvantageLitigationDepartmentOfJusticeInvestigationsMember" xlink:to="lab_ci_MedicareAdvantageLitigationDepartmentOfJusticeInvestigationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DisposalGroupsIncludingDiscontinuedOperationsAmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries_dad40f83-c07d-4e4d-9462-843bccecd7e0_terseLabel_en-US" xlink:label="lab_ci_DisposalGroupsIncludingDiscontinuedOperationsAmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted GAAP net assets of The Cigna Goup's subsidiaries, disposal groups</link:label>
    <link:label id="lab_ci_DisposalGroupsIncludingDiscontinuedOperationsAmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries_label_en-US" xlink:label="lab_ci_DisposalGroupsIncludingDiscontinuedOperationsAmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Amount of Restricted Net Assets for Consolidated and Unconsolidated Subsidiaries</link:label>
    <link:label id="lab_ci_DisposalGroupsIncludingDiscontinuedOperationsAmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries_documentation_en-US" xlink:label="lab_ci_DisposalGroupsIncludingDiscontinuedOperationsAmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Amount of Restricted Net Assets for Consolidated and Unconsolidated Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupsIncludingDiscontinuedOperationsAmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries" xlink:href="ci-20231231.xsd#ci_DisposalGroupsIncludingDiscontinuedOperationsAmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DisposalGroupsIncludingDiscontinuedOperationsAmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries" xlink:to="lab_ci_DisposalGroupsIncludingDiscontinuedOperationsAmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_2115858d-ac44-4b70-9fc9-e1ed2d8b4f78_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_43ad76da-38f0-49f7-a016-d2bf70c1e3fa_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FiniteLivedIntangibleAssetsNetIncludingDisposalGroupsAssetsHeldForSale_d8f34a5f-748f-44e3-93bf-c5158d892630_totalLabel_en-US" xlink:label="lab_ci_FiniteLivedIntangibleAssetsNetIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Value, including held for sale assets</link:label>
    <link:label id="lab_ci_FiniteLivedIntangibleAssetsNetIncludingDisposalGroupsAssetsHeldForSale_label_en-US" xlink:label="lab_ci_FiniteLivedIntangibleAssetsNetIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets, Net, Including Disposal Groups Assets Held For Sale</link:label>
    <link:label id="lab_ci_FiniteLivedIntangibleAssetsNetIncludingDisposalGroupsAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_FiniteLivedIntangibleAssetsNetIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets, Net, Including Disposal Groups Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsNetIncludingDisposalGroupsAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsNetIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FiniteLivedIntangibleAssetsNetIncludingDisposalGroupsAssetsHeldForSale" xlink:to="lab_ci_FiniteLivedIntangibleAssetsNetIncludingDisposalGroupsAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_f75be518-1683-4e82-b2ce-21472c916a64_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurred costs related to:</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_94127211-cba4-4227-b09e-b5132d72f917_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_6eab8911-bce3-45c8-91dc-816c3e4ae2dc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit agreement term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NotesDue202435InterestMember_86e79deb-a1b9-420d-b960-274a4f1fe557_terseLabel_en-US" xlink:label="lab_ci_NotesDue202435InterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$1,000&#160;million, 3.500% Notes due June 2024</link:label>
    <link:label id="lab_ci_NotesDue202435InterestMember_label_en-US" xlink:label="lab_ci_NotesDue202435InterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2024 3.5% Interest [Member]</link:label>
    <link:label id="lab_ci_NotesDue202435InterestMember_documentation_en-US" xlink:label="lab_ci_NotesDue202435InterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior notes payable bearing interest at 3.5% due in 2024. Debt assumed acquisition from Express Scripts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue202435InterestMember" xlink:href="ci-20231231.xsd#ci_NotesDue202435InterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NotesDue202435InterestMember" xlink:to="lab_ci_NotesDue202435InterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries_d4603df4-8f5c-4217-ad8f-d7186939c769_terseLabel_en-US" xlink:label="lab_us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends received from subsidiaries</link:label>
    <link:label id="lab_us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries_label_en-US" xlink:label="lab_us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-04, Cash Dividends Paid to Registrant, Consolidated Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries" xlink:to="lab_us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OtherShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_ede84d68-d891-4982-89fe-075a3c02dca0_terseLabel_en-US" xlink:label="lab_ci_OtherShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, including held for sale assets</link:label>
    <link:label id="lab_ci_OtherShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_OtherShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Short Term Investments Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_OtherShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_OtherShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Short Term Investments Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_OtherShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OtherShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_OtherShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_RestructuringChargesNetOfTaxExpense_7a2c31fb-1eaa-49aa-a4e2-9694deeb195d_verboseLabel_en-US" xlink:label="lab_ci_RestructuringChargesNetOfTaxExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge for organizational efficiency plan recorded in Selling, general and administrative expenses, after-tax</link:label>
    <link:label id="lab_ci_RestructuringChargesNetOfTaxExpense_6ceeebad-aeb6-400f-aec6-89cdba76ecbc_terseLabel_en-US" xlink:label="lab_ci_RestructuringChargesNetOfTaxExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge for organizational efficiency plan, after-tax (Selling, general and administrative expenses)</link:label>
    <link:label id="lab_ci_RestructuringChargesNetOfTaxExpense_label_en-US" xlink:label="lab_ci_RestructuringChargesNetOfTaxExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges, Net Of Tax Expense</link:label>
    <link:label id="lab_ci_RestructuringChargesNetOfTaxExpense_documentation_en-US" xlink:label="lab_ci_RestructuringChargesNetOfTaxExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges, Net Of Tax Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RestructuringChargesNetOfTaxExpense" xlink:href="ci-20231231.xsd#ci_RestructuringChargesNetOfTaxExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_RestructuringChargesNetOfTaxExpense" xlink:to="lab_ci_RestructuringChargesNetOfTaxExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_UnearnedPremiumsNoncurrent_bdda908a-3dc2-4faf-98d1-4b292a24841f_terseLabel_en-US" xlink:label="lab_ci_UnearnedPremiumsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unearned premiums, non-current</link:label>
    <link:label id="lab_ci_UnearnedPremiumsNoncurrent_label_en-US" xlink:label="lab_ci_UnearnedPremiumsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unearned Premiums, Noncurrent</link:label>
    <link:label id="lab_ci_UnearnedPremiumsNoncurrent_documentation_en-US" xlink:label="lab_ci_UnearnedPremiumsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unearned Premiums, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsNoncurrent" xlink:href="ci-20231231.xsd#ci_UnearnedPremiumsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_UnearnedPremiumsNoncurrent" xlink:to="lab_ci_UnearnedPremiumsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_173515dd-f32b-48c9-9710-465a2df3a252_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_62521e28-f3fa-4404-bdfa-2d5382af66a9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_662be19e-d7bd-49d8-a79c-bdec54d24f1f_totalLabel_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid claims and claim expenses, including held for sale liabilities</link:label>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_cbf2d8d6-ed27-4b79-b773-768d03789172_periodStartLabel_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, including held for sale liabilities</link:label>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_1e2c9a31-746e-45ee-9bea-19c15011a686_periodEndLabel_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, including held for sale liabilities</link:label>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_dfa204a8-641a-4c61-acf5-5be9bc1c3570_terseLabel_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid claims and claim expenses, including held for sale liabilities</link:label>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_label_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Claims And Claims Adjustment Expense Including Disposal Groups</link:label>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_documentation_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Claims And Claims Adjustment Expense Including Disposal Groups</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups" xlink:to="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EarningsPerShareEffectOfDilution_1811bfc1-0f68-40d5-bf0a-d6871007fbd2_terseLabel_en-US" xlink:label="lab_ci_EarningsPerShareEffectOfDilution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EPS, effect of dilution (in dollars per share)</link:label>
    <link:label id="lab_ci_EarningsPerShareEffectOfDilution_label_en-US" xlink:label="lab_ci_EarningsPerShareEffectOfDilution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Effect Of Dilution</link:label>
    <link:label id="lab_ci_EarningsPerShareEffectOfDilution_documentation_en-US" xlink:label="lab_ci_EarningsPerShareEffectOfDilution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The decrease in net income (loss) on a per share basis when the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period is assumed.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EarningsPerShareEffectOfDilution" xlink:href="ci-20231231.xsd#ci_EarningsPerShareEffectOfDilution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EarningsPerShareEffectOfDilution" xlink:to="lab_ci_EarningsPerShareEffectOfDilution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_e87edd50-aaec-441b-a332-c982600d7ab4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_b4081ccd-56a9-4235-849d-67c6b391aad5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsUndistributedEarningsFromEquityMethodInvestees_802cd57f-3a45-473f-9a24-6894210e358b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsUndistributedEarningsFromEquityMethodInvestees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed earnings from equity method subidiaries</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsUndistributedEarningsFromEquityMethodInvestees_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsUndistributedEarningsFromEquityMethodInvestees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings, Undistributed Earnings from Equity Method Investees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsUndistributedEarningsFromEquityMethodInvestees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsUndistributedEarningsFromEquityMethodInvestees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsUndistributedEarningsFromEquityMethodInvestees" xlink:to="lab_us-gaap_RetainedEarningsUndistributedEarningsFromEquityMethodInvestees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward_5a86fa2f-ded2-4327-8f87-1f907013299a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefit, Expected Net Premium [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefit, Expected Net Premium [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_57babaa8-a39d-4633-9cfb-16702f772d76_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures for Financial Instruments Not Carried at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_56789b5d-6561-4a78-b907-ff4da42dbe9f_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SpecialItemChargeBenefitAfterTaxLitigation_102f889d-898d-4998-817c-5f1ee9c1b189_verboseLabel_en-US" xlink:label="lab_ci_SpecialItemChargeBenefitAfterTaxLitigation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Benefits) charges associated with litigation matters, after-tax (Selling, general and administrative expenses)</link:label>
    <link:label id="lab_ci_SpecialItemChargeBenefitAfterTaxLitigation_label_en-US" xlink:label="lab_ci_SpecialItemChargeBenefitAfterTaxLitigation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Item Charge (Benefit) After Tax Litigation</link:label>
    <link:label id="lab_ci_SpecialItemChargeBenefitAfterTaxLitigation_documentation_en-US" xlink:label="lab_ci_SpecialItemChargeBenefitAfterTaxLitigation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After-tax charges associated with litigation matters that are classified as special items, attributable to the parent. Special items reflect amounts that management does not believe are representative of underlying results of operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitAfterTaxLitigation" xlink:href="ci-20231231.xsd#ci_SpecialItemChargeBenefitAfterTaxLitigation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SpecialItemChargeBenefitAfterTaxLitigation" xlink:to="lab_ci_SpecialItemChargeBenefitAfterTaxLitigation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_38eb5334-66d6-4d53-9154-31b0e75257d2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage_0296b17a-125c-4e93-8bae-138cf35a4ded_terseLabel_en-US" xlink:label="lab_ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Favorable (unfavorable) variance, percentage</link:label>
    <link:label id="lab_ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage_label_en-US" xlink:label="lab_ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Unpaid Medical Claims And Claims Adjustment Expense Incurred Claims Prior Years Percentage</link:label>
    <link:label id="lab_ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage_documentation_en-US" xlink:label="lab_ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of payments made in the reporting period to settle claims incurred in prior periods and related claims settlement costs as a percentage of incurred claims as reported in the prior year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage" xlink:href="ci-20231231.xsd#ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage" xlink:to="lab_ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_e44cfbeb-5c53-4e23-933a-7344c6e476e1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized appreciation (depreciation) on securities and derivatives</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod_9fec770c-e9cf-4dbd-b88a-dc29473a45c0_terseLabel_en-US" xlink:label="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Perfromance period</link:label>
    <link:label id="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod_label_en-US" xlink:label="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Performance Period</link:label>
    <link:label id="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod_documentation_en-US" xlink:label="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The period of time over which performance is measured to determine achievement for the performance awards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" xlink:href="ci-20231231.xsd#ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" xlink:to="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale_c4bb65af-c0e3-453a-9d3f-0a742a161c9d_terseLabel_en-US" xlink:label="lab_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noninsurance customer receivables, including held for sale assets</link:label>
    <link:label id="lab_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noninsurance Customer Receivables Excluding Pharmaceutical Manufacturers Receivable Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noninsurance Customer Receivables Excluding Pharmaceutical Manufacturers Receivable Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_6b82482a-9dbb-457c-86c4-04c4abf10bb8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for debt extinguishment</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_6938508f-bb4b-49a5-a77c-54e2388c20d8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for debt extinguishment</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureLessThan12MonthsNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale_a2b419cb-16eb-4384-a5b1-61dc04c814bb_terseLabel_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureLessThan12MonthsNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Issues, including held for sale assets</link:label>
    <link:label id="lab_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureLessThan12MonthsNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureLessThan12MonthsNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities In Unrealized Loss Positions, Qualitative Disclosure, Less Than 12 Months, Number Of Positions, Before Reclassification To Disposal Group, Assets Held For Sale</link:label>
    <link:label id="lab_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureLessThan12MonthsNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureLessThan12MonthsNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities In Unrealized Loss Positions, Qualitative Disclosure, Less Than 12 Months, Number Of Positions, Before Reclassification To Disposal Group, Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureLessThan12MonthsNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureLessThan12MonthsNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureLessThan12MonthsNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureLessThan12MonthsNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7e54ef87-b2b1-4493-84b9-8384e08fb244_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteeObligationsLiquidationProceeds_80c93c1b-d489-492d-9fd3-7b2118a54219_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsLiquidationProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets maintained by employers (minimum)</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsLiquidationProceeds_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsLiquidationProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor Obligations, Liquidation Proceeds, Monetary Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsLiquidationProceeds" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsLiquidationProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsLiquidationProceeds" xlink:to="lab_us-gaap_GuaranteeObligationsLiquidationProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember_6ac3e069-b462-4429-b8e0-24c4adba11aa_terseLabel_en-US" xlink:label="lab_ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of collateral contractually required to meet or exceed carrying value of recoverable</link:label>
    <link:label id="lab_ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember_label_en-US" xlink:label="lab_ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded Credit Risk, Secured, Contractually Required Fair Value [Member]</link:label>
    <link:label id="lab_ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember_documentation_en-US" xlink:label="lab_ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded Credit Risk, Secured, Contractually Required Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember" xlink:href="ci-20231231.xsd#ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember" xlink:to="lab_ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NotesDue20416125InterestMember_daf683fa-ff08-4445-9cc5-f11896a6ae94_terseLabel_en-US" xlink:label="lab_ci_NotesDue20416125InterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$448&#160;million, 6.125% Notes due November 2041</link:label>
    <link:label id="lab_ci_NotesDue20416125InterestMember_label_en-US" xlink:label="lab_ci_NotesDue20416125InterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2041, 6.125% Interest [Member]</link:label>
    <link:label id="lab_ci_NotesDue20416125InterestMember_documentation_en-US" xlink:label="lab_ci_NotesDue20416125InterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior notes payable bearing interest at 6.125% due in 2041. Debt assumed acquisition from Express Scripts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20416125InterestMember" xlink:href="ci-20231231.xsd#ci_NotesDue20416125InterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NotesDue20416125InterestMember" xlink:to="lab_ci_NotesDue20416125InterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_9cf05092-e522-4a13-b65f-ba9e23a8c91c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_fe19182a-248f-4f62-920c-22d506071dcd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_585262fe-3b87-4427-ba20-4cbd09b3a3e3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_15a0c6d5-2107-4198-9579-d35c3e5336aa_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_02b2b956-e182-42d1-ab09-52c7f49ba2e8_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_2b18d95a-4dea-4991-b857-f1edb1bdbdfa_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_cf19ee96-cb8d-4c18-864c-b5a4a767fb4c_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_9aa19e9a-fce9-4b69-af10-5a650942f5d3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments per Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CededCreditRiskSecuredMember_8a8a2c7c-a593-4de1-9b09-163d72e9949a_terseLabel_en-US" xlink:label="lab_us-gaap_CededCreditRiskSecuredMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured</link:label>
    <link:label id="lab_us-gaap_CededCreditRiskSecuredMember_label_en-US" xlink:label="lab_us-gaap_CededCreditRiskSecuredMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded Credit Risk, Secured [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskSecuredMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskSecuredMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CededCreditRiskSecuredMember" xlink:to="lab_us-gaap_CededCreditRiskSecuredMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AllOtherCountriesMember_24d209f0-b4ea-496b-aed8-5bf32128ff22_terseLabel_en-US" xlink:label="lab_ci_AllOtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign countries</link:label>
    <link:label id="lab_ci_AllOtherCountriesMember_label_en-US" xlink:label="lab_ci_AllOtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other Countries [Member]</link:label>
    <link:label id="lab_ci_AllOtherCountriesMember_documentation_en-US" xlink:label="lab_ci_AllOtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other countries not specified within the taxonomy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AllOtherCountriesMember" xlink:href="ci-20231231.xsd#ci_AllOtherCountriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AllOtherCountriesMember" xlink:to="lab_ci_AllOtherCountriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_802f15a9-2cfb-44e6-8fe4-979cf169d907_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase due to current year positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock_01b22ad2-38fb-4749-9fe6-6de3f6efb618_terseLabel_en-US" xlink:label="lab_ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Value Information for Other Long-Term Investments</link:label>
    <link:label id="lab_ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Long-Term Investments [Table Text Block]</link:label>
    <link:label id="lab_ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock_documentation_en-US" xlink:label="lab_ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock" xlink:href="ci-20231231.xsd#ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock" xlink:to="lab_ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale_10d0f620-1c2a-4a4a-ad43-87d37e4c556f_terseLabel_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years, including assets held for sale</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax_bee2e5f1-0abc-4c3e-b45c-628be3b540cb_negatedLabel_en-US" xlink:label="lab_ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on sale of business, after-tax</link:label>
    <link:label id="lab_ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax_label_en-US" xlink:label="lab_ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Item, Gain (Loss) On Sale Of Business, Net Of Tax</link:label>
    <link:label id="lab_ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax_documentation_en-US" xlink:label="lab_ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Item, Gain (Loss) On Sale Of Business, Net Of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax" xlink:href="ci-20231231.xsd#ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax" xlink:to="lab_ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_f9703533-7faf-4326-838c-c8e411a3db8a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_8332075a-3658-414b-bc9e-8d0a53817f3c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInSeparateAccountsOfSubsidiaries_7e13e05b-7ee7-49fc-99d3-1b95101362d4_terseLabel_en-US" xlink:label="lab_ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInSeparateAccountsOfSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan assets invested in separate accounts of subsidiaries</link:label>
    <link:label id="lab_ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInSeparateAccountsOfSubsidiaries_label_en-US" xlink:label="lab_ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInSeparateAccountsOfSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Fair Value Of Plan Assets Invested In Separate Accounts Of Subsidiaries</link:label>
    <link:label id="lab_ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInSeparateAccountsOfSubsidiaries_documentation_en-US" xlink:label="lab_ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInSeparateAccountsOfSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets invested in the separate accounts of subisdiaries of the Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInSeparateAccountsOfSubsidiaries" xlink:href="ci-20231231.xsd#ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInSeparateAccountsOfSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInSeparateAccountsOfSubsidiaries" xlink:to="lab_ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInSeparateAccountsOfSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NotesDue2023375InterestMember_9da2e3f2-f82f-45c2-93ac-e844f3a3279f_terseLabel_en-US" xlink:label="lab_ci_NotesDue2023375InterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$1,187&#160;million, 3.75% Notes due July 2023</link:label>
    <link:label id="lab_ci_NotesDue2023375InterestMember_label_en-US" xlink:label="lab_ci_NotesDue2023375InterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2023, 3.75% Interest [Member]</link:label>
    <link:label id="lab_ci_NotesDue2023375InterestMember_documentation_en-US" xlink:label="lab_ci_NotesDue2023375InterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior notes payable bearing interest at 3.75% due in 2023. Debt issued to finance acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue2023375InterestMember" xlink:href="ci-20231231.xsd#ci_NotesDue2023375InterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NotesDue2023375InterestMember" xlink:to="lab_ci_NotesDue2023375InterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock_c69b62c5-0aeb-48a9-b39d-40670252655d_terseLabel_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Security Investments</link:label>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock_label_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI And Equity Securities Without Readily Determinable Fair Value [Table Text Block]</link:label>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock_documentation_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI And Equity Securities Without Readily Determinable Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock" xlink:to="lab_ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_ec5126fb-a7bd-4f82-acfd-a65d4064e999_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_e12f9dd5-7ac7-4409-a7ac-7b8ff615fb00_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_7f2ea31c-26de-4940-b9b5-4c0b7d4d6b29_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities of Businesses Held for Sale</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ExpressScriptsLitigationWithElevanceMember_afc3cb63-5c6c-4b83-a7bd-2398ae6ab3bc_terseLabel_en-US" xlink:label="lab_ci_ExpressScriptsLitigationWithElevanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Express Scripts Litigation with Elevance</link:label>
    <link:label id="lab_ci_ExpressScriptsLitigationWithElevanceMember_label_en-US" xlink:label="lab_ci_ExpressScriptsLitigationWithElevanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Express Scripts Litigation With Elevance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ExpressScriptsLitigationWithElevanceMember" xlink:href="ci-20231231.xsd#ci_ExpressScriptsLitigationWithElevanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ExpressScriptsLitigationWithElevanceMember" xlink:to="lab_ci_ExpressScriptsLitigationWithElevanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_65767d53-7d8d-4ffe-8b2c-43dd9f97fda9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_4e989509-e04a-4c87-954b-e6c9243aa857_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized net (losses)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_e239be26-d0a1-4b7b-987f-9c563e663534_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Appreciation (Depreciation) on Debt Securities</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember_fa2fc0d5-0e82-47c6-b28b-47c6b830d88b_terseLabel_en-US" xlink:label="lab_ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Account Balance, Above Guaranteed Minimum Crediting Rate, Based On Greater Of Guaranteed Minimum Cash Value Or Actual Cash Value</link:label>
    <link:label id="lab_ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember_label_en-US" xlink:label="lab_ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Account Balance, Above Guaranteed Minimum Crediting Rate, Based On Greater Of Guaranteed Minimum Cash Value Or Actual Cash Value [Member]</link:label>
    <link:label id="lab_ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember_documentation_en-US" xlink:label="lab_ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Account Balance, Above Guaranteed Minimum Crediting Rate, Based On Greater Of Guaranteed Minimum Cash Value Or Actual Cash Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember" xlink:href="ci-20231231.xsd#ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember" xlink:to="lab_ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_f681ce32-a3ae-4cf4-a403-ef557d0dc889_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translation of foreign currencies attributable to parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_UnitedStatedHealthcareMember_a04ab682-d914-4e7e-9dbd-158e8f7e4d2c_terseLabel_en-US" xlink:label="lab_ci_UnitedStatedHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Healthcare</link:label>
    <link:label id="lab_ci_UnitedStatedHealthcareMember_label_en-US" xlink:label="lab_ci_UnitedStatedHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Stated Healthcare [Member]</link:label>
    <link:label id="lab_ci_UnitedStatedHealthcareMember_documentation_en-US" xlink:label="lab_ci_UnitedStatedHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Stated Healthcare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnitedStatedHealthcareMember" xlink:href="ci-20231231.xsd#ci_UnitedStatedHealthcareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_UnitedStatedHealthcareMember" xlink:to="lab_ci_UnitedStatedHealthcareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_16ec5f17-8584-4e5a-a9b4-b2f2e1bc6e89_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period over which compensation expense will be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_e59d6f6b-4a58-4723-b982-6f4c6becc414_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_eb81dff1-fae6-41ce-b4da-390c7a86f506_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHAREHOLDERS' COMPREHENSIVE INCOME</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_442fcce4-9da1-4316-9eeb-3844318e6e09_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_22906cf3-5249-49d7-b8b1-ecccd73afbb6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Expected Benefit Payments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_f66991f5-06d9-4ea0-9d18-91509d495d61_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded status</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Funded (Unfunded) Status of Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:to="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_6a455d71-b3db-4428-953d-3dc79e145d26_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_57a71e5d-3132-42f5-8e45-0b6a422e6ba4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DefinedBenefitPlanBenefitsPaidOther_511286a0-9398-40e0-a080-e0332c7fd2eb_negatedTerseLabel_en-US" xlink:label="lab_ci_DefinedBenefitPlanBenefitsPaidOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ci_DefinedBenefitPlanBenefitsPaidOther_label_en-US" xlink:label="lab_ci_DefinedBenefitPlanBenefitsPaidOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Benefits Paid Other</link:label>
    <link:label id="lab_ci_DefinedBenefitPlanBenefitsPaidOther_documentation_en-US" xlink:label="lab_ci_DefinedBenefitPlanBenefitsPaidOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of payments from sources other than plan assets made for which participants are entitled under a pension plan, including pension benefits, death benefits, and benefits due on termination of employment. Also includes payments made under a postretirement benefit plan, including prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DefinedBenefitPlanBenefitsPaidOther" xlink:href="ci-20231231.xsd#ci_DefinedBenefitPlanBenefitsPaidOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DefinedBenefitPlanBenefitsPaidOther" xlink:to="lab_ci_DefinedBenefitPlanBenefitsPaidOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_790184fc-9304-43e6-bf48-a2fb772085a3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_6c3cd5ab-e6b4-405e-b8a0-597b44f38eac_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postretirement benefits liability adjustment</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EvernorthHealthIncorporatedMember_a61b0c4e-b6e3-4201-ba12-fbd75f02a930_terseLabel_en-US" xlink:label="lab_ci_EvernorthHealthIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evernorth Health, Inc.</link:label>
    <link:label id="lab_ci_EvernorthHealthIncorporatedMember_label_en-US" xlink:label="lab_ci_EvernorthHealthIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evernorth Health Incorporated [Member]</link:label>
    <link:label id="lab_ci_EvernorthHealthIncorporatedMember_documentation_en-US" xlink:label="lab_ci_EvernorthHealthIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evernorth Health Incorporated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EvernorthHealthIncorporatedMember" xlink:href="ci-20231231.xsd#ci_EvernorthHealthIncorporatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EvernorthHealthIncorporatedMember" xlink:to="lab_ci_EvernorthHealthIncorporatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_97699b07-669b-4a0b-8331-b378ff689d1b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_17eb91ad-89ab-424d-9db1-11044db3e461_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_90053f3f-d956-4f1a-bbd0-f6d260959d10_terseLabel_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, including held for sale assets</link:label>
    <link:label id="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectsOfReinsuranceTable_cbdf4ca8-fda5-41cf-a3a4-0b7eb16aff2e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectsOfReinsuranceTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of Reinsurance [Table]</link:label>
    <link:label id="lab_us-gaap_EffectsOfReinsuranceTable_label_en-US" xlink:label="lab_us-gaap_EffectsOfReinsuranceTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of Reinsurance [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectsOfReinsuranceTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectsOfReinsuranceTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectsOfReinsuranceTable" xlink:to="lab_us-gaap_EffectsOfReinsuranceTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_43037fdb-7413-4bd3-ab94-638a67ec8808_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_A364DayRevolvingCreditAgreementMaturingApril2024Member_21a01c73-98c5-4983-958d-446350e3b811_terseLabel_en-US" xlink:label="lab_ci_A364DayRevolvingCreditAgreementMaturingApril2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">364-day Revolving Credit Agreement, Maturing April 2024</link:label>
    <link:label id="lab_ci_A364DayRevolvingCreditAgreementMaturingApril2024Member_label_en-US" xlink:label="lab_ci_A364DayRevolvingCreditAgreementMaturingApril2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">364 Day Revolving Credit Agreement, Maturing April 2024 [Member]</link:label>
    <link:label id="lab_ci_A364DayRevolvingCreditAgreementMaturingApril2024Member_documentation_en-US" xlink:label="lab_ci_A364DayRevolvingCreditAgreementMaturingApril2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">364 Day Revolving Credit Agreement, Maturing April 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_A364DayRevolvingCreditAgreementMaturingApril2024Member" xlink:href="ci-20231231.xsd#ci_A364DayRevolvingCreditAgreementMaturingApril2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_A364DayRevolvingCreditAgreementMaturingApril2024Member" xlink:to="lab_ci_A364DayRevolvingCreditAgreementMaturingApril2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_562caf12-50ce-4a9b-b85b-66cfeb8050fe_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:to="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_316abb3a-253e-45ad-b4e0-65925b8ac650_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_220e7995-1588-4db2-8863-41d5bf06baaf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rollforward of Accrued Liability</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_bb081ff5-991f-4672-9b7d-39243ef60361_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities_228eef08-1497-4eff-8cb1-2927bc0395a1_terseLabel_en-US" xlink:label="lab_ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities and equity securities</link:label>
    <link:label id="lab_ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities_label_en-US" xlink:label="lab_ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Maturities Prepayments And Calls Of Debt And Equity Securities</link:label>
    <link:label id="lab_ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities_documentation_en-US" xlink:label="lab_ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities, repayments and calls of debt and equity securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities" xlink:href="ci-20231231.xsd#ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities" xlink:to="lab_ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_IncomeBeforeTaxesMember_1c7c9b76-6b4c-495a-a341-20ff069f66ff_terseLabel_en-US" xlink:label="lab_ci_IncomeBeforeTaxesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Tax Income</link:label>
    <link:label id="lab_ci_IncomeBeforeTaxesMember_label_en-US" xlink:label="lab_ci_IncomeBeforeTaxesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Before Taxes [Member]</link:label>
    <link:label id="lab_ci_IncomeBeforeTaxesMember_documentation_en-US" xlink:label="lab_ci_IncomeBeforeTaxesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings before income taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncomeBeforeTaxesMember" xlink:href="ci-20231231.xsd#ci_IncomeBeforeTaxesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_IncomeBeforeTaxesMember" xlink:to="lab_ci_IncomeBeforeTaxesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance_ab4e20bd-db8f-4525-831f-7f72fc02b2b7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future policy benefits reserve, reinsurance recoverables</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefit, Reinsurance Recoverable, after Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_f660837a-8ae6-4c5f-a8db-dde81d13e469_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of issuing stock for employee benefit plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_4506d617-18fc-4f51-9e46-f5369523ba5d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_3e698bf7-53ef-4b50-83b1-8eb157b51435_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax expense at nominal rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeparateAccountAssets_8365f640-997c-4020-b96a-62931407d897_terseLabel_en-US" xlink:label="lab_us-gaap_SeparateAccountAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate account assets</link:label>
    <link:label id="lab_us-gaap_SeparateAccountAssets_d8ccfa6c-9bbb-4740-b43e-2ce60acb76cc_totalLabel_en-US" xlink:label="lab_us-gaap_SeparateAccountAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate account assets</link:label>
    <link:label id="lab_us-gaap_SeparateAccountAssets_label_en-US" xlink:label="lab_us-gaap_SeparateAccountAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate Account Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeparateAccountAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeparateAccountAssets" xlink:to="lab_us-gaap_SeparateAccountAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_e5268844-4d24-4382-85e7-bfcef8ff55c5_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments, carrying value</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_c90562ce-9f47-42fb-a97c-d1751f83a53d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_bf463509-3424-42a8-9ba2-66bb8ac6ae7e_totalLabel_en-US" xlink:label="lab_ci_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding liabilities for the periods presented, net of reinsurance, including assets held for sale</link:label>
    <link:label id="lab_ci_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shortduration Insurance Contracts Liability For Unpaid Claims And Allocated Claim Adjustment Expense Used In Claims Development Net, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shortduration Insurance Contracts Liability For Unpaid Claims And Allocated Claim Adjustment Expense Used In Claims Development Net, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentsMember_d8e969a4-b7c0-44ef-a684-bc4d415e345f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentsMember" xlink:to="lab_us-gaap_OtherInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_5c6d7ecc-f6f7-4802-bcd0-4b22703f958f_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceLossReservesAbstract_c4295b9e-4c5a-498c-9379-e124f4ce0ccb_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceLossReservesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Loss Reserves [Abstract]</link:label>
    <link:label id="lab_us-gaap_InsuranceLossReservesAbstract_label_en-US" xlink:label="lab_us-gaap_InsuranceLossReservesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Loss Reserves [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceLossReservesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceLossReservesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceLossReservesAbstract" xlink:to="lab_us-gaap_InsuranceLossReservesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_0e9faf93-837f-4e44-a950-95cdf82d8919_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_68fb25ec-aaa6-4bef-a358-bff1f135016e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign income (tax benefits) taxes</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CededCreditRiskCollateralizationAxis_0b442997-607a-4001-ac7f-86257c522768_terseLabel_en-US" xlink:label="lab_us-gaap_CededCreditRiskCollateralizationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded Credit Risk, Collateralization [Axis]</link:label>
    <link:label id="lab_us-gaap_CededCreditRiskCollateralizationAxis_label_en-US" xlink:label="lab_us-gaap_CededCreditRiskCollateralizationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded Credit Risk, Collateralization [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskCollateralizationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskCollateralizationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CededCreditRiskCollateralizationAxis" xlink:to="lab_us-gaap_CededCreditRiskCollateralizationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_2be3c68c-acc5-4a4c-a4d1-e0d3e9f36a70_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_be1b3a7a-9ee9-4c12-86d7-ec18a9bad553_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_82a669e2-ceff-4027-ae60-68bf810a7224_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGainsIncludingDisposalGroupsAssetsHeldForSale_52fb7894-1ec5-43ed-8d25-09b35a06427f_terseLabel_en-US" xlink:label="lab_ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGainsIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized appreciation on investments and foreign currency translation</link:label>
    <link:label id="lab_ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGainsIncludingDisposalGroupsAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGainsIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities Unrealized Gains On Investments And Unrealized Currency Transaction Gains, Including Disposal Groups Assets Held For Sale</link:label>
    <link:label id="lab_ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGainsIncludingDisposalGroupsAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGainsIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of deferred tax liability, including held for sale amounts, attributable to taxable temporary differences from unrealized gains on investments and foreign currency translation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGainsIncludingDisposalGroupsAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGainsIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGainsIncludingDisposalGroupsAssetsHeldForSale" xlink:to="lab_ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGainsIncludingDisposalGroupsAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_88a80a7a-2a23-4912-a2ec-f0f76ff9952f_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_9f8ba0eb-cd5c-4d92-a4bb-5df69cfd3b8c_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_89301bd4-9885-4e2a-bc46-7d86c70f43cb_negatedLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents reclassified to assets of businesses held for sale</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_387685de-a90d-459d-b066-e65c5317b852_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_f9848de7-f009-456d-935a-f0bb41835fe3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestmentsAbstract_6f0d3e9e-8827-4fa8-9518-20235c9680ee_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term</link:label>
    <link:label id="lab_us-gaap_LongTermInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract" xlink:to="lab_us-gaap_LongTermInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract_cc2c0aac-c3d8-41c6-bc09-ebb736af0383_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Summarized Financial Information [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Summarized Financial Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_94110b14-dbd9-4c02-bbf7-2ea7e04d8f55_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_66e8bdca-a233-4ff2-b56c-6f3d970c522e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Redeemable Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_73a19972-3c64-4d3e-884b-e2f53ed4a47b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DefinedBenefitPlanGainLossDueToLitigation_5622534c-8caf-41a2-a037-4419b7d56d77_negatedLabel_en-US" xlink:label="lab_ci_DefinedBenefitPlanGainLossDueToLitigation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in pension liability due to litigation settlement</link:label>
    <link:label id="lab_ci_DefinedBenefitPlanGainLossDueToLitigation_441d6306-22d5-4309-8ff9-e151c7d1f80d_negatedTerseLabel_en-US" xlink:label="lab_ci_DefinedBenefitPlanGainLossDueToLitigation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement &#8211; plan amendment</link:label>
    <link:label id="lab_ci_DefinedBenefitPlanGainLossDueToLitigation_label_en-US" xlink:label="lab_ci_DefinedBenefitPlanGainLossDueToLitigation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Gain (Loss) Due To Litigation</link:label>
    <link:label id="lab_ci_DefinedBenefitPlanGainLossDueToLitigation_documentation_en-US" xlink:label="lab_ci_DefinedBenefitPlanGainLossDueToLitigation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Gain (Loss) Due To Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DefinedBenefitPlanGainLossDueToLitigation" xlink:href="ci-20231231.xsd#ci_DefinedBenefitPlanGainLossDueToLitigation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DefinedBenefitPlanGainLossDueToLitigation" xlink:to="lab_ci_DefinedBenefitPlanGainLossDueToLitigation" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_HealthcareMember_1c8e74a8-1087-4141-8a82-da6c9ff3d7f8_terseLabel_en-US" xlink:label="lab_ci_HealthcareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cigna Healthcare</link:label>
    <link:label id="lab_ci_HealthcareMember_label_en-US" xlink:label="lab_ci_HealthcareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_HealthcareMember" xlink:href="ci-20231231.xsd#ci_HealthcareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_HealthcareMember" xlink:to="lab_ci_HealthcareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_0c76bb94-0695-47ff-8fd0-3c470c29a985_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionReferenceTermOfTradedOptions_c40db993-e89a-4f1d-a0d8-2bfab58d7100_terseLabel_en-US" xlink:label="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionReferenceTermOfTradedOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining maturity of traded options</link:label>
    <link:label id="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionReferenceTermOfTradedOptions_label_en-US" xlink:label="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionReferenceTermOfTradedOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Reference Term Of Traded Options</link:label>
    <link:label id="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionReferenceTermOfTradedOptions_documentation_en-US" xlink:label="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionReferenceTermOfTradedOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The maximum period of time which a traded option of the reporting entity might be outstanding. The volatility of traded options is not used as a component of the expected volatility of outstanding share based compensation option awards as the term of these options does not correlate to the expected term of share-based option awards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionReferenceTermOfTradedOptions" xlink:href="ci-20231231.xsd#ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionReferenceTermOfTradedOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionReferenceTermOfTradedOptions" xlink:to="lab_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionReferenceTermOfTradedOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_762b51f0-4bcb-452e-aca8-bb4a1504d52d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_RevolvingCreditAgreementsApril2023Member_799e6015-5c0e-423e-a23e-b8c199665ca6_terseLabel_en-US" xlink:label="lab_ci_RevolvingCreditAgreementsApril2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving credit agreements, April 2023</link:label>
    <link:label id="lab_ci_RevolvingCreditAgreementsApril2023Member_label_en-US" xlink:label="lab_ci_RevolvingCreditAgreementsApril2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Agreements April 2023 [Member]</link:label>
    <link:label id="lab_ci_RevolvingCreditAgreementsApril2023Member_documentation_en-US" xlink:label="lab_ci_RevolvingCreditAgreementsApril2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving credit agreements entered into in April 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RevolvingCreditAgreementsApril2023Member" xlink:href="ci-20231231.xsd#ci_RevolvingCreditAgreementsApril2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_RevolvingCreditAgreementsApril2023Member" xlink:to="lab_ci_RevolvingCreditAgreementsApril2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6423f9fb-70a9-4918-9bb5-3514740dda53_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DepreciationAndAmortizationTypeDomain_7b887318-46e1-41f0-b787-201455649b9f_terseLabel_en-US" xlink:label="lab_ci_DepreciationAndAmortizationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation And Amortization Type [Domain]</link:label>
    <link:label id="lab_ci_DepreciationAndAmortizationTypeDomain_label_en-US" xlink:label="lab_ci_DepreciationAndAmortizationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation And Amortization Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DepreciationAndAmortizationTypeDomain" xlink:href="ci-20231231.xsd#ci_DepreciationAndAmortizationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DepreciationAndAmortizationTypeDomain" xlink:to="lab_ci_DepreciationAndAmortizationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_d466c268-b975-4ea3-9915-d82448bc13dc_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fees and other revenues</link:label>
    <link:label id="lab_us-gaap_ServiceMember_0cd5d6c1-93ca-4443-ade3-7a4f0486dc76_verboseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FiniteLivedIntangibleAssetsGrossVOBAIncludingDisposalGroupsAssetHeldForSale_cb9e3031-9f3b-4eb9-b634-e6a4406d7590_terseLabel_en-US" xlink:label="lab_ci_FiniteLivedIntangibleAssetsGrossVOBAIncludingDisposalGroupsAssetHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, including held for sale assets</link:label>
    <link:label id="lab_ci_FiniteLivedIntangibleAssetsGrossVOBAIncludingDisposalGroupsAssetHeldForSale_label_en-US" xlink:label="lab_ci_FiniteLivedIntangibleAssetsGrossVOBAIncludingDisposalGroupsAssetHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets Gross VOBA Including Disposal Groups Asset Held For Sale</link:label>
    <link:label id="lab_ci_FiniteLivedIntangibleAssetsGrossVOBAIncludingDisposalGroupsAssetHeldForSale_documentation_en-US" xlink:label="lab_ci_FiniteLivedIntangibleAssetsGrossVOBAIncludingDisposalGroupsAssetHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets Gross VOBA Including Disposal Groups Asset Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsGrossVOBAIncludingDisposalGroupsAssetHeldForSale" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsGrossVOBAIncludingDisposalGroupsAssetHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FiniteLivedIntangibleAssetsGrossVOBAIncludingDisposalGroupsAssetHeldForSale" xlink:to="lab_ci_FiniteLivedIntangibleAssetsGrossVOBAIncludingDisposalGroupsAssetHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d026a2c3-4b4c-4156-bccb-8ecc05f203d8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_2c853ea3-b84f-4289-9bfc-dea69f3c7c26_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charged (Credited) to costs and expenses</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_0e924e10-2505-4f77-863d-181515b723a6_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettledLitigationMember_8b72133e-396a-4292-9de8-52c2b9383531_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettledLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember" xlink:to="lab_us-gaap_SettledLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialGuaranteeMember_aaafc115-e3a7-4401-8a8f-60ee1f43104f_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Guarantees</link:label>
    <link:label id="lab_us-gaap_FinancialGuaranteeMember_label_en-US" xlink:label="lab_us-gaap_FinancialGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Guarantee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialGuaranteeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialGuaranteeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialGuaranteeMember" xlink:to="lab_us-gaap_FinancialGuaranteeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e8e4dac2-201d-4c54-9200-ff8a6346aceb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_a797b464-51b6-4410-b123-19881da8ee55_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postretirement benefits liability</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_20f16819-0f7b-4cbf-b042-54f5eb09e6df_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_3170352e-a66f-4217-9266-27bdeb72d89b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Table]</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_5c13f354-425e-4a83-be62-26ad9ffe1de5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' net income per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsHistoricalClaimsDurationYearOne_85205a93-d240-4490-a5dc-bfb24dbb5c74_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsHistoricalClaimsDurationYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of health claims paid within one year</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsHistoricalClaimsDurationYearOne_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsHistoricalClaimsDurationYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Historical Claims Duration, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsHistoricalClaimsDurationYearOne" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsHistoricalClaimsDurationYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsHistoricalClaimsDurationYearOne" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsHistoricalClaimsDurationYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity_ebb27c81-bc87-4264-922a-31ea642393cc_terseLabel_en-US" xlink:label="lab_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amount of options to increase commitments</link:label>
    <link:label id="lab_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity_label_en-US" xlink:label="lab_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Accordion Feature, Incremental Increase In Maximum Borrowing Capacity</link:label>
    <link:label id="lab_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity_documentation_en-US" xlink:label="lab_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Accordion Feature, Incremental Increase In Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity" xlink:href="ci-20231231.xsd#ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity" xlink:to="lab_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_a5b1ba60-ed01-4c04-9391-7478a2cd6643_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measured at Net Asset Value Per Share [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:to="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_3377e7a7-9505-46c1-b74b-0858bab001ab_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Name - Express Scripts</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_927a5e85-ad18-4b5f-8b6d-1bc82abcb489_terseLabel_en-US" xlink:label="lab_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage and related Cigna Healthcare businesses</link:label>
    <link:label id="lab_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_label_en-US" xlink:label="lab_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage And Related Cigna Healthcare Businesses [Member]</link:label>
    <link:label id="lab_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_documentation_en-US" xlink:label="lab_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage And Related Cigna Healthcare Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember" xlink:to="lab_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_d77d6a79-1a25-4c7a-a4ae-e571a5b552bb_periodStartLabel_en-US" xlink:label="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, including held for sale assets</link:label>
    <link:label id="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_9420ec7c-4514-4783-91bc-c212704c96f2_periodEndLabel_en-US" xlink:label="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, including held for sale assets</link:label>
    <link:label id="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AccumulatedDefinedBenefitPlansAdjustmentSettlementMember_b93c71a9-79dd-427f-9ebe-f1c52abf33b9_terseLabel_en-US" xlink:label="lab_ci_AccumulatedDefinedBenefitPlansAdjustmentSettlementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustment for settlement (Interest expense and other)</link:label>
    <link:label id="lab_ci_AccumulatedDefinedBenefitPlansAdjustmentSettlementMember_label_en-US" xlink:label="lab_ci_AccumulatedDefinedBenefitPlansAdjustmentSettlementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Settlement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccumulatedDefinedBenefitPlansAdjustmentSettlementMember" xlink:href="ci-20231231.xsd#ci_AccumulatedDefinedBenefitPlansAdjustmentSettlementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AccumulatedDefinedBenefitPlansAdjustmentSettlementMember" xlink:to="lab_ci_AccumulatedDefinedBenefitPlansAdjustmentSettlementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_891824fc-1ed4-457e-af67-e7471338efab_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance sheet location of non-current finance lease assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_8d3c0335-5746-489c-8952-0a7c9640503d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense and other</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_bd4719ce-4367-457c-99ad-04572ddfa08f_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_36aa7b62-b97e-4682-89dd-8f3270e18012_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_fcd45d0b-e073-4d7d-9ba1-c5ffbb34cf9b_terseLabel_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset-backed securities, including assets held for sale</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Fair Value, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Fair Value, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_673e7fac-70d7-46d6-b7f8-c1ae14b27195_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_c368e68c-0a89-455e-a8bf-f7462c654508_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_cca68087-5e9c-44a6-a440-482587db7222_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated stock repurchase, amount authorized</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteedInsuranceContractTypeOfBenefitAxis_7eaae711-fb43-4bf6-bc86-495f1e651bff_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteedInsuranceContractTypeOfBenefitAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guaranteed Insurance Contract, Type of Benefit [Axis]</link:label>
    <link:label id="lab_us-gaap_GuaranteedInsuranceContractTypeOfBenefitAxis_label_en-US" xlink:label="lab_us-gaap_GuaranteedInsuranceContractTypeOfBenefitAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guaranteed Insurance Contract, Type of Benefit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteedInsuranceContractTypeOfBenefitAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteedInsuranceContractTypeOfBenefitAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteedInsuranceContractTypeOfBenefitAxis" xlink:to="lab_us-gaap_GuaranteedInsuranceContractTypeOfBenefitAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_52e8e19b-daf1-4da3-ba12-f814e7962c43_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Total Income Taxes to the Amount Computed Using the Nominal Federal Income Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember_6a8bc46d-bd55-44f3-8698-5522a781d4ea_terseLabel_en-US" xlink:label="lab_ci_SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities limited partnerships and real estate limited partnerships</link:label>
    <link:label id="lab_ci_SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember_label_en-US" xlink:label="lab_ci_SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Limited Partnerships And Real Estate Limited Partnerships [Member]</link:label>
    <link:label id="lab_ci_SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember_documentation_en-US" xlink:label="lab_ci_SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Limited Partnerships And Real Estate Limited Partnerships</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember" xlink:href="ci-20231231.xsd#ci_SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember" xlink:to="lab_ci_SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_12ffc579-c5a4-4914-a727-5d1a3d386dc2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_ff2c13af-8288-416e-98e7-9c12c50acca2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_IntangibleAssetsNetExcludingGoodwillIncludingVoba_41bafb9c-3daa-4b9b-abc4-161606786ba6_totalLabel_en-US" xlink:label="lab_ci_IntangibleAssetsNetExcludingGoodwillIncludingVoba" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Value</link:label>
    <link:label id="lab_ci_IntangibleAssetsNetExcludingGoodwillIncludingVoba_label_en-US" xlink:label="lab_ci_IntangibleAssetsNetExcludingGoodwillIncludingVoba" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Net Excluding Goodwill Including VOBA</link:label>
    <link:label id="lab_ci_IntangibleAssetsNetExcludingGoodwillIncludingVoba_documentation_en-US" xlink:label="lab_ci_IntangibleAssetsNetExcludingGoodwillIncludingVoba" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. Includes insurance contracts acquired in a business combination that are reported in deferred policy acquisition costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingVoba" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsNetExcludingGoodwillIncludingVoba"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingVoba" xlink:to="lab_ci_IntangibleAssetsNetExcludingGoodwillIncludingVoba" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_47fad0e8-952d-4b2b-ba88-04e137c62a62_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2029 - 2033</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_dd4354f3-8a18-42f0-99d7-9dfdc6e65024_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_ac19cbcc-deb1-46fa-bdce-59eabe598912_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of preferred stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromSubsidiariesNetOfTax_96ad0372-71ed-4bdd-b527-161a233fba9a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromSubsidiariesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in income of subsidiaries</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromSubsidiariesNetOfTax_9b7cbee8-3688-40cf-93a4-d2bcf73d91f1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromSubsidiariesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in income of subsidiaries</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromSubsidiariesNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromSubsidiariesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Subsidiaries, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromSubsidiariesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromSubsidiariesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate_c2b0c45f-9745-4417-ad54-5d65a95581f7_terseLabel_en-US" xlink:label="lab_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price discount, spread on variable rate</link:label>
    <link:label id="lab_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate_label_en-US" xlink:label="lab_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Discount, Spread On Variable Rate</link:label>
    <link:label id="lab_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate_documentation_en-US" xlink:label="lab_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Discount, Spread On Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate" xlink:href="ci-20231231.xsd#ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate" xlink:to="lab_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitActivityTableTextBlock_b2f05c69-7870-424b-a7c1-bc05ef6fb992_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Policy Benefit Activity</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityTableTextBlock" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_d24e24e2-1d8e-41a2-a88e-981e0c2c65a6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) included in Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AnnuitizationElectionPeriod_ca8f2b95-16be-4a98-a69a-6ab5f82e358b_terseLabel_en-US" xlink:label="lab_ci_AnnuitizationElectionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annuitization election period</link:label>
    <link:label id="lab_ci_AnnuitizationElectionPeriod_label_en-US" xlink:label="lab_ci_AnnuitizationElectionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annuitization Election Period</link:label>
    <link:label id="lab_ci_AnnuitizationElectionPeriod_documentation_en-US" xlink:label="lab_ci_AnnuitizationElectionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The period of time prior to a policy anniversary when an annuitization election must occur.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AnnuitizationElectionPeriod" xlink:href="ci-20231231.xsd#ci_AnnuitizationElectionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AnnuitizationElectionPeriod" xlink:to="lab_ci_AnnuitizationElectionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DeferredTaxAssetsValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale_017387a9-61e8-46ee-9c16-5aacc33ea593_negatedLabel_en-US" xlink:label="lab_ci_DeferredTaxAssetsValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance for deferred tax assets</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DeferredTaxAssetsValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance, Including Disposal Groups Assets Held For Sale</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DeferredTaxAssetsValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance, Including Disposal Groups Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DeferredTaxAssetsValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale" xlink:to="lab_ci_DeferredTaxAssetsValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_1d2baf2d-3053-4f92-b994-753bc285b1cd_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (primarily short-term and other long-term investments)</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_0ad1dcb5-897b-4840-a03a-0a2dab9868f0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from short-term investments sold (purchased)</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_3bbb7809-ff58-462b-8eda-b512e5285049_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_f4e8b6c7-0762-4de8-84ba-2f30f4c59401_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange_2737e20f-23fb-46a7-8f44-311621f56423_terseLabel_en-US" xlink:label="lab_ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes due to capital markets versus expected</link:label>
    <link:label id="lab_ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange_label_en-US" xlink:label="lab_ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Risk Benefit, Increase (Decrease) From Interest Rate Change And Equity Market Change</link:label>
    <link:label id="lab_ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange_documentation_en-US" xlink:label="lab_ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Risk Benefit, Increase (Decrease) From Interest Rate Change And Equity Market Change</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange" xlink:href="ci-20231231.xsd#ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange" xlink:to="lab_ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_76da3300-04d3-4694-bb85-a56fa7f48486_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred income tax liabilities classified as liabilities of businesses held for sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups_48904b9f-8b4a-41b4-9e08-387661ccbbf1_totalLabel_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups_label_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance And Contractholder Liabilities, Including Disposal Groups</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups_documentation_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance And Contractholder Liabilities, Including Disposal Groups</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups" xlink:to="lab_ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_e1031365-facd-49d0-a600-b3adbc754b4c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput_c8f8829a-bff1-4587-9a19-1b5b1ea4a360_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unobservable Adjustment</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_59f29ab8-fdff-4ec5-8d18-d40aab766c28_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets of businesses held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_29669c1d-a4c5-4c30-a417-6cac200faf5a_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical costs and other benefit expenses</link:label>
    <link:label id="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_label_en-US" xlink:label="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Benefits and Claims Incurred, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet" xlink:to="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_cee987d3-1980-4674-8377-699e02c9fcca_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit from options exercised</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Exercise of Option, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceNetAmountAtRisk_81539fe0-d05d-43e4-b451-796a37e9d999_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceNetAmountAtRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amount at risk</link:label>
    <link:label id="lab_us-gaap_PolicyholderAccountBalanceNetAmountAtRisk_label_en-US" xlink:label="lab_us-gaap_PolicyholderAccountBalanceNetAmountAtRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Account Balance, Net Amount at Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceNetAmountAtRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceNetAmountAtRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderAccountBalanceNetAmountAtRisk" xlink:to="lab_us-gaap_PolicyholderAccountBalanceNetAmountAtRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PremiumsEarnedNet_c0682765-3be8-4559-b821-543a77cd11d4_terseLabel_en-US" xlink:label="lab_us-gaap_PremiumsEarnedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums</link:label>
    <link:label id="lab_us-gaap_PremiumsEarnedNet_af5255db-e107-4c62-a146-207f2e0c5a82_totalLabel_en-US" xlink:label="lab_us-gaap_PremiumsEarnedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total premiums</link:label>
    <link:label id="lab_us-gaap_PremiumsEarnedNet_label_en-US" xlink:label="lab_us-gaap_PremiumsEarnedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Earned, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PremiumsEarnedNet" xlink:to="lab_us-gaap_PremiumsEarnedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_144695ce-0662-4311-b970-8b96ee1924ff_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized investment gains on equity securities with no readily determinable fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_bc86e127-a020-4f0e-8c61-a26e498dbe49_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value and Significant Unobservable Inputs Used in Pricing Debt Securities</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_33a735ec-d2a8-401c-b132-c11c430cca7f_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost_81a4e473-717c-43ef-b315-2d83abd70e84_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policy acquisition expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense, Deferred Policy Acquisition Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationsStatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_be9576f1-d7c3-43f1-a2c0-29fe0dd07ec8_terseLabel_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationsStatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum statutory surplus required by regulators, disposal groups</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationsStatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_label_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationsStatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Statutory Accounting Practices, Statutory Capital and Surplus Required</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationsStatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_documentation_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationsStatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Statutory Accounting Practices, Statutory Capital and Surplus Required</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationsStatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationsStatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DisposalGroupIncludingDiscontinuedOperationsStatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:to="lab_ci_DisposalGroupIncludingDiscontinuedOperationsStatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierFinanceProgramPaymentTimingPeriod_a94d3351-a0e1-47ed-af5e-0ee4462a59c1_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramPaymentTimingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment term (in months)</link:label>
    <link:label id="lab_us-gaap_SupplierFinanceProgramPaymentTimingPeriod_label_en-US" xlink:label="lab_us-gaap_SupplierFinanceProgramPaymentTimingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Finance Program, Payment Timing, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramPaymentTimingPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierFinanceProgramPaymentTimingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierFinanceProgramPaymentTimingPeriod" xlink:to="lab_us-gaap_SupplierFinanceProgramPaymentTimingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_afec352a-274f-42ea-a8eb-c34d06efd537_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CommitmentToFundPartnershipMember_efaeb3f2-b78f-4f96-9029-2ef5f38a7215_terseLabel_en-US" xlink:label="lab_ci_CommitmentToFundPartnershipMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment to fund partnership</link:label>
    <link:label id="lab_ci_CommitmentToFundPartnershipMember_label_en-US" xlink:label="lab_ci_CommitmentToFundPartnershipMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment To Fund Partnership [Member]</link:label>
    <link:label id="lab_ci_CommitmentToFundPartnershipMember_documentation_en-US" xlink:label="lab_ci_CommitmentToFundPartnershipMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment To Fund Partnership</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CommitmentToFundPartnershipMember" xlink:href="ci-20231231.xsd#ci_CommitmentToFundPartnershipMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CommitmentToFundPartnershipMember" xlink:to="lab_ci_CommitmentToFundPartnershipMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_7fdbfed9-edb2-467b-9a74-a0b56bfc0933_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember_3a16a0c4-7c59-4cab-a1e2-d32245ac811f_verboseLabel_en-US" xlink:label="lab_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Berkshire</link:label>
    <link:label id="lab_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember_label_en-US" xlink:label="lab_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Berkshire Hathway Life Insurance Company Of Nebraska [Member]</link:label>
    <link:label id="lab_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember_documentation_en-US" xlink:label="lab_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Berkshire Hathway Life Insurance Company Of Nebraska</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember" xlink:href="ci-20231231.xsd#ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember" xlink:to="lab_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_4e6ba9e7-bef9-436e-b582-790d5c190787_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_686285a5-cb18-4842-9d4f-ee31d3d90663_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postretirement Benefits Liability Adjustment Included in AOCI</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract_ddb4f8d8-0883-4d07-a920-693cb97238db_terseLabel_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Value</link:label>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract_label_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Carrying Amount, Before Reclassification To Disposal Group, Assets Held For Sale [Abstract]</link:label>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract_documentation_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Carrying Amount, Before Reclassification To Disposal Group, Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract" xlink:to="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_7e503cae-7e21-48df-a0d4-ec9262175ac4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_a01f373f-f95e-410b-a6c3-a968ecf4c1b4_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current year</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity_ec50e785-051e-4646-9f40-e0d75478a3d5_terseLabel_en-US" xlink:label="lab_ci_OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translation of foreign currencies, before tax</link:label>
    <link:label id="lab_ci_OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity_label_en-US" xlink:label="lab_ci_OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Before Tax, Including Temporary Equity</link:label>
    <link:label id="lab_ci_OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity_documentation_en-US" xlink:label="lab_ci_OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Before Tax, Including Temporary Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity" xlink:to="lab_ci_OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NotesDue2024613InterestMember_198e06e4-7911-4a99-a5e8-6abc39a6da0c_terseLabel_en-US" xlink:label="lab_ci_NotesDue2024613InterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$500 million, 0.613% Notes due March 2024</link:label>
    <link:label id="lab_ci_NotesDue2024613InterestMember_label_en-US" xlink:label="lab_ci_NotesDue2024613InterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2024 .613% Interest [Member]</link:label>
    <link:label id="lab_ci_NotesDue2024613InterestMember_documentation_en-US" xlink:label="lab_ci_NotesDue2024613InterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable bearing .613% interest due in 2024.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue2024613InterestMember" xlink:href="ci-20231231.xsd#ci_NotesDue2024613InterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NotesDue2024613InterestMember" xlink:to="lab_ci_NotesDue2024613InterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_cace0f0f-26a1-48a2-a9dc-91d816de5036_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable_3d595fac-7e2f-417f-b91d-fccb3b757a45_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable_label_en-US" xlink:label="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:to="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale_d97bc303-92f7-419b-93cb-2eacacdc5584_terseLabel_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years through ten years, including assets held for sale</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded_16406442-2611-44c8-b083-87583aa07c0c_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total reinsurance recoveries</link:label>
    <link:label id="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded_label_en-US" xlink:label="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Benefits and Claims Incurred, Ceded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" xlink:to="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_088cc4a8-bb13-4df1-b35a-acf6be5a012d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_A364DayRevolvingCreditAgreementMaturingApril2023Member_8aeaf444-b4e2-4855-b22a-a1638d51495d_terseLabel_en-US" xlink:label="lab_ci_A364DayRevolvingCreditAgreementMaturingApril2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">364 Day Revolving Credit Agreement, Maturing April 2023</link:label>
    <link:label id="lab_ci_A364DayRevolvingCreditAgreementMaturingApril2023Member_label_en-US" xlink:label="lab_ci_A364DayRevolvingCreditAgreementMaturingApril2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">364 Day Revolving Credit Agreement, Maturing April 2023 [Member]</link:label>
    <link:label id="lab_ci_A364DayRevolvingCreditAgreementMaturingApril2023Member_documentation_en-US" xlink:label="lab_ci_A364DayRevolvingCreditAgreementMaturingApril2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">364 Day Revolving Credit Agreement, Maturing April 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_A364DayRevolvingCreditAgreementMaturingApril2023Member" xlink:href="ci-20231231.xsd#ci_A364DayRevolvingCreditAgreementMaturingApril2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_A364DayRevolvingCreditAgreementMaturingApril2023Member" xlink:to="lab_ci_A364DayRevolvingCreditAgreementMaturingApril2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_065c432e-7d2e-4bf9-8cd0-8ee5f08601e6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding - January 1 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8995f08e-d821-43af-ab52-7b6cfe481b10_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding - December 31 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a53da0a6-a8ba-4f70-b85f-2b44c52a700b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_3651b610-eddf-40cf-a506-e4ceb350bd15_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_e6e8124c-540b-4767-9430-18f639da2460_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, before Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale_875a888c-eca8-4826-b42b-4be2003ae526_totalLabel_en-US" xlink:label="lab_ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Value, including held for sale assets</link:label>
    <link:label id="lab_ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale_label_en-US" xlink:label="lab_ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Net Excluding Goodwill Including Disposals Groups Assets Held For Sale</link:label>
    <link:label id="lab_ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Net Excluding Goodwill Including Disposals Groups Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale" xlink:to="lab_ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_ddb7ad5f-b1e8-4306-ba21-a99fa13af768_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_54af60db-3f49-4d58-9815-255df224b9fe_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_81e5ef7a-9747-40f0-82f6-6713c95b81a5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage, less than</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_ecf42b31-eb97-49de-8b33-7919ad552754_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_43483415-8032-40a8-b0d5-741c39d06c60_verboseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased and internally developed software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_165bd41e-03fc-47e0-9272-c179dc774450_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal-use software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity_32bc3f77-b58c-44af-a49f-32cbc475c55f_terseLabel_en-US" xlink:label="lab_ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net translation gains (losses) on foreign currencies</link:label>
    <link:label id="lab_ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity_label_en-US" xlink:label="lab_ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Including Temporary Equity</link:label>
    <link:label id="lab_ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity_documentation_en-US" xlink:label="lab_ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Including Temporary Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity" xlink:to="lab_ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Ltv80To100PercentMember_0fa66ef2-3a2b-4530-bffc-7db7bcd293dc_terseLabel_en-US" xlink:label="lab_us-gaap_Ltv80To100PercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">80% to 100%</link:label>
    <link:label id="lab_us-gaap_Ltv80To100PercentMember_label_en-US" xlink:label="lab_us-gaap_Ltv80To100PercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt-to-Value Ratio, 80 to 100 Percent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Ltv80To100PercentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Ltv80To100PercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Ltv80To100PercentMember" xlink:to="lab_us-gaap_Ltv80To100PercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_e15854b1-ecf4-41f3-a543-4b033f5bd777_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoanToValueDomain_df5975b8-00f7-48e8-b270-287a80c36e67_terseLabel_en-US" xlink:label="lab_us-gaap_LoanToValueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt-to-Value [Domain]</link:label>
    <link:label id="lab_us-gaap_LoanToValueDomain_label_en-US" xlink:label="lab_us-gaap_LoanToValueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt-to-Value [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoanToValueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoanToValueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoanToValueDomain" xlink:to="lab_us-gaap_LoanToValueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_06f09be8-80f6-4fab-b968-e8c07b54631d_terseLabel_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrelated Party</link:label>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrelated Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonrelatedPartyMember" xlink:to="lab_us-gaap_NonrelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7a5ff1c3-b105-4e5c-9bc4-a1a9b9b4e0c0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_4591555a-e0cc-49af-85ed-62f9af1ac495_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_1ec6d706-0b91-4d40-9ad2-9c0399d07b4f_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OtherOperationsInternationalBusinessesToBeSoldMember_5c72d20b-aa72-4653-9e19-e6c15952c103_terseLabel_en-US" xlink:label="lab_ci_OtherOperationsInternationalBusinessesToBeSoldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International businesses [to be] sold to Chubb</link:label>
    <link:label id="lab_ci_OtherOperationsInternationalBusinessesToBeSoldMember_label_en-US" xlink:label="lab_ci_OtherOperationsInternationalBusinessesToBeSoldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operations, International Businesses To Be Sold [Member]</link:label>
    <link:label id="lab_ci_OtherOperationsInternationalBusinessesToBeSoldMember_documentation_en-US" xlink:label="lab_ci_OtherOperationsInternationalBusinessesToBeSoldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International businesses to be sold to Chubb (excludes interest in Turkiye joint venture).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherOperationsInternationalBusinessesToBeSoldMember" xlink:href="ci-20231231.xsd#ci_OtherOperationsInternationalBusinessesToBeSoldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OtherOperationsInternationalBusinessesToBeSoldMember" xlink:to="lab_ci_OtherOperationsInternationalBusinessesToBeSoldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ProceedsFromRepaymentsOfOtherShortTermDebt_845c9fc0-674a-4fd7-a111-0569e6450070_terseLabel_en-US" xlink:label="lab_ci_ProceedsFromRepaymentsOfOtherShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in short-term debt</link:label>
    <link:label id="lab_ci_ProceedsFromRepaymentsOfOtherShortTermDebt_label_en-US" xlink:label="lab_ci_ProceedsFromRepaymentsOfOtherShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From (Repayments Of) Other Short-Term Debt</link:label>
    <link:label id="lab_ci_ProceedsFromRepaymentsOfOtherShortTermDebt_documentation_en-US" xlink:label="lab_ci_ProceedsFromRepaymentsOfOtherShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of cash outflow for principal payment on finance lease and the net proceeds from (repayments of) short-term debt, defined as borrowing having initial term of repayment of one year or less.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ProceedsFromRepaymentsOfOtherShortTermDebt" xlink:href="ci-20231231.xsd#ci_ProceedsFromRepaymentsOfOtherShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ProceedsFromRepaymentsOfOtherShortTermDebt" xlink:to="lab_ci_ProceedsFromRepaymentsOfOtherShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InvestmentIncomeAndGainsAndLossesAbstract_label_en-US" xlink:label="lab_ci_InvestmentIncomeAndGainsAndLossesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income And Gains And Losses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InvestmentIncomeAndGainsAndLossesAbstract" xlink:href="ci-20231231.xsd#ci_InvestmentIncomeAndGainsAndLossesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InvestmentIncomeAndGainsAndLossesAbstract" xlink:to="lab_ci_InvestmentIncomeAndGainsAndLossesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity_32848846-0060-40c4-a762-196c008fd026_totalLabel_en-US" xlink:label="lab_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss, net of tax</link:label>
    <link:label id="lab_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity_label_en-US" xlink:label="lab_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Including Temporary Equity</link:label>
    <link:label id="lab_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity_documentation_en-US" xlink:label="lab_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Including Temporary Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity" xlink:to="lab_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember_6a9811a3-3094-49b9-b5c1-8a18f19e7ff9_terseLabel_en-US" xlink:label="lab_ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral provisions exist that may mitigate risk of credit loss</link:label>
    <link:label id="lab_ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember_label_en-US" xlink:label="lab_ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded Credit Risk, Secured, Collateral Provisions Exist That May Mitigate Risk [Member]</link:label>
    <link:label id="lab_ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember_documentation_en-US" xlink:label="lab_ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded Credit Risk, Secured, Collateral Provisions Exist That May Mitigate Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember" xlink:href="ci-20231231.xsd#ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember" xlink:to="lab_ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_1078df8a-24ea-4b89-b4e3-c6d81f9ac8d1_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantees</link:label>
    <link:label id="lab_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_label_en-US" xlink:label="lab_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantees, Indemnifications and Warranties Policies [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:to="lab_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OrganizationalEfficiencyPlanCharges_b16f0670-f148-4bad-9b87-6edf9f5e4592_terseLabel_en-US" xlink:label="lab_ci_OrganizationalEfficiencyPlanCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge for organizational efficiency plan, 2020 (Selling, general and administrative expenses)</link:label>
    <link:label id="lab_ci_OrganizationalEfficiencyPlanCharges_8daba981-cc5e-4e64-ae88-3079152a85d3_verboseLabel_en-US" xlink:label="lab_ci_OrganizationalEfficiencyPlanCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge for organizational efficiency plan, 2020</link:label>
    <link:label id="lab_ci_OrganizationalEfficiencyPlanCharges_label_en-US" xlink:label="lab_ci_OrganizationalEfficiencyPlanCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organizational Efficiency Plan Charges</link:label>
    <link:label id="lab_ci_OrganizationalEfficiencyPlanCharges_documentation_en-US" xlink:label="lab_ci_OrganizationalEfficiencyPlanCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organizational Efficiency Plan Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OrganizationalEfficiencyPlanCharges" xlink:href="ci-20231231.xsd#ci_OrganizationalEfficiencyPlanCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OrganizationalEfficiencyPlanCharges" xlink:to="lab_ci_OrganizationalEfficiencyPlanCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OtherOperationsSegmentOtherMember_2002eeed-2a80-4e2e-bbb4-c96f5e09d2e1_terseLabel_en-US" xlink:label="lab_ci_OtherOperationsSegmentOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ci_OtherOperationsSegmentOtherMember_label_en-US" xlink:label="lab_ci_OtherOperationsSegmentOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operations Segment, Other [Member]</link:label>
    <link:label id="lab_ci_OtherOperationsSegmentOtherMember_documentation_en-US" xlink:label="lab_ci_OtherOperationsSegmentOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operations Segment, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherOperationsSegmentOtherMember" xlink:href="ci-20231231.xsd#ci_OtherOperationsSegmentOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OtherOperationsSegmentOtherMember" xlink:to="lab_ci_OtherOperationsSegmentOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_74558795-18ce-4a50-993b-616cf7778750_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease ROU assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessExitCosts1_5e9d66ed-1ad9-40d9-91d0-5a38767d3d88_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-time expenses related to abandonment of leased assets and impairment of property and equipment</link:label>
    <link:label id="lab_us-gaap_BusinessExitCosts1_label_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Exit Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessExitCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessExitCosts1" xlink:to="lab_us-gaap_BusinessExitCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EvernorthMember_3766c212-458e-43b7-a4b6-278da68560e6_terseLabel_en-US" xlink:label="lab_ci_EvernorthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evernorth Health Services</link:label>
    <link:label id="lab_ci_EvernorthMember_label_en-US" xlink:label="lab_ci_EvernorthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evernorth [Member]</link:label>
    <link:label id="lab_ci_EvernorthMember_documentation_en-US" xlink:label="lab_ci_EvernorthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Services includes pharmacy benefits management (PBM), pharmacy home delivery, and certain medical management services. This segment includes Express Scripts business from the date of acquisition with the exception of Express Scripts Medicare Part D business that is reported in the Government operating segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EvernorthMember" xlink:href="ci-20231231.xsd#ci_EvernorthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EvernorthMember" xlink:to="lab_ci_EvernorthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_f7045b39-a828-4582-b087-28aeae6bd12e_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign income taxes</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember_2f59b0b0-c011-45cc-910d-d0979b2608ee_terseLabel_en-US" xlink:label="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not rated</link:label>
    <link:label id="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember_label_en-US" xlink:label="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nationally Recognized Statisical Rating Organizations (NRSRO), Not Rated [Member]</link:label>
    <link:label id="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember_documentation_en-US" xlink:label="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nationally Recognized Statisical Rating Organizations (NRSRO), Not Rated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember" xlink:href="ci-20231231.xsd#ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember" xlink:to="lab_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups_fdf366f9-f855-418b-97fa-b3426a9cc0e2_terseLabel_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid claims classified as liabilities of business held for sale</link:label>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups_label_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Claims And Claims Adjustment Expense Attributable To Disposal Groups</link:label>
    <link:label id="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups_documentation_en-US" xlink:label="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Claims And Claims Adjustment Expense Attributable To Disposal Groups</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups" xlink:to="lab_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale_afe76487-4dc3-4f47-b5ba-306d766252be_terseLabel_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after ten years, including assets held for sale</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock_7a8bc70a-84dd-4490-9d49-b29e2bbba51c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variances in Incurred Costs Related to Prior Years' Unpaid Claims and Claims Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock" xlink:to="lab_us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_434a5379-9431-4df1-a4f2-09ae9e917bf1_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_RightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract_4a134bdc-fb85-44de-87c1-ab6a793abf58_terseLabel_en-US" xlink:label="lab_ci_RightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU assets obtained in exchange for lease obligations:</link:label>
    <link:label id="lab_ci_RightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract_label_en-US" xlink:label="lab_ci_RightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Assets Obtained In Exchange For Lease Liabilities [Abstract]</link:label>
    <link:label id="lab_ci_RightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract_documentation_en-US" xlink:label="lab_ci_RightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Assets Obtained In Exchange For Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract" xlink:href="ci-20231231.xsd#ci_RightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_RightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract" xlink:to="lab_ci_RightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax_2929642a-3503-46de-854c-5c3d29e08b4c_verboseLabel_en-US" xlink:label="lab_ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized appreciation (depreciation) on securities and derivatives</link:label>
    <link:label id="lab_ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax_label_en-US" xlink:label="lab_ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-For-Sale Securities And Derivatives Adjustment, Net Of Tax</link:label>
    <link:label id="lab_ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax_documentation_en-US" xlink:label="lab_ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-For-Sale Securities And Derivatives Adjustment, Net Of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax" xlink:to="lab_ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DerivativeLiabilitiesBeforeReclassificationToDisposalGroupLiabilitiesHeldForSale_8d30eceb-b44a-49d2-8cc7-1ccc27c461b8_terseLabel_en-US" xlink:label="lab_ci_DerivativeLiabilitiesBeforeReclassificationToDisposalGroupLiabilitiesHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities, including held for sale liabilities</link:label>
    <link:label id="lab_ci_DerivativeLiabilitiesBeforeReclassificationToDisposalGroupLiabilitiesHeldForSale_label_en-US" xlink:label="lab_ci_DerivativeLiabilitiesBeforeReclassificationToDisposalGroupLiabilitiesHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liabilities Before Reclassification To Disposal Group Liabilities Held For Sale</link:label>
    <link:label id="lab_ci_DerivativeLiabilitiesBeforeReclassificationToDisposalGroupLiabilitiesHeldForSale_documentation_en-US" xlink:label="lab_ci_DerivativeLiabilitiesBeforeReclassificationToDisposalGroupLiabilitiesHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liabilities Before Reclassification To Disposal Group Liabilities Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DerivativeLiabilitiesBeforeReclassificationToDisposalGroupLiabilitiesHeldForSale" xlink:href="ci-20231231.xsd#ci_DerivativeLiabilitiesBeforeReclassificationToDisposalGroupLiabilitiesHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DerivativeLiabilitiesBeforeReclassificationToDisposalGroupLiabilitiesHeldForSale" xlink:to="lab_ci_DerivativeLiabilitiesBeforeReclassificationToDisposalGroupLiabilitiesHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitIssuanceAndDerecognition_881be85c-62eb-4724-a022-11b266a0db4e_terseLabel_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitIssuanceAndDerecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances and lapses</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitIssuanceAndDerecognition_label_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitIssuanceAndDerecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefit, Expected Future Policy Benefit, Issuance And Derecognition</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitIssuanceAndDerecognition_documentation_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitIssuanceAndDerecognition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefit, Expected Future Policy Benefit, Issuance And Derecognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitIssuanceAndDerecognition" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitIssuanceAndDerecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitIssuanceAndDerecognition" xlink:to="lab_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitIssuanceAndDerecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_3cf963c8-02d9-469f-9c57-8810a65fdd8d_totalLabel_en-US" xlink:label="lab_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments including held for sale assets</link:label>
    <link:label id="lab_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_adcb9fba-d212-44c1-b603-fe7f1c96a3c3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_475ca90f-d00f-433c-b9be-98d009937e07_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealEstateLoanMember_f253c435-d284-4114-8a39-7819622ab6be_terseLabel_en-US" xlink:label="lab_us-gaap_RealEstateLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Loan</link:label>
    <link:label id="lab_us-gaap_RealEstateLoanMember_label_en-US" xlink:label="lab_us-gaap_RealEstateLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateLoanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstateLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealEstateLoanMember" xlink:to="lab_us-gaap_RealEstateLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups_9eab500d-8150-49d7-b6bb-c0b50927efc0_totalLabel_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, non-current</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups_label_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance And Contractholder Liabilities, Noncurrent, Including Disposal Groups</link:label>
    <link:label id="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups_documentation_en-US" xlink:label="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance And Contractholder Liabilities, Noncurrent, Including Disposal Groups</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups" xlink:to="lab_ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5c63fd18-3a83-433c-8268-9c054a0bd625_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c8afb6ee-3e87-46bf-9792-66617f158988_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile shareholders' net income to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CededCreditRiskTable_f0af5013-761f-4fe6-abb1-cc42bea94b84_terseLabel_en-US" xlink:label="lab_us-gaap_CededCreditRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded Credit Risk [Table]</link:label>
    <link:label id="lab_us-gaap_CededCreditRiskTable_label_en-US" xlink:label="lab_us-gaap_CededCreditRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded Credit Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CededCreditRiskTable" xlink:to="lab_us-gaap_CededCreditRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_4482d142-1b03-4125-bc22-3a70b7165c66_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AccountsReceivableUncommittedFactoringFacilityInitialTerm_4d42dd33-2749-4648-bad3-bc28cd1f0c15_terseLabel_en-US" xlink:label="lab_ci_AccountsReceivableUncommittedFactoringFacilityInitialTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial term, uncommitted factoring facility (in years)</link:label>
    <link:label id="lab_ci_AccountsReceivableUncommittedFactoringFacilityInitialTerm_label_en-US" xlink:label="lab_ci_AccountsReceivableUncommittedFactoringFacilityInitialTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Uncommitted Factoring Facility, Initial Term</link:label>
    <link:label id="lab_ci_AccountsReceivableUncommittedFactoringFacilityInitialTerm_documentation_en-US" xlink:label="lab_ci_AccountsReceivableUncommittedFactoringFacilityInitialTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial term length for uncommitted Accounts receivable factoring facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccountsReceivableUncommittedFactoringFacilityInitialTerm" xlink:href="ci-20231231.xsd#ci_AccountsReceivableUncommittedFactoringFacilityInitialTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AccountsReceivableUncommittedFactoringFacilityInitialTerm" xlink:to="lab_ci_AccountsReceivableUncommittedFactoringFacilityInitialTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet_f9a306b4-942f-47e2-9106-66cbf898011d_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial mortgage loans</link:label>
    <link:label id="lab_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet_label_en-US" xlink:label="lab_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Loans on Real Estate, Commercial and Consumer, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet" xlink:to="lab_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_PartnershipInterestMember_8f871b56-f1cb-4143-a1b6-1e0d1830e615_terseLabel_en-US" xlink:label="lab_srt_PartnershipInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities partnerships</link:label>
    <link:label id="lab_srt_PartnershipInterestMember_300e683c-253a-4257-8d83-0e2e9ddc24c9_verboseLabel_en-US" xlink:label="lab_srt_PartnershipInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities partnerships</link:label>
    <link:label id="lab_srt_PartnershipInterestMember_label_en-US" xlink:label="lab_srt_PartnershipInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partnership Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PartnershipInterestMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PartnershipInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_PartnershipInterestMember" xlink:to="lab_srt_PartnershipInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_29495d09-660e-459e-be12-ccf89c3e6b48_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ReinsuranceRecoverablesNonCurrent_970f3315-b543-4128-8980-8403f91d5f09_terseLabel_en-US" xlink:label="lab_ci_ReinsuranceRecoverablesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance recoverables</link:label>
    <link:label id="lab_ci_ReinsuranceRecoverablesNonCurrent_label_en-US" xlink:label="lab_ci_ReinsuranceRecoverablesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Recoverables, Noncurrent</link:label>
    <link:label id="lab_ci_ReinsuranceRecoverablesNonCurrent_documentation_en-US" xlink:label="lab_ci_ReinsuranceRecoverablesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount, after valuation allowance, recoverable after one year under reinsurance contracts including premium paid under reinsurance contracts. Examples include, but are not limited to, settled and unsettled claims, incurred but not reported losses, loss adjustment expense, premium paid, policy benefits and policy reserves.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverablesNonCurrent" xlink:href="ci-20231231.xsd#ci_ReinsuranceRecoverablesNonCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ReinsuranceRecoverablesNonCurrent" xlink:to="lab_ci_ReinsuranceRecoverablesNonCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_44f6e324-e98c-4f13-969a-115a532f4a68_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of vested shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_852a63e8-7091-40e6-86c1-c8a2e1afeace_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_RetirementAndLifeInsuranceContractsMember_26a00362-cfec-4d5c-bd66-7d280afc44c0_terseLabel_en-US" xlink:label="lab_ci_RetirementAndLifeInsuranceContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retiree and Life Insurance Benefits</link:label>
    <link:label id="lab_ci_RetirementAndLifeInsuranceContractsMember_label_en-US" xlink:label="lab_ci_RetirementAndLifeInsuranceContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement And Life Insurance Contracts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RetirementAndLifeInsuranceContractsMember" xlink:href="ci-20231231.xsd#ci_RetirementAndLifeInsuranceContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_RetirementAndLifeInsuranceContractsMember" xlink:to="lab_ci_RetirementAndLifeInsuranceContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ReinsuranceRecoverableAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_daaabb87-cb7b-445d-b812-909be9263b11_negatedTerseLabel_en-US" xlink:label="lab_ci_ReinsuranceRecoverableAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for uncollectible reinsurance, including assets held for sale</link:label>
    <link:label id="lab_ci_ReinsuranceRecoverableAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_ReinsuranceRecoverableAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Recoverable, Allowance for Credit Loss, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_ReinsuranceRecoverableAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_ReinsuranceRecoverableAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Recoverable, Allowance for Credit Loss, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverableAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_ReinsuranceRecoverableAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ReinsuranceRecoverableAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_ReinsuranceRecoverableAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_4e3dd040-6bfc-4ca8-a443-5a785890c9e6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_bb4f8ad4-d218-4b24-ab2b-a707ea51f4da_terseLabel_en-US" xlink:label="lab_ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value</link:label>
    <link:label id="lab_ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_label_en-US" xlink:label="lab_ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:label id="lab_ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_documentation_en-US" xlink:label="lab_ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the fair value measurement of assets and liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3, by class of assets and liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:href="ci-20231231.xsd#ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="lab_ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_20776a0f-c074-4f91-9f73-78cccf10098f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures, net of cash sold</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses, Net of Cash Divested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_1e6a1a5a-6683-4610-899d-7cc5a3e0ff38_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ad80a2d7-ddaa-42c3-8ef4-5665853a6040_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_e62c0db6-8c2e-4bfb-97bc-d1010252f34d_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDivestituresPlanAssets_7c7964dc-a79e-4437-84f5-325598377b7a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDivestituresPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded in divestiture</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDivestituresPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDivestituresPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Divestiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDivestituresPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDivestituresPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDivestituresPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanDivestituresPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_43b3ac05-1710-4bb5-801f-5587037b8529_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent_dfceb851-1805-416e-8b93-f50c78cd3082_terseLabel_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future policy benefits, non-current</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent_label_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefit, Before Reinsurance, Noncurrent</link:label>
    <link:label id="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent_documentation_en-US" xlink:label="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefit, Before Reinsurance, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent" xlink:to="lab_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_c92ed37a-fbce-4cf9-be8e-6ce026d80486_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in short-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NotesDue20425375InterestMember_363540f8-26a1-4152-a25e-4d815e7595e3_terseLabel_en-US" xlink:label="lab_ci_NotesDue20425375InterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$317&#160;million, 5.375% Notes due February 2042</link:label>
    <link:label id="lab_ci_NotesDue20425375InterestMember_label_en-US" xlink:label="lab_ci_NotesDue20425375InterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2042, 5.375% Interest [Member]</link:label>
    <link:label id="lab_ci_NotesDue20425375InterestMember_documentation_en-US" xlink:label="lab_ci_NotesDue20425375InterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable bearing interest at 5.375% due in 2042.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20425375InterestMember" xlink:href="ci-20231231.xsd#ci_NotesDue20425375InterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NotesDue20425375InterestMember" xlink:to="lab_ci_NotesDue20425375InterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_ba27f951-c65c-454a-a964-b2469297aa3f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_41f80bdb-ad9b-49d6-ab95-d43268b3264d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable at year-end (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b982bb87-086b-4b7b-b5df-a6dec0fd72b2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTableTextBlock_c3116096-268f-46ff-ae1a-b9fe89d63817_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Information on Separate Account Assets Priced at NAV</link:label>
    <link:label id="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTableTextBlock" xlink:to="lab_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DeferredTaxAssetsOtherIncludingDisposalGroupsAssetsHeldForSale_1f699a8c-d2d0-4551-a10f-645f7ac5a28d_terseLabel_en-US" xlink:label="lab_ci_DeferredTaxAssetsOtherIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsOtherIncludingDisposalGroupsAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DeferredTaxAssetsOtherIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other, Including Disposal Groups Assets Held For Sale</link:label>
    <link:label id="lab_ci_DeferredTaxAssetsOtherIncludingDisposalGroupsAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DeferredTaxAssetsOtherIncludingDisposalGroupsAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other, Including Disposal Groups Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsOtherIncludingDisposalGroupsAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsOtherIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DeferredTaxAssetsOtherIncludingDisposalGroupsAssetsHeldForSale" xlink:to="lab_ci_DeferredTaxAssetsOtherIncludingDisposalGroupsAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_55d7fb66-3e8d-4190-aa3d-24b8ee7777d6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative gain (loss) recognized in the income statement</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_73e0be81-b311-43e6-ad4b-cb496ecd2322_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Losses) gains included in Shareholders' net income</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_6eae1cc7-2800-401a-85e8-2d7c5160569d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent_84addfa5-0a65-4b95-8361-920eee67920a_negatedLabel_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments classified as assets of business held for sale</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent_label_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Including Discontinued Operation, Current Investments, Current</link:label>
    <link:label id="lab_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent_documentation_en-US" xlink:label="lab_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Including Discontinued Operation, Current Investments, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent" xlink:to="lab_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_OtherVariableInterestEntitiesMember_fbff90ff-372d-4d76-9e5a-b3e2892dab74_terseLabel_en-US" xlink:label="lab_ci_OtherVariableInterestEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Variable Interest Entities</link:label>
    <link:label id="lab_ci_OtherVariableInterestEntitiesMember_label_en-US" xlink:label="lab_ci_OtherVariableInterestEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Variable Interest Entities [Member]</link:label>
    <link:label id="lab_ci_OtherVariableInterestEntitiesMember_documentation_en-US" xlink:label="lab_ci_OtherVariableInterestEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Variable Interest Entities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherVariableInterestEntitiesMember" xlink:href="ci-20231231.xsd#ci_OtherVariableInterestEntitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_OtherVariableInterestEntitiesMember" xlink:to="lab_ci_OtherVariableInterestEntitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_61f24b5a-4dcb-48ea-b216-4492e4c9de7f_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' other comprehensive loss, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember_b71206f9-02f6-4ec0-a47c-99c0db57171a_terseLabel_en-US" xlink:label="lab_ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lincoln National Life and Lincoln Life &amp; Annuity of New York</link:label>
    <link:label id="lab_ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember_label_en-US" xlink:label="lab_ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Lincoln National Life Insurance Company And Lincoln Life And Annuity Of New York [Member]</link:label>
    <link:label id="lab_ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember_documentation_en-US" xlink:label="lab_ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance recoverables resulting from the 1998 sale of the Companys individual life insurance and annuity business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember" xlink:href="ci-20231231.xsd#ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember" xlink:to="lab_ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndirectGuaranteeOfIndebtednessMember_637d55f6-c307-4e7c-8f0e-7ed05f65e4d6_terseLabel_en-US" xlink:label="lab_us-gaap_IndirectGuaranteeOfIndebtednessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantee of CHSS' credit facilities</link:label>
    <link:label id="lab_us-gaap_IndirectGuaranteeOfIndebtednessMember_label_en-US" xlink:label="lab_us-gaap_IndirectGuaranteeOfIndebtednessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indirect Guarantee of Indebtedness [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndirectGuaranteeOfIndebtednessMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndirectGuaranteeOfIndebtednessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndirectGuaranteeOfIndebtednessMember" xlink:to="lab_us-gaap_IndirectGuaranteeOfIndebtednessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2cb265fc-e1b9-458f-a436-c02a54bb49ab_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_b67249ea-3d88-4be1-8945-0a4492ebe950_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale_cfc2103c-8c6d-4e50-8077-63440b1522d3_totalLabel_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total, including held for sale assets</link:label>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Carrying Amount, Before Reclassification To Disposal Group, Assets Held For Sale</link:label>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Carrying Amount, Before Reclassification To Disposal Group, Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_VariableInterestEntitiesAbstract_6cc84db1-3135-4155-a680-c36686b7c772_terseLabel_en-US" xlink:label="lab_ci_VariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_ci_VariableInterestEntitiesAbstract_label_en-US" xlink:label="lab_ci_VariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_VariableInterestEntitiesAbstract" xlink:href="ci-20231231.xsd#ci_VariableInterestEntitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_VariableInterestEntitiesAbstract" xlink:to="lab_ci_VariableInterestEntitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale_c21276e1-c03a-4d46-ae65-06f77b814312_terseLabel_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years through ten years, including assets held for sale</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_961f1504-e66e-4ef9-859d-9616be639427_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate for operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue_64100d3c-a3a9-4da6-859a-6da2491ae77e_terseLabel_en-US" xlink:label="lab_ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage with cash values at more than 110% of guaranteed cash value</link:label>
    <link:label id="lab_ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue_label_en-US" xlink:label="lab_ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Account Balance, Percentage With Cash Values At More Than 110 Percent Of Guaranteed Cash Value</link:label>
    <link:label id="lab_ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue_documentation_en-US" xlink:label="lab_ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Account Balance, Percentage With Cash Values At More Than 110 Percent Of Guaranteed Cash Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue" xlink:href="ci-20231231.xsd#ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue" xlink:to="lab_ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_6d7e003a-d147-47cc-b0f1-1577c1981b8f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets at fair value:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_4b4875e5-54ff-42e6-af0b-ced943e54d93_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_15ccbace-d1f5-45d9-9771-f525d595d7cc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale_7185572f-7f92-4835-a273-b8992b3d461c_terseLabel_en-US" xlink:label="lab_ci_AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost, including held for sale assets</link:label>
    <link:label id="lab_ci_AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities Amortized Cost Basis Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities Amortized Cost Basis Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_26acc7fa-48df-429b-9b0d-9afd3dbe8027_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_87792917-105d-48c3-938c-185700384be8_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term for finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_a0306649-b7d7-4622-9706-fb6db9e6dc96_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred income tax liabilities(1)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost_3e852b12-7194-451b-9129-30d0a22de005_totalLabel_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Amortized Cost</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost_label_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Amortized Cost</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost_documentation_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost" xlink:to="lab_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1dd7cadd-02ac-45da-ac5d-92c322215d86_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember_da25999e-1421-460a-a07d-00084185213f_terseLabel_en-US" xlink:label="lab_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument, Economic Hedge</link:label>
    <link:label id="lab_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember_label_en-US" xlink:label="lab_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument, Economic Hedge [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember" xlink:to="lab_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_81c7e07f-48b4-4f59-9f92-28ca62fd8e22_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities of Business Held for Sale</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DepartmentOfDefenseMember_bde4455c-d7b8-4903-8759-5a505cce0ea3_terseLabel_en-US" xlink:label="lab_ci_DepartmentOfDefenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department Of Defense [Member]</link:label>
    <link:label id="lab_ci_DepartmentOfDefenseMember_label_en-US" xlink:label="lab_ci_DepartmentOfDefenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department Of Defense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DepartmentOfDefenseMember" xlink:href="ci-20231231.xsd#ci_DepartmentOfDefenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DepartmentOfDefenseMember" xlink:to="lab_ci_DepartmentOfDefenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceAccountingPolicy_ba57f765-ca22-48d9-a597-17d7235231d8_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance</link:label>
    <link:label id="lab_us-gaap_ReinsuranceAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_ReinsuranceAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceAccountingPolicy" xlink:to="lab_us-gaap_ReinsuranceAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_504d8713-4b9e-4403-af78-5ffc1fb84538_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill disposed</link:label>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_label_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Written off Related to Sale of Business Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:to="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_45a38f7c-425e-4baa-b6d3-e94e7646b99a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_546ba820-ebe2-478e-b40f-1749c1154d13_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross losses on sales</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_8bac2713-e754-4055-8d09-5603d4d61230_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_842d8caa-fc91-4b1e-9a7f-3df6c66ed97b_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL ASSETS</link:label>
    <link:label id="lab_us-gaap_Assets_9895fa06-da94-4eae-96b4-fb9ff30eecad_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_c27ccc40-7ace-4622-84ad-8e72b9541d61_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_aaa3e217-e4f0-4510-9f9e-7ce733e82639_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_1d58f753-4715-4daa-ae53-526b9baa58e0_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets of businesses held for sale, non-current</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember_58b8c4b6-fff6-492e-b364-453be0063461_terseLabel_en-US" xlink:label="lab_ci_SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_ci_SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember_label_en-US" xlink:label="lab_ci_SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Allowance, Investment Valuation Reserves, Available-For-Sale Debt Securities [Member]</link:label>
    <link:label id="lab_ci_SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember_documentation_en-US" xlink:label="lab_ci_SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Allowance, Investment Valuation Reserves, Available-For-Sale Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember" xlink:href="ci-20231231.xsd#ci_SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember" xlink:to="lab_ci_SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount_d3bb5817-11e9-43c4-844a-b563e9d8b5bc_terseLabel_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount_label_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Accounting Practices, Statutory Net Income Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount" xlink:to="lab_us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_bf674333-4245-4e28-9556-f73167b25a82_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DerivativeNotionalAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale_e519278a-3d86-4727-a933-d8ee4c8f4937_terseLabel_en-US" xlink:label="lab_ci_DerivativeNotionalAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional Value, including held for sale assets</link:label>
    <link:label id="lab_ci_DerivativeNotionalAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DerivativeNotionalAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Notional Amount Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_DerivativeNotionalAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DerivativeNotionalAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Notional Amount Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DerivativeNotionalAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DerivativeNotionalAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DerivativeNotionalAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_DerivativeNotionalAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1_324a8231-7074-4cbb-9930-87e8915582a9_terseLabel_en-US" xlink:label="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average attained age of contractholders (weighted by exposure)</link:label>
    <link:label id="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1_label_en-US" xlink:label="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Amount at Risk by Product and Guarantee, Weighted Average Attained Age</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1" xlink:to="lab_us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_InternationalHealthMember_2deb2c24-bdec-4a52-a226-ff52fd1210a0_terseLabel_en-US" xlink:label="lab_ci_InternationalHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Health</link:label>
    <link:label id="lab_ci_InternationalHealthMember_label_en-US" xlink:label="lab_ci_InternationalHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Health [Member]</link:label>
    <link:label id="lab_ci_InternationalHealthMember_documentation_en-US" xlink:label="lab_ci_InternationalHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InternationalHealthMember" xlink:href="ci-20231231.xsd#ci_InternationalHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_InternationalHealthMember" xlink:to="lab_ci_InternationalHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_NotesDue20335400InterestMember_6151381d-8e42-40f0-afbb-cff2bb0259ce_terseLabel_en-US" xlink:label="lab_ci_NotesDue20335400InterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$800 million, 5.400% Notes due March 2033</link:label>
    <link:label id="lab_ci_NotesDue20335400InterestMember_label_en-US" xlink:label="lab_ci_NotesDue20335400InterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2033, 5.400% Interest [Member]</link:label>
    <link:label id="lab_ci_NotesDue20335400InterestMember_documentation_en-US" xlink:label="lab_ci_NotesDue20335400InterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2033, 5.400% Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20335400InterestMember" xlink:href="ci-20231231.xsd#ci_NotesDue20335400InterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_NotesDue20335400InterestMember" xlink:to="lab_ci_NotesDue20335400InterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_ContractualAllowancePharmaceuticalManufacturersReceivables_763590df-13a4-4076-9c52-100858878c00_terseLabel_en-US" xlink:label="lab_ci_ContractualAllowancePharmaceuticalManufacturersReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical manufacturers receivables allowance</link:label>
    <link:label id="lab_ci_ContractualAllowancePharmaceuticalManufacturersReceivables_label_en-US" xlink:label="lab_ci_ContractualAllowancePharmaceuticalManufacturersReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Allowance, Pharmaceutical Manufacturers Receivables</link:label>
    <link:label id="lab_ci_ContractualAllowancePharmaceuticalManufacturersReceivables_documentation_en-US" xlink:label="lab_ci_ContractualAllowancePharmaceuticalManufacturersReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of contractual allowances for certain rebates receivables with pharmaceutical manufacturers, classified as current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ContractualAllowancePharmaceuticalManufacturersReceivables" xlink:href="ci-20231231.xsd#ci_ContractualAllowancePharmaceuticalManufacturersReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_ContractualAllowancePharmaceuticalManufacturersReceivables" xlink:to="lab_ci_ContractualAllowancePharmaceuticalManufacturersReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_50bee0e0-9aec-452f-a145-279186633360_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualPayments_1f2eadd3-046d-4967-878c-3d2107d825d8_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts paid for loss contigency</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualPayments_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualPayments" xlink:to="lab_us-gaap_LossContingencyAccrualPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bffb9836-e934-4a4f-b8ed-cbb591b6a218_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_7a4275b3-e1b8-412a-887e-eeb71a4c4387_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target allocation percentages</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Target Allocation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_32491bcc-31ee-4d7f-a2c9-84cab62115c0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_efb3d0c4-100f-4616-9797-ec86b0466a49_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_cce8ef8e-9fbd-441f-9ac3-af54b42427f5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealEstateMember_f986b8bf-e286-47bc-9851-1a4c35ff9de5_terseLabel_en-US" xlink:label="lab_us-gaap_RealEstateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real estate funds, including pooled separate accounts</link:label>
    <link:label id="lab_us-gaap_RealEstateMember_label_en-US" xlink:label="lab_us-gaap_RealEstateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealEstateMember" xlink:to="lab_us-gaap_RealEstateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_9b6d6018-63f6-4c5f-8085-1415b65ad3ac_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_a82d07e4-d6f5-4b87-b13b-b626b8221fc0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Equipment (including Computer Equipment)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Other Types [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances_e72d1ba7-3618-458a-ba11-e7c40dc201d9_terseLabel_en-US" xlink:label="lab_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market risk benefits reinsurance recoverable, including IBNR and outstanding claims, less premiums due</link:label>
    <link:label id="lab_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances_label_en-US" xlink:label="lab_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Risk Benefit Reinsurance Recoverable After Allowance And Related Balances</link:label>
    <link:label id="lab_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances_documentation_en-US" xlink:label="lab_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Includes incurred but not reported claims and outstanding claims,off-set by premiums due, related to market risk benefit contracts, as a well as reinsurance recoverable, defined as amount, after allowance for credit loss, recoverable under reinsurance for contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances" xlink:href="ci-20231231.xsd#ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances" xlink:to="lab_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries_8add9b53-13e3-4dc9-a816-17321de54c2f_negatedLabel_en-US" xlink:label="lab_ci_RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net realized investment (gains) losses</link:label>
    <link:label id="lab_ci_RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries_label_en-US" xlink:label="lab_ci_RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gain Loss Including Equity Method Subsidiaries</link:label>
    <link:label id="lab_ci_RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries_documentation_en-US" xlink:label="lab_ci_RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net realized gains or (losses) on investments during the period, including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity. Includes gains (losses) on investments held by equity method subsidiaries.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries" xlink:href="ci-20231231.xsd#ci_RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries" xlink:to="lab_ci_RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount_2524dea1-a172-4a50-bc22-eb6d5ab4d3af_totalLabel_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount_label_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Carrying Amount</link:label>
    <link:label id="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount_documentation_en-US" xlink:label="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount" xlink:to="lab_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_RestrictedStockGrantsAndUnitsMember_6458eb98-85f6-471d-92fa-bd14607047e4_terseLabel_en-US" xlink:label="lab_ci_RestrictedStockGrantsAndUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Grants and Units</link:label>
    <link:label id="lab_ci_RestrictedStockGrantsAndUnitsMember_label_en-US" xlink:label="lab_ci_RestrictedStockGrantsAndUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Grants And Units [Member]</link:label>
    <link:label id="lab_ci_RestrictedStockGrantsAndUnitsMember_documentation_en-US" xlink:label="lab_ci_RestrictedStockGrantsAndUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock grants are the most widely used form of restricted stock awards and are used for substantially all US based employees receiving such awards. Recipients of restricted stock grants are entitled to earn dividends and to vote during the vesting period, but forfeit their awards if their employment terminates before the vesting date. Awards of restricted stock units are generally limited to international employees. A restricted stock unit represents a right to receive a common share of stock when the unit vests. Recipients of restricted stock units are entitled to receive hypothetical dividends, but cannot vote during the vesting period. They forfeit their units if their employment terminates before the vesting date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RestrictedStockGrantsAndUnitsMember" xlink:href="ci-20231231.xsd#ci_RestrictedStockGrantsAndUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_RestrictedStockGrantsAndUnitsMember" xlink:to="lab_ci_RestrictedStockGrantsAndUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_RealEstateJointVenturesMember_70c49a23-05f8-49b3-bc68-2ba416f8d993_terseLabel_en-US" xlink:label="lab_ci_RealEstateJointVenturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real estate joint ventures</link:label>
    <link:label id="lab_ci_RealEstateJointVenturesMember_label_en-US" xlink:label="lab_ci_RealEstateJointVenturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Joint Ventures [Member]</link:label>
    <link:label id="lab_ci_RealEstateJointVenturesMember_documentation_en-US" xlink:label="lab_ci_RealEstateJointVenturesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RealEstateJointVenturesMember" xlink:href="ci-20231231.xsd#ci_RealEstateJointVenturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_RealEstateJointVenturesMember" xlink:to="lab_ci_RealEstateJointVenturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale_a0ee44c7-dc28-44c6-88e5-08de661d6768_terseLabel_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less, including assets held for sale</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale_label_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:label id="lab_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale_documentation_en-US" xlink:label="lab_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One, Before Reclassification To Disposal Group Assets Held For Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:to="lab_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfCondensedFinancialStatementsTable_fa9a7a49-c3f4-42c9-a74c-3f74f1888e7d_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements [Table]</link:label>
    <link:label id="lab_srt_ScheduleOfCondensedFinancialStatementsTable_label_en-US" xlink:label="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReduction_f879ab94-2488-4d5b-a120-a3bcee4d38c5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NotesReduction" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amounts due to/(from) affiliates settled through capital transactions</link:label>
    <link:label id="lab_us-gaap_NotesReduction_label_en-US" xlink:label="lab_us-gaap_NotesReduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReduction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesReduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReduction" xlink:to="lab_us-gaap_NotesReduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201613Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-13 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember_label_en-US" xlink:label="lab_us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful Life, Shorter of Lease Term or Asset Utility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember" xlink:to="lab_us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>ci-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:fd466b51-e399-4368-bda1-c8c0817d4afc,g:199c158e-5fac-4def-904c-2de015f58c08-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.thecignagroup.com/role/CoverPage" xlink:type="simple" xlink:href="ci-20231231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_4d46727f-2bfd-4b36-9858-b7b729d9951d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_DocumentType_4d46727f-2bfd-4b36-9858-b7b729d9951d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_a0c9ec6f-2c7b-4514-b32a-1f75ed2579c7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_DocumentAnnualReport_a0c9ec6f-2c7b-4514-b32a-1f75ed2579c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_1c7f920b-9fc9-42c3-bbc7-017c174d1d63" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_DocumentPeriodEndDate_1c7f920b-9fc9-42c3-bbc7-017c174d1d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_97ee3206-c462-416c-aab1-1226736d9a5e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_CurrentFiscalYearEndDate_97ee3206-c462-416c-aab1-1226736d9a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_40b5aec2-7d45-422b-a89f-bea12907fc47" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_DocumentTransitionReport_40b5aec2-7d45-422b-a89f-bea12907fc47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_9a586b4a-453e-45db-8387-fedbff037509" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_EntityFileNumber_9a586b4a-453e-45db-8387-fedbff037509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_2137b79a-7353-4860-81f2-3d17070c3fd7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_EntityRegistrantName_2137b79a-7353-4860-81f2-3d17070c3fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f4cb10cf-0b3f-4c67-b1ef-297b68b63326" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f4cb10cf-0b3f-4c67-b1ef-297b68b63326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3ceee007-9d39-4ae0-ac24-46f7ae7f4fbc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_EntityTaxIdentificationNumber_3ceee007-9d39-4ae0-ac24-46f7ae7f4fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c5ac2ac9-eab7-458d-94e0-e9385c4b01b3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_EntityAddressAddressLine1_c5ac2ac9-eab7-458d-94e0-e9385c4b01b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_d9d0141e-7647-4358-a31e-897e72c388a4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_EntityAddressCityOrTown_d9d0141e-7647-4358-a31e-897e72c388a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_dd4a17a6-36ee-4f93-b738-8c4c674ce492" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_EntityAddressStateOrProvince_dd4a17a6-36ee-4f93-b738-8c4c674ce492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_91108d35-f2b2-4d61-b174-0187c70b7bd7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_EntityAddressPostalZipCode_91108d35-f2b2-4d61-b174-0187c70b7bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c22ab8ae-7e46-46bf-8f40-b88443619510" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_CityAreaCode_c22ab8ae-7e46-46bf-8f40-b88443619510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_862af2f9-4c51-4411-93ed-527ee592476b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_LocalPhoneNumber_862af2f9-4c51-4411-93ed-527ee592476b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8bd13d82-666c-48e0-b728-ea99089f2c12" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_Security12bTitle_8bd13d82-666c-48e0-b728-ea99089f2c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_dacccf4d-eafc-4eab-b81e-4503347617e5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_TradingSymbol_dacccf4d-eafc-4eab-b81e-4503347617e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_89c8d41e-9dfd-4d2a-9c0a-25ec0c9a7bcf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_SecurityExchangeName_89c8d41e-9dfd-4d2a-9c0a-25ec0c9a7bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_02d53dbc-3809-4367-9202-5f17ef2b11c2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_02d53dbc-3809-4367-9202-5f17ef2b11c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_3c986ddd-c989-4225-bd0f-75f86562304c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_EntityVoluntaryFilers_3c986ddd-c989-4225-bd0f-75f86562304c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_6a633b65-24b0-4774-8ab4-42a300939721" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_EntityCurrentReportingStatus_6a633b65-24b0-4774-8ab4-42a300939721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_fb4807d0-459c-4612-b936-91f900748952" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_EntityInteractiveDataCurrent_fb4807d0-459c-4612-b936-91f900748952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_433abc5f-d908-485b-86ac-967854addf15" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_EntityFilerCategory_433abc5f-d908-485b-86ac-967854addf15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_1b1180d8-b766-4872-9505-cf5ce7817890" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_EntitySmallBusiness_1b1180d8-b766-4872-9505-cf5ce7817890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_01cba479-ad6c-471d-bb3f-73628bd7c236" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_EntityEmergingGrowthCompany_01cba479-ad6c-471d-bb3f-73628bd7c236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_16bed57e-f8db-4508-99d3-0dbad8766835" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_IcfrAuditorAttestationFlag_16bed57e-f8db-4508-99d3-0dbad8766835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_9849007d-3707-48d7-a302-43ae51cf3477" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_9849007d-3707-48d7-a302-43ae51cf3477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_459e3e42-1a04-4728-b9fb-b3f73f75a2f8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_EntityShellCompany_459e3e42-1a04-4728-b9fb-b3f73f75a2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_32f2416b-30b8-4df0-995c-2789634fbb5e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_EntityPublicFloat_32f2416b-30b8-4df0-995c-2789634fbb5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_753ba644-c81b-443d-98c5-b738746e137b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_753ba644-c81b-443d-98c5-b738746e137b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_79e78d07-ead6-41da-bd17-16ddea08736e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_79e78d07-ead6-41da-bd17-16ddea08736e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_48eb0da8-56a0-4303-b325-24dd64814e37" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_AmendmentFlag_48eb0da8-56a0-4303-b325-24dd64814e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_3fe7d2cb-a259-45db-b484-4a62e997e5c3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_DocumentFiscalPeriodFocus_3fe7d2cb-a259-45db-b484-4a62e997e5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_01db15c5-293b-4e4b-a5c0-5619e190b28c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_DocumentFiscalYearFocus_01db15c5-293b-4e4b-a5c0-5619e190b28c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f7179070-789b-4a25-a923-cc184663bfee" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_58640f40-683e-4fa1-960e-ee893593f30a" xlink:to="loc_dei_EntityCentralIndexKey_f7179070-789b-4a25-a923-cc184663bfee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/AuditInformation" xlink:type="simple" xlink:href="ci-20231231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_AuditInformationAbstract_6e206dc6-db69-48f6-9854-80cb0df02158" xlink:href="ci-20231231.xsd#ci_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_604f7c15-990f-4707-a7ae-53a0e9c423b8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_AuditInformationAbstract_6e206dc6-db69-48f6-9854-80cb0df02158" xlink:to="loc_dei_AuditorName_604f7c15-990f-4707-a7ae-53a0e9c423b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_44205839-e1c1-4b19-ac81-21a9994af869" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_AuditInformationAbstract_6e206dc6-db69-48f6-9854-80cb0df02158" xlink:to="loc_dei_AuditorLocation_44205839-e1c1-4b19-ac81-21a9994af869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_be40a95f-06df-4179-b5fc-76a61add30e9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_AuditInformationAbstract_6e206dc6-db69-48f6-9854-80cb0df02158" xlink:to="loc_dei_AuditorFirmId_be40a95f-06df-4179-b5fc-76a61add30e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="ci-20231231.xsd#ConsolidatedStatementsofIncome"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_60008ecc-bf7e-41e9-9f24-00a2079a33fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0712072b-e7e3-4fd1-96ca-f1084021dc7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_60008ecc-bf7e-41e9-9f24-00a2079a33fa" xlink:to="loc_us-gaap_StatementTable_0712072b-e7e3-4fd1-96ca-f1084021dc7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9033a4d1-4a10-4af2-88c9-fbfb151902f9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0712072b-e7e3-4fd1-96ca-f1084021dc7e" xlink:to="loc_srt_ProductOrServiceAxis_9033a4d1-4a10-4af2-88c9-fbfb151902f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8234b12c-5174-45de-99d4-c29b3d4c681a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9033a4d1-4a10-4af2-88c9-fbfb151902f9" xlink:to="loc_srt_ProductsAndServicesDomain_8234b12c-5174-45de-99d4-c29b3d4c681a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_ba37fac5-eec3-4b75-9470-cd759d786e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8234b12c-5174-45de-99d4-c29b3d4c681a" xlink:to="loc_us-gaap_ProductMember_ba37fac5-eec3-4b75-9470-cd759d786e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_e9bfbab3-7b4c-4582-afd1-42011f7fb685" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8234b12c-5174-45de-99d4-c29b3d4c681a" xlink:to="loc_us-gaap_ServiceMember_e9bfbab3-7b4c-4582-afd1-42011f7fb685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1b04d75a-3365-432c-802a-75103ee2c0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0712072b-e7e3-4fd1-96ca-f1084021dc7e" xlink:to="loc_us-gaap_StatementLineItems_1b04d75a-3365-432c-802a-75103ee2c0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_f6bb4d0e-7c30-42e5-ae7a-6c7b540554d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1b04d75a-3365-432c-802a-75103ee2c0a7" xlink:to="loc_us-gaap_RevenuesAbstract_f6bb4d0e-7c30-42e5-ae7a-6c7b540554d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ab5bec7b-0d94-412d-8d5a-7e27405b14cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_f6bb4d0e-7c30-42e5-ae7a-6c7b540554d0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ab5bec7b-0d94-412d-8d5a-7e27405b14cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_91937a04-2bff-4e9d-8c61-9a19935790ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_f6bb4d0e-7c30-42e5-ae7a-6c7b540554d0" xlink:to="loc_us-gaap_PremiumsEarnedNet_91937a04-2bff-4e9d-8c61-9a19935790ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_be2d07c9-98cf-4a3e-8323-e93de8e21f51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_f6bb4d0e-7c30-42e5-ae7a-6c7b540554d0" xlink:to="loc_us-gaap_NetInvestmentIncome_be2d07c9-98cf-4a3e-8323-e93de8e21f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_67d51f46-ee02-4f00-bf14-2f18c23df7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_f6bb4d0e-7c30-42e5-ae7a-6c7b540554d0" xlink:to="loc_us-gaap_Revenues_67d51f46-ee02-4f00-bf14-2f18c23df7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BenefitsLossesAndExpensesAbstract_ab361a9f-df47-45f2-b26d-bf59b3e63fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BenefitsLossesAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1b04d75a-3365-432c-802a-75103ee2c0a7" xlink:to="loc_us-gaap_BenefitsLossesAndExpensesAbstract_ab361a9f-df47-45f2-b26d-bf59b3e63fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_e0911b6a-6991-45ca-b0f9-6ac4973b4566" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BenefitsLossesAndExpensesAbstract_ab361a9f-df47-45f2-b26d-bf59b3e63fe2" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_e0911b6a-6991-45ca-b0f9-6ac4973b4566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_89017d72-6baf-4edf-8fef-a0b88c8edbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BenefitsLossesAndExpensesAbstract_ab361a9f-df47-45f2-b26d-bf59b3e63fe2" xlink:to="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet_89017d72-6baf-4edf-8fef-a0b88c8edbf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3e3e4cd2-804f-4a58-8a82-826563885efb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BenefitsLossesAndExpensesAbstract_ab361a9f-df47-45f2-b26d-bf59b3e63fe2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3e3e4cd2-804f-4a58-8a82-826563885efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_52a3055b-441d-4371-a36a-4690d369831d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BenefitsLossesAndExpensesAbstract_ab361a9f-df47-45f2-b26d-bf59b3e63fe2" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_52a3055b-441d-4371-a36a-4690d369831d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BenefitsLossesAndExpenses_54103cc3-dad8-4f3d-9311-d1ad212075a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BenefitsLossesAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BenefitsLossesAndExpensesAbstract_ab361a9f-df47-45f2-b26d-bf59b3e63fe2" xlink:to="loc_us-gaap_BenefitsLossesAndExpenses_54103cc3-dad8-4f3d-9311-d1ad212075a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_39082257-c592-4378-9183-a06180212fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1b04d75a-3365-432c-802a-75103ee2c0a7" xlink:to="loc_us-gaap_OperatingIncomeLoss_39082257-c592-4378-9183-a06180212fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_512fce66-1a5b-48a3-931c-c480c51c82b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1b04d75a-3365-432c-802a-75103ee2c0a7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_512fce66-1a5b-48a3-931c-c480c51c82b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a5dd658f-7052-4e78-96b7-1a0fee0a5065" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1b04d75a-3365-432c-802a-75103ee2c0a7" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a5dd658f-7052-4e78-96b7-1a0fee0a5065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_aa3c45da-6b95-478b-8c0c-dea40b883cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1b04d75a-3365-432c-802a-75103ee2c0a7" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_aa3c45da-6b95-478b-8c0c-dea40b883cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RealizedInvestmentGainLoss_b907df40-3d2e-48de-b80b-5976971717d6" xlink:href="ci-20231231.xsd#ci_RealizedInvestmentGainLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1b04d75a-3365-432c-802a-75103ee2c0a7" xlink:to="loc_ci_RealizedInvestmentGainLoss_b907df40-3d2e-48de-b80b-5976971717d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9453674e-af54-432a-9f34-0d4675ba749b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1b04d75a-3365-432c-802a-75103ee2c0a7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9453674e-af54-432a-9f34-0d4675ba749b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7a2e1d74-f3a0-4744-b92f-ac94d8b55244" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1b04d75a-3365-432c-802a-75103ee2c0a7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7a2e1d74-f3a0-4744-b92f-ac94d8b55244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c3749166-3172-4f47-8838-961b53426bde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1b04d75a-3365-432c-802a-75103ee2c0a7" xlink:to="loc_us-gaap_ProfitLoss_c3749166-3172-4f47-8838-961b53426bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c483db32-bfef-45f1-a9dc-f49ab383e081" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1b04d75a-3365-432c-802a-75103ee2c0a7" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c483db32-bfef-45f1-a9dc-f49ab383e081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d6659186-9348-4b31-acde-429cd9a330a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1b04d75a-3365-432c-802a-75103ee2c0a7" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d6659186-9348-4b31-acde-429cd9a330a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2ce47802-2cd9-43d2-9cb5-7687b02c5f88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1b04d75a-3365-432c-802a-75103ee2c0a7" xlink:to="loc_us-gaap_EarningsPerShareAbstract_2ce47802-2cd9-43d2-9cb5-7687b02c5f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b3d12842-3199-42f0-82ec-7457636256bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2ce47802-2cd9-43d2-9cb5-7687b02c5f88" xlink:to="loc_us-gaap_EarningsPerShareBasic_b3d12842-3199-42f0-82ec-7457636256bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_47c8924a-da3b-4c56-8df9-d80026819f64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2ce47802-2cd9-43d2-9cb5-7687b02c5f88" xlink:to="loc_us-gaap_EarningsPerShareDiluted_47c8924a-da3b-4c56-8df9-d80026819f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="ci-20231231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7d0a42d5-275f-4280-a039-458194dd2748" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2d1f5591-46f7-46a7-86c7-b1381beee814" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7d0a42d5-275f-4280-a039-458194dd2748" xlink:to="loc_us-gaap_ProfitLoss_2d1f5591-46f7-46a7-86c7-b1381beee814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_dff289ab-636b-44be-ae0b-f7927fe2ba37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7d0a42d5-275f-4280-a039-458194dd2748" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_dff289ab-636b-44be-ae0b-f7927fe2ba37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax_5a1fb18a-d78b-4807-a8ef-9390a3afdcf3" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_dff289ab-636b-44be-ae0b-f7927fe2ba37" xlink:to="loc_ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax_5a1fb18a-d78b-4807-a8ef-9390a3afdcf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent_433bfe8e-c2ff-4dec-b274-8c5e04700a63" xlink:href="ci-20231231.xsd#ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_dff289ab-636b-44be-ae0b-f7927fe2ba37" xlink:to="loc_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent_433bfe8e-c2ff-4dec-b274-8c5e04700a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity_b839811a-04f1-4117-94ab-1e15b36cae90" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_dff289ab-636b-44be-ae0b-f7927fe2ba37" xlink:to="loc_ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity_b839811a-04f1-4117-94ab-1e15b36cae90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_2c667a22-8a1f-43b6-a4a2-2df350ca7b83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_dff289ab-636b-44be-ae0b-f7927fe2ba37" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_2c667a22-8a1f-43b6-a4a2-2df350ca7b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity_149a561b-51cf-4218-ada9-94e5cdd8bfb1" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_dff289ab-636b-44be-ae0b-f7927fe2ba37" xlink:to="loc_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity_149a561b-51cf-4218-ada9-94e5cdd8bfb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity_bef07c5a-b68a-4db2-973a-c31cf81fc994" xlink:href="ci-20231231.xsd#ci_ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7d0a42d5-275f-4280-a039-458194dd2748" xlink:to="loc_ci_ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity_bef07c5a-b68a-4db2-973a-c31cf81fc994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract_7f3e2009-a9e4-4b51-83d3-201875827f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7d0a42d5-275f-4280-a039-458194dd2748" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract_7f3e2009-a9e4-4b51-83d3-201875827f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_c95740ed-e7bc-4cd6-9717-854d5438da48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract_7f3e2009-a9e4-4b51-83d3-201875827f3d" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_c95740ed-e7bc-4cd6-9717-854d5438da48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_55d422b7-6642-445e-b706-32f7d7c40570" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract_7f3e2009-a9e4-4b51-83d3-201875827f3d" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_55d422b7-6642-445e-b706-32f7d7c40570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TemporaryEquityOtherComprehensiveIncome_7b42aa40-aec4-4b24-95f4-045b4332fd50" xlink:href="ci-20231231.xsd#ci_TemporaryEquityOtherComprehensiveIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract_7f3e2009-a9e4-4b51-83d3-201875827f3d" xlink:to="loc_ci_TemporaryEquityOtherComprehensiveIncome_7b42aa40-aec4-4b24-95f4-045b4332fd50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_f66d8a10-e42c-42e7-8608-ff4ef78ba8e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract_7f3e2009-a9e4-4b51-83d3-201875827f3d" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_f66d8a10-e42c-42e7-8608-ff4ef78ba8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c7b850a8-462a-4be2-ad15-2cb7cb83db26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7d0a42d5-275f-4280-a039-458194dd2748" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_c7b850a8-462a-4be2-ad15-2cb7cb83db26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ci-20231231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_07801dba-ff19-46be-9a55-049e5a7077bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5fe2f15e-3076-4c86-aa36-b972395cac8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_07801dba-ff19-46be-9a55-049e5a7077bc" xlink:to="loc_us-gaap_AssetsAbstract_5fe2f15e-3076-4c86-aa36-b972395cac8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d097c453-c772-42ea-9a49-fd00d2d829a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5fe2f15e-3076-4c86-aa36-b972395cac8b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d097c453-c772-42ea-9a49-fd00d2d829a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_a1b046b8-920f-407d-b1b3-f84da1e82f49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5fe2f15e-3076-4c86-aa36-b972395cac8b" xlink:to="loc_us-gaap_ShortTermInvestments_a1b046b8-920f-407d-b1b3-f84da1e82f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_c3cef5f2-870a-43bb-b34b-3358edb0e23d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5fe2f15e-3076-4c86-aa36-b972395cac8b" xlink:to="loc_us-gaap_ReceivablesNetCurrent_c3cef5f2-870a-43bb-b34b-3358edb0e23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_fbc5eba4-14ca-4acc-bb15-141071fd5708" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5fe2f15e-3076-4c86-aa36-b972395cac8b" xlink:to="loc_us-gaap_InventoryNet_fbc5eba4-14ca-4acc-bb15-141071fd5708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_cddab2d4-202e-4902-9d30-e62b49f5261c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5fe2f15e-3076-4c86-aa36-b972395cac8b" xlink:to="loc_us-gaap_OtherAssetsCurrent_cddab2d4-202e-4902-9d30-e62b49f5261c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_2b04e471-a4ef-4ed6-9e61-955fce4f86e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5fe2f15e-3076-4c86-aa36-b972395cac8b" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_2b04e471-a4ef-4ed6-9e61-955fce4f86e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_89b9ca0b-c4bc-4ac4-b96e-937caf3d9704" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5fe2f15e-3076-4c86-aa36-b972395cac8b" xlink:to="loc_us-gaap_AssetsCurrent_89b9ca0b-c4bc-4ac4-b96e-937caf3d9704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_3f8075f7-6d0d-4294-b0ba-ef4a140a86aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5fe2f15e-3076-4c86-aa36-b972395cac8b" xlink:to="loc_us-gaap_LongTermInvestments_3f8075f7-6d0d-4294-b0ba-ef4a140a86aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverablesNonCurrent_7bcc9ebe-737d-4b84-b37b-483f241b2beb" xlink:href="ci-20231231.xsd#ci_ReinsuranceRecoverablesNonCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5fe2f15e-3076-4c86-aa36-b972395cac8b" xlink:to="loc_ci_ReinsuranceRecoverablesNonCurrent_7bcc9ebe-737d-4b84-b37b-483f241b2beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_9eb7ec6f-248e-4d88-8968-7d33e879bb47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5fe2f15e-3076-4c86-aa36-b972395cac8b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_9eb7ec6f-248e-4d88-8968-7d33e879bb47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e3bbdd30-c231-4b20-9db0-1d3ea92931a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5fe2f15e-3076-4c86-aa36-b972395cac8b" xlink:to="loc_us-gaap_Goodwill_e3bbdd30-c231-4b20-9db0-1d3ea92931a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_cc9636d7-68ca-498d-bcf7-99fd262719fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5fe2f15e-3076-4c86-aa36-b972395cac8b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_cc9636d7-68ca-498d-bcf7-99fd262719fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_991d615b-c317-4e9a-835e-71b98ab01fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5fe2f15e-3076-4c86-aa36-b972395cac8b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_991d615b-c317-4e9a-835e-71b98ab01fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountAssets_562a0ae5-2e29-4dc1-b205-2c53ff9da884" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeparateAccountAssets"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5fe2f15e-3076-4c86-aa36-b972395cac8b" xlink:to="loc_us-gaap_SeparateAccountAssets_562a0ae5-2e29-4dc1-b205-2c53ff9da884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_21c74a99-32db-445a-8925-d44910a7daee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5fe2f15e-3076-4c86-aa36-b972395cac8b" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_21c74a99-32db-445a-8925-d44910a7daee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f2964746-eeb4-4e08-acc4-a577c36dce49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5fe2f15e-3076-4c86-aa36-b972395cac8b" xlink:to="loc_us-gaap_Assets_f2964746-eeb4-4e08-acc4-a577c36dce49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_746791af-2947-4d23-a95f-ab3f378ef107" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_07801dba-ff19-46be-9a55-049e5a7077bc" xlink:to="loc_us-gaap_LiabilitiesAbstract_746791af-2947-4d23-a95f-ab3f378ef107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesCurrent_e3b37d0a-6060-4566-a4b1-691fcdeb83fa" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_746791af-2947-4d23-a95f-ab3f378ef107" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesCurrent_e3b37d0a-6060-4566-a4b1-691fcdeb83fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PharmacyAndServiceCostsPayable_8c4aeb50-a7c4-4368-8ee2-997437ee302f" xlink:href="ci-20231231.xsd#ci_PharmacyAndServiceCostsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_746791af-2947-4d23-a95f-ab3f378ef107" xlink:to="loc_ci_PharmacyAndServiceCostsPayable_8c4aeb50-a7c4-4368-8ee2-997437ee302f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_855bfc9d-9774-4eeb-a3fb-b175e1c832db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_746791af-2947-4d23-a95f-ab3f378ef107" xlink:to="loc_us-gaap_AccountsPayableCurrent_855bfc9d-9774-4eeb-a3fb-b175e1c832db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccruedExpensesAndOtherLiabilities_2252d263-1972-487c-8150-6eb87f5ab344" xlink:href="ci-20231231.xsd#ci_AccruedExpensesAndOtherLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_746791af-2947-4d23-a95f-ab3f378ef107" xlink:to="loc_ci_AccruedExpensesAndOtherLiabilities_2252d263-1972-487c-8150-6eb87f5ab344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_e6d47e06-aa12-42f5-baa2-2024a524ad7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_746791af-2947-4d23-a95f-ab3f378ef107" xlink:to="loc_us-gaap_DebtCurrent_e6d47e06-aa12-42f5-baa2-2024a524ad7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_05c404e2-6f3e-4cfc-ab91-627d9ddbc801" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_746791af-2947-4d23-a95f-ab3f378ef107" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_05c404e2-6f3e-4cfc-ab91-627d9ddbc801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bc643462-2fe8-464f-aa92-9e7e8ae40935" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_746791af-2947-4d23-a95f-ab3f378ef107" xlink:to="loc_us-gaap_LiabilitiesCurrent_bc643462-2fe8-464f-aa92-9e7e8ae40935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent_cd47ff5d-f140-4aa7-80e6-4c37b3d2bf61" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_746791af-2947-4d23-a95f-ab3f378ef107" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent_cd47ff5d-f140-4aa7-80e6-4c37b3d2bf61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_739a651d-ac56-4a3e-b2f1-3423c289e019" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_746791af-2947-4d23-a95f-ab3f378ef107" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_739a651d-ac56-4a3e-b2f1-3423c289e019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_9a488e61-d43c-4f19-bde5-e55d792728f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_746791af-2947-4d23-a95f-ab3f378ef107" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_9a488e61-d43c-4f19-bde5-e55d792728f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_42c75317-eaa1-4e35-815a-8c96c7f283b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_746791af-2947-4d23-a95f-ab3f378ef107" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_42c75317-eaa1-4e35-815a-8c96c7f283b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountsLiability_0808cc88-36b0-4874-af01-602d8e0d8c12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeparateAccountsLiability"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_746791af-2947-4d23-a95f-ab3f378ef107" xlink:to="loc_us-gaap_SeparateAccountsLiability_0808cc88-36b0-4874-af01-602d8e0d8c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_0b9aabc4-3269-4e2b-be04-0353e1362960" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_746791af-2947-4d23-a95f-ab3f378ef107" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_0b9aabc4-3269-4e2b-be04-0353e1362960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7f6976f4-02f7-424a-9b6d-5f84fbd269af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_746791af-2947-4d23-a95f-ab3f378ef107" xlink:to="loc_us-gaap_Liabilities_7f6976f4-02f7-424a-9b6d-5f84fbd269af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_adf6612f-ccb3-42bc-9452-303391173ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_07801dba-ff19-46be-9a55-049e5a7077bc" xlink:to="loc_us-gaap_CommitmentsAndContingencies_adf6612f-ccb3-42bc-9452-303391173ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_9baec4be-e0e4-41b7-99e0-150fa6616d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_07801dba-ff19-46be-9a55-049e5a7077bc" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_9baec4be-e0e4-41b7-99e0-150fa6616d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1965ba24-7849-451a-b5e6-5970a23120e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_07801dba-ff19-46be-9a55-049e5a7077bc" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1965ba24-7849-451a-b5e6-5970a23120e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_084a1a85-063c-4bd3-8406-725c71c0662e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1965ba24-7849-451a-b5e6-5970a23120e7" xlink:to="loc_us-gaap_CommonStockValue_084a1a85-063c-4bd3-8406-725c71c0662e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_cbbba846-5f6f-48c2-af1f-4e39eb04a96f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1965ba24-7849-451a-b5e6-5970a23120e7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_cbbba846-5f6f-48c2-af1f-4e39eb04a96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e5698585-2265-4e11-ba4d-87bbc267d6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1965ba24-7849-451a-b5e6-5970a23120e7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e5698585-2265-4e11-ba4d-87bbc267d6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_77623f3a-eba2-4818-acde-dbb06b8b0ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1965ba24-7849-451a-b5e6-5970a23120e7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_77623f3a-eba2-4818-acde-dbb06b8b0ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_b3e736bd-d686-4f26-a56f-219f1530534a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1965ba24-7849-451a-b5e6-5970a23120e7" xlink:to="loc_us-gaap_TreasuryStockValue_b3e736bd-d686-4f26-a56f-219f1530534a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2fa9fa3b-065f-4504-bbf2-5d130eaff72d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1965ba24-7849-451a-b5e6-5970a23120e7" xlink:to="loc_us-gaap_StockholdersEquity_2fa9fa3b-065f-4504-bbf2-5d130eaff72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_7cf452b6-f6d5-40d3-883a-23e54811a43e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1965ba24-7849-451a-b5e6-5970a23120e7" xlink:to="loc_us-gaap_MinorityInterest_7cf452b6-f6d5-40d3-883a-23e54811a43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b8c9be3c-60bc-4094-a42c-d40faa418c33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1965ba24-7849-451a-b5e6-5970a23120e7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b8c9be3c-60bc-4094-a42c-d40faa418c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b4a7ef56-e0ce-4eff-a0eb-bf7fbd92cef0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_07801dba-ff19-46be-9a55-049e5a7077bc" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_b4a7ef56-e0ce-4eff-a0eb-bf7fbd92cef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ci-20231231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_cc4f5e39-9b38-40c6-8c1c-b064fa23dfb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_883a9a6c-90ca-493c-bf71-4a55fa94f476" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cc4f5e39-9b38-40c6-8c1c-b064fa23dfb2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_883a9a6c-90ca-493c-bf71-4a55fa94f476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_420e34b0-57fd-42eb-9560-ff2a44bbdf83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cc4f5e39-9b38-40c6-8c1c-b064fa23dfb2" xlink:to="loc_us-gaap_CommonStockSharesIssued_420e34b0-57fd-42eb-9560-ff2a44bbdf83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8380c289-b4fc-4941-a2da-31c837dac769" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cc4f5e39-9b38-40c6-8c1c-b064fa23dfb2" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_8380c289-b4fc-4941-a2da-31c837dac769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity" xlink:type="simple" xlink:href="ci-20231231.xsd#ConsolidatedStatementsofChangesinTotalEquity"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_719a2793-b867-486e-978d-921a74de25d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_14267a74-fbe3-4047-9bef-c0956fdbe795" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_719a2793-b867-486e-978d-921a74de25d9" xlink:to="loc_us-gaap_StatementTable_14267a74-fbe3-4047-9bef-c0956fdbe795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_37fbeaed-08e0-4d78-93a2-ec792cf57210" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_14267a74-fbe3-4047-9bef-c0956fdbe795" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_37fbeaed-08e0-4d78-93a2-ec792cf57210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3d07bfff-4968-4e72-a8e9-2844e646432c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_37fbeaed-08e0-4d78-93a2-ec792cf57210" xlink:to="loc_us-gaap_EquityComponentDomain_3d07bfff-4968-4e72-a8e9-2844e646432c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_c14443dd-40ab-415a-9e75-a9d3d7b465e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3d07bfff-4968-4e72-a8e9-2844e646432c" xlink:to="loc_us-gaap_ParentMember_c14443dd-40ab-415a-9e75-a9d3d7b465e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0539bce5-d0c7-4a98-a8be-91f653d3d047" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_c14443dd-40ab-415a-9e75-a9d3d7b465e6" xlink:to="loc_us-gaap_CommonStockMember_0539bce5-d0c7-4a98-a8be-91f653d3d047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c220a094-d17f-4921-9ade-614916f710e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_c14443dd-40ab-415a-9e75-a9d3d7b465e6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c220a094-d17f-4921-9ade-614916f710e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fc394785-3d14-465c-bd18-6ef4d968758e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_c14443dd-40ab-415a-9e75-a9d3d7b465e6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fc394785-3d14-465c-bd18-6ef4d968758e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_eaf14480-212a-405c-afec-25d0e7c44bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_c14443dd-40ab-415a-9e75-a9d3d7b465e6" xlink:to="loc_us-gaap_RetainedEarningsMember_eaf14480-212a-405c-afec-25d0e7c44bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_917dac81-ceab-4ef1-b3b5-b905299149f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_c14443dd-40ab-415a-9e75-a9d3d7b465e6" xlink:to="loc_us-gaap_TreasuryStockCommonMember_917dac81-ceab-4ef1-b3b5-b905299149f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_27d6fd77-c932-489d-a7ff-91e6b7dbefab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3d07bfff-4968-4e72-a8e9-2844e646432c" xlink:to="loc_us-gaap_NoncontrollingInterestMember_27d6fd77-c932-489d-a7ff-91e6b7dbefab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_5f7c1e3d-bd83-4ae5-96ba-c817067b22ee" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_14267a74-fbe3-4047-9bef-c0956fdbe795" xlink:to="loc_srt_RestatementAxis_5f7c1e3d-bd83-4ae5-96ba-c817067b22ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_ba014aee-de58-4c41-9647-f86f30f87f17" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_5f7c1e3d-bd83-4ae5-96ba-c817067b22ee" xlink:to="loc_srt_RestatementDomain_ba014aee-de58-4c41-9647-f86f30f87f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_53b41195-a443-4179-85a9-28acec3574bf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_ba014aee-de58-4c41-9647-f86f30f87f17" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_53b41195-a443-4179-85a9-28acec3574bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_11e1437c-a93e-46bd-92e7-bddf9a1ca03c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_ba014aee-de58-4c41-9647-f86f30f87f17" xlink:to="loc_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_11e1437c-a93e-46bd-92e7-bddf9a1ca03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_84fb7230-9607-4d56-8936-32261bea76bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_14267a74-fbe3-4047-9bef-c0956fdbe795" xlink:to="loc_us-gaap_StatementLineItems_84fb7230-9607-4d56-8936-32261bea76bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_834a3ca4-b746-401b-a69e-0354b45499b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_84fb7230-9607-4d56-8936-32261bea76bc" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_834a3ca4-b746-401b-a69e-0354b45499b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6dabe4c4-4f42-4ded-b252-809527a0e5db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_834a3ca4-b746-401b-a69e-0354b45499b9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6dabe4c4-4f42-4ded-b252-809527a0e5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6b6bd6c7-a436-4b31-9301-caef91b2dfbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_834a3ca4-b746-401b-a69e-0354b45499b9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6b6bd6c7-a436-4b31-9301-caef91b2dfbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c9878097-fb51-42a7-af86-3c3b36820209" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_834a3ca4-b746-401b-a69e-0354b45499b9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c9878097-fb51-42a7-af86-3c3b36820209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_d84ee238-1511-49af-a016-50a714c81e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_834a3ca4-b746-401b-a69e-0354b45499b9" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_d84ee238-1511-49af-a016-50a714c81e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_a4609949-f3ca-43cb-8300-e76d15048421" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_834a3ca4-b746-401b-a69e-0354b45499b9" xlink:to="loc_us-gaap_DividendsCommonStockCash_a4609949-f3ca-43cb-8300-e76d15048421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_ace51d98-bda8-4c20-b6ec-755b86b17d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_834a3ca4-b746-401b-a69e-0354b45499b9" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_ace51d98-bda8-4c20-b6ec-755b86b17d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NoncontrollingInterestOtherChanges_c2719ad2-1dbe-4481-9965-1ea9dab74f83" xlink:href="ci-20231231.xsd#ci_NoncontrollingInterestOtherChanges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_834a3ca4-b746-401b-a69e-0354b45499b9" xlink:to="loc_ci_NoncontrollingInterestOtherChanges_c2719ad2-1dbe-4481-9965-1ea9dab74f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2f3c6a29-45e4-463e-b7f9-0a29503b5731" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_834a3ca4-b746-401b-a69e-0354b45499b9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2f3c6a29-45e4-463e-b7f9-0a29503b5731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_6078a518-9be4-4612-9670-24bc6a8b3314" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_84fb7230-9607-4d56-8936-32261bea76bc" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_6078a518-9be4-4612-9670-24bc6a8b3314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_6235d2a8-077d-4c5f-aa02-969a0825843f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_6078a518-9be4-4612-9670-24bc6a8b3314" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_6235d2a8-077d-4c5f-aa02-969a0825843f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TemporaryEquityOtherComprehensiveIncome_02fd3b2b-a868-4d90-9b2c-ced864c3d547" xlink:href="ci-20231231.xsd#ci_TemporaryEquityOtherComprehensiveIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_6078a518-9be4-4612-9670-24bc6a8b3314" xlink:to="loc_ci_TemporaryEquityOtherComprehensiveIncome_02fd3b2b-a868-4d90-9b2c-ced864c3d547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome_05138657-9235-4030-97fb-0074c2db63ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_6078a518-9be4-4612-9670-24bc6a8b3314" xlink:to="loc_us-gaap_TemporaryEquityNetIncome_05138657-9235-4030-97fb-0074c2db63ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityOtherChanges_6783863e-f7f6-4192-9398-c0c1ec30ef92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityOtherChanges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_6078a518-9be4-4612-9670-24bc6a8b3314" xlink:to="loc_us-gaap_TemporaryEquityOtherChanges_6783863e-f7f6-4192-9398-c0c1ec30ef92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_653c51a9-c6d1-4f55-99cf-3b959cc72150" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_6078a518-9be4-4612-9670-24bc6a8b3314" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_653c51a9-c6d1-4f55-99cf-3b959cc72150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_9871ce2f-1b19-4cf9-9a32-0a3fbadb656f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_84fb7230-9607-4d56-8936-32261bea76bc" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_9871ce2f-1b19-4cf9-9a32-0a3fbadb656f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquityParenthetical" xlink:type="simple" xlink:href="ci-20231231.xsd#ConsolidatedStatementsofChangesinTotalEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_2c6c2105-5e7a-4b04-b102-08c45375801b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_79ab09db-0d23-4292-8859-9c95c5dfb436" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_2c6c2105-5e7a-4b04-b102-08c45375801b" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_79ab09db-0d23-4292-8859-9c95c5dfb436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ci-20231231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_5dfee745-8d50-48a6-9c83-0bd93ce56bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_3bb0eba1-9e2d-4bde-ad95-103e76529b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5dfee745-8d50-48a6-9c83-0bd93ce56bd1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_3bb0eba1-9e2d-4bde-ad95-103e76529b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c14d7be2-e9ca-4fad-9069-8b39df58f1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_3bb0eba1-9e2d-4bde-ad95-103e76529b7e" xlink:to="loc_us-gaap_ProfitLoss_c14d7be2-e9ca-4fad-9069-8b39df58f1ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fe9626a8-caea-4306-83fa-d7e4bbf2d921" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_3bb0eba1-9e2d-4bde-ad95-103e76529b7e" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fe9626a8-caea-4306-83fa-d7e4bbf2d921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f3ad9ced-34df-45ac-9e6b-b654df63c0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fe9626a8-caea-4306-83fa-d7e4bbf2d921" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f3ad9ced-34df-45ac-9e6b-b654df63c0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RealizedInvestmentGainLoss_9ee46561-0981-4f22-b999-4abb738456cc" xlink:href="ci-20231231.xsd#ci_RealizedInvestmentGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fe9626a8-caea-4306-83fa-d7e4bbf2d921" xlink:to="loc_ci_RealizedInvestmentGainLoss_9ee46561-0981-4f22-b999-4abb738456cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_52abc0e4-8975-441a-be30-ffbb9aba1ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fe9626a8-caea-4306-83fa-d7e4bbf2d921" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_52abc0e4-8975-441a-be30-ffbb9aba1ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_76d1d9ca-5395-486d-b6e7-4ea29d43582b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fe9626a8-caea-4306-83fa-d7e4bbf2d921" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_76d1d9ca-5395-486d-b6e7-4ea29d43582b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d3eec14f-b92f-4720-87b9-7883fbd78abd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fe9626a8-caea-4306-83fa-d7e4bbf2d921" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d3eec14f-b92f-4720-87b9-7883fbd78abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_871c5645-3d15-4007-98b4-cb13c6308482" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_3bb0eba1-9e2d-4bde-ad95-103e76529b7e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_871c5645-3d15-4007-98b4-cb13c6308482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_cf1bf869-a5e3-4c43-8722-138b5a54cd88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_871c5645-3d15-4007-98b4-cb13c6308482" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_cf1bf869-a5e3-4c43-8722-138b5a54cd88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_cd3fe33f-e74c-4ead-a270-d8cb4ad95a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_871c5645-3d15-4007-98b4-cb13c6308482" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_cd3fe33f-e74c-4ead-a270-d8cb4ad95a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReinsuranceRecoverable_57b0ded1-8466-4193-983c-6bee4c4f8a60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInReinsuranceRecoverable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_871c5645-3d15-4007-98b4-cb13c6308482" xlink:to="loc_us-gaap_IncreaseDecreaseInReinsuranceRecoverable_57b0ded1-8466-4193-983c-6bee4c4f8a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities_25d80a10-4e1e-499c-a9ef-8a2f31996fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInsuranceLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_871c5645-3d15-4007-98b4-cb13c6308482" xlink:to="loc_us-gaap_IncreaseDecreaseInInsuranceLiabilities_25d80a10-4e1e-499c-a9ef-8a2f31996fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable_4c8a0804-e19f-45e0-b6cb-47e6c43c8bfb" xlink:href="ci-20231231.xsd#ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_871c5645-3d15-4007-98b4-cb13c6308482" xlink:to="loc_ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable_4c8a0804-e19f-45e0-b6cb-47e6c43c8bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities_89587e8f-8a50-4159-b465-f7f1e0ac9217" xlink:href="ci-20231231.xsd#ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_871c5645-3d15-4007-98b4-cb13c6308482" xlink:to="loc_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities_89587e8f-8a50-4159-b465-f7f1e0ac9217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_331732c4-5ab6-4ad6-b2b8-06b480a19ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_871c5645-3d15-4007-98b4-cb13c6308482" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_331732c4-5ab6-4ad6-b2b8-06b480a19ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7b99d50-f623-4afa-94af-3b2917175040" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_3bb0eba1-9e2d-4bde-ad95-103e76529b7e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7b99d50-f623-4afa-94af-3b2917175040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_61adb62e-d63c-4d5d-87dc-027d9ab4cf30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5dfee745-8d50-48a6-9c83-0bd93ce56bd1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_61adb62e-d63c-4d5d-87dc-027d9ab4cf30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract_0d81ffe4-686e-40f8-ab00-5d996bdd679b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_61adb62e-d63c-4d5d-87dc-027d9ab4cf30" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract_0d81ffe4-686e-40f8-ab00-5d996bdd679b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ProceedsFromSaleOfDebtAndEquitySecurities_40097fd9-0b55-4de3-ac8e-d8d70e8b6a8c" xlink:href="ci-20231231.xsd#ci_ProceedsFromSaleOfDebtAndEquitySecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract_0d81ffe4-686e-40f8-ab00-5d996bdd679b" xlink:to="loc_ci_ProceedsFromSaleOfDebtAndEquitySecurities_40097fd9-0b55-4de3-ac8e-d8d70e8b6a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract_561db483-9ce3-4045-8e34-1cdf92f9f627" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_61adb62e-d63c-4d5d-87dc-027d9ab4cf30" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract_561db483-9ce3-4045-8e34-1cdf92f9f627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities_df4dd4d4-079b-4704-8556-4791fa741d7c" xlink:href="ci-20231231.xsd#ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract_561db483-9ce3-4045-8e34-1cdf92f9f627" xlink:to="loc_ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities_df4dd4d4-079b-4704-8556-4791fa741d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfLoansReceivable_7fd36b1d-b44e-43b6-8deb-b3cb19eed5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollectionOfLoansReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract_561db483-9ce3-4045-8e34-1cdf92f9f627" xlink:to="loc_us-gaap_ProceedsFromCollectionOfLoansReceivable_7fd36b1d-b44e-43b6-8deb-b3cb19eed5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_fd0448fb-4c7c-44f9-92c2-e7c69d27e1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract_561db483-9ce3-4045-8e34-1cdf92f9f627" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_fd0448fb-4c7c-44f9-92c2-e7c69d27e1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestmentsAbstract_f68ccce4-8e5a-4ab8-801d-1dae81a0f2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestmentsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_61adb62e-d63c-4d5d-87dc-027d9ab4cf30" xlink:to="loc_us-gaap_PaymentsToAcquireInvestmentsAbstract_f68ccce4-8e5a-4ab8-801d-1dae81a0f2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PaymentsToAcquireDebtAndEquitySecurities_09becc16-f277-4163-b235-d1605e7b1843" xlink:href="ci-20231231.xsd#ci_PaymentsToAcquireDebtAndEquitySecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PaymentsToAcquireInvestmentsAbstract_f68ccce4-8e5a-4ab8-801d-1dae81a0f2c8" xlink:to="loc_ci_PaymentsToAcquireDebtAndEquitySecurities_09becc16-f277-4163-b235-d1605e7b1843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMortgageNotesReceivable_f0d60176-766d-4711-a3e0-35bf2e999c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMortgageNotesReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PaymentsToAcquireInvestmentsAbstract_f68ccce4-8e5a-4ab8-801d-1dae81a0f2c8" xlink:to="loc_us-gaap_PaymentsToAcquireMortgageNotesReceivable_f0d60176-766d-4711-a3e0-35bf2e999c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_461e4545-9d64-4d8f-875d-e9ffa50dfc6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PaymentsToAcquireInvestmentsAbstract_f68ccce4-8e5a-4ab8-801d-1dae81a0f2c8" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_461e4545-9d64-4d8f-875d-e9ffa50dfc6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PaymentsForProceedsFromPropertyPlantAndEquipment_f1136391-38fb-40e2-8c74-01a55aa5d8b0" xlink:href="ci-20231231.xsd#ci_PaymentsForProceedsFromPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_61adb62e-d63c-4d5d-87dc-027d9ab4cf30" xlink:to="loc_ci_PaymentsForProceedsFromPropertyPlantAndEquipment_f1136391-38fb-40e2-8c74-01a55aa5d8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_93d6812b-a115-45ff-95c7-39b0241ebca8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_61adb62e-d63c-4d5d-87dc-027d9ab4cf30" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_93d6812b-a115-45ff-95c7-39b0241ebca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_1d2eb343-f370-4cee-911d-47ca8c5e7d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_61adb62e-d63c-4d5d-87dc-027d9ab4cf30" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_1d2eb343-f370-4cee-911d-47ca8c5e7d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_c54e62c6-88d4-4ce8-8b48-70eaad30890a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_61adb62e-d63c-4d5d-87dc-027d9ab4cf30" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_c54e62c6-88d4-4ce8-8b48-70eaad30890a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_083ff425-f725-47b6-a9b9-bb06a7c1fb53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_61adb62e-d63c-4d5d-87dc-027d9ab4cf30" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_083ff425-f725-47b6-a9b9-bb06a7c1fb53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_c3f0198e-12fa-4963-81ec-fd9462ca1b30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5dfee745-8d50-48a6-9c83-0bd93ce56bd1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_c3f0198e-12fa-4963-81ec-fd9462ca1b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionsToContractHoldersFunds_34184cae-9d50-4a4c-b74f-8e01c862ecae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionsToContractHoldersFunds"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_c3f0198e-12fa-4963-81ec-fd9462ca1b30" xlink:to="loc_us-gaap_AdditionsToContractHoldersFunds_34184cae-9d50-4a4c-b74f-8e01c862ecae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WithdrawalFromContractHoldersFunds_aa2eb9ea-60ac-49ea-970e-2d0c1f782e48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WithdrawalFromContractHoldersFunds"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_c3f0198e-12fa-4963-81ec-fd9462ca1b30" xlink:to="loc_us-gaap_WithdrawalFromContractHoldersFunds_aa2eb9ea-60ac-49ea-970e-2d0c1f782e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ProceedsFromRepaymentsOfOtherShortTermDebt_a297939d-9e27-4626-9bf5-560dc96265b2" xlink:href="ci-20231231.xsd#ci_ProceedsFromRepaymentsOfOtherShortTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_c3f0198e-12fa-4963-81ec-fd9462ca1b30" xlink:to="loc_ci_ProceedsFromRepaymentsOfOtherShortTermDebt_a297939d-9e27-4626-9bf5-560dc96265b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_4f561ab8-3683-4a71-86fd-51ccb1e03dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_c3f0198e-12fa-4963-81ec-fd9462ca1b30" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_4f561ab8-3683-4a71-86fd-51ccb1e03dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_57461a88-dd36-4c17-8369-a472ab0b025e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_c3f0198e-12fa-4963-81ec-fd9462ca1b30" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_57461a88-dd36-4c17-8369-a472ab0b025e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_befe35d3-03ae-4b45-9ce9-9aa51138ed6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_c3f0198e-12fa-4963-81ec-fd9462ca1b30" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_befe35d3-03ae-4b45-9ce9-9aa51138ed6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d9ecc5c0-1284-4dc0-a1b5-71aca5257462" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_c3f0198e-12fa-4963-81ec-fd9462ca1b30" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d9ecc5c0-1284-4dc0-a1b5-71aca5257462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_16653433-5046-4004-b0b0-515fb2071655" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_c3f0198e-12fa-4963-81ec-fd9462ca1b30" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_16653433-5046-4004-b0b0-515fb2071655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_0d6ffae8-1e4e-4cf8-a778-bfed536450f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_c3f0198e-12fa-4963-81ec-fd9462ca1b30" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_0d6ffae8-1e4e-4cf8-a778-bfed536450f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_b915d850-538e-45d1-8a3d-4c0118da7003" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_c3f0198e-12fa-4963-81ec-fd9462ca1b30" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_b915d850-538e-45d1-8a3d-4c0118da7003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4a3c2e0c-c201-4711-8652-c0e4771682c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_c3f0198e-12fa-4963-81ec-fd9462ca1b30" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4a3c2e0c-c201-4711-8652-c0e4771682c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_29c22b5a-285c-400d-911d-1a8f697fc4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5dfee745-8d50-48a6-9c83-0bd93ce56bd1" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_29c22b5a-285c-400d-911d-1a8f697fc4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_58baa33d-880a-4dd1-9f4f-1ef34e01fa4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5dfee745-8d50-48a6-9c83-0bd93ce56bd1" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_58baa33d-880a-4dd1-9f4f-1ef34e01fa4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_c5ab03a5-8bff-49c0-8523-fbfe34825a05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5dfee745-8d50-48a6-9c83-0bd93ce56bd1" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_c5ab03a5-8bff-49c0-8523-fbfe34825a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_afb78a75-c3ab-40ca-8576-9a90ab65113e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5dfee745-8d50-48a6-9c83-0bd93ce56bd1" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_afb78a75-c3ab-40ca-8576-9a90ab65113e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_f3287294-957e-47ac-85f0-bb3cc1cbb4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5dfee745-8d50-48a6-9c83-0bd93ce56bd1" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_f3287294-957e-47ac-85f0-bb3cc1cbb4c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e5b8b146-f68e-46e5-bf93-2d873ce9e70b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5dfee745-8d50-48a6-9c83-0bd93ce56bd1" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e5b8b146-f68e-46e5-bf93-2d873ce9e70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_75b937dd-39d5-4d69-a40c-44cfcf0457e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5dfee745-8d50-48a6-9c83-0bd93ce56bd1" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_75b937dd-39d5-4d69-a40c-44cfcf0457e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_81f71ce1-c455-4540-80de-10b9f287a598" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_75b937dd-39d5-4d69-a40c-44cfcf0457e4" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_81f71ce1-c455-4540-80de-10b9f287a598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_9feb7d0d-7db1-4f1a-9784-c2ed74a99e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_75b937dd-39d5-4d69-a40c-44cfcf0457e4" xlink:to="loc_us-gaap_InterestPaidNet_9feb7d0d-7db1-4f1a-9784-c2ed74a99e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="ci-20231231.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bfc554a2-8a06-4d18-8cb1-2ea300457767" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_96241d3e-a0c7-4087-8139-f0ea92dfe9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bfc554a2-8a06-4d18-8cb1-2ea300457767" xlink:to="loc_us-gaap_NatureOfOperations_96241d3e-a0c7-4087-8139-f0ea92dfe9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="ci-20231231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f45b1a6b-64a7-414d-9336-e70bbaed8f79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_256bbccd-a650-47ac-8f9b-12480b336801" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f45b1a6b-64a7-414d-9336-e70bbaed8f79" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_256bbccd-a650-47ac-8f9b-12480b336801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/AccountsReceivableNet" xlink:type="simple" xlink:href="ci-20231231.xsd#AccountsReceivableNet"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/AccountsReceivableNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_724df74e-744b-4476-9a5e-b4541063fdb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_6575ea7d-5026-4213-89e6-8e1889d940bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_724df74e-744b-4476-9a5e-b4541063fdb7" xlink:to="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_6575ea7d-5026-4213-89e6-8e1889d940bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SupplierFinanceProgram" xlink:type="simple" xlink:href="ci-20231231.xsd#SupplierFinanceProgram"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/SupplierFinanceProgram" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_8c512a86-52af-4b12-9576-f3467408e92b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramTextBlock_8bbe65aa-5cc1-4913-beb8-57c1566b1c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierFinanceProgramTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8c512a86-52af-4b12-9576-f3467408e92b" xlink:to="loc_us-gaap_SupplierFinanceProgramTextBlock_8bbe65aa-5cc1-4913-beb8-57c1566b1c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/MergersAcquisitionsandDivestitures" xlink:type="simple" xlink:href="ci-20231231.xsd#MergersAcquisitionsandDivestitures"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/MergersAcquisitionsandDivestitures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a1753d6a-addd-455e-ba91-9837a5b7f59f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_c4867123-3282-4eeb-9b0c-e0f7a8ad23ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a1753d6a-addd-455e-ba91-9837a5b7f59f" xlink:to="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_c4867123-3282-4eeb-9b0c-e0f7a8ad23ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSale" xlink:type="simple" xlink:href="ci-20231231.xsd#AssetsandLiabilitiesofBusinessesHeldforSale"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSale" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_cc98852c-5f0e-44d5-990a-29b841ae29ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_7c9e0d86-72ea-4c88-903f-f13248818e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_cc98852c-5f0e-44d5-990a-29b841ae29ae" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_7c9e0d86-72ea-4c88-903f-f13248818e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EarningsPerShare" xlink:type="simple" xlink:href="ci-20231231.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fe3bb5db-7e61-4d2e-a959-e8626df22719" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_d2338e4a-d64a-4ab1-a204-4985ba070b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fe3bb5db-7e61-4d2e-a959-e8626df22719" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_d2338e4a-d64a-4ab1-a204-4985ba070b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/Debt" xlink:type="simple" xlink:href="ci-20231231.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3653cbc5-80c6-4715-a551-38b9f8625d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_8838ab01-27d3-43b6-a969-a3303c450e41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3653cbc5-80c6-4715-a551-38b9f8625d1e" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_8838ab01-27d3-43b6-a969-a3303c450e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/CommonandPreferredStock" xlink:type="simple" xlink:href="ci-20231231.xsd#CommonandPreferredStock"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/CommonandPreferredStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_1475a591-58a7-4b42-a4b0-47829da67af5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ScheduleOfCommonStockByClassScheduleOfPreferredStockByClassTextBlock_1790da65-31cd-46ab-8ca6-6315e3441555" xlink:href="ci-20231231.xsd#ci_ScheduleOfCommonStockByClassScheduleOfPreferredStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1475a591-58a7-4b42-a4b0-47829da67af5" xlink:to="loc_ci_ScheduleOfCommonStockByClassScheduleOfPreferredStockByClassTextBlock_1790da65-31cd-46ab-8ca6-6315e3441555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilities" xlink:type="simple" xlink:href="ci-20231231.xsd#InsuranceandContractholderLiabilities"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceLossReservesAbstract_4fc869b4-6ac9-4965-a16f-88a97cb871fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceLossReservesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_07eb173a-c3ff-4ce9-85a9-6c7008adb669" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceLossReservesAbstract_4fc869b4-6ac9-4965-a16f-88a97cb871fb" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_07eb173a-c3ff-4ce9-85a9-6c7008adb669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/Reinsurance" xlink:type="simple" xlink:href="ci-20231231.xsd#Reinsurance"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/Reinsurance" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceDisclosuresAbstract_b1a5ea67-ce25-4eb4-a273-ea298665c1df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceTextBlock_d33b8cc8-73cf-44c4-a91f-44b754a42983" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract_b1a5ea67-ce25-4eb4-a273-ea298665c1df" xlink:to="loc_us-gaap_ReinsuranceTextBlock_d33b8cc8-73cf-44c4-a91f-44b754a42983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/Investments" xlink:type="simple" xlink:href="ci-20231231.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_2ed9ca90-7f7a-4fe0-9da9-5e2bd5a064ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_94de4c46-7593-497e-b38e-c516f6f15491" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_2ed9ca90-7f7a-4fe0-9da9-5e2bd5a064ca" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_94de4c46-7593-497e-b38e-c516f6f15491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="ci-20231231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6cba885b-55f6-490b-92c5-a925e29a1c64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_7788e839-7ea7-4431-a366-6cce9009fe4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6cba885b-55f6-490b-92c5-a925e29a1c64" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_7788e839-7ea7-4431-a366-6cce9009fe4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/VariableInterestEntities" xlink:type="simple" xlink:href="ci-20231231.xsd#VariableInterestEntities"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/VariableInterestEntities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_VariableInterestEntitiesAbstract_ff3d0041-82cf-4659-af86-4b16a9e337e3" xlink:href="ci-20231231.xsd#ci_VariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_2a24e22f-94b1-4a5e-a58c-63cd8ccd28b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_VariableInterestEntitiesAbstract_ff3d0041-82cf-4659-af86-4b16a9e337e3" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_2a24e22f-94b1-4a5e-a58c-63cd8ccd28b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiaries" xlink:type="simple" xlink:href="ci-20231231.xsd#CollectivelySignificantOperatingUnconsolidatedSubsidiaries"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiaries" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_f3319655-73ff-4f59-a689-4f79d612b4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_5c92e688-997c-4dc9-8be2-3dc89c29b042" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_f3319655-73ff-4f59-a689-4f79d612b4bb" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_5c92e688-997c-4dc9-8be2-3dc89c29b042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" xlink:href="ci-20231231.xsd#AccumulatedOtherComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_6d2318d2-b7e9-4f07-a527-b6cb4ed88459" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock_ad2f7d65-7639-4061-a4fb-8215daf6cd4a" xlink:href="ci-20231231.xsd#ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_6d2318d2-b7e9-4f07-a527-b6cb4ed88459" xlink:to="loc_ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock_ad2f7d65-7639-4061-a4fb-8215daf6cd4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/OrganizationalEfficiencyPlan" xlink:type="simple" xlink:href="ci-20231231.xsd#OrganizationalEfficiencyPlan"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/OrganizationalEfficiencyPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_2552df72-e2dd-46f5-9977-e89e9238263c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_ef905f43-e1aa-4fd3-8c72-aeb6ec6d8eff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_2552df72-e2dd-46f5-9977-e89e9238263c" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_ef905f43-e1aa-4fd3-8c72-aeb6ec6d8eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/Pension" xlink:type="simple" xlink:href="ci-20231231.xsd#Pension"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/Pension" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_446934d4-b72b-4451-9755-2f4ccd45158c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_c25c98ef-dac8-44d6-b7a9-30983e2abe62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_446934d4-b72b-4451-9755-2f4ccd45158c" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_c25c98ef-dac8-44d6-b7a9-30983e2abe62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EmployeeIncentivePlans" xlink:type="simple" xlink:href="ci-20231231.xsd#EmployeeIncentivePlans"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/EmployeeIncentivePlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bbad73f0-b5b7-402c-8455-54b2313b0c14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1d64d8d1-0a41-4229-bf76-33b44b503720" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bbad73f0-b5b7-402c-8455-54b2313b0c14" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1d64d8d1-0a41-4229-bf76-33b44b503720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipment" xlink:type="simple" xlink:href="ci-20231231.xsd#GoodwillOtherIntangiblesandPropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract_843330dd-44c4-4592-ba48-f9952e74702d" xlink:href="ci-20231231.xsd#ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentDisclosureTextBlock_2abe491e-cc48-490d-bfda-a3922bece59d" xlink:href="ci-20231231.xsd#ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract_843330dd-44c4-4592-ba48-f9952e74702d" xlink:to="loc_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentDisclosureTextBlock_2abe491e-cc48-490d-bfda-a3922bece59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/Leases" xlink:type="simple" xlink:href="ci-20231231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_08ff9c12-8107-492c-b15e-4306967c06ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_3871a9e1-7c9b-48b3-9153-41fe447e460e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_08ff9c12-8107-492c-b15e-4306967c06ae" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_3871a9e1-7c9b-48b3-9153-41fe447e460e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_cdcd319f-01de-4b7f-8eaa-158c0e388d36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_08ff9c12-8107-492c-b15e-4306967c06ae" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_cdcd319f-01de-4b7f-8eaa-158c0e388d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ShareholdersEquityandDividendRestrictions" xlink:type="simple" xlink:href="ci-20231231.xsd#ShareholdersEquityandDividendRestrictions"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ShareholdersEquityandDividendRestrictions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8c23f09e-b000-4402-8bdd-7b01677d92e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_StockholdersEquityAndDividendRestrictionsTextBlock_7814e561-ebeb-4f53-bca9-50d0b511c458" xlink:href="ci-20231231.xsd#ci_StockholdersEquityAndDividendRestrictionsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8c23f09e-b000-4402-8bdd-7b01677d92e4" xlink:to="loc_ci_StockholdersEquityAndDividendRestrictionsTextBlock_7814e561-ebeb-4f53-bca9-50d0b511c458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ci-20231231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b02c7226-ec85-429b-9455-73b373a73b18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_9800bcdc-d2af-4577-87c8-ada124bf2dde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b02c7226-ec85-429b-9455-73b373a73b18" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_9800bcdc-d2af-4577-87c8-ada124bf2dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ContingenciesandOtherMatters" xlink:type="simple" xlink:href="ci-20231231.xsd#ContingenciesandOtherMatters"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ContingenciesandOtherMatters" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_dbc8b00a-3c1c-483a-93cd-a455250045a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2a73ceef-e187-4b0a-a02b-89604aa58af1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_dbc8b00a-3c1c-483a-93cd-a455250045a9" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2a73ceef-e187-4b0a-a02b-89604aa58af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SegmentInformation" xlink:type="simple" xlink:href="ci-20231231.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_ae64f455-adf5-4443-8915-81897f1c01ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_57c51d94-e089-44f6-b8e0-83c9bc868abf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ae64f455-adf5-4443-8915-81897f1c01ae" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_57c51d94-e089-44f6-b8e0-83c9bc868abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroup" xlink:type="simple" xlink:href="ci-20231231.xsd#ScheduleICondensedFinancialInformationofTheCignaGroup"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroup" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_32c7e2f7-b1de-402a-8589-bb5a69eb4be4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_55d9b687-2555-4c31-829f-4c55a374d7aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_32c7e2f7-b1de-402a-8589-bb5a69eb4be4" xlink:to="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_55d9b687-2555-4c31-829f-4c55a374d7aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ScheduleIIValuationandQualifyingAccountsandReserves" xlink:type="simple" xlink:href="ci-20231231.xsd#ScheduleIIValuationandQualifyingAccountsandReserves"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ScheduleIIValuationandQualifyingAccountsandReserves" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_ec0f7dea-cd1b-4d17-b7f4-d04e7cd13e5c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_20c489ce-cd5c-47a8-8741-897d95883de9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_ec0f7dea-cd1b-4d17-b7f4-d04e7cd13e5c" xlink:to="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_20c489ce-cd5c-47a8-8741-897d95883de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ci-20231231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6fbd01d4-737e-4b8b-8c79-ec4190dd7382" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6fbd01d4-737e-4b8b-8c79-ec4190dd7382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8595bb1c-2f75-4404-ab0c-0427e8466173" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8595bb1c-2f75-4404-ab0c-0427e8466173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_63b985cc-3823-4426-b1ef-878d53daf213" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_63b985cc-3823-4426-b1ef-878d53daf213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_2a39e3fb-29e3-438c-a622-eed870a59584" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_2a39e3fb-29e3-438c-a622-eed870a59584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CapitalizationOfDeferredPolicyAcquisitionCostsPolicyPolicyTextBlock_c85e7d72-3994-4d9c-bbff-0b07f69dfdc2" xlink:href="ci-20231231.xsd#ci_CapitalizationOfDeferredPolicyAcquisitionCostsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_ci_CapitalizationOfDeferredPolicyAcquisitionCostsPolicyPolicyTextBlock_c85e7d72-3994-4d9c-bbff-0b07f69dfdc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherAssetsCurrentAndNoncurrentPolicyPolicyTextBlock_fcbaf3c6-cf1e-48e3-8558-b46ba71fefc1" xlink:href="ci-20231231.xsd#ci_OtherAssetsCurrentAndNoncurrentPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_ci_OtherAssetsCurrentAndNoncurrentPolicyPolicyTextBlock_fcbaf3c6-cf1e-48e3-8558-b46ba71fefc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RedeemableNoncontrollingInterestsPolicyPolicyTextBlock_29c150bc-f29b-4bdd-954a-2d24cf647e59" xlink:href="ci-20231231.xsd#ci_RedeemableNoncontrollingInterestsPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_ci_RedeemableNoncontrollingInterestsPolicyPolicyTextBlock_29c150bc-f29b-4bdd-954a-2d24cf647e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccountsPayableAccruedExpensesOtherLiabilitiesPolicyPolicyTextBlock_7d7f0e6e-48a5-458c-ab87-9ddd6cf2a21d" xlink:href="ci-20231231.xsd#ci_AccountsPayableAccruedExpensesOtherLiabilitiesPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_ci_AccountsPayableAccruedExpensesOtherLiabilitiesPolicyPolicyTextBlock_7d7f0e6e-48a5-458c-ab87-9ddd6cf2a21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_c0d6a392-a9ed-4ace-8da6-b3d19158a01d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_c0d6a392-a9ed-4ace-8da6-b3d19158a01d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_4612db7e-28a2-4edd-acc0-6473cc85ddbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_4612db7e-28a2-4edd-acc0-6473cc85ddbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_87e28d55-c0ca-444b-b0fb-8cd0bba8af23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_87e28d55-c0ca-444b-b0fb-8cd0bba8af23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_7fafa2cd-1a46-4689-b414-918bf22cb073" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_7fafa2cd-1a46-4689-b414-918bf22cb073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_1b057196-f41e-4a04-a7b5-91eccae3c931" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_1b057196-f41e-4a04-a7b5-91eccae3c931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_7b344b0f-eac2-4011-8603-dadcb49fd6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_7b344b0f-eac2-4011-8603-dadcb49fd6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_71e568b0-2761-4be4-9f5c-19e864e56298" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_71e568b0-2761-4be4-9f5c-19e864e56298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceUnearnedPremiumsPolicyTextBlock_ae1df549-3373-42e5-a675-da41da351eae" xlink:href="ci-20231231.xsd#ci_InsuranceUnearnedPremiumsPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_ci_InsuranceUnearnedPremiumsPolicyTextBlock_ae1df549-3373-42e5-a675-da41da351eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy_87312654-769a-44c0-a6d2-74d3d34a9651" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy_87312654-769a-44c0-a6d2-74d3d34a9651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FuturePolicyBenefitsLiabilityPolicy_a4fd45b0-9931-4026-ba44-2f38e4b22447" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FuturePolicyBenefitsLiabilityPolicy"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_us-gaap_FuturePolicyBenefitsLiabilityPolicy_a4fd45b0-9931-4026-ba44-2f38e4b22447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ContractholderDepositFundsPolicyPolicyTextBlock_02fe88d4-4076-4181-a934-dab29ec51c14" xlink:href="ci-20231231.xsd#ci_ContractholderDepositFundsPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_ci_ContractholderDepositFundsPolicyPolicyTextBlock_02fe88d4-4076-4181-a934-dab29ec51c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitPolicyTextBlock_a47c9383-e082-47cc-a26d-b2dbe2e87f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketRiskBenefitPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_us-gaap_MarketRiskBenefitPolicyTextBlock_a47c9383-e082-47cc-a26d-b2dbe2e87f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceAccountingPolicy_74a9a028-939d-4cde-b3e0-00451a2dd03c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceAccountingPolicy"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_us-gaap_ReinsuranceAccountingPolicy_74a9a028-939d-4cde-b3e0-00451a2dd03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_899274b0-3d97-48ee-b89a-0cc631e2e404" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_899274b0-3d97-48ee-b89a-0cc631e2e404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_aaecc33b-202c-4d6f-988c-2d0294a3f91a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_aaecc33b-202c-4d6f-988c-2d0294a3f91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_be78c505-b27d-4f80-8c78-87c29736ac8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_be78c505-b27d-4f80-8c78-87c29736ac8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountsPolicy_2fd25ac0-464a-45d5-89aa-4bb8af390913" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountsPolicy"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_us-gaap_PolicyholderAccountsPolicy_2fd25ac0-464a-45d5-89aa-4bb8af390913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_63e539a6-63a3-48ad-a925-aea94faf5c54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_63e539a6-63a3-48ad-a925-aea94faf5c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_f6c13630-3cb3-4456-a3d4-1ef2fc099003" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_f6c13630-3cb3-4456-a3d4-1ef2fc099003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_e163ad4e-0543-4aa8-93f9-236c41f11b72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_e163ad4e-0543-4aa8-93f9-236c41f11b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy_c17408f3-d272-46fa-8f73-6ee6d10f3516" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy_c17408f3-d272-46fa-8f73-6ee6d10f3516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_4088f53c-2e46-4e06-9033-425bfd428d25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_4088f53c-2e46-4e06-9033-425bfd428d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_4530c2fc-a098-474d-8505-649ec193ff66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_4530c2fc-a098-474d-8505-649ec193ff66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_e29f2968-9946-4148-8466-92c7adf57c97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_e29f2968-9946-4148-8466-92c7adf57c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_ca298233-23a1-4883-b1ce-6084db1009c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_ca298233-23a1-4883-b1ce-6084db1009c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_5043d09e-8dd3-4ff1-b8cd-9d6bc4a55373" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_5043d09e-8dd3-4ff1-b8cd-9d6bc4a55373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_308206a5-3936-4c51-bfb9-2778f5ca08bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_308206a5-3936-4c51-bfb9-2778f5ca08bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_ba024fb3-2f96-45da-8185-dc886d45578b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_ba024fb3-2f96-45da-8185-dc886d45578b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_8ae4a1f9-641d-4cd8-8c15-2f71f46288f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_8ae4a1f9-641d-4cd8-8c15-2f71f46288f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_ef7adda9-3f1d-42aa-9b8a-f1e1267c20df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd575f50-da22-4aba-990f-04f64acc251f" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_ef7adda9-3f1d-42aa-9b8a-f1e1267c20df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ReceivablesLoansNotesReceivableandOthersPolicies" xlink:type="simple" xlink:href="ci-20231231.xsd#ReceivablesLoansNotesReceivableandOthersPolicies"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ReceivablesLoansNotesReceivableandOthersPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_90079d32-1bc6-40d8-9bdf-d809a371334b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_75480819-1e0e-4b89-aeea-f1fc58183b18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_90079d32-1bc6-40d8-9bdf-d809a371334b" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_75480819-1e0e-4b89-aeea-f1fc58183b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsDebtandEquitySecuritiesPolicies" xlink:type="simple" xlink:href="ci-20231231.xsd#InvestmentsDebtandEquitySecuritiesPolicies"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsDebtandEquitySecuritiesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_175355ca-e6d6-4993-ad2a-081631410da1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_a56304b2-a45d-4361-9c3d-152d01af15a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_175355ca-e6d6-4993-ad2a-081631410da1" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_a56304b2-a45d-4361-9c3d-152d01af15a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/AccountsReceivableNetTables" xlink:type="simple" xlink:href="ci-20231231.xsd#AccountsReceivableNetTables"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/AccountsReceivableNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_7441b385-3330-4f16-9207-fe54bbbee258" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_c9f8dccb-f397-4a6e-8766-d7d6630f14b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_7441b385-3330-4f16-9207-fe54bbbee258" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_c9f8dccb-f397-4a6e-8766-d7d6630f14b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleTables" xlink:type="simple" xlink:href="ci-20231231.xsd#AssetsandLiabilitiesofBusinessesHeldforSaleTables"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_69e3623b-1f2c-43ed-b762-70f2c39acb64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_8eba256c-c1b7-49b6-8623-253b47d2899b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_69e3623b-1f2c-43ed-b762-70f2c39acb64" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_8eba256c-c1b7-49b6-8623-253b47d2899b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="ci-20231231.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2c1dcb64-d3f8-4f40-aea4-0a0283294483" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_cbf21cd2-450d-4e00-95de-a27a5cd825b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2c1dcb64-d3f8-4f40-aea4-0a0283294483" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_cbf21cd2-450d-4e00-95de-a27a5cd825b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_fe2d1849-79a0-42cc-a11c-66e2ea743054" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2c1dcb64-d3f8-4f40-aea4-0a0283294483" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_fe2d1849-79a0-42cc-a11c-66e2ea743054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/DebtTables" xlink:type="simple" xlink:href="ci-20231231.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2714dd66-0911-4d61-8d02-fdbd9aacaa20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ScheduleOfShortTermDebtLongTermDebtTableTextBlock_1fe00e42-bd30-41fa-8e15-65cd03f4ddd8" xlink:href="ci-20231231.xsd#ci_ScheduleOfShortTermDebtLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2714dd66-0911-4d61-8d02-fdbd9aacaa20" xlink:to="loc_ci_ScheduleOfShortTermDebtLongTermDebtTableTextBlock_1fe00e42-bd30-41fa-8e15-65cd03f4ddd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ScheduleOfIssuancesOfLongTermDebtTableTextBlock_42f4ea43-d5d4-4848-88c1-9a368d9c37f0" xlink:href="ci-20231231.xsd#ci_ScheduleOfIssuancesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2714dd66-0911-4d61-8d02-fdbd9aacaa20" xlink:to="loc_ci_ScheduleOfIssuancesOfLongTermDebtTableTextBlock_42f4ea43-d5d4-4848-88c1-9a368d9c37f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_477b42a3-0a58-4916-9f09-ad904684431b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2714dd66-0911-4d61-8d02-fdbd9aacaa20" xlink:to="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_477b42a3-0a58-4916-9f09-ad904684431b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_e497523a-7534-4a5e-9bf8-1a5e4764f246" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2714dd66-0911-4d61-8d02-fdbd9aacaa20" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_e497523a-7534-4a5e-9bf8-1a5e4764f246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/CommonandPreferredStockTables" xlink:type="simple" xlink:href="ci-20231231.xsd#CommonandPreferredStockTables"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/CommonandPreferredStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3397ee2d-59cb-4075-a98e-8499628863d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_63199587-30e6-49bc-b307-dcecae376c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3397ee2d-59cb-4075-a98e-8499628863d5" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_63199587-30e6-49bc-b307-dcecae376c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsDeclaredTableTextBlock_6a7662ed-d8ac-453d-82e5-443977552b16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsDeclaredTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3397ee2d-59cb-4075-a98e-8499628863d5" xlink:to="loc_us-gaap_DividendsDeclaredTableTextBlock_6a7662ed-d8ac-453d-82e5-443977552b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesTables" xlink:type="simple" xlink:href="ci-20231231.xsd#InsuranceandContractholderLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceLossReservesAbstract_36442a54-2dfe-4185-92b4-194692e6865b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceLossReservesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_a37bd495-064f-42dd-aa0d-08cac21c56eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceLossReservesAbstract_36442a54-2dfe-4185-92b4-194692e6865b" xlink:to="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_a37bd495-064f-42dd-aa0d-08cac21c56eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock_c76ea827-d4a7-46b2-baf3-612fd5cb18b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceLossReservesAbstract_36442a54-2dfe-4185-92b4-194692e6865b" xlink:to="loc_us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock_c76ea827-d4a7-46b2-baf3-612fd5cb18b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock_6ec14a27-a59f-45cc-9955-2020154dd72b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceLossReservesAbstract_36442a54-2dfe-4185-92b4-194692e6865b" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock_6ec14a27-a59f-45cc-9955-2020154dd72b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityTableTextBlock_7e633445-9643-48da-8794-c313d4c2301b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceLossReservesAbstract_36442a54-2dfe-4185-92b4-194692e6865b" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitActivityTableTextBlock_7e633445-9643-48da-8794-c313d4c2301b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitActivityTableTextBlock_2667e9cb-b898-4eed-aaf1-64f0448cd8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketRiskBenefitActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceLossReservesAbstract_36442a54-2dfe-4185-92b4-194692e6865b" xlink:to="loc_us-gaap_MarketRiskBenefitActivityTableTextBlock_2667e9cb-b898-4eed-aaf1-64f0448cd8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock_320f29c7-b018-4f4a-95b0-699ab3995659" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceLossReservesAbstract_36442a54-2dfe-4185-92b4-194692e6865b" xlink:to="loc_us-gaap_ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock_320f29c7-b018-4f4a-95b0-699ab3995659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ReinsuranceTables" xlink:type="simple" xlink:href="ci-20231231.xsd#ReinsuranceTables"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ReinsuranceTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceDisclosuresAbstract_aa6875d7-7ca1-4ecb-804f-6fa5ae58efcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock_8a8eb9df-6429-4fe6-8c26-dfc53cd88e88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract_aa6875d7-7ca1-4ecb-804f-6fa5ae58efcc" xlink:to="loc_us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock_8a8eb9df-6429-4fe6-8c26-dfc53cd88e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectsOfReinsuranceTableTextBlock_4d9eca3d-ae1b-4192-b0a5-438560aa3ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectsOfReinsuranceTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract_aa6875d7-7ca1-4ecb-804f-6fa5ae58efcc" xlink:to="loc_us-gaap_EffectsOfReinsuranceTableTextBlock_4d9eca3d-ae1b-4192-b0a5-438560aa3ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitActivityTableTextBlock_8498abc9-2731-4972-a2ff-f3256a2a533e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketRiskBenefitActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract_aa6875d7-7ca1-4ecb-804f-6fa5ae58efcc" xlink:to="loc_us-gaap_MarketRiskBenefitActivityTableTextBlock_8498abc9-2731-4972-a2ff-f3256a2a533e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsTables" xlink:type="simple" xlink:href="ci-20231231.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_4928cd06-304a-4b54-95f4-0e62cf6b6097" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_d4393d57-8a51-49fd-9289-183bdc79d51f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_4928cd06-304a-4b54-95f4-0e62cf6b6097" xlink:to="loc_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_d4393d57-8a51-49fd-9289-183bdc79d51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_1933561a-98e7-43cb-a266-98a4bd996a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_4928cd06-304a-4b54-95f4-0e62cf6b6097" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_1933561a-98e7-43cb-a266-98a4bd996a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_af3d9db5-c1c4-41e7-9cca-f4481c990ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_4928cd06-304a-4b54-95f4-0e62cf6b6097" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_af3d9db5-c1c4-41e7-9cca-f4481c990ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_1907683f-be57-46a8-9f61-e2a432ec084e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_4928cd06-304a-4b54-95f4-0e62cf6b6097" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_1907683f-be57-46a8-9f61-e2a432ec084e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock_d431f12f-fb2d-41ee-a046-21b5e02ac4d5" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_4928cd06-304a-4b54-95f4-0e62cf6b6097" xlink:to="loc_ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock_d431f12f-fb2d-41ee-a046-21b5e02ac4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock_0985e103-a158-4d4d-a504-e577b5ea53c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_4928cd06-304a-4b54-95f4-0e62cf6b6097" xlink:to="loc_us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock_0985e103-a158-4d4d-a504-e577b5ea53c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock_64fbcd0e-ddfc-4478-b8d6-4a019e8c13db" xlink:href="ci-20231231.xsd#ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_4928cd06-304a-4b54-95f4-0e62cf6b6097" xlink:to="loc_ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock_64fbcd0e-ddfc-4478-b8d6-4a019e8c13db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_5c011a6e-53ea-494e-8bf3-8c55b829a8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_4928cd06-304a-4b54-95f4-0e62cf6b6097" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_5c011a6e-53ea-494e-8bf3-8c55b829a8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeTextBlock_95f9a8b6-5f23-4238-8d85-af9a09666f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_4928cd06-304a-4b54-95f4-0e62cf6b6097" xlink:to="loc_us-gaap_InvestmentIncomeTextBlock_95f9a8b6-5f23-4238-8d85-af9a09666f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_88b3e301-d936-4c59-8372-c2aeb1b43010" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_4928cd06-304a-4b54-95f4-0e62cf6b6097" xlink:to="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_88b3e301-d936-4c59-8372-c2aeb1b43010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="ci-20231231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_30ebd00a-1fd0-4cdf-a77a-45d6d475789f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_0b879bba-687a-4b80-8b49-1b5f29135069" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_30ebd00a-1fd0-4cdf-a77a-45d6d475789f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_0b879bba-687a-4b80-8b49-1b5f29135069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_f7f33e65-40af-4425-a92b-a8e3ca931e79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_30ebd00a-1fd0-4cdf-a77a-45d6d475789f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_f7f33e65-40af-4425-a92b-a8e3ca931e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_096e5162-7d62-43dd-932e-1885b7a0b694" xlink:href="ci-20231231.xsd#ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_30ebd00a-1fd0-4cdf-a77a-45d6d475789f" xlink:to="loc_ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_096e5162-7d62-43dd-932e-1885b7a0b694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueOfSeparateAccountAssetsTableTextBlock_63c76d70-deb3-4c37-8363-54a5fb335da3" xlink:href="ci-20231231.xsd#ci_FairValueOfSeparateAccountAssetsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_30ebd00a-1fd0-4cdf-a77a-45d6d475789f" xlink:to="loc_ci_FairValueOfSeparateAccountAssetsTableTextBlock_63c76d70-deb3-4c37-8363-54a5fb335da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTableTextBlock_bcb64dbe-c84b-4744-aa34-45b1586c7572" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_30ebd00a-1fd0-4cdf-a77a-45d6d475789f" xlink:to="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTableTextBlock_bcb64dbe-c84b-4744-aa34-45b1586c7572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_a2d9d4f4-dcfc-46a9-afdd-32522b66158b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_30ebd00a-1fd0-4cdf-a77a-45d6d475789f" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_a2d9d4f4-dcfc-46a9-afdd-32522b66158b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiariesTables" xlink:type="simple" xlink:href="ci-20231231.xsd#CollectivelySignificantOperatingUnconsolidatedSubsidiariesTables"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiariesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_01aef678-2680-42e5-8ce8-ec71ed9e28b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_9c57468f-af14-4004-b4de-675a976bc163" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_01aef678-2680-42e5-8ce8-ec71ed9e28b4" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_9c57468f-af14-4004-b4de-675a976bc163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="ci-20231231.xsd#AccumulatedOtherComprehensiveIncomeLossTables"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_467d5bcf-f8a3-4567-8c27-aa5d759cd3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_be1c8e3b-2522-43fd-9666-763f80f222e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_467d5bcf-f8a3-4567-8c27-aa5d759cd3a8" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_be1c8e3b-2522-43fd-9666-763f80f222e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/OrganizationalEfficiencyPlanTables" xlink:type="simple" xlink:href="ci-20231231.xsd#OrganizationalEfficiencyPlanTables"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/OrganizationalEfficiencyPlanTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_58e9e988-5efb-4776-82d8-12eabaf8e8ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_ff14ab4d-ccab-46fe-b31c-f1d065174114" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_58e9e988-5efb-4776-82d8-12eabaf8e8ec" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_ff14ab4d-ccab-46fe-b31c-f1d065174114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/PensionTables" xlink:type="simple" xlink:href="ci-20231231.xsd#PensionTables"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/PensionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6f6c7432-d67f-400e-a60f-bfb1e594c4e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetFundedStatusTableTextBlock_4a06b16d-a859-4dce-87f5-afeaef8df4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNetFundedStatusTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6f6c7432-d67f-400e-a60f-bfb1e594c4e1" xlink:to="loc_us-gaap_ScheduleOfNetFundedStatusTableTextBlock_4a06b16d-a859-4dce-87f5-afeaef8df4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_d02e8f10-776c-4599-a09f-800db54e2c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6f6c7432-d67f-400e-a60f-bfb1e594c4e1" xlink:to="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_d02e8f10-776c-4599-a09f-800db54e2c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_a0e3ede2-17e6-4271-a7b7-d1328b0ccf1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6f6c7432-d67f-400e-a60f-bfb1e594c4e1" xlink:to="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_a0e3ede2-17e6-4271-a7b7-d1328b0ccf1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_8a393af5-028c-4154-bc78-5ceedcd260a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6f6c7432-d67f-400e-a60f-bfb1e594c4e1" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_8a393af5-028c-4154-bc78-5ceedcd260a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_ae2e1581-f703-48e2-a121-171f19267f67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6f6c7432-d67f-400e-a60f-bfb1e594c4e1" xlink:to="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_ae2e1581-f703-48e2-a121-171f19267f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_39d14beb-d52d-4d39-a238-a30a89f4dafb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6f6c7432-d67f-400e-a60f-bfb1e594c4e1" xlink:to="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_39d14beb-d52d-4d39-a238-a30a89f4dafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock_69e1b8c0-4ae0-4cab-aaaf-9bc1ff29c5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanDisclosuresTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6f6c7432-d67f-400e-a60f-bfb1e594c4e1" xlink:to="loc_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock_69e1b8c0-4ae0-4cab-aaaf-9bc1ff29c5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EmployeeIncentivePlansTables" xlink:type="simple" xlink:href="ci-20231231.xsd#EmployeeIncentivePlansTables"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/EmployeeIncentivePlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f4cdeb10-a1a0-4837-9467-7e77665b29ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_7421f1a4-7ca8-43fa-a5d3-4724ae06d983" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f4cdeb10-a1a0-4837-9467-7e77665b29ee" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_7421f1a4-7ca8-43fa-a5d3-4724ae06d983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8364acec-8586-4d25-9ad5-616f7049e1c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f4cdeb10-a1a0-4837-9467-7e77665b29ee" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8364acec-8586-4d25-9ad5-616f7049e1c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_e269b24a-29a3-44f0-9551-eedb101ff9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f4cdeb10-a1a0-4837-9467-7e77665b29ee" xlink:to="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_e269b24a-29a3-44f0-9551-eedb101ff9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4f9bc08d-cdf6-4e87-965b-76695eb242dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f4cdeb10-a1a0-4837-9467-7e77665b29ee" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4f9bc08d-cdf6-4e87-965b-76695eb242dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_3e2734fb-47b7-4522-852d-d497fda0082c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f4cdeb10-a1a0-4837-9467-7e77665b29ee" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_3e2734fb-47b7-4522-852d-d497fda0082c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_9b7e06f4-8b9a-4541-adf9-7c53a394cfb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f4cdeb10-a1a0-4837-9467-7e77665b29ee" xlink:to="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_9b7e06f4-8b9a-4541-adf9-7c53a394cfb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ca40a38d-e392-465c-a161-2c0f95791225" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f4cdeb10-a1a0-4837-9467-7e77665b29ee" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ca40a38d-e392-465c-a161-2c0f95791225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentTables" xlink:type="simple" xlink:href="ci-20231231.xsd#GoodwillOtherIntangiblesandPropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract_b7fe6df2-ab1b-4b92-a123-0272380f37ba" xlink:href="ci-20231231.xsd#ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_b1bb9b21-2d00-47a5-8b1d-07ddd71a7b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract_b7fe6df2-ab1b-4b92-a123-0272380f37ba" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_b1bb9b21-2d00-47a5-8b1d-07ddd71a7b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_57f7b272-62d3-4743-8873-39fdf50569d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract_b7fe6df2-ab1b-4b92-a123-0272380f37ba" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_57f7b272-62d3-4743-8873-39fdf50569d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_dfee9c6d-f691-4e01-88ca-02b3c9439d24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract_b7fe6df2-ab1b-4b92-a123-0272380f37ba" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_dfee9c6d-f691-4e01-88ca-02b3c9439d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2db05187-3eaf-4ba5-8209-0238afe312ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract_b7fe6df2-ab1b-4b92-a123-0272380f37ba" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2db05187-3eaf-4ba5-8209-0238afe312ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ComponentsOfDepreciationAndAmortizationTableTextBlock_fbb84fa3-b304-4b5f-ad75-eb06b7af4d19" xlink:href="ci-20231231.xsd#ci_ComponentsOfDepreciationAndAmortizationTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract_b7fe6df2-ab1b-4b92-a123-0272380f37ba" xlink:to="loc_ci_ComponentsOfDepreciationAndAmortizationTableTextBlock_fbb84fa3-b304-4b5f-ad75-eb06b7af4d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_22373488-8ab8-4a7f-97eb-8ce247f27102" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract_b7fe6df2-ab1b-4b92-a123-0272380f37ba" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_22373488-8ab8-4a7f-97eb-8ce247f27102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/LeasesTables" xlink:type="simple" xlink:href="ci-20231231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_393e17d7-96f4-4bcb-80b4-eea8caab5f15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AssetsAndLiabilitiesLesseeTableTextBlock_19c5d27b-4cc4-401f-a62f-5effae3848b1" xlink:href="ci-20231231.xsd#ci_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_393e17d7-96f4-4bcb-80b4-eea8caab5f15" xlink:to="loc_ci_AssetsAndLiabilitiesLesseeTableTextBlock_19c5d27b-4cc4-401f-a62f-5effae3848b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_26fd3874-46cd-4326-bde2-fa25a95d594c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_393e17d7-96f4-4bcb-80b4-eea8caab5f15" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_26fd3874-46cd-4326-bde2-fa25a95d594c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CashFlowActivitiesLesseeTableTextBlock_ef7f441e-828c-4be4-9c94-7d97b6a49cec" xlink:href="ci-20231231.xsd#ci_CashFlowActivitiesLesseeTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_393e17d7-96f4-4bcb-80b4-eea8caab5f15" xlink:to="loc_ci_CashFlowActivitiesLesseeTableTextBlock_ef7f441e-828c-4be4-9c94-7d97b6a49cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3735c293-2df9-4a0a-85ea-b8cf8855f7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_393e17d7-96f4-4bcb-80b4-eea8caab5f15" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3735c293-2df9-4a0a-85ea-b8cf8855f7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_6b996f2e-03f5-43e7-99bc-d77d85b48e11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_393e17d7-96f4-4bcb-80b4-eea8caab5f15" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_6b996f2e-03f5-43e7-99bc-d77d85b48e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ShareholdersEquityandDividendRestrictionsTables" xlink:type="simple" xlink:href="ci-20231231.xsd#ShareholdersEquityandDividendRestrictionsTables"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ShareholdersEquityandDividendRestrictionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_146465e4-18c3-45b9-a78a-7adc55a08a16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesDisclosureTextBlock_13d0a182-808f-47a4-b527-f36cc1826697" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatutoryAccountingPracticesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_146465e4-18c3-45b9-a78a-7adc55a08a16" xlink:to="loc_us-gaap_StatutoryAccountingPracticesDisclosureTextBlock_13d0a182-808f-47a4-b527-f36cc1826697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="ci-20231231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_06730160-1f1a-4743-965b-78eea11fc518" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0202d1ac-065c-4f0a-8064-b82824cbbb75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_06730160-1f1a-4743-965b-78eea11fc518" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0202d1ac-065c-4f0a-8064-b82824cbbb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0ef4f0f6-648b-43c8-826c-b9a4c7e49a84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_06730160-1f1a-4743-965b-78eea11fc518" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0ef4f0f6-648b-43c8-826c-b9a4c7e49a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_665636f9-8a52-4731-a100-387cf0ada57b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_06730160-1f1a-4743-965b-78eea11fc518" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_665636f9-8a52-4731-a100-387cf0ada57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_cee2046a-edc4-46e0-8109-31eb6739a56d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_06730160-1f1a-4743-965b-78eea11fc518" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_cee2046a-edc4-46e0-8109-31eb6739a56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="ci-20231231.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_2b10acaf-d7eb-4db9-a969-5c981fe8a15b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ScheduleOfSpecialItemsTableTextBlock_41c5c76c-159c-4ef0-902a-8ae45c1d4ddc" xlink:href="ci-20231231.xsd#ci_ScheduleOfSpecialItemsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2b10acaf-d7eb-4db9-a969-5c981fe8a15b" xlink:to="loc_ci_ScheduleOfSpecialItemsTableTextBlock_41c5c76c-159c-4ef0-902a-8ae45c1d4ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_686ff50c-e384-4033-be1d-817168de6895" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2b10acaf-d7eb-4db9-a969-5c981fe8a15b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_686ff50c-e384-4033-be1d-817168de6895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_58834a6e-7a6e-4a41-af13-89927e1af37e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2b10acaf-d7eb-4db9-a969-5c981fe8a15b" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_58834a6e-7a6e-4a41-af13-89927e1af37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_3a07fd63-36aa-47ad-bf42-0c3c7a7342f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2b10acaf-d7eb-4db9-a969-5c981fe8a15b" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_3a07fd63-36aa-47ad-bf42-0c3c7a7342f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SECScheduleArticle1204CondensedFinancialInformationofRegistrantTables" xlink:type="simple" xlink:href="ci-20231231.xsd#SECScheduleArticle1204CondensedFinancialInformationofRegistrantTables"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/SECScheduleArticle1204CondensedFinancialInformationofRegistrantTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_c3590e11-0e98-4f63-b15c-c803538b7adc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfIssuancesOfLongTermDebtTableTextBlock_5ab50fbc-c0a2-429c-bd2c-e394530c8128" xlink:href="ci-20231231.xsd#ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfIssuancesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_c3590e11-0e98-4f63-b15c-c803538b7adc" xlink:to="loc_ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfIssuancesOfLongTermDebtTableTextBlock_5ab50fbc-c0a2-429c-bd2c-e394530c8128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfMaturitiesOfLongTermDebtTableTextBlock_373e59fb-e57c-413b-a5e8-7049d2735442" xlink:href="ci-20231231.xsd#ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_c3590e11-0e98-4f63-b15c-c803538b7adc" xlink:to="loc_ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfMaturitiesOfLongTermDebtTableTextBlock_373e59fb-e57c-413b-a5e8-7049d2735442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#DescriptionofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/DescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e56887df-3f29-4ae9-b0b2-6a839e62159d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d107b796-83e2-4fa1-8066-f7a61e98687d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e56887df-3f29-4ae9-b0b2-6a839e62159d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d107b796-83e2-4fa1-8066-f7a61e98687d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f2fbd874-4ccb-4c26-aac0-7976c0f1b94d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d107b796-83e2-4fa1-8066-f7a61e98687d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f2fbd874-4ccb-4c26-aac0-7976c0f1b94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f5bf3f86-0da3-4414-a020-37c51b47e082" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f2fbd874-4ccb-4c26-aac0-7976c0f1b94d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f5bf3f86-0da3-4414-a020-37c51b47e082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_dbcf59ec-0f2b-4b87-86ba-2f1209fbe45d" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f5bf3f86-0da3-4414-a020-37c51b47e082" xlink:to="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_dbcf59ec-0f2b-4b87-86ba-2f1209fbe45d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_63b037f1-eca5-411a-87ab-40a657020818" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d107b796-83e2-4fa1-8066-f7a61e98687d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_63b037f1-eca5-411a-87ab-40a657020818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_a14ae116-8f84-46d5-9fa0-9ba03e083aef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_63b037f1-eca5-411a-87ab-40a657020818" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_a14ae116-8f84-46d5-9fa0-9ba03e083aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_b20ba251-5913-407e-b49f-f322ff5c774a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_a14ae116-8f84-46d5-9fa0-9ba03e083aef" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_b20ba251-5913-407e-b49f-f322ff5c774a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_c80a42e6-a684-4fa7-9a27-93c3900c44a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d107b796-83e2-4fa1-8066-f7a61e98687d" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_c80a42e6-a684-4fa7-9a27-93c3900c44a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_84796b95-ef6b-4968-8256-18f72aae26fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c80a42e6-a684-4fa7-9a27-93c3900c44a9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_84796b95-ef6b-4968-8256-18f72aae26fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_adec772e-4791-470c-834a-5e306707eb92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_84796b95-ef6b-4968-8256-18f72aae26fa" xlink:to="loc_us-gaap_SubsequentEventMember_adec772e-4791-470c-834a-5e306707eb92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d06bc839-e71e-42a2-bd00-5e3652c820a1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d107b796-83e2-4fa1-8066-f7a61e98687d" xlink:to="loc_srt_CounterpartyNameAxis_d06bc839-e71e-42a2-bd00-5e3652c820a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_424bc2d7-e268-4f4b-8308-d5a486013378" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d06bc839-e71e-42a2-bd00-5e3652c820a1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_424bc2d7-e268-4f4b-8308-d5a486013378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_HealthCareServiceCorporationHCSCMember_16a3dc9d-a222-4d93-885c-d9280f23b145" xlink:href="ci-20231231.xsd#ci_HealthCareServiceCorporationHCSCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_424bc2d7-e268-4f4b-8308-d5a486013378" xlink:to="loc_ci_HealthCareServiceCorporationHCSCMember_16a3dc9d-a222-4d93-885c-d9280f23b145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_301e469f-c0ac-471a-86bc-21f626726d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d107b796-83e2-4fa1-8066-f7a61e98687d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_301e469f-c0ac-471a-86bc-21f626726d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_f3f54084-cf84-49dd-86b2-61e5088f4ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_301e469f-c0ac-471a-86bc-21f626726d8e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_f3f54084-cf84-49dd-86b2-61e5088f4ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationNameOfSegmentExtensibleList_145d5a91-aed4-41af-821e-573e59c607c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationNameOfSegmentExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_301e469f-c0ac-471a-86bc-21f626726d8e" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationNameOfSegmentExtensibleList_145d5a91-aed4-41af-821e-573e59c607c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_92dd1635-9395-43ce-ba75-43d2d4a55041" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8e72dc53-da78-428d-abc1-b757a4e7bc89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_92dd1635-9395-43ce-ba75-43d2d4a55041" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8e72dc53-da78-428d-abc1-b757a4e7bc89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f490b621-10a5-41e1-bf03-8f7c334cad07" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8e72dc53-da78-428d-abc1-b757a4e7bc89" xlink:to="loc_srt_ProductOrServiceAxis_f490b621-10a5-41e1-bf03-8f7c334cad07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a1c94549-2222-442d-a822-ab25b2cb21ae" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f490b621-10a5-41e1-bf03-8f7c334cad07" xlink:to="loc_srt_ProductsAndServicesDomain_a1c94549-2222-442d-a822-ab25b2cb21ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PharmacyBenefitsManagementServicesMember_cca7b844-79b5-4e0d-abf6-8a51804fc719" xlink:href="ci-20231231.xsd#ci_PharmacyBenefitsManagementServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a1c94549-2222-442d-a822-ab25b2cb21ae" xlink:to="loc_ci_PharmacyBenefitsManagementServicesMember_cca7b844-79b5-4e0d-abf6-8a51804fc719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AdministrativeServicesOnlyHealthCareServicesMember_d9f03a1a-72e2-4005-a98f-1f75fe976f7f" xlink:href="ci-20231231.xsd#ci_AdministrativeServicesOnlyHealthCareServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a1c94549-2222-442d-a822-ab25b2cb21ae" xlink:to="loc_ci_AdministrativeServicesOnlyHealthCareServicesMember_d9f03a1a-72e2-4005-a98f-1f75fe976f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_f56ec8b7-94b9-4778-8643-bb6b223db168" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8e72dc53-da78-428d-abc1-b757a4e7bc89" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_f56ec8b7-94b9-4778-8643-bb6b223db168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_1d3d310a-ba23-48cc-97e9-8d1aab192a14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_f56ec8b7-94b9-4778-8643-bb6b223db168" xlink:to="loc_us-gaap_LossContingencyNatureDomain_1d3d310a-ba23-48cc-97e9-8d1aab192a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceGuaranteeMember_50b26335-e05f-4c40-8062-598ecbeb6063" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceGuaranteeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_1d3d310a-ba23-48cc-97e9-8d1aab192a14" xlink:to="loc_us-gaap_PerformanceGuaranteeMember_50b26335-e05f-4c40-8062-598ecbeb6063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteesMember_a4dfc594-1ba9-4f2d-af7d-c2d9eddbd6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_1d3d310a-ba23-48cc-97e9-8d1aab192a14" xlink:to="loc_us-gaap_GuaranteesMember_a4dfc594-1ba9-4f2d-af7d-c2d9eddbd6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_1a435c9f-3d65-4d80-8881-f435cc41b638" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8e72dc53-da78-428d-abc1-b757a4e7bc89" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_1a435c9f-3d65-4d80-8881-f435cc41b638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8ba89608-b475-41d0-8700-e3ea722e920a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_1a435c9f-3d65-4d80-8881-f435cc41b638" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8ba89608-b475-41d0-8700-e3ea722e920a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_8c0dff9e-c1e6-4796-ad3b-95090c0c5984" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8ba89608-b475-41d0-8700-e3ea722e920a" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_8c0dff9e-c1e6-4796-ad3b-95090c0c5984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_c16c10de-a1c6-4939-808b-9c871474451f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8e72dc53-da78-428d-abc1-b757a4e7bc89" xlink:to="loc_srt_RestatementAxis_c16c10de-a1c6-4939-808b-9c871474451f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_3e17293a-6630-42d5-accc-ac429e9f3ea6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_c16c10de-a1c6-4939-808b-9c871474451f" xlink:to="loc_srt_RestatementDomain_3e17293a-6630-42d5-accc-ac429e9f3ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_33dad479-495a-4eca-8edf-24ead8c26597" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_3e17293a-6630-42d5-accc-ac429e9f3ea6" xlink:to="loc_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_33dad479-495a-4eca-8edf-24ead8c26597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_97584087-78c5-4dcc-a1c5-f72cacd8dd40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8e72dc53-da78-428d-abc1-b757a4e7bc89" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_97584087-78c5-4dcc-a1c5-f72cacd8dd40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3c933e77-fa30-4241-8a6a-d637e8c1cdc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_97584087-78c5-4dcc-a1c5-f72cacd8dd40" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3c933e77-fa30-4241-8a6a-d637e8c1cdc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9afc7947-fbae-46bc-8242-1975f429a0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_97584087-78c5-4dcc-a1c5-f72cacd8dd40" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9afc7947-fbae-46bc-8242-1975f429a0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d1bf8b36-f2f2-48d8-8973-cda5529ddd4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_97584087-78c5-4dcc-a1c5-f72cacd8dd40" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d1bf8b36-f2f2-48d8-8973-cda5529ddd4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_24547149-db3d-4946-a661-22e4e39675ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_97584087-78c5-4dcc-a1c5-f72cacd8dd40" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_24547149-db3d-4946-a661-22e4e39675ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_b952bc9f-1990-4d77-9186-bd912bb4d81e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_97584087-78c5-4dcc-a1c5-f72cacd8dd40" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_b952bc9f-1990-4d77-9186-bd912bb4d81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_56afc234-e089-4881-ae92-421cc5a0ed6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_97584087-78c5-4dcc-a1c5-f72cacd8dd40" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_56afc234-e089-4881-ae92-421cc5a0ed6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_82aeaf26-3899-46cd-8ae9-7957b1d238dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6bcd1954-21d5-4f1b-b070-ef3c235305d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_82aeaf26-3899-46cd-8ae9-7957b1d238dd" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6bcd1954-21d5-4f1b-b070-ef3c235305d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_ee22d329-df30-47b7-89d3-99714123d26d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6bcd1954-21d5-4f1b-b070-ef3c235305d9" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_ee22d329-df30-47b7-89d3-99714123d26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_f27a7d5d-4ee6-481c-8ca3-ae9a46b92e24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_ee22d329-df30-47b7-89d3-99714123d26d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_f27a7d5d-4ee6-481c-8ca3-ae9a46b92e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_aeee30bc-2080-446d-8158-5c23b6e9deb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_f27a7d5d-4ee6-481c-8ca3-ae9a46b92e24" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_aeee30bc-2080-446d-8158-5c23b6e9deb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f1803428-ff8a-4fab-8404-1c40ab824c12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6bcd1954-21d5-4f1b-b070-ef3c235305d9" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f1803428-ff8a-4fab-8404-1c40ab824c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f90bfa0d-5cc0-4e0a-9436-dc109fc28962" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f1803428-ff8a-4fab-8404-1c40ab824c12" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f90bfa0d-5cc0-4e0a-9436-dc109fc28962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_88d6a2e5-e2fa-439f-a6ba-b63d65437277" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f90bfa0d-5cc0-4e0a-9436-dc109fc28962" xlink:to="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_88d6a2e5-e2fa-439f-a6ba-b63d65437277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c2693c9-3639-439f-ab34-3ff9aab5c8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6bcd1954-21d5-4f1b-b070-ef3c235305d9" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c2693c9-3639-439f-ab34-3ff9aab5c8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PharmaceuticalManufacturerReceivable_4f8f69d0-a782-4952-a28d-5d8692ac506a" xlink:href="ci-20231231.xsd#ci_PharmaceuticalManufacturerReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c2693c9-3639-439f-ab34-3ff9aab5c8b8" xlink:to="loc_ci_PharmaceuticalManufacturerReceivable_4f8f69d0-a782-4952-a28d-5d8692ac506a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable_d4299082-b87f-4b03-9573-c764d0639b08" xlink:href="ci-20231231.xsd#ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c2693c9-3639-439f-ab34-3ff9aab5c8b8" xlink:to="loc_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable_d4299082-b87f-4b03-9573-c764d0639b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceCustomerReceivables_a524e74e-d630-469b-9345-9bee41674159" xlink:href="ci-20231231.xsd#ci_InsuranceCustomerReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c2693c9-3639-439f-ab34-3ff9aab5c8b8" xlink:to="loc_ci_InsuranceCustomerReceivables_a524e74e-d630-469b-9345-9bee41674159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_538ab548-e345-4324-8a4a-34375c0eef09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c2693c9-3639-439f-ab34-3ff9aab5c8b8" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_538ab548-e345-4324-8a4a-34375c0eef09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale_6c5f5404-17e9-4b80-a167-8a55d80a8c5d" xlink:href="ci-20231231.xsd#ci_PharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c2693c9-3639-439f-ab34-3ff9aab5c8b8" xlink:to="loc_ci_PharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale_6c5f5404-17e9-4b80-a167-8a55d80a8c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale_820eea69-e373-4a43-b4ba-42d92f171762" xlink:href="ci-20231231.xsd#ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c2693c9-3639-439f-ab34-3ff9aab5c8b8" xlink:to="loc_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale_820eea69-e373-4a43-b4ba-42d92f171762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceCustomerReceivablesBeforeReclassificationToDisposalGroupAssetsHeldForSale_11048432-c591-446d-93c5-8da89ed2b6e7" xlink:href="ci-20231231.xsd#ci_InsuranceCustomerReceivablesBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c2693c9-3639-439f-ab34-3ff9aab5c8b8" xlink:to="loc_ci_InsuranceCustomerReceivablesBeforeReclassificationToDisposalGroupAssetsHeldForSale_11048432-c591-446d-93c5-8da89ed2b6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccountsAndOtherReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale_1d44d476-3182-4875-8b54-27579ab5b690" xlink:href="ci-20231231.xsd#ci_AccountsAndOtherReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c2693c9-3639-439f-ab34-3ff9aab5c8b8" xlink:to="loc_ci_AccountsAndOtherReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale_1d44d476-3182-4875-8b54-27579ab5b690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale_0467ffce-d1e9-44aa-97b1-0b1b1b8bc076" xlink:href="ci-20231231.xsd#ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c2693c9-3639-439f-ab34-3ff9aab5c8b8" xlink:to="loc_ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale_0467ffce-d1e9-44aa-97b1-0b1b1b8bc076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_f9bc1eb6-41c3-436c-a054-9d57ab27c210" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c2693c9-3639-439f-ab34-3ff9aab5c8b8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_f9bc1eb6-41c3-436c-a054-9d57ab27c210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_8da34ac0-a5fb-413f-83e3-951dc5b58a48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c2693c9-3639-439f-ab34-3ff9aab5c8b8" xlink:to="loc_us-gaap_ReceivablesNetCurrent_8da34ac0-a5fb-413f-83e3-951dc5b58a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails_1" xlink:type="simple" xlink:href="ci-20231231.xsd#AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails_1"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/AccountsReceivableNetNarrativeDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#AccountsReceivableNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/AccountsReceivableNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_657e3736-5b76-4186-8750-e029a4f8299f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AllowanceForReceivablesCurrent_e9e4d729-673e-432f-be0d-74e130595d91" xlink:href="ci-20231231.xsd#ci_AllowanceForReceivablesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_657e3736-5b76-4186-8750-e029a4f8299f" xlink:to="loc_ci_AllowanceForReceivablesCurrent_e9e4d729-673e-432f-be0d-74e130595d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ContractualAllowancePharmaceuticalManufacturersReceivables_0e8207fe-2528-4bea-bdd0-3b2c238e0b83" xlink:href="ci-20231231.xsd#ci_ContractualAllowancePharmaceuticalManufacturersReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_657e3736-5b76-4186-8750-e029a4f8299f" xlink:to="loc_ci_ContractualAllowancePharmaceuticalManufacturersReceivables_0e8207fe-2528-4bea-bdd0-3b2c238e0b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ContractualAllowanceNoninsuranceCustomerReceivables_e503ebfa-1789-4b15-9865-7e481ea5e37e" xlink:href="ci-20231231.xsd#ci_ContractualAllowanceNoninsuranceCustomerReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_657e3736-5b76-4186-8750-e029a4f8299f" xlink:to="loc_ci_ContractualAllowanceNoninsuranceCustomerReceivables_e503ebfa-1789-4b15-9865-7e481ea5e37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AllowanceForReceivablesOther_2b7e151d-0d15-41d4-ab46-b92e365c70a3" xlink:href="ci-20231231.xsd#ci_AllowanceForReceivablesOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_657e3736-5b76-4186-8750-e029a4f8299f" xlink:to="loc_ci_AllowanceForReceivablesOther_2b7e151d-0d15-41d4-ab46-b92e365c70a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_a90aa7fe-8426-45bd-a772-a07995e10d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_657e3736-5b76-4186-8750-e029a4f8299f" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_a90aa7fe-8426-45bd-a772-a07995e10d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccountsReceivableUncommittedFactoringFacilityTotalCapacity_ba4580a9-14dc-4ef5-86cf-676bc8b81c23" xlink:href="ci-20231231.xsd#ci_AccountsReceivableUncommittedFactoringFacilityTotalCapacity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_657e3736-5b76-4186-8750-e029a4f8299f" xlink:to="loc_ci_AccountsReceivableUncommittedFactoringFacilityTotalCapacity_ba4580a9-14dc-4ef5-86cf-676bc8b81c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccountsReceivableUncommittedFactoringFacilityInitialTerm_cae19564-37a1-461d-9b15-e92a0642dc0b" xlink:href="ci-20231231.xsd#ci_AccountsReceivableUncommittedFactoringFacilityInitialTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_657e3736-5b76-4186-8750-e029a4f8299f" xlink:to="loc_ci_AccountsReceivableUncommittedFactoringFacilityInitialTerm_cae19564-37a1-461d-9b15-e92a0642dc0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccountsReceivableUncommittedFactoringFacilityAutomaticRenewalTerm_0765eb37-dc56-4136-a773-f83d49b8f113" xlink:href="ci-20231231.xsd#ci_AccountsReceivableUncommittedFactoringFacilityAutomaticRenewalTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_657e3736-5b76-4186-8750-e029a4f8299f" xlink:to="loc_ci_AccountsReceivableUncommittedFactoringFacilityAutomaticRenewalTerm_0765eb37-dc56-4136-a773-f83d49b8f113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccountsReceivableUncommittedFactoringFacilityAmountSold_f737882a-1a15-41ad-9106-035c4b141903" xlink:href="ci-20231231.xsd#ci_AccountsReceivableUncommittedFactoringFacilityAmountSold"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_657e3736-5b76-4186-8750-e029a4f8299f" xlink:to="loc_ci_AccountsReceivableUncommittedFactoringFacilityAmountSold_f737882a-1a15-41ad-9106-035c4b141903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccountsReceivableUncommittedFactoringFacilityAccountsReceivableReceivedButNotRemitted_e30730a6-0d57-425c-b88a-46a85c04179f" xlink:href="ci-20231231.xsd#ci_AccountsReceivableUncommittedFactoringFacilityAccountsReceivableReceivedButNotRemitted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_657e3736-5b76-4186-8750-e029a4f8299f" xlink:to="loc_ci_AccountsReceivableUncommittedFactoringFacilityAccountsReceivableReceivedButNotRemitted_e30730a6-0d57-425c-b88a-46a85c04179f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SupplierFinanceProgramDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#SupplierFinanceProgramDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/SupplierFinanceProgramDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_5e60fd8b-a8f2-4314-b97b-b34e36e38415" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramPaymentTimingPeriod_486b1b78-aa14-4f50-b0bd-796cbdbbc500" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierFinanceProgramPaymentTimingPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5e60fd8b-a8f2-4314-b97b-b34e36e38415" xlink:to="loc_us-gaap_SupplierFinanceProgramPaymentTimingPeriod_486b1b78-aa14-4f50-b0bd-796cbdbbc500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligationCurrent_bd3c1b3a-acf0-459b-95ad-b09e67fcee29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierFinanceProgramObligationCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5e60fd8b-a8f2-4314-b97b-b34e36e38415" xlink:to="loc_us-gaap_SupplierFinanceProgramObligationCurrent_bd3c1b3a-acf0-459b-95ad-b09e67fcee29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold_149d0c0d-a607-44b1-963e-cb1b7602c686" xlink:href="ci-20231231.xsd#ci_SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5e60fd8b-a8f2-4314-b97b-b34e36e38415" xlink:to="loc_ci_SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold_149d0c0d-a607-44b1-963e-cb1b7602c686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration_22009236-9ffa-4399-80a1-305d9d8f3634" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5e60fd8b-a8f2-4314-b97b-b34e36e38415" xlink:to="loc_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration_22009236-9ffa-4399-80a1-305d9d8f3634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/MergersAcquisitionsandDivestituresNarrativeDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#MergersAcquisitionsandDivestituresNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/MergersAcquisitionsandDivestituresNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0fcf88f0-722b-4cdf-8b85-1467cb9248c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_24b06e65-06c7-4267-bfa2-93f30d521799" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0fcf88f0-722b-4cdf-8b85-1467cb9248c5" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_24b06e65-06c7-4267-bfa2-93f30d521799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6a51ba1a-4690-42e0-a676-0aaa8cd777c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_24b06e65-06c7-4267-bfa2-93f30d521799" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6a51ba1a-4690-42e0-a676-0aaa8cd777c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_13686732-66dc-4c6b-8312-faf0e2616600" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6a51ba1a-4690-42e0-a676-0aaa8cd777c0" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_13686732-66dc-4c6b-8312-faf0e2616600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_USGroupDisabilityAndLifeInsuranceBusinessMember_f4557c5d-e578-4069-9508-7c210dfb6552" xlink:href="ci-20231231.xsd#ci_USGroupDisabilityAndLifeInsuranceBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_13686732-66dc-4c6b-8312-faf0e2616600" xlink:to="loc_ci_USGroupDisabilityAndLifeInsuranceBusinessMember_f4557c5d-e578-4069-9508-7c210dfb6552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember_33affdf5-a487-46f6-881a-795acc377d4e" xlink:href="ci-20231231.xsd#ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_13686732-66dc-4c6b-8312-faf0e2616600" xlink:to="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember_33affdf5-a487-46f6-881a-795acc377d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember_f9e6f9a6-b8f1-47aa-8030-1ded1f315ad1" xlink:href="ci-20231231.xsd#ci_InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember_33affdf5-a487-46f6-881a-795acc377d4e" xlink:to="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember_f9e6f9a6-b8f1-47aa-8030-1ded1f315ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_09fb5cb1-9b87-4162-8e78-96bedd0af8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_24b06e65-06c7-4267-bfa2-93f30d521799" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_09fb5cb1-9b87-4162-8e78-96bedd0af8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_53e8e118-2c6e-4a33-b505-8ddafa95fee6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_09fb5cb1-9b87-4162-8e78-96bedd0af8ad" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_53e8e118-2c6e-4a33-b505-8ddafa95fee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_6025245c-b319-414c-a254-254ef9debd83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_53e8e118-2c6e-4a33-b505-8ddafa95fee6" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_6025245c-b319-414c-a254-254ef9debd83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2284a726-42d2-44c6-8ba0-9a535a0e81b5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_24b06e65-06c7-4267-bfa2-93f30d521799" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2284a726-42d2-44c6-8ba0-9a535a0e81b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_4742df6a-48d0-44b5-88c7-1f641e65955a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2284a726-42d2-44c6-8ba0-9a535a0e81b5" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_4742df6a-48d0-44b5-88c7-1f641e65955a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CHSSJVLLCMember_2f06d015-adde-46f7-8d16-7e992ecb89b0" xlink:href="ci-20231231.xsd#ci_CHSSJVLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_4742df6a-48d0-44b5-88c7-1f641e65955a" xlink:to="loc_ci_CHSSJVLLCMember_2f06d015-adde-46f7-8d16-7e992ecb89b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis_c0ff3576-edcd-4c0e-818a-7a1bf7cffc43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsByNatureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_24b06e65-06c7-4267-bfa2-93f30d521799" xlink:to="loc_us-gaap_GuaranteeObligationsByNatureAxis_c0ff3576-edcd-4c0e-818a-7a1bf7cffc43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_8a705479-a12e-4a8a-89fa-0bc94d142e46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_c0ff3576-edcd-4c0e-818a-7a1bf7cffc43" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_8a705479-a12e-4a8a-89fa-0bc94d142e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndirectGuaranteeOfIndebtednessMember_97b3e2e0-e293-4898-b900-f8b8759fc915" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndirectGuaranteeOfIndebtednessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain_8a705479-a12e-4a8a-89fa-0bc94d142e46" xlink:to="loc_us-gaap_IndirectGuaranteeOfIndebtednessMember_97b3e2e0-e293-4898-b900-f8b8759fc915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_466d1bfe-fd12-454e-ad13-8ee07baab186" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_24b06e65-06c7-4267-bfa2-93f30d521799" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_466d1bfe-fd12-454e-ad13-8ee07baab186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_366b784b-b253-45c1-8273-89106030c732" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsMaximumExposure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_466d1bfe-fd12-454e-ad13-8ee07baab186" xlink:to="loc_us-gaap_GuaranteeObligationsMaximumExposure_366b784b-b253-45c1-8273-89106030c732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_bc37d38f-5ea9-474a-8f10-8fec070eadb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_466d1bfe-fd12-454e-ad13-8ee07baab186" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_bc37d38f-5ea9-474a-8f10-8fec070eadb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_212093dc-8050-40cf-8e77-b286fbf4ba10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_466d1bfe-fd12-454e-ad13-8ee07baab186" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_212093dc-8050-40cf-8e77-b286fbf4ba10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax_f826ac61-e0fb-40c5-af9a-62a399c53940" xlink:href="ci-20231231.xsd#ci_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_466d1bfe-fd12-454e-ad13-8ee07baab186" xlink:to="loc_ci_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax_f826ac61-e0fb-40c5-af9a-62a399c53940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TransactionRelatedCosts_6da464c1-41e5-465a-acf4-edc673361bf4" xlink:href="ci-20231231.xsd#ci_TransactionRelatedCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_466d1bfe-fd12-454e-ad13-8ee07baab186" xlink:to="loc_ci_TransactionRelatedCosts_6da464c1-41e5-465a-acf4-edc673361bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TransactionRelatedCostsAfterTax_316cd410-74df-4305-9eb7-81e05339cbdc" xlink:href="ci-20231231.xsd#ci_TransactionRelatedCostsAfterTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_466d1bfe-fd12-454e-ad13-8ee07baab186" xlink:to="loc_ci_TransactionRelatedCostsAfterTax_316cd410-74df-4305-9eb7-81e05339cbdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#AssetsandLiabilitiesofBusinessesHeldforSaleDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_01caa578-a3f1-485a-8178-c821ee3318c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2309b2cb-7325-4877-b910-70ab8cf09273" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_01caa578-a3f1-485a-8178-c821ee3318c6" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2309b2cb-7325-4877-b910-70ab8cf09273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_35e7494b-cca6-4371-9195-b68d254e86e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2309b2cb-7325-4877-b910-70ab8cf09273" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_35e7494b-cca6-4371-9195-b68d254e86e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08c137a4-d24c-4ccd-aeee-9c62935be0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_35e7494b-cca6-4371-9195-b68d254e86e0" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08c137a4-d24c-4ccd-aeee-9c62935be0b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_abbb0223-f2d1-460a-bc4a-b8b70b0a8ef7" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08c137a4-d24c-4ccd-aeee-9c62935be0b8" xlink:to="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_abbb0223-f2d1-460a-bc4a-b8b70b0a8ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember_9480b36c-616e-4036-9ec5-d842692317e1" xlink:href="ci-20231231.xsd#ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08c137a4-d24c-4ccd-aeee-9c62935be0b8" xlink:to="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember_9480b36c-616e-4036-9ec5-d842692317e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember_565d24f8-6b4f-4d18-9df8-ddf88a2928cc" xlink:href="ci-20231231.xsd#ci_InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember_9480b36c-616e-4036-9ec5-d842692317e1" xlink:to="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember_565d24f8-6b4f-4d18-9df8-ddf88a2928cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_028a776c-3049-4622-82b1-6cdfbdd92a61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2309b2cb-7325-4877-b910-70ab8cf09273" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_028a776c-3049-4622-82b1-6cdfbdd92a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_61844c39-f781-486a-b140-a752feaca7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_028a776c-3049-4622-82b1-6cdfbdd92a61" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_61844c39-f781-486a-b140-a752feaca7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_f492db42-aaee-4b30-9628-c21c4efd139a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_61844c39-f781-486a-b140-a752feaca7e8" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_f492db42-aaee-4b30-9628-c21c4efd139a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_aea17603-91d4-4c9c-a013-378426eb3683" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_61844c39-f781-486a-b140-a752feaca7e8" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_aea17603-91d4-4c9c-a013-378426eb3683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_10524b29-87c3-4b3e-97bb-18505f664a20" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2309b2cb-7325-4877-b910-70ab8cf09273" xlink:to="loc_srt_CounterpartyNameAxis_10524b29-87c3-4b3e-97bb-18505f664a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_454b3e43-fac9-43b0-bf3f-097d3306fcb6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_10524b29-87c3-4b3e-97bb-18505f664a20" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_454b3e43-fac9-43b0-bf3f-097d3306fcb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_HealthCareServiceCorporationHCSCMember_2dcd070a-24ce-48d8-956d-da59c7363ff6" xlink:href="ci-20231231.xsd#ci_HealthCareServiceCorporationHCSCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_454b3e43-fac9-43b0-bf3f-097d3306fcb6" xlink:to="loc_ci_HealthCareServiceCorporationHCSCMember_2dcd070a-24ce-48d8-956d-da59c7363ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1c9139a1-e77b-4725-88e7-48d73f1dc5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2309b2cb-7325-4877-b910-70ab8cf09273" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1c9139a1-e77b-4725-88e7-48d73f1dc5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b4997d48-4b5e-41c4-b99f-e4b2b5590466" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1c9139a1-e77b-4725-88e7-48d73f1dc5ac" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b4997d48-4b5e-41c4-b99f-e4b2b5590466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_88b89a2f-fe5c-4e8b-8970-408c56b22f96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b4997d48-4b5e-41c4-b99f-e4b2b5590466" xlink:to="loc_us-gaap_SubsequentEventMember_88b89a2f-fe5c-4e8b-8970-408c56b22f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be7977e-77e6-4b11-924d-26c138eca95d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2309b2cb-7325-4877-b910-70ab8cf09273" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be7977e-77e6-4b11-924d-26c138eca95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_685172bd-a217-49dc-a330-959ae0d47b29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be7977e-77e6-4b11-924d-26c138eca95d" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_685172bd-a217-49dc-a330-959ae0d47b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationSegmentThatIncludesDisposalGroup_7ff49ed8-3888-4aee-bc63-dea215652d49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationSegmentThatIncludesDisposalGroup"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be7977e-77e6-4b11-924d-26c138eca95d" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationSegmentThatIncludesDisposalGroup_7ff49ed8-3888-4aee-bc63-dea215652d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_d7b7fcd3-60cf-484a-b5ef-f85ca24b09a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be7977e-77e6-4b11-924d-26c138eca95d" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_d7b7fcd3-60cf-484a-b5ef-f85ca24b09a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_fb629032-121f-4e43-8553-31d07b4581aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_d7b7fcd3-60cf-484a-b5ef-f85ca24b09a2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_fb629032-121f-4e43-8553-31d07b4581aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationInvestments_94500be5-b262-43f2-bf0f-7bb123681105" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_d7b7fcd3-60cf-484a-b5ef-f85ca24b09a2" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationInvestments_94500be5-b262-43f2-bf0f-7bb123681105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_225c57c2-8838-4525-b880-fd3496638f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_d7b7fcd3-60cf-484a-b5ef-f85ca24b09a2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_225c57c2-8838-4525-b880-fd3496638f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationOtherAssetsGoodwill_8e7e5dda-80de-4d52-822c-6877616838dc" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationOtherAssetsGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_d7b7fcd3-60cf-484a-b5ef-f85ca24b09a2" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationOtherAssetsGoodwill_8e7e5dda-80de-4d52-822c-6877616838dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_cf6ccb82-ad49-4796-86d8-56ddf200091e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DisposalGroupIncludingDiscontinuedOperationOtherAssetsGoodwill_8e7e5dda-80de-4d52-822c-6877616838dc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_cf6ccb82-ad49-4796-86d8-56ddf200091e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_ab0a7f48-8607-436c-8bd4-a2ab2eadbeb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DisposalGroupIncludingDiscontinuedOperationOtherAssetsGoodwill_8e7e5dda-80de-4d52-822c-6877616838dc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_ab0a7f48-8607-436c-8bd4-a2ab2eadbeb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_8b581dca-6c02-4db4-856b-a917afd77deb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_d7b7fcd3-60cf-484a-b5ef-f85ca24b09a2" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_8b581dca-6c02-4db4-856b-a917afd77deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities_58abb551-ffbb-4843-9777-aa4ff70c6f9c" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_d7b7fcd3-60cf-484a-b5ef-f85ca24b09a2" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities_58abb551-ffbb-4843-9777-aa4ff70c6f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationLiabilitiesExcludingInsuranceAndContractholderLiabilities_fc5c74f7-a583-4e91-bef0-3ea9f1d851a2" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationLiabilitiesExcludingInsuranceAndContractholderLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_d7b7fcd3-60cf-484a-b5ef-f85ca24b09a2" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationLiabilitiesExcludingInsuranceAndContractholderLiabilities_fc5c74f7-a583-4e91-bef0-3ea9f1d851a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_9b514e17-337c-48a4-9031-41cb1d98fc63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_d7b7fcd3-60cf-484a-b5ef-f85ca24b09a2" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_9b514e17-337c-48a4-9031-41cb1d98fc63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossInvestmentsAndDerivatives_63c14ae7-889f-4d12-b609-fe1b9da6cc98" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossInvestmentsAndDerivatives"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_d7b7fcd3-60cf-484a-b5ef-f85ca24b09a2" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossInvestmentsAndDerivatives_63c14ae7-889f-4d12-b609-fe1b9da6cc98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossForeignCurrencyTranslation_d494f140-38f9-4e16-8763-a8bcea9dc696" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossForeignCurrencyTranslation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_d7b7fcd3-60cf-484a-b5ef-f85ca24b09a2" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossForeignCurrencyTranslation_d494f140-38f9-4e16-8763-a8bcea9dc696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxAbstract_6ac6503f-9766-4f80-aea8-0cd1c1b8b8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2be7977e-77e6-4b11-924d-26c138eca95d" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxAbstract_6ac6503f-9766-4f80-aea8-0cd1c1b8b8aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_19e14886-0874-40a1-ade4-d70c3bf00851" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxAbstract_6ac6503f-9766-4f80-aea8-0cd1c1b8b8aa" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_19e14886-0874-40a1-ade4-d70c3bf00851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax_c3a13a14-9ac3-4d26-8075-6b5aa60d642d" xlink:href="ci-20231231.xsd#ci_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxAbstract_6ac6503f-9766-4f80-aea8-0cd1c1b8b8aa" xlink:to="loc_ci_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax_c3a13a14-9ac3-4d26-8075-6b5aa60d642d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList_0c51db2e-d893-4151-9cdd-4e4d734321f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxAbstract_6ac6503f-9766-4f80-aea8-0cd1c1b8b8aa" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList_0c51db2e-d893-4151-9cdd-4e4d734321f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_feb8baa2-cc95-4244-b3a3-12dde206f3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_fb4e11f8-6d0f-427c-82fe-88ff26803180" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_feb8baa2-cc95-4244-b3a3-12dde206f3b2" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_fb4e11f8-6d0f-427c-82fe-88ff26803180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_4877d5c0-25ec-4bcd-8740-f89b636d963a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_feb8baa2-cc95-4244-b3a3-12dde206f3b2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_4877d5c0-25ec-4bcd-8740-f89b636d963a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_acbdd1e0-d397-47bd-9539-5b032cce70b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_4877d5c0-25ec-4bcd-8740-f89b636d963a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_acbdd1e0-d397-47bd-9539-5b032cce70b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8207f15c-041e-44b4-9eeb-59d476c0950c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_4877d5c0-25ec-4bcd-8740-f89b636d963a" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8207f15c-041e-44b4-9eeb-59d476c0950c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9c080539-dfaf-484d-855f-a921db04341c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_4877d5c0-25ec-4bcd-8740-f89b636d963a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9c080539-dfaf-484d-855f-a921db04341c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_79005d89-ed3f-4d1e-88a0-8e70ff288206" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_feb8baa2-cc95-4244-b3a3-12dde206f3b2" xlink:to="loc_us-gaap_EarningsPerShareBasic_79005d89-ed3f-4d1e-88a0-8e70ff288206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EarningsPerShareEffectOfDilution_e33c520e-e0fd-4190-a730-33af25616bc3" xlink:href="ci-20231231.xsd#ci_EarningsPerShareEffectOfDilution"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_feb8baa2-cc95-4244-b3a3-12dde206f3b2" xlink:to="loc_ci_EarningsPerShareEffectOfDilution_e33c520e-e0fd-4190-a730-33af25616bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ddc3303a-6d81-4bad-afb2-6ddc8682dc5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_feb8baa2-cc95-4244-b3a3-12dde206f3b2" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ddc3303a-6d81-4bad-afb2-6ddc8682dc5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EarningsPerShareOutstandingEmployeeStockOptionsNotIncludedintheComputationofDilutedEarningsPerShareDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#EarningsPerShareOutstandingEmployeeStockOptionsNotIncludedintheComputationofDilutedEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/EarningsPerShareOutstandingEmployeeStockOptionsNotIncludedintheComputationofDilutedEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c0020fee-ee3c-4e2f-8185-01333cbc68ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d93374ba-786a-4cf2-b33e-73b2ca8cdbc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c0020fee-ee3c-4e2f-8185-01333cbc68ef" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d93374ba-786a-4cf2-b33e-73b2ca8cdbc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3a5aaecb-0be7-42b7-a081-e7ca9fac9063" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d93374ba-786a-4cf2-b33e-73b2ca8cdbc6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3a5aaecb-0be7-42b7-a081-e7ca9fac9063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bb532f1f-4242-4185-a137-2a29b1bdf28d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3a5aaecb-0be7-42b7-a081-e7ca9fac9063" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bb532f1f-4242-4185-a137-2a29b1bdf28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_47f2761e-f4f0-485e-b380-25df5a56d2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bb532f1f-4242-4185-a137-2a29b1bdf28d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_47f2761e-f4f0-485e-b380-25df5a56d2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4c30931c-b81f-4280-b5bd-b36727f6632b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d93374ba-786a-4cf2-b33e-73b2ca8cdbc6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4c30931c-b81f-4280-b5bd-b36727f6632b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9bc6a32f-421a-4f92-8885-ade4a90e4c96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4c30931c-b81f-4280-b5bd-b36727f6632b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9bc6a32f-421a-4f92-8885-ade4a90e4c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EarningsPerShareSharesofCommonStockHeldinTreasuryDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#EarningsPerShareSharesofCommonStockHeldinTreasuryDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/EarningsPerShareSharesofCommonStockHeldinTreasuryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_45604981-0056-438f-bff4-d265508a52fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_0a6d568b-6c56-4b03-a293-7e823b781839" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_45604981-0056-438f-bff4-d265508a52fb" xlink:to="loc_us-gaap_TreasuryStockCommonShares_0a6d568b-6c56-4b03-a293-7e823b781839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_fd75da21-7d27-4fb0-87e2-a7c1df0508eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_45604981-0056-438f-bff4-d265508a52fb" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_fd75da21-7d27-4fb0-87e2-a7c1df0508eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#DebtOutstandingAmountsofDebtandFinanceLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e26cd3cf-9b1e-4636-9691-330d08c0bad2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b92bbfdc-7447-43de-a351-7ada1ad802a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e26cd3cf-9b1e-4636-9691-330d08c0bad2" xlink:to="loc_us-gaap_DebtInstrumentTable_b92bbfdc-7447-43de-a351-7ada1ad802a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_13ce7046-1856-4eed-8d33-50864fb496d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b92bbfdc-7447-43de-a351-7ada1ad802a8" xlink:to="loc_us-gaap_DebtInstrumentAxis_13ce7046-1856-4eed-8d33-50864fb496d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_13ce7046-1856-4eed-8d33-50864fb496d4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue2022305InterestMember_0b4f7cef-c1da-4793-8267-fdea40f15e7b" xlink:href="ci-20231231.xsd#ci_NotesDue2022305InterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue2022305InterestMember_0b4f7cef-c1da-4793-8267-fdea40f15e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue202383InterestMember_da69f836-d779-4b0a-b0c3-1bfbc41c4d3e" xlink:href="ci-20231231.xsd#ci_NotesDue202383InterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue202383InterestMember_da69f836-d779-4b0a-b0c3-1bfbc41c4d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue2023765InterestMember_d1f7f934-c42f-4115-986d-1d026e974231" xlink:href="ci-20231231.xsd#ci_NotesDue2023765InterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue2023765InterestMember_d1f7f934-c42f-4115-986d-1d026e974231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue2023FloatingRateInterestMember_3de6bb36-51fc-4b70-9369-b9bf2fc5e0a7" xlink:href="ci-20231231.xsd#ci_NotesDue2023FloatingRateInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue2023FloatingRateInterestMember_3de6bb36-51fc-4b70-9369-b9bf2fc5e0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20233InterestMember_9b56e686-aa46-4f95-85aa-35a3bf278974" xlink:href="ci-20231231.xsd#ci_NotesDue20233InterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue20233InterestMember_9b56e686-aa46-4f95-85aa-35a3bf278974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue2023375InterestMember_4ca36e50-60d4-4a96-8951-f71c697d2a70" xlink:href="ci-20231231.xsd#ci_NotesDue2023375InterestMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue2023375InterestMember_4ca36e50-60d4-4a96-8951-f71c697d2a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue2024613InterestMember_2c696c6e-af28-4558-827b-347f45c247fb" xlink:href="ci-20231231.xsd#ci_NotesDue2024613InterestMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue2024613InterestMember_2c696c6e-af28-4558-827b-347f45c247fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue202435InterestMember_0cf626e7-f2b2-4dd9-bc8a-b0dd672ce38e" xlink:href="ci-20231231.xsd#ci_NotesDue202435InterestMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue202435InterestMember_0cf626e7-f2b2-4dd9-bc8a-b0dd672ce38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue2025325InterestMember_fc4d3865-8751-4314-adf3-d6e379b431cb" xlink:href="ci-20231231.xsd#ci_NotesDue2025325InterestMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue2025325InterestMember_fc4d3865-8751-4314-adf3-d6e379b431cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20254125InterestMember_7a8cecc1-6612-45da-ab21-60680981a313" xlink:href="ci-20231231.xsd#ci_NotesDue20254125InterestMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue20254125InterestMember_7a8cecc1-6612-45da-ab21-60680981a313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue202645InterestMember_a1376905-d16b-4bea-a86b-a2a5ac70d27c" xlink:href="ci-20231231.xsd#ci_NotesDue202645InterestMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue202645InterestMember_a1376905-d16b-4bea-a86b-a2a5ac70d27c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue2026125Member_872f9814-c551-46f7-ac43-ed0d4e7be2ed" xlink:href="ci-20231231.xsd#ci_NotesDue2026125Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue2026125Member_872f9814-c551-46f7-ac43-ed0d4e7be2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20265685Member_974fb48d-4bf5-48ad-ac89-a388df9548d3" xlink:href="ci-20231231.xsd#ci_NotesDue20265685Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue20265685Member_974fb48d-4bf5-48ad-ac89-a388df9548d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue202734InterestMember_10fdd3c2-f0af-4eb6-a71d-5939201848c3" xlink:href="ci-20231231.xsd#ci_NotesDue202734InterestMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue202734InterestMember_10fdd3c2-f0af-4eb6-a71d-5939201848c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebenturesDue20277875InterestMember_4bacb714-295b-48fb-82c4-ac1c44842af4" xlink:href="ci-20231231.xsd#ci_DebenturesDue20277875InterestMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_DebenturesDue20277875InterestMember_4bacb714-295b-48fb-82c4-ac1c44842af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue2027305Member_9aaaa792-16b0-4d65-b089-66e9cd1efb4e" xlink:href="ci-20231231.xsd#ci_NotesDue2027305Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue2027305Member_9aaaa792-16b0-4d65-b089-66e9cd1efb4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20284375InterestMember_f6fc037d-f7b5-4559-9508-03389db47889" xlink:href="ci-20231231.xsd#ci_NotesDue20284375InterestMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue20284375InterestMember_f6fc037d-f7b5-4559-9508-03389db47889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue203024InterestMember_ae6c48a0-4523-40ac-9a1a-087e1ff92fcd" xlink:href="ci-20231231.xsd#ci_NotesDue203024InterestMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue203024InterestMember_ae6c48a0-4523-40ac-9a1a-087e1ff92fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20312375InterestMember_d9f84c65-ffd2-4963-8f05-985987a09506" xlink:href="ci-20231231.xsd#ci_NotesDue20312375InterestMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue20312375InterestMember_d9f84c65-ffd2-4963-8f05-985987a09506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_StepDownNotesDueJanuary2033Member_28f34d73-b92a-4a84-a73c-02241f9db473" xlink:href="ci-20231231.xsd#ci_StepDownNotesDueJanuary2033Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_StepDownNotesDueJanuary2033Member_28f34d73-b92a-4a84-a73c-02241f9db473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20335400InterestMember_3fd17c2c-95a9-4709-9f4e-12bc43453ed3" xlink:href="ci-20231231.xsd#ci_NotesDue20335400InterestMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue20335400InterestMember_3fd17c2c-95a9-4709-9f4e-12bc43453ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue2036615InterestMember_8eab6683-19ef-47ca-8678-ac54b7f95a6c" xlink:href="ci-20231231.xsd#ci_NotesDue2036615InterestMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue2036615InterestMember_8eab6683-19ef-47ca-8678-ac54b7f95a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue203848InterestMember_f245ed76-5ce2-45ff-8b3f-b4ca7ddf4275" xlink:href="ci-20231231.xsd#ci_NotesDue203848InterestMember"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue203848InterestMember_f245ed76-5ce2-45ff-8b3f-b4ca7ddf4275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue204032InterestMember_fbb9de83-e91e-4c66-bd6f-47d4dd55f0a2" xlink:href="ci-20231231.xsd#ci_NotesDue204032InterestMember"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue204032InterestMember_fbb9de83-e91e-4c66-bd6f-47d4dd55f0a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20415875InterestMember_2f46cf67-25c2-481e-8f06-f570b7c8bdf2" xlink:href="ci-20231231.xsd#ci_NotesDue20415875InterestMember"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue20415875InterestMember_2f46cf67-25c2-481e-8f06-f570b7c8bdf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20416125InterestMember_9ab259ea-9c53-4a31-baeb-744b893d0739" xlink:href="ci-20231231.xsd#ci_NotesDue20416125InterestMember"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue20416125InterestMember_9ab259ea-9c53-4a31-baeb-744b893d0739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20425375InterestMember_30d6242c-8ead-4b74-bec1-f81cbd9e0135" xlink:href="ci-20231231.xsd#ci_NotesDue20425375InterestMember"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue20425375InterestMember_30d6242c-8ead-4b74-bec1-f81cbd9e0135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue204648InterestMember_14eb3599-ece1-446c-8b3b-3916eb10f5ab" xlink:href="ci-20231231.xsd#ci_NotesDue204648InterestMember"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue204648InterestMember_14eb3599-ece1-446c-8b3b-3916eb10f5ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20473875Member_0ce71e42-352a-4039-b358-7b815da0f655" xlink:href="ci-20231231.xsd#ci_NotesDue20473875Member"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue20473875Member_0ce71e42-352a-4039-b358-7b815da0f655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue204849InterestMember_9ffaeb2e-0e1b-4723-be7a-40ff6ccbed81" xlink:href="ci-20231231.xsd#ci_NotesDue204849InterestMember"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue204849InterestMember_9ffaeb2e-0e1b-4723-be7a-40ff6ccbed81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue205034InterestMember_3996ec7a-492b-4556-a710-41bc8d0b347a" xlink:href="ci-20231231.xsd#ci_NotesDue205034InterestMember"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue205034InterestMember_3996ec7a-492b-4556-a710-41bc8d0b347a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue205134InterestMember_7d424d5c-23ee-41bd-ad37-ccfbf524bff0" xlink:href="ci-20231231.xsd#ci_NotesDue205134InterestMember"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_30f4f6fa-ad85-4756-83d5-4b95b5516c16" xlink:to="loc_ci_NotesDue205134InterestMember_7d424d5c-23ee-41bd-ad37-ccfbf524bff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_87cb89b0-3be7-4f1e-92ab-a75065ae7abb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b92bbfdc-7447-43de-a351-7ada1ad802a8" xlink:to="loc_us-gaap_DebtInstrumentLineItems_87cb89b0-3be7-4f1e-92ab-a75065ae7abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrentAbstract_b24ad6f5-1f0f-43b5-a94b-4ecd810d775b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_87cb89b0-3be7-4f1e-92ab-a75065ae7abb" xlink:to="loc_us-gaap_DebtCurrentAbstract_b24ad6f5-1f0f-43b5-a94b-4ecd810d775b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_fb39ec65-47d3-4182-b617-479e3b12b6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaper"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtCurrentAbstract_b24ad6f5-1f0f-43b5-a94b-4ecd810d775b" xlink:to="loc_us-gaap_CommercialPaper_fb39ec65-47d3-4182-b617-479e3b12b6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_8a157720-651a-4d44-a2ff-2d097368c4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtCurrentAbstract_b24ad6f5-1f0f-43b5-a94b-4ecd810d775b" xlink:to="loc_us-gaap_LongTermDebtCurrent_8a157720-651a-4d44-a2ff-2d097368c4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent_a28d3802-e99c-46a0-a03f-066f90823b1c" xlink:href="ci-20231231.xsd#ci_OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtCurrentAbstract_b24ad6f5-1f0f-43b5-a94b-4ecd810d775b" xlink:to="loc_ci_OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent_a28d3802-e99c-46a0-a03f-066f90823b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_c71b1106-4fb0-413c-a270-9e75428f69f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtCurrentAbstract_b24ad6f5-1f0f-43b5-a94b-4ecd810d775b" xlink:to="loc_us-gaap_DebtCurrent_c71b1106-4fb0-413c-a270-9e75428f69f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_e3bf7ed4-99f1-4390-88c3-4a62cb8307cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_87cb89b0-3be7-4f1e-92ab-a75065ae7abb" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_e3bf7ed4-99f1-4390-88c3-4a62cb8307cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_8eb49dca-de7e-453f-aac3-9a4f06c94e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_e3bf7ed4-99f1-4390-88c3-4a62cb8307cd" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_8eb49dca-de7e-453f-aac3-9a4f06c94e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebtNoncurrent_bec5a710-3ff7-4292-853e-98e915c31872" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_e3bf7ed4-99f1-4390-88c3-4a62cb8307cd" xlink:to="loc_us-gaap_OtherLongTermDebtNoncurrent_bec5a710-3ff7-4292-853e-98e915c31872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_4df93f1c-5251-4d6a-ad55-baf464138f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_e3bf7ed4-99f1-4390-88c3-4a62cb8307cd" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_4df93f1c-5251-4d6a-ad55-baf464138f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_be45b385-dae5-4fc1-8908-631c3525a3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_87cb89b0-3be7-4f1e-92ab-a75065ae7abb" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_be45b385-dae5-4fc1-8908-631c3525a3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_da890867-9fef-48ab-b41b-b20e628d6f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_87cb89b0-3be7-4f1e-92ab-a75065ae7abb" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_da890867-9fef-48ab-b41b-b20e628d6f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/DebtShorttermandCreditFacilitiesDebtDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#DebtShorttermandCreditFacilitiesDebtDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/DebtShorttermandCreditFacilitiesDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e5818b8c-ff28-4e46-b4b6-05fce9794e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_547f336d-259c-4a7e-bc94-7ecef6dc322c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e5818b8c-ff28-4e46-b4b6-05fce9794e3a" xlink:to="loc_us-gaap_DebtInstrumentTable_547f336d-259c-4a7e-bc94-7ecef6dc322c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_14bfd139-ad28-4200-97c2-edb26bb7ec47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_547f336d-259c-4a7e-bc94-7ecef6dc322c" xlink:to="loc_us-gaap_DebtInstrumentAxis_14bfd139-ad28-4200-97c2-edb26bb7ec47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6507db27-fe55-475e-9474-e7adedf6b153" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_14bfd139-ad28-4200-97c2-edb26bb7ec47" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6507db27-fe55-475e-9474-e7adedf6b153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RevolvingCreditAgreementsApril2023Member_983a43d9-ddfb-49a4-9dd1-a0afbdd5350c" xlink:href="ci-20231231.xsd#ci_RevolvingCreditAgreementsApril2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6507db27-fe55-475e-9474-e7adedf6b153" xlink:to="loc_ci_RevolvingCreditAgreementsApril2023Member_983a43d9-ddfb-49a4-9dd1-a0afbdd5350c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member_df9c889c-b6d7-42c3-8381-3db8eac24fad" xlink:href="ci-20231231.xsd#ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_RevolvingCreditAgreementsApril2023Member_983a43d9-ddfb-49a4-9dd1-a0afbdd5350c" xlink:to="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member_df9c889c-b6d7-42c3-8381-3db8eac24fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_A364DayRevolvingCreditAgreementMaturingApril2024Member_c13f798b-8769-43c2-8e5c-65e1f59448fe" xlink:href="ci-20231231.xsd#ci_A364DayRevolvingCreditAgreementMaturingApril2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_RevolvingCreditAgreementsApril2023Member_983a43d9-ddfb-49a4-9dd1-a0afbdd5350c" xlink:to="loc_ci_A364DayRevolvingCreditAgreementMaturingApril2024Member_c13f798b-8769-43c2-8e5c-65e1f59448fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member_423fea11-a153-41ec-89c3-2dd023af17c4" xlink:href="ci-20231231.xsd#ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6507db27-fe55-475e-9474-e7adedf6b153" xlink:to="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member_423fea11-a153-41ec-89c3-2dd023af17c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member_8614897e-7893-4673-957a-fa97120e17e5" xlink:href="ci-20231231.xsd#ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member_423fea11-a153-41ec-89c3-2dd023af17c4" xlink:to="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member_8614897e-7893-4673-957a-fa97120e17e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RevolvingCreditFacilityMaturingApril2025Member_8ed67b5a-90df-4b4d-8a07-e752953bdd6e" xlink:href="ci-20231231.xsd#ci_RevolvingCreditFacilityMaturingApril2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member_423fea11-a153-41ec-89c3-2dd023af17c4" xlink:to="loc_ci_RevolvingCreditFacilityMaturingApril2025Member_8ed67b5a-90df-4b4d-8a07-e752953bdd6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_A364DayRevolvingCreditAgreementMaturingApril2023Member_d1c0150d-e05f-49d6-ad34-fb0afab8e298" xlink:href="ci-20231231.xsd#ci_A364DayRevolvingCreditAgreementMaturingApril2023Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member_423fea11-a153-41ec-89c3-2dd023af17c4" xlink:to="loc_ci_A364DayRevolvingCreditAgreementMaturingApril2023Member_d1c0150d-e05f-49d6-ad34-fb0afab8e298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_54c50f33-0b69-4627-8602-0fada7d30365" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_547f336d-259c-4a7e-bc94-7ecef6dc322c" xlink:to="loc_us-gaap_CreditFacilityAxis_54c50f33-0b69-4627-8602-0fada7d30365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_44dd777f-52db-4a2e-a033-25c4dcbd4fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_54c50f33-0b69-4627-8602-0fada7d30365" xlink:to="loc_us-gaap_CreditFacilityDomain_44dd777f-52db-4a2e-a033-25c4dcbd4fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_7198325d-9e59-485a-86c1-b54cae2c63aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_44dd777f-52db-4a2e-a033-25c4dcbd4fd0" xlink:to="loc_us-gaap_LetterOfCreditMember_7198325d-9e59-485a-86c1-b54cae2c63aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_e895afa3-3088-4e7e-9479-371616ea4791" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_44dd777f-52db-4a2e-a033-25c4dcbd4fd0" xlink:to="loc_us-gaap_CommercialPaperMember_e895afa3-3088-4e7e-9479-371616ea4791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5fc3350f-1e00-4d3f-80df-1b5ab5fefda3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_547f336d-259c-4a7e-bc94-7ecef6dc322c" xlink:to="loc_us-gaap_DebtInstrumentLineItems_5fc3350f-1e00-4d3f-80df-1b5ab5fefda3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_0803aa09-f6d2-4a16-b9f5-ef270534f404" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fc3350f-1e00-4d3f-80df-1b5ab5fefda3" xlink:to="loc_us-gaap_LineOfCredit_0803aa09-f6d2-4a16-b9f5-ef270534f404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8859b231-aac2-4889-9829-02c7e5faf819" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fc3350f-1e00-4d3f-80df-1b5ab5fefda3" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8859b231-aac2-4889-9829-02c7e5faf819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_f6c1af6c-8371-408d-a423-5b43330c1f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fc3350f-1e00-4d3f-80df-1b5ab5fefda3" xlink:to="loc_us-gaap_DebtInstrumentTerm_f6c1af6c-8371-408d-a423-5b43330c1f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtInstrumentExtensionTerm_b0175ecd-319d-4c5a-ab48-31bef99acf7d" xlink:href="ci-20231231.xsd#ci_DebtInstrumentExtensionTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fc3350f-1e00-4d3f-80df-1b5ab5fefda3" xlink:to="loc_ci_DebtInstrumentExtensionTerm_b0175ecd-319d-4c5a-ab48-31bef99acf7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LineOfCreditFacilityConversionToTermLoanTerm_c42dc0b4-4278-4c4c-b374-0433e18eabc3" xlink:href="ci-20231231.xsd#ci_LineOfCreditFacilityConversionToTermLoanTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fc3350f-1e00-4d3f-80df-1b5ab5fefda3" xlink:to="loc_ci_LineOfCreditFacilityConversionToTermLoanTerm_c42dc0b4-4278-4c4c-b374-0433e18eabc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity_4cef702a-aeae-4ac8-98ce-f380bea3121e" xlink:href="ci-20231231.xsd#ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fc3350f-1e00-4d3f-80df-1b5ab5fefda3" xlink:to="loc_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity_4cef702a-aeae-4ac8-98ce-f380bea3121e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity_93a66266-26a7-48dc-a575-9811762291b8" xlink:href="ci-20231231.xsd#ci_LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fc3350f-1e00-4d3f-80df-1b5ab5fefda3" xlink:to="loc_ci_LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity_93a66266-26a7-48dc-a575-9811762291b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NumberOfRevolvingCreditFacility_673b4e06-1a79-41a6-aed8-7568728604f2" xlink:href="ci-20231231.xsd#ci_NumberOfRevolvingCreditFacility"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fc3350f-1e00-4d3f-80df-1b5ab5fefda3" xlink:to="loc_ci_NumberOfRevolvingCreditFacility_673b4e06-1a79-41a6-aed8-7568728604f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement_0db2a3b9-0443-4ff5-9c62-8f391266e771" xlink:href="ci-20231231.xsd#ci_NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fc3350f-1e00-4d3f-80df-1b5ab5fefda3" xlink:to="loc_ci_NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement_0db2a3b9-0443-4ff5-9c62-8f391266e771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant_98617731-8a11-4f59-b0ed-094bb2eb8110" xlink:href="ci-20231231.xsd#ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fc3350f-1e00-4d3f-80df-1b5ab5fefda3" xlink:to="loc_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant_98617731-8a11-4f59-b0ed-094bb2eb8110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CommercialPaperAverageRatePaid_54fec063-0983-4ca5-9819-6c6e664f065b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CommercialPaperAverageRatePaid"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5fc3350f-1e00-4d3f-80df-1b5ab5fefda3" xlink:to="loc_srt_CommercialPaperAverageRatePaid_54fec063-0983-4ca5-9819-6c6e664f065b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/DebtLongtermDebtDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#DebtLongtermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/DebtLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1783bde5-73a3-4937-a045-e303dd35ed05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1ae8a697-0d42-4cc3-8185-8b1d796f2ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1783bde5-73a3-4937-a045-e303dd35ed05" xlink:to="loc_us-gaap_DebtInstrumentTable_1ae8a697-0d42-4cc3-8185-8b1d796f2ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_037fb956-38f0-4971-8ff9-00ae209d15b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1ae8a697-0d42-4cc3-8185-8b1d796f2ff9" xlink:to="loc_us-gaap_DebtInstrumentAxis_037fb956-38f0-4971-8ff9-00ae209d15b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0e22b25a-33c6-4084-8ee9-d62e6bc32e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_037fb956-38f0-4971-8ff9-00ae209d15b3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0e22b25a-33c6-4084-8ee9-d62e6bc32e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20265685Member_c3f3cad8-5cff-44dc-a5a1-3fc971e0f0f3" xlink:href="ci-20231231.xsd#ci_NotesDue20265685Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0e22b25a-33c6-4084-8ee9-d62e6bc32e5d" xlink:to="loc_ci_NotesDue20265685Member_c3f3cad8-5cff-44dc-a5a1-3fc971e0f0f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20335400InterestMember_f0f3bfd5-22bf-4145-aa95-612f83854eba" xlink:href="ci-20231231.xsd#ci_NotesDue20335400InterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0e22b25a-33c6-4084-8ee9-d62e6bc32e5d" xlink:to="loc_ci_NotesDue20335400InterestMember_f0f3bfd5-22bf-4145-aa95-612f83854eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue202435InterestMember_c45438dc-b092-478c-96b1-4b1a570d26d2" xlink:href="ci-20231231.xsd#ci_NotesDue202435InterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0e22b25a-33c6-4084-8ee9-d62e6bc32e5d" xlink:to="loc_ci_NotesDue202435InterestMember_c45438dc-b092-478c-96b1-4b1a570d26d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_83485655-68bd-40ff-b16e-ee96350b815b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1ae8a697-0d42-4cc3-8185-8b1d796f2ff9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_83485655-68bd-40ff-b16e-ee96350b815b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ea182cd8-7797-45f7-9b46-15a68e308920" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_83485655-68bd-40ff-b16e-ee96350b815b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ea182cd8-7797-45f7-9b46-15a68e308920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_ff01b60e-0bf2-4a8c-9bf0-679bbd727e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ea182cd8-7797-45f7-9b46-15a68e308920" xlink:to="loc_us-gaap_SeniorNotesMember_ff01b60e-0bf2-4a8c-9bf0-679bbd727e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_bf663c6d-85f6-4a45-b150-630dbf038a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1ae8a697-0d42-4cc3-8185-8b1d796f2ff9" xlink:to="loc_us-gaap_VariableRateAxis_bf663c6d-85f6-4a45-b150-630dbf038a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_420eab64-0102-4118-a9a2-d48e999ac2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_bf663c6d-85f6-4a45-b150-630dbf038a5d" xlink:to="loc_us-gaap_VariableRateDomain_420eab64-0102-4118-a9a2-d48e999ac2eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UsTreasuryUstInterestRateMember_61d534fc-320b-4285-8d37-fe94a29c94aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UsTreasuryUstInterestRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_420eab64-0102-4118-a9a2-d48e999ac2eb" xlink:to="loc_us-gaap_UsTreasuryUstInterestRateMember_61d534fc-320b-4285-8d37-fe94a29c94aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_ee7cfff4-80c5-43ac-8fdb-b0b699dfad8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1ae8a697-0d42-4cc3-8185-8b1d796f2ff9" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_ee7cfff4-80c5-43ac-8fdb-b0b699dfad8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_629aaabf-3801-42a8-a8a6-ed6970cd71ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ee7cfff4-80c5-43ac-8fdb-b0b699dfad8e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_629aaabf-3801-42a8-a8a6-ed6970cd71ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_59205d4c-e2e2-44b2-89d1-6e929e3326e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_629aaabf-3801-42a8-a8a6-ed6970cd71ad" xlink:to="loc_us-gaap_SubsequentEventMember_59205d4c-e2e2-44b2-89d1-6e929e3326e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_fa696c47-d3c6-42db-a4db-a1ac95e2e238" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1ae8a697-0d42-4cc3-8185-8b1d796f2ff9" xlink:to="loc_srt_StatementScenarioAxis_fa696c47-d3c6-42db-a4db-a1ac95e2e238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_10474e20-edb8-4bf5-a810-33d403f8d58d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_fa696c47-d3c6-42db-a4db-a1ac95e2e238" xlink:to="loc_srt_ScenarioUnspecifiedDomain_10474e20-edb8-4bf5-a810-33d403f8d58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_3bbf3aab-ab55-4baf-b28d-68935e2b5616" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_10474e20-edb8-4bf5-a810-33d403f8d58d" xlink:to="loc_srt_ScenarioForecastMember_3bbf3aab-ab55-4baf-b28d-68935e2b5616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_91ee2108-8002-4a88-b1e0-63f0ebcb9dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1ae8a697-0d42-4cc3-8185-8b1d796f2ff9" xlink:to="loc_us-gaap_DebtInstrumentLineItems_91ee2108-8002-4a88-b1e0-63f0ebcb9dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e9ae7596-68fb-4d3d-9944-108e502fd1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91ee2108-8002-4a88-b1e0-63f0ebcb9dc6" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e9ae7596-68fb-4d3d-9944-108e502fd1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ace8d909-e6f5-4bf5-826e-88a19f8dd6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91ee2108-8002-4a88-b1e0-63f0ebcb9dc6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ace8d909-e6f5-4bf5-826e-88a19f8dd6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees_fe6eb714-826d-475c-939b-6ccd7ea5de3d" xlink:href="ci-20231231.xsd#ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91ee2108-8002-4a88-b1e0-63f0ebcb9dc6" xlink:to="loc_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees_fe6eb714-826d-475c-939b-6ccd7ea5de3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate_b47d03d5-3405-40fb-a74c-0c283c5459ba" xlink:href="ci-20231231.xsd#ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91ee2108-8002-4a88-b1e0-63f0ebcb9dc6" xlink:to="loc_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate_b47d03d5-3405-40fb-a74c-0c283c5459ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_133c0dcf-4efa-45e7-a443-32aaf3e93c69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91ee2108-8002-4a88-b1e0-63f0ebcb9dc6" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_133c0dcf-4efa-45e7-a443-32aaf3e93c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_22efe96a-a4f2-4e64-981e-9cbdb2028056" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91ee2108-8002-4a88-b1e0-63f0ebcb9dc6" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_22efe96a-a4f2-4e64-981e-9cbdb2028056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_GainLossOnExtinguishmentOfDebtNetOfTax_bf5b2376-da0e-49cf-893f-8cd609398729" xlink:href="ci-20231231.xsd#ci_GainLossOnExtinguishmentOfDebtNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91ee2108-8002-4a88-b1e0-63f0ebcb9dc6" xlink:to="loc_ci_GainLossOnExtinguishmentOfDebtNetOfTax_bf5b2376-da0e-49cf-893f-8cd609398729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_511d853d-e035-421b-9c8b-94c45ec07f77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91ee2108-8002-4a88-b1e0-63f0ebcb9dc6" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_511d853d-e035-421b-9c8b-94c45ec07f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_b545837e-793d-44ed-9ea6-8f72d8c88133" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91ee2108-8002-4a88-b1e0-63f0ebcb9dc6" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_b545837e-793d-44ed-9ea6-8f72d8c88133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/DebtDebtMaturitiesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#DebtDebtMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/DebtDebtMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8d6248a3-a326-45d7-a6b3-1c2d18e55493" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_38cd2099-2f79-40cd-8ffd-18e1331287c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8d6248a3-a326-45d7-a6b3-1c2d18e55493" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_38cd2099-2f79-40cd-8ffd-18e1331287c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e10895d5-29f8-4ed2-9c47-86f08b7faca5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_38cd2099-2f79-40cd-8ffd-18e1331287c9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e10895d5-29f8-4ed2-9c47-86f08b7faca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_b6d2c536-8360-478f-b99c-290d1b46cfc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_38cd2099-2f79-40cd-8ffd-18e1331287c9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_b6d2c536-8360-478f-b99c-290d1b46cfc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_6ea087a9-f492-4877-b40e-df102280a494" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_38cd2099-2f79-40cd-8ffd-18e1331287c9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_6ea087a9-f492-4877-b40e-df102280a494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_09eee422-b03e-474d-9390-174654435823" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_38cd2099-2f79-40cd-8ffd-18e1331287c9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_09eee422-b03e-474d-9390-174654435823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_9900962e-6fa6-4504-a90a-4ee17726cba4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_38cd2099-2f79-40cd-8ffd-18e1331287c9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_9900962e-6fa6-4504-a90a-4ee17726cba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_988e9555-321c-40e6-b01b-61e93cffb9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_38cd2099-2f79-40cd-8ffd-18e1331287c9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_988e9555-321c-40e6-b01b-61e93cffb9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/DebtInterestExpenseDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#DebtInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/DebtInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_99692f1e-3597-4950-92d5-09f21ce96347" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_c1cf0d49-4699-45bc-877c-2dbecaa1446b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_99692f1e-3597-4950-92d5-09f21ce96347" xlink:to="loc_us-gaap_InterestExpenseDebt_c1cf0d49-4699-45bc-877c-2dbecaa1446b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/CommonandPreferredStockShareActivityDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#CommonandPreferredStockShareActivityDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/CommonandPreferredStockShareActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_27032aca-8156-4615-8c7a-38586547b3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_5474ff1e-4312-455f-82ae-52643960f961" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_27032aca-8156-4615-8c7a-38586547b3f5" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_5474ff1e-4312-455f-82ae-52643960f961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d10fcffb-30b9-49c2-8cd8-f84b2e87960f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_27032aca-8156-4615-8c7a-38586547b3f5" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d10fcffb-30b9-49c2-8cd8-f84b2e87960f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3a471ea5-1eca-4480-a265-c1bc19260148" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_27032aca-8156-4615-8c7a-38586547b3f5" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3a471ea5-1eca-4480-a265-c1bc19260148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_dbdc9eff-b86c-4bc7-909e-f34f21ba5a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_27032aca-8156-4615-8c7a-38586547b3f5" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_dbdc9eff-b86c-4bc7-909e-f34f21ba5a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_45eacc78-bce4-4339-901a-6c6b5aa31b05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_dbdc9eff-b86c-4bc7-909e-f34f21ba5a2c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_45eacc78-bce4-4339-901a-6c6b5aa31b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3ce96ff7-4d81-4f2f-8315-a242e5989e35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_dbdc9eff-b86c-4bc7-909e-f34f21ba5a2c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3ce96ff7-4d81-4f2f-8315-a242e5989e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_df559d55-b003-4ed4-b27b-1ba1ebb7a677" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_27032aca-8156-4615-8c7a-38586547b3f5" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_df559d55-b003-4ed4-b27b-1ba1ebb7a677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d7a361f7-1bbf-4a3f-8f1c-d825ed028892" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_df559d55-b003-4ed4-b27b-1ba1ebb7a677" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d7a361f7-1bbf-4a3f-8f1c-d825ed028892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_48496881-de1e-4a97-b9b1-0f880f3e298d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_df559d55-b003-4ed4-b27b-1ba1ebb7a677" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_48496881-de1e-4a97-b9b1-0f880f3e298d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_138be32b-f30e-428c-8558-cbf01c225aed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_df559d55-b003-4ed4-b27b-1ba1ebb7a677" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_138be32b-f30e-428c-8558-cbf01c225aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7f483f5e-41ab-4e29-af57-80eb19b76af4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_df559d55-b003-4ed4-b27b-1ba1ebb7a677" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7f483f5e-41ab-4e29-af57-80eb19b76af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_9157c442-de08-4545-9c06-644c5c00d596" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_27032aca-8156-4615-8c7a-38586547b3f5" xlink:to="loc_us-gaap_TreasuryStockCommonShares_9157c442-de08-4545-9c06-644c5c00d596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_566719b7-f96d-48e2-a154-4062a4678d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_27032aca-8156-4615-8c7a-38586547b3f5" xlink:to="loc_us-gaap_CommonStockSharesIssued_566719b7-f96d-48e2-a154-4062a4678d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/CommonandPreferredStockDividendsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#CommonandPreferredStockDividendsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/CommonandPreferredStockDividendsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_50dd974f-692c-486b-9c71-3fd6738facd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_729e00d7-7eda-4f1a-821d-cab776e3926f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_50dd974f-692c-486b-9c71-3fd6738facd3" xlink:to="loc_us-gaap_SubsequentEventTable_729e00d7-7eda-4f1a-821d-cab776e3926f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a57b2b64-bdca-4c86-84b9-7adc2049b0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_729e00d7-7eda-4f1a-821d-cab776e3926f" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a57b2b64-bdca-4c86-84b9-7adc2049b0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_45c94795-a319-4331-8115-917c6eb9552e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a57b2b64-bdca-4c86-84b9-7adc2049b0f5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_45c94795-a319-4331-8115-917c6eb9552e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d1006b10-c5cc-4cff-a517-c510d8f488a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_45c94795-a319-4331-8115-917c6eb9552e" xlink:to="loc_us-gaap_SubsequentEventMember_d1006b10-c5cc-4cff-a517-c510d8f488a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_91240d03-cb38-408b-b712-1541717a9cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_729e00d7-7eda-4f1a-821d-cab776e3926f" xlink:to="loc_us-gaap_SubsequentEventLineItems_91240d03-cb38-408b-b712-1541717a9cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_ef29ff16-b42b-461f-88c2-40fa5ec2de53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_91240d03-cb38-408b-b712-1541717a9cdb" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_ef29ff16-b42b-461f-88c2-40fa5ec2de53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_cdac8c5d-2320-4c56-b9c4-5db1c5078122" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_50dd974f-692c-486b-9c71-3fd6738facd3" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_cdac8c5d-2320-4c56-b9c4-5db1c5078122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_68de6a13-7d28-4070-88a1-16ab4bb176d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_50dd974f-692c-486b-9c71-3fd6738facd3" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_68de6a13-7d28-4070-88a1-16ab4bb176d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/CommonandPreferredStockAcceleratedShareRepurchaseAgreementsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#CommonandPreferredStockAcceleratedShareRepurchaseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/CommonandPreferredStockAcceleratedShareRepurchaseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c65f2b01-dca4-4b0e-8559-f9f22fb8071b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesTable_b5a01be6-12e6-45b0-913e-56e057fe1144" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c65f2b01-dca4-4b0e-8559-f9f22fb8071b" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesTable_b5a01be6-12e6-45b0-913e-56e057fe1144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3a10647b-487a-4fd2-90f6-fbabe2d778c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesTable_b5a01be6-12e6-45b0-913e-56e057fe1144" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3a10647b-487a-4fd2-90f6-fbabe2d778c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f18d4c6a-3d65-4c6b-9342-69f09859405d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3a10647b-487a-4fd2-90f6-fbabe2d778c1" xlink:to="loc_us-gaap_EquityComponentDomain_f18d4c6a-3d65-4c6b-9342-69f09859405d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_41eaafa8-3c45-42a9-91c9-08faae4ca2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f18d4c6a-3d65-4c6b-9342-69f09859405d" xlink:to="loc_us-gaap_TreasuryStockCommonMember_41eaafa8-3c45-42a9-91c9-08faae4ca2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7debca7c-0b29-4e22-a55b-6d2c085dbb10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f18d4c6a-3d65-4c6b-9342-69f09859405d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7debca7c-0b29-4e22-a55b-6d2c085dbb10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4865ad6b-01ef-41e4-990a-d070dd014b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesTable_b5a01be6-12e6-45b0-913e-56e057fe1144" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4865ad6b-01ef-41e4-990a-d070dd014b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4a582dcb-51fa-428d-85a9-304359834b44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4865ad6b-01ef-41e4-990a-d070dd014b5e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4a582dcb-51fa-428d-85a9-304359834b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d1173319-4341-48a1-ba74-cdf38e7077bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4a582dcb-51fa-428d-85a9-304359834b44" xlink:to="loc_us-gaap_SubsequentEventMember_d1173319-4341-48a1-ba74-cdf38e7077bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesLineItems_2e42e2f4-403e-4aa8-a5fc-4e9ac7d902a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesTable_b5a01be6-12e6-45b0-913e-56e057fe1144" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesLineItems_2e42e2f4-403e-4aa8-a5fc-4e9ac7d902a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_304e3a2b-d730-461c-a22a-1508c7c5a075" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_2e42e2f4-403e-4aa8-a5fc-4e9ac7d902a0" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_304e3a2b-d730-461c-a22a-1508c7c5a075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_6e5de15e-8ac4-4f4e-94ec-0624d679b8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_2e42e2f4-403e-4aa8-a5fc-4e9ac7d902a0" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_6e5de15e-8ac4-4f4e-94ec-0624d679b8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_b347f6f6-ff1e-4908-9947-a9e405c6adb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_2e42e2f4-403e-4aa8-a5fc-4e9ac7d902a0" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_b347f6f6-ff1e-4908-9947-a9e405c6adb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_fad71771-dc4e-4e42-b99b-6352a8f1a1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_2e42e2f4-403e-4aa8-a5fc-4e9ac7d902a0" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_fad71771-dc4e-4e42-b99b-6352a8f1a1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AcceleratedShareRepurchasesVolumeWeightedAverageSharePriceLessDiscount_f50c7ef0-6c07-489c-be39-6156e3f67bef" xlink:href="ci-20231231.xsd#ci_AcceleratedShareRepurchasesVolumeWeightedAverageSharePriceLessDiscount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_2e42e2f4-403e-4aa8-a5fc-4e9ac7d902a0" xlink:to="loc_ci_AcceleratedShareRepurchasesVolumeWeightedAverageSharePriceLessDiscount_f50c7ef0-6c07-489c-be39-6156e3f67bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InsuranceandContractholderLiabilitiesAccountBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceLossReservesAbstract_ffaa5c87-ebcc-40d8-8fe9-1485d38b728f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceLossReservesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesTable_14d779d0-58cf-476b-a88b-43cfe2ebcb04" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceLossReservesAbstract_ffaa5c87-ebcc-40d8-8fe9-1485d38b728f" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesTable_14d779d0-58cf-476b-a88b-43cfe2ebcb04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_9cf9d419-0df1-492a-a083-c703995f7c23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesTable_14d779d0-58cf-476b-a88b-43cfe2ebcb04" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_9cf9d419-0df1-492a-a083-c703995f7c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_38bb23d7-6c70-4d3d-aeab-455aa8b2469d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9cf9d419-0df1-492a-a083-c703995f7c23" xlink:to="loc_us-gaap_SegmentDomain_38bb23d7-6c70-4d3d-aeab-455aa8b2469d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember_1d918370-798e-4ab2-8a1a-d64c2c5cd445" xlink:href="ci-20231231.xsd#ci_CignaHealthcareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_38bb23d7-6c70-4d3d-aeab-455aa8b2469d" xlink:to="loc_ci_CignaHealthcareMember_1d918370-798e-4ab2-8a1a-d64c2c5cd445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherOperationsSegmentMember_a5e81b8b-2270-4c32-a567-4e0261b586d0" xlink:href="ci-20231231.xsd#ci_OtherOperationsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_38bb23d7-6c70-4d3d-aeab-455aa8b2469d" xlink:to="loc_ci_OtherOperationsSegmentMember_a5e81b8b-2270-4c32-a567-4e0261b586d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_faf0b33e-b19b-4d7e-95e9-0dd8e0d346d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesTable_14d779d0-58cf-476b-a88b-43cfe2ebcb04" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_faf0b33e-b19b-4d7e-95e9-0dd8e0d346d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_0934a5a7-a99a-4109-9214-c1c12e7b3d35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_faf0b33e-b19b-4d7e-95e9-0dd8e0d346d8" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_0934a5a7-a99a-4109-9214-c1c12e7b3d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_e80ac8fd-73b3-47f4-b9db-a4cd56b97c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_0934a5a7-a99a-4109-9214-c1c12e7b3d35" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_e80ac8fd-73b3-47f4-b9db-a4cd56b97c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b544d375-6a1c-4a89-b358-61b0c166fc2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesTable_14d779d0-58cf-476b-a88b-43cfe2ebcb04" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b544d375-6a1c-4a89-b358-61b0c166fc2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3e2ac1e6-44fc-452e-a91a-2c6ff0b357ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b544d375-6a1c-4a89-b358-61b0c166fc2b" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3e2ac1e6-44fc-452e-a91a-2c6ff0b357ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_77116709-4ad1-4968-a134-84f4c217453f" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3e2ac1e6-44fc-452e-a91a-2c6ff0b357ce" xlink:to="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_77116709-4ad1-4968-a134-84f4c217453f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_df93e24c-edad-4bcb-8a18-5da813ae5778" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesTable_14d779d0-58cf-476b-a88b-43cfe2ebcb04" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_df93e24c-edad-4bcb-8a18-5da813ae5778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_229dddc4-1f2a-493d-98cc-a953e844ed2b" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_df93e24c-edad-4bcb-8a18-5da813ae5778" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_229dddc4-1f2a-493d-98cc-a953e844ed2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent_c33ee336-7aae-432e-8c42-0b5886cc80a7" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_229dddc4-1f2a-493d-98cc-a953e844ed2b" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent_c33ee336-7aae-432e-8c42-0b5886cc80a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrentIncludingDisposalGroups_51af779e-45fa-40f5-bf3b-705dcf962031" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrentIncludingDisposalGroups"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_229dddc4-1f2a-493d-98cc-a953e844ed2b" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrentIncludingDisposalGroups_51af779e-45fa-40f5-bf3b-705dcf962031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent_a6062824-1985-45fd-b683-e33bca8f0e82" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_229dddc4-1f2a-493d-98cc-a953e844ed2b" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent_a6062824-1985-45fd-b683-e33bca8f0e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitsCurrentIncludingDisposalGroups_4a36a5d7-cbf7-4540-9020-3b0e78257fe2" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitsCurrentIncludingDisposalGroups"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_229dddc4-1f2a-493d-98cc-a953e844ed2b" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitsCurrentIncludingDisposalGroups_4a36a5d7-cbf7-4540-9020-3b0e78257fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositCurrent_461927be-2a7a-466a-a883-7ef6bcbc10bc" xlink:href="ci-20231231.xsd#ci_PolicyholderContractDepositCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_229dddc4-1f2a-493d-98cc-a953e844ed2b" xlink:to="loc_ci_PolicyholderContractDepositCurrent_461927be-2a7a-466a-a883-7ef6bcbc10bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositCurrentIncludingDisposalGroups_a5fafb1b-f192-4402-ba2c-a7faf758baea" xlink:href="ci-20231231.xsd#ci_PolicyholderContractDepositCurrentIncludingDisposalGroups"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_229dddc4-1f2a-493d-98cc-a953e844ed2b" xlink:to="loc_ci_PolicyholderContractDepositCurrentIncludingDisposalGroups_a5fafb1b-f192-4402-ba2c-a7faf758baea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitLiabilityAmountCurrent_f36e9158-6fa5-40b6-9c0f-4154681a0ac2" xlink:href="ci-20231231.xsd#ci_MarketRiskBenefitLiabilityAmountCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_229dddc4-1f2a-493d-98cc-a953e844ed2b" xlink:to="loc_ci_MarketRiskBenefitLiabilityAmountCurrent_f36e9158-6fa5-40b6-9c0f-4154681a0ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsCurrent_e4afa7dd-722d-4ba2-ab22-fcbf4259182d" xlink:href="ci-20231231.xsd#ci_UnearnedPremiumsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_229dddc4-1f2a-493d-98cc-a953e844ed2b" xlink:to="loc_ci_UnearnedPremiumsCurrent_e4afa7dd-722d-4ba2-ab22-fcbf4259182d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsCurrentIncludingDisposalGroups_c15d4427-37d0-4eec-93f0-2d516d96ca3d" xlink:href="ci-20231231.xsd#ci_UnearnedPremiumsCurrentIncludingDisposalGroups"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_229dddc4-1f2a-493d-98cc-a953e844ed2b" xlink:to="loc_ci_UnearnedPremiumsCurrentIncludingDisposalGroups_c15d4427-37d0-4eec-93f0-2d516d96ca3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups_6f568bb1-633c-42e6-a2c7-f195ca9dbc6f" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_229dddc4-1f2a-493d-98cc-a953e844ed2b" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups_6f568bb1-633c-42e6-a2c7-f195ca9dbc6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInsuranceAndContractholderLiabilities_037d49aa-c472-431a-bf7a-087e9401bc66" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationCurrentInsuranceAndContractholderLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_229dddc4-1f2a-493d-98cc-a953e844ed2b" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInsuranceAndContractholderLiabilities_037d49aa-c472-431a-bf7a-087e9401bc66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesCurrent_3ff77f30-7b8a-4e67-b490-ae44593a1269" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract_229dddc4-1f2a-493d-98cc-a953e844ed2b" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesCurrent_3ff77f30-7b8a-4e67-b490-ae44593a1269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_914a1b11-a07e-4be1-9fcd-ff56addcda0a" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_df93e24c-edad-4bcb-8a18-5da813ae5778" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_914a1b11-a07e-4be1-9fcd-ff56addcda0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent_a2a1dfc6-5770-4389-89f6-93a4be4317e0" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_914a1b11-a07e-4be1-9fcd-ff56addcda0a" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent_a2a1dfc6-5770-4389-89f6-93a4be4317e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrentIncludingDisposalGroups_b372e2cb-ebe1-4676-99a1-59f0461fc5a5" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrentIncludingDisposalGroups"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_914a1b11-a07e-4be1-9fcd-ff56addcda0a" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrentIncludingDisposalGroups_b372e2cb-ebe1-4676-99a1-59f0461fc5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent_c0c6faf4-21d4-497d-be07-94e340653933" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_914a1b11-a07e-4be1-9fcd-ff56addcda0a" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent_c0c6faf4-21d4-497d-be07-94e340653933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitsNoncurrentIncludingDisposalGroups_3047fc46-ed9f-4c15-863a-6c603f65d920" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitsNoncurrentIncludingDisposalGroups"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_914a1b11-a07e-4be1-9fcd-ff56addcda0a" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitsNoncurrentIncludingDisposalGroups_3047fc46-ed9f-4c15-863a-6c603f65d920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositNoncurrent_d6bb15d0-9839-4379-950e-64eeb84f755d" xlink:href="ci-20231231.xsd#ci_PolicyholderContractDepositNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_914a1b11-a07e-4be1-9fcd-ff56addcda0a" xlink:to="loc_ci_PolicyholderContractDepositNoncurrent_d6bb15d0-9839-4379-950e-64eeb84f755d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositNoncurrentIncludingDisposalGroups_65ee050c-c5b9-468b-ac47-d719a9e83212" xlink:href="ci-20231231.xsd#ci_PolicyholderContractDepositNoncurrentIncludingDisposalGroups"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_914a1b11-a07e-4be1-9fcd-ff56addcda0a" xlink:to="loc_ci_PolicyholderContractDepositNoncurrentIncludingDisposalGroups_65ee050c-c5b9-468b-ac47-d719a9e83212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitLiabilityAmountNoncurrent_8e55709f-ba70-4cc0-b7d1-86da3c562ddc" xlink:href="ci-20231231.xsd#ci_MarketRiskBenefitLiabilityAmountNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_914a1b11-a07e-4be1-9fcd-ff56addcda0a" xlink:to="loc_ci_MarketRiskBenefitLiabilityAmountNoncurrent_8e55709f-ba70-4cc0-b7d1-86da3c562ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsNoncurrent_2032c77d-a2a7-4515-8777-466d868cf56c" xlink:href="ci-20231231.xsd#ci_UnearnedPremiumsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_914a1b11-a07e-4be1-9fcd-ff56addcda0a" xlink:to="loc_ci_UnearnedPremiumsNoncurrent_2032c77d-a2a7-4515-8777-466d868cf56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsNoncurrentIncludingDisposalGroups_a6688c36-7f3d-4483-ad5b-631ca8ff4aba" xlink:href="ci-20231231.xsd#ci_UnearnedPremiumsNoncurrentIncludingDisposalGroups"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_914a1b11-a07e-4be1-9fcd-ff56addcda0a" xlink:to="loc_ci_UnearnedPremiumsNoncurrentIncludingDisposalGroups_a6688c36-7f3d-4483-ad5b-631ca8ff4aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups_04310084-8a62-43d8-bacc-cd75c4b7be75" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_914a1b11-a07e-4be1-9fcd-ff56addcda0a" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups_04310084-8a62-43d8-bacc-cd75c4b7be75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInsuranceAndContractholderLiabilities_77b13b28-6c44-4eba-ac9b-731a2b621947" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInsuranceAndContractholderLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_914a1b11-a07e-4be1-9fcd-ff56addcda0a" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInsuranceAndContractholderLiabilities_77b13b28-6c44-4eba-ac9b-731a2b621947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent_9d09fb84-bacd-4b55-a59a-49a2bccbd0c8" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract_914a1b11-a07e-4be1-9fcd-ff56addcda0a" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesNoncurrent_9d09fb84-bacd-4b55-a59a-49a2bccbd0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_2b751012-01d4-4bea-83dc-f20f81dff4a3" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_df93e24c-edad-4bcb-8a18-5da813ae5778" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_2b751012-01d4-4bea-83dc-f20f81dff4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_bd36a74e-3bbb-4e02-805f-26b52403b417" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_2b751012-01d4-4bea-83dc-f20f81dff4a3" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_bd36a74e-3bbb-4e02-805f-26b52403b417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_6a659029-7370-43ce-a67b-075c7a847047" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_2b751012-01d4-4bea-83dc-f20f81dff4a3" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_6a659029-7370-43ce-a67b-075c7a847047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefits_78c3976e-140a-4f06-8777-1fa82c4ba13c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_2b751012-01d4-4bea-83dc-f20f81dff4a3" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefits_78c3976e-140a-4f06-8777-1fa82c4ba13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitsIncludingDisposalGroups_5e1c5d98-b1d1-487b-a144-120710ce738c" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitsIncludingDisposalGroups"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_2b751012-01d4-4bea-83dc-f20f81dff4a3" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitsIncludingDisposalGroups_5e1c5d98-b1d1-487b-a144-120710ce738c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderContractDeposits_1260fb6c-1908-4938-a39a-6e4f1ce4bb59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderContractDeposits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_2b751012-01d4-4bea-83dc-f20f81dff4a3" xlink:to="loc_us-gaap_PolicyholderContractDeposits_1260fb6c-1908-4938-a39a-6e4f1ce4bb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositsIncludingDisposalGroups_44597fa9-5540-43e7-8c83-549f329d2c02" xlink:href="ci-20231231.xsd#ci_PolicyholderContractDepositsIncludingDisposalGroups"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_2b751012-01d4-4bea-83dc-f20f81dff4a3" xlink:to="loc_ci_PolicyholderContractDepositsIncludingDisposalGroups_44597fa9-5540-43e7-8c83-549f329d2c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitLiabilityAmount_f77d7b81-3a37-4a95-9f16-304138adb3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketRiskBenefitLiabilityAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_2b751012-01d4-4bea-83dc-f20f81dff4a3" xlink:to="loc_us-gaap_MarketRiskBenefitLiabilityAmount_f77d7b81-3a37-4a95-9f16-304138adb3c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnearnedPremiums_e637e315-59ad-48f1-bd8f-de223aad538f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnearnedPremiums"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_2b751012-01d4-4bea-83dc-f20f81dff4a3" xlink:to="loc_us-gaap_UnearnedPremiums_e637e315-59ad-48f1-bd8f-de223aad538f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsIncludingDisposalGroups_1dbcdfbb-ea9a-4b5f-a662-cdb1939b65a5" xlink:href="ci-20231231.xsd#ci_UnearnedPremiumsIncludingDisposalGroups"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_2b751012-01d4-4bea-83dc-f20f81dff4a3" xlink:to="loc_ci_UnearnedPremiumsIncludingDisposalGroups_1dbcdfbb-ea9a-4b5f-a662-cdb1939b65a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups_a8e269ea-b046-44f5-8c46-a11b6400fa11" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_2b751012-01d4-4bea-83dc-f20f81dff4a3" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups_a8e269ea-b046-44f5-8c46-a11b6400fa11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities_a3f98794-e8a7-469b-ad34-a016401b9b2d" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_2b751012-01d4-4bea-83dc-f20f81dff4a3" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities_a3f98794-e8a7-469b-ad34-a016401b9b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilities_67c1b32b-5c14-4f35-ba90-a2cda681d025" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesAbstract_2b751012-01d4-4bea-83dc-f20f81dff4a3" xlink:to="loc_ci_InsuranceAndContractholderLiabilities_67c1b32b-5c14-4f35-ba90-a2cda681d025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups_8bc86b5b-8164-4c1b-85f6-64a44cc8de22" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_df93e24c-edad-4bcb-8a18-5da813ae5778" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups_8bc86b5b-8164-4c1b-85f6-64a44cc8de22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups_a58f96bf-d2b0-4e2b-a8ad-0611603bb774" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_df93e24c-edad-4bcb-8a18-5da813ae5778" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups_a58f96bf-d2b0-4e2b-a8ad-0611603bb774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnearnedPremiumsAttributableToDisposalGroups_4bff3abb-3aa6-45f6-add1-e9382791edd9" xlink:href="ci-20231231.xsd#ci_UnearnedPremiumsAttributableToDisposalGroups"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_df93e24c-edad-4bcb-8a18-5da813ae5778" xlink:to="loc_ci_UnearnedPremiumsAttributableToDisposalGroups_4bff3abb-3aa6-45f6-add1-e9382791edd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractDepositsAttributableToDisposalGroups_9574bc20-418f-4875-b2ec-09a0e3a5f931" xlink:href="ci-20231231.xsd#ci_PolicyholderContractDepositsAttributableToDisposalGroups"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_df93e24c-edad-4bcb-8a18-5da813ae5778" xlink:to="loc_ci_PolicyholderContractDepositsAttributableToDisposalGroups_9574bc20-418f-4875-b2ec-09a0e3a5f931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails_1" xlink:type="simple" xlink:href="ci-20231231.xsd#InsuranceandContractholderLiabilitiesAccountBalancesDetails_1"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails_2" xlink:type="simple" xlink:href="ci-20231231.xsd#InsuranceandContractholderLiabilitiesAccountBalancesDetails_2"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails_2" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceLossReservesAbstract_189ea67f-8a1f-4f8f-825c-2111b8b74f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceLossReservesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_943cf325-e91c-4f77-a9ea-393d9f2fc081" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceLossReservesAbstract_189ea67f-8a1f-4f8f-825c-2111b8b74f5d" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_943cf325-e91c-4f77-a9ea-393d9f2fc081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1ede6328-852a-4481-9a84-fe7525b1f734" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_943cf325-e91c-4f77-a9ea-393d9f2fc081" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1ede6328-852a-4481-9a84-fe7525b1f734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fc28f75b-8fa0-44b8-8f7f-56bbc820650f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1ede6328-852a-4481-9a84-fe7525b1f734" xlink:to="loc_us-gaap_SegmentDomain_fc28f75b-8fa0-44b8-8f7f-56bbc820650f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember_ea7fda5c-5e23-480e-a36a-0f0f2e3674af" xlink:href="ci-20231231.xsd#ci_CignaHealthcareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_fc28f75b-8fa0-44b8-8f7f-56bbc820650f" xlink:to="loc_ci_CignaHealthcareMember_ea7fda5c-5e23-480e-a36a-0f0f2e3674af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_f5b498e1-b741-40f2-96e6-944bb4434460" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_943cf325-e91c-4f77-a9ea-393d9f2fc081" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_f5b498e1-b741-40f2-96e6-944bb4434460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_6bd0f982-f8e9-406e-b583-dd17084cf6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f5b498e1-b741-40f2-96e6-944bb4434460" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_6bd0f982-f8e9-406e-b583-dd17084cf6f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_14a91f79-5cfa-4c35-a12b-95a03334a79d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_6bd0f982-f8e9-406e-b583-dd17084cf6f0" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_14a91f79-5cfa-4c35-a12b-95a03334a79d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3fdac428-b093-4800-b6a4-6b840e564d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_943cf325-e91c-4f77-a9ea-393d9f2fc081" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3fdac428-b093-4800-b6a4-6b840e564d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_64e2c88e-cb6a-47f1-bb8f-bf6eae619254" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3fdac428-b093-4800-b6a4-6b840e564d9a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_64e2c88e-cb6a-47f1-bb8f-bf6eae619254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_01057672-0f99-41ab-ac4d-d725d13a1b31" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_64e2c88e-cb6a-47f1-bb8f-bf6eae619254" xlink:to="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_01057672-0f99-41ab-ac4d-d725d13a1b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_f5e6cd1b-2bb6-49df-8a69-ad28ce6daf40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_943cf325-e91c-4f77-a9ea-393d9f2fc081" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_f5e6cd1b-2bb6-49df-8a69-ad28ce6daf40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses_bd214679-959b-45b4-b53e-4c28af5cda13" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_f5e6cd1b-2bb6-49df-8a69-ad28ce6daf40" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses_bd214679-959b-45b4-b53e-4c28af5cda13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_50e54382-f5ac-4b17-a080-4c6552315175" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_f5e6cd1b-2bb6-49df-8a69-ad28ce6daf40" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_50e54382-f5ac-4b17-a080-4c6552315175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_1e64b94d-eb5c-4286-be2c-ce8f1ac01aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_50e54382-f5ac-4b17-a080-4c6552315175" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_1e64b94d-eb5c-4286-be2c-ce8f1ac01aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_65368357-e6c8-4a10-87b0-15cbc9cc5dff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_50e54382-f5ac-4b17-a080-4c6552315175" xlink:to="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_65368357-e6c8-4a10-87b0-15cbc9cc5dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_8aa77910-5a84-4004-86f4-3a61a26427ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_50e54382-f5ac-4b17-a080-4c6552315175" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_8aa77910-5a84-4004-86f4-3a61a26427ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_086b0b21-7804-467b-841a-8948d707daf0" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_50e54382-f5ac-4b17-a080-4c6552315175" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_086b0b21-7804-467b-841a-8948d707daf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups_0e224b19-9b18-46a5-afb0-362393bdbc13" xlink:href="ci-20231231.xsd#ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_50e54382-f5ac-4b17-a080-4c6552315175" xlink:to="loc_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups_0e224b19-9b18-46a5-afb0-362393bdbc13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_f4409300-df26-4473-afa8-cecd5c2257c5" xlink:href="ci-20231231.xsd#ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_50e54382-f5ac-4b17-a080-4c6552315175" xlink:to="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_f4409300-df26-4473-afa8-cecd5c2257c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_bcd75c0d-6357-40f9-b2d1-df2e139691ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_50e54382-f5ac-4b17-a080-4c6552315175" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_bcd75c0d-6357-40f9-b2d1-df2e139691ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_8b47d5d4-c059-4a9c-a7d6-644d6137fccc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_bcd75c0d-6357-40f9-b2d1-df2e139691ec" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_8b47d5d4-c059-4a9c-a7d6-644d6137fccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_8fe1941e-4385-4590-9b1a-291ae4809dce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_bcd75c0d-6357-40f9-b2d1-df2e139691ec" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_8fe1941e-4385-4590-9b1a-291ae4809dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_eaf98e0c-1ad0-41fd-b104-8c83fd1e940d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_bcd75c0d-6357-40f9-b2d1-df2e139691ec" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_eaf98e0c-1ad0-41fd-b104-8c83fd1e940d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_eed8d682-33f6-4af8-b3d9-5941b5259e94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_50e54382-f5ac-4b17-a080-4c6552315175" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_eed8d682-33f6-4af8-b3d9-5941b5259e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_53470baa-6546-40f6-b1dd-e0a4211d9f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_eed8d682-33f6-4af8-b3d9-5941b5259e94" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_53470baa-6546-40f6-b1dd-e0a4211d9f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_927dbd2b-1be2-41df-9ccb-a20d3a8d3d13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_eed8d682-33f6-4af8-b3d9-5941b5259e94" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_927dbd2b-1be2-41df-9ccb-a20d3a8d3d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_accdb0cb-64da-4324-8b52-b6c5d9491727" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_eed8d682-33f6-4af8-b3d9-5941b5259e94" xlink:to="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_accdb0cb-64da-4324-8b52-b6c5d9491727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_3e0c5928-b507-4df9-94ea-b507e2a77edf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_50e54382-f5ac-4b17-a080-4c6552315175" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_3e0c5928-b507-4df9-94ea-b507e2a77edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_c7b66a3b-2496-4729-94d0-9a4b861cc948" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_50e54382-f5ac-4b17-a080-4c6552315175" xlink:to="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_c7b66a3b-2496-4729-94d0-9a4b861cc948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_9248cd7a-d7bc-447b-922a-887187f7cdfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_50e54382-f5ac-4b17-a080-4c6552315175" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_9248cd7a-d7bc-447b-922a-887187f7cdfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_361ebc5c-5b1d-448b-afd2-fb4bcd04927f" xlink:href="ci-20231231.xsd#ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_50e54382-f5ac-4b17-a080-4c6552315175" xlink:to="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_361ebc5c-5b1d-448b-afd2-fb4bcd04927f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups_2dad7600-ea29-4ac8-92a1-2e69fec13538" xlink:href="ci-20231231.xsd#ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_50e54382-f5ac-4b17-a080-4c6552315175" xlink:to="loc_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups_2dad7600-ea29-4ac8-92a1-2e69fec13538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_6e5e2092-0951-4afc-942a-78266dd4c527" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_50e54382-f5ac-4b17-a080-4c6552315175" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_6e5e2092-0951-4afc-942a-78266dd4c527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups_2bf79a63-c813-479f-be38-430e7a1ef986" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_50e54382-f5ac-4b17-a080-4c6552315175" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups_2bf79a63-c813-479f-be38-430e7a1ef986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceLossReservesAbstract_b39682cf-4885-4868-a289-fd9a57ba443b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceLossReservesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_a5b0df87-ce62-4a9b-8364-e48180186423" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceLossReservesAbstract_b39682cf-4885-4868-a289-fd9a57ba443b" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_a5b0df87-ce62-4a9b-8364-e48180186423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_6bcaa5d6-f64d-4684-aef4-d75be6c5446a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_a5b0df87-ce62-4a9b-8364-e48180186423" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_6bcaa5d6-f64d-4684-aef4-d75be6c5446a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_aa2a178c-a256-4d1e-97fe-bdd6d4b5ad65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6bcaa5d6-f64d-4684-aef4-d75be6c5446a" xlink:to="loc_us-gaap_SegmentDomain_aa2a178c-a256-4d1e-97fe-bdd6d4b5ad65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember_9586e2d6-7ea5-447e-9ea8-0c0d8cfc4e88" xlink:href="ci-20231231.xsd#ci_CignaHealthcareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_aa2a178c-a256-4d1e-97fe-bdd6d4b5ad65" xlink:to="loc_ci_CignaHealthcareMember_9586e2d6-7ea5-447e-9ea8-0c0d8cfc4e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncatastrophicEventAxis_57221361-49b0-4a9b-a11d-e73c19c4316f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncatastrophicEventAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_a5b0df87-ce62-4a9b-8364-e48180186423" xlink:to="loc_us-gaap_NoncatastrophicEventAxis_57221361-49b0-4a9b-a11d-e73c19c4316f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncatastrophicEventDomain_402f0a28-5745-48f5-85bd-150ea037de7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncatastrophicEventDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncatastrophicEventAxis_57221361-49b0-4a9b-a11d-e73c19c4316f" xlink:to="loc_us-gaap_NoncatastrophicEventDomain_402f0a28-5745-48f5-85bd-150ea037de7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CompletionFactorsMember_bea9dc7e-c924-403a-acce-573bb8061ee3" xlink:href="ci-20231231.xsd#ci_CompletionFactorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncatastrophicEventDomain_402f0a28-5745-48f5-85bd-150ea037de7c" xlink:to="loc_ci_CompletionFactorsMember_bea9dc7e-c924-403a-acce-573bb8061ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicalCostTrendMember_3e5c06cc-b228-4d9b-a052-c9efc0a9e9c5" xlink:href="ci-20231231.xsd#ci_MedicalCostTrendMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncatastrophicEventDomain_402f0a28-5745-48f5-85bd-150ea037de7c" xlink:to="loc_ci_MedicalCostTrendMember_3e5c06cc-b228-4d9b-a052-c9efc0a9e9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_6ce79b47-38e4-49a6-adb6-d542990d341f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_a5b0df87-ce62-4a9b-8364-e48180186423" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_6ce79b47-38e4-49a6-adb6-d542990d341f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_1ce676ff-c954-46e8-a6b1-048c84aac9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_6ce79b47-38e4-49a6-adb6-d542990d341f" xlink:to="loc_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_1ce676ff-c954-46e8-a6b1-048c84aac9e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_96373b64-636c-4a2e-a5be-a9e9a40384aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_1ce676ff-c954-46e8-a6b1-048c84aac9e2" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_96373b64-636c-4a2e-a5be-a9e9a40384aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage_c4d18dd2-965e-46f4-8daf-9cd6ed3c29ce" xlink:href="ci-20231231.xsd#ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_1ce676ff-c954-46e8-a6b1-048c84aac9e2" xlink:to="loc_ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage_c4d18dd2-965e-46f4-8daf-9cd6ed3c29ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_3ae0fc09-0713-40b6-95eb-f706c3e24e07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_320c9398-9776-4f58-ab51-01fb61e82afc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_3ae0fc09-0713-40b6-95eb-f706c3e24e07" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_320c9398-9776-4f58-ab51-01fb61e82afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_61ba94e1-0a3c-42f6-855e-13f9f1e1354e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_320c9398-9776-4f58-ab51-01fb61e82afc" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_61ba94e1-0a3c-42f6-855e-13f9f1e1354e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b45527ab-d83f-4dfb-bbb9-3d96655df6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_61ba94e1-0a3c-42f6-855e-13f9f1e1354e" xlink:to="loc_us-gaap_SegmentDomain_b45527ab-d83f-4dfb-bbb9-3d96655df6cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember_2428738f-6a9e-4069-b1a2-154af4f1873a" xlink:href="ci-20231231.xsd#ci_CignaHealthcareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b45527ab-d83f-4dfb-bbb9-3d96655df6cd" xlink:to="loc_ci_CignaHealthcareMember_2428738f-6a9e-4069-b1a2-154af4f1873a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_483ebcb1-656d-401f-b72f-8f6ae442c811" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_320c9398-9776-4f58-ab51-01fb61e82afc" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_483ebcb1-656d-401f-b72f-8f6ae442c811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_c5810afd-b7c1-49ad-b590-121c83d1848b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_483ebcb1-656d-401f-b72f-8f6ae442c811" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_c5810afd-b7c1-49ad-b590-121c83d1848b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member_600f9937-88b5-4454-97b2-5b7b88f275fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_c5810afd-b7c1-49ad-b590-121c83d1848b" xlink:to="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member_600f9937-88b5-4454-97b2-5b7b88f275fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2023Member_b0468eca-271a-4d3c-9b53-c34f0b905cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_c5810afd-b7c1-49ad-b590-121c83d1848b" xlink:to="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2023Member_b0468eca-271a-4d3c-9b53-c34f0b905cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClaimsDevelopmentLineItems_1350537e-166d-465d-a520-03c7665095bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClaimsDevelopmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_320c9398-9776-4f58-ab51-01fb61e82afc" xlink:to="loc_us-gaap_ClaimsDevelopmentLineItems_1350537e-166d-465d-a520-03c7665095bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_8028705b-1d49-4bcf-a8cc-1a48b460e755" xlink:href="ci-20231231.xsd#ci_ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_1350537e-166d-465d-a520-03c7665095bd" xlink:to="loc_ci_ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_8028705b-1d49-4bcf-a8cc-1a48b460e755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_ec00d6e1-2769-49af-bb54-838f72076c58" xlink:href="ci-20231231.xsd#ci_ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_1350537e-166d-465d-a520-03c7665095bd" xlink:to="loc_ci_ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_ec00d6e1-2769-49af-bb54-838f72076c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_9ca96bd8-23cb-49ad-8297-1cf73fbcad5c" xlink:href="ci-20231231.xsd#ci_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_1350537e-166d-465d-a520-03c7665095bd" xlink:to="loc_ci_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_9ca96bd8-23cb-49ad-8297-1cf73fbcad5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseLongDurationNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_c407f65d-fd09-4a92-b4ea-ca2c4eb9cf8b" xlink:href="ci-20231231.xsd#ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseLongDurationNetBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_1350537e-166d-465d-a520-03c7665095bd" xlink:to="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseLongDurationNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_c407f65d-fd09-4a92-b4ea-ca2c4eb9cf8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_8d799857-c82d-414e-a16c-08df4161aae9" xlink:href="ci-20231231.xsd#ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_1350537e-166d-465d-a520-03c7665095bd" xlink:to="loc_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups_8d799857-c82d-414e-a16c-08df4161aae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups_afdd1317-0504-4861-a2f4-5e04a368f2b7" xlink:href="ci-20231231.xsd#ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_1350537e-166d-465d-a520-03c7665095bd" xlink:to="loc_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups_afdd1317-0504-4861-a2f4-5e04a368f2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_de11bf54-fd1e-442b-a6d7-cbbd72a428f3" xlink:href="ci-20231231.xsd#ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_1350537e-166d-465d-a520-03c7665095bd" xlink:to="loc_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups_de11bf54-fd1e-442b-a6d7-cbbd72a428f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsHistoricalClaimsDurationYearOne_7f5881ea-b68d-44e8-95b8-1c1152769449" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsHistoricalClaimsDurationYearOne"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_1350537e-166d-465d-a520-03c7665095bd" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsHistoricalClaimsDurationYearOne_7f5881ea-b68d-44e8-95b8-1c1152769449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortdurationInsuranceContractsNumberOfPaidClaims_39bf2673-e91e-43f6-9f9f-a5363b3ec043" xlink:href="ci-20231231.xsd#ci_ShortdurationInsuranceContractsNumberOfPaidClaims"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_1350537e-166d-465d-a520-03c7665095bd" xlink:to="loc_ci_ShortdurationInsuranceContractsNumberOfPaidClaims_39bf2673-e91e-43f6-9f9f-a5363b3ec043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsInterestRatesandDurationDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InsuranceandContractholderLiabilitiesFuturePolicyBenefitsInterestRatesandDurationDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsInterestRatesandDurationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_bd62f7de-85f3-4018-a11b-eae6d0628c82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesTable_a7504327-8e88-4ef6-9c0e-b2b3b9a0b4ee" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_bd62f7de-85f3-4018-a11b-eae6d0628c82" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesTable_a7504327-8e88-4ef6-9c0e-b2b3b9a0b4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_964694ae-43da-4a62-91e0-59dec087d183" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesTable_a7504327-8e88-4ef6-9c0e-b2b3b9a0b4ee" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_964694ae-43da-4a62-91e0-59dec087d183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0dde4536-854f-4b56-8742-8b2f457ba3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_964694ae-43da-4a62-91e0-59dec087d183" xlink:to="loc_us-gaap_SegmentDomain_0dde4536-854f-4b56-8742-8b2f457ba3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember_a09dfb53-792d-4c0b-bdf3-85be800bca7e" xlink:href="ci-20231231.xsd#ci_CignaHealthcareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0dde4536-854f-4b56-8742-8b2f457ba3b7" xlink:to="loc_ci_CignaHealthcareMember_a09dfb53-792d-4c0b-bdf3-85be800bca7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherOperationsSegmentMember_3dfa8c5d-e39d-44f1-8c19-cbf1e99efbe1" xlink:href="ci-20231231.xsd#ci_OtherOperationsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0dde4536-854f-4b56-8742-8b2f457ba3b7" xlink:to="loc_ci_OtherOperationsSegmentMember_3dfa8c5d-e39d-44f1-8c19-cbf1e99efbe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3077296d-ef39-4932-b4f1-c4f2405b4e87" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesTable_a7504327-8e88-4ef6-9c0e-b2b3b9a0b4ee" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3077296d-ef39-4932-b4f1-c4f2405b4e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate_3a090480-d556-43ae-8e77-d77f5dadfb0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3077296d-ef39-4932-b4f1-c4f2405b4e87" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate_3a090480-d556-43ae-8e77-d77f5dadfb0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate_14c030bd-94fb-491d-b3cc-675504d46a81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3077296d-ef39-4932-b4f1-c4f2405b4e87" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate_14c030bd-94fb-491d-b3cc-675504d46a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration_534716e3-d853-44bc-848e-652ed113dbaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3077296d-ef39-4932-b4f1-c4f2405b4e87" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration_534716e3-d853-44bc-848e-652ed113dbaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_14bd98ae-b7c6-4308-a714-9a94df5825d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesTable_0e635474-8e0d-4339-a995-8b0da9ff4200" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_14bd98ae-b7c6-4308-a714-9a94df5825d5" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesTable_0e635474-8e0d-4339-a995-8b0da9ff4200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d43a8536-a105-4117-8e95-c438286102d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesTable_0e635474-8e0d-4339-a995-8b0da9ff4200" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d43a8536-a105-4117-8e95-c438286102d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_883e9428-230c-4d23-9d41-c1ae384cadd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d43a8536-a105-4117-8e95-c438286102d5" xlink:to="loc_us-gaap_SegmentDomain_883e9428-230c-4d23-9d41-c1ae384cadd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember_e9721e9d-23ff-45d4-8375-42829f8bcd05" xlink:href="ci-20231231.xsd#ci_CignaHealthcareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_883e9428-230c-4d23-9d41-c1ae384cadd3" xlink:to="loc_ci_CignaHealthcareMember_e9721e9d-23ff-45d4-8375-42829f8bcd05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherOperationsSegmentMember_05afed99-6c12-4cb3-8e60-8f234513c4b2" xlink:href="ci-20231231.xsd#ci_OtherOperationsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_883e9428-230c-4d23-9d41-c1ae384cadd3" xlink:to="loc_ci_OtherOperationsSegmentMember_05afed99-6c12-4cb3-8e60-8f234513c4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_522c3e85-8c9d-473c-9c47-3089ffdbe821" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesTable_0e635474-8e0d-4339-a995-8b0da9ff4200" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_522c3e85-8c9d-473c-9c47-3089ffdbe821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ea7967b4-64e8-4f05-8376-b3b3e3c57f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_522c3e85-8c9d-473c-9c47-3089ffdbe821" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ea7967b4-64e8-4f05-8376-b3b3e3c57f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_f1548435-6f02-49e2-97ce-9781ae3e4982" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_ea7967b4-64e8-4f05-8376-b3b3e3c57f0b" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_f1548435-6f02-49e2-97ce-9781ae3e4982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_d13cb9f1-0f75-4e35-88df-0f58940f458a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_ea7967b4-64e8-4f05-8376-b3b3e3c57f0b" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_d13cb9f1-0f75-4e35-88df-0f58940f458a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8256806d-6555-4cd4-b829-00e4914072ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesTable_0e635474-8e0d-4339-a995-8b0da9ff4200" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8256806d-6555-4cd4-b829-00e4914072ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_af26598a-0c4a-4843-b6e4-5041176d89fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8256806d-6555-4cd4-b829-00e4914072ca" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_af26598a-0c4a-4843-b6e4-5041176d89fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_64ee2106-bfe0-4c13-9807-75c4dcae78a4" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_af26598a-0c4a-4843-b6e4-5041176d89fc" xlink:to="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_64ee2106-bfe0-4c13-9807-75c4dcae78a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember_b8d353c5-606f-4a95-8a84-fe5c483d57e1" xlink:href="ci-20231231.xsd#ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_af26598a-0c4a-4843-b6e4-5041176d89fc" xlink:to="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember_b8d353c5-606f-4a95-8a84-fe5c483d57e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesTable_0e635474-8e0d-4339-a995-8b0da9ff4200" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward_ca38ca0e-7ece-4584-94e9-503d29bcd9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward_ca38ca0e-7ece-4584-94e9-503d29bcd9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange_87b4e1c0-ec7b-48de-8150-f0c754a4b946" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward_ca38ca0e-7ece-4584-94e9-503d29bcd9b7" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange_87b4e1c0-ec7b-48de-8150-f0c754a4b946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax_a2286de2-a758-450b-a20a-4aa4e4ba4387" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward_ca38ca0e-7ece-4584-94e9-503d29bcd9b7" xlink:to="loc_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax_a2286de2-a758-450b-a20a-4aa4e4ba4387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience_32348cac-89d4-43c3-a140-f81524992558" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward_ca38ca0e-7ece-4584-94e9-503d29bcd9b7" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience_32348cac-89d4-43c3-a140-f81524992558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumIssuanceAndDerecognition_e3a01072-8ec0-4731-8f25-5874d148d595" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumIssuanceAndDerecognition"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward_ca38ca0e-7ece-4584-94e9-503d29bcd9b7" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumIssuanceAndDerecognition_e3a01072-8ec0-4731-8f25-5874d148d595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumNetPremiumCollected_1c24c3f2-7f49-4273-af59-45e9a860291e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumNetPremiumCollected"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward_ca38ca0e-7ece-4584-94e9-503d29bcd9b7" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumNetPremiumCollected_1c24c3f2-7f49-4273-af59-45e9a860291e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumInterestIncomeAndOtherChanges_0c2c07b7-1e51-4bf1-9cf8-2e33411a0d4e" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumInterestIncomeAndOtherChanges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward_ca38ca0e-7ece-4584-94e9-503d29bcd9b7" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumInterestIncomeAndOtherChanges_0c2c07b7-1e51-4bf1-9cf8-2e33411a0d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance_155f4714-cde7-46cf-a75a-0a8e7ed834fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward_ca38ca0e-7ece-4584-94e9-503d29bcd9b7" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance_155f4714-cde7-46cf-a75a-0a8e7ed834fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax_b5aa6642-320d-42db-9c39-50a2150452aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward_ca38ca0e-7ece-4584-94e9-503d29bcd9b7" xlink:to="loc_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax_b5aa6642-320d-42db-9c39-50a2150452aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange_80c6d431-d02c-473f-88b5-e00a0920c722" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward_ca38ca0e-7ece-4584-94e9-503d29bcd9b7" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange_80c6d431-d02c-473f-88b5-e00a0920c722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward_9ae186a1-d9b8-44bf-9b76-7df02cad82cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward_9ae186a1-d9b8-44bf-9b76-7df02cad82cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange_3ad7d162-4fbd-497c-8993-9070c792dd67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward_9ae186a1-d9b8-44bf-9b76-7df02cad82cc" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange_3ad7d162-4fbd-497c-8993-9070c792dd67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax_d330757a-ee9c-4ebc-ae21-4c289a4b3515" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward_9ae186a1-d9b8-44bf-9b76-7df02cad82cc" xlink:to="loc_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax_d330757a-ee9c-4ebc-ae21-4c289a4b3515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience_ff8d1fb6-109b-44c2-9504-1175c28f269d" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward_9ae186a1-d9b8-44bf-9b76-7df02cad82cc" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience_ff8d1fb6-109b-44c2-9504-1175c28f269d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitIssuanceAndDerecognition_7312e625-2335-43db-b9ef-5f131f991eb0" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitIssuanceAndDerecognition"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward_9ae186a1-d9b8-44bf-9b76-7df02cad82cc" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitIssuanceAndDerecognition_7312e625-2335-43db-b9ef-5f131f991eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits_147c40b6-915d-445c-bace-9401950bb722" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward_9ae186a1-d9b8-44bf-9b76-7df02cad82cc" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits_147c40b6-915d-445c-bace-9401950bb722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitInterestExpenseAndOtherChanges_706cc250-3989-4e05-a364-a14da7503e41" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitInterestExpenseAndOtherChanges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward_9ae186a1-d9b8-44bf-9b76-7df02cad82cc" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitInterestExpenseAndOtherChanges_706cc250-3989-4e05-a364-a14da7503e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance_5bb417dc-66a9-4332-a69e-add6e9aa1dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward_9ae186a1-d9b8-44bf-9b76-7df02cad82cc" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance_5bb417dc-66a9-4332-a69e-add6e9aa1dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax_457be560-39b4-4931-bed8-65275e89bc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward_9ae186a1-d9b8-44bf-9b76-7df02cad82cc" xlink:to="loc_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax_457be560-39b4-4931-bed8-65275e89bc4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange_c929faf6-8440-456c-88cc-9fda9bfb0673" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward_9ae186a1-d9b8-44bf-9b76-7df02cad82cc" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange_c929faf6-8440-456c-88cc-9fda9bfb0673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther_2c9181ca-5fa7-4328-bc5a-765ee33c8eae" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther_2c9181ca-5fa7-4328-bc5a-765ee33c8eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitOther_8ed6a004-5c72-4fe0-9b29-1819642eeb9a" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitOther_8ed6a004-5c72-4fe0-9b29-1819642eeb9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefits_013d8047-7973-456b-af7b-57ce7d9d8e69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefits_013d8047-7973-456b-af7b-57ce7d9d8e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceBeforeReclassificationToDisposalGroupAssetsHeldForSale_a8f9175b-d605-4178-b404-6cee4c568043" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceBeforeReclassificationToDisposalGroupAssetsHeldForSale_a8f9175b-d605-4178-b404-6cee4c568043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitsCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience_744f3f08-c963-4f95-bd1c-708481e83f08" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitsCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitsCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience_744f3f08-c963-4f95-bd1c-708481e83f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumUndiscountedBeforeReinsurance_f18c9bd9-181d-459b-85bc-72ba1c882c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumUndiscountedBeforeReinsurance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumUndiscountedBeforeReinsurance_f18c9bd9-181d-459b-85bc-72ba1c882c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumDiscountedBeforeReinsurance_091ff56d-c29a-43cd-970a-971c14521c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumDiscountedBeforeReinsurance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumDiscountedBeforeReinsurance_091ff56d-c29a-43cd-970a-971c14521c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance_c92da5b8-5843-42dc-aeee-48dc2cb421ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance_c92da5b8-5843-42dc-aeee-48dc2cb421ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance_bedfdbcd-5df3-4b1d-bda3-a25607893346" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance_bedfdbcd-5df3-4b1d-bda3-a25607893346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverablesLiabilityForFuturePolicyBenefitsAssetsHeldForSale_cf2f4580-192c-4047-87cd-3e0c0fa25f1e" xlink:href="ci-20231231.xsd#ci_ReinsuranceRecoverablesLiabilityForFuturePolicyBenefitsAssetsHeldForSale"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_ci_ReinsuranceRecoverablesLiabilityForFuturePolicyBenefitsAssetsHeldForSale_cf2f4580-192c-4047-87cd-3e0c0fa25f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FuturePolicyBenefitsDomesticContractsObservableInputsFromPublishedSpotRateCurveMaximumTerm_6441beae-5fe0-4107-a238-e5ae65c50052" xlink:href="ci-20231231.xsd#ci_FuturePolicyBenefitsDomesticContractsObservableInputsFromPublishedSpotRateCurveMaximumTerm"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_ci_FuturePolicyBenefitsDomesticContractsObservableInputsFromPublishedSpotRateCurveMaximumTerm_6441beae-5fe0-4107-a238-e5ae65c50052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability_fc173459-925f-46ee-9ed1-d4360e2fa6a4" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability_fc173459-925f-46ee-9ed1-d4360e2fa6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability_ccb75d59-ff7c-4b36-aa2f-a183ab2a3bd2" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability_ccb75d59-ff7c-4b36-aa2f-a183ab2a3bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups_b6545fb3-8b0a-4c18-ad4b-492abaa15700" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups_b6545fb3-8b0a-4c18-ad4b-492abaa15700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LiabilityForFuturePolicyBenefitsPercentSupportedByAssetsHeldInTrust_578b0297-0026-4abb-b5b9-97c8e2bae490" xlink:href="ci-20231231.xsd#ci_LiabilityForFuturePolicyBenefitsPercentSupportedByAssetsHeldInTrust"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_3d9ad5aa-2ea8-45d0-ab21-1490eca452cb" xlink:to="loc_ci_LiabilityForFuturePolicyBenefitsPercentSupportedByAssetsHeldInTrust_578b0297-0026-4abb-b5b9-97c8e2bae490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_48e490ff-27c7-4f36-a430-4a7b25a467c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesTable_bfa7e1a3-c302-478a-b94b-a1b4bd5f69ed" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_48e490ff-27c7-4f36-a430-4a7b25a467c8" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesTable_bfa7e1a3-c302-478a-b94b-a1b4bd5f69ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0cb6dfee-b9be-471c-9e5d-1daadbac437b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesTable_bfa7e1a3-c302-478a-b94b-a1b4bd5f69ed" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0cb6dfee-b9be-471c-9e5d-1daadbac437b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f75a328f-aa49-4c13-9e83-5809a4a22eab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0cb6dfee-b9be-471c-9e5d-1daadbac437b" xlink:to="loc_us-gaap_SegmentDomain_f75a328f-aa49-4c13-9e83-5809a4a22eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember_257d06dd-ac93-4a3f-bc43-a22229cceca9" xlink:href="ci-20231231.xsd#ci_CignaHealthcareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f75a328f-aa49-4c13-9e83-5809a4a22eab" xlink:to="loc_ci_CignaHealthcareMember_257d06dd-ac93-4a3f-bc43-a22229cceca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherOperationsSegmentMember_491dc72b-3123-4a34-b725-0cc0aa6349ca" xlink:href="ci-20231231.xsd#ci_OtherOperationsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f75a328f-aa49-4c13-9e83-5809a4a22eab" xlink:to="loc_ci_OtherOperationsSegmentMember_491dc72b-3123-4a34-b725-0cc0aa6349ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2f4cf21f-d6b6-4685-bcd2-3084e980b3e1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesTable_bfa7e1a3-c302-478a-b94b-a1b4bd5f69ed" xlink:to="loc_srt_RangeAxis_2f4cf21f-d6b6-4685-bcd2-3084e980b3e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cb7dd406-5c85-473b-87e6-e9387327541d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2f4cf21f-d6b6-4685-bcd2-3084e980b3e1" xlink:to="loc_srt_RangeMember_cb7dd406-5c85-473b-87e6-e9387327541d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b3130a62-94ff-4c79-80ea-ff5cbc76fa78" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cb7dd406-5c85-473b-87e6-e9387327541d" xlink:to="loc_srt_MinimumMember_b3130a62-94ff-4c79-80ea-ff5cbc76fa78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f90ab486-1edf-4992-965e-0b63af5f7e16" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cb7dd406-5c85-473b-87e6-e9387327541d" xlink:to="loc_srt_MaximumMember_f90ab486-1edf-4992-965e-0b63af5f7e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis_824181d3-9c46-4fbc-8332-a0bdb15db02a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesTable_bfa7e1a3-c302-478a-b94b-a1b4bd5f69ed" xlink:to="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis_824181d3-9c46-4fbc-8332-a0bdb15db02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain_fa8149ba-1609-4e44-ade7-05a825222023" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis_824181d3-9c46-4fbc-8332-a0bdb15db02a" xlink:to="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain_fa8149ba-1609-4e44-ade7-05a825222023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member_4f84fe85-3005-4f06-8239-cf1dbd11b6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain_fa8149ba-1609-4e44-ade7-05a825222023" xlink:to="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member_4f84fe85-3005-4f06-8239-cf1dbd11b6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis_dac932d7-310e-4a87-8d1e-3d361d33dd62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesTable_bfa7e1a3-c302-478a-b94b-a1b4bd5f69ed" xlink:to="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis_dac932d7-310e-4a87-8d1e-3d361d33dd62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain_2a8063a7-0f6b-474f-a6e9-02a18da63ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis_dac932d7-310e-4a87-8d1e-3d361d33dd62" xlink:to="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain_2a8063a7-0f6b-474f-a6e9-02a18da63ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember_4240ca54-57af-45a6-bd41-2debdb4441d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain_2a8063a7-0f6b-474f-a6e9-02a18da63ad6" xlink:to="loc_us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember_4240ca54-57af-45a6-bd41-2debdb4441d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member_4ed89537-b50c-4218-91b9-7feb05cad266" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain_2a8063a7-0f6b-474f-a6e9-02a18da63ad6" xlink:to="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member_4ed89537-b50c-4218-91b9-7feb05cad266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember_fbb3a3cc-0a50-48e9-a220-1bcc462e5a12" xlink:href="ci-20231231.xsd#ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain_2a8063a7-0f6b-474f-a6e9-02a18da63ad6" xlink:to="loc_ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember_fbb3a3cc-0a50-48e9-a220-1bcc462e5a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_ae822dd6-3898-4db7-9493-057ffcde4b24" xlink:href="ci-20231231.xsd#ci_InsuranceAndContractholderLiabilitiesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesTable_bfa7e1a3-c302-478a-b94b-a1b4bd5f69ed" xlink:to="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_ae822dd6-3898-4db7-9493-057ffcde4b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderContractDeposits_0987eeef-0e95-4232-8149-de850051e0dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderContractDeposits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_ae822dd6-3898-4db7-9493-057ffcde4b24" xlink:to="loc_us-gaap_PolicyholderContractDeposits_0987eeef-0e95-4232-8149-de850051e0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderContractBalancePercentReinsuredExternally_b56bb511-863b-49c7-95f6-c83d386231c7" xlink:href="ci-20231231.xsd#ci_PolicyholderContractBalancePercentReinsuredExternally"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_ae822dd6-3898-4db7-9493-057ffcde4b24" xlink:to="loc_ci_PolicyholderContractBalancePercentReinsuredExternally_b56bb511-863b-49c7-95f6-c83d386231c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate_f65dfa96-d541-4f25-b841-64a92420f565" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_ae822dd6-3898-4db7-9493-057ffcde4b24" xlink:to="loc_us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate_f65dfa96-d541-4f25-b841-64a92420f565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceNetAmountAtRisk_d040e58a-38f7-4bfc-a3b6-2a6797cea163" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceNetAmountAtRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_ae822dd6-3898-4db7-9493-057ffcde4b24" xlink:to="loc_us-gaap_PolicyholderAccountBalanceNetAmountAtRisk_d040e58a-38f7-4bfc-a3b6-2a6797cea163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashSurrenderValueDuePolicyholdersAmount_213c7856-36f5-420b-b517-4fede21c2f94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashSurrenderValueDuePolicyholdersAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_ae822dd6-3898-4db7-9493-057ffcde4b24" xlink:to="loc_us-gaap_CashSurrenderValueDuePolicyholdersAmount_213c7856-36f5-420b-b517-4fede21c2f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage_857c2e86-be5d-45ba-b2b0-df7c447059cd" xlink:href="ci-20231231.xsd#ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_ae822dd6-3898-4db7-9493-057ffcde4b24" xlink:to="loc_ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage_857c2e86-be5d-45ba-b2b0-df7c447059cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderFunds_ec2ca56e-70db-40aa-a700-1d5018321e98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderFunds"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_ae822dd6-3898-4db7-9493-057ffcde4b24" xlink:to="loc_us-gaap_PolicyholderFunds_ec2ca56e-70db-40aa-a700-1d5018321e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate_d0b104ea-0f82-4c4f-906d-d2a9e1d93f18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_ae822dd6-3898-4db7-9493-057ffcde4b24" xlink:to="loc_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate_d0b104ea-0f82-4c4f-906d-d2a9e1d93f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating_e3ea5f09-a736-4562-9674-8620a71ea717" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_ae822dd6-3898-4db7-9493-057ffcde4b24" xlink:to="loc_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating_e3ea5f09-a736-4562-9674-8620a71ea717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue_fa1591a2-323d-4d21-87c1-a830d660a69b" xlink:href="ci-20231231.xsd#ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InsuranceAndContractholderLiabilitiesLineItems_ae822dd6-3898-4db7-9493-057ffcde4b24" xlink:to="loc_ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue_fa1591a2-323d-4d21-87c1-a830d660a69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesSummaryofMarketRiskBenefitDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InsuranceandContractholderLiabilitiesSummaryofMarketRiskBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesSummaryofMarketRiskBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceLossReservesAbstract_45f26fa7-6956-47f9-9859-983b8dfe8230" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceLossReservesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AnnuitizationElectionPeriod_dddb89cb-eab8-48ab-b155-a765c633630a" xlink:href="ci-20231231.xsd#ci_AnnuitizationElectionPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceLossReservesAbstract_45f26fa7-6956-47f9-9859-983b8dfe8230" xlink:to="loc_ci_AnnuitizationElectionPeriod_dddb89cb-eab8-48ab-b155-a765c633630a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitRollForward_ba250ca2-8d1f-47cc-b8d3-ebde0d7f58b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketRiskBenefitRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceLossReservesAbstract_45f26fa7-6956-47f9-9859-983b8dfe8230" xlink:to="loc_us-gaap_MarketRiskBenefitRollForward_ba250ca2-8d1f-47cc-b8d3-ebde0d7f58b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk_eb500e24-0f2a-469a-8667-ea82756ef08c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketRiskBenefitRollForward_ba250ca2-8d1f-47cc-b8d3-ebde0d7f58b8" xlink:to="loc_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk_eb500e24-0f2a-469a-8667-ea82756ef08c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange_7eaf4265-ea3b-4b3f-b256-905c200b9a87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketRiskBenefitRollForward_ba250ca2-8d1f-47cc-b8d3-ebde0d7f58b8" xlink:to="loc_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange_7eaf4265-ea3b-4b3f-b256-905c200b9a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff_c225058d-d985-4b59-b9a8-926fefe05fad" xlink:href="ci-20231231.xsd#ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketRiskBenefitRollForward_ba250ca2-8d1f-47cc-b8d3-ebde0d7f58b8" xlink:to="loc_ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff_c225058d-d985-4b59-b9a8-926fefe05fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange_d1878ada-e021-4b6c-baf6-bff6db5a69d9" xlink:href="ci-20231231.xsd#ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketRiskBenefitRollForward_ba250ca2-8d1f-47cc-b8d3-ebde0d7f58b8" xlink:to="loc_ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange_d1878ada-e021-4b6c-baf6-bff6db5a69d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected_0d1b63d4-2ac0-4518-931d-e3dfaa80c491" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketRiskBenefitRollForward_ba250ca2-8d1f-47cc-b8d3-ebde0d7f58b8" xlink:to="loc_us-gaap_MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected_0d1b63d4-2ac0-4518-931d-e3dfaa80c491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitIncreaseDecreaseFromOtherAssumption_c8141f95-06b6-42d6-b6a7-b72478c1280e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketRiskBenefitIncreaseDecreaseFromOtherAssumption"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketRiskBenefitRollForward_ba250ca2-8d1f-47cc-b8d3-ebde0d7f58b8" xlink:to="loc_us-gaap_MarketRiskBenefitIncreaseDecreaseFromOtherAssumption_c8141f95-06b6-42d6-b6a7-b72478c1280e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange_c748c76a-8f94-4a30-84fc-12d218bd878b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketRiskBenefitRollForward_ba250ca2-8d1f-47cc-b8d3-ebde0d7f58b8" xlink:to="loc_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange_c748c76a-8f94-4a30-84fc-12d218bd878b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax_ac65f954-00dd-42bb-a4d2-77e95e6d7281" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketRiskBenefitRollForward_ba250ca2-8d1f-47cc-b8d3-ebde0d7f58b8" xlink:to="loc_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax_ac65f954-00dd-42bb-a4d2-77e95e6d7281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk_7c919a02-e918-4f3e-957c-912249efa870" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketRiskBenefitRollForward_ba250ca2-8d1f-47cc-b8d3-ebde0d7f58b8" xlink:to="loc_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk_7c919a02-e918-4f3e-957c-912249efa870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance_e9b15c49-4ea4-49f7-b6d4-dbdcfcd81c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketRiskBenefitRollForward_ba250ca2-8d1f-47cc-b8d3-ebde0d7f58b8" xlink:to="loc_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance_e9b15c49-4ea4-49f7-b6d4-dbdcfcd81c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceLossReservesAbstract_e884e0ea-0bc1-40b8-a471-912cb3e23b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceLossReservesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeTable_ebc76333-11de-4b64-a3af-70ab75328475" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetAmountAtRiskByProductAndGuaranteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceLossReservesAbstract_e884e0ea-0bc1-40b8-a471-912cb3e23b0a" xlink:to="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeTable_ebc76333-11de-4b64-a3af-70ab75328475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_41b5215c-76d8-4d5e-b789-bb0463fc2a57" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeTable_ebc76333-11de-4b64-a3af-70ab75328475" xlink:to="loc_srt_ProductOrServiceAxis_41b5215c-76d8-4d5e-b789-bb0463fc2a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2f4c7b77-cb82-4786-86ba-abb4b9d84c7d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_41b5215c-76d8-4d5e-b789-bb0463fc2a57" xlink:to="loc_srt_ProductsAndServicesDomain_2f4c7b77-cb82-4786-86ba-abb4b9d84c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableAnnuityMember_913170ee-b8ec-400b-b572-d2abd1b67ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableAnnuityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2f4c7b77-cb82-4786-86ba-abb4b9d84c7d" xlink:to="loc_us-gaap_VariableAnnuityMember_913170ee-b8ec-400b-b572-d2abd1b67ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems_24c5bc6a-8230-4071-8bd3-9fae346e1f29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeTable_ebc76333-11de-4b64-a3af-70ab75328475" xlink:to="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems_24c5bc6a-8230-4071-8bd3-9fae346e1f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue_88f4b34e-136f-4b20-86f7-e261a29d46ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems_24c5bc6a-8230-4071-8bd3-9fae346e1f29" xlink:to="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue_88f4b34e-136f-4b20-86f7-e261a29d46ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk_5f506865-9ff2-4bd1-8742-793d5a1df79a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems_24c5bc6a-8230-4071-8bd3-9fae346e1f29" xlink:to="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk_5f506865-9ff2-4bd1-8742-793d5a1df79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1_6d67ef1c-f754-412a-9b96-0eccb5bec320" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems_24c5bc6a-8230-4071-8bd3-9fae346e1f29" xlink:to="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1_6d67ef1c-f754-412a-9b96-0eccb5bec320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated_1e7e1be4-d3bd-451f-ac50-93f3634d3a82" xlink:href="ci-20231231.xsd#ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems_24c5bc6a-8230-4071-8bd3-9fae346e1f29" xlink:to="loc_ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated_1e7e1be4-d3bd-451f-ac50-93f3634d3a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#ReinsuranceReinsuranceRecoverablesDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceDisclosuresAbstract_9cb98098-f555-4f71-a6ce-501c85eb1a63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskTable_cdfbb835-c3c6-45c8-b378-5d649d73cff8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract_9cb98098-f555-4f71-a6ce-501c85eb1a63" xlink:to="loc_us-gaap_CededCreditRiskTable_cdfbb835-c3c6-45c8-b378-5d649d73cff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e087c824-ad62-48fc-b3c0-f4990abef8d4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskTable_cdfbb835-c3c6-45c8-b378-5d649d73cff8" xlink:to="loc_srt_ProductOrServiceAxis_e087c824-ad62-48fc-b3c0-f4990abef8d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_290c18ca-13d0-4099-b84c-6105ac3f8ac7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e087c824-ad62-48fc-b3c0-f4990abef8d4" xlink:to="loc_srt_ProductsAndServicesDomain_290c18ca-13d0-4099-b84c-6105ac3f8ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableAnnuityMember_ed1f18b7-bb97-4e43-8571-8823ad62e3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableAnnuityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_290c18ca-13d0-4099-b84c-6105ac3f8ac7" xlink:to="loc_us-gaap_VariableAnnuityMember_ed1f18b7-bb97-4e43-8571-8823ad62e3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OngoingOperationsMember_4f59927e-1fcf-4134-86d3-65c3383fbfc4" xlink:href="ci-20231231.xsd#ci_OngoingOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableAnnuityMember_ed1f18b7-bb97-4e43-8571-8823ad62e3ae" xlink:to="loc_ci_OngoingOperationsMember_4f59927e-1fcf-4134-86d3-65c3383fbfc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AcquisitionDispositionRunoffActivitiesMember_b5931976-6ee6-41b0-a26e-67b34e682c91" xlink:href="ci-20231231.xsd#ci_AcquisitionDispositionRunoffActivitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableAnnuityMember_ed1f18b7-bb97-4e43-8571-8823ad62e3ae" xlink:to="loc_ci_AcquisitionDispositionRunoffActivitiesMember_b5931976-6ee6-41b0-a26e-67b34e682c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskCollateralizationAxis_1da7d1fc-9fd0-4e87-a038-5d90a2b4a3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskCollateralizationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskTable_cdfbb835-c3c6-45c8-b378-5d649d73cff8" xlink:to="loc_us-gaap_CededCreditRiskCollateralizationAxis_1da7d1fc-9fd0-4e87-a038-5d90a2b4a3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskCollateralizationDomain_7c0d3474-c069-4537-9c6d-8f6dbe8c0927" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskCollateralizationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskCollateralizationAxis_1da7d1fc-9fd0-4e87-a038-5d90a2b4a3d0" xlink:to="loc_us-gaap_CededCreditRiskCollateralizationDomain_7c0d3474-c069-4537-9c6d-8f6dbe8c0927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskSecuredMember_03a5e257-9204-409b-806f-094f769f61ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskSecuredMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskCollateralizationDomain_7c0d3474-c069-4537-9c6d-8f6dbe8c0927" xlink:to="loc_us-gaap_CededCreditRiskSecuredMember_03a5e257-9204-409b-806f-094f769f61ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember_a4912f64-6762-4826-9c62-81e210d4222b" xlink:href="ci-20231231.xsd#ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskSecuredMember_03a5e257-9204-409b-806f-094f769f61ce" xlink:to="loc_ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember_a4912f64-6762-4826-9c62-81e210d4222b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember_a84a942b-43ad-4848-95f6-2f7f31d77130" xlink:href="ci-20231231.xsd#ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskSecuredMember_03a5e257-9204-409b-806f-094f769f61ce" xlink:to="loc_ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember_a84a942b-43ad-4848-95f6-2f7f31d77130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskUnsecuredMember_fae971eb-9f9b-4370-b4a3-919ac6327f42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskUnsecuredMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskCollateralizationDomain_7c0d3474-c069-4537-9c6d-8f6dbe8c0927" xlink:to="loc_us-gaap_CededCreditRiskUnsecuredMember_fae971eb-9f9b-4370-b4a3-919ac6327f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis_f3feb2d0-8087-47c8-90a8-2bfa4feacbd5" xlink:href="ci-20231231.xsd#ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskTable_cdfbb835-c3c6-45c8-b378-5d649d73cff8" xlink:to="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis_f3feb2d0-8087-47c8-90a8-2bfa4feacbd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain_d3a61ac1-2a4c-43af-b3e9-5cdf7c65e081" xlink:href="ci-20231231.xsd#ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis_f3feb2d0-8087-47c8-90a8-2bfa4feacbd5" xlink:to="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain_d3a61ac1-2a4c-43af-b3e9-5cdf7c65e081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember_98ad4c15-83c7-4493-bee4-3719e73c95d6" xlink:href="ci-20231231.xsd#ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain_d3a61ac1-2a4c-43af-b3e9-5cdf7c65e081" xlink:to="loc_ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember_98ad4c15-83c7-4493-bee4-3719e73c95d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember_e191d18f-c324-4e75-b96e-4438e75436ba" xlink:href="ci-20231231.xsd#ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember_98ad4c15-83c7-4493-bee4-3719e73c95d6" xlink:to="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember_e191d18f-c324-4e75-b96e-4438e75436ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember_0272dc8f-1450-4191-b028-f4190f809d66" xlink:href="ci-20231231.xsd#ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain_d3a61ac1-2a4c-43af-b3e9-5cdf7c65e081" xlink:to="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember_0272dc8f-1450-4191-b028-f4190f809d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember_63b21643-e33f-4b8c-b07c-773ab0e3a957" xlink:href="ci-20231231.xsd#ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain_d3a61ac1-2a4c-43af-b3e9-5cdf7c65e081" xlink:to="loc_ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember_63b21643-e33f-4b8c-b07c-773ab0e3a957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskAxis_c8e57490-0b90-4cd9-b8c2-9d24eac929bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskTable_cdfbb835-c3c6-45c8-b378-5d649d73cff8" xlink:to="loc_us-gaap_CededCreditRiskAxis_c8e57490-0b90-4cd9-b8c2-9d24eac929bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskReinsurerDomain_d2f32e8a-170b-4b36-b44a-0ac48336925f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskReinsurerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskAxis_c8e57490-0b90-4cd9-b8c2-9d24eac929bb" xlink:to="loc_us-gaap_CededCreditRiskReinsurerDomain_d2f32e8a-170b-4b36-b44a-0ac48336925f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember_7bd2da0e-3631-4bf4-bba3-ea1978845499" xlink:href="ci-20231231.xsd#ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain_d2f32e8a-170b-4b36-b44a-0ac48336925f" xlink:to="loc_ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember_7bd2da0e-3631-4bf4-bba3-ea1978845499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EmpowerAnnuityInsuranceCompanyMember_1da06ff7-2ced-4739-b850-b21cc24ae2be" xlink:href="ci-20231231.xsd#ci_EmpowerAnnuityInsuranceCompanyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain_d2f32e8a-170b-4b36-b44a-0ac48336925f" xlink:to="loc_ci_EmpowerAnnuityInsuranceCompanyMember_1da06ff7-2ced-4739-b850-b21cc24ae2be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PrudentialInsuranceCompanyOfAmericaMember_46ed0501-bf0a-431e-84b3-fe3b84720f6b" xlink:href="ci-20231231.xsd#ci_PrudentialInsuranceCompanyOfAmericaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain_d2f32e8a-170b-4b36-b44a-0ac48336925f" xlink:to="loc_ci_PrudentialInsuranceCompanyOfAmericaMember_46ed0501-bf0a-431e-84b3-fe3b84720f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LifeInsuranceCompanyOfNorthAmericaMember_dc19cc71-fc10-4296-bd62-2d6b1075e359" xlink:href="ci-20231231.xsd#ci_LifeInsuranceCompanyOfNorthAmericaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain_d2f32e8a-170b-4b36-b44a-0ac48336925f" xlink:to="loc_ci_LifeInsuranceCompanyOfNorthAmericaMember_dc19cc71-fc10-4296-bd62-2d6b1075e359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReinsurerMember_ec3afb2c-48f6-483c-943e-e73fabeab019" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReinsurerMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain_d2f32e8a-170b-4b36-b44a-0ac48336925f" xlink:to="loc_us-gaap_OtherReinsurerMember_ec3afb2c-48f6-483c-943e-e73fabeab019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaAndOtherRecoverablesMember_df3ecea1-064b-4f6a-b589-02116d05674b" xlink:href="ci-20231231.xsd#ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaAndOtherRecoverablesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain_d2f32e8a-170b-4b36-b44a-0ac48336925f" xlink:to="loc_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaAndOtherRecoverablesMember_df3ecea1-064b-4f6a-b589-02116d05674b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f841ea3e-adac-495f-927d-0e20dbca5127" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskTable_cdfbb835-c3c6-45c8-b378-5d649d73cff8" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f841ea3e-adac-495f-927d-0e20dbca5127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_976f030c-08b0-408d-97e6-28d704d695e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f841ea3e-adac-495f-927d-0e20dbca5127" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_976f030c-08b0-408d-97e6-28d704d695e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_67a53fb5-eba9-4bb8-8f17-29db061df10a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_976f030c-08b0-408d-97e6-28d704d695e0" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_67a53fb5-eba9-4bb8-8f17-29db061df10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteedInsuranceContractTypeOfBenefitAxis_6f7aeec3-487f-43dc-befb-0343534d9a45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteedInsuranceContractTypeOfBenefitAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskTable_cdfbb835-c3c6-45c8-b378-5d649d73cff8" xlink:to="loc_us-gaap_GuaranteedInsuranceContractTypeOfBenefitAxis_6f7aeec3-487f-43dc-befb-0343534d9a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteedInsuranceContractTypeOfBenefitDomain_10846e88-747d-45c6-8881-ffa0d2dca126" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteedInsuranceContractTypeOfBenefitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteedInsuranceContractTypeOfBenefitAxis_6f7aeec3-487f-43dc-befb-0343534d9a45" xlink:to="loc_us-gaap_GuaranteedInsuranceContractTypeOfBenefitDomain_10846e88-747d-45c6-8881-ffa0d2dca126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteedMinimumDeathBenefitMember_96a8e27c-b9fa-482f-9ae3-aad7aca07337" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteedMinimumDeathBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteedInsuranceContractTypeOfBenefitDomain_10846e88-747d-45c6-8881-ffa0d2dca126" xlink:to="loc_us-gaap_GuaranteedMinimumDeathBenefitMember_96a8e27c-b9fa-482f-9ae3-aad7aca07337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_a51c6474-c49c-47fb-82fd-37c6d8964f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskTable_cdfbb835-c3c6-45c8-b378-5d649d73cff8" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_a51c6474-c49c-47fb-82fd-37c6d8964f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_58e04a65-a2a0-4e31-8359-8bd59c24edb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_a51c6474-c49c-47fb-82fd-37c6d8964f1d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_58e04a65-a2a0-4e31-8359-8bd59c24edb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_d7d7e8ab-db8d-4988-bfa3-9e868752303f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_58e04a65-a2a0-4e31-8359-8bd59c24edb2" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_d7d7e8ab-db8d-4988-bfa3-9e868752303f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c5c5822b-d0e4-4c66-b788-4ac12d709ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskTable_cdfbb835-c3c6-45c8-b378-5d649d73cff8" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c5c5822b-d0e4-4c66-b788-4ac12d709ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fcea88b1-19c0-4ffa-8c5f-fa104fe57e68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c5c5822b-d0e4-4c66-b788-4ac12d709ed8" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fcea88b1-19c0-4ffa-8c5f-fa104fe57e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_2781b815-a283-495c-a252-3557a30f086b" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fcea88b1-19c0-4ffa-8c5f-fa104fe57e68" xlink:to="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_2781b815-a283-495c-a252-3557a30f086b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskLineItems_f0967b3a-d22c-4477-954b-0ec991c8f627" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskTable_cdfbb835-c3c6-45c8-b378-5d649d73cff8" xlink:to="loc_us-gaap_CededCreditRiskLineItems_f0967b3a-d22c-4477-954b-0ec991c8f627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale_42e0d10f-76ea-435c-89d1-3ca6283c1fc4" xlink:href="ci-20231231.xsd#ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskLineItems_f0967b3a-d22c-4477-954b-0ec991c8f627" xlink:to="loc_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale_42e0d10f-76ea-435c-89d1-3ca6283c1fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverableAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_d325d884-4977-4138-bde1-67e8afe4217f" xlink:href="ci-20231231.xsd#ci_ReinsuranceRecoverableAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskLineItems_f0967b3a-d22c-4477-954b-0ec991c8f627" xlink:to="loc_ci_ReinsuranceRecoverableAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_d325d884-4977-4138-bde1-67e8afe4217f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance_52d41dc4-7eb6-4f51-ba98-5e8faba974f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskLineItems_f0967b3a-d22c-4477-954b-0ec991c8f627" xlink:to="loc_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance_52d41dc4-7eb6-4f51-ba98-5e8faba974f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale_c18b75a5-159c-4d8d-bdaf-adb52b030906" xlink:href="ci-20231231.xsd#ci_ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskLineItems_f0967b3a-d22c-4477-954b-0ec991c8f627" xlink:to="loc_ci_ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale_c18b75a5-159c-4d8d-bdaf-adb52b030906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverables_c71dfd18-3e47-47fb-a785-1a6624c46449" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceRecoverables"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskLineItems_f0967b3a-d22c-4477-954b-0ec991c8f627" xlink:to="loc_us-gaap_ReinsuranceRecoverables_c71dfd18-3e47-47fb-a785-1a6624c46449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationReinsuranceRecoverablesIncludingReinsurancePremiumPaid_eb3e8760-0599-4142-af29-c96acf994130" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationReinsuranceRecoverablesIncludingReinsurancePremiumPaid"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskLineItems_f0967b3a-d22c-4477-954b-0ec991c8f627" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationReinsuranceRecoverablesIncludingReinsurancePremiumPaid_eb3e8760-0599-4142-af29-c96acf994130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ReinsuranceEffectsofReinsuranceDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#ReinsuranceEffectsofReinsuranceDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ReinsuranceEffectsofReinsuranceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceDisclosuresAbstract_c66a1e64-62c3-450d-ba08-a27ed82c6c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectsOfReinsuranceTable_cf6e2b7a-48c6-4fb6-a480-19629500cca2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectsOfReinsuranceTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract_c66a1e64-62c3-450d-ba08-a27ed82c6c3b" xlink:to="loc_us-gaap_EffectsOfReinsuranceTable_cf6e2b7a-48c6-4fb6-a480-19629500cca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8a4174a6-3a49-46a7-aa21-db0666646844" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectsOfReinsuranceTable_cf6e2b7a-48c6-4fb6-a480-19629500cca2" xlink:to="loc_srt_ProductOrServiceAxis_8a4174a6-3a49-46a7-aa21-db0666646844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dc9985a9-4f2e-422c-9253-0d8fc4fa08db" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8a4174a6-3a49-46a7-aa21-db0666646844" xlink:to="loc_srt_ProductsAndServicesDomain_dc9985a9-4f2e-422c-9253-0d8fc4fa08db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortDurationContractsMember_0f3fca67-f1cf-44b0-ad55-3eb04d97bf9a" xlink:href="ci-20231231.xsd#ci_ShortDurationContractsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc9985a9-4f2e-422c-9253-0d8fc4fa08db" xlink:to="loc_ci_ShortDurationContractsMember_0f3fca67-f1cf-44b0-ad55-3eb04d97bf9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LongDurationContractsMember_bfb021ee-2583-437b-b4c2-891347118f01" xlink:href="ci-20231231.xsd#ci_LongDurationContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc9985a9-4f2e-422c-9253-0d8fc4fa08db" xlink:to="loc_ci_LongDurationContractsMember_bfb021ee-2583-437b-b4c2-891347118f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectsOfReinsuranceLineItems_b1adb37d-84a1-4f5e-9536-7ee040675d49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectsOfReinsuranceLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectsOfReinsuranceTable_cf6e2b7a-48c6-4fb6-a480-19629500cca2" xlink:to="loc_us-gaap_EffectsOfReinsuranceLineItems_b1adb37d-84a1-4f5e-9536-7ee040675d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract_7c584db7-0e3f-49ab-b063-04dd5c7bf6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectsOfReinsuranceLineItems_b1adb37d-84a1-4f5e-9536-7ee040675d49" xlink:to="loc_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract_7c584db7-0e3f-49ab-b063-04dd5c7bf6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectPremiumsEarned_1fa9cac8-52fc-4e52-b55e-85ca85175a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DirectPremiumsEarned"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract_7c584db7-0e3f-49ab-b063-04dd5c7bf6cf" xlink:to="loc_us-gaap_DirectPremiumsEarned_1fa9cac8-52fc-4e52-b55e-85ca85175a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumedPremiumsEarned_d6f2abf3-59d3-4517-9f46-63a35082e28e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssumedPremiumsEarned"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract_7c584db7-0e3f-49ab-b063-04dd5c7bf6cf" xlink:to="loc_us-gaap_AssumedPremiumsEarned_d6f2abf3-59d3-4517-9f46-63a35082e28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededPremiumsEarned_f640faa1-ea8f-45a3-9c87-469f814c64f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededPremiumsEarned"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract_7c584db7-0e3f-49ab-b063-04dd5c7bf6cf" xlink:to="loc_us-gaap_CededPremiumsEarned_f640faa1-ea8f-45a3-9c87-469f814c64f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_3f900e35-0534-4ce7-951a-e200d2300c25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract_7c584db7-0e3f-49ab-b063-04dd5c7bf6cf" xlink:to="loc_us-gaap_PremiumsEarnedNet_3f900e35-0534-4ce7-951a-e200d2300c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract_d197e451-9ccf-417f-adcf-680d50c90eef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectsOfReinsuranceLineItems_b1adb37d-84a1-4f5e-9536-7ee040675d49" xlink:to="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract_d197e451-9ccf-417f-adcf-680d50c90eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded_e3f2315d-796e-49c4-af17-2bd3182855d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract_d197e451-9ccf-417f-adcf-680d50c90eef" xlink:to="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded_e3f2315d-796e-49c4-af17-2bd3182855d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsWrittenNet_2cf9e26f-fc24-441f-b99f-c96277478bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PremiumsWrittenNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectsOfReinsuranceLineItems_b1adb37d-84a1-4f5e-9536-7ee040675d49" xlink:to="loc_us-gaap_PremiumsWrittenNet_2cf9e26f-fc24-441f-b99f-c96277478bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceDisclosuresAbstract_b48cc20d-ee36-4362-b876-a522038d81fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskTable_b559f65c-8f3f-4161-aad0-9c6105511091" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReinsuranceDisclosuresAbstract_b48cc20d-ee36-4362-b876-a522038d81fb" xlink:to="loc_us-gaap_CededCreditRiskTable_b559f65c-8f3f-4161-aad0-9c6105511091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_79e9e404-d393-4a56-878a-2458b45d7e69" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskTable_b559f65c-8f3f-4161-aad0-9c6105511091" xlink:to="loc_srt_ProductOrServiceAxis_79e9e404-d393-4a56-878a-2458b45d7e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ef607699-df41-461e-b348-b2cf4d65d951" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_79e9e404-d393-4a56-878a-2458b45d7e69" xlink:to="loc_srt_ProductsAndServicesDomain_ef607699-df41-461e-b348-b2cf4d65d951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableAnnuityMember_afeb7a14-c3a1-49fa-9927-2071a0b89b70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableAnnuityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ef607699-df41-461e-b348-b2cf4d65d951" xlink:to="loc_us-gaap_VariableAnnuityMember_afeb7a14-c3a1-49fa-9927-2071a0b89b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskAxis_59f4180a-37ea-4479-8a6c-333126ef6976" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskTable_b559f65c-8f3f-4161-aad0-9c6105511091" xlink:to="loc_us-gaap_CededCreditRiskAxis_59f4180a-37ea-4479-8a6c-333126ef6976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskReinsurerDomain_2d9f4347-aeb2-47dc-9446-a67282d1633e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskReinsurerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskAxis_59f4180a-37ea-4479-8a6c-333126ef6976" xlink:to="loc_us-gaap_CededCreditRiskReinsurerDomain_2d9f4347-aeb2-47dc-9446-a67282d1633e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember_4c6d974b-2c8d-4129-9a1f-f177f9667fc6" xlink:href="ci-20231231.xsd#ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain_2d9f4347-aeb2-47dc-9446-a67282d1633e" xlink:to="loc_ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember_4c6d974b-2c8d-4129-9a1f-f177f9667fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SunLifeAssuranceCompanyOfCanadaMember_7f358959-09d9-43c3-9576-731d3274d1fd" xlink:href="ci-20231231.xsd#ci_SunLifeAssuranceCompanyOfCanadaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain_2d9f4347-aeb2-47dc-9446-a67282d1633e" xlink:to="loc_ci_SunLifeAssuranceCompanyOfCanadaMember_7f358959-09d9-43c3-9576-731d3274d1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LibertyMutualInsuranceMember_eff4016f-2d79-4c18-b5ab-ce0f72c17392" xlink:href="ci-20231231.xsd#ci_LibertyMutualInsuranceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain_2d9f4347-aeb2-47dc-9446-a67282d1633e" xlink:to="loc_ci_LibertyMutualInsuranceMember_eff4016f-2d79-4c18-b5ab-ce0f72c17392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SCORSEMember_192f62dd-8c71-4213-8884-d2f7ad73deda" xlink:href="ci-20231231.xsd#ci_SCORSEMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskReinsurerDomain_2d9f4347-aeb2-47dc-9446-a67282d1633e" xlink:to="loc_ci_SCORSEMember_192f62dd-8c71-4213-8884-d2f7ad73deda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskCollateralizationAxis_87529216-d463-4454-8cbb-278f2abf27e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskCollateralizationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskTable_b559f65c-8f3f-4161-aad0-9c6105511091" xlink:to="loc_us-gaap_CededCreditRiskCollateralizationAxis_87529216-d463-4454-8cbb-278f2abf27e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskCollateralizationDomain_b3580836-35f0-4ea2-93ad-496c3f6072ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskCollateralizationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskCollateralizationAxis_87529216-d463-4454-8cbb-278f2abf27e4" xlink:to="loc_us-gaap_CededCreditRiskCollateralizationDomain_b3580836-35f0-4ea2-93ad-496c3f6072ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskSecuredMember_6ff00671-5eb2-4743-a3e3-c55d609a7de8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskSecuredMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskCollateralizationDomain_b3580836-35f0-4ea2-93ad-496c3f6072ef" xlink:to="loc_us-gaap_CededCreditRiskSecuredMember_6ff00671-5eb2-4743-a3e3-c55d609a7de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_898c305f-41df-4185-923a-112d04e6b158" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskTable_b559f65c-8f3f-4161-aad0-9c6105511091" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_898c305f-41df-4185-923a-112d04e6b158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c47cdc60-f292-4ee8-a21a-43437ac367d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_898c305f-41df-4185-923a-112d04e6b158" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c47cdc60-f292-4ee8-a21a-43437ac367d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember_ae9b493b-f1e0-405f-8e0a-70b668ccb5ff" xlink:href="ci-20231231.xsd#ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c47cdc60-f292-4ee8-a21a-43437ac367d5" xlink:to="loc_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember_ae9b493b-f1e0-405f-8e0a-70b668ccb5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_60fbd7be-554e-471e-9ee4-b116af40c635" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskTable_b559f65c-8f3f-4161-aad0-9c6105511091" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_60fbd7be-554e-471e-9ee4-b116af40c635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6e204d93-745d-43ea-a96f-88f219ce64e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_60fbd7be-554e-471e-9ee4-b116af40c635" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6e204d93-745d-43ea-a96f-88f219ce64e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CededCreditCollateralizationRiskMember_48e00cd1-2256-4559-a6c6-eb71dd269141" xlink:href="ci-20231231.xsd#ci_CededCreditCollateralizationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_6e204d93-745d-43ea-a96f-88f219ce64e7" xlink:to="loc_ci_CededCreditCollateralizationRiskMember_48e00cd1-2256-4559-a6c6-eb71dd269141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededCreditRiskLineItems_9daba6c4-2da0-4d45-bc78-3fb1c33bda64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededCreditRiskLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskTable_b559f65c-8f3f-4161-aad0-9c6105511091" xlink:to="loc_us-gaap_CededCreditRiskLineItems_9daba6c4-2da0-4d45-bc78-3fb1c33bda64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CededReinsuranceAgreementReinsuredRiskPercentage_1d9c3083-9539-4651-8854-42d61d9b4d51" xlink:href="ci-20231231.xsd#ci_CededReinsuranceAgreementReinsuredRiskPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskLineItems_9daba6c4-2da0-4d45-bc78-3fb1c33bda64" xlink:to="loc_ci_CededReinsuranceAgreementReinsuredRiskPercentage_1d9c3083-9539-4651-8854-42d61d9b4d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CededReinsuranceAgreementCoverageLimitAmountRemaining_622e13fc-e182-47c5-bc4e-9f999fc47a96" xlink:href="ci-20231231.xsd#ci_CededReinsuranceAgreementCoverageLimitAmountRemaining"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskLineItems_9daba6c4-2da0-4d45-bc78-3fb1c33bda64" xlink:to="loc_ci_CededReinsuranceAgreementCoverageLimitAmountRemaining_622e13fc-e182-47c5-bc4e-9f999fc47a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ae907849-ef32-4854-9973-82553ec2c298" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskLineItems_9daba6c4-2da0-4d45-bc78-3fb1c33bda64" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ae907849-ef32-4854-9973-82553ec2c298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances_fce623e3-b72a-410b-82e5-e51df1b497ca" xlink:href="ci-20231231.xsd#ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskLineItems_9daba6c4-2da0-4d45-bc78-3fb1c33bda64" xlink:to="loc_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances_fce623e3-b72a-410b-82e5-e51df1b497ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceReceivablesIncurredButNotReportedClaims_81a15277-b8a5-48d2-bbc5-9e172d394725" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceReceivablesIncurredButNotReportedClaims"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskLineItems_9daba6c4-2da0-4d45-bc78-3fb1c33bda64" xlink:to="loc_us-gaap_ReinsuranceReceivablesIncurredButNotReportedClaims_81a15277-b8a5-48d2-bbc5-9e172d394725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsReceivableAtCarryingValue_acb7a0c1-bdc7-4351-b5ff-8d217a47247a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PremiumsReceivableAtCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskLineItems_9daba6c4-2da0-4d45-bc78-3fb1c33bda64" xlink:to="loc_us-gaap_PremiumsReceivableAtCarryingValue_acb7a0c1-bdc7-4351-b5ff-8d217a47247a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueMeasurementNonPerformanceRiskAdjustment_0b4c8480-8441-40e7-a3b1-7e2080ce1957" xlink:href="ci-20231231.xsd#ci_FairValueMeasurementNonPerformanceRiskAdjustment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CededCreditRiskLineItems_9daba6c4-2da0-4d45-bc78-3fb1c33bda64" xlink:to="loc_ci_FairValueMeasurementNonPerformanceRiskAdjustment_0b4c8480-8441-40e7-a3b1-7e2080ce1957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InvestmentsInvestmentsbyCategoryDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_560b6ee0-4e65-4a92-b8fe-344cce983ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_075eaddf-70bd-4da3-ba18-caa6e915f6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_560b6ee0-4e65-4a92-b8fe-344cce983ff1" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_075eaddf-70bd-4da3-ba18-caa6e915f6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_5b2a04e9-2ec2-4297-a4b3-7abff9cc9a90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_075eaddf-70bd-4da3-ba18-caa6e915f6ed" xlink:to="loc_us-gaap_InvestmentTypeAxis_5b2a04e9-2ec2-4297-a4b3-7abff9cc9a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_2b4171c3-1114-4e09-bab4-0190e51a735a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_5b2a04e9-2ec2-4297-a4b3-7abff9cc9a90" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_2b4171c3-1114-4e09-bab4-0190e51a735a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_66b5eb96-0d2d-4409-80e6-5b49b03366d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2b4171c3-1114-4e09-bab4-0190e51a735a" xlink:to="loc_us-gaap_DebtSecuritiesMember_66b5eb96-0d2d-4409-80e6-5b49b03366d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_f186052f-8dcd-4851-b3b7-bdbb9795f33b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2b4171c3-1114-4e09-bab4-0190e51a735a" xlink:to="loc_us-gaap_EquitySecuritiesMember_f186052f-8dcd-4851-b3b7-bdbb9795f33b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgagesMember_0b5d04fc-06af-4231-b85e-0681c631b0be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgagesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2b4171c3-1114-4e09-bab4-0190e51a735a" xlink:to="loc_us-gaap_MortgagesMember_0b5d04fc-06af-4231-b85e-0681c631b0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyLoansMember_489d31a6-22c0-42ee-b012-68b882e133a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyLoansMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2b4171c3-1114-4e09-bab4-0190e51a735a" xlink:to="loc_us-gaap_PolicyLoansMember_489d31a6-22c0-42ee-b012-68b882e133a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestmentsMember_18a20092-3dda-4274-a1b5-7d132d1a3296" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermInvestmentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2b4171c3-1114-4e09-bab4-0190e51a735a" xlink:to="loc_us-gaap_OtherLongTermInvestmentsMember_18a20092-3dda-4274-a1b5-7d132d1a3296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_ea02b691-3f65-4729-9638-ff9fd950dde5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2b4171c3-1114-4e09-bab4-0190e51a735a" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_ea02b691-3f65-4729-9638-ff9fd950dde5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_7fbc3be3-54e2-4e09-b721-efb0a417081a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_075eaddf-70bd-4da3-ba18-caa6e915f6ed" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_7fbc3be3-54e2-4e09-b721-efb0a417081a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_d142f902-8368-4bd5-a4f2-d0ed62ca74e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_7fbc3be3-54e2-4e09-b721-efb0a417081a" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_d142f902-8368-4bd5-a4f2-d0ed62ca74e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_194c20d5-8043-461c-a51e-6836f5c6004b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_d142f902-8368-4bd5-a4f2-d0ed62ca74e8" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_194c20d5-8043-461c-a51e-6836f5c6004b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_45438892-fc51-4b58-ad84-ef875e593712" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_075eaddf-70bd-4da3-ba18-caa6e915f6ed" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_45438892-fc51-4b58-ad84-ef875e593712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7264ecc3-6447-40ba-803f-61216ec97245" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_45438892-fc51-4b58-ad84-ef875e593712" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7264ecc3-6447-40ba-803f-61216ec97245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_9eceb8bf-7087-4b6d-833a-e05e22977108" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7264ecc3-6447-40ba-803f-61216ec97245" xlink:to="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_9eceb8bf-7087-4b6d-833a-e05e22977108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_da230ba2-1d72-4077-bd84-4fa669d2753f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_075eaddf-70bd-4da3-ba18-caa6e915f6ed" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_da230ba2-1d72-4077-bd84-4fa669d2753f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract_c0115f40-5c5b-4757-953d-fb646f89a4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestmentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_da230ba2-1d72-4077-bd84-4fa669d2753f" xlink:to="loc_us-gaap_ShortTermInvestmentsAbstract_c0115f40-5c5b-4757-953d-fb646f89a4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_bb2ae3b6-cbb1-4f5a-b1c1-bdcbdbf6b237" xlink:href="ci-20231231.xsd#ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_c0115f40-5c5b-4757-953d-fb646f89a4bc" xlink:to="loc_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_bb2ae3b6-cbb1-4f5a-b1c1-bdcbdbf6b237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent_3d76d2d8-a8ba-4851-b1ab-4a604f50a7d9" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_c0115f40-5c5b-4757-953d-fb646f89a4bc" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent_3d76d2d8-a8ba-4851-b1ab-4a604f50a7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_54855a7e-2308-4893-b8ca-6eaff30ddf34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_c0115f40-5c5b-4757-953d-fb646f89a4bc" xlink:to="loc_us-gaap_ShortTermInvestments_54855a7e-2308-4893-b8ca-6eaff30ddf34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestmentsAbstract_70f34c23-d71a-4aae-8157-6f017e3ecd74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_da230ba2-1d72-4077-bd84-4fa669d2753f" xlink:to="loc_us-gaap_LongTermInvestmentsAbstract_70f34c23-d71a-4aae-8157-6f017e3ecd74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_c7a6de6c-26ed-498d-b376-3b82400ad7ec" xlink:href="ci-20231231.xsd#ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_70f34c23-d71a-4aae-8157-6f017e3ecd74" xlink:to="loc_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_c7a6de6c-26ed-498d-b376-3b82400ad7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent_815b597b-d9f0-43bd-bd34-9532e1018b37" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_70f34c23-d71a-4aae-8157-6f017e3ecd74" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent_815b597b-d9f0-43bd-bd34-9532e1018b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_253f2d23-c78f-44eb-82be-b682c212daaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_70f34c23-d71a-4aae-8157-6f017e3ecd74" xlink:to="loc_us-gaap_LongTermInvestments_253f2d23-c78f-44eb-82be-b682c212daaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShortTermAndLongTermInvestmentsAbstract_ec90f714-c412-4d60-9722-3702b2857adb" xlink:href="ci-20231231.xsd#ci_ShortTermAndLongTermInvestmentsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_da230ba2-1d72-4077-bd84-4fa669d2753f" xlink:to="loc_ci_ShortTermAndLongTermInvestmentsAbstract_ec90f714-c412-4d60-9722-3702b2857adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_db5cdd29-64b2-4aa5-ac65-d0349eb910d4" xlink:href="ci-20231231.xsd#ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ShortTermAndLongTermInvestmentsAbstract_ec90f714-c412-4d60-9722-3702b2857adb" xlink:to="loc_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_db5cdd29-64b2-4aa5-ac65-d0349eb910d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationInvestments_65459a57-5653-4dd8-9e92-975a98068df0" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ShortTermAndLongTermInvestmentsAbstract_ec90f714-c412-4d60-9722-3702b2857adb" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationInvestments_65459a57-5653-4dd8-9e92-975a98068df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_0753133d-a331-47dc-a365-0dd3bbc855fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ShortTermAndLongTermInvestmentsAbstract_ec90f714-c412-4d60-9722-3702b2857adb" xlink:to="loc_us-gaap_Investments_0753133d-a331-47dc-a365-0dd3bbc855fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails_1" xlink:type="simple" xlink:href="ci-20231231.xsd#InvestmentsInvestmentsbyCategoryDetails_1"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_27ec4d18-feb7-470c-9f08-88481e71011b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_64ad4643-89e8-48bc-ac11-65bfc895fa28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_27ec4d18-feb7-470c-9f08-88481e71011b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_64ad4643-89e8-48bc-ac11-65bfc895fa28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale_04d662da-fc5a-4e11-8547-251f1714ff51" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_64ad4643-89e8-48bc-ac11-65bfc895fa28" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale_04d662da-fc5a-4e11-8547-251f1714ff51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale_be85eb7f-67e0-45aa-b66f-3735e80fad94" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_64ad4643-89e8-48bc-ac11-65bfc895fa28" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale_be85eb7f-67e0-45aa-b66f-3735e80fad94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale_8270d9cf-8b81-4cf6-aac9-78766f77c4f7" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_64ad4643-89e8-48bc-ac11-65bfc895fa28" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale_8270d9cf-8b81-4cf6-aac9-78766f77c4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale_a33a0e12-965a-4a4a-98c9-d73e306d0315" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_64ad4643-89e8-48bc-ac11-65bfc895fa28" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale_a33a0e12-965a-4a4a-98c9-d73e306d0315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_d62050dd-1dac-4197-b196-412f4607453d" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_64ad4643-89e8-48bc-ac11-65bfc895fa28" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_d62050dd-1dac-4197-b196-412f4607453d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_b13e997c-e56a-4929-8ec7-b668f4725713" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_64ad4643-89e8-48bc-ac11-65bfc895fa28" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_b13e997c-e56a-4929-8ec7-b668f4725713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_e14936c3-c9ce-42e6-978e-11ecd350554e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_27ec4d18-feb7-470c-9f08-88481e71011b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_e14936c3-c9ce-42e6-978e-11ecd350554e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale_ca477427-5b67-48eb-bc20-95228ae81163" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_e14936c3-c9ce-42e6-978e-11ecd350554e" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale_ca477427-5b67-48eb-bc20-95228ae81163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale_64db2e4f-355c-4c0b-ad38-8f5858572c17" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_e14936c3-c9ce-42e6-978e-11ecd350554e" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale_64db2e4f-355c-4c0b-ad38-8f5858572c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale_f4369e89-160b-4606-b71f-91adc3d3a3a2" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_e14936c3-c9ce-42e6-978e-11ecd350554e" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale_f4369e89-160b-4606-b71f-91adc3d3a3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale_eeb1e42d-6a62-42f9-a58a-4dbed7cfa2e6" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_e14936c3-c9ce-42e6-978e-11ecd350554e" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale_eeb1e42d-6a62-42f9-a58a-4dbed7cfa2e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_7060f9bd-5a70-47d9-b90e-4ab5e5285293" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_e14936c3-c9ce-42e6-978e-11ecd350554e" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_7060f9bd-5a70-47d9-b90e-4ab5e5285293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale_ad46e7b6-7918-4844-8b7c-6df19662e1a8" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_e14936c3-c9ce-42e6-978e-11ecd350554e" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale_ad46e7b6-7918-4844-8b7c-6df19662e1a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsNarrativeDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_4c4ba8a0-3adb-4461-8c03-bba2288400b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_a5b704ca-3fd3-4aba-9955-3f293572b005" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_4c4ba8a0-3adb-4461-8c03-bba2288400b7" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_a5b704ca-3fd3-4aba-9955-3f293572b005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePortfolioSegmentAxis_1521fe61-a41d-493a-8d13-e2d68a26124d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablePortfolioSegmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_a5b704ca-3fd3-4aba-9955-3f293572b005" xlink:to="loc_us-gaap_FinancingReceivablePortfolioSegmentAxis_1521fe61-a41d-493a-8d13-e2d68a26124d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePortfolioSegmentDomain_f0243570-b719-43e7-b594-222403620c58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablePortfolioSegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivablePortfolioSegmentAxis_1521fe61-a41d-493a-8d13-e2d68a26124d" xlink:to="loc_us-gaap_FinancingReceivablePortfolioSegmentDomain_f0243570-b719-43e7-b594-222403620c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPortfolioSegmentMember_b202a505-fc7d-44ee-838d-e3cb458f1337" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPortfolioSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivablePortfolioSegmentDomain_f0243570-b719-43e7-b594-222403620c58" xlink:to="loc_us-gaap_CommercialPortfolioSegmentMember_b202a505-fc7d-44ee-838d-e3cb458f1337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_1c7e338e-f1ec-4a4f-b5c9-4b5aad893eee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_a5b704ca-3fd3-4aba-9955-3f293572b005" xlink:to="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_1c7e338e-f1ec-4a4f-b5c9-4b5aad893eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_51cba97d-ede1-419e-aa75-91a4f5cdb056" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_1c7e338e-f1ec-4a4f-b5c9-4b5aad893eee" xlink:to="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_51cba97d-ede1-419e-aa75-91a4f5cdb056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateLoanMember_17ccbc8a-155a-4838-99b0-ef11d51d81f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstateLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_51cba97d-ede1-419e-aa75-91a4f5cdb056" xlink:to="loc_us-gaap_RealEstateLoanMember_17ccbc8a-155a-4838-99b0-ef11d51d81f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_20834b32-b1e8-4e47-acae-5e60037ca154" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_a5b704ca-3fd3-4aba-9955-3f293572b005" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_20834b32-b1e8-4e47-acae-5e60037ca154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_3736ff89-b347-4a36-8d7a-c557639cc139" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_20834b32-b1e8-4e47-acae-5e60037ca154" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_3736ff89-b347-4a36-8d7a-c557639cc139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_VillageMDMember_5946c46f-3946-4d34-95d3-7041cba47523" xlink:href="ci-20231231.xsd#ci_VillageMDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_3736ff89-b347-4a36-8d7a-c557639cc139" xlink:to="loc_ci_VillageMDMember_5946c46f-3946-4d34-95d3-7041cba47523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_b765db54-b8cc-4aa1-8c00-315a4812a204" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_a5b704ca-3fd3-4aba-9955-3f293572b005" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_b765db54-b8cc-4aa1-8c00-315a4812a204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_da2da696-32a2-45fd-868f-3d9ff34e3c55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b765db54-b8cc-4aa1-8c00-315a4812a204" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_da2da696-32a2-45fd-868f-3d9ff34e3c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_ce4b1032-9d50-4ad8-ac0c-c87b8e87c619" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b765db54-b8cc-4aa1-8c00-315a4812a204" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_ce4b1032-9d50-4ad8-ac0c-c87b8e87c619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_9a9f1a16-40de-4dfa-94df-3e943c321a14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b765db54-b8cc-4aa1-8c00-315a4812a204" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_9a9f1a16-40de-4dfa-94df-3e943c321a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_1644a646-8d1b-40ba-867f-bdda404915df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b765db54-b8cc-4aa1-8c00-315a4812a204" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_1644a646-8d1b-40ba-867f-bdda404915df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_4a630eb3-bb24-42a6-8016-c0c706f26833" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b765db54-b8cc-4aa1-8c00-315a4812a204" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_4a630eb3-bb24-42a6-8016-c0c706f26833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesDividend_2624a642-8142-41bb-81c3-b89b4e8a45ce" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesDividend"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b765db54-b8cc-4aa1-8c00-315a4812a204" xlink:to="loc_ci_EquitySecuritiesDividend_2624a642-8142-41bb-81c3-b89b4e8a45ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueValueOfSharesForAnnualDividendAccrual_aa4ea593-9375-4273-bcea-8e59cb5fb0b1" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesWithoutReadilyDeterminableFairValueValueOfSharesForAnnualDividendAccrual"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b765db54-b8cc-4aa1-8c00-315a4812a204" xlink:to="loc_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueValueOfSharesForAnnualDividendAccrual_aa4ea593-9375-4273-bcea-8e59cb5fb0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_97646b51-7f2f-4cd9-bda9-e7401c36a4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_041ebb23-6c3f-4c99-858c-ee21b5d73f91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_97646b51-7f2f-4cd9-bda9-e7401c36a4fe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_041ebb23-6c3f-4c99-858c-ee21b5d73f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1f9522c2-a347-408b-8ba8-a58a5141a008" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_041ebb23-6c3f-4c99-858c-ee21b5d73f91" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1f9522c2-a347-408b-8ba8-a58a5141a008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bc29f687-dfd2-4991-b9e9-91a73fc3a24b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1f9522c2-a347-408b-8ba8-a58a5141a008" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bc29f687-dfd2-4991-b9e9-91a73fc3a24b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_2b985f3d-cc3a-4a46-bc14-55297903ad8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bc29f687-dfd2-4991-b9e9-91a73fc3a24b" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_2b985f3d-cc3a-4a46-bc14-55297903ad8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_467c2de8-01fa-4561-a25a-ec74bcef3b00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bc29f687-dfd2-4991-b9e9-91a73fc3a24b" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_467c2de8-01fa-4561-a25a-ec74bcef3b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_a99f4cb4-e934-4bf3-aa2b-ec5d0cff7c52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bc29f687-dfd2-4991-b9e9-91a73fc3a24b" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_a99f4cb4-e934-4bf3-aa2b-ec5d0cff7c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_5965133a-4278-449c-b8d9-43cc95947cae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bc29f687-dfd2-4991-b9e9-91a73fc3a24b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_5965133a-4278-449c-b8d9-43cc95947cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_2daa9ae3-cf2d-4aad-8963-988a1736daf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bc29f687-dfd2-4991-b9e9-91a73fc3a24b" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_2daa9ae3-cf2d-4aad-8963-988a1736daf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88f85a2a-b715-4d94-a5f3-03039fb5ff61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_041ebb23-6c3f-4c99-858c-ee21b5d73f91" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88f85a2a-b715-4d94-a5f3-03039fb5ff61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_7f906ce3-58ef-42bc-8124-7d4d421d69b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88f85a2a-b715-4d94-a5f3-03039fb5ff61" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_7f906ce3-58ef-42bc-8124-7d4d421d69b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_904b3336-83c1-494f-b253-5cffd37cabae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88f85a2a-b715-4d94-a5f3-03039fb5ff61" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_904b3336-83c1-494f-b253-5cffd37cabae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7ef6cd39-4e7b-45e4-8d0e-174d3698bdc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88f85a2a-b715-4d94-a5f3-03039fb5ff61" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7ef6cd39-4e7b-45e4-8d0e-174d3698bdc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a7dc5a70-702e-4b89-84ef-d6e9031b554a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88f85a2a-b715-4d94-a5f3-03039fb5ff61" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a7dc5a70-702e-4b89-84ef-d6e9031b554a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_07d404a3-d87f-4542-ab7b-67be61d27cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88f85a2a-b715-4d94-a5f3-03039fb5ff61" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_07d404a3-d87f-4542-ab7b-67be61d27cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale_6d579a06-eb5b-4327-b90c-2974d594b433" xlink:href="ci-20231231.xsd#ci_AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88f85a2a-b715-4d94-a5f3-03039fb5ff61" xlink:to="loc_ci_AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale_6d579a06-eb5b-4327-b90c-2974d594b433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_6c40c2f4-3b05-4595-be65-6e3618e91390" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88f85a2a-b715-4d94-a5f3-03039fb5ff61" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_6c40c2f4-3b05-4595-be65-6e3618e91390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale_f2cb720a-16d0-4dff-b4b8-26fb16cba5ff" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88f85a2a-b715-4d94-a5f3-03039fb5ff61" xlink:to="loc_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale_f2cb720a-16d0-4dff-b4b8-26fb16cba5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale_91c20150-1795-4050-9eb3-3924e8b117e9" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88f85a2a-b715-4d94-a5f3-03039fb5ff61" xlink:to="loc_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale_91c20150-1795-4050-9eb3-3924e8b117e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale_98c71293-65ec-420a-88ee-cdef5a6faf3c" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88f85a2a-b715-4d94-a5f3-03039fb5ff61" xlink:to="loc_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale_98c71293-65ec-420a-88ee-cdef5a6faf3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InvestmentsDebtSecuritieswithaDeclineinFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_c5312a38-735f-416e-943a-1cf2d6d19e18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7ba9122b-8c3e-4dfd-bcac-06991298d210" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_c5312a38-735f-416e-943a-1cf2d6d19e18" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7ba9122b-8c3e-4dfd-bcac-06991298d210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InvestmentsCreditRatingAxis_78437caa-f65e-427b-bb6b-ddf958a6c5f4" xlink:href="ci-20231231.xsd#ci_InvestmentsCreditRatingAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7ba9122b-8c3e-4dfd-bcac-06991298d210" xlink:to="loc_ci_InvestmentsCreditRatingAxis_78437caa-f65e-427b-bb6b-ddf958a6c5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InvestmentsCreditRatingDomain_70c6bc53-4288-443e-a3de-37a99c4b0b4e" xlink:href="ci-20231231.xsd#ci_InvestmentsCreditRatingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InvestmentsCreditRatingAxis_78437caa-f65e-427b-bb6b-ddf958a6c5f4" xlink:to="loc_ci_InvestmentsCreditRatingDomain_70c6bc53-4288-443e-a3de-37a99c4b0b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InvestmentGradeMember_194712f9-249b-4871-810b-604ba3ca6d2c" xlink:href="ci-20231231.xsd#ci_InvestmentGradeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InvestmentsCreditRatingDomain_70c6bc53-4288-443e-a3de-37a99c4b0b4e" xlink:to="loc_ci_InvestmentGradeMember_194712f9-249b-4871-810b-604ba3ca6d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_BelowInvestmentGradeMember_c2dd934d-0c6c-455d-94c6-160bd6eac2bb" xlink:href="ci-20231231.xsd#ci_BelowInvestmentGradeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InvestmentsCreditRatingDomain_70c6bc53-4288-443e-a3de-37a99c4b0b4e" xlink:to="loc_ci_BelowInvestmentGradeMember_c2dd934d-0c6c-455d-94c6-160bd6eac2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b2f7c266-7d8f-43c3-bf92-537cda7dd096" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7ba9122b-8c3e-4dfd-bcac-06991298d210" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b2f7c266-7d8f-43c3-bf92-537cda7dd096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_584c4302-dd92-4070-b033-120041e75c96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b2f7c266-7d8f-43c3-bf92-537cda7dd096" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_584c4302-dd92-4070-b033-120041e75c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_f1550952-1dcc-4908-977b-179b0a204810" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_584c4302-dd92-4070-b033-120041e75c96" xlink:to="loc_us-gaap_DebtSecuritiesMember_f1550952-1dcc-4908-977b-179b0a204810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f3b3c70-7029-4455-8afb-0af4fc5c073d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7ba9122b-8c3e-4dfd-bcac-06991298d210" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f3b3c70-7029-4455-8afb-0af4fc5c073d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_92f3cfd5-9564-422d-ac1e-df1993f43e81" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f3b3c70-7029-4455-8afb-0af4fc5c073d" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_92f3cfd5-9564-422d-ac1e-df1993f43e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_f285bf0b-5226-4305-b1b3-fc6f62b98e47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_92f3cfd5-9564-422d-ac1e-df1993f43e81" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_f285bf0b-5226-4305-b1b3-fc6f62b98e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost_d51f290b-76c0-48b0-9d05-6b593b571f6b" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_92f3cfd5-9564-422d-ac1e-df1993f43e81" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost_d51f290b-76c0-48b0-9d05-6b593b571f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_77d83033-978e-4b10-9543-984c630f32ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_92f3cfd5-9564-422d-ac1e-df1993f43e81" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_77d83033-978e-4b10-9543-984c630f32ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_3fc61ee9-dbfa-4d82-9b6c-39ec8c5e1c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_92f3cfd5-9564-422d-ac1e-df1993f43e81" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_3fc61ee9-dbfa-4d82-9b6c-39ec8c5e1c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_0bf28d1f-b56a-4aaa-a53b-9de21706ea2e" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_92f3cfd5-9564-422d-ac1e-df1993f43e81" xlink:to="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_0bf28d1f-b56a-4aaa-a53b-9de21706ea2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_89e04671-8afa-473d-ab76-ef580f9eebe0" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_92f3cfd5-9564-422d-ac1e-df1993f43e81" xlink:to="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_89e04671-8afa-473d-ab76-ef580f9eebe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_a4a07251-120a-43ba-ad6b-d3e3b3894b71" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_92f3cfd5-9564-422d-ac1e-df1993f43e81" xlink:to="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_a4a07251-120a-43ba-ad6b-d3e3b3894b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureLessThan12MonthsNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale_be49e601-f969-43f7-9aaa-2bf689a297bb" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureLessThan12MonthsNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract_92f3cfd5-9564-422d-ac1e-df1993f43e81" xlink:to="loc_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureLessThan12MonthsNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale_be49e601-f969-43f7-9aaa-2bf689a297bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_5b5fc440-c5f0-4e34-acc6-404af043b62f" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f3b3c70-7029-4455-8afb-0af4fc5c073d" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_5b5fc440-c5f0-4e34-acc6-404af043b62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_e9506309-ac9d-4e59-adbb-fe604e673358" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_5b5fc440-c5f0-4e34-acc6-404af043b62f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_e9506309-ac9d-4e59-adbb-fe604e673358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost_19c0bec4-096c-4900-a84f-ca53449973b8" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_5b5fc440-c5f0-4e34-acc6-404af043b62f" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost_19c0bec4-096c-4900-a84f-ca53449973b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_6e27f868-3fc9-4b4b-8394-a7e044ab628c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_5b5fc440-c5f0-4e34-acc6-404af043b62f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_6e27f868-3fc9-4b4b-8394-a7e044ab628c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_68c61950-c007-435e-9cea-24b9d5b89c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_5b5fc440-c5f0-4e34-acc6-404af043b62f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_68c61950-c007-435e-9cea-24b9d5b89c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_30f5bc28-4318-4735-8645-9c33fb2e1120" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_5b5fc440-c5f0-4e34-acc6-404af043b62f" xlink:to="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_30f5bc28-4318-4735-8645-9c33fb2e1120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_a9449cce-c484-4415-9acd-b511a1180b87" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_5b5fc440-c5f0-4e34-acc6-404af043b62f" xlink:to="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_a9449cce-c484-4415-9acd-b511a1180b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_74cf61f1-c27f-4651-a534-56ce1c0de7de" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_5b5fc440-c5f0-4e34-acc6-404af043b62f" xlink:to="loc_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_74cf61f1-c27f-4651-a534-56ce1c0de7de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureTwelveMonthsOrLongerNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale_2925c021-1e20-46b5-aa62-7076ab083923" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureTwelveMonthsOrLongerNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract_5b5fc440-c5f0-4e34-acc6-404af043b62f" xlink:to="loc_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureTwelveMonthsOrLongerNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale_2925c021-1e20-46b5-aa62-7076ab083923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_b939beae-103a-4093-bbba-8b4434ad756c" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3f3b3c70-7029-4455-8afb-0af4fc5c073d" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_b939beae-103a-4093-bbba-8b4434ad756c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_824f3c31-5da3-4a3a-943e-8d2c8efddd9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_b939beae-103a-4093-bbba-8b4434ad756c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_824f3c31-5da3-4a3a-943e-8d2c8efddd9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost_d05927f2-ba80-4e8a-a6e1-166d9ddb7a6a" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_b939beae-103a-4093-bbba-8b4434ad756c" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost_d05927f2-ba80-4e8a-a6e1-166d9ddb7a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_fa0ef40b-52fb-4896-9d99-626003515f47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_b939beae-103a-4093-bbba-8b4434ad756c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_fa0ef40b-52fb-4896-9d99-626003515f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_8222dd49-b790-45a8-bb98-fc62b3a0d381" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_b939beae-103a-4093-bbba-8b4434ad756c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_8222dd49-b790-45a8-bb98-fc62b3a0d381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale_f3ef991b-83fe-4e7e-9c47-94da96dfe7ef" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_b939beae-103a-4093-bbba-8b4434ad756c" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale_f3ef991b-83fe-4e7e-9c47-94da96dfe7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_a7d7b9de-237f-4246-94bd-8b2e932badd5" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_b939beae-103a-4093-bbba-8b4434ad756c" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_a7d7b9de-237f-4246-94bd-8b2e932badd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_f94789dd-ea77-45f2-a9a5-f1aa0e70e08a" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_b939beae-103a-4093-bbba-8b4434ad756c" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_f94789dd-ea77-45f2-a9a5-f1aa0e70e08a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale_56e5c2a1-0c21-488f-b4c8-5853a4bae7b4" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract_b939beae-103a-4093-bbba-8b4434ad756c" xlink:to="loc_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale_56e5c2a1-0c21-488f-b4c8-5853a4bae7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails_1" xlink:type="simple" xlink:href="ci-20231231.xsd#InvestmentsDebtSecuritieswithaDeclineinFairValueDetails_1"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InvestmentsEquitySecurityInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6a70f8a2-5809-4140-8836-f111bffed38f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract_3a3c1e71-3b6a-4a68-8595-54db4ffd1137" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6a70f8a2-5809-4140-8836-f111bffed38f" xlink:to="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract_3a3c1e71-3b6a-4a68-8595-54db4ffd1137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_91b2985f-a5bc-47fa-86cc-cb5f1b2e1c35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract_3a3c1e71-3b6a-4a68-8595-54db4ffd1137" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_91b2985f-a5bc-47fa-86cc-cb5f1b2e1c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost_3bc94702-93b2-4393-a658-fd505afe4d88" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract_3a3c1e71-3b6a-4a68-8595-54db4ffd1137" xlink:to="loc_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost_3bc94702-93b2-4393-a658-fd505afe4d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost_6be74c57-319b-4c17-8f2a-9eccb8f1eed1" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract_3a3c1e71-3b6a-4a68-8595-54db4ffd1137" xlink:to="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost_6be74c57-319b-4c17-8f2a-9eccb8f1eed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFvNiCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_57a2cc8a-b292-4e00-9e95-169dd6efdc26" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesFvNiCostBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract_3a3c1e71-3b6a-4a68-8595-54db4ffd1137" xlink:to="loc_ci_EquitySecuritiesFvNiCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_57a2cc8a-b292-4e00-9e95-169dd6efdc26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_b4e3e5ff-af05-460a-8e19-0786e6d158ea" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract_3a3c1e71-3b6a-4a68-8595-54db4ffd1137" xlink:to="loc_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_b4e3e5ff-af05-460a-8e19-0786e6d158ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_94d4d670-1126-4c75-9366-63055ebd80d3" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract_3a3c1e71-3b6a-4a68-8595-54db4ffd1137" xlink:to="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale_94d4d670-1126-4c75-9366-63055ebd80d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract_3ca3fc0f-f9c3-4911-a4e9-b898adee24e3" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6a70f8a2-5809-4140-8836-f111bffed38f" xlink:to="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract_3ca3fc0f-f9c3-4911-a4e9-b898adee24e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_e631244d-5ea0-4536-8486-7dad424cc1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract_3ca3fc0f-f9c3-4911-a4e9-b898adee24e3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_e631244d-5ea0-4536-8486-7dad424cc1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_d38d36e7-207d-4ab8-b94e-537330089ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract_3ca3fc0f-f9c3-4911-a4e9-b898adee24e3" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_d38d36e7-207d-4ab8-b94e-537330089ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount_aba1460d-ff47-4f54-ab90-6312c179405b" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract_3ca3fc0f-f9c3-4911-a4e9-b898adee24e3" xlink:to="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount_aba1460d-ff47-4f54-ab90-6312c179405b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFvNiBeforeReclassificationToDisposalGroupAssetsHeldForSale_b7e234d2-8e1c-44b4-817b-14563fba73fe" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesFvNiBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract_3ca3fc0f-f9c3-4911-a4e9-b898adee24e3" xlink:to="loc_ci_EquitySecuritiesFvNiBeforeReclassificationToDisposalGroupAssetsHeldForSale_b7e234d2-8e1c-44b4-817b-14563fba73fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale_a27ed7e3-90fd-4987-8053-35b60daa986d" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract_3ca3fc0f-f9c3-4911-a4e9-b898adee24e3" xlink:to="loc_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale_a27ed7e3-90fd-4987-8053-35b60daa986d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale_bcab960a-c3ac-460f-aef4-28dfd000b370" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract_3ca3fc0f-f9c3-4911-a4e9-b898adee24e3" xlink:to="loc_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale_bcab960a-c3ac-460f-aef4-28dfd000b370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_5ec6a6c4-bfd9-40fe-b746-7a54471f7b39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6a70f8a2-5809-4140-8836-f111bffed38f" xlink:to="loc_us-gaap_OtherCommitmentsTable_5ec6a6c4-bfd9-40fe-b746-7a54471f7b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_df285630-ec74-49ae-bf70-89fa754a7c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_5ec6a6c4-bfd9-40fe-b746-7a54471f7b39" xlink:to="loc_us-gaap_OtherCommitmentsAxis_df285630-ec74-49ae-bf70-89fa754a7c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_4b0f008a-4887-4cbd-b695-f07b15668030" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_df285630-ec74-49ae-bf70-89fa754a7c3e" xlink:to="loc_us-gaap_OtherCommitmentsDomain_4b0f008a-4887-4cbd-b695-f07b15668030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CommitmentToPurchaseEquitySecuritiesMember_d781f325-1256-4895-aa16-a721aff87c59" xlink:href="ci-20231231.xsd#ci_CommitmentToPurchaseEquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_4b0f008a-4887-4cbd-b695-f07b15668030" xlink:to="loc_ci_CommitmentToPurchaseEquitySecuritiesMember_d781f325-1256-4895-aa16-a721aff87c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cb50cc2b-e9d2-4b23-8ee1-bb5b02dab875" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_5ec6a6c4-bfd9-40fe-b746-7a54471f7b39" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cb50cc2b-e9d2-4b23-8ee1-bb5b02dab875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4d04466e-b482-475a-9010-b1bac40ff13d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cb50cc2b-e9d2-4b23-8ee1-bb5b02dab875" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4d04466e-b482-475a-9010-b1bac40ff13d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFVNIMember_ac3bfd8a-34ad-4115-b531-d10eb6aa9f43" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesFVNIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4d04466e-b482-475a-9010-b1bac40ff13d" xlink:to="loc_ci_EquitySecuritiesFVNIMember_ac3bfd8a-34ad-4115-b531-d10eb6aa9f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_aa72cf31-7346-451d-8b1d-42cbbe3fa184" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_5ec6a6c4-bfd9-40fe-b746-7a54471f7b39" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_aa72cf31-7346-451d-8b1d-42cbbe3fa184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c2921636-17f0-4503-ad57-382d2144460c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_aa72cf31-7346-451d-8b1d-42cbbe3fa184" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c2921636-17f0-4503-ad57-382d2144460c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_4582970e-6e4f-42d6-9947-91dfaf129a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_c2921636-17f0-4503-ad57-382d2144460c" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_4582970e-6e4f-42d6-9947-91dfaf129a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesByIndustryAxis_ddce9802-3be7-4f50-9a6d-5d1462b1b49c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesByIndustryAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_5ec6a6c4-bfd9-40fe-b746-7a54471f7b39" xlink:to="loc_us-gaap_EquitySecuritiesByIndustryAxis_ddce9802-3be7-4f50-9a6d-5d1462b1b49c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_399fdf47-4ba3-4805-9ad6-1be8d78f3b95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesIndustryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_ddce9802-3be7-4f50-9a6d-5d1462b1b49c" xlink:to="loc_us-gaap_EquitySecuritiesIndustryMember_399fdf47-4ba3-4805-9ad6-1be8d78f3b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthcareSectorMember_e3bc95e9-0172-4f1c-8440-ba5986abc6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthcareSectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesIndustryMember_399fdf47-4ba3-4805-9ad6-1be8d78f3b95" xlink:to="loc_us-gaap_HealthcareSectorMember_e3bc95e9-0172-4f1c-8440-ba5986abc6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f2d19029-b8b0-42be-8ba8-466f63af884d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_5ec6a6c4-bfd9-40fe-b746-7a54471f7b39" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f2d19029-b8b0-42be-8ba8-466f63af884d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4d59ea51-fa14-4f1d-b29c-211ad9bcc33e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f2d19029-b8b0-42be-8ba8-466f63af884d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4d59ea51-fa14-4f1d-b29c-211ad9bcc33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6e1d8f94-3c11-437d-9d2f-1c289c6e5b02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4d59ea51-fa14-4f1d-b29c-211ad9bcc33e" xlink:to="loc_us-gaap_SubsequentEventMember_6e1d8f94-3c11-437d-9d2f-1c289c6e5b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_c0c39de0-76df-4fdf-b29a-a4476afee460" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_5ec6a6c4-bfd9-40fe-b746-7a54471f7b39" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_c0c39de0-76df-4fdf-b29a-a4476afee460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_079d81be-c56e-4c6f-b1dd-ae371b31eb15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c0c39de0-76df-4fdf-b29a-a4476afee460" xlink:to="loc_us-gaap_OtherCommitment_079d81be-c56e-4c6f-b1dd-ae371b31eb15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PaymentsToAcquireDebtAndEquitySecurities_6eda7e8e-0f8e-4896-b18b-018df43d865e" xlink:href="ci-20231231.xsd#ci_PaymentsToAcquireDebtAndEquitySecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c0c39de0-76df-4fdf-b29a-a4476afee460" xlink:to="loc_ci_PaymentsToAcquireDebtAndEquitySecurities_6eda7e8e-0f8e-4896-b18b-018df43d865e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_8cb1c69b-14e1-4230-83d2-77ae41c843da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c0c39de0-76df-4fdf-b29a-a4476afee460" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_8cb1c69b-14e1-4230-83d2-77ae41c843da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoanPortfolioDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InvestmentsCommercialMortgageLoanPortfolioDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoanPortfolioDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_846e856d-2756-4589-9926-b0c53f716553" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_828a9d02-cfa8-4fb4-b60d-435203f9ef9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_846e856d-2756-4589-9926-b0c53f716553" xlink:to="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_828a9d02-cfa8-4fb4-b60d-435203f9ef9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_6f1298f1-69e2-4ab0-8c87-3b72fcb0b113" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_828a9d02-cfa8-4fb4-b60d-435203f9ef9f" xlink:to="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_6f1298f1-69e2-4ab0-8c87-3b72fcb0b113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_978b7439-9157-4aec-99b6-8feee37302ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_6f1298f1-69e2-4ab0-8c87-3b72fcb0b113" xlink:to="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_978b7439-9157-4aec-99b6-8feee37302ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateLoanMember_3d9e96dc-61da-410b-b904-5f1a4d3f261c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstateLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_978b7439-9157-4aec-99b6-8feee37302ae" xlink:to="loc_us-gaap_RealEstateLoanMember_3d9e96dc-61da-410b-b904-5f1a4d3f261c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePortfolioSegmentAxis_73d1b16f-7103-4d45-b5f5-e1c8d0d21df8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablePortfolioSegmentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_828a9d02-cfa8-4fb4-b60d-435203f9ef9f" xlink:to="loc_us-gaap_FinancingReceivablePortfolioSegmentAxis_73d1b16f-7103-4d45-b5f5-e1c8d0d21df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePortfolioSegmentDomain_e27d71b7-d0cd-4afe-b164-6563bf836e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivablePortfolioSegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivablePortfolioSegmentAxis_73d1b16f-7103-4d45-b5f5-e1c8d0d21df8" xlink:to="loc_us-gaap_FinancingReceivablePortfolioSegmentDomain_e27d71b7-d0cd-4afe-b164-6563bf836e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPortfolioSegmentMember_492617d1-68d3-46c1-ba95-24758c116c76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPortfolioSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivablePortfolioSegmentDomain_e27d71b7-d0cd-4afe-b164-6563bf836e7f" xlink:to="loc_us-gaap_CommercialPortfolioSegmentMember_492617d1-68d3-46c1-ba95-24758c116c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoanToValueAxis_91e758b3-b56c-4a9e-8b17-3ec2a2d2e04b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoanToValueAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_828a9d02-cfa8-4fb4-b60d-435203f9ef9f" xlink:to="loc_us-gaap_LoanToValueAxis_91e758b3-b56c-4a9e-8b17-3ec2a2d2e04b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoanToValueDomain_21c41a7f-f46e-4e3a-ad23-91c0286862ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoanToValueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LoanToValueAxis_91e758b3-b56c-4a9e-8b17-3ec2a2d2e04b" xlink:to="loc_us-gaap_LoanToValueDomain_21c41a7f-f46e-4e3a-ad23-91c0286862ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LtvLessThan60PercentMember_54213cd3-6022-48c7-9f0d-020dddb234f9" xlink:href="ci-20231231.xsd#ci_LtvLessThan60PercentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LoanToValueDomain_21c41a7f-f46e-4e3a-ad23-91c0286862ba" xlink:to="loc_ci_LtvLessThan60PercentMember_54213cd3-6022-48c7-9f0d-020dddb234f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_Ltv60To79PercentMember_d5cd4329-71d6-43c5-af27-543959d962af" xlink:href="ci-20231231.xsd#ci_Ltv60To79PercentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LoanToValueDomain_21c41a7f-f46e-4e3a-ad23-91c0286862ba" xlink:to="loc_ci_Ltv60To79PercentMember_d5cd4329-71d6-43c5-af27-543959d962af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Ltv80To100PercentMember_f326e24f-b0a7-4cc0-b78d-05a0f373dcc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Ltv80To100PercentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LoanToValueDomain_21c41a7f-f46e-4e3a-ad23-91c0286862ba" xlink:to="loc_us-gaap_Ltv80To100PercentMember_f326e24f-b0a7-4cc0-b78d-05a0f373dcc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LtvGreaterThan100PercentMember_404dba71-8091-4fd2-89e1-dcb6ee35be92" xlink:href="ci-20231231.xsd#ci_LtvGreaterThan100PercentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LoanToValueDomain_21c41a7f-f46e-4e3a-ad23-91c0286862ba" xlink:to="loc_ci_LtvGreaterThan100PercentMember_404dba71-8091-4fd2-89e1-dcb6ee35be92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9982b693-2f70-4001-a966-36c203608fc9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_828a9d02-cfa8-4fb4-b60d-435203f9ef9f" xlink:to="loc_srt_RangeAxis_9982b693-2f70-4001-a966-36c203608fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ea831426-b003-4057-a13a-09a7c9f47ce1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9982b693-2f70-4001-a966-36c203608fc9" xlink:to="loc_srt_RangeMember_ea831426-b003-4057-a13a-09a7c9f47ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_ad0a5a48-7e16-442d-9e2a-4ecc763d4c7c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ea831426-b003-4057-a13a-09a7c9f47ce1" xlink:to="loc_srt_WeightedAverageMember_ad0a5a48-7e16-442d-9e2a-4ecc763d4c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_bb1bbdb3-e8be-4d71-967c-37a903596efd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_828a9d02-cfa8-4fb4-b60d-435203f9ef9f" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_bb1bbdb3-e8be-4d71-967c-37a903596efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss_14b56184-8b00-4067-a283-eee36e2d3b68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_bb1bbdb3-e8be-4d71-967c-37a903596efd" xlink:to="loc_us-gaap_FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss_14b56184-8b00-4067-a283-eee36e2d3b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest_f160420d-e2b5-417d-aa2d-be983f3baf37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_bb1bbdb3-e8be-4d71-967c-37a903596efd" xlink:to="loc_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest_f160420d-e2b5-417d-aa2d-be983f3baf37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss_fe2445f3-39a1-48ff-8b4c-b5763dd4e44e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_bb1bbdb3-e8be-4d71-967c-37a903596efd" xlink:to="loc_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss_fe2445f3-39a1-48ff-8b4c-b5763dd4e44e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio_52df0bed-7176-4e9b-a2ce-2cb355131451" xlink:href="ci-20231231.xsd#ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_bb1bbdb3-e8be-4d71-967c-37a903596efd" xlink:to="loc_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio_52df0bed-7176-4e9b-a2ce-2cb355131451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FinancingReceivableCreditQualityLoanToValueRatio_f80a2f9f-1420-4206-91e3-0f56065a224b" xlink:href="ci-20231231.xsd#ci_FinancingReceivableCreditQualityLoanToValueRatio"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_bb1bbdb3-e8be-4d71-967c-37a903596efd" xlink:to="loc_ci_FinancingReceivableCreditQualityLoanToValueRatio_f80a2f9f-1420-4206-91e3-0f56065a224b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_cab3639e-97dc-4925-b5d8-6509f8eacd3c" xlink:href="ci-20231231.xsd#ci_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_bb1bbdb3-e8be-4d71-967c-37a903596efd" xlink:to="loc_ci_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale_cab3639e-97dc-4925-b5d8-6509f8eacd3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale_c01dcda3-0bc3-4ef3-975c-a2db4d521bb9" xlink:href="ci-20231231.xsd#ci_FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_bb1bbdb3-e8be-4d71-967c-37a903596efd" xlink:to="loc_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale_c01dcda3-0bc3-4ef3-975c-a2db4d521bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FinancingReceivableCreditQualityLoanToValueRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale_9605ae16-4abf-4b8f-b34a-77889dd9e269" xlink:href="ci-20231231.xsd#ci_FinancingReceivableCreditQualityLoanToValueRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_bb1bbdb3-e8be-4d71-967c-37a903596efd" xlink:to="loc_ci_FinancingReceivableCreditQualityLoanToValueRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale_9605ae16-4abf-4b8f-b34a-77889dd9e269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InvestmentsOtherLongTermInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_834cc129-1619-4d2c-ad98-cff183736052" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_a6bd8653-b039-4c61-9672-55d8fb6d5dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_834cc129-1619-4d2c-ad98-cff183736052" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_a6bd8653-b039-4c61-9672-55d8fb6d5dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_9c02725b-9ad0-4a25-a25c-3a84ea6963d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_a6bd8653-b039-4c61-9672-55d8fb6d5dcd" xlink:to="loc_us-gaap_InvestmentTypeAxis_9c02725b-9ad0-4a25-a25c-3a84ea6963d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_442b6cda-a28f-44ef-86d3-7d477f052d33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_9c02725b-9ad0-4a25-a25c-3a84ea6963d6" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_442b6cda-a28f-44ef-86d3-7d477f052d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateInvestmentMember_fd3672bd-1b30-4e9d-888a-dd5606d61d90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstateInvestmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_442b6cda-a28f-44ef-86d3-7d477f052d33" xlink:to="loc_us-gaap_RealEstateInvestmentMember_fd3672bd-1b30-4e9d-888a-dd5606d61d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PartnershipInterestMember_6f27dc0c-6bd7-48c1-88a6-9c9497064e76" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PartnershipInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_442b6cda-a28f-44ef-86d3-7d477f052d33" xlink:to="loc_srt_PartnershipInterestMember_6f27dc0c-6bd7-48c1-88a6-9c9497064e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsMember_49d7bb80-5798-48f6-b6dd-de0cd5a0c543" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInvestmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_442b6cda-a28f-44ef-86d3-7d477f052d33" xlink:to="loc_us-gaap_OtherInvestmentsMember_49d7bb80-5798-48f6-b6dd-de0cd5a0c543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_9ae15585-ef0c-4c41-9d57-c3dad4dfa53c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_a6bd8653-b039-4c61-9672-55d8fb6d5dcd" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_9ae15585-ef0c-4c41-9d57-c3dad4dfa53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear_66d5f241-9eab-4d2f-900b-08e8addd596a" xlink:href="ci-20231231.xsd#ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_9ae15585-ef0c-4c41-9d57-c3dad4dfa53c" xlink:to="loc_ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear_66d5f241-9eab-4d2f-900b-08e8addd596a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_33671e42-442a-4f69-bb65-e8a1d17629a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_9ae15585-ef0c-4c41-9d57-c3dad4dfa53c" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_33671e42-442a-4f69-bb65-e8a1d17629a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_3bf081a8-aba4-4b31-8751-49a4a1060d50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_9ae15585-ef0c-4c41-9d57-c3dad4dfa53c" xlink:to="loc_us-gaap_OtherLongTermInvestments_3bf081a8-aba4-4b31-8751-49a4a1060d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherLongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_532839b4-bffc-4aea-9d91-3be542e49ba4" xlink:href="ci-20231231.xsd#ci_OtherLongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_9ae15585-ef0c-4c41-9d57-c3dad4dfa53c" xlink:to="loc_ci_OtherLongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_532839b4-bffc-4aea-9d91-3be542e49ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CommitmentsToContributeAdditionalEquityAndCapital_32a97bd7-e758-4db3-bec1-ef91ea015831" xlink:href="ci-20231231.xsd#ci_CommitmentsToContributeAdditionalEquityAndCapital"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_9ae15585-ef0c-4c41-9d57-c3dad4dfa53c" xlink:to="loc_ci_CommitmentsToContributeAdditionalEquityAndCapital_32a97bd7-e758-4db3-bec1-ef91ea015831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsSummaryofDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InvestmentsSummaryofDerivativeInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsSummaryofDerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_b3d1bc5b-7682-40b4-8e68-2b20f5bd3c05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_4ab28ae3-d381-44e7-a6bc-38e502e05c18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_b3d1bc5b-7682-40b4-8e68-2b20f5bd3c05" xlink:to="loc_us-gaap_DerivativeTable_4ab28ae3-d381-44e7-a6bc-38e502e05c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_d4aa312f-dca0-4d5b-a2b7-be0c0ca6d2f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_4ab28ae3-d381-44e7-a6bc-38e502e05c18" xlink:to="loc_us-gaap_HedgingDesignationAxis_d4aa312f-dca0-4d5b-a2b7-be0c0ca6d2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_615a68c8-d312-475e-b279-723898bc08e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_d4aa312f-dca0-4d5b-a2b7-be0c0ca6d2f5" xlink:to="loc_us-gaap_HedgingDesignationDomain_615a68c8-d312-475e-b279-723898bc08e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_eeaccf21-370f-4a86-8e7e-3b2bc9c0a28d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_615a68c8-d312-475e-b279-723898bc08e9" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_eeaccf21-370f-4a86-8e7e-3b2bc9c0a28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember_fa7417e6-013f-484f-ae18-0f9d94045a29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_615a68c8-d312-475e-b279-723898bc08e9" xlink:to="loc_us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember_fa7417e6-013f-484f-ae18-0f9d94045a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7721957f-5940-42ff-b1de-d285499755fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_4ab28ae3-d381-44e7-a6bc-38e502e05c18" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7721957f-5940-42ff-b1de-d285499755fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_58289131-f276-413b-998d-0f7f43472870" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7721957f-5940-42ff-b1de-d285499755fb" xlink:to="loc_us-gaap_HedgingRelationshipDomain_58289131-f276-413b-998d-0f7f43472870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_9741fd83-0ca1-4e6b-a9cb-9711be486a46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_58289131-f276-413b-998d-0f7f43472870" xlink:to="loc_us-gaap_FairValueHedgingMember_9741fd83-0ca1-4e6b-a9cb-9711be486a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_5628cd51-f692-4f7e-b4c8-38b976ce5cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_58289131-f276-413b-998d-0f7f43472870" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_5628cd51-f692-4f7e-b4c8-38b976ce5cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_66c1beb9-4f1f-4841-8715-c61583f72dac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_4ab28ae3-d381-44e7-a6bc-38e502e05c18" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_66c1beb9-4f1f-4841-8715-c61583f72dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7f95e3b8-be7b-4d55-9169-d32e70350483" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_66c1beb9-4f1f-4841-8715-c61583f72dac" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7f95e3b8-be7b-4d55-9169-d32e70350483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_9f575094-558a-4b42-9b85-f279b4fe1913" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7f95e3b8-be7b-4d55-9169-d32e70350483" xlink:to="loc_us-gaap_CurrencySwapMember_9f575094-558a-4b42-9b85-f279b4fe1913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_23b5e799-aa08-45f1-b9f4-1dcceead296e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7f95e3b8-be7b-4d55-9169-d32e70350483" xlink:to="loc_us-gaap_InterestRateSwapMember_23b5e799-aa08-45f1-b9f4-1dcceead296e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_dfcd7be1-2d39-42ec-a2ca-bc970d9608e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_4ab28ae3-d381-44e7-a6bc-38e502e05c18" xlink:to="loc_us-gaap_DerivativeLineItems_dfcd7be1-2d39-42ec-a2ca-bc970d9608e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_fb025141-9582-4b83-86f3-8ac9705156b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_dfcd7be1-2d39-42ec-a2ca-bc970d9608e2" xlink:to="loc_us-gaap_DerivativeNotionalAmount_fb025141-9582-4b83-86f3-8ac9705156b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DerivativeNotionalAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale_8bb8e11a-6864-47b9-94f8-ca8d79533701" xlink:href="ci-20231231.xsd#ci_DerivativeNotionalAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_dfcd7be1-2d39-42ec-a2ca-bc970d9608e2" xlink:to="loc_ci_DerivativeNotionalAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale_8bb8e11a-6864-47b9-94f8-ca8d79533701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InvestmentsComponentsofNetInvestmentIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_InvestmentIncomeAndGainsAndLossesAbstract_4e9d1aa2-6a42-4d95-9cec-66c5e3c893ee" xlink:href="ci-20231231.xsd#ci_InvestmentIncomeAndGainsAndLossesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_d9577f30-ec3d-442e-ae4d-b2c8cc55e3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_InvestmentIncomeAndGainsAndLossesAbstract_4e9d1aa2-6a42-4d95-9cec-66c5e3c893ee" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_d9577f30-ec3d-442e-ae4d-b2c8cc55e3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_9f9cef05-a71b-427e-b813-2a0dd5d98509" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_d9577f30-ec3d-442e-ae4d-b2c8cc55e3a4" xlink:to="loc_us-gaap_InvestmentTypeAxis_9f9cef05-a71b-427e-b813-2a0dd5d98509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_527c1052-b240-47fe-9d55-6c8870b975ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_9f9cef05-a71b-427e-b813-2a0dd5d98509" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_527c1052-b240-47fe-9d55-6c8870b975ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_6526deda-0e8d-4848-9b34-c4772b01a948" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_527c1052-b240-47fe-9d55-6c8870b975ca" xlink:to="loc_us-gaap_DebtSecuritiesMember_6526deda-0e8d-4848-9b34-c4772b01a948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_b5b76746-b1c6-4740-be36-5ccb877d4ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_527c1052-b240-47fe-9d55-6c8870b975ca" xlink:to="loc_us-gaap_EquitySecuritiesMember_b5b76746-b1c6-4740-be36-5ccb877d4ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgagesMember_19ca68dc-440f-4b0d-9e46-c4b93518815a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgagesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_527c1052-b240-47fe-9d55-6c8870b975ca" xlink:to="loc_us-gaap_MortgagesMember_19ca68dc-440f-4b0d-9e46-c4b93518815a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyLoansMember_4af3883a-7791-4a6b-8757-26443efc6b96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyLoansMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_527c1052-b240-47fe-9d55-6c8870b975ca" xlink:to="loc_us-gaap_PolicyLoansMember_4af3883a-7791-4a6b-8757-26443efc6b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestmentsMember_fc4f2457-bd3f-4aca-8f42-056cc3560a10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermInvestmentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_527c1052-b240-47fe-9d55-6c8870b975ca" xlink:to="loc_us-gaap_OtherLongTermInvestmentsMember_fc4f2457-bd3f-4aca-8f42-056cc3560a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CashCashEquivalentsAndShortTermInvestmentsMember_8ac06e76-02d3-44cf-b545-d5d1999afa9e" xlink:href="ci-20231231.xsd#ci_CashCashEquivalentsAndShortTermInvestmentsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_527c1052-b240-47fe-9d55-6c8870b975ca" xlink:to="loc_ci_CashCashEquivalentsAndShortTermInvestmentsMember_8ac06e76-02d3-44cf-b545-d5d1999afa9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_38e92676-0e59-46b0-8bdc-a6e1aa48b0e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_d9577f30-ec3d-442e-ae4d-b2c8cc55e3a4" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_38e92676-0e59-46b0-8bdc-a6e1aa48b0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue_1d65ee40-d002-49b3-8f6a-71b907c23a1e" xlink:href="ci-20231231.xsd#ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_38e92676-0e59-46b0-8bdc-a6e1aa48b0e5" xlink:to="loc_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue_1d65ee40-d002-49b3-8f6a-71b907c23a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInvestmentExpense_098a23d4-4b70-4ed8-9489-14ecc2534148" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_38e92676-0e59-46b0-8bdc-a6e1aa48b0e5" xlink:to="loc_us-gaap_InvestmentIncomeInvestmentExpense_098a23d4-4b70-4ed8-9489-14ecc2534148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_b72c4959-9a6e-44a5-9520-6ab0cff80c29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_38e92676-0e59-46b0-8bdc-a6e1aa48b0e5" xlink:to="loc_us-gaap_NetInvestmentIncome_b72c4959-9a6e-44a5-9520-6ab0cff80c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsRealizedGainsandLossesonInvestmentsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InvestmentsRealizedGainsandLossesonInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsRealizedGainsandLossesonInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_93daaa4a-5bc4-4c4a-a165-a72d7ff09da3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RealizedInvestmentGainLossExcludingImpairments_98c60d7a-2add-4b39-bfa2-91ffad98ea8e" xlink:href="ci-20231231.xsd#ci_RealizedInvestmentGainLossExcludingImpairments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_93daaa4a-5bc4-4c4a-a165-a72d7ff09da3" xlink:to="loc_ci_RealizedInvestmentGainLossExcludingImpairments_98c60d7a-2add-4b39-bfa2-91ffad98ea8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal_e8302511-f116-4466-ac55-fba85f3a66c4" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_93daaa4a-5bc4-4c4a-a165-a72d7ff09da3" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal_e8302511-f116-4466-ac55-fba85f3a66c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RealizedInvestmentGainLoss_7d29a904-f31a-4754-a50b-a7d471a69786" xlink:href="ci-20231231.xsd#ci_RealizedInvestmentGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_93daaa4a-5bc4-4c4a-a165-a72d7ff09da3" xlink:to="loc_ci_RealizedInvestmentGainLoss_7d29a904-f31a-4754-a50b-a7d471a69786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/InvestmentsSalesInformationforAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#InvestmentsSalesInformationforAvailableforSaleDebtSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/InvestmentsSalesInformationforAvailableforSaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1957ed94-6725-42a9-9880-45e22eed457b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_55520bc8-1bc5-4d73-96d4-43ace4efa175" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1957ed94-6725-42a9-9880-45e22eed457b" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_55520bc8-1bc5-4d73-96d4-43ace4efa175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_d0965c47-24db-466a-83a0-b46a13b388ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1957ed94-6725-42a9-9880-45e22eed457b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_d0965c47-24db-466a-83a0-b46a13b388ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_1ea0ce64-0d6f-48a5-80a7-da82860cc77f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1957ed94-6725-42a9-9880-45e22eed457b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_1ea0ce64-0d6f-48a5-80a7-da82860cc77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_70f85806-a4c4-4919-b736-fb25dcee305e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64ca39d0-34c7-4fe5-a3a0-f9aac902b7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_70f85806-a4c4-4919-b736-fb25dcee305e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64ca39d0-34c7-4fe5-a3a0-f9aac902b7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f83e43d7-5851-4918-8c81-7dc2b648ea19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64ca39d0-34c7-4fe5-a3a0-f9aac902b7cc" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f83e43d7-5851-4918-8c81-7dc2b648ea19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d23009ac-4679-4a20-9660-336257aa798d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f83e43d7-5851-4918-8c81-7dc2b648ea19" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d23009ac-4679-4a20-9660-336257aa798d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_baa26582-721a-4e00-bd97-b022632d510c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d23009ac-4679-4a20-9660-336257aa798d" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_baa26582-721a-4e00-bd97-b022632d510c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_078d1916-6edc-4bad-864d-4685f3579945" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d23009ac-4679-4a20-9660-336257aa798d" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_078d1916-6edc-4bad-864d-4685f3579945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_aaa9d664-65d5-42bd-8909-dc827b55ed75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d23009ac-4679-4a20-9660-336257aa798d" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_aaa9d664-65d5-42bd-8909-dc827b55ed75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1f7a670d-7258-416a-9a51-fbdc622995b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d23009ac-4679-4a20-9660-336257aa798d" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1f7a670d-7258-416a-9a51-fbdc622995b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_aab38264-1646-4ca6-a11b-7914b989222c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d23009ac-4679-4a20-9660-336257aa798d" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_aab38264-1646-4ca6-a11b-7914b989222c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bb6dfb79-a1d0-47ad-a25c-0b0ea08173b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64ca39d0-34c7-4fe5-a3a0-f9aac902b7cc" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bb6dfb79-a1d0-47ad-a25c-0b0ea08173b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_952d6370-9667-49b9-8d95-b752e6adb8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bb6dfb79-a1d0-47ad-a25c-0b0ea08173b8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_952d6370-9667-49b9-8d95-b752e6adb8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f532defa-75df-45e3-8dd3-31b57081854b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_952d6370-9667-49b9-8d95-b752e6adb8b9" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f532defa-75df-45e3-8dd3-31b57081854b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c8ae3e83-8c07-4941-9d2f-d64d71661615" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_952d6370-9667-49b9-8d95-b752e6adb8b9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c8ae3e83-8c07-4941-9d2f-d64d71661615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9a073dd9-d942-4227-85d5-88d4bb482809" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_952d6370-9667-49b9-8d95-b752e6adb8b9" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9a073dd9-d942-4227-85d5-88d4bb482809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0e1569f8-3ebf-4cb9-9725-f63d804fc35a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64ca39d0-34c7-4fe5-a3a0-f9aac902b7cc" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0e1569f8-3ebf-4cb9-9725-f63d804fc35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_47dd7d82-c5d9-47a7-af7c-ab19b8e7def6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0e1569f8-3ebf-4cb9-9725-f63d804fc35a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_47dd7d82-c5d9-47a7-af7c-ab19b8e7def6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d4350623-0ef6-4935-9196-181e8b60785c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_47dd7d82-c5d9-47a7-af7c-ab19b8e7def6" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d4350623-0ef6-4935-9196-181e8b60785c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3d88d160-fc76-4f8e-a4a2-10098e8a7c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64ca39d0-34c7-4fe5-a3a0-f9aac902b7cc" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3d88d160-fc76-4f8e-a4a2-10098e8a7c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_889ef326-29c7-4053-b964-62c1923c397d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3d88d160-fc76-4f8e-a4a2-10098e8a7c5a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_889ef326-29c7-4053-b964-62c1923c397d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ForwardsSwapsOptionsMember_d71e7b3f-7bd0-4fe8-bae1-0c5daab2b450" xlink:href="ci-20231231.xsd#ci_ForwardsSwapsOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_889ef326-29c7-4053-b964-62c1923c397d" xlink:to="loc_ci_ForwardsSwapsOptionsMember_d71e7b3f-7bd0-4fe8-bae1-0c5daab2b450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SwapMember_54a542c4-2531-456c-be8c-7a7fc85848a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ForwardsSwapsOptionsMember_d71e7b3f-7bd0-4fe8-bae1-0c5daab2b450" xlink:to="loc_us-gaap_SwapMember_54a542c4-2531-456c-be8c-7a7fc85848a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e986a12d-1460-41bf-bcae-f308fa44dc12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_64ca39d0-34c7-4fe5-a3a0-f9aac902b7cc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e986a12d-1460-41bf-bcae-f308fa44dc12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_61dd1a74-2f56-42a9-959d-d7b94c0cc9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e986a12d-1460-41bf-bcae-f308fa44dc12" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_61dd1a74-2f56-42a9-959d-d7b94c0cc9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6439b49f-16bc-4c8b-b332-9c94a75312e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_61dd1a74-2f56-42a9-959d-d7b94c0cc9ca" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6439b49f-16bc-4c8b-b332-9c94a75312e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_916a7181-e7fc-4cd9-b6a9-94a91397f59e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_61dd1a74-2f56-42a9-959d-d7b94c0cc9ca" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_916a7181-e7fc-4cd9-b6a9-94a91397f59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_c285a837-95c7-4e65-9314-2507c91b18e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_61dd1a74-2f56-42a9-959d-d7b94c0cc9ca" xlink:to="loc_us-gaap_OtherShortTermInvestments_c285a837-95c7-4e65-9314-2507c91b18e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_1d34b63a-caca-41a5-9a5e-6116f833f1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_61dd1a74-2f56-42a9-959d-d7b94c0cc9ca" xlink:to="loc_us-gaap_DerivativeAssets_1d34b63a-caca-41a5-9a5e-6116f833f1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_54b8fd52-06f3-410d-92fe-f6eadfc5c08d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_61dd1a74-2f56-42a9-959d-d7b94c0cc9ca" xlink:to="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_54b8fd52-06f3-410d-92fe-f6eadfc5c08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale_d0619554-cbff-41fa-ae06-0a840ab1c11e" xlink:href="ci-20231231.xsd#ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_61dd1a74-2f56-42a9-959d-d7b94c0cc9ca" xlink:to="loc_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale_d0619554-cbff-41fa-ae06-0a840ab1c11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EquitySecuritiesFvNiBeforeReclassificationToDisposalGroupAssetsHeldForSale_5a09e84d-1056-4d46-aece-50d2d2b9a2a2" xlink:href="ci-20231231.xsd#ci_EquitySecuritiesFvNiBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_61dd1a74-2f56-42a9-959d-d7b94c0cc9ca" xlink:to="loc_ci_EquitySecuritiesFvNiBeforeReclassificationToDisposalGroupAssetsHeldForSale_5a09e84d-1056-4d46-aece-50d2d2b9a2a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_659b711b-8f8c-4d53-abb0-603702fbe675" xlink:href="ci-20231231.xsd#ci_OtherShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_61dd1a74-2f56-42a9-959d-d7b94c0cc9ca" xlink:to="loc_ci_OtherShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale_659b711b-8f8c-4d53-abb0-603702fbe675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale_64c0f42e-46ae-4b7f-855c-36b60b5d7a21" xlink:href="ci-20231231.xsd#ci_DerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_61dd1a74-2f56-42a9-959d-d7b94c0cc9ca" xlink:to="loc_ci_DerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale_64c0f42e-46ae-4b7f-855c-36b60b5d7a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7ee83c96-eef2-4643-b524-512dfd7efde1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e986a12d-1460-41bf-bcae-f308fa44dc12" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7ee83c96-eef2-4643-b524-512dfd7efde1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_dbb12fd5-444c-4780-a17f-18b02065eefb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7ee83c96-eef2-4643-b524-512dfd7efde1" xlink:to="loc_us-gaap_DerivativeLiabilities_dbb12fd5-444c-4780-a17f-18b02065eefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DerivativeLiabilitiesBeforeReclassificationToDisposalGroupLiabilitiesHeldForSale_8e907ecd-8730-47b0-9cef-bab4397116a4" xlink:href="ci-20231231.xsd#ci_DerivativeLiabilitiesBeforeReclassificationToDisposalGroupLiabilitiesHeldForSale"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7ee83c96-eef2-4643-b524-512dfd7efde1" xlink:to="loc_ci_DerivativeLiabilitiesBeforeReclassificationToDisposalGroupLiabilitiesHeldForSale_8e907ecd-8730-47b0-9cef-bab4397116a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_31dd46c9-0a5e-4980-8103-91642c8ac353" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5bb4cc41-24e7-4211-9bc4-e535c7ce4095" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_31dd46c9-0a5e-4980-8103-91642c8ac353" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5bb4cc41-24e7-4211-9bc4-e535c7ce4095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2475c8a0-e4f2-47d3-a1cd-dbfccf88ccea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5bb4cc41-24e7-4211-9bc4-e535c7ce4095" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2475c8a0-e4f2-47d3-a1cd-dbfccf88ccea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dfc7d50f-3b62-41d7-8519-0655df596549" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2475c8a0-e4f2-47d3-a1cd-dbfccf88ccea" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dfc7d50f-3b62-41d7-8519-0655df596549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2d8f7608-5359-4196-951c-bd76acf7bc6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dfc7d50f-3b62-41d7-8519-0655df596549" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2d8f7608-5359-4196-951c-bd76acf7bc6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_3a4d9c54-58b8-4f61-96ab-1a334fda1ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5bb4cc41-24e7-4211-9bc4-e535c7ce4095" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_3a4d9c54-58b8-4f61-96ab-1a334fda1ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6334f544-2fdb-4baf-9fd1-ef38b9216e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_3a4d9c54-58b8-4f61-96ab-1a334fda1ed5" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6334f544-2fdb-4baf-9fd1-ef38b9216e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SeparateAccountAssetsMember_0d2cf362-8fe0-4daf-97fa-c6a11c08b517" xlink:href="ci-20231231.xsd#ci_SeparateAccountAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6334f544-2fdb-4baf-9fd1-ef38b9216e7e" xlink:to="loc_ci_SeparateAccountAssetsMember_0d2cf362-8fe0-4daf-97fa-c6a11c08b517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c09052d7-bdc9-4258-ac2d-6a77e45d5b95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5bb4cc41-24e7-4211-9bc4-e535c7ce4095" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c09052d7-bdc9-4258-ac2d-6a77e45d5b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7ebe968a-c16e-4e9e-a5d6-10725aceb3e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c09052d7-bdc9-4258-ac2d-6a77e45d5b95" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7ebe968a-c16e-4e9e-a5d6-10725aceb3e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_83aafadc-3a67-4f5b-8cee-a9208819f290" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7ebe968a-c16e-4e9e-a5d6-10725aceb3e1" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_83aafadc-3a67-4f5b-8cee-a9208819f290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_6b30f4f4-11e6-4947-89d6-9e271087be29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5bb4cc41-24e7-4211-9bc4-e535c7ce4095" xlink:to="loc_us-gaap_InvestmentTypeAxis_6b30f4f4-11e6-4947-89d6-9e271087be29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_e5841a2c-cc1d-4037-abb8-f7f963447d26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_6b30f4f4-11e6-4947-89d6-9e271087be29" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_e5841a2c-cc1d-4037-abb8-f7f963447d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PartnershipInterestMember_0fdae4c2-e759-48a7-8c53-8f2bcf54f544" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PartnershipInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_e5841a2c-cc1d-4037-abb8-f7f963447d26" xlink:to="loc_srt_PartnershipInterestMember_0fdae4c2-e759-48a7-8c53-8f2bcf54f544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_69b5fbaa-0f74-478c-b2ea-3c68bd5e80cd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5bb4cc41-24e7-4211-9bc4-e535c7ce4095" xlink:to="loc_srt_RangeAxis_69b5fbaa-0f74-478c-b2ea-3c68bd5e80cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3b7e3406-801a-4677-bcbb-4dce10aed67d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_69b5fbaa-0f74-478c-b2ea-3c68bd5e80cd" xlink:to="loc_srt_RangeMember_3b7e3406-801a-4677-bcbb-4dce10aed67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_54863555-dc86-46cc-bd63-2e62dbb11e13" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3b7e3406-801a-4677-bcbb-4dce10aed67d" xlink:to="loc_srt_MaximumMember_54863555-dc86-46cc-bd63-2e62dbb11e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_8bcbb3fc-9713-4251-9126-24dd422ea770" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5bb4cc41-24e7-4211-9bc4-e535c7ce4095" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_8bcbb3fc-9713-4251-9126-24dd422ea770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e9fd610f-13ed-43f4-b2e0-bdc09bc8430b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_8bcbb3fc-9713-4251-9126-24dd422ea770" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e9fd610f-13ed-43f4-b2e0-bdc09bc8430b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SwapMember_d64fa164-5a5e-422f-b00d-c36a113a1d02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e9fd610f-13ed-43f4-b2e0-bdc09bc8430b" xlink:to="loc_us-gaap_SwapMember_d64fa164-5a5e-422f-b00d-c36a113a1d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b564d935-fec3-4907-b1c8-81d5f36b9a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5bb4cc41-24e7-4211-9bc4-e535c7ce4095" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b564d935-fec3-4907-b1c8-81d5f36b9a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtAndEquitySecuritiesClassifiedInLevel2PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale_a8cf5f69-78b3-493b-bdd0-63e7e73db986" xlink:href="ci-20231231.xsd#ci_DebtAndEquitySecuritiesClassifiedInLevel2PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b564d935-fec3-4907-b1c8-81d5f36b9a9c" xlink:to="loc_ci_DebtAndEquitySecuritiesClassifiedInLevel2PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale_a8cf5f69-78b3-493b-bdd0-63e7e73db986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MaximumPercentLevel2InvestmentsForeignBondsBrokerQuoteBeforeReclassificationToDisposalGroupAssetsHeldForSale_4ebbda2d-e716-4b05-89a6-f13b435bc957" xlink:href="ci-20231231.xsd#ci_MaximumPercentLevel2InvestmentsForeignBondsBrokerQuoteBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b564d935-fec3-4907-b1c8-81d5f36b9a9c" xlink:to="loc_ci_MaximumPercentLevel2InvestmentsForeignBondsBrokerQuoteBeforeReclassificationToDisposalGroupAssetsHeldForSale_4ebbda2d-e716-4b05-89a6-f13b435bc957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DerivativeCreditRiskValuationAdjustmentDerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale_73137cbe-7c41-49cf-b2e2-98026a759dd7" xlink:href="ci-20231231.xsd#ci_DerivativeCreditRiskValuationAdjustmentDerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b564d935-fec3-4907-b1c8-81d5f36b9a9c" xlink:to="loc_ci_DerivativeCreditRiskValuationAdjustmentDerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale_73137cbe-7c41-49cf-b2e2-98026a759dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtAndEquitySecuritiesClassifiedInLevel3PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale_31581ec0-0a33-4892-b8ca-18f783576a3a" xlink:href="ci-20231231.xsd#ci_DebtAndEquitySecuritiesClassifiedInLevel3PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b564d935-fec3-4907-b1c8-81d5f36b9a9c" xlink:to="loc_ci_DebtAndEquitySecuritiesClassifiedInLevel3PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale_31581ec0-0a33-4892-b8ca-18f783576a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeAssets_c4530221-0b65-4b5a-bfbe-c81f7ecfe260" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b564d935-fec3-4907-b1c8-81d5f36b9a9c" xlink:to="loc_us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeAssets_c4530221-0b65-4b5a-bfbe-c81f7ecfe260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilitiesBeforeReclassificationToDisposalGroupAssetsHeldForSale_4f58e2b6-9a08-4bc6-b0c4-c5a13ed32cfd" xlink:href="ci-20231231.xsd#ci_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilitiesBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b564d935-fec3-4907-b1c8-81d5f36b9a9c" xlink:to="loc_ci_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilitiesBeforeReclassificationToDisposalGroupAssetsHeldForSale_4f58e2b6-9a08-4bc6-b0c4-c5a13ed32cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities_81b6d9d5-c920-4daf-8f7a-04c763f1e829" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b564d935-fec3-4907-b1c8-81d5f36b9a9c" xlink:to="loc_us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities_81b6d9d5-c920-4daf-8f7a-04c763f1e829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_ff1bf4aa-abaf-4581-99d7-7d41430001f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b564d935-fec3-4907-b1c8-81d5f36b9a9c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_ff1bf4aa-abaf-4581-99d7-7d41430001f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecreaseIncludingDisposalGroups_121bb2eb-e8f0-4300-8f62-1202c37cdbc5" xlink:href="ci-20231231.xsd#ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecreaseIncludingDisposalGroups"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b564d935-fec3-4907-b1c8-81d5f36b9a9c" xlink:to="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecreaseIncludingDisposalGroups_121bb2eb-e8f0-4300-8f62-1202c37cdbc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLiquidatingInvestmentPeriodFromInceptionSecuritiesPartnerships_99e6eeae-386d-45d5-b960-0823dea5a655" xlink:href="ci-20231231.xsd#ci_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLiquidatingInvestmentPeriodFromInceptionSecuritiesPartnerships"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b564d935-fec3-4907-b1c8-81d5f36b9a9c" xlink:to="loc_ci_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLiquidatingInvestmentPeriodFromInceptionSecuritiesPartnerships_99e6eeae-386d-45d5-b960-0823dea5a655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5562fa0a-9cbe-4512-929b-0a79258def80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_785ef25d-ccde-4b35-bbb8-a9c579396651" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5562fa0a-9cbe-4512-929b-0a79258def80" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_785ef25d-ccde-4b35-bbb8-a9c579396651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_3519acc8-4c1e-4aae-9951-476b5f27dbf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_785ef25d-ccde-4b35-bbb8-a9c579396651" xlink:to="loc_us-gaap_FinancialInstrumentAxis_3519acc8-4c1e-4aae-9951-476b5f27dbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3f940319-0867-4fb4-a314-0c45db7acd13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3519acc8-4c1e-4aae-9951-476b5f27dbf9" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3f940319-0867-4fb4-a314-0c45db7acd13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_bd16e019-706a-4ffa-95b5-4d8b0e6ed3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3f940319-0867-4fb4-a314-0c45db7acd13" xlink:to="loc_us-gaap_DebtSecuritiesMember_bd16e019-706a-4ffa-95b5-4d8b0e6ed3c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CorporateAndGovernmentDebtSecuritiesMember_a9242938-808f-4dae-a2d3-024867985929" xlink:href="ci-20231231.xsd#ci_CorporateAndGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesMember_bd16e019-706a-4ffa-95b5-4d8b0e6ed3c5" xlink:to="loc_ci_CorporateAndGovernmentDebtSecuritiesMember_a9242938-808f-4dae-a2d3-024867985929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_63232a38-c8f0-42c3-a412-e3f7f8f70488" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesMember_bd16e019-706a-4ffa-95b5-4d8b0e6ed3c5" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_63232a38-c8f0-42c3-a412-e3f7f8f70488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_4ec187bf-6c6c-4243-8887-17b7389d2e33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesMember_bd16e019-706a-4ffa-95b5-4d8b0e6ed3c5" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_4ec187bf-6c6c-4243-8887-17b7389d2e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_4ccb9916-f387-4469-94b8-003850fa0ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_785ef25d-ccde-4b35-bbb8-a9c579396651" xlink:to="loc_us-gaap_ValuationTechniqueAxis_4ccb9916-f387-4469-94b8-003850fa0ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_618da81e-32fa-42f8-aac8-e31c06eaa18e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_4ccb9916-f387-4469-94b8-003850fa0ab8" xlink:to="loc_us-gaap_ValuationTechniqueDomain_618da81e-32fa-42f8-aac8-e31c06eaa18e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnobservableInputsDevelopedByCompanyMember_303e17c0-2f66-4e9e-a7de-ee9fbe912e0b" xlink:href="ci-20231231.xsd#ci_UnobservableInputsDevelopedByCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_618da81e-32fa-42f8-aac8-e31c06eaa18e" xlink:to="loc_ci_UnobservableInputsDevelopedByCompanyMember_303e17c0-2f66-4e9e-a7de-ee9fbe912e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnobservableInputsNotDevelopedByCompanyMember_ff6d8d54-843b-433f-8ec8-6fe1596eb18a" xlink:href="ci-20231231.xsd#ci_UnobservableInputsNotDevelopedByCompanyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_618da81e-32fa-42f8-aac8-e31c06eaa18e" xlink:to="loc_ci_UnobservableInputsNotDevelopedByCompanyMember_ff6d8d54-843b-433f-8ec8-6fe1596eb18a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b1a46642-d5da-4129-a47c-e7bfa6414504" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_785ef25d-ccde-4b35-bbb8-a9c579396651" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b1a46642-d5da-4129-a47c-e7bfa6414504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8352e7ed-f610-4824-aa5e-e6d351ab0bef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b1a46642-d5da-4129-a47c-e7bfa6414504" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8352e7ed-f610-4824-aa5e-e6d351ab0bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_fa7dac15-5329-4e54-8bef-f3b2a71a457c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_8352e7ed-f610-4824-aa5e-e6d351ab0bef" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_fa7dac15-5329-4e54-8bef-f3b2a71a457c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3cb6bb77-c3cf-4889-9101-7389ac17922f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_785ef25d-ccde-4b35-bbb8-a9c579396651" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3cb6bb77-c3cf-4889-9101-7389ac17922f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fd087ed8-c815-4ccd-94cd-4f81f8d851af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3cb6bb77-c3cf-4889-9101-7389ac17922f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fd087ed8-c815-4ccd-94cd-4f81f8d851af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_893d8ea8-0545-4e3e-abe8-afb8d9511eea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fd087ed8-c815-4ccd-94cd-4f81f8d851af" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_893d8ea8-0545-4e3e-abe8-afb8d9511eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_12f579c4-1df0-45aa-8463-868040eca092" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_785ef25d-ccde-4b35-bbb8-a9c579396651" xlink:to="loc_srt_RangeAxis_12f579c4-1df0-45aa-8463-868040eca092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_356c1bfd-1c90-4be2-ae9a-fc0a7e11d68f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_12f579c4-1df0-45aa-8463-868040eca092" xlink:to="loc_srt_RangeMember_356c1bfd-1c90-4be2-ae9a-fc0a7e11d68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5e691bc0-1b33-4833-9639-38dbc3b197ae" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_356c1bfd-1c90-4be2-ae9a-fc0a7e11d68f" xlink:to="loc_srt_MinimumMember_5e691bc0-1b33-4833-9639-38dbc3b197ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_23eecbdf-33c6-4fe2-b915-fc6b4938bdfc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_356c1bfd-1c90-4be2-ae9a-fc0a7e11d68f" xlink:to="loc_srt_MaximumMember_23eecbdf-33c6-4fe2-b915-fc6b4938bdfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_4d5e70bb-75ab-4deb-9f41-50cece3e1d66" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_356c1bfd-1c90-4be2-ae9a-fc0a7e11d68f" xlink:to="loc_srt_WeightedAverageMember_4d5e70bb-75ab-4deb-9f41-50cece3e1d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1d399c59-68ea-4e02-9593-d0b29dafb682" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_785ef25d-ccde-4b35-bbb8-a9c579396651" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1d399c59-68ea-4e02-9593-d0b29dafb682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_0b8f4b25-9463-4551-89ed-68fc84ebd71a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1d399c59-68ea-4e02-9593-d0b29dafb682" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_0b8f4b25-9463-4551-89ed-68fc84ebd71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MeasurementInputLiquidityMember_69b18327-69fe-4221-a82c-2a79aa82dadf" xlink:href="ci-20231231.xsd#ci_MeasurementInputLiquidityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0b8f4b25-9463-4551-89ed-68fc84ebd71a" xlink:to="loc_ci_MeasurementInputLiquidityMember_69b18327-69fe-4221-a82c-2a79aa82dadf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_cf129118-d018-4248-9fc6-e8e369e03024" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_785ef25d-ccde-4b35-bbb8-a9c579396651" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_cf129118-d018-4248-9fc6-e8e369e03024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_8362a071-005a-402d-8303-b91582c18e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_cf129118-d018-4248-9fc6-e8e369e03024" xlink:to="loc_us-gaap_MarketableSecurities_8362a071-005a-402d-8303-b91582c18e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MarketableSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale_c16a86ac-1cae-4857-a0f3-a1ebbbddcdcc" xlink:href="ci-20231231.xsd#ci_MarketableSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_cf129118-d018-4248-9fc6-e8e369e03024" xlink:to="loc_ci_MarketableSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale_c16a86ac-1cae-4857-a0f3-a1ebbbddcdcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput_0bacfb14-3557-4412-9aca-da005e41f5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_cf129118-d018-4248-9fc6-e8e369e03024" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput_0bacfb14-3557-4412-9aca-da005e41f5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput_1ef687b3-4ea0-419e-9c4f-5bc043e98a11" xlink:href="ci-20231231.xsd#ci_DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_cf129118-d018-4248-9fc6-e8e369e03024" xlink:to="loc_ci_DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput_1ef687b3-4ea0-419e-9c4f-5bc043e98a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_06418c6b-2e22-4c09-a812-1dbb29ead764" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_48dadf0e-9479-476f-8524-4cc992a2abac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_06418c6b-2e22-4c09-a812-1dbb29ead764" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_48dadf0e-9479-476f-8524-4cc992a2abac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_ad12ae11-175c-46ac-afaf-2733a8bf1020" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_48dadf0e-9479-476f-8524-4cc992a2abac" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_ad12ae11-175c-46ac-afaf-2733a8bf1020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a645a429-4268-4279-8252-e053873a4829" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_ad12ae11-175c-46ac-afaf-2733a8bf1020" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a645a429-4268-4279-8252-e053873a4829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtAndEquitySecuritiesMember_bd0c9fa9-1219-420c-8c05-e37ffb4c7489" xlink:href="ci-20231231.xsd#ci_DebtAndEquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a645a429-4268-4279-8252-e053873a4829" xlink:to="loc_ci_DebtAndEquitySecuritiesMember_bd0c9fa9-1219-420c-8c05-e37ffb4c7489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fa229ba4-c18f-4b14-8ba1-596296a58c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_48dadf0e-9479-476f-8524-4cc992a2abac" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fa229ba4-c18f-4b14-8ba1-596296a58c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f780c0d-4651-4050-b1a3-6731014137fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fa229ba4-c18f-4b14-8ba1-596296a58c6a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f780c0d-4651-4050-b1a3-6731014137fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0b4f30e7-3cfc-40e1-a15d-b2d39a768d50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f780c0d-4651-4050-b1a3-6731014137fa" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0b4f30e7-3cfc-40e1-a15d-b2d39a768d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3d8d38f8-a440-45c3-b387-0649af1726e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_48dadf0e-9479-476f-8524-4cc992a2abac" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3d8d38f8-a440-45c3-b387-0649af1726e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3eda2431-7afa-4c3c-b240-5d44dbdf13a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3d8d38f8-a440-45c3-b387-0649af1726e1" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3eda2431-7afa-4c3c-b240-5d44dbdf13a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_996b73bf-5480-4de9-a2c0-1123145b9d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3eda2431-7afa-4c3c-b240-5d44dbdf13a1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_996b73bf-5480-4de9-a2c0-1123145b9d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_8ae6f8ec-c5df-4778-84cf-290a2fe13ee9" xlink:href="ci-20231231.xsd#ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3eda2431-7afa-4c3c-b240-5d44dbdf13a1" xlink:to="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_8ae6f8ec-c5df-4778-84cf-290a2fe13ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_d638b7cb-aaaa-46a0-9949-2de0bd0af227" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3eda2431-7afa-4c3c-b240-5d44dbdf13a1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_d638b7cb-aaaa-46a0-9949-2de0bd0af227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_483f14cd-1d45-4b7c-b2b5-465e5ea3bad1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3eda2431-7afa-4c3c-b240-5d44dbdf13a1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_483f14cd-1d45-4b7c-b2b5-465e5ea3bad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits_07cb5ea2-f308-4cd3-b105-f07090f3c0bc" xlink:href="ci-20231231.xsd#ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3eda2431-7afa-4c3c-b240-5d44dbdf13a1" xlink:to="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits_07cb5ea2-f308-4cd3-b105-f07090f3c0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract_1b652b78-0730-4119-96f3-e2dbf6671523" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3eda2431-7afa-4c3c-b240-5d44dbdf13a1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract_1b652b78-0730-4119-96f3-e2dbf6671523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_3e5fc4f0-35de-4b0d-a6d2-7aae47c90716" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract_1b652b78-0730-4119-96f3-e2dbf6671523" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_3e5fc4f0-35de-4b0d-a6d2-7aae47c90716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales_75f45764-6bc2-4296-94c9-3a0210abfdc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract_1b652b78-0730-4119-96f3-e2dbf6671523" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales_75f45764-6bc2-4296-94c9-3a0210abfdc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_b8431ddc-15d2-4a3b-b25a-8700bcb64b87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract_1b652b78-0730-4119-96f3-e2dbf6671523" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_b8431ddc-15d2-4a3b-b25a-8700bcb64b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements_87edd136-4a7d-4a33-89cb-fb05c3efd903" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract_1b652b78-0730-4119-96f3-e2dbf6671523" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements_87edd136-4a7d-4a33-89cb-fb05c3efd903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_6cd676bf-74bd-41f6-aee0-c7548556ed2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3eda2431-7afa-4c3c-b240-5d44dbdf13a1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_6cd676bf-74bd-41f6-aee0-c7548556ed2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_8f8d0618-e710-46ca-b512-8885f5cc6946" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_6cd676bf-74bd-41f6-aee0-c7548556ed2b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_8f8d0618-e710-46ca-b512-8885f5cc6946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_4d229edc-9887-45f7-9331-938c69057f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_6cd676bf-74bd-41f6-aee0-c7548556ed2b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_4d229edc-9887-45f7-9331-938c69057f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_0893a975-64f9-44c2-a216-503223b6d86e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_6cd676bf-74bd-41f6-aee0-c7548556ed2b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_0893a975-64f9-44c2-a216-503223b6d86e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_17bbfb5c-7641-48bf-b9d1-e5301e2005f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3eda2431-7afa-4c3c-b240-5d44dbdf13a1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_17bbfb5c-7641-48bf-b9d1-e5301e2005f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_10e8a4cf-f879-4989-a086-69f7625efed4" xlink:href="ci-20231231.xsd#ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_3eda2431-7afa-4c3c-b240-5d44dbdf13a1" xlink:to="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_10e8a4cf-f879-4989-a086-69f7625efed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAttributedToInstrumentsHeldIncludedInEarnings_912dbc49-7861-4921-9c0d-c294d8c0f561" xlink:href="ci-20231231.xsd#ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAttributedToInstrumentsHeldIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3d8d38f8-a440-45c3-b387-0649af1726e1" xlink:to="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAttributedToInstrumentsHeldIncludedInEarnings_912dbc49-7861-4921-9c0d-c294d8c0f561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss_8303508a-f31c-4523-8244-9e7692800586" xlink:href="ci-20231231.xsd#ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3d8d38f8-a440-45c3-b387-0649af1726e1" xlink:to="loc_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss_8303508a-f31c-4523-8244-9e7692800586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsFairValuesofSeparateAccountAssetsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#FairValueMeasurementsFairValuesofSeparateAccountAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurementsFairValuesofSeparateAccountAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9a56b45a-edf6-428c-be4b-05e56fb0e23b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_61380f11-88ab-447e-bbd5-6c8557c92714" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9a56b45a-edf6-428c-be4b-05e56fb0e23b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_61380f11-88ab-447e-bbd5-6c8557c92714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ab44dbe6-a1d7-4c32-ab85-45890f585a94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_61380f11-88ab-447e-bbd5-6c8557c92714" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ab44dbe6-a1d7-4c32-ab85-45890f585a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1fe65bc-5433-45da-bfa4-4dff8f8ade83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ab44dbe6-a1d7-4c32-ab85-45890f585a94" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1fe65bc-5433-45da-bfa4-4dff8f8ade83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_27c3d602-3ee6-4aa5-8551-411c5bcdb010" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1fe65bc-5433-45da-bfa4-4dff8f8ade83" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_27c3d602-3ee6-4aa5-8551-411c5bcdb010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8f28de40-5379-485c-a6df-faf80c7a4417" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1fe65bc-5433-45da-bfa4-4dff8f8ade83" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8f28de40-5379-485c-a6df-faf80c7a4417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c0faccba-7b47-4d8b-99e5-5331a89cbcc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1fe65bc-5433-45da-bfa4-4dff8f8ade83" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c0faccba-7b47-4d8b-99e5-5331a89cbcc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_3de66032-f5ab-43ad-bfa5-cbaeb3f36dce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_61380f11-88ab-447e-bbd5-6c8557c92714" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_3de66032-f5ab-43ad-bfa5-cbaeb3f36dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_e1feda87-e375-4be5-be29-508ee75f6295" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_3de66032-f5ab-43ad-bfa5-cbaeb3f36dce" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_e1feda87-e375-4be5-be29-508ee75f6295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_46a5f8be-8e14-4553-a1f5-39d0e021e914" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_e1feda87-e375-4be5-be29-508ee75f6295" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_46a5f8be-8e14-4553-a1f5-39d0e021e914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ccfa13e5-bc49-4796-bdc4-6ad977a5b98b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_61380f11-88ab-447e-bbd5-6c8557c92714" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ccfa13e5-bc49-4796-bdc4-6ad977a5b98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_GuaranteedSeparateAccountAssets_26dffe73-d8fe-4aae-bd6e-af40c285eb09" xlink:href="ci-20231231.xsd#ci_GuaranteedSeparateAccountAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ccfa13e5-bc49-4796-bdc4-6ad977a5b98b" xlink:to="loc_ci_GuaranteedSeparateAccountAssets_26dffe73-d8fe-4aae-bd6e-af40c285eb09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy_d9df8372-52b1-432b-baed-ba183a524d9d" xlink:href="ci-20231231.xsd#ci_NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ccfa13e5-bc49-4796-bdc4-6ad977a5b98b" xlink:to="loc_ci_NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy_d9df8372-52b1-432b-baed-ba183a524d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SeparateAccountAssetsClassifiedInFairValueHierarchy_ea59f724-6989-4f09-b88b-35f6f4943cf0" xlink:href="ci-20231231.xsd#ci_SeparateAccountAssetsClassifiedInFairValueHierarchy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ccfa13e5-bc49-4796-bdc4-6ad977a5b98b" xlink:to="loc_ci_SeparateAccountAssetsClassifiedInFairValueHierarchy_ea59f724-6989-4f09-b88b-35f6f4943cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NonGuaranteedSeparateAccountAssetsPricedAtNetAssetValueAsAPracticalExpedient_4fbfd118-6aa6-4f9d-9c99-b73b56a0d16f" xlink:href="ci-20231231.xsd#ci_NonGuaranteedSeparateAccountAssetsPricedAtNetAssetValueAsAPracticalExpedient"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ccfa13e5-bc49-4796-bdc4-6ad977a5b98b" xlink:to="loc_ci_NonGuaranteedSeparateAccountAssetsPricedAtNetAssetValueAsAPracticalExpedient_4fbfd118-6aa6-4f9d-9c99-b73b56a0d16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeparateAccountAssets_77642e7f-0314-45c4-b3cd-9b7372b290c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeparateAccountAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ccfa13e5-bc49-4796-bdc4-6ad977a5b98b" xlink:to="loc_us-gaap_SeparateAccountAssets_77642e7f-0314-45c4-b3cd-9b7372b290c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsAdditionalInformationonSeparateAccountAssetsPricedatNetAssetValueDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#FairValueMeasurementsAdditionalInformationonSeparateAccountAssetsPricedatNetAssetValueDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurementsAdditionalInformationonSeparateAccountAssetsPricedatNetAssetValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_829d8eb8-d15c-48e4-af1c-232deb7acd6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable_ab791894-c7cf-4bf1-93d2-a364e31858ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_829d8eb8-d15c-48e4-af1c-232deb7acd6f" xlink:to="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable_ab791894-c7cf-4bf1-93d2-a364e31858ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_8057f4c9-d8b9-4eb7-a490-4af21eb66da4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable_ab791894-c7cf-4bf1-93d2-a364e31858ef" xlink:to="loc_us-gaap_InvestmentTypeAxis_8057f4c9-d8b9-4eb7-a490-4af21eb66da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_6a0746b5-a2fc-4bbe-bc2b-7cac52c9edad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_8057f4c9-d8b9-4eb7-a490-4af21eb66da4" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_6a0746b5-a2fc-4bbe-bc2b-7cac52c9edad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PartnershipInterestMember_341bca72-6c79-4cb7-a38e-a51190febad7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PartnershipInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6a0746b5-a2fc-4bbe-bc2b-7cac52c9edad" xlink:to="loc_srt_PartnershipInterestMember_341bca72-6c79-4cb7-a38e-a51190febad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateFundsMember_a74a15a7-51c8-4f40-8166-d53c12bd7287" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstateFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6a0746b5-a2fc-4bbe-bc2b-7cac52c9edad" xlink:to="loc_us-gaap_RealEstateFundsMember_a74a15a7-51c8-4f40-8166-d53c12bd7287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgeFundsMember_f11eaae8-264a-4868-8291-511582e4a693" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgeFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6a0746b5-a2fc-4bbe-bc2b-7cac52c9edad" xlink:to="loc_us-gaap_HedgeFundsMember_f11eaae8-264a-4868-8291-511582e4a693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_423ed2ab-c640-4a58-87b8-e7c4f84ae954" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable_ab791894-c7cf-4bf1-93d2-a364e31858ef" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_423ed2ab-c640-4a58-87b8-e7c4f84ae954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4123351e-8d10-49bc-b81e-a2a4b955d69e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_423ed2ab-c640-4a58-87b8-e7c4f84ae954" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4123351e-8d10-49bc-b81e-a2a4b955d69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SeparateAccountAssetsMember_006c70b0-0f44-421d-8b47-f75823befcb4" xlink:href="ci-20231231.xsd#ci_SeparateAccountAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4123351e-8d10-49bc-b81e-a2a4b955d69e" xlink:to="loc_ci_SeparateAccountAssetsMember_006c70b0-0f44-421d-8b47-f75823befcb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_90e4c2e5-c5a0-48d0-be99-db09cd1cb9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable_ab791894-c7cf-4bf1-93d2-a364e31858ef" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_90e4c2e5-c5a0-48d0-be99-db09cd1cb9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9c41257f-f7f4-466b-aa0c-faf75bede922" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_90e4c2e5-c5a0-48d0-be99-db09cd1cb9ec" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9c41257f-f7f4-466b-aa0c-faf75bede922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_c34f17de-121b-4d7c-9acc-5aa2cfb7d865" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9c41257f-f7f4-466b-aa0c-faf75bede922" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_c34f17de-121b-4d7c-9acc-5aa2cfb7d865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_59aba48f-3c05-4474-b803-ff7af43a7df7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable_ab791894-c7cf-4bf1-93d2-a364e31858ef" xlink:to="loc_srt_RangeAxis_59aba48f-3c05-4474-b803-ff7af43a7df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dd8744b2-63d8-42c2-834e-7251d2a66e57" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_59aba48f-3c05-4474-b803-ff7af43a7df7" xlink:to="loc_srt_RangeMember_dd8744b2-63d8-42c2-834e-7251d2a66e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_faf8c076-06c3-4eb5-8877-34e4503b59ac" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_dd8744b2-63d8-42c2-834e-7251d2a66e57" xlink:to="loc_srt_MinimumMember_faf8c076-06c3-4eb5-8877-34e4503b59ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_594dc836-17ce-47d3-8b07-c51af1a58840" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_dd8744b2-63d8-42c2-834e-7251d2a66e57" xlink:to="loc_srt_MaximumMember_594dc836-17ce-47d3-8b07-c51af1a58840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_31a222aa-1116-4993-8a7b-79ef2e2e0ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable_ab791894-c7cf-4bf1-93d2-a364e31858ef" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_31a222aa-1116-4993-8a7b-79ef2e2e0ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8bd38ee6-fbff-41b8-977a-505515340caa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_31a222aa-1116-4993-8a7b-79ef2e2e0ba9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8bd38ee6-fbff-41b8-977a-505515340caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_2aca254e-8c46-44ad-9865-8d84362c7c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8bd38ee6-fbff-41b8-977a-505515340caa" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_2aca254e-8c46-44ad-9865-8d84362c7c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems_01c0bfbe-931c-4ebd-b8da-44ef20644e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable_ab791894-c7cf-4bf1-93d2-a364e31858ef" xlink:to="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems_01c0bfbe-931c-4ebd-b8da-44ef20644e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestment_cd574453-315e-45f4-8d4a-fc7797ca38bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AlternativeInvestment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems_01c0bfbe-931c-4ebd-b8da-44ef20644e3b" xlink:to="loc_us-gaap_AlternativeInvestment_cd574453-315e-45f4-8d4a-fc7797ca38bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AlternativeInvestmentBeforeReclassificationToDisposalGroupAssetsHeldForSale_2f7c838e-6d3c-4e8c-994a-5e5700bcd407" xlink:href="ci-20231231.xsd#ci_AlternativeInvestmentBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems_01c0bfbe-931c-4ebd-b8da-44ef20644e3b" xlink:to="loc_ci_AlternativeInvestmentBeforeReclassificationToDisposalGroupAssetsHeldForSale_2f7c838e-6d3c-4e8c-994a-5e5700bcd407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_867ffba2-89b0-41f3-9211-26b4fe00ec52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems_01c0bfbe-931c-4ebd-b8da-44ef20644e3b" xlink:to="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments_867ffba2-89b0-41f3-9211-26b4fe00ec52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1_de5501c7-0674-46a3-ae1c-73c22a7a1d41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems_01c0bfbe-931c-4ebd-b8da-44ef20644e3b" xlink:to="loc_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1_de5501c7-0674-46a3-ae1c-73c22a7a1d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_48b587ab-2a2d-4f71-b94e-ac72ac21dac5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a3fdc0ca-40b3-4aa1-ae33-e02ce2b0d071" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_48b587ab-2a2d-4f71-b94e-ac72ac21dac5" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a3fdc0ca-40b3-4aa1-ae33-e02ce2b0d071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2c331f80-8257-4cbb-bbaf-614a19d0cc40" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a3fdc0ca-40b3-4aa1-ae33-e02ce2b0d071" xlink:to="loc_srt_RangeAxis_2c331f80-8257-4cbb-bbaf-614a19d0cc40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_de06fd70-8a11-4f1f-a7d8-98fcb70d1bca" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2c331f80-8257-4cbb-bbaf-614a19d0cc40" xlink:to="loc_srt_RangeMember_de06fd70-8a11-4f1f-a7d8-98fcb70d1bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f24c4f27-e9e7-483b-81d2-a3315a3fe28c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_de06fd70-8a11-4f1f-a7d8-98fcb70d1bca" xlink:to="loc_srt_MaximumMember_f24c4f27-e9e7-483b-81d2-a3315a3fe28c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_87ce2ebd-8df8-4440-b256-70a1f5fae3c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a3fdc0ca-40b3-4aa1-ae33-e02ce2b0d071" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_87ce2ebd-8df8-4440-b256-70a1f5fae3c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RealizedInvestmentLossesCommercialMortgageLoansRealEstateEntitiesCertainEquitySecuritiesWithNoReadilyDeterminableFairValue_24b5da77-68df-4ba2-b3dc-35d6d1206090" xlink:href="ci-20231231.xsd#ci_RealizedInvestmentLossesCommercialMortgageLoansRealEstateEntitiesCertainEquitySecuritiesWithNoReadilyDeterminableFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_87ce2ebd-8df8-4440-b256-70a1f5fae3c2" xlink:to="loc_ci_RealizedInvestmentLossesCommercialMortgageLoansRealEstateEntitiesCertainEquitySecuritiesWithNoReadilyDeterminableFairValue_24b5da77-68df-4ba2-b3dc-35d6d1206090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_4674c041-90a6-4bf9-8f25-4ea245a5a55b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_87ce2ebd-8df8-4440-b256-70a1f5fae3c2" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_4674c041-90a6-4bf9-8f25-4ea245a5a55b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_ad0bfa97-d473-4d65-ada8-545b4ac269ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_48b587ab-2a2d-4f71-b94e-ac72ac21dac5" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_ad0bfa97-d473-4d65-ada8-545b4ac269ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9ce80e51-dde4-481b-9343-9503c7d2b354" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8d6ce69a-624d-4b6a-97f5-10ce86e27508" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9ce80e51-dde4-481b-9343-9503c7d2b354" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8d6ce69a-624d-4b6a-97f5-10ce86e27508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_509a76c7-71c6-452b-8e55-4551b70301de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8d6ce69a-624d-4b6a-97f5-10ce86e27508" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_509a76c7-71c6-452b-8e55-4551b70301de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1a40eb46-02b4-4b17-a77e-10ed00283c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_509a76c7-71c6-452b-8e55-4551b70301de" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1a40eb46-02b4-4b17-a77e-10ed00283c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_23941799-f011-4cf2-a80e-abe9e78d9566" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1a40eb46-02b4-4b17-a77e-10ed00283c0c" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_23941799-f011-4cf2-a80e-abe9e78d9566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_bf8e2998-bc22-489f-8e64-17cad09c6a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_23941799-f011-4cf2-a80e-abe9e78d9566" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_bf8e2998-bc22-489f-8e64-17cad09c6a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_0a3aaee5-69ef-4bdd-8e53-c0d1fbe58be6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_23941799-f011-4cf2-a80e-abe9e78d9566" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_0a3aaee5-69ef-4bdd-8e53-c0d1fbe58be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_67e364a3-942f-43ab-902e-34eb2ab9c7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8d6ce69a-624d-4b6a-97f5-10ce86e27508" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_67e364a3-942f-43ab-902e-34eb2ab9c7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dda89ea7-e781-4471-8e95-07d9535aec78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_67e364a3-942f-43ab-902e-34eb2ab9c7cf" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dda89ea7-e781-4471-8e95-07d9535aec78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_11ff43a0-6806-4253-9270-92b984a977f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dda89ea7-e781-4471-8e95-07d9535aec78" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_11ff43a0-6806-4253-9270-92b984a977f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a633b42c-981a-492a-bf44-7cd7266d85d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dda89ea7-e781-4471-8e95-07d9535aec78" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a633b42c-981a-492a-bf44-7cd7266d85d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2056a181-13d3-4908-a774-b1f19a162357" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8d6ce69a-624d-4b6a-97f5-10ce86e27508" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2056a181-13d3-4908-a774-b1f19a162357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet_3df14b26-41d9-4c95-ae3b-9d42acae70c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2056a181-13d3-4908-a774-b1f19a162357" xlink:to="loc_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet_3df14b26-41d9-4c95-ae3b-9d42acae70c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_35b409f7-40e7-4c85-a27d-348b2a6b21d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2056a181-13d3-4908-a774-b1f19a162357" xlink:to="loc_us-gaap_LongTermDebtFairValue_35b409f7-40e7-4c85-a27d-348b2a6b21d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MortgageLoansOnRealEstateCommercialAndConsumerNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_fa06396a-f705-436b-973f-66460144510f" xlink:href="ci-20231231.xsd#ci_MortgageLoansOnRealEstateCommercialAndConsumerNetBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2056a181-13d3-4908-a774-b1f19a162357" xlink:to="loc_ci_MortgageLoansOnRealEstateCommercialAndConsumerNetBeforeReclassificationToDisposalGroupAssetsHeldForSale_fa06396a-f705-436b-973f-66460144510f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LongTermDebtFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_21e1813d-9717-4e88-b62a-d8f10f1ec4fd" xlink:href="ci-20231231.xsd#ci_LongTermDebtFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2056a181-13d3-4908-a774-b1f19a162357" xlink:to="loc_ci_LongTermDebtFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale_21e1813d-9717-4e88-b62a-d8f10f1ec4fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/VariableInterestEntitiesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#VariableInterestEntitiesDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/VariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_VariableInterestEntitiesAbstract_d70cae9a-876e-4b42-9fa7-1818583a61da" xlink:href="ci-20231231.xsd#ci_VariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_44f94251-50e2-4a7b-9ec1-c5ab753a2cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_VariableInterestEntitiesAbstract_d70cae9a-876e-4b42-9fa7-1818583a61da" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_44f94251-50e2-4a7b-9ec1-c5ab753a2cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_12932d22-c3c3-4949-8dad-7821dad93a74" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_44f94251-50e2-4a7b-9ec1-c5ab753a2cc6" xlink:to="loc_srt_ConsolidatedEntitiesAxis_12932d22-c3c3-4949-8dad-7821dad93a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_fdc0dc28-e31d-490e-b402-b1cd9be79e58" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_12932d22-c3c3-4949-8dad-7821dad93a74" xlink:to="loc_srt_ConsolidatedEntitiesDomain_fdc0dc28-e31d-490e-b402-b1cd9be79e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_f95cfeab-6e55-4a4b-8424-b9433774ceff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_fdc0dc28-e31d-490e-b402-b1cd9be79e58" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_f95cfeab-6e55-4a4b-8424-b9433774ceff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_70383645-6696-4b0e-8048-e9a0eb1b0937" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_fdc0dc28-e31d-490e-b402-b1cd9be79e58" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_70383645-6696-4b0e-8048-e9a0eb1b0937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_3cfadafa-873c-400c-9f0c-60cfe23e644e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_44f94251-50e2-4a7b-9ec1-c5ab753a2cc6" xlink:to="loc_us-gaap_OtherCommitmentsAxis_3cfadafa-873c-400c-9f0c-60cfe23e644e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_4312b3fa-ae24-4a98-a637-f69e072401aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_3cfadafa-873c-400c-9f0c-60cfe23e644e" xlink:to="loc_us-gaap_OtherCommitmentsDomain_4312b3fa-ae24-4a98-a637-f69e072401aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CommitmentToFundPartnershipMember_b1b49135-1c48-42ac-b6fb-9e82d182e878" xlink:href="ci-20231231.xsd#ci_CommitmentToFundPartnershipMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_4312b3fa-ae24-4a98-a637-f69e072401aa" xlink:to="loc_ci_CommitmentToFundPartnershipMember_b1b49135-1c48-42ac-b6fb-9e82d182e878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_85d92008-1f05-4e63-88ba-096ba268e17e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_44f94251-50e2-4a7b-9ec1-c5ab753a2cc6" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_85d92008-1f05-4e63-88ba-096ba268e17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_20f85ce5-e17f-40e9-9ae6-e19e7af85379" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_85d92008-1f05-4e63-88ba-096ba268e17e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_20f85ce5-e17f-40e9-9ae6-e19e7af85379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember_bfa986b0-9d3a-4eb6-8e90-5e581f17c11e" xlink:href="ci-20231231.xsd#ci_SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_20f85ce5-e17f-40e9-9ae6-e19e7af85379" xlink:to="loc_ci_SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember_bfa986b0-9d3a-4eb6-8e90-5e581f17c11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_e26a2b25-09e1-4ca1-943d-ae86a56b0cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_44f94251-50e2-4a7b-9ec1-c5ab753a2cc6" xlink:to="loc_us-gaap_InvestmentTypeAxis_e26a2b25-09e1-4ca1-943d-ae86a56b0cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_994efbc5-f302-4369-acb1-a360e51dc492" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_e26a2b25-09e1-4ca1-943d-ae86a56b0cfd" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_994efbc5-f302-4369-acb1-a360e51dc492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember_b9727130-e0ab-475f-b3cb-fca6b5522d64" xlink:href="ci-20231231.xsd#ci_SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_994efbc5-f302-4369-acb1-a360e51dc492" xlink:to="loc_ci_SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember_b9727130-e0ab-475f-b3cb-fca6b5522d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RealEstateJointVenturesMember_39036898-f5d2-44e6-868f-af2365abc0b4" xlink:href="ci-20231231.xsd#ci_RealEstateJointVenturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_994efbc5-f302-4369-acb1-a360e51dc492" xlink:to="loc_ci_RealEstateJointVenturesMember_39036898-f5d2-44e6-868f-af2365abc0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AssetBackedAndCorporateSecuritiesMember_15e165a9-b6f3-44ad-879c-7067e6d216da" xlink:href="ci-20231231.xsd#ci_AssetBackedAndCorporateSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_994efbc5-f302-4369-acb1-a360e51dc492" xlink:to="loc_ci_AssetBackedAndCorporateSecuritiesMember_15e165a9-b6f3-44ad-879c-7067e6d216da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherVariableInterestEntitiesMember_743521b5-a18e-4a06-9d05-aac2274d71ea" xlink:href="ci-20231231.xsd#ci_OtherVariableInterestEntitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_994efbc5-f302-4369-acb1-a360e51dc492" xlink:to="loc_ci_OtherVariableInterestEntitiesMember_743521b5-a18e-4a06-9d05-aac2274d71ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_66d5d966-7b06-4705-9dfd-7cc4188e141f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_44f94251-50e2-4a7b-9ec1-c5ab753a2cc6" xlink:to="loc_srt_RangeAxis_66d5d966-7b06-4705-9dfd-7cc4188e141f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6be5d0bc-5e33-4c60-8048-c260223cb9f1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_66d5d966-7b06-4705-9dfd-7cc4188e141f" xlink:to="loc_srt_RangeMember_6be5d0bc-5e33-4c60-8048-c260223cb9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9c7c213a-e09b-4b21-b4be-571a4d73c1c0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6be5d0bc-5e33-4c60-8048-c260223cb9f1" xlink:to="loc_srt_MaximumMember_9c7c213a-e09b-4b21-b4be-571a4d73c1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_bb0d8526-b55d-4e76-a5c2-74a7538954f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_44f94251-50e2-4a7b-9ec1-c5ab753a2cc6" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_bb0d8526-b55d-4e76-a5c2-74a7538954f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_VariableInterestEntitiesNumberOfEntities_48c51bc4-4d52-49fd-9d9a-68b74005d744" xlink:href="ci-20231231.xsd#ci_VariableInterestEntitiesNumberOfEntities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_bb0d8526-b55d-4e76-a5c2-74a7538954f5" xlink:to="loc_ci_VariableInterestEntitiesNumberOfEntities_48c51bc4-4d52-49fd-9d9a-68b74005d744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_49bbd250-07be-4e5f-9d20-71ce36c2a4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestInVariableInterestEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_bb0d8526-b55d-4e76-a5c2-74a7538954f5" xlink:to="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_49bbd250-07be-4e5f-9d20-71ce36c2a4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_805294f0-a578-413d-b111-8b554c68d6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_bb0d8526-b55d-4e76-a5c2-74a7538954f5" xlink:to="loc_us-gaap_OtherCommitment_805294f0-a578-413d-b111-8b554c68d6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount_3d62bb41-19aa-4418-ba84-3cd99193fee4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_bb0d8526-b55d-4e76-a5c2-74a7538954f5" xlink:to="loc_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount_3d62bb41-19aa-4418-ba84-3cd99193fee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_59888027-7918-42cd-b278-6b133e4f58a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_bb0d8526-b55d-4e76-a5c2-74a7538954f5" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_59888027-7918-42cd-b278-6b133e4f58a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuarantyLiabilities_763ffe5e-1264-4b74-ad0f-eb217a6107b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuarantyLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_bb0d8526-b55d-4e76-a5c2-74a7538954f5" xlink:to="loc_us-gaap_GuarantyLiabilities_763ffe5e-1264-4b74-ad0f-eb217a6107b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_00bf8a02-9afb-4f47-a18d-5d088b47a0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsMaximumExposure"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_bb0d8526-b55d-4e76-a5c2-74a7538954f5" xlink:to="loc_us-gaap_GuaranteeObligationsMaximumExposure_00bf8a02-9afb-4f47-a18d-5d088b47a0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiariesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#CollectivelySignificantOperatingUnconsolidatedSubsidiariesDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiariesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_c88bb662-c92f-4ab2-9fa7-92ba9f5a5a31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3e54dddf-7d30-408e-ae37-30effbaafef9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_c88bb662-c92f-4ab2-9fa7-92ba9f5a5a31" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3e54dddf-7d30-408e-ae37-30effbaafef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_758f2d49-0482-4e41-bd51-1e59caab88ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3e54dddf-7d30-408e-ae37-30effbaafef9" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_758f2d49-0482-4e41-bd51-1e59caab88ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_4be28edc-5d77-4789-ac27-a7ce8e0d6862" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_758f2d49-0482-4e41-bd51-1e59caab88ca" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_4be28edc-5d77-4789-ac27-a7ce8e0d6862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OperatingJointVenturesMember_e48823ba-0660-473e-9581-65ed3f240ffc" xlink:href="ci-20231231.xsd#ci_OperatingJointVenturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_4be28edc-5d77-4789-ac27-a7ce8e0d6862" xlink:to="loc_ci_OperatingJointVenturesMember_e48823ba-0660-473e-9581-65ed3f240ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b6cf0d3d-2fc5-45e2-873e-6a073e9d83fe" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3e54dddf-7d30-408e-ae37-30effbaafef9" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b6cf0d3d-2fc5-45e2-873e-6a073e9d83fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_654ddc0a-7feb-4a4f-8136-fb2adadf2683" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b6cf0d3d-2fc5-45e2-873e-6a073e9d83fe" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_654ddc0a-7feb-4a4f-8136-fb2adadf2683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OperatingJointVenturesMember_d226600c-6c7e-4048-af50-5e11afaf1d03" xlink:href="ci-20231231.xsd#ci_OperatingJointVenturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_654ddc0a-7feb-4a4f-8136-fb2adadf2683" xlink:to="loc_ci_OperatingJointVenturesMember_d226600c-6c7e-4048-af50-5e11afaf1d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d72f7e34-600f-415d-a554-d1c02877dec8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3e54dddf-7d30-408e-ae37-30effbaafef9" xlink:to="loc_srt_StatementGeographicalAxis_d72f7e34-600f-415d-a554-d1c02877dec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e5cf14f5-817b-43f9-8235-77eaed1caf97" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_d72f7e34-600f-415d-a554-d1c02877dec8" xlink:to="loc_srt_SegmentGeographicalDomain_e5cf14f5-817b-43f9-8235-77eaed1caf97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_6fd2a708-983a-42da-ae85-b1ccd0155fc6" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CN"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e5cf14f5-817b-43f9-8235-77eaed1caf97" xlink:to="loc_country_CN_6fd2a708-983a-42da-ae85-b1ccd0155fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_92c3502e-f795-4696-bfa5-086d7c982409" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_3e54dddf-7d30-408e-ae37-30effbaafef9" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_92c3502e-f795-4696-bfa5-086d7c982409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract_1e509a82-1853-407f-81df-a0f35df2e3da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_92c3502e-f795-4696-bfa5-086d7c982409" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract_1e509a82-1853-407f-81df-a0f35df2e3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_04a763f6-c819-40b9-be65-70a22aff0d90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract_1e509a82-1853-407f-81df-a0f35df2e3da" xlink:to="loc_us-gaap_EquityMethodInvestments_04a763f6-c819-40b9-be65-70a22aff0d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f819554b-1888-4c9b-b1e7-74d8501c0798" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract_1e509a82-1853-407f-81df-a0f35df2e3da" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f819554b-1888-4c9b-b1e7-74d8501c0798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_9c6f4bb3-3f4d-4c7d-bb3c-c66b7de9c396" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract_1e509a82-1853-407f-81df-a0f35df2e3da" xlink:to="loc_us-gaap_IncomeStatementAbstract_9c6f4bb3-3f4d-4c7d-bb3c-c66b7de9c396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_962a7936-e69b-4c8a-8805-07de43591c38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9c6f4bb3-3f4d-4c7d-bb3c-c66b7de9c396" xlink:to="loc_us-gaap_Revenues_962a7936-e69b-4c8a-8805-07de43591c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0f87ba6f-95f6-44a6-8a77-3626e5eb994f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9c6f4bb3-3f4d-4c7d-bb3c-c66b7de9c396" xlink:to="loc_us-gaap_ProfitLoss_0f87ba6f-95f6-44a6-8a77-3626e5eb994f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_BalanceSheetAbstract_382c0fd3-7776-4b90-84dc-7316333195ab" xlink:href="ci-20231231.xsd#ci_BalanceSheetAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract_1e509a82-1853-407f-81df-a0f35df2e3da" xlink:to="loc_ci_BalanceSheetAbstract_382c0fd3-7776-4b90-84dc-7316333195ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2df9050f-99ab-431f-8baf-d5178b52c43e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_BalanceSheetAbstract_382c0fd3-7776-4b90-84dc-7316333195ab" xlink:to="loc_us-gaap_Assets_2df9050f-99ab-431f-8baf-d5178b52c43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f28eb687-7f87-47ec-afe9-488e8ea1d686" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_BalanceSheetAbstract_382c0fd3-7776-4b90-84dc-7316333195ab" xlink:to="loc_us-gaap_Liabilities_f28eb687-7f87-47ec-afe9-488e8ea1d686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_3d368b09-0d5f-4c57-9609-9483fa998efc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_bc5dbb46-014f-4f33-ab69-7c17af53b41e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_3d368b09-0d5f-4c57-9609-9483fa998efc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_bc5dbb46-014f-4f33-ab69-7c17af53b41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_34bdf377-3985-4444-9a75-46743a81ee50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_bc5dbb46-014f-4f33-ab69-7c17af53b41e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_34bdf377-3985-4444-9a75-46743a81ee50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8a778763-13a1-4829-84b5-ebe9efd735cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_34bdf377-3985-4444-9a75-46743a81ee50" xlink:to="loc_us-gaap_EquityComponentDomain_8a778763-13a1-4829-84b5-ebe9efd735cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_da780c2e-471e-42e3-a704-d5c754ed72cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8a778763-13a1-4829-84b5-ebe9efd735cb" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_da780c2e-471e-42e3-a704-d5c754ed72cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember_a83a5578-6f99-4427-ade0-e01ea5f9dd06" xlink:href="ci-20231231.xsd#ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_da780c2e-471e-42e3-a704-d5c754ed72cb" xlink:to="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember_a83a5578-6f99-4427-ade0-e01ea5f9dd06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesGainLossOnSaleOfBusinessParentMember_c7a492b7-8ce6-49bd-aef1-572469261f32" xlink:href="ci-20231231.xsd#ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesGainLossOnSaleOfBusinessParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember_a83a5578-6f99-4427-ade0-e01ea5f9dd06" xlink:to="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesGainLossOnSaleOfBusinessParentMember_c7a492b7-8ce6-49bd-aef1-572469261f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesRealizedInvestmentGainsLossesParentMember_c71e69be-9620-40d1-9287-4cf33cb0c2f3" xlink:href="ci-20231231.xsd#ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesRealizedInvestmentGainsLossesParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember_a83a5578-6f99-4427-ade0-e01ea5f9dd06" xlink:to="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesRealizedInvestmentGainsLossesParentMember_c71e69be-9620-40d1-9287-4cf33cb0c2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesSellingGeneralAdministrativeExpenseParentMember_e0976088-afe9-4c60-9bb6-910751fea746" xlink:href="ci-20231231.xsd#ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesSellingGeneralAdministrativeExpenseParentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember_a83a5578-6f99-4427-ade0-e01ea5f9dd06" xlink:to="loc_ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesSellingGeneralAdministrativeExpenseParentMember_e0976088-afe9-4c60-9bb6-910751fea746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember_167e0bee-9972-47ab-9a17-e98c46533425" xlink:href="ci-20231231.xsd#ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_da780c2e-471e-42e3-a704-d5c754ed72cb" xlink:to="loc_ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember_167e0bee-9972-47ab-9a17-e98c46533425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLiabilityForFuturePolicyBenefitParentMember_80bc23af-8ce3-4ae8-a210-8c5c1cad9a88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociLiabilityForFuturePolicyBenefitParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember_167e0bee-9972-47ab-9a17-e98c46533425" xlink:to="loc_us-gaap_AociLiabilityForFuturePolicyBenefitParentMember_80bc23af-8ce3-4ae8-a210-8c5c1cad9a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember_74690803-c94b-48ba-9103-027851c03ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember_167e0bee-9972-47ab-9a17-e98c46533425" xlink:to="loc_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember_74690803-c94b-48ba-9103-027851c03ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_0e47c035-d18d-43e9-a47a-8e7d150b8284" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_da780c2e-471e-42e3-a704-d5c754ed72cb" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_0e47c035-d18d-43e9-a47a-8e7d150b8284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_93370329-5a19-4afd-b513-35503190be35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_0e47c035-d18d-43e9-a47a-8e7d150b8284" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_93370329-5a19-4afd-b513-35503190be35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember_6c13c6c2-4964-4aca-bd62-ca3ceb39be85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_0e47c035-d18d-43e9-a47a-8e7d150b8284" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember_6c13c6c2-4964-4aca-bd62-ca3ceb39be85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_08b73290-933e-46d4-88d4-05797bc82a46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_da780c2e-471e-42e3-a704-d5c754ed72cb" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_08b73290-933e-46d4-88d4-05797bc82a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_11b4b316-47c0-4a94-8881-e6c331146cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_08b73290-933e-46d4-88d4-05797bc82a46" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_11b4b316-47c0-4a94-8881-e6c331146cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccumulatedDefinedBenefitPlansAdjustmentGainLossOnSaleOfBusinessMember_b3df4ee4-783b-4805-91df-a398fbd3b078" xlink:href="ci-20231231.xsd#ci_AccumulatedDefinedBenefitPlansAdjustmentGainLossOnSaleOfBusinessMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_08b73290-933e-46d4-88d4-05797bc82a46" xlink:to="loc_ci_AccumulatedDefinedBenefitPlansAdjustmentGainLossOnSaleOfBusinessMember_b3df4ee4-783b-4805-91df-a398fbd3b078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccumulatedDefinedBenefitPlansAdjustmentSettlementMember_8e1a9ad8-09da-492f-b97f-069e55ebbd5e" xlink:href="ci-20231231.xsd#ci_AccumulatedDefinedBenefitPlansAdjustmentSettlementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_08b73290-933e-46d4-88d4-05797bc82a46" xlink:to="loc_ci_AccumulatedDefinedBenefitPlansAdjustmentSettlementMember_8e1a9ad8-09da-492f-b97f-069e55ebbd5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_7910a38d-93e4-49f1-a9d2-967c3a5946b5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_bc5dbb46-014f-4f33-ab69-7c17af53b41e" xlink:to="loc_srt_RestatementAxis_7910a38d-93e4-49f1-a9d2-967c3a5946b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_e6f3b25a-c96d-461b-9220-b64480b07e64" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_7910a38d-93e4-49f1-a9d2-967c3a5946b5" xlink:to="loc_srt_RestatementDomain_e6f3b25a-c96d-461b-9220-b64480b07e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_72e12168-ed5f-49a5-913c-f5b61eb880b7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_e6f3b25a-c96d-461b-9220-b64480b07e64" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_72e12168-ed5f-49a5-913c-f5b61eb880b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_9ced25da-76f3-46b7-b32c-272e5fcc7521" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_e6f3b25a-c96d-461b-9220-b64480b07e64" xlink:to="loc_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_9ced25da-76f3-46b7-b32c-272e5fcc7521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_bc5dbb46-014f-4f33-ab69-7c17af53b41e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f49ee473-ef10-4d3f-a8a5-1936926dd60c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f49ee473-ef10-4d3f-a8a5-1936926dd60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_a0fdfa1c-de53-4c02-acb6-1e139d9fb2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax_a0fdfa1c-de53-4c02-acb6-1e139d9fb2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_8d724253-228a-4798-ab72-0dd7a021fff6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_8d724253-228a-4798-ab72-0dd7a021fff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_b6822e23-ea18-4fec-a32e-01a209b7c246" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_b6822e23-ea18-4fec-a32e-01a209b7c246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity_9dac0312-2714-4d53-8175-8d16b9d4e6f8" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:to="loc_ci_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity_9dac0312-2714-4d53-8175-8d16b9d4e6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity_0648d874-02f8-45b7-9572-e9af183bcc8f" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:to="loc_ci_OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity_0648d874-02f8-45b7-9572-e9af183bcc8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity_e708dda3-df67-4c5e-bbb4-8789ea798065" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:to="loc_ci_OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity_e708dda3-df67-4c5e-bbb4-8789ea798065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_3f9da1cf-9973-4426-bca6-46b064351cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax_3f9da1cf-9973-4426-bca6-46b064351cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_e4f34572-d88d-4f5c-adb0-45abc86504cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_e4f34572-d88d-4f5c-adb0-45abc86504cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_ef264ff6-f884-431d-9c8f-68be0fe46233" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_ef264ff6-f884-431d-9c8f-68be0fe46233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity_dd781111-98a7-424b-86fa-c1bdade546e4" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:to="loc_ci_OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity_dd781111-98a7-424b-86fa-c1bdade546e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity_c35211c3-47fc-48c0-97d8-1703a610a8de" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:to="loc_ci_OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity_c35211c3-47fc-48c0-97d8-1703a610a8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity_eab2683e-53ae-4a9a-bd3f-cfa93ef500b5" xlink:href="ci-20231231.xsd#ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:to="loc_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity_eab2683e-53ae-4a9a-bd3f-cfa93ef500b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TemporaryEquityOtherComprehensiveIncome_dd04cdba-088b-4c31-8dcc-0f503d88fd5f" xlink:href="ci-20231231.xsd#ci_TemporaryEquityOtherComprehensiveIncome"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:to="loc_ci_TemporaryEquityOtherComprehensiveIncome_dd04cdba-088b-4c31-8dcc-0f503d88fd5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4d5b21d6-0480-4b4b-8ca2-efdef9ca67a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4d5b21d6-0480-4b4b-8ca2-efdef9ca67a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ff524993-09ae-46dd-85e8-dc5a1b3ae0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_da6e3119-3950-4453-ad5a-2a6d17ad7136" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ff524993-09ae-46dd-85e8-dc5a1b3ae0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails_1" xlink:type="simple" xlink:href="ci-20231231.xsd#AccumulatedOtherComprehensiveIncomeLossDetails_1"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/OrganizationalEfficiencyPlanDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#OrganizationalEfficiencyPlanDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/OrganizationalEfficiencyPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_d44f5651-3194-4fe2-aefb-5c93d7365415" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_a5508bed-5c60-4fdc-89d8-0b882dfd02d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessExitCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_d44f5651-3194-4fe2-aefb-5c93d7365415" xlink:to="loc_us-gaap_BusinessExitCosts1_a5508bed-5c60-4fdc-89d8-0b882dfd02d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_e3fde5b1-01a3-4165-a646-858d8d039438" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_d44f5651-3194-4fe2-aefb-5c93d7365415" xlink:to="loc_us-gaap_RestructuringCharges_e3fde5b1-01a3-4165-a646-858d8d039438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RestructuringChargesNetOfTaxExpense_a91bae3d-b63c-4431-9b04-d099172e90ec" xlink:href="ci-20231231.xsd#ci_RestructuringChargesNetOfTaxExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_d44f5651-3194-4fe2-aefb-5c93d7365415" xlink:to="loc_ci_RestructuringChargesNetOfTaxExpense_a91bae3d-b63c-4431-9b04-d099172e90ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_364fb8ab-bef8-4164-aa7f-e326415b1ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_d44f5651-3194-4fe2-aefb-5c93d7365415" xlink:to="loc_us-gaap_RestructuringReserveRollForward_364fb8ab-bef8-4164-aa7f-e326415b1ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_c156e53d-fa19-4626-bcf7-75ae05b6ee7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_364fb8ab-bef8-4164-aa7f-e326415b1ee4" xlink:to="loc_us-gaap_RestructuringReserve_c156e53d-fa19-4626-bcf7-75ae05b6ee7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_740e5682-7f75-4804-9fcb-08f0e681af1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_364fb8ab-bef8-4164-aa7f-e326415b1ee4" xlink:to="loc_us-gaap_SeveranceCosts1_740e5682-7f75-4804-9fcb-08f0e681af1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_6cdc1896-d4a2-47a2-98d3-a0bea2d21495" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_364fb8ab-bef8-4164-aa7f-e326415b1ee4" xlink:to="loc_us-gaap_PaymentsForRestructuring_6cdc1896-d4a2-47a2-98d3-a0bea2d21495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_235ddf36-7870-4fe1-a0a9-b62348459e30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_364fb8ab-bef8-4164-aa7f-e326415b1ee4" xlink:to="loc_us-gaap_RestructuringReserve_235ddf36-7870-4fe1-a0a9-b62348459e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/PensionNarrativeDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#PensionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/PensionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_03346a1e-dc16-41ef-9f1b-4c4511cf2be0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9d955988-994d-4d63-9d43-74aac35d5aec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_03346a1e-dc16-41ef-9f1b-4c4511cf2be0" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9d955988-994d-4d63-9d43-74aac35d5aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_2d83e6f4-cd42-4315-adea-258430fb08f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9d955988-994d-4d63-9d43-74aac35d5aec" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_2d83e6f4-cd42-4315-adea-258430fb08f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_8de01719-8f67-4a62-ad32-e3e6c66d45fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2d83e6f4-cd42-4315-adea-258430fb08f2" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_8de01719-8f67-4a62-ad32-e3e6c66d45fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_dba4885e-1249-4a8b-ac35-c9eb3832eba9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_8de01719-8f67-4a62-ad32-e3e6c66d45fa" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_dba4885e-1249-4a8b-ac35-c9eb3832eba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_27817705-8133-4c50-981b-a536b6574e96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTaxStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9d955988-994d-4d63-9d43-74aac35d5aec" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_27817705-8133-4c50-981b-a536b6574e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_5aa2fcf8-e5d5-45fb-9393-bf63dd310b84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTaxStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_27817705-8133-4c50-981b-a536b6574e96" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_5aa2fcf8-e5d5-45fb-9393-bf63dd310b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QualifiedPlanMember_263e8b0d-e708-453c-a7f3-c470425ef022" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_QualifiedPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_5aa2fcf8-e5d5-45fb-9393-bf63dd310b84" xlink:to="loc_us-gaap_QualifiedPlanMember_263e8b0d-e708-453c-a7f3-c470425ef022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonqualifiedPlanMember_a721e233-b4ce-48ff-a59c-5b0554a4b8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonqualifiedPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_5aa2fcf8-e5d5-45fb-9393-bf63dd310b84" xlink:to="loc_us-gaap_NonqualifiedPlanMember_a721e233-b4ce-48ff-a59c-5b0554a4b8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb3ae8b5-fa8f-464a-aacd-1b23d22e259e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9d955988-994d-4d63-9d43-74aac35d5aec" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb3ae8b5-fa8f-464a-aacd-1b23d22e259e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DefinedBenefitPlanMarketRelatedValueOfPensionPlanAssets_63211f4d-e971-44fe-8266-746c2d96af02" xlink:href="ci-20231231.xsd#ci_DefinedBenefitPlanMarketRelatedValueOfPensionPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb3ae8b5-fa8f-464a-aacd-1b23d22e259e" xlink:to="loc_ci_DefinedBenefitPlanMarketRelatedValueOfPensionPlanAssets_63211f4d-e971-44fe-8266-746c2d96af02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_f106b842-e782-4cf3-a902-c2462945a2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb3ae8b5-fa8f-464a-aacd-1b23d22e259e" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_f106b842-e782-4cf3-a902-c2462945a2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_f5d47461-7726-4ba4-ad23-8985447293ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb3ae8b5-fa8f-464a-aacd-1b23d22e259e" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_f5d47461-7726-4ba4-ad23-8985447293ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_fa7efe4f-56b9-457d-b562-5fc7a0851031" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb3ae8b5-fa8f-464a-aacd-1b23d22e259e" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_fa7efe4f-56b9-457d-b562-5fc7a0851031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DefinedBenefitPlanGainLossDueToLitigation_a5226c28-bbe6-45ae-9a04-cedd4896ebe2" xlink:href="ci-20231231.xsd#ci_DefinedBenefitPlanGainLossDueToLitigation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb3ae8b5-fa8f-464a-aacd-1b23d22e259e" xlink:to="loc_ci_DefinedBenefitPlanGainLossDueToLitigation_a5226c28-bbe6-45ae-9a04-cedd4896ebe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInSeparateAccountsOfSubsidiaries_5df9fd5c-063f-4f6f-9474-c80fce89aaf3" xlink:href="ci-20231231.xsd#ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInSeparateAccountsOfSubsidiaries"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb3ae8b5-fa8f-464a-aacd-1b23d22e259e" xlink:to="loc_ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInSeparateAccountsOfSubsidiaries_5df9fd5c-063f-4f6f-9474-c80fce89aaf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInFundsOfferedByUnaffiliatedEntity_426c7757-cbd1-4e2f-a16c-5f4b9a227a5f" xlink:href="ci-20231231.xsd#ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInFundsOfferedByUnaffiliatedEntity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_fb3ae8b5-fa8f-464a-aacd-1b23d22e259e" xlink:to="loc_ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInFundsOfferedByUnaffiliatedEntity_426c7757-cbd1-4e2f-a16c-5f4b9a227a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#PensionProjectedBenefitObligationsandAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d0d02ab5-528b-4d0c-89df-695e92cb1658" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_d96502fa-9f1e-4637-b2fd-09fb65ed8137" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d0d02ab5-528b-4d0c-89df-695e92cb1658" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_d96502fa-9f1e-4637-b2fd-09fb65ed8137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_195f414b-e5d1-48a6-b1e2-6a7b41a5a9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_d96502fa-9f1e-4637-b2fd-09fb65ed8137" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_195f414b-e5d1-48a6-b1e2-6a7b41a5a9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_408bd6ff-197c-4b06-ac67-23e9cfde3d42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_195f414b-e5d1-48a6-b1e2-6a7b41a5a9e5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_408bd6ff-197c-4b06-ac67-23e9cfde3d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_6c0b2c98-7ff2-45b4-93bf-2e1006438fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_408bd6ff-197c-4b06-ac67-23e9cfde3d42" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_6c0b2c98-7ff2-45b4-93bf-2e1006438fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_71e22efc-ee47-4dae-82e2-2a3fe246b0e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_d96502fa-9f1e-4637-b2fd-09fb65ed8137" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_71e22efc-ee47-4dae-82e2-2a3fe246b0e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_309e5378-2304-49ff-b06d-941b8aa263ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_71e22efc-ee47-4dae-82e2-2a3fe246b0e9" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_309e5378-2304-49ff-b06d-941b8aa263ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_97bede39-48b1-43ad-855b-2076b61592c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_309e5378-2304-49ff-b06d-941b8aa263ea" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_97bede39-48b1-43ad-855b-2076b61592c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_6fb420dd-4388-4c05-bb2f-58c51054ab60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_309e5378-2304-49ff-b06d-941b8aa263ea" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_6fb420dd-4388-4c05-bb2f-58c51054ab60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_8cad5b76-13e7-402a-a6ae-878f631e1296" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_309e5378-2304-49ff-b06d-941b8aa263ea" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_8cad5b76-13e7-402a-a6ae-878f631e1296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_f397d144-5d7c-41c9-849b-cf6333370c19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_309e5378-2304-49ff-b06d-941b8aa263ea" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_f397d144-5d7c-41c9-849b-cf6333370c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DefinedBenefitPlanBenefitsPaidFromPlanAssets_4fa078d7-0e5f-49e9-833a-04dc75cc4c30" xlink:href="ci-20231231.xsd#ci_DefinedBenefitPlanBenefitsPaidFromPlanAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_309e5378-2304-49ff-b06d-941b8aa263ea" xlink:to="loc_ci_DefinedBenefitPlanBenefitsPaidFromPlanAssets_4fa078d7-0e5f-49e9-833a-04dc75cc4c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation_24ee2b23-9625-4cf0-bfb6-4660cd39be73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDivestituresBenefitObligation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_309e5378-2304-49ff-b06d-941b8aa263ea" xlink:to="loc_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation_24ee2b23-9625-4cf0-bfb6-4660cd39be73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DefinedBenefitPlanBenefitsPaidOther_f695bbc1-34d4-48a1-8fcf-05f10a183f5b" xlink:href="ci-20231231.xsd#ci_DefinedBenefitPlanBenefitsPaidOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_309e5378-2304-49ff-b06d-941b8aa263ea" xlink:to="loc_ci_DefinedBenefitPlanBenefitsPaidOther_f695bbc1-34d4-48a1-8fcf-05f10a183f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_baf1f9e7-64e8-439a-8d14-63cb412aed1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_309e5378-2304-49ff-b06d-941b8aa263ea" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_baf1f9e7-64e8-439a-8d14-63cb412aed1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_995ab554-adc6-462c-86f6-73dd62326001" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_71e22efc-ee47-4dae-82e2-2a3fe246b0e9" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_995ab554-adc6-462c-86f6-73dd62326001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_fa881269-2d67-47e4-a2a9-cda3a4a815d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_995ab554-adc6-462c-86f6-73dd62326001" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_fa881269-2d67-47e4-a2a9-cda3a4a815d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_2e8a980c-75ad-45ef-8605-da1e6c66faef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_995ab554-adc6-462c-86f6-73dd62326001" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_2e8a980c-75ad-45ef-8605-da1e6c66faef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_e65f29a6-ff01-44d6-bda9-e54d9dc416c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_995ab554-adc6-462c-86f6-73dd62326001" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_e65f29a6-ff01-44d6-bda9-e54d9dc416c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDivestituresPlanAssets_0b47bcd7-d176-4b67-b8b7-fd96f08546ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDivestituresPlanAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_995ab554-adc6-462c-86f6-73dd62326001" xlink:to="loc_us-gaap_DefinedBenefitPlanDivestituresPlanAssets_0b47bcd7-d176-4b67-b8b7-fd96f08546ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_aee5cf5a-1fb2-46c3-bb1c-15da7cea8063" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_995ab554-adc6-462c-86f6-73dd62326001" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_aee5cf5a-1fb2-46c3-bb1c-15da7cea8063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_97a5ec71-9131-43d9-b1b6-c4fe2669308e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_995ab554-adc6-462c-86f6-73dd62326001" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_97a5ec71-9131-43d9-b1b6-c4fe2669308e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_ebd6b23d-878b-47b7-abe4-81c665a2736b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_995ab554-adc6-462c-86f6-73dd62326001" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_ebd6b23d-878b-47b7-abe4-81c665a2736b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansNoncurrentLiabilitiesAbstract_ade325a2-3cf7-496d-b333-60a731bfd70d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansNoncurrentLiabilitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_71e22efc-ee47-4dae-82e2-2a3fe246b0e9" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansNoncurrentLiabilitiesAbstract_ade325a2-3cf7-496d-b333-60a731bfd70d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_24441121-be4d-4a69-94a4-416ed5bcc34e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansNoncurrentLiabilitiesAbstract_ade325a2-3cf7-496d-b333-60a731bfd70d" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_24441121-be4d-4a69-94a4-416ed5bcc34e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_2eaa3326-5535-4ba1-851d-12ad72e3d0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansNoncurrentLiabilitiesAbstract_ade325a2-3cf7-496d-b333-60a731bfd70d" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_2eaa3326-5535-4ba1-851d-12ad72e3d0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_33e53f28-ec18-4e52-b4c6-bedf5aaedc29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansNoncurrentLiabilitiesAbstract_ade325a2-3cf7-496d-b333-60a731bfd70d" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_33e53f28-ec18-4e52-b4c6-bedf5aaedc29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/PensionBenefitPaymentsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#PensionBenefitPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/PensionBenefitPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b4dee3c4-d88d-4433-bf50-cc2ef2beff3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c8395a36-82aa-4c66-8700-2e7cac4cab24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b4dee3c4-d88d-4433-bf50-cc2ef2beff3b" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c8395a36-82aa-4c66-8700-2e7cac4cab24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_9c509351-ca3b-4f2b-b26c-d32c71c61098" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c8395a36-82aa-4c66-8700-2e7cac4cab24" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_9c509351-ca3b-4f2b-b26c-d32c71c61098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_13d39d96-f382-41e4-af45-6e79ce387ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_9c509351-ca3b-4f2b-b26c-d32c71c61098" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_13d39d96-f382-41e4-af45-6e79ce387ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_07388c9a-011e-496b-afa6-ce3cda941b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_13d39d96-f382-41e4-af45-6e79ce387ee3" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_07388c9a-011e-496b-afa6-ce3cda941b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0367085b-a6e7-4a1a-9e16-aa0bc4d754be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c8395a36-82aa-4c66-8700-2e7cac4cab24" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0367085b-a6e7-4a1a-9e16-aa0bc4d754be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_9aff012e-75df-43d5-a648-5457af4598ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0367085b-a6e7-4a1a-9e16-aa0bc4d754be" xlink:to="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_9aff012e-75df-43d5-a648-5457af4598ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_c5131c36-7538-483a-abc2-2195388ca29e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_9aff012e-75df-43d5-a648-5457af4598ec" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_c5131c36-7538-483a-abc2-2195388ca29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_af17df38-9f8b-4d96-8ca5-554b247b21d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_9aff012e-75df-43d5-a648-5457af4598ec" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_af17df38-9f8b-4d96-8ca5-554b247b21d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_f99977f2-5b63-436e-b002-a378c135bf27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_9aff012e-75df-43d5-a648-5457af4598ec" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_f99977f2-5b63-436e-b002-a378c135bf27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_ea3ced50-e3be-4a2d-a679-45e91f1b3473" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_9aff012e-75df-43d5-a648-5457af4598ec" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_ea3ced50-e3be-4a2d-a679-45e91f1b3473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_90e4bc7b-6b0a-413f-8849-d4a900d2b99b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_9aff012e-75df-43d5-a648-5457af4598ec" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_90e4bc7b-6b0a-413f-8849-d4a900d2b99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_77963b0b-76b4-40a7-9164-6a356180c4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_9aff012e-75df-43d5-a648-5457af4598ec" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_77963b0b-76b4-40a7-9164-6a356180c4e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/PensionAmountsIncludedinAccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#PensionAmountsIncludedinAccumulatedOtherComprehensiveIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/PensionAmountsIncludedinAccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b56ef063-240b-45ff-99e7-1643767a8f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4427acbb-7337-4ee4-b16a-5a86e7a36ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b56ef063-240b-45ff-99e7-1643767a8f2d" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4427acbb-7337-4ee4-b16a-5a86e7a36ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_31d99f26-8918-4a6f-aaca-04e6bd278c70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4427acbb-7337-4ee4-b16a-5a86e7a36ea2" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_31d99f26-8918-4a6f-aaca-04e6bd278c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_3e59c9f7-cfaa-4d5a-90d4-d49ca1986d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_31d99f26-8918-4a6f-aaca-04e6bd278c70" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_3e59c9f7-cfaa-4d5a-90d4-d49ca1986d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_3b903f4c-71a8-4b13-9d1d-48ee06bc1c05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3e59c9f7-cfaa-4d5a-90d4-d49ca1986d0a" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_3b903f4c-71a8-4b13-9d1d-48ee06bc1c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_36d9ab13-3f8b-4047-aa39-b077bf81a098" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4427acbb-7337-4ee4-b16a-5a86e7a36ea2" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_36d9ab13-3f8b-4047-aa39-b077bf81a098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_5222aaf1-e7c8-4680-a7d4-a037da772e23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_36d9ab13-3f8b-4047-aa39-b077bf81a098" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_5222aaf1-e7c8-4680-a7d4-a037da772e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_d5ae9992-eddb-4971-b676-779c757b9873" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_36d9ab13-3f8b-4047-aa39-b077bf81a098" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_d5ae9992-eddb-4971-b676-779c757b9873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_f62a59bd-b16d-4a85-8d7a-70bfc3131496" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_36d9ab13-3f8b-4047-aa39-b077bf81a098" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_f62a59bd-b16d-4a85-8d7a-70bfc3131496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/PensionNetPensionCostDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#PensionNetPensionCostDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/PensionNetPensionCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_76a6805a-8a8f-44b6-a967-56cf8b6c601d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e2a5459b-33a3-46be-b77a-756c2d0cc5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_76a6805a-8a8f-44b6-a967-56cf8b6c601d" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e2a5459b-33a3-46be-b77a-756c2d0cc5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_a749852b-f673-4775-b8c2-f735da88a65e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e2a5459b-33a3-46be-b77a-756c2d0cc5cc" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_a749852b-f673-4775-b8c2-f735da88a65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_fb40ba40-036a-4cd5-bea3-dcd3dc64bcca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a749852b-f673-4775-b8c2-f735da88a65e" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_fb40ba40-036a-4cd5-bea3-dcd3dc64bcca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_d22a658a-d5ca-4d35-9008-0b2a949aea8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_fb40ba40-036a-4cd5-bea3-dcd3dc64bcca" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_d22a658a-d5ca-4d35-9008-0b2a949aea8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bbdbfbeb-7a13-47f5-8454-63103d0720db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e2a5459b-33a3-46be-b77a-756c2d0cc5cc" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bbdbfbeb-7a13-47f5-8454-63103d0720db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6043ac78-112b-447d-874b-2036f3234291" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_bbdbfbeb-7a13-47f5-8454-63103d0720db" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6043ac78-112b-447d-874b-2036f3234291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_33be0c05-c557-4c91-9706-64eef537af27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6043ac78-112b-447d-874b-2036f3234291" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_33be0c05-c557-4c91-9706-64eef537af27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_90508747-9650-4023-886a-9dac1842cce8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6043ac78-112b-447d-874b-2036f3234291" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_90508747-9650-4023-886a-9dac1842cce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_5325f7be-1532-45fe-9650-56d2972bcf9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6043ac78-112b-447d-874b-2036f3234291" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_5325f7be-1532-45fe-9650-56d2972bcf9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DefinedBenefitPlanAmortizationAbstract_c45c7223-a08a-4e9d-a7d7-4861cb3c2b8d" xlink:href="ci-20231231.xsd#ci_DefinedBenefitPlanAmortizationAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6043ac78-112b-447d-874b-2036f3234291" xlink:to="loc_ci_DefinedBenefitPlanAmortizationAbstract_c45c7223-a08a-4e9d-a7d7-4861cb3c2b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_90a0cfcb-8e0f-4373-8582-ffb0b2829830" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DefinedBenefitPlanAmortizationAbstract_c45c7223-a08a-4e9d-a7d7-4861cb3c2b8d" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_90a0cfcb-8e0f-4373-8582-ffb0b2829830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DefinedBenefitPlanGainLossDueToLitigation_0c9a6421-b518-422b-af0d-be3d9004438f" xlink:href="ci-20231231.xsd#ci_DefinedBenefitPlanGainLossDueToLitigation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6043ac78-112b-447d-874b-2036f3234291" xlink:to="loc_ci_DefinedBenefitPlanGainLossDueToLitigation_0c9a6421-b518-422b-af0d-be3d9004438f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_1840495e-79dd-46b0-a7de-a1615ac22320" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6043ac78-112b-447d-874b-2036f3234291" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_1840495e-79dd-46b0-a7de-a1615ac22320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_4405aff1-6ce2-4c04-ba69-7a09c652087d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_6043ac78-112b-447d-874b-2036f3234291" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_4405aff1-6ce2-4c04-ba69-7a09c652087d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/PensionAssumptionsUsedforPensionDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#PensionAssumptionsUsedforPensionDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/PensionAssumptionsUsedforPensionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b6636603-1387-4526-9dde-1ef894557d82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c9ab1c1a-2f95-4506-a54a-8a556d9d5a44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b6636603-1387-4526-9dde-1ef894557d82" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c9ab1c1a-2f95-4506-a54a-8a556d9d5a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_5cb3b6ad-94e5-4cb6-a745-b89b4897a325" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c9ab1c1a-2f95-4506-a54a-8a556d9d5a44" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_5cb3b6ad-94e5-4cb6-a745-b89b4897a325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_962f0e2b-45db-464e-ae27-5edee0869f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_5cb3b6ad-94e5-4cb6-a745-b89b4897a325" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_962f0e2b-45db-464e-ae27-5edee0869f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_77cc1d89-8a8c-45b5-9d46-6bce11eec492" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_962f0e2b-45db-464e-ae27-5edee0869f6c" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_77cc1d89-8a8c-45b5-9d46-6bce11eec492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_63115f65-b1b1-48a3-9c7d-a1007ffaf3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c9ab1c1a-2f95-4506-a54a-8a556d9d5a44" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_63115f65-b1b1-48a3-9c7d-a1007ffaf3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsDiscountRateAbstract_f47cd20f-da43-4eb3-98be-bb95bdc800a0" xlink:href="ci-20231231.xsd#ci_DefinedBenefitPlanAssumptionsUsedInCalculationsDiscountRateAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_63115f65-b1b1-48a3-9c7d-a1007ffaf3e7" xlink:to="loc_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsDiscountRateAbstract_f47cd20f-da43-4eb3-98be-bb95bdc800a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_f713fd3c-d431-4db5-989d-dfaa1b308002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsDiscountRateAbstract_f47cd20f-da43-4eb3-98be-bb95bdc800a0" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_f713fd3c-d431-4db5-989d-dfaa1b308002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_1938fb3b-dd52-4385-b9e4-52dfe9e8baad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsDiscountRateAbstract_f47cd20f-da43-4eb3-98be-bb95bdc800a0" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_1938fb3b-dd52-4385-b9e4-52dfe9e8baad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsExpectedLongTermReturnOnPlanAssetsAbstract_8ac24756-3133-4669-adfc-a02934529dd2" xlink:href="ci-20231231.xsd#ci_DefinedBenefitPlanAssumptionsUsedInCalculationsExpectedLongTermReturnOnPlanAssetsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_63115f65-b1b1-48a3-9c7d-a1007ffaf3e7" xlink:to="loc_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsExpectedLongTermReturnOnPlanAssetsAbstract_8ac24756-3133-4669-adfc-a02934529dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_31caeee7-c82f-417c-909a-d3ee9f30305a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsExpectedLongTermReturnOnPlanAssetsAbstract_8ac24756-3133-4669-adfc-a02934529dd2" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_31caeee7-c82f-417c-909a-d3ee9f30305a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/PensionPensionPlanAssetsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#PensionPensionPlanAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/PensionPensionPlanAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_98ad7a62-3abf-4de1-b619-7a385db71306" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_91ded823-7639-4695-9c6b-330d8cc8c0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_98ad7a62-3abf-4de1-b619-7a385db71306" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_91ded823-7639-4695-9c6b-330d8cc8c0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_e65a3f3c-a2aa-4d28-a590-9c6f05b40630" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_91ded823-7639-4695-9c6b-330d8cc8c0e2" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_e65a3f3c-a2aa-4d28-a590-9c6f05b40630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_33f512da-bc01-4110-a499-b8969875765f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_e65a3f3c-a2aa-4d28-a590-9c6f05b40630" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_33f512da-bc01-4110-a499-b8969875765f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_53e9e8e7-c332-4639-83c2-57e2a50dfdb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_33f512da-bc01-4110-a499-b8969875765f" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_53e9e8e7-c332-4639-83c2-57e2a50dfdb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_da571522-6d88-44e3-a8a7-177e40fab549" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_91ded823-7639-4695-9c6b-330d8cc8c0e2" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_da571522-6d88-44e3-a8a7-177e40fab549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_8fbb1f9a-90db-4af4-b065-3095f1ac599f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_da571522-6d88-44e3-a8a7-177e40fab549" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_8fbb1f9a-90db-4af4-b065-3095f1ac599f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_38caa2ad-c1b5-40b7-9ab7-ec1056eb6e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDebtSecurityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8fbb1f9a-90db-4af4-b065-3095f1ac599f" xlink:to="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_38caa2ad-c1b5-40b7-9ab7-ec1056eb6e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_26df8b15-6a73-4734-873c-1d9f467cf305" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_38caa2ad-c1b5-40b7-9ab7-ec1056eb6e1d" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_26df8b15-6a73-4734-873c-1d9f467cf305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_da5c7972-a813-4991-950e-055ec03fe8c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_38caa2ad-c1b5-40b7-9ab7-ec1056eb6e1d" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_da5c7972-a813-4991-950e-055ec03fe8c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_b2e15ea0-e868-44b9-b82c-d2c81c9354fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_38caa2ad-c1b5-40b7-9ab7-ec1056eb6e1d" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_b2e15ea0-e868-44b9-b82c-d2c81c9354fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FundInvestmentsAndPooledSeparateAccountsMember_ef7ba25a-a973-4dbe-ba06-940e0b97856e" xlink:href="ci-20231231.xsd#ci_FundInvestmentsAndPooledSeparateAccountsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_38caa2ad-c1b5-40b7-9ab7-ec1056eb6e1d" xlink:to="loc_ci_FundInvestmentsAndPooledSeparateAccountsMember_ef7ba25a-a973-4dbe-ba06-940e0b97856e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherPlanAssetCategoriesMember_f536ebd5-e902-44ee-b84d-e52d48cbe9d6" xlink:href="ci-20231231.xsd#ci_OtherPlanAssetCategoriesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_8fbb1f9a-90db-4af4-b065-3095f1ac599f" xlink:to="loc_ci_OtherPlanAssetCategoriesMember_f536ebd5-e902-44ee-b84d-e52d48cbe9d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_b2a1324b-a6ef-4f1b-b7a2-28cead8f458e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_OtherPlanAssetCategoriesMember_f536ebd5-e902-44ee-b84d-e52d48cbe9d6" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_b2a1324b-a6ef-4f1b-b7a2-28cead8f458e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_7174f28d-eba1-48b5-81c9-d4a94a801ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_b2a1324b-a6ef-4f1b-b7a2-28cead8f458e" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember_7174f28d-eba1-48b5-81c9-d4a94a801ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_8e971e0e-4126-4705-9ddf-1a6858c4e2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_b2a1324b-a6ef-4f1b-b7a2-28cead8f458e" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember_8e971e0e-4126-4705-9ddf-1a6858c4e2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PartnershipInterestMember_172fbe5c-9a9f-42c4-87d9-822f82cabb3c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PartnershipInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_OtherPlanAssetCategoriesMember_f536ebd5-e902-44ee-b84d-e52d48cbe9d6" xlink:to="loc_srt_PartnershipInterestMember_172fbe5c-9a9f-42c4-87d9-822f82cabb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateMember_e64d7281-f9d5-45bb-8fd8-1826827812e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_OtherPlanAssetCategoriesMember_f536ebd5-e902-44ee-b84d-e52d48cbe9d6" xlink:to="loc_us-gaap_RealEstateMember_e64d7281-f9d5-45bb-8fd8-1826827812e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgagesMember_b55d6c1c-383a-4fae-9258-3a09262b64ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgagesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_OtherPlanAssetCategoriesMember_f536ebd5-e902-44ee-b84d-e52d48cbe9d6" xlink:to="loc_us-gaap_MortgagesMember_b55d6c1c-383a-4fae-9258-3a09262b64ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgeFundsMember_a5ffd74f-ec30-451a-a8ed-bf2d15db78d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgeFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_OtherPlanAssetCategoriesMember_f536ebd5-e902-44ee-b84d-e52d48cbe9d6" xlink:to="loc_us-gaap_HedgeFundsMember_a5ffd74f-ec30-451a-a8ed-bf2d15db78d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_GuaranteedDepositAccountContractMember_f250285e-f1dc-4eb2-9c3e-e404f4de4586" xlink:href="ci-20231231.xsd#ci_GuaranteedDepositAccountContractMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_OtherPlanAssetCategoriesMember_f536ebd5-e902-44ee-b84d-e52d48cbe9d6" xlink:to="loc_ci_GuaranteedDepositAccountContractMember_f250285e-f1dc-4eb2-9c3e-e404f4de4586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CashAndCashEquivalentsInvestmentTradeReceivablesNetMember_065f17f8-38e0-45f4-844a-f449a0262082" xlink:href="ci-20231231.xsd#ci_CashAndCashEquivalentsInvestmentTradeReceivablesNetMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_OtherPlanAssetCategoriesMember_f536ebd5-e902-44ee-b84d-e52d48cbe9d6" xlink:to="loc_ci_CashAndCashEquivalentsInvestmentTradeReceivablesNetMember_065f17f8-38e0-45f4-844a-f449a0262082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e4883cee-310e-4f0b-9a5e-116581477f49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_91ded823-7639-4695-9c6b-330d8cc8c0e2" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e4883cee-310e-4f0b-9a5e-116581477f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_ae9c4bb9-f11e-4fa5-beb5-3bd5659923d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e4883cee-310e-4f0b-9a5e-116581477f49" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_ae9c4bb9-f11e-4fa5-beb5-3bd5659923d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_34b03024-7b8f-4b40-a772-e28196462cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e4883cee-310e-4f0b-9a5e-116581477f49" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_34b03024-7b8f-4b40-a772-e28196462cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/PensionAnnualExpensefor401kPlansDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#PensionAnnualExpensefor401kPlansDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/PensionAnnualExpensefor401kPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0d786952-96be-4798-a6fd-22fc7e9addfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_441c1d1d-993a-492c-8f7f-11706722ebec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0d786952-96be-4798-a6fd-22fc7e9addfd" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_441c1d1d-993a-492c-8f7f-11706722ebec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EmployeeIncentivePlansSharesofCommonStockAvailableforAwardDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#EmployeeIncentivePlansSharesofCommonStockAvailableforAwardDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/EmployeeIncentivePlansSharesofCommonStockAvailableforAwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_094de17d-bad9-413d-aa4b-956c060afc74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2b77724a-efcc-40a6-a70a-e14788c13f65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_094de17d-bad9-413d-aa4b-956c060afc74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2b77724a-efcc-40a6-a70a-e14788c13f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EmployeeIncentivePlansNarrativeDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#EmployeeIncentivePlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/EmployeeIncentivePlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3402f417-ee49-4a91-9faf-46d2f1d6d773" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f21c368-40af-45ac-afb2-6c9879f3e6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3402f417-ee49-4a91-9faf-46d2f1d6d773" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f21c368-40af-45ac-afb2-6c9879f3e6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f80cf4fc-9eb3-4778-a614-8819793d5dc8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f21c368-40af-45ac-afb2-6c9879f3e6a7" xlink:to="loc_srt_RangeAxis_f80cf4fc-9eb3-4778-a614-8819793d5dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_788d29f2-9f34-42f8-8c55-b62b5811ee99" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f80cf4fc-9eb3-4778-a614-8819793d5dc8" xlink:to="loc_srt_RangeMember_788d29f2-9f34-42f8-8c55-b62b5811ee99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c55545e1-4213-46bd-921e-289962631a49" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_788d29f2-9f34-42f8-8c55-b62b5811ee99" xlink:to="loc_srt_MinimumMember_c55545e1-4213-46bd-921e-289962631a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f22bb035-45f7-48b3-b17b-17762ef19f76" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_788d29f2-9f34-42f8-8c55-b62b5811ee99" xlink:to="loc_srt_MaximumMember_f22bb035-45f7-48b3-b17b-17762ef19f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_049f33a2-9c15-4dc8-9fa2-6c326c58b96d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f21c368-40af-45ac-afb2-6c9879f3e6a7" xlink:to="loc_us-gaap_AwardTypeAxis_049f33a2-9c15-4dc8-9fa2-6c326c58b96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ceaca6b-3da9-4334-a3d3-d2ce00940b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_049f33a2-9c15-4dc8-9fa2-6c326c58b96d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ceaca6b-3da9-4334-a3d3-d2ce00940b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_790a40ea-92ab-4786-80b7-5ee5ead1c0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ceaca6b-3da9-4334-a3d3-d2ce00940b9f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_790a40ea-92ab-4786-80b7-5ee5ead1c0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RestrictedStockGrantsAndUnitsMember_884aa8b2-0ae7-4800-a840-27dd194b99da" xlink:href="ci-20231231.xsd#ci_RestrictedStockGrantsAndUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ceaca6b-3da9-4334-a3d3-d2ce00940b9f" xlink:to="loc_ci_RestrictedStockGrantsAndUnitsMember_884aa8b2-0ae7-4800-a840-27dd194b99da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_d0e0eb55-85cf-4a3a-b391-fc4596f671f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2ceaca6b-3da9-4334-a3d3-d2ce00940b9f" xlink:to="loc_us-gaap_PerformanceSharesMember_d0e0eb55-85cf-4a3a-b391-fc4596f671f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b7b91b4-63c2-4f79-b109-bb2fc9483131" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f21c368-40af-45ac-afb2-6c9879f3e6a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b7b91b4-63c2-4f79-b109-bb2fc9483131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_57c1ff3f-a851-4979-aceb-9ce17bb11896" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b7b91b4-63c2-4f79-b109-bb2fc9483131" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_57c1ff3f-a851-4979-aceb-9ce17bb11896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_571efb72-669f-48ea-a85d-57e51375c0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b7b91b4-63c2-4f79-b109-bb2fc9483131" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_571efb72-669f-48ea-a85d-57e51375c0b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionReferenceTermOfTradedOptions_d1d11e8f-ab8b-4714-8cda-633dbf045001" xlink:href="ci-20231231.xsd#ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionReferenceTermOfTradedOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b7b91b4-63c2-4f79-b109-bb2fc9483131" xlink:to="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionReferenceTermOfTradedOptions_d1d11e8f-ab8b-4714-8cda-633dbf045001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d2e6f481-b89d-45f1-a9ff-98e3c6d5f10e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b7b91b4-63c2-4f79-b109-bb2fc9483131" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d2e6f481-b89d-45f1-a9ff-98e3c6d5f10e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_de03b4aa-eb2d-4f93-9574-5a396753b51b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b7b91b4-63c2-4f79-b109-bb2fc9483131" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_de03b4aa-eb2d-4f93-9574-5a396753b51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateFairValueIncludingMonteCarloFactor_5297dc96-674c-447b-83ea-8380bda1c026" xlink:href="ci-20231231.xsd#ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateFairValueIncludingMonteCarloFactor"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b7b91b4-63c2-4f79-b109-bb2fc9483131" xlink:to="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateFairValueIncludingMonteCarloFactor_5297dc96-674c-447b-83ea-8380bda1c026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfEmployeesHolding_f1ab0476-f8a5-4753-bb44-a5b3baece8d6" xlink:href="ci-20231231.xsd#ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfEmployeesHolding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b7b91b4-63c2-4f79-b109-bb2fc9483131" xlink:to="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfEmployeesHolding_f1ab0476-f8a5-4753-bb44-a5b3baece8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_49dad7ec-f539-49a2-9366-da1ec8299fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b7b91b4-63c2-4f79-b109-bb2fc9483131" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_49dad7ec-f539-49a2-9366-da1ec8299fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod_59b88d83-92e3-4bee-b39e-7d88c29302a3" xlink:href="ci-20231231.xsd#ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b7b91b4-63c2-4f79-b109-bb2fc9483131" xlink:to="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod_59b88d83-92e3-4bee-b39e-7d88c29302a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfOriginalGrantAwardedAtEndOfPerformancePeriod_aea18f61-e6bf-49e2-976b-1b1bb5ffb64d" xlink:href="ci-20231231.xsd#ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfOriginalGrantAwardedAtEndOfPerformancePeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b7b91b4-63c2-4f79-b109-bb2fc9483131" xlink:to="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfOriginalGrantAwardedAtEndOfPerformancePeriod_aea18f61-e6bf-49e2-976b-1b1bb5ffb64d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EmployeeIncentivePlansBlackScholesOptionPricingModelAssumptionsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#EmployeeIncentivePlansBlackScholesOptionPricingModelAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/EmployeeIncentivePlansBlackScholesOptionPricingModelAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_853415a0-58f1-41f5-bfc5-30cb6c512fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_50899dfb-7063-4cd3-bf0c-45d837ba408e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_853415a0-58f1-41f5-bfc5-30cb6c512fe6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_50899dfb-7063-4cd3-bf0c-45d837ba408e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f95d4fae-a2be-417d-a3d2-dd4b35e856d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_50899dfb-7063-4cd3-bf0c-45d837ba408e" xlink:to="loc_us-gaap_AwardTypeAxis_f95d4fae-a2be-417d-a3d2-dd4b35e856d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33f1d53e-3d12-4374-8bae-f29c9ec44a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f95d4fae-a2be-417d-a3d2-dd4b35e856d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33f1d53e-3d12-4374-8bae-f29c9ec44a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8d00972d-a1b6-4a0f-b4ee-27029358a9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33f1d53e-3d12-4374-8bae-f29c9ec44a0d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8d00972d-a1b6-4a0f-b4ee-27029358a9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06532ef4-5a69-4556-a233-358b60a3adfa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_50899dfb-7063-4cd3-bf0c-45d837ba408e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06532ef4-5a69-4556-a233-358b60a3adfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2ed8ebd6-4258-4a9b-9390-7b655bc11ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06532ef4-5a69-4556-a233-358b60a3adfa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2ed8ebd6-4258-4a9b-9390-7b655bc11ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7c963827-add0-48e5-9ad5-ee2e57fdf311" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06532ef4-5a69-4556-a233-358b60a3adfa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7c963827-add0-48e5-9ad5-ee2e57fdf311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d3dba5ea-3af8-44f5-9b6c-12c5618154b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06532ef4-5a69-4556-a233-358b60a3adfa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d3dba5ea-3af8-44f5-9b6c-12c5618154b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1d76a41e-ffc8-4dd4-aa77-6912e2116148" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06532ef4-5a69-4556-a233-358b60a3adfa" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1d76a41e-ffc8-4dd4-aa77-6912e2116148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8126eff9-1622-4002-bf56-47317b390c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06532ef4-5a69-4556-a233-358b60a3adfa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8126eff9-1622-4002-bf56-47317b390c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinCommonStockOptionsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#EmployeeIncentivePlansStatusofandChangesinCommonStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinCommonStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_69e7d702-ac2e-4750-9804-fbf5faf5b2aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d7363df-f4b2-4c8d-885f-ae7782d7625a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_69e7d702-ac2e-4750-9804-fbf5faf5b2aa" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d7363df-f4b2-4c8d-885f-ae7782d7625a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a0cdc1bc-bb73-4c95-be90-cb66f6bf658e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d7363df-f4b2-4c8d-885f-ae7782d7625a" xlink:to="loc_us-gaap_AwardTypeAxis_a0cdc1bc-bb73-4c95-be90-cb66f6bf658e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f29b58b3-830e-460d-aae4-7d162a78bd1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a0cdc1bc-bb73-4c95-be90-cb66f6bf658e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f29b58b3-830e-460d-aae4-7d162a78bd1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_77532387-9458-4d7c-86ba-900f39bf0a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f29b58b3-830e-460d-aae4-7d162a78bd1a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_77532387-9458-4d7c-86ba-900f39bf0a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3dc4382-5413-4b30-8d82-a56734f6a845" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d7363df-f4b2-4c8d-885f-ae7782d7625a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3dc4382-5413-4b30-8d82-a56734f6a845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7dd4ebea-4cf5-499d-9d77-7ea3968aadd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3dc4382-5413-4b30-8d82-a56734f6a845" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7dd4ebea-4cf5-499d-9d77-7ea3968aadd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_03fdf5b6-2c28-4093-a75c-28e6264dca9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7dd4ebea-4cf5-499d-9d77-7ea3968aadd5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_03fdf5b6-2c28-4093-a75c-28e6264dca9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d6e908c6-421d-4143-9de7-565fe15e4ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7dd4ebea-4cf5-499d-9d77-7ea3968aadd5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d6e908c6-421d-4143-9de7-565fe15e4ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_489e5a9b-9727-4cbb-ae8a-dbedc55a76dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7dd4ebea-4cf5-499d-9d77-7ea3968aadd5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_489e5a9b-9727-4cbb-ae8a-dbedc55a76dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_99a8a8ca-cbb7-4cc0-823b-527bc07adf29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7dd4ebea-4cf5-499d-9d77-7ea3968aadd5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_99a8a8ca-cbb7-4cc0-823b-527bc07adf29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ab476230-8988-4d6d-9dcf-26f5c088a3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7dd4ebea-4cf5-499d-9d77-7ea3968aadd5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ab476230-8988-4d6d-9dcf-26f5c088a3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_728b60f1-a610-4889-828e-f1c1bad6d4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3dc4382-5413-4b30-8d82-a56734f6a845" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_728b60f1-a610-4889-828e-f1c1bad6d4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7308615e-b62f-4710-a7ea-f3c9a35e2ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3dc4382-5413-4b30-8d82-a56734f6a845" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7308615e-b62f-4710-a7ea-f3c9a35e2ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b271a280-19de-41d4-aaea-53f11537a8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7308615e-b62f-4710-a7ea-f3c9a35e2ff4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b271a280-19de-41d4-aaea-53f11537a8d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_049e3c8f-87e6-492e-a583-9d62dcb59ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7308615e-b62f-4710-a7ea-f3c9a35e2ff4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_049e3c8f-87e6-492e-a583-9d62dcb59ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0b1028ec-4d4b-4526-87e8-04d1288ed300" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7308615e-b62f-4710-a7ea-f3c9a35e2ff4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0b1028ec-4d4b-4526-87e8-04d1288ed300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_5536be2a-24a2-48a3-afe6-e2c973b02001" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7308615e-b62f-4710-a7ea-f3c9a35e2ff4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_5536be2a-24a2-48a3-afe6-e2c973b02001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4f438921-0381-434b-bb5a-c2a21e1abf5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7308615e-b62f-4710-a7ea-f3c9a35e2ff4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4f438921-0381-434b-bb5a-c2a21e1abf5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d9a462e3-cd5f-402f-8daf-2ab50a1c927b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3dc4382-5413-4b30-8d82-a56734f6a845" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d9a462e3-cd5f-402f-8daf-2ab50a1c927b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsExercisedDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#EmployeeIncentivePlansSummaryofInformationforStockOptionsExercisedDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsExercisedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1d4725fc-e7d5-4b5c-8fe0-4e297a987789" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a1755c74-5f67-410e-b220-eb02e4c3c85d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1d4725fc-e7d5-4b5c-8fe0-4e297a987789" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a1755c74-5f67-410e-b220-eb02e4c3c85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f053b9c5-a667-4d3b-96f3-7767d43e5011" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a1755c74-5f67-410e-b220-eb02e4c3c85d" xlink:to="loc_us-gaap_AwardTypeAxis_f053b9c5-a667-4d3b-96f3-7767d43e5011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_23d3667f-5eff-4814-bf5d-178c9cb937a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f053b9c5-a667-4d3b-96f3-7767d43e5011" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_23d3667f-5eff-4814-bf5d-178c9cb937a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7a9cd7a8-99d8-4827-9f7d-20668505d994" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_23d3667f-5eff-4814-bf5d-178c9cb937a1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7a9cd7a8-99d8-4827-9f7d-20668505d994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fbd6b3a7-ceec-4ffe-80d1-21790a846f79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a1755c74-5f67-410e-b220-eb02e4c3c85d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fbd6b3a7-ceec-4ffe-80d1-21790a846f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e337c658-97b2-4060-8190-146f8f88203e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fbd6b3a7-ceec-4ffe-80d1-21790a846f79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e337c658-97b2-4060-8190-146f8f88203e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_98ba89ad-8391-4f45-9e10-1e3edf3fab51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fbd6b3a7-ceec-4ffe-80d1-21790a846f79" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_98ba89ad-8391-4f45-9e10-1e3edf3fab51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_ac776e85-a52e-445a-a985-48b62f702eed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fbd6b3a7-ceec-4ffe-80d1-21790a846f79" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_ac776e85-a52e-445a-a985-48b62f702eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsOutstandingDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#EmployeeIncentivePlansSummaryofInformationforStockOptionsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8c839da7-3503-4ede-ab41-9115c0b4400f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_83e5586d-c045-443b-bbfe-41f01ed4ca74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8c839da7-3503-4ede-ab41-9115c0b4400f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_83e5586d-c045-443b-bbfe-41f01ed4ca74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e089dbee-3c48-41b7-bb80-a23696c2b327" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_83e5586d-c045-443b-bbfe-41f01ed4ca74" xlink:to="loc_us-gaap_AwardTypeAxis_e089dbee-3c48-41b7-bb80-a23696c2b327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da84a41e-e8bc-4a72-8875-d37cf4282273" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e089dbee-3c48-41b7-bb80-a23696c2b327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da84a41e-e8bc-4a72-8875-d37cf4282273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a2f4e19b-2a7b-4006-bed3-52b6389716f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da84a41e-e8bc-4a72-8875-d37cf4282273" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a2f4e19b-2a7b-4006-bed3-52b6389716f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3e7c602-8a1c-4dde-b567-a86f46e54971" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_83e5586d-c045-443b-bbfe-41f01ed4ca74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3e7c602-8a1c-4dde-b567-a86f46e54971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsOutstandingAbstract_173d68be-c5e2-4a1c-a9bf-a66822c06a25" xlink:href="ci-20231231.xsd#ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsOutstandingAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3e7c602-8a1c-4dde-b567-a86f46e54971" xlink:to="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsOutstandingAbstract_173d68be-c5e2-4a1c-a9bf-a66822c06a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_31283480-727a-4273-b5ee-a4c5121787ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsOutstandingAbstract_173d68be-c5e2-4a1c-a9bf-a66822c06a25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_31283480-727a-4273-b5ee-a4c5121787ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e1e3de55-e68d-4b8c-a139-7e2d2cac2521" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsOutstandingAbstract_173d68be-c5e2-4a1c-a9bf-a66822c06a25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e1e3de55-e68d-4b8c-a139-7e2d2cac2521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_23a2dbf8-3124-492d-bbdb-f385d19dafbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsOutstandingAbstract_173d68be-c5e2-4a1c-a9bf-a66822c06a25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_23a2dbf8-3124-492d-bbdb-f385d19dafbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_cf0c78f5-e99a-4e9e-834d-ac8d826cf38f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsOutstandingAbstract_173d68be-c5e2-4a1c-a9bf-a66822c06a25" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_cf0c78f5-e99a-4e9e-834d-ac8d826cf38f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsExercisableAbstract_c1ae1848-afb6-4906-bb88-a2569f693723" xlink:href="ci-20231231.xsd#ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsExercisableAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e3e7c602-8a1c-4dde-b567-a86f46e54971" xlink:to="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsExercisableAbstract_c1ae1848-afb6-4906-bb88-a2569f693723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ba970a20-ad86-4a7c-8b3e-3bcd7515ad75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsExercisableAbstract_c1ae1848-afb6-4906-bb88-a2569f693723" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ba970a20-ad86-4a7c-8b3e-3bcd7515ad75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a458f80c-5518-49b2-a47d-48354d6f67df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsExercisableAbstract_c1ae1848-afb6-4906-bb88-a2569f693723" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a458f80c-5518-49b2-a47d-48354d6f67df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1c1486e6-1711-495a-839a-9d9c1ffa0b03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsExercisableAbstract_c1ae1848-afb6-4906-bb88-a2569f693723" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1c1486e6-1711-495a-839a-9d9c1ffa0b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_89c5cfb7-9f80-409f-ad53-aa64f0966652" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsExercisableAbstract_c1ae1848-afb6-4906-bb88-a2569f693723" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_89c5cfb7-9f80-409f-ad53-aa64f0966652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinRestrictedStockAwardsandSPSsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#EmployeeIncentivePlansStatusofandChangesinRestrictedStockAwardsandSPSsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinRestrictedStockAwardsandSPSsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_61818e96-bcf3-450a-b83c-7375de57ac05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f7f44e11-8eb4-4ae9-ba9c-e36a091a0d42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_61818e96-bcf3-450a-b83c-7375de57ac05" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f7f44e11-8eb4-4ae9-ba9c-e36a091a0d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ffcb153f-0634-46c1-8c2c-78f94faabe79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f7f44e11-8eb4-4ae9-ba9c-e36a091a0d42" xlink:to="loc_us-gaap_AwardTypeAxis_ffcb153f-0634-46c1-8c2c-78f94faabe79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_499e61de-9733-48af-b3bc-8759ba21b658" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ffcb153f-0634-46c1-8c2c-78f94faabe79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_499e61de-9733-48af-b3bc-8759ba21b658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RestrictedStockGrantsAndUnitsMember_e29f22f7-9e93-449e-bc12-b0c7197ecfa1" xlink:href="ci-20231231.xsd#ci_RestrictedStockGrantsAndUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_499e61de-9733-48af-b3bc-8759ba21b658" xlink:to="loc_ci_RestrictedStockGrantsAndUnitsMember_e29f22f7-9e93-449e-bc12-b0c7197ecfa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ef4c1ffb-3e54-4899-be80-cfef7a36348d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_499e61de-9733-48af-b3bc-8759ba21b658" xlink:to="loc_us-gaap_PerformanceSharesMember_ef4c1ffb-3e54-4899-be80-cfef7a36348d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f63835f7-7d5d-439e-ba94-719fcf5e1b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f7f44e11-8eb4-4ae9-ba9c-e36a091a0d42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f63835f7-7d5d-439e-ba94-719fcf5e1b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7d09feec-b7f6-4a11-bb6a-77944a1e42c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f63835f7-7d5d-439e-ba94-719fcf5e1b2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7d09feec-b7f6-4a11-bb6a-77944a1e42c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3d1bc345-c214-47df-b9d1-808286fbc028" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7d09feec-b7f6-4a11-bb6a-77944a1e42c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3d1bc345-c214-47df-b9d1-808286fbc028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_001f2b82-fe70-40d9-b45c-78e39ceb6990" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7d09feec-b7f6-4a11-bb6a-77944a1e42c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_001f2b82-fe70-40d9-b45c-78e39ceb6990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7bcffc69-20b6-4503-8280-e99cceb9e227" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7d09feec-b7f6-4a11-bb6a-77944a1e42c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7bcffc69-20b6-4503-8280-e99cceb9e227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_fb17a29e-dd38-457b-b443-8e5575816fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7d09feec-b7f6-4a11-bb6a-77944a1e42c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_fb17a29e-dd38-457b-b443-8e5575816fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_87eef8cb-188c-4ba2-a091-303e7a9751d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7d09feec-b7f6-4a11-bb6a-77944a1e42c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_87eef8cb-188c-4ba2-a091-303e7a9751d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e429a90-78f8-49a5-888c-ac3be29c3170" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f63835f7-7d5d-439e-ba94-719fcf5e1b2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e429a90-78f8-49a5-888c-ac3be29c3170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_26895869-e775-45e2-a642-b515ed85328f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e429a90-78f8-49a5-888c-ac3be29c3170" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_26895869-e775-45e2-a642-b515ed85328f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2bacb9ee-60a1-4e20-8bec-3ee5c1320c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e429a90-78f8-49a5-888c-ac3be29c3170" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2bacb9ee-60a1-4e20-8bec-3ee5c1320c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9209f8cb-5626-488a-81d3-d8d24fb6f1ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e429a90-78f8-49a5-888c-ac3be29c3170" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9209f8cb-5626-488a-81d3-d8d24fb6f1ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_23d05e17-7761-43cc-be7b-e270afab9acf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e429a90-78f8-49a5-888c-ac3be29c3170" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_23d05e17-7761-43cc-be7b-e270afab9acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_81615a21-b7ab-48e2-8b93-1a37a0fb63eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e429a90-78f8-49a5-888c-ac3be29c3170" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_81615a21-b7ab-48e2-8b93-1a37a0fb63eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EmployeeIncentivePlansFairValueofVestedRestrictedStockandSPSsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#EmployeeIncentivePlansFairValueofVestedRestrictedStockandSPSsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/EmployeeIncentivePlansFairValueofVestedRestrictedStockandSPSsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1bbd0ce1-9dfa-434f-9c11-529aa7ed8e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85f7364f-eed1-4852-82be-ce3ad7cb98f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1bbd0ce1-9dfa-434f-9c11-529aa7ed8e3d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85f7364f-eed1-4852-82be-ce3ad7cb98f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_35c9263d-370d-419d-bf0b-480a806c3a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85f7364f-eed1-4852-82be-ce3ad7cb98f3" xlink:to="loc_us-gaap_AwardTypeAxis_35c9263d-370d-419d-bf0b-480a806c3a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d5d993c-1131-406d-98de-852150c7557c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_35c9263d-370d-419d-bf0b-480a806c3a8e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d5d993c-1131-406d-98de-852150c7557c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RestrictedStockGrantsAndUnitsMember_14c3bb8b-bf08-42c3-85c1-65f84770f231" xlink:href="ci-20231231.xsd#ci_RestrictedStockGrantsAndUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d5d993c-1131-406d-98de-852150c7557c" xlink:to="loc_ci_RestrictedStockGrantsAndUnitsMember_14c3bb8b-bf08-42c3-85c1-65f84770f231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ad290fb0-5ce3-459a-b6ae-79a4df9cc5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d5d993c-1131-406d-98de-852150c7557c" xlink:to="loc_us-gaap_PerformanceSharesMember_ad290fb0-5ce3-459a-b6ae-79a4df9cc5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c253baea-ef50-4baf-aad9-a553fe5e6109" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_85f7364f-eed1-4852-82be-ce3ad7cb98f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c253baea-ef50-4baf-aad9-a553fe5e6109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_21ab2800-ca9c-44c1-a4b8-cf762a8ac6f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c253baea-ef50-4baf-aad9-a553fe5e6109" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_21ab2800-ca9c-44c1-a4b8-cf762a8ac6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_a323651f-88a7-4cc1-a893-0c90c282215a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c253baea-ef50-4baf-aad9-a553fe5e6109" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_a323651f-88a7-4cc1-a893-0c90c282215a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/EmployeeIncentivePlansCompensationCostandTaxEffectsofSharebasedCompensationDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#EmployeeIncentivePlansCompensationCostandTaxEffectsofSharebasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/EmployeeIncentivePlansCompensationCostandTaxEffectsofSharebasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bd8f7da1-73e7-471d-8ba3-2ccb2abbdddd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5a61c24e-8528-4996-a07f-4e1116f5ebb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bd8f7da1-73e7-471d-8ba3-2ccb2abbdddd" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5a61c24e-8528-4996-a07f-4e1116f5ebb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_43016ba4-9c6b-498d-9f7c-ad68169c5586" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bd8f7da1-73e7-471d-8ba3-2ccb2abbdddd" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_43016ba4-9c6b-498d-9f7c-ad68169c5586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#GoodwillOtherIntangiblesandPropertyandEquipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a47f8ff6-4035-40d8-95e0-6adfa4402d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentTable_3bdb0ad4-8136-4b2a-8cce-3c11c888613b" xlink:href="ci-20231231.xsd#ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a47f8ff6-4035-40d8-95e0-6adfa4402d9d" xlink:to="loc_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentTable_3bdb0ad4-8136-4b2a-8cce-3c11c888613b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6c53e895-baed-4e49-94bd-14f131cce474" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentTable_3bdb0ad4-8136-4b2a-8cce-3c11c888613b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6c53e895-baed-4e49-94bd-14f131cce474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_539571a3-c912-426d-aa35-0d963cd2d3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6c53e895-baed-4e49-94bd-14f131cce474" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_539571a3-c912-426d-aa35-0d963cd2d3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_575fde30-9938-4409-b97d-1aecc2f20aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_539571a3-c912-426d-aa35-0d963cd2d3a0" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_575fde30-9938-4409-b97d-1aecc2f20aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_557a99aa-feb0-44b0-8988-3b3baac04037" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_539571a3-c912-426d-aa35-0d963cd2d3a0" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_557a99aa-feb0-44b0-8988-3b3baac04037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_5b0a2387-cfa6-4240-a9cc-5ad1e3874666" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_539571a3-c912-426d-aa35-0d963cd2d3a0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_5b0a2387-cfa6-4240-a9cc-5ad1e3874666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_e929ce8d-75e1-4d5e-9a88-11793d50ca94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_539571a3-c912-426d-aa35-0d963cd2d3a0" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_e929ce8d-75e1-4d5e-9a88-11793d50ca94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_64c38809-c316-42e0-a457-cc4de41c4e07" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentTable_3bdb0ad4-8136-4b2a-8cce-3c11c888613b" xlink:to="loc_srt_RangeAxis_64c38809-c316-42e0-a457-cc4de41c4e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_45ac7ed2-72b9-441b-a5ee-a898a6add483" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_64c38809-c316-42e0-a457-cc4de41c4e07" xlink:to="loc_srt_RangeMember_45ac7ed2-72b9-441b-a5ee-a898a6add483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8e6de656-8eea-400b-94be-7b3f0469caf4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_45ac7ed2-72b9-441b-a5ee-a898a6add483" xlink:to="loc_srt_MinimumMember_8e6de656-8eea-400b-94be-7b3f0469caf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9264e1d5-1e38-4a49-8d6a-29558410d04f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_45ac7ed2-72b9-441b-a5ee-a898a6add483" xlink:to="loc_srt_MaximumMember_9264e1d5-1e38-4a49-8d6a-29558410d04f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems_7ccde0df-cbb5-4fa7-a323-d2dfef7f9fb6" xlink:href="ci-20231231.xsd#ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentTable_3bdb0ad4-8136-4b2a-8cce-3c11c888613b" xlink:to="loc_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems_7ccde0df-cbb5-4fa7-a323-d2dfef7f9fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_39b9db0c-ea90-4d29-ac2a-3523789c0de2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems_7ccde0df-cbb5-4fa7-a323-d2dfef7f9fb6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_39b9db0c-ea90-4d29-ac2a-3523789c0de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_9688255c-c597-4ca2-9f7f-ce67ca963ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems_7ccde0df-cbb5-4fa7-a323-d2dfef7f9fb6" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_9688255c-c597-4ca2-9f7f-ce67ca963ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c4d0fe2d-e76a-4d73-9964-92155fb33d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems_7ccde0df-cbb5-4fa7-a323-d2dfef7f9fb6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c4d0fe2d-e76a-4d73-9964-92155fb33d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_44290e35-c7f3-4e1d-996f-0d0b1fa18b95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems_7ccde0df-cbb5-4fa7-a323-d2dfef7f9fb6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_44290e35-c7f3-4e1d-996f-0d0b1fa18b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_f4f65563-607e-4c19-a12a-c39d863a0cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems_7ccde0df-cbb5-4fa7-a323-d2dfef7f9fb6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_f4f65563-607e-4c19-a12a-c39d863a0cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentGoodwillActivityDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#GoodwillOtherIntangiblesandPropertyandEquipmentGoodwillActivityDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentGoodwillActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract_e0ffd127-d178-4958-9689-4c10b7b2f237" xlink:href="ci-20231231.xsd#ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_66517519-7179-422d-a0ec-a77c79f6fc7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract_e0ffd127-d178-4958-9689-4c10b7b2f237" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_66517519-7179-422d-a0ec-a77c79f6fc7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c5d6da25-c2c5-4b9a-b71e-a75d6a2f65ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_66517519-7179-422d-a0ec-a77c79f6fc7f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c5d6da25-c2c5-4b9a-b71e-a75d6a2f65ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2d1c4de5-d233-4aa8-afd5-3224a6ee6b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c5d6da25-c2c5-4b9a-b71e-a75d6a2f65ca" xlink:to="loc_us-gaap_SegmentDomain_2d1c4de5-d233-4aa8-afd5-3224a6ee6b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EvernorthMember_2af30902-c9e0-4f5e-9998-5cdc447a9cfd" xlink:href="ci-20231231.xsd#ci_EvernorthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2d1c4de5-d233-4aa8-afd5-3224a6ee6b0f" xlink:to="loc_ci_EvernorthMember_2af30902-c9e0-4f5e-9998-5cdc447a9cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember_55446462-9136-462f-8020-eec8dcf9ca8b" xlink:href="ci-20231231.xsd#ci_CignaHealthcareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2d1c4de5-d233-4aa8-afd5-3224a6ee6b0f" xlink:to="loc_ci_CignaHealthcareMember_55446462-9136-462f-8020-eec8dcf9ca8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherOperationsSegmentMember_6862b985-30d7-47be-8c63-fc371196f262" xlink:href="ci-20231231.xsd#ci_OtherOperationsSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2d1c4de5-d233-4aa8-afd5-3224a6ee6b0f" xlink:to="loc_ci_OtherOperationsSegmentMember_6862b985-30d7-47be-8c63-fc371196f262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_9cb78ec2-15fd-4d6d-a1e2-da594b322052" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_66517519-7179-422d-a0ec-a77c79f6fc7f" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_9cb78ec2-15fd-4d6d-a1e2-da594b322052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_cd48f390-5871-453e-a355-921dd0ca8ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9cb78ec2-15fd-4d6d-a1e2-da594b322052" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_cd48f390-5871-453e-a355-921dd0ca8ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_824c4d96-7b5e-4a32-a768-3e2de1ef9927" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_cd48f390-5871-453e-a355-921dd0ca8ba6" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_824c4d96-7b5e-4a32-a768-3e2de1ef9927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5e859cde-dbb3-45e8-920d-8a81fdb51e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_66517519-7179-422d-a0ec-a77c79f6fc7f" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5e859cde-dbb3-45e8-920d-8a81fdb51e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1dab4f32-a04b-4652-a161-65bb14d7c1de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5e859cde-dbb3-45e8-920d-8a81fdb51e7f" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1dab4f32-a04b-4652-a161-65bb14d7c1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember_2ed40afb-eafd-4912-886c-5ccaeef16522" xlink:href="ci-20231231.xsd#ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1dab4f32-a04b-4652-a161-65bb14d7c1de" xlink:to="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember_2ed40afb-eafd-4912-886c-5ccaeef16522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_a3493f3a-4490-46f4-b2fc-f50f2ad8be94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_66517519-7179-422d-a0ec-a77c79f6fc7f" xlink:to="loc_us-gaap_GoodwillLineItems_a3493f3a-4490-46f4-b2fc-f50f2ad8be94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_e681ba8a-705a-4c70-91a7-09e851ac8332" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_a3493f3a-4490-46f4-b2fc-f50f2ad8be94" xlink:to="loc_us-gaap_GoodwillRollForward_e681ba8a-705a-4c70-91a7-09e851ac8332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3e2f9f26-1920-42e0-9bda-0269b5be49b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_e681ba8a-705a-4c70-91a7-09e851ac8332" xlink:to="loc_us-gaap_Goodwill_3e2f9f26-1920-42e0-9bda-0269b5be49b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_GoodwillIncludingDisposalGroups_0b0fb299-0c2e-4431-a8cc-cddd865a0da6" xlink:href="ci-20231231.xsd#ci_GoodwillIncludingDisposalGroups"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_e681ba8a-705a-4c70-91a7-09e851ac8332" xlink:to="loc_ci_GoodwillIncludingDisposalGroups_0b0fb299-0c2e-4431-a8cc-cddd865a0da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_e681da4c-af0f-4002-a21d-3608d52bfcc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_e681ba8a-705a-4c70-91a7-09e851ac8332" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_e681da4c-af0f-4002-a21d-3608d52bfcc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_faf2f059-3f87-4238-9a03-22754c2dab1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_e681ba8a-705a-4c70-91a7-09e851ac8332" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_faf2f059-3f87-4238-9a03-22754c2dab1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_GoodwillTransfersToAssetsOfBusinessesHeldForSale_9cb5dbd5-f8c0-4395-98c9-82585f8fa6ec" xlink:href="ci-20231231.xsd#ci_GoodwillTransfersToAssetsOfBusinessesHeldForSale"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_e681ba8a-705a-4c70-91a7-09e851ac8332" xlink:to="loc_ci_GoodwillTransfersToAssetsOfBusinessesHeldForSale_9cb5dbd5-f8c0-4395-98c9-82585f8fa6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_8fde5b82-1501-4bc3-811f-a3feb008157c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_e681ba8a-705a-4c70-91a7-09e851ac8332" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_8fde5b82-1501-4bc3-811f-a3feb008157c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_cf393fb6-ffa4-4ecb-bf5a-6838b1a447d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_e681ba8a-705a-4c70-91a7-09e851ac8332" xlink:to="loc_us-gaap_Goodwill_cf393fb6-ffa4-4ecb-bf5a-6838b1a447d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_GoodwillIncludingDisposalGroups_e754142c-8109-409c-a4f8-84f61000c30a" xlink:href="ci-20231231.xsd#ci_GoodwillIncludingDisposalGroups"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_e681ba8a-705a-4c70-91a7-09e851ac8332" xlink:to="loc_ci_GoodwillIncludingDisposalGroups_e754142c-8109-409c-a4f8-84f61000c30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_080615d1-8786-4db7-8343-0b21c9ac5c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_a3493f3a-4490-46f4-b2fc-f50f2ad8be94" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_080615d1-8786-4db7-8343-0b21c9ac5c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract_f30286cf-5404-4ddf-9494-389fa1d7b91f" xlink:href="ci-20231231.xsd#ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_094a1de1-4a64-4df7-96c2-6789bfa2b496" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract_f30286cf-5404-4ddf-9494-389fa1d7b91f" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_094a1de1-4a64-4df7-96c2-6789bfa2b496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f2be4b97-f856-43f0-9975-35eb86d04cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_094a1de1-4a64-4df7-96c2-6789bfa2b496" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f2be4b97-f856-43f0-9975-35eb86d04cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1cde6508-f4da-4a40-b46d-4647e545bdf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f2be4b97-f856-43f0-9975-35eb86d04cfd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1cde6508-f4da-4a40-b46d-4647e545bdf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_b4ad5756-1165-446d-9618-c3b930125f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1cde6508-f4da-4a40-b46d-4647e545bdf3" xlink:to="loc_us-gaap_CustomerRelationshipsMember_b4ad5756-1165-446d-9618-c3b930125f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_98e234fc-298c-4ee0-9c2b-6b5c9aaf4634" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1cde6508-f4da-4a40-b46d-4647e545bdf3" xlink:to="loc_us-gaap_TradeNamesMember_98e234fc-298c-4ee0-9c2b-6b5c9aaf4634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_e8ec1a9e-a759-4752-b39a-2f387fdc209d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1cde6508-f4da-4a40-b46d-4647e545bdf3" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_e8ec1a9e-a759-4752-b39a-2f387fdc209d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_8547ab9c-c63c-4521-84db-311a6642c9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_094a1de1-4a64-4df7-96c2-6789bfa2b496" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_8547ab9c-c63c-4521-84db-311a6642c9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_106fba00-6a70-4f39-89f2-1d3ed9b60af9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_8547ab9c-c63c-4521-84db-311a6642c9f3" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_106fba00-6a70-4f39-89f2-1d3ed9b60af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_02f4eb1f-99c4-4186-a166-307799af338b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_106fba00-6a70-4f39-89f2-1d3ed9b60af9" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_02f4eb1f-99c4-4186-a166-307799af338b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b4bb9ae5-3875-43ac-9ffd-6cc8d6b96a24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_094a1de1-4a64-4df7-96c2-6789bfa2b496" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b4bb9ae5-3875-43ac-9ffd-6cc8d6b96a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ecaa3a4a-fb41-4d59-b36f-b8c5280630b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b4bb9ae5-3875-43ac-9ffd-6cc8d6b96a24" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ecaa3a4a-fb41-4d59-b36f-b8c5280630b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_f03adbcb-696c-4c97-969d-3c709c0d23fd" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ecaa3a4a-fb41-4d59-b36f-b8c5280630b5" xlink:to="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_f03adbcb-696c-4c97-969d-3c709c0d23fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_78c7aeb9-08ed-46ef-8a39-567e716c18bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_094a1de1-4a64-4df7-96c2-6789bfa2b496" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_78c7aeb9-08ed-46ef-8a39-567e716c18bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_863be35a-e096-4317-84ae-4e9c2a16892f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_78c7aeb9-08ed-46ef-8a39-567e716c18bf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_863be35a-e096-4317-84ae-4e9c2a16892f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ac17d755-444c-40fa-9cb9-478f0cd9c674" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_863be35a-e096-4317-84ae-4e9c2a16892f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ac17d755-444c-40fa-9cb9-478f0cd9c674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ee02cbfe-e54c-4f32-abb1-99059425720c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_863be35a-e096-4317-84ae-4e9c2a16892f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ee02cbfe-e54c-4f32-abb1-99059425720c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9992240b-f17f-4743-8d64-648a60111dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_863be35a-e096-4317-84ae-4e9c2a16892f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9992240b-f17f-4743-8d64-648a60111dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsGrossIncludingDisposalGroupsHeldForSale_b52e405a-2ce0-442a-8859-a1f936d10372" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsGrossIncludingDisposalGroupsHeldForSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_863be35a-e096-4317-84ae-4e9c2a16892f" xlink:to="loc_ci_FiniteLivedIntangibleAssetsGrossIncludingDisposalGroupsHeldForSale_b52e405a-2ce0-442a-8859-a1f936d10372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale_c235a9b9-fac0-42de-bc88-96b5a1a83e32" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_863be35a-e096-4317-84ae-4e9c2a16892f" xlink:to="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale_c235a9b9-fac0-42de-bc88-96b5a1a83e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsNetIncludingDisposalGroupsAssetsHeldForSale_a42ef434-e176-405c-8b05-456e4e9cfae1" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsNetIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_863be35a-e096-4317-84ae-4e9c2a16892f" xlink:to="loc_ci_FiniteLivedIntangibleAssetsNetIncludingDisposalGroupsAssetsHeldForSale_a42ef434-e176-405c-8b05-456e4e9cfae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_87f2bb77-2568-445f-9cdc-91fc5ff6212b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_78c7aeb9-08ed-46ef-8a39-567e716c18bf" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_87f2bb77-2568-445f-9cdc-91fc5ff6212b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_fbcd1537-1593-4127-8530-2ac1c5dfa565" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_87f2bb77-2568-445f-9cdc-91fc5ff6212b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_fbcd1537-1593-4127-8530-2ac1c5dfa565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4d7d9399-7892-4648-9580-ac520442d46f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_87f2bb77-2568-445f-9cdc-91fc5ff6212b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4d7d9399-7892-4648-9580-ac520442d46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale_bfa41733-05ba-4f7e-9735-01e9998a2bd8" xlink:href="ci-20231231.xsd#ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_87f2bb77-2568-445f-9cdc-91fc5ff6212b" xlink:to="loc_ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale_bfa41733-05ba-4f7e-9735-01e9998a2bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale_9d2a92c0-9603-4f51-a7a9-13cf9cdf44d9" xlink:href="ci-20231231.xsd#ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_87f2bb77-2568-445f-9cdc-91fc5ff6212b" xlink:to="loc_ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale_9d2a92c0-9603-4f51-a7a9-13cf9cdf44d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherIntangibleAssetsAbstract_935cf249-3502-465b-909d-dce5a0408f57" xlink:href="ci-20231231.xsd#ci_OtherIntangibleAssetsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_78c7aeb9-08ed-46ef-8a39-567e716c18bf" xlink:to="loc_ci_OtherIntangibleAssetsAbstract_935cf249-3502-465b-909d-dce5a0408f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_8db285bb-1c47-4be7-97fa-ac7098469348" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_OtherIntangibleAssetsAbstract_935cf249-3502-465b-909d-dce5a0408f57" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_8db285bb-1c47-4be7-97fa-ac7098469348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_66e30921-1edf-4d96-9188-525ba071a56f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_OtherIntangibleAssetsAbstract_935cf249-3502-465b-909d-dce5a0408f57" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_66e30921-1edf-4d96-9188-525ba071a56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale_5dee079a-84d0-42fb-9343-2f85c599575e" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_OtherIntangibleAssetsAbstract_935cf249-3502-465b-909d-dce5a0408f57" xlink:to="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale_5dee079a-84d0-42fb-9343-2f85c599575e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale_4b3aba09-4509-4ece-ad3b-8557cb145901" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_OtherIntangibleAssetsAbstract_935cf249-3502-465b-909d-dce5a0408f57" xlink:to="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale_4b3aba09-4509-4ece-ad3b-8557cb145901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsValueOfBusinessAcquiredAbstract_ffc8acad-86e2-41a9-82b0-50924ee3004a" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsValueOfBusinessAcquiredAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_78c7aeb9-08ed-46ef-8a39-567e716c18bf" xlink:to="loc_ci_IntangibleAssetsValueOfBusinessAcquiredAbstract_ffc8acad-86e2-41a9-82b0-50924ee3004a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsGrossVoba_03ca2525-f0e5-4b3a-8076-5bc2f7be3da7" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsGrossVoba"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_IntangibleAssetsValueOfBusinessAcquiredAbstract_ffc8acad-86e2-41a9-82b0-50924ee3004a" xlink:to="loc_ci_FiniteLivedIntangibleAssetsGrossVoba_03ca2525-f0e5-4b3a-8076-5bc2f7be3da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVoba_b685940f-1fd5-46df-a9b2-6dd66a325a36" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVoba"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_IntangibleAssetsValueOfBusinessAcquiredAbstract_ffc8acad-86e2-41a9-82b0-50924ee3004a" xlink:to="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVoba_b685940f-1fd5-46df-a9b2-6dd66a325a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsNetVoba_d9971922-e33b-46f6-9a5b-070a401a334e" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsNetVoba"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_IntangibleAssetsValueOfBusinessAcquiredAbstract_ffc8acad-86e2-41a9-82b0-50924ee3004a" xlink:to="loc_ci_FiniteLivedIntangibleAssetsNetVoba_d9971922-e33b-46f6-9a5b-070a401a334e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsGrossVOBAIncludingDisposalGroupsAssetHeldForSale_cf2e3d63-73ef-4578-b6d3-e7edf7a553fc" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsGrossVOBAIncludingDisposalGroupsAssetHeldForSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_IntangibleAssetsValueOfBusinessAcquiredAbstract_ffc8acad-86e2-41a9-82b0-50924ee3004a" xlink:to="loc_ci_FiniteLivedIntangibleAssetsGrossVOBAIncludingDisposalGroupsAssetHeldForSale_cf2e3d63-73ef-4578-b6d3-e7edf7a553fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVOBAIncludingDisposalGroupsAssetsHeldForSale_077d2cd3-49fc-424e-9cfc-1aa4b0573e7d" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVOBAIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_IntangibleAssetsValueOfBusinessAcquiredAbstract_ffc8acad-86e2-41a9-82b0-50924ee3004a" xlink:to="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVOBAIncludingDisposalGroupsAssetsHeldForSale_077d2cd3-49fc-424e-9cfc-1aa4b0573e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsNetVOBAIncludingDisposalGroupsAssetsHeldForSale_f0ce4888-e09a-4873-ac62-10660d8eb8b8" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsNetVOBAIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_IntangibleAssetsValueOfBusinessAcquiredAbstract_ffc8acad-86e2-41a9-82b0-50924ee3004a" xlink:to="loc_ci_FiniteLivedIntangibleAssetsNetVOBAIncludingDisposalGroupsAssetsHeldForSale_f0ce4888-e09a-4873-ac62-10660d8eb8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4eb8709b-c248-4c48-a3f7-8e8d78d5a6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_78c7aeb9-08ed-46ef-8a39-567e716c18bf" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4eb8709b-c248-4c48-a3f7-8e8d78d5a6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVoba_b5dd56a7-148d-4d77-8a5a-79f87a6cdf56" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsGrossExcludingGoodwillIncludingVoba"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4eb8709b-c248-4c48-a3f7-8e8d78d5a6c6" xlink:to="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVoba_b5dd56a7-148d-4d77-8a5a-79f87a6cdf56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVoba_16dc338b-29df-47f8-8ab1-2a413f3ad8d2" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVoba"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4eb8709b-c248-4c48-a3f7-8e8d78d5a6c6" xlink:to="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVoba_16dc338b-29df-47f8-8ab1-2a413f3ad8d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingVoba_33f15c7e-f99c-4b1f-875a-bc900592f30c" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsNetExcludingGoodwillIncludingVoba"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4eb8709b-c248-4c48-a3f7-8e8d78d5a6c6" xlink:to="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingVoba_33f15c7e-f99c-4b1f-875a-bc900592f30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups_f0f5dc4c-876c-40f4-9c4e-dd4256a93725" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4eb8709b-c248-4c48-a3f7-8e8d78d5a6c6" xlink:to="loc_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups_f0f5dc4c-876c-40f4-9c4e-dd4256a93725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVOBAIncludingDisposalGroups_e2cef6ec-8772-4583-98dc-5d9ef8abe434" xlink:href="ci-20231231.xsd#ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVOBAIncludingDisposalGroups"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4eb8709b-c248-4c48-a3f7-8e8d78d5a6c6" xlink:to="loc_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVOBAIncludingDisposalGroups_e2cef6ec-8772-4583-98dc-5d9ef8abe434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups_68067fcb-d9e4-4832-931a-0271d9a0ab09" xlink:href="ci-20231231.xsd#ci_IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4eb8709b-c248-4c48-a3f7-8e8d78d5a6c6" xlink:to="loc_ci_IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups_68067fcb-d9e4-4832-931a-0271d9a0ab09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationValueOfBusinessAcquired_7253ddc6-3aba-4863-aa1a-1637f7dfc80c" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationValueOfBusinessAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_78c7aeb9-08ed-46ef-8a39-567e716c18bf" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationValueOfBusinessAcquired_7253ddc6-3aba-4863-aa1a-1637f7dfc80c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_120dfa41-16a7-46e2-b74c-9188848d7e78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_78c7aeb9-08ed-46ef-8a39-567e716c18bf" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_120dfa41-16a7-46e2-b74c-9188848d7e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="ci-20231231.xsd#GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails_1"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract_0d6654dd-68ea-4cb1-83f7-cfb1b108f690" xlink:href="ci-20231231.xsd#ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fd50eb62-73ed-4f16-a9b6-9f770d9b8c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract_0d6654dd-68ea-4cb1-83f7-cfb1b108f690" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fd50eb62-73ed-4f16-a9b6-9f770d9b8c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5ce7d595-ecf6-4be0-bcae-66e3d31c79be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fd50eb62-73ed-4f16-a9b6-9f770d9b8c8b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5ce7d595-ecf6-4be0-bcae-66e3d31c79be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4e5c4998-4df1-45fb-bf54-d96df35392ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5ce7d595-ecf6-4be0-bcae-66e3d31c79be" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4e5c4998-4df1-45fb-bf54-d96df35392ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_7a2cb7ef-c1fb-4e80-bb9e-14673a0d189f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4e5c4998-4df1-45fb-bf54-d96df35392ba" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_7a2cb7ef-c1fb-4e80-bb9e-14673a0d189f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember_a3be4642-f550-496d-8579-15182509f386" xlink:href="ci-20231231.xsd#ci_AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4e5c4998-4df1-45fb-bf54-d96df35392ba" xlink:to="loc_ci_AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember_a3be4642-f550-496d-8579-15182509f386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_bb0de3ef-6ee7-461f-914d-b011242ec2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fd50eb62-73ed-4f16-a9b6-9f770d9b8c8b" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_bb0de3ef-6ee7-461f-914d-b011242ec2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_1fd17d67-5d9a-4d40-803f-69446c71ad1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_bb0de3ef-6ee7-461f-914d-b011242ec2ae" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_1fd17d67-5d9a-4d40-803f-69446c71ad1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_a0a9c23a-48e3-4b7c-b7b6-b144484bbcfa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_1fd17d67-5d9a-4d40-803f-69446c71ad1d" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_a0a9c23a-48e3-4b7c-b7b6-b144484bbcfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_236e008a-42fb-4e12-9fd8-4de25221df87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fd50eb62-73ed-4f16-a9b6-9f770d9b8c8b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_236e008a-42fb-4e12-9fd8-4de25221df87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9c347026-d014-4a67-b44d-cb73a0e671e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_236e008a-42fb-4e12-9fd8-4de25221df87" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9c347026-d014-4a67-b44d-cb73a0e671e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_a8c072e9-cfe0-4ec5-83bd-f95552d7d75e" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9c347026-d014-4a67-b44d-cb73a0e671e3" xlink:to="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_a8c072e9-cfe0-4ec5-83bd-f95552d7d75e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e27b48ec-8f2d-4184-87ee-d2f072ca328f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fd50eb62-73ed-4f16-a9b6-9f770d9b8c8b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e27b48ec-8f2d-4184-87ee-d2f072ca328f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PropertyPlantAndEquipmentIncludingAssetsHeldForSaleAbstract_73ce8ce3-99df-49a0-bc7e-41113697b4bb" xlink:href="ci-20231231.xsd#ci_PropertyPlantAndEquipmentIncludingAssetsHeldForSaleAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e27b48ec-8f2d-4184-87ee-d2f072ca328f" xlink:to="loc_ci_PropertyPlantAndEquipmentIncludingAssetsHeldForSaleAbstract_73ce8ce3-99df-49a0-bc7e-41113697b4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PropertyPlantAndEquipmentGrossIncludingDisposalGroups_1f9426f4-dd74-492b-a541-8d5e41447285" xlink:href="ci-20231231.xsd#ci_PropertyPlantAndEquipmentGrossIncludingDisposalGroups"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_PropertyPlantAndEquipmentIncludingAssetsHeldForSaleAbstract_73ce8ce3-99df-49a0-bc7e-41113697b4bb" xlink:to="loc_ci_PropertyPlantAndEquipmentGrossIncludingDisposalGroups_1f9426f4-dd74-492b-a541-8d5e41447285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups_469a3016-67ac-482c-a104-d3a46b19d658" xlink:href="ci-20231231.xsd#ci_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_PropertyPlantAndEquipmentIncludingAssetsHeldForSaleAbstract_73ce8ce3-99df-49a0-bc7e-41113697b4bb" xlink:to="loc_ci_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups_469a3016-67ac-482c-a104-d3a46b19d658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups_56a2cbc2-4e23-439f-bc7e-6e548f9f17a8" xlink:href="ci-20231231.xsd#ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_PropertyPlantAndEquipmentIncludingAssetsHeldForSaleAbstract_73ce8ce3-99df-49a0-bc7e-41113697b4bb" xlink:to="loc_ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups_56a2cbc2-4e23-439f-bc7e-6e548f9f17a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract_37fac2be-da06-4d5e-a23b-f5faf470ef30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e27b48ec-8f2d-4184-87ee-d2f072ca328f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract_37fac2be-da06-4d5e-a23b-f5faf470ef30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentGrossCurrent_0472c4e9-1c0d-40e0-9780-9922c48b483b" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentGrossCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract_37fac2be-da06-4d5e-a23b-f5faf470ef30" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentGrossCurrent_0472c4e9-1c0d-40e0-9780-9922c48b483b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentCurrent_01bfdd00-8a97-4b81-bab4-641fc5395226" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract_37fac2be-da06-4d5e-a23b-f5faf470ef30" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentCurrent_01bfdd00-8a97-4b81-bab4-641fc5395226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_70a254c0-1fa7-4b2c-9be0-9b7ee1d6c8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract_37fac2be-da06-4d5e-a23b-f5faf470ef30" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_70a254c0-1fa7-4b2c-9be0-9b7ee1d6c8d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_64954884-b7fa-4652-8267-c30dd78001b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e27b48ec-8f2d-4184-87ee-d2f072ca328f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_64954884-b7fa-4652-8267-c30dd78001b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8f7da334-887c-456a-8930-67913bfaa004" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_64954884-b7fa-4652-8267-c30dd78001b1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8f7da334-887c-456a-8930-67913bfaa004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0488e7b6-ef61-4f4b-b184-9def49e3b9b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_64954884-b7fa-4652-8267-c30dd78001b1" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0488e7b6-ef61-4f4b-b184-9def49e3b9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9fe247a9-73b8-4307-a07e-37f9a4f05bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_64954884-b7fa-4652-8267-c30dd78001b1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9fe247a9-73b8-4307-a07e-37f9a4f05bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails_1" xlink:type="simple" xlink:href="ci-20231231.xsd#GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails_1"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentComponentsofDepreciationandAmortizationExpenseDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#GoodwillOtherIntangiblesandPropertyandEquipmentComponentsofDepreciationandAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentComponentsofDepreciationandAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract_dc8b959a-2163-40a6-a0b2-0f4b94df678b" xlink:href="ci-20231231.xsd#ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ScheduleOfDepreciationAndAmortizationTable_a3d82468-4101-4fc1-a837-b6d074e21849" xlink:href="ci-20231231.xsd#ci_ScheduleOfDepreciationAndAmortizationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract_dc8b959a-2163-40a6-a0b2-0f4b94df678b" xlink:to="loc_ci_ScheduleOfDepreciationAndAmortizationTable_a3d82468-4101-4fc1-a837-b6d074e21849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DepreciationAndAmortizationByTypeAxis_64fc2cc9-46ac-4e3a-9540-cdbf1b9a3184" xlink:href="ci-20231231.xsd#ci_DepreciationAndAmortizationByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ScheduleOfDepreciationAndAmortizationTable_a3d82468-4101-4fc1-a837-b6d074e21849" xlink:to="loc_ci_DepreciationAndAmortizationByTypeAxis_64fc2cc9-46ac-4e3a-9540-cdbf1b9a3184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DepreciationAndAmortizationTypeDomain_6ac0cd3f-222c-4db9-8fe6-7b2eeb1bfa26" xlink:href="ci-20231231.xsd#ci_DepreciationAndAmortizationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DepreciationAndAmortizationByTypeAxis_64fc2cc9-46ac-4e3a-9540-cdbf1b9a3184" xlink:to="loc_ci_DepreciationAndAmortizationTypeDomain_6ac0cd3f-222c-4db9-8fe6-7b2eeb1bfa26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_f0ef052a-ac76-4941-9dc0-f7ead35163c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DepreciationAndAmortizationTypeDomain_6ac0cd3f-222c-4db9-8fe6-7b2eeb1bfa26" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_f0ef052a-ac76-4941-9dc0-f7ead35163c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember_7eb819fc-f8b4-40a2-bab5-c72b7055732e" xlink:href="ci-20231231.xsd#ci_AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DepreciationAndAmortizationTypeDomain_6ac0cd3f-222c-4db9-8fe6-7b2eeb1bfa26" xlink:to="loc_ci_AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember_7eb819fc-f8b4-40a2-bab5-c72b7055732e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceContractsAcquiredInBusinessCombinationMember_178c121b-11cd-4c13-b7ed-d0206ee0339e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceContractsAcquiredInBusinessCombinationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DepreciationAndAmortizationTypeDomain_6ac0cd3f-222c-4db9-8fe6-7b2eeb1bfa26" xlink:to="loc_us-gaap_InsuranceContractsAcquiredInBusinessCombinationMember_178c121b-11cd-4c13-b7ed-d0206ee0339e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_cb9d44be-a228-43ed-940b-0fa29cbc1327" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DepreciationAndAmortizationTypeDomain_6ac0cd3f-222c-4db9-8fe6-7b2eeb1bfa26" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_cb9d44be-a228-43ed-940b-0fa29cbc1327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DepreciationAndAmortizationByTypeLineItems_5604167a-4d17-4fab-b245-83239cdc4c89" xlink:href="ci-20231231.xsd#ci_DepreciationAndAmortizationByTypeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ScheduleOfDepreciationAndAmortizationTable_a3d82468-4101-4fc1-a837-b6d074e21849" xlink:to="loc_ci_DepreciationAndAmortizationByTypeLineItems_5604167a-4d17-4fab-b245-83239cdc4c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_be7710ac-98f1-49c2-a878-f2ac4dd8e2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DepreciationAndAmortizationByTypeLineItems_5604167a-4d17-4fab-b245-83239cdc4c89" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_be7710ac-98f1-49c2-a878-f2ac4dd8e2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentEstimatedAnnualPreTaxAmortizationforIntangibleAssetsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#GoodwillOtherIntangiblesandPropertyandEquipmentEstimatedAnnualPreTaxAmortizationforIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentEstimatedAnnualPreTaxAmortizationforIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract_81769014-22f5-4c0a-ae07-1529e09b442a" xlink:href="ci-20231231.xsd#ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e886d843-9bea-4964-a394-cb8628887525" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract_81769014-22f5-4c0a-ae07-1529e09b442a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e886d843-9bea-4964-a394-cb8628887525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_e786db3e-585b-4360-9c3d-3e0aae5df5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract_81769014-22f5-4c0a-ae07-1529e09b442a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_e786db3e-585b-4360-9c3d-3e0aae5df5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d73e5c84-f7e0-40a6-a95d-eafec8b4c1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract_81769014-22f5-4c0a-ae07-1529e09b442a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d73e5c84-f7e0-40a6-a95d-eafec8b4c1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_72e73a99-aa65-46b8-91c3-f6758e098f29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract_81769014-22f5-4c0a-ae07-1529e09b442a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_72e73a99-aa65-46b8-91c3-f6758e098f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_4b22a590-2640-4521-8dc9-53b392f0c1c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract_81769014-22f5-4c0a-ae07-1529e09b442a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_4b22a590-2640-4521-8dc9-53b392f0c1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_298053cb-62eb-4bb3-9ca7-11b5b1e6e491" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_f59e4ba9-8071-45e7-9482-686ba4454146" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_298053cb-62eb-4bb3-9ca7-11b5b1e6e491" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_f59e4ba9-8071-45e7-9482-686ba4454146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_33c89212-7e3f-4266-befa-438535665556" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f59e4ba9-8071-45e7-9482-686ba4454146" xlink:to="loc_srt_RangeAxis_33c89212-7e3f-4266-befa-438535665556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2943c26d-9253-4fb7-a386-58e147a96ebc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_33c89212-7e3f-4266-befa-438535665556" xlink:to="loc_srt_RangeMember_2943c26d-9253-4fb7-a386-58e147a96ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_513ed6b0-3240-448c-8a00-74d3f7b84c4c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2943c26d-9253-4fb7-a386-58e147a96ebc" xlink:to="loc_srt_MaximumMember_513ed6b0-3240-448c-8a00-74d3f7b84c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_bbb45c27-dbf3-42a6-99e0-ae529a35d379" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f59e4ba9-8071-45e7-9482-686ba4454146" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_bbb45c27-dbf3-42a6-99e0-ae529a35d379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e7a17ece-9443-4d91-be52-a29921253fde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bbb45c27-dbf3-42a6-99e0-ae529a35d379" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e7a17ece-9443-4d91-be52-a29921253fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ec7e164a-c973-4454-a6e7-088dcd94df9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bbb45c27-dbf3-42a6-99e0-ae529a35d379" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ec7e164a-c973-4454-a6e7-088dcd94df9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_0ea9ca2c-b573-44a0-ab62-1301ec4624d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bbb45c27-dbf3-42a6-99e0-ae529a35d379" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_0ea9ca2c-b573-44a0-ab62-1301ec4624d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d37be72f-0bcc-4d85-8781-c7e9d6e8737e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bbb45c27-dbf3-42a6-99e0-ae529a35d379" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d37be72f-0bcc-4d85-8781-c7e9d6e8737e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_3bd54559-744a-4865-b78f-12d5706a837d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bbb45c27-dbf3-42a6-99e0-ae529a35d379" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_3bd54559-744a-4865-b78f-12d5706a837d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_07b9549e-7dca-43d7-b347-7e9f2035d11b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_5a0dee02-3cef-4673-94ac-031801854507" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07b9549e-7dca-43d7-b347-7e9f2035d11b" xlink:to="loc_us-gaap_OperatingLeaseCost_5a0dee02-3cef-4673-94ac-031801854507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FinanceLeaseLeaseCostAbstract_f83f3fac-b904-4e8a-b188-d325018f0f3e" xlink:href="ci-20231231.xsd#ci_FinanceLeaseLeaseCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07b9549e-7dca-43d7-b347-7e9f2035d11b" xlink:to="loc_ci_FinanceLeaseLeaseCostAbstract_f83f3fac-b904-4e8a-b188-d325018f0f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_b7edbdea-3ac1-4905-a836-b0202ce8094f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_FinanceLeaseLeaseCostAbstract_f83f3fac-b904-4e8a-b188-d325018f0f3e" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_b7edbdea-3ac1-4905-a836-b0202ce8094f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_2f12d914-39d5-4037-88f0-e13c2371e467" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_FinanceLeaseLeaseCostAbstract_f83f3fac-b904-4e8a-b188-d325018f0f3e" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_2f12d914-39d5-4037-88f0-e13c2371e467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_FinanceLeaseCost_34f13e1d-f518-4ac4-8931-2413f25e1b30" xlink:href="ci-20231231.xsd#ci_FinanceLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07b9549e-7dca-43d7-b347-7e9f2035d11b" xlink:to="loc_ci_FinanceLeaseCost_34f13e1d-f518-4ac4-8931-2413f25e1b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_0beeb8d7-de2a-4341-8802-d0cb35a12bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07b9549e-7dca-43d7-b347-7e9f2035d11b" xlink:to="loc_us-gaap_VariableLeaseCost_0beeb8d7-de2a-4341-8802-d0cb35a12bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_243e272f-e61c-4bb7-a100-13c25df59841" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07b9549e-7dca-43d7-b347-7e9f2035d11b" xlink:to="loc_us-gaap_LeaseCost_243e272f-e61c-4bb7-a100-13c25df59841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/LeasesSupplementalCashFlowInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#LeasesSupplementalCashFlowInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/LeasesSupplementalCashFlowInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_16c0d0e5-93da-42d4-a5a1-be0c6b620052" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CashFlowActivitiesLesseeAbstract_cd80f978-d021-449c-90aa-f66888929297" xlink:href="ci-20231231.xsd#ci_CashFlowActivitiesLesseeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_16c0d0e5-93da-42d4-a5a1-be0c6b620052" xlink:to="loc_ci_CashFlowActivitiesLesseeAbstract_cd80f978-d021-449c-90aa-f66888929297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_88d09f8a-e07f-4ff9-903f-5ebb838da2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CashFlowActivitiesLesseeAbstract_cd80f978-d021-449c-90aa-f66888929297" xlink:to="loc_us-gaap_OperatingLeasePayments_88d09f8a-e07f-4ff9-903f-5ebb838da2f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_d7bcec6d-9ca2-42b1-aa6a-1625529816a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CashFlowActivitiesLesseeAbstract_cd80f978-d021-449c-90aa-f66888929297" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_d7bcec6d-9ca2-42b1-aa6a-1625529816a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_0da39322-1ba0-4dec-af57-1b46057fdc6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CashFlowActivitiesLesseeAbstract_cd80f978-d021-449c-90aa-f66888929297" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_0da39322-1ba0-4dec-af57-1b46057fdc6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract_4bda3cae-4eea-492e-86f3-d80c6e52a7ad" xlink:href="ci-20231231.xsd#ci_RightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_16c0d0e5-93da-42d4-a5a1-be0c6b620052" xlink:to="loc_ci_RightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract_4bda3cae-4eea-492e-86f3-d80c6e52a7ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_707ebe8c-449f-47c8-956d-9a8afac1ef7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_RightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract_4bda3cae-4eea-492e-86f3-d80c6e52a7ad" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_707ebe8c-449f-47c8-956d-9a8afac1ef7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_d1998bc5-68b2-423b-9824-1a8cc19485ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_RightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract_4bda3cae-4eea-492e-86f3-d80c6e52a7ad" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_d1998bc5-68b2-423b-9824-1a8cc19485ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c7f9ddd7-0d43-443e-bab9-9ecd73ddb256" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AssetsAndLiabilitiesLesseeOperatingLeasesAbstract_5bde98f9-28b8-4bde-acd8-9a4d7e8cafff" xlink:href="ci-20231231.xsd#ci_AssetsAndLiabilitiesLesseeOperatingLeasesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c7f9ddd7-0d43-443e-bab9-9ecd73ddb256" xlink:to="loc_ci_AssetsAndLiabilitiesLesseeOperatingLeasesAbstract_5bde98f9-28b8-4bde-acd8-9a4d7e8cafff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e1e13b43-d271-4a23-a46c-04a86a3130da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_AssetsAndLiabilitiesLesseeOperatingLeasesAbstract_5bde98f9-28b8-4bde-acd8-9a4d7e8cafff" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e1e13b43-d271-4a23-a46c-04a86a3130da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_896e0234-3c28-4e6c-9c4d-911188bc61a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_AssetsAndLiabilitiesLesseeOperatingLeasesAbstract_5bde98f9-28b8-4bde-acd8-9a4d7e8cafff" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_896e0234-3c28-4e6c-9c4d-911188bc61a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0d396878-f328-4ca9-96a8-b2cc42a148de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_AssetsAndLiabilitiesLesseeOperatingLeasesAbstract_5bde98f9-28b8-4bde-acd8-9a4d7e8cafff" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0d396878-f328-4ca9-96a8-b2cc42a148de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3bddd339-ce7e-4ec1-ba1a-d075d50af598" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_AssetsAndLiabilitiesLesseeOperatingLeasesAbstract_5bde98f9-28b8-4bde-acd8-9a4d7e8cafff" xlink:to="loc_us-gaap_OperatingLeaseLiability_3bddd339-ce7e-4ec1-ba1a-d075d50af598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OperatingLeaseLiabilityCurrentIncludingDisposalGroupsAssetsHeldForSale_b8dd5e0d-b354-4d80-b028-4471e1e83ca8" xlink:href="ci-20231231.xsd#ci_OperatingLeaseLiabilityCurrentIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_AssetsAndLiabilitiesLesseeOperatingLeasesAbstract_5bde98f9-28b8-4bde-acd8-9a4d7e8cafff" xlink:to="loc_ci_OperatingLeaseLiabilityCurrentIncludingDisposalGroupsAssetsHeldForSale_b8dd5e0d-b354-4d80-b028-4471e1e83ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OperatingLeaseLiabilityNoncurrentIncludingDisposalGroupsAssetsHeldForSale_a779054d-0de1-4476-8bea-337e7c94ad95" xlink:href="ci-20231231.xsd#ci_OperatingLeaseLiabilityNoncurrentIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_AssetsAndLiabilitiesLesseeOperatingLeasesAbstract_5bde98f9-28b8-4bde-acd8-9a4d7e8cafff" xlink:to="loc_ci_OperatingLeaseLiabilityNoncurrentIncludingDisposalGroupsAssetsHeldForSale_a779054d-0de1-4476-8bea-337e7c94ad95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OperatingLeaseLiabilityIncludingDisposalGroupsAssetsHeldForSale_40497044-d3da-4255-9cbf-aef96f1a2940" xlink:href="ci-20231231.xsd#ci_OperatingLeaseLiabilityIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_AssetsAndLiabilitiesLesseeOperatingLeasesAbstract_5bde98f9-28b8-4bde-acd8-9a4d7e8cafff" xlink:to="loc_ci_OperatingLeaseLiabilityIncludingDisposalGroupsAssetsHeldForSale_40497044-d3da-4255-9cbf-aef96f1a2940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AssetsAndLiabilitiesLesseeFinanceLeasesAbstract_273d2604-8d5e-4370-8f58-802474cb2945" xlink:href="ci-20231231.xsd#ci_AssetsAndLiabilitiesLesseeFinanceLeasesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c7f9ddd7-0d43-443e-bab9-9ecd73ddb256" xlink:to="loc_ci_AssetsAndLiabilitiesLesseeFinanceLeasesAbstract_273d2604-8d5e-4370-8f58-802474cb2945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_452254a1-f138-4d36-a7fe-c937570c41c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_AssetsAndLiabilitiesLesseeFinanceLeasesAbstract_273d2604-8d5e-4370-8f58-802474cb2945" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_452254a1-f138-4d36-a7fe-c937570c41c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_bf12bdf2-3412-4c9a-96b8-766feab771d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_AssetsAndLiabilitiesLesseeFinanceLeasesAbstract_273d2604-8d5e-4370-8f58-802474cb2945" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_bf12bdf2-3412-4c9a-96b8-766feab771d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_cd9b4a9d-b270-4163-b98b-d8a3304ed53a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_AssetsAndLiabilitiesLesseeFinanceLeasesAbstract_273d2604-8d5e-4370-8f58-802474cb2945" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_cd9b4a9d-b270-4163-b98b-d8a3304ed53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_c59afa8d-1aa7-42c3-b5fb-e68d0116d662" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_AssetsAndLiabilitiesLesseeFinanceLeasesAbstract_273d2604-8d5e-4370-8f58-802474cb2945" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_c59afa8d-1aa7-42c3-b5fb-e68d0116d662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_cad53fa8-c490-49a7-a5a5-5afaaed286be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_AssetsAndLiabilitiesLesseeFinanceLeasesAbstract_273d2604-8d5e-4370-8f58-802474cb2945" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_cad53fa8-c490-49a7-a5a5-5afaaed286be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_3484295c-618b-4193-bf32-b9f922c2d9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_AssetsAndLiabilitiesLesseeFinanceLeasesAbstract_273d2604-8d5e-4370-8f58-802474cb2945" xlink:to="loc_us-gaap_FinanceLeaseLiability_3484295c-618b-4193-bf32-b9f922c2d9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_744da3c8-3d4a-4d82-90e3-af668a127f77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c7f9ddd7-0d43-443e-bab9-9ecd73ddb256" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_744da3c8-3d4a-4d82-90e3-af668a127f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_a5aa267f-86e1-4c03-aa67-8934a18ad321" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c7f9ddd7-0d43-443e-bab9-9ecd73ddb256" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_a5aa267f-86e1-4c03-aa67-8934a18ad321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_8c3500cf-25e3-45fc-a34d-21f6d16f3a44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c7f9ddd7-0d43-443e-bab9-9ecd73ddb256" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_8c3500cf-25e3-45fc-a34d-21f6d16f3a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_4765261e-c3e2-4f10-bc4d-f929f233804e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c7f9ddd7-0d43-443e-bab9-9ecd73ddb256" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_4765261e-c3e2-4f10-bc4d-f929f233804e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_7e5aa16a-7b2e-4327-9f80-cae1ce848e63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c7f9ddd7-0d43-443e-bab9-9ecd73ddb256" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_7e5aa16a-7b2e-4327-9f80-cae1ce848e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_8a6666e7-572d-4929-ac51-063aaa9f8a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c7f9ddd7-0d43-443e-bab9-9ecd73ddb256" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_8a6666e7-572d-4929-ac51-063aaa9f8a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets_c9f71218-9ff3-4949-910f-8a22ef37862e" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c7f9ddd7-0d43-443e-bab9-9ecd73ddb256" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets_c9f71218-9ff3-4949-910f-8a22ef37862e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilities_a41af49c-9282-4fe9-8a6a-21bc8a6d3922" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c7f9ddd7-0d43-443e-bab9-9ecd73ddb256" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilities_a41af49c-9282-4fe9-8a6a-21bc8a6d3922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_bc4715d4-7eec-48b8-a468-8e49490d0c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_004561a8-fe5e-409b-a91a-5450b63d69d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bc4715d4-7eec-48b8-a468-8e49490d0c3a" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_004561a8-fe5e-409b-a91a-5450b63d69d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_71db3fc9-886e-4498-9c41-95394064db1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_004561a8-fe5e-409b-a91a-5450b63d69d0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_71db3fc9-886e-4498-9c41-95394064db1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8ce7e89f-6ebc-4a57-b368-b156f4eee10b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_004561a8-fe5e-409b-a91a-5450b63d69d0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8ce7e89f-6ebc-4a57-b368-b156f4eee10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_527cd32c-ad25-4aed-a38b-d412da51b13f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_004561a8-fe5e-409b-a91a-5450b63d69d0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_527cd32c-ad25-4aed-a38b-d412da51b13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6505d399-73f2-4fda-b9be-c7fb8e9dbc86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_004561a8-fe5e-409b-a91a-5450b63d69d0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6505d399-73f2-4fda-b9be-c7fb8e9dbc86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7f70756a-ced4-4734-b1e3-8b822d4cd728" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_004561a8-fe5e-409b-a91a-5450b63d69d0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7f70756a-ced4-4734-b1e3-8b822d4cd728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_9c1cad0f-a4d6-402d-a0b9-10029191ffc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_004561a8-fe5e-409b-a91a-5450b63d69d0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_9c1cad0f-a4d6-402d-a0b9-10029191ffc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_23d03136-499b-4591-9465-b4fe2716ebb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_004561a8-fe5e-409b-a91a-5450b63d69d0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_23d03136-499b-4591-9465-b4fe2716ebb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_49db7914-a3d5-428d-9d15-3ac6fec4efd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_004561a8-fe5e-409b-a91a-5450b63d69d0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_49db7914-a3d5-428d-9d15-3ac6fec4efd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_23c101e0-273b-4bcd-afe1-1b6976adbb51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_004561a8-fe5e-409b-a91a-5450b63d69d0" xlink:to="loc_us-gaap_OperatingLeaseLiability_23c101e0-273b-4bcd-afe1-1b6976adbb51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_852e3987-f5a1-4406-99cb-bc2636bd25a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bc4715d4-7eec-48b8-a468-8e49490d0c3a" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_852e3987-f5a1-4406-99cb-bc2636bd25a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_5efdcfe6-84e5-4747-9583-8d833eb281b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_852e3987-f5a1-4406-99cb-bc2636bd25a9" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_5efdcfe6-84e5-4747-9583-8d833eb281b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_84b9708f-6dfc-4171-9642-c15fb539b40a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_852e3987-f5a1-4406-99cb-bc2636bd25a9" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_84b9708f-6dfc-4171-9642-c15fb539b40a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_d32f32e9-f332-493f-bbe1-ed88e446605a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_852e3987-f5a1-4406-99cb-bc2636bd25a9" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_d32f32e9-f332-493f-bbe1-ed88e446605a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_aff41036-e2a6-41d1-a454-eff26b9d526e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_852e3987-f5a1-4406-99cb-bc2636bd25a9" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_aff41036-e2a6-41d1-a454-eff26b9d526e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_db03f793-aa9d-4e16-8efb-06b60afcc1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_852e3987-f5a1-4406-99cb-bc2636bd25a9" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_db03f793-aa9d-4e16-8efb-06b60afcc1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_b0fb84d2-8ae7-46dd-82ae-8f6ad849d83f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_852e3987-f5a1-4406-99cb-bc2636bd25a9" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_b0fb84d2-8ae7-46dd-82ae-8f6ad849d83f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_1d3c1152-78b6-4c8b-a496-ed4ce038762a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_852e3987-f5a1-4406-99cb-bc2636bd25a9" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_1d3c1152-78b6-4c8b-a496-ed4ce038762a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_f48119a2-4598-4f43-811a-84e1af62c150" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_852e3987-f5a1-4406-99cb-bc2636bd25a9" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_f48119a2-4598-4f43-811a-84e1af62c150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_34a66cc1-a9ba-4b16-9759-54aa067e610a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_852e3987-f5a1-4406-99cb-bc2636bd25a9" xlink:to="loc_us-gaap_FinanceLeaseLiability_34a66cc1-a9ba-4b16-9759-54aa067e610a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="ci-20231231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ShareholdersEquityandDividendRestrictionsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#ShareholdersEquityandDividendRestrictionsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ShareholdersEquityandDividendRestrictionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e352cfd9-f33f-4851-b751-2447e6b04907" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount_5096f189-d4a8-4122-9577-8967b9161fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e352cfd9-f33f-4851-b751-2447e6b04907" xlink:to="loc_us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount_5096f189-d4a8-4122-9577-8967b9161fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryCapitalAndSurplusApplyingNationalAssociationOfInsuranceCommissionersNAICPractices_a6b6bcac-50e1-46e0-9fee-4d2dbbbe1aec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatutoryCapitalAndSurplusApplyingNationalAssociationOfInsuranceCommissionersNAICPractices"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e352cfd9-f33f-4851-b751-2447e6b04907" xlink:to="loc_us-gaap_StatutoryCapitalAndSurplusApplyingNationalAssociationOfInsuranceCommissionersNAICPractices_a6b6bcac-50e1-46e0-9fee-4d2dbbbe1aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_f95ad31c-6bbf-42ae-9b0e-d428d79f6948" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e352cfd9-f33f-4851-b751-2447e6b04907" xlink:to="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_f95ad31c-6bbf-42ae-9b0e-d428d79f6948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldByInsuranceRegulators_3adda592-b1f6-4df8-96c2-bb9dc590a012" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldByInsuranceRegulators"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e352cfd9-f33f-4851-b751-2447e6b04907" xlink:to="loc_us-gaap_AssetsHeldByInsuranceRegulators_3adda592-b1f6-4df8-96c2-bb9dc590a012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments_b9b97ad8-5ad4-459d-9068-12301a6ae2cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e352cfd9-f33f-4851-b751-2447e6b04907" xlink:to="loc_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments_b9b97ad8-5ad4-459d-9068-12301a6ae2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_StatutoryAccountingPracticesAmountPermittedLendingAuthorityOfLifeInsuranceSubsidiaryToParent_63b315be-f406-4c43-8c56-1aec8bd0ddc7" xlink:href="ci-20231231.xsd#ci_StatutoryAccountingPracticesAmountPermittedLendingAuthorityOfLifeInsuranceSubsidiaryToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e352cfd9-f33f-4851-b751-2447e6b04907" xlink:to="loc_ci_StatutoryAccountingPracticesAmountPermittedLendingAuthorityOfLifeInsuranceSubsidiaryToParent_63b315be-f406-4c43-8c56-1aec8bd0ddc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries_47a60623-4a15-47a1-afdf-4f0bb6b5a1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e352cfd9-f33f-4851-b751-2447e6b04907" xlink:to="loc_us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries_47a60623-4a15-47a1-afdf-4f0bb6b5a1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsUndistributedEarningsFromEquityMethodInvestees_49ff31e6-b17e-49f6-a415-0e32b32b951d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsUndistributedEarningsFromEquityMethodInvestees"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e352cfd9-f33f-4851-b751-2447e6b04907" xlink:to="loc_us-gaap_RetainedEarningsUndistributedEarningsFromEquityMethodInvestees_49ff31e6-b17e-49f6-a415-0e32b32b951d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAdditionalDisclosuresAbstract_d9c3d675-1eee-47a0-8256-15a4b6768e16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e352cfd9-f33f-4851-b751-2447e6b04907" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAdditionalDisclosuresAbstract_d9c3d675-1eee-47a0-8256-15a4b6768e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationsStatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_3968058d-de8a-40f8-b606-9f84cb4b8da2" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationsStatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAdditionalDisclosuresAbstract_d9c3d675-1eee-47a0-8256-15a4b6768e16" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationsStatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_3968058d-de8a-40f8-b606-9f84cb4b8da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupsIncludingDiscontinuedOperationsAssetsHeldByInsuranceRegulators_bac92135-ab45-4f95-a16f-3ab6a1bf53b0" xlink:href="ci-20231231.xsd#ci_DisposalGroupsIncludingDiscontinuedOperationsAssetsHeldByInsuranceRegulators"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAdditionalDisclosuresAbstract_d9c3d675-1eee-47a0-8256-15a4b6768e16" xlink:to="loc_ci_DisposalGroupsIncludingDiscontinuedOperationsAssetsHeldByInsuranceRegulators_bac92135-ab45-4f95-a16f-3ab6a1bf53b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupsIncludingDiscontinuedOperationsStatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments_4eb08697-73ba-41ec-9740-b354cb86789c" xlink:href="ci-20231231.xsd#ci_DisposalGroupsIncludingDiscontinuedOperationsStatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAdditionalDisclosuresAbstract_d9c3d675-1eee-47a0-8256-15a4b6768e16" xlink:to="loc_ci_DisposalGroupsIncludingDiscontinuedOperationsStatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments_4eb08697-73ba-41ec-9740-b354cb86789c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupsIncludingDiscontinuedOperationsAmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries_2d06e385-c574-4663-86a6-a78e424eaaf8" xlink:href="ci-20231231.xsd#ci_DisposalGroupsIncludingDiscontinuedOperationsAmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAdditionalDisclosuresAbstract_d9c3d675-1eee-47a0-8256-15a4b6768e16" xlink:to="loc_ci_DisposalGroupsIncludingDiscontinuedOperationsAmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries_2d06e385-c574-4663-86a6-a78e424eaaf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/IncomeTaxesComponentsofIncomeTaxesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#IncomeTaxesComponentsofIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/IncomeTaxesComponentsofIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8fdc9da7-e2d0-44cc-bdf9-c3b7c43ba5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7ae46e82-963b-48ed-834d-173430982488" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8fdc9da7-e2d0-44cc-bdf9-c3b7c43ba5c7" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7ae46e82-963b-48ed-834d-173430982488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_fd1e03c9-7799-4960-8bba-85a521632dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7ae46e82-963b-48ed-834d-173430982488" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_fd1e03c9-7799-4960-8bba-85a521632dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_4a420976-43ad-42d3-808b-8b6bee44ffb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7ae46e82-963b-48ed-834d-173430982488" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_4a420976-43ad-42d3-808b-8b6bee44ffb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_36435cec-702a-4262-9255-cc58d0b5213f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7ae46e82-963b-48ed-834d-173430982488" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_36435cec-702a-4262-9255-cc58d0b5213f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d38b9781-0f87-4c97-87b4-b8457f95dd97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7ae46e82-963b-48ed-834d-173430982488" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d38b9781-0f87-4c97-87b4-b8457f95dd97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_825a76d3-385d-4b15-8471-2771bc0acfb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8fdc9da7-e2d0-44cc-bdf9-c3b7c43ba5c7" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_825a76d3-385d-4b15-8471-2771bc0acfb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_3fa9910b-22ce-4150-92ed-c7618b5558b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_825a76d3-385d-4b15-8471-2771bc0acfb4" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_3fa9910b-22ce-4150-92ed-c7618b5558b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_c803fa68-de70-4321-a56a-81ae3a75fb9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_825a76d3-385d-4b15-8471-2771bc0acfb4" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_c803fa68-de70-4321-a56a-81ae3a75fb9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_9bc350e1-fbc8-486a-a299-60be8c782651" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_825a76d3-385d-4b15-8471-2771bc0acfb4" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_9bc350e1-fbc8-486a-a299-60be8c782651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8bf79c01-60ed-4932-9ec7-41d90ad96501" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_825a76d3-385d-4b15-8471-2771bc0acfb4" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8bf79c01-60ed-4932-9ec7-41d90ad96501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d224d664-232b-4d65-a8c4-f60a63252864" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8fdc9da7-e2d0-44cc-bdf9-c3b7c43ba5c7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d224d664-232b-4d65-a8c4-f60a63252864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#IncomeTaxesNominalTaxRateReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f41a4bb6-f833-4841-a339-27e4c367fcf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncomeTaxDisclosureTable_0efea929-4a88-443d-a9a2-2eaca40f9e59" xlink:href="ci-20231231.xsd#ci_IncomeTaxDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f41a4bb6-f833-4841-a339-27e4c367fcf9" xlink:to="loc_ci_IncomeTaxDisclosureTable_0efea929-4a88-443d-a9a2-2eaca40f9e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_3d2ad9ef-0e93-4fc8-9e3e-233e75c74431" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_IncomeTaxDisclosureTable_0efea929-4a88-443d-a9a2-2eaca40f9e59" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_3d2ad9ef-0e93-4fc8-9e3e-233e75c74431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_073c6a40-fe09-4dfd-9ff7-4997f7a72ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_3d2ad9ef-0e93-4fc8-9e3e-233e75c74431" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_073c6a40-fe09-4dfd-9ff7-4997f7a72ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_d3dfb467-93fa-40ea-9e06-b3e133bdedbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_073c6a40-fe09-4dfd-9ff7-4997f7a72ebc" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_d3dfb467-93fa-40ea-9e06-b3e133bdedbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_48ea7e87-d431-491f-92b2-fecc262ecb15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_073c6a40-fe09-4dfd-9ff7-4997f7a72ebc" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_48ea7e87-d431-491f-92b2-fecc262ecb15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2a5d62c9-97b9-4b87-9987-c575e8fb208d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_IncomeTaxDisclosureTable_0efea929-4a88-443d-a9a2-2eaca40f9e59" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2a5d62c9-97b9-4b87-9987-c575e8fb208d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cb3eef26-f3a5-4751-be0a-92dd6cba671b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2a5d62c9-97b9-4b87-9987-c575e8fb208d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cb3eef26-f3a5-4751-be0a-92dd6cba671b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_8ee643af-7422-400e-ba93-4ec0d37412f8" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cb3eef26-f3a5-4751-be0a-92dd6cba671b" xlink:to="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_8ee643af-7422-400e-ba93-4ec0d37412f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember_d7bfaafc-266c-457d-86e0-6b0f63996212" xlink:href="ci-20231231.xsd#ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cb3eef26-f3a5-4751-be0a-92dd6cba671b" xlink:to="loc_ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember_d7bfaafc-266c-457d-86e0-6b0f63996212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncomeTaxDisclosureLineItems_600cd2c8-2589-4e9a-9591-d1e9110cf7d7" xlink:href="ci-20231231.xsd#ci_IncomeTaxDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_IncomeTaxDisclosureTable_0efea929-4a88-443d-a9a2-2eaca40f9e59" xlink:to="loc_ci_IncomeTaxDisclosureLineItems_600cd2c8-2589-4e9a-9591-d1e9110cf7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70c94002-7f91-46d7-832e-a2f2dfb0cae1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_IncomeTaxDisclosureLineItems_600cd2c8-2589-4e9a-9591-d1e9110cf7d7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70c94002-7f91-46d7-832e-a2f2dfb0cae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_71bb0cd0-81fc-4c82-b6a9-c0009dfefdc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70c94002-7f91-46d7-832e-a2f2dfb0cae1" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_71bb0cd0-81fc-4c82-b6a9-c0009dfefdc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_2cc6309a-17a1-4834-b722-811c2c6cefe8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationDispositionOfBusiness"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70c94002-7f91-46d7-832e-a2f2dfb0cae1" xlink:to="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_2cc6309a-17a1-4834-b722-811c2c6cefe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings_cff2ad61-b7fd-4b3c-818b-233618f7b621" xlink:href="ci-20231231.xsd#ci_IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70c94002-7f91-46d7-832e-a2f2dfb0cae1" xlink:to="loc_ci_IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings_cff2ad61-b7fd-4b3c-818b-233618f7b621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncomeTaxReconciliationHealthInsuranceIndustryTax_385dbb6a-48ba-45f7-a6c7-a02bb0a69bea" xlink:href="ci-20231231.xsd#ci_IncomeTaxReconciliationHealthInsuranceIndustryTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70c94002-7f91-46d7-832e-a2f2dfb0cae1" xlink:to="loc_ci_IncomeTaxReconciliationHealthInsuranceIndustryTax_385dbb6a-48ba-45f7-a6c7-a02bb0a69bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_59c20e55-ca6a-4b94-a626-dfedeffc77c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70c94002-7f91-46d7-832e-a2f2dfb0cae1" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_59c20e55-ca6a-4b94-a626-dfedeffc77c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount_5ec43ffd-63d6-4f20-9fd9-aa7c23477b1b" xlink:href="ci-20231231.xsd#ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70c94002-7f91-46d7-832e-a2f2dfb0cae1" xlink:to="loc_ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount_5ec43ffd-63d6-4f20-9fd9-aa7c23477b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount_2872e8d3-78d6-4fe7-8dfd-8fb49a9c69d5" xlink:href="ci-20231231.xsd#ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70c94002-7f91-46d7-832e-a2f2dfb0cae1" xlink:to="loc_ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount_2872e8d3-78d6-4fe7-8dfd-8fb49a9c69d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_95f8363a-ca80-44fe-ace3-76d81caaa927" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70c94002-7f91-46d7-832e-a2f2dfb0cae1" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_95f8363a-ca80-44fe-ace3-76d81caaa927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_370c2ed0-d5e7-4985-96a8-6d85557dcc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70c94002-7f91-46d7-832e-a2f2dfb0cae1" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_370c2ed0-d5e7-4985-96a8-6d85557dcc4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_63056b4e-57ed-4cc4-946b-31837b4ea666" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_70c94002-7f91-46d7-832e-a2f2dfb0cae1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_63056b4e-57ed-4cc4-946b-31837b4ea666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0074dadf-c389-4b33-bfe3-627ce7cb4978" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_IncomeTaxDisclosureLineItems_600cd2c8-2589-4e9a-9591-d1e9110cf7d7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0074dadf-c389-4b33-bfe3-627ce7cb4978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7b812808-3bc3-40ac-9cd4-ebdb122f7a92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0074dadf-c389-4b33-bfe3-627ce7cb4978" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7b812808-3bc3-40ac-9cd4-ebdb122f7a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_37c03290-eb01-4088-a456-535d72992d83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0074dadf-c389-4b33-bfe3-627ce7cb4978" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_37c03290-eb01-4088-a456-535d72992d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings_ba8ac23e-a5e7-4915-9dc5-30c054d0adb4" xlink:href="ci-20231231.xsd#ci_EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0074dadf-c389-4b33-bfe3-627ce7cb4978" xlink:to="loc_ci_EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings_ba8ac23e-a5e7-4915-9dc5-30c054d0adb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EffectiveIncomeTaxRateReconciliationHealthInsuranceIndustryTax_cc22b4c1-53af-425d-b844-e4c47855b7ec" xlink:href="ci-20231231.xsd#ci_EffectiveIncomeTaxRateReconciliationHealthInsuranceIndustryTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0074dadf-c389-4b33-bfe3-627ce7cb4978" xlink:to="loc_ci_EffectiveIncomeTaxRateReconciliationHealthInsuranceIndustryTax_cc22b4c1-53af-425d-b844-e4c47855b7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_b43f2be6-0358-494d-84f5-58fd4dbcf7ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0074dadf-c389-4b33-bfe3-627ce7cb4978" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_b43f2be6-0358-494d-84f5-58fd4dbcf7ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent_f417f050-c946-461a-a6fc-cd0e8f772844" xlink:href="ci-20231231.xsd#ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0074dadf-c389-4b33-bfe3-627ce7cb4978" xlink:to="loc_ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent_f417f050-c946-461a-a6fc-cd0e8f772844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent_e1e31c04-1b7b-4c38-a02e-3488293f6ed2" xlink:href="ci-20231231.xsd#ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0074dadf-c389-4b33-bfe3-627ce7cb4978" xlink:to="loc_ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent_e1e31c04-1b7b-4c38-a02e-3488293f6ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_5a8ea0aa-5b64-4d1b-8cf5-98a6cf46f840" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0074dadf-c389-4b33-bfe3-627ce7cb4978" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_5a8ea0aa-5b64-4d1b-8cf5-98a6cf46f840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_e5860973-8d86-406e-b101-bf49a12702da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0074dadf-c389-4b33-bfe3-627ce7cb4978" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_e5860973-8d86-406e-b101-bf49a12702da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_fe5eb65e-6ce0-45d1-a015-68c960597c74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_0074dadf-c389-4b33-bfe3-627ce7cb4978" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_fe5eb65e-6ce0-45d1-a015-68c960597c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/IncomeTaxesPretaxIncomeFromForeignOperationsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#IncomeTaxesPretaxIncomeFromForeignOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/IncomeTaxesPretaxIncomeFromForeignOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_437f07f4-99d0-442c-9383-13934d48d9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_bf10e7c4-fc60-4bd9-9fed-0d787f1da08d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_437f07f4-99d0-442c-9383-13934d48d9c1" xlink:to="loc_us-gaap_ConcentrationRiskTable_bf10e7c4-fc60-4bd9-9fed-0d787f1da08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_77036fdf-7edc-4512-aadc-e9e706c00e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_bf10e7c4-fc60-4bd9-9fed-0d787f1da08d" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_77036fdf-7edc-4512-aadc-e9e706c00e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fd656535-cf14-4815-a59f-fdb4bda15e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_77036fdf-7edc-4512-aadc-e9e706c00e5c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fd656535-cf14-4815-a59f-fdb4bda15e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncomeBeforeTaxesMember_48d77d6b-1f85-45cf-a823-8856a90424bc" xlink:href="ci-20231231.xsd#ci_IncomeBeforeTaxesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fd656535-cf14-4815-a59f-fdb4bda15e0c" xlink:to="loc_ci_IncomeBeforeTaxesMember_48d77d6b-1f85-45cf-a823-8856a90424bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_d23c2402-611a-4272-b6e2-7e72834b73bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_bf10e7c4-fc60-4bd9-9fed-0d787f1da08d" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_d23c2402-611a-4272-b6e2-7e72834b73bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_00693308-38c6-4cb1-801f-786e192a9d74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_d23c2402-611a-4272-b6e2-7e72834b73bd" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_00693308-38c6-4cb1-801f-786e192a9d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_c19a6a3c-40a7-480e-afaf-7a554f7866ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_00693308-38c6-4cb1-801f-786e192a9d74" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_c19a6a3c-40a7-480e-afaf-7a554f7866ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionAxis_f52379b5-554e-4d5c-8669-a0e5e23eadec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicDistributionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_bf10e7c4-fc60-4bd9-9fed-0d787f1da08d" xlink:to="loc_us-gaap_GeographicDistributionAxis_f52379b5-554e-4d5c-8669-a0e5e23eadec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionDomain_3bb8be2e-364d-4f47-8caa-bb7a0308d79d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicDistributionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeographicDistributionAxis_f52379b5-554e-4d5c-8669-a0e5e23eadec" xlink:to="loc_us-gaap_GeographicDistributionDomain_3bb8be2e-364d-4f47-8caa-bb7a0308d79d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicDistributionForeignMember_bc8cc37f-f40e-47bc-baf4-ba584a0d0a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicDistributionForeignMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeographicDistributionDomain_3bb8be2e-364d-4f47-8caa-bb7a0308d79d" xlink:to="loc_us-gaap_GeographicDistributionForeignMember_bc8cc37f-f40e-47bc-baf4-ba584a0d0a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_3ee75cfb-d431-429d-9958-c98be7ed8f58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_bf10e7c4-fc60-4bd9-9fed-0d787f1da08d" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_3ee75cfb-d431-429d-9958-c98be7ed8f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_7948fb1f-a714-4eff-9328-e8fea5b5a88c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_3ee75cfb-d431-429d-9958-c98be7ed8f58" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_7948fb1f-a714-4eff-9328-e8fea5b5a88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/IncomeTaxesForeignJurisdictionTaxAttributesandSaleofMedicareAdvantageandRelatedBusinessesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#IncomeTaxesForeignJurisdictionTaxAttributesandSaleofMedicareAdvantageandRelatedBusinessesDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/IncomeTaxesForeignJurisdictionTaxAttributesandSaleofMedicareAdvantageandRelatedBusinessesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c1cb268c-32b5-4862-9491-c22a995cea67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsForeignTaxAttributes_0ebcab7d-8b32-4b43-b78c-876903322949" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsForeignTaxAttributes"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c1cb268c-32b5-4862-9491-c22a995cea67" xlink:to="loc_ci_DeferredTaxAssetsForeignTaxAttributes_0ebcab7d-8b32-4b43-b78c-876903322949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsValuationAllowanceForeignTaxAttributes_25eeb393-098a-40be-97d9-b6daea75e529" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsValuationAllowanceForeignTaxAttributes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c1cb268c-32b5-4862-9491-c22a995cea67" xlink:to="loc_ci_DeferredTaxAssetsValuationAllowanceForeignTaxAttributes_25eeb393-098a-40be-97d9-b6daea75e529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4425785a-a4e0-45c7-a5b8-8457329d9aec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c1cb268c-32b5-4862-9491-c22a995cea67" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4425785a-a4e0-45c7-a5b8-8457329d9aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_9153fd1f-80b0-4434-bf2d-2c212c91a62f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4425785a-a4e0-45c7-a5b8-8457329d9aec" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_9153fd1f-80b0-4434-bf2d-2c212c91a62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ffa05469-a518-4b25-9911-0d912dd10c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9153fd1f-80b0-4434-bf2d-2c212c91a62f" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ffa05469-a518-4b25-9911-0d912dd10c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_165931e6-a79a-4d25-a695-e5bf3ac4a679" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_ffa05469-a518-4b25-9911-0d912dd10c6d" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_165931e6-a79a-4d25-a695-e5bf3ac4a679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a236bf07-68cc-4170-ba45-d274e9f1daad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4425785a-a4e0-45c7-a5b8-8457329d9aec" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a236bf07-68cc-4170-ba45-d274e9f1daad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_22c96bb3-6724-4645-afea-acc0db7e9507" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a236bf07-68cc-4170-ba45-d274e9f1daad" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_22c96bb3-6724-4645-afea-acc0db7e9507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_a1ba6aec-cfcb-4fc3-bc44-8d717e678b76" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_22c96bb3-6724-4645-afea-acc0db7e9507" xlink:to="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_a1ba6aec-cfcb-4fc3-bc44-8d717e678b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f82bc7ae-1c5e-4766-8f79-2c487ff3586a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4425785a-a4e0-45c7-a5b8-8457329d9aec" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f82bc7ae-1c5e-4766-8f79-2c487ff3586a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_ae668793-e91c-4c53-a7a5-da04d7ec5ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f82bc7ae-1c5e-4766-8f79-2c487ff3586a" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_ae668793-e91c-4c53-a7a5-da04d7ec5ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_fab27700-70d7-4145-b9fc-3d94db20e602" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f82bc7ae-1c5e-4766-8f79-2c487ff3586a" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_fab27700-70d7-4145-b9fc-3d94db20e602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#IncomeTaxesDeferredIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_cfad954d-e960-48c5-940c-d72f2db4ec8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncomeTaxDisclosureTable_e62a3e3f-6275-4543-a604-0d2dace787a8" xlink:href="ci-20231231.xsd#ci_IncomeTaxDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cfad954d-e960-48c5-940c-d72f2db4ec8c" xlink:to="loc_ci_IncomeTaxDisclosureTable_e62a3e3f-6275-4543-a604-0d2dace787a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_71e40927-fd0e-4725-ada6-94b22a258eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_IncomeTaxDisclosureTable_e62a3e3f-6275-4543-a604-0d2dace787a8" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_71e40927-fd0e-4725-ada6-94b22a258eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_eb7d0659-4754-4012-bb34-b53011930611" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_71e40927-fd0e-4725-ada6-94b22a258eb2" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_eb7d0659-4754-4012-bb34-b53011930611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_a68c2433-cf7b-4e12-85a1-0aecbd5ad834" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_eb7d0659-4754-4012-bb34-b53011930611" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_a68c2433-cf7b-4e12-85a1-0aecbd5ad834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_29f87912-1ff0-4ca4-86b2-0f57f25bd946" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_IncomeTaxDisclosureTable_e62a3e3f-6275-4543-a604-0d2dace787a8" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_29f87912-1ff0-4ca4-86b2-0f57f25bd946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_554bb828-d461-4f07-8702-5bf251f172f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_29f87912-1ff0-4ca4-86b2-0f57f25bd946" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_554bb828-d461-4f07-8702-5bf251f172f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_099193b6-b1b1-4985-8984-6654058e2dfd" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_554bb828-d461-4f07-8702-5bf251f172f8" xlink:to="loc_ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember_099193b6-b1b1-4985-8984-6654058e2dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncomeTaxDisclosureLineItems_48ccdf2a-28d9-46fc-b64c-bfcd03f4c275" xlink:href="ci-20231231.xsd#ci_IncomeTaxDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_IncomeTaxDisclosureTable_e62a3e3f-6275-4543-a604-0d2dace787a8" xlink:to="loc_ci_IncomeTaxDisclosureLineItems_48ccdf2a-28d9-46fc-b64c-bfcd03f4c275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5e61f79e-40b4-4a09-b5c4-76345b6b585b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_IncomeTaxDisclosureLineItems_48ccdf2a-28d9-46fc-b64c-bfcd03f4c275" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5e61f79e-40b4-4a09-b5c4-76345b6b585b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_e2f58077-721d-4fee-bba1-213d016b7545" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5e61f79e-40b4-4a09-b5c4-76345b6b585b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_e2f58077-721d-4fee-bba1-213d016b7545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities_85867eaf-99a3-46da-9ad5-e9fa3ca7c2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5e61f79e-40b4-4a09-b5c4-76345b6b585b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities_85867eaf-99a3-46da-9ad5-e9fa3ca7c2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_28237ccc-adff-4454-bff8-e4c797618c03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5e61f79e-40b4-4a09-b5c4-76345b6b585b" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_28237ccc-adff-4454-bff8-e4c797618c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_ff9e0e24-d01e-4382-96cf-1ef15b3a2c20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5e61f79e-40b4-4a09-b5c4-76345b6b585b" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_ff9e0e24-d01e-4382-96cf-1ef15b3a2c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_6e85ebb9-c887-401e-8867-8b7dc647c917" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5e61f79e-40b4-4a09-b5c4-76345b6b585b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_6e85ebb9-c887-401e-8867-8b7dc647c917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsPolicyAcquisitionExpenses_73b9177a-3ee6-4ea9-965c-88d8da5da932" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsPolicyAcquisitionExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5e61f79e-40b4-4a09-b5c4-76345b6b585b" xlink:to="loc_ci_DeferredTaxAssetsPolicyAcquisitionExpenses_73b9177a-3ee6-4ea9-965c-88d8da5da932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTranslation_cfe6f5c9-e0be-40b5-82b1-849db42769f7" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTranslation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5e61f79e-40b4-4a09-b5c4-76345b6b585b" xlink:to="loc_ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTranslation_cfe6f5c9-e0be-40b5-82b1-849db42769f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsForeignTaxAttributes_e67e1c05-d64a-4bb6-b2d7-0ce245f749d6" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsForeignTaxAttributes"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5e61f79e-40b4-4a09-b5c4-76345b6b585b" xlink:to="loc_ci_DeferredTaxAssetsForeignTaxAttributes_e67e1c05-d64a-4bb6-b2d7-0ce245f749d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_38bac068-cdec-46c9-b557-a794140369ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5e61f79e-40b4-4a09-b5c4-76345b6b585b" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_38bac068-cdec-46c9-b557-a794140369ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_285be239-c373-4390-aed2-0b8a4edcfbde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5e61f79e-40b4-4a09-b5c4-76345b6b585b" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_285be239-c373-4390-aed2-0b8a4edcfbde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2bf74426-bd79-4810-8fe4-5128cb59a03c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5e61f79e-40b4-4a09-b5c4-76345b6b585b" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2bf74426-bd79-4810-8fe4-5128cb59a03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_ec338cdf-31e7-470a-b09b-421b66558bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5e61f79e-40b4-4a09-b5c4-76345b6b585b" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_ec338cdf-31e7-470a-b09b-421b66558bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract_24b35941-0125-41c1-854e-10cefe11dd00" xlink:href="ci-20231231.xsd#ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_IncomeTaxDisclosureLineItems_48ccdf2a-28d9-46fc-b64c-bfcd03f4c275" xlink:to="loc_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract_24b35941-0125-41c1-854e-10cefe11dd00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIncludingDisposalGroupsAssetsHeldForSale_808b80b7-03bc-4b73-b42a-81ca03038b83" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract_24b35941-0125-41c1-854e-10cefe11dd00" xlink:to="loc_ci_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIncludingDisposalGroupsAssetsHeldForSale_808b80b7-03bc-4b73-b42a-81ca03038b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilitiesIncludingDisposalGroupsAssetsHeldForSale_eafee7d2-aa2e-4edd-b89f-4dcedec1a923" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilitiesIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract_24b35941-0125-41c1-854e-10cefe11dd00" xlink:to="loc_ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilitiesIncludingDisposalGroupsAssetsHeldForSale_eafee7d2-aa2e-4edd-b89f-4dcedec1a923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsOperatingLossCarryforwardsIncludingDisposalGroupsAssetsHeldForSale_26aa65f1-8f91-447e-b325-58d8807ee2f5" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsOperatingLossCarryforwardsIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract_24b35941-0125-41c1-854e-10cefe11dd00" xlink:to="loc_ci_DeferredTaxAssetsOperatingLossCarryforwardsIncludingDisposalGroupsAssetsHeldForSale_26aa65f1-8f91-447e-b325-58d8807ee2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_35e43ea7-e816-4f18-a27e-246937e69e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract_24b35941-0125-41c1-854e-10cefe11dd00" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_35e43ea7-e816-4f18-a27e-246937e69e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOtherIncludingDisposalGroupsAssetsHeldForSale_f4d74fa8-1bf4-40b2-a2e1-5b54e9c057cd" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOtherIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract_24b35941-0125-41c1-854e-10cefe11dd00" xlink:to="loc_ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOtherIncludingDisposalGroupsAssetsHeldForSale_f4d74fa8-1bf4-40b2-a2e1-5b54e9c057cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsPolicyAcquisitionExpensesIncludingDisposalGroupsAssetsHeldForSale_68dc0201-4efd-4680-8adf-ce03518268d4" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsPolicyAcquisitionExpensesIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract_24b35941-0125-41c1-854e-10cefe11dd00" xlink:to="loc_ci_DeferredTaxAssetsPolicyAcquisitionExpensesIncludingDisposalGroupsAssetsHeldForSale_68dc0201-4efd-4680-8adf-ce03518268d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTransactionIncludingDisposalGroupsAssetsHeldForSale_b07c8a6f-37b2-4a84-a907-8ab6a4c0e835" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTransactionIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract_24b35941-0125-41c1-854e-10cefe11dd00" xlink:to="loc_ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTransactionIncludingDisposalGroupsAssetsHeldForSale_b07c8a6f-37b2-4a84-a907-8ab6a4c0e835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsForeignTaxAttributesIncludingDisposalGroupsAssetsHeldForSale_92740912-39bd-4545-a1fa-65f6498a463f" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsForeignTaxAttributesIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract_24b35941-0125-41c1-854e-10cefe11dd00" xlink:to="loc_ci_DeferredTaxAssetsForeignTaxAttributesIncludingDisposalGroupsAssetsHeldForSale_92740912-39bd-4545-a1fa-65f6498a463f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsOtherIncludingDisposalGroupsAssetsHeldForSale_3acb3742-83b3-4133-bd98-b3b30c25addf" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsOtherIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract_24b35941-0125-41c1-854e-10cefe11dd00" xlink:to="loc_ci_DeferredTaxAssetsOtherIncludingDisposalGroupsAssetsHeldForSale_3acb3742-83b3-4133-bd98-b3b30c25addf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale_050cad33-79b9-43ee-9327-639cd7534345" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract_24b35941-0125-41c1-854e-10cefe11dd00" xlink:to="loc_ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale_050cad33-79b9-43ee-9327-639cd7534345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale_eb25f0de-c8e2-4900-91df-67c45ba509ab" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract_24b35941-0125-41c1-854e-10cefe11dd00" xlink:to="loc_ci_DeferredTaxAssetsValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale_eb25f0de-c8e2-4900-91df-67c45ba509ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale_0501e8b0-c939-47b3-9616-c0e1b68e0372" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract_24b35941-0125-41c1-854e-10cefe11dd00" xlink:to="loc_ci_DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale_0501e8b0-c939-47b3-9616-c0e1b68e0372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f7b5aab8-295e-4f2e-a13c-566e22562f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_IncomeTaxDisclosureLineItems_48ccdf2a-28d9-46fc-b64c-bfcd03f4c275" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f7b5aab8-295e-4f2e-a13c-566e22562f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_ed9a29e9-d0a7-436c-8617-400df05fb619" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f7b5aab8-295e-4f2e-a13c-566e22562f1c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_ed9a29e9-d0a7-436c-8617-400df05fb619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_a0b91cec-1a4b-4fae-a11d-5b52b134c94d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f7b5aab8-295e-4f2e-a13c-566e22562f1c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_a0b91cec-1a4b-4fae-a11d-5b52b134c94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost_76d559dc-e5fb-4e6e-8170-93590aaf0b71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f7b5aab8-295e-4f2e-a13c-566e22562f1c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost_76d559dc-e5fb-4e6e-8170-93590aaf0b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGains_a9da800e-db53-4c28-a379-616ff09bd1d0" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGains"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f7b5aab8-295e-4f2e-a13c-566e22562f1c" xlink:to="loc_ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGains_a9da800e-db53-4c28-a379-616ff09bd1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_8f0c0400-bd1e-4d5e-b968-9dfdbe89b0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f7b5aab8-295e-4f2e-a13c-566e22562f1c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_8f0c0400-bd1e-4d5e-b968-9dfdbe89b0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_e70cb22e-f537-43c1-8177-c12cb0ed4edd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f7b5aab8-295e-4f2e-a13c-566e22562f1c" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_e70cb22e-f537-43c1-8177-c12cb0ed4edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract_83c9f6ce-6f84-4756-813c-fd1d4b42430a" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_IncomeTaxDisclosureLineItems_48ccdf2a-28d9-46fc-b64c-bfcd03f4c275" xlink:to="loc_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract_83c9f6ce-6f84-4756-813c-fd1d4b42430a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesPropertyPlantAndEquipmentIncludingDisposalGroupsAssetsHeldForSale_aba65e5e-685d-4dcb-b8a8-93375df788d6" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesPropertyPlantAndEquipmentIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract_83c9f6ce-6f84-4756-813c-fd1d4b42430a" xlink:to="loc_ci_DeferredTaxLiabilitiesPropertyPlantAndEquipmentIncludingDisposalGroupsAssetsHeldForSale_aba65e5e-685d-4dcb-b8a8-93375df788d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIncludingDisposalGroupsAssetsHeldForSale_74eb4ac5-79f2-4bd4-9edf-5555ae284281" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract_83c9f6ce-6f84-4756-813c-fd1d4b42430a" xlink:to="loc_ci_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIncludingDisposalGroupsAssetsHeldForSale_74eb4ac5-79f2-4bd4-9edf-5555ae284281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCostIncludingDisposalGroupsAssetsHeldForSale_d0740fa9-92aa-450d-8fc2-d3358da9aa94" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCostIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract_83c9f6ce-6f84-4756-813c-fd1d4b42430a" xlink:to="loc_ci_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCostIncludingDisposalGroupsAssetsHeldForSale_d0740fa9-92aa-450d-8fc2-d3358da9aa94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGainsIncludingDisposalGroupsAssetsHeldForSale_c1257d86-1660-4881-8097-6ff45a13df84" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGainsIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract_83c9f6ce-6f84-4756-813c-fd1d4b42430a" xlink:to="loc_ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGainsIncludingDisposalGroupsAssetsHeldForSale_c1257d86-1660-4881-8097-6ff45a13df84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesOtherIncludingDisposalGroupsAssetsHeldForSale_d8adbbc3-185a-4725-af6f-e30a8225349f" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesOtherIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract_83c9f6ce-6f84-4756-813c-fd1d4b42430a" xlink:to="loc_ci_DeferredTaxLiabilitiesOtherIncludingDisposalGroupsAssetsHeldForSale_d8adbbc3-185a-4725-af6f-e30a8225349f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale_c1da6fc9-910f-4ed7-9cf8-14c7460e83cf" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract_83c9f6ce-6f84-4756-813c-fd1d4b42430a" xlink:to="loc_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale_c1da6fc9-910f-4ed7-9cf8-14c7460e83cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxLiabilitiesNetIncludingDisposalGroup_5c302276-7aa4-4f04-8654-f167079301ee" xlink:href="ci-20231231.xsd#ci_DeferredTaxLiabilitiesNetIncludingDisposalGroup"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_IncomeTaxDisclosureLineItems_48ccdf2a-28d9-46fc-b64c-bfcd03f4c275" xlink:to="loc_ci_DeferredTaxLiabilitiesNetIncludingDisposalGroup_5c302276-7aa4-4f04-8654-f167079301ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_8b521453-063b-4f88-87fc-c8196079f703" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_IncomeTaxDisclosureLineItems_48ccdf2a-28d9-46fc-b64c-bfcd03f4c275" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_8b521453-063b-4f88-87fc-c8196079f703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_2c119b5e-480e-4c36-b27c-c8794cffff85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_IncomeTaxDisclosureLineItems_48ccdf2a-28d9-46fc-b64c-bfcd03f4c275" xlink:to="loc_us-gaap_DeferredTaxLiabilities_2c119b5e-480e-4c36-b27c-c8794cffff85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsGrossInOtherAssetsNoncurrent_99f00a1a-1b04-4b55-b14f-c65be03093db" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsGrossInOtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_IncomeTaxDisclosureLineItems_48ccdf2a-28d9-46fc-b64c-bfcd03f4c275" xlink:to="loc_ci_DeferredTaxAssetsGrossInOtherAssetsNoncurrent_99f00a1a-1b04-4b55-b14f-c65be03093db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DeferredTaxAssetsInvestmentsSubjectToFederalCapitalLossUtilizationRules_621787e6-a7f8-41c0-82e7-7d2e89ebf196" xlink:href="ci-20231231.xsd#ci_DeferredTaxAssetsInvestmentsSubjectToFederalCapitalLossUtilizationRules"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_IncomeTaxDisclosureLineItems_48ccdf2a-28d9-46fc-b64c-bfcd03f4c275" xlink:to="loc_ci_DeferredTaxAssetsInvestmentsSubjectToFederalCapitalLossUtilizationRules_621787e6-a7f8-41c0-82e7-7d2e89ebf196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails_1" xlink:type="simple" xlink:href="ci-20231231.xsd#IncomeTaxesDeferredIncomeTaxesDetails_1"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/IncomeTaxesUncertainTaxPositionsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#IncomeTaxesUncertainTaxPositionsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/IncomeTaxesUncertainTaxPositionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_51d0ea0b-7fbc-4791-85e9-e60100329da2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0b7f8f6c-2579-4124-903e-ce1d3915fcaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_51d0ea0b-7fbc-4791-85e9-e60100329da2" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0b7f8f6c-2579-4124-903e-ce1d3915fcaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_9edc9fa0-4a13-40ef-a533-d426fed5f022" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0b7f8f6c-2579-4124-903e-ce1d3915fcaf" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_9edc9fa0-4a13-40ef-a533-d426fed5f022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_9b55021c-ebdd-47b3-9ec6-2555ed87dc2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0b7f8f6c-2579-4124-903e-ce1d3915fcaf" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_9b55021c-ebdd-47b3-9ec6-2555ed87dc2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_574623bb-28ff-41be-b77d-a46e046a79c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0b7f8f6c-2579-4124-903e-ce1d3915fcaf" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_574623bb-28ff-41be-b77d-a46e046a79c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_6f046457-910f-4582-bc17-f7a863f65d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0b7f8f6c-2579-4124-903e-ce1d3915fcaf" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_6f046457-910f-4582-bc17-f7a863f65d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_ea78e208-adef-4488-8fe6-48a62c5375df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0b7f8f6c-2579-4124-903e-ce1d3915fcaf" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_ea78e208-adef-4488-8fe6-48a62c5375df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_1d239076-30a1-46df-b53e-06977153da2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0b7f8f6c-2579-4124-903e-ce1d3915fcaf" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_1d239076-30a1-46df-b53e-06977153da2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_b1e70962-624d-43b0-be4a-2d3595d36ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0b7f8f6c-2579-4124-903e-ce1d3915fcaf" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_b1e70962-624d-43b0-be4a-2d3595d36ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_29aa2008-0e31-4dbe-bb22-496bca2fb847" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_51d0ea0b-7fbc-4791-85e9-e60100329da2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_29aa2008-0e31-4dbe-bb22-496bca2fb847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#ContingenciesandOtherMattersDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_aa128ba9-f52f-442c-80d8-259dfe334cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CommitmentsAndContingenciesTable_06c8151f-4952-4105-90e7-4927c8d4225c" xlink:href="ci-20231231.xsd#ci_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_aa128ba9-f52f-442c-80d8-259dfe334cf1" xlink:to="loc_ci_CommitmentsAndContingenciesTable_06c8151f-4952-4105-90e7-4927c8d4225c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_48868583-ace5-454a-8877-1deb87019a39" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CommitmentsAndContingenciesTable_06c8151f-4952-4105-90e7-4927c8d4225c" xlink:to="loc_srt_ProductOrServiceAxis_48868583-ace5-454a-8877-1deb87019a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_449a7a9b-a7ea-4b4f-92a9-2e85e5c0ed75" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_48868583-ace5-454a-8877-1deb87019a39" xlink:to="loc_srt_ProductsAndServicesDomain_449a7a9b-a7ea-4b4f-92a9-2e85e5c0ed75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RetirementAndLifeInsuranceContractsMember_fd25d8a7-35bb-4920-ad17-7bb3cce9eed4" xlink:href="ci-20231231.xsd#ci_RetirementAndLifeInsuranceContractsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_449a7a9b-a7ea-4b4f-92a9-2e85e5c0ed75" xlink:to="loc_ci_RetirementAndLifeInsuranceContractsMember_fd25d8a7-35bb-4920-ad17-7bb3cce9eed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis_6e461fd5-b3cd-4ebb-a654-a78e490e218e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsByNatureAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CommitmentsAndContingenciesTable_06c8151f-4952-4105-90e7-4927c8d4225c" xlink:to="loc_us-gaap_GuaranteeObligationsByNatureAxis_6e461fd5-b3cd-4ebb-a654-a78e490e218e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_e4416ac9-3975-492f-b8ec-41a98c808bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_6e461fd5-b3cd-4ebb-a654-a78e490e218e" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_e4416ac9-3975-492f-b8ec-41a98c808bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialGuaranteeMember_832cb212-fa5b-4d87-8d91-de8cd802c4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialGuaranteeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain_e4416ac9-3975-492f-b8ec-41a98c808bb4" xlink:to="loc_us-gaap_FinancialGuaranteeMember_832cb212-fa5b-4d87-8d91-de8cd802c4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember_f55038b5-c7ce-4ea0-9e96-e992a9497f95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndemnificationGuaranteeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain_e4416ac9-3975-492f-b8ec-41a98c808bb4" xlink:to="loc_us-gaap_IndemnificationGuaranteeMember_f55038b5-c7ce-4ea0-9e96-e992a9497f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_d04f5a91-efdf-4805-9428-fc72e2ad0d79" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CommitmentsAndContingenciesTable_06c8151f-4952-4105-90e7-4927c8d4225c" xlink:to="loc_srt_LitigationCaseAxis_d04f5a91-efdf-4805-9428-fc72e2ad0d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_068eaeaf-5905-4542-b3f1-b667d4c1e360" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_d04f5a91-efdf-4805-9428-fc72e2ad0d79" xlink:to="loc_srt_LitigationCaseTypeDomain_068eaeaf-5905-4542-b3f1-b667d4c1e360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ExpressScriptsLitigationWithElevanceMember_cbd72139-f1f2-4c00-b0f7-06ee425f81d7" xlink:href="ci-20231231.xsd#ci_ExpressScriptsLitigationWithElevanceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_068eaeaf-5905-4542-b3f1-b667d4c1e360" xlink:to="loc_ci_ExpressScriptsLitigationWithElevanceMember_cbd72139-f1f2-4c00-b0f7-06ee425f81d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ExpressScriptsCounterclaimsAgainstElevanceMember_b14073d9-70ac-40c8-8812-61239079e544" xlink:href="ci-20231231.xsd#ci_ExpressScriptsCounterclaimsAgainstElevanceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ExpressScriptsLitigationWithElevanceMember_cbd72139-f1f2-4c00-b0f7-06ee425f81d7" xlink:to="loc_ci_ExpressScriptsCounterclaimsAgainstElevanceMember_b14073d9-70ac-40c8-8812-61239079e544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageLitigationPrivateIndividualMember_4038d068-d058-45c7-93fa-afe85e554158" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageLitigationPrivateIndividualMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_068eaeaf-5905-4542-b3f1-b667d4c1e360" xlink:to="loc_ci_MedicareAdvantageLitigationPrivateIndividualMember_4038d068-d058-45c7-93fa-afe85e554158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageLitigationDepartmentOfJusticeInvestigationsMember_d6b6b7bc-822d-4b74-941c-68245f615aa8" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageLitigationDepartmentOfJusticeInvestigationsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_068eaeaf-5905-4542-b3f1-b667d4c1e360" xlink:to="loc_ci_MedicareAdvantageLitigationDepartmentOfJusticeInvestigationsMember_d6b6b7bc-822d-4b74-941c-68245f615aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_2294979a-72f1-4b7d-a042-0d8fe6fcc24f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CommitmentsAndContingenciesTable_06c8151f-4952-4105-90e7-4927c8d4225c" xlink:to="loc_us-gaap_LitigationStatusAxis_2294979a-72f1-4b7d-a042-0d8fe6fcc24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_431c9ba1-7f94-4417-b2f3-1ef641ff673d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_2294979a-72f1-4b7d-a042-0d8fe6fcc24f" xlink:to="loc_us-gaap_LitigationStatusDomain_431c9ba1-7f94-4417-b2f3-1ef641ff673d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JudicialRulingMember_3ad5cd32-cbae-4e75-a315-21972b58d429" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_JudicialRulingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_431c9ba1-7f94-4417-b2f3-1ef641ff673d" xlink:to="loc_us-gaap_JudicialRulingMember_3ad5cd32-cbae-4e75-a315-21972b58d429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_9cef1bad-7641-4d41-8dc7-3a4dd505ebbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_431c9ba1-7f94-4417-b2f3-1ef641ff673d" xlink:to="loc_us-gaap_PendingLitigationMember_9cef1bad-7641-4d41-8dc7-3a4dd505ebbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_29d08b5e-6519-45ab-a503-ca081738ae15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_431c9ba1-7f94-4417-b2f3-1ef641ff673d" xlink:to="loc_us-gaap_SettledLitigationMember_29d08b5e-6519-45ab-a503-ca081738ae15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_eab5fe5d-b44e-4668-9e53-dc80f72d1994" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CommitmentsAndContingenciesTable_06c8151f-4952-4105-90e7-4927c8d4225c" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_eab5fe5d-b44e-4668-9e53-dc80f72d1994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_8a7e0618-0252-4c76-a328-fa5065b67fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_eab5fe5d-b44e-4668-9e53-dc80f72d1994" xlink:to="loc_us-gaap_LossContingencyNatureDomain_8a7e0618-0252-4c76-a328-fa5065b67fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PricingConcessionsMember_1f8b06e2-955d-40b4-ae62-6657a39f11e9" xlink:href="ci-20231231.xsd#ci_PricingConcessionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_8a7e0618-0252-4c76-a328-fa5065b67fb1" xlink:to="loc_ci_PricingConcessionsMember_1f8b06e2-955d-40b4-ae62-6657a39f11e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PricingConcessionsThroughRemainingContractTermMember_7bb7685b-9ee0-4127-986b-0f4a21710224" xlink:href="ci-20231231.xsd#ci_PricingConcessionsThroughRemainingContractTermMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_PricingConcessionsMember_1f8b06e2-955d-40b4-ae62-6657a39f11e9" xlink:to="loc_ci_PricingConcessionsThroughRemainingContractTermMember_7bb7685b-9ee0-4127-986b-0f4a21710224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PricingConcessionsAfterRemainingTermOfAgreementMember_9fd0c2dc-862f-4d14-ae84-de538debb059" xlink:href="ci-20231231.xsd#ci_PricingConcessionsAfterRemainingTermOfAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_PricingConcessionsMember_1f8b06e2-955d-40b4-ae62-6657a39f11e9" xlink:to="loc_ci_PricingConcessionsAfterRemainingTermOfAgreementMember_9fd0c2dc-862f-4d14-ae84-de538debb059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DamagesForServiceIssuesMember_1195eca2-92cd-41b2-911a-392608bd2486" xlink:href="ci-20231231.xsd#ci_DamagesForServiceIssuesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_8a7e0618-0252-4c76-a328-fa5065b67fb1" xlink:to="loc_ci_DamagesForServiceIssuesMember_1195eca2-92cd-41b2-911a-392608bd2486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceRelatedAssessmentsMember_a21b5aa0-7025-4968-9b91-59fdea8714bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceRelatedAssessmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_8a7e0618-0252-4c76-a328-fa5065b67fb1" xlink:to="loc_us-gaap_InsuranceRelatedAssessmentsMember_a21b5aa0-7025-4968-9b91-59fdea8714bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LitigationMattersAndRegulatoryMattersMember_ed036c5e-9f9e-4410-b142-8ecba74485b9" xlink:href="ci-20231231.xsd#ci_LitigationMattersAndRegulatoryMattersMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_8a7e0618-0252-4c76-a328-fa5065b67fb1" xlink:to="loc_ci_LitigationMattersAndRegulatoryMattersMember_ed036c5e-9f9e-4410-b142-8ecba74485b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CommitmentsAndContingenciesLineItems_4f7de799-ae5c-4205-a5a9-1533b1fdbd86" xlink:href="ci-20231231.xsd#ci_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CommitmentsAndContingenciesTable_06c8151f-4952-4105-90e7-4927c8d4225c" xlink:to="loc_ci_CommitmentsAndContingenciesLineItems_4f7de799-ae5c-4205-a5a9-1533b1fdbd86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_2c6fcb72-5c62-47f2-91a3-e2acb5f75f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsMaximumExposure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems_4f7de799-ae5c-4205-a5a9-1533b1fdbd86" xlink:to="loc_us-gaap_GuaranteeObligationsMaximumExposure_2c6fcb72-5c62-47f2-91a3-e2acb5f75f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsLiquidationProceeds_bb7774c3-2a7e-47aa-8dbc-8604f86d73ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsLiquidationProceeds"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems_4f7de799-ae5c-4205-a5a9-1533b1fdbd86" xlink:to="loc_us-gaap_GuaranteeObligationsLiquidationProceeds_bb7774c3-2a7e-47aa-8dbc-8604f86d73ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_c75ec347-67a9-49f7-ad1b-fcb43d806578" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems_4f7de799-ae5c-4205-a5a9-1533b1fdbd86" xlink:to="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_c75ec347-67a9-49f7-ad1b-fcb43d806578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_ccb4a8a8-8999-4b9f-9487-c58e98525b99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems_4f7de799-ae5c-4205-a5a9-1533b1fdbd86" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_ccb4a8a8-8999-4b9f-9487-c58e98525b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_ff3d3d16-07b3-48c1-8f80-537e1ba7cade" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems_4f7de799-ae5c-4205-a5a9-1533b1fdbd86" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_ff3d3d16-07b3-48c1-8f80-537e1ba7cade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_ebf182fb-04d1-4927-9258-f5350e85e80f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems_4f7de799-ae5c-4205-a5a9-1533b1fdbd86" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_ebf182fb-04d1-4927-9258-f5350e85e80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_0dacb5a5-3234-4829-b40e-8c865162bf7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems_4f7de799-ae5c-4205-a5a9-1533b1fdbd86" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_0dacb5a5-3234-4829-b40e-8c865162bf7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_153c4ac7-bc37-4f45-8c7a-fc9a57095f68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems_4f7de799-ae5c-4205-a5a9-1533b1fdbd86" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_153c4ac7-bc37-4f45-8c7a-fc9a57095f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CommitmentsAndContingenciesNumberOfExpert_2436307e-d976-42f3-b925-39800268f682" xlink:href="ci-20231231.xsd#ci_CommitmentsAndContingenciesNumberOfExpert"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems_4f7de799-ae5c-4205-a5a9-1533b1fdbd86" xlink:to="loc_ci_CommitmentsAndContingenciesNumberOfExpert_2436307e-d976-42f3-b925-39800268f682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CommitmentsAndContingenciesNumberOfAdditionalExpert_f808dcaa-92a5-4155-8dea-8c0c32433118" xlink:href="ci-20231231.xsd#ci_CommitmentsAndContingenciesNumberOfAdditionalExpert"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems_4f7de799-ae5c-4205-a5a9-1533b1fdbd86" xlink:to="loc_ci_CommitmentsAndContingenciesNumberOfAdditionalExpert_f808dcaa-92a5-4155-8dea-8c0c32433118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_ceef3895-851f-4a6e-9918-ed1a8586f8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CommitmentsAndContingenciesLineItems_4f7de799-ae5c-4205-a5a9-1533b1fdbd86" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_ceef3895-851f-4a6e-9918-ed1a8586f8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#SegmentInformationSummaryofSpecialItemsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_95cc30aa-212e-4ac3-adef-ca7ac824b946" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemsBeforeTaxAbstract_74b60726-e332-4329-a24d-a881ce8cc579" xlink:href="ci-20231231.xsd#ci_SpecialItemsBeforeTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_95cc30aa-212e-4ac3-adef-ca7ac824b946" xlink:to="loc_ci_SpecialItemsBeforeTaxAbstract_74b60726-e332-4329-a24d-a881ce8cc579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes_b1278ca1-469d-4fc4-bb4f-39e88175d69a" xlink:href="ci-20231231.xsd#ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_74b60726-e332-4329-a24d-a881ce8cc579" xlink:to="loc_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes_b1278ca1-469d-4fc4-bb4f-39e88175d69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_6a13f67e-9383-4014-9975-48fed385178c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_74b60726-e332-4329-a24d-a881ce8cc579" xlink:to="loc_us-gaap_RestructuringCharges_6a13f67e-9383-4014-9975-48fed385178c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitBeforeTaxLitigation_4a322c36-9fee-4b50-8b13-eb4c2222bd46" xlink:href="ci-20231231.xsd#ci_SpecialItemChargeBenefitBeforeTaxLitigation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_74b60726-e332-4329-a24d-a881ce8cc579" xlink:to="loc_ci_SpecialItemChargeBenefitBeforeTaxLitigation_4a322c36-9fee-4b50-8b13-eb4c2222bd46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TransactionRelatedCosts_516fcc8d-0686-4ab5-b898-170c2787c104" xlink:href="ci-20231231.xsd#ci_TransactionRelatedCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_74b60726-e332-4329-a24d-a881ce8cc579" xlink:to="loc_ci_TransactionRelatedCosts_516fcc8d-0686-4ab5-b898-170c2787c104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitTaxMatters_f9b99715-658d-44e0-a5f1-213524de5f4b" xlink:href="ci-20231231.xsd#ci_SpecialItemChargeBenefitTaxMatters"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_74b60726-e332-4329-a24d-a881ce8cc579" xlink:to="loc_ci_SpecialItemChargeBenefitTaxMatters_f9b99715-658d-44e0-a5f1-213524de5f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax_01928477-6961-4dde-98b8-0bc4bcd907ee" xlink:href="ci-20231231.xsd#ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_74b60726-e332-4329-a24d-a881ce8cc579" xlink:to="loc_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax_01928477-6961-4dde-98b8-0bc4bcd907ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OrganizationalEfficiencyPlanCharges_ba46db2e-91f6-4a3a-9cd3-5f7ea6c6175d" xlink:href="ci-20231231.xsd#ci_OrganizationalEfficiencyPlanCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_74b60726-e332-4329-a24d-a881ce8cc579" xlink:to="loc_ci_OrganizationalEfficiencyPlanCharges_ba46db2e-91f6-4a3a-9cd3-5f7ea6c6175d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes_2cbdfde9-abab-45d9-a7dc-13f4a465a9e2" xlink:href="ci-20231231.xsd#ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_74b60726-e332-4329-a24d-a881ce8cc579" xlink:to="loc_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes_2cbdfde9-abab-45d9-a7dc-13f4a465a9e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossFromContractAdjustmentBeforeTaxes_369513bb-d0bd-4b2a-abee-13f08f961010" xlink:href="ci-20231231.xsd#ci_SpecialItemGainLossFromContractAdjustmentBeforeTaxes"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_74b60726-e332-4329-a24d-a881ce8cc579" xlink:to="loc_ci_SpecialItemGainLossFromContractAdjustmentBeforeTaxes_369513bb-d0bd-4b2a-abee-13f08f961010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity_6e03776b-6289-43b7-a331-5273d06651f5" xlink:href="ci-20231231.xsd#ci_SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_74b60726-e332-4329-a24d-a881ce8cc579" xlink:to="loc_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity_6e03776b-6289-43b7-a331-5273d06651f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemsAfterTaxAbstract_da28363a-f5d6-4aab-be73-9b98e160d55d" xlink:href="ci-20231231.xsd#ci_SpecialItemsAfterTaxAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_95cc30aa-212e-4ac3-adef-ca7ac824b946" xlink:to="loc_ci_SpecialItemsAfterTaxAbstract_da28363a-f5d6-4aab-be73-9b98e160d55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax_f4ff515c-4afd-400c-b7b9-414721d737b4" xlink:href="ci-20231231.xsd#ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsAfterTaxAbstract_da28363a-f5d6-4aab-be73-9b98e160d55d" xlink:to="loc_ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax_f4ff515c-4afd-400c-b7b9-414721d737b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RestructuringChargesNetOfTaxExpense_563ee90f-dc49-43f1-8f91-e55bd40ba3e5" xlink:href="ci-20231231.xsd#ci_RestructuringChargesNetOfTaxExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsAfterTaxAbstract_da28363a-f5d6-4aab-be73-9b98e160d55d" xlink:to="loc_ci_RestructuringChargesNetOfTaxExpense_563ee90f-dc49-43f1-8f91-e55bd40ba3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitAfterTaxLitigation_6323884f-2bb3-4dd5-b6dc-d0d76cbbb762" xlink:href="ci-20231231.xsd#ci_SpecialItemChargeBenefitAfterTaxLitigation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsAfterTaxAbstract_da28363a-f5d6-4aab-be73-9b98e160d55d" xlink:to="loc_ci_SpecialItemChargeBenefitAfterTaxLitigation_6323884f-2bb3-4dd5-b6dc-d0d76cbbb762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TransactionRelatedCostsAfterTax_d2d64009-fe0d-4f66-a432-090590f5cf75" xlink:href="ci-20231231.xsd#ci_TransactionRelatedCostsAfterTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsAfterTaxAbstract_da28363a-f5d6-4aab-be73-9b98e160d55d" xlink:to="loc_ci_TransactionRelatedCostsAfterTax_d2d64009-fe0d-4f66-a432-090590f5cf75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitTaxMattersAfterTax_169a3d43-85d6-4fe9-94ac-a502c90b2a3d" xlink:href="ci-20231231.xsd#ci_SpecialItemChargeBenefitTaxMattersAfterTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsAfterTaxAbstract_da28363a-f5d6-4aab-be73-9b98e160d55d" xlink:to="loc_ci_SpecialItemChargeBenefitTaxMattersAfterTax_169a3d43-85d6-4fe9-94ac-a502c90b2a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax_fcac45b3-06bb-45d5-80da-47822ec02e5e" xlink:href="ci-20231231.xsd#ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsAfterTaxAbstract_da28363a-f5d6-4aab-be73-9b98e160d55d" xlink:to="loc_ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax_fcac45b3-06bb-45d5-80da-47822ec02e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OrganizationalEfficiencyPlanChargesNetOfTax_9875e237-2c7c-44ec-bf59-73e5066be1f9" xlink:href="ci-20231231.xsd#ci_OrganizationalEfficiencyPlanChargesNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsAfterTaxAbstract_da28363a-f5d6-4aab-be73-9b98e160d55d" xlink:to="loc_ci_OrganizationalEfficiencyPlanChargesNetOfTax_9875e237-2c7c-44ec-bf59-73e5066be1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax_a7557303-8227-42ca-a748-978a96da934f" xlink:href="ci-20231231.xsd#ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsAfterTaxAbstract_da28363a-f5d6-4aab-be73-9b98e160d55d" xlink:to="loc_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax_a7557303-8227-42ca-a748-978a96da934f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossFromContractAdjustmentNetOfTax_11c6a17c-d7d5-4f4e-9e66-d368899bd094" xlink:href="ci-20231231.xsd#ci_SpecialItemGainLossFromContractAdjustmentNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsAfterTaxAbstract_da28363a-f5d6-4aab-be73-9b98e160d55d" xlink:to="loc_ci_SpecialItemGainLossFromContractAdjustmentNetOfTax_11c6a17c-d7d5-4f4e-9e66-d368899bd094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity_f5d1b09b-df53-480f-a0ae-42b12688e275" xlink:href="ci-20231231.xsd#ci_SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsAfterTaxAbstract_da28363a-f5d6-4aab-be73-9b98e160d55d" xlink:to="loc_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity_f5d1b09b-df53-480f-a0ae-42b12688e275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#SegmentInformationSummarizedSegmentFinancialInformationDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c4f2b589-a629-4e7a-b9f3-68bbb0d3c680" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8fed7dea-4301-46e1-8f9c-ca4be2acc31f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c4f2b589-a629-4e7a-b9f3-68bbb0d3c680" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8fed7dea-4301-46e1-8f9c-ca4be2acc31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_beda560a-f2ea-41b9-924d-644896f9cf69" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8fed7dea-4301-46e1-8f9c-ca4be2acc31f" xlink:to="loc_srt_ConsolidationItemsAxis_beda560a-f2ea-41b9-924d-644896f9cf69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_a55e94f3-ced0-4f10-957b-c08f604f55bd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_beda560a-f2ea-41b9-924d-644896f9cf69" xlink:to="loc_srt_ConsolidationItemsDomain_a55e94f3-ced0-4f10-957b-c08f604f55bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_9d9485e6-ad50-498c-bdc3-09adaaefca51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_a55e94f3-ced0-4f10-957b-c08f604f55bd" xlink:to="loc_us-gaap_OperatingSegmentsMember_9d9485e6-ad50-498c-bdc3-09adaaefca51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CorporateAndEliminationsMember_5d0926eb-1bee-41f2-bda9-03d58d8b8db7" xlink:href="ci-20231231.xsd#ci_CorporateAndEliminationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_a55e94f3-ced0-4f10-957b-c08f604f55bd" xlink:to="loc_ci_CorporateAndEliminationsMember_5d0926eb-1bee-41f2-bda9-03d58d8b8db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_06ef57c8-5a97-490d-be4b-144cd1fa1644" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CorporateAndEliminationsMember_5d0926eb-1bee-41f2-bda9-03d58d8b8db7" xlink:to="loc_us-gaap_CorporateNonSegmentMember_06ef57c8-5a97-490d-be4b-144cd1fa1644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_4e7ebd34-729d-4532-a890-cc5a2501a040" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_CorporateAndEliminationsMember_5d0926eb-1bee-41f2-bda9-03d58d8b8db7" xlink:to="loc_us-gaap_IntersegmentEliminationMember_4e7ebd34-729d-4532-a890-cc5a2501a040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5fb144f6-dbc4-4165-9d4f-95184cdbf60a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8fed7dea-4301-46e1-8f9c-ca4be2acc31f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5fb144f6-dbc4-4165-9d4f-95184cdbf60a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8b416362-bc1b-43f4-b3fc-f04b1877ab89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5fb144f6-dbc4-4165-9d4f-95184cdbf60a" xlink:to="loc_us-gaap_SegmentDomain_8b416362-bc1b-43f4-b3fc-f04b1877ab89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EvernorthMember_685f8617-e185-4e9c-ba71-8d28f753d013" xlink:href="ci-20231231.xsd#ci_EvernorthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8b416362-bc1b-43f4-b3fc-f04b1877ab89" xlink:to="loc_ci_EvernorthMember_685f8617-e185-4e9c-ba71-8d28f753d013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember_db9fb140-0aa6-4600-acf3-c446080c3772" xlink:href="ci-20231231.xsd#ci_CignaHealthcareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8b416362-bc1b-43f4-b3fc-f04b1877ab89" xlink:to="loc_ci_CignaHealthcareMember_db9fb140-0aa6-4600-acf3-c446080c3772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherOperationsSegmentMember_b22ee93d-6dcc-4079-b4cf-c223c1c3b2dc" xlink:href="ci-20231231.xsd#ci_OtherOperationsSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8b416362-bc1b-43f4-b3fc-f04b1877ab89" xlink:to="loc_ci_OtherOperationsSegmentMember_b22ee93d-6dcc-4079-b4cf-c223c1c3b2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_25606fa6-a978-4d92-9c81-636119b601c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8fed7dea-4301-46e1-8f9c-ca4be2acc31f" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_25606fa6-a978-4d92-9c81-636119b601c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NonInvestmentRevenue_a36c60e4-5a46-45b5-a61e-6896c5997f89" xlink:href="ci-20231231.xsd#ci_NonInvestmentRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_25606fa6-a978-4d92-9c81-636119b601c7" xlink:to="loc_ci_NonInvestmentRevenue_a36c60e4-5a46-45b5-a61e-6896c5997f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_99ed04cc-59a0-48e1-803f-ba0ae0e51833" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_25606fa6-a978-4d92-9c81-636119b601c7" xlink:to="loc_us-gaap_NetInvestmentIncome_99ed04cc-59a0-48e1-803f-ba0ae0e51833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1e7c5d73-6903-4152-bc68-fdca804f3019" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_25606fa6-a978-4d92-9c81-636119b601c7" xlink:to="loc_us-gaap_Revenues_1e7c5d73-6903-4152-bc68-fdca804f3019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RealizedInvestmentGainsLossesEquityMethodInvestments_261b130b-3edd-4288-85ee-56d1e92d328a" xlink:href="ci-20231231.xsd#ci_RealizedInvestmentGainsLossesEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_25606fa6-a978-4d92-9c81-636119b601c7" xlink:to="loc_ci_RealizedInvestmentGainsLossesEquityMethodInvestments_261b130b-3edd-4288-85ee-56d1e92d328a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SegmentRevenues_c38915e0-70a7-4411-a9ae-e9acb617f2c9" xlink:href="ci-20231231.xsd#ci_SegmentRevenues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_25606fa6-a978-4d92-9c81-636119b601c7" xlink:to="loc_ci_SegmentRevenues_c38915e0-70a7-4411-a9ae-e9acb617f2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5b522171-0a0a-4483-9c3e-8a8380405453" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_25606fa6-a978-4d92-9c81-636119b601c7" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_5b522171-0a0a-4483-9c3e-8a8380405453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_085e25c3-15f4-4506-96d3-74757ac43ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_25606fa6-a978-4d92-9c81-636119b601c7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_085e25c3-15f4-4506-96d3-74757ac43ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract_543bb99c-69a7-4bd1-90f7-226fbd98d9fd" xlink:href="ci-20231231.xsd#ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_25606fa6-a978-4d92-9c81-636119b601c7" xlink:to="loc_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract_543bb99c-69a7-4bd1-90f7-226fbd98d9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax_5d021948-c671-4371-9613-6f98dd37ea25" xlink:href="ci-20231231.xsd#ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract_543bb99c-69a7-4bd1-90f7-226fbd98d9fd" xlink:to="loc_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax_5d021948-c671-4371-9613-6f98dd37ea25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries_e5a99102-339c-43c2-97ad-7c4ba8747d2a" xlink:href="ci-20231231.xsd#ci_RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract_543bb99c-69a7-4bd1-90f7-226fbd98d9fd" xlink:to="loc_ci_RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries_e5a99102-339c-43c2-97ad-7c4ba8747d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_eedc12c3-c493-4d4d-9052-39a02205118e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract_543bb99c-69a7-4bd1-90f7-226fbd98d9fd" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_eedc12c3-c493-4d4d-9052-39a02205118e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemsBeforeTaxAbstract_9ea3b9b9-09c5-4a00-8cb8-ee381b14fa68" xlink:href="ci-20231231.xsd#ci_SpecialItemsBeforeTaxAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract_543bb99c-69a7-4bd1-90f7-226fbd98d9fd" xlink:to="loc_ci_SpecialItemsBeforeTaxAbstract_9ea3b9b9-09c5-4a00-8cb8-ee381b14fa68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes_33aaa567-92ae-4364-a0e9-f408eba0ffa7" xlink:href="ci-20231231.xsd#ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_9ea3b9b9-09c5-4a00-8cb8-ee381b14fa68" xlink:to="loc_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes_33aaa567-92ae-4364-a0e9-f408eba0ffa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_23356235-1b88-4de4-9f31-1341f1c1b61a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_9ea3b9b9-09c5-4a00-8cb8-ee381b14fa68" xlink:to="loc_us-gaap_RestructuringCharges_23356235-1b88-4de4-9f31-1341f1c1b61a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargeBenefitBeforeTaxLitigation_6c7181a7-be29-4692-8704-9eb7c1c31e7b" xlink:href="ci-20231231.xsd#ci_SpecialItemChargeBenefitBeforeTaxLitigation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_9ea3b9b9-09c5-4a00-8cb8-ee381b14fa68" xlink:to="loc_ci_SpecialItemChargeBenefitBeforeTaxLitigation_6c7181a7-be29-4692-8704-9eb7c1c31e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_TransactionRelatedCosts_0fcdb797-6abc-473c-9988-3c9f2317cda4" xlink:href="ci-20231231.xsd#ci_TransactionRelatedCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_9ea3b9b9-09c5-4a00-8cb8-ee381b14fa68" xlink:to="loc_ci_TransactionRelatedCosts_0fcdb797-6abc-473c-9988-3c9f2317cda4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax_bf2b13d9-cf26-4351-9df5-089e09d72157" xlink:href="ci-20231231.xsd#ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_9ea3b9b9-09c5-4a00-8cb8-ee381b14fa68" xlink:to="loc_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax_bf2b13d9-cf26-4351-9df5-089e09d72157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OrganizationalEfficiencyPlanCharges_deae12a5-26c6-4d7b-bf48-aa87cd7b5b1c" xlink:href="ci-20231231.xsd#ci_OrganizationalEfficiencyPlanCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_9ea3b9b9-09c5-4a00-8cb8-ee381b14fa68" xlink:to="loc_ci_OrganizationalEfficiencyPlanCharges_deae12a5-26c6-4d7b-bf48-aa87cd7b5b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes_c3543720-dbe7-46e0-a614-eb7e18469d56" xlink:href="ci-20231231.xsd#ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_9ea3b9b9-09c5-4a00-8cb8-ee381b14fa68" xlink:to="loc_ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes_c3543720-dbe7-46e0-a614-eb7e18469d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SpecialItemGainLossFromContractAdjustmentBeforeTaxes_919a7701-8d3e-4fb9-9bba-2c452eeb392e" xlink:href="ci-20231231.xsd#ci_SpecialItemGainLossFromContractAdjustmentBeforeTaxes"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_SpecialItemsBeforeTaxAbstract_9ea3b9b9-09c5-4a00-8cb8-ee381b14fa68" xlink:to="loc_ci_SpecialItemGainLossFromContractAdjustmentBeforeTaxes_919a7701-8d3e-4fb9-9bba-2c452eeb392e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_842a323a-1755-43b1-918d-ecc1076c51f5" xlink:href="ci-20231231.xsd#ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract_543bb99c-69a7-4bd1-90f7-226fbd98d9fd" xlink:to="loc_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_842a323a-1755-43b1-918d-ecc1076c51f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#SegmentInformationRevenuefromExternalCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_0c308b82-2b3f-40eb-bb83-fbcae227c0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_d8efcf90-5ce1-4791-908f-d2402326eba3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0c308b82-2b3f-40eb-bb83-fbcae227c0b5" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_d8efcf90-5ce1-4791-908f-d2402326eba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_525ae2e8-9a9b-4d21-ba68-bbf48469ba93" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_d8efcf90-5ce1-4791-908f-d2402326eba3" xlink:to="loc_srt_ProductOrServiceAxis_525ae2e8-9a9b-4d21-ba68-bbf48469ba93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8f5676a3-702c-4805-a859-c4791593eaa0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_525ae2e8-9a9b-4d21-ba68-bbf48469ba93" xlink:to="loc_srt_ProductsAndServicesDomain_8f5676a3-702c-4805-a859-c4791593eaa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_53106612-ec63-4847-a2c3-0a49a6904c05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8f5676a3-702c-4805-a859-c4791593eaa0" xlink:to="loc_us-gaap_ProductMember_53106612-ec63-4847-a2c3-0a49a6904c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NetworkPharmacyMember_9329420c-5851-4504-9844-052e22ad6e18" xlink:href="ci-20231231.xsd#ci_NetworkPharmacyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_53106612-ec63-4847-a2c3-0a49a6904c05" xlink:to="loc_ci_NetworkPharmacyMember_9329420c-5851-4504-9844-052e22ad6e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_HomeDeliveryAndSpecialtyMember_adfddf98-2c4c-47a6-9302-a6b47c75d393" xlink:href="ci-20231231.xsd#ci_HomeDeliveryAndSpecialtyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_53106612-ec63-4847-a2c3-0a49a6904c05" xlink:to="loc_ci_HomeDeliveryAndSpecialtyMember_adfddf98-2c4c-47a6-9302-a6b47c75d393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherPharmacyMember_e4fe1e4a-a6c5-46c6-b5da-d364aaea55f7" xlink:href="ci-20231231.xsd#ci_OtherPharmacyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_53106612-ec63-4847-a2c3-0a49a6904c05" xlink:to="loc_ci_OtherPharmacyMember_e4fe1e4a-a6c5-46c6-b5da-d364aaea55f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_HealthcareMember_202b8f7a-e91e-49ec-84cd-efd561cb25ff" xlink:href="ci-20231231.xsd#ci_HealthcareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8f5676a3-702c-4805-a859-c4791593eaa0" xlink:to="loc_ci_HealthcareMember_202b8f7a-e91e-49ec-84cd-efd561cb25ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EmployerInsuredMember_fadc646a-86a7-473d-bb7c-55bfbb1bd584" xlink:href="ci-20231231.xsd#ci_EmployerInsuredMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_HealthcareMember_202b8f7a-e91e-49ec-84cd-efd561cb25ff" xlink:to="loc_ci_EmployerInsuredMember_fadc646a-86a7-473d-bb7c-55bfbb1bd584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_MedicareAdvantageMember_8f5c8fbe-5b7a-45d2-90b0-89909b533bde" xlink:href="ci-20231231.xsd#ci_MedicareAdvantageMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_HealthcareMember_202b8f7a-e91e-49ec-84cd-efd561cb25ff" xlink:to="loc_ci_MedicareAdvantageMember_8f5c8fbe-5b7a-45d2-90b0-89909b533bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_StopLossMember_cc175733-f410-4354-85ee-86d4b46c89dd" xlink:href="ci-20231231.xsd#ci_StopLossMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_HealthcareMember_202b8f7a-e91e-49ec-84cd-efd561cb25ff" xlink:to="loc_ci_StopLossMember_cc175733-f410-4354-85ee-86d4b46c89dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IndividualAndFamilyPlansMember_dddce853-ed99-4166-985f-39754cc74bc7" xlink:href="ci-20231231.xsd#ci_IndividualAndFamilyPlansMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_HealthcareMember_202b8f7a-e91e-49ec-84cd-efd561cb25ff" xlink:to="loc_ci_IndividualAndFamilyPlansMember_dddce853-ed99-4166-985f-39754cc74bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherHealthcareMember_7e91185a-5ee4-4b37-90e4-f518bc7d6548" xlink:href="ci-20231231.xsd#ci_OtherHealthcareMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_HealthcareMember_202b8f7a-e91e-49ec-84cd-efd561cb25ff" xlink:to="loc_ci_OtherHealthcareMember_7e91185a-5ee4-4b37-90e4-f518bc7d6548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_430447f6-63eb-4893-988e-62dc2b337bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8f5676a3-702c-4805-a859-c4791593eaa0" xlink:to="loc_us-gaap_ServiceMember_430447f6-63eb-4893-988e-62dc2b337bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ServiceFeesMember_1e16c8df-cdb9-4e4c-9480-4f3b2ebc9977" xlink:href="ci-20231231.xsd#ci_ServiceFeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ServiceMember_430447f6-63eb-4893-988e-62dc2b337bd7" xlink:to="loc_ci_ServiceFeesMember_1e16c8df-cdb9-4e4c-9480-4f3b2ebc9977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceOtherMember_06f45cc3-7a0c-4db2-a2c3-b9a6832fa57e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ServiceMember_430447f6-63eb-4893-988e-62dc2b337bd7" xlink:to="loc_us-gaap_ServiceOtherMember_06f45cc3-7a0c-4db2-a2c3-b9a6832fa57e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3b6fb471-1bf1-4d9c-b45b-54e193d91a76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_d8efcf90-5ce1-4791-908f-d2402326eba3" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3b6fb471-1bf1-4d9c-b45b-54e193d91a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_96f8d4ea-1d21-45d9-8d98-eaa32a2d26d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3b6fb471-1bf1-4d9c-b45b-54e193d91a76" xlink:to="loc_us-gaap_SegmentDomain_96f8d4ea-1d21-45d9-8d98-eaa32a2d26d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EvernorthMember_61a6aa59-fc40-4a3b-bba4-4ff5dba3e1cd" xlink:href="ci-20231231.xsd#ci_EvernorthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_96f8d4ea-1d21-45d9-8d98-eaa32a2d26d0" xlink:to="loc_ci_EvernorthMember_61a6aa59-fc40-4a3b-bba4-4ff5dba3e1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_CignaHealthcareMember_192b579f-e5d9-4329-90a7-ee555364aca5" xlink:href="ci-20231231.xsd#ci_CignaHealthcareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_96f8d4ea-1d21-45d9-8d98-eaa32a2d26d0" xlink:to="loc_ci_CignaHealthcareMember_192b579f-e5d9-4329-90a7-ee555364aca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherOperationsSegmentMember_fb482638-0e17-427e-bb8f-ee4be4621ab3" xlink:href="ci-20231231.xsd#ci_OtherOperationsSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_96f8d4ea-1d21-45d9-8d98-eaa32a2d26d0" xlink:to="loc_ci_OtherOperationsSegmentMember_fb482638-0e17-427e-bb8f-ee4be4621ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_3cab96fc-5ef7-4c47-9075-aa8d6e8b6b35" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_d8efcf90-5ce1-4791-908f-d2402326eba3" xlink:to="loc_srt_ConsolidationItemsAxis_3cab96fc-5ef7-4c47-9075-aa8d6e8b6b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_114ecb44-306a-4215-9ed0-44cb5d2d5b4e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_3cab96fc-5ef7-4c47-9075-aa8d6e8b6b35" xlink:to="loc_srt_ConsolidationItemsDomain_114ecb44-306a-4215-9ed0-44cb5d2d5b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_b563428b-a0c0-4ce7-a6a9-ce28d9c0284c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_114ecb44-306a-4215-9ed0-44cb5d2d5b4e" xlink:to="loc_us-gaap_IntersegmentEliminationMember_b563428b-a0c0-4ce7-a6a9-ce28d9c0284c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_e4c9fa20-0533-4cc3-9f46-adc5efcefeb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_114ecb44-306a-4215-9ed0-44cb5d2d5b4e" xlink:to="loc_us-gaap_OperatingSegmentsMember_e4c9fa20-0533-4cc3-9f46-adc5efcefeb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_595ae2b4-ad8c-4b0f-bf1d-6179f224eca0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_d8efcf90-5ce1-4791-908f-d2402326eba3" xlink:to="loc_us-gaap_SubsegmentsAxis_595ae2b4-ad8c-4b0f-bf1d-6179f224eca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_b23ac703-2b2f-453f-97b3-fc203b70a516" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_595ae2b4-ad8c-4b0f-bf1d-6179f224eca0" xlink:to="loc_us-gaap_SubsegmentsDomain_b23ac703-2b2f-453f-97b3-fc203b70a516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_UnitedStatedHealthcareMember_811f0170-3449-4668-8ed4-d42868b47fa4" xlink:href="ci-20231231.xsd#ci_UnitedStatedHealthcareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_b23ac703-2b2f-453f-97b3-fc203b70a516" xlink:to="loc_ci_UnitedStatedHealthcareMember_811f0170-3449-4668-8ed4-d42868b47fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InternationalHealthMember_91744309-705a-4baf-8bdb-2fe20859e046" xlink:href="ci-20231231.xsd#ci_InternationalHealthMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_b23ac703-2b2f-453f-97b3-fc203b70a516" xlink:to="loc_ci_InternationalHealthMember_91744309-705a-4baf-8bdb-2fe20859e046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherOperationsInternationalBusinessesToBeSoldAndInterestInJointVentureInTurkeyMember_2b9e688d-a99f-47bf-913c-d226bd78349f" xlink:href="ci-20231231.xsd#ci_OtherOperationsInternationalBusinessesToBeSoldAndInterestInJointVentureInTurkeyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_b23ac703-2b2f-453f-97b3-fc203b70a516" xlink:to="loc_ci_OtherOperationsInternationalBusinessesToBeSoldAndInterestInJointVentureInTurkeyMember_2b9e688d-a99f-47bf-913c-d226bd78349f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherOperationsInternationalBusinessesToBeSoldMember_1f8a0964-9be0-48d7-84dd-6cff85f57143" xlink:href="ci-20231231.xsd#ci_OtherOperationsInternationalBusinessesToBeSoldMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_OtherOperationsInternationalBusinessesToBeSoldAndInterestInJointVentureInTurkeyMember_2b9e688d-a99f-47bf-913c-d226bd78349f" xlink:to="loc_ci_OtherOperationsInternationalBusinessesToBeSoldMember_1f8a0964-9be0-48d7-84dd-6cff85f57143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_InterestInJointVentureInTurkeyMember_ca45ef86-906d-4751-a708-42dfc336b598" xlink:href="ci-20231231.xsd#ci_InterestInJointVentureInTurkeyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_OtherOperationsInternationalBusinessesToBeSoldAndInterestInJointVentureInTurkeyMember_2b9e688d-a99f-47bf-913c-d226bd78349f" xlink:to="loc_ci_InterestInJointVentureInTurkeyMember_ca45ef86-906d-4751-a708-42dfc336b598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OtherOperationsSegmentOtherMember_7f72dd1a-0caf-4d49-89d2-8147abc23c60" xlink:href="ci-20231231.xsd#ci_OtherOperationsSegmentOtherMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_b23ac703-2b2f-453f-97b3-fc203b70a516" xlink:to="loc_ci_OtherOperationsSegmentOtherMember_7f72dd1a-0caf-4d49-89d2-8147abc23c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_6236a2c6-5f72-493c-af99-2fae694cfe11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_d8efcf90-5ce1-4791-908f-d2402326eba3" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_6236a2c6-5f72-493c-af99-2fae694cfe11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d9173848-03d2-4b78-9d90-111c04c4a539" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_6236a2c6-5f72-493c-af99-2fae694cfe11" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d9173848-03d2-4b78-9d90-111c04c4a539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_5d6af6d9-a113-4bbe-a440-799924128469" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_6236a2c6-5f72-493c-af99-2fae694cfe11" xlink:to="loc_us-gaap_PremiumsEarnedNet_5d6af6d9-a113-4bbe-a440-799924128469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NonInvestmentRevenue_3e8d4a16-7c6f-408e-a8a6-54063aff499d" xlink:href="ci-20231231.xsd#ci_NonInvestmentRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_6236a2c6-5f72-493c-af99-2fae694cfe11" xlink:to="loc_ci_NonInvestmentRevenue_3e8d4a16-7c6f-408e-a8a6-54063aff499d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SegmentInformationFinancialandPerformanceGuaranteesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#SegmentInformationFinancialandPerformanceGuaranteesDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/SegmentInformationFinancialandPerformanceGuaranteesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4fcde402-0687-424a-8495-c740255219de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_7d630b10-e1c7-4fc4-beb4-b25ec9520e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4fcde402-0687-424a-8495-c740255219de" xlink:to="loc_us-gaap_LossContingenciesTable_7d630b10-e1c7-4fc4-beb4-b25ec9520e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8b8cae90-9627-4904-897d-50b8b96929a4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7d630b10-e1c7-4fc4-beb4-b25ec9520e4e" xlink:to="loc_srt_ProductOrServiceAxis_8b8cae90-9627-4904-897d-50b8b96929a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6def74bd-fda0-4d93-9981-9b65e6c406d7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8b8cae90-9627-4904-897d-50b8b96929a4" xlink:to="loc_srt_ProductsAndServicesDomain_6def74bd-fda0-4d93-9981-9b65e6c406d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_PharmacyBenefitsManagementServicesMember_93f44201-c647-421f-a365-c2b8a8aa0ab0" xlink:href="ci-20231231.xsd#ci_PharmacyBenefitsManagementServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6def74bd-fda0-4d93-9981-9b65e6c406d7" xlink:to="loc_ci_PharmacyBenefitsManagementServicesMember_93f44201-c647-421f-a365-c2b8a8aa0ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_873cd3ae-01af-4fec-826f-a7bf8182cfc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7d630b10-e1c7-4fc4-beb4-b25ec9520e4e" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_873cd3ae-01af-4fec-826f-a7bf8182cfc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_ba6841d9-862a-4635-99ec-727b8126f74a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_873cd3ae-01af-4fec-826f-a7bf8182cfc5" xlink:to="loc_us-gaap_LossContingencyNatureDomain_ba6841d9-862a-4635-99ec-727b8126f74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteesMember_a2ee601a-f211-485b-bb5b-9e9c34795b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_ba6841d9-862a-4635-99ec-727b8126f74a" xlink:to="loc_us-gaap_GuaranteesMember_a2ee601a-f211-485b-bb5b-9e9c34795b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_829b59a7-f992-476b-ad75-8dfcbbf44d98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7d630b10-e1c7-4fc4-beb4-b25ec9520e4e" xlink:to="loc_us-gaap_LossContingenciesLineItems_829b59a7-f992-476b-ad75-8dfcbbf44d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_02824542-440a-4605-8c2e-7b3f000a3ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_829b59a7-f992-476b-ad75-8dfcbbf44d98" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_02824542-440a-4605-8c2e-7b3f000a3ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SegmentInformationUSandForeignRevenuesfromExternalCustomersDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#SegmentInformationUSandForeignRevenuesfromExternalCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/SegmentInformationUSandForeignRevenuesfromExternalCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_2e25e7cb-8dc7-4423-bedb-4f071eba0da1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_c1b45832-dbd8-4c09-9c3e-b71fba583d50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2e25e7cb-8dc7-4423-bedb-4f071eba0da1" xlink:to="loc_us-gaap_LossContingenciesTable_c1b45832-dbd8-4c09-9c3e-b71fba583d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2f0df1bd-3518-416c-b12d-4eb89e8d500c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c1b45832-dbd8-4c09-9c3e-b71fba583d50" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2f0df1bd-3518-416c-b12d-4eb89e8d500c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1eab0b69-7d00-418a-81b1-fb4a23834005" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2f0df1bd-3518-416c-b12d-4eb89e8d500c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1eab0b69-7d00-418a-81b1-fb4a23834005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RevenuesIncludingNetInvestmentIncomeBenchmarkMember_291f6821-656f-4693-8694-a74d56b6c333" xlink:href="ci-20231231.xsd#ci_RevenuesIncludingNetInvestmentIncomeBenchmarkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1eab0b69-7d00-418a-81b1-fb4a23834005" xlink:to="loc_ci_RevenuesIncludingNetInvestmentIncomeBenchmarkMember_291f6821-656f-4693-8694-a74d56b6c333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RevenuesFromExternalCustomersMember_9798c967-9411-4f32-b349-982d46b549c0" xlink:href="ci-20231231.xsd#ci_RevenuesFromExternalCustomersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1eab0b69-7d00-418a-81b1-fb4a23834005" xlink:to="loc_ci_RevenuesFromExternalCustomersMember_9798c967-9411-4f32-b349-982d46b549c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_aeb1d721-930c-4aa8-a64b-ad35165773ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c1b45832-dbd8-4c09-9c3e-b71fba583d50" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_aeb1d721-930c-4aa8-a64b-ad35165773ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0febb7d6-687d-4011-971e-fe765b28ff08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_aeb1d721-930c-4aa8-a64b-ad35165773ac" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0febb7d6-687d-4011-971e-fe765b28ff08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_83331639-217e-48ba-a5d9-5b4852b4ce55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_0febb7d6-687d-4011-971e-fe765b28ff08" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_83331639-217e-48ba-a5d9-5b4852b4ce55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_19a06b15-bac5-4e65-a884-60c1eadc4347" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_0febb7d6-687d-4011-971e-fe765b28ff08" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_19a06b15-bac5-4e65-a884-60c1eadc4347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_d76236b9-bc66-410a-aad3-c3872bd86865" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c1b45832-dbd8-4c09-9c3e-b71fba583d50" xlink:to="loc_srt_MajorCustomersAxis_d76236b9-bc66-410a-aad3-c3872bd86865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a02e8aff-a448-4ed3-8ee1-9dc5484019d0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_d76236b9-bc66-410a-aad3-c3872bd86865" xlink:to="loc_srt_NameOfMajorCustomerDomain_a02e8aff-a448-4ed3-8ee1-9dc5484019d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_USFederalGovernmentAgenciesMember_4ad6eb8c-ebe1-4e90-9e58-f63bc6adc43d" xlink:href="ci-20231231.xsd#ci_USFederalGovernmentAgenciesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a02e8aff-a448-4ed3-8ee1-9dc5484019d0" xlink:to="loc_ci_USFederalGovernmentAgenciesMember_4ad6eb8c-ebe1-4e90-9e58-f63bc6adc43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5b4e8133-c55e-45f6-a6f3-30f4bfb4eb6c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c1b45832-dbd8-4c09-9c3e-b71fba583d50" xlink:to="loc_srt_StatementGeographicalAxis_5b4e8133-c55e-45f6-a6f3-30f4bfb4eb6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_786cac2a-160e-4735-94eb-2bd6e66df563" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_5b4e8133-c55e-45f6-a6f3-30f4bfb4eb6c" xlink:to="loc_srt_SegmentGeographicalDomain_786cac2a-160e-4735-94eb-2bd6e66df563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_07cff080-3bf9-4a5a-919e-8b464cedfbbe" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_786cac2a-160e-4735-94eb-2bd6e66df563" xlink:to="loc_country_US_07cff080-3bf9-4a5a-919e-8b464cedfbbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AllOtherCountriesMember_49de1e67-ff09-421e-98b9-00b30b464459" xlink:href="ci-20231231.xsd#ci_AllOtherCountriesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_786cac2a-160e-4735-94eb-2bd6e66df563" xlink:to="loc_ci_AllOtherCountriesMember_49de1e67-ff09-421e-98b9-00b30b464459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SingleForeignCountryMember_7b6dd258-565b-4454-bf54-5c5c77fa9e2b" xlink:href="ci-20231231.xsd#ci_SingleForeignCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_AllOtherCountriesMember_49de1e67-ff09-421e-98b9-00b30b464459" xlink:to="loc_ci_SingleForeignCountryMember_7b6dd258-565b-4454-bf54-5c5c77fa9e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_b3409ab9-2776-451e-a069-95762099b86d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c1b45832-dbd8-4c09-9c3e-b71fba583d50" xlink:to="loc_us-gaap_LossContingenciesLineItems_b3409ab9-2776-451e-a069-95762099b86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NonInvestmentRevenue_3dd0ebcf-77a2-475a-a17e-6e3b5a3f3eef" xlink:href="ci-20231231.xsd#ci_NonInvestmentRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b3409ab9-2776-451e-a069-95762099b86d" xlink:to="loc_ci_NonInvestmentRevenue_3dd0ebcf-77a2-475a-a17e-6e3b5a3f3eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DisposalGroupIncludingDiscontinuedOperationsNonInvestmentRevenue_b9bffd43-0d71-4abc-8ecd-7aa3ed79d895" xlink:href="ci-20231231.xsd#ci_DisposalGroupIncludingDiscontinuedOperationsNonInvestmentRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b3409ab9-2776-451e-a069-95762099b86d" xlink:to="loc_ci_DisposalGroupIncludingDiscontinuedOperationsNonInvestmentRevenue_b9bffd43-0d71-4abc-8ecd-7aa3ed79d895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_75e5193a-b039-4657-a4b5-e948c781ed6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b3409ab9-2776-451e-a069-95762099b86d" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_75e5193a-b039-4657-a4b5-e948c781ed6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/SegmentInformationRevenuesfromUSFederalGovernmentAgenciesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#SegmentInformationRevenuesfromUSFederalGovernmentAgenciesDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/SegmentInformationRevenuesfromUSFederalGovernmentAgenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_69246696-7ffb-4eba-896c-5348a1f59bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_8c729181-43f5-48dc-a4ea-fc543c28b4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_69246696-7ffb-4eba-896c-5348a1f59bd3" xlink:to="loc_us-gaap_ConcentrationRiskTable_8c729181-43f5-48dc-a4ea-fc543c28b4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_8dcbff0a-f0b6-435b-bd1b-43c83bad09cc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_8c729181-43f5-48dc-a4ea-fc543c28b4ae" xlink:to="loc_srt_MajorCustomersAxis_8dcbff0a-f0b6-435b-bd1b-43c83bad09cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ec0897d7-bb29-4c93-bdc4-0e540655f9d7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_8dcbff0a-f0b6-435b-bd1b-43c83bad09cc" xlink:to="loc_srt_NameOfMajorCustomerDomain_ec0897d7-bb29-4c93-bdc4-0e540655f9d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AnthemMember_c8a9b3d9-b279-4840-83d0-5250a3e123ed" xlink:href="ci-20231231.xsd#ci_AnthemMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ec0897d7-bb29-4c93-bdc4-0e540655f9d7" xlink:to="loc_ci_AnthemMember_c8a9b3d9-b279-4840-83d0-5250a3e123ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DepartmentOfDefenseMember_b311c806-d8e8-4d87-beba-2eb10eb4b40b" xlink:href="ci-20231231.xsd#ci_DepartmentOfDefenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ec0897d7-bb29-4c93-bdc4-0e540655f9d7" xlink:to="loc_ci_DepartmentOfDefenseMember_b311c806-d8e8-4d87-beba-2eb10eb4b40b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2dfa3ddf-fde6-401a-99f8-73142926f77f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_8c729181-43f5-48dc-a4ea-fc543c28b4ae" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2dfa3ddf-fde6-401a-99f8-73142926f77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0fff1237-ce8a-43e7-9b3b-45a829627c69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2dfa3ddf-fde6-401a-99f8-73142926f77f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0fff1237-ce8a-43e7-9b3b-45a829627c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_df96b8b2-0fef-4f8d-9f22-17f39805bb88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0fff1237-ce8a-43e7-9b3b-45a829627c69" xlink:to="loc_us-gaap_SalesRevenueNetMember_df96b8b2-0fef-4f8d-9f22-17f39805bb88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_b7289c0e-cf9a-46d1-ae84-a298710f04d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_8c729181-43f5-48dc-a4ea-fc543c28b4ae" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_b7289c0e-cf9a-46d1-ae84-a298710f04d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b3c33f50-682a-49d4-a378-1f0532a597b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b7289c0e-cf9a-46d1-ae84-a298710f04d5" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b3c33f50-682a-49d4-a378-1f0532a597b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_fdb1a7cd-6f03-43ab-93f9-700269f8ec77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_b3c33f50-682a-49d4-a378-1f0532a597b3" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_fdb1a7cd-6f03-43ab-93f9-700269f8ec77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_db86693c-60a8-4db2-b6d8-b8e614627a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_8c729181-43f5-48dc-a4ea-fc543c28b4ae" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_db86693c-60a8-4db2-b6d8-b8e614627a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_af9ca61e-7ca7-4d19-89bd-9bab0d83be2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_db86693c-60a8-4db2-b6d8-b8e614627a4e" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_af9ca61e-7ca7-4d19-89bd-9bab0d83be2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_d74069ee-6a17-4d79-b81e-43c29ff923e6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_822e001c-ea68-4a02-9957-a8366455fecf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_d74069ee-6a17-4d79-b81e-43c29ff923e6" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_822e001c-ea68-4a02-9957-a8366455fecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_6fe75eca-1a8b-40b4-b4e6-34aff379e26b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_822e001c-ea68-4a02-9957-a8366455fecf" xlink:to="loc_srt_ConsolidatedEntitiesAxis_6fe75eca-1a8b-40b4-b4e6-34aff379e26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_2a1280e7-536a-464d-9209-b1c65e47c3e3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_6fe75eca-1a8b-40b4-b4e6-34aff379e26b" xlink:to="loc_srt_ConsolidatedEntitiesDomain_2a1280e7-536a-464d-9209-b1c65e47c3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_a8fe39da-3e4b-43f8-b869-c83de79172a3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_2a1280e7-536a-464d-9209-b1c65e47c3e3" xlink:to="loc_srt_ParentCompanyMember_a8fe39da-3e4b-43f8-b869-c83de79172a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ef0d86c5-7e0a-43a7-a125-c21375ae328c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_822e001c-ea68-4a02-9957-a8366455fecf" xlink:to="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ef0d86c5-7e0a-43a7-a125-c21375ae328c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_0c122427-9dfd-4d3f-aadd-afbea48079b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ef0d86c5-7e0a-43a7-a125-c21375ae328c" xlink:to="loc_us-gaap_RevenuesAbstract_0c122427-9dfd-4d3f-aadd-afbea48079b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_4a03fe13-307e-4079-b889-3d77b722a55d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_0c122427-9dfd-4d3f-aadd-afbea48079b6" xlink:to="loc_us-gaap_NetInvestmentIncome_4a03fe13-307e-4079-b889-3d77b722a55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntercompanyInterestIncome_a4a4fe51-092b-4561-a101-7231b919717c" xlink:href="ci-20231231.xsd#ci_IntercompanyInterestIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_0c122427-9dfd-4d3f-aadd-afbea48079b6" xlink:to="loc_ci_IntercompanyInterestIncome_a4a4fe51-092b-4561-a101-7231b919717c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_74ba58a3-ac7e-4e1d-b2bd-5b4025d3c5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_0c122427-9dfd-4d3f-aadd-afbea48079b6" xlink:to="loc_us-gaap_Revenues_74ba58a3-ac7e-4e1d-b2bd-5b4025d3c5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_eacafdec-ae6c-4c8f-8c1d-5d171b6fa2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ef0d86c5-7e0a-43a7-a125-c21375ae328c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_eacafdec-ae6c-4c8f-8c1d-5d171b6fa2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b7b0ab56-aad8-4775-8b06-57150fc86969" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_eacafdec-ae6c-4c8f-8c1d-5d171b6fa2cb" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b7b0ab56-aad8-4775-8b06-57150fc86969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BenefitsLossesAndExpenses_13fd1b80-81f9-4253-8c9e-ef477b7fe630" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BenefitsLossesAndExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_eacafdec-ae6c-4c8f-8c1d-5d171b6fa2cb" xlink:to="loc_us-gaap_BenefitsLossesAndExpenses_13fd1b80-81f9-4253-8c9e-ef477b7fe630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4001e067-f825-4a33-b804-c6b2a85fe783" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ef0d86c5-7e0a-43a7-a125-c21375ae328c" xlink:to="loc_us-gaap_OperatingIncomeLoss_4001e067-f825-4a33-b804-c6b2a85fe783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_50cf0e69-92ee-40df-ab31-fb2f15c22068" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ef0d86c5-7e0a-43a7-a125-c21375ae328c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_50cf0e69-92ee-40df-ab31-fb2f15c22068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntercompanyInterestExpense_a97d90bb-245a-46b4-867d-6db94553286b" xlink:href="ci-20231231.xsd#ci_IntercompanyInterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ef0d86c5-7e0a-43a7-a125-c21375ae328c" xlink:to="loc_ci_IntercompanyInterestExpense_a97d90bb-245a-46b4-867d-6db94553286b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0a26c945-a728-43ee-aada-648726a95542" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ef0d86c5-7e0a-43a7-a125-c21375ae328c" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0a26c945-a728-43ee-aada-648726a95542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RealizedInvestmentGainLoss_fa5f6487-0be2-4090-98c7-3a2f1caeb07a" xlink:href="ci-20231231.xsd#ci_RealizedInvestmentGainLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ef0d86c5-7e0a-43a7-a125-c21375ae328c" xlink:to="loc_ci_RealizedInvestmentGainLoss_fa5f6487-0be2-4090-98c7-3a2f1caeb07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_618932cc-5796-4bb9-b821-9efbcfa54bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ef0d86c5-7e0a-43a7-a125-c21375ae328c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_618932cc-5796-4bb9-b821-9efbcfa54bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9680b972-0219-4d59-b07a-ef5f422eb1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ef0d86c5-7e0a-43a7-a125-c21375ae328c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9680b972-0219-4d59-b07a-ef5f422eb1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LossOfParentCompany_5d8969d2-c858-4911-a901-5809fa615f7c" xlink:href="ci-20231231.xsd#ci_LossOfParentCompany"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ef0d86c5-7e0a-43a7-a125-c21375ae328c" xlink:to="loc_ci_LossOfParentCompany_5d8969d2-c858-4911-a901-5809fa615f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_53ffdc6f-e367-4722-bdb8-ee2e0667250f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromSubsidiariesNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ef0d86c5-7e0a-43a7-a125-c21375ae328c" xlink:to="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_53ffdc6f-e367-4722-bdb8-ee2e0667250f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d46039a2-dcff-44e1-a29b-f185ef0b08e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ef0d86c5-7e0a-43a7-a125-c21375ae328c" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d46039a2-dcff-44e1-a29b-f185ef0b08e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_984083b9-e3f0-4dce-989f-3e786579434e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ef0d86c5-7e0a-43a7-a125-c21375ae328c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_984083b9-e3f0-4dce-989f-3e786579434e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_0a5fb7f5-25a9-4bf1-85c4-b67f650a7cec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_984083b9-e3f0-4dce-989f-3e786579434e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_0a5fb7f5-25a9-4bf1-85c4-b67f650a7cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent_e538178a-0545-41e2-a91b-11e11c8fdfc8" xlink:href="ci-20231231.xsd#ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_984083b9-e3f0-4dce-989f-3e786579434e" xlink:to="loc_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent_e538178a-0545-41e2-a91b-11e11c8fdfc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2202b6af-0148-4a24-8d72-ad71b2c5188d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_984083b9-e3f0-4dce-989f-3e786579434e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2202b6af-0148-4a24-8d72-ad71b2c5188d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_bff9e34a-c640-4927-9845-bf1db0a42272" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_984083b9-e3f0-4dce-989f-3e786579434e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_bff9e34a-c640-4927-9845-bf1db0a42272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_84828c32-be93-4559-8127-5bb466c85dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_984083b9-e3f0-4dce-989f-3e786579434e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_84828c32-be93-4559-8127-5bb466c85dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b43b8743-1e70-4eba-a875-657895983811" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_ef0d86c5-7e0a-43a7-a125-c21375ae328c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_b43b8743-1e70-4eba-a875-657895983811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_790b0f4e-45c5-4bc9-8ef1-7f046f5bcf5a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_e7aeb4ec-f2ec-4c8b-bc02-7ad53bd3bd75" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_790b0f4e-45c5-4bc9-8ef1-7f046f5bcf5a" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_e7aeb4ec-f2ec-4c8b-bc02-7ad53bd3bd75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_3884bd5a-0956-4155-a61a-f66e0ab69434" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_e7aeb4ec-f2ec-4c8b-bc02-7ad53bd3bd75" xlink:to="loc_srt_ConsolidatedEntitiesAxis_3884bd5a-0956-4155-a61a-f66e0ab69434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_008988c4-9310-4def-84c2-4ea96f8f780d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_3884bd5a-0956-4155-a61a-f66e0ab69434" xlink:to="loc_srt_ConsolidatedEntitiesDomain_008988c4-9310-4def-84c2-4ea96f8f780d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_daba0927-9609-4a8a-be34-6ffba006d119" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_008988c4-9310-4def-84c2-4ea96f8f780d" xlink:to="loc_srt_ParentCompanyMember_daba0927-9609-4a8a-be34-6ffba006d119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d984c454-b7b9-46b4-abf9-7540aaf2b9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_e7aeb4ec-f2ec-4c8b-bc02-7ad53bd3bd75" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d984c454-b7b9-46b4-abf9-7540aaf2b9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_628d1a5a-84f8-40db-ba54-4f0d5c208e90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d984c454-b7b9-46b4-abf9-7540aaf2b9e7" xlink:to="loc_us-gaap_RelatedPartyDomain_628d1a5a-84f8-40db-ba54-4f0d5c208e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_c24bc482-c300-416a-845d-61b4341b3063" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_628d1a5a-84f8-40db-ba54-4f0d5c208e90" xlink:to="loc_us-gaap_NonrelatedPartyMember_c24bc482-c300-416a-845d-61b4341b3063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_61abf133-bd23-4f1c-8418-d25cbce2add5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_628d1a5a-84f8-40db-ba54-4f0d5c208e90" xlink:to="loc_us-gaap_RelatedPartyMember_61abf133-bd23-4f1c-8418-d25cbce2add5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SubsidiariesMember_d4ca4c12-faae-454d-aa9d-02dbf3c7c5cc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyMember_61abf133-bd23-4f1c-8418-d25cbce2add5" xlink:to="loc_srt_SubsidiariesMember_d4ca4c12-faae-454d-aa9d-02dbf3c7c5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_9a68d313-64ab-4a39-838e-743fca482800" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_e7aeb4ec-f2ec-4c8b-bc02-7ad53bd3bd75" xlink:to="loc_srt_CondensedFinancialStatementsCaptionsLineItems_9a68d313-64ab-4a39-838e-743fca482800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_82a1e4ae-ae54-4b11-b88c-7215a6359423" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_9a68d313-64ab-4a39-838e-743fca482800" xlink:to="loc_us-gaap_AssetsAbstract_82a1e4ae-ae54-4b11-b88c-7215a6359423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f8be9b13-5b26-4ead-9300-81a63e1cc73c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_82a1e4ae-ae54-4b11-b88c-7215a6359423" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f8be9b13-5b26-4ead-9300-81a63e1cc73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_051b3cd3-58a8-4a50-9217-2a81a2b77d32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_82a1e4ae-ae54-4b11-b88c-7215a6359423" xlink:to="loc_us-gaap_ShortTermInvestments_051b3cd3-58a8-4a50-9217-2a81a2b77d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_95c81250-72f8-4e8e-b3d4-f7c256e0291b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_82a1e4ae-ae54-4b11-b88c-7215a6359423" xlink:to="loc_us-gaap_OtherAssetsCurrent_95c81250-72f8-4e8e-b3d4-f7c256e0291b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7f712f86-0b38-484f-88bd-a94a85b57051" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_82a1e4ae-ae54-4b11-b88c-7215a6359423" xlink:to="loc_us-gaap_AssetsCurrent_7f712f86-0b38-484f-88bd-a94a85b57051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndOtherNoncurrentAssets_5db8aa0a-e3fa-48de-a3aa-370091340b45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_82a1e4ae-ae54-4b11-b88c-7215a6359423" xlink:to="loc_us-gaap_InvestmentsAndOtherNoncurrentAssets_5db8aa0a-e3fa-48de-a3aa-370091340b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c386fe04-b023-497f-a6fd-d4ce78366834" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_82a1e4ae-ae54-4b11-b88c-7215a6359423" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c386fe04-b023-497f-a6fd-d4ce78366834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2686154d-2823-42da-85fb-86d3ad17f40c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_82a1e4ae-ae54-4b11-b88c-7215a6359423" xlink:to="loc_us-gaap_Assets_2686154d-2823-42da-85fb-86d3ad17f40c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_2bad65c9-e945-4756-9491-019d33cd7864" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_9a68d313-64ab-4a39-838e-743fca482800" xlink:to="loc_us-gaap_LiabilitiesAbstract_2bad65c9-e945-4756-9491-019d33cd7864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_15836f3e-f461-4277-abb8-70414ba137d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_2bad65c9-e945-4756-9491-019d33cd7864" xlink:to="loc_us-gaap_DebtCurrent_15836f3e-f461-4277-abb8-70414ba137d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_08ee9cd6-de64-4ef3-9316-09ec6ea52ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_2bad65c9-e945-4756-9491-019d33cd7864" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_08ee9cd6-de64-4ef3-9316-09ec6ea52ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3fa526e0-a7a9-46bc-9f35-e033761aa291" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_2bad65c9-e945-4756-9491-019d33cd7864" xlink:to="loc_us-gaap_LiabilitiesCurrent_3fa526e0-a7a9-46bc-9f35-e033761aa291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b0959a38-fd5f-4802-a132-5c6a965ad2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_2bad65c9-e945-4756-9491-019d33cd7864" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b0959a38-fd5f-4802-a132-5c6a965ad2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_303f3ab6-fdff-4190-930f-0aa2884199b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_2bad65c9-e945-4756-9491-019d33cd7864" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_303f3ab6-fdff-4190-930f-0aa2884199b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_716ad076-b13d-42d0-806d-e0129fcb5650" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_2bad65c9-e945-4756-9491-019d33cd7864" xlink:to="loc_us-gaap_Liabilities_716ad076-b13d-42d0-806d-e0129fcb5650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ShareholdersEquityAbstract_d6cb56ad-8561-4be9-a6f3-c1d3b2612915" xlink:href="ci-20231231.xsd#ci_ShareholdersEquityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_9a68d313-64ab-4a39-838e-743fca482800" xlink:to="loc_ci_ShareholdersEquityAbstract_d6cb56ad-8561-4be9-a6f3-c1d3b2612915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0b0b927e-b119-4531-864f-64db44ed13ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ShareholdersEquityAbstract_d6cb56ad-8561-4be9-a6f3-c1d3b2612915" xlink:to="loc_us-gaap_CommonStockValue_0b0b927e-b119-4531-864f-64db44ed13ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e483a4c8-43c2-4068-8535-ac0d10b7c7eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ShareholdersEquityAbstract_d6cb56ad-8561-4be9-a6f3-c1d3b2612915" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e483a4c8-43c2-4068-8535-ac0d10b7c7eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6bd0a0f2-a9cd-49f3-9629-fe2b68523691" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ShareholdersEquityAbstract_d6cb56ad-8561-4be9-a6f3-c1d3b2612915" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6bd0a0f2-a9cd-49f3-9629-fe2b68523691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5f4d6a03-9a78-4f3e-b202-9875b61c07e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ShareholdersEquityAbstract_d6cb56ad-8561-4be9-a6f3-c1d3b2612915" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5f4d6a03-9a78-4f3e-b202-9875b61c07e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_43ce0621-46a7-4d2c-ac86-79e8ca442a69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ShareholdersEquityAbstract_d6cb56ad-8561-4be9-a6f3-c1d3b2612915" xlink:to="loc_us-gaap_TreasuryStockValue_43ce0621-46a7-4d2c-ac86-79e8ca442a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8571610c-c6ba-4c85-b00c-36e782285ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_ShareholdersEquityAbstract_d6cb56ad-8561-4be9-a6f3-c1d3b2612915" xlink:to="loc_us-gaap_StockholdersEquity_8571610c-c6ba-4c85-b00c-36e782285ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ad82950f-a488-436e-84ab-02e46258e41a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_9a68d313-64ab-4a39-838e-743fca482800" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ad82950f-a488-436e-84ab-02e46258e41a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_6dbf5cf5-1265-44dc-9780-98f3a15e08ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_9a68d313-64ab-4a39-838e-743fca482800" xlink:to="loc_us-gaap_CommonStockSharesIssued_6dbf5cf5-1265-44dc-9780-98f3a15e08ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ac544a62-b6c9-48a7-a192-f86433ce39d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_9a68d313-64ab-4a39-838e-743fca482800" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ac544a62-b6c9-48a7-a192-f86433ce39d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_93c00400-21ae-49b9-96e7-4a02d5d17bbb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_9b19d6ad-a64a-44ad-822d-ed064e46b4c2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_93c00400-21ae-49b9-96e7-4a02d5d17bbb" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_9b19d6ad-a64a-44ad-822d-ed064e46b4c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_e24e475b-f836-4075-b4e2-a7a0fc2d20a5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_9b19d6ad-a64a-44ad-822d-ed064e46b4c2" xlink:to="loc_srt_ConsolidatedEntitiesAxis_e24e475b-f836-4075-b4e2-a7a0fc2d20a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_367d9b81-638d-4267-96fd-4473bdb6ccc6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_e24e475b-f836-4075-b4e2-a7a0fc2d20a5" xlink:to="loc_srt_ConsolidatedEntitiesDomain_367d9b81-638d-4267-96fd-4473bdb6ccc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_a163478c-09f8-426e-b248-5478c3026267" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_367d9b81-638d-4267-96fd-4473bdb6ccc6" xlink:to="loc_srt_ParentCompanyMember_a163478c-09f8-426e-b248-5478c3026267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6536d45f-4d9a-4d9d-b0d4-a288bcfd52a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_9b19d6ad-a64a-44ad-822d-ed064e46b4c2" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6536d45f-4d9a-4d9d-b0d4-a288bcfd52a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e73594bb-c0a7-4d79-95e3-1a69beb752fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6536d45f-4d9a-4d9d-b0d4-a288bcfd52a3" xlink:to="loc_us-gaap_RelatedPartyDomain_e73594bb-c0a7-4d79-95e3-1a69beb752fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_b691af29-9a06-46e6-9a36-94cbd3e10999" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_e73594bb-c0a7-4d79-95e3-1a69beb752fd" xlink:to="loc_us-gaap_NonrelatedPartyMember_b691af29-9a06-46e6-9a36-94cbd3e10999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_91d22520-0744-425c-9922-24047f7add63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_e73594bb-c0a7-4d79-95e3-1a69beb752fd" xlink:to="loc_us-gaap_RelatedPartyMember_91d22520-0744-425c-9922-24047f7add63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SubsidiariesMember_81113dbb-bdba-45fb-8a9a-31ef04daa1c2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyMember_91d22520-0744-425c-9922-24047f7add63" xlink:to="loc_srt_SubsidiariesMember_81113dbb-bdba-45fb-8a9a-31ef04daa1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7983508b-6996-48f4-bca4-28296bffdf40" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_9b19d6ad-a64a-44ad-822d-ed064e46b4c2" xlink:to="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7983508b-6996-48f4-bca4-28296bffdf40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ce11e329-996a-4f80-b8f5-5951671f722b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7983508b-6996-48f4-bca4-28296bffdf40" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ce11e329-996a-4f80-b8f5-5951671f722b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_902b11ed-f0c0-4775-aa8d-28a1cfa51f87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ce11e329-996a-4f80-b8f5-5951671f722b" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_902b11ed-f0c0-4775-aa8d-28a1cfa51f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d388704f-0ec7-45b8-9375-cddd5fb27742" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ce11e329-996a-4f80-b8f5-5951671f722b" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d388704f-0ec7-45b8-9375-cddd5fb27742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_796e2501-7717-4f59-811d-fe6ee76cb53f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromSubsidiariesNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d388704f-0ec7-45b8-9375-cddd5fb27742" xlink:to="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_796e2501-7717-4f59-811d-fe6ee76cb53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_05454add-ba3b-4c3e-b0cb-ac492b99b4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d388704f-0ec7-45b8-9375-cddd5fb27742" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_05454add-ba3b-4c3e-b0cb-ac492b99b4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries_1674f337-9b78-402b-9c35-d095d4b25ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d388704f-0ec7-45b8-9375-cddd5fb27742" xlink:to="loc_us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries_1674f337-9b78-402b-9c35-d095d4b25ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities_19606547-71b9-4a38-adba-f23e9ea60dcd" xlink:href="ci-20231231.xsd#ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d388704f-0ec7-45b8-9375-cddd5fb27742" xlink:to="loc_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities_19606547-71b9-4a38-adba-f23e9ea60dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_c47e6371-e6f5-487a-802a-28632b440c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d388704f-0ec7-45b8-9375-cddd5fb27742" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_c47e6371-e6f5-487a-802a-28632b440c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a71248a-45e8-4e4b-96a2-b5524e390202" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ce11e329-996a-4f80-b8f5-5951671f722b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a71248a-45e8-4e4b-96a2-b5524e390202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_397f03c4-e4d4-4917-b251-275fcca95a57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7983508b-6996-48f4-bca4-28296bffdf40" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_397f03c4-e4d4-4917-b251-275fcca95a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IncreaseDecreaseInAmountsDueFromAffiliates_b636c96d-1f5f-4a1c-af6d-84ca8f14baae" xlink:href="ci-20231231.xsd#ci_IncreaseDecreaseInAmountsDueFromAffiliates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_397f03c4-e4d4-4917-b251-275fcca95a57" xlink:to="loc_ci_IncreaseDecreaseInAmountsDueFromAffiliates_b636c96d-1f5f-4a1c-af6d-84ca8f14baae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_5c005ee0-a364-41ee-b46e-b6dd4e03ad1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_397f03c4-e4d4-4917-b251-275fcca95a57" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_5c005ee0-a364-41ee-b46e-b6dd4e03ad1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9689a92f-1bc9-4806-b76a-11257c6e4f19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_397f03c4-e4d4-4917-b251-275fcca95a57" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9689a92f-1bc9-4806-b76a-11257c6e4f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dad29f47-16c3-48ff-9392-07527555cf9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7983508b-6996-48f4-bca4-28296bffdf40" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dad29f47-16c3-48ff-9392-07527555cf9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_1e2fb9f6-12b9-4b33-b347-90bc9468ca76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dad29f47-16c3-48ff-9392-07527555cf9d" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_1e2fb9f6-12b9-4b33-b347-90bc9468ca76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_65dcc118-6c80-48da-bf26-7e3e847d63b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dad29f47-16c3-48ff-9392-07527555cf9d" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_65dcc118-6c80-48da-bf26-7e3e847d63b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_28946d72-62a0-4eb2-a89a-0b5e96a0d855" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dad29f47-16c3-48ff-9392-07527555cf9d" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_28946d72-62a0-4eb2-a89a-0b5e96a0d855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_b09427b2-2f9d-4e40-bb33-bb80266c1a78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dad29f47-16c3-48ff-9392-07527555cf9d" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_b09427b2-2f9d-4e40-bb33-bb80266c1a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_5dcfcc7f-dd22-48d9-afb4-08433564603c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dad29f47-16c3-48ff-9392-07527555cf9d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_5dcfcc7f-dd22-48d9-afb4-08433564603c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ac4b4223-bd03-4726-846a-fc737fc6e38c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dad29f47-16c3-48ff-9392-07527555cf9d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ac4b4223-bd03-4726-846a-fc737fc6e38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_ba907e22-f47d-4b31-8c19-6bc311a8e235" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dad29f47-16c3-48ff-9392-07527555cf9d" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_ba907e22-f47d-4b31-8c19-6bc311a8e235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d7efeb5f-68fe-452d-9887-1d6522fff9af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dad29f47-16c3-48ff-9392-07527555cf9d" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d7efeb5f-68fe-452d-9887-1d6522fff9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_abca783f-d258-4746-8538-86c33548cfb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dad29f47-16c3-48ff-9392-07527555cf9d" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_abca783f-d258-4746-8538-86c33548cfb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0db98a0f-4c96-439d-b59b-108552bb886f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dad29f47-16c3-48ff-9392-07527555cf9d" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0db98a0f-4c96-439d-b59b-108552bb886f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_eed66d96-d9b2-4548-b860-120a90e718c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_dad29f47-16c3-48ff-9392-07527555cf9d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_eed66d96-d9b2-4548-b860-120a90e718c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_eb3ff58e-5edd-47fc-a601-0452e0c978c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7983508b-6996-48f4-bca4-28296bffdf40" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_eb3ff58e-5edd-47fc-a601-0452e0c978c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3b749033-fd8c-4087-9fd1-34329217b8b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7983508b-6996-48f4-bca4-28296bffdf40" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3b749033-fd8c-4087-9fd1-34329217b8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5d34f720-ca07-4ddb-bcb4-6d30872ad51c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7983508b-6996-48f4-bca4-28296bffdf40" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5d34f720-ca07-4ddb-bcb4-6d30872ad51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReduction_a5b225ee-6db0-4aca-b6a7-c45e0829502e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesReduction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7983508b-6996-48f4-bca4-28296bffdf40" xlink:to="loc_us-gaap_NotesReduction_a5b225ee-6db0-4aca-b6a7-c45e0829502e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_3f3a1380-6415-4143-9cfc-6c5f5c1fb57f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_c0984e01-adf3-4cc3-9367-991817129903" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_3f3a1380-6415-4143-9cfc-6c5f5c1fb57f" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_c0984e01-adf3-4cc3-9367-991817129903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_e728ac71-a878-48d7-9cb3-2bfa1713ad46" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_c0984e01-adf3-4cc3-9367-991817129903" xlink:to="loc_srt_ConsolidatedEntitiesAxis_e728ac71-a878-48d7-9cb3-2bfa1713ad46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_90852a49-a395-43d4-8b33-bd96b76d3f75" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_e728ac71-a878-48d7-9cb3-2bfa1713ad46" xlink:to="loc_srt_ConsolidatedEntitiesDomain_90852a49-a395-43d4-8b33-bd96b76d3f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_f3b64acb-dd21-4bcd-8e48-53bc4a134216" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_90852a49-a395-43d4-8b33-bd96b76d3f75" xlink:to="loc_srt_ParentCompanyMember_f3b64acb-dd21-4bcd-8e48-53bc4a134216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_dac02865-e8f8-41c9-b0fc-23ae33828bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_c0984e01-adf3-4cc3-9367-991817129903" xlink:to="loc_us-gaap_DebtInstrumentAxis_dac02865-e8f8-41c9-b0fc-23ae33828bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f151a95f-9479-4efc-a161-d4ef67378aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_dac02865-e8f8-41c9-b0fc-23ae33828bcb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f151a95f-9479-4efc-a161-d4ef67378aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RevolvingCreditAgreementsApril2023Member_d792033f-443c-4033-9807-405341196503" xlink:href="ci-20231231.xsd#ci_RevolvingCreditAgreementsApril2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f151a95f-9479-4efc-a161-d4ef67378aa9" xlink:to="loc_ci_RevolvingCreditAgreementsApril2023Member_d792033f-443c-4033-9807-405341196503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member_6f8ff458-f6d3-4934-89c3-f097e36c9426" xlink:href="ci-20231231.xsd#ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_RevolvingCreditAgreementsApril2023Member_d792033f-443c-4033-9807-405341196503" xlink:to="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member_6f8ff458-f6d3-4934-89c3-f097e36c9426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_A364DayRevolvingCreditAgreementMaturingApril2024Member_8212c99e-d8b7-486a-9d42-f8b03cf1cbe3" xlink:href="ci-20231231.xsd#ci_A364DayRevolvingCreditAgreementMaturingApril2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_RevolvingCreditAgreementsApril2023Member_d792033f-443c-4033-9807-405341196503" xlink:to="loc_ci_A364DayRevolvingCreditAgreementMaturingApril2024Member_8212c99e-d8b7-486a-9d42-f8b03cf1cbe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member_d869a9a0-e9c7-4900-8939-b05c7d7f639d" xlink:href="ci-20231231.xsd#ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f151a95f-9479-4efc-a161-d4ef67378aa9" xlink:to="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member_d869a9a0-e9c7-4900-8939-b05c7d7f639d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member_9489e6dc-d49e-4035-8d68-059a99802581" xlink:href="ci-20231231.xsd#ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member_d869a9a0-e9c7-4900-8939-b05c7d7f639d" xlink:to="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member_9489e6dc-d49e-4035-8d68-059a99802581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RevolvingCreditFacilityMaturingApril2025Member_18cd1097-db71-43b6-9ef2-43a369d241b2" xlink:href="ci-20231231.xsd#ci_RevolvingCreditFacilityMaturingApril2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member_d869a9a0-e9c7-4900-8939-b05c7d7f639d" xlink:to="loc_ci_RevolvingCreditFacilityMaturingApril2025Member_18cd1097-db71-43b6-9ef2-43a369d241b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_A364DayRevolvingCreditAgreementMaturingApril2023Member_04d297b9-03df-4675-9d18-313d679cfebd" xlink:href="ci-20231231.xsd#ci_A364DayRevolvingCreditAgreementMaturingApril2023Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member_d869a9a0-e9c7-4900-8939-b05c7d7f639d" xlink:to="loc_ci_A364DayRevolvingCreditAgreementMaturingApril2023Member_04d297b9-03df-4675-9d18-313d679cfebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_388cdad5-618c-4661-81c3-e8106567cd77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_c0984e01-adf3-4cc3-9367-991817129903" xlink:to="loc_us-gaap_CreditFacilityAxis_388cdad5-618c-4661-81c3-e8106567cd77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_abaeb070-f0d2-4524-bc32-bfa67beba4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_388cdad5-618c-4661-81c3-e8106567cd77" xlink:to="loc_us-gaap_CreditFacilityDomain_abaeb070-f0d2-4524-bc32-bfa67beba4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_d15b0cab-5bbe-4864-a6d3-11aacebe3d80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_abaeb070-f0d2-4524-bc32-bfa67beba4b5" xlink:to="loc_us-gaap_LetterOfCreditMember_d15b0cab-5bbe-4864-a6d3-11aacebe3d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_3377a6c2-b9c8-46a8-946a-6d908e52742a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_abaeb070-f0d2-4524-bc32-bfa67beba4b5" xlink:to="loc_us-gaap_CommercialPaperMember_3377a6c2-b9c8-46a8-946a-6d908e52742a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_cd4fceb5-8e5c-4e70-9c75-38c1c9ab3666" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_c0984e01-adf3-4cc3-9367-991817129903" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_cd4fceb5-8e5c-4e70-9c75-38c1c9ab3666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_a5407bc1-214c-4a93-b713-75a74c285585" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_cd4fceb5-8e5c-4e70-9c75-38c1c9ab3666" xlink:to="loc_us-gaap_LineOfCredit_a5407bc1-214c-4a93-b713-75a74c285585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_900ee688-59e6-414d-9717-60a4fa8e5b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_cd4fceb5-8e5c-4e70-9c75-38c1c9ab3666" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_900ee688-59e6-414d-9717-60a4fa8e5b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_c9a31589-c526-4e29-9929-ed41c4b86933" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_cd4fceb5-8e5c-4e70-9c75-38c1c9ab3666" xlink:to="loc_us-gaap_DebtInstrumentTerm_c9a31589-c526-4e29-9929-ed41c4b86933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtInstrumentExtensionTerm_ef4c29b0-8d29-4007-aaf1-c286dc16e76d" xlink:href="ci-20231231.xsd#ci_DebtInstrumentExtensionTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_cd4fceb5-8e5c-4e70-9c75-38c1c9ab3666" xlink:to="loc_ci_DebtInstrumentExtensionTerm_ef4c29b0-8d29-4007-aaf1-c286dc16e76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LineOfCreditFacilityConversionToTermLoanTerm_6b4a2a6f-1bd7-461f-9113-6295eb44f9e7" xlink:href="ci-20231231.xsd#ci_LineOfCreditFacilityConversionToTermLoanTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_cd4fceb5-8e5c-4e70-9c75-38c1c9ab3666" xlink:to="loc_ci_LineOfCreditFacilityConversionToTermLoanTerm_6b4a2a6f-1bd7-461f-9113-6295eb44f9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity_20e5f11d-ea7d-4f0d-a92b-a2b26eba56cf" xlink:href="ci-20231231.xsd#ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_cd4fceb5-8e5c-4e70-9c75-38c1c9ab3666" xlink:to="loc_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity_20e5f11d-ea7d-4f0d-a92b-a2b26eba56cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity_95a34650-adc7-4373-9f3f-e35d36034d62" xlink:href="ci-20231231.xsd#ci_LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_cd4fceb5-8e5c-4e70-9c75-38c1c9ab3666" xlink:to="loc_ci_LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity_95a34650-adc7-4373-9f3f-e35d36034d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement_79d967a0-ab8e-46bf-8b97-c9344863f5ff" xlink:href="ci-20231231.xsd#ci_NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_cd4fceb5-8e5c-4e70-9c75-38c1c9ab3666" xlink:to="loc_ci_NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement_79d967a0-ab8e-46bf-8b97-c9344863f5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant_1042e0ff-55e6-4ef1-8587-6e4718992f9b" xlink:href="ci-20231231.xsd#ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_cd4fceb5-8e5c-4e70-9c75-38c1c9ab3666" xlink:to="loc_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant_1042e0ff-55e6-4ef1-8587-6e4718992f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CommercialPaperAverageRatePaid_5f6b2acc-8c4f-4a16-9ac3-5c040d41210a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CommercialPaperAverageRatePaid"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_cd4fceb5-8e5c-4e70-9c75-38c1c9ab3666" xlink:to="loc_srt_CommercialPaperAverageRatePaid_5f6b2acc-8c4f-4a16-9ac3-5c040d41210a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_bb8c194f-112f-4c1d-a579-6d17141115d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6ca32003-39ab-447d-8366-f07c5d687d10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bb8c194f-112f-4c1d-a579-6d17141115d3" xlink:to="loc_us-gaap_DebtInstrumentTable_6ca32003-39ab-447d-8366-f07c5d687d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_92ad50b3-ec9b-4f81-b29c-280375fbda50" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6ca32003-39ab-447d-8366-f07c5d687d10" xlink:to="loc_srt_ConsolidatedEntitiesAxis_92ad50b3-ec9b-4f81-b29c-280375fbda50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_b8e0cc6c-dfb5-4d22-b357-87fccde5e058" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_92ad50b3-ec9b-4f81-b29c-280375fbda50" xlink:to="loc_srt_ConsolidatedEntitiesDomain_b8e0cc6c-dfb5-4d22-b357-87fccde5e058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_eb2fab26-637a-4d2d-ab10-a3ddbf7fb6da" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_b8e0cc6c-dfb5-4d22-b357-87fccde5e058" xlink:to="loc_srt_ParentCompanyMember_eb2fab26-637a-4d2d-ab10-a3ddbf7fb6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c69c4ad0-721d-4fd7-8b97-0a8b15269bce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6ca32003-39ab-447d-8366-f07c5d687d10" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c69c4ad0-721d-4fd7-8b97-0a8b15269bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_eb776046-ff0e-4e23-9fb3-ef7954044330" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c69c4ad0-721d-4fd7-8b97-0a8b15269bce" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_eb776046-ff0e-4e23-9fb3-ef7954044330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_07d6365f-6939-402b-80cd-1398363c0404" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_eb776046-ff0e-4e23-9fb3-ef7954044330" xlink:to="loc_us-gaap_SeniorNotesMember_07d6365f-6939-402b-80cd-1398363c0404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_39e82ce3-6ded-4bcc-bf3d-4a8c72de158e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6ca32003-39ab-447d-8366-f07c5d687d10" xlink:to="loc_us-gaap_DebtInstrumentAxis_39e82ce3-6ded-4bcc-bf3d-4a8c72de158e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_817cce55-81ad-41a8-9717-8ba62a239c09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_39e82ce3-6ded-4bcc-bf3d-4a8c72de158e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_817cce55-81ad-41a8-9717-8ba62a239c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20265685Member_bd359382-f69d-4383-a878-b463cf875de0" xlink:href="ci-20231231.xsd#ci_NotesDue20265685Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_817cce55-81ad-41a8-9717-8ba62a239c09" xlink:to="loc_ci_NotesDue20265685Member_bd359382-f69d-4383-a878-b463cf875de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue20335400InterestMember_c5dded23-8d94-4eb2-9a40-27c5d3068be9" xlink:href="ci-20231231.xsd#ci_NotesDue20335400InterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_817cce55-81ad-41a8-9717-8ba62a239c09" xlink:to="loc_ci_NotesDue20335400InterestMember_c5dded23-8d94-4eb2-9a40-27c5d3068be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_NotesDue202435InterestMember_53dccdba-f8da-445e-85f7-6755382ef93f" xlink:href="ci-20231231.xsd#ci_NotesDue202435InterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_817cce55-81ad-41a8-9717-8ba62a239c09" xlink:to="loc_ci_NotesDue202435InterestMember_53dccdba-f8da-445e-85f7-6755382ef93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_7fb39523-c25c-4c46-ac1b-f2f04cc644f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6ca32003-39ab-447d-8366-f07c5d687d10" xlink:to="loc_us-gaap_VariableRateAxis_7fb39523-c25c-4c46-ac1b-f2f04cc644f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_8808cf23-711d-482d-9cc6-6ce75795f467" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_7fb39523-c25c-4c46-ac1b-f2f04cc644f6" xlink:to="loc_us-gaap_VariableRateDomain_8808cf23-711d-482d-9cc6-6ce75795f467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UsTreasuryUstInterestRateMember_3dae3e84-e6d5-4347-b398-9060f425ac8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UsTreasuryUstInterestRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_8808cf23-711d-482d-9cc6-6ce75795f467" xlink:to="loc_us-gaap_UsTreasuryUstInterestRateMember_3dae3e84-e6d5-4347-b398-9060f425ac8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a45d101c-de46-4c31-9228-bc79241c6146" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6ca32003-39ab-447d-8366-f07c5d687d10" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a45d101c-de46-4c31-9228-bc79241c6146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_64d2b8a0-4e76-4249-8e0c-dfdf68f64dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a45d101c-de46-4c31-9228-bc79241c6146" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_64d2b8a0-4e76-4249-8e0c-dfdf68f64dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_4f6bea70-7195-4f64-8270-5ee4de8aceaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_64d2b8a0-4e76-4249-8e0c-dfdf68f64dd8" xlink:to="loc_us-gaap_SubsequentEventMember_4f6bea70-7195-4f64-8270-5ee4de8aceaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_234f645c-20c4-4b5a-9a42-8602f96a5220" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6ca32003-39ab-447d-8366-f07c5d687d10" xlink:to="loc_srt_StatementScenarioAxis_234f645c-20c4-4b5a-9a42-8602f96a5220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_37737e2e-6c3a-4f50-a8f2-e71321555f7f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_234f645c-20c4-4b5a-9a42-8602f96a5220" xlink:to="loc_srt_ScenarioUnspecifiedDomain_37737e2e-6c3a-4f50-a8f2-e71321555f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_a2ff735c-5d50-48ab-b06f-0541f725bfee" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_37737e2e-6c3a-4f50-a8f2-e71321555f7f" xlink:to="loc_srt_ScenarioForecastMember_a2ff735c-5d50-48ab-b06f-0541f725bfee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4e4cc760-ed20-49b7-8ae3-85dbdd35ecb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6ca32003-39ab-447d-8366-f07c5d687d10" xlink:to="loc_us-gaap_DebtInstrumentLineItems_4e4cc760-ed20-49b7-8ae3-85dbdd35ecb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_99395926-f663-46b7-9ee8-a1c68ba542bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e4cc760-ed20-49b7-8ae3-85dbdd35ecb8" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_99395926-f663-46b7-9ee8-a1c68ba542bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees_9c83fbba-fc1b-4f17-803c-cf94a8a96a6b" xlink:href="ci-20231231.xsd#ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e4cc760-ed20-49b7-8ae3-85dbdd35ecb8" xlink:to="loc_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees_9c83fbba-fc1b-4f17-803c-cf94a8a96a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8e9312bd-2a96-4120-940b-ee48a50254a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e4cc760-ed20-49b7-8ae3-85dbdd35ecb8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8e9312bd-2a96-4120-940b-ee48a50254a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate_582fc862-15da-4214-9c72-3465966fa3c7" xlink:href="ci-20231231.xsd#ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e4cc760-ed20-49b7-8ae3-85dbdd35ecb8" xlink:to="loc_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate_582fc862-15da-4214-9c72-3465966fa3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_4160e017-abc6-437a-ad47-f34111160822" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e4cc760-ed20-49b7-8ae3-85dbdd35ecb8" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_4160e017-abc6-437a-ad47-f34111160822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6fef36cb-1df1-44e4-9b03-11a524683f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e4cc760-ed20-49b7-8ae3-85dbdd35ecb8" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6fef36cb-1df1-44e4-9b03-11a524683f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_GainLossOnExtinguishmentOfDebtNetOfTax_3b01df75-0157-4bc1-971f-b41384060178" xlink:href="ci-20231231.xsd#ci_GainLossOnExtinguishmentOfDebtNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e4cc760-ed20-49b7-8ae3-85dbdd35ecb8" xlink:to="loc_ci_GainLossOnExtinguishmentOfDebtNetOfTax_3b01df75-0157-4bc1-971f-b41384060178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_95f3d88e-54c3-4e96-bb46-225b8e5c4bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e4cc760-ed20-49b7-8ae3-85dbdd35ecb8" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_95f3d88e-54c3-4e96-bb46-225b8e5c4bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_799dc15d-a74f-413f-a85d-e2b152fe8b35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4e4cc760-ed20-49b7-8ae3-85dbdd35ecb8" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_799dc15d-a74f-413f-a85d-e2b152fe8b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupDebtMaturitiesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#ScheduleICondensedFinancialInformationofTheCignaGroupDebtMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupDebtMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_aa5cd71c-90e1-47c2-8973-bec400e65e86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a3880b97-9f1f-4a8a-9123-242c3b6e6b02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_aa5cd71c-90e1-47c2-8973-bec400e65e86" xlink:to="loc_us-gaap_DebtInstrumentTable_a3880b97-9f1f-4a8a-9123-242c3b6e6b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_abd4be00-bf83-4b5f-a8f2-16f2ed267240" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a3880b97-9f1f-4a8a-9123-242c3b6e6b02" xlink:to="loc_srt_ConsolidatedEntitiesAxis_abd4be00-bf83-4b5f-a8f2-16f2ed267240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_c069de4d-d2df-43b2-9bcd-529fb856fac1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_abd4be00-bf83-4b5f-a8f2-16f2ed267240" xlink:to="loc_srt_ConsolidatedEntitiesDomain_c069de4d-d2df-43b2-9bcd-529fb856fac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_5029f2b2-7ef3-4282-9229-c0325e4b621d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_c069de4d-d2df-43b2-9bcd-529fb856fac1" xlink:to="loc_srt_ParentCompanyMember_5029f2b2-7ef3-4282-9229-c0325e4b621d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_eca782d3-a6f5-4b0c-b518-eacf99a2156f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a3880b97-9f1f-4a8a-9123-242c3b6e6b02" xlink:to="loc_us-gaap_DebtInstrumentLineItems_eca782d3-a6f5-4b0c-b518-eacf99a2156f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_30fc31e1-2bf0-4c18-a125-2b7c650568b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_eca782d3-a6f5-4b0c-b518-eacf99a2156f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_30fc31e1-2bf0-4c18-a125-2b7c650568b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_00a5e940-a7d3-4409-900a-323117b0fcc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_eca782d3-a6f5-4b0c-b518-eacf99a2156f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_00a5e940-a7d3-4409-900a-323117b0fcc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_07aa2b3e-97e5-4ff7-835c-f988d2ec3166" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_eca782d3-a6f5-4b0c-b518-eacf99a2156f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_07aa2b3e-97e5-4ff7-835c-f988d2ec3166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_12cf8241-1712-43eb-ae13-975de2374b36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_eca782d3-a6f5-4b0c-b518-eacf99a2156f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_12cf8241-1712-43eb-ae13-975de2374b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_8efae55a-79f8-4d32-b71c-291d04fab503" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_eca782d3-a6f5-4b0c-b518-eacf99a2156f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_8efae55a-79f8-4d32-b71c-291d04fab503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_ce1a3192-04cd-4f44-9ab9-1cff3111ee2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_eca782d3-a6f5-4b0c-b518-eacf99a2156f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_ce1a3192-04cd-4f44-9ab9-1cff3111ee2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupIntercompanyBalancesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#ScheduleICondensedFinancialInformationofTheCignaGroupIntercompanyBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupIntercompanyBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_5f0933fb-2695-4c02-8f71-c89699dfb6a8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_e35d1d5d-a05b-40ca-9017-6fafab8b5f22" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_5f0933fb-2695-4c02-8f71-c89699dfb6a8" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_e35d1d5d-a05b-40ca-9017-6fafab8b5f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_15ed9696-aed6-422c-92a4-46e55e6e6627" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_e35d1d5d-a05b-40ca-9017-6fafab8b5f22" xlink:to="loc_srt_ConsolidatedEntitiesAxis_15ed9696-aed6-422c-92a4-46e55e6e6627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_7ad3c118-ad09-4822-9568-e38eead40267" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_15ed9696-aed6-422c-92a4-46e55e6e6627" xlink:to="loc_srt_ConsolidatedEntitiesDomain_7ad3c118-ad09-4822-9568-e38eead40267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_d43082ee-94a5-4189-b5af-0cb3b5efa4b1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_7ad3c118-ad09-4822-9568-e38eead40267" xlink:to="loc_srt_ParentCompanyMember_d43082ee-94a5-4189-b5af-0cb3b5efa4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_84859e49-31ef-43a4-a9c9-ce9e0572d8e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_e35d1d5d-a05b-40ca-9017-6fafab8b5f22" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_84859e49-31ef-43a4-a9c9-ce9e0572d8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_55b438ff-83aa-4149-b4b5-cb1592291e34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_84859e49-31ef-43a4-a9c9-ce9e0572d8e6" xlink:to="loc_us-gaap_RelatedPartyDomain_55b438ff-83aa-4149-b4b5-cb1592291e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_6d6abf18-7442-4504-b764-1bc55e0f7321" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_55b438ff-83aa-4149-b4b5-cb1592291e34" xlink:to="loc_us-gaap_NonrelatedPartyMember_6d6abf18-7442-4504-b764-1bc55e0f7321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_e032240b-cda4-4875-aaa1-10ad83f83a09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_55b438ff-83aa-4149-b4b5-cb1592291e34" xlink:to="loc_us-gaap_RelatedPartyMember_e032240b-cda4-4875-aaa1-10ad83f83a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SubsidiariesMember_a6c23ba8-8812-40ad-9ee5-e5780a6e36ce" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyMember_e032240b-cda4-4875-aaa1-10ad83f83a09" xlink:to="loc_srt_SubsidiariesMember_a6c23ba8-8812-40ad-9ee5-e5780a6e36ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_EvernorthHealthIncorporatedMember_bafafa55-01fb-4500-8543-1fe590bc2239" xlink:href="ci-20231231.xsd#ci_EvernorthHealthIncorporatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SubsidiariesMember_a6c23ba8-8812-40ad-9ee5-e5780a6e36ce" xlink:to="loc_ci_EvernorthHealthIncorporatedMember_bafafa55-01fb-4500-8543-1fe590bc2239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_ThreeWhollyOwnedSubsidiariesMember_69269e6f-6717-463f-82c2-5c10aea7183f" xlink:href="ci-20231231.xsd#ci_ThreeWhollyOwnedSubsidiariesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SubsidiariesMember_a6c23ba8-8812-40ad-9ee5-e5780a6e36ce" xlink:to="loc_ci_ThreeWhollyOwnedSubsidiariesMember_69269e6f-6717-463f-82c2-5c10aea7183f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_cb892534-3baf-427b-bf5b-4c3eadbad43a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_e35d1d5d-a05b-40ca-9017-6fafab8b5f22" xlink:to="loc_srt_CondensedFinancialStatementsCaptionsLineItems_cb892534-3baf-427b-bf5b-4c3eadbad43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_4863b634-8c04-42c5-a2bb-e3f6f1418b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_cb892534-3baf-427b-bf5b-4c3eadbad43a" xlink:to="loc_us-gaap_OtherAssetsCurrent_4863b634-8c04-42c5-a2bb-e3f6f1418b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_IntercompanyReceivablesInterestRate_6f29d92f-78e2-44b3-87e5-d78752153d6d" xlink:href="ci-20231231.xsd#ci_IntercompanyReceivablesInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_cb892534-3baf-427b-bf5b-4c3eadbad43a" xlink:to="loc_ci_IntercompanyReceivablesInterestRate_6f29d92f-78e2-44b3-87e5-d78752153d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_AverageInterestRateOnIntercompanyLoan_d9b75563-b658-4d4f-a870-334965b1938b" xlink:href="ci-20231231.xsd#ci_AverageInterestRateOnIntercompanyLoan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_cb892534-3baf-427b-bf5b-4c3eadbad43a" xlink:to="loc_ci_AverageInterestRateOnIntercompanyLoan_d9b75563-b658-4d4f-a870-334965b1938b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_DueFromAffiliateNoncurrentNet_8ea56a33-49e3-41c8-b8aa-283146895093" xlink:href="ci-20231231.xsd#ci_DueFromAffiliateNoncurrentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_cb892534-3baf-427b-bf5b-4c3eadbad43a" xlink:to="loc_ci_DueFromAffiliateNoncurrentNet_8ea56a33-49e3-41c8-b8aa-283146895093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupGuaranteesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#ScheduleICondensedFinancialInformationofTheCignaGroupGuaranteesDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupGuaranteesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_ae7eb7a5-3ca9-4877-9a47-18bf58e9e37b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_0953086c-4431-4998-8bdf-3d546e5cd721" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGuaranteeObligationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_ae7eb7a5-3ca9-4877-9a47-18bf58e9e37b" xlink:to="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_0953086c-4431-4998-8bdf-3d546e5cd721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_42f5622f-a48c-48bf-b867-9de82888e419" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_0953086c-4431-4998-8bdf-3d546e5cd721" xlink:to="loc_srt_ConsolidatedEntitiesAxis_42f5622f-a48c-48bf-b867-9de82888e419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_9157f396-cd3f-4e9a-9d2d-cf2f24cf2e76" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_42f5622f-a48c-48bf-b867-9de82888e419" xlink:to="loc_srt_ConsolidatedEntitiesDomain_9157f396-cd3f-4e9a-9d2d-cf2f24cf2e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_b6290fca-165e-4375-b129-898ac1ddb3ee" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_9157f396-cd3f-4e9a-9d2d-cf2f24cf2e76" xlink:to="loc_srt_ParentCompanyMember_b6290fca-165e-4375-b129-898ac1ddb3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_52d209a7-a4a5-454b-b2bb-b580f89e195f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_0953086c-4431-4998-8bdf-3d546e5cd721" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_52d209a7-a4a5-454b-b2bb-b580f89e195f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a94ccd1d-c4cc-45fc-b186-fd314044b622" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_52d209a7-a4a5-454b-b2bb-b580f89e195f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a94ccd1d-c4cc-45fc-b186-fd314044b622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_66b2eedc-e025-40ac-8a4b-7ba72570f382" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a94ccd1d-c4cc-45fc-b186-fd314044b622" xlink:to="loc_us-gaap_SubsequentEventMember_66b2eedc-e025-40ac-8a4b-7ba72570f382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsLineItems_602f70b3-67cc-4553-894c-3d5ce6bae2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_0953086c-4431-4998-8bdf-3d546e5cd721" xlink:to="loc_us-gaap_GuaranteeObligationsLineItems_602f70b3-67cc-4553-894c-3d5ce6bae2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_c6bb7158-e4ab-4196-adca-e5107621cd41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsMaximumExposure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_602f70b3-67cc-4553-894c-3d5ce6bae2fd" xlink:to="loc_us-gaap_GuaranteeObligationsMaximumExposure_c6bb7158-e4ab-4196-adca-e5107621cd41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_22699da8-f97b-4d7e-88f1-75b141333661" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsCurrentCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_602f70b3-67cc-4553-894c-3d5ce6bae2fd" xlink:to="loc_us-gaap_GuaranteeObligationsCurrentCarryingValue_22699da8-f97b-4d7e-88f1-75b141333661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_GuaranteeObligationsPayments_82327bd3-bd70-4c02-bc56-1ae9c6925a69" xlink:href="ci-20231231.xsd#ci_GuaranteeObligationsPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_602f70b3-67cc-4553-894c-3d5ce6bae2fd" xlink:to="loc_ci_GuaranteeObligationsPayments_82327bd3-bd70-4c02-bc56-1ae9c6925a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShareRepurchaseDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#ScheduleICondensedFinancialInformationofTheCignaGroupShareRepurchaseDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShareRepurchaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_889fcc00-4b45-4e38-b7e6-3b0efbe53690" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4da5978-9c2c-478d-bb57-28050f174ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_889fcc00-4b45-4e38-b7e6-3b0efbe53690" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4da5978-9c2c-478d-bb57-28050f174ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_8a0211f6-0c2e-48ab-a728-ce0786afb276" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4da5978-9c2c-478d-bb57-28050f174ba2" xlink:to="loc_srt_ConsolidatedEntitiesAxis_8a0211f6-0c2e-48ab-a728-ce0786afb276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_48e35d29-c796-4665-8550-d974d9ec8eca" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_8a0211f6-0c2e-48ab-a728-ce0786afb276" xlink:to="loc_srt_ConsolidatedEntitiesDomain_48e35d29-c796-4665-8550-d974d9ec8eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_20985ff3-0b9c-40e2-baea-7dcc761532e2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_48e35d29-c796-4665-8550-d974d9ec8eca" xlink:to="loc_srt_ParentCompanyMember_20985ff3-0b9c-40e2-baea-7dcc761532e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_32eaa36a-0332-4b87-aadd-b42af55f4096" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4da5978-9c2c-478d-bb57-28050f174ba2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_32eaa36a-0332-4b87-aadd-b42af55f4096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8d38e46c-3e5d-4687-8d52-98cf03cc940c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_32eaa36a-0332-4b87-aadd-b42af55f4096" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8d38e46c-3e5d-4687-8d52-98cf03cc940c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d2a5150e-308c-472c-96af-275f0e3d609a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8d38e46c-3e5d-4687-8d52-98cf03cc940c" xlink:to="loc_us-gaap_SubsequentEventMember_d2a5150e-308c-472c-96af-275f0e3d609a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_669aa06b-f8c1-4124-b189-9e072a2e0663" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4da5978-9c2c-478d-bb57-28050f174ba2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_669aa06b-f8c1-4124-b189-9e072a2e0663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_9201ff63-5aa2-4dbd-a833-e1356e2a8ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_669aa06b-f8c1-4124-b189-9e072a2e0663" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_9201ff63-5aa2-4dbd-a833-e1356e2a8ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_8d030bfd-a5ca-469a-9252-63738b95745d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_669aa06b-f8c1-4124-b189-9e072a2e0663" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_8d030bfd-a5ca-469a-9252-63738b95745d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_d4606d59-1163-4917-b9ff-1bcd2fc26b95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_669aa06b-f8c1-4124-b189-9e072a2e0663" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_d4606d59-1163-4917-b9ff-1bcd2fc26b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_af34c5f1-b812-4412-a33f-820176bc943e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_669aa06b-f8c1-4124-b189-9e072a2e0663" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_af34c5f1-b812-4412-a33f-820176bc943e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.thecignagroup.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails" xlink:type="simple" xlink:href="ci-20231231.xsd#ScheduleIIValuationandQualifyingAccountsandReservesDetails"/>
  <link:presentationLink xlink:role="http://www.thecignagroup.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_e3159fe6-1825-4952-adf3-afe305c8037d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a2a69560-79f8-4bf2-b850-2dbee6455881" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_e3159fe6-1825-4952-adf3-afe305c8037d" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a2a69560-79f8-4bf2-b850-2dbee6455881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6ae4b692-55a6-4ad6-ba69-0f3e53635287" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a2a69560-79f8-4bf2-b850-2dbee6455881" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6ae4b692-55a6-4ad6-ba69-0f3e53635287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_80e1720e-3e2a-450b-bc70-41a88097ade4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_6ae4b692-55a6-4ad6-ba69-0f3e53635287" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_80e1720e-3e2a-450b-bc70-41a88097ade4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember_d9afbc42-2c7e-41eb-8653-38898e1afca2" xlink:href="ci-20231231.xsd#ci_SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_80e1720e-3e2a-450b-bc70-41a88097ade4" xlink:to="loc_ci_SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember_d9afbc42-2c7e-41eb-8653-38898e1afca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember_14c13719-a528-4b9a-bd8a-9d55f6658f0b" xlink:href="ci-20231231.xsd#ci_SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_80e1720e-3e2a-450b-bc70-41a88097ade4" xlink:to="loc_ci_SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember_14c13719-a528-4b9a-bd8a-9d55f6658f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember_f50b6a85-a909-4814-b2aa-509702fd1f53" xlink:href="ci-20231231.xsd#ci_SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_80e1720e-3e2a-450b-bc70-41a88097ade4" xlink:to="loc_ci_SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember_f50b6a85-a909-4814-b2aa-509702fd1f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_aea14131-c1b3-47af-b4e5-ddfb7f7435fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_80e1720e-3e2a-450b-bc70-41a88097ade4" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_aea14131-c1b3-47af-b4e5-ddfb7f7435fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForReinsuranceRecoverableMember_2f09390c-7fbd-4c38-a04b-c1c7ccd9de9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForReinsuranceRecoverableMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_80e1720e-3e2a-450b-bc70-41a88097ade4" xlink:to="loc_us-gaap_AllowanceForReinsuranceRecoverableMember_2f09390c-7fbd-4c38-a04b-c1c7ccd9de9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_034f1d8a-0f9e-4cf9-a020-d66f67f4ee9c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a2a69560-79f8-4bf2-b850-2dbee6455881" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_034f1d8a-0f9e-4cf9-a020-d66f67f4ee9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_77a72fed-8e03-4128-acea-79fc55ad93d5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_034f1d8a-0f9e-4cf9-a020-d66f67f4ee9c" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_77a72fed-8e03-4128-acea-79fc55ad93d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_1a0d75e0-0c3b-4380-9e02-7aecdb9fc186" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_77a72fed-8e03-4128-acea-79fc55ad93d5" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_1a0d75e0-0c3b-4380-9e02-7aecdb9fc186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_98abb62f-88e3-4a31-a2bb-83e4ecdde4ac" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a2a69560-79f8-4bf2-b850-2dbee6455881" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_98abb62f-88e3-4a31-a2bb-83e4ecdde4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_b3c1552a-2f35-4118-b5dc-6241728fce1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_98abb62f-88e3-4a31-a2bb-83e4ecdde4ac" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_b3c1552a-2f35-4118-b5dc-6241728fce1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_678947e1-be01-4a22-9c7c-9bcf83b40686" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_b3c1552a-2f35-4118-b5dc-6241728fce1e" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_678947e1-be01-4a22-9c7c-9bcf83b40686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_09e92374-6401-47cf-82c1-8e6adabfaf1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_b3c1552a-2f35-4118-b5dc-6241728fce1e" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_09e92374-6401-47cf-82c1-8e6adabfaf1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_3e9706da-4f08-4614-ba56-4fe3db8a86e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_b3c1552a-2f35-4118-b5dc-6241728fce1e" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_3e9706da-4f08-4614-ba56-4fe3db8a86e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_e2aac5be-a1bd-473c-aee1-9318b00ca85b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_b3c1552a-2f35-4118-b5dc-6241728fce1e" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_e2aac5be-a1bd-473c-aee1-9318b00ca85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_efad6477-a428-4516-9bff-26a7a74007a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_b3c1552a-2f35-4118-b5dc-6241728fce1e" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_efad6477-a428-4516-9bff-26a7a74007a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_176f04dc-70fe-4859-85bf-1ad4b05e60b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_98abb62f-88e3-4a31-a2bb-83e4ecdde4ac" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_176f04dc-70fe-4859-85bf-1ad4b05e60b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_ci_RestrictedStockGrantsAndUnitsMember" xlink:href="ci-20231231.xsd#ci_RestrictedStockGrantsAndUnitsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ci_RestrictedStockGrantsAndUnitsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_PerformanceSharesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ci-20231231_g1.jpg
<TEXT>
begin 644 ci-20231231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
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MO.;27FV[):^?<64YQ@\TPD,?E]15*4[VDMG9M/?71IH]3HK\1O\ B-$\,_\
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MVMW/9QW!0=P"Z[D8'(*\$'((J[X#_9Z\"_"[5#?>'?!_AO1;[!7[3::?%',
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MBV<=&21"&5AZ@@UXV9>#.5U8MX*K*G+SM*/W:/\ $?M&?W.45_/+_P $H/\
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M((61">5VX=OR'BOPWS')HO$1_>T5]I*S7^*.MO5-KNT:1DF?;U>2?MH_MO\
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MFB1M.#P1U%?LW9?MV?!^_NDAC^(7AM6D. 9+CRU'U9@ /Q-<!\=_^">'PO\
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M .#N7_E%;IW_ &/>F_\ I/>U^HE?EW_P=R_\HK=._P"Q[TW_ -)[VOB^!_\
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MWDFNIY9#^+NQ_&OKROXNXRS"IC,[Q-:H_MRBO)1?*E]R-H[!1117S)04444
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MJFDZI;QW=G>6DRS6]W"ZADDC=25964@A@2""#5ZAIIV8'YL_\'6__*(W6/\
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MZ[+=]"#^K3]@G_DQCX+_ /8B:'_Z;X*^$_\ @[E_Y16Z=_V/>F_^D][7Z-?
MSX81_!+X)^#O!<5X^H1^$=#LM%2Z>/RVN1;0)")"N3M+;,XR<9QDU^<O_!W+
M_P HK=._['O3?_2>]K^1.$JD:G$^'G'9U;KYMFTMC^9>O6/V"_\ D^;X+_\
M8]Z'_P"G""O)Z]8_8+_Y/F^"_P#V/>A_^G""OZYS#_=:G^&7Y,Q/[5****_A
M,Z HHHH _G1_X/(_^3Y_A?\ ]B(O_IPNZ_(&OU^_X/(_^3Y_A?\ ]B(O_IPN
MZ_(&O[&\/?\ DG<+_A_5F,MS]0_^#1K_ )2IZA_V(FI_^E%G7]$O[7OPMF^.
M7[)OQ0\$VR^9<>,/"6JZ'$N<;GN;.6$#J.[CO7\[7_!HU_RE3U#_ +$34_\
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MAFCCFAF4I)&ZAE=2,$$'@@CC!JKHGA;3/#7F?V;IMCI_G8\S[-;I%YF,XSM
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MI-B@G:"Z@G_:%?HC17-D^93R_&TL;32;IM-)[.P]S^.7_ASK^U5_T;[\6/\
MPG+C_P")KTO]C'_@DS^TUX,_;"^$^L:M\"?BAIVEZ3XRTB\O+NXT"XCAM88[
MV%Y)'8KA55022>@!K^L^BOU*OXS9A5IRIO#P]Y-;RZ_,CV:"BBBOQLL****
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MT_X)K?'S]K+5;>U\ ?"7QOKT=P<"^_LQ[;3TZ??NY@D"=?XG%?M?_P $C/\
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MV'17\K_P(_8J_;,_X.#O$&M>.+[Q1<:IH%O=M$VM>+-5ELM"@G^\;>SMX8W
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ML<]7"T*E2%6I!.4+\K:3<;JSL]U=:.VZ"L'XB?#'P]\6O#W]D^)M'T_6]/\
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M&\<WT.I>*_$]C<SZA<PVT=LDK)>7$2D1Q@*OR1J. .F:_G>_X+1?$Z3X)_\
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M+^B?M0?LKM\0OA7X3TO2_B+\,H);LV.CZ?';GQ#IGWY[?9&HWS1X,L74G$B
M$R+CQG_@U2_X*W-XU\.1_LR>/M2+:KHL$ESX%O+A\M=6BY>;3B3R6B&Z2(<_
MNPZ\") >NMBL'6X3Q%?AJ@J?,TJT;N4E%7U3;U5GZ).75,.NI>_X/.;C5%^
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M5Q&WQ4^ <0=3(FE:R[(#\R@S6@!(]#M/Y'TK]@/^"7/_ "C,_9U_[)CX:_\
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M(S@D9]S3M)T:ST&S^SV-I;65N"6$4$2QH">IPH HHJN9VMT LT445(!1110
M57U/2[76K&2UO+>WN[:3&^*:,21O@@C*G@X(!^HHHHO;5 1Z-X>T_P .0-%I
M]C9V$<C;V2WA6)6/3)"@<U<HHIMMZL JCK7AG3?$BQKJ.GV.H+"24%S LNS/
M7&X'&<"BBA2:=T!:L[*'3K2.WMX8[>"%0D<<:A40#H !P!4E%%( HHHH ***
$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ci-20231231_g2.jpg
<TEXT>
begin 644 ci-20231231_g2.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0,217AI9@  34T *@    @ ! $[  (
M   8   !2H=I  0    !   !8IR=  $    P   "VNH<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M2V]C:&%R+"!2=6)Y(" @(" @5$PQ-$$   60 P "    %    K"0!  "
M%    L22D0 "     SDU  "2D@ "     SDU  #J'  '   !#    :0
M'.H    !
M
M
M
M
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJ&[6Y>SE6PFBAN2I$4DT1D1
M6[$J&4L/8,/K7C?@[XC?$'QAH'B/4;%?#WGZ'<-$MF;&=?M87DXD\\[&(!Q\
MK#.,^M 'M5%</X1^*^@^)OAR_B^[D72K6V+1WL<S[O(D&/E! RY.Y=H RVX
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M!_ NAZ[;:G>&UN;Q=5:Y$UVT>28L7#%F9%/4#:> K,00/=** /)_%%E+X_\
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MM;22.U:WP K><J^3L"\;B=Y((;-?35% %6X2_?3"EI<6\-\4 66:$RQJW<E
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MISCJ*TO(US_H(Z?_ . #_P#QZ@#2HK-\C7/^@CI__@ __P >H\C7/^@CI_\
MX /_ /'J -*BLWR-<_Z".G_^ #__ !ZCR-<_Z".G_P#@ _\ \>H TJ*S?(US
M_H(Z?_X /_\ 'J/(US_H(Z?_ . #_P#QZ@#2HK-\C7/^@CI__@ __P >H\C7
M/^@CI_\ X /_ /'J -*BLWR-<_Z".G_^ #__ !ZCR-<_Z".G_P#@ _\ \>H
MTJ*S?(US_H(Z?_X /_\ 'J/(US_H(Z?_ . #_P#QZ@#2HK-\C7/^@CI__@ _
M_P >H\C7/^@CI_\ X /_ /'J -*BLWR-<_Z".G_^ #__ !ZCR-<_Z".G_P#@
M _\ \>H TJ*S?(US_H(Z?_X /_\ 'J/(US_H(Z?_ . #_P#QZ@#2HK-\C7/^
M@CI__@ __P >H\C7/^@CI_\ X /_ /'J -*BLWR-<_Z".G_^ #__ !ZCR-<_
MZ".G_P#@ _\ \>H TJ*S?(US_H(Z?_X /_\ 'J/(US_H(Z?_ . #_P#QZ@#2
MHK-\C7/^@CI__@ __P >H\C7/^@CI_\ X /_ /'J -*BLWR-<_Z".G_^ #__
M !ZCR-<_Z".G_P#@ _\ \>H TJ*S?(US_H(Z?_X /_\ 'J/(US_H(Z?_ . #
M_P#QZ@#2HK-\C7/^@CI__@ __P >H\C7/^@CI_\ X /_ /'J -*BLWR-<_Z"
M.G_^ #__ !ZCR-<_Z".G_P#@ _\ \>H TJ*S?(US_H(Z?_X /_\ 'J/(US_H
M(Z?_ . #_P#QZ@#2HK-\C7/^@CI__@ __P >H\C7/^@CI_\ X /_ /'J -*B
MLWR-<_Z".G_^ #__ !ZCR-<_Z".G_P#@ _\ \>H TJ*S?(US_H(Z?_X /_\
M'J/(US_H(Z?_ . #_P#QZ@#2HK-\C7/^@CI__@ __P >H\C7/^@CI_\ X /_
M /'J -*BLWR-<_Z".G_^ #__ !ZCR-<_Z".G_P#@ _\ \>H TJ*S?(US_H(Z
M?_X /_\ 'J/(US_H(Z?_ . #_P#QZ@#2HK-\C7/^@CI__@ __P >H\C7/^@C
MI_\ X /_ /'J -*BLWR-<_Z".G_^ #__ !ZCR-<_Z".G_P#@ _\ \>H TJ*S
M?(US_H(Z?_X /_\ 'J/(US_H(Z?_ . #_P#QZ@#2HK-\C7/^@CI__@ __P >
MH\C7/^@CI_\ X /_ /'J -*BLWR-<_Z".G_^ #__ !ZCR-<_Z".G_P#@ _\
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M_3A;UTE<WX\_Y%VU_P"PUI7_ *<+>NDH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,W2_\ D(ZS
M_P!?J_\ I/#6E6;I?_(1UG_K]7_TGAK2H **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F_'G_(NVO\
MV&M*_P#3A;UTE<WX\_Y%VU_[#6E?^G"WKI* "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#-TO_D(
MZS_U^K_Z3PUI5FZ7_P A'6?^OU?_ $GAK2H **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F_'G_ "+M
MK_V&M*_].%O725S?CS_D7;7_ +#6E?\ IPMZZ2@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S=+
M_P"0CK/_ %^K_P"D\-:59NE_\A'6?^OU?_2>&M*@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .;\>?
M\B[:_P#8:TK_ -.%O725S?CS_D7;7_L-:5_Z<+>NDH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\K^+OQ-N-#TZ70/ K?
MVCXJF!WP6L;3R6<(4EY"%! 8<8!]<\XP0#U2BO+O@%K/B_6_A\MQXRC9X@P&
MGWD[$SW47.6<'J!QASRP^F6]1H **** "BBB@#-TO_D(ZS_U^K_Z3PUI5FZ7
M_P A'6?^OU?_ $GAK2H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH AO))XK&>2TA\^=(V:*(L%\Q@.%R>F3QFN*\'
M^(?$/B;PC<31:CI/]IQ7DL4KSV4B?9-KMF.6V\P,& "@9D'#9.=OS]O<0K<6
MTL#LZK(A0M&Y1@",9##D'W'(KD8?AV(]'O[.3Q)JS7&H7)FN+Y%MUEDCWLPA
M(\HILR[$_+EBS#[IV@ KZ;XTU:\:RNKJVM+>T\RTM+R *[2&>X16#(^0 BF1
M."I)!)R,8.AX9\2WVJZA"FH+;"'4;,W]BL$;*T40<+MD)8AFPZ'("]2,<9,\
M'@VWCU2"^GU/4+MXV66:.=HRES,N=LS@(,,-W 4JORK\ORC%G1?"]IH=Y-<0
M7-S/N4Q0).4*VL6XMY<>%!VY/\18\ 9P * ,7XEZ_H^EZ-96VIZM8V<[ZKIL
MR17%RD;-&E] SN 2"54 DGH "36A_P +'\$?]#EX?_\ !I!_\51X\_Y%VU_[
M#6E?^G"WKI* .;_X6/X(_P"AR\/_ /@T@_\ BJ/^%C^"/^AR\/\ _@T@_P#B
MJZ2B@#F_^%C^"/\ H<O#_P#X-(/_ (JC_A8_@C_H<O#_ /X-(/\ XJNDHH Y
MO_A8_@C_ *'+P_\ ^#2#_P"*H_X6/X(_Z'+P_P#^#2#_ .*KI** .;_X6/X(
M_P"AR\/_ /@T@_\ BJ/^%C^"/^AR\/\ _@T@_P#BJZ2B@#F_^%C^"/\ H<O#
M_P#X-(/_ (JC_A8_@C_H<O#_ /X-(/\ XJNDHH YO_A8_@C_ *'+P_\ ^#2#
M_P"*H_X6/X(_Z'+P_P#^#2#_ .*KI** .;_X6/X(_P"AR\/_ /@T@_\ BJ/^
M%C^"/^AR\/\ _@T@_P#BJZ2B@#F_^%C^"/\ H<O#_P#X-(/_ (JC_A8_@C_H
M<O#_ /X-(/\ XJNDHH YO_A8_@C_ *'+P_\ ^#2#_P"*H_X6/X(_Z'+P_P#^
M#2#_ .*KI** .;_X6/X(_P"AR\/_ /@T@_\ BJ/^%C^"/^AR\/\ _@T@_P#B
MJZ2B@#F_^%C^"/\ H<O#_P#X-(/_ (JC_A8_@C_H<O#_ /X-(/\ XJNDHH Y
MO_A8_@C_ *'+P_\ ^#2#_P"*H_X6/X(_Z'+P_P#^#2#_ .*KI** .;_X6/X(
M_P"AR\/_ /@T@_\ BJ/^%C^"/^AR\/\ _@T@_P#BJZ2B@#F_^%C^"/\ H<O#
M_P#X-(/_ (JC_A8_@C_H<O#_ /X-(/\ XJNDHH YO_A8_@C_ *'+P_\ ^#2#
M_P"*H_X6/X(_Z'+P_P#^#2#_ .*KI** .;_X6/X(_P"AR\/_ /@T@_\ BJ/^
M%C^"/^AR\/\ _@T@_P#BJZ2B@#F_^%C^"/\ H<O#_P#X-(/_ (JC_A8_@C_H
M<O#_ /X-(/\ XJNDHH YO_A8_@C_ *'+P_\ ^#2#_P"*H_X6/X(_Z'+P_P#^
M#2#_ .*KI** .;_X6/X(_P"AR\/_ /@T@_\ BJ/^%C^"/^AR\/\ _@T@_P#B
MJZ2B@#F_^%C^"/\ H<O#_P#X-(/_ (JC_A8_@C_H<O#_ /X-(/\ XJNDHH Y
MO_A8_@C_ *'+P_\ ^#2#_P"*H_X6/X(_Z'+P_P#^#2#_ .*KI*\XUSXG7&IZ
MK+X=^&%BFO:NF5GO6;%C8'UDD_B/^RO\QB@"A\2OCOX>\(^'UD\-:AIVO:K<
MDK;Q6URLT<6,9>4HW YX&06[="1I>"OC5X1\4^&8-1U#6-.T2\SY=Q97U['$
MR. ,E=Q&Y#GAOPZ@BH]-^#6DWBW-]\0IF\5ZS>Q[)KBZRL<"GJD"*1Y8'8C!
M],=*;J'PC&D7K:K\,-5D\+:@>9+5<R65SCL\1SCIC*]/3- '3?\ "Q_!'_0Y
M>'__  :0?_%4?\+'\$?]#EX?_P#!I!_\57,V/Q6GT*]BTKXJ:0WAR[D.R+48
MR9+"Y/\ LR?P'V;IW(KT>&:*Y@2:WD26*10R2(P96!Z$$=10!SW_  L?P1_T
M.7A__P &D'_Q5'_"Q_!'_0Y>'_\ P:0?_%5TE% '-_\ "Q_!'_0Y>'__  :0
M?_%4?\+'\$?]#EX?_P#!I!_\57244 <W_P +'\$?]#EX?_\ !I!_\51_PL?P
M1_T.7A__ ,&D'_Q5=)10!S?_  L?P1_T.7A__P &D'_Q5'_"Q_!'_0Y>'_\
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M-)XQT,I&I8B/4(I&(]E5B2?8#-9?BCXGV^GZL?#OA&Q?Q)XE8[39VS8CM?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M HHHH S=+_Y".L_]?J_^D\-:59NE_P#(1UG_ *_5_P#2>&M*@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH)"J2
MQP!R2>U9%MXM\/7FARZU;ZYI[Z7#(T<M[]I00HP;:07)P.2,>N01U% &O15*
MXUG3+74+6QNM2M(;R\R;:WDG59)\==BDY;\*?:ZG87UQ<P6-[;7,UH_EW$<,
MJNT+?W7 .5/L: ,7QY_R+MK_ -AK2O\ TX6]=)7-^//^1=M?^PUI7_IPMZZ2
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M /!#/_\ )E'V'QO_ -##X?\ _!#/_P#)E=)10!S?V'QO_P!##X?_ /!#/_\
M)E'V'QO_ -##X?\ _!#/_P#)E=)10!S?V'QO_P!##X?_ /!#/_\ )E'V'QO_
M -##X?\ _!#/_P#)E=)10!S?V'QO_P!##X?_ /!#/_\ )E'V'QO_ -##X?\
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MYI'_ #Y^(/\ PG-0_P#C% '245S?_">:1_SY^(/_  G-0_\ C%'_  GFD?\
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MS4/_ (Q1_P )YI'_ #Y^(/\ PG-0_P#C% '245S?_">:1_SY^(/_  G-0_\
MC%'_  GFD?\ /GX@_P#"<U#_ .,4 =)17-_\)YI'_/GX@_\ "<U#_P",4?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,W2
M_P#D(ZS_ -?J_P#I/#6E6;I?_(1UG_K]7_TGAK2H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F_'G
M_(NVO_8:TK_TX6]=)7-^//\ D7;7_L-:5_Z<+>NDH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,
MW2_^0CK/_7ZO_I/#6E6;I?\ R$=9_P"OU?\ TGAK2H **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F_
M'G_(NVO_ &&M*_\ 3A;UTE<WX\_Y%VU_[#6E?^G"WKI* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?Q+TVZO-&LI;?6KZP1=5TU##;I 59FOH '/F1LVY201@@9 R",@Z'_"+ZO\
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M\(OJ_P#T/?B#_OQI_P#\BT =)17-_P#"+ZO_ -#WX@_[\:?_ /(M'_"+ZO\
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M\(OJ_P#T/?B#_OQI_P#\BT =)17-_P#"+ZO_ -#WX@_[\:?_ /(M'_"+ZO\
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M\(OJ_P#T/?B#_OQI_P#\BT =)17-_P#"+ZO_ -#WX@_[\:?_ /(M'_"+ZO\
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M\(OJ_P#T/?B#_OQI_P#\BT =)17-_P#"+ZO_ -#WX@_[\:?_ /(M'_"+ZO\
M]#WX@_[\:?\ _(M '245S?\ PB^K_P#0]^(/^_&G_P#R+1_PB^K_ /0]^(/^
M_&G_ /R+0!I:7_R$=9_Z_5_])X:TJQ/#=K-9-JMO<W]QJ$J7HW7-RL8D?,$1
MY$:JO&<<*.!W/-;= !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 <WX\_P"1=M?^PUI7_IPMZZ2N;\>?
M\B[:_P#8:TK_ -.%O724 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% &;I?\ R$=9_P"OU?\ TGAK
M2K-TO_D(ZS_U^K_Z3PUI4 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!S?CS_D7;7_L-:5_Z<+>NDKF
M_'G_ "+MK_V&M*_].%O724 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% &;I?_(1UG_K]7_TGAK2K
M-TO_ )".L_\ 7ZO_ *3PUI4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!S?CS_ )%VU_[#6E?^G"WK
MI*YOQY_R+MK_ -AK2O\ TX6]=)0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9NE_P#(1UG_ *_5
M_P#2>&M*LW2_^0CK/_7ZO_I/#6E0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '-^//^1=M?^PUI7_I
MPMZZ2N;\>?\ (NVO_8:TK_TX6]=)0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC15L_+E1!&I4 G*R#.XDY0X(!P->[\(Z1?>)[;7KF*9KRW7"H+AUA=LJ0[1
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M!_X3FH?_ !BC_A/-(_Y\_$'_ (3FH?\ QBNDHH YO_A/-(_Y\_$'_A.:A_\
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M?[V52H9@/)R0"Z@GMN'J*E_X3S2/^?/Q!_X3FH?_ !BB^_Y*GH7_ &!=2_\
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M .1=NO\ L-:K_P"G"XH /^$\TC_GS\0?^$YJ'_QBC_A/-(_Y\_$'_A.:A_\
M&*Z2B@#F_P#A/-(_Y\_$'_A.:A_\8H_X3S2/^?/Q!_X3FH?_ !BNDKFM/EU.
M[UCQ-I_]JR@0S1"UE:&,M;*\2L0H"@'!)P7W<XSN'% "_P#">:1_SY^(/_"<
MU#_XQ1_PGFD?\^?B#_PG-0_^,57TNXUN?3ELSJ;W$WFW+1:@T$>Z>W4[48J
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M\)1J_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z?_\ )5=)10!S?_"4:O\
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M#N(&"3\IR!QGT2N;L?\ DJ>N_P#8%TW_ -'WU !_PE&K_P#0B>(/^_\ I_\
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M?WS_ &*^OT0I?RQSFWB)4S^9N!G,!./*<_O,<DD9KUF&1)K>.2-]Z.H96_O
MC@T <]_PE&K_ /0B>(/^_P#I_P#\E4?\)1J__0B>(/\ O_I__P E5TE% '-_
M\)1J_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z?_\ )5=)10!YWX!\1ZI!
M\-O#447@O7+E(])M56:*:Q"2 0J R[KD-@]1D ^H%=!_PE&K_P#0B>(/^_\
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MMED\%ZY !JVFL'DFL2"1?0$+\MR3EB H[9(R0,D>B5S?CS_D7;7_ +#6E?\
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M#_O_ *?_ /)5=)10!S?_  E&K_\ 0B>(/^_^G_\ R51_PE&K_P#0B>(/^_\
MI_\ \E5TE% ')>![J:]U3Q=<7-C<:?*^LINMKEHS)'BPM!R8V9>0,\,>",X.
M0.MKF_"__(Q>,_\ L-1_^F^SKI* "BBB@ HHHH **** "BBB@ HHHH XFYU.
M[TWXI:L;+0]0U?S-&T_<+)[=?*Q->8W>=+'UR<;<_=.<<9TO^$HU?_H1/$'_
M '_T_P#^2JQ]9_X27_A/-=_X0S^RO[2_LK3/^0MYGD[/.OL_ZOYL],=J\K^(
MGB;XWZ/XM\/6LD-B'EGS:KH22-;WDG>.7S#DX7)P<#&6_AR #VS_ (2C5_\
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M[_Z?_P#)5=)10!S?_"4:O_T(GB#_ +_Z?_\ )5'_  E&K_\ 0B>(/^_^G_\
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M0?\ ?_3_ /Y*H^''_)+/"G_8%L__ $0E=)0!S?\ PE&K_P#0B>(/^_\ I_\
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M1G!5W@RXN;CXE:E-J+V%_J$OVM9R(S]JTJ*.95AA)+$+'(AW@!5W%2_SY)4
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M )*H_P"$HU?_ *$3Q!_W_P!/_P#DJNDHH YO_A*-7_Z$3Q!_W_T__P"2J/\
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M;QY4AM(%B3:H$:L H PPC#?\"H 9_P )1J__ $(GB#_O_I__ ,E4?\)1J_\
MT(GB#_O_ *?_ /)5=)10!S?_  E&K_\ 0B>(/^_^G_\ R51_PE&K_P#0B>(/
M^_\ I_\ \E5TE% ')>![J:]U3Q=<7-C<:?*^LINMKEHS)'BPM!R8V9><9X8\
M$=#D5UM<WX7_ .1B\9_]AJ/_ --]G724 %%%% !1110 4444 %%%% !1110!
MQ-S/K</Q2U;^P=/L+TMHVG^=]MOWMMG[Z\V[=L,F[/S9SC&!USQ?&J>,V5F7
M0?#I5"0Q'B";"D=0?]#JI<6M_>?$;78M+U'^SI_[(TP^=Y"R\>=?9&UN/QK'
MO/"OBN<ZHZ:PTL;L@D0V<<1O"OWB$!P>..<;\8/&#6D(*6[L-*YTBZCXV= Z
M>'_#S*PR&&OS$$?^ =4['Q3XCU.WDN--L/"=Y#%GS)+?Q-)(J8)!R1:8'(/Y
M'TJW:Z5KMO:R3:EKC:I:&V?-A]@2!GRO"Y7D'M@5Q5FEU9:'J]D=-U*ZL;BU
MMM/GO+C1I1=11?O$:)D0+]I\M6P)(EQAP27VY,R23T8'2CQGK9T(ZV+?P>=)
M'!O_ /A*'\@?-M_UGV3;][Y>O7BI],\2^)M;L_M>C:=X5U"VW%?.M/$LDJ9'
M4;EM",UQ,<NOO\-_%=AJL6NW-R^CSVT,*Z4VR\DD0JMP,0K('D+@>5D^4$.[
M Z>A>&]-FM+?4=9U&\^TW6J[)Y&M]/DM-JK&%4"!V>0/@<Y.[.!@8 J1&8GC
M/6Y+6]N8X/![P:>Q2\E7Q0Y6V8=1(?LF$(]#BI5\4>(WN[6U6P\)M<7D7G6L
M(\2R;YX\9WH/LF67'.1Q6=! ]OH44UI'K%WHECJL,\%O>VL[W:0A<, DB^<Z
MI(0R[@6^4@94)67HVEZI!<):36%W'=7^IV^H6TYMGV06BSO(87?&(V6/<NQB
M#^\P >< '177B[7['5(]-O;3PC;W\L9ECM9O$\B2N@R2P0VF2/E;G&/E/I4N
MF>)?$VMV?VO1M.\*ZA;;BOG6GB625,CJ-RVA&:K>*H[BY^)&AI;7FM::L6EW
MHDO=.T[SE!>2W98V=X9(QD0R''#951_$ W+Z?JGBRQT[PY;:1'J$-J)I!</>
M:=.C3,;G)$J+:.5!C;(8>2N6/S':0 #M;K7/%EBL37VD>&;832K#$9O$4J;Y
M&.%09M.6)X ')H_MWQ8=2.GC2/#'VT0B<VW_  D4OF",G:'V_9,[<@C/3(KB
M9=>U[4FU.VU"S\1S6*:GI4]C]JTB0RH([\/<?ZJW1<*D:,!F3C^,DE5H0S>(
M=%N%E@G\23WMC'?^9))H4DIF9KU"D098-K*ZJ7)7)Y.&48P >@:KXG\2:%:"
MZUNP\*:=;LX037?B62)"Q!(7<UH!G /'M5J+4_&<T>^'0?#LB9(W)X@F(R#@
MC_CS[$$55UR9M-\=Z9K][97UWIO]GRVT;VEE+</:S,RN2T2*7 =5QN"G&W!Q
MN&<36]4O] E\.VOA'2M;T^P,\<DUG!IN^W6V:X'F JD,C(VPLP3?%M7'\0\L
M@'4?;O&__0O>'_\ P?3_ /R'5&?Q5XBM=7@TJYL?"<.HW*[X+.3Q-(LTJ\\J
MAM,D?*>@['TKD;76O'JR:1*M[JL\$]RXD-]I3P_*MQM"/''9,RAH=K;B8AN9
MB&P-J]7XLNY;?QII[01:FICT;4%^U66G2W A=_)*881LF_\ =.0ISD@#!W $
M N76L>,+&TENKW1?#=O;PH7EFE\0S(D:@9+%C:8  [FG1:GXSGA2:#0?#LD4
MBAD=-?F*L#R""+/D5P">(O&-SIQL]1E\0,LUG&\MS'X=<,MPT!/D!/)_U9?(
M9NJGC>N1B]#JOBNWOM&M$.H:=HZZ5"'\K3II) /(;>=GV23;,K@85Y%SM \M
MMP) -3QI>>,6T&V%UH6AQI_:VFD-'K4SDM]N@VC!M1P6P"<\ DX.,'H/MWC?
M_H7O#_\ X/I__D.N+AO]<N?#!A\43ZK+?QZMH;?Z7IZV\.TW=LVZ-EC4%SN_
M>(6;8X*C@9;UB@#F_MWC?_H7O#__ (/I_P#Y#H^W>-_^A>\/_P#@^G_^0ZZ2
MB@#F_MWC?_H7O#__ (/I_P#Y#J*ZUCQA8VDMU>Z+X;M[>%"\LTOB&9$C4#)8
ML;3  '<UU-97B>WM[KPU>0WD=X\+*"QL5+3QX8$2(HR25(#8 8G;@*Q^4@',
MV?B[6#H>G7MI8>$(]-O"D-C(/$<B1RL>$C3-H/FX("CG@C'%78_$/BB74Y=-
MBTOPN]]"@DEM5\1RF6-3T8I]DR ?4BN4TZ[OF^"NFO>Z?=32?;K QO::5-YM
MQ%%-"YE>%5+*0L;#<0 VP$8#J*T+K2M3O-0O=-LK:Y@O8YM2G>\>!DBD2>-A
M"%E(VL<M&" <CR>0,"@#;T_Q#XHU:W:?2]+\+WL*N8VDMO$<LBAAU4E;0C([
MBK7V[QO_ -"]X?\ _!]/_P#(=0>#0\]YJ%_%97-A920VL$5O<VS0,'C0ASL8
M XY1<]#LX)&#75T <W]N\;_]"]X?_P#!]/\ _(='V[QO_P!"]X?_ /!]/_\
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M.#P#I8M-/U,AM=M[EHX]+N-RYO!<3$1>7YB1K\X!=5R%&.HSZ-0!S?V[QO\
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M"  6E\3^)&O;>S73_"ANKJ+SK> >)9-\T?\ ?5?LF67W'%7?MWC?_H7O#_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[RJ@4HZD;F5N<8SQ0!VU%8G_  EEA+X:L-:L$GOHM26,V4$(59;@NNY5 <J
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MK=XV;<DBNRJ/EY_B&,$+WZ6'7)6\.S:K<:)J=LT:,ZV+QQO<2 #("K&[#)Z
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MG@'.<DWM%\'V6D^%[G0+FYN=6LKIYWE%^(R6$S%I%_=H@P6=CTS\Q&<  %%
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FH74D;BXEDQEB @V $$@1[!DG(/&"B@#H**** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_01a.jpg
<TEXT>
begin 644 image_01a.jpg
MB5!.1PT*&@H    -24A$4@  !!H   'T" 8   "3JDX*    "7!(67,  $SE
M  !,Y0%USO"5  "@G$E$051XG.S="=Q54____PN92<;;$%)(D2$R9\Z0(7,R
M9BI3YNDF9$A(ALCT=5.FRI@D1(K;D)(T((EH0$4#&7/;_\=[_Q['_^I<:^VS
MA[7/V>><U_/Q6(_;W77MM=<^USY[[_79:WU6C0<      .! C92Z$0
MH#(0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
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M(:U[%0"$52.U_V'NW+G6"Y<R$R>U<.%":_V]>_<NN/WHT:.-V^KASH4''GC
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MB[J4F-Z(V1[<GGGFF4AU*:&KW@ZY>GC3^6-[RZ^WI^J<1Z6W<J;Z].:PE"O
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M/1*7@8;77GLM,!%FW)=+63V'T^#B7J5\%+I^Y->AH/:$"1-BM\T6:(]ZKP*
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MH0Z7GAO"J,;OD:01:- (A#%CQCAI7SF<PS:EN%?9EK7LW+ESHF/)L8T (=
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M]CU*.]"@>^H**ZQ@W,=55UT5NIZLG<-9OU?MM--.QCKBKLBCT0QZ)G)QKP*
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M+[_\LO?TTT][_?OW]P8-&N2]\\X[WLR9,TO=1    *#L$&@       #.$&@
M      #.$&@       #.$&@       #.$&@       #.$&@       #.$&@
M      #.$&@       #.$&@       #.$&@       #.$&@       #.$&@
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M1V>O\M@"#;?>>FO!52<T':E?OW[>[;??[G^W-MIHHX+?@3/.."-6.SGW
M &1!G4##_???;^RL[+;;;HEV-&S8L#IUFD8>)$T\^=133QG;O]566R6J-RPZ
M>Y7'%FCX[W__&[DN)7U\]=57O6;-FED##0J*39PX,7+=G'L     LJ!.H&'\
M^/'&SLH**ZS@_?'''[%W=/WUU]>I\ZJKKO)67''%)?XM:>+)+EVZ&-NO_!#%
M0&>O\K@,-.3\_OOOWH$''F@--EQRR261Z^3< P   ) %=0(-6OY1RT":.BP?
M?/!![!V9.E6OO/**M_ONN]?Y]V^__3;V?G;880=CV_OV[1N[SBCH[%6>- (-
MLFC1(J]APX;&NC7B(2K./0    !94"?0(/OMMY^QPW+GG7?&VHF&BZ^^^NI+
MU+744DMY\^;-\W,_Y._GN>>>B[6?7W_]U5MVV66-;?_\\\]CU1D5G;W*DU:@
M0?KTZ6,=U3!W[MQ(=7'N 0   ,@"8Z#AVFNO-798CCWVV%@[^>233^K4M<46
M6_@_>_;99YT,&Y>WWGK+V.ZUUEHK5GUQT-FK/&D&&F;,F&$--$3-T\"Y!P
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M(S'5_\$''SBI/ZXT1S1LNNFFWN677^[-F#$C<3LK^=S3$JEIG1LM6K0@T
M   X5##0\-133QD?PENU:A58\9 A0^ILL\\^^P1N,VS8L#K;'';888';].W;
MU]B^W7;;+7 [DRP$&IHT:6(,FFAEC:1./?741!VJG7?>N<ZV>BO_\\\_)VZ;
M:/E!TYSYWKU[.ZD_KF),G=#G>/'%%WN__?9;['96\KF7OR2EBJ:;F)9/C<HV
M6H)  P   !!/P4"#EBHT/80ON^RR@?D33&^_]6]!%BY<Z"V]]-)+;+/VVFL'
M;M.Y<V=C^^(,J2YUH$'';^IHMV[=.O*QF#S^^..Q.U1:;4)_\_QM=]]]=R=M
MRS&M!*!<'Z5D"S1H2=4P)4K H67+EI&69*VM4L\]+05JVE8)-ETP!44)-
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M?K*_2I5VH&'1HD5>@P8-C/O8;+/-0M=3R>?>JZ^^:MQ>(QV2G'N]>O5*W#8
M    2XH4:)!]]MG'^%#^V&./&9-%:CI%7#OOO'.=^I0TS[04G<IGGWT6>U^2
MA4##U*E3C=NK(YHD_\2IIYZ:N$/UTT\_&7-PJ#S^^..QVY9U:0<:[KCC#NO?
M1G^WL"KYW%.04],X7)Y[RO5BFBY"H $   !()G*@P3;7VC2L7IU2)8B,Z\(+
M+PRU'Y4UUE@C\5SR+ 0:9*>==C+6<?755\<Y+/^-\C+++..D0W7666<9ZU#P
M)VPN@7*39J!!*TK81@FIO/322Z'KJO1S[Z*++C+6H0#$].G3([?-EMR60 ,
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MKW[]^H'!A5S1*(?ITZ>7^O    " LD>@ 4!9"0HTQ"VKK;::-V;,F%(?&@
M % 1"#0 *"NN PW-FC7S/OOLLU(?%@   % Q"#0 *"NC1HWR#CKH(*]>O7J)
M @QKK+&&'[2PY74     $ ^!!@!E:<Z<.5Z_?OV\TTX[S6O:M&FHP(/R,+1K
MU\[KV[>OMVC1HE(? @   %"1"#0 J B+%R_VIDZ=ZKWUUEO>RR^_[#W]]-->
M__[]O4&#!GGOO/..-W/FS%(W$0   *@*!!H      ( S!!H      ( S!!H
M     ( S!!H      ( S!!H      ( S!!H      ( S!!H      ( S!!H
M     ( S!!H      ( S!!H      ( S!!H      ( S!!H      ( S!!H
M     ( S!!H      ( S!!H      ( S!!H      ( S%1%H6+!@@7?//??4
M*1,F3"AUTU!%9LV:Y;W^^NO>TT\_[3WXX(/&<_+//_]<8IM*/G>S?FP#!PZL
MTS;]&P   (!D*B+0\,477^A ZA1U'( T*;APR267>(T;-S:>@_GEYY]_7F+[
M2CYWLWYLVV^_?9VVZ=]@]MMOOWG3IDWS)DV:Y(T>/=K[^../O:E3IWJ__OIK
MJ9M6-73]F#)EBO?AAQ]Z$R=.]&;.G.G]_???I6Y6'3I7OOKJ*_\<&3MVK'\M
MF#=O7JF;A9 6+ESH__WTMYL\>;(W=^Y<[Z^__BIULP  928PT*"WLR^]]%*L
M,F3($&_DR)'>N''C_(?3/_[X([6#R'J'!I6I9\^>WO+++Q\JP$"@(7O'1J A
MV/OOO^]U[][=.^"  [R&#1MZ2RVUE/6\7F>==;S]]]_?N^:::[QWWWTW5*?D
MIY]^BGU_2;NHHYP5__WO?[USSCG'VW3338U_@_KUZWO[[;>?UZ=/'V_^_/DE
M::/N[\\__[QWVFFG>9MOOKFWS#++6,^3O??>VS]/]'R0/\(K#;KF:E^FO_,[
M[[R3RCYGSYZ=ZOFI[Y@K^MN]\LHKWE577>6U:=/&6V.--8Q_.YU[^MN>>>:9
MWA-//.$'(P  "!(8:/C7O_X5J1,55-0AVW''';WSSCO/>_/--YT>1-8[-*@\
M.H_C? \(-&3GV @TU/7CCS]ZUU]_O;?))ILDNMZON^ZZWN677^X'F6WT1M[5
M_<5UF3%C1O$^=(LQ8\9XN^ZZ:Z1V*^B@OU\Q.O"BT2P*1NGO'>=S5J>V<^?.
MWD<??>2L3;KN//;88]Y99YWE;;/--M:@A\I..^WD;+^U*1B0YOFYVVZ[)6K?
M[[__[D\3:]^^O;?JJJO&:L-JJZWF77GEE=[WWW_OZ%,# %2:&K']T&6@(;\T
M;=K4G\?N8MAGUCLTJ"S//OML[/.>0$-VCHU P_]/'8]NW;K%[G382KUZ];R.
M'3L:.^X$&NQZ].CA?W9QV[_MMMMZWWSS3:IMU(C'1HT:.?F\3SCAA%AM6+1H
MD3=BQ COYIMO]@X]]%!OK;76BK3?:@LT:*K399==%OES"BJZ9I#;!@!@4B.V
M'Z89:,B5??;9Q_OZZZ\3'436.S2H'!H2OL$&&UC/9XW<V7KKK;T]]]S3VW??
M?>N4_"'9E7SN9OW8"#3\/YKOW[QY\U2O\RNOO+(_U>A___O?/_LET&#6I4L7
M)\>@Z]3GGW^>2AMON>46;^FEEW;V><<)-'SRR2>)@C$JU11HT.BBH.E/28M&
M^9'' 0!06XW8?EB,0(/*>NNMYWWYY9>Q#R+K'1I4CL&#!QO/M08-&GA]^_;U
MWPQ'4<GG;M:/C4"#YPT8,,!;8845BG*=5]EKK[W^V3>!AKKT9M[E<31ITL1/
MY.>2IL2X_KSC!!J4_RGI?JLIT&"['KLLIYQRBOL/$P!0MFK$]L-B!1I4E+5_
MSIPYL0XBZQT:5(Z33CK)>*[%S3M2R>=NUH^MV@,-]]]_?^@WG)J#?\011_C#
MKN^\\T[OH8<>\K>_[;;;_#>92D:XRBJK%*Q'\^5S"#0L24D?@T8)Z&^@.?$O
MO_RRG]- "0$??OAAKVW;MH%_Q\,..\Q9&\,$0M06Y4;HT*&#=^&%%WI77'&%
MUZE3)^^HHX[R-MML,V-;"31$*VD&&O0L=L@AAWCGGGNN_[?3_QY]]-&!(_EJ
MEUZ]>J7PB0( RE&-V'YH"S3<>NNM!;,B#QHTR.O7KY]W^^VW^YVSC3;:J. -
MZHPSSHAU$%GOT*!R-&O6K,YYUK)ER]CU+5BPP#]/\\N$"1,<MKHTLOZ]K.9
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MSX56HE  5/<KW7_UG>J>K*F1&C6F9+;*B0$ 0)D1: " C'KUZM4JT* 5,@
M ("E&8$& ,A ;V=-TS?TYA8   !8FA%H ( ,M#1DRR##CCON6'2S    @,(1
M: " #"9,F- JT."Z7!\   #0# @T $ &_?OW_Y<@0\>.'9?*9'<   ! 2P0:
M " #+=N[9*!!J[\     (-   '5[YYUW_B7(H&4?O_SRRZ*;!0    2!0 ,
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M>/ZZ*"+0H%PG>5).A.VVVRZQ';X"#2'=?\M\;0$HI\K?-?S')$TAT( D!!H
MNP\^^"#JT*%#;O=HY2'PY?333_?>/M>.VI@Q8[RV9Y---HF3JA7-]GOELPP8
M,*#IVE9+B.>OJT8'&M0ASSN9ZL2)$U.UQ4>@(;3[;UFO+0#E5?F[AOZ8I"T$
M&I"$0 -@M]]^^]6\QW[_^]^/Y^B.'S\^'O*M#.-*5*8$=NHX=>S8L>;GE=Q.
M*RZX2M.AUYNXK;?>.NK;MV\T=.C0:/CPX=%QQQT7'7SPP=%FFVUF?%/GTE%3
MTL=:;Z<U_U[SD^^YYYYX+OU?_O*7Z-IKKXUZ]>I5\ZVAOI.BI>UP*!G=SW[V
ML[C3I>.M_WO((8?$HS/2?/[BBR]NJK;9A'C^^M#H0(.&].=)B2:5>#--6WP$
M&D*[_Y;QV@)0;A519SAKJ?4#>^FEEV:N5^6SSSXK^OBD1J"A& 0: +,___G/
M-1\&#S_\\.B==]ZI68?>+FKNK2T+N<KNN^_NU,Y[[[VW9H=>#[=Z<%VX<&'-
M>M2)F#QY<G3888=%*ZRP@E-'35G8M:I$K4Y(K=^GQQ]_/%I__?6MG[_YYILS
MM<L7V^^5.B[J8.B^FI3@31V<I'GGRRVW7#PGO%G:9A+B^>O+[W__>Z=G.%,9
M/'BP]5CEG?SRYS__>:MM5H^UZ1IW$>+]MVS7%H#RBP,-+A5HO5_;S:9,RU.Z
M(M!0# (-@-ENN^UFO3=K&;UZ:)[QNNNN:ZU/;_^ST-#B6F]-M8QDEH"SEJX[
M]]QSHU-//353NRZ__')KF[2*1!IOO_UVM,$&&QCKV&BCC>)@1E%:_EZI(W/F
MF6<F=GQ,;KKIIII+]*E#U2QM:RG4\S=DIYQRBO%8:8I!GI3[H65"5R5$5%Z!
M/ (-(=Y_RW1M 6@.!!H\(=!0# (-0&M:<]VV2L(^^^R3:1ZTWM+;I@0,&S8L
M4SN/.NHHZ^^'.OM%T%*4MF4)]]UWW[KJTML_V_=P]=57Y[0'R:J_5UI^\]>_
M_G7TZ:>?.M5WWWWW6=_JZVUI/<O?A=RVED(\?T/V[;??6CO,YYQS3J[;[MZ]
M>ZMM3I@P(4ZJZ#O0$.K]MTS7%H#F0*#!$P(-Q2#0 +2FY<],UX4>5&?.G)FY
M7LTG-]6[Y99;UEV7VF%[<!XY<F3F-KK2M 93FS0<.,L:]J;AVBJ:KU^4N7/G
M1@,'#HS>??==;W6>==99UF>!W_WN=TW1MB6%>OZ&[*&''K)^#R^__')NV]7T
M ]/UI\!''H&&4.^_9;FV #0/ @V>$&@H!H$&H#4-S35=%UVZ='&J]\X[[S36
MJ[=:]2YK=N"!!QKK^O&/?QQW (K2HT</8[LT##X+O=7[WO>^9ZSSJ:>>\MSZ
MXNCMJ(:BF_93">^:K6VAGK\A4_)+TS';=MMM<]OFXL6+C<M+5I\1\@@TE.'^
MZTO(USV XA%H\(1 0S$(- "M'7_\\<;K8LB0(4[U*F&=[7Y?SS!9K>=N&W+[
MY)-/.K71A>;<VX8\SYHU*W.]2O!GJE.K5C23$TXXP;B?RIY?-)]M"_7\#9FF
M)*VQQAK&8W;!!1?DMEV-+FFY/8T,J,HCT!#Z_=>WD*][ ,5JVD"#YLC=???=
MT447710G'SKZZ*/C^90:QJK_]M___=_.\].6U,A 0Z/W+0L-#]12;UJNZMAC
MCXW;]XM?_"*>ESQ[]FQOV\D2:- YJZ&4>L#0 \&@08/BAQ'-J7WBB2=R7\=[
M29]\\DD\SU%9R:O?I8K^?_TW_4W_IF@A'3,IPS50)-L06Q\/]"NNN**Q;B5;
M2\OT\*^RUUY[.;?/Q1_^\ =CNSIW[NQ4KU83,-7;J5,G3RT/@VT_E32N:#[;
M%NKY&S+=KTW'3-,)YLV;E\LVM?*!EI!<<GOZWTJN6)5'H"'T^Z]O(5_W (K5
M5($&9?'6<DP__>E/:RXW52W_]F__%AUPP 'QO$%7>0<:BMRWJ5.GQDLHM2PS
M9LQHU<8KK[PR7A,\J7U;;;55=/WUUSMW4.L)-&BYJ9X]>R8>/R6K.N.,,W)=
M7G7*E"GQ0ZGM[>F21?^F5Z]>T1__^$<OVT[[?4I(QZS(:Z!L;&_0M5Z[*ULR
MMWH"B%IUP52'KW,\JV...<;8+JUI[T)!+]NUGK3L89DH^:7M>OSZZZ^;IFVA
MGK\AZ]^_O_&8_>0G/\EMFUJRL>7V]#NUI#P"#:'??WT+^;H'4*R*N%002J!!
M;UMM2XFE*>K(O?766YFWGV>@H>A]2].95R=UBRVVJ+MMW;IUB]YXXXU<VZ:'
M_ $#!M3=MO777S]Z\,$',[?-Y/GGGX_G\&;]+K???GOG-Q=E.V92]#50-K:A
MK.>??[YSW6W:M#'6G3;!F$8[F3Z_VFJK%?Y0JB7V3&W3VUA7MNO^MMMN\]#R
M,.A-L>T:_.*++YJB;2&?OZ'2L^!**ZUD/&[CQHW+99OWW'-/JVVML\XZK4:Z
MY1%H"/G^FX>0KWL Q:J(2P5%!QH^__SS>+W>K!V0)8OF#S[VV&.9VI%'H"&4
M?4OJF#[RR"/6X7QI2MNV;3,G14MJF]X6*@%3UK8IT[ROCO/$B1-;#>/,VJ;K
MKKLN<SO*=,Q"N0;*YM)++S4>@ZP)#:N4P\!4K]9C3TO#ATUU].W;UZEMKI0T
MSC92QL>H QU[4]U:Q[Y9O/CBB\9]U&B.HOEJ6ZCG;\ALJS!H"<0\1O1H])MI
M9*7I=S./0$/(]]\\A'S= RA615PJ*#+0H,0X.^RP@Y=.R)*=)'6<Z^4[T!#2
MOM7JF&JXGNU-13U%;X/T8^6S;7IS\<,?_M"Y;7J#X#HL\;+++O/Z7:I<<<45
MF=I2EF,6TC50-G_]ZU^-^Y]E&<HEW7[[[<9ZZYF;OO_^^QOK4/Z6(DV?/MW8
MKG;MVGFI?\*$"<;Z-;VG66CJ@&D?-=6@:+[:%NKY&[*##CK(>,SVW'//7+8W
M9LR85MO2B"+35,T\ @TAWW_S$/)U#Z!8%7&IH*A @X9C[;SSSHD="STD[KKK
MKM&AAQX:OQGMWKV[=2F>:EEUU57K7B_=9Z AM'VS=4SOO__^^(?3]+>--]XX
MVG???>,(ON9F:G]L2[Q5R^:;;UYWXL-:G>9##CG$^#>]16G?OGW4M6O7>%DM
M'<>D8[W''GO4U:XE:6BT;;WU:E''?+OMMHO;K*+_WS9$LEI49Y9AUV4X9J%=
M V6CY?5L4TU<EE3<9Y]]C'7JG$IK[;77-M91:TJ0WE"^]-)+T>.//QX_Q"LH
MZ3L?B"T1I'*"^*!1/J;ZFRDS^_#APXW[J/.F:+[:%NKY&RK]IBO ZWK?2$M3
MY%K^=NJW4L?>)(] 0\CWWSR$?-T#*%9%7"HH*M P>/!@ZW;5H=4R0L\]]YPQ
M@JWUAI4@3@^0MCKVWGOONMKC,] 0VK[9.J::]][RORFIH.V-\7OOO1>-'3LV
M6F&%%:QM^^4O?^FE;:;EI;;99ILXF>#[[[_?JAX]^)U\\LDUDPS>=====;5-
MU*%5Q]96YX8;;ABOSF%:(4$/:'I+9EH#O%I\!HY".682VC501J:W>BJ[[;9;
M_"!<+UM'68$=33M(0_< 4QU*W-ER?KNN"8W:V6FGG:Q!RDTVV21.X/C  P\X
M)Y8=/7JT<1M''GFD4[U5MGG,ZA0U"P6+3?NH<[%H/MH6\OD;*B5]-NV[IA%J
MU)IO??KT:;6M?OWZ6?]]'H$&"?'^FY>0KWL Q:J(2P5%!!JTY)]MFWKCFC:Y
MH'[8+[GD$NO;9OU IN4KT!#BOMDZIBW+J%&C4OV :CWZ33?=U%B''LAT+%W;
MMN1^ZVV\YDRJ YI$#WRV/ K[[;=?ZG95:5BT[7CI;UJF,8GF99J".M6BH;SU
M"/V8A7@-E)'R6]BRXVM)T'HZ-KIF;2-%%"A+ZR]_^8NQCI;+/&J:@7)JI+GO
M5(N6H,P:V!); K<1(T9DKG-)^CVTM5W7>-G9.D(J6:;%A=BVD,_?4"FH:]K?
M P\\T/NV])*CY7;T8F/^_/G6S^05: CQ_IN'D*][ ,6KB$L%C0XT?/755];E
M$_6#IIM[O93UV%2?WC:GC3S["#2$NF]I @W#A@VKJUTZ7LK+8*JKGHYS4MN4
MC$@K%M3#]@9&09 //_PP=3VVAU(532NH)T.YS@TM V:K[]%''TU=5\C'+-1K
MH*R4_-(6!-*PUE=>>:7FYS7D6YTF6[)7S;VNYX'9-CVA.L)$WV^MX%R:HA$(
M67Y[U/$QU:=@E2^V?#9%+DWGBVVJD^;&%\U7VT(^?T.DD7"V95TG39KD=5L*
MBIOR"^D%2"UY!1HDM/MO'D*^[@$4KR(N%30ZT*!AW*9MJ7/B,@S/EJQ(;U?3
M\!%H"'7?DCJFZ@"G>?/=TI0I4XSUZ0UTVND 26T[YYQSZFZ7*$>"J;Z;;KHI
M=1VVCHN6@$PSDJ$E9>>VS0_V&9PI\IB%>@V4F?)XV.9(:]I+CQX]XFD#"BXI
M[\J==]X977/--?&0;MN:[2H: EQOX.>BBRXRUG7LL<>FSLN1IFBXNFDZ4BW*
M[V&JR^?\9]N\;<W;+S/;J@(J__F?_]DT;0OY_ W1^/'CC?NGCG.6H'$MFJ9B
M^JU-VDZ>@08)Z?[K6\C7/8 P5,2E@D8'&FS)!UV7K7OGG7>,\RC39@3W$6@(
M==^2.J9Z<Y^5[2U]VO6F:[5-PUGUACP+6[VGG79:JL]K36M-/S#5X3)D_\HK
MK[0^L.A[=MFWHH^9A'H-E)T2D-E&BM1;=%XKETH](W*J3C_]=&.=9YQQ1IPT
MUD?[JJ5GSYYUO>U3/A)3/9,G3ZY[/VUT?9FV<>^]]WK;1J,I:*I$L:;]TAOF
M(D<-^6Y;R.=OB';991?CONE8^:3<&:9<2+?<<DOB9_,.-$@H]U^?0K[N 82C
M(BX5-#+0\.RSSQJWXY+=?DE:![MEW>J<:/A:$M= 0\C[5JMCJH<A%].F33/6
MFW89J%IMTUN!K#1GVA0H2+N,E&TI.W4T7'Z %02PO15->ZZ%>LQ"O@::@<X=
M!:HT%SS+ Z[F.FME#V7/S\J4<%1%N3=,_UW?C_)\Z)S5_&O-^7WXX8?CD2]:
MU29I)1OE&4FK0X<.QCI\CGK1<&+3-K*L'A,*TW55+4K*VDQM"_G\#<W;;[]M
M311\SSWW>-V6WOZWW(9>8J31B$"#A'#_]2GDZQY ."KB4D$C PVV'P2M+>R#
M?OQ,]3_YY).)GW4--(2\;[4ZIJ[#BM7IMBV5.&_>O,QM4R9WU^7#3&\@-!0S
M#=NT"1]9F/7VS%3WSW[VLU2?#_68A7P-- O-F;[JJJNL2<IJE8$#!]:5"\3D
MJ*..2KT]=13FS)E3L[Z77WXY'F9NJT-#EM,^F&M)7E,=2G;JRXX[[FC<1EF'
M&=NF.JGX6JTCI+:%?/Z&1KE-3/NT^NJK9QXU9Z+1 BT#&OK?SSSS3*K/-RK0
M($7??WT)^;H'$):*N%30R$###COLT&H;2K3C:RZCDM:9,M1K[E\2UT!#R/MF
MZYCJ[;5IV<-ZV=X2*8=#UK9I_J(KY3UH6:_FEJ;1MFU;8[N2'CS3T .4J6X-
M'4TSU#;48Q;R-5!VRF^A %6MI673%KV]S=KYUANY--O06^"T0X/5:=';85M=
M>O.6AFT969]OYVQS^&^XX09OVVB4&3-F1,LOO[QQ?]9;;[U,>6A";UO(YV]H
M;*-WCCON.&_;T._=]MMOWVH;@P8-2EU'(P(-H=Q_?0CYN@<0GHJX5-"H0(-^
MC+56=<MMI!T>EY8ITJQ(<A*70$/H^V;KF';ITL5+NS2/TE1_FJ2$MK;I1]V5
M*0"BCFK2U <-&36U*>V;_31L2UVE6?HQQ&,6^C509@I,:84-UP?<EN7G/_]Y
MW?.$TW34-+]7B?7JH7]ORCBOHO,J3?X279^FS_L,--ARTF@U@S+1G'C;6UD%
MH+7D73.V+>3S-R1SY\ZU'I\__>E/WK9C>K.NE5T6+%B0NHZ\ PTAW7]=A7S=
M PA315PJ:%2@8>;,F<9M:"BC3Z;,^=6EJVIQ"32$OF^VCFF_?OV\M.OYYY\W
MUI]F)05;V_0 XDH)ETQU?_SQQS4_9UM7NE>O7LYMJK(EV4HSGSS$8Q;Z-5!6
M>JBW93Q745;S$T\\,<X>KBDDZB"\\,(+\><NO/#".".Z:11(M6B)MGH>=@<,
M&%#SX5G;>OSQQS/MJSYG:VN:H.4FFVQB_*PRP?MB&K6C4N]RLD52I[C64KN7
M7WYYT[8MY/,W)+_YS6^L]QM?20(U2L"T"M/8L6/KJB?/0$-H]U\7(5_W ,)5
M$9<*&A5H4+(LTS;T!E5S]%2F3Y_^CZ*;MLH33SSQCZ(EQ%3T@UXM6C%!15GM
M54S#\#2O-HE+H"'T?;-U3+4DDP_Z 3,E$=QVVVTSM\U'<K6SSCK+6'?2VY+K
MKKO.^#EE+/?EY)-/-F[CZJNO3OQLB,<L]&N@C)1X;I555C$>5SW\*M%<FGOT
M<\\]5_,!4TO[I:5_:ZM'Q36Y[)Y[[FFL5QW\)%MLL87QLSX3U_WH1S\R;L-7
M'I*\::AZK;?ZNB\U<]M"/G]#8DMX>.JIIWK;QM"A0UO5KV!AO<E]\PHTA'C_
MS2KDZQY V"KB4D&C @VV9?T:4?0 FL0ET!#ZOMDZIC[7ES?E--!#0]:V:34+
M5V>??;:Q;IWSM>B-BNES/G,!:/E/TS;./??<Q,^&>,Q"OP;*1F\-34$5%5UK
M"M;40U-;:B7"2[L\HZESL&1Q38JHD0&F>I7K(VDXNRT(X'.T0<>.'8W;F#IU
MJK=MY&GDR)'6[T[):+_YYINF;EO(YV\H]$;>=GSJO>_8S)HU*UIVV65;U9\F
MKU-+>00:0KW_9A7R=0\@;!5QJ:!1@08-'2RJ(Z+A;4E< @VA[YNM8ZKA?KZ8
M,KXK#T'6MOF8!YJUTVQ[</$9F!DW;IQQ&\.&#4O\;(C'+/1KH&QL6<%=YM'J
M87+777<UUJN@8)J'S5&C1M7\+EP3B6F*CFVHL4:[U*)ARJ;/39PXT:E-2U*R
M--,V?'7 \J1L^;;O3://?"5M#;EM(9^_H;!U2M.\.$A+B8M;UJ_K-XL\ @VA
MWG^S"/FZ!Q"^BKA4T*A @X:=%]41T3S )"Z!AM#WS=8Q];F^O"D1EM88S]JV
M(CO-ZNR;/N<S,*,L]:9M#!DR)/&S(1ZST*^!LM$#H&E?-17%A9*-FI)VJMQU
MUUV)G]?]T/8]*-CHPZ:;;FJL/RE@<.BAAQH_5^^<[UILV=KU^Q&RN^^^VSB]
M346K=129K+"1;0OY_ V%+=>).O0^3)HTJ57=^OXUDB*+/ (-H=Y_ZQ7R=0^@
M'"KB4D&C @V:VQ=R1\0ET!#ZOMDZICZ76#(-6]9:V%G;5F2G^1>_^(7Q<W?<
M<8=SFZHT1#?KPU&(QRST:Z!,-#?8M)]Z4_KJJZ\ZUZ]UTDWUJZ.>9/+DR=;O
M08G-?-#2@J;Z+[KHHIJ?4Y#.]#DE./5!;_YL^Q[R6T'E1VG3IHVQW9J#GK6#
M5\:VA7S^AD!Y<VS'1],=?#"M>N 2%/ =: CY_EN/D*][ .51$9<*&A5H&#Y\
MN'$;RN2O-9/S+.HX)G$)-(2^;[:.J<^.\^:;;V[\,<O:MB([S2-&C#!^SN<2
M=K;AC"[?9Y''+/1KH$PF3)A@/)8:->2#KGM3_>NLLT[B9_7P:ON]Z-^_OY?V
MV1[$D]ZH*LN[Z7.]>_?VTJZ77GK)6/]JJZWFI?X\* O^6FNM96RWWJSZ##:7
MH6TAG[\AL 6,M]IJ*V_;4+Z*EO6?<,()\?')4FR)%KMV[6K]3*V5,T*^_Z85
M\G4/H%PJXE)!HP(-MKF1H2P+YA)H"'W?;!U3GQUG_4BVK%_KVF=M6Y&=YE__
M^M?&S_WN=[]S;E.5WFZ9MG'FF6<F?C;$8Q;Z-5 FQQQSC/%8:ADU']Y__WWK
M/3]I**W68;=]UE?[;",3DNHW#<E6T9*H/BAAFZG^+EVZ>*G?MX4+%UJ'\:OX
MS#E3EK:%?/X639WO]NW;&]L^9LP8;]LQ!1H:76HM*1GR_3>-D*][ .53$9<*
M&A5H&#]^O'$;>@L5 I= 0^C[9NN8^EHW64LGF>8NIWD+$F*GV?9&(\V*$&F=
M<<89QFVD6=DBQ&,6^C50)K:AU^>==YZW;=AR#6@IMB2V-V7''7><E[8-'CPX
MTX.^AG:;/I=F9%4:EUQRB;%^+1L7FL6+%\<!%MMONZ[SI;5MH9Z_17OXX8>M
MW\EKK[WF;3NA!QI"O__64O2U!:#Y5,2E@D8%&I24)N0?7Y= 0^C[9NN8ZH'(
MA]=??]U8?_?NW3.WK<A.\YUWWFG\7-^^?9W;5+7__OL;MY$FX62(QRST:Z!,
M=MYY9^.QU'0;7VRK)SSTT$.)G[6M[M"G3Q\O;;.M]YZ4:T&=!R6@-7U6]RA7
M P<.--;M\VVO#SH.RC=@^UT?,&# 4MVV4,_?HBG1H:G=.^RP@]?MA!YH"/W^
M:Q/"M06@^53$I8)&!1H4$3=MP^?</Q<N@8;0]\W6,=4/J@_WW'./L?Y33CDE
M<]N*[#3/GCT[]^_3EME[YLR9B9\-\9B%?@V4R>Z[[VX\EE=>>:6W;=C>ZC[V
MV&.)G[4M?Z=V^]"S9T]C_6E6C]"\;--G;[[Y9N=V=>C0P5CW_???[URW3\I;
M8OM-5R?[JZ^^6JK;%O+Y6Q1U4K4<M:G=EUUVF==MA1YH"/W^:Q/"M06@^53$
MI8)&!1I$2;-,VUFP8('7[63A$FB0D/?-UC'5D&(?/SZV^?G777==YK85V6G6
M0XCI84A)E!8M6N3<KG???3=>D<-4_Q=??)'X^1"/F81\#93)88<=9CR.RAWB
MR[+++FO<AH)L2:9.G6K\K#HJ/M@>PK522Q);,CO78?&VWTD=Q\\^^\RI;I]L
MUZ^*DME]_/''2WW;0CY_BV++/Z+?*=]+((8>: C]_FL2RK4%H/E4Q*6"1@8:
M#CKH(.-V?";9R\HUT!#ROMDZIBH^WL8I&9JI[ADS9F1N6]&=YI_^]*?&S_I(
MH&G+ 9%VB&JHQRSD:Z!,E('==!Q]3=V9,V>.]7Z@1&))- ]XN>66,W[>=8K"
MO'GSK&W3LG-)M!:]Z;/KKKMNG$LF*]LJ,=VZ=<M<IV_77GNM]=AIJ/9;;[U%
MVZ*PS]^B'''$$<8V[[;;;MZWI141]+SEJVAZGJGM6D7$]IE:0K__MA32M06@
M^53$I8)&!AI^__O?&[>C#+FUEAMJ!-= 0\C[5BO0H'F9+FQ#YM=88XV:;PV2
MVE9TI_FLL\XR?G;???=U;I<>WDQU*T%D&J$>LY"O@3)1TC'3<51GV8>KK[[:
M6+_67/_FFV]2U7'  0<8Z[C@@@N<VF9;C46CK]*T3;]9MK7C'WSPP<SMVF67
M77+97U\T?<WVEG3EE5=.-25K:6I;J.=O$73-Z'LPM?N::ZXINGF)M%REJ>TG
MG712IOK*</^M"O': M!<*N)202,##9]\\DFTP@HK&+?E<ZG%+%P##2'O6ZU
M@]J<IA-I8XO^ITTT&6JG6:,Q3)_]SG>^DVJDALWCCS]N_2Z>?OKI5'6$>LQ"
MO@;*1/-T;>>(CQ%(&CECJEMSR]/2,'!3'9TZ=<H\<D"?Z]RYL['>@P\^.'4]
MO7OW-M:A!*Q9Z&'==B_0V]FBZ;YA"ZYH.M:T:=-H6PLAG[^--GGR9.OW\^&'
M'Q;=O$2^ PUEN/]*J-<6@.92$9<*&AEH$%O'5!%_GTLHU<LUT""A[ENM0(/+
M#[(>LO6#9JHS;5*C4#O-HKF-IL_OM==>F=MDFY*A!]RT0CYFH5X#9:*\*;:
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M0 ,2$6@      *1%H &)"#0      -(BT(!$!!H      &D1:$ B @T
M@+0(-" 1@08     0%H$&I!H[MRYT1_^\(=69<&"!44W#0     0& (-
M  # &P(-      # &P(-      # &P(-      # &P(-      # &P(-
M  # &P(-      # &P(-      # &P(-      # &P(-      # &P(-
M  # &P(-      # &P(-      # &P(-      # &P(-      # &P(-
M  # &P(-      # &P(-      # &P(-      # &P(-      # &P(-
M  # &P(-      # &P(-      # &P(-      # &P(-      # &P(-
M  # &P(-      # &P(-      # &P(-      # &P(-      # &P(-
M  # &P(-      # &P(-      # &P(-      # &P(-      # &P(-
M  # &P(-      # &P(-      # &P(-      # &P(-      # &P(-
M  # &P(-      # &P(-      # &P(-      # &P(-      # &P(-
M  # &P(-      # &P(-      # &P(-      # &P(-      # &P(-
M  # &P(-      # &P(-      # &P(-      # &P(-      # &P(-
M  # &P(-      # &P(-      # &P(-      # &P(-      # &P(-
M  # &P(-      # &P(-      # &P(-      # &P(-      # &P(-
M  # &P(-      # &P(-      # &P(-      # &P(-      # &P(-
M  # &P(-      # &P(-      # &P(-      # &P(-      # &P(-
M  # &P(-      # &P(-      # &P(-      # &P(-      # &P(-
M  # &P(-      # &P(-      # &P(-      # &P(-      # &\49_A_\
3T&UL:D2WVP    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
MB5!.1PT*&@H    -24A$4@  !!H   'T" 8   "3JDX*    "7!(67,  $SE
M  !,Y0%USO"5  "@G$E$051XG.S="=Q54____PN92<;;$%)(D2$R9\Z0(7,R
M9BI3YNDF9$A(ALCT=5.FRI@D1(K;D)(T((EH0$4#&7/;_\=[_Q['_^I<:^VS
MA[7/V>><U_/Q6(_;W77MM=<^USY[[_79:WU6C0<      .! C92Z$0
MH#(0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:        ,X0:        ,X0:        ,X0:        ,X0:
M ,X0:      JT,"! [U[[KEGB:)_ X"T.0DT_/;;;]Z4*5.\CS[ZR!LW;ISW
MY9=?>G_\\8>+]CGQ\\\_^^W[\,,/O8D3)WHS9\[T_O[[[U(WRY?EMA63SJ%I
MTZ9YDR9-\D:/'NU]_/''WM2I4[U??_VUU$T#D"&Z/G[[[;?>YY]_[M]S=.W\
MY)-/O!DS9GB+%R\N=?, (%.VWWY[/>PO4?1O )"V6(&&O_[ZRQLZ=*AWVFFG
M>4V:-/&66FJI.A>Q>O7J>2U:M/ NO?12_T&PV/[[W_]ZYYQSCK?IIIL:VU>_
M?GUOO_WV\_KTZ>/-GS^?MA79^^^_[W7OWMT[X( #O(8-&QH_AUQ99YUUO/WW
MW]^[YIIKO'???=<__P!4!P44="T\[KCCO"VVV,);8845K->*I9=>VMMPPPV]
M@P\^V+]>C!@QPOO]]]]+?0B ,Z^__KKWTDLO12I#A@SQA@\?[HT=.]9_$;1P
MX<)2'P:*B$ #@%*)'&AX[+''_.""[4'/5O;>>V__+77:QHP9X^VZZZZ1VJ:.
M_?777^_]^>>?5=NV8OCQQQ_]8]EDDTTBGS^UR[KKKNM=?OGE_@@( )5'(YDT
MO+=ERY:)KA4JJZRRBG?BB2=ZK[WV6E6.%D-E^=>__I7X.Z'2N'%CKT.'#E[O
MWKV]N7/GEOJPD"("#0!*)72@03>B-FW:)+JQ+;OLLEZ/'CU2.QC5K9$4<=NW
M[;;;>M]\\TW5M2UM>J/8K5LW;]555W7R@)0K^CP[=NSH#YDN=YHRT[-GSSIE
MPH0)95$_X()&*]UUUUW^*":7UXI<T8B(AQ]^F%%1*%NN @VUBT8)Z5[ZZ:>?
MEOKPD ("#0!*)52@04/M&C5JY.RFUJE3)^=OEKITZ>*D;1MLL($_5+=:VI8V
M39MIWKQY*IV&7%EYY97]3O/__O>_4A]N;)I.8SJV__N__RN+^H&DE)]EAQUV
M2/5:D2L*.+SRRBNE/F0@LC0"#;FB@,.]]]Y;ZD.$8P0: )1*C03]PG???>=M
MO/'&SF]H&OKNRLTWW^RT;9H:XFHH89;;EK8! P8$SJ=V7?;::Z]2'W)L!!I0
MS5YXX05_BD.QKA6YHEPY0#E),]"0*QK=@,I!H % J=2([8<:7KK[[KL'WI#T
MEOW""R_TGGWV63]1WWOOO>?_]T477>0G^0O:5@^72:D#I01@MGUH/O^55U[I
MO?SRRWZ&<K510V?;MFT;F(#PL,,.J^BVI>W^^^\//(;\S^&((X[P+KOL,N_.
M.^_T'GKH(7_[VVZ[S3OOO//\Q)AA.B'+++-,J0\[-@(-J%:///)(Z&N%1B\I
MH-BY<V<_B*L\#KIFZG_U_\\XXPRO=>O6WHHKKABJOJ9-FY;Z\(%(BA%H4-'W
M"96!0 . 4@D,-&@XNNTFM-QRRQ5,4JBEQK2RP/+++V^L8^VUU_83!,:E)32U
M<H.MC>>>>ZZW:-$BZ_8*BFRTT4;6[9]ZZJF*;%O:U+:@ (O*:JNMYJ](,G[\
M^%!UZCQ[\\TW_3<M*ZVT$H&&C-4/Q-&_?_^"UPJ-BCK]]-/][W_8Y2MU_=6*
M$PI(K+[ZZ@0:4#%L@89;;[TU<.6)@0,'>@\\\(#_$JA5JU8% PT*_KWSSCNE
M/EPX0* !0*E8 PT__/"#-7F?DCKJ+7Q8PX8-LP8;=-.+Z^Z[[[;>)!4$"6/6
MK%G6J2%:'4$/K)76MC1I99&@Z1)Z>+G@@@N\>?/FQ=Z'IHXH2)&_'P(-I:L?
MB$JCN I=*\X\\TQ_^EX26L%"UV/3"#L"#2@WMD"#KO%13)PXT1\=&11LT/+3
M*'\$&@"4BC70<.VUUUIO/AK:'I66Q335I9$1<1XD]89;0^Y-=1YZZ*&1ZE+"
M0MN*$'&.-<MM2Y-&: 2-XFC0H('WQAMO.-O?E"E3_&'2!!I*7S\0Q<\__QRX
MS*U&(6@Y2I<4<.C:M>L206\"#2@WK@(-.3?>>&-@L$'/("AO!!H E(HQT*#L
M_;;\"NK8Q5TQ0G/M374JJ!&5AN>;ZM(;LNG3IT>N[_SSSS?6M\TVVU14V])T
MQ1576!]6UEAC#?\-BFLZ5__][W\3:"AQ_4 4EUQRB?5:H:4M/_OLL]3VK=4M
MMMQR2P(-*$NN PURTDDG6;^/5UUUE</6HQ0(-  H%6.@04D);3>=X<.'Q]Z9
M\@Z8ZEQ__?4C!R]L08NX6<2___Y[?W2%J<XQ8\943-O2\L477UC;J*DV:<_U
M?/+))_U 3KDBT(!JH2"";926DCB.'3LV]39H=,/QQQ]/H %E)XU P[???FN=
MWJJ$X"AO!!H E(HQT-"M6S?C#4?Y N*.9LC1@UW2FZ022-H>5/6V*JYCCSW6
M6*=6AJB$MJ7IM--.LP:GBI6]>LB0(4793QH(-*!:!+T][=.G3U';\NBCCQ9U
M?T!2:00:I'W[]L9Z%8#X_???';4>I4"@ 4"I& ,-AQQRB/&&<_;99R?>H6W(
M[,477QRZCL<??]Q8AX;#)J%E.4WU-F_>O"+:EA8EK;2-9E#[M$QJ.?GIIY^\
M5UYYQ>O5JY>?N%)!%!7]M_Y-/]/ON%3)@09]5N^__[Z_+TV3TN>HU4.TDH#^
M6\N8#AHT*''2OS@4&'SFF6?\=FF% K5+4Y5NN>46_^_\RR^_%+U-^>;/G^\'
MT6Z__?9_SL=33SW5;Z?^[=577_5S'I2#;[[YQAJ(52;\I('L+)H]>[:_E+/F
MPFNY7IUC6G5(JP0DF4Y6BNM4.:N4[U%:@08%^6P!P*^__MI1ZY>4M7,XR_<J
MG9LOOOBBGTS\K+/.BG2O(M  H%2,@8;&C1NGUBG1$'=3W=MMMUWH.K16NJF.
MRR^_/%';="&W/03/F3.G[-N6%HU8L#V@Z &[7.@!XL ##[1^SK6+?J=MV[;^
MC3\.34_:=]]]_RD[[+"#<3_-FC5;XO>"R@DGG%"T^H,H;\;;;[_MY\YHV;*E
MOWI H<\S5_3[=]UU5^H/_*-&C?+:M6OGY_4(:L_**Z_LG7+**?[4H'R:"I7_
M&<6='I5/*\H\\L@C?DZ<0LL_JFAZTN&''^XO 9EE-]QP@_48DDS+*Q8EJ#1]
M-[3:3CYU:O?::Z_ O]]UUUT7N0W%O$[I3;;VE7^\)YYX8JSZ@BA_D>FS[=*E
M2^PZ*_%[E%:@X:VWWK)^+EHAQJ5BGL-!RN%>]?GGGWLGGWRR=6I+KFC9;_V>
MDF3G(]  H%1JI/8_Z(V2[8*F' M)C1\_WEBW'@+TQB$,V_0+%T/G;>M+/_?<
M<V7?MK3D$JOE%P6L="//.IV38=85MY6==MHI\IM)!6#B[L]6-+6I6/6;?/75
M5]XUUUSC;;311HGWM=9::WE]^_:-\=<,IHZ31F9%>:!440=$;Z!KOW%/Z^%-
MZ]W;EK4-4_10/G/FS,3M2,/FFV]N;'.+%BU*W;10--7"U/X1(T;\\SOZ[&UY
M>O)+E$3(I;A.29LV;8SU??KIIY'K"J(WV*;]*#@51Z5^C](*-$R8,,'Z6;A:
M+:I4YW"^<KA7Z5ZCESBVT:)!]ZH>/7HL\>Q%H % J=1([7]0=-9V 7.1"5QO
M+6SUCQPYLN#V&AYF>S/AXLV^WDB:ZM:R:.7<MK0H>F[[>Q8K-T,2__G/?PJ^
M*0A3E(@RRL-&)08:3 \S28N&-KN:>J- IAY4D[1'HQMR#W"N']YR"0I=?&YK
MKKEFZ@E8H]+]P];>.^ZXH]3-"Z50H$%Y>&Q+&YM*V&MWJ:Y3\O###QOK4BXG
MEVS?S<F3)T>JI]*_1VD%&O3FW/8YO/SRRXG;7<IS.%_6[U6+%R^VYLP(6S2Z
M(:U[%0"$52.U_V'NW+G6"Y<R$R>U<.%":_V]>_<NN/WHT:.-V^KASH4''GC
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MB[J4F-Z(V1[<GGGFF4AU*:&KW@ZY>GC3^6-[RZ^WI^J<1Z6W<J;Z].:PE"O
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M/1*7@8;77GLM,!%FW)=+63V'T^#B7J5\%+I^Y->AH/:$"1-BM\T6:(]ZKP*
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MH0Z7GAO"J,;OD:01:- (A#%CQCAI7SF<PS:EN%?9EK7LW+ESHF/)L8T (=
MH!AJQ/9#S5NU7=!S1?/0-)Q?TRF4C$=%_ZWM]#/3-@I0V#(2%UKVJ%FS9L;M
M-)?2%=.\495"\SZSW+8T!(U4B;)&=C'T[=O7V,[++[_<V3[..^\\XSX>>NBA
M@MM66J!!<T/UUE]S=4UO'9.4,,O%FN;,JB3)>%Z;ANB:YCN'>7C3O%O;@Z4>
M]E5&CQ[]3]%\<!7E ,@5+6>KHB'.N:)UZU7TH*RBA^/\?409ENZ2[@MI72NR
M$&C0^>9"UJ]3HLZ8YO#G;Z_.5EA3ITXUMB'*:(1J_!Y)6B,:-((U[#D0I!S.
MX=I*?:]28D[3MDJ@ZX+R1)B>Q0DT "B&&@GZ!25E*K0D992BA(FVAPP%'PHE
MY;)UM%V^T5?"2],^- ^O7-N6AJ>>>LKZ=R[54E,VMF1T+N?:VH8":]AX(944
M:-!#O6W).1=%&<T+N>...XS;:J2#*Z8'_C /;U&FDKDN"H:6@BV)H$JA46R%
M9"'0\/333R<ZAIRL7Z=RCCGF&&,=X\:-"[6]D@(F/<YJ_!Z)+="PPPX[>/ON
MNZ^Q*#"B9X=Z]>H5/+8HTV)-RN4<EBS<J_KTZ6/<]IEGGHG[\=2Q^NJKUZF?
M0 . 8JB10K^DY=QLJU!$*0I8*!F0;7W[==99IV"#]]MO/^.VKMXH2<.&#8W[
MT$VI7-N6!F6EMOVMM>Q8EMBRDX=YXQ"6[8'ATDLO+;AMI00:>O3H81VMY*K<
M?__]!=MA2SZK8;VN:/FR. ]O81/CIE%T#2Z%$2-&6-L4=6Y_/KV1?.&%%PH6
M#6.VM2%IH.'55U]-= PY6;].Y6B9:U,=8:<F;;?==G6VU5O7* 'J:OP>29+E
M+76>:WJ!5FBP'9NFKR0)R);+.9R5>Y7:8=K6Y;+HIOQA!!H %$.-A/G%.7/F
M^ FOXEYP-<\QE\_!-H=/RU\68GN3HBBZ*[8DF%]\\479MBT-VJ?M[^WJ#9\K
M>@ QM=/E6P.M_&':1Y<N70IN6PF!AKONNBO5A[8H#V^77'*)<5M72Q#*MMMN
M&^OA34.(B_$YF8HZ*:6@ +.M3<6:]A4T\B%IH$&!%!>R?IW*T7!L)?+,KV.S
MS38KN*WMOJ'IEE%4X_=(D@0::E.PR+;<Y9IKKAE[5&(YG,-9NE==>>653OZ>
M09HW;UZG?@(- (JA1J)L\-)++QGG+ ;=D)5%6F^=<AY^^&'C[QYUU%$%]Z\;
MB6E;=2Q<"'H8+;1D5I;;E@;]36T/*E&',*;MXHLO-K93;SI=L;TQ/??<<PMN
M6^Z!!G6T3)FS<T5SNO46[::;;O([EAJ!HPSA/_[XHW_NJJ.77S2?.N[#F]ZL
MFK95XBU73-.8PCR\7731145YR+5=CTM!>1B66VXY8YLTC+X8RB'0D/7K5&W'
M'7><L9Y"H]FZ=^]NW$YOJ:.HQN^1N HTR-"A0ZVYM)0(,8ZLG\-9NU?9 C/*
M'>**$E;FUT^@ 4 QU$B<#3_]]%,_D[B" QJ)H)M?_?KUO7777=<?%GGZZ:?[
MR9I,#W"V&U&889>V[.7MV[>/<QC&XS+5KSENY=RVM)B&P*JX6N[-%=M; Y?+
M@C[XX(/&?>A\+Z2< PU*C*CYP:;Z5UMM-7]N;ISUP&W9LL,\O-GF";M,S&J:
MQA3FX>V**ZXPMDU9V77=3+.$.1?3HON$Z;C#!)A=*(= 0]:O4[6IXVBJ1\<0
MQ-3IT1#V[[__/M+^J_5[Y#+0(%V[=K5^+]YXXXW(]67Y',[BO>J&&VXP;AMF
M:<RPE!LMSKT* )*JD6+O5,F)3!?6,$L!:4B^:5M-S7!!$7Y3_1HF7<YM2\L9
M9YQA;).&7NJFGA6VF_E]]]WG;!^WWWZ[<1]ZD"NDG ,-@P</-M:]WGKK>1,G
M3HQ=[YMOOAG[X4V_8]K696)6/9C&>7B[_OKK4V];%FG90=-Q*SA=#.40:,CZ
M=:JVWW__W7^YD%^/EGFVL>5GVF>??2(?1[5^CUP'&O[\\T]_RHNI3G7*H\KR
M.9S%>Y5M&H?+$2!:OC3.O0H DJJ18NY0P^U-<SM5M,)%(9,F33)NJX=^%VS9
MZH\__OBR;EM:@E:>T%)A6:'LSZ8VNISBH65=3?L(DVV[G ,-9YYYIK'NI"L\
M:-AJW(<WV]!:5_E2YLV;9ZP_S,.;+0BB$5&5S#:O6J48R6/+(="0]>M4OA-/
M/-%8E][PFF@XNNGW]88ZJFK]'KD.-(BM ZX2M<.;Y7,XB_>JM)?,U4INIFEK
M!!H %$.-%'.'6I?:=%'=<,,-0VT?--=WVK1IB=O7L6-'8]UAYA%GN6UIT7!7
MVWS'4@XOS6=[D.K0H8.S?;1KU\ZXCS!)L,HYT&#*:!TFL6LA>@,6]^%MS)@Q
MQFU//OGDQ.T2V^<9YN%-:[:;MCWGG'.<M"VKE%S.UIE1IOJTE4.@(>O7J;#M
MU;0&$]/T&2VY.'?NW,C[KM;O41J!!K%-*8@Z(C/+YW 6[U6V\_BRRRY+W"ZQ
M)5\ET "@&&JDF#NT98H^^^RS0]=ANR'J[7I239LV-=8];-BPLF];6I0MW-2N
M-=98P\].G@5:HM74QA8M6CC;AX8,F_8Q8<*$@MN6:Z!A_OSYQGKUQBDIS86.
M^_"F8=VF->.54\0%VX-EF(>WK[[Z*O5S,:MVW757X[%KZ+*&<*>I' (-6;].
MY?OCCS^,4X@T)SR?;>61-FW:Q#J.:OT>I15HL+V5CWI^9_4<SNJ]2B-Y3=L>
M?/#!B=LE@P8-BGVO H"D:J18.].T":T_;;KH15F'W)9MNE.G3HG:]]UWWQGK
M58<E;(*@++<M+0\]])#U >6>>^XI:=MR--ID^>67K].^99==UENP8$'B^F?/
MGFW,WJWZU>DMQ#;2QU6@(:WZ;7.NM;),4J;E(\,^O(GI[:E&W\1=MJTV/00F
M>7A3 E?3]E$3XI4;VW!WE;Y]^Z:Z[W((-&3].F5RRBFG&#^3#S_\<(G?T]!Y
MU]>*:OP>I15H4$XETTHZ*DJP&596S^$LWZN4TRI_6^6N<9'GRI;LDT #@&*H
MD6+M3$F:3!<\!1]T<PI+2VS:ZDER8;9E,M9;N$IH6UKT &][X%MGG76\A0L7
MEKJ)OM:M6QO;Z"(;MFU>ZLX[[QQJ^U&C1AFWO_?>>Q.W+<WZWWWW76.]>CN6
MA-Y6VJ;DA'UXL[UEBKJ,7CZ=SZ8'Z2@/;T<>>:1Q>Y<)T[)('0U3 D$5K>*1
MY@BH<@@T2):O4R9:R<54IT8OUJ8WVOF_H\ZAE@V,JQJ_1VD%&L3VG*%K\2>?
M?!*ZGBR>PUF^5]D2I+M8XG+++;=,=*\"@"1JI!@[4B#!=L&[[KKK(M6EA\*5
M5U[96-?PX<-CM]$V!>"VVVZKB+:E*6B)++WQ*H9KK[VVX,]-[7.Q%*>RIIOJ
M#CLL<_SX\:G^?=.JWS920HG_DKCFFFNLYU/8AS>-DC)MKY$.2I 55Z]>O:QM
M"_OP]L@CCQBWWW3331.UK1S8EK]3.??<<U/;;[D$&K)\G3+1E!=-D\NO<Y--
M-OGG=R9/GFS<[T$''93H>*KQ>Y1FH$'? ],*!2JGG79:Z'JR> YG^5YE6ZDC
M:9X&V_<NRKT* )*HD6+LR+:NO3KE<88YMF_?WEB?D@3%H;E]IOH4J?[RRR\K
MIFUIT5LIT_"_7'$U!<!$4W+..^\\?RWV(!]__+'U<]3/XM+J&K;CSA\^;#-S
MYDSC]A=<<$'L=A6C?MM\W$)!GR":2VM[F([R\*;S0L-/377$?;.F-_)!YWG8
MA[>??OK)6VFEE9RVK5PH\5^#!@VLGV%:QU\N@88L7Z=LU DUU3MZ]&C_Y[:E
M*/5Y)E&-WZ,T PVB%S^F^C6*2U,XP\CB.9SE>]74J5.-V^LZJ7W$95M2.,J]
M"@"2J)&T=_+66V_Y0R1-%SN]W8I#HP-L%U -$X]*D7937?OOOW]%M2U-MF&7
M*LHED<;ZYG/FS/EGV&&A0(.8YNVK''C@@;';8!LFVKQY\]!UJ%-L^HX<<, !
ML=M5C/IMRSQ&S51>VUEGG64]CZ(\O(DM9XH"$-.G3X_<MA-.."&P;5$>WFS'
MJ>1Z&HY;R8)R->@\C;,"0B'E$FB0K%ZG;&RCAW)O9+?::JLZ/],*34DZ43G5
M]CU*.]"@>^H**ZQ@W,=55UT5NIZLG<-9OU?MM--.QCKBKLBCT0QZ)G)QKP*
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M+[_\LO?TTT][_?OW]P8-&N2]\\X[WLR9,TO=1    *#L$&@       #.$&@
M      #.$&@       #.$&@       #.$&@       #.$&@       #.$&@
M      #.$&@       #.$&@       #.$&@       #.$&@       #.$&@
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M1V>O\M@"#;?>>FO!52<T':E?OW[>[;??[G^W-MIHHX+?@3/.."-6.SGW
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M6_@_>_;99YT,&Y>WWGK+V.ZUUEHK5GUQT-FK/&D&&F;,F&$--$3-T\"Y!P
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M(S'5_\$''SBI/ZXT1S1LNNFFWN677^[-F#$C<3LK^=S3$JEIG1LM6K0@T
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MRS&M!*!<'Z5D"S1H2=4P)4K H67+EI&69*VM4L\]+05JVE8)-ETP!44)-
M  #Q%0PTB-X<FA[$@Y;WT^B%_-_7 WTAS9LWK[.=.E V6V^]M;%M+[SP0L%]
MY2MUH,&VM*""*2XHRW[<#I5IJ5(5O:EVR90X,.Z*!ZXD7=YR\>+%?L+"3S[Y
MQ.O7KY\?.#$E7<P5K> Q=^[<R.VLU'/OQ1=?-&Y[U557.6F;EAPET     "X
M$RK08)N[?=MMMQE_7W.RE8\A__?#9(<W#;%6LCP39<G/'P&1*]]__WW!?>4K
M=:#AB2>>,&Y[]]UW1SX6$XU ,7U>83I4FJ=OZXB.&3/&+Z-'C_ZG:.Z\BA)R
MYLK[[[_OE_?>>^^?\NZ[[_I%JU:H[+333G7VL<LNNS@Y_KB2!AI,-$VD4Z=.
MUF##GGON&7E:0*6>>__YSW^,;5/0Q@5]SIHB0J !    <"-4H*%7KU[&!_TC
MCCC"^/L??_RQ\2UM& \^^&"=;<\ZZRSC[[[QQAO&=C5NW#C4OO*5.M#0IT\?
MX[;///-,K.,Q67WUU6-UJ.Z]]UYKISCMTJQ9,V?''T<:@88<G1>VX]8J$%%4
MZKFG96I-;=-(!U=,?V,"#0   $ \H0(->@MM>M!?=]UUC;]_WWWWU?G=DT\^
M.52#M/QE_K;;;+.-\7=-JU2HG'CBB:'VE:_4@88>/7H8MWWEE5=B'8_)1AMM
M%*M#U:U;MY(%&M9??WUGQQ]'FH$&.>&$$ZS'K=%!857;N3=\^'!G;=/J'P0:
M     #="!1JT3*1I:+&*$K7E.^FDD^K\GH(/86CYRU57776);9503],D\FGN
MOJE-8?>5K]2!ABNOO#+5#JV8<F"$Z5!I"<92!1K4T2^EM ,-.F=L22-?>NFE
M2/54XKEWR267&-NFZ3BN;+OMM@0:     $="!1IDUUUW-3[L/_GDDW5^U_1V
M<-RX<:$;M??>>]?97M,D:M.\ZC766,/8IBC[JJW4@89++[W4N*U&E+BBT2%Q
M.E077701@884.^%:W<&TC[ C@:12SSTE?32U30DL7=EBBRT(-     ".A XT
MV#HBYYUWWA*_IVSY^;^S\LHK1QH"_N]__[M.'9HF4=MGGWUF;(^24$;95VVE
M#C38IH*\_OKKL8['1/DKXG2HKKCB"F/;VK9MZYU^^NFIEHLOOMC9\<=1C$"#
MZ9Q740<XK$H]]VZ]]59CVUY^^65G;6O8L"&!!@   ,"1T(&&YY]_WOBPG_\P
M/GCPX#J_L]=>>T5JE&DYN_PE#A]YY!%C>_;==]](^ZJMU(&&N^ZZR[AMG*4Z
M;=9>>^U8':KKK[_>V+:! P<Z:UM6%2/08#N?EUIJ*7_%AC J]=R[__[[4S_W
M5EMM-0(-    @".A PU:+M+TL%^O7CWOEU]^^>?W3'.]];8VBMFS9]>I0QGK
M:R_W=\899QC;<\TUUT3:5VVE#C1HE0'3MEK>SP7EOUANN>6<=O9Z]NSII&U9
M5HQ @SKTIGVHS)@Q(U0=E7KN]>_?W]@VC71P04N-FNHGT     #$$SK0()ML
MLHGQ@7SDR)'__,Z>>^Y9Y^<:Y1!5HT:-ZM3SZ:>?_O/S+;?<TMB6H4.'1MY7
M3JD##4.&##%N>]EEE\4^IC!M"].ALK7MG'/.<=*V+"M&H$'3 &R!AHD3)X:J
MHU+/O3%CQABWC9*_(HC^C@0:     '<B!1ILR_!I:3Q9O'BQM])**]7Y^9PY
M<R(W[+CCCJM3S\,//^S_;,&"!=[22R]=Y^<:9CY__OS(^\HI=:#AFV^^,6Y[
M\,$'QSZFV@8-&A2[0Z7514S;MFC1PDG;LJP8@88GGGC"&FB8,&%"J#HJ]=S[
M_???_9%3^=MNM]UV3MIF6HZ70 ,    07Z1 0Y\^?8P/Y(<==IC_\[%CQ];Y
M69,F36(US#1G7(D!Y;777C.V0\OG)5'J0(.LN>::=;9==]UUEY@V$E?7KET3
M=:@T?<6TO:;55+)B!!INN^TV:Z#!M(2L226?>UMOO76=;158_/;;;Q.W3<$4
M @T   " .Y$"#5HVTO1 KB1O<N^]]];YV8DGGABK8:-&C;(&$KIUZV9LA_(V
M))&%0(.269JV=[',H&VZ2=@.U9%''FG<7F^$*UDQ @V''WZX<1_J3/_QQQ^A
MZJCD<T]!1M/V"GXFL7#A0F_YY9<GT      X%"G0H&4CM7RDZ:%<G9SCCS_>
M64= G:O\#D!N:L3^^^]O;$/2Q'59"#38EAE,.E=^\N3)QGJC=*AL*R-LNNFF
M?K*_2I5VH&'1HD5>@P8-C/O8;+/-0M=3R>?>JZ^^:MQ>(QV2G'N]>O5*W#8
M    2XH4:)!]]MG'^%#^V&./&9-%:CI%7#OOO'.=^I0TS[04G<IGGWT6>U^2
MA4##U*E3C=NK(YHD_\2IIYZ:N$/UTT\_&7-PJ#S^^..QVY9U:0<:[KCC#NO?
M1G^WL"KYW%.04],X7)Y[RO5BFBY"H $   !()G*@P3;7VC2L7IU2)8B,Z\(+
M+PRU'Y4UUE@C\5SR+ 0:9*>==C+6<?755\<Y+/^-\C+++..D0W7666<9ZU#P
M)VPN@7*39J!!*TK81@FIO/322Z'KJO1S[Z*++C+6H0#$].G3([?-EMR60 ,
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MKW[]^H'!A5S1*(?ITZ>7^O    " LD>@ 4!9"0HTQ"VKK;::-V;,F%(?&@
M % 1"#0 *"NN PW-FC7S/OOLLU(?%@   % Q"#0 *"NC1HWR#CKH(*]>O7J)
M @QKK+&&'[2PY74     $ ^!!@!E:<Z<.5Z_?OV\TTX[S6O:M&FHP(/R,+1K
MU\[KV[>OMVC1HE(? @   %"1"#0 J B+%R_VIDZ=ZKWUUEO>RR^_[#W]]-->
M__[]O4&#!GGOO/..-W/FS%(W$0   *@*!!H      ( S!!H      ( S!!H
M     ( S!!H      ( S!!H      ( S!!H      ( S!!H      ( S!!H
M     ( S!!H      ( S!!H      ( S!!H      ( S!!H      ( S!!H
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MZHPSSHAU$%GOT*!R-&O6K,YYUK)ER]CU+5BPP#]/\\N$"1,<MKHTLOZ]K.9
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MSX56HE  5/<KW7_UG>J>K*F1&C6F9+;*B0$ 0)D1: " C'KUZM4JT* 5,@
M ("E&8$& ,A ;V=-TS?TYA8   !8FA%H ( ,M#1DRR##CCON6'2S    @,(1
M: " #"9,F- JT."Z7!\   #0# @T $ &_?OW_Y<@0\>.'9?*9'<   ! 2P0:
M " #+=N[9*!!J[\     (-   '5[YYUW_B7(H&4?O_SRRZ*;!0    2!0 ,
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M>/ZZ*"+0H%PG>5).A.VVVRZQ';X"#2'=?\M\;0$HI\K?-?S')$TAT( D!!H
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MG712IOK*</^M"O': M!<*N)202,##9]\\DFTP@HK&+?E<ZG%+%P##2'O6ZU
M@]J<IA-I8XO^ITTT&6JG6:,Q3)_]SG>^DVJDALWCCS]N_2Z>?OKI5'6$>LQ"
MO@;*1/-T;>>(CQ%(&CECJEMSR]/2,'!3'9TZ=<H\<D"?Z]RYL['>@P\^.'4]
MO7OW-M:A!*Q9Z&'==B_0V]FBZ;YA"ZYH.M:T:=-H6PLAG[^--GGR9.OW\^&'
M'Q;=O$2^ PUEN/]*J-<6@.92$9<*&AEH$%O'5!%_GTLHU<LUT""A[ENM0(/+
M#[(>LO6#9JHS;5*C4#O-HKF-IL_OM==>F=MDFY*A!]RT0CYFH5X#9:*\*;:
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M0 ,2$6@      *1%H &)"#0      -(BT(!$!!H      &D1:$ B @T
M@+0(-" 1@08     0%H$&I!H[MRYT1_^\(=69<&"!44W#0     0& (-
M  # &P(-      # &P(-      # &P(-      # &P(-      # &P(-
M  # &P(-      # &P(-      # &P(-      # &P(-      # &P(-
M  # &P(-      # &P(-      # &P(-      # &P(-      # &P(-
M  # &P(-      # &P(-      # &P(-      # &P(-      # &P(-
M  # &P(-      # &P(-      # &P(-      # &P(-      # &P(-
M  # &P(-      # &P(-      # &P(-      # &P(-      # &P(-
M  # &P(-      # &P(-      # &P(-      # &P(-      # &P(-
M  # &P(-      # &P(-      # &P(-      # &P(-      # &P(-
M  # &P(-      # &P(-      # &P(-      # &P(-      # &P(-
M  # &P(-      # &P(-      # &P(-      # &P(-      # &P(-
M  # &P(-      # &P(-      # &P(-      # &P(-      # &P(-
M  # &P(-      # &P(-      # &P(-      # &P(-      # &P(-
M  # &P(-      # &P(-      # &P(-      # &P(-      # &P(-
M  # &P(-      # &P(-      # &P(-      # &P(-      # &P(-
M  # &P(-      # &P(-      # &P(-      # &P(-      # &P(-
M  # &P(-      # &P(-      # &P(-      # &P(-      # &P(-
M  # &P(-      # &P(-      # &P(-      # &P(-      # &\49_A_\
3T&UL:D2WVP    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_11a.jpg
<TEXT>
begin 644 image_11a.jpg
MB5!.1PT*&@H    -24A$4@   ?0   "." ,   #PQ@JK    8%!,5$4   #_
M__^9,FED,F:799G*F,S]R_\R-&:8FLQE:)G+SO\R9F5EF9B8S,O+__[,_\N8
MF67+S)C^_\N99F7,F9C_S,O,S,R9F9EF9F;___\
M  "8DL&[    &G123E/_________________________________ !0B -H
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M[BJ\:G^WL;-RM=&[_PV#)D=ZU,E>%9K<E3EW'F*.05)%+ZT&>(!#'3JA5&D
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&3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image_1a.jpg
<TEXT>
begin 644 image_1a.jpg
MB5!.1PT*&@H    -24A$4@   ?0   "." ,   #PQ@JK    8%!,5$4   #_
M__^9,FED,F:799G*F,S]R_\R-&:8FLQE:)G+SO\R9F5EF9B8S,O+__[,_\N8
MF67+S)C^_\N99F7,F9C_S,O,S,R9F9EF9F;___\
M  "8DL&[    &G123E/_________________________________ !0B -H
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M[BJ\:G^WL;-RM=&[_PV#)D=ZU,E>%9K<E3EW'F*.05)%+ZT&>(!#'3JA5&D
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&3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>image_21a.jpg
<TEXT>
begin 644 image_21a.jpg
MB5!.1PT*&@H    -24A$4@   QT   $I" 8   #V[4\!    "7!(67,  $SE
M  !,Y0%USO"5  #GLDE$051XG.R=!7Q<9=;_W_?_LHOMLC@49W&WMO@"Q6$7
M*14*=:>TI:[4W=T]J:7>INYN<?=,/!.9>&;BYW]_)PQ;2I*.WSO)^;Z?\]EW
MM^W,E6?N/;_GV/^0( B"( B"( B"$_D?M0] $ 1!$ 1!$(3ZC8@.P2JJJJK4
M/@1!$ 1!$ 3!S1#1(5R3*N7_2JK***8DG;;G7"#O/!\Z5QA!AO)"M0]-$ 1!
M$ 1!< -$= AU4EY50?D51@HU)9%']DGJI%M(/1*6TM@T+SI6$$S)I=E4IOR=
MRJI*M0]5$ 1!$ 1!T"@B.H0Z@> (,B;2B)0-]'[D:'H@J!O=']25G@KM0\UC
MI]&BS .469Y/I57E:A^J( B"( B"H%%$= @U4E)91MGE!70P/X!&IFZDMR)&
MT%T!'>DO?BWI_WQ;T U^K>FAH.[TK2(\EF<=H4"CCH5'I=1\"((@"((@"%<A
MHD.HD9R*(@HLUM%/B<OHUH!V=+TB,B VKK8[ CK0BV$#:$GF(>7?%'*JE2 (
M@B (@B!<B8@.X0^8B\8O%D;1T&1/>CU\&$<UKO-M6:/HN-'O>[HSH"/].V8R
MS=#OIC!C,D<\I,N5( B"( B"8$9$A_ '(#BB3*E<J_%J^& 6%#6)C:OMGL#.
M]%[D*"XVCRO14X44E@N"( B"( B_(:)#^ -9Y?FT4!$<B%S<'M"^UK2JJ^UZ
MW];4*+ +M8B;06NRCY.ILE3M4Q$$01 $01 T@H@.X7?R*HK)MRB6.NH6T*/!
M/>FO?JTL$AQFN\F_#3T1\C/U3EQ!8:8D_CQ!$ 1!$ 1!$-'A!% 74:D84HPJ
M^;^Y1WU#;$DZ>6:?HL;A@ZT2&U?;NY$CR=-PDM.T!$$0!$$0!$%$AX,Q5I92
M:JF!0HR)=+XHDB)-*911ED<5I/T:!TP:[_1;E,,>T?%(< ]J'CN=O'-]U#XE
M01 $01 $00.(Z' @B&Q@0O>NW$LT+V,?C4K=1 LR]M,6PSDZ71#&+6AC2M(I
MHSR/BBI+-#/3HNRWJ>,S]+OH^;!^W"+7'M%QLU\;KN^8D;Z;LBL*9'"@( B"
M( A" T=$AX- "A6B'"<*0NB[V!GT8EA_>C"H&_TS^"=Z-K0O-0T?0M_'S:;Q
M:5MH=^YEBC:E:L89-Y07DG]Q''5/6$)_\__!ZEJ.JPT#!-%FMZMN,1TM"*:L
M\@*U3U$0!$$0!$%0$1$=#@+1 J14S=;OH6<4D0'G_7<GW+<EW>37AM.6WHD<
M26WCY]+(E VT-/,0'<H/H*B2-"JH,*IV[+$E>EJ5=8P^BYY@E]BXVCZ)'L\1
M'UUIIFKG)@B"( B"(*B/B X'45AAH@V&T_1#_!RZS8+T)(@21$+:QL\C#RZZ
M3N,9&4C1<G7A^>6B&)X\CNB,(T7'<Z&_\.="C F"( B"( @-%Q$=#@!1CM0R
M PU.7L>I5)C2?2V'_*^^K>CO_C_2X\&]Z(.HT=0W:27/MX@P)E-N>9%+C_]P
M?B!'8.X)[.10T8$Y'Q@8>+(@E$HJRUQZ3H(@"((@"()V$-'A +++"^A\411]
M%3N%;O9O0]?YMK3*.4?]PV,AO:AY[#1:G'F 3A>&4UI9#IFJG.NHHY ==2B;
M#6?IX> >?!R.%!TPS.WPRCE+F>7YRO>IV\$+YXLZ&A3QYU84.4P(559647EY
M)147E5%>KDD5*RPHI=+2"CX62R@KJZ2BPE+*SZOY\_"_%Q:4\&?:BLE4?HUC
M+N'CL/28_WC\%5207^*RZYN?5\+7N$0YIRJ--( 0!$$0!'="1(<#"#3J:'[F
M/FH2/H2+J*UUS"%2,%CO[H!.G)+4,W$9;<DY1\EEV4X];D1HDDJS:$'&/KHS
MH(/58LD2@YB9J=]-P<8$U=L&XWS1OABI;$@I0Q<Q1P#'' YP=&06^5Q,5L7"
M@O64G57,CKXE&+*+*3(LDP+]TFK\O #?5(H(S:#,#-NC;NFI!74>,SX_QV"D
MDA+K&RI " 3YI[OL^OI=3N%KG)920!45VF]_+0B"( A:0T2' ]B7YT?MXN=Q
MIRI[''1SP?D+8?VY-@2%YG[%<5SKX0P0Y<#GCT[99'>;W-KLOL NG'9VO""$
MG7Y7@2@&!)5?41P=R/.G==DG:+;>F\:D>M&@Y+74*W$Y;<LY3XG*WS$IU\$>
MX !#<*Q8>)D&]-RKBLV8<(I\+B135J9E4^#]?5)IP8QS-'KPD1H_;^2 0S1W
MZEDZ?]KV>IPC^V/J/&9\/L2-(=OZ)@JA07H:,Z3F8W>&#>US@*_Q0>\HCG8(
M@B (@F =(CKL &D62-E9GG6$G@OM1[<%M'>8LXY"<]1Z3$O?2:EE.9P6Y.@"
M\\)*$QW*#Z3>22OH%O\?G2(Z[@[L1!WBY]-6Q<%W=HM@E."75I93<64)I909
MZ$"^/U^_=KIY]'+8 #['*]L!=]4MHH.*($%ZG#TI,]C1/WU<1ZV_W$BW_<\X
M5>R=%Y?2IG6!%!=CL.B8=VP.I<_?64-/WCVSQL][Y-9I]%'3%;1FJ:_-UV7F
MQ--U'O.'RN?O\ JEA/@<JS_[P)XH>KK1+)==WWMOF,37>.J8DYP6)@B"( B"
M=8CHL ,XT7!8QZ=MY:)I1]9$H-#\OJ"N]+XB/(:EK*>C!4%DK"IU:(I27D4Q
MBX$.NOE<U.X,T8$(2K.H,30_8Q^9G%Q,GEZ6R_4P<_3>U"UA";< ?BU\,#T>
MTHON".A UROWY\H4LE?#!E+_I-44;$RT2Q")Z*@9$1V"( B"()@1T6$'F.(=
M:DJF/DDKG>*PP]!^%U/"ARO"XT)1%!DJ"AUV_#GEA;0V^SBUB)WQA[DBCC2(
MF5<4YWZ"(LR,=J8QU012SS#U/$RY#]MR+M"P9$]Z/W(T1UBN)0)O]6]'[T;^
M2CMS+W'AOJV(Z*@9$1V"( B"()@1T6$'V%GWSO.E-O%SG"8ZD Z$CEBOA@^B
M7HG+*, 8[[#CQR3R99F'Z:N8ZJY;[B@Z< _0DG=(L@>GHS4*[%*=1N7;ZIJ%
M\:BA011D5.HF.EL88?LQB.BH$1$=@B (@B"8$=%A!YCDC8G;'T>-<YKH,-N=
M@1TX56AZ^B[R+8IU2+M7M+&=DKZ#WHT8:=%L$5L,A?%/A?3F">RHM7 4.15%
M%&),HM79QZEGPE)J&CZ4[@WJ;'4'+G3M^B)F(JW,.FISS8R(CIH1T2$(@B (
M@AD1'7: 2=L#DM;0JV&#G"XZ8$B!0NH0A ?:O9;;V0T*48+!R1[<+<L9,SI@
M-RAB!K4IOR2MHJ(*D]W7'(7[J T)*M;1DLQ#]'GTQ#\5B%MC-_I7']_09$^^
MGK8(#WU:(9T]F4#MOO6B1C=.MLCNO7X2W?'_QM?IZ-YUW03E[TVTZ/,^;+J2
MMJP/)EV<90Y\?1<=M__O>+K[+Q,MOG[7LD=OFTX?-EE!,R:<YODF@B (@B!8
MAX@.._ OCJ=.NH7T=&@?EX@.I PU"NI"7\=.I4V&,Q1=DF;7\>L5T?%KZD9J
M'#'$::(#8@!%]C\E+N.A?/:".A2T*!Z6XDEOA ^C!X*Z_:E W!I#BA52RSKJ
M%I"N)(,**JQOWYJ;8Z*(T$R:,^4L=6ZUS2+[YD,/>O@?4VMUFB%(FCZ]B)I_
M[$GMFV^YYN>A]>VY4PFD3[>LYJ>^BPZ(#40F6GRZGCJVV&KQ?:G-NO^X@Z_Q
MKBUATC)7$ 1!$&Q 1(<=G"^*I,]C)M#]05U=(CK,ANGE<))1 %U88;(YXI%5
M7D#3];LX>N*L]"H(@GL#.U/?I)6*Z+ OTH%B[V/YP=0O:34U"1_,@L%1QXF(
M"<0,9GM8B\E8SL[^F>,Z\O((LLBFC#Y!SS\XM\XHQ_?_WL@[ZYXK_:_Y>9@?
M@2B'I:D_]5UT//CW*=2IU5::/?D,;5P3:/%]J<VV;@A6KG$TA09E\#1T01 $
M01"L0T2''1S)#Z)G0ONR8^U*T8&H!%K #DWVH&A3&L_;L 5$#=9D'Z?O8J<[
MK7L5/A?I6V/3O.PN)-^5>YFZZ!9QC<C-?HXM?'\M;!#]FK*!)Y5;2V5E%967
M5U)Q41D/"K3$3AR.HS>>75RKTWS/7R?2B/Z'.'J!FI%K?1[$!B:CXU@LH;Z+
MCL?OG$%3QYZDR^<Q,+'(XOM2F^7GE? UQL1W>V:Z"((@"$)#142''1S*#[![
M"KD]]E'46)JKWTLQ)>DV'7]N11%Y9I^BUK&S--TR-[740$<5@=<W:16W#W;&
M($-$CYHKX@OWU!7 &7[[A25UBHYQPXY2D'^Z(F8<7T-0WT7'$W?-X(GGX2$9
M+,8$01 $05 7$1UVH+;H0'O8#Q7A@8B+27'HK2V"QG! U(;\&#_7J:(#-2.3
MTK99+3IP/AC:=[H@C'HGKJ"7POH[[5K>&="17@CM3UMRSEMUC+8BHD-$AR (
M@B T)$1TV(':HN-F12C@^T>E;*0S!>$L/*P!W:3.%(;3X.1U] __MDXY1GLF
MDJ/PW*\X3A$LV^FYT%^X(-U9UQ(U+?C\U5G'K#I&6Q'1(:)#$ 1!$!H2(CKL
M0&W188XD8$[(//U>'O97:46T U&$V))TFJ'?3;?YMW-.!"&P(T\\7Y=]PJK9
M(F55%910FDD+,P[0OV,FNZQN!NEJ$#L5596V+ F+T;KH0&>M]U]=1HMFG2=#
M=K%--G'D<1$=@B (@B P(CKL0 NB RUI[P[LQ-VLXDLRJ*3*<L<>CC52K+"[
MC\)T9QP?.E?U2EQ.>_-\64A82JYR7*<*PWE:.L[/UI:XUMK85"^*,^F=,CW]
M2K0N.M#]"87N8X8<X6.UQ?KWV"NB0Q $01 $1D2''6A!=, 91S>K#Z)&DY?A
M+$<N+,5<,X'6N^C"=8L34JP>#N[!D91 8P)5D.71@U.%830B=0,]JQR7LV:(
MU&3#DCUYZ*,C9HK4A=9%![X?': ^>7,5]>JXRR9[_]7EJHF.^V^>0M]\Y$&#
M>NWC]L3H9&6KX;M2D_/)9+0N/5 0!$$0A/\BHL,.M" ZS(8VLBBV1I<G:PO*
M3Q2$TF=1$^B!H.X./29$89X.Z4/;<R]2=GF!1<<%88(HPTQ%J*#KU:U.2ONJ
MS08FK27?HEB;A@1:@]9%ARO,F:+#D?9+-V^Z?"&9AT *@B (@F ;(CKL0$NB
M T70Z.ZT./,@%:,FP8JH0I Q@4:E;J(W(H8Y])CN"NA('T:.I=,%X1Q1L00,
M (0(:J^;3W<$=G#Y#!01'2(Z1'0(@B (@N,1T6$'6A(=?_5MQ47E0U(\>&Z'
M->E!*64&\L[SH99Q,]G)=U3]Q$MA ZE/TBH*-299?"P!Q?$T)G4S-0T?JLIU
M%-$AHD-$AR (@B X'A$==J ET0&#6&@3/X?V* ("$0-+,565D;X\M[IU;D!;
MAT476L3-H(V&,Y1JQ;% _#0)&\+%XR(Z1'34AH@.01 $07 O1'38P?&"$'HY
M; #=[-=&=<%AMK<C1]#8-"\*-R5;?![H8H6N5RNRCE"SJ-%T=X!]#O^-_M4S
M+X8F>U"@44?Y%<77/ ;,\(@N2:/I^ET\]/ F?W6NJ8@.$1TB.@1!$ 3!\8CH
ML ,,UGL_<A3=%=A1=;%AMD>">]"WL=/H0E&4U07E.)]?4S;R(+Z_V)%BA?:[
M+X;VI^6*B"FL-%E47Y)3443;<RY2!]T"EW:K$M%1N^BX_7_'T5W73:![KY]H
MD^'?JB4Z;O_?\?S]N(ZV'K_9!OZTCWPOI2BBP[EK0A $01#J,R(Z[."BXMA_
M$SN5V\*J+3;,]C?_'^C%L/ZT+\^/)Y1;(SR0DG4P/X"^B)[(D0I;:SOP_4.2
M/>BT(F+*JRHL.H;DLFP:H0B>QN%#N.N5B YU1<>=_S>!&MTXB9Z]?S8?IRWV
MU#UU1U&<*3H@.)ZZ=Q8U?F(!O?6\;<=O-K3-#0W24T&^<]LH"X(@"$)]1D2'
M'006ZWCPW0NA_547&U?: T'=.%4*CKPU7:S080H#!E'(_5;$<*LC#J@%02T&
M)I#OS_.G).7[+0$U)4C#PK^[)\!U@P!%=-0N.NZ]81(]<]]L:O7%1IKTZW&;
M[#_OKU5-=-QWTV3ZNID']>ON3>.''[/Y'&#[=D522E*>S.D0!$$0!#L0T6$'
M,:8TFIF^BSZ('*VZT+C2X/@/3UG/Z5+63"A'1 )=KQ#!&9Z\GHO*K?G>6Y2_
MC[:[4])W4&Y%D<6")[TLA[SS?.GU\&%VI76)Z+"<:XF.1VZ=1A^\MIR6S+E
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M$(BV1@A.%(10B[@9]'A(+U6N#P1MX_#!/-@0T]==B8@.$1V"( B"T)#0I.C
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MU+><.:'CB&%] U$JO#/1R2DT*(,.[(GBXFHT+,']1(T7WIM(9]2Z>'3FFH"
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M]16(G\RR?/(MBJ4U6<=I6(HG#^'#X+W[ KLX9*X'ZEBZ)BRFG;F76'1IE>"
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MX!,4$9JA]*$0T!.V0#K"I>L->HX/7E6FPH= &\S<:>?(RR/13&=&P!J@-.E
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M";L@'0!*\H45Q2S*7I5Z@CI&.'"[E242=_AH/.+3@SX-^9/F).VG:P6AK%V
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M#8$@'0*F0) .XV,BDXY$03JL* 3I4"=LF714%8V_WG2Y$(U;:0C2802R)"*
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MY?#)L967OZD0I,.T$*1#GC"5="!)A@,Y!DDHX<V![H+Y,]S)XVJ\F<^(,H
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MX?.0D'IY)'+%PQ(3CVR9=.APYD0XZV5 <)6^SFN*=BT<>:7TP.X )AZXKI#
MJP'<5J@MXW,8$99)[FY1[$N"I/DI(XFW*2%(ASJA5M*!ZQ_7/2JJ2@JB464!
M\4#"C'>%M2Q<H!*$[<$$Q]E3S_."G%+'J+X0I$-!(,%%-2-4(@\@$= I_)6T
M]_9XV,_"9G"%X:W@B7<%?MXA="9UB5I*P^,V<^4"!"(:>I$*_9*+ NGWL-J/
MMBML@U]1#'D51M+-PO [PD]*R$.T"6RJ&%N23ND2,4*EP%@@V1\E;3,J*)@*
M9NCX7DP"0W4$E19#*Q0@>=CV4SD^K$'!YR!0.0&A B$RQ$>D.O+SBEF@#+^
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ME\G[:2SI@-.Y0_(A:J496>?GHVKTDF8X+4LY2GZ%,7J/_ZT.3)) .1C3K)!
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M^]A7!9.NE+[6K#G0R]VFF2.W4<&#9L<F'[IT/IH3#CQ/K(%P ()TR -[(AT
M*G@@'N=<(WA:DVXLM]+WI24#K62H"/_TV7::+YUKZ+30-ED]P1>DPS!8!>F
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M)M?XF7!K?S5P-$U,V,[:D_KT(A"C^Q?%,)$RQSXU#QA"W:7/0IN7@(" @("
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MA=8JZ"1Z1"^_JW6MKFBE&<D&@H':NJ=)H=J"-C>(T$V=RH7 =V*:&;9;0$!
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MCY>%*:0#T[;&QCNQ2WA]?AW E?P0&B 1LM:!H[DB9$S%@S4=&>>%ID- 0$#
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E4862#H5"H5 H% J%0A%5_!O< <!U^^\440    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>image_2a.jpg
<TEXT>
begin 644 image_2a.jpg
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MC[:[4])W4&Y%D<6")[TLA[SS?.GU\&%VI76)Z+"<:XF.1VZ=1A^\MIR6S+E
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M$(BV1@A.%(10B[@9]'A(+U6N#P1MX_#!/-@0T]==B8@.$1V"( B"T)#0I.C
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MU+><.:'CB&%] U$JO#/1R2DT*(,.[(GBXFHT+,']1(T7WIM(9]2Z>'3FFH"
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M]16(G\RR?/(MBJ4U6<=I6(HG#^'#X+W[ KLX9*X'ZEBZ)BRFG;F76'1IE>"
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MX!,4$9JA]*$0T!.V0#K"I>L->HX/7E6FPH= &\S<:>?(RR/13&=&P!J@-.E
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M";L@'0!*\H45Q2S*7I5Z@CI&.'"[E242=_AH/.+3@SX-^9/F).VG:P6AK%V
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M#8$@'0*F0) .XV,BDXY$03JL* 3I4"=LF714%8V_WG2Y$(U;:0C2802R)"*
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MY?#)L967OZD0I,.T$*1#GC"5="!)A@,Y!DDHX<V![H+Y,]S)XVJ\F<^(,H
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MX?.0D'IY)'+%PQ(3CVR9=.APYD0XZV5 <)6^SFN*=BT<>:7TP.X )AZXKI#
MJP'<5J@MXW,8$99)[FY1[$N"I/DI(XFW*2%(ASJA5M*!ZQ_7/2JJ2@JB464!
M\4#"C'>%M2Q<H!*$[<$$Q]E3S_."G%+'J+X0I$-!(,%%-2-4(@\@$= I_)6T
M]_9XV,_"9G"%X:W@B7<%?MXA="9UB5I*P^,V<^4"!"(:>I$*_9*+ NGWL-J/
MMBML@U]1#'D51M+-PO [PD]*R$.T"6RJ&%N23ND2,4*EP%@@V1\E;3,J*)@*
M9NCX7DP"0W4$E19#*Q0@>=CV4SD^K$'!YR!0.0&A B$RQ$>D.O+SBEF@#+^
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ME\G[:2SI@-.Y0_(A:J496>?GHVKTDF8X+4LY2GZ%,7J/_ZT.3)) .1C3K)!
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M^]A7!9.NE+[6K#G0R]VFF2.W4<&#9L<F'[IT/IH3#CQ/K(%P ()TR -[(AT
M*G@@'N=<(WA:DVXLM]+WI24#K62H"/_TV7::+YUKZ+30-ED]P1>DPS!8!>F
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M)M?XF7!K?S5P-$U,V,[:D_KT(A"C^Q?%,)$RQSXU#QA"W:7/0IN7@(" @("
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MA=8JZ"1Z1"^_JW6MKFBE&<D&@H':NJ=)H=J"-C>(T$V=RH7 =V*:&;9;0$!
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MCY>%*:0#T[;&QCNQ2WA]?AW E?P0&B 1LM:!H[DB9$S%@S4=&>>%ID- 0$#
M3$ 2@]5:)'!(1+P]$NGT\3#:M/HFS9KL1H-ZNE"W'_;0]^V=J/V;Z^F]5];<
MCD_:;*#N/SK3X%XN-'+ ,9HO)<;;-GCQW_MZ)5%"7"Z3!7,@)BJ;#CEK>+N6
M.UPV6^S8[$/'74+HPMDH\I&2]R@IX<_.TOZ]LFSIRD'EBGY69A%%2DGES6OQ
MO"WK5MR@Z>/.4/^N!ZC+=[OIVX^VTD>OK^-C_G[KM?1IVPU\/OITVD_CAIS@
MXPYBB./NXUEYW)%LXKR:"TA<D9!ZWDB@#8X>M1[/M<MOD,?5>$Z$C?W^J(@L
MVKBJ]N]8O?2:E(B'<J)<6JJ_;Q>N\;#@=-JSS<\LU\Z:9=>9%()P7[L42QJ_
M%"G1SV<2H0\9PKG'M1;@FR(1S  F]2/Z'^5[;D"W@[=CU,!C_%VNQ\(H)#"-
M_T:'M-0"7ARH:9]P/>!8HG*B ZH?(*B[G7SO.J:[MOJ2UXT[[18$Z; @C"4=
M$&$W]1_$$ZL"BF+K'9-;%>8B':@@O*@9P2U/=;4[584II ."^0$Q:^APMH=>
MI"-=^B[/PDBN(CWDW<THE_>>T2OH4/8-2BO+U?OX"@@(" C4#B1'6%U'XK-1
M2B;[=3E [5HZTLO_74HO/+:0GGEX/C5^<#X]W6 >/?7/.?34?;/_%])_-WYP
M'CW[B ,]]^@":O;X0FK5>"DGR$-Z'Z9].P-XA=8<<'>+HM]_V4L?O+J6FCVQ
MR&SQ8J,E]'K3%4RHD."M7G*-$R^T-2%!LR20E(.4(4E?N? JD[LVS5?R-CW_
MGP72L7>@__YK'C5Z8.X=Q[[A_7/Y?#1Y:+YTW!WXN+=LN)B/^T@I:<5Q3TK(
MY?-J+B!!1O4!9.#=5FMJ/9YMFJTDQ\57.3E&BY@Q..<:P>2JMN]XX_D5-/J/
M8W3L8+!!^Q@?F\.D[N<O=ICEVFG^Y")ZZ>DE?,Y^_'0;31Q^DC\?U3-4A>H#
MKC&0.%2N0"CQ6;B7<,_AW.L"]U:+IQ;3=Q\[<:7+\_K_B &J%*B$U;1/P_H>
MH2,'@IF8Z( J!_[^Q\^VW?&[KSVWG'Z2?K9QU<T[R+8@'19$444)^W[ MP+F
M@_HFPZ]H1G("#L^+K/("'KVK+W9F7J0OPOZBAK[&3<O21;. (=0[VI%<<WWU
M_FZ(P$_E^M"@F'6LMS#D^V#,V#=Z%1W,NDZE>I L$+'L\D+>W^Y1R[@5[9]>
MOQGTG94C<S5B9*Z @(" &8"6#E0DMJ[SI G#_E][9P)=57VM\?=>VZ==G=[3
M5K23?57!6FNM,HG65BH5M4\%<2@%1(8JRN"(#$5DEID0YGG&$"#,,X1Y#H$$
M2 A)F (D(0P2! 'QW_/;\> EW'/N.3?W!I#]K?5?JW)S[SGG?\Y9W=_>W][?
M?//\7R=( $Y@>_-_=33_^Q\=?"^^1Z!<H=P ":*IEB 3(@A%VA)N]6#)_-T2
MV-WSL[YAG9?;^O&W.@IY>O#.6*D@O-MDKF3S"<[R<B/__S=L 8'I^M7[S)"8
M]9+))J"$L)7Y[\[FIO\,[SK8]\KW#))]_^B#)6;JI%3)O@=FNL,%FO^T[?E"
MC@B G<Z!H!G9'<?U$G@' Y4#B)?3,;A7C6M/E^OS4TFC6H9<J6J%X1%[=KA7
MW+.R5N .(:[_0KQ%#);)<=@#R%HP\._[]YXP?;JNDF?N9]_K*L_A+=_I9,I9
M9.:^VV-D02KY?=XKR&6U2B/,X'X;A #23Y62?-CT[+C"/%YQQ&7G5M-ZGZD\
M4?FR@1R,BB'$L?BS\^<'ALG]5=)12OC\PCEQ(__HX"?FEN30+MKT<?Q/<EU3
M-SM&,OX'PY#]8'A8.[NO]$B$2SB0*E5):R-5CIT>G,AM0+*HS'0X&.?+D3P<
MTF'CL+5'<T\DF:<R.IM;MS40:=JWD]RE5GS.-7Z0,]YL.[W'%%XX$_I "H5"
MH0@*,OAD/#=9075LK[7FL?+#S&W?[6(%4.$1#;=%@/ILU;%";,C*DOT.I^\@
MFJ2C^**J\-!O!UG!\PJ1S1 \1ZKJ05_!\6.GI7+3]<-$(6<<+]+70*#ZTM.3
MS/#8C2*QH2)0$K68D@[OBTK%RW^;+%) 9&;<\^*0*@<5!^N9MM^],A;9+ZIH
MC#%UGOM$%A6X<K?VDD2 _?L-7IIJ$J;L%$+L1CJ0/W9HM41ZA&R09.C?8XT0
M;"4=5QBV3T<?CSX=3'!JO'>P&.S1W$P0[Q=D[M\],,:42VT:-N&@2O%<YL=F
MPV>[13+E%>?-%R;WW'$3FS=/)$^E03K8HWUG\TW<T36F@?5]2-L-(2H>? XI
MZI<W1Z9R>9%S*10*A2(XD%NL6;%7^@;(SO[ZIAZ298U6 $\6F "H8^NEDJ&E
MXN$7I4DZ?ORM3A(X5KEWD&GS]D*+G!VX1*)2$B!C0\+5\.5I0FP(H#E>I*^!
MS#B!^Y./C!;9#X$\Q,,I\QX*2CJ\+ZH5G/\+3TZ4_2+0+XY#.2?-[.EI<B[V
MNU>M\DCSKW<7B21J_>K]LL:-V"*5-ZI@]N]7?WB4]'_0@^5&.G[WRW[6<S95
MR+Z-Q?-VF_?>F"OR224=5Q@T7^>>.V'&%B2:.U*:F!N#]#G@W(V'QQ]VO&L:
M[1DD/099'HSXG+#U]!X)IO&]"(=TT(M1-O5-(2Z'SQ\7XN05]'XPY6J*19KN
MV=Y<"(#7X_YT6R/3;-]P,__$%M\D *D5S>"3CZXR-3*[B\/Y3<GU',G'3=*O
MTES^7J%0*!3A@8 32=6*I7LD QKMX,M>/_EV)R$V3>HE7)19^45IDH[ 116H
M>X?E,B&J),WE2)RH.(P:O%GD-/1@E,;Y(]NI4': $(]5B7M,?IAR,24=_A<R
M*61S$T<E2Q-^8,6#Z@/-W/2NV']ORZ%X3NS*&A/;YB2D2:\5I(3%@($!O=:*
M/"L8Z8#$4#U!FL40 GJ&[&/3<([\CGXMB"GOIBV)5-)Q!?"%N2"^$I5V?A"T
MF9P&:J1,?7-GR[A8,N]^ OWBR#E;(+X>5=):AT4Z",AQ%,=9G$9X-Z.^8.#O
M,42DP?LWJ<T\'_>7V_YI.A^*-QM/[?8T*:OX,2$JN>=/F$W6'K;,&6?NMT@<
MT[>"'8M^E9>S^LA]42@4"D5X0-+!*-;V+9=(TVHT9#U.@2]!4=]NJR1(O-KE
M5<4#7)IL)XY.+E%S.;IZ^D20W1 0$NR5QOD34))Y9S@ C?+(Q<*!D@[_RP[^
MJ52L7;E7II39"$8Z'KU_J&G=8H%,((.D$ORS[T6)@FPS<^I.64L7[+;^YJ",
MT U&.A@RP/O-/M&[P7[:QZ:'B+X0AA#P7/ W2/&4=%Q!0":H8N N3O:= +O"
MSI;B$_'^@;$RMI4*!0W-?IK&@X'^A.3/LLTSN[N9'UI!MY]1L@3I!.O(HW:<
MWA^V[ A?D4'Y"TS57>T]'_N.U#?,T".+S.[/#X>]!T7-Y=;+='*'&9@_W[38
M-U+&#M]C[7M@(_]#%B&#Y*6<WAO6<10*A>)Z1^')ST5F85<X"#1"!4VV-(K)
M.C4>'R]:<L;CLNK6C#//6B0 >18!HE/C.4$-W^_V8:)(NL*5]X0B'5P/U0."
M++*[3@MI"G]CDZY0LC([<*0QFV#0[PA@ CC\$ACQ6K]6O/G]KV(\!:Q,K+(G
M4C&9B.PV^TZUB%X-,M[H\LEF>_D]@LQ*OQEH^GV\6@)5O\WEUQ/I8-\)P'E6
M I^=IQ\=8YZH,DJ>9_Z&X-[+WO_UH9'2OQ,XR0VY'L\TOT?PS]_QKC$.N7FC
M6;*'](30]+UT0::0#JIM7 /2+"HGC L.1CIH..>_J;0P30R)%AX</(MXO=B$
MA&I'Q7(#Y)XIZ;B"P&5[^)'%4D% 9@79:)4S7JH)V\_LC_CQD!J]OG>(^57*
MZ^)AX;67X\Z4-\T_LON9S:<R2W1\QMEN*,R0Z5<_\##.]CM)+X@<:_KQ]>;H
M%X6^JRO!@+<(3>T0.@A?Y;16X@5";\T_LOJ9U2?3Q&10H5 H%/Z!_IL@C<94
MMP")AE8";:H39/B1 N$%09:>( E/ !9Z=/PDR,P2%*,1IP_BUANZ" 'A=YCL
M0]#S>MT$D7C8V=MP$(IT,-:7#&[35V=*X(3\)-CJW7F5:-I??&JBJ7CW0 GT
M;KNQB^NT+JZCWO-3S.2QVWQ-L[*=G]'F=VF7>)F./MAQ($\$@1 $]O5?[RP4
M+XCE2[)DWZE4X*< B:-R\9>*P\T=-_<48A1JXACW!L)",)N?6^BKXG0]D0X(
M'=/<>EG7$?CLT(#=H\,*>7ZX-TP*LZ=+N4T<X[V L'#O;.\2O#SH[ZE;(TZ"
M?_IZ @<Y\!V> >Y7F[<6BO\-WT<>QS7;#N7!2 ?$%H(+*;WO]GXRDA</&([)
MI#2J;-PGWDW(%'NMI.,* IG2GK-Y9GWA+NE96%.8)@'QWK/Y,F8VTF#,[I#\
MA4)NOK^E=DC" 3&!'#!ZED;N@R5TZ&9JU]'SA690W@)3+:.#N66K^^0N*BQ_
M3&\K%0H_GB1N0-:&J2)[3*6)4;Z3CJZ2?9EW(DF(T9D+D9LYKE H%-<39DS9
M8>K5C O92R#C/\OT$E.ZWEU62?\'@0TZ<\:\'BWX3!8&8TA$")SH%<!%&7)"
MY8.L.H$-V7JRMF1J^6Y)S.I"D0X"MU=?B)> >G=Z@<G<%7QA#K=MRV$A OA!
M$-03L!'(NA$Q&K)IWL7KP2L(U#&D(U@EV^UVC")2T%F($,W$2&]LPSF"93+C
M[#L9;K3\],9@Y,A]Y;P(:@DDW2HWD!(( TWL-#?["=BO)])!18]]Q2RR^/.#
M(2'/#_>&_HCV+1?+0 #NG=/T-RH9$ BJ%MQ'8GK;I ]?#'HL(!FW?*?S)=_A
M.MEKR /) @@(A >)%:-O(1'!2 ?O8*<VR\QCY8?+]]_ZYVPAJJE;#\NU05"I
M<#QN$58E'=<AR/*O/I5FVN1,E ;M8 WLES9Q-S15T]N+^_F!LP5A3<T*AK6%
MZ=*G\<#.]\SWDVH[2KWN26TNOB3;3T>^ZF,#,@,).7#VB! .A4*A4/@'HW'S
M<@LE,TZF'6,YMX"+H)>)-S0\(R<BV P%LJYX!D ,D&_1$%NM\@@Q("-X)ECV
MXQP=#*%(!U*2%HUFFWDSTGUE\%<NS1;I%-?MM#<$DTAJR#A#OKSB:,%I">ZI
M]) 1=^KC@ P0M"*E(JBDJH$DRPL@(1P#V135&RHWMES':1&4XL2^._V(YVNY
MGDA'B\:SS,9U!RYQ_@X&B#2RIZ8-9LKH8S?"Q_0IFL0AO79?$-/$MB8=-F.&
M)LDS4J/:>"$*D!@F3T%$ F60$ ,J%[B60XKR'4;F0I#'#M]BGJDZ3HP%:U6?
M*'XY?(<*#?>("B8D1DG'=0@:L:DT,)WI_AWOB+NX&^EX.*V-F7!TA8SWI8\C
M$O(F0)"_[M0N4SNKK_EERFOBH1'L^+4R>TH5(AQ?$J_@FBY\U7#NMU%=H5 H
M%$7(M0*CY4NRA4@0](8RGB,KBHR'H!=/#2]R*/Z&/T,^126 P X=.1*LS(P"
M(0'ARJIL1(MTG#E]3AS(J0(Y!;J0#C+#N& '>AZ$ CTTR-+H#7"3/A%8XD".
MJ1Q$[\3Q,YZK0N*Y8@7WW"\RX%14""K=[C&:_M?J))@Y">F>KT5)Q^7@'D'Z
M&''[1OV9KH,9J#!V;KM,*FQV7Q.O!.]8X<FSXN?!D(?10S9+@H!I51!=I'.!
MY)1W& +SRO-3I,H8C'1 +'A?:C\S6:J-5%GX>^1B2!#+E>EMWK3.MYE%EI1T
M7(<@P":SCS%ARP/C3(6=[U\6Z-/0CC<&(V;[Y\T5P@%)B"3LB5+QQ]:*^S<]
M)C\,F"B%].NG6QN9CP[&F?3/#XH,3:%0*!17+Y#A,#6*P-<MT")#_M0?1YMQ
MP[=<-M[3#P@TJ08@0V'<)Q-V(H%HD0[ ^;9[=Y%,#W+:'T@!DC,";Z](7)PE
MP7UQ([;BB^#R@V;S1.[%E*%PFNVI)"$KH_> ?7(['O*W1^X;;(;%;O3Q^THZ
M@@'2P/,3TWV-]$&YO5\MF\ZWGN-,V4ON\^Y=!4+PJ;:Q, ND:@4Q80]X%]G+
M9@UGR3-"Y0,"3$6.2B)D.1CIP!4=<MRDWHR+XZII4'^K\6SI0Z&* K&A^L%(
M7R4=URGRK( _\62J>75/K)CU031HZB;8__FVQN9/Z>VDPI!SKB!JV7^J"Z<N
MG)$^BN<L@G-W:O.B<]G\DIS#8^GMS=1CZZ)R;(5"H5!$%FC/R7+2%.X4$%']
M0-K3I\LJT;%?C8@FZ6"<+7T72$Z<]@CI#%4$@KQ0(&@C"QXW/D6RS$Z5!_8=
M'3]5* P(&8U:$B!Q(]@DF&2RDI.<RQX4T+'U$L]NZTHZW#%M<JJ0.3?22G5A
MUM2=0N@STH]()1#"@&R/-==Z=I%L061L< Z\PSPCD 6[4LD$-@A+,-+!, 5(
M*$,>J*)1(:&Z5;/:>*F2/'A7K!D[/,D,[K=>W,^5=%RG^/S+<R;__*=F6/XB
M4SVCD[EM:T,Q(JR4UDK,_S BS/P\5WHX(B6I*@Y^EZ9N>D66GDPQ'0[%F2<R
M.LK8X+_L^LB,/++4I)W)B<JQ%0J%0A%9+)R3(7ISI_&>!#'(0IBB0X/L\6.1
M'Y82"423=-"83>#F5@UB#&F=Y^*D<A0*!'STL5!U($!VZK%@:A9]-CBU$UP&
M!IOA **#E\B4"2E%!H0.Y(![#B$A@PZ1H-D]]#4IZ7"#7]*Q:7V.B>FQ5NX3
ME3 6?AYS+"(2:.#(]3$JEY')?DD'@R"84(7$BNJ(3&K[;A>I=K#'-,(KZ5#(
M]":\-^IFQ\A(W$Z'XLT2BP 4G"^,V+2H4$!J18,[D[L&6.?2?/\(TSMWILDX
M<R@J$[P4"H5"$3D0>!. $E@@KW *ALB$_N'7_4V[]Q:)MMP)TK-QYKQHSY'Q
M()\*=Y'-I9?"#SF(%ND@4.><"/BH2CCM$V-(\<C@VD.AR'W\J&CXW8);[@M!
M'R-Q(PDRXVW?62C!I=OQF9I$=IU)2*&@I",XD,(Q1AFI&H&[TV\2\#/=;?&\
MW;*7D(5!?==;Y&'0Q0;T/_UAF$B@QH_88A(79<F8Z>6+L\R8H44N]DQH@W1P
M'*203"]S(QV,V<5?)_#]AW3@#8*$:]:TG4HZ%,:<O7!>QNAB&KCML[UB0D@5
MY(+4(:)3X0@&N]>D\(LS8N)WTB(;D)$+)6P(5"@4"D5T03:5GHJ!?=:Y-A:3
MG7WY;Y-$/^YF&$=PQ;A/ MJ!O=?)M*1P%P&5W:CN%=%L)"=C3%#G-M*V0MD!
MTF2?E1&ZD1SRAF-TZ[<6N :W3")J\_9"D[@XV_/Y>@'2G4ECDD/V\1"X$F1"
MND)!24=P<'S&2K=L-E\">J??Y'JZ=UAN-F_(D7<)\DX/#XW<?(]>#7M,+E(H
M_%>H;C!AJFKYX3+]S!Y&@%3RM3K3S8Z4/%?2P3[R3@3N)0WMR"VY/QA6*NE0
M".C9(-"G65R#?(5"H5#X 0'?KIWYID_75>;V'SF3#K*@S:W A(RW6Y#(9_0+
MD(4E>\I8SG#7((L(<6Y48KPBTJ0#&1E2J;CQVZ3* 0%PZH$@(*3A%L)$_T<H
M$% R&0KS/K?@%ME;_YYK1-862= ;0I;\A2<GNAZ_^L.C3=]NJSTUQROIN!PT
M@R=M/"@CEQ^O-.(2GXW+"6:,&35XDS2=\WPRRII&\F[MEPOYH\>&BD=1GT]1
M\S>2*WHP^-_\&^2$O>=]G3UMISF2%WQDKDTZ2!#@0![8S\6XY+86T84\([U4
MTJ%0*!0*A:)$(*@A\".[ZJ8U1_;1H=52LW;E/M>)551!"'"ZM%LF&G&WH"W4
M>O_-N9+Q]=)+8,.+.6##EZ:*5 GW=0),MT5 AFSE[_\_R=7;PG9H;_+*#"%F
M>&^$ G(E3 I#!?WH\O'+8*QP),%]Q'CNE5KQ2CH"X)5TO&'=:R:/42F$G!9?
M3'=C?WF&AL2LE]^SJQ7!?@\RBW0/.1-$Q8[IJ8@Q)K?KA\MED /$E^>8J@;[
M:"_^FYXBY'*UJD\0DT&N&VD@]P02S[-&%8/5YJT%4DV!5(^QW@<J7O9G.)7S
M;![*.2G2+:H>3&V#X."OPV=*.A0*A4*A4'B&5])! $DU!$+A9@1XM9,.>E.0
MI1! 84J(T9K;>O*149+UY?IOO:&+HX\& 2-!+GM$T,J^AL*5)AUDTLG2XSZM
MI.-K>"4=9/\9*8M!YB=CMUZV"/(Q<43ZQ"C;(B=X9T-&@GW&+2/C"R3V$ ,(
M#'XNB^9F2(\'DCS\,S +M%?SAK/$=!-"S6\<ROE4O@LY0/)(58OA 0PN8/&N
M\ Q D'EGQX_<<O&SF?$[1/H'X8&<0V"HP$">Z/]*VGCIH" E'0J%0J%0*%SA
MAW3TZKQ2_ &N9=(1K47P2[\'XTW94R_2K:N!=)!15])Q*;R2#@8K/%MUG#3:
M4QDHOOB,OW%[KP+7$U5&6N_A"L?[#(' G9S>&HP\YR:DBWNXO>8FI$E5A?,O
M_OP5#7<X)00B;7N>+*HP$!((#D:3R"+MSS#OA)!R3/:.:@XR+YS2^8WBE3PE
M'0J%0J%0*%SAE70@VVC?<K%9L^+:EE=%:Z&W)^.-5,6KJ_J5)ATTZ".?J??\
M%"4= ?!*.I#343F[]8;.,M:X^.(SN__"RS/4HO%LD2]"!)W LP41X!WDW0U<
M9ZU]Y-^#N=3S/8@(G_%]EDU,@GV&)\O7GQ<YVG_]V9>7D1HE'0J%0J%0*%SA
ME730I-JLP:R+F7PG7&^D QT],BR<II&_^/%L0#)#X(PTQNT8Y<L.D-]/WGS(
M\V][05YNH02YSS\Q(6*D@Z T,^.HR'"0"WV324>D%KX:=6K$B4ED[J'"L/?C
M2D))AT*A4"@4"E>0[=Z5=L0**IE>Y4PZ".#(R(\>LEDD'HZ_9Q$2Y!FQ/=>(
MHS&F=L%6V3*]I$?B6B0=3!]BBE#9,KVE^79(S(:P)DL5GOS<^MXA&8?K=CPF
M$S$Y"^^&2 *9#H[3.*B['9]QK4/ZK1=I32B0$:>"@_<#O3-.O\FSUJU]HNS;
M&0_]+\$0BG1 HID,!H'P,P&M-$A'X/0I>C[B)Z8*6;M6H:1#H5 H% J%*Y!)
MD 6>/':KJSD@! $/"AI5"9:=8'L+T+0Z+':#-+T&6[AK/W!'_VN2=" ;@FQ@
ME(B6'B/ DY]Z/T<;>'_LS3XFXTK=CD?PS-2B07W7^3Z&&YB(]$&S^:;BW<YF
MARQ<Z!F;BA0K%)#J0#R9X$4&W^V:,";D'-Q(K!M"D0Y&0#=M,$O&$OLY1FF0
M#GN@P6MU$LR$45NEA\(/,;K:H*1#H5 H% J%)V  AA^$DR2*J3MDIU]],5YD
M/DZZ<TB,[4A.9IP>AV"+*3R/E1]6ZJ2#Z5.WWMA%KH41N($+TD4%P\F'PUZ,
M-45_/R<A3<P+W7I<W$#_ W(LI@7]['O='(]+9049%T[5^_:<\"45"@:((21I
MXN@B8T"NW2D;SSEQK1D^B16&=KBS.^TA^XRL#-+FYG ?#%13:&2>.'JK5,R<
MCL&>445:L31;")Y71(-T\-SA<0%)>NBW@T72UK+I/#-M<JI4G(+U85Q+4-*A
M4"@4"H7"$\@XO_C41)$^.05.!*%_?G"8Z=]SK:N<*+ QU6E!/)Y^=$RIDPXD
M+1@$0AP(N /-"!FC2W:>X-#MO*I5'FEB>ZTSJ5MS?;F:!]\K(\$_$BH"<;>]
M)U"=-GF[!,4E 1EUW,@9# "A<1L#_//O=Y5*#/?,C_]P*-(!\>,^#>Z[WK5Q
M.ACH><!LC[XAM^H<7A:]NQ3UC?@AAM$@'50V,-^K9=W##]];)"0_[W"A=2_.
M7O.$ RCI4"@4"H5"X0D[4O+$]1C'9+?@"6G1LU:P.&[$%FE$IB<D'"!)HE>@
MM$D'%0Y&F7[X_F*3$+=#_ ?LA;\!#?6A*C 0A%K5)TJ#,A4=7)U+@L3%V=)[
M$$INQOA5C/QHYJ<)G8J%7Q!\DUF/Z;Y:1ORZ'8^]>LPBF4S8\@M(+,^2TW "
M" W7^\[K<^198 "!5U!QP?&>4;5N1(TJ"/>4T;!^ GNOI ,3/B9_-6LX2_PX
MG%;7=HEF<+_U9L+(9)%ZK5^]7^14W(N2DM:K!4HZ% J%0J%0> )Z?33R!+4$
MA$YC/HNRW]U,B\:SS+)%61(\H>'W.B860%2HE%!=*&W2096C1:/99MZ,],L"
M/KP*D(011#)=R5GN5&0$^*]W%XD)6SC]'(& !. (S=A=IZJ#?5PR^Q F@GJ9
M=.2Q"=OV6\C./&;B)Z:(L9V3K(K%>>!\C>$<_1Q^D63=MWHUISCV=?!\X<X-
M\4&FA@\$]R/4<R15&NL>(34K?U>LHT,\]XY*"^[>$!H_51JOI.,?S\69\1:1
MP#.#Y]1I(<'[ID-)AT*A4"@4"D\@F"/8HCGZSA_W$#F(4["(]P!9ZCK/?6(F
MC=DJ0:"?K#O'(?!%SG0UD0YZ+ C,R:+C#(T\QVD/"&H)2FFL+ZG<Z?BQTS)N
MM]'?ITD@[D0\^'>"[(IW#S"-:T\39V@(BQ?@2,U>=FVW["+A<+[''<5[ K,Z
MY%R8P?D%U]/.(F5_?L"Y:L3U(.?C.<(IFV<PU',$F>G=99544>B#<=HKR!GG
M#R&@!\0/O)*.)J_,,(F+L\S^O2>$L#JM:W$$KE\HZ5 H% J%0N$)R$_("$,B
M&(U[ETL6W,ZZ(U^I_T*\>#C,^<H-&2^'G/V?FKS<4[*0MI#%IH<#60E_QSC=
M)O427$>J7@G282,E.5=Z#9@8Y>8U0F#[;-6Q9L[T-!D3&R[LQN[^/=;(^%JJ
M*&[[ EF@"O'JBU,E &=/V5OVF+UFS^D7R-Q58)(W'91&Z@DCMTB%A'X49%,0
M1Z??AU!!;) &(;NC[\ OV _&P"*!<KN6V[[;]:LI3M-E@MK*I7ND5X;QL5S+
M_KW'A5@Q#6W>S'33N2VD::R85;K][L._&RQCAL,99>R5=%#MV[CN@"]OEF\J
ME'0H% J%0J'P#*0M!)G#!VPTC]PWQ#7@LC/^-"*7*]-;M/]OUI\ADYB0::U9
ML5?6TH699D;\#@GBD>H\]-M!$C!"6MRD1%>2=) 99Q\:OCS5E1AQ_63J"<Y+
MZJ'!,6F.[M5YI>NHV4NK'IVE&E/YGH%BW,@>)TS9+GN^*G&/&3-TLVEO$0T"
M?_H/OG;(=M]WFKSI,9EF!=X$U'ZD<S8844L%  F:E^<(R1Y$JL%+4TV/#BM$
MMI0P98?(HX;VWR"]'Y! *C1N\C][<<U3)VT7 NP72CK\0TF'0J%0*!0*7V"2
MT"8KD((@/'AG;,CQL1*DWM#9W'%S#U.QW "9"/7RWR9+@RV+X(_*"?T;^$&0
M97>2]5PMI /DYYX2^1+7X!:DT\A<Y=[!TBQ\*.?3L*H"@, >"13G_XIU3 )P
M+WO$7K*G["U[S%ZSYW5K3I%^"21L]#:X&3\&KKMOZR,-_C1@9^T^&O:@ +N'
M!#-))%:,KW4[+F2(JA*RO;]4'"'#"FI5GR 3U>AU@:Q260IE* F9I1^'J@[5
MDG#&"ROI\ \E'0J%0J%0*'R#(&KBJ&3).I<3YW!O)"%2Z[8;NT@&'RG-CI1<
M7X%CI$@'7B/(>V)[KI7L.C(@MW,FV,=[))S,>B!HS!\:LT%Z2@B>O1*TDB[(
M)9.FZ/?HV7&%C)F-!%8NVV-:-9\OQ(QK"55E*<FB^L-S0[\'8XC#A9(._U#2
MH5 H% J%PC=HJ*8O8&;\3E._5KR,:BU-TD&VFYX/9%H0#C_C3B-%.L3D\/0Y
MLWQQME1]*H5P[6:/Z&^A<;DD8!H5Q(/QJOARA.I[B=2ZX^:>4N% 'D?C>$D-
M"&U0,4)FAUP+8SPOE;-P%G(K9&%4VL8,39+>HG"AI,,_E'0H% J%0J$(&P1?
M2(QPI/[C[X>(O"5:02/2&H)2@L8/FLT7PL-X5[^(%.FP0;5C;D*:J5LC3BH!
M3M=O]R3TZ;I* EYZ&DH"?@-ITANOS)"]#]7\'<["99Y _<&[8D62!>%@.E0D
M 8'%4X3* \2#?A4F=$7Z.K@WD"9\5MB[3T^$3P24=/B'D@Z%0J%0*!1A@_YA
MJ@QX0G1JNTSZ R 'T9#(0#AJ/#Y. FV:N#%."Z-_.>*DP]Z#[AU6B"^$6\",
MO.?YOTZ0AFY\3TH"SHT]6)6X5V1F%<H-$((0R3U'-D=3_QOU9TC3..0@&F9U
M_";3N6BVKUEMO!A,1OHZJ#0-B]U@,C,*OGIVPK\.)1W^H:1#H5 H% I%B8$)
MW:9U.6;<\"2I0CSYR"C)6!,$AYI Y18H(J,B.TT&G+&[R*D8CUHT,2F\<XTT
MZ;"1N"C+M'YK@4RK<KLN/L<4;]G"3&D,+PG8@Z*]/V#&C]PBDZ!P0K___V)D
M_T)-< JVZ*N@[P$"^5J=!*ENL&=4E<)M&@]]'5]*Q8-^%^XQ) KRP: "Q@/[
M?88@O5P'>\V]IF>$QO?4K8>%W)24."GI\ \E'0J%0J%0*"("LOU'"TZ;M2OW
MF5Z=5HJ17;7*(TREWPP461'9:QJNF6*%U 6Y$>OV'W4761:?4<U@DA)9>R84
M(1V";,R>GA:6E"H8Z!]XO6Z">:+**"$UQ1=-QAU;+S7+%V?Y(C9XCN#,3<,X
M%8]@OVVO&E9 /752:EBF>L' WC,5*WG3(3-BP$:Y/@)B]A'R!Y&B8L$^$\1_
MO?<?R_U@[^_]13\)\AEM_-+3D\2X;V;\#G'+QI^E-+$MZ9 9TF^]:?KJ3//T
MHZ-EG"_/!<\'S]%=/^DEY\ZU_.(''PM)XAI9]_ZBK\C!JI8?+H,.!O9>)QXE
M]*#X,:AT0\[^$W*OD=2YW6?(4TKRX1))N;XI4-*A4"@4"H4B(BC*5E\0AV4R
MP3A.$^SA)(U!W=NOS9%@F"P_?1EX*K"H9-1^9K)\UO;MA:;?QZO%C1S)%C(J
M>B:.Y'\6L<"7)FRRZ1C-C1RTZ;*%^2$>%AS7CP0'R0XC<1?,WB55AV"_;2_V
M9,NF@Q91*8S(-7&>^'B0Q<=TCYX%KH$^B>X?+9=&=ZH6M9_Y1,S_V'?(Q;-5
MQTG@_&;]F:93FZ4B7:,"@_E>5L91J<10W8B&I,H-A2?/2M4#,T-(+%4%C!%;
MM5A@WGE]KA!:SIUK>=PBIPPSH#K%8C3QV.%)X@3.,\C]9J0RQ*P$BJI+P#XS
M+GCFU)VN]YEGF'L<K0K1M00E'0J%0J%0**(&2 A984SM%LS.D.9O&L\9^1K3
M?;4LC 8G6X'^+"N H[JP->F0]#LPI2D:P>YGI\[).5$YR4@ON&P13.8>+@QK
M.A/$@^]"NH+]MKTX-I612$V "@9(VM[L8R*]0BHV8\H.V>=!?=;)OA/$$QAS
M/V9/VRG!/;X5!-17$W@.F)2&"SRFAE08("&<.]=")0,2QS6R(+KL;S3WEN<:
M8H2YH=M]YEE@PAF$\'J'D@Z%0J%0*!11!YGXHF4N+@@%*_#?[+\K_?/Z,N+'
M#O;;I7U]7Y^'N6SOB_];:9^77URZA\7/_<I=Q]5RGZ]V*.E0*!0*A4*A4"@4
E4862#H5"H5 H% J%0A%5_!O< <!U^^\440    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288964606272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">The Cigna Group<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-4991898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">900 Cottage Grove Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bloomfield<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">06002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">226-6000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292,355,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Part III of this Form 10-K incorporates by reference information from the registrant's definitive proxy statement related to the 2024 annual meeting of shareholders.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001739940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288968322032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Hartford, Connecticut<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">238<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288964665120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">$ 44,237<span></span>
</td>
<td colspan="2" class="nump">$ 39,916<span></span>
</td>
<td colspan="2" class="nump">$ 41,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net investment income</a></td>
<td class="nump">1,166<span></span>
</td>
<td colspan="2" class="nump">1,155<span></span>
</td>
<td colspan="2" class="nump">1,549<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUES</a></td>
<td class="nump">195,265<span></span>
</td>
<td colspan="2" class="nump">180,518<span></span>
</td>
<td colspan="2" class="nump">174,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BenefitsLossesAndExpensesAbstract', window );"><strong>Benefits and expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Pharmacy and other service costs</a></td>
<td class="nump">133,801<span></span>
</td>
<td colspan="2" class="nump">124,834<span></span>
</td>
<td colspan="2" class="nump">117,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet', window );">Medical costs and other benefit expenses</a></td>
<td class="nump">36,287<span></span>
</td>
<td colspan="2" class="nump">32,184<span></span>
</td>
<td colspan="2" class="nump">33,565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">14,822<span></span>
</td>
<td colspan="2" class="nump">13,174<span></span>
</td>
<td colspan="2" class="nump">13,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">1,819<span></span>
</td>
<td colspan="2" class="nump">1,876<span></span>
</td>
<td colspan="2" class="nump">1,998<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BenefitsLossesAndExpenses', window );">TOTAL BENEFITS AND EXPENSES</a></td>
<td class="nump">186,729<span></span>
</td>
<td colspan="2" class="nump">172,068<span></span>
</td>
<td colspan="2" class="nump">166,128<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">8,536<span></span>
</td>
<td colspan="2" class="nump">8,450<span></span>
</td>
<td colspan="2" class="nump">7,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest expense and other</a></td>
<td class="num">(1,446)<span></span>
</td>
<td colspan="2" class="num">(1,228)<span></span>
</td>
<td colspan="2" class="num">(1,208)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Debt extinguishment costs</a></td>
<td class="nump">0<span></span>
</td>
<td colspan="2" class="nump">0<span></span>
</td>
<td colspan="2" class="num">(141)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">(Loss) gain on sale of businesses</a></td>
<td class="num">(1,499)<span></span>
</td>
<td colspan="2" class="nump">1,662<span></span>
</td>
<td colspan="2" class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_RealizedInvestmentGainLoss', window );">Net realized investment (losses) gains</a></td>
<td class="num">(78)<span></span>
</td>
<td colspan="2" class="num">(487)<span></span>
</td>
<td colspan="2" class="nump">198<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">5,513<span></span>
</td>
<td colspan="2" class="nump">8,397<span></span>
</td>
<td colspan="2" class="nump">6,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">TOTAL INCOME TAXES</a></td>
<td class="nump">141<span></span>
</td>
<td colspan="2" class="nump">1,615<span></span>
</td>
<td colspan="2" class="nump">1,370<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">5,372<span></span>
</td>
<td colspan="2" class="nump">6,782<span></span>
</td>
<td colspan="2" class="nump">5,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net income attributable to noncontrolling interests</a></td>
<td class="nump">208<span></span>
</td>
<td colspan="2" class="nump">78<span></span>
</td>
<td colspan="2" class="nump">50<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">SHAREHOLDERS' NET INCOME</a></td>
<td class="nump">$ 5,164<span></span>
</td>
<td colspan="2" class="nump">$ 6,704<span></span>
</td>
<td colspan="2" class="nump">$ 5,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Shareholders' net income per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 17.57<span></span>
</td>
<td colspan="2" class="nump">$ 21.66<span></span>
</td>
<td colspan="2" class="nump">$ 15.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 17.39<span></span>
</td>
<td colspan="2" class="nump">$ 21.41<span></span>
</td>
<td colspan="2" class="nump">$ 15.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Pharmacy revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 137,243<span></span>
</td>
<td colspan="2" class="nump">$ 128,566<span></span>
</td>
<td colspan="2" class="nump">$ 121,413<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Fees and other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 12,619<span></span>
</td>
<td colspan="2" class="nump">$ 10,881<span></span>
</td>
<td colspan="2" class="nump">$ 9,953<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_RealizedInvestmentGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net realized gains or (losses) on investments during the period, including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_RealizedInvestmentGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BenefitsLossesAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of expense recognized during the period for future policy benefits, claims and claims adjustment costs, and for selling, general and administrative costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.5,6,7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BenefitsLossesAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BenefitsLossesAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BenefitsLossesAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetInvestmentIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 220<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetInvestmentIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of policies assumed or ceded, of expense related to the provision for policy benefits and costs incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderBenefitsAndClaimsIncurredNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PremiumsEarnedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-17(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480149/944-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479655/944-605-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(c))<br> -SubTopic 220<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(1))<br> -SubTopic 220<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PremiumsEarnedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288968291456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 5,372<span></span>
</td>
<td colspan="2" class="nump">$ 6,782<span></span>
</td>
<td colspan="2" class="nump">$ 5,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss), net of tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax', window );">Net unrealized appreciation (depreciation) on securities and derivatives</a></td>
<td class="nump">503<span></span>
</td>
<td colspan="2" class="num">(1,598)<span></span>
</td>
<td colspan="2" class="num">(302)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent', window );">Net long-duration insurance and contractholder liabilities measurement adjustments</a></td>
<td class="num">(715)<span></span>
</td>
<td colspan="2" class="nump">509<span></span>
</td>
<td colspan="2" class="nump">67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity', window );">Net translation gains (losses) on foreign currencies</a></td>
<td class="nump">5<span></span>
</td>
<td colspan="2" class="nump">77<span></span>
</td>
<td colspan="2" class="num">(232)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Postretirement benefits liability adjustment</a></td>
<td class="nump">1<span></span>
</td>
<td colspan="2" class="nump">420<span></span>
</td>
<td colspan="2" class="nump">410<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity', window );">Other comprehensive loss, net of tax</a></td>
<td class="num">(206)<span></span>
</td>
<td colspan="2" class="num">(592)<span></span>
</td>
<td colspan="2" class="num">(57)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity', window );">Total comprehensive income</a></td>
<td class="nump">5,166<span></span>
</td>
<td colspan="2" class="nump">6,190<span></span>
</td>
<td colspan="2" class="nump">5,363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract', window );"><strong>Comprehensive income (loss) attributable to noncontrolling interests</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest', window );">Net income attributable to redeemable noncontrolling interests</a></td>
<td class="nump">180<span></span>
</td>
<td colspan="2" class="nump">11<span></span>
</td>
<td colspan="2" class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest', window );">Net income attributable to other noncontrolling interests</a></td>
<td class="nump">28<span></span>
</td>
<td colspan="2" class="nump">67<span></span>
</td>
<td colspan="2" class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_TemporaryEquityOtherComprehensiveIncome', window );">Other comprehensive loss attributable to redeemable noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td colspan="2" class="num">(2)<span></span>
</td>
<td colspan="2" class="num">(14)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Total comprehensive income attributable to noncontrolling interests</a></td>
<td class="nump">208<span></span>
</td>
<td colspan="2" class="nump">76<span></span>
</td>
<td colspan="2" class="nump">36<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">SHAREHOLDERS' COMPREHENSIVE INCOME</a></td>
<td class="nump">$ 4,958<span></span>
</td>
<td colspan="2" class="nump">$ 6,114<span></span>
</td>
<td colspan="2" class="nump">$ 5,327<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest, Including Temporary Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>OCI, Liability For Future Policy Benefit And Market Risk Benefit, Instrument-Specific Credit Risk, Gain (Loss), After Reclassification Adjustment And Tax, Portion Attributable To Parent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Available-For-Sale Securities And Derivatives Adjustment, Net Of Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Including Temporary Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Net of Tax, Including Temporary Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_TemporaryEquityOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of other comprehensive income or(loss) attributable to temporary equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_TemporaryEquityOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Portion of net income (loss) attributable to nonredeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.19)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.19)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288960817360">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7,822<span></span>
</td>
<td colspan="2" class="nump">$ 5,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">925<span></span>
</td>
<td colspan="2" class="nump">905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,722<span></span>
</td>
<td colspan="2" class="nump">17,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,645<span></span>
</td>
<td colspan="2" class="nump">4,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,169<span></span>
</td>
<td colspan="2" class="nump">1,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Assets of businesses held for sale</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,068<span></span>
</td>
<td colspan="2" class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">37,351<span></span>
</td>
<td colspan="2" class="nump">30,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,985<span></span>
</td>
<td colspan="2" class="nump">16,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesNonCurrent', window );">Reinsurance recoverables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,835<span></span>
</td>
<td colspan="2" class="nump">5,416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,695<span></span>
</td>
<td colspan="2" class="nump">3,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44,259<span></span>
</td>
<td colspan="2" class="nump">45,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">30,863<span></span>
</td>
<td colspan="2" class="nump">32,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,421<span></span>
</td>
<td colspan="2" class="nump">2,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate account assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,430<span></span>
</td>
<td colspan="2" class="nump">7,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Assets of businesses held for sale, non-current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,922<span></span>
</td>
<td colspan="2" class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">152,761<span></span>
</td>
<td colspan="2" class="nump">143,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesCurrent', window );">Current insurance and contractholder liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,514<span></span>
</td>
<td colspan="2" class="nump">5,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PharmacyAndServiceCostsPayable', window );">Pharmacy and other service costs payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,815<span></span>
</td>
<td colspan="2" class="nump">17,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,553<span></span>
</td>
<td colspan="2" class="nump">7,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AccruedExpensesAndOtherLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,955<span></span>
</td>
<td colspan="2" class="nump">7,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Short-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,775<span></span>
</td>
<td colspan="2" class="nump">2,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Liabilities of businesses held for sale</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,104<span></span>
</td>
<td colspan="2" class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">48,716<span></span>
</td>
<td colspan="2" class="nump">41,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesNoncurrent', window );">Non-current insurance and contractholder liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,904<span></span>
</td>
<td colspan="2" class="nump">11,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,173<span></span>
</td>
<td colspan="2" class="nump">7,786<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,441<span></span>
</td>
<td colspan="2" class="nump">2,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">28,155<span></span>
</td>
<td colspan="2" class="nump">28,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountsLiability', window );">Separate account liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,430<span></span>
</td>
<td colspan="2" class="nump">7,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Liabilities of businesses held for sale, non-current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">591<span></span>
</td>
<td colspan="2" class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">106,410<span></span>
</td>
<td colspan="2" class="nump">99,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Contingencies &#8212; Note 24</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Redeemable noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">107<span></span>
</td>
<td colspan="2" class="nump">66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Shareholders' equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">4<span></span>
</td>
<td colspan="2" class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">30,669<span></span>
</td>
<td colspan="2" class="nump">30,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,864)<span></span>
</td>
<td colspan="2" class="num">(1,658)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">41,652<span></span>
</td>
<td colspan="2" class="nump">37,940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Less: Treasury stock, at cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(24,238)<span></span>
</td>
<td colspan="2" class="num">(21,844)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL SHAREHOLDERS' EQUITY</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">46,223<span></span>
</td>
<td colspan="2" class="nump">44,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Other noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21<span></span>
</td>
<td colspan="2" class="nump">13<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">46,244<span></span>
</td>
<td colspan="2" class="nump">44,688<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 152,761<span></span>
</td>
<td colspan="2" class="nump">$ 143,885<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Par value per share, $0.01; shares issued, 400 million as of December&#160;31, 2023 and 398 million as of December&#160;31, 2022; authorized shares, 600 million.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AccruedExpensesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of other current liabilities and obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AccruedExpensesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_InsuranceAndContractholderLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts as of the balance sheet date of all current insurance and contractholder liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_InsuranceAndContractholderLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_InsuranceAndContractholderLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts as of the balance sheet date of all current insurance and contractholder liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_InsuranceAndContractholderLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_PharmacyAndServiceCostsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects amounts due to pharmacies for prescriptions filled through our retail network of pharmacies. Also includes amounts due to clients for their portion of rebates that must be contractually shared.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_PharmacyAndServiceCostsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ReinsuranceRecoverablesNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after valuation allowance, recoverable after one year under reinsurance contracts including premium paid under reinsurance contracts. Examples include, but are not limited to, settled and unsettled claims, incurred but not reported losses, loss adjustment expense, premium paid, policy benefits and policy reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ReinsuranceRecoverablesNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (12)(c)<br> -Section S99<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph 14<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph 15<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (16)(c)<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeparateAccountAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset at fair value held for benefit of separate account policyholder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480078/944-80-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480141/944-80-45-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480109/944-80-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeparateAccountAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeparateAccountsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for variable contract in which all or portion of contract holder's funds is allocated to specific separate account and supported by assets held in separate account.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480078/944-80-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480109/944-80-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480141/944-80-45-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480109/944-80-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeparateAccountsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288970081872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">399,894,000<span></span>
</td>
<td class="nump">397,819,000<span></span>
</td>
<td class="nump">394,194,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288967772528">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Total Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2"><div>Total</div></th>
<th class="th"><div>Previously Reported</div></th>
<th class="th"><div>Revision of Prior Period, Accounting Standards Update, Adjustment</div></th>
<th class="th"><div>Shareholders' Equity</div></th>
<th class="th">
<div>Shareholders' Equity </div>
<div>Previously Reported</div>
</th>
<th class="th">
<div>Shareholders' Equity </div>
<div>Revision of Prior Period, Accounting Standards Update, Adjustment</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Previously Reported</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Previously Reported</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive (Loss)</div></th>
<th class="th">
<div>Accumulated Other Comprehensive (Loss) </div>
<div>Previously Reported</div>
</th>
<th class="th">
<div>Accumulated Other Comprehensive (Loss) </div>
<div>Revision of Prior Period, Accounting Standards Update, Adjustment</div>
</th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th">
<div>Retained Earnings </div>
<div>Previously Reported</div>
</th>
<th class="th">
<div>Retained Earnings </div>
<div>Revision of Prior Period, Accounting Standards Update, Adjustment</div>
</th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th">
<div>Treasury Stock </div>
<div>Previously Reported</div>
</th>
<th class="th"><div>Other Non- controlling Interests</div></th>
<th class="th">
<div>Other Non- controlling Interests </div>
<div>Previously Reported</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 50,189<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 50,328<span></span>
</td>
<td class="num">$ (139)<span></span>
</td>
<td class="nump">$ 50,182<span></span>
</td>
<td class="nump">$ 50,321<span></span>
</td>
<td class="num">$ (139)<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 28,975<span></span>
</td>
<td class="nump">$ 28,975<span></span>
</td>
<td class="num">$ (1,025)<span></span>
</td>
<td class="num">$ (861)<span></span>
</td>
<td class="num">$ (164)<span></span>
</td>
<td class="nump">$ 28,600<span></span>
</td>
<td class="nump">$ 28,575<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="num">$ (6,372)<span></span>
</td>
<td class="num">$ (6,372)<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Changes in Total Equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Effect of issuing stock for employee benefit plans</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">511<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(93)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(43)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,401<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common dividends declared</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,347)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7,710)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NoncontrollingInterestOtherChanges', window );">Other transactions impacting noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(25)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">46,976<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,068)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,175)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Balance at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">58<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Change in Redeemable Noncontrolling Interests</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_TemporaryEquityOtherComprehensiveIncome', window );">Other comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(14)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityOtherChanges', window );">Other transactions impacting noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 54<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Change in Redeemable Noncontrolling Interests</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Accounting Standards Update 2016-13 [Member]<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Effect of issuing stock for employee benefit plans</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 583<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(590)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(590)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(590)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,771<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common dividends declared</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,387)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,387)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,387)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7,593)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,593)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,593)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NoncontrollingInterestOtherChanges', window );">Other transactions impacting noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(72)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44,688<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,658)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,844)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Change in Redeemable Noncontrolling Interests</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_TemporaryEquityOtherComprehensiveIncome', window );">Other comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(2)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityOtherChanges', window );">Other transactions impacting noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">66<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Changes in Total Equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Effect of issuing stock for employee benefit plans</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">365<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(112)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(206)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(206)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(206)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,192<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common dividends declared</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,452)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,452)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,452)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,282)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,282)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,282)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NoncontrollingInterestOtherChanges', window );">Other transactions impacting noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(61)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">46,244<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,864)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (24,238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Change in Redeemable Noncontrolling Interests</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_TemporaryEquityOtherComprehensiveIncome', window );">Other comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">180<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityOtherChanges', window );">Other transactions impacting noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(139)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Balance at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 107<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="22"></td></tr>
<tr><td colspan="22"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_NoncontrollingInterestOtherChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other activity associated with noncontrolling interest that is not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_NoncontrollingInterestOtherChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_TemporaryEquityOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of other comprehensive income or(loss) attributable to temporary equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_TemporaryEquityOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 72: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (3)<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityNetIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of net income or loss attributable to temporary equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityNetIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityOtherChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in temporary equity from changes classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityOtherChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288968281504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Total Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="12">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common dividends declared (in dollars per share)</a></td>
<td class="nump">$ 1.23<span></span>
</td>
<td class="nump">$ 1.23<span></span>
</td>
<td class="nump">$ 1.23<span></span>
</td>
<td class="nump">$ 1.23<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 4.92<span></span>
</td>
<td class="nump">$ 4.48<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288960002704">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Operating Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5,372<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 6,782<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 5,420<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,035<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,937<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,923<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_RealizedInvestmentGainLoss', window );">Realized investment losses (gains), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">78<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">487<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(198)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income tax benefit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,659)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(472)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(216)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Loss (gain) on sale of businesses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,499<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,662)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Debt extinguishment costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">141<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in assets and liabilities, net of non-operating effects:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Accounts receivable, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,663)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,237)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(2,843)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(868)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,055)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(557)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReinsuranceRecoverable', window );">Reinsurance recoverable and Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(539)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">393<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(655)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInsuranceLiabilities', window );">Insurance liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">584<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(336)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">805<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable', window );">Pharmacy and other service costs payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,030<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,760<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,961<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities', window );">Accounts payable and Accrued expenses and other liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,481<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,734<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">77<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">463<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">325<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">333<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH PROVIDED BY OPERATING ACTIVITIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,813<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,656<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">7,191<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract', window );"><strong>Proceeds from investments sold:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ProceedsFromSaleOfDebtAndEquitySecurities', window );">Debt securities and equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,078<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,744<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,030<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract', window );"><strong>Investment maturities and repayments:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities', window );">Debt securities and equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">972<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,327<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,628<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfLoansReceivable', window );">Commercial mortgage loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">186<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">98<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">180<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments', window );">Other sales, maturities and repayments (primarily short-term and other long-term investments)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">586<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,039<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,936<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestmentsAbstract', window );"><strong>Investments purchased or originated:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PaymentsToAcquireDebtAndEquitySecurities', window );">Debt securities and equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,334)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,756)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(3,553)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMortgageNotesReceivable', window );">Commercial mortgage loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(118)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(161)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(327)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Other (primarily short-term and other long-term investments)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,205)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,563)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(2,554)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PaymentsForProceedsFromPropertyPlantAndEquipment', window );">Property and equipment purchases, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,573)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,295)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(1,154)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, net of cash acquired</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(447)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,833)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested', window );">Divestitures, net of cash sold</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,835<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(61)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(332)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(170)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">97<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,174)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,098<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(3,611)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Financing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionsToContractHoldersFunds', window );">Deposits and interest credited to contractholder deposit funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">167<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">164<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">153<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WithdrawalFromContractHoldersFunds', window );">Withdrawals and benefit payments from contractholder deposit funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(223)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(220)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(168)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ProceedsFromRepaymentsOfOtherShortTermDebt', window );">Net change in short-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,198<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,059)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">975<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Payments for debt extinguishment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(136)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,967)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(500)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(4,578)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Net proceeds on issuance of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,491<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,260<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,284)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,607)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(7,742)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">187<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">389<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">326<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Common stock dividend paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,450)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,384)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(1,341)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(413)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(23)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">39<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH USED IN FINANCING ACTIVITIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,294)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(11,240)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(8,212)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of foreign currency rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(86)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(65)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,361<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">428<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(4,697)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash January 1, including held for sale assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,976<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">5,548<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">10,245<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash December 31, including held for sale assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">8,337<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,976<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,548<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations', window );">Cash and cash equivalents reclassified to assets of businesses held for sale</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(467)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(425)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash and cash equivalents December 31,</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">7,870<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,976<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,123<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosure of Cash Information:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid, net of refunds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,471<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,850<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,240<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,330<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,229<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,253<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Restricted cash and cash equivalents were reported in other long-term investments.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of accounts payable, accrued liabilities and other operating obligations not separately disclosed in the statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_PaymentsForProceedsFromPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For (Proceeds From) Property, Plant, And Equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_PaymentsForProceedsFromPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_PaymentsToAcquireDebtAndEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Debt And Equity Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_PaymentsToAcquireDebtAndEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from maturities, repayments and calls of debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ProceedsFromRepaymentsOfOtherShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease and the net proceeds from (repayments of) short-term debt, defined as borrowing having initial term of repayment of one year or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ProceedsFromRepaymentsOfOtherShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ProceedsFromSaleOfDebtAndEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sales of debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ProceedsFromSaleOfDebtAndEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_RealizedInvestmentGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net realized gains or (losses) on investments during the period, including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_RealizedInvestmentGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionsToContractHoldersFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a segregated fund account during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionsToContractHoldersFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInsuranceLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in insurance liability balances during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInsuranceLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReinsuranceRecoverable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of benefits the ceding insurer expects to recover on insurance policies ceded to other insurance entities as of the balance sheet date for all guaranteed benefit types.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReinsuranceRecoverable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMortgageNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the purchase of receivables arising from the mortgage note on real estate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMortgageNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollectionOfLoansReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the collection, including prepayments, of loans receivable issued for financing of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollectionOfLoansReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the cash inflow during the period from the sale of a component of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WithdrawalFromContractHoldersFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a segregated fund account during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WithdrawalFromContractHoldersFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288973799296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of Business</a></td>
<td class="text"><div style="margin-bottom:10pt"><span id="ic54f78bd196a45c4afa77338709a7ea1_5265"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1 &#8211; Description of Business</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Cigna Group, together with its subsidiaries (either individually or collectively referred to as the "Company," "we," "us" or "our"), is a global health company committed to creating a better future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. Powered by our people and our brands, we advance our mission to improve the health and vitality of those we serve. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our subsidiaries offer a differentiated set of pharmacy, medical, behavioral, dental and related products and services. The majority of these products and services are offered through employers and other groups such as governmental and non-governmental organizations, unions and associations. Cigna Healthcare also offers commercial health and dental insurance and Medicare products to individuals in the United States and selected international markets. In addition to these operations, The Cigna Group also has certain run-off operations.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A full description of our segments follows:</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Evernorth Health Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> partners with health plans, employers, governmental organizations and health care providers to solve challenges in the areas of pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty distribution, and care delivery and management solutions. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cigna Healthcare</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> includes the U.S. Healthcare and International Health operating segments which provide comprehensive medical and coordinated solutions to clients and customers. During the fourth quarter of 2023, the U.S. Commercial and U.S. Government operating segments merged to form the U.S. Healthcare operating segment. U.S. Healthcare provides commercial medical plans and specialty benefits and solutions for insured and self-insured clients, Medicare Advantage, Medicare Supplement and Medicare Part D plans for seniors and individual health insurance plans. International Health provides health care solutions in our international markets, as well as health care benefits for globally mobile individuals and employees of multinational organizations. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2024, the Company entered into a definitive agreement to sell the Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits and CareAllies businesses within the <span style="-sec-ix-hidden:f-490">U.S. Healthcare</span> operating segment to Health Care Service Corporation ("HCSC") for $3.3 billion cash, subject to applicable regulatory approvals and other customary closing conditions (the "HCSC transaction").</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> comprises the remainder of our business operations, which includes ongoing businesses and exited businesses. Our ongoing businesses include continuing business (corporate-owned life insurance ("COLI")), and our run-off businesses. Our run-off businesses include (i) variable annuity reinsurance business (formerly referred to as guaranteed minimum death benefit ("GMDB") and guaranteed minimum income benefit ("GMIB") business) that was effectively exited through reinsurance with Berkshire Hathaway Life Insurance Company of Nebraska ("Berkshire") in 2013, (ii) settlement annuity business, and (iii) individual life insurance and annuity and retirement benefits businesses which were sold through reinsurance agreements. Our exited businesses include the international life, accident and supplemental benefits businesses sold in July 2022 (the "Chubb transaction") and our interest in a joint venture in T&#252;rkiye sold in December 2022.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">reflects amounts not allocated to operating segments, including net interest expense (defined as interest on corporate financing less net investment income on investments not supporting segment and other operations), certain litigation matters, expense associated with our frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs and eliminations for products and services sold between segments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288973562192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt"><span id="i0260500cfa11442391009e7f8cffe4ab_1054"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2 &#8211; Summary of Significant Accounting Policies&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Basis of Presentation</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Consolidated Financial Statements include the accounts of The Cigna Group and its consolidated subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. These Consolidated Financial Statements were prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"). Certain amounts in prior years related to the adoption of Targeted Improvements for the Accounting of Long-Duration Contracts, have been reclassified to conform to the current year presentation. See "Recent Accounting Pronouncements" below.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amounts recorded in the Consolidated Financial Statements necessarily reflect management's estimates and assumptions about medical costs, investment and receivable valuations, interest rates and other factors. Significant estimates are discussed throughout these Notes; however, actual results could differ from those estimates. The impact of a change in estimate is generally included in earnings in the period of adjustment.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Recent Accounting Pronouncements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Targeted Improvements to the Accounting for Long-Duration Contracts, Accounting Standards Update ("ASU") 2018-12 and related amendments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Cigna Group adopted LDTI January 1, 2023, which includes the following key provisions:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Changes to the measurement of the future policy benefits liability for traditional and limited-pay insurance contracts:</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Assumptions used to measure cash flows (such as mortality, morbidity and lapse assumptions) are updated at least annually with the effect of changes in those assumptions remeasured retrospectively and reflected in current period net income. </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Discount rate assumptions are updated quarterly based on market-level yields for low credit risk fixed income instruments ("upper-medium grade fixed income instrument"), with any changes reflected in other comprehensive income. The upper-medium grade fixed income instrument yield is interpreted to mean A-rated.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Deferred policy acquisition costs ("DAC") related to long-duration insurance contracts are amortized on a constant-level basis over the expected term of the related contracts. Other related deferred or capitalized balances (such as unearned revenue liability and value of business acquired) may use this simplified amortization method. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Market risk benefits ("MRB"), defined as protecting the contractholder from other-than-nominal capital market risk and exposing the insurer to that risk, are measured at fair value, with changes in fair value recognized in net income each period, except for the effect of the Company's change in nonperformance risk (own credit risk), which is recognized in other comprehensive income. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Additional disclosures, including disaggregated roll forwards for the liability for future policy benefits, market risk benefits, contractholder deposit funds and DAC, as well as information about significant inputs, judgments, assumptions and methods used in measurement.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The transition methods applied at adoption were:</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The liability for future policy benefits was remeasured using a modified retrospective approach applied to all outstanding contracts as of the beginning of the earliest period presented and was recognized in the opening balance of retained earnings. The impact of remeasuring the future policy benefits liability for the discount rate was recorded through accumulated other comprehensive income. </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">DAC followed the transition method used for future policyholder benefits.</span></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Market risk benefits were remeasured at fair value at the beginning of the earliest period presented. The difference between this fair value and carrying value was recognized in the opening balance of retained earnings, excluding the effect of the Company's change in nonperformance risk (own credit risk), which was recognized in accumulated other comprehensive income. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Effects of adoption:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The new guidance applies to our long-duration insurance products predominantly within the Cigna Healthcare segment and Other Operations.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The cumulative effects of adopting the new standard were immaterial. The impacts were a decrease to January 1, 2021 Shareholders' equity of $139 million and an increase to Shareholders' net income for the years ended December 31, 2022 and December 31, 2021 of $36 million and $5 million, respectively. The corresponding impact to diluted earnings per share was an increase of $0.11 and $0.02 for the years ended December 31, 2022 and December 31, 2021, respectively. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The prior periods within our Consolidated Statements of Income, Consolidated Statements of Comprehensive Income, Consolidated Balance Sheets, Consolidated Statements of Changes in Total Equity and Consolidated Statements of Cash Flows were restated to conform to the current presentation. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Prior period balances in the Company's footnote disclosures have been updated to reflect adjustments resulting from the adoption of this standard. Refer to Note 10 to the Consolidated Financial Statements for the Company's updated accounting policies. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">It is possible that our income recognition pattern could change on a prospective basis for several reasons: </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Applying periodic assumption updates, versus the locked-in model, may change our timing of profit or loss recognition. </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">DAC amortization is on a constant level basis over the expected term of the related contracts and no longer tied to the emergence of profit on such contracts. </span></div><div style="text-indent:45pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, in December 2022, the Financial Accounting Standards Board ("FASB") published ASU 2022-05, which simplified the retrospective adoption of LDTI by permitting companies to make an accounting policy election to exclude contracts that are sold and removed from the balance sheet prior to the effective date of the standard from the retrospective adoption of LDTI. The Cigna Group made this policy election for the contracts sold in the Chubb transaction and our divested interest in a joint venture in T&#252;rkiye. </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Accounting Guidance Not Yet Adopted</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">There are no significant accounting pronouncements not yet adopted as of December&#160;31, 2023.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Significant Accounting Policies</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's accounting policies are described either in this Note or in the applicable Notes to the Consolidated Financial Statements as listed in the table of contents on page </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="#ibc59a92ac8bc42f794e728f24ce1b626_55" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">80</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Cash and Cash Equivalents</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash and cash equivalents are carried at cost that approximates fair value. Cash equivalents consist of short-term investments with maturities of three months or less from the time of purchase. The Company reclassifies cash overdraft positions to liabilities when the legal right of offset does not exist.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Inventories</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inventories consist of prescription drugs and medical supplies and are stated at the lower of first-in-first-out cost or net realizable value.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Other Assets (Current and Non-Current)</span><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other current assets consist primarily of prepaid expenses, income tax receivables, accrued investment income and the current portion of reinsurance recoverables. Other assets (non-current) consist primarily of the Company's net deferred tax asset associated with foreign tax attributes (see Note 23) and the carrying value of our equity-method investments in business-related joint ventures in China, the U.S. and other foreign jurisdictions. Earnings or losses from these equity-method investments in joint ventures are recorded in Fees and other revenues. See Note 15 for additional information on unconsolidated subsidiaries. Additionally, Other assets (non-current) includes operating lease right-of-use assets, various insurance-related assets and overfunded pension obligations (see Note 18). See Note 21 for the Company's accounting policy related to leases. </span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Redeemable Noncontrolling Interests</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Redeemable noncontrolling interests in our Consolidated Balance Sheets represents the noncontrolling shareholders' preferred and common stock interests of the Company's consolidated less than fully owned subsidiaries. Those shareholders may choose to require the Company to purchase their equity interest. For certain entities, we may also have the right to require those shareholders to sell their equity interest to us. As these redeemable noncontrolling interests provide for redemption features not solely within our control, we classify the redeemable noncontrolling interests outside of permanent equity. The noncontrolling interest was initially recorded at fair value. In subsequent reporting periods, the values are adjusted to reflect the earnings, losses and distributions attributable to the noncontrolling interest. When a shareholder's right to require the Company to purchase its equity interest is exercisable, the redeemable noncontrolling interest is recorded at estimated redemption value. When the estimated redemption value for a redeemable noncontrolling interest exceeds its initial carrying value, an adjustment to increase or decrease the redeemable noncontrolling interest is recorded with an offsetting adjustment to Retained earnings or Additional paid-in capital in the absence of Retained earnings. When an adjustment is made to the carrying value of the redeemable noncontrolling interest, the calculation of Shareholders' net income per share will be adjusted if the redemption value exceeds fair value.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">E.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Accrued Expenses and Other Current and Non-Current Liabilities</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued expenses and other liabilities (current) primarily includes financial and performance guarantee liabilities (see section G) and other liabilities arising from pharmacy contracts, management compensation, various insurance-related liabilities, including experience-rated refunds, reinsurance contracts and the risk adjustment and minimum medical loss ratio rebate accruals under The Patient Protection and Affordable Care Act (the "ACA"), and amounts due to financial institutions under the accounts receivable factoring facility (see Note 3). Other non-current liabilities primarily include uncertain tax positions (see Note 23), amounts held for self-funded clients to cover the administration and payment of claims that may emerge post contract termination, lease liabilities (see Note 21) and underfunded pension obligations (see Note 18).</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company accrues for legal and regulatory matters when a loss contingency is both probable and estimable. The estimated loss is generally recorded in Selling, general and administrative expenses and represents the Company's best estimate of the loss contingency. If the loss estimate is a range, the Company accrues the minimum amount in the range if no amount is better than any other estimated amount in the range. Legal costs to defend the Company's litigation and arbitration matters are expensed as incurred in cases that the Company cannot reasonably estimate the ultimate cost to defend. If the Company can reasonably estimate the cost to defend, a liability </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">for these costs is accrued when the claim is reported. Litigation and legal or regulatory matters that the Company has identified with a reasonable possibility of material loss are described in Note 24.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">F.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:9.4pt;text-decoration:underline">Translation of Foreign Currencies</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company generally conducts its international business through foreign operating entities that maintain assets and liabilities in local currencies that are their functional currencies. The Company uses exchange rates as of the balance sheet date to translate assets and liabilities into U.S. dollars. Translation gains or losses on functional currencies, net of applicable taxes, are recorded in Accumulated other comprehensive loss. The Company uses average monthly exchange rates during the year to translate revenues and expenses into U.S. dollars.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">G.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:7.73pt;text-decoration:underline">Pharmacy Revenues and Costs</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Pharmacy revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Pharmacy revenues are primarily derived from providing pharmacy benefit management services to clients and customers. Pharmacy revenues are recognized when control of the promised goods or services is transferred to clients and customers, in an amount that reflects the consideration the Company expects to receive for those goods or services.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company provides or makes available various services supporting benefit management and claims administration and is generally obligated to provide prescription drugs to clients' members using multiple distribution methods including retail networks, home delivery and specialty pharmacies. These goods and services are integrated into a single performance obligation to process claims, dispense prescription drugs and provide other services over the contract period (generally three years). This performance obligation is satisfied as the business stands ready to fulfill its obligation.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenues for dispensing prescription drugs through retail pharmacies are reported gross and consist of the prescription price (ingredient cost and dispensing fee) contracted with clients, including the customer copayment and any associated fees for services, because the Company acts as the principal in these arrangements. When a prescription is presented to a retail network pharmacy, the Company is solely responsible for customer eligibility, drug utilization review, drug-to-drug interaction review, any required clinical intervention, plan provision information, payment to the pharmacy and client billing. These revenues are recognized based on the full prescription price when the pharmacy claim is processed and approved for payment. The Company also provides benefit design and formulary consultation services to clients and negotiates separate contractual relationships with clients and network pharmacies. These factors indicate that the Company has control over these transactions until the prescription is processed. Revenues are billed, due and recognized at contract rates either on a periodic basis or as services are provided (such as based on volume of claims processed). This recognition pattern aligns with the benefits from services provided.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Home delivery and specialty pharmacy revenues are due and recognized as each prescription is shipped, net of reserves for discounts and contractual allowances estimated based on historical experience. Any differences between estimates and actual collections are reflected in Pharmacy revenues when payments are received. Historically, adjustments to original estimates and returns have not been material. The Company has elected the practical expedient to account for shipping and handling as a fulfillment activity.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may also provide certain financial and performance guarantees, including a minimum level of discounts a client may receive, generic utilization rates and various service levels. Clients may be entitled to receive compensation if we fail to meet the guarantees. Actual performance is compared to the contractual guarantee for each measure throughout the period and the Company defers revenue for any estimated payouts within Accrued expenses and other liabilities (current). These estimates are adjusted and paid at the end of the annual guarantee period. Historically, adjustments to original estimates have not been material. The liability for these financial and performance guarantees was $1.6 billion as of December&#160;31, 2023 and $1.3 billion as of December&#160;31, 2022.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company administers programs through which we may receive rebates and other vendor consideration from pharmaceutical manufacturers. The amounts of such rebates or other vendor consideration shared with pharmacy benefit management services clients vary based on the contractual arrangement with the client and in some cases the type of consideration received from the pharmaceutical manufacturer. Rebates and other vendor consideration payable to pharmacy benefit management services clients are recorded as a reduction of Pharmacy revenues. Estimated amounts payable to clients are based on contractual sharing arrangements between the Company and the client and these amounts are adjusted when amounts are collected from pharmaceutical manufacturers in accordance with the contractual arrangement between the Company and the client. Historically, these adjustments have not been material.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In retail, home delivery and specialty transactions, amounts may be collected from third-party payors. These are billed and collected in accordance with the Company's standard accounts receivable collection procedures. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other pharmacy service revenues are earned by distributing specialty pharmaceuticals and medical supplies to providers, clinics and hospitals. These revenues are billed, due and recognized at contracted rates as prescriptions and supplies are shipped and services are provided.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Pharmacy costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Pharmacy costs include the cost of prescriptions sold, network pharmacy claim costs and copayments. Also included are direct costs of dispensing prescriptions including supplies, shipping and handling and direct costs associated with clinical programs, such as drug utilization management and medication adherence counseling. Home delivery and specialty pharmacy costs are recognized when the drug is shipped and retail network costs are recognized when the drug is processed and approved for payment. Rebates and other vendor consideration received when providing pharmacy benefit management services are recorded as a reduction of pharmacy costs. Rebates are recognized as prescriptions are shipped or processed and approved for payment. Historically, the effect of adjustments resulting from the reconciliation of rebates recognized to the amounts billed and collected, net of contractual allowances, has not been material. The Company maintains reimbursement guarantees with certain retail network pharmacies. For each such guarantee, the Company records a pharmacy and other service costs payable or prepaid asset for applicable retail network claims based on our actual performance throughout the period against the contractual reimbursement rate. The Company's contracts with certain retail pharmacies give the Company the right to adjust reimbursement rates during the annual guarantee period.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Incremental costs of obtaining service and pharmacy contracts for short-term arrangements are expensed as incurred.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">H.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:7.73pt;text-decoration:underline">Premiums and Related Expenses</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Premiums for short-duration group health, accident and life insurance and managed care coverages are recognized as revenue on a pro rata basis over the contract period. Benefits and expenses are recognized when incurred and, for our Cigna Healthcare business, are presented net of pharmaceutical manufacturer rebates. For experience-rated contracts, premium revenue includes an adjustment for experience-rated refunds based on contract terms and calculated using the customer's experience (including estimates of incurred but not reported claims).</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Premiums received for the Company's Medicare Advantage plans, Medicare Part D plans and Individual and Family Plans from the Centers for Medicare and Medicaid Services ("CMS") and customers are recognized as revenue ratably over the contract period. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CMS provides risk-adjusted premium payments for Medicare Advantage plans and Medicare Part D plans based on our customer demographics and medical diagnoses, which may change from period to period based on the underlying health of our customers. The Company recognizes changes to risk-adjusted premiums as revenue when the amounts are determinable and collection is reasonably assured. Revenue adjustments are generally settled semi-annually with CMS. The final revenue adjustment is generally settled with CMS in the year following the contract year.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medicare Part D premiums include payments from CMS for risk-sharing adjustments that are estimated quarterly based on claim experience by comparing actual incurred prescription drug costs to the estimated costs submitted in the original contracts. These adjustments may result in more or less revenue from CMS. Final revenue adjustments generally occur in the year following the contract year. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The ACA prescribed a risk-adjustment program to mitigate the risk for participating health insurance companies selling individual coverage on the public exchanges. The risk-adjustment program reallocates funds from insurers with lower risk populations to insurers with higher risk populations based on the relative risk scores of participants. We estimate our receivable or payable based on the risk of our customers compared to the risk of other customers in the same state and market, considering data obtained from industry studies and the United States Department of Health and Human Services ("HHS"). Receivables or payables are recorded as adjustments to premium revenue based on our year-to-date experience when the amounts are reasonably estimable and collection is reasonably assured. Final revenue adjustments are determined by HHS in the year following the policy year.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Premium revenue may also include an adjustment to reflect the estimated effect of rebates due to customers under medical loss ratio provisions of the ACA. These rebate liabilities are settled in the subsequent year.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Premiums for long-duration insurance contracts, including individual life, accident and supplemental health insurance and annuity products, and excluding universal life and investment-related products, are recognized as revenue when due. Cigna Healthcare's long-duration premium revenues are associated with contracts that provide coverage greater than one year or are guaranteed to be renewed at the option of the policyholder beyond one year. Benefits and expenses are matched with premiums. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue for universal life products is recognized as follows:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Investment income on assets supporting universal life products is recognized in Net investment income as earned.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Charges for mortality, administration and policy surrender are recognized in Premiums as earned. Administrative fees are considered earned when services are provided.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Benefits and expenses for universal life products consist of benefit claims in excess of policyholder account balances and income earned by policyholders. Expenses are recognized when claims are incurred and income is credited to policyholders in accordance with contract provisions.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The unrecognized portion of premiums received is recorded as unearned premiums included in Insurance and contractholder liabilities (current and non-current) (see Note 10 to the Consolidated Financial Statements for further information).</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">I.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:11.61pt;text-decoration:underline">Fees and Related Expenses</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The majority of the Company's service fees are derived from administrative services only ("ASO") arrangements, fee-for-service clinical solutions, Wholesale Marketplace Drug Formulary Management services, health benefit management services and administration of services to specialty pharmacy manufacturers.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASO arrangements allow plan sponsors to self-fund claims and assume the risk of medical or other benefit costs. Most of the Company's ASO arrangements are for medical and specialty solutions, including pharmacy benefits. Generally, the Company's ASO arrangements are short-term. Contract modifications typically occur on renewal and are prospective in nature.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In return for fees from these clients, the Company provides access to our participating provider networks and other services supporting benefit management, including claims administration, behavioral health services, disease management, utilization management and cost containment programs. In general, the Company considers these services to be a combined performance obligation to provide cost effective administration of plan benefits over the contract period. Fees are billed, due and recognized monthly at contracted rates based on current membership or utilization. This recognition pattern aligns with the benefits from services provided to clients. These revenues are reported in Fees and other revenues in the Consolidated Statements of Income.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company may also provide performance guarantees that provide potential refunds to clients if certain service standards, clinical outcomes or financial metrics are not met. If these standards, outcomes and metrics are not met, the Company may be financially at risk up to a stated percentage of the contracted fee or a stated dollar amount. The Company defers revenue by recording a liability for estimated payouts associated with these guarantees within Accrued expenses and other liabilities. The amount of revenue deferred is estimated for each type of guarantee using either a most likely amount or expected value method depending on the nature of the guarantee and the information available to estimate refunds. Estimates are refined each reporting period as additional information on the Company's performance becomes available and upon final reconciliation and settlement following the guarantee period. Amounts accrued and paid for these performance guarantees during the reporting periods were not material.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expenses associated with administrative programs and services are recognized as incurred in Selling, general and administrative expenses.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company also earns revenue, as part of its integrated pharmacy benefits performance obligation, by offering fee-for-service clinical solutions to our clients, such as drug utilization management and medication adherence counseling. These clinical programs help clients to drive better health outcomes at a lower cost by identifying and addressing potentially unsafe or wasteful prescribing, dispensing and utilization of prescription drugs and communicating with, or supporting communications with physicians, pharmacies and patients. Fees are billed, due and recognized at contracted rates either on a periodic basis or as services are provided. This recognition pattern aligns with the benefits from services provided. These revenues are reported in Fees and other revenues in the Consolidated Statements of Income. Direct costs associated with these programs are recognized in Pharmacy and other service costs, and other related expenses are recorded as incurred in Selling, general and administrative expenses.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company earns fees from our Wholesale Marketplace Drug Formulary Management services. These services include either our drug formulary administrative service arrangements or our formulary processing arrangements. Drug formulary administrative services may include formulary consultation, administration of rebate contracts, rebate submission, collection from drug manufacturers and the distribution of rebates to clients. Services may also include facilitating audits of data submissions and reporting of rebates to clients. Clients agree to pay administrative fees that are billed, due and recognized at contracted rates as services are performed. These revenues are reported gross in Fees and other revenues and associated costs are reported in Pharmacy and other service costs in the Consolidated Statements of Income. For certain other clients in our formulary processing arrangements, the Company does not control the right to retain rebates before they are transferred to the client for services performed. Clients agree to allow the Company to retain a portion of each rebate collected in exchange for formulary processing services provided. These drug formulary service and administrative fee revenues are reported net in Fees and other revenues in the Consolidated Statements of Income. Revenue is recognized as rebates are processed.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company also earns fees by providing health benefit management solutions that drive cost reductions and improve quality outcomes. Clients are primarily sponsors of health benefit plans and fees may be stated as a per-member-per-month fee or as a per-claim fee. The Company considers the services to be a single performance obligation to stand ready to provide utilization management services over the contract period (generally three years). In certain arrangements, the Company assumes the financial obligation for third-party provider costs for medical services provided to the health plan's customers. Fees are recorded gross in Fees and other revenues in the Consolidated Statements of Income because the Company is acting as a principal in arranging for and controlling the services provided by third-party network providers. Contractual fees vary based on enrollment and provider costs and are billed, due </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and recognized monthly. Direct costs associated with these programs are recognized in Pharmacy and other service costs, and other related expenses are recorded in Selling, general and administrative expenses as incurred.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain health benefit management contracts require the Company to share the results of medical cost experience that differ from specified targets. This variable consideration is estimated at contract inception and adjusted through the contract period. The estimated profits and costs are recognized net in Fees and other revenues.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company also earns other service fees related to administrating services to specialty pharmacy manufacturers that are recorded in Fees and other revenues in the Consolidated Statements of Income. These revenues are billed, due and recognized at contracted rates as services are provided.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288973487920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">Accounts Receivable, Net</a></td>
<td class="text"><div><span id="i320b3e5344194d5b9823c6f2e7007e05_14"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3 &#8211; Accounts Receivable, Net</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We bill pharmaceutical manufacturers based on management's interpretation of contractual terms and estimate a contractual allowance based on the best information available at the time a claim is processed. Contractual allowances for certain rebates receivable from pharmaceutical manufacturers are determined by reviewing payment experience and specific known items that could be adjusted under contract terms. The Company's estimation process for contractual allowances for pharmaceutical manufacturer receivables generally results in an allowance for balances outstanding greater than 90 days. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contractual allowances for certain receivables from third-party payors are based on their contractual terms and are estimated based on the Company's best information available at the time revenue is recognized. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Discounts and claims adjustments issued to customers in the form of client credits and other non-credit adjustments are based on the current status of each customer's receivable balance, current economic and market conditions and a variety of other factors, including the length of time the receivables are past due, the financial health of customers and our past experience. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The allowance for expected credit losses for current accounts receivable is based primarily on past collections experience relative to the length of time receivables are past due; however, when available evidence reasonably supports an assumption that counterparty credit risk over the expected payment period will differ from current and historical payment collections, a forecasting adjustment is reflected in the allowance for expected credit losses.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Receivables and any associated allowance are written off only when all collection attempts have failed and such amounts are determined unrecoverable. We regularly review the adequacy of these allowances based on a variety of factors, including age of the outstanding receivable and collection history. When circumstances related to specific collection patterns change, estimates of the recoverability of receivables are adjusted.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's accounts receivable include amounts due from pharmaceutical manufacturers, clients, third-party payors and customers, and are presented net of allowances. These balances include:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt">Pharmaceutical manufacturers receivables - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">amounts due from pharmaceutical manufacturers. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt">Noninsurance customer receivables - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">amounts due from customers for noninsurance services, primarily pharmacy benefit management and ASO contracts.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt">Insurance customer receivables - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">amounts due from customers under insurance and managed care contracts, primarily premiums receivable and amounts due from CMS.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt">Other receivables - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">all other accounts receivable not included in the categories above.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following amounts were included within Accounts receivable, net:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical manufacturers receivables</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,169</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,108&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noninsurance customer receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,044</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Insurance customer receivables</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,359</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,963&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">272</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18,844</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net classified as assets of businesses held for sale</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,122)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17,722</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,218&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These receivables are reported net of our allowances of $3.7 billion as of December&#160;31, 2023 and $1.9 billion as of December&#160;31, 2022 as follows:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Included in our Pharmaceutical manufacturers receivables are contractual allowances for certain rebates receivable with pharmaceutical manufacturers of $3.1 billion as of December&#160;31, 2023 and $1.3 billion as of December&#160;31, 2022. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Included in our Noninsurance customer receivables are contractual allowances from third-party payors of $386 million as of December&#160;31, 2023 and $336 million as of December&#160;31, 2022 based upon the contractual payment terms. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The remaining allowances of $219 million as of December&#160;31, 2023 and $226 million as of December&#160;31, 2022 include discounts and claims adjustments issued to customers in the form of client credits, an allowance for current expected credit losses and other non-credit adjustments. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's allowance for current expected credit losses was $90 million as of December&#160;31, 2023 and $86 million as of December&#160;31, 2022.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounts Receivable Factoring Facility</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2023, the Company entered into an uncommitted factoring facility (the "Facility") under which certain accounts receivable may be sold on a non-recourse basis to a financial institution. The Facility's total capacity is $1.0 billion with an initial term of two years, followed by automatic one year renewal terms unless terminated by either party. The transactions under the Facility are accounted for as a sale and recorded as a reduction to accounts receivable in the Consolidated Balance Sheets because control of, and risk related to, the accounts receivable are transferred to the financial institution. Although the sale is made without recourse, we provide collection services related to the transferred assets. Amounts associated with this Facility are reflected within Net cash provided by operating activities in the Consolidated Statements of Cash Flows. Factoring fees paid under this Facility are reflected in Interest expense and other in the Consolidated Statements of Income. </span></div>For the year ended December&#160;31, 2023, we sold $2.1 billion of accounts receivable under the Facility and factoring fees paid were not material. As of December&#160;31, 2023, all sold accounts receivable have been collected from manufacturers, $515 million of which have not been remitted to the financial institution. Such amounts are recorded within Accrued expenses and other liabilities in the Consolidated Balance Sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//310-10/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288973482096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplier Finance Program<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramTextBlock', window );">Supplier Finance Program</a></td>
<td class="text">Note 4 &#8211; Supplier Finance Program<div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company facilitates a voluntary supplier finance program (the "Program") that provides suppliers the opportunity to sell their accounts receivable due from us (i.e., our payment obligations to the suppliers) to a financial institution, on a non-recourse basis, in order to be paid earlier than our payment terms require. The Cigna Group is not a party to the Program and agrees to commercial terms with its suppliers independently of their participation in the Program. Amounts due to suppliers that participate in the Program are generally paid within one month following the invoice date. A supplier's participation in the Program has no impact on the Company's payment terms and the Company has no economic interest in a supplier's decision to participate in the Program. The suppliers, at their sole discretion, determine which invoices, if any, to sell to the financial institution. No guarantees or pledged assets are provided by the Company or any of our subsidiaries under the Program. </span></div>As of December&#160;31, 2023 and December&#160;31, 2022, $1.5&#160;billion and $1.3&#160;billion, respectively, of the Company's outstanding payment obligations were confirmed as valid within the Program by the financial institution and are reflected in <span style="-sec-ix-hidden:f-550"><span style="-sec-ix-hidden:f-551">Accounts payable</span></span> in the Consolidated Balance Sheets. The amounts confirmed as valid for both periods are predominately associated with one supplier. As of December&#160;31, 2023, we have been informed by the financial institution that $298&#160;million of the Company's outstanding payment obligations were voluntarily elected by suppliers to be sold to the financial institution under the Program.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplierFinanceProgramTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplier finance program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479468/405-50-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479468/405-50-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479468/405-50-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477128/405-50-55-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplierFinanceProgramTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288973562192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mergers, Acquisitions and Divestitures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Mergers, Acquisitions and Divestitures</a></td>
<td class="text">Note 5 &#8211; Mergers, Acquisitions and Divestitures<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Investment in CarepathRx Health Systems Solutions</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2023, Evernorth Health, Inc. acquired a minority interest in CarepathRx Health Systems Solutions ("CHSS"), a provider of integrated hospital pharmacy solutions to support patients across their complete health care journey. This equity method investment is reported in Other assets and the Company's share of CHSS' net income or loss is reported in Fees and other revenues. The purchase price has been allocated to the acquired tangible and intangible assets, including customer relationships, trade names, internal-use software and goodwill. Amortization of the acquired intangibles is included in Fees and other revenues. The Company's share of CHSS' net loss and amortization of acquired intangibles were immaterial for the year ended December&#160;31, 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company guaranteed $125&#160;million of CHSS' credit facilities through July 2026. The fair value of the guarantee is reflected in other liabilities and is not material. The acquisition also includes separate put and call options to increase our ownership, which </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">become exercisable annually beginning as early as April 2025. The net fair value of the options, determined using a Monte Carlo simulation, are not material and are included in Other non-current liabilities and Other assets, respectively.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt;text-decoration:underline">Divestiture of International Businesses</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2022, the Company completed the sale of its life, accident and supplemental benefits businesses in six countries (Hong Kong, Indonesia, New Zealand, South Korea, Taiwan and Thailand) (the "Chubb transaction") for approximately $5.4 billion in cash and recognized a gain of $1.7&#160;billion pre-tax ($1.4&#160;billion after-tax), which included recognition of previously unrealized capital losses on investments sold and translation loss on foreign currencies. In 2023, we recorded immaterial adjustments to the sales price reflecting resolution of certain contractual matters. In December 2022, the Company also divested its ownership interest in a joint venture in T&#252;rkiye. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Integration and Transaction-related Costs</span>As part of our strategic plan, we incurred non-routine costs associated with the disposition and acquisition of certain businesses. In 2023, the Company incurred net costs related to the HCSC and Chubb transactions. In 2022 and 2021, the Company incurred costs related to the Chubb transaction, the sale of the Group Disability and Life business, the acquisition of MDLIVE and the terminated merger with Elevance Health, Inc. ("Elevance"), formerly known as Anthem, Inc. These costs were $45 million pre-tax ($35 million after-tax) for the year ended December&#160;31, 2023, compared with $135 million pre-tax ($103 million after-tax) for the year ended December&#160;31, 2022 and $169 million pre-tax ($71 million after-tax) for the year ended December&#160;31, 2021. These costs consisted primarily of certain projects to separate or integrate the Company's systems, products and services, fees for legal, advisory and other professional services and certain employment-related costs. After-tax costs for the year ended December 31, 2021 included a tax benefit from the resolution of a tax matter related to the sold Group Disability and Life business.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//805/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288973799168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets and Liabilities of Businesses Held for Sale<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Assets and Liabilities of Business Held for Sale</a></td>
<td class="text"><div style="margin-top:10pt"><span id="i4615696355794df3b07481211e495cbe_15"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 6 &#8211; Assets and Liabilities of Businesses Held for Sale</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The Company classifies assets and liabilities as held for sale ("disposal group") when management commits to a plan to sell the disposal group, the sale is probable within one year and the disposal group is available for immediate sale in its present condition. The Company considers various factors, particularly whether actions required to complete the plan indicate it is unlikely that significant changes to the plan will be made or the plan will be withdrawn. Assets held for sale are measured at the lower of carrying value or fair value less costs to sell. Any loss resulting from the measurement is recognized in the period the held-for-sale criteria are met. Conversely, gains are not recognized until the date of the sale. When the disposal group is classified as held for sale, depreciation and amortization for most long-lived assets ceases and the Company tests the assets for impairment. Deferred policy acquisition costs continue to be amortized.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2024, the Company entered into the HCSC transaction for a total purchase price of approximately $3.3 billion cash, subject to applicable regulatory approvals and other customary closing conditions. The transaction is expected to close in the first quarter of 2025. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the fourth quarter of 2023, the Company determined that the Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare Supplement and CareAllies businesses met the criteria to be classified as held for sale and aggregated and classified the assets and liabilities as held for sale in our Consolidated Balance Sheet as of December 31, 2023. The Company measured the assets and liabilities held for sale at estimated fair value less costs to sell and recognized an estimated loss of $1.5 billion pre-tax ($1.4 billion after-tax) that was included within <span style="-sec-ix-hidden:f-569">(Loss) gain on sale of businesses</span> in the Consolidated Statements of Income for the year ended December 31, 2023. The estimated loss on sale represents primarily asset write-downs and estimated costs to sell.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The assets and liabilities of businesses held for sale were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:88.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.456%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">467</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,438</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,122</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets, including Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,963</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets of businesses held for sale</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,990</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Insurance and contractholder liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,636</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">All other liabilities</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,059</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities of businesses held for sale</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,695</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Includes Goodwill of $396&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288973505840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text"><div style="margin-top:10pt"><span id="id4b9b7f855c9494fb643b90b2afe1341_14"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7 &#8211; Earnings Per Share</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company computes basic earnings per share using the weighted-average number of unrestricted common and deferred shares outstanding. Diluted earnings per share also includes the dilutive effect of outstanding employee stock options and restricted stock using the treasury stock method and the effect of strategic performance shares.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic and diluted earnings per share were computed as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="51" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Shares in thousands, dollars in millions, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of<br/>Dilution</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of<br/>Dilution</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of<br/>Dilution</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shareholders' net income</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,164</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,164</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,704&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,704&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,370&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,370&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">293,892</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">293,892</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">309,546&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">309,546&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">337,962&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">337,962&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,990</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,990</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total shares</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">293,892</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,990</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">296,882</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">309,546&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,519&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">313,065&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">337,962&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,004&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340,966&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Earnings per share</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17.57</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.18)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17.39</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.66&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.25)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.41&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.89&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.14)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.75&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amounts reflected above for the years ended December&#160;31, 2022 and 2021 have been restated to reflect the impact of adopting amended accounting guidance for long-duration insurance contracts (discussed in Note 2 to the Consolidated Financial Statements).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following outstanding employee stock options were not included in the computation of diluted earnings per share because their effect was anti-dilutive:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.261%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Anti-dilutive options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288973842368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt"><span id="ic993c64b84024ee5a62a006b05ea76db_438"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8 &#8211; Debt</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The outstanding amounts of debt (net of issuance costs, discounts or premiums) and finance leases were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term debt</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$17&#160;million, 8.300% Notes due January 2023</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$63&#160;million, 7.650% Notes due March 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$700 million, Floating Rate Notes due July 2023</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1,000 million, 3.000% Notes due July 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1,187 million, 3.750% Notes due July 2023</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,186&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$500 million, 0.613% Notes due March 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1,000&#160;million, 3.500% Notes due June 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">996</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, including finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">42</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total short-term debt</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,775</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,993&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$500 million, 0.613% Notes due March 2024</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1,000&#160;million, 3.500% Notes due June 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$900&#160;million, 3.250% Notes due April 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">882</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">872&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$2,200&#160;million, 4.125% Notes due November 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,197</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1,500&#160;million, 4.500% Notes due February 2026</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,503&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$800 million, 1.250% Notes due March 2026 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">798</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$700 million, 5.685% Notes due March 2026</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">698</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1,500&#160;million, 3.400% Notes due March 2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,450</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$259&#160;million, 7.875% Debentures due May 2027</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">259</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$600&#160;million, 3.050% Notes due October 2027 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">597</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$3,800&#160;million, 4.375% Notes due October 2028</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,787</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,785&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1,500&#160;million, 2.400% Notes due March 2030 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,493</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1,500 million, 2.375% Notes due March 2031 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,397</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,380&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$45&#160;million, 8.080% Step Down Notes due January 2033 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$800 million, 5.400% Notes due March 2033</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">794</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$190&#160;million, 6.150% Notes due November 2036</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">190</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$2,200&#160;million, 4.800% Notes due August 2038 </span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,193</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,192&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$750&#160;million, 3.200% Notes due March 2040</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">744</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$121&#160;million, 5.875% Notes due March 2041</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">119</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$448&#160;million, 6.125% Notes due November 2041</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">487</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$317&#160;million, 5.375% Notes due February 2042</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">315</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1,500&#160;million, 4.800% Notes due July 2046</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,467</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1,000&#160;million, 3.875% Notes due October 2047</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">989</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$3,000&#160;million, 4.900% Notes due December 2048</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,970</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1,250&#160;million, 3.400% Notes due March 2050</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,236&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1,500 million, 3.400% Notes due March 2051</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,479</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, including finance leases</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28,155</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,100&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Included in the February 2024 debt tender offers discussed below.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">The Company has entered into interest rate swap contracts hedging a portion of these fixed-rate debt instruments. See Note 12 to the Consolidated Financial Statements for further information about the Company's interest rate risk management and these derivative instruments.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Interest rate step down to 8.080% effective January 15, 2023.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Short-term and Credit Facilities Debt</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revolving Credit Agreements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Our revolving credit agreements provide us with the ability to borrow amounts for general corporate purposes, including providing liquidity support if necessary under our commercial paper program discussed below. As of December&#160;31, 2023, there were no outstanding balances under these revolving credit agreements.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2023, The Cigna Group entered into the following revolving credit agreements (the "Credit Agreements"):</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a $4.0 billion five-year revolving credit and letter of credit agreement that will mature in April 2028 with an option to extend the maturity date for additional one-year periods, subject to consent of the banks. The Company can borrow up to $4.0 billion under the credit agreement for general corporate purposes, with up to $500 million available for issuance of letters of credit. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a $1.0 billion 364-day revolving credit agreement that will mature in April 2024. The Company can borrow up to $1.0 billion under the credit agreement for general corporate purposes. This agreement includes the option to "term out" any revolving loans that are outstanding at maturity by converting them into a term loan maturing on the one-year anniversary of conversion.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Each of the Credit Agreements include an option to increase commitments in an aggregate amount of up to $1.5 billion across both facilities for a maximum total commitment of $6.5 billion. The Credit Agreements allow for borrowings at either a base rate or an adjusted term Secured Overnight Funding Rate ("SOFR") plus, in each case, an applicable margin based on the Company's senior unsecured credit ratings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Each of the two facilities is diversified among 21 large commercial banks, all of which had an A- equivalent or higher rating by at least one Nationally Recognized Statistical Rating Organization ("NRSRO") as of December&#160;31, 2023. Each facility also contains customary covenants and restrictions, including a financial covenant that the Company's leverage ratio, as defined in the Credit Agreements, may not exceed 60% subject to certain exceptions upon the consummation of an acquisition. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Credit Agreements replaced a prior $3.0 billion five-year revolving credit and letter of credit agreement maturing in April 2027; a $1.0 billion three-year revolving credit agreement maturing in April 2025; and a $1.0 billion 364-day revolving credit agreement maturing in April 2023. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Commercial Paper. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under our commercial paper program, we may issue short-term, unsecured commercial paper notes privately placed on a discounted basis through certain broker-dealers at any time not to exceed an aggregate amount of $5.0 billion. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. The weighted average interest rate of our commercial paper was 5.63% at December&#160;31, 2023.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Long-term debt</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Debt Issuance and Debt Tender Offers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> On February 5, 2024, we issued $4.5 billion of new senior notes. The proceeds from this debt were used to pay the consideration for the cash tender offers as described below. We intend to use the remaining net proceeds to fund the repayment of our senior notes maturing in March 2024 and for general corporate purposes, which may include repayment of indebtedness and repurchases of shares of our common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Concurrent with the debt issuance, we commenced tender offers to purchase for cash up to $2.25 billion in aggregate principal amount of outstanding notes, which included any and all of the $1.0 billion senior notes due June 2024. Following the early tender results, we increased the tender offers to up to $2.55 billion aggregate principal amount. On February 22, 2024, we purchased $1.8 billion principal amount of notes at early settlement of the tender offers. The tender offers will expire on March 5, 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 7, 2023, the Company issued $1.5&#160;billion of new senior notes. The proceeds of this issuance were used for general corporate purposes, and included repayment of outstanding debt securities. Interest on this debt is paid semi-annually.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.486%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Proceeds</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$700 million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 15, 2026</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.685%</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$698 million</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$800 million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 15, 2033</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.400%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$796 million</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Redeemable at any time discounted at the U.S. Treasury rate plus 20 basis points. Redeemable at par on or after March 15, 2024.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Redeemable at any time discounted at the U.S. Treasury rate plus 25 basis points. Redeemable at par on or after December 15, 2032.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Debt Maturities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Maturities of outstanding long-term debt as of December&#160;31, 2023 are as follows and exclude the impact of the 2024 debt issuance and debt tender offers described above:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:88.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.039%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Scheduled Maturities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,359</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maturities after 2028</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16,122</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Long-term debt maturity amounts include current maturities of long-term debt. Finance leases are excluded from this table. See Note 21 - Leases for finance lease maturity amounts.&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Interest Expense</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest expense on long-term and short-term debt was $1.4 billion in 2023 and $1.3 billion in both 2022 and 2021.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Debt Covenants</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company was in compliance with its debt covenants as of December&#160;31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288964603504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ScheduleOfCommonStockByClassScheduleOfPreferredStockByClassTextBlock', window );">Common and Preferred Stock</a></td>
<td class="text"><div><span id="i8317cb59d11e40858991b6bc9c38bb8b_16"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 9 &#8211; Common and Preferred Stock</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Cigna Group has a total of 25&#160;million shares of $1 par value preferred stock authorized for issuance. No shares of preferred stock were outstanding at December 31, 2023, 2022 or 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the share activity of The Cigna Group:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.042%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Shares in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common: Par value $0.01; 600,000 shares authorized</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding- January 1,</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">298,676</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">322,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">354,771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net issued for stock option exercises and other benefit plans</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,619</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,173&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,375&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchased common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(7,791)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27,445)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35,198)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding- December 31,</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">292,504</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298,676&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">322,948&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">107,390</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issued- December 31,</span></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">399,894</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">397,819&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">394,194&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Dividends</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During 2023, 2022 and 2021, The Cigna Group declared quarterly cash dividends of $1.23, $1.12 and $1.00 per share of the Company's common stock, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides details of the Company's dividend payments:</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Record Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payment Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount per Share</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Amount Paid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"> (in millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 8, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 23, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$1.23</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$368</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 7, 2023</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 22, 2023</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$1.23</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$362</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 6, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 21, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$1.23</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$362</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 6, 2023</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 21, 2023</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$1.23</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$358</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 9, 2022</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 24, 2022</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.12</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$357</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 8, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 23, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.12</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$352</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2022</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 22, 2022</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.12</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$341</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 6, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 21, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.12</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$334</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 10, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 25, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.00</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$345</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 8, 2021</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 23, 2021</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.00</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$342</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 8, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 23, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.00</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$330</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2021</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 22, 2021</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.00</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$324</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February&#160;2, 2024, the Board of Directors declared the first quarter cash dividend of $1.40 per share of The Cigna Group common stock to be paid on March&#160;21, 2024 to shareholders of record on March&#160;6, 2024. The Company currently intends to pay regular quarterly dividends, with future declarations subject to approval by its Board of Directors and the Board's determination that the declaration of dividends remains in the best interests of The Cigna Group and its shareholders. The decision of whether to pay future dividends and the amount of any such dividends will be based on the Company's financial position, results of operations, cash flows, capital requirements, the requirements of applicable law and any other factors the Board may deem relevant.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accelerated Share Repurchase Agreements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2024, as part of our existing share repurchase program, we entered into separate accelerated share repurchase agreements ("2024 ASR agreements") with Deutsche Bank AG and Bank of America, N.A. (collectively, the "2024 Counterparties") to repurchase $3.2 billion of common stock in aggregate. We remitted $3.2 billion to the 2024 Counterparties and received an initial delivery of approximately 7.6&#160;million shares of our common stock on February 15, 2024 representing $2.6 billion of the total remitted. The final number of shares to be received under the ASR agreements will be determined based on the daily volume-weighted average share price of our common stock over the term of the agreements, less a discount and subject to adjustments pursuant to the terms and conditions of the ASR agreements. We expect final settlement under the ASR agreements to occur in the second quarter of 2024. At final settlement, we may be entitled to receive additional shares of our common stock from the Counterparties or we may be required to make a payment. If we are obligated to make a payment, we may elect to satisfy such obligation in cash or shares of our common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2022, as part of our existing share repurchase program, we entered into separate accelerated share repurchase agreements ("2022 ASR agreements") with Mizuho Markets Americas LLC and Morgan Stanley &amp; Co. LLC (collectively, the "2022 Counterparties") to repurchase $3.5 billion of common stock in aggregate. In July 2022, we remitted $3.5 billion to the 2022 Counterparties and received an initial delivery of 10.4&#160;million shares of our common stock representing $2.8 billion of the total remitted. Upon final settlement of the 2022 ASR agreements in November 2022, we received an additional 1.9 million shares of our common stock for no additional consideration as the value of this stock was held back by the 2022 Counterparties pending final settlement of the agreements. The total number of shares of our common stock repurchased under the 2022 ASR agreements was 12.3&#160;million based on an average daily volume-weighted average share price of our common stock over the term of the agreements, less a discount, of $285.10 per share.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ScheduleOfCommonStockByClassScheduleOfPreferredStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element may be used to capture the complete disclosure pertaining to an entity's common stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation. B Preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ScheduleOfCommonStockByClassScheduleOfPreferredStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288973562192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insurance and Contractholder Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceLossReservesAbstract', window );"><strong>Insurance Loss Reserves [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock', window );">Insurance and Contractholder Liabilities</a></td>
<td class="text">Insurance and Contractholder Liabilities<div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt;text-decoration:underline">Account Balances &#8211; Insurance and Contractholder Liabilities</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's insurance and contractholder liabilities were comprised of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unpaid claims and claim expenses</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cigna Healthcare</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,017</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">75</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,092</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Operations</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">99</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">154</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">253</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Future policy benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cigna Healthcare</span></div></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">97</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">518</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">615</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">163</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,375</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,538</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractholder deposit funds</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cigna Healthcare</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">133</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">145</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Operations</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">362</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,178</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,540</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,358&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,709&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market risk benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">966</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,003</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unearned premiums</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">846</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">868</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,633</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11,421</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18,054</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Insurance and contractholder liabilities classified as liabilities of businesses held for sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,119)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(517)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,636)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total insurance and contractholder liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,514</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,904</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16,418</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,409&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,976&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,385&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Amounts classified as liabilities of businesses held for sale include $823&#160;million of Unpaid claims, $429&#160;million of Future policy benefits, $261&#160;million of Unearned premiums and $123&#160;million of Contractholder deposit funds as of December&#160;31, 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Insurance and contractholder liabilities expected to be paid within one year are classified as current. The Company adopted amended accounting guidance for long-duration insurance contracts on January 1, 2023, discussed further in Note 2 to the Consolidated Financial Statements, which resulted in restatement of prior period amounts. Additionally, see below updated accounting policies and incremental disclosures associated with future policy benefits (Note 10C), contractholder deposit funds (Note 10D), and market risk benefits (Note 10E).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy - Unearned Premium. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The unrecognized portion of premiums received is recorded as unearned premiums included in Insurance and contractholder liabilities (current and non-current). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company evaluates certain insurance contracts subject to premium deficiency testing and recognizes a premium deficiency loss and corresponding reserve when expected claims costs, claims adjustment expenses, maintenance costs, and unamortized acquisition costs exceed unearned premium. Anticipated investment income is considered in the calculation of premium deficiency. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt;text-decoration:underline">Unpaid Claims and Claim Expenses &#8211; Cigna Healthcare</span><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This liability reflects estimates of the ultimate cost of claims that have been incurred but not reported, expected development on reported claims, claims that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily comprised of accruals for incentives and other amounts payable to health care professionals and facilities. </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company compares key assumptions used to establish the medical costs payable to actual experience for each reporting period. The unpaid claims liability is adjusted through current period Shareholders' net income when actual experience differs from these assumptions. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trend. </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The liability is primarily calculated using "completion factors" developed by comparing the claim incurral date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1) electronic (auto-adjudication) versus manual </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">claim processing; 2) frequency and timeliness of provider claims submissions; 3) number of customers and 4) the mix of products. The Company uses historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period. </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company relies more heavily on medical cost trend analysis that reflects expected claim payment patterns and other relevant operational considerations for more recent months. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of health benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and deductibles, changes in provider practices and changes in consumer demographics and consumption behavior.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The total of incurred but not reported liabilities plus expected development on reported claims and reported claims in process was $4.8 billion at December&#160;31, 2023 and $3.9 billion at December&#160;31, 2022. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Activity, net of intercompany transactions, in the unpaid claims liability for the Cigna Healthcare segment was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.042%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,176</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,261&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,695&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Reinsurance and other amounts recoverable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">221</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance, net</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,955</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,458&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incurred costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35,953</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,342&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,755&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(279)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(259)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total incurred</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35,674</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,083&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,536&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Paid costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">31,322</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,583&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,929&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,451</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">34,773</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,128&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,994&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,856</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,955&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Add: Reinsurance and other amounts recoverable</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">236</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,092</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,176&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,261&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Includes $823&#160;million classified as liabilities of businesses held for sale as of December 31, 2023.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reinsurance and other amounts recoverable reflect amounts due from reinsurers and policyholders to cover incurred but not reported and pending claims of certain business for which the Company administers the plan benefits without any right of offset. See Note 11 to the Consolidated Financial Statements for additional information on reinsurance.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Variances in incurred costs related to prior years' unpaid claims and claim expenses that resulted from the differences between actual experience and the Company's key assumptions were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.889%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="24" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="12" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual completion factors</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical cost trend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">209</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total favorable variance</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">279</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Percentage of current year incurred costs as reported for the year ended December&#160;31, 2022.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Percentage of current year incurred costs as reported for the year ended December&#160;31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Favorable prior year development in both years reflects lower than expected utilization of medical services as compared to our assumptions.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table depicts the incurred and paid claims development and unpaid claims liability as of December&#160;31, 2023 (net of reinsurance) reported in the Cigna Healthcare segment. The information about incurred and paid claims development for the year ended December&#160;31, 2022 is presented as supplementary information and is unaudited.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incurred Costs</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incurral Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022<br/>(Unaudited)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unpaid Claims &amp; Claim Expenses</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,309&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30,050</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">209</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">34,878</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,498</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative incurred costs for the periods presented</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">64,928</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Costs Paid</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incurral Year</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022<br/>(Unaudited)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,687&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29,841</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30,380</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative paid costs for the periods presented</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">60,221</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding liabilities for the periods presented, net of reinsurance</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,707</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-duration liabilities not included in development table above</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">149</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unpaid claims and claims expenses - Cigna Healthcare</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,856</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reinsurance and other amounts recoverable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">236</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unpaid claims and claim expenses - Cigna Healthcare</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,092</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Incurred claims do not typically remain outstanding for multiple years; more than 95% of health claims incurred in a year are paid by the end of the following year.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There is no single or common claim frequency metric used in the health care industry. The Company believes a relevant metric for its health insurance business is the number of customers for whom an insured medical claim was paid. Customers for whom no insured medical claim was paid are excluded from the calculation. Claims that did not result in a liability are not included in the frequency metric. The claim frequency for 2023 and 2022 was approximately 5.5 million and 5.0&#160;million, respectively.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Future Policy Benefits</span><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting Policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Future policy benefits represent the present value of estimated future obligations, estimated using actuarial methods, for long-duration insurance policies and annuity products currently in force, consisting primarily of reserves for annuity contracts, life insurance benefits, and certain supplemental health products that are guaranteed renewable beyond one year.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contracts are grouped at a level no higher than issue year, based on the original contract issue date, and at lower levels of disaggregation within each issue year for certain businesses to reflect factors including product type, plan type and currency. Management estimates these obligations based on assumptions for premiums, interest rates, mortality or morbidity, future claim adjudication expenses and surrenders. Mortality, morbidity and surrender assumptions are based on the Company's own experience and published actuarial tables, and are updated at least annually, to the extent changes in circumstances require. Interest rate assumptions are based on</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">market-level yields for low credit risk fixed income instruments ("upper-medium grade fixed income instrument"). For interest accretion purposes, interest rates are fixed at the year of the cohort's inception, however for purposes of liability measurement, are updated to the current rate quarterly, with all changes in the interest rate from inception to current period reported through Accumulated other comprehensive loss. For contracts issued domestically, we use observable inputs from a published spot rate curve for terms up to 30 years and extrapolate for longer terms using a constant forward rate approach. For contracts issued by foreign operating entities with functional currencies other than the U.S. dollar, we use observable inputs to approximate a risk free rate and add a credit spread adjustment to align with a low-credit risk fixed income instrument. For terms beyond the last observable risk free rates, which vary by international market, we extrapolate to the ultimate forward rate assuming a constant credit spread.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the annuity business, the premium paying period is shorter than the benefit coverage period, and a deferred profit liability is reported in future policy benefits representing gross premium received in excess of net premiums. Deferred profit liability is amortized based on expected future benefit payments.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, approximately 34% of the liability for future policy benefits, excluding amounts held for sale, was supported by assets in trust for the benefit of the ceding company under reinsurance agreements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cigna Healthcare</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The weighted average interest rates applied and duration for future policy benefits in the Cigna Healthcare segment, consisting primarily of supplemental health products including individual Medicare supplement, limited benefit health products and individual private medical insurance, were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest accretion rate </span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.54</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.58&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current discount rate </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4.92</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average duration </span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7.9 years</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.7 years</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The net liability for future policy benefits for the segment's supplemental health products represents the present value of benefits expected to be paid to policyholders, net of the present value of expected net premiums, which is the portion of expected future gross premium expected to be collected from policyholders that is required to provide for all expected future benefits and expenses. The present values of expected net premiums and expected future policy benefits for the Cigna Healthcare segment are as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.262%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Present value of expected net premiums</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,557</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reversal of effect of beginning of period discount rate assumptions</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,537</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(367)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of assumption changes and actual variances from expected experience </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">314</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuances and lapses </span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,255</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,067&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net premiums collected</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,370)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,280)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest and other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">94</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance at original discount rate</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,387</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,094&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of end of period discount rate assumptions</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,154)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,537)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (3)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,233</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,557&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Present value of expected policy benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,945</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,794&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reversal of effect of discount rate assumptions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,611</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(379)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of assumption changes and actual variances from expected experience </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">112</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,148&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuances and lapses </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,309</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit payments</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,374)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,401)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest and other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance at original discount rate</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,853</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,556&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of discount rate assumptions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,611)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,633</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,945&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability for future policy benefits </span></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">388&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">215</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total liability for future policy benefits </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)(7)</span></div></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">615</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes the effect of actual variances from expectations, which (decreased)/increased the total liability for future policy benefits by $(12) million and $46 million, respectively, for the years ended December&#160;31, 2023 and December&#160;31, 2022.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes the foreign exchange rate impact of translating from transactional and functional currency to United States dollar and the impact of flooring the liability at zero. The flooring impact is calculated at the cohort level after discounting the reserves at the current discount rate.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">As of December&#160;31, 2023 and December&#160;31, 2022 undiscounted expected future gross premiums were $18.7 billion and $17.5 billion, respectively. As of December&#160;31, 2023 and December&#160;31, 2022 discounted expected future gross premiums were $13.5 billion and $12.2 billion, respectively.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">As of December&#160;31, 2023 and December&#160;31, 2022, undiscounted expected future policy benefits were $13.3 billion and $12.7 billion, respectively.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">The liability for future policyholder benefits includes immaterial businesses shown as reconciling items above, most of which are in run-off. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">$72 million and $155 million reported in Reinsurance recoverables in the Consolidated Balance Sheets as of December&#160;31, 2023 and December&#160;31, 2022, respectively, relate to the liability for future policy benefits. Additionally, $79 million of reinsurance recoverables are reported in assets of businesses held for sale in the Consolidated Balance Sheets as of December&#160;31, 2023.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes $429 million of future policy benefits classified as liabilities of businesses held for sale in the Consolidated Balance Sheets as of December&#160;31, 2023.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other Operations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The weighted average interest rates applied and duration for future policy benefits in Other Operations, consisting of annuity and life insurance products, were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest accretion rate </span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5.64</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.64&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current discount rate </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4.87</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average duration </span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11.4 years</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5 years</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Obligations for annuities represent discounted periodic benefits to be paid to an individual or groups of individuals over their remaining lives. Other Operations</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">'</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> traditional insurance contracts, which are in run-off, have no premium remaining to be collected; </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">therefore, future policy benefit reserves represent the present value of expected future policy benefits, discounted using the current discount rate, and the remaining amortizable deferred profit liability.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Future policy benefits for Other Operations includes deferred profit liability of $384 million and $390&#160;million as of December&#160;31, 2023 and December&#160;31, 2022, respectively. Future policy benefits excluding deferred profit liability were $3.2&#160;billion as of both December&#160;31, 2023 and December&#160;31, 2022, and $4.3&#160;billion as of December&#160;31, 2021. These balances exclude amounts classified as liabilities of businesses held for sale of $3.8&#160;billion as of December&#160;31, 2021. The change in future policy benefits reserves year-to-date was primarily driven by changes in the current discount rate. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Undiscounted expected future policy benefits were $4.5&#160;billion as of December&#160;31, 2023 and $4.6&#160;billion as of December&#160;31, 2022. As of December&#160;31, 2023 and December&#160;31, 2022, $1.0&#160;billion and $1.1&#160;billion, respectively, of the future policy benefit reserve was recoverable through treaties with external reinsurers.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt;text-decoration:underline">Contractholder Deposit Funds</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting Policy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Liabilities for contractholder deposit funds primarily include deposits received from customers for investment-related and universal life products as well as investment earnings on their fund balances in Other Operations. These liabilities are adjusted to reflect administrative charges and, for universal life fund balances, mortality charges. Interest credited on these funds is accrued ratably over the contract period. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contractholder deposit fund liabilities within Other Operations were $6.5 billion, $6.7 billion and $6.9 billion as of December&#160;31, 2023, December&#160;31, 2022 and December&#160;31, 2021, respectively. Approximately 39% of the balance is reinsured externally as of both December&#160;31, 2023 and December&#160;31, 2022. Activity in these liabilities is presented net of reinsurance in the Consolidated Statements of Cash Flows. The net year-to-date decrease in contractholder deposit fund liabilities generally relates to withdrawals and benefit payments from contractholder deposit funds, partially offset by deposits and interest credited to contractholder deposit funds.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, the weighted average crediting rate, net amount at risk and cash surrender value for contractholder deposit fund liabilities not effectively exited through reinsurance were 3.31%, $3.0 billion and $2.8 billion, respectively. The comparative amounts as of December&#160;31, 2022 were 3.08%, $3.0 billion and $2.4 billion, respectively. More than 99% of the $4.0 billion liability as of December&#160;31, 2023 and the $4.1 billion liability as of December&#160;31, 2022 not reinsured externally is for contracts with guaranteed interest rates of 3% - 4%, and approximately $1.2 billion represented contracts with policies at the guarantee. At both of these same period ends, $1.2 billion was 50-150 basis points ("bps") above the guarantee and the remaining $1.6 billion as of December&#160;31, 2023 and $1.7 billion as of December&#160;31, 2022 represented contracts above the guarantee that pay the policyholder based on the greater of a guaranteed minimum cash value or the actual cash value. More than 90% of these contracts have actual cash values of at least 110% of the guaranteed cash value.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt;text-decoration:underline">Market Risk Benefits</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Liabilities for market risk benefits consist of variable annuity reinsurance contracts (formerly referred to as GMDB and GMIB contracts) in Other Operations. These liabilities arise under annuities and riders to annuities written by ceding companies that guarantee the benefit received at death and, for a subset of policies, also provide contractholders the option, within 30 days of a policy anniversary after the appropriate waiting period, to elect minimum income payments. The Company's capital market risk exposure on variable annuity reinsurance contracts arises when the reinsured guaranteed minimum benefit exceeds the contractholder's account value in the related underlying mutual funds at the time the insurance benefit is payable under the respective contract. The Company receives and pays premium periodically based on the terms of the reinsurance agreements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting Policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Variable annuity reinsurance liabilities are measured as MRBs at fair value, net of nonperformance risk, with fluctuations in value gross of reinsurer nonperformance risk reported in benefit expenses, while fluctuations in the Company's own nonperformance risk (own credit risk) are reported in Accumulated other comprehensive loss. Nonperformance risk reflects risk that a party might default and therefore not fulfill its obligations (i.e. nonpayment risk). The nonperformance risk adjustment reflects a market participant's view of nonpayment risk by adding an additional spread to the discount rate in the calculation of both (a) the variable annuity reinsurance liabilities to be paid by the Company and (b) the variable annuity reinsurance assets to be paid by the reinsurers, after considering collateral. The Company classifies variable annuity assets and liabilities in Level 3 of the fair value hierarchy described in Note 13 to the Consolidated Financial Statements because assumptions related to future annuitant behavior are largely unobservable. As discussed further in Note 11 to the Consolidated Financial Statements, due to the reinsurance agreements covering these liabilities, the liabilities do not generally impact net income except for the change in nonperformance risk on the reinsurance recoverable, which is reported in benefit expenses and does not offset the nonperformance risk valuation on the liability. Variable annuity liabilities are established using capital market assumptions and assumptions related to future annuitant behavior (including mortality, lapse and annuity election rates). </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Market risk benefits activity was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.444%"><tr><td style="width:1.0%"></td><td style="width:74.877%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Balance, beginning of year</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">1,268</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">1,824&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Balance, beginning of year, before the effect of nonperformance risk (own credit risk)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">1,379</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">1,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Changes due to expected run-off</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">(19)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(54)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Changes due to capital markets versus expected</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">(254)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(567)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Changes due to policyholder behavior versus expected</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">(5)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(14)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Assumption changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Balance, end of period, before the effect of changes in nonperformance risk (own credit risk)</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">1,085</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">1,379&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Nonperformance risk (own credit risk), end of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Balance, end of period</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">1,003</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">1,268&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Reinsured market risk benefit, end of period</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">1,081</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">1,374&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the account value, net amount at risk, average attained age of contractholders (weighted by exposure) and the number of contractholders for guarantees assumed by the Company. The net amount at risk is the amount that the Company would have to pay to contractholders if all deaths or annuitizations occurred as of the earliest possible date in accordance with the insurance contract. As of December&#160;31, 2023, the account value increased primarily due to favorable equity market performance, which resulted in an decrease to the net amount at risk. The Company should be reimbursed in full for these payments unless the Berkshire reinsurance limit is exceeded.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions, excludes impact of reinsurance ceded)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Account value</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,736</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,436&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net amount at risk</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,609</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Average attained age of contractholders (weighted by exposure)</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">77.3 years</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74.7 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of contractholders (estimated)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">140,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceLossReservesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceLossReservesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//944-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288968481872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reinsurance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceDisclosuresAbstract', window );"><strong>Reinsurance Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceTextBlock', window );">Reinsurance</a></td>
<td class="text"><div style="margin-bottom:10pt"><span id="i06222830be1a4df2a23a97244932bcc5_626"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 11 &#8211; Reinsurance</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's insurance subsidiaries enter into agreements with other insurance companies to limit losses from large exposures and to permit recovery of a portion of incurred losses. Reinsurance is ceded primarily in acquisition and disposition transactions when the underwriting company is not being acquired. Reinsurance does not relieve the originating insurer of liability. Therefore, reinsured liabilities must continue to be reported along with the related reinsurance recoverables. The Company regularly evaluates the financial condition of its reinsurers and monitors concentrations of its credit risk.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt;text-decoration:underline">Reinsurance Recoverables</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reinsurance recoverables represent amounts due from reinsurers for both paid and unpaid claims of the Company's insurance businesses. The Company bears the risk of loss if its reinsurers and retrocessionaires do not meet or are unable to meet their reinsurance obligations to the Company. Most reinsurance recoverables are classified as non-current assets. The current portion of reinsurance recoverables is reported in Other current assets and consists primarily of recoverables on paid claims expected to be settled within one year. Reinsurance recoverables are presented net of allowances, consisting primarily of an allowance for expected credit losses which is recognized on reinsurance recoverable balances each period and adjusted through Medical costs and other benefit expenses. Estimates of the allowance for expected credit losses are based on internal and external data used to develop expected loss rates over the anticipated duration of the recoverable asset that vary by external credit rating and collateral level. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The majority of the Company's reinsurance recoverables resulted from acquisition and disposition transactions in which the underwriting company was not acquired. The Company reviews its reinsurance arrangements and establishes reserves against the recoverables.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's reinsurance recoverables as of December&#160;31, 2023 are presented at amount due by range of external credit rating and collateral level in the following table, with reinsurance recoverables that are market risk benefits separately presented at fair value:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.237%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Fair value of collateral contractually required to meet or exceed carrying value of recoverable</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Collateral provisions exist that may mitigate risk of credit loss </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">No collateral</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ongoing Operations</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">A- equivalent and higher current ratings </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">BBB- to BBB+ equivalent current credit ratings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">59</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">59</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Not rated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">151</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">182</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">338</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total recoverables related to ongoing operations</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">151</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">331</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">487</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition, disposition or run-off activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BBB+ equivalent and higher current ratings </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lincoln National Life and Lincoln Life &amp; Annuity of New York</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,656</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,656</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Empower Annuity Insurance Company</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">130</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">130</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prudential Insurance Company of America</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">341</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">341</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Life Insurance Company of North America</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">356</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">356</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">166</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Not rated</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total recoverables related to acquisition, disposition or run-off activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">507</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,038</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">148</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,693</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reinsurance recoverables before market risk benefits</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">658</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,043</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">479</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,180</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allowance for uncollectible reinsurance</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(35)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market risk benefits </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,081</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reinsurance recoverables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,226</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Certified by a NRSRO.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes collateral provisions requiring the reinsurer to fully collateralize its obligation if its external credit rating is downgraded to a specified level.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Prior to the adoption of LDTI, "acquisition, disposition or run-off activities" in the table above included Berkshire and certain Other recoverables that are related to the Company's variable annuity reinsurance products discussed in section B below. These amounts are now reported at fair market value as MRBs, as further discussed in Note 10 to the Consolidated Financial Statements. At December&#160;31, 2022, we reported $711 million of recoverables related to the GMDB variable annuity reinsurance product. The restated December&#160;31, 2022 variable annuity reinsurance recoverable balance is $1.4 billion, which also includes the GMIB variable annuity reinsurance product that was classified in Other assets prior to the adoption of LDTI.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes $183 million of current reinsurance recoverables that are reported in Other current assets and $208 million of reinsurance recoverables classified as assets of businesses held for sale.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Collateral levels are defined internally based on the fair value of the collateral relative to the carrying amount of the reinsurance recoverable, the frequency at which collateral is required to be replenished and the potential for volatility in the collateral's fair value.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Effective Exit of Variable Annuity Reinsurance Business</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company entered into an agreement with Berkshire to effectively exit the variable annuity reinsurance business via a reinsurance transaction in 2013. Variable annuity contracts are accounted for as assumed and ceded reinsurance and categorized as market risk benefits as discussed in Note 10 to the Consolidated Financial Statements. Berkshire reinsured 100% of the Company's future cash flows in this business, net of other reinsurance arrangements existing at that time. The reinsurance agreement is subject to an overall limit with approximately $3.1 billion remaining at December&#160;31, 2023. As a result of the reinsurance transaction, amounts payable are offset by a corresponding reinsurance recoverable, provided the increased recoverable remains within the overall Berkshire limit.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reinsurer </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Collateral and Other Terms</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">at December&#160;31, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Berkshire</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">873</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,116&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95% were secured by assets in a trust.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sun Life Assurance Company of Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">92</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liberty Re (Bermuda) Ltd.</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">104</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100% were secured by assets in a trust.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SCOR SE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80% were secured by a letter of credit.</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market risk benefits </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,398&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">All reinsurers are rated A- equivalent and higher by an NRSRO.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes IBNR and outstanding claims of $19 million. These amounts are excluded from market risk benefits at December&#160;31, 2023 in Note 10 and Note 11A to the Consolidated Financial Statements. At December&#160;31, 2022, IBNR and outstanding claims of $27 million offset by premium due of $3 million were excluded from the market risk benefits as restated due to the adoption of LDTI.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The impact of nonperformance risk (i.e., the risk that a counterparty might default) on the variable annuity reinsurance asset was immaterial for the years ended 2023, 2022 and 2021.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Effects of Reinsurance</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents direct, assumed and ceded earned premiums for both short-duration and long-duration insurance contracts. It also presents reinsurance recoveries that have been netted against Medical costs and other benefit expenses in the Company's Consolidated Statements of Income.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.042%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Premiums</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-duration contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Direct</span></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">42,266</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,747&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,513&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">303</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ceded</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(277)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(265)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total short-duration contract premiums</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">42,292</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,898&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,700&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-duration contracts</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Direct</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,084</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assumed</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ceded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(211)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(286)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(398)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-duration contract premiums</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,945</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,018&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,454&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total premiums</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44,237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,916&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,154&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total reinsurance recoveries</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">456</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Total short-duration contracts written premiums were $41.1 billion, $35.0 billion and $35.6 billion for 2023, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure pertaining to the existence, magnitude and information about insurance that has been ceded to or assumed from another insurance company, including the methodologies and assumptions used in determining recorded amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479838/944-20-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479838/944-20-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479629/944-605-55-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479629/944-605-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288969950032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text"><div><span id="iba773ce036514c4ba5209af3290a59b4_16"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12 &#8211; Investments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Cigna Group's investment portfolio consists of a broad range of investments including debt securities, equity securities, commercial mortgage loans, policy loans, other long-term investments, short-term investments and derivative financial instruments. The sections below provide more detail regarding our investment balances and realized investment gains and losses. See Note 13 for information about the valuation of the Company's investment portfolio.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Debt securities, commercial mortgage loans, derivative financial instruments and short-term investments with contractual maturities during the next twelve months are classified on the balance sheet as current investments, unless they are held as statutory deposits or restricted for other purposes and then they are classified in Long-term investments. Equity securities may include funds that are used in our cash management strategy and are classified as current investments. All other investments are classified as Long-term investments.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the Company's investments by category and current or long-term classification:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.212%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">590</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,265</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,855</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,218&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,872&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,331</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,362</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial mortgage loans</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">182</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,351</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,533</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,547&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Policy loans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,211</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,211</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term investments</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,181</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,181</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,728&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,728&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,009</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19,339</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20,348</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments classified as assets of businesses held for sale </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,354)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,438)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments per Consolidated Balance Sheets</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">925</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17,985</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18,910</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">905&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,288&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,193&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Investments related to the HCSC transaction that were held for sale as of December&#160;31, 2023. These investments were primarily comprised of debt securities and commercial mortgage loans, and to a lesser extent, other long term investments. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt;text-decoration:underline">Investment Portfolio</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Securities</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Debt securities (including bonds, mortgage and other asset-backed securities and preferred stocks redeemable by the investor) are classified as available for sale and are carried at fair value with changes in fair value recorded either in Accumulated other comprehensive loss within Shareholders' equity or in credit loss expense based on fluctuations in the allowance for credit losses, as further discussed below. Prior to the adoption of LDTI on January 1, 2023, net unrealized appreciation on debt securities supporting the Company's run-off settlement annuity business was reported in Non-current insurance and contractholder liabilities rather than Accumulated other comprehensive loss. See Note 16 for impact to Accumulated other comprehensive loss. When the Company intends to sell or determines that it is more likely than not to be required to sell an impaired debt security, the excess of amortized cost over fair value is directly written down with a charge to Net realized investment (losses) gains. Certain asset-backed securities are considered variable interest entities. See Note 14 for additional information. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company reviews declines in fair value from a debt security's amortized cost basis to determine whether a credit loss exists, and when appropriate, recognizes a credit loss allowance with a corresponding charge to credit loss expense, presented in Net realized investment (losses) gains in the Company's Consolidated Statements of Income. The allowance for credit loss represents the excess of amortized cost over the greater of its fair value or the net present value of the debt security's projected future cash flows (based on qualitative and quantitative factors, including the probability of default and the estimated timing and amount of recovery). Each period, the allowance for credit loss is adjusted as needed through credit loss expense.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company does not measure an allowance for credit losses for accrued interest receivables. When interest payments are delinquent based on contractual terms or when certain terms (interest rate or maturity date) of the investment have been restructured, accrued interest, reported in Other current assets, is written off through a charge to Net investment income and interest income is recognized on a cash basis.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The amortized cost and fair value by contractual maturity periods for debt securities were as follows as of December&#160;31, 2023:</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">622</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">605</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,914</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,761</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,194</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,005</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,251</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,119</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset-backed securities</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">398</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">365</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,379</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,855</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Actual maturities of these securities could differ from their contractual maturities used in the table above because issuers may have the right to call or prepay obligations, with or without penalties.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gross unrealized appreciation (depreciation) on debt securities by type of issuer is shown below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.046%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for Credit Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Appreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal government and agency</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">251</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">267</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State and local government</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">355</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">352</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,338</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(33)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">158</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(630)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,833</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset-backed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">398</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">365</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,379</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(33)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">195</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(686)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,855</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal government and agency</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State and local government</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,742&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(981)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,806&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset-backed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,842&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,059)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,872&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Review of declines in fair value. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Management reviews impaired debt securities to determine whether a credit loss allowance is needed based on criteria that include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">severity of decline;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">financial health and specific prospects of the issuer; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">changes in the regulatory, economic or general market environment of the issuer's industry or geographic region.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The table below summarizes debt securities with a decline in fair value from amortized cost for which an allowance for credit losses has not been recorded, by investment grade and the length of time these securities have been in an unrealized loss position. Unrealized depreciation on these debt securities is primarily due to declines in fair value resulting from increasing interest rates since these securities were purchased. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of Issues</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of Issues</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">One year or less</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investment grade</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">330</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">338</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">142</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(594)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Below investment grade</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">161</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">170</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">135</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">964&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,287&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More than one year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investment grade</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,441</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,036</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(595)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,590</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,487&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(336)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Below investment grade</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">701</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">775</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(74)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">486</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,633</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(686)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,353</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,901&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,960&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,059)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,777&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Equity Securities</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Equity securities with a readily determinable fair value consist primarily of public equity investments in the health care sector and mutual funds that invest in fixed income debt securities while those without a readily determinable fair value consist of private equity investments. Changes in the fair values of equity securities that have a readily determinable fair value are reported in Net realized investment (losses) gains. Equity securities without a readily determinable fair value are carried at cost minus impairment, if any, plus or minus changes resulting from observable price changes. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides the values of the Company's equity security investments. The amount of impairments or value changes resulting from observable price changes on equity securities with no readily determinable fair value still held was not material to the financial statements as of December&#160;31, 2023 or 2022.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023 </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">656</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities with no readily determinable fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,248</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,311</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,904</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,362</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,053&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we became a minority owner in VillageMD by investing $2.7&#160;billion in VillageMD preferred equity. VillageMD is a provider of primary, multi-specialty and urgent care services that is majority-owned by Walgreens Boots Alliance, Inc. These securities are included in Equity securities with no readily determinable fair value in the above table. A compounding dividend of 5.5% accrues annually on $2.2&#160;billion of our cost basis in these shares. Consistent with our strategy to invest in targeted startup and growth-stage companies in the health care industry, approximately 95% of our investments in equity securities are in the health care sector.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Commercial Mortgage Loans</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Commercial mortgage loans are carried at unpaid principal balances, net of an allowance for expected credit losses, and classified as either current or long-term investments based on their contractual maturities. Changes in the allowance for expected credit losses are recognized as credit loss expense and presented in Net realized investment (losses) gains in the Company's Consolidated Statements of Income. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Each period, the Company establishes (or adjusts) its allowance for expected credit losses for commercial mortgage loans. The allowance for expected credit losses is based on a credit risk category that is assigned to each loan at origination using key credit quality indicators, including debt service coverage and loan-to-value ratios. Credit risk categories are updated as key credit quality indicators change. An expected loss rate, assigned based on the credit risk category, is applied to each loan's unpaid principal balance to develop the aggregate allowance for expected credit losses. Commercial mortgage loans are considered impaired and written off against the allowance when it is probable that the Company will not collect all amounts due per the terms of the promissory note. In the event of a foreclosure, the allowance for credit losses is based on the excess of the carrying value of the mortgage loan over the fair value of its underlying collateral.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Mortgage loans held by the Company are made exclusively to commercial borrowers and are diversified by property type, location and borrower. Loans are generally issued at fixed rates of interest and are secured by high quality, primarily completed and substantially leased operating properties.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Credit quality</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Company regularly evaluates and monitors credit risk, beginning with the initial underwriting of a mortgage loan and continuing throughout the investment holding period. Mortgage origination professionals employ an internal credit quality rating system designed to evaluate the relative risk of the transaction at origination that is then updated each year as part of the annual portfolio loan review. The Company evaluates and monitors credit quality on a consistent and ongoing basis.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Quality ratings are based on our evaluation of a number of key inputs related to the loan, including real estate market-related factors such as rental rates and vacancies, and property-specific inputs such as growth rate assumptions and lease rollover statistics. However, the two most significant contributors to the credit quality rating are the debt service coverage and loan-to-value ratios. The debt service coverage ratio measures the amount of property cash flow available to meet annual interest and principal payments on debt, with a ratio below 1.0 indicating that there is not enough cash flow to cover the required loan payments. The loan-to-value ratio, commonly expressed as a percentage, compares the amount of the loan to the fair value of the underlying property collateralizing the loan.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the credit risk profile of the Company's commercial mortgage loan portfolio:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.890%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Loan-to-Value Ratio</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Debt Service Coverage Ratio</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Loan-to-Value Ratio</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Debt Service Coverage Ratio</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Loan-to-Value Ratio</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Below 60%</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">802</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.13</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">901&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.12</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60% to 79%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">574</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.77</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.73</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80% to 100%</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">157</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.65</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.17</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,533</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.82</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">64</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.89</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Policy Loans</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Policy loans, primarily associated with our corporate-owned life insurance business, are carried at unpaid principal balances plus accumulated interest, the total of which approximates fair value. These loans are collateralized by life insurance policy cash values and therefore have minimal exposure to credit loss. Interest rates are reset annually based on a rolling average of benchmark interest rates.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other Long-term Investments</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other long-term investments include investments in unconsolidated entities, including certain limited partnerships and limited liability companies holding real estate, securities or loans and health care-related investments. These investments are carried at cost plus the Company's ownership percentage of reporting income or loss, based on the financial statements of the underlying investments that are generally reported at fair value. Income or loss from these investments is reported on a one quarter lag due to the timing of when financial information is received from the general partner or manager of the investments. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other long-term investments also include investment real estate carried at depreciated cost less any impairment write-downs to fair value when cash flows indicate that the carrying value may not be recoverable. Depreciation is generally recorded using the straight-line method based on the estimated useful life of each asset. Investment real estate as of December&#160;31, 2023 and 2022 is expected to be held longer than one year and may include real estate acquired through the foreclosure of commercial mortgage loans.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, foreign currency swaps carried at fair value and certain restricted deposits are reported in the table below as "Other." See discussion below for information on the Company's accounting policies for derivative financial instruments.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other long-term investments and related commitments are diversified by issuer, property type and geographic regions. These investments are primarily unconsolidated variable interest entities (see Note 14 for additional information). The following table provides unfunded commitment and carrying value information for these investments. The Company expects to disburse approximately 25% of the committed amounts in 2024. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our limited partnership investments are reduced as the Company receives cash distributions for returns on its investment that were previously recognized in Net investment income. The amount of these cash distributions was $253 million in 2023, $487 million in 2022 and $568 million in 2021. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.237%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Commitments as of</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value as of December 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Real estate investments</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,319&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">712</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities partnerships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,085</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">175</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,181</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,728&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,797</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Short-term Investments and Cash Equivalents</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Security investments with maturities of greater than three months to one year from time of purchase are classified as short-term, available for sale and carried at fair value that approximates cost. Cash equivalents consist of short-term investments with maturities of three months or less from the time of purchase and are carried at cost that approximates fair value.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Derivative Financial Instruments</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company uses derivative financial instruments to manage the characteristics of investment assets (such as duration, yield, currency and liquidity) to meet the varying demands of the related insurance and contractholder liabilities. The Company also uses derivative financial instruments to hedge the risk of changes in the net assets of certain of its foreign subsidiaries due to changes in foreign currency exchange rates and to hedge the interest rate risk of certain long-term debt.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Derivatives are recorded in our Consolidated Balance Sheets at fair value and are classified as current or non-current according to their contractual maturities. Further information on our policies for determining fair value are discussed in Note 13. The Company applies hedge accounting when derivatives are designated, qualified and highly effective as hedges. Under hedge accounting, the changes in fair value of the derivative and the hedged risk are generally recognized together and offset each other when reported in Shareholders' net income. Various qualitative or quantitative methods appropriate for each hedge are used to formally assess and document hedge effectiveness at inception and each period throughout the life of a hedge.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's derivative financial instruments are presented as follows:&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Fair value hedges of the foreign exchange-related changes in fair values of certain foreign-denominated bonds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: Swap fair values are reported in Long-term investments or Other non-current liabilities. Offsetting changes in fair values attributable to the foreign exchange risk of the swap contracts and the hedged bonds are reported in Net realized investment (losses) gains. The portion of the swap contracts' changes in fair value excluded from the assessment of hedge effectiveness is recorded in Other comprehensive loss and recognized in Net investment income as swap coupon payments are accrued, offsetting the foreign-denominated coupons received on the designated bonds. Net cash flows are reported in Operating activities, while exchanges of notional principal amounts are reported in Investing activities.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Fair value hedges of the interest rate exposure on the Company's long-term debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: Using fair value hedge accounting, the fair values of the swap contracts are reported in other assets or other liabilities. The critical terms of these swaps match those of the long-term debt being hedged. As a result, the carrying value of the hedged debt is adjusted to reflect changes in its fair value driven by the SOFR. The effects of those adjustments on interest expense are offset by the effects of corresponding changes in the swaps' fair value. The net impact from the hedge reported in Interest expense and other reflects interest expense on the hedged debt at the variable interest rate. Cash flows relating to these contracts are reported in Operating activities.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Net investment hedges of certain foreign subsidiaries that conduct their business principally in currencies other than the U.S. dollar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: The fair values of the foreign currency swap and forward contracts are reported in other assets or other liabilities. The changes in fair values of these instruments are reported in Other comprehensive loss, specifically in translation of foreign currencies. The portion of the change in fair values relating to foreign exchange spot rates will be recognized in earnings upon deconsolidation of the hedged foreign subsidiaries. The remaining changes in fair value of these instruments are excluded from our effectiveness assessment and recognized in Interest expense and other over the term of the instrument. Cash flows relating to these contracts are reported in Investing activities. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The effects of derivative financial instruments used in our individual hedging strategies were not material to the Consolidated Financial Statements as of December&#160;31, 2023 and December&#160;31, 2022. The gross fair values of our derivative financial instruments are presented in Note 13 to the Consolidated Financial Statements. The following table summarizes the types and notional quantity of derivative instruments held by the Company: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.177%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Value as of</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purpose</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Instrument</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;text-decoration:underline">Fair value hedge:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> To hedge the foreign exchange-related changes in fair values of certain foreign-denominated bonds. The notional value of these derivatives matches the amortized cost of the hedged bonds. A majority of these instruments are denominated in Euros, with the remaining instruments denominated in British Pounds Sterling and Australian Dollars.</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency swap contracts</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,026</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,083&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Fair value hedge:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> To convert a portion of the interest rate exposure on the Company's long-term debt from fixed to variable rates. This more closely aligns the Company's interest expense with the interest income received on its cash equivalent and short-term investment balances. The variable rates are benchmarked to SOFR.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;text-decoration:underline">Net investment hedge:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> To reduce the risk of changes in net assets due to changes in foreign currency spot exchange rates for certain foreign subsidiaries that conduct their business principally in currencies other than the U.S. Dollar. The notional value of hedging instruments matches the hedged amount of subsidiary net assets. Foreign currency swap contracts are denominated in Euros.</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency swap contracts </span></div></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">415</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Concentration of Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company did not have a concentration of investments in a single issuer or borrower exceeding 10% of shareholders' equity as of December&#160;31, 2023 or 2022.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Net Investment Income</span><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> When interest and principal payments on investments are current, the Company recognizes interest income when it is earned. The Company recognizes interest income on a cash basis when interest payments are delinquent based on contractual terms or when certain terms (interest rate or maturity date) of the investment have been restructured. For unconsolidated entities that are included in other long-term investments, investment income is generally recognized according to the Company's share of the reported income or loss on the underlying investments. Investment income attributed to the Company's separate accounts is excluded from our earnings because associated gains and losses generally accrue directly to separate account policyholders.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The components of Net investment income were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">123</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial mortgage loans</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">65</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Policy loans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term investments</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">123</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments and cash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">339</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total investment income</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,210</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,209&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,608&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less investment expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,166</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,155&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,549&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt;text-decoration:underline">Realized Investment Gains and Losses</span><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Realized investment gains and losses are based on specifically identified assets and result from sales, investment asset write-downs, change in the fair value of certain derivatives and equity securities and changes in allowances for credit losses on debt securities and commercial mortgage loan investments. With the adoption of amended accounting guidance for long-duration insurance contracts on January 1, 2023 (discussed in Note 2 to the Consolidated Financial Statements), realized investment gains and losses no longer exclude amounts that were previously required to adjust future policy benefits for the run-off settlement annuity business. Prior period net realized investment losses have been updated to reflect the impact of adopting LDTI. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following realized gains and losses on investments exclude realized gains and losses attributed to the Company's separate accounts because those gains and losses generally accrue directly to separate account policyholders:</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.344%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.042%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net realized investment (losses) gains, excluding credit loss expense and asset write-downs</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(68)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(451)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Credit (loss) / recovery and other investment write-down (losses)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net realized investment (losses) gains, before income taxes</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(78)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(487)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>Net realized investment losses for the years ended December&#160;31, 2023 and December&#160;31, 2022 were primarily due to mark-to-market losses on a strategic health care equity securities investment.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br> -Publisher SEC<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//946-320/tableOfContent<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//940-320/tableOfContent<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288969898384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:10pt"><span id="i45a6e991e4ac4434bd4db2e67316940b_1591"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13 &#8211; Fair Value Measurements</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company carries certain financial instruments at fair value in the financial statements including debt securities, certain equity securities, short-term investments and derivatives. Other financial instruments are measured at fair value only under certain conditions, such as when impaired or when there are observable price changes for equity securities with no readily determinable fair value.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value is defined as the price at which an asset could be exchanged in an orderly transaction between market participants at the balance sheet date. A liability's fair value is defined as the amount that would be paid to transfer the liability to a market participant, not the amount that would be paid to settle the liability with the creditor.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's financial assets and liabilities carried at fair value have been classified based upon a hierarchy defined by GAAP. The hierarchy gives the highest ranking to fair values determined using unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest ranking to fair values determined using methodologies and models with unobservable inputs (Level 3). An asset's or a liability's classification is based on the lowest level of input that is significant to its measurement. For example, a financial asset or liability carried at fair value would be classified in Level 3 if unobservable inputs were significant to the instrument's fair value, even though the measurement may be derived using inputs that are both observable (Levels 1 and 2) and unobservable (Level 3).</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company estimates fair values using prices from third parties or internal pricing methods. Fair value estimates received from third-party pricing services are based on reported trade activity and quoted market prices when available and other market information that a market participant would use to estimate fair value. The internal pricing methods are performed by the Company's investment professionals and generally involve using discounted cash flow analyses, incorporating current market inputs for similar financial instruments with comparable terms and credit quality as well as other qualitative factors. In instances where there is little or no market activity for the same or similar instruments, fair value is estimated using methods, models and assumptions that the Company believes a hypothetical market participant would use to determine a current transaction price. These valuation techniques involve some level of estimation and judgment that becomes significant with increasingly complex instruments or pricing models.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is responsible for determining fair value and for assigning the appropriate level within the fair value hierarchy based on the significance of unobservable inputs. The Company reviews methodologies, processes and controls of third-party pricing services and compares prices on a test basis to those obtained from other external pricing sources or internal estimates. The Company performs ongoing analyses of both prices received from third-party pricing services and those developed internally to determine that they represent appropriate estimates of fair value. The controls executed by the Company include evaluating changes in prices and monitoring for potentially stale valuations. The Company also performs sample testing of sales values to confirm the accuracy of prior fair value estimates. The minimal exceptions identified during these processes indicate that adjustments to prices are infrequent and do not significantly impact valuations. An annual due-diligence review of the most significant pricing service is conducted to review their processes, methodologies and controls. This review includes a walk-through of inputs for a sample of securities held across various asset types to validate the documented pricing process.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Financial Assets and Financial Liabilities Carried at Fair Value</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides information about the Company's financial assets and liabilities carried at fair value. Further information regarding insurance assets and liabilities carried at fair value is provided in Note 10E to the Consolidated Financial Statements. Separate account assets are also recorded at fair value on the Company's Consolidated Balance Sheets and are reported separately in the Separate Accounts section below as gains and losses related to these assets generally accrue directly to contractholders:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial assets at fair value</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal government and agency</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">130</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">137</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">267</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State and local government</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">352</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">352</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,432</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">401</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,833</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset-backed</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">365</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">130</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,278</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,278&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">447</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,855</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,872&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">47</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">131</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">132</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial liabilities at fair value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Excludes certain equity securities that have no readily determinable fair value.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Level 1 Financial Assets</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inputs for instruments classified in Level 1 include unadjusted quoted prices for identical assets in active markets accessible at the measurement date. Active markets provide pricing data for trades occurring at least weekly and include exchanges and dealer markets.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Assets in Level 1 include actively-traded U.S. government bonds and exchange-listed equity securities. A relatively small portion of the Company's investment assets are classified in this category given the narrow definition of Level 1 and the Company's investment asset strategy to maximize investment returns.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Level 2 Financial Assets and Financial Liabilities</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inputs for instruments classified in Level 2 include quoted prices for similar assets or liabilities in active markets, quoted prices from those willing to trade in markets that are not active or other inputs that are market observable or can be corroborated by market data for the term of the instrument. Such other inputs include market interest rates and volatilities, spreads and yield curves. An instrument is classified in Level 2 if the Company determines that unobservable inputs are insignificant.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Debt and equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Approximately 94% of the Company's investments in debt and equity securities are classified in Level 2 including most public and private corporate debt and equity securities, federal agency and municipal bonds, non-government mortgage-backed securities and preferred stocks. Third-party pricing services and internal methods often use recent trades of securities with similar features and characteristics because many debt securities do not trade daily. Pricing models are used to determine these prices when recent trades are not available. These models calculate fair values by discounting future cash flows at estimated market interest rates. Such market rates are derived by calculating the appropriate spreads over comparable U.S. Treasury securities based on the credit quality, industry and structure of the asset. Typical inputs and assumptions to pricing models include, but are not limited to, a combination of benchmark yields, reported trades, issuer spreads, liquidity, benchmark securities, bids, offers, reference data and industry and economic events. For mortgage-backed securities, inputs and assumptions may also include characteristics of the issuer, collateral attributes, prepayment speeds and credit rating. Nearly all of these instruments are valued using recent trades or pricing models. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Short-term investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> are carried at fair value that approximates cost. The Company compares market prices for these securities to recorded amounts on a regular basis to validate that current carrying amounts approximate exit prices. The short-term nature of the investments and corroboration of the reported amounts over the holding period support their classification in Level 2.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Derivative assets and liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> classified in Level 2 represent over-the-counter instruments such as foreign currency forward and swap contracts. Fair values for these instruments are determined using market observable inputs including forward currency and interest rate curves and widely published market observable indices. Credit risk related to the counterparty and the Company is considered when estimating the fair values of these derivatives. However, the Company is largely protected by collateral arrangements with counterparties and determined that no adjustments for credit risk were required as of December&#160;31, 2023 or December&#160;31, 2022. The nature and use of these derivative financial instruments are described in Note 12.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Level 3 Financial Assets and Financial Liabilities</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain inputs for instruments classified in Level 3 are unobservable (supported by little or no market activity) and significant to their resulting fair value measurement. Unobservable inputs reflect the Company's best estimate of what hypothetical market participants would use to determine a transaction price for the asset or liability at the reporting date. Additionally, as discussed in Note 10E to the Consolidated Financial Statements, the Company classifies variable annuity assets and liabilities in Level 3 of the fair value hierarchy.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company classifies certain newly-issued, privately-placed, complex or illiquid securities in Level 3. Approximately 5% of debt and equity securities are priced using significant unobservable inputs and classified in this category.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair values of mortgage and other asset-backed securities, as well as corporate and government debt securities, are primarily determined using pricing models that incorporate the specific characteristics of each asset and related assumptions including the investment type and structure, credit quality, industry and maturity date in comparison to current market indices, spreads and liquidity of assets with similar characteristics. Inputs and assumptions for pricing may also include characteristics of the issuer, collateral attributes and prepayment speeds for mortgage and other asset-backed securities. Recent trades in the subject security or similar securities are assessed when available, and the Company may also review published research in its evaluation, as well as the issuer's financial statements.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Quantitative Information about Unobservable Inputs</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The significant unobservable input used to value our corporate and government debt securities and mortgage and other asset-backed securities is an adjustment for liquidity. This adjustment is needed to reflect current market conditions and issuer circumstances when there is limited trading activity for the security. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the fair value and significant unobservable inputs that were developed directly by the Company and used in pricing these debt securities. The range and weighted average basis point amounts for liquidity reflect the Company's best estimates of the unobservable adjustments a market participant would make to calculate these fair values. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.101%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value as of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Adjustment Range (Weighted Average by Quantity) as of</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Fair value in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">401</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liquidity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">70 - 1235 (310)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">bps</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60 - 1060 (270)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset-backed securities</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liquidity</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">95 - 640 (310) </span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">bps</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105 - 520 (310)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Level 3 debt securities</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">447</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">An increase in liquidity spread adjustments would result in a lower fair value measurement, while a decrease would result in a higher fair value measurement.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the changes in financial assets and financial liabilities classified in Level 3. Gains and losses reported in the table may include net changes in fair value that are attributable to both observable and unobservable inputs.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.066%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt and Equity Securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">447</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Losses) gains included in Shareholders' net income</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) included in Other comprehensive loss</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchases, sales and settlements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(52)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total purchases, sales and settlements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(42)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Transfers into/(out of) Level 3</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transfers into Level 3</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">95</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transfers out of Level 3</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(59)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(376)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total transfers into/(out of) Level 3</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(252)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">447</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total losses included in Shareholders' net income attributable to instruments held at the reporting date</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in unrealized gain or (loss) included in Other comprehensive loss for assets held at the end of the reporting period</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total gains and losses included in Shareholders' net income in the tables above are reflected in the Consolidated Statements of Income as Net realized investment (losses) gains and Net investment income.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gains and losses included in Other comprehensive loss, net of tax in the tables above are reflected in Net unrealized appreciation (depreciation) on securities and derivatives in the Consolidated Statements of Comprehensive Income.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transfers into or out of the Level 3 category occur when unobservable inputs, such as the Company's best estimate of what a market participant would use to determine a current transaction price, become more or less significant to the fair value measurement. Market activity typically decreases during periods of economic uncertainty and this decrease in activity reduces the availability of market observable data. As a result, the level of unobservable judgment that must be applied to the pricing of certain instruments increases and is typically observed through the widening of liquidity spreads. Transfers between Level 2 and Level 3 during 2023 and 2022 primarily reflected changes in liquidity estimates for certain private placement issuers across several sectors. See discussion under Quantitative Information about Unobservable Inputs above for more information.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Separate Accounts</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Separate account assets and liabilities are contractholder funds maintained in accounts with specific investment objectives. The assets of these accounts are legally segregated and are not subject to claims that arise out of any of the Company's other businesses. These separate account assets are carried at fair value with equal amounts recorded for related separate account liabilities. The investment income and fair value gains and losses of separate account assets generally accrue directly to the contractholders and, together with their deposits and withdrawals, are excluded from the Company's Consolidated Statements of Income and Cash Flows. Fees and charges earned for mortality risks, asset management or administrative services are reported in either Premiums or Fees and other revenues. Investments that are measured using the practical expedient of net asset value ("NAV") are excluded from the fair value hierarchy. The separate account activity for the year ended December&#160;31, 2023 and 2022 was primarily driven by changes in the market values of the underlying separate account investments.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair values of Separate account assets were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Guaranteed separate accounts (See Note 24)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">226</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">352</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">578</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-guaranteed separate accounts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">158</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,797</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">217</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,172</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">384</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,149</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,904&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">217</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,750</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,521&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-guaranteed separate accounts priced at NAV as a practical expedient </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">680</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,430</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,278&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Non-guaranteed separate accounts include $4.0 billion as of December&#160;31, 2023 and December&#160;31, 2022 in assets supporting the Company's pension plans, including $0.2 billion classified in Level 3 as of December&#160;31, 2023 and December&#160;31, 2022.</span></div><div style="margin-bottom:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Separate account assets classified as Level 1 primarily include exchange-listed equity securities. Level 2 assets primarily include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">corporate and structured bonds valued using recent trades of similar securities or pricing models that discount future cash flows at estimated market interest rates as described above; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">actively-traded institutional and retail mutual fund investments.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Separate account assets classified in Level 3 primarily support the Company's pension plans and include certain newly-issued, privately-placed, complex or illiquid securities that are priced using methods discussed above, as well as commercial mortgage loans. Activity, including transfers into and out of Level 3, was not material for the years ended December&#160;31, 2023 or 2022. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Separate account investments in securities partnerships, real estate and hedge funds are generally valued based on the separate account's ownership share of the equity of the investee (NAV as a practical expedient), including changes in the fair values of its underlying investments. Substantially all of these assets support the Company's pension plans. The following table provides additional information on these investments:</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.322%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value as of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Commitment as of December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Redemption Frequency<br/>(if currently eligible)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Redemption Notice<br/>Period</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities partnerships</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">419</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">254</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Not applicable</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Not applicable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Real estate funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">258</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quarterly</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30 - 90 days</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Up to annually, varying by fund</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30 - 90 days</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">680</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">254</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, the Company does not have plans to sell any of these assets at less than fair value. These investments are structured to satisfy longer-term investment objectives. Securities partnerships are contractually non-redeemable and the underlying investment assets are expected to be liquidated by the fund managers within ten years after inception.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Assets and Liabilities Measured at Fair Value under Certain Conditions</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Some financial assets and liabilities are not carried at fair value, such as commercial mortgage loans that are carried at unpaid principal, investment real estate that is carried at depreciated cost and equity securities with no readily determinable fair value when there are no observable market transactions. However, these financial assets and liabilities may be measured using fair value under certain conditions, such as when investments become impaired and are written down to their fair value, or when there are observable price changes from orderly market transactions of equity securities that otherwise had no readily determinable fair value.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the years ended December&#160;31, 2023 and 2022, realized investment gains and losses, including those from impairments recognized and observable price changes, were not material. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Fair Value Disclosures for Financial Instruments Not Carried at Fair Value</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table includes the Company's financial instruments not recorded at fair value but for which fair value disclosure is required. In addition to universal life products and finance leases, financial instruments that are carried in the Company's Consolidated Balance Sheets at amounts that approximate fair value are excluded from the following table:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.045%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification in Fair Value Hierarchy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial mortgage loans</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,430</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,533</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,491&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt, including current maturities, excluding finance leases</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28,033</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29,585</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,653&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,994&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288968542816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_VariableInterestEntitiesAbstract', window );"><strong>Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Variable Interest Entities</a></td>
<td class="text"><div><span id="ie01e129ab42145fc8bf7e377e885a1a4_13"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14 &#8211; Variable Interest Entities</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">When the Company becomes involved with a variable interest entity and when there is a change in the Company's involvement with an entity, the Company must determine if it is the primary beneficiary and must consolidate the entity. The Company is considered the primary beneficiary if it has the power to direct the entity's most significant economic activities and has the right to receive benefits or obligation to absorb losses that could be significant to the entity. The Company evaluates the following criteria:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the structure and purpose of the entity;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the risks and rewards created by and shared through the entity; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the Company's ability to direct its activities, receive its benefits and absorb its losses relative to the other parties involved with the entity including its sponsors, equity holders, guarantors, creditors and servicers. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company determined it was not a primary beneficiary in any material variable interest entity as of December&#160;31, 2023 or 2022. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's involvement in variable interest entities for which it is not the primary beneficiary is described below.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Securities limited partnerships and real estate limited partnerships</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The Company owns interests in securities limited partnerships and real estate limited partnerships that are defined as unconsolidated variable interest entities. These partnerships invest in the equity or mezzanine debt of privately-held companies and real estate properties. General partners unaffiliated with the Company control decisions that most significantly impact the partnership's operations and the limited partners do not have substantive kick-out or participating rights. The Company has invested in approximately 190 limited partnerships that have a carrying value of $2.9 billion as of December&#160;31, 2023 reported in other long-term investments. As of December&#160;31, 2023, we have commitments to contribute an additional $2.6 billion to these entities and the Company's maximum exposure to loss from these investments is $5.5 billion, calculated as the sum of our carrying value and the additional funding commitments. Our noncontrolling interest in each of these limited partnerships is generally less than 8% of the partnership ownership interests. See Note 12 for further information on the Company's accounting policy for other long-term investments. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has guaranteed debt payments to mortgage lenders for certain real estate limited partnerships should potential environmental obligations arise. No liability has been incurred related to these guarantees, and the Company's maximum exposure to these guarantees was approximately $488 million as of December&#160;31, 2023.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other variable interest entities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The Company is involved in other types of variable interest entities, including certain asset-backed and corporate securities, real estate joint ventures that develop properties for residential and commercial use, independent physician associations ("IPAs") that provide care management services and international health care joint ventures. As of December&#160;31, 2023, the Company's maximum exposure to loss is $0.5 billion from certain asset-backed and corporate securities and $0.9 billion from real estate joint ventures, which represents the sum of our carrying value and the additional funding commitments for these entities. The </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">carrying values and maximum exposures for the remaining unconsolidated variable interest entities were not material as of December&#160;31, 2023.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has not provided, and does not intend to provide, financial support to any of the variable interest entities in excess of its maximum exposure. We perform ongoing qualitative analyses of our involvement with these variable interest entities to determine if consolidation is required.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_VariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_VariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289064810608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collectively Significant Operating Unconsolidated Subsidiaries<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Collectively Significant Operating Unconsolidated Subsidiaries</a></td>
<td class="text"><div style="margin-bottom:10pt"><span id="ie9e3a7152b194e0d81f599bfea9605e2_2394"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 15 &#8211; Collectively Significant Operating Unconsolidated Subsidiaries</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to equity method investments, including certain limited partnerships and limited liability companies holding real estate, securities or loans (as disclosed in Note 12), we maintain a portfolio of operating joint ventures accounted for as equity method investments. Operating joint ventures accounted for under the equity method had a carrying value of $911 million as of December&#160;31, 2023 and $734 million as of December&#160;31, 2022, of which $214 million as of December&#160;31, 2023 and $602 million as of December&#160;31, 2022 related to our joint venture in China. Total Accumulated Other Comprehensive Income ("AOCI") includes losses of $510&#160;million as of December&#160;31, 2023 and $88&#160;million as of December&#160;31, 2022 related to the Company's share from unconsolidated entities reported on the equity method primarily driven by the requirement to update discount rate assumptions for certain long-duration liabilities following the adoption of LDTI (discussed in Note 2 to the Consolidated Financial Statements).</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the years ended December 31, 2023, 2022 and 2021, none of our unconsolidated subsidiary investments were individually significant.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We record in our Consolidated Statements of Income our proportionate share of net income or loss generated by equity method operating joint ventures within Fees and other revenues. In certain instances, income or loss is reported on a one month lag due to the timing of when financial information is received.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The below summarized results of operations and financial position of the operating joint venture investments accounted for under the equity method reflects the latest available financial information and does not represent the Company's proportionate share of the assets, liabilities or earnings of such entities. Prior period operating joint venture amounts have been retrospectively restated to reflect the adoption of amended accounting guidance for long-duration insurance contracts, as discussed in Note 2 to the Consolidated Financial Statements. </span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,962</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,665&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,750&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">98</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">26,681</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,026&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">25,534</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,462&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 323<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481543/323-740-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 323<br> -Publisher FASB<br> -URI https://asc.fasb.org//323/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288973704928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock', window );">Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-bottom:10pt"><span id="i28e542229591430e91381eec66292ee8_1746"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 16 &#8211; Accumulated Other Comprehensive Income (Loss)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AOCI includes net unrealized (depreciation) appreciation on securities and derivatives, change in discount rate and instrument specific credit risk for certain long-duration insurance contractholder liabilities (Note 10 to the Consolidated Financial Statements), foreign currency translation and the net postretirement benefits liability adjustment. AOCI includes the Company's share from unconsolidated entities reported on the equity method. Generally, tax effects in AOCI are established at the currently enacted tax rate and reclassified to Shareholders' net income in the same period that the related pre-tax AOCI reclassifications are recognized.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Shareholders' other comprehensive (loss), net of tax, for the years ended 2023, 2022 and 2021, is primarily driven by the change in discount rates for certain long-duration liabilities, unrealized changes in the market values of securities and derivatives and changes in postretirement benefits liabilities, including the impacts from unconsolidated entities reported on the equity method.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the components of AOCI, including the restatement for amended accounting guidance for long-duration insurance contracts (discussed in Note 2 to the Consolidated Financial Statements), are as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.205%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Securities and Derivatives</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance, as previously disclosed</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative effect of accounting for Long-duration Insurance Contracts guidance (ASU 2018-12)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance, as retrospectively restated</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(332)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,266&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized appreciation (depreciation) on securities and derivatives</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">620</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,274)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(335)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax (expense) benefit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(146)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized appreciation (depreciation) on securities and derivatives</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">474</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,807)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(283)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustment for losses included in Shareholders' net income ((Loss) gain on sale of businesses)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustment for losses (gains) included in Shareholders' net income (Net realized investment (losses) gains)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustment for (gains) included in Shareholders' net income (Selling, general and administrative expenses)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustment for tax (benefit) expense included in Shareholders' net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net losses (gains) reclassified from AOCI to Shareholders' net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">503</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,598)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(302)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">171</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(332)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,266&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.205%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net long-duration insurance and contractholder liabilities measurement adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance, as previously disclosed</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative effect of accounting for Long-duration Insurance Contracts guidance (ASU 2018-12)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(832)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance, as retrospectively restated</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(256)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(765)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(832)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current period change in discount rate for certain long-duration liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(913)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">222</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period change in discount rate for certain long-duration liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(691)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current period change in instrument-specific credit risk for market risk benefits</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(29)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period change in instrument-specific credit risk for market risk benefits</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(24)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(715)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(971)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(256)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(765)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">Established upon the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.205%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Translation of foreign currencies</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance, as retrospectively restated</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Translation of foreign currencies</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(277)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(213)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net translation of foreign currencies</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(310)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(232)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustment for losses included in Net income ((Loss) gain on sale of businesses)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustment for tax expense included in Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net translation losses reclassified from AOCI to Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Translation of foreign currencies</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(213)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(232)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net translation (loss) on foreign currencies attributable to noncontrolling interests</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shareholders' other comprehensive income (loss), net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(149)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.205%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Postretirement benefits liability</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(916)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,336)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,746)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustment for amortization of net prior actuarial losses and prior service costs (Interest expense and other)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustment for (gains) included in Shareholders' net income ((Loss) gain on sale of businesses)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustment for settlement (Interest expense and other)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustment for tax (benefit) included in Shareholders' net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net adjustments reclassified from AOCI to Shareholders' net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation update</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(46)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change due to valuation update</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(34)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(915)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(916)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,336)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.205%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Accumulated other comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance, as previously disclosed</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(861)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative effect of accounting for Long-duration Insurance Contracts guidance (ASU 2018-12)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance, as retrospectively restated</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,658)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,068)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,025)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shareholders' other comprehensive (loss), net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(206)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(590)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,864)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,658)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,068)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclousre of the changes in the componenets of other comprehensive income/loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289064733616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organizational Efficiency Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Organizational Efficiency Plan</a></td>
<td class="text"><div style="margin-bottom:10pt"><span id="ib4ae12875cf34f83a32bfa168076339d_4120"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 17 &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Organizational Efficiency Plan</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the fourth quarter of 2023, the Company approved a strategic realignment to drive greater operating effectiveness and efficiency. This plan positions us to be more efficient and focused to deliver differentiated value and services to our clients and customers. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recognized a charge in Selling, general and administrative expenses of $252 million, pre-tax ($193 million, after-tax). This charge included $232 million of accrued expenses primarily for severance costs related to headcount reductions, as well as, $20 million of one-time expenses related to abandonment of leased assets and impairment of property and equipment. We expect substantially all of the accrued liability to be paid by the end of 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes a roll forward of the accrued liability recorded in Accrued expenses and other liabilities:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December&#160;31, 2022</span></div></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fourth quarter 2023 charge</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">232</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 payments</span></div></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(30)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December&#160;31, 2023</span></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">202</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//420/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289066145040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Pension</a></td>
<td class="text"><div style="margin-bottom:10pt"><span id="i99ce20099cc349af960781819814ec06_8144"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 18 &#8211; Pension</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">About Our Plans</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company sponsors U.S. and non-U.S. defined benefit pension plans; future benefit accruals for the domestic plans are frozen.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Company measures the assets and liabilities of its domestic pension plans as of December 31. Benefit obligations are measured at the present value of estimated future payments based on actuarial assumptions. The Company uses the corridor method to account for changes in the benefit obligation when actual results differ from those assumed, or when assumptions change. These changes are called net unrecognized actuarial gains (losses). Under the corridor method, net unrecognized actuarial gains (losses) are initially recorded in Accumulated other comprehensive loss. When the unrecognized gain (loss) exceeds 10% of the </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">benefit obligation, that excess is amortized to expense over the expected remaining lives of plan participants. The net plan expense is reported in Interest expense and other in the Consolidated Statements of Income.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For balance sheet purposes, we measure plan assets at fair value. When the actual return differs from the expected return, those differences are reflected in the net unrealized actuarial gain (loss) discussed above. However, to measure pension benefit costs, we use a market-related asset valuation that differs from the actual fair value for domestic pension plan assets invested in non-fixed income investments. The market-related value recognizes the difference between actual and expected long-term returns in the portfolio over five years, a method that reduces the short-term impact of market fluctuations on pension costs. The market-related asset value was approximately $4.0 billion, compared with a fair value of approximately $4.1 billion at December&#160;31, 2023. </span></div><div><span><br/></span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Funded Status and Amounts Included in Accumulated Other Comprehensive Loss</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the projected benefit obligations and assets related to our U.S. and non-U.S. pension plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change in benefit obligation</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit obligation, January 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,948</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">204</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actuarial losses (gains), net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">93</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,094)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits paid from plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(294)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(296)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(18)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit obligation, December 31</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,934</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,948&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change in plan assets</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets, January 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">246</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(366)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(294)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(296)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets, December 31</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,138</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,186&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Funded status</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">204</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts presented in Consolidated Balance Sheets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">204</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> 2023 losses reflect a decrease in the discount rate while 2022 gains reflect an increase in the discount rate.</span></div><div style="text-indent:4.5pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We fund our qualified pension plans at least at the minimum amount required by the Employee Retirement Income Security Act of 1974 and the Pension Protection Act of 2006. The Company made immaterial contributions to the qualified pension plans in 2023. For 2024, contributions to the qualified pension plans are expected to be immaterial. Future years' contributions will ultimately be based on a wide range of factors including but not limited to asset returns, discount rates and funding targets. Non-qualified pension plans are generally funded on a pay-as-you-go basis as there are no plan assets for these plans.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Benefit payments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The following benefit payments are expected to be paid in:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:88.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">316</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">317</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">314</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">311</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2029 - 2033</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,484</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amounts reflected in the pension assets/(liabilities) shown above that have not yet been reported in Net income and, therefore, have been included in Accumulated other comprehensive loss consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrecognized net (losses)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,207)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,208)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrecognized prior service cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Postretirement benefits liability adjustment</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,211)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,213)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Cost of Our Plans</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net pension cost was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">204</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected long-term return on plan assets</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(204)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(272)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(269)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization of:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior actuarial losses, net</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">52</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlement loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (benefit) cost</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">53</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Assumptions Used for Pension</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discount rate:</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension benefit obligation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5.10%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.43%</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension benefit cost</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5.43%</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.82%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expected long-term return on plan assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension benefit cost</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6.50%</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.75%</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortality table for pension obligations</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">White Collar mortality table with MP 2021 projection scale</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">White Collar mortality table with MP 2021 projection scale</span></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company develops discount rates by applying actual annualized yields for high-quality bonds by duration to the expected pension plan liability cash flows. The bond yields represent a diverse mix of actively traded high quality fixed income securities that have an above average return at each duration as management believes this approach is representative of the yield achieved through plan asset investment strategy.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The expected long-term return on plan assets was developed considering historical long-term actual returns, expected long-term market conditions, plan asset mix and management's plan asset investment strategy.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">E.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Pension Plan Assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, pension assets included $4.0 billion invested in the separate accounts of Connecticut General Life Insurance Company, a subsidiary of the Company, and an additional $0.1 billion invested in funds of unaffiliated investment managers.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair values of pension assets by category are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal government and agency</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,780</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,349&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">121</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fund investments</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">278</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,191</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,947&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International, including funds and pooled separate accounts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities partnerships</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">419</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Real estate funds, including pooled separate accounts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">270</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial mortgage loans</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Guaranteed deposit account contract</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents and other current assets, net</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">131</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total pension assets at fair value</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,138</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,186&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> A pooled separate account has several participating benefit plans and each owns a share of the total pool of investments.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's current target investment allocation percentages are 90% fixed income and 10% in other investments, including private equity (securities partnerships), public equity securities, and real estate, and are developed by management as guidelines, although the fair values of each asset category are expected to vary as a result of changes in market conditions. The Company will evaluate further allocation changes to equity securities, other investments and fixed income securities as funding levels change.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See Note 13 for further details regarding how fair value is determined, including the level within the fair value hierarchy and the procedures we use to validate fair value measurements. The Company classifies substantially all debt securities in Level 2 for pension plan assets. These assets are valued using recent trades of similar securities or are fund investments priced using their daily net asset value that is the exit price. All domestic equity securities and international equity funds within pension assets are classified as Level 3.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Securities partnerships, real estate and hedge funds are valued using net asset value as a practical expedient and are excluded from the fair value hierarchy. See Note 13 for additional disclosures related to these assets invested in the separate accounts of the Company's subsidiary. Certain securities as described in Note 13, as well as commercial mortgage loans and guaranteed deposit account contracts, are classified in Level 3 because unobservable inputs used in their valuation are significant.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">F.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:9.4pt;text-decoration:underline">401(k) Plan</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company sponsors a 401(k) plan. All employees are immediately eligible for the plan at hire and the Company matches a portion of employees' contributions to the plan. Participants in the plan may invest in various funds that invest in the Company's common stock, several diversified stock funds, a bond fund or stable value funds. The Company common stock fund under the plan constitutes an "employee stock ownership plan" as defined in the Internal Revenue Code. Dividends from the Company common stock fund are reinvested in a participant's stock fund account unless the participant elects to receive the dividends in cash.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company may elect to increase its matching contributions if the Company's annual performance meets certain targets. The Company's annual expense for the plan was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">296</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288967588192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Employee Incentive Plans</a></td>
<td class="text"><div style="margin-bottom:10pt"><span id="ia59fe69ab3a747a18a0ea7f12e4444a7_5726"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 19 &#8211; Employee Incentive Plans</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">About Our Plans</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The People Resources Committee (the "Committee") of the Board of Directors awards stock options, restricted stock grants, restricted stock units, deferred stock and strategic performance shares to certain employees. The Company issues original issue shares for these awards.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company records compensation expense for stock and option awards over their vesting periods primarily based on the estimated fair value at the grant date. Fair value is determined differently for each type of award as discussed below.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Shares of common stock available for award were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares available for award</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Stock Options</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Company awards options to purchase The Cigna Group common stock at the market price of the stock on the grant date. Options vest over periods ranging from one year to three years and expire no later than 10 years from grant date. Fair value is estimated using the Black-Scholes option-pricing model by applying the assumptions presented below. That fair value is reduced by options expected to be forfeited during the vesting period. The Company estimates forfeitures at the grant date based on our experience and adjusts the expense to reflect actual forfeitures over the vesting period. The fair value of options, net of forfeitures, is recognized in Selling, general and administrative expenses on a straight-line basis over the vesting period.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Black-Scholes option-pricing model assumptions and the resulting fair value of options are presented in the following table: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.749%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.58</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.98&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.85&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected option life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4.7 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5 years</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average fair value of options</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">79.66</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.61&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.84&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The dividend yield reflects expected future dividends. The Company intends to continue to pay dividends for the foreseeable future. The expected volatility reflects the past daily stock price volatility of The Cigna Group stock. The Company does not consider volatility implied in the market prices of traded options to be a good indicator of future volatility because remaining traded options will expire within one year. The risk-free interest rate is derived using the four-year U.S. Treasury bond yield rate as of the award date for the primary annual grant. Expected option life reflects the Company's historical experience.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table shows the status of, and changes in, common stock options:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Options in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding - January 1</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,992</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">186.54</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,490&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169.47&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,742&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152.40&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">915</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">294.37</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,375&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,524&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">213.81&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,080)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">174.66</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,617)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149.97&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,584)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.08&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired or canceled</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(131)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">246.95</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(256)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">211.22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(192)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199.10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding - December 31</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,696</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">202.02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,992&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186.54&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,490&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169.47&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable at year-end</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,616</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">179.28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,410&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">168.97&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,612&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152.92&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Compensation expense of $67 million related to unvested stock options at December&#160;31, 2023 will be recognized over the next two years (weighted average period).</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The table below summarizes information for stock options exercised:</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intrinsic value of options exercised</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">126</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash received for options exercised</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">187</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax benefit from options exercised</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes information for outstanding common stock options:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options<br/>Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options<br/>Exercisable</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number (in thousands)</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,696</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,616</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intrinsic value (in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">652</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">555</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">202.02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">179.28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average remaining contractual life</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5.9 years</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4.7 years</span></td></tr></table></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Restricted Stock</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company awards restricted stock (grants and units) to the Company's employees that vest over periods ranging from <span style="-sec-ix-hidden:f-2151">one</span> to three years. Recipients of restricted stock awards accumulate dividends during the vesting period, but generally forfeit their awards and accumulated dividends if their employment terminates before the vesting date.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Fair value of restricted stock awards is equal to the market price of The Cigna Group's common stock on the date of grant. This fair value is reduced by awards that are expected to forfeit. At the grant date, the Company estimates forfeitures based on experience and adjusts the expense to reflect actual forfeitures over the vesting period. This fair value, net of forfeitures, is recognized in Selling, general and administrative expenses over the vesting period on a straight-line basis.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table shows the status of, and changes in, restricted stock awards:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Awards in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grants/Units</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Fair Value at Award Date</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grants/Units</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Fair Value at Award Date</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grants/Units</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Fair Value at Award Date</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding - January 1</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,535</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">219.25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,524&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.85&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186.12&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">294.60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">229.60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">899&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">213.82&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(759)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">214.70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(714)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197.83&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(866)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184.07&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(72)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">256.24</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(151)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.02&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(109)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197.01&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding - December 31</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,404</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">257.38</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,535&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">219.25&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,524&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.85&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of vested restricted stock at the vesting date was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of vested restricted stock</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">220</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Approximately 8,900 employees held 1.4 million restricted stock awards at the end of 2023 with $196 million of related compensation expense to be recognized over the next two years (weighted average period).</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Strategic Performance Shares ("SPS")</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company awards SPSs to executives and certain other key employees generally with a performance period of three years. Half of these shares are subject to a market condition (total shareholder return relative to industry peer companies) and half are subject to a performance condition (cumulative adjusted net income). These targets are set by the Committee at the beginning of the performance period. Holders of these awards receive shares of The Cigna Group common stock at the end of the performance period ranging anywhere from 0 to 200% of the original awards.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Compensation expense for SPSs is recorded over the performance period. Fair value is determined at the grant date for "market condition" SPSs using a Monte Carlo simulation model and not subsequently adjusted regardless of the final outcome. Expense is initially accrued for "performance condition" SPSs based on the most likely outcome, but evaluated for adjustment each period for updates in the expected outcome. Expense is adjusted to the actual outcome (number of shares awarded times the share price at the grant date) at the end of the performance period.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table shows the status of, and changes in, SPSs:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Awards in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Fair Value at Award Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Fair Value at Award Date</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Fair Value at Award Date</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding - January 1</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">780</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">212.68</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197.07&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190.02&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">219</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">293.85</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">213.90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(250)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">191.78</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(261)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">183.60&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196.29&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(63)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">237.50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(113)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207.75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197.38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding - December 31</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">686</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">243.90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">212.68&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197.07&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The weighted average fair value per share of SPSs for expense purposes, including the Monte Carlo factor, at the award date for the years ended December&#160;31, 2023, 2022 and 2021 was $329.11, $258.37 and $239.57, respectively.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of vested SPSs at the vesting date was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.212%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Shares in thousands; $ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares of The Cigna Group common stock distributed upon SPS vesting</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">257</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">76</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Approximately 600 employees held 686,000 SPSs at the end of 2023 and $61&#160;million of related compensation expense is expected to be recognized over the next two years. The amount of expense for "performance condition" SPSs will vary based on actual performance in 2024 and 2025.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">E.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Compensation Cost and Tax Effects of Share-based Compensation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company records tax benefits in Shareholders' net income during the vesting period based on the amount of expense being recognized. The difference between tax benefits based on the expense and the actual tax benefit realized are also recorded in income tax expense when stock options are exercised, or when restricted stock and SPSs vest.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total compensation cost for shared-based awards</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">286</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax benefits recognized</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">92</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288973818624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill, Other Intangibles and Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract', window );"><strong>Goodwill Other Intangibles And Property And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentDisclosureTextBlock', window );">Goodwill, Other Intangibles, and Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:10pt"><span id="id61656c4028645fb94828ae2f199db59_5551"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 20 &#8211; Goodwill, Other Intangibles and Property and Equipment</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Goodwill</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Goodwill represents the excess of the cost of businesses acquired over the fair value of their net assets. The resulting goodwill is assigned to those reporting units expected to realize cash flows from the acquisition, based on those reporting units' relative fair values. The Company's reporting units are aligned with its operating segments as described in Note 1.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company conducts its annual quantitative evaluation for goodwill impairment during the third quarter at the reporting unit level and writes it down through Shareholders' net income if impaired. On a quarterly basis, the Company performs a qualitative impairment assessment to determine if events or changes in circumstances indicate that it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value. Fair value of a reporting unit is generally estimated based on discounted cash flow analysis and market approach models using assumptions that the Company believes a hypothetical market participant would use to determine a current transaction price. Following a change in reporting units or held for sale determination, goodwill is allocated using relative fair value. The significant assumptions and estimates used in determining fair value primarily include the discount rate and future cash flows. A discount rate is selected to correspond with each reporting unit's weighted average cost of capital, consistent with </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">that used for investment decisions considering the specific and detailed operating plans and strategies within each reporting unit. Projections of future cash flows differ by reporting unit and are consistent with our ongoing strategic projections. Future cash flows for Evernorth Health Services are primarily driven by the forecasted gross margins of the business, as well as operating expenses and long-term growth rates. Future cash flows for our other reporting units are primarily driven by forecasted revenues, benefit expenses, operating expenses and long-term growth rates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Goodwill activity.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Goodwill activity was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Evernorth Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cigna Healthcare</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,128&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,683&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,045&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill disposed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impact of foreign currency translation and other adjustments</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,130&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,681&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,811&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill transferred to assets of businesses held for sale</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,553)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,553)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impact of foreign currency translation and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill at December 31, 2023</span></div></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35,130</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,129</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44,259</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Includes $234 million classified as assets of businesses held for sale, all reported within Other Operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"> </span></div><div><span><br/></span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Other Intangible Assets</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Company's Other intangible assets primarily include purchased customer and producer relationships, trademarks and provider networks. The fair value of purchased customer relationships and the amortization method were determined as of the dates of purchase using an income approach that relies on projected future net cash flows including key assumptions for customer attrition and discount rates. The Company's definite-lived intangible assets are amortized on an accelerated or straight-line basis, reflecting their pattern of economic benefits, over periods from <span style="-sec-ix-hidden:f-2278">three</span> to 30 years. Management revises amortization periods if it believes there has been a change in the length of time that an intangible asset will continue to have value. Costs incurred to renew or extend the terms of these intangible assets are generally expensed as incurred.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's amortized intangible assets are tested for impairment whenever events or changes in circumstances indicate that the </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">carrying amount may not be recoverable.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> If the total of the expected future undiscounted cash flows generated by the underlying asset group is less than the carrying amount of the asset group, the Company recognizes an impairment charge equal to the difference between the carrying value of the asset group and its estimated fair value. The Company's indefinite-lived intangible assets are reviewed for impairment at least annually by comparing their fair value with their carrying value. If the carrying value exceeds fair value, that excess is recognized as an impairment loss.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Components of other assets, including other intangibles.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Other intangible assets were comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29,978</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,645</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22,333</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade Name - Express Scripts</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">317</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38,695</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,755</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30,940</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Value of business acquired ("VOBA" reported in Other assets)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">211</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">142</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">69</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38,906</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,897</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">31,009</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,974&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,099&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,875&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade Name - Express Scripts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,722&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,230&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,492&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Value of business acquired (reported in Other assets)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,932&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,363&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,569&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Includes $69&#160;million of VOBA and $77&#160;million of Other intangible assets classified as assets of businesses held for sale.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"> </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has indefinite-lived intangible assets totaling $8.5 billion at December&#160;31, 2023 and December&#160;31, 2022, largely consisting of the Express Scripts trade name.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Property and Equipment</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Property and equipment is carried at cost less accumulated depreciation. Cost includes interest, real estate taxes and other costs incurred during construction when applicable. Internal-use software that is acquired, developed or modified solely to meet the Company's internal needs, with no plan to market externally, is also included in this category. Costs directly related to acquiring, developing or modifying internal-use software are capitalized.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company calculates depreciation and amortization principally using the straight-line method generally based on the estimated useful life of each asset as follows: buildings and improvements, 10 to 40 years; purchased and internally developed software, <span style="-sec-ix-hidden:f-2323">three</span> to five years; and furniture and equipment (including computer equipment), <span style="-sec-ix-hidden:f-2325">three</span> to 10 years. Improvements to leased facilities are depreciated over <span style="-sec-ix-hidden:f-2327">the lesser of the remaining lease term or the estimated life of the improvement</span>. The Company considers events and circumstances that would indicate the carrying value of property, equipment or capitalized software might not be recoverable. An impairment charge is recorded if the Company determines the carrying value of any of these assets is not recoverable. The Company also reviews and shortens the estimated useful lives of these assets, if necessary.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Components of property and equipment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Property and equipment was comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Internal-use software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,155</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,161</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,994</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other property and equipment</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,282</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,405</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">877</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,437</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,566</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,871</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Internal-use software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other property and equipment</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,256&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,330&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,204&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,430&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,774&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Includes $176&#160;million of Property and equipment net carrying value classified as assets of businesses held for sale. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Components of depreciation and amortization.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Depreciation and amortization expense was comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Internal-use software</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,216</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,068&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other property and equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">260</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Value of business acquired (reported in Other assets)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangibles</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,552</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,606&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,548&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total depreciation and amortization</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,035</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,937&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,923&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company estimates annual pre-tax amortization for intangible assets, including internal-use software, over the next five calendar years to be as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:88.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax Amortization</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,892</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,357</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,803</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,559</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,484</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discloses the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain or loss on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss. This element may be used as a single block of text to include the entire intangible asset disclosure including data and tables. Disclosure of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, building and production equipment. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures. This element may be used as a single block of text to include the entire PPE disclosure, including data and tables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288968530416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:10pt"><span id="i5991b33a7b8f493f949a254d6e300e2d_1953"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 21 &#8211; Leases</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's leases are primarily for office space and certain computer and other equipment and have terms of up to 35 years.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Company determines if an arrangement is a lease and its lease classification (operating or finance) at inception. Both operating and finance leases result in (1) a right-of-use ("ROU") asset that represents our right to use the underlying asset for the lease term and (2) a lease liability that represents our obligation to make lease payments arising from the lease. ROU assets and lease liabilities are reflected in the following lines in the Company's Consolidated Balance Sheets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROU Asset</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current Lease Liability</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-Current Lease Liability</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities (current)</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other liabilities (non-current)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. Most of the Company's leases do not provide an implicit rate, so the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The ROU asset also includes any lease pre-payments made and excludes lease incentives for operating leases. The Company's expected life of a lease may consider options to extend or terminate a lease when it is reasonably certain that the Company will exercise that option.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has lease agreements with lease and non-lease components that are accounted for as a single lease component. Operating lease ROU assets are amortized on a straight-line basis over the lease term, which is representative of the pattern in which benefit is expected to be derived from the right to use the underlying asset. Variable lease payments are expensed as incurred and represent amounts that are neither fixed in nature, such as maintenance and other services provided by the lessor, nor tied to an index or rate.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The components of lease expense were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">115</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of ROU assets</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total finance lease cost</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">198</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Supplemental cash flow information related to leases was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.931%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash outflows from operating leases</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">132</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash outflows from finance leases</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing cash outflows from finance leases</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROU assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">103</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating and finance lease ROU assets and lease liabilities were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.319%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating leases:</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease ROU assets in <span style="-sec-ix-hidden:f-2410"><span style="-sec-ix-hidden:f-2411">Other assets</span></span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">370</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2414"><span style="-sec-ix-hidden:f-2415">Accrued expenses and other liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2418"><span style="-sec-ix-hidden:f-2419">Other non-current liabilities</span></span></span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">340</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">445</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance leases:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">177</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2428"><span style="-sec-ix-hidden:f-2429">Property and equipment, net</span></span></span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">104</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2432"><span style="-sec-ix-hidden:f-2433">Short-term debt</span></span></span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">42</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2436"><span style="-sec-ix-hidden:f-2437">Long-term debt</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2023, the weighted average remaining lease term was 6 years for operating leases and 3 years for finance leases, and the weighted average discount rate was 3.45% for operating leases and 4.29% for finance leases.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Maturities of lease liabilities are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">102</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">83</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">63</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">98</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">497</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">115</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">52</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">445</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:10pt"><span id="i5991b33a7b8f493f949a254d6e300e2d_1953"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 21 &#8211; Leases</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's leases are primarily for office space and certain computer and other equipment and have terms of up to 35 years.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Company determines if an arrangement is a lease and its lease classification (operating or finance) at inception. Both operating and finance leases result in (1) a right-of-use ("ROU") asset that represents our right to use the underlying asset for the lease term and (2) a lease liability that represents our obligation to make lease payments arising from the lease. ROU assets and lease liabilities are reflected in the following lines in the Company's Consolidated Balance Sheets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROU Asset</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current Lease Liability</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-Current Lease Liability</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities (current)</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other liabilities (non-current)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. Most of the Company's leases do not provide an implicit rate, so the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The ROU asset also includes any lease pre-payments made and excludes lease incentives for operating leases. The Company's expected life of a lease may consider options to extend or terminate a lease when it is reasonably certain that the Company will exercise that option.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has lease agreements with lease and non-lease components that are accounted for as a single lease component. Operating lease ROU assets are amortized on a straight-line basis over the lease term, which is representative of the pattern in which benefit is expected to be derived from the right to use the underlying asset. Variable lease payments are expensed as incurred and represent amounts that are neither fixed in nature, such as maintenance and other services provided by the lessor, nor tied to an index or rate.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The components of lease expense were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">115</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of ROU assets</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total finance lease cost</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">198</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Supplemental cash flow information related to leases was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.931%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash outflows from operating leases</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">132</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash outflows from finance leases</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing cash outflows from finance leases</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROU assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">103</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating and finance lease ROU assets and lease liabilities were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.319%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating leases:</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease ROU assets in <span style="-sec-ix-hidden:f-2410"><span style="-sec-ix-hidden:f-2411">Other assets</span></span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">370</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2414"><span style="-sec-ix-hidden:f-2415">Accrued expenses and other liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2418"><span style="-sec-ix-hidden:f-2419">Other non-current liabilities</span></span></span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">340</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">445</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance leases:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">177</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2428"><span style="-sec-ix-hidden:f-2429">Property and equipment, net</span></span></span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">104</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2432"><span style="-sec-ix-hidden:f-2433">Short-term debt</span></span></span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">42</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2436"><span style="-sec-ix-hidden:f-2437">Long-term debt</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2023, the weighted average remaining lease term was 6 years for operating leases and 3 years for finance leases, and the weighted average discount rate was 3.45% for operating leases and 4.29% for finance leases.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Maturities of lease liabilities are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">102</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">83</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">63</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">98</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">497</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">115</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">52</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">445</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289066145040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders Equity and Dividend Restrictions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_StockholdersEquityAndDividendRestrictionsTextBlock', window );">Shareholders' Equity And Dividend Restrictions</a></td>
<td class="text"><div style="margin-bottom:10pt"><span id="i3bcdef59d091463883ab932d4c87d696_1547"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 22 &#8211; Shareholders' Equity and Dividend Restrictions</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">State insurance departments and foreign jurisdictions that regulate certain of the Company's subsidiaries prescribe accounting practices (differing in some respects from GAAP) to determine statutory net income and surplus. The Company's life, accident and health insurance and Health Maintenance Organization ("HMO") subsidiaries are regulated by such statutory requirements. The statutory net income of the Company's life, accident and health insurance and HMO subsidiaries for the years ended, and their statutory surplus as of December 31 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In billions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surplus</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's HMO and life, accident and health insurance subsidiaries are also subject to minimum statutory surplus requirements and may be required to maintain investments on deposit with state departments of insurance or other regulatory bodies. Additionally, these subsidiaries may be subject to regulatory restrictions on the amount of annual dividends or other distributions (such as loans or cash advances) that insurance companies may extend to their parent companies without prior approval. These amounts, including restricted GAAP net assets of the Company's subsidiaries, were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:88.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In billions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Minimum statutory surplus required by regulators </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments on deposit with regulatory bodies</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maximum dividend distributions permitted in 2024 without regulatory approval</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maximum loans to the parent company permitted without regulatory approval</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted GAAP net assets of The Cigna Group's subsidiaries</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Excludes amounts associated with foreign operated equity method joint ventures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Permitted practices used by the Company's insurance subsidiaries in 2023 that differed from prescribed regulatory accounting had an immaterial impact on statutory surplus.</span></div>Undistributed earnings for equity method investments are $1.0 billion&#160;as of December&#160;31, 2023<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_StockholdersEquityAndDividendRestrictionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Footnote describing statutory requirements by various states for shareholders' equity and dividend restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_StockholdersEquityAndDividendRestrictionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288973790448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div><span id="if56053e95d5e46d0a8e1a2d4abbd865a_14"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 23 &#8211; Income Taxes</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Deferred income taxes are reflected in the Consolidated Balance Sheets for differences between the financial and income tax reporting bases of the Company's underlying assets and liabilities, and are established based upon enacted tax rates and laws. Deferred income tax assets are recognized when available evidence indicates that realization is more likely than not and a valuation allowance is established to the extent this standard is not met. The deferred income tax provision generally represents the net change in deferred income tax assets and liabilities during the reporting period excluding adjustments to Accumulated other comprehensive income (loss) or amounts recorded in connection with a business combination. The current income tax provision generally represents estimated amounts due on income tax returns for the year reported to various jurisdictions plus the effect of any uncertain tax positions. The Company recognizes a liability for uncertain tax positions if management believes the probability that the positions will be sustained is 50% or less. For uncertain positions that management believes are more likely than not to be sustained, the Company recognizes a liability based upon management's estimate of the most likely settlement outcome with the taxing authority. The liabilities for uncertain tax positions are classified as current when the position is expected to be settled within 12 months or the statute of limitation expires within 12 months.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income taxes attributable to the Company's foreign operations are generally provided using the respective foreign jurisdictions' tax rate.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Income Tax Expense</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The components of income taxes were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current taxes</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. income taxes</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,459</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,679&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign income taxes</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">161</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State income taxes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">180</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current taxes</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,087&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,586&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deferred taxes (benefits)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. income tax benefits</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(533)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(275)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign income (tax benefits) taxes</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,046)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State income tax benefits</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(80)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(169)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total deferred tax benefits</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,659)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(472)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(216)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total income taxes</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">141</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,615&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,370&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total income taxes were different from the amount computed using the nominal federal income tax rate for the following reasons:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.891%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="36" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax expense at nominal rate</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,158</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,763&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,426&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impact of sale of businesses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impact of businesses held for sale</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(213)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3.9)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of foreign earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State income tax (benefit), net of federal income tax benefit</span></div></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(39)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.7)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss tax attributes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,674)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(30.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other foreign tax attributes</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(153)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2.8)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,290</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(55)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.9)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total income taxes</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">141</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,615&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,370&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Consolidated pre-tax income from the Company's foreign operations was approximately 48% of the Company's pre-tax income in 2023, 46% in 2022 and 26% in 2021. The increase over 2022 is primarily driven by an increase to the Company's international pharmaceutical operations, partially offset by a reduction in earnings from the sold entities. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Foreign Jurisdiction Tax Attributes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Impacting the effective tax rate for the year ended December&#160;31, 2023 was the recording of the Company's net deferred tax asset associated with foreign tax law changes and agreements in certain tax jurisdictions. The Company established deferred tax assets of approximately $1.8 billion associated with the foreign tax attributes and a related $772 million valuation allowance against these deferred tax assets based on projections of future earnings and requirements to utilize the assets within certain time periods. It is possible in future periods that the Company may revalue these net deferred tax assets due to modifications in certain assumptions such as forecasted future earnings. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Sale of Medicare Advantage and Related Businesses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The Company recorded $584 million of deferred tax benefits and an equal amount of valuation allowance in connection with the HCSC transaction. The valuation allowance has been recorded due to the uncertainty relative to the recovery of the deferred tax benefits as the Company does not currently have capital gain capacity to offset these capital losses. </span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Deferred Income Taxes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred income tax assets and liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deferred tax assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee and retiree benefit plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">217</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other insurance and contractholder liabilities</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">353</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">200</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred loss - sale of business</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">584</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">244</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Policy acquisition expenses</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized depreciation on investments and foreign currency translation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">81</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign tax attributes</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,827</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">242</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets before valuation allowance</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,787</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,322&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,498)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets, net of valuation allowance</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,289</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,114&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">371</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition-related basis differences</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,476</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,900&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net deferred income tax liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6,187)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,786)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Deferred tax liabilities, net in the Consolidated Balance Sheets as of December&#160;31, 2023, excludes $1,055&#160;million reported in Other assets and $69&#160;million reported in liabilities of businesses held for sale.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Management believes that future results will be sufficient to realize a majority of the Company's gross deferred tax assets. As of December&#160;31, 2023, we had approximately $218&#160;million in deferred tax assets ("DTAs") associated with unrealized investment losses that are partially recorded in Accumulated other comprehensive loss. We have determined that a valuation allowance against the DTAs is not currently required based on the Company's ability to carry back losses and our ability and intent to hold certain securities until recovery. We continue to monitor and evaluate the need for any valuation allowance in the future. As of December&#160;31, 2023, we had approximately $1.8 billion in DTAs associated with the foreign tax attributes as discussed above. We have determined that approximately $772 million valuation allowance against these DTAs is required based on the Company's taxable income projections and the requirement to utilize the assets within certain time periods. Additionally, the Company has $584 million of deferred tax assets and a full valuation allowance associated with the HCSC transaction, as discussed above. Valuation allowances are established against deferred tax assets when it is determined that it is more likely than not that the asset will not be recognized. Valuation allowances have been established against certain federal, state and foreign tax attributes. There are multiple expiration dates associated with these tax attributes.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Uncertain Tax Positions</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reconciliations of unrecognized tax benefits were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1,</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,343</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,230&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,210&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Decrease) / Increase due to prior year positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase due to current year positions</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">107</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction related to settlements with taxing authorities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction related to lapse of applicable statute of limitations</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31,</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,230&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Substantially all unrecognized tax benefits would impact Shareholders' net income if recognized. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company classifies net interest expense on uncertain tax positions as a component of income tax expense and in Other non-current liabilities in the Consolidated Balance Sheets. In addition to the amounts in the table above, the liability for net interest </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">expense on uncertain tax positions was approximately $220 million as of December&#160;31, 2023, $176 million as of December&#160;31, 2022 and $148 million as of December&#160;31, 2021.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Other Tax Matters</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The statutes of limitations for The Cigna Group's consolidated federal income tax returns through 2016 have closed. However, The Cigna Group filed amended returns for both the 2015 and 2016 tax years, which are under review by the Internal Revenue Service ("IRS"). Additionally, the IRS is examining The Cigna Group's returns for 2017 and 2018. The statutes of limitations for Express Scripts' consolidated federal income tax returns through 2012 has closed. However, for 2010 through 2012 tax years, there remains a significant disputed matter. The IRS is also examining Express Scripts' consolidated federal income tax returns for 2013 through 2018. The Company has established adequate reserves for these matters.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company conducts business in a number of state and foreign jurisdictions and may be engaged in multiple audit proceedings at any given time. Generally, no further state or foreign audit activity is expected for tax years prior to 2014 for The Cigna Group's entities and 2010 for Express Scripts' entities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Pillar Two. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 15, 2022, the European Union ("EU") Member States formally adopted the EU's Pillar Two Directive, which generally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation and Development ("OECD") Pillar Two Framework that was supported by over 130 countries worldwide. The EU effective dates are January 1, 2024, and January 1, 2025, for different aspects of the directive. A significant number of other countries are also implementing similar legislation, and the OECD continues to release additional guidance on these rules. The Company is within the scope of the OECD Pillar Two model rules and continues to evaluate the potential impact on future periods of the Pillar Two Framework, pending legislative adoption by additional individual countries but expects the impact to not materially change its results from operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288964522416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Other Matters<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies and Other Matters</a></td>
<td class="text"><div style="margin-bottom:10pt"><span id="i27908228960e40488ce1e12ef7d7a82d_2913"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 24 &#8211; Contingencies and Other Matters</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company, through its subsidiaries, is contingently liable for various guarantees provided in the ordinary course of business.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Financial Guarantees: Retiree and Life Insurance Benefits</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company guarantees that separate account assets will be sufficient to pay certain life insurance or retiree benefits. For the majority of these benefits, the sponsoring employers are primarily responsible for ensuring that assets are sufficient to pay these benefits and are required to maintain assets that exceed a certain percentage of benefit obligations. If employers fail to do so, the Company or an affiliate of the buyer of the retirement benefits business has the right to redirect the management of the related assets to provide for benefit payments. As of December&#160;31, 2023, employers maintained assets that generally exceeded the benefit obligations under these arrangements of approximately $420 million. An additional liability is established if management believes that the Company will be required to make payments under the guarantees; there were no additional liabilities required for these guarantees, net of reinsurance, as of December&#160;31, 2023. Separate account assets supporting these guarantees are classified in Levels 1 and 2 of the GAAP fair value hierarchy.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company does not expect that these financial guarantees will have a material effect on the Company's consolidated results of operations, liquidity or financial condition.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Certain Other Guarantees</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company had indemnification obligations as of December&#160;31, 2023 in connection with acquisition and disposition transactions. These indemnification obligations are triggered by the breach of representations or covenants provided by the Company, such as representations for the presentation of financial statements, filing of tax returns, compliance with laws or regulations or identification of outstanding litigation. These obligations are typically subject to various time limitations, defined by the contract or by operation of law, such as statutes of limitation. In some cases, the maximum potential amount due is subject to contractual limitations based on a stated dollar amount or a percentage of the transaction purchase price, while in other cases limitations are not specified or applicable. The Company does not believe that it is possible to determine the maximum potential amount due under these obligations because not all amounts due under these indemnification obligations are subject to limitation. There were no liabilities for these indemnification obligations as of December&#160;31, 2023.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Guaranty Fund Assessments</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company operates in a regulatory environment that may require its participation in assessments under state insurance guaranty association laws. The Company's exposure to assessments for certain obligations of insolvent insurance companies to policyholders and claimants is based on its share of business written in the relevant jurisdictions.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There were no material charges or credits resulting from existing or new guaranty fund assessments for the year ended December&#160;31, 2023.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Legal and Regulatory Matters</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is routinely involved in numerous claims, lawsuits, regulatory inquiries and audits, government investigations, including under the federal False Claims Act and state false claims acts initiated by a government investigating body or by a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> relator's filing of a complaint under court seal, and other legal matters arising, for the most part, in the ordinary course of managing a global health company. Additionally, the Company has received and is cooperating with subpoenas or similar processes from various governmental agencies requesting information, all arising in the normal course of its business. Disputed tax matters arising from audits by the Internal Revenue Service or other state and foreign jurisdictions, including those resulting in litigation, are accounted for under GAAP guidance for uncertain tax positions, as described in Note 23.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pending litigation and legal or regulatory matters that the Company has identified with a reasonably possible material loss and certain other material litigation matters are described below. For those matters that the Company has identified with a reasonably possible material loss, the Company provides disclosure in the aggregate of accruals and range of loss, or a statement that such information cannot be estimated. The Company's accrual for the matter discussed below under "Litigation Matters" is not material. Due to numerous uncertain factors presented in this case, it is not possible to estimate an aggregate range of loss (if any) for this matter at this time. In light of the uncertainties involved in this matter, there is no assurance that its ultimate resolution will not exceed the amount currently accrued by the Company. An adverse outcome in this matter could be material to the Company's results of operations, financial condition or liquidity for any particular period. The outcomes of lawsuits are inherently unpredictable and we may be unsuccessful in this ongoing litigation matter or any future claims or litigation.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Litigation Matters</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Express Scripts Litigation with Elevance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. In March 2016, Elevance filed a lawsuit in the United States District Court for the Southern District of New York alleging various breach of contract claims against Express Scripts relating to the parties' rights and obligations under the periodic pricing review section of the pharmacy benefit management agreement between the parties including allegations that Express Scripts failed to negotiate new pricing concessions in good faith, as well as various alleged service issues. Elevance also requested that the court enter declaratory judgment that Express Scripts is required to provide Elevance competitive benchmark pricing, that Elevance can terminate the agreement and that Express Scripts is required to provide Elevance with post-termination services at competitive benchmark pricing for one year following any termination by Elevance. Elevance claimed it is entitled to $13 billion in additional pricing concessions over the remaining term of the agreement, as well as $1.8 billion for one year following any contract termination by Elevance and $150 million damages for service issues ("Elevance's Allegations"). On April 19, 2016, in response to Elevance's complaint, Express Scripts filed its answer denying Elevance's Allegations in their entirety and asserting affirmative defenses and counterclaims against Elevance. The court subsequently granted Elevance's motion to dismiss two of six counts of Express Scripts' amended counterclaims. Express Scripts filed its Motion for Summary Judgment on August 27, 2021. Elevance completed filing of its Response to Express Scripts' Motion for Summary Judgment on October 16, 2021. Express Scripts filed its Reply in Support of its Motion for Summary Judgment on November 19, 2021. On March 31, 2022, the court granted summary judgment in favor of Express Scripts on all of Elevance's pricing claims for damages totaling $14.8 billion and on most of Elevance's claims relating to service issues. Elevance's only remaining service claims relate to the review or processing of prior authorizations, with alleged damages over $100&#160;million. On November 1, 2023, the parties signed a settlement agreement pursuant to which Express Scripts agreed to resolve the service-related claims. The settlement agreement is not an admission of liability or fault by Express Scripts, the Company or its subsidiaries. Following the settlement, Elevance retains the right to appeal the pricing-related claims that were previously dismissed by the court and Express Scripts retains the ability to reassert its own pricing-related claims in the event any appeal by Elevance is successful. Elevance filed its Notice of Appeal of its pricing-related claims on December 12, 2023. Elevance&#8217;s opening appellate brief is due March 25, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288970079024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-bottom:10pt"><span id="ia1cd7ace6b8e4804a5b34bf3f9213da6_446"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 25 &#8211; Segment Information</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See Note 1 to the Consolidated Financial Statements for a description of our segments. A description of our basis for reporting segment operating results is outlined below. Intersegment revenues primarily reflect pharmacy and care services transactions between the Evernorth Health Services and Cigna Healthcare segments.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company uses "pre-tax adjusted income (loss) from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management believes these metrics best reflect the underlying results of business operations and permit analysis of trends in underlying revenue, expenses and profitability. We define pre-tax adjusted income from operations as income before income taxes excluding pre-tax income (loss) attributable to noncontrolling interests, net realized investment results, amortization of acquired intangible assets, and special items. The Cigna Group's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">that management believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future underlying performance of the business. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company does not report total assets by segment because this is not a metric used to allocate resources or evaluate segment performance.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the special items charges (benefits) recorded by the Company, as well as the respective financial statement line items impacted: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.372%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="33" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">After-tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">After-tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">After-tax</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss (gain) on sale of businesses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,499</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,429</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,662)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,332)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charge for organizational efficiency plan<br/>&#160;(Selling, general and administrative expenses)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">252</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">193</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charges (benefits) associated with litigation matters<br/>&#160;(Selling, general and administrative expenses)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">201</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">171</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Integration and transaction-related costs<br/>&#160;(Selling, general and administrative expenses)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax (benefits), net<br/>&#160;(Income taxes, less amount attributable to noncontrolling interests)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,071)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt extinguishment costs </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total impact from special items</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,997</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">757</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,533)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,232)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Effective January 1, 2023, we adopted amended accounting guidance for long-duration insurance contracts. See Note 2 to the Consolidated Financial Statements for further information. Prior period summarized segment information has been retrospectively adjusted to conform to this new basis of accounting. Summarized segment financial information was as follows:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.349%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Evernorth Health Services</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cigna Healthcare</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Operations</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate and Eliminations</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="33" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from external customers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">147,588</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46,219</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">291</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">194,099</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,670</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,332</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(10,002)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net investment income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">241</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">597</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">305</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,166</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">153,499</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51,148</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">596</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(9,978)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">195,265</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net realized investment results from certain equity method investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">57</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">57</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">153,499</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51,205</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">596</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(9,978)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">195,322</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,438</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">569</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,035</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,768</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,664</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">76</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,995)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,513</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax adjustments to reconcile to adjusted income from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Income) attributable to noncontrolling interests</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(144)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(146)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net realized investment losses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">133</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">135</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,774</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,819</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Special items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on sale of businesses</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,481</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,499</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charge for organizational efficiency plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">252</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">252</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charges associated with litigation matters</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">157</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">201</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Integration and transaction-related costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted income (loss) from operations</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,442</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,478</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">96</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,698)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,318</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Evernorth Health Services</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cigna Healthcare</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Operations</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate and Eliminations</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="33" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from external customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135,786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,463&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,535&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,998)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net investment income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140,335&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,911&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,263&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,991)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180,518&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net realized investment results from certain equity method investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140,335&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,037&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,263&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,991)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180,644&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,283&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,937&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,421&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,470&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,101&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,595)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,397&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax adjustments to reconcile to adjusted income from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Income) attributable to noncontrolling interests</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net realized investment losses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,772&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,876&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Special items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) on sale of businesses</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,662)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,662)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charge for organizational efficiency plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Benefits) associated with litigation matters</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Integration and transaction-related costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted income (loss) from operations</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,127&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,099&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,466)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,269&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes the Company's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.046%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Evernorth Health Services</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cigna Healthcare</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate and Eliminations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from external customers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,203&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,271&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,474)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net investment income (loss)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131,912&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,643&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,989&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,475)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174,069&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net realized investment results from certain equity method investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131,912&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,643&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,989&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,475)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174,069&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,316&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,923&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,908&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,804&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,790)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,790&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax adjustments to reconcile to adjusted income from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Income) attributable to noncontrolling interests</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net realized investment losses (gains) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(247)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,937&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,998&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Special items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charge for organizational efficiency plan</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Benefits) associated with litigation matters</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Integration and transaction-related costs</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt extinguishment costs </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted income (loss) from operations</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,818&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,601&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">903&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,339)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,983&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Includes the Company's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. </span></div><div><span id="i447ccaf65a4944e2ab470d4dcddafa7a_953"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue from external customers includes Pharmacy revenues, Premiums and Fees and other revenues. Prior period amounts have been retrospectively adjusted to reflect adoption of amended accounting guidance for long-duration insurance contracts (as discussed in Note 2 to the Consolidated Financial Statements) and to reflect the merger of the U.S. Commercial and U.S. Government operating segments into the U.S. Healthcare operating segment (as discussed in Note 1 to the Consolidated Financial Statements). The following table presents these revenues by product, premium and service type:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.761%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.042%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Products (Pharmacy revenues) (ASC 606)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Network revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">67,514</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Home delivery and specialty revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">65,732</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61,283&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,391&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,047</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intercompany eliminations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5,050)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,416)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,398)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total pharmacy revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">137,243</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,566&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121,413&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance premiums (ASC 944)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cigna Healthcare</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">U.S. Healthcare</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employer insured</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16,490</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,771</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,896&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,362&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stop loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,143</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Individual and Family Plans</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,088</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,636&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,528&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,095</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Healthcare</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">40,587</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,188&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,149&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International Health</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,295</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Cigna Healthcare</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43,882</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,094&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,737&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Divested International businesses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intercompany eliminations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total premiums</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44,237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,916&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,154&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Services (Fees) (ASC 606)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Evernorth Health Services</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,866</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,234&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,070&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cigna Healthcare</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,566</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Operations</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">210</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intercompany eliminations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5,026)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,583)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,067)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total fees and other revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,619</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,881&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,953&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues from external customers</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">194,099</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179,363&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172,520&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">U.S. and foreign revenues from external customers are shown below. The Company's foreign revenues are generated by its foreign operating entities. In the periods shown, no single foreign country contributed more than 2% of consolidated revenues from external customers.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">189,840</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174,540&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166,626&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign countries </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,259</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues from external customers</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">194,099</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179,363&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172,520&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> The divested International businesses as described in Note 5 comprised of $1.6 billion and $3.2 billion in 2022 and 2021, respectively.</span></div>Revenues from U.S. Federal Government agencies, under a number of contracts, were 15% of consolidated revenues in 2023 and 14% in both 2022 and 2021. These amounts were reported in the Evernorth Health Services and Cigna Healthcare segments.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//280/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289103035600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule I - Condensed Financial Information of The Cigna Group<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract', window );"><strong>Condensed Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock', window );">Schedule I - Condensed Financial Information of The Cigna Group</a></td>
<td class="text"><div style="margin-bottom:10pt;text-align:center"><span id="i04dc17a35c054b6d8e303f8417c40a64_204"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">THE CIGNA GROUP AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">SCHEDULE I</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">CONDENSED FINANCIAL INFORMATION OF THE CIGNA GROUP</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">(REGISTRANT)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">STATEMENTS OF INCOME</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intercompany interest income</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">516</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">538</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income from operations</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">536</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest and other expense</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,332)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,215)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,197)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intercompany interest expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(147)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt extinguishment costs</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(131)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(914)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(881)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(878)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefits</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(192)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Loss of Parent Company</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(722)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(698)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(698)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity in income of subsidiaries</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,886</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,402&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,068&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders' net income</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,164</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,704&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,370&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders' other comprehensive income (loss), net of tax</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized appreciation (depreciation) on securities and derivatives</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">503</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,598)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(302)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net long-duration insurance and contractholder liabilities measurement adjustments</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(715)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net translation gains (losses) of foreign currencies</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Postretirement benefits liability adjustment</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shareholders' other comprehensive loss, net of tax</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(206)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(590)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders' comprehensive income</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,958</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,114&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,327&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 1 to Schedule 1 for further information.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">See Notes to Financial Statements on the following pages.</span></div><div style="margin-bottom:10pt;text-align:center"><span id="i119a375e8e4342d49fe6b4b067c6a227_195"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">THE CIGNA GROUP AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">SCHEDULE I</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">CONDENSED FINANCIAL INFORMATION OF THE CIGNA GROUP</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">(REGISTRANT)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">BALANCE SHEETS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">303</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">309</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments in subsidiaries</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">69,703</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70,679&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intercompany receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11,475</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">77</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TOTAL ASSETS</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">81,564</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81,265&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,448</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,854</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,295&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,302</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,044&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">27,151</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,815&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intercompany payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,874</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TOTAL LIABILITIES</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35,341</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,590&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders' Equity</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock (shares issued, 400 and 398; authorized, 600)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30,669</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,233&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,864)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,658)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41,652</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,940&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less treasury stock, at cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(24,238)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21,844)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TOTAL SHAREHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46,223</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,675&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">81,564</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81,265&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 1 to Schedule 1 for further information.</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">See Notes to Financial Statements on the following pages.</span></div><div style="margin-bottom:10pt;text-align:center"><span id="i328d757352ff45b69e14fe0a6159da0e_253"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">THE CIGNA GROUP AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">SCHEDULE I</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">CONDENSED FINANCIAL INFORMATION OF THE CIGNA GROUP</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">(REGISTRANT)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">STATEMENTS OF CASH FLOWS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shareholders' net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,164</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments to reconcile shareholders' net income</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">to net cash provided by operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity in income of subsidiaries</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5,886)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,402)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,068)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt extinguishment costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends received from subsidiaries</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,381</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,056&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,726&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">540</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">640</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NET CASH PROVIDED BY OPERATING ACTIVITIES</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,839</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,661&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,782&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change in amounts due from affiliates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">622</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(901)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,007)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net proceeds from short-term investments sold (purchased)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">622</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(802)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,057)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change in amounts due to affiliates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,473</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change in commercial paper</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,027)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments for debt extinguishment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayment of long-term debt</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2,822)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(430)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,199)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net proceeds on issuance of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,491</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">187</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common dividends paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,384)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,341)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2,284)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,607)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,742)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax withholding on stock compensation and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NET CASH USED IN FINANCING ACTIVITIES</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2,278)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(740)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,849)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">183</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,124)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of year</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">152</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,157&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of year </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">335</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncash Investing and Financing Activities:</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Net amounts due to/(from) affiliates settled through capital transactions</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5,221)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,037)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,429)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 1 to Schedule 1 for further information.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Includes restricted cash reported in Other non-current assets as of December&#160;31, 2023 and December 31, 2022.</span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">See Notes to Financial Statements on the following pages.</span></div><div style="margin-bottom:10pt;text-align:center"><span id="i3e615b8bf0cc4c7e95f93f8da300a4b8_1153"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">THE CIGNA GROUP AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SCHEDULE I</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CONDENSED FINANCIAL INFORMATION OF THE CIGNA GROUP</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(REGISTRANT)</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONDENSED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying condensed financial statements should be read in conjunction with the Consolidated Financial Statements and the accompanying notes thereto contained in this Annual Report on Form 10-K ("Form 10-K").</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> - For purposes of these condensed financial statements, The Cigna Group's (the "Company") wholly-owned and majority-owned subsidiaries are recorded using the equity method of accounting. On January 1, 2023, The Cigna Group and its subsidiaries adopted Targeted Improvements to the Accounting for Long-Duration Contracts, Accounting Standards Update ("ASU") 2018-12 and related amendments. See Note 2 - Summary of significant accounting policies included in Part II, Item 8 of this Form 10-K for a description of the key provisions and impacts.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Cigna Group, through its predecessor companies, was incorporated in Delaware in 1981. Cigna Corporation was renamed The Cigna Group in February 2023.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> - See Note 8 &#8211; Debt included in Part II, Item 8 of this Form 10-K for a description of the short-term and long-term debt obligations of The Cigna Group and its subsidiaries.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Short-term and Credit Facilities Debt</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revolving Credit Agreements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Our revolving credit agreements provide us with the ability to borrow amounts for general corporate purposes, including for the purpose of providing liquidity support if necessary under our commercial paper program discussed below. As of December&#160;31, 2023, there were no outstanding balances under these revolving credit agreements. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2023, The Cigna Group entered into the following revolving credit agreements (the "Credit Agreements"):</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a $4.0 billion five-year revolving credit and letter of credit agreement that will mature in April 2028 with an option to extend the maturity date for additional one-year periods, subject to consent of the banks. The Company can borrow up to $4.0 billion under the credit agreement for general corporate purposes, with up to $500 million available for issuance of letters of credit. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a $1.0 billion 364-day revolving credit agreement that will mature in April 2024. The Company can borrow up to $1.0 billion under the credit agreement for general corporate purposes. This agreement includes the option to "term out" any revolving loans that are outstanding at maturity by converting them into a term loan maturing on the one-year anniversary of conversion.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Each of the Credit Agreements include an option to increase commitments in an aggregate amount of up to $1.5 billion across both facilities for a maximum total commitment of $6.5 billion. The Credit Agreements allow for borrowings at either a base rate or an adjusted term Secured Overnight Funding Rate ("SOFR") plus, in each case, an applicable margin based on the Company's senior unsecured credit ratings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Each of the two facilities is diversified among 21 banks. Each facility also contains customary covenants and restrictions, including a financial covenant that the Company's leverage ratio, as defined in the Credit Agreements, may not exceed 60%, subject to certain exceptions upon the consummation of an acquisition. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Credit Agreements replaced a prior $3.0 billion five-year revolving credit and letter of credit agreement maturing on April 2027, a $1.0 billion three-year revolving credit agreement maturing on April 2025 and a $1.0 billion 364-day revolving credit agreement maturing in April 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Commercial Paper. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under our commercial paper program, we may issue short-term, unsecured commercial paper notes privately placed on a discounted basis through certain broker-dealers at any time not to exceed an aggregate amount of $5.0 billion. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. The commercial paper program had approximately</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$1.2&#160;billion outstanding at December&#160;31, 2023 and an average interest rate of 5.63%.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Long-Term Debt</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Debt Issuance and Debt Tender Offers. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February 5, 2024, we issued $4.5 billion of new senior notes. The proceeds from this debt were used to pay the consideration for the cash tender offers as described below. We intend to use the remaining net proceeds to fund the repayment of our senior notes maturing in March 2024 and for general corporate purposes, which may include repayment of indebtedness and repurchases of shares of our common stock.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Concurrent with the debt issuance, The Company and its subsidiaries commenced tender offers to purchase for cash up to $2.25 billion in aggregate principal amount of outstanding notes, which included any and all of the $1.0 billion senior notes due June 2024. Following the early tender results, we increased the tender offers to up to $2.55 billion. On February 22, 2024, we purchased $1.8 billion principal amount of notes at early settlement of the tender offers. The tender offers will expire on March 5, 2024. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 7, 2023, the Company issued $1.5&#160;billion of new senior notes. The proceeds of this issuance were used for general </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">corporate purposes, and included repayment of outstanding debt securities. Interest on this debt is paid semi-annually.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.486%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Proceeds</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$700 million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 15, 2026</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.685%</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$698 million</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$800 million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 15, 2033</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.400%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$796 million</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Redeemable at any time discounted at the U.S. Treasury rate plus 20 basis points. Redeemable at par on or after March 15, 2024.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Redeemable at any time discounted at the U.S. Treasury rate plus 25 basis points. Redeemable at par on or after December 15, 2032. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Debt Maturities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Maturities of the Company's long-term debt are as follows and exclude the impacts of the 2024 debt issuance and debt tender offers discussed above. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:88.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,214</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,957</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,734</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,056</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maturities after 2028</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15,091</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Debt Covenants. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company was in compliance with its debt covenants as of December&#160;31, 2023.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> - The Company's intercompany receivables consist primarily of net intercompany loan amounts due from Evernorth Health, Inc. of $8.5&#160;billion as of December&#160;31, 2023 and $8.3&#160;billion as of December&#160;31, 2022. Interest income on the loan receivable was accrued at an average rate of 5.21% in 2023.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's intercompany payables primarily reflect intercompany balances related to cash pooling arrangements as well as net intercompany loan borrowing from three indirect wholly-owned subsidiaries as of December&#160;31, 2023. Interest expense on the loan payable was accrued at an average rate of 3.65% in 2023.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> - The Company guaranteed approximately $2.9 billion primarily related to intercompany indebtedness and financial obligations of certain direct and indirect wholly-owned subsidiaries. There were immaterial liabilities required for these guarantees as of December&#160;31, 2023. Effective January 2024, the amount of such guarantees increased to $6.4 billion.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 5</span> - In February 2024, as part of our existing share repurchase program, we entered into separate ASR agreements ("2024 ASR agreements") with Deutsche Bank AG and Bank of America, N.A. (collectively, the "2024 Counterparties") to repurchase $3.2 billion of common stock in aggregate. We remitted $3.2 billion to the 2024 Counterparties and received an initial delivery of approximately 7.6&#160;million shares of our common stock on February 15, 2024 representing $2.6 billion of the total remitted. We expect final settlement under the 2024 ASR agreements to occur in the second quarter of 2024.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.5-04(Schedule I))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480922/205-10-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289064810608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II - Valuation and Qualifying Accounts and Reserves<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsAbstract', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">Schedule II - Valuation and Qualifying Accounts and Reserves</a></td>
<td class="text">THE CIGNA GROUP AND SUBSIDIARIES<div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SCHEDULE II</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">VALUATION AND QUALIFYING ACCOUNTS AND RESERVES</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.045%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at beginning of year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charged (Credited) to costs and expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charged (Credited) to other accounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at end of year</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investment asset valuation reserves</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(22)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial mortgage loans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">160</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(88)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">163</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax asset valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">208</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,286</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,498</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reinsurance recoverables </span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investment asset valuation reserves</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial mortgage loans</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax asset valuation allowance </span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reinsurance recoverables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investment asset valuation reserves</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial mortgage loans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax asset valuation allowance </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reinsurance recoverables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:700;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts ("LDTI") in 2023. See Note 2 to the Consolidated Financial Statements included in Part II, Item 8 of this Form 10-K for further information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288964584112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288967990256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Basis of Presentation</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Consolidated Financial Statements include the accounts of The Cigna Group and its consolidated subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. These Consolidated Financial Statements were prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"). Certain amounts in prior years related to the adoption of Targeted Improvements for the Accounting of Long-Duration Contracts, have been reclassified to conform to the current year presentation. See "Recent Accounting Pronouncements" below.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amounts recorded in the Consolidated Financial Statements necessarily reflect management's estimates and assumptions about medical costs, investment and receivable valuations, interest rates and other factors. Significant estimates are discussed throughout these Notes; however, actual results could differ from those estimates. The impact of a change in estimate is generally included in earnings in the period of adjustment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements, Recently Adopted Accounting Guidance and Accounting Guidance Not Yet Adopted</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Recent Accounting Pronouncements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Targeted Improvements to the Accounting for Long-Duration Contracts, Accounting Standards Update ("ASU") 2018-12 and related amendments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Cigna Group adopted LDTI January 1, 2023, which includes the following key provisions:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Changes to the measurement of the future policy benefits liability for traditional and limited-pay insurance contracts:</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Assumptions used to measure cash flows (such as mortality, morbidity and lapse assumptions) are updated at least annually with the effect of changes in those assumptions remeasured retrospectively and reflected in current period net income. </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Discount rate assumptions are updated quarterly based on market-level yields for low credit risk fixed income instruments ("upper-medium grade fixed income instrument"), with any changes reflected in other comprehensive income. The upper-medium grade fixed income instrument yield is interpreted to mean A-rated.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Deferred policy acquisition costs ("DAC") related to long-duration insurance contracts are amortized on a constant-level basis over the expected term of the related contracts. Other related deferred or capitalized balances (such as unearned revenue liability and value of business acquired) may use this simplified amortization method. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Market risk benefits ("MRB"), defined as protecting the contractholder from other-than-nominal capital market risk and exposing the insurer to that risk, are measured at fair value, with changes in fair value recognized in net income each period, except for the effect of the Company's change in nonperformance risk (own credit risk), which is recognized in other comprehensive income. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Additional disclosures, including disaggregated roll forwards for the liability for future policy benefits, market risk benefits, contractholder deposit funds and DAC, as well as information about significant inputs, judgments, assumptions and methods used in measurement.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The transition methods applied at adoption were:</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The liability for future policy benefits was remeasured using a modified retrospective approach applied to all outstanding contracts as of the beginning of the earliest period presented and was recognized in the opening balance of retained earnings. The impact of remeasuring the future policy benefits liability for the discount rate was recorded through accumulated other comprehensive income. </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">DAC followed the transition method used for future policyholder benefits.</span></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Market risk benefits were remeasured at fair value at the beginning of the earliest period presented. The difference between this fair value and carrying value was recognized in the opening balance of retained earnings, excluding the effect of the Company's change in nonperformance risk (own credit risk), which was recognized in accumulated other comprehensive income. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Effects of adoption:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The new guidance applies to our long-duration insurance products predominantly within the Cigna Healthcare segment and Other Operations.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The cumulative effects of adopting the new standard were immaterial. The impacts were a decrease to January 1, 2021 Shareholders' equity of $139 million and an increase to Shareholders' net income for the years ended December 31, 2022 and December 31, 2021 of $36 million and $5 million, respectively. The corresponding impact to diluted earnings per share was an increase of $0.11 and $0.02 for the years ended December 31, 2022 and December 31, 2021, respectively. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The prior periods within our Consolidated Statements of Income, Consolidated Statements of Comprehensive Income, Consolidated Balance Sheets, Consolidated Statements of Changes in Total Equity and Consolidated Statements of Cash Flows were restated to conform to the current presentation. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Prior period balances in the Company's footnote disclosures have been updated to reflect adjustments resulting from the adoption of this standard. Refer to Note 10 to the Consolidated Financial Statements for the Company's updated accounting policies. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">It is possible that our income recognition pattern could change on a prospective basis for several reasons: </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Applying periodic assumption updates, versus the locked-in model, may change our timing of profit or loss recognition. </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">DAC amortization is on a constant level basis over the expected term of the related contracts and no longer tied to the emergence of profit on such contracts. </span></div><div style="text-indent:45pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, in December 2022, the Financial Accounting Standards Board ("FASB") published ASU 2022-05, which simplified the retrospective adoption of LDTI by permitting companies to make an accounting policy election to exclude contracts that are sold and removed from the balance sheet prior to the effective date of the standard from the retrospective adoption of LDTI. The Cigna Group made this policy election for the contracts sold in the Chubb transaction and our divested interest in a joint venture in T&#252;rkiye. </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Accounting Guidance Not Yet Adopted</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">There are no significant accounting pronouncements not yet adopted as of December&#160;31, 2023.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash and cash equivalents are carried at cost that approximates fair value. Cash equivalents consist of short-term investments with maturities of three months or less from the time of purchase. The Company reclassifies cash overdraft positions to liabilities when the legal right of offset does not exist.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inventories consist of prescription drugs and medical supplies and are stated at the lower of first-in-first-out cost or net realizable value.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_OtherAssetsCurrentAndNoncurrentPolicyPolicyTextBlock', window );">Other Assets (Current and Non-Current)</a></td>
<td class="text">Other current assets consist primarily of prepaid expenses, income tax receivables, accrued investment income and the current portion of reinsurance recoverables. Other assets (non-current) consist primarily of the Company's net deferred tax asset associated with foreign tax attributes (see Note 23) and the carrying value of our equity-method investments in business-related joint ventures in China, the U.S. and other foreign jurisdictions. Earnings or losses from these equity-method investments in joint ventures are recorded in Fees and other revenues. See Note 15 for additional information on unconsolidated subsidiaries. Additionally, Other assets (non-current) includes operating lease right-of-use assets, various insurance-related assets and overfunded pension obligations (see Note 18). See Note 21 for the Company's accounting policy related to leases.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_RedeemableNoncontrollingInterestsPolicyPolicyTextBlock', window );">Redeemable Noncontrolling Interest</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Redeemable noncontrolling interests in our Consolidated Balance Sheets represents the noncontrolling shareholders' preferred and common stock interests of the Company's consolidated less than fully owned subsidiaries. Those shareholders may choose to require the Company to purchase their equity interest. For certain entities, we may also have the right to require those shareholders to sell their equity interest to us. As these redeemable noncontrolling interests provide for redemption features not solely within our control, we classify the redeemable noncontrolling interests outside of permanent equity. The noncontrolling interest was initially recorded at fair value. In subsequent reporting periods, the values are adjusted to reflect the earnings, losses and distributions attributable to the noncontrolling interest. When a shareholder's right to require the Company to purchase its equity interest is exercisable, the redeemable noncontrolling interest is recorded at estimated redemption value. When the estimated redemption value for a redeemable noncontrolling interest exceeds its initial carrying value, an adjustment to increase or decrease the redeemable noncontrolling interest is recorded with an offsetting adjustment to Retained earnings or Additional paid-in capital in the absence of Retained earnings. When an adjustment is made to the carrying value of the redeemable noncontrolling interest, the calculation of Shareholders' net income per share will be adjusted if the redemption value exceeds fair value.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AccountsPayableAccruedExpensesOtherLiabilitiesPolicyPolicyTextBlock', window );">Accrued Expenses and Other Current and Non-Current Liabilities</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued expenses and other liabilities (current) primarily includes financial and performance guarantee liabilities (see section G) and other liabilities arising from pharmacy contracts, management compensation, various insurance-related liabilities, including experience-rated refunds, reinsurance contracts and the risk adjustment and minimum medical loss ratio rebate accruals under The Patient Protection and Affordable Care Act (the "ACA"), and amounts due to financial institutions under the accounts receivable factoring facility (see Note 3). Other non-current liabilities primarily include uncertain tax positions (see Note 23), amounts held for self-funded clients to cover the administration and payment of claims that may emerge post contract termination, lease liabilities (see Note 21) and underfunded pension obligations (see Note 18).</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company accrues for legal and regulatory matters when a loss contingency is both probable and estimable. The estimated loss is generally recorded in Selling, general and administrative expenses and represents the Company's best estimate of the loss contingency. If the loss estimate is a range, the Company accrues the minimum amount in the range if no amount is better than any other estimated amount in the range. Legal costs to defend the Company's litigation and arbitration matters are expensed as incurred in cases that the Company cannot reasonably estimate the ultimate cost to defend. If the Company can reasonably estimate the cost to defend, a liability </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">for these costs is accrued when the claim is reported. Litigation and legal or regulatory matters that the Company has identified with a reasonable possibility of material loss are described in Note 24.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Translation of Foreign Currencies</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company generally conducts its international business through foreign operating entities that maintain assets and liabilities in local currencies that are their functional currencies. The Company uses exchange rates as of the balance sheet date to translate assets and liabilities into U.S. dollars. Translation gains or losses on functional currencies, net of applicable taxes, are recorded in Accumulated other comprehensive loss. The Company uses average monthly exchange rates during the year to translate revenues and expenses into U.S. dollars.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Pharmacy revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Pharmacy revenues are primarily derived from providing pharmacy benefit management services to clients and customers. Pharmacy revenues are recognized when control of the promised goods or services is transferred to clients and customers, in an amount that reflects the consideration the Company expects to receive for those goods or services.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company provides or makes available various services supporting benefit management and claims administration and is generally obligated to provide prescription drugs to clients' members using multiple distribution methods including retail networks, home delivery and specialty pharmacies. These goods and services are integrated into a single performance obligation to process claims, dispense prescription drugs and provide other services over the contract period (generally three years). This performance obligation is satisfied as the business stands ready to fulfill its obligation.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenues for dispensing prescription drugs through retail pharmacies are reported gross and consist of the prescription price (ingredient cost and dispensing fee) contracted with clients, including the customer copayment and any associated fees for services, because the Company acts as the principal in these arrangements. When a prescription is presented to a retail network pharmacy, the Company is solely responsible for customer eligibility, drug utilization review, drug-to-drug interaction review, any required clinical intervention, plan provision information, payment to the pharmacy and client billing. These revenues are recognized based on the full prescription price when the pharmacy claim is processed and approved for payment. The Company also provides benefit design and formulary consultation services to clients and negotiates separate contractual relationships with clients and network pharmacies. These factors indicate that the Company has control over these transactions until the prescription is processed. Revenues are billed, due and recognized at contract rates either on a periodic basis or as services are provided (such as based on volume of claims processed). This recognition pattern aligns with the benefits from services provided.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Home delivery and specialty pharmacy revenues are due and recognized as each prescription is shipped, net of reserves for discounts and contractual allowances estimated based on historical experience. Any differences between estimates and actual collections are reflected in Pharmacy revenues when payments are received. Historically, adjustments to original estimates and returns have not been material. The Company has elected the practical expedient to account for shipping and handling as a fulfillment activity.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may also provide certain financial and performance guarantees, including a minimum level of discounts a client may receive, generic utilization rates and various service levels. Clients may be entitled to receive compensation if we fail to meet the guarantees. Actual performance is compared to the contractual guarantee for each measure throughout the period and the Company defers revenue for any estimated payouts within Accrued expenses and other liabilities (current). These estimates are adjusted and paid at the end of the annual guarantee period. Historically, adjustments to original estimates have not been material. The liability for these financial and performance guarantees was $1.6 billion as of December&#160;31, 2023 and $1.3 billion as of December&#160;31, 2022.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company administers programs through which we may receive rebates and other vendor consideration from pharmaceutical manufacturers. The amounts of such rebates or other vendor consideration shared with pharmacy benefit management services clients vary based on the contractual arrangement with the client and in some cases the type of consideration received from the pharmaceutical manufacturer. Rebates and other vendor consideration payable to pharmacy benefit management services clients are recorded as a reduction of Pharmacy revenues. Estimated amounts payable to clients are based on contractual sharing arrangements between the Company and the client and these amounts are adjusted when amounts are collected from pharmaceutical manufacturers in accordance with the contractual arrangement between the Company and the client. Historically, these adjustments have not been material.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In retail, home delivery and specialty transactions, amounts may be collected from third-party payors. These are billed and collected in accordance with the Company's standard accounts receivable collection procedures. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other pharmacy service revenues are earned by distributing specialty pharmaceuticals and medical supplies to providers, clinics and hospitals. These revenues are billed, due and recognized at contracted rates as prescriptions and supplies are shipped and services are provided.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Pharmacy costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Pharmacy costs include the cost of prescriptions sold, network pharmacy claim costs and copayments. Also included are direct costs of dispensing prescriptions including supplies, shipping and handling and direct costs associated with clinical programs, such as drug utilization management and medication adherence counseling. Home delivery and specialty pharmacy costs are recognized when the drug is shipped and retail network costs are recognized when the drug is processed and approved for payment. Rebates and other vendor consideration received when providing pharmacy benefit management services are recorded as a reduction of pharmacy costs. Rebates are recognized as prescriptions are shipped or processed and approved for payment. Historically, the effect of adjustments resulting from the reconciliation of rebates recognized to the amounts billed and collected, net of contractual allowances, has not been material. The Company maintains reimbursement guarantees with certain retail network pharmacies. For each such guarantee, the Company records a pharmacy and other service costs payable or prepaid asset for applicable retail network claims based on our actual performance throughout the period against the contractual reimbursement rate. The Company's contracts with certain retail pharmacies give the Company the right to adjust reimbursement rates during the annual guarantee period.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Incremental costs of obtaining service and pharmacy contracts for short-term arrangements are expensed as incurred.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">H.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:7.73pt;text-decoration:underline">Premiums and Related Expenses</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Premiums for short-duration group health, accident and life insurance and managed care coverages are recognized as revenue on a pro rata basis over the contract period. Benefits and expenses are recognized when incurred and, for our Cigna Healthcare business, are presented net of pharmaceutical manufacturer rebates. For experience-rated contracts, premium revenue includes an adjustment for experience-rated refunds based on contract terms and calculated using the customer's experience (including estimates of incurred but not reported claims).</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Premiums received for the Company's Medicare Advantage plans, Medicare Part D plans and Individual and Family Plans from the Centers for Medicare and Medicaid Services ("CMS") and customers are recognized as revenue ratably over the contract period. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CMS provides risk-adjusted premium payments for Medicare Advantage plans and Medicare Part D plans based on our customer demographics and medical diagnoses, which may change from period to period based on the underlying health of our customers. The Company recognizes changes to risk-adjusted premiums as revenue when the amounts are determinable and collection is reasonably assured. Revenue adjustments are generally settled semi-annually with CMS. The final revenue adjustment is generally settled with CMS in the year following the contract year.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medicare Part D premiums include payments from CMS for risk-sharing adjustments that are estimated quarterly based on claim experience by comparing actual incurred prescription drug costs to the estimated costs submitted in the original contracts. These adjustments may result in more or less revenue from CMS. Final revenue adjustments generally occur in the year following the contract year. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The ACA prescribed a risk-adjustment program to mitigate the risk for participating health insurance companies selling individual coverage on the public exchanges. The risk-adjustment program reallocates funds from insurers with lower risk populations to insurers with higher risk populations based on the relative risk scores of participants. We estimate our receivable or payable based on the risk of our customers compared to the risk of other customers in the same state and market, considering data obtained from industry studies and the United States Department of Health and Human Services ("HHS"). Receivables or payables are recorded as adjustments to premium revenue based on our year-to-date experience when the amounts are reasonably estimable and collection is reasonably assured. Final revenue adjustments are determined by HHS in the year following the policy year.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Premium revenue may also include an adjustment to reflect the estimated effect of rebates due to customers under medical loss ratio provisions of the ACA. These rebate liabilities are settled in the subsequent year.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Premiums for long-duration insurance contracts, including individual life, accident and supplemental health insurance and annuity products, and excluding universal life and investment-related products, are recognized as revenue when due. Cigna Healthcare's long-duration premium revenues are associated with contracts that provide coverage greater than one year or are guaranteed to be renewed at the option of the policyholder beyond one year. Benefits and expenses are matched with premiums. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue for universal life products is recognized as follows:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Investment income on assets supporting universal life products is recognized in Net investment income as earned.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Charges for mortality, administration and policy surrender are recognized in Premiums as earned. Administrative fees are considered earned when services are provided.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Benefits and expenses for universal life products consist of benefit claims in excess of policyholder account balances and income earned by policyholders. Expenses are recognized when claims are incurred and income is credited to policyholders in accordance with contract provisions.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The unrecognized portion of premiums received is recorded as unearned premiums included in Insurance and contractholder liabilities (current and non-current) (see Note 10 to the Consolidated Financial Statements for further information).</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">I.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:11.61pt;text-decoration:underline">Fees and Related Expenses</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The majority of the Company's service fees are derived from administrative services only ("ASO") arrangements, fee-for-service clinical solutions, Wholesale Marketplace Drug Formulary Management services, health benefit management services and administration of services to specialty pharmacy manufacturers.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASO arrangements allow plan sponsors to self-fund claims and assume the risk of medical or other benefit costs. Most of the Company's ASO arrangements are for medical and specialty solutions, including pharmacy benefits. Generally, the Company's ASO arrangements are short-term. Contract modifications typically occur on renewal and are prospective in nature.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In return for fees from these clients, the Company provides access to our participating provider networks and other services supporting benefit management, including claims administration, behavioral health services, disease management, utilization management and cost containment programs. In general, the Company considers these services to be a combined performance obligation to provide cost effective administration of plan benefits over the contract period. Fees are billed, due and recognized monthly at contracted rates based on current membership or utilization. This recognition pattern aligns with the benefits from services provided to clients. These revenues are reported in Fees and other revenues in the Consolidated Statements of Income.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company may also provide performance guarantees that provide potential refunds to clients if certain service standards, clinical outcomes or financial metrics are not met. If these standards, outcomes and metrics are not met, the Company may be financially at risk up to a stated percentage of the contracted fee or a stated dollar amount. The Company defers revenue by recording a liability for estimated payouts associated with these guarantees within Accrued expenses and other liabilities. The amount of revenue deferred is estimated for each type of guarantee using either a most likely amount or expected value method depending on the nature of the guarantee and the information available to estimate refunds. Estimates are refined each reporting period as additional information on the Company's performance becomes available and upon final reconciliation and settlement following the guarantee period. Amounts accrued and paid for these performance guarantees during the reporting periods were not material.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expenses associated with administrative programs and services are recognized as incurred in Selling, general and administrative expenses.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company also earns revenue, as part of its integrated pharmacy benefits performance obligation, by offering fee-for-service clinical solutions to our clients, such as drug utilization management and medication adherence counseling. These clinical programs help clients to drive better health outcomes at a lower cost by identifying and addressing potentially unsafe or wasteful prescribing, dispensing and utilization of prescription drugs and communicating with, or supporting communications with physicians, pharmacies and patients. Fees are billed, due and recognized at contracted rates either on a periodic basis or as services are provided. This recognition pattern aligns with the benefits from services provided. These revenues are reported in Fees and other revenues in the Consolidated Statements of Income. Direct costs associated with these programs are recognized in Pharmacy and other service costs, and other related expenses are recorded as incurred in Selling, general and administrative expenses.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company earns fees from our Wholesale Marketplace Drug Formulary Management services. These services include either our drug formulary administrative service arrangements or our formulary processing arrangements. Drug formulary administrative services may include formulary consultation, administration of rebate contracts, rebate submission, collection from drug manufacturers and the distribution of rebates to clients. Services may also include facilitating audits of data submissions and reporting of rebates to clients. Clients agree to pay administrative fees that are billed, due and recognized at contracted rates as services are performed. These revenues are reported gross in Fees and other revenues and associated costs are reported in Pharmacy and other service costs in the Consolidated Statements of Income. For certain other clients in our formulary processing arrangements, the Company does not control the right to retain rebates before they are transferred to the client for services performed. Clients agree to allow the Company to retain a portion of each rebate collected in exchange for formulary processing services provided. These drug formulary service and administrative fee revenues are reported net in Fees and other revenues in the Consolidated Statements of Income. Revenue is recognized as rebates are processed.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company also earns fees by providing health benefit management solutions that drive cost reductions and improve quality outcomes. Clients are primarily sponsors of health benefit plans and fees may be stated as a per-member-per-month fee or as a per-claim fee. The Company considers the services to be a single performance obligation to stand ready to provide utilization management services over the contract period (generally three years). In certain arrangements, the Company assumes the financial obligation for third-party provider costs for medical services provided to the health plan's customers. Fees are recorded gross in Fees and other revenues in the Consolidated Statements of Income because the Company is acting as a principal in arranging for and controlling the services provided by third-party network providers. Contractual fees vary based on enrollment and provider costs and are billed, due </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and recognized monthly. Direct costs associated with these programs are recognized in Pharmacy and other service costs, and other related expenses are recorded in Selling, general and administrative expenses as incurred.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain health benefit management contracts require the Company to share the results of medical cost experience that differ from specified targets. This variable consideration is estimated at contract inception and adjusted through the contract period. The estimated profits and costs are recognized net in Fees and other revenues.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company also earns other service fees related to administrating services to specialty pharmacy manufacturers that are recorded in Fees and other revenues in the Consolidated Statements of Income. These revenues are billed, due and recognized at contracted rates as services are provided.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Goods and Service</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Pharmacy revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Pharmacy revenues are primarily derived from providing pharmacy benefit management services to clients and customers. Pharmacy revenues are recognized when control of the promised goods or services is transferred to clients and customers, in an amount that reflects the consideration the Company expects to receive for those goods or services.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company provides or makes available various services supporting benefit management and claims administration and is generally obligated to provide prescription drugs to clients' members using multiple distribution methods including retail networks, home delivery and specialty pharmacies. These goods and services are integrated into a single performance obligation to process claims, dispense prescription drugs and provide other services over the contract period (generally three years). This performance obligation is satisfied as the business stands ready to fulfill its obligation.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenues for dispensing prescription drugs through retail pharmacies are reported gross and consist of the prescription price (ingredient cost and dispensing fee) contracted with clients, including the customer copayment and any associated fees for services, because the Company acts as the principal in these arrangements. When a prescription is presented to a retail network pharmacy, the Company is solely responsible for customer eligibility, drug utilization review, drug-to-drug interaction review, any required clinical intervention, plan provision information, payment to the pharmacy and client billing. These revenues are recognized based on the full prescription price when the pharmacy claim is processed and approved for payment. The Company also provides benefit design and formulary consultation services to clients and negotiates separate contractual relationships with clients and network pharmacies. These factors indicate that the Company has control over these transactions until the prescription is processed. Revenues are billed, due and recognized at contract rates either on a periodic basis or as services are provided (such as based on volume of claims processed). This recognition pattern aligns with the benefits from services provided.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Home delivery and specialty pharmacy revenues are due and recognized as each prescription is shipped, net of reserves for discounts and contractual allowances estimated based on historical experience. Any differences between estimates and actual collections are reflected in Pharmacy revenues when payments are received. Historically, adjustments to original estimates and returns have not been material. The Company has elected the practical expedient to account for shipping and handling as a fulfillment activity.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may also provide certain financial and performance guarantees, including a minimum level of discounts a client may receive, generic utilization rates and various service levels. Clients may be entitled to receive compensation if we fail to meet the guarantees. Actual performance is compared to the contractual guarantee for each measure throughout the period and the Company defers revenue for any estimated payouts within Accrued expenses and other liabilities (current). These estimates are adjusted and paid at the end of the annual guarantee period. Historically, adjustments to original estimates have not been material. The liability for these financial and performance guarantees was $1.6 billion as of December&#160;31, 2023 and $1.3 billion as of December&#160;31, 2022.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company administers programs through which we may receive rebates and other vendor consideration from pharmaceutical manufacturers. The amounts of such rebates or other vendor consideration shared with pharmacy benefit management services clients vary based on the contractual arrangement with the client and in some cases the type of consideration received from the pharmaceutical manufacturer. Rebates and other vendor consideration payable to pharmacy benefit management services clients are recorded as a reduction of Pharmacy revenues. Estimated amounts payable to clients are based on contractual sharing arrangements between the Company and the client and these amounts are adjusted when amounts are collected from pharmaceutical manufacturers in accordance with the contractual arrangement between the Company and the client. Historically, these adjustments have not been material.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In retail, home delivery and specialty transactions, amounts may be collected from third-party payors. These are billed and collected in accordance with the Company's standard accounts receivable collection procedures. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other pharmacy service revenues are earned by distributing specialty pharmaceuticals and medical supplies to providers, clinics and hospitals. These revenues are billed, due and recognized at contracted rates as prescriptions and supplies are shipped and services are provided.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Pharmacy costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Pharmacy costs include the cost of prescriptions sold, network pharmacy claim costs and copayments. Also included are direct costs of dispensing prescriptions including supplies, shipping and handling and direct costs associated with clinical programs, such as drug utilization management and medication adherence counseling. Home delivery and specialty pharmacy costs are recognized when the drug is shipped and retail network costs are recognized when the drug is processed and approved for payment. Rebates and other vendor consideration received when providing pharmacy benefit management services are recorded as a reduction of pharmacy costs. Rebates are recognized as prescriptions are shipped or processed and approved for payment. Historically, the effect of adjustments resulting from the reconciliation of rebates recognized to the amounts billed and collected, net of contractual allowances, has not been material. The Company maintains reimbursement guarantees with certain retail network pharmacies. For each such guarantee, the Company records a pharmacy and other service costs payable or prepaid asset for applicable retail network claims based on our actual performance throughout the period against the contractual reimbursement rate. The Company's contracts with certain retail pharmacies give the Company the right to adjust reimbursement rates during the annual guarantee period.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Incremental costs of obtaining service and pharmacy contracts for short-term arrangements are expensed as incurred.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">H.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:7.73pt;text-decoration:underline">Premiums and Related Expenses</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Premiums for short-duration group health, accident and life insurance and managed care coverages are recognized as revenue on a pro rata basis over the contract period. Benefits and expenses are recognized when incurred and, for our Cigna Healthcare business, are presented net of pharmaceutical manufacturer rebates. For experience-rated contracts, premium revenue includes an adjustment for experience-rated refunds based on contract terms and calculated using the customer's experience (including estimates of incurred but not reported claims).</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Premiums received for the Company's Medicare Advantage plans, Medicare Part D plans and Individual and Family Plans from the Centers for Medicare and Medicaid Services ("CMS") and customers are recognized as revenue ratably over the contract period. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CMS provides risk-adjusted premium payments for Medicare Advantage plans and Medicare Part D plans based on our customer demographics and medical diagnoses, which may change from period to period based on the underlying health of our customers. The Company recognizes changes to risk-adjusted premiums as revenue when the amounts are determinable and collection is reasonably assured. Revenue adjustments are generally settled semi-annually with CMS. The final revenue adjustment is generally settled with CMS in the year following the contract year.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medicare Part D premiums include payments from CMS for risk-sharing adjustments that are estimated quarterly based on claim experience by comparing actual incurred prescription drug costs to the estimated costs submitted in the original contracts. These adjustments may result in more or less revenue from CMS. Final revenue adjustments generally occur in the year following the contract year. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The ACA prescribed a risk-adjustment program to mitigate the risk for participating health insurance companies selling individual coverage on the public exchanges. The risk-adjustment program reallocates funds from insurers with lower risk populations to insurers with higher risk populations based on the relative risk scores of participants. We estimate our receivable or payable based on the risk of our customers compared to the risk of other customers in the same state and market, considering data obtained from industry studies and the United States Department of Health and Human Services ("HHS"). Receivables or payables are recorded as adjustments to premium revenue based on our year-to-date experience when the amounts are reasonably estimable and collection is reasonably assured. Final revenue adjustments are determined by HHS in the year following the policy year.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Premium revenue may also include an adjustment to reflect the estimated effect of rebates due to customers under medical loss ratio provisions of the ACA. These rebate liabilities are settled in the subsequent year.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Premiums for long-duration insurance contracts, including individual life, accident and supplemental health insurance and annuity products, and excluding universal life and investment-related products, are recognized as revenue when due. Cigna Healthcare's long-duration premium revenues are associated with contracts that provide coverage greater than one year or are guaranteed to be renewed at the option of the policyholder beyond one year. Benefits and expenses are matched with premiums. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue for universal life products is recognized as follows:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Investment income on assets supporting universal life products is recognized in Net investment income as earned.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Charges for mortality, administration and policy surrender are recognized in Premiums as earned. Administrative fees are considered earned when services are provided.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Benefits and expenses for universal life products consist of benefit claims in excess of policyholder account balances and income earned by policyholders. Expenses are recognized when claims are incurred and income is credited to policyholders in accordance with contract provisions.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The unrecognized portion of premiums received is recorded as unearned premiums included in Insurance and contractholder liabilities (current and non-current) (see Note 10 to the Consolidated Financial Statements for further information).</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">I.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:11.61pt;text-decoration:underline">Fees and Related Expenses</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The majority of the Company's service fees are derived from administrative services only ("ASO") arrangements, fee-for-service clinical solutions, Wholesale Marketplace Drug Formulary Management services, health benefit management services and administration of services to specialty pharmacy manufacturers.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASO arrangements allow plan sponsors to self-fund claims and assume the risk of medical or other benefit costs. Most of the Company's ASO arrangements are for medical and specialty solutions, including pharmacy benefits. Generally, the Company's ASO arrangements are short-term. Contract modifications typically occur on renewal and are prospective in nature.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In return for fees from these clients, the Company provides access to our participating provider networks and other services supporting benefit management, including claims administration, behavioral health services, disease management, utilization management and cost containment programs. In general, the Company considers these services to be a combined performance obligation to provide cost effective administration of plan benefits over the contract period. Fees are billed, due and recognized monthly at contracted rates based on current membership or utilization. This recognition pattern aligns with the benefits from services provided to clients. These revenues are reported in Fees and other revenues in the Consolidated Statements of Income.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company may also provide performance guarantees that provide potential refunds to clients if certain service standards, clinical outcomes or financial metrics are not met. If these standards, outcomes and metrics are not met, the Company may be financially at risk up to a stated percentage of the contracted fee or a stated dollar amount. The Company defers revenue by recording a liability for estimated payouts associated with these guarantees within Accrued expenses and other liabilities. The amount of revenue deferred is estimated for each type of guarantee using either a most likely amount or expected value method depending on the nature of the guarantee and the information available to estimate refunds. Estimates are refined each reporting period as additional information on the Company's performance becomes available and upon final reconciliation and settlement following the guarantee period. Amounts accrued and paid for these performance guarantees during the reporting periods were not material.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expenses associated with administrative programs and services are recognized as incurred in Selling, general and administrative expenses.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company also earns revenue, as part of its integrated pharmacy benefits performance obligation, by offering fee-for-service clinical solutions to our clients, such as drug utilization management and medication adherence counseling. These clinical programs help clients to drive better health outcomes at a lower cost by identifying and addressing potentially unsafe or wasteful prescribing, dispensing and utilization of prescription drugs and communicating with, or supporting communications with physicians, pharmacies and patients. Fees are billed, due and recognized at contracted rates either on a periodic basis or as services are provided. This recognition pattern aligns with the benefits from services provided. These revenues are reported in Fees and other revenues in the Consolidated Statements of Income. Direct costs associated with these programs are recognized in Pharmacy and other service costs, and other related expenses are recorded as incurred in Selling, general and administrative expenses.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company earns fees from our Wholesale Marketplace Drug Formulary Management services. These services include either our drug formulary administrative service arrangements or our formulary processing arrangements. Drug formulary administrative services may include formulary consultation, administration of rebate contracts, rebate submission, collection from drug manufacturers and the distribution of rebates to clients. Services may also include facilitating audits of data submissions and reporting of rebates to clients. Clients agree to pay administrative fees that are billed, due and recognized at contracted rates as services are performed. These revenues are reported gross in Fees and other revenues and associated costs are reported in Pharmacy and other service costs in the Consolidated Statements of Income. For certain other clients in our formulary processing arrangements, the Company does not control the right to retain rebates before they are transferred to the client for services performed. Clients agree to allow the Company to retain a portion of each rebate collected in exchange for formulary processing services provided. These drug formulary service and administrative fee revenues are reported net in Fees and other revenues in the Consolidated Statements of Income. Revenue is recognized as rebates are processed.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company also earns fees by providing health benefit management solutions that drive cost reductions and improve quality outcomes. Clients are primarily sponsors of health benefit plans and fees may be stated as a per-member-per-month fee or as a per-claim fee. The Company considers the services to be a single performance obligation to stand ready to provide utilization management services over the contract period (generally three years). In certain arrangements, the Company assumes the financial obligation for third-party provider costs for medical services provided to the health plan's customers. Fees are recorded gross in Fees and other revenues in the Consolidated Statements of Income because the Company is acting as a principal in arranging for and controlling the services provided by third-party network providers. Contractual fees vary based on enrollment and provider costs and are billed, due </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and recognized monthly. Direct costs associated with these programs are recognized in Pharmacy and other service costs, and other related expenses are recorded in Selling, general and administrative expenses as incurred.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain health benefit management contracts require the Company to share the results of medical cost experience that differ from specified targets. This variable consideration is estimated at contract inception and adjusted through the contract period. The estimated profits and costs are recognized net in Fees and other revenues.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company also earns other service fees related to administrating services to specialty pharmacy manufacturers that are recorded in Fees and other revenues in the Consolidated Statements of Income. These revenues are billed, due and recognized at contracted rates as services are provided.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We bill pharmaceutical manufacturers based on management's interpretation of contractual terms and estimate a contractual allowance based on the best information available at the time a claim is processed. Contractual allowances for certain rebates receivable from pharmaceutical manufacturers are determined by reviewing payment experience and specific known items that could be adjusted under contract terms. The Company's estimation process for contractual allowances for pharmaceutical manufacturer receivables generally results in an allowance for balances outstanding greater than 90 days. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contractual allowances for certain receivables from third-party payors are based on their contractual terms and are estimated based on the Company's best information available at the time revenue is recognized. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Discounts and claims adjustments issued to customers in the form of client credits and other non-credit adjustments are based on the current status of each customer's receivable balance, current economic and market conditions and a variety of other factors, including the length of time the receivables are past due, the financial health of customers and our past experience. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The allowance for expected credit losses for current accounts receivable is based primarily on past collections experience relative to the length of time receivables are past due; however, when available evidence reasonably supports an assumption that counterparty credit risk over the expected payment period will differ from current and historical payment collections, a forecasting adjustment is reflected in the allowance for expected credit losses.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Receivables and any associated allowance are written off only when all collection attempts have failed and such amounts are determined unrecoverable. We regularly review the adequacy of these allowances based on a variety of factors, including age of the outstanding receivable and collection history. When circumstances related to specific collection patterns change, estimates of the recoverability of receivables are adjusted.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's accounts receivable include amounts due from pharmaceutical manufacturers, clients, third-party payors and customers, and are presented net of allowances. These balances include:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt">Pharmaceutical manufacturers receivables - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">amounts due from pharmaceutical manufacturers. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt">Noninsurance customer receivables - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">amounts due from customers for noninsurance services, primarily pharmacy benefit management and ASO contracts.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt">Insurance customer receivables - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">amounts due from customers under insurance and managed care contracts, primarily premiums receivable and amounts due from CMS.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt">Other receivables - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">all other accounts receivable not included in the categories above.</span></div>the Company entered into an uncommitted factoring facility (the "Facility") under which certain accounts receivable may be sold on a non-recourse basis to a financial institutionThe transactions under the Facility are accounted for as a sale and recorded as a reduction to accounts receivable in the Consolidated Balance Sheets because control of, and risk related to, the accounts receivable are transferred to the financial institutionAmounts associated with this Facility are reflected within Net cash provided by operating activities in the Consolidated Statements of Cash Flows. Factoring fees paid under this Facility are reflected in Interest expense and other in the Consolidated Statements of Income.As of December&#160;31, 2023, all sold accounts receivable have been collected from manufacturers, $515 million of which have not been remitted to the financial institution. Such amounts are recorded within Accrued expenses and other liabilities in the Consolidated Balance Sheets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Assets and Liabilities of Businesses Held for Sale</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The Company classifies assets and liabilities as held for sale ("disposal group") when management commits to a plan to sell the disposal group, the sale is probable within one year and the disposal group is available for immediate sale in its present condition. The Company considers various factors, particularly whether actions required to complete the plan indicate it is unlikely that significant changes to the plan will be made or the plan will be withdrawn. Assets held for sale are measured at the lower of carrying value or fair value less costs to sell. Any loss resulting from the measurement is recognized in the period the held-for-sale criteria are met. Conversely, gains are not recognized until the date of the sale. When the disposal group is classified as held for sale, depreciation and amortization for most long-lived assets ceases and the Company tests the assets for impairment. Deferred policy acquisition costs continue to be amortized.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company computes basic earnings per share using the weighted-average number of unrestricted common and deferred shares outstanding. Diluted earnings per share also includes the dilutive effect of outstanding employee stock options and restricted stock using the treasury stock method and the effect of strategic performance shares.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceUnearnedPremiumsPolicyTextBlock', window );">Unearned Premium</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy - Unearned Premium. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The unrecognized portion of premiums received is recorded as unearned premiums included in Insurance and contractholder liabilities (current and non-current). </span></div>The Company evaluates certain insurance contracts subject to premium deficiency testing and recognizes a premium deficiency loss and corresponding reserve when expected claims costs, claims adjustment expenses, maintenance costs, and unamortized acquisition costs exceed unearned premium. Anticipated investment income is considered in the calculation of premium deficiency.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy', window );">Unpaid Claims and Claims Expenses</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This liability reflects estimates of the ultimate cost of claims that have been incurred but not reported, expected development on reported claims, claims that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily comprised of accruals for incentives and other amounts payable to health care professionals and facilities. </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company compares key assumptions used to establish the medical costs payable to actual experience for each reporting period. The unpaid claims liability is adjusted through current period Shareholders' net income when actual experience differs from these assumptions. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trend. </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The liability is primarily calculated using "completion factors" developed by comparing the claim incurral date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1) electronic (auto-adjudication) versus manual </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">claim processing; 2) frequency and timeliness of provider claims submissions; 3) number of customers and 4) the mix of products. The Company uses historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period. </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company relies more heavily on medical cost trend analysis that reflects expected claim payment patterns and other relevant operational considerations for more recent months. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of health benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and deductibles, changes in provider practices and changes in consumer demographics and consumption behavior.</span></div>There is no single or common claim frequency metric used in the health care industry. The Company believes a relevant metric for its health insurance business is the number of customers for whom an insured medical claim was paid. Customers for whom no insured medical claim was paid are excluded from the calculation. Claims that did not result in a liability are not included in the frequency metric.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FuturePolicyBenefitsLiabilityPolicy', window );">Future Policy Benefits</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting Policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Future policy benefits represent the present value of estimated future obligations, estimated using actuarial methods, for long-duration insurance policies and annuity products currently in force, consisting primarily of reserves for annuity contracts, life insurance benefits, and certain supplemental health products that are guaranteed renewable beyond one year.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contracts are grouped at a level no higher than issue year, based on the original contract issue date, and at lower levels of disaggregation within each issue year for certain businesses to reflect factors including product type, plan type and currency. Management estimates these obligations based on assumptions for premiums, interest rates, mortality or morbidity, future claim adjudication expenses and surrenders. Mortality, morbidity and surrender assumptions are based on the Company's own experience and published actuarial tables, and are updated at least annually, to the extent changes in circumstances require. Interest rate assumptions are based on</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">market-level yields for low credit risk fixed income instruments ("upper-medium grade fixed income instrument"). For interest accretion purposes, interest rates are fixed at the year of the cohort's inception, however for purposes of liability measurement, are updated to the current rate quarterly, with all changes in the interest rate from inception to current period reported through Accumulated other comprehensive loss. For contracts issued domestically, we use observable inputs from a published spot rate curve for terms up to 30 years and extrapolate for longer terms using a constant forward rate approach. For contracts issued by foreign operating entities with functional currencies other than the U.S. dollar, we use observable inputs to approximate a risk free rate and add a credit spread adjustment to align with a low-credit risk fixed income instrument. For terms beyond the last observable risk free rates, which vary by international market, we extrapolate to the ultimate forward rate assuming a constant credit spread.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the annuity business, the premium paying period is shorter than the benefit coverage period, and a deferred profit liability is reported in future policy benefits representing gross premium received in excess of net premiums. Deferred profit liability is amortized based on expected future benefit payments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ContractholderDepositFundsPolicyPolicyTextBlock', window );">Contractholder Deposit Funds</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting Policy. </span>Liabilities for contractholder deposit funds primarily include deposits received from customers for investment-related and universal life products as well as investment earnings on their fund balances in Other Operations. These liabilities are adjusted to reflect administrative charges and, for universal life fund balances, mortality charges. Interest credited on these funds is accrued ratably over the contract period.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketRiskBenefitPolicyTextBlock', window );">Market Risk Benefits</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting Policy.</span> Variable annuity reinsurance liabilities are measured as MRBs at fair value, net of nonperformance risk, with fluctuations in value gross of reinsurer nonperformance risk reported in benefit expenses, while fluctuations in the Company's own nonperformance risk (own credit risk) are reported in Accumulated other comprehensive loss. Nonperformance risk reflects risk that a party might default and therefore not fulfill its obligations (i.e. nonpayment risk). The nonperformance risk adjustment reflects a market participant's view of nonpayment risk by adding an additional spread to the discount rate in the calculation of both (a) the variable annuity reinsurance liabilities to be paid by the Company and (b) the variable annuity reinsurance assets to be paid by the reinsurers, after considering collateral. The Company classifies variable annuity assets and liabilities in Level 3 of the fair value hierarchy described in Note 13 to the Consolidated Financial Statements because assumptions related to future annuitant behavior are largely unobservable. As discussed further in Note 11 to the Consolidated Financial Statements, due to the reinsurance agreements covering these liabilities, the liabilities do not generally impact net income except for the change in nonperformance risk on the reinsurance recoverable, which is reported in benefit expenses and does not offset the nonperformance risk valuation on the liability. Variable annuity liabilities are established using capital market assumptions and assumptions related to future annuitant behavior (including mortality, lapse and annuity election rates).<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceAccountingPolicy', window );">Reinsurance</a></td>
<td class="text">Reinsurance and other amounts recoverable reflect amounts due from reinsurers and policyholders to cover incurred but not reported and pending claims of certain business for which the Company administers the plan benefits without any right of offset. See Note 11 to the Consolidated Financial Statements for additional information on reinsurance<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's insurance subsidiaries enter into agreements with other insurance companies to limit losses from large exposures and to permit recovery of a portion of incurred losses. Reinsurance is ceded primarily in acquisition and disposition transactions when the underwriting company is not being acquired. Reinsurance does not relieve the originating insurer of liability. Therefore, reinsured liabilities must continue to be reported along with the related reinsurance recoverables. The Company regularly evaluates the financial condition of its reinsurers and monitors concentrations of its credit risk.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reinsurance recoverables represent amounts due from reinsurers for both paid and unpaid claims of the Company's insurance businesses. The Company bears the risk of loss if its reinsurers and retrocessionaires do not meet or are unable to meet their reinsurance obligations to the Company. Most reinsurance recoverables are classified as non-current assets. The current portion of reinsurance recoverables is reported in Other current assets and consists primarily of recoverables on paid claims expected to be settled within one year. Reinsurance recoverables are presented net of allowances, consisting primarily of an allowance for expected credit losses which is recognized on reinsurance recoverable balances each period and adjusted through Medical costs and other benefit expenses. Estimates of the allowance for expected credit losses are based on internal and external data used to develop expected loss rates over the anticipated duration of the recoverable asset that vary by external credit rating and collateral level. </span></div>The Company reviews its reinsurance arrangements and establishes reserves against the recoverables.<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Collateral levels are defined internally based on the fair value of the collateral relative to the carrying amount of the reinsurance recoverable, the frequency at which collateral is required to be replenished and the potential for volatility in the collateral's fair value.</span></div>Variable annuity contracts are accounted for as assumed and ceded reinsurance and categorized as market risk benefits as discussed in Note 10 to the Consolidated Financial Statements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Cigna Group's investment portfolio consists of a broad range of investments including debt securities, equity securities, commercial mortgage loans, policy loans, other long-term investments, short-term investments and derivative financial instruments. The sections below provide more detail regarding our investment balances and realized investment gains and losses. See Note 13 for information about the valuation of the Company's investment portfolio.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Debt securities, commercial mortgage loans, derivative financial instruments and short-term investments with contractual maturities during the next twelve months are classified on the balance sheet as current investments, unless they are held as statutory deposits or restricted for other purposes and then they are classified in Long-term investments. Equity securities may include funds that are used in our cash management strategy and are classified as current investments. All other investments are classified as Long-term investments.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Debt securities (including bonds, mortgage and other asset-backed securities and preferred stocks redeemable by the investor) are classified as available for sale and are carried at fair value with changes in fair value recorded either in Accumulated other comprehensive loss within Shareholders' equity or in credit loss expense based on fluctuations in the allowance for credit losses, as further discussed below. Prior to the adoption of LDTI on January 1, 2023, net unrealized appreciation on debt securities supporting the Company's run-off settlement annuity business was reported in Non-current insurance and contractholder liabilities rather than Accumulated other comprehensive loss. See Note 16 for impact to Accumulated other comprehensive loss. When the Company intends to sell or determines that it is more likely than not to be required to sell an impaired debt security, the excess of amortized cost over fair value is directly written down with a charge to Net realized investment (losses) gains. Certain asset-backed securities are considered variable interest entities. See Note 14 for additional information. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company reviews declines in fair value from a debt security's amortized cost basis to determine whether a credit loss exists, and when appropriate, recognizes a credit loss allowance with a corresponding charge to credit loss expense, presented in Net realized investment (losses) gains in the Company's Consolidated Statements of Income. The allowance for credit loss represents the excess of amortized cost over the greater of its fair value or the net present value of the debt security's projected future cash flows (based on qualitative and quantitative factors, including the probability of default and the estimated timing and amount of recovery). Each period, the allowance for credit loss is adjusted as needed through credit loss expense.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company does not measure an allowance for credit losses for accrued interest receivables. When interest payments are delinquent based on contractual terms or when certain terms (interest rate or maturity date) of the investment have been restructured, accrued interest, reported in Other current assets, is written off through a charge to Net investment income and interest income is recognized on a cash basis.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Review of declines in fair value. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Management reviews impaired debt securities to determine whether a credit loss allowance is needed based on criteria that include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">severity of decline;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">financial health and specific prospects of the issuer; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">changes in the regulatory, economic or general market environment of the issuer's industry or geographic region.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Equity securities with a readily determinable fair value consist primarily of public equity investments in the health care sector and mutual funds that invest in fixed income debt securities while those without a readily determinable fair value consist of private equity investments. Changes in the fair values of equity securities that have a readily determinable fair value are reported in Net realized investment (losses) gains. Equity securities without a readily determinable fair value are carried at cost minus impairment, if any, plus or minus changes resulting from observable price changes. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Commercial mortgage loans are carried at unpaid principal balances, net of an allowance for expected credit losses, and classified as either current or long-term investments based on their contractual maturities. Changes in the allowance for expected credit losses are recognized as credit loss expense and presented in Net realized investment (losses) gains in the Company's Consolidated Statements of Income. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Each period, the Company establishes (or adjusts) its allowance for expected credit losses for commercial mortgage loans. The allowance for expected credit losses is based on a credit risk category that is assigned to each loan at origination using key credit quality indicators, including debt service coverage and loan-to-value ratios. Credit risk categories are updated as key credit quality indicators change. An expected loss rate, assigned based on the credit risk category, is applied to each loan's unpaid principal balance to develop the aggregate allowance for expected credit losses. Commercial mortgage loans are considered impaired and written off against the allowance when it is probable that the Company will not collect all amounts due per the terms of the promissory note. In the event of a foreclosure, the allowance for credit losses is based on the excess of the carrying value of the mortgage loan over the fair value of its underlying collateral.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Mortgage loans held by the Company are made exclusively to commercial borrowers and are diversified by property type, location and borrower. Loans are generally issued at fixed rates of interest and are secured by high quality, primarily completed and substantially leased operating properties.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Credit quality</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Company regularly evaluates and monitors credit risk, beginning with the initial underwriting of a mortgage loan and continuing throughout the investment holding period. Mortgage origination professionals employ an internal credit quality rating system designed to evaluate the relative risk of the transaction at origination that is then updated each year as part of the annual portfolio loan review. The Company evaluates and monitors credit quality on a consistent and ongoing basis.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Quality ratings are based on our evaluation of a number of key inputs related to the loan, including real estate market-related factors such as rental rates and vacancies, and property-specific inputs such as growth rate assumptions and lease rollover statistics. However, the two most significant contributors to the credit quality rating are the debt service coverage and loan-to-value ratios. The debt service coverage ratio measures the amount of property cash flow available to meet annual interest and principal payments on debt, with a ratio below 1.0 indicating that there is not enough cash flow to cover the required loan payments. The loan-to-value ratio, commonly expressed as a percentage, compares the amount of the loan to the fair value of the underlying property collateralizing the loan.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Policy loans, primarily associated with our corporate-owned life insurance business, are carried at unpaid principal balances plus accumulated interest, the total of which approximates fair value. These loans are collateralized by life insurance policy cash values and therefore have minimal exposure to credit loss. Interest rates are reset annually based on a rolling average of benchmark interest rates.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other long-term investments include investments in unconsolidated entities, including certain limited partnerships and limited liability companies holding real estate, securities or loans and health care-related investments. These investments are carried at cost plus the Company's ownership percentage of reporting income or loss, based on the financial statements of the underlying investments that are generally reported at fair value. Income or loss from these investments is reported on a one quarter lag due to the timing of when financial information is received from the general partner or manager of the investments. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other long-term investments also include investment real estate carried at depreciated cost less any impairment write-downs to fair value when cash flows indicate that the carrying value may not be recoverable. Depreciation is generally recorded using the straight-line method based on the estimated useful life of each asset. Investment real estate as of December&#160;31, 2023 and 2022 is expected to be held longer than one year and may include real estate acquired through the foreclosure of commercial mortgage loans.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, foreign currency swaps carried at fair value and certain restricted deposits are reported in the table below as "Other." See discussion below for information on the Company's accounting policies for derivative financial instruments.</span></div>Other long-term investments and related commitments are diversified by issuer, property type and geographic regions. These investments are primarily unconsolidated variable interest entities (see Note 14 for additional information).Our limited partnership investments are reduced as the Company receives cash distributions for returns on its investment that were previously recognized in Net investment income. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Security investments with maturities of greater than three months to one year from time of purchase are classified as short-term, available for sale and carried at fair value that approximates cost. Cash equivalents consist of short-term investments with maturities of three months or less from the time of purchase and are carried at cost that approximates fair value.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> When interest and principal payments on investments are current, the Company recognizes interest income when it is earned. The Company recognizes interest income on a cash basis when interest payments are delinquent based on contractual terms or when certain terms (interest rate or maturity date) of the investment have been restructured. For unconsolidated entities that are included in other long-term investments, investment income is generally recognized according to the Company's share of the reported income or loss on the underlying investments. Investment income attributed to the Company's separate accounts is excluded from our earnings because associated gains and losses generally accrue directly to separate account policyholders.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy. </span>Realized investment gains and losses are based on specifically identified assets and result from sales, investment asset write-downs, change in the fair value of certain derivatives and equity securities and changes in allowances for credit losses on debt securities and commercial mortgage loan investments. With the adoption of amended accounting guidance for long-duration insurance contracts on January 1, 2023 (discussed in Note 2 to the Consolidated Financial Statements), realized investment gains and losses no longer exclude amounts that were previously required to adjust future policy benefits for the run-off settlement annuity business. Prior period net realized investment losses have been updated to reflect the impact of adopting LDTI.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company uses derivative financial instruments to manage the characteristics of investment assets (such as duration, yield, currency and liquidity) to meet the varying demands of the related insurance and contractholder liabilities. The Company also uses derivative financial instruments to hedge the risk of changes in the net assets of certain of its foreign subsidiaries due to changes in foreign currency exchange rates and to hedge the interest rate risk of certain long-term debt.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Derivatives are recorded in our Consolidated Balance Sheets at fair value and are classified as current or non-current according to their contractual maturities. Further information on our policies for determining fair value are discussed in Note 13. The Company applies hedge accounting when derivatives are designated, qualified and highly effective as hedges. Under hedge accounting, the changes in fair value of the derivative and the hedged risk are generally recognized together and offset each other when reported in Shareholders' net income. Various qualitative or quantitative methods appropriate for each hedge are used to formally assess and document hedge effectiveness at inception and each period throughout the life of a hedge.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's derivative financial instruments are presented as follows:&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Fair value hedges of the foreign exchange-related changes in fair values of certain foreign-denominated bonds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: Swap fair values are reported in Long-term investments or Other non-current liabilities. Offsetting changes in fair values attributable to the foreign exchange risk of the swap contracts and the hedged bonds are reported in Net realized investment (losses) gains. The portion of the swap contracts' changes in fair value excluded from the assessment of hedge effectiveness is recorded in Other comprehensive loss and recognized in Net investment income as swap coupon payments are accrued, offsetting the foreign-denominated coupons received on the designated bonds. Net cash flows are reported in Operating activities, while exchanges of notional principal amounts are reported in Investing activities.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Fair value hedges of the interest rate exposure on the Company's long-term debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: Using fair value hedge accounting, the fair values of the swap contracts are reported in other assets or other liabilities. The critical terms of these swaps match those of the long-term debt being hedged. As a result, the carrying value of the hedged debt is adjusted to reflect changes in its fair value driven by the SOFR. The effects of those adjustments on interest expense are offset by the effects of corresponding changes in the swaps' fair value. The net impact from the hedge reported in Interest expense and other reflects interest expense on the hedged debt at the variable interest rate. Cash flows relating to these contracts are reported in Operating activities.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline">Net investment hedges of certain foreign subsidiaries that conduct their business principally in currencies other than the U.S. dollar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: The fair values of the foreign currency swap and forward contracts are reported in other assets or other liabilities. The changes in fair values of these instruments are reported in Other comprehensive loss, specifically in translation of foreign currencies. The portion of the change in fair values relating to foreign exchange spot rates will be recognized in earnings upon deconsolidation of the hedged foreign subsidiaries. The remaining changes in fair value of these instruments are excluded from our effectiveness assessment and recognized in Interest expense and other over the term of the instrument. Cash flows relating to these contracts are reported in Investing activities. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;text-decoration:underline">Fair value hedge:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> To hedge the foreign exchange-related changes in fair values of certain foreign-denominated bonds. The notional value of these derivatives matches the amortized cost of the hedged bonds. A majority of these instruments are denominated in Euros, with the remaining instruments denominated in British Pounds Sterling and Australian Dollars.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Fair value hedge:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> To convert a portion of the interest rate exposure on the Company's long-term debt from fixed to variable rates. This more closely aligns the Company's interest expense with the interest income received on its cash equivalent and short-term investment balances. The variable rates are benchmarked to SOFR.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;text-decoration:underline">Net investment hedge:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> To reduce the risk of changes in net assets due to changes in foreign currency spot exchange rates for certain foreign subsidiaries that conduct their business principally in currencies other than the U.S. Dollar. The notional value of hedging instruments matches the hedged amount of subsidiary net assets. Foreign currency swap contracts are denominated in Euros.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company carries certain financial instruments at fair value in the financial statements including debt securities, certain equity securities, short-term investments and derivatives. Other financial instruments are measured at fair value only under certain conditions, such as when impaired or when there are observable price changes for equity securities with no readily determinable fair value.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value is defined as the price at which an asset could be exchanged in an orderly transaction between market participants at the balance sheet date. A liability's fair value is defined as the amount that would be paid to transfer the liability to a market participant, not the amount that would be paid to settle the liability with the creditor.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's financial assets and liabilities carried at fair value have been classified based upon a hierarchy defined by GAAP. The hierarchy gives the highest ranking to fair values determined using unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest ranking to fair values determined using methodologies and models with unobservable inputs (Level 3). An asset's or a liability's classification is based on the lowest level of input that is significant to its measurement. For example, a financial asset or liability carried at fair value would be classified in Level 3 if unobservable inputs were significant to the instrument's fair value, even though the measurement may be derived using inputs that are both observable (Levels 1 and 2) and unobservable (Level 3).</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company estimates fair values using prices from third parties or internal pricing methods. Fair value estimates received from third-party pricing services are based on reported trade activity and quoted market prices when available and other market information that a market participant would use to estimate fair value. The internal pricing methods are performed by the Company's investment professionals and generally involve using discounted cash flow analyses, incorporating current market inputs for similar financial instruments with comparable terms and credit quality as well as other qualitative factors. In instances where there is little or no market activity for the same or similar instruments, fair value is estimated using methods, models and assumptions that the Company believes a hypothetical market participant would use to determine a current transaction price. These valuation techniques involve some level of estimation and judgment that becomes significant with increasingly complex instruments or pricing models.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is responsible for determining fair value and for assigning the appropriate level within the fair value hierarchy based on the significance of unobservable inputs. The Company reviews methodologies, processes and controls of third-party pricing services and compares prices on a test basis to those obtained from other external pricing sources or internal estimates. The Company performs ongoing analyses of both prices received from third-party pricing services and those developed internally to determine that they represent appropriate estimates of fair value. The controls executed by the Company include evaluating changes in prices and monitoring for potentially stale valuations. The Company also performs sample testing of sales values to confirm the accuracy of prior fair value estimates. The minimal exceptions identified during these processes indicate that adjustments to prices are infrequent and do not significantly impact valuations. An annual due-diligence review of the most significant pricing service is conducted to review their processes, methodologies and controls. This review includes a walk-through of inputs for a sample of securities held across various asset types to validate the documented pricing process.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Level 1 Financial Assets</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inputs for instruments classified in Level 1 include unadjusted quoted prices for identical assets in active markets accessible at the measurement date. Active markets provide pricing data for trades occurring at least weekly and include exchanges and dealer markets.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Assets in Level 1 include actively-traded U.S. government bonds and exchange-listed equity securities. A relatively small portion of the Company's investment assets are classified in this category given the narrow definition of Level 1 and the Company's investment asset strategy to maximize investment returns.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Level 2 Financial Assets and Financial Liabilities</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inputs for instruments classified in Level 2 include quoted prices for similar assets or liabilities in active markets, quoted prices from those willing to trade in markets that are not active or other inputs that are market observable or can be corroborated by market data for the term of the instrument. Such other inputs include market interest rates and volatilities, spreads and yield curves. An instrument is classified in Level 2 if the Company determines that unobservable inputs are insignificant.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Debt and equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Approximately 94% of the Company's investments in debt and equity securities are classified in Level 2 including most public and private corporate debt and equity securities, federal agency and municipal bonds, non-government mortgage-backed securities and preferred stocks. Third-party pricing services and internal methods often use recent trades of securities with similar features and characteristics because many debt securities do not trade daily. Pricing models are used to determine these prices when recent trades are not available. These models calculate fair values by discounting future cash flows at estimated market interest rates. Such market rates are derived by calculating the appropriate spreads over comparable U.S. Treasury securities based on the credit quality, industry and structure of the asset. Typical inputs and assumptions to pricing models include, but are not limited to, a combination of benchmark yields, reported trades, issuer spreads, liquidity, benchmark securities, bids, offers, reference data and industry and economic events. For mortgage-backed securities, inputs and assumptions may also include characteristics of the issuer, collateral attributes, prepayment speeds and credit rating. Nearly all of these instruments are valued using recent trades or pricing models. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Short-term investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> are carried at fair value that approximates cost. The Company compares market prices for these securities to recorded amounts on a regular basis to validate that current carrying amounts approximate exit prices. The short-term nature of the investments and corroboration of the reported amounts over the holding period support their classification in Level 2.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Derivative assets and liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> classified in Level 2 represent over-the-counter instruments such as foreign currency forward and swap contracts. Fair values for these instruments are determined using market observable inputs including forward currency and interest rate curves and widely published market observable indices. Credit risk related to the counterparty and the Company is considered when estimating the fair values of these derivatives. However, the Company is largely protected by collateral arrangements with counterparties and determined that no adjustments for credit risk were required as of December&#160;31, 2023 or December&#160;31, 2022. The nature and use of these derivative financial instruments are described in Note 12.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Level 3 Financial Assets and Financial Liabilities</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain inputs for instruments classified in Level 3 are unobservable (supported by little or no market activity) and significant to their resulting fair value measurement. Unobservable inputs reflect the Company's best estimate of what hypothetical market participants would use to determine a transaction price for the asset or liability at the reporting date. Additionally, as discussed in Note 10E to the Consolidated Financial Statements, the Company classifies variable annuity assets and liabilities in Level 3 of the fair value hierarchy.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company classifies certain newly-issued, privately-placed, complex or illiquid securities in Level 3. Approximately 5% of debt and equity securities are priced using significant unobservable inputs and classified in this category.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair values of mortgage and other asset-backed securities, as well as corporate and government debt securities, are primarily determined using pricing models that incorporate the specific characteristics of each asset and related assumptions including the investment type and structure, credit quality, industry and maturity date in comparison to current market indices, spreads and liquidity of assets with similar characteristics. Inputs and assumptions for pricing may also include characteristics of the issuer, collateral attributes and prepayment speeds for mortgage and other asset-backed securities. Recent trades in the subject security or similar securities are assessed when available, and the Company may also review published research in its evaluation, as well as the issuer's financial statements.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Quantitative Information about Unobservable Inputs</span></div>The significant unobservable input used to value our corporate and government debt securities and mortgage and other asset-backed securities is an adjustment for liquidity. This adjustment is needed to reflect current market conditions and issuer circumstances when there is limited trading activity for the security.<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total gains and losses included in Shareholders' net income in the tables above are reflected in the Consolidated Statements of Income as Net realized investment (losses) gains and Net investment income.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gains and losses included in Other comprehensive loss, net of tax in the tables above are reflected in Net unrealized appreciation (depreciation) on securities and derivatives in the Consolidated Statements of Comprehensive Income.</span></div>Transfers into or out of the Level 3 category occur when unobservable inputs, such as the Company's best estimate of what a market participant would use to determine a current transaction price, become more or less significant to the fair value measurement. Market activity typically decreases during periods of economic uncertainty and this decrease in activity reduces the availability of market observable data. As a result, the level of unobservable judgment that must be applied to the pricing of certain instruments increases and is typically observed through the widening of liquidity spreads<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Assets and Liabilities Measured at Fair Value under Certain Conditions</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Some financial assets and liabilities are not carried at fair value, such as commercial mortgage loans that are carried at unpaid principal, investment real estate that is carried at depreciated cost and equity securities with no readily determinable fair value when there are no observable market transactions. However, these financial assets and liabilities may be measured using fair value under certain conditions, such as when investments become impaired and are written down to their fair value, or when there are observable price changes from orderly market transactions of equity securities that otherwise had no readily determinable fair value.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderAccountsPolicy', window );">Separate Accounts</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Separate account assets and liabilities are contractholder funds maintained in accounts with specific investment objectives. The assets of these accounts are legally segregated and are not subject to claims that arise out of any of the Company's other businesses. These separate account assets are carried at fair value with equal amounts recorded for related separate account liabilities. The investment income and fair value gains and losses of separate account assets generally accrue directly to the contractholders and, together with their deposits and withdrawals, are excluded from the Company's Consolidated Statements of Income and Cash Flows. Fees and charges earned for mortality risks, asset management or administrative services are reported in either Premiums or Fees and other revenues. Investments that are measured using the practical expedient of net asset value ("NAV") are excluded from the fair value hierarchy. The separate account activity for the year ended December&#160;31, 2023 and 2022 was primarily driven by changes in the market values of the underlying separate account investments.</span></div><div style="margin-bottom:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Separate account assets classified as Level 1 primarily include exchange-listed equity securities. Level 2 assets primarily include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">corporate and structured bonds valued using recent trades of similar securities or pricing models that discount future cash flows at estimated market interest rates as described above; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">actively-traded institutional and retail mutual fund investments.</span></div>Separate account assets classified in Level 3 primarily support the Company's pension plans and include certain newly-issued, privately-placed, complex or illiquid securities that are priced using methods discussed above, as well as commercial mortgage loans.Separate account investments in securities partnerships, real estate and hedge funds are generally valued based on the separate account's ownership share of the equity of the investee (NAV as a practical expedient), including changes in the fair values of its underlying investments<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entities</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">When the Company becomes involved with a variable interest entity and when there is a change in the Company's involvement with an entity, the Company must determine if it is the primary beneficiary and must consolidate the entity. The Company is considered the primary beneficiary if it has the power to direct the entity's most significant economic activities and has the right to receive benefits or obligation to absorb losses that could be significant to the entity. The Company evaluates the following criteria:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the structure and purpose of the entity;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the risks and rewards created by and shared through the entity; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the Company's ability to direct its activities, receive its benefits and absorb its losses relative to the other parties involved with the entity including its sponsors, equity holders, guarantors, creditors and servicers. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Securities limited partnerships and real estate limited partnerships</span>. The Company owns interests in securities limited partnerships and real estate limited partnerships that are defined as unconsolidated variable interest entities. These partnerships invest in the equity or mezzanine debt of privately-held companies and real estate properties. General partners unaffiliated with the Company control decisions that most significantly impact the partnership's operations and the limited partners do not have substantive kick-out or participating rights. The Company has invested in approximately 190 limited partnerships that have a carrying value of $2.9 billion as of December&#160;31, 2023 reported in other long-term investments. We perform ongoing qualitative analyses of our involvement with these variable interest entities to determine if consolidation is required.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method Operating Joint Ventures</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We record in our Consolidated Statements of Income our proportionate share of net income or loss generated by equity method operating joint ventures within Fees and other revenues. In certain instances, income or loss is reported on a one month lag due to the timing of when financial information is received.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">AOCI</a></td>
<td class="text">Generally, tax effects in AOCI are established at the currently enacted tax rate and reclassified to Shareholders' net income in the same period that the related pre-tax AOCI reclassifications are recognized.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy', window );">Pension Plans</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Company measures the assets and liabilities of its domestic pension plans as of December 31. Benefit obligations are measured at the present value of estimated future payments based on actuarial assumptions. The Company uses the corridor method to account for changes in the benefit obligation when actual results differ from those assumed, or when assumptions change. These changes are called net unrecognized actuarial gains (losses). Under the corridor method, net unrecognized actuarial gains (losses) are initially recorded in Accumulated other comprehensive loss. When the unrecognized gain (loss) exceeds 10% of the </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">benefit obligation, that excess is amortized to expense over the expected remaining lives of plan participants. The net plan expense is reported in Interest expense and other in the Consolidated Statements of Income.</span></div>For balance sheet purposes, we measure plan assets at fair value. When the actual return differs from the expected return, those differences are reflected in the net unrealized actuarial gain (loss) discussed above. However, to measure pension benefit costs, we use a market-related asset valuation that differs from the actual fair value for domestic pension plan assets invested in non-fixed income investments. The market-related value recognizes the difference between actual and expected long-term returns in the portfolio over five years, a method that reduces the short-term impact of market fluctuations on pension costs.<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company develops discount rates by applying actual annualized yields for high-quality bonds by duration to the expected pension plan liability cash flows. The bond yields represent a diverse mix of actively traded high quality fixed income securities that have an above average return at each duration as management believes this approach is representative of the yield achieved through plan asset investment strategy.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The expected long-term return on plan assets was developed considering historical long-term actual returns, expected long-term market conditions, plan asset mix and management's plan asset investment strategy.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See Note 13 for further details regarding how fair value is determined, including the level within the fair value hierarchy and the procedures we use to validate fair value measurements. The Company classifies substantially all debt securities in Level 2 for pension plan assets. These assets are valued using recent trades of similar securities or are fund investments priced using their daily net asset value that is the exit price. All domestic equity securities and international equity funds within pension assets are classified as Level 3.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Securities partnerships, real estate and hedge funds are valued using net asset value as a practical expedient and are excluded from the fair value hierarchy. See Note 13 for additional disclosures related to these assets invested in the separate accounts of the Company's subsidiary. Certain securities as described in Note 13, as well as commercial mortgage loans and guaranteed deposit account contracts, are classified in Level 3 because unobservable inputs used in their valuation are significant.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Employee Incentive Plans</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company records compensation expense for stock and option awards over their vesting periods primarily based on the estimated fair value at the grant date. Fair value is determined differently for each type of award as discussed below.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Company awards options to purchase The Cigna Group common stock at the market price of the stock on the grant date. Options vest over periods ranging from one year to three years and expire no later than 10 years from grant date. Fair value is estimated using the Black-Scholes option-pricing model by applying the assumptions presented below. That fair value is reduced by options expected to be forfeited during the vesting period. The Company estimates forfeitures at the grant date based on our experience and adjusts the expense to reflect actual forfeitures over the vesting period. The fair value of options, net of forfeitures, is recognized in Selling, general and administrative expenses on a straight-line basis over the vesting period.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Fair value of restricted stock awards is equal to the market price of The Cigna Group's common stock on the date of grant. This fair value is reduced by awards that are expected to forfeit. At the grant date, the Company estimates forfeitures based on experience and adjusts the expense to reflect actual forfeitures over the vesting period. This fair value, net of forfeitures, is recognized in Selling, general and administrative expenses over the vesting period on a straight-line basis.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Compensation expense for SPSs is recorded over the performance period. Fair value is determined at the grant date for "market condition" SPSs using a Monte Carlo simulation model and not subsequently adjusted regardless of the final outcome. Expense is initially accrued for "performance condition" SPSs based on the most likely outcome, but evaluated for adjustment each period for updates in the expected outcome. Expense is adjusted to the actual outcome (number of shares awarded times the share price at the grant date) at the end of the performance period.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Goodwill represents the excess of the cost of businesses acquired over the fair value of their net assets. The resulting goodwill is assigned to those reporting units expected to realize cash flows from the acquisition, based on those reporting units' relative fair values. The Company's reporting units are aligned with its operating segments as described in Note 1.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company conducts its annual quantitative evaluation for goodwill impairment during the third quarter at the reporting unit level and writes it down through Shareholders' net income if impaired. On a quarterly basis, the Company performs a qualitative impairment assessment to determine if events or changes in circumstances indicate that it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value. Fair value of a reporting unit is generally estimated based on discounted cash flow analysis and market approach models using assumptions that the Company believes a hypothetical market participant would use to determine a current transaction price. Following a change in reporting units or held for sale determination, goodwill is allocated using relative fair value. The significant assumptions and estimates used in determining fair value primarily include the discount rate and future cash flows. A discount rate is selected to correspond with each reporting unit's weighted average cost of capital, consistent with </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">that used for investment decisions considering the specific and detailed operating plans and strategies within each reporting unit. Projections of future cash flows differ by reporting unit and are consistent with our ongoing strategic projections. Future cash flows for Evernorth Health Services are primarily driven by the forecasted gross margins of the business, as well as operating expenses and long-term growth rates. Future cash flows for our other reporting units are primarily driven by forecasted revenues, benefit expenses, operating expenses and long-term growth rates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Other Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Company's Other intangible assets primarily include purchased customer and producer relationships, trademarks and provider networks. The fair value of purchased customer relationships and the amortization method were determined as of the dates of purchase using an income approach that relies on projected future net cash flows including key assumptions for customer attrition and discount rates. The Company's definite-lived intangible assets are amortized on an accelerated or straight-line basis, reflecting their pattern of economic benefits, over periods from <span style="-sec-ix-hidden:f-2278">three</span> to 30 years. Management revises amortization periods if it believes there has been a change in the length of time that an intangible asset will continue to have value. Costs incurred to renew or extend the terms of these intangible assets are generally expensed as incurred.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's amortized intangible assets are tested for impairment whenever events or changes in circumstances indicate that the </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">carrying amount may not be recoverable.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> If the total of the expected future undiscounted cash flows generated by the underlying asset group is less than the carrying amount of the asset group, the Company recognizes an impairment charge equal to the difference between the carrying value of the asset group and its estimated fair value. The Company's indefinite-lived intangible assets are reviewed for impairment at least annually by comparing their fair value with their carrying value. If the carrying value exceeds fair value, that excess is recognized as an impairment loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Property and equipment is carried at cost less accumulated depreciation. Cost includes interest, real estate taxes and other costs incurred during construction when applicable. Internal-use software that is acquired, developed or modified solely to meet the Company's internal needs, with no plan to market externally, is also included in this category. Costs directly related to acquiring, developing or modifying internal-use software are capitalized.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company calculates depreciation and amortization principally using the straight-line method generally based on the estimated useful life of each asset as follows: buildings and improvements, 10 to 40 years; purchased and internally developed software, <span style="-sec-ix-hidden:f-2323">three</span> to five years; and furniture and equipment (including computer equipment), <span style="-sec-ix-hidden:f-2325">three</span> to 10 years. Improvements to leased facilities are depreciated over <span style="-sec-ix-hidden:f-2327">the lesser of the remaining lease term or the estimated life of the improvement</span>. The Company considers events and circumstances that would indicate the carrying value of property, equipment or capitalized software might not be recoverable. An impairment charge is recorded if the Company determines the carrying value of any of these assets is not recoverable. The Company also reviews and shortens the estimated useful lives of these assets, if necessary.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span> The Company determines if an arrangement is a lease and its lease classification (operating or finance) at inception. Both operating and finance leases result in (1) a right-of-use ("ROU") asset that represents our right to use the underlying asset for the lease term and (2) a lease liability that represents our obligation to make lease payments arising from the lease.<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. Most of the Company's leases do not provide an implicit rate, so the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The ROU asset also includes any lease pre-payments made and excludes lease incentives for operating leases. The Company's expected life of a lease may consider options to extend or terminate a lease when it is reasonably certain that the Company will exercise that option.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has lease agreements with lease and non-lease components that are accounted for as a single lease component. Operating lease ROU assets are amortized on a straight-line basis over the lease term, which is representative of the pattern in which benefit is expected to be derived from the right to use the underlying asset. Variable lease payments are expensed as incurred and represent amounts that are neither fixed in nature, such as maintenance and other services provided by the lessor, nor tied to an index or rate.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Deferred income taxes are reflected in the Consolidated Balance Sheets for differences between the financial and income tax reporting bases of the Company's underlying assets and liabilities, and are established based upon enacted tax rates and laws. Deferred income tax assets are recognized when available evidence indicates that realization is more likely than not and a valuation allowance is established to the extent this standard is not met. The deferred income tax provision generally represents the net change in deferred income tax assets and liabilities during the reporting period excluding adjustments to Accumulated other comprehensive income (loss) or amounts recorded in connection with a business combination. The current income tax provision generally represents estimated amounts due on income tax returns for the year reported to various jurisdictions plus the effect of any uncertain tax positions. The Company recognizes a liability for uncertain tax positions if management believes the probability that the positions will be sustained is 50% or less. For uncertain positions that management believes are more likely than not to be sustained, the Company recognizes a liability based upon management's estimate of the most likely settlement outcome with the taxing authority. The liabilities for uncertain tax positions are classified as current when the position is expected to be settled within 12 months or the statute of limitation expires within 12 months.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income taxes attributable to the Company's foreign operations are generally provided using the respective foreign jurisdictions' tax rate.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Management believes that future results will be sufficient to realize a majority of the Company's gross deferred tax assets. As of December&#160;31, 2023, we had approximately $218&#160;million in deferred tax assets ("DTAs") associated with unrealized investment losses that are partially recorded in Accumulated other comprehensive loss. We have determined that a valuation allowance against the DTAs is not currently required based on the Company's ability to carry back losses and our ability and intent to hold certain securities until recovery. We continue to monitor and evaluate the need for any valuation allowance in the future. As of December&#160;31, 2023, we had approximately $1.8 billion in DTAs associated with the foreign tax attributes as discussed above. We have determined that approximately $772 million valuation allowance against these DTAs is required based on the Company's taxable income projections and the requirement to utilize the assets within certain time periods. Additionally, the Company has $584 million of deferred tax assets and a full valuation allowance associated with the HCSC transaction, as discussed above. Valuation allowances are established against deferred tax assets when it is determined that it is more likely than not that the asset will not be recognized. Valuation allowances have been established against certain federal, state and foreign tax attributes. There are multiple expiration dates associated with these tax attributes.</span></div>The Company classifies net interest expense on uncertain tax positions as a component of income tax expense and in Other non-current liabilities in the Consolidated Balance Sheets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies', window );">Guarantees</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Financial Guarantees: Retiree and Life Insurance Benefits</span>The Company guarantees that separate account assets will be sufficient to pay certain life insurance or retiree benefits. For the majority of these benefits, the sponsoring employers are primarily responsible for ensuring that assets are sufficient to pay these benefits and are required to maintain assets that exceed a certain percentage of benefit obligations. If employers fail to do so, the Company or an affiliate of the buyer of the retirement benefits business has the right to redirect the management of the related assets to provide for benefit payments.An additional liability is established if management believes that the Company will be required to make payments under the guarantees;Separate account assets supporting these guarantees are classified in Levels 1 and 2 of the GAAP fair value hierarchy.<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Certain Other Guarantees</span>The Company had indemnification obligations as of December&#160;31, 2023 in connection with acquisition and disposition transactions. These indemnification obligations are triggered by the breach of representations or covenants provided by the Company, such as representations for the presentation of financial statements, filing of tax returns, compliance with laws or regulations or identification of outstanding litigation. These obligations are typically subject to various time limitations, defined by the contract or by operation of law, such as statutes of limitation. In some cases, the maximum potential amount due is subject to contractual limitations based on a stated dollar amount or a percentage of the transaction purchase price, while in other cases limitations are not specified or applicable. The Company does not believe that it is possible to determine the maximum potential amount due under these obligations because not all amounts due under these indemnification obligations are subject to limitation.<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline">Guaranty Fund Assessments</span><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company operates in a regulatory environment that may require its participation in assessments under state insurance guaranty association laws. The Company's exposure to assessments for certain obligations of insolvent insurance companies to policyholders and claimants is based on its share of business written in the relevant jurisdictions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">Intersegment revenues primarily reflect pharmacy and care services transactions between the Evernorth Health Services and Cigna Healthcare segments.<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company uses "pre-tax adjusted income (loss) from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management believes these metrics best reflect the underlying results of business operations and permit analysis of trends in underlying revenue, expenses and profitability. We define pre-tax adjusted income from operations as income before income taxes excluding pre-tax income (loss) attributable to noncontrolling interests, net realized investment results, amortization of acquired intangible assets, and special items. The Cigna Group's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">that management believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. </span></div>The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future underlying performance of the business.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AccountsPayableAccruedExpensesOtherLiabilitiesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes an entity's accounting policy for accounts payable, accrued expenses and other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AccountsPayableAccruedExpensesOtherLiabilitiesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ContractholderDepositFundsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes an entity's accounting policy for contractholder deposit funds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ContractholderDepositFundsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_InsuranceUnearnedPremiumsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Insurance, Unearned Premiums</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_InsuranceUnearnedPremiumsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_OtherAssetsCurrentAndNoncurrentPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting policies related to Other Assets, Current and Noncurrent and the items included therein.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_OtherAssetsCurrentAndNoncurrentPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_RedeemableNoncontrollingInterestsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for noncontrolling shareholders' preferred and common stock interests of consolidated, less than fully owned subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_RedeemableNoncontrollingInterestsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-5A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-2AA<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org//705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-21D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FuturePolicyBenefitsLiabilityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for liability for future benefit to be paid to or on behalf of policyholder. Includes, but is not limited to, input, judgment, assumption, and method used in measuring liability and change in input, judgment, and assumption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FuturePolicyBenefitsLiabilityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for guarantees, indemnifications and product warranties, and methodologies used in determining the amount of such liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//460/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketRiskBenefitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk. Includes, but is not limited to, input, judgment, assumption and method used in measuring market risk benefit, and change in input, judgment, and assumption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-7C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketRiskBenefitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for pension plans. This accounting policy may address (1) the types of plans sponsored by the entity (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 715<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481097/715-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 80<br> -Topic 715<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480576/715-80-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 715<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for contracts reported in separate accounts, including the extent and terms of minimum guarantees, basis of presentation for separate account assets and liabilities and related separate account activity, the liability valuation method and assumptions used in valuing each type of policyholder and contract holder account maintained by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of reinsurance accounting policy, for example, but not limited to, description of the methodologies and assumptions underlying determination of reinsurance recoverables, reinsurance payables and retention policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479629/944-605-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479629/944-605-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for estimating the ultimate cost of settling insurance claims relating to insured events that have occurred on or before a particular date (ordinarily, the statement of financial position date). The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claims adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288970485920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Receivables, Loans, Notes Receivable, and Others (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We bill pharmaceutical manufacturers based on management's interpretation of contractual terms and estimate a contractual allowance based on the best information available at the time a claim is processed. Contractual allowances for certain rebates receivable from pharmaceutical manufacturers are determined by reviewing payment experience and specific known items that could be adjusted under contract terms. The Company's estimation process for contractual allowances for pharmaceutical manufacturer receivables generally results in an allowance for balances outstanding greater than 90 days. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contractual allowances for certain receivables from third-party payors are based on their contractual terms and are estimated based on the Company's best information available at the time revenue is recognized. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Discounts and claims adjustments issued to customers in the form of client credits and other non-credit adjustments are based on the current status of each customer's receivable balance, current economic and market conditions and a variety of other factors, including the length of time the receivables are past due, the financial health of customers and our past experience. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The allowance for expected credit losses for current accounts receivable is based primarily on past collections experience relative to the length of time receivables are past due; however, when available evidence reasonably supports an assumption that counterparty credit risk over the expected payment period will differ from current and historical payment collections, a forecasting adjustment is reflected in the allowance for expected credit losses.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Receivables and any associated allowance are written off only when all collection attempts have failed and such amounts are determined unrecoverable. We regularly review the adequacy of these allowances based on a variety of factors, including age of the outstanding receivable and collection history. When circumstances related to specific collection patterns change, estimates of the recoverability of receivables are adjusted.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's accounts receivable include amounts due from pharmaceutical manufacturers, clients, third-party payors and customers, and are presented net of allowances. These balances include:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt">Pharmaceutical manufacturers receivables - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">amounts due from pharmaceutical manufacturers. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt">Noninsurance customer receivables - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">amounts due from customers for noninsurance services, primarily pharmacy benefit management and ASO contracts.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt">Insurance customer receivables - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">amounts due from customers under insurance and managed care contracts, primarily premiums receivable and amounts due from CMS.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt">Other receivables - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">all other accounts receivable not included in the categories above.</span></div>the Company entered into an uncommitted factoring facility (the "Facility") under which certain accounts receivable may be sold on a non-recourse basis to a financial institutionThe transactions under the Facility are accounted for as a sale and recorded as a reduction to accounts receivable in the Consolidated Balance Sheets because control of, and risk related to, the accounts receivable are transferred to the financial institutionAmounts associated with this Facility are reflected within Net cash provided by operating activities in the Consolidated Statements of Cash Flows. Factoring fees paid under this Facility are reflected in Interest expense and other in the Consolidated Statements of Income.As of December&#160;31, 2023, all sold accounts receivable have been collected from manufacturers, $515 million of which have not been remitted to the financial institution. Such amounts are recorded within Accrued expenses and other liabilities in the Consolidated Balance Sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288973751744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments, Debt and Equity Securities (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Cigna Group's investment portfolio consists of a broad range of investments including debt securities, equity securities, commercial mortgage loans, policy loans, other long-term investments, short-term investments and derivative financial instruments. The sections below provide more detail regarding our investment balances and realized investment gains and losses. See Note 13 for information about the valuation of the Company's investment portfolio.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Debt securities, commercial mortgage loans, derivative financial instruments and short-term investments with contractual maturities during the next twelve months are classified on the balance sheet as current investments, unless they are held as statutory deposits or restricted for other purposes and then they are classified in Long-term investments. Equity securities may include funds that are used in our cash management strategy and are classified as current investments. All other investments are classified as Long-term investments.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Debt securities (including bonds, mortgage and other asset-backed securities and preferred stocks redeemable by the investor) are classified as available for sale and are carried at fair value with changes in fair value recorded either in Accumulated other comprehensive loss within Shareholders' equity or in credit loss expense based on fluctuations in the allowance for credit losses, as further discussed below. Prior to the adoption of LDTI on January 1, 2023, net unrealized appreciation on debt securities supporting the Company's run-off settlement annuity business was reported in Non-current insurance and contractholder liabilities rather than Accumulated other comprehensive loss. See Note 16 for impact to Accumulated other comprehensive loss. When the Company intends to sell or determines that it is more likely than not to be required to sell an impaired debt security, the excess of amortized cost over fair value is directly written down with a charge to Net realized investment (losses) gains. Certain asset-backed securities are considered variable interest entities. See Note 14 for additional information. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company reviews declines in fair value from a debt security's amortized cost basis to determine whether a credit loss exists, and when appropriate, recognizes a credit loss allowance with a corresponding charge to credit loss expense, presented in Net realized investment (losses) gains in the Company's Consolidated Statements of Income. The allowance for credit loss represents the excess of amortized cost over the greater of its fair value or the net present value of the debt security's projected future cash flows (based on qualitative and quantitative factors, including the probability of default and the estimated timing and amount of recovery). Each period, the allowance for credit loss is adjusted as needed through credit loss expense.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company does not measure an allowance for credit losses for accrued interest receivables. When interest payments are delinquent based on contractual terms or when certain terms (interest rate or maturity date) of the investment have been restructured, accrued interest, reported in Other current assets, is written off through a charge to Net investment income and interest income is recognized on a cash basis.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Review of declines in fair value. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Management reviews impaired debt securities to determine whether a credit loss allowance is needed based on criteria that include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">severity of decline;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">financial health and specific prospects of the issuer; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">changes in the regulatory, economic or general market environment of the issuer's industry or geographic region.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Equity securities with a readily determinable fair value consist primarily of public equity investments in the health care sector and mutual funds that invest in fixed income debt securities while those without a readily determinable fair value consist of private equity investments. Changes in the fair values of equity securities that have a readily determinable fair value are reported in Net realized investment (losses) gains. Equity securities without a readily determinable fair value are carried at cost minus impairment, if any, plus or minus changes resulting from observable price changes. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Commercial mortgage loans are carried at unpaid principal balances, net of an allowance for expected credit losses, and classified as either current or long-term investments based on their contractual maturities. Changes in the allowance for expected credit losses are recognized as credit loss expense and presented in Net realized investment (losses) gains in the Company's Consolidated Statements of Income. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Each period, the Company establishes (or adjusts) its allowance for expected credit losses for commercial mortgage loans. The allowance for expected credit losses is based on a credit risk category that is assigned to each loan at origination using key credit quality indicators, including debt service coverage and loan-to-value ratios. Credit risk categories are updated as key credit quality indicators change. An expected loss rate, assigned based on the credit risk category, is applied to each loan's unpaid principal balance to develop the aggregate allowance for expected credit losses. Commercial mortgage loans are considered impaired and written off against the allowance when it is probable that the Company will not collect all amounts due per the terms of the promissory note. In the event of a foreclosure, the allowance for credit losses is based on the excess of the carrying value of the mortgage loan over the fair value of its underlying collateral.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Mortgage loans held by the Company are made exclusively to commercial borrowers and are diversified by property type, location and borrower. Loans are generally issued at fixed rates of interest and are secured by high quality, primarily completed and substantially leased operating properties.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Credit quality</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Company regularly evaluates and monitors credit risk, beginning with the initial underwriting of a mortgage loan and continuing throughout the investment holding period. Mortgage origination professionals employ an internal credit quality rating system designed to evaluate the relative risk of the transaction at origination that is then updated each year as part of the annual portfolio loan review. The Company evaluates and monitors credit quality on a consistent and ongoing basis.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Quality ratings are based on our evaluation of a number of key inputs related to the loan, including real estate market-related factors such as rental rates and vacancies, and property-specific inputs such as growth rate assumptions and lease rollover statistics. However, the two most significant contributors to the credit quality rating are the debt service coverage and loan-to-value ratios. The debt service coverage ratio measures the amount of property cash flow available to meet annual interest and principal payments on debt, with a ratio below 1.0 indicating that there is not enough cash flow to cover the required loan payments. The loan-to-value ratio, commonly expressed as a percentage, compares the amount of the loan to the fair value of the underlying property collateralizing the loan.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Policy loans, primarily associated with our corporate-owned life insurance business, are carried at unpaid principal balances plus accumulated interest, the total of which approximates fair value. These loans are collateralized by life insurance policy cash values and therefore have minimal exposure to credit loss. Interest rates are reset annually based on a rolling average of benchmark interest rates.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other long-term investments include investments in unconsolidated entities, including certain limited partnerships and limited liability companies holding real estate, securities or loans and health care-related investments. These investments are carried at cost plus the Company's ownership percentage of reporting income or loss, based on the financial statements of the underlying investments that are generally reported at fair value. Income or loss from these investments is reported on a one quarter lag due to the timing of when financial information is received from the general partner or manager of the investments. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other long-term investments also include investment real estate carried at depreciated cost less any impairment write-downs to fair value when cash flows indicate that the carrying value may not be recoverable. Depreciation is generally recorded using the straight-line method based on the estimated useful life of each asset. Investment real estate as of December&#160;31, 2023 and 2022 is expected to be held longer than one year and may include real estate acquired through the foreclosure of commercial mortgage loans.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, foreign currency swaps carried at fair value and certain restricted deposits are reported in the table below as "Other." See discussion below for information on the Company's accounting policies for derivative financial instruments.</span></div>Other long-term investments and related commitments are diversified by issuer, property type and geographic regions. These investments are primarily unconsolidated variable interest entities (see Note 14 for additional information).Our limited partnership investments are reduced as the Company receives cash distributions for returns on its investment that were previously recognized in Net investment income. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Security investments with maturities of greater than three months to one year from time of purchase are classified as short-term, available for sale and carried at fair value that approximates cost. Cash equivalents consist of short-term investments with maturities of three months or less from the time of purchase and are carried at cost that approximates fair value.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> When interest and principal payments on investments are current, the Company recognizes interest income when it is earned. The Company recognizes interest income on a cash basis when interest payments are delinquent based on contractual terms or when certain terms (interest rate or maturity date) of the investment have been restructured. For unconsolidated entities that are included in other long-term investments, investment income is generally recognized according to the Company's share of the reported income or loss on the underlying investments. Investment income attributed to the Company's separate accounts is excluded from our earnings because associated gains and losses generally accrue directly to separate account policyholders.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounting policy. </span>Realized investment gains and losses are based on specifically identified assets and result from sales, investment asset write-downs, change in the fair value of certain derivatives and equity securities and changes in allowances for credit losses on debt securities and commercial mortgage loan investments. With the adoption of amended accounting guidance for long-duration insurance contracts on January 1, 2023 (discussed in Note 2 to the Consolidated Financial Statements), realized investment gains and losses no longer exclude amounts that were previously required to adjust future policy benefits for the run-off settlement annuity business. Prior period net realized investment losses have been updated to reflect the impact of adopting LDTI.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288967746096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Accounts Receivable, Net</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following amounts were included within Accounts receivable, net:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical manufacturers receivables</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,169</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,108&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noninsurance customer receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,044</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Insurance customer receivables</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,359</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,963&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">272</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18,844</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net classified as assets of businesses held for sale</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,122)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17,722</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,218&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289064713104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets and Liabilities of Businesses Held for Sale (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Assets and Liabilities of Business Held for Sale</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The assets and liabilities of businesses held for sale were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:88.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.456%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">467</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,438</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,122</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets, including Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,963</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets of businesses held for sale</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,990</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Insurance and contractholder liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,636</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">All other liabilities</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,059</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities of businesses held for sale</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,695</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Includes Goodwill of $396&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-4A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-4B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5D<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3A<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288964595600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic and diluted earnings per share were computed as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="51" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Shares in thousands, dollars in millions, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of<br/>Dilution</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of<br/>Dilution</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of<br/>Dilution</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shareholders' net income</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,164</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,164</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,704&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,704&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,370&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,370&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">293,892</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">293,892</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">309,546&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">309,546&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">337,962&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">337,962&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,990</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,990</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total shares</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">293,892</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,990</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">296,882</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">309,546&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,519&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">313,065&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">337,962&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,004&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340,966&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Earnings per share</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17.57</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.18)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17.39</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.66&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.25)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.41&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.89&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.14)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.75&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amounts reflected above for the years ended December&#160;31, 2022 and 2021 have been restated to reflect the impact of adopting amended accounting guidance for long-duration insurance contracts (discussed in Note 2 to the Consolidated Financial Statements).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Outstanding Employee Stock Options Not Included in the Computation of Diluted Earnings Per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following outstanding employee stock options were not included in the computation of diluted earnings per share because their effect was anti-dilutive:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.261%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Anti-dilutive options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288970023024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ScheduleOfShortTermDebtLongTermDebtTableTextBlock', window );">Outstanding Amounts of Debt and Finance Leases</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The outstanding amounts of debt (net of issuance costs, discounts or premiums) and finance leases were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term debt</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$17&#160;million, 8.300% Notes due January 2023</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$63&#160;million, 7.650% Notes due March 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$700 million, Floating Rate Notes due July 2023</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1,000 million, 3.000% Notes due July 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1,187 million, 3.750% Notes due July 2023</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,186&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$500 million, 0.613% Notes due March 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1,000&#160;million, 3.500% Notes due June 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">996</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, including finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">42</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total short-term debt</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,775</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,993&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$500 million, 0.613% Notes due March 2024</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1,000&#160;million, 3.500% Notes due June 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$900&#160;million, 3.250% Notes due April 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">882</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">872&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$2,200&#160;million, 4.125% Notes due November 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,197</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1,500&#160;million, 4.500% Notes due February 2026</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,503&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$800 million, 1.250% Notes due March 2026 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">798</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$700 million, 5.685% Notes due March 2026</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">698</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1,500&#160;million, 3.400% Notes due March 2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,450</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$259&#160;million, 7.875% Debentures due May 2027</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">259</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$600&#160;million, 3.050% Notes due October 2027 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">597</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$3,800&#160;million, 4.375% Notes due October 2028</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,787</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,785&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1,500&#160;million, 2.400% Notes due March 2030 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,493</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1,500 million, 2.375% Notes due March 2031 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,397</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,380&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$45&#160;million, 8.080% Step Down Notes due January 2033 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$800 million, 5.400% Notes due March 2033</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">794</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$190&#160;million, 6.150% Notes due November 2036</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">190</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$2,200&#160;million, 4.800% Notes due August 2038 </span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,193</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,192&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$750&#160;million, 3.200% Notes due March 2040</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">744</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$121&#160;million, 5.875% Notes due March 2041</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">119</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$448&#160;million, 6.125% Notes due November 2041</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">487</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$317&#160;million, 5.375% Notes due February 2042</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">315</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1,500&#160;million, 4.800% Notes due July 2046</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,467</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1,000&#160;million, 3.875% Notes due October 2047</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">989</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$3,000&#160;million, 4.900% Notes due December 2048</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,970</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1,250&#160;million, 3.400% Notes due March 2050</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,236&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1,500 million, 3.400% Notes due March 2051</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,479</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, including finance leases</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28,155</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,100&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Included in the February 2024 debt tender offers discussed below.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">The Company has entered into interest rate swap contracts hedging a portion of these fixed-rate debt instruments. See Note 12 to the Consolidated Financial Statements for further information about the Company's interest rate risk management and these derivative instruments.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Interest rate step down to 8.080% effective January 15, 2023.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ScheduleOfIssuancesOfLongTermDebtTableTextBlock', window );">Summary of Debt Issuances</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 7, 2023, the Company issued $1.5&#160;billion of new senior notes. The proceeds of this issuance were used for general corporate purposes, and included repayment of outstanding debt securities. Interest on this debt is paid semi-annually.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.486%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Proceeds</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$700 million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 15, 2026</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.685%</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$698 million</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$800 million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 15, 2033</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.400%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$796 million</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Redeemable at any time discounted at the U.S. Treasury rate plus 20 basis points. Redeemable at par on or after March 15, 2024.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Redeemable at any time discounted at the U.S. Treasury rate plus 25 basis points. Redeemable at par on or after December 15, 2032.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Maturities of Outstanding Long-Term Debt</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Maturities of outstanding long-term debt as of December&#160;31, 2023 are as follows and exclude the impact of the 2024 debt issuance and debt tender offers described above:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:88.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.039%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Scheduled Maturities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,359</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maturities after 2028</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16,122</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span> Long-term debt maturity amounts include current maturities of long-term debt. Finance leases are excluded from this table. See Note 21 - Leases for finance lease maturity amounts.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ScheduleOfIssuancesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Issuances Of Long-Term Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ScheduleOfIssuancesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ScheduleOfShortTermDebtLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance-sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation. Also, Pertinent information about each long-term debt arrangement including the carrying amount as of the balance sheet date, by type of long-term debt. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ScheduleOfShortTermDebtLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (S-X 210.12-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288966448192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Preferred Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Share Activity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the share activity of The Cigna Group:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.042%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Shares in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common: Par value $0.01; 600,000 shares authorized</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding- January 1,</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">298,676</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">322,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">354,771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net issued for stock option exercises and other benefit plans</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,619</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,173&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,375&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchased common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(7,791)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27,445)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35,198)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding- December 31,</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">292,504</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298,676&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">322,948&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">107,390</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issued- December 31,</span></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">399,894</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">397,819&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">394,194&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsDeclaredTableTextBlock', window );">Dividend Payments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides details of the Company's dividend payments:</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Record Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payment Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount per Share</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Amount Paid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"> (in millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 8, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 23, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$1.23</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$368</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 7, 2023</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 22, 2023</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$1.23</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$362</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 6, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 21, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$1.23</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$362</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 6, 2023</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 21, 2023</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$1.23</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$358</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 9, 2022</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 24, 2022</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.12</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$357</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 8, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 23, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.12</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$352</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2022</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 22, 2022</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.12</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$341</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 6, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 21, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.12</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$334</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 10, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 25, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.00</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$345</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 8, 2021</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 23, 2021</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.00</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$342</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 8, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 23, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.00</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$330</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2021</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 22, 2021</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.00</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$324</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsDeclaredTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to dividends declared, including paid and unpaid dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsDeclaredTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-5<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481142/505-10-45-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-10<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288967978896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insurance and Contractholder Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceLossReservesAbstract', window );"><strong>Insurance Loss Reserves [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Summary of Insurance and Contractholder Liabilities, Activity in the Unpaid Claims Liability and Liability Details for Unpaid Claims and Claim Expenses</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's insurance and contractholder liabilities were comprised of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unpaid claims and claim expenses</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cigna Healthcare</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,017</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">75</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,092</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Operations</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">99</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">154</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">253</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Future policy benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cigna Healthcare</span></div></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">97</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">518</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">615</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">163</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,375</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,538</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractholder deposit funds</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cigna Healthcare</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">133</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">145</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Operations</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">362</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,178</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,540</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,358&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,709&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market risk benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">966</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,003</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unearned premiums</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">846</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">868</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,633</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11,421</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18,054</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Insurance and contractholder liabilities classified as liabilities of businesses held for sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,119)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(517)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,636)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total insurance and contractholder liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,514</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,904</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16,418</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,409&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,976&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,385&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Amounts classified as liabilities of businesses held for sale include $823&#160;million of Unpaid claims, $429&#160;million of Future policy benefits, $261&#160;million of Unearned premiums and $123&#160;million of Contractholder deposit funds as of December&#160;31, 2023. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Activity, net of intercompany transactions, in the unpaid claims liability for the Cigna Healthcare segment was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.042%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,176</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,261&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,695&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Reinsurance and other amounts recoverable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">221</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance, net</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,955</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,458&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incurred costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35,953</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,342&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,755&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(279)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(259)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total incurred</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35,674</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,083&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,536&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Paid costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">31,322</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,583&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,929&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,451</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">34,773</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,128&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,994&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,856</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,955&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Add: Reinsurance and other amounts recoverable</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">236</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,092</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,176&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,261&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Includes $823&#160;million classified as liabilities of businesses held for sale as of December 31, 2023.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock', window );">Variances in Incurred Costs Related to Prior Years' Unpaid Claims and Claims Expenses</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Variances in incurred costs related to prior years' unpaid claims and claim expenses that resulted from the differences between actual experience and the Company's key assumptions were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.889%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="24" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="12" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual completion factors</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical cost trend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">209</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total favorable variance</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">279</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Percentage of current year incurred costs as reported for the year ended December&#160;31, 2022.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Percentage of current year incurred costs as reported for the year ended December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock', window );">Summary of Incurred and Paid Claims Development, Claims Frequency Metrics and Incurred but Not Yet Reported Liabilities</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table depicts the incurred and paid claims development and unpaid claims liability as of December&#160;31, 2023 (net of reinsurance) reported in the Cigna Healthcare segment. The information about incurred and paid claims development for the year ended December&#160;31, 2022 is presented as supplementary information and is unaudited.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incurred Costs</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incurral Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022<br/>(Unaudited)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unpaid Claims &amp; Claim Expenses</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,309&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30,050</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">209</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">34,878</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,498</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative incurred costs for the periods presented</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">64,928</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Costs Paid</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incurral Year</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022<br/>(Unaudited)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,687&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29,841</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30,380</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative paid costs for the periods presented</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">60,221</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding liabilities for the periods presented, net of reinsurance</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,707</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-duration liabilities not included in development table above</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">149</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unpaid claims and claims expenses - Cigna Healthcare</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,856</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reinsurance and other amounts recoverable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">236</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unpaid claims and claim expenses - Cigna Healthcare</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,092</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitActivityTableTextBlock', window );">Future Policy Benefit Activity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The weighted average interest rates applied and duration for future policy benefits in the Cigna Healthcare segment, consisting primarily of supplemental health products including individual Medicare supplement, limited benefit health products and individual private medical insurance, were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest accretion rate </span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.54</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.58&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current discount rate </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4.92</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average duration </span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7.9 years</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.7 years</span></td></tr></table></div>The present values of expected net premiums and expected future policy benefits for the Cigna Healthcare segment are as follows: <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.262%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Present value of expected net premiums</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,557</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reversal of effect of beginning of period discount rate assumptions</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,537</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(367)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of assumption changes and actual variances from expected experience </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">314</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuances and lapses </span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,255</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,067&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net premiums collected</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,370)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,280)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest and other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">94</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance at original discount rate</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,387</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,094&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of end of period discount rate assumptions</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,154)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,537)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (3)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,233</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,557&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Present value of expected policy benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,945</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,794&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reversal of effect of discount rate assumptions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,611</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(379)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of assumption changes and actual variances from expected experience </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">112</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,148&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuances and lapses </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,309</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit payments</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,374)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,401)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest and other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance at original discount rate</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,853</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,556&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of discount rate assumptions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,611)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,633</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,945&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability for future policy benefits </span></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">388&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">215</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total liability for future policy benefits </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)(7)</span></div></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">615</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes the effect of actual variances from expectations, which (decreased)/increased the total liability for future policy benefits by $(12) million and $46 million, respectively, for the years ended December&#160;31, 2023 and December&#160;31, 2022.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes the foreign exchange rate impact of translating from transactional and functional currency to United States dollar and the impact of flooring the liability at zero. The flooring impact is calculated at the cohort level after discounting the reserves at the current discount rate.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">As of December&#160;31, 2023 and December&#160;31, 2022 undiscounted expected future gross premiums were $18.7 billion and $17.5 billion, respectively. As of December&#160;31, 2023 and December&#160;31, 2022 discounted expected future gross premiums were $13.5 billion and $12.2 billion, respectively.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">As of December&#160;31, 2023 and December&#160;31, 2022, undiscounted expected future policy benefits were $13.3 billion and $12.7 billion, respectively.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">The liability for future policyholder benefits includes immaterial businesses shown as reconciling items above, most of which are in run-off. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">$72 million and $155 million reported in Reinsurance recoverables in the Consolidated Balance Sheets as of December&#160;31, 2023 and December&#160;31, 2022, respectively, relate to the liability for future policy benefits. Additionally, $79 million of reinsurance recoverables are reported in assets of businesses held for sale in the Consolidated Balance Sheets as of December&#160;31, 2023.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes $429 million of future policy benefits classified as liabilities of businesses held for sale in the Consolidated Balance Sheets as of December&#160;31, 2023.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The weighted average interest rates applied and duration for future policy benefits in Other Operations, consisting of annuity and life insurance products, were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest accretion rate </span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5.64</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.64&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current discount rate </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4.87</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average duration </span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11.4 years</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5 years</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketRiskBenefitActivityTableTextBlock', window );">Summary of Market Risk Benefit</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Market risk benefits activity was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.444%"><tr><td style="width:1.0%"></td><td style="width:74.877%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Balance, beginning of year</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">1,268</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">1,824&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Balance, beginning of year, before the effect of nonperformance risk (own credit risk)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">1,379</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">1,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Changes due to expected run-off</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">(19)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(54)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Changes due to capital markets versus expected</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">(254)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(567)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Changes due to policyholder behavior versus expected</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">(5)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(14)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Assumption changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Balance, end of period, before the effect of changes in nonperformance risk (own credit risk)</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">1,085</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">1,379&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Nonperformance risk (own credit risk), end of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Balance, end of period</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">1,003</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">1,268&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Reinsured market risk benefit, end of period</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">1,081</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">1,374&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reinsurer </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Collateral and Other Terms</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">at December&#160;31, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Berkshire</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">873</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,116&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95% were secured by assets in a trust.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sun Life Assurance Company of Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">92</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liberty Re (Bermuda) Ltd.</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">104</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100% were secured by assets in a trust.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SCOR SE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80% were secured by a letter of credit.</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market risk benefits </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,398&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">All reinsurers are rated A- equivalent and higher by an NRSRO.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes IBNR and outstanding claims of $19 million. These amounts are excluded from market risk benefits at December&#160;31, 2023 in Note 10 and Note 11A to the Consolidated Financial Statements. At December&#160;31, 2022, IBNR and outstanding claims of $27 million offset by premium due of $3 million were excluded from the market risk benefits as restated due to the adoption of LDTI.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock', window );">Account Value, Net Amount at Risk and the Number of Contractholders for Guarantees Assumed in the Event of Death</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the account value, net amount at risk, average attained age of contractholders (weighted by exposure) and the number of contractholders for guarantees assumed by the Company. The net amount at risk is the amount that the Company would have to pay to contractholders if all deaths or annuitizations occurred as of the earliest possible date in accordance with the insurance contract. As of December&#160;31, 2023, the account value increased primarily due to favorable equity market performance, which resulted in an decrease to the net amount at risk. The Company should be reimbursed in full for these payments unless the Berkshire reinsurance limit is exceeded.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions, excludes impact of reinsurance ceded)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Account value</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,736</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,436&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net amount at risk</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,609</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Average attained age of contractholders (weighted by exposure)</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">77.3 years</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74.7 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of contractholders (estimated)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">140,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceLossReservesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceLossReservesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of beginning balance to ending balance for liability for future policy benefit, with separate presentation of expected future net premium and expected future benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29E<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketRiskBenefitActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of beginning balance to ending balance for contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29G<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29G<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-7B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketRiskBenefitActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reasons for the change in incurred claims and claim adjustment expenses recognized in the income statement attributable to insured events of prior fiscal years. Also includes disclosures of additional premiums or return premiums accrued as a result of changes in incurred claims and claim adjustment expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.W)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479583/944-40-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the guaranteed benefits in excess of the current account balance, quantifies such excesses (the net amounts at risk) and includes other relevant, pertinent information as of the most recent balance sheet date by product type.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 944<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479808/944-20-55-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480109/944-80-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted information about claims development by accident year for short-duration insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -SubTopic 40<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288967594496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reinsurance (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceDisclosuresAbstract', window );"><strong>Reinsurance Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock', window );">Reinsurance Recoverables by Range of External Credit Rating and Collateral Level</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's reinsurance recoverables as of December&#160;31, 2023 are presented at amount due by range of external credit rating and collateral level in the following table, with reinsurance recoverables that are market risk benefits separately presented at fair value:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.237%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Fair value of collateral contractually required to meet or exceed carrying value of recoverable</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Collateral provisions exist that may mitigate risk of credit loss </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">No collateral</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ongoing Operations</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">A- equivalent and higher current ratings </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">BBB- to BBB+ equivalent current credit ratings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">59</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">59</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Not rated</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">151</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">182</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">338</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total recoverables related to ongoing operations</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">151</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">331</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">487</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition, disposition or run-off activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BBB+ equivalent and higher current ratings </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lincoln National Life and Lincoln Life &amp; Annuity of New York</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,656</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,656</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Empower Annuity Insurance Company</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">130</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">130</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prudential Insurance Company of America</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">341</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">341</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Life Insurance Company of North America</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">356</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">356</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">166</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Not rated</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total recoverables related to acquisition, disposition or run-off activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">507</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,038</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">148</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,693</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reinsurance recoverables before market risk benefits</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">658</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,043</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">479</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,180</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allowance for uncollectible reinsurance</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(35)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market risk benefits </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,081</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reinsurance recoverables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,226</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Certified by a NRSRO.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes collateral provisions requiring the reinsurer to fully collateralize its obligation if its external credit rating is downgraded to a specified level.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Prior to the adoption of LDTI, "acquisition, disposition or run-off activities" in the table above included Berkshire and certain Other recoverables that are related to the Company's variable annuity reinsurance products discussed in section B below. These amounts are now reported at fair market value as MRBs, as further discussed in Note 10 to the Consolidated Financial Statements. At December&#160;31, 2022, we reported $711 million of recoverables related to the GMDB variable annuity reinsurance product. The restated December&#160;31, 2022 variable annuity reinsurance recoverable balance is $1.4 billion, which also includes the GMIB variable annuity reinsurance product that was classified in Other assets prior to the adoption of LDTI.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes $183 million of current reinsurance recoverables that are reported in Other current assets and $208 million of reinsurance recoverables classified as assets of businesses held for sale.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectsOfReinsuranceTableTextBlock', window );">Effects of Reinsurance</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents direct, assumed and ceded earned premiums for both short-duration and long-duration insurance contracts. It also presents reinsurance recoveries that have been netted against Medical costs and other benefit expenses in the Company's Consolidated Statements of Income.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.042%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Premiums</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-duration contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Direct</span></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">42,266</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,747&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,513&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">303</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ceded</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(277)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(265)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total short-duration contract premiums</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">42,292</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,898&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,700&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-duration contracts</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Direct</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,084</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assumed</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ceded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(211)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(286)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(398)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-duration contract premiums</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,945</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,018&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,454&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total premiums</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44,237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,916&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,154&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total reinsurance recoveries</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">456</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Total short-duration contracts written premiums were $41.1 billion, $35.0 billion and $35.6 billion for 2023, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketRiskBenefitActivityTableTextBlock', window );">Reinsurance Recoverables for Variable Annuity Business</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Market risk benefits activity was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.444%"><tr><td style="width:1.0%"></td><td style="width:74.877%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Balance, beginning of year</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">1,268</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">1,824&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Balance, beginning of year, before the effect of nonperformance risk (own credit risk)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">1,379</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">1,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Changes due to expected run-off</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">(19)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(54)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Changes due to capital markets versus expected</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">(254)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(567)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Changes due to policyholder behavior versus expected</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">(5)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(14)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Assumption changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Balance, end of period, before the effect of changes in nonperformance risk (own credit risk)</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">1,085</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">1,379&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Nonperformance risk (own credit risk), end of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Balance, end of period</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">1,003</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">1,268&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Reinsured market risk benefit, end of period</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">1,081</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">1,374&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reinsurer </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Collateral and Other Terms</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">at December&#160;31, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Berkshire</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">873</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,116&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95% were secured by assets in a trust.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sun Life Assurance Company of Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">92</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liberty Re (Bermuda) Ltd.</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">104</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100% were secured by assets in a trust.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SCOR SE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80% were secured by a letter of credit.</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market risk benefits </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,398&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">All reinsurers are rated A- equivalent and higher by an NRSRO.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes IBNR and outstanding claims of $19 million. These amounts are excluded from market risk benefits at December&#160;31, 2023 in Note 10 and Note 11A to the Consolidated Financial Statements. At December&#160;31, 2022, IBNR and outstanding claims of $27 million offset by premium due of $3 million were excluded from the market risk benefits as restated due to the adoption of LDTI.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectsOfReinsuranceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effects of reinsurance, for example, but not limited to, disclosure of direct, assumed, and ceded insurance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 605<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479655/944-605-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectsOfReinsuranceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketRiskBenefitActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of beginning balance to ending balance for contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29G<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29G<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-7B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketRiskBenefitActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of reinsurer or group of reinsurers for whom the entity has a concentration of credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -SubTopic 825<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479383/944-825-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288967751328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock', window );">Investments by category and current or long-term classification</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the Company's investments by category and current or long-term classification:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.212%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">590</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,265</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,855</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,218&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,872&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,331</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,362</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial mortgage loans</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">182</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,351</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,533</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,547&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Policy loans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,211</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,211</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term investments</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,181</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,181</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,728&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,728&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,009</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19,339</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20,348</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments classified as assets of businesses held for sale </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,354)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,438)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments per Consolidated Balance Sheets</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">925</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17,985</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18,910</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">905&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,288&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,193&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span> Investments related to the HCSC transaction that were held for sale as of December&#160;31, 2023. These investments were primarily comprised of debt securities and commercial mortgage loans, and to a lesser extent, other long term investments.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Debt Securities by Contractual Maturity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The amortized cost and fair value by contractual maturity periods for debt securities were as follows as of December&#160;31, 2023:</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">622</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">605</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,914</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,761</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,194</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,005</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,251</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,119</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset-backed securities</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">398</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">365</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,379</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,855</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Gross Unrealized Appreciation (Depreciation) on Debt Securities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gross unrealized appreciation (depreciation) on debt securities by type of issuer is shown below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.046%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for Credit Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Appreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal government and agency</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">251</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">267</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State and local government</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">355</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">352</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,338</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(33)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">158</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(630)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,833</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset-backed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">398</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">365</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,379</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(33)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">195</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(686)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,855</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal government and agency</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State and local government</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,742&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(981)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,806&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset-backed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,842&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,059)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,872&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Summary of Debt Securities with a Decline in Fair Value</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The table below summarizes debt securities with a decline in fair value from amortized cost for which an allowance for credit losses has not been recorded, by investment grade and the length of time these securities have been in an unrealized loss position. Unrealized depreciation on these debt securities is primarily due to declines in fair value resulting from increasing interest rates since these securities were purchased. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of Issues</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of Issues</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">One year or less</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investment grade</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">330</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">338</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">142</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(594)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Below investment grade</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">161</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">170</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">135</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">964&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,287&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More than one year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investment grade</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,441</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,036</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(595)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,590</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,487&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(336)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Below investment grade</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">701</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">775</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(74)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">486</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,633</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(686)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,353</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,901&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,960&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,059)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,777&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock', window );">Equity Security Investments</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides the values of the Company's equity security investments. The amount of impairments or value changes resulting from observable price changes on equity securities with no readily determinable fair value still held was not material to the financial statements as of December&#160;31, 2023 or 2022.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023 </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">656</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities with no readily determinable fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,248</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,311</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,904</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,362</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,053&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock', window );">Summary of the Credit Risk Profile of the Commercial Mortgage Loan Portfolio</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the credit risk profile of the Company's commercial mortgage loan portfolio:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.890%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Loan-to-Value Ratio</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Debt Service Coverage Ratio</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Loan-to-Value Ratio</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Debt Service Coverage Ratio</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Loan-to-Value Ratio</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Below 60%</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">802</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.13</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">901&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.12</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60% to 79%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">574</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.77</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.73</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80% to 100%</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">157</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.65</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.17</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,533</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.82</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">64</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.89</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock', window );">Carrying Value Information for Other Long-Term Investments</a></td>
<td class="text">The following table provides unfunded commitment and carrying value information for these investments. The Company expects to disburse approximately 25% of the committed amounts in 2024. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our limited partnership investments are reduced as the Company receives cash distributions for returns on its investment that were previously recognized in Net investment income. The amount of these cash distributions was $253 million in 2023, $487 million in 2022 and $568 million in 2021. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.237%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Commitments as of</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value as of December 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Real estate investments</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,319&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">712</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities partnerships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,085</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">175</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,181</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,728&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,797</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock', window );">Summary of Derivative Instruments Held</a></td>
<td class="text">The following table summarizes the types and notional quantity of derivative instruments held by the Company: <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.177%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Value as of</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purpose</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Instrument</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;text-decoration:underline">Fair value hedge:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> To hedge the foreign exchange-related changes in fair values of certain foreign-denominated bonds. The notional value of these derivatives matches the amortized cost of the hedged bonds. A majority of these instruments are denominated in Euros, with the remaining instruments denominated in British Pounds Sterling and Australian Dollars.</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency swap contracts</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,026</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,083&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Fair value hedge:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> To convert a portion of the interest rate exposure on the Company's long-term debt from fixed to variable rates. This more closely aligns the Company's interest expense with the interest income received on its cash equivalent and short-term investment balances. The variable rates are benchmarked to SOFR.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;text-decoration:underline">Net investment hedge:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> To reduce the risk of changes in net assets due to changes in foreign currency spot exchange rates for certain foreign subsidiaries that conduct their business principally in currencies other than the U.S. Dollar. The notional value of hedging instruments matches the hedged amount of subsidiary net assets. Foreign currency swap contracts are denominated in Euros.</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency swap contracts </span></div></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">415</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeTextBlock', window );">Components of Net Investment Income</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The components of Net investment income were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">123</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial mortgage loans</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">65</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Policy loans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term investments</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">123</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments and cash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">339</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total investment income</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,210</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,209&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,608&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less investment expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,166</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,155&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,549&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock', window );">Realized Gains and Losses on Investments</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following realized gains and losses on investments exclude realized gains and losses attributed to the Company's separate accounts because those gains and losses generally accrue directly to separate account policyholders:</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.344%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.042%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net realized investment (losses) gains, excluding credit loss expense and asset write-downs</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(68)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(451)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Credit (loss) / recovery and other investment write-down (losses)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net realized investment (losses) gains, before income taxes</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(78)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(487)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI And Equity Securities Without Readily Determinable Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Other Long-Term Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financing receivables by credit quality indicator. The credit quality indicator is a statistic about the credit quality of financing receivables. Examples include, but not limited to, consumer credit risk scores, credit-rating-agency ratings, an entity's internal credit risk grades, loan-to-value ratios, collateral, collection experience and other internal metrics.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of data and information required in the supplementary schedule applicable to management investment companies listing holdings of unaffiliated investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized gains and losses on investments reported in the statement of income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-8<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-5<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288970585008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Financial Assets and Financial Liabilities Carried at Fair Value</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides information about the Company's financial assets and liabilities carried at fair value. Further information regarding insurance assets and liabilities carried at fair value is provided in Note 10E to the Consolidated Financial Statements. Separate account assets are also recorded at fair value on the Company's Consolidated Balance Sheets and are reported separately in the Separate Accounts section below as gains and losses related to these assets generally accrue directly to contractholders:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial assets at fair value</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal government and agency</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">130</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">137</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">267</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State and local government</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">352</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">352</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,432</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">401</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,833</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset-backed</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">365</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">130</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,278</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,278&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">447</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,855</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,872&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">47</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">131</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">132</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial liabilities at fair value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Excludes certain equity securities that have no readily determinable fair value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value and Significant Unobservable Inputs Used in Pricing Debt Securities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the fair value and significant unobservable inputs that were developed directly by the Company and used in pricing these debt securities. The range and weighted average basis point amounts for liquidity reflect the Company's best estimates of the unobservable adjustments a market participant would make to calculate these fair values. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.101%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value as of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Adjustment Range (Weighted Average by Quantity) as of</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Fair value in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">401</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liquidity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">70 - 1235 (310)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">bps</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60 - 1060 (270)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset-backed securities</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liquidity</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">95 - 640 (310) </span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">bps</span></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105 - 520 (310)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">bps</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Level 3 debt securities</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">447</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock', window );">Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the changes in financial assets and financial liabilities classified in Level 3. Gains and losses reported in the table may include net changes in fair value that are attributable to both observable and unobservable inputs.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.066%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt and Equity Securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">447</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Losses) gains included in Shareholders' net income</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) included in Other comprehensive loss</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchases, sales and settlements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(52)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(207)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total purchases, sales and settlements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(42)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Transfers into/(out of) Level 3</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transfers into Level 3</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">95</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transfers out of Level 3</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(59)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(376)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total transfers into/(out of) Level 3</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(252)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">447</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total losses included in Shareholders' net income attributable to instruments held at the reporting date</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in unrealized gain or (loss) included in Other comprehensive loss for assets held at the end of the reporting period</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FairValueOfSeparateAccountAssetsTableTextBlock', window );">Fair Values of Separate Account Assets</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair values of Separate account assets were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Guaranteed separate accounts (See Note 24)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">226</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">352</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">578</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-guaranteed separate accounts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">158</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,797</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">217</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,172</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">384</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,149</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,904&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">217</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,750</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,521&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-guaranteed separate accounts priced at NAV as a practical expedient </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">680</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,430</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,278&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Non-guaranteed separate accounts include $4.0 billion as of December&#160;31, 2023 and December&#160;31, 2022 in assets supporting the Company's pension plans, including $0.2 billion classified in Level 3 as of December&#160;31, 2023 and December&#160;31, 2022.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTableTextBlock', window );">Additional Information on Separate Account Assets Priced at NAV</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Separate account investments in securities partnerships, real estate and hedge funds are generally valued based on the separate account's ownership share of the equity of the investee (NAV as a practical expedient), including changes in the fair values of its underlying investments. Substantially all of these assets support the Company's pension plans. The following table provides additional information on these investments:</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.322%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value as of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Commitment as of December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Redemption Frequency<br/>(if currently eligible)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Redemption Notice<br/>Period</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities partnerships</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">419</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">254</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Not applicable</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Not applicable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Real estate funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">258</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quarterly</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30 - 90 days</span></div></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Up to annually, varying by fund</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30 - 90 days</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">680</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">254</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Fair Value Disclosures for Financial Instruments Not Carried at Fair Value</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table includes the Company's financial instruments not recorded at fair value but for which fair value disclosure is required. In addition to universal life products and finance leases, financial instruments that are carried in the Company's Consolidated Balance Sheets at amounts that approximate fair value are excluded from the following table:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.045%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification in Fair Value Hierarchy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial mortgage loans</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,430</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,533</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,491&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt, including current maturities, excluding finance leases</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28,033</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29,585</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,653&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,994&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets and liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3, by class of assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_FairValueOfSeparateAccountAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclose the aggregate fair value of separate account assets, by fair value level.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_FairValueOfSeparateAccountAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2C<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2C<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investments in certain entities that calculate net asset value per share or equivalent measured at fair value on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288973836640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collectively Significant Operating Unconsolidated Subsidiaries (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Operating Joint Venture Investments</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The below summarized results of operations and financial position of the operating joint venture investments accounted for under the equity method reflects the latest available financial information and does not represent the Company's proportionate share of the assets, liabilities or earnings of such entities. Prior period operating joint venture amounts have been retrospectively restated to reflect the adoption of amended accounting guidance for long-duration insurance contracts, as discussed in Note 2 to the Consolidated Financial Statements. </span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,962</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,665&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,750&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">98</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">26,681</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,026&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">25,534</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,462&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140289064713104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Changes in the Components of AOCI</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the components of AOCI, including the restatement for amended accounting guidance for long-duration insurance contracts (discussed in Note 2 to the Consolidated Financial Statements), are as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.205%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Securities and Derivatives</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance, as previously disclosed</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative effect of accounting for Long-duration Insurance Contracts guidance (ASU 2018-12)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance, as retrospectively restated</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(332)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,266&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized appreciation (depreciation) on securities and derivatives</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">620</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,274)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(335)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax (expense) benefit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(146)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized appreciation (depreciation) on securities and derivatives</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">474</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,807)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(283)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustment for losses included in Shareholders' net income ((Loss) gain on sale of businesses)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustment for losses (gains) included in Shareholders' net income (Net realized investment (losses) gains)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustment for (gains) included in Shareholders' net income (Selling, general and administrative expenses)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustment for tax (benefit) expense included in Shareholders' net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net losses (gains) reclassified from AOCI to Shareholders' net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">503</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,598)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(302)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">171</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(332)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,266&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.205%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net long-duration insurance and contractholder liabilities measurement adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance, as previously disclosed</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative effect of accounting for Long-duration Insurance Contracts guidance (ASU 2018-12)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(832)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance, as retrospectively restated</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(256)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(765)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(832)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current period change in discount rate for certain long-duration liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(913)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">222</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period change in discount rate for certain long-duration liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(691)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current period change in instrument-specific credit risk for market risk benefits</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(29)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period change in instrument-specific credit risk for market risk benefits</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(24)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(715)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(971)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(256)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(765)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">Established upon the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.205%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Translation of foreign currencies</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance, as retrospectively restated</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Translation of foreign currencies</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(277)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(213)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net translation of foreign currencies</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(310)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(232)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustment for losses included in Net income ((Loss) gain on sale of businesses)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustment for tax expense included in Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net translation losses reclassified from AOCI to Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Translation of foreign currencies</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(213)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(232)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net translation (loss) on foreign currencies attributable to noncontrolling interests</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shareholders' other comprehensive income (loss), net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(149)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.205%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Postretirement benefits liability</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(916)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,336)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,746)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustment for amortization of net prior actuarial losses and prior service costs (Interest expense and other)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustment for (gains) included in Shareholders' net income ((Loss) gain on sale of businesses)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustment for settlement (Interest expense and other)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustment for tax (benefit) included in Shareholders' net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net adjustments reclassified from AOCI to Shareholders' net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation update</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(46)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change due to valuation update</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(34)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(915)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(916)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,336)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.205%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Accumulated other comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance, as previously disclosed</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(861)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative effect of accounting for Long-duration Insurance Contracts guidance (ASU 2018-12)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance, as retrospectively restated</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,658)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,068)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,025)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shareholders' other comprehensive (loss), net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(206)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(590)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,864)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,658)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,068)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288967981888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organizational Efficiency Plan (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Rollforward of Accrued Liability</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes a roll forward of the accrued liability recorded in Accrued expenses and other liabilities:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December&#160;31, 2022</span></div></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fourth quarter 2023 charge</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">232</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 payments</span></div></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(30)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December&#160;31, 2023</span></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">202</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288964531120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetFundedStatusTableTextBlock', window );">Summary of the Projected Benefit Obligations and Assets Related to Pension Plans</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the projected benefit obligations and assets related to our U.S. and non-U.S. pension plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change in benefit obligation</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit obligation, January 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,948</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">204</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actuarial losses (gains), net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">93</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,094)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits paid from plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(294)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(296)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(18)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit obligation, December 31</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,934</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,948&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change in plan assets</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets, January 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">246</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(366)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(294)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(296)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contributions</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets, December 31</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,138</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,186&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Funded status</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">204</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts presented in Consolidated Balance Sheets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">204</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> 2023 losses reflect a decrease in the discount rate while 2022 gains reflect an increase in the discount rate.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock', window );">Benefit Payments</a></td>
<td class="text">The following benefit payments are expected to be paid in:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:88.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">316</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">317</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">314</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">311</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2029 - 2033</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,484</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock', window );">Postretirement Benefits Liability Adjustment Included in AOCI</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amounts reflected in the pension assets/(liabilities) shown above that have not yet been reported in Net income and, therefore, have been included in Accumulated other comprehensive loss consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrecognized net (losses)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,207)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,208)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrecognized prior service cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Postretirement benefits liability adjustment</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,211)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,213)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Components of Net Pension Cost</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net pension cost was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">204</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected long-term return on plan assets</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(204)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(272)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(269)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization of:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior actuarial losses, net</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">52</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlement loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (benefit) cost</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">53</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Assumptions Used for Pension</a></td>
<td class="text"><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discount rate:</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension benefit obligation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5.10%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.43%</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension benefit cost</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5.43%</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.82%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expected long-term return on plan assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension benefit cost</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6.50%</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.75%</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortality table for pension obligations</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">White Collar mortality table with MP 2021 projection scale</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">White Collar mortality table with MP 2021 projection scale</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock', window );">Fair Value of Pension Assets by Category</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair values of pension assets by category are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal government and agency</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,780</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,349&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">121</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fund investments</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">278</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,191</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,947&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International, including funds and pooled separate accounts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Securities partnerships</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">419</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Real estate funds, including pooled separate accounts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">270</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial mortgage loans</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Guaranteed deposit account contract</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents and other current assets, net</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">131</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total pension assets at fair value</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,138</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,186&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> A pooled separate account has several participating benefit plans and each owns a share of the total pool of investments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock', window );">Annual Expense for 401(k) Plans</a></td>
<td class="text">The Company's annual expense for the plan was as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">296</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Subparagraph (d)(5)<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the net gain (loss) and net prior service cost or credit recognized in other comprehensive income (loss) for the period for pension plans and/or other employee benefit plans, and reclassification adjustments of other comprehensive income (loss) for the period, as those amounts, including amortization of the net transition asset or obligation, are recognized as components of net periodic benefit cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Subparagraph (f)<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Subparagraph (h)<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetFundedStatusTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of net funded status of pension plans and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetFundedStatusTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288968563344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Shares of Common Stock Available for Award</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Shares of common stock available for award were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares available for award</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Black-Sholes Option-Pricing Model Assumptions</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Black-Scholes option-pricing model assumptions and the resulting fair value of options are presented in the following table: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.749%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.58</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.98&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.85&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected option life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4.7 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5 years</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average fair value of options</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">79.66</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.61&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.84&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Status of and Changes in Common Stock Options</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table shows the status of, and changes in, common stock options:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Options in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding - January 1</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,992</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">186.54</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,490&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169.47&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,742&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152.40&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">915</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">294.37</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,375&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,524&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">213.81&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,080)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">174.66</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,617)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149.97&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,584)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.08&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired or canceled</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(131)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">246.95</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(256)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">211.22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(192)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199.10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding - December 31</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,696</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">202.02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,992&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186.54&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,490&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169.47&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable at year-end</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,616</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">179.28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,410&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">168.97&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,612&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152.92&#160;</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Information for Stock Options Exercised and Outstanding</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The table below summarizes information for stock options exercised:</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intrinsic value of options exercised</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">126</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash received for options exercised</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">187</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax benefit from options exercised</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes information for outstanding common stock options:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options<br/>Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options<br/>Exercisable</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number (in thousands)</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,696</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,616</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intrinsic value (in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">652</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">555</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">202.02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">179.28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average remaining contractual life</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5.9 years</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4.7 years</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Status of and Changes in Restricted Stock Awards and the Fair Value of Vested Restricted Stock</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table shows the status of, and changes in, restricted stock awards:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Awards in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grants/Units</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Fair Value at Award Date</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grants/Units</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Fair Value at Award Date</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grants/Units</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Fair Value at Award Date</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding - January 1</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,535</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">219.25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,524&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.85&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186.12&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">294.60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">229.60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">899&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">213.82&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(759)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">214.70</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(714)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197.83&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(866)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184.07&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(72)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">256.24</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(151)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.02&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(109)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197.01&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding - December 31</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,404</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">257.38</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,535&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">219.25&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,524&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.85&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of vested restricted stock at the vesting date was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of vested restricted stock</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">220</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock', window );">Status of and Changes in SPSs</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table shows the status of, and changes in, SPSs:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Awards in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Fair Value at Award Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Fair Value at Award Date</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Fair Value at Award Date</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding - January 1</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">780</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">212.68</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197.07&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190.02&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">219</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">293.85</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">213.90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(250)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">191.78</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(261)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">183.60&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196.29&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(63)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">237.50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(113)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207.75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197.38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding - December 31</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">686</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">243.90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">212.68&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197.07&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of vested SPSs at the vesting date was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.212%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Shares in thousands; $ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares of The Cigna Group common stock distributed upon SPS vesting</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">257</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">76</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Compensation Cost and Tax Effects of Share-based Compensation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline">Compensation Cost and Tax Effects of Share-based Compensation</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company records tax benefits in Shareholders' net income during the vesting period based on the amount of expense being recognized. The difference between tax benefits based on the expense and the actual tax benefit realized are also recorded in income tax expense when stock options are exercised, or when restricted stock and SPSs vest.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total compensation cost for shared-based awards</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">286</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax benefits recognized</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">92</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288968067280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill, Other Intangibles and Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract', window );"><strong>Goodwill Other Intangibles And Property And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Goodwill Activity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Goodwill activity.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Goodwill activity was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Evernorth Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cigna Healthcare</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,128&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,683&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,045&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill disposed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impact of foreign currency translation and other adjustments</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,130&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,681&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,811&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill transferred to assets of businesses held for sale</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,553)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,553)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impact of foreign currency translation and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill at December 31, 2023</span></div></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35,130</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,129</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44,259</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Includes $234 million classified as assets of businesses held for sale, all reported within Other Operations.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Other Indefinite-Lived Intangible Assets</a></td>
<td class="text">Other intangible assets were comprised of the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29,978</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,645</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22,333</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade Name - Express Scripts</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">317</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38,695</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,755</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30,940</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Value of business acquired ("VOBA" reported in Other assets)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">211</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">142</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">69</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38,906</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,897</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">31,009</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,974&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,099&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,875&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade Name - Express Scripts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,722&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,230&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,492&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Value of business acquired (reported in Other assets)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,932&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,363&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,569&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Includes $69&#160;million of VOBA and $77&#160;million of Other intangible assets classified as assets of businesses held for sale.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Other Finite-Lived Intangible Assets</a></td>
<td class="text">Other intangible assets were comprised of the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29,978</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,645</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22,333</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade Name - Express Scripts</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">317</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38,695</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,755</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30,940</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Value of business acquired ("VOBA" reported in Other assets)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">211</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">142</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">69</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38,906</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,897</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">31,009</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,974&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,099&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,875&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade Name - Express Scripts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,722&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,230&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,492&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Value of business acquired (reported in Other assets)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,932&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,363&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,569&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Includes $69&#160;million of VOBA and $77&#160;million of Other intangible assets classified as assets of businesses held for sale.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and equipment was comprised of the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Internal-use software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,155</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,161</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,994</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other property and equipment</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,282</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,405</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">877</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,437</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,566</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,871</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Internal-use software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other property and equipment</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,256&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,330&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,204&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,430&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,774&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span> Includes $176&#160;million of Property and equipment net carrying value classified as assets of businesses held for sale.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ComponentsOfDepreciationAndAmortizationTableTextBlock', window );">Components of Depreciation and Amortization Expense</a></td>
<td class="text">Depreciation and amortization expense was comprised of the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Internal-use software</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,216</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,068&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other property and equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">260</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Value of business acquired (reported in Other assets)</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangibles</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,552</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,606&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,548&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total depreciation and amortization</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,035</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,937&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,923&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated Annual Pre-Tax Amortization for Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company estimates annual pre-tax amortization for intangible assets, including internal-use software, over the next five calendar years to be as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:88.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax Amortization</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,892</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,357</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,803</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,559</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,484</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ComponentsOfDepreciationAndAmortizationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discloses the depreciation and amortization of property and equipment and other intangibles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ComponentsOfDepreciationAndAmortizationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288966323344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Operating and Finance Lease Right of Use ("ROU") Assets and Lease Liabilities</a></td>
<td class="text">ROU assets and lease liabilities are reflected in the following lines in the Company's Consolidated Balance Sheets:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROU Asset</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current Lease Liability</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-Current Lease Liability</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities (current)</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other liabilities (non-current)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt</span></td></tr></table><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating and finance lease ROU assets and lease liabilities were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.319%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating leases:</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease ROU assets in <span style="-sec-ix-hidden:f-2410"><span style="-sec-ix-hidden:f-2411">Other assets</span></span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">370</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2414"><span style="-sec-ix-hidden:f-2415">Accrued expenses and other liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2418"><span style="-sec-ix-hidden:f-2419">Other non-current liabilities</span></span></span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">340</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">445</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance leases:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">177</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2428"><span style="-sec-ix-hidden:f-2429">Property and equipment, net</span></span></span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">104</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2432"><span style="-sec-ix-hidden:f-2433">Short-term debt</span></span></span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">42</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-2436"><span style="-sec-ix-hidden:f-2437">Long-term debt</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Lease Expense</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The components of lease expense were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">115</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of ROU assets</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total finance lease cost</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">198</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CashFlowActivitiesLesseeTableTextBlock', window );">Supplemental Cash Flow Information Related to Leases</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Supplemental cash flow information related to leases was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.931%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash outflows from operating leases</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">132</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash outflows from finance leases</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing cash outflows from finance leases</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ROU assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">103</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Maturities of lease liabilities are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">102</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">83</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">63</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">98</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">497</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">115</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">52</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">445</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Maturities of Finance Lease Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Maturities of lease liabilities are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">102</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">83</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">63</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">98</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">497</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">115</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">52</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">445</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee right-of-use assets and lease liabilities for operating and finance leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_CashFlowActivitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee cash flows related to finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_CashFlowActivitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288973701760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders Equity and Dividend Restrictions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesDisclosureTextBlock', window );">Statutory Net Income and Net Assets of the Company's Subsidiaries</a></td>
<td class="text">The statutory net income of the Company's life, accident and health insurance and HMO subsidiaries for the years ended, and their statutory surplus as of December 31 were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In billions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surplus</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table>These amounts, including restricted GAAP net assets of the Company's subsidiaries, were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:88.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In billions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Minimum statutory surplus required by regulators </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments on deposit with regulatory bodies</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maximum dividend distributions permitted in 2024 without regulatory approval</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maximum loans to the parent company permitted without regulatory approval</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted GAAP net assets of The Cigna Group's subsidiaries</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Excludes amounts associated with foreign operated equity method joint ventures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of how the entity's reporting under GAAP as of the balance sheet date differs from the results based on prescribed and permitted accounting practices of the state or country of domicile in which a relevant statutory filing is made, or differences in results based on the National Association of Insurance Commissioners (NAIC) prescribed practices, or a combination thereof. Describes the accounting practices used and the related monetary effect on statutory surplus, net income, and risk-based capital. If an insurance enterprise's risk-based capital would have triggered a regulatory event had it not used a permitted practice, that fact is disclosed in the financial statements. Permitted statutory accounting practices include practices not prescribed but allowed by the domiciliary state insurance department regulatory authority.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 505<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479989/944-505-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 505<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479989/944-505-50-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 505<br> -Section 55<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479956/944-505-55-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 505<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479956/944-505-55-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 505<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479989/944-505-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288973965712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components of Income Tax Expense</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The components of income taxes were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current taxes</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. income taxes</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,459</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,679&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign income taxes</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">161</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State income taxes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">180</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current taxes</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,087&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,586&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deferred taxes (benefits)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. income tax benefits</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(533)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(275)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign income (tax benefits) taxes</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,046)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State income tax benefits</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(80)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(169)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total deferred tax benefits</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,659)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(472)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(216)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total income taxes</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">141</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,615&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,370&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Total Income Taxes to the Amount Computed Using the Nominal Federal Income Tax Rate</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total income taxes were different from the amount computed using the nominal federal income tax rate for the following reasons:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.891%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="36" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax expense at nominal rate</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,158</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,763&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,426&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impact of sale of businesses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impact of businesses held for sale</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(213)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3.9)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of foreign earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State income tax (benefit), net of federal income tax benefit</span></div></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(39)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.7)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss tax attributes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,674)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(30.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other foreign tax attributes</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(153)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2.8)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,290</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(55)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.9)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total income taxes</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">141</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,615&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,370&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Deferred Income Tax Assets and Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred income tax assets and liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deferred tax assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee and retiree benefit plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">217</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other insurance and contractholder liabilities</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">353</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">200</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred loss - sale of business</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">584</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">244</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Policy acquisition expenses</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized depreciation on investments and foreign currency translation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">81</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign tax attributes</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,827</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">242</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets before valuation allowance</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,787</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,322&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,498)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets, net of valuation allowance</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,289</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,114&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">371</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition-related basis differences</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,105</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,476</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,900&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net deferred income tax liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6,187)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,786)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Deferred tax liabilities, net in the Consolidated Balance Sheets as of December&#160;31, 2023, excludes $1,055&#160;million reported in Other assets and $69&#160;million reported in liabilities of businesses held for sale.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliations of Unrecognized Tax Benefits</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reconciliations of unrecognized tax benefits were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1,</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,343</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,230&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,210&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Decrease) / Increase due to prior year positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase due to current year positions</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">107</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction related to settlements with taxing authorities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction related to lapse of applicable statute of limitations</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31,</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,230&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288966086208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ScheduleOfSpecialItemsTableTextBlock', window );">Summary of Special Items</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the special items charges (benefits) recorded by the Company, as well as the respective financial statement line items impacted: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.372%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="33" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">After-tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">After-tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">After-tax</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss (gain) on sale of businesses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,499</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,429</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,662)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,332)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charge for organizational efficiency plan<br/>&#160;(Selling, general and administrative expenses)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">252</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">193</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charges (benefits) associated with litigation matters<br/>&#160;(Selling, general and administrative expenses)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">201</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">171</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Integration and transaction-related costs<br/>&#160;(Selling, general and administrative expenses)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax (benefits), net<br/>&#160;(Income taxes, less amount attributable to noncontrolling interests)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,071)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt extinguishment costs </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total impact from special items</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,997</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">757</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,533)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,232)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Summarized Segment Financial Information</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Effective January 1, 2023, we adopted amended accounting guidance for long-duration insurance contracts. See Note 2 to the Consolidated Financial Statements for further information. Prior period summarized segment information has been retrospectively adjusted to conform to this new basis of accounting. Summarized segment financial information was as follows:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.349%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Evernorth Health Services</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cigna Healthcare</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Operations</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate and Eliminations</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="33" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from external customers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">147,588</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46,219</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">291</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">194,099</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,670</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,332</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(10,002)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net investment income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">241</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">597</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">305</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,166</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">153,499</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51,148</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">596</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(9,978)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">195,265</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net realized investment results from certain equity method investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">57</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">57</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">153,499</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51,205</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">596</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(9,978)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">195,322</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,438</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">569</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,035</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,768</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,664</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">76</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,995)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,513</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax adjustments to reconcile to adjusted income from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Income) attributable to noncontrolling interests</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(144)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(146)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net realized investment losses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">133</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">135</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,774</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,819</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Special items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on sale of businesses</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,481</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,499</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charge for organizational efficiency plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">252</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">252</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charges associated with litigation matters</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">157</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">201</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Integration and transaction-related costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted income (loss) from operations</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,442</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,478</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">96</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,698)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,318</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Evernorth Health Services</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cigna Healthcare</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Operations</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate and Eliminations</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="33" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from external customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135,786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,463&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,535&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,998)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net investment income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140,335&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,911&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,263&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,991)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180,518&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net realized investment results from certain equity method investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140,335&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,037&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,263&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,991)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180,644&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,283&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,937&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,421&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,470&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,101&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,595)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,397&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax adjustments to reconcile to adjusted income from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Income) attributable to noncontrolling interests</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net realized investment losses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,772&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,876&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Special items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) on sale of businesses</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,662)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,662)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charge for organizational efficiency plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Benefits) associated with litigation matters</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Integration and transaction-related costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted income (loss) from operations</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,127&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,099&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,466)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,269&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Includes the Company's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.046%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Evernorth Health Services</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cigna Healthcare</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate and Eliminations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from external customers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,203&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,271&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,474)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net investment income (loss)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131,912&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,643&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,989&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,475)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174,069&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net realized investment results from certain equity method investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted revenues</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131,912&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,643&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,989&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,475)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174,069&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,316&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,923&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income (loss) before income taxes</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,908&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,804&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,790)</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,790&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pre-tax adjustments to reconcile to adjusted income from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Income) attributable to noncontrolling interests</span></div></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net realized investment losses (gains) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(247)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,937&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,998&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Special items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charge for organizational efficiency plan</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Benefits) associated with litigation matters</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Integration and transaction-related costs</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt extinguishment costs </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax adjusted income (loss) from operations</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,818&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,601&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">903&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,339)</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,983&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span> Includes the Company's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Revenue from External Customers</a></td>
<td class="text"><div><span id="i447ccaf65a4944e2ab470d4dcddafa7a_953"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue from external customers includes Pharmacy revenues, Premiums and Fees and other revenues. Prior period amounts have been retrospectively adjusted to reflect adoption of amended accounting guidance for long-duration insurance contracts (as discussed in Note 2 to the Consolidated Financial Statements) and to reflect the merger of the U.S. Commercial and U.S. Government operating segments into the U.S. Healthcare operating segment (as discussed in Note 1 to the Consolidated Financial Statements). The following table presents these revenues by product, premium and service type:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.761%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.042%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Products (Pharmacy revenues) (ASC 606)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Network revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">67,514</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Home delivery and specialty revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">65,732</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61,283&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,391&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,047</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intercompany eliminations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5,050)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,416)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,398)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total pharmacy revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">137,243</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,566&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121,413&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance premiums (ASC 944)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cigna Healthcare</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">U.S. Healthcare</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employer insured</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16,490</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,771</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,896&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,362&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stop loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,143</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Individual and Family Plans</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,088</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,636&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,528&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,095</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Healthcare</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">40,587</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,188&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,149&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International Health</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,295</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Cigna Healthcare</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43,882</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,094&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,737&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Divested International businesses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intercompany eliminations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total premiums</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44,237</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,916&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,154&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Services (Fees) (ASC 606)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Evernorth Health Services</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,866</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,234&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,070&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cigna Healthcare</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,566</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Operations</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">210</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intercompany eliminations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5,026)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,583)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,067)</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total fees and other revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,619</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,881&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,953&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues from external customers</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">194,099</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179,363&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172,520&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Foreign and U.S. Revenues from External Customers</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">U.S. and foreign revenues from external customers are shown below. The Company's foreign revenues are generated by its foreign operating entities. In the periods shown, no single foreign country contributed more than 2% of consolidated revenues from external customers.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">189,840</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174,540&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166,626&#160;</span></td><td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign countries </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,259</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues from external customers</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">194,099</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179,363&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172,520&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> The divested International businesses as described in Note 5 comprised of $1.6 billion and $3.2 billion in 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ScheduleOfSpecialItemsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of pre- and after-tax amounts reported as special items, attributable to the parent. Special items are amounts that management does not believe are representative of underlying results of operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ScheduleOfSpecialItemsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288969836784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEC Schedule, Article 12-04, Condensed Financial Information of Registrant (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract', window );"><strong>Condensed Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfIssuancesOfLongTermDebtTableTextBlock', window );">Summary of Debt Issuances</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 7, 2023, the Company issued $1.5&#160;billion of new senior notes. The proceeds of this issuance were used for general </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">corporate purposes, and included repayment of outstanding debt securities. Interest on this debt is paid semi-annually.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.486%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Proceeds</span></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$700 million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 15, 2026</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.685%</span></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$698 million</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$800 million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 15, 2033</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.400%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$796 million</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Redeemable at any time discounted at the U.S. Treasury rate plus 20 basis points. Redeemable at par on or after March 15, 2024.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span> Redeemable at any time discounted at the U.S. Treasury rate plus 25 basis points. Redeemable at par on or after December 15, 2032.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-Term Debt</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Maturities of the Company's long-term debt are as follows and exclude the impacts of the 2024 debt issuance and debt tender offers discussed above. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:88.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,214</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,957</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,734</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"></td><td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,056</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maturities after 2028</span></td><td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15,091</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfIssuancesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Condensed Financial Information Of Parent Company Only, Schedule Of Issuances Of Long-Term Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfIssuancesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Condensed Financial Information Of Parent Company Only, Schedule Of Maturities Of Long-Term Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288959441504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business (Details) - Medicare Advantage and related Cigna Healthcare businesses - Held-for-Sale - Subsequent Event<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jan. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationNameOfSegmentExtensibleList', window );">Disposal Group, Not Discontinued Operation, Name of Segment [Extensible Enumeration]</a></td>
<td class="text">Cigna Healthcare<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember', window );">Health Care Service Corporation (HCSC)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Sale price</a></td>
<td class="nump">$ 3.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationNameOfSegmentExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates business segment that includes disposal group not classified as discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationNameOfSegmentExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ci_HealthCareServiceCorporationHCSCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ci_HealthCareServiceCorporationHCSCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288968195904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Decrease to shareholders' equity</a></td>
<td class="num">$ (46,244)<span></span>
</td>
<td class="num">$ (44,688)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (46,976)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (50,189)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Increase to shareholders' net income</a></td>
<td class="nump">$ 5,164<span></span>
</td>
<td class="nump">$ 6,704<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 5,370<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Increase to diluted earnings per share (in dollars per share)</a></td>
<td class="nump">$ 17.39<span></span>
</td>
<td class="nump">$ 21.41<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 15.75<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember', window );">Revision of Prior Period, Accounting Standards Update, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Decrease to shareholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Increase to shareholders' net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Increase to diluted earnings per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_PharmacyBenefitsManagementServicesMember', window );">Pharmacy Benefits Management Services | Guarantees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Performance guarantee liability</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_AdministrativeServicesOnlyHealthCareServicesMember', window );">Administrative Services Only Health Care Services | Performance Guarantee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Loss contingency accrual provision</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Amounts paid for loss contigency</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow reducing loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-6<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 80: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 81: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 82: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 83: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 84: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 85: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 86: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 87: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 88: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 89: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 90: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 91: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 92: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ci_PharmacyBenefitsManagementServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ci_PharmacyBenefitsManagementServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_GuaranteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_GuaranteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ci_AdministrativeServicesOnlyHealthCareServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ci_AdministrativeServicesOnlyHealthCareServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_PerformanceGuaranteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_PerformanceGuaranteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288968054448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Receivable, Net - Amounts Included in Accounts Receivable, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PharmaceuticalManufacturerReceivable', window );">Pharmaceutical manufacturer receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,108<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable', window );">Noninsurance customer receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,899<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceCustomerReceivables', window );">Insurance customer receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,963<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Pharmaceutical manufacturers receivable, including held for sale assets</a></td>
<td class="nump">$ 8,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Noninsurance customer receivables, including held for sale assets</a></td>
<td class="nump">8,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceCustomerReceivablesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Insurance customer receivables, including held for sale assets</a></td>
<td class="nump">2,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AccountsAndOtherReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Other receivables, including held for sale assets</a></td>
<td class="nump">272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Total</a></td>
<td class="nump">18,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">17,722<span></span>
</td>
<td class="nump">$ 17,218<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Held-for-Sale | Medicare Advantage and related Cigna Healthcare businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Accounts receivable, net classified as assets of businesses held for sale</a></td>
<td class="num">$ (1,122)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AccountsAndOtherReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts and Other Receivables, Net, Current, Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AccountsAndOtherReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_InsuranceCustomerReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivables due from customers under insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_InsuranceCustomerReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_InsuranceCustomerReceivablesBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Insurance Customer Receivables, Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_InsuranceCustomerReceivablesBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivables due from customers that are not under insurance contracts. These include pharmacy sales and fees due from employer clients.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noninsurance Customer Receivables Excluding Pharmaceutical Manufacturers Receivable Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_PharmaceuticalManufacturerReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivables due from pharmaceutical manufacturers related to rebate contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_PharmaceuticalManufacturerReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_PharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pharmaceutical Manufacturers Receivable Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_PharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivables, Net, Current Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288966707216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable, Net - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AllowanceForReceivablesCurrent', window );">Allowance for receivables, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ContractualAllowancePharmaceuticalManufacturersReceivables', window );">Pharmaceutical manufacturers receivables allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ContractualAllowanceNoninsuranceCustomerReceivables', window );">Noninsurance customer receivables allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">386<span></span>
</td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AllowanceForReceivablesOther', window );">Remaining allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for current expected credit losses on accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AccountsReceivableUncommittedFactoringFacilityTotalCapacity', window );">Total capacity, uncommitted factoring facility</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AccountsReceivableUncommittedFactoringFacilityInitialTerm', window );">Initial term, uncommitted factoring facility (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AccountsReceivableUncommittedFactoringFacilityAutomaticRenewalTerm', window );">Automatic renewal term, uncommitted factoring facility (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AccountsReceivableUncommittedFactoringFacilityAmountSold', window );">Accounts receivable sold, uncommitted factoring facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AccountsReceivableUncommittedFactoringFacilityAccountsReceivableReceivedButNotRemitted', window );">Accounts receivable received but not remitted, uncommitted factoring facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AccountsReceivableUncommittedFactoringFacilityAccountsReceivableReceivedButNotRemitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of, as of the reporting date, of receivables sold to a financial institution under an uncommitted Accounts receivable factoring facility that have been received from the manufacturers but not yet remitted to the financial institution.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AccountsReceivableUncommittedFactoringFacilityAccountsReceivableReceivedButNotRemitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AccountsReceivableUncommittedFactoringFacilityAmountSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables sold to a financial institution under an uncommitted Accounts receivable factoring facility during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AccountsReceivableUncommittedFactoringFacilityAmountSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AccountsReceivableUncommittedFactoringFacilityAutomaticRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Automatic renewal term for uncommitted Accounts receivable factoring facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AccountsReceivableUncommittedFactoringFacilityAutomaticRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AccountsReceivableUncommittedFactoringFacilityInitialTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial term length for uncommitted Accounts receivable factoring facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AccountsReceivableUncommittedFactoringFacilityInitialTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AccountsReceivableUncommittedFactoringFacilityTotalCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of certain accounts receivable that may be sold on a non-recourse basis to a financial institution under an uncommitted Accounts receivable factoring facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AccountsReceivableUncommittedFactoringFacilityTotalCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AllowanceForReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for receivables, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AllowanceForReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AllowanceForReceivablesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other allowances classified as current, including allowances, discounts and claims adjustments issued to customers in the form of client credits, allowance for current expected credit losses and other non-credit adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AllowanceForReceivablesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ContractualAllowanceNoninsuranceCustomerReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual allowances from third-party payors based upon the contractual payment terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ContractualAllowanceNoninsuranceCustomerReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ContractualAllowancePharmaceuticalManufacturersReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual allowances for certain rebates receivables with pharmaceutical manufacturers, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ContractualAllowancePharmaceuticalManufacturersReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288966384448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplier Finance Program (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramPaymentTimingPeriod', window );">Payment term (in months)</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramObligationCurrent', window );">Outstanding payment obligations, current</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold', window );">Outstanding payment obligations, current, voluntarily elected by suppliers to be sold to the financial institution</a></td>
<td class="nump">$ 298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration', window );">Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accounts payable<span></span>
</td>
<td class="text">Accounts payable<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplier Finance Program, Outstanding Payment Obligation, Current, Voluntarily Elected To Be Sold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplierFinanceProgramObligationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation for supplier finance program, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479468/405-50-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479468/405-50-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479468/405-50-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplierFinanceProgramObligationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes obligation for supplier finance program, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479468/405-50-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplierFinanceProgramPaymentTimingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period when payment is expected to be made to finance provider or intermediary in supplier finance program, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479468/405-50-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplierFinanceProgramPaymentTimingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288968389072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mergers, Acquisitions and Divestitures - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_TransactionRelatedCosts', window );">Integration and transaction-related costs, pre-tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
<td class="nump">$ 169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_TransactionRelatedCostsAfterTax', window );">Integration and transaction-related costs, after-tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">$ 103<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ci_CHSSJVLLCMember', window );">CHSS JV LLC | Guarantee of CHSS' credit facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsMaximumExposure', window );">Maximum guarantee exposure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember', window );">International life, accident, supplemental benefits businesses sold to Chubb | Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Sale price</a></td>
<td class="nump">$ 5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain (loss) on sale of business, pre-tax</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax', window );">Gain (loss) on sale of business, after-tax</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Not Discontinued Operation, Gain (Loss) On Disposal, Net Of Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_TransactionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre-tax transaction-related costs primarily consisting of fees for legal, advisory and other professional services, as well as employee costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_TransactionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_TransactionRelatedCostsAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>After-tax transaction-related costs including the impact of tax benefits realized from termination of merger agreement. Transaction-related costs consist primarily of fees for legal, advisory and other professional services as well as employee costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_TransactionRelatedCostsAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ci_CHSSJVLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ci_CHSSJVLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_IndirectGuaranteeOfIndebtednessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_IndirectGuaranteeOfIndebtednessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288968192288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets and Liabilities of Businesses Held for Sale (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember', window );">Medicare Advantage and related Cigna Healthcare businesses | Held-for-Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract', window );"><strong>Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 467<span></span>
</td>
<td class="nump">$ 467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DisposalGroupIncludingDiscontinuedOperationInvestments', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,438<span></span>
</td>
<td class="nump">1,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,122<span></span>
</td>
<td class="nump">1,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DisposalGroupIncludingDiscontinuedOperationOtherAssetsGoodwill', window );">Other assets, including Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,963<span></span>
</td>
<td class="nump">2,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Goodwill classified as Assets of businesses held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">396<span></span>
</td>
<td class="nump">396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets of businesses held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,990<span></span>
</td>
<td class="nump">5,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities', window );">Insurance and contractholder liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,636<span></span>
</td>
<td class="nump">1,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DisposalGroupIncludingDiscontinuedOperationLiabilitiesExcludingInsuranceAndContractholderLiabilities', window );">All other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,059<span></span>
</td>
<td class="nump">1,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Total liabilities of businesses held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,695<span></span>
</td>
<td class="nump">$ 2,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxAbstract', window );"><strong>Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Estimated loss on sale, pre-tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax', window );">Estimated loss on sale, after-tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList', window );">Loss on sale of businesses, location, Consolidated Statements of Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(Loss) gain on sale of businesses<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember', window );">Medicare Advantage and related Cigna Healthcare businesses | Held-for-Sale | Health Care Service Corporation (HCSC) | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Sale price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember', window );">International life, accident and supplemental benefits businesses | Held-for-Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract', window );"><strong>Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Goodwill classified as Assets of businesses held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 234<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember', window );">International life, accident, supplemental benefits businesses sold to Chubb | Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Sale price</a></td>
<td class="nump">$ 5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxAbstract', window );"><strong>Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Estimated loss on sale, pre-tax</a></td>
<td class="num">(1,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax', window );">Estimated loss on sale, after-tax</a></td>
<td class="num">$ (1,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group,Including Discontinued Operation, Insurance And Contractholder Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DisposalGroupIncludingDiscontinuedOperationInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DisposalGroupIncludingDiscontinuedOperationInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DisposalGroupIncludingDiscontinuedOperationLiabilitiesExcludingInsuranceAndContractholderLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Liabilities Excluding Insurance And Contractholder Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DisposalGroupIncludingDiscontinuedOperationLiabilitiesExcludingInsuranceAndContractholderLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DisposalGroupIncludingDiscontinuedOperationOtherAssetsGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill and amount classified as other assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DisposalGroupIncludingDiscontinuedOperationOtherAssetsGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Not Discontinued Operation, Gain (Loss) On Disposal, Net Of Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income that includes gain (loss) recognized on sale or disposal of disposal group. Excludes discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ci_HealthCareServiceCorporationHCSCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ci_HealthCareServiceCorporationHCSCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288968457424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Shareholders' net income</a></td>
<td class="nump">$ 5,164<span></span>
</td>
<td class="nump">$ 6,704<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 5,370<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Shares:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted average (in shares)</a></td>
<td class="nump">293,892<span></span>
</td>
<td class="nump">309,546<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">337,962<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Common stock equivalents (in shares)</a></td>
<td class="nump">2,990<span></span>
</td>
<td class="nump">3,519<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,004<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Total shares (in shares)</a></td>
<td class="nump">296,882<span></span>
</td>
<td class="nump">313,065<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">340,966<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">EPS, basic (in dollars per share)</a></td>
<td class="nump">$ 17.57<span></span>
</td>
<td class="nump">$ 21.66<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 15.89<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_EarningsPerShareEffectOfDilution', window );">EPS, effect of dilution (in dollars per share)</a></td>
<td class="num">(0.18)<span></span>
</td>
<td class="num">(0.25)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(0.14)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">EPS, diluted (in dollars per share)</a></td>
<td class="nump">$ 17.39<span></span>
</td>
<td class="nump">$ 21.41<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 15.75<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_EarningsPerShareEffectOfDilution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in net income (loss) on a per share basis when the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period is assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_EarningsPerShareEffectOfDilution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288966105648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Outstanding Employee Stock Options Not Included in the Computation of Diluted Earnings Per Share (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive options (in shares)</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288964535024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Shares of Common Stock Held in Treasury (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Shares of common stock held in treasury</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,143<span></span>
</td>
<td class="nump">107,390<span></span>
</td>
<td class="nump">71,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Stock repurchased (in shares)</a></td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">10,400<span></span>
</td>
<td class="nump">12,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288960113824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Outstanding Amounts of Debt and Finance Leases (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 15, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrentAbstract', window );"><strong>Short-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Commercial paper</a></td>
<td class="nump">$ 1,237,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent', window );">Other, including finance leases</a></td>
<td class="nump">42,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Total short-term debt</a></td>
<td class="nump">2,775,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,993,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermDebtNoncurrent', window );">Other, including finance leases</a></td>
<td class="nump">66,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Total long-term debt</a></td>
<td class="nump">28,155,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,100,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue202383InterestMember', window );">$17&#160;million, 8.3% Notes due January 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrentAbstract', window );"><strong>Short-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current maturities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="nump">$ 17,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">8.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue2023765InterestMember', window );">$63&#160;million, 7.65% Notes due March 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrentAbstract', window );"><strong>Short-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current maturities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="nump">$ 63,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">7.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue2023FloatingRateInterestMember', window );">$700&#160;million, Floating Rate Notes due July 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrentAbstract', window );"><strong>Short-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current maturities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="nump">700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue20233InterestMember', window );">$1,000&#160;million, 3% Notes due July 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrentAbstract', window );"><strong>Short-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current maturities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">994,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue2023375InterestMember', window );">$1,187&#160;million, 3.75% Notes due July 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrentAbstract', window );"><strong>Short-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current maturities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,186,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="nump">$ 1,187,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue2024613InterestMember', window );">$500 million, 0.613% Notes due March 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrentAbstract', window );"><strong>Short-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current maturities</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">499,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">0.613%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue202435InterestMember', window );">$1,000&#160;million, 3.500% Notes due June 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrentAbstract', window );"><strong>Short-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current maturities</a></td>
<td class="nump">$ 996,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">990,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue2025325InterestMember', window );">$900&#160;million, 3.250% Notes due April 2025 (2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 882,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">872,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="nump">$ 900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue20254125InterestMember', window );">$2,200&#160;million, 4.125% Notes due November 2025 (1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 2,197,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,195,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="nump">$ 2,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">4.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue202645InterestMember', window );">$1,500&#160;million, 4.500% Notes due February 2026 (1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 1,502,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,503,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue2026125Member', window );">$800 million, 1.250% Notes due March 2026 (1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 798,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">797,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="nump">$ 800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue20265685Member', window );">$700 million, 5.685% Notes due March 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 698,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="nump">$ 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">5.685%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue202734InterestMember', window );">$1,500&#160;million, 3.400% Notes due March 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 1,450,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,436,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_DebenturesDue20277875InterestMember', window );">$259&#160;million, 7.875% Debentures due May 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 259,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="nump">$ 259,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">7.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue2027305Member', window );">$600&#160;million, 3.050% Notes due October 2027 (1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 597,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">3.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue20284375InterestMember', window );">$3,800&#160;million, 4.375% Notes due October 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 3,787,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,785,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="nump">$ 3,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue203024InterestMember', window );">$1,500&#160;million, 2.400% Notes due March 2030 (1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 1,493,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,492,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue20312375InterestMember', window );">$1,500 million, 2.375% Notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 1,397,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,380,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">2.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_StepDownNotesDueJanuary2033Member', window );">$45&#160;million, 8.080% Step Down Notes due January 2033 (3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="nump">$ 45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">8.08%<span></span>
</td>
<td class="nump">8.08%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue20335400InterestMember', window );">$800 million, 5.400% Notes due March 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 794,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="nump">$ 800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">5.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue2036615InterestMember', window );">$190&#160;million, 6.150% Notes due November 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 190,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="nump">$ 190,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">6.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue203848InterestMember', window );">$2,200&#160;million, 4.800% Notes due August 2038</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 2,193,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,192,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="nump">$ 2,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue204032InterestMember', window );">$750&#160;million, 3.200% Notes due March 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 744,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">743,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue20415875InterestMember', window );">$121&#160;million, 5.875% Notes due March 2041</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 119,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="nump">$ 121,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">5.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue20416125InterestMember', window );">$448&#160;million, 6.125% Notes due November 2041</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 487,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">488,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="nump">$ 448,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue20425375InterestMember', window );">$317&#160;million, 5.375% Notes due February 2042</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 315,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">315,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="nump">$ 317,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">5.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue204648InterestMember', window );">$1,500&#160;million, 4.800% Notes due July 2046</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 1,467,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,466,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue20473875Member', window );">$1,000&#160;million, 3.875% Notes due October 2047</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 989,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">989,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue204849InterestMember', window );">$3,000&#160;million, 4.900% Notes due December 2048</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 2,970,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,968,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="nump">$ 3,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">4.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue205034InterestMember', window );">$1,250&#160;million, 3.400% Notes due March 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 1,237,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,236,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue205134InterestMember', window );">$1,500 million, 3.400% Notes due March 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 1,479,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,478,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Short-Term Debt, Current Maturities Of Long-Term Debt, And Lease Obligations, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommercialPaper">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommercialPaper</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue202383InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue202383InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue2023765InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue2023765InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue2023FloatingRateInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue2023FloatingRateInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue20233InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue20233InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue2023375InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue2023375InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue2024613InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue2024613InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue202435InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue202435InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue2025325InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue2025325InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue20254125InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue20254125InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue202645InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue202645InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue2026125Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue2026125Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue20265685Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue20265685Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue202734InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue202734InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_DebenturesDue20277875InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_DebenturesDue20277875InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue2027305Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue2027305Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue20284375InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue20284375InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue203024InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue203024InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue20312375InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue20312375InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_StepDownNotesDueJanuary2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_StepDownNotesDueJanuary2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue20335400InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue20335400InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue2036615InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue2036615InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue203848InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue203848InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue204032InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue204032InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue20415875InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue20415875InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue20416125InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue20416125InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue20425375InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue20425375InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue204648InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue204648InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue20473875Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue20473875Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue204849InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue204849InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue205034InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue205034InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue205134InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue205134InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288955106480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Short-term and Credit Facilities Debt (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>USD ($) </div>
<div>revolvingCreditFacility </div>
<div>position</div>
</th>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CommercialPaperAverageRatePaid', window );">Commercial paper average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.63%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_RevolvingCreditAgreementsApril2023Member', window );">Revolving credit agreements, April 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Outstanding balances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity', window );">Aggregate amount of options to increase commitments</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity', window );">Maximum total commitment</a></td>
<td class="nump">$ 6,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NumberOfRevolvingCreditFacility', window );">Number of revolving credit facilities | revolvingCreditFacility</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement', window );">Number of participating banks | position</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant', window );">Leverage ratio covenant</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member', window );">Five-year Revolving Credit Agreement, Maturing April 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 4,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Credit agreement term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtInstrumentExtensionTerm', window );">Credit agreement extension term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member', window );">Five-year Revolving Credit Agreement, Maturing April 2028 | Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_A364DayRevolvingCreditAgreementMaturingApril2024Member', window );">364-day Revolving Credit Agreement, Maturing April 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Credit agreement term</a></td>
<td class="text">364 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LineOfCreditFacilityConversionToTermLoanTerm', window );">Credit facility, conversion to term loan, term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member', window );">Revolving Credit And Letter Of Credit Facility Maturing April 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Credit agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_RevolvingCreditFacilityMaturingApril2025Member', window );">Revolving Credit Facility Maturing April 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Credit agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_A364DayRevolvingCreditAgreementMaturingApril2023Member', window );">364 Day Revolving Credit Agreement, Maturing April 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Credit agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">364 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtInstrumentExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Extension Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtInstrumentExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Accordion Feature, Incremental Increase In Maximum Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LineOfCreditFacilityConversionToTermLoanTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Conversion To Term Loan, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LineOfCreditFacilityConversionToTermLoanTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The debt-to adjusted capital ratio which the Company must not exceed in accordance with the terms of the line of credit facility agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Maximum Borrowing Capacity And Accordion Feature, Incremental Increase In Maximum Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of banks participating in revolving credit and letter of credit agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_NumberOfRevolvingCreditFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Revolving Credit Facility</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_NumberOfRevolvingCreditFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CommercialPaperAverageRatePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average rate paid on commercial paper.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (a)<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (b)<br> -Subparagraph (3)<br> -Publisher SEC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CommercialPaperAverageRatePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_RevolvingCreditAgreementsApril2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_RevolvingCreditAgreementsApril2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_A364DayRevolvingCreditAgreementMaturingApril2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_A364DayRevolvingCreditAgreementMaturingApril2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_RevolvingCreditFacilityMaturingApril2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_RevolvingCreditFacilityMaturingApril2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_A364DayRevolvingCreditAgreementMaturingApril2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_A364DayRevolvingCreditAgreementMaturingApril2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288965558560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Long-term Debt (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 07, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><sup>[1]</sup></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><sup>[1]</sup></th>
<th class="th">
<div>Feb. 22, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 05, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on repurchase of debt, pre-tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td colspan="2" class="nump">$ 0<span></span>
</td>
<td colspan="2" class="nump">$ 141,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,967,000,000<span></span>
</td>
<td colspan="2" class="nump">$ 500,000,000<span></span>
</td>
<td colspan="2" class="nump">$ 4,578,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Aggregate principal amount of outstanding debt securities redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,550,000,000<span></span>
</td>
<td class="nump">$ 2,250,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Aggregate principal amount of outstanding debt securities redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue20265685Member', window );">$700 million, 5.685% Notes due March 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.685%<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000,000<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue20265685Member', window );">$700 million, 5.685% Notes due March 2026 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal</a></td>
<td class="nump">$ 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">5.685%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees', window );">Net proceeds</a></td>
<td class="nump">$ 698,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue20265685Member', window );">$700 million, 5.685% Notes due March 2026 | Senior Notes | Treasury rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate', window );">Redemption price discount, spread on variable rate</a></td>
<td class="nump">0.0020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue20335400InterestMember', window );">$800 million, 5.400% Notes due March 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.40%<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000,000<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue20335400InterestMember', window );">$800 million, 5.400% Notes due March 2033 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal</a></td>
<td class="nump">$ 800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">5.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees', window );">Net proceeds</a></td>
<td class="nump">$ 796,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue20335400InterestMember', window );">$800 million, 5.400% Notes due March 2033 | Senior Notes | Treasury rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate', window );">Redemption price discount, spread on variable rate</a></td>
<td class="nump">0.0025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue202435InterestMember', window );">$1,000&#160;million, 3.500% Notes due June 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue202435InterestMember', window );">$1,000&#160;million, 3.500% Notes due June 2024 | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Aggregate principal amount of outstanding debt securities redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Discount, Spread On Variable Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Long-term Debt, Net Of Discounts And Underwriting Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue20265685Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue20265685Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_UsTreasuryUstInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_UsTreasuryUstInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue20335400InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue20335400InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue202435InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue202435InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288970115872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Debt Maturities (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2025</a></td>
<td class="nump">3,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2026</a></td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2027</a></td>
<td class="nump">2,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2028</a></td>
<td class="nump">3,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Maturities after 2028</a></td>
<td class="nump">$ 16,122<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288966342368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Interest Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense on long-term and short-term debt</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288968263712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Preferred Stock - Share Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized for issuance (in shares)</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value of preferred stock (in dollars per share)</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Shares of preferred stock outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Changes in Total Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Outstanding - beginning balance (in shares)</a></td>
<td class="nump">298,676,000<span></span>
</td>
<td class="nump">322,948,000<span></span>
</td>
<td class="nump">354,771,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Issued for stock option exercises and other benefit plans (in shares)</a></td>
<td class="nump">1,619,000<span></span>
</td>
<td class="nump">3,173,000<span></span>
</td>
<td class="nump">3,375,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock (in shares)</a></td>
<td class="num">(7,791,000)<span></span>
</td>
<td class="num">(27,445,000)<span></span>
</td>
<td class="num">(35,198,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Outstanding - ending balance (in shares)</a></td>
<td class="nump">292,504,000<span></span>
</td>
<td class="nump">298,676,000<span></span>
</td>
<td class="nump">322,948,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock (in shares)</a></td>
<td class="nump">107,390,000<span></span>
</td>
<td class="nump">99,143,000<span></span>
</td>
<td class="nump">71,246,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">399,894,000<span></span>
</td>
<td class="nump">397,819,000<span></span>
</td>
<td class="nump">394,194,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288965462256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Preferred Stock - Dividends (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="12">3 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 02, 2024</div></th>
<th class="th"><div>Dec. 21, 2023</div></th>
<th class="th"><div>Sep. 21, 2023</div></th>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Mar. 23, 2023</div></th>
<th class="th"><div>Dec. 21, 2022</div></th>
<th class="th"><div>Sep. 22, 2022</div></th>
<th class="th"><div>Jun. 23, 2022</div></th>
<th class="th"><div>Mar. 24, 2022</div></th>
<th class="th"><div>Dec. 22, 2021</div></th>
<th class="th"><div>Sep. 23, 2021</div></th>
<th class="th"><div>Jun. 23, 2021</div></th>
<th class="th"><div>Mar. 25, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common dividends declared (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.23<span></span>
</td>
<td class="nump">$ 1.23<span></span>
</td>
<td class="nump">$ 1.23<span></span>
</td>
<td class="nump">$ 1.23<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 4.92<span></span>
</td>
<td class="nump">$ 4.48<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Amount per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.23<span></span>
</td>
<td class="nump">$ 1.23<span></span>
</td>
<td class="nump">$ 1.23<span></span>
</td>
<td class="nump">$ 1.23<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Total amount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 358<span></span>
</td>
<td class="nump">$ 362<span></span>
</td>
<td class="nump">$ 362<span></span>
</td>
<td class="nump">$ 368<span></span>
</td>
<td class="nump">$ 334<span></span>
</td>
<td class="nump">$ 341<span></span>
</td>
<td class="nump">$ 352<span></span>
</td>
<td class="nump">$ 357<span></span>
</td>
<td class="nump">$ 324<span></span>
</td>
<td class="nump">$ 330<span></span>
</td>
<td class="nump">$ 342<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,450<span></span>
</td>
<td class="nump">$ 1,384<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,341<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common dividends declared (in dollars per share)</a></td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="31"></td></tr>
<tr><td colspan="31"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288968357952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Preferred Stock - Accelerated Share Repurchase Agreements (Details) - USD ($)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 15, 2024</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesLineItems', window );"><strong>Accelerated Share Repurchases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Accelerated stock repurchase, amount authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt', window );">Accelerated stock repurchase, amount remitted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Stock repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">10.4<span></span>
</td>
<td class="nump">12.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,282,000,000<span></span>
</td>
<td class="nump">$ 7,593,000,000<span></span>
</td>
<td class="nump">$ 7,710,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AcceleratedShareRepurchasesVolumeWeightedAverageSharePriceLessDiscount', window );">Accelerated stock repurchase, volume weighted average share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesLineItems', window );"><strong>Accelerated Share Repurchases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Accelerated stock repurchase, amount authorized</a></td>
<td class="nump">$ 3,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt', window );">Accelerated stock repurchase, amount remitted</a></td>
<td class="nump">$ 3,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Stock repurchased (in shares)</a></td>
<td class="nump">7.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember', window );">Treasury Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesLineItems', window );"><strong>Accelerated Share Repurchases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,282,000,000<span></span>
</td>
<td class="nump">$ 7,593,000,000<span></span>
</td>
<td class="nump">$ 7,710,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember', window );">Treasury Stock | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesLineItems', window );"><strong>Accelerated Share Repurchases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Stock repurchased</a></td>
<td class="nump">$ 2,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesLineItems', window );"><strong>Accelerated Share Repurchases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AcceleratedShareRepurchasesVolumeWeightedAverageSharePriceLessDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accelerated Share Repurchases, Volume Weighted Average Share Price, Less Discount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AcceleratedShareRepurchasesVolumeWeightedAverageSharePriceLessDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash receipt from (payment to) bank; or stock received from (issuance to) bank in the settlement of the accelerated share repurchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481138/505-30-25-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288952106016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Insurance and Contractholder Liabilities - Account Balances (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_MarketRiskBenefitLiabilityAmountCurrent', window );">Market risk benefits, current</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_UnearnedPremiumsCurrent', window );">Unearned premiums, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">576<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_UnearnedPremiumsCurrentIncludingDisposalGroups', window );">Unearned premiums, current, including held for sale liabilities</a></td>
<td class="nump">846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups', window );">Total, current</a></td>
<td class="nump">6,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesCurrent', window );">Current insurance and contractholder liabilities</a></td>
<td class="nump">5,514<span></span>
</td>
<td class="nump">5,409<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract', window );"><strong>Non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_MarketRiskBenefitLiabilityAmountNoncurrent', window );">Market risk benefits, non-current</a></td>
<td class="nump">966<span></span>
</td>
<td class="nump">1,217<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_UnearnedPremiumsNoncurrent', window );">Unearned premiums, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_UnearnedPremiumsNoncurrentIncludingDisposalGroups', window );">Unearned premiums, non-current, including held for sale liabilities</a></td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups', window );">Total, non-current</a></td>
<td class="nump">11,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesNoncurrent', window );">Non-current insurance and contractholder liabilities</a></td>
<td class="nump">10,904<span></span>
</td>
<td class="nump">11,976<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketRiskBenefitLiabilityAmount', window );">Market risk benefits</a></td>
<td class="nump">1,003<span></span>
</td>
<td class="nump">1,268<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnearnedPremiums', window );">Unearned premiums</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">598<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_UnearnedPremiumsIncludingDisposalGroups', window );">Unearned premiums, including held for sale liabilities</a></td>
<td class="nump">868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups', window );">Total</a></td>
<td class="nump">18,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilities', window );">Total insurance and contractholder liabilities</a></td>
<td class="nump">16,418<span></span>
</td>
<td class="nump">17,385<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Held-for-Sale | Medicare Advantage and related Cigna Healthcare businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInsuranceAndContractholderLiabilities', window );">Insurance and contractholder liabilities current, classified as held for sale</a></td>
<td class="num">(1,119)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract', window );"><strong>Non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInsuranceAndContractholderLiabilities', window );">Insurance and contractholder liabilities, non-current, classified as held for sale</a></td>
<td class="num">(517)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities', window );">Insurance and contractholder liabilities classified as held for sale</a></td>
<td class="num">(1,636)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups', window );">Unpaid claims classified as liabilities of business held for sale</a></td>
<td class="nump">823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups', window );">Future policy benefits classified as liabilities of business held for sale</a></td>
<td class="nump">429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_UnearnedPremiumsAttributableToDisposalGroups', window );">Unearned premiums classified as liabilities of business held for sale</a></td>
<td class="nump">261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PolicyholderContractDepositsAttributableToDisposalGroups', window );">Contractholder deposit funds classified as liabilities held for sale</a></td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember', window );">Cigna Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent', window );">Unpaid claims and claim expenses, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,117<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrentIncludingDisposalGroups', window );">Unpaid claims and claim expenses, current, including held for sale liabilities</a></td>
<td class="nump">5,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent', window );">Future policy benefits, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForFuturePolicyBenefitsCurrentIncludingDisposalGroups', window );">Future policy benefits, current, including held for sale liabilities</a></td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PolicyholderContractDepositCurrent', window );">Contractholder deposit funds, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PolicyholderContractDepositCurrentIncludingDisposalGroups', window );">Contractholder deposit funds, current, including held for sale liabilities</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract', window );"><strong>Non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent', window );">Unpaid claims and claim expenses, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrentIncludingDisposalGroups', window );">Unpaid claims and claim expenses, non-current, including held for sale liabilities</a></td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent', window );">Future policy benefits, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">544<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForFuturePolicyBenefitsNoncurrentIncludingDisposalGroups', window );">Future policy benefits, non-current, including held for sale liabilities</a></td>
<td class="nump">518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PolicyholderContractDepositNoncurrent', window );">Contractholder deposit funds, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PolicyholderContractDepositNoncurrentIncludingDisposalGroups', window );">Contractholder deposit funds, non-current, including liabilities held for sale</a></td>
<td class="nump">133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Unpaid claims and claim expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,176<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4,261<span></span>
</td>
<td class="nump">$ 3,695<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups', window );">Unpaid claims and claim expenses, including held for sale liabilities</a></td>
<td class="nump">5,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefits', window );">Total liability for future policy benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">587<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForFuturePolicyBenefitsIncludingDisposalGroups', window );">Future policy benefits, including held for sale liabilities</a></td>
<td class="nump">615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderContractDeposits', window );">Contractholder deposit funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PolicyholderContractDepositsIncludingDisposalGroups', window );">Contractholder deposit funds, including liabilities held for sale</a></td>
<td class="nump">145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_OtherOperationsSegmentMember', window );">Other Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent', window );">Unpaid claims and claim expenses, current</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent', window );">Future policy benefits, current</a></td>
<td class="nump">163<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PolicyholderContractDepositCurrent', window );">Contractholder deposit funds, current</a></td>
<td class="nump">362<span></span>
</td>
<td class="nump">351<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract', window );"><strong>Non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent', window );">Unpaid claims and claim expenses, non-current</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent', window );">Future policy benefits, non-current</a></td>
<td class="nump">3,375<span></span>
</td>
<td class="nump">3,442<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PolicyholderContractDepositNoncurrent', window );">Contractholder deposit funds, non-current</a></td>
<td class="nump">6,178<span></span>
</td>
<td class="nump">6,358<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Unpaid claims and claim expenses</a></td>
<td class="nump">253<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefits', window );">Total liability for future policy benefits</a></td>
<td class="nump">3,538<span></span>
</td>
<td class="nump">3,592<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderContractDeposits', window );">Contractholder deposit funds</a></td>
<td class="nump">$ 6,540<span></span>
</td>
<td class="nump">$ 6,709<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInsuranceAndContractholderLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Current Insurance And Contractholder Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DisposalGroupIncludingDiscontinuedOperationCurrentInsuranceAndContractholderLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group,Including Discontinued Operation, Insurance And Contractholder Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInsuranceAndContractholderLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Noncurrent Insurance And Contractholder Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInsuranceAndContractholderLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_InsuranceAndContractholderLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Insurance And Contractholder Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_InsuranceAndContractholderLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_InsuranceAndContractholderLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Insurance And Contractholder Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_InsuranceAndContractholderLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_InsuranceAndContractholderLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts as of the balance sheet date of all current insurance and contractholder liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_InsuranceAndContractholderLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_InsuranceAndContractholderLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Insurance And Contractholder Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_InsuranceAndContractholderLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Insurance And Contractholder Liabilities, Current, Including Disposal Groups</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Insurance And Contractholder Liabilities, Including Disposal Groups</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_InsuranceAndContractholderLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts as of the balance sheet date of all current insurance and contractholder liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_InsuranceAndContractholderLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Insurance And Contractholder Liabilities, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Insurance And Contractholder Liabilities, Noncurrent, Including Disposal Groups</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Claims And Claims Adjustment Expense Attributable To Disposal Groups</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Claims And Claims Adjustment Expense, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrentIncludingDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount (expected to be paid within one year) needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrentIncludingDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Claims And Claims Adjustment Expense Including Disposal Groups</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Claims And Claims Adjustment Expense, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrentIncludingDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount (expected to be paid after one year) needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrentIncludingDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Future Policy Benefit, Before Reinsurance, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Future Policy Benefit, Before Reinsurance, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Future Policy Benefits Attributable To Disposal Groups</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForFuturePolicyBenefitsCurrentIncludingDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued obligation to policyholders that relates to insured events for long-duration contracts, expected to be paid within one year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForFuturePolicyBenefitsCurrentIncludingDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForFuturePolicyBenefitsIncludingDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Future Policy Benefits Including Disposal Groups</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForFuturePolicyBenefitsIncludingDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForFuturePolicyBenefitsNoncurrentIncludingDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued obligation to policyholders that relates to insured events for long-duration contracts, expected to be paid after one year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForFuturePolicyBenefitsNoncurrentIncludingDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_MarketRiskBenefitLiabilityAmountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Market Risk Benefit, Liability, Amount, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_MarketRiskBenefitLiabilityAmountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_MarketRiskBenefitLiabilityAmountNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Market Risk Benefit, Liability, Amount, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_MarketRiskBenefitLiabilityAmountNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_PolicyholderContractDepositCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Policyholder Contract Deposit, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_PolicyholderContractDepositCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_PolicyholderContractDepositCurrentIncludingDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Policyholder Contract Deposit, Current Including Disposal Groups</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_PolicyholderContractDepositCurrentIncludingDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_PolicyholderContractDepositNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Policyholder Contract Deposit, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_PolicyholderContractDepositNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_PolicyholderContractDepositNoncurrentIncludingDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Policyholder Contract Deposit, Noncurrent Including Disposal Groups</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_PolicyholderContractDepositNoncurrentIncludingDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_PolicyholderContractDepositsAttributableToDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Policyholder Contract Deposits Attributable To Disposal Groups</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_PolicyholderContractDepositsAttributableToDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_PolicyholderContractDepositsIncludingDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Policyholder Contract Deposits Including Disposal Groups</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_PolicyholderContractDepositsIncludingDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_UnearnedPremiumsAttributableToDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unearned Premiums Attributable To Disposal Groups</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_UnearnedPremiumsAttributableToDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_UnearnedPremiumsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unearned Premiums, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_UnearnedPremiumsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_UnearnedPremiumsCurrentIncludingDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of premiums written on insurance contracts that have not been earned as of the balance sheet date, expected to be paid in one year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_UnearnedPremiumsCurrentIncludingDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_UnearnedPremiumsIncludingDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unearned Premiums Including Disposal Groups</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_UnearnedPremiumsIncludingDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_UnearnedPremiumsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unearned Premiums, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_UnearnedPremiumsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_UnearnedPremiumsNoncurrentIncludingDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of premiums written on insurance contracts that have not been earned as of the balance sheet date, expected to be paid after one year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_UnearnedPremiumsNoncurrentIncludingDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before effect of reinsurance, of present value of future benefit to be paid to or on behalf of policyholder and related expense less present value of future net premium receivable under insurance contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29E<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-6<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(13)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketRiskBenefitLiabilityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability position for contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29G<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29G<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-7B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketRiskBenefitLiabilityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderContractDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability due to policyholder for deposit held under long-duration contract issued by insurance entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479250/944-40-25-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderContractDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnearnedPremiums">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of premiums written on insurance contracts that have not been earned as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(13)(a)(2))<br> -SubTopic 210<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnearnedPremiums</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ci_OtherOperationsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ci_OtherOperationsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288968007328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insurance and Contractholder Liabilities - Unpaid Claims and Claim Expenses - Cigna Healthcare - Activity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Held-for-Sale | Medicare Advantage and related Cigna Healthcare businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract', window );"><strong>Paid costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups', window );">Unpaid claims classified as liabilities of business held for sale</a></td>
<td class="nump">$ 823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember', window );">Cigna Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Liability for Claims and Claims Adjustment Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses', window );">Total of incurred but not reported liabilities plus expected claim development on reported claims, including reported claims in process</a></td>
<td class="nump">4,800<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Beginning balance</a></td>
<td class="nump">4,176<span></span>
</td>
<td class="nump">4,261<span></span>
</td>
<td class="nump">$ 3,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments', window );">Less: Reinsurance and other amounts recoverable</a></td>
<td class="nump">221<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet', window );">Beginning balance, net</a></td>
<td class="nump">3,955<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">3,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract', window );"><strong>Incurred costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current year</a></td>
<td class="nump">35,953<span></span>
</td>
<td class="nump">31,342<span></span>
</td>
<td class="nump">31,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior years</a></td>
<td class="num">(279)<span></span>
</td>
<td class="num">(259)<span></span>
</td>
<td class="num">(219)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total incurred</a></td>
<td class="nump">35,674<span></span>
</td>
<td class="nump">31,083<span></span>
</td>
<td class="nump">31,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract', window );"><strong>Paid costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current year</a></td>
<td class="nump">31,322<span></span>
</td>
<td class="nump">27,583<span></span>
</td>
<td class="nump">27,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior years</a></td>
<td class="nump">3,451<span></span>
</td>
<td class="nump">3,545<span></span>
</td>
<td class="nump">3,065<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total paid</a></td>
<td class="nump">34,773<span></span>
</td>
<td class="nump">31,128<span></span>
</td>
<td class="nump">30,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet', window );">Ending balance, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,955<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments', window );">Add: Reinsurance and other amounts recoverable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Ending balance (1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,176<span></span>
</td>
<td class="nump">$ 4,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups', window );">Ending balance, net, including held for sale liabilities</a></td>
<td class="nump">4,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups', window );">Add: Reinsurance, including held for sale liabilities</a></td>
<td class="nump">236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups', window );">Ending balance, including held for sale liabilities</a></td>
<td class="nump">$ 5,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Claims And Claims Adjustment Expense Attributable To Disposal Groups</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the total liability for incurred but not reported claims plus expected claim development on reported claims, including reported claims in process. Excludes amounts due for physician incentives and other medical care expenses and services payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Claims And Claims Adjustment Expense Including Disposal Groups</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Unpaid Claims And Claims Adjustment Expense Net Including Disposal Groups</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reinsurance Recoverable For Unpaid Claims And Claims Adjustments Including Disposal Groups</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -SubTopic 40<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -SubTopic 40<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability as of the balance sheet date for amounts representing estimated cost of settling unpaid claims under the terms of the underlying insurance policies, less estimated reinsurance recoveries on such claims. This includes an estimate for claims which have been incurred but not reported. Claim adjustment expenses represent the costs estimated to be incurred in the settlement of unpaid claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(13)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -SubTopic 40<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLossesAndLossAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after valuation allowance, recoverable under reinsurance contracts for losses reported to the ceding insurer but not yet paid and amounts expected for incurred losses and settlement expenses, which have not yet been reported to the ceding insurer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479584/944-310-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479838/944-20-50-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479616/944-310-45-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288960049648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insurance and Contractholder Liabilities - Unpaid Claims and Claims Expenses - Cigna Healthcare - Variances in Incurred Costs Related to Prior Years' Unpaid Claims and Claims Expenses (Details) - Cigna Healthcare - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract', window );"><strong>Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Favorable (unfavorable) variance, amount</a></td>
<td class="nump">$ 279<span></span>
</td>
<td class="nump">$ 259<span></span>
</td>
<td class="nump">$ 219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage', window );">Favorable (unfavorable) variance, percentage</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember', window );">Actual completion factors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract', window );"><strong>Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Favorable (unfavorable) variance, amount</a></td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage', window );">Favorable (unfavorable) variance, percentage</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember', window );">Medical cost trend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract', window );"><strong>Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Favorable (unfavorable) variance, amount</a></td>
<td class="nump">$ 209<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage', window );">Favorable (unfavorable) variance, percentage</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payments made in the reporting period to settle claims incurred in prior periods and related claims settlement costs as a percentage of incurred claims as reported in the prior year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncatastrophicEventAxis=ci_CompletionFactorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncatastrophicEventAxis=ci_CompletionFactorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncatastrophicEventAxis=ci_MedicalCostTrendMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncatastrophicEventAxis=ci_MedicalCostTrendMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288968246016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insurance and Contractholder Liabilities - Unpaid Claims and Claims Expenses - Cigna Healthcare - Incurred and Paid Claims Development and Unpaid Claims Liability (Details) - Cigna Healthcare<br> claim in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>claim</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>claim</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Incurred Costs, including assets held for sale</a></td>
<td class="nump">$ 64,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Cumulative Costs Paid, including assets held for sale</a></td>
<td class="nump">60,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Outstanding liabilities for the periods presented, net of reinsurance, including assets held for sale</a></td>
<td class="nump">4,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseLongDurationNetBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Other long-duration liabilities not included in development table above, including assets held for sale</a></td>
<td class="nump">149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups', window );">Net unpaid claims and claims expenses - Cigna Healthcare</a></td>
<td class="nump">4,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups', window );">Reinsurance and other amounts recoverable, including assets held for sale</a></td>
<td class="nump">236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups', window );">Unpaid claims and claim expenses, including held for sale liabilities</a></td>
<td class="nump">$ 5,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsHistoricalClaimsDurationYearOne', window );">Percent of health claims paid within one year</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShortdurationInsuranceContractsNumberOfPaidClaims', window );">Claim frequency | claim</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember', window );">Incurral Year - 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Incurred Costs, including assets held for sale</a></td>
<td class="nump">$ 30,050<span></span>
</td>
<td class="nump">$ 30,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Cumulative Costs Paid, including assets held for sale</a></td>
<td class="nump">29,841<span></span>
</td>
<td class="nump">$ 26,687<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Outstanding liabilities for the periods presented, net of reinsurance, including assets held for sale</a></td>
<td class="nump">209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember', window );">Incurral Year - 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Incurred Costs, including assets held for sale</a></td>
<td class="nump">34,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Cumulative Costs Paid, including assets held for sale</a></td>
<td class="nump">30,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Outstanding liabilities for the periods presented, net of reinsurance, including assets held for sale</a></td>
<td class="nump">$ 4,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Claims And Claims Adjustment Expense Including Disposal Groups</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseLongDurationNetBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Unpaid Claims And Claims Adjustment Expense Long Duration Net, Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseLongDurationNetBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Unpaid Claims And Claims Adjustment Expense Net Including Disposal Groups</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reinsurance Recoverable For Unpaid Claims And Claims Adjustments Including Disposal Groups</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-Duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net, Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-Duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net, Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shortduration Insurance Contracts Liability For Unpaid Claims And Allocated Claim Adjustment Expense Used In Claims Development Net, Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ShortdurationInsuranceContractsNumberOfPaidClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of customers for whom an insured medical claim was paid. Customers for whom no insured medical claim was paid and claims that did not result in a liability are excluded from the calculation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ShortdurationInsuranceContractsNumberOfPaidClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClaimsDevelopmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClaimsDevelopmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsHistoricalClaimsDurationYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of average annual payout, after reinsurance, in the first year after a claim is incurred, beginning with the earliest accident year disclosed for short-duration insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4G<br> -SubTopic 40<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-4G<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsHistoricalClaimsDurationYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288970463504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Insurance and Contractholder Liabilities - Future Policy Benefits - Interest Rates and Duration (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember', window );">Cigna Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesLineItems', window );"><strong>Insurance and Contractholder Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate', window );">Interest accretion rate</a></td>
<td class="nump">2.54%<span></span>
</td>
<td class="nump">2.58%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate', window );">Current discount rate</a></td>
<td class="nump">4.92%<span></span>
</td>
<td class="nump">5.57%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration', window );">Weighted average duration</a></td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_OtherOperationsSegmentMember', window );">Other Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesLineItems', window );"><strong>Insurance and Contractholder Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate', window );">Interest accretion rate</a></td>
<td class="nump">5.64%<span></span>
</td>
<td class="nump">5.64%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate', window );">Current discount rate</a></td>
<td class="nump">4.87%<span></span>
</td>
<td class="nump">5.19%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration', window );">Weighted average duration</a></td>
<td class="text">11 years 4 months 24 days<span></span>
</td>
<td class="text">11 years 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_InsuranceAndContractholderLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_InsuranceAndContractholderLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current weighted-average discount rate used to measure liability for future policy benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29E<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average duration of liability for future policy benefit, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Original weighted-average discount rate at contract issue date used to measure liability for future policy benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29E<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ci_OtherOperationsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ci_OtherOperationsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288965596992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insurance and Contractholder Liabilities - Future Policy Benefits - Present Value of Expected Premiums and Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward', window );"><strong>Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FuturePolicyBenefitsDomesticContractsObservableInputsFromPublishedSpotRateCurveMaximumTerm', window );">Observable inputs from published spot rate curve term (in years)</a></td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForFuturePolicyBenefitsPercentSupportedByAssetsHeldInTrust', window );">Percent of the liability for future policy benefits supported by assets held in trust</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Held-for-Sale | Medicare Advantage and related Cigna Healthcare businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward', window );"><strong>Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups', window );">Future policy benefits classified as liabilities of business held for sale</a></td>
<td class="nump">$ 429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember', window );">Cigna Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward', window );"><strong>Liability for Future Policy Benefit, Expected Net Premium [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange', window );">Beginning balance</a></td>
<td class="nump">8,557<span></span>
</td>
<td class="nump">$ 9,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax', window );">Reversal of effect of beginning of period discount rate assumptions</a></td>
<td class="nump">1,537<span></span>
</td>
<td class="num">(367)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience', window );">Effect of assumption changes and actual variances from expected experience (1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">314<span></span>
</td>
<td class="nump">$ 1,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumIssuanceAndDerecognition', window );">Issuances and lapses</a></td>
<td class="nump">1,255<span></span>
</td>
<td class="nump">1,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumNetPremiumCollected', window );">Net premiums collected</a></td>
<td class="num">(1,370)<span></span>
</td>
<td class="num">(1,280)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumInterestIncomeAndOtherChanges', window );">Interest and other</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance', window );">Ending balance at original discount rate</a></td>
<td class="nump">10,387<span></span>
</td>
<td class="nump">10,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax', window );">Effect of end of period discount rate assumptions</a></td>
<td class="num">(1,154)<span></span>
</td>
<td class="num">(1,537)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange', window );">Ending balance</a></td>
<td class="nump">9,233<span></span>
</td>
<td class="nump">8,557<span></span>
</td>
<td class="nump">9,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward', window );"><strong>Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange', window );">Beginning balance</a></td>
<td class="nump">8,945<span></span>
</td>
<td class="nump">9,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax', window );">Reversal of effect of discount rate assumptions</a></td>
<td class="nump">1,611<span></span>
</td>
<td class="num">(379)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience', window );">Effect of assumption changes and actual variances from expected experience (1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="nump">1,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitIssuanceAndDerecognition', window );">Issuances and lapses</a></td>
<td class="nump">1,309<span></span>
</td>
<td class="nump">1,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits', window );">Benefit payments</a></td>
<td class="num">(1,374)<span></span>
</td>
<td class="num">(1,401)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitInterestExpenseAndOtherChanges', window );">Interest and other</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance', window );">Ending balance at original discount rate</a></td>
<td class="nump">10,853<span></span>
</td>
<td class="nump">10,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax', window );">Effect of discount rate assumptions</a></td>
<td class="num">(1,220)<span></span>
</td>
<td class="num">(1,611)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange', window );">Ending balance</a></td>
<td class="nump">9,633<span></span>
</td>
<td class="nump">8,945<span></span>
</td>
<td class="nump">9,794<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther', window );">Liability for future policy benefits</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForFuturePolicyBenefitOther', window );">Other</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefits', window );">Total liability for future policy benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Total liability for future policy benefits, including assets held for sale</a></td>
<td class="nump">615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForFuturePolicyBenefitsCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience', window );">Effect of actual variances from expectations</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumUndiscountedBeforeReinsurance', window );">Undiscounted expected future gross premiums</a></td>
<td class="nump">18,700<span></span>
</td>
<td class="nump">17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumDiscountedBeforeReinsurance', window );">Discounted expected future gross premiums</a></td>
<td class="nump">13,500<span></span>
</td>
<td class="nump">12,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance', window );">Undiscounted expected future policy benefits</a></td>
<td class="nump">13,300<span></span>
</td>
<td class="nump">12,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance', window );">Future policy benefits reserve, reinsurance recoverables</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember', window );">Cigna Healthcare | Held-for-Sale | Medicare Advantage and related Cigna Healthcare businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward', window );"><strong>Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesLiabilityForFuturePolicyBenefitsAssetsHeldForSale', window );">Future policy benefits reserve, reinsurance recoverables reported in assets of businesses held for sale</a></td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_OtherOperationsSegmentMember', window );">Other Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward', window );"><strong>Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefits', window );">Total liability for future policy benefits</a></td>
<td class="nump">3,538<span></span>
</td>
<td class="nump">3,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance', window );">Undiscounted expected future policy benefits</a></td>
<td class="nump">4,500<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance', window );">Future policy benefits reserve, reinsurance recoverables</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability', window );">Future policy benefits, DPL</a></td>
<td class="nump">384<span></span>
</td>
<td class="nump">390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability', window );">Future policy benefit, excluding DPL</a></td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_OtherOperationsSegmentMember', window );">Other Operations | Disposed of by Sale | International life, accident and supplemental benefits businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward', window );"><strong>Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups', window );">Future policy benefits classified as liabilities of business held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_FuturePolicyBenefitsDomesticContractsObservableInputsFromPublishedSpotRateCurveMaximumTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future Policy Benefits, Domestic Contracts, Observable Inputs From Published Spot Rate Curve, Maximum Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_FuturePolicyBenefitsDomesticContractsObservableInputsFromPublishedSpotRateCurveMaximumTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Future Policy Benefit, Before Reinsurance And Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability for Future Policy Benefit, before Reinsurance, Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Future Policy Benefit, Excluding Deferred Profit Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Future Policy Benefit, Expected Future Policy Benefit, Cumulative Increase (Decrease) From Cash Flow Change And Actual Variance From Expected Experience</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitInterestExpenseAndOtherChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Future Policy Benefit, Expected Future Policy Benefit, Interest Expense And Other Changes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitInterestExpenseAndOtherChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitIssuanceAndDerecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Future Policy Benefit, Expected Future Policy Benefit, Issuance And Derecognition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitIssuanceAndDerecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Future Policy Benefit, Expected Net Premium, Cumulative Increase (Decrease) From Cash Flow Change And Actual Variance From Expected Experience</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumInterestIncomeAndOtherChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Future Policy Benefit, Expected Net Premium, Interest Income And Other Changes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumInterestIncomeAndOtherChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumIssuanceAndDerecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Future Policy Benefit, Expected Net Premium, Issuance And Derecognition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumIssuanceAndDerecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForFuturePolicyBenefitOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Future Policy Benefit, Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForFuturePolicyBenefitOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Future Policy Benefits Attributable To Disposal Groups</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForFuturePolicyBenefitsCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Future Policy Benefits Cumulative Increase Decrease Of Actual Variance From Expected Experience</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForFuturePolicyBenefitsCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Future Policy Benefits, Deferred Profit Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LiabilityForFuturePolicyBenefitsPercentSupportedByAssetsHeldInTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Future Policy Benefits, Percent Supported By Assets Held In Trust</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LiabilityForFuturePolicyBenefitsPercentSupportedByAssetsHeldInTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ReinsuranceRecoverablesLiabilityForFuturePolicyBenefitsAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reinsurance Recoverables, Liability For Future Policy Benefits, Assets Held-For-Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ReinsuranceRecoverablesLiabilityForFuturePolicyBenefitsAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive income (loss) (AOCI) from (increase) decrease in expected future policy benefit component of liability for future policy benefit from change in discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13I<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-13I<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive income (loss) (AOCI) from increase (decrease) in expected net premium component of liability for future policy benefit from change in discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13I<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-13I<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumDiscountedBeforeReinsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before effect of reinsurance, of discounted balance for expected future gross premium component of liability for future policy benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumDiscountedBeforeReinsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumUndiscountedBeforeReinsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before effect of reinsurance, of undiscounted balance for expected future gross premium component of liability for future policy benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29E<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumUndiscountedBeforeReinsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before effect of reinsurance and after current period update of cash flow assumption and discount rate change, of expected future policy benefit and expense component of liability for future policy benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29E<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before effect of reinsurance and current period update of cash flow assumption, of expected future policy benefit and expense component of liability for future policy benefit, discounted at original rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before effect of reinsurance, of undiscounted balance for expected future policy benefit and expense component of liability for future policy benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29E<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before effect of reinsurance and after current period update of cash flow assumption and discount rate change, of expected net premium component of liability for future policy benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29E<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumNetPremiumCollected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of premium collected from policyholder to fund expected benefit payment for expected net premium component of liability for future policy benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-13I<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumNetPremiumCollected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before effect of reinsurance and current period update of cash flow assumption, of expected net premium component of liability for future policy benefit, discounted at original rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, recoverable under reinsurance of liability for future policy benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29E<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before effect of reinsurance, of present value of future benefit to be paid to or on behalf of policyholder and related expense less present value of future net premium receivable under insurance contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29E<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-6<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(13)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to policyholder from benefit payment for expected future policy benefit and expense component of liability for future policy benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-13I<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ci_OtherOperationsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ci_OtherOperationsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288952033376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Insurance and Contractholder Liabilities - Contractholder Deposit Funds (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesLineItems', window );"><strong>Insurance and Contractholder Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PolicyholderContractBalancePercentReinsuredExternally', window );">Contractholder deposit fund liabilities, approximate percent reinsured externally</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember', window );">Cigna Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesLineItems', window );"><strong>Insurance and Contractholder Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderContractDeposits', window );">Contractholder deposit funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_OtherOperationsSegmentMember', window );">Other Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesLineItems', window );"><strong>Insurance and Contractholder Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderContractDeposits', window );">Contractholder deposit funds</a></td>
<td class="nump">$ 6,540<span></span>
</td>
<td class="nump">$ 6,709<span></span>
</td>
<td class="nump">$ 6,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate', window );">Weighted average crediting rate</a></td>
<td class="nump">3.31%<span></span>
</td>
<td class="nump">3.08%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderAccountBalanceNetAmountAtRisk', window );">Net amount at risk</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashSurrenderValueDuePolicyholdersAmount', window );">Cash surrender value</a></td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_OtherOperationsSegmentMember', window );">Other Operations | Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesLineItems', window );"><strong>Insurance and Contractholder Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage', window );">Contractholder deposit funds not reinsured externally, percent with guaranteed interest rates of 0300 to 0400</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderFunds', window );">Contractholder deposit funds not reinsured externally</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_OtherOperationsSegmentMember', window );">Other Operations | Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400 | Policyholder Account Balance, at Guaranteed Minimum Crediting Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesLineItems', window );"><strong>Insurance and Contractholder Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderFunds', window );">Contractholder deposit funds not reinsured externally</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_OtherOperationsSegmentMember', window );">Other Operations | Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400 | Policyholder Account Balance, above Guaranteed Minimum Crediting Rate, Range from 0051 to 0150</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesLineItems', window );"><strong>Insurance and Contractholder Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderFunds', window );">Contractholder deposit funds not reinsured externally</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_OtherOperationsSegmentMember', window );">Other Operations | Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400 | Policyholder Account Balance, Above Guaranteed Minimum Crediting Rate, Based On Greater Of Guaranteed Minimum Cash Value Or Actual Cash Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesLineItems', window );"><strong>Insurance and Contractholder Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderFunds', window );">Contractholder deposit funds not reinsured externally</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue', window );">Percentage with cash values at more than 110% of guaranteed cash value</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_OtherOperationsSegmentMember', window );">Other Operations | Minimum | Policyholder Account Balance, above Guaranteed Minimum Crediting Rate, Range from 0051 to 0150</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesLineItems', window );"><strong>Insurance and Contractholder Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate', window );">Above guaranteed minimum crediting rate</a></td>
<td class="nump">0.0050<span></span>
</td>
<td class="nump">0.0050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_OtherOperationsSegmentMember', window );">Other Operations | Minimum | Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesLineItems', window );"><strong>Insurance and Contractholder Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating', window );">Guaranteed minimum credit rating</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_OtherOperationsSegmentMember', window );">Other Operations | Maximum | Policyholder Account Balance, above Guaranteed Minimum Crediting Rate, Range from 0051 to 0150</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesLineItems', window );"><strong>Insurance and Contractholder Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate', window );">Above guaranteed minimum crediting rate</a></td>
<td class="nump">0.0150<span></span>
</td>
<td class="nump">0.0150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_OtherOperationsSegmentMember', window );">Other Operations | Maximum | Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InsuranceAndContractholderLiabilitiesLineItems', window );"><strong>Insurance and Contractholder Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating', window );">Guaranteed minimum credit rating</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_InsuranceAndContractholderLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_InsuranceAndContractholderLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of policyholder account balance representing contract with guaranteed interest rates of 3%-4%.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Policyholder Account Balance, Percentage With Cash Values At More Than 110 Percent Of Guaranteed Cash Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_PolicyholderContractBalancePercentReinsuredExternally">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Policyholder Contract Balance, Percent Reinsured Externally</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_PolicyholderContractBalancePercentReinsuredExternally</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashSurrenderValueDuePolicyholdersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash to be paid to policyholder upon termination and surrender of long-duration contract issued by insurance entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29F<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashSurrenderValueDuePolicyholdersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value above guaranteed minimum crediting rate on policyholder account balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29F<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Guaranteed minimum crediting rate on policyholder account balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29F<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderAccountBalanceNetAmountAtRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of guaranteed benefit in excess of current account balance of policyholder account balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29F<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderAccountBalanceNetAmountAtRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average crediting rate for liability for policyholder account balance, calculated at a point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29F<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderContractDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability due to policyholder for deposit held under long-duration contract issued by insurance entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479250/944-40-25-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderContractDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due to policyholder. Includes, but is not limited to, unpaid policy dividend, retrospective refund, and undistributed earnings on participating business. Excludes future policy benefit and claim expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29F<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-7A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(14)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ci_OtherOperationsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ci_OtherOperationsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis=us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis=us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis=us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis=us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis=us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis=us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis=ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis=ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288952042048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insurance and Contractholder Liabilities - Summary of Market Risk Benefit (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceLossReservesAbstract', window );"><strong>Insurance Loss Reserves [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AnnuitizationElectionPeriod', window );">Annuitization election period</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketRiskBenefitRollForward', window );"><strong>Market Risk Benefit [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk', window );">Balance, beginning of year</a></td>
<td class="nump">$ 1,268<span></span>
</td>
<td class="nump">$ 1,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange', window );">Balance, beginning of year, before the effect of nonperformance risk (own credit risk)</a></td>
<td class="nump">1,379<span></span>
</td>
<td class="nump">1,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff', window );">Changes due to expected run-off</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange', window );">Changes due to capital markets versus expected</a></td>
<td class="num">(254)<span></span>
</td>
<td class="num">(567)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected', window );">Changes due to policyholder behavior versus expected</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketRiskBenefitIncreaseDecreaseFromOtherAssumption', window );">Assumption changes</a></td>
<td class="num">(16)<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange', window );">Balance, end of period, before the effect of changes in nonperformance risk (own credit risk)</a></td>
<td class="nump">1,085<span></span>
</td>
<td class="nump">1,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax', window );">Nonperformance risk (own credit risk), end of period</a></td>
<td class="num">(82)<span></span>
</td>
<td class="num">(111)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk', window );">Balance, end of period</a></td>
<td class="nump">1,003<span></span>
</td>
<td class="nump">1,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance', window );">Reinsured market risk benefit, end of period</a></td>
<td class="nump">$ 1,081<span></span>
</td>
<td class="nump">$ 1,374<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AnnuitizationElectionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of time prior to a policy anniversary when an annuitization election must occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AnnuitizationElectionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Market Risk Benefit, Increase (Decrease) Due to Expected Run-Off</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Market Risk Benefit, Increase (Decrease) From Interest Rate Change And Equity Market Change</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive income (loss) (AOCI) from (increase) decrease in instrument-specific credit risk on contract or contract feature in long-duration contract issued by insurance entity protecting contract holder from other-than-nominal capital market risk and exposing insurance entity to other-than-nominal capital market risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29G<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29G<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-7B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13K<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-13K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceLossReservesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceLossReservesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before effect of reinsurance and after accumulated increase (decrease) in instrument-specific credit risk, of contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29G<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29G<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-7B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480112/944-40-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before effect of reinsurance and cumulative increase (decrease) in instrument-specific credit risk, of contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29G<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29G<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-7B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk from change associated with actual policyholder behavior different from expected.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29G<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29G<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-7B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13K<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-13K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketRiskBenefitIncreaseDecreaseFromOtherAssumption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk from change in assumption, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29G<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29G<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-7B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13K<br> -Subparagraph (j)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-13K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketRiskBenefitIncreaseDecreaseFromOtherAssumption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, recoverable under reinsurance for contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29G<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29G<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-7B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketRiskBenefitRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketRiskBenefitRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288964740096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insurance and Contractholder Liabilities - Net Amount of Risk and Average Age of Contractholders (Details) - Variable Annuity<br> position in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>position</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>position</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems', window );"><strong>Net Amount at Risk by Product and Guarantee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue', window );">Account value</a></td>
<td class="nump">$ 7,736<span></span>
</td>
<td class="nump">$ 7,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk', window );">Net amount at risk</a></td>
<td class="nump">$ 1,609<span></span>
</td>
<td class="nump">$ 2,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1', window );">Average attained age of contractholders (weighted by exposure)</a></td>
<td class="text">77 years 3 months 18 days<span></span>
</td>
<td class="text">74 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated', window );">Guaranteed Minimum Death Benefits Total Contractholders | position</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Amount At Risk By Product And Guarantee, Number Of Contractholders Estimated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of the general accounts corresponding to the specified product, guarantee type and subset of the guarantee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480109/944-80-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 944<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479808/944-20-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net amount at risk, representing the guaranteed benefit in excess of the current account balance corresponding to the specified product, guarantee type and subset of the guarantee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 944<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479808/944-20-55-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 80<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(3),(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480109/944-80-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average attained age of policyholders or contract holders in the specified guarantee type and subset of guarantee class, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 944<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479808/944-20-55-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph ((d)(5))<br> -SubTopic 80<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480109/944-80-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_VariableAnnuityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_VariableAnnuityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288951667408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Reinsurance - Reinsurance Recoverables (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">$ 4,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverableAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Allowance for uncollectible reinsurance, including assets held for sale</a></td>
<td class="num">(35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance', window );">Market risk benefits</a></td>
<td class="nump">1,081<span></span>
</td>
<td class="nump">$ 1,374<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Total reinsurance recoverables, including assets held for sale</a></td>
<td class="nump">5,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Held-for-Sale | Medicare Advantage and related Cigna Healthcare businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DisposalGroupIncludingDiscontinuedOperationReinsuranceRecoverablesIncludingReinsurancePremiumPaid', window );">Reinsurance recoverable classified as assets of businesses held for sale</a></td>
<td class="nump">208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverables', window );">Reinsurance recoverables</a></td>
<td class="nump">183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskAxis=ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaAndOtherRecoverablesMember', window );">Berkshire Hathway Life Insurance Company Of Nebraska and Other Recoverables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance', window );">Market risk benefits</a></td>
<td class="nump">1,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskCollateralizationAxis=ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember', window );">Fair value of collateral contractually required to meet or exceed carrying value of recoverable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskCollateralizationAxis=ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember', window );">Collateral provisions exist that may mitigate risk of credit loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">3,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskCollateralizationAxis=us-gaap_CededCreditRiskUnsecuredMember', window );">No collateral</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_VariableAnnuityMember', window );">Variable Annuity | Berkshire Hathway Life Insurance Company Of Nebraska and Other Recoverables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance', window );">Market risk benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_VariableAnnuityMember', window );">Variable Annuity | Berkshire Hathway Life Insurance Company Of Nebraska and Other Recoverables | GMDB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance', window );">Market risk benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 711<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_OngoingOperationsMember', window );">Ongoing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_OngoingOperationsMember', window );">Ongoing Operations | A- equivalent and higher current ratings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_OngoingOperationsMember', window );">Ongoing Operations | BBB- to BBB+ equivalent current credit ratings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_OngoingOperationsMember', window );">Ongoing Operations | Not rated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_OngoingOperationsMember', window );">Ongoing Operations | Fair value of collateral contractually required to meet or exceed carrying value of recoverable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_OngoingOperationsMember', window );">Ongoing Operations | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | A- equivalent and higher current ratings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_OngoingOperationsMember', window );">Ongoing Operations | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | BBB- to BBB+ equivalent current credit ratings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_OngoingOperationsMember', window );">Ongoing Operations | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | Not rated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_OngoingOperationsMember', window );">Ongoing Operations | Collateral provisions exist that may mitigate risk of credit loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_OngoingOperationsMember', window );">Ongoing Operations | Collateral provisions exist that may mitigate risk of credit loss | A- equivalent and higher current ratings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_OngoingOperationsMember', window );">Ongoing Operations | Collateral provisions exist that may mitigate risk of credit loss | BBB- to BBB+ equivalent current credit ratings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_OngoingOperationsMember', window );">Ongoing Operations | Collateral provisions exist that may mitigate risk of credit loss | Not rated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_OngoingOperationsMember', window );">Ongoing Operations | No collateral</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_OngoingOperationsMember', window );">Ongoing Operations | No collateral | A- equivalent and higher current ratings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_OngoingOperationsMember', window );">Ongoing Operations | No collateral | BBB- to BBB+ equivalent current credit ratings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_OngoingOperationsMember', window );">Ongoing Operations | No collateral | Not rated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_AcquisitionDispositionRunoffActivitiesMember', window );">Acquisition, disposition or run-off activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">3,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_AcquisitionDispositionRunoffActivitiesMember', window );">Acquisition, disposition or run-off activities | BBB+ equivalent and higher current ratings | Lincoln National Life and Lincoln Life &amp; Annuity of New York</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">2,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_AcquisitionDispositionRunoffActivitiesMember', window );">Acquisition, disposition or run-off activities | BBB+ equivalent and higher current ratings | Empower Annuity Insurance Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_AcquisitionDispositionRunoffActivitiesMember', window );">Acquisition, disposition or run-off activities | BBB+ equivalent and higher current ratings | Prudential Insurance Company of America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_AcquisitionDispositionRunoffActivitiesMember', window );">Acquisition, disposition or run-off activities | BBB+ equivalent and higher current ratings | Life Insurance Company of North America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_AcquisitionDispositionRunoffActivitiesMember', window );">Acquisition, disposition or run-off activities | BBB+ equivalent and higher current ratings | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_AcquisitionDispositionRunoffActivitiesMember', window );">Acquisition, disposition or run-off activities | Not rated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_AcquisitionDispositionRunoffActivitiesMember', window );">Acquisition, disposition or run-off activities | Fair value of collateral contractually required to meet or exceed carrying value of recoverable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_AcquisitionDispositionRunoffActivitiesMember', window );">Acquisition, disposition or run-off activities | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | BBB+ equivalent and higher current ratings | Lincoln National Life and Lincoln Life &amp; Annuity of New York</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_AcquisitionDispositionRunoffActivitiesMember', window );">Acquisition, disposition or run-off activities | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | BBB+ equivalent and higher current ratings | Empower Annuity Insurance Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_AcquisitionDispositionRunoffActivitiesMember', window );">Acquisition, disposition or run-off activities | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | BBB+ equivalent and higher current ratings | Prudential Insurance Company of America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_AcquisitionDispositionRunoffActivitiesMember', window );">Acquisition, disposition or run-off activities | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | BBB+ equivalent and higher current ratings | Life Insurance Company of North America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_AcquisitionDispositionRunoffActivitiesMember', window );">Acquisition, disposition or run-off activities | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | BBB+ equivalent and higher current ratings | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_AcquisitionDispositionRunoffActivitiesMember', window );">Acquisition, disposition or run-off activities | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | Not rated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_AcquisitionDispositionRunoffActivitiesMember', window );">Acquisition, disposition or run-off activities | Collateral provisions exist that may mitigate risk of credit loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">3,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_AcquisitionDispositionRunoffActivitiesMember', window );">Acquisition, disposition or run-off activities | Collateral provisions exist that may mitigate risk of credit loss | BBB+ equivalent and higher current ratings | Lincoln National Life and Lincoln Life &amp; Annuity of New York</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">2,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_AcquisitionDispositionRunoffActivitiesMember', window );">Acquisition, disposition or run-off activities | Collateral provisions exist that may mitigate risk of credit loss | BBB+ equivalent and higher current ratings | Empower Annuity Insurance Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_AcquisitionDispositionRunoffActivitiesMember', window );">Acquisition, disposition or run-off activities | Collateral provisions exist that may mitigate risk of credit loss | BBB+ equivalent and higher current ratings | Prudential Insurance Company of America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_AcquisitionDispositionRunoffActivitiesMember', window );">Acquisition, disposition or run-off activities | Collateral provisions exist that may mitigate risk of credit loss | BBB+ equivalent and higher current ratings | Life Insurance Company of North America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_AcquisitionDispositionRunoffActivitiesMember', window );">Acquisition, disposition or run-off activities | Collateral provisions exist that may mitigate risk of credit loss | BBB+ equivalent and higher current ratings | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_AcquisitionDispositionRunoffActivitiesMember', window );">Acquisition, disposition or run-off activities | Collateral provisions exist that may mitigate risk of credit loss | Not rated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_AcquisitionDispositionRunoffActivitiesMember', window );">Acquisition, disposition or run-off activities | No collateral</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_AcquisitionDispositionRunoffActivitiesMember', window );">Acquisition, disposition or run-off activities | No collateral | BBB+ equivalent and higher current ratings | Lincoln National Life and Lincoln Life &amp; Annuity of New York</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_AcquisitionDispositionRunoffActivitiesMember', window );">Acquisition, disposition or run-off activities | No collateral | BBB+ equivalent and higher current ratings | Empower Annuity Insurance Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_AcquisitionDispositionRunoffActivitiesMember', window );">Acquisition, disposition or run-off activities | No collateral | BBB+ equivalent and higher current ratings | Prudential Insurance Company of America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_AcquisitionDispositionRunoffActivitiesMember', window );">Acquisition, disposition or run-off activities | No collateral | BBB+ equivalent and higher current ratings | Life Insurance Company of North America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_AcquisitionDispositionRunoffActivitiesMember', window );">Acquisition, disposition or run-off activities | No collateral | BBB+ equivalent and higher current ratings | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_AcquisitionDispositionRunoffActivitiesMember', window );">Acquisition, disposition or run-off activities | No collateral | Not rated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Reinsurance recoverables before market risk benefits, including assets held for sale</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DisposalGroupIncludingDiscontinuedOperationReinsuranceRecoverablesIncludingReinsurancePremiumPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Reinsurance Recoverables, Including Reinsurance Premium Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DisposalGroupIncludingDiscontinuedOperationReinsuranceRecoverablesIncludingReinsurancePremiumPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ReinsuranceRecoverableAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reinsurance Recoverable, Allowance for Credit Loss, Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ReinsuranceRecoverableAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reinsurance Recoverables, Gross, Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reinsurance Recoverables, Including Reinsurance Premium Paid, Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededCreditRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 825<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479383/944-825-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededCreditRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, recoverable under reinsurance for contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29G<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29G<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-7B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceRecoverables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after valuation allowance, recoverable under reinsurance contracts including premium paid under reinsurance contracts. Examples include, but are not limited to, settled and unsettled claims, incurred but not reported losses, loss adjustment expense, premium paid, policy benefits and policy reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479838/944-20-50-5<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479616/944-310-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceRecoverables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededCreditRiskAxis=ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaAndOtherRecoverablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededCreditRiskAxis=ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaAndOtherRecoverablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededCreditRiskCollateralizationAxis=ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededCreditRiskCollateralizationAxis=ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededCreditRiskCollateralizationAxis=ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededCreditRiskCollateralizationAxis=ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededCreditRiskCollateralizationAxis=us-gaap_CededCreditRiskUnsecuredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededCreditRiskCollateralizationAxis=us-gaap_CededCreditRiskUnsecuredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_VariableAnnuityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_VariableAnnuityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteedInsuranceContractTypeOfBenefitAxis=us-gaap_GuaranteedMinimumDeathBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteedInsuranceContractTypeOfBenefitAxis=us-gaap_GuaranteedMinimumDeathBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ci_OngoingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ci_OngoingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ci_AcquisitionDispositionRunoffActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ci_AcquisitionDispositionRunoffActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis=ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededCreditRiskAxis=ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededCreditRiskAxis=ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededCreditRiskAxis=ci_EmpowerAnnuityInsuranceCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededCreditRiskAxis=ci_EmpowerAnnuityInsuranceCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededCreditRiskAxis=ci_PrudentialInsuranceCompanyOfAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededCreditRiskAxis=ci_PrudentialInsuranceCompanyOfAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededCreditRiskAxis=ci_LifeInsuranceCompanyOfNorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededCreditRiskAxis=ci_LifeInsuranceCompanyOfNorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededCreditRiskAxis=us-gaap_OtherReinsurerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededCreditRiskAxis=us-gaap_OtherReinsurerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288968394064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reinsurance - Effects of Reinsurance (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract', window );"><strong>Premiums</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Total premiums</a></td>
<td class="nump">$ 44,237<span></span>
</td>
<td class="nump">$ 39,916<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 41,154<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract', window );"><strong>Total reinsurance recoveries</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded', window );">Total reinsurance recoveries</a></td>
<td class="nump">456<span></span>
</td>
<td class="nump">702<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">552<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_ShortDurationContractsMember', window );">Short-duration contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract', window );"><strong>Premiums</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DirectPremiumsEarned', window );">Direct</a></td>
<td class="nump">42,266<span></span>
</td>
<td class="nump">36,747<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">36,513<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssumedPremiumsEarned', window );">Assumed</a></td>
<td class="nump">303<span></span>
</td>
<td class="nump">416<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">335<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededPremiumsEarned', window );">Ceded</a></td>
<td class="num">(277)<span></span>
</td>
<td class="num">(265)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(148)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Total premiums</a></td>
<td class="nump">42,292<span></span>
</td>
<td class="nump">36,898<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">36,700<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract', window );"><strong>Total reinsurance recoveries</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsWrittenNet', window );">Written premiums</a></td>
<td class="nump">41,100<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">35,600<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_LongDurationContractsMember', window );">Long-duration contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract', window );"><strong>Premiums</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DirectPremiumsEarned', window );">Direct</a></td>
<td class="nump">2,084<span></span>
</td>
<td class="nump">3,219<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,753<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssumedPremiumsEarned', window );">Assumed</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">99<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededPremiumsEarned', window );">Ceded</a></td>
<td class="num">(211)<span></span>
</td>
<td class="num">(286)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(398)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Total premiums</a></td>
<td class="nump">$ 1,945<span></span>
</td>
<td class="nump">$ 3,018<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4,454<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssumedPremiumsEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of earned premiums assumed from other entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-17(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480149/944-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479655/944-605-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479655/944-605-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssumedPremiumsEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededPremiumsEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of earned premiums ceded to other entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-17(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480149/944-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479655/944-605-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479686/944-605-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479655/944-605-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479655/944-605-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededPremiumsEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DirectPremiumsEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before premiums ceded to other entities and premiums assumed by the entity, of premiums earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-17(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480149/944-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479655/944-605-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479655/944-605-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DirectPremiumsEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PremiumsEarnedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-17(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480149/944-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479655/944-605-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(c))<br> -SubTopic 220<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(1))<br> -SubTopic 220<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PremiumsEarnedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PremiumsWrittenNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums written.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -SubTopic 605<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479655/944-605-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -SubTopic 605<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479655/944-605-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PremiumsWrittenNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reduction of provision for policy benefits and costs incurred for policies ceded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479838/944-20-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ci_ShortDurationContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ci_ShortDurationContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ci_LongDurationContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ci_LongDurationContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288952267552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reinsurance - Effective Exit of Variable Annuity Reinsurance Business (Details) - Variable Annuity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances', window );">Market risk benefits reinsurance recoverable, including IBNR and outstanding claims, less premiums due</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 1,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceReceivablesIncurredButNotReportedClaims', window );">Incurred but not yet paid and outstanding claims</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsReceivableAtCarryingValue', window );">Premiums due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FairValueMeasurementNonPerformanceRiskAdjustment', window );">Impact of non-performance risk</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_VariableAnnuityMember', window );">Berkshire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CededReinsuranceAgreementReinsuredRiskPercentage', window );">Percent of future claim payments reinsured</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CededReinsuranceAgreementCoverageLimitAmountRemaining', window );">Remaining overall limit under reinsurance agreement</a></td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances', window );">Market risk benefits reinsurance recoverable, including IBNR and outstanding claims, less premiums due</a></td>
<td class="nump">$ 873<span></span>
</td>
<td class="nump">1,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_VariableAnnuityMember', window );">Berkshire | Secured | Market risk benefits reinsurance recoverable, including IBNR and outstanding claims, less premiums due | Collateralization risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_VariableAnnuityMember', window );">Sun Life Assurance Company of Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances', window );">Market risk benefits reinsurance recoverable, including IBNR and outstanding claims, less premiums due</a></td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_VariableAnnuityMember', window );">Liberty Re (Bermuda) Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances', window );">Market risk benefits reinsurance recoverable, including IBNR and outstanding claims, less premiums due</a></td>
<td class="nump">$ 104<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_VariableAnnuityMember', window );">Liberty Re (Bermuda) Ltd. | Secured | Market risk benefits reinsurance recoverable, including IBNR and outstanding claims, less premiums due | Collateralization risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_VariableAnnuityMember', window );">SCOR SE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances', window );">Market risk benefits reinsurance recoverable, including IBNR and outstanding claims, less premiums due</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_VariableAnnuityMember', window );">SCOR SE | Secured | Market risk benefits reinsurance recoverable, including IBNR and outstanding claims, less premiums due | Collateralization risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededCreditRiskLineItems', window );"><strong>Ceded Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_CededReinsuranceAgreementCoverageLimitAmountRemaining">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of overall limit to claims covered under ceded reinsurance agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_CededReinsuranceAgreementCoverageLimitAmountRemaining</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_CededReinsuranceAgreementReinsuredRiskPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percent of future claim payments reinsured under reinsurance agreement(s), net of existing retrocessional arrangements at the time agreement was made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_CededReinsuranceAgreementReinsuredRiskPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_FairValueMeasurementNonPerformanceRiskAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurement, Non-Performance Risk Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_FairValueMeasurementNonPerformanceRiskAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Includes incurred but not reported claims and outstanding claims,off-set by premiums due, related to market risk benefit contracts, as a well as reinsurance recoverable, defined as amount, after allowance for credit loss, recoverable under reinsurance for contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededCreditRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 825<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479383/944-825-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededCreditRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PremiumsReceivableAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount as of the balance sheet date due the entity from (a) agents and insureds, (b) uncollected premiums and (c) others, net of the allowance for doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PremiumsReceivableAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceReceivablesIncurredButNotReportedClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated amount after valuation allowance of reinsurance recoverables, due from reinsurers for incurred claims not yet reported, and claims settlement expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479584/944-310-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479616/944-310-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceReceivablesIncurredButNotReportedClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_VariableAnnuityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_VariableAnnuityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededCreditRiskAxis=ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededCreditRiskAxis=ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededCreditRiskCollateralizationAxis=us-gaap_CededCreditRiskSecuredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededCreditRiskCollateralizationAxis=us-gaap_CededCreditRiskSecuredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=ci_CededCreditCollateralizationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=ci_CededCreditCollateralizationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededCreditRiskAxis=ci_SunLifeAssuranceCompanyOfCanadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededCreditRiskAxis=ci_SunLifeAssuranceCompanyOfCanadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededCreditRiskAxis=ci_LibertyMutualInsuranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededCreditRiskAxis=ci_LibertyMutualInsuranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededCreditRiskAxis=ci_SCORSEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededCreditRiskAxis=ci_SCORSEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288951363504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Investments by Category (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Investments including held for sale assets</a></td>
<td class="nump">$ 1,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Current investments</a></td>
<td class="nump">925<span></span>
</td>
<td class="nump">$ 905<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestmentsAbstract', window );"><strong>Long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Investments including held for sale assets</a></td>
<td class="nump">19,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments per Consolidated Balance Sheets</a></td>
<td class="nump">17,985<span></span>
</td>
<td class="nump">16,288<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShortTermAndLongTermInvestmentsAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Investments including held for sale assets</a></td>
<td class="nump">20,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Total investments</a></td>
<td class="nump">18,910<span></span>
</td>
<td class="nump">17,193<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Held-for-Sale | Medicare Advantage and related Cigna Healthcare businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent', window );">Investments classified as assets of business held for sale</a></td>
<td class="num">(84)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestmentsAbstract', window );"><strong>Long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent', window );">Investments classified as assets of business held for sale</a></td>
<td class="num">(1,354)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShortTermAndLongTermInvestmentsAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DisposalGroupIncludingDiscontinuedOperationInvestments', window );">Investments classified as assets of business held for sale</a></td>
<td class="num">(1,438)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember', window );">Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Investments including held for sale assets</a></td>
<td class="nump">590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Current investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">654<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestmentsAbstract', window );"><strong>Long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Investments including held for sale assets</a></td>
<td class="nump">9,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments per Consolidated Balance Sheets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,218<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShortTermAndLongTermInvestmentsAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Investments including held for sale assets</a></td>
<td class="nump">9,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Total investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,872<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Investments including held for sale assets</a></td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Current investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestmentsAbstract', window );"><strong>Long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Investments including held for sale assets</a></td>
<td class="nump">3,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments per Consolidated Balance Sheets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">577<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShortTermAndLongTermInvestmentsAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Investments including held for sale assets</a></td>
<td class="nump">3,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Total investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">622<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MortgagesMember', window );">Commercial mortgage loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Investments including held for sale assets</a></td>
<td class="nump">182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Current investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestmentsAbstract', window );"><strong>Long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Investments including held for sale assets</a></td>
<td class="nump">1,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments per Consolidated Balance Sheets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,547<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShortTermAndLongTermInvestmentsAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Investments including held for sale assets</a></td>
<td class="nump">1,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Total investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,614<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_PolicyLoansMember', window );">Policy loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Investments including held for sale assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Current investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestmentsAbstract', window );"><strong>Long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Investments including held for sale assets</a></td>
<td class="nump">1,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments per Consolidated Balance Sheets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,218<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShortTermAndLongTermInvestmentsAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Investments including held for sale assets</a></td>
<td class="nump">1,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Total investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,218<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherLongTermInvestmentsMember', window );">Other long-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Investments including held for sale assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Current investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestmentsAbstract', window );"><strong>Long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Investments including held for sale assets</a></td>
<td class="nump">4,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments per Consolidated Balance Sheets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,728<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShortTermAndLongTermInvestmentsAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Investments including held for sale assets</a></td>
<td class="nump">4,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Total investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,728<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Investments including held for sale assets</a></td>
<td class="nump">206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Current investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestmentsAbstract', window );"><strong>Long-term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Investments including held for sale assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments per Consolidated Balance Sheets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShortTermAndLongTermInvestmentsAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Investments including held for sale assets</a></td>
<td class="nump">$ 206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Total investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group Including Discontinued Operation, Current Investments, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DisposalGroupIncludingDiscontinuedOperationInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DisposalGroupIncludingDiscontinuedOperationInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group Including Discontinued Operation Noncurrent Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long Term Investments Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ShortTermAndLongTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-Term And Long-Term Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ShortTermAndLongTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short Term Investments Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(h))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MortgagesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MortgagesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_PolicyLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_PolicyLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherLongTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_OtherLongTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288968312208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Debt Securities by Contractual Maturity Periods (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Due in one year or less, including assets held for sale</a></td>
<td class="nump">$ 622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Due after one year through five years, including assets held for sale</a></td>
<td class="nump">3,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Due after five years through ten years, including assets held for sale</a></td>
<td class="nump">3,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Due after ten years, including assets held for sale</a></td>
<td class="nump">2,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Mortgage and other asset-backed securities, including assets held for sale</a></td>
<td class="nump">398<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Total, including assets held for sale</a></td>
<td class="nump">10,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Due in one year or less, including assets held for sale</a></td>
<td class="nump">605<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Due after one year through five years, including assets held for sale</a></td>
<td class="nump">3,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Due after five years through ten years, including assets held for sale</a></td>
<td class="nump">3,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Due after ten years, including assets held for sale</a></td>
<td class="nump">2,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Mortgage and other asset-backed securities, including assets held for sale</a></td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Total, including assets held for sale</a></td>
<td class="nump">$ 9,855<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss, Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10, Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10, Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five, Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One, Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Excluding Accrued Interest, Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10, Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10, Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five, Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One, Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Amortized Cost, Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Fair Value, Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288969744240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative gain (loss) recognized in the income statement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Derivative gain (loss) recognized in other comprehensive income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Derivative gain (loss) reclassified from other comprehensive income into shareholders' net income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity securities with no readily determinable fair value</a></td>
<td class="nump">3,311<span></span>
</td>
<td class="nump">$ 484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ci_VillageMDMember', window );">VillageMD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity securities with no readily determinable fair value</a></td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_EquitySecuritiesDividend', window );">Dividend</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueValueOfSharesForAnnualDividendAccrual', window );">Value of shares for annual dividend accrual</a></td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_EquitySecuritiesDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, Dividend</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_EquitySecuritiesDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueValueOfSharesForAnnualDividendAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value, Value Of Shares For Annual Dividend Accrual</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_EquitySecuritiesWithoutReadilyDeterminableFairValueValueOfSharesForAnnualDividendAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ci_VillageMDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ci_VillageMDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288951535376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Gross Unrealized Appreciation (Depreciation) on Debt Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest', window );">Allowance for Credit Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Appreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,059)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Amortized cost, including held for sale assets</a></td>
<td class="nump">$ 10,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Allowance for Credit Loss, including held for sale assets</a></td>
<td class="num">(33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Unrealized Appreciation, including held for sale assets</a></td>
<td class="nump">195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Unrealized Depreciation, including held for sale assets</a></td>
<td class="num">(686)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Fair Value, including held for sale assets</a></td>
<td class="nump">9,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">Federal government and agency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest', window );">Allowance for Credit Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Appreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Amortized cost, including held for sale assets</a></td>
<td class="nump">251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Allowance for Credit Loss, including held for sale assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Unrealized Appreciation, including held for sale assets</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Unrealized Depreciation, including held for sale assets</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Fair Value, including held for sale assets</a></td>
<td class="nump">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">State and local government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest', window );">Allowance for Credit Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Appreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Amortized cost, including held for sale assets</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Allowance for Credit Loss, including held for sale assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Unrealized Appreciation, including held for sale assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Unrealized Depreciation, including held for sale assets</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Fair Value, including held for sale assets</a></td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Foreign government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest', window );">Allowance for Credit Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Appreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Amortized cost, including held for sale assets</a></td>
<td class="nump">355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Allowance for Credit Loss, including held for sale assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Unrealized Appreciation, including held for sale assets</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Unrealized Depreciation, including held for sale assets</a></td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Fair Value, including held for sale assets</a></td>
<td class="nump">352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest', window );">Allowance for Credit Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Appreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(981)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Amortized cost, including held for sale assets</a></td>
<td class="nump">9,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Allowance for Credit Loss, including held for sale assets</a></td>
<td class="num">(33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Unrealized Appreciation, including held for sale assets</a></td>
<td class="nump">158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Unrealized Depreciation, including held for sale assets</a></td>
<td class="num">(630)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Fair Value, including held for sale assets</a></td>
<td class="nump">8,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Mortgage and other asset-backed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest', window );">Allowance for Credit Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Appreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Amortized cost, including held for sale assets</a></td>
<td class="nump">398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Allowance for Credit Loss, including held for sale assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Unrealized Appreciation, including held for sale assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Unrealized Depreciation, including held for sale assets</a></td>
<td class="num">(34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Fair Value, including held for sale assets</a></td>
<td class="nump">$ 365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Debt Securities Amortized Cost Basis Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Securities Debt Securities Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available For Sale, Allowance For Credit Loss, Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, before allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288951859952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Debt Securities with a Decline in Fair Value (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>position</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>position</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,901<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost', window );">Total Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,960<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,059)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of Issues | position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,777<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Total Fair Value, including held for sale assets</a></td>
<td class="nump">$ 6,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Total Amortized Cost, including held for sale assets</a></td>
<td class="nump">7,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Total Unrealized Depreciation, including held for sale assets</a></td>
<td class="num">$ (686)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Total Number of Issues, including held for sale assets | position</a></td>
<td class="nump">2,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InvestmentsCreditRatingAxis=ci_InvestmentGradeMember', window );">Investment grade | Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract', window );"><strong>One year or less</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,533<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (594)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of Issues | position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Fair Value, including held for sale assets</a></td>
<td class="nump">$ 330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Amortized Cost, including held for sale assets</a></td>
<td class="nump">338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Unrealized Depreciation, including held for sale assets</a></td>
<td class="num">$ (8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureLessThan12MonthsNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Number of Issues, including held for sale assets | position</a></td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract', window );"><strong>More than one year</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,151<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (336)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of Issues | position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Fair Value, including held for sale assets</a></td>
<td class="nump">$ 5,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Amortized Cost, including held for sale assets</a></td>
<td class="nump">6,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Unrealized Depreciation, including held for sale assets</a></td>
<td class="num">$ (595)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureTwelveMonthsOrLongerNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Number of Issues, including held for sale assets | position</a></td>
<td class="nump">1,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InvestmentsCreditRatingAxis=ci_BelowInvestmentGradeMember', window );">Below investment grade | Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract', window );"><strong>One year or less</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 887<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (77)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of Issues | position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Fair Value, including held for sale assets</a></td>
<td class="nump">$ 161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Amortized Cost, including held for sale assets</a></td>
<td class="nump">170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Unrealized Depreciation, including held for sale assets</a></td>
<td class="num">$ (9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureLessThan12MonthsNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Number of Issues, including held for sale assets | position</a></td>
<td class="nump">135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract', window );"><strong>More than one year</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 330<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (52)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of Issues | position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Fair Value, including held for sale assets</a></td>
<td class="nump">$ 701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Amortized Cost, including held for sale assets</a></td>
<td class="nump">775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Unrealized Depreciation, including held for sale assets</a></td>
<td class="num">$ (74)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureTwelveMonthsOrLongerNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Number of Issues, including held for sale assets | position</a></td>
<td class="nump">486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Securities Continuous Unrealized Loss Position 12 Months Or Longer Accumulated Loss Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Securities Continuous Unrealized Loss Position Less Than 12 Months Accumulated Loss Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Amortized Cost Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Amortized Cost Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureLessThan12MonthsNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Securities In Unrealized Loss Positions, Qualitative Disclosure, Less Than 12 Months, Number Of Positions, Before Reclassification To Disposal Group, Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureLessThan12MonthsNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Securities In Unrealized Loss Positions, Qualitative Disclosure, Number Of Positions, Before Reclassification To Disposal Group, Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureTwelveMonthsOrLongerNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Securities In Unrealized Loss Positions, Qualitative Disclosure, Twelve Months Or Longer, Number Of Positions, Before Reclassification To Disposal Group, Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureTwelveMonthsOrLongerNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months Or Longer</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, 12 Months Or Longer, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less Than 12 Months</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Less Than 12 Months, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Total</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Unrealized Loss Position, Accumulated Loss, Before Reclassification To Disposal Group, Assets Held-For-Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Unrealized Loss Position, Amortized Cost, Before Reclassification To Disposal Group, Assets Held-For-Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Unrealized Loss Position, Before Reclassification To Disposal Group, Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_InvestmentsCreditRatingAxis=ci_InvestmentGradeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_InvestmentsCreditRatingAxis=ci_InvestmentGradeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_InvestmentsCreditRatingAxis=ci_BelowInvestmentGradeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_InvestmentsCreditRatingAxis=ci_BelowInvestmentGradeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288969406416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Equity Security Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract', window );"><strong>Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Equity securities with readily determinable fair values</a></td>
<td class="nump">$ 656<span></span>
</td>
<td class="nump">$ 673<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost', window );">Equity securities with no readily determinable fair value</a></td>
<td class="nump">3,248<span></span>
</td>
<td class="nump">380<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost', window );">Total</a></td>
<td class="nump">3,904<span></span>
</td>
<td class="nump">1,053<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract', window );"><strong>Carrying Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities with readily determinable fair values</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity securities with no readily determinable fair value</a></td>
<td class="nump">3,311<span></span>
</td>
<td class="nump">484<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount', window );">Total</a></td>
<td class="nump">3,362<span></span>
</td>
<td class="nump">622<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PaymentsToAcquireDebtAndEquitySecurities', window );">Amount funded</a></td>
<td class="nump">$ 4,334<span></span>
</td>
<td class="nump">$ 2,756<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td colspan="2" class="nump">$ 3,553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=ci_EquitySecuritiesFVNIMember', window );">Equity Securities FV NI | Product Concentration Risk | Health Care Sector</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Carrying Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Carrying Amount, Before Reclassification To Disposal Group, Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_PaymentsToAcquireDebtAndEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Debt And Equity Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_PaymentsToAcquireDebtAndEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=ci_EquitySecuritiesFVNIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=ci_EquitySecuritiesFVNIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesByIndustryAxis=us-gaap_HealthcareSectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesByIndustryAxis=us-gaap_HealthcareSectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288952271408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Commercial Mortgage Loan Portfolio (Details) - Real Estate Loan - Commercial Portfolio Segment<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Carrying value, after allowance for credit loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Carrying value, after allowance for credit loss, including assets held for sale</a></td>
<td class="nump">$ 1,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=us-gaap_RealEstateLoanMember', window );">Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio', window );">Average Debt Service Coverage Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FinancingReceivableCreditQualityLoanToValueRatio', window );">Average Loan-to-Value Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Average Debt Service Coverage Ratio, including assets held for sale</a></td>
<td class="nump">1.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FinancingReceivableCreditQualityLoanToValueRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Average Loan-to-Value Ratio, including assets held for sale</a></td>
<td class="nump">0.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=us-gaap_RealEstateLoanMember', window );">Below 60%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Carrying value, after allowance for credit loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Carrying value, after allowance for credit loss, including assets held for sale</a></td>
<td class="nump">$ 802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=us-gaap_RealEstateLoanMember', window );">Below 60% | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio', window );">Average Debt Service Coverage Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Average Debt Service Coverage Ratio, including assets held for sale</a></td>
<td class="nump">2.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=us-gaap_RealEstateLoanMember', window );">60% to 79%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Carrying value, after allowance for credit loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Carrying value, after allowance for credit loss, including assets held for sale</a></td>
<td class="nump">$ 574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=us-gaap_RealEstateLoanMember', window );">60% to 79% | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio', window );">Average Debt Service Coverage Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Average Debt Service Coverage Ratio, including assets held for sale</a></td>
<td class="nump">1.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=us-gaap_RealEstateLoanMember', window );">80% to 100%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Carrying value, after allowance for credit loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Carrying value, after allowance for credit loss, including assets held for sale</a></td>
<td class="nump">$ 157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=us-gaap_RealEstateLoanMember', window );">80% to 100% | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio', window );">Average Debt Service Coverage Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Average Debt Service Coverage Ratio, including assets held for sale</a></td>
<td class="nump">0.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Credit Quality Debt Service Coverage Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Credit Quality Debt Service Coverage Ratio, Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_FinancingReceivableCreditQualityLoanToValueRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable Credit Quality Loan To Value Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_FinancingReceivableCreditQualityLoanToValueRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_FinancingReceivableCreditQualityLoanToValueRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable Credit Quality Loan To Value Ratio, Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_FinancingReceivableCreditQualityLoanToValueRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Excluding Accrued Interest, after Allowance for Credit Loss, Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of financing receivable. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=us-gaap_RealEstateLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=us-gaap_RealEstateLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablePortfolioSegmentAxis=us-gaap_CommercialPortfolioSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablePortfolioSegmentAxis=us-gaap_CommercialPortfolioSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoanToValueAxis=ci_LtvLessThan60PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoanToValueAxis=ci_LtvLessThan60PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoanToValueAxis=ci_Ltv60To79PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoanToValueAxis=ci_Ltv60To79PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoanToValueAxis=us-gaap_Ltv80To100PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoanToValueAxis=us-gaap_Ltv80To100PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288966866768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Other Long-Term Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear', window );">Unfunded commitments, percentage expected to fund in next fiscal year</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Income distributions</a></td>
<td class="nump">$ 253<span></span>
</td>
<td class="nump">$ 487<span></span>
</td>
<td class="nump">$ 568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Other long-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_OtherLongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Other long term investments, including held for sale assets</a></td>
<td class="nump">4,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CommitmentsToContributeAdditionalEquityAndCapital', window );">Unfunded commitments</a></td>
<td class="nump">2,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_RealEstateInvestmentMember', window );">Real estate investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Other long-term investments</a></td>
<td class="nump">1,606<span></span>
</td>
<td class="nump">1,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CommitmentsToContributeAdditionalEquityAndCapital', window );">Unfunded commitments</a></td>
<td class="nump">712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=srt_PartnershipInterestMember', window );">Securities partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Other long-term investments</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">2,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CommitmentsToContributeAdditionalEquityAndCapital', window );">Unfunded commitments</a></td>
<td class="nump">2,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherInvestmentsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Other long-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_OtherLongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Other long term investments, including held for sale assets</a></td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CommitmentsToContributeAdditionalEquityAndCapital', window );">Unfunded commitments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_CommitmentsToContributeAdditionalEquityAndCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment commitments of estimated payments required under contractual arrangements diversified by issuer, property type and geographic regions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_CommitmentsToContributeAdditionalEquityAndCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_OtherLongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Long Term Investments Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_OtherLongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unfunded Commitments, Percentage Expected To Fund In Next Fiscal Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-21D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_RealEstateInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_RealEstateInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=srt_PartnershipInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=srt_PartnershipInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_OtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288964576704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Summary of Derivative Instruments (Details) - Designated as Hedging Instrument - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Fair Value Hedging | Foreign currency swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional Value</a></td>
<td class="nump">$ 1,026<span></span>
</td>
<td class="nump">$ 1,083<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Fair Value Hedging | Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional Value</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Net Investment Hedging | Foreign currency swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional Value</a></td>
<td class="nump">$ 415<span></span>
</td>
<td class="nump">$ 460<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288966777280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Components of Net Investment Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue', window );">Investment income</a></td>
<td class="nump">$ 1,210<span></span>
</td>
<td class="nump">$ 1,209<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,608<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInvestmentExpense', window );">Less investment expenses</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">59<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net investment income</a></td>
<td class="nump">1,166<span></span>
</td>
<td class="nump">1,155<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,549<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember', window );">Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue', window );">Investment income</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">572<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">689<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue', window );">Investment income</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">12<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MortgagesMember', window );">Commercial mortgage loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue', window );">Investment income</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">60<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_PolicyLoansMember', window );">Policy loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue', window );">Investment income</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">63<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherLongTermInvestmentsMember', window );">Other long-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue', window );">Investment income</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">390<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">758<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=ci_CashCashEquivalentsAndShortTermInvestmentsMember', window );">Short-term investments and cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue', window );">Investment income</a></td>
<td class="nump">$ 339<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 26<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein. Also includes the total amount of revenue recognized for the period from operating leases, including minimum lease revenue, contingent revenue, percentage revenue and sublease revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInvestmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses related to the generation of investment income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInvestmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetInvestmentIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 220<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetInvestmentIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MortgagesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MortgagesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_PolicyLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_PolicyLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherLongTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_OtherLongTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=ci_CashCashEquivalentsAndShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=ci_CashCashEquivalentsAndShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288968413984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Realized Gains and Losses on Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_RealizedInvestmentGainLossExcludingImpairments', window );">Net realized investment (losses) gains, excluding credit loss expense and asset write-downs</a></td>
<td class="num">$ (68)<span></span>
</td>
<td class="num">$ (451)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 196<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal', window );">Credit (loss) / recovery and other investment write-down (losses)</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_RealizedInvestmentGainLoss', window );">Net realized investment (losses) gains, before income taxes</a></td>
<td class="num">$ (78)<span></span>
</td>
<td class="num">$ (487)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 198<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, And Commercial Mortgage Loans, Allowance For Credit Loss, Expense (Recovery) And Impairments On Investments Total</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_RealizedInvestmentGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net realized gains or (losses) on investments during the period, including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_RealizedInvestmentGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_RealizedInvestmentGainLossExcludingImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net realized gains or (losses) on investments during the period before impairments, including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_RealizedInvestmentGainLossExcludingImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288955561280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Debt Securities, including held for sale assets</a></td>
<td class="nump">9,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Debt Securities, including held for sale assets</a></td>
<td class="nump">9,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Forwards, swaps, options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Debt Securities, including held for sale assets</a></td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring | Forwards, swaps, options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Debt Securities, including held for sale assets</a></td>
<td class="nump">9,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Recurring | Forwards, swaps, options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Debt Securities, including held for sale assets</a></td>
<td class="nump">447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Recurring | Forwards, swaps, options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">Federal government and agency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Debt Securities, including held for sale assets</a></td>
<td class="nump">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">Federal government and agency | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Debt Securities, including held for sale assets</a></td>
<td class="nump">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">Federal government and agency | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Debt Securities, including held for sale assets</a></td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">Federal government and agency | Significant Other Observable Inputs (Level 2) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Debt Securities, including held for sale assets</a></td>
<td class="nump">137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">Federal government and agency | Significant Unobservable Inputs (Level 3) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Debt Securities, including held for sale assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">State and local government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Debt Securities, including held for sale assets</a></td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">State and local government | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Debt Securities, including held for sale assets</a></td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">State and local government | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Debt Securities, including held for sale assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">State and local government | Significant Other Observable Inputs (Level 2) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Debt Securities, including held for sale assets</a></td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">State and local government | Significant Unobservable Inputs (Level 3) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Debt Securities, including held for sale assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Foreign government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Debt Securities, including held for sale assets</a></td>
<td class="nump">352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Foreign government | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Debt Securities, including held for sale assets</a></td>
<td class="nump">352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Foreign government | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Debt Securities, including held for sale assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Foreign government | Significant Other Observable Inputs (Level 2) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Debt Securities, including held for sale assets</a></td>
<td class="nump">352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Foreign government | Significant Unobservable Inputs (Level 3) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Debt Securities, including held for sale assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Debt Securities, including held for sale assets</a></td>
<td class="nump">8,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Debt Securities, including held for sale assets</a></td>
<td class="nump">8,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Debt Securities, including held for sale assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate | Significant Other Observable Inputs (Level 2) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Debt Securities, including held for sale assets</a></td>
<td class="nump">8,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate | Significant Unobservable Inputs (Level 3) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Debt Securities, including held for sale assets</a></td>
<td class="nump">401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Mortgage and other asset-backed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Debt Securities, including held for sale assets</a></td>
<td class="nump">365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Mortgage and other asset-backed | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Debt Securities, including held for sale assets</a></td>
<td class="nump">365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Mortgage and other asset-backed | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Debt Securities, including held for sale assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Mortgage and other asset-backed | Significant Other Observable Inputs (Level 2) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Debt Securities, including held for sale assets</a></td>
<td class="nump">319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Mortgage and other asset-backed | Significant Unobservable Inputs (Level 3) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets at fair value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Debt Securities, including held for sale assets</a></td>
<td class="nump">$ 46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Securities Debt Securities Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=ci_ForwardsSwapsOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=ci_ForwardsSwapsOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288968264576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtAndEquitySecuritiesClassifiedInLevel2PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Percent of debt and equity securities classified in Level 2, including assets held for sale</a></td>
<td class="nump">94.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtAndEquitySecuritiesClassifiedInLevel3PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Percent of debt and equity securities classified in Level 3, including assets held for sale</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=ci_SeparateAccountAssetsMember', window );">Separate Account Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease', window );">Separate accounts assets classified in Level 3, period increase (decrease), including transfers in and out of Level 3</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=ci_SeparateAccountAssetsMember', window );">Separate Account Assets | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLiquidatingInvestmentPeriodFromInceptionSecuritiesPartnerships', window );">Expected liquidation period after inception</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeAssets', window );">Adjustment for credit risk on derivatives assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities', window );">Adjustment for credit risk on derivatives liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtAndEquitySecuritiesClassifiedInLevel2PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt And Equity Securities Classified In Level2 Percentage Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtAndEquitySecuritiesClassifiedInLevel2PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtAndEquitySecuritiesClassifiedInLevel3PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percent of debt and equity securities classified in Level 3 Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtAndEquitySecuritiesClassifiedInLevel3PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLiquidatingInvestmentPeriodFromInceptionSecuritiesPartnerships">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected liquidation period after inception of the underlying securities partnership assets measured at net asset value per share or unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLiquidatingInvestmentPeriodFromInceptionSecuritiesPartnerships</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of credit risk valuation adjustment to derivative assets to properly reflect the credit quality of the counterparties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of credit risk valuation adjustment to derivative liabilities to properly reflect the credit quality of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=ci_SeparateAccountAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=ci_SeparateAccountAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_SwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_SwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288951838704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Quantitative Information About Unobservable Inputs (Details) - Recurring - Significant Unobservable Inputs (Level 3)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember', window );">Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_MarketableSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Fair Value, including held for sale assets</a></td>
<td class="nump">$ 447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ci_CorporateAndGovernmentDebtSecuritiesMember', window );">Corporate | Securities Priced by the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_MarketableSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Fair Value, including held for sale assets</a></td>
<td class="nump">$ 401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ci_CorporateAndGovernmentDebtSecuritiesMember', window );">Corporate | Securities Priced by the Company | Minimum | Liquidity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput', window );">Unobservable Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput', window );">Unobservable Adjustment, including held for sale assets</a></td>
<td class="nump">0.0070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ci_CorporateAndGovernmentDebtSecuritiesMember', window );">Corporate | Securities Priced by the Company | Maximum | Liquidity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput', window );">Unobservable Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput', window );">Unobservable Adjustment, including held for sale assets</a></td>
<td class="nump">0.1235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ci_CorporateAndGovernmentDebtSecuritiesMember', window );">Corporate | Securities Priced by the Company | Weighted Average | Liquidity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput', window );">Unobservable Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput', window );">Unobservable Adjustment, including held for sale assets</a></td>
<td class="nump">0.0310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Mortgage and other asset-backed securities | Securities Priced by the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_MarketableSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Fair Value, including held for sale assets</a></td>
<td class="nump">$ 46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Mortgage and other asset-backed securities | Securities Priced by the Company | Minimum | Liquidity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput', window );">Unobservable Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput', window );">Unobservable Adjustment, including held for sale assets</a></td>
<td class="nump">0.0095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Mortgage and other asset-backed securities | Securities Priced by the Company | Maximum | Liquidity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput', window );">Unobservable Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput', window );">Unobservable Adjustment, including held for sale assets</a></td>
<td class="nump">0.0640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Mortgage and other asset-backed securities | Securities Priced by the Company | Weighted Average | Liquidity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput', window );">Unobservable Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput', window );">Unobservable Adjustment, including held for sale assets</a></td>
<td class="nump">0.0310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Including Disposal Group, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_MarketableSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable Securities Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_MarketableSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ci_CorporateAndGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ci_CorporateAndGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=ci_UnobservableInputsDevelopedByCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=ci_UnobservableInputsDevelopedByCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=ci_MeasurementInputLiquidityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=ci_MeasurementInputLiquidityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288968125792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract', window );"><strong>Transfers into/(out of) Level 3</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss', window );">Change in unrealized gain or (loss) included in Other comprehensive loss for assets held at the end of the reporting period</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">$ (60)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=ci_DebtAndEquitySecuritiesMember', window );">Debt and Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Beginning balance</a></td>
<td class="nump">447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Beginning balance, including held for sale assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">(Losses) gains included in Shareholders' net income</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss', window );">Gains (losses) included in Other comprehensive loss</a></td>
<td class="nump">8<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract', window );"><strong>Purchases, sales and settlements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Purchases</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements', window );">Settlements</a></td>
<td class="num">(52)<span></span>
</td>
<td class="num">(207)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements', window );">Total purchases, sales and settlements</a></td>
<td class="num">(42)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract', window );"><strong>Transfers into/(out of) Level 3</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3', window );">Transfers into Level 3</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Transfers out of Level 3</a></td>
<td class="num">(59)<span></span>
</td>
<td class="num">(376)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Total transfers into/(out of) Level 3</a></td>
<td class="nump">36<span></span>
</td>
<td class="num">(252)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Ending balance, including held for sale assets</a></td>
<td class="nump">447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAttributedToInstrumentsHeldIncludedInEarnings', window );">Total losses included in Shareholders' net income attributable to instruments held at the reporting date</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAttributedToInstrumentsHeldIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents total gains or losses for the period (realized and unrealized), arising from assets included in income attributable to instruments held at the reporting date, measured at fair value on a recurring basis using unobservable inputs (Level 3), which are included in earnings or resulted in a change in asset value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAttributedToInstrumentsHeldIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Unrealized Gain (Loss) Included In Other Comprehensive Income (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in other comprehensive income (OCI) from asset measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases, (sales), issuances and (settlements) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=ci_DebtAndEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=ci_DebtAndEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288952273376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Values of Separate Account Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_GuaranteedSeparateAccountAssets', window );">Guaranteed separate accounts</a></td>
<td class="nump">$ 578<span></span>
</td>
<td class="nump">$ 585<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy', window );">Non-guaranteed separate accounts</a></td>
<td class="nump">6,172<span></span>
</td>
<td class="nump">5,936<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SeparateAccountAssetsClassifiedInFairValueHierarchy', window );">Subtotal</a></td>
<td class="nump">6,750<span></span>
</td>
<td class="nump">6,521<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonGuaranteedSeparateAccountAssetsPricedAtNetAssetValueAsAPracticalExpedient', window );">Non-guaranteed separate accounts priced at NAV as a practical expedient</a></td>
<td class="nump">680<span></span>
</td>
<td class="nump">757<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparateAccountAssets', window );">Separate account assets</a></td>
<td class="nump">7,430<span></span>
</td>
<td class="nump">7,278<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy', window );">Non-guaranteed separate accounts</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_GuaranteedSeparateAccountAssets', window );">Guaranteed separate accounts</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy', window );">Non-guaranteed separate accounts</a></td>
<td class="nump">158<span></span>
</td>
<td class="nump">211<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SeparateAccountAssetsClassifiedInFairValueHierarchy', window );">Subtotal</a></td>
<td class="nump">384<span></span>
</td>
<td class="nump">414<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_GuaranteedSeparateAccountAssets', window );">Guaranteed separate accounts</a></td>
<td class="nump">352<span></span>
</td>
<td class="nump">382<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy', window );">Non-guaranteed separate accounts</a></td>
<td class="nump">5,797<span></span>
</td>
<td class="nump">5,522<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SeparateAccountAssetsClassifiedInFairValueHierarchy', window );">Subtotal</a></td>
<td class="nump">6,149<span></span>
</td>
<td class="nump">5,904<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_GuaranteedSeparateAccountAssets', window );">Guaranteed separate accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy', window );">Non-guaranteed separate accounts</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SeparateAccountAssetsClassifiedInFairValueHierarchy', window );">Subtotal</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy', window );">Non-guaranteed separate accounts</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_GuaranteedSeparateAccountAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Guaranteed Separate Account Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_GuaranteedSeparateAccountAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of the assets held by the Entity for the benefit of separate account policyholders without guarantees classified in the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_NonGuaranteedSeparateAccountAssetsPricedAtNetAssetValueAsAPracticalExpedient">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of the assets held by the Entity for the benefit of separate account policyholders without guarantees and priced at net asset value as a practical expedient.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_NonGuaranteedSeparateAccountAssetsPricedAtNetAssetValueAsAPracticalExpedient</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SeparateAccountAssetsClassifiedInFairValueHierarchy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of the assets held by the Entity for the benefit of separate account policyholders classified in the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SeparateAccountAssetsClassifiedInFairValueHierarchy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeparateAccountAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset at fair value held for benefit of separate account policyholder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480078/944-80-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480141/944-80-45-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480109/944-80-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeparateAccountAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288951782848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information on Separate Account Assets Priced at Net Asset Value (Details) - Separate Account Assets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments', window );">Unfunded Commitments</a></td>
<td class="nump">$ 254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=ci_SeparateAccountAssetsMember', window );">Recurring | NAV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AlternativeInvestment', window );">Fair Value</a></td>
<td class="nump">680<span></span>
</td>
<td class="nump">$ 757<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=srt_PartnershipInterestMember', window );">Securities partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments', window );">Unfunded Commitments</a></td>
<td class="nump">254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=srt_PartnershipInterestMember', window );">Securities partnerships | Recurring | NAV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AlternativeInvestment', window );">Fair Value</a></td>
<td class="nump">419<span></span>
</td>
<td class="nump">451<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_RealEstateFundsMember', window );">Real estate funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments', window );">Unfunded Commitments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_RealEstateFundsMember', window );">Real estate funds | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1', window );">Redemption Notice Period</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_RealEstateFundsMember', window );">Real estate funds | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1', window );">Redemption Notice Period</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_RealEstateFundsMember', window );">Real estate funds | Recurring | NAV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AlternativeInvestment', window );">Fair Value</a></td>
<td class="nump">$ 258<span></span>
</td>
<td class="nump">302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_HedgeFundsMember', window );">Hedge funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments', window );">Unfunded Commitments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_HedgeFundsMember', window );">Hedge funds | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1', window );">Redemption Notice Period</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_HedgeFundsMember', window );">Hedge funds | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1', window );">Redemption Notice Period</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_HedgeFundsMember', window );">Hedge funds | Recurring | NAV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems', window );"><strong>Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AlternativeInvestment', window );">Fair Value</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment other than investment in equity security, investment in debt security and equity method investment. Includes, but is not limited to, investment in certain entities that calculate net asset value per share. Example includes, but is not limited to, investment in hedge fund, venture capital fund, private equity fund, and real estate partnership or fund.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 54B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482134/820-10-35-54B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notice period the entity is required to deliver before it can redeem an investment calculated using net asset value per share, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, investments calculated by per unit, per membership interest, other equity or ownership interest and alternative investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unfunded commitments for which the entity is obligated, to those certain investments for which net asset value per share is calculated (including by unit, membership interest, or other equity (ownership interest) unit measure) (alternative investments).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=ci_SeparateAccountAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=ci_SeparateAccountAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=srt_PartnershipInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=srt_PartnershipInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_RealEstateFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_RealEstateFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_HedgeFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_HedgeFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288968552944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Assets and Liabilities Measured at Fair Value under Certain Conditions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_RealizedInvestmentLossesCommercialMortgageLoansRealEstateEntitiesCertainEquitySecuritiesWithNoReadilyDeterminableFairValue', window );">Realized investment losses on assets measured at fair value under certain conditions, after-tax</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount', window );">Realized investment gains on equity securities with no readily determinable fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_RealizedInvestmentLossesCommercialMortgageLoansRealEstateEntitiesCertainEquitySecuritiesWithNoReadilyDeterminableFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Realized investment losses on impaired real estate, partnership entities, commercial mortgage loans and certain equity securities with no readily determinable fair value, after-tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_RealizedInvestmentLossesCommercialMortgageLoansRealEstateEntitiesCertainEquitySecuritiesWithNoReadilyDeterminableFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain from upward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288968268032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value Disclosures for Financial Instruments Not Carried at Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt, including current maturities, excluding finance leases</a></td>
<td class="nump">$ 28,033<span></span>
</td>
<td class="nump">$ 28,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet', window );">Commercial mortgage loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_MortgageLoansOnRealEstateCommercialAndConsumerNetBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Commercial mortgage loans, including assets held for sale</a></td>
<td class="nump">1,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet', window );">Commercial mortgage loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt, including current maturities, excluding finance leases</a></td>
<td class="nump">29,585<span></span>
</td>
<td class="nump">$ 30,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_MortgageLoansOnRealEstateCommercialAndConsumerNetBeforeReclassificationToDisposalGroupAssetsHeldForSale', window );">Commercial mortgage loans, including assets held for sale</a></td>
<td class="nump">$ 1,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_MortgageLoansOnRealEstateCommercialAndConsumerNetBeforeReclassificationToDisposalGroupAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Mortgage Loans on Real Estate, Commercial and Consumer, Net, Before Reclassification To Disposal Group Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_MortgageLoansOnRealEstateCommercialAndConsumerNetBeforeReclassificationToDisposalGroupAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The balance represents the amount of loans that are secured by real estate mortgages, offset by the reserve to cover probable credit losses on the loan portfolio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288969629904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Variable Interest Entities (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>limitedPartnership </div>
<div>entity</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>entity</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_VariableInterestEntitiesNumberOfEntities', window );">Number of VIEs | entity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember', window );">Variable Interest Entity, Not Primary Beneficiary | Securities limited partnerships and real estate limited partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_VariableInterestEntitiesNumberOfEntities', window );">Number of VIEs | limitedPartnership</a></td>
<td class="nump">190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestInVariableInterestEntity', window );">VIEs, Carrying value</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount', window );">Maximum exposure to loss, variable interest entities</a></td>
<td class="nump">5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember', window );">Variable Interest Entity, Not Primary Beneficiary | Real estate joint ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount', window );">Maximum exposure to loss, variable interest entities</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuarantyLiabilities', window );">Guaranty liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsMaximumExposure', window );">Maximum guarantee exposure</a></td>
<td class="nump">488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember', window );">Variable Interest Entity, Not Primary Beneficiary | Asset-backed and corporate securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount', window );">Maximum exposure to loss, variable interest entities</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember', window );">Variable Interest Entity, Not Primary Beneficiary | Other Variable Interest Entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestInVariableInterestEntity', window );">VIEs, Carrying value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount', window );">Maximum exposure to loss, variable interest entities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember', window );">Variable Interest Entity, Not Primary Beneficiary | Securities limited partnerships and real estate limited partnerships | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage, less than</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember', window );">Variable Interest Entity, Not Primary Beneficiary | Commitment to fund partnership | Securities limited partnerships and real estate limited partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Additional commitments</a></td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_VariableInterestEntitiesNumberOfEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Variable Interest Entities, Number Of Entities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_VariableInterestEntitiesNumberOfEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuarantyLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents a non-contingent liability for the fair value of an obligation to stand ready to perform over the term of a guaranty issued in the event that specified triggering events or conditions occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482050/460-10-25-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuarantyLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestInVariableInterestEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Portion of equity (net assets) in a variable interest entity (VIE) not attributable, directly or indirectly, to the parent entity. That is, this is the portion of equity in a VIE that is attributable to the noncontrolling interest (previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestInVariableInterestEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The reporting entity's maximum amount of exposure to loss as a result of its involvement with the Variable Interest Entity (VIE).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph b<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481420/860-30-50-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481420/860-30-50-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481420/860-30-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=ci_SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=ci_SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=ci_RealEstateJointVenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=ci_RealEstateJointVenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=ci_AssetBackedAndCorporateSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=ci_AssetBackedAndCorporateSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=ci_OtherVariableInterestEntitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=ci_OtherVariableInterestEntitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ci_SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ci_SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=ci_CommitmentToFundPartnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=ci_CommitmentToFundPartnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288966641792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collectively Significant Operating Unconsolidated Subsidiaries (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract', window );"><strong>Equity Method Investment, Summarized Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Loss related to unconsolidated entities reported on the equity method</a></td>
<td class="nump">$ 1,864<span></span>
</td>
<td class="nump">$ 1,658<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">195,265<span></span>
</td>
<td class="nump">180,518<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 174,069<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">5,372<span></span>
</td>
<td class="nump">6,782<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,420<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_BalanceSheetAbstract', window );"><strong>Balance Sheet [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">152,761<span></span>
</td>
<td class="nump">143,885<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">106,410<span></span>
</td>
<td class="nump">99,131<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ci_OperatingJointVenturesMember', window );">Operating joint ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract', window );"><strong>Equity Method Investment, Summarized Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments, carrying value</a></td>
<td class="nump">911<span></span>
</td>
<td class="nump">734<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Loss related to unconsolidated entities reported on the equity method</a></td>
<td class="nump">510<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ci_OperatingJointVenturesMember', window );">Operating joint ventures | China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract', window );"><strong>Equity Method Investment, Summarized Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments, carrying value</a></td>
<td class="nump">214<span></span>
</td>
<td class="nump">602<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ci_OperatingJointVenturesMember', window );">Operating joint ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">5,962<span></span>
</td>
<td class="nump">4,665<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,750<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">98<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 180<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_BalanceSheetAbstract', window );"><strong>Balance Sheet [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">26,681<span></span>
</td>
<td class="nump">21,026<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">$ 25,534<span></span>
</td>
<td class="nump">$ 19,462<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_BalanceSheetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance Sheet</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_BalanceSheetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ci_OperatingJointVenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ci_OperatingJointVenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ci_OperatingJointVenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ci_OperatingJointVenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288960634656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="nump">$ 44,688<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 46,976<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 50,189<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity', window );">Other comprehensive loss, net of tax</a></td>
<td class="num">(206)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(592)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(57)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_TemporaryEquityOtherComprehensiveIncome', window );">Less: Net translation (loss) on foreign currencies attributable to noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(14)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Shareholders other comprehensive income (loss), net of tax</a></td>
<td class="num">(206)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(590)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(43)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="nump">46,244<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">44,688<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">46,976<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">50,328<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember', window );">Revision of Prior Period, Accounting Standards Update, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(139)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="num">(1,658)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,068)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,025)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Shareholders other comprehensive income (loss), net of tax</a></td>
<td class="num">(206)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(590)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(43)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="num">(1,864)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,658)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,068)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive (Loss) | Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(861)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive (Loss) | Revision of Prior Period, Accounting Standards Update, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(164)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember', window );">Securities and Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="num">(332)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,266<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,568<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax', window );">Other comprehensive income (loss) before reclassifications, before tax</a></td>
<td class="nump">620<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,274)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(335)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Other comprehensive income (loss), before reclassifications, tax</a></td>
<td class="num">(146)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">467<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">52<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications, after-tax</a></td>
<td class="nump">474<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,807)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(283)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Reclassification adjustment, tax</a></td>
<td class="num">(8)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(10)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amounts reclassified from AOCI to net income</a></td>
<td class="nump">29<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">209<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(19)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Shareholders other comprehensive income (loss), net of tax</a></td>
<td class="nump">503<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,598)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(302)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="nump">171<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(332)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,266<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember', window );">Securities and Derivatives | Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">900<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember', window );">Securities and Derivatives | Revision of Prior Period, Accounting Standards Update, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">668<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesGainLossOnSaleOfBusinessParentMember', window );">AOCI, Accumulated Gain (Loss), Debt Securities, Available-For-Sale And Derivatives, (Gain) Loss On Sale Of Business, Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Reclassification adjustment, before tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">172<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesRealizedInvestmentGainsLossesParentMember', window );">Reclassification adjustment for losses (gains) included in Shareholders' net income (Net realized investment (losses) gains)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Reclassification adjustment, before tax</a></td>
<td class="nump">38<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">47<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(24)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesSellingGeneralAdministrativeExpenseParentMember', window );">Reclassification adjustment for (gains) included in Shareholders' net income (Selling, general and administrative expenses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Reclassification adjustment, before tax</a></td>
<td class="num">(1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember', window );">Net long-duration insurance and contractholder liabilities measurement adjustments (1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="num">(256)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(765)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(832)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Shareholders other comprehensive income (loss), net of tax</a></td>
<td class="num">(715)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">509<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">67<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="num">(971)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(256)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(765)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember', window );">Net long-duration insurance and contractholder liabilities measurement adjustments (1) | Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember', window );">Net long-duration insurance and contractholder liabilities measurement adjustments (1) | Revision of Prior Period, Accounting Standards Update, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(832)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociLiabilityForFuturePolicyBenefitParentMember', window );">Current period change in discount rate for certain long-duration liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax', window );">Other comprehensive income (loss) before reclassifications, before tax</a></td>
<td class="num">(913)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">642<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">59<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Other comprehensive income (loss), before reclassifications, tax</a></td>
<td class="nump">222<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(122)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications, after-tax</a></td>
<td class="num">(691)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">520<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">56<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember', window );">Current period change in instrument-specific credit risk for market risk benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax', window );">Other comprehensive income (loss) before reclassifications, before tax</a></td>
<td class="num">(29)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(14)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">13<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Other comprehensive income (loss), before reclassifications, tax</a></td>
<td class="nump">5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications, after-tax</a></td>
<td class="num">(24)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(11)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Translation of foreign currencies including portion attributable to noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity', window );">Other comprehensive income (loss) including temporary equity, before reclassifications, before tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(277)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(213)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity', window );">Other comprehensive income (loss) including temporary equity, before reclassifications, tax</a></td>
<td class="nump">5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(33)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(19)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity', window );">Other comprehensive income (loss) including temporary equity, before reclassifications, after-tax</a></td>
<td class="nump">5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(310)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(232)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Reclassification adjustment, before tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">358<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Reclassification adjustment, tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">29<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amounts reclassified from AOCI to net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">387<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity', window );">Translation of foreign currencies, before tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">81<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(213)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity', window );">Other Comprehensive Income (Loss), Tax, Including Temporary Equity</a></td>
<td class="nump">5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(19)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity', window );">Other comprehensive loss, net of tax</a></td>
<td class="nump">5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">77<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(232)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Translation of foreign currencies attributable to parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="num">(154)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(233)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(15)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Shareholders other comprehensive income (loss), net of tax</a></td>
<td class="nump">5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">79<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(218)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="num">(149)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(154)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(233)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember', window );">Translation of foreign currencies attributable to noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_TemporaryEquityOtherComprehensiveIncome', window );">Less: Net translation (loss) on foreign currencies attributable to noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(14)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Postretirement benefits liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="num">(916)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,336)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,746)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax', window );">Other comprehensive income (loss) before reclassifications, before tax</a></td>
<td class="num">(46)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">487<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">448<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Other comprehensive income (loss), before reclassifications, tax</a></td>
<td class="nump">12<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(115)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(106)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications, after-tax</a></td>
<td class="num">(34)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">372<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">342<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Reclassification adjustment, tax</a></td>
<td class="num">(11)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(16)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(21)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Net amounts reclassified from AOCI to net income</a></td>
<td class="nump">35<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">48<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">68<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Shareholders other comprehensive income (loss), net of tax</a></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">420<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">410<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="num">(915)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(916)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,336)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember', window );">Reclassification adjustment for amortization of net prior actuarial losses and prior service costs (Interest expense and other)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Reclassification adjustment, before tax</a></td>
<td class="nump">46<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">65<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">85<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ci_AccumulatedDefinedBenefitPlansAdjustmentGainLossOnSaleOfBusinessMember', window );">Reclassification adjustment for (gains) included in Shareholders' net income ((Loss) gain on sale of businesses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Reclassification adjustment, before tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ci_AccumulatedDefinedBenefitPlansAdjustmentSettlementMember', window );">Reclassification adjustment for settlement (Interest expense and other)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Reclassification adjustment, before tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Before Reclassifications, After Tax, Including Temporary Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), before Reclassifications, before Tax, Including Temporary Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss) before Reclassifications, Tax, Including Temporary Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Before Tax, Including Temporary Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Net of Tax, Including Temporary Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Tax, Including Temporary Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_TemporaryEquityOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of other comprehensive income or(loss) attributable to temporary equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_TemporaryEquityOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-17A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesGainLossOnSaleOfBusinessParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesGainLossOnSaleOfBusinessParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesRealizedInvestmentGainsLossesParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesRealizedInvestmentGainsLossesParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesSellingGeneralAdministrativeExpenseParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesSellingGeneralAdministrativeExpenseParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociLiabilityForFuturePolicyBenefitParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociLiabilityForFuturePolicyBenefitParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=ci_AccumulatedDefinedBenefitPlansAdjustmentGainLossOnSaleOfBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=ci_AccumulatedDefinedBenefitPlansAdjustmentGainLossOnSaleOfBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=ci_AccumulatedDefinedBenefitPlansAdjustmentSettlementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=ci_AccumulatedDefinedBenefitPlansAdjustmentSettlementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288968312048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organizational Efficiency Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">One-time expenses related to abandonment of leased assets and impairment of property and equipment</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charge for organizational efficiency plan recorded in Selling, general and administrative expenses, pre-tax</a></td>
<td class="nump">252<span></span>
</td>
<td class="nump">$ 252<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_RestructuringChargesNetOfTaxExpense', window );">Charge for organizational efficiency plan recorded in Selling, general and administrative expenses, after-tax</a></td>
<td class="nump">193<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">$ 119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring Reserve, Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments</a></td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring Reserve, Ending Balance</a></td>
<td class="nump">$ 202<span></span>
</td>
<td class="nump">$ 202<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_RestructuringChargesNetOfTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges, Net Of Tax Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_RestructuringChargesNetOfTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessExitCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessExitCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288969296528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember', window );">Non-Qualified Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DefinedBenefitPlanMarketRelatedValueOfPensionPlanAssets', window );">Market-related valuation of pension plan assets</a></td>
<td class="nump">4,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets</a></td>
<td class="nump">4,138,000,000<span></span>
</td>
<td class="nump">$ 4,186,000,000<span></span>
</td>
<td class="nump">$ 4,846,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Contributions to qualifed pension plans</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInSeparateAccountsOfSubsidiaries', window );">Plan assets invested in separate accounts of subsidiaries</a></td>
<td class="nump">4,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInFundsOfferedByUnaffiliatedEntity', window );">Plan assets invested in funds offered by an unaffiliated insurance company</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plans | Qualified Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Contributions to qualifed pension plans</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Expected contributions to qualified pension plans in next fiscal year</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInFundsOfferedByUnaffiliatedEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan Fair Value Of Plan Assets Invested In Funds Offered By Unaffiliated Entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInFundsOfferedByUnaffiliatedEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInSeparateAccountsOfSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of plan assets invested in the separate accounts of subisdiaries of the Company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInSeparateAccountsOfSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DefinedBenefitPlanMarketRelatedValueOfPensionPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The market-related value of plan assets, used to measure pension costs, which differs from the actual fair value for domestic pension plan assets invested in non-fixed income investments. The 'market-related' value recognizes the difference between actual and expected long-term returns in the portfolio over five years, a method that reduces the short-term impact of market fluctuations on pension costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DefinedBenefitPlanMarketRelatedValueOfPensionPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288968125920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension - Projected Benefit Obligations and Assets (Details) - Pension Plans - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in benefit obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation, January 1</a></td>
<td class="nump">$ 3,948<span></span>
</td>
<td class="nump">$ 5,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial (gains), net</a></td>
<td class="nump">93<span></span>
</td>
<td class="num">(1,094)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DefinedBenefitPlanBenefitsPaidFromPlanAssets', window );">Benefits paid from plan assets</a></td>
<td class="num">(294)<span></span>
</td>
<td class="num">(296)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DefinedBenefitPlanBenefitsPaidOther', window );">Other</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation, December 31</a></td>
<td class="nump">3,934<span></span>
</td>
<td class="nump">3,948<span></span>
</td>
<td class="nump">5,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in plan assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, January 1</a></td>
<td class="nump">4,186<span></span>
</td>
<td class="nump">4,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="nump">246<span></span>
</td>
<td class="num">(366)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(294)<span></span>
</td>
<td class="num">(296)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, December 31</a></td>
<td class="nump">4,138<span></span>
</td>
<td class="nump">4,186<span></span>
</td>
<td class="nump">$ 4,846<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansNoncurrentLiabilitiesAbstract', window );"><strong>Amounts presented in Consolidated Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Other assets</a></td>
<td class="nump">$ 204<span></span>
</td>
<td class="nump">$ 238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DefinedBenefitPlanBenefitsPaidFromPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payments made from plan assets for which participants are entitled under a pension plan, including pension benefits, death benefits, and benefits due on termination of employment. Also includes payments made under a postretirement benefit plan, including prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DefinedBenefitPlanBenefitsPaidFromPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DefinedBenefitPlanBenefitsPaidOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payments from sources other than plan assets made for which participants are entitled under a pension plan, including pension benefits, death benefits, and benefits due on termination of employment. Also includes payments made under a postretirement benefit plan, including prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DefinedBenefitPlanBenefitsPaidOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansNoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansNoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288968413984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pension - Benefit Payments (Details) - Pension Plans<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract', window );"><strong>Benefit payments including expected future services [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2025</a></td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2026</a></td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2027</a></td>
<td class="nump">314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2028</a></td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2029 - 2033</a></td>
<td class="nump">$ 1,484<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288973800720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pension - Amounts Included in Accumulated Other Comprehensive Income (Details) - Pension Plans - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax', window );">Unrecognized net (losses)</a></td>
<td class="num">$ (1,207)<span></span>
</td>
<td class="num">$ (1,208)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Unrecognized prior service cost</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax', window );">Postretirement benefits liability adjustment</a></td>
<td class="num">$ (1,211)<span></span>
</td>
<td class="num">$ (1,213)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288964780128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension - Net Pension Cost (Details) - Pension Plans - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract', window );"><strong>Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected long-term return on plan assets</a></td>
<td class="num">(204)<span></span>
</td>
<td class="num">(272)<span></span>
</td>
<td class="num">(269)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DefinedBenefitPlanAmortizationAbstract', window );"><strong>Amortization of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Prior actuarial losses, net</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlement loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net (benefit) cost</a></td>
<td class="nump">$ 53<span></span>
</td>
<td class="num">$ (41)<span></span>
</td>
<td class="num">$ (53)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DefinedBenefitPlanAmortizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DefinedBenefitPlanAmortizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R119.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288966848256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension - Assumptions Used for Pension (Details) - Pension Plans<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsDiscountRateAbstract', window );"><strong>Discount rate:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Pension benefit obligation</a></td>
<td class="nump">5.10%<span></span>
</td>
<td class="nump">5.43%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Pension benefit cost</a></td>
<td class="nump">5.43%<span></span>
</td>
<td class="nump">2.82%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsExpectedLongTermReturnOnPlanAssetsAbstract', window );"><strong>Expected long-term return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Pension benefit cost</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Assumptions Used in Calculations, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DefinedBenefitPlanAssumptionsUsedInCalculationsDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DefinedBenefitPlanAssumptionsUsedInCalculationsExpectedLongTermReturnOnPlanAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Assumptions Used in Calculations, Expected Long-Term Return On Plan Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DefinedBenefitPlanAssumptionsUsedInCalculationsExpectedLongTermReturnOnPlanAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R120.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288955135760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pension - Pension Plan Assets (Details) - Pension Plans - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Pension assets at fair value</a></td>
<td class="nump">$ 4,138<span></span>
</td>
<td class="nump">$ 4,186<span></span>
</td>
<td class="nump">$ 4,846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Pension assets at fair value</a></td>
<td class="nump">$ 3,191<span></span>
</td>
<td class="nump">2,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocation percentages</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Federal government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Pension assets at fair value</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Corporate securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Pension assets at fair value</a></td>
<td class="nump">2,780<span></span>
</td>
<td class="nump">2,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Mortgage and other asset-backed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Pension assets at fair value</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Fund investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Pension assets at fair value</a></td>
<td class="nump">$ 278<span></span>
</td>
<td class="nump">478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target allocation percentages</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Pension assets at fair value</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Domestic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Pension assets at fair value</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">International, including funds and pooled separate accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Pension assets at fair value</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Securities partnerships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Pension assets at fair value</a></td>
<td class="nump">419<span></span>
</td>
<td class="nump">452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Real estate funds, including pooled separate accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Pension assets at fair value</a></td>
<td class="nump">270<span></span>
</td>
<td class="nump">315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Commercial mortgage loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Pension assets at fair value</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Guaranteed deposit account contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Pension assets at fair value</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Cash equivalents and other current assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Pension assets at fair value</a></td>
<td class="nump">$ 131<span></span>
</td>
<td class="nump">$ 235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanDebtSecurityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanDebtSecurityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=ci_FundInvestmentsAndPooledSeparateAccountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=ci_FundInvestmentsAndPooledSeparateAccountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=ci_OtherPlanAssetCategoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=ci_OtherPlanAssetCategoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=srt_PartnershipInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=srt_PartnershipInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_RealEstateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_RealEstateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_MortgagesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_MortgagesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=ci_GuaranteedDepositAccountContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=ci_GuaranteedDepositAccountContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=ci_CashAndCashEquivalentsInvestmentTradeReceivablesNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=ci_CashAndCashEquivalentsInvestmentTradeReceivablesNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R121.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288959836240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension - Annual Expense for 401(k) Plans (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Expense</a></td>
<td class="nump">$ 296<span></span>
</td>
<td class="nump">$ 274<span></span>
</td>
<td class="nump">$ 268<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R122.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288966578400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Employee Incentive Plans - Shares of Common Stock Available for Award (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common shares available for award (in shares)</a></td>
<td class="nump">14.4<span></span>
</td>
<td class="nump">16.6<span></span>
</td>
<td class="nump">19.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R123.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288968155968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Incentive Plans - Narrative (Details)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>employee </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionReferenceTermOfTradedOptions', window );">Remaining maturity of traded options</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation expense to be recognized</a></td>
<td class="nump">$ 67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period over which compensation expense will be recognized</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ci_RestrictedStockGrantsAndUnitsMember', window );">Restricted Stock Grants and Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation expense to be recognized</a></td>
<td class="nump">$ 196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period over which compensation expense will be recognized</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfEmployeesHolding', window );">Number of employees holding share-based payment awards | employee</a></td>
<td class="nump">8,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards outstanding (in shares) | shares</a></td>
<td class="nump">1,404<span></span>
</td>
<td class="nump">1,535<span></span>
</td>
<td class="nump">1,524<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">SPSs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation expense to be recognized</a></td>
<td class="nump">$ 61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period over which compensation expense will be recognized</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateFairValueIncludingMonteCarloFactor', window );">Weighted average fair value per share for expense purposes, including the Monte Carlo Factor | $ / shares</a></td>
<td class="nump">$ 329.11<span></span>
</td>
<td class="nump">$ 258.37<span></span>
</td>
<td class="nump">$ 239.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfEmployeesHolding', window );">Number of employees holding share-based payment awards | employee</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards outstanding (in shares) | shares</a></td>
<td class="nump">686<span></span>
</td>
<td class="nump">780<span></span>
</td>
<td class="nump">860<span></span>
</td>
<td class="nump">808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod', window );">Perfromance period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Employee Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Restricted Stock Grants and Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | SPSs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfOriginalGrantAwardedAtEndOfPerformancePeriod', window );">Percentage of original shares granted that may be awarded at end of performance period</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Employee Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Restricted Stock Grants and Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | SPSs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfOriginalGrantAwardedAtEndOfPerformancePeriod', window );">Percentage of original shares granted that may be awarded at end of performance period</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateFairValueIncludingMonteCarloFactor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Granted, Weighted Average Grant Date Fair Value Including Monte Carlo Factor</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateFairValueIncludingMonteCarloFactor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfEmployeesHolding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of employees holding share based payment awards at the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfEmployeesHolding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfOriginalGrantAwardedAtEndOfPerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percent of the original grant amount that holders of strategic performance shares will be awarded in shares of the Company's common stock at the end of the performance period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfOriginalGrantAwardedAtEndOfPerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionReferenceTermOfTradedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum period of time which a traded option of the reporting entity might be outstanding. The volatility of traded options is not used as a component of the expected volatility of outstanding share based compensation option awards as the term of these options does not correlate to the expected term of share-based option awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionReferenceTermOfTradedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of time over which performance is measured to determine achievement for the performance awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ci_RestrictedStockGrantsAndUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ci_RestrictedStockGrantsAndUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R124.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288966688080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Incentive Plans - Black-Scholes Option-Pricing Model Assumptions (Details) - Employee Stock Options - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">1.58%<span></span>
</td>
<td class="nump">1.98%<span></span>
</td>
<td class="nump">1.85%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option life</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options (in dollars per share)</a></td>
<td class="nump">$ 79.66<span></span>
</td>
<td class="nump">$ 50.61<span></span>
</td>
<td class="nump">$ 44.84<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R125.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288968212704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Incentive Plans - Status of and Changes in Common Stock Options (Details) - Employee Stock Options - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding - January 1 (in shares)</a></td>
<td class="nump">6,992<span></span>
</td>
<td class="nump">8,490<span></span>
</td>
<td class="nump">9,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">915<span></span>
</td>
<td class="nump">1,375<span></span>
</td>
<td class="nump">1,524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(1,080)<span></span>
</td>
<td class="num">(2,617)<span></span>
</td>
<td class="num">(2,584)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Expired or canceled (in shares)</a></td>
<td class="num">(131)<span></span>
</td>
<td class="num">(256)<span></span>
</td>
<td class="num">(192)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding - December 31 (in shares)</a></td>
<td class="nump">6,696<span></span>
</td>
<td class="nump">6,992<span></span>
</td>
<td class="nump">8,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable at year-end (in shares)</a></td>
<td class="nump">4,616<span></span>
</td>
<td class="nump">4,410<span></span>
</td>
<td class="nump">5,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding - January 1 (in dollars per share)</a></td>
<td class="nump">$ 186.54<span></span>
</td>
<td class="nump">$ 169.47<span></span>
</td>
<td class="nump">$ 152.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">294.37<span></span>
</td>
<td class="nump">226.95<span></span>
</td>
<td class="nump">213.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">174.66<span></span>
</td>
<td class="nump">149.97<span></span>
</td>
<td class="nump">129.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired or canceled (in dollars per share)</a></td>
<td class="nump">246.95<span></span>
</td>
<td class="nump">211.22<span></span>
</td>
<td class="nump">199.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding - December 31 (in dollars per share)</a></td>
<td class="nump">202.02<span></span>
</td>
<td class="nump">186.54<span></span>
</td>
<td class="nump">169.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable at year-end (in dollars per share)</a></td>
<td class="nump">$ 179.28<span></span>
</td>
<td class="nump">$ 168.97<span></span>
</td>
<td class="nump">$ 152.92<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R126.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288969333104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Incentive Plans - Summary of Information for Stock Options Exercised (Details) - Employee Stock Options - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 126<span></span>
</td>
<td class="nump">$ 313<span></span>
</td>
<td class="nump">$ 268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received for options exercised</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">389<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Tax benefit from options exercised</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R127.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288968524288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Incentive Plans - Summary of Information for Stock Options Outstanding (Details) - Employee Stock Options - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsOutstandingAbstract', window );"><strong>Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number (in shares)</a></td>
<td class="nump">6,696<span></span>
</td>
<td class="nump">6,992<span></span>
</td>
<td class="nump">8,490<span></span>
</td>
<td class="nump">9,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Total intrinsic value</a></td>
<td class="nump">$ 652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 202.02<span></span>
</td>
<td class="nump">$ 186.54<span></span>
</td>
<td class="nump">$ 169.47<span></span>
</td>
<td class="nump">$ 152.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsExercisableAbstract', window );"><strong>Options Exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number (in shares)</a></td>
<td class="nump">4,616<span></span>
</td>
<td class="nump">4,410<span></span>
</td>
<td class="nump">5,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Total intrinsic value</a></td>
<td class="nump">$ 555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 179.28<span></span>
</td>
<td class="nump">$ 168.97<span></span>
</td>
<td class="nump">$ 152.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsExercisableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Information About Options Exercisable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsExercisableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Information About Options Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R128.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288959570704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Incentive Plans - Status of and Changes in Restricted Stock Awards and SPSs (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ci_RestrictedStockGrantsAndUnitsMember', window );">Restricted Stock Grants and Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Grants/Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding - January 1 (in shares)</a></td>
<td class="nump">1,535<span></span>
</td>
<td class="nump">1,524<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awarded (in shares)</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">876<span></span>
</td>
<td class="nump">899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(759)<span></span>
</td>
<td class="num">(714)<span></span>
</td>
<td class="num">(866)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(72)<span></span>
</td>
<td class="num">(151)<span></span>
</td>
<td class="num">(109)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding - December 31 (in shares)</a></td>
<td class="nump">1,404<span></span>
</td>
<td class="nump">1,535<span></span>
</td>
<td class="nump">1,524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Fair Value at Award Date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding - January 1 (in dollars per share)</a></td>
<td class="nump">$ 219.25<span></span>
</td>
<td class="nump">$ 202.85<span></span>
</td>
<td class="nump">$ 186.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Awarded (in dollars per share)</a></td>
<td class="nump">294.60<span></span>
</td>
<td class="nump">229.60<span></span>
</td>
<td class="nump">213.82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">214.70<span></span>
</td>
<td class="nump">197.83<span></span>
</td>
<td class="nump">184.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">256.24<span></span>
</td>
<td class="nump">215.02<span></span>
</td>
<td class="nump">197.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding - December 31 (in dollars per share)</a></td>
<td class="nump">$ 257.38<span></span>
</td>
<td class="nump">$ 219.25<span></span>
</td>
<td class="nump">$ 202.85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">SPSs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Grants/Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding - January 1 (in shares)</a></td>
<td class="nump">780<span></span>
</td>
<td class="nump">860<span></span>
</td>
<td class="nump">808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awarded (in shares)</a></td>
<td class="nump">219<span></span>
</td>
<td class="nump">294<span></span>
</td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(250)<span></span>
</td>
<td class="num">(261)<span></span>
</td>
<td class="num">(206)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(113)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding - December 31 (in shares)</a></td>
<td class="nump">686<span></span>
</td>
<td class="nump">780<span></span>
</td>
<td class="nump">860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Fair Value at Award Date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding - January 1 (in dollars per share)</a></td>
<td class="nump">$ 212.68<span></span>
</td>
<td class="nump">$ 197.07<span></span>
</td>
<td class="nump">$ 190.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Awarded (in dollars per share)</a></td>
<td class="nump">293.85<span></span>
</td>
<td class="nump">230.69<span></span>
</td>
<td class="nump">213.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">191.78<span></span>
</td>
<td class="nump">183.60<span></span>
</td>
<td class="nump">196.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">237.50<span></span>
</td>
<td class="nump">207.75<span></span>
</td>
<td class="nump">197.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding - December 31 (in dollars per share)</a></td>
<td class="nump">$ 243.90<span></span>
</td>
<td class="nump">$ 212.68<span></span>
</td>
<td class="nump">$ 197.07<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ci_RestrictedStockGrantsAndUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ci_RestrictedStockGrantsAndUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R129.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288959881888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Incentive Plans - Fair Value of Vested Restricted Stock and SPSs (Details) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ci_RestrictedStockGrantsAndUnitsMember', window );">Restricted Stock Grants and Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of vested shares</a></td>
<td class="nump">$ 220<span></span>
</td>
<td class="nump">$ 167<span></span>
</td>
<td class="nump">$ 183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">SPSs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares of The Cigna Group common stock distributed upon SPS vesting (in shares)</a></td>
<td class="nump">257<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="nump">243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of vested shares</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ci_RestrictedStockGrantsAndUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ci_RestrictedStockGrantsAndUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R130.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288955258368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Incentive Plans - Compensation Cost and Tax Effects of Share-based Compensation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total compensation cost for shared-based awards</a></td>
<td class="nump">$ 286<span></span>
</td>
<td class="nump">$ 264<span></span>
</td>
<td class="nump">$ 268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefits recognized</a></td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R131.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288951491136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill, Other Intangibles and Property and Equipment - Narrative (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems', window );"><strong>Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets</a></td>
<td class="nump">$ 8.5<span></span>
</td>
<td class="nump">$ 8.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems', window );"><strong>Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization period, other intangible assets</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems', window );"><strong>Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization period, other intangible assets</a></td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and Improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems', window );"><strong>Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life, property, plant and equipment</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and Improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems', window );"><strong>Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life, property, plant and equipment</a></td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Purchased and internally developed software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems', window );"><strong>Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life, property, plant and equipment</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Purchased and internally developed software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems', window );"><strong>Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life, property, plant and equipment</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember', window );">Furniture and Equipment (including Computer Equipment) | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems', window );"><strong>Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life, property, plant and equipment</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember', window );">Furniture and Equipment (including Computer Equipment) | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems', window );"><strong>Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life, property, plant and equipment</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems', window );"><strong>Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Estimated useful life, leasehold improvements</a></td>
<td class="text">Useful Life, Shorter of Lease Term or Asset Utility [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R132.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288951838416">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Goodwill, Other Intangibles, and Property and Equipment - Goodwill Activity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at January 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 45,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_GoodwillIncludingDisposalGroups', window );">Balance at January 1, including held for sale assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,045<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill disposed</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(234)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_GoodwillTransfersToAssetsOfBusinessesHeldForSale', window );">Goodwill transferred to assets of businesses held for sale</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,553)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Impact of foreign currency translation and other adjustments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44,259<span></span>
</td>
<td class="nump">45,811<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Held-for-Sale | International life, accident and supplemental benefits businesses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Goodwill classified as Assets of businesses held for sale</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 234<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_EvernorthMember', window );">Evernorth Health Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at January 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_GoodwillIncludingDisposalGroups', window );">Balance at January 1, including held for sale assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,128<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill disposed</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_GoodwillTransfersToAssetsOfBusinessesHeldForSale', window );">Goodwill transferred to assets of businesses held for sale</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Impact of foreign currency translation and other adjustments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35,130<span></span>
</td>
<td class="nump">35,130<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember', window );">Cigna Healthcare</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at January 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_GoodwillIncludingDisposalGroups', window );">Balance at January 1, including held for sale assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,683<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill disposed</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_GoodwillTransfersToAssetsOfBusinessesHeldForSale', window );">Goodwill transferred to assets of businesses held for sale</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,553)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Impact of foreign currency translation and other adjustments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,129<span></span>
</td>
<td class="nump">10,681<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_OtherOperationsSegmentMember', window );">Other Operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at January 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_GoodwillIncludingDisposalGroups', window );">Balance at January 1, including held for sale assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill disposed</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(234)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_GoodwillTransfersToAssetsOfBusinessesHeldForSale', window );">Goodwill transferred to assets of businesses held for sale</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Impact of foreign currency translation and other adjustments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_GoodwillIncludingDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Including Disposal Groups</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_GoodwillIncludingDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_GoodwillTransfersToAssetsOfBusinessesHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Transfers To Assets Of Businesses Held-For-Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_GoodwillTransfersToAssetsOfBusinessesHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ci_EvernorthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ci_EvernorthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ci_OtherOperationsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ci_OtherOperationsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R133.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288954167296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill, Other Intangibles, and Property and Equipment - Other Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,230<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale', window );">Accumulated Amortization, including held for sale assets</a></td>
<td class="nump">$ 7,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-lived intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost</a></td>
<td class="nump">8,500<span></span>
</td>
<td class="nump">8,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Carrying Value</a></td>
<td class="nump">8,500<span></span>
</td>
<td class="nump">8,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_OtherIntangibleAssetsAbstract', window );"><strong>Other intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,722<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying Value</a></td>
<td class="nump">30,863<span></span>
</td>
<td class="nump">32,492<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale', window );">Cost, including held for sale assets</a></td>
<td class="nump">38,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale', window );">Net Carrying Value, including held for sale assets</a></td>
<td class="nump">30,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_IntangibleAssetsValueOfBusinessAcquiredAbstract', window );"><strong>Value of business acquired ("VOBA" reported in Other assets)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FiniteLivedIntangibleAssetsGrossVoba', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVoba', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FiniteLivedIntangibleAssetsNetVoba', window );">Net Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FiniteLivedIntangibleAssetsGrossVOBAIncludingDisposalGroupsAssetHeldForSale', window );">Cost, including held for sale assets</a></td>
<td class="nump">211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVOBAIncludingDisposalGroupsAssetsHeldForSale', window );">Accumulated Amortization, including held for sale assets</a></td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FiniteLivedIntangibleAssetsNetVOBAIncludingDisposalGroupsAssetsHeldForSale', window );">Net Carrying Value, including held for sale assets</a></td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVoba', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,932<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVoba', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,363<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_IntangibleAssetsNetExcludingGoodwillIncludingVoba', window );">Net Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,569<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups', window );">Cost, including held for sale assets</a></td>
<td class="nump">38,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVOBAIncludingDisposalGroups', window );">Accumulated Amortization, including held for sale assets</a></td>
<td class="nump">7,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups', window );">Net Carrying Value, including held for sale assets</a></td>
<td class="nump">31,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Held-for-Sale | Medicare Advantage and related Cigna Healthcare businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DisposalGroupIncludingDiscontinuedOperationValueOfBusinessAcquired', window );">VOBA, held for sale</a></td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets', window );">Other intangible assets, held for sale</a></td>
<td class="nump">77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,974<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,099<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,875<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FiniteLivedIntangibleAssetsGrossIncludingDisposalGroupsHeldForSale', window );">Cost, including held for sale assets</a></td>
<td class="nump">29,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale', window );">Accumulated Amortization, including held for sale assets</a></td>
<td class="nump">7,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FiniteLivedIntangibleAssetsNetIncludingDisposalGroupsAssetsHeldForSale', window );">Net Carrying Value, including held for sale assets</a></td>
<td class="nump">22,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade Name - Express Scripts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-lived intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,400<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,400<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale', window );">Cost, including held for sale assets</a></td>
<td class="nump">8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale', window );">Net Carrying Value, including held for sale assets</a></td>
<td class="nump">8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale', window );">Accumulated Amortization, including held for sale assets</a></td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_OtherIntangibleAssetsAbstract', window );"><strong>Other intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">348<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 217<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale', window );">Cost, including held for sale assets</a></td>
<td class="nump">317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale', window );">Net Carrying Value, including held for sale assets</a></td>
<td class="nump">$ 207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DisposalGroupIncludingDiscontinuedOperationValueOfBusinessAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Value Of Business Acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DisposalGroupIncludingDiscontinuedOperationValueOfBusinessAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite Lived Intangible Assets, Accumulated Amortization, Including Disposal Groups Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVOBAIncludingDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite Lived Intangible Assets Accumulated Amortization Including VOBA Including Disposal Groups</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVOBAIncludingDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVoba">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. Includes insurance contracts acquired in a business combination that are reported in deferred policy acquisition costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVoba</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVOBAIncludingDisposalGroupsAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite Lived Intangible Assets Accumulated Amortization VOBA Including Disposal Groups Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVOBAIncludingDisposalGroupsAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVoba">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of insurance contracts acquired in a business combination that are reported in deferred policy acquisition costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVoba</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_FiniteLivedIntangibleAssetsGrossIncludingDisposalGroupsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite Lived Intangible Assets Gross, Including Disposal Groups, Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_FiniteLivedIntangibleAssetsGrossIncludingDisposalGroupsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_FiniteLivedIntangibleAssetsGrossVOBAIncludingDisposalGroupsAssetHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite Lived Intangible Assets Gross VOBA Including Disposal Groups Asset Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_FiniteLivedIntangibleAssetsGrossVOBAIncludingDisposalGroupsAssetHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_FiniteLivedIntangibleAssetsGrossVoba">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of insurance contracts acquired in a business combination that are reported in deferred policy acquisition costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_FiniteLivedIntangibleAssetsGrossVoba</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_FiniteLivedIntangibleAssetsNetIncludingDisposalGroupsAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite Lived Intangible Assets, Net, Including Disposal Groups Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_FiniteLivedIntangibleAssetsNetIncludingDisposalGroupsAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_FiniteLivedIntangibleAssetsNetVOBAIncludingDisposalGroupsAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite Lived Intangible Assets Net VOBA Including Disposal Groups Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_FiniteLivedIntangibleAssetsNetVOBAIncludingDisposalGroupsAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_FiniteLivedIntangibleAssetsNetVoba">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of insurance contracts acquired in a business combination that are reported in deferred policy acquisition costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_FiniteLivedIntangibleAssetsNetVoba</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indefinite Lived Intangible Assets Excluding Goodwill, Including Disposal Groups Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets Gross Excluding Goodwill, Including Disposal Groups Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets Gross Excluding Goodwill Including VOBA Including Disposal Groups</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_IntangibleAssetsGrossExcludingGoodwillIncludingVoba">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill. Inlcudes insurance contracts acquired in a business combination that are reported in deferred policy acquisition costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_IntangibleAssetsGrossExcludingGoodwillIncludingVoba</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets Net Excluding Goodwill Including Disposals Groups Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets Net Excluding Goodwill Including VOBA Including Disposal Groups</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_IntangibleAssetsNetExcludingGoodwillIncludingVoba">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. Includes insurance contracts acquired in a business combination that are reported in deferred policy acquisition costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_IntangibleAssetsNetExcludingGoodwillIncludingVoba</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_IntangibleAssetsValueOfBusinessAcquiredAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets, Value Of Business Acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_IntangibleAssetsValueOfBusinessAcquiredAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_OtherIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_OtherIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R134.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288952037296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill, Other Intangibles, and Property and Equipment - Property and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PropertyPlantAndEquipmentIncludingAssetsHeldForSaleAbstract', window );"><strong>Property and equipment, including held for sale assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PropertyPlantAndEquipmentGrossIncludingDisposalGroups', window );">Cost</a></td>
<td class="nump">$ 12,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups', window );">Accumulated Amortization</a></td>
<td class="nump">8,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups', window );">Net Carrying Value</a></td>
<td class="nump">3,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Total property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,430<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,774<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Held-for-Sale | Medicare Advantage and related Cigna Healthcare businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract', window );"><strong>Property and equipment classified as Assets of businesses held for sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent', window );">Property and equipment, net carrying value classified as assets of business held for sale</a></td>
<td class="nump">176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Internal-use software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PropertyPlantAndEquipmentIncludingAssetsHeldForSaleAbstract', window );"><strong>Property and equipment, including held for sale assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PropertyPlantAndEquipmentGrossIncludingDisposalGroups', window );">Cost</a></td>
<td class="nump">10,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups', window );">Accumulated Amortization</a></td>
<td class="nump">7,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups', window );">Net Carrying Value</a></td>
<td class="nump">2,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Total property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,100<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,848<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ci_AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember', window );">Other property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PropertyPlantAndEquipmentIncludingAssetsHeldForSaleAbstract', window );"><strong>Property and equipment, including held for sale assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PropertyPlantAndEquipmentGrossIncludingDisposalGroups', window );">Cost</a></td>
<td class="nump">2,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups', window );">Accumulated Amortization</a></td>
<td class="nump">1,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups', window );">Net Carrying Value</a></td>
<td class="nump">$ 877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Total property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,330<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 926<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including disposal groups, of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_PropertyPlantAndEquipmentGrossIncludingDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including disposal groups, before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_PropertyPlantAndEquipmentGrossIncludingDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_PropertyPlantAndEquipmentIncludingAssetsHeldForSaleAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property, Plant And Equipment, Including Assets Held-For-Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_PropertyPlantAndEquipmentIncludingAssetsHeldForSaleAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including disposal groups, after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ci_AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ci_AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R135.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288969455760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill, Other Intangibles, and Property and Equipment - Components of Depreciation and Amortization Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DepreciationAndAmortizationByTypeLineItems', window );"><strong>Depreciation And Amortization By Type [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 3,035<span></span>
</td>
<td class="nump">$ 2,937<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 2,923<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DepreciationAndAmortizationByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Internal-use software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DepreciationAndAmortizationByTypeLineItems', window );"><strong>Depreciation And Amortization By Type [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,216<span></span>
</td>
<td class="nump">1,068<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,097<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DepreciationAndAmortizationByTypeAxis=ci_AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember', window );">Other property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DepreciationAndAmortizationByTypeLineItems', window );"><strong>Depreciation And Amortization By Type [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">260<span></span>
</td>
<td class="nump">251<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">253<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DepreciationAndAmortizationByTypeAxis=us-gaap_InsuranceContractsAcquiredInBusinessCombinationMember', window );">Value of business acquired (reported in Other assets)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DepreciationAndAmortizationByTypeLineItems', window );"><strong>Depreciation And Amortization By Type [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">25<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DepreciationAndAmortizationByTypeAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DepreciationAndAmortizationByTypeLineItems', window );"><strong>Depreciation And Amortization By Type [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 1,552<span></span>
</td>
<td class="nump">$ 1,606<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,548<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DepreciationAndAmortizationByTypeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DepreciationAndAmortizationByTypeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DepreciationAndAmortizationByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DepreciationAndAmortizationByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DepreciationAndAmortizationByTypeAxis=ci_AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DepreciationAndAmortizationByTypeAxis=ci_AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DepreciationAndAmortizationByTypeAxis=us-gaap_InsuranceContractsAcquiredInBusinessCombinationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DepreciationAndAmortizationByTypeAxis=us-gaap_InsuranceContractsAcquiredInBusinessCombinationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DepreciationAndAmortizationByTypeAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DepreciationAndAmortizationByTypeAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R136.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288966091536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill, Other Intangibles, and Property and Equipment - Estimated Annual Pre-Tax Amortization for Intangible Assets (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract', window );"><strong>Goodwill Other Intangibles And Property And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 2,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">2,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">1,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">1,559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2028</a></td>
<td class="nump">$ 1,484<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>R137.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288967591376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term for operating leases</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term for finance leases</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate for operating leases</a></td>
<td class="nump">3.45%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate for finance leases</a></td>
<td class="nump">4.29%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term length for operating leases</a></td>
<td class="text">35 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>R138.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288969984512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
<td class="nump">$ 170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FinanceLeaseLeaseCostAbstract', window );"><strong>Finance lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of ROU assets</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_FinanceLeaseCost', window );">Total finance lease cost</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 233<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost associated with finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_FinanceLeaseLeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Lease Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_FinanceLeaseLeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>R139.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288967984400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Cash Flow Information Related to Leases (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CashFlowActivitiesLesseeAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash outflows from operating leases</a></td>
<td class="nump">$ 132<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
<td class="nump">$ 167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash outflows from finance leases</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash outflows from finance leases</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_RightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract', window );"><strong>ROU assets obtained in exchange for lease obligations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Finance leases</a></td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_CashFlowActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flow Activities, Lessee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_CashFlowActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_RightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use Assets Obtained In Exchange For Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_RightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>R140.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288959929488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Operating and Finance Lease Right of Use ("ROU") Assets and Lease Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AssetsAndLiabilitiesLesseeOperatingLeasesAbstract', window );"><strong>Operating leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease ROU assets</a></td>
<td class="nump">$ 370<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">340<span></span>
</td>
<td class="nump">346<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">445<span></span>
</td>
<td class="nump">460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AssetsAndLiabilitiesLesseeFinanceLeasesAbstract', window );"><strong>Finance leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization', window );">Accumulated depreciation</a></td>
<td class="num">(73)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Property and equipment, net</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Short-term debt</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term debt</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total finance lease liabilities</a></td>
<td class="nump">$ 108<span></span>
</td>
<td class="nump">$ 99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Balance sheet location of operating lease ROU assets</a></td>
<td class="text">Other assets<span></span>
</td>
<td class="text">Other assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Balance sheet location of current operating lease liabilities</a></td>
<td class="text">Accrued expenses and other liabilities<span></span>
</td>
<td class="text">Accrued expenses and other liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Balance sheet location of non-current operating lease liabilities</a></td>
<td class="text">Other non-current liabilities<span></span>
</td>
<td class="text">Other non-current liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Balance sheet location of non-current finance lease assets</a></td>
<td class="text">Property and equipment<span></span>
</td>
<td class="text">Property and equipment<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Balance sheet location of current finance lease liabilities</a></td>
<td class="text">Short-term debt<span></span>
</td>
<td class="text">Short-term debt<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Balance sheet location of non-current finance lease liabilities</a></td>
<td class="text">Long-term debt<span></span>
</td>
<td class="text">Long-term debt<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AssetsAndLiabilitiesLesseeFinanceLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee, Finance Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AssetsAndLiabilitiesLesseeFinanceLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AssetsAndLiabilitiesLesseeOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee, Operating Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AssetsAndLiabilitiesLesseeOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>165
<FILENAME>R141.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288951771232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities of Lease Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">445<span></span>
</td>
<td class="nump">$ 460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total</a></td>
<td class="nump">$ 108<span></span>
</td>
<td class="nump">$ 99<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>166
<FILENAME>R142.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288970507936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders Equity and Dividend Restrictions (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount', window );">Net income</a></td>
<td class="nump">$ 5.3<span></span>
</td>
<td class="nump">$ 5.7<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryCapitalAndSurplusApplyingNationalAssociationOfInsuranceCommissionersNAICPractices', window );">Surplus</a></td>
<td class="nump">14.9<span></span>
</td>
<td class="nump">$ 16.4<span></span>
</td>
<td class="nump">$ 13.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired', window );">Minimum statutory surplus required by regulators</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldByInsuranceRegulators', window );">Investments on deposit with regulatory bodies</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments', window );">Maximum dividend distributions permitted in 2024 without regulatory approval</a></td>
<td class="nump">2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_StatutoryAccountingPracticesAmountPermittedLendingAuthorityOfLifeInsuranceSubsidiaryToParent', window );">Maximum loans to the parent company permitted without regulatory approval</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries', window );">Restricted GAAP net assets of The Cigna Group's subsidiaries</a></td>
<td class="nump">12.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsUndistributedEarningsFromEquityMethodInvestees', window );">Undistributed earnings from equity method subidiaries</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_StatutoryAccountingPracticesAmountPermittedLendingAuthorityOfLifeInsuranceSubsidiaryToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum permitted amount certain of the Company's life insurance subsidiaries may loan to the parent company without prior approval from the state's Department of Insurance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_StatutoryAccountingPracticesAmountPermittedLendingAuthorityOfLifeInsuranceSubsidiaryToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of restricted net assets of consolidated and unconsolidated subsidiaries as of the end of the most recently completed fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(3)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldByInsuranceRegulators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of cash and investment securities on deposit with state regulatory authorities in connection with capital requirements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 825<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479383/944-825-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldByInsuranceRegulators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsUndistributedEarningsFromEquityMethodInvestees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consolidated retained earnings that represent undistributed (not yet received) earnings from 50 percent or less owned persons accounted for by the equity method (equity method investees).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsUndistributedEarningsFromEquityMethodInvestees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of dividends available for payment after computation of statutory restrictions on capital surplus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of statutory capital required to be maintained as of the balance sheet date under prescribed or permitted statutory accounting practices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 505<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479989/944-505-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net income for the period determined using accounting principles prescribed or permitted by insurance regulators.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryCapitalAndSurplusApplyingNationalAssociationOfInsuranceCommissionersNAICPractices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of statutory capital and surplus computed using statutory accounting practices prescribed by the National Association of Insurance Commissioners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 505<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479989/944-505-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryCapitalAndSurplusApplyingNationalAssociationOfInsuranceCommissionersNAICPractices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>167
<FILENAME>R143.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288968141824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">U.S. income taxes</a></td>
<td class="nump">$ 1,459<span></span>
</td>
<td class="nump">$ 1,679<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,267<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign income taxes</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">207<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State income taxes</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">112<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current taxes</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">2,087<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,586<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred taxes (benefits)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">U.S. income tax benefits</a></td>
<td class="num">(533)<span></span>
</td>
<td class="num">(275)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(163)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign income (tax benefits) taxes</a></td>
<td class="num">(1,046)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">69<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State income tax benefits</a></td>
<td class="num">(80)<span></span>
</td>
<td class="num">(169)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(122)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax benefits</a></td>
<td class="num">(1,659)<span></span>
</td>
<td class="num">(472)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(216)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income taxes</a></td>
<td class="nump">$ 141<span></span>
</td>
<td class="nump">$ 1,615<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,370<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>168
<FILENAME>R144.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288951722832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Nominal Tax Rate Reconciliation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>$</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax expense at nominal rate</a></td>
<td class="nump">$ 1,158<span></span>
</td>
<td class="nump">$ 1,763<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,426<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings', window );">Effect of foreign earnings</a></td>
<td class="num">(173)<span></span>
</td>
<td class="num">(96)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(33)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income tax (benefit), net of federal income tax benefit</a></td>
<td class="num">(39)<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(9)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount', window );">Swiss tax attributes</a></td>
<td class="num">(1,674)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount', window );">Other foreign tax attributes</a></td>
<td class="num">(153)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">1,290<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(14)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income taxes</a></td>
<td class="nump">$ 141<span></span>
</td>
<td class="nump">$ 1,615<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,370<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>%</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax expense at nominal rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings', window );">Effect of foreign earnings</a></td>
<td class="num">(3.10%)<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax (benefit), net of federal income tax benefit</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent', window );">Swiss tax attributes</a></td>
<td class="num">(30.40%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent', window );">Other foreign tax attributes</a></td>
<td class="num">(2.80%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">23.40%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="num">(0.90%)<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total income taxes</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">19.20%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">20.20%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposed of by Sale | International life, accident and supplemental benefits businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>$</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationDispositionOfBusiness', window );">Impact of sale of businesses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (37)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>%</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness', window );">Impact of sale of businesses</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Held-for-Sale | Medicare Advantage and related Cigna Healthcare businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>$</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationDispositionOfBusiness', window );">Impact of sale of businesses</a></td>
<td class="num">$ (213)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>%</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness', window );">Impact of sale of businesses</a></td>
<td class="num">(3.90%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Other Foreign Tax Attributes, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Other Foreign Tax Attributes, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to permanently reinvested foreign earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Swiss Tax Attributes, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Swiss Tax Attributes, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to permanently reinvested foreign earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to disposition of a business not qualifying as a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationDispositionOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the disposition of a business not qualifying as a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationDispositionOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>169
<FILENAME>R145.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288966448192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Pre-tax Income From Foreign Operations (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=ci_IncomeBeforeTaxesMember', window );">Pre-Tax Income | Geographic Concentration Risk | Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="nump">48.00%<span></span>
</td>
<td class="nump">46.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481027/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=ci_IncomeBeforeTaxesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=ci_IncomeBeforeTaxesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionForeignMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionForeignMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>170
<FILENAME>R146.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288968259888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Foreign Jurisdiction Tax Attributes and Sale of Medicare Advantage and Related Businesses (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DeferredTaxAssetsForeignTaxAttributes', window );">Deferred tax assets associated with foreign tax attributes</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DeferredTaxAssetsValuationAllowanceForeignTaxAttributes', window );">Valuation allowance against deferred tax assets associated with foreign tax attributes</a></td>
<td class="nump">772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Deferred loss - sale of business</a></td>
<td class="nump">584<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Held-for-Sale | Medicare Advantage and related Cigna Healthcare businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Deferred loss - sale of business</a></td>
<td class="nump">584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DeferredTaxAssetsForeignTaxAttributes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Foreign Tax Attributes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DeferredTaxAssetsForeignTaxAttributes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DeferredTaxAssetsValuationAllowanceForeignTaxAttributes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Valuation Allowance, Foreign Tax Attributes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DeferredTaxAssetsValuationAllowanceForeignTaxAttributes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>171
<FILENAME>R147.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288951654160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Employee and retiree benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities', window );">Other insurance and contractholder liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Deferred loss - sale of business</a></td>
<td class="nump">$ 584<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther', window );">Other accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DeferredTaxAssetsPolicyAcquisitionExpenses', window );">Policy acquisition expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTranslation', window );">Unrealized depreciation on investments and foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DeferredTaxAssetsForeignTaxAttributes', window );">Foreign tax attributes</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets before valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance for deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(208)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract', window );"><strong>Deferred tax assets, including held for sale assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIncludingDisposalGroupsAssetsHeldForSale', window );">Employee and retiree benefit plans</a></td>
<td class="nump">217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilitiesIncludingDisposalGroupsAssetsHeldForSale', window );">Other insurance and contractholder liabilities</a></td>
<td class="nump">353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DeferredTaxAssetsOperatingLossCarryforwardsIncludingDisposalGroupsAssetsHeldForSale', window );">Loss carryforwards</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Deferred loss - sale of business</a></td>
<td class="nump">584<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOtherIncludingDisposalGroupsAssetsHeldForSale', window );">Other accrued liabilities</a></td>
<td class="nump">244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DeferredTaxAssetsPolicyAcquisitionExpensesIncludingDisposalGroupsAssetsHeldForSale', window );">Policy acquisition expenses</a></td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTransactionIncludingDisposalGroupsAssetsHeldForSale', window );">Unrealized depreciation on investments and foreign currency translation</a></td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DeferredTaxAssetsForeignTaxAttributesIncludingDisposalGroupsAssetsHeldForSale', window );">Foreign tax attributes</a></td>
<td class="nump">1,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DeferredTaxAssetsOtherIncludingDisposalGroupsAssetsHeldForSale', window );">Other</a></td>
<td class="nump">242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale', window );">Deferred tax assets before valuation allowance</a></td>
<td class="nump">3,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DeferredTaxAssetsValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale', window );">Valuation allowance for deferred tax assets</a></td>
<td class="num">(1,498)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">2,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets', window );">Acquisition-related basis differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract', window );"><strong>Deferred tax liabilities, including held for sale liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DeferredTaxLiabilitiesPropertyPlantAndEquipmentIncludingDisposalGroupsAssetsHeldForSale', window );">Depreciation and amortization</a></td>
<td class="nump">371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIncludingDisposalGroupsAssetsHeldForSale', window );">Acquisition-related basis differences</a></td>
<td class="nump">8,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DeferredTaxLiabilitiesOtherIncludingDisposalGroupsAssetsHeldForSale', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale', window );">Total deferred tax liabilities</a></td>
<td class="nump">8,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DeferredTaxLiabilitiesNetIncludingDisposalGroup', window );">Deferred tax liabilities, net, including amounts reported in Liabilities of businesses held for sale</a></td>
<td class="num">(6,187)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred income tax liabilities(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,786)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DeferredTaxAssetsGrossInOtherAssetsNoncurrent', window );">Deferred tax assets reported in Other Assets</a></td>
<td class="nump">1,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DeferredTaxAssetsInvestmentsSubjectToFederalCapitalLossUtilizationRules', window );">Deferred tax assets associated with unrealized investment losses</a></td>
<td class="nump">218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Held-for-Sale | Medicare Advantage and related Cigna Healthcare businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Deferred loss - sale of business</a></td>
<td class="nump">584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance for deferred tax assets</a></td>
<td class="num">(584)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract', window );"><strong>Deferred tax assets, including held for sale assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Deferred loss - sale of business</a></td>
<td class="nump">584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract', window );"><strong>Deferred tax liabilities, including held for sale liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities', window );">Net deferred income tax liabilities classified as liabilities of businesses held for sale</a></td>
<td class="nump">$ 69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Components of Deferred Tax Assets Including Disposal Groups</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DeferredTaxAssetsForeignTaxAttributes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Foreign Tax Attributes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DeferredTaxAssetsForeignTaxAttributes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DeferredTaxAssetsForeignTaxAttributesIncludingDisposalGroupsAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Foreign Tax Attributes, Including Disposal Groups Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DeferredTaxAssetsForeignTaxAttributesIncludingDisposalGroupsAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DeferredTaxAssetsGrossInOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Gross reported in Other Assets Noncurrent on the Balance Sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DeferredTaxAssetsGrossInOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Gross, Including Disposal Groups Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DeferredTaxAssetsInvestmentsSubjectToFederalCapitalLossUtilizationRules">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets relative to investments subject to Federal capital loss utilization rules. Capital losses can only be utilized to extent there are capital gains in a given year. If capital losses exceed capital gains, the taxpayer can utilize capital losses to the extent there are capital gains in the applicable carryback period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DeferredTaxAssetsInvestmentsSubjectToFederalCapitalLossUtilizationRules</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Net of Valuation Allowance, Including Disposal Groups Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DeferredTaxAssetsOperatingLossCarryforwardsIncludingDisposalGroupsAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Loss Carryforwards, Including Disposal Groups Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DeferredTaxAssetsOperatingLossCarryforwardsIncludingDisposalGroupsAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DeferredTaxAssetsOtherIncludingDisposalGroupsAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Other, Including Disposal Groups Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DeferredTaxAssetsOtherIncludingDisposalGroupsAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DeferredTaxAssetsPolicyAcquisitionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Policy Acquisition Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DeferredTaxAssetsPolicyAcquisitionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DeferredTaxAssetsPolicyAcquisitionExpensesIncludingDisposalGroupsAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Policy Acquisition Expenses, Including Disposal Groups Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DeferredTaxAssetsPolicyAcquisitionExpensesIncludingDisposalGroupsAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIncludingDisposalGroupsAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Including Disposal Groups Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIncludingDisposalGroupsAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOtherIncludingDisposalGroupsAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other, Including Disposal Groups Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOtherIncludingDisposalGroupsAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilitiesIncludingDisposalGroupsAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Policyholder Liabilities, Including Disposal Groups Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilitiesIncludingDisposalGroupsAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTransactionIncludingDisposalGroupsAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets, including held for sale amounts, attributable to taxable temporary differences from unrealized losses on investments and foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTransactionIncludingDisposalGroupsAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets attributable to taxable temporary differences from unrealized losses on investments and foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DeferredTaxAssetsValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Valuation Allowance, Including Disposal Groups Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DeferredTaxAssetsValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIncludingDisposalGroupsAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Goodwill and Intangible Assets, Including Disposal Groups Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIncludingDisposalGroupsAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Gross, Including Disposal Groups</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Gross, Including Disposal Groups Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DeferredTaxLiabilitiesNetIncludingDisposalGroup">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Net, Including Disposal Group</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DeferredTaxLiabilitiesNetIncludingDisposalGroup</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DeferredTaxLiabilitiesOtherIncludingDisposalGroupsAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Other, Including Disposal Groups Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DeferredTaxLiabilitiesOtherIncludingDisposalGroupsAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DeferredTaxLiabilitiesPropertyPlantAndEquipmentIncludingDisposalGroupsAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Property, Plant and Equipment, Including Disposal Groups Assets Held For Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DeferredTaxLiabilitiesPropertyPlantAndEquipmentIncludingDisposalGroupsAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax effect as of the balance sheet date of the amount of the estimated future tax deductions arising from estimated policyholder reserves, which will be deductible from future taxable income when actual costs are incurred, and which can only be realized if sufficient tax-basis income is generated in future periods to enable the tax deduction to be taken.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>172
<FILENAME>R148.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288970585296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Uncertain Tax Positions (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at January 1,</a></td>
<td class="nump">$ 1,343<span></span>
</td>
<td class="nump">$ 1,230<span></span>
</td>
<td class="nump">$ 1,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">(Decrease) / Increase due to prior year positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">(Decrease) due to prior year tax positions</a></td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase due to current year positions</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Reduction related to settlements with taxing authorities</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Reduction related to lapse of applicable statute of limitations</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at December 31,</a></td>
<td class="nump">1,399<span></span>
</td>
<td class="nump">1,343<span></span>
</td>
<td class="nump">1,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued', window );">Liability for net interest expense on uncertain tax positions</a></td>
<td class="nump">$ 220<span></span>
</td>
<td class="nump">$ 176<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense accrued for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>173
<FILENAME>R149.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288960102960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Other Matters (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 19, 2016 </div>
<div>claim</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_InsuranceRelatedAssessmentsMember', window );">Guaranty Fund Assessments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Loss contingency accrual provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=ci_LitigationMattersAndRegulatoryMattersMember', window );">Litigation Matters and Regulatory Matters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Reserves for litigation matters, pre-tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ci_ExpressScriptsLitigationWithElevanceMember', window );">Express Scripts Litigation with Elevance | Judicial Ruling | Pricing Concessions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought by Elevance</a></td>
<td class="nump">$ 14,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ci_ExpressScriptsLitigationWithElevanceMember', window );">Express Scripts Litigation with Elevance | Pending Litigation | Pricing Concessions Through Remaining Contract Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought by Elevance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ci_ExpressScriptsLitigationWithElevanceMember', window );">Express Scripts Litigation with Elevance | Pending Litigation | Pricing Concessions After Remaining Term of Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought by Elevance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ci_ExpressScriptsLitigationWithElevanceMember', window );">Express Scripts Litigation with Elevance | Pending Litigation | Damages for Service Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought by Elevance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ci_ExpressScriptsCounterclaimsAgainstElevanceMember', window );">Express Scripts counterclaims against Elevance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsDismissedNumber', window );">Number of counts dismissed | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of counts | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_IndemnificationGuaranteeMember', window );">Indemnification obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsCurrentCarryingValue', window );">Liability for guarantees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_RetirementAndLifeInsuranceContractsMember', window );">Retiree and Life Insurance Benefits | Financial Guarantees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsMaximumExposure', window );">Maximum guarantee exposure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">420,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsLiquidationProceeds', window );">Assets maintained by employers (minimum)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">420,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsCurrentCarryingValue', window );">Liability for guarantees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsCurrentCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsCurrentCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsLiquidationProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates, if estimable, the approximate extent to which the proceeds from liquidation of any assets held either as collateral or by third parties would be expected to cover the maximum potential amount of future payments under the guarantee or each group of similar guarantees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsLiquidationProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsDismissedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of claims dismissed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsDismissedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_InsuranceRelatedAssessmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_InsuranceRelatedAssessmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=ci_LitigationMattersAndRegulatoryMattersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=ci_LitigationMattersAndRegulatoryMattersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ci_ExpressScriptsLitigationWithElevanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ci_ExpressScriptsLitigationWithElevanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=ci_PricingConcessionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=ci_PricingConcessionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=ci_PricingConcessionsThroughRemainingContractTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=ci_PricingConcessionsThroughRemainingContractTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=ci_PricingConcessionsAfterRemainingTermOfAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=ci_PricingConcessionsAfterRemainingTermOfAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=ci_DamagesForServiceIssuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=ci_DamagesForServiceIssuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ci_ExpressScriptsCounterclaimsAgainstElevanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ci_ExpressScriptsCounterclaimsAgainstElevanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_IndemnificationGuaranteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_IndemnificationGuaranteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ci_RetirementAndLifeInsuranceContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ci_RetirementAndLifeInsuranceContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_FinancialGuaranteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_FinancialGuaranteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>174
<FILENAME>R150.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288968126752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Summary of Special Items (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemsBeforeTaxAbstract', window );"><strong>Pre-tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes', window );">(Gain) loss on sale of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,499<span></span>
</td>
<td class="num">$ (1,662)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charge for organizational efficiency plan (Selling, general and administrative expenses)</a></td>
<td class="nump">$ 252<span></span>
</td>
<td class="nump">252<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemChargeBenefitBeforeTaxLitigation', window );">(Benefits) charges associated with litigation matters (Selling, general and administrative expenses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_TransactionRelatedCosts', window );">Integration and transaction-related costs, pre-tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemChargeBenefitTaxMatters', window );">Deferred tax (benefits), net (Income taxes, less amount attributable to noncontrolling interests)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax', window );">Debt extinguishment costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity', window );">Total impact from special items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,997<span></span>
</td>
<td class="num">(1,533)<span></span>
</td>
<td class="nump">451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemsAfterTaxAbstract', window );"><strong>After-tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax', window );">(Gain) loss on sale of business, after-tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,429<span></span>
</td>
<td class="num">(1,332)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_RestructuringChargesNetOfTaxExpense', window );">Charge for organizational efficiency plan, after-tax (Selling, general and administrative expenses)</a></td>
<td class="nump">$ 193<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemChargeBenefitAfterTaxLitigation', window );">(Benefits) charges associated with litigation matters, after-tax (Selling, general and administrative expenses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_TransactionRelatedCostsAfterTax', window );">Integration and transaction-related costs, after-tax (Selling, general and administrative expenses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemChargeBenefitTaxMattersAfterTax', window );">Deferred tax (benefits), net, after-tax (Income taxes, less amount attributable to noncontrolling interests)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,071)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax', window );">Debt extinguishment costs, after-tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity', window );">Total impact from special items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 757<span></span>
</td>
<td class="num">$ (1,232)<span></span>
</td>
<td class="nump">$ 279<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_RestructuringChargesNetOfTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges, Net Of Tax Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_RestructuringChargesNetOfTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SpecialItemChargeBenefitAfterTaxLitigation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>After-tax charges associated with litigation matters that are classified as special items, attributable to the parent. Special items reflect amounts that management does not believe are representative of underlying results of operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SpecialItemChargeBenefitAfterTaxLitigation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SpecialItemChargeBenefitBeforeTaxLitigation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>After-tax charges associated with litigation matters that are classified as special items, attributable to the parent. Special items reflect amounts that management does not believe are representative of underlying results of operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SpecialItemChargeBenefitBeforeTaxLitigation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SpecialItemChargeBenefitTaxMatters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Special Item Charge Benefit Tax Matters</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SpecialItemChargeBenefitTaxMatters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SpecialItemChargeBenefitTaxMattersAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Special Item Charge Benefit Tax Matters After Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SpecialItemChargeBenefitTaxMattersAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Special Item Charges Debt Extinguishment Costs Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Special Item Charges Debt Extinguishment Costs Net Of Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Special Item, Gain (Loss) On Sale Of Business, Before Taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Special Item, Gain (Loss) On Sale Of Business, Net Of Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of before-tax tax amounts classified as special items, attributable to the parent. Special items are excluded from the calculation of 'adjusted income (loss) from operations' because management believes they are not representative of the underlying results of operations. This is generally because the nature and size of these matters are not indicative of our ongoing business operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of after-tax amounts classified as special items, attributable to the parent. Special items are excluded from the calculation of 'adjusted income (loss) from operations' because management believes they are not representative of the underlying results of operations. This is generally because the nature and size of these matters are not indicative of our ongoing business operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SpecialItemsAfterTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SpecialItemsAfterTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SpecialItemsBeforeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SpecialItemsBeforeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_TransactionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre-tax transaction-related costs primarily consisting of fees for legal, advisory and other professional services, as well as employee costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_TransactionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_TransactionRelatedCostsAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>After-tax transaction-related costs including the impact of tax benefits realized from termination of merger agreement. Transaction-related costs consist primarily of fees for legal, advisory and other professional services as well as employee costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_TransactionRelatedCostsAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>175
<FILENAME>R151.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288955018080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Summarized Segment Financial Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Revenues from customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 194,099<span></span>
</td>
<td class="nump">$ 179,363<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 172,520<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net investment income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,166<span></span>
</td>
<td class="nump">1,155<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,549<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195,265<span></span>
</td>
<td class="nump">180,518<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">174,069<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_RealizedInvestmentGainsLossesEquityMethodInvestments', window );">Net realized investment results from certain equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SegmentRevenues', window );">Adjusted revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195,322<span></span>
</td>
<td class="nump">180,644<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">174,069<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,035<span></span>
</td>
<td class="nump">2,937<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,923<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,513<span></span>
</td>
<td class="nump">8,397<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,790<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract', window );"><strong>Pre-tax adjustments to reconcile to adjusted income from operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax', window );">(Income) loss attributable to noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(146)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(58)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries', window );">Net realized investment (gains) losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="nump">613<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(198)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,819<span></span>
</td>
<td class="nump">1,876<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,998<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemsBeforeTaxAbstract', window );"><strong>Special items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes', window );">(Gain) loss on sale of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,499<span></span>
</td>
<td class="num">(1,662)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charge for organizational efficiency plan</a></td>
<td class="nump">$ 252<span></span>
</td>
<td class="nump">252<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">168<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemChargeBenefitBeforeTaxLitigation', window );">(Benefits) charges associated with litigation matters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(27)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_TransactionRelatedCosts', window );">Integration and transaction-related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">169<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax', window );">Debt extinguishment costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">141<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Pre-tax adjusted income (loss) from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,318<span></span>
</td>
<td class="nump">9,269<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,983<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_EvernorthMember', window );">Evernorth Health Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Revenues from customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,588<span></span>
</td>
<td class="nump">135,786<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">127,692<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember', window );">Cigna Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Revenues from customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,219<span></span>
</td>
<td class="nump">41,738<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">41,369<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_OtherOperationsSegmentMember', window );">Other Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Revenues from customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">291<span></span>
</td>
<td class="nump">1,839<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,459<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Evernorth Health Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net investment income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">17<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,499<span></span>
</td>
<td class="nump">140,335<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">131,912<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_RealizedInvestmentGainsLossesEquityMethodInvestments', window );">Net realized investment results from certain equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SegmentRevenues', window );">Adjusted revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,499<span></span>
</td>
<td class="nump">140,335<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">131,912<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,438<span></span>
</td>
<td class="nump">2,283<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,316<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,768<span></span>
</td>
<td class="nump">4,421<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,908<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract', window );"><strong>Pre-tax adjustments to reconcile to adjusted income from operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax', window );">(Income) loss attributable to noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(144)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(31)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries', window );">Net realized investment (gains) losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,774<span></span>
</td>
<td class="nump">1,772<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,937<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemsBeforeTaxAbstract', window );"><strong>Special items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes', window );">(Gain) loss on sale of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charge for organizational efficiency plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemChargeBenefitBeforeTaxLitigation', window );">(Benefits) charges associated with litigation matters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_TransactionRelatedCosts', window );">Integration and transaction-related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax', window );">Debt extinguishment costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Pre-tax adjusted income (loss) from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,442<span></span>
</td>
<td class="nump">6,127<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,818<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Cigna Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net investment income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597<span></span>
</td>
<td class="nump">638<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,003<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,148<span></span>
</td>
<td class="nump">44,911<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">44,643<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_RealizedInvestmentGainsLossesEquityMethodInvestments', window );">Net realized investment results from certain equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SegmentRevenues', window );">Adjusted revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,205<span></span>
</td>
<td class="nump">45,037<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">44,643<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">569<span></span>
</td>
<td class="nump">638<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">551<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,664<span></span>
</td>
<td class="nump">3,470<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,804<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract', window );"><strong>Pre-tax adjustments to reconcile to adjusted income from operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax', window );">(Income) loss attributable to noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries', window );">Net realized investment (gains) losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="nump">530<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(247)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">47<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemsBeforeTaxAbstract', window );"><strong>Special items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes', window );">(Gain) loss on sale of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,481<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charge for organizational efficiency plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemChargeBenefitBeforeTaxLitigation', window );">(Benefits) charges associated with litigation matters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_TransactionRelatedCosts', window );">Integration and transaction-related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax', window );">Debt extinguishment costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Pre-tax adjusted income (loss) from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,478<span></span>
</td>
<td class="nump">4,099<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,601<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Other Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net investment income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">305<span></span>
</td>
<td class="nump">424<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">530<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">596<span></span>
</td>
<td class="nump">2,263<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,989<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_RealizedInvestmentGainsLossesEquityMethodInvestments', window );">Net realized investment results from certain equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SegmentRevenues', window );">Adjusted revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">596<span></span>
</td>
<td class="nump">2,263<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,989<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">52<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="nump">2,101<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">868<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract', window );"><strong>Pre-tax adjustments to reconcile to adjusted income from operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax', window );">(Income) loss attributable to noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(24)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries', window );">Net realized investment (gains) losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">45<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemsBeforeTaxAbstract', window );"><strong>Special items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes', window );">(Gain) loss on sale of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="num">(1,662)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charge for organizational efficiency plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemChargeBenefitBeforeTaxLitigation', window );">(Benefits) charges associated with litigation matters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_TransactionRelatedCosts', window );">Integration and transaction-related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax', window );">Debt extinguishment costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Pre-tax adjusted income (loss) from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="nump">509<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">903<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=ci_CorporateAndEliminationsMember', window );">Corporate and Eliminations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net investment income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,978)<span></span>
</td>
<td class="num">(6,991)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,475)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_RealizedInvestmentGainsLossesEquityMethodInvestments', window );">Net realized investment results from certain equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SegmentRevenues', window );">Adjusted revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,978)<span></span>
</td>
<td class="num">(6,991)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,475)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,995)<span></span>
</td>
<td class="num">(1,595)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,790)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemsBeforeTaxAbstract', window );"><strong>Special items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Pre-tax adjusted income (loss) from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,698)<span></span>
</td>
<td class="num">(1,466)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,339)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Revenues from customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract', window );"><strong>Pre-tax adjustments to reconcile to adjusted income from operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax', window );">(Income) loss attributable to noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries', window );">Net realized investment (gains) losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemsBeforeTaxAbstract', window );"><strong>Special items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes', window );">(Gain) loss on sale of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charge for organizational efficiency plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">168<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemChargeBenefitBeforeTaxLitigation', window );">(Benefits) charges associated with litigation matters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(27)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_TransactionRelatedCosts', window );">Integration and transaction-related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">169<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax', window );">Debt extinguishment costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">141<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Eliminations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Revenues from customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,002)<span></span>
</td>
<td class="num">(6,998)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,474)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Eliminations | Evernorth Health Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Revenues from customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,670)<span></span>
</td>
<td class="num">(4,463)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,203)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Eliminations | Cigna Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Revenues from customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,332)<span></span>
</td>
<td class="num">(2,535)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,271)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Eliminations | Other Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Revenues from customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of pre-tax income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_NonInvestmentRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue excluding net investment income and realized investment results.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_NonInvestmentRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net realized gains or (losses) on investments during the period, including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity. Includes gains (losses) on investments held by equity method subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_RealizedInvestmentGainsLossesEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment to exclude net realized gains (losses) from equity method subsidiaries (recorded in Other revenues) from Operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_RealizedInvestmentGainsLossesEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SegmentRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total revenues less realized investment gains from equity method subsidiaries, special items and other reconciling items determined by management.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SegmentRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SpecialItemChargeBenefitBeforeTaxLitigation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>After-tax charges associated with litigation matters that are classified as special items, attributable to the parent. Special items reflect amounts that management does not believe are representative of underlying results of operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SpecialItemChargeBenefitBeforeTaxLitigation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Special Item Charges Debt Extinguishment Costs Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Special Item, Gain (Loss) On Sale Of Business, Before Taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_SpecialItemsBeforeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_SpecialItemsBeforeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_TransactionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre-tax transaction-related costs primarily consisting of fees for legal, advisory and other professional services, as well as employee costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_TransactionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetInvestmentIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 220<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetInvestmentIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ci_EvernorthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ci_EvernorthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ci_OtherOperationsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ci_OtherOperationsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=ci_CorporateAndEliminationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=ci_CorporateAndEliminationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>176
<FILENAME>R152.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288967857328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Revenue from External Customers (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">$ 44,237<span></span>
</td>
<td class="nump">$ 39,916<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 41,154<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Total revenues from external customers</a></td>
<td class="nump">194,099<span></span>
</td>
<td class="nump">179,363<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">172,520<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Eliminations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(9)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Total revenues from external customers</a></td>
<td class="num">(10,002)<span></span>
</td>
<td class="num">(6,998)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,474)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Divested International businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,596<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,205<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">281<span></span>
</td>
<td class="nump">225<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">221<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_EvernorthMember', window );">Evernorth Health Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Total revenues from external customers</a></td>
<td class="nump">147,588<span></span>
</td>
<td class="nump">135,786<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">127,692<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_EvernorthMember', window );">Evernorth Health Services | Intersegment Eliminations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Total revenues from external customers</a></td>
<td class="num">(5,670)<span></span>
</td>
<td class="num">(4,463)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,203)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember', window );">Cigna Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Total revenues from external customers</a></td>
<td class="nump">46,219<span></span>
</td>
<td class="nump">41,738<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">41,369<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember', window );">Cigna Healthcare | Intersegment Eliminations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Total revenues from external customers</a></td>
<td class="num">(4,332)<span></span>
</td>
<td class="num">(2,535)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,271)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember', window );">Cigna Healthcare | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">43,882<span></span>
</td>
<td class="nump">38,094<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">37,737<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember', window );">Cigna Healthcare | Operating Segments | U.S. Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">40,587<span></span>
</td>
<td class="nump">35,188<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">35,149<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember', window );">Cigna Healthcare | Operating Segments | International Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">3,295<span></span>
</td>
<td class="nump">2,906<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,588<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_OtherOperationsSegmentMember', window );">Other Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Total revenues from external customers</a></td>
<td class="nump">291<span></span>
</td>
<td class="nump">1,839<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,459<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ci_OtherOperationsSegmentMember', window );">Other Operations | Intersegment Eliminations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Total revenues from external customers</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Pharmacy revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">137,243<span></span>
</td>
<td class="nump">128,566<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">121,413<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Pharmacy revenues | Intersegment Eliminations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="num">(5,050)<span></span>
</td>
<td class="num">(4,416)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,398)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_NetworkPharmacyMember', window );">Network revenues | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">67,514<span></span>
</td>
<td class="nump">64,946<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">64,992<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_HomeDeliveryAndSpecialtyMember', window );">Home delivery and specialty revenues | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">65,732<span></span>
</td>
<td class="nump">61,283<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">54,391<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_OtherPharmacyMember', window );">Other revenues | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">9,047<span></span>
</td>
<td class="nump">6,753<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,428<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_EmployerInsuredMember', window );">Employer insured | Cigna Healthcare | Operating Segments | U.S. Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">16,490<span></span>
</td>
<td class="nump">15,199<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">14,315<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_MedicareAdvantageMember', window );">Medicare Advantage | Cigna Healthcare | Operating Segments | U.S. Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">8,771<span></span>
</td>
<td class="nump">7,896<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,362<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_StopLossMember', window );">Stop loss | Cigna Healthcare | Operating Segments | U.S. Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">6,143<span></span>
</td>
<td class="nump">5,461<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,868<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_IndividualAndFamilyPlansMember', window );">Individual and Family Plans | Cigna Healthcare | Operating Segments | U.S. Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">5,088<span></span>
</td>
<td class="nump">2,636<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,528<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_OtherHealthcareMember', window );">Other | Cigna Healthcare | Operating Segments | U.S. Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">4,095<span></span>
</td>
<td class="nump">3,996<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,076<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">12,619<span></span>
</td>
<td class="nump">10,881<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">9,953<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service | Intersegment Eliminations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="num">(5,026)<span></span>
</td>
<td class="num">(2,583)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,067)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_ServiceFeesMember', window );">Fees | Evernorth Health Services | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">10,866<span></span>
</td>
<td class="nump">7,234<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,070<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_ServiceFeesMember', window );">Fees | Cigna Healthcare | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">6,566<span></span>
</td>
<td class="nump">6,053<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,743<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_ServiceFeesMember', window );">Fees | Other Operations | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">19<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceOtherMember', window );">Other revenues | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 210<span></span>
</td>
<td class="nump">$ 168<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 188<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_NonInvestmentRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue excluding net investment income and realized investment results.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_NonInvestmentRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PremiumsEarnedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-17(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480149/944-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479655/944-605-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(c))<br> -SubTopic 220<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(1))<br> -SubTopic 220<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PremiumsEarnedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=ci_OtherOperationsInternationalBusinessesToBeSoldAndInterestInJointVentureInTurkeyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=ci_OtherOperationsInternationalBusinessesToBeSoldAndInterestInJointVentureInTurkeyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=ci_OtherOperationsSegmentOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=ci_OtherOperationsSegmentOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ci_EvernorthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ci_EvernorthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ci_CignaHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=ci_UnitedStatedHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=ci_UnitedStatedHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=ci_InternationalHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=ci_InternationalHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ci_OtherOperationsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ci_OtherOperationsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ci_NetworkPharmacyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ci_NetworkPharmacyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ci_HomeDeliveryAndSpecialtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ci_HomeDeliveryAndSpecialtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ci_OtherPharmacyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ci_OtherPharmacyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ci_EmployerInsuredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ci_EmployerInsuredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ci_MedicareAdvantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ci_MedicareAdvantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ci_StopLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ci_StopLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ci_IndividualAndFamilyPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ci_IndividualAndFamilyPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ci_OtherHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ci_OtherHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ci_ServiceFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ci_ServiceFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>177
<FILENAME>R153.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288973818624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Information - Financial and Performance Guarantees (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ci_PharmacyBenefitsManagementServicesMember', window );">Pharmacy Benefits Management Services | Guarantees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Guarantee liability</a></td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ci_PharmacyBenefitsManagementServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ci_PharmacyBenefitsManagementServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_GuaranteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_GuaranteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>178
<FILENAME>R154.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288952088688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - U.S. and Foreign Revenues from External Customers (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Revenues from external customers</a></td>
<td class="nump">$ 194,099<span></span>
</td>
<td class="nump">$ 179,363<span></span>
</td>
<td class="nump">$ 172,520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Revenues from external customers</a></td>
<td class="nump">189,840<span></span>
</td>
<td class="nump">174,540<span></span>
</td>
<td class="nump">166,626<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=ci_AllOtherCountriesMember', window );">Foreign countries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NonInvestmentRevenue', window );">Revenues from external customers</a></td>
<td class="nump">$ 4,259<span></span>
</td>
<td class="nump">4,823<span></span>
</td>
<td class="nump">5,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DisposalGroupIncludingDiscontinuedOperationsNonInvestmentRevenue', window );">Revenues, disposal group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=ci_RevenuesIncludingNetInvestmentIncomeBenchmarkMember', window );">Revenues | Customer Concentration Risk | U.S. Federal Government Agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=ci_RevenuesFromExternalCustomersMember', window );">Revenues from external customers | Geographic Concentration Risk | Single foreign country</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DisposalGroupIncludingDiscontinuedOperationsNonInvestmentRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operations, Non Investment Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DisposalGroupIncludingDiscontinuedOperationsNonInvestmentRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_NonInvestmentRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue excluding net investment income and realized investment results.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_NonInvestmentRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=ci_AllOtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=ci_AllOtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=ci_RevenuesIncludingNetInvestmentIncomeBenchmarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=ci_RevenuesIncludingNetInvestmentIncomeBenchmarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ci_USFederalGovernmentAgenciesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ci_USFederalGovernmentAgenciesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=ci_RevenuesFromExternalCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=ci_RevenuesFromExternalCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=ci_SingleForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=ci_SingleForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>179
<FILENAME>R155.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288967959168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule I - Condensed Financial Information of The Cigna Group - Statements of Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net investment income (loss)</a></td>
<td class="nump">$ 1,166<span></span>
</td>
<td class="nump">$ 1,155<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,549<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUES</a></td>
<td class="nump">195,265<span></span>
</td>
<td class="nump">180,518<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">174,069<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">14,822<span></span>
</td>
<td class="nump">13,174<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">13,012<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BenefitsLossesAndExpenses', window );">TOTAL BENEFITS AND EXPENSES</a></td>
<td class="nump">186,729<span></span>
</td>
<td class="nump">172,068<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">166,128<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">8,536<span></span>
</td>
<td class="nump">8,450<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">7,941<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest expense and other</a></td>
<td class="num">(1,446)<span></span>
</td>
<td class="num">(1,228)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(1,208)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Debt extinguishment costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(141)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_RealizedInvestmentGainLoss', window );">Net realized investment (losses) gains</a></td>
<td class="num">(78)<span></span>
</td>
<td class="num">(487)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">198<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">5,513<span></span>
</td>
<td class="nump">8,397<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,790<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefits</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">1,615<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,370<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">SHAREHOLDERS' NET INCOME</a></td>
<td class="nump">5,164<span></span>
</td>
<td class="nump">6,704<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,370<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss), net of tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent', window );">Net long-duration insurance and contractholder liabilities measurement adjustments</a></td>
<td class="num">(715)<span></span>
</td>
<td class="nump">509<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">67<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">SHAREHOLDERS' COMPREHENSIVE INCOME</a></td>
<td class="nump">4,958<span></span>
</td>
<td class="nump">6,114<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,327<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">The Cigna Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Net investment income (loss)</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_IntercompanyInterestIncome', window );">Intercompany interest income</a></td>
<td class="nump">516<span></span>
</td>
<td class="nump">478<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">471<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUES</a></td>
<td class="nump">538<span></span>
</td>
<td class="nump">483<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">471<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BenefitsLossesAndExpenses', window );">TOTAL BENEFITS AND EXPENSES</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">536<span></span>
</td>
<td class="nump">481<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">463<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest expense and other</a></td>
<td class="num">(1,332)<span></span>
</td>
<td class="num">(1,215)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,197)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_IntercompanyInterestExpense', window );">Intercompany interest expense</a></td>
<td class="num">(118)<span></span>
</td>
<td class="num">(147)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(13)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Debt extinguishment costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(131)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="num">(914)<span></span>
</td>
<td class="num">(881)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(878)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefits</a></td>
<td class="num">(192)<span></span>
</td>
<td class="num">(183)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(180)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LossOfParentCompany', window );">Loss of Parent Company</a></td>
<td class="num">(722)<span></span>
</td>
<td class="num">(698)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(698)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromSubsidiariesNetOfTax', window );">Equity in income of subsidiaries</a></td>
<td class="nump">5,886<span></span>
</td>
<td class="nump">7,402<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,068<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">SHAREHOLDERS' NET INCOME</a></td>
<td class="nump">5,164<span></span>
</td>
<td class="nump">6,704<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,370<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss), net of tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Net unrealized appreciation (depreciation) on securities and derivatives</a></td>
<td class="nump">503<span></span>
</td>
<td class="num">(1,598)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(302)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent', window );">Net long-duration insurance and contractholder liabilities measurement adjustments</a></td>
<td class="num">(715)<span></span>
</td>
<td class="nump">509<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">67<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Net translation gains (losses) of foreign currencies</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(218)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent', window );">Postretirement benefits liability adjustment</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">420<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">410<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Shareholders' other comprehensive loss, net of tax</a></td>
<td class="num">(206)<span></span>
</td>
<td class="num">(590)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(43)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">SHAREHOLDERS' COMPREHENSIVE INCOME</a></td>
<td class="nump">$ 4,958<span></span>
</td>
<td class="nump">$ 6,114<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 5,327<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_IntercompanyInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest expense associated with intercompany loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_IntercompanyInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_IntercompanyInterestIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest expense associated with intercompany loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_IntercompanyInterestIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LossOfParentCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LossOfParentCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>OCI, Liability For Future Policy Benefit And Market Risk Benefit, Instrument-Specific Credit Risk, Gain (Loss), After Reclassification Adjustment And Tax, Portion Attributable To Parent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_RealizedInvestmentGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net realized gains or (losses) on investments during the period, including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_RealizedInvestmentGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BenefitsLossesAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of expense recognized during the period for future policy benefits, claims and claims adjustment costs, and for selling, general and administrative costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.5,6,7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BenefitsLossesAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromSubsidiariesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) of subsidiary attributable to the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromSubsidiariesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetInvestmentIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 220<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetInvestmentIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>180
<FILENAME>R156.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288960147536">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Schedule I - Condensed Financial Information of The Cigna Group - Balance Sheets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7,822<span></span>
</td>
<td class="nump">$ 5,924<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">925<span></span>
</td>
<td class="nump">905<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,169<span></span>
</td>
<td class="nump">1,298<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">37,351<span></span>
</td>
<td class="nump">30,122<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,421<span></span>
</td>
<td class="nump">2,704<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">152,761<span></span>
</td>
<td class="nump">143,885<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Short-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,775<span></span>
</td>
<td class="nump">2,993<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">48,716<span></span>
</td>
<td class="nump">41,225<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,441<span></span>
</td>
<td class="nump">2,766<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">28,155<span></span>
</td>
<td class="nump">28,100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">106,410<span></span>
</td>
<td class="nump">99,131<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShareholdersEquityAbstract', window );"><strong>Shareholders' Equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">30,669<span></span>
</td>
<td class="nump">30,233<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,864)<span></span>
</td>
<td class="num">(1,658)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">41,652<span></span>
</td>
<td class="nump">37,940<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Less: Treasury stock, at cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(24,238)<span></span>
</td>
<td class="num">(21,844)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL SHAREHOLDERS' EQUITY</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">46,223<span></span>
</td>
<td class="nump">44,675<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 152,761<span></span>
</td>
<td class="nump">$ 143,885<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">399,894,000<span></span>
</td>
<td class="nump">397,819,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">394,194,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">600,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">The Cigna Group</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 303<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">309<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">81,564<span></span>
</td>
<td class="nump">81,265<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Short-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,448<span></span>
</td>
<td class="nump">2,749<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,854<span></span>
</td>
<td class="nump">1,295<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,302<span></span>
</td>
<td class="nump">4,044<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,151<span></span>
</td>
<td class="nump">26,815<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35,341<span></span>
</td>
<td class="nump">36,590<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ShareholdersEquityAbstract', window );"><strong>Shareholders' Equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">30,669<span></span>
</td>
<td class="nump">30,233<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,864)<span></span>
</td>
<td class="num">(1,658)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">41,652<span></span>
</td>
<td class="nump">37,940<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Less: Treasury stock, at cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(24,238)<span></span>
</td>
<td class="num">(21,844)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL SHAREHOLDERS' EQUITY</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">46,223<span></span>
</td>
<td class="nump">44,675<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 81,564<span></span>
</td>
<td class="nump">$ 81,265<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">398,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">The Cigna Group | Nonrelated Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 77<span></span>
</td>
<td class="nump">$ 99<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">The Cigna Group | Subsidiaries</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndOtherNoncurrentAssets', window );">Investments and Other Noncurrent Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">69,703<span></span>
</td>
<td class="nump">70,679<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,475<span></span>
</td>
<td class="nump">10,366<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,874<span></span>
</td>
<td class="nump">$ 5,705<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Par value per share, $0.01; shares issued, 400 million as of December&#160;31, 2023 and 398 million as of December&#160;31, 2022; authorized shares, 600 million.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ShareholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ShareholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments, and noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>181
<FILENAME>R157.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288951085664">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Schedule I - Condensed Financial Information of The Cigna Group - Statements of Cash Flows (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 21, 2023</div></th>
<th class="th"><div>Sep. 21, 2023</div></th>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Mar. 23, 2023</div></th>
<th class="th"><div>Dec. 21, 2022</div></th>
<th class="th"><div>Sep. 22, 2022</div></th>
<th class="th"><div>Jun. 23, 2022</div></th>
<th class="th"><div>Mar. 24, 2022</div></th>
<th class="th"><div>Dec. 22, 2021</div></th>
<th class="th"><div>Sep. 23, 2021</div></th>
<th class="th"><div>Jun. 23, 2021</div></th>
<th class="th"><div>Mar. 25, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Operating Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Shareholders' net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,164<span></span>
</td>
<td class="nump">$ 6,704<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 5,370<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile shareholders' net income to net cash provided by (used in) operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Debt extinguishment costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">141<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,481<span></span>
</td>
<td class="nump">1,734<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">77<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">463<span></span>
</td>
<td class="nump">325<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">333<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH PROVIDED BY OPERATING ACTIVITIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,813<span></span>
</td>
<td class="nump">8,656<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">7,191<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Investing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Net proceeds from short-term investments sold (purchased)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,205)<span></span>
</td>
<td class="num">(1,563)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(2,554)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,174)<span></span>
</td>
<td class="nump">3,098<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(3,611)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Financing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Payments for debt extinguishment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(136)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,967)<span></span>
</td>
<td class="num">(500)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(4,578)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Net proceeds on issuance of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,491<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,260<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="nump">389<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">326<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Common dividends paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (358)<span></span>
</td>
<td class="num">$ (362)<span></span>
</td>
<td class="num">$ (362)<span></span>
</td>
<td class="num">$ (368)<span></span>
</td>
<td class="num">$ (334)<span></span>
</td>
<td class="num">$ (341)<span></span>
</td>
<td class="num">$ (352)<span></span>
</td>
<td class="num">$ (357)<span></span>
</td>
<td class="num">$ (324)<span></span>
</td>
<td class="num">$ (330)<span></span>
</td>
<td class="num">$ (342)<span></span>
</td>
<td class="num">$ (345)<span></span>
</td>
<td class="num">(1,450)<span></span>
</td>
<td class="num">(1,384)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(1,341)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,284)<span></span>
</td>
<td class="num">(7,607)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(7,742)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(413)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">39<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH USED IN FINANCING ACTIVITIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,294)<span></span>
</td>
<td class="num">(11,240)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(8,212)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,361<span></span>
</td>
<td class="nump">428<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(4,697)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash and cash equivalents January 1,</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,976<span></span>
</td>
<td class="nump">5,123<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of year (2)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,870<span></span>
</td>
<td class="nump">5,976<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,123<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">The Cigna Group</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Operating Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Shareholders' net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,164<span></span>
</td>
<td class="nump">6,704<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,370<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile shareholders' net income to net cash provided by (used in) operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromSubsidiariesNetOfTax', window );">Equity in income of subsidiaries</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,886)<span></span>
</td>
<td class="num">(7,402)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,068)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Debt extinguishment costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">131<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries', window );">Dividends received from subsidiaries</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,381<span></span>
</td>
<td class="nump">2,056<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,726<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">540<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">184<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640<span></span>
</td>
<td class="nump">298<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">439<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH PROVIDED BY OPERATING ACTIVITIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,839<span></span>
</td>
<td class="nump">1,661<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,782<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Investing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Net proceeds from short-term investments sold (purchased)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(50)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">622<span></span>
</td>
<td class="num">(802)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,057)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Financing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebt', window );">Net change in short-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,237<span></span>
</td>
<td class="num">(2,027)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">997<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Payments for debt extinguishment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(126)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,822)<span></span>
</td>
<td class="num">(430)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,199)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Net proceeds on issuance of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,491<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,260<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="nump">389<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">326<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Common dividends paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,450)<span></span>
</td>
<td class="num">(1,384)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,341)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,284)<span></span>
</td>
<td class="num">(7,607)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,742)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax withholding on stock compensation and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(110)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(86)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH USED IN FINANCING ACTIVITIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,278)<span></span>
</td>
<td class="num">(740)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,849)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,124)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash and cash equivalents January 1,</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,157<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of year (2)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335<span></span>
</td>
<td class="nump">152<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">33<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">The Cigna Group | Subsidiaries</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Investing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_IncreaseDecreaseInAmountsDueFromAffiliates', window );">Net change in amounts due from affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">622<span></span>
</td>
<td class="num">(901)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,007)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Financing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt', window );">Net change in amounts due to affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,473<span></span>
</td>
<td class="nump">10,392<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,062<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReduction', window );">Net amounts due to/(from) affiliates settled through capital transactions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,221)<span></span>
</td>
<td class="num">$ (5,037)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (8,429)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="18"></td></tr>
<tr><td colspan="18"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Restricted cash and cash equivalents were reported in other long-term investments.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of accounts payable, accrued liabilities and other operating obligations not separately disclosed in the statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_IncreaseDecreaseInAmountsDueFromAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>(Increase) Decrease In Amounts Due From Affiliates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_IncreaseDecreaseInAmountsDueFromAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents disclosure of the aggregate cash dividends paid to the entity by consolidated subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromSubsidiariesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) of subsidiary attributable to the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromSubsidiariesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of notes retired (or transferred to another entity) in noncash investing or financing transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>182
<FILENAME>R158.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288959819776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule I - Condensed Financial Information of The Cigna Group - Short-term and Credit Facilities Debt (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>USD ($) </div>
<div>bank </div>
<div>position</div>
</th>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CommercialPaperAverageRatePaid', window );">Commercial paper average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.63%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_RevolvingCreditAgreementsApril2023Member', window );">Revolving credit agreements, April 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Outstanding balances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity', window );">Aggregate amount of options to increase commitments</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity', window );">Maximum total commitment</a></td>
<td class="nump">$ 6,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement', window );">Number of participating banks | position</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant', window );">Leverage ratio covenant</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member', window );">Five-year Revolving Credit Agreement, Maturing April 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 4,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Credit agreement term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtInstrumentExtensionTerm', window );">Credit agreement extension term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member', window );">Five-year Revolving Credit Agreement, Maturing April 2028 | Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_A364DayRevolvingCreditAgreementMaturingApril2024Member', window );">364-day Revolving Credit Agreement, Maturing April 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Credit agreement term</a></td>
<td class="text">364 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LineOfCreditFacilityConversionToTermLoanTerm', window );">Credit facility, conversion to term loan, term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member', window );">Revolving Credit And Letter Of Credit Facility Maturing April 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Credit agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_RevolvingCreditFacilityMaturingApril2025Member', window );">Revolving Credit Facility Maturing April 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Credit agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_A364DayRevolvingCreditAgreementMaturingApril2023Member', window );">364 Day Revolving Credit Agreement, Maturing April 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Credit agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">364 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">The Cigna Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CommercialPaperAverageRatePaid', window );">Commercial paper average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.63%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">The Cigna Group | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Outstanding balances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">The Cigna Group | Revolving credit agreements, April 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Outstanding balances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity', window );">Aggregate amount of options to increase commitments</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity', window );">Maximum total commitment</a></td>
<td class="nump">$ 6,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement', window );">Number of participating banks | bank</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant', window );">Leverage ratio covenant</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">The Cigna Group | Five-year Revolving Credit Agreement, Maturing April 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 4,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Credit agreement term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtInstrumentExtensionTerm', window );">Credit agreement extension term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">The Cigna Group | Five-year Revolving Credit Agreement, Maturing April 2028 | Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">The Cigna Group | 364-day Revolving Credit Agreement, Maturing April 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Credit agreement term</a></td>
<td class="text">364 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_LineOfCreditFacilityConversionToTermLoanTerm', window );">Credit facility, conversion to term loan, term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">The Cigna Group | Revolving Credit And Letter Of Credit Facility Maturing April 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Credit agreement term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">The Cigna Group | Revolving Credit Facility Maturing April 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Credit agreement term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">The Cigna Group | 364 Day Revolving Credit Agreement, Maturing April 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Credit agreement term</a></td>
<td class="text">364 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtInstrumentExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Extension Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtInstrumentExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Accordion Feature, Incremental Increase In Maximum Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LineOfCreditFacilityConversionToTermLoanTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Conversion To Term Loan, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LineOfCreditFacilityConversionToTermLoanTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The debt-to adjusted capital ratio which the Company must not exceed in accordance with the terms of the line of credit facility agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Maximum Borrowing Capacity And Accordion Feature, Incremental Increase In Maximum Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of banks participating in revolving credit and letter of credit agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CommercialPaperAverageRatePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average rate paid on commercial paper.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (a)<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (b)<br> -Subparagraph (3)<br> -Publisher SEC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CommercialPaperAverageRatePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_RevolvingCreditAgreementsApril2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_RevolvingCreditAgreementsApril2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_A364DayRevolvingCreditAgreementMaturingApril2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_A364DayRevolvingCreditAgreementMaturingApril2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_RevolvingCreditFacilityMaturingApril2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_RevolvingCreditFacilityMaturingApril2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_A364DayRevolvingCreditAgreementMaturingApril2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_A364DayRevolvingCreditAgreementMaturingApril2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>183
<FILENAME>R159.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288954738976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule I - Condensed Financial Information of The Cigna Group - Long-term Debt (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 07, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 22, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 05, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Debt extinguishment costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 141,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,967,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,578,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Aggregate principal amount of outstanding debt securities redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2,550,000,000<span></span>
</td>
<td class="nump">$ 2,250,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Aggregate principal amount of outstanding debt securities redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue20265685Member', window );">$700 million, 5.685% Notes due March 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.685%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue20335400InterestMember', window );">$800 million, 5.400% Notes due March 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue202435InterestMember', window );">$1,000&#160;million, 3.500% Notes due June 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Gross value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ci_NotesDue202435InterestMember', window );">$1,000&#160;million, 3.500% Notes due June 2024 | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Aggregate principal amount of outstanding debt securities redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | $700 million, 5.685% Notes due March 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal</a></td>
<td class="nump">700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees', window );">Net proceeds</a></td>
<td class="nump">$ 698,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">5.685%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | $700 million, 5.685% Notes due March 2026 | Treasury rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate', window );">Redemption price discount, spread on variable rate</a></td>
<td class="nump">0.0020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | $800 million, 5.400% Notes due March 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal</a></td>
<td class="nump">$ 800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees', window );">Net proceeds</a></td>
<td class="nump">$ 796,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">5.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | $800 million, 5.400% Notes due March 2033 | Treasury rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate', window );">Redemption price discount, spread on variable rate</a></td>
<td class="nump">0.0025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">The Cigna Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Debt extinguishment costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">131,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,822,000,000<span></span>
</td>
<td class="nump">$ 430,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4,199,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">The Cigna Group | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Aggregate principal amount of outstanding debt securities redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,550,000,000<span></span>
</td>
<td class="nump">2,250,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">The Cigna Group | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Aggregate principal amount of outstanding debt securities redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">The Cigna Group | $1,000&#160;million, 3.500% Notes due June 2024 | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Aggregate principal amount of outstanding debt securities redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">The Cigna Group | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">The Cigna Group | Senior Notes | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">The Cigna Group | Senior Notes | $700 million, 5.685% Notes due March 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal</a></td>
<td class="nump">700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees', window );">Net proceeds</a></td>
<td class="nump">$ 698,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">5.685%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">The Cigna Group | Senior Notes | $700 million, 5.685% Notes due March 2026 | Treasury rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate', window );">Redemption price discount, spread on variable rate</a></td>
<td class="nump">0.0020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">The Cigna Group | Senior Notes | $800 million, 5.400% Notes due March 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal</a></td>
<td class="nump">$ 800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees', window );">Net proceeds</a></td>
<td class="nump">$ 796,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">5.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">The Cigna Group | Senior Notes | $800 million, 5.400% Notes due March 2033 | Treasury rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate', window );">Redemption price discount, spread on variable rate</a></td>
<td class="nump">0.0025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Discount, Spread On Variable Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Long-term Debt, Net Of Discounts And Underwriting Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue20265685Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue20265685Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue20335400InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue20335400InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ci_NotesDue202435InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ci_NotesDue202435InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_UsTreasuryUstInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_UsTreasuryUstInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>184
<FILENAME>R160.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288968043136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule I - Condensed Financial Information of The Cigna Group - Debt Maturities (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2025</a></td>
<td class="nump">3,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2026</a></td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2027</a></td>
<td class="nump">2,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2028</a></td>
<td class="nump">3,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Maturities after 2028</a></td>
<td class="nump">16,122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">The Cigna Group</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">1,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2025</a></td>
<td class="nump">2,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2026</a></td>
<td class="nump">2,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2027</a></td>
<td class="nump">2,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2028</a></td>
<td class="nump">3,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Maturities after 2028</a></td>
<td class="nump">$ 15,091<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>185
<FILENAME>R161.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288965593504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule I - Condensed Financial Information of The Cigna Group - Intercompany Balances (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">$ 2,169<span></span>
</td>
<td class="nump">$ 1,298<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">The Cigna Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">The Cigna Group | Evernorth Health, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="nump">$ 8,300<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_IntercompanyReceivablesInterestRate', window );">Interest rate, intercompany receivables</a></td>
<td class="nump">5.21%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">The Cigna Group | Three wholly-owned subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ci_AverageInterestRateOnIntercompanyLoan', window );">Average interest rate on intercompany loan</a></td>
<td class="nump">3.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_AverageInterestRateOnIntercompanyLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average monthly interest on an intercompany loan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_AverageInterestRateOnIntercompanyLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ci_IntercompanyReceivablesInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual fixed rate of interest at which interest income on intercompany receivables was accrued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ci_IntercompanyReceivablesInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ci_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 5<br> -Subsection 04<br> -Paragraph c<br> -Subparagraph Schedule I<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 7<br> -Subsection 05<br> -Paragraph c<br> -Subparagraph Schedule II<br> -Publisher SEC<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 9<br> -Subsection 06<br> -Publisher SEC<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ci_EvernorthHealthIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ci_EvernorthHealthIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ci_ThreeWhollyOwnedSubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ci_ThreeWhollyOwnedSubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>186
<FILENAME>R162.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288969601088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule I - Condensed Financial Information of The Cigna Group - Guarantees (Details) - The Cigna Group - USD ($)<br> $ in Billions</strong></div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsLineItems', window );"><strong>Guarantor Obligations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsMaximumExposure', window );">Maximum guarantee exposure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsLineItems', window );"><strong>Guarantor Obligations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsMaximumExposure', window );">Maximum guarantee exposure</a></td>
<td class="nump">$ 6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>187
<FILENAME>R163.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288967488896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule I - Condensed Financial Information of The Cigna Group - Share Repurchase (Details) - USD ($)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 15, 2024</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Accelerated stock repurchase, amount authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt', window );">Accelerated stock repurchase, amount remitted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Stock repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">10.4<span></span>
</td>
<td class="nump">12.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,282,000,000<span></span>
</td>
<td class="nump">$ 7,593,000,000<span></span>
</td>
<td class="nump">$ 7,710,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Accelerated stock repurchase, amount authorized</a></td>
<td class="nump">$ 3,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt', window );">Accelerated stock repurchase, amount remitted</a></td>
<td class="nump">$ 3,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Stock repurchased (in shares)</a></td>
<td class="nump">7.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">The Cigna Group | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Accelerated stock repurchase, amount authorized</a></td>
<td class="nump">$ 3,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt', window );">Accelerated stock repurchase, amount remitted</a></td>
<td class="nump">$ 3,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Stock repurchased (in shares)</a></td>
<td class="nump">7.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Stock repurchased</a></td>
<td class="nump">$ 2,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash receipt from (payment to) bank; or stock received from (issuance to) bank in the settlement of the accelerated share repurchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481138/505-30-25-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>188
<FILENAME>R164.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140288952051216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II - Valuation and Qualifying Accounts and Reserves (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=ci_SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember', window );">Available-for-sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of year</a></td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charged (Credited) to costs and expenses</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charged (Credited) to other accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Other deductions</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of year</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Valuation allowance</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=ci_SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember', window );">Commercial mortgage loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of year</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charged (Credited) to costs and expenses</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charged (Credited) to other accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Other deductions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of year</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Valuation allowance</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=ci_SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of year</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charged (Credited) to costs and expenses</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charged (Credited) to other accounts</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Other deductions</a></td>
<td class="num">(88)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of year</a></td>
<td class="nump">163<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Valuation allowance</a></td>
<td class="nump">163<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember', window );">Deferred tax asset valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of year</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">246<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charged (Credited) to costs and expenses</a></td>
<td class="nump">1,286<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charged (Credited) to other accounts</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Other deductions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of year</a></td>
<td class="nump">1,498<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="nump">246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Valuation allowance</a></td>
<td class="nump">1,498<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="nump">246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForReinsuranceRecoverableMember', window );">Reinsurance recoverables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of year</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charged (Credited) to costs and expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charged (Credited) to other accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Other deductions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of year</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Valuation allowance</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=ci_SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=ci_SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=ci_SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=ci_SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=ci_SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=ci_SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForReinsuranceRecoverableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForReinsuranceRecoverableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>190
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M0=5 Y3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%
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M7%++SVKV;TNMRJ_,_K$Y>=_Q6\0DBM!E*N"RT(]0LT[M\K<YKC6M8]@ 7-H
M;,[@=[2N8\K7:D)[!PIR \8IWI)$W^W^YZZ!.:XUMF/X 5SZ 6S.XF?3FULT
M28-0,HXF4E)PYMF2Y$U$UEIJ9KVZ_4]S6&MHQTC^O3+Y]\RY>[$Y=1,F)/%#
M\)_92E!V[IKS;#4<?AKR IT?"J6^5,'\F-H>:(YK799P#)?@E2[!:[2ML-A
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M#(*9SRD37AJ[N:U*8UECR01L%=$UYU3]64(IF\0;>\>)9W8HT$[X:5S1 [P
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M.XFFZ-VP,%T6E'4PZWLI\6C8#?J^G?X%4$L#!!0    ( /MU75B11;!\C0@
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MT873UW)]BPZ ::@*U7.5JUQR*+R'FM%4$Q20U1O$)VI9/428&F.]"*%JQE"
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M+Y0"R%<"=K_ZB^K@\-NXR;]02P,$%     @ ^W5=6(P- ?P?!@  AA@  !@
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M@<+7B]N(^.2X^#?Z)R(T??V>%!&/?G+/ [LY30@XI1:G0TOC]4ZG?[N:2U5
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M@5!]_:4B#7G=,&Z+MW=L+INK*(/R:S:9,JR<3Z8<*Q>3J<#*_<G4Q\J#R33
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MP]OMPA -:J":B6HC5+-0S48U!]5<5/-0S4>U -5"5(O:O9UC-&B":BFEU6>
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M9DN_&]?WTT%[XD.SF\,=.Y6@V@#5AJAFH)J):B-4LU#-1C4'U5Q4\U#-1[4
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MBC^ O\$[8 ,>R5X^M(4<E+*V@W( %\4 W",#Z((YE68<S-(0AQI^T<Q#M\'
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M;L/9.N0L%E&Y$OR>YY2O]U/*-'DLK^V-5>]![B$19'!O&N&>+C G+8_6Q#Z
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M(:J1(;4W2(2Y$&),70 V;E_?0C%I<:TIF("%&&,RLBMTG;V]C63VA-X^8>8
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M[#J32J>X]HQ=1&(E=0N!DJ[7<F=HGD9_@LR!.\&,[2>06>#W]!6#%M>:Z(/
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M:.[O3VQP*&NTDL\1SVM.*U@Y+]O5Y2!X/<?=]S1\.[B82P9NZ^"\))(L(%F
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MP^D@"5%%9N74A@0-;E/M7";"^GHF$(G]TC,DQ'?DR[V=CA^#,U/CXFQ^)@J
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MT?B'1:SD0Y^CX!A=E]F:1R*L*.D8>,G/2(=:E[>(:Y++T"+:-BI<2!R[I/K
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M2?))NO  ?8\K^?TOF"#\;=SO_A=02P,$%     @ ^W5=6(H.F[[7"   ?1D
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M[3[O9^-$W8GJAK8P>HNA9BBJC&^O1=;OWPIRW<U8?ZU=%\"BL\C&I&"ERN>
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MB6\/&[].XHTW9?@BF!F/'A@N,WS02<L;\'QN\)Y7W["#YA/Q\C]02P,$%
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MV1X3VSGJFN<H8/.\'[8LY@\Y3#A$4D)%?8\J"#,_M&6:X\(JU!G,&I6Z/XO
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MR=6^*5?D9.?4$O/1N?C9DO"II,OE0"0GEW\"\@%B["^HY@(BIQ>-O++_*)!
M#&I6Z+8?&P(Y%[/ O<'3,#\WIKOXX#7!]ZZ;?=SS#.(-*G1$#)RVNE'?U%53
M=)R)Z<3H=>R!_H7S\PH LC7_B 2#&-G$_M*BN]K]3N72_CRC7VY_Y/*1QU\:
MMNY .ILNHI$H[0]'[)>JV/&/-: XICS^N%$2$4T+</^N@-N:+[1!]^N=M_\#
M4$L#!!0    ( /MU75@FF53@< @  (H6   9    >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;,5876_C-A;]*X0[F&8 U99D.;;3)( G:;M3=-)@,FVQ6.P#
M+=&V&DG4D%0\Z:_?<TE:EK_2[,ONBRV1EY?G?AU>ZG(MU:->"6'8U[*H]%5O
M94Q],1CH="5*KONR%A5F%E*5W.!5+0>Z5H)G=E%9#.(P/!^4/*]ZUY=V[%Y=
M7\K&%'DE[A7335ER]?Q>%')]U8MZFX%/^7)E:&!P?5GSI7@0YK?Z7N%MT&K)
M\E)4.I<54V)QU9M%%^\3DK<"O^=BK3O/C"R92_E(+Q^RJUY(@$0A4D,:./Z>
MQ(TH"E($&%^\SEZ[)2WL/F^T_VAMARUSKL6-+/[(,[.ZZDUZ+!,+WA3FDUS_
M0WA[1J0OE86VOVSM9.-QCZ6--K+TBX&@S"OWS[]Z/W063,(3"V*_(+:XW486
MY2TW_/I2R353) UM]&!-M:L!+J\H* ]&83;'.G-](\N2G%-E[![^$$J)C#T8
MF3Y>#@STD]0@];K>.UWQ"5U1S#[*RJPT^Z'*1+:K8 !@+;IX@^Y]_*+&6Y'V
MV3 *6!S&PQ?T#5MKAU;?\(2^'[XTN7EF_YK-M5%(B'\?,]*I2(ZKH"*YT#5/
MQ54/5:"%>A*]Z[??1.?A]R\ 3%J R4O:_\MPO*SK3AK!INSM-Y,XBKYGIU6S
MSRO!;O)EQ=E/2C8U6W'-.#/2\(+)!8M'R+RBH"+2*PZC:?!-Q&JNV!,O&L'J
M5J&V"GEC5E+E?V$ O,%RK1M>I:+/[F1'Q?ZJM5""@3BT <B\6C)N&#) E'.A
MVBRPOS&#5OQ'?8M](0N0"ZTP?%Y8.%I41C.#2;N?JWZ*/?;=,_>"H;ZMZ#\%
M5SYY=S<^>W"@\PIRLM' I]]9. X-0?$.OF#WK5O>A/T0GC\/PR ,PXWE'>?\
MNC7V._8SKQKP(B-#IY/@?'S.AG$<3),)&XZ28#R.V!U8FISI_>K<)FO+;^*K
M4&FN:0.$6,(>\)6HQ"(WK"YXI:'X/)JR81"-A_@=CD?LDZ@;E2+<4)BZ_' Z
MS\;!>!J]8V?Q.$B2$1Z&HR":3M[M0MZ-SC0.1F%R /XS#@O=P#"G.@K'P7 :
MLNDTB)(A&T=!G)RS#]:J/8U#R$RF"?['P82@3Q. 2-@M0ID)Q(#=-HK"WDD,
M,I["$1QD=2;2@E.V?8&;C5#%,TNY7K&LU6;3ND^J\!<Y77A"Z&H@<HD$&4H5
M!+OFU?.W>L=O <XI70M[TA3/IY)3TGX:> S/"WVH<0,(!?9<4AY?(%"I5$A*
MCI*^=Z/N95;*!L^$S^8H^VRKU@_?\SQC9\A:7[^;I/W($74V";IOWH-#YP+V
M9G@^83\WE6!C/VY?$-,]J9@]B-JXH)W[R>U('!W*MS'>B+<#!]*CB8NJ@S@-
MNF]QXE]=L" \=A@G?MP!'NY+=0&/_60'<+PGGT3[@.,#P%OI8>+(P$&,PJ#[
M&H_\JTLJZ!YU$4<[B#M277P;T0[B??EAN 4X]G-;Q/&>=)RP7ROVHY@KRSYN
M&JZEG'PO.;(."7J;*V2U5'I;132_R)4VFWK:K29?3,E>[>P7Y0[K& G&0M8C
M:3'F?>8\G-"DU;*212:4+1OEJJ*5=>%)7-WY>D(3A2.F,JCVO#*VS*$)E875
MRP:F=.B@98( 79A9L45C&L!V)G-B68WN=?XG7$%*>$VUC&J;0S=.FR/>(@9I
M'?FMK7FAT,9999C!"4?3G1UH_9:1E*#&VA\\ MZ!N\D,T(S1Q_Q)&Q*6KJN<
M/[!'KOT&ZY6PYX/WQ,;.=ML-;.YH!"O(D[I)NVRY!J=0O.;V^)#5'HLM8&65
MYG!/+75.IEEV1+=L@>-:X5T:N,19@"7M<YT3@RF!7@WF$_^Y9.R.6$AU7>2I
MY=2"KRUF0NE.O@5W =AF<0E#,R%*Z"G$$Z],G\W2%,^ 09V0S=#M@<AF2R7\
M9A^Z]6&+ PT2NA_K&=DHG+VY-D3Q+L_55@LR9*EXB8023-C 911 Y+*H*>+4
MF6Q!'"SG6Q!G/5L&LX=/G='>.Y>IMP+'<DJV\NJ1S7ZRWK#/0#@KA8*C G;7
MG_79&:X,Q>:(<IYUFF\HUD*17;D@S4#9@?)FV(_9W/>!T+I3N<A/O@2J)<SH
MLS_(AC(W9-+.,FBD_8YL9P&C:@1@41RA$3F#/,A$@2'U[".NY-<<=S% 9^/^
M^9&^E,*Q TUV@A>-/)G +M<C4M#>Q-#4L8P@NN9W8X4_R9'1!:L:RZ.0\YLZ
MUFJQ-V@?73NY&ZJV7C8< -F=TLG0#3RS)UDTI?AN;:^3Y H8C]NQ3XT:@13'
MS7SRNY+RC17;W0-6"$U=?9;KU!8U.;Q+9MF?N&TZI(@Y->QF$R]2Z2*42G1^
MC@C]%KM&VMB+K]0">7=I84QA)T][!MO(%#R]H3DM:)_V7*$KB*7UV:%26UA4
MVG-;7SF&,Y>X-APPR^&E1:=S9*%DZ>EK)RG18V_5>_ZQZDO^"-V;!JW//BQ(
MT)YQ\R)?VF(^$&NQVF\2]D # ^J%9U:_DI(0?K"<*-4+J/O$2ZYC".E4_W]Q
M4GR"DS[F?S4K24?SHX"L9R'-?OGEQN;21ZF6*/0'W"8*\<S>\K*F6VK?"IQ@
MJ?@5+#5Z)4M9[Q7/WGOK7<X:'>&L_<U?Q5E1V$]>0U/[C#3Y.T;ZK<;<08UY
MX2-A(>OOP!*N"]S:O(7?J96H/WT-:+J$5K*[$(6KT1_X7H:[ ]C=ABVT7&\N
M^YA;B8(X$&_HH$XYN1;N8\ I4[OD\[GUTP%+G_!Y>_W=DM,QWQ':*.X/6Z>T
MS$U^\Q3]OR7PP';8\634CSH]=O_81ZA!Y_L@JG!IOX+2S15JW*?"=K3]T#IS
MWQ>WXNXK+:IY20UI(198&O;'HQY3[LNG>S&RME\;Y](86=K'E>#P+0E@?B&E
MV;S0!NWGY^O_ %!+ P04    " #[=5U89/(\G00>  "=80  &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q.2YX;6RU/6F3VS:6?P75TYZHJ]BR*)(Z[,15MA//
M>"M.7':2J:VM_4")4(L3BE1X=+OSZ_== $&*E&7/YH-;%P$\O/L"_.U#4?Y>
M[;6NU:=#EE??7>WK^OCLZ=-JN]>'N)H61YW#+[NB/,0U?"SOGE;'4L<)#3ID
M3^>SV>+I(4[SJQ??TG?ORQ??%DV=I;E^7ZJJ.1SB\O&5SHJ'[Z[\*_/%A_1N
M7^,73U]\>XSO]$==_WI\7\*GIW:6)#WHO$J+7)5Z]]W52__9JQ"?IP=^2_5#
MY;Q7N)--4?R.']XFWUW-$""=Z6V-,\3P<J]?ZRS#B0",/V3.*[LD#G3?F]G?
MT-YA+YNXTJ^+[%]I4N^_NUI=J43OXB:K/Q0/_]2RGPCGVQ9917_5 S\;PHK;
MIJJ+@PR&SX<TY]?XD^#!&;":C0R8RX YP<T+$93?QW7\XMNR>% E/@VSX1O:
M*HT&X-(<B?*Q+N'7%,;5+][F55/&^5:K.$_4ZR*O2T#4OL@27:H?TWB39FF=
MZNK;IS6LAF.>;F7F5SSS?&1F?Z[>P73[2OV0)SKI3O 4P+2PS@VLK^9G9_Q>
M;Z<J\#TUG\V#,_,%=N\!S1=\=N\_%E6E/NA*E_>Z4O_S<E,1&OYW:-<\9S@\
M)\K0L^H8;_5W5R D-.'5B[__S5_,GI^!.+00A^=F_X^H=7;F8;@O74Z]G*J7
MVVW1Y+5Z%6<XHE)__]MJ[OO/U<63_++7\//A&.>/WU0J[0S;=H=ESK '76KX
M_7 LTTHGJMBI&B;:%1GHFS2_>Z: ;?1A Z,,ZYQ\,U>3MSE(5Y:!HJANU.NF
M+#7LY:<BO]W*^U^*.L[._/)K?HQ3 #2+TT/%,.-;I3^!_JP SM?I71ZK?^HX
MJ_?;&&"^5I$W\Y?PNHSXPWH.KZ'GTY?1FC\L%^IGV%&I?C[J,D955JGU6OE1
MJ.91H/S94OG+I9JO0O6FJ1N8^%ADZ?91;72N=VD]L/)ZJ2)_I19^I,) 16&H
MHM7R=!5_$:C "P"ZP(N"%2PY@W=A.,?/ &N/EHD^%E5:JUV3)P.+@C[P X W
MC. ?S(5@^Z>+!HNY6L"N 3PO"F'!R(=W082?E[.U>A>7OX.M F+_WNXP6*KU
M8J%\;S:#_?CP9@XXA+^+%1!&QV4.G %\?4@;(,XJ7"B@^0I^C);T-EJOA(P+
M;X% ^EXXAVE6W@S0_/925@2*5U6Z2V&QN.K\ ERY:2J0N0I98:^S!#@4;&.<
M:37Q;^ ?4'T-KY&_I$^+8'$C(%TL"<A#$>#V&IC"6\_HS<(+@=+X2SA#AH*=
MK6'/\&;I!:N(%G]Y0,G]6O#3?)LU";#S"B1+9 @'= 3"4]?A?.W^/,RK\-Q\
MX7>GZ9,/L7#M=Q<[RXHQ;>!$#4PO)RP*\;8&(.H"0%6TL8>TWJ>P>*[5(X"H
MD,>[&!0%,74UFXJ3XH@SQ>#9)/C*>A,TE;IKTH2@0=QF17YWFS0L%@X/&"AA
M3[GZKSAOP)52LB-/)6D%3@/JP5U3DF@!B#\5M59SA+TF0/(*D)[$",6;-(=9
M4^"RCS5\ 3 A#1[VZ78/+E<%K@T\E*+[59G?$9>@:P%$$-JTP)T0^X )2)(4
MH8VS[-%3E=: *U#"JCGR8LY6B>R(640\<%!)4P,8N(&L@,WB;U55 &PX%)$-
M6QI4;Q/:GS][?>/U:=CE _/@]_ @KGL84B7FH1]NK$VS #^JVY8?WS,_,G6;
MO-3;XBY/_T1.+<I:^-(R+?RLP?V$S=+[HDR81YH3]A9Y(K1?S* 38XSPN;PU
M3C==YM/W<=8 0H$W=5F#RS[(6%6S^3>P.S*,0(5^+M(K!Q3 :,((KF0W#<0:
M>C9#OXI!!W"J8Y$G.%0<#. SG;>R):9S6U3(@\:0)O\&)YCXSEA23V&P4>M<
MP*;'<9$F!U8$U/])O/9'DU;$COP(#-]JG9P@'*@,%-ZFQYA9'1Q 7@[H4!PT
MT@LP4Z6 <:8)RM VSK9-%O>H[.Q\:M3?Z]8?H+?J!^,/&/_HQ%#^LD];[?N(
MD0^&,+ !P/N!B"<^#D@G?4$;Q"\%9_4^KM4^OD?YTTAB8H8$5'@-O $,KY%#
M=>*UN$_T/8CJD>4[MT]8[3T\LWW,S/P(XD3;GO1F0,0=RP+\0G"O$!D%*:>#
M3E+ I:)]6T\)?T<&2=&-/,:/\0;,#"V-CX'N <%-L\>NTP?*I6SBK"+E"5N&
MG:3W,ADO)GJJG;$ 2X98Y^4!O!V 1_J+A^WBK<C7@"KH"E9#<&]KT,:H3 $L
MT*K'3-8'1=8<CNS?V'T05U7 QC5L)3X>,[0:.B;%2QH$EQ(-VQ4UI'V[U@;X
MPO+&"6NT?!2C16%%&J/JNP.2(*[BY%Z7E4862(FCI\R! %)9(#A& @A6F<"N
M#F8A3^(RJ5@.,,C>"K$0#E='@>&,$_T'ZA^00M1@AR)!OT\C @2*+:H(PE07
MP4CK&(W"[_JQ@\^F8K.,!FJ3I=6>UK6,1:+O4)P@SXC72I14-K:#:#>:W?7K
M6W2F1C?A\ONR:.[VQN ;LGW< \2LK*MO5*ZM3B&]=PI)DNYV\*C:E<4!=P'H
M<';:MZ_UH%ZW$BW&TA%LYD4PM$CZ.U4#J(GPXR&&#<%4H/1[^&4DB.A:9">Z
MUN4!_$$8WE-6H'9+X5$#'0PXQ+\#;4L 'ZGB. *M4B- 0/\6V;VV*I?(]N\F
MN<,->$87$OBPP#WRH*%'#C+.>AM)JK<QFRG! P=CP B$"=H5H+=='25RG][M
M@14K3#FA\D# M_LXO].54?QM?-K#$_@[@'AP_;9('6+73)-] "U2%R4CWV5+
M)@#CM\-6CH(3,X-FJ\+-7)W.>V5(C&K8R(E!$.^:#0 Z5RAZX@;2>^%J"J&1
MS:>TP3[@\",S!R]1P7HX&V(@!9_0N"RX:(NN9PHB"TJ^E46>;M4D;NKB%D4&
M48 +W"@4^:8"YLA1$H1$S&HPV7,UOP%9 (XB7P+Q!]32&84AK&Z*>V02LPWP
M6PXI:?#JN0IN5-Z0OX^&D1)I6J@0WK".2#_)+$FSK:L!A0Z\#1@0BIW@!;[:
MI+EQ3F.0:)#,1]"3O"*K I$RLD(FR(7IS!PD2T0^.Z)CYD^7[3ETCOBX;(1*
MS5I>,?_ PJ3G#IB50T*BT7FTK'+9\H9]K*ISE".P5'QB/& "\(G(QJ&T&$$?
M1FU)"S] 7$?6 JFP:S ")IZ!/>&^.LL[FMK@I 06@5G %=1HX.]1DF#N4]EK
M"48@M8Y6QR,U2@->:]!ZN>M2P%*@>M%G<FAK=1<;* 298,$0 !XE] ,9WYW"
MTQ%^5^0,[.(5J:8&,O_)_B=[OA#DL*VS_D4,QL2,[VFQ#%F.%1++@/A!-@@J
MT!"A@]A*=@IV$,PX:N&BJ>4]S7$$,W>(MV*2Q(P0\P#F&%L0SH"(I:#,T9=L
M@;$2;#P'B1;:)Q"9P#48RAV*NS(^0FAJ0HK<:%\ ')Q2"$F9$6I*FP $HYYO
MQR\Y9DUUJ2<LKMB8;ZL>(*2[#J<KM9'<!!#C-/](&8Q@NC[WU!Q]3K!"(,T>
M^0ZT'V# K;&J$+95\5:LCU!VS%LQ<G,2;%2:3"L!'E>2-JV>J3<RX+\A6I(,
M?A?$;L:4MD695/CCJU<:7(P<V6;#Z6";RL17S/!<J\!;K"/U(V#MF?J@NTFN
MKL..KN^]^ )SF!W'SX/EZ2J,J,!;1Q$L,YM1NC):01@M?, B E(;<S+GF4WH
M4@HGB&!H@-L+,,GI>TN8Z#WE.AX)#Y/Y$I-T\XC^8L+.I.AD 9AAL0QQZ&Q%
M$T7!0KTGDGQF:5@3L;?T(A@(+^OYNK,T[L3'Q&N(Z=C9(I*EB=Y!Z"V7M)X_
M7ZE@YJW7(1+M!#>AMXH6'0R!4_E%^ \6E@;=!2B5V$EC.^3&W]YR8J/J9@J_
M+NDXFM*[?">B[NUO2:/9\RYY"N,M<+@G;CRYA#C%&=U"@S3C1@01M:$D7,R6
M:"^<:'-]Y3@!MQI#K9)-^A%PV^IE]#1 ^RHR<UAOQ)E!65>ZGJJ/6G.JS_<O
MSO5)!&CB"M@5UWDIL9$;5" VI^HW]+:IM),Z284^7TMND)CVFYX^&JB*B.65
M3*.)?"04TK3:1M</>C!@(I?PG%?.GNT7Z;56DTV^AT'X5.IJNFOU1#@=7L%!
M?<E0#7A*UVHY4[/I'!Z\5HNYO!TP^_/9&GY<*G^]A->%"/8NOB^84^\%\3 -
MZ!]X9$U3@A:"]RN!YSU8!DRAWFG7_23=TJ-57+6\:NP"/:<'L0&&"/?YE\WO
M3]4;N]66>3J&&.4&)%E4H774@*0:YX^=+*+K&@&@/<^)H)-< G%KT92GX:XM
M'JJ:H$KT,=W6+)!VLR3FKO?KP,L^V; I'E%=:B)&WI&YFQ:1)OX<L=\,MRN]
M\085Q4707L($[)M"S)S7K*FK!J('SMJ7C]V5V9-M\A@\1WAZVMK?U\0@;TT\
MBD)HO8:@ES+]>WPX/N\G34^\#C0U8.\"*F[!FUDT(WFB"<$LKI8K,$'A>@7F
M]D IVWO=9UBS?PXFW'V"W(9@B3N#>0]DT\<V,@CE?.$M5EC8G:^]5>@+A #Z
M:N9.?VR=A;-PS3PTPS\W-67@D%==VSDZU/J2#IN1E5[.3 6X6WER9T4SYY8G
M7"9B20&N@SWXX5K]!,N,:/^J5?^WIQS-+LJ7>22?+;X/K&-<E=8Y%,DH:)_U
MXU%R.:7&>@-&/1;5%--ACA5$@)72<X[Q2!>MHR=.4#40AL=MQ9#@A@@-B86V
MH-^^0$^2=)=4B\@+A;D16!8C_.)P8!<*]MIF2@ZZALB:DW6B-]Q$-T333567
MO0SV!J-F2IBW4:U,1!GUNC*3M(2QODS*NG$HX<)N#ICU6(I-VDF#$> 8>DCR
MZ704[/?\*,6E V%*ZT X%9JIT2CD:R1I(NX:^AQ,#4<YPV1]+B=Z])#+N.LC
M'J&V 1Z)/855F OY1$D5X*9H&EG?%Q^+IC/S&?.;F$5$/9 !>:1$_IY+CZ^,
M$^B4(MY+*6*D\0.L!\L]ZP)YC[EB,N(FU6.3Q<4F2^]BB2C;7SGWV.;\ 05[
M4"K>V3IUI\(;YWF#Z#6Y-N,_8)J#TK48GTB1@1+P-@M"FDKZLLA7E9ELM=(#
MZNVTRY2VE8#T@+C=CKG*#"-;:&S.Y YV"(R/=4( 3S^0@MGHQP(E4PK]4]ML
MP*G1N[)H,/F*4TAF!9@6<\G&-TG!O^"Q'G40XEQ$D0)\^%121C2C/(K^.H,/
MD[*30Q.3YY"D57QW5VHFE&E#T%RI,0MQ K 7<F@*7TS<8]S4-L4C^$#5!\M3
MY(%O&8]$,.2U=W$.3N"AFROD:H7#/^U&77<<H3*%;H_3&5B]HK2?AQH4J(/4
MY939)DTH^]%)X;L9Y%[)D$#$* V -%-Y[43=ASIP(1T[E&DCBN(A[X<<QX8*
M351E-C)!YD]X#F>S/0] 0!U7-3&N%&XX-M.?J)[FYKK2<@N(J3G(DE(*>D\.
MFL;!YFZ&6^; QQ3"Y4H$]$%M07^FTNFP2S^17N/J=@Z6H.%0<'(%,J++6]2S
MS0'X.D[TV--7-U,*I2P)L?S*X<^Q*8\%E>F[]"5H>3HI#A*CBL';%GL@&?7]
M;35MSU-[X'P,M8EK9%9\OE77!T!MP[TC7@?MO2PU8>X/(!4 A"3@C'V6]1.C
M'8C9F%AX*/3O%OBL=VX*@*":V9/3QF.A&K7>8TD)'"/LAV#$M=T6)+0)N!T'
M%*<M\\B#1O,- H6JC[10FA^;6FJ#L<."U;$0< &X>RYG8G$.'/ C@AS,)&JB
MXM\G6!0T,^U.E+>VS[.:)SU<QQP7/,1E(GPG&?T1\#=D_30X6287CL4]L%+<
MH\GM._G6I,A9FU"6I[9Z$BGPZ_3C%'"!@?<9+& AM[6JZ+(09Y=:"[ HA4F"
MFV'.YXYUMYL$I\@07*F(@YC<7B FO'U&F!@&RJBCB#MP=N&Q+57W&"MM'IG/
M<E,P8,FE[;H$$AZVI?PN.5 -].C5V>O4ICJ,R31FP#/> /6L'.-'I], '+D*
M!=$EB1A4SGMA_,_/BJ[#IA=-CBTV4,!CG5JF&[^.M&]9)X5:X$KL&#*PM4U3
M.;7O<-D/ QAC1*80J9Y9ONT'LFJR7R WNVM+PR^' W2OY\@%X1.CO+IY]N%]
M>N*D$LTDC.GD-#UR%M%/D9X:RF3IFI53"7QKHSH#L]&=FG.-IG1)YLV-[V)P
M%[3L;J#=2 /G83(1-;.0N*^ZI3V%:CG&UQO?Z^>R%>.^WEDWS2U&)>E]FF#B
MC?-I.+<=BB[A(24<"J+Z,W'7H9T#0+A'H3(1AL6<=YI '.&.@8S)VU/;2*([
MGT:A>H(OF+LS50!L?*0&>GHFG*XQ60C!PA)>_M4GCZ7!<KH6];Z<+N4=$A1E
MY!*NM"PEE/FF.D\"*ZS5<$AAYQWJF,7DL)M,M[F(X>C$S.#*NU&D$G ZG99]
MN>YJDAXX6Z"F/(WVM)?BIT84ZX!)4IL*E1R"9-F8%C%6EKU2TSOC;*P:W9D=
MZ4X[1JW1,E[\I>GNL3+>^XO(,5CH6WE1A'FNM1?XH?J +ES%]5A-)6GF$S,.
M.S#8]G0EP/5SL8RV5)-@L;Q1/]@YVB>L&T<6B1/R][9:022VX#N^/*;-$43?
MFZ\6ZBU,QP-PEBP^HK<)/T41GBM8+"FC93?><M#$]X+EC)KVYZO9C2/V-FV%
M^?-UJ);]FAPZPC8&[&[?Q\3@$E]F6,JSFY8<T6=1A@<*HI"@ MS=G-3J@ANB
MT#P(+,7&2=YGPV&JK\.(YERNQZA^CL(+WP>HL+SZ_TQA'P^>>'ZX&J,PYHY]
MJE:^ZOD"3%O&8CCS1VD[QZ2SO_HBZJ[H[ X@?N%L^"P]YW/F,L#4*3U#IN="
MZ(FT^/$2_7^MPMD,4^>KE:1_)Q%LR >F7Z^E$G61(9DL;B9+! )/%5W3@:).
MT9="WI:R9TAH$E"LZ2>)!NN)WMO-4SHH0(Y<;=L\+@(.?*GKB0^4<C-OU^%B
M.//F=2HBU4A)A+-\(]6RSK9-8 0.('$Q4[=ME*%.CHQ#)DY@MJT=,??IG,9.
MU%;Y:TYN#M5S*PF;;%6T76"7%87M"722G;7Z4Y>%U+S,,S(,NW[;]D.)V#E*
M-_U#.PP3#,N:Z6VVS@P9\F^FI(#&7*E!O*);*U/H4T/9L?92]KWV5^ 3;5R*
M^\MI9+[I9UN_#)HOAB5H5S8GF*;S,5A0G+\('N\\>OKR8&$*3F!:CL($>N&7
M\\&.'$QQP@"1@O2 01.WJ[?)2(@T'W(N%T,\@+WVR'[444IU),S=\<$&5@5<
MO%!ED]\6N]T458ZZ7LZ[0NU';7[=C3[=@I)3/G(Z>YU6"3G$JC[BN>K1 V1C
MI.CJ$FZ-,-'\)>JJW^E]O>R<G"O'=A)3DV&[90D?SQ_>^]K- _J7;D]/[WC?
M".-][1'#KX?RY(#I7Q3O]M?IQ+AH\20+0ZY'MV)AHJN_)-J,IHN0(DEZ&8LV
M5TMZQE^?C39]?QJ*382WD;S]V<GZMR6:5+OU)T<WL>N:;EOL=4-$JA/:T!SF
MHP)+Q?V/YGOX>$\Y*IV64J#E$O@]AETG-/\&3:K3Y'1RYLT;5#$>GW7*"R<C
M99;J!9+/$992HZGWAKFDM8R?*\N=5]Z>BTS.V8[:6<\Z RW@DA.3QI:1Y-EH
M21$)?()>J^?'<X&PK^M@%79U=;">M5]\O8X=!;;-N(T#QJ8P:&VQ0$+]1A>#
MP_ZD:TX'M^.;@R<;<TN"5*YM2O#K%"1AU^TZ/K.ZA%)G,[+"J"C?MW5Q2V=%
MJ.!N<W5)":C/!WK+1_R]7[_</0E=C^D,=\"#B\\\./]"]PYLKC^=]7RCJ3_L
M&GFV:>.<V!/^W+X54S.J(:1IBR18%2Q12;5=J-/^Z?;OY53S&SK5/- .\&.O
M$^CLJ6CGQ(&<Y)??G4/+%)5T>SK:D[*WIOE33B)(Y$]&KLVX(E6S#%^=,[9X
M%!< KZ3LFI8$4RL= W;52) K&I3ULH?QVA*W::8MN;4*.+64' *'>#U@.VN[
MY6@9Z)1BN=1BZ\65%F1BS0$/HFHJTP"='ZVA:HO\YM#*F4L+NC><<(G_1.VR
MF"S<D 8^]4*>A7O,8*RR<>I.#(F%?Q(R=0LB:UL0,6D)RJ*:_AW#VMGC5ZC8
M]C2$*)H>"W3:$P=:W(9<2*<-&J^0B*N]>H-NU]2FT#L*T"0BY%C*1:2[ R50
M2A=9QIT2!=$S*>,'<\ZX7X(2<3LCM!X\"T:<)N;V;]3$5FZYO-%G56I='Y_S
M3.&K'G*9>5XZSD^>!N*+K1B&_E0 I<811&O;=<%>SF>4TDG3(2>.B.N C5*W
MY.X2F00"@EK_B8?VL*? YZV![#,RF47J"F9-8:SQB#4Q"\U6(PN%8PN]:YL$
M6VD! ];.\/E&8>/2P3#_XF%S:7H;$,:T:R3$$#FM4+W@"&8/GJA;%3Z1$G!'
M"X"=;%TIZ^GJI#]_VQ_&;K!=#_BP9M7 Z &!J^*#J3IC,J[RNJN@98UFMW@]
MT2;&XWS'(N6&ELVQNKJ1IM3.(@-^,4SY.3<B,)[ \G/^QLC.AR"A<A.(OA2T
MW#R*VY%TAVX"-U?&+G'0PAT@,B$YDQBB;*\(R)P?.NPW>]+BMP60XIV3@;1'
MV\GD^W:L"TAG';Y9Y0,J =NWV/=*!J]?D: 9Y^?3W5G;P."*>@OR!#O/L:T'
MS3X[^1A%5NH?[[Y_103[Q[NWK]H!-Y=[%6EE;BIH8UHZ )B:LT#M]P]E6M?B
M$;OU^-0<<G$IKAWO4%PL;$T%"N];[R3& \T5FS(C+2!Q6=66([LZE+/-A71/
MB=<0S%2"QS");\0U!:C9\2D?)8M+_()R#-X@._NI<Q,"]:S166[+;M(8TSE0
M[W3-;>-C6MO6%J8Q>/UTL0]R](6T)1)4?%\"2ZO17P,28%#*%[U4'9^+$?1-
M9:X>$$E)S;1RR!YIS4>B#PW)@%P@Q2H*3Y]+FUBOV93<#[ED@AE&4N&B^BT<
M_9/*1'PY9X94LETYDB0A!=W1 ]QZ).(WUN0Q$!/\=@[C?6=:^NHH!GWWX15A
M8!>G8KYMW3XO<@"43GY0,A*H++UUNZQ!)6+2 X)NSHRWGAG@:6"*3@ZS):JY
M_.=AGV;Z9('3ILVAF2?X@]/E=7.2,[VL@^^G0:CE5!)]XI9B<M,>@4/QJ)[<
M%6I,#R>+R"SOFFR'9][IZ+6339ND4U"FN!$Y@DXPBWLZ (+3WF:AB8T,DL>(
M]QQ1E\<]7I@J)'0FIZZCA)N4<O=@H#30F<LC.NG#X4N1R(1/8KYKX:R\N]SG
MY +E5(0]&0EHFVPNF$[2WJ<SM2&U)VK/'-5G=9TAV<%;[]T\8S(RU>FRLE3<
M<UD!(3]2B2RPJ0$K/&J?PAKE=H_^>K4MTPTS'I_<#"X_N;G1V[CI7A'C'L.4
M9 1#BMV!YHP\L7R& 6V&O6)MTR(% .,7R'W!J5*/#M/*T\,ZBKL))7G9-;Q>
MIU"2:GLDIPVFI$;I7*F#2O_8=LBU.:XA.2GR$\B<S(S38W1.$W%QH) (1:*P
M>D0R^7X>.57;J0,-:.:^-K97&]F$;\^\=GK">_=-7<02D[:U[M!VSE.'1.?\
MAKU,F2*!F^GP;9RQB=2__%*!P2.W;5?2*W.6O=,_1'WDUW+=)[ZNYN&91_&K
M'3O";DO"9?8"&T*P760=KM5KR7P*L]NLIE0/U(1O] QO^D]VR5>9>W#L!),Y
MM>Y$V._4&]HKM K]3B:(L%.$BL@G'303?W&C%E&+H$Y+T0ARG"3OI7B:K2+!
MUI"U/!G1@T--5G/< _:Z#$-*E,;[7@WE/UCG<""R&!R\\NDU6(:#QWX[K8X=
MQW$HV^'9S$A<X[$;])[DL'3/2Y_87,KFT7K%-S8D=4[1]0:B=K..;R47ZO0-
M99N]ZF5CI&=2OK57M!D[]U T6<(!(/)9_'B:, +Z[ZC]D2*52K7%OC_%8RFV
MYKRQ]5%!XO ^'G! P'5*J>HD3@.BM.0;3\EI[+K6K<M\-B_5=^A-AY!3JF#)
M:<_38U\G>F7B%[6L.73S:9RWB3^Q:*>X[7H,U9Y0N2$+<]@T964:X %U8J&J
M-G8"(YQA:SM._4KC9?QIJ7L.TH%C# YM\$CUD*8T+>;4<&%Z?SJ!%8Z]N:B<
M_+*#UFNU]);!@EY#>/WIE+M0D!9T"GONA>M0O?S/A&&YG :FLSFTK<T_C8K&
MQ!Y7!-T3SNAJ$S_BUZ&+UY\Z5^;CC7CT'P.@5P)[XMOS[;?V_QYXR5?NMX_S
M?USPCNY2K%2F=S!T-EU&5WPYA_E0%T>Z@!\\XKHXT-L].-.ZQ ?@]UT!_I5\
MP 7L_\CPXO\ 4$L#!!0    ( /MU75AC+AS@>@P  %(B   9    >&PO=V]R
M:W-H965T<R]S:&5E=#(P+GAM;*5:^V_;.!+^5PA?=B_!N8XE^=E'@"1M[P*T
M:9'T]K XW ^T1-O<2J*7E))X__K[9JB7$SO-8H'6MB1RWO/-#)6W]\9^=VNE
M"O&0I;E[UUL7Q>;UZ:F+URJ3;F V*L>3I;&9+'!I5Z=N8Y5,>%.6GH;#X>0T
MDSKOG;WE>U_MV5M3%JG.U5<K7)EETFXO5&KNW_6"7GWC1J_6!=TX/7N[D2MU
MJXI_;[Y:7)TV5!*=J=QIDPNKEN]ZY\'KBQ&MYP6_:'7O.K\%:;(PYCM=7"7O
M>D,22*4J+HB"Q->=NE1I2H0@QN\5S5[#DC9V?]?4/[+NT&4AG;HTZ7]T4JS?
M]68]D:BE+-/BQMS_2U7ZC(E>;%+'G^+>KXW&/1&7KC!9M1D29#KWW_*ALD-G
MPVQX8$-8;0A9;L^(I7PO"WGVUII[86DUJ-$/5I5W0SB=DU-N"XNG&ON*LQNE
M<U=:F<?J[6D!@G3[-*XV7_C-X8'-02@^F[Q8._$A3U2R2^ 4DC3BA+4X%^&S
M%-^K>""BH"_"81@]0R]JU(N87O1C]<1[[>+4X$HY\=_SA2LL0N)_^[3V-$?[
M:5*:O'8;&:MW/>2!4_9.]<Y^_ELP&;YY1N)1(_'H.>H_<LCSFZ]-H400B)__
M-@N#X(WHJO]MK<2ER38RW_[=B?:^*Q=.)UI:#;NHO% 6#PLCY,HJA?0K'$*R
M6 M3K/E1O2]F6K0)BU.=Z4+ N@[72VLRD4J[4D(];"J+RSRAA1ME::55L;E3
M=BO,4DBQ,993%!<ZCTMK55+1&NRHH)V(%0)-;*P&A.ATB_5([-]+[;1/<G!)
MM -3?PT?YTXR $"-M<(=F*%$M-I[BR7YJM)C2\1S4XB%HIM,$V+L\D^,\HNL
M2K6Z4TS,6+W2N61:O!16@B*IE@N=ZF([(,L#:HQ5?6ST2Y+F.1DP0YY#CAPT
M2D566BBL)*M@H4P-*+,+B!U82[IM.W)5UI2+E"S6<32>K$IX H92=S(ML=,Q
ME24DSF,M4V*;Z,;Z<'8MHO4^RTRN"X,++(P1#59Z8U:K8^A"_M3N^ZZM;CHR
MB?,X-F7.)MJ85,?;W;5=^4EQRJJ\$#*C34XD, K'5$<TF%,L$))B(W7"@I8Y
M_XQ3J3,6KS@0\(O2(6U\='5MM5#2>NN0-NQ#Q*#0>\UB56%-#"HPAM04X(GA
MT,BHDD(X:2G.2"5R*-\%:6UW'&<6J5Y5!L6JCL0#(*LK#GJ9R4-5\%]J"A**
MR_P5YPY9#MH5E7KUO4Z2':2J71MWR*POG/*[1%E[Q(+3#A=M(C+9#BEPZOH#
M0( ZK)(JND&I2'%%80U&)E=B"_,_$Q:D<!48V)>3D0$=*9H*6NOZM4P<8UVI
M9-XNX[!I1*EBMT*M^[6.U]X"L5GE^@^LX,9CKT!H!5)F+)3$-L":-CX.9?(;
MTIDT75M3KM;B,[C$G&FN,I^'TH7*U1+\29Z<H_$#Q,\X1ZOP?9'@9!EJ3%A<
M30">@QOQ40_518+60)3.FS\!<J5FTY+C,+>>+]3SG)&ML=XPU"2E3_I:JJX9
M."AP5Q;B#DV=6&Q;KC4V>&ST<9,2>ED\3$D*'Z&9_ T@6FR?)NW!0$4@H.V"
M;(P++ZX "#7OYH-5X%YZA&\+P"Z<WE%;V 4$EDU:?*^J:LF6=P4$U>C+6%;J
M$?!@A2;9%8]MN M#SVDM.3#0(ZEL 3_5?=*CW) U<C)PPB$L&^W\$YXA4W&A
M,!2"M(H40@7C0G100@X$$@?Y]UWYNE 'ND/6;R3%&1)S1]PE$%10?5*OQ?%5
MCCXW3<E?)^)C\X3D[PA)U9+ZMQ(I0G[QWFJ@EK,E5I0K\,V6Y&^H=,/WLJ6X
ML>9..PX3]:!=%=29W$*<@E"ZK0N=_!/'X8FX-EW1OID"GU_RE2&V7P -%<*?
MOQ(D)P1A.(75UY@9.@CK_0&:P8DX\DU<^&;GUWSH/RXN+EZ1LOC^1Y=H36G'
MP9Y@3:3^'L_IW[7A53!4, [$6 2S4$31K%+B4<[YS@-L3:6<:97SVZ,H$*/9
M% 6_R<C^3CK",;;,7YGET@]DO@%ZK,8/;/,)7:))<W'-O"'G)[U4O*E^PC=^
MEMGFC3C/\[("EVL,B;]B2&QL$/8GX\FCJP_9QMR#<;WOJHGT&@4>6S*(AOS_
MJRT3B$I=U=--8'^>H4K$4D2CX D-NL="[]UYC9*\;O8W>SJRTV]?KH/)1 1S
M$8SPV?5OO7(J1C0B/.]@^>?\-QY.1=0?(FZ"T0R_)O.H87  *1;<$>_'B2,Q
M&<_P"9*C"-^CZ9P^^\%L*,YW2F))[N8)G[*YR^PX&I^(S_NH'T<G(N@/9\&/
M1#P>41J.^V$XX;"[5.B@N-T"J$IQ?7-[\V7  '"5QRE\[[HPT,$3#T\,HNM&
M2BJT1BQ+PJ]V&]H.KBYM9U@WH ? 6U/G>9^OK$PJUPF'NN[EK(HL:?P5#8JM
MFTR9F$U=T3^]_W;5%[T_Y_%>71\*WP4L8#6:W<@*B;A0=*0$0/:E!6:333>Y
MOUQT0F^W T!3H3V+*AV[WH*)DS*F"0&C?>F<[UI==>!S 9<C5KBZ.M5,$\0N
MIYF\&;"J E2%HJ\3*+6?;R[05N+'LK0L^@X7/VH/6XESA\DF82T^-M/5;8$;
MW!8,Q'GQI'2'J*>=4>]HBL2LBM^3AOJ1B?[Y^?W%BZSCNPM+'0EM?R+"\T3V
MM+P4<D?!8"067M)^U5/)U)DZ!EPEX]7+9/2!0+U79Z9I0J8:/#;/1?" L[7)
MPZ-@%G4MV521'S8N+YI_CL+A;-=1!\CNCF@5!6QH9U"Q5FG"6.90^P;=CH2S
MUP=L NC*62@/ L",IN7G-FVG3Z(['23BR-%WJK9=TQ)5;6+3UN]5HN\9$(:I
M/-Y2NGA_=SCH&N.: 0]F1"6G!MA/141C@Y3QY9'4O3,D%9V0U%C2$D3BMQIA
M+EHN%9_>B@\/FN7]I0ZJNDIWY\:+RK@[K3N?;'D+&IX)Z^,MW]&VD(7'JN9'
MYR;$D:1[-HYK?XH[+8' W4>= 804#8=!-&CEKXG5_:QWM_3G)<H'AH^<,JM,
MZ8_ =L8/N@O+K3!&_>%#;6]=E>ZO8EAKIO8D*Q@.?WHZNBW+HJ0S"NG68@D8
M=M[+B)3:5OUZBC=583@P3W$WSN%:X02&9%6C6F=/XU#P<.7B-T6XPK[F4$[3
MZI22_2TW@)X'GK;AY*-H$-1P!J+T,J-B^&38 HX[]C -H/M2I^/O?E-T-G+K
MW6TI09<T,W,/$1M@"VIMGA"_@QG(O037]S676:LX^;O@[*5V]8D*GTQ6:K=.
M8P,,'LU8-TT_0DW.T^GR:<7H8!2%GH?);\IF;J_).@(<B=F4.KJ@'P03,1__
MA/IGZ3@HYE BFWB,I'-=F+)T$/>VK!KZ<[>G-[Z4N4RDF(?H:L=8!\Z,!^(8
M;+,RD9@7"LSQP1!];SCSX?H2KI=?;L3M!V@AHKF8[=L$A"X*?]SKF[+!@8XS
M//$Z#X?\'<UG;&OTLCOGBI16G'P')T7BFN_M/*\NKF_\X5)9H-3[@&H/0X\P
M$E0NW]<085CVK1N?I^P'CWV>[8 (\:[>/YS_Y:[H1]J$TT[YK=-I@QS09<;'
M'K2H[0#8<[LZ%NL#PX=T;;.4E.IPPT$ I!&&,<- ;G(,P_R6E-.7:![K@1KT
MVR-EWV0(C^UV(RE0,WIM6+]'/*GK^;/%QI^Y4;>D,P(P6Y=4VKGE4VQ%[^/8
M157*DBWQ(ZB+*9OQ\>NA1X<]]2$-50U 3='?4X; +><7,FSZSKF\6Z.->M4<
M'=(.>I'1WNF^2:IJWT!<%;Z-;#CO@41=MVMKB8Y@H51.A80[^>J [:4GKG7C
MT5:MG8!MPY2,A4PS5'<^5H;^E0W-+SYW(W@773E-V 5D?HQAE:%N=^W3UO_W
M;&N:=\-^B%D>8_"D/QU-_8]Q$#$,DA>B821&@-$H&F,V)3F.P^GT!)\3S+['
M&,5/JA'7[6?6NHW0B/@!1<%D!GPBIH"K3SL^>R)EB#EZA#D]!+R,^M-Q*]PT
M%+.QF,\;R8* ))M-\ G\JR5+]])O!0OZ\]&8#@*"&1B,QJ-J7[, =AKUPXC-
M,^_/ S+8"%#;K#P005@UIK7384A#_CAD&SQK+A17JQ%H><N=@>5H%+3M0Q^X
M,QX,FVZ"QP7<F31W*$7V9":]'*3)W?>=@WVODD\[[_DS95?\UPS.XXE_Y=_<
M;?Y@XMS_G4"[W/^U!>K4BMJ%5"VQ=3B8CGO */X+!G]1F W_U0"2N3 9_UPK
MF2A+"_!\:8#UU04Q:/Z,Y.S_4$L#!!0    ( /MU75A.G](:.AX  '1B   9
M    >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;,U=Z7/;1I;_5[JTSD2J@FB"
M-YW$5;(\GO&6DW@M)ZFMK?T  DT28Q!@<$CF_/7[CCYQ4)SL[-1^H7@ W:]?
MO_=[9T/?/Q7EEVHO92V^'K*\^N%J7]?'5R]?5O%>'J)J5!QE#K]LB_(0U?"Q
MW+VLCJ6,$KKID+V<C,>+EX<HS:]>?T_??2Q??U\T=9;F\F,IJN9PB,K3&YD5
M3S]<A5?ZBT_I;E_C%R]??W^,=O)!UK\</Y;PZ:49)4D/,J_2(A>EW/YP=1>^
M>C/#Z^F"7U/Y5#GO!:YD4Q1?\,/[Y(>K,1(D,QG7.$($?Q[EO<PR' C(^%V-
M>66FQ!O=]WKT=[1V6,LFJN1]D?V6)O7^AZO5E4CD-FJR^E/Q]%>IUC/'\>(B
MJ^A5//&UD^F5B)NJ+@[J9J#@D.;\-_JJ^.#<L!H/W#!1-TR(;IZ(J'P;U='K
M[\OB291X-8R&;VBI=#<0E^:X*0]U";^F<%_]^GW^**L:N%Q7W[^L84#\^F6L
M;G[#-T\&;@XGXL<BK_>5^'.>R,0?X"508LB9:'+>3,Z.^%;&(S$- S$93Z9G
MQIN:Y4UIO.GSRQ/_=;>IZA+$X+_[5LKCS/K'0=5X51VC6/YP!;)?R?)17KW^
MT[^%B_%W9ZB<&2IGYT9_;A/.WMQ/VD]%+05LSY_^;34)P^^$RX?/>RGNTUT>
MB;^417/\MA*I^54<B[+>%EE:B+@ S:O@^F(K(K$IBR@1993O)'Z1.N.E>9PU
M29KO0!LVM:ADW)1IG<HJ$/+W)JU/WE=Q<3C(,DZC3!Q@KAUHOLB**(>?CC!O
M?-*?BGHO2_B0[VYK61[<*0-1[>'>SO<BRA,@HDP?(]1UL4WS**>ITARVOJ&+
M1L2 BE&A$AO$)7$LB\<TD4B2A!'J*,T <G912>LJFM+ET2;*8%C)TP$29NG?
M9>)>L ,PY%^SHJHD3/D@I> ]F0I 4KB8\92 :0-@*6"UXC'*&OX.6(Q?W!>'
M8Y2?!K9H)-ZV&7Z&N\_QA>@=X.M36N]1($A]&AP\JM6<(H$WP",D-Y=?82%/
M,GM$3A(P1,#/.(NJ*MVFP"18&EZH."C8[D05(%U9XMJ\36[R3%85WG"B<?8R
M2_#BJH;9ZZ(\P9J.196BC):P$;"4-*YA%N0PB\^Q*>$*M57P36Y'<ZA*<_&A
M3\Y&XL]M 8:5GY3$ Q^;/$'ZHII&;"H>"\4ECJH]7)O#!M"F(?+4<G<B0EK3
M]Z]_).ZR3"W#D_'.S0.THYB#G(!XT_Y$FTPJVPOR6@W*%ZC$"<@'8I'#2*XF
MKG#549,0D\"^ E&,Y6$#M&KT[GPS$=?O<[!A68:*=R/NU;"6_,]%#;(U]'U+
MV,4+,5^/X74=3!9S^KN:X]_%?,;?ABO^=CGIV<=I**;!E%\7$S&;B_ER*19
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MUCTID>%=:EM3<@/1GE/ 50UYD*]:,="=(>0=SO\641^MM10G&944<:'FOJ#
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M$MPKL>;/%8]'E0J(<,40FQ988WBFI-$26;\\1!NE/1.OS./QRM:-W$(1EX[
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M9 9[U)1]AJO#0!#^)F;WV\V=*("L&%F $HZ/*-S:TN&XNBES"BK2VCM-:(_
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M#OO] #A =(.8C<%H#ZD^,4+JHR^&W('QDD1P<OE=J^[MVS"9'5E]:OADV==
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MHS2[=#?!UO$K3&9#L%6\1!5"]'D!GB\L9+R]X0/ZSW)7_P%02P,$%     @
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M^-B) .X+B_G4?XB!X2_,\E]02P,$%     @ ^W5=6*L<?!:W#@  52<  !D
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M#J02?E03PR'.;'"*B/N^" 9&#<US\GN1.WK$&XK7W&:LD;N ?^*,./-] =W
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M(S^5:I?+#\X^0')Z)Y&;!;:.AE<71\K)C[CD2R@W_,.I>1E"N>;+E4'V<[0
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M/QV#1H>_"X2;PF[Y%?W"%B# _'6MP'H<#<#O2VN+^H86:/ZS<?M?4$L#!!0
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M 0L;3):I1 )K!5&DD$CKL:(A0=G*2\LWC5_BF?R]4B66I>=[2_$B 0?D#I5
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M#VY(E:J@Q5]I"A[#&@FK(K W1DDI$<3'1"^Z@]D@T]^KUR[CD*8<:X=!3T
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M45&JKGK"V0RI:2X^<*<,0^#TOI+S> _<7(KI0GS.7>>'@QZR'L4PMG)*'2B
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MTZDMA1QE2J!<C>WDE>EK<P(<T=%H3#7ZT4[CD.V=5Y7K52E^^4(UYL05.GR
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M!FA9/$11=0$J6Z[2C,OV6JYN-!;[(46E+'91I(:'79Y?/R\BDY?DHPO;L\
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MZWB@RX&N/%BU=D/47%D:R=QV13,P:A:@]PM%M%0'=K";JOO_ %!+ P04
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M3%@AS79?'^#BM^*B$?Y*UL'>*0)L&N!L!G3PD&NG'A*#^P7P/I(%O/7-RJE
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M<360"*9F]LY5G$AO'"J&L! %BE(8V')SGA89@M/CU6S(9]*/QDI#C3J2OJM
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M+G4?P^J.$@GY&^Q6 /(,4N,,3#=X\A5JT:\-O_/CV#>Z4!8_ZS_-<AOXT#T
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M0TRKPAC/9;22\'%8IQ ."W2K[(6:&8RU#9)006NV@E(-B;=C*R  DK]8!HN
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MU7('VDZ+AE"TF0*N].XBC9*.BL'(HRA%);!P$#<;%Y26VH_UU54?!(\FKLW
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M[L/3WC<(L>7<@S8BY?L(Q(Y=9A7XHG@5@CZ3-(@H[Y8, U44HMY @V"4B>#
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MMRB:X!#>=H3DO,0J0PH'?X'05-"W@#F\(IXPM<DK*E9_2.L5_!,2F\B0L29
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M>*4Q-)_[^XJJDMHZH])1U"K)4D&OFALI-]/6F(W&5IL5X-25J6$T_:E8,HI
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M:..?$50:YR^&,,42,2R%GQ:,D7@<IOW(&T,I@0Z&?%*^Q"IJDZ&F+>6^3JJ
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MEX]TY4=T._XP=NEB=%O^$V4=V*4%>+]R+N8?1*#_4OK5?P!02P,$%     @
M^W5=6(3R:3O+ @  3P8  !D   !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL
M?55M;]HP$/XKIZR:6BEJWB@$!DC0;EH_M$-MMWV8]L$D%V+5L9GME.[?[YQ
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MQNE(8>SW+19UYH?PPCRCT1B^MC5"TLU;@P[L ,7@#AOM3F34+;[,L/ M?G^
M._A^X@UZ.';5XR2F?M]B<6<2F%HO@1.G<=S-.\'1(:HO..D6>X+9 3X.#P6S
M-X)?T%'L*MU)# ._;[)A9Q*:BIVXAWW%X2O%/51?WP[:4WR(CX(7@4FW]J*8
M':!9?*Q6!KU_:X5R;6\0BCH I97[S>YG]Y>42_=O?H&[&P[%OBZHMY2X(M?@
M(J&:D>[6X PM&ONG7@I-_WT[W-!%"Z4!T/I*"+TSS ;[J]O\?U!+ P04
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M0',R..%#EE+]U665:/=3+?C1BI)!Q] .)<X:&QI@X0%RBI4IT;TW6+LXXN)
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M$X]E"]R(>J3+E.0F>9N##.@, 9Z2YN&UE<%JV7_,MU1ETAU=U=UW<2C8 (A
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;+U:^8_;-A;^5XAITO4
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M$7]?"3W*?W]+L*^NFGY8_E/;J&T%+7?1DKMJRRV-W-JL3P*E(Q:/J ,YU&C
M?/;2+D&:7F7US*V>IBQLY<N D:"HMC8;GW1S2Q4.N$ IBD:8"FLF";Y6IAH1
M[B<2?H_)\VBNJ?/>*H$SI ;#/XGR#GVSN7Z^H1>/_U'5^</1ZE)18:A\*"<R
M)RL\9542X\$WH8L53Z**BIS59&T^:-&. <UMP_/7#2?V6:O:_:/6\[K6\P7E
M#DRA4<^2Z-ZUFHMV73RE6.Q&W@FO[:],FP"WAMTS#:YG&EX_-.X8.^P-<ST
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M7RMA6/ ]CM9OX/6UX4BV$V^@^S-8? =02P,$%     @ ^W5=6/,XY.-'!P
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M>83G.%T$$[Q9\NP+<!3#^'&T\-T9*LN#"+D6W2'B.,7ODX;7T#X]$0%=:KQ
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MAUO!D7AH ];76KOZA1@T%Y 7?P!02P,$%     @ ^W5=6!,5P",8"   *QD
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MBMH^Q7/KB*\A\%H"C_2V@DC+C\*(LQ.M-DSC:>"&/\A4H@;EBAJC<FLTO"V
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M)NJ<F:6$NMA ^<$S"U%H]B3*M<1@J>X<A(2$U 9RO:B)R 8(B0SZ\MA&@P)
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MLS3:CWHO^4(6TDEA#P4WZ/YP<."(\9V;@MP4.S>,&X%)B=DE<B85<VO!EKJ
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MY#V^3MDD832 2@1L$;!1"KZ$2L2@,#Q[,HNC^%6O;E3\OJ1RF\(&A+7OO;"
M4)95[<]F314;QVS:3-QNF[B[#) U:\F:_0NR^B?8'U U:/A_JGY,U:AS^2N%
M6=$5U\)F E7.WP/;K^TM^L)?'G?#_17\ S<KJ2Q@7<+4\.443@#&7VM]P^F*
MKI(+[>!B2J]KP7-A< #T+[5VVP8Z:/^W,/\'4$L#!!0    ( /MU75B3-N.
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M%4SGIODVTEPXO?/?(];:.5WZTZW@T+Q0 )YOM';=!2KH/U!=_0U02P,$%
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M482Q(RXED<(N3N--=')P_\A<HJ0>P/, Q-7[%K*+OA]M9F*#:RO(9.4\)^7
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M0=)#24E0QH^5C1,Z5SL;CH "5T#A*4#?9\-TY=6SI6WCZ-<WCI_Q%_3$T8I
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MT?$IY\:4TZO<D,[] )AJXG'BETL>^&B< ;^?:TW/&S=3ZD^(X1]02P,$%
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M_XJ&[>RD,R1@FX_039A)L-UF)]EV2KM[T=D+88N@J;"H)9-T9G_\2L+!"(R
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M1-,YW# W/P.@K(-97TF)NXG=H/V]B/\!4$L#!!0    ( /MU75B+SQ+=\@(
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M0C[Z>IK*3A&8,I#?UY2*_4(=T/2>X7]02P,$%     @ ^W5=6!9"#E>=$@
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M*)HKFM:<%5X[[\HL*TO<*BAH-<2J!.K';FE"/3T#=M;KT]'NV=D6:+\1E)9
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M].6%?XH"[/7R'XU7[UNJ%DQHPF&.E-')^6E E%=$;QC9.8V828.*XY8-_D1
MV0#<GTMIMH9-,/R6BK]02P,$%     @ ^W5=6$EZ,S>+!   (Q,  !D   !X
M;"]W;W)K<VAE971S+W-H965T-S8N>&ULK5A=;Z,X%/TK%KM:S4AMP7R&;A*I
M+3/:>9B=JIV=?5CM@P-.0 7,V*9I]]>O;2B!X)!42A\: _<>^QSNO;YXOB7T
MB:48<_!2Y"5;&"GGU;5ILCC%!6)7I,*E>+(FM$!<7-*-R2J*4:*<BMRT+<LW
M"Y25QG*N[MW3Y9S4/,]*?$\!JXL"T==;G)/MPH#&VXV';)-R><-<SBNTP8^8
M_U7=4W%E=BA)5N"29:0$%*\7Q@V\CJ O'93%CPQO66\,))45(4_RXDNR,"RY
M(ISCF$L()'Z>\1W.<XDDUO&S!36Z.:5C?_R&_EF1%V16B.$[DO^=)3Q=&#,#
M)'B-ZIP_D.T?N"7D2;R8Y$S]!]O&-O ,$->,DZ)U%BLHLK+Y12^M$#T'053O
M8+<.]KZ#>\#!:1V<4QW<UL%5RC14E X1XF@YIV0+J+06:'*@Q%3>@GY6RO?^
MR*EXF@D_OKPC12'E+Q-P+Q3'E.($/'(2/X%+\)@BBL&-?#49?P4?(LQ1EK./
MXM&OP 1,/F9SDXMU2#0S;N>\;>:T#\P);?"5E#QEX%.9X&0(8 H"'0O[C<6M
M/8D8X?@*./ "V);M:!9T=[J[K7&/3G>'$VR<[ITX"L\Y@/?I9RWE_N=FQ3@5
MB?&O3N(&PM5#R&IQS2H4XX4AR@'#]!D;R]]^@;[UNTZ><X)%9P(;2.=VTKE3
MZ,M=##,5PZCF*:'9?^*&J)$@8ZQ&98S!AZQLP_>C3MQF$E]-(BOG\]+V+/4W
M-Y_[PDVNYKW"G0EL()S7">=-"X<H>$9YC0%9@VI/1:E60O(<408J3!OEM,(U
MDP0]X>">8I/+>*]B9P(;*.9WBOF3BJGBR'1RB>V5<5%1LW)S+-#\4:#M1]A1
MBVC*8L LZ)@%D_6GW1/4+G !_JR+E7CG@F?#^ +(6/FA8D5N&]]X*AY'&8MS
MPFHIR73A"LY9N,X)%IT);*#YK--\-AE-K>:LT;SJLO'TU&OP9_TPN++VL^\4
MH^B(T8!?V/$+W\&OR8A^=3Z2)^$HQGW+TE;DDRVC4RP'7*&U:ZJLZ0Q*4;D1
M! 6I[X2C'#1;NK95LLZ9#V=%B\Z%-E2QUYK"R9CYUJNCEV"%-UE9RO$*Y:=L
MXBWZ8!</9W[@CX-&8^K8=NC.QE&C,_7<(("'P\;>$;8G"7\1[4G;J;0[2:4^
MCO +IG'&9,:(@DM4P5WA$J\S#BJA!3LJA3U:-/1AJ!%B;.C P-'(H#%T N^P
M"+OF%TXVB,L'7-4T3L6W7 +B7M4XRM$9K>@R"$*H(:FQM /7]30T-::.!\/9
M8:*[5A5.]ZK#\,;-X-38UG2HH>A170U;G:DV#2*-Z3@-AFQW_26<;C"_4XQ$
M>_!ZXLOTQ@%K!4ZH*?@:TS"$KBYFQY8!M%W_,+M=+PBGFT'M]I8UZ7R,ZKA_
M<\)P%NI>I<XTF&D2.=*:NG"(VI U>Z<'!:8;=0K#1.[5)6\^P;N[W4G/C3K?
MV+M_*T^ U*G$#J8Y/OJ*J"C>#.1X+2"M*WG>0IL3F>:"DTJ=4:P(YZ10PQ2C
M!%-I()ZO">%O%W*"[EQL^3]02P,$%     @ ^W5=6/:OF@N/!P  74D  !D
M  !X;"]W;W)K<VAE971S+W-H965T-S<N>&ULK9QK4^)(%(;_2A<[M353M2-T
M!Q!=M2H**,I-KLK6?HC02FIR89*@N_]^.PG)2&A"4_M^49*\[Y-S."&GDT!?
M?+C>#W_)>4#^L2W'ORPL@V!U7BSZ\R6W#?_$77%';'EU/=L(Q*+W5O17'C<6
MD<FVBJQ4JA9MPW0*5Q?1NKYW=>&N \MT>-\C_MJV#>_?:VZY'Y<%6DA6#,RW
M91"N*%Y=K(PW/N3!>-7WQ%(QI2Q,FSN^Z3K$XZ^7!9V>ZPT:.2+)Q.0?_J?7
M),SEQ75_A NMQ66A%(;$+3X/0H8A_KWS&VY9(4H$\G-#+:0[#8V?7R?T9I2]
MR.;%\/F-:TW-1;"\+-0*9,%?C;45#-R/.[[)J!+RYJ[E1W_)QT9;*I#YV@]<
M>V,6$=BF$_\W_MF\$Y\,M+S'P#8&IFK0-@9-U5#>&,JJALK&4%$U5#>&JJKA
M=&,X5374-H::JN%L8SA3-=!24KF2LB4MMG*U:5)NJEQOFA2<*E><)B6G.S6O
M[+,D1:?*5:=)V:ERW6E2>*I<>9J4GBK7GB;%I\K59TGUF7+U65)]IOY93S_L
MRM5G2?69<O594GVF_(EG2?69<O594GVV4_WJ/DM2?:9<?994G^U47]MG2:K/
ME*NO)=77=JJ_;R]:4GTM;CAQAXC:2]T(C*L+S_T@7J@7O/!%U*,BO^@JIA/V
MTV'@B:VF\ 57-ZYMAUW-69"^:&3<\_B"# -W_H-\)W7SW5QP9^&3KW4>&*;E
M?Q-KQ\,Z^?KE&_E"BL1?&A[WB>F0L6,&_A]BI7C=,2U+]$K_HAB($,,=%>>;
M<'IQ.&Q/.!KIN$ZP]$G#6?"%Q*_K^0#*<@A%\>:D[Q!+WJ%KEDML\I<34F)_
M$%9B94E$-_GV.I^?$$8CNR:QU_/M0[[*M3?R[?=K1]C97GLSW]XQ/&'7]MIO
MU7-G$ON=2NYLK[VEDKNVUWZODGMYK_U!)?<X>"JQMU5RU_;:.^JYR^Q=E=PK
M>^T]A=RU_0=M7R%WK;37_JB0>XY]H)![3O!#]=QEA\U(/7>9?:R>N\P^4<]=
M9I^JYRX[;)[4<Y?9G]5SE]EGZKG+[+K^_PYZ_4"?.73@Z <Z1<Z;O]7WM'1D
MH$4\;5\UUB\^_[GF3D :[^'?O]I"05H!M_V_)?%=Q[BR'!?>%SCW5\:<7Q;$
MA;_/O7=>N/K]-UHM_2EKJDA8'0EK(&%-).P6";M#PEI(V#T2]H"$M9&P#A+6
M1<)Z2%@?"7M$P@9(V! )&R%A8R1L@H1-D; G).P9"9LA8;H.I4%[NH[JPUO#
MF7(ZG"GGT9,;'8OTEL:"SRTCO-OQU12K74LL^&3%O?B>QC?9""=W#\>.<)"P
M.A+60,*:2-@M$G:'A+60L'LD[ $):R-A'22LBX3U8E@M@H5/)-^OZ$EX4??^
M>>2B(GI4$0U41$.9B+)MT4A%-%81351$TUAT^EFTK7@ZJ'@^J)@=5.CZ;K3E
MD[-,M/JU3%6N953UW=V54\E6ZZFDK:>2VWITVUV+Z^>TMQS1<7+!QW:<BL)A
M5E<1-51$3171K4R4/<SN5$0M%=&]BNBA<NAX:Q]4= XJN@<5/63Q^TC8(Q(V
M0,*&2-@("1LC81,D;(J$/2%ASTC8# G3\T_Y1U]G06EU$&VKV5739E?-;78C
M-S L8FQ:GF'*'N)>YR*.;6O5G1.I5LDT];I$4\V<]AL*FJ9,D]G7K42CE3,=
M3:(I9T[_+5E>V7XFTYQFVIE$PS+QM&4QES(M319S)IZN3%/)M#5D\?M(V",2
M-D#"ADC8" D;(V$3)&R*A#TA8<](V P)T_7=#S M5TK9"RF)2JMESBGZ37ZC
M^(O*GB+JDE,UW3DWZHTCV5NM[#1M9:>YE.P34%DGRR4<V\F0L#H2UD#"FDC8
M+1)VAX2UD+![).P!"6LC81TDK(N$]9"P/A+VB(0-D+ A$C9"PL9(V 0)FR)A
M3TC8,Q(V0\+T_#Y^],4XE(;JPULCF%HZ@JE%=-AWN&K(X0P25D?"&DA8$PF[
M1<+ND+ 6$G:/A#T@86TDK(.$=9&P'A+61\(>D; !$C9$PD9(V!@)FR!A4R3L
M"0E[1L)F2)BN0VG0GJZC^O#6<.8L'<Z<Y=Z007R'ZTSR!#ASY^HF-XIC!RY(
M6 ,):R)AMTC8'1+60L+ND; ')*R-A'60L"X2UD/"^DC8(Q(V0,*&2-@("1LC
M81,D;(J$/2%ASTC8# G3\]OWT0,7* W5A[<&+C2<&V9[S:<?WM-#SZA(_,U
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M/42*V$,X;>V> ,/= I7E0SO3'85FIT E="PUW7%%Z"%,Z"V.]^\*-J%/K(Z
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M%<7]1M%1/+,G_@57BJ>VN0:L3_3&0+]?<JYV'3- =<LT_1]02P,$%     @
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MKV^A-!09OIA3:3_1NHSU'!074O&L!&L%&6';;_Q2)F(/$'1. ((2$!P#HA.
ML 2$UNA6F;5UC14>#01?(V&B-9M9V-Q8M'9#F'F-CTKHNT3CU&C*9"$PBP%A
MEJ )9TKHS*:<)B#0'<%S0HDB(-%'=%.H0@":<4KB#1H#@P51YL:4*1 @%7K
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#@T+GAM;,U;VX[;.!+]%<([6"1
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M(,G IR1->3&4M^.*IR8"'$=M&O=-&NA$&A"!3SSV;0G>93&-^P[&'),.&'0
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M]P?9M+*R7X;W+%N*Q0KOY]>G*->QJ==QNX+]"?/KH]!J$W\4W3H<H(H"%(U
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MIG3Y=#TWZXU5&S]ZELK2(//+@CXU4#L!>K]2RCYOG('VXV7R+U!+ P04
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M7[#;1!%7-?'"6,;%)GM\4>V>YMOT)+N^?GQP)_OM$T\E0UUSQ;+6?"X9Q],
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M_Q3S%W+YB(N";,D7D)AE?\&EP!H:"$Z,DZ0(%ADD49K_][\70M0"H-,3@(H
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MB$J],(N+\B]XV!\[&H!P4_ LV1<6-4BB=/<_^+EOB*,"D+040/L"Z-0">%\
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MH\=RG/*,6;USN'6>@92T):P"&M(3:(A5H+&E5G6I@(:X!!K2\*0.Q;B>K"Z
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M>%: QJS2-:;>R4#C*:#Q7@ TGE6@L:56=:J QG,)-)X.- 2.Z]<(<Q7Z6E1
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MR6,^).L\V[)= H@"\L";,)2:,A%D#I1C]FR3!V5AT<]Y'H1ENI2KB)R#.\;
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MI7B2/:Z@4Z9"&\#\@D-&%B]Z@?*F>?(?4$L#!!0    ( /MU75A6S9D/0P4
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MJ"R OB\D&5R\V G*+GCP"U!+ P04    " #[=5U8G1F6*OP,  #,AP  &@
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M]>^)K'VAU=G:*AS#UGCY\)A1*4[))3AM3@ES57F97&QJ4-EL0L=,(Q?MZ&$
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M*NP$>C^5TJP[5D%U23/\%U!+ P04    " #[=5U8^C'6_5D%  #U)P  &@
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M<VAE970Q,#4N>&ULK5A;;]LV%/XKA%=L"9#4DGQ+LL1 XS1;@00+DK9[&/9
M2\<648IT2<IN]^MW2"F2;,EL$_C%UN7PZ/O.G;S<2/5%IP"&?,NXT%>]U)C5
M1;^OXQ0RJM_*%0A\LY JHP9OU;*O5PIHXA9EO!\%P;B?429ZTTOW[$%-+V5N
M.!/PH(C.LXRJ[]? Y>:J%_:>'SRR96KL@_[T<D67\ 3FT^I!X5V_TI*P#(1F
M4A %BZO>N_!B%KD%3N(S@XUN7!-+92[E%WOS(;GJ!181<(B-54'Q;PTSX-QJ
M0AQ?2Z6]ZIMV8?/Z6?NM(X]DYE3#3/*_66+2J]Y9CR2PH#DWCW+S)Y2$1E9?
M++EVOV13R@8]$N?:R*Q<C @R)HI_^JTT1&-!.-ZS("H71+L+AGL6#,H% T>T
M0.9HW5!#IY=*;HBRTJC-7CC;N-7(A@GKQB>C\"W#=69Z2YDBGRG/@=P#U;D"
M])'1Y)3,4BJ6H D3Y [6P,F W#)!1<PH)^^T!I2B(FD\O&-TSC@S#%?-J%(,
M$D(-:7SBZ 8,95P?H_Y/3S?DZ,TQ>6._<,\X1Z_JR[Y!4A9:/RX)7!<$HCT$
MPHC<2V%23=Z+!))M!7VT1F62Z-DDUY%7XPW$;\D@/"%1$ TZ ,U^?GGD@3.H
M/#1P^@9[]'U45.@%*.L)(_M'F(M$+HZ?G=)EL4+AL%NA+0P7>D5CN.IAYFM0
M:^A-?_TE' >_=[$]D+(M[L.*^]"G?5K$H V07&"1XNP_#*DE%B<B%3GB4F,D
M,1'S'#UOI?XR*2@2RPRQI+;6K(%8*8+UCM B9E/@+BQ1E #&KURX2P4KJ0P3
M2[("Q6329=<"[,2!M?5Q/47SKYO&:DN<CH-*9LL&H\H&(Z\-;F!N7**]_YHS
M\YT\09PKEV1=$+VZ7NKZ RG;HCVN:(^]85]7C9/G:E,6*'29((_6"LJZZYIJ
MID_()R'G%@.=<R ?Q JS!&4D5B;.J.T8)UB3>)QS=T/^>92<$^P$&ZJ2?[LL
M.3ZD)0^D;,N2D\J2$V\ 7<.2"6%--:<<2S5TL2U4C!N!.QQ.=H+;^YE7DCBK
M2)R]C,1)F?CVD4MIF^*:HO.+/.\BZ?W$2UUZUK+8Y'S<G>KG%<ES+\FC.ZQ5
M@#7-ECB]5=F>4HHE3?($&\%O1.!\AV]EUNG+\Q:RTVC'E6V1,.S&'@;U)!%X
MT?_A0+NJ##]9ESO;?=#"=K:#OD/D='2^!W]C$@J]%><A5W&*$R$6$QM'Q72#
MH61X,1-U@@T/&5*'TK9M@*@V0.1U8&6 3J91.V2"7;]TR(S.]OBEGG]"[X@Q
M??J!"P8=P; ;[UU"43#9 ZT>3T+_?/)1&IQ[5Z\)G&$;T+"%NDMH7YS7\T0X
M.O1 &1YTK#B4MFW^]6 1>KOM#G\O[7'+_N>C71^U9<)HN,='=<L._3V[QEAX
MQXNRW;N;U;"$V2$TF.SI5V'=E4-_6RX2P+PBHMKM<S#>Q=R6.8T:J;V-N6ZR
MH;_+XC[Q!\.07\&+P[W=;)NSU?8>M>ZVD;_;;K-XS304M;MH>^;SHWAEKD9U
M3XZ\+:^,KV*D^*EY"'=V1K%Y;MP^ -,;9Q*C\N)0H[GUJ_=["36=45!"V]K,
M[59HOTQ!NM\XG<E +=VAE<9I*!>F.)6HGE8'8^_<<=#.\^OP8E8<;]5JBM.V
M>ZJ6=OCBL$"5P=L)5EA5'& 5-T:NW!G07!HC,W>9 D7C60%\OY#2/-_8#U3'
MB-/_ 5!+ P04    " #[=5U8YW$9(I0%  #"'   &@   'AL+W=O<FMS:&5E
M=',O<VAE970Q,#8N>&ULS5E1;]LV$/XKA%<,+=!$(F59=F8;<&-T"Y"T7KQT
M#T4?:)FVB4JB2E))!NS'CY1DR9)H)<Y4("^))=T=O_M$GC[RQ@^,?Q<[0B1X
M#(-(3'H[*>,+RQ+^CH18G+.81.K)AO$02W7)MY:(.<'KU"D,+&3; RO$-.I-
MQ^F]!9^.62(#&I$%!R()0\S_^4 "]C#IP=[^QBW=[J2^84W',=Z2)9%W\8*K
M*ZN(LJ8AB01E$>!D,^G-X,7<L;5#:O&%D@=Q\!OH5%:,?=<75^M)S]:(2$!\
MJ4-@]>^>7)(@T)$4CA]YT%XQIG8\_+V/_C%-7B6SPH)<LN!ONI:[26_8 VNR
MP4D@;]G#'R1/R-7Q?!:(]"]XR&WM'O 3(5F8.RL$(8VR__@Q)^+  ?:/.*#<
M 3W7P<D=G+J#<\2AGSOT4V:R5%(>YECBZ9BS!\"UM8JF?Z1DIMXJ?1KI][Z4
M7#VERD]./V+*P1<<) 3<$"P23M1+E0*<@?*) &P#EB3&'$L"9K[/DDB"F1!$
M&;Z=$XEI(-XIE[OE'+Q]\PZ\ 30"-S0(U)L58TLJG'HTR\\Q?<@PH2.8YL0_
M!PY\#Y"-'(/[Y?/=4=7=4NP4%*&"(I3&<YZDZ/T^:1RMP37%*QI0214_.75K
MH&;R+?$3SFFT3:T^L8@7-SY@007X>JT& %>2A.*;B9P,3=^,1M>!"Q%CGTQZ
M:J$+PN]);_KK+W!@_V:BJJ-@%>*<@CBG+?KT]T3-F$@2Q8O8SQZ<S1[CK,BB
M>6DT7:_NIZXW'%OWA_D8;(9N85.!V2]@]EMAJE=TMCT1:A9Q< !C #U4P]HT
M<D?.P S6+<"ZK6"7R4HRB0,3*+<)RG/M&BB#D8N@&=2@ #7X7PR"F%-?/< 2
M?)I] 5@M('5+EWP?!X \QF1-5=4QY31HPAW64VK:>*YGSL@K,O+:::ZEH##K
MA6]"Z#5'[SMUB 8C5)_;\W9(7^&WEC4Y+!(;MD99Y)_L18#-I;G5_=3JTU&P
M2J:C(M/1JRK;HRZ)ZRA8A3AHEYK [KPBYB$/IWC?MNOKX"FK*N #$0-; ?^9
M,*F +G29$5I\S%(Y"6XP_ZY?O-+'X&JM2DQ:</;*Y9K<DP# =\9T6@<\]75V
M%:U*3RE@X.M2,+!3"=-5M"IYI8B!W:J8/-SA%$=H4%\'!B/;.;(,2B$#NU<R
ML*E2H%M7708C!(^(!EA*&?AR+0.;.L49]NNPFD9]V#\"JQ0SL%W-+.DVHAM5
M*=1G_[/<$0X^K_2TPJM 3?HH3LK:@<RUHS7^R=._HVA5-DHA!+W753M:5=#)
MY'44K4I>*;9@N]HZN78,F[/>K6\K3$9#=&36EVH)MFJ*E]6.47.'XXV\.EZ#
ME8N. $:E2$'M(J6M>J"FS!C _J@&S&#ECNPC]0.58@2UBY'#^G$7L6.UPS'6
MCO;8)^_^?X;N0 <')Z]+=Z!NCTY^ANY I>Y W>H.U)04=?7=:E*%66H.U+WF
M0"8Y42\;)J-C$@F5F@.]7'.@IIPPP#(8'855:@[T?,W16C/ O^#)+7S[6"<O
M@Y^A/U"I/]#KTA^H4_W15;0J>:7^0.WZXT6+<]@X8D6-??P31E6X6H-4#Y#+
MC[S3_I'_"K^!69@=(NZPVM&O"-'])B&QWO!+IGM/NH<$E% '>,WBM)O$-N O
MS+=$VUR%,6?W>5M#.6C#O(>A9X4^&KAFT?9LGBAJM/,EBZ0^G$P/$G0+XAPL
M"5%S21&']A&4D6 !7:<P/M((1S[% 5AJ7-E0.O FX>D&@D99ATZ%/S>]6.N@
M@1,2!5PWP@1(06;G[<7=K-EV"2_F:4^J=G^&1A=S1;CAB6/O^W-6.436W;M1
M7-%(@(!LU'#VN:=J',\:9MF%9'':0EHQ*5F8_MP1O"9<&ZCG&Z;(R2_T $7;
M<OH?4$L#!!0    ( /MU75C;)C:P2@4  +8F   :    >&PO=V]R:W-H965T
M<R]S:&5E=#$P-RYX;6S-FFMKXS@4AO^*R [+#'1J6\JMW220ICM,85M*0[L?
MEOV@VDHBQI>LI#0=V!^_\J56G#JG<5:!0&ECQ^>UWG-TQ%-;@W4B?L@%8PJ]
M1F$LAZV%4LM+QY'^@D54GB=+%NMO9HF(J-*'8N[(I6 TR(*BT,&NVW4BRN/6
M:)"=NQ>C0;)2(8_9O4!R%454_+QB8;(>MKS6VXD'/E^H](0S&BSIG$V9>ES>
M"WWDE"H!CU@L>1(CP6;#UMB[G)!>&I!=\<396FY\1JF5YR3YD1[<!,.6FXZ(
MA<Q7J035?U[8A(5AJJ3'\4\AVBKOF09N?GY3_Y:9UV:>J623)/R3!VHQ;/5;
M*& SN@K50[+^S@I#G53/3T*9_4;KXEJWA?R55$E4!.L11#S._]+7(A$; 5YW
M1P N O!V0'M' "D"2&8T'UEFZYHJ.AJ(9(U$>K562S]DN<FBM1L>IV6<*J&_
MY3I.C;Y1+M 3#5<,W3(J5X+I&BF)OJ)Q$/ TTS1$-W$^7]*\ZY\I6U)!%4-C
MWT]6L4)C*9F.N1?<9P&B"MVQXF0A_?F:*<I#^47K[HK^BAZGU^CSIR_H$^(Q
MNN5AJ.\G!X[2-M/!.GYAZ2JWA'=8\C"Z36*UD.CW.&!!5<#1^2F3A-^2=(5!
MQ6OFGR/BG2'L8E(SH,G^X1@8#BEK1C(]\F'-SG1I7IA46<W.M%^E2\8D4@M=
MA D-_5689GJ['/=,H.F""H;^^D-KHQO%(OEW7:;S@;3K!Y(N,9=R27TV;.DU
M1#+QPEJC7W_QNNYO=5FR)%;)6;O,61M2'SW&LU4Z&] DB2*>)ZS.<*[2RU32
M)?!EA#OM@?.RZ0.\TX$^.J6/#NCC@?DK(7@\1_^BN_%3G050H&G-+(E5O'9+
MK]U3F>==FSFS)%;)6:_,60^<'R9G=3;SV.[&[.[VW:W9W7O7 ;U.K[RF,JA^
M.:@^.*AI.FGSBNFU7\5,R 5?UO8?*-2T$);$*IXO2L\7IS)Y+VSFS))8)6>>
M:VC$M;),%S)=<)V&[W6HEPVR\@Z9]7KAWF,1A[6;%M666C43V&0"GTHO%".Q
ME3=+:M6\&<[S0"3Z8#$O@C=[H.U=;/= S44=KWXY]PQ,>3!-/3#]7X$N8UJK
MM&'K>]02)Q5&CD%=GL$NKW,R4]@JP-E2J^;-()P'TL[^"WKW'79L@PE\IT.=
M&+#R8+)Z-^?UXGW+8QZMHEI#H%KC*EI2JWHW_.;U3V;V6R5 6VK5O!D&]$!<
MTG,F8-$R>VYRERCN9XG@25!K')8B+@KHS[K>F<"1!YK$AMDPS&RUC4%?=S4&
MK-:TP+;4JMX-XV'O5!H#6R5"6VK5O!DBQ" Y-6J,#Z0N=C<&''FH28-O&,:W
MNL;8 _UAU<:%/L93-VQ($;=/ID&L\J8MM6K>#&]B^#D?C/Y%</4Q97^+EXJ+
M-M&?N+@>_;$!.@P#W7<6S 'HAZ,;%^$8R(<-\N'>R4Q>J[AH2ZV:-X.+&'[>
MMR_T%S(0],-W.M2) 3@,4]?&;(=Q']9I7+]C$!TQ1$?<4YGWQ"H-VE*KYLW0
M((&?^#6AF@^D -R'(P\U:="-P+RUU1*[01_6:5S:8[ <V7CE>CKO7.V^=#T&
M_Q'#?^2C)X4-6@*6 D ?CCS4I($U L-:M27V0'Q8KW&)C_&(CQ@B)"?SFI98
MI4M;:M6\&;HD_^=5+7G_'I9LL5'-)>TMO'<V=@9%3,RS#5,291MO\DU"Y=ER
M4]8XVXKDF,OS'5VW5,QY+%'(9CK4/>_I62?R35+Y@4J6V3ZCYT2I),H^+A@-
MF$@OT-_/DD2]':0W*+>JC?X#4$L#!!0    ( /MU75C7!'-!W@(  ,L'   :
M    >&PO=V]R:W-H965T<R]S:&5E=#$P."YX;6RM55%/VS 0_BNG;)I *J1-
M"YM8&XFV8T,""5'!'J8]N,FUL7#L8#LM[-?O[*190:$;8B^)??%]_NZ[R]UP
MK?2=R1 M/.1"FE&065N<A*%),LR9.50%2OJR4#IGEK9Z&9I"(TN]4R["J-L]
M#G/&91 /O>U*QT-56L$E7FDP99XS_3A&H=:CH!=L#-=\F5EG".-AP98X0WM3
M7&G:A0U*RG.4ABL)&A>CX+1W,CERY_V!6XYKL[4&%\E<J3NW.4]'0=<10H&)
M=0B,7BN<H! .B&C<UYA!<Z5SW%YOT,]\[!3+G!F<*/&=IS8;!9\"2''!2F&O
MU?H;UO%X@HD2QC]A79_M!I"4QJJ\=B8&.9?5FSW4.FPY](Y?<(AJA^BYP^ %
MAW[MT/>!5LQ\6%-F63S4:@W:G28TM_#:>&^*ADN7Q9G5])63GXW/&-=PRT2)
M<(G,E!HI1=;  9P:@[1@,H4+SN9<<,O1;$ZEP"QL.9<R10T3U)8J!R9*IMRE
MR<#>%,DDS#Y!WLRFL/=^?QA:8N[N#Y.:Y;AB&;W LA?!I9(V,_"%[DF? H04
M<A-WM(E['.U$G&)R"/U>!Z)NU&\A-/EW]V@'G7Z3AK['Z_\U#1T8,\%D@C#S
M?_%7K<J"RV4'SK@D.V<"9I99GR>8L**2^<<%(<(YF<W/-GVKZP?MU[M6<6(*
MEN HH%Y@4*\PB#^\ZQUW/[=I\Y_ GB@U:)0:[$*/KY$)_HOJC\L5&NM5$(IJ
MU8#K"E71YEM%NG#2KK:*-*F+-&F*M -L85$?6/;0IMU.0NWA0IML;\=YHMA1
MH]C1JQ5;D@!>,+PON7T$@TFIJQ]\S6T&4H&;"5P\4D\D::CSL+G +3';A-K)
MXQ5"O1VG$BK<ZHLYZJ4?%X827TI;M8K&VDRD4]^(G]G'-*FJP?('IAISETPO
MG90"%P39/?Q(W'4U.JJ-587OOG-EJ9?[94;*HG8'Z/M"*;O9N N:^1W_!E!+
M P04    " #[=5U8A5D'>*D#  !Y#P  &@   'AL+W=O<FMS:&5E=',O<VAE
M970Q,#DN>&ULQ5?O;]HZ%/U7K+QI:B76_ (*'2"MH+Y7J=VJH6X?GO;!A M8
M<^P\VX%.>G_\NS9I&K8T&U6>]@7BV/?XGF,?YWJTD^JKW@ 8\I!RH<?>QICL
MPO=ULH&4ZC.9@<">E50I-=A4:U]G"NC2!:7<CX*@[Z>4"6\R<N_NU&0D<\.9
M@#M%=)ZF5'V[!"YW8R_T'E]\9.N-L2_\R2BC:YB#N<_N%+;\$F7)4A":24$4
MK,;>N_!B&L8VP(WXQ&"G*\_$4EE(^=4VKI=C+[ 9 8?$6 B*?UN8 N<6"?/X
MIP#URCEM8/7Y$?W*D4<R"ZIA*OEGMC2;L3?PR!)6-.?FH]S]!06AGL5+)-?N
ME^R*L8%'DEP;F1;!F$'*Q/Z?/A1"5 +"[C,!41$0_6I 7 0XY?Q]9H[6C!HZ
M&2FY(\J.1C3[X+1QT<B&";N,<Z.PEV&<F5Q1IL@GRG,@MT!UK@#7R&CRAE1Z
M9DPG7-I.37#GD"LFJ$@8Y>1::*/R?<A[:<B4*L5@2:BIQI_,P%#&]2G"WL]G
MY.35*7E%F""WC'-<3#WR#7*Q&?E)D??E/N_HF;QGD)R1..R0*(CBFO#IKX='
MA^$^*EC*&)4R1@ZO^W,9_R5SMA9LQ1(J#/E@-J#(AX4&M:4+#JA8EJ-8)S>P
M!4ZBTSKJC7-98U_HC"8P]M"Y%AB\R>L_PG[PMDZ(EL .9(E+66*''O]4E@ZY
MI!PW#9"Y.YW^5#+/F%AW*IMI;JAQVP^W469-KLG?-XA(KO&U_E*G5-RF4BV!
M'2C5+97J-FZ@&RG6;PRH%,^@A>F@.1*>+U$@/ 24LIK@D94K9ACH#H&'Q]Z5
M4P\(1_-"K8_V\YZ[>>VAOIU$@R!&SVRKW.M&]7M/HPY(]4I2O9>YXE[(YQP1
MUSJB<9YCU[DEL -)^J4D_=_KB'Z;2K4$=J#4>:G4>>/FF<HT!>5D2*4R:RPJ
M")>T_F/1"'4LZSU8O^*%L#L,ZZTP*-D,7L:F:G6J-: 3-L"7[CNK*8<ZMH.:
M!./@.T<WYO/"M1N6;(?-;+$,^&89N9U>1Z$Q_M@%:PGL@&H8/%50P>^U=#%_
M2V*UA7:H5J7>#-NS=3/6T<S#'WW3#[OUQ@Z?2K^PN?;[_S[=Q<35A*-A;]#[
MSNG%L.K'.PZ&P^>(/15O86/%T^Z95<Q533+L_5"&-&=T[.;T*_<B>RF]I6K-
MT' <5@@?G)UC):#V][Q]P\C,7946TN#%RSUN\&X,R@[ _I64YK%A;U_E;7OR
M'U!+ P04    " #[=5U89G\V9;\$  #&'0  &@   'AL+W=O<FMS:&5E=',O
M<VAE970Q,3 N>&ULM5E=;]LV%/TKA%8,+9!%$IWX([,-)$ZW!5C:($&SAV$/
MM'QM<Y5$E:3L!-B/'RG+^HAEMA:HET2R><_E.;R7/B#'6\:_BC6 1"]1&(N)
MLY8RN7)=$:PA(N*<)1"K;Y:,1T2J5[YR1<*!++*@*'2QY_7=B-#8F8ZSSQ[X
M=,Q2&=(8'C@2:101_GH#(=M.'-_9?_!(5VNI/W"GXX2LX GDE^2!JS>W0%G0
M"&)!68PX+"?.M7\UPP,=D(UXIK 5E6>DJ<P9^ZI?[A83Q],S@A "J2&(^K>!
M&82A1E+S^):#.D5.'5A]WJ/_EI%79.9$P(R%?]&%7$^<H8,6L"1I*!_9]@_(
M"5UJO("%(ON+MOE8ST%!*B2+\F U@XC&N__D)1>B$G Q/!* \P#\)@#[1P)Z
M>4 O([J;64;KED@R'7.V15R/5FCZ(=,FBU9L:*R7\4ER]2U5<7+Z3#@E\Q#0
M72R!@Y#H8RRII"#0^UN0A(;B WJ':(SN:1@JX<78E2JOCG:#/,?-+@<^DN,6
M@G/4\\\0]G /?7FZ1>_??4 AC:B$Q0/A,@8NUC1!H%._-B28_7@"W(CB*ED*
M;7"A#<Y@+T[3YO4,/7"JBQ[=0 Q+&E#UW"2+$5XWZ)5(2  31W6@ +X!9_KS
M3W[?^[5) DM@-25ZA1*]#+UWHA+H[S_52'0G(1+_-"G0LZF );": A>% A?&
M6OB41G/@B"W1\]U'@?X[7JLW.Z!^!J1WT<W4&[N;*A'3B-KL+HO97;:LU$],
M-E6K(O $0<IWG9ZW(DK*7A2(Q NU3Y,0*3@BH7%0$WWC3$]=<DM@-5'[A:C]
M;HJ^;U,!2V U!0:% H/3BOYPSV[B/S@H;W_TM@6,B5O2&A:TAN9N463.T(QP
M_DKC%=J0,(4F'CN4084''GEOB1A3M20R*HB,C$3NR0N-T@C!2\)$R@%)AD(F
M%+G-OG;IOG8A_UEO(CHZ6+#+RP.BQJFT).I[I4WQK.]PCY7=ZU^FE$ ;I8+2
MJ=G#&"=P:MO:0JO+57%U?C=[5XYK2P5+:'452O_FFPV<K?[(TU0;Y' C,,^E
M+=?2H?E&^S/]/26<Q&J%0T6,AD>\20YB,B?F/&UYE#[+-QNM_9JM=GP BM5K
MY'-HI2Z&P[>,C!G;,BJ]F6_?G%T+ ?*7.0F^*L>EG5C >,*XWLE$X=L:!;%J
MOVRAU94K#9C?D0/SK5HP6VAU%4H3YIM=F+5=[-"7'?[*F^?2EFOIS/SO6+,6
MO?)9KI5)/7Z0T:B%)=N6B]:%"?1+%^B/.FH32YXN5Z$+AXA+AXB_XQ!_T-6;
M89JGB1H/9+JP>+BT>-AHGJQM"^8TI^C1A=G#E<.ZMJ=UW9Z!*)A\*1K5M7L&
MV(7'Q*7'Q!T= V*KYX"VT.HJE X5FQWJY^W^O#H!'JC6(BLX0R$(@>2:Q(W\
M=X@^KOKN<^^M434G;DNL-*K8OE&=L4BU1*14T/O/,HUKS='A,:.9R\DEU871
MQ:71Q1T976S5Z-I"JZM0&EUL-KK7BP75=WNJ&(*BK)H7?W!X--<_\++F=*?2
M<2N7;/J&\Y[P%8U55<-2P7OG U5"?'=IN'N1+,GNW>9,2A9ECVL@"^!Z@/I^
MR9C<O^BKO.+J=OH_4$L#!!0    ( /MU75BQT8RW]P4  %,@   :    >&PO
M=V]R:W-H965T<R]S:&5E=#$Q,2YX;6S%6EUOVS84_2N$5PPMT$8B;<ERYAA(
M; 4-T'1%W6X/Q1YHF[:Y2J)+TDXS[,>/E&3)DFGF8RSZTEC2O8>7A[SDN62'
M=XQ_%6M")/B>)IFXZ*REW)Q[GIBO28K%&=N03'U9,IYBJ1[YRA,;3O B=TH3
M#_E^Z*689IW1,'_W@8^&;"L3FI$/'(AMFF)^?T42=G?1@9W]BX]TM9;ZA3<:
M;O"*3(G\O/G U9-7H2QH2C)!608X65YT+N'Y-0JU0V[Q!R5WXN WT%V9,?95
M/]PL+CJ^CH@D9"XU!%9_=F1,DD0CJ3B^E:"=JDWM>/A[CWZ==UYU9H8%&;/D
M3[J0ZXM.U $+LL3;1'YD=V])V:% X\U9(O)_P5UIZW? ?"LD2TMG%4%*L^(O
M_EX2<>  PQ,.J'1 ;8?>"8=NZ=!M.W1/./1*A]YC6PA*A^"Q+82E0SZ87D%6
MSO0$2SP:<G8'N+96:/I'/ERYMR*89GIF32577ZGRDR,U(OD@[TAR#Z9TE=$E
MG>-,@M\WA&-)LQ7XG,U9)EA"%UB2!9AN9X(N*.:4"/!R0B2FB7@%WH#/TPEX
M^>(5> %H!FYIDJB9(X:>5%'JMKQY&=%5$1$Z$1%$X)9E<BU G"W(H@G@J>Y5
M?43[/EXA*^*$S,] %[X&R$==0T#CQ[LC@WO\>'=HZ4VW&K%NCM<]@1=_VU)Y
M#VZ)7+,%N,EV1$B5ZO*U&AF].M!_U"!=TPQG<XH395 L/SJ-OUS.A.0JF?\R
M#4O1;,_<K%[ASL4&S\E%1RUA@O =Z8Q^_06&_F\F2EV"Q8[ &G3W*KI[-O31
M.R:$6D*3?.Y+!K;-;%#$4ZDS@9,-X_J-XEFN"2#%,*7Y,)GH+IKMY\WJ]7\W
M@E'8&WJ[0QH-1F$0-8TF]@Y\@:;1CJU.S^0TJ#@-K%/X1G&8$C"5BD(]=1^8
MF('+B>D2+'8$UB QK$@,K>/ZD>Q(MB7&%;;P# ^GS2! 8=":70:SR ]@>W[9
MXS@QO\+CF=OO^>&@B7W]1.P&4_V*J;X5Y;T2:#2?<B:N^D<D!-T^:C%U;!3V
MHY;1Q![%"9X,S?>0WV+IB<@-EJ**I<B:E%<X45N&RLI<T-HS,G*9D2[!8D=@
M#08'%8,#ZSA\8E)MN%@((HU9.3A.MP#U0]B::P:S7C>*6LD[L<=R8K99G9Y)
M#_1KK>D_@J"$XAE-\EW3J []X_[[80^V<F)LL!L,8+?%YN2!D$[P9/=Z+E$'
MHAQ:HZK%]]^,JOU1K?1RRT_P985Z:C(Z18M=H35I1#6-Z.=(Y;)=5YR[1(M=
MH34YKZL3:%7C>\X+W:NVW3WGXC688\[O]:3>X61KW(M+[$9.P_;Z:##J=UO"
M.;9'^5P6ZJ(!_J2JH6RWH1>.E\9CHRAJ$_0C"@!85P#0JHU/KG#@7S!>JXPT
M]MUI(> 4+7:%UJ2SK@5@^)-6.JM ?S+G+M%B5VA-SNNJ MIE]_];Z8YU/X+M
MZM]@%/JHG<C6*)_+0ETU0*ND?II4<5HW.$6+7:$U::Q+!SAP>20"'0GYDDF7
M:+$KM.99;UUD(+NBMYV+H..:(1B$[6+?8-4+VX<GL<&JVP_JK;@9?BW]D5WZ
MVP\K2N>&0(K:X1_;O('M5:,T:AX_G@J^%MS(+KB?<H: G&IHIVBQ*[0FC;6&
M1G8-_=!! CI6P"@,H[90-IE!'X7MJ? CI#*JI3*R2^5''0J@XX-P% 1MU3\V
MF,%!KYW@L3VBY_98:]_FFUJ^H0?/.<%ERK9*/( UWA$P(T1?W JY+R X6>I[
MNKQ(P NVR:4;6X)/F*^(MKE)-YSM\KU#: =M>#F?:TR].2N]!]ZQ;/5FLN6%
M[ANS+$].H:_K],W8&9@2 MXS20#:(XP/JY9:/U;;E,B!EUNNC+D"JF3EF8DI
M[^">,B4J<'VC+$ >9''P7;VM;JTO\[O:UOLK>'X-#>_'Z'QBLH_1^;7I_24*
MU(? ^"7<7YA[=:C%=?NMXIQF B1DJ<+VS_I*^_/B!KMXD&R3W[C.F)0LS7^N
M"5X0K@W4]R53))</NH'J_Q&,_@-02P,$%     @ ^W5=6-. 0'NQ#P  ]8(
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M:Z&B42PTN1&$B/*= XYA'U4#H:)1+#0YT$(#^>9M$8-T]X%-"L<?'+H$K,+
M5P<J8!6YF@T 7P@+_Y ['CZP2Q':ONHPM"^B;O  1KT]2]G;WMG9O;<[?& G
M(Q[L=T!6@Q:ED%6_1>7:"PKNF_<[GF=>??Q>B;EZHR<!5-*.A28WC2#M_B'W
M2GS4O1)4-(J%)@=:B A_[[T2<\G144,E]/YPKT1'LP1+]\T[)<\V'3S++HO9
MF=&M@ZH"L-#D)Q((%1 <<I<E0-UE046C6&ARH(4P"?;>93&7'!TU5"41  E*
M6NH7"(40F+=9+MM'7-1DU0YN,ELD^5W#]\@\K=IA3OBTPMJEF1DKZV8+1IYN
M>C,*&%)4S8"*1K'0Y- +S1 <<M\D0-TW046C6&ARH(6\"<SRYODR3@- ZL2V
MFMT%6 6>NK,"&/F:5+9 2)U@_'."GIIN&@QUC>.H&<: T:FM6E'(2I-R&?2>
M[6,62,^6;AH 3],)8E4< E:^FH1,(2--)EP@Y$=@WC/03N6<$=;ENN%DI]6*
MS1J'R:QD\Y1/[FGUM9W<ETGYE76?;UC.;E/-LXQ050DJ&L5"D^,O5$D0'7(^
M1Q4RJ&@4"TT.M- \P<\Z01! AP/4U&3(2'VJ%@6,;,W4%@J-$![^]$ (I/RK
MC](:FBBW. J8G&JX:2B8>OB3#@Z$4+*_>G  ,K)MU>^AD:TYH1H*3AZ:.?F7
MWD/IN/H&GD:WV1UM%'BS4-?N&3WN^71@-% I.BH:Q4*36T)0]/"0%#U$I>BH
M:!0+30ZTH.CA4RFZZ/(\OKS7)^4/POY<I_4/TZ1GGN[#W5E1@,FI$ZJY$J"5
M=KX7]#U\(GW?,RJZ< SI^.!6 ![U4*,!D7^-E@D%KP^?RNOW"X;Y3@$0=34D
M@"QP!V>Q("M'MWP3]IZK^6QY0N$POV?0^8%4HL&36(PXLEN"2H=[9PGI>Z]I
M=;WS9VBBLCMJA)'=$80UW+U(_]1#<^&04 [<&YJXT6"J,N'(3SP5O#0R\]*=
MA&577XQVYJA, 9-(96. C7X:C@0/C1[#0PUW_A/R)?E^TGS7S3]?MO//VW;^
M 7T&'NRH^@Q04%5H0#:ZR382%#0R4]!]'S =F8Z<=DX-30;W4\!&/UM&@LY%
MYBR-W<1:I=$K[8$ \Z7&DCE4-(J%)H=9D+G(.R!KCHS,<72@,=$H%IH<:,$/
MH[TS62*(@_F#9TU#F2P#/@=C:0:CX'/1CH.[J$E'T6ZB!IB$ZMT?L.%W$,UA
MIDC0M&COYQA&T),'/77-";12FY-"5OWFE&O?>Z*YF8V-GS9'K#Z8KSUZ>*.N
M<V*AR7$7M#$Z9 9VA)I[@8I&L=#D!]@+_AJ;^>N!WP<1[V:[@(GZ1@@*V=B:
M QJQ(+NQF>Q>%55=LCKM$H,>]H*V^_P@ES5CCNU;J&@4"TV.IV#2\2%3L&/4
MM5I4-(J%)@=:D/MX[Q3L&$B;CFTU!1NRLEU7S>L%S4)/]Q8-P9KCGY6E$ .K
MDX/G0P%&WF#Q #+R-.PH%C0V/GR60@P];49U&>*U:J(Z!:TL77,+^AO_I#2%
M&%J/5(D_8.0.#OM"1IY&A,>""\=/6++4^0317S7S C0:C%Z((FMV[&+!D&,S
M0\98X(N'"X^N*F$ &T]=CP5L=$]CB'OO^-GQ0!94L18#F^.JIT,3;Y!& QG9
MFM5,V^J_DL?,!TU/,;< UA4/3K=HS-3>")I)]QS%A][;;BPSC]MUT)9WU[).
M_]JJNJ;%5FV>=S*KUTF9)MG#R?LFCWSS4W/73F>,MWW5)(J_[UCNPQG;UK+M
M'? ;)<Q5'OVF U0XB@:G-)G3:[)#4L6'JZ%%&_=M/%AP2K1[[^.QS'SQ"5MG
M#]#2Q#-X#0-@-#C0!QE%NK=.6+UWX%AF,HE[S+[K<4V91@Y7S7-S^)1QTSTW
M1W.V?D<=QW= U*5;-#BEC7IOYK'\@PYWW/?UH,)1-#@EVKU7]EAFOOVDX3XD
MPNJ"#62C'L6G9B#%M=Y+<JR]&74[V"M6U]EF.6?\+1LUWQ<7CJ+!*:'OO=['
M.F3.[\/5T**-NAJ.!J=$N_=R(<NL0IXTAC?0H7$,[[2AD(UFS=5N7P*J?-5_
M7:69P/]N_T%>=YIRD?"^=,-83IJQV_8VKB=+=INQ64UXO^.1*%8/5/Y+4MZQ
MQN8][XK%/=L<Z^0%&L/>Z<UF;OC0'.::/ASFNNQ.BS89INWKUU^2:\;(KT7-
MB/. P(VJ(DOG;35HFG.IU(B%ZZ9>FTLUP+?KLAT/:<X_+5OXEU WF%0+QNII
M4B<7YTO&*W[)LJPB;24W+QC>?MLXW 3N[+5S-!E\_\8^>V=#WSMGEY#]U#E[
M"WU/G;-WT/>\P2Q^!=ZHX&_-U>WV^A/AQL7Y*KEC'WE[<+9%,G;+7;)>-OEQ
M97JWV'ZHBQ7O&T?DIJCK8MG^N6 )YV&- ?_]MN -T'UH+O"M*+^V8;OX/U!+
M P04    " #[=5U8?RAK91($  #Q$0  &@   'AL+W=O<FMS:&5E=',O<VAE
M970Q,3,N>&ULQ5C+;N,V%/T50AT4,T 2O?Q(4MM 8FG0+H(Q'$R[&'1!2]<V
M,1*I(6D[Z=?W4I(56U94NQ70C2V1]QR2YU"7C]%.R.]J#:#)2YIP-;;66F?W
MMJVB-:14W8@,.-8LA4RIQE>YLE4F@<8Y*$ULSW$&=DH9MR:CO&PF)R.QT0GC
M,)-$;=*4RM='2,1N;+G6OF#.5FMM"NS)**,K> ;]-9M)?+,KEIBEP!43G$A8
MCJT']SYT<T >\3N#G3IX)F8H"R&^FY??XK'EF!Y! I$V%!3_MC"%)#%,V(\?
M):E5M6F A\][]L_YX'$P"ZI@*I(_6*S78^O6(C$LZ2;1<['[%<H!]0U?)!*5
M_Y)=&>M8)-HH+=(2C#U(&2_^Z4LIQ $ >9H!7@GPZH#!.P"_!/AU0.\=0*\$
M],X%]$M /G2[&'LN7$ UG8RDV!%IHI'-/.3JYVC4BW$S49ZUQ%J&.#WY(E>4
ML[^H<8TF)%PN6<2 1Z]DEE!./@:@*4O4)W)-OCX'Y..'3^0#89P\L21!B!K9
M&GMAN.RH;/&Q:-%[IT6?/ FNUXJ$/(:X 3]MQ[M>"X&-PZ\T\/8:/'JMC %$
M-\1WKXCG>'Y3A_X;/#@?[C7 P_/A;HL8?C4A_)S/?X=O#DK+3:0WDO$5H3PF
M<TBHAI@\F&^::0:*?'M88!1^Y'\V^5\TT&MNP&2^>Y71",86IC8%<@O6Y.>?
MW('S2Y/V79(%79*%'9$=N=2K7.JUL4^^<+C6F+ )O."2H= 26;JD!:$+M$UP
M3.>:B"5) !-I3*A2H%7N*$LSRN2^/I.X[$C]FE?!CPW+3$V3L46?AGF?S JT
MG7C.R-X>VM7:[4OMZI(L[(CLR*Y^95>_U:[IFLH5$%S7B3A.N/"6<#.3<"5$
M0F):,SGV&9=/_ BOR HX2 PV!M$85P%FOCZSPE;^7Z&-."7H2Y-O1><&A[[U
MO9IQ_5-OZS%!0TPM)#P-<0>W5<R1>(-*O,'_+AY=:I#OR3<XD<^]\VORG1$3
M-,0,:_(-3N5S[YKE&U;R#2](Z/-B;I-O<Y$D!/=:.RKCQBP^[#*+=TD6=$D6
M=D1V9,UM9<UMZ\QNM.:*/,**<6Z*'BE.ZPB:[&EEOM2>VY.96<OK09?-A1V1
M'6E^5VE^UZKY,VPQ':"H9"J4;MR_WIVF2[^>+EL;N71"=TD6=D1V)*[KO!TG
MG%9Y9_35[!Z:SP7.B;#7?GT#T<Y_J;*=LH5=L1UK>W!4<_]-NL!CT#_DBI+W
M>.-6G]'G! 4-034#P_9!7"J2?7"T30'W >9.09%(;+@N3GA5:75O\9"?UFOE
M4W.?D1^9WVB*RY GW%XPKG"?O$1*YV:(>QA9W"\4+UID^0%Z(30>Q_/'-= 8
MI G ^J40>O]B&JAN>29_ U!+ P04    " #[=5U8*U[*6AD$  "C%0  &@
M 'AL+W=O<FMS:&5E=',O<VAE970Q,30N>&ULM9AM;]LV$,>_"J$-0PLLD2D[
MMI/9!FJKPPJLA=>@VXMA+VCI9!.12)6D[ 38AQ])R;+E*)J=LGD12Q3OK[L?
MGTXWV7'Q(#< "CUF*9-3;Z-4?N?[,MI 1N0USX'I)PD7&5'Z5JQ]F0L@L37*
M4C_H]89^1BCS9A/;MA2S"2]42ADL!9)%EA'Q-(>4[Z8>]O8-G^EZHTR#/YOD
M9 WWH+[D2Z'O_%HEIADP23E# I*I]P[?A7AH#&R//RGLY-$U,J&L.'\P-Q_B
MJ=<S'D$*D3(21/]L80%I:I2T'U\K4:]^IS$\OMZK_VJ#U\&LB(0%3_^BL=I,
MO;&'8DA(D:K/?/<;5 '=&+V(I]+^1[NR[^C&0U$A%<\J8^U!1EGY2QXK$$<&
M.M!V@Z R"$X-7GI#OS+HGVLPJ P&EDP9BN40$D5F$\%W2)C>6LU<6)C66H=/
MF1GW>R7T4ZKMU&Q9#>$5^D2$(&80T)L0%*&I?*M;O]R'Z,V/;R>^TB\S)GY4
M"<]+X> %81R@CYRIC43O60QQ4\#77M:N!GM7YT&G8@C1->KCGU'0"_HM#BW.
M-P]:S,/SS7%'-/T:?-_J#5[0^\39U1\%26E"(4;+E+ VQIT:9D^XDSF)8.KI
M12]!;,&;_?0#'O9^:>/C4BQT)-9@-ZC9#:QZ_\6Q2'1+C.; ])6R]%!(991R
M60A ?_^N'Z,/"C+Y3QO5@4NJ+L5"1V(-JC<UU9O.&6DI$BE!R39HI?'(&IO3
M9#OK3?SM,8E.^4M).!)KD!C6)(;=)*I-T1!I9=%I?ND$<BD6.A)K8!O5V$;?
M=5F.7%)U*18Z$FM0'==4QYV3\2,1#Z"N!*1$:;A;DA;$IDP\07DU4?/NI5N^
M8'BT= >]_=_)&N[TY5)LCL0:V&YK;+??LIO=/D>"^^-6)+?/-KX!'@_;NH8M
M7<>#TZZ-<'#OD*CU.@-:Z&Q*T%5AQEXBQ=%7FSWH*7$\"UJ#K92''7MWU>78
M]: UQ&XO7SFH^"A=Q><.*Z)L"]*L"<J0A)SH]!7TAT3$"Z:?ZN4ABY6D,26"
M0CL7?/["Z/;KTI7A2JU),3A0#%Y%,2E8;,@E('3#Z@GI;@4C24)32LH^>B<G
M+ (4\2PG[*D5:_ ,*WZ):J>?%U-UI-:D>LCH<7=*WT@;T+_H_]/[;L%+CSRG
M:J$KM2;,0XJ/OV^.CYTF^4[50E=J3;2'/!]W)_K?<I*\(BU'K4"=?BRX4FL"
M/7PNX.[OA?>/.41F>XS:R=)3M&:O9?"H4*(G-$G1$Q#1BOL5Z7P[;J<?&:[4
M2MS^4?4J [&V54")[#%>5H?JUKK2^,[6UT[:Y_AN4=8+#S)E^5+GT&M]=*$4
M$BW9NS;U/E%6!,L;Q7-;(UMQI7AF+S= 8A"F@WZ><*[V-^8%=5UV]A]02P,$
M%     @ ^W5=6!S3O\>+!   $14  !H   !X;"]W;W)K<VAE971S+W-H965T
M,3$U+GAM;+58;8_:.!#^*U:N.NU*NYLX"6][@+206[4GK8J*>OULB %?DYBS
M'>C]^[.3; *.,131+Y"7F2?SS-@SXQGN*?O.-Q@+\"--,CYR-D)LGUV7+S<X
M1?R);G$FWZPH2Y&0MVSM\BW#*"Z4TL3U/:_KIHADSGA8/)NQ\9#F(B$9GC'
M\S1%[+\)3NA^Y$#G_<$7LMX(]< =#[=HC>=8?-W.F+QS:Y28I#CCA&: X=7(
M>8'/$1PHA4+B;X+W_. :*"H+2K^KFT_QR/&413C!2Z$@D/S;X2E.$H4D[?BW
M G7J;RK%P^MW]->"O"2S0!Q/:?*-Q&(S<OH.B/$*Y8GX0O<?<46HH_"6-.'%
M+]A7LIX#ECD7-*V4I04IR<I_]*-RQ($"[)Y0\"L%7U<(3R@$E4)PJ4)8*82%
M9THJA1\B)-!XR.@>,"4MT=1%X<Q"6](GF8K[7##YED@],9Y5(7P$,T;_D<'
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MX:[\F?1X;ZSXD7Y#S9KC2RU@A;CDY QI3#LFV\+I.DR:I78XM\*RPB\+&-^
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M%Q!= (0-('PO(&H D8E,[8J)0XH53F:"'Y#0UL"F!R:8!@WNTU+G_44)V*6
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M!O<9BRV%UH:1#5!Z#S'4.U'WC/5$\<IT46NNH"<SPQWTV41H ]C?<*Z.$WU
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M^GQN'%^AA/&_I.U]0TJ*O;%*]F",0/*Z6]ESK\,)()J^ HA[0'PI(.D!R:6
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M(@Y+$8?6$?61I9-\F"RUKU<;$:H'Q!=(":I](>*[QY>=ZJ('1D6;"M9Z756
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MQ]G7%:-S)M("^O\+SM7C07J!\D<69O\"4$L#!!0    ( /MU75BF1)LV?P,
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M77KZDU6"9CG?.HUX\8E.%=;4T/K(11I7P;('<9B4W_1[E8A6 '8& D@50-0
M>R# J@*L<P/L*L N,E-**?(04$&7\RP]H2Q'2[;\HDAF$2WEATD^[O<BD[^&
M,DXLW\>'*/W!&/J4K%F2CP&ZC6C"T3MT+Z@X<I1N$4TV:+6GR8YQ%";HCG&1
MA6O!-A*3KK^AZQ/--KR W=_><_0F8(*&$7\K67Y%!N)[FLG0ZDLR_+-/CUS"
M^=P04D3>%6-==?BF[# 9Z# FZ'.:B#U'[Y,-VW0)#*F^3@%Y3L$-&64,V%I'
M%OX=$9-80(=6YX<3(#PX/QR/J+'J ;4*/GN KS<X'S.:B')POB2A %,^2IEO
M/5?\0-=LH<F]A;/LB6G+WW[!COD'E*XIR8*)R#JIM.M4V@6[-9#*,G/&8-;L
M*;,V)5DP$5DG:[,Z:[/1"?CW47 A9UN8[.3R_XLF1_D^01B]D>N^W '>0LDL
M29V"-']9/2WQS)K-C:=VDB 0L;N@   YIEF#.J*<6I0S*JK8X>22>D&$TVO:
M;;5<:NAC/-=1)  8WX<5N+4"=U3!@]P77A;@]AI^Y\Y\10$$PNHH "#/<6 -
M7JW!&]4@W_1;%IXAPP-Z2!05  ;/L*(" ID#(^'7*OP+%HC<_UG\R#+Y#GA)
ME=^?V+:IY'T%@'KK*(! K774D87-QDJ8H_OEU\)DR=&Y?F*9-(WH PTS]$"C
M(T-4E"X!29?"P+>^.>5N.BE;,!5;-Z\MBX9?O:-NTBBB&4<'.8.*J0/.G*H!
MKS7@!/LZ4?=7"&<2W5/G#X##GJ-C,C"%2".5G+W/GBFM)/3;7?9MW5&5 3#B
MJ[  @F%+]X:$-:X,C]NRUO9[IBX+Z(FMNZJN/@S[KNY9JC  Y]FZZ0X(:SP2
M'C43RIY\IC:[KVWFZ.J;? 7A\$PWB2JNC\N38.(!<8V5P9=X&76K/E/LK+^F
M9JYN>:I8  >LT0#"===H5VQC<?"XQ\E+-U# :-C%._.4;,%4;-V4-9X*NS]5
M(>!13W9QZJ9D"Z9BZZ:NL7)XW,N]LDS ?4?F>JK%!D">8ZKK" "9WL B:KP=
M'C=W9Q8*N._ Y&)790 @7_79 ,BR!C8^TE@Y,FIISJP6*I*./28S=31 E*,Z
M;1!E#A0,I/%.9-P[G5TR5#R=]AU+E0* ,%;?M1#*M0:4--:(C%NC5Y<-%6^[
M.XZG^B, U%M7 0!JKZNNL,8:$>O_*QO(I']=3<H63,76S6OCS,BX,_OYLJ%J
MH&M)B.ZHU@7 %?[+5></A#/;?JXKM?%I9-RG75XV5(3=LL'J53HK"&>9NN.K
MT@"<+!P&_BH@C2DCXZ;LXKJAXNMZ8:R[O3$#<)[5*XA .FG5AX0UUHF,_Q_U
MFKJAHNP.AJOWQ@R F:[NJDX:P.73UAHP :3Q-N02;_.ZLJ%JHK/V[/:$JK0"
M,&")!@!.6:*E5J-UE!2S;%<<R7&T3H^)*(]4ZJ?UL=]U<=BE/+_!5T%Y>-?0
ME&>)GVFV"Q..(K:5E*8<%PUEY?%<>2/20W%@]9@*D<;%Y9[1#<MR@/Q]FZ;B
M^29OH#XD7?X'4$L#!!0    ( /MU75A&7L35>0,  +H,   :    >&PO=V]R
M:W-H965T<R]S:&5E=#$R.2YX;6S%5]MNVS@0_15"+8H$:"-+\B5);0.)U;0!
M-H 1-^E#T0=:&EM$)%(E*;OY^QU2LM87V<@" OIBD=2<XYE#SG T7 OYHA(
M3?YD*5<C)]$ZOW9=%260474A<N#X9B%D1C5.Y=)5N00:6U"6NGZGTW<SRK@S
M'MJUJ1P/1:%3QF$JB2JRC,K76TC%>N1XSF;AD2T3;1;<\3"G2YB!?LJG$F=N
MS1*S#+AB@A,)BY%SXUV'5\;>&CPS6*NM,3&1S(5X,9/[>.1TC$.00J0- \7'
M"B:0IH8(W?A=<3KU7QK@]GC#?F=CQUCF5,%$I#]8K).1<^F0&!:T2/6C6'^#
M*IZ>X8M$JNPO65>V'8=$A=(BJ\#H0<9X^:1_*AVV %[_","O /X^H'L$$%2
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M4Y^0Z7$>D?.S3^2,Y)S<Y8RA@1JZ&OTW7KAQ[>ND\M4_XFO')W>"ZTR1&YY
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M%T)C [;+#&<J2&. WU,A]'9C+FBF=/@/4$L#!!0    ( /MU75C0;P= \00
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MA 6G";JCZFY53XRL7(>828/]Q@V7V.!!V0#<GTMI7B>VZ;1_&=D_4$L#!!0
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ME2#C8,PR8?ZB?87U'!1OA61Y9:P\R-.B_*6O52".#'#884 J ](V"#H,_,K
M;QOX'09!91!\=(=^9=#_Z YA91":V)?!,I&>4DG'0\[VB&NT8M,7YKB,M0IP
M6NC,6DBNGJ;*3H[OBYCE@)[H*PATA28LW[ ""BD06Z+&PXLI2)IFXE+!GA=3
M=/'M$GU#:8$>TBQ322*&KE0.:5HWKC:_*S<G'9MC@AY8(=<"S8H$DB:!JY34
M<LA!SATYRSB%N(=\_ LB'O$M#DT^;DXLYK./F^,S:OSZ<'S#YW?P3;:<J[-
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M9A^BJSO;^5M??]=@0U(S]O;%PZ .M?A>XD'EG#(!$K)087O]L5JML^(3A.)
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M(#23@BA8CH.;^'H6.P.'^)/!1F\]$RME(>5W^_(E'P>171%PR(REH/CW"+?
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MT%HDZ>&&DB651@#W5T+H]Q/S \5WF/%_4$L#!!0    ( /MU75AK2KY=T1$
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M1)OH29L(U>9[]7 OJWO9=D,;+JN5TL9[MJ[;]FM(()3-5: 'LGC\E5@<&_)
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M6T[*)JC8IO'C.GX<;0?/'NZEK[U^;.@57=>4'^^ZXN-#Y"H51.4QFUJ97.6
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MI>%F,F:)]CX)[GV^/'F $SNK!"RM;:ID0ZR7N #,:%I]N@R\=A\IGF#9+V^
MD[OJE"ZO$@= S!X4@LPTI52/_M.%HJ^EI$%*.MPG9<M)V005VS02VFFD"PM:
MNR<-<$;GV  %6>:4#X"!UE&ENK"IE-JBI+A%V2MM@',[B[KL0I8A H5,1=(N
M)%UXX84J;8"?QUFPY3S+,D2@D*E@VJ&DN$/9*VF <SN+M/QNRS)$H)"I2-JL
MI$NE8 Y) YS+611*MIR43:0[YV=2[7U2/#^S?]( /X&S_G9BQ)IB #"1;V8,
M(**YPN!TM#$0;C7.Z^:V5F+(X>:]6)>;LD*DH=TCB+1ZC)1-4+%-PZ*]3'K(
M-=-24C]#RI:3L@DJMNG^4=I.9<OU:BY9 IS.-3 9L'":.3T'8,SZ9P!R/).(
MS+2#RO#\R7*& "=PUL+.<QQGF96<A6!Q9JXV)T!8F,S8[TR[F6SY+97#9 GP
M$SNK:1L:<R2U#!$H9*J@-C$9;F)VRA+@',YB !OI0$T+@$%-"X+--RUM7#+<
MN+AO9D=J4#(@2V)M9@>\HF*U&1LS,YN3:8N2+5D4EU0!3N:LB^TFCEF66=)
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MUL ]DW2WO6-SU%N>DP__.J8<D_SJ'NZ57IN*Y3@,Z!D:(L4@^_BA?Q5].V;
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MK0 A+*^T>'J'ABYE"P)+]02Q:TF$JCQTABTE%P+%B"UW9;TS0QLK>"?%/[/
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MLT6TE.S5+D_S7$INI:_WL72]N%M%DKE.GAZS0=,T2N,L_-)-_O7K:',O&5F
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MO1C%B>3;_$7].RXEC_/##:,!$UD&=?V><_ETDA50[8A9_@]02P,$%     @
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MID\LF:!9W,J&S-(G-LN.B9 U9XB)S-(G-@N<;HAJX0"994!OEMW3#3$F,LN
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M4K-#[*/=H.X4^R("A6<U.\1& G74O1*!PJ.;'6(G[08]35,57WIXKK-#;"4
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M#\/^'X\_?2Z[NNE?YD?'3=W-3U!+ 0(4 Q0    ( /MU75@'04UB@0   +$
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ ^W5=6#Y6H&GP    *P(  !$              ( !KP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ ^W5=6)E<G",0!@  G"<  !,
M     ( !S@$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #[=5U8
MGG<"BJ<'   V,   &               @($/"   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ ^W5=6'5>' (^ @  PP4  !@
M     ("![ \  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (
M /MU75B11;!\C0@  "<G   8              " @6 2  !X;"]W;W)K<VAE
M971S+W-H965T,RYX;6Q02P$"% ,4    " #[=5U8C T!_!\&  "&&   &
M            @($C&P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#
M%     @ ^W5=6!V(H+Q@"0  (2D  !@              ("!>"$  'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( /MU75B5$(%ZH@(  -T'
M   8              " @0XK  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q0
M2P$"% ,4    " #[=5U8,86:;M41  #B# $ &               @('F+0
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ ^W5=6%4_BC>@
M P  N!$  !@              ("!\3\  'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;%!+ 0(4 Q0    ( /MU75B*RJ[*90T  #9,   8              "
M@<=#  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #[=5U8
MV1?G4B((  "F$P  &0              @(%B40  >&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;%!+ 0(4 Q0    ( /MU75B?,+,G2B,  "=W   9
M      " @;M9  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%
M  @ ^W5=6(H.F[[7"   ?1D  !D              ("!/'T  'AL+W=O<FMS
M:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " #[=5U8O^GBI]T#  "]"
M&0              @(%*A@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+
M 0(4 Q0    ( /MU75C2BE/NY04  "$-   9              " @5Z*  !X
M;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ ^W5=6!C99=,:
M!@  +@X  !D              ("!>I   'AL+W=O<FMS:&5E=',O<VAE970Q
M-2YX;6Q02P$"% ,4    " #[=5U88 \9&( $  "<"@  &0
M@('+E@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( /MU
M75@,+E%JV@P  ,DC   9              " @8*;  !X;"]W;W)K<VAE971S
M+W-H965T,3<N>&UL4$L! A0#%     @ ^W5=6":95.!P"   BA8  !D
M         ("!DZ@  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
M    " #[=5U89/(\G00>  "=80  &0              @($ZL0  >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( /MU75AC+AS@>@P  %(B
M   9              " @77/  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL
M4$L! A0#%     @ ^W5=6$Z?TAHZ'@  =&(  !D              ("!)MP
M 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #[=5U8L_%'
MY+X9  !"5   &0              @(&7^@  >&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;%!+ 0(4 Q0    ( /MU75B#A3?"0P<  *(3   9
M  " @8P4 0!X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @
M^W5=6-KX6/Z^!0  3 X  !D              ("!!AP! 'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6Q02P$"% ,4    " #[=5U847E8\EH(   !'   &0
M            @('[(0$ >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4
M Q0    ( /MU75BYE(.1  0  ,X(   9              " @8PJ 0!X;"]W
M;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ ^W5=6*L<?!:W#@
M52<  !D              ("!PRX! 'AL+W=O<FMS:&5E=',O<VAE970R-RYX
M;6Q02P$"% ,4    " #[=5U847IU]3@-  #X)@  &0              @(&Q
M/0$ >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( /MU75BX
M *O0'0P  +\A   9              " @2!+ 0!X;"]W;W)K<VAE971S+W-H
M965T,CDN>&UL4$L! A0#%     @ ^W5=6'"=,NWI!P  ]R,  !D
M     ("!=%<! 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /MU75C-YO+WJA(  &PT   9              "
M@2J0 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ ^W5=
M6)8'2QV%!   80L  !D              ("!"Z,! 'AL+W=O<FMS:&5E=',O
M<VAE970S-BYX;6Q02P$"% ,4    " #[=5U89#JB:T,"  "*!@  &0
M        @(''IP$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0
M   ( /MU75@WE&TXN%\  $*D 0 9              " @4&J 0!X;"]W;W)K
M<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ ^W5=6$,G$Q+]!0  G@\
M !D              ("!, H" 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q0
M2P$"% ,4    " #[=5U80M9C]#D/   U+0  &0              @(%D$ (
M>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( /MU75B$\FD[
MRP(  $\&   9              " @=0? @!X;"]W;W)K<VAE971S+W-H965T
M-#$N>&UL4$L! A0#%     @ ^W5=6&;-<D'W @  J@8  !D
M ("!UB(" 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " #[
M=5U8^L08OC$$   5"@  &0              @($$)@( >&PO=V]R:W-H965T
M<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( /MU75B%?R%K60<  / 3   9
M          " @6PJ @!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#
M%     @ ^W5=6,10&^8C!   Q@D  !D              ("!_#$" 'AL+W=O
M<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " #[=5U8-E@J-",/   @
M+P  &0              @(%6-@( >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM
M;%!+ 0(4 Q0    ( /MU75@U5,MK@@D  +,9   9              " @;!%
M @!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ ^W5=6.H*
M[5Y$#0  W28  !D              ("!:4\" 'AL+W=O<FMS:&5E=',O<VAE
M970T."YX;6Q02P$"% ,4    " #[=5U81.!.(F@*  #+'P  &0
M    @('D7 ( >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (
M /MU75AO4II9T0,  "4(   9              " @8-G @!X;"]W;W)K<VAE
M971S+W-H965T-3 N>&UL4$L! A0#%     @ ^W5=6/,XY.-'!P  K1<  !D
M             ("!BVL" 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"
M% ,4    " #[=5U8OMO^A[0"  #;!0  &0              @($)<P( >&PO
M=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( /MU75@0E#R%I0<
M (P4   9              " @?1U @!X;"]W;W)K<VAE971S+W-H965T-3,N
M>&UL4$L! A0#%     @ ^W5=6!,5P",8"   *QD  !D              ("!
MT'T" 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " #[=5U8
M9A 4.EH&  !M%0  &0              @($?A@( >&PO=V]R:W-H965T<R]S
M:&5E=#4U+GAM;%!+ 0(4 Q0    ( /MU75A)=V4H5 4  &<0   9
M      " @;", @!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%
M  @ ^W5=6),VXX"4 P  K@<  !D              ("!.Y(" 'AL+W=O<FMS
M:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " #[=5U8Z\C#YN\&  "L$@
M&0              @($&E@( >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+
M 0(4 Q0    ( /MU75BQLGT^[PL  &HD   9              " @2R= @!X
M;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ ^W5=6)^K7+CR
M P  N0@  !D              ("!4JD" 'AL+W=O<FMS:&5E=',O<VAE970V
M,"YX;6Q02P$"% ,4    " #[=5U8)"]C?@H#  #Z!P  &0
M@(%[K0( >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( /MU
M75@V925QZ 4  $$@   9              " @;RP @!X;"]W;W)K<VAE971S
M+W-H965T-C(N>&UL4$L! A0#%     @ ^W5=6";6ZG^.!   ?1(  !D
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M=#8W+GAM;%!+ 0(4 Q0    ( /MU75B_-LT'H00  %X0   9
M  " @4'/ @!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @
M^W5=6(DUA*30 @  :@@  !D              ("!&=0" 'AL+W=O<FMS:&5E
M=',O<VAE970V.2YX;6Q02P$"% ,4    " #[=5U8B\\2W?("  "'"@  &0
M            @($@UP( >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4
M Q0    ( /MU75@60@Y7G1(  'C*   9              " @4G: @!X;"]W
M;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @ ^W5=6-JZ):>S!@
M030  !D              ("!'>T" 'AL+W=O<FMS:&5E=',O<VAE970W,BYX
M;6Q02P$"% ,4    " #[=5U8K>;(=P8+  !1;   &0              @($'
M] ( >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    ( /MU75CI
M)/092 (  "L&   9              " @43_ @!X;"]W;W)K<VAE971S+W-H
M965T-S0N>&UL4$L! A0#%     @ ^W5=6,KBVE-V @  H@8  !D
M     ("!PP$# 'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6Q02P$"% ,4
M" #[=5U827HS-XL$   C$P  &0              @(%P! , >&PO=V]R:W-H
M965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    ( /MU75CVKYH+CP<  %U)   9
M              " @3() P!X;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L!
M A0#%     @ ^W5=6 #BEGXP!@  FCT  !D              ("!^! # 'AL
M+W=O<FMS:&5E=',O<VAE970W."YX;6Q02P$"% ,4    " #[=5U857N&QMP*
M  #T9   &0              @(%?%P, >&PO=V]R:W-H965T<R]S:&5E=#<Y
M+GAM;%!+ 0(4 Q0    ( /MU75CA*@T?]@4  'X>   9              "
M@7(B P!X;"]W;W)K<VAE971S+W-H965T.# N>&UL4$L! A0#%     @ ^W5=
M6(XU51;P P  <1(  !D              ("!GR@# 'AL+W=O<FMS:&5E=',O
M<VAE970X,2YX;6Q02P$"% ,4    " #[=5U8E1N((_X$  #(%P  &0
M        @('&+ , >&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4 Q0
M   ( /MU75A.1)CP(P,  !P,   9              " @?LQ P!X;"]W;W)K
M<VAE971S+W-H965T.#,N>&UL4$L! A0#%     @ ^W5=6"2-#\HC"0  >#T
M !D              ("!534# 'AL+W=O<FMS:&5E=',O<VAE970X-"YX;6Q0
M2P$"% ,4    " #[=5U8CXK3)Y0&  #R-   &0              @(&O/@,
M>&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+ 0(4 Q0    ( /MU75B=S+W/
M'00  (D.   9              " @7I% P!X;"]W;W)K<VAE971S+W-H965T
M.#8N>&UL4$L! A0#%     @ ^W5=6/T:TUA( P  R @  !D
M ("!SDD# 'AL+W=O<FMS:&5E=',O<VAE970X-RYX;6Q02P$"% ,4    " #[
M=5U8;.-:!R4/   SN   &0              @(%-30, >&PO=V]R:W-H965T
M<R]S:&5E=#@X+GAM;%!+ 0(4 Q0    ( /MU75@QPYVC!04  -\7   9
M          " @:E< P!X;"]W;W)K<VAE971S+W-H965T.#DN>&UL4$L! A0#
M%     @ ^W5=6)^ !ZCB!0  TB@  !D              ("!Y6$# 'AL+W=O
M<FMS:&5E=',O<VAE970Y,"YX;6Q02P$"% ,4    " #[=5U8".K,"7P(  !J
M2   &0              @('^9P, >&PO=V]R:W-H965T<R]S:&5E=#DQ+GAM
M;%!+ 0(4 Q0    ( /MU75@ @8<1-P,   H,   9              " @;%P
M P!X;"]W;W)K<VAE971S+W-H965T.3(N>&UL4$L! A0#%     @ ^W5=6,*A
M8#V6 P  I T  !D              ("!'W0# 'AL+W=O<FMS:&5E=',O<VAE
M970Y,RYX;6Q02P$"% ,4    " #[=5U8',=]:^ '  #X00  &0
M    @('L=P, >&PO=V]R:W-H965T<R]S:&5E=#DT+GAM;%!+ 0(4 Q0    (
M /MU75C9M&=9"@8  )$L   9              " @0.  P!X;"]W;W)K<VAE
M971S+W-H965T.34N>&UL4$L! A0#%     @ ^W5=6+R;]'C_!   =18  !D
M             ("!1(8# 'AL+W=O<FMS:&5E=',O<VAE970Y-BYX;6Q02P$"
M% ,4    " #[=5U85LV9#T,%  #W(P  &0              @(%ZBP, >&PO
M=V]R:W-H965T<R]S:&5E=#DW+GAM;%!+ 0(4 Q0    ( /MU75BDR3BAB 0
M *X:   9              " @?20 P!X;"]W;W)K<VAE971S+W-H965T.3@N
M>&UL4$L! A0#%     @ ^W5=6+D)3OCM @  A0L  !D              ("!
MLY4# 'AL+W=O<FMS:&5E=',O<VAE970Y.2YX;6Q02P$"% ,4    " #[=5U8
M7,X0Y4H%  "/'@  &@              @('7F , >&PO=V]R:W-H965T<R]S
M:&5E=#$P,"YX;6Q02P$"% ,4    " #[=5U826HTP[L#   1"P  &@
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M:&5E=#$P-2YX;6Q02P$"% ,4    " #[=5U8YW$9(I0%  #"'   &@
M        @(&ZO@, >&PO=V]R:W-H965T<R]S:&5E=#$P-BYX;6Q02P$"% ,4
M    " #[=5U8VR8VL$H%  "V)@  &@              @(&&Q , >&PO=V]R
M:W-H965T<R]S:&5E=#$P-RYX;6Q02P$"% ,4    " #[=5U8UP1S0=X"  #+
M!P  &@              @($(R@, >&PO=V]R:W-H965T<R]S:&5E=#$P."YX
M;6Q02P$"% ,4    " #[=5U8A5D'>*D#  !Y#P  &@              @($>
MS0, >&PO=V]R:W-H965T<R]S:&5E=#$P.2YX;6Q02P$"% ,4    " #[=5U8
M9G\V9;\$  #&'0  &@              @('_T , >&PO=V]R:W-H965T<R]S
M:&5E=#$Q,"YX;6Q02P$"% ,4    " #[=5U8L=&,M_<%  !3(   &@
M        @('VU0, >&PO=V]R:W-H965T<R]S:&5E=#$Q,2YX;6Q02P$"% ,4
M    " #[=5U8TX! >[$/  #U@@  &@              @($EW , >&PO=V]R
M:W-H965T<R]S:&5E=#$Q,BYX;6Q02P$"% ,4    " #[=5U8?RAK91($  #Q
M$0  &@              @($.[ , >&PO=V]R:W-H965T<R]S:&5E=#$Q,RYX
M;6Q02P$"% ,4    " #[=5U8*U[*6AD$  "C%0  &@              @(%8
M\ , >&PO=V]R:W-H965T<R]S:&5E=#$Q-"YX;6Q02P$"% ,4    " #[=5U8
M'-._QXL$   1%0  &@              @(&I] , >&PO=V]R:W-H965T<R]S
M:&5E=#$Q-2YX;6Q02P$"% ,4    " #[=5U8C*\Y.&L"  !?!@  &@
M        @(%L^0, >&PO=V]R:W-H965T<R]S:&5E=#$Q-BYX;6Q02P$"% ,4
M    " #[=5U8(KF"QZ4"  "W!@  &@              @($/_ , >&PO=V]R
M:W-H965T<R]S:&5E=#$Q-RYX;6Q02P$"% ,4    " #[=5U8F:F==W$#  #%
M"P  &@              @('L_@, >&PO=V]R:W-H965T<R]S:&5E=#$Q."YX
M;6Q02P$"% ,4    " #[=5U8ZC4GM*4"  #\!P  &@              @(&5
M @0 >&PO=V]R:W-H965T<R]S:&5E=#$Q.2YX;6Q02P$"% ,4    " #[=5U8
MUW8OG\4&  #N.0  &@              @(%R!00 >&PO=V]R:W-H965T<R]S
M:&5E=#$R,"YX;6Q02P$"% ,4    " #[=5U8-,18OG8"  "+!@  &@
M        @(%O# 0 >&PO=V]R:W-H965T<R]S:&5E=#$R,2YX;6Q02P$"% ,4
M    " #[=5U8U$_H&F8"   ^!@  &@              @($=#P0 >&PO=V]R
M:W-H965T<R]S:&5E=#$R,BYX;6Q02P$"% ,4    " #[=5U8D+@#\8\'  !P
M00  &@              @(&[$00 >&PO=V]R:W-H965T<R]S:&5E=#$R,RYX
M;6Q02P$"% ,4    " #[=5U8ID2;-G\#  "G"@  &@              @(&"
M&00 >&PO=V]R:W-H965T<R]S:&5E=#$R-"YX;6Q02P$"% ,4    " #[=5U8
M721N;V4$  "F$0  &@              @($Y'00 >&PO=V]R:W-H965T<R]S
M:&5E=#$R-2YX;6Q02P$"% ,4    " #[=5U8E8O=-PL#  "U"   &@
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M:&5E=#$S,"YX;6Q02P$"% ,4    " #[=5U8T&\'0/$$  #O(@  &@
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M:&5E=#$S-2YX;6Q02P$"% ,4    " #[=5U83 1J4H0"   ^!@  &@
M        @(%;5 0 >&PO=V]R:W-H965T<R]S:&5E=#$S-BYX;6Q02P$"% ,4
M    " #[=5U8(U-=1HH"   ?"   &@              @($75P0 >&PO=V]R
M:W-H965T<R]S:&5E=#$S-RYX;6Q02P$"% ,4    " #[=5U86B 1TT4#  "7
M"P  &@              @('9600 >&PO=V]R:W-H965T<R]S:&5E=#$S."YX
M;6Q02P$"% ,4    " #[=5U8-[I;NE@#  !Q"P  &@              @(%6
M700 >&PO=V]R:W-H965T<R]S:&5E=#$S.2YX;6Q02P$"% ,4    " #[=5U8
MB4IF6A $  !N$@  &@              @('F8 0 >&PO=V]R:W-H965T<R]S
M:&5E=#$T,"YX;6Q02P$"% ,4    " #[=5U8,52"ZHX#  !?$@  &@
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M:&5E=#$T-2YX;6Q02P$"% ,4    " #[=5U8K_>IVXL#  !Q#0  &@
M        @(%&>P0 >&PO=V]R:W-H965T<R]S:&5E=#$T-BYX;6Q02P$"% ,4
M    " #[=5U8]HF3_2H'  #3+0  &@              @($)?P0 >&PO=V]R
M:W-H965T<R]S:&5E=#$T-RYX;6Q02P$"% ,4    " #[=5U8C_F<7@,$  "$
M#0  &@              @(%KA@0 >&PO=V]R:W-H965T<R]S:&5E=#$T."YX
M;6Q02P$"% ,4    " #[=5U8\FV6/80&   G-0  &@              @(&F
MB@0 >&PO=V]R:W-H965T<R]S:&5E=#$T.2YX;6Q02P$"% ,4    " #[=5U8
M$ 6JUST%  "3&0  &@              @(%BD00 >&PO=V]R:W-H965T<R]S
M:&5E=#$U,"YX;6Q02P$"% ,4    " #[=5U8:TJ^7=$1  "8I@  &@
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M:&5E=#$U-2YX;6Q02P$"% ,4    " #[=5U8([,2S3 *   V1   &@
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M:&5E=#$V,"YX;6Q02P$"% ,4    " #[=5U8BG>FTT@$   A$0  &@
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M<F5L<R\N<F5L<U!+ 0(4 Q0    ( /MU75A;:;X:-@L  *QK   /
M      "  0X7!0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #[=5U8J1"*
MME,$   '8   &@              @ %Q(@4 >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " #[=5U87)CO5B #  !#6P  $P
M    @ '\)@4 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     K "L *PO  !-
%*@4    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>191
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>192
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>194
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>889</ContextCount>
  <ElementCount>949</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>264</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome</Role>
      <ShortName>Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Changes in Total Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity</Role>
      <ShortName>Consolidated Statements of Changes in Total Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Statements of Changes in Total Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Changes in Total Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Accounts Receivable, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/AccountsReceivableNet</Role>
      <ShortName>Accounts Receivable, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Supplier Finance Program</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/SupplierFinanceProgram</Role>
      <ShortName>Supplier Finance Program</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Mergers, Acquisitions and Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/MergersAcquisitionsandDivestitures</Role>
      <ShortName>Mergers, Acquisitions and Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Assets and Liabilities of Businesses Held for Sale</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSale</Role>
      <ShortName>Assets and Liabilities of Businesses Held for Sale</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Common and Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/CommonandPreferredStock</Role>
      <ShortName>Common and Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Insurance and Contractholder Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InsuranceandContractholderLiabilities</Role>
      <ShortName>Insurance and Contractholder Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Reinsurance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/Reinsurance</Role>
      <ShortName>Reinsurance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/VariableInterestEntities</Role>
      <ShortName>Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Collectively Significant Operating Unconsolidated Subsidiaries</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiaries</Role>
      <ShortName>Collectively Significant Operating Unconsolidated Subsidiaries</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Accumulated Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLoss</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Organizational Efficiency Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/OrganizationalEfficiencyPlan</Role>
      <ShortName>Organizational Efficiency Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Pension</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/Pension</Role>
      <ShortName>Pension</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Employee Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/EmployeeIncentivePlans</Role>
      <ShortName>Employee Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Goodwill, Other Intangibles and Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipment</Role>
      <ShortName>Goodwill, Other Intangibles and Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Shareholders Equity and Dividend Restrictions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ShareholdersEquityandDividendRestrictions</Role>
      <ShortName>Shareholders Equity and Dividend Restrictions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Contingencies and Other Matters</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ContingenciesandOtherMatters</Role>
      <ShortName>Contingencies and Other Matters</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Schedule I - Condensed Financial Information of The Cigna Group</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroup</Role>
      <ShortName>Schedule I - Condensed Financial Information of The Cigna Group</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Schedule II - Valuation and Qualifying Accounts and Reserves</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ScheduleIIValuationandQualifyingAccountsandReserves</Role>
      <ShortName>Schedule II - Valuation and Qualifying Accounts and Reserves</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Receivables, Loans, Notes Receivable, and Others (Policies)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.thecignagroup.com/role/ReceivablesLoansNotesReceivableandOthersPolicies</Role>
      <ShortName>Receivables, Loans, Notes Receivable, and Others (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Investments, Debt and Equity Securities (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InvestmentsDebtandEquitySecuritiesPolicies</Role>
      <ShortName>Investments, Debt and Equity Securities (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Accounts Receivable, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/AccountsReceivableNetTables</Role>
      <ShortName>Accounts Receivable, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/AccountsReceivableNet</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Assets and Liabilities of Businesses Held for Sale (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleTables</Role>
      <ShortName>Assets and Liabilities of Businesses Held for Sale (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSale</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/EarningsPerShare</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/Debt</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Common and Preferred Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/CommonandPreferredStockTables</Role>
      <ShortName>Common and Preferred Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/CommonandPreferredStock</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Insurance and Contractholder Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesTables</Role>
      <ShortName>Insurance and Contractholder Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/InsuranceandContractholderLiabilities</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Reinsurance (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ReinsuranceTables</Role>
      <ShortName>Reinsurance (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/Reinsurance</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/Investments</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/FairValueMeasurements</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Collectively Significant Operating Unconsolidated Subsidiaries (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiariesTables</Role>
      <ShortName>Collectively Significant Operating Unconsolidated Subsidiaries (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiaries</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLoss</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Organizational Efficiency Plan (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/OrganizationalEfficiencyPlanTables</Role>
      <ShortName>Organizational Efficiency Plan (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/OrganizationalEfficiencyPlan</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Pension (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/PensionTables</Role>
      <ShortName>Pension (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/Pension</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Employee Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/EmployeeIncentivePlansTables</Role>
      <ShortName>Employee Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/EmployeeIncentivePlans</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Goodwill, Other Intangibles and Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentTables</Role>
      <ShortName>Goodwill, Other Intangibles and Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipment</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/Leases</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Shareholders Equity and Dividend Restrictions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ShareholdersEquityandDividendRestrictionsTables</Role>
      <ShortName>Shareholders Equity and Dividend Restrictions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/ShareholdersEquityandDividendRestrictions</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/IncomeTaxes</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/SegmentInformation</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - SEC Schedule, Article 12-04, Condensed Financial Information of Registrant (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/SECScheduleArticle1204CondensedFinancialInformationofRegistrantTables</Role>
      <ShortName>SEC Schedule, Article 12-04, Condensed Financial Information of Registrant (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/DescriptionofBusinessDetails</Role>
      <ShortName>Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/DescriptionofBusiness</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Accounts Receivable, Net - Amounts Included in Accounts Receivable, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails</Role>
      <ShortName>Accounts Receivable, Net - Amounts Included in Accounts Receivable, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Accounts Receivable, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/AccountsReceivableNetNarrativeDetails</Role>
      <ShortName>Accounts Receivable, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Supplier Finance Program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/SupplierFinanceProgramDetails</Role>
      <ShortName>Supplier Finance Program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/SupplierFinanceProgram</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Mergers, Acquisitions and Divestitures - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/MergersAcquisitionsandDivestituresNarrativeDetails</Role>
      <ShortName>Mergers, Acquisitions and Divestitures - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Assets and Liabilities of Businesses Held for Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails</Role>
      <ShortName>Assets and Liabilities of Businesses Held for Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Earnings Per Share - Outstanding Employee Stock Options Not Included in the Computation of Diluted Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/EarningsPerShareOutstandingEmployeeStockOptionsNotIncludedintheComputationofDilutedEarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share - Outstanding Employee Stock Options Not Included in the Computation of Diluted Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Earnings Per Share - Shares of Common Stock Held in Treasury (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/EarningsPerShareSharesofCommonStockHeldinTreasuryDetails</Role>
      <ShortName>Earnings Per Share - Shares of Common Stock Held in Treasury (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Debt - Outstanding Amounts of Debt and Finance Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails</Role>
      <ShortName>Debt - Outstanding Amounts of Debt and Finance Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Debt - Short-term and Credit Facilities Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/DebtShorttermandCreditFacilitiesDebtDetails</Role>
      <ShortName>Debt - Short-term and Credit Facilities Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Debt - Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/DebtLongtermDebtDetails</Role>
      <ShortName>Debt - Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Debt - Debt Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/DebtDebtMaturitiesDetails</Role>
      <ShortName>Debt - Debt Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Debt - Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/DebtInterestExpenseDetails</Role>
      <ShortName>Debt - Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Common and Preferred Stock - Share Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/CommonandPreferredStockShareActivityDetails</Role>
      <ShortName>Common and Preferred Stock - Share Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Common and Preferred Stock - Dividends (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/CommonandPreferredStockDividendsDetails</Role>
      <ShortName>Common and Preferred Stock - Dividends (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - Common and Preferred Stock - Accelerated Share Repurchase Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/CommonandPreferredStockAcceleratedShareRepurchaseAgreementsDetails</Role>
      <ShortName>Common and Preferred Stock - Accelerated Share Repurchase Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - Insurance and Contractholder Liabilities - Account Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails</Role>
      <ShortName>Insurance and Contractholder Liabilities - Account Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - Insurance and Contractholder Liabilities - Unpaid Claims and Claim Expenses - Cigna Healthcare - Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails</Role>
      <ShortName>Insurance and Contractholder Liabilities - Unpaid Claims and Claim Expenses - Cigna Healthcare - Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - Insurance and Contractholder Liabilities - Unpaid Claims and Claims Expenses - Cigna Healthcare - Variances in Incurred Costs Related to Prior Years' Unpaid Claims and Claims Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails</Role>
      <ShortName>Insurance and Contractholder Liabilities - Unpaid Claims and Claims Expenses - Cigna Healthcare - Variances in Incurred Costs Related to Prior Years' Unpaid Claims and Claims Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - Insurance and Contractholder Liabilities - Unpaid Claims and Claims Expenses - Cigna Healthcare - Incurred and Paid Claims Development and Unpaid Claims Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails</Role>
      <ShortName>Insurance and Contractholder Liabilities - Unpaid Claims and Claims Expenses - Cigna Healthcare - Incurred and Paid Claims Development and Unpaid Claims Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9954516 - Disclosure - Insurance and Contractholder Liabilities - Future Policy Benefits - Interest Rates and Duration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsInterestRatesandDurationDetails</Role>
      <ShortName>Insurance and Contractholder Liabilities - Future Policy Benefits - Interest Rates and Duration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9954517 - Disclosure - Insurance and Contractholder Liabilities - Future Policy Benefits - Present Value of Expected Premiums and Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails</Role>
      <ShortName>Insurance and Contractholder Liabilities - Future Policy Benefits - Present Value of Expected Premiums and Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9954518 - Disclosure - Insurance and Contractholder Liabilities - Contractholder Deposit Funds (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails</Role>
      <ShortName>Insurance and Contractholder Liabilities - Contractholder Deposit Funds (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9954519 - Disclosure - Insurance and Contractholder Liabilities - Summary of Market Risk Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesSummaryofMarketRiskBenefitDetails</Role>
      <ShortName>Insurance and Contractholder Liabilities - Summary of Market Risk Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9954520 - Disclosure - Insurance and Contractholder Liabilities - Net Amount of Risk and Average Age of Contractholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails</Role>
      <ShortName>Insurance and Contractholder Liabilities - Net Amount of Risk and Average Age of Contractholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>9954521 - Disclosure - Reinsurance - Reinsurance Recoverables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails</Role>
      <ShortName>Reinsurance - Reinsurance Recoverables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>9954522 - Disclosure - Reinsurance - Effects of Reinsurance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ReinsuranceEffectsofReinsuranceDetails</Role>
      <ShortName>Reinsurance - Effects of Reinsurance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>9954523 - Disclosure - Reinsurance - Effective Exit of Variable Annuity Reinsurance Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails</Role>
      <ShortName>Reinsurance - Effective Exit of Variable Annuity Reinsurance Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>9954524 - Disclosure - Investments - Investments by Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails</Role>
      <ShortName>Investments - Investments by Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>9954525 - Disclosure - Investments - Debt Securities by Contractual Maturity Periods (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails</Role>
      <ShortName>Investments - Debt Securities by Contractual Maturity Periods (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>9954526 - Disclosure - Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InvestmentsNarrativeDetails</Role>
      <ShortName>Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>9954527 - Disclosure - Investments - Gross Unrealized Appreciation (Depreciation) on Debt Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesDetails</Role>
      <ShortName>Investments - Gross Unrealized Appreciation (Depreciation) on Debt Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>9954528 - Disclosure - Investments - Debt Securities with a Decline in Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails</Role>
      <ShortName>Investments - Debt Securities with a Decline in Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>9954529 - Disclosure - Investments - Equity Security Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails</Role>
      <ShortName>Investments - Equity Security Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>9954530 - Disclosure - Investments - Commercial Mortgage Loan Portfolio (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoanPortfolioDetails</Role>
      <ShortName>Investments - Commercial Mortgage Loan Portfolio (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>9954531 - Disclosure - Investments - Other Long-Term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails</Role>
      <ShortName>Investments - Other Long-Term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>9954532 - Disclosure - Investments - Summary of Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InvestmentsSummaryofDerivativeInstrumentsDetails</Role>
      <ShortName>Investments - Summary of Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>9954533 - Disclosure - Investments - Components of Net Investment Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeDetails</Role>
      <ShortName>Investments - Components of Net Investment Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>9954534 - Disclosure - Investments - Realized Gains and Losses on Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/InvestmentsRealizedGainsandLossesonInvestmentsDetails</Role>
      <ShortName>Investments - Realized Gains and Losses on Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>9954536 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>9954537 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>9954538 - Disclosure - Fair Value Measurements - Quantitative Information About Unobservable Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails</Role>
      <ShortName>Fair Value Measurements - Quantitative Information About Unobservable Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>9954539 - Disclosure - Fair Value Measurements - Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>9954540 - Disclosure - Fair Value Measurements - Fair Values of Separate Account Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/FairValueMeasurementsFairValuesofSeparateAccountAssetsDetails</Role>
      <ShortName>Fair Value Measurements - Fair Values of Separate Account Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>9954541 - Disclosure - Fair Value Measurements - Additional Information on Separate Account Assets Priced at Net Asset Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/FairValueMeasurementsAdditionalInformationonSeparateAccountAssetsPricedatNetAssetValueDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information on Separate Account Assets Priced at Net Asset Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>9954542 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value under Certain Conditions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails</Role>
      <ShortName>Fair Value Measurements - Assets and Liabilities Measured at Fair Value under Certain Conditions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>9954543 - Disclosure - Fair Value Measurements - Fair Value Disclosures for Financial Instruments Not Carried at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value Disclosures for Financial Instruments Not Carried at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>9954544 - Disclosure - Variable Interest Entities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/VariableInterestEntitiesDetails</Role>
      <ShortName>Variable Interest Entities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/VariableInterestEntities</ParentRole>
      <Position>110</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>9954545 - Disclosure - Collectively Significant Operating Unconsolidated Subsidiaries (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiariesDetails</Role>
      <ShortName>Collectively Significant Operating Unconsolidated Subsidiaries (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiariesTables</ParentRole>
      <Position>111</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>9954546 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>112</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>9954547 - Disclosure - Organizational Efficiency Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/OrganizationalEfficiencyPlanDetails</Role>
      <ShortName>Organizational Efficiency Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/OrganizationalEfficiencyPlanTables</ParentRole>
      <Position>113</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>9954548 - Disclosure - Pension - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/PensionNarrativeDetails</Role>
      <ShortName>Pension - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>114</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>9954549 - Disclosure - Pension - Projected Benefit Obligations and Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails</Role>
      <ShortName>Pension - Projected Benefit Obligations and Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>115</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>9954550 - Disclosure - Pension - Benefit Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/PensionBenefitPaymentsDetails</Role>
      <ShortName>Pension - Benefit Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>116</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>9954551 - Disclosure - Pension - Amounts Included in Accumulated Other Comprehensive Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/PensionAmountsIncludedinAccumulatedOtherComprehensiveIncomeDetails</Role>
      <ShortName>Pension - Amounts Included in Accumulated Other Comprehensive Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>117</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>9954552 - Disclosure - Pension - Net Pension Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/PensionNetPensionCostDetails</Role>
      <ShortName>Pension - Net Pension Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>118</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R119.htm</HtmlFileName>
      <LongName>9954553 - Disclosure - Pension - Assumptions Used for Pension (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/PensionAssumptionsUsedforPensionDetails</Role>
      <ShortName>Pension - Assumptions Used for Pension (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>119</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R120.htm</HtmlFileName>
      <LongName>9954554 - Disclosure - Pension - Pension Plan Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/PensionPensionPlanAssetsDetails</Role>
      <ShortName>Pension - Pension Plan Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>120</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R121.htm</HtmlFileName>
      <LongName>9954555 - Disclosure - Pension - Annual Expense for 401(k) Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/PensionAnnualExpensefor401kPlansDetails</Role>
      <ShortName>Pension - Annual Expense for 401(k) Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>121</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R122.htm</HtmlFileName>
      <LongName>9954556 - Disclosure - Employee Incentive Plans - Shares of Common Stock Available for Award (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/EmployeeIncentivePlansSharesofCommonStockAvailableforAwardDetails</Role>
      <ShortName>Employee Incentive Plans - Shares of Common Stock Available for Award (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>122</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R123.htm</HtmlFileName>
      <LongName>9954557 - Disclosure - Employee Incentive Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/EmployeeIncentivePlansNarrativeDetails</Role>
      <ShortName>Employee Incentive Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>123</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R124.htm</HtmlFileName>
      <LongName>9954558 - Disclosure - Employee Incentive Plans - Black-Scholes Option-Pricing Model Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/EmployeeIncentivePlansBlackScholesOptionPricingModelAssumptionsDetails</Role>
      <ShortName>Employee Incentive Plans - Black-Scholes Option-Pricing Model Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>124</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R125.htm</HtmlFileName>
      <LongName>9954559 - Disclosure - Employee Incentive Plans - Status of and Changes in Common Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinCommonStockOptionsDetails</Role>
      <ShortName>Employee Incentive Plans - Status of and Changes in Common Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>125</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R126.htm</HtmlFileName>
      <LongName>9954560 - Disclosure - Employee Incentive Plans - Summary of Information for Stock Options Exercised (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsExercisedDetails</Role>
      <ShortName>Employee Incentive Plans - Summary of Information for Stock Options Exercised (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>126</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R127.htm</HtmlFileName>
      <LongName>9954561 - Disclosure - Employee Incentive Plans - Summary of Information for Stock Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsOutstandingDetails</Role>
      <ShortName>Employee Incentive Plans - Summary of Information for Stock Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>127</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R128.htm</HtmlFileName>
      <LongName>9954562 - Disclosure - Employee Incentive Plans - Status of and Changes in Restricted Stock Awards and SPSs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinRestrictedStockAwardsandSPSsDetails</Role>
      <ShortName>Employee Incentive Plans - Status of and Changes in Restricted Stock Awards and SPSs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>128</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R129.htm</HtmlFileName>
      <LongName>9954563 - Disclosure - Employee Incentive Plans - Fair Value of Vested Restricted Stock and SPSs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/EmployeeIncentivePlansFairValueofVestedRestrictedStockandSPSsDetails</Role>
      <ShortName>Employee Incentive Plans - Fair Value of Vested Restricted Stock and SPSs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>129</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R130.htm</HtmlFileName>
      <LongName>9954564 - Disclosure - Employee Incentive Plans - Compensation Cost and Tax Effects of Share-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/EmployeeIncentivePlansCompensationCostandTaxEffectsofSharebasedCompensationDetails</Role>
      <ShortName>Employee Incentive Plans - Compensation Cost and Tax Effects of Share-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>130</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R131.htm</HtmlFileName>
      <LongName>9954565 - Disclosure - Goodwill, Other Intangibles and Property and Equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentNarrativeDetails</Role>
      <ShortName>Goodwill, Other Intangibles and Property and Equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentTables</ParentRole>
      <Position>131</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R132.htm</HtmlFileName>
      <LongName>9954566 - Disclosure - Goodwill, Other Intangibles, and Property and Equipment - Goodwill Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentGoodwillActivityDetails</Role>
      <ShortName>Goodwill, Other Intangibles, and Property and Equipment - Goodwill Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>132</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R133.htm</HtmlFileName>
      <LongName>9954567 - Disclosure - Goodwill, Other Intangibles, and Property and Equipment - Other Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails</Role>
      <ShortName>Goodwill, Other Intangibles, and Property and Equipment - Other Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>133</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R134.htm</HtmlFileName>
      <LongName>9954568 - Disclosure - Goodwill, Other Intangibles, and Property and Equipment - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails</Role>
      <ShortName>Goodwill, Other Intangibles, and Property and Equipment - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>134</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R135.htm</HtmlFileName>
      <LongName>9954569 - Disclosure - Goodwill, Other Intangibles, and Property and Equipment - Components of Depreciation and Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentComponentsofDepreciationandAmortizationExpenseDetails</Role>
      <ShortName>Goodwill, Other Intangibles, and Property and Equipment - Components of Depreciation and Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>135</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R136.htm</HtmlFileName>
      <LongName>9954570 - Disclosure - Goodwill, Other Intangibles, and Property and Equipment - Estimated Annual Pre-Tax Amortization for Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentEstimatedAnnualPreTaxAmortizationforIntangibleAssetsDetails</Role>
      <ShortName>Goodwill, Other Intangibles, and Property and Equipment - Estimated Annual Pre-Tax Amortization for Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>136</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R137.htm</HtmlFileName>
      <LongName>9954571 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>137</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R138.htm</HtmlFileName>
      <LongName>9954572 - Disclosure - Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/LeasesComponentsofLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>138</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R139.htm</HtmlFileName>
      <LongName>9954573 - Disclosure - Leases - Supplemental Cash Flow Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/LeasesSupplementalCashFlowInformationRelatedtoLeasesDetails</Role>
      <ShortName>Leases - Supplemental Cash Flow Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>139</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R140.htm</HtmlFileName>
      <LongName>9954574 - Disclosure - Leases - Operating and Finance Lease Right of Use ("ROU") Assets and Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Operating and Finance Lease Right of Use ("ROU") Assets and Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>140</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R141.htm</HtmlFileName>
      <LongName>9954575 - Disclosure - Leases - Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>141</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R142.htm</HtmlFileName>
      <LongName>9954576 - Disclosure - Shareholders Equity and Dividend Restrictions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ShareholdersEquityandDividendRestrictionsDetails</Role>
      <ShortName>Shareholders Equity and Dividend Restrictions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/ShareholdersEquityandDividendRestrictionsTables</ParentRole>
      <Position>142</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R143.htm</HtmlFileName>
      <LongName>9954577 - Disclosure - Income Taxes - Components of Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/IncomeTaxesComponentsofIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Components of Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>143</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R144.htm</HtmlFileName>
      <LongName>9954578 - Disclosure - Income Taxes - Nominal Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Nominal Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>144</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R145.htm</HtmlFileName>
      <LongName>9954579 - Disclosure - Income Taxes - Pre-tax Income From Foreign Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/IncomeTaxesPretaxIncomeFromForeignOperationsDetails</Role>
      <ShortName>Income Taxes - Pre-tax Income From Foreign Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>145</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R146.htm</HtmlFileName>
      <LongName>9954580 - Disclosure - Income Taxes - Foreign Jurisdiction Tax Attributes and Sale of Medicare Advantage and Related Businesses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/IncomeTaxesForeignJurisdictionTaxAttributesandSaleofMedicareAdvantageandRelatedBusinessesDetails</Role>
      <ShortName>Income Taxes - Foreign Jurisdiction Tax Attributes and Sale of Medicare Advantage and Related Businesses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>146</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R147.htm</HtmlFileName>
      <LongName>9954581 - Disclosure - Income Taxes - Deferred Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Deferred Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>147</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R148.htm</HtmlFileName>
      <LongName>9954582 - Disclosure - Income Taxes - Uncertain Tax Positions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/IncomeTaxesUncertainTaxPositionsDetails</Role>
      <ShortName>Income Taxes - Uncertain Tax Positions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>148</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R149.htm</HtmlFileName>
      <LongName>9954583 - Disclosure - Contingencies and Other Matters (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails</Role>
      <ShortName>Contingencies and Other Matters (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/ContingenciesandOtherMatters</ParentRole>
      <Position>149</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R150.htm</HtmlFileName>
      <LongName>9954584 - Disclosure - Segment Information - Summary of Special Items (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails</Role>
      <ShortName>Segment Information - Summary of Special Items (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>150</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R151.htm</HtmlFileName>
      <LongName>9954585 - Disclosure - Segment Information - Summarized Segment Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails</Role>
      <ShortName>Segment Information - Summarized Segment Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>151</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R152.htm</HtmlFileName>
      <LongName>9954586 - Disclosure - Segment Information - Revenue from External Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails</Role>
      <ShortName>Segment Information - Revenue from External Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>152</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R153.htm</HtmlFileName>
      <LongName>9954587 - Disclosure - Segment Information - Financial and Performance Guarantees (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/SegmentInformationFinancialandPerformanceGuaranteesDetails</Role>
      <ShortName>Segment Information - Financial and Performance Guarantees (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>153</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R154.htm</HtmlFileName>
      <LongName>9954588 - Disclosure - Segment Information - U.S. and Foreign Revenues from External Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/SegmentInformationUSandForeignRevenuesfromExternalCustomersDetails</Role>
      <ShortName>Segment Information - U.S. and Foreign Revenues from External Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>154</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R155.htm</HtmlFileName>
      <LongName>9954590 - Disclosure - Schedule I - Condensed Financial Information of The Cigna Group - Statements of Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails</Role>
      <ShortName>Schedule I - Condensed Financial Information of The Cigna Group - Statements of Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>155</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R156.htm</HtmlFileName>
      <LongName>9954591 - Disclosure - Schedule I - Condensed Financial Information of The Cigna Group - Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails</Role>
      <ShortName>Schedule I - Condensed Financial Information of The Cigna Group - Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>156</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R157.htm</HtmlFileName>
      <LongName>9954592 - Disclosure - Schedule I - Condensed Financial Information of The Cigna Group - Statements of Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails</Role>
      <ShortName>Schedule I - Condensed Financial Information of The Cigna Group - Statements of Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>157</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R158.htm</HtmlFileName>
      <LongName>9954593 - Disclosure - Schedule I - Condensed Financial Information of The Cigna Group - Short-term and Credit Facilities Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails</Role>
      <ShortName>Schedule I - Condensed Financial Information of The Cigna Group - Short-term and Credit Facilities Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>158</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R159.htm</HtmlFileName>
      <LongName>9954594 - Disclosure - Schedule I - Condensed Financial Information of The Cigna Group - Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails</Role>
      <ShortName>Schedule I - Condensed Financial Information of The Cigna Group - Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>159</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R160.htm</HtmlFileName>
      <LongName>9954595 - Disclosure - Schedule I - Condensed Financial Information of The Cigna Group - Debt Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupDebtMaturitiesDetails</Role>
      <ShortName>Schedule I - Condensed Financial Information of The Cigna Group - Debt Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>160</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R161.htm</HtmlFileName>
      <LongName>9954596 - Disclosure - Schedule I - Condensed Financial Information of The Cigna Group - Intercompany Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupIntercompanyBalancesDetails</Role>
      <ShortName>Schedule I - Condensed Financial Information of The Cigna Group - Intercompany Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>161</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R162.htm</HtmlFileName>
      <LongName>9954597 - Disclosure - Schedule I - Condensed Financial Information of The Cigna Group - Guarantees (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupGuaranteesDetails</Role>
      <ShortName>Schedule I - Condensed Financial Information of The Cigna Group - Guarantees (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroup</ParentRole>
      <Position>162</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R163.htm</HtmlFileName>
      <LongName>9954598 - Disclosure - Schedule I - Condensed Financial Information of The Cigna Group - Share Repurchase (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShareRepurchaseDetails</Role>
      <ShortName>Schedule I - Condensed Financial Information of The Cigna Group - Share Repurchase (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>163</Position>
    </Report>
    <Report instance="ci-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R164.htm</HtmlFileName>
      <LongName>9954599 - Disclosure - Schedule II - Valuation and Qualifying Accounts and Reserves (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.thecignagroup.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails</Role>
      <ShortName>Schedule II - Valuation and Qualifying Accounts and Reserves (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.thecignagroup.com/role/ScheduleIIValuationandQualifyingAccountsandReserves</ParentRole>
      <Position>164</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="ci-20231231.htm">ci-20231231.htm</File>
    <File>ci-20231231.xsd</File>
    <File>ci-20231231_cal.xml</File>
    <File>ci-20231231_def.xml</File>
    <File>ci-20231231_lab.xml</File>
    <File>ci-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ci-20231231_g1.jpg</File>
    <File>ci-20231231_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="4">http://fasb.org/srt/2023</BaseTaxonomy>
    <BaseTaxonomy items="2384">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>197
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ci-20231231.htm": {
   "nsprefix": "ci",
   "nsuri": "http://www.thecignagroup.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "ci-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "ci-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "ci-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ci-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "ci-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ci-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 639,
   "keyCustom": 310,
   "axisStandard": 61,
   "axisCustom": 3,
   "memberStandard": 116,
   "memberCustom": 136,
   "hidden": {
    "total": 53,
    "http://fasb.org/us-gaap/2023": 44,
    "http://www.thecignagroup.com/20231231": 5,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 889,
   "entityCount": 1,
   "segmentCount": 264,
   "elementCount": 1748,
   "unitCount": 11,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 2384,
    "http://xbrl.sec.gov/dei/2023": 38,
    "http://xbrl.sec.gov/ecd/2023": 4,
    "http://fasb.org/srt/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://www.thecignagroup.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.thecignagroup.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
     "longName": "0000003 - Statement - Consolidated Statements of Income",
     "shortName": "Consolidated Statements of Income",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PremiumsEarnedNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "longName": "0000004 - Statement - Consolidated Statements of Comprehensive Income",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ci:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets",
     "longName": "0000005 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:InventoryNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.thecignagroup.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "0000006 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "link:footnote",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R7": {
     "role": "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity",
     "longName": "0000007 - Statement - Consolidated Statements of Changes in Total Equity",
     "shortName": "Consolidated Statements of Changes in Total Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-33",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquityParenthetical",
     "longName": "0000008 - Statement - Consolidated Statements of Changes in Total Equity (Parenthetical)",
     "shortName": "Consolidated Statements of Changes in Total Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-185",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockDividendsPerShareDeclared",
       "us-gaap:CommonStockDividendsPerShareDeclared",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "0000009 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncreaseDecreaseInDeferredIncomeTaxes",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.thecignagroup.com/role/DescriptionofBusiness",
     "longName": "0000010 - Disclosure - Description of Business",
     "shortName": "Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "0000011 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.thecignagroup.com/role/AccountsReceivableNet",
     "longName": "0000012 - Disclosure - Accounts Receivable, Net",
     "shortName": "Accounts Receivable, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.thecignagroup.com/role/SupplierFinanceProgram",
     "longName": "0000013 - Disclosure - Supplier Finance Program",
     "shortName": "Supplier Finance Program",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplierFinanceProgramTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplierFinanceProgramTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.thecignagroup.com/role/MergersAcquisitionsandDivestitures",
     "longName": "0000014 - Disclosure - Mergers, Acquisitions and Divestitures",
     "shortName": "Mergers, Acquisitions and Divestitures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSale",
     "longName": "0000015 - Disclosure - Assets and Liabilities of Businesses Held for Sale",
     "shortName": "Assets and Liabilities of Businesses Held for Sale",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.thecignagroup.com/role/EarningsPerShare",
     "longName": "0000016 - Disclosure - Earnings Per Share",
     "shortName": "Earnings Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.thecignagroup.com/role/Debt",
     "longName": "0000017 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.thecignagroup.com/role/CommonandPreferredStock",
     "longName": "0000018 - Disclosure - Common and Preferred Stock",
     "shortName": "Common and Preferred Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ci:ScheduleOfCommonStockByClassScheduleOfPreferredStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ci:ScheduleOfCommonStockByClassScheduleOfPreferredStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilities",
     "longName": "0000019 - Disclosure - Insurance and Contractholder Liabilities",
     "shortName": "Insurance and Contractholder Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.thecignagroup.com/role/Reinsurance",
     "longName": "0000020 - Disclosure - Reinsurance",
     "shortName": "Reinsurance",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ReinsuranceTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ReinsuranceTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.thecignagroup.com/role/Investments",
     "longName": "0000021 - Disclosure - Investments",
     "shortName": "Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.thecignagroup.com/role/FairValueMeasurements",
     "longName": "0000022 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.thecignagroup.com/role/VariableInterestEntities",
     "longName": "0000023 - Disclosure - Variable Interest Entities",
     "shortName": "Variable Interest Entities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiaries",
     "longName": "0000024 - Disclosure - Collectively Significant Operating Unconsolidated Subsidiaries",
     "shortName": "Collectively Significant Operating Unconsolidated Subsidiaries",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLoss",
     "longName": "0000025 - Disclosure - Accumulated Other Comprehensive Income (Loss)",
     "shortName": "Accumulated Other Comprehensive Income (Loss)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ci:AccumulatedOtherComprehensiveIncomeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ci:AccumulatedOtherComprehensiveIncomeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.thecignagroup.com/role/OrganizationalEfficiencyPlan",
     "longName": "0000026 - Disclosure - Organizational Efficiency Plan",
     "shortName": "Organizational Efficiency Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.thecignagroup.com/role/Pension",
     "longName": "0000027 - Disclosure - Pension",
     "shortName": "Pension",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.thecignagroup.com/role/EmployeeIncentivePlans",
     "longName": "0000028 - Disclosure - Employee Incentive Plans",
     "shortName": "Employee Incentive Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipment",
     "longName": "0000029 - Disclosure - Goodwill, Other Intangibles and Property and Equipment",
     "shortName": "Goodwill, Other Intangibles and Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ci:GoodwillOtherIntangiblesAndPropertyAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ci:GoodwillOtherIntangiblesAndPropertyAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.thecignagroup.com/role/Leases",
     "longName": "0000030 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.thecignagroup.com/role/ShareholdersEquityandDividendRestrictions",
     "longName": "0000031 - Disclosure - Shareholders Equity and Dividend Restrictions",
     "shortName": "Shareholders Equity and Dividend Restrictions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ci:StockholdersEquityAndDividendRestrictionsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ci:StockholdersEquityAndDividendRestrictionsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.thecignagroup.com/role/IncomeTaxes",
     "longName": "0000032 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.thecignagroup.com/role/ContingenciesandOtherMatters",
     "longName": "0000033 - Disclosure - Contingencies and Other Matters",
     "shortName": "Contingencies and Other Matters",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.thecignagroup.com/role/SegmentInformation",
     "longName": "0000034 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroup",
     "longName": "0000035 - Disclosure - Schedule I - Condensed Financial Information of The Cigna Group",
     "shortName": "Schedule I - Condensed Financial Information of The Cigna Group",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.thecignagroup.com/role/ScheduleIIValuationandQualifyingAccountsandReserves",
     "longName": "0000036 - Disclosure - Schedule II - Valuation and Qualifying Accounts and Reserves",
     "shortName": "Schedule II - Valuation and Qualifying Accounts and Reserves",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-185",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-185",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.thecignagroup.com/role/ReceivablesLoansNotesReceivableandOthersPolicies",
     "longName": "9954472 - Disclosure - Receivables, Loans, Notes Receivable, and Others (Policies)",
     "shortName": "Receivables, Loans, Notes Receivable, and Others (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:TradeAndOtherAccountsReceivablePolicy",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R40": {
     "role": "http://www.thecignagroup.com/role/InvestmentsDebtandEquitySecuritiesPolicies",
     "longName": "9954473 - Disclosure - Investments, Debt and Equity Securities (Policies)",
     "shortName": "Investments, Debt and Equity Securities (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R41": {
     "role": "http://www.thecignagroup.com/role/AccountsReceivableNetTables",
     "longName": "9954474 - Disclosure - Accounts Receivable, Net (Tables)",
     "shortName": "Accounts Receivable, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleTables",
     "longName": "9954475 - Disclosure - Assets and Liabilities of Businesses Held for Sale (Tables)",
     "shortName": "Assets and Liabilities of Businesses Held for Sale (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.thecignagroup.com/role/EarningsPerShareTables",
     "longName": "9954476 - Disclosure - Earnings Per Share (Tables)",
     "shortName": "Earnings Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.thecignagroup.com/role/DebtTables",
     "longName": "9954477 - Disclosure - Debt (Tables)",
     "shortName": "Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ci:ScheduleOfShortTermDebtLongTermDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ci:ScheduleOfShortTermDebtLongTermDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.thecignagroup.com/role/CommonandPreferredStockTables",
     "longName": "9954478 - Disclosure - Common and Preferred Stock (Tables)",
     "shortName": "Common and Preferred Stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesTables",
     "longName": "9954479 - Disclosure - Insurance and Contractholder Liabilities (Tables)",
     "shortName": "Insurance and Contractholder Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.thecignagroup.com/role/ReinsuranceTables",
     "longName": "9954480 - Disclosure - Reinsurance (Tables)",
     "shortName": "Reinsurance (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCededCreditRiskByReinsurerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCededCreditRiskByReinsurerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.thecignagroup.com/role/InvestmentsTables",
     "longName": "9954481 - Disclosure - Investments (Tables)",
     "shortName": "Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.thecignagroup.com/role/FairValueMeasurementsTables",
     "longName": "9954482 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiariesTables",
     "longName": "9954483 - Disclosure - Collectively Significant Operating Unconsolidated Subsidiaries (Tables)",
     "shortName": "Collectively Significant Operating Unconsolidated Subsidiaries (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossTables",
     "longName": "9954484 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.thecignagroup.com/role/OrganizationalEfficiencyPlanTables",
     "longName": "9954485 - Disclosure - Organizational Efficiency Plan (Tables)",
     "shortName": "Organizational Efficiency Plan (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.thecignagroup.com/role/PensionTables",
     "longName": "9954486 - Disclosure - Pension (Tables)",
     "shortName": "Pension (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfNetFundedStatusTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfNetFundedStatusTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.thecignagroup.com/role/EmployeeIncentivePlansTables",
     "longName": "9954487 - Disclosure - Employee Incentive Plans (Tables)",
     "shortName": "Employee Incentive Plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentTables",
     "longName": "9954488 - Disclosure - Goodwill, Other Intangibles and Property and Equipment (Tables)",
     "shortName": "Goodwill, Other Intangibles and Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.thecignagroup.com/role/LeasesTables",
     "longName": "9954489 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ci:AssetsAndLiabilitiesLesseeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ci:AssetsAndLiabilitiesLesseeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.thecignagroup.com/role/ShareholdersEquityandDividendRestrictionsTables",
     "longName": "9954490 - Disclosure - Shareholders Equity and Dividend Restrictions (Tables)",
     "shortName": "Shareholders Equity and Dividend Restrictions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StatutoryAccountingPracticesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ci:StockholdersEquityAndDividendRestrictionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StatutoryAccountingPracticesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ci:StockholdersEquityAndDividendRestrictionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.thecignagroup.com/role/IncomeTaxesTables",
     "longName": "9954491 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.thecignagroup.com/role/SegmentInformationTables",
     "longName": "9954492 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ci:ScheduleOfSpecialItemsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ci:ScheduleOfSpecialItemsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.thecignagroup.com/role/SECScheduleArticle1204CondensedFinancialInformationofRegistrantTables",
     "longName": "9954493 - Disclosure - SEC Schedule, Article 12-04, Condensed Financial Information of Registrant (Tables)",
     "shortName": "SEC Schedule, Article 12-04, Condensed Financial Information of Registrant (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ci:CondensedFinancialInformationOfParentCompanyOnlyScheduleOfIssuancesOfLongTermDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ci:CondensedFinancialInformationOfParentCompanyOnlyScheduleOfIssuancesOfLongTermDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.thecignagroup.com/role/DescriptionofBusinessDetails",
     "longName": "9954494 - Disclosure - Description of Business (Details)",
     "shortName": "Description of Business (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-75",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R62": {
     "role": "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "9954495 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-76",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails",
     "longName": "9954496 - Disclosure - Accounts Receivable, Net - Amounts Included in Accounts Receivable, Net (Details)",
     "shortName": "Accounts Receivable, Net - Amounts Included in Accounts Receivable, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "ci:PharmaceuticalManufacturerReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "ci:PharmaceuticalManufacturerReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.thecignagroup.com/role/AccountsReceivableNetNarrativeDetails",
     "longName": "9954497 - Disclosure - Accounts Receivable, Net - Narrative (Details)",
     "shortName": "Accounts Receivable, Net - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "ci:AllowanceForReceivablesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "ci:AllowanceForReceivablesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.thecignagroup.com/role/SupplierFinanceProgramDetails",
     "longName": "9954498 - Disclosure - Supplier Finance Program (Details)",
     "shortName": "Supplier Finance Program (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:SupplierFinanceProgramPaymentTimingPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:SupplierFinanceProgramPaymentTimingPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.thecignagroup.com/role/MergersAcquisitionsandDivestituresNarrativeDetails",
     "longName": "9954499 - Disclosure - Mergers, Acquisitions and Divestitures - Narrative (Details)",
     "shortName": "Mergers, Acquisitions and Divestitures - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ci:TransactionRelatedCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-86",
      "name": "us-gaap:GuaranteeObligationsMaximumExposure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails",
     "longName": "9954500 - Disclosure - Assets and Liabilities of Businesses Held for Sale (Details)",
     "shortName": "Assets and Liabilities of Businesses Held for Sale (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-83",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-89",
      "name": "us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.thecignagroup.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails",
     "longName": "9954501 - Disclosure - Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Details)",
     "shortName": "Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.thecignagroup.com/role/EarningsPerShareOutstandingEmployeeStockOptionsNotIncludedintheComputationofDilutedEarningsPerShareDetails",
     "longName": "9954502 - Disclosure - Earnings Per Share - Outstanding Employee Stock Options Not Included in the Computation of Diluted Earnings Per Share (Details)",
     "shortName": "Earnings Per Share - Outstanding Employee Stock Options Not Included in the Computation of Diluted Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-91",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-91",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.thecignagroup.com/role/EarningsPerShareSharesofCommonStockHeldinTreasuryDetails",
     "longName": "9954503 - Disclosure - Earnings Per Share - Shares of Common Stock Held in Treasury (Details)",
     "shortName": "Earnings Per Share - Shares of Common Stock Held in Treasury (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:TreasuryStockCommonShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R71": {
     "role": "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails",
     "longName": "9954504 - Disclosure - Debt - Outstanding Amounts of Debt and Finance Leases (Details)",
     "shortName": "Debt - Outstanding Amounts of Debt and Finance Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:CommercialPaper",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ci:ScheduleOfShortTermDebtLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:CommercialPaper",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ci:ScheduleOfShortTermDebtLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.thecignagroup.com/role/DebtShorttermandCreditFacilitiesDebtDetails",
     "longName": "9954505 - Disclosure - Debt - Short-term and Credit Facilities Debt (Details)",
     "shortName": "Debt - Short-term and Credit Facilities Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "srt:CommercialPaperAverageRatePaid",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-163",
      "name": "ci:NumberOfRevolvingCreditFacility",
      "unitRef": "revolvingcreditfacility",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.thecignagroup.com/role/DebtLongtermDebtDetails",
     "longName": "9954506 - Disclosure - Debt - Long-term Debt (Details)",
     "shortName": "Debt - Long-term Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R74": {
     "role": "http://www.thecignagroup.com/role/DebtDebtMaturitiesDetails",
     "longName": "9954507 - Disclosure - Debt - Debt Maturities (Details)",
     "shortName": "Debt - Debt Maturities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R75": {
     "role": "http://www.thecignagroup.com/role/DebtInterestExpenseDetails",
     "longName": "9954508 - Disclosure - Debt - Interest Expense (Details)",
     "shortName": "Debt - Interest Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InterestExpenseDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InterestExpenseDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.thecignagroup.com/role/CommonandPreferredStockShareActivityDetails",
     "longName": "9954509 - Disclosure - Common and Preferred Stock - Share Activity (Details)",
     "shortName": "Common and Preferred Stock - Share Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.thecignagroup.com/role/CommonandPreferredStockDividendsDetails",
     "longName": "9954510 - Disclosure - Common and Preferred Stock - Dividends (Details)",
     "shortName": "Common and Preferred Stock - Dividends (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-185",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockDividendsPerShareDeclared",
       "us-gaap:CommonStockDividendsPerShareDeclared",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-198",
      "name": "us-gaap:CommonStockDividendsPerShareCashPaid",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DividendsDeclaredTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.thecignagroup.com/role/CommonandPreferredStockAcceleratedShareRepurchaseAgreementsDetails",
     "longName": "9954511 - Disclosure - Common and Preferred Stock - Accelerated Share Repurchase Agreements (Details)",
     "shortName": "Common and Preferred Stock - Accelerated Share Repurchase Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-211",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-216",
      "name": "ci:AcceleratedShareRepurchasesVolumeWeightedAverageSharePriceLessDiscount",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails",
     "longName": "9954512 - Disclosure - Insurance and Contractholder Liabilities - Account Balances (Details)",
     "shortName": "Insurance and Contractholder Liabilities - Account Balances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "ci:MarketRiskBenefitLiabilityAmountCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "ci:MarketRiskBenefitLiabilityAmountCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails",
     "longName": "9954513 - Disclosure - Insurance and Contractholder Liabilities - Unpaid Claims and Claim Expenses - Cigna Healthcare - Activity (Details)",
     "shortName": "Insurance and Contractholder Liabilities - Unpaid Claims and Claim Expenses - Cigna Healthcare - Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-83",
      "name": "ci:LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-217",
      "name": "ci:LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails",
     "longName": "9954514 - Disclosure - Insurance and Contractholder Liabilities - Unpaid Claims and Claims Expenses - Cigna Healthcare - Variances in Incurred Costs Related to Prior Years' Unpaid Claims and Claims Expenses (Details)",
     "shortName": "Insurance and Contractholder Liabilities - Unpaid Claims and Claims Expenses - Cigna Healthcare - Variances in Incurred Costs Related to Prior Years' Unpaid Claims and Claims Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-223",
      "name": "us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-223",
      "name": "ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails",
     "longName": "9954515 - Disclosure - Insurance and Contractholder Liabilities - Unpaid Claims and Claims Expenses - Cigna Healthcare - Incurred and Paid Claims Development and Unpaid Claims Liability (Details)",
     "shortName": "Insurance and Contractholder Liabilities - Unpaid Claims and Claims Expenses - Cigna Healthcare - Incurred and Paid Claims Development and Unpaid Claims Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-217",
      "name": "ci:ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-217",
      "name": "ci:ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsInterestRatesandDurationDetails",
     "longName": "9954516 - Disclosure - Insurance and Contractholder Liabilities - Future Policy Benefits - Interest Rates and Duration (Details)",
     "shortName": "Insurance and Contractholder Liabilities - Future Policy Benefits - Interest Rates and Duration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-217",
      "name": "us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LiabilityForFuturePolicyBenefitActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-217",
      "name": "us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LiabilityForFuturePolicyBenefitActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails",
     "longName": "9954517 - Disclosure - Insurance and Contractholder Liabilities - Future Policy Benefits - Present Value of Expected Premiums and Benefits (Details)",
     "shortName": "Insurance and Contractholder Liabilities - Future Policy Benefits - Present Value of Expected Premiums and Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ci:FuturePolicyBenefitsDomesticContractsObservableInputsFromPublishedSpotRateCurveMaximumTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "us-gaap:FuturePolicyBenefitsLiabilityPolicy",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ci:FuturePolicyBenefitsDomesticContractsObservableInputsFromPublishedSpotRateCurveMaximumTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "us-gaap:FuturePolicyBenefitsLiabilityPolicy",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails",
     "longName": "9954518 - Disclosure - Insurance and Contractholder Liabilities - Contractholder Deposit Funds (Details)",
     "shortName": "Insurance and Contractholder Liabilities - Contractholder Deposit Funds (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "ci:PolicyholderContractBalancePercentReinsuredExternally",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "ci:PolicyholderContractBalancePercentReinsuredExternally",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesSummaryofMarketRiskBenefitDetails",
     "longName": "9954519 - Disclosure - Insurance and Contractholder Liabilities - Summary of Market Risk Benefit (Details)",
     "shortName": "Insurance and Contractholder Liabilities - Summary of Market Risk Benefit (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ci:AnnuitizationElectionPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ci:AnnuitizationElectionPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails",
     "longName": "9954520 - Disclosure - Insurance and Contractholder Liabilities - Net Amount of Risk and Average Age of Contractholders (Details)",
     "shortName": "Insurance and Contractholder Liabilities - Net Amount of Risk and Average Age of Contractholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-252",
      "name": "us-gaap:NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-252",
      "name": "us-gaap:NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails",
     "longName": "9954521 - Disclosure - Reinsurance - Reinsurance Recoverables (Details)",
     "shortName": "Reinsurance - Reinsurance Recoverables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCededCreditRiskByReinsurerTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCededCreditRiskByReinsurerTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.thecignagroup.com/role/ReinsuranceEffectsofReinsuranceDetails",
     "longName": "9954522 - Disclosure - Reinsurance - Effects of Reinsurance (Details)",
     "shortName": "Reinsurance - Effects of Reinsurance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PremiumsEarnedNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:EffectsOfReinsuranceTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.thecignagroup.com/role/ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails",
     "longName": "9954523 - Disclosure - Reinsurance - Effective Exit of Variable Annuity Reinsurance Business (Details)",
     "shortName": "Reinsurance - Effective Exit of Variable Annuity Reinsurance Business (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c-252",
      "name": "ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-252",
      "name": "ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails",
     "longName": "9954524 - Disclosure - Investments - Investments by Category (Details)",
     "shortName": "Investments - Investments by Category (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "ci:ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "ci:ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails",
     "longName": "9954525 - Disclosure - Investments - Debt Securities by Contractual Maturity Periods (Details)",
     "shortName": "Investments - Debt Securities by Contractual Maturity Periods (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "ci:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "ci:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.thecignagroup.com/role/InvestmentsNarrativeDetails",
     "longName": "9954526 - Disclosure - Investments - Narrative (Details)",
     "shortName": "Investments - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ci:EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-351",
      "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesDetails",
     "longName": "9954527 - Disclosure - Investments - Gross Unrealized Appreciation (Depreciation) on Debt Securities (Details)",
     "shortName": "Investments - Gross Unrealized Appreciation (Depreciation) on Debt Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R95": {
     "role": "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails",
     "longName": "9954528 - Disclosure - Investments - Debt Securities with a Decline in Fair Value (Details)",
     "shortName": "Investments - Debt Securities with a Decline in Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails",
     "longName": "9954529 - Disclosure - Investments - Equity Security Investments (Details)",
     "shortName": "Investments - Equity Security Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:EquitySecuritiesFvNiCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ci:EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:EquitySecuritiesFvNiCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ci:EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R97": {
     "role": "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoanPortfolioDetails",
     "longName": "9954530 - Disclosure - Investments - Commercial Mortgage Loan Portfolio (Details)",
     "shortName": "Investments - Commercial Mortgage Loan Portfolio (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "c-367",
      "name": "us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FinancingReceivableCreditQualityIndicatorsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-367",
      "name": "us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FinancingReceivableCreditQualityIndicatorsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R98": {
     "role": "http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails",
     "longName": "9954531 - Disclosure - Investments - Other Long-Term Investments (Details)",
     "shortName": "Investments - Other Long-Term Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "ci:UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "ci:ScheduleOfOtherLongTermInvestmentsTableTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "ci:UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "ci:ScheduleOfOtherLongTermInvestmentsTableTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R99": {
     "role": "http://www.thecignagroup.com/role/InvestmentsSummaryofDerivativeInstrumentsDetails",
     "longName": "9954532 - Disclosure - Investments - Summary of Derivative Instruments (Details)",
     "shortName": "Investments - Summary of Derivative Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "c-375",
      "name": "us-gaap:DerivativeNotionalAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-375",
      "name": "us-gaap:DerivativeNotionalAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R100": {
     "role": "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeDetails",
     "longName": "9954533 - Disclosure - Investments - Components of Net Investment Income (Details)",
     "shortName": "Investments - Components of Net Investment Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentIncomeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentIncomeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R101": {
     "role": "http://www.thecignagroup.com/role/InvestmentsRealizedGainsandLossesonInvestmentsDetails",
     "longName": "9954534 - Disclosure - Investments - Realized Gains and Losses on Investments (Details)",
     "shortName": "Investments - Realized Gains and Losses on Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ci:RealizedInvestmentGainLossExcludingImpairments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ci:RealizedInvestmentGainLossExcludingImpairments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R102": {
     "role": "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
     "longName": "9954536 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value (Details)",
     "shortName": "Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ci:EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-446",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R103": {
     "role": "http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails",
     "longName": "9954537 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "ci:DebtAndEquitySecuritiesClassifiedInLevel2PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "ci:DebtAndEquitySecuritiesClassifiedInLevel2PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R104": {
     "role": "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails",
     "longName": "9954538 - Disclosure - Fair Value Measurements - Quantitative Information About Unobservable Inputs (Details)",
     "shortName": "Fair Value Measurements - Quantitative Information About Unobservable Inputs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "104",
     "firstAnchor": {
      "contextRef": "c-474",
      "name": "us-gaap:MarketableSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-474",
      "name": "us-gaap:MarketableSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R105": {
     "role": "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails",
     "longName": "9954539 - Disclosure - Fair Value Measurements - Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value (Details)",
     "shortName": "Fair Value Measurements - Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "105",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ci:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ci:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ci:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ci:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R106": {
     "role": "http://www.thecignagroup.com/role/FairValueMeasurementsFairValuesofSeparateAccountAssetsDetails",
     "longName": "9954540 - Disclosure - Fair Value Measurements - Fair Values of Separate Account Assets (Details)",
     "shortName": "Fair Value Measurements - Fair Values of Separate Account Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "106",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "ci:GuaranteedSeparateAccountAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ci:FairValueOfSeparateAccountAssetsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "ci:GuaranteedSeparateAccountAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ci:FairValueOfSeparateAccountAssetsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R107": {
     "role": "http://www.thecignagroup.com/role/FairValueMeasurementsAdditionalInformationonSeparateAccountAssetsPricedatNetAssetValueDetails",
     "longName": "9954541 - Disclosure - Fair Value Measurements - Additional Information on Separate Account Assets Priced at Net Asset Value (Details)",
     "shortName": "Fair Value Measurements - Additional Information on Separate Account Assets Priced at Net Asset Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "107",
     "firstAnchor": {
      "contextRef": "c-505",
      "name": "us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-505",
      "name": "us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R108": {
     "role": "http://www.thecignagroup.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails",
     "longName": "9954542 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value under Certain Conditions (Details)",
     "shortName": "Fair Value Measurements - Assets and Liabilities Measured at Fair Value under Certain Conditions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "108",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R109": {
     "role": "http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails",
     "longName": "9954543 - Disclosure - Fair Value Measurements - Fair Value Disclosures for Financial Instruments Not Carried at Fair Value (Details)",
     "shortName": "Fair Value Measurements - Fair Value Disclosures for Financial Instruments Not Carried at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "109",
     "firstAnchor": {
      "contextRef": "c-511",
      "name": "us-gaap:LongTermDebtFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-511",
      "name": "us-gaap:LongTermDebtFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R110": {
     "role": "http://www.thecignagroup.com/role/VariableInterestEntitiesDetails",
     "longName": "9954544 - Disclosure - Variable Interest Entities (Details)",
     "shortName": "Variable Interest Entities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "110",
     "firstAnchor": {
      "contextRef": "c-516",
      "name": "ci:VariableInterestEntitiesNumberOfEntities",
      "unitRef": "entity",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "ci:VariableInterestEntitiesNumberOfEntities",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-516",
      "name": "ci:VariableInterestEntitiesNumberOfEntities",
      "unitRef": "entity",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "ci:VariableInterestEntitiesNumberOfEntities",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R111": {
     "role": "http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiariesDetails",
     "longName": "9954545 - Disclosure - Collectively Significant Operating Unconsolidated Subsidiaries (Details)",
     "shortName": "Collectively Significant Operating Unconsolidated Subsidiaries (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "111",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-523",
      "name": "us-gaap:EquityMethodInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R112": {
     "role": "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
     "longName": "9954546 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "112",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-536",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R113": {
     "role": "http://www.thecignagroup.com/role/OrganizationalEfficiencyPlanDetails",
     "longName": "9954547 - Disclosure - Organizational Efficiency Plan (Details)",
     "shortName": "Organizational Efficiency Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "113",
     "firstAnchor": {
      "contextRef": "c-185",
      "name": "us-gaap:BusinessExitCosts1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-185",
      "name": "us-gaap:BusinessExitCosts1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R114": {
     "role": "http://www.thecignagroup.com/role/PensionNarrativeDetails",
     "longName": "9954548 - Disclosure - Pension - Narrative (Details)",
     "shortName": "Pension - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "114",
     "firstAnchor": {
      "contextRef": "c-597",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-597",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R115": {
     "role": "http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails",
     "longName": "9954549 - Disclosure - Pension - Projected Benefit Obligations and Assets (Details)",
     "shortName": "Pension - Projected Benefit Obligations and Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "115",
     "firstAnchor": {
      "contextRef": "c-486",
      "name": "us-gaap:DefinedBenefitPlanBenefitObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetFundedStatusTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-595",
      "name": "us-gaap:DefinedBenefitPlanActuarialGainLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetFundedStatusTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R116": {
     "role": "http://www.thecignagroup.com/role/PensionBenefitPaymentsDetails",
     "longName": "9954550 - Disclosure - Pension - Benefit Payments (Details)",
     "shortName": "Pension - Benefit Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "116",
     "firstAnchor": {
      "contextRef": "c-487",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-487",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R117": {
     "role": "http://www.thecignagroup.com/role/PensionAmountsIncludedinAccumulatedOtherComprehensiveIncomeDetails",
     "longName": "9954551 - Disclosure - Pension - Amounts Included in Accumulated Other Comprehensive Income (Details)",
     "shortName": "Pension - Amounts Included in Accumulated Other Comprehensive Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "117",
     "firstAnchor": {
      "contextRef": "c-487",
      "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-487",
      "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R118": {
     "role": "http://www.thecignagroup.com/role/PensionNetPensionCostDetails",
     "longName": "9954552 - Disclosure - Pension - Net Pension Cost (Details)",
     "shortName": "Pension - Net Pension Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "118",
     "firstAnchor": {
      "contextRef": "c-595",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetFundedStatusTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-595",
      "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R119": {
     "role": "http://www.thecignagroup.com/role/PensionAssumptionsUsedforPensionDetails",
     "longName": "9954553 - Disclosure - Pension - Assumptions Used for Pension (Details)",
     "shortName": "Pension - Assumptions Used for Pension (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "119",
     "firstAnchor": {
      "contextRef": "c-487",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-487",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R120": {
     "role": "http://www.thecignagroup.com/role/PensionPensionPlanAssetsDetails",
     "longName": "9954554 - Disclosure - Pension - Pension Plan Assets (Details)",
     "shortName": "Pension - Pension Plan Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "120",
     "firstAnchor": {
      "contextRef": "c-487",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-607",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R121": {
     "role": "http://www.thecignagroup.com/role/PensionAnnualExpensefor401kPlansDetails",
     "longName": "9954555 - Disclosure - Pension - Annual Expense for 401(k) Plans (Details)",
     "shortName": "Pension - Annual Expense for 401(k) Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "121",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R122": {
     "role": "http://www.thecignagroup.com/role/EmployeeIncentivePlansSharesofCommonStockAvailableforAwardDetails",
     "longName": "9954556 - Disclosure - Employee Incentive Plans - Shares of Common Stock Available for Award (Details)",
     "shortName": "Employee Incentive Plans - Shares of Common Stock Available for Award (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "122",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R123": {
     "role": "http://www.thecignagroup.com/role/EmployeeIncentivePlansNarrativeDetails",
     "longName": "9954557 - Disclosure - Employee Incentive Plans - Narrative (Details)",
     "shortName": "Employee Incentive Plans - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "123",
     "firstAnchor": {
      "contextRef": "c-630",
      "name": "ci:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionReferenceTermOfTradedOptions",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-630",
      "name": "ci:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionReferenceTermOfTradedOptions",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R124": {
     "role": "http://www.thecignagroup.com/role/EmployeeIncentivePlansBlackScholesOptionPricingModelAssumptionsDetails",
     "longName": "9954558 - Disclosure - Employee Incentive Plans - Black-Scholes Option-Pricing Model Assumptions (Details)",
     "shortName": "Employee Incentive Plans - Black-Scholes Option-Pricing Model Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "124",
     "firstAnchor": {
      "contextRef": "c-630",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-630",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R125": {
     "role": "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinCommonStockOptionsDetails",
     "longName": "9954559 - Disclosure - Employee Incentive Plans - Status of and Changes in Common Stock Options (Details)",
     "shortName": "Employee Incentive Plans - Status of and Changes in Common Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "125",
     "firstAnchor": {
      "contextRef": "c-633",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-630",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R126": {
     "role": "http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsExercisedDetails",
     "longName": "9954560 - Disclosure - Employee Incentive Plans - Summary of Information for Stock Options Exercised (Details)",
     "shortName": "Employee Incentive Plans - Summary of Information for Stock Options Exercised (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "126",
     "firstAnchor": {
      "contextRef": "c-630",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-630",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R127": {
     "role": "http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsOutstandingDetails",
     "longName": "9954561 - Disclosure - Employee Incentive Plans - Summary of Information for Stock Options Outstanding (Details)",
     "shortName": "Employee Incentive Plans - Summary of Information for Stock Options Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "127",
     "firstAnchor": {
      "contextRef": "c-636",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-636",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R128": {
     "role": "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinRestrictedStockAwardsandSPSsDetails",
     "longName": "9954562 - Disclosure - Employee Incentive Plans - Status of and Changes in Restricted Stock Awards and SPSs (Details)",
     "shortName": "Employee Incentive Plans - Status of and Changes in Restricted Stock Awards and SPSs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "128",
     "firstAnchor": {
      "contextRef": "c-639",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-642",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R129": {
     "role": "http://www.thecignagroup.com/role/EmployeeIncentivePlansFairValueofVestedRestrictedStockandSPSsDetails",
     "longName": "9954563 - Disclosure - Employee Incentive Plans - Fair Value of Vested Restricted Stock and SPSs (Details)",
     "shortName": "Employee Incentive Plans - Fair Value of Vested Restricted Stock and SPSs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "129",
     "firstAnchor": {
      "contextRef": "c-642",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-642",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R130": {
     "role": "http://www.thecignagroup.com/role/EmployeeIncentivePlansCompensationCostandTaxEffectsofSharebasedCompensationDetails",
     "longName": "9954564 - Disclosure - Employee Incentive Plans - Compensation Cost and Tax Effects of Share-based Compensation (Details)",
     "shortName": "Employee Incentive Plans - Compensation Cost and Tax Effects of Share-based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "130",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R131": {
     "role": "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentNarrativeDetails",
     "longName": "9954565 - Disclosure - Goodwill, Other Intangibles and Property and Equipment - Narrative (Details)",
     "shortName": "Goodwill, Other Intangibles and Property and Equipment - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "131",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-664",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R132": {
     "role": "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentGoodwillActivityDetails",
     "longName": "9954566 - Disclosure - Goodwill, Other Intangibles, and Property and Equipment - Goodwill Activity (Details)",
     "shortName": "Goodwill, Other Intangibles, and Property and Equipment - Goodwill Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "132",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-47",
      "name": "ci:GoodwillIncludingDisposalGroups",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R133": {
     "role": "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails",
     "longName": "9954567 - Disclosure - Goodwill, Other Intangibles, and Property and Equipment - Other Intangible Assets (Details)",
     "shortName": "Goodwill, Other Intangibles, and Property and Equipment - Other Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "133",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R134": {
     "role": "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails",
     "longName": "9954568 - Disclosure - Goodwill, Other Intangibles, and Property and Equipment - Property and Equipment (Details)",
     "shortName": "Goodwill, Other Intangibles, and Property and Equipment - Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "134",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "ci:PropertyPlantAndEquipmentGrossIncludingDisposalGroups",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "ci:PropertyPlantAndEquipmentGrossIncludingDisposalGroups",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R135": {
     "role": "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentComponentsofDepreciationandAmortizationExpenseDetails",
     "longName": "9954569 - Disclosure - Goodwill, Other Intangibles, and Property and Equipment - Components of Depreciation and Amortization Expense (Details)",
     "shortName": "Goodwill, Other Intangibles, and Property and Equipment - Components of Depreciation and Amortization Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "135",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-682",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R136": {
     "role": "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentEstimatedAnnualPreTaxAmortizationforIntangibleAssetsDetails",
     "longName": "9954570 - Disclosure - Goodwill, Other Intangibles, and Property and Equipment - Estimated Annual Pre-Tax Amortization for Intangible Assets (Details)",
     "shortName": "Goodwill, Other Intangibles, and Property and Equipment - Estimated Annual Pre-Tax Amortization for Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "136",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R137": {
     "role": "http://www.thecignagroup.com/role/LeasesNarrativeDetails",
     "longName": "9954571 - Disclosure - Leases - Narrative (Details)",
     "shortName": "Leases - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "137",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R138": {
     "role": "http://www.thecignagroup.com/role/LeasesComponentsofLeaseExpenseDetails",
     "longName": "9954572 - Disclosure - Leases - Components of Lease Expense (Details)",
     "shortName": "Leases - Components of Lease Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "138",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R139": {
     "role": "http://www.thecignagroup.com/role/LeasesSupplementalCashFlowInformationRelatedtoLeasesDetails",
     "longName": "9954573 - Disclosure - Leases - Supplemental Cash Flow Information Related to Leases (Details)",
     "shortName": "Leases - Supplemental Cash Flow Information Related to Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "139",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ci:CashFlowActivitiesLesseeTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ci:CashFlowActivitiesLesseeTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R140": {
     "role": "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails",
     "longName": "9954574 - Disclosure - Leases - Operating and Finance Lease Right of Use (\"ROU\") Assets and Lease Liabilities (Details)",
     "shortName": "Leases - Operating and Finance Lease Right of Use (\"ROU\") Assets and Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "140",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R141": {
     "role": "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails",
     "longName": "9954575 - Disclosure - Leases - Maturities of Lease Liabilities (Details)",
     "shortName": "Leases - Maturities of Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "141",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R142": {
     "role": "http://www.thecignagroup.com/role/ShareholdersEquityandDividendRestrictionsDetails",
     "longName": "9954576 - Disclosure - Shareholders Equity and Dividend Restrictions (Details)",
     "shortName": "Shareholders Equity and Dividend Restrictions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "142",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StatutoryAccountingPracticesStatutoryNetIncomeAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ci:StockholdersEquityAndDividendRestrictionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StatutoryAccountingPracticesStatutoryNetIncomeAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ci:StockholdersEquityAndDividendRestrictionsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R143": {
     "role": "http://www.thecignagroup.com/role/IncomeTaxesComponentsofIncomeTaxesDetails",
     "longName": "9954577 - Disclosure - Income Taxes - Components of Income Taxes (Details)",
     "shortName": "Income Taxes - Components of Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "143",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R144": {
     "role": "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails",
     "longName": "9954578 - Disclosure - Income Taxes - Nominal Tax Rate Reconciliation (Details)",
     "shortName": "Income Taxes - Nominal Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "144",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R145": {
     "role": "http://www.thecignagroup.com/role/IncomeTaxesPretaxIncomeFromForeignOperationsDetails",
     "longName": "9954579 - Disclosure - Income Taxes - Pre-tax Income From Foreign Operations (Details)",
     "shortName": "Income Taxes - Pre-tax Income From Foreign Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "145",
     "firstAnchor": {
      "contextRef": "c-699",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-699",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R146": {
     "role": "http://www.thecignagroup.com/role/IncomeTaxesForeignJurisdictionTaxAttributesandSaleofMedicareAdvantageandRelatedBusinessesDetails",
     "longName": "9954580 - Disclosure - Income Taxes - Foreign Jurisdiction Tax Attributes and Sale of Medicare Advantage and Related Businesses (Details)",
     "shortName": "Income Taxes - Foreign Jurisdiction Tax Attributes and Sale of Medicare Advantage and Related Businesses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "146",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "ci:DeferredTaxAssetsForeignTaxAttributes",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "ci:DeferredTaxAssetsValuationAllowanceForeignTaxAttributes",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R147": {
     "role": "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails",
     "longName": "9954581 - Disclosure - Income Taxes - Deferred Income Taxes (Details)",
     "shortName": "Income Taxes - Deferred Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "147",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R148": {
     "role": "http://www.thecignagroup.com/role/IncomeTaxesUncertainTaxPositionsDetails",
     "longName": "9954582 - Disclosure - Income Taxes - Uncertain Tax Positions (Details)",
     "shortName": "Income Taxes - Uncertain Tax Positions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "148",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-33",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R149": {
     "role": "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails",
     "longName": "9954583 - Disclosure - Contingencies and Other Matters (Details)",
     "shortName": "Contingencies and Other Matters (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "149",
     "firstAnchor": {
      "contextRef": "c-710",
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-710",
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R150": {
     "role": "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails",
     "longName": "9954584 - Disclosure - Segment Information - Summary of Special Items (Details)",
     "shortName": "Segment Information - Summary of Special Items (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "150",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ci:SpecialItemChargeBenefitTaxMatters",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ci:ScheduleOfSpecialItemsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R151": {
     "role": "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails",
     "longName": "9954585 - Disclosure - Segment Information - Summarized Segment Financial Information (Details)",
     "shortName": "Segment Information - Summarized Segment Financial Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "151",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ci:NonInvestmentRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ci:RealizedInvestmentGainsLossesEquityMethodInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R152": {
     "role": "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails",
     "longName": "9954586 - Disclosure - Segment Information - Revenue from External Customers (Details)",
     "shortName": "Segment Information - Revenue from External Customers (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "152",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PremiumsEarnedNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-718",
      "name": "us-gaap:PremiumsEarnedNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R153": {
     "role": "http://www.thecignagroup.com/role/SegmentInformationFinancialandPerformanceGuaranteesDetails",
     "longName": "9954587 - Disclosure - Segment Information - Financial and Performance Guarantees (Details)",
     "shortName": "Segment Information - Financial and Performance Guarantees (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "153",
     "firstAnchor": {
      "contextRef": "c-78",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "us-gaap:CostOfSalesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R154": {
     "role": "http://www.thecignagroup.com/role/SegmentInformationUSandForeignRevenuesfromExternalCustomersDetails",
     "longName": "9954588 - Disclosure - Segment Information - U.S. and Foreign Revenues from External Customers (Details)",
     "shortName": "Segment Information - U.S. and Foreign Revenues from External Customers (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "154",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ci:NonInvestmentRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-800",
      "name": "ci:NonInvestmentRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R155": {
     "role": "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails",
     "longName": "9954590 - Disclosure - Schedule I - Condensed Financial Information of The Cigna Group - Statements of Income (Details)",
     "shortName": "Schedule I - Condensed Financial Information of The Cigna Group - Statements of Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "155",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetInvestmentIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-809",
      "name": "us-gaap:NetInvestmentIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R156": {
     "role": "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails",
     "longName": "9954591 - Disclosure - Schedule I - Condensed Financial Information of The Cigna Group - Balance Sheets (Details)",
     "shortName": "Schedule I - Condensed Financial Information of The Cigna Group - Balance Sheets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "156",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-812",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R157": {
     "role": "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails",
     "longName": "9954592 - Disclosure - Schedule I - Condensed Financial Information of The Cigna Group - Statements of Cash Flows (Details)",
     "shortName": "Schedule I - Condensed Financial Information of The Cigna Group - Statements of Cash Flows (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "157",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-809",
      "name": "us-gaap:CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R158": {
     "role": "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails",
     "longName": "9954593 - Disclosure - Schedule I - Condensed Financial Information of The Cigna Group - Short-term and Credit Facilities Debt (Details)",
     "shortName": "Schedule I - Condensed Financial Information of The Cigna Group - Short-term and Credit Facilities Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "158",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "srt:CommercialPaperAverageRatePaid",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-809",
      "name": "srt:CommercialPaperAverageRatePaid",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R159": {
     "role": "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails",
     "longName": "9954594 - Disclosure - Schedule I - Condensed Financial Information of The Cigna Group - Long-term Debt (Details)",
     "shortName": "Schedule I - Condensed Financial Information of The Cigna Group - Long-term Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "159",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-839",
      "name": "us-gaap:DebtInstrumentRepurchasedFaceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-7",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R160": {
     "role": "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupDebtMaturitiesDetails",
     "longName": "9954595 - Disclosure - Schedule I - Condensed Financial Information of The Cigna Group - Debt Maturities (Details)",
     "shortName": "Schedule I - Condensed Financial Information of The Cigna Group - Debt Maturities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "160",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-812",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ci:CondensedFinancialInformationOfParentCompanyOnlyScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R161": {
     "role": "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupIntercompanyBalancesDetails",
     "longName": "9954596 - Disclosure - Schedule I - Condensed Financial Information of The Cigna Group - Intercompany Balances (Details)",
     "shortName": "Schedule I - Condensed Financial Information of The Cigna Group - Intercompany Balances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "161",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:OtherAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-848",
      "name": "us-gaap:OtherAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R162": {
     "role": "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupGuaranteesDetails",
     "longName": "9954597 - Disclosure - Schedule I - Condensed Financial Information of The Cigna Group - Guarantees (Details)",
     "shortName": "Schedule I - Condensed Financial Information of The Cigna Group - Guarantees (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "162",
     "firstAnchor": {
      "contextRef": "c-812",
      "name": "us-gaap:GuaranteeObligationsMaximumExposure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-812",
      "name": "us-gaap:GuaranteeObligationsMaximumExposure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R163": {
     "role": "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShareRepurchaseDetails",
     "longName": "9954598 - Disclosure - Schedule I - Condensed Financial Information of The Cigna Group - Share Repurchase (Details)",
     "shortName": "Schedule I - Condensed Financial Information of The Cigna Group - Share Repurchase (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "163",
     "firstAnchor": {
      "contextRef": "c-211",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-853",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    },
    "R164": {
     "role": "http://www.thecignagroup.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails",
     "longName": "9954599 - Disclosure - Schedule II - Valuation and Qualifying Accounts and Reserves (Details)",
     "shortName": "Schedule II - Valuation and Qualifying Accounts and Reserves (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "164",
     "firstAnchor": {
      "contextRef": "c-855",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-880",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ci-20231231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "ci_A364DayRevolvingCreditAgreementMaturingApril2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "A364DayRevolvingCreditAgreementMaturingApril2023Member",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtShorttermandCreditFacilitiesDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "364 Day Revolving Credit Agreement, Maturing April 2023",
        "label": "364 Day Revolving Credit Agreement, Maturing April 2023 [Member]",
        "documentation": "364 Day Revolving Credit Agreement, Maturing April 2023"
       }
      }
     },
     "auth_ref": []
    },
    "ci_A364DayRevolvingCreditAgreementMaturingApril2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "A364DayRevolvingCreditAgreementMaturingApril2024Member",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtShorttermandCreditFacilitiesDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "364-day Revolving Credit Agreement, Maturing April 2024",
        "label": "364 Day Revolving Credit Agreement, Maturing April 2024 [Member]",
        "documentation": "364 Day Revolving Credit Agreement, Maturing April 2024"
       }
      }
     },
     "auth_ref": []
    },
    "ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesGainLossOnSaleOfBusinessParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesGainLossOnSaleOfBusinessParentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-For-Sale And Derivatives, (Gain) Loss On Sale Of Business, Parent",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-For-Sale And Derivatives, (Gain) Loss On Sale Of Business, Parent [Member]",
        "documentation": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-For-Sale And Derivatives, (Gain) Loss On Sale Of Business, Parent"
       }
      }
     },
     "auth_ref": []
    },
    "ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities and Derivatives",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-For-Sale And Derivatives, Parent [Member]",
        "documentation": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-For-Sale And Derivatives, Parent"
       }
      }
     },
     "auth_ref": []
    },
    "ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesRealizedInvestmentGainsLossesParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesRealizedInvestmentGainsLossesParentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification adjustment for losses (gains) included in Shareholders' net income (Net realized investment (losses) gains)",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-For-Sale And Derivatives, Realized Investment (Gains) Losses, Parent [Member]",
        "documentation": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-For-Sale And Derivatives, Realized Investment (Gains) Losses, Parent"
       }
      }
     },
     "auth_ref": []
    },
    "ci_AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesSellingGeneralAdministrativeExpenseParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesSellingGeneralAdministrativeExpenseParentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification adjustment for (gains) included in Shareholders' net income (Selling, general and administrative expenses)",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-For-Sale And Derivatives, Selling General Administrative Expense, Parent [Member]",
        "documentation": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-For-Sale And Derivatives, Selling General Administrative Expense, Parent"
       }
      }
     },
     "auth_ref": []
    },
    "ci_AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net long-duration insurance and contractholder liabilities measurement adjustments (1)",
        "label": "AOCI, Liability For Future Policy Benefit And Market Risk Benefit, Instrument-Specific Credit Risk, Parent [Member]",
        "documentation": "AOCI, Liability For Future Policy Benefit And Market Risk Benefit, Instrument-Specific Credit Risk, Parent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AcceleratedShareRepurchasesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AcceleratedShareRepurchasesLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/CommonandPreferredStockAcceleratedShareRepurchaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accelerated Share Repurchases [Line Items]",
        "label": "Accelerated Share Repurchases [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AcceleratedShareRepurchasesSettlementPaymentOrReceipt",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/CommonandPreferredStockAcceleratedShareRepurchaseAgreementsDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShareRepurchaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accelerated stock repurchase, amount remitted",
        "label": "Accelerated Share Repurchases, Settlement (Payment) or Receipt",
        "documentation": "Amount of cash receipt from (payment to) bank; or stock received from (issuance to) bank in the settlement of the accelerated share repurchase agreement."
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "us-gaap_AcceleratedShareRepurchasesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AcceleratedShareRepurchasesTable",
     "presentation": [
      "http://www.thecignagroup.com/role/CommonandPreferredStockAcceleratedShareRepurchaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accelerated Share Repurchases [Table]",
        "label": "Accelerated Share Repurchases [Table]",
        "documentation": "A table reflecting activity in an accelerated share repurchase (ASR) program."
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "ci_AcceleratedShareRepurchasesVolumeWeightedAverageSharePriceLessDiscount": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AcceleratedShareRepurchasesVolumeWeightedAverageSharePriceLessDiscount",
     "presentation": [
      "http://www.thecignagroup.com/role/CommonandPreferredStockAcceleratedShareRepurchaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accelerated stock repurchase, volume weighted average share price (in dollars per share)",
        "label": "Accelerated Share Repurchases, Volume Weighted Average Share Price, Less Discount",
        "documentation": "Accelerated Share Repurchases, Volume Weighted Average Share Price, Less Discount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdateExtensibleList",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Standards Update [Extensible List]",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "documentation": "Indicates amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r475",
      "r476",
      "r477",
      "r557",
      "r558",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r659",
      "r848",
      "r849",
      "r850",
      "r881",
      "r882",
      "r891",
      "r892",
      "r893",
      "r905",
      "r906",
      "r907",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r944",
      "r945",
      "r950",
      "r951",
      "r952",
      "r953",
      "r963",
      "r964",
      "r966",
      "r967",
      "r968",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1589"
     ]
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails": {
       "parentTag": "us-gaap_ReceivablesNetCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Accounts and Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "ci_AccountsAndOtherReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AccountsAndOtherReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails_1": {
       "parentTag": "ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables, including held for sale assets",
        "label": "Accounts and Other Receivables, Net, Current, Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Accounts and Other Receivables, Net, Current, Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ci_AccountsPayableAccruedExpensesOtherLiabilitiesPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AccountsPayableAccruedExpensesOtherLiabilitiesPolicyPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses and Other Current and Non-Current Liabilities",
        "label": "Accounts Payable Accrued Expenses Other Liabilities Policy [Policy Text Block]",
        "documentation": "Describes an entity's accounting policy for accounts payable, accrued expenses and other liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r1414"
     ]
    },
    "ci_AccountsReceivableUncommittedFactoringFacilityAccountsReceivableReceivedButNotRemitted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AccountsReceivableUncommittedFactoringFacilityAccountsReceivableReceivedButNotRemitted",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable received but not remitted, uncommitted factoring facility",
        "label": "Accounts Receivable, Uncommitted Factoring Facility, Accounts Receivable Received But Not Remitted",
        "documentation": "Amount of, as of the reporting date, of receivables sold to a financial institution under an uncommitted Accounts receivable factoring facility that have been received from the manufacturers but not yet remitted to the financial institution."
       }
      }
     },
     "auth_ref": []
    },
    "ci_AccountsReceivableUncommittedFactoringFacilityAmountSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AccountsReceivableUncommittedFactoringFacilityAmountSold",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable sold, uncommitted factoring facility",
        "label": "Accounts Receivable, Uncommitted Factoring Facility, Amount Sold",
        "documentation": "Amount of receivables sold to a financial institution under an uncommitted Accounts receivable factoring facility during the period."
       }
      }
     },
     "auth_ref": []
    },
    "ci_AccountsReceivableUncommittedFactoringFacilityAutomaticRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AccountsReceivableUncommittedFactoringFacilityAutomaticRenewalTerm",
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Automatic renewal term, uncommitted factoring facility (in years)",
        "label": "Accounts Receivable, Uncommitted Factoring Facility, Automatic Renewal Term",
        "documentation": "Automatic renewal term for uncommitted Accounts receivable factoring facility."
       }
      }
     },
     "auth_ref": []
    },
    "ci_AccountsReceivableUncommittedFactoringFacilityInitialTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AccountsReceivableUncommittedFactoringFacilityInitialTerm",
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial term, uncommitted factoring facility (in years)",
        "label": "Accounts Receivable, Uncommitted Factoring Facility, Initial Term",
        "documentation": "Initial term length for uncommitted Accounts receivable factoring facility."
       }
      }
     },
     "auth_ref": []
    },
    "ci_AccountsReceivableUncommittedFactoringFacilityTotalCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AccountsReceivableUncommittedFactoringFacilityTotalCapacity",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total capacity, uncommitted factoring facility",
        "label": "Accounts Receivable, Uncommitted Factoring Facility, Total Capacity",
        "documentation": "Total amount of certain accounts receivable that may be sold on a non-recourse basis to a financial institution under an uncommitted Accounts receivable factoring facility."
       }
      }
     },
     "auth_ref": []
    },
    "ci_AccruedExpensesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AccruedExpensesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other liabilities",
        "label": "Accrued Expenses And Other Liabilities",
        "documentation": "Carrying value as of the balance sheet date of other current liabilities and obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "ci_AccumulatedDefinedBenefitPlansAdjustmentGainLossOnSaleOfBusinessMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentGainLossOnSaleOfBusinessMember",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification adjustment for (gains) included in Shareholders' net income ((Loss) gain on sale of businesses)",
        "label": "Accumulated Defined Benefit Plans Adjustment, Gain (Loss) On Sale Of Business [Member]",
        "documentation": "Accumulated Defined Benefit Plans Adjustment, Gain (Loss) On Sale Of Business"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Postretirement benefits liability",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r31",
      "r73",
      "r1568",
      "r1569",
      "r1570"
     ]
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification adjustment for amortization of net prior actuarial losses and prior service costs (Interest expense and other)",
        "label": "Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Parent [Member]",
        "documentation": "Accumulated other comprehensive income (loss) related to gain (loss) component of defined benefit plans attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r31",
      "r73",
      "r434",
      "r435",
      "r1568"
     ]
    },
    "ci_AccumulatedDefinedBenefitPlansAdjustmentSettlementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentSettlementMember",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification adjustment for settlement (Interest expense and other)",
        "label": "Accumulated Defined Benefit Plans Adjustment Settlement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r404",
      "r1092"
     ]
    },
    "ci_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails_1": {
       "parentTag": "ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accumulated Amortization",
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Including Disposal Groups",
        "documentation": "Amount, including disposal groups, of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Translation of foreign currencies attributable to noncontrolling interest",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Noncontrolling Interest [Member]",
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r31",
      "r73",
      "r955",
      "r961",
      "r1568",
      "r1569",
      "r1570"
     ]
    },
    "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Translation of foreign currencies including portion attributable to noncontrolling interest",
        "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r31",
      "r73",
      "r433",
      "r1569",
      "r1570"
     ]
    },
    "ci_AccumulatedOtherComprehensiveIncomeDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AccumulatedOtherComprehensiveIncomeDisclosureTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "Accumulated Other Comprehensive Income (Loss) [Text Block]",
        "documentation": "Disclousre of the changes in the componenets of other comprehensive income/loss."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r434",
      "r955",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiariesDetails",
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "negatedLabel": "Loss related to unconsolidated entities reported on the equity method",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73",
      "r240",
      "r413",
      "r1086",
      "r1155",
      "r1159"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r434",
      "r955",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r31",
      "r73",
      "r910",
      "r913",
      "r993",
      "r1150",
      "r1151",
      "r1568",
      "r1569",
      "r1570",
      "r1586",
      "r1587",
      "r1588"
     ]
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedTranslationAdjustmentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Translation of foreign currencies attributable to parent",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r31",
      "r73",
      "r434",
      "r435",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r1568"
     ]
    },
    "ci_AcquisitionDispositionRunoffActivitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AcquisitionDispositionRunoffActivitiesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition, disposition or run-off activities",
        "label": "Acquisition Disposition Runoff Activities [Member]",
        "documentation": "Products related to acquisition, disposition or runoff activities."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1485"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.thecignagroup.com/role/CommonandPreferredStockAcceleratedShareRepurchaseAgreementsDetails",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r848",
      "r849",
      "r850",
      "r1187",
      "r1586",
      "r1587",
      "r1588",
      "r1725",
      "r1785"
     ]
    },
    "us-gaap_AdditionsToContractHoldersFunds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionsToContractHoldersFunds",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits and interest credited to contractholder deposit funds",
        "label": "Additions to Contract Holders Funds",
        "documentation": "The cash inflow from a segregated fund account during the period."
       }
      }
     },
     "auth_ref": [
      "r1572"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1491"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1491"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1491"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1491"
     ]
    },
    "ci_AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-tax adjusted income (loss) from operations",
        "label": "Adjusted Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:",
        "verboseLabel": "Adjustments to reconcile shareholders' net income to net cash provided by (used in) operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_AdministrativeServicesOnlyHealthCareServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AdministrativeServicesOnlyHealthCareServicesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Administrative Services Only Health Care Services",
        "label": "Administrative Services Only Health Care Services [Member]",
        "documentation": "Administrative Services Only Health Care Services"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1455",
      "r1467",
      "r1477",
      "r1503"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1458",
      "r1470",
      "r1480",
      "r1506"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r1491"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r1498"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r1462",
      "r1471",
      "r1481",
      "r1498",
      "r1507",
      "r1511",
      "r1519"
     ]
    },
    "ci_AllOtherCountriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AllOtherCountriesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationUSandForeignRevenuesfromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign countries",
        "label": "All Other Countries [Member]",
        "documentation": "All other countries not specified within the taxonomy."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r1517"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansCompensationCostandTaxEffectsofSharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total compensation cost for shared-based awards",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r843",
      "r855"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for current expected credit losses on accounts receivable",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r551",
      "r614"
     ]
    },
    "ci_AllowanceForReceivablesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AllowanceForReceivablesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for receivables, current",
        "label": "Allowance For Receivables Current",
        "documentation": "Amount of allowance for receivables, classified as current."
       }
      }
     },
     "auth_ref": []
    },
    "ci_AllowanceForReceivablesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AllowanceForReceivablesOther",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining allowances",
        "label": "Allowance For Receivables, Other",
        "documentation": "Amount of other allowances classified as current, including allowances, discounts and claims adjustments issued to customers in the form of client credits, allowance for current expected credit losses and other non-credit adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllowanceForReinsuranceRecoverableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForReinsuranceRecoverableMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reinsurance recoverables",
        "label": "SEC Schedule, 12-09, Allowance, Reinsurance Recoverable [Member]",
        "documentation": "Allowance for portion expected to be uncollectible of recoverable from reinsurer for paid and unpaid claims and claim settlement expense."
       }
      }
     },
     "auth_ref": [
      "r1581",
      "r1582",
      "r1583",
      "r1584",
      "r1585"
     ]
    },
    "us-gaap_AlternativeInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AlternativeInvestment",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsAdditionalInformationonSeparateAccountAssetsPricedatNetAssetValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Alternative Investment",
        "documentation": "Fair value of investment other than investment in equity security, investment in debt security and equity method investment. Includes, but is not limited to, investment in certain entities that calculate net asset value per share. Example includes, but is not limited to, investment in hedge fund, venture capital fund, private equity fund, and real estate partnership or fund."
       }
      }
     },
     "auth_ref": [
      "r929",
      "r941"
     ]
    },
    "ci_AlternativeInvestmentBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AlternativeInvestmentBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsAdditionalInformationonSeparateAccountAssetsPricedatNetAssetValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, including held for sale assets",
        "label": "Alternative Investment, Before Reclassification To Disposal Group, Assets Held For Sale",
        "documentation": "Alternative Investment, Before Reclassification To Disposal Group, Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_BenefitsLossesAndExpenses",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of acquired intangible assets",
        "verboseLabel": "Amortization of acquired intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r113",
      "r117"
     ]
    },
    "us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/ShareholdersEquityandDividendRestrictionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted GAAP net assets of The Cigna Group's subsidiaries",
        "label": "Amount of Restricted Net Assets for Consolidated and Unconsolidated Subsidiaries",
        "documentation": "Amount of restricted net assets of consolidated and unconsolidated subsidiaries as of the end of the most recently completed fiscal year."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "ci_AnnuitizationElectionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AnnuitizationElectionPeriod",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesSummaryofMarketRiskBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annuitization election period",
        "label": "Annuitization Election Period",
        "documentation": "The period of time prior to a policy anniversary when an annuitization election must occur."
       }
      }
     },
     "auth_ref": []
    },
    "ci_AnthemMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AnthemMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuesfromUSFederalGovernmentAgenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anthem [Member]",
        "label": "Anthem [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareOutstandingEmployeeStockOptionsNotIncludedintheComputationofDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive options (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareOutstandingEmployeeStockOptionsNotIncludedintheComputationofDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareOutstandingEmployeeStockOptionsNotIncludedintheComputationofDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareOutstandingEmployeeStockOptionsNotIncludedintheComputationofDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails": {
       "parentTag": "us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Reversal of effect of discount rate assumptions",
        "negatedPeriodEndLabel": "Effect of discount rate assumptions",
        "label": "AOCI, Liability for Future Policy Benefit, Expected Future Policy Benefit, before Tax",
        "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) (AOCI) from (increase) decrease in expected future policy benefit component of liability for future policy benefit from change in discount rate."
       }
      }
     },
     "auth_ref": [
      "r1418",
      "r1422",
      "r1769",
      "r1774"
     ]
    },
    "us-gaap_AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails": {
       "parentTag": "us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedPeriodStartLabel": "Reversal of effect of beginning of period discount rate assumptions",
        "periodEndLabel": "Effect of end of period discount rate assumptions",
        "label": "AOCI, Liability for Future Policy Benefit, Expected Net Premium, before Tax",
        "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) (AOCI) from increase (decrease) in expected net premium component of liability for future policy benefit from change in discount rate."
       }
      }
     },
     "auth_ref": [
      "r1418",
      "r1422",
      "r1769",
      "r1774"
     ]
    },
    "us-gaap_AociLiabilityForFuturePolicyBenefitParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AociLiabilityForFuturePolicyBenefitParentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current period change in discount rate for certain long-duration liabilities",
        "label": "AOCI, Liability for Future Policy Benefit, Parent [Member]",
        "documentation": "Accumulated other comprehensive income (loss) (AOCI) from (increase) decrease in liability for future policy benefit from change in discount rate, attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r424",
      "r434",
      "r435",
      "r899",
      "r1568"
     ]
    },
    "us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesSummaryofMarketRiskBenefitDetails": {
       "parentTag": "us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesSummaryofMarketRiskBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Nonperformance risk (own credit risk), end of period",
        "label": "AOCI, Market Risk Benefit, Instrument-Specific Credit Risk, before Tax",
        "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) (AOCI) from (increase) decrease in instrument-specific credit risk on contract or contract feature in long-duration contract issued by insurance entity protecting contract holder from other-than-nominal capital market risk and exposing insurance entity to other-than-nominal capital market risk."
       }
      }
     },
     "auth_ref": [
      "r1421",
      "r1424",
      "r1771",
      "r1775"
     ]
    },
    "us-gaap_AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current period change in instrument-specific credit risk for market risk benefits",
        "label": "AOCI, Market Risk Benefit, Instrument-Specific Credit Risk, Parent [Member]",
        "documentation": "Accumulated other comprehensive income (loss) (AOCI) from (increase) decrease in instrument-specific credit risk on contract or contract feature in long-duration contract issued by insurance entity protecting contract holder from other-than-nominal capital market risk and exposing insurance entity to other-than-nominal capital market risk, attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r424",
      "r434",
      "r435",
      "r899",
      "r1568"
     ]
    },
    "ci_AssetBackedAndCorporateSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AssetBackedAndCorporateSecuritiesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/VariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset-backed and corporate securities",
        "label": "Asset Backed And Corporate Securities [Member]",
        "documentation": "Asset Backed And Corporate Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetBackedSecuritiesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails",
      "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesDetails",
      "http://www.thecignagroup.com/role/PensionPensionPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mortgage and other asset-backed",
        "verboseLabel": "Mortgage and other asset-backed securities",
        "label": "Asset-Backed Securities [Member]",
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans."
       }
      }
     },
     "auth_ref": [
      "r1397",
      "r1597",
      "r1602",
      "r1603"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiariesDetails",
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "terseLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r408",
      "r454",
      "r512",
      "r533",
      "r539",
      "r602",
      "r683",
      "r684",
      "r686",
      "r687",
      "r688",
      "r690",
      "r692",
      "r694",
      "r695",
      "r895",
      "r901",
      "r949",
      "r1080",
      "r1225",
      "r1414",
      "r1444",
      "r1643",
      "r1644",
      "r1740"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_AssetsAndLiabilitiesLesseeFinanceLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AssetsAndLiabilitiesLesseeFinanceLeasesAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance leases:",
        "label": "Assets And Liabilities, Lessee, Finance Leases [Abstract]",
        "documentation": "Assets And Liabilities, Lessee, Finance Leases"
       }
      }
     },
     "auth_ref": []
    },
    "ci_AssetsAndLiabilitiesLesseeOperatingLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AssetsAndLiabilitiesLesseeOperatingLeasesAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases:",
        "label": "Assets And Liabilities, Lessee, Operating Leases [Abstract]",
        "documentation": "Assets And Liabilities, Lessee, Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "ci_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating and Finance Lease Right of Use (\"ROU\") Assets and Lease Liabilities",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "documentation": "Tabular disclosure of lessee right-of-use assets and lease liabilities for operating and finance leases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "terseLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r418",
      "r454",
      "r602",
      "r683",
      "r684",
      "r686",
      "r687",
      "r688",
      "r690",
      "r692",
      "r694",
      "r695",
      "r895",
      "r901",
      "r949",
      "r1414",
      "r1643",
      "r1644",
      "r1740"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets at fair value:",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsHeldByInsuranceRegulators": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsHeldByInsuranceRegulators",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/ShareholdersEquityandDividendRestrictionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments on deposit with regulatory bodies",
        "label": "Assets Held by Insurance Regulators",
        "documentation": "Carrying amount of cash and investment securities on deposit with state regulatory authorities in connection with capital requirements."
       }
      }
     },
     "auth_ref": [
      "r1173"
     ]
    },
    "ci_AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentComponentsofDepreciationandAmortizationExpenseDetails",
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other property and equipment",
        "terseLabel": "Other property and equipment",
        "label": "Assets Held Under Capital Leases And Other Capitalized Property Plant And Equipment [Member]",
        "documentation": "Long lived property, plant or equipment assets held by a lessee through a captial lease and all other long term captalized assts related to property plant and equipment not otherwise previously categorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets of businesses held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Assets",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r217",
      "r223",
      "r263",
      "r396",
      "r397"
     ]
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets of businesses held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r217",
      "r223",
      "r261",
      "r263",
      "r396",
      "r397"
     ]
    },
    "us-gaap_AssumedPremiumsEarned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssumedPremiumsEarned",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ReinsuranceEffectsofReinsuranceDetails": {
       "parentTag": "us-gaap_PremiumsEarnedNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceEffectsofReinsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assumed",
        "label": "Assumed Premiums Earned",
        "documentation": "Amount of earned premiums assumed from other entities."
       }
      }
     },
     "auth_ref": [
      "r1122",
      "r1163",
      "r1166",
      "r1760"
     ]
    },
    "ci_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.thecignagroup.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r1449",
      "r1450",
      "r1463"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.thecignagroup.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r1449",
      "r1450",
      "r1463"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.thecignagroup.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r1449",
      "r1450",
      "r1463"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Appreciation",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized Depreciation",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "ci_AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized cost, including held for sale assets",
        "label": "Available For Sale Debt Securities Amortized Cost Basis Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Available For Sale Debt Securities Amortized Cost Basis Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Appreciation, including held for sale assets",
        "label": "Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized Depreciation, including held for sale assets",
        "label": "Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": "ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized Depreciation, including held for sale assets",
        "label": "Available For Sale Securities Continuous Unrealized Loss Position 12 Months Or Longer Accumulated Loss Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Available For Sale Securities Continuous Unrealized Loss Position 12 Months Or Longer Accumulated Loss Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": "ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized Depreciation, including held for sale assets",
        "label": "Available For Sale Securities Continuous Unrealized Loss Position Less Than 12 Months Accumulated Loss Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Available For Sale Securities Continuous Unrealized Loss Position Less Than 12 Months Accumulated Loss Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": "ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost, including held for sale assets",
        "label": "Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Amortized Cost Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Amortized Cost Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": "ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, including held for sale assets",
        "label": "Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": "ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost, including held for sale assets",
        "label": "Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Amortized Cost Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Amortized Cost Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": "ci_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, including held for sale assets",
        "label": "Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1600"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r572",
      "r1068"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1599"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r571",
      "r1067"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1601"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r573",
      "r1069"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1598"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r570",
      "r1066"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping."
       }
      }
     },
     "auth_ref": [
      "r1596",
      "r1597"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r1065",
      "r1596"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r564",
      "r622",
      "r1057",
      "r1595"
     ]
    },
    "ci_AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, including held for sale assets",
        "verboseLabel": "Debt Securities, including held for sale assets",
        "label": "Available For Sale Securities Debt Securities Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Available For Sale Securities Debt Securities Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureLessThan12MonthsNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureLessThan12MonthsNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": "ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Issues, including held for sale assets",
        "label": "Available For Sale Securities In Unrealized Loss Positions, Qualitative Disclosure, Less Than 12 Months, Number Of Positions, Before Reclassification To Disposal Group, Assets Held For Sale",
        "documentation": "Available For Sale Securities In Unrealized Loss Positions, Qualitative Disclosure, Less Than 12 Months, Number Of Positions, Before Reclassification To Disposal Group, Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Number of Issues, including held for sale assets",
        "label": "Available For Sale Securities In Unrealized Loss Positions, Qualitative Disclosure, Number Of Positions, Before Reclassification To Disposal Group, Assets Held For Sale",
        "documentation": "Available For Sale Securities In Unrealized Loss Positions, Qualitative Disclosure, Number Of Positions, Before Reclassification To Disposal Group, Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureTwelveMonthsOrLongerNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureTwelveMonthsOrLongerNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": "ci_AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Issues, including held for sale assets",
        "label": "Available For Sale Securities In Unrealized Loss Positions, Qualitative Disclosure, Twelve Months Or Longer, Number Of Positions, Before Reclassification To Disposal Group, Assets Held For Sale",
        "documentation": "Available For Sale Securities In Unrealized Loss Positions, Qualitative Disclosure, Twelve Months Or Longer, Number Of Positions, Before Reclassification To Disposal Group, Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_AverageInterestRateOnIntercompanyLoan": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "AverageInterestRateOnIntercompanyLoan",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupIntercompanyBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average interest rate on intercompany loan",
        "label": "Average Interest Rate On Intercompany Loan",
        "documentation": "The average monthly interest on an intercompany loan"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1514"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r1515"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1510"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1510"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1510"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1510"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1510"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1510"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansBlackScholesOptionPricingModelAssumptionsDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansFairValueofVestedRestrictedStockandSPSsDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansNarrativeDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinCommonStockOptionsDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinRestrictedStockAwardsandSPSsDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsExercisedDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsOutstandingDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r814",
      "r815",
      "r816",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r1513"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1512"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1511"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1511"
     ]
    },
    "ci_BalanceSheetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "BalanceSheetAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet [Abstract]",
        "label": "Balance Sheet [Abstract]",
        "documentation": "Balance Sheet"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Axis]",
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Domain]",
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r180"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "ci_BelowInvestmentGradeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "BelowInvestmentGradeMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Below investment grade",
        "label": "Below Investment Grade [Member]",
        "documentation": "External credit-ratings or internal groupings that could be used to describe the current status of the payment and performance risk of debt and securities investments that connote non-investment grade."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BenefitsLossesAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BenefitsLossesAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL BENEFITS AND EXPENSES",
        "label": "Benefits, Losses and Expenses",
        "documentation": "The total amount of expense recognized during the period for future policy benefits, claims and claims adjustment costs, and for selling, general and administrative costs."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_BenefitsLossesAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BenefitsLossesAndExpensesAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Benefits and expenses",
        "label": "Benefits, Losses and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaAndOtherRecoverablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "BerkshireHathwayLifeInsuranceCompanyOfNebraskaAndOtherRecoverablesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Berkshire Hathway Life Insurance Company Of Nebraska and Other Recoverables",
        "label": "Berkshire Hathway Life Insurance Company Of Nebraska And Other Recoverables [Member]",
        "documentation": "Berkshire Hathway Life Insurance Company Of Nebraska And Other Recoverables"
       }
      }
     },
     "auth_ref": []
    },
    "ci_BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Berkshire",
        "label": "Berkshire Hathway Life Insurance Company Of Nebraska [Member]",
        "documentation": "Berkshire Hathway Life Insurance Company Of Nebraska"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BuildingAndBuildingImprovementsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Buildings and Improvements",
        "label": "Building and Building Improvements [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combinations",
        "label": "Business Combinations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_BusinessExitCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessExitCosts1",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/OrganizationalEfficiencyPlanDetails": {
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/OrganizationalEfficiencyPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One-time expenses related to abandonment of leased assets and impairment of property and equipment",
        "label": "Business Exit Costs",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "ci_CHSSJVLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "CHSSJVLLCMember",
     "presentation": [
      "http://www.thecignagroup.com/role/MergersAcquisitionsandDivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CHSS JV LLC",
        "label": "CHSS JV LLC [Member]",
        "documentation": "CHSS JV LLC"
       }
      }
     },
     "auth_ref": []
    },
    "country_CN": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "CN",
     "presentation": [
      "http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "China",
        "label": "CHINA"
       }
      }
     },
     "auth_ref": []
    },
    "ci_CapitalizationOfDeferredPolicyAcquisitionCostsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "CapitalizationOfDeferredPolicyAcquisitionCostsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Policy Acquisition Costs",
        "label": "Capitalization Of Deferred Policy Acquisition Costs Policy [Policy Text Block]",
        "documentation": "Describes an insurance entity's accounting policy for deferred policy acquisition costs, including the nature and amount of capitalized costs incurred to write or acquire insurance contracts, and the basis for and methodologies applied in capitalizing and amortizing such costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying Value",
        "label": "Reported Value Measurement [Member]",
        "documentation": "Measured as reported on the statement of financial position (balance sheet)."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r194"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r401",
      "r1363"
     ]
    },
    "ci_CashAndCashEquivalentsInvestmentTradeReceivablesNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "CashAndCashEquivalentsInvestmentTradeReceivablesNetMember",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionPensionPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents and other current assets, net",
        "label": "Cash And Cash Equivalents Investment Trade Receivables Net [Member]",
        "documentation": "Reflects cash, cash equivalents and net receivables for investment sales and purchases. Cash and cash equivalents includes currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "ci_CashCashEquivalentsAndShortTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "CashCashEquivalentsAndShortTermInvestmentsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Short-term investments and cash",
        "label": "Cash Cash Equivalents And Short Term Investments [Member]",
        "documentation": "Aggregate of cash, cash equivalents and short-term investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents and restricted cash and cash equivalents December 31,",
        "periodStartLabel": "Cash, cash equivalents and restricted cash and cash equivalents January 1,",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of year (2)",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r252",
      "r449"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cash and cash equivalents reclassified to assets of businesses held for sale",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r252",
      "r449"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash January 1, including held for sale assets",
        "periodEndLabel": "Cash, cash equivalents and restricted cash December 31, including held for sale assets",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r252",
      "r449"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r252"
     ]
    },
    "us-gaap_CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends received from subsidiaries",
        "label": "SEC Schedule, 12-04, Cash Dividends Paid to Registrant, Consolidated Subsidiaries",
        "documentation": "This element represents disclosure of the aggregate cash dividends paid to the entity by consolidated subsidiaries."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "ci_CashFlowActivitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "CashFlowActivitiesLesseeAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesSupplementalCashFlowInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:",
        "label": "Cash Flow Activities, Lessee [Abstract]",
        "documentation": "Cash Flow Activities, Lessee"
       }
      }
     },
     "auth_ref": []
    },
    "ci_CashFlowActivitiesLesseeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "CashFlowActivitiesLesseeTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Cash Flow Information Related to Leases",
        "label": "Cash Flow Activities Lessee [Table Text Block]",
        "documentation": "Tabular disclosure of lessee cash flows related to finance and operating leases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashSurrenderValueDuePolicyholdersAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashSurrenderValueDuePolicyholdersAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash surrender value",
        "label": "Policyholder Account Balance, Cash Surrender Value",
        "documentation": "Amount of cash to be paid to policyholder upon termination and surrender of long-duration contract issued by insurance entity."
       }
      }
     },
     "auth_ref": [
      "r1142",
      "r1423"
     ]
    },
    "us-gaap_CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]",
        "label": "Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_CededCreditCollateralizationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "CededCreditCollateralizationRiskMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collateralization risk",
        "label": "Ceded Credit Collateralization Risk [Member]",
        "documentation": "Concentration risk related to collateralization of a specified benchmark, such as reinsurance recoverables."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CededCreditRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CededCreditRiskAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails",
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ceded Credit Risk, Reinsurer [Axis]",
        "label": "Reinsurer, Name [Axis]",
        "documentation": "Information by name of reinsurer or group of reinsurers in reinsurance contract."
       }
      }
     },
     "auth_ref": [
      "r1538",
      "r1748"
     ]
    },
    "us-gaap_CededCreditRiskCollateralizationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CededCreditRiskCollateralizationAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails",
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ceded Credit Risk, Collateralization [Axis]",
        "label": "Ceded Credit Risk, Collateralization [Axis]",
        "documentation": "Information as to collaterization of reinsurance recoverables."
       }
      }
     },
     "auth_ref": [
      "r1538"
     ]
    },
    "us-gaap_CededCreditRiskCollateralizationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CededCreditRiskCollateralizationDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails",
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ceded Credit Risk, Collateralization [Domain]",
        "label": "Ceded Credit Risk, Collateralization [Domain]",
        "documentation": "Collateralization of ceded credit risk."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CededCreditRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CededCreditRiskLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails",
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ceded Credit Risk [Line Items]",
        "label": "Ceded Credit Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1174"
     ]
    },
    "us-gaap_CededCreditRiskReinsurerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CededCreditRiskReinsurerDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails",
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ceded Credit Risk, Reinsurer [Domain]",
        "label": "Reinsurer, Name [Domain]",
        "documentation": "Name of reinsurer or group of reinsurers in reinsurance contract."
       }
      }
     },
     "auth_ref": [
      "r1748"
     ]
    },
    "ci_CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collateral provisions exist that may mitigate risk of credit loss",
        "label": "Ceded Credit Risk, Secured, Collateral Provisions Exist That May Mitigate Risk [Member]",
        "documentation": "Ceded Credit Risk, Secured, Collateral Provisions Exist That May Mitigate Risk"
       }
      }
     },
     "auth_ref": []
    },
    "ci_CededCreditRiskSecuredContractuallyRequiredFairValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "CededCreditRiskSecuredContractuallyRequiredFairValueMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of collateral contractually required to meet or exceed carrying value of recoverable",
        "label": "Ceded Credit Risk, Secured, Contractually Required Fair Value [Member]",
        "documentation": "Ceded Credit Risk, Secured, Contractually Required Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CededCreditRiskSecuredMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CededCreditRiskSecuredMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails",
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured",
        "label": "Ceded Credit Risk, Secured [Member]",
        "documentation": "Reinsurance recoverable that is secured by collateral."
       }
      }
     },
     "auth_ref": [
      "r1538"
     ]
    },
    "us-gaap_CededCreditRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CededCreditRiskTable",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails",
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ceded Credit Risk [Table]",
        "label": "Ceded Credit Risk [Table]",
        "documentation": "Disclosure of information about reinsurer or group of reinsurers for whom the entity has a concentration of credit risk."
       }
      }
     },
     "auth_ref": [
      "r1174"
     ]
    },
    "us-gaap_CededCreditRiskUnsecuredMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CededCreditRiskUnsecuredMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "No collateral",
        "label": "Ceded Credit Risk, Unsecured [Member]",
        "documentation": "Reinsurance recoverable that is not secured by collateral."
       }
      }
     },
     "auth_ref": [
      "r1538"
     ]
    },
    "us-gaap_CededPremiumsEarned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CededPremiumsEarned",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ReinsuranceEffectsofReinsuranceDetails": {
       "parentTag": "us-gaap_PremiumsEarnedNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceEffectsofReinsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Ceded",
        "label": "Ceded Premiums Earned",
        "documentation": "Amount of earned premiums ceded to other entities."
       }
      }
     },
     "auth_ref": [
      "r1121",
      "r1160",
      "r1161",
      "r1164",
      "r1166",
      "r1760"
     ]
    },
    "ci_CededReinsuranceAgreementCoverageLimitAmountRemaining": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "CededReinsuranceAgreementCoverageLimitAmountRemaining",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining overall limit under reinsurance agreement",
        "label": "Ceded Reinsurance Agreement, Coverage Limit, Amount Remaining",
        "documentation": "Amount remaining of overall limit to claims covered under ceded reinsurance agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ci_CededReinsuranceAgreementReinsuredRiskPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "CededReinsuranceAgreementReinsuredRiskPercentage",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percent of future claim payments reinsured",
        "label": "Ceded Reinsurance Agreement Reinsured Risk Percentage",
        "documentation": "Percent of future claim payments reinsured under reinsurance agreement(s), net of existing retrocessional arrangements at the time agreement was made."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1489"
     ]
    },
    "ci_CignaHealthcareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "CignaHealthcareMember",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentGoodwillActivityDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsInterestRatesandDurationDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails",
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cigna Healthcare",
        "label": "Cigna Healthcare [Member]",
        "documentation": "Cigna Healthcare"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClaimsDevelopmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClaimsDevelopmentLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Claims Development [Line Items]",
        "label": "Claims Development [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1490"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1490"
     ]
    },
    "us-gaap_CommercialPaper": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaper",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails": {
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper",
        "label": "Commercial Paper",
        "documentation": "Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r295",
      "r1753"
     ]
    },
    "srt_CommercialPaperAverageRatePaid": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CommercialPaperAverageRatePaid",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtShorttermandCreditFacilitiesDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper average interest rate",
        "label": "Commercial Paper, Average Rate Paid",
        "documentation": "Average rate paid on commercial paper."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r343"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtShorttermandCreditFacilitiesDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Paper",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r1433",
      "r1434",
      "r1435",
      "r1438"
     ]
    },
    "us-gaap_CommercialPortfolioSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPortfolioSegmentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoanPortfolioDetails",
      "http://www.thecignagroup.com/role/InvestmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Portfolio Segment",
        "label": "Commercial Portfolio Segment [Member]",
        "documentation": "Portfolio segment of the company's total financing receivables related to commercial receivables."
       }
      }
     },
     "auth_ref": []
    },
    "ci_CommitmentToFundPartnershipMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "CommitmentToFundPartnershipMember",
     "presentation": [
      "http://www.thecignagroup.com/role/VariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment to fund partnership",
        "label": "Commitment To Fund Partnership [Member]",
        "documentation": "Commitment To Fund Partnership"
       }
      }
     },
     "auth_ref": []
    },
    "ci_CommitmentToPurchaseEquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "CommitmentToPurchaseEquitySecuritiesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment to purchase equity securities",
        "label": "Commitment To Purchase Equity Securities [Member]",
        "documentation": "Commitment To Purchase Equity Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingencies \u2014 Note 24",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r202",
      "r1084",
      "r1211"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMatters"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingencies and Other Matters",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r670",
      "r671",
      "r1344",
      "r1634"
     ]
    },
    "ci_CommitmentsAndContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "CommitmentsAndContingenciesLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments And Contingencies [Line Items]",
        "label": "Commitments And Contingencies [Line Items]",
        "documentation": "Commitments And Contingencies"
       }
      }
     },
     "auth_ref": []
    },
    "ci_CommitmentsAndContingenciesNumberOfAdditionalExpert": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "CommitmentsAndContingenciesNumberOfAdditionalExpert",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of additional experts",
        "label": "Commitments And Contingencies, Number Of Additional Expert",
        "documentation": "Commitments And Contingencies, Number Of Additional Expert"
       }
      }
     },
     "auth_ref": []
    },
    "ci_CommitmentsAndContingenciesNumberOfExpert": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "CommitmentsAndContingenciesNumberOfExpert",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of experts",
        "label": "Commitments And Contingencies, Number Of Expert",
        "documentation": "Commitments And Contingencies, Number Of Expert"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment and Contingencies",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r1345"
     ]
    },
    "ci_CommitmentsAndContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "CommitmentsAndContingenciesTable",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments And Contingencies [Table]",
        "label": "Commitments And Contingencies [Table]",
        "documentation": "Commitments And Contingencies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_CommitmentsToContributeAdditionalEquityAndCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "CommitmentsToContributeAdditionalEquityAndCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unfunded commitments",
        "label": "Commitments To Contribute Additional Equity And Capital",
        "documentation": "Investment commitments of estimated payments required under contractual arrangements diversified by issuer, property type and geographic regions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockDividendsPerShareCashPaid",
     "presentation": [
      "http://www.thecignagroup.com/role/CommonandPreferredStockDividendsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount per share (in dollars per share)",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockDividendsPerShareDeclared",
     "presentation": [
      "http://www.thecignagroup.com/role/CommonandPreferredStockDividendsDetails",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common dividends declared (in dollars per share)",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r1429",
      "r1430",
      "r1431",
      "r1433",
      "r1434",
      "r1435",
      "r1438",
      "r1586",
      "r1587",
      "r1725",
      "r1778",
      "r1785"
     ]
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/CommonandPreferredStockShareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.thecignagroup.com/role/CommonandPreferredStockShareActivityDetails",
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.thecignagroup.com/role/CommonandPreferredStockShareActivityDetails",
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r1212"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.thecignagroup.com/role/CommonandPreferredStockShareActivityDetails",
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.thecignagroup.com/role/CommonandPreferredStockShareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding - beginning balance (in shares)",
        "periodEndLabel": "Outstanding - ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r234",
      "r1212",
      "r1231",
      "r1785",
      "r1786"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r1085",
      "r1414"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1495"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1494"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1496"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1493"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Benefits [Abstract]",
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_CompletionFactorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "CompletionFactorsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actual completion factors",
        "label": "Completion Factors [Member]",
        "documentation": "Amounts relating to actual claims emerging differently from assumptions about claim payment speed used to set reserves."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets",
        "label": "Components of Deferred Tax Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ComponentsOfDeferredTaxAssetsIncludingDisposalGroupsAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets, including held for sale assets",
        "label": "Components of Deferred Tax Assets Including Disposal Groups [Abstract]",
        "documentation": "Components of Deferred Tax Assets Including Disposal Groups"
       }
      }
     },
     "auth_ref": []
    },
    "ci_ComponentsOfDepreciationAndAmortizationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ComponentsOfDepreciationAndAmortizationTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of Depreciation and Amortization Expense",
        "label": "Components Of Depreciation And Amortization [Table Text Block]",
        "documentation": "Discloses the depreciation and amortization of property and equipment and other intangibles."
       }
      }
     },
     "auth_ref": []
    },
    "ci_ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive income",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest, Including Temporary Equity",
        "documentation": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest, Including Temporary Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "SHAREHOLDERS' COMPREHENSIVE INCOME",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r429",
      "r431",
      "r439",
      "r1060",
      "r1104"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive income attributable to noncontrolling interests",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r156",
      "r169",
      "r429",
      "r431",
      "r438",
      "r1059",
      "r1103"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive income (loss) attributable to noncontrolling interests",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesPretaxIncomeFromForeignOperationsDetails",
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails",
      "http://www.thecignagroup.com/role/ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails",
      "http://www.thecignagroup.com/role/SegmentInformationRevenuesfromUSFederalGovernmentAgenciesDetails",
      "http://www.thecignagroup.com/role/SegmentInformationUSandForeignRevenuesfromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r100",
      "r195",
      "r196",
      "r547",
      "r1343"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesPretaxIncomeFromForeignOperationsDetails",
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails",
      "http://www.thecignagroup.com/role/ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails",
      "http://www.thecignagroup.com/role/SegmentInformationRevenuesfromUSFederalGovernmentAgenciesDetails",
      "http://www.thecignagroup.com/role/SegmentInformationUSandForeignRevenuesfromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r100",
      "r195",
      "r196",
      "r547",
      "r1174",
      "r1343"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesPretaxIncomeFromForeignOperationsDetails",
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails",
      "http://www.thecignagroup.com/role/ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails",
      "http://www.thecignagroup.com/role/SegmentInformationRevenuesfromUSFederalGovernmentAgenciesDetails",
      "http://www.thecignagroup.com/role/SegmentInformationUSandForeignRevenuesfromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r100",
      "r195",
      "r196",
      "r547",
      "r1343",
      "r1538"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesPretaxIncomeFromForeignOperationsDetails",
      "http://www.thecignagroup.com/role/SegmentInformationRevenuesfromUSFederalGovernmentAgenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Line Items]",
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1343"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesPretaxIncomeFromForeignOperationsDetails",
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails",
      "http://www.thecignagroup.com/role/ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails",
      "http://www.thecignagroup.com/role/SegmentInformationRevenuesfromUSFederalGovernmentAgenciesDetails",
      "http://www.thecignagroup.com/role/SegmentInformationUSandForeignRevenuesfromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r100",
      "r195",
      "r196",
      "r547"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesPretaxIncomeFromForeignOperationsDetails",
      "http://www.thecignagroup.com/role/SegmentInformationRevenuesfromUSFederalGovernmentAgenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Table]",
        "label": "Concentration Risk [Table]",
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r96",
      "r100",
      "r101",
      "r195",
      "r291",
      "r1343"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesPretaxIncomeFromForeignOperationsDetails",
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails",
      "http://www.thecignagroup.com/role/ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails",
      "http://www.thecignagroup.com/role/SegmentInformationRevenuesfromUSFederalGovernmentAgenciesDetails",
      "http://www.thecignagroup.com/role/SegmentInformationUSandForeignRevenuesfromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r100",
      "r195",
      "r196",
      "r547",
      "r1343"
     ]
    },
    "srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Financial Information Disclosure [Abstract]",
        "label": "Condensed Financial Information Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroup"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule I - Condensed Financial Information of The Cigna Group",
        "label": "Condensed Financial Information of Parent Company Only Disclosure [Text Block]",
        "documentation": "The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r461",
      "r1528"
     ]
    },
    "ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfIssuancesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "CondensedFinancialInformationOfParentCompanyOnlyScheduleOfIssuancesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SECScheduleArticle1204CondensedFinancialInformationofRegistrantTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Debt Issuances",
        "label": "Condensed Financial Information Of Parent Company Only, Schedule Of Issuances Of Long-Term Debt [Table Text Block]",
        "documentation": "Condensed Financial Information Of Parent Company Only, Schedule Of Issuances Of Long-Term Debt"
       }
      }
     },
     "auth_ref": []
    },
    "ci_CondensedFinancialInformationOfParentCompanyOnlyScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "CondensedFinancialInformationOfParentCompanyOnlyScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SECScheduleArticle1204CondensedFinancialInformationofRegistrantTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Long-Term Debt",
        "label": "Condensed Financial Information Of Parent Company Only, Schedule Of Maturities Of Long-Term Debt [Table Text Block]",
        "documentation": "Condensed Financial Information Of Parent Company Only, Schedule Of Maturities Of Long-Term Debt"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CondensedFinancialStatementsCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CondensedFinancialStatementsCaptionsLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupIntercompanyBalancesDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Financial Statements, Captions [Line Items]",
        "label": "Condensed Financial Statements, Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r386",
      "r387",
      "r388",
      "r461",
      "r1528"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupDebtMaturitiesDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupGuaranteesDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupIntercompanyBalancesDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShareRepurchaseDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails",
      "http://www.thecignagroup.com/role/VariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Axis]",
        "label": "Consolidated Entities [Axis]",
        "documentation": "Information by consolidated entity or group of entities."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r461",
      "r895",
      "r896",
      "r901",
      "r902",
      "r998",
      "r1355",
      "r1559",
      "r1562",
      "r1563",
      "r1642",
      "r1645",
      "r1646"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupDebtMaturitiesDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupGuaranteesDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupIntercompanyBalancesDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShareRepurchaseDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails",
      "http://www.thecignagroup.com/role/VariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Domain]",
        "label": "Consolidated Entities [Domain]",
        "documentation": "Entity or group of entities consolidated into reporting entity."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r461",
      "r895",
      "r896",
      "r901",
      "r902",
      "r998",
      "r1355",
      "r1559",
      "r1562",
      "r1563",
      "r1642",
      "r1645",
      "r1646"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Axis]",
        "label": "Consolidation Items [Axis]",
        "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r461",
      "r514",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r537",
      "r541",
      "r683",
      "r684",
      "r685",
      "r686",
      "r688",
      "r689",
      "r691",
      "r693",
      "r694",
      "r1560",
      "r1561",
      "r1643",
      "r1644"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Domain]",
        "label": "Consolidation Items [Domain]",
        "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r461",
      "r514",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r537",
      "r541",
      "r683",
      "r684",
      "r685",
      "r686",
      "r688",
      "r689",
      "r691",
      "r693",
      "r694",
      "r1560",
      "r1561",
      "r1643",
      "r1644"
     ]
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entities",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined)."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r160",
      "r163"
     ]
    },
    "ci_ContractholderDepositFundsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ContractholderDepositFundsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractholder Deposit Funds",
        "label": "Contractholder Deposit Funds, Policy [Policy Text Block]",
        "documentation": "Describes an entity's accounting policy for contractholder deposit funds."
       }
      }
     },
     "auth_ref": []
    },
    "ci_ContractualAllowanceNoninsuranceCustomerReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ContractualAllowanceNoninsuranceCustomerReceivables",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noninsurance customer receivables allowance",
        "label": "Contractual Allowance, Noninsurance Customer Receivables",
        "documentation": "Amount of contractual allowances from third-party payors based upon the contractual payment terms."
       }
      }
     },
     "auth_ref": []
    },
    "ci_ContractualAllowancePharmaceuticalManufacturersReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ContractualAllowancePharmaceuticalManufacturersReceivables",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pharmaceutical manufacturers receivables allowance",
        "label": "Contractual Allowance, Pharmaceutical Manufacturers Receivables",
        "documentation": "Amount of contractual allowances for certain rebates receivables with pharmaceutical manufacturers, classified as current."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of Outstanding Long-Term Debt",
        "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r1580"
     ]
    },
    "ci_CorporateAndEliminationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "CorporateAndEliminationsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate and Eliminations",
        "label": "Corporate And Eliminations [Member]",
        "documentation": "Reflects amounts not allocated to other segments, such as net interest expense (defined as interest on corporate debt less net investment income on investments not supporting segment operations), interest on uncertain tax positions, certain litigation matters, intersegment eliminations, compensation cost for stock options, expense associated with its frozen pension plans, certain corporate project and overhead costs."
       }
      }
     },
     "auth_ref": []
    },
    "ci_CorporateAndGovernmentDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "CorporateAndGovernmentDebtSecuritiesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate",
        "label": "Corporate And Government Debt Securities [Member]",
        "documentation": "This category includes information about debt securities that are issued by either a domestic or foreign corporate business entity with a promise of repayment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesDetails",
      "http://www.thecignagroup.com/role/PensionPensionPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Corporate",
        "terseLabel": "Corporate securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r1397",
      "r1399",
      "r1776"
     ]
    },
    "us-gaap_CorporateNonSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateNonSegmentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate",
        "label": "Corporate, Non-Segment [Member]",
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r532",
      "r533",
      "r534",
      "r535",
      "r541",
      "r1593"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_BenefitsLossesAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pharmacy and other service costs",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r1038"
     ]
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Goods and Service",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r1547"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails",
      "http://www.thecignagroup.com/role/DescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]",
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r458",
      "r459",
      "r700",
      "r726",
      "r997",
      "r1365",
      "r1367"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtShorttermandCreditFacilitiesDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtShorttermandCreditFacilitiesDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Rating, Nationally Recognized Statistical Rating Organization (NRSRO) [Axis]",
        "label": "Credit Rating, Nationally Recognized Statistical Rating Organization (NRSRO) [Axis]",
        "documentation": "Credit Rating, Nationally Recognized Statistical Rating Organization (NRSRO)"
       }
      }
     },
     "auth_ref": []
    },
    "ci_CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSRODomain",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Rating, Nationally Recognized Statistical Rating Organization (NRSRO) [Domain]",
        "label": "Credit Rating, Nationally Recognized Statistical Rating Organization (NRSRO) [Domain]",
        "documentation": "Credit Rating, Nationally Recognized Statistical Rating Organization (NRSRO)"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails",
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment upon Adoption",
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "documentation": "Increase (decrease) to financial statements for cumulative-effect adjustment in period of adoption of amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r474",
      "r482",
      "r489",
      "r607",
      "r613",
      "r848",
      "r849",
      "r850",
      "r881",
      "r882",
      "r908",
      "r910",
      "r911",
      "r913",
      "r914",
      "r915",
      "r920",
      "r923",
      "r925",
      "r926",
      "r991"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails",
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative Effect, Period Of Adoption [Axis]",
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "documentation": "Information by cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r474",
      "r482",
      "r489",
      "r607",
      "r613",
      "r848",
      "r849",
      "r850",
      "r881",
      "r882",
      "r908",
      "r910",
      "r911",
      "r913",
      "r914",
      "r915",
      "r920",
      "r923",
      "r925",
      "r926",
      "r991"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails",
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative Effect, Period Of Adoption [Domain]",
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "documentation": "Cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r474",
      "r482",
      "r489",
      "r607",
      "r613",
      "r848",
      "r849",
      "r850",
      "r881",
      "r882",
      "r908",
      "r910",
      "r911",
      "r913",
      "r914",
      "r915",
      "r920",
      "r923",
      "r925",
      "r926",
      "r991"
     ]
    },
    "us-gaap_CurrencySwapMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrencySwapMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency swap contracts",
        "label": "Currency Swap [Member]",
        "documentation": "Swap involving the exchange of principal and interest in one currency for another currency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesComponentsofIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesComponentsofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. income taxes",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1546",
      "r1577",
      "r1719"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesComponentsofIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesComponentsofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign income taxes",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1546",
      "r1577"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesComponentsofIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesComponentsofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current taxes",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r878",
      "r886",
      "r1577"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesComponentsofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current taxes",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesComponentsofIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesComponentsofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income taxes",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1546",
      "r1577",
      "r1719"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuesfromUSFederalGovernmentAgenciesDetails",
      "http://www.thecignagroup.com/role/SegmentInformationUSandForeignRevenuesfromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r547"
     ]
    },
    "us-gaap_CustomerRelationshipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerRelationshipsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer relationships",
        "label": "Customer Relationships [Member]",
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "ci_DamagesForServiceIssuesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DamagesForServiceIssuesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Damages for Service Issues",
        "label": "Damages For Service Issues [Member]",
        "documentation": "Damages sought in litigation for service issues."
       }
      }
     },
     "auth_ref": []
    },
    "ci_DebenturesDue20277875InterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DebenturesDue20277875InterestMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$259\u00a0million, 7.875% Debentures due May 2027",
        "label": "Debentures due 2027 7.875% Interest [Member]",
        "documentation": "Debentures bearing interest at 7.875% due in 2027."
       }
      }
     },
     "auth_ref": []
    },
    "ci_DebtAndEquitySecuritiesClassifiedInLevel2PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DebtAndEquitySecuritiesClassifiedInLevel2PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percent of debt and equity securities classified in Level 2, including assets held for sale",
        "label": "Debt And Equity Securities Classified In Level2 Percentage Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Debt And Equity Securities Classified In Level2 Percentage Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DebtAndEquitySecuritiesClassifiedInLevel3PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DebtAndEquitySecuritiesClassifiedInLevel3PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percent of debt and equity securities classified in Level 3, including assets held for sale",
        "label": "Debt And Equity Securities Classified In Level 3 Percentage Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Percent of debt and equity securities classified in Level 3 Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DebtAndEquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DebtAndEquitySecuritiesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt and Equity Securities",
        "label": "Debt and Equity Securities [Member]",
        "documentation": "Subtotal of debt and equity securities carried at fair value on the balance sheet."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets",
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term debt",
        "totalLabel": "Total short-term debt",
        "verboseLabel": "Short-term debt",
        "label": "Debt, Current",
        "documentation": "Amount of debt and lease obligation, classified as current."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_DebtCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtCurrentAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term debt",
        "label": "Debt, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r451",
      "r696",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r712",
      "r719",
      "r720",
      "r722"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtLongtermDebtDetails",
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails",
      "http://www.thecignagroup.com/role/DebtShorttermandCreditFacilitiesDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r228",
      "r229",
      "r296",
      "r298",
      "r461",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r703",
      "r708",
      "r709",
      "r710",
      "r711",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r965",
      "r1388",
      "r1389",
      "r1390",
      "r1391",
      "r1392",
      "r1575"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtLongtermDebtDetails",
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross value",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r298",
      "r723"
     ]
    },
    "ci_DebtInstrumentExtensionTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DebtInstrumentExtensionTerm",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtShorttermandCreditFacilitiesDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit agreement extension term",
        "label": "Debt Instrument, Extension Term",
        "documentation": "Debt Instrument, Extension Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtLongtermDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Principal",
        "terseLabel": "Principal",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r697",
      "r965",
      "r1389",
      "r1390"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtLongtermDebtDetails",
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate",
        "verboseLabel": "Interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r698"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtLongtermDebtDetails",
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails",
      "http://www.thecignagroup.com/role/DebtShorttermandCreditFacilitiesDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupDebtMaturitiesDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r703",
      "r708",
      "r709",
      "r710",
      "r711",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r721",
      "r965",
      "r1388",
      "r1389",
      "r1390",
      "r1391",
      "r1392",
      "r1575"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtLongtermDebtDetails",
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails",
      "http://www.thecignagroup.com/role/DebtShorttermandCreditFacilitiesDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r461",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r703",
      "r708",
      "r709",
      "r710",
      "r711",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r965",
      "r1388",
      "r1389",
      "r1390",
      "r1391",
      "r1392",
      "r1575"
     ]
    },
    "ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtLongtermDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption price discount, spread on variable rate",
        "label": "Debt Instrument, Redemption Price, Discount, Spread On Variable Rate",
        "documentation": "Debt Instrument, Redemption Price, Discount, Spread On Variable Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtLongtermDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate principal amount of outstanding debt securities redeemed",
        "label": "Debt Instrument, Repurchased Face Amount",
        "documentation": "Face (par) amount of the original debt instrument that was repurchased."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtLongtermDebtDetails",
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails",
      "http://www.thecignagroup.com/role/DebtShorttermandCreditFacilitiesDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupDebtMaturitiesDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r133",
      "r136",
      "r198",
      "r199",
      "r200",
      "r205",
      "r270",
      "r271",
      "r461",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r703",
      "r708",
      "r709",
      "r710",
      "r711",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r721",
      "r965",
      "r1388",
      "r1389",
      "r1390",
      "r1391",
      "r1392",
      "r1575"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtShorttermandCreditFacilitiesDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit agreement term",
        "label": "Debt Instrument, Term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "ci_DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Allowance for Credit Loss, including held for sale assets",
        "label": "Debt Securities, Available For Sale, Allowance For Credit Loss, Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Debt Securities, Available For Sale, Allowance For Credit Loss, Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Allowance for Credit Loss",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Excluding Accrued Interest",
        "documentation": "Amount excluding accrued interest, of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss",
        "documentation": "Amortized cost excluding accrued interest, before allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "ci_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total, including assets held for sale",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss, Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss, Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": "ci_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after ten years, including assets held for sale",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10, Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10, Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": "ci_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after five years through ten years, including assets held for sale",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10, Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10, Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": "ci_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after one year through five years, including assets held for sale",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five, Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five, Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": "ci_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due in one year or less, including assets held for sale",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One, Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One, Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsRealizedGainsandLossesonInvestmentsDetails": {
       "parentTag": "ci_RealizedInvestmentGainLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsRealizedGainsandLossesonInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Credit (loss) / recovery and other investment write-down (losses)",
        "label": "Debt Securities, Available-For-Sale, And Commercial Mortgage Loans, Allowance For Credit Loss, Expense (Recovery) And Impairments On Investments Total",
        "documentation": "Debt Securities, Available-For-Sale, And Commercial Mortgage Loans, Allowance For Credit Loss, Expense (Recovery) And Impairments On Investments Total"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": "ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r627",
      "r1385"
     ]
    },
    "ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "More than one year",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months Or Longer [Abstract]",
        "documentation": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months Or Longer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized Depreciation",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r627"
     ]
    },
    "ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails_1": {
       "parentTag": "ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, 12 Months Or Longer, Amortized Cost",
        "documentation": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, 12 Months Or Longer, Amortized Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Issues",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r1617"
     ]
    },
    "ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Amortized Cost",
        "label": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Amortized Cost",
        "documentation": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Amortized Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r627",
      "r1385"
     ]
    },
    "ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One year or less",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less Than 12 Months [Abstract]",
        "documentation": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less Than 12 Months"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": "ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized Depreciation",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r627"
     ]
    },
    "ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails_1": {
       "parentTag": "ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Less Than 12 Months, Amortized Cost",
        "documentation": "Debt Securities, Available-For-Sale, Continuous Unrealized Loss Position, Less Than 12 Months, Amortized Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Issues",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r1617"
     ]
    },
    "ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionTotalAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Total [Abstract]",
        "documentation": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Total"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest",
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1614"
     ]
    },
    "ci_DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total, including assets held for sale",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest, Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Debt Securities, Available-for-Sale, Excluding Accrued Interest, Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": "ci_DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after ten years, including assets held for sale",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10, Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10, Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": "ci_DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after five years through ten years, including assets held for sale",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10, Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10, Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": "ci_DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after one year through five years, including assets held for sale",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five, Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five, Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": "ci_DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due in one year or less, including assets held for sale",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One, Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One, Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unobservable Adjustment, including held for sale assets",
        "label": "Debt Securities, Available-For-Sale, Including Disposal Group, Measurement Input",
        "documentation": "Debt Securities, Available-For-Sale, Including Disposal Group, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": "ci_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mortgage and other asset-backed securities, including assets held for sale",
        "label": "Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Amortized Cost, Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Amortized Cost, Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails": {
       "parentTag": "ci_DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritiesbyContractualMaturityPeriodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mortgage and other asset-backed securities, including assets held for sale",
        "label": "Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Fair Value, Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Fair Value, Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleMeasurementInput",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unobservable Adjustment",
        "label": "Debt Securities, Available-for-Sale, Measurement Input",
        "documentation": "Value of input used to measure investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSalesInformationforAvailableforSaleDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross gains on sales",
        "label": "Debt Securities, Available-for-Sale, Realized Gain",
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSalesInformationforAvailableforSaleDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross losses on sales",
        "label": "Debt Securities, Available-for-Sale, Realized Loss",
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails",
      "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": "ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r624",
      "r1385"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": "ci_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Unrealized Depreciation",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r625"
     ]
    },
    "ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails_1": {
       "parentTag": "ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total Unrealized Depreciation, including held for sale assets",
        "label": "Debt Securities, Available-For-Sale, Unrealized Loss Position, Accumulated Loss, Before Reclassification To Disposal Group, Assets Held-For-Sale",
        "documentation": "Debt Securities, Available-For-Sale, Unrealized Loss Position, Accumulated Loss, Before Reclassification To Disposal Group, Assets Held-For-Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Amortized Cost, including held for sale assets",
        "label": "Debt Securities, Available-For-Sale, Unrealized Loss Position, Amortized Cost, Before Reclassification To Disposal Group, Assets Held-For-Sale",
        "documentation": "Debt Securities, Available-For-Sale, Unrealized Loss Position, Amortized Cost, Before Reclassification To Disposal Group, Assets Held-For-Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails_1": {
       "parentTag": "ci_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Fair Value, including held for sale assets",
        "label": "Debt Securities, Available-For-Sale, Unrealized Loss Position, Before Reclassification To Disposal Group, Assets Held For Sale",
        "documentation": "Debt Securities, Available-For-Sale, Unrealized Loss Position, Before Reclassification To Disposal Group, Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Debt Securities with a Decline in Fair Value",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r1385",
      "r1615"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Number of Issues",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r626"
     ]
    },
    "us-gaap_DebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails",
      "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeDetails",
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities",
        "label": "Debt Securities [Member]",
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r1431",
      "r1788"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesComponentsofIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesComponentsofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. income tax benefits",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1577",
      "r1718",
      "r1719"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesComponentsofIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesComponentsofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign income (tax benefits) taxes",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r1577",
      "r1718"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesComponentsofIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesComponentsofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax benefits",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r283",
      "r333",
      "r885",
      "r886",
      "r1577"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesComponentsofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred taxes (benefits)",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r232",
      "r297",
      "r872"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities, net",
        "label": "Deferred Income Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r860",
      "r861",
      "r1081"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesComponentsofIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesComponentsofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income tax benefits",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1577",
      "r1718",
      "r1719"
     ]
    },
    "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsCapitalLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails",
      "http://www.thecignagroup.com/role/IncomeTaxesForeignJurisdictionTaxAttributesandSaleofMedicareAdvantageandRelatedBusinessesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred loss - sale of business",
        "label": "Deferred Tax Assets, Capital Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r1717"
     ]
    },
    "ci_DeferredTaxAssetsForeignTaxAttributes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DeferredTaxAssetsForeignTaxAttributes",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails",
      "http://www.thecignagroup.com/role/IncomeTaxesForeignJurisdictionTaxAttributesandSaleofMedicareAdvantageandRelatedBusinessesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred tax assets associated with foreign tax attributes",
        "terseLabel": "Foreign tax attributes",
        "label": "Deferred Tax Assets, Foreign Tax Attributes",
        "documentation": "Deferred Tax Assets, Foreign Tax Attributes"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DeferredTaxAssetsForeignTaxAttributesIncludingDisposalGroupsAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DeferredTaxAssetsForeignTaxAttributesIncludingDisposalGroupsAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign tax attributes",
        "label": "Deferred Tax Assets, Foreign Tax Attributes, Including Disposal Groups Assets Held For Sale",
        "documentation": "Deferred Tax Assets, Foreign Tax Attributes, Including Disposal Groups Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets before valuation allowance",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ci_DeferredTaxAssetsGrossInOtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DeferredTaxAssetsGrossInOtherAssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets reported in Other Assets",
        "label": "Deferred Tax Assets Gross In Other Assets Noncurrent",
        "documentation": "Deferred Tax Assets Gross reported in Other Assets Noncurrent on the Balance Sheet."
       }
      }
     },
     "auth_ref": []
    },
    "ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "ci_DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets before valuation allowance",
        "label": "Deferred Tax Assets, Gross, Including Disposal Groups Assets Held For Sale",
        "documentation": "Deferred Tax Assets, Gross, Including Disposal Groups Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DeferredTaxAssetsInvestmentsSubjectToFederalCapitalLossUtilizationRules": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DeferredTaxAssetsInvestmentsSubjectToFederalCapitalLossUtilizationRules",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets associated with unrealized investment losses",
        "label": "Deferred Tax Assets, Investments Subject To Federal Capital Loss Utilization Rules",
        "documentation": "Deferred tax assets relative to investments subject to Federal capital loss utilization rules. Capital losses can only be utilized to extent there are capital gains in a given year. If capital losses exceed capital gains, the taxpayer can utilize capital losses to the extent there are capital gains in the applicable carryback period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, net of valuation allowance",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1716"
     ]
    },
    "ci_DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails_1": {
       "parentTag": "ci_DeferredTaxLiabilitiesNetIncludingDisposalGroup",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, net of valuation allowance",
        "label": "Deferred Tax Assets, Net of Valuation Allowance, Including Disposal Groups Assets Held For Sale",
        "documentation": "Deferred Tax Assets, Net of Valuation Allowance, Including Disposal Groups Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r1717"
     ]
    },
    "ci_DeferredTaxAssetsOperatingLossCarryforwardsIncludingDisposalGroupsAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsIncludingDisposalGroupsAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Including Disposal Groups Assets Held For Sale",
        "documentation": "Deferred Tax Assets, Operating Loss Carryforwards, Including Disposal Groups Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r1717"
     ]
    },
    "ci_DeferredTaxAssetsOtherIncludingDisposalGroupsAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DeferredTaxAssetsOtherIncludingDisposalGroupsAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other, Including Disposal Groups Assets Held For Sale",
        "documentation": "Deferred Tax Assets, Other, Including Disposal Groups Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DeferredTaxAssetsPolicyAcquisitionExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DeferredTaxAssetsPolicyAcquisitionExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Policy acquisition expenses",
        "label": "Deferred Tax Assets, Policy Acquisition Expenses",
        "documentation": "Deferred Tax Assets, Policy Acquisition Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DeferredTaxAssetsPolicyAcquisitionExpensesIncludingDisposalGroupsAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DeferredTaxAssetsPolicyAcquisitionExpensesIncludingDisposalGroupsAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Policy acquisition expenses",
        "label": "Deferred Tax Assets, Policy Acquisition Expenses, Including Disposal Groups Assets Held For Sale",
        "documentation": "Deferred Tax Assets, Policy Acquisition Expenses, Including Disposal Groups Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee and retiree benefit plans",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r1717"
     ]
    },
    "ci_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIncludingDisposalGroupsAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIncludingDisposalGroupsAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee and retiree benefit plans",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Including Disposal Groups Assets Held For Sale",
        "documentation": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Including Disposal Groups Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued liabilities",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r1717"
     ]
    },
    "ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOtherIncludingDisposalGroupsAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOtherIncludingDisposalGroupsAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued liabilities",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other, Including Disposal Groups Assets Held For Sale",
        "documentation": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other, Including Disposal Groups Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other insurance and contractholder liabilities",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Policyholder Liabilities",
        "documentation": "The tax effect as of the balance sheet date of the amount of the estimated future tax deductions arising from estimated policyholder reserves, which will be deductible from future taxable income when actual costs are incurred, and which can only be realized if sufficient tax-basis income is generated in future periods to enable the tax deduction to be taken."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r1717"
     ]
    },
    "ci_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilitiesIncludingDisposalGroupsAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilitiesIncludingDisposalGroupsAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other insurance and contractholder liabilities",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Policyholder Liabilities, Including Disposal Groups Assets Held For Sale",
        "documentation": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Policyholder Liabilities, Including Disposal Groups Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTransactionIncludingDisposalGroupsAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTransactionIncludingDisposalGroupsAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "ci_DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized depreciation on investments and foreign currency translation",
        "label": "Deferred Tax Assets, Unrealized Losses On Investments And Foreign Currency Transaction, Including Disposal Groups Assets Held For Sale",
        "documentation": "Amount of deferred tax assets, including held for sale amounts, attributable to taxable temporary differences from unrealized losses on investments and foreign currency translation."
       }
      }
     },
     "auth_ref": []
    },
    "ci_DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTranslation",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized depreciation on investments and foreign currency translation",
        "label": "Deferred Tax Assets, Unrealized Losses On Investments And Foreign Currency Translation",
        "documentation": "Amount of deferred tax assets attributable to taxable temporary differences from unrealized losses on investments and foreign currency translation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails",
      "http://www.thecignagroup.com/role/IncomeTaxesForeignJurisdictionTaxAttributesandSaleofMedicareAdvantageandRelatedBusinessesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "negatedLabel": "Valuation allowance for deferred tax assets",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ci_DeferredTaxAssetsValuationAllowanceForeignTaxAttributes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DeferredTaxAssetsValuationAllowanceForeignTaxAttributes",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesForeignJurisdictionTaxAttributesandSaleofMedicareAdvantageandRelatedBusinessesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance against deferred tax assets associated with foreign tax attributes",
        "label": "Deferred Tax Assets, Valuation Allowance, Foreign Tax Attributes",
        "documentation": "Deferred Tax Assets, Valuation Allowance, Foreign Tax Attributes"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DeferredTaxAssetsValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DeferredTaxAssetsValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "ci_DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance for deferred tax assets",
        "label": "Deferred Tax Assets, Valuation Allowance, Including Disposal Groups Assets Held For Sale",
        "documentation": "Deferred Tax Assets, Valuation Allowance, Including Disposal Groups Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "ci_DeferredTaxLiabilitiesNetIncludingDisposalGroup",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net deferred income tax liabilities(1)",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r1716"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Policy acquisition expenses",
        "label": "Deferred Tax Liabilities, Deferred Expense, Deferred Policy Acquisition Cost",
        "documentation": "The amount as of the balance sheet date of the estimated future tax effects attributable to policy acquisition costs being expensed for tax purposes but capitalized in conformity with generally accepted accounting principles, which will reverse in future periods when amortization of such capitalized costs cannot be deducted for tax purposes."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r1717"
     ]
    },
    "ci_DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCostIncludingDisposalGroupsAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCostIncludingDisposalGroupsAssetsHeldForSale",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Policy acquisition expenses",
        "label": "Deferred Tax Liabilities, Deferred Expense, Deferred Policy Acquisition Cost, Including Disposal Groups Assets Held For Sale",
        "documentation": "Deferred Tax Liabilities, Deferred Expense, Deferred Policy Acquisition Cost, Including Disposal Groups Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition-related basis differences",
        "label": "Deferred Tax Liabilities, Goodwill and Intangible Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r1717"
     ]
    },
    "ci_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIncludingDisposalGroupsAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIncludingDisposalGroupsAssetsHeldForSale",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition-related basis differences",
        "label": "Deferred Tax Liabilities, Goodwill and Intangible Assets, Including Disposal Groups Assets Held For Sale",
        "documentation": "Deferred Tax Liabilities, Goodwill and Intangible Assets, Including Disposal Groups Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities, including held for sale liabilities",
        "label": "Deferred Tax Liabilities, Gross, Including Disposal Groups [Abstract]",
        "documentation": "Deferred Tax Liabilities, Gross, Including Disposal Groups"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails_1": {
       "parentTag": "ci_DeferredTaxLiabilitiesNetIncludingDisposalGroup",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross, Including Disposal Groups Assets Held For Sale",
        "documentation": "Deferred Tax Liabilities, Gross, Including Disposal Groups Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DeferredTaxLiabilitiesNetIncludingDisposalGroup": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DeferredTaxLiabilitiesNetIncludingDisposalGroup",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Deferred tax liabilities, net, including amounts reported in Liabilities of businesses held for sale",
        "label": "Deferred Tax Liabilities, Net, Including Disposal Group",
        "documentation": "Deferred Tax Liabilities, Net, Including Disposal Group"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Liabilities, Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r1717"
     ]
    },
    "ci_DeferredTaxLiabilitiesOtherIncludingDisposalGroupsAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DeferredTaxLiabilitiesOtherIncludingDisposalGroupsAssetsHeldForSale",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Liabilities, Other, Including Disposal Groups Assets Held For Sale",
        "documentation": "Deferred Tax Liabilities, Other, Including Disposal Groups Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r1717"
     ]
    },
    "ci_DeferredTaxLiabilitiesPropertyPlantAndEquipmentIncludingDisposalGroupsAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipmentIncludingDisposalGroupsAssetsHeldForSale",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment, Including Disposal Groups Assets Held For Sale",
        "documentation": "Deferred Tax Liabilities, Property, Plant and Equipment, Including Disposal Groups Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGains",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized appreciation on investments and foreign currency translation",
        "label": "Deferred Tax Liabilities Unrealized Gains On Investments And Unrealized Currency Transaction Gains",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on investments and foreign currency translation."
       }
      }
     },
     "auth_ref": []
    },
    "ci_DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGainsIncludingDisposalGroupsAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DeferredTaxLiabilitiesUnrealizedGainsOnInvestmentsAndUnrealizedCurrencyTransactionGainsIncludingDisposalGroupsAssetsHeldForSale",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "ci_DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized appreciation on investments and foreign currency translation",
        "label": "Deferred Tax Liabilities Unrealized Gains On Investments And Unrealized Currency Transaction Gains, Including Disposal Groups Assets Held For Sale",
        "documentation": "Amount of deferred tax liability, including held for sale amounts, attributable to taxable temporary differences from unrealized gains on investments and foreign currency translation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/PensionAmountsIncludedinAccumulatedOtherComprehensiveIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/PensionAmountsIncludedinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Postretirement benefits liability adjustment",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax",
        "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r73",
      "r1691"
     ]
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/PensionAmountsIncludedinAccumulatedOtherComprehensiveIncomeDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/PensionAmountsIncludedinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized net (losses)",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax",
        "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r778"
     ]
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/PensionAmountsIncludedinAccumulatedOtherComprehensiveIncomeDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/PensionAmountsIncludedinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrecognized prior service cost",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax",
        "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit)."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r778"
     ]
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actual return on plan assets",
        "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)",
        "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses."
       }
      }
     },
     "auth_ref": [
      "r748",
      "r1399"
     ]
    },
    "us-gaap_DefinedBenefitPlanActuarialGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanActuarialGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Actuarial (gains), net",
        "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)",
        "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "ci_DefinedBenefitPlanAmortizationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DefinedBenefitPlanAmortizationAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionNetPensionCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of:",
        "label": "Defined Benefit Plan, Amortization [Abstract]",
        "documentation": "Defined Benefit Plan, Amortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/PensionNetPensionCostDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/PensionNetPensionCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prior actuarial losses, net",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r735",
      "r773",
      "r795",
      "r1399",
      "r1400"
     ]
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r732",
      "r733",
      "r756",
      "r1224",
      "r1399",
      "r1751"
     ]
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionAssumptionsUsedforPensionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension benefit obligation",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate",
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionAssumptionsUsedforPensionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension benefit cost",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate",
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionAssumptionsUsedforPensionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension benefit cost",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets",
        "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r781",
      "r800"
     ]
    },
    "ci_DefinedBenefitPlanAssumptionsUsedInCalculationsDiscountRateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DefinedBenefitPlanAssumptionsUsedInCalculationsDiscountRateAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionAssumptionsUsedforPensionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate:",
        "label": "Defined Benefit Plan, Assumptions Used in Calculations, Discount Rate [Abstract]",
        "documentation": "Defined Benefit Plan, Assumptions Used in Calculations, Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DefinedBenefitPlanAssumptionsUsedInCalculationsExpectedLongTermReturnOnPlanAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DefinedBenefitPlanAssumptionsUsedInCalculationsExpectedLongTermReturnOnPlanAssetsAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionAssumptionsUsedforPensionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected long-term return on plan assets:",
        "label": "Defined Benefit Plan, Assumptions Used in Calculations, Expected Long-Term Return On Plan Assets [Abstract]",
        "documentation": "Defined Benefit Plan, Assumptions Used in Calculations, Expected Long-Term Return On Plan Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanBenefitObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanBenefitObligation",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Benefit obligation, January 1",
        "periodEndLabel": "Benefit obligation, December 31",
        "label": "Defined Benefit Plan, Benefit Obligation",
        "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "ci_DefinedBenefitPlanBenefitsPaidFromPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DefinedBenefitPlanBenefitsPaidFromPlanAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Benefits paid from plan assets",
        "label": "Defined Benefit Plan Benefits Paid From Plan Assets",
        "documentation": "The amount of payments made from plan assets for which participants are entitled under a pension plan, including pension benefits, death benefits, and benefits due on termination of employment. Also includes payments made under a postretirement benefit plan, including prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services."
       }
      }
     },
     "auth_ref": []
    },
    "ci_DefinedBenefitPlanBenefitsPaidOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DefinedBenefitPlanBenefitsPaidOther",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other",
        "label": "Defined Benefit Plan Benefits Paid Other",
        "documentation": "The amount of payments from sources other than plan assets made for which participants are entitled under a pension plan, including pension benefits, death benefits, and benefits due on termination of employment. Also includes payments made under a postretirement benefit plan, including prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionPensionPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "label": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "documentation": "Information by defined benefit plan asset investment."
       }
      }
     },
     "auth_ref": [
      "r757",
      "r758",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r784",
      "r1397",
      "r1398",
      "r1399"
     ]
    },
    "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in benefit obligation",
        "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in plan assets",
        "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionNarrativeDetails",
      "http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contributions to qualifed pension plans",
        "verboseLabel": "Contributions",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets."
       }
      }
     },
     "auth_ref": [
      "r750",
      "r760",
      "r799",
      "r1397",
      "r1398",
      "r1399",
      "r1400"
     ]
    },
    "us-gaap_DefinedBenefitPlanDebtSecurityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanDebtSecurityMember",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionPensionPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities",
        "label": "Defined Benefit Plan, Debt Security [Member]",
        "documentation": "Debt instrument issued by corporation, government and governmental agency, municipality, and other institution; in which defined benefit plan asset is invested."
       }
      }
     },
     "auth_ref": [
      "r1673"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionAmountsIncludedinAccumulatedOtherComprehensiveIncomeDetails",
      "http://www.thecignagroup.com/role/PensionAssumptionsUsedforPensionDetails",
      "http://www.thecignagroup.com/role/PensionBenefitPaymentsDetails",
      "http://www.thecignagroup.com/role/PensionNarrativeDetails",
      "http://www.thecignagroup.com/role/PensionNetPensionCostDetails",
      "http://www.thecignagroup.com/role/PensionPensionPlanAssetsDetails",
      "http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanDivestituresBenefitObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanDivestituresBenefitObligation",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Ceded in divestiture",
        "label": "Defined Benefit Plan, Benefit Obligation, Divestiture",
        "documentation": "Amount of decrease in benefit obligation of defined benefit plan from disposal or classification as held-for-sale."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "us-gaap_DefinedBenefitPlanDivestituresPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanDivestituresPlanAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Ceded in divestiture",
        "label": "Defined Benefit Plan, Plan Assets, Divestiture",
        "documentation": "Amount of decrease in plan assets of defined benefit plan from disposal or classification as held-for-sale."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "us-gaap_DefinedBenefitPlanEquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanEquitySecuritiesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionPensionPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities",
        "label": "Defined Benefit Plan, Equity Securities [Member]",
        "documentation": "Security representing ownership in corporation or other legal entity for which ownership is represented by share of stock, in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant."
       }
      }
     },
     "auth_ref": [
      "r1397",
      "r1399"
     ]
    },
    "us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanEquitySecuritiesNonUsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionPensionPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International, including funds and pooled separate accounts",
        "label": "Defined Benefit Plan, Equity Securities, Non-US [Member]",
        "documentation": "Security representing ownership in corporation or other legal entity, not domiciled in United States of America (US), for which ownership is represented by share of stock; in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant."
       }
      }
     },
     "auth_ref": [
      "r1397",
      "r1398",
      "r1399"
     ]
    },
    "us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanEquitySecuritiesUsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionPensionPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic",
        "label": "Defined Benefit Plan, Equity Securities, US [Member]",
        "documentation": "Security representing ownership in corporation or other legal entity, domiciled in United States of America (US), for which ownership is represented by share of stock; in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant."
       }
      }
     },
     "auth_ref": [
      "r1397",
      "r1398",
      "r1399"
     ]
    },
    "us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Benefit payments including expected future services [Abstract]",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029 - 2033",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected contributions to qualified pension plans in next fiscal year",
        "label": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year",
        "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r768",
      "r1400"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/PensionNetPensionCostDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/PensionNetPensionCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expected long-term return on plan assets",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r735",
      "r772",
      "r794",
      "r1399",
      "r1400"
     ]
    },
    "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanFairValueOfPlanAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/PensionNarrativeDetails",
      "http://www.thecignagroup.com/role/PensionPensionPlanAssetsDetails",
      "http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan assets",
        "periodStartLabel": "Fair value of plan assets, January 1",
        "periodEndLabel": "Fair value of plan assets, December 31",
        "verboseLabel": "Pension assets at fair value",
        "label": "Defined Benefit Plan, Plan Assets, Amount",
        "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee."
       }
      }
     },
     "auth_ref": [
      "r747",
      "r758",
      "r760",
      "r761",
      "r1397",
      "r1398",
      "r1399"
     ]
    },
    "ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInFundsOfferedByUnaffiliatedEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DefinedBenefitPlanFairValueOfPlanAssetsInvestedInFundsOfferedByUnaffiliatedEntity",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan assets invested in funds offered by an unaffiliated insurance company",
        "label": "Defined Benefit Plan Fair Value Of Plan Assets Invested In Funds Offered By Unaffiliated Entity",
        "documentation": "Defined Benefit Plan Fair Value Of Plan Assets Invested In Funds Offered By Unaffiliated Entity"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DefinedBenefitPlanFairValueOfPlanAssetsInvestedInSeparateAccountsOfSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DefinedBenefitPlanFairValueOfPlanAssetsInvestedInSeparateAccountsOfSubsidiaries",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan assets invested in separate accounts of subsidiaries",
        "label": "Defined Benefit Plan Fair Value Of Plan Assets Invested In Separate Accounts Of Subsidiaries",
        "documentation": "Fair value of plan assets invested in the separate accounts of subisdiaries of the Company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanFundedStatusOfPlan",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Funded status",
        "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan",
        "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status."
       }
      }
     },
     "auth_ref": [
      "r732",
      "r756",
      "r1399"
     ]
    },
    "ci_DefinedBenefitPlanGainLossDueToLitigation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DefinedBenefitPlanGainLossDueToLitigation",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionNarrativeDetails",
      "http://www.thecignagroup.com/role/PensionNetPensionCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Increase in pension liability due to litigation settlement",
        "negatedTerseLabel": "Litigation settlement \u2013 plan amendment",
        "label": "Defined Benefit Plan, Gain (Loss) Due To Litigation",
        "documentation": "Defined Benefit Plan, Gain (Loss) Due To Litigation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanInterestCost",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/PensionNetPensionCostDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/PensionNetPensionCostDetails",
      "http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest cost",
        "label": "Defined Benefit Plan, Interest Cost",
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r735",
      "r739",
      "r771",
      "r793",
      "r1399",
      "r1400"
     ]
    },
    "ci_DefinedBenefitPlanMarketRelatedValueOfPensionPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DefinedBenefitPlanMarketRelatedValueOfPensionPlanAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market-related valuation of pension plan assets",
        "label": "Defined Benefit Plan Market Related Value Of Pension Plan Assets",
        "documentation": "The market-related value of plan assets, used to measure pension costs, which differs from the actual fair value for domestic pension plan assets invested in non-fixed income investments. The 'market-related' value recognizes the difference between actual and expected long-term returns in the portfolio over five years, a method that reduces the short-term impact of market fluctuations on pension costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/PensionNetPensionCostDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/PensionNetPensionCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (benefit) cost",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r769",
      "r791",
      "r1399",
      "r1400"
     ]
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionNetPensionCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Benefits paid",
        "label": "Defined Benefit Plan, Plan Assets, Benefits Paid",
        "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services."
       }
      }
     },
     "auth_ref": [
      "r752",
      "r1711"
     ]
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionPensionPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Target allocation percentages",
        "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage",
        "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan."
       }
      }
     },
     "auth_ref": [
      "r757",
      "r1399"
     ]
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/PensionNetPensionCostDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/PensionNetPensionCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Settlement loss",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement",
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement."
       }
      }
     },
     "auth_ref": [
      "r734",
      "r776",
      "r798"
     ]
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanServiceCost",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/PensionNetPensionCostDetails": {
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/PensionNetPensionCostDetails",
      "http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service cost",
        "label": "Defined Benefit Plan, Service Cost",
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r737",
      "r770",
      "r792",
      "r1399",
      "r1400"
     ]
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionAnnualExpensefor401kPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expense",
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_DefinedContributionPlanDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanDisclosuresTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual Expense for 401(k) Plans",
        "label": "Defined Contribution Plan Disclosures [Table Text Block]",
        "documentation": "Tabular disclosure of defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "ci_DepartmentOfDefenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DepartmentOfDefenseMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuesfromUSFederalGovernmentAgenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Department Of Defense [Member]",
        "label": "Department Of Defense [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DepreciationAndAmortizationByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DepreciationAndAmortizationByTypeAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentComponentsofDepreciationandAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation And Amortization By Type [Axis]",
        "label": "Depreciation And Amortization By Type [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DepreciationAndAmortizationByTypeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DepreciationAndAmortizationByTypeLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentComponentsofDepreciationandAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation And Amortization By Type [Line Items]",
        "label": "Depreciation And Amortization By Type [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DepreciationAndAmortizationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DepreciationAndAmortizationTypeDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentComponentsofDepreciationandAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation And Amortization Type [Domain]",
        "label": "Depreciation And Amortization Type [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentComponentsofDepreciationandAmortizationExpenseDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r517"
     ]
    },
    "us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]",
        "label": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes derivative asset."
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "us-gaap_DerivativeAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative assets",
        "label": "Derivative Asset",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r420",
      "r948",
      "r1189",
      "r1190",
      "r1191",
      "r1193",
      "r1194",
      "r1196",
      "r1197",
      "r1199",
      "r1201",
      "r1202",
      "r1218",
      "r1219",
      "r1306",
      "r1309",
      "r1310",
      "r1311",
      "r1313",
      "r1314",
      "r1367",
      "r1431",
      "r1782"
     ]
    },
    "ci_DerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative assets, including held for sale assets",
        "label": "Derivative Assets Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Derivative Assets Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Contract [Domain]",
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r1199",
      "r1202",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1306",
      "r1307",
      "r1310",
      "r1313",
      "r1429",
      "r1431"
     ]
    },
    "us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeCreditRiskValuationAdjustmentDerivativeAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment for credit risk on derivatives assets",
        "label": "Derivative Credit Risk Valuation Adjustment, Derivative Assets",
        "documentation": "Amount of credit risk valuation adjustment to derivative assets to properly reflect the credit quality of the counterparties."
       }
      }
     },
     "auth_ref": []
    },
    "ci_DerivativeCreditRiskValuationAdjustmentDerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DerivativeCreditRiskValuationAdjustmentDerivativeAssetsBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment for credit risk on derivatives assets",
        "label": "Derivative Credit Risk Valuation Adjustment, Derivative Assets, Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Derivative Credit Risk Valuation Adjustment, Derivative Assets, Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment for credit risk on derivatives liabilities",
        "label": "Derivative Credit Risk Valuation Adjustment, Derivative Liabilities",
        "documentation": "Amount of credit risk valuation adjustment to derivative liabilities to properly reflect the credit quality of the entity."
       }
      }
     },
     "auth_ref": []
    },
    "ci_DerivativeCreditRiskValuationAdjustmentDerivativeLiabilitiesBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DerivativeCreditRiskValuationAdjustmentDerivativeLiabilitiesBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment for credit risk on derivatives liabilities",
        "label": "Derivative Credit Risk Valuation Adjustment, Derivative Liabilities, Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Derivative Credit Risk Valuation Adjustment, Derivative Liabilities, Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative gain (loss) recognized in the income statement",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r1723"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instrument [Axis]",
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r179",
      "r181",
      "r182",
      "r1199",
      "r1202",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1306",
      "r1307",
      "r1310",
      "r1313",
      "r1367",
      "r1429",
      "r1431"
     ]
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Relationship [Axis]",
        "label": "Hedging Relationship [Axis]",
        "documentation": "Information by type of hedging relationship."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r177",
      "r181"
     ]
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative liabilities",
        "label": "Derivative Liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r420",
      "r948",
      "r1189",
      "r1190",
      "r1191",
      "r1193",
      "r1196",
      "r1197",
      "r1199",
      "r1201",
      "r1202",
      "r1226",
      "r1228",
      "r1229",
      "r1307",
      "r1308",
      "r1309",
      "r1310",
      "r1311",
      "r1313",
      "r1314",
      "r1367",
      "r1782"
     ]
    },
    "ci_DerivativeLiabilitiesBeforeReclassificationToDisposalGroupLiabilitiesHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DerivativeLiabilitiesBeforeReclassificationToDisposalGroupLiabilitiesHeldForSale",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative liabilities, including held for sale liabilities",
        "label": "Derivative Liabilities Before Reclassification To Disposal Group Liabilities Held For Sale",
        "documentation": "Derivative Liabilities Before Reclassification To Disposal Group Liabilities Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative [Line Items]",
        "label": "Derivative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "us-gaap_DerivativeNotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeNotionalAmount",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notional Value",
        "label": "Derivative, Notional Amount",
        "documentation": "Nominal or face amount used to calculate payment on derivative."
       }
      }
     },
     "auth_ref": [
      "r1721",
      "r1722"
     ]
    },
    "ci_DerivativeNotionalAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DerivativeNotionalAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notional Value, including held for sale assets",
        "label": "Derivative Notional Amount Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Derivative Notional Amount Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeTable",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative [Table]",
        "label": "Derivative [Table]",
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r170",
      "r171",
      "r172",
      "r175",
      "r178",
      "r181",
      "r183",
      "r185",
      "r187",
      "r916"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Financial Instruments",
        "label": "Derivatives, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r170",
      "r171",
      "r175",
      "r184",
      "r460"
     ]
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DesignatedAsHedgingInstrumentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Designated as Hedging Instrument",
        "label": "Designated as Hedging Instrument [Member]",
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_DirectPremiumsEarned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DirectPremiumsEarned",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ReinsuranceEffectsofReinsuranceDetails": {
       "parentTag": "us-gaap_PremiumsEarnedNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceEffectsofReinsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Direct",
        "label": "Direct Premiums Earned",
        "documentation": "Amount, before premiums ceded to other entities and premiums assumed by the entity, of premiums earned."
       }
      }
     },
     "auth_ref": [
      "r1120",
      "r1162",
      "r1165",
      "r1760"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Incentive Plans",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r809",
      "r813",
      "r844",
      "r845",
      "r847",
      "r1408"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares of Common Stock Available for Award",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r145"
     ]
    },
    "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax [Abstract]",
        "label": "Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails",
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails",
      "http://www.thecignagroup.com/role/DescriptionofBusinessDetails",
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentGoodwillActivityDetails",
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails",
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails",
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails",
      "http://www.thecignagroup.com/role/IncomeTaxesForeignJurisdictionTaxAttributesandSaleofMedicareAdvantageandRelatedBusinessesDetails",
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails",
      "http://www.thecignagroup.com/role/MergersAcquisitionsandDivestituresNarrativeDetails",
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Axis]",
        "label": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails",
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails",
      "http://www.thecignagroup.com/role/DescriptionofBusinessDetails",
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentGoodwillActivityDetails",
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails",
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails",
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails",
      "http://www.thecignagroup.com/role/IncomeTaxesForeignJurisdictionTaxAttributesandSaleofMedicareAdvantageandRelatedBusinessesDetails",
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails",
      "http://www.thecignagroup.com/role/MergersAcquisitionsandDivestituresNarrativeDetails",
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Domain]",
        "label": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails",
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails",
      "http://www.thecignagroup.com/role/MergersAcquisitionsandDivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposed of by Sale",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r42"
     ]
    },
    "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails",
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails",
      "http://www.thecignagroup.com/role/DescriptionofBusinessDetails",
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentGoodwillActivityDetails",
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails",
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails",
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails",
      "http://www.thecignagroup.com/role/IncomeTaxesForeignJurisdictionTaxAttributesandSaleofMedicareAdvantageandRelatedBusinessesDetails",
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails",
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Held-for-Sale",
        "label": "Disposal Group, Held-for-Sale, Not Discontinued Operations [Member]",
        "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r42",
      "r396"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails": {
       "parentTag": "ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails",
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accounts receivable, net classified as assets of businesses held for sale",
        "terseLabel": "Accounts receivable, net",
        "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net",
        "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r217",
      "r223",
      "r263"
     ]
    },
    "ci_DisposalGroupIncludingDiscontinuedOperationAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated Amortization",
        "label": "Disposal Group Including Discontinued Operation Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ShareholdersEquityandDividendRestrictionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts associated with businesses held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets of businesses held for sale, non-current",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r9",
      "r217",
      "r223",
      "r263",
      "r396",
      "r397"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]",
        "label": "Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents",
        "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r217",
      "r223",
      "r263"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails",
      "http://www.thecignagroup.com/role/DescriptionofBusinessDetails",
      "http://www.thecignagroup.com/role/MergersAcquisitionsandDivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale price",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation."
       }
      }
     },
     "auth_ref": []
    },
    "ci_DisposalGroupIncludingDiscontinuedOperationCurrentInsuranceAndContractholderLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationCurrentInsuranceAndContractholderLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Insurance and contractholder liabilities current, classified as held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Current Insurance And Contractholder Liabilities",
        "documentation": "Disposal Group, Including Discontinued Operation, Current Insurance And Contractholder Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails": {
       "parentTag": "ci_DisposalGroupIncludingDiscontinuedOperationInvestments",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investments classified as assets of business held for sale",
        "label": "Disposal Group Including Discontinued Operation, Current Investments, Current",
        "documentation": "Disposal Group Including Discontinued Operation, Current Investments, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails": {
       "parentTag": "ci_DeferredTaxLiabilitiesNetIncludingDisposalGroup",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net deferred income tax liabilities classified as liabilities of businesses held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities",
        "documentation": "Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r217",
      "r223",
      "r263"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwill1",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails",
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentGoodwillActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill classified as Assets of businesses held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Goodwill",
        "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r217",
      "r223",
      "r263"
     ]
    },
    "ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails_2": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance and contractholder liabilities",
        "negatedTotalLabel": "Insurance and contractholder liabilities classified as held for sale",
        "label": "Disposal Group,Including Discontinued Operation, Insurance And Contractholder Liabilities",
        "documentation": "Disposal Group,Including Discontinued Operation, Insurance And Contractholder Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other intangible assets, held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets",
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r217",
      "r223",
      "r263"
     ]
    },
    "ci_DisposalGroupIncludingDiscontinuedOperationInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails": {
       "parentTag": "ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "negatedTotalLabel": "Investments classified as assets of business held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Investments",
        "documentation": "Disposal Group, Including Discontinued Operation, Investments"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DisposalGroupIncludingDiscontinuedOperationLiabilitiesExcludingInsuranceAndContractholderLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationLiabilitiesExcludingInsuranceAndContractholderLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All other liabilities",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities Excluding Insurance And Contractholder Liabilities",
        "documentation": "Disposal Group, Including Discontinued Operation, Liabilities Excluding Insurance And Contractholder Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInsuranceAndContractholderLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationNoncurrentInsuranceAndContractholderLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails_1": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Insurance and contractholder liabilities, non-current, classified as held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Noncurrent Insurance And Contractholder Liabilities",
        "documentation": "Disposal Group, Including Discontinued Operation, Noncurrent Insurance And Contractholder Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails": {
       "parentTag": "ci_DisposalGroupIncludingDiscontinuedOperationInvestments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investments classified as assets of business held for sale",
        "label": "Disposal Group Including Discontinued Operation Noncurrent Investments Current",
        "documentation": "Disposal Group Including Discontinued Operation Noncurrent Investments"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Operating Lease Liabilities",
        "documentation": "Disposal Group, Including Discontinued Operation, Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease ROU assets, held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Operating Lease Right Of Use Assets",
        "documentation": "Disposal Group, Including Discontinued Operation, Operating Lease Right Of Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group, Including Discontinued Operation, Other Assets",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets",
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r217",
      "r223",
      "r263"
     ]
    },
    "ci_DisposalGroupIncludingDiscontinuedOperationOtherAssetsGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherAssetsGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets, including Goodwill",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets Goodwill",
        "documentation": "Goodwill and amount classified as other assets attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails": {
       "parentTag": "ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net carrying value classified as assets of business held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current",
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r217",
      "r223",
      "r261",
      "r263"
     ]
    },
    "ci_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentGrossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentGrossCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails": {
       "parentTag": "ci_PropertyPlantAndEquipmentGrossIncludingDisposalGroups",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cost",
        "label": "Disposal Group Including Discontinued Operation Property Plant And Equipment Gross Current",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale, attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "ci_DisposalGroupIncludingDiscontinuedOperationReinsuranceRecoverablesIncludingReinsurancePremiumPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationReinsuranceRecoverablesIncludingReinsurancePremiumPaid",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reinsurance recoverable classified as assets of businesses held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Reinsurance Recoverables, Including Reinsurance Premium Paid",
        "documentation": "Disposal Group, Including Discontinued Operation, Reinsurance Recoverables, Including Reinsurance Premium Paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationSegmentThatIncludesDisposalGroup": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationSegmentThatIncludesDisposalGroup",
     "presentation": [
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group, Including Discontinued Operation, Segment that Includes Disposal Group",
        "label": "Disposal Group, Including Discontinued Operation, Segment that Includes Disposal Group",
        "documentation": "Identification of the segment that the disposal group, including discontinued operation is reported."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r264"
     ]
    },
    "ci_DisposalGroupIncludingDiscontinuedOperationValueOfBusinessAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationValueOfBusinessAcquired",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "VOBA, held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Value Of Business Acquired",
        "documentation": "Disposal Group, Including Discontinued Operation, Value Of Business Acquired"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossForeignCurrencyTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossForeignCurrencyTranslation",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gross translation loss on foreign currencies",
        "label": "Disposal Group, Including Discontinued Operations, Accumulated Gross Unrealized Gain (Loss) Foreign Currency Translation",
        "documentation": "Disposal Group, Including Discontinued Operations, Accumulated Gross Unrealized Gain (Loss) Foreign Currency Translation"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossInvestmentsAndDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossInvestmentsAndDerivatives",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross unrealized appreciation on securities and derivatives",
        "label": "Disposal Group, Including Discontinued Operations, Accumulated Gross Unrealized Gain (Loss), Investments And Derivatives",
        "documentation": "Disposal Group, Including Discontinued Operations, Accumulated Gross Unrealized Gain (Loss), Investments And Derivatives"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DisposalGroupIncludingDiscontinuedOperationsNonInvestmentRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationsNonInvestmentRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationUSandForeignRevenuesfromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues, disposal group",
        "label": "Disposal Group, Including Discontinued Operations, Non Investment Revenue",
        "documentation": "Disposal Group, Including Discontinued Operations, Non Investment Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DisposalGroupIncludingDiscontinuedOperationsStatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationsStatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ShareholdersEquityandDividendRestrictionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum statutory surplus required by regulators, disposal groups",
        "label": "Disposal Group, Including Discontinued Operations, Statutory Accounting Practices, Statutory Capital and Surplus Required",
        "documentation": "Disposal Group, Including Discontinued Operations, Statutory Accounting Practices, Statutory Capital and Surplus Required"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails",
      "http://www.thecignagroup.com/role/MergersAcquisitionsandDivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (loss) on sale of business, pre-tax",
        "negatedLabel": "Estimated loss on sale, pre-tax",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal",
        "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r650",
      "r1574",
      "r1630"
     ]
    },
    "ci_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails",
      "http://www.thecignagroup.com/role/MergersAcquisitionsandDivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (loss) on sale of business, after-tax",
        "negatedLabel": "Estimated loss on sale, after-tax",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) On Disposal, Net Of Tax",
        "documentation": "Disposal Group, Not Discontinued Operation, Gain (Loss) On Disposal, Net Of Tax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList",
     "presentation": [
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on sale of businesses, location, Consolidated Statements of Income",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income that includes gain (loss) recognized on sale or disposal of disposal group. Excludes discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationNameOfSegmentExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupNotDiscontinuedOperationNameOfSegmentExtensibleList",
     "presentation": [
      "http://www.thecignagroup.com/role/DescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group, Not Discontinued Operation, Name of Segment [Extensible Enumeration]",
        "label": "Disposal Group, Not Discontinued Operation, Name of Segment [Extensible Enumeration]",
        "documentation": "Indicates business segment that includes disposal group not classified as discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "ci_DisposalGroupsIncludingDiscontinuedOperationsAmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsAmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/ShareholdersEquityandDividendRestrictionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted GAAP net assets of The Cigna Goup's subsidiaries, disposal groups",
        "label": "Disposal Groups, Including Discontinued Operations, Amount of Restricted Net Assets for Consolidated and Unconsolidated Subsidiaries",
        "documentation": "Disposal Groups, Including Discontinued Operations, Amount of Restricted Net Assets for Consolidated and Unconsolidated Subsidiaries"
       }
      }
     },
     "auth_ref": []
    },
    "ci_DisposalGroupsIncludingDiscontinuedOperationsAssetsHeldByInsuranceRegulators": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsAssetsHeldByInsuranceRegulators",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/ShareholdersEquityandDividendRestrictionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments on deposit with regulatory bodies, disposal groups",
        "label": "Disposal Groups, Including Discontinued Operations, Assets Held by Insurance Regulators",
        "documentation": "Disposal Groups, Including Discontinued Operations, Assets Held by Insurance Regulators"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSale"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets and Liabilities of Business Held for Sale",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r260"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails",
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails",
      "http://www.thecignagroup.com/role/DescriptionofBusinessDetails",
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentGoodwillActivityDetails",
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails",
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails",
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails",
      "http://www.thecignagroup.com/role/IncomeTaxesForeignJurisdictionTaxAttributesandSaleofMedicareAdvantageandRelatedBusinessesDetails",
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails",
      "http://www.thecignagroup.com/role/MergersAcquisitionsandDivestituresNarrativeDetails",
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Domain]",
        "label": "Disposal Group Name [Domain]",
        "documentation": "Name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r1401",
      "r1404"
     ]
    },
    "ci_DisposalGroupsIncludingDiscontinuedOperationsStatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsStatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ShareholdersEquityandDividendRestrictionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum dividend distributions permitted in 2022 without regulatory approval, disposal groups",
        "label": "Disposal Groups, Including Discontinued Operations, Statutory Accounting Practices, Statutory Amount Available for Dividend Payments",
        "documentation": "Disposal Groups, Including Discontinued Operations, Statutory Accounting Practices, Statutory Amount Available for Dividend Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsCommonStockCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsCommonStockCash",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Common dividends declared",
        "label": "Dividends, Common Stock, Cash",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "us-gaap_DividendsDeclaredTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsDeclaredTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/CommonandPreferredStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend Payments",
        "label": "Dividends Declared [Table Text Block]",
        "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r1449",
      "r1450",
      "r1463"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r1449",
      "r1450",
      "r1463",
      "r1499"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1484"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r1447"
     ]
    },
    "ci_DueFromAffiliateNoncurrentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "DueFromAffiliateNoncurrentNet",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupIntercompanyBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intercompany receivables, net",
        "label": "Due From Affiliate Noncurrent Net",
        "documentation": "Amount of receivables, net of payables, due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership, due after 1 year (or 1 business cycle)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders' net income per share",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "calculation": {
      "http://www.thecignagroup.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails": {
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic (in dollars per share)",
        "terseLabel": "EPS, basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r479",
      "r480",
      "r482",
      "r483",
      "r485",
      "r491",
      "r494",
      "r500",
      "r501",
      "r502",
      "r506",
      "r926",
      "r927",
      "r1061",
      "r1105",
      "r1371"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "calculation": {
      "http://www.thecignagroup.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails",
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in dollars per share)",
        "verboseLabel": "Increase to diluted earnings per share (in dollars per share)",
        "totalLabel": "EPS, diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r479",
      "r480",
      "r482",
      "r483",
      "r485",
      "r494",
      "r500",
      "r501",
      "r502",
      "r506",
      "r926",
      "r927",
      "r1061",
      "r1105",
      "r1371"
     ]
    },
    "ci_EarningsPerShareEffectOfDilution": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "EarningsPerShareEffectOfDilution",
     "calculation": {
      "http://www.thecignagroup.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails": {
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EPS, effect of dilution (in dollars per share)",
        "label": "Earnings Per Share Effect Of Dilution",
        "documentation": "The decrease in net income (loss) on a per share basis when the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period is assumed."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r503",
      "r504",
      "r505"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of foreign currency rate changes on cash, cash equivalents and restricted cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1729"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total income taxes",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "%",
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Tax expense at nominal rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r863",
      "r887"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1713",
      "r1720"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationDispositionOfBusiness",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact of sale of businesses",
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Business, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to disposition of a business not qualifying as a discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r1713",
      "r1720"
     ]
    },
    "ci_EffectiveIncomeTaxRateReconciliationHealthInsuranceIndustryTax": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationHealthInsuranceIndustryTax",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Health insurance industry tax",
        "label": "Effective Income Tax Rate Reconciliation Health Insurance Industry Tax",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) due to the non-deductibility for federal income tax purposes of the health insurance industry tax assessed under Health Care Reform."
       }
      }
     },
     "auth_ref": []
    },
    "ci_EffectiveIncomeTaxRateReconciliationImpactOfBusinessesHeldForSalePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationImpactOfBusinessesHeldForSalePercent",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "auth_ref": []
    },
    "ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other foreign tax attributes",
        "label": "Effective Income Tax Rate Reconciliation, Other Foreign Tax Attributes, Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, Other Foreign Tax Attributes, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ci_EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other foreign tax attributes",
        "label": "Effective Income Tax Rate Reconciliation, Other Foreign Tax Attributes, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Other Foreign Tax Attributes, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "ci_EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Effect of foreign earnings",
        "label": "Effective Income Tax Rate Reconciliation Permanently Reinvested Foreign Earnings",
        "documentation": "Percentage of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to permanently reinvested foreign earnings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income tax (benefit), net of federal income tax benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1713",
      "r1720"
     ]
    },
    "ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Swiss tax attributes",
        "label": "Effective Income Tax Rate Reconciliation, Swiss Tax Attributes, Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, Swiss Tax Attributes, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ci_EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Swiss tax attributes",
        "label": "Effective Income Tax Rate Reconciliation, Swiss Tax Attributes, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Swiss Tax Attributes, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectsOfReinsuranceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectsOfReinsuranceLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceEffectsofReinsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effects of Reinsurance [Line Items]",
        "label": "Effects of Reinsurance [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectsOfReinsuranceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectsOfReinsuranceTable",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceEffectsofReinsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effects of Reinsurance [Table]",
        "label": "Effects of Reinsurance [Table]",
        "documentation": "Disclosure of information about the effects of reinsurance, including, but not limited to, disclosure of direct, assumed, and ceded insurance."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_EffectsOfReinsuranceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectsOfReinsuranceTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effects of Reinsurance",
        "label": "Effects of Reinsurance [Table Text Block]",
        "documentation": "Tabular disclosure of the effects of reinsurance, for example, but not limited to, disclosure of direct, assumed, and ceded insurance."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation expense to be recognized",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period over which compensation expense will be recognized",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansCompensationCostandTaxEffectsofSharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax benefits recognized",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsExercisedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax benefit from options exercised",
        "label": "Share-Based Payment Arrangement, Exercise of Option, Tax Benefit",
        "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareOutstandingEmployeeStockOptionsNotIncludedintheComputationofDilutedEarningsPerShareDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansBlackScholesOptionPricingModelAssumptionsDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansNarrativeDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinCommonStockOptionsDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsExercisedDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsOutstandingDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Options",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "ci_EmployerInsuredMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "EmployerInsuredMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employer insured",
        "label": "Employer Insured [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_EmpowerAnnuityInsuranceCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "EmpowerAnnuityInsuranceCompanyMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Empower Annuity Insurance Company",
        "label": "Empower Annuity Insurance Company [Member]",
        "documentation": "Empower Annuity Insurance Company"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1446"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1446"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1446"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1524"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1446"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1446"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1446"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1446"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1525"
     ]
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from External Customer [Line Items]",
        "label": "Revenue from External Customer [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.thecignagroup.com/role/CommonandPreferredStockAcceleratedShareRepurchaseAgreementsDetails",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r391",
      "r433",
      "r434",
      "r435",
      "r471",
      "r472",
      "r473",
      "r476",
      "r486",
      "r488",
      "r507",
      "r607",
      "r613",
      "r728",
      "r848",
      "r849",
      "r850",
      "r881",
      "r882",
      "r908",
      "r910",
      "r911",
      "r912",
      "r913",
      "r915",
      "r925",
      "r955",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r993",
      "r1150",
      "r1151",
      "r1152",
      "r1187",
      "r1251"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiariesDetails",
      "http://www.thecignagroup.com/role/InvestmentsNarrativeDetails",
      "http://www.thecignagroup.com/role/MergersAcquisitionsandDivestituresNarrativeDetails",
      "http://www.thecignagroup.com/role/VariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Domain]",
        "label": "Investment, Name [Domain]",
        "documentation": "Name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r598",
      "r599",
      "r601"
     ]
    },
    "us-gaap_EquityMethodInvestmentDividendsOrDistributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentDividendsOrDistributions",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income distributions",
        "label": "Proceeds from Equity Method Investment, Distribution",
        "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r18",
      "r242",
      "r1094"
     ]
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]",
        "label": "Equity Method Investment, Nonconsolidated Investee [Axis]",
        "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r454",
      "r602",
      "r949"
     ]
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]",
        "label": "Equity Method Investment, Nonconsolidated Investee [Domain]",
        "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r454",
      "r602",
      "r949"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.thecignagroup.com/role/VariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage, less than",
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentSummarizedFinancialInformationAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investment, Summarized Financial Information [Abstract]",
        "label": "Equity Method Investment, Summarized Financial Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity method investments, carrying value",
        "label": "Equity Method Investments",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r596",
      "r1564",
      "r1608"
     ]
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiaries"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collectively Significant Operating Unconsolidated Subsidiaries",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r600",
      "r603",
      "r1526"
     ]
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentsPolicy",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Operating Joint Ventures",
        "label": "Equity Method Investments [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r197",
      "r599"
     ]
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentsTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiariesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Joint Venture Investments",
        "label": "Equity Method Investments [Table Text Block]",
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information."
       }
      }
     },
     "auth_ref": [
      "r597"
     ]
    },
    "us-gaap_EquitySecuritiesByIndustryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesByIndustryAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Industry Sector [Axis]",
        "label": "Industry Sector [Axis]",
        "documentation": "Information by industry sector, examples include but are not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate."
       }
      }
     },
     "auth_ref": [
      "r1191",
      "r1195",
      "r1198",
      "r1265",
      "r1281",
      "r1302",
      "r1332",
      "r1379",
      "r1431"
     ]
    },
    "ci_EquitySecuritiesDividend": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "EquitySecuritiesDividend",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend",
        "label": "Equity Securities, Dividend",
        "documentation": "Equity Securities, Dividend"
       }
      }
     },
     "auth_ref": []
    },
    "ci_EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Security Investments",
        "label": "Equity Securities, FV-NI And Equity Securities Without Readily Determinable Fair Value [Table Text Block]",
        "documentation": "Equity Securities, FV-NI And Equity Securities Without Readily Determinable Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Amortized Cost",
        "documentation": "Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Amortized Cost"
       }
      }
     },
     "auth_ref": []
    },
    "ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost",
        "label": "Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Amortized Cost [Abstract]",
        "documentation": "Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Amortized Cost"
       }
      }
     },
     "auth_ref": []
    },
    "ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total, including held for sale assets",
        "label": "Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Amortized Cost, Before Reclassification To Disposal Group, Assets Held For Sale",
        "documentation": "Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Amortized Cost, Before Reclassification To Disposal Group, Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Carrying Amount",
        "documentation": "Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Carrying Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total, including held for sale assets",
        "label": "Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Carrying Amount, Before Reclassification To Disposal Group, Assets Held For Sale",
        "documentation": "Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Carrying Amount, Before Reclassification To Disposal Group, Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSaleAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying Value",
        "label": "Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Carrying Amount, Before Reclassification To Disposal Group, Assets Held For Sale [Abstract]",
        "documentation": "Equity Securities, FV-NI And Without Readily Determinable Fair Value, And Hybrid Instruments, Carrying Amount, Before Reclassification To Disposal Group, Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_EquitySecuritiesFVNIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "EquitySecuritiesFVNIMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Securities FV NI",
        "label": "Equity Securities FV NI [Member]",
        "documentation": "Equity Securities FV NI"
       }
      }
     },
     "auth_ref": []
    },
    "ci_EquitySecuritiesFvNiBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "EquitySecuritiesFvNiBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails": {
       "parentTag": "ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities with readily determinable fair values, including held for sale assets",
        "verboseLabel": "Equity securities, including held for sale assets",
        "label": "Equity Securities Fv Ni Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Equity Securities Fv Ni Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesFvNiCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiCost",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails": {
       "parentTag": "ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities with readily determinable fair values",
        "label": "Equity Securities, FV-NI, Cost",
        "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r1078"
     ]
    },
    "ci_EquitySecuritiesFvNiCostBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "EquitySecuritiesFvNiCostBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails": {
       "parentTag": "ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities with readily determinable fair values, including held for sale assets",
        "label": "Equity Securities Fv Ni Cost Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Equity Securities Fv Ni Cost Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails": {
       "parentTag": "ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity securities with readily determinable fair values",
        "terseLabel": "Equity securities",
        "label": "Equity Securities, FV-NI",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r946",
      "r1073"
     ]
    },
    "us-gaap_EquitySecuritiesIndustryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesIndustryMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Industry Sector [Domain]",
        "label": "Industry Sector [Domain]",
        "documentation": "Industry sector consisting of government, private and corporate entities engaged in business activities, including but not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate."
       }
      }
     },
     "auth_ref": [
      "r1191",
      "r1195",
      "r1198",
      "r1265",
      "r1281",
      "r1302",
      "r1332",
      "r1431"
     ]
    },
    "us-gaap_EquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities",
        "label": "Equity Securities [Member]",
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r1439",
      "r1440",
      "r1441",
      "r1788"
     ]
    },
    "ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails": {
       "parentTag": "ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities with no readily determinable fair value",
        "label": "Equity Securities Without Readily Determinable Fair Value, Amortized Cost",
        "documentation": "Equity Securities Without Readily Determinable Fair Value, Amortized Cost"
       }
      }
     },
     "auth_ref": []
    },
    "ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails": {
       "parentTag": "ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities with no readily determinable fair values including held for sale assets",
        "label": "Equity Securities Without Readily Determinable Fair Value, Amortized Cost, Before Reclassification To Disposal Group, Assets Held For Sale",
        "documentation": "Equity Securities Without Readily Determinable Fair Value, Amortized Cost, Before Reclassification To Disposal Group, Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails": {
       "parentTag": "ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails",
      "http://www.thecignagroup.com/role/InvestmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities with no readily determinable fair value",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "documentation": "Amount of investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "ci_EquitySecuritiesWithoutReadilyDeterminableFairValueAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails": {
       "parentTag": "ci_EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmountBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities with no readily determinable fair value, including held for sale assets",
        "label": "Equity Securities Without Readily Determinable Fair Value Amount Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Equity Securities Without Readily Determinable Fair Value Amount Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of impairments or value changes resulting from observable price changes on equity securities with no readily available fair value still held",
        "label": "Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount",
        "documentation": "Amount of impairment loss on investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Realized investment gains on equity securities with no readily determinable fair value",
        "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount",
        "documentation": "Amount of gain from upward price adjustment on investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "ci_EquitySecuritiesWithoutReadilyDeterminableFairValueValueOfSharesForAnnualDividendAccrual": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueValueOfSharesForAnnualDividendAccrual",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value of shares for annual dividend accrual",
        "label": "Equity Securities Without Readily Determinable Fair Value, Value Of Shares For Annual Dividend Accrual",
        "documentation": "Equity Securities Without Readily Determinable Fair Value, Value Of Shares For Annual Dividend Accrual"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1492"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1455",
      "r1467",
      "r1477",
      "r1503"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r1452",
      "r1464",
      "r1474",
      "r1500"
     ]
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Estimate of Fair Value Measurement [Member]",
        "documentation": "Measured as an estimate of fair value."
       }
      }
     },
     "auth_ref": [
      "r710",
      "r948",
      "r1389",
      "r1390"
     ]
    },
    "ci_EvernorthHealthIncorporatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "EvernorthHealthIncorporatedMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupIntercompanyBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Evernorth Health, Inc.",
        "label": "Evernorth Health Incorporated [Member]",
        "documentation": "Evernorth Health Incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "ci_EvernorthMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "EvernorthMember",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentGoodwillActivityDetails",
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Evernorth Health Services",
        "label": "Evernorth [Member]",
        "documentation": "Health Services includes pharmacy benefits management (PBM), pharmacy home delivery, and certain medical management services. This segment includes Express Scripts business from the date of acquisition with the exception of Express Scripts Medicare Part D business that is reported in the Government operating segment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1498"
     ]
    },
    "ci_ExpressScriptsCounterclaimsAgainstElevanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ExpressScriptsCounterclaimsAgainstElevanceMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Express Scripts counterclaims against Elevance",
        "label": "Express Scripts Counterclaims Against Elevance [Member]",
        "documentation": "Express Scripts Counterclaims Against Elevance"
       }
      }
     },
     "auth_ref": []
    },
    "ci_ExpressScriptsLitigationWithElevanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ExpressScriptsLitigationWithElevanceMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Express Scripts Litigation with Elevance",
        "label": "Express Scripts Litigation With Elevance [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValuesofSeparateAccountAssetsDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r931",
      "r932",
      "r939"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValuesofSeparateAccountAssetsDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r931",
      "r932",
      "r939"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Assets and Financial Liabilities Carried at Fair Value",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r188",
      "r190",
      "r290"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value and Significant Unobservable Inputs Used in Pricing Debt Securities",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "ci_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value",
        "label": "Fair Value Assets And Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of assets and liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3, by class of assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsAdditionalInformationonSeparateAccountAssetsPricedatNetAssetValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Domain]",
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r190"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsAdditionalInformationonSeparateAccountAssetsPricedatNetAssetValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Axis]",
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r190"
     ]
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r193",
      "r194"
     ]
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures for Financial Instruments Not Carried at Fair Value",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r193"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsAdditionalInformationonSeparateAccountAssetsPricedatNetAssetValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValuesofSeparateAccountAssetsDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r710",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r932",
      "r1003",
      "r1004",
      "r1005",
      "r1389",
      "r1390",
      "r1397",
      "r1398",
      "r1399"
     ]
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementBasisAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Basis [Axis]",
        "label": "Measurement Basis [Axis]",
        "documentation": "Information by measurement basis."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r188",
      "r710",
      "r1389",
      "r1390"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsAdditionalInformationonSeparateAccountAssetsPricedatNetAssetValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r931",
      "r932",
      "r934",
      "r935",
      "r940"
     ]
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosureItemAmountsDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement [Domain]",
        "label": "Fair Value Measurement [Domain]",
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value."
       }
      }
     },
     "auth_ref": [
      "r710",
      "r1389",
      "r1390"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_FairValueHedgingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueHedgingMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hedging",
        "label": "Fair Value Hedging [Member]",
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValuesofSeparateAccountAssetsDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r710",
      "r760",
      "r765",
      "r932",
      "r1003",
      "r1397",
      "r1398",
      "r1399"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValuesofSeparateAccountAssetsDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Other Observable Inputs (Level 2)",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r710",
      "r760",
      "r765",
      "r932",
      "r1004",
      "r1389",
      "r1390",
      "r1397",
      "r1398",
      "r1399"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValuesofSeparateAccountAssetsDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Unobservable Inputs (Level 3)",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r710",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r932",
      "r1005",
      "r1389",
      "r1390",
      "r1397",
      "r1398",
      "r1399"
     ]
    },
    "us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsAdditionalInformationonSeparateAccountAssetsPricedatNetAssetValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption Notice Period",
        "label": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Investment Redemption, Notice Period",
        "documentation": "Notice period the entity is required to deliver before it can redeem an investment calculated using net asset value per share, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, investments calculated by per unit, per membership interest, other equity or ownership interest and alternative investments."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsAdditionalInformationonSeparateAccountAssetsPricedatNetAssetValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]",
        "label": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ci_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLiquidatingInvestmentPeriodFromInceptionSecuritiesPartnerships": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLiquidatingInvestmentPeriodFromInceptionSecuritiesPartnerships",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected liquidation period after inception",
        "label": "Fair Value Investments Entities That Calculate Net Asset Value Per Share Liquidating Investment Period From Inception Securities Partnerships",
        "documentation": "Expected liquidation period after inception of the underlying securities partnership assets measured at net asset value per share or unit."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsAdditionalInformationonSeparateAccountAssetsPricedatNetAssetValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Table]",
        "label": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Table]",
        "documentation": "Disclosure of information about investments in certain entities that calculate net asset value per share or equivalent measured at fair value on a recurring or nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Information on Separate Account Assets Priced at NAV",
        "label": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of investments in certain entities that calculate net asset value per share or equivalent measured at fair value on a recurring or nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsAdditionalInformationonSeparateAccountAssetsPricedatNetAssetValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unfunded Commitments",
        "label": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments",
        "documentation": "The amount of unfunded commitments for which the entity is obligated, to those certain investments for which net asset value per share is calculated (including by unit, membership interest, or other equity (ownership interest) unit measure) (alternative investments)."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasuredAtNetAssetValuePerShareMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsAdditionalInformationonSeparateAccountAssetsPricedatNetAssetValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NAV",
        "label": "Fair Value Measured at Net Asset Value Per Share [Member]",
        "documentation": "Fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r760",
      "r929",
      "r940"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsAdditionalInformationonSeparateAccountAssetsPricedatNetAssetValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "ci_FairValueMeasurementNonPerformanceRiskAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "FairValueMeasurementNonPerformanceRiskAdjustment",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact of non-performance risk",
        "label": "Fair Value Measurement, Non-Performance Risk Adjustment",
        "documentation": "Fair Value Measurement, Non-Performance Risk Adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAttributedToInstrumentsHeldIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAttributedToInstrumentsHeldIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total losses included in Shareholders' net income attributable to instruments held at the reporting date",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Attributed To Instruments Held Included In Earnings",
        "documentation": "This element represents total gains or losses for the period (realized and unrealized), arising from assets included in income attributable to instruments held at the reporting date, measured at fair value on a recurring basis using unobservable inputs (Level 3), which are included in earnings or resulted in a change in asset value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "(Losses) gains included in Shareholders' net income",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gains (losses) included in Other comprehensive loss",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)",
        "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from asset measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossRequiredToAdjustFuturePolicyBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gains (losses) required to adjust future policy benefits for settlement annuities",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Required To Adjust Future Policy Benefits",
        "documentation": "This element represents total gains or losses for the period (realized and unrealized), arising from assets measured at fair value on a recurring basis using unobservable inputs (Level 3), which are included in gains or losses required to adjust future policy benefits for settlement annuities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Separate accounts assets classified in Level 3, period increase (decrease), including transfers in and out of Level 3",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease)",
        "documentation": "Amount of increase (decrease) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecreaseIncludingDisposalGroups": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecreaseIncludingDisposalGroups",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Separate accounts assets classified in Level 3, including disposal groups, period increase (decrease), including transfers in and out of Level 3",
        "label": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease), Including Disposal Groups",
        "documentation": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease), Including Disposal Groups"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails": {
       "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases",
        "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total purchases, sales and settlements",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements)",
        "documentation": "Amount of purchases, (sales), issuances and (settlements) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlementsAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases, sales and settlements",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Sales",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales",
        "documentation": "Amount of sale of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails": {
       "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Settlements",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements",
        "documentation": "Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails": {
       "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfers into Level 3",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3",
        "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total transfers into/(out of) Level 3",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net",
        "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfers into/(out of) Level 3",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails": {
       "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Transfers out of Level 3",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3",
        "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in unrealized gain or (loss) included in Other comprehensive loss for assets held at the end of the reporting period",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Unrealized Gain (Loss) Included In Other Comprehensive Income (Loss)",
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Unrealized Gain (Loss) Included In Other Comprehensive Income (Loss)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value",
        "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "ci_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, including held for sale assets",
        "periodEndLabel": "Ending balance, including held for sale assets",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsAdditionalInformationonSeparateAccountAssetsPricedatNetAssetValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsChangesinLevel3FinancialAssetsandFinancialLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValuesofSeparateAccountAssetsDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r710",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r1003",
      "r1004",
      "r1005",
      "r1389",
      "r1390",
      "r1397",
      "r1398",
      "r1399"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsAdditionalInformationonSeparateAccountAssetsPricedatNetAssetValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r930",
      "r940"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r52"
     ]
    },
    "ci_FairValueOfSeparateAccountAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "FairValueOfSeparateAccountAssetsTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Values of Separate Account Assets",
        "label": "Fair Value Of Separate Account Assets [Table Text Block]",
        "documentation": "Disclose the aggregate fair value of separate account assets, by fair value level."
       }
      }
     },
     "auth_ref": []
    },
    "ci_FinanceLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "FinanceLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total finance lease cost",
        "label": "Finance Lease, Cost",
        "documentation": "Total cost associated with finance lease."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "parentTag": "ci_FinanceLeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest on lease liabilities",
        "label": "Finance Lease, Interest Expense",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r974",
      "r981",
      "r1413"
     ]
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesSupplementalCashFlowInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash outflows from finance leases",
        "label": "Finance Lease, Interest Payment on Liability",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r976",
      "r984"
     ]
    },
    "ci_FinanceLeaseLeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "FinanceLeaseLeaseCostAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease cost:",
        "label": "Finance Lease, Lease Cost [Abstract]",
        "documentation": "Finance Lease, Lease Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Leases",
        "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails",
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total finance lease liabilities",
        "terseLabel": "Total",
        "label": "Finance Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r972",
      "r988"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term debt",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance sheet location of current finance lease liabilities",
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r973"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of Finance Lease Liabilities",
        "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1734"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Long-term debt",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance sheet location of non-current finance lease liabilities",
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r973"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Finance Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finance Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: imputed interest",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesSupplementalCashFlowInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing cash outflows from finance leases",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r975",
      "r984"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property and equipment, net",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseRightOfUseAsset",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated depreciation",
        "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization",
        "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r1533",
      "r1540"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "parentTag": "ci_FinanceLeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of ROU assets",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r974",
      "r981",
      "r1413"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseRightOfUseAsset",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, gross",
        "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization",
        "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r1530"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance sheet location of non-current finance lease assets",
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r973"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate for finance leases",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r987",
      "r1413"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term for finance leases",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r986",
      "r1413"
     ]
    },
    "us-gaap_FinancialGuaranteeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialGuaranteeMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Guarantees",
        "label": "Financial Guarantee [Member]",
        "documentation": "An agreement (contract) that requires the guarantor to make payments to the guaranteed party based on another entity's failure to pay specified obligations, such as debt, to a lender."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails",
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails",
      "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r615",
      "r616",
      "r617",
      "r618",
      "r620",
      "r623",
      "r628",
      "r629",
      "r721",
      "r727",
      "r916",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1100",
      "r1385",
      "r1548",
      "r1549",
      "r1550",
      "r1551",
      "r1552",
      "r1553",
      "r1554",
      "r1604",
      "r1605",
      "r1606",
      "r1607"
     ]
    },
    "us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoanPortfolioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Allowance for credit losses",
        "label": "Financing Receivable, Allowance for Credit Loss, Excluding Accrued Interest",
        "documentation": "Amount excluding accrued interest, of allowance for credit loss on financing receivable. Excludes net investment in lease."
       }
      }
     },
     "auth_ref": [
      "r1612"
     ]
    },
    "ci_FinancingReceivableCreditQualityDebtServiceCoverageRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "FinancingReceivableCreditQualityDebtServiceCoverageRatio",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoanPortfolioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average Debt Service Coverage Ratio",
        "label": "Financing Receivable, Credit Quality Debt Service Coverage Ratio",
        "documentation": "Financing Receivable, Credit Quality Debt Service Coverage Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "ci_FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoanPortfolioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average Debt Service Coverage Ratio, including assets held for sale",
        "label": "Financing Receivable, Credit Quality Debt Service Coverage Ratio, Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Financing Receivable, Credit Quality Debt Service Coverage Ratio, Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancingReceivableCreditQualityIndicatorsTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of the Credit Risk Profile of the Commercial Mortgage Loan Portfolio",
        "label": "Financing Receivable Credit Quality Indicators [Table Text Block]",
        "documentation": "Tabular disclosure of financing receivables by credit quality indicator. The credit quality indicator is a statistic about the credit quality of financing receivables. Examples include, but not limited to, consumer credit risk scores, credit-rating-agency ratings, an entity's internal credit risk grades, loan-to-value ratios, collateral, collection experience and other internal metrics."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r1613"
     ]
    },
    "ci_FinancingReceivableCreditQualityLoanToValueRatio": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "FinancingReceivableCreditQualityLoanToValueRatio",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoanPortfolioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average Loan-to-Value Ratio",
        "label": "Financing Receivable Credit Quality Loan To Value Ratio",
        "documentation": "Financing Receivable Credit Quality Loan To Value Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "ci_FinancingReceivableCreditQualityLoanToValueRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "FinancingReceivableCreditQualityLoanToValueRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoanPortfolioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average Loan-to-Value Ratio, including assets held for sale",
        "label": "Financing Receivable Credit Quality Loan To Value Ratio, Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Financing Receivable Credit Quality Loan To Value Ratio, Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoanPortfolioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying value, after allowance for credit loss",
        "label": "Financing Receivable, Excluding Accrued Interest, after Allowance for Credit Loss",
        "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of financing receivable. Excludes net investment in lease."
       }
      }
     },
     "auth_ref": [
      "r1612"
     ]
    },
    "ci_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoanPortfolioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying value, after allowance for credit loss, including assets held for sale",
        "label": "Financing Receivable, Excluding Accrued Interest, after Allowance for Credit Loss, Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Financing Receivable, Excluding Accrued Interest, after Allowance for Credit Loss, Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoanPortfolioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying value, before allowance for credit loss",
        "label": "Financing Receivable, Excluding Accrued Interest, before Allowance for Credit Loss",
        "documentation": "Amortized cost excluding accrued interest, before allowance for credit loss, of financing receivable. Excludes net investment in lease."
       }
      }
     },
     "auth_ref": [
      "r619",
      "r621",
      "r1612"
     ]
    },
    "us-gaap_FinancingReceivablePortfolioSegmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancingReceivablePortfolioSegmentAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoanPortfolioDetails",
      "http://www.thecignagroup.com/role/InvestmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Receivable Portfolio Segment [Axis]",
        "label": "Financing Receivable Portfolio Segment [Axis]",
        "documentation": "Information by the level at which an entity develops and documents a systematic methodology to determine its allowance for credit losses."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r355",
      "r356",
      "r615",
      "r616",
      "r1376",
      "r1548",
      "r1549",
      "r1550",
      "r1551",
      "r1552",
      "r1553",
      "r1554",
      "r1555",
      "r1556",
      "r1557"
     ]
    },
    "us-gaap_FinancingReceivablePortfolioSegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancingReceivablePortfolioSegmentDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoanPortfolioDetails",
      "http://www.thecignagroup.com/role/InvestmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Receivable Portfolio Segment [Domain]",
        "label": "Financing Receivable Portfolio Segment [Domain]",
        "documentation": "Level at which an entity develops and documents a systematic methodology to determine its allowance for credit losses."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r355",
      "r356",
      "r1548",
      "r1549",
      "r1550",
      "r1551",
      "r1552",
      "r1553",
      "r1554",
      "r1555",
      "r1556",
      "r1557"
     ]
    },
    "us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoanPortfolioDetails",
      "http://www.thecignagroup.com/role/InvestmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Financing Receivable [Axis]",
        "label": "Class of Financing Receivable [Axis]",
        "documentation": "Information by class of financing receivable determined on the basis of initial measurement attribute, risk characteristics and method of monitoring and assessing credit risk."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r109",
      "r353",
      "r354",
      "r355",
      "r356",
      "r550",
      "r552",
      "r553",
      "r554",
      "r555",
      "r617",
      "r618",
      "r620",
      "r1375",
      "r1377",
      "r1378",
      "r1383",
      "r1384",
      "r1548",
      "r1549",
      "r1550",
      "r1551",
      "r1552",
      "r1553",
      "r1554",
      "r1555",
      "r1556",
      "r1557"
     ]
    },
    "us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoanPortfolioDetails",
      "http://www.thecignagroup.com/role/InvestmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Financing Receivable [Domain]",
        "label": "Class of Financing Receivable [Domain]",
        "documentation": "Financing receivables determined on the basis of initial measurement attribute, risk characteristics and method of monitoring and assessing credit risk."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r355",
      "r356",
      "r552",
      "r553",
      "r554",
      "r555",
      "r1375",
      "r1548",
      "r1549",
      "r1550",
      "r1551",
      "r1552",
      "r1553",
      "r1554",
      "r1555",
      "r1556",
      "r1557"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization period, other intangible assets",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r648"
     ]
    },
    "ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails": {
       "parentTag": "ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVOBAIncludingDisposalGroups",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails_1": {
       "parentTag": "ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Amortization, including held for sale assets",
        "label": "Finite Lived Intangible Assets, Accumulated Amortization, Including Disposal Groups Assets Held For Sale",
        "documentation": "Finite Lived Intangible Assets, Accumulated Amortization, Including Disposal Groups Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVOBAIncludingDisposalGroups": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVOBAIncludingDisposalGroups",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails": {
       "parentTag": "ci_IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accumulated Amortization, including held for sale assets",
        "label": "Finite Lived Intangible Assets Accumulated Amortization Including VOBA Including Disposal Groups",
        "documentation": "Finite Lived Intangible Assets Accumulated Amortization Including VOBA Including Disposal Groups"
       }
      }
     },
     "auth_ref": []
    },
    "ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVoba": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVoba",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails_1": {
       "parentTag": "ci_IntangibleAssetsNetExcludingGoodwillIncludingVoba",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accumulated Amortization",
        "label": "Finite Lived Intangible Assets Accumulated Amortization Including VOBA",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. Includes insurance contracts acquired in a business combination that are reported in deferred policy acquisition costs."
       }
      }
     },
     "auth_ref": []
    },
    "ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVOBAIncludingDisposalGroupsAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortizationVOBAIncludingDisposalGroupsAssetsHeldForSale",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails": {
       "parentTag": "ci_FiniteLivedIntangibleAssetsNetVOBAIncludingDisposalGroupsAssetsHeldForSale",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Amortization, including held for sale assets",
        "label": "Finite Lived Intangible Assets Accumulated Amortization VOBA Including Disposal Groups Assets Held For Sale",
        "documentation": "Finite Lived Intangible Assets Accumulated Amortization VOBA Including Disposal Groups Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationVoba": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortizationVoba",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails": {
       "parentTag": "ci_FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVoba",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Amortization",
        "label": "Finite Lived Intangible Assets Accumulated Amortization VOBA",
        "documentation": "Accumulated amount of amortization of insurance contracts acquired in a business combination that are reported in deferred policy acquisition costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentEstimatedAnnualPreTaxAmortizationforIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentEstimatedAnnualPreTaxAmortizationforIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentEstimatedAnnualPreTaxAmortizationforIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentEstimatedAnnualPreTaxAmortizationforIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentEstimatedAnnualPreTaxAmortizationforIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r647",
      "r648",
      "r649",
      "r1039",
      "r1043"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r1043"
     ]
    },
    "ci_FiniteLivedIntangibleAssetsGrossIncludingDisposalGroupsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "FiniteLivedIntangibleAssetsGrossIncludingDisposalGroupsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails": {
       "parentTag": "ci_FiniteLivedIntangibleAssetsNetIncludingDisposalGroupsAssetsHeldForSale",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost, including held for sale assets",
        "label": "Finite Lived Intangible Assets Gross, Including Disposal Groups, Held For Sale",
        "documentation": "Finite Lived Intangible Assets Gross, Including Disposal Groups, Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_FiniteLivedIntangibleAssetsGrossVOBAIncludingDisposalGroupsAssetHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "FiniteLivedIntangibleAssetsGrossVOBAIncludingDisposalGroupsAssetHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails": {
       "parentTag": "ci_IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost, including held for sale assets",
        "label": "Finite Lived Intangible Assets Gross VOBA Including Disposal Groups Asset Held For Sale",
        "documentation": "Finite Lived Intangible Assets Gross VOBA Including Disposal Groups Asset Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_FiniteLivedIntangibleAssetsGrossVoba": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "FiniteLivedIntangibleAssetsGrossVoba",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails": {
       "parentTag": "ci_IntangibleAssetsGrossExcludingGoodwillIncludingVoba",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost",
        "label": "Finite Lived Intangible Assets Gross VOBA",
        "documentation": "Amount before amortization of insurance contracts acquired in a business combination that are reported in deferred policy acquisition costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r116"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails_1": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Carrying Value",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r1039"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-lived intangible assets",
        "label": "Finite-Lived Intangible Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_FiniteLivedIntangibleAssetsNetIncludingDisposalGroupsAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "FiniteLivedIntangibleAssetsNetIncludingDisposalGroupsAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails": {
       "parentTag": "ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Carrying Value, including held for sale assets",
        "label": "Finite Lived Intangible Assets, Net, Including Disposal Groups Assets Held For Sale",
        "documentation": "Finite Lived Intangible Assets, Net, Including Disposal Groups Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_FiniteLivedIntangibleAssetsNetVOBAIncludingDisposalGroupsAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "FiniteLivedIntangibleAssetsNetVOBAIncludingDisposalGroupsAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails_1": {
       "parentTag": "ci_IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Carrying Value, including held for sale assets",
        "label": "Finite Lived Intangible Assets Net VOBA Including Disposal Groups Assets Held For Sale",
        "documentation": "Finite Lived Intangible Assets Net VOBA Including Disposal Groups Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_FiniteLivedIntangibleAssetsNetVoba": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "FiniteLivedIntangibleAssetsNetVoba",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails": {
       "parentTag": "ci_IntangibleAssetsNetExcludingGoodwillIncludingVoba",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Carrying Value",
        "label": "Finite Lived Intangible Assets Net VOBA",
        "documentation": "Amount after amortization of insurance contracts acquired in a business combination that are reported in deferred policy acquisition costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Translation of Foreign Currencies",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignGovernmentDebtSecuritiesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign government",
        "label": "Debt Security, Government, Non-US [Member]",
        "documentation": "Debt security issued by government not domiciled in United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r1673",
      "r1776"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r1459",
      "r1471",
      "r1481",
      "r1507"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r1459",
      "r1471",
      "r1481",
      "r1507"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r1459",
      "r1471",
      "r1481",
      "r1507"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1459",
      "r1471",
      "r1481",
      "r1507"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1459",
      "r1471",
      "r1481",
      "r1507"
     ]
    },
    "ci_ForwardsSwapsOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ForwardsSwapsOptionsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forwards, swaps, options",
        "label": "Forwards Swaps Options [Member]",
        "documentation": "Forwards Swaps Options"
       }
      }
     },
     "auth_ref": []
    },
    "ci_FundInvestmentsAndPooledSeparateAccountsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "FundInvestmentsAndPooledSeparateAccountsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionPensionPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fund investments",
        "label": "Fund Investments And Pooled Separate Accounts [Member]",
        "documentation": "Security representing ownership in an investment entity that invests funds in debt instruments for which ownership is represented by either shares or units, in which defined benefit plan asset is invested."
       }
      }
     },
     "auth_ref": []
    },
    "ci_FuturePolicyBenefitsDomesticContractsObservableInputsFromPublishedSpotRateCurveMaximumTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "FuturePolicyBenefitsDomesticContractsObservableInputsFromPublishedSpotRateCurveMaximumTerm",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Observable inputs from published spot rate curve term (in years)",
        "label": "Future Policy Benefits, Domestic Contracts, Observable Inputs From Published Spot Rate Curve, Maximum Term",
        "documentation": "Future Policy Benefits, Domestic Contracts, Observable Inputs From Published Spot Rate Curve, Maximum Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FuturePolicyBenefitsLiabilityPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FuturePolicyBenefitsLiabilityPolicy",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future Policy Benefits",
        "label": "Liability for Future Policy Benefit [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for liability for future benefit to be paid to or on behalf of policyholder. Includes, but is not limited to, input, judgment, assumption, and method used in measuring liability and change in input, judgment, and assumption."
       }
      }
     },
     "auth_ref": [
      "r1131",
      "r1136",
      "r1138"
     ]
    },
    "ci_GainLossOnExtinguishmentOfDebtNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "GainLossOnExtinguishmentOfDebtNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtLongtermDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on repurchase of debt, after-tax",
        "label": "Gain (Loss) On Extinguishment Of Debt, Net Of Tax",
        "documentation": "Gain (Loss) On Extinguishment Of Debt, Net Of Tax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfBusiness",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Loss) gain on sale of businesses",
        "negatedLabel": "Loss (gain) on sale of businesses",
        "label": "Gain (Loss) on Disposition of Business",
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant."
       }
      }
     },
     "auth_ref": [
      "r900",
      "r1574"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      },
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/DebtLongtermDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt extinguishment costs",
        "negatedTerseLabel": "Debt extinguishment costs",
        "negatedLabel": "Loss on repurchase of debt, pre-tax",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r124",
      "r125"
     ]
    },
    "us-gaap_GeographicConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeographicConcentrationRiskMember",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesPretaxIncomeFromForeignOperationsDetails",
      "http://www.thecignagroup.com/role/SegmentInformationUSandForeignRevenuesfromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographic Concentration Risk",
        "label": "Geographic Concentration Risk [Member]",
        "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa)."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r1343"
     ]
    },
    "us-gaap_GeographicDistributionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeographicDistributionAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesPretaxIncomeFromForeignOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographic Distribution [Axis]",
        "label": "Geographic Distribution [Axis]",
        "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r1062",
      "r1063",
      "r1380"
     ]
    },
    "us-gaap_GeographicDistributionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeographicDistributionDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesPretaxIncomeFromForeignOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographic Distribution [Domain]",
        "label": "Geographic Distribution [Domain]",
        "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r1062",
      "r1063"
     ]
    },
    "us-gaap_GeographicDistributionForeignMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeographicDistributionForeignMember",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesPretaxIncomeFromForeignOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Geographic Distribution, Foreign [Member]",
        "documentation": "Allocation of business activity identified as foreign."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r1062",
      "r1063",
      "r1381"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets",
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentGoodwillActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "periodStartLabel": "Balance at January 1",
        "periodEndLabel": "Balance at December 31",
        "label": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r634",
      "r1056",
      "r1386",
      "r1414",
      "r1619",
      "r1626"
     ]
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAcquiredDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentGoodwillActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill acquired",
        "label": "Goodwill, Acquired During Period",
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination."
       }
      }
     },
     "auth_ref": [
      "r637",
      "r1386"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r633",
      "r645",
      "r1386"
     ]
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentGoodwillActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact of foreign currency translation and other adjustments",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "ci_GoodwillIncludingDisposalGroups": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "GoodwillIncludingDisposalGroups",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentGoodwillActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at January 1, including held for sale assets",
        "periodEndLabel": "Balance at December 31, including held for sale assets",
        "label": "Goodwill, Including Disposal Groups",
        "documentation": "Goodwill, Including Disposal Groups"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentGoodwillActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Line Items]",
        "label": "Goodwill [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r1386"
     ]
    },
    "ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "GoodwillOtherIntangiblesAndPropertyAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill Other Intangibles And Property And Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_GoodwillOtherIntangiblesAndPropertyAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "GoodwillOtherIntangiblesAndPropertyAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill, Other Intangibles, and Property and Equipment",
        "label": "Goodwill Other Intangibles And Property And Equipment Disclosure [Text Block]",
        "documentation": "Discloses the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain or loss on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss. This element may be used as a single block of text to include the entire intangible asset disclosure including data and tables. Disclosure of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, building and production equipment. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures. This element may be used as a single block of text to include the entire PPE disclosure, including data and tables."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillRollForward",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentGoodwillActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Roll Forward]",
        "label": "Goodwill [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ci_GoodwillTransfersToAssetsOfBusinessesHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "GoodwillTransfersToAssetsOfBusinessesHeldForSale",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentGoodwillActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Goodwill transferred to assets of businesses held for sale",
        "label": "Goodwill, Transfers To Assets Of Businesses Held-For-Sale",
        "documentation": "Goodwill, Transfers To Assets Of Businesses Held-For-Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentGoodwillActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Goodwill disposed",
        "label": "Goodwill, Written off Related to Sale of Business Unit",
        "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r639",
      "r1386"
     ]
    },
    "us-gaap_GuaranteeObligationsByNatureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GuaranteeObligationsByNatureAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails",
      "http://www.thecignagroup.com/role/MergersAcquisitionsandDivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guarantor Obligations, Nature [Axis]",
        "label": "Guarantor Obligations, Nature [Axis]",
        "documentation": "Information by nature of guarantee."
       }
      }
     },
     "auth_ref": [
      "r679",
      "r680",
      "r681",
      "r682"
     ]
    },
    "us-gaap_GuaranteeObligationsCurrentCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GuaranteeObligationsCurrentCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupGuaranteesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability for guarantees",
        "label": "Guarantor Obligations, Current Carrying Value",
        "documentation": "The current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees."
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "us-gaap_GuaranteeObligationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GuaranteeObligationsLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupGuaranteesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guarantor Obligations [Line Items]",
        "label": "Guarantor Obligations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r679",
      "r680",
      "r681",
      "r682"
     ]
    },
    "us-gaap_GuaranteeObligationsLiquidationProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GuaranteeObligationsLiquidationProceeds",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets maintained by employers (minimum)",
        "label": "Guarantor Obligations, Liquidation Proceeds, Monetary Amount",
        "documentation": "Indicates, if estimable, the approximate extent to which the proceeds from liquidation of any assets held either as collateral or by third parties would be expected to cover the maximum potential amount of future payments under the guarantee or each group of similar guarantees."
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "us-gaap_GuaranteeObligationsMaximumExposure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GuaranteeObligationsMaximumExposure",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails",
      "http://www.thecignagroup.com/role/MergersAcquisitionsandDivestituresNarrativeDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupGuaranteesDetails",
      "http://www.thecignagroup.com/role/VariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum guarantee exposure",
        "label": "Guarantor Obligations, Maximum Exposure, Undiscounted",
        "documentation": "Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "us-gaap_GuaranteeObligationsNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GuaranteeObligationsNatureDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails",
      "http://www.thecignagroup.com/role/MergersAcquisitionsandDivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guarantor Obligations, Nature [Domain]",
        "label": "Guarantor Obligations, Nature [Domain]",
        "documentation": "Represents a description of the nature of the guarantee or each group of similar guarantees."
       }
      }
     },
     "auth_ref": [
      "r679",
      "r680",
      "r681",
      "r682"
     ]
    },
    "ci_GuaranteeObligationsPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "GuaranteeObligationsPayments",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupGuaranteesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments made on guarantees",
        "label": "Guarantee Obligations Payments",
        "documentation": "Payments related to guarantee obligation."
       }
      }
     },
     "auth_ref": []
    },
    "ci_GuaranteedDepositAccountContractMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "GuaranteedDepositAccountContractMember",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionPensionPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guaranteed deposit account contract",
        "label": "Guaranteed Deposit Account Contract [Member]",
        "documentation": "Investment account administered by an insurance company that provides a guaranteed fixed rate of return; in which defined benefit plan asset is invested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GuaranteedInsuranceContractTypeOfBenefitAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GuaranteedInsuranceContractTypeOfBenefitAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guaranteed Insurance Contract, Type of Benefit [Axis]",
        "label": "Guaranteed Insurance Contract, Type of Benefit [Axis]",
        "documentation": "Information by benefit for guaranteed benefit obligations in traditional and nontraditional long-duration contracts with policy and contract holders."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r324",
      "r1770"
     ]
    },
    "us-gaap_GuaranteedInsuranceContractTypeOfBenefitDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GuaranteedInsuranceContractTypeOfBenefitDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guaranteed Insurance Contract, Type of Benefit [Domain]",
        "label": "Guaranteed Insurance Contract, Type of Benefit [Domain]",
        "documentation": "Benefit for guaranteed benefit obligations in traditional and nontraditional long-duration contracts with policy and contract holders."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r1169",
      "r1770"
     ]
    },
    "us-gaap_GuaranteedMinimumDeathBenefitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GuaranteedMinimumDeathBenefitMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GMDB",
        "label": "Guaranteed Minimum Death Benefit [Member]",
        "documentation": "Feature in an insurance contract that guarantees a minimum amount that will be payable upon the death of the insured."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r324",
      "r1770"
     ]
    },
    "ci_GuaranteedSeparateAccountAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "GuaranteedSeparateAccountAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValuesofSeparateAccountAssetsDetails": {
       "parentTag": "ci_SeparateAccountAssetsClassifiedInFairValueHierarchy",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValuesofSeparateAccountAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guaranteed separate accounts",
        "label": "Guaranteed Separate Account Assets",
        "documentation": "Guaranteed Separate Account Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GuaranteesIndemnificationsAndWarrantiesPolicies",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guarantees",
        "label": "Guarantees, Indemnifications and Warranties Policies [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for guarantees, indemnifications and product warranties, and methodologies used in determining the amount of such liabilities."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "us-gaap_GuaranteesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GuaranteesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationFinancialandPerformanceGuaranteesDetails",
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guarantees",
        "label": "Guarantees [Member]",
        "documentation": "A guaranty by which one person assumes responsibility for paying another's debts or fulfilling another's responsibilities; or a promise, pledge, assurance, especially one given in writing, that attests: (a) to the quality or durability of a product or service; (b) that something will be performed in a specified manner; or (c) that execution, completion, or existence of something is as represented or stipulated by agreement."
       }
      }
     },
     "auth_ref": [
      "r1650"
     ]
    },
    "us-gaap_GuarantyLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GuarantyLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/VariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guaranty liability",
        "label": "Guaranty Liabilities",
        "documentation": "This item represents a non-contingent liability for the fair value of an obligation to stand ready to perform over the term of a guaranty issued in the event that specified triggering events or conditions occur."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r1640"
     ]
    },
    "ci_HealthCareServiceCorporationHCSCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "HealthCareServiceCorporationHCSCMember",
     "presentation": [
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails",
      "http://www.thecignagroup.com/role/DescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Health Care Service Corporation (HCSC)",
        "label": "Health Care Service Corporation (HCSC) [Member]",
        "documentation": "Health Care Service Corporation (HCSC)"
       }
      }
     },
     "auth_ref": []
    },
    "ci_HealthcareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "HealthcareMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cigna Healthcare",
        "label": "Healthcare [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_HealthcareSectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HealthcareSectorMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Health Care Sector",
        "label": "Healthcare Sector [Member]",
        "documentation": "Sector of the economy consisting of companies engaged in healthcare-related business activities."
       }
      }
     },
     "auth_ref": [
      "r1431",
      "r1787",
      "r1789",
      "r1790",
      "r1791"
     ]
    },
    "us-gaap_HedgeFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HedgeFundsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsAdditionalInformationonSeparateAccountAssetsPricedatNetAssetValueDetails",
      "http://www.thecignagroup.com/role/PensionPensionPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedge funds",
        "label": "Hedge Funds [Member]",
        "documentation": "Investments in registered hedge funds."
       }
      }
     },
     "auth_ref": [
      "r1673"
     ]
    },
    "us-gaap_HedgingDesignationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HedgingDesignationAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Designation [Axis]",
        "label": "Hedging Designation [Axis]",
        "documentation": "Information by designation of purpose of derivative instrument."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r904"
     ]
    },
    "us-gaap_HedgingDesignationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HedgingDesignationDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Designation [Domain]",
        "label": "Hedging Designation [Domain]",
        "documentation": "Designation of purpose of derivative instrument."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_HedgingRelationshipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HedgingRelationshipDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Relationship [Domain]",
        "label": "Hedging Relationship [Domain]",
        "documentation": "Nature or intent of a hedge."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "ci_HomeDeliveryAndSpecialtyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "HomeDeliveryAndSpecialtyMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Home delivery and specialty revenues",
        "label": "Home Delivery And Specialty [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r1449",
      "r1450",
      "r1463"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairments of other intangible assets",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r43"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets and Liabilities of Businesses Held for Sale",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r266"
     ]
    },
    "ci_IncomeBeforeTaxesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "IncomeBeforeTaxesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesPretaxIncomeFromForeignOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Tax Income",
        "label": "Income Before Taxes [Member]",
        "documentation": "Earnings before income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "ci_IncomeLossAttributableToNoncontrollingInterestBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "IncomeLossAttributableToNoncontrollingInterestBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "(Income) loss attributable to noncontrolling interests",
        "label": "Income Loss Attributable To Noncontrolling Interest Before Tax",
        "documentation": "Amount of pre-tax income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails": {
       "parentTag": "ci_LossOfParentCompany",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r241",
      "r303",
      "r512",
      "r532",
      "r538",
      "r541",
      "r1063",
      "r1095",
      "r1373"
     ]
    },
    "us-gaap_IncomeLossFromSubsidiariesNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromSubsidiariesNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity in income of subsidiaries",
        "negatedLabel": "Equity in income of subsidiaries",
        "label": "Income (Loss) from Subsidiaries, Net of Tax",
        "documentation": "Amount after tax of income (loss) of subsidiary attributable to the parent entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails",
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails",
      "http://www.thecignagroup.com/role/DescriptionofBusinessDetails",
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentGoodwillActivityDetails",
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails",
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails",
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails",
      "http://www.thecignagroup.com/role/IncomeTaxesForeignJurisdictionTaxAttributesandSaleofMedicareAdvantageandRelatedBusinessesDetails",
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails",
      "http://www.thecignagroup.com/role/MergersAcquisitionsandDivestituresNarrativeDetails",
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Axis]",
        "label": "Disposal Group Name [Axis]",
        "documentation": "Information by name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r1401",
      "r1404"
     ]
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails",
      "http://www.thecignagroup.com/role/DescriptionofBusinessDetails",
      "http://www.thecignagroup.com/role/IncomeTaxesForeignJurisdictionTaxAttributesandSaleofMedicareAdvantageandRelatedBusinessesDetails",
      "http://www.thecignagroup.com/role/MergersAcquisitionsandDivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "presentation": [
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails",
      "http://www.thecignagroup.com/role/DescriptionofBusinessDetails",
      "http://www.thecignagroup.com/role/IncomeTaxesForeignJurisdictionTaxAttributesandSaleofMedicareAdvantageandRelatedBusinessesDetails",
      "http://www.thecignagroup.com/role/MergersAcquisitionsandDivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r42",
      "r57",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r265"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_IncomeTaxDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "IncomeTaxDisclosureLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails",
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Line Items]",
        "label": "Income Tax Disclosure [Line Items]",
        "documentation": "Income Tax Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "ci_IncomeTaxDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "IncomeTaxDisclosureTable",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails",
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Table]",
        "label": "Income Tax Disclosure [Table]",
        "documentation": "Income Tax Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r856",
      "r864",
      "r870",
      "r876",
      "r883",
      "r888",
      "r889",
      "r890",
      "r1184"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails": {
       "parentTag": "ci_LossOfParentCompany",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/IncomeTaxesComponentsofIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/IncomeTaxesComponentsofIncomeTaxesDetails",
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "TOTAL INCOME TAXES",
        "totalLabel": "Total income taxes",
        "terseLabel": "Income tax benefits",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r334",
      "r487",
      "r488",
      "r520",
      "r862",
      "r884",
      "r1107"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$",
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r858",
      "r859",
      "r870",
      "r871",
      "r875",
      "r877",
      "r1180"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1713"
     ]
    },
    "us-gaap_IncomeTaxReconciliationDispositionOfBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationDispositionOfBusiness",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact of sale of businesses",
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Business, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the disposition of a business not qualifying as a discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r1713"
     ]
    },
    "ci_IncomeTaxReconciliationHealthInsuranceIndustryTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "IncomeTaxReconciliationHealthInsuranceIndustryTax",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Health insurance industry tax",
        "label": "Income Tax Reconciliation Health Insurance Industry Tax",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) due to the non-deductibility for federal income tax purposes of the health insurance industry tax assessed under Health Care Reform."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax expense at nominal rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherReconcilingItems",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1713"
     ]
    },
    "ci_IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Effect of foreign earnings",
        "label": "Income Tax Reconciliation Permanently Reinvested Foreign Earnings",
        "documentation": "The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to permanently reinvested foreign earnings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income tax (benefit), net of federal income tax benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1713"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes paid, net of refunds",
        "label": "Income Taxes Paid, Net",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable, net",
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ci_IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and Accrued expenses and other liabilities",
        "verboseLabel": "Other liabilities",
        "label": "Increase Decrease In Accounts Payable Accrued And Other Operating Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of accounts payable, accrued liabilities and other operating obligations not separately disclosed in the statement of cash flows."
       }
      }
     },
     "auth_ref": []
    },
    "ci_IncreaseDecreaseInAmountsDueFromAffiliates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "IncreaseDecreaseInAmountsDueFromAffiliates",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net change in amounts due from affiliates",
        "label": "Increase Decrease In Amounts Due From Affiliates",
        "documentation": "(Increase) Decrease In Amounts Due From Affiliates"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred income tax benefit",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_IncreaseDecreaseInInsuranceLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInsuranceLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance liabilities",
        "label": "Increase (Decrease) in Insurance Liabilities",
        "documentation": "The increase (decrease) in insurance liability balances during the period."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventories",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net changes in assets and liabilities, net of non-operating effects:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other, net",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ci_IncreaseDecreaseInPharmacyAndServiceCostsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "IncreaseDecreaseInPharmacyAndServiceCostsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pharmacy and other service costs payable",
        "label": "Increase Decrease In Pharmacy And Service Costs Payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInReinsuranceRecoverable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInReinsuranceRecoverable",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Reinsurance recoverable and Other assets",
        "label": "Increase (Decrease) in Reinsurance Recoverable",
        "documentation": "The increase (decrease) during the reporting period in the amount of benefits the ceding insurer expects to recover on insurance policies ceded to other insurance entities as of the balance sheet date for all guaranteed benefit types."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.thecignagroup.com/role/CommonandPreferredStockShareActivityDetails",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in Total Equity",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Redeemable Noncontrolling Interests",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.thecignagroup.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock equivalents (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r496",
      "r497",
      "r502",
      "r812"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails_1": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentNarrativeDetails",
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived intangible assets",
        "netLabel": "Cost",
        "verboseLabel": "Net Carrying Value",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r259"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived intangible assets",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails": {
       "parentTag": "ci_IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost, including held for sale assets",
        "verboseLabel": "Net Carrying Value, including held for sale assets",
        "label": "Indefinite Lived Intangible Assets Excluding Goodwill, Including Disposal Groups Assets Held For Sale",
        "documentation": "Indefinite Lived Intangible Assets Excluding Goodwill, Including Disposal Groups Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndemnificationGuaranteeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndemnificationGuaranteeMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indemnification obligations",
        "label": "Indemnification Agreement [Member]",
        "documentation": "An agreement (contract) that contingently requires the guarantor to make payments to the guaranteed party in compensation for that party's or parties' loss or injury attributable to specified events or actions, such as a patent infringement action against an entity that relied on certain representations as to ownership rights made by a software vendor."
       }
      }
     },
     "auth_ref": [
      "r1641"
     ]
    },
    "us-gaap_IndirectGuaranteeOfIndebtednessMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndirectGuaranteeOfIndebtednessMember",
     "presentation": [
      "http://www.thecignagroup.com/role/MergersAcquisitionsandDivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guarantee of CHSS' credit facilities",
        "label": "Indirect Guarantee of Indebtedness [Member]",
        "documentation": "An indirect guarantee of the indebtedness of another party arises under an agreement that obligates one entity to transfer funds to a second entity upon the occurrence of specified events, under conditions whereby (a) the funds become legally available to creditors of the second entity and (b) those creditors may enforce the second entity's claims against the first entity under the agreement. Examples of indirect guarantees include agreements to advance funds if a second entity's net income, coverage of fixed charges, or working capital falls below a specified minimum."
       }
      }
     },
     "auth_ref": [
      "r1641"
     ]
    },
    "ci_IndividualAndFamilyPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "IndividualAndFamilyPlansMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual and Family Plans",
        "label": "Individual And Family Plans [Member]",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1462",
      "r1471",
      "r1481",
      "r1498",
      "r1507",
      "r1511",
      "r1519"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1517"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1451",
      "r1523"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1451",
      "r1523"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1451",
      "r1523"
     ]
    },
    "us-gaap_InsuranceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InsuranceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_InsuranceAndContractholderLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "InsuranceAndContractholderLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails_2": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total insurance and contractholder liabilities",
        "label": "Insurance And Contractholder Liabilities",
        "documentation": "Insurance And Contractholder Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ci_InsuranceAndContractholderLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "InsuranceAndContractholderLiabilitiesAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Insurance And Contractholder Liabilities [Abstract]",
        "documentation": "Insurance And Contractholder Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ci_InsuranceAndContractholderLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "InsuranceAndContractholderLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails_1": {
       "parentTag": "ci_InsuranceAndContractholderLiabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current insurance and contractholder liabilities",
        "totalLabel": "Current insurance and contractholder liabilities",
        "label": "Insurance And Contractholder Liabilities Current",
        "documentation": "The carrying amounts as of the balance sheet date of all current insurance and contractholder liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ci_InsuranceAndContractholderLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "InsuranceAndContractholderLiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current",
        "label": "Insurance And Contractholder Liabilities, Current [Abstract]",
        "documentation": "Insurance And Contractholder Liabilities, Current"
       }
      }
     },
     "auth_ref": []
    },
    "ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails_1": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total, current",
        "label": "Insurance And Contractholder Liabilities, Current, Including Disposal Groups",
        "documentation": "Insurance And Contractholder Liabilities, Current, Including Disposal Groups"
       }
      }
     },
     "auth_ref": []
    },
    "ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "InsuranceAndContractholderLiabilitiesIncludingDisposalGroups",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails_2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Insurance And Contractholder Liabilities, Including Disposal Groups",
        "documentation": "Insurance And Contractholder Liabilities, Including Disposal Groups"
       }
      }
     },
     "auth_ref": []
    },
    "ci_InsuranceAndContractholderLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "InsuranceAndContractholderLiabilitiesLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsInterestRatesandDurationDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance and Contractholder Liabilities [Line Items]",
        "label": "Insurance and Contractholder Liabilities [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_InsuranceAndContractholderLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "InsuranceAndContractholderLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails_1": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current insurance and contractholder liabilities",
        "totalLabel": "Non-current insurance and contractholder liabilities",
        "label": "Insurance And Contractholder Liabilities Noncurrent",
        "documentation": "The carrying amounts as of the balance sheet date of all current insurance and contractholder liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ci_InsuranceAndContractholderLiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "InsuranceAndContractholderLiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current",
        "label": "Insurance And Contractholder Liabilities, Noncurrent [Abstract]",
        "documentation": "Insurance And Contractholder Liabilities, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails_1": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total, non-current",
        "label": "Insurance And Contractholder Liabilities, Noncurrent, Including Disposal Groups",
        "documentation": "Insurance And Contractholder Liabilities, Noncurrent, Including Disposal Groups"
       }
      }
     },
     "auth_ref": []
    },
    "ci_InsuranceAndContractholderLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "InsuranceAndContractholderLiabilitiesTable",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsInterestRatesandDurationDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance And Contractholder Liabilities [Table]",
        "label": "Insurance And Contractholder Liabilities [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InsuranceContractsAcquiredInBusinessCombinationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InsuranceContractsAcquiredInBusinessCombinationMember",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentComponentsofDepreciationandAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value of business acquired (reported in Other assets)",
        "label": "Insurance Contracts Acquired in Business Combination [Member]",
        "documentation": "Written contracts detailing the terms and conditions of insurance acquired in a business combination."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "ci_InsuranceCustomerReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "InsuranceCustomerReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails": {
       "parentTag": "us-gaap_ReceivablesNetCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance customer receivables",
        "label": "Insurance Customer Receivables",
        "documentation": "Receivables due from customers under insurance contracts."
       }
      }
     },
     "auth_ref": []
    },
    "ci_InsuranceCustomerReceivablesBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "InsuranceCustomerReceivablesBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails_1": {
       "parentTag": "ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance customer receivables, including held for sale assets",
        "label": "Insurance Customer Receivables, Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Insurance Customer Receivables, Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InsuranceLossReservesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InsuranceLossReservesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance Loss Reserves [Abstract]",
        "label": "Insurance Loss Reserves [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InsuranceRelatedAssessmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InsuranceRelatedAssessmentsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guaranty Fund Assessments",
        "label": "Insurance-related Assessments [Member]",
        "documentation": "Any funding mandated by statute or regulatory authority that is related directly or indirectly to underwriting activities, including pools for self-insurance and excluding premium taxes and income taxes. The funds derived from the assessments generally enable a government guarantor to pay insurance claims in the event that the underwriting insurer is insolvent or otherwise unable to meet its payment obligations."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "ci_InsuranceUnearnedPremiumsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "InsuranceUnearnedPremiumsPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unearned Premium",
        "label": "Insurance, Unearned Premiums [Policy Text Block]",
        "documentation": "Insurance, Unearned Premiums"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Intangible Assets",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r1035",
      "r1036",
      "r1037",
      "r1039",
      "r1368"
     ]
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails": {
       "parentTag": "ci_IntangibleAssetsGrossExcludingGoodwillIncludingVoba",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cost",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "ci_IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails": {
       "parentTag": "ci_IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails_1": {
       "parentTag": "ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cost, including held for sale assets",
        "label": "Intangible Assets Gross Excluding Goodwill, Including Disposal Groups Assets Held For Sale",
        "documentation": "Intangible Assets Gross Excluding Goodwill, Including Disposal Groups Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails": {
       "parentTag": "ci_IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cost, including held for sale assets",
        "label": "Intangible Assets Gross Excluding Goodwill Including VOBA Including Disposal Groups",
        "documentation": "Intangible Assets Gross Excluding Goodwill Including VOBA Including Disposal Groups"
       }
      }
     },
     "auth_ref": []
    },
    "ci_IntangibleAssetsGrossExcludingGoodwillIncludingVoba": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "IntangibleAssetsGrossExcludingGoodwillIncludingVoba",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails_1": {
       "parentTag": "ci_IntangibleAssetsNetExcludingGoodwillIncludingVoba",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cost",
        "label": "Intangible Assets Gross Excluding Goodwill Including VOBA",
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill. Inlcudes insurance contracts acquired in a business combination that are reported in deferred policy acquisition costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails": {
       "parentTag": "ci_IntangibleAssetsNetExcludingGoodwillIncludingVoba",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets",
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other intangible assets",
        "totalLabel": "Net Carrying Value",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r115"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails_1": {
       "parentTag": "ci_IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Carrying Value, including held for sale assets",
        "label": "Intangible Assets Net Excluding Goodwill Including Disposals Groups Assets Held For Sale",
        "documentation": "Intangible Assets Net Excluding Goodwill Including Disposals Groups Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Carrying Value, including held for sale assets",
        "label": "Intangible Assets Net Excluding Goodwill Including VOBA Including Disposal Groups",
        "documentation": "Intangible Assets Net Excluding Goodwill Including VOBA Including Disposal Groups"
       }
      }
     },
     "auth_ref": []
    },
    "ci_IntangibleAssetsNetExcludingGoodwillIncludingVoba": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "IntangibleAssetsNetExcludingGoodwillIncludingVoba",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Carrying Value",
        "label": "Intangible Assets Net Excluding Goodwill Including VOBA",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. Includes insurance contracts acquired in a business combination that are reported in deferred policy acquisition costs."
       }
      }
     },
     "auth_ref": []
    },
    "ci_IntangibleAssetsValueOfBusinessAcquiredAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "IntangibleAssetsValueOfBusinessAcquiredAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value of business acquired (\"VOBA\" reported in Other assets)",
        "label": "Intangible Assets, Value Of Business Acquired [Abstract]",
        "documentation": "Intangible Assets, Value Of Business Acquired"
       }
      }
     },
     "auth_ref": []
    },
    "ci_IntercompanyInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "IntercompanyInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Intercompany interest expense",
        "label": "Intercompany interest",
        "documentation": "Interest expense associated with intercompany loan."
       }
      }
     },
     "auth_ref": []
    },
    "ci_IntercompanyInterestIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "IntercompanyInterestIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intercompany interest income",
        "label": "Intercompany Interest Income",
        "documentation": "Interest expense associated with intercompany loan."
       }
      }
     },
     "auth_ref": []
    },
    "ci_IntercompanyReceivablesInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "IntercompanyReceivablesInterestRate",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupIntercompanyBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate, intercompany receivables",
        "label": "Intercompany Receivables Interest Rate",
        "documentation": "Annual fixed rate of interest at which interest income on intercompany receivables was accrued."
       }
      }
     },
     "auth_ref": []
    },
    "ci_InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeDetails": {
       "parentTag": "us-gaap_NetInvestmentIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment income",
        "label": "Interest And Dividend Income Operating And Operating Leases Income Statement Lease Revenue",
        "documentation": "Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein. Also includes the total amount of revenue recognized for the period from operating leases, including minimum lease revenue, contingent revenue, percentage revenue and sublease revenue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense on long-term and short-term debt",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r716",
      "r724",
      "r1391",
      "r1392"
     ]
    },
    "ci_InterestInJointVentureInTurkeyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "InterestInJointVentureInTurkeyMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest in Turkiye Joint Venture",
        "label": "Interest In Joint Venture In Turkey [Member]",
        "documentation": "Interest In Joint Venture In Turkey"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r447",
      "r448"
     ]
    },
    "us-gaap_InterestRateSwapMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestRateSwapMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate swap contracts",
        "label": "Interest Rate Swap [Member]",
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period."
       }
      }
     },
     "auth_ref": [
      "r1359",
      "r1436",
      "r1437"
     ]
    },
    "ci_InternationalHealthMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "InternationalHealthMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International Health",
        "label": "International Health [Member]",
        "documentation": "International Health"
       }
      }
     },
     "auth_ref": []
    },
    "ci_InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember",
     "presentation": [
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails",
      "http://www.thecignagroup.com/role/MergersAcquisitionsandDivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International life, accident, supplemental benefits businesses sold to Chubb",
        "label": "International Life Accident Supplemental Benefits Businesses Excluding Turkey Joint Venture [Member]",
        "documentation": "Sold life, accident and supplemental benefits businesses in Hong Kong, Indonesia, New Zealand, South Korea, Taiwan and Thailand."
       }
      }
     },
     "auth_ref": []
    },
    "ci_InternationalLifeAccidentSupplementalBenefitsBusinessesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "InternationalLifeAccidentSupplementalBenefitsBusinessesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails",
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentGoodwillActivityDetails",
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails",
      "http://www.thecignagroup.com/role/MergersAcquisitionsandDivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International life, accident and supplemental benefits businesses",
        "label": "International Life Accident Supplemental Benefits Businesses [Member]",
        "documentation": "Life, accident and supplemental benefits businesses in Hong Kong, Indonesia, New Zealand, South Korea, Taiwan, Thailand and interest in a joint venture in Turkey."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntersegmentEliminationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntersegmentEliminationMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intersegment Eliminations",
        "label": "Intersegment Eliminations [Member]",
        "documentation": "Eliminating entries used in operating segment consolidation."
       }
      }
     },
     "auth_ref": [
      "r514",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r537",
      "r541"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r1364",
      "r1414"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r400",
      "r415",
      "r630",
      "r631",
      "r632",
      "r1034",
      "r1369"
     ]
    },
    "ci_InvestmentGradeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "InvestmentGradeMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment grade",
        "label": "Investment Grade [Member]",
        "documentation": "External credit-ratings or internal groupings that could be used to describe the current status of the payment and performance risk of debt and securities investments that connote investment grade."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentHoldingsScheduleOfInvestmentsTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments by category and current or long-term classification",
        "label": "Investment Holdings, Schedule of Investments [Table Text Block]",
        "documentation": "Tabular disclosure of data and information required in the supplementary schedule applicable to management investment companies listing holdings of unaffiliated investments."
       }
      }
     },
     "auth_ref": [
      "r1779",
      "r1780",
      "r1781",
      "r1782",
      "r1783",
      "r1784"
     ]
    },
    "ci_InvestmentIncomeAndGainsAndLossesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "InvestmentIncomeAndGainsAndLossesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income And Gains And Losses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeInvestmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInvestmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeDetails": {
       "parentTag": "us-gaap_NetInvestmentIncome",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less investment expenses",
        "label": "Investment Income, Investment Expense",
        "documentation": "Amount of expenses related to the generation of investment income."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r1442",
      "r1761"
     ]
    },
    "us-gaap_InvestmentIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of Net Investment Income",
        "label": "Investment Income [Table Text Block]",
        "documentation": "Tabular disclosure of investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r1762"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtandEquitySecuritiesPolicies",
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r1106",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1276",
      "r1278"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsAdditionalInformationonSeparateAccountAssetsPricedatNetAssetValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails",
      "http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails",
      "http://www.thecignagroup.com/role/VariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Type [Axis]",
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r1190",
      "r1192",
      "r1193",
      "r1196",
      "r1200",
      "r1256",
      "r1265",
      "r1281",
      "r1289",
      "r1302",
      "r1315",
      "r1316",
      "r1332",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1431"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsAdditionalInformationonSeparateAccountAssetsPricedatNetAssetValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails",
      "http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails",
      "http://www.thecignagroup.com/role/VariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments [Domain]",
        "label": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r1190",
      "r1192",
      "r1193",
      "r1196",
      "r1200",
      "r1256",
      "r1265",
      "r1281",
      "r1289",
      "r1302",
      "r1315",
      "r1316",
      "r1332",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1431"
     ]
    },
    "us-gaap_Investments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Investments",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails": {
       "parentTag": "ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total investments",
        "label": "Investments",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments."
       }
      }
     },
     "auth_ref": [
      "r1077"
     ]
    },
    "us-gaap_InvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments [Abstract]",
        "label": "Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsAndOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsAndOtherNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments and Other Noncurrent Assets",
        "label": "Investments and Other Noncurrent Assets",
        "documentation": "Amount of investments, and noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Investments including held for sale assets",
        "label": "Investments Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Investments Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities by Contractual Maturity",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "ci_InvestmentsCreditRatingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "InvestmentsCreditRatingAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments Credit Rating [Axis]",
        "label": "Investments Credit Rating [Axis]",
        "documentation": "Information by credit rating of debt and securities investments."
       }
      }
     },
     "auth_ref": []
    },
    "ci_InvestmentsCreditRatingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "InvestmentsCreditRatingDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments Credit Rating [Domain]",
        "label": "Investments Credit Rating [Domain]",
        "documentation": "External credit-ratings or internal groupings that could be used to describe the current status of the payment and performance risk of debt and securities investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/Investments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r305",
      "r315",
      "r352",
      "r559",
      "r561",
      "r942",
      "r943"
     ]
    },
    "us-gaap_JudicialRulingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "JudicialRulingMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Judicial Ruling",
        "label": "Judicial Ruling [Member]",
        "documentation": "Litigation outcome that occurs as a result of judicial intervention, supervision, or approval."
       }
      }
     },
     "auth_ref": [
      "r1635"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r980",
      "r1413"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of Lease Expense",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1733"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeFinanceLeasesTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Finance Leases [Text Block]",
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r970"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of Operating Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1734"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term length for operating leases",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1732"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r970"
     ]
    },
    "us-gaap_LetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LetterOfCreditMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtShorttermandCreditFacilitiesDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letter of Credit",
        "label": "Letter of Credit [Member]",
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiariesDetails",
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES",
        "terseLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r454",
      "r602",
      "r683",
      "r684",
      "r686",
      "r687",
      "r688",
      "r690",
      "r692",
      "r694",
      "r695",
      "r896",
      "r901",
      "r902",
      "r949",
      "r1210",
      "r1372",
      "r1444",
      "r1643",
      "r1740",
      "r1741"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities",
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r300",
      "r1090",
      "r1414",
      "r1576",
      "r1609",
      "r1728"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r399",
      "r454",
      "r602",
      "r683",
      "r684",
      "r686",
      "r687",
      "r688",
      "r690",
      "r692",
      "r694",
      "r695",
      "r896",
      "r901",
      "r902",
      "r949",
      "r1414",
      "r1643",
      "r1740",
      "r1741"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities, Fair Value Disclosure [Abstract]",
        "label": "Liabilities, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities of businesses held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities",
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r217",
      "r223",
      "r263",
      "r396",
      "r397"
     ]
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities of businesses held for sale",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r217",
      "r223",
      "r261",
      "r263",
      "r396",
      "r397"
     ]
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities of businesses held for sale, non-current",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent",
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r9",
      "r217",
      "r223",
      "r263",
      "r396",
      "r397"
     ]
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails": {
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_InsuranceAndContractholderLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Unpaid claims and claim expenses",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance (1)",
        "label": "Liability for Claims and Claims Adjustment Expense",
        "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r309"
     ]
    },
    "ci_LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpaid claims classified as liabilities of business held for sale",
        "label": "Liability For Claims And Claims Adjustment Expense Attributable To Disposal Groups",
        "documentation": "Liability For Claims And Claims Adjustment Expense Attributable To Disposal Groups"
       }
      }
     },
     "auth_ref": []
    },
    "ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpaid claims and claim expenses, current",
        "label": "Liability For Claims And Claims Adjustment Expense, Current",
        "documentation": "Liability For Claims And Claims Adjustment Expense, Current"
       }
      }
     },
     "auth_ref": []
    },
    "ci_LiabilityForClaimsAndClaimsAdjustmentExpenseCurrentIncludingDisposalGroups": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseCurrentIncludingDisposalGroups",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails_1": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpaid claims and claim expenses, current, including held for sale liabilities",
        "label": "Liability For Claims And Claims Adjustment Expense Current Including Disposal Groups",
        "documentation": "The amount (expected to be paid within one year) needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date."
       }
      }
     },
     "auth_ref": []
    },
    "ci_LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total of incurred but not reported liabilities plus expected claim development on reported claims, including reported claims in process",
        "label": "Liability For Claims And Claims Adjustment Expense Excluding Physician Incentives And Other Expenses",
        "documentation": "Represents the total liability for incurred but not reported claims plus expected claim development on reported claims, including reported claims in process. Excludes amounts due for physician incentives and other medical care expenses and services payable."
       }
      }
     },
     "auth_ref": []
    },
    "ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails": {
       "parentTag": "ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Unpaid claims and claim expenses, including held for sale liabilities",
        "periodStartLabel": "Beginning balance, including held for sale liabilities",
        "periodEndLabel": "Ending balance, including held for sale liabilities",
        "terseLabel": "Unpaid claims and claim expenses, including held for sale liabilities",
        "label": "Liability For Claims And Claims Adjustment Expense Including Disposal Groups",
        "documentation": "Liability For Claims And Claims Adjustment Expense Including Disposal Groups"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability for Claims and Claims Adjustment Expense [Line Items]",
        "label": "Liability for Claims and Claims Adjustment Expense [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpaid claims and claim expenses, non-current",
        "label": "Liability For Claims And Claims Adjustment Expense, Noncurrent",
        "documentation": "Liability For Claims And Claims Adjustment Expense, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "ci_LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrentIncludingDisposalGroups": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrentIncludingDisposalGroups",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpaid claims and claim expenses, non-current, including held for sale liabilities",
        "label": "Liability For Claims And Claims Adjustment Expense Noncurrent Including Disposal Groups",
        "documentation": "The amount (expected to be paid after one year) needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseTable",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability for Claims and Claims Adjustment Expense [Table]",
        "label": "Liability for Claims and Claims Adjustment Expense [Table]",
        "documentation": "Disclosure of information about the liability for claims and claims adjustment expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForFuturePolicyBenefitActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForFuturePolicyBenefitActivityTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future Policy Benefit Activity",
        "label": "Liability for Future Policy Benefit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of beginning balance to ending balance for liability for future policy benefit, with separate presentation of expected future net premium and expected future benefit."
       }
      }
     },
     "auth_ref": [
      "r1132",
      "r1153",
      "r1422"
     ]
    },
    "ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails": {
       "parentTag": "us-gaap_LiabilityForFuturePolicyBenefits",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Liability for future policy benefits",
        "label": "Liability For Future Policy Benefit, Before Reinsurance And Other",
        "documentation": "Liability For Future Policy Benefit, Before Reinsurance And Other"
       }
      }
     },
     "auth_ref": []
    },
    "ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LiabilityForFuturePolicyBenefitBeforeReinsuranceBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liability for future policy benefits, including assets held for sale",
        "label": "Liability for Future Policy Benefit, before Reinsurance, Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Liability for Future Policy Benefit, before Reinsurance, Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future policy benefits, current",
        "label": "Liability For Future Policy Benefit, Before Reinsurance, Current",
        "documentation": "Liability For Future Policy Benefit, Before Reinsurance, Current"
       }
      }
     },
     "auth_ref": []
    },
    "ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future policy benefits, non-current",
        "label": "Liability For Future Policy Benefit, Before Reinsurance, Noncurrent",
        "documentation": "Liability For Future Policy Benefit, Before Reinsurance, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsInterestRatesandDurationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current discount rate",
        "label": "Liability for Future Policy Benefit, Current Weighted-Average Discount Rate",
        "documentation": "Current weighted-average discount rate used to measure liability for future policy benefit."
       }
      }
     },
     "auth_ref": [
      "r1136",
      "r1422"
     ]
    },
    "ci_LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future policy benefit, excluding DPL",
        "label": "Liability For Future Policy Benefit, Excluding Deferred Profit Liability",
        "documentation": "Liability For Future Policy Benefit, Excluding Deferred Profit Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumDiscountedBeforeReinsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumDiscountedBeforeReinsurance",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discounted expected future gross premiums",
        "label": "Liability for Future Policy Benefit, Expected Future Gross Premium, Discounted, before Reinsurance",
        "documentation": "Amount, before effect of reinsurance, of discounted balance for expected future gross premium component of liability for future policy benefit."
       }
      }
     },
     "auth_ref": [
      "r1133"
     ]
    },
    "us-gaap_LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumUndiscountedBeforeReinsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumUndiscountedBeforeReinsurance",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Undiscounted expected future gross premiums",
        "label": "Liability for Future Policy Benefit, Expected Future Gross Premium, Undiscounted, before Reinsurance",
        "documentation": "Amount, before effect of reinsurance, of undiscounted balance for expected future gross premium component of liability for future policy benefit."
       }
      }
     },
     "auth_ref": [
      "r1133",
      "r1422"
     ]
    },
    "us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails": {
       "parentTag": "us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "verboseLabel": "Ending balance",
        "label": "Liability for Future Policy Benefit, Expected Future Policy Benefit, before Reinsurance, after Discount Rate Change",
        "documentation": "Amount, before effect of reinsurance and after current period update of cash flow assumption and discount rate change, of expected future policy benefit and expense component of liability for future policy benefit."
       }
      }
     },
     "auth_ref": [
      "r1132",
      "r1133",
      "r1153",
      "r1422"
     ]
    },
    "ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of assumption changes and actual variances from expected experience (1)",
        "label": "Liability For Future Policy Benefit, Expected Future Policy Benefit, Cumulative Increase (Decrease) From Cash Flow Change And Actual Variance From Expected Experience",
        "documentation": "Liability For Future Policy Benefit, Expected Future Policy Benefit, Cumulative Increase (Decrease) From Cash Flow Change And Actual Variance From Expected Experience"
       }
      }
     },
     "auth_ref": []
    },
    "ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitInterestExpenseAndOtherChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitInterestExpenseAndOtherChanges",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest and other",
        "label": "Liability For Future Policy Benefit, Expected Future Policy Benefit, Interest Expense And Other Changes",
        "documentation": "Liability For Future Policy Benefit, Expected Future Policy Benefit, Interest Expense And Other Changes"
       }
      }
     },
     "auth_ref": []
    },
    "ci_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitIssuanceAndDerecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitIssuanceAndDerecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuances and lapses",
        "label": "Liability For Future Policy Benefit, Expected Future Policy Benefit, Issuance And Derecognition",
        "documentation": "Liability For Future Policy Benefit, Expected Future Policy Benefit, Issuance And Derecognition"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Ending balance at original discount rate",
        "label": "Liability for Future Policy Benefit, Expected Future Policy Benefit, Original Discount Rate, before Cash Flow and Reinsurance",
        "documentation": "Amount, before effect of reinsurance and current period update of cash flow assumption, of expected future policy benefit and expense component of liability for future policy benefit, discounted at original rate."
       }
      }
     },
     "auth_ref": [
      "r1422",
      "r1769",
      "r1774"
     ]
    },
    "us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitRollForward",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]",
        "label": "Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Undiscounted expected future policy benefits",
        "label": "Liability for Future Policy Benefit, Expected Future Policy Benefit, Undiscounted, before Reinsurance",
        "documentation": "Amount, before effect of reinsurance, of undiscounted balance for expected future policy benefit and expense component of liability for future policy benefit."
       }
      }
     },
     "auth_ref": [
      "r1133",
      "r1422"
     ]
    },
    "us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails": {
       "parentTag": "ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Ending balance",
        "label": "Liability for Future Policy Benefit, Expected Net Premium, before Reinsurance, after Discount Rate Change",
        "documentation": "Amount, before effect of reinsurance and after current period update of cash flow assumption and discount rate change, of expected net premium component of liability for future policy benefit."
       }
      }
     },
     "auth_ref": [
      "r1132",
      "r1133",
      "r1153",
      "r1422"
     ]
    },
    "ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of assumption changes and actual variances from expected experience (1)",
        "label": "Liability For Future Policy Benefit, Expected Net Premium, Cumulative Increase (Decrease) From Cash Flow Change And Actual Variance From Expected Experience",
        "documentation": "Liability For Future Policy Benefit, Expected Net Premium, Cumulative Increase (Decrease) From Cash Flow Change And Actual Variance From Expected Experience"
       }
      }
     },
     "auth_ref": []
    },
    "ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumInterestIncomeAndOtherChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LiabilityForFuturePolicyBenefitExpectedNetPremiumInterestIncomeAndOtherChanges",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest and other",
        "label": "Liability For Future Policy Benefit, Expected Net Premium, Interest Income And Other Changes",
        "documentation": "Liability For Future Policy Benefit, Expected Net Premium, Interest Income And Other Changes"
       }
      }
     },
     "auth_ref": []
    },
    "ci_LiabilityForFuturePolicyBenefitExpectedNetPremiumIssuanceAndDerecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LiabilityForFuturePolicyBenefitExpectedNetPremiumIssuanceAndDerecognition",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuances and lapses",
        "label": "Liability For Future Policy Benefit, Expected Net Premium, Issuance And Derecognition",
        "documentation": "Liability For Future Policy Benefit, Expected Net Premium, Issuance And Derecognition"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumNetPremiumCollected": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForFuturePolicyBenefitExpectedNetPremiumNetPremiumCollected",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net premiums collected",
        "label": "Liability for Future Policy Benefit, Expected Net Premium, Net Premium Collected",
        "documentation": "Amount of premium collected from policyholder to fund expected benefit payment for expected net premium component of liability for future policy benefit."
       }
      }
     },
     "auth_ref": [
      "r1416",
      "r1422",
      "r1769",
      "r1774"
     ]
    },
    "us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Ending balance at original discount rate",
        "label": "Liability for Future Policy Benefit, Expected Net Premium, Original Discount Rate, before Cash Flow and Reinsurance",
        "documentation": "Amount, before effect of reinsurance and current period update of cash flow assumption, of expected net premium component of liability for future policy benefit, discounted at original rate."
       }
      }
     },
     "auth_ref": [
      "r1422",
      "r1769",
      "r1774"
     ]
    },
    "us-gaap_LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForFuturePolicyBenefitExpectedNetPremiumRollForward",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability for Future Policy Benefit, Expected Net Premium [Roll Forward]",
        "label": "Liability for Future Policy Benefit, Expected Net Premium [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ci_LiabilityForFuturePolicyBenefitOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LiabilityForFuturePolicyBenefitOther",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails": {
       "parentTag": "ci_LiabilityForFuturePolicyBenefitBeforeReinsuranceBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Liability For Future Policy Benefit, Other",
        "documentation": "Liability For Future Policy Benefit, Other"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future policy benefits reserve, reinsurance recoverables",
        "label": "Liability for Future Policy Benefit, Reinsurance Recoverable, after Allowance",
        "documentation": "Amount, after allowance for credit loss, recoverable under reinsurance of liability for future policy benefit."
       }
      }
     },
     "auth_ref": [
      "r1132",
      "r1134",
      "r1153",
      "r1422"
     ]
    },
    "us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForFuturePolicyBenefitWeightedAverageDuration",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsInterestRatesandDurationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average duration",
        "label": "Liability for Future Policy Benefit, Weighted-Average Duration",
        "documentation": "Weighted-average duration of liability for future policy benefit, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1135"
     ]
    },
    "us-gaap_LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsInterestRatesandDurationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest accretion rate",
        "label": "Liability for Future Policy Benefit, Weighted-Average Interest Accretion Rate",
        "documentation": "Original weighted-average discount rate at contract issue date used to measure liability for future policy benefit."
       }
      }
     },
     "auth_ref": [
      "r1136",
      "r1422"
     ]
    },
    "us-gaap_LiabilityForFuturePolicyBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForFuturePolicyBenefits",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_InsuranceAndContractholderLiabilities",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liability for future policy benefits",
        "label": "Liability for Future Policy Benefit, before Reinsurance",
        "documentation": "Amount, before effect of reinsurance, of present value of future benefit to be paid to or on behalf of policyholder and related expense less present value of future net premium receivable under insurance contract."
       }
      }
     },
     "auth_ref": [
      "r1132",
      "r1137",
      "r1153",
      "r1422",
      "r1752"
     ]
    },
    "us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance and Contractholder Liabilities",
        "label": "Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]",
        "documentation": "The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments."
       }
      }
     },
     "auth_ref": [
      "r1125"
     ]
    },
    "ci_LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future policy benefits classified as liabilities of business held for sale",
        "label": "Liability For Future Policy Benefits Attributable To Disposal Groups",
        "documentation": "Liability For Future Policy Benefits Attributable To Disposal Groups"
       }
      }
     },
     "auth_ref": []
    },
    "ci_LiabilityForFuturePolicyBenefitsCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LiabilityForFuturePolicyBenefitsCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of actual variances from expectations",
        "label": "Liability For Future Policy Benefits Cumulative Increase Decrease Of Actual Variance From Expected Experience",
        "documentation": "Liability For Future Policy Benefits Cumulative Increase Decrease Of Actual Variance From Expected Experience"
       }
      }
     },
     "auth_ref": []
    },
    "ci_LiabilityForFuturePolicyBenefitsCurrentIncludingDisposalGroups": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LiabilityForFuturePolicyBenefitsCurrentIncludingDisposalGroups",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_LiabilityForFuturePolicyBenefitsIncludingDisposalGroups",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails_1": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future policy benefits, current, including held for sale liabilities",
        "label": "Liability For Future Policy Benefits Current Including Disposal Groups",
        "documentation": "Amount of accrued obligation to policyholders that relates to insured events for long-duration contracts, expected to be paid within one year."
       }
      }
     },
     "auth_ref": []
    },
    "ci_LiabilityForFuturePolicyBenefitsDeferredProfitLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LiabilityForFuturePolicyBenefitsDeferredProfitLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future policy benefits, DPL",
        "label": "Liability For Future Policy Benefits, Deferred Profit Liability",
        "documentation": "Liability For Future Policy Benefits, Deferred Profit Liability"
       }
      }
     },
     "auth_ref": []
    },
    "ci_LiabilityForFuturePolicyBenefitsIncludingDisposalGroups": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LiabilityForFuturePolicyBenefitsIncludingDisposalGroups",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Future policy benefits, including held for sale liabilities",
        "label": "Liability For Future Policy Benefits Including Disposal Groups",
        "documentation": "Liability For Future Policy Benefits Including Disposal Groups"
       }
      }
     },
     "auth_ref": []
    },
    "ci_LiabilityForFuturePolicyBenefitsNoncurrentIncludingDisposalGroups": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LiabilityForFuturePolicyBenefitsNoncurrentIncludingDisposalGroups",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future policy benefits, non-current, including held for sale liabilities",
        "label": "Liability For Future Policy Benefits Noncurrent Including Disposal Groups",
        "documentation": "Amount of accrued obligation to policyholders that relates to insured events for long-duration contracts, expected to be paid after one year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForFuturePolicyBenefitsPaymentForBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Benefit payments",
        "label": "Liability for Future Policy Benefit, Expected Future Policy Benefit, Benefit Payment",
        "documentation": "Amount of cash outflow to policyholder from benefit payment for expected future policy benefit and expense component of liability for future policy benefit."
       }
      }
     },
     "auth_ref": [
      "r1417",
      "r1422",
      "r1573",
      "r1769",
      "r1774"
     ]
    },
    "ci_LiabilityForFuturePolicyBenefitsPercentSupportedByAssetsHeldInTrust": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LiabilityForFuturePolicyBenefitsPercentSupportedByAssetsHeldInTrust",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percent of the liability for future policy benefits supported by assets held in trust",
        "label": "Liability For Future Policy Benefits, Percent Supported By Assets Held In Trust",
        "documentation": "Liability For Future Policy Benefits, Percent Supported By Assets Held In Trust"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paid costs related to:",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails": {
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current year",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year",
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails": {
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior years",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years",
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total incurred",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims",
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incurred costs related to:",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseLongDurationNetBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseLongDurationNetBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails": {
       "parentTag": "ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-duration liabilities not included in development table above, including assets held for sale",
        "label": "Liability For Unpaid Claims And Claims Adjustment Expense Long Duration Net, Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Liability For Unpaid Claims And Claims Adjustment Expense Long Duration Net, Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, net",
        "periodEndLabel": "Ending balance, net",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Net",
        "documentation": "Liability as of the balance sheet date for amounts representing estimated cost of settling unpaid claims under the terms of the underlying insurance policies, less estimated reinsurance recoveries on such claims. This includes an estimate for claims which have been incurred but not reported. Claim adjustment expenses represent the costs estimated to be incurred in the settlement of unpaid claims."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r309",
      "r1752"
     ]
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, net, including held for sale liabilities",
        "periodEndLabel": "Ending balance, net, including held for sale liabilities",
        "totalLabel": "Net unpaid claims and claims expenses - Cigna Healthcare",
        "label": "Liability For Unpaid Claims And Claims Adjustment Expense Net Including Disposal Groups",
        "documentation": "Liability For Unpaid Claims And Claims Adjustment Expense Net Including Disposal Groups"
       }
      }
     },
     "auth_ref": []
    },
    "ci_LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Favorable (unfavorable) variance, percentage",
        "label": "Liability For Unpaid Medical Claims And Claims Adjustment Expense Incurred Claims Prior Years Percentage",
        "documentation": "Amount of payments made in the reporting period to settle claims incurred in prior periods and related claims settlement costs as a percentage of incurred claims as reported in the prior year."
       }
      }
     },
     "auth_ref": []
    },
    "ci_LibertyMutualInsuranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LibertyMutualInsuranceMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Liberty Re (Bermuda) Ltd.",
        "label": "Liberty Mutual Insurance [Member]",
        "documentation": "Liberty Mutual Insurance"
       }
      }
     },
     "auth_ref": []
    },
    "ci_LifeInsuranceCompanyOfNorthAmericaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LifeInsuranceCompanyOfNorthAmericaMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Life Insurance Company of North America",
        "label": "Life Insurance Company Of North America [Member]",
        "documentation": "Life Insurance Company Of North America"
       }
      }
     },
     "auth_ref": []
    },
    "ci_LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lincoln National Life and Lincoln Life &amp; Annuity of New York",
        "label": "The Lincoln National Life Insurance Company And Lincoln Life And Annuity Of New York [Member]",
        "documentation": "Reinsurance recoverables resulting from the 1998 sale of the Companys individual life insurance and annuity business."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtShorttermandCreditFacilitiesDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding balances",
        "label": "Long-Term Line of Credit",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r298",
      "r1754"
     ]
    },
    "ci_LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtShorttermandCreditFacilitiesDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate amount of options to increase commitments",
        "label": "Line Of Credit Facility, Accordion Feature, Incremental Increase In Maximum Borrowing Capacity",
        "documentation": "Line Of Credit Facility, Accordion Feature, Incremental Increase In Maximum Borrowing Capacity"
       }
      }
     },
     "auth_ref": []
    },
    "ci_LineOfCreditFacilityConversionToTermLoanTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LineOfCreditFacilityConversionToTermLoanTerm",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtShorttermandCreditFacilitiesDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit facility, conversion to term loan, term",
        "label": "Line Of Credit Facility, Conversion To Term Loan, Term",
        "documentation": "Line Of Credit Facility, Conversion To Term Loan, Term"
       }
      }
     },
     "auth_ref": []
    },
    "ci_LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtShorttermandCreditFacilitiesDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leverage ratio covenant",
        "label": "Line Of Credit Facility Debt To Adjusted Capital Ratio Covenant",
        "documentation": "The debt-to adjusted capital ratio which the Company must not exceed in accordance with the terms of the line of credit facility agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility [Line Items]",
        "label": "Line of Credit Facility [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1575"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtShorttermandCreditFacilitiesDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum borrowing capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "ci_LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtShorttermandCreditFacilitiesDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum total commitment",
        "label": "Line Of Credit Facility, Maximum Borrowing Capacity And Accordion Feature, Incremental Increase In Maximum Borrowing Capacity",
        "documentation": "Line Of Credit Facility, Maximum Borrowing Capacity And Accordion Feature, Incremental Increase In Maximum Borrowing Capacity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityTable",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility [Table]",
        "label": "Line of Credit Facility [Table]",
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r1575"
     ]
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Axis]",
        "label": "Litigation Case [Axis]",
        "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Domain]",
        "label": "Litigation Case [Domain]",
        "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information."
       }
      }
     },
     "auth_ref": []
    },
    "ci_LitigationMattersAndRegulatoryMattersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LitigationMattersAndRegulatoryMattersMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Matters and Regulatory Matters",
        "label": "Litigation Matters And Regulatory Matters [Member]",
        "documentation": "Litigation Matters And Regulatory Matters"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settled value plus interest and attorneys fees",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "documentation": "Amount awarded to other party in judgment or settlement of litigation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationStatusAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Status [Axis]",
        "label": "Litigation Status [Axis]",
        "documentation": "Information by status of pending, threatened, or settled litigation."
       }
      }
     },
     "auth_ref": [
      "r1635"
     ]
    },
    "us-gaap_LitigationStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationStatusDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Status [Domain]",
        "label": "Litigation Status [Domain]",
        "documentation": "Status of pending, threatened, or settled litigation."
       }
      }
     },
     "auth_ref": [
      "r1635"
     ]
    },
    "us-gaap_LoanToValueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoanToValueAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoanPortfolioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt-to-Value [Axis]",
        "label": "Debt-to-Value [Axis]",
        "documentation": "Information by debt-to-value ratio, for example, but not limited to, 80 percent to 100 percent. Element name and standard label in Debt-to-Value [numeric lower end] to [numeric higher end] Percent [Member] or Debt-to-Value Greater Than [low end numeric value] Percent [Member] or Debt-to-Value Less Than [high end numeric value] Percent [Member] formats."
       }
      }
     },
     "auth_ref": [
      "r1382"
     ]
    },
    "us-gaap_LoanToValueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoanToValueDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoanPortfolioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt-to-Value [Domain]",
        "label": "Debt-to-Value [Domain]",
        "documentation": "Debt-to-value (DTV) ratio, for example, but not limited to, 80 percent to 100 percent. Element name and standard label in DTV [numeric lower end] to [numeric higher end] Percent [Member] or DTV Greater Than [low end numeric value] Percent [Member] or DTV Less Than [high end numeric value] Percent [Member] formats."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable, Net",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses."
       }
      }
     },
     "auth_ref": [
      "r1594"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "ci_LongDurationContractsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LongDurationContractsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceEffectsofReinsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-duration contracts",
        "label": "Long Duration Contracts [Member]",
        "documentation": "Insurance contracts, primarily Life and Disability contracts, that are expected to remain in force for an extended period of time, generally one year or longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets",
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt",
        "totalLabel": "Total long-term debt",
        "label": "Long-Term Debt and Lease Obligation",
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r1082"
     ]
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtAndCapitalLeaseObligationsAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt",
        "label": "Long-Term Debt and Lease Obligation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtByMaturityAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt",
        "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails": {
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current maturities",
        "label": "Long-Term Debt, Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_LongTermDebtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt, including current maturities, excluding finance leases",
        "label": "Long-Term Debt, Fair Value",
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission."
       }
      }
     },
     "auth_ref": []
    },
    "ci_LongTermDebtFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LongTermDebtFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt, including current maturities, excluding finance leases, including assets held for sale",
        "label": "Long-Term Debt, Fair Value, Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Long-Term Debt, Fair Value, Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtDebtMaturitiesDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities after 2028",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r461",
      "r1648"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtDebtMaturitiesDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r461",
      "r714"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtDebtMaturitiesDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Long-Term Debt, Maturity, Year Five",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r461",
      "r714"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtDebtMaturitiesDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Long-Term Debt, Maturity, Year Four",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r461",
      "r714"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtDebtMaturitiesDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r461",
      "r714"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtDebtMaturitiesDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r461",
      "r714"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails": {
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_LongTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails": {
       "parentTag": "us-gaap_Investments",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Long-term investments",
        "terseLabel": "Investments per Consolidated Balance Sheets",
        "label": "Long-Term Investments",
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_LongTermInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermInvestmentsAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term",
        "label": "Long-Term Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails_1": {
       "parentTag": "ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Investments including held for sale assets",
        "label": "Long Term Investments Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Long Term Investments Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtLongtermDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtLongtermDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r123"
     ]
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails",
      "http://www.thecignagroup.com/role/SegmentInformationFinancialandPerformanceGuaranteesDetails",
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingency Nature [Axis]",
        "label": "Loss Contingency Nature [Axis]",
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r673",
      "r674",
      "r678",
      "r1636",
      "r1637"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationFinancialandPerformanceGuaranteesDetails",
      "http://www.thecignagroup.com/role/SegmentInformationUSandForeignRevenuesfromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Line Items]",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r673",
      "r674",
      "r678",
      "r1636",
      "r1637"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationFinancialandPerformanceGuaranteesDetails",
      "http://www.thecignagroup.com/role/SegmentInformationUSandForeignRevenuesfromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r673",
      "r674",
      "r678",
      "r1636",
      "r1637"
     ]
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyAccrualAtCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails",
      "http://www.thecignagroup.com/role/SegmentInformationFinancialandPerformanceGuaranteesDetails",
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance guarantee liability",
        "verboseLabel": "Reserves for litigation matters, pre-tax",
        "netLabel": "Guarantee liability",
        "label": "Loss Contingency Accrual",
        "documentation": "Amount of loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r1527"
     ]
    },
    "us-gaap_LossContingencyAccrualPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyAccrualPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts paid for loss contigency",
        "label": "Loss Contingency Accrual, Payments",
        "documentation": "Amount of cash outflow reducing loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r1635"
     ]
    },
    "us-gaap_LossContingencyAccrualProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyAccrualProvision",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails",
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss contingency accrual provision",
        "label": "Loss Contingency Accrual, Provision",
        "documentation": "Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges."
       }
      }
     },
     "auth_ref": [
      "r1635"
     ]
    },
    "us-gaap_LossContingencyClaimsDismissedNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyClaimsDismissedNumber",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of counts dismissed",
        "label": "Loss Contingency, Claims Dismissed, Number",
        "documentation": "Number of claims dismissed."
       }
      }
     },
     "auth_ref": [
      "r1636",
      "r1637"
     ]
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyDamagesSoughtValue",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Damages sought by Elevance",
        "label": "Loss Contingency, Damages Sought, Value",
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r1635",
      "r1636",
      "r1637"
     ]
    },
    "us-gaap_LossContingencyNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyNatureDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails",
      "http://www.thecignagroup.com/role/SegmentInformationFinancialandPerformanceGuaranteesDetails",
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingency, Nature [Domain]",
        "label": "Loss Contingency, Nature [Domain]",
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r673",
      "r674",
      "r678",
      "r1636",
      "r1637"
     ]
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyPendingClaimsNumber",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of counts",
        "label": "Loss Contingency, Pending Claims, Number",
        "documentation": "Number of pending claims pertaining to a loss contingency."
       }
      }
     },
     "auth_ref": [
      "r1636",
      "r1637"
     ]
    },
    "ci_LossOfParentCompany": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LossOfParentCompany",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss of Parent Company",
        "label": "Income before equity in earnings of subsidiaries"
       }
      }
     },
     "auth_ref": []
    },
    "ci_Ltv60To79PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "Ltv60To79PercentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoanPortfolioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "60% to 79%",
        "label": "LTV 60 to 79 Percent [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Ltv80To100PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Ltv80To100PercentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoanPortfolioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "80% to 100%",
        "label": "Debt-to-Value Ratio, 80 to 100 Percent [Member]",
        "documentation": "Debt-to-value (DTV) ratio from 80 percent to 100 percent. Element name and standard label in DTV [numeric lower end] to [numeric higher end] Percent [Member] format."
       }
      }
     },
     "auth_ref": []
    },
    "ci_LtvGreaterThan100PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LtvGreaterThan100PercentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoanPortfolioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Greater than 100%",
        "label": "Ltv Greater Than 100 Percent [Member]",
        "documentation": "Debt-to-value ratio greater than 100 percent. Element name an standard label in DTV [numeric lower end] to [numeric higher end] Percent [Member] format."
       }
      }
     },
     "auth_ref": []
    },
    "ci_LtvLessThan60PercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "LtvLessThan60PercentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoanPortfolioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Below 60%",
        "label": "LTV Less Than 60 Percent [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuesfromUSFederalGovernmentAgenciesDetails",
      "http://www.thecignagroup.com/role/SegmentInformationUSandForeignRevenuesfromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r547",
      "r1396",
      "r1649",
      "r1764",
      "r1773"
     ]
    },
    "us-gaap_MarketRiskBenefitActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketRiskBenefitActivityTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesTables",
      "http://www.thecignagroup.com/role/ReinsuranceTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Market Risk Benefit",
        "verboseLabel": "Reinsurance Recoverables for Variable Annuity Business",
        "label": "Market Risk Benefit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of beginning balance to ending balance for contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk."
       }
      }
     },
     "auth_ref": [
      "r1145",
      "r1424"
     ]
    },
    "us-gaap_MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesSummaryofMarketRiskBenefitDetails": {
       "parentTag": "us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesSummaryofMarketRiskBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, beginning of year",
        "periodEndLabel": "Balance, end of period",
        "label": "Market Risk Benefit, after Increase (Decrease) from Instrument-Specific Credit Risk",
        "documentation": "Amount, before effect of reinsurance and after accumulated increase (decrease) in instrument-specific credit risk, of contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk."
       }
      }
     },
     "auth_ref": [
      "r1126",
      "r1145",
      "r1158",
      "r1424"
     ]
    },
    "us-gaap_MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesSummaryofMarketRiskBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesSummaryofMarketRiskBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, beginning of year, before the effect of nonperformance risk (own credit risk)",
        "periodEndLabel": "Balance, end of period, before the effect of changes in nonperformance risk (own credit risk)",
        "label": "Market Risk Benefit, before Reinsurance and Cumulative Increase (Decrease) from Instrument-Specific Credit Risk Change",
        "documentation": "Amount, before effect of reinsurance and cumulative increase (decrease) in instrument-specific credit risk, of contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk."
       }
      }
     },
     "auth_ref": [
      "r1145",
      "r1158",
      "r1424"
     ]
    },
    "ci_MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesSummaryofMarketRiskBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes due to expected run-off",
        "label": "Market Risk Benefit, Increase (Decrease) Due to Expected Run-Off",
        "documentation": "Market Risk Benefit, Increase (Decrease) Due to Expected Run-Off"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesSummaryofMarketRiskBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes due to policyholder behavior versus expected",
        "label": "Market Risk Benefit, Increase (Decrease) from Actual Policyholder Behavior Different from Expected",
        "documentation": "Amount of increase (decrease) in contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk from change associated with actual policyholder behavior different from expected."
       }
      }
     },
     "auth_ref": [
      "r1419",
      "r1424",
      "r1771",
      "r1775"
     ]
    },
    "ci_MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesSummaryofMarketRiskBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes due to capital markets versus expected",
        "label": "Market Risk Benefit, Increase (Decrease) From Interest Rate Change And Equity Market Change",
        "documentation": "Market Risk Benefit, Increase (Decrease) From Interest Rate Change And Equity Market Change"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketRiskBenefitIncreaseDecreaseFromOtherAssumption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketRiskBenefitIncreaseDecreaseFromOtherAssumption",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesSummaryofMarketRiskBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assumption changes",
        "label": "Market Risk Benefit, Increase (Decrease) from Other Assumption",
        "documentation": "Amount of increase (decrease) in contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk from change in assumption, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1420",
      "r1424",
      "r1771",
      "r1775"
     ]
    },
    "us-gaap_MarketRiskBenefitLiabilityAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketRiskBenefitLiabilityAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Market risk benefits",
        "label": "Market Risk Benefit, Liability, Amount",
        "documentation": "Amount of liability position for contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk."
       }
      }
     },
     "auth_ref": [
      "r1146",
      "r1424"
     ]
    },
    "ci_MarketRiskBenefitLiabilityAmountCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "MarketRiskBenefitLiabilityAmountCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "us-gaap_MarketRiskBenefitLiabilityAmount",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails_1": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market risk benefits, current",
        "label": "Market Risk Benefit, Liability, Amount, Current",
        "documentation": "Market Risk Benefit, Liability, Amount, Current"
       }
      }
     },
     "auth_ref": []
    },
    "ci_MarketRiskBenefitLiabilityAmountNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "MarketRiskBenefitLiabilityAmountNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market risk benefits, non-current",
        "label": "Market Risk Benefit, Liability, Amount, Noncurrent",
        "documentation": "Market Risk Benefit, Liability, Amount, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketRiskBenefitPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketRiskBenefitPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market Risk Benefits",
        "label": "Market Risk Benefit [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk. Includes, but is not limited to, input, judgment, assumption and method used in measuring market risk benefit, and change in input, judgment, and assumption."
       }
      }
     },
     "auth_ref": [
      "r1147"
     ]
    },
    "us-gaap_MarketRiskBenefitReinsuranceRecoverableAfterAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketRiskBenefitReinsuranceRecoverableAfterAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails": {
       "parentTag": "ci_ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesSummaryofMarketRiskBenefitDetails",
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Reinsured market risk benefit, end of period",
        "terseLabel": "Market risk benefits",
        "label": "Market Risk Benefit, Reinsurance Recoverable, after Allowance",
        "documentation": "Amount, after allowance for credit loss, recoverable under reinsurance for contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk."
       }
      }
     },
     "auth_ref": [
      "r1424",
      "r1772"
     ]
    },
    "ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market risk benefits reinsurance recoverable, including IBNR and outstanding claims, less premiums due",
        "label": "Market Risk Benefit Reinsurance Recoverable After Allowance And Related Balances",
        "documentation": "Includes incurred but not reported claims and outstanding claims,off-set by premiums due, related to market risk benefit contracts, as a well as reinsurance recoverable, defined as amount, after allowance for credit loss, recoverable under reinsurance for contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk."
       }
      }
     },
     "auth_ref": []
    },
    "ci_MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market risk benefits reinsurance recoverable, including IBNR and outstanding claims, less premiums due",
        "label": "Market Risk Benefit Reinsurance Recoverable After Allowance And Related Balances [Member]",
        "documentation": "Market risk benefit reinsurance recoverable, including IBNR and outstanding claims, less premiums due."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketRiskBenefitRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketRiskBenefitRollForward",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesSummaryofMarketRiskBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market Risk Benefit [Roll Forward]",
        "label": "Market Risk Benefit [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Marketable Securities",
        "documentation": "Amount of investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r1566"
     ]
    },
    "ci_MarketableSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "MarketableSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, including held for sale assets",
        "label": "Marketable Securities Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Marketable Securities Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansNarrativeDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsAdditionalInformationonSeparateAccountAssetsPricedatNetAssetValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails",
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentNarrativeDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails",
      "http://www.thecignagroup.com/role/LeasesNarrativeDetails",
      "http://www.thecignagroup.com/role/VariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r673",
      "r674",
      "r675",
      "r676",
      "r806",
      "r1033",
      "r1144",
      "r1201",
      "r1202",
      "r1259",
      "r1280",
      "r1285",
      "r1286",
      "r1326",
      "r1356",
      "r1357",
      "r1375",
      "r1393",
      "r1407",
      "r1423",
      "r1647",
      "r1742",
      "r1743",
      "r1744",
      "r1745",
      "r1746",
      "r1747"
     ]
    },
    "ci_MaximumPercentLevel2InvestmentsForeignBondsBrokerQuoteBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "MaximumPercentLevel2InvestmentsForeignBondsBrokerQuoteBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum percentage of investments classified in Level 2 representing foreign bonds priced using unadjusted broker quotes",
        "label": "Maximum Percent Level2 Investments Foreign Bonds Broker Quote Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Maximum Percent Level2 Investments Foreign Bonds Broker Quote Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1490"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1490"
     ]
    },
    "ci_MeasurementInputLiquidityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "MeasurementInputLiquidityMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidity",
        "label": "Measurement Input, Liquidity [Member]",
        "documentation": "Measurement Input, Liquidity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "ci_MedicalCostTrendMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "MedicalCostTrendMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medical cost trend",
        "label": "Medical Cost Trend [Member]",
        "documentation": "Amounts relating to actual claims emerging differently from assumptions about the level of claims per member used to set reserves."
       }
      }
     },
     "auth_ref": []
    },
    "ci_MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails",
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails",
      "http://www.thecignagroup.com/role/DescriptionofBusinessDetails",
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails",
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails",
      "http://www.thecignagroup.com/role/IncomeTaxesDeferredIncomeTaxesDetails",
      "http://www.thecignagroup.com/role/IncomeTaxesForeignJurisdictionTaxAttributesandSaleofMedicareAdvantageandRelatedBusinessesDetails",
      "http://www.thecignagroup.com/role/IncomeTaxesNominalTaxRateReconciliationDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails",
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicare Advantage and related Cigna Healthcare businesses",
        "label": "Medicare Advantage And Related Cigna Healthcare Businesses [Member]",
        "documentation": "Medicare Advantage And Related Cigna Healthcare Businesses"
       }
      }
     },
     "auth_ref": []
    },
    "ci_MedicareAdvantageLitigationDepartmentOfJusticeInvestigationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "MedicareAdvantageLitigationDepartmentOfJusticeInvestigationsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicare Advantage, DOJ Investigations",
        "label": "Medicare Advantage Litigation Department Of Justice Investigations [Member]",
        "documentation": "Litigation related to the industry-wide investigations by the Department of Justice into the risk adjustment practices of Medicare Advantage organizations."
       }
      }
     },
     "auth_ref": []
    },
    "ci_MedicareAdvantageLitigationPrivateIndividualMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "MedicareAdvantageLitigationPrivateIndividualMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicare Advantage, Private Individual",
        "label": "Medicare Advantage Litigation Private Individual [Member]",
        "documentation": "A qui tam action filed by a private individual on behalf of the government relating to risk adjustment practices within the Medicare Advantage business."
       }
      }
     },
     "auth_ref": []
    },
    "ci_MedicareAdvantageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "MedicareAdvantageMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicare Advantage",
        "label": "Medicare Advantage [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/MergersAcquisitionsandDivestitures"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mergers, Acquisitions and Divestitures",
        "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]",
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r284"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansNarrativeDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsAdditionalInformationonSeparateAccountAssetsPricedatNetAssetValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails",
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentNarrativeDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r673",
      "r674",
      "r675",
      "r676",
      "r806",
      "r1033",
      "r1144",
      "r1201",
      "r1202",
      "r1259",
      "r1280",
      "r1285",
      "r1286",
      "r1326",
      "r1356",
      "r1357",
      "r1375",
      "r1393",
      "r1407",
      "r1423",
      "r1647",
      "r1742",
      "r1743",
      "r1744",
      "r1745",
      "r1746",
      "r1747"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other noncontrolling interests",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r299",
      "r454",
      "r602",
      "r683",
      "r686",
      "r687",
      "r688",
      "r694",
      "r695",
      "r949",
      "r1089",
      "r1214"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1510"
     ]
    },
    "us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MortgageLoansOnRealEstateCommercialAndConsumerNet",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial mortgage loans",
        "label": "Mortgage Loans on Real Estate, Commercial and Consumer, Net",
        "documentation": "The balance represents the amount of loans that are secured by real estate mortgages, offset by the reserve to cover probable credit losses on the loan portfolio."
       }
      }
     },
     "auth_ref": [
      "r1074"
     ]
    },
    "ci_MortgageLoansOnRealEstateCommercialAndConsumerNetBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "MortgageLoansOnRealEstateCommercialAndConsumerNetBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial mortgage loans, including assets held for sale",
        "label": "Mortgage Loans on Real Estate, Commercial and Consumer, Net, Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Mortgage Loans on Real Estate, Commercial and Consumer, Net, Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MortgagesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MortgagesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails",
      "http://www.thecignagroup.com/role/PensionPensionPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commercial mortgage loans",
        "label": "Mortgages [Member]",
        "documentation": "A loan to finance the purchase of real estate where the lender has a lien on the property as collateral for the loan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1518"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuesfromUSFederalGovernmentAgenciesDetails",
      "http://www.thecignagroup.com/role/SegmentInformationUSandForeignRevenuesfromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]",
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r547",
      "r1396",
      "r1649",
      "r1764",
      "r1773"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1491"
     ]
    },
    "ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "A- equivalent and higher current ratings",
        "label": "Nationally Recognized Statisical Rating Organizations (NRSRO), A- Or Higher [Member]",
        "documentation": "Nationally Recognized Statisical Rating Organizations (NRSRO), A- Or Higher"
       }
      }
     },
     "auth_ref": []
    },
    "ci_NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BBB- to BBB+ equivalent current credit ratings",
        "label": "Nationally Recognized Statisical Rating Organizations (NRSRO), BBB- To BBB+ Rating [Member]",
        "documentation": "Nationally Recognized Statisical Rating Organizations (NRSRO), BBB- To BBB+ Rating"
       }
      }
     },
     "auth_ref": []
    },
    "ci_NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Not rated",
        "label": "Nationally Recognized Statisical Rating Organizations (NRSRO), Not Rated [Member]",
        "documentation": "Nationally Recognized Statisical Rating Organizations (NRSRO), Not Rated"
       }
      }
     },
     "auth_ref": []
    },
    "ci_NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BBB+ equivalent and higher current ratings",
        "label": "Nationally Recognized Statistical Rating Organizations (NRSRO), BBB+ Or Higher [Member]",
        "documentation": "Nationally Recognized Statistical Rating Organizations (NRSRO), BBB+ Or Higher"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.thecignagroup.com/role/DescriptionofBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Business",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r338"
     ]
    },
    "us-gaap_NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Account value",
        "label": "Net Amount at Risk by Product and Guarantee, General Account Value",
        "documentation": "Value of the general accounts corresponding to the specified product, guarantee type and subset of the guarantee."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_NetAmountAtRiskByProductAndGuaranteeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetAmountAtRiskByProductAndGuaranteeLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Amount at Risk by Product and Guarantee [Line Items]",
        "label": "Net Amount at Risk by Product and Guarantee [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "us-gaap_NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net amount at risk",
        "label": "Net Amount at Risk by Product and Guarantee, Net Amount at Risk",
        "documentation": "Net amount at risk, representing the guaranteed benefit in excess of the current account balance corresponding to the specified product, guarantee type and subset of the guarantee."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r324"
     ]
    },
    "ci_NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guaranteed Minimum Death Benefits Total Contractholders",
        "label": "Net Amount At Risk By Product And Guarantee, Number Of Contractholders Estimated",
        "documentation": "Net Amount At Risk By Product And Guarantee, Number Of Contractholders Estimated"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetAmountAtRiskByProductAndGuaranteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetAmountAtRiskByProductAndGuaranteeTable",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Amount at Risk, by Product and Guarantee [Table]",
        "label": "Net Amount at Risk, by Product and Guarantee [Table]",
        "documentation": "For contracts with guaranteed benefits in excess of the current account balance, sets forth the amounts of such excesses (the net amounts at risk) and other pertinent information by type of guarantee by type of insurance product), as of the most recent balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r324"
     ]
    },
    "us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average attained age of contractholders (weighted by exposure)",
        "label": "Net Amount at Risk by Product and Guarantee, Weighted Average Attained Age",
        "documentation": "Weighted average attained age of policyholders or contract holders in the specified guarantee type and subset of guarantee class, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r324"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH USED IN FINANCING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows from Financing Activities",
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows from Investing Activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows from Investing Activities",
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH PROVIDED BY OPERATING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows from Operating Activities",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Income (Loss)",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r254",
      "r304",
      "r397",
      "r427",
      "r430",
      "r435",
      "r454",
      "r475",
      "r479",
      "r480",
      "r482",
      "r483",
      "r487",
      "r488",
      "r498",
      "r512",
      "r532",
      "r538",
      "r541",
      "r602",
      "r683",
      "r684",
      "r686",
      "r687",
      "r688",
      "r690",
      "r692",
      "r694",
      "r695",
      "r927",
      "r949",
      "r1098",
      "r1233",
      "r1249",
      "r1250",
      "r1373",
      "r1442",
      "r1643"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: Net income attributable to noncontrolling interests",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r287",
      "r427",
      "r430",
      "r487",
      "r488",
      "r1097",
      "r1570"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAttributableToNonredeemableNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income attributable to other noncontrolling interests",
        "label": "Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest",
        "documentation": "Portion of net income (loss) attributable to nonredeemable noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAttributableToRedeemableNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income attributable to redeemable noncontrolling interests",
        "label": "Net Income (Loss) Attributable to Redeemable Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to redeemable noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails",
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "SHAREHOLDERS' NET INCOME",
        "terseLabel": "Increase to shareholders' net income",
        "verboseLabel": "Shareholders' net income",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r479",
      "r480",
      "r482",
      "r483",
      "r491",
      "r492",
      "r499",
      "r502",
      "r512",
      "r532",
      "r538",
      "r541",
      "r1373"
     ]
    },
    "us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income",
        "label": "Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest",
        "documentation": "Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r287",
      "r288"
     ]
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetInvestmentHedgingMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Investment Hedging",
        "label": "Net Investment Hedging [Member]",
        "documentation": "Hedges of a net investment in a foreign operation."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_NetInvestmentIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetInvestmentIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net investment income",
        "totalLabel": "Net investment income",
        "verboseLabel": "Net investment income (loss)",
        "label": "Net Investment Income",
        "documentation": "Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r1101",
      "r1102",
      "r1236",
      "r1442"
     ]
    },
    "ci_NetworkPharmacyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NetworkPharmacyMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Network revenues",
        "label": "Network Pharmacy [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r482",
      "r489",
      "r506",
      "r557",
      "r558",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r659",
      "r848",
      "r849",
      "r850",
      "r879",
      "r880",
      "r881",
      "r882",
      "r891",
      "r892",
      "r893",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r944",
      "r945",
      "r950",
      "r951",
      "r952",
      "r953",
      "r963",
      "r964",
      "r966",
      "r967",
      "r968",
      "r969",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r1040",
      "r1041",
      "r1042",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1175"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r482",
      "r489",
      "r506",
      "r557",
      "r558",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r659",
      "r848",
      "r849",
      "r850",
      "r879",
      "r880",
      "r881",
      "r882",
      "r891",
      "r892",
      "r893",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r944",
      "r945",
      "r950",
      "r951",
      "r952",
      "r953",
      "r963",
      "r964",
      "r966",
      "r967",
      "r968",
      "r969",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r1040",
      "r1041",
      "r1042",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1175"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements, Recently Adopted Accounting Guidance and Accounting Guidance Not Yet Adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1490"
     ]
    },
    "ci_NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValuesofSeparateAccountAssetsDetails": {
       "parentTag": "ci_SeparateAccountAssetsClassifiedInFairValueHierarchy",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValuesofSeparateAccountAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-guaranteed separate accounts",
        "label": "Non Guaranteed Separate Account Assets Classified In Fair Value Hierarchy",
        "documentation": "The fair value of the assets held by the Entity for the benefit of separate account policyholders without guarantees classified in the fair value hierarchy."
       }
      }
     },
     "auth_ref": []
    },
    "ci_NonGuaranteedSeparateAccountAssetsPricedAtNetAssetValueAsAPracticalExpedient": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NonGuaranteedSeparateAccountAssetsPricedAtNetAssetValueAsAPracticalExpedient",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValuesofSeparateAccountAssetsDetails": {
       "parentTag": "us-gaap_SeparateAccountAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValuesofSeparateAccountAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-guaranteed separate accounts priced at NAV as a practical expedient",
        "label": "Non Guaranteed Separate Account Assets Priced At Net Asset Value As A Practical Expedient",
        "documentation": "The fair value of the assets held by the Entity for the benefit of separate account policyholders without guarantees and priced at net asset value as a practical expedient."
       }
      }
     },
     "auth_ref": []
    },
    "ci_NonInvestmentRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NonInvestmentRevenue",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails",
      "http://www.thecignagroup.com/role/SegmentInformationUSandForeignRevenuesfromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenues from customers",
        "totalLabel": "Total revenues from external customers",
        "terseLabel": "Revenues from external customers",
        "label": "Non Investment Revenue",
        "documentation": "Revenue excluding net investment income and realized investment results."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r1459",
      "r1471",
      "r1481",
      "r1498",
      "r1507"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1488"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1487"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1498"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1518"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1518"
     ]
    },
    "us-gaap_NoncatastrophicEventAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncatastrophicEventAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncatastrophic Event [Axis]",
        "label": "Noncatastrophic Event [Axis]",
        "documentation": "Information by type of noncatastrophic event causing change in the insurer's provision."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_NoncatastrophicEventDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncatastrophicEventDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncatastrophic Event [Domain]",
        "label": "Noncatastrophic Event [Domain]",
        "documentation": "Noncatastrophic event causing change in the insurer's provision."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_NoncontrollingInterestInVariableInterestEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestInVariableInterestEntity",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/VariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "VIEs, Carrying value",
        "label": "Noncontrolling Interest in Variable Interest Entity",
        "documentation": "Portion of equity (net assets) in a variable interest entity (VIE) not attributable, directly or indirectly, to the parent entity. That is, this is the portion of equity in a VIE that is attributable to the noncontrolling interest (previously referred to as minority interest)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Non- controlling Interests",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r728",
      "r1586",
      "r1587",
      "r1588",
      "r1785"
     ]
    },
    "ci_NoncontrollingInterestOtherChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NoncontrollingInterestOtherChanges",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other transactions impacting noncontrolling interests",
        "label": "Noncontrolling Interest Other Changes",
        "documentation": "Other activity associated with noncontrolling interest that is not separately disclosed."
       }
      }
     },
     "auth_ref": []
    },
    "ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails": {
       "parentTag": "us-gaap_ReceivablesNetCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noninsurance customer receivables",
        "label": "Noninsurance Customer Receivables Excluding Pharmaceutical Manufacturers Receivable",
        "documentation": "Receivables due from customers that are not under insurance contracts. These include pharmacy sales and fees due from employer clients."
       }
      }
     },
     "auth_ref": []
    },
    "ci_NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails_1": {
       "parentTag": "ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noninsurance customer receivables, including held for sale assets",
        "label": "Noninsurance Customer Receivables Excluding Pharmaceutical Manufacturers Receivable Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Noninsurance Customer Receivables Excluding Pharmaceutical Manufacturers Receivable Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonqualifiedPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonqualifiedPlanMember",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Qualified Plan",
        "label": "Nonqualified Plan [Member]",
        "documentation": "Plan without tax-exempt status in accordance with applicable tax provision of designated taxing authority. Taxing authority includes, but is not limited to, U.S. Internal Revenue Service (IRS). Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r1536",
      "r1651",
      "r1652",
      "r1653",
      "r1654",
      "r1655",
      "r1656",
      "r1657",
      "r1658",
      "r1659",
      "r1660",
      "r1661",
      "r1662",
      "r1663",
      "r1664",
      "r1665",
      "r1666",
      "r1667",
      "r1668",
      "r1669",
      "r1670",
      "r1671",
      "r1672",
      "r1673",
      "r1674",
      "r1675",
      "r1676",
      "r1677",
      "r1678",
      "r1679",
      "r1680",
      "r1681",
      "r1682",
      "r1683",
      "r1684",
      "r1685",
      "r1686",
      "r1687",
      "r1688",
      "r1689",
      "r1690",
      "r1691",
      "r1692",
      "r1693",
      "r1694",
      "r1695",
      "r1696",
      "r1697",
      "r1698",
      "r1699",
      "r1700",
      "r1701",
      "r1702",
      "r1703",
      "r1704",
      "r1705",
      "r1706",
      "r1707",
      "r1708",
      "r1709",
      "r1710"
     ]
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupIntercompanyBalancesDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonrelated Party",
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r1578",
      "r1579"
     ]
    },
    "us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotDesignatedAsHedgingInstrumentEconomicHedgeMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSummaryofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Not Designated as Hedging Instrument, Economic Hedge",
        "label": "Not Designated as Hedging Instrument, Economic Hedge [Member]",
        "documentation": "Derivative instrument, not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP), used as economic hedge for exposure to risk."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "ci_NotesDue2022305InterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NotesDue2022305InterestMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes Due 2022, 3.05% Interest",
        "label": "Notes Due 2022, 3.05% Interest [Member]",
        "documentation": "Senior notes payable bearing interest at 3.05% due in 2022. Debt assumed acquisition from Express Scripts."
       }
      }
     },
     "auth_ref": []
    },
    "ci_NotesDue2023375InterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NotesDue2023375InterestMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$1,187\u00a0million, 3.75% Notes due July 2023",
        "label": "Notes Due 2023, 3.75% Interest [Member]",
        "documentation": "Senior notes payable bearing interest at 3.75% due in 2023. Debt issued to finance acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "ci_NotesDue20233InterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NotesDue20233InterestMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$1,000\u00a0million, 3% Notes due July 2023",
        "label": "Notes Due 2023, 3% Interest [Member]",
        "documentation": "Senior notes payable bearing interest at 3% due in 2023. Debt assumed acquisition from Express Scripts."
       }
      }
     },
     "auth_ref": []
    },
    "ci_NotesDue2023765InterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NotesDue2023765InterestMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$63\u00a0million, 7.65% Notes due March 2023",
        "label": "Notes due 2023 7.65% Interest [Member]",
        "documentation": "Notes payable bearing interest at 7.65% due in 2023."
       }
      }
     },
     "auth_ref": []
    },
    "ci_NotesDue202383InterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NotesDue202383InterestMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$17\u00a0million, 8.3% Notes due January 2023",
        "label": "Notes Due 2023, 8.3% Interest [Member]",
        "documentation": "Notes payable bearing interest at 8.3% due in 2023."
       }
      }
     },
     "auth_ref": []
    },
    "ci_NotesDue2023FloatingRateInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NotesDue2023FloatingRateInterestMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$700\u00a0million, Floating Rate Notes due July 2023",
        "label": "Notes Due 2023 Floating Rate Interest [Member]",
        "documentation": "Senior notes payable with floating interest due in 2023. Debt issued to finance acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "ci_NotesDue202435InterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NotesDue202435InterestMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtLongtermDebtDetails",
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$1,000\u00a0million, 3.500% Notes due June 2024",
        "label": "Notes Due 2024 3.5% Interest [Member]",
        "documentation": "Senior notes payable bearing interest at 3.5% due in 2024. Debt assumed acquisition from Express Scripts."
       }
      }
     },
     "auth_ref": []
    },
    "ci_NotesDue2024613InterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NotesDue2024613InterestMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$500 million, 0.613% Notes due March 2024",
        "label": "Notes Due 2024 .613% Interest [Member]",
        "documentation": "Notes payable bearing .613% interest due in 2024."
       }
      }
     },
     "auth_ref": []
    },
    "ci_NotesDue2025325InterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NotesDue2025325InterestMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$900\u00a0million, 3.250% Notes due April 2025 (2)",
        "label": "Notes Due 2025 3.25% Interest [Member]",
        "documentation": "Notes payable bearing interest at 3.25% due in 2025."
       }
      }
     },
     "auth_ref": []
    },
    "ci_NotesDue20254125InterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NotesDue20254125InterestMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$2,200\u00a0million, 4.125% Notes due November 2025 (1)",
        "label": "Notes Due 2025, 4.125% Interest [Member]",
        "documentation": "Senior notes payable bearing interest at 4.125% due in 2025. Debt issued to finance acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "ci_NotesDue2026125Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NotesDue2026125Member",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$800 million, 1.250% Notes due March 2026 (1)",
        "label": "Notes due 2026, 1.25% [Member]",
        "documentation": "Notes payable bearing interest at 1.25% due in 2026."
       }
      }
     },
     "auth_ref": []
    },
    "ci_NotesDue202645InterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NotesDue202645InterestMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$1,500\u00a0million, 4.500% Notes due February 2026 (1)",
        "label": "Notes Due 2026, 4.5% Interest [Member]",
        "documentation": "Senior notes payable bearing interest at 4.5% due in 2026. Debt assumed acquisition from Express Scripts."
       }
      }
     },
     "auth_ref": []
    },
    "ci_NotesDue20265685Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NotesDue20265685Member",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtLongtermDebtDetails",
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$700 million, 5.685% Notes due March 2026",
        "label": "Notes due 2026, 5.685% [Member]",
        "documentation": "Notes due 2026, 5.685%"
       }
      }
     },
     "auth_ref": []
    },
    "ci_NotesDue2027305Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NotesDue2027305Member",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$600\u00a0million, 3.050% Notes due October 2027 (1)",
        "label": "Notes Due 2027, 3.05% [Member]",
        "documentation": "Notes payable bearing interest at 3.05% due October 15, 2027."
       }
      }
     },
     "auth_ref": []
    },
    "ci_NotesDue202734InterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NotesDue202734InterestMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$1,500\u00a0million, 3.400% Notes due March 2027",
        "label": "Notes Due 2027, 3.4% Interest [Member]",
        "documentation": "Senior notes payable bearing interest at 3.4% due in 2027. Debt assumed acquisition from Express Scripts."
       }
      }
     },
     "auth_ref": []
    },
    "ci_NotesDue20284375InterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NotesDue20284375InterestMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$3,800\u00a0million, 4.375% Notes due October 2028",
        "label": "Notes Due 2028, 4.375% Interest [Member]",
        "documentation": "Senior notes payable bearing interest at 4.375% due in 2028. Debt issued to finance acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "ci_NotesDue203024InterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NotesDue203024InterestMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$1,500\u00a0million, 2.400% Notes due March 2030 (1)",
        "label": "Notes Due 2030, 2.4% Interest [Member]",
        "documentation": "Notes Due 2030, 2.4% Interest"
       }
      }
     },
     "auth_ref": []
    },
    "ci_NotesDue20312375InterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NotesDue20312375InterestMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$1,500 million, 2.375% Notes due 2031",
        "label": "Notes Due 2031, 2.375% Interest [Member]",
        "documentation": "Notes payable bearing interest at 2.375% due in 2031."
       }
      }
     },
     "auth_ref": []
    },
    "ci_NotesDue20335400InterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NotesDue20335400InterestMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtLongtermDebtDetails",
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$800 million, 5.400% Notes due March 2033",
        "label": "Notes Due 2033, 5.400% Interest [Member]",
        "documentation": "Notes Due 2033, 5.400% Interest"
       }
      }
     },
     "auth_ref": []
    },
    "ci_NotesDue2036615InterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NotesDue2036615InterestMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$190\u00a0million, 6.150% Notes due November 2036",
        "label": "Notes due 2036 6.15% Interest [Member]",
        "documentation": "Notes payable bearing interest at 6.15% due in 2036."
       }
      }
     },
     "auth_ref": []
    },
    "ci_NotesDue203848InterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NotesDue203848InterestMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$2,200\u00a0million, 4.800% Notes due August 2038",
        "label": "Notes Due 2038, 4.8% Interest [Member]",
        "documentation": "Senior notes payable bearing interest at 4.8% due in 2038. Debt issued to finance acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "ci_NotesDue204032InterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NotesDue204032InterestMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$750\u00a0million, 3.200% Notes due March 2040",
        "label": "Notes Due 2040, 3.2% Interest [Member]",
        "documentation": "Notes Due 2040, 3.2% Interest"
       }
      }
     },
     "auth_ref": []
    },
    "ci_NotesDue20415875InterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NotesDue20415875InterestMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$121\u00a0million, 5.875% Notes due March 2041",
        "label": "Notes Due 2041, 5.875% Interest [Member]",
        "documentation": "Notes payable bearing interest at 5.875% due in 2041."
       }
      }
     },
     "auth_ref": []
    },
    "ci_NotesDue20416125InterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NotesDue20416125InterestMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$448\u00a0million, 6.125% Notes due November 2041",
        "label": "Notes Due 2041, 6.125% Interest [Member]",
        "documentation": "Senior notes payable bearing interest at 6.125% due in 2041. Debt assumed acquisition from Express Scripts."
       }
      }
     },
     "auth_ref": []
    },
    "ci_NotesDue20425375InterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NotesDue20425375InterestMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$317\u00a0million, 5.375% Notes due February 2042",
        "label": "Notes Due 2042, 5.375% Interest [Member]",
        "documentation": "Notes payable bearing interest at 5.375% due in 2042."
       }
      }
     },
     "auth_ref": []
    },
    "ci_NotesDue204648InterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NotesDue204648InterestMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$1,500\u00a0million, 4.800% Notes due July 2046",
        "label": "Notes Due 2046, 4.8% Interest [Member]",
        "documentation": "Senior notes payable bearing interest at 4.8% due in 2046. Debt assumed acquisition from Express Scripts."
       }
      }
     },
     "auth_ref": []
    },
    "ci_NotesDue20473875Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NotesDue20473875Member",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$1,000\u00a0million, 3.875% Notes due October 2047",
        "label": "Notes Due 2047, 3.875% [Member]",
        "documentation": "Notes payable bearing interest at 3.875% due October 15, 2047."
       }
      }
     },
     "auth_ref": []
    },
    "ci_NotesDue204849InterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NotesDue204849InterestMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$3,000\u00a0million, 4.900% Notes due December 2048",
        "label": "Notes Due 2048, 4.9% Interest [Member]",
        "documentation": "Senior notes payable bearing interest at 4.9% due in 2048. Debt issued to finance acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "ci_NotesDue205034InterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NotesDue205034InterestMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$1,250\u00a0million, 3.400% Notes due March 2050",
        "label": "Notes Due 2050, 3.4% Interest [Member]",
        "documentation": "Notes Due 2050, 3.4% Interest"
       }
      }
     },
     "auth_ref": []
    },
    "ci_NotesDue205134InterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NotesDue205134InterestMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$1,500 million, 3.400% Notes due March 2051",
        "label": "Notes Due 2051, 3.4% Interest [Member]",
        "documentation": "Notes payable bearing interest at 3.4% due 2051."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesReduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesReduction",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net amounts due to/(from) affiliates settled through capital transactions",
        "label": "Notes Reduction",
        "documentation": "The value of notes retired (or transferred to another entity) in noncash investing or financing transactions."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r88",
      "r89"
     ]
    },
    "ci_NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtShorttermandCreditFacilitiesDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of participating banks",
        "label": "Number Of Banks Participating In Revolving Credit And Letter Of Credit Agreement",
        "documentation": "Number of banks participating in revolving credit and letter of credit agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ci_NumberOfRevolvingCreditFacility": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "NumberOfRevolvingCreditFacility",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtShorttermandCreditFacilitiesDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of revolving credit facilities",
        "label": "Number Of Revolving Credit Facility",
        "documentation": "Number Of Revolving Credit Facility"
       }
      }
     },
     "auth_ref": []
    },
    "ci_OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net long-duration insurance and contractholder liabilities measurement adjustments",
        "label": "OCI, Liability For Future Policy Benefit And Market Risk Benefit, Instrument-Specific Credit Risk, Gain (Loss), After Reclassification Adjustment And Tax, Portion Attributable To Parent",
        "documentation": "OCI, Liability For Future Policy Benefit And Market Risk Benefit, Instrument-Specific Credit Risk, Gain (Loss), After Reclassification Adjustment And Tax, Portion Attributable To Parent"
       }
      }
     },
     "auth_ref": []
    },
    "ci_OngoingOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "OngoingOperationsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ongoing Operations",
        "label": "Ongoing Operations [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r532",
      "r538",
      "r541",
      "r1373"
     ]
    },
    "ci_OperatingJointVenturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "OperatingJointVenturesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating joint ventures",
        "label": "Operating Joint Ventures [Member]",
        "documentation": "Operating Joint Ventures"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r982",
      "r1413"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails",
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease liabilities",
        "terseLabel": "Total",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "ci_OperatingLeaseLiabilityCurrentIncludingDisposalGroupsAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "OperatingLeaseLiabilityCurrentIncludingDisposalGroupsAssetsHeldForSale",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails": {
       "parentTag": "ci_OperatingLeaseLiabilityIncludingDisposalGroupsAssetsHeldForSale",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other liabilities, including held for sale liabilities",
        "label": "Operating Lease Liability Current Including Disposal Groups Assets Held For Sale",
        "documentation": "Operating Lease Liability Current Including Disposal Groups Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance sheet location of current operating lease liabilities",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r973"
     ]
    },
    "ci_OperatingLeaseLiabilityIncludingDisposalGroupsAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "OperatingLeaseLiabilityIncludingDisposalGroupsAssetsHeldForSale",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease liabilities, including held for sale liabilities",
        "label": "Operating Lease Liability Including Disposal Groups Assets Held For Sale",
        "documentation": "Operating Lease Liability Including Disposal Groups Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "ci_OperatingLeaseLiabilityNoncurrentIncludingDisposalGroupsAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "OperatingLeaseLiabilityNoncurrentIncludingDisposalGroupsAssetsHeldForSale",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails": {
       "parentTag": "ci_OperatingLeaseLiabilityIncludingDisposalGroupsAssetsHeldForSale",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities, including held for sale liabilities",
        "label": "Operating Lease Liability Noncurrent Including Disposal Groups Assets Held For Sale",
        "documentation": "Operating Lease Liability Noncurrent Including Disposal Groups Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance sheet location of non-current operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r973"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesSupplementalCashFlowInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash outflows from operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r977",
      "r984"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease ROU assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesOperatingandFinanceLeaseRightofUseROUAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance sheet location of operating lease ROU assets",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r973"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate for operating leases",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r987",
      "r1413"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term for operating leases",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r986",
      "r1413"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Segments",
        "label": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r541"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_OrganizationalEfficiencyPlanCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "OrganizationalEfficiencyPlanCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charge for organizational efficiency plan, 2020 (Selling, general and administrative expenses)",
        "verboseLabel": "Charge for organizational efficiency plan, 2020",
        "label": "Organizational Efficiency Plan Charges",
        "documentation": "Organizational Efficiency Plan Charges"
       }
      }
     },
     "auth_ref": []
    },
    "ci_OrganizationalEfficiencyPlanChargesNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "OrganizationalEfficiencyPlanChargesNetOfTax",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charge for organizational efficiency plan, 2020 (Selling, general and administrative expenses)",
        "label": "Organizational Efficiency Plan Charges, Net Of Tax",
        "documentation": "Organizational Efficiency Plan Charges, Net Of Tax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupIntercompanyBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r1414"
     ]
    },
    "ci_OtherAssetsCurrentAndNoncurrentPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "OtherAssetsCurrentAndNoncurrentPolicyPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Assets (Current and Non-Current)",
        "label": "Other Assets Current And Noncurrent Policy [Policy Text Block]",
        "documentation": "Accounting policies related to Other Assets, Current and Noncurrent and the items included therein."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "verboseLabel": "Other non-current assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_OtherCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitment",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails",
      "http://www.thecignagroup.com/role/VariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commitment",
        "terseLabel": "Additional commitments",
        "label": "Other Commitment",
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails",
      "http://www.thecignagroup.com/role/VariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Axis]",
        "label": "Other Commitments [Axis]",
        "documentation": "Information by type of other commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails",
      "http://www.thecignagroup.com/role/VariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Domain]",
        "label": "Other Commitments [Domain]",
        "documentation": "Other future obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Line Items]",
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Table]",
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net unrealized appreciation (depreciation) on securities and derivatives",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r30",
      "r286"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Postretirement benefits liability adjustment",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent",
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r30",
      "r240",
      "r286"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net translation gains (losses) of foreign currencies",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r30",
      "r286"
     ]
    },
    "ci_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net unrealized appreciation (depreciation) on securities and derivatives",
        "label": "Other Comprehensive Income (Loss), Available-For-Sale Securities And Derivatives Adjustment, Net Of Tax",
        "documentation": "Other Comprehensive Income (Loss), Available-For-Sale Securities And Derivatives Adjustment, Net Of Tax"
       }
      }
     },
     "auth_ref": []
    },
    "ci_OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails_1": {
       "parentTag": "ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive income (loss) including temporary equity, before reclassifications, after-tax",
        "label": "Other Comprehensive Income (Loss), Before Reclassifications, After Tax, Including Temporary Equity",
        "documentation": "Other Comprehensive Income (Loss), Before Reclassifications, After Tax, Including Temporary Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss) before reclassifications, before tax",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, before Tax",
        "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r434",
      "r955",
      "r958",
      "r961",
      "r1099",
      "r1568"
     ]
    },
    "ci_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": {
       "parentTag": "ci_OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss) including temporary equity, before reclassifications, before tax",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, before Tax, Including Temporary Equity",
        "documentation": "Other Comprehensive Income (Loss), before Reclassifications, before Tax, Including Temporary Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive income (loss) before reclassifications, after-tax",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r73",
      "r434",
      "r955",
      "r958",
      "r961",
      "r1568"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTax",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other comprehensive income (loss), before reclassifications, tax",
        "label": "Other Comprehensive Income (Loss) before Reclassifications, Tax",
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r433",
      "r1099"
     ]
    },
    "ci_OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": {
       "parentTag": "ci_OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other comprehensive income (loss) including temporary equity, before reclassifications, tax",
        "label": "Other Comprehensive Income (Loss) before Reclassifications, Tax, Including Temporary Equity",
        "documentation": "Other Comprehensive Income (Loss) before Reclassifications, Tax, Including Temporary Equity"
       }
      }
     },
     "auth_ref": []
    },
    "ci_OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": {
       "parentTag": "ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Translation of foreign currencies, before tax",
        "label": "Other Comprehensive Income (Loss), Before Tax, Including Temporary Equity",
        "documentation": "Other Comprehensive Income (Loss), Before Tax, Including Temporary Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative gain (loss) recognized in other comprehensive income",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r423"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative gain (loss) reclassified from other comprehensive income into shareholders' net income",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r425"
     ]
    },
    "ci_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net translation gains (losses) on foreign currencies",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Including Temporary Equity",
        "documentation": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Including Temporary Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss)",
        "totalLabel": "Shareholders other comprehensive income (loss), net of tax",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r51",
      "r428",
      "r431",
      "r437",
      "r955",
      "r956",
      "r961",
      "r1058",
      "r1099",
      "r1568",
      "r1569"
     ]
    },
    "ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails_1": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ci_ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive loss, net of tax",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Including Temporary Equity",
        "documentation": "Other Comprehensive Income (Loss), Net of Tax, Including Temporary Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Shareholders' other comprehensive loss, net of tax",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r30",
      "r286",
      "r428",
      "r431"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss), net of tax",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Postretirement benefits liability adjustment",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r240"
     ]
    },
    "ci_OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": {
       "parentTag": "ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other Comprehensive Income (Loss), Tax, Including Temporary Equity",
        "label": "Other Comprehensive Income (Loss), Tax, Including Temporary Equity",
        "documentation": "Other Comprehensive Income (Loss), Tax, Including Temporary Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCurrentAssetsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Current Assets",
        "label": "Other Current Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other current assets."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r186"
     ]
    },
    "us-gaap_OtherDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherDebtSecuritiesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other debt securities",
        "label": "Other Debt Obligations [Member]",
        "documentation": "Investments in debt securities classified as other."
       }
      }
     },
     "auth_ref": [
      "r1616",
      "r1673",
      "r1727"
     ]
    },
    "ci_OtherHealthcareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "OtherHealthcareMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Healthcare [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_OtherIntangibleAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "OtherIntangibleAssetsAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other intangible assets",
        "label": "Other Intangible Assets [Abstract]",
        "documentation": "Other Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIntangibleAssetsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentComponentsofDepreciationandAmortizationExpenseDetails",
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "verboseLabel": "Other intangibles",
        "label": "Other Intangible Assets [Member]",
        "documentation": "Intangible assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherInvestmentsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Investments [Member]",
        "documentation": "Primary financial statement caption encompassing other investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r1414"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_OtherLongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails": {
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other, including finance leases",
        "label": "Other Long-Term Debt, Noncurrent",
        "documentation": "Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r1209"
     ]
    },
    "us-gaap_OtherLongTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLongTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term investments",
        "label": "Other Long-Term Investments",
        "documentation": "Amount of long-term investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r1075",
      "r1565"
     ]
    },
    "ci_OtherLongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "OtherLongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long term investments, including held for sale assets",
        "label": "Other Long Term Investments Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Other Long Term Investments Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLongTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLongTermInvestmentsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term investments",
        "verboseLabel": "Other long-term investments",
        "label": "Other Long-Term Investments [Member]",
        "documentation": "Long-term investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r1776"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense and other",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r250"
     ]
    },
    "ci_OtherOperationsInternationalBusinessesToBeSoldAndInterestInJointVentureInTurkeyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "OtherOperationsInternationalBusinessesToBeSoldAndInterestInJointVentureInTurkeyMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Divested International businesses",
        "label": "Other Operations, International Businesses To Be Sold And Interest In Joint Venture In Turkey [Member]",
        "documentation": "Other Operations, International Businesses To Be Sold And Interest In Joint Venture In Turkey"
       }
      }
     },
     "auth_ref": []
    },
    "ci_OtherOperationsInternationalBusinessesToBeSoldMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "OtherOperationsInternationalBusinessesToBeSoldMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International businesses [to be] sold to Chubb",
        "label": "Other Operations, International Businesses To Be Sold [Member]",
        "documentation": "International businesses to be sold to Chubb (excludes interest in Turkiye joint venture)."
       }
      }
     },
     "auth_ref": []
    },
    "ci_OtherOperationsSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "OtherOperationsSegmentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentGoodwillActivityDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsInterestRatesandDurationDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails",
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Operations",
        "label": "Other Operations Segment [Member]",
        "documentation": "Other Operations Segment"
       }
      }
     },
     "auth_ref": []
    },
    "ci_OtherOperationsSegmentOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "OtherOperationsSegmentOtherMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Operations Segment, Other [Member]",
        "documentation": "Other Operations Segment, Other"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1490"
     ]
    },
    "ci_OtherPharmacyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "OtherPharmacyMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenues",
        "label": "Other Pharmacy [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_OtherPlanAssetCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "OtherPlanAssetCategoriesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionPensionPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other investments",
        "label": "Other Plan Asset Categories [Member]",
        "documentation": "Other investments not separately identified, in which defined benefit plan is invested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherReinsurerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherReinsurerMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Reinsurer, Other [Member]",
        "documentation": "Reinsurer classified as other."
       }
      }
     },
     "auth_ref": [
      "r1748"
     ]
    },
    "ci_OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails": {
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other, including finance leases",
        "label": "Other Short-Term Debt, Current Maturities Of Long-Term Debt, And Lease Obligations, Current",
        "documentation": "Other Short-Term Debt, Current Maturities Of Long-Term Debt, And Lease Obligations, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments",
        "label": "Other Short-Term Investments",
        "documentation": "Amount of short-term investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r1076",
      "r1567"
     ]
    },
    "ci_OtherShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "OtherShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments, including held for sale assets",
        "label": "Other Short Term Investments Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Other Short Term Investments Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_OtherVariableInterestEntitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "OtherVariableInterestEntitiesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/VariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Variable Interest Entities",
        "label": "Other Variable Interest Entities [Member]",
        "documentation": "Other Variable Interest Entities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1457",
      "r1469",
      "r1479",
      "r1505"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1460",
      "r1472",
      "r1482",
      "r1508"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1460",
      "r1472",
      "r1482",
      "r1508"
     ]
    },
    "srt_ParentCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ParentCompanyMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupDebtMaturitiesDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupGuaranteesDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupIntercompanyBalancesDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShareRepurchaseDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Cigna Group",
        "label": "Parent Company [Member]",
        "documentation": "Registrant with controlling financial interest in one or more subsidiaries. Controlling interest in subsidiary includes, but is not limited to, primary beneficiary of variable interest entity (VIE). Controlling interest in subsidiary excludes broker-dealer with controlling financial interest in subsidiary but control is likely to be temporary."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ParentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders' Equity",
        "label": "Parent [Member]",
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "srt_PartnershipInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "PartnershipInterestMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsAdditionalInformationonSeparateAccountAssetsPricedatNetAssetValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails",
      "http://www.thecignagroup.com/role/PensionPensionPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities partnerships",
        "verboseLabel": "Securities partnerships",
        "label": "Partnership Interest [Member]",
        "documentation": "A general or limited ownership interest in a partnership or unincorporated joint venture."
       }
      }
     },
     "auth_ref": [
      "r1431"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1486"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForLossesAndLossAdjustmentExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total paid",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid",
        "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r45"
     ]
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other, net",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r1531",
      "r1571"
     ]
    },
    "ci_PaymentsForProceedsFromPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "PaymentsForProceedsFromPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Property and equipment purchases, net",
        "label": "Payments For (Proceeds From) Property, Plant, And Equipment",
        "documentation": "Payments For (Proceeds From) Property, Plant, And Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      },
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchase of common stock",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/OrganizationalEfficiencyPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments",
        "label": "Payments for Restructuring",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r662",
      "r1573"
     ]
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments for debt extinguishment",
        "negatedLabel": "Payments for debt extinguishment",
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDividendsCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      },
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/CommonandPreferredStockDividendsDetails",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Common stock dividend paid",
        "terseLabel": "Total amount paid",
        "negatedLabel": "Common dividends paid",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax withholding on stock compensation and other",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisitions, net of cash acquired",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "ci_PaymentsToAcquireDebtAndEquitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "PaymentsToAcquireDebtAndEquitySecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt securities and equity securities",
        "terseLabel": "Amount funded",
        "label": "Payments To Acquire Debt And Equity Securities",
        "documentation": "Payments To Acquire Debt And Equity Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireInvestmentsAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments purchased or originated:",
        "label": "Payments to Acquire Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireMortgageNotesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireMortgageNotesReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Commercial mortgage loans",
        "label": "Payments to Acquire Mortgage Notes Receivable",
        "documentation": "The cash outflow from the purchase of receivables arising from the mortgage note on real estate."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireOtherInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other (primarily short-term and other long-term investments)",
        "negatedTerseLabel": "Net proceeds from short-term investments sold (purchased)",
        "label": "Payments to Acquire Other Investments",
        "documentation": "Amount of cash outflow to acquire investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1489"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1489"
     ]
    },
    "us-gaap_PendingLitigationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PendingLitigationMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pending Litigation",
        "label": "Pending Litigation [Member]",
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process."
       }
      }
     },
     "auth_ref": [
      "r1635"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/Pension"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension",
        "label": "Retirement Benefits [Text Block]",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r731",
      "r757",
      "r759",
      "r765",
      "r783",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r801",
      "r802",
      "r803",
      "r1399"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accrued expenses and other liabilities",
        "label": "Liability, Defined Benefit Plan, Current",
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r732",
      "r733",
      "r756",
      "r1399"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other non-current liabilities",
        "label": "Liability, Defined Benefit Plan, Noncurrent",
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r732",
      "r733",
      "r756",
      "r1399"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansNoncurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansNoncurrentLiabilitiesAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts presented in Consolidated Balance Sheets",
        "label": "Liability, Defined Benefit Plan [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementPlansPensionsPolicy",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Plans",
        "label": "Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for pension plans. This accounting policy may address (1) the types of plans sponsored by the entity (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r34",
      "r144"
     ]
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionPlansDefinedBenefitMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValuesofSeparateAccountAssetsDetails",
      "http://www.thecignagroup.com/role/PensionAmountsIncludedinAccumulatedOtherComprehensiveIncomeDetails",
      "http://www.thecignagroup.com/role/PensionAssumptionsUsedforPensionDetails",
      "http://www.thecignagroup.com/role/PensionBenefitPaymentsDetails",
      "http://www.thecignagroup.com/role/PensionNarrativeDetails",
      "http://www.thecignagroup.com/role/PensionNetPensionCostDetails",
      "http://www.thecignagroup.com/role/PensionPensionPlanAssetsDetails",
      "http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Plans",
        "label": "Pension Plan [Member]",
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits."
       }
      }
     },
     "auth_ref": [
      "r732",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r780",
      "r781",
      "r782",
      "r784",
      "r787",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r803",
      "r804",
      "r808",
      "r1399",
      "r1400",
      "r1404",
      "r1405",
      "r1406"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1488"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1498"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1491"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1487"
     ]
    },
    "us-gaap_PerformanceGuaranteeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PerformanceGuaranteeMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Guarantee",
        "label": "Performance Guarantee [Member]",
        "documentation": "An agreement (contract) that requires the guarantor to make payments to a guaranteed party based on another entity's failure to perform under an obligating agreement. This may include the issuance of a performance standby letter of credit which requires the guarantor to make payments if a specified party fails to perform under a nonfinancial contractual obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansFairValueofVestedRestrictedStockandSPSsDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansNarrativeDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinRestrictedStockAwardsandSPSsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SPSs",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "ci_PharmaceuticalManufacturerReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "PharmaceuticalManufacturerReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails": {
       "parentTag": "us-gaap_ReceivablesNetCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pharmaceutical manufacturer receivables",
        "label": "Pharmaceutical Manufacturer Receivable",
        "documentation": "Receivables due from pharmaceutical manufacturers related to rebate contracts."
       }
      }
     },
     "auth_ref": []
    },
    "ci_PharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "PharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails_1": {
       "parentTag": "ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pharmaceutical manufacturers receivable, including held for sale assets",
        "label": "Pharmaceutical Manufacturers Receivable Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Pharmaceutical Manufacturers Receivable Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_PharmacyAndServiceCostsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "PharmacyAndServiceCostsPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pharmacy and other service costs payable",
        "label": "Pharmacy And Service Costs Payable",
        "documentation": "Reflects amounts due to pharmacies for prescriptions filled through our retail network of pharmacies. Also includes amounts due to clients for their portion of rebates that must be contractually shared."
       }
      }
     },
     "auth_ref": []
    },
    "ci_PharmacyBenefitsManagementServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "PharmacyBenefitsManagementServicesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationFinancialandPerformanceGuaranteesDetails",
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pharmacy Benefits Management Services",
        "label": "Pharmacy Benefits Management Services [Member]",
        "documentation": "Pharmacy benefit management services provided to corporate client, other employer groups and their employees. These services include pharmacy home delivery, retail network administration and specialty pharmacy"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanAssetCategoriesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanAssetCategoriesDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionPensionPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]",
        "label": "Defined Benefit Plan, Plan Assets, Category [Domain]",
        "documentation": "Defined benefit plan asset investment."
       }
      }
     },
     "auth_ref": [
      "r757",
      "r758",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r784",
      "r1397",
      "r1398",
      "r1399"
     ]
    },
    "us-gaap_PolicyLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PolicyLoansMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Policy loans",
        "verboseLabel": "Policy loans",
        "label": "Policy Loans [Member]",
        "documentation": "Loan issued by an insurance company, collateralized by the cash value of the borrower's life insurance policy."
       }
      }
     },
     "auth_ref": [
      "r1776"
     ]
    },
    "us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Above guaranteed minimum crediting rate",
        "label": "Policyholder Account Balance, above Guaranteed Minimum Crediting Rate",
        "documentation": "Value above guaranteed minimum crediting rate on policyholder account balance."
       }
      }
     },
     "auth_ref": [
      "r1144",
      "r1423"
     ]
    },
    "us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Policyholder Account Balance, above Guaranteed Minimum Crediting Rate [Axis]",
        "label": "Policyholder Account Balance, above Guaranteed Minimum Crediting Rate [Axis]",
        "documentation": "Information by range above guaranteed minimum crediting rate on policyholder account balance."
       }
      }
     },
     "auth_ref": [
      "r1144",
      "r1423"
     ]
    },
    "ci_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Policyholder Account Balance, Above Guaranteed Minimum Crediting Rate, Based On Greater Of Guaranteed Minimum Cash Value Or Actual Cash Value",
        "label": "Policyholder Account Balance, Above Guaranteed Minimum Crediting Rate, Based On Greater Of Guaranteed Minimum Cash Value Or Actual Cash Value [Member]",
        "documentation": "Policyholder Account Balance, Above Guaranteed Minimum Crediting Rate, Based On Greater Of Guaranteed Minimum Cash Value Or Actual Cash Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Policyholder Account Balance, above Guaranteed Minimum Crediting Rate [Domain]",
        "label": "Policyholder Account Balance, above Guaranteed Minimum Crediting Rate [Domain]",
        "documentation": "Range above guaranteed minimum crediting rate on policyholder account balance."
       }
      }
     },
     "auth_ref": [
      "r1144",
      "r1423"
     ]
    },
    "us-gaap_PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Policyholder Account Balance, above Guaranteed Minimum Crediting Rate, Range from 0051 to 0150",
        "label": "Policyholder Account Balance, above Guaranteed Minimum Crediting Rate, Range from 0051 to 0150 [Member]",
        "documentation": "Range from 51 basis points to 150 basis points above guaranteed minimum crediting rate on policyholder account balance."
       }
      }
     },
     "auth_ref": [
      "r1423",
      "r1544"
     ]
    },
    "us-gaap_PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Policyholder Account Balance, at Guaranteed Minimum Crediting Rate",
        "label": "Policyholder Account Balance, at Guaranteed Minimum Crediting Rate [Member]",
        "documentation": "Range at zero basis point above guaranteed minimum crediting rate on policyholder account balance."
       }
      }
     },
     "auth_ref": [
      "r1423",
      "r1544"
     ]
    },
    "us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditRating": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PolicyholderAccountBalanceGuaranteedMinimumCreditRating",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guaranteed minimum credit rating",
        "label": "Policyholder Account Balance, Guaranteed Minimum Credit Rating",
        "documentation": "Guaranteed minimum crediting rate on policyholder account balance."
       }
      }
     },
     "auth_ref": [
      "r1144",
      "r1423"
     ]
    },
    "ci_PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractholder deposit funds not reinsured externally, percent with guaranteed interest rates of 0300 to 0400",
        "label": "Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Percentage",
        "documentation": "Percentage of policyholder account balance representing contract with guaranteed interest rates of 3%-4%."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Policyholder Account Balance, Guaranteed Minimum Crediting Rate Range [Axis]",
        "label": "Policyholder Account Balance, Guaranteed Minimum Crediting Rate Range [Axis]",
        "documentation": "Information by range of guaranteed minimum crediting rate on policyholder account balance."
       }
      }
     },
     "auth_ref": [
      "r1144",
      "r1423"
     ]
    },
    "us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Policyholder Account Balance, Guaranteed Minimum Crediting Rate Range [Domain]",
        "label": "Policyholder Account Balance, Guaranteed Minimum Crediting Rate Range [Domain]",
        "documentation": "Range of guaranteed minimum crediting rate on policyholder account balance."
       }
      }
     },
     "auth_ref": [
      "r1144",
      "r1423"
     ]
    },
    "us-gaap_PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400",
        "label": "Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 to 0399 [Member]",
        "documentation": "Range of guaranteed minimum crediting rate on policyholder account balance from 3.00 percent to 3.99 percent."
       }
      }
     },
     "auth_ref": [
      "r1544"
     ]
    },
    "us-gaap_PolicyholderAccountBalanceNetAmountAtRisk": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PolicyholderAccountBalanceNetAmountAtRisk",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net amount at risk",
        "label": "Policyholder Account Balance, Net Amount at Risk",
        "documentation": "Amount of guaranteed benefit in excess of current account balance of policyholder account balance."
       }
      }
     },
     "auth_ref": [
      "r1141",
      "r1423"
     ]
    },
    "ci_PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage with cash values at more than 110% of guaranteed cash value",
        "label": "Policyholder Account Balance, Percentage With Cash Values At More Than 110 Percent Of Guaranteed Cash Value",
        "documentation": "Policyholder Account Balance, Percentage With Cash Values At More Than 110 Percent Of Guaranteed Cash Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PolicyholderAccountBalanceWeightedAverageCreditingRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PolicyholderAccountBalanceWeightedAverageCreditingRate",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average crediting rate",
        "label": "Policyholder Account Balance, Weighted Average Crediting Rate",
        "documentation": "Weighted-average crediting rate for liability for policyholder account balance, calculated at a point in time."
       }
      }
     },
     "auth_ref": [
      "r1140",
      "r1423"
     ]
    },
    "us-gaap_PolicyholderAccountsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PolicyholderAccountsPolicy",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Separate Accounts",
        "label": "Policyholder Accounts, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for contracts reported in separate accounts, including the extent and terms of minimum guarantees, basis of presentation for separate account assets and liabilities and related separate account activity, the liability valuation method and assumptions used in valuing each type of policyholder and contract holder account maintained by the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PolicyholderBenefitsAndClaimsIncurredNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PolicyholderBenefitsAndClaimsIncurredNet",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_BenefitsLossesAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medical costs and other benefit expenses",
        "label": "Policyholder Benefits and Claims Incurred, Net",
        "documentation": "Amount, after effects of policies assumed or ceded, of expense related to the provision for policy benefits and costs incurred."
       }
      }
     },
     "auth_ref": [
      "r1763"
     ]
    },
    "us-gaap_PolicyholderBenefitsAndClaimsIncurredNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PolicyholderBenefitsAndClaimsIncurredNetAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceEffectsofReinsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total reinsurance recoveries",
        "label": "Policyholder Benefits and Claims Incurred, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_PolicyholderContractBalancePercentReinsuredExternally": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "PolicyholderContractBalancePercentReinsuredExternally",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractholder deposit fund liabilities, approximate percent reinsured externally",
        "label": "Policyholder Contract Balance, Percent Reinsured Externally",
        "documentation": "Policyholder Contract Balance, Percent Reinsured Externally"
       }
      }
     },
     "auth_ref": []
    },
    "ci_PolicyholderContractDepositCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "PolicyholderContractDepositCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "us-gaap_PolicyholderContractDeposits",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractholder deposit funds, current",
        "label": "Policyholder Contract Deposit, Current",
        "documentation": "Policyholder Contract Deposit, Current"
       }
      }
     },
     "auth_ref": []
    },
    "ci_PolicyholderContractDepositCurrentIncludingDisposalGroups": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "PolicyholderContractDepositCurrentIncludingDisposalGroups",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_PolicyholderContractDepositsIncludingDisposalGroups",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails_1": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractholder deposit funds, current, including held for sale liabilities",
        "label": "Policyholder Contract Deposit, Current Including Disposal Groups",
        "documentation": "Policyholder Contract Deposit, Current Including Disposal Groups"
       }
      }
     },
     "auth_ref": []
    },
    "ci_PolicyholderContractDepositNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "PolicyholderContractDepositNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractholder deposit funds, non-current",
        "label": "Policyholder Contract Deposit, Noncurrent",
        "documentation": "Policyholder Contract Deposit, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "ci_PolicyholderContractDepositNoncurrentIncludingDisposalGroups": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "PolicyholderContractDepositNoncurrentIncludingDisposalGroups",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractholder deposit funds, non-current, including liabilities held for sale",
        "label": "Policyholder Contract Deposit, Noncurrent Including Disposal Groups",
        "documentation": "Policyholder Contract Deposit, Noncurrent Including Disposal Groups"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PolicyholderContractDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PolicyholderContractDeposits",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_InsuranceAndContractholderLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Contractholder deposit funds",
        "terseLabel": "Contractholder deposit funds",
        "label": "Policyholder Contract Deposit",
        "documentation": "Amount of liability due to policyholder for deposit held under long-duration contract issued by insurance entity."
       }
      }
     },
     "auth_ref": [
      "r1768"
     ]
    },
    "ci_PolicyholderContractDepositsAttributableToDisposalGroups": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "PolicyholderContractDepositsAttributableToDisposalGroups",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractholder deposit funds classified as liabilities held for sale",
        "label": "Policyholder Contract Deposits Attributable To Disposal Groups",
        "documentation": "Policyholder Contract Deposits Attributable To Disposal Groups"
       }
      }
     },
     "auth_ref": []
    },
    "ci_PolicyholderContractDepositsIncludingDisposalGroups": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "PolicyholderContractDepositsIncludingDisposalGroups",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Contractholder deposit funds, including liabilities held for sale",
        "label": "Policyholder Contract Deposits Including Disposal Groups",
        "documentation": "Policyholder Contract Deposits Including Disposal Groups"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PolicyholderFunds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PolicyholderFunds",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractholder deposit funds not reinsured externally",
        "label": "Policyholder Account Balance",
        "documentation": "Amount due to policyholder. Includes, but is not limited to, unpaid policy dividend, retrospective refund, and undistributed earnings on participating business. Excludes future policy benefit and claim expense."
       }
      }
     },
     "auth_ref": [
      "r1139",
      "r1143",
      "r1144",
      "r1423",
      "r1750"
     ]
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValueDisclosuresforFinancialInstrumentsNotCarriedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Portion at Fair Value Measurement",
        "label": "Portion at Fair Value Measurement [Member]",
        "documentation": "Measured at fair value for financial reporting purposes."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.thecignagroup.com/role/CommonandPreferredStockShareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Par value of preferred stock (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r725"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.thecignagroup.com/role/CommonandPreferredStockShareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock authorized for issuance (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r1212"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.thecignagroup.com/role/CommonandPreferredStockShareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares of preferred stock outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r1212",
      "r1231",
      "r1785",
      "r1786"
     ]
    },
    "us-gaap_PremiumsEarnedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PremiumsEarnedNet",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails": {
       "parentTag": "ci_NonInvestmentRevenue",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/ReinsuranceEffectsofReinsuranceDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/ReinsuranceEffectsofReinsuranceDetails",
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Premiums",
        "totalLabel": "Total premiums",
        "label": "Premiums Earned, Net",
        "documentation": "Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r337",
      "r1123",
      "r1167"
     ]
    },
    "us-gaap_PremiumsReceivableAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PremiumsReceivableAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Premiums due",
        "label": "Premiums Receivable, Net",
        "documentation": "The carrying amount as of the balance sheet date due the entity from (a) agents and insureds, (b) uncollected premiums and (c) others, net of the allowance for doubtful accounts."
       }
      }
     },
     "auth_ref": [
      "r1756",
      "r1757",
      "r1758"
     ]
    },
    "us-gaap_PremiumsWrittenNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PremiumsWrittenNet",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceEffectsofReinsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written premiums",
        "label": "Premiums Written, Net",
        "documentation": "Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums written."
       }
      }
     },
     "auth_ref": [
      "r1534",
      "r1535"
     ]
    },
    "ci_PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "PretaxAdjustmentsToReconcileAdjustedIncomeFromOperationsAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-tax adjustments to reconcile to adjusted income from operations",
        "label": "Pretax Adjustments To Reconcile Adjusted Income From Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_PricingConcessionsAfterRemainingTermOfAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "PricingConcessionsAfterRemainingTermOfAgreementMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pricing Concessions After Remaining Term of Agreement",
        "label": "Pricing Concessions After Remaining Term Of Agreement [Member]",
        "documentation": "Pricing concessions sought in litigation for one year arfter contract termination."
       }
      }
     },
     "auth_ref": []
    },
    "ci_PricingConcessionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "PricingConcessionsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pricing Concessions",
        "label": "Pricing Concessions [Member]",
        "documentation": "Pricing Concessions"
       }
      }
     },
     "auth_ref": []
    },
    "ci_PricingConcessionsThroughRemainingContractTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "PricingConcessionsThroughRemainingContractTermMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pricing Concessions Through Remaining Contract Term",
        "label": "Pricing Concessions Through Remaining Contract Term [Member]",
        "documentation": "Pricing concessions sought in litigation for remainder of contract term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromCollectionOfLoansReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromCollectionOfLoansReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial mortgage loans",
        "label": "Proceeds from Collection of Loans Receivable",
        "documentation": "The cash inflow associated with the collection, including prepayments, of loans receivable issued for financing of goods and services."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromDivestitureOfBusinessesNetOfCashDivested",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Divestitures, net of cash sold",
        "label": "Proceeds from Divestiture of Businesses, Net of Cash Divested",
        "documentation": "This element represents the cash inflow during the period from the sale of a component of the entity."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds on issuance of long-term debt",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r1181"
     ]
    },
    "ci_ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtLongtermDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds",
        "label": "Proceeds From Issuance Of Long-term Debt, Net Of Discounts And Underwriting Fees",
        "documentation": "Proceeds From Issuance Of Long-term Debt, Net Of Discounts And Underwriting Fees"
       }
      }
     },
     "auth_ref": []
    },
    "ci_ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities and equity securities",
        "label": "Proceeds From Maturities Prepayments And Calls Of Debt And Equity Securities",
        "documentation": "Proceeds from maturities, repayments and calls of debt and equity securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other, net",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r1532",
      "r1572"
     ]
    },
    "us-gaap_ProceedsFromRepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRepaymentsOfDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings."
       }
      }
     },
     "auth_ref": []
    },
    "ci_ProceedsFromRepaymentsOfOtherShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ProceedsFromRepaymentsOfOtherShortTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net change in short-term debt",
        "label": "Proceeds From (Repayments Of) Other Short-Term Debt",
        "documentation": "Amount of cash outflow for principal payment on finance lease and the net proceeds from (repayments of) short-term debt, defined as borrowing having initial term of repayment of one year or less."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net change in amounts due to affiliates",
        "label": "Proceeds from (Repayments of) Related Party Debt",
        "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRepaymentsOfShortTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net change in short-term debt",
        "label": "Proceeds from (Repayments of) Short-Term Debt",
        "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from investments sold:",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfHeldToMaturitySecuritiesAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment maturities and repayments:",
        "label": "Proceeds from Sale and Maturity of Held-to-Maturity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfOtherInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other sales, maturities and repayments (primarily short-term and other long-term investments)",
        "label": "Proceeds from Sale and Maturity of Other Investments",
        "documentation": "The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsSalesInformationforAvailableforSaleDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r442",
      "r560",
      "r592"
     ]
    },
    "ci_ProceedsFromSaleOfDebtAndEquitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ProceedsFromSaleOfDebtAndEquitySecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities and equity securities",
        "label": "Proceeds From Sale Of Debt And Equity Securities",
        "documentation": "Proceeds from sales of debt and equity securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsExercisedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash received for options exercised",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r40"
     ]
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductConcentrationRiskMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product Concentration Risk",
        "label": "Product Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Pharmacy revenues",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r1394"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails",
      "http://www.thecignagroup.com/role/ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails",
      "http://www.thecignagroup.com/role/ReinsuranceEffectsofReinsuranceDetails",
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails",
      "http://www.thecignagroup.com/role/SegmentInformationFinancialandPerformanceGuaranteesDetails",
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails",
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r1038",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1360",
      "r1394",
      "r1415",
      "r1541",
      "r1638",
      "r1639",
      "r1649",
      "r1764"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails",
      "http://www.thecignagroup.com/role/ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails",
      "http://www.thecignagroup.com/role/ReinsuranceEffectsofReinsuranceDetails",
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails",
      "http://www.thecignagroup.com/role/SegmentInformationFinancialandPerformanceGuaranteesDetails",
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails",
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r1038",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1360",
      "r1394",
      "r1415",
      "r1541",
      "r1638",
      "r1639",
      "r1649",
      "r1764"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ci_ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiariesDetails",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income",
        "terseLabel": "Net income",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r427",
      "r430",
      "r445",
      "r454",
      "r475",
      "r487",
      "r488",
      "r512",
      "r532",
      "r538",
      "r541",
      "r602",
      "r683",
      "r684",
      "r686",
      "r687",
      "r688",
      "r690",
      "r692",
      "r694",
      "r695",
      "r894",
      "r897",
      "r898",
      "r927",
      "r949",
      "r1063",
      "r1096",
      "r1186",
      "r1233",
      "r1249",
      "r1250",
      "r1373",
      "r1411",
      "r1412",
      "r1443",
      "r1570",
      "r1643"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r1540",
      "r1631"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment classified as Assets of businesses held for sale",
        "label": "Property, Plant and Equipment Assets Held-for-Sale Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentNarrativeDetails",
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails": {
       "parentTag": "ci_PropertyPlantAndEquipmentGrossIncludingDisposalGroups",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r403",
      "r1093"
     ]
    },
    "ci_PropertyPlantAndEquipmentGrossIncludingDisposalGroups": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "PropertyPlantAndEquipmentGrossIncludingDisposalGroups",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails_1": {
       "parentTag": "ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cost",
        "label": "Property Plant And Equipment Gross Including Disposal Groups",
        "documentation": "Amount, including disposal groups, before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": []
    },
    "ci_PropertyPlantAndEquipmentIncludingAssetsHeldForSaleAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "PropertyPlantAndEquipmentIncludingAssetsHeldForSaleAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, including held for sale assets",
        "label": "Property, Plant And Equipment, Including Assets Held-For-Sale [Abstract]",
        "documentation": "Property, Plant And Equipment, Including Assets Held-For-Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails": {
       "parentTag": "ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net carrying value",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r1070",
      "r1093",
      "r1414"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total property and equipment",
        "label": "Property, Plant and Equipment, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_PropertyPlantAndEquipmentNetIncludingDisposalGroups": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "PropertyPlantAndEquipmentNetIncludingDisposalGroups",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Carrying Value",
        "label": "Property Plant And Equipment Net Including Disposal Groups",
        "documentation": "Amount, including disposal groups, after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentOtherTypesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentOtherTypesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and Equipment (including Computer Equipment)",
        "label": "Property, Plant and Equipment, Other Types [Member]",
        "documentation": "Long-lived, physical assets used to produce goods and services and not intended for resale, classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r330",
      "r332",
      "r1091"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentNarrativeDetails",
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful life, property, plant and equipment",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful life, leasehold improvements",
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r1629"
     ]
    },
    "ci_PrudentialInsuranceCompanyOfAmericaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "PrudentialInsuranceCompanyOfAmericaMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prudential Insurance Company of America",
        "label": "Prudential Insurance Company Of America [Member]",
        "documentation": "Prudential Insurance Company Of America"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r1486"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1486"
     ]
    },
    "us-gaap_QualifiedPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "QualifiedPlanMember",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Qualified Plan",
        "label": "Qualified Plan [Member]",
        "documentation": "Plan with tax-exempt status designed and operated in accordance with applicable tax provision of designated taxing authority. Taxing authority includes, but is not limited to, U.S. Internal Revenue Service (IRS). Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r1536",
      "r1651",
      "r1652",
      "r1653",
      "r1654",
      "r1655",
      "r1656",
      "r1657",
      "r1658",
      "r1659",
      "r1660",
      "r1661",
      "r1662",
      "r1663",
      "r1664",
      "r1665",
      "r1666",
      "r1667",
      "r1668",
      "r1669",
      "r1670",
      "r1671",
      "r1672",
      "r1673",
      "r1674",
      "r1675",
      "r1676",
      "r1677",
      "r1678",
      "r1679",
      "r1680",
      "r1681",
      "r1682",
      "r1683",
      "r1684",
      "r1685",
      "r1686",
      "r1687",
      "r1688",
      "r1689",
      "r1690",
      "r1691",
      "r1692",
      "r1693",
      "r1694",
      "r1695",
      "r1696",
      "r1697",
      "r1698",
      "r1699",
      "r1700",
      "r1701",
      "r1702",
      "r1703",
      "r1704",
      "r1705",
      "r1706",
      "r1707",
      "r1708",
      "r1709",
      "r1710"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansNarrativeDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsAdditionalInformationonSeparateAccountAssetsPricedatNetAssetValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails",
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentNarrativeDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails",
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoanPortfolioDetails",
      "http://www.thecignagroup.com/role/LeasesNarrativeDetails",
      "http://www.thecignagroup.com/role/VariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r673",
      "r674",
      "r675",
      "r676",
      "r757",
      "r806",
      "r839",
      "r840",
      "r841",
      "r1006",
      "r1033",
      "r1144",
      "r1201",
      "r1202",
      "r1259",
      "r1280",
      "r1285",
      "r1286",
      "r1326",
      "r1356",
      "r1357",
      "r1375",
      "r1393",
      "r1407",
      "r1423",
      "r1431",
      "r1632",
      "r1647",
      "r1743",
      "r1744",
      "r1745",
      "r1746",
      "r1747"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansNarrativeDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsAdditionalInformationonSeparateAccountAssetsPricedatNetAssetValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails",
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentNarrativeDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails",
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoanPortfolioDetails",
      "http://www.thecignagroup.com/role/LeasesNarrativeDetails",
      "http://www.thecignagroup.com/role/VariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r673",
      "r674",
      "r675",
      "r676",
      "r757",
      "r806",
      "r839",
      "r840",
      "r841",
      "r1006",
      "r1033",
      "r1144",
      "r1201",
      "r1202",
      "r1259",
      "r1280",
      "r1285",
      "r1286",
      "r1326",
      "r1356",
      "r1357",
      "r1375",
      "r1393",
      "r1407",
      "r1423",
      "r1431",
      "r1632",
      "r1647",
      "r1743",
      "r1744",
      "r1745",
      "r1746",
      "r1747"
     ]
    },
    "us-gaap_RealEstateFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RealEstateFundsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsAdditionalInformationonSeparateAccountAssetsPricedatNetAssetValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Real estate funds",
        "label": "Real Estate Funds [Member]",
        "documentation": "Investments in funds that invest in commercial or residential real estate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RealEstateInvestmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RealEstateInvestmentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Real estate investments",
        "label": "Real Estate Investment [Member]",
        "documentation": "This element represents direct equity investments in real estate projects (Land, buildings and improvements owned for income production and capital accretion potential) and certain loans accounted for as real estate investments. For loans accounted for as real estate investments, the entity (lender) has virtually the same risks and rewards as those of owners or joint venture participants. Such arrangements are treated as if the entity actually has an ownership interest in the property. In such arrangements, the entity (lender) participates in expected residual profits, which may be in the form of an equity kicker or a higher than usual effective interest rate. At the outset and during the construction and development of the property, the borrower generally has little or no equity in the property and the entity's (lender's) only source of repayment is the property. The entity (lender) generally (a) agrees to provide substantially all funds to acquire, develop, and construct the property, (b) funds the commitment or origination fees or both, and (c) funds interest during the development and construction of the property."
       }
      }
     },
     "auth_ref": [
      "r1337",
      "r1338",
      "r1339",
      "r1362"
     ]
    },
    "ci_RealEstateJointVenturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "RealEstateJointVenturesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/VariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Real estate joint ventures",
        "label": "Real Estate Joint Ventures [Member]",
        "documentation": "Real Estate Joint Ventures"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RealEstateLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RealEstateLoanMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoanPortfolioDetails",
      "http://www.thecignagroup.com/role/InvestmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Real Estate Loan",
        "label": "Real Estate Loan [Member]",
        "documentation": "Loan to finance the purchase of real estate, including but not limited to, land or building."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RealEstateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RealEstateMember",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionPensionPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Real estate funds, including pooled separate accounts",
        "label": "Real Estate [Member]",
        "documentation": "Property consisting of land, land improvement and buildings."
       }
      }
     },
     "auth_ref": [
      "r1650"
     ]
    },
    "us-gaap_RealizedGainLossOnInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RealizedGainLossOnInvestmentsTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Realized Gains and Losses on Investments",
        "label": "Realized Gain (Loss) on Investments [Table Text Block]",
        "documentation": "Tabular disclosure of realized gains and losses on investments reported in the statement of income."
       }
      }
     },
     "auth_ref": []
    },
    "ci_RealizedInvestmentGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "RealizedInvestmentGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      },
      "http://www.thecignagroup.com/role/InvestmentsRealizedGainsandLossesonInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/InvestmentsRealizedGainsandLossesonInvestmentsDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net realized investment (losses) gains",
        "negatedLabel": "Realized investment losses (gains), net",
        "totalLabel": "Net realized investment (losses) gains, before income taxes",
        "label": "Realized Investment Gain Loss",
        "documentation": "The net realized gains or (losses) on investments during the period, including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity."
       }
      }
     },
     "auth_ref": []
    },
    "ci_RealizedInvestmentGainLossExcludingImpairments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "RealizedInvestmentGainLossExcludingImpairments",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsRealizedGainsandLossesonInvestmentsDetails": {
       "parentTag": "ci_RealizedInvestmentGainLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsRealizedGainsandLossesonInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net realized investment (losses) gains, excluding credit loss expense and asset write-downs",
        "label": "Realized Investment Gain Loss Excluding Impairments",
        "documentation": "The net realized gains or (losses) on investments during the period before impairments, including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity."
       }
      }
     },
     "auth_ref": []
    },
    "ci_RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net realized investment (gains) losses",
        "label": "Realized Investment Gain Loss Including Equity Method Subsidiaries",
        "documentation": "The net realized gains or (losses) on investments during the period, including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity. Includes gains (losses) on investments held by equity method subsidiaries."
       }
      }
     },
     "auth_ref": []
    },
    "ci_RealizedInvestmentGainsLossesEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "RealizedInvestmentGainsLossesEquityMethodInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails": {
       "parentTag": "ci_SegmentRevenues",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net realized investment results from certain equity method investments",
        "label": "Realized Investment Gains Losses Equity Method Investments",
        "documentation": "Adjustment to exclude net realized gains (losses) from equity method subsidiaries (recorded in Other revenues) from Operating revenues."
       }
      }
     },
     "auth_ref": []
    },
    "ci_RealizedInvestmentLossesCommercialMortgageLoansRealEstateEntitiesCertainEquitySecuritiesWithNoReadilyDeterminableFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "RealizedInvestmentLossesCommercialMortgageLoansRealEstateEntitiesCertainEquitySecuritiesWithNoReadilyDeterminableFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueunderCertainConditionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Realized investment losses on assets measured at fair value under certain conditions, after-tax",
        "label": "Realized Investment Losses Commercial Mortgage Loans And Real Estate Entities With No Readily Determinable Fair Value",
        "documentation": "Realized investment losses on impaired real estate, partnership entities, commercial mortgage loans and certain equity securities with no readily determinable fair value, after-tax."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables [Abstract]",
        "label": "Receivables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails": {
       "parentTag": "ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails",
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "totalLabel": "Accounts receivable, net",
        "label": "Receivables, Net, Current",
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r1414"
     ]
    },
    "ci_ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Receivables, Net, Current Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Receivables, Net, Current Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": {
       "parentTag": "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Reclassification adjustment, before tax",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax",
        "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r434",
      "r955",
      "r960",
      "r961",
      "r1099",
      "r1568"
     ]
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails_1": {
       "parentTag": "ci_OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net amounts reclassified from AOCI to net income",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r73",
      "r434",
      "r955",
      "r960",
      "r961",
      "r1568"
     ]
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReclassificationFromAociCurrentPeriodTax",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": {
       "parentTag": "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification adjustment, tax",
        "label": "Reclassification from AOCI, Current Period, Tax",
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r426",
      "r433",
      "r1099"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesUncertainTaxPositionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1452",
      "r1464",
      "r1474",
      "r1500"
     ]
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Redeemable noncontrolling interests",
        "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount",
        "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r130"
     ]
    },
    "ci_RedeemableNoncontrollingInterestsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "RedeemableNoncontrollingInterestsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable Noncontrolling Interest",
        "label": "Redeemable Noncontrolling Interests Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for noncontrolling shareholders' preferred and common stock interests of consolidated, less than fully owned subsidiaries."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReinsuranceAccountingPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReinsuranceAccountingPolicy",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reinsurance",
        "label": "Reinsurance Accounting Policy [Policy Text Block]",
        "documentation": "Disclosure of reinsurance accounting policy, for example, but not limited to, description of the methodologies and assumptions underlying determination of reinsurance recoverables, reinsurance payables and retention policy."
       }
      }
     },
     "auth_ref": [
      "r1425",
      "r1426"
     ]
    },
    "us-gaap_ReinsuranceDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReinsuranceDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reinsurance Disclosures [Abstract]",
        "label": "Reinsurance Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceEffectsofReinsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total reinsurance recoveries",
        "label": "Policyholder Benefits and Claims Incurred, Ceded",
        "documentation": "Amount of reduction of provision for policy benefits and costs incurred for policies ceded."
       }
      }
     },
     "auth_ref": [
      "r1748",
      "r1763"
     ]
    },
    "us-gaap_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReinsurancePremiumsForInsuranceCompaniesByProductSegmentNetAmountAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceEffectsofReinsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Premiums",
        "label": "Premiums Earned, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReinsuranceReceivablesIncurredButNotReportedClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReinsuranceReceivablesIncurredButNotReportedClaims",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incurred but not yet paid and outstanding claims",
        "label": "Reinsurance Recoverables, Incurred but Not Reported Claims",
        "documentation": "Estimated amount after valuation allowance of reinsurance recoverables, due from reinsurers for incurred claims not yet reported, and claims settlement expenses."
       }
      }
     },
     "auth_ref": [
      "r1766",
      "r1767"
     ]
    },
    "ci_ReinsuranceRecoverableAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ReinsuranceRecoverableAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails": {
       "parentTag": "ci_ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Allowance for uncollectible reinsurance, including assets held for sale",
        "label": "Reinsurance Recoverable, Allowance for Credit Loss, Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Reinsurance Recoverable, Allowance for Credit Loss, Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails": {
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Less: Reinsurance and other amounts recoverable",
        "periodEndLabel": "Add: Reinsurance and other amounts recoverable",
        "label": "Reinsurance Recoverable for Unpaid Claims and Claims Adjustments",
        "documentation": "Amount, after valuation allowance, recoverable under reinsurance contracts for losses reported to the ceding insurer but not yet paid and amounts expected for incurred losses and settlement expenses, which have not yet been reported to the ceding insurer."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r309",
      "r1749",
      "r1766",
      "r1767"
     ]
    },
    "ci_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails": {
       "parentTag": "ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Less: Reinsurance, including held for sale liabilities",
        "periodEndLabel": "Add: Reinsurance, including held for sale liabilities",
        "terseLabel": "Reinsurance and other amounts recoverable, including assets held for sale",
        "label": "Reinsurance Recoverable For Unpaid Claims And Claims Adjustments Including Disposal Groups",
        "documentation": "Reinsurance Recoverable For Unpaid Claims And Claims Adjustments Including Disposal Groups"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReinsuranceRecoverables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReinsuranceRecoverables",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reinsurance recoverables",
        "label": "Reinsurance Recoverables, Including Reinsurance Premium Paid",
        "documentation": "Amount, after valuation allowance, recoverable under reinsurance contracts including premium paid under reinsurance contracts. Examples include, but are not limited to, settled and unsettled claims, incurred but not reported losses, loss adjustment expense, premium paid, policy benefits and policy reserves."
       }
      }
     },
     "auth_ref": [
      "r1749",
      "r1759",
      "r1765"
     ]
    },
    "ci_ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails": {
       "parentTag": "ci_ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reinsurance recoverables before market risk benefits, including assets held for sale",
        "label": "Reinsurance Recoverables, Gross, Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Reinsurance Recoverables, Gross, Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total reinsurance recoverables, including assets held for sale",
        "label": "Reinsurance Recoverables, Including Reinsurance Premium Paid, Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Reinsurance Recoverables, Including Reinsurance Premium Paid, Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_ReinsuranceRecoverablesLiabilityForFuturePolicyBenefitsAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ReinsuranceRecoverablesLiabilityForFuturePolicyBenefitsAssetsHeldForSale",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future policy benefits reserve, reinsurance recoverables reported in assets of businesses held for sale",
        "label": "Reinsurance Recoverables, Liability For Future Policy Benefits, Assets Held-For-Sale",
        "documentation": "Reinsurance Recoverables, Liability For Future Policy Benefits, Assets Held-For-Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_ReinsuranceRecoverablesNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ReinsuranceRecoverablesNonCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reinsurance recoverables",
        "label": "Reinsurance Recoverables, Noncurrent",
        "documentation": "Amount, after valuation allowance, recoverable after one year under reinsurance contracts including premium paid under reinsurance contracts. Examples include, but are not limited to, settled and unsettled claims, incurred but not reported losses, loss adjustment expense, premium paid, policy benefits and policy reserves."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReinsuranceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReinsuranceTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/Reinsurance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reinsurance",
        "label": "Reinsurance [Text Block]",
        "documentation": "The entire disclosure pertaining to the existence, magnitude and information about insurance that has been ceded to or assumed from another insurance company, including the methodologies and assumptions used in determining recorded amounts."
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1072",
      "r1425",
      "r1426"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupIntercompanyBalancesDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r994",
      "r995",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1230",
      "r1232",
      "r1255"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupIntercompanyBalancesDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r457",
      "r994",
      "r995",
      "r996",
      "r997",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1230",
      "r1232",
      "r1255"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupIntercompanyBalancesDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r994",
      "r995",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1230",
      "r1232",
      "r1255",
      "r1739"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.thecignagroup.com/role/DebtLongtermDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of long-term debt",
        "terseLabel": "Repayment of long-term debt",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r1182"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails",
      "http://www.thecignagroup.com/role/DescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]",
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r459",
      "r700",
      "r726",
      "r997",
      "r1366",
      "r1367"
     ]
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity",
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revision of Prior Period [Axis]",
        "label": "Revision of Prior Period [Axis]",
        "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r471",
      "r472",
      "r473",
      "r475",
      "r476",
      "r479",
      "r480",
      "r481",
      "r482",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r506",
      "r608",
      "r609",
      "r882",
      "r921",
      "r925",
      "r926",
      "r927",
      "r969",
      "r992",
      "r993",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1175"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1453",
      "r1465",
      "r1475",
      "r1501"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r1454",
      "r1466",
      "r1476",
      "r1502"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1461",
      "r1473",
      "r1483",
      "r1509"
     ]
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity",
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revision of Prior Period [Domain]",
        "label": "Revision of Prior Period [Domain]",
        "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r471",
      "r472",
      "r473",
      "r475",
      "r476",
      "r479",
      "r480",
      "r481",
      "r482",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r506",
      "r608",
      "r609",
      "r882",
      "r921",
      "r925",
      "r926",
      "r927",
      "r969",
      "r992",
      "r993",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1175"
     ]
    },
    "ci_RestrictedStockGrantsAndUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "RestrictedStockGrantsAndUnitsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansFairValueofVestedRestrictedStockandSPSsDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansNarrativeDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinRestrictedStockAwardsandSPSsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Grants and Units",
        "label": "Restricted Stock Grants And Units [Member]",
        "documentation": "Restricted stock grants are the most widely used form of restricted stock awards and are used for substantially all US based employees receiving such awards. Recipients of restricted stock grants are entitled to earn dividends and to vote during the vesting period, but forfeit their awards if their employment terminates before the vesting date. Awards of restricted stock units are generally limited to international employees. A restricted stock unit represents a right to receive a common share of stock when the unit vests. Recipients of restricted stock units are entitled to receive hypothetical dividends, but cannot vote during the vesting period. They forfeit their units if their employment terminates before the vesting date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and Related Activities [Abstract]",
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/OrganizationalEfficiencyPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organizational Efficiency Plan",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r660",
      "r661",
      "r662",
      "r664",
      "r669"
     ]
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails": {
       "parentTag": "ci_SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 5.0
      },
      "http://www.thecignagroup.com/role/OrganizationalEfficiencyPlanDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/OrganizationalEfficiencyPlanDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Charge for organizational efficiency plan recorded in Selling, general and administrative expenses, pre-tax",
        "terseLabel": "Charge for organizational efficiency plan (Selling, general and administrative expenses)",
        "verboseLabel": "Charge for organizational efficiency plan",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r665",
      "r667",
      "r1633"
     ]
    },
    "ci_RestructuringChargesNetOfTaxExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "RestructuringChargesNetOfTaxExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails": {
       "parentTag": "ci_SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/OrganizationalEfficiencyPlanDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Charge for organizational efficiency plan recorded in Selling, general and administrative expenses, after-tax",
        "terseLabel": "Charge for organizational efficiency plan, after-tax (Selling, general and administrative expenses)",
        "label": "Restructuring Charges, Net Of Tax Expense",
        "documentation": "Restructuring Charges, Net Of Tax Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/OrganizationalEfficiencyPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Restructuring Reserve, Beginning Balance",
        "periodEndLabel": "Restructuring Reserve, Ending Balance",
        "label": "Restructuring Reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r662",
      "r666"
     ]
    },
    "us-gaap_RestructuringReserveRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringReserveRollForward",
     "presentation": [
      "http://www.thecignagroup.com/role/OrganizationalEfficiencyPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Reserve [Roll Forward]",
        "label": "Restructuring Reserve [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained earnings",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r272",
      "r1087",
      "r1154",
      "r1159",
      "r1183",
      "r1213",
      "r1414"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained Earnings",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r471",
      "r472",
      "r473",
      "r476",
      "r486",
      "r488",
      "r607",
      "r613",
      "r848",
      "r849",
      "r850",
      "r881",
      "r882",
      "r908",
      "r911",
      "r912",
      "r915",
      "r925",
      "r1150",
      "r1152",
      "r1187",
      "r1785"
     ]
    },
    "us-gaap_RetainedEarningsUndistributedEarningsFromEquityMethodInvestees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsUndistributedEarningsFromEquityMethodInvestees",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ShareholdersEquityandDividendRestrictionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Undistributed earnings from equity method subidiaries",
        "label": "Retained Earnings, Undistributed Earnings from Equity Method Investees",
        "documentation": "Amount of consolidated retained earnings that represent undistributed (not yet received) earnings from 50 percent or less owned persons accounted for by the equity method (equity method investees)."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "ci_RetirementAndLifeInsuranceContractsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "RetirementAndLifeInsuranceContractsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retiree and Life Insurance Benefits",
        "label": "Retirement And Life Insurance Contracts [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetirementPlanTaxStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetirementPlanTaxStatusAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Tax Status [Axis]",
        "label": "Retirement Plan Tax Status [Axis]",
        "documentation": "Information by tax status of plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r1536",
      "r1651",
      "r1652",
      "r1653",
      "r1654",
      "r1655",
      "r1656",
      "r1657",
      "r1658",
      "r1659",
      "r1660",
      "r1661",
      "r1662",
      "r1663",
      "r1664",
      "r1665",
      "r1666",
      "r1667",
      "r1668",
      "r1669",
      "r1670",
      "r1671",
      "r1672",
      "r1673",
      "r1674",
      "r1675",
      "r1676",
      "r1677",
      "r1678",
      "r1679",
      "r1680",
      "r1681",
      "r1682",
      "r1683",
      "r1684",
      "r1685",
      "r1686",
      "r1687",
      "r1688",
      "r1689",
      "r1690",
      "r1691",
      "r1692",
      "r1693",
      "r1694",
      "r1695",
      "r1696",
      "r1697",
      "r1698",
      "r1699",
      "r1700",
      "r1701",
      "r1702",
      "r1703",
      "r1704",
      "r1705",
      "r1706",
      "r1707",
      "r1708",
      "r1709",
      "r1710"
     ]
    },
    "us-gaap_RetirementPlanTaxStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetirementPlanTaxStatusDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Tax Status [Domain]",
        "label": "Retirement Plan Tax Status [Domain]",
        "documentation": "Tax status of plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r1536",
      "r1651",
      "r1652",
      "r1653",
      "r1654",
      "r1655",
      "r1656",
      "r1657",
      "r1658",
      "r1659",
      "r1660",
      "r1661",
      "r1662",
      "r1663",
      "r1664",
      "r1665",
      "r1666",
      "r1667",
      "r1668",
      "r1669",
      "r1670",
      "r1671",
      "r1672",
      "r1673",
      "r1674",
      "r1675",
      "r1676",
      "r1677",
      "r1678",
      "r1679",
      "r1680",
      "r1681",
      "r1682",
      "r1683",
      "r1684",
      "r1685",
      "r1686",
      "r1687",
      "r1688",
      "r1689",
      "r1690",
      "r1691",
      "r1692",
      "r1693",
      "r1694",
      "r1695",
      "r1696",
      "r1697",
      "r1698",
      "r1699",
      "r1700",
      "r1701",
      "r1702",
      "r1703",
      "r1704",
      "r1705",
      "r1706",
      "r1707",
      "r1708",
      "r1709",
      "r1710"
     ]
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetirementPlanTypeAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValuesofSeparateAccountAssetsDetails",
      "http://www.thecignagroup.com/role/PensionAmountsIncludedinAccumulatedOtherComprehensiveIncomeDetails",
      "http://www.thecignagroup.com/role/PensionAssumptionsUsedforPensionDetails",
      "http://www.thecignagroup.com/role/PensionBenefitPaymentsDetails",
      "http://www.thecignagroup.com/role/PensionNarrativeDetails",
      "http://www.thecignagroup.com/role/PensionNetPensionCostDetails",
      "http://www.thecignagroup.com/role/PensionPensionPlanAssetsDetails",
      "http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Type [Axis]",
        "label": "Retirement Plan Type [Axis]",
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r732",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r780",
      "r781",
      "r782",
      "r784",
      "r787",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r803",
      "r804",
      "r805",
      "r808",
      "r1399",
      "r1400",
      "r1401",
      "r1402",
      "r1403",
      "r1404",
      "r1405",
      "r1406"
     ]
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetirementPlanTypeDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValuesofSeparateAccountAssetsDetails",
      "http://www.thecignagroup.com/role/PensionAmountsIncludedinAccumulatedOtherComprehensiveIncomeDetails",
      "http://www.thecignagroup.com/role/PensionAssumptionsUsedforPensionDetails",
      "http://www.thecignagroup.com/role/PensionBenefitPaymentsDetails",
      "http://www.thecignagroup.com/role/PensionNarrativeDetails",
      "http://www.thecignagroup.com/role/PensionNetPensionCostDetails",
      "http://www.thecignagroup.com/role/PensionPensionPlanAssetsDetails",
      "http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Type [Domain]",
        "label": "Retirement Plan Type [Domain]",
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r732",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r780",
      "r781",
      "r782",
      "r784",
      "r787",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r803",
      "r804",
      "r805",
      "r808",
      "r1399",
      "r1400",
      "r1401",
      "r1402",
      "r1403",
      "r1404",
      "r1405",
      "r1406"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails": {
       "parentTag": "ci_NonInvestmentRevenue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r514",
      "r531",
      "r536",
      "r537",
      "r543",
      "r545",
      "r547",
      "r729",
      "r730",
      "r1038"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r1234",
      "r1358",
      "r1370"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails": {
       "parentTag": "ci_SegmentRevenues",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiariesDetails",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL REVENUES",
        "terseLabel": "Revenues",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r454",
      "r513",
      "r514",
      "r531",
      "r536",
      "r537",
      "r543",
      "r545",
      "r547",
      "r602",
      "r683",
      "r684",
      "r686",
      "r687",
      "r688",
      "r690",
      "r692",
      "r694",
      "r695",
      "r949",
      "r1063",
      "r1643"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_RevenuesFromExternalCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "RevenuesFromExternalCustomersMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationUSandForeignRevenuesfromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues from external customers",
        "label": "Revenues From External Customers [Member]",
        "documentation": "Revenues From External Customers"
       }
      }
     },
     "auth_ref": []
    },
    "ci_RevenuesIncludingNetInvestmentIncomeBenchmarkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "RevenuesIncludingNetInvestmentIncomeBenchmarkMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationUSandForeignRevenuesfromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenues, Including Net Investment Income Benchmark [Member]",
        "documentation": "Revenues, Including Net Investment Income Benchmark"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity",
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revision of Prior Period, Accounting Standards Update, Adjustment",
        "label": "Revision of Prior Period, Accounting Standards Update, Adjustment [Member]",
        "documentation": "Cumulative increase (decrease) to previously issued financial statements for retrospective application of amendment to accounting standards and adjustment for reclassification from amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r475",
      "r476",
      "r482",
      "r489",
      "r608",
      "r609",
      "r882",
      "r921",
      "r927",
      "r969",
      "r992",
      "r993",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159"
     ]
    },
    "ci_RevolvingCreditAgreementsApril2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "RevolvingCreditAgreementsApril2023Member",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtShorttermandCreditFacilitiesDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving credit agreements, April 2023",
        "label": "Revolving Credit Agreements April 2023 [Member]",
        "documentation": "Revolving credit agreements entered into in April 2023"
       }
      }
     },
     "auth_ref": []
    },
    "ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtShorttermandCreditFacilitiesDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving Credit And Letter Of Credit Facility Maturing April 2027",
        "label": "Revolving Credit And Letter Of Credit Facility Maturing April 2027 [Member]",
        "documentation": "Revolving Credit And Letter Of Credit Facility Maturing April 2027"
       }
      }
     },
     "auth_ref": []
    },
    "ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027RevolvingCreditFacilityMaturingApril2025And364DayRevolvingCreditAgreementMaturingApril2023Member",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtShorttermandCreditFacilitiesDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving credit agreements, April 2022",
        "label": "Revolving Credit And Letter Of Credit Facility Maturing April 2027, Revolving Credit Facility Maturing April 2025, And 364 Day Revolving Credit Agreement, Maturing April 2023 [Member]",
        "documentation": "Revolving Credit And Letter Of Credit Facility Maturing April 2027, Revolving Credit Facility Maturing April 2025, And 364 Day Revolving Credit Agreement, Maturing April 2023"
       }
      }
     },
     "auth_ref": []
    },
    "ci_RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtShorttermandCreditFacilitiesDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Five-year Revolving Credit Agreement, Maturing April 2028",
        "label": "Revolving Credit And Letter Of Credit Facility Maturing April 2028 [Member]",
        "documentation": "Revolving Credit And Letter Of Credit Facility Maturing April 2028"
       }
      }
     },
     "auth_ref": []
    },
    "ci_RevolvingCreditFacilityMaturingApril2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "RevolvingCreditFacilityMaturingApril2025Member",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtShorttermandCreditFacilitiesDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShorttermandCreditFacilitiesDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving Credit Facility Maturing April 2025",
        "label": "Revolving Credit Facility Maturing April 2025 [Member]",
        "documentation": "Revolving Credit Facility Maturing April 2025"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesSupplementalCashFlowInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance leases",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r985",
      "r1413"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesSupplementalCashFlowInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r985",
      "r1413"
     ]
    },
    "ci_RightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "RightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesSupplementalCashFlowInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ROU assets obtained in exchange for lease obligations:",
        "label": "Right-Of-Use Assets Obtained In Exchange For Lease Liabilities [Abstract]",
        "documentation": "Right-Of-Use Assets Obtained In Exchange For Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1518"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1518"
     ]
    },
    "ci_SCORSEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "SCORSEMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SCOR SE",
        "label": "SCOR SE [Member]",
        "documentation": "SCOR SE"
       }
      }
     },
     "auth_ref": []
    },
    "ci_SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "SEC Schedule, 12-09, Allowance, Credit Loss, Uncollectible Premium Receivables, And Financing Receivables [Member]",
        "documentation": "SEC Schedule, 12-09, Allowance, Credit Loss, Uncollectible Premium Receivables, And Financing Receivables"
       }
      }
     },
     "auth_ref": []
    },
    "ci_SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available-for-sale debt securities",
        "label": "SEC Schedule, 12-09, Allowance, Investment Valuation Reserves, Available-For-Sale Debt Securities [Member]",
        "documentation": "SEC Schedule, 12-09, Allowance, Investment Valuation Reserves, Available-For-Sale Debt Securities"
       }
      }
     },
     "auth_ref": []
    },
    "ci_SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial mortgage loans",
        "label": "SEC Schedule, 12-09, Allowance, Investment Valuation Reserves, Commercial Mortgage Loans [Member]",
        "documentation": "SEC Schedule, 12-09, Allowance, Investment Valuation Reserves, Commercial Mortgage Loans"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuesfromUSFederalGovernmentAgenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r547",
      "r1537"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtLongtermDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast",
        "label": "Forecast [Member]",
        "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact."
       }
      }
     },
     "auth_ref": [
      "r807",
      "r1558",
      "r1591"
     ]
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioPreviouslyReportedMember",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Previously Reported",
        "label": "Previously Reported [Member]",
        "documentation": "Represents amount as previously reported before adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r471",
      "r473",
      "r475",
      "r476",
      "r479",
      "r480",
      "r488",
      "r506",
      "r882",
      "r921",
      "r925",
      "r926",
      "r969",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1175",
      "r1539",
      "r1542",
      "r1543",
      "r1545",
      "r1590",
      "r1610",
      "r1611",
      "r1726",
      "r1735",
      "r1736"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtLongtermDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Domain]",
        "label": "Scenario [Domain]",
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r489",
      "r807",
      "r1527",
      "r1591"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetAmountsIncludedinAccountsReceivableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/AccountsReceivableNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable, Net",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in the Components of AOCI",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r1730",
      "r1731"
     ]
    },
    "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Pension Assets by Category",
        "label": "Schedule of Allocation of Plan Assets [Table Text Block]",
        "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Postretirement Benefits Liability Adjustment Included in AOCI",
        "label": "Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the net gain (loss) and net prior service cost or credit recognized in other comprehensive income (loss) for the period for pension plans and/or other employee benefit plans, and reclassification adjustments of other comprehensive income (loss) for the period, as those amounts, including amortization of the net transition asset or obligation, are recognized as components of net periodic benefit cost."
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareOutstandingEmployeeStockOptionsNotIncludedintheComputationofDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Employee Stock Options Not Included in the Computation of Diluted Earnings Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assumptions Used for Pension",
        "label": "Defined Benefit Plan, Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails",
      "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573"
     ]
    },
    "us-gaap_ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variances in Incurred Costs Related to Prior Years' Unpaid Claims and Claims Expenses",
        "label": "Schedule of Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the reasons for the change in incurred claims and claim adjustment expenses recognized in the income statement attributable to insured events of prior fiscal years. Also includes disclosures of additional premiums or return premiums accrued as a result of changes in incurred claims and claim adjustment expenses."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r311"
     ]
    },
    "us-gaap_ScheduleOfCededCreditRiskByReinsurerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCededCreditRiskByReinsurerTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reinsurance Recoverables by Range of External Credit Rating and Collateral Level",
        "label": "Ceded Credit Risk [Table Text Block]",
        "documentation": "Tabular disclosure of reinsurer or group of reinsurers for whom the entity has a concentration of credit risk."
       }
      }
     },
     "auth_ref": [
      "r1538"
     ]
    },
    "ci_ScheduleOfCommonStockByClassScheduleOfPreferredStockByClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ScheduleOfCommonStockByClassScheduleOfPreferredStockByClassTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/CommonandPreferredStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common and Preferred Stock",
        "label": "Schedule Of Common Stock By Class Schedule Of Preferred Stock By Class [Text Block]",
        "documentation": "This element may be used to capture the complete disclosure pertaining to an entity's common stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation. B Preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued and outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of Income Tax Expense",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "srt_ScheduleOfCondensedFinancialStatementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfCondensedFinancialStatementsTable",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupIntercompanyBalancesDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Financial Statements [Table]",
        "label": "Condensed Financial Statements [Table]",
        "documentation": "Disclosure of information about condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r386",
      "r387",
      "r388",
      "r461",
      "r1528"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Income Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionAmountsIncludedinAccumulatedOtherComprehensiveIncomeDetails",
      "http://www.thecignagroup.com/role/PensionAssumptionsUsedforPensionDetails",
      "http://www.thecignagroup.com/role/PensionBenefitPaymentsDetails",
      "http://www.thecignagroup.com/role/PensionNarrativeDetails",
      "http://www.thecignagroup.com/role/PensionNetPensionCostDetails",
      "http://www.thecignagroup.com/role/PensionPensionPlanAssetsDetails",
      "http://www.thecignagroup.com/role/PensionProjectedBenefitObligationsandAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r140",
      "r141",
      "r142",
      "r143"
     ]
    },
    "ci_ScheduleOfDepreciationAndAmortizationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ScheduleOfDepreciationAndAmortizationTable",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentComponentsofDepreciationandAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Depreciation And Amortization [Table]",
        "label": "Schedule Of Depreciation And Amortization [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDerivativeInstrumentsTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Derivative Instruments Held",
        "label": "Schedule of Derivative Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r170",
      "r171",
      "r172",
      "r175",
      "r178",
      "r181",
      "r183",
      "r185"
     ]
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets and Liabilities of Business Held for Sale",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r42",
      "r57",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r265"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computation of Basic and Diluted Earnings Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1592"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Total Income Taxes to the Amount Computed Using the Nominal Federal Income Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Cost and Tax Effects of Share-based Compensation",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from External Customers by Products and Services [Table]",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from External Customers",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiariesDetails",
      "http://www.thecignagroup.com/role/InvestmentsNarrativeDetails",
      "http://www.thecignagroup.com/role/MergersAcquisitionsandDivestituresNarrativeDetails",
      "http://www.thecignagroup.com/role/VariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Axis]",
        "label": "Investment, Name [Axis]",
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r598",
      "r599",
      "r601"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Equity Method Investments [Line Items]",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r598",
      "r599",
      "r601",
      "r602",
      "r949"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "presentation": [
      "http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Equity Method Investments [Table]",
        "label": "Schedule of Equity Method Investments [Table]",
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r454",
      "r598",
      "r599",
      "r601",
      "r602",
      "r949"
     ]
    },
    "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Benefit Payments",
        "label": "Schedule of Expected Benefit Payments [Table Text Block]",
        "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoanPortfolioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Receivable, Credit Quality Indicator [Table]",
        "label": "Financing Receivable, Credit Quality Indicator [Table]",
        "documentation": "Disclosure of information about credit quality indicator for financing receivable."
       }
      }
     },
     "auth_ref": [
      "r1383",
      "r1613"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r116",
      "r1039"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Finite-Lived Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r116"
     ]
    },
    "ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Line Items]",
        "label": "Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Line Items]",
        "documentation": "Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "ci_ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ScheduleOfGoodwillOtherIntangibleAssetsAndPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Table]",
        "label": "Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Table]",
        "documentation": "Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfGoodwillTable",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentGoodwillActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Goodwill [Table]",
        "label": "Schedule of Goodwill [Table]",
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons."
       }
      }
     },
     "auth_ref": [
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r1386"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill Activity",
        "label": "Schedule of Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r1386",
      "r1618",
      "r1619",
      "r1620",
      "r1621",
      "r1622",
      "r1623",
      "r1624",
      "r1625",
      "r1626",
      "r1627",
      "r1628"
     ]
    },
    "us-gaap_ScheduleOfGuaranteeObligationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfGuaranteeObligationsTable",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupGuaranteesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Guarantor Obligations [Table]",
        "label": "Schedule of Guarantor Obligations [Table]",
        "documentation": "Tabular disclosure about the type or nature of guarantees, for example performance, indemnification, payment and other guarantees, and related information such as term, origin and purpose, triggering event, maximum exposure, and carrying value. Represents the guarantor's disclosures which include the information about each guarantee, or each group of similar guarantees, even if the likelihood of the guarantor's need to make any payments under the guarantee is remote. This excludes disclosures for product warranties."
       }
      }
     },
     "auth_ref": [
      "r679",
      "r680",
      "r681",
      "r682"
     ]
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Indefinite-Lived Intangible Assets",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r259"
     ]
    },
    "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Investment Income [Line Items]",
        "label": "Net Investment Income [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsComponentsofNetInvestmentIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Income [Table]",
        "label": "Investment Income [Table]",
        "documentation": "Disclosure of information about investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r1100"
     ]
    },
    "us-gaap_ScheduleOfInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInvestmentsLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoanPortfolioDetails",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails",
      "http://www.thecignagroup.com/role/InvestmentsNarrativeDetails",
      "http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investments [Line Items]",
        "label": "Schedule of Investments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1277",
      "r1279",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1289",
      "r1290",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335"
     ]
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInvestmentsTable",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails",
      "http://www.thecignagroup.com/role/InvestmentsNarrativeDetails",
      "http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investments [Table]",
        "label": "Schedule of Investments [Table]",
        "documentation": "Disclosure of information about investments owned by investment company."
       }
      }
     },
     "auth_ref": [
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1277",
      "r1279",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1289",
      "r1290",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1317",
      "r1318",
      "r1319",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335"
     ]
    },
    "ci_ScheduleOfIssuancesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ScheduleOfIssuancesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Debt Issuances",
        "label": "Schedule Of Issuances Of Long-Term Debt [Table Text Block]",
        "documentation": "Schedule Of Issuances Of Long-Term Debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of Insurance and Contractholder Liabilities, Activity in the Unpaid Claims Liability and Liability Details for Unpaid Claims and Claim Expenses",
        "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Long-Term Debt",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Account Value, Net Amount at Risk and the Number of Contractholders for Guarantees Assumed in the Event of Death",
        "label": "Schedule of Net Amount of Risk by Product and Guarantee [Table Text Block]",
        "documentation": "Tabular disclosure of the guaranteed benefits in excess of the current account balance, quantifies such excesses (the net amounts at risk) and includes other relevant, pertinent information as of the most recent balance sheet date by product type."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r324"
     ]
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of Net Pension Cost",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "us-gaap_ScheduleOfNetFundedStatusTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNetFundedStatusTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/PensionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of the Projected Benefit Obligations and Assets Related to Pension Plans",
        "label": "Schedule of Net Funded Status [Table Text Block]",
        "documentation": "Tabular disclosure of net funded status of pension plans and/or other employee benefit plans."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ci_ScheduleOfOtherLongTermInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ScheduleOfOtherLongTermInvestmentsTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying Value Information for Other Long-Term Investments",
        "label": "Schedule Of Other Long-Term Investments [Table Text Block]",
        "documentation": "Schedule Of Other Long-Term Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/OrganizationalEfficiencyPlanTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rollforward of Accrued Liability",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r121"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign and U.S. Revenues from External Customers",
        "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]",
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r244"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r111"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summarized Segment Financial Information",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r111"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansBlackScholesOptionPricingModelAssumptionsDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansFairValueofVestedRestrictedStockandSPSsDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansNarrativeDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinCommonStockOptionsDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinRestrictedStockAwardsandSPSsDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsExercisedDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsOutstandingDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShareRepurchaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r810",
      "r811",
      "r814",
      "r815",
      "r816",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Information for Stock Options Exercised and Outstanding",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r146"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Black-Sholes Option-Pricing Model Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Status of and Changes in Restricted Stock Awards and the Fair Value of Vested Restricted Stock",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "ci_ScheduleOfShortTermDebtLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ScheduleOfShortTermDebtLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Amounts of Debt and Finance Leases",
        "label": "Schedule Of Short Term Debt Long Term Debt [Table Text Block]",
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance-sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation. Also, Pertinent information about each long-term debt arrangement including the carrying amount as of the balance sheet date, by type of long-term debt. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "ci_ScheduleOfSpecialItemsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ScheduleOfSpecialItemsTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Special Items",
        "label": "Schedule Of Special Items [Table Text Block]",
        "documentation": "Schedule of pre- and after-tax amounts reported as special items, attributable to the parent. Special items are amounts that management does not believe are representative of underlying results of operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/CommonandPreferredStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Activity",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r126",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r233",
      "r234",
      "r270",
      "r271",
      "r272"
     ]
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Status of and Changes in Common Stock Options",
        "label": "Schedule of Stock Options Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in stock options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliations of Unrecognized Tax Benefits",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r1410",
      "r1715"
     ]
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleIIValuationandQualifyingAccountsandReserves"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule II - Valuation and Qualifying Accounts and Reserves",
        "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]",
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r470"
     ]
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "presentation": [
      "http://www.thecignagroup.com/role/VariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Variable Interest Entities [Table]",
        "label": "Schedule of Variable Interest Entities [Table]",
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r159",
      "r162",
      "r164",
      "r166",
      "r895",
      "r896",
      "r901",
      "r902",
      "r1014",
      "r1015",
      "r1016"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Annual Pre-Tax Amortization for Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "ci_SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/VariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities limited partnerships and real estate limited partnerships",
        "label": "Securities Limited Partnerships And Real Estate Limited Partnerships [Member]",
        "documentation": "Securities Limited Partnerships And Real Estate Limited Partnerships"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1445"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1448"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentGoodwillActivityDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsInterestRatesandDurationDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails",
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r509",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r541",
      "r547",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r663",
      "r668",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1386",
      "r1541",
      "r1764"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiariesDetails",
      "http://www.thecignagroup.com/role/SegmentInformationUSandForeignRevenuesfromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r545",
      "r546",
      "r1191",
      "r1195",
      "r1197",
      "r1265",
      "r1281",
      "r1302",
      "r1332",
      "r1346",
      "r1347",
      "r1348",
      "r1349",
      "r1350",
      "r1351",
      "r1352",
      "r1353",
      "r1354",
      "r1361",
      "r1395",
      "r1431",
      "r1649",
      "r1764"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting [Abstract]",
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r524",
      "r535",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r547"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r545",
      "r1374"
     ]
    },
    "ci_SegmentRevenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "SegmentRevenues",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Adjusted revenues",
        "label": "Segment Revenues",
        "documentation": "Total revenues less realized investment gains from equity method subsidiaries, special items and other reconciling items determined by management."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_BenefitsLossesAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative expenses",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "us-gaap_SeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeniorNotesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtLongtermDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Notes",
        "label": "Senior Notes [Member]",
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeparateAccountAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeparateAccountAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      },
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValuesofSeparateAccountAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets",
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValuesofSeparateAccountAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Separate account assets",
        "totalLabel": "Separate account assets",
        "label": "Separate Account Asset",
        "documentation": "Amount of asset at fair value held for benefit of separate account policyholder."
       }
      }
     },
     "auth_ref": [
      "r1079",
      "r1168",
      "r1170",
      "r1427"
     ]
    },
    "ci_SeparateAccountAssetsClassifiedInFairValueHierarchy": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "SeparateAccountAssetsClassifiedInFairValueHierarchy",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValuesofSeparateAccountAssetsDetails": {
       "parentTag": "us-gaap_SeparateAccountAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFairValuesofSeparateAccountAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Subtotal",
        "label": "Separate Account Assets Classified In Fair Value Hierarchy",
        "documentation": "The fair value of the assets held by the Entity for the benefit of separate account policyholders classified in the fair value hierarchy."
       }
      }
     },
     "auth_ref": []
    },
    "ci_SeparateAccountAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "SeparateAccountAssetsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsAdditionalInformationonSeparateAccountAssetsPricedatNetAssetValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Separate Account Assets",
        "label": "Separate Account Assets [Member]",
        "documentation": "A separate investment account established and maintained by an insurance entity under relevant state insurance law to which funds have been allocated for certain contracts of the insurance entity. Funds in a separate account are not commingled with other assets of the insurance entity for investment purposes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeparateAccountsLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeparateAccountsLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Separate account liabilities",
        "label": "Separate Account, Liability",
        "documentation": "Amount of liability for variable contract in which all or portion of contract holder's funds is allocated to specific separate account and supported by assets held in separate account."
       }
      }
     },
     "auth_ref": [
      "r1083",
      "r1168",
      "r1171",
      "r1172",
      "r1428"
     ]
    },
    "ci_ServiceFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ServiceFeesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fees",
        "label": "Service, Fees [Member]",
        "documentation": "Service, Fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ServiceMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome",
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fees and other revenues",
        "verboseLabel": "Service",
        "label": "Service [Member]",
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service."
       }
      }
     },
     "auth_ref": [
      "r1394"
     ]
    },
    "us-gaap_ServiceOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ServiceOtherMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenues",
        "label": "Service, Other [Member]",
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, financial service, and other financial service, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1650"
     ]
    },
    "us-gaap_SettledLitigationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SettledLitigationMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ContingenciesandOtherMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settled Litigation",
        "label": "Settled Litigation [Member]",
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval."
       }
      }
     },
     "auth_ref": [
      "r1635"
     ]
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/OrganizationalEfficiencyPlanDetails": {
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/OrganizationalEfficiencyPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance Costs",
        "label": "Severance Costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r1408"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinRestrictedStockAwardsandSPSsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinRestrictedStockAwardsandSPSsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateFairValueIncludingMonteCarloFactor": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateFairValueIncludingMonteCarloFactor",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average fair value per share for expense purposes, including the Monte Carlo Factor",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Granted, Weighted Average Grant Date Fair Value Including Monte Carlo Factor",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Granted, Weighted Average Grant Date Fair Value Including Monte Carlo Factor"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinRestrictedStockAwardsandSPSsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awarded (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinRestrictedStockAwardsandSPSsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awarded (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansNarrativeDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinRestrictedStockAwardsandSPSsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards outstanding (in shares)",
        "periodStartLabel": "Outstanding - January 1 (in shares)",
        "periodEndLabel": "Outstanding - December 31 (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r826",
      "r827"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinRestrictedStockAwardsandSPSsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grants/Units",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinRestrictedStockAwardsandSPSsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding - January 1 (in dollars per share)",
        "periodEndLabel": "Outstanding - December 31 (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r826",
      "r827"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinRestrictedStockAwardsandSPSsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Fair Value at Award Date",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfEmployeesHolding": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfEmployeesHolding",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of employees holding share-based payment awards",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Number Of Employees Holding",
        "documentation": "Number of employees holding share based payment awards at the reporting date."
       }
      }
     },
     "auth_ref": []
    },
    "ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfOriginalGrantAwardedAtEndOfPerformancePeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfOriginalGrantAwardedAtEndOfPerformancePeriod",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of original shares granted that may be awarded at end of performance period",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Percent Of Original Grant Awarded At End Of Performance Period",
        "documentation": "The percent of the original grant amount that holders of strategic performance shares will be awarded in shares of the Company's common stock at the end of the performance period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinRestrictedStockAwardsandSPSsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansFairValueofVestedRestrictedStockandSPSsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of vested shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinRestrictedStockAwardsandSPSsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionReferenceTermOfTradedOptions": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionReferenceTermOfTradedOptions",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining maturity of traded options",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Reference Term Of Traded Options",
        "documentation": "The maximum period of time which a traded option of the reporting entity might be outstanding. The volatility of traded options is not used as a component of the expected volatility of outstanding share based compensation option awards as the term of these options does not correlate to the expected term of share-based option awards."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansBlackScholesOptionPricingModelAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansBlackScholesOptionPricingModelAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansBlackScholesOptionPricingModelAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsExercisableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsExercisableAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Exercisable",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Information About Options Exercisable [Abstract]",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Information About Options Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardInformationAboutOptionsOutstandingAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Outstanding",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Information About Options Outstanding [Abstract]",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Information About Options Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansBlackScholesOptionPricingModelAssumptionsDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansFairValueofVestedRestrictedStockandSPSsDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansNarrativeDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinCommonStockOptionsDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinRestrictedStockAwardsandSPSsDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsExercisedDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsOutstandingDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShareRepurchaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r810",
      "r811",
      "r814",
      "r815",
      "r816",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansSharesofCommonStockAvailableforAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares available for award (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinCommonStockOptionsDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable at year-end (in shares)",
        "verboseLabel": "Number (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinCommonStockOptionsDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable at year-end (in dollars per share)",
        "verboseLabel": "Weighted average exercise price (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsExercisedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic value of options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinCommonStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expired or canceled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r1712"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinCommonStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired or canceled (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r1712"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinCommonStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansBlackScholesOptionPricingModelAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average fair value of options (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinCommonStockOptionsDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding - January 1 (in shares)",
        "periodEndLabel": "Options outstanding - December 31 (in shares)",
        "terseLabel": "Number (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r818",
      "r819"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinCommonStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinCommonStockOptionsDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding - January 1 (in dollars per share)",
        "periodEndLabel": "Outstanding - December 31 (in dollars per share)",
        "terseLabel": "Weighted average exercise price (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r818",
      "r819"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinCommonStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Perfromance period",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Performance Period",
        "documentation": "The period of time over which performance is measured to determine achievement for the performance awards."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansBlackScholesOptionPricingModelAssumptionsDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansFairValueofVestedRestrictedStockandSPSsDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansNarrativeDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinCommonStockOptionsDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinRestrictedStockAwardsandSPSsDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsExercisedDetails",
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsOutstandingDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r814",
      "r815",
      "r816",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinCommonStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinCommonStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Incentive Plans",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r809",
      "r817",
      "r836",
      "r837",
      "r838",
      "r839",
      "r842",
      "r851",
      "r852",
      "r853",
      "r854"
     ]
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Status of and Changes in SPSs",
        "label": "Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1409"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansBlackScholesOptionPricingModelAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected option life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansSummaryofInformationforStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "ci_ShareholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ShareholdersEquityAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders' Equity",
        "label": "Shareholders Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_ShortDurationContractsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ShortDurationContractsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceEffectsofReinsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-duration contracts",
        "label": "Short Duration Contracts [Member]",
        "documentation": "Insurance contracts, primarily Accident and Health contracts, that are expected to remain in force for a short duration, generally one year or less."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortDurationInsuranceContractAccidentYear2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortDurationInsuranceContractAccidentYear2022Member",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incurral Year - 2022",
        "label": "Short-Duration Insurance Contract, Accident Year 2022 [Member]",
        "documentation": "Accident year 2022 in which covered event occurs under terms of short-duration insurance contract."
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "us-gaap_ShortDurationInsuranceContractAccidentYear2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortDurationInsuranceContractAccidentYear2023Member",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incurral Year - 2023",
        "label": "Short-Duration Insurance Contract, Accident Year 2023 [Member]",
        "documentation": "Accident year 2023 in which covered event occurs under terms of short-duration insurance contract."
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "ci_ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails": {
       "parentTag": "ci_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative Costs Paid, including assets held for sale",
        "label": "Short-Duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net, Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Short-Duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net, Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails": {
       "parentTag": "ci_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incurred Costs, including assets held for sale",
        "label": "Short-Duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net, Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Short-Duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net, Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_ShortTermAndLongTermInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ShortTermAndLongTermInvestmentsAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Short-Term And Long-Term Investments [Abstract]",
        "documentation": "Short-Term And Long-Term Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails": {
       "parentTag": "ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets",
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investments",
        "terseLabel": "Current investments",
        "netLabel": "Short-term investments",
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r302",
      "r1567"
     ]
    },
    "us-gaap_ShortTermInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestmentsAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current",
        "label": "Short-Term Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails_1": {
       "parentTag": "ci_InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Investments including held for sale assets",
        "label": "Short Term Investments Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Short Term Investments Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestmentsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsInvestmentsbyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments",
        "label": "Short-Term Investments [Member]",
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r1337",
      "r1338",
      "r1339",
      "r1362"
     ]
    },
    "us-gaap_ShortdurationInsuranceContractsAccidentYearAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortdurationInsuranceContractsAccidentYearAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-duration Insurance Contracts, Accident Year [Axis]",
        "label": "Short-Duration Insurance Contracts, Accident Year [Axis]",
        "documentation": "Information by accident year in which a covered event occurs under the terms of the short-duration insurance contract."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ShortdurationInsuranceContractsAccidentYearDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortdurationInsuranceContractsAccidentYearDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-duration Insurance Contracts, Accident Year [Domain]",
        "label": "Short-Duration Insurance Contracts, Accident Year [Domain]",
        "documentation": "Accident year in which a covered event occurs under the terms of the short-duration insurance contract."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortdurationInsuranceContractsClaimsDevelopmentTable",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-duration Insurance Contracts, Claims Development [Table]",
        "label": "Short-Duration Insurance Contracts, Claims Development [Table]",
        "documentation": "Disclosure of information about undiscounted information about claims development by accident year for short-duration insurance contracts."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Incurred and Paid Claims Development, Claims Frequency Metrics and Incurred but Not Yet Reported Liabilities",
        "label": "Short-Duration Insurance Contracts, Claims Development [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted information about claims development by accident year for short-duration insurance contracts."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ShortdurationInsuranceContractsHistoricalClaimsDurationYearOne": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortdurationInsuranceContractsHistoricalClaimsDurationYearOne",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percent of health claims paid within one year",
        "label": "Short-Duration Insurance Contracts, Historical Claims Duration, Year One",
        "documentation": "Percentage of average annual payout, after reinsurance, in the first year after a claim is incurred, beginning with the earliest accident year disclosed for short-duration insurance contracts."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ci_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails": {
       "parentTag": "ci_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Outstanding liabilities for the periods presented, net of reinsurance, including assets held for sale",
        "label": "Shortduration Insurance Contracts Liability For Unpaid Claims And Allocated Claim Adjustment Expense Used In Claims Development Net, Before Reclassification To Disposal Group Assets Held For Sale",
        "documentation": "Shortduration Insurance Contracts Liability For Unpaid Claims And Allocated Claim Adjustment Expense Used In Claims Development Net, Before Reclassification To Disposal Group Assets Held For Sale"
       }
      }
     },
     "auth_ref": []
    },
    "ci_ShortdurationInsuranceContractsNumberOfPaidClaims": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ShortdurationInsuranceContractsNumberOfPaidClaims",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Claim frequency",
        "label": "Shortduration Insurance Contracts Number Of Paid Claims",
        "documentation": "The number of customers for whom an insured medical claim was paid. Customers for whom no insured medical claim was paid and claims that did not result in a liability are excluded from the calculation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r450"
     ]
    },
    "ci_SingleForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "SingleForeignCountryMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationUSandForeignRevenuesfromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Single foreign country",
        "label": "Single Foreign Country [Member]",
        "documentation": "Single Foreign Country"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentComponentsofDepreciationandAmortizationExpenseDetails",
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentNarrativeDetails",
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Purchased and internally developed software",
        "terseLabel": "Internal-use software",
        "label": "Software and Software Development Costs [Member]",
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "ci_SpecialItemChargeBenefitAfterTaxLitigation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "SpecialItemChargeBenefitAfterTaxLitigation",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails": {
       "parentTag": "ci_SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "(Benefits) charges associated with litigation matters, after-tax (Selling, general and administrative expenses)",
        "label": "Special Item Charge (Benefit) After Tax Litigation",
        "documentation": "After-tax charges associated with litigation matters that are classified as special items, attributable to the parent. Special items reflect amounts that management does not believe are representative of underlying results of operations."
       }
      }
     },
     "auth_ref": []
    },
    "ci_SpecialItemChargeBenefitBeforeTaxLitigation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "SpecialItemChargeBenefitBeforeTaxLitigation",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails": {
       "parentTag": "ci_SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "(Benefits) charges associated with litigation matters (Selling, general and administrative expenses)",
        "terseLabel": "(Benefits) charges associated with litigation matters",
        "label": "Special Item Charge (Benefit) Before Tax Litigation",
        "documentation": "After-tax charges associated with litigation matters that are classified as special items, attributable to the parent. Special items reflect amounts that management does not believe are representative of underlying results of operations."
       }
      }
     },
     "auth_ref": []
    },
    "ci_SpecialItemChargeBenefitTaxMatters": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "SpecialItemChargeBenefitTaxMatters",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails": {
       "parentTag": "ci_SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax (benefits), net (Income taxes, less amount attributable to noncontrolling interests)",
        "label": "Special Item Charge Benefit Tax Matters",
        "documentation": "Special Item Charge Benefit Tax Matters"
       }
      }
     },
     "auth_ref": []
    },
    "ci_SpecialItemChargeBenefitTaxMattersAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "SpecialItemChargeBenefitTaxMattersAfterTax",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails": {
       "parentTag": "ci_SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax (benefits), net, after-tax (Income taxes, less amount attributable to noncontrolling interests)",
        "label": "Special Item Charge Benefit Tax Matters After Tax",
        "documentation": "Special Item Charge Benefit Tax Matters After Tax"
       }
      }
     },
     "auth_ref": []
    },
    "ci_SpecialItemChargesDebtExtinguishmentCostsBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "SpecialItemChargesDebtExtinguishmentCostsBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails": {
       "parentTag": "ci_SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity",
       "weight": -1.0,
       "order": 6.0
      },
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt extinguishment costs",
        "label": "Special Item Charges Debt Extinguishment Costs Before Tax",
        "documentation": "Special Item Charges Debt Extinguishment Costs Before Tax"
       }
      }
     },
     "auth_ref": []
    },
    "ci_SpecialItemChargesDebtExtinguishmentCostsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "SpecialItemChargesDebtExtinguishmentCostsNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails": {
       "parentTag": "ci_SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt extinguishment costs, after-tax",
        "label": "Special Item Charges Debt Extinguishment Costs Net Of Tax",
        "documentation": "Special Item Charges Debt Extinguishment Costs Net Of Tax"
       }
      }
     },
     "auth_ref": []
    },
    "ci_SpecialItemGainLossFromContractAdjustmentBeforeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "SpecialItemGainLossFromContractAdjustmentBeforeTaxes",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Contractual adjustment for a former client (Pharmacy revenues)",
        "negatedTerseLabel": "Contractual adjustment for a former client",
        "label": "Special Item, Gain (Loss) From Contract Adjustment, Before Taxes",
        "documentation": "Special Item, Gain (Loss) From Contract Adjustment, Before Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "ci_SpecialItemGainLossFromContractAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "SpecialItemGainLossFromContractAdjustmentNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Contractual adjustment for a former client (Pharmacy revenues)",
        "label": "Special Item, Gain (Loss) From Contract Adjustment, Net Of Tax",
        "documentation": "Special Item, Gain (Loss) From Contract Adjustment, Net Of Tax"
       }
      }
     },
     "auth_ref": []
    },
    "ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentBeforeTaxes",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Risk corridors recovery (Selling, general and administrative expenses)",
        "negatedTerseLabel": "Risk corridors recovery",
        "label": "Special Item, Gain (Loss) On Risk Corridor Allowance Adjustment, Before Taxes",
        "documentation": "Special Item, Gain (Loss) On Risk Corridor Allowance Adjustment, Before Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "ci_SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "SpecialItemGainLossOnRiskCorridorAllowanceAdjustmentNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Risk corridors recovery (Selling, general and administrative expenses)",
        "label": "Special Item, Gain (Loss) On Risk Corridor Allowance Adjustment, Net Of Tax",
        "documentation": "Special Item, Gain (Loss) On Risk Corridor Allowance Adjustment, Net Of Tax"
       }
      }
     },
     "auth_ref": []
    },
    "ci_SpecialItemGainLossOnSaleOfBusinessBeforeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "SpecialItemGainLossOnSaleOfBusinessBeforeTaxes",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails": {
       "parentTag": "ci_SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "(Gain) loss on sale of business",
        "label": "Special Item, Gain (Loss) On Sale Of Business, Before Taxes",
        "documentation": "Special Item, Gain (Loss) On Sale Of Business, Before Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "ci_SpecialItemGainLossOnSaleOfBusinessNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "SpecialItemGainLossOnSaleOfBusinessNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails": {
       "parentTag": "ci_SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "(Gain) loss on sale of business, after-tax",
        "label": "Special Item, Gain (Loss) On Sale Of Business, Net Of Tax",
        "documentation": "Special Item, Gain (Loss) On Sale Of Business, Net Of Tax"
       }
      }
     },
     "auth_ref": []
    },
    "ci_SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total impact from special items",
        "label": "Special Item Gain Or Loss Before Tax Attributable To Reportng Entity",
        "documentation": "Sum of before-tax tax amounts classified as special items, attributable to the parent. Special items are excluded from the calculation of 'adjusted income (loss) from operations' because management believes they are not representative of the underlying results of operations. This is generally because the nature and size of these matters are not indicative of our ongoing business operations."
       }
      }
     },
     "auth_ref": []
    },
    "ci_SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total impact from special items",
        "label": "Special Item Gain Or Loss Net Of Tax Attributable To Reportng Entity",
        "documentation": "Sum of after-tax amounts classified as special items, attributable to the parent. Special items are excluded from the calculation of 'adjusted income (loss) from operations' because management believes they are not representative of the underlying results of operations. This is generally because the nature and size of these matters are not indicative of our ongoing business operations."
       }
      }
     },
     "auth_ref": []
    },
    "ci_SpecialItemsAfterTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "SpecialItemsAfterTaxAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After-tax",
        "label": "Special Items After Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_SpecialItemsBeforeTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "SpecialItemsBeforeTaxAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Pre-tax",
        "terseLabel": "Special items",
        "label": "Special Items Before Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentGoodwillActivityDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesContractholderDepositFundsDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsInterestRatesandDurationDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesFuturePolicyBenefitsPresentValueofExpectedPremiumsandBenefitsDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareIncurredandPaidClaimsDevelopmentandUnpaidClaimsLiabilityDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails",
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r509",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r541",
      "r547",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r652",
      "r663",
      "r668",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1386",
      "r1541",
      "r1764"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.thecignagroup.com/role/CommonandPreferredStockAcceleratedShareRepurchaseAgreementsDetails",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r69",
      "r391",
      "r433",
      "r434",
      "r435",
      "r471",
      "r472",
      "r473",
      "r476",
      "r486",
      "r488",
      "r507",
      "r607",
      "r613",
      "r728",
      "r848",
      "r849",
      "r850",
      "r881",
      "r882",
      "r908",
      "r910",
      "r911",
      "r912",
      "r913",
      "r915",
      "r925",
      "r955",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r993",
      "r1150",
      "r1151",
      "r1152",
      "r1187",
      "r1251"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/CollectivelySignificantOperatingUnconsolidatedSubsidiariesDetails",
      "http://www.thecignagroup.com/role/SegmentInformationUSandForeignRevenuesfromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r375",
      "r545",
      "r546",
      "r1191",
      "r1195",
      "r1197",
      "r1265",
      "r1281",
      "r1302",
      "r1332",
      "r1342",
      "r1346",
      "r1347",
      "r1348",
      "r1349",
      "r1350",
      "r1351",
      "r1352",
      "r1353",
      "r1354",
      "r1361",
      "r1395",
      "r1431",
      "r1649",
      "r1764"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r472",
      "r473",
      "r507",
      "r1038",
      "r1176",
      "r1188",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1212",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1232",
      "r1234",
      "r1235",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1251",
      "r1432"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtLongtermDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]",
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r489",
      "r807",
      "r1527",
      "r1529",
      "r1591"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r472",
      "r473",
      "r507",
      "r1038",
      "r1176",
      "r1188",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1212",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1232",
      "r1234",
      "r1235",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1251",
      "r1432"
     ]
    },
    "ci_StatutoryAccountingPracticesAmountPermittedLendingAuthorityOfLifeInsuranceSubsidiaryToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "StatutoryAccountingPracticesAmountPermittedLendingAuthorityOfLifeInsuranceSubsidiaryToParent",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/ShareholdersEquityandDividendRestrictionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum loans to the parent company permitted without regulatory approval",
        "label": "Statutory Accounting Practices Amount Permitted Lending Authority Of Life Insurance Subsidiary To Parent",
        "documentation": "Maximum permitted amount certain of the Company's life insurance subsidiaries may loan to the parent company without prior approval from the state's Department of Insurance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatutoryAccountingPracticesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatutoryAccountingPracticesDisclosureTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/ShareholdersEquityandDividendRestrictionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory Net Income and Net Assets of the Company's Subsidiaries",
        "label": "Statutory Accounting Practices Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of how the entity's reporting under GAAP as of the balance sheet date differs from the results based on prescribed and permitted accounting practices of the state or country of domicile in which a relevant statutory filing is made, or differences in results based on the National Association of Insurance Commissioners (NAIC) prescribed practices, or a combination thereof. Describes the accounting practices used and the related monetary effect on statutory surplus, net income, and risk-based capital. If an insurance enterprise's risk-based capital would have triggered a regulatory event had it not used a permitted practice, that fact is disclosed in the financial statements. Permitted statutory accounting practices include practices not prescribed but allowed by the domiciliary state insurance department regulatory authority."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r210",
      "r211",
      "r212",
      "r213",
      "r1755"
     ]
    },
    "us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ShareholdersEquityandDividendRestrictionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum dividend distributions permitted in 2024 without regulatory approval",
        "label": "Statutory Accounting Practices, Statutory Amount Available for Dividend Payments",
        "documentation": "Amount of dividends available for payment after computation of statutory restrictions on capital surplus."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ShareholdersEquityandDividendRestrictionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum statutory surplus required by regulators",
        "label": "Statutory Accounting Practices, Statutory Capital and Surplus Required",
        "documentation": "Amount of statutory capital required to be maintained as of the balance sheet date under prescribed or permitted statutory accounting practices."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "us-gaap_StatutoryAccountingPracticesStatutoryNetIncomeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatutoryAccountingPracticesStatutoryNetIncomeAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ShareholdersEquityandDividendRestrictionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income",
        "label": "Statutory Accounting Practices, Statutory Net Income Amount",
        "documentation": "Amount of net income for the period determined using accounting principles prescribed or permitted by insurance regulators."
       }
      }
     },
     "auth_ref": [
      "r1088"
     ]
    },
    "us-gaap_StatutoryCapitalAndSurplusApplyingNationalAssociationOfInsuranceCommissionersNAICPractices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatutoryCapitalAndSurplusApplyingNationalAssociationOfInsuranceCommissionersNAICPractices",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ShareholdersEquityandDividendRestrictionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Surplus",
        "label": "Statutory Capital and Surplus Applying National Association of Insurance Commissioners (NAIC) Practices",
        "documentation": "Amount of statutory capital and surplus computed using statutory accounting practices prescribed by the National Association of Insurance Commissioners."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "ci_StepDownNotesDueJanuary2033Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "StepDownNotesDueJanuary2033Member",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtOutstandingAmountsofDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$45\u00a0million, 8.080% Step Down Notes due January 2033 (3)",
        "label": "Step Down Notes Due January 2033 [Member]",
        "documentation": "Step-down debt due in January 2033."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1456",
      "r1468",
      "r1478",
      "r1504"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan",
     "presentation": [
      "http://www.thecignagroup.com/role/CommonandPreferredStockShareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued for stock option exercises and other benefit plans (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Benefit Plan",
        "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansFairValueofVestedRestrictedStockandSPSsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares of The Cigna Group common stock distributed upon SPS vesting (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r233",
      "r234",
      "r272"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.thecignagroup.com/role/EmployeeIncentivePlansStatusofandChangesinCommonStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r233",
      "r234",
      "r272",
      "r823"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of issuing stock for employee benefit plans",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r233",
      "r234",
      "r272"
     ]
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/CommonandPreferredStockAcceleratedShareRepurchaseAgreementsDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShareRepurchaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accelerated stock repurchase, amount authorized",
        "label": "Stock Repurchase Program, Authorized Amount",
        "documentation": "Amount of stock repurchase plan authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://www.thecignagroup.com/role/CommonandPreferredStockShareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repurchased common stock (in shares)",
        "label": "Stock Repurchased During Period, Shares",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r233",
      "r234",
      "r272",
      "r1182",
      "r1251",
      "r1340"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL SHAREHOLDERS' EQUITY",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r237",
      "r238",
      "r256",
      "r1214",
      "r1231",
      "r1252",
      "r1253",
      "r1414",
      "r1444",
      "r1576",
      "r1609",
      "r1728",
      "r1785"
     ]
    },
    "ci_StockholdersEquityAndDividendRestrictionsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "StockholdersEquityAndDividendRestrictionsTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/ShareholdersEquityandDividendRestrictions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders' Equity And Dividend Restrictions",
        "label": "Stockholders Equity And Dividend Restrictions [Text Block]",
        "documentation": "Footnote describing statutory requirements by various states for shareholders' equity and dividend restrictions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity",
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "negatedTerseLabel": "Decrease to shareholders' equity",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r167",
      "r391",
      "r392",
      "r434",
      "r471",
      "r472",
      "r473",
      "r476",
      "r486",
      "r607",
      "r613",
      "r728",
      "r848",
      "r849",
      "r850",
      "r881",
      "r882",
      "r908",
      "r910",
      "r911",
      "r912",
      "r913",
      "r915",
      "r925",
      "r955",
      "r957",
      "r961",
      "r993",
      "r1151",
      "r1152",
      "r1185",
      "r1214",
      "r1231",
      "r1252",
      "r1253",
      "r1341",
      "r1443",
      "r1576",
      "r1609",
      "r1728",
      "r1785"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders' equity",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityPolicyTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AOCI",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r1254"
     ]
    },
    "ci_StopLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "StopLossMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stop loss",
        "label": "Stop Loss [Member]",
        "documentation": "An insurance product that provides additional coverage on Administrative Services Only plans that provides reimbursement for claims in excess of a predetermined amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsegmentsAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsegments [Axis]",
        "label": "Subsegments [Axis]",
        "documentation": "Information by business subsegments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsegmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsegmentsDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsegments [Domain]",
        "label": "Subsegments [Domain]",
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/CommonandPreferredStockDividendsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r962",
      "r999"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails",
      "http://www.thecignagroup.com/role/CommonandPreferredStockAcceleratedShareRepurchaseAgreementsDetails",
      "http://www.thecignagroup.com/role/CommonandPreferredStockDividendsDetails",
      "http://www.thecignagroup.com/role/DebtLongtermDebtDetails",
      "http://www.thecignagroup.com/role/DescriptionofBusinessDetails",
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupGuaranteesDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShareRepurchaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r962",
      "r999"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.thecignagroup.com/role/CommonandPreferredStockDividendsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r962",
      "r999"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails",
      "http://www.thecignagroup.com/role/CommonandPreferredStockAcceleratedShareRepurchaseAgreementsDetails",
      "http://www.thecignagroup.com/role/CommonandPreferredStockDividendsDetails",
      "http://www.thecignagroup.com/role/DebtLongtermDebtDetails",
      "http://www.thecignagroup.com/role/DescriptionofBusinessDetails",
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupGuaranteesDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShareRepurchaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r962",
      "r999"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/AssetsandLiabilitiesofBusinessesHeldforSaleDetails",
      "http://www.thecignagroup.com/role/CommonandPreferredStockAcceleratedShareRepurchaseAgreementsDetails",
      "http://www.thecignagroup.com/role/CommonandPreferredStockDividendsDetails",
      "http://www.thecignagroup.com/role/DebtLongtermDebtDetails",
      "http://www.thecignagroup.com/role/DescriptionofBusinessDetails",
      "http://www.thecignagroup.com/role/InvestmentsEquitySecurityInvestmentsDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupGuaranteesDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShareRepurchaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r962",
      "r999"
     ]
    },
    "srt_SubsidiariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SubsidiariesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupIntercompanyBalancesDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiaries",
        "label": "Subsidiaries [Member]",
        "documentation": "Entity in which controlling financial interest is held. Includes, but is not limited to, variable interest entity (VIE) consolidated by primary beneficiary. Excludes entity in which broker-dealer holds controlling financial interest but control is likely to be temporary."
       }
      }
     },
     "auth_ref": [
      "r1696",
      "r1737",
      "r1738",
      "r1739"
     ]
    },
    "ci_SunLifeAssuranceCompanyOfCanadaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "SunLifeAssuranceCompanyOfCanadaMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Sun Life Assurance Company of Canada",
        "label": "Sun Life Assurance Company Of Canada [Member]",
        "documentation": "Sun Life Assurance Company of Canada"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Disclosure of Cash Information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails": {
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current year",
        "label": "Current Year Claims and Claims Adjustment Expense",
        "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs."
       }
      }
     },
     "auth_ref": [
      "r1128"
     ]
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails": {
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimExpensesCignaHealthcareActivityDetails",
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesUnpaidClaimsandClaimsExpensesCignaHealthcareVariancesinIncurredCostsRelatedtoPriorYearsUnpaidClaimsandClaimsExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior years",
        "negatedTerseLabel": "Favorable (unfavorable) variance, amount",
        "label": "Prior Year Claims and Claims Adjustment Expense",
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs."
       }
      }
     },
     "auth_ref": [
      "r1128"
     ]
    },
    "us-gaap_SupplierFinanceProgramObligationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplierFinanceProgramObligationCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/SupplierFinanceProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding payment obligations, current",
        "label": "Supplier Finance Program, Obligation, Current",
        "documentation": "Amount of obligation for supplier finance program, classified as current."
       }
      }
     },
     "auth_ref": [
      "r656",
      "r657",
      "r658"
     ]
    },
    "us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://www.thecignagroup.com/role/SupplierFinanceProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration]",
        "label": "Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes obligation for supplier finance program, classified as current."
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "ci_SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/SupplierFinanceProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding payment obligations, current, voluntarily elected by suppliers to be sold to the financial institution",
        "label": "Supplier Finance Program, Outstanding Payment Obligation, Current, Voluntarily Elected To Be Sold",
        "documentation": "Supplier Finance Program, Outstanding Payment Obligation, Current, Voluntarily Elected To Be Sold"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplierFinanceProgramPaymentTimingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplierFinanceProgramPaymentTimingPeriod",
     "presentation": [
      "http://www.thecignagroup.com/role/SupplierFinanceProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment term (in months)",
        "label": "Supplier Finance Program, Payment Timing, Period",
        "documentation": "Period when payment is expected to be made to finance provider or intermediary in supplier finance program, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "us-gaap_SupplierFinanceProgramTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplierFinanceProgramTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/SupplierFinanceProgram"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier Finance Program",
        "label": "Supplier Finance Program [Text Block]",
        "documentation": "The entire disclosure for supplier finance program."
       }
      }
     },
     "auth_ref": [
      "r653",
      "r654",
      "r655",
      "r1387"
     ]
    },
    "us-gaap_SwapMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SwapMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Swaps",
        "label": "Swap [Member]",
        "documentation": "A forward-based contract in which two parties agree to swap streams of payments over a specified period. The payment streams are based on an agreed-upon (or notional) principal amount. The term notional is used because swap contracts generally involve no exchange of principal at either inception or maturity. Rather, the notional amount serves as a basis for calculation of the payment streams to be exchanged."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r1219",
      "r1223",
      "r1229",
      "r1242",
      "r1248",
      "r1312",
      "r1313",
      "r1431"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1497"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r454",
      "r602",
      "r949"
     ]
    },
    "us-gaap_TemporaryEquityNetIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityNetIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income",
        "label": "Temporary Equity, Net Income",
        "documentation": "The portion of net income or loss attributable to temporary equity interest."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityOtherChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityOtherChanges",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other transactions impacting noncontrolling interests",
        "label": "Temporary Equity, Other Changes",
        "documentation": "Amount of increase (decrease) in temporary equity from changes classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "ci_TemporaryEquityOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "TemporaryEquityOtherComprehensiveIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails_1": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other comprehensive loss attributable to redeemable noncontrolling interests",
        "netLabel": "Other comprehensive loss",
        "terseLabel": "Less: Net translation (loss) on foreign currencies attributable to noncontrolling interests",
        "label": "Temporary Equity Other Comprehensive Income",
        "documentation": "The portion of other comprehensive income or(loss) attributable to temporary equity interest."
       }
      }
     },
     "auth_ref": []
    },
    "ci_ThreeWhollyOwnedSubsidiariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "ThreeWhollyOwnedSubsidiariesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupIntercompanyBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Three wholly-owned subsidiaries",
        "label": "Three Wholly Owned Subsidiaries [Member]",
        "documentation": "Three Wholly Owned Subsidiaries"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1489"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1496"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.thecignagroup.com/role/ReceivablesLoansNotesReceivableandOthersPolicies",
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r548",
      "r549",
      "r556"
     ]
    },
    "us-gaap_TradeNamesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeNamesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/GoodwillOtherIntangiblesandPropertyandEquipmentOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade Name - Express Scripts",
        "label": "Trade Names [Member]",
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1517"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r1519"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.thecignagroup.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ci_TransactionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "TransactionRelatedCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails": {
       "parentTag": "ci_SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/MergersAcquisitionsandDivestituresNarrativeDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummarizedSegmentFinancialInformationDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Integration and transaction-related costs, pre-tax",
        "terseLabel": "Integration and transaction-related costs",
        "label": "Transaction Related Costs",
        "documentation": "Pre-tax transaction-related costs primarily consisting of fees for legal, advisory and other professional services, as well as employee costs."
       }
      }
     },
     "auth_ref": []
    },
    "ci_TransactionRelatedCostsAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "TransactionRelatedCostsAfterTax",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails": {
       "parentTag": "ci_SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/MergersAcquisitionsandDivestituresNarrativeDetails",
      "http://www.thecignagroup.com/role/SegmentInformationSummaryofSpecialItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Integration and transaction-related costs, after-tax",
        "terseLabel": "Integration and transaction-related costs, after-tax (Selling, general and administrative expenses)",
        "label": "Transaction Related Costs After Tax",
        "documentation": "After-tax transaction-related costs including the impact of tax benefits realized from termination of merger agreement. Transaction-related costs consist primarily of fees for legal, advisory and other professional services as well as employee costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails",
      "http://www.thecignagroup.com/role/InvestmentsDebtSecuritieswithaDeclineinFairValueDetails",
      "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r721",
      "r727",
      "r916",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1100",
      "r1548",
      "r1549",
      "r1550",
      "r1551",
      "r1552",
      "r1553",
      "r1554",
      "r1604",
      "r1605",
      "r1606",
      "r1607"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1520"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1521"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1519"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r1519"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r1522"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1520"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.thecignagroup.com/role/CommonandPreferredStockAcceleratedShareRepurchaseAgreementsDetails",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.thecignagroup.com/role/CommonandPreferredStockShareActivityDetails",
      "http://www.thecignagroup.com/role/EarningsPerShareSharesofCommonStockHeldinTreasuryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares of common stock held in treasury",
        "verboseLabel": "Treasury stock (in shares)",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockSharesAcquired",
     "presentation": [
      "http://www.thecignagroup.com/role/CommonandPreferredStockAcceleratedShareRepurchaseAgreementsDetails",
      "http://www.thecignagroup.com/role/EarningsPerShareSharesofCommonStockHeldinTreasuryDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShareRepurchaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock repurchased (in shares)",
        "label": "Treasury Stock, Shares, Acquired",
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r234",
      "r272"
     ]
    },
    "us-gaap_TreasuryStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockValue",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedBalanceSheets",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Treasury stock, at cost",
        "label": "Treasury Stock, Value",
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r137",
      "r138"
     ]
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/CommonandPreferredStockAcceleratedShareRepurchaseAgreementsDetails",
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofChangesinTotalEquity",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupShareRepurchaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchase of common stock",
        "terseLabel": "Stock repurchased",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r137",
      "r272"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationUSandForeignRevenuesfromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "ci_USFederalGovernmentAgenciesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "USFederalGovernmentAgenciesMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationUSandForeignRevenuesfromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Federal Government Agencies",
        "label": "U.S. Federal Government Agencies [Member]",
        "documentation": "U.S. Federal Government Agencies"
       }
      }
     },
     "auth_ref": []
    },
    "ci_USGroupDisabilityAndLifeInsuranceBusinessMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "USGroupDisabilityAndLifeInsuranceBusinessMember",
     "presentation": [
      "http://www.thecignagroup.com/role/MergersAcquisitionsandDivestituresNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S Group Disability and Life Insurance",
        "label": "U.S Group Disability And Life Insurance Business [Member]",
        "documentation": "U.S Group Disability And Life Insurance Business"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USStatesAndPoliticalSubdivisionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USStatesAndPoliticalSubdivisionsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and local government",
        "label": "US States and Political Subdivisions Debt Securities [Member]",
        "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments."
       }
      }
     },
     "auth_ref": [
      "r1397",
      "r1776"
     ]
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasuryAndGovernmentMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesCarriedatFairValueDetails",
      "http://www.thecignagroup.com/role/InvestmentsGrossUnrealizedAppreciationDepreciationonDebtSecuritiesDetails",
      "http://www.thecignagroup.com/role/PensionPensionPlanAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal government and agency",
        "verboseLabel": "Federal government securities",
        "label": "US Treasury and Government [Member]",
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r1064",
      "r1397",
      "r1776"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r1516"
     ]
    },
    "us-gaap_UnearnedPremiums": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnearnedPremiums",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_InsuranceAndContractholderLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Unearned premiums",
        "label": "Unearned Premiums",
        "documentation": "Carrying amount of premiums written on insurance contracts that have not been earned as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "ci_UnearnedPremiumsAttributableToDisposalGroups": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "UnearnedPremiumsAttributableToDisposalGroups",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unearned premiums classified as liabilities of business held for sale",
        "label": "Unearned Premiums Attributable To Disposal Groups",
        "documentation": "Unearned Premiums Attributable To Disposal Groups"
       }
      }
     },
     "auth_ref": []
    },
    "ci_UnearnedPremiumsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "UnearnedPremiumsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unearned premiums, current",
        "label": "Unearned Premiums, Current",
        "documentation": "Unearned Premiums, Current"
       }
      }
     },
     "auth_ref": []
    },
    "ci_UnearnedPremiumsCurrentIncludingDisposalGroups": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "UnearnedPremiumsCurrentIncludingDisposalGroups",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_UnearnedPremiumsIncludingDisposalGroups",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails_1": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unearned premiums, current, including held for sale liabilities",
        "label": "Unearned Premiums Current Including Disposal Groups",
        "documentation": "Carrying amount of premiums written on insurance contracts that have not been earned as of the balance sheet date, expected to be paid in one year."
       }
      }
     },
     "auth_ref": []
    },
    "ci_UnearnedPremiumsIncludingDisposalGroups": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "UnearnedPremiumsIncludingDisposalGroups",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesIncludingDisposalGroups",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Unearned premiums, including held for sale liabilities",
        "label": "Unearned Premiums Including Disposal Groups",
        "documentation": "Unearned Premiums Including Disposal Groups"
       }
      }
     },
     "auth_ref": []
    },
    "ci_UnearnedPremiumsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "UnearnedPremiumsNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unearned premiums, non-current",
        "label": "Unearned Premiums, Noncurrent",
        "documentation": "Unearned Premiums, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "ci_UnearnedPremiumsNoncurrentIncludingDisposalGroups": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "UnearnedPremiumsNoncurrentIncludingDisposalGroups",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails": {
       "parentTag": "ci_InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesAccountBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unearned premiums, non-current, including held for sale liabilities",
        "label": "Unearned Premiums Noncurrent Including Disposal Groups",
        "documentation": "Carrying amount of premiums written on insurance contracts that have not been earned as of the balance sheet date, expected to be paid after one year."
       }
      }
     },
     "auth_ref": []
    },
    "ci_UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsOtherLongTermInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unfunded commitments, percentage expected to fund in next fiscal year",
        "label": "Unfunded Commitments, Percentage Expected To Fund In Next Fiscal Year",
        "documentation": "Unfunded Commitments, Percentage Expected To Fund In Next Fiscal Year"
       }
      }
     },
     "auth_ref": []
    },
    "ci_UnitedStatedHealthcareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "UnitedStatedHealthcareMember",
     "presentation": [
      "http://www.thecignagroup.com/role/SegmentInformationRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Healthcare",
        "label": "United Stated Healthcare [Member]",
        "documentation": "United Stated Healthcare"
       }
      }
     },
     "auth_ref": []
    },
    "ci_UnobservableInputsDevelopedByCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "UnobservableInputsDevelopedByCompanyMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities Priced by the Company",
        "label": "Unobservable Inputs Developed By Company [Member]",
        "documentation": "Significant unobservable inputs used in pricing Level 3 securities that were developed directly by the Company."
       }
      }
     },
     "auth_ref": []
    },
    "ci_UnobservableInputsNotDevelopedByCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "UnobservableInputsNotDevelopedByCompanyMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities Not Priced by the Company",
        "label": "Unobservable Inputs Not Developed By Company [Member]",
        "documentation": "Significant unobservable inputs used in pricing Level 3 securities that were not developed directly by the Company"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy",
     "presentation": [
      "http://www.thecignagroup.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpaid Claims and Claims Expenses",
        "label": "Unpaid Policy Claims and Claims Adjustment Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for estimating the ultimate cost of settling insurance claims relating to insured events that have occurred on or before a particular date (ordinarily, the statement of financial position date). The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claims adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims."
       }
      }
     },
     "auth_ref": [
      "r1127",
      "r1129"
     ]
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Appreciation (Depreciation) on Debt Securities",
        "label": "Unrealized Gain (Loss) on Investments [Table Text Block]",
        "documentation": "Tabular disclosure of unrealized gains and losses on investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesUncertainTaxPositionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at January 1,",
        "periodEndLabel": "Balance at December 31,",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r857",
      "r865"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesUncertainTaxPositionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "(Decrease) due to prior year tax positions",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesUncertainTaxPositionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Reduction related to settlements with taxing authorities",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesUncertainTaxPositionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase due to current year positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesUncertainTaxPositionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Decrease) / Increase due to prior year positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesUncertainTaxPositionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability for net interest expense on uncertain tax positions",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued",
        "documentation": "Amount of interest expense accrued for an underpayment of income taxes."
       }
      }
     },
     "auth_ref": [
      "r1714"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/IncomeTaxesUncertainTaxPositionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Reduction related to lapse of applicable statute of limitations",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "us-gaap_UsTreasuryUstInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UsTreasuryUstInterestRateMember",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtLongtermDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury rate",
        "label": "US Treasury (UST) Interest Rate [Member]",
        "documentation": "Interest rate on direct treasury obligation of U.S. government (UST)."
       }
      }
     },
     "auth_ref": [
      "r1724"
     ]
    },
    "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceOfDeferredTaxAssetsMember",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax asset valuation allowance",
        "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]",
        "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward."
       }
      }
     },
     "auth_ref": [
      "r1581",
      "r1582",
      "r1583",
      "r1584",
      "r1585"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesBalance",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of year",
        "periodEndLabel": "Balance at end of year",
        "terseLabel": "Valuation allowance",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "documentation": "Amount of valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r469"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charged (Credited) to costs and expenses",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charged (Credited) to other accounts",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account",
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesDeductions",
     "crdr": "debit",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other deductions",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "documentation": "Valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r464",
      "r465",
      "r468",
      "r469"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "documentation": "Information by valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r464",
      "r465",
      "r468",
      "r469"
     ]
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r463",
      "r464",
      "r465",
      "r468",
      "r469"
     ]
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "presentation": [
      "http://www.thecignagroup.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "documentation": "Disclosure of valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r463",
      "r464",
      "r465",
      "r468",
      "r469"
     ]
    },
    "us-gaap_ValuationTechniqueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Approach and Technique [Axis]",
        "label": "Valuation Approach and Technique [Axis]",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ValuationTechniqueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Approach and Technique [Domain]",
        "label": "Valuation Approach and Technique [Domain]",
        "documentation": "Valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_VariableAnnuityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableAnnuityMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InsuranceandContractholderLiabilitiesNetAmountofRiskandAverageAgeofContractholdersDetails",
      "http://www.thecignagroup.com/role/ReinsuranceEffectiveExitofVariableAnnuityReinsuranceBusinessDetails",
      "http://www.thecignagroup.com/role/ReinsuranceReinsuranceRecoverablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Annuity",
        "label": "Variable Annuity [Member]",
        "documentation": "Contract providing periodic payment that varies according to investment experience of separate account in which amount paid to provide for annuity is allocated."
       }
      }
     },
     "auth_ref": [
      "r1424",
      "r1428",
      "r1777"
     ]
    },
    "ci_VariableInterestEntitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "VariableInterestEntitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entities [Abstract]",
        "label": "Variable Interest Entities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ci_VariableInterestEntitiesNumberOfEntities": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "VariableInterestEntitiesNumberOfEntities",
     "presentation": [
      "http://www.thecignagroup.com/role/VariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of VIEs",
        "label": "Variable Interest Entities, Number Of Entities",
        "documentation": "Variable Interest Entities, Number Of Entities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "presentation": [
      "http://www.thecignagroup.com/role/VariableInterestEntities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entities",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableInterestEntityEntityMaximumLossExposureAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.thecignagroup.com/role/VariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum exposure to loss, variable interest entities",
        "label": "Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount",
        "documentation": "The reporting entity's maximum amount of exposure to loss as a result of its involvement with the Variable Interest Entity (VIE)."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r165"
     ]
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableInterestEntityLineItems",
     "presentation": [
      "http://www.thecignagroup.com/role/VariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entity [Line Items]",
        "label": "Variable Interest Entity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r895",
      "r896",
      "r901",
      "r902",
      "r1014",
      "r1015",
      "r1016"
     ]
    },
    "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember",
     "presentation": [
      "http://www.thecignagroup.com/role/VariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entity, Not Primary Beneficiary",
        "label": "Variable Interest Entity, Not Primary Beneficiary [Member]",
        "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "presentation": [
      "http://www.thecignagroup.com/role/VariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entity, Primary Beneficiary",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r895",
      "r896",
      "r901",
      "r902"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.thecignagroup.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease cost",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r983",
      "r1413"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtLongtermDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Axis]",
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://www.thecignagroup.com/role/DebtLongtermDebtDetails",
      "http://www.thecignagroup.com/role/ScheduleICondensedFinancialInformationofTheCignaGroupLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Domain]",
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "ci_VillageMDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.thecignagroup.com/20231231",
     "localname": "VillageMDMember",
     "presentation": [
      "http://www.thecignagroup.com/role/InvestmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "VillageMD",
        "label": "VillageMD [Member]",
        "documentation": "VillageMD"
       }
      }
     },
     "auth_ref": []
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://www.thecignagroup.com/role/FairValueMeasurementsQuantitativeInformationAboutUnobservableInputsDetails",
      "http://www.thecignagroup.com/role/InvestmentsCommercialMortgageLoanPortfolioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average",
        "label": "Weighted Average [Member]",
        "documentation": "Average of a range of values, calculated with consideration of proportional relevance."
       }
      }
     },
     "auth_ref": [
      "r1356",
      "r1357",
      "r1742",
      "r1744",
      "r1747"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.thecignagroup.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shares (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r502"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesIssuedBasic",
     "calculation": {
      "http://www.thecignagroup.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average (in shares)",
        "label": "Weighted Average Number of Shares Issued, Basic",
        "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic)."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.thecignagroup.com/role/EarningsPerShareComputationofBasicandDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares:",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WithdrawalFromContractHoldersFunds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WithdrawalFromContractHoldersFunds",
     "crdr": "credit",
     "calculation": {
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.thecignagroup.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Withdrawals and benefit payments from contractholder deposit funds",
        "label": "Withdrawal from Contract Holders Funds",
        "documentation": "The cash outflow for a segregated fund account during the period."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a),(b),(c)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(i)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(i),(j),(k)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(i-k)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-11"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-14"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21D",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481097/715-30-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "605",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479655/944-605-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "((d)(5))",
   "SubTopic": "80",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "80",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2C",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2C"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b),(d)",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "280",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-4"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4B"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4G"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(3)",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-13"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "310",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-29"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "310",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-7"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "310",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-7A"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "405",
   "SubTopic": "30",
   "Section": "15",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482578/405-30-15-2"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Subparagraph": "(12)(c)",
   "Section": "S99",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Subparagraph": "(16)(c)",
   "Paragraph": "3A",
   "Section": "S99",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Subparagraph": "14",
   "Paragraph": "3A",
   "Section": "S99",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Subparagraph": "15",
   "Paragraph": "3A",
   "Section": "S99",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "70",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)-(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-21"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2AA",
   "Subparagraph": "a",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-2AA"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-4"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-4"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "b",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-4"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-5A"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-5A"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-6"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-6"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-9"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r180": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r181": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r182": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r183": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5"
  },
  "r184": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7"
  },
  "r185": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8"
  },
  "r186": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182"
  },
  "r187": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "25",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1"
  },
  "r188": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r189": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r190": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r191": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r192": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r193": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11"
  },
  "r194": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12"
  },
  "r195": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r196": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r197": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r198": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r199": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r200": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r201": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r202": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r203": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r204": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r205": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r206": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3"
  },
  "r207": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "505",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479989/944-505-50-1"
  },
  "r208": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "505",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479989/944-505-50-1"
  },
  "r209": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "505",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479989/944-505-50-1"
  },
  "r210": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "505",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479989/944-505-50-3"
  },
  "r211": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "505",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479989/944-505-50-6"
  },
  "r212": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "505",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479956/944-505-55-1"
  },
  "r213": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "505",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479956/944-505-55-2"
  },
  "r214": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "80",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(3),(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r215": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "805",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479919/944-805-30-1"
  },
  "r216": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205-20/tableOfContent"
  },
  "r217": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11"
  },
  "r218": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A"
  },
  "r219": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A"
  },
  "r220": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B"
  },
  "r221": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A"
  },
  "r222": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r223": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r224": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r225": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D"
  },
  "r226": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r227": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r228": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r229": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r230": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r231": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r232": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r233": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r234": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r235": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r236": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r237": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r238": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r239": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r240": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r241": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r242": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r243": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r244": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r245": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.19)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r246": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r247": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r248": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r249": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r250": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r251": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r252": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r253": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r254": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r255": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r256": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r257": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r258": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r259": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r260": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r261": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-9"
  },
  "r262": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r263": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r264": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r265": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A"
  },
  "r266": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r267": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r268": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r269": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A"
  },
  "r270": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r271": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r272": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r273": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481138/505-30-25-5"
  },
  "r274": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r275": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Subparagraph": "(d)(5)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r276": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r277": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r278": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r279": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r280": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r281": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r282": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r283": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r284": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//805/tableOfContent"
  },
  "r285": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r286": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r287": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r288": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r289": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "83",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480647/815-10-15-83"
  },
  "r290": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r291": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r292": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//940-320/tableOfContent"
  },
  "r293": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r294": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r295": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r296": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r297": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r298": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r299": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r300": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r301": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r302": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r303": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r304": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r305": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//942-320/tableOfContent"
  },
  "r306": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04.5,6,7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r307": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3"
  },
  "r308": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3"
  },
  "r309": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(cc)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3"
  },
  "r310": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r311": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479583/944-40-S99-1"
  },
  "r312": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r313": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r314": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r315": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//946-320/tableOfContent"
  },
  "r316": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r317": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15"
  },
  "r318": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6"
  },
  "r319": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r320": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r321": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r322": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r323": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7"
  },
  "r324": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "944",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479808/944-20-55-15"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(n)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "220",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-5"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(13)(a)(2))",
   "SubTopic": "210",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(1))",
   "SubTopic": "220",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(c))",
   "SubTopic": "220",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "323",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//323/tableOfContent"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(4)",
   "Publisher": "SEC"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(5)",
   "Publisher": "SEC"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(1)(i)",
   "Publisher": "SEC"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(1)(ii)",
   "Publisher": "SEC"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Subsection": "Instruction 5",
   "Publisher": "SEC"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "(b)",
   "Publisher": "SEC"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1404",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1404",
   "Paragraph": "(b)",
   "Publisher": "SEC"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "(a)",
   "Subparagraph": "(4)",
   "Publisher": "SEC"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "(c)",
   "Publisher": "SEC"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "(a)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "(a)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "(a)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "(a)",
   "Subparagraph": "(4)",
   "Publisher": "SEC"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "(a)",
   "Subparagraph": "(5)",
   "Publisher": "SEC"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "(c)",
   "Publisher": "SEC"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Publisher": "SEC"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iii)(A)",
   "Publisher": "SEC"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iii)(B)",
   "Publisher": "SEC"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iii)(A)",
   "Publisher": "SEC"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iii)(B)",
   "Publisher": "SEC"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iii)(C)",
   "Publisher": "SEC"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "(m)",
   "Subparagraph": "(1)(iii)",
   "Publisher": "SEC"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "5",
   "Subsection": "04",
   "Paragraph": "c",
   "Subparagraph": "Schedule I",
   "Publisher": "SEC"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "7",
   "Subsection": "05",
   "Paragraph": "c",
   "Subparagraph": "Schedule II",
   "Publisher": "SEC"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "9",
   "Subsection": "06",
   "Publisher": "SEC"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.5-04(Schedule I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480922/205-10-S99-6"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-17A"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(3)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//280/tableOfContent"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-3"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-42"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-42"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-42"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "44",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-44"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-3B"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-20/tableOfContent"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479468/405-50-50-3"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479468/405-50-50-3"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479468/405-50-50-3"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479468/405-50-50-3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479468/405-50-50-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479468/405-50-50-4"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//420/tableOfContent"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//460/tableOfContent"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3A"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3A"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-8"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480606/715-80-35-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-9"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1B"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482134/820-10-35-54B"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-2"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479838/944-20-50-3"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479838/944-20-50-4"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(h))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//944-40/tableOfContent"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480112/944-40-45-3"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-1"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4B"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-6"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-6"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-6"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-6"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-6"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-6"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-6"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7B"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7B"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7C"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479686/944-605-45-1"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479655/944-605-50-1"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479655/944-605-50-1"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479655/944-605-50-1"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479655/944-605-50-1"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479655/944-605-50-1"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479655/944-605-50-1"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479655/944-605-50-1"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480141/944-80-45-2"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-2"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-2"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1A"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r1317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r1337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r1338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r1339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r1340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r1341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r1342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r1343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r1344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r1345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480598/954-450-50-1"
  },
  "r1346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r1347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r1348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r1349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r1350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r1351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r1352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r1353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r1354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r1355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r1356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r1357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r1358": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r1359": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(1)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r1360": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r1361": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r1362": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "SubTopic": "320",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r1363": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r1364": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r1365": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r1366": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r1367": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r1368": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r1369": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r1370": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r1371": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r1372": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r1373": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r1374": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r1375": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r1376": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-10"
  },
  "r1377": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-11"
  },
  "r1378": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-12"
  },
  "r1379": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-12"
  },
  "r1380": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-12"
  },
  "r1381": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-12"
  },
  "r1382": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-15"
  },
  "r1383": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "79",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-79"
  },
  "r1384": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "80",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-80"
  },
  "r1385": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r1386": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r1387": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147477128/405-50-55-3"
  },
  "r1388": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r1389": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r1390": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r1391": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r1392": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r1393": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r1394": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1395": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1396": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1397": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1398": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1399": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r1400": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-18"
  },
  "r1401": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r1402": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r1403": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r1404": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r1405": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r1406": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r1407": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r1408": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1409": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1410": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r1411": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r1412": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r1413": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r1414": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r1415": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r1416": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13I"
  },
  "r1417": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13I"
  },
  "r1418": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13I",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13I"
  },
  "r1419": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13K",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13K"
  },
  "r1420": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13K",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13K"
  },
  "r1421": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13K",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13K"
  },
  "r1422": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29E"
  },
  "r1423": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r1424": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29G"
  },
  "r1425": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479629/944-605-55-12"
  },
  "r1426": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479629/944-605-55-15"
  },
  "r1427": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480078/944-80-55-17"
  },
  "r1428": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480078/944-80-55-18"
  },
  "r1429": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r1430": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1431": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r1432": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r1433": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1434": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r1435": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1436": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r1437": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r1438": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1439": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r1440": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r1441": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r1442": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r1443": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r1444": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r1445": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1446": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1447": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r1448": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r1449": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r1450": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r1451": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r1452": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r1453": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1454": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1455": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1456": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1457": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1458": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1459": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1460": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1461": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r1462": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r1463": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r1464": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r1465": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1466": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1467": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1468": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1469": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1470": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1471": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1472": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1473": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1474": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1475": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1476": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1477": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1478": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1479": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1480": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1481": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1482": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1483": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1484": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1485": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1486": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1487": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1488": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1489": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1490": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1491": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1492": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1493": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1494": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1495": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1496": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1497": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1498": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1499": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1500": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1501": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1502": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1503": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1504": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1505": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1506": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1507": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1508": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1509": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1510": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1511": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1512": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1513": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1514": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1515": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1516": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1517": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1518": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1519": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1520": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1521": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1522": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1523": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1524": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1525": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1526": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "323",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481543/323-740-50-2"
  },
  "r1527": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r1528": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-11"
  },
  "r1529": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r1530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r1531": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r1532": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r1533": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r1534": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "SubTopic": "605",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479655/944-605-50-1"
  },
  "r1535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "SubTopic": "605",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479655/944-605-50-1"
  },
  "r1536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r1538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r1539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r1540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r1541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r1542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r1543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r1544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r1545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r1546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r1547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//705/tableOfContent"
  },
  "r1548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r1549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "(a)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "(a)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1405",
   "Paragraph": "(a)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "11",
   "Subsection": "03",
   "Publisher": "SEC"
  },
  "r1559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r1560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(ii)",
   "Publisher": "SEC"
  },
  "r1561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iii)",
   "Publisher": "SEC"
  },
  "r1562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r1563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r1564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r1569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r1570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r1571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r1572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r1573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r1574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r1575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(S-X 210.12-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r1581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r1582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r1583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r1584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r1585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r1586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r1587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r1588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r1589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r1590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12"
  },
  "r1591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r1592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r1593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r1594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//310-10/tableOfContent"
  },
  "r1595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r1596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r1597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r1598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r1599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r1600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r1601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r1602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r1603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r1604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r1605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1606": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1607": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1608": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r1609": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r1610": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r1611": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r1612": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r1613": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r1614": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r1615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r1616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r1617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r1618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A"
  },
  "r1628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r1629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482190/360-10-35-3"
  },
  "r1630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5"
  },
  "r1631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r1632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r1633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3"
  },
  "r1634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r1635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r1636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r1637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r1638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r1639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r1640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482050/460-10-25-4"
  },
  "r1641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3"
  },
  "r1642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r1647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r1648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r1649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r1650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2"
  },
  "r1699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r1700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r1701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r1702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r1703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r1704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r1705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r1706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r1707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r1708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r1709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r1710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-8"
  },
  "r1711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-4"
  },
  "r1712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r1714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r1715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r1716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r1717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r1718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r1719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r1722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B"
  },
  "r1723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r1724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-6A"
  },
  "r1725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r1726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r1727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r1728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r1729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r1730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r1731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r1732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r1733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r1734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r1735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r1736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r1737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r1738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r1739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r1740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479838/944-20-50-3"
  },
  "r1749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479838/944-20-50-5"
  },
  "r1750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(14)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(13)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r1765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479616/944-310-45-5"
  },
  "r1766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479616/944-310-45-6"
  },
  "r1767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479584/944-310-50-2"
  },
  "r1768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479250/944-40-25-14"
  },
  "r1769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-6"
  },
  "r1770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7B"
  },
  "r1771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7B"
  },
  "r1772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7B"
  },
  "r1773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r1774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r1775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r1776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r1777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-2"
  },
  "r1778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r1779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r1780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r1790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>198
<FILENAME>0001739940-24-000005-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001739940-24-000005-xbrl.zip
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MI7M.NJON$8-NM,]=\\B=,"A.]Z1W]XD6!BWIG@[O*U1%H*NJ[AGTOJA36UW
M7=4]<\Z#.E4I?]U3Z;RI4Y6Z0#>>CJY'WY'@=<_Z]TV=JI2][DG\'JA3E>+6
M/17/@3I5*7X,R_5WU#3=\]%\J--\%D)7=4]+]T^=YJ.HFNXYZ5ZHTYQTHWWN
MFCMUFI/B=$]Z]TR=YJ0EW=/A7*C3G'2E>P:]+^I4X884-=TSYSRH4Y7RUSV5
MSILZ5:D+W4>Q]TJ=JA2\[EG_OJE3E;+7/8G? W6J4-QUW5/Q'*A3E>+7/MO.
MA5_,9^/+NNX9]O[YQ9P4I7N2O1=^,2?=Z)Y4Y\\OYJ0XW3/S/?.+.6E)]_P]
M%WXQ)UWIGM_OBU]4N)=O7??4/@]^4:7\=4_O\^87%>JBH7ONOU=^4:7@=<_Z
M]\TOJI2][DG\'OA%E>+6/17/@5]4*7ZTV7;254Z5<$8\<;QH=T"I..IS%N6<
ML]#Q G%617@V@2^C("3>%W$>=@A%>+$+6A'W0+.9'T.G/$I/J$_UZ+#3;]1E
M#EA-VQV#'$F?P@ONJ.S".^)T[=\I\:*!N.,L#J$_"4.Z]7;34Y3%#R']*Q8P
M&\.?^\EH^224Q1M4O7=!4AV/A"'HRTF.&5YX_\*-OU//[04<OM+K(%HMUAVG
M8M7U4[&ETQ:W.G ,+;E1<#L1N]=UQ#9UE(] TY-K,J33"B4O[, +T_.".@$?
M!4FU?^]T.\9(]V>DJDXY7;([='25!GLL(I@:UT!'7>FFMYP.UD1+?RV>;<Y$
M+W9-(NC.;GJSGR>+;O%+3#AX'JJF&UI]8AUT0[<#PH?$F9Q1G_98%'XC/G2.
MHGWIG?H0#VC9-Z/^/<PV::(E_-ZC?O#D$ 8-13@\1<).@=!VA\QG821BK'$6
MDH8WOC=Y%J@6<W"QB9:W-/C1(6ILHN5>#7YTB%Z;:,GD@K,TFA,6"B/HYLX)
M]4V;5FJH:MK..=!W1#F-M:.<!3ELY650<E)=>*,;>] A)>-5WV@T"-PK?TP3
MNN+YKY0ND*F=W[O=O__Q]:LRUG3:Z=T\>*R?F''6;2YZ@RO?99PZT>R)'OQ$
M'\!E"?^DC>VC([VV\\O)%_#"O;-)=POGC+&7E .U/DG*^\IZM.TX4M+=>#3R
MY.N)EV7TLX[RXBDM_C[F/^CD[P'SHS_@7JC*CI/\!4^W%4K14GP&I3JB=#EO
M7+='7KIUJQX9+6UIXGYT<?]2!&F7]L^3M=#RK :OV/&:!Z_;0LOKMJ$$EWEQ
M0G@Y,0=\9OT?=2]Y,!3S]N)(*@=2HW0B\"WEW8% UF1U 8L@N!B.O&!"J9S-
M>C,21153S6CIUX*J.1^6O866)2VHFO,APUMHI_:>TX?H"C)8'L]FXD!  'TJ
M#<]C*IQ:LX)_)G7LLT36?BSJ,I7V4*Y]H)_3,N!C5D!V)?LN2GA!>6CGF^)1
MGL*)#RUTE.X&XF[4:_B-94G>>)E2//)6B6^\G-_;\K[T B)&V.^@)]0.Z&B9
M*8R"5XAXNX268UE#\AI$/\OB1DL1H!&W4G2C3=77$7=#NX#%+J%-FA$)7"G"
M-4Y?JW5;0P^N<<JY-X$K1;C&26>UHJ$+USCIW)>\E>);XZ2S5BEK"'"-D\V]
M"5PEPFV-<\Q:U=80XK;&:>;^)*X4XQIGFO6JA@C7.-'<E[R5XEOC/+,.#D4?
M8&N<7^Y<T$H1K7%>6:_5FQI!6N.,<O>25HIIC7/)1J6J7Q2B<2JY+WFKQ'=9
MMTP2?J9R04DF]$93PU&=LF[I9'YB5XIVC7/*1J6D3X!2UCB9W+F@E2):XRRR
M6=5Q0+ZL<3JY/XDKQ;B^>66E5-8O!B_KFUWN3=Y*\:UOCEF!GEY''ZYOEKE'
MB:O$>$6W/+,;T=%Y\.AGDO\[\6/")Z" BC8PK^B69>8E=*5(US?'K%1JU5))
M.V]>T3?9W*/$E6)<WZRS4J_;^@4L%7V3SOT)7"G"-<XYF]6F?@#7..?<E[R5
MXEO?G+-:JI3UP[>^&>?>Y*T2WU7=\LTY>=LU'8<TJ[HEF[E(7"G&]<TTJW9=
MQUG@57TSS3U*7"G&]<TTJ^6:CMQX5=]4<X\25XIQ?7/-:EW#7+.J;ZZY-WDK
MQ;?&N6:C I&A/LC6.,O<O:158KJF<7[9K+:T\]DUC;/+?<E;*;[US2UK)0W7
M/=3TS2SW)F^E^-8WKZS9.N);WZQR;_)6BF_=<LK\YEN5;!"7&J'KEEC>T7'@
MC9G?[W#JLJC=YU0>OQ&V1YQY0CKZ.!C=DLQEV?ON5QJ!E[GI)3]<$H=YT(YO
MXMPZN"U327/7YE ]KI34J$2W;!212L*E4SFJZQ\W.:^_;?;QM^MH<]Q%=2P>
ML["HLC<T4R#$[,B(Z[HEWNU*O7I.)B]U;<N:J.JC"=U2\OPU@<*+ZI;9YQX4
M;F$RTZ-1>-8(1S:BE_KA9V>E0'OY8GLSEYV]X;6S4Z:O&P6A/*!N5?G9M74*
M7,:.;BS%>_O#QHX3:X5>6#<B Y%*PJ4SR-9UQV65[E@W8N1NM7M:5M>NA\X4
M6I#F+,D>-8#"8'0C5C8,.W>]LE"AX>C&I^2O"0P&U-"21ND$PR'E#B/>+8'F
M:L,#-]#R%5\#OP]QUU 8R_UD1!?EW:4^"[@<_=B6LPIY!.KSP\!CKCC5^D+(
M87H<J;AZ2SC479QI2OR)*HJL&S^$]*\8"KX8PY\535R\8:>0 D,'&U8SK--
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M*@*7I[%5RASM,@!<,B^IE#G:O1\0R/S]\_#5A9EE_"DB$@5M- E:H8+P;OJ
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M@+&%J2UHS$B_2_1KO_\V@!LF@\!S*0?;".*I/7Z)"021$:7N-^:S83Q,CM$
MFQ.;D=T1O[\T WJKHBYY,"Q52J7[H 0RUB?;U)C3-L#"'#BA8\7%00%SRA%?
M4Z$C[X8,9/<$6724O8%L 2&KLONN:CR>L!M@K3(9\J329 X0LBJ];%7C\0T#
M66T@J]3+XAUO0=M]MQ^"\1N06!=8[>CU<HR5X'#L&H\3&2LQ5K*GO@3M@-)^
M4/IV43/MEFHV:->NE4RV:VQ'V [:$4%C.\9VD$=GZ$80=T]N&JO4?T5[%=T
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M!@G[]0DM'=@#-"-0KQ))73HB<@&[XP2Q'\D[\A^%2@7BMJ-KFM1)_GQ+>7=
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MPFT2DM\"\JVK#U8R*:1M_???FF7;_B0/:;0NB3.-,9,;LSL;TQMW<GANT@W
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M3B3YE88W[ T&.T<O=G0WEYOEQ^O *PPG<,D<MWL6_*(&A2Z2[#Z!K<.)8=A
M%,HT2XRMU8!F/F(C3E5-7_[\\\W-30^$(L)''>&3]B*<MY;S[%$.J1E9J"<2
MTW20W[#]YXK3Q=AG)#7H5'H":5QH96:SR137+S/W"%$J%OXUYO\D%<+=)'*1
M%N0.6#"E9&Q],5)&!+PGPA0/0OCP%8;(H#)(9WH,)F>V4343#AN3=T5.WB4.
MM,;0HB+\M1YSS1%^)^ )?EE2CCE(K_+.G8?+R6 Y ZJF_D9_P2%U/I'*0R]
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MR&/JSN-YT52A090$:NY4/Q<>:[*E9H(TMH^TW)0]$NROP;&4(18MG!G=VA#
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M,S4<82])MY["0TU5@6HTY*0H7\U#W4ILPFM=4@NM5U"%5ZK4NXG3(3C'BM/
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M-/HM',2(>A[5H#2JAP5(3"]XL^!PH7A9^=!KB)?MTZ)*]+?6@F^*_ ;?@(S
MNE]]?$6AG2L^CO3\9 9Y4:XG]]U<&IPM 7O3,OL]"KK% $-S.N!1D6-[(R)]
MM9NBK3?K*^Y]\A(1>OR9-=&:(LYE#1 WA2Q\H5)8#,AD21P3M ;%P>65]FD9
MK(M9/0$-:5?,4W>BW@S'#R;?4!7AO3C0Y(DV*@?/[)Z0B-7138U84DUOIGCM
MI;A$$ KI6->)-> Q34K7C&G&#5O  T192&17@EU+%?>%R _[=YUO[.\$[3WB
MMCWM]O;#X)@*+FF>7^';XGS%C3AM9B8S5=!QQNS(>6Z36S423UT6Y,+C !S*
MLM89^^'&?KZ4Y)1&7$^(E)_38]=Y>JW_OH'&:%$\_*&@,>U[,%\EU$X;!60N
M309246)_@T^7%=7<E)W9)E!S")R#]@HO0E^*0AS""L-7LTBW$I Z%(7[2KNU
M<F/P,,L$GCTL?-E_1=J:]+Q.)I,X30L:$.LEDWF2,<\V)\OQBAQ#[L\03]%V
M[$,L683^&'56L=9$.+_$6N65>VSI*7.X8Y+&>F\R>&-\G&!KQLF471A)#GXE
MG&TM2,+NVTMY@D:XZVS@.ZT.>4<:^(AU0A)L_=_>2CNY%_K;/SDGV#4= PAY
M:+NUR8EU:#,/0[$S4C33#_%DJ4QR!JJD<<J2(JCRJH%)MI5)&KC<,?D(RJ7H
MW 9?IWO]+,2T+;72@^=3P=9"@=D"%RPRS(.PL'/XW6"G%[S6WETW^'B-6P3;
MC[^B5^0DB]8JCFOW[/^E9L%GU)EA9$DOS".>\J1;:KI<IV=IEV!\H2@&6V=?
M5%13,M>\H6YP]R>UKU["Q_>G-%3SV*5AO, LUOEYA^7B4(@@2T(1!SO;W7^1
M4&":M::N9?P"=@O'S@^A<<'5D/@FY5\HCBS2Y4G\WUO)(-H_"H_Z8?1B$.WU
MAX='>^JP_V+8WXO4SN"@?_"?H_W^UKR[0-<>'/5W#[:WU8OH:']O=V\W/(Q?
M',;;T=%A? #W&_QGO]_?I:L?0W/U[U:I.7_SX3AX>W;\[O-;%]/"5$#&F42Z
MFBZL*0VGI7JI_^45@I'2</8R(71$ERYZY6]T"QZ%;!!_;#VRWC9[954!_XOU
M+\O'/?CHYY:_'_9V#_NM'VWW=MHO^5%OU=_O;>\LO]7/M/?&Q=9RLD\GI4(G
M*D7A^.^MW:V&9! ">TI=W$D<:*D5>-_+[0 ^DQ_>W,.Y!VWXSW1JUMDVS+DD
M)C% '%*]RY[[(9J&\XS3>YPM$)_(T@F+KB8N JPTZHH<UCT*-9;*NF&OH!G(
M+GN,[86)&TTR[=[*J9TW@$3"L)8_:C!!BIC2^MO]W8Y]DI-\ A<1%P)-GL._
MO;&PY/F'@'46(R[;,Z-5RY[,7=4+?FMW]SI\[9G@J1?O)CMH3DYF+HE"A!'\
M='-OD >\8E</\:@B480&*,"6_'U_I]>'^(XA$Q()@G;_8K\.(H#Y'2Y=6;Y%
MO'BOMZ^O72LGKEVX88\T?L5BTTZ(2VS&T:0F6 W!_QA2P'JM?'!*B0A"O$Y7
M5(-C9"VIP!7NV+]=(E%[]SC%[+L'[B5*S@M&P)MOXZY_)*>8RFCT6_"6O10;
MAO7'*5'Y.;DSE]_M-CG$U;\]N3PAA^OON[U=\]:CL!QW$.F O("$EYH2LP*Z
M!<QC1_4QJAM<>PA\.7D\\I[9>FV;\CTEXDFX(7N]G</#!S'2+U[T^MO[#W*K
MO=[NSHN[F/M;3!EC\SU;]FJAE?O+9M+<H#_]@K=X-9>4;+[%21+'J7IPY7&K
M]TQB\C:_P<*"I)V-:%?Q+0]>\#V^>E>__M7=\04M>0UXU[FCE$^W%G>4]0]7
MT@?3'O!\FSZ8)4MHZWJA+C&? G"E('U+R,RX%_A,E5578WZ:?(.NN\5C#'%6
MQ!P3YU>>BXWT?_?2CPFA#%QUDWZG"0,@1^A1$PA%-_^M\EA0FR.RW?Z)2^)"
M-T8&P37$(!/E8,LVDK^1_+M)_JD_FHC<Z1!"XE7*.6A_*@O19"ERWYVPFB?B
MQ5)),R5LQ.'"88TTH@P;,;CZIWN#37=\<JW)B;AD1R *(>JG\3U\[+$I:G.,
M-L?H3L?HLYG&Q8(55J&EVUNI*S7%^;&Z=U$0BPG(.GREU'Q]DYQC<C>5I4]/
M&^:83.2(\%94 (R2TB1JS,#OMBK:Y@!M#E#[ 7*&FSN$O:;+2DOF:J,2;&O1
MC8H-G*%%+KO&:BI^Y4J/@<YHM4;[?^&,++W]Y@!]:PL4(K@4Z1)M !SK)F[X
M]FI/#A*":[I;I)6E3L50)KNGPHRG3PM-!T6QL+Z?'^(;%\]EAI035U=2D_=Z
M8H1'5SK2(5 *TQ0_G2.$N/UH+CU.]SBWZU]W,_,APF"2?*%=<_K KAUVFSP3
M,DY=,R/6'IK\Y3D5#DT/S6_1Q''P]$E<4Q8?&=/9P; M)@.WZ-#JI>#+=3K"
MA&LXOY$A-WKH0SKUII2-J>%*)EHTDDI><V3I/@=51Z[#)"5?"OV>@"*5;DBE
ME0$$Z-*<<&.[NE $I%#&EH,>);PF9!:Q+) [%3,[.K&N<Z73V$+:DW"NE-;5
M[X0*10X'_ ,B4?[B=3\<@OC%!D%,7<W#'+L0F2\8(5>QFB;4;L[Y->Z(+.L)
MU>ITNP\8*^SX39>1V5F\54<Z7*4R2C7@C!JD95XG;K/UOYY$/:_?[QWU'Z:@
MM[/=>[&W]S"WVNT='K1?<N];[?1>[!RLVZKZV[W^T?);W>9PA]$5VC6P!7+,
MX@'^WR7.]M+"VSH5)&_U3$G.+\SIO="GE^"7\X.@E_A9M^SB?>.9[VR+W]/X
MN]?8%/RL?+[9S[^ZGV\4%CRGX]D3V\JV,-ILY$J=HO9]_J7FK+UN W*$]T&7
M,T]@U[:>KR2P>[;S_.[QXAH)RQJ>NPLAF_ Z*4_&89:I=.6*K2V._T[W_\22
M?7A[WNKK[+SX*\[.TBS)5V&RGI827-;]UH1*$AZS1==\=>GC<?9X%9)KP,GO
M)=M$>^5.DSX1ZI[N*59X,^.,WDFK//P.?LO3?W1;=$Y;N*B9\D??%V9PA:#O
MK^W(][(=QY<?.\&;DTYP]FFS'[ ?KXO\BK+78#R)O.-,$Y1UP(]!*I@'V:9[
M>Q]/:Q<-3?*YX?9_ET>FM42X^#\3W?\%T?T?>W3_P;.MSQ?'Y=;SV_V5'\LP
MGIM""N5,?Z'?:'@2/[B"7P_#MS9NZ]TV;6</*UQ(,ODH$?M^K]GMT+:,11%[
MO_=B:<3>OT?$_B.<@#<G&UT@$3"3C#HVW-CW!S#F/[(]IW)DBTVGOU\(EKZ+
MLSKGC=/CV/&G9LKG.SD?VXX_.;'[=J;\^[+FN]M/V)KO/D[1X&X[)[5,SEA'
M1%1T@JTW@R1\;!_CR9W.QW0SGMQFL#MA_(N5^15/;N/N[%IL/(M[>Q9WX(/8
M1 KMKL;<B)F-KGOH%/KWM2F22-_LR,8D/KA)?!@;]YVDP*UU,ZQ%]S5E#XK+
M>5JR]?4A]3?;M"<6;.^]>,+!]MYW$FS_P"?Z/C['#[Q-C<1_2X'_FVSCPP'C
MUF^+O\)OV: -OQ7:T XV\0@>+YM]]_- Q$:3WV[_=K;>[]?[?"V3 DUR:H.:
MNJ=76>0W_.\'?YG&X#O9O0TD\6L@B1LYNL7%>32@XO>R7RTH12HR6%/)+,V)
M:O5D-G;1M0!ZE*Z0AY]E(QF-MA'#;XER^!$V[*$QZ]_S7FUTW$/JN++"QB,<
M';S1;!O-MM%L&\WV?6BV4QK]L1&Y.^DSWBP:C?*/O^T<[KW:[-M&K3T<:H*E
MJZ'4[I1:WZ@TM_5#CP.W0[HWLK?QUS:*;55[=9[%:JJ(W3>X>/U>:S8^GCQI
MC/[^0)KMVR2!UT[M7<+ZN^_R\A&KV3^"L'X[F-2/L)N/"5'Y$?;O+X6Z"UFH
M/9+Q([T'FG_]Z.%)J1TH&]WR)4V;B)9O -&A?QVX;>=QP&U?_Q@>XWWOJ)TM
M^4Z/]B@/]N*K'FOK_WZLBZ :%TH%0V$ + V5M@SR7<XK_FP+'*FMYQTF%0=G
MH!N,ZK (X1RJF.B]X2MO3K:>"YFX_I+EP>\R@_:SK;-/^*VB0$07#<]=3)+]
MW<M_?R/_WT3^C_]?)SB!0."7=Q ,''>"<_CG^8=.\/ZR$WR X. "_G8)__P,
M?_O\_W6"?W\6Y.NOQS^P=#Y2G^_7O<0VV807"R_R^!/\3U[PR>=.<'KFO^A_
MP4O^U__"RSZ%_WVT+_W#/^%_[^%_\-G'M_"_?\'_/K4)0P?D /ZGA>*WXUYP
M-ARJB!2EGAR]TY'AT6%:YG8\^H=?[S,$X-5W+U2/A&=_4*%*4]TPH+Y$"MS2
M]\?RZC_\[_S;W##:_Y5;;1CM-XSVMV:*5\5HOSRP_<YV^=N0VO]06_KHO/8_
MU&XN8:_?[.O38X&_\QX_Y7[R]26"G]O@_O>[P<O:L,YQK9G.WPHX^L*=>]7J
M9;37O?:WOZJB_U<V>^T*7&_2?&!W\F25K'#K5RC@LI6_1;K=KQ-XGSI,P@_0
MR/9];>-O>9'&V(\5/),0/2R#-)DD-+%X%H33*<3_%):GX<U2$V:ZE/J/W$3\
M?;V!^_: />3N?@?;MRXLMT]NXT0Y)G='V>WM/3P69>F>/BEK[=+XW=-8_\!<
M%?-D=._###-4]($8\I/WKU?&6/$][?4XP2U]3TL(SL*RZ@27L/IPFN/&O\5A
MU?^"_P_^.@V3K$..4[C9^0?7M10,I:0OLCSK$G_%8CT\AVK9S*EN*TT?K=6<
MZL65R6]OGFA[[I[Z7^4C+"PZMC_4'>;,+<(9[!XT:\([+];HR?[QMQ?]_L&K
M1RGQWF%1M]=X=_9HN.B2?%#[9+M'?J*E*L) M,1+>P]6KE)9F$4J^%B,P/'X
M,V0LU[.MM^\_EHC3(K?N(JU+;H#JP%JJF[RX(AW^<:JRX#B*D#P7O].AOZ(D
MYL.A0N16-2[R>C2F:?"DXNG'(HUA!*L+OT-7X12H7O!YK$H5$ UT4)>*$&'=
M<AP6F*^'Y8.D@OXN@RH/5!;!77&80C56].5\&&S!2<UXA1 SAO ) M9@J[?R
MNNKF0_OAF/> SLU4N*9A >=9@*\9MP&)PQ0\!CZ'9J/V]@FVZ>+BX]9S6B\_
M,BRS#(8JK,"8!8,B#_$:??L@Y*VB!>&B<UJ?S-.(<["&55"H/VH(Y0+^Z3#E
MW:EF4Y2A=!:,PVL5A,$8WBM<2X@YW!\5)$/X<U27H*7@@U*IJY*?[B:!Y\0%
M>CM@5G5'8-)A_]LJC*62_(^_'1UN]]=;/>P=+-</B^9:KE1#T&D($Q1Y$ANE
ME=A$E!@?311)DG<C</"WH J_=$,]X@1N$,[PG$[A'\.\"!3X2 DFTMR3A[C.
MK%3VY,LF=$"RLS(I*SSW<*[EFC*\IA,&!RFO,_R:?%"H9#*HBY))8O7'M,YA
MJK[0[Y;8DX+WLU=;'6*? Y><PIIA]T-&9A4Y7)UDP00;6/ &<&R30O\T_H;[
M2'@D[XI%W5CAQ[;"=QBCM[*#=@&KI1ZI(J\0! @6!==X/(3C$E/.F5JECB,$
M11^?'(.E0<N9)G#"$%$&%A?%TYB7O&'#S\@XP=$#(RL'%YS9*X6Y[0JAA7IK
MP-9F9)_@(!SL!S?C7%LCMC9BMO*&G$.$R>:7;3SLHE$7\*,C_)S8,W"%HR*<
M!&4=C3'!;HB=<^T=)7$O.#%'L%"1PB?#IRW4&#0$_I?[XP.7V;"QR%#'EF+H
MK/KPC3T])UT[4*!_2Y7"2]"*CPPKWOP/V)^DFM'YAQUK@^W=(1SUI79]SOBR
MH_-6I3%I[LLP5?=^LOMLR-JHP47>QI-7@[>-(%N-#DS3_,8H@ZYQ$#Q;K'5!
MV^GO!'9,^-2=>A(7]0@^-9J)33=VF.#E<BO4B+T 6UI8-YKH"+0EGGSP[6_1
MFD8_#!/XT"@_!%!,P:4Y#LIDE,&'$2KL:5[0VD =8334\D:B.06HO2[ZXK#(
M)W3I=9C6JHM8Z#B8Y+%**:2HX*S"'0)\?'6MTGR*VX)Q0CKK*B)IBX/I>%8F
M$1@0K1TQ9L/D%6UA."-U[<=9R00UIMDUB") +2M^>#! Z Z!5*0SCE,@P -9
M*O V<5B%@<1N:^H/_3#'?OE\((ACPZ(*3L%;6+U6$/L,AS:K)P/T)8;SAUM"
M;OH#BC 8<Y6F^$_I-Y/^,3!?$X[5RWJ*)Q E>E[CN(<Z+[S_M#IDT4F'0 ?.
M2N'HDY)V.Z3=9@W"P1+&_,9M@L<RKP=.U !V0GP/_!I'+0FY'K!D=DY@$1(@
M\8&7K2HACAEC8B7V_:(0K?>D3A$01M^GDU[:'['/^5,)"D'%H+3.YK6PW)05
M$"4UC&\E7A?^FEF#?@.47(I9:\)*)^#D!F$\5@6V\>$?JT*%%3N(G +!=YCI
M^X7B!M,>;/3'BO7'@@DL*]40RSP'DO&A@B>AK!F=R+"(X6=BNFX43EGJW+AC
M F&_/FF3G -]L+9%DH-=Y8,,8CM1JI(40)TE?]2*CPX)+=[A.BD3C!UFK6$'
MZI=A&,G)IE,9(?#(B8I$Y8"EI07\.R,TTB5W$N&#Z4_P=\E##TVZ\"OCDR=4
MY+@?O?VZ:(H?+_.RD#]_)3K#]JE+8A'M;ZBMF4;M.BF#@5V^CA=,XH".K>G,
M1"L/%^"!!%,[4G#OZZ2H:GL_C"WFCW*GY3=*(]P1N/?L8U>@*Z3@,#$,5QU,
M]A>@:4JRL\4U>NSPC>D8EX,;(+:9]"(H(W32.]IS@;^4N E4C9'L#!\C7.[/
MX.;8/_>"W]B6C[#SG@(0[PJ[LZ1S=<B"'TTU,Y>Y -2G*#^\%ZMKU,F=8)RG
MF.Z-6%LZ#AU[#Z3PP0N$GT<R ?T&P(,HZ>]P2W K. @!.:5YC@@NT,N!7T4P
MO&A<:KKE$LPU60CZM>Y 2;H9']+8DC7U/7X\C7([\_B*58M7^<P=;X2<?O@C
MIUFEAB(\&?3!8!8TH6#H* S014B*N LA->@$AUHC%QB-J\TRHL.8.0E/5U_$
M24F'Q?Z-#[SVN>UY_UC;HK7EU+.'6"=*4$5U')6U6%M).-+?^_E0O[QS)S9S
ME-;-.(G&$$L@&@@WE%I1X*!VHS2/KKPLKRE)%?D0%1UJ<%Z\_,1Q?)U'COJQ
M*EN%13KS%:=H:!N3P"Y&X(AEJ)+RC$O"$IG,;[2WDU$>1F-,>J#FM*_9S:N8
MO835P'MG>5E0C>+<#2Y0?DPR,E+J@AO"VM1&3:V/FO+)P[&^0R][Y04G5]@B
M7J#D)%B#:#7EQBV&OX=L/8:!B5>N93&&J^I(-2$&KC)@955BTG;*]2Y'RCFS
M$*;DCT#$GU*9%I,*<%OK*7!J=(1QG 1GX768I)(CP"=(\QN-BK!($/,,#7C'
M#490H[Q*\!= /4K1F-R8!6 )6'VAKA-X)R:>P^7R[A2*-I!\"LFELO<4C=$O
MA' 4MA'#-;Z6?(U"*(SP/_"CBO;5+KBQSQA?#M2<[7"-!"BTV'@Z5-["5UV$
MMK;5M#1KJCF^]^2*3\6]8M?%+7Y(-L[4/SJW%9OUUT#*^&P1V#=6DPR/I86,
MA.:4:8GN!1HF)Z 20D1Q 86$?0K^_AC=%HD[&+H)/ZD2^FJ8&9:P'%%/Z;"K
M_WL08G1$OUOZ*5ES&[3)>#Q^KS.NOWLAC/Y>#SP)_5SIK..D31V]Y"U6+R%F
MBF=;2;KG2IQ?,HN"."DB%;R>I_;'L_=+^*=7'8]D3D5 3(=?:L!3Y4;L\QD)
M VLD2\9UC+"!S"CKI*(<B GX)U[88%N@C3<!'@@%V1BVRV?F+'6"5%&11%OY
M*)RRC4\PW3(,SA!9DA>P.O'T-8A[L27[X?H!=K;7LB%@/773=^MCS)%$KPAW
M;I'?4OU,2C=3XMEMK1-NQCF84BZQ.I -3K/<ECWI!?3H*3RZ\_.F8.KC1='Q
MCM(PH=P&<;65)>>'0<G%"GYD0BHSG)#O,O1+Q!W241C9%[+<#N5NP)?Y_JHQ
M;2P73\P1^6X/^V+"C)6<>ML0H8,+>Q Y3=].%(S'2WR2CGC0'>-9=*B\*OD$
MK%-T,">8B*,=JU"2<1!H3!3"1TSZ$?ZB$P5%4EZQ/T.J!-R-4#!D.K@9+G);
M,*C6!6"I^\*7)W5:)>94:'@(X=/@N%@DK'A969YY?_.!N_B-$;W*%!RI'-;L
M U2XG\.BO:Z4(JB7KNV4HBTY(2O/ 3O\]?RAF\C_80_JPE[Y-3FG"T\?290^
M@+9$1_5";=I=0(6^H?*"?%>8$:J-B2FPNU1(&%*Z':QL@;[^#:*%Z*BU'T<"
M5DC0W0+-7L,N5#5):BF<_J*6=)VNI^G\;F/XX\N/O94>0D15P0D _8^YVV=)
M3_4ZKB&I,V,;W!S9\P!+X)5B#QI)^>$LM;C,6'>OT>;"@65/MQ,,ZLK/6I4M
M'C-<2'1(V*F5HW_.">T\)9049[0Q>0\;:!QW/\5M2W:4P@N1E2"9AI5G< U0
M@CJV,)-GDA@"W,2O4S>H,HS9&I?H)!L,'ORE=NA=+P.3_BV8"_U3;372SD+\
M!149(EOFX>;7V%IYHS3GU]D+CJ?P[%^2";P[L/*'!_^E80=-N).!@-M&NX**
M@;CC7S'^8&/+'U9S\*"6)<9G;O?7)N1Y<T)R>O9IM:KO',X5M3$+*BKQ6_98
MF[DQ/-E0[.Z&14S@6%!%;$HU<:F&*9>XC>Z+=<,Z1=S$#-O<$"KTS#95AW!N
M43/IPK_YM><]!FL1:I/1I$@$Q]G40B'/*:A!^)"5I-.)7K"&FZAJG".N^L);
M-O6^ELALDI1CS"SPM0,%?DHF(*20<_V@H&%C<X0=Q.B1Z2Y64$>\-;C9'9W>
MY:X04 \W8^Q:Y;H"/AI^?PKW*9Q9*AJVQK\#%P@^%;T[^&.>XA=*>+(T++PO
M8?"D0>3,FR>=+6>?3(&"ZJNPTX+ C<(,&PK#^'=\8_Y+I#:?(>-N(P+.D?)V
M5PH>89)*T/6E\G?FU?Q#Q+DJJ8'1VAM%61GIE<\ZBWZI(U@.6!'5QQ''"\(P
M36NJTK KB<WV5,RF%YEZ3?WZT;CH&P?/RGKP.\'-<NP@3";PF5;J9&Q)IP3/
MMMZ_PXDVA1JPN!(- &EVJIK594GX_C2_ :'\!0O':6H*3:XAH(T?J)#[#3#6
M98RP/"\MVTMSM:RZ::#Z>_<W4&UK>XCVR<?5H4MUU2]Y:^.6:5\PC5O#Y LU
M9V75&'9/@P'853IY?\D-\6'$[IEE;>#3FSM_B=6$J;\A+J*&*LJ<R*O47])-
M\/2J!>A('!N27B75(F049OG3?(H*$0ZN44ZF2"2/$?."'53]6&7LQN&RM<R@
M)&$BA,1-7:NL;MX!'IG3+3C2!'\#I-,B,>!1]&5F@Z@TPZO7';AP0@DRANI@
M FX:(<2>767Y#06C6Z"HB^ 3J=URZWE+??1)B=IGV,SCD^- M$?9-(OE!,\_
M6P#1AH3/U:!8.(8#;-O# CGZ>=RYA,.[2M21K',)R2(6TV\S./7LX5N+<GM;
MPZ.9@ALRQ;R]Q-W^N$0UV+1]BRX$M>=I.\*\R%^Q[XL.#JDH56!%37JGIEID
MZU):C$"LM,^/R"%AEM"Z3U!R@AR6GD:\K18OQ#]1X>!\B"=9&N!+D*=R.-,Z
M$KO0!MA"\NY3AQR+NJ)J G.V&*NF,-ABZ+)K-=& P-_P--Q;_NY=,GCU#7O.
METKRI>*-WGJ-[:)H<[K!)_;&X/!O0>@::?>A&B<EVK9)L+/=_1>_NMB!E%C(
M* AW;=P(T+U-*>H$KCI@>!:J1_8_?#RKF$ X;4\@A?2>>I'A ([H.3=!WRJ"
MOH:B6VGX1%",I%2L)(<Y-M53Y,&"4HJ@O+R;I%!]?WTDY>G3/.F)KJN-L2W*
MCJI'NQWX/0IG<@Q$=?NDJ2 A1A<'22!7CFZ QGS3W-3/.]JQC50]L%0)B2T;
M@W41+1OLDY#M@XB!M]/O'!T=M<J8S?$R\MEBF,&7HZSWYW!8==_"GU(UTU&6
M4W=R,^$=3U#=Z;$;H5T3H;VDUNIUE=8=%-:]!:+:K@[IPK:JB8$Y;>1P'>40
M0^<U%<,^2N'^=HL0.OC;-R>M\[<U=\%(IL4EJK0H7P;(_9_@8QF%!DF_D<#5
M2. 25L+'ELM[UHB"51Z3<]VOB?-A=#()PO2NI4$4>IU,4Y)RHJ8>P--A7G*,
MF>>RB=ATU/DZ$!_JQ"@?;B?/)\5D4\*WB5@L#Z$/A \71@5:'\U3$KO3]R*>
MOK<!QCO ^)WU!\9O%.Y#QTMS19M5U[Q%LWG 3E _N,8EO$9>^-.@(1/T$++\
M(4X&]%FA$),NKH,N3;74K^:J+W>L0[74G7K!)[Z94^RBQ+_#A"@5*3]!M>EG
M6Y?DYC*(_SH\SXJ=$IMO;618#9"64=]F!RUQ6#M*_#; MP#+D'03^7',[1:#
M:MO!M'E=E<BB(^4.K]YG^W -&2I]J76HJ3RP+A9C)(SPF#HE3@T.=J>>+[N^
M[2]+#_.)TYUH0,WKM.QV"?W--#JU]U=*!X%+I9)\H38&IQ/4TKIXG)+W35YL
M*D\/JYQ%)%?KO7QT.G?G(/Z=)91%@F/N6E=%8V,EN>O$3I9US7*-N0G?C0"N
M1@#G:-%6)X)S?29SWC3K.,Q_V2Z7EK#=$4@41%<.YSY"?"2)H39U)(Y/W=3I
MP?&G;O;@1+('FY.V$@)-'NV[VG.&LQ]*B\0*F;[,Y)@:O"P^'R2Y%LRPR1&J
MBZS&#ZZ4PV('SG&XOFT,/UX8R .E5RM]<YR(Y5\0QY@>*)UYL=/"SJH&#WPO
M^%7S0.N[8_A#>5N(@4J$5+H_L'S8W6(/J2>#O/TT+OY4%5XI@?@4$SY*W2D\
M09YQ%U)4@>>E4L5DBKG)"BEF4^.D#)NOC*@6>;G"!<?$FBHK\C35E.P5_M*Z
M'LCO7?N#0;Y&/.^9+F*L]B1B3 GBFH&0<-6;2XU&N%VZ.>I(Q,YS?@);AN%V
MWN8$%;_[/:*Y:XRGU7R7^BQ1'E/A^!.\;_/^;F\APDFI;1!.-\%^0X+'S>#@
MJX+)-)T4)!U)['NHFCV*<!_*5B(3B3MJ98 LSU3,<'B4DM(P$]"(%E05NC[R
M=)KO?SQ+=\'EPC4Y:?,\P!BY>/C_1@E4&JY,8"/ES^;I<0YB*U;@"8"?3^"A
M544':IT6N[B#8RIA5:07CKU!TJ'#+.34R@?:8Z#!\?C*&ST)ACPU,,W/F?1N
MN>-NYKJI._/?]R9*N>W,QJU90''B9YMY_(4#D*KR2IK+O+M6*AIGL-\CIHZ8
M7PXI8,WV2MY=+_@EP9G$"=P/7""5C:HQE;WP #!9Q& F[97PQ[*L^2\Z2YW.
MB(AUE-&L#VG#I)9/\L&0$A*=MK#EG7 7BZ9TUNS1+ON<PU-/':?8PN4[4"/S
M[%@]CHE!STSM,4F(#N;/,OLFG&J:T\WN\=XA8^3(#/,U!-3ZUO. (!DL9)[1
MC&;E>N! I8FZ9H_9<,EP8XSFW7/(K:])][)(LCF\8<H>G"^,Y4B:Y58+TT!!
MCG2<$,-7Q@2[.=)MI=>Z,,B.NG\Z\%248^SGTL3$8^Q<I4:F10F6;ZV"WA3Y
M#3(.HK^N1K/[I7U6HXB:%N4G)"'EY>-QL!3C;D+-&W+;\9T_9Q(&0F/2*7YY
MXG95P95NNY[$^)G/^NSJ+"<MES)'M0C?**<2F,.=+AV0>-AY=I?I"L+6L02G
M8>$'I7Q"-*P1<=;PM7%!MQFH"DG9]3P[4#LUF$12)712(NJC+G$?]5)1=_)1
M CTS R4 "YLSUQB,)50 A\V127SB7>*<BR3+\FMAO+*9$M2Y)!K.L8N8LCO%
MX6*SH)R5%>PQ[21\;R M[MS[%G)ML:ICZ8TS\\S[V_T][OMF+6*X^V65L5ZB
M;7V721_8;)Z,\-AWATE1X@2!L J[,4^K]M+RGI["IRYHD]P!7ERC% $QNL\,
M$QS,9$2843VP[S1)A1QIWMAQ[E&'NDVS.#< 9<&H+_.I[>R^9XIV-6?UV&F6
M9D'&IYD3,A(MD@P,\V]$21,0K$O@*BI1:QY5I2$7SD?"!R_]C-17?M^6V37Q
M]I=Y]DO99E8?44N5UALW8TP\/);PZ[;-)_*)=%H''*.S4DYQ&]WTELS?(6=&
M*&H2U53&C9G)"X8 --GT*?P7TX(>4HH!2J11R"4)(_9ZC_AIO*&L?A8 Y'5$
M[ NF2"U&I94PR'#WK\L1?S@!UL\K]K<<)]/59X)(C:"E0,N#N%-5S5R[XZU6
M#YL :Y/7)4)$%C=?2R.0ZUX^%&/$)C?Y< F3XXB.FQU1+Q-.5BZ8I("HIY'H
M6/K;VT15!@&$D(QRL.7:6'%H)1 )-86O,UF>IL.'P10V09'8RZ @6"NI/HYG
MADIU07J[.B 'J7?G-.O9RFV_;9PUC#Z':3C"<V.'%G%C+[L )][3S+T'?<VS
MK9/C$V1EX!P$_[%0-V$1EXZ6)UB\<9DV$'$#$>^O/T1\A=0D1FF;4> 6DVS%
MR62:,"?D!(,LE/H>E%3GC(R=SI7*^7!(8,0; 4L/MD42(E3=HSR1YN@.&88I
MW]Y4KE;#.<_(09Q*IR=?K9MA@./7HHE+NW"Q :#K727NL\9[-Y FG#+Y8M->
MY)<F4UP1SI!QOVX!2R:M0910>H:V9!)RG'1EYV>I:5+F-')4W"5O09HY6QFN
M3+I(GS1*I,P-E-(+@3_@XS.O)KS,=)'-LA1U7/@JP%V;XE'?%(I7<]S>2HP7
M_(^\Z+5RQO3L,3T=UO/-='@JR2U*\UWG*9L/\\T7SC>190WOTQ#\*O&IPB8*
MB1DW$KFJ!A)FJ>39AYBJ!7_XN"1;[6/'5RJ:GGL^GI4)+"]S*CBZX)\PY=TB
MWC\9*4SU#WL;,2 XVX08)X>FIF6\)A+DNI2DM<F)MGE$<$VAI-:4P390"KSJ
M4N,59H#X$.0R-Y61#A3I\ AHSJDFA1_GF,4^Q#%YLAF62QE=Q4FH:95,) FU
M<B&UXV =6EDM)DA:BP5(>*-,_UUQ/91H_6@6IS?8DW+&4F"1N5N9GG%G\_A.
MVH:E4UTG)WFA1$0+A2!-1@\X[7ST(V5X3;_/>7B20\I+PC,9K6PJG1(C-^?J
MW=B,J,W[O3]]=_[KF9FHWDA'PO\+;L+9LL?F%3DLXM0ASH?F9Y.QXG 6=!,\
MNZ& U:L9INI+(G4,FA7DCN>5I?(Z47OO'+XJW4RMMW0_^)Y2YR7#&)FC#DYZ
MDBG_H+K#A3M!78RX-EPHI /&TA<7V/DO\_SF= ^NXU.1H#G4V.4E_Y$UP<G"
MZ@F=A=N'SJU*4>A:'EF +U/!9QC\ =/23QF)@!\L?))YRGH_\>]-^FZ<1![$
MF](BYFNBK6UH3A&+RWR#F9,_\,J''3EFG6;&N,/KT%557>.E[!SRWV;1K!<@
M ^76W.M])Z_7,E#B>P;E=HZ%UIU>X/!5?KS&!X57-J1.QT(:0&SE^?$.SMJ!
ML/X%SL5GW%\NPO.&F[TZM>7D)] J:;A)S[ZHJ"8U;%YU-[C[DWHLIN0MGOXC
MG$Q?';L#;K :&9R?=UC #A<0G@K9M]SK"I;@5.@IP19&8L?@6MT]?_^M7B1N
M2?S?6\D@VC\*C_IA]&(0[?6'AT=[ZK#_8MC?B]3.X*!_\)^C_?VM>>U.U^[L
MJ4&LXCB*#@9[PVC[Q>[>?G_WJ+]_.#S8/SC:^\_!WAY=_!A:LW\G$?[X^>W9
MI^#CQ=FGX\_G'S]<ZK54,C! $M@%V(8N%1"FI7JI_^45)B'3</8R(1Q]ERYZ
MY>\S1D@@1Q7Z6)+1IF//']LD<&^;$\%5 ?^+]2_+QSWXZ.>6OQ_V=@_[K1]M
M]W;:+_E1;]7?[VWO++_5S[3W)JNOY62?#DJ%N*44A>._MW:W&I)1Y=.7.],*
M<3Q)'&BI%87_<CN S^2'[W./OWR#M;X'[?;/=&36V2Y\) /_<:H*W9;@L>P6
M:A(FF4P*]-"[N;FD@Y%'-+9!? 3Z #$-./P/];>^1FG"<N)CL'_E>F#+MW7.
ME@(Y]OW<;W2"DX_OS@DRVP#X^.29<'519UTDS6K^Z/S?S8\^2YY3R9\T99C!
M3^- 1>7T]>FM>$;HNX+PN$-5R"P"^.4W[T]?TR._>7_^VGS_.2=2;K!%Q."$
MX6+9%QV]NC]%?OEK55Q!U 97O0WA#A@-OL-Y=.?F:R?4I$(NXP<U*,+R*D1S
MW-_>V>W \\ #8?B<2E9?'LGN)JX4O@5?<R#X-/*N,<]2KJ0XCIAWZ(:&/L'9
M3)8,>E3J'&M[N'!4*,V(C^]D3C[,*T&)]"E'_,&8%K6C9.!DVYIH(; M_ZQQ
MWL=VO\^8H;K@>R,8#P$YP>\@CA6VDU4US_GX_(^_]??[KXJK9*;,74Y51.,W
MZ4Y+N'W6YL2?HT#T02#FCGZA,'. @TR(.Y[J0$)Q!!+U]^W>00!!2JJ+-!#3
M@TOPQ7X;7A/$.X)ZMK?%:X\.@@E?NEY;M,!K$E7TV@C-6JSY7@U+2Q, 5I?J
M1WQZ#XB/44SQZ53WXPT"J7UMN!9/=)>^F0S!C:GM2Y'D!=HVOUEFBCFPC*?_
MV:9;778J9=A))+NBX86&(4>S.>:,ZTFI&(O9!3'7=JPNQ?Z<Q[?C=HON-$R0
MW)?4H<Z;Y /P^:78$5R8!3:LAAE'[E!*AE6'Q^R$L?JCYNE+/->Q8Z=:J2]3
M-'@$.P&5C. '7/),A87,3[$;P%E'S7>9Y5G7AX[6&69@2FW3=#=9C^:3TC,W
MON&MG]\-]K\D--9+_P[V]H#6# WVNS'MF>=,80:W5#39*D2\9UG-C?+ZJ>3)
ME8,P9?3(N;9&$>+Q22]GL?-C^LXM*V__8IY9AZ9Q@3!<&57N5,G3F3NV#%'F
M$2M[69W_6PX*/?AL<M4YF76>JTF3-D/N3;5>1H[;PYEQ/:73]1'(IM19.!PF
M:1*R:6):DF)#^>G@N7;7$L^UMC9DF9'\)*'!4W8",.]G'/YC<=O7RN0O#TY!
M;2R)6*C%,8A =Z#-,*%<FD=7/,\Q&Z5V5I6^VA@,#1%:9$% T4@IS*Y!-RUX
M,P-W=O]+&VU]#7?B,Q  E!5=-*I#4&:5LH CMG$<V5*M"S0TZ+3KY#JGVF0O
M^ !6K.TZVW^EK\-?YVM#FF8IW!B$+B$[2'$4@DXX1TO?-\^U'BW1]Y3M3]9
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MQ&UOV3[#$!L[BQ_,.*M2#\I$1">@3!!5)U(4^H*IR^!-XC\+2_6ER<UNQD(
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M;<.,'D55B1F0,PS+JDNM$%QQ8P<+F29*N#_HUK,O4W@=^C?1T:;'TF5.<DK
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MJ%#4$_5'J>SZ8=++==2"%O 5167B+,_ $9R\+;Z:,7Q!]$KY4\K83[TV2(<
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M^00:WQ#?5DWA>Z=&9C:3K(\>*J:/-?91_TL]C\K@OZJR+_-HQ%8C3[T:.0*
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M^M*Q.X_AP<."!(//7E@/$E:5$7T:WKT"OB$L*(+@3QY61^51!IX'_CO![Z5
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ME4'D2,)0O0E33H/"I])T4A'L,E_,Q2 UBROP@0^?8 3QHN9%$"_1(I)WD#:
M)#WK$=O&E'4<'X8(A94;.1OS<-8<-JONJ^3A8]WBY/3$5'5[XI^<!DL&9U%>
M;1/!2T(L,S^S\18YGP?$SXJUC<1N-&Y<9,3@Q6.TEX7&ZR?9.D2<-F]S7N*2
M=V$+O+*EWJ?:I0\S,8=K[DMJV6#J3J_N1M^]-D551)T>GN?Q4RVT)CHF,3XX
MM\-SKUK$/JFKTL.N>]W5"4W5CHD*(Q;.D5+.1B%4^1LZ<K  KUMNTW0YB4PF
MT%HHH>:Y05\3:7$E(-6&FQU%19)JP]1/O&+0/2_QFF9WD=[.2/!V%$'86UD@
ME!;]Z*YWBO=\"MU(^S3!X\?&.0R3%-I.\U6U1@@;7VV?7N%V%L]$YSMI3S=/
MCOV]3M[[4!/3,=$2%H\TG,UD/!X>O/^>&K,X/SY'U\6\'!!8[0SG*,\4KF#Y
M=1)C++GE7F3LK7=);\EA!U*2M85Q?$U0]W-2T\=MER7R9?;1\&<+?&BEK\O:
M,I[VB47%B R&H 3?,P0DP?R+LAF901T[V=\/R#W^VZ;#^&[:U8(+^(1]I#><
MYXL% :BH"JG!:161N(6^L-&M=PQS ?'%- DE/%A:S_&\!B4CMV8;/+^;M23W
MNY7&$*JD(>:XK%9[M0,_0>A;RV,['!EEGRAMX>@<)-;(_!->QIM54]N"IS;U
M\-%"<0CABD3AX10"0)9<"BS(/([=*]X'5PGCJ;W$SL^ZRO)Z@/.B]40WM,O8
MN](VN@,SBVU/)YUCR*07>GM=\^_I!S/ )^9.3-[ 1)%F[,.#M^_/H00R$I0:
M%5AO^J4:%]R-E=HK3^::BV1$9Z8_WIF)0' \>_ DD1:R B16S'P!AK2<NW+*
MV(Q#.[ WXQZW0^\2NP9S_]0C61!\^GRS!,SZO>I,2:MGKO4I2K 31WE% CJ_
M--1'"OT2A-[7P2@N&507J4T<3"0Y+HRV@!!HXH$+=3]L)3T/D(9X3JKIX DE
M6<,/3?@SFXUBK];H^/G_(Y?@@K-*Q];VCA!WDV4*LT[8OMG.L[=7@&-+UN-L
M9T18K]4A9?_V^20I6/K@C=FHNT@V8^UY5'PK$9#XHJ:/(%"V-"IBJ9OG]>"-
M&#%4IZDL-M_H,]*6XBYI#"'QEKDVCQ  R_.W$CB)Q*K)-C3*&IK>6/ 3 G=U
MAQ2S<OB1V'+E.?(&[693A[ZB;-C(K<I0@]@X0I=D65+0>$VED\74#78-4F^$
ME.2+^53[[5=7U"9X+BBO]'5&RVX)<+%)<M[C*V^0>@2*PV)-]SSFPJ1:-@D,
MGEX[SK30([B^N=*)[R3I!_.TQD;+$V5QU,I_'MKC5Y3]8PT?G%YLDK63M8.A
M#GN8%B')D$D KJUW\/" XBGC=7#02+@\?$(_='? E+Y!0(K"WTDL?6. WXE>
MQ3Z]Q$YOU&GR9#<N\UO+&BQBM!V@!YV3YT "*2:T=BL/(CC],M,G/$LJ03W=
M)G)#<8$+4*0<,Q B;,AJ(VQ&9+TNXW3GO>DF;A$8P\W,A("Z/@0K@5&%!1-<
M8)!"UOUN\)>2N -L1!">:F&T;F /(^6[Y7)3B^GO_+C"DI^$]UB(9AK!OL:T
M]HA)?# I7.%@?TKO%T;U<][BB"3N**KE _"2(-*954SMY@(_<=+)#3<5B"@6
M6[4J:2@(7AQ!=QD^06?;#,%HA+/M>$YY/#>?=O_P$<$*EA_#XXOW60KH"\>0
M/N*__LNWCX^_>:'/S%1BH.^5"+XBDI&V98)MCK4R\C-7T.'KE)XP+.I@%46;
M('8[FD*E-A?S@"RJ;JV95>M?9;R.@-[7S0I/BNO;0ZI;'?[RO=&4V6N/#-20
MNEN&S8B<J7,,[G3MSBR\% X *8YWO5J=C#!=, 03'S2!&)N,4OD%!BIF$I$N
M*^&M![5Z>,5F+20D.BO: T>N [=E<E(WP2_2RE'*H./'PE\_0?V(YULOQERA
M>?=!1 )=LO@.G$\_&5,(C=Y[SR-RMQ)^GW4.*$^^@^7?BAF0KBU7*D]-MZD'
M^QMIZV^*0Z-VX[P'X=M!9Q3C G4"$QV'$3#N?778JL/?WE>';QH?;9SEA&N1
M]+T:[UVZ;]AP#H)ES^.5#T&G7KZ(W8=>8BKZ$TFN,+GL;!:>4:@TDROLE97=
M26*$8S!R\FWH#9-7HNW\Y_<GIT.U")<IC+UAJA_YY.A8HRU+HFDQ( HY@6AA
M-VN:]&6!1#J=\4]_[!\Y!;Q#!$@?]YNCIY_XN.K<C#_Q'9CT,?)932O>U)7N
ML;29[!I0D;4>+P0DD$_!Q-XSV7F<>1K4+/414L)CY<E)J<]&Y"\H0HF@KS'J
M2NJ4[(1VD0.#'OFDAO(M"4=LRF3+)U3:2E,^Y)_K0L@XNY0/<3L38AQ O#WU
M2LO /68?N@.+AMT8(-DD(30(8)LY5>U\2.T]&0#:<>JRQ,&UQ##,S;W.&1A(
MOW=(/M?WGKA 7*6,2S QW.)_],^(*R%&!PI2$I*]#"OW>>W5;(Q[QV?)3+AV
MW'UZ]-T+R9-1;M9$8&8BL$F# W?F2=NU]HA"*WFUZ#O%6BT>;?3S-B/F!:9-
M4:6?!4"I;S!ZBMV);I=Y]IDS/M&UB%9+\@;)EUW+\F'?B\Y&L9J9"B-G3$$:
M=:?E%TM4S>2'V&A$.Q="WALF9PWC3TSVBQ!?,BDE]T;SD3NB:IT)D_OANCFT
M/_<2-S%4#J^:?\RX)2R\1;MQD@]CHK9'I@P<,]F81713BOS[>,W8R#Q19L]<
MA8 NC%)=V-.9ZU]V5ZE&@&-[M?D_:0>AUD F#4F*&[;3=SM?;45G=7UQN"CG
MZ^^>/ M/@5"I I3\N\/C;S_G74\HF[[K#1]_TAM2YN?QLQ>_3WO'V".\2$;D
M^,D11J#/J="C>K .]M0P<2=[5$Y^\?M,PQ==<OLV(4^/OJ:Q4!&86=XI0F-4
MBMRV^MC,1&DAH/5*,-=^AA5X<3]MGS]MI+$S/FLT37H<G/+A8?K=G<!,7I^^
M.[D3.A\G.S3<TT,HFF^S%4DC$!6&'+% ,UT821! 9#C9QPFND#\N">QBQ(.4
M:J<,M-#*JQ 2%3=;DI%//TT\&*+E28R#G1 M@85H,GRS<)5]:89'>W!8**:I
MTIF<&+!(2VGVC9R_3L6TTJH/AAB4\B$R1 6(?<D%XXISBC:P5AU/ENHRTP79
ML6*I$4$&H+C/>E ZQ0H8!E^MU/=RMP*TLD%EQ=T'/)@2V&>B;O.9H-1&G@S+
M3KD@H@\URU?Y#"[<=XP,LAXV";!C(EN?[06@_)&:GI)B-?J>+QO>VO1H(EPN
M?Z]8"BW^ 1<9%0^WR\@X6D8\OA1_N>D 176N87I]\CT[__Y=MT&8CK9"V88D
MPHM](RU\5)N11*(#O_3;G]>ZT!S:ON?Z+I3A,#9"8_3+V/2,- %ZH<.BUY@F
MYA^DAR)V1FN\<_Z*@8<OW_Y)U4,5:LIUO'[_LI2S^I1L] ;29/X?D^\)MAEB
MY!.N'#Y^=/Q(F!D9%K)8N$H&5\E#Z/YQ8[QMLB[_(PQQT2Q5(BT:.BMAC-DZ
MJ<R-#*'G27+GQM'DI.ME)Y*U2WD)IEIUQI%UUJ^:17@F2@VX6 U;/,ZQ9I?I
M"DJS'T'_]"Y-^GH4ZQ&-CE;XB'O]H]!C)\T\BFCF;$2L"$9!=FH>'0UX[[OM
M8CWE^>YZ"CUN5?S?@VHZ^_IY_OQQ/OMV.GOZ>/[-\Z?E-X^_G3]^.BN/I\\>
M/_NOY]\\/]CK*@Q>HWSTI/RZ_/KYK"B?/'TR>S[].O]F6CQ__NAY_GAV_&SV
M7\?'3YX_/3[X]]_'Z=N1GEJ7R\GQR=$H?< 7? A<\3NR^]7L$Q[K_=GY?TQ>
MGYS^\O;]^><X^/*K=;/ZC7W)G>^SP[LD6/("C,X7BV8:[(:>H8J:XRR!2N<
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M:*CEPN@D*9%XX8CGM*&&PR?R5DBG!EP=I5.OH/NN%B%0NU\,7VPQE%1H@=$
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M3#(L=IV^6\Y>=D_MB^G&7!ERMUKBKV+,^&1D<E(FLLZ)?*M]X3=.#YYI2M]
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MCG_6_G)>4#56L*AS>@6J]L18K*=R58.,3Y"Y3-\<"\Y,MX'<(BUZ:R'2J^O
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M944'#^2^U$YYCQYV90+256Z4@9AA6NI+H;(J>N'-DHKZCNI1#K(M:F>4F$,
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ME7L$LN 36O#(.JJ6)A@6$R!F98)"H-0-\*BR=BNYAK"S])-S.TSH8CE<%C@
M.9G8]Y<"RR<.L\\&Y$W:1'+"O3JBX#ZA#E0F=J4&H65[^)OEF_B;MCQ ['>/
M*D3(0E49RJ6UYH%I-#*DAK),9"3H#%6#Y5!%#%8K2B3?KHBS5$#)TNSB=3,H
MB>][\LG&PYG##IR^!YVGF-\!7<UFU3.Q_H[G>]3M:MB]GY"HD+2!\W((]2U
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M>E5>EO-'_.S(>N*,2 F@"NP/4R9?&/.@92BA1Z!$+6:)U9TZO':',;2?E0B
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MSCV-%[74->35B$:_M:8W1*4=$MZR*;#6K"Y>+ZEQ>,)ZPL/C<B"E#<_<KY:
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M:NJ9Y1B,LH%XS8WZ]D"T=ZO##GG.[G!2DYJ150Z%%S-C,@A46@LR O*6JI+
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M^@AR@?957W;1X^18;(B0Y]D5=@N\-2:MG\*&02X-%G=@?XX+ NQ?.69%,<6
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MG6(]IW>*,2HG2;K4YY5^M .*%/H?#7Q']0"10C.TD-"9A1Z;[XK"!J["Y!2
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MP&C>I W(N&<B\<EQ[BTSZK[6UA@!SNOGM)6Q= ?;DT&*O-;P3]%O)8)HZ?*
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M -+!KI[O\[*<C#)[YL=084#1)QN"1:\H4R6GV-@D*<-JZM<QT/Y5A=T58P'
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MM'X4@4R>M(8MN\76X8I7:;\#7/T-5P;E?9)9]&.6S^RGOY15GF(SVX^DP<S
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M)+K*RX'=X&,"Y0[YL*1<6S3)J-QC+044).A\@>S,#1P[U34FZJORVK!QYZN
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MA8("!V7CRR3>HG9T9G//G#I-09=-03VSV;<T!6D*VCU?H=<K6U^D"4@34$I
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MGBN&^K9EOSV]--+0K:CM7Q?5_MW4"2?,& >A$803QQ?A/F>&DWD]UV.^^V2
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M=.01<P/N27@#4H"%G P!JPAG)WQZ8]A-NP4H"J-EA'^WUZ!Q[,WG4>;53]\
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M*G[O\CR0=/5615WN%]VTP@A/?*C<"@^XCQA#ND.@%9*M6:=KUK_ZC,$=A(N
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M%9&),NB5W>@EQE+F,=#,1'B2MS!H*-]=SYW?:/T;7)]4K'\Y,[0W09C^/0B
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M_ F.$:7+U>09CUB#^^#,^-AR?Y0,=&.CW:_@PT!TJVZQAT->Q5K)[MMJ_("
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M:OC7J7!M-+F C4/X_Y%\L_BZ 5_]N/YYN]\8-/._P@'#>9_OL=2/M#6^/8
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M'Z>,=%^*_25#AK&^/]>Q3B4OH@<.CZ [E*"?!-2YS4 %ECSL#9N/13*FC&&
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M?_#@?LDW]T[H758<EID(7B&EKDQPSG./))]F?Y>._$VUP-3?+_O=BX"'*4I
M9-PF&T K[U'1^2#/YX-T#I(/TNJ<,A_D:*#;OA*0LCF^IC[^SXDG,(?Q:]&
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MSJ_N@C;;/]MO].3QSNX@4(YV[5A;X9:-@Q5-^BQX(L>T:Y1]&:Z 69Z)=\;
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MB!>0MJ\  2#>F-*K(7MX 0\1Z.")!Q=6:(_F\ [BCK2/;"G:5P=FSC[XG4W
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MZ[@PMAU("WABE8Z8?T2 6C JKN09MO)?($S@GSZ%*<XI%TDS'X/O?R3?PI:
MP-'&OC==V-;Z8_E^/*86Z^RZE&>D:Z\4%NC-<'T$=A(I3BP+3GG<3.UY#C#$
MC43$.9[[?#6:\W6G &_!^WUBA; 5'SV?D6EETT7RA[X /MCO8.Z$+!8RV5!M
M0F"B0TH1S$#M8,;G[KPEI !.@;<BF3G3 $U=V*HA"6PV6K*$AO:$L $.M,(X
M@R5::;P\^,R> @?!M(C3T+YF39+EZ/%W+^Y$O/X8R(R+)_/AD">'$0[7B#4
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MJE2C0J5T) I&5YE&AR%+VY KT4@BL?71\^&?[K[BZ@QR=W/$54>BNE\JH?M
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M&TOF3'WSC%'PVN6OA/"HM"$0G[T 6]H"J\ S[^*,-(XZ1,Q?C$9W85)\8):
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M5JC$GZ'3F-$WNH>+;'.?PLBH>#_!(0L#,=\\/JWG0B'Q4^&Y!E)^T1XQFTV
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MOB2X$&3?3()8R J*<XW<L^B(%>YG'J6X6P\OLI5'K*U?NA55<^:#0%THAX&
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M :%WC8'$*DM]#/U30?;^IX[1/#JT.P#MIM[O&S4QC16^RL37!EON /CJ7MR
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MWZ\(]D^Y)LXK>0M09*;W!C8F38CE/>3;<O/7H?_+3=94US["_N 7B#'UV$D
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M'MP7REO4Y.MCDJ?&5']./4X\/WRB_C2UFUGP-B]N!J9J1*ORM@XIJ;<%9PO
MV5P%IZJ?4Q&-Q?5EH/G4HG" #AW*^DOM)(8EJ+M0O1C^%F\DUH/F36[#PCI(
M^^+&Z.D]91^HJB$'E=/EH+?#T&L:JX'%2H6N4(5V0\^WJ5*A=Y;=T2:^ ?8+
M@[Z+9F.WK31KI5D?4F+OA5F6 -+KE16.J13NC:0799WXP:J1]7=0DJLKU0ML
MMIO\(F]7706K/.I&=[5FJSQB6RG:\HGM$I [ "U;-P=*R3Z<MX31"V.>AO,
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MWH\AU06',T1*>#IB5J1^&%_'HH@6VVFW4#:G)-ZSY\Z>I&6@/24D>CU^Q!G
M5N>SY8]DZ *:MCQDZ$;=MYRCMZR'0K>[T,-"^R^> )'0&PS;?:=O.\/>8-BR
M1]U^BW7MWLAN#5ECT+$[_VQV*_*AIS!6Y!_9Q2!DSI\7S@A.^-X9/SLO$5H
M^MW Q>B 6+Q#?BV7?QN$[RZSMKKRFF$),C-BV)%9 Y<[=J81>R__^.!ZT73L
MO+SW?+HB>NA#<KUV6O4A(/*OXWW7ZGSOPF,LWBR^KL%7[S(^[]?JS5[F5_5:
M(^?GS78[UQ/+-M6N]7O-@NVI4^MTNP7;4[_6Z]H%VU.[UJWG6^EUXE.OUNWD
M??>A]]2MU?NM@NVI76O9Q:.[5F?U2IF1NW97^9UWBK.19.QV6Z-&ISFPF[U.
MJV_W!NUZH]MMMAW6[;!^Q_EG_:)^T;AH]"]ZG4ZK06U,#Q L2 G[)<GHJ%C!
M21R+&M G/(8'O:LCGS.A/&HJ(VB'UT^._\C(-<1#ES?I4.7>>]87+Z:[N:[.
M"UQN?6E=1*D2DKU?4>Y&>CO>/U? BQ0)%9WQR'XTUWWPZ]:Z2WT7W:6NUW27
M,I>_M\O7NK[PO/9$NPCK#;:*,$SG\(!0C1YNUC5Z,'>^M_) 67IM6/TIF@=G
M*'_FV@]Q[9RQ?PO\"TLO6;I=6[)D0+ W5K/,W#'7?1AIJL9.)).FER"]F6[S
MT1D[_I!A^Q$96+1$3+%>Q8@C*(4_O6 >C5\LUXN&XR!B[O&FWJS)(<P%CH+E
M".Z:HYSO[ 7) =Q##G+K.,45Z9!PK]P]T?.RKI-5'QD68%C :A;0+F)]E=VO
M7-J]:C^C7X-A$H9)&"9Q['9QG0T;YQY,8VC6*Y>]C-*ES?N!&7(TY%A<<LQ%
MC=TBRNQF@V1VV\ALPR0,DRB S.X=66;G9!=VY;)3;7;3?;^-2#?4>@[4FHM8
M^X44Z<W*9;M>;9:Z79QA$H9)G >3L.LG<M<W6Y7+,L\V-RS L( S80&-0NH)
M;:$GI MN#9,P3,(PB6(QB0<VF0:A$[YP#G'MA"'6+_,V)]OPBRB+)W2 )QA^
M\+K;O"?>"6L,+[Q?%T^>ZS+_/>)(MW)YS7/G,5&>C4;82"<8B3XZ_J/UY=/#
MK?7FZOX/RZXW>A>-N$'+#@F N^;XG?7S9]G*/)?CU-YT#.WA["T<0&O&SY8
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MY\_2T9XOJKC&/;2OP;7-)O;^:[5W2<HM8*3FU,\;!%[G:=D; K<, AL$/D:
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MS0#G WD%1"M]:K,73"8!;B$8_FF< @7HC1.#YVYT3<"Y1]CDI:IV'=T#=J\
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MUVB RM\R#+%8 *%F$!X+17H'L[Z'P6/H3 Q'+ D >SW#$DL+0!N[6!F66"R
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M$5'Z\.#\,A9?:8#6L,W4M?)"T.X!(S1=!PH&$>PR"U?,_*$G(@,\7O#5F<U
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M"0KT#U1C2$7>ST\>B *!0*3'Q%W0A/SBD V"$(Q@+NB4$H%:SMBCA>A'\PC
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MI?2/BL4]AF#._YJ]]^>3"S<@EQ:^J6)%P"G@+7WE,.@W*I?-6O-O[Y)[O[2
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M',&K^;?44$KTA0BW"(4.:6HU0R:>_5:M"1DIH\+K+F4(O'WBH6GX&&#7!W+
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MC7>9*'J6!;J:"Y:28U2=)D[D";6LGH3E@DO%Z9#8<@0M$%!)O0NN?XJ&.A9
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M6ZQK]T9V:\@:@X[=^6<?)S]N,03J2P H@NE<T4/HN.S*=ZFQB%8']<F+AN,
M:XS2\YD:&?.9&DOF,PDLIN,T[?J@R=K-5JO1;[GM0;]G-X>=D<VZ]7J7U=O_
M;+0JER=*J;)1OO*9SA8F93<:'RPY"5VK#ZMB7OK:T6A[ 6UK.] F "I/$!^
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MQYG"1S,:8I:+2?1:RYV4*5[P1WQ)"H/D5BB:?BVVD=?X;370^,W@C-+XY4/
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M T^%6AZB$,!U@/\B(W\*HBE&KN/)8Y%Z7!B%L#><>^GQD<+#,(@B->YY @8
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M=PTI.9MR&N;^V/L3_::481AYCSX-!\%=/3G^(U/N'7H8(_V8.T>5HT($);[
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M;L\ZD.2CRS<O-!TAN%0?DF9@W+$R]KJ])*J=O2/<J/TN$S7B1^ID,)6&6LX
ML?X(T*I<YTQ=:6^9T.OVJ^@EH;??R:(.H6M(Z(916[=HG=I.M59[IG7DBP54
M'&NJ&Z7!4;F%V&VLW/E)7>5^Q8_1I5_Q8W3I5YV)F_(LI5Q=I2 [I+-92JIQ
MMBRE Q&>VE&=KBE#E>V%+EH%9\ZY^N2Y5N60U>0J2HZZ$VOM,24V9+EWD1+/
MG&"6IL0LQ8F#J6)D9Z?U.D!\2_K0.5/))E(_4\DF\DFI9#QWNP-)6:?I$5=1
M2\4#\EV4O!5RM@Y+7A5S"FLW"[FV#.[^2-YSMKZ:3'!*7/-RM]H9*LM=#>6N
M=*2 ^6'MVPX*7K6/.=P2S^%N75VHT%3L,,O%+N-ZGW/TNN-:N!;\;$(EJ- \
M[#!^&H"?6A8_N3'>#Y5 /&?_,&V,B112\TI!Q5-450HT]#B-1"F;Z956"CYY
M3VPD75_U@EJU73=@BC6@%X@5VI\5N1%*T)F$="8:?/851]]&U0:Q0A.T&N@K
M,_2M/8F>.QHNI56<LTV:IJ"+/\]57E>K:+=7FJ:B5G',Q?^!S/QX@M3DYK2*
M&[#FFM J*G1YJ\&6)XS.N#."HV^S6D6%7F\UT%=CZ-M4%C_W59Q=JSAG(J6&
MCM=&$RDK;K^R.F$ ?A^-7"2)E!.A?\H$]U"<09<X,6$R0T#Z>##5#+W'R@)W
M071166@JC5 7$3]K#\SD/H9+:0/G3"/4I6-SO"IK ^WF#^KR8*J.)OKAD,56
M&^ V>MMR]<0$PBPJXO3!7LM5;H1W4:Z>F"18.L%55Z^TM]LMR=QS)A#JD[;\
M^NVF$.HTA5 YXM=/1*_&3=JV1>^)R7@5T94.QU-R_"_]D<S<XNVB9#XQ5Z\B
M^AH4?>7:TU"X07PAX2R=,Y7/P%0^M:@(\V317/$,546S@3Z?D9[3LNTG 5:&
M!S=^(I]?ZDKG&S \FFC0=V)*7!8EI7R4[(_XY89Q!\6O=&+.6Q8_Y4,LDQN_
MG9>OYTQJ,]#+U[SI6_$,E>6K2J=M'XE!?[9"+\J3UW@4^OILGB:4@A,SVK)T
MA%/[>"(\Q\^&E8(34]:R^*GEXR<WNGNB%)PS)\W00;P.\[+2ZJH%[::F&09F
MNLNY9G>N6J!SJ[MM =M 7[RC" O[1(35<B;8]T?^<J.\B_+WQ"RPBN@K,O2M
M78C&;?9+B><S)HEI8ZFE@'7%4U04S]H8'5.E ];RF-OLUV<3-:%2-- BKP21
MT6I/)6<81W]4"F[2=U&E:" !K@3ZJ@Q]:W?,X1;_I52*,^; :>/"'+C3,\\K
M'J"R-H'3DHX:^XDV(?91F^ =]-K7)LZ1M*>-:=*>W.L  7=0=%&;.$?2GC:F
M27NR7KLE+W=07$B;D,^8M*>)X\%4*7)FG:Q/5#Q"57U"% =3?33.P?&?A*\A
M60OOO&<WW1/?=*-^.;+<1]U"YIZ*MG4+N:&40TV4<@FJ/[H#]T1T4'>0&\HX
MU$3Y +_GGH;.ZP9G3#C41*7I?C<5MU]9+U"QPKUTU$+F%GO;4K6AG#U-G&!G
M#J7'8I6;Y%T4JPVTF3M4X:Z)&J]P[[W,/6,^GR:B][%PGM+I@K?5;#Y-- ;3
MR4@\DN2?ZH8OU^DN<P,F0Q.RMZ&N;9HTSD?)_LA>;M)V4?8VU+5-D\1#+)/;
MM)V7K^=,R).DEN;-5#Q%50DKH=]FE&>-[PRAVSQN@A#EJRYPX[9M 7N6Y#9)
M89,O^IS<QFW?+LK?LR2W22I#7SX.KK?B^9S);1+Z^7+,R+K"N=W\-HE-B"WI
M=U;&W/9M6S0W-&M5DW3 1Z7/?F=N^W91]C8T:U63#,3/VO-+N.U[(>&JG#/7
M2T9'GB0V+5PKGJ&J<)5%#.KF-VC+$:XBMWM;%JY*4ZE2,A9'BKP[&\?/1H6K
MTE2NE"SGXR>W7'LB7,^9+"4K@ZFB9&<PU!6N[69,R2H-W)8?8UY+OMZ <="$
M?&TJ:4J> $KVNM$*-UZ[*%\;:G2FR1KB9Q'+Y,9KY^7K.1.C9&QT)A9UQ3M=
MOK:;&"4;:+P>JWQ.#?16)&Z_MBU?FTJ,4K"5F=CG6A]NOW91OC:5&*6(^?C)
M[=>>R-=S)D8I;74JJWB*JA)6*948];\;ATI7GG;<NG0]2U:4PEI^3;AQR]&W
M6>%[EJPHA;7\FO#)6KV5S>?,BE)HRZ]Q"[*YW;PHA>9%'0O=;IM\*WRT5NOB
MN:G,*%AH:N@\>,OQLUGYVU1F%"R4BY_<^.V'@%7/F1FETJ$$+0C8BJ>H*F!5
M$8U?XXCQ^XY82?BVSAB-&[ @&I"PZHGI414QEM:Q&1HOR^7HVZ@ 5D_,GJJ(
MOC)%WPD/_O96/I\SN4JE[CZI^<*@BJ>H+)_I\,NR#:G4.H5!-V!>-"&<3\RM
MJHBNU%\CR7WV3G/KN(O"N8%^52705V/H6]L[S8WG2PGG<V9FJ7KS RDJ'J"R
M7#8JR66>\]RZ7#[+[,G)F(;=M#Y[K;G1W$6Y?);9DQ.1H>^5&<WTO1J5K:5%
M] 40XG.X)/Y0L%W+V>#VA87MFJY%!(>8 0GV@<^UWN;F_APF+GHQI>-"$VDP
MS<F[Z(\ X(99!P7 $;NL(HK*N2C:+^-KYOESXM^QA>[QS8'GV',![RW^$H>?
M['USJLUV 03YYH6F(SAPJW=@?:P  6;A25*@&8BE*?,,EY-+Q)>[HGPQ\Z>J
M*E$3@.D(5VM?\*89VH,[?VNN;:"(7U$=^CR#DYKXAJ"REHL-#_4AZ-0]%M*-
M,L&VC3O.>%IPU]TNXVE?G6J)\:B,\11F ?6$^JG&]G-HSAP2>RR+/-I&3$6V
M.P==]/[.:-Z_G1J-1Y>\Q[NRK<,H(ZHG#\L37[<K)BH>(@UN:60H"."/U(=
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M4>[FYDL)@5".]RN-,L3+7I-ZY)I.9H@((SM(_9R9MT BN-A6: ZHUP+,N8&
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M'P@)\N2(,9A.C!QG3B1'ZFD"99I5W:PR<&0:97EE0!^/!].\*?5]5@:D.LI
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M#M$<)N%X5W$H*;65W&XX6 I[75VA X8%S!KWO=0'8==(\C*^&78]E0D20Y7
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ML'88Y-TL=F=,+OTOM$D7\5>VRYJ:A4LSI%^GWH#/;[O?^F1EVO!6VZ6_FQ%
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MSMN$T=]TC37HR"O3BO392 >EZ Z08]":$V0*-FB"Z#K9;B;A.;&A%'FLM[]
M8*(+ 998>8^^N5[:5NS6=F/5#3:^A'OV_*-QLWQQ7M8O890(EFFY4D/OB=1
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MG*(OWOO<7BR(3^C;9B1\)L05@'EMX(;Q4=\F,7VD<.\O@?"=  8&P6:U1@P
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M&;"&X.,:0[20D$$ ^J'YY/DS>P[_&,;DPQ0\<_[OS3Q*O=BZ_W"+ =TBB(4
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M>#V6>+V=XQDN@?D]+@60UZR^A,3Q21SUZY,E4"?65CE>$## )8*%,:NY, <
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M1L&RV,1=$FRFX=+D8"!RM+)!$[Q$UQ/1*03W'H,L(Q>)E%>C"T9%(GXSKM0
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M'#4?'B;YM82/W50F$#N:/].<(7HAR,P!(QR6I54Q2?"""]_Z5)6P7*/ \_6
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M;;1KCE2E5T*]$[R,[BL<! 1!0E= 0MHE2 COB_N3T=EI.^(R\*)I.QT(Z%_
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MX--6[UR63R^!,]#F/(^]<.!%D:'KK7B]EE3=[M0*5('(,.)GSBR-VQ\89WX
MJ9>(T;TG:]LAWTDZ)/5@?S#<G>WJ)KU083>"?R7FZI/M_-!-PLNCF:F]^6B6
MO:+O:H)N-^OAA400$J&X1$ [J"*!4++D:(8H@GU>[SLA+X2\$/*BG?*B 3DQ
M0CDQ'0DY(>1$^W/WNR,GJH 4&A_.T>>Y&UP6'_?FXV[ !@DN$US6,B[CF/#E
ME>R$&N,"44[PH.#!$WCP+-Z;4@.7TQ2DA;Q7$=Q^FQDBDWQZ4D#_%6!N5^%I
MYA1UUQ^KQL*L; 5<=UQ* 2'?+7)N+-"J#FEO/E50NZ#VBU%[ U0N4RH?=[FU
MFJ#R-IK^1X H"@:YU*&"\%4M:6XI2.22),*-T' H!/,G)EGX8T$BUT\BQTA#
MZ\W'RMD1@H8;"W4H"'"?5]%[3G;?-3>HK,*>G#43#%"'H]Y<GG;9<A0-5[M%
MSPU& \;834L==3D:(*B]6]3> )5/D,I'JBJH7%!YE7:\.JPH&C %@_YL5T^0
M2 =)I()\#74XH_)-$Q3T&BGH',J1AT@Y8[FJ;#N14'#T[/](8,")7(+:#% U
MIQ5%Q>&#)+^MC5]D=?-?XMA<5I/1YILJLO*NPV:H""=WB]:;"RW("JH61>YR
M:$%0>[>HO0$J5P65"RJOP^I73@DME#!'M'QS1-#/]=-/%7$'><2$W]EU(H*"
M.DA!9U'.N%V4\PIR&+[EH\V++(;ZC%6U;6&(R36$(42@NENTWF 88MJ;:WUY
MVF4'35![MZB] 2J?"2H75%Z'$Z#5&X90AI6%(03]=)!^J@A#*+38:Z)4!5<A
M**A+%'06Y2CMHIQ7D/[P@]O<3"1"U&>G-@0 K"IJ;ZX,L\UNNV.1BK!TM^BY
MIBC#$0OVP$6:('5!ZO60>CT2>R0DMB#CZBWX:H!!$79M+JNSEEP9"AJY)(T<
MC1,<4=(';KT$^5P_^1R3+-,V29;*.RAU*3Y0N/';Z;M0";IKFZ%=ZVYVT$I<
MU_/M;3DGX:G&7(TB,4I:W#<<9J53=\SRL@*J,1!H(2.$C#A51C27XZ)B%>>L
MKW(L&"$CA(P0,J(U,J(!V2!C3*^O:MD[3B$;+B,;Q,B='OG2E_(KXZD1GDS(
M)BD42F0EZ2[\/THAR5Y+"]^%Y^!/5]J 4$)A)(&L(E(MLF0T4 K,_!V(2P,%
MVJU#3!"B3^0='NN-,L!U[^^R[A(<H#=_([^-Y _=<I%[4$01OBFC":?Y.;(I
M-??96IH^;@1\BB,8ED]6WW;$H3HQZ&J?H,_@$ZZ^4WKS:1;.Y*V([PI"^FI;
MRWQ:*FM8J0PZ4=":H#4.K9V3EJAJ2%J:FC79.TU:XOGRSY]Y%\0.<M_$O8J+
MHJ2Y"DPGW=L678CN@='Z7C=U:TFD'QM"SJMO/7,C3X@1G7-F5QU .FMC6JV?
MJH@NE<VF4;&3MG(]?;3/%'47"AD).2+D2#?D2!6562IF[$WZLZD0,T+,"#$C
MQ$RUY7LJXOI/^S-Y*,2+$"^M%R_5=ER_!O%R?N:OG!.L*^T-8=OUX=D-&04S
M"V86S%P7,U?BDF Z[;BO3*NJ^1>\+GA=\'KEO'X.CVM#&G:09]F&7YWB<7KY
M\YNG+TP2):FP]7SUMW!"2YHL%,X^>-L-\LGM+.0=PUK!'M[>P ?L@(*K2GI)
M&>Z8,E-N9'9"]!;SSHL^5JHFI412#QWRUO!@W<O#Y"6/JDCSV5M]73Q2:EF'
M#P5V7TI>=-&EDY7DV9*W(=)?[W_<2YX#LPDXSMOHGO1,'+*7GJ73[*T/9$FV
M"^(P)E#EOJ0,%74@/6R(2Y)P+&R(G0,,YL . &%LX0\77@RCK,@"J)PL?0>.
M _9%MU 5Y33([=.O8;JZ9&+>F",!4<(K^I(=X=%*^V@P@^Q127NY6IFCC++F
MYO]GX?PV3_\<N01WU5@L1S-]INC+Z6*I*>O)3",39;I6M"61%V-E_"]U.NHE
MG^+QECS=9R[\I&H^D8?'8C$*RMR[0;C47#(:WJ@\WA[>:(W,^5UJ,Z<#)=I.
M$.DVRYZX!1E,',;!,?U+?P!MK4&^VODL'1U=-=0PC:CAP/9J_.T=U9+,&>]Q
MKISA4\H'Y-L?$=]>BJ%F\O$ME/G:1Z;:Y\#&C_@;/^ZEF!>$V*-A1=I[6">O
M%C\3*OOOEDLP-V !C]*.]@4;U!*XS/ E7Q-)'_9$^QLCS'&2%K:U FD>27<4
MZTR$T^S@&[2=0#_LZ86=0];$<? +SU[^1 6V(F2+%HVT>*$ZC,E]VWDKZ:!S
M]A*/GW3#I#^.-1F,2G^H.P[]E2>M=<.1GG33)]*SX6VDY4:W'F$"AI7\RD'A
MLH(GB$&G#=_"[OM;GVE4MA:JZ,B&6"[8%Z"<7)<.";_]L8&W;FP3Q)+[9XG\
MQS>\%\FFPRQA48;'?DU^[>!A6)Q.M27,P/27'J-<.B-<LFZ:]C/-3\%E)1XG
MJ"]=:>T[=#8KPUWZ+@ZT(/#$0/K#,>"!0/GK*WM'&0)T\N\?'C[CV_ZO#ESB
MO$B!:N]+%O' #'<(T.-_<;=VL#Q0T^PY*Z/+77^W@Q/& \=7W,-VZ-;+G^'<
M?.O&7J_AMYYG$BJ,=<NBFQ#FA$O/.IXO/@]O@J5^M:V;(-\2_G1]ARZ9F0N6
MAQ8YVT_)-/2%8;(9@/S'I8,A4^Q\!B#2"+S*(Y(\IOMIP)R7'NY2L>?_ 7\F
M5PMS!0MEY>((8$6:>,HK@C8*+I.96'!>AHO, (,8/XGYPB9LV?2]"Z0VH!"'
M66IT$/@6)T8_2^[Z2Y^^F_Q:XA;"4>K(8O2PEK;K2398MDDRAM>N8)"E!^]\
MAN=AJM+*?K88Z>M(_ ZP)[SV*QQ]=/"Q=26]893V5GK4X50&TCV8SO"O?#Y&
M;@/J->"HX)LG, DI2^(V.3"H!(/27R:/0J-'@8H>20W,0L-B3AS\-9"RRJ0!
M47U0%#XDZ,$A3P9Y=M%=-2D)I 7+VK&WL/&I0P6.V3M'$ @&):F(E*3G#6$"
M=$^"&*X7V,W/2)K(LS:8WT#&?2K%'BT8UMU[+)8I(2'8P'GN#L0V<G-,%AQI
MU4<Y[<(Q!GQ;B'!"81;+B%0&W@\/_H<Y$T#4GRW@/$(]C7SIA\*#S<,MP!/X
MBT>8)NPF_L2 AQ*'8K,?H/@+Q@R_6-,O]D\+MOC?P%3PAK7O^52_N!L0WC:<
M^YM(F/_'AUWQJ/-)SP?^1MIG'ZQ!ZM@.G%RL-/%-,/*"B;<7YCVM==_TF%N$
MBW0]\+*H3V=L\1FJX+9H%>#/\;QAM2]O!])'?;G!3$?#7O4/JQ$4$OKJW[[K
M,35J$8**S]LXMO^XX5' (,.1S;/=RH9Q4:)NB>[BD<!T#FA.)G"62\>G5!O(
M)M@_8CRAO HE??353G]A](D";H7A@O_X2"?1:8=:"@Z=NJ@N4A5ER64@,MFG
M;^*WP4'BC^! *6%)R MO0YI+L-)&!X)9$!@*GW/01("U]#/S[Z<4*FOA$JI4
M5I75Q\,.%0%JZ/"4]U5!XNT&Y49*:='4@\\,-Q8Q=!-TQ@E4? V.^0Q<+^*H
M;,]S,(+G @(9:4!!V1C0L['R-F'\,?%4\)IA_(B^ .GD>_F/9">8C-4M43XZ
M#:DC>:CM[7WBOV6<L4GDC&V<.+CQ2&X6($I_WNAK6..M;C[K+RY&().[ UN3
M/(K]7<P_RZ/^\YCOQDVBB'(0[MP/(1^(&=]'?L3[E_N8C[\$C/D!^/(!I<(#
M#/?>!-<D$3V&<8F[U'<P,K FJ=F+/RH/]Y0?<FU"T2U>4G(JDCQ,43"IN&_E
MT^@>^AFV217<H>C@;3E;C0:K8QZDD7'8+%/?N>0V_,<[<&QVIOYR:UATR?2A
M=^GQ1MF@+F5&]G5,?8,AH\"@1B)X<_#U +[Z+?OY9#(8R3+WJ^&@[.?J:%3J
MB;Q)S09#==J^.6F'WWVD/B4\:.!ADG]K>=JOCKRZ7:4LQ>\$6,':9TN"]Y@8
M-<C4?!U8[)&ZHP-[PM1;F[(,[T*Y1U7*/<B^5[H1GT#:TSWX.TK\U"94#A7(
MN;9L\QW\!XR(8"2+2"]$=]#VQFNF6O #S\R'.+[7+<MZJ!O]IZVY#;4" &&$
M/;Z#N0OCVP&Z3R3R4-J%MNH=&&E+C!#<6:L?L%DF25JQ_P2R_V:1ZD# -:4W
M'RO*U614%Y)QC0$&":$BA$K-0@7-!VHY-"505! HG-1J(5!>6>LG--9H@"FV
MU\)@Y1H#Z/B)Z 35/@%R@E5RA\<<2)('=L:?X(@OA'FH:=C6;29GH7FZ(W-:
MB-\B..A"*KAA[AG1IHCC+O<2;K@30R>5<JR#([6,=XJG:^57T-^THUIY%$@5
M>7@IF3)&F2+/NJR117?@*^*>4S7RY3EG@IPSO ;_6;C();3Q>:I7F/-M5;V7
M$QS3WESI*R-AQ@NN:077G*IR+\<Q,^086>YR%QWA^!;=V"^%*YF$\]LZ61(*
MBG\8WL;V/8[T2*KHZNZR1D.PQF=7T$I'>+&O@@TBG5LA"\C  F/ACI[LCAX"
M$QD>PA/A7#.W6<&>WLFWRHTJE%13]<E<6=)-Y=LC)'?*/OGX*R@8O&/E7Y^#
MHBPFM._"FC=X])Y6O/UNNY=J'SA2L/BHKTZNP"FJ4O#6'8,0LD_(OFN5?8?%
M7?TB3>W-9_WIJ,LF;!LD6CETNM8@.]RE"B6Q')*59[LD62*YM'US):V,]1HS
M(Q#A 7YB.+Q:2_RY[[(*;2SS9B60^L*F)=Y+W4=L-=?UB>/"(R^L]AM_2/>7
M0C+H#&5DYY =_,!>P$XSQ)@^0W/ NG/FXDD[8NDF1=M(%V:6*I3]6X0(\Q?=
ML-"<^)9L6)97&3O2VE,9"\+ =7.A;=ZL2/S76Q[2#:(/O>PH'@0['"Q]=S>(
MI$+!=K)UKQTI;M5& TV9M*^0M(W%K6).W9V3-CZG,+E=<111'2RJ@T_>B!0D
M#@L02*C27^E^Q+8-I8R[A%D@=@1WY -Y]3LB*NISMR9$@9%" )B+UM*+P<7@
M8O!S!G\%2;*?".R';DJ/B(QH!5BT*TE_)-;RI>ITV;.3_=HFX$N'OJ\S>HW-
M _/"U_L!Z[UP=BJU"'$1*TRN&/7F(F6WFI1=P;FOCW./7+K7=I.^-GZ1U<U_
MB6-SN7J,;#159.6=X&S!V8*S*]#)"2Z/4?[II5#Z<HMQ]X/^JT(E/0$EW>5*
M5L')@I/++^U-DZP<*^IJ67G:FV>S^3-W*H*3!"=U2B>F[> *^05+Y,83H?M>
M08$<[>!"(VM8IID,MXF"N/JX?=K"J-08J]ZZS/2BZ*U;I-[.,,Y8OH8PCN"%
M;O%"BP(?8P6L/T'Z@O2KC1142_LU10K&:F^>O9<K'BD0M'<M8K<NWWJ,J,4"
M6N)59+  R< <SG6I#X0#"S%YT=!@QYE\UD:7&D&6KZ$$L06A;T'K16B]I3ZU
M2(T0O-"XW&_2IYX@P(:@?4'[U3K5U1)_74[U%(A?O8K[]^LFOOIIKS:O>H:&
M=I>CEN+&NNC&WMO.SG9 ?(D+ZMJ86QLV[DV7Q/N9#!'O1Q6A-<$*%1M9!WCA
MDMXVA^01H_4<NTK06[=%;X,.[001(T="V KBOYBP;9%'.\%FQVHVGB-$;]NH
MKW[BJ\:E+6OM:KWYM#_E:/]7)X!?P47RD28FXE:Y/HD@-^X'<YA_U/7V)"*@
MVRU:;^>M\D3<*@M>:%SN-^F$3WC9JH+T!>F?Y8)72_MUN>!3,(*R\ SB4KEM
MQ%<_[=5UJ3R9=;T'6L.7RMU#2ZVZQ]FIR)&5[>R5@4"47O[5B,8#?7A:>B,_
M'5Y!4[$3)%G=07PA3(0P.=?(/[VC8<TY#=.*<AH$PPJ&;3G#UJ3]&XQ'33$I
M9-9EATE(#R$]NB$]JE+W+0KI33&K9CH6RE^P[]6S;^W<VTA:TE3K?M/=2\B0
M(P'5L+<H;"#)%SGB5Y?X57!4X=<A92FTLW')RY]Z&@B)P<7@8O F!K^J8LMB
MC0*5VHHNQ?/B^;+/OX+<;]$&[YS=NXKV OREE<NKR7$A???F4==WQRY]DE?(
M'W\M31_WZ&ZY='RR^HQM?XGK,1>3?S_$]16Q"=XL"]G0V1Q"P3R">8XQ#Y\]
M\EBJ3#+\]$ RO&"IMM"=8*EB+'4DI:G8Q2:732:]N2J4CN"0!I96,@V_)A9)
M7=YQ603AVK(LTL7,>L$=W>&."YID^?86AQNP"(###MW*Q.]0P$,T)&N"G]36
MQ0=FP]Y<RV:""I0?06T7<:AG!_J "2*\?B*LR 4M07"*(+B.$5Q)CZXFBCOJ
MT<U47D<W 5;6-G*ZH!(MXP+--+#$LC@3 NZKKBM?T3?J@FRDM<_S07RO23:'
MMK-!:D%N=9!;C:[/-=XE"B(L3(2UW;[-$+#J;$M"T%0KO9N:B.JX=S,%[^:<
MIKV"GCHHHRIT;W)@GL0-3TUT(!KX7(!]1@V[->4J!V'%6#DXT<Z^:!6QJE8:
M!]618UFWAT-K<F^NG0,=*6BL@Q*O+J=&&RJ]^32+<2;D5BMIJEJY59=3HPU5
MT(?3<[P:05 =%%*G>C5EK2W6/F:8Q5H1ESHUD8GHX=(8SXW;=L.C#6D'EVS_
M,!$(%>1VB1L>;2AN>%XU$=;G#'%;D@B2:B5)E?2%:J*IX[[0E)L)+BYXVD9/
M%]23I>)]>,&C9?OE=>N")X F8@/MH1/EXQ9UR46JJLW&J5MT @KG.:=Q906'
M%6[,U0@YN>FRJI)Q(9FU[)A6=@U7C="Z$$:OD!M";K3$V*Y0<)Q_7RI7=%\J
MA($0!D(85&Y$U!;+D;&=!Z<9CS %!/<+[F^+*5!1V*VLIZ"";.@/1]F\%V$6
M",$@!$/S9L&%4DEDUO)CTO&( 8W*_N;A#L'_KHRG>;B>K_X6SG+)_L8C,"Q?
M9SU-X&?A>H+WW]#7W*ICVAZ"K7SA_!:U/V$CXW.X?\9B.9KI,T5?3A=+35E/
M9AJ9*-.UHBV)O!@KXW_1O.C@J;W7AR>@S(8W$T8<\!59W7G1Q]/>@:?D&X7W
ME'P#DCVYLJWN/!I6="##:&65\0:.&?R)(]X:'IS.,L4N&7!Z>03L\IT\&3"V
MO49&P*]=R;"DM6XXTI-N^F0@U=)V)IYO'C/3V7W1+?V14,1NATX49K?=P>3(
M"N:[ /*-N%/R;/@(.' +HTC/&\+R@Z0E]=<E$U2UI(=^O&2XDD7("H99Z"[\
M%TYU">/ +'7)V^@>; (R-[G-4MT>M:)&H,3*.,6P5C#;VQMY6N<A']PT3$I0
MQN^:.[=WJ;V1M<$(]\(E(#D,[R5!:^_$[E:UNVO# L(V=%/:@''J;6B.G+L#
MI;,VEM(.[%;XM^?BY@-C /V[/G'>X:]RSR KM=Z)8REY+,N-;CTRF8K;[I!'
M="1LYZ4O$5 <]A8.QW:D1V+1#@6PY3^))Q'KR7!LUJD@=6!_QI%6ONLY+^PQ
M^]'1=QL8!$8&U31('V96W:;T\;XU5,[\2;M!?]BN@:_X!,+Y[Z@X'O"G#S#Z
M>]->_DP8.Z.>1, &VL&+/#";F*9LAF@>8&.IO2(M"&@&R?6W< (P@)O1+L\&
M\E0HN-(Z4EH[]E;2PX@Q;*OKH0T(6LA8(B<F% ]^G%!),/)&!UUD>S %8L$Q
M+M$^6_6EQ0N\Y G,24H%<,PKEO>*Q& 2ZQ&F@Z0!VX$?N20YV8W^1-AX,$\=
M;>#PJ)@>W 6'-9#B0X2E[>#M!C-Q;"L8=7\?0''N' -WR7R15K!VJG9YE@.L
MQ?5-H+U'MC^@4>%=+OYM!):RA!6,K@2?+3FK>(;?2#O? 1X"%1T;(I&@ F.8
M'EYH#S/+%HC'U'<NN0W_\2[L1V98E 3H0^_2T@V8==^PI9*-??WNV5AY&W0P
M!D/F9 3)!\&;@Z\'\-5OG,]'@]%XS/UJ.)!+?JZ.1J6>R)O4=# 9EWVWF).8
MDYC3=<YI<G"D(PE7!9M2'<[FDS._X\3?E@151YN[NZD%LJ]>Q4:DV]P5I*!V
MA%QS8R@Y=Q$?T-)PJ/T#[S/!@'(S(?S3V:9,&]UVDP@Z!S261SV$(FF*532J
MO)KMBW)2Z!YB8HK8PI);&/L[= \_)'P>L9<E]_*KC^*>[B-XHI\Q0.&*310B
M48C$3FVA$(D7%(EG5JZ4WJ*V]<+^9A'IA>@.1J]-XA;2%V?MR:E]DL7@8G Q
MN!A<#'[ZX!5!TM!$I$E;]!H_!/1Y[ZI.=)4_8@A<11=&_M+*E7!/^"F(2R.3
ME1Q?Q=^S.WW;=_F7\+^#9?6PT:V'9V(^D2_PZXT;7<RSA.7O9&GJKHO9(=34
M?[ _&.[.=G7S+[#[NSO$57+_2LQ5\')NWN*X-U?5+ 1/+4D8Q?BPLR@9@L$%
M@Y_'X*F*Q0J9'+M]JUGD!\'D@LFOF<E+ OO4R>6R$G!X7(@45QY5PN/3WCS+
MX9T&!SH/^;)UU)A+C&$JWQ&*_/SU4R&2_&SQ2=']?SY\Z &%/1&@KZ5IN[Y#
M]@F4A3^_K:.GSB3188)$9[VYS,'4$(Z6:'=?3$)/SZGU*BNJ2]> *</>?-0?
MG5\JWAY9+%CIE;$2:)9JN2CETI1G*;DW'_=E92)82K#4Y9=6TH&XJ'K:\R2X
MW*. 0IJ= UG4'K:)<VM?%61HOF\PS?$-ZJ&VC%M03)0GK'^%0F6,.5 9W0(@
M[>#-UGM:&;=?BB;:SM47,)YU]T9(T8!/QUGP\NX$BT7+G]?,$C7=H2@C8(M)
MER]*!5NT\M:A3KZH_=9!&??F%6"?M8DFSVLRW#IJ/,&SF%W5K8."K5C4;%]K
M8?[6%EP<#2\;I^?();P-G9X=-6RA>!+4E4===8>N.50V ^TWSL;7!)6UDLK*
M&6:7%6(%HKGJL#>?9$5:IXVMJZ2S\B97FM8Z$,Q590SF*JW1L%?5.9=OR'\!
M>QAQ+1'8BQ7@U=8L5SPOGA?/=^OY5W2=54FAUBNP3MI:^9",UG]S?K>M1^*<
M?9%5,K%(Q=2(OJ:)>R[!,=WDF$KNN<IRC8KI>$-U++A&<$W[BV]"?S=BF;JN
MP50-$^VR=PR=CLV(B[ +E-_P)'MEEV%E@SJ8XM ?S?*3'(2%W;&:EGT)6%[C
MCY$FY%'63A9J]WJ)[^RKM(SF/:L*1,4K_+[6FFBS(,(.U4T<,0*Y]#9%O(2L
MD]-I<^XJ":UU=1/[U,:Y:N,87K/>7!M7U3JP)7=I78@D5U@8\0I*E]J:!5Y+
M/#FK%33,OQAV.6 LJOE>,TO45!BAR9B6E)]?*]A"L$5K"B,N%A'6%."**ZN\
M%GA,%ZB,J#4@G'4]-!5<CVG^?9ZP@3M6'9&-^'*$D\8'?15Z\WJIJ^Z0+H?*
M1D!ET[.C&H+*VABSO:P0*Q"SU<:]^2A+;)TVN*Z2SEI7'7%2R%9#2.5QU[%L
M@EX000/M=#N(#O8KXA/<@^WI9@5-BL[8I4+X;V>]K<VP<>?B3E>X,2V1C.>'
M#67E1#./+P,OE#^J33%_=,Q!2.U.M+ Z:KS C7 71)>07B7V1@@PO@!K(AM>
MF_7FD[XJ9ZW 5R+-A$ 3 NVJ!5JIF$C5$JVNJREPI^=C3LB_=';;*Q4:93+J
MZG+F6L<II:,Z:6ZIYRZMJ4**D=R;*WUU)-R<5C.X, FJ O:_2I/@_,LX63WG
MDH0OZ4I[*2/,1.G/.(F+PE40KH*0"RV2"V??T9]79C52>_-I?S8^.S%$2 HA
M*82DJ"31H@X3(I--459.8(>(_I#3R46$$-H20FA[%*&BW) T>Y1.#>'SQ_GP
MF"-,?>M/.&BM7=.D-+/D-P_W#/YW93S-PR7!+L$9+]G?2V:8Z"S(07_&5KAP
M?HMSB>GG\)]PO<'9CS0@CO"$;QUBTC#.NV=CY6U"PD@\%>S",'Y$7\"B?2__
MD:WN/!I6M'_#-!LL"9"44S7%T[<<)'EY!-.4AZ/T_B3_BTM FC(6R]%,GRGZ
M<KI8:LIZ,M/(1)FN%6U)Y,58&?]+D\'-"Y[:..$B=OHCN5D C?^\T=>PQEO=
M?-9?7#S8Y.[ UB2/8G\7\\^2_7?O_$,N4&;#FREC6/B*K.Z\Z./9L>.I[S#H
MB+>&!T>_/!S7I,?S\3^^X;U(L0A);T#NTN4;E;=T^4;KS-+!3 !1! MXE'8@
M4Y8OM00O"[+)0 I.PHU.0GHVO(VD2T#>*W@AZ &@<*!EE%726C<<Z0D+0/$4
M7,/UI)T#XMK!7]IK:><O8$D288/&%< N_%OR-D3:@&* X9>Z0_"=GNU(NK62
MMK[GZZ:T!AGM(AJO%SR+CZV-7V0%_UC:6P*S67BIR6X,$_%[;9?0B=N^5V+N
M.&/'> *3C3/E@72_T:U'$LT]'L#%)TEFY^C$-_H3*3 %W "'[,"QI(N# _6D
M4&LF2Z??F*!"B?M6>M0-R\T[KV++QG?"SCL&O )FN@1O5H*?^;#"[0Y^AB_L
M2\8:CN2E+^U,^ +.A_UB&>R%0US?I-2[=NRM9"^ \I[HBV GER3\W4#:$VD9
M;992=_OV1\)U9PN.)<6GOW_]?&>M]C_^!]N%[VP+/B1V(*I9?L"_'N M[TU[
M^3-A5H 13L#:V,$+/<<GS8F2@[SZ@"1HFZ;]C+OO!7MN/QDK2GHD09KXU[T-
M9VJ]_-G=(]0]&L=1]2U*)'PPI@-Z] &WE#MZ"01VEC>H5+'LHS3J>H9I@I@P
M5]*S[L(30*+ GXX!XL&S&1_"4]82/W ]^(K-5J<+_T"6!*U,9@^J<E]2AHJ*
M2X'_508A3;+-BPP?:NC!,9KZSB6WX3_>K0QW9^HOMX9%#X,^]"Y-#J-=QLBC
M%A#[.E;Y@R%3^T$R<?#FX.L!?/5;]O/1>" K"O>KX4 N^;DZ&I5Z(F]2L\%0
MG8HY=75.FG9PI",)[P7+6 _^;);Y&<>#9JY#FR[B0\$B13*E0.K[:]@();4/
M!0FH'3'67,,])\#XV0);R#0Q=)&)R)W.+85O^]M-%TSCX@5)D9J04KD#U[MI
M]V",OZ!!1>W31C>N<WLG"*Y:@CNSV*W<SO"D_=98K4S23(0\)PIRQ%EQ*RA_
MJS9_JJH*MLN<1;4ITV<7J36YZ"HRHL/+F4S$Y.FKD8<F,)KTYN/1%30>J#II
M,B"&DZ\T!5\+OKX$7_N. U;&G;7Z:EM+]@>7SZ>].0=M7+"Y8/.6)"=UA,WK
M3U\NI;YGH+XGV8((P5R"N01S5:Q#Q\/>7%:GK6>V"W7M;:&_?OQ^L7L C%VW
M7CE7^ 7NZL]+N1_+F"BH:%E>[8[!>Q:&57G-*VB\!@^M&*'[U@D4KB"%JW*7
M73I!X=VQGRJ1XAPR5A',M%G(7$%)K;#$2\A*#AUIB+>=!89OAHXNBQLI0"/;
M!$G0YFI"@1C9J-L39"X7$736ZJ\O"\=8?;9<S_%IANN9'A$MG9H-LR*R._:B
MP$X1@DH(JM8+JC#'Z%3/=DP]6T[?1B&IA*1JFZ1J%*"AE9+JHC&(1DVJ"<-K
MJ/CV54@+(2V$M&BAM-BW:S@2 7'XE:H:3C<D#PI 4T3@!1<L@560+CY;M/:J
M+ST3:4&6<,Z2CO7)-JUKM9\MXF M]=\-T]0?R9</TB*L=L6<]_\IUXI)3M'5
M],)W/;,$6<UZ<V60!WJR8"5)Z77O'+(FCD-6027N(/&=X<*F!87#3E "O]6=
ME[ZTQ?+>&W='L+@6-A0K\WWG$<O0@X)]Y\E8AH7N,,Y6_S?=^AO<^A7N]C]T
M\]$AQ'*E][;MN=(=3$ZWEJ0O?;:6M-K8)<EK>QS6L):FOV)E\"=?[(=%^OK"
M?B*L.GH@W<&A;G?(6WC^0+:P9%@3K#F7%"R*4G.$&M0#0N9#\);H)&^4^"@G
MP]Y\-,AV]?V3I"^7#E9OZY;EZR:B*5@5$>QI5S?T/]_6/S9P0NXGV[FC\PH7
M=X>S16HM2<H3A/ =Y$G(D)3A?&S?8?@$"]TU0@0&)!TZGX%TSQ <D#0I@>#O
M05+K'GE\P3KQ&#["TX&"$63!A7]Y_HY2-0C<9V]S Q\]$DHCNF40+DB%8:U\
M&!BX0]\!T_PRL!H=CJ<T :7<;V5?FL!ZL%K(H> (WPWWYQ_$P0]@?C*?DI3>
M?,8CI&#S]K WL@7Y;'$YH!Q1I7P>>L-1+**B^#K3"%_G -[-C(]W(P][]2JC
MW I1/K3+O;T%#4F1";Z 9_&(Q/6[#:^XU&XJ\O'=1*P<+H3.J'?P#&"S^8<@
M=Q=Z9U!+2$E6RE<8T_E)]4RG&+Q(@GBW(?&:2+S[L#&^M=/!V 2KP5H:._CY
M0C=1Q;M]R2(4100FKR-."7Z*&D(BO\"F0!F\!)/$\"2&:=.GHC@$C<?!78F
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MELJK9]"X]0Q\IDI=H[#>T=2>"<T9JH'/9*-$G^C)"*M,Y&QA[D5547<'/WG
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MD _#^!%] 2(55%/N(UG)DBU':0CQ1AY.]C8X\=\2HGBD1:)X$Y4;[O1'<K,
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M_!A!6:W(PBND$>M ;QY-CIG; 2?Q&$PYPE)</*_AC3+LC)'>,D,U(0T#R*,
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M31Z:3Y\#*0.;P 4>VT=W2]Q]4TT0(SI&U;QLAQT&:1/<PC.^?V&1O&@B@Z0
M"+%M I0@=I>]]T:RT^E.!O =%%F'4^L<%E\OR%+W78K08R\-NFD4_H<A5E)
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MHN/VK=8HLTQZ<UG)5@&WU;ZM1QM> 256(;9S0"<N1(E3H$2MG-06U% C->1
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M$JRHR'')F>EL7MFNSME>SFBCX5ZC.\1.15F"P/1!J8%6A/\SRRT:Q0?%$:Q
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MT=JB*F,O8J;$1J#<K?EOQ"3K#=6U[SVP.HAC;*DQ>V<M%3""/)@Q*'T"$[5
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MG#Y_0*W&2O0$,-&?MS_KX! :Y.N*D.#OGAMN8'4%0*'#<0XH]-"I3:^I?HM
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MKWJBXD*5B))37RRGE@5=.',J@K_/NJ/I2'*JY-2&<3M$Y%0>[M*1WD"<.'5
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M0JS%^! 'K*X#<&YH16#YV#YY"DZ.>_8A;$7)ZJT($8'5U#/+$$OP2TTY'RC
M!W-G@2J!@/G3RVW, >]"*_8N-.I=-+1GI;5RQ= 8&6@\VUI;J/IV(?*H;DS!
M?(I^5 X8<0VZ.'0<)0X7"(==P]=]=OR$=/!O67"<D_<I!50P@<)0=@(OAHZ1
M!5$H)]P8%7%G1 8_$[M+D2(" E^3/__4'?2 ,"$!&1[(^PG>8&]AMVP,3>)*
M8_<B._.-YVZ(Q][X=^ %#[Z*WPFSU9=+T,1TKHE^C+>-8BFZ-I6:/D47HBO>
M]W+L+07!B9RAS'J C_'=.D,FBL$7][=2,=T49-(/%S!MAVKS[Y;Q_=X- ]P
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M7H8V&S,8SN+[(4(*=X<%"7H",E])A["=*K>&6DF-M7J8+X95I:[Z(/3+;%2
M53X;G=H<BBY4FY+14-.TV6BF#@=],E,'4Y408SS69AHAT_^HD^%8A"9BXP01
MIBILP,>=_(KK(CPA@D&*7X"%IZ&# "RTWO#.Q(J]"*GP%<7_C/^%M:![N'C
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MZ8Z\)>81G(9R1WYLX C)J[B&XJ;LG:JWQ,+9.S49E[_!4\:I8_!TAGE7O79
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MH'4UK8AY$6WNDBKS?$34H%7K<IJG[S%&Y06I1Y1$QC7^-SQ2;=(\<4TZ<TV
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MC:U.4>!@YDW44L6V)PW*)$F=*\79@<2#]MA[,G-';+;@HEN/]:BOPR %C(
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MU9](O.& WXEN++:ST'T)J YW1'T_;0O(AF^R?"23Y^+=5F*H.HX+1XB3I_.
ML2[P*1,N@:L"X]SN:6"0\#K:-A1X 1?@:=W;K6K@E8](P5T;;?@4,1M!G05L
M "H(V0N(&+@>ZI/$2R*>8^_RNUG? 3I\([C5<$R+VLENDJ3((3HPT7;=?O3+
MD?SG/8EO;J'/.XX*?<;JX4*?>">)#JOTL N/%TO"==C]P4>!CJL56$I_('?1
MN@RZ&\46L3NH'3M$E?2/<YJJCF.GWK R_/GWNN7]I=LA^33?8D9]H'Q-S _.
M5[+2D;$?#*K8_4_SK^$,I,[2/0L/Y!?IFCA)N/;8!+V7WN!),]8'*9(HJG*I
MVO.C[X,LLP$@^=ZXCH-6V @#Z3>8B@="_KLU)]('QP=MZQ@;T]0%=>_' U['
MNG3[(\@V"K/)A!]><SU*OP?^!?+.B0=/K?]T]/D<S!HVKWP'ZB-8EZ;UH-^9
M]GOITNA,6L_QZTB?,/'AI'YC*M#SB^@W)EK37V?>S]-<"Q2)Q1!%>>7Z= 'N
M/6)3J[>M0_MAU_^)=&5_^X@^ \\S#/(?R="R*6_T2L9/EB=[Y$S\N?"V0<$G
M<C?SB/[M3I_#:.]U^T5?^^BZ)^<)DTP2=9\>^:NRJ7G,]DV'X)N>7A)IVZX1
M07ELV3ZO,G(@9U5&7L\SF8/,2L\HM%0X]O3S#'U.,/HNJ!;=(XWM13D:]89R
MV?K,6^W[>/C;C4JET!=>O5\AIZ&"G"*Q1)VI5+#N\!;H4',I(9\!V3S2S()$
MJ*">2L+ZBO':\>:*,)::D#9]3TRZ WIR85 .==;ION:).,:Z:N2E,O3C[/C?
MN0 "63/DY!Q?%4@ D[)( )G[V:S#>P,%=CI-QBCE![6GP>)W[NE;CL7O? PB
MK=^O3_P&&&AH.-10 ^WR&]=;86RZ4#[W%E%FS[=:6E^N2&R*Q%:3,J5VIDIW
M-$Y'LIMCU01L,H]V0+D20V-'W>Y Y06,^X;V;W3%[G!&Q!1 N?69BD%]'I:&
M&YPF-YOG9X?3%HZMPA:H]7'L"#BV?[:R%YN"TL$ZF$4BK2ZZ-M:H\$MC6Q87
MGS'VW4MWG6B.PA?./X\*OS38>7&.Q<*KIO1)R34T;3FS\>@&N@U+O9,H/,?W
M/[W>OX";59CJO(ED%49D=)W]N-KO3 ==>=*"3449H:U[QR'DI"[35;IC;45R
M@AV0NQ-U5-%6IE9FO76$K7?_"?%,3=VU,4=E6;S\%NMDWKKP+AB,B+'6YRW5
M5T2B8LORM)9OG#<D0JP\N2UR?647ZJ"*WK9\15@+J_?$L92=HWM:]<<7BW'%
M!RR@=G1VRJL;G:S#@Z/LX!,63*Y<UR9F^L19+2IFV%,*C#OC8!3:]3NE-TX?
M!YGI/F'''Z57\K8^GYWP$>'EJFV=7%7I28;J4#M3K<&F3@27>31U55669/#K
ML#,=I.%Z1&SY>K%ELK_5%M%E'FU(?34IJ@8RV>3N>R)ZW! YJ,(VU5?IHF*E
MBU)5IUT1'JZ19;YNX95@"Q8XQ/,7UNJL$IEZ)+8LW7F3V"HL5WW%-2IVQI;3
MD9/FF*X3Y/)"C2.%(%1NNNJKV5&Q9F>8/CC)(3=6E$8J$U^\"FM\(;BW\@.,
M#]+(83*4* *(MY-[J,*$5E5:E-8<PSXFRYI\.$UDRWBT=545^61PK-R9#N2S
M8X@-39==Y73R<DD\PP)[AHC'3XA<:[MZ,:#P6PS!5Z'QZRN/&"K@*XJ<D6#8
M2A6^4E]YQ'#0F6KI^#27.:,8GA$&2O*9[/IW77H7=@7V_2V$O17P*.RS3$(W
M-_$VB_(NLI&H[ZO-@"GUU3P,53!@33Y1)W8L/!JP^HH>AMA0,;W%%AN6NC8L
MV-T#RQJ>8240"!YK]MQ@03S)"#V/PA[2Q>I*#JFO;US#G<(JC$!]10M#!-(8
M-/G,F]C&\&@%ZBLO&(XZ4Z4MM6^M[Y7':N/V4/SU( 'S7T&97'5-V2ZV;)Q!
MA5:$U%L=>3A1A><;[_V.-1<[ISO$HHZN/&C!#J]*97FABD6ADCA!+VZ=2CK?
M.U/'5570E%5)$ZJ2QNFL20/U0D;OT8MV>TR4H]!7%NHJ0SO[G52@DJA/J8>]
M2TVB,Y4>\JI_I(7NP\5GVJ(!RUHMPUK1?MF;/O?84)*%,VC#4/<%_R7Y"VPI
M%76L"YCC"I_ *PG\N(QV;,E^LU=MGA6UV?O1WP1H N##W;:9^J8]&+CE'O:Y
MT9]@%#CUDJW,]Z!Z/GQ\?UR1)!N2X<BVS<H^;P:3V:)<ZW>FDXP^];O]8G%)
MR\Y"&5YP%C*B0&;,PG*BR%J"TW8JW3SK&7D\.F7TRL^NW/ZI*ZW"&4A0^C@2
MZ[WH;<OIHF:,L.[;!J^S=;)C+LC14VB95 /@\W:PH"UP@W2?-BI'K$7K3H.V
M30/8P(6[\2)*FD?\T [P.6.A.\A^,/]48UC64SAN>?QBV3!R_"(K!?0HN1+<
M'+\*OI0Q^11UZ>SSF@UC7SFP-TAY&XGC1V]/M_?-[_%WH/,TKRVFOQ(B?72!
MO/* =HF.J6R20+=L;)3\I'N4*@OW)<$"V$09[B'>$@4ER;?(*I2"M*MWU&(T
M\>#" C7M&8LU70[\<>6Y!C%#8!'IA4BA3QCK@.FFZ[Y]=$ET'VYC2GF'50P;
M.-&:XT)B*]) AU4 1EDCM^QCP"'G_4X'J- I[W2Z9O$*^G*?;*(7P-9T!":,
M#N?H$8.J6FQF387!MV!M="_Y%7@S/C?? R-%N38V+X+IP^Q,(/4:(^J1/+'9
MTO;7EA^UY48;AD_VI ><4H2SDN9[2E4K>1(_OH>=PH\693\^ R/=T-!$86 4
M&C2@NW7.D99N4O-1JBR(^41B,(+])=VG/M5:*ZJNL>$U:C73VO1]HGHN:AP\
M]]QE+I/WI'T)2S3"Q5;NMNM3SJ>N&=.:09+W"C7K#78\@6TSWI[T!KP['1[=
MU73 M89GS=A;H\%U\8<7 LP%_S7R*M?H])^.%PB@\=CEJ8W4#< I,W04\]!Q
M9[#HS[1_I^6L0I@-7(_G&E$SZNP.;_/!0867&?#MUK8 ?\]-"_!)[T@'<+4O
MO_KV$VT SK^62%H+?P6^ANNAA$=S0-W/-"M9KFQW32+_V (Q,+%/,^AG<(J>
M+.14E&)JMZC!@-V'Y9&-,8N_ ;MD8T&H$@$!0@Y&GRE^^8],4*Q92/V>2.JC
M87R.=S .E?_MMY;Z.M('>!F<*\L-_4BA,6NQ^7%7(Z XNTARU_C6W>R48)E
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M)&@VZDR#%Y<=5-H_UM6C24%]"5HZ0,+%-,+339T5\>@''(/@U$V+>9F4\5Z
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M%TT$PM]GH0^O@/4"R31 $KUD7>TNH#5<@7]B$9M.UY>5GL$G0IM._BG^L(7
MUCZ8#%:T&RQ<'^];N1Z]#\WL;EEO5&XF&;J_D.8(ARW-P4)&U6DP*I^6LW:3
M=6P9[_R1U1);S\F11\.,*O5^]%,#825N;+0O5K"0\"+J)YW>Y),G6B^.6-TF
M\*=GS5@5'%5Z<IDJV2M"D\>%BE@:'&(Y)IVYXV#AWW]"';@W8(0C2#26*\8T
M\79-X7G+0THD:Q>#A>69^ (O ):)"MQW"2S9Y)G85-._>%:  (OP"O<%U]!S
MPZ=%?I&D-8\^BV6.GQQ)C[]DTTIFR^_2[\5SBXJ9?7:?'<\H,7+D6]^G?P6N
M,PF\:@GDP@_!('&18<K& L\2T/)-P_*,<(DMM UZP;0P- H?A9G"+(#/ERYP
MCVU]PV,><-F1'#=@OU,ATSUOC838R)"^3QV42F*R]<!"T"6MA=^R;T]ZOR.$
MJ1? ()[ J?1T&X:P?<-&4DSP5U ]885]+%ZP&KJ]]BUFC8%1OZ%0XYD5W5C
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M2E0040%8]+@.,U.P7?>IT%(N!^L26RWL.X+"384/9%>W;-25&Y._LO5(U/T
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M8!S=@L*6?AC_\A74!Y92ZS-]!M&F=7_"$[%AGSO2YXWGKG]);Y;U5*2F3&*
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M#*_!/(!H<@V;!8"_ ICXKE.SJ0 ]O=/7LK\JVJ->[^@#WOKFE[<FN3,8[._
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M9],P5;!8.J)M-$]X*D/#/"ZEY70-4RM-\@M<<:IAZCQHF'V!LZ;@+)-_'9>
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M_C4G-NW'28?"=+9, W;_+ZL%H-ND_H_PE5@&:[@<=2#?R&S3Z-O>!?''2NL
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M)C?_(YZ;>5S]ULAQTX>3L;6H6L:[LW9MK3>##0]U,5P>,_3VWAC/_K/?H5P
M%3SO$#>A <WX^>;B**^.P]U4)_P=+71?DID#*.)PO][=?466Z]$I3T2:6\!O
M/'/^EL',:J58@_P@;'@@LRIC&H!]FL;*3V+'*$E0M[@1FYNAQR$],6W#L1J9
MH>@GB(W0-B )F2 5X%[BD>B!I&!KB!;^,:F%[P*WF@UNC0M=>:#NUY7O0TV&
M69EK?3FI"F\1"K<4LN^0M.Q#ZF_2%4ZAM#8-IPT]9!\'1#X$CW#8=$'6L,(P
M@4Q8&@!E31,Z##C,=%D/DV,^,)_L?S9PO0"4NQGQUEY,S,@PYXQ3H[<;E=%P
MV!2Z]%X(4&:0L)_#G\4&NK_".):?^G4H%*3DI_B4-:E3CSX5IVT,I2&C1K:[
M#KRT:4H1B!PT!NANV,:KS\R"V<I>+]-",D^\,W":58"97\SG!KO%MB#:I-2F
MO"TQ[0V4/Y\-J46!'SD1Z*C&1#BLC6/WJ"H:;@6BPJ,^08_Z:F//+X;1C-?U
M%F7'USJ8O>1CS,G$4O)VJ&Q3S2OA=V3Y3+33FN4GUQD]?D7%\SIJ%T^S--A.
M W9<ZIH,[T2=WYOF!TV46H-*6JY UJ$/%FPFDWG2Z1S,R.&+Z]UX)FXF"A7T
M(#/1BD^)2]DV';6Q" H5L>200L XL\O0U(G&&![>F:26GSSD,3&-E<_6AFF
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MI\*S+IACIVVDK@VW8V*_@R*QSGI_^V0L *;^,^:-!QG!L%V):\-$1&R0.3E
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M9;1NCX4K_8V"SJF-Z;FQYXJ:*C1Q-_)X)'/F-WQ7#QB5A>7.I=]8;/@Y=I+
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M_1@>39R44,P1V]L3AZPD=IX/@D)7:P">]XP<J0[/NL"SP//9,UM/ 70>2V2
MEDB_GW:\BH17WC!55B2V0AY97O!5@(I'1G4I-J5VN6%3)?E*ZF"NW<\-;T;P
MK"37FQE.Z  S;(E,IY9I$<=\DY:V<=)$AB;G.U1HNT6>R6_$#[R5&:P\V 1V
M8(58MBHW0:T5J3H\0O= V/=DZ"H"N@*Z%XE!GPS=GLA2;#)^#L6EL_&3@1.U
M-5).3HH2$.$0(B4!1.,((-<4R?I('#*U O\]YJ*ZV#2>3*17*YA+MA58,Y:]
M"M(@()X(;5TZM,4(*#RRV _Q>WQ0A42WB&L)]]IY\V0K!/.>H)9 5/W98[[
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MJ)?X??'?EQ03RDT7B3Y6&ZWR^AU=H\WQSDXX;.F@P+BL;=$MO"SQ6-^ZK59
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M2#PK.,U+,K^"ZI$RE)CB=G4&O?9:(V4@>AL);)8J: ;%C>P,;*J 3>5D22(
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M$"C^FD(J?LXUW>:(<*6*(&^EW+FZ/6$A'7_SG+E>[E$]W-"I%>XQTK0.VGD
M0&4R!5D#9T50:6F7_^*&\,2(#RAX9)"A!N:#!H0"T@WIWK?L4)W",^/X(<8
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MNH%JLK+HY(U)(>O8L'N4\7G'MJY:X\G(?J>4W)D.:,JVXY*I"TR+XR%1C9[
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M;9 SE>.6;4X7]R:6=>HXXX!G,W!:S8%*L8U6&Z4;N<ZK\L^28';2&K803$,
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MO"E?(KK<4J6AX (W VUOJ+U0TJ?48B$G+,P$Y0\^#T94]T#5HT0S[ EC%7M
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M)J^4"7KTT46C]^6H6KE\LI\7!GOU OKLZ)T$8@8M$A8-1),,PX&::[KS:ME
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M8DBGE"(Q<@D<9.[1(@V>$69L7IC1%F7P3)B%D0;+%B @/0*%4NRS1!>L,L2
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MSV>_.!_LV?2G^:]G7[Y,SSY^)B<?9_;TY(-#9B=?3C],3\X=<GKV<?81GN9
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M-K.5_M 1F9'4!4ZX+N&@A\@1-6,XVQDR&D VTKK(M%$_1O0025L5X]F"GC7
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M:F? G7?$#DFW()P2$$:JYYQ< M#!&W;$,N@' /^FP]E3#Z*18#F_4D*P[%G
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M*..,MJ8@LCVSO;9'%/NUT"H;,KS2MBQ_O>+ R73B!@)45L6'8(Y/ ;OW@S6
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M-U,11O6:9K>"A5)8W\2^DVTU/ X"+Q=<;.I^UQ *@OT $9O@] T\CX=8"%.
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M_*H+#Z<M0:_%<N,%7)\#U:UY)9>JT>@/5I,G9Q=5%/\051/3&W?:"Q<LL<.
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M',>M6[@+":[ER/(S $SGLIE[8CX?47?N^D!M6XZ%LE#7OC.::3EP8_[6Y8$
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M/'ZNF'XV"*+FA7D7J'$<Z)OW/!F<]DALQ_765X3=<Y>NS\_29$VV42MGY_-
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MD) =$CO];7Y[$04T<=2O@T,C^EXR.0)>8\F]#*B53B'&;N'6UL1UCK%8]CE
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M"+ 1+;%7&?3FG(C'Z@1ZD7.:V;P/)VO?$WP[(F!BC3>\^PIHT:JL'/$F05*
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M=',UQY^.'F\B92(6O2]0?:U@C"X0LO+@I8C&BQCC9B^!,:71^[H+PHOJ1=9
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MB!/TS0LKWR9\]CZ%3,IH1!:TQ2D6N>P8I* )JI!92R'V&K73AY81K)*9<?5
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M@.MXMLVJ!+^_O%XOF CRSGNP4HK6;*J5?^26^$X:%3EC_"QQMV=HVP=/YJ^
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M8D0'F@I;8:QD(122H+),T65KC3M"=9U(5<\#.N%L6N8SZ<9<E5OS%^7;*/H
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MV'J6.@!Z4I":MVZLJ:P#O?2Q]TB*9\@8H3JG"[]['747"^-&T-WO1UGRB7(
MUWKZ8GNI%9V*H,AESS2$6O=(5'[YH:<':FZ)LZ94&PP;Y*H%7$7F8])901!5
MID)&6M5[V./S>SA;BZU3V/4TR'+$L?8IJ+AY//@9_-O6I3=O"5L?O:M/?Z>K
MCY</?H!WJJ5)BMH#5<36CXGOF!"6.2:55;[0/F-UCUEYF%!<!];/<?C=--&-
M1&R$?<_G\/:FKQL;U?>-W6XMZ@>EY6QUKR/SA,VV]:=M31PKUM81C@^9E_GP
MPXK=.-[5(N6B;&F#>P.[]NA*@9!2F]U242AA:DFYLR29<#LGW,4WY3^O-U=W
M]?G3'';V1J=B%$CE4YL<9B 0M9I13"0$$CX>:?G,U9V!T!%D_&C@?R Y1H/*
M=*KHQX<ET ]EXL_7:;,L2_816_,$],&'**&RE==F@4M(T3.M6 )),L&FW44Z
M)Q PDCT\(%SG8FT/&'X^OB\C5,^?R.= 4D%7A8P!DBB6/42G(3D^*4,UAB0=
M.PN[K?4C%Q^IM=> \)N#I7-G.0D-:1D$J-KFQ$HV Y-QJ57">%=R5BX=GX(X
M,LN)4YO> V-L*MY-6V*A-2JJ#=RJS6MI,RA\D!&*T12#"$D\SI6?K<1B\D37
MJ.#JQL >(NJEJB&1E$[9"PBV]?,71D#4"<$E7UTRPB>[NXW&"35:D^>S1D5'
M)YYT$S-O?KU<7RW_>WL4[^KC<2*+'))6.GJ0 5M\2YE675:@V$BNDJ_6]YX8
M^CI%![8*^VN!:P*FGJ&VQV5=A6>_ 2-1:VT2V)'% ):BU&A,JQTX0VW/7/W!
M1@/5M P\4ZF'R"HJTA5L%IKIE)*O -KV\DUD[0IJ<] KH8ZE'N&O*KVFY^0Y
M"D)NDP[M^'D?M%[%B[?7FRL^T77/U_3[+#-A^<?!NSS];?VS>?^0M8RIFM8\
MK_5S:!.K1 W@)2N]HHVJCP<,'%4Q<;B=]7Y-ORZO?]U\%]<K*FWVLTTHT+9Q
M#@Q50*\B Y>=3"=3385=2J=#9]/J"1$CA.U[L/*Q 73::7?TX;=;N1.O:S;Z
M_\_RZN/=S?CNW[?!U&:7\3^MG<B"Q209(=CVC[*]E>0=)U]D"V)5:HWPL?9N
M'7\$F2,$T*< SM0<FT$#Y8]4KB_H!Z:_M+?]Y;E*O,OZRT=ZV_[ZMCW-SU?L
MAF[SU9?U1MT?KYKZKM]/9TUX+J<KLZU)7=_']=; ^?6WN/JT\,E'I=EHLM&U
M>J;B@ T;T1I352,DHYQVAXR?^>"1BPNDLC:K&B&G5B6N@H9D6EM+H:5I/4I,
MZ:T4_^19\0[@>BPD1P% YW*9S^U0;G,!BRRB(^G;W"+/OH7PJ74P2""<E[74
MG-'W+MY\@911*JFF@=)I)]\-!MLY'VU7:_K(Q"Q_I\](OWM:_KY%UOC8OTA,
MWIS'0GAK4PT>V,.5V^U#3"F %KHX$9QA([0S7$XD>:H3>VZ*P4W$^\VJ/)AI
M<%,7TQ3L/N>;=6!O/V30H56X5)82(;G2WK.:)%Q4R?J9SG>2#8Z@+LYQ%QX+
MA7%1-;FH>?,[6Y>-/-:?FWA!/U.^7F^;2QZV*1.U<L)HD"(WF=Q\DB),ZX(1
M"_O!VM-<5Z73ED;P.$>^'.= SN37X5LV!E9T-P*US8L_<#>Q6I_8 KGM.!,Q
M0R@U026M#:F4M.O][&&JO0S1MV#D&S K6'KDK=Z]_>&N>_ GUFW?7U]=K^EF
MXMA=[[U5^7M<_Q==_;3<_-?M]WY8M;J2MJ=MMJ0N\]LUE>7V1^ZR<]M>6C]1
MOHB;3?N)1VJQJ<L=2M$K%8)58(IC_JA4(663P;B0=?;HJ-2=L8=Q]S="+X=S
M7J6AF7,0^/H^WKRO.[U3IK]<,F=^O5S]?'69_^MFQ/'FF[A9YH7%7*2,&:*Q
MR!ZJM) H%\A2*&>UP-C=PCJ0Q!,DTW-N?G39(;)-4$)AE]R6"D&V29B*V&8(
MV8:P6R3L#$>>U^N9$@0/[MZIQSO1.[&'=?SWK?2LKI&5GP91LP$L),#+JH!J
M%C44(VWH'=383=5(SL <F)F(7[T3G9L%2F^--@&H%3)BZS+N6P,I87(MIBA?
MNMO;O9Y*/_>D7 9I"TH%147>C@\:0JH>(NM<=,DE<GH*(7_XZ_W9NS4<PNE]
M7N\?<M1]W@VQE9)OA.]=]N&.E"JHI!;&EJY->HYM*$?TD-C4HNP<Z;2[ /'E
MSQ])>)W$SGZG^%4\?/991J=\ %79QD8V3H'/K%6:H=)958'4^_'%@ ^?[]V6
M&Q+:!][1N$ MT5:28%I;#[3L2OOH*[BJ4M-M.MG>^;)GR!A)7(Z"QR<QE!.Y
MUS?RQQN\_)*@N[D4)$5%YPO3)#SOC+^*-NGVBXV\;1&,ZHVH5RD:27@/"ZY^
M/)U*T]_1@C4)6R*!*RUX@H:]+N0-&S+*"A5E$KOKP%]98*B@[6AXZ<B;;O+H
M04>7=ZLO"\_?U5:,OF _"ME7(]"ZM"AQ9?@ZS."LMYZB4#GT?A*UDZB1XIFC
MH6P:SG8#W#.1W\]C#)PQVOL$+C@%Z*ID@@P[1K8HJJ*H%'N[GZ^0,W>$516K
MA>.-!YM;(^%<($GM(&@70IL0DFKOR--)$=;S6IJ]</2LKSX1U\:IW!+5F)0J
M1&KCSS 8"'PNH,@$E766H?N[^JZ56^>U0Z>"WIQ<';0P_YMXT488__R1Z.J$
MYV+=ECYO.?[NT^C43/C!4-^;:K.K18J(5FF$E*UF,&$#LM90;=$B2A63Z_TN
MYRD5I\K)9N;<;2C'%"BR>!8B.4"?"'QQ%4@%8XMPT>?2>4,/EA])=9[([<=B
MZ]A#[JL-G]D4N3;E,PG0-K2BZC:9 8,#B8%0%Z\R3E(4N O'Y]5>G;G?X_#[
M=?>X:?A@2$7-SE%+IK G75M.,!4##$Z7 VJVRGK[$<]UZSB6_KLCU"6R9R85
M:-?Z"K3F%5%2>\W)9H3/1*9[-NX+ D:264=P]DF7D*,/MZ^DNJ&C>?QW5Z50
M;3W;(,MM\P#3V@A@@%BSDIIT2JE[&N$Y0D:24AWX??IA=TS3W3=(?K,J=_'B
M6Y)NM^I$BH*B!3;96T%,K9!84@(2)4'!R&K[]QG>2=9(K1L[8*(W(P9UHQZ^
MXWT;-Q^_O[C\8V9WZE42QGGE_/KI='*OV'EOZ[Q?7_Z^Y$_[YM,_-ZW9["VI
MJP]O\M7R]ZWUQ."3+GMC0,7(:BFA8?"UUSF&C3%EO9>Z=I8"^U-W>E.02U:L
M91LH_XE^BY^V3+B-1F?O0U)1 LF +)A]2\>6"%2*L+;-T;6]2ZE>HV<DXV<B
M_#SM(M*)/=WTYDL4_?SQ<GWU"ZU_W9(64-8LF*"0M&S]W1""5@&4E5I4Y336
M.!-ROB!L)'OJS! ZGF']L/0%GI_IL;4HO*Q)H8*L/@!&Q00J:\$XZ1268*I(
MO7&TBZBA$NIS@:@KISH6_7[&\X^7JP_W<"[11-DL4!%3 L:VA"39I2A)(]40
M#1]$]R+@YVD9J@WV3'#IPI=)5-8/F\UU"^ _HLO71-MJ=6=B>X%M! M"X\ K
M687+Z/'QRY*N^NIYJ@[L<?UG $YG5DT,H0<)Z$7R;8ALM1"-].RB.@W)US9K
MMOJHT+AJ>DN<G40=V ;[SPN@8QDUA:6S;/M?E<U#FDQP,C?[77JD]O+ @$^>
MMUV#I$A&U>Z9O=<I&JK']?PVSJD\ZHZ;[R_7K%.OU_ECW#S"LY=1;GLDJ!08
MSUJRX64,@I'!9Y\=?VCOPI'=5!W8S?I/A9].O.J.H=M._[]<_A+_W3I*MIHI
MWCV3^_/'N*9OF-K22EUHM;D9.J)+="KG E;&EH/4&9(P&9R,+"A342PM)T+6
MH;0.U=5Z9KQ-RM?)XT:WU+^/ZZM/6_M.HDO2>@'2)@OHMCEPS<22%Z6T9UNN
M=^IM7]KV"D"*/Z]!U8UO/5LF/'<(-SFE+P\!"\H07 9-I!M]KLWCSA S*<EF
M'U7J/91]?^I.FSZW)K[CW]+-?W]8O?GU\IIY].U-$^$WM2XOELRKS4*V$605
M-9@B IN^J8W^27P.65+00;9?7\\[';3>@?'ZLPCE4Y'RY<RX*1C1W0[XY?)-
M_G_7RS5M<ZT/!P4[3;[&(%DQB"8G6&)XUTQ<(R*;N,$'U;O<?2=10[0=G0E$
MTW!J:F%[_Y#SP>ZC0UV<;*/(V^X+>TR1J (Y[Z,(V57JK<3WIV[N5R2\VQA#
MY<.0K3NMDPP%9'M+)E.<SK$6^S^O2*9&V:F/2@YAXIS-<:BF4!5[DPY5!918
M(?B$(*3)*++6)4_;KKQ#<YRS".W>@.K,JWZO^WCO]P&M]W%9[AZGW+9]^N;3
MV\O5YO)B69H]_\4@Y>"2*$DY""*)]AK1LIF2V5&,_">!JL#',[)/?_QW-+4C
ME<7-!+F96-MI1O9CXSCGK77,QDZ3O/S;]365NQ+ ^Z-Z4,>^2"9@+B:"8(\2
M,,MF\"@%[+^66DIN!W:,_W(P)2,]=IX8:^?@W9Q/Z=F2CI5/HV;6[2C8AO;!
M&HA8?79H!=/86<1U>4H_VVSCF4197T[U-, >0?]+A+^-ORVOXD4;[Z5#$YT8
MP"F1V^XU!&P33F4@35BSRQ-,ZMB3NJ$&(L]GD$W!NSWKRV^_WWY)O/C__E__
M'U!+ P04    " #]=5U8;U!6L5", 0!9R!( $P   &-I+3(P,C,Q,C,Q7V1E
M9BYX;6SL?5EW6T>2YGO_"H_G=:*<^U*GJ^?0LEWE/BY+Q[*KYPTGET@)72#
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M#1?H 7=X0-]]YL!CSV[(@B<.YB=8L8<:)PW%N8X3AZMW=C'.MXAFWRU.D:U
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MB=4N!0&\D@9RXLR7))PW7X8_GB=Q=]#\R0Q_="Z;(% #BA)N(UUUPF TM<Q
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MJ\R50-4Z '0<NFR(_QR7+;MHH0.6_#C.PRFF^6><A7Z$<8[YSK6SMU%BS8=
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MBG5D2CI#5B17=5BI%@5#"A8[=4J?3_^ 3OFRBQI.K7] 45[DJ 0$,E!!1<G
M&^$@"9X4ELREWZH(\@7W#]A)_2W[!^RBNZ[3@6^OKF=;P X8N#5UGBW/BIPC
M7Z=4< G25FL4R4[MMF7%]E#/FFT=::QQ#?>K.D$#IU=A.O_XJ0R9,RU4%!Z<
MK7-.HL0ZF2<"=YKI8HP*8JL;M@V5V^N>_<40?VB(-]%3XX81O^#5]32]#S.\
M>#?%A<Q6(2Y[/6X!LF'OB*V!]=]&XG =3OI20.-=9GNP2E> 2D()J8[JB0QB
MD068MUE*9DJ*6U5LGC9+GN@?<222["+WML'-FU#^JS#%MSC],$SX:C*]FMQL
MFG][]?931X2<,J-=$H1*6+LK./#:9,A!^V2ED:5LGNVWW;/Z;2C1D8XF70JX
M VOW[76<X;^N:X>4#_3E5_IG-]1/OMK9'-#:",J*VE #;05H9:G3MD)J;,T^
M N6+:?)XC+"%]CKH*[$&UO)0W )81S'!1T$=)Q;81'6;Z7" W#N(Z3P.,"I/
MVZER=,IJK(,>%;T%O@#2^1NU]DR9UBTC>B;$AEA?OWS81=S=\^#V*'0N.A]$
M@8(Z@4(7P7E;"Q5=TB8*47S''#A6?*21HIY6_QY2/J5J>^,TMR)F"((3_7U.
M$&2-#6H?D&5ER5#O,K[VI=J^01Y_+]H_+FO?WF3U__H^S&]^$6?W_O7 EJ(\
MDITOG:/WN@:Y8S*23 9:FS9:9'5$(F^"_X7;#;C=E"-=W[T]O92[ZKBC@8LX
MFT]#F@^RC;:D+,'4=@/*U91 C73Z.)U";:Y'9]'QV+X!_1>R-R![2X9TG<BR
MX4@*L_>DA?J?VH_T0QB1BF:#$HWP3 K@@M,":JC(:2U!\LQL5-KQT.EE\SZ@
MCWP'V"-C#K! #E=WVYCM#M@_=SZ>#;S2C$74$(41H&01$ LK8&/D0AK'.5OI
ML;>I><K6SWYQ-.M'2\?=!B]2JI'RV<^3.4EKG'^:A/'L%TQ(KT@<X<\X'PBA
MD[9)@'.2[!<M:%G.,2A9*F^,=,7A\;;$S0MX<;P]/@W:=O?981VOY^]Q>M/#
MXJ^32?Y].!H-'%K4.=?Y;[41>-8ULTXD,,Y:PPVM9HL.+X=A>'$4[%=K'5Q[
M[(!^"9D/4C$I12<@Y)K#:;T!9\CQTR;G(AACGA]QI_R$L]>JD#YIL/_^MY\.
MC^NMWQ'7($06;%&.L#)+!H=)X&)6$$2(HK:OQ-AIPN+62+]PKYD>.S <;U"\
M+CN@'[A(7E). 4QB9.OFJ,B%,A&"YS:4;&W&V)AZ>\!\<2=P7RI]M/5:]U[Q
M[?#SZM;3WU9)O9^,",*=UF4#[4*,6G,H)<8J.@G>6@LAJ%(L2Z;XIL;?5JA>
M'!F/K=F')#7]D/0.X$\EI]LMKR2=K"JT'NTD*/0<(A8&$H,O/#O-5V/MAQ%W
M;Z1?R'P"#'A(<'NH+7 'RFZGAX^:*^06I+2)9!H4>"9KZ]<4>?:N)-/:%MT7
MZXOC;J_*?4A*U\^N.[M(Z?KR>M'KA'Y]-OMM/,4P&OX/?7O;OOI.M)9>PN]P
M.OQ _Y1^-C R<170@G-^4?@O(!KFH2"//@?R#KUKN?$> O;%\?=$>?"0Z?YD
MF/[#9(K#=^-7U],ICM/'1=OET<W+G)57I5;F25<\G3#<@+-&0G QT2&3DUE-
MTNN<ZH^C_<+U$V'"FJA7BYRL;48-+,ZJA[^XG$#P2=QU#(%FLI!'8 RHXA@$
M# Y8RCSQZ*+KXA:_X0J^)*L\$5@[%E,:WFJMW6)VF/["/7+EG 'FK +% H>0
M44$FQU?&PAAY!UW&>T]Y\L\Q&=)HN,\NZNTP+66/&3!)!D[_1UY!J&666=!!
MPJP&$W4(AF6C1-[-I'@.PWU.@'(]ZZ[KK)7MX7\ZLNH8S'J&?5]'4,R&<80_
M#6?S 4N:YR@0LJN#,+FFPR;E7).]LI5*"EXZ3=%NMI(72>L3(L>CQW_[(3/?
MA^F8[*C9&YR^?1^F^/IZ/IN'<;6MOK^\&DT^(EEJD_3/UU<+RXKD<9MZ3K]!
M'_EJ<GEU/5^(9$*Z&5V33[#ZD7L/I^D16ZNA-L<29Z-A.!?$\UP?._R ;S%=
M3^]$DS'_0*_M'82ORRJTSW:W2I)YR1-$5[-=!;V 4<<,41HK;#%&BN97M8VP
M'UREF-YCOA[AZW(@HIM"[^REM"H&L+6[D4HUP5-*<FAD%"FXE&-J7M[8= 5]
M#:4Y"G<?%$\>3_FG,ECFP(5_^W']!]RTO ]D'V**P&(M9A;10F"N5CF3)U\;
M;;#F%SX=+N=8/2J.2=+5G)$3(4L'^77KD=T= K(%OHZZ6FS"=ISF%B=#AJU(
M>J FC\&X&+4497&H*4$^B-- ?K@%$82//.8B7.OY@\=AVH:N&<^6:+LHL ."
MK7%A;MM#*%N$-1RAJ,) .8UT!I#A)'0N.FB316YMI3X*IO_H15N]3;H0>@?=
M#0Y\BRXN:QW0P)-U$$@X)!I.UD/QM>RGRB>C"IZA2LW;MS0!?BHLZ]G!Z5_I
MCS*W?3#L.XSS.Q&;&["S2:D_IQ_],!S7F\J?,,QPMG=4:Y^'M I/';S 1G&F
M^KP?QS-R1ZO'^9F9SJ;H?&0@%X=GH;W-BQ!K/V=F=$ ;8NNPT2-0#KYBN/>Q
M-XY2]"+&DA-8I6K)148(4G.P(0<>LF,B-)]0\!!&7_&8%CI^$)L_4*JG$B.Y
MOXZ;CFTRH67*U#:Q!A1B!I>E!,V<424J;[+JE!S'C$@<K-<G>;*S?+NHMKN'
MZ&[#YRUP=37OYA%,1QIS<Z#.GJ3 @0+ODQ"2D3EO2B!CB"PB90FDDYG^%+VN
M52@F\=8&<;]$V#2^IB<>["+GMIDOB]8'WUVCJ),OF5X,EL/9LM,BBZK8A 42
MSZ&6!4MPPE@H&8-BA6NT\6D+<],CCG"]WT0)DPXDV':HZ!U<TLD56#D87YPT
MD*WUM,(ZZY0E"3R6F&J/SBPWN X;GG!6>CU,?IV]L-*:5;IE7FSQ4D%2U:/E
M7(-W)@//3!CT5I'Z=M+K@T><EV(/DV##=+ 57#^,)F%.7O$O88XK ,GX-#$2
M]30OB=9J&7AI/$0?BRA)(PN;)TAO]ZSSTG4CF;;M\G,7X.HFXZ,V:)RIQ;TU
M<\QK<#H$D#I(PF4=L7$G39_U'GV(]!JVTEE%95<W&)6"-*@9&%9G=H7::L77
M@F[+D_$VBV#9;EI=?<29Z?4@";9MU' 'ES)\E7&BU@LE@Q"*J+W"M"-;ST:0
MRA:EDZ#_[&0M/WS$66GV0 FV[6YP%Y=\8,2G8NCP)ZM=Q-H9)-/)D%PU^7(V
M5B24J[T -RAV]0GGI=>#Y->PIO\^+"W%*JY2[71GZ&"PM'THR16MNDC(!J7U
MD7Z0=GIA'S[BK!1[H 3;%L;?Q:7X V VN(0I<3"&$^4T.=\A"OJ6&<>\XT%R
MN9-J'S[CO'1[H S;UH+? 6;4*JR:K6 \TY"YB;1$)%BN]FD208=D619V<W.C
MIYYP5HH]3'XMJYY7<!'?EO-<K"A$)W*Y:V,C96KSEZ0D8";[#FU$@9NKY]9^
M]'EI<C^)K5%AH_B3T<8M$9$S5:)RF=93Z@RXD F1\Q"D<YE\+_JKG?;;.Y]]
M7DK<4V9KM-@HUF2E6MD@."LYRR2@L%#;PT?RH2W/H+WT@G&G7-I)EP^><%8:
M/4Q^:_1Z4--HC+2^VJ;@%IQU#]WG&%*TM'D(6B+1KD1RLA(9;HDGI9P2H6P.
M*VWQH.>OY=;27*/L1G$F*]FG7270_U@O@$YW1LX6&>>1T:YB#/J4.=*6LY.S
M^OFCG[]"#Y?8&A4V"B@Y]3#214M,3-H,Q49=XR$>O&8.F)3.YZBL<WX77:YY
MQEDI]5 9KM%NFZ"29&+UE AH$IWYK X5D+7;10(?>*C-+Y"7XD5)NUB]#Y]P
M3IH]4'YK]-HFJE25\8!QV1>G$NTBI63RF[V1X JK]XC:.QL8T6]S@[&GGW%6
MNCU4AFNT>TADZ>T<K[Z;_#Y>(OS/,+X.TX\$5"[#U*[(VBD!HA<!5'!TW%N9
M@ FA>%EL*IL-Y(V/>?XZ;BO)-6IN$V.24BO&5J^$2^8V"=I4=*@3$1@=&T4A
M<!')TU9:XDX.[;IG/'\%-Y3AFER*-I$F:0Q?W5T<AFB,D\ ]DH=F4P!GK".C
M7:MHR?4.9I<0XII'G)5N#Y3@&M6VB4!)<J57K3VA-&9K0">L,>M2P$59(*H4
M;,Y%";MY4MQ33S@KQ1XFOS5Z;1.34DR*55PQ^HS$-_0<@2P# S&;RKRL<M:Z
ML"T:PS_UA'/2ZX'R6Z/7-BE.BNN' 111E$G%6! Z$>,<P2-+ST#1ED6;7*U(
MW46S:YYQ5KH]5(9KM-LF"*6X>7B'Z$,4VF, GS1Y:4%RB %C+:2)SLO,K-PE
M@K'N&>>EW0-EN$:[;>)32NB'7IIDV0A%!AZ9 _4:PRJ(F#@4QU/,'AF7NYRV
MZYYQ5MH]5(9KM-LF/J7, TN *XQ2>P^8D(-2BZ%<,H+TW&#DK.BP2W+,PR><
ME68/D]\:O;:)3Y'[3*?%IS0LM!R5 *FKL\VD!T+HP$;'=0ZL&+W3VWKGL\]*
ME_O*;(T6VV0X*:?\ZIE0"AT! H$AC[1*(6G7L!5A68QRQ.QV*?1X^(2STNAA
M\ENCUS:!)\T>W!U+[PVF"L2+6&\K%G?'#!2/R646I;)A![T^?,(YZ?5 ^:VI
MY&@3<M+\ 2YRLX3*.H&0B!5-IE5+"RF56+10L91=LOX?/N&L]'J8_-;HM4F)
M],T(D?FGSLY1J$ ^M 9>I]PK&34$KXAUF&CW8-E:W46'D!48QU;\3\VZ:1PB
MWPYZ2KV:7%[B- W#Z$VX6H10I,=Z):5LKEVS71V-Q&TMZD49N8AFM?#N8'6O
M0#B.J@]2RZ2=3#MH?/#39/SN5YQ>WEGFP 6NK14,C*[]H+*J<XA+ 9&9M]*X
MI'+KSOEK8#Q_51\JV[;%M8MQTV_?3Z;S%4Q_#_/;QF&ORUW(%^.\Z#WU.HZ&
M[VY&^2Q7$83+TC$!Z'T"90*#4!O\,V.*9TX0<3??'C4$]'RY<D3%=#'6Z [3
MD^61<U8+3VM.&9>)F%[+BM%J)5PQ?M7>:VD;/%]&'"K+AI6\ZS:R.KHV7 WG
M8;3*P4^KIG.K6,P*O"^U),HS<*Y.E@E&D'TDF5W-ZVIZ?FQ&>!X&8X=:Z=C0
M^'DR3LOS$*/R=>1\1DM>C::]*M0I1#ZHPDSR"ILW05Z/I'].=*F_)ZBRI_ [
MH,3BX'L$6L2D%V$+64IMW%Q[DFI);X=#SW62W%G1F!=/P#EK<K120P>CP;:3
MPD#EXF7A";2HQ6#9U,"+UA!#489.2U=6A\_U=."<-6\Z4$Y')NGGD_=5F$X_
M?NJU2_16.DJG(0<D#[PD#H[,9#"2)TEX@RS=]H"]C^<\[))F$N]BUN ];,L(
M:^V'M)@8E]_@--%?A'<XR*$",Q9\J?E]CE8?%:<O@J$A-\N4U2JBQMQX"MTY
M,J69-GH<V%=7L'#="?IEH$UPBGDX_R&DX6CAN->_/Z@W^;8?WK(G^5X+ZK@7
MN2Y)2DU.-$=6*]3(5'4LT[=1AZB)$SFTGC758R]RK6R1TF00NH9M EGCD<QO
ML)BPF)RD$*G3U9U$+_)==+Q-+_)=I'K*O<A5+)E+3V93;0DE2#;>)@&8HS Q
MTFI4ZUN7T^Y%OI->M^A%OH-\>^U%O@6N%]N+?!>=;=V+? ^!]TD(HYDE*!8*
MZD56 9E:RBH@&XL.WF(BU]V>@2?8B[P+'NPBY[:MC7_!#Y/1!_*6;LRNBW=3
M7!POLXNKZ7!4M;-,WG(R*)D]Y%PB*!_(@\^90V"AQ)PU':.;+^"V?=JQG8U]
M53/I5JYMFY6O0JQW?-4(?UWNF> ?;RX%R9^^1>Z6Y<+%)^?H/(PFUTA=DN"D
MXR!S=!B24"5L+J8_$$1_1.E,IX]SIDN%M-U%+J11WX6/CPEH%;"Z!9RX+-:[
M",X:#ZJV[W&H$QB-O&BOE"N;VZ;L]^RS(DX/XF^;&;(OT^W*/WSL]S1]XFXR
M66I "5DP<!(YKW4_'!/0&R5!Y$R_% JW:7.CII-=WOF=JR<CVIV8TZT-M[5,
MEG7EABOGR:>USA-R8R5X;0.4X"T7#+G%S34J!X(XZG[\3$G4X*W8@P&=<O=1
MB7YJ@9"-C3J KV$Z%54&%YBE74,+KR6=D6:SQ;#;,[\PLR$S6^JWK4FRHPVU
M%$OFB7'-,B#3!-AG4VLD%)1()EL@NUMXU]J$[?TP/T=B]J#O#G(+[@MQ$9#2
M*FE6I 06JQ5OR*1RA@E@Y.T%FR639N7T/KQ$X@&*<PG6'RC?#O('[B.Z-9ZW
MP=11H'X=GN,$Z0_5U9.J/T#0'03HUV)3*F=K;0$M<B2>"ZR9][+V(U$YQ:Q*
M;IWNWI_R-P3F^]#]+O+M(GWYWOFZ+,GDWDFA,WC4M$BG:PNPQ"'2Z@.*9&0(
MC76^#D?_<83#-;2:2WBH>+NO?KP%A<YKLBTD2.8<J)HX[97U("TWW&"@/_/6
M[_DZ(&>@],,%W,6+/ASCDH<#YAAQC'D@2T70ZKB!Z(L&+,(R+551K/48^+O/
M/W: \*<FJ3E[2[2#=_HNEL_.SQ_#R^O+;R?3Z>3WZGN$*_J;^<>!<]I'<@QK
M443M*>8\>"<\,)$LZA**X\WK8'? =W[L:*J1SC,S:N[[H-"!%$KM;$3[$RCF
M,@3R@4%'):5DB1?110>$^RC.@PD'2K=M .H^F.]K<FLUA1>H(N-68\H@N<]
MAFZ="J8<?1NQ>!]2L9NOVI]XP/-69T/AM1TTO&ZG>349?\#I MRDPOMI$FY@
M)B5R8E&!$I:LD*021&D5,"(>\MK[=XL)0+L\\=DKO3/QMAU-O [F14KTR83R
M!ZR!1OQQG*:+N&,8+?X89O2C1P\EE;!8)HC'&)!,FN3H4$H(13H6,1 C^.9;
MD.:PSI)/_2FJ[=3D78R<BW$^;)E>!F.$,2!,L&0DY01!VSHX@G-KA/ \;KX$
MZ1/Q65+U)-3;>$+T=97JZ_+()=+ 6!D5,@,\D+^N>##TIF4'5AMGA3-,;=/'
M^NF'/'NNM!1BXTG1M\B^#>-_SMZ$Z7R8AE=A3A!_'&^Z</QT4S=@.8H@(_ED
M2DE0A7Q[GXP 5Z3G1%NT=HNVG"V@G U5^E-(VP'5Z[;%*J)?)Q?YOZ]G<US6
MC/]22\5?33[@.!!@[PRWEIQ\5^^15=$>(L,,S*L8!4;:YS8WBMSOV<^>,CV(
MO.&<Z]ETOAH$OB!_(;S#6@/\)@SS0*N"B1E)4!RQ-X7%0>?!)(/&U#8EVW68
MI$?=B:W0=Y_C*IM1/&]:-);RXP.QNRFOKFTFYK=M)@XJI5[W02W+IC<"[;A$
MVG-$P9DC1K :6G<.(M$$C"P,8XH^)[/-JW*:)=(\H O&6V!9T>I2+:?@3H.+
M/%MOBBBE=3#^!$ND=]'Q-B72NTCUA$NDF;0E>FU ND+;HK=TDA%R8"R@8#YS
M';NMC#RUK*N=]+JY1'H7^?99$;L-KI=:(KV3SK8MC=U'X+T2 H6(0@>0,IEZ
M8:3 (7K(1J")20K4K3N!G7J)=#<\V$'.;4L4[LRZ-MJX9:IZDD6FD!WH5 HH
MM8B*!0ZR)%HQLL+*+L-*[W[VL:W_?<6^=C[XOC)K6^R\86IJ?7 L60.MEH!Q
MI2$$K\%P49QT6F'<903(B4^>/5BI!\NPLS=4R=597TEI)6O,.C)/AHEU";R)
M'%3D05N6A<F[S#I\^(1S4NR!\NNH(>?2Q_V5_LWBA'%2.6TT<<O%O)@?1$Z)
M0:"U&JE9G1/5.@=F'8YSL;\/EG$/>K]E^#:H.K*_UR,ZCO5]N,8V4.  <7?4
MRGL-.@S<B52OJBP17^EBP4=E@.M@'$KFO&A= =$G"398WGUQ8!<I=Z#[MS@>
M3J:+(VII:!3&HV$(+)9%2(I.I$B>AK$^QFR%Q>89D ] '*?/\J':F;04;0?)
MTO\(TV$]S>HUP8+.L1A#IDP&IPL9-(%LRLAUC3ZR3+BD"\V]ZU4,YW+('R3;
M#DI9[^*YY?(VB#HZW!^B.<[!?IB6GE#Y 2+N8%-?@TP)AB$:!8S7BP;.'00?
M!&3ET-<T78&M=_6^E+[A(.]:Y[M(M@-=_S;[M6:874\__C:[UW+[]LPQ/-<R
MG 12L A*U/VLCIDLZ%40/M'7UC6-&R#U?[@?JK5)=R+OX)A_>QUG^*_KFJG_
MH9YM2^,5T:92B@+'D@8E0P)7<H182WI]+B&[U@WP'X%R+H=^"TEW,-YK#:RE
M.;L%L(Y,@$=!'<<2:**ZS70X0.Y=.'N/ C3"AQ!B >D8IRTKT'9(KP5@IE>#
MI6SY:K?1YT:(#59"OWS81=S=\^#VV-+DR^JL$J! V@E5%.!\YF#0"X]2"H.M
MDR[6 NG?/FBDJ*?5OX>4&QH'-6EP,82EGGQO$X[)))HL&%[H]#-)6<B+6XU:
M]A]4_<)#\KJBE%O-3-J0D;GVX<_=$&@CU8:U20M MSA^&\^N, W+$/,MF[<!
MM<OQOTGECP'I]\AOI*1)5Q)NN,$_#8XS914*5KOI.U"Q:-K,ZBQ F163Q66]
MW6S.TU+[(P=[GUK?1; =:?N'R113^'2M+&,L,M2Q7;'V_XVA0!0N@W%>TA*C
M-GRKW.$M57W_Z?T=X W5LD;1!\BT [?^_IGU0TAX.X(/?4"KO2$@M:UYEAF\
M5PHX<ZB9*)G'UJ-5'\-R[&2-GSI(K-Y3TITSX,GQ>H399<\\8)U6OJ"^(\L2
MG O<$_/K$/-..?$\AAVV8TDS;;3-W7HSG23$//N!1/+C;'8=Q@E?EWO#@7'^
MNGPWG*7*\-G%./\VIJ?^/AW6NL0?$.F\1(/1<E4QY]I+/H&7/H))Y/]@T!GE
MYO8H#8 \;]H<01E==M#Y!3->7E7QOYD.$RXQO[V:8LBOQW<C[H.H;&8R:Y"*
MZ9HU4:>)D@?,DG R::7]%NF?>S_^V=.F'\%W< >]"OSJ>IK>AQGF.T<JES*Q
MG HH<HI :;1DC"L)4H10)'HRT;LM UL+ZWESIBOY=W!5\5>2S>RGR6R&L]?C
M[_^HV]SU</:^XJ6-D/ /A,""O@X95S5G!HVJI:P(/L4<ZW@FIEM706X$=1[T
M:"O[M@UV*K8*;3VPQ3'Y:_AC0)94%-(:R($A*$\\)F>,OJ1L&)V+S@J_\639
M[EG/6^?=B+1A.YKUBUX9-J\YST[+.AY TGDF>"0J.OJB$NU<B=EBNYV<>Q_/
M\Z9$<XDW[%ZSQ$9G5OBXF.5VWTX>1#)>G*PC=3R!4PIK4^E@P!4KLDO.T;G6
MF F/83D/%C21]*/M9MIWDJ@-,";C,,YO2+LXG6)^.Y^D?WXW_##,.,ZSO3M+
M;/O!K3I-[+601ITG5FXH[S))*$:N Z0H7:UTBD!.IP"N%;?<!I]R\QSP1["T
MSGE8W/71&8:,90L6,UF]A0?RIWF&%**U!J47IG2<[M!G]XDF>MZ4W;"S8$^E
M_\1CJ1]!VRAJBF#,B=:2'&UZ*GJP(2?!E(^L>0SUQ/+E#E?QE@ESNXBZU[RH
M;8"][(2YG52W=8+4/G+OE1A*ISK%0D.0O$[WK;W6.-?@N4T&H]=:])!,>X()
M<]WP81=Q]Y8PESEC)G(&2:=$2RT%@N:6ON4LNZ*<"UME3IU3PMQ.BMHJ86X7
M*7=PZ7ICG]^WR=_@].W[,,7O,(WH/WF 1?A2ZNP3)2(HPPLX5R=:L!+(3189
M=6MW=!M<1R=&&TNSN0H>I4EO?NI%2CC":;TG7BSC<W#^\_CZUB[L+L_LV+O=
M>_F-'-_'GS_[3%F!2J HBB@D:WOYFONK"VU!Z$.RV3,16M>_;X/KT WMB6?<
M&/A1!\8C&N""OB@=&>W>) %MD&E;D'/5>DC6)DQ].<K->;&ZE345_LDXT,LT
MR^__=;T8$G)Y-1G75WAA$,K F5&6]F1GJ[^8!7A6#)1(GR2RM2ZU'K#W)*!C
M.=-M5;]J.C5300?6\PJF6TMQ&U =N=9K 1W)K6ZGN$E74N^-$H6[K)()(+/1
M9.J;"%XJ <87YIWVBC7O1]$C%38YU#TS81=A=\" 90GUPAZ\,1.7(^<YAE#H
M5)5)U3O'X&D?3!Z8*R&@2D%@ZXKU1\'T[T$U4-:D"TEWX%I?Y+P09FUB/\P_
MCF]'&2RG!6>,*=@$+ I/QI409&;I"":+Q)S.,:Z.C3C<#'T*T#E0H9W$^PFV
M+K8^Y8P.F9;).-;.EZC >Q8@,\MR9EQ%?>9]"[HU'1N(O8,.A4^$&+< ]K+O
M9'92W?8Q^#WDWN^=3-!.Y!1!\YK+6FNSG*8S33(EM7=2Q>:!B^=Q)],1'W80
M=X]W,MS*FZL'Q<E8#AQBL I2+M*A9=;&CC-73O!.9A=%;7DGL[V4N^AP5"W9
MSX?@F^GDW31<7ES/WT^FP__!?).\R >T0)1!1,A6LGHGD" ($8!KYI)-=&C:
MYAD<VT'KGQZ=AS:[4$H73L?C<GB+\_E-:/3-32[DZ^DOF'!X-1\8U!FY1G A
MD72*0O *R5(V0N7:OM/U>1?P.- SY%7W"NLZNK& /;M(Y,[5F\HHE2VFQFX*
MKQGVS-4J8@O!(_ENY-GEV#J+_0DX9\B85L+OP*NY!^T?872-2V2O)K71 &V6
M>5!"MMQ:#CD1;15) J*O-9Y2B^ *#[RTSBO9!M>Y,Z6%.AI64:;A4^O_QV1T
M?8G_A<-W[^EO;^<_+GYI41;Z$\YFR]+00=$L6:Q]IA.K$Z9]@HC2@^':H"S&
M1ES)=EY3)=4&RQEQZ#CZ>;0&LWWJRH]C>C5JC7H8T^LPGD]#HO=A1 _]:1AB
M'44[K!OK8@W?AE']S?US5@YY6*MDE68+/C!+A9CU"<K%$U ^\S<7+U'4IG(Y
M9%"1?#WRR1SH'!R7 ;6U;N,;OMLS#]C6MGK0;5,VE:WUF8%VM4;9F@C!N4A^
M9RHH:E$34VT6UDN>2;>:O;,S=23BD\LX^?9Z1J*:D2>P^-R;NU*?BL^*>V"Y
M<++QR+D,S$E(EDGO=;%)-&]D^12@OJ\-.M3_8VDG!^NABP#A#9;;(-@V8+JZ
M-;@+Y,AI)H<KZL&4DT.EW+GJI8M1R&S)OK+LIFU7P$ ,UYHLO2B4\<V;&W>O
M\FW323K6^"[";=O;ZE4UX?Z&831_G\BNO@U-\^RYDP3%>E=-^=I?-_  V:@D
MDDY9*;W18EC[T4<(Z>\OZ4E#,36,PA*>UV1]3U]?5;>)A+>DY2VLH-'Q2*>/
M$'6-2=84!$-.$3)A>-3.9+91>T\]X9DJL9G0.MALR8^]FLS"Z*_5FWHU"K/9
ML S3 NAMO]7"HB2_.G)?NR9:!*^Q;CW9(<M2F=PZG+4!TOD:9"UUT4'X\PEX
MGQHH;P;8U03X3>".- J^I4JWI\L!^NAWCUD.Y_52!1UJ)-\'4)QY\((K2#QQ
M@3;*+)MW/#T.83:-C#\J7W910]<\^1N.<IE,Z5O\>3)?A%O'\^'X&O/GD_3V
M"$7'0G(E@Y51TIY;%$2_: R>LC;1DSW<.N=X3ZA':#?45NE/4:HCC7601O#C
M.$TN\;.3=1,.?OL><4XG_.<\V[J&T83.?IQ]^_'>6F?T$:/K/!R_6[_.FUEU
M6I&-:#68P%-MZ>0A2NV S#J6N#$E-1_&VL_*SM<$.T%F=-';=1? /X?+3Q,R
MMX#=AWVW/>3C6'VGR**G=NZ.*="UJ; #?(DB)%[3[.N(1Z4%TK'' XAD2K6L
MM$VMRQ%.BKD;S,\S)NXNFF\;ZOP[YF$-WEWD#V$Q4H!$^0N.:N+!2GAO&>W]
M-'/<6LZ-)8M,A5PCO<9!X%*!4T4EP:W2<G/RQ_[//[*YVI5V)WVKIFT,=BM3
MZ-7U=$IO\$6<+?Y^((3/.2<%O BR\FL[4.]2(BEIB:YV!EVU1?>]BU]Y<G\<
M.JW[^4,4T)8O2U ??YA,R0,<7M;9%+=_R/]]/9LOZI;_N*(S F]1#Y*4B%(:
ML"$@6<[T/KFD!+"HG3,ID?]F-])ECP>?'EL.TN.D-R6T/;+V0'MWK[ZSA0\T
M#X7<,<*O:_T**QIBD1$LTSD5;P23O LF/8+G"\':JJSMF)J[B_CA>D[VY9O)
M:)@^?HMCTM3\6RR3FJ@Y7,IU^:8$PXQP@F3FG:ZP,T3C)-#;$U-PA:$3.Y%L
MAX>_"$9UI8RV*=<;$,\V\%X%:8+.%E(LEH K!IX)!C(RM$[46NR#6;0!PTLE
M4TO5-)QT4^=^+6#>B&4II.^0L WG2\(KP[VP$4&$VM[%U)DKC@AOL1BR*1-G
M,6WDS>;GG"TW&HNX[3";S> >XVR@T[-$'J$0=G),F8 8!$G#TL^M=C&LML+9
MBQ8O;2?I1R$-I^/4.$.8_A/GOPQG_[S=[SYMAS>%M4N:%VG0\QH)*Z'.?(L&
M?&*UZE\KXWA@(6T^@;9\V-D2I MA-QR/0PA_&V.8CK'V5;T<7E\N%SY %4JP
M.8,5HL8C@H 0A8!"IYX2VG,G-@_K?.3#SU;=+83YZ.R;ENI];%M*7&>EA 5I
M,P.%6*>"%@8B:VZR-REL,:)UMV>^-#*T$/U#COB>@KB/H3=%&Q<C!R-E E6[
M1]%Q9NOQIE/P.:;503@'QG1?&IOZ5M*:(-XA@=][2)Z^2_FTB"T6/&#TMB@?
M B1ER8Z2/ !Y90&8L^@5X[0DLY%W'8$[6RZ>@C+7\/.0*/,NXAO(4JPMDH&-
M+M1QIA:B\@P"*J6]#%RLSAH^<+,[6R9U)O8U]#@D&+P5SI\GX[0B%L]5X)%S
M",PB&7[(P9>4H=!.'$A>F2S[-DQY^/#3(TT_MYT'JN%XMU>?@0^""#R79( $
M0<:@=!Z<+^04RD#H:6>TN+E\:;]GGQYM#E7H?A=3>VKC%.CSF/T7I14HZ%W#
M*C!E+"W!!P[:%U8'W20=-I<T-H7TA6Q=Z.ZX%Z%W7IS$R*,(18'@69%58#-$
M9+9V4).*&2W]ZG3E!G>A+V\KZU K_5Z*;GX-)%.V)&7(</ %5.(:G)$!3#),
M%J.S%[L=C'O!>,'$:JRCWBY([_ _FQBYSHP\%%D[SUH/7C,$HQ"C4\7JU>D@
MNUV&O8P-J+VL>[LLW4QAHQ&99@F2C@3;N @A*0O9<A\\.BGXYLNO0Q"\>.:T
MT$R_%Z=W6.]0:\MH\XMAT4@A,8@V<]H&<Y!)&T'".?CN]&5L,QU)O=M+U#N@
M!),B63*QR(FLV4+U,+36UKR1[(Q+M/K-5'C\\\]9]8VDVNV%ZN8=*QCC7*JI
MTT5F4,I)"+E.PY&\IB 6%>+F&.#.CWV9Q&BA@R-<KFY> %.2,^84N&#JU4AV
MM,LE.@6SU4E%&W%U L'A@>07R*PC:.MX%ZUWU['-]9RUD<LH'#ER2H'"&,CT
M\A&LY$%$([A7FPMQNL-WSKP\$:T>X]+USJGO,UEWY#76EZG>&FD-0==&(9Z0
MIA0S2XVZ$[\, ZM+^1_C O;S;72TFC,N@"TBG!$#.)D3%,&*X[F>]YOCSCL]
M\O1HTL]EZUXB[Z AW"Z7+8.8I0E6(<@8XZ*[(3BF"P@3M5!,1L5;#T[9!=_I
M<6D_+4]Z4M'QKEP?#5(%HST3G@[1Q85Q0@C&1F!D_MG@E&5;6$H-@)P9DXZ@
MG8ZWJG47+ -+GJJW!H$K5D=T,W,3W. E.$'N0^ R=;@]K<-T9D3J1!7]7I4^
M6C"-/.GLR>'DM1>((UX'3H8]%\QREM!*MSG>N.?#SXPE/6FAX17HDM=/W+#,
M!EP85J))P.O0,N6E@R#)BC>H"D^H8M2^\?;R%)XS(TUS%?1V*_HHF6MVK2W!
M@ZZUSDJB!9><!*U\D<+7H>X'78:^G.VD:^DWO/!<\GC3_=N@6)MM=!QDD!94
M\!I\X:8.!>;2A1QE:MTO>1.F,R-.)ZIH> &ZQ+=Z+3- (RU*KD'[&GAPA4/,
MKD!&(60(64M7&E-C%<.94N$@47=[(?K8/L9S3+F0,X^AA@PC.?/!& $I1^ZE
MCV:;Y.,M'W9F6N](RD>XZ'ST?M:A,)YD$9E:-$[4M;V8(:.91Z,8*_2'-@';
M%\.8WO1QO O,[2ZX@BS>6:\ 7<T5,9Y\L2P5!,9-+2KT<8M.!JU1G1_?CJJW
M8UQ,#HQ-/$H102=>1\-+#3'4>D21<C D*B8:Y62<'UO:2[CQA>,N@>:+^7PZ
MC-?SVO+_U\G*5NIB<B;J"(YH6[/AZ4^Z&# J*)62JQ9:T[N I]"<'I$.OJ8\
MBJ+ZC?4^"3MH5[R)9.J+6/N&B#IB@@3(#.>&R1BMW3S9^! $9\ZI3A72MOQE
MU4EX$J:*I<A G@*YAZ:VQB3K+F<.Z*43UG/,>7,3@UV>>(8\Z4S@_05]GX3L
MM259"&(Q=Z5>8]#Y*S !\X&A#)JDMMDMV_?I9\B77A3Q:!#XW[]9D22MYY^+
MOUC\O$KJ%RQ?U?_^]LN/GZ3Z^^^__VG^'E,=0O"NPOE3FEQ^LY#K)ZF%)Z3V
MV_@J#&]/Y'![--^>Q[.5R087:3[\0-ON=S@/P]'L_HIFP\NK$3Y-MZX!??-9
M7/?%>(OJ'AU/17#XQQS'&?/7_:58?7Y3BD:3,ME2(D;:]7PN-2G:T]8G7$*3
M0U$K!;N]YEI] MIG MK-;#!?AX!)H>D J)-GBJUC[\A]DEYF7T1)S/$C2F8!
MLN$>'$:CASMO?]PZ)!MM=WVM2TG[JHHFS_]<IQ5A_LO7\^DU?OXA;0+TGGX_
M6@P[HLWN9C#SP?/KGQS>3B8'&BD<^3FU:9-R''QP"@I:+73DQ4K5F(%/ NI[
MEE]/7%@=>]],)QT,,[L_9'P;,!T-V;L'Y#BC\QHJ:I4"!TNY<]67)%RQ-1I2
M IF=*A*\8@MH$V-R@AG-6M_=]J#R#3/G^M+X+L)MF]V\8C<N9^ &6W+0"30*
M2>X%0ZA##H 55@1*8U78W+UU[4?W/[;M $E/&HJI@U'!&P=RZZB\0P[1*EYG
MY0CP!@UX6G942BIE6IO:&R"]C .]I5XZR#??/'9[&X!]S-)=!^XX1W]3E6Y/
MEP/TT?5@V[5 3<RL>">@./0$U"!$[23DS"US*A53>MQQCF@X')<ONZBA:Y[\
M#4>Y3*;T+?X\F:\?EGI[G'(5/!E-'G2JL]V2U!"XB.!U8%)*%:S/7;)G>ZA'
M'CY[N-*?HE1'&NO  .II)+0D(R\ILO,C\PLSCT$T08&)3C'41F4?&O.RGY6]
M#'/L!%G2,%W@X.G46\#NP]8[]O3Y31;@*;*HU?CY/2C0M=FP WRC4"3G$!*A
M!F5KJGMT_Y^]-VUNZTBR0']11M2^?*1DN]L1MJ5GJ7OB?6+4DB7A-05X %!N
MS:]_65A("@0)7*#N!0AJ(D;-S;BG,L^MRLS*I4 L!@/6X7RZ==3ZK)B[PQ2]
M8.)VT7S;L-GOF$>+>];\-8SGX5--$_@3;TC&>2-4M(X<XMIF8IQI:ZP LM;(
M3N-AT; R0[9"9RX#CWOD4!S^_!.;KGUI=S*T:AJ:LQV3%G_^[TJ"[S]_FXW2
M*(Q)IO3KT5>L_]6[^6><KM,"KF,67)E%EUT?09';25Z!1++5A0M%IQQXMX[K
M+=$-S\7A[I7/1:D]N%T/U_4P)^69<09XWYM*TVF@9/53=2!3/G(RY9FK_5F-
MUD0ZS3<[%S9-<^@,^))).KQ&>[ ;._41XFA4]+2G8]1UY)TS$.F8@82N\) 8
M#YM5AQ?:ZND$JC^F_U,7O?7 L0>#,_[$-/E*YDJ\P=TBJ_W)I7%26Z"WTX$*
MG(&SD0'7*2:?DLZE];WYP6!?$_N&T6C/[:+V%MFU"\%:3U!US5!0C"EPIBB0
MP? @C!(66\?6#P+ZFBC8OR;[*TLZM-<:<R:R*#A81\!5;;/FR-$"YY7+EEDR
M4]H.LCMY???I>'8"E;6M7SIXCWYR*2@$R8X<I\AIZS9!0RBT=4LCI)<QQ[2'
M-]P:U2NAXDF5V;9^ZB#Y/;6,HA3SDC'(1=36"E;2,H(CRS9EG830=K-?THX=
M\5A$KX2/)U-B#TVYNJ_EUV43[_6OU[*,BXD$+(.I!JYBQ4,4F==E(9?>>(Y]
MMAH]!OMKH.U)]=U#A[ /MW_]M:QP"3>_CLMD^F5Q"T"K>C^=_(73^;>W878;
M;N;?[@KD_C6F1_\]'<UQNAX$_O]BV!U <%'9K+."Q+2OO= 2!)MK-;_*ADM;
M4FK-[.%6]Q*XWX*!FTGTYTF?/FHQCEOI^^EH,MUOG06Y5QSK5&L-2GM6S:L
MPO. RC&?$Y[7:[+WVGZ\).=#G;.(BWTO;'Z-H7B'+ $/N5;6EPR1U_!*<K)D
MCEZQT\?(-D"_4E(/J^P>TO6Z+V#YX_?TEW<21,PN&S(AI2SD=83B(,KL0=-K
M&+70GE9Q<L(^QOT2.'LZ2_U(/3=LYMIB#0]L+'ZMI;(LA@!&URZ2C!83><Z
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MJ?:6(%NI-A>A,Z=D\D&B(L>9*3J8=K?@Z.]:\+3W^"*'; UC@$'4:&QRQ*'
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M=>PK,O":7L&+<LXLZ>$L>?J@?29M8X<P_C7#_.OXD>8.EY%/P9N8'0B9XO*
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ME_68+<DE"T:0XU\*'1G6@V,8H!2=8K*&MAK70'/?/72X8_(HL4]:R*RA>;,
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M;\(,\[OQ/Z9(WTS?E<=_'6:?_QUN;O'==-GCZ>X'ZSN6&&60*0$+FH%RI(9
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MA0#!,G(;LV;<2<'1[Y6Z?.!AM@!Q:51I(^T>&G4?%:*@DS5RIC  *TZ 2JJ
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MM)FB@R!X;3NJI U)&IM;%QB<ABZ[#)23LJ6+%AKWKCZD/^-]$^55 _%U27%
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M^+(N@=D']A!&W?Z03W7S>'XL>FZ[[ID"?=L''>!;810F<M>-4A84BX'.'5G
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M*=U^N5W,8]JXY*P96<M7MJ9?62PF94G6"]I(#A<J<)DA<*NR--[%G)I;#"V
M7S)EA]=L#\[.H8NHK]S](H+-20?+P#*!Y+$Y#T[109(->B9YU%J%,Z'G=\!_
MT+.E9OL8Y/KLL?#DGL_(;F$J2,C.DCFCE8 0Z?4R-J+A6=B46_<[.@SI)1-P
M -VUS?[<\<8\M$'>A-GHT.[;)FOK S. L4XXDL*2P\H2"$];OO8JJLV,Y"VI
M@\-@O41ZGJ>BVZ:][K"FMQK0ARXR*99$42 C(Q5HKX'>4PT&I>$./9=^C];L
M@^&]4$:?J<*?S)UMLC]W-K8/7'$1*5K! G"36:W+(@^2+"$0ID1N4B0%E<X;
M]D#@+Y3O+X$*C\EO!R;_=Z;\@2OV/ G&-2.'E-YTQ>@K7VMSI!<*7>3<XNYI
MIB<"_X/\)Z/"8_*[7LC__<%WZ,)<LEQX"4;7[F_U_78.$1)11@=30I&[ARGV
MB_'547EPQ3YFK!^@SN?[9?X]FG\./]$J2:ZC\5U14XNJGDX/ZJ&&Y_"%GJ1B
M1Q8995K&O3PHI36X4"*P4%1).C$K6\^ .+N*'1N#YT)$<$DN^A%DB"DD8,;3
MS[W+@K=.T'NQ%3M=^')(Q4X779RZ8N?[&75+A_-/VK#'GQ;)UM:I>NT6H-"N
M7+-S(L1H(N1<O';!)+V9_?+\1,#-!YQS&4XG-6X=^7>4.-LV5GL"U2HO9Q]<
MVRMJ]E?W*8I>6JICIX:/D.6@NF;)Q%2' PI7<^V(VT%F!&F#]TE%%M7N]@@G
MT/$3Y2(G47$'$?:EVG],0\9UKV&OR'0N'H3R$92S'!QG$0Q3,<@43!:[?:*M
M'SWH%,6&0M^FR4,EUC"'BO"\P9O)W]M!)9&SERH#K90\(*TS>)4,<,-B-AB2
MB+O',C_]^2]?EXUDU]\P@4?%:E$4FX0Q8'.=!2YK(Y7B!6C:E'*P.3/?TWB
MEU3P?(BEU5+R/>3JM$V;WF,M/PJ>GR!@$X+T6D=Z@';/O>!9.Y649(+L+%J)
M8G4^%Y,2N&"UNX'5J?F^=_Y,/;#@^6R(VD6I/1!T:^50X5HSKP7P7+M5>>;
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M" P,DY:)$K*YVQBZP=P:@WI&-G=,==TW/-=DUM\:U;X+(&&5.AE'&<R5B+&
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M,7?L+3ME6H]F!K$?8\<NBCDZF\(0L*^,'2TU?A"MPC[J.KJ-I1)MTJR #(9
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M_X#H?9Y__(SS?+,O&(\L% HW_:IN- =R[EQ"4"H7P0S]G^Q6RW<8](9/+GO
M6.>,,5C/G5<0;:Q#;$KMZDL"4!H2''?:Y7)2TCM.Y=Z(-OK(D\XH6CZ5:KV;
MY5YG,EUM-:U$4LD%7\5H 95GH+ (GH,Q"5N[$O=1'/V=:"P[F#751X<D\(^(
MWM+2/\WFD_^L;KFK1_$!"#N]$VU'=YP7HT/U^*A9-%/"<<R%8B2K3-" HL[1
M"K0S0Q0!;,2H1?3D(*5G8B9;WI+&MY)=9-_0.A;SY=E[G"^G>;[X//GZ&]UE
M<X)Z"4HJ'B): 2;6HII8URQ=!M2<>U9RP#2HM(D^Y98QT%<WAO H@/&#UM::
MFK46<X?BM@\9SW]9+&FMOUY,T]5(8K0*N48+FD<'JB@&CAL#2<O(14A6-.=[
MW CDV=A .W%WN!W^5TZ??L!3.,^(V8$PBCQU9QPXX3G!X]J)K-#XUG73=S$\
M.\T?).2>S#*WQYRO+CLE9$X" T13&VE1$S ;*D%45,4IS%YW; +Z$<Q+C3C:
M:*>GV1S4M7U[59=U&4/6U;L?J/&:CMXZ=(CI=)E>VDCO/6NXFZ^/"RDUS^!2
MY=?S(4)P]"4*5,%KG8SOQK3U).QY>+O2DS#G'=0]0M'%U9!L1M$%"PQ840J4
MX E<K80OEEP-&7*)83O3TB,?</0'QB,I<$L]Q1[2[]F_]-/W6R]DO\[S_USD
M:?R^VDN>915%UA UTJI=8A"R]Y "\S'Q&'R._7R^AV"]>G]M-#82(]\UP,NM
M- 3BB"W>=^ =W3MKH]H!K;<M]#)2+_<]J)'.8VT+G96%CDYCZJ!5%FMGG]4A
MI^R%>"ZF,]P1.I[E[*".L;K_KR_\JUX_J0JW*0,7/(!*-H+'&$$CBEB"3<ZT
M;H49@NLT6B\/4NB0+O]#M-'0]ZDY]P\X_;1^OM$> RI70$:F:W>@(I^.22C%
M8E$2;2HMGC*N/_"E^2W[2[OA)))K$)>6-P3&+M['$.4?XW'[ .'?5=\!DFO\
M+'D;3DK.*A4$&)D<A4]1@),J@Q6:4_QO3-;-=N\1GIW;ZV\7@376VQ\DJ2\7
M7ZZ>.+"XR*P!"H!E?3;7X)RU0&"49C+08@=%E5LT]\.'CG?/'B3V60N9-;XP
M_\!_WP*BO4K120/<Q@S*)@DN,$NN)<?"43NG!G'?;%/>[0]]@LK;6V8]_>/'
MJ9TD1R$$(G#.#2CO"27: -;G(K+(+*#OY2&?-LO?\?,]K?1VW[JZ3'5_F,IE
M"-A7?K^6&C^(A&T?=1V=W\^%)%WE!"NAT)[CP4'M!P+-M.9:*A81GY]MM>'W
M&\^T=M'2""9UMY_PZAB_(IO#B$+3S>^B(KDH3."=(2<L.26-H-.==^L*&83P
M-!))C=2]Q; :ZJK#P]J;\V6>3W&Y(O._<AS.8M+D26H)DNM<)X8IPJ,02K36
MVXC2A=9-61N!'-%.CM@R=+A.VE)P;,2SY[PD42P%%RZ#2;+*Q47PGE:A*3:I
M,[238G<2(1M>\1L">ED6=D1E]N6LW$.2?T_+1>V#?3O[\F6R7/_K,V=L*0$I
M</:ASLHN$KS@'(0)JF3&<M3=WNJ:K>)EV?2)6$//.M6]5G3SCS[DE+]\K1;P
M;K:<Q/H=DUGB% II31*OXX5L?3A#"9A)[E9&\JHM\J0Z\KKV6-*KY1_;3AXL
MTQF+:&)U2>%&K@Y<7O^3NM?G;_-\23I^.YNN>18:CWUJ J4OP41S8;4FE_@)
MSW$:\\?/.2]73LAD^NG7R93^;(+G'VL/4EW(6UQ9[2VV%6<CQ?^TB5PJCC:1
M8A"$-F!9Y3(LF,ETNZ6']\/<,'&^"<%EAE>6%"EZ!<6"K#Q^G+:RE)"9(($%
MEICM=N0_@FMT0H@Q[.J1#'D;!1V;ZN''5U\1I>3%,7!"UV$;(4 (6,!PA=PG
M%F.3M[;3*5!IIL:-%2B[B+-CX<(0&,^O F4GX3]0P;"/Y'I6H&1F2K($!RF"
M48470)L<>%=BL"S5#NZGH,!!%2@M]+>+P%I7H/SP(%^$BJH("]EG6HR3 1Q?
MO<I*KNF@R<(UJ4 YD2*&7<3^8!'#+C)KFRS]<#D^]R:LJN-Q\Z(F%NB2(??B
MC]E\^0D_Y=]G.%W<---?16R7CO8O_W,Q67[_6$M15W]<Y_F^F]&WI\GY=_*]
M\_P+^2MTUUS?1V="!9W06C#DG8"JB8L@4P2IDTF<HDCFM]//'@__$8/W,=W!
MIV,C'9Z;-B&>U8ZVAR'__?5?.$\K?L,WZ;\OUO)Z,YU>X/F;+[5/[4P9JR)3
M'#RKO*FA>'!%:% 9A=)(_]6M7ZMZK..%V/_)F,*#E_;84\A_GBQJN$9_OBBS
M^;7<?YLN*'I;?>N[&0E_/I_\D);I-*3\0#3CS#!O*;)3R5D)I@URQX'+1#&C
M9XX\GUH[S0OWR(V0PVK$GUO.RB43L_$(1JA$>]H@>%LT<!:S,UE8S=QKSJJ-
M7>V5L]I%0<?.63W>B;CJMU_W,#"/UD0+ED>Z2+2@ "+K.CI6<PI#)..I&^7%
M9D@GG>_:R00&=8KOIXH>LZK(%:]BOKE%-MQ"5[7S Z!V*AC> >;1RX4/5_/=
MH5:===2S>.4&8#VNUW[L%9$'1\5R4 :8"(JV%;?UZ,ZTK7)B3#@963=*BT=P
M';LFN+G]-%?&D<\A(;WBUGLHK";18A& CF6@G^JS=<EK8Y['^;-CH-M,OP<<
M0+LHIT<*9K&<?"%G\<\R &LH+@OO7>6(%*"<+[2IC*J]89B8CP99\]3*#OC&
MMZ1NBKZ;'>FEI0XG4XVSOY,K^"%_)>GDM-Y6#\-E*!%SUF!\KCG(E.I)+2&R
MQ$O(VH7<^G3:$>+SM:N>NNK+\/I8(Y"Q61J%$KP2I<[(#>"9R+7A. @,OO8S
MOLQNT!&"ME:*Z6D^@[I^AH!];?=LJ?&#>O+V4=?1VSU30N<S6J"#FE=N#$[G
MJ=? +!W;4F..MELR\ZFW>XYG6KMHJ6]CR]>+Y6(E 7%Y(7->*H<* ^,8A;E"
MUYX$R^B7X)U";VWIV*%R%\ZI-W+NI,B'R^H/TD)/.M1;T.35( 8C95 B@G<<
M07F!$"IGJXW)"F.2TZFU=_T(G)=F(/MHH<,)\D/]2"44OJH@N2DQ>3--;V?3
MQ05]^2XOSV0J7 5!QLQ3G>%",L LZ81-JK8H9\MB:T*5G4$^P0J)0Q[?^BJQ
MP['T^XQ"BSS_\G,.-R'EF=1!,5\L*%9K\:*KLT=LHFO;T;5M@N"I]2R.C4!>
MF/4<KHRVW.X[6_.>3<D%F9&>8MEB*_N<-&3^5A8P1AG&E=*<;1^-/A+8%V*2
M)ZK]A@D'6N'&_;9O8SW/)&*9"#NWM;'>03#D0B17"#_/496TU88; GHY=GHL
M+8[8-_M?.)^L9TFLA_A=%17O74^X[0>V*@G<"7BCJKZ-G_G]QLQ"8.3+D\<5
MM$ZD8VL =11@%5HMG=>JM&;JW@+I4"?N8_R<T\5Y_K,\).]U]EBIXBGPY:!9
M%J J[Y;/D5?:]D!+1Q%CZSAS(+2Q*O-:VL9=[ZV'%HY=>U?;=.H-/SN?)#JW
MT]5*5LD]+KP420B(LG+&>N7!)4Q@';FDF+Q$.RA*V-+E]-#G'^NAIHN>9XWE
MW;B];1.FJQJ, :@:MIL^C&3\[M,VFMJB^@/$/)X1U-;I%(6#+'FJKEL&"EH%
MN6XQ^9"MSWK0&\F)*?^1SM4Q=;^+=#MD)C=?FN_GDR\X__Y3GI*PR;.??[]J
MY/0ZEHP!S*J6#U4 IP2Y\5Y)2?Y\S*7UR_YN",?ME&VEU]EH2NF09MR,]MUL
M^2!@RZ231FDPQM>V,)*-8XI$Y9'EP /SLG5KS<X@G[$AM5)-A^/H3XHUYVO2
MMS4ETHI7.!9,6!"<K;R&C$7PA7XQC,Q>R%SIN!J;RR8<S]$G;2;W#M5"=S%=
MT8H/0-6I+&@SHN/4_QRNL2TF<("X1S@8KD:K2BZ")'28Z<)3Z!V@D1:*\9E9
MH1AO3M<^IA%L*=09RP9VD7+;5ZH;+'_-?KV8IO<X7T[S?/%Y\O6JV)H'Y;G4
MP*.J4U8P0C"E'GU.).Y$=G<KN#;DYK=^S/@9]Q:JF'628^,A03<7W)J$X(^\
M_#R[Q<9Q_T]S?H=?UMQ"3B<O&'/ 2WUARD:"<P&!>1-0&)>Y'>0<;(E.#\'X
M'!V'4?76<-APQ?T0KJMI P.0-4QZ/8YF_,37>%J==55)XP39%H2"%:=CUD!0
M2JWF\. Q&_K29XOT=](.JM<Z06-Y)%%VBK:RBR;:.BLWY#F_3^BVS;=OV<6;
M:;JILMCP]]>]8W2EF\# )XF5>-K4 DA6.?P=+]Q&SK<\_[8!,F[ZHZ5*9T?3
M1X?<VLU6^HO^Q6K;9&%0!*%IG^3:;H8<O)*)'$)G4!/4>+<8Y>"0YSZ*Y^C2
M-))YP_G#FQ&])8/]-)M/_K,J>[FTTR$(.V5%MJ,[3H;D4#T^:A;-E- A5S(
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M/W9:8UC4=-EX-KC*Q^GUVLK(XW&O[[CA7KI"5@6DI 4HZ>@Z\%F!%JEDGUU
M'#Y,>0@'KR@>1_D-JU#Z"_*ZY.'7Q?S3Q[S\_+#TX4:\#J-05AN07-9^!.,!
M4XF 3'BIM/ IB=:O?G?R7K8M,) :)WG+;N/UJE)'\H@Y9PO1B0**VPB>>80D
M<_9%,LETZ[:!H7F:\DT\%/*:W\\-8;/U6 R6LKKC4%[2>VBJ:NL/;)RBZD;X
MJ*FIK)R3,6>"(<N@"@O@46?@W&C'E;5%M=[Z.<'4E.<D;R<D6",]'49/QG8T
MM=F0)1>CBRR_CCK<"S.'I:;ZZ&7BJ:EL-,I"_AQN%MTEX0"U9Y6?PG10S#2O
M/7S.J:E>FN^6FNJC@3&S$%WH>LFIJ5YZZYJ.V$?HHXXZE$5SD1!"9.0I<<X
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M5)EU>G3HI]Y1/OWI5O'???"E^=3[2[OA37!#Q!7RNI#1QS/NHOSV)WRWUWN
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MN<(=))V2G=Q2^N."X^I$="%P(.MY)W''L:B;JK0[7 [0QP!V]FY"8U*N2,]
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M3A-%C3JT]H' A%H+<T24J!!*4)M=9I[\;E,@N*B%8T:RT'KR]Z20.XW6PF,
MMX_FV[:1_"VG69W]]29]17JP/M55GE?ES/>F@SUH6RM,8@HQ@*$7#%3T]2GS
M"62TK"X-$;+#Y+O]O_]\F@I[:7<QMFH&L&.?L()^H\,:5NLEQO69,S)DJ1$R
M\S4WQBTYC9A!91\%V=W.BQ$+D^Y0-JG0[Z]-BG,&4,FXP*%#MUJ=8>0V65U3
M5XJ S0J"CW6AEG6%Q>2CL:U=EUTT30HL>^NR.USZ*V+<2H8W,5Y\OMA<DV\^
M+Y;KV7]?KCC(F8D82H:L*\6;)N\0.+GZ3'LEM!6L=4-#?RI?&IA:*&N E,+3
M0CGSW@NA6(#";2'(*UG7\"DPRJ%AG//4O!/B:8I>&FSZ*J%AF((,LUV7XY8N
MD+M]8$&+K&K7D(AU-+*J6Y"=KDM7BI<F<2;M[ID<A]-Q4K@97S-M^S7[7Y-;
MV+G\;^XR%07)TM/S7+"V'8J4(43GR"D(&CDZF>^/\^@'MP/I>T$P'%.3#1M(
MGV:*1-:9 50B%R459&Y)I$Q'<(&1':E-KF(MF/DA4.Q!RPN"W5 :&J#?M.].
MQUNIV2)"L!:$-HYN;EW()4D1/"]1EV($%ZW3K?O2.BGDM0DPC**V*2R#+2$F
MKJ4%KKT$Q04=3BT9"'*)HTX%M6D=I9_N,MAQM7_H]M<^JIL"U%2RR4OOP=*-
M7\LZZ9W7C@%&+1B9IDF9]@-_#X%:+X.B[Z<Z/V"AH.)62F Z(*AB,W@K-3">
MZ_X9%"&YG2;&4-2=^-F<BE[;>OR#L>230"_(DO>&R;HBB0-:],!E7;23BE+)
M3P2JO03V^$+<:V!YJ6,1RH/4K-YK.H!G/D&*62-3S!5M=W+]Y"=.R,!J*LT!
M8J6/!EH>OF4N!>%T","CLJ!"MG1X"]);9IEWRGBI6L^;[$;9J*NC&VKR@3'4
M7 V#F$ /_-*'-!J3)?." \^IP&:O@^?.@19T[S/+R4QK;_;LINM$@7*P"AK>
M*9>CE#O@N/,#JU/.S'JLY>@U7E9(4G72CBA.1^V]MGK'7)KF-#US'!U71ZWM
MNMUGX0$;JVU\J""13H<'I>LO.6; ) /YF-K&P)7V;'=HLRE)IP>U\334-KES
MGX]_X/G%G5&AUW-G;\152G08,8$SF<3%L<Z(# R(;J$R7<Y,[1Y+U_.CIV4T
M#RGQ<?/)_U@$/&,RHJ#G%PK+=7>RI.N260,Z1%%LR#+A;I^IRY=&O3,&55+W
MO'!O";<MPNV?+]P0'(S37K$"O*Z)588L-?1!@$G)&)1"H]P]XGV_;[\PD+32
M0EM3^>E\WX:XY+WE7@C(4M9])H7L>*2GEUF&BG&44NTV?W=_YX7!81_ICOQD
MO/_AS5/V]W<E!470W68D6$E/J]+603!)0K;D^UG46I;=8[\;$O3"P#2HOHY=
MH;2+K^^L<V9M$I$X4;Y$\@-5!A_I=QQ1!::)7;N[H618&E\8-L?6ZI@52[V8
M*"QFY9RK%3D(RED)&(T SHQAR>7@[F]+ZO^.OL+P&-H:I()I=\SB1EJ*J+',
M!XA".5"1?D%9++CLDG5)HXFM9Q/WH>^$8@*#JV?8B-&.(.NE+Z)3T@8M<.7J
M.G=+A*)&L+XX2Z2FHG=[A'M\^!A%#4,I<>\P=V\-'#N(\#WEW*18YYN \#7E
M8^L.# P<!"I>ER,DEP:M$3]='(VIF6&3<4]&WS>T2EFXCC9#\9ZLO3I+QUG"
M?XB>,>U%D?>[[ [-@9PN;H:5_K"9M%UWY79SCJRWHE-4D4@WF]9210X#>0TI
M*4%7JY=6Z.:/V'9Z7@:V1M+7L>,1G1C*(N9B<F7(D@.CG03O4@2=?"YT\V9U
M?RAQXY?PI8%Q GIL&WGH=W,_P8)QS-@2 Q#)BCQ9*<!+7O<+6YX\,@RL2WUH
M&VI.$WQ'T57#J .QT&,'V9;@S1G=T3*E:* 62!#Q1@(B$<^-M,6F$ET'N^UP
M.DXHW#"^7@98&-J#@_O2.^."I5JQ3[22/ZQJ,#!8%3>%A(Z\8Q)=ZXK? \@]
M(>2-K;RME]G1-Q0^]G=C+2A\ZMM'VD_861R-UA->?^_W<YS7&7TW'[W%=Q8V
M*%=MM")2G;BKR%K+Y#R(PJR(*(5K7>N]FZIVJPFW?NMR&FQ)FN5@1$WE$O>%
MFUH[8L 7:UGRP<7F$Z*[TC;66L+&&-F^E+"A*J:RDG K2S]\^T@_8C/.4L=L
MD_8:<BRF-GPP"!$SU K_)'FT/K1> ]R!K.-/:FX)A\6P:AF@#V<[]_0#KL96
M=B%QH('*'<@[SO#DYJKM"IT#]7(D"*FLH_+>U4'G')0NFY7QBCQDDXK4THN
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M_.=FG(.U3)I"5S/)I'8L<P&(]+OLLV4F,I9UZQF!NV@ZU@:M%FK?A:1#Q#]
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MM\,*[GSH>2GX&(D-T-3T,WZ98YIL"?"O<"79:;[X7)?^OZOO7Y)K(2O%$ 4
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M"9@ 'YGF=8"$1LN4AE*4"RAMI\-S_\NT\_ECA^.#ZGG66-Z-+^!W8=I.H.F
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MTL@>!I$^XAR$0>2J+I"07=].Q"Y^^G;[)RO3SH$6N9IS[&)8]T1 G47NC.8
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MVD"W;7A_\)B2'$VITT01*HD7N<D,@HP,9)26_&-C4SG(8(Z"=<96-9ZZ&E)
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MZ*-J33__$);SL((FDGZ0J>Q$.*KJ@M9CLU:=]*.R5.U^]I/R5'40Q\!,59C
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MLKT1S$Y*@VVY\@Y8$47JG\GYF,#5[[/Y]4?XB)7O:[L4H9-03@0&]*:2"Q&
MQ>QK)[8QQ5KC"]_/K-8:U8NWPG8Z&V=+?#7'/+G^;;98_'.:9E=7F*XG] Z]
MG>/GR?+S+=9!$NJF#'_Z\=:W-PLK)%(+WC (JVDE0K,H 9@AX7)9LBAF/]?;
ML!A?AFD^@3X'R.W>E]R;\C,6G-/J/L!?:_[3+;4N0FW-$BR)2&&\@\*BK@R8
MN417G%:F.7E9#WAG9'5#*^?!E.X1MYM;A.03O,/)E +P^A79^ZQ2:Y+!;TL&
M"P\J\,1<B;ER-'H&7$>"G5Q*.60,S2\T.V([0PL:1"WWS>?@>=&K6M7EY^45
M2>$KOBZ%=M&W.)_,\IMRD6<KJL]5#,65+J(>X+P$<B=3H9.=2\ZRM<6ZHA%#
MBW1S%RSGF?,:1!,-#ZPN^#8O3!>$+=LZ.J%Z@A:/YMKL82I'J*)UZT<WI,Z!
MDP4S\\@KX2]%#9!J*7LHR1C(0>5.Y0\G;"R/M82<@*WTT<#(-G*1_V>Y#D.W
MX27P[ QRQI.*3"O/Z^6\9 XPY4B A6_28=@3U\A-)@/HM<]I=(Q2!BCP^YU<
MJHKFU^GC;MT["A;)':LE'Y=1)6$,N76RJ#HO5'@634[,2DT^GR\)1>NJF0-@
MCFM6X]POCZ6U 0SM<: _P57]UJ5U/FB'@D7D@H12Q]J2+\]"3,6KJ+GMMD4U
MNZC9 !L_RAI<Q;WN; [1S^B7?:\^P?PCY@^S6C1&WW_]5ZUDJS24&*1RFEE=
M0;NTFH$D:&NWD"$6**(U6>=!0%^ZD;70WRC9QIV@UZ.7-AO^I<+@N,W =.$4
MS=J:(05CZ4M4.7KP=N0;Y]TX_S:YH[4W0%YR3X8-\W(]K_<2)4 R$1F(F@!S
M*C% VIV#$CYRGL";UK/4NF)[Z99UH)8:IBG[G>Q8(%OM*AEKO7LTPM*A7@J3
M%B@4TIP[. '/:ZC5"V<+UZ1XQTLED3"!D5(*$Y!UY 8MC^/6*OZP^@.+UN^A
M6KU-B/GS?[RNU=>+>O7W>KK\7#N"5I^ZN.Y0E-YCY?6!BYNEUT?W*T1OL(16
MM&[KVMF??\A'M6J2_.&S#[_%7_'=K2>])IAO;TF2D<9H9YA3A@+-*!2]V5RS
MX&V@5]Y+;N^X(CLNWW=^]!/TJ>S2PJU[[^,E,$#4\ML$XN1J56>T816]B(OK
M.:361:N//.CX/M"59_06OM7+FNT4U<97GKL?,KJ1[=?7CK[*1\33ME2'GC5?
MXC8XJF?&RG>]!?H2?/;)F<24\YRB]"09R$SQD^ RA.Q=XOO?^/W/.67-M!?4
M )%E'<?]&;^/B1QH5WCH*<>26)/":B'1FVDMIWQ3?EHN)E-<+!JC?_ QHQO?
M'FW=(Y7>(Y\!#IIU;<U 9G3GP]L-!K^98=H8\>YGC&XWN[7RR.3N^P(9P%;>
MSF=?<'[][2W%&:MDV[^7DR\KN]Y6_N%O" M\-_GXZ?I-^><"5^ NRO4J3[*^
MYL+\,WZ98YILKSXN/L_FUY/_77W96)LC #Y1TQA/5:UYS5?R66#Z/Q]G7_\#
M4_Z/-4<;/>7-].I;SU#S]N>L[27E&S/Y\9-[!9E]4(Y%$OX@P=UW;*3":A!_
MP&<<)B@= N+A;N\[I)=DDBIS224)^$<E\J\^W3])M]MR4E]*,#'4:_2DR9TS
MR+S@AF49N$H4 ?H">_W>#@\Z07Z&(^SEELO<6L@#9#/?XGQ%\D^;WIIPY/<?
M1-?JL'G@*6>I^(ZBO:],\^CAL/EV_2,2N/_[__K_ 5!+ P04    " #]=5U8
MA4"/BB=L  !7<   $@   &-I+3(P,C,Q,C,Q7V<Q+FIP9Z2Z=UP3T?LF&@0I
M(B @2E&B4J5WI,8&B A(;T)41(1(ER8A45 Z1$! 04"EB91([T0Z4D1Z+R'T
MFH"$@;0;?[MW]W/W?O^X>_<D9S*?R9SRON<MSS-S:!.T!="9N_J&^B &!@;0
M0_H'1,."-/6"W)Z"0,;&("D0",0*8C0[ V*@GS'\.YAQ@YC^G8- <B)F//_S
MG/X+HDV#;H%.,##\^_[WPGB2\5]A9F)B/,G"S,+RK[*RL;.QLIYB96$YQ7'J
M%/MI>F%AX^3B.,WY[_Q?)_^:_VM%_YYF96$]_;]=:#]!W*R@"H9.1H8KH!/<
M#(S<#+1V$)@^UY,,_U5 _[TPG&!D.LE,G](I=OH-56?HTV=D/$&?[$DFNF@,
MH?3_04S<)WDN*]Y@YC5[Q'+%YZS2Z\0OK"(WRUKXS ?QHLJ/?</83IT[SR\@
M*"8N(7E52D553?V:AN:MVWKZ!G<,[UI86EG;V-K9.S]Q>>KZS,W=[X5_0&!0
M\,OP-V\C(J.B8Y*2WZ>DIGWXF/XU)S<OO^!;X??RBLJJZIK:NOK6MO:.SJ[N
M7SU#PR.C8^,3DU/81=S2\LKJVOH&86__[P'Q$#@Z_B<7 XB1X?\N_U$N;KI<
M)^AKP,3R3RZ&$X'_;N!F.GE9D9GGAAG+(Q_>*TJO6<_>3/Q2UL(FHFR.YWOL
M.WCJG*@*5HSP3[3_DNS_FV!A_[\D^Q^"_4^YID"G&1GHB\?(#8* *.2O,9*@
M_U$Q8"2,:VJSG0;B1KKUA[3;@Z-4X\7'.K'%*CG.P6*8- ]VOIMJ"J15O^Q
MG:(9Y!,N0/II8>[&6#U7Q]7S]X?%'UUXN>7C45NIP_(I1O$*LO+SM:5,2G,
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MN_2>@N#LE SDPH?C@F@R(S[M)X*+<-;I\K#'L-G0BR /3VOUQ/#/_B#LJZ7
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MO$3+M)LI#7^;*E>JZDH*5+<_VXB0KL-M:@ ./+AS3J-1+VF\)?TDL4%)<4I
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MMIKKV\QW[Y!7(39_^Z%]-61!^K!7+48@6[=':*"_7W]C\M/)(AV[1V ,WN!
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MQ<:03Q]])#W"9O_KH],ZF;&8S(+O)X>T2+LLVFT+>?FDA3F%$KJ^H L@3[T
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MA-IVK+4D,,;"[J#2)W4WB\?L\+)LQNQ(!6!^]U>1GV/-5P-U HGX#I^V-;Q
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M6!;402@QLX :[+9Z!<,RLN/PW4ZOV-UT_[IS8UXW6T]'/_#:7RW[%2 H[\H
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MHX[:*4\43\A^R>-G)N7R "LL7"?"P+:+5S:H.-Y=,Y<=^BH5\B;B%[D1[%F
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M.A<JEU5:!VX8CUL5U&#&2NAX&?:3%;"PMT?'=OU;MC-/I]#4^4'WA]2%AN!
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M^,E>S0)P4GHP'+%O8^#)>;I,\8RW(L;(MTFE8&2N"H@/'XJZ$=J??12A,'7
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MNR8A;C^\I[*&DJO6-QT=]>'"1NCU%R*X<3+C35)2AW3$8 $6#D<]#P/A7-Z
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M+FIP9^R\!51<S98H?' +$-PM:' -;B%X\!""!W>WQDFPH!T@0/! (!"":Y
MP0G!-;B[=*,---V/W+DS]Y][9][,W'GS9O[UOFKVZCJG=I^JO6O7UK- SB)7
M@/MJ2JI*  H*"O#V[@,@5]&(%4$.M@"@H0%P @" #:"C2 *H=SU* $!1BW8
MT._Z*'=_EMDYO[\!?@! G=NC!;#N[MV[NY:Y X!V[Q^P_F@ H.YF96_AR<VH
MZV/IS_BG]NRI@+ \ &"\1?L39TGO.%CU%OV?^MW)27_JHXF+ $!R\E_Z?^$R
M2N'O)__!Y;\T07Y!80E^ 0D!448!(0D! 0DA\7_QWMU^ &Z %6 /6 "> #?
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M_OI*JA*D'7=1T*O4EM!0IZ)9C>"2!647)]3?:1_'@L2-F?26/21 M8'C=I'
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M[H=]_F,;;G YN7G0TYJX<)#D0A.W\"EL"GV8D K'6&SMG9H2ZCQQQ-LUQ$1
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M71_V1<F_G8[)>T"(S+5 UL%QR@;E>U-C/G5Q'W.INWC8*;2B;HM@L_P&Z%*
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M*6+JU0T-IU1OS<=B8BV?B=! ;3D:.3Q[>?6I4)3]K1;F+TT$[-; 'K?B4I5
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MJ[V,RP?E-07<9;#,3MI3"5N,9D:8:!A0ER,3![GXXKC@L)RNQP%V_@&Z^+O
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M56[23[P*^QLQC<N^W"A"'L5=;\>7?2BFKAW[!"Z/9/5*OFG(F6E#@;E>-XD
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M9R1@* !PH&!C(;X<QR7\MW+XEUJ26;48=2?(M0#-%&(UZ0=-JJ"/]D=R<E%
M&I<^#=-N[;6;>>2Z,.K,'D19=OV=A@[HB "IWC?U/S<^U4=4\ KK>DM8:MXC
MUF[BEWK<>8;<B=&V?*R>3L7!0%615=220P)-%% #9_A[%+K2:A#X@UBV6/4#
MJ4=K']F,:SF,QL<O"SD%&88+'KD8."*EM\*M.AC@AN=;UB\MH+*>Q$$S0*#'
M,X=_F2)6#;U1@0PP4'ODHH OMX'FENK&ZG\6:[-<V+2-#,_V4G+1^7R/(V\
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M7&ISR<\XYZ=,%% &8_PVLY6NI9-:U5[RX>U9;QC 98C;R>9'SY6'^;O('..
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M%% $.F^"+'3-;74(KV]ECBFGN+:RE9##;2SL6E="$#G<6?AF8#<< <8JZO\
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M6$C:U2ATX\C=*[Y71P.UOX^W9>1-;_NB]*J8&AC #@?0 0$T$GH*H;H1-'B
M#A ]JQ=\+H[-ZOT]O#[&H>+?QVLT6:W7(;V3Z]Y!O"GS ERCL !WN*S74B?>
MY'> MY@LU*2H[NV[[=Z^E7[[U&E0IYUX,SFZUPE/GT*O"[6$?@59_Q7<:;F>
M,G-36/;ZK\'>J/<KDC95G/SUT>]%UF= S+# SR<NR>3;:7V?U/2^KO+GH35
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MBALJ7SD2XQ3JXS$<M\L-/(#+I3I3_<?D_M9L<_GZ^HNRD=21X.Z\+2!(C<F
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M(I)"G$4(>F%"2>#'&47!X%X>DPA^RB9,>R3^F@(T/#MX+;%,:G@NCEJ>BVX
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M:>S#C*84)GZ<L(SX&0L#TQ%@IY,S-W6[[2C<QNIZ3%A..W4AJZ.*>6()C*S
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M?B=(X=F3JHS*?V[?"S[_L<8,IR[S$$RPZT&$20(3%*<P2")9( DC[AG%5%]
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MS,_N"G:0M+P=M$2KUL573>&&!MD!Y>"3161-XM@L(#Q?N-HT2!M&IADB=BH
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ME&N68C<0@J9O;1I,9W*K*="&:-;D@IK>%:@IGM"AIHW.5+ZT\Q/.ZT;3!N#
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M,1BB @:PR)ZZP^<::(#"IHO5'< #%#YU!=@&H16H,9(=DMLXE!8GT+8(5(\
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M]"CW4W6-.)Q@WO8/1QD\Z.-P_$GS?J#?L,R/:H+OF_7H1&G@,(*AHR+C'9;
MF*8A]!AQ$A1A0KQ$MQGH*^,O[6N^O>?@0W:7XSI/6;_]YVO8G?Z6)T#$\H=<
M4]>FODSX(9]A_8*6GZ^-.EN_SQ,L#9M]GGK,^*+[FSBZ/V#Z+$[SC2[X4%3;
MZAM^5AV3_#B.TA3[D,2N,+YQD$*<> 0Z!/$8T=0E,=&\WCX]T](^Y);:02G7
M)@(34$FV#-F4=&M?K)X!^O2W/BE\MK_Z%CEY.]V0"A2MX-NTF&E?04^'W4P7
MS]]YNN%47B@_-,TO=LJ=^E@STEXJ/Y8J/_E1N5U!FFTV\M;M7NP\=_= $"/,
MRBW.-B#GV[^*4J4C]R/\"JXV5=%$'/.#J>@F4S%B<AZQ_#,QFZRC4.1RE)(3
M<?)OLJ8?=M56)DW3INW?#F\VSZ"2/9_8-%?;>O([>J%]YO6YKK'UN!A<7FN^
M8-[=F9?9DUC!3[Q)G,ZJ?_0.7O9_=W485?]8?2/V7MWA?N=T@ZLJ2S.JGK\M
M7M32.*R)@^,D"'T_@ F)9.Z13V'B)A22B',4\"")0MV:%[,2OK0=J>=/?9-U
M58.FS(#,:6IYKDPK8,V[',YN=(L5LN5]LV>H*_@A93NX>>MX7X'!PVV<0 T
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MV@DPCE$0PY0$B3BP,2(L#>9#UT$N\@@/.=6OGSTM;4:6Q0S1NRU_0.:>U[U
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M/;HSG'QYKIW A(.>YC=Z?%R8IO/\/O/JZQVNN(H)T562<L1C/X!10E0]V$A
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M,!21!Y$(,"2<4\BIB&+/]_PTXG8]\=P2:*3#YN^:U]0RIGTNE6VC0F8_J.H
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M_LV/O;_<Y^NU]H_1CZGG_0EH/@#;RJ6XO=W6&Z 8,M:H)]$>W.%<83CQIM5
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MR5W1CY7/6)00WX,\]"E$&0TA%C2".(I(%+$HBJC5H?DRV%J:*=S2SAGX(2\
M*]=K7-7@@5=R^4LP_FQW+K\,C V/_Y=![(+V9<TMU.P>F/M[3 !Y!/WG6ER
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MY'!J[W8\XXP[^318/=W7)YIC7(KC3[R\K?##74ZE-;&I<K)5:T9:$#R_+=J
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MF?N5BI59P'*\;)G-(-8VX,^X^HUOU.C[8;NN'T_#)S?EDY.WYX?F'-$T]'$
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M:9Q9A2^'IUR: =L[N'B0)$-IOM*&:#L%;0"VF=9U"^'$JK2'GJ)611Y;>B]
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M@2-0FBF!\P&:6 7LL&DIW'50<K?^3V/@:/4?F636M7^:T<.5/_#T&6EN9/C
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MIM2'5)4N01X)8$I9"D46$1H$L<!I9!=R/#K7TJS )\2!__BW-/"#O^@"D"!
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M=V1DK)I..#=EV2=::X ^V>#],U"$@S\4Z>9ZP SZLTK4.: CZU(G6-IH#"N
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MF@09#(,(\02G7NR'-OIS,"5S4YXMS4TYGHYJT)%]@18=+BLS%3J)!$;6GR[
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M)::]+_MWN MY.$'64:SC,EHF#7(X@6T_NN%FT$NZ->P.,>SZU=($1Y@@F)+
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M)[V<8/-U:LNIBX>]\-LN?:KHY:929T&[^E^W<L1KT6;,M)W<"/>0U 0,1GZ
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MKJN_YW=RXK9D*V*)GU$>0BR0ZM?'(IAF@L+43\(4I5'  Z,4(U<$S4UM7T'
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MG?X9.^^4SOK)&=M'E<PO0#_905?$ZG+,CM?>AQ((J(\*JZVB'A8+T*(!6CC
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MXY3A4%6T0Q"%80@)CF*8AH*F.$F(H%;LF /EF)MI4))O2?@M,P,'CH29Y9@
MWY'MRW[AT 78@WJA[[/ZFNSE SI/7KX23E>9@ .EF#8+\#JH7F0 7MG<,#/Y
M>U%Q6MX7JJ;!'?[9;:Z62<P%QGX,690E$$4H@5D68T@X"Q*>BCA#9"E%R4OV
M;8VKM9DQ/-&;S60\['.\>=G16^'U-E;.7]B9OE/H"A103#T,0\$CZ5E&/B11
M(L$6U&=>P((L3EIT/Q1L8FR['B=!]CVG^C,&H2MLS98-!VB-O"ST)=0Q4IV,
M[HS]!1 <&?-3O4QJK"^H>FB,+SUN?3EE45;F5 &9MURN"/QXT9GF;X>EA._*
MO47E9<WW#&4^)M*LAVD20H3B$*8IE__,O) F"0ZQ*N2L]M@7;[9FJ:"5%[U5
M<[PYK8\K%BT#JKH.P4V1^ =5)%[QK-;&WO5<(;]\639+L6=D^,VJH'4P 873
MN=)G"T T(N<*IS68@1>ER.]*L+\[ 0UP>H^BBZV8;P?G.O+F=WZS%'^&%X;_
M<SY@FQO&67\=)Z\GYRGU5'>;\]3^Y<7HO.6T#\A\5Q9,L1NQ+?_KIT(H/O:F
MN$93:%M=Z^#B^;98/>_2];><833F(0IQ OU <84(3&"&Y68Z8B&AU..9CU+3
MT,WKQ9G;<>U6HQYQ<T^G'JN%=9$B1^-WWDV<?E1&=NK<#HA5R*D['*\(3G4@
MQ&1AK.X ZP>\.FS5=079^E.W(=VS^/6282\6@L0P3; '44 IS.($08:\( M2
M+XX29'@^,%"$N>W@V^*13TWQR"[JK;^EW]O+#ZI+-'2T+NZ\)QB#D<VH0:7/
M&FS5./#]QQ\!5\5978S$?&JO#AD1AR55+X$YM&+JR79G4A#UDM[F]4XOMC3L
M[O$?>+5IJNMUNQ)5&^@KKWGUG=?O.=M0?=&YC 1.41A12%.*Y#*4)I#@.(:)
M[V4^04F:9&A9\'N\YH:79:9=&TVXK)EP?0'&FV]-4CS;2FAW:68,N=DMFE,8
M)XKF^O .=-1P"^ 'T,L68*O'[HRIR2SN5%F K3+NKM]LT7-T'V?<[:07=+9@
M'-[86;\_S&9]J4K5TCNEE,I;56U^S>L_VY@E3B,1> A!$@4A1-0+((DQAE[D
M!Y@*GU%NQ3-_OKNYG3JTTH(]<8&2U\Y*70#9S#:Y@VYDBW0:M1'BN\Q0<61I
M+G0VJ7TQ4_S0JAB^-=26\,=\\UC_L\K7:U[\QM=+'J41]>, 1A&+(0HS K'T
M;R!152IB0K*,6=&MO^QB;C:CE0P\M9+:6HH7$)I:AVN &=TB-,*!5CJ5,>>0
M[>BT[L[F_8L.)I[KIQ1\.;]//FE]R*8]<\UQ<<>K1W5E\ZZI=[>CN;T5G\OB
MOONS]$\T>>?MKA)O^\821X3X&>;02ZDO_8@$PS1C&8S\$$59&@8LRY;?>45*
M@Z1SAX+93)*^>"/OA_KG;T/J,C@>O8L'<:\T(B.;K69KVO  *<&!DGP!6D%!
MC^WY5@"E7?\I552O87Z^[1>F;E]^E6$T/LU[I>&<Z(3O-8;5YOAO!/1/'@FZ
M[&NJ8\(1\.D='8[1^C!W^C==]/Y6[#(DEAE/%:UI #W,"40D36&&/:*"!%@:
MDQ1S845X^K*+N;G3[WE-J_Q);R%+L>7@L/.JCR!IYE5?A\_(RU,CG$*EGT$U
M"O'<:1P<>=A'.IC4PSZMX*&'?>;)8=/\4T$K93_>\^:_GQH2T&W5Z7?X*5_C
ME=H*TM0COI_YD*O(=A0%5.ZFD8!"^"$/, G3S+>[-S#O?*8W!PM0G-E*7@NX
MF95P#.)4_$>-L."73NPWBN"F<8ZVHG?AI>KNH,<[ZG@#;P^@([-CT?&DYL@>
MD$,S-:"%8>9KQWOWC:_7#:E-0Q!R\P/+=MA=J7O^@JOU\Q)Y2>S[OJJKH0)P
M"",P(SZ').(!S8@G38B5 V/5^]Q\FT9D!K[CU8:#I]5&44PUT:UZPN&UG#8%
M?ZZ!X+9<OW;#8F;G1@-[9%/78\#<";YH:6Q *[NBYVN,GQ;?G7$;A)HC^V;7
M]Z0F;A LAU9N6"/##-T-I:KA6E?#4)N^$A?U5TYY_EW%KG^6^Q+-UK[,?,0\
MCCSHHYA!%$8))")CD(>>W'LC0GA,;&R<:<=S,V^=W(NF[LT":,&U9=L5HMWI
M ?Y0FC0E$2Q9>HR'QLS.C0'XR"9N%*RM39TM<(ZLG'&WDQHX6S .;9OU^T,)
M,YYPSIKPN(:Q7/;5_L#^<U.OE4UMBW<W3RVSB,4D#"*8H$QZ<B@2,/,(A9G/
M*$OCD'AFJ2K#19B;J6LTZ,H!J%G7_MA*;>F\#1@3,\LV+M(CV[@6Y#86]R76
M.PTZV!?=PW^T_QWE<&PXJ,X(*:P%F)BK8BA +VDL!K<T@'Z]*^@@VRT?=5F>
MUO8.S<P6+!*4^C$4<11 A+&TF2CR8>+3*!5<".YS8^)UU]+-S:;N"J[05D50
M[70\G:'24%!84&\['^:+U^6O.WBC'RQN"^5TX_:U/VX3<3.,,*X69.JO.;X3
M7:._TCC;D:2/-0YGZ-&==SD=,?I8:.U1HH_6R4!>54[64JAUI>=,QRZ@*O-]
M6ZM+K+;X'K[GRR1,F>)*AB(D"41^A&'J!UA^ TB$$0HSAGPK*E7CKN>W-K?'
MU$I82_94<[Q)%&89CS.8> F!R*,9Q E'TEW*O!0C'$4A,@L:'!?Q:0(#MYA7
M8V)NMH\<!\>1'1--X[.3>@'VON(%:$0'.]D=LM!:X^6*>-:\XVFY9JT!>4$O
M:]^"/<U +\SK(\XKE9/%A^[]PHBG7N;!!/L^1"2AD$0I@3QBF(A(A&%B=&CF
M5JRY+2PZW'*MPBV9#K?<;?)H&Y[YN W#6P#^\WB0M#-&0I<?P,5=X2L-Z]B7
MKP<!M$HSG9_*)]L*NAQ%<T:$UQG-J5@2IA]5*P8%]^"?9E5PV-=D3 ON\>FS
M+XS0^K#-W=]P7BA"N-M"-78KNO#A)<]P'/-$P$#5PT$)81!C@F"<Q5D81@'!
MH55>XJF.YK:^_J*$? /NI;A 3DE]8%J*7I$[NXW%27SEYBS3W@XEA$(4D5!N
ME;T01F$<AXB** D#NTC5JQ">-"Y520E^41"_&15CLZV:BR]S9!=!B0C:+[.A
MCI,6(3<.^;?>C5V"Q-'>ZV0WD^ZT+BE[N*^Z^/S :F3KDO[Y4*[D&_6'_]KD
MZ^>E?(XD&8F@EP3J. W%,(N25-H(@B@6A$699T+&=KH+*^L[!5WZ[=W-9_#M
M[S=?/_S]]O/[#U^__05\^(_?/]W]'\NJ9"_!-#,&UT$TLAEH!%J F_6ZRLEF
MK0.5UB5HF 0=5B@["8*K$F4O.YBV1ME)!5\4*3O]I/5A21>OM#O0_[V@Y>.C
M2D1G'S&5@R+WX_('3<S51&FJ4KQ+%&,1)@&%7N )B$)?E2./?4BR+/ #+PJD
MQV!X,C)4AKFY:9T>O1MO74-\ 38[?8#H%%(_:8V,M\2#!^OB*<840S"R(=JB
MO]-A 7I:@*T:H--C&TVN5!E_%(Q/(:88C8F.'%J I4?8"P/1LT(M$K@] E0\
MQ'E1K_/U1CN0FT(:+X"+O8ES;'J]G$R ;?2_UP\<-)6DW)3NOG9,3IY$#&YX
MJF.':S7OG3%<W=1 -[9EVKL5'_,B7_//^7=-22\_U%S*T)Q?W"EQEH0R/T91
M "GR54VTF, L\:6/RP-!Y5XX"&*KVV+SKN>VFG62J[G;R ZU\& G?7<4^(=6
MP+9(K_F@&+K)HT ]\JKE$&5[E]H:,%>NMGG'T[K@UH"\<,WM6QAFTN[XXU-9
MX>JYV0#\QM>?E"7ER]A+?8I) &,FO7$4)0',TDA 3C"-HS#&7F;DEU_J:&[F
M2@JF[@^E9'9FZ"209D;'!3PCFYBMB*#;JRNL/IW'RMJ87 +"D>DXV<VDAN*2
MLH=FX>+S@RHYWA2L:6]7E*?E)F493:,P\=74#R'RY>:<$,Z@\'@2>8F?AF%H
MN#D_V]'<C( .%E+))8VXO?)?5M7A3@-[<2/M#*Z1C<)II"[3O5I^BS:%[9Q
M-]'6]MN&Z.-GY;JQ#D[>P%GOX*2XJG*N> 'D'C6O6MX N<E5.U32UB"N'SA?
MN]FH&L%XMA+;Z;>GK(AV48>#RF27GQ^X>7S E72>:E78[%'E*#7\WE4EOP6=
MNO[V>??(%_RLL]E5'OOV$EUZ?9M'3895JRPG*O>ZZJ+=7TI'C2'J"Q@&82S-
MM, 0)Q&"H4=\E'C"C[A5SOEXHL[-T'?"@;(A&5OEPM+O&W%8#;>KLQBLL;>W
M2@/X5JD ^FJ"GIZ R.6G]URK:T/QT0]2 CV%%V#["2B='6Z*1Q\65YOH\02=
M=M,].N O-NGC]VA?C/(KKU4$M.KK??F(\V*)6428P Q&0<HA8CZ!*0H$C&@8
M)@'VX]@SBG8ZVOK<#/I7_CVOV]B1+U5>5BJB/R\9^*.1UZ(LY$LDSQODJ_$9
MV88.A\:J0.-)"*ZHM_BRS<G*)YY4IU\-\?1#@UDAY:Y>!>)\E,*\*XMU7FSR
MXGY'.]D$5#;/W>&?7-J/=85E'WF!JV=-#?*;5$Z^*165/=UW.1)+PF*"L.*.
MI5X&D9"6@" 20\IY(O\_QP$2-H$W(\HZMPB>1H6N@'=S2@C62B-K#LK1AM?,
M:9S)H(UL\=KQ:H,+U;P&.U7[O+GMB+;/:W45EU)?O6V^F%/BR[$'P1U3YFB2
M3DVM.3;D1[@X1^]RP+&OX%4EO4W\L[E+^KVH.%ZILNM*4E[?%I^*[[RA5%$T
M*Q^EA/E]T7";T^<[Z>/6J^8H+I!K!J<J=!.GB?0OD0=Q%A$H_$@DE(C8\/3!
MK5AS<TQWF@#&GRI.\V8#*_]?OE-)G_V)1JDVZ8T^@_5.+8O#5'<C;'!:_2KC
M-OK9=J.56A#:RW,5";8=QT8U<%N GG*Z1D2K'NCT W>O/((6A^>O,I*31Y&Q
M;FRE^]9EB>*#T&/YI^;'[<4GRX5\C>N"FMJ=V.R^AE7S-5C.9U=G]<Y'[<S)
MOKN^IKL'<([/WJV!^]8'9KSQ\K["3P\Y?9_7S<>L3J1^YO524(^AC"#H4:IR
ML@("Y2800Q%1$?D($1(8L8]=[FIN*^].4M 7%?RAA+4,-CL#L-G&RPUL(R]\
M Q&S3\6Z"(:K9*S3'4V;CG51X1<)69??&&8J^F?0TF3]RG&]D3;LMOBJKCU5
M^.Q;7.?2E)5$%1U6"^&GXFFSEG^6NN:KQGUMXBHYC0A!@D/N)1E$R L@]DD&
M0T*\E$9!0(BPL2T.99N;,>JGRK?QF)UZRG78*@BTALK=W.D(M))@7\MA0;,N
M1]_,\+W2F(YL*:<?3FLC.P+PCJRR2\DF->,C0'IH]\?H8B!%^#=-J:3\5D6J
MN\XI7GW;$)8WMTE=>%;"4I0(WX<>21A$F&.8I@)!GJ1>)D(OI)Y1J*!=MW,S
M[UIFO>E3$W,%[LOOO"H>C6M^6H)N9GK=0SFR5?W]6T/'UFR?MS*#OM":>L8J
MW-">VML*-U=TWF:=3DOA;07$"]INN[>'62EU UMMZ%HG[<F>OO*5(ONXH6O9
MC?H^I/M,5Z4RHHH&7K/ +Q%%C&722 6(>A!1SF":91G,(ISZ."4I3ZQR'(8(
M,3<+=EO=XR+_;[U\R"GW08B<YOK4ZHM\SLZ*#1H4,YLV-M2CQV+TQ-=6KE4
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M926%Y?4;<"\%-P]U.0-O@C/AR04*AI2&$#%,($ZEC>5I&J8ACSA#W(P$]WJ
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M]QA3P?_B/F.RCH<'>GTJZG6E/2U]<;=,TS@)<!;"+%646RR(84IC"K,DI&G
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M5F <X7^V>W^HX>H"RQO"Z=V_6_J,9<I9B$/BPR".%-^,2&$:"0$C/PP2%O*
MA9D=%?R%'N?F=V@RJUZN#V_$M#9+EX VM4<.X1O=$&U!:X1=]%-^6GE=VA]#
M:)P9GDO]36QQ#-5_:6I,7[2S,8SGRP_%6M6#9TQ^5_4[^>-M=5?^*)9)@+V,
M91S2-$P@BGP.B1=+(T,3EB$OCFB*3:S*F3[F9D<:,4$KYP(H2562E)+5S):<
M _2\]7 $T\CV8A!"QF;" (,S6QSY=F,3Y \[4W"NS4DFOX%2W70W>=3^I$$G
M =P]WO]:/.7OBII5[.,*WYN>.!Q_>VXS5TL)[O)'M>W^];<OGQ0+9IU+@#@S
M/X$X@=3EDXCK01IYWI[#!_RAA'44^WH>B4$'%">:G.R@XKQ*_0.+"T]>RU/Y
MC=^K)?\K?U+U7XO[3T43FI&7Q=OG]H^[&&^>AG'*T@R**);KM_ 2F(:,PBCC
M(@W#,"/I0!9**SGF9BF^;1X?<9,>W8K:N_SM:3*43M)ND,QV%!- /[+]Z6?X
M=+!OE>C#OM!IE^T3T] _#L+4.;FCG12O1-TX"*K3Q(S#FAM27.O@NJ>-J>4K
M=8:J<R-O17O=V]X&\76]]+.4>R+", M9"A%2_"D!#Z''! \3*KMA1A%1PT68
MF_%LA(95(S7XODVRD=/ZJ;TN5]6PK(Z%KQBA\^9S&MQ?X>8;=,D [3@T:>BW
M G0A"_JAFVG&P*:\U-AC,2'/R^/+J:!7M][GOP ;%92P+L$CQ_6FXMLY0A6A
M[ +\>,CI V ZH:EN$C<4$PRFZXUT1H1B&&C:E681L%(*M,[IL8G6'GYJQB/-
MVB?RG_H?FMRH1SCS5Z!D_\N^\']I>ZDZVMM:B\&VB5: \/4/SHM.,LW'^O.)
M4]7C:IOD7/'UIBJ4, VAC33JHESE)5 GX4#DWSEXYKB2BF.)R/JA9"J@6='E
ML UM.ZT?Y%M-<_FCA%]'YS7B K':J/Z;> \%0!]--_')5WZCYRIE#6IWPO)7
MU^B]7]/JJI:&;9*^<I6W3->:3NG= Z[NN5R_O21CE*FR5%X,$8XH)#P,8$1P
M%G.*_)@*&R+E8YU8K= 3T)\U8FF#(=_!<C;K^2(G+1<BI[F<SL^-Y5"S72*L
M3<8WOEIIEJA[.6Q5.\,Q>\R+7*HL6Y!3M[M468"GBL,U_FFW0SHZ0G' ,AI%
M,62A*B'& Q_BB'LP2P@*DL1+,+-*H;QZA*8H<F \0K_8#,L;!\.!,BJB1,X5
M1GUUD>C'D,1R=!)$>92QA#)&[>ANKQV0:=ANC8?$ <9F._YK<1O9*=T3#[3R
MN=N;G]/>T<;[:!>3[JK/*7FX93[[K/U^>*]F9+^4)&UJ\G!V^]2F._1*2K[=
MU;;_RN]5>&19U4M!?9]E/(;<)W*135D(TS"(H2 ^C?R,$(&->,8=RS4WJ_^I
M1_HH75;&GU26 /B1KQ_D2MQ*_0Q(R71=+]95D;W76)AOXEP.[>7=]2L-V-A;
M[OT2O@?5?;>J@9UNB[TRO^09?.K%<74:OLX@FF_/7VDPITJKG7A0K7:=(T!_
M>BOJLK/)]J<C(-3?M([1_,!LWHZMKY=1UB-!^U*N<OJ\]"(/8<YB&/!$KKI!
M%D*2\0@BDOF)3TB2"JN0/Z->Y[:F]B@X?VT.V+2PEGFV1GB;>>W.41QYH>L!
MN)<#VY-Y 1JIP1_M?T>YC+,"SE6BJU&?T^:QVL#P(DW5ZN6A"4N*F5&VKA.A
M5$JB5=[2P<MSLR<]\<![8Q[GT]B<-QI.8!G90!Q+9#)&:4!"TPDDKLAK.FQQ
MXO2F$PJ]S'(Z]:#UYKX)$+[#/Y7SLBK5JM@0Q=*41R(* TBQSR'"F$-"40AI
MB$.<)KY(D\APHWZJC[E-Z$9.74!V)ZD=]>XY1"_NCUW@-/(,'QDBX]VG"Z@F
MVDD>A<S)/O 2""?W="=?G&I_=DGRWE[KXJ/6)F\P,WK#,=ISDG1.HZ)HNFUR
MP?\FFUAS]D^>WS_(_]ZHC*Y[KG^KK/36Y=KN&%6I<OX.5ZOR(Z9RG)<HXG)W
M)@3D =6Y61[,>"BMKI]YOJ!^$L:FQZ,S5G-NAK_3!.!&E7XLA=S'@UKAI.][
MVNLS\+2IGDI]N[FKOZ/B$;2F0*L*&EV-C>*,Q^ORTC5CX6>T>IZJ17^\C@@Y
M5D>DY:ON\]PWF=6:Z^^V*RO2HK8 VT^[!:[YB_;$^S5)=J>;_T._8&//8L9*
MS-"Y^1_V1=MX7_\"'\I)!W#.LD_E@\X9@Y=N\+^"M/;LT7G!;\6[BK-\+=MJ
MF/+*0DJ@HOWN2G7*\;G$A?KO,O'B($$B@CBC,42")9 (E$"4IDF&!&*^;WH@
M8=/OW'S51FKIH=*6H9)N!5>APSH4=E4JNC/UHSE_LLU07'0'QP)X9/],B:WB
MXEN,/VXQWLD.[DI]I D^:XSO1L/8G+%Z)*PG\B <8V[%+CT N=-<TS:-3<8\
M/4##/@_UD-<'G,>4U5HUT0MZ>JO++7_E=(7K.A=YPYM\5^[=O.]NUC^6U3>\
MXDL11"R,J2JJHLJ$>RF"610D,$E2'R$J_\@SPQ+6[J2R6D$FB/GNQY;M3B]4
M95]]Q*%J_=HF9#D<0H.CAM<8F-%/!J12C9'K#T^C%SA43!G$_0"EO=@CJ1Y0
M^KW&\%GLLU]C&"?;%D\YG':[5M>PG]ED.NMJNCVA:W3VMG#.&Q\6,W;3U79O
MFU,E1+YM2\7?4#E%-CK[2O9>U[\777UZ5:F\$?@._UQ&OB<HE1NP) H]B"B2
M:RUF"&+!*8_2A&;4:#_F5*JY[=9V8H*;IZ>*TWP 6X2;\3J_L+[:*(R\L.JJ
ML#L%%F"K()3"0J6B_-U.+:#U KUQ4YHM &E,]]V9/#;K,#:G6#L*<W,CTZ1A
M<$YA/ R3<]OX0$J?(PM'6]?*BU(<4RI@R''0!/9F+$MAZ'F,I4'*PB"P8NTY
MV=7<+.NW7N;W3E9+&I[3P)I92S=P3;&W@"^<T8LEUNPY<BZBX8H&YW1'TS+=
M7%3X!9G-Y3>LST]^*]>\?K_A@8=2E'TJY)R037<5&+,L08AFD'I!!%'FQ1 S
MC\ XBW@0\DCPR#,\-3_7S]RLP_\=+CS/^W_^+S_V_OTQ7ZTT513Z:^9Y_P:T
M'H!M.'@O/54E/5 J&>^6S^)]\?C"%8HC&XT&)"FGQD9C]V^@D]:^/.-9S(S/
M#%QA-]4I "]RN7<O-)1/^%FSDQ&.=19TWF&)UPVXZH/,"PWW7X%V6_.ZWC2$
M,%V1.$S_:Y,WY:+<$)B8('IR@W_VY:FV["8:]#;A1H_;'V'O.,HZ Z]&\'-9
MW'<_ZZ#%'9-?DK#08W$(8QSY$!',I./&0TBDPQ9E4<1%8$27/*3SN1GKV\U:
MUR'5J0./JEA.K1*,]!Q0%!9[U?DL#J6M!^7RV?.84(_M!G:<BK<"],XG-<I*
M@=X_+8@4KP?=_,1X3/ G6A)NP%I#J^Y9NO%XJLKO.6O6A"VAH8H[7<L]I XL
M+0$IJZK\(?]1@TTA35++!5;QIS:8Z@>NY;_DZE U%#TK5>- 1U"M?_#5=PX>
MRV+]4(-?]((D.UF!LDE1E1W09ZJ.07*AV;EX]09@(2<^R-4-D5R$U.S[*_BT
M!H_XN;TRXO\;_.*_ 8S7M,J?.E*_ THNIF?P+D;EW\$OP1OYM<@?=X??[6LK
MKO62XBG4U6^;W\AWPC<]157#M?PE>@-^'(;M;M=4J1>7ST1O )7=/RL=L38L
MJETA$:Q;1.7+#9Y:\B=.I5SR=V=T +CN1"9-<5?8%'=E*@!-F:N6O6W[V"/^
MF3]N'ALVGE;23IJ>Y6,-.XJF0N-57C*I0'P4X8HW_H!Z7/X*]\7=51V4GP@O
M&L:TWB_S&O"?>@!9PR#7U:'M59[M&-E(OWCMOVOY?TG>]) \U;/N]$$"110+
MW+#^Y+L4;VK>]'.@LGIZU]]?P<VJ+A>J%+7\G%7C_8F$B409<"RGRXY[[L6H
M[H=Q'WXU+\8<[,9<4]!NO]F]'C1]GE1!18\?]EBW0U/E]U*SU>IY-WUW'_NC
M.G,\,HO;Z=E.335I]DI^*T&/3_).#5H^/N'BN3?GW?B3@VWTZ5LDZQ8GNRP:
MJFO_3FAP&\..$GN)[Y^*I\WZ3C9S\S.OEW[DAQ2G%%*DRG=PE,$T%C&,*/;B
M+(Y$F(8V!XFG.IJ;[]F3$VA!@9(4_*%D-?1Z+F)K=I;H K&17<AA8%F?(UY"
MPM$IXLEN)CU#O*3LX0GBQ>>'\%USN2:S._SS\VY1[G[;5@SJ_MGP MSLSB'>
ME?6ZSX#2(T9Y&1W""1$HY#[T1!!"A,,08N1AF&1!@*D?>]PS/8V<3NJYF:R6
M6:-W%F19P6S:,;^XJ9[G2(Y^+]WHH_.">VHOP/8OK>:]W[0CW],>*/4/R*GZ
MO%77Q85-^)78T(+/\&N9BI5LCE^-)6'VQ*-WCF-[*E$FI.6>&-U])N^I.[^V
M0NK?RY7JKM[MPGK7L@?'E%G@ISZC'@S\B$$41ADD3/@04Q8Q$6%*4C2L:JJ%
M%'-S1?KQ!.09R(G/[Q4OJ3HJZ@YZI/G8G8KLQSD.+;AJ,VYFFZ_11V-D=Z)7
MA;538 'Z593V(C]&K)-T%9#.R[C:R/!*I5T'P'2ZW.N0QH964-B?RA^EBC<E
MS=\UL_Z+/L%68:=I1ECB1P2&. @@\H@'22HW?U[L^T% 8NPEEIS]9AW/S52^
M"/K'[#\WS<@LP(#R"(;PFYF_,4 =V>*]P%/?+MS<OONT *W8H)%[X39JUQ8K
M9PSTAMU.S$IO!\9+IGK+]X=9*Y4S7_$'547F.V\8I7[CZULA6[Y9KZN<;/2U
M[%WYFU2[+-82@I4N,-?<)RX3$65^0AF,?"^%B*4I)#A((8T3DH0)$6F<V)2&
MN5(>*]LV04;AG>I#WREME>J*2>&>.NHBN]A3:'MC:QFX>^UXFEG%"4=I9&.Y
MIPEH&>E^^5S6]9L%D#HI#U%JM0 W!\.UK]DV -"=-76$L2,C>ZTTD]I>1] =
MFF17S5K?0WSL;OCEHL#S[ZJ3)O7\/S9899[K3/-2<Y%\58O%DD9>%J+(@Y[/
M!42I-,V98 RR-&:)X!&1>W;#VP3;ON?F779<2$I.N"YAPX&D134^[;7&_^+)
M_IBHCFPQMZ*#G>P=1T4KO09;Y>Y. K;Q ?F8H$]TS.T:?)L3ZJ'PG3QGMFYP
MJM/BH9KVSGP'-V&]./S:!-')#0&5W]]G_IVO@M[9QL>RXOE]\;8L6/VV*O_D
MU7]LRC4?2&(0^4$693R!44I]B)2GGZ4>@RD1<8@2%N.4&"XL4\H]MT6IU5V%
M,RKEU?HD_<Q>MM[V.+B)6=7H@$#%OTDQ5)"HM "B00@0!1%XJG*J8C9K]:=-
MT9RAR%\0C1WX+P6>^2WXI!_5Q=5RKI_*V$%%[5?2ZMU\!<'>@76K.M"Z@T9Y
MH+4'$S&D3/JE&"_U<_UB)G(39OGEV/@:KS%^)_V42869RL=Y#81[_M&K=#_L
MB%3N\9O-OCH5VM[$?RDKS3-ZN/&73A[GC^J?)T[81!(B[N, !C$A[76Y4+6U
M42(]*<X8#:PJCKD5;VZ>DCJ":PY,[<Y!'0^:V;'HZPW%R)Z(&H6#L]%=B%2K
MW[$3TIV*XY^7C@.^H^-3Q\)->IHZ#K"'AZLC]3*P=N3+W?N'GZU(-Y16&\ZZ
MGIHEZ6:U*G^HC".YY#3[?*7&DL5$X-"G$,<L@XBP &*?<1A'G/L^IPBCU*JZ
MI!NYYF;DWW5)9;JPR)92"G?":_9-VIQRK:3\EH4I'0VFV1KP"D/T"@>^"[!5
M"K1:;4WZ=OQN]L:O/:7\?&[\[.M=ND7;545,1U)-6S/3+90OJFHZ;GZ885=I
M@VT$Q=(+-1MC"E..0X@H#6'F^QG,O#00B9^0(!0VQKG7]MP,[+?]K&T[^]G'
MC,I]<<BB /*0R<T+\P7,@C"!'A<1P9P*@6*;<(^AF$T6NE&[0BY"4<9]Z07@
M!/D0!0&#6>@%,$,LH"A%J?P<E]]Y1<J1O[=^'_\"7YS9JCL0BY%73B75-N;.
MW:)W1%E'"U>_Y4D7GR,J'2X@QQX9[-WG:_XY_ZZ7'#E@N5R,FE.CFT>UX?AO
M?:S4)F;\'XZK.XDO7Z8!RH*()! )1"&*P@RFB(0PP%Z 12P7D#"V].:'R#&W
MQ45^1;&U1SYH (P]\+%A'=_CEAI K0+8Z= <MR]T(AO5=;YZZBR T@1H59SZ
MU]=@Z<Z?'B3%U/[S-5 =\9>O:FZ8:?QGOGY@%?Z!5RK>^)TZ6,%4)T](0_)1
MT0,ML2\2DF8<QHQ)1\;'"20H83"D280SX=&,9LN"WROJ7S,[>+E3H[F9-7.S
MW_5X4W0G<ZUSN@@ON)#;VY:?IFXI?5I='K0NTA-Z*FM5HDKI9&<R#0;&S#HZ
M GL:0[@3ML&S$Q>T\H*/9Y&T-G?FX#BR; 8=3FK$S $XM%<6;P[-J])LXE]P
MM7Z^JW!1R^95E;ZWS_V_:%J9A 8\8Z$/(P]'$,64P%0(#V*!&8OE_V%A=>QJ
MWO7<?+-6/J %',3=8P&[F0$:!\R1#=$>CHMQR'WL@7&60&7<\<0I5+: O$RB
MLFYA:"&"@45(VU*C/:)7Z>U5>5'G5 >'+L,8,2_A 4QYB%5Q3P))*@*U!XTB
MCEG@^<RNCL%(DL[-]#7G=WDG8W.W9%L%8:Q1-3.5LQBKD2UK4__ZK6&=[+?'
MZF1O*V'W]%4!"MW(_^/LR \HYC#RJ#BK!3&6G!.7DA@9[I>5*,;N<. :LR[I
MGY\T\_U[S8C;Y !K6>KC0B^S" 4T18I1#B&Y9G@A),2C,/$"GR1IP#*26*T>
M]C+,;5UH9-5YG0\<O,OO"]Q&L]+R\5$:GEKI"%A>-S$G*JC^2?[ZVY=O0,4G
MJBOO7W+YF&[GC>6*,F ,#=>*<4=FBE6@!HW\B\;8UXOC1G\W$1<MW>_'LA(\
M7V\JEU9^.)ZN[/< "::US,,A>F%SKVAJF#6]73_PZBN7UEE^-E57;X43GD5I
M!"-*8HB"A$'BHPQ&OKK:)C@2H177[[%.YF8/M8QV5NPH=F9FZEI$1M_GMY))
M9U)).D(ML',(.+(<1[N8U#2<4_)P[I]]=D Z9/4G7W_-ZS_?-D?R'>7><U-
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M\L@EV/&,XF -YY^;K;93\%#::[A78\\PY<A0$GJ7RB/B.[J)4U.NBN7V:%^
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M6TE]<9M5_ZQM?D(PQT'H0M>7]0T3RF$:4@1Q2 CB4>+SR,CD.CS-W);X#I5
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MG&//35.3&#&3R>>FU!LZ0=H2"DA#J5F@F)$ 3BOGL6$=_425JTS.FG#04KX
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M8;+(^L2,M]:V7,AV$#TV0-;P85@O=I!T](S"L1$?6:WUH-ZEO^ODM&C*$2Y
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MPRAVM%WQHY,[NPVCIA3T2#7P3H\O78V8@%G);$(_R]$:[&].UF#O\0T4X^#
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MFH0FNF00%7-3,Y*)?P.9K&"B3A(FK3<O$X>>&AH=Y+$OKQ3]B_TSV6)[*%N
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MZ#)$OB-$GT#*(K'JF<M@RMP0$I1Z#J/(\V.NYTPTF79^;KY;]B2&>I IV<)
MDQ'/PE2K) MF:D +=)0&0J<*!>LY$8,(NRX4EG0$$4$>\8B;A'I]+*Q#/F5M
M$%5_MNQ@-VS^JX6SG@*VC=[8!_.&W+J"[Z*M4M#2+%O B5-"3;8]16T"DB75
MK37EI,K<!(1]]6[TKGES-G8O+<9;]LSR#:N6$:51S+T$DE3&1_IA!!.'>N(0
MSU@<A<*:XUSG%O_UT'.[MJ_-92:[4=8$ZG<(V\/LM+:X#(F1=4)#&;B]% /]
MAFC#L9C(R5WGQ[1?!5BQ2N:H-=[L;%NW[EZ<JRH@%[O*GUF_@$>U&$&U2:N,
M9KC,9'>6:K?967OY(M/>ZCH9^7WS-\IDHIRZ'4A?>EW0+'4O.PS\\49E>\]/
MUI/L,)W]]F-'GAA80U-\3QN!VDO33O@FI]\WY=-J4]T\/:F><E_4!R?^4E5%
M$\4ER]HU/2K>RB2WJA*_%,;/EYN/;[_)0V!&Q*)P'<Q<S_.%,I5IUR3T89QZ
M#'+/=3SFARDG@5&5S=%(G9V15[-E6'5S/$GJ&83SD,_86T;+9-=$7>JTAD_0
M,@I:3D&/57E"VG;0V>$6_"+Y_15T'%NL SJZ5&Q5"AV/T&EKB8X.^*MJH^//
M.&QSD8$[,K?Y'4O7GP6-=>#/+7NJ*X%77_FW,A-6P).@3'97_4^&RP_9,UL&
M;AH1QT/0IZE,'B0>3%@009XP0C'!D?BUR=8QE)"Y;0Q;VNMVM$"LHMALFQ@L
M$[U-8 JD1U;QD@4H>0"2B05HV'A9-)A+DH&DV9Z2OA0U2RIX,!F3*MA+P=I7
MGQ>/-[1!H##@I=:N:^%O V%BH>3\U(UAZJ(((HH0Q'[D0T?\'Z(^#_S R*-T
M;**Y*;>6SDSW('X623V590.?D5521V+7"W74QAGG$+'6D/'(-!/W93S-[.OV
MC&>>'Z8._B[C6509T3I@Y7V^EOV"U+]-*37IQG[_\ZF0%4CK^O'+,$E#ESK"
M/')D,T8O<H6AY'HP\DF*$Q(R[&LU[+J(BKDIDK9N'VNHE&$C,DYH 9X;]D#6
MA05)UHPUSC!AZ:FCT44PLJYJZ0==Z%5-NRSN+'L?R.-Q_1OQQ'.Q>F9UX$\K
M-94#TW*W #5_]G3;1?!:4GS#:)A4*UX$T[[*O&PP\T*M;^LX(6&CO>><D:;F
M\E=^0PO5CNA=\8BS?$DPB2+9#2T,L5">$8L@IDCUM*5>X$?"_M(Z9>I/.3=-
MN:4:U&1WE=:_<M"2#OZHB=?L F0@@-,*<1Q81]9^QQ$M3! UJBAK!M(%I68U
M)YJL!JT9X_WBM(9O#C/I/F2YO%[[) N\?Q(*4-7^:[K@5>\V3!XD[X0XV-)G
MB'I1Z, D]GR(4$)A$HK#7^+1) FC*'$2;&+&:<\\-X4D/K?0S!33!UG/_!H%
MNI&53D,S4$0O0$?V0EJ^*0/?<$87];V5(MV>-66,EB4+2G_>2:TF8SCV+27S
M 8QC7NJZ+ML\7-G'HMBL;QFFV>KE7>.%5RF[;=<+]4_3L;KZ4)0W>;[!JW?9
M<T993F\(*<5_+N.8$H^[ 8PH9Q!1DL*8D  Z5);?)A'V8D>SS/98-,Y-W2FB
MI650*;+KK!=%.* -Y;()F"1=.S9E-/F>UI\SD=K(FK9FL5_VH6$2-%R"/IN@
MWP^IEK6PJVMF5<&&FEW0\@MNYB)K[8"F.<A\HLBH*\O>)-II;*D<#9L:;>*I
MXJ_&1JX7R#7Z5 /37_-U)@C8R,/1ECC9L+XYM<>1BTF:(H@P<F03>0^F$:60
M)L@/'3_V74>KXZ?NA'/;M/OT]K3! DB2#2]+M$'7.[S8A'+DG?1"%,W3.S6A
ML96Z>6ZZ:=,R-9E_E7*I^Y[Q*:2]"OZ8_^\BR]=_%]OWIF0?\[M-^4_VTF0"
MNI21F*<4NJ',LN)A#)/$<2 F.(D='(9^D&B>*'3FFYNBZ1PH60XDG=D+ XIZ
MT)"O;2=JH7W6OK>-X>A.\P:^C_DN;/(7-<WG4S,'(:EM/=M&=")+6 -9*V:L
M"3Q'35*M0:8R+TTXZIF*1J\-,_O>9159*??;5R[+!+.\:EJ8JHQ[F6U5*;OS
MC<PZ;*^D>E%+W(NB)&:0XEA8A=B)8>HS#AU.@R!A;IRD1E;AA?3,39>_?WQ:
M%2],%<^6,0?"Z%%E"\S,Q$N%I&=%3@C]R%N HA(J,D%#)[@I2_%(W9?ZCU'"
MIRSA9\D2O92:20U52]#MV[&VAC4V<U5HO4J8DV7FZI*7]RPGTHK>2*TM78XT
MJZ/S916Z<KU,L)-&D8L@QTX $1,Z->;8@P%WJ>?Y)/4"3]/J'3#]W!1G3:>\
M(\<=I:J84VE0+7R(&,Z:PR.#.W:@PI9ZU>EZAWYQ"J]A5V$@'>PU$Z.BKFTZ
MCXS^1);T"%(P,; O /&HO3UDS*G,[POX[5GCEXPRL.XPKK)*C%IWF12SU;''
M^_'N/'5)&$8A#,+0A2@),4P)#Z#G8Q:Y./0X,8H&UIMV;CN&HEIN&-_$J.T2
M-JQ%K(>WGCEM'\61MX8.P"W)T^0=F"%EJXBQWJ335C0V N)5>6.SMP<6#M@\
M/:TR5C81*]_*XK[$C]NU@1R$W=3U('&$*8MH1& <N2'T R\*TC"BF%"C[/_3
M\\U-";7D@C8VJR'8,*?_#,AZ"L@B=&.?UX^@-M)!71,86PGN9V:;-DM=C_57
MJ>::KQD?E'_?X!+G:\;H=_8D?ERS1GW5+1R6<13'V/,2&,>Q.!1C/Q*'XC"$
M#L$>0V'@Q*E6[;?S4\U-DVS)!55#KXP)4^W&M8]BY^ ]>]BU"-K(.J2'5TMJ
M:\@T#7.LH:9]6+6(WD0'TPM0-#F :@)S]+!Y[OVI#I::?/0.D;IO#/"L-V4]
M?N0,ESFCXACTF&T>J_W3BS@L^JXL3!\2@H6%ELB&B-2#/*!IE*(DC4,MCXW!
MG'/3K2VYH*'7P VL";*&4]T^=*,[UAN2%V ?P,KH@#@850,'NWUT)W.R'T?9
MDG?=#)L3'G;-@:;SLIMQMN-I-WQU8)#E:E7\*:?Y4)3OBDVZYIM5H_^K6T98
M]BSC/NO:UNNEX[@N"SF&//4Y1%XHFXLE#A1#>R&BU$?8+.+29/:YZ>R.>)4M
M41>AK]M[$%G/E)2,9NNV+XAL*M(P)DM.-IP9QF8:R4KO2#Z:!$96_2V-8$OD
M NQ*Y&TM@$^JX$+#@<4PSB' V8KI-)I[V@#/(;"\BO8<-,B QN"LQ/==,8!;
M8?I^S=5_D>+Q"><OGPJ<+T/?33T7.=!+ Z'SG 1#'*4!#!CWD1/YW/6TJH?J
M3C@[-5<3O:U4HHY@0I]E/<*%FL.:K@UMX,]:K-;A'%MG-4AV48N28O U!WV:
MP2?[2!JT7K:,Z%2UHA\8P VZC[)9Z^IE^[W*K=?D:S7K3VP V(FNP3JC3-?+
MUX"GG0Z[)N\-# YEI5#^,FI1==I;"ILJ#IS @X[/?(@2Q&&"T@CB /ENG#*?
M<JT0I2/CSTT7;\EK6CH:9O?LPZ=G(UX RL@:U0 /\^#)PUS;"H;<&WW:X,;#
MK+T*5CSRV-"ERYDPV*@L$LQN<OI)2&#U,1>Z00S_LVE\VS126]+ 2P*/BW6=
MQ@@B3D.8!E$ 0TJ]A 01QUYHMJ[U)Y_;HE<TB_U+$@O6^"=(FZ[!IFO? ']=
MQ3 .JJ-KC9IL4",KZZ8KRD%-.A"TM[VPP2\-^<>;= Y0+.:H6=,Z!E-/K)+,
M07FMKP:,87QJ_"K;ALC8[9(]B &%=JRGD/<,;Q@O2K;?3K92U7H%">+!U89F
MLLKOXU-1XO*E3KU>,LQ2+\ >),@-(7)Q &./RG]22A@-B8="S78_(Y!GI! G
M:!FD6)0]WOXO=^_:W#BNI G_%43LSDYUO,(9WB^[GUQ5KFY/5)6]5>Z>F+<_
M*'"CS=,RZ4-2KO+\^@5 4J)D2P(H@.:9B9C3+EL",A^0B40B\\FMCKUY?+>2
MO5KS7A/0]*ITS6$6W'H*$$00;A>%CE4;<@NK?/RR\2R<//:^\0I;-L[MXNZH
MU]OEMA'O K1*@A=:+H#44]CO!=BH"C:Z@E;9-UU=Y:/X&Z_R1 ?W-UQMG6.^
MQ<4X&!2P,>=4(02+> T"#C9G.8\[6\0^+G[F]1)%<>#X 8()35U1C!K#)$$8
MAB1T4Y8DL>MJQ2?V)YC;667#N2Q#FW\*$35#%"\@5#N*G .,Y1U-"Y/1--+[
MBAMFB-X,_R;DS_O*'>)U?O$Y;>]^_[;]*Q>TO6?:F(R/>?U8UFCU:U6N'^LE
M=FD8Q]QWCT+"8! A"E&6\?])7)K1)&5>I'H_I#WYW%[_37[(8Z?! A1E 3LE
M%@.__)ZMJ+REY;HPL.H8)I7Y[T>MU$G/VBK^EJW,RP2HK?0#]ZB7'[0*6$1;
MV=.UBOI4Y9.HJF2_/20IXT7-4O\*@!]5WC2L:*],^ZY[W  VHKE9#9I[U(![
MQ!W?HFSXZ91_LEM))&N?N),#,%K);]7WC#6 <BNWV"::M-2ZCRBG75^HLF#@
MF8]AIF'IZ.4YZ-GJCSB5WSI:UX%7.GX,_:+^W[Y___<_/G_^T-']^(Y+ Y9P
M]S)RF>A&CR%.&8*^ET2N3YV0NJJ)M'M#SVVC$>*!?_\#< '5J\#WT#JY'9R!
M@65C/U!?GSEJ'P?U2O?Q>$QEAA4>"ZVR]-<U/EQROO?YR<K)7Y=S6"I^X!/C
MSKDW52F*R9\%<U!S45!Q>'X4Z_M[S;+UZG.>L8^L)E7^V';X%%WM+G\VXI#.
MO?3+@C\+5?NXA5[JN"E.(0H%6U/,C1=RPQ!&.$A9'&<X)HG. =F89'.S>)=U
MDS\(CABPEIIPGSGC7L!*$+3?E]R9SA\>J[+M8:1Y,VAN-=7.ZF^R1I8M<J_3
M0K)I\:..N%7<*+8 K6K@LUPTH= "#'0$?V[U P,%#<8)C(-N*,!@3JY)(Q/&
MX=P/:9B?0,_44Y8O.Z;59]?#MWFS$NUA6! E#H8T=%(8.$X&4XQB&.,P"VCD
M>6&0+I]8A<M3]OJUX75>Y^$D]MYJ*98XA+G>._Q+SPZL>(/T*H+'+>2YJ%@V
M<KIP*!NI8WJ_8F=J1OYV5S[]&_]::V+X#UO+\NI@DQB'8VKT[_?1SXQDP&A*
M\I?P ;@;TEYC[)>IN8X3IS[Q8>8CT=8ICB'V,NYT(4IHRD(W84HQ2N49Y^8]
M75Q_N-)DO#@)JIJS8Q0JR^_W4-9_[>Y/IR'<44;)% 7&R?FF)<%05?\%#8;R
M%[6#2Z(+^99J_>()Y2O9 J*LOJ,5:\G&UN6Z_KVH&%KE_\6HN'>]*6O)-_:9
MU?7M/2I<[XO(QZ\O<"WCG<O$CS"A.(*.2Q(8>!F!*:4$1HF7)@'R6$Q5FS/9
MD7!NINNZB^;R=>.GO5H]9&]I 4^&S=Y^62R;2:'@3J>(C8XP*RLH;K068*LG
MV"K:]A3N55T H2P0VG*/"K3Z@C][C=4C>I966CDP^/8K/E%\T>K*&XE8VEV*
M@X%/2]-.%3^UB]H@#&MY(KU-GA&ZO+B[:RXKF47UM6S^DS5]NR=&MYZNPG:L
M.M;<=E<N<\7N1&(.E[PLF'AKA\3<@&L"N"I@JXN:658&]_A^:@-7R]OC"$@-
MT^KI@G8DQ,"'ZLX3A&Z/$<H33&+ =-7M[9'V]T:<(=J*C%OT\_,VQ>=@://
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M^"-O>?,B;_AH3^Q%ELW%H//K97O>^,I^-K<_V.J)M7G+2Y?XJ4NS#-+(RV"
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M5=(DZZ;'CF<,YB-\>>?/,1V#GC$\=CCUS(UJLD_;QMME6>8R#_-S#1&7:6E
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M5]7:-W^O?\A4<M17UMRP*B]I3KK??BCK9ADP)XK]&$.7D @&@>- 1+E!Q"Q
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M]\DN@=BCW"RZ 74=DKBAK\J&9UJV^9G,LQA';*S><7/YQFMB^X![^0'TNBV
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M/^/1R(&!FWH0,2^!49!YB(1NZ/F1WK9K"NE)]]!7L);I&;131K+4M[D;YM=
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MC7M97#1-E>-U(V<MN322Q;U<\4'O>AZ$I<M<ZKJ."PD)N7=//-&&)@XA=;*
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MGG)N;IF(OS[VJ0;\L)%W4HN@[(K+#;D0#X >2S 8"[Z:]30+J67SN)NT<37
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MD85QU; '[F0@)_%PB"#*? \&F/JB6XX'W93[&\S'C"6ASO7<B?GF=KQOQ5T
M*? "#$0&?PJA@91:D]#K%.9J5WH&D;2=<W<FB/H<&&K0F&*X.#';M/P5:JJ_
M8*=0_)K^92#**Y%IP+[PL=>53+03*<B_%R46.Z2HY+@J'M<B25FH*/MC\*GY
MO]95Q:W=>U3GM8R8]N>TO@A$)#1?%7532<>C_HVM:!>$Y_^]1)6H$ZR7+&(I
M":,84B=-^2D)(XBC+( N_V6*&$)^DBE&,-]:E[D9QY9N2/!!RVL/A0 GVNM5
MG&]5;HL%42-]K?8.1+IW?-]4OT1[ZX?M]/WH/]$C9/N"E4,A\\\8&( ARU3
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MSV3G K+A4R5=YZ"RU[RM0AFV+-#DG3*UMFH6["U6S++)VZC4MS[>:+5I]+0
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MX@EF6=$N,"(P<6,?9C1T<$(BPG=1K5ZVAV::V\[8"PI0*^EXLN_#X*J=$(Q
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M^NZZB6T1%L6QJ+<@R4-0C/E/?@K=-$A2-^7[*%>7TUFOQZF9/24U$&(WQ<-
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M).5VFHI+G#2 R$,93,,$1Y[K!3YU-?>@YTDR-;]-[1W4SK2;[=K(J[WW.G.
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M,Q'F@2OT8XA!"-TP1%[L0,;1A@$36]X@C6&4,L<E3A2D-)L7;#7V +3QM-7
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MO!8]"E]D<QVVDE2MFV @R6(W1DD 8T9C04.'(&8>@4GD>21QL1?0L,?.3EN
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MWEU%AC/#0J>9JIS--JK)9;=L%5=__]^H6".^"W&[N3 [Y-$]:'M&G4;$]Z*
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MTQG.H6-V4E$@-04;59O$A$,##82Z0U5^'WCPM0\BIC,)1CJ7F,)D,#FH&&>
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M7;*^O"7KVSK;.I=%U'343IYTC3,6 UNO+=;%+<Y$J<@QZD2-F]$6AZ,/G^:
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M+K;.X[3/3J:%_NGSN6G).R$SKW?SLL%'$G3-0 ,$_TL#DDJIE#"U?Y;%1V=
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MEFN'[H6)[\-YU\/$&9C0B;-!:F.8=</DGY9@"Q=0>($-ZS/0@:S3$&(&%&I
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M/JX*GM\M 6W)-&]#< 3#TT+!#3)#FU^+!6BG,C0TVN=K'</'O#W"Y3B-U99
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MA]R+"$PX3R#*!(59QD+HDRSR/3^, V;:X=0Q:5,3-HJ#-OR9-SRH-I-EPP7
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MIY'P$YA&J1*U$88X(PB20 3<)S3F=IKBN.1/38(W0UNE&5& O^YS>@]HARW
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M"U#,F-OZ_?;IO)]H</0'EEJ2?O#>'GC[_(>>.V#N%AE\)T;R7_3<$3<^A8M
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M5WI\:K52]]<_\H?'58&+9\!R(9\MD>/-L*7U]G6]TZ^TI?QS,^%C(F_#T=+
MUZ9OK(*_U^9S3\.;$$4])[!P7';RQ-,4IY[R1 4X""'*_ #B@%,H/)'$0F29
M5/>LAJGL/'YJ&E9-7>^4^SWLS(S,_H@,K%.8@V$_2N0@SZZF@NP^?-P!'P<9
M>S&KX_!5/<//*WE2+I4845/G-J*GE@N;=S$3*<$>)Y"RB$+$,OD=(T)@Q$2<
M4<%"DE*K^+/)JE/[O-]WM90^O33-L#:,-+M&<'#?<TNO4OAV#(Y&_Q]"4EBA
MY"K8;+3FN-%F&QA>A)NM;K9/PE7/OZ+5&B\6SS<X9[^7!\H&K'-S[9XZ-5'3
M33D%+1M \0&>RI_!L<H5\PQ>2]!/RZ1A\1Y!,/6 >H#TWWX0]LH*MEQJM&3A
M?A!T<XA[/J&G\H3+>_7_JG/IDS2>I(S\*JVR(J>JF8K\@S3-=G_1N7+'$.N:
M9Q*G*E^N.;M^Y'4WEW*>9J'G$X9@EJ811#S JK%)#!.6QC3Q! HIF2_YG8H!
M&*I@8]%N]*UG];?>Y6# 3UXRTTS7EC_P+5MJ6F73RD:I>:NV5:#46,BZS)>\
M5"9-C\:!X[\PAEKDI%Z"D02^Y&(&]#O084:-Q&SY!/4EZ@W9^^7N';N.[#T7
M]P8$L$7!H6([]L:Y4HY'HWM<!7OL[7BAI(].0,]BG!WOXYFUOLBON,F_"M,D
M3B/&(<X\!E&4,4B\.(8\CF@4^@E)H\"J.J<?'5.S$_9Z'BI">^:M]MT8LW-F
M!+B'#I'V0=J^<.<RG%Q5\O2D8MS2GLN@>E'K<^'C>@_]*Y0W]SVO__MIV<Q%
M44$=W4_M*Z=<RFDU/GTNLA2EC"=02(59"L&8P2R,L/PG(<A/PTCPT,X(L%I_
M>HI\2ZS2VQLJ=?-OZZE]%IM@)O#< SM6*Z2:7O"FI?PGD"_!!FBE$]<M%COT
M.YVJ9P^;NZEY%FN//17/'I8#4^]Z/*1G&'BUO+OEQ4,W2MW&-V*ARX8X3-,@
M@4BHF0J1G^H-B6@6IQZW*K0^L=;4U#5%*I0+/5@&AD^@:1@E=H/1T"%C!8\B
M<[=_ZQ 1Y/-XN HGGUAIW-CR>99?!)H-;G$YL>W;^N$!%RJ+I=,^4JR*A[JL
M<=/GD0;4PYA"&K(4(I_&D%"I$'%"DC#&P@M3H_(F%\1,3<(<&V V UM^0+<W
MZH:CWFDK%^VEF?@::X<&EF_#;HZC271VJ XZKLZ0E G,M+,#S6SPG>4S^PGB
M3NF(5@%5^*S@]WQ9YD^\;GBAFF]^SI=<5['-,^3['O$19(2IVE+5=UO-F0\X
M3KB'6"HBJ\'RM@1,3>!VBZ1JPVB'@[;ARQO%Q$_@#\5'77EI*66M-\I,L@X)
M_\#2= #DK45H7_@<B4WKY4<5E7W!V1>/O9_CRB=WVU83U(+ZZVJQ^+@J_L(%
MF\<Q3PFC&.(@#*4Q*Z0XC&(*8Q&R+/%4:QXK8]9F\:F)PG?W\E]<N8N^<L;Y
M@Z[$^"+?%36"1I*M J.?EI(2><!9CR2UV).^'CHW2+^.@VY#.VB4S#\4^:"A
MWVG_<GO8!G/0G5CZE?USYT$Y[YXS>$;/F2HX+WY7P[_K',Y?Y7+K0@K7Y5>N
M*I[D=_H6EWGYVW)%5,]U]1U_6CZN*_EGB4>^J M'WS[KV]^IA)DF&)B$6+[
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MG<N3[%'^JU MF_ FI7JYE)]X4>+B&?PE/WCY"_6[0Z_FP[JLP(I*&>(F[=H
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M]NJ@KMV_7%=W/>@J%ZK</5@T7B1XR=9.6O)*RJKR?/J'I(Y4IIV9I)*2U3/
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MT,B<.A"CB,(DD=7^@\B-7-WFYO:H6IIYW=(,.M: I%ZU=>T^47_X/_C^X;]
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MQ'T26+:M);P04QJE6%@>3'J;$@(3XC"8X)3YC/#8,0LH>GZ:I=D,DDHH$[:
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M_PH(EA_S^X=-\<C[BJ)R7ZNV]*X=ZV=Y?9,]9.K,^MR4 UJ5-WK3^/HY+G/
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MD/2MHWC+4NCM7%#M<'&]\'ZH&' FLX5 AX2)U=[X<7XRGWT?3Q..<E:!VV!
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MFT=M&4TV@,YJQ@>\ 31578\'OJD.B-F/PYV2WEUM<?\FAX79I -$0_&=RE&
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M 7(&TZ"]FQ*15HH8@)UYK,'PNG?F9<.<5V?5'1CY6%MEDL20U4:&/-;R<63
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MB\G%)_PVFY-WOC%M6D;%N:>=EO9?VGBM!Z=#M9DA89+:JKC7K=-'</$8'8.
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M(DC:[#7M_;[F70OS$+)GRCBE)-\KET*4;!EF^N[:*!]-9+^3BAL"\7G5-:A
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MONYV(*E[ ;*SABO/X8IVI[E!)Z*VQD8=FFZZ^XB6S04>)*_9_;>K5;8JRZ\
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M,*Q +)&C]BHIY(WWZ@'D->W>]?-UE6V=0'N]?=BKP$SD)D-PVH/*J<X5+[6
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MS''+TYH:I&%5U $*UQ-5<2_63/0D1(' 9-%DA^O,=1\39&NSTU$YY*U?IQ]
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MF-9"[IM)(=-/]TNO<W 44&7NM0+!,^WFPB-$9AE@D;03M60Z-V\2>1RIXR:
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MQ>$[Q:]WRA0_5>H^MLQ0[C.G876T/OS%V_$-=TJJ,QPTDX4")V- %<<@8'#
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M?=& 15BFI2J*J=;GT<;Z/=T:'ZG0[:/H6.EVAHS["/2OR9?K+Z]F\_GLSQH
MAJ_T-\OOE\YI'RE2KZ]S:G-1Y\$[X8&)9%&74!QO_AS] /IZ"IW:(ZNI=CI
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MW1"\!L-%<=)IA?&0J5V/K=%3!4E+0)PLSUZ (93<GEZ:E%:R)J\C\W306I?
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MU;-?/;+^#]?2M*'(QE7YLO_I^S]KP$!B7R^!%1M!H^.1[*00529)UF(-0^$
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M87M?^V>_>F3]'ZZE:4.1=6 5GH3T9$CG\TF9I#M%U+50=%3>(0?:I'F=*BG
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M'1Z,3W+U)]-,L>QLT02EC\9;?< T)5M>W;'M@JX3.:1Q4EL@>^! !<[ V<B
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M?UYM"=L;/?<_'IC?%,OJ\=]A\X2"P'\M\"9C_O^.'7:Z7A9QOGS\I7(58*6
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MDB&=F"&T>NXP7MD1$1RC0(,,1S&1!*X*!(,>:!?E+@=Z*[>^.=. [%[M]R!
M:PGS [3>-] 7K_.[WI^$8BEH!=H&"K)U,!"SXB RDM>H%$7JIW/5=Z/YC"%^
M",AV!WE[C?>-\.WR?O#+F.;DEW'-UE+ [+R6%J)F"93@#CR/'FS!R'0*69BN
MK/N+G(R;\^MX-9P*'>,FG(\2P)LPQ_S^YB\SI!>S]^7[3X?YE[^'JUM\/[MK
M/G/_B_49;8PRR)2 !<U .5);H @+>$Q)&8$Z\.WW,L;E8=R!0&,MH-'%OA=T
MQEUC>]:8!W2B3M4#Z;P#E:,%K[P$IFTI*:.*8OM-N?V>V7>OP\,#V&&%WYEW
ML^9N52,^OV3>640LP-!KVH6D@'JT!1E=O5#*D>6=B@4.]%$VZ>F[,O5 "+SB
M3QRECWZ\@C4;*]N^NJJRNMA?6\?1$V_"U=6WRZA-C)IS<$;6&U.)!$?K$I*C
MZ-L9LD[)[K69[_SHOFN6CH/62=31F2E[ZD[\)TX^?UE@OJCM(S[C$S_BLAB=
M2_ &LJ8@5!6A(3KZR:C@A1*L:--Z0NMAE/:=Z6YO_@;28==(?8>+B^OZ^F+Q
M83+_QV5FBJ$F3T6Z8D'%DB#(:$ $8[U-&+@YW>G8!G%])RV&QN,QFNH @C48
M^GA+#[XASI91T4^W^)C;^1UWEX++9)TFZ9E2?0Y6;XWR>J\+,PJ>1/&J,0)W
MI:WOH*,-  ?14S^^X3XY[I6G0L;_TFF;!#H#L5[A43I2*"<B@UQL4LHR[=/V
M&Y;'TW$N#=(;>(TG4%0'5O$QQ\LKTI>81 K:(%B6R0=F(4"PC '/FG$G!4??
M^M;R=T2<2T?R5AOM_I+O##I['V:2]Q Y4QB %2= )57 ,Y,AB^"19R\+'Q)F
M>Q-\+EW!A_']6FNT:_B^P"<Q2:Q>HL2@"_.T-J6I\UUJC;Q5X(Q@P7*D_]N3
M ?=54L^EA?<PD&VGQ5Z=QP>OXS\GBR_WR9[YQ>+W.O[R2[CAG*T^]#A==/_)
MRQ*X]CP(D$*2LY(%KRU".00G63:&!>/C$5[ET02>3>OMYO[F:75[_LV//MY>
M7X?9MVGY/<S^@<L#BE6GJ&&;'VU_[HF;'^TIB-;-CWZ;SN<?L/9S):S>]\?1
M1=1+@V \A>O*%@_>U1Z:3D:7"ZT=R1IOF:\2=(0UOKBYN24Y_\]2AS]?8:I_
MWTW^O<PY1^=3! QU;*L+$2+7FK88HY.1TLC-"3C/6--7'M!)VZ.C5?S( +82
M9P?^Y'?K[<.CB;XQ",T2&6.7>2'QI 0D%@D8,[)LBW:Q=;3S&CWC5K"U1U)S
M'?2(I^4<@LT19;66CN2YF-W6IAT?_Z2-HTS2RM6MI_08-6,H%$5E(H R/I"/
M:RPM*B>L-EB8:WU#J@WEXUJ[=DC:!M'AU7HPF/]<&N*/BS!;# /IYR8]OSR.
M;YM05N/)+8:BA-$DBYK$C[5UD2!3XIE.Q%OTP;4.T$_"V+A&^W0+8G10C+Y>
MR#'Z3BJ;?/]TBY^FZ[%,'VYOWI=RF02I0;L,V=<F$)%VS<H8>-I0B0^F2]B>
M)#KDR>,6]#:'YBGD/^ZATE;V[I85/0OG=^,WELN(5N+/_TT.^[>[?[]:6YD[
MZT(.@$QP8MN0B$,Q$$LQ.>I@?-[>7J\E1>/4:8P*QZ'TU:,C_!SO=P7OC\_3
MWN"7\'4RG?TT*40VZ>WQ]-Y+EGDT,BL0(3%0NEXWD3P#REQ"<"PIOU.+N&.<
MA 9\C%,0<GJ?X-0J/Q?8+WLW7LSGM]=_5J5?)L<5KP.HV;+MF\BTJ@W%TM$*
M95WBPK'6PV</H7.<,I(^8'N,RGJ$Y2#N>K+*)6LHJ"U>U;:C#)PJ";C(@KN8
M:0-KW=>YGQBN>6'+#Q+#[0.*(V.XGV]RD]5R,4V39ZS"RZS>">Y3^-=E2$:3
M65# 6,YD%V*$H+( :]%K--D*U]I#.9S:<:IC!L?UB=2W/UC]'5AO\#/Y^OE3
M;X?.-GGN Q. GKPL522"US:!YT(HCR4XVSKA=\)#Y^8E,^=RZ+R/6CLQP-^+
M=)<9S^@CUZDV4<= .XTOY(X9BAQRS*FD['AR@[O1[89V-Z^/.3U>FVOM8'C2
MH^.TCYJ7^PLYTU)%11]=716[^(S3\O2?#3P#["!23EP9<[RX3E(L@\XIK-VV
M64P<%(N.' ?+JY%-4:*0<;.*I,]BF?67;UP;>_/MC]DTWZ8%103W96MW[0JP
M]A:74@+G&>NYI((@0P'+0K1:"J=LZWNI.Q/7<^W-/HC9M+3#:&?DIO K'M[/
M/I*@)NFNS9WB40O:'\":7$LT-4*TSD.,3!E9D@AZI[3PEM[PSSU[7/ ,I.)I
M0WGW@9<Y263%P7S=YZ>H9*.UD*);=E QX$P,$&)4T6='[[88'O(B >--E3A>
MI]\#Y$@!=W#Z^?<PFRP]SV7=XK=57R7/);>L3EISF,@ +V^B6E%OOL2:=+ A
MM6[ ^RPAHZ/E6 5/6TN[ \CL8GY_N[]((%32,=4S3E$'B#+:QEVL#>9+0*D,
M\B+\"#[0;WNUO1JL"&G8K6QXC9T)'/]"0?<L7*UNI-Q=)W&NJ"@5 I>&PODH
M&*UCBK!1&!Z$S\ILUA:=!)C/D-J_MW4@> Z Z;&:/!/ ;K8FT44SXXPF.1;:
M=&A; &>5 .MEUH'G8GWK&/H ,ONWI:<#ZC$:/!.0;O1SNE@LR#^BEY^17YIL
M+!:>H%BM0'$1P$=O@&%*44=,4K1.F!Q)\K@EGWV!MY5FQZT)W6F9WE87_/WF
M:>G/\\7DNF8B+SE:Y!$59!EK^Q->("3-P,LBC519!K>].W$+2L:M 1T>GV,H
MK.MKPD]21,]EBPY/@>S^U>U2&@>RTRA%\>B1/TWFZ6I:.V4^G#C[%+UCWD'1
MNHY8(L &DQ TX\EIC#PT;]+W.D5'-X=#DME#IOLNADRYQ.BDAB13[1&1'$1I
M'>ALE,]6IE):7]I\CHYQXYF&2/BNT]NQ0N_CV/CI$2DR9Y,3=0*:(<?5E43T
M)P9%^3I<%8O+.W4//+LTP_':W)91V$>T?4#CN?-0SQ)W*5#TG>M>[WUMW)K
M<*9#DL6%S8[//W1&82^=[I91V$/ '42.SY]Q8^:%NV@A1F_K1$4)3E>WD#S$
M*BF4H74!TOED%/91\$X9A7VD/6Z,]O[F\W1R\_G]G^0#5BW,[V=>:N^%1> E
M%8HR9>UD11&$T4E*)TLL:?L C!>^?-QMI8'&IDW%-RX +M)_WT[FDTH\N6/+
M*0GTXX?;FVDI%VDQ^;HL=5JQ%;67W%L#!I%V7QX9!&$0C*WGO\:)M'G)[;F&
M-'L\<=P3S:90&4S0'>PY&Z[:V^G551TI%*Y6C7B6.S//P9+H$OA2S2PZ"X')
MZKK1QBRB"F1]AXU^GJ5K7(@U<W('4\49P&NUC]O$LE1606+&D]BD!9],!E=O
M(:-+C"SRB0'6PT#7]HC8$W('J*<_T'W$5&>[K.PSDT&CT,2!8*JZC!$<,P68
M5\4:7PQ/K=WIU^CI&V"'Z/]UB!VNC'&=K>?96!^EW]:101^0W 3ZY2]A,GL\
M:B\HST4QBER 95PK3)5>G5Z%@K.LA!#;.ZL>_ORN$':$^J>GUD6?@%NO4 J*
MOY)32H'+S[0++#Y]"8O?P[??R16M]P#K/UFS[%3P2D10Y.,2R\K=#;(2Q1;)
ML[5\L^/F'O#;EYJN7+9!P3BHGOK;9/]V,W\BS1+06XZ1O!)?6;(,JBL"]=9@
M,E+8HEK7P;Y.45?(.\%&>XQ"1K9\CYJSOUM*Y\ZBI^GGF\G_8&VJMJ"5-$GA
MZNY#[V>?P\U*D.\^?/SP?ND7%UDP"G*)'2.76%D*Q<@A=B!B":I@2#'K[7:O
M"2WC%L@T"U3'T<VY@W&UM+,,AH?$0025JHTO)'#TH%,=!V0TLLT>#H/ <<RP
M=B3\M$3O <H<N9)K7S;G2S[?O'GS?O;7R><O.%M?M7 AJ\0U.)E(Y'6B0414
M("WW2/;"ZX<QYR]7<S6BYHSQ>PB"IN.JLU<$O\;QQ0:_R#W/W!7:[P1Y]V@U
M1&^0.)>.7BAIXO:&_$U(&0V[XV!G%^P.I<AS!"Z)^].4_KA[?QV;"BMR(J:Y
MT@P4B0 B$PX*_<B*8SZ;8XSOOO2,-C"\7_,[J$K/$<?OILOFL^OPT\@HN%$2
M4,IZT\@E8M<FL%:&R% &OWGEOAF"GU(RVB#Q\\3N$6KL[Y!J&3LDA]HJSX!%
M^D.E7&N&D@"?A:+(P0L?6_>3?(:,<>\D#)V[WEO0_6%E5>R,L_6J$T4*= &X
M9<NI 0:B4@%82,I):;S095C8;%#455YG?X6_#J!CI#_N;OG;Y"9-KV[6UO:W
M2<'[ECUOI]=_AIMO%S=Y]:GZ+KU:52F]+^_PG_\UG:TS C9FD0-#D$;6YNQ%
M08R!;&_@WCJGM/+;F^FWHZ<KP!T%D.G8VAH7HC]?_SG])\Y6?&SRNV*'$R^F
M% LB809E95W,Y*G2_I^24 %%W')5:L<G=968:02KYA(>>>[L[#:3+"?A:I.5
M]^7B&F?D0*ZK9PUFIAG%,H4%\DTY@B.I04$9G;*"%;/#%-E=']=57J41=(:1
M]=A[XO=FE<SG=+;X\I2EG+A/R7(HB9,'(3S)K%X&$=E$SJQ&J7?9\79[6E<N
M>+/]; !)=^"<+R<EW,MH?128*/:-(M6[0A2P.)G *XF 5A;Z"@I(>>L&2<_1
M,>[@E0%PU$SHXUJ=-SC[Q_S+9(9_#8LO_PS?7E@;&&=A_H] CMV*WX=KU>NU
M4B0F<N. &44R+"9 U,X#$YP;,L'&JNV;6BMJQIV7,HS5&D53'5BUU8#WCU\0
M%[_53Z]KNHM3' .MJI #K32O"WAA,S 4+,<4-&]>#_\2+5U9M^,/JIJ(O%/H
MK!:AMZ8PR1(P%^NE2)?!6S0@7+9,9>,UMKZM\S(UXQX:M-'V#A Z0/0=@&AI
M1M_>SJHH+^9S7*SMJ+%!RQ(U8 R>['ATX JG2-7GR S/A3=O//X2+?T!Z!!=
M/^=9'2OX#@!TWULH/]JN[\KP/]%7O"_K&2-US9EB Y+[2$ZC+12OY@012P0F
ME=1291]4ZY[N^]#7E6-U_$8WF&K."':KE<J94P:= ZML[6M%LG3.4>A; LLB
MI\"%&0EX/6R2PR'E0$@>H+:N0/G[Y&9R?7O]$U(TLV)I73EE@D-A26:^A'K]
MB-R.@!)"R#:DP*R4K?WZ'<@Z#_@=@HH7 =A&11V@[JXA0;CZ2VT9]_8JS.=U
M4->#HTN>;#++&R7*DZ-K::D22QFD328[;U3AK7LU;R%IW+F7S??9E@KH&T^K
M!:@=,A6,AB!"O6\N.9#H?&U3J7T2"G-L?;-K*U'C6K"F$-@=7@?HHS> _16O
M<IG.Z"6^FRYJ4T&R_).;6\S?]>7)-EMT(4*.%&DI3SM +/7^&CKCK!:2R=;U
M-P>2VBT8#P',:W <2'L=@/37FS2]QEH=B77^Y>-3@%H DO/DKE[D41O,-]^>
MR&9.7W%UFR<WGY^7RUW!E$[:"4%28:A )6/J#!T'*B0NLF4><^NNHJ?A;-P9
MP,WW^ [AT,$BV8O!=^$:5_:G) S.10[<)[(_Y+B#2[I "9RI@MJB:8WZ TD=
M>])??ZA[;3L8" +C)I%_)RN22%T7^2M%CK6C_TW^@/7R?GY;6W7_%</5XDO]
MQ)O;^>0&Y_/[9*2PCD?'ZS[K9,TQ)/I)"Y!:VR!986Z'6JC#G]^1&S(4,J:G
M5E,'5G=C<_OM?G) 8;[V& R01:W.4-:"URK6Z1+>\^2*&;J'VF][308;;'3Z
MT)<;#A/YN&;LA;D!M#KG\S=(3GS]]9-@X=/TR1*^RU)5C_^7Z>PC>?R72B#+
MG!6P!FOY(:T;YS,'F8*AE93X+GUFV]/5597Z@5"9]J*W'D%[/^2=&+J3]&^'
M"R-+H;-S=40\:41Q268A(P=3H]6"2G!;#@1Q2SJ[JI$?"-2CZ75_D/L[D-]@
M;>&5/S7;VW\/LW_@W0"?NYS$"Y(JM+SNQ76I158\)P46(VUM17.(P=/6AJX$
M^LFJTKK>YR!"NZK6/P[$IU-8CQ;XP9U_]/X?,[R>W%[_$2;YP#6;:FMN'31P
M78_)L\NT9D.!D*,6D4GFV?8F!Z>DN*L+!$.Y&N/K^O E,%V$JR:&^0797";+
M<\G<@41E[S([P3KB*A@C5%)&J=8W$%X@I:LRW3;&M870QS6?3Q;!ZV<@AZV^
M2XP2G34,F/:>_!PE(!3A(7D34O%>[=+<=7 RNRJM.]I0]J75<QG$^',IF!;S
M:7D\1:[!%,;7OG>0$8P[,W*:^8O)F,"Q=K06M2I/,]I) W,0A,7L1#))MFYG
M,NS\Q95\WS^6[^H,KQ@4T=:JK'J&5\AY#LHQX-X(KQE+*;2N/'F1F*XG,>Z#
MB<U=MXWX^YBY]W2^G N*6Q4,R*#(JII@(03!H5;6T_^4<>K'',?82*7;9C+N
M(]\^\/',1+E,6[_3]>Y%$0BJ.@9>: DLNY)4H564=S*G/\A,QKUTNM-,QGT$
M/*[W_O'+=+;XZ?;.DUN7)*^SAJS(DH*Q4'@=$Z?JF*^L-<4DD:GL;2Q^>S_1
MUYXP.A".U=VTO2!'[F(Q)2__!2YBB4QP1!"Z)I&EC1!5$N \E\IR[@K;WMW[
ME0>,DP 8! VMQ-A!+OZYC?4AO(P\Y"AM!J<"K\>\2.&E-& 1F6+&ZMS\<.A5
M@L9-(K5U0MIKH ,X?7\:,/]E.MMHA#"I55ZK1?D1/]?*L'>XN+B>WMXL[@,
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M:0INHG(I"98!D7"LI!$0G340M!!,NNQX.:^"FV?ORT6M?3'U;E"ICC(WO'9
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M_N_:6^$[+@IWAFE18\B4ZVDNA90R6HHP8_36ZR*;3VE[GI)QLS0# ZB!\#N
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M[K;1U#W<#H'"D[1G0[UT@+/J0'R>K0=D5&/T/!.=09()FDBR\;5@@I.?G*-
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MAQ2-$-[KT+I'\$6"QNT7[ :)[9361;?.*K1\B_'O.6TPIR"=('/B1AF@$-(
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MP@[!P3%ZZ11JBUN+O3[/DY*:&2&!$?%T3\BZS<8;X(YG%PRS3@]6Z?4"79V
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MB39I5D &0\SQ5%N3.5FPT3H5[8U6_S=@I2E"CAJPLH^Z>L+BAHD+(KEB#7-
MENJ)%?*%O>810K(&8[$AFL&:* ^<@=')@)6]0+#'#(Q]--(3N-[^7*6;WM7P
M9]V3A2KYJ"F:<L&!*H8N!8,!.$JI2D*>TX">VT-B.DG(G> ./4()/:%IG;K<
MD*Q<92?_-IV%19[_J();F5!=$3J-%%FO='I?"M?6:BJ[6M7T>]TE%;" +XE#
M+M(%+[C)=K!]*8UYZ>20/ YJ+[>@C*/W<=."GS(I )?Y38RSJ^GR1A#KB=1)
MQ"+IFG$E,U"I<F$+0C3(>60N:&X?HG=#AN^%+^@$4J,J?]9<$SV=IR_,'HG,
M,RW(?0DIDL-1Y_IB% D,6IN53CH,F6'I?(C0"6[L)HKI"6LOC!ZQ.61O'-D+
M&1^H[#.@3@8XLT)CS$$V?[%]%?.!]H+" ?.!]M%+IU![,H7&2<2"*8+$.D>N
MZ  N9F+,"^8<]T7XUN7_KV,^T%Y@.&0^T#Z:Z0!M=X5A=;+$RAY-D*RHHH#S
M7"<<*0K^/8G(9V$Y<S9DT3IA]Y2*3F8!#75%'BGV[H#SCES*+[/YY']7*KHV
MA:R=XB@BQ,@3*"9M+1ET4&SQ1BIEDV@],&\[5>,>4<?J_448':V$$6&UF"\O
M/N)\.:5/^CKY_ON4/I)8NXE,*,3.*@K(MN8-'9*,HI84J(@0*0JJ@= N2*)O
MN8<B^M,=@EXDH"?0'*_E66N1CXR;/W'ZY=J6?- E( (K5M5"J0A!9 09C0M)
M9\?B3EUK6W!R^X6=3%AI?4L=+M0>D' -8!ELEHH9<*RNX3.6 HP8 J@4,V>8
MD]EMP-PN6!CSE#A"68_5?8#D1E;X7_%?DV]7WVZG53DCM=9U9QA=I2;6ER4C
M060C:@TESWRG&J(M*G_PI2,K_1"5S5K(KP,7],6IB:[R+TL$;[FL604Z]W@=
MEJ=24H),PMKA&N0/G&TZ6$_GX/%,,U5T!:L-0Q>S+\EP5H#+3(Z6)+^=SM>Z
MX34RDI93D@U7"7]68TOWTOH^8TOW44$'<+HW33$959 ;!7I5O2A$@<!8@BCK
M"XNLRY-:CWT9>TIE>XT^/ZQR'_%V (R[0WG#D7P[UN%VU,,[7 _X?'_;O12T
M4:D.("\YDH5Y1I<^CPX<3[I($SSZP>J;#J1YW/;P$[Y\G4"E8W?ZA#J=ZW%C
M_+OK#I&<?I^N2[\^YGFL2OZ2#^SO1!>++L:#=:'*1 8Z&!(#([/-5J;@W:,T
MXL86H!.1V\D3R$D ..L<#>-:R'5L=<WQFOU[??C76['?SJ9I\78^^WN>_^?5
M;'FH6%0.(:%(D"VGT"TP#<ZC@<)E4%*'Z/7V*II34MQ+U>)I[:1;3(Q]F=QZ
MA_2]DU404=6SQD/ZGZNU?!H-#+"22QM#!ENO>>5CJ>ZF .^8,&BU3VF[K9R4
MY%X*ADY]J?2*BK&M9;?+5AY]V4JN'<^1 4-)BG->0' 1@;MBG=36H,1FKM?1
MY/92,]"GZW5:-'007Q]X?%Q$I243@@,+1M.UJ1%"H7,A.EYLCB4+,USF>"]2
M>WE^/"'@3ZG<L4_Y/3G<=U[#!H>Q:)=%,."1.1).-!!85! UULR<%+&D]H[1
MT73W\K;2N7=T6GR<XP5P?^:.X\$DGS1$+ZZ;(>B:0V J6B,+SZYY%>0Q]/:2
M6#V'J^!0-7< Z4TER/\]67Y]TC^T>-A ]+#;:&79Y Y.9N0<QCE]5/XEK_]Y
M40H/12$"UI8B11X?>)\LV*2XDHPQ7G8JM3NRLKPI4^..^!S5./H"S,A;)(>6
M!?WY\BK1#SZX1Q<77/ 01 Z07:%#AH1"AXP1P,D4HK0QA;A][.U8U(\[?'0L
M[^HLL-*).=U+8/\Z7:[NU<]?D71Q&:\N23$?\KK/=/7#'^M48E+]^\D_KB:)
M9#;]<O??KT7U&Z& Q)-7JKS+:-RK55Y<>)]-SIA!.I.@=HG5Y:<,F!,R9=1H
M]!XF-0('N[T3LE=K5[V#YOQ&$?[G%59!7M=C48#W;0VG,+M:/CVVVLXK/.R[
M!QYJV$ @IYA\J+41!1F"KZ\/2G,!7O@ #*T7VJ5<W&"]G$-./CQB0O-M^/8Y
MQZ]3,OI\O0K6.IV+T EB3'76-YT_H?:YT&&CK9?>&#U8C_4 _'12+'(L*H=8
MNML$ CU$[#=WZ5V)['JBC.8>(UV8*G)B ^E6\EYS4-8$781-H30?B[>9E$Y
M.#I6'H.X@>(ZP-_G.4X7],U5LI_HPIM$DMJ]M6%WW"UJ1>YB\[^Z+M25Q2LF
MZR XMVIN#PJP;DUDD9RI8#&FW1IL]@!M2_I'1GH+0,TZT6X'R'ZX->RZ!CPD
M;C(C'BPS2#P4NL!TT*"2"XR\_R0?IUH:I.V?TC$NTL9#Q9/4_)$J&C?#\6XV
M_SY;3<N:IK_,?N3Y=/V0L($I]$()+RG^9:[4=X0,*)($)A2)S3OM'S\7;<A'
M[/Y]8S=S'*O6V= R[N!\6CDT;S'^/:<GK!@II$!B):ZR?")*0$4N=I;%%E<L
M4\XU/J9>(&?<6MQF:&HM^%&W[]TPL]KCME%$*D?N;"A@HHG$BI+@G+/ ;;#2
M^22R;.V,/4O,N 6JS1'41N@=G$%/(Z.5RZEB#-YS T42[4H9#UY17$04.,UJ
MV!]:'S^;*>FD"Z"WV+.!VKH$W\WL4NX2.@IVI""K5**05) "H"QY9"8C<M=Z
M8/%SM(SK2+70\U;H'"#T<=WN3;GY'_ER]CVGMS_?S;Y]Q^G/F[D73&9N(P-1
MC+D>YV?)W'+V)63/17[<CK_![=[]^WI#RR&JG0TMY][ \V&V?):O4DQR22MP
M2@904A9PF21G2N;:FQRXV][@L-=7CGOC#0^A5M+NX/[:97AMX*B,40*23B0W
M+CS%$S9")A\1C>)*L\'*Y;H?,-V;6]5:H3UA](69MTYJD6U.4 RGF-<)1;:M
MZ? V26J.@85<3E#2>7:#J?>"P@&#J??12Z=0>S+^N)!;@)%KT)+$I7(][(D-
M\F2#0$L"U7:PF21G/9AZ+S <,IAZ'\WTA+:7%Z/)&$P(UD*4L9#8'(5*G'&H
MR1CBUGHA!CO;CM]L.'PS:L=7<"NU]@36G;:KE<0<67K-09,Y4K"?*+RG7U1Q
MO+CDR-Q/<1^?]T;$O1!RU$;$?=35$Q;O[=^3-\L)O$PNHP.F%;&2)87Q(9/E
MEN"2UYSGX?; /B6G$YRU!\$.&Q$/T4@/PY57ML=%H8,^*N"I/J)I1(KHC01G
M'%,L1V1^ISF&9S9FNY>[]'!E]("@FXRB-I&'DH!'3V2'+ "S1RB1H<V<)^-V
MN@3/:SSW7LIZ;CSW'I(;>SSW9'I_O'0VGH?(@(?5_!#ZQ1OI0;H4H@S<6]SI
MV6?;>.[[7]K)>.Y]5#9K(;^Q%?]@KKB0.<>0"D@9#5V9Q'[P=(V6:(+RTM&_
MVBDIT'PN>_,\>S/%'RR_D17_WWGRY>LRIS<_R'^Z%8-*.EL6 EB-=2A]#N"+
MXJ!9S)%\'I+#3IN M@!@XY>/DPMO!83CY=E!2'+/PUZYP+>[CWB2GAP=#X9\
M8/)^F0"OO83$@O")?&#C6@_$?HZ63H;(].)C-E5=IQ"\#NU8<$4%H2F@(T],
M:<W!^9R(L1*=RB%9WCHH?IZ:<6/B-MK> 4('B'[D8;Z/F%AW(D^6-T_;Q@?N
MI+!@?%G-GN> 3D00:#W2[Q*F1^',IOF[+W])?]@X1(VS063:P1$ST!G^_K;E
M/A8N/.>.K(Y^44(YNO7)(<PN2^,SDTP,5FLP$$^=C*WJ[=;M"DH=F-9?<?[W
MO*QBO2O(OG#2"&26 V.:[B0F$CC)Y"HTHF."NZR;W]L;Z.@DB]T%4A[?_,>J
M;>P!_D_)/W!R8N0&G<%(X1_28>"T!61% O),AT)*,<6XW3UH1L^K++L_#K/C
MZ;N#\_5AJ\N;'SBYK&*XYN:QGT;^'L82N *I=:U/K[,A,"(D))O.BA>=VL_&
MW(?"5UG_V.9,'E#58\]+?HFQS>/6GK#+<S'.UL4R&1DH[C/XJ KH$)F2V3OD
M?.LYW8*25UD^=/0)?7(=G]\4L'=?:]9Y,;D>^G_;V+_6)$[3[=_<4^D[)+WE
MA,N[D4!-QX,U)FK@N6%#BO 4 \684=Q%$T!D(4!%Y@$='=P\A2!\QF3-8'F"
MX0>*;3A^5N?-DU:4AX,YUT&Y<C5IQ,CBE?5UPDH!IX6J!3W>"Q1(U]VP*91C
MR.\DU#P6<UNR'2=3< >.][UBQQ7SJZTMJXP[)BXP<P[<Z@BJQA)8L("P4J(+
MA3,QV%3 Q\1T@KM3P^/YTN4C=-43Z(X2Z'TI7+\#H%$:5>TN$*9Z=21B)[2
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M_V..I<S.9_4,_3)?U^$GB@ZMM=I"#(E"N"P*(#>1;G\5/ IA<8=1(<W)FG;
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MZ!)-5T,9N$S2)V^@R#I#FM>2F*(TF&Q]S-)9.IVCXZGC&2B#]+SK#)0A0N\
M/%N';S KG8L>@?$Z8\&;0/R@ >(E)KRL@!TGBGB2IM[ M(_FA\Y &:*&#F"U
M6V*726.9T\2*J8V5R!%\Y@8068@J6:U"OTM7.IF!<HC]:Z^E+J'WRVH]^X(W
M(\/OQ6 W[JK'6@PE,EB=2GU0U<2Q<J"5MO4@>]=\'?6^M/96"7PP;+9/?6^O
MPSZQ^L-T^WMLUKGV'_^=S[_EOR_FZ\^KLZBYY)$.O]72@7(2 4,4(+C7U5Z@
M.,+6JD$D]X;<,7 U<(5!2R6?'J;KAH:/_UZ<8>$VD><$OFP&II(?1:QIT'1/
M"&6#X&G\4N)=*.VMUKT_!.^CTA,%+B$QGQ7OO;5%@ Y&DFA-AL"8 )3612YU
M**+U(^.^M/96[M$I> >K]33A^^OB8GF64<:<-(,L T66*!+)UM8].=GSPH-4
M1YB(L!.IO97.]PG>P4H]4>S.ON4SS[(*T08P@5'PRV4!YY2'I- SED3P?OQ:
MT9U([:VXOE/L#E7JZ6&WLGB[FVSU\7->9BQ$SIFUWLC  E@3%"B&%CPW"@Q*
M;;AC4>7Q&X_WH[VW0OW^T-U&[:>PW.;5E\T&JC?S>'Z1<IK-7\5X\>5BLV=W
M4\A2GY"7^7/]V]\R_;7%EWQH^<8AWVQ>X]%, %,4@FB3"R-W5RA"I-*E@*^#
M20B0TAJ+KHC6Y>S=%H(H)2S&0 =32@LJ9P6!&P2-SF2+% ]@ZQ42+[409 "J
M#BL$&:*S#GR')QZF)4_>%V' ^5JSAZ;4Q6MU%%\V(0D*/VWK\<.G7P@R2/6[
M%8(,T4.7:+IZF999^^B+A5CJ&V'2")XE11ZUC\B],XFU?L,_J4*007K>M1!D
MB- [ ,_6"@09/)-%1; <24B!2_"))U N9V9"Y)&U3M"?:"'((,T/+009HH8.
M8+7;6[$TR6-E16Y>"IBR= "EA\"L#<5Q;%_Y^.(*00ZQ?^VUU"7T=@C$?L_K
M.GE[54=OU^&S9;','_&/,RV$0"P<LHUT[(QC@);.-#)I$UHKLA@_2[X__;T]
MNQ\,KQUF<1U%UR>,\W?+V6)Y9ZW&:R)]MKX5 ]FM[+T7D%,B?7C+(1AKP%H?
MK;;!NR,\##5AI;<G^U[0WQ(!A_:.37<4;ODM1J#V(57#6?NCG0:7+()EH43)
M)5='V,0RA.+>GO.[ /9^^CRX]_'>@)(1,^SUY%[^KA[:0W/GC_^TYEGQ'8B>
M(-]M#9)YIP#-H2N@5#" WEC0)A):332,_VGRW9D.BZ+C E*B)+<G9 BVGA82
MAD@L1AU;US^_T'SW$%0=EN\>HK,.7-4G\F]HE7=:!"C&$A?6:@@N"BA6ZH3.
MH=&MRYA//]\]2/6[Y;N'Z*%+-%TEX$I0+*!BP*2I/3&)^,@DI!233-&H$)N/
M?SVI?/<@/>^:[QXB] [ LS71FH0@.3B$I&/-XDH-GC$'+ CTRF.FN_VO?/=@
MS0_-=P]10P>PVBTF"B&%$G( B[P>P$*!B=)UX0MG,C$K6!J_;O'$\]V'V+_V
M6NH2>IN8JPYPG<6K?UICKQLWU3 E,5H'G),M4,K6$9ZJ+FZ6ID@AE?#C+^)Y
MGL93R%L/@LE6(#;469>8O+O'6<J06=W>'+6V9#@\!V^9J6NP<M'2XC$:9X:N
MV3XBVEIB8=""[2&*Z1)E/^QO]DPS$HP%;S2K^YLE.$>>BD\8N5,BQCS^Z_+@
M!=M'?(\X*L[V5DV70+LN^GYDZ8^60A=+;@FGW]6JQWS)I39)>"M"+$=LSMYS
M9],1WPZ."L)&:IOTT>O1#:>OOBR6Z]E_+O5X+;NH=+2"SA8R"J14]JD^:-/%
M[@R/0481W+TL]T[+91_[5F\]>B.@:ARY=WF[W>7J;;E3+$$7-[)88@"766V=
ML71Q:R>@E$"1N1/>W=_;/L93Z5/D3>/(C02,[6^B3;0T_?CC1^57V:G<_'R1
M/RY^FZVO=^:RZ-&H.LM<UYI=(>I +)8@9)D\8TK)^^FYG>ZT)S[76_OFL:ZU
M%M*?'EA/R_%]CHM/\]E_<KHJ!KMA]D->K\\WV<X5/R-7E"FO,UB?4LTU;2K"
M,B W7&.DDRS&O^UVH[6W5LRCNG4CJ+/3NJ;'Q7JF%--8"@<3,SFOD2D(=<V#
M1>:CT8*"K=;U#+O2UML"I:,"LX&ZFJU.&K/W=[6Z^/)ULSGO'ZN<RF)Y]2\.
M;O#=]H/;=_$.8F6*5EUCI#%, I>./$<M#-!M1F%K+LXKK6URK=M3NRU=BK7"
M,'($4;PF63 #J%6MO]$4MOND4?TUL[TYJ@Z<V3Y 9QT$QT^44F@*UX+!!%YE
MXB+64B^K:CV%#\IYBU*T[HH[_=*E0:K?K71IB!ZZ1--5+84WHK!</0Y=2^Z-
M(J\T"PLZIYR9,[Z8UD68)U6Z-$C/NY8N#1%Z!^#96C-C;8P\.5_K3R,Q%31=
MXLJ "3%SGG-4OK5K<**E2X,T/[1T:8@:.H#5;M4.1G*NB]%UV3 'Y5""CQ0<
M(6?,EH)%YO'?[$^\=.D0^]=>2Q-"[_&,^8^1UYOY:SR/M>6G_I/*;!VO]![7
MMTYK438FP0HD5!)4#L2MJ_5@P>N0HF,,[Z7G=GO?&DI(;_4C!R/CV1>O4=74
MY7UXC^4;AN>?KO[2VW!^E2&_*X"S8KDL249(JJYJ3]40.)\@%40>)"/.6]OC
M9L3W])0V+N)V6:\[NOI/#/>/YS5_X)Y[Z0HY[9"2%J"DHZO'9P5:I))]=@%Q
M_)3T(1Q,XUF<V EH#(23\DFNBXE^6\P_?<S++P^+BF[4X3 *9;4!R64M6C<>
M,)4(R(272@N?DFCMJ>Q.7F]UB=/Y+R.I]$7<[D_)YJI^3O*(.6<+T8D"BML(
MGGF$)'/V13+)=.OFN[%Y.A4?:"S4-K<+#2%T"B.1[V2*+CD\]#GTR1_8_!ET
M-](G>/[T#I-%(T!B((RD7&?3\/IT3HY%"N1RL]:S6KI]_O2<9.^$!&NDI\/L
M*<"(IG;&L>1B=)'EOR85-T?58<^?0W36@=OPQ'-,-AIEH= 6-]LGDW" VK/*
M2F$Z*&::EP&?_O/G(-7O]OPY1 ]=HNEZ=*HLFHN$$"(C[YYS!JB\K\][QCNK
MK=&MF^Y/ZOESD)YWGE0\0.@=@&?KNYN6-9U0W4=9.WCJ(7,R"M"V]HRS5%)H
M/;CP1)\_!VE^Z//G$#5T *N'-_=/WV_<WM>XSI\6RUE>;8YA0FVY%@),<@Z4
MRA+0H05N;5:L8-#*CQ[C/DG>*3V%'F(+Q])8!V!\A(VK(^M*"+SXS4CQ  J+
M@L",!LF\+ARC]K[Y6)JGB.GMO;.1^N]?=$UTT0&H'DFPYK#^D./%<K;^?CU?
MWD4DYR)!Y$&#8L&"1_HE1\ZTR<'DYA,1=Z%K6J@U@L#V4H[#]-$!QO[QX>,R
M(UWPWRG4_MOB6U[.J]]QQ8PPJ;C -1BT=52*5. L>;,\^:*,C44VWR'Q+$&]
M76"'ZG\QEC+V1A9],RP:8>OU8OEUL:03>$=,=!*O!X6ACM9;01=['</CZ\P2
MS3(PK7-DLF3R)9HG!)\AJ+O'M+;8:J>,#FZMS=W^$\9_Y?2 E2 RUQD99&>J
MZQ!J>"0B)!$=CUYJ55J_9SU#3F]3.QJCJI4BIJT?^/5BGM[,O^75^G+?Z#R]
M6] /)Y9(S+4Z(VZJ(JX9R\4&%!H!?;V(4RW/0&; *Y99\-:1U+86!0S[9F]C
M.AK!:%S93PNJS;C[1QS1*T:*EB24I"%[)FJ$0XPXE2!KD92+(?MDMH+H^6],
M:]':^N!M!=J!"7MDQM'_7-!I>N0:12Z%"H F%U"%!P@6!0@7,R97E'9'&$OU
M*&V3U5FTA,+VV5.'Z^4D\/:/:\XLMZH(1_(*6$NVZ#JO!GNST%VA8QSS^-,S
MGJ*NMQ"P!3H&0W O59T$"']?S&^8<]E;GBD*45P8"GA9[<=*!3@:IUU46:36
MO96#".PM8IP$BOLJ;$(TKI;KLW>X7,_I)WV>?;T><'G%!+>BA*PC>:^>Q"5B
M3;,D#TZ(0N$+AB!W0AU]Y0[BZ$^W:'N6@,G*UT<PJNTDW<'E]3[C^2\K4D6^
MCD6,2E8X#L6GVA88 KB2'' GC!/6<0J FQ<__$C#-.F%<3VP@^3< 4[^OEBN
M/^&GV_M7ZV0BCR"=1+I_,8,7VH%$YH41P:CFVTWND3!-]F!<E!PBY2ZRX_^5
MTZ=<LQ_7'* N)9$[!SE*1C#G".AR@E!$XK68T:760W'NTS#-V,1Q@7*0G*=-
M(?WM I=(-C.GG_/7Q6JVODJ&O5[,-^6OU](1F@FG,Q2>8NT9$^"CS) 54T6E
M3 [>]E32;M^:9EKA.  91\#3(N8UKCZ_FJ?Z?]51_X;G-:EZFU_]N,24W^>8
MZ5^%<_+>\S6/S.C";:$+T^5Z*@HY8THA%*4\,KI!V?WQ9(^ :._/3S-L<#1<
M'4<-'?@ZN_4 9N6<C"0[R6MP6%@@EY^.$^=&.ZZL+4<HO]MW!LEHCW-3%MX=
MJJ4NH?<KSI;_Q/,+DNAM_],99A]5")XN;U[9PKKM+&B0=*R-]E[(-/Y:]$=)
MZRV5>3 HML+N< UUX;H_9.R6FX^X_)37K\XW/V73D+>,5:V?\IE4@4DF%-A0
MU\P&5<<86P&98EMOE!$QC;^_:Q=*>TMLC@_,YOH[A3;75_/Y!9[7WM[YJNY@
M5XS_ZZH]X,#IO]M^</OIOX-8F:#]E27KR&93X% 7'RKK': I"80HT6:/*943
M7EQ^=: V8=,L7*RO^DQJZ_CMB/<SI7CDB2?POJ9HO(C@BBUT9"TS5H@<\DCO
M.<\3=CKMKD-0],2EUU!'#6WQ&+?<+W1?+;[G_&9>+_#9M[RY$#Y\)JVL%H7$
M_F4Q_[!>Q'^]^D971'6RZ>)X]6]<IKWOO\,_V>YF;,Q^HSOS%M1ORUWDO\_G
M=?M"1>,EC0%7.;W#[Y=583<'P-<>;YL@8*(HB,L$B(I,OS:1&89T#%KG2 ^C
M^.#! O4G_U1_\@_WQ'*)\T^;6^*G[[=_Y>KC&R7^?E'S"6_+I<)O=/SK8OFW
MFO(Z$\&2[Z(0<HD1%,,ZF)?1'\EW<BYR64SKTOZQ>)DXCCH>HA],,.@!'%U[
MNH]?@K\CB:C^J?%%_^#GCGV;/\]('U>V5$P4Q2WDK C@6%L+"E+\9)(H/)ED
M;?/\R[17]DU>;^OY7#UU0"]S?J(('F4MGF=58!HC8 D"3/3.^B*SP=:SFYL1
M?]*7\A#,/CU6YICJG[B<ZGUE:=.Y6QR+194(OLZN5-;6$(4K<(Y[ZV72*>ZT
MO'E+^=3-!WL9)'-492\.E7P/<+DN874N"5\HIBU2@1+%@8M:0S B:%?G[ON=
M'H=V <R4)<0'*.N^NO>0W,0*__ML/OMR\>6*<")2*YTYT5R[#4U(X 7/()SW
M1AC)<;?WP"TJ_^&C$RM]'Y4M6LAO:L7C'W<(+T*$P&0MXBMU>RY!/W ;ZE@'
M(W+AOMB=A@!N4_S=CT[SF-%,\7O+KX,GVDOS=CT+BRGB76*MG>'$ 5UPU:FJ
M%DX*$[4+WK1.@?] 0"]C=J;P% [72 =PVE]PMVS/4PV<?\<OUR.U1,P8L192
M)"177]+I1)ED[5+.C'G%0O/Y/&/P,:T;? "LAJ:TQM9Q!SB_SO5LLO-O-V.:
MKZV(9ZA81C+W&,AK= 9<;;36.>N,B4=6=@JN!H#U26(F#KPFQ\EB#*5-6SWZ
M/J_6RUD=]+WA8I,+KAWY_YC/;AKPG5.(CLP-PUQ=$,8 G6(@;$K<J^!]NM?-
M\$B=Z X?FMA:]P*O$;32P0WW+B_+8OD%YS%?/D%<CZ%AF>5 ;K'3D5P;E A!
M>@XE*NU-,9:7UIW'3Y R<6EH+_!KJ; .<+?W@]EO-W5G+MC@>5!@ZFQ45:RG
M$(S1+T&4Z)637+8NXCN<ZEX*G:<,?8ZL^U-&^^:7?Y+9F<T_76X#X6?:1EZ*
M+&17- ?EB7>,.9"/G[D-@7/G6^]O:$E_Y]YJ8^RU@OZA0.CE$(3MO(?[O/_R
MQ]?9\KH$F#@GQGDNP=)M8VJ[NLNU;U"G.A];<VEU9*'YUHY6Q'?N31\!_D>'
MP+2AW-XBOVG1N-T1];Y2G\GUJZN?WI9-\UJZ#'%79XDGSK.CZR"X&MW6-ZR8
MD/0D4RA,:<;XUGCP6-1V[M6/<PQZ14,'QN$F:9.7WV97H<T#,?V^V/1MYDMK
MN/JX6./YW7]?BTE^7ZS_7[Y;1YU$-D4Y7E<SI/I<PP%]*>!=EM$D^C-K/;5M
M-&:F'3XYL?'H R(O^:Q<VM9?%\NK?U3_'C]+F<F@$"$'0=(I7H+75H%&Z8W5
M,F@>3N4 /<KA-+,V7OJI.AQ,)^JW7<YE>S-?K9<7FTS*9K+!Q\\XO[+-F[QQ
M3O\WSSY]KC+]EI?X*6_^Z<^XSC>6_LT\GE\D"OC^OJ"__QJ7YXM?,1+!9UIX
MFZ(W8*R*H)0-X"2YP$XZ%A+RR,3V.2,=,SC-<),3]@X[P]Q+/;G7W1K7E^;J
MOQ;G55AGA6-@RAHH#C5YVUJ2JI4"U$$&S#&['69('Y_N:8:]O.1SU@0A'?B8
M(TKHVI>X%-69\@F3S1&*KN-4?*U6D<8 72DY.N%]":U?&H_&W$[GR[VP\]4W
MA$[4--UY]KW.@/K@7'+D/XLL084Z$$OZ##8Y%X673* <S^0\H&<GJ/L7!O7I
M-'JB,-YZM*^&O+PM;Y>S3[,YGF]<U,U_2U[K^I=Y>EL>2@XS<E<,AVSJ\G&?
MZ0*P)@ // 1=2C J3>A^[<74;N^D[*\3U1.X3K %^Z=SC/_Z$#_3WUA=RNG=
M<A8W$6#*Y[>O#?O/(FKTW;%;N \31!\MWDY+Q34RT*[4M=1%0RBQ+O2)P43-
M1<FM:T->2HNW9L[[5 )89LCZQD0!6F$1E":3; ,JUGR[SU\MWD,Q.UZ+]Q#U
M=Q"?_]CG4;Q.FT'K*.HTJCK$!&42D)(*4F>G3?-YAL,;NDZ@]7L0")YMZ!JB
MD0[@-$J9LY2%)RTSR,3)_Y-6@0LDDB)\]#DJA:QUF^%+;^@:!*MC-'0-T7$'
M.'^Z-\@EQKP5)$\>#!#9!4(=,BXLH]!;._2Q]12N/U-#UR"<[-S0-41I':"O
M04S-C)8BE_I@;CS9)6WH*I 2B-E@&$I,S7<J'ZGIX03ZO0]Q#XZL^U-&^R.E
MCJLZ4+@VWOT\^S9+%&B_I\CB3.3D<DAT\NM^(84^@)>>@0U&ZQ Y+Z7Y5*ZQ
MF>K\[F^,TE:'9!3(O-0S],\%Q>6S\]GZ^T8D-GHCG;" *;%:2J_!8UVTDD76
MMJ0B>3=]=+NS=?)]%MV=HP-@\]).TOO9ZE^_+FL"^7*-YD8@2:: .B-(+'2U
MJ$(""28"%U$;[KA6H6MK]!A3)]^FT<TI.A@RO9RA?=JWGKM6:O,*/^/)&E2<
M L(221(I*4"T%HSG(@O.#5>MYZF,Q\W)MVD<?&JF!TDOQV4?1=RMV5V]N6IY
MW%JZ>^:X,+D4#]P( 8HQ0>&IKNN_);>!O-RHF[]@'9?%D^_4F,0<'0%.)UCW
M\(%^^L5J47">7G^N(ES-YG=V<;P=I>AAV$='7T&ROPCZ*'<P/MMD"9@81=W"
MHQEXQQ04 FK!HH/ UMG0EU+NX).51J8"104ZW=$E<$X7P&RM$V1HA6Z>2/ZK
MW&$@9L<K=QBB_@Y<J1]?09'%%'F($(*M>7A?UU1Z!C$84TPH1C<OU7F1Y0Z#
M0/!LN<,0C70 IU&>.(OP0==!T$[6/9B&U?U!68%-Y$"A=2'QHS_-G7BYPR!8
M':/<88B..\#Y,Z-0+04BTEGPJKZ#)!O!F8#@&2O2A\)0M-X ^6<J=QB$D]WG
MUPY06@?H:Q O9YFBDDZ 5G6_0I ,7*(_HC96JF+0J6YVX[VX<H=#W(,CZ_Z4
MT7X59K^]6*_6%(G/YI_>+\[/?UTLZ[\\LRFI'#*2_(L&Y7T"THL%F^O$#(>8
M4C<GX%E..K_E&^.Q<>ZN 3A>UA&YZOQELB0*F0V(*.HL6B\!K8X@7#;"J!31
MMYY-U)R)$ST8#9$YWF'9 R9[GY.OF[SZAS4NUUV<EA_S_7];+E:KLV0H?'*Q
MEC_Q!(HK26K)%K31)7.=5<!1)J>V9>-$:WOZ/3&'0J4'VU*CI3>KU45./U\L
M;Z8D;]A>W7W.^.6/O(PSDL.9<C[K306@%9;$'@*YM@XAA9RBUFA-:MZ?,IC*
M$ZW &1'KXRIZ.)3])93G^5--_W=Q]9.<2YZM+^I*\?F=X<DW1_S,>W3H(@()
MHXHDDC,K9  M;(C,8BIBI\6/1S0$6YDZT;*;?LU"6QB]B)/UT+?$H*P1-1CT
MKB;E3%50+"!,T9$YA[+YIIQI0I#^ZFKZ/3F'P>3 $.27>1]GY<H UUSBE1"L
MJ&5.=;RRX;5FW'FZ+ER&PB,/2#)1J3>K\X")$PT^^LAC'0:)'L*,=A?#O0J\
M:W>U#IW)]1XKU_>89,Y0P%4W%)<ZR9\!TAT&14:/4F=1BNKLT SG\D3#G#Y.
MU<B@^O,<N[,@+$?A&'"?ZGR%384YB47+PKF6%EWJ+3^V(VLO)LL\"L*G.9"#
MX'8Z>>DGGY5W*43_44!,^2RC*^!L-N3#BTP7:IV0F8Q(,6B?TRAM0<=A[T1=
MR4[/Y$2P.P7KN$TTU]SO*)W &;GHD:)8%4!I8:J<'#"5N' N)\F.GO%HRN&)
M.J,G>B[' ]\I',U#4[#/"DMK:4(6"$*AH. :)6"A&RV+Z*T,3#Q8"3BY.WL0
MPR_F!:"+@]L--%_ .=XU(E!%2><%!R8=!R7IC@M!(T2!@F>.H737P]LR #V%
M-X93.)MCP.WEO4H\*YKD49FZB"$F3>ICI$.7L(# H!GRZ(7MK;1P1]9.U$KV
MD6L= SZGV#U_\>4++K\ORIOY9EU"_13]YM'ZF]8]]'M\>O1.^D/%T4<_/4_*
M"ETB9)LT'2P=P97,0&7A+7IGK6O]/OM2^NF16ZUCW61:C 7%&=E](1AD<F6S
MBC(ZW;R8\*]^^H&8':^??HCZ.PAG[DT59UH&'S6@J<0G&<";(L%:8Y.26;/F
M$R!?9#_](! \OSY@@$8Z@-/^@GNFAU;()(G[ CH7\J <5W7^4 )N7?0Q>&GQ
MZ,FK$^^G'P2K8_33#]%Q!SA_IC4;?4P6'7B?'#$B+/AB$T',&*>93MZW+M+Y
M,_73#\+)[OWT Y36 ?H:1,XE)!,D6HBY/J&4DL&QQ$%PZQF%S:;8;@HP?WMI
M_?2'N ='UOTIH_VI9\6/BS6>OYFOE[/Y:A8O9QQF*6TTFFX 6T<<,,/ <<^
MDS1<<4XPV5NZ?1>^.K< C;$Z3H:O'7 Z.$SOE@N29%K]2LIZO$?.NX#.8P(G
M/2>)*PT^<V(HRYR*+!AT:V][*U$G6A_5!L9M5=8!!F_\L+S\-HOY<?%^Q#]^
MRO-<9NO*]S6O9'OO2. ,(P4LV5$8H^L(1:41T-,?E:M/;9:L:6Z=:VM&_(G6
M%K7!]#00>)G/*W>>>(__P/+(QSMX8MDFDCX>65RD^SK1 9*:25 Y9<"@.'C.
M=61!*<;*7X\LCT903F:MG4D0&1D[I60M5RBU<KXPGI.*:)NW0OWUR#(0L^,]
ML@Q1?P<.SX^YU\R<3R%GD%$Y(CE8(MZQ.O_?>!-%D*+U>J 7^<@R" 3//K(,
MT4@'<!HEL9K(8]NL5,DND#>'5H!S5D.B\+8HX82PLO6-^L(?60;!ZAB/+$-T
MW '.G\[7HR@J<Q] H UU(XF!D),$+8*1SEMNFH_:^#,]L@S"R<Z/+$.4U@'Z
MFI0G9AL-(^DAKWTJY"P%;2R@,T69K!4QW4M2^<4]LASB'AQ9]Q.B/<[V9_9.
M_/TJ+"[6#X/OV]HL*Y-Q(4/46="-0B)!'THM/Z#;)#*#XM[PXOL9BN,0VOEE
MWAAVBVXQ<,KW_Y.3GPC,3BIR *VP"(J,*.F&W$-447/!K;.Y=;ZG.1/3') >
M$3KZH+ A<'E9Y^7^$RO/,I$QAVQ< A4<J85+#S:+)")&H44W;M0V9J;QKOY<
MY^< ^+RL<_1L7Y*0*%(H#NB>476T12+_. 4HTNG$?<(2>FMK:]E@VOQE]<]U
MQII!JY<3%[:+)0P6R_M<\RGTSU\OYAOU7>!YW6 MSF)AT;I"EY+W9-RSST#&
M/@'&VL!H(HEJ%%_PN&Q.TV!Z*B>Q8\B]K(S$G5;=&^U%CID[Y8 NHSK9J68C
M@Z,_"FU\,5Y:(8^>D7B$T),O?>LD(W$H!GJQ4VTZUJ]"S(#>,A0,,#E3$_T1
M7) 99(C):JZ1?NW,!]QO#/,I9"0.1NCH(YJ'P&7O\T)F+"PZ\>SNB.#'H)*?
MH=*N.!9!:^Y(,T$ *DOQI9-:)5.,3;TY<$]S\V*R$J.<H>D!]+*,S[.Q(X]<
M.9,-<,LYB45CK6I'\,E'7@JRP(Y>AW+$:3NGD);HV% U@]9+,U\[1HG\S/FH
M8PFU =:QNB&1 MJD)2 :59@WQNA1!I\?E\T7DYCHV."- KE3;.&@GWZQ6A2<
MI]>?JQA7L_G[3+J:19+.IDYJ(\$5_84/[SZL6C=Q[/GYT=LX6HBECT8.PQUW
MV=,QBT6"T@PA.!G!2JM3UA8C:QU&OY1&CF*+4IG,L<M!44B9/5"4&2%+@\QS
M9$DU-S=_-7(,Q.QXC1Q#U-]!$'1OB$Z)@6M9@!E)Q)M(;$1!(G3%JX+TGS>?
MH?$B&SD&@>#Y:5D#--(!G$8IWE;>9\-3!F^EK/.T"P09(CBK?4#!@]'];$HY
MC4:.0; Z1B/'$!U/^Y1WSZ.[7+U"#/UC/ENOKAH#LO!%B$+^?_;$C?*9C!(7
M$%BTW-L<R_WY;H\\Q>WPH<Z+>T<'PF(TK71PE[[+RTV /+^:)G##1E$UN1-
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M'#0=0+0YN2Q;-VB\E/Y^IXN5A@26<R+S[C0=<E%GIF:)R<;@76E>O_%7?_]
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M&O,W=<2YO\Q[ ,H5OI7&:',28$7P9+%Y -0YU]=XAP934FZG$J==H#*EDWZ
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M -!,@!V8_Y]GJZ^+%9[_K8:0K\]QM9J56;S41S5Z/@;K<A3 =4F@4BUJY%E
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MV=?K8I^@,&E+$N/<:'+6B0MON(,H@Y>,"UUV&V<Z (+/D-,MW Z'P6(<G70
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MMN^=:P3U2VN/IK*]!3+> &J6C=$J9S .Z6),D8.KEF(JD4?.7#&>[31>1A]
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M? A@&DT:/D1['8#T3.,\A33(F OKGB@*N: K)U>S"(46@N?B6H^%^9\U:7C
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M64':0GF'P].OX3G#+W7AH0$Z2=E'%3PY9X+$IKB1$+V+D%V0DBG,6K:.?+Q
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M&-82WE!YC%X1>\( F2L92TG6IL'2 /<C<=SQ"WU?[4W4.N[M_JX43%?3[_C
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M7FS[62:G$CW:*3E<>N!9]=A1,.T1%R)Q[F.-"KDZX3W)VDG95BZL5ZG0?V[
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M+700@:>-JGUNG<_5QI@PDQS7G-CVFO8(9YHNACI_UPN;7%9"Z/0RHO989=P
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M:)':\X"HK=S'!=6'Q9<PF_YWV#Q[EC)-TU5T\"+,;NRQ&)3)D?Q+STL]264
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M4IE$J(D]'Y@03'/N6L_^?IFBT?HUC8+& ;0T=C.GE]MX>@PR^NB!^:1!!<;
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M<C/> %<QIKE&F,&^Y4YI9 +(F1#B,??<"C;2$.DA9-8-BYP(0-N'4(^FS08
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MW_)M*ZO.N)0"9P@'!;=OZSQ<ZWU REH6@S)!F_T3R8ZEHK%$\M&@.JE6&CC
MGB4-/L=Y_H&]C.1"B2B(818YS'*'<*&0Y4Z@:+CV2I,8BA]AN^AI+")_'-:*
M*Z 8F$[S).+A*X =D<:"#R(&?G',YQ#',#_V8PAI*)?22*12<KFLU")MI$>"
M<6U)$L:%7C&N!AY#/,^YKOQ.V#K4$ W6F261>S5[V%71HN0%9YYJQVWIEC_;
M*6GT,<00!.POGADL\O9RT$ N'.H8R,4.[#O+3V@# =$PKYFS 1M?(D5P8 [Z
MA-4PPW6Y.P<]1+#-YJ"CQ[F;C4+.43BDO6' A.<(Q]R'3XADBC3[>1TYZ$$:
M[96#'B+>RI'A&3@ 5YMN[=H:QX)!CBH@6W.,- L8"2KR0U;P4^+^=//#%5O,
M+ _237>\H"K?V"/(:G79^Y1^@:_/%IM12HX1XC66*.BH$0]:Y7?W%M'H"(Z.
M.X[WQWU?7+Y>]+^XYLN(L,5[\[-W6B%9%D)"*429:_HL,B9II!CAU.0>'BJ-
M[60>\ESRA 60!WL3HRBA25 ]>6J#4TI@,A3R45N06%0(;"><KL)JFIOK^>)M
MN5_[<\DA"!CZ7'*(.AJ UU<[C8MUZ.%C7*X-;TA&.NTHPBGF#E4ZH#Q8$A&5
MF-%8.*=+/RG92DAK0#I&UT_G<!XM^ ;0L^NYC5-4&X\C\LGDQBV!(!LU1Y8:
MK0A.F(?QGW$/>]PV6ISX-.?<0:)O$44/GD$XYAD(!R.I<]LS$X +IC0B"0M&
MK<BSDD:/R[V"QVV#5#[@<=L0^;< I3V/JE)PQ"H?D$R8P;:S#AF6\JQ33"7X
M -&KTF^07NWCMD&J'_BX;8@>6H#54S;N\WS!:2GSQ Z);;ZCPMGM9-#(Z2@)
M!Q_ %I\5\#(U=>O&3W'*'2;X%B'T,*=KD_%6DHB4MPIX(7E6GP/?SUF'@V;N
M68U@_:3ZZ6S2@3H?DE0?HH"VD^KK$7\?@-V00VGA;HC,@UQSE\Z_Q;?Y/U_5
MM-P5\B^Z=-NDY? 4>]GO%TRXCRB8(]/O.:JZDZI/Z?-JY[SMKK[;V<VGV?0F
M5Q]-N\7U/-ZE:(/B6)H8D;0D8U@9V!< Z6QD34J&LBC[&)$].:?C*3WJ'<[=
M",OG=-QK:WWP4!HQ)AY%*\%:6$R1,;E<1C,IN1 I^E[AUGTO<_J35"]?<V)\
M/7K4,Y+**B=_@9E%-YT$8""\RZ/?)O$VW2E35")ZBXC5#G&<>RWS*!'C-B6F
M3*2RUV&^?Q]N_7[%AT!C*;HK+/4&D;.^<U%+J,91(<%DOL9S<$$HAHU&O!21
M*\]BB<>$+U-0U4(5T.P>J!P@YMH#I1Y:YDW[?ITB,\$B%GDNHTC9 Y8&><U"
M5(8H:DN@9,NGVX+'(=KLRHFVOAEYT<B^M=]7Y>CW5Z>8X!XCO4 JYC[J#*XY
M(+8\Z8@P)6QD5)>H5QM$5,4GC*<YJD;23P/AC$VU\IUWB#VAE%.%3$@!O$.6
M<J.1@&QRT7*-E7&];A\#0AA/:6C)NRZFZNV3QP^3>P.XV=(0]@*V%$N1Y/8
MN=,97ETLM$$L*.44I5:(TD]*MI!1-^AUG%Z[LD(^&"<_XMQUQQ?5?9@!X/SM
MN;SZ=V!ES8;EEJ<H",*&YD2[)+!W,$&*,N(,,8JH)\?8EJJZE]>O6PY5! 3E
MY-> N=A(Y$+Q_/K7,F1]AF\D 3GJ0NZ&B*D(S(M0NLII\^VZI0-%#<-!XCP<
M!D^FQ!\.@_7[RMGEN[^_YW/V7AK1>IM"],A&Z1'W.B'M@1L1B").)DM]Z<S)
MB\34<V=/YW^4T40#EN5KG,(?7?X:9_F=W=DLG(6KR6RR6"6(?L0U>Q=..6R=
MD'F/@?.O\FPKAR42B@B</%P-BU=7]J.LKKM2" 9/:^+*ZZ0!I&V&$.?'PC'/
M.-[([(*P%(C3&&F2&QQ1P4!6)J*8>';*4I2L] 2F%XFIZ_F,@Z<RDF_I_+OU
MXC(_%QQC$G'NLZ/!=G/+&#CTF",O';5:I*ATZ<JX+634<8XJG7D'2K\% .5.
M31^[6?>8E8U%%=@G''-W AKSY3" 3^E8'M=!$Q&>4BQ+UWOOIJA.(=.)855.
M)W7?P&V[;FZXL$8%@YU#E(L<FW<<::D"DL$9+@3(YVDRM.=]?0A0BC>Q.@U0
M"HKVB,FHESGC4F9$@)W,UF?QI]F[OS/DKR>+;YN7?P[NMI9*#\0CJZC.#RIB
M]O$LDEPK*JT1@M/"=F@O4;T0)E\GPL;13.TI778Z^3\QW$= ,W>K0SM9D3+!
M"+M(P:3FWM3:*\0LF%1OH\/*[C5&+Z_?"RGJ=2*EG& ;N)'=^W%YT-AM Z=K
MP/Q]&Z\W,77S>/OWSNW?<0&;8FY!A2#?^<U*C'!RY_Y?0-IT=7;?&N<+2;1A
MU'NXC1J)N,NM]_-T.Q.3\R G[OIU?AA@PD9DIQ>D]>N$=&MH:.":<,?BVL=8
M7Z OC-38&441I@2NRT$ &["EX;HL$J?Y.;XM?2Z_0$HO0)J? 9#'::'N&9PW
MTY.BT@L1M)$F4.2U  _"$(*LP00)C4VRDHC4(W.W9>%^@5#\.B%10);-F)6-
MA?UZ[1:3,+&Y9_3'" XF(/U"L)2"EPE%)A7BBE+D@M,H1AJQE(H*7+HUQGZJ
M^D'KE5>4%%9. ^[=JOQAP]39#SN9YCJN\PYVSU4W^[KL_)_?NBDH;_'&+B;^
M(G")F;$4!9\2XCR2_&S6H42T ,DZK/L]G!A:?]*?Q'Y ?.6IQ3'5UH 17#?+
MOX+O?P.!3G[$>VXW.^US[KH(2ETNYQ-WO;SE_];TWR5$C.98,W D(TL8O "?
M^^N;A%A46H*;R5GQ!Z>%2.^'XM>>+*B@Y@9L[DMLW^UCN$$M[#1^C?YZ?EO;
M'_[[^C:,T$,L%]B*Y%02B H+OJ]+!&GA.7)2)2FP53Z6'I4],DN5$_@U8-IS
MJ]3 3-W[TJ>W'WZ;6#>93I8W[[OY^^OE]3Q^[J83?[.^_)W-PN]V_F=<KOL0
MY9]]F($2KK,TOGZ/?I(F_BU0/5G]E4UH[BP!@5^BG]K%(O^-6X#=B1&6W2/$
M*)@F2EN$!1>(DTCAJD$<(B3FYGPI)*_W7MO:Y:]RV4/%7=BT6@;!KN'C;S//
MZ!IHFOF;\[F=+4!AF6L00?[=](EH^A@V"OO+29L0)GEXIZ4<Z:! 0D$11[T@
M6I<NF#\I@W4K;EL^&NOCJ>'-]@M8IUD,:S/U>0K2&"8'EY*)C%OD)0>-F5QD
MK<'\@.<0'+:<4E4ZS#T6+W4[ ;6\A4Z*DB;J+H[4QH7F&BZ\C"(7#4-<"(,T
M :Z%<UQ*KT5(ISIN>I)<=[1=R^@?0^<-!->V<'H7O7:<.:TX0R0J?#NZQ&HE
M$(A0&V$T.)JD,'QWD-/OVO_*2QM+J:,8LIIIM?7&PH'CX]=O,2Z/&&15[-.5
M&VSM%T<;O;64P0XGGF>9PX[@SH,YC(D@E3"723B?A.UC0WZ:WEI1V>AX]"C1
MN'J6X9#SF")E@V NP/]4K^[.__36&HRO0WMK#5%9_=8FVWL!,:VY"\(B;(1$
MG B!K"06)2GAE'(R^T1E]N$K[JTU2-%]>FL-D7J#R-ETZ\?::.TY,HQD=SHF
MI+FGX()8(Y-.2N->UYB?J;?6(,WVZZTU1,P-]M8*UEF\NM/+/+[>:@M7(,:1
M3 G^ ,M 2*\'OS]);ZU!VMS36VN(:!L(,WZ)TRP0X&3Y,-"Z>'/S\$]6VRC
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M(L=SP;(,@4><6^&7=DSW$M5D N$4D!Q';>W L;]H+XS4QAJ:$'&K5[58(J?
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M&^ TY/+5.%NL)'IAG0=GEX'W084&J\]E'K6BD0:Y,L&U3^4#. ?2V@NXYC\
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M77NP?8FMLUDX3BQ&6,:EP'"MSEDGIN!:G5A"D8G )&8\R/T)[5-27+>QZLG
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M$6T#E[67KB+16Z5I8,C*)&#/8(^<(!I%ZY,QEA*02D-5+"=MQW/(T5-2W@W
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M^MN5G:.04"BT))TI,QAL:5>KU>ZS+VI/;!P=M2><A4>_M'\ME^%$!6G,I85
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M;ZV=D;# J#BS5TE6&O/"L[@VWW37]?\!4$L#!!0    ( /UU75B 'Z*HF@D
M (/$   4    97AH7S(Q>#$P+6MX,C-Q-"YH=&WM76U3&SD2_GZ_0@=UV=TJ
M;&QC K$)58XAA 23%&:3W?UR)<_(M@[-:$K28,ROOY9F!C"VL]EXMFJ5'CX8
M\+RINY]^IB5U2T=3$XGCHRFCX?&_COY=JY$3&:01BPT)%*.&A235/)Z0+R'3
M-Z16R\_JRV2N^&1J2*O1:I,O4MWP6YH=-]P(=ES<YV@W^_]HUSWD:"3#^?%1
MR&\)#U]O\2;=;[?;K/&RT0C;+YNM5^RP?;#?:HX.PO&K9GO\W^867 JG9]=H
M,Q?L]5;$X]J4V>=W]MN)Z<YX:*:=9J/QGZV%\PR[,S4J^"3NN-;"T;$$V?+#
M@112=;8;[J=KC]3&-.)BWOGIFD=,DTLV(U<RHO%/.YK&NJ:9XN/L1,WO6:?9
M@H>[?V=9:P[@/H+'K&A=LV6;='HWY2,.NFH>[=JS"XD>Y"J[68V_V"SR8ONP
MU6QVR3 =:1YRJC@\1HZ)F3)RQ29<&T6M+9^V_J'=8%1UO.;8WR=3>Z5,%]!4
M .V("3DC5#&BGTET#1+U 1"4G"F9)H2Z;T]8P*(14R^VFR\;W;WFCL7U'IEQ
M,[4ZX(K\+U5<ASPP7,;N$JDF-.;WU'Y1A]M*_>QAL31$9,V9R52$]HL=PF.G
M5#J9*#8!!]LA =P0?"0U\*TS1*O1U=!"/N8!M1HL;CIW!\%*RV+L6#G,E!IB
MF(H(UR1D8U!.:)]WE0I&FK5&Z^?9+_9:,&@J7+O)L/9;_2]:U= 1W"XWZTBJ
MD*D:6%?01+-.\4<WY#H1=-[AL;.1NZ@;434!SQU)8V34V0>#WC)E0$J1.ZGS
MU^QP[M.O7M6;KPZM6QMHC0F+!^<>7W<>OVO"Y6,'!_7]@_VUAQOUYMIC7[MM
MJU%OM;[MMKNNR5FS03$ZH?'KK;VMXH*$AB%0:Z>5W)$FZ.()60DV7M)-II;2
M&>Q/J<*1ZFD,")V32QJQ!TCDXGLNV?LG?KT@VI]8;T2#FPFX7AS6\J:REZS!
M@F[N$D8F'9"=:"EX2*P<W7^F6I9XU*FE%\#[/Y3D':,".# GF?,XJ'^#_7]P
MW9PP06?P;MD,+F/WXY7@BZ!P<) JD<K&B=\%"P]U4([Q<W_P2?">$! (TCA@
MY(*/&40J>X?=@A_.8YTJ=ZPO(Y!^O@E+^*25 9Q!8XJ/"B*X#L)3""8-5\SU
M&!TLRD&"AQKY..42'RGHP%H^9X$A4[<\@+M?7/2Q$ #:8."-HK</\>& A[6>
M$=!=Y<$&8:*':AA OQSD#M&Y_H+]/[$XUG-Q2V-.-^\F^*2&IY*CXX"^'6'K
MPVD\3M,(E^-_@!=?&MS,T3F^-7I?@N$OW^]@>M/;V[QG2K,-3>XAUOM3KB2!
M'B#/(_NLU_]\R.P'UL!;> P/-V1X#T&?S3%D??W^X,V:/AY\'?'O'03R42M3
MCK#/GV&AIT92(>_K0\@3LP":DQJDC' "T0\51?C_<4SZT+2Q5.CB_T>YD?+!
M,A+LXVDH<74'"JDK/LA04(R+X6(#M*.!:U"0A\VXJ !W7V$) Q_@EE3CXH%,
MYHH%<@3D0V6X: #O .%J%!0S);B8H)SY(0_AOPX%7&N9*HZ+"PJI*R[(4/ X
MEHZ+#3#/(:Q!@E3P1Y\J"9<@ZR@LREYQ0X8(FTB%BQ4V3QWS$/QKK%]2)HF'
M"BDOD\1#%UB#AFMVAVWHP(E<L4%F_\_<5HQA8X)"ZHH%;&HA])XM%'J*W\N-
M(D0/%9(+C90.3E,EDU7I)L-ZKUZ[K']&PPAOF)CP-,))"+53:%+L^DJGL6$J
M45RSAV(#7(2 ?(+Q3,@1O!K*34#S4!MG*7C$QJ-('N)_ 097C#\'P@ZY,"$:
M-GC#5)1N.M/L(?PS%.0!(HW#*AT1>3IB!@57CE)2*9J'JD ^U?@$ [*,[J*'
MBBBEN^@A\E<!H$I(KGA 5MG(%1.0)^$1,BKX6ERXZ]9D.UY>7+%86/&P;E=H
M2Z3FMM"OHYA=,^Z6K5UL,5_6K?%X"1UI*5*S?,G:%>:>?DY5<>>$3EAMI!B]
MJ=&Q8:I#Q8S.]5:9:T*N;4RUZ%V9B][]&.RZ@F2J3'?D;YDS)L'1D06;N=!5
MI D .!=PGN2;3$AXJ(E"ZHH#+ 3BD%-L<]2YT!4'2%OCH#4-IJEFQB C@@71
M*S:069+[.QHE>LJQU<$NB%XQ@RRIXL%#7915\>"A$ZR$05GE#A[JH\QR!P\]
M814<JFQWQ-GNBU 8RA0M,RS*7C&#A8.IDPN98AM.0%XHNXB!:^!(IC5#UGEX
M$+LB KEY"92':BBA!,I#V.?&E\*V&-L^&LCSVG.K(_-SM'OI9$9'NVD.XGKW
M1YL/>!@*1DZI-JZ>[0*-VU^P$8U+VFW/)[DS!*Q90=MEK,;T63+%CZR-96GQ
MT,!Z$.0UKU6%*RI2N'2;*3P6O5>A 3Y.>-@][6ED\/:/4RP,<)*.*-9QOV&B
M4G#VHAM(SJ(W[["X?+;G^O*G3<@>SKBY9PIQ5=L7J40XXR$C9RQFJBI^WSI^
M)^,)^0 ?2,GB$1)HPP2\PX6/)3T/A(!P.R[4%>\K(%#B^@=^:P0?(8#)AX'B
MR2:UC1[*C7;NX'1X3@:4"_)I2E5$@WG1<<25)( V GA<#*T7!"!+5IK:=ULM
M?>]NK!ZJ :__/]@_&RNLW!Z7V]<^<R'HA U.G-,_[LIKL\NS'9G)SV]?;+</
MNA_<9\]NW]KNGE[V^D_.<=_]@H4M$%<A//+%EZD43%-X6YQP;10?I;;+6/$'
M"OY@M]QMVIZ]- *W4MKP'%7(4%)>J8>H/[U+%$B^:L%,+(Y?3F*YAZ@O;)\-
M$FC2"R,>6_ZG1BJ-R?_Q=AF>02 ?.6"I:R'YI&20*A:QV'S_^\!#M:"-!=;@
M 5EE<D4'N?F']EW )CP@)^R6"9ED3("I6X!X7[[G:/C5<,'OW6PB&="83MR+
M =N2VA4Y9'# 10-H(X)L5&"8*%MZYB:37VSO'7;7IJ/BBA1PUB,N8**4%2X]
M5$(I*UQZ"'GP>)M@=O4;JA'"]?Q?K99<K9;\K;?].U=+]I!"+^2<"M*+X.J
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MI24JB,J!'F,@"B*VAP=.QQXT3^O5# M,M48]ZKO,8LH("RE)=:W_B#8AGP%
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MNJQ]463#G&Y=8/?]-YOVW3>J_@=02P,$%     @ _75=6-2^I4JT P  20X
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M/FSPT81F>/9:\]3D9!)'O]U5;NRND'\#4$L#!!0    ( /UU75CY+</[VP,
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M((D)!=ED7C+!D"Z )$AN[Y'0[X]"(KHI2\&FF]F<$(FA:%]=OT\?N:MN,8R
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M&_W.@ E2T[5*;6,>H7KO3E!+.1 R%L?W)[BVBJ4F9M8/GO0SZTS[Y"*J"=]
M51*\\_TJX<1;=P;2S4824\OD$%RG&6:FGE!8%[S*<$"#P(;+_>GP0!;//G'!
M/GA:-8!5^-I;V"D=#F7J<&:(G($T,T_V@V]''E00BCIK'ZPW &GA6LZ>[S!U
M238(O8<%]'IXTC,M>B-$: @)F>Z>#5**G870 5 HST2#&5,P4OWL-\]+\G'D
M?4<!'U+W3#50)A/3]#8"J2_E"5D:#-<YJ'3.9X3*I:1D:(B:XB$D&\_X#?-N
MR^3^B;!.6ATCVH;E=4=P*)^'-@]>NI<&XS_=8%F/!DC>:-!]WZ77[J7PCKD3
M5A:3<A'$*$F* SOQ[8B4V@R,N_*YF<U+MS3!%%/S$F_4B 7S\:@=6ER%(\FE
MY$:O'J<P6& (I,+-&^-9H(;Y=S$U1,PP:/2-L7B@YMW3X;?T# [.V-2[W:&=
M)[O_) -OY";KU\IF!AB;BERZ<Y7APUA3(Q1\^E0=??OU\;,73R(E4\.^1T'<
MR4@$5N2#F-!S4UR]E@#],\OXX+.,PTK^)M4<EW@Y"H4GWHBP JT?<:FU*//#
MXYXR%^L[%$+TM2767908P@'WURSEV.&DU5@(:+BVTX'Y-Y&B/=#(?)E61D7Z
M+MFZ]-Q))BC]MBTFJ<4X=%:(C%FGJ_[0.#4\+^0J/2JI.L3<S>.)%];9S2IT
M[ZMN%XZW[4)W/!#VM0:>("67Z)R1:1:835X9@/.B2:F)"S?2I YXW!6\0C8H
MUUMG"_+K\ <Z\8BEYK0P*B9>!:08&>CZ(Q<ME&>D1[+YS"(?X0DAW.'  #_%
M8 >&+;JT.&^)@&THJ!S>%XIJ\I+ZMHD,U,57XKSC(UD>A9#!+5#O*L#C6# #
M1LGZ^F/U4#\"M*:T,]*]%+=DO15TS)HQ 8PY<:Y08VU#(;RX0YM8 5T9;:/C
MW>.&S@+#^&>X=5"T&Y;JZ48N"^Z960-BH!/*A/AK-K3XA^],7:"EY#'(\".>
MKWA\4+HA/!JKY.1:F<I37 QM-W14DB-):204C0FLFZZX+GB,>\*H1Z=-J!(S
M[AB]I; C2A8=MH8UW'+3P)!TN,K)@4BI=R'0FNIR'&.=&;$V)07RP*X>JYK1
M6L;*7\L#(3)0U >_4&@O\'7(>":K:'-RHXH6*XT7X=@=]$B*@%,,& TQ]2!B
MQ?LAHLT;@\%8<<E5J?5*D*I?!=1YD#)G+!*<2+!"VUC.J@&S8\:*(A_)8OI+
MR=C W;8S<E P3O*3K%K7EOZ(0YJW[!?/ITK+O<<YCMXQCHQ.VV]=%]FC,1UJ
MHQ4D1?^:,"R-$D3-A#=^Z#%B(7HF>5.#X#""GFP:M)(P0>P@WJS-\Y% @99+
M!?'<E.U58D:5?GC2VQWQ;31',:'GMJ:<IER#C3FJ3#*-R2>ERS4?W2*G/7Z.
M+O/;%BA4V.3FE[$IZ/)MOO0@;T(GDN-Z)8]==__V[L/'Z%_B52HX\5_)P8-%
M_F)UJ(A>.Y H9O+CA/,!(_!>T4(35%(Y22R,_72ZBX:L$X,_5F2'S64?RW0?
M^UYMM X'[ F77#"6'AU&\[SA]/D,G#I^N G<^&3' ##QO;CQ@M)>8DBNO.@F
M7CC#)WX1LPQ?<2 ZJ1LZM?V&;#Y6'&.0N24HP64/]E>7VH6% $C8@IQ9SYN.
M$^F9;BJ>J&8,8XRJPL5$T"[4B')$$"U-"@A85T:N!V'M+D210TN:H^V)809*
M7R_&;2F7YWI^'R_,11[25M*'M0%LSZ<<V:R3FVID>0&@4PN3]E:NL![<3[8"
MJ'!%V1F>6L)34\)MX@T%*%Y9BC!<EF+T*-P0FH25.K.!M:=/30\"ZW ?QG9]
M)*HN"$A<3,+["9?U[V_H4JI![PS_N8+'=#SI$N!O5L4[L+XT7!VJ(I"\+ZAG
M&U:_Y*-H(9"(KAHZLWR1!;F"?%7[,CS".#IP5R7.?O^;8+JDIU4"!A1RY:QX
MJ[YEL>CLY2R&2',0X1+$MR;XAI]T 3_0C9ERSQ-T"^XHA3]N-_U5#=WK7-SY
M*;7W4[YSC ]N+]: 65>=T3CN@!$AL&L"U+E-#I$G9UZ"39GVFG5@+]9GQM=7
M<LB@8ONTJ5O?L&$JEUWF_+=YY((E^1K/QF3JK0-T55AI1+>94_/$SD7C;HYJ
M(K77:=YRPT12*8*GE\4P%N3"(+C:27>VBSMS^KG$;?5! W%5%CK)0#ER]XF]
M=(A($\_!\G:SF"UOP6F *0_A3+3_Z,+N>$%(65+$J<)%=7A%>2L'/N!.XIB
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MKP)*IYT1&!WU'RBCL@0&3TWI4'L!-4GSZ=IK10+4"Z5JKX9))Z,>=N&4/9T
MM &@GC<6Q0\T7BU@SSA?V<G0(6RD,,LDEJ-U+>R:"HA+^AY5*4FS2(,QK? 9
M#21'LL#Q4Y4U;"G\L8,*1E5+M(7UJT("\3:U;15Y#KR.A+5U*J?P=F'%!)\L
M7=*M:F#(S"HFPP/1 $<#TP O#3 R\,+K#RIMT,3?J[D)(L^\2OR![&:$DF I
MTL9:YM0,V7T!+-1N6_R0YQKP2I"6P)G+.3 YN$_,3O0I0Z0@R_C9+YZ>'$]
MQG$"R:) / OLCB(G1:4LKD@0!SYK0V(-LE"!M.&:C*5VH%,0NC<J5? ]* ^4
M!]@@L"-)_=RO5X'\XEB8B\SB[JGVY'X[G9BN:+9-.OBMXX^%=+@02!*C+M)*
MWVB7RD+\K*1E22M7L4"^L_ :-2WY(Y\7M!G(?Y@SD[7:U .P.Z^Z2+O (Y6T
M ,%0>X.-846S9]4,%#9H,<>44ZP-X'DZ>3P6)I1I#? .H&*N"Y7MT]O?F^X#
MWD#DH#V4\-HG+1K4;*^M-:4RC8/'KI:PF(>+@8S 9]_ F4$E5<8IVD:8+AS0
MJD)=H[I"2 PRL@KOW:H<) ;>#K$ #NTH YJS 2@$;RCYO51B0!39%LT('=X7
M"(4E+9J"1.#>]_3^EN7(+ (LQI>^Q6 F^-;Q+Q,DQX:/;EV*O+7\E3=<R_>*
M7Y5D4Z-S;X/#WXP-PR$3-'OT9APM:I5TI@0V0X-IFB+CMQ<&9<EO)!E,O:=C
M4N#1P40F\.RL*61M+*W/UJ< +D2VBLZ&X6J1463#]9;?M23PT8;DH1<R_075
M DEZ9WIC TC?MVZ/P(F)K_SY@MODANF>#,QH>)#W, #"\<  PIN@_D E?$RM
MWC-T^#8G(_*Q7<;F&.VG%!O\G/2DGU%]I+4 "B^J&CZP)JQ512#%6PI6C1_?
M1>06@&9,K9YB J[G!W_U,-W@KP;&XX %%F3S K,/  -W7BZS7PMW$N0<]!N=
M 9R6 8P#-S-X[S%3D1%5>:X00-4^P.<ASU:G$HQCJ=! +HS%B W8Q<PAT@Z<
M35CX-A*&]HLY>4MT,##WL9!3@[+&V!E]2 _@$AIHFEH4&HA <X(/_OR<L"\#
M 8);TF'\4B^F8%K)(+.GCO#0*?4>Q[3P#8X!1\F5KL&'Q?/C26:28+P/:QG&
M<V#/D"@)8'1E4^U@/^!AU^PGPV=9H() @)Q[V$2  EX%D%8'%(_3XT[KE8^:
M2J24\SM,,2F0X[0!<,J%:1@<3$,<-D0M<:I>S+6+NIEEYP1$:(7_7--J?FG
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M#C.-.;90C@!]D%B#SW#_SEGGBVWJ(6QVX3(MRO^T)3D4>U\K3?%%+!T/8BX
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MMR'.]&>W.'7_NAY?:;K^3^P]HNCV*NR'AJ*?\;^'^HS^'=;_ U!+ 0(4 Q0
M   ( /QU75AUN>+)*](% (6_3P /              "  0    !C:2TR,#(S
M,3(S,2YH=&U02P$"% ,4    " #]=5U8!&)Z8:E-  !#W0, #P
M    @ %8T@4 8VDM,C R,S$R,S$N>'-D4$L! A0#%     @ _75=6#[OV#1+
MB@  4#P& !,              ( !+B & &-I+3(P,C,Q,C,Q7V-A;"YX;6Q0
M2P$"% ,4    " #]=5U8;U!6L5", 0!9R!( $P              @ &JJ@8
M8VDM,C R,S$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( /UU75B%0(^*)VP  %=P
M   2              "  2LW" !C:2TR,#(S,3(S,5]G,2YJ<&=02P$"% ,4
M    " #]=5U8<L51 1R4   -W   $@              @ &"HP@ 8VDM,C R
M,S$R,S%?9S(N:G!G4$L! A0#%     @ _75=6.Y][:'IO@, ^C<F !,
M         ( !SC<) &-I+3(P,C,Q,C,Q7VQA8BYX;6Q02P$"% ,4    " #]
M=5U8]C!'2P@D @"Y$AH $P              @ 'H]@P 8VDM,C R,S$R,S%?
M<')E+GAM;%!+ 0(4 Q0    ( /UU75@?GT"N^ 4  *4>   >
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M &5X:%\R,W@Q,"UK>#(S<30N:'1M4$L! A0#%     @ _75=6)*O\K-P!P
M620  !               ( !;S0/ &5X:%\S,3%X,C-Q-"YH=&U02P$"% ,4
M    " #]=5U8=3C^":0'  !8)0  $               @ $-/ \ 97AH7S,Q
M,G@R,W$T+FAT;5!+ 0(4 Q0    ( /UU75C4OJ5*M ,  $D.   0
M      "  =]##P!E>&A?,S(Q>#(S<30N:'1M4$L! A0#%     @ _75=6/DM
MP_O; P  M X  !               ( !P4</ &5X:%\S,C)X,C-Q-"YH=&U0
M2P$"% ,4    " #]=5U8L2W"Z\(8  !0<@  '@              @ '*2P\
M97AH7S0W>&1E<V-R:7!T:6]N;V9S96-U<FDN:'1M4$L! A0#%     @ _75=
M6/86O6;T$@  CG4  !X              ( !R&0/ &5X:%\Y-S%X:6YC96YT
F:79E8V]M<&5N<V%T+FAT;5!+!08     $@ 2 *H$  #X=P\    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>199
<FILENAME>ci-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ci="http://www.thecignagroup.com/20231231"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ci-20231231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ci:MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ci:HealthCareServiceCorporationHCSCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ci:MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:PharmacyBenefitsManagementServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:GuaranteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:PharmacyBenefitsManagementServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:GuaranteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AdministrativeServicesOnlyHealthCareServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:PerformanceGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AdministrativeServicesOnlyHealthCareServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:PerformanceGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AdministrativeServicesOnlyHealthCareServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:PerformanceGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ci:MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ci:CHSSJVLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:IndirectGuaranteeOfIndebtednessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ci:InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ci:InternationalLifeAccidentSupplementalBenefitsBusinessesExcludingTurkeyJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ci:MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ci:MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue202383InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue202383InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2023765InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2023765InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2023FloatingRateInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2023FloatingRateInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20233InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20233InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2023375InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2023375InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2024613InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2024613InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue202435InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue202435InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2025325InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2025325InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20254125InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20254125InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue202645InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue202645InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2026125Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2026125Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20265685Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20265685Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue202734InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue202734InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:DebenturesDue20277875InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:DebenturesDue20277875InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2027305Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2027305Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20284375InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20284375InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue203024InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue203024InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20312375InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20312375InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:StepDownNotesDueJanuary2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:StepDownNotesDueJanuary2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20335400InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20335400InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2036615InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue2036615InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue203848InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue203848InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue204032InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue204032InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20415875InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20415875InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20416125InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20416125InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20425375InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20425375InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue204648InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue204648InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20473875Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20473875Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue204849InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue204849InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue205034InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue205034InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue205134InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue205134InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:StepDownNotesDueJanuary2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-15</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditAgreementsApril2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:A364DayRevolvingCreditAgreementMaturingApril2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:A364DayRevolvingCreditAgreementMaturingApril2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditAgreementsApril2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditFacilityMaturingApril2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditFacilityMaturingApril2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:A364DayRevolvingCreditAgreementMaturingApril2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:A364DayRevolvingCreditAgreementMaturingApril2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue202435InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-22</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-22</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-07</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20265685Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-07</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20265685Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-07</startDate>
            <endDate>2023-03-07</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20335400InterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-07</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20335400InterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-07</startDate>
            <endDate>2023-03-07</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20265685Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:UsTreasuryUstInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-07</startDate>
            <endDate>2023-03-07</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20335400InterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:UsTreasuryUstInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-07</startDate>
            <endDate>2023-03-07</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <startDate>2023-03-23</startDate>
            <endDate>2023-03-23</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <startDate>2023-09-21</startDate>
            <endDate>2023-09-21</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <startDate>2023-12-21</startDate>
            <endDate>2023-12-21</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <startDate>2022-03-24</startDate>
            <endDate>2022-03-24</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <startDate>2022-06-23</startDate>
            <endDate>2022-06-23</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <startDate>2022-09-22</startDate>
            <endDate>2022-09-22</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <startDate>2022-12-21</startDate>
            <endDate>2022-12-21</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-25</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <startDate>2021-06-23</startDate>
            <endDate>2021-06-23</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <startDate>2021-09-23</startDate>
            <endDate>2021-09-23</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <startDate>2021-12-22</startDate>
            <endDate>2021-12-22</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-02</startDate>
            <endDate>2024-02-02</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-15</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-15</startDate>
            <endDate>2024-02-15</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-15</startDate>
            <endDate>2024-02-15</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NoncatastrophicEventAxis">ci:CompletionFactorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NoncatastrophicEventAxis">ci:CompletionFactorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NoncatastrophicEventAxis">ci:MedicalCostTrendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NoncatastrophicEventAxis">ci:MedicalCostTrendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ci:MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ci:InternationalLifeAccidentSupplementalBenefitsBusinessesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">us-gaap:PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">us-gaap:PolicyholderAccountBalanceAtGuaranteedMinimumCreditingRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateRangeFrom0051To0150Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">ci:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateAxis">ci:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRateBasedOnGreaterOfGuaranteedMinimumCashValueOrActualCashValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeAxis">us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditingRateRangeFrom0300To0399Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSROAOrHigherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSROBBBToBBBRatingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OngoingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:LincolnNationalLifeInsuranceCompanyAndLincolnLifeAndAnnuityOfNewYorkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:EmpowerAnnuityInsuranceCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:EmpowerAnnuityInsuranceCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:EmpowerAnnuityInsuranceCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:EmpowerAnnuityInsuranceCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:PrudentialInsuranceCompanyOfAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:PrudentialInsuranceCompanyOfAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:PrudentialInsuranceCompanyOfAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:PrudentialInsuranceCompanyOfAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:LifeInsuranceCompanyOfNorthAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:LifeInsuranceCompanyOfNorthAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:LifeInsuranceCompanyOfNorthAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:LifeInsuranceCompanyOfNorthAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">us-gaap:OtherReinsurerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">us-gaap:OtherReinsurerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">us-gaap:OtherReinsurerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">us-gaap:OtherReinsurerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisticalRatingOrganizationsNRSROBBBOrHigherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:CreditRatingNationallyRecognizedStatisticalRatingOrganizationNRSROAxis">ci:NationallyRecognizedStatisicalRatingOrganizationsNRSRONotRatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:AcquisitionDispositionRunoffActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredContractuallyRequiredFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">ci:CededCreditRiskSecuredCollateralProvisionsExistThatMayMitigateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskUnsecuredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:BerkshireHathwayLifeInsuranceCompanyOfNebraskaAndOtherRecoverablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:BerkshireHathwayLifeInsuranceCompanyOfNebraskaAndOtherRecoverablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteedInsuranceContractTypeOfBenefitAxis">us-gaap:GuaranteedMinimumDeathBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:BerkshireHathwayLifeInsuranceCompanyOfNebraskaAndOtherRecoverablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:BerkshireHathwayLifeInsuranceCompanyOfNebraskaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskSecuredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ci:CededCreditCollateralizationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:SunLifeAssuranceCompanyOfCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:SunLifeAssuranceCompanyOfCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:LibertyMutualInsuranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:LibertyMutualInsuranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:LibertyMutualInsuranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskSecuredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ci:CededCreditCollateralizationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:SCORSEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:SCORSEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskAxis">ci:SCORSEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CededCreditRiskCollateralizationAxis">us-gaap:CededCreditRiskSecuredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalancesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ci:CededCreditCollateralizationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:VariableAnnuityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ShortDurationContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ShortDurationContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ShortDurationContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:LongDurationContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:LongDurationContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:LongDurationContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MortgagesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MortgagesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:PolicyLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:PolicyLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:InvestmentsCreditRatingAxis">ci:InvestmentGradeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:InvestmentsCreditRatingAxis">ci:InvestmentGradeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:InvestmentsCreditRatingAxis">ci:BelowInvestmentGradeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ci:InvestmentsCreditRatingAxis">ci:BelowInvestmentGradeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ci:VillageMDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">ci:EquitySecuritiesFVNIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">us-gaap:HealthcareSectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">ci:LtvLessThan60PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">ci:LtvLessThan60PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">ci:LtvLessThan60PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">ci:LtvLessThan60PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">ci:Ltv60To79PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">ci:Ltv60To79PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">ci:Ltv60To79PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">ci:Ltv60To79PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">us-gaap:Ltv80To100PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">us-gaap:Ltv80To100PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">us-gaap:Ltv80To100PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LoanToValueAxis">us-gaap:Ltv80To100PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablePortfolioSegmentAxis">us-gaap:CommercialPortfolioSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RealEstateInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RealEstateInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MortgagesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MortgagesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MortgagesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:PolicyLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:PolicyLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:PolicyLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ci:CashCashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ci:CashCashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ci:CashCashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ci:ForwardsSwapsOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-448">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ci:ForwardsSwapsOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ci:ForwardsSwapsOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ci:ForwardsSwapsOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ci:ForwardsSwapsOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ci:ForwardsSwapsOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ci:ForwardsSwapsOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ci:ForwardsSwapsOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:SwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:SwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ci:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ci:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ci:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ci:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ci:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ci:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-463">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ci:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-464">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ci:CorporateAndGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-467">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-469">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-470">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-471">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ci:MeasurementInputLiquidityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ci:UnobservableInputsDevelopedByCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-473">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:DebtAndEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-476">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:DebtAndEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-477">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:DebtAndEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-478">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:DebtAndEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-479">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:DebtAndEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-481">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-483">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-485">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-488">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-489">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-491">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-492">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RealEstateFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RealEstateFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-495">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RealEstateFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-496">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RealEstateFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-497">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RealEstateFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-498">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-499">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-500">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:HedgeFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ci:SeparateAccountAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ci:SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ci:SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">ci:CommitmentToFundPartnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ci:SecuritiesLimitedPartnershipsAndRealEstateLimitedPartnershipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ci:RealEstateJointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ci:AssetBackedAndCorporateSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ci:OtherVariableInterestEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ci:OperatingJointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ci:OperatingJointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ci:OperatingJointVenturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ci:OperatingJointVenturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ci:OperatingJointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ci:OperatingJointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ci:OperatingJointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ci:OperatingJointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ci:OperatingJointVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-532">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-533">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-534">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-536">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-538">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-539">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-540">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesGainLossOnSaleOfBusinessParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-541">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesGainLossOnSaleOfBusinessParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-542">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesGainLossOnSaleOfBusinessParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-543">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesRealizedInvestmentGainsLossesParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-544">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesRealizedInvestmentGainsLossesParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-545">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesRealizedInvestmentGainsLossesParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesSellingGeneralAdministrativeExpenseParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-547">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesSellingGeneralAdministrativeExpenseParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-548">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesSellingGeneralAdministrativeExpenseParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-549">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCIAccumulatedGainLossDebtSecuritiesAvailableForSaleAndDerivativesParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-552">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-553">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-555">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociLiabilityForFuturePolicyBenefitParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-556">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociLiabilityForFuturePolicyBenefitParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-557">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociLiabilityForFuturePolicyBenefitParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-558">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-559">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-560">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-561">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-562">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-563">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-564">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AOCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-565">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-566">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-568">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-569">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-570">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-571">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-572">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-573">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-574">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-577">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-579">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-580">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-581">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-582">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-583">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-584">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AccumulatedDefinedBenefitPlansAdjustmentGainLossOnSaleOfBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-585">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AccumulatedDefinedBenefitPlansAdjustmentGainLossOnSaleOfBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-586">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AccumulatedDefinedBenefitPlansAdjustmentGainLossOnSaleOfBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-587">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AccumulatedDefinedBenefitPlansAdjustmentSettlementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-588">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AccumulatedDefinedBenefitPlansAdjustmentSettlementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-589">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ci:AccumulatedDefinedBenefitPlansAdjustmentSettlementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-590">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-591">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-592">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-594">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-595">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-596">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-597">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-598">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-599">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-600">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">ci:FundInvestmentsAndPooledSeparateAccountsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">ci:FundInvestmentsAndPooledSeparateAccountsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDebtSecurityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDebtSecurityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-612">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:RealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:RealEstateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MortgagesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-620">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:MortgagesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">ci:GuaranteedDepositAccountContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">ci:GuaranteedDepositAccountContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">ci:CashAndCashEquivalentsInvestmentTradeReceivablesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-624">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">ci:CashAndCashEquivalentsInvestmentTradeReceivablesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">ci:OtherPlanAssetCategoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-631">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-632">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-633">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-634">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-635">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-636">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-637">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ci:RestrictedStockGrantsAndUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-638">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ci:RestrictedStockGrantsAndUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-639">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ci:RestrictedStockGrantsAndUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-640">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ci:RestrictedStockGrantsAndUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-641">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ci:RestrictedStockGrantsAndUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-642">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ci:RestrictedStockGrantsAndUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-643">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ci:RestrictedStockGrantsAndUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-644">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ci:RestrictedStockGrantsAndUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-645">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ci:RestrictedStockGrantsAndUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-646">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-647">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-648">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-649">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-650">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-651">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-652">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-653">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-654">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-655">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-656">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-657">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-658">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-659">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-660">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-661">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-662">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ci:InternationalLifeAccidentSupplementalBenefitsBusinessesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-663">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-664">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-665">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-666">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-667">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-668">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-669">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-670">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-671">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-672">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-673">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-674">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-675">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-676">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-677">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-678">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-679">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ci:AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-680">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-681">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ci:AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-682">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ci:DepreciationAndAmortizationByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-683">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ci:DepreciationAndAmortizationByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-684">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ci:DepreciationAndAmortizationByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-685">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ci:DepreciationAndAmortizationByTypeAxis">ci:AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-686">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ci:DepreciationAndAmortizationByTypeAxis">ci:AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ci:DepreciationAndAmortizationByTypeAxis">ci:AssetsHeldUnderCapitalLeasesAndOtherCapitalizedPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-688">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ci:DepreciationAndAmortizationByTypeAxis">us-gaap:InsuranceContractsAcquiredInBusinessCombinationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-689">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ci:DepreciationAndAmortizationByTypeAxis">us-gaap:InsuranceContractsAcquiredInBusinessCombinationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-690">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ci:DepreciationAndAmortizationByTypeAxis">us-gaap:InsuranceContractsAcquiredInBusinessCombinationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-691">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ci:DepreciationAndAmortizationByTypeAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-692">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ci:DepreciationAndAmortizationByTypeAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-693">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ci:DepreciationAndAmortizationByTypeAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-694">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ci:InternationalLifeAccidentSupplementalBenefitsBusinessesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-695">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ci:InternationalLifeAccidentSupplementalBenefitsBusinessesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-696">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ci:InternationalLifeAccidentSupplementalBenefitsBusinessesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-697">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ci:MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-698">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ci:MedicareAdvantageAndRelatedCignaHealthcareBusinessesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-699">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">ci:IncomeBeforeTaxesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-700">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">ci:IncomeBeforeTaxesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">ci:IncomeBeforeTaxesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:RetirementAndLifeInsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:FinancialGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:RetirementAndLifeInsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:FinancialGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-705">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ci:ExpressScriptsLitigationWithElevanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ci:PricingConcessionsThroughRemainingContractTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="c-706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ci:ExpressScriptsLitigationWithElevanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ci:PricingConcessionsAfterRemainingTermOfAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="c-707">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ci:ExpressScriptsLitigationWithElevanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ci:DamagesForServiceIssuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="c-708">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ci:ExpressScriptsCounterclaimsAgainstElevanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-19</startDate>
            <endDate>2016-04-19</endDate>
        </period>
    </context>
    <context id="c-709">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ci:ExpressScriptsCounterclaimsAgainstElevanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-19</instant>
        </period>
    </context>
    <context id="c-710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ci:ExpressScriptsLitigationWithElevanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ci:PricingConcessionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-31</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-711">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ci:ExpressScriptsLitigationWithElevanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ci:DamagesForServiceIssuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:InsuranceRelatedAssessmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ci:LitigationMattersAndRegulatoryMattersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-714">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-717">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-721">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-722">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">ci:CorporateAndEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-724">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-725">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">ci:CorporateAndEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-732">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-733">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-735">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-736">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-737">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-738">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-739">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-740">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-741">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-742">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">ci:CorporateAndEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-743">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:NetworkPharmacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-744">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:NetworkPharmacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-745">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:NetworkPharmacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-746">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:HomeDeliveryAndSpecialtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-747">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:HomeDeliveryAndSpecialtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-748">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:HomeDeliveryAndSpecialtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-749">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OtherPharmacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-750">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OtherPharmacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-751">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OtherPharmacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-752">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-753">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-754">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-755">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:EmployerInsuredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-756">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:EmployerInsuredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-757">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:EmployerInsuredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-758">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-759">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-760">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-761">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:StopLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-762">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:StopLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-763">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:StopLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-764">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:IndividualAndFamilyPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-765">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:IndividualAndFamilyPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-766">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:IndividualAndFamilyPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-767">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OtherHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-768">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OtherHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-769">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:OtherHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-770">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-771">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-772">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:UnitedStatedHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-773">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:InternationalHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-774">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:InternationalHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-775">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:InternationalHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-776">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:OtherOperationsInternationalBusinessesToBeSoldAndInterestInJointVentureInTurkeyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-777">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:OtherOperationsInternationalBusinessesToBeSoldAndInterestInJointVentureInTurkeyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-778">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:OtherOperationsInternationalBusinessesToBeSoldAndInterestInJointVentureInTurkeyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-779">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:OtherOperationsSegmentOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-780">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:OtherOperationsSegmentOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-781">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">ci:OtherOperationsSegmentOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-782">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-783">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-784">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:EvernorthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-785">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-786">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-787">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:CignaHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-788">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-789">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-790">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ci:ServiceFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ci:OtherOperationsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-791">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-792">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-793">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-794">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-795">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-796">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-797">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ci:SingleForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">ci:RevenuesFromExternalCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-798">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ci:SingleForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">ci:RevenuesFromExternalCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-799">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ci:SingleForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">ci:RevenuesFromExternalCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-800">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ci:AllOtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ci:AllOtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ci:AllOtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ci:USFederalGovernmentAgenciesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">ci:RevenuesIncludingNetInvestmentIncomeBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ci:USFederalGovernmentAgenciesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">ci:RevenuesIncludingNetInvestmentIncomeBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ci:USFederalGovernmentAgenciesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">ci:RevenuesIncludingNetInvestmentIncomeBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-809">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-813">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-817">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-818">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-819">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-820">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-822">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditAgreementsApril2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-824">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="c-825">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="c-826">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditAndLetterOfCreditFacilityMaturingApril2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="c-827">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:A364DayRevolvingCreditAgreementMaturingApril2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="c-828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:A364DayRevolvingCreditAgreementMaturingApril2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="c-829">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditAgreementsApril2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="c-830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="c-831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditAndLetterOfCreditFacilityMaturingApril2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="c-832">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditFacilityMaturingApril2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="c-833">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:RevolvingCreditFacilityMaturingApril2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="c-834">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:A364DayRevolvingCreditAgreementMaturingApril2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="c-835">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:A364DayRevolvingCreditAgreementMaturingApril2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="c-836">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-837">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c-838">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue202435InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c-839">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-22</instant>
        </period>
    </context>
    <context id="c-840">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-22</instant>
        </period>
    </context>
    <context id="c-841">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-07</instant>
        </period>
    </context>
    <context id="c-842">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20265685Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-07</instant>
        </period>
    </context>
    <context id="c-843">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20265685Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-07</startDate>
            <endDate>2023-03-07</endDate>
        </period>
    </context>
    <context id="c-844">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20335400InterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-07</instant>
        </period>
    </context>
    <context id="c-845">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20335400InterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-07</startDate>
            <endDate>2023-03-07</endDate>
        </period>
    </context>
    <context id="c-846">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20265685Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:UsTreasuryUstInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-07</startDate>
            <endDate>2023-03-07</endDate>
        </period>
    </context>
    <context id="c-847">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ci:NotesDue20335400InterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:UsTreasuryUstInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-07</startDate>
            <endDate>2023-03-07</endDate>
        </period>
    </context>
    <context id="c-848">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ci:EvernorthHealthIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-849">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ci:EvernorthHealthIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-850">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ci:EvernorthHealthIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-851">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ci:ThreeWhollyOwnedSubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-852">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="c-853">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-15</instant>
        </period>
    </context>
    <context id="c-854">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-15</startDate>
            <endDate>2024-02-15</endDate>
        </period>
    </context>
    <context id="c-855">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-856">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-857">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-858">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-859">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-860">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-861">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-862">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-863">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-864">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-865">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-866">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-867">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForReinsuranceRecoverableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-868">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForReinsuranceRecoverableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-869">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForReinsuranceRecoverableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-870">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-871">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-872">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-873">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-874">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-875">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-876">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-877">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-878">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForReinsuranceRecoverableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-879">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForReinsuranceRecoverableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-880">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-881">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceInvestmentValuationReservesAvailableForSaleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-882">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-883">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceInvestmentValuationReservesCommercialMortgageLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-884">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-885">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">ci:SECSchedule1209AllowanceCreditLossUncollectiblePremiumReceivablesAndFinancingReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-886">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-887">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-888">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForReinsuranceRecoverableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-889">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001739940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForReinsuranceRecoverableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="revolvingcreditfacility">
        <measure>ci:revolvingCreditFacility</measure>
    </unit>
    <unit id="position">
        <measure>ci:position</measure>
    </unit>
    <unit id="claim">
        <measure>ci:claim</measure>
    </unit>
    <unit id="entity">
        <measure>ci:entity</measure>
    </unit>
    <unit id="limitedpartnership">
        <measure>ci:limitedPartnership</measure>
    </unit>
    <unit id="employee">
        <measure>ci:employee</measure>
    </unit>
    <unit id="bank">
        <measure>ci:bank</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-2">2023</dei:DocumentFiscalYearFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-3">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-4">0001739940</dei:EntityCentralIndexKey>
    <us-gaap:AccountingStandardsUpdateExtensibleList contextRef="c-8" id="f-237">http://fasb.org/us-gaap/2023#AccountingStandardsUpdate201613Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:DisposalGroupNotDiscontinuedOperationNameOfSegmentExtensibleList contextRef="c-74" id="f-490">http://www.thecignagroup.com/20231231#CignaHealthcareMember</us-gaap:DisposalGroupNotDiscontinuedOperationNameOfSegmentExtensibleList>
    <us-gaap:LossContingencyAccrualProvision contextRef="c-80" id="f-510" unitRef="usd" xsi:nil="true"/>
    <us-gaap:LossContingencyAccrualProvision contextRef="c-81" id="f-511" unitRef="usd" xsi:nil="true"/>
    <us-gaap:LossContingencyAccrualProvision contextRef="c-82" id="f-512" unitRef="usd" xsi:nil="true"/>
    <us-gaap:LossContingencyAccrualPayments contextRef="c-80" id="f-513" unitRef="usd" xsi:nil="true"/>
    <us-gaap:LossContingencyAccrualPayments contextRef="c-81" id="f-514" unitRef="usd" xsi:nil="true"/>
    <us-gaap:LossContingencyAccrualPayments contextRef="c-82" id="f-515" unitRef="usd" xsi:nil="true"/>
    <us-gaap:SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration contextRef="c-13" id="f-550">http://fasb.org/us-gaap/2023#AccountsPayableCurrent</us-gaap:SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration contextRef="c-12" id="f-551">http://fasb.org/us-gaap/2023#AccountsPayableCurrent</us-gaap:SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList contextRef="c-90" id="f-569">http://fasb.org/us-gaap/2023#GainLossOnSaleOfBusiness</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList>
    <ci:FairValueMeasurementNonPerformanceRiskAdjustment contextRef="c-254" id="f-1253" unitRef="usd" xsi:nil="true"/>
    <ci:FairValueMeasurementNonPerformanceRiskAdjustment contextRef="c-255" id="f-1254" unitRef="usd" xsi:nil="true"/>
    <ci:FairValueMeasurementNonPerformanceRiskAdjustment contextRef="c-318" id="f-1255" unitRef="usd" xsi:nil="true"/>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="c-1" id="f-1517" unitRef="usd" xsi:nil="true"/>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="c-7" id="f-1518" unitRef="usd" xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-1" id="f-1519" unitRef="usd" xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-7" id="f-1520" unitRef="usd" xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-1" id="f-1521" unitRef="usd" xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-7" id="f-1522" unitRef="usd" xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease contextRef="c-513" id="f-1755" unitRef="usd" xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease contextRef="c-514" id="f-1756" unitRef="usd" xsi:nil="true"/>
    <ci:RealizedInvestmentLossesCommercialMortgageLoansRealEstateEntitiesCertainEquitySecuritiesWithNoReadilyDeterminableFairValue contextRef="c-1" id="f-1757" unitRef="usd" xsi:nil="true"/>
    <ci:RealizedInvestmentLossesCommercialMortgageLoansRealEstateEntitiesCertainEquitySecuritiesWithNoReadilyDeterminableFairValue contextRef="c-7" id="f-1758" unitRef="usd" xsi:nil="true"/>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount contextRef="c-1" id="f-1759" unitRef="usd" xsi:nil="true"/>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount contextRef="c-7" id="f-1760" unitRef="usd" xsi:nil="true"/>
    <us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount contextRef="c-522" id="f-1774" unitRef="usd" xsi:nil="true"/>
    <us-gaap:NoncontrollingInterestInVariableInterestEntity contextRef="c-522" id="f-1775" unitRef="usd" xsi:nil="true"/>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer contextRef="c-626" id="f-2066" unitRef="usd" xsi:nil="true"/>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear contextRef="c-627" id="f-2067" unitRef="usd" xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-637" id="f-2151">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-663" id="f-2278">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-673" id="f-2323">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-675" id="f-2325">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration contextRef="c-677" id="f-2327">http://fasb.org/us-gaap/2023#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-12" id="f-2410">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-13" id="f-2411">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-12" id="f-2414">http://www.thecignagroup.com/20231231#AccruedExpensesAndOtherLiabilities</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-13" id="f-2415">http://www.thecignagroup.com/20231231#AccruedExpensesAndOtherLiabilities</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-13" id="f-2418">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-12" id="f-2419">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-12" id="f-2428">http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-13" id="f-2429">http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-12" id="f-2432">http://fasb.org/us-gaap/2023#DebtCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-13" id="f-2433">http://fasb.org/us-gaap/2023#DebtCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-13" id="f-2436">http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-12" id="f-2437">http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:LossContingencyAccrualProvision contextRef="c-712" id="f-2655" unitRef="usd" xsi:nil="true"/>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-713" id="f-2656" unitRef="usd" xsi:nil="true"/>
    <dei:DocumentType contextRef="c-1" id="f-5">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-6">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-7">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-8">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-9">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-10">001-38769</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-11">The Cigna Group</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-12">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-13">82-4991898</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-14">900 Cottage Grove Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-15">Bloomfield</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-16">CT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-17">06002</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-18">860</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-19">226-6000</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-20">Common Stock, Par Value $0.01</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-21">CI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-22">NYSE</dei:SecurityExchangeName>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-23">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-24">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-25">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-26">No</dei:EntityVoluntaryFilers>
    <dei:EntityFilerCategory contextRef="c-1" id="f-27">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-28">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-29">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-30">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-31">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-32">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-8" id="f-33" unitRef="usd">82800000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-34" unitRef="shares">292355022</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-35">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Part III of this Form 10-K incorporates by reference information from the registrant's definitive proxy statement related to the 2024 annual meeting of shareholders.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName contextRef="c-1" id="f-36">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-37">Hartford, Connecticut</dei:AuditorLocation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-4" decimals="-6" id="f-38" unitRef="usd">137243000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-6" id="f-39" unitRef="usd">128566000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-6" id="f-40" unitRef="usd">121413000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:PremiumsEarnedNet contextRef="c-1" decimals="-6" id="f-41" unitRef="usd">44237000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-7" decimals="-6" id="f-42" unitRef="usd">39916000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-8" decimals="-6" id="f-43" unitRef="usd">41154000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="-6" id="f-44" unitRef="usd">12619000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-6" id="f-45" unitRef="usd">10881000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="-6" id="f-46" unitRef="usd">9953000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NetInvestmentIncome contextRef="c-1" decimals="-6" id="f-47" unitRef="usd">1166000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome contextRef="c-7" decimals="-6" id="f-48" unitRef="usd">1155000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome contextRef="c-8" decimals="-6" id="f-49" unitRef="usd">1549000000</us-gaap:NetInvestmentIncome>
    <us-gaap:Revenues contextRef="c-1" decimals="-6" id="f-50" unitRef="usd">195265000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-7" decimals="-6" id="f-51" unitRef="usd">180518000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-8" decimals="-6" id="f-52" unitRef="usd">174069000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-6" id="f-53" unitRef="usd">133801000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-7" decimals="-6" id="f-54" unitRef="usd">124834000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-8" decimals="-6" id="f-55" unitRef="usd">117553000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredNet contextRef="c-1" decimals="-6" id="f-56" unitRef="usd">36287000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredNet>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredNet contextRef="c-7" decimals="-6" id="f-57" unitRef="usd">32184000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredNet>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredNet contextRef="c-8" decimals="-6" id="f-58" unitRef="usd">33565000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredNet>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-6" id="f-59" unitRef="usd">14822000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-7" decimals="-6" id="f-60" unitRef="usd">13174000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-8" decimals="-6" id="f-61" unitRef="usd">13012000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-6" id="f-62" unitRef="usd">1819000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-7" decimals="-6" id="f-63" unitRef="usd">1876000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-8" decimals="-6" id="f-64" unitRef="usd">1998000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:BenefitsLossesAndExpenses contextRef="c-1" decimals="-6" id="f-65" unitRef="usd">186729000000</us-gaap:BenefitsLossesAndExpenses>
    <us-gaap:BenefitsLossesAndExpenses contextRef="c-7" decimals="-6" id="f-66" unitRef="usd">172068000000</us-gaap:BenefitsLossesAndExpenses>
    <us-gaap:BenefitsLossesAndExpenses contextRef="c-8" decimals="-6" id="f-67" unitRef="usd">166128000000</us-gaap:BenefitsLossesAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-6" id="f-68" unitRef="usd">8536000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-7" decimals="-6" id="f-69" unitRef="usd">8450000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-8" decimals="-6" id="f-70" unitRef="usd">7941000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-6" id="f-71" unitRef="usd">-1446000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-7" decimals="-6" id="f-72" unitRef="usd">-1228000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-8" decimals="-6" id="f-73" unitRef="usd">-1208000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-1" decimals="-6" id="f-74" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-7" decimals="-6" id="f-75" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-8" decimals="-6" id="f-76" unitRef="usd">-141000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-1" decimals="-6" id="f-77" unitRef="usd">-1499000000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-7" decimals="-6" id="f-78" unitRef="usd">1662000000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-8" decimals="-6" id="f-79" unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <ci:RealizedInvestmentGainLoss contextRef="c-1" decimals="-6" id="f-80" unitRef="usd">-78000000</ci:RealizedInvestmentGainLoss>
    <ci:RealizedInvestmentGainLoss contextRef="c-7" decimals="-6" id="f-81" unitRef="usd">-487000000</ci:RealizedInvestmentGainLoss>
    <ci:RealizedInvestmentGainLoss contextRef="c-8" decimals="-6" id="f-82" unitRef="usd">198000000</ci:RealizedInvestmentGainLoss>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-83" unitRef="usd">5513000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-7" decimals="-6" id="f-84" unitRef="usd">8397000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-8" decimals="-6" id="f-85" unitRef="usd">6790000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-86" unitRef="usd">141000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-7" decimals="-6" id="f-87" unitRef="usd">1615000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-8" decimals="-6" id="f-88" unitRef="usd">1370000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-6" id="f-89" unitRef="usd">5372000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-7" decimals="-6" id="f-90" unitRef="usd">6782000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-8" decimals="-6" id="f-91" unitRef="usd">5420000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-92" unitRef="usd">208000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-7" decimals="-6" id="f-93" unitRef="usd">78000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-8" decimals="-6" id="f-94" unitRef="usd">50000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-1" decimals="-6" id="f-95" unitRef="usd">5164000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-7" decimals="-6" id="f-96" unitRef="usd">6704000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-8" decimals="-6" id="f-97" unitRef="usd">5370000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-98"
      unitRef="usdPerShare">17.57</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-99"
      unitRef="usdPerShare">21.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-8"
      decimals="2"
      id="f-100"
      unitRef="usdPerShare">15.89</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-101"
      unitRef="usdPerShare">17.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-102"
      unitRef="usdPerShare">21.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-8"
      decimals="2"
      id="f-103"
      unitRef="usdPerShare">15.75</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-6" id="f-104" unitRef="usd">5372000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-7" decimals="-6" id="f-105" unitRef="usd">6782000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-8" decimals="-6" id="f-106" unitRef="usd">5420000000</us-gaap:ProfitLoss>
    <ci:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax contextRef="c-1" decimals="-6" id="f-107" unitRef="usd">503000000</ci:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax>
    <ci:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax contextRef="c-7" decimals="-6" id="f-108" unitRef="usd">-1598000000</ci:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax>
    <ci:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax contextRef="c-8" decimals="-6" id="f-109" unitRef="usd">-302000000</ci:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAndDerivativesAdjustmentNetOfTax>
    <ci:OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent contextRef="c-1" decimals="-6" id="f-110" unitRef="usd">-715000000</ci:OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent>
    <ci:OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent contextRef="c-7" decimals="-6" id="f-111" unitRef="usd">509000000</ci:OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent>
    <ci:OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent contextRef="c-8" decimals="-6" id="f-112" unitRef="usd">67000000</ci:OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent>
    <ci:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity contextRef="c-1" decimals="-6" id="f-113" unitRef="usd">5000000</ci:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity>
    <ci:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity contextRef="c-7" decimals="-6" id="f-114" unitRef="usd">77000000</ci:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity>
    <ci:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity contextRef="c-8" decimals="-6" id="f-115" unitRef="usd">-232000000</ci:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxIncludingTemporaryEquity>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-1" decimals="-6" id="f-116" unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-7" decimals="-6" id="f-117" unitRef="usd">-420000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-8" decimals="-6" id="f-118" unitRef="usd">-410000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <ci:OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity contextRef="c-1" decimals="-6" id="f-119" unitRef="usd">-206000000</ci:OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity>
    <ci:OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity contextRef="c-7" decimals="-6" id="f-120" unitRef="usd">-592000000</ci:OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity>
    <ci:OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity contextRef="c-8" decimals="-6" id="f-121" unitRef="usd">-57000000</ci:OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity>
    <ci:ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity contextRef="c-1" decimals="-6" id="f-122" unitRef="usd">5166000000</ci:ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity>
    <ci:ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity contextRef="c-7" decimals="-6" id="f-123" unitRef="usd">6190000000</ci:ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity>
    <ci:ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity contextRef="c-8" decimals="-6" id="f-124" unitRef="usd">5363000000</ci:ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestIncludingTemporaryEquity>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-125" unitRef="usd">180000000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest contextRef="c-7" decimals="-6" id="f-126" unitRef="usd">11000000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest contextRef="c-8" decimals="-6" id="f-127" unitRef="usd">19000000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-128" unitRef="usd">28000000</us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest contextRef="c-7" decimals="-6" id="f-129" unitRef="usd">67000000</us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest contextRef="c-8" decimals="-6" id="f-130" unitRef="usd">31000000</us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest>
    <ci:TemporaryEquityOtherComprehensiveIncome contextRef="c-1" decimals="-6" id="f-131" unitRef="usd">0</ci:TemporaryEquityOtherComprehensiveIncome>
    <ci:TemporaryEquityOtherComprehensiveIncome contextRef="c-7" decimals="-6" id="f-132" unitRef="usd">-2000000</ci:TemporaryEquityOtherComprehensiveIncome>
    <ci:TemporaryEquityOtherComprehensiveIncome contextRef="c-8" decimals="-6" id="f-133" unitRef="usd">-14000000</ci:TemporaryEquityOtherComprehensiveIncome>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-134" unitRef="usd">208000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-7" decimals="-6" id="f-135" unitRef="usd">76000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-8" decimals="-6" id="f-136" unitRef="usd">36000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-6" id="f-137" unitRef="usd">4958000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-7" decimals="-6" id="f-138" unitRef="usd">6114000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-8" decimals="-6" id="f-139" unitRef="usd">5327000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-12" decimals="-6" id="f-140" unitRef="usd">7822000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-13" decimals="-6" id="f-141" unitRef="usd">5924000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments contextRef="c-12" decimals="-6" id="f-142" unitRef="usd">925000000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c-13" decimals="-6" id="f-143" unitRef="usd">905000000</us-gaap:ShortTermInvestments>
    <us-gaap:ReceivablesNetCurrent contextRef="c-12" decimals="-6" id="f-144" unitRef="usd">17722000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent contextRef="c-13" decimals="-6" id="f-145" unitRef="usd">17218000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet contextRef="c-12" decimals="-6" id="f-146" unitRef="usd">5645000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-13" decimals="-6" id="f-147" unitRef="usd">4777000000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent contextRef="c-12" decimals="-6" id="f-148" unitRef="usd">2169000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-13" decimals="-6" id="f-149" unitRef="usd">1298000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c-12" decimals="-6" id="f-150" unitRef="usd">3068000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c-13" decimals="-6" id="f-151" unitRef="usd">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsCurrent contextRef="c-12" decimals="-6" id="f-152" unitRef="usd">37351000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-13" decimals="-6" id="f-153" unitRef="usd">30122000000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments contextRef="c-12" decimals="-6" id="f-154" unitRef="usd">17985000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c-13" decimals="-6" id="f-155" unitRef="usd">16288000000</us-gaap:LongTermInvestments>
    <ci:ReinsuranceRecoverablesNonCurrent contextRef="c-12" decimals="-6" id="f-156" unitRef="usd">4835000000</ci:ReinsuranceRecoverablesNonCurrent>
    <ci:ReinsuranceRecoverablesNonCurrent contextRef="c-13" decimals="-6" id="f-157" unitRef="usd">5416000000</ci:ReinsuranceRecoverablesNonCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-12" decimals="-6" id="f-158" unitRef="usd">3695000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-13" decimals="-6" id="f-159" unitRef="usd">3774000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:Goodwill contextRef="c-12" decimals="-6" id="f-160" unitRef="usd">44259000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-13" decimals="-6" id="f-161" unitRef="usd">45811000000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-12" decimals="-6" id="f-162" unitRef="usd">30863000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-13" decimals="-6" id="f-163" unitRef="usd">32492000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-12" decimals="-6" id="f-164" unitRef="usd">3421000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-13" decimals="-6" id="f-165" unitRef="usd">2704000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:SeparateAccountAssets contextRef="c-12" decimals="-6" id="f-166" unitRef="usd">7430000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets contextRef="c-13" decimals="-6" id="f-167" unitRef="usd">7278000000</us-gaap:SeparateAccountAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent contextRef="c-12" decimals="-6" id="f-168" unitRef="usd">2922000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent contextRef="c-13" decimals="-6" id="f-169" unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-12" decimals="-6" id="f-170" unitRef="usd">152761000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-13" decimals="-6" id="f-171" unitRef="usd">143885000000</us-gaap:Assets>
    <ci:InsuranceAndContractholderLiabilitiesCurrent contextRef="c-12" decimals="-6" id="f-172" unitRef="usd">5514000000</ci:InsuranceAndContractholderLiabilitiesCurrent>
    <ci:InsuranceAndContractholderLiabilitiesCurrent contextRef="c-13" decimals="-6" id="f-173" unitRef="usd">5409000000</ci:InsuranceAndContractholderLiabilitiesCurrent>
    <ci:PharmacyAndServiceCostsPayable contextRef="c-12" decimals="-6" id="f-174" unitRef="usd">19815000000</ci:PharmacyAndServiceCostsPayable>
    <ci:PharmacyAndServiceCostsPayable contextRef="c-13" decimals="-6" id="f-175" unitRef="usd">17070000000</ci:PharmacyAndServiceCostsPayable>
    <us-gaap:AccountsPayableCurrent contextRef="c-12" decimals="-6" id="f-176" unitRef="usd">8553000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-13" decimals="-6" id="f-177" unitRef="usd">7775000000</us-gaap:AccountsPayableCurrent>
    <ci:AccruedExpensesAndOtherLiabilities contextRef="c-12" decimals="-6" id="f-178" unitRef="usd">9955000000</ci:AccruedExpensesAndOtherLiabilities>
    <ci:AccruedExpensesAndOtherLiabilities contextRef="c-13" decimals="-6" id="f-179" unitRef="usd">7978000000</ci:AccruedExpensesAndOtherLiabilities>
    <us-gaap:DebtCurrent contextRef="c-12" decimals="-6" id="f-180" unitRef="usd">2775000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent contextRef="c-13" decimals="-6" id="f-181" unitRef="usd">2993000000</us-gaap:DebtCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c-12" decimals="-6" id="f-182" unitRef="usd">2104000000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c-13" decimals="-6" id="f-183" unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-12" decimals="-6" id="f-184" unitRef="usd">48716000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-13" decimals="-6" id="f-185" unitRef="usd">41225000000</us-gaap:LiabilitiesCurrent>
    <ci:InsuranceAndContractholderLiabilitiesNoncurrent contextRef="c-12" decimals="-6" id="f-186" unitRef="usd">10904000000</ci:InsuranceAndContractholderLiabilitiesNoncurrent>
    <ci:InsuranceAndContractholderLiabilitiesNoncurrent contextRef="c-13" decimals="-6" id="f-187" unitRef="usd">11976000000</ci:InsuranceAndContractholderLiabilitiesNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-12" decimals="-6" id="f-188" unitRef="usd">7173000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-13" decimals="-6" id="f-189" unitRef="usd">7786000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-12" decimals="-6" id="f-190" unitRef="usd">3441000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-13" decimals="-6" id="f-191" unitRef="usd">2766000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c-12" decimals="-6" id="f-192" unitRef="usd">28155000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c-13" decimals="-6" id="f-193" unitRef="usd">28100000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:SeparateAccountsLiability contextRef="c-12" decimals="-6" id="f-194" unitRef="usd">7430000000</us-gaap:SeparateAccountsLiability>
    <us-gaap:SeparateAccountsLiability contextRef="c-13" decimals="-6" id="f-195" unitRef="usd">7278000000</us-gaap:SeparateAccountsLiability>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent contextRef="c-12" decimals="-6" id="f-196" unitRef="usd">591000000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent contextRef="c-13" decimals="-6" id="f-197" unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:Liabilities contextRef="c-12" decimals="-6" id="f-198" unitRef="usd">106410000000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-13" decimals="-6" id="f-199" unitRef="usd">99131000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-12" id="f-200" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-13" id="f-201" unitRef="usd" xsi:nil="true"/>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount contextRef="c-12" decimals="-6" id="f-202" unitRef="usd">107000000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount contextRef="c-13" decimals="-6" id="f-203" unitRef="usd">66000000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockValue contextRef="c-12" decimals="-6" id="f-204" unitRef="usd">4000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-13" decimals="-6" id="f-205" unitRef="usd">4000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-12" decimals="-6" id="f-206" unitRef="usd">30669000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-13" decimals="-6" id="f-207" unitRef="usd">30233000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-12" decimals="-6" id="f-208" unitRef="usd">-1864000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-13" decimals="-6" id="f-209" unitRef="usd">-1658000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-12" decimals="-6" id="f-210" unitRef="usd">41652000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-13" decimals="-6" id="f-211" unitRef="usd">37940000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockValue contextRef="c-12" decimals="-6" id="f-212" unitRef="usd">24238000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue contextRef="c-13" decimals="-6" id="f-213" unitRef="usd">21844000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="-6" id="f-214" unitRef="usd">46223000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-13" decimals="-6" id="f-215" unitRef="usd">44675000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c-12" decimals="-6" id="f-216" unitRef="usd">21000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c-13" decimals="-6" id="f-217" unitRef="usd">13000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-12" decimals="-6" id="f-218" unitRef="usd">46244000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-13" decimals="-6" id="f-219" unitRef="usd">44688000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-12" decimals="-6" id="f-220" unitRef="usd">152761000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-13" decimals="-6" id="f-221" unitRef="usd">143885000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-13"
      decimals="INF"
      id="f-222"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-12"
      decimals="INF"
      id="f-223"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="c-12" decimals="-6" id="f-224" unitRef="shares">400000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-13" decimals="-6" id="f-225" unitRef="shares">398000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-12"
      decimals="INF"
      id="f-226"
      unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-13"
      decimals="INF"
      id="f-227"
      unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-14" decimals="-6" id="f-228" unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-15" decimals="-6" id="f-229" unitRef="usd">28975000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-16" decimals="-6" id="f-230" unitRef="usd">-861000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-17" decimals="-6" id="f-231" unitRef="usd">28575000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-18" decimals="-6" id="f-232" unitRef="usd">-6372000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-19" decimals="-6" id="f-233" unitRef="usd">50321000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-20" decimals="-6" id="f-234" unitRef="usd">7000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-21" decimals="-6" id="f-235" unitRef="usd">50328000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="c-21" decimals="-6" id="f-236" unitRef="usd">58000000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-22" decimals="-6" id="f-238" unitRef="usd">-164000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-23" decimals="-6" id="f-239" unitRef="usd">25000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-24" decimals="-6" id="f-240" unitRef="usd">-139000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-25" decimals="-6" id="f-241" unitRef="usd">-139000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-26" decimals="-6" id="f-242" unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-27" decimals="-6" id="f-243" unitRef="usd">28975000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-28" decimals="-6" id="f-244" unitRef="usd">-1025000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-29" decimals="-6" id="f-245" unitRef="usd">28600000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-30" decimals="-6" id="f-246" unitRef="usd">-6372000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-31" decimals="-6" id="f-247" unitRef="usd">50182000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-32" decimals="-6" id="f-248" unitRef="usd">7000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-33" decimals="-6" id="f-249" unitRef="usd">50189000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="c-33" decimals="-6" id="f-250" unitRef="usd">58000000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-34" decimals="-6" id="f-251" unitRef="usd">604000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-35" decimals="-6" id="f-252" unitRef="usd">-93000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-36" decimals="-6" id="f-253" unitRef="usd">511000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-8" decimals="-6" id="f-254" unitRef="usd">511000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-37" decimals="-6" id="f-255" unitRef="usd">-43000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-36" decimals="-6" id="f-256" unitRef="usd">-43000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-8" decimals="-6" id="f-257" unitRef="usd">-43000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <ci:TemporaryEquityOtherComprehensiveIncome contextRef="c-8" decimals="-6" id="f-258" unitRef="usd">-14000000</ci:TemporaryEquityOtherComprehensiveIncome>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-38" decimals="-6" id="f-259" unitRef="usd">5370000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-36" decimals="-6" id="f-260" unitRef="usd">5370000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-39" decimals="-6" id="f-261" unitRef="usd">31000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-8" decimals="-6" id="f-262" unitRef="usd">5401000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:TemporaryEquityNetIncome contextRef="c-8" decimals="-6" id="f-263" unitRef="usd">19000000</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-8"
      decimals="INF"
      id="f-264"
      unitRef="usdPerShare">4.00</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash contextRef="c-38" decimals="-6" id="f-265" unitRef="usd">1347000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-36" decimals="-6" id="f-266" unitRef="usd">1347000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-8" decimals="-6" id="f-267" unitRef="usd">1347000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-35" decimals="-6" id="f-268" unitRef="usd">7710000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-36" decimals="-6" id="f-269" unitRef="usd">7710000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-8" decimals="-6" id="f-270" unitRef="usd">7710000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <ci:NoncontrollingInterestOtherChanges contextRef="c-34" decimals="-6" id="f-271" unitRef="usd">-5000000</ci:NoncontrollingInterestOtherChanges>
    <ci:NoncontrollingInterestOtherChanges contextRef="c-36" decimals="-6" id="f-272" unitRef="usd">-5000000</ci:NoncontrollingInterestOtherChanges>
    <ci:NoncontrollingInterestOtherChanges contextRef="c-39" decimals="-6" id="f-273" unitRef="usd">-20000000</ci:NoncontrollingInterestOtherChanges>
    <ci:NoncontrollingInterestOtherChanges contextRef="c-8" decimals="-6" id="f-274" unitRef="usd">-25000000</ci:NoncontrollingInterestOtherChanges>
    <us-gaap:TemporaryEquityOtherChanges contextRef="c-8" decimals="-6" id="f-275" unitRef="usd">-9000000</us-gaap:TemporaryEquityOtherChanges>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-40" decimals="-6" id="f-276" unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-41" decimals="-6" id="f-277" unitRef="usd">29574000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-42" decimals="-6" id="f-278" unitRef="usd">-1068000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-43" decimals="-6" id="f-279" unitRef="usd">32623000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-44" decimals="-6" id="f-280" unitRef="usd">-14175000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-6" id="f-281" unitRef="usd">46958000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-46" decimals="-6" id="f-282" unitRef="usd">18000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-47" decimals="-6" id="f-283" unitRef="usd">46976000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="c-47" decimals="-6" id="f-284" unitRef="usd">54000000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-48" decimals="-6" id="f-285" unitRef="usd">659000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-49" decimals="-6" id="f-286" unitRef="usd">-76000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-50" decimals="-6" id="f-287" unitRef="usd">583000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-7" decimals="-6" id="f-288" unitRef="usd">583000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-51" decimals="-6" id="f-289" unitRef="usd">-590000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-50" decimals="-6" id="f-290" unitRef="usd">-590000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-7" decimals="-6" id="f-291" unitRef="usd">-590000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <ci:TemporaryEquityOtherComprehensiveIncome contextRef="c-7" decimals="-6" id="f-292" unitRef="usd">-2000000</ci:TemporaryEquityOtherComprehensiveIncome>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-52" decimals="-6" id="f-293" unitRef="usd">6704000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-50" decimals="-6" id="f-294" unitRef="usd">6704000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-53" decimals="-6" id="f-295" unitRef="usd">67000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-7" decimals="-6" id="f-296" unitRef="usd">6771000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:TemporaryEquityNetIncome contextRef="c-7" decimals="-6" id="f-297" unitRef="usd">11000000</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-7"
      decimals="INF"
      id="f-298"
      unitRef="usdPerShare">4.48</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash contextRef="c-52" decimals="-6" id="f-299" unitRef="usd">1387000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-50" decimals="-6" id="f-300" unitRef="usd">1387000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-7" decimals="-6" id="f-301" unitRef="usd">1387000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-49" decimals="-6" id="f-302" unitRef="usd">7593000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-50" decimals="-6" id="f-303" unitRef="usd">7593000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-7" decimals="-6" id="f-304" unitRef="usd">7593000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <ci:NoncontrollingInterestOtherChanges contextRef="c-48" decimals="-6" id="f-305" unitRef="usd">0</ci:NoncontrollingInterestOtherChanges>
    <ci:NoncontrollingInterestOtherChanges contextRef="c-50" decimals="-6" id="f-306" unitRef="usd">0</ci:NoncontrollingInterestOtherChanges>
    <ci:NoncontrollingInterestOtherChanges contextRef="c-53" decimals="-6" id="f-307" unitRef="usd">-72000000</ci:NoncontrollingInterestOtherChanges>
    <ci:NoncontrollingInterestOtherChanges contextRef="c-7" decimals="-6" id="f-308" unitRef="usd">-72000000</ci:NoncontrollingInterestOtherChanges>
    <us-gaap:TemporaryEquityOtherChanges contextRef="c-7" decimals="-6" id="f-309" unitRef="usd">3000000</us-gaap:TemporaryEquityOtherChanges>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-54" decimals="-6" id="f-310" unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-55" decimals="-6" id="f-311" unitRef="usd">30233000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-56" decimals="-6" id="f-312" unitRef="usd">-1658000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-57" decimals="-6" id="f-313" unitRef="usd">37940000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-58" decimals="-6" id="f-314" unitRef="usd">-21844000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-59" decimals="-6" id="f-315" unitRef="usd">44675000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-60" decimals="-6" id="f-316" unitRef="usd">13000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-13" decimals="-6" id="f-317" unitRef="usd">44688000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="c-13" decimals="-6" id="f-318" unitRef="usd">66000000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-61" decimals="-6" id="f-319" unitRef="usd">477000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-62" decimals="-6" id="f-320" unitRef="usd">-112000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-63" decimals="-6" id="f-321" unitRef="usd">365000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-1" decimals="-6" id="f-322" unitRef="usd">365000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-64" decimals="-6" id="f-323" unitRef="usd">-206000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-63" decimals="-6" id="f-324" unitRef="usd">-206000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-6" id="f-325" unitRef="usd">-206000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <ci:TemporaryEquityOtherComprehensiveIncome contextRef="c-1" decimals="-6" id="f-326" unitRef="usd">0</ci:TemporaryEquityOtherComprehensiveIncome>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-65" decimals="-6" id="f-327" unitRef="usd">5164000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-63" decimals="-6" id="f-328" unitRef="usd">5164000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-66" decimals="-6" id="f-329" unitRef="usd">28000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-330" unitRef="usd">5192000000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:TemporaryEquityNetIncome contextRef="c-1" decimals="-6" id="f-331" unitRef="usd">180000000</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-1"
      decimals="INF"
      id="f-332"
      unitRef="usdPerShare">4.92</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash contextRef="c-65" decimals="-6" id="f-333" unitRef="usd">1452000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-63" decimals="-6" id="f-334" unitRef="usd">1452000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-1" decimals="-6" id="f-335" unitRef="usd">1452000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-61" decimals="-6" id="f-336" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-62" decimals="-6" id="f-337" unitRef="usd">2282000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-63" decimals="-6" id="f-338" unitRef="usd">2282000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-1" decimals="-6" id="f-339" unitRef="usd">2282000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <ci:NoncontrollingInterestOtherChanges contextRef="c-61" decimals="-6" id="f-340" unitRef="usd">-41000000</ci:NoncontrollingInterestOtherChanges>
    <ci:NoncontrollingInterestOtherChanges contextRef="c-63" decimals="-6" id="f-341" unitRef="usd">-41000000</ci:NoncontrollingInterestOtherChanges>
    <ci:NoncontrollingInterestOtherChanges contextRef="c-66" decimals="-6" id="f-342" unitRef="usd">-20000000</ci:NoncontrollingInterestOtherChanges>
    <ci:NoncontrollingInterestOtherChanges contextRef="c-1" decimals="-6" id="f-343" unitRef="usd">-61000000</ci:NoncontrollingInterestOtherChanges>
    <us-gaap:TemporaryEquityOtherChanges contextRef="c-1" decimals="-6" id="f-344" unitRef="usd">-139000000</us-gaap:TemporaryEquityOtherChanges>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-67" decimals="-6" id="f-345" unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-68" decimals="-6" id="f-346" unitRef="usd">30669000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-69" decimals="-6" id="f-347" unitRef="usd">-1864000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-70" decimals="-6" id="f-348" unitRef="usd">41652000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-71" decimals="-6" id="f-349" unitRef="usd">-24238000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-72" decimals="-6" id="f-350" unitRef="usd">46223000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-73" decimals="-6" id="f-351" unitRef="usd">21000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-12" decimals="-6" id="f-352" unitRef="usd">46244000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="c-12" decimals="-6" id="f-353" unitRef="usd">107000000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-6" id="f-354" unitRef="usd">5372000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-7" decimals="-6" id="f-355" unitRef="usd">6782000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-8" decimals="-6" id="f-356" unitRef="usd">5420000000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-6" id="f-357" unitRef="usd">3035000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-7" decimals="-6" id="f-358" unitRef="usd">2937000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-8" decimals="-6" id="f-359" unitRef="usd">2923000000</us-gaap:DepreciationDepletionAndAmortization>
    <ci:RealizedInvestmentGainLoss contextRef="c-1" decimals="-6" id="f-360" unitRef="usd">-78000000</ci:RealizedInvestmentGainLoss>
    <ci:RealizedInvestmentGainLoss contextRef="c-7" decimals="-6" id="f-361" unitRef="usd">-487000000</ci:RealizedInvestmentGainLoss>
    <ci:RealizedInvestmentGainLoss contextRef="c-8" decimals="-6" id="f-362" unitRef="usd">198000000</ci:RealizedInvestmentGainLoss>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes contextRef="c-1" decimals="-6" id="f-363" unitRef="usd">1659000000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes contextRef="c-7" decimals="-6" id="f-364" unitRef="usd">472000000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes contextRef="c-8" decimals="-6" id="f-365" unitRef="usd">216000000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-1" decimals="-6" id="f-366" unitRef="usd">-1499000000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-7" decimals="-6" id="f-367" unitRef="usd">1662000000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-8" decimals="-6" id="f-368" unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-1" decimals="-6" id="f-369" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-7" decimals="-6" id="f-370" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-8" decimals="-6" id="f-371" unitRef="usd">-141000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="c-1" decimals="-6" id="f-372" unitRef="usd">1663000000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="c-7" decimals="-6" id="f-373" unitRef="usd">2237000000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="c-8" decimals="-6" id="f-374" unitRef="usd">2843000000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-6" id="f-375" unitRef="usd">868000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-7" decimals="-6" id="f-376" unitRef="usd">1055000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-8" decimals="-6" id="f-377" unitRef="usd">557000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInReinsuranceRecoverable contextRef="c-1" decimals="-6" id="f-378" unitRef="usd">539000000</us-gaap:IncreaseDecreaseInReinsuranceRecoverable>
    <us-gaap:IncreaseDecreaseInReinsuranceRecoverable contextRef="c-7" decimals="-6" id="f-379" unitRef="usd">-393000000</us-gaap:IncreaseDecreaseInReinsuranceRecoverable>
    <us-gaap:IncreaseDecreaseInReinsuranceRecoverable contextRef="c-8" decimals="-6" id="f-380" unitRef="usd">655000000</us-gaap:IncreaseDecreaseInReinsuranceRecoverable>
    <us-gaap:IncreaseDecreaseInInsuranceLiabilities contextRef="c-1" decimals="-6" id="f-381" unitRef="usd">584000000</us-gaap:IncreaseDecreaseInInsuranceLiabilities>
    <us-gaap:IncreaseDecreaseInInsuranceLiabilities contextRef="c-7" decimals="-6" id="f-382" unitRef="usd">-336000000</us-gaap:IncreaseDecreaseInInsuranceLiabilities>
    <us-gaap:IncreaseDecreaseInInsuranceLiabilities contextRef="c-8" decimals="-6" id="f-383" unitRef="usd">805000000</us-gaap:IncreaseDecreaseInInsuranceLiabilities>
    <ci:IncreaseDecreaseInPharmacyAndServiceCostsPayable contextRef="c-1" decimals="-6" id="f-384" unitRef="usd">2030000000</ci:IncreaseDecreaseInPharmacyAndServiceCostsPayable>
    <ci:IncreaseDecreaseInPharmacyAndServiceCostsPayable contextRef="c-7" decimals="-6" id="f-385" unitRef="usd">1760000000</ci:IncreaseDecreaseInPharmacyAndServiceCostsPayable>
    <ci:IncreaseDecreaseInPharmacyAndServiceCostsPayable contextRef="c-8" decimals="-6" id="f-386" unitRef="usd">1961000000</ci:IncreaseDecreaseInPharmacyAndServiceCostsPayable>
    <ci:IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities contextRef="c-1" decimals="-6" id="f-387" unitRef="usd">3481000000</ci:IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities>
    <ci:IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities contextRef="c-7" decimals="-6" id="f-388" unitRef="usd">1734000000</ci:IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities>
    <ci:IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities contextRef="c-8" decimals="-6" id="f-389" unitRef="usd">77000000</ci:IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-1" decimals="-6" id="f-390" unitRef="usd">-463000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-7" decimals="-6" id="f-391" unitRef="usd">-325000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-8" decimals="-6" id="f-392" unitRef="usd">-333000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-6" id="f-393" unitRef="usd">11813000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-7" decimals="-6" id="f-394" unitRef="usd">8656000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-8" decimals="-6" id="f-395" unitRef="usd">7191000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <ci:ProceedsFromSaleOfDebtAndEquitySecurities contextRef="c-1" decimals="-6" id="f-396" unitRef="usd">1078000000</ci:ProceedsFromSaleOfDebtAndEquitySecurities>
    <ci:ProceedsFromSaleOfDebtAndEquitySecurities contextRef="c-7" decimals="-6" id="f-397" unitRef="usd">1744000000</ci:ProceedsFromSaleOfDebtAndEquitySecurities>
    <ci:ProceedsFromSaleOfDebtAndEquitySecurities contextRef="c-8" decimals="-6" id="f-398" unitRef="usd">2030000000</ci:ProceedsFromSaleOfDebtAndEquitySecurities>
    <ci:ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities contextRef="c-1" decimals="-6" id="f-399" unitRef="usd">972000000</ci:ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities>
    <ci:ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities contextRef="c-7" decimals="-6" id="f-400" unitRef="usd">1327000000</ci:ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities>
    <ci:ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities contextRef="c-8" decimals="-6" id="f-401" unitRef="usd">1628000000</ci:ProceedsFromMaturitiesPrepaymentsAndCallsOfDebtAndEquitySecurities>
    <us-gaap:ProceedsFromCollectionOfLoansReceivable contextRef="c-1" decimals="-6" id="f-402" unitRef="usd">186000000</us-gaap:ProceedsFromCollectionOfLoansReceivable>
    <us-gaap:ProceedsFromCollectionOfLoansReceivable contextRef="c-7" decimals="-6" id="f-403" unitRef="usd">98000000</us-gaap:ProceedsFromCollectionOfLoansReceivable>
    <us-gaap:ProceedsFromCollectionOfLoansReceivable contextRef="c-8" decimals="-6" id="f-404" unitRef="usd">180000000</us-gaap:ProceedsFromCollectionOfLoansReceivable>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments contextRef="c-1" decimals="-6" id="f-405" unitRef="usd">586000000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments contextRef="c-7" decimals="-6" id="f-406" unitRef="usd">1039000000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments contextRef="c-8" decimals="-6" id="f-407" unitRef="usd">1936000000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <ci:PaymentsToAcquireDebtAndEquitySecurities contextRef="c-1" decimals="-6" id="f-408" unitRef="usd">4334000000</ci:PaymentsToAcquireDebtAndEquitySecurities>
    <ci:PaymentsToAcquireDebtAndEquitySecurities contextRef="c-7" decimals="-6" id="f-409" unitRef="usd">2756000000</ci:PaymentsToAcquireDebtAndEquitySecurities>
    <ci:PaymentsToAcquireDebtAndEquitySecurities contextRef="c-8" decimals="-6" id="f-410" unitRef="usd">3553000000</ci:PaymentsToAcquireDebtAndEquitySecurities>
    <us-gaap:PaymentsToAcquireMortgageNotesReceivable contextRef="c-1" decimals="-6" id="f-411" unitRef="usd">118000000</us-gaap:PaymentsToAcquireMortgageNotesReceivable>
    <us-gaap:PaymentsToAcquireMortgageNotesReceivable contextRef="c-7" decimals="-6" id="f-412" unitRef="usd">161000000</us-gaap:PaymentsToAcquireMortgageNotesReceivable>
    <us-gaap:PaymentsToAcquireMortgageNotesReceivable contextRef="c-8" decimals="-6" id="f-413" unitRef="usd">327000000</us-gaap:PaymentsToAcquireMortgageNotesReceivable>
    <us-gaap:PaymentsToAcquireOtherInvestments contextRef="c-1" decimals="-6" id="f-414" unitRef="usd">1205000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments contextRef="c-7" decimals="-6" id="f-415" unitRef="usd">1563000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments contextRef="c-8" decimals="-6" id="f-416" unitRef="usd">2554000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <ci:PaymentsForProceedsFromPropertyPlantAndEquipment contextRef="c-1" decimals="-6" id="f-417" unitRef="usd">1573000000</ci:PaymentsForProceedsFromPropertyPlantAndEquipment>
    <ci:PaymentsForProceedsFromPropertyPlantAndEquipment contextRef="c-7" decimals="-6" id="f-418" unitRef="usd">1295000000</ci:PaymentsForProceedsFromPropertyPlantAndEquipment>
    <ci:PaymentsForProceedsFromPropertyPlantAndEquipment contextRef="c-8" decimals="-6" id="f-419" unitRef="usd">1154000000</ci:PaymentsForProceedsFromPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-1" decimals="-6" id="f-420" unitRef="usd">447000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-7" decimals="-6" id="f-421" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-8" decimals="-6" id="f-422" unitRef="usd">1833000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested contextRef="c-1" decimals="-6" id="f-423" unitRef="usd">13000000</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested contextRef="c-7" decimals="-6" id="f-424" unitRef="usd">4835000000</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested contextRef="c-8" decimals="-6" id="f-425" unitRef="usd">-61000000</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-1" decimals="-6" id="f-426" unitRef="usd">332000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-7" decimals="-6" id="f-427" unitRef="usd">170000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-8" decimals="-6" id="f-428" unitRef="usd">-97000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-6" id="f-429" unitRef="usd">-5174000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-7" decimals="-6" id="f-430" unitRef="usd">3098000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-8" decimals="-6" id="f-431" unitRef="usd">-3611000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:AdditionsToContractHoldersFunds contextRef="c-1" decimals="-6" id="f-432" unitRef="usd">167000000</us-gaap:AdditionsToContractHoldersFunds>
    <us-gaap:AdditionsToContractHoldersFunds contextRef="c-7" decimals="-6" id="f-433" unitRef="usd">164000000</us-gaap:AdditionsToContractHoldersFunds>
    <us-gaap:AdditionsToContractHoldersFunds contextRef="c-8" decimals="-6" id="f-434" unitRef="usd">153000000</us-gaap:AdditionsToContractHoldersFunds>
    <us-gaap:WithdrawalFromContractHoldersFunds contextRef="c-1" decimals="-6" id="f-435" unitRef="usd">223000000</us-gaap:WithdrawalFromContractHoldersFunds>
    <us-gaap:WithdrawalFromContractHoldersFunds contextRef="c-7" decimals="-6" id="f-436" unitRef="usd">220000000</us-gaap:WithdrawalFromContractHoldersFunds>
    <us-gaap:WithdrawalFromContractHoldersFunds contextRef="c-8" decimals="-6" id="f-437" unitRef="usd">168000000</us-gaap:WithdrawalFromContractHoldersFunds>
    <ci:ProceedsFromRepaymentsOfOtherShortTermDebt contextRef="c-1" decimals="-6" id="f-438" unitRef="usd">1198000000</ci:ProceedsFromRepaymentsOfOtherShortTermDebt>
    <ci:ProceedsFromRepaymentsOfOtherShortTermDebt contextRef="c-7" decimals="-6" id="f-439" unitRef="usd">-2059000000</ci:ProceedsFromRepaymentsOfOtherShortTermDebt>
    <ci:ProceedsFromRepaymentsOfOtherShortTermDebt contextRef="c-8" decimals="-6" id="f-440" unitRef="usd">975000000</ci:ProceedsFromRepaymentsOfOtherShortTermDebt>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts contextRef="c-1" decimals="-6" id="f-441" unitRef="usd">0</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts contextRef="c-7" decimals="-6" id="f-442" unitRef="usd">0</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts contextRef="c-8" decimals="-6" id="f-443" unitRef="usd">136000000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-1" decimals="-6" id="f-444" unitRef="usd">2967000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-7" decimals="-6" id="f-445" unitRef="usd">500000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-8" decimals="-6" id="f-446" unitRef="usd">4578000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-1" decimals="-6" id="f-447" unitRef="usd">1491000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-7" decimals="-6" id="f-448" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-8" decimals="-6" id="f-449" unitRef="usd">4260000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-1" decimals="-6" id="f-450" unitRef="usd">2284000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-7" decimals="-6" id="f-451" unitRef="usd">7607000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-8" decimals="-6" id="f-452" unitRef="usd">7742000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-6" id="f-453" unitRef="usd">187000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-7" decimals="-6" id="f-454" unitRef="usd">389000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-8" decimals="-6" id="f-455" unitRef="usd">326000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-1" decimals="-6" id="f-456" unitRef="usd">1450000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-7" decimals="-6" id="f-457" unitRef="usd">1384000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-8" decimals="-6" id="f-458" unitRef="usd">1341000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-1" decimals="-6" id="f-459" unitRef="usd">-413000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-7" decimals="-6" id="f-460" unitRef="usd">-23000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-8" decimals="-6" id="f-461" unitRef="usd">39000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-6" id="f-462" unitRef="usd">-4294000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-7" decimals="-6" id="f-463" unitRef="usd">-11240000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-8" decimals="-6" id="f-464" unitRef="usd">-8212000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-1" decimals="-6" id="f-465" unitRef="usd">16000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-7" decimals="-6" id="f-466" unitRef="usd">-86000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-8" decimals="-6" id="f-467" unitRef="usd">-65000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-6" id="f-468" unitRef="usd">2361000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-7" decimals="-6" id="f-469" unitRef="usd">428000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-8" decimals="-6" id="f-470" unitRef="usd">-4697000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-13" decimals="-6" id="f-471" unitRef="usd">5976000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-47" decimals="-6" id="f-472" unitRef="usd">5548000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-33" decimals="-6" id="f-473" unitRef="usd">10245000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-12" decimals="-6" id="f-474" unitRef="usd">8337000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-13" decimals="-6" id="f-475" unitRef="usd">5976000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-47" decimals="-6" id="f-476" unitRef="usd">5548000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations contextRef="c-12" decimals="-6" id="f-477" unitRef="usd">467000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations contextRef="c-13" decimals="-6" id="f-478" unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations contextRef="c-47" decimals="-6" id="f-479" unitRef="usd">425000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-12" decimals="-6" id="f-480" unitRef="usd">7870000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-13" decimals="-6" id="f-481" unitRef="usd">5976000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-47" decimals="-6" id="f-482" unitRef="usd">5123000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-6" id="f-483" unitRef="usd">1471000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-7" decimals="-6" id="f-484" unitRef="usd">1850000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-8" decimals="-6" id="f-485" unitRef="usd">2240000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-6" id="f-486" unitRef="usd">1330000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-7" decimals="-6" id="f-487" unitRef="usd">1229000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-8" decimals="-6" id="f-488" unitRef="usd">1253000000</us-gaap:InterestPaidNet>
    <us-gaap:NatureOfOperations contextRef="c-1" id="f-489">&lt;div style="margin-bottom:10pt"&gt;&lt;span id="ic54f78bd196a45c4afa77338709a7ea1_5265"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 1 &#x2013; Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Cigna Group, together with its subsidiaries (either individually or collectively referred to as the "Company," "we," "us" or "our"), is a global health company committed to creating a better future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. Powered by our people and our brands, we advance our mission to improve the health and vitality of those we serve. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Our subsidiaries offer a differentiated set of pharmacy, medical, behavioral, dental and related products and services. The majority of these products and services are offered through employers and other groups such as governmental and non-governmental organizations, unions and associations. Cigna Healthcare also offers commercial health and dental insurance and Medicare products to individuals in the United States and selected international markets. In addition to these operations, The Cigna Group also has certain run-off operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A full description of our segments follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Evernorth Health Services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; partners with health plans, employers, governmental organizations and health care providers to solve challenges in the areas of pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty distribution, and care delivery and management solutions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Cigna Healthcare&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; includes the U.S. Healthcare and International Health operating segments which provide comprehensive medical and coordinated solutions to clients and customers. During the fourth quarter of 2023, the U.S. Commercial and U.S. Government operating segments merged to form the U.S. Healthcare operating segment. U.S. Healthcare provides commercial medical plans and specialty benefits and solutions for insured and self-insured clients, Medicare Advantage, Medicare Supplement and Medicare Part D plans for seniors and individual health insurance plans. International Health provides health care solutions in our international markets, as well as health care benefits for globally mobile individuals and employees of multinational organizations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In January 2024, the Company entered into a definitive agreement to sell the Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits and CareAllies businesses within the &lt;span style="-sec-ix-hidden:f-490"&gt;U.S. Healthcare&lt;/span&gt; operating segment to Health Care Service Corporation ("HCSC") for $3.3 billion cash, subject to applicable regulatory approvals and other customary closing conditions (the "HCSC transaction").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Other Operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; comprises the remainder of our business operations, which includes ongoing businesses and exited businesses. Our ongoing businesses include continuing business (corporate-owned life insurance ("COLI")), and our run-off businesses. Our run-off businesses include (i) variable annuity reinsurance business (formerly referred to as guaranteed minimum death benefit ("GMDB") and guaranteed minimum income benefit ("GMIB") business) that was effectively exited through reinsurance with Berkshire Hathaway Life Insurance Company of Nebraska ("Berkshire") in 2013, (ii) settlement annuity business, and (iii) individual life insurance and annuity and retirement benefits businesses which were sold through reinsurance agreements. Our exited businesses include the international life, accident and supplemental benefits businesses sold in July 2022 (the "Chubb transaction") and our interest in a joint venture in T&#xfc;rkiye sold in December 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;reflects amounts not allocated to operating segments, including net interest expense (defined as interest on corporate financing less net investment income on investments not supporting segment and other operations), certain litigation matters, expense associated with our frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs and eliminations for products and services sold between segments.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="c-75" decimals="-8" id="f-491" unitRef="usd">3300000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-492">&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span id="i0260500cfa11442391009e7f8cffe4ab_1054"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 2 &#x2013; Summary of Significant Accounting Policies&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Consolidated Financial Statements include the accounts of The Cigna Group and its consolidated subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. These Consolidated Financial Statements were prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"). Certain amounts in prior years related to the adoption of Targeted Improvements for the Accounting of Long-Duration Contracts, have been reclassified to conform to the current year presentation. See "Recent Accounting Pronouncements" below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amounts recorded in the Consolidated Financial Statements necessarily reflect management's estimates and assumptions about medical costs, investment and receivable valuations, interest rates and other factors. Significant estimates are discussed throughout these Notes; however, actual results could differ from those estimates. The impact of a change in estimate is generally included in earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Targeted Improvements to the Accounting for Long-Duration Contracts, Accounting Standards Update ("ASU") 2018-12 and related amendments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Cigna Group adopted LDTI January 1, 2023, which includes the following key provisions:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Changes to the measurement of the future policy benefits liability for traditional and limited-pay insurance contracts:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Assumptions used to measure cash flows (such as mortality, morbidity and lapse assumptions) are updated at least annually with the effect of changes in those assumptions remeasured retrospectively and reflected in current period net income. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Discount rate assumptions are updated quarterly based on market-level yields for low credit risk fixed income instruments ("upper-medium grade fixed income instrument"), with any changes reflected in other comprehensive income. The upper-medium grade fixed income instrument yield is interpreted to mean A-rated.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Deferred policy acquisition costs ("DAC") related to long-duration insurance contracts are amortized on a constant-level basis over the expected term of the related contracts. Other related deferred or capitalized balances (such as unearned revenue liability and value of business acquired) may use this simplified amortization method. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Market risk benefits ("MRB"), defined as protecting the contractholder from other-than-nominal capital market risk and exposing the insurer to that risk, are measured at fair value, with changes in fair value recognized in net income each period, except for the effect of the Company's change in nonperformance risk (own credit risk), which is recognized in other comprehensive income. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Additional disclosures, including disaggregated roll forwards for the liability for future policy benefits, market risk benefits, contractholder deposit funds and DAC, as well as information about significant inputs, judgments, assumptions and methods used in measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;The transition methods applied at adoption were:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;The liability for future policy benefits was remeasured using a modified retrospective approach applied to all outstanding contracts as of the beginning of the earliest period presented and was recognized in the opening balance of retained earnings. The impact of remeasuring the future policy benefits liability for the discount rate was recorded through accumulated other comprehensive income. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;DAC followed the transition method used for future policyholder benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Market risk benefits were remeasured at fair value at the beginning of the earliest period presented. The difference between this fair value and carrying value was recognized in the opening balance of retained earnings, excluding the effect of the Company's change in nonperformance risk (own credit risk), which was recognized in accumulated other comprehensive income. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Effects of adoption:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;The new guidance applies to our long-duration insurance products predominantly within the Cigna Healthcare segment and Other Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;The cumulative effects of adopting the new standard were immaterial. The impacts were a decrease to January 1, 2021 Shareholders' equity of $139 million and an increase to Shareholders' net income for the years ended December 31, 2022 and December 31, 2021 of $36 million and $5 million, respectively. The corresponding impact to diluted earnings per share was an increase of $0.11 and $0.02 for the years ended December 31, 2022 and December 31, 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;The prior periods within our Consolidated Statements of Income, Consolidated Statements of Comprehensive Income, Consolidated Balance Sheets, Consolidated Statements of Changes in Total Equity and Consolidated Statements of Cash Flows were restated to conform to the current presentation. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Prior period balances in the Company's footnote disclosures have been updated to reflect adjustments resulting from the adoption of this standard. Refer to Note 10 to the Consolidated Financial Statements for the Company's updated accounting policies. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;It is possible that our income recognition pattern could change on a prospective basis for several reasons: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Applying periodic assumption updates, versus the locked-in model, may change our timing of profit or loss recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;DAC amortization is on a constant level basis over the expected term of the related contracts and no longer tied to the emergence of profit on such contracts. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additionally, in December 2022, the Financial Accounting Standards Board ("FASB") published ASU 2022-05, which simplified the retrospective adoption of LDTI by permitting companies to make an accounting policy election to exclude contracts that are sold and removed from the balance sheet prior to the effective date of the standard from the retrospective adoption of LDTI. The Cigna Group made this policy election for the contracts sold in the Chubb transaction and our divested interest in a joint venture in T&#xfc;rkiye. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Accounting Guidance Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;There are no significant accounting pronouncements not yet adopted as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's accounting policies are described either in this Note or in the applicable Notes to the Consolidated Financial Statements as listed in the table of contents on page &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;&lt;a href="#ibc59a92ac8bc42f794e728f24ce1b626_55" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;80&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;A.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash and cash equivalents are carried at cost that approximates fair value. Cash equivalents consist of short-term investments with maturities of three months or less from the time of purchase. The Company reclassifies cash overdraft positions to liabilities when the legal right of offset does not exist.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;B.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Inventories consist of prescription drugs and medical supplies and are stated at the lower of first-in-first-out cost or net realizable value.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline"&gt;Other Assets (Current and Non-Current)&lt;/span&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other current assets consist primarily of prepaid expenses, income tax receivables, accrued investment income and the current portion of reinsurance recoverables. Other assets (non-current) consist primarily of the Company's net deferred tax asset associated with foreign tax attributes (see Note 23) and the carrying value of our equity-method investments in business-related joint ventures in China, the U.S. and other foreign jurisdictions. Earnings or losses from these equity-method investments in joint ventures are recorded in Fees and other revenues. See Note 15 for additional information on unconsolidated subsidiaries. Additionally, Other assets (non-current) includes operating lease right-of-use assets, various insurance-related assets and overfunded pension obligations (see Note 18). See Note 21 for the Company's accounting policy related to leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;D.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline"&gt;Redeemable Noncontrolling Interests&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Redeemable noncontrolling interests in our Consolidated Balance Sheets represents the noncontrolling shareholders' preferred and common stock interests of the Company's consolidated less than fully owned subsidiaries. Those shareholders may choose to require the Company to purchase their equity interest. For certain entities, we may also have the right to require those shareholders to sell their equity interest to us. As these redeemable noncontrolling interests provide for redemption features not solely within our control, we classify the redeemable noncontrolling interests outside of permanent equity. The noncontrolling interest was initially recorded at fair value. In subsequent reporting periods, the values are adjusted to reflect the earnings, losses and distributions attributable to the noncontrolling interest. When a shareholder's right to require the Company to purchase its equity interest is exercisable, the redeemable noncontrolling interest is recorded at estimated redemption value. When the estimated redemption value for a redeemable noncontrolling interest exceeds its initial carrying value, an adjustment to increase or decrease the redeemable noncontrolling interest is recorded with an offsetting adjustment to Retained earnings or Additional paid-in capital in the absence of Retained earnings. When an adjustment is made to the carrying value of the redeemable noncontrolling interest, the calculation of Shareholders' net income per share will be adjusted if the redemption value exceeds fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;E.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline"&gt;Accrued Expenses and Other Current and Non-Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued expenses and other liabilities (current) primarily includes financial and performance guarantee liabilities (see section G) and other liabilities arising from pharmacy contracts, management compensation, various insurance-related liabilities, including experience-rated refunds, reinsurance contracts and the risk adjustment and minimum medical loss ratio rebate accruals under The Patient Protection and Affordable Care Act (the "ACA"), and amounts due to financial institutions under the accounts receivable factoring facility (see Note 3). Other non-current liabilities primarily include uncertain tax positions (see Note 23), amounts held for self-funded clients to cover the administration and payment of claims that may emerge post contract termination, lease liabilities (see Note 21) and underfunded pension obligations (see Note 18).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company accrues for legal and regulatory matters when a loss contingency is both probable and estimable. The estimated loss is generally recorded in Selling, general and administrative expenses and represents the Company's best estimate of the loss contingency. If the loss estimate is a range, the Company accrues the minimum amount in the range if no amount is better than any other estimated amount in the range. Legal costs to defend the Company's litigation and arbitration matters are expensed as incurred in cases that the Company cannot reasonably estimate the ultimate cost to defend. If the Company can reasonably estimate the cost to defend, a liability &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;for these costs is accrued when the claim is reported. Litigation and legal or regulatory matters that the Company has identified with a reasonable possibility of material loss are described in Note 24.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;F.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:9.4pt;text-decoration:underline"&gt;Translation of Foreign Currencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company generally conducts its international business through foreign operating entities that maintain assets and liabilities in local currencies that are their functional currencies. The Company uses exchange rates as of the balance sheet date to translate assets and liabilities into U.S. dollars. Translation gains or losses on functional currencies, net of applicable taxes, are recorded in Accumulated other comprehensive loss. The Company uses average monthly exchange rates during the year to translate revenues and expenses into U.S. dollars.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;G.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:7.73pt;text-decoration:underline"&gt;Pharmacy Revenues and Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Pharmacy revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Pharmacy revenues are primarily derived from providing pharmacy benefit management services to clients and customers. Pharmacy revenues are recognized when control of the promised goods or services is transferred to clients and customers, in an amount that reflects the consideration the Company expects to receive for those goods or services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company provides or makes available various services supporting benefit management and claims administration and is generally obligated to provide prescription drugs to clients' members using multiple distribution methods including retail networks, home delivery and specialty pharmacies. These goods and services are integrated into a single performance obligation to process claims, dispense prescription drugs and provide other services over the contract period (generally three years). This performance obligation is satisfied as the business stands ready to fulfill its obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Revenues for dispensing prescription drugs through retail pharmacies are reported gross and consist of the prescription price (ingredient cost and dispensing fee) contracted with clients, including the customer copayment and any associated fees for services, because the Company acts as the principal in these arrangements. When a prescription is presented to a retail network pharmacy, the Company is solely responsible for customer eligibility, drug utilization review, drug-to-drug interaction review, any required clinical intervention, plan provision information, payment to the pharmacy and client billing. These revenues are recognized based on the full prescription price when the pharmacy claim is processed and approved for payment. The Company also provides benefit design and formulary consultation services to clients and negotiates separate contractual relationships with clients and network pharmacies. These factors indicate that the Company has control over these transactions until the prescription is processed. Revenues are billed, due and recognized at contract rates either on a periodic basis or as services are provided (such as based on volume of claims processed). This recognition pattern aligns with the benefits from services provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Home delivery and specialty pharmacy revenues are due and recognized as each prescription is shipped, net of reserves for discounts and contractual allowances estimated based on historical experience. Any differences between estimates and actual collections are reflected in Pharmacy revenues when payments are received. Historically, adjustments to original estimates and returns have not been material. The Company has elected the practical expedient to account for shipping and handling as a fulfillment activity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We may also provide certain financial and performance guarantees, including a minimum level of discounts a client may receive, generic utilization rates and various service levels. Clients may be entitled to receive compensation if we fail to meet the guarantees. Actual performance is compared to the contractual guarantee for each measure throughout the period and the Company defers revenue for any estimated payouts within Accrued expenses and other liabilities (current). These estimates are adjusted and paid at the end of the annual guarantee period. Historically, adjustments to original estimates have not been material. The liability for these financial and performance guarantees was $1.6 billion as of December&#160;31, 2023 and $1.3 billion as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company administers programs through which we may receive rebates and other vendor consideration from pharmaceutical manufacturers. The amounts of such rebates or other vendor consideration shared with pharmacy benefit management services clients vary based on the contractual arrangement with the client and in some cases the type of consideration received from the pharmaceutical manufacturer. Rebates and other vendor consideration payable to pharmacy benefit management services clients are recorded as a reduction of Pharmacy revenues. Estimated amounts payable to clients are based on contractual sharing arrangements between the Company and the client and these amounts are adjusted when amounts are collected from pharmaceutical manufacturers in accordance with the contractual arrangement between the Company and the client. Historically, these adjustments have not been material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In retail, home delivery and specialty transactions, amounts may be collected from third-party payors. These are billed and collected in accordance with the Company's standard accounts receivable collection procedures. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other pharmacy service revenues are earned by distributing specialty pharmaceuticals and medical supplies to providers, clinics and hospitals. These revenues are billed, due and recognized at contracted rates as prescriptions and supplies are shipped and services are provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Pharmacy costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Pharmacy costs include the cost of prescriptions sold, network pharmacy claim costs and copayments. Also included are direct costs of dispensing prescriptions including supplies, shipping and handling and direct costs associated with clinical programs, such as drug utilization management and medication adherence counseling. Home delivery and specialty pharmacy costs are recognized when the drug is shipped and retail network costs are recognized when the drug is processed and approved for payment. Rebates and other vendor consideration received when providing pharmacy benefit management services are recorded as a reduction of pharmacy costs. Rebates are recognized as prescriptions are shipped or processed and approved for payment. Historically, the effect of adjustments resulting from the reconciliation of rebates recognized to the amounts billed and collected, net of contractual allowances, has not been material. The Company maintains reimbursement guarantees with certain retail network pharmacies. For each such guarantee, the Company records a pharmacy and other service costs payable or prepaid asset for applicable retail network claims based on our actual performance throughout the period against the contractual reimbursement rate. The Company's contracts with certain retail pharmacies give the Company the right to adjust reimbursement rates during the annual guarantee period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Incremental costs of obtaining service and pharmacy contracts for short-term arrangements are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;H.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:7.73pt;text-decoration:underline"&gt;Premiums and Related Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Premiums for short-duration group health, accident and life insurance and managed care coverages are recognized as revenue on a pro rata basis over the contract period. Benefits and expenses are recognized when incurred and, for our Cigna Healthcare business, are presented net of pharmaceutical manufacturer rebates. For experience-rated contracts, premium revenue includes an adjustment for experience-rated refunds based on contract terms and calculated using the customer's experience (including estimates of incurred but not reported claims).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Premiums received for the Company's Medicare Advantage plans, Medicare Part D plans and Individual and Family Plans from the Centers for Medicare and Medicaid Services ("CMS") and customers are recognized as revenue ratably over the contract period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;CMS provides risk-adjusted premium payments for Medicare Advantage plans and Medicare Part D plans based on our customer demographics and medical diagnoses, which may change from period to period based on the underlying health of our customers. The Company recognizes changes to risk-adjusted premiums as revenue when the amounts are determinable and collection is reasonably assured. Revenue adjustments are generally settled semi-annually with CMS. The final revenue adjustment is generally settled with CMS in the year following the contract year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Medicare Part D premiums include payments from CMS for risk-sharing adjustments that are estimated quarterly based on claim experience by comparing actual incurred prescription drug costs to the estimated costs submitted in the original contracts. These adjustments may result in more or less revenue from CMS. Final revenue adjustments generally occur in the year following the contract year. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The ACA prescribed a risk-adjustment program to mitigate the risk for participating health insurance companies selling individual coverage on the public exchanges. The risk-adjustment program reallocates funds from insurers with lower risk populations to insurers with higher risk populations based on the relative risk scores of participants. We estimate our receivable or payable based on the risk of our customers compared to the risk of other customers in the same state and market, considering data obtained from industry studies and the United States Department of Health and Human Services ("HHS"). Receivables or payables are recorded as adjustments to premium revenue based on our year-to-date experience when the amounts are reasonably estimable and collection is reasonably assured. Final revenue adjustments are determined by HHS in the year following the policy year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Premium revenue may also include an adjustment to reflect the estimated effect of rebates due to customers under medical loss ratio provisions of the ACA. These rebate liabilities are settled in the subsequent year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Premiums for long-duration insurance contracts, including individual life, accident and supplemental health insurance and annuity products, and excluding universal life and investment-related products, are recognized as revenue when due. Cigna Healthcare's long-duration premium revenues are associated with contracts that provide coverage greater than one year or are guaranteed to be renewed at the option of the policyholder beyond one year. Benefits and expenses are matched with premiums. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Revenue for universal life products is recognized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Investment income on assets supporting universal life products is recognized in Net investment income as earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Charges for mortality, administration and policy surrender are recognized in Premiums as earned. Administrative fees are considered earned when services are provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Benefits and expenses for universal life products consist of benefit claims in excess of policyholder account balances and income earned by policyholders. Expenses are recognized when claims are incurred and income is credited to policyholders in accordance with contract provisions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The unrecognized portion of premiums received is recorded as unearned premiums included in Insurance and contractholder liabilities (current and non-current) (see Note 10 to the Consolidated Financial Statements for further information).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;I.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:11.61pt;text-decoration:underline"&gt;Fees and Related Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The majority of the Company's service fees are derived from administrative services only ("ASO") arrangements, fee-for-service clinical solutions, Wholesale Marketplace Drug Formulary Management services, health benefit management services and administration of services to specialty pharmacy manufacturers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ASO arrangements allow plan sponsors to self-fund claims and assume the risk of medical or other benefit costs. Most of the Company's ASO arrangements are for medical and specialty solutions, including pharmacy benefits. Generally, the Company's ASO arrangements are short-term. Contract modifications typically occur on renewal and are prospective in nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In return for fees from these clients, the Company provides access to our participating provider networks and other services supporting benefit management, including claims administration, behavioral health services, disease management, utilization management and cost containment programs. In general, the Company considers these services to be a combined performance obligation to provide cost effective administration of plan benefits over the contract period. Fees are billed, due and recognized monthly at contracted rates based on current membership or utilization. This recognition pattern aligns with the benefits from services provided to clients. These revenues are reported in Fees and other revenues in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company may also provide performance guarantees that provide potential refunds to clients if certain service standards, clinical outcomes or financial metrics are not met. If these standards, outcomes and metrics are not met, the Company may be financially at risk up to a stated percentage of the contracted fee or a stated dollar amount. The Company defers revenue by recording a liability for estimated payouts associated with these guarantees within Accrued expenses and other liabilities. The amount of revenue deferred is estimated for each type of guarantee using either a most likely amount or expected value method depending on the nature of the guarantee and the information available to estimate refunds. Estimates are refined each reporting period as additional information on the Company's performance becomes available and upon final reconciliation and settlement following the guarantee period. Amounts accrued and paid for these performance guarantees during the reporting periods were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expenses associated with administrative programs and services are recognized as incurred in Selling, general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company also earns revenue, as part of its integrated pharmacy benefits performance obligation, by offering fee-for-service clinical solutions to our clients, such as drug utilization management and medication adherence counseling. These clinical programs help clients to drive better health outcomes at a lower cost by identifying and addressing potentially unsafe or wasteful prescribing, dispensing and utilization of prescription drugs and communicating with, or supporting communications with physicians, pharmacies and patients. Fees are billed, due and recognized at contracted rates either on a periodic basis or as services are provided. This recognition pattern aligns with the benefits from services provided. These revenues are reported in Fees and other revenues in the Consolidated Statements of Income. Direct costs associated with these programs are recognized in Pharmacy and other service costs, and other related expenses are recorded as incurred in Selling, general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company earns fees from our Wholesale Marketplace Drug Formulary Management services. These services include either our drug formulary administrative service arrangements or our formulary processing arrangements. Drug formulary administrative services may include formulary consultation, administration of rebate contracts, rebate submission, collection from drug manufacturers and the distribution of rebates to clients. Services may also include facilitating audits of data submissions and reporting of rebates to clients. Clients agree to pay administrative fees that are billed, due and recognized at contracted rates as services are performed. These revenues are reported gross in Fees and other revenues and associated costs are reported in Pharmacy and other service costs in the Consolidated Statements of Income. For certain other clients in our formulary processing arrangements, the Company does not control the right to retain rebates before they are transferred to the client for services performed. Clients agree to allow the Company to retain a portion of each rebate collected in exchange for formulary processing services provided. These drug formulary service and administrative fee revenues are reported net in Fees and other revenues in the Consolidated Statements of Income. Revenue is recognized as rebates are processed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company also earns fees by providing health benefit management solutions that drive cost reductions and improve quality outcomes. Clients are primarily sponsors of health benefit plans and fees may be stated as a per-member-per-month fee or as a per-claim fee. The Company considers the services to be a single performance obligation to stand ready to provide utilization management services over the contract period (generally three years). In certain arrangements, the Company assumes the financial obligation for third-party provider costs for medical services provided to the health plan's customers. Fees are recorded gross in Fees and other revenues in the Consolidated Statements of Income because the Company is acting as a principal in arranging for and controlling the services provided by third-party network providers. Contractual fees vary based on enrollment and provider costs and are billed, due &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;and recognized monthly. Direct costs associated with these programs are recognized in Pharmacy and other service costs, and other related expenses are recorded in Selling, general and administrative expenses as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Certain health benefit management contracts require the Company to share the results of medical cost experience that differ from specified targets. This variable consideration is estimated at contract inception and adjusted through the contract period. The estimated profits and costs are recognized net in Fees and other revenues.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company also earns other service fees related to administrating services to specialty pharmacy manufacturers that are recorded in Fees and other revenues in the Consolidated Statements of Income. These revenues are billed, due and recognized at contracted rates as services are provided.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-493">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Consolidated Financial Statements include the accounts of The Cigna Group and its consolidated subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. These Consolidated Financial Statements were prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"). Certain amounts in prior years related to the adoption of Targeted Improvements for the Accounting of Long-Duration Contracts, have been reclassified to conform to the current year presentation. See "Recent Accounting Pronouncements" below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amounts recorded in the Consolidated Financial Statements necessarily reflect management's estimates and assumptions about medical costs, investment and receivable valuations, interest rates and other factors. Significant estimates are discussed throughout these Notes; however, actual results could differ from those estimates. The impact of a change in estimate is generally included in earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-494">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Targeted Improvements to the Accounting for Long-Duration Contracts, Accounting Standards Update ("ASU") 2018-12 and related amendments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Cigna Group adopted LDTI January 1, 2023, which includes the following key provisions:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Changes to the measurement of the future policy benefits liability for traditional and limited-pay insurance contracts:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Assumptions used to measure cash flows (such as mortality, morbidity and lapse assumptions) are updated at least annually with the effect of changes in those assumptions remeasured retrospectively and reflected in current period net income. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Discount rate assumptions are updated quarterly based on market-level yields for low credit risk fixed income instruments ("upper-medium grade fixed income instrument"), with any changes reflected in other comprehensive income. The upper-medium grade fixed income instrument yield is interpreted to mean A-rated.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Deferred policy acquisition costs ("DAC") related to long-duration insurance contracts are amortized on a constant-level basis over the expected term of the related contracts. Other related deferred or capitalized balances (such as unearned revenue liability and value of business acquired) may use this simplified amortization method. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Market risk benefits ("MRB"), defined as protecting the contractholder from other-than-nominal capital market risk and exposing the insurer to that risk, are measured at fair value, with changes in fair value recognized in net income each period, except for the effect of the Company's change in nonperformance risk (own credit risk), which is recognized in other comprehensive income. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Additional disclosures, including disaggregated roll forwards for the liability for future policy benefits, market risk benefits, contractholder deposit funds and DAC, as well as information about significant inputs, judgments, assumptions and methods used in measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;The transition methods applied at adoption were:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;The liability for future policy benefits was remeasured using a modified retrospective approach applied to all outstanding contracts as of the beginning of the earliest period presented and was recognized in the opening balance of retained earnings. The impact of remeasuring the future policy benefits liability for the discount rate was recorded through accumulated other comprehensive income. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;DAC followed the transition method used for future policyholder benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Market risk benefits were remeasured at fair value at the beginning of the earliest period presented. The difference between this fair value and carrying value was recognized in the opening balance of retained earnings, excluding the effect of the Company's change in nonperformance risk (own credit risk), which was recognized in accumulated other comprehensive income. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Effects of adoption:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;The new guidance applies to our long-duration insurance products predominantly within the Cigna Healthcare segment and Other Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;The cumulative effects of adopting the new standard were immaterial. The impacts were a decrease to January 1, 2021 Shareholders' equity of $139 million and an increase to Shareholders' net income for the years ended December 31, 2022 and December 31, 2021 of $36 million and $5 million, respectively. The corresponding impact to diluted earnings per share was an increase of $0.11 and $0.02 for the years ended December 31, 2022 and December 31, 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;The prior periods within our Consolidated Statements of Income, Consolidated Statements of Comprehensive Income, Consolidated Balance Sheets, Consolidated Statements of Changes in Total Equity and Consolidated Statements of Cash Flows were restated to conform to the current presentation. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Prior period balances in the Company's footnote disclosures have been updated to reflect adjustments resulting from the adoption of this standard. Refer to Note 10 to the Consolidated Financial Statements for the Company's updated accounting policies. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;It is possible that our income recognition pattern could change on a prospective basis for several reasons: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Applying periodic assumption updates, versus the locked-in model, may change our timing of profit or loss recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;DAC amortization is on a constant level basis over the expected term of the related contracts and no longer tied to the emergence of profit on such contracts. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additionally, in December 2022, the Financial Accounting Standards Board ("FASB") published ASU 2022-05, which simplified the retrospective adoption of LDTI by permitting companies to make an accounting policy election to exclude contracts that are sold and removed from the balance sheet prior to the effective date of the standard from the retrospective adoption of LDTI. The Cigna Group made this policy election for the contracts sold in the Chubb transaction and our divested interest in a joint venture in T&#xfc;rkiye. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Accounting Guidance Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;There are no significant accounting pronouncements not yet adopted as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-25" decimals="-6" id="f-495" unitRef="usd">-139000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-76" decimals="-6" id="f-496" unitRef="usd">36000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-77" decimals="-6" id="f-497" unitRef="usd">5000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-76"
      decimals="2"
      id="f-498"
      unitRef="usdPerShare">0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-77"
      decimals="2"
      id="f-499"
      unitRef="usdPerShare">0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-500">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash and cash equivalents are carried at cost that approximates fair value. Cash equivalents consist of short-term investments with maturities of three months or less from the time of purchase. The Company reclassifies cash overdraft positions to liabilities when the legal right of offset does not exist.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-501">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Inventories consist of prescription drugs and medical supplies and are stated at the lower of first-in-first-out cost or net realizable value.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <ci:OtherAssetsCurrentAndNoncurrentPolicyPolicyTextBlock contextRef="c-1" id="f-502">Other current assets consist primarily of prepaid expenses, income tax receivables, accrued investment income and the current portion of reinsurance recoverables. Other assets (non-current) consist primarily of the Company's net deferred tax asset associated with foreign tax attributes (see Note 23) and the carrying value of our equity-method investments in business-related joint ventures in China, the U.S. and other foreign jurisdictions. Earnings or losses from these equity-method investments in joint ventures are recorded in Fees and other revenues. See Note 15 for additional information on unconsolidated subsidiaries. Additionally, Other assets (non-current) includes operating lease right-of-use assets, various insurance-related assets and overfunded pension obligations (see Note 18). See Note 21 for the Company's accounting policy related to leases.</ci:OtherAssetsCurrentAndNoncurrentPolicyPolicyTextBlock>
    <ci:RedeemableNoncontrollingInterestsPolicyPolicyTextBlock contextRef="c-1" id="f-503">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Redeemable noncontrolling interests in our Consolidated Balance Sheets represents the noncontrolling shareholders' preferred and common stock interests of the Company's consolidated less than fully owned subsidiaries. Those shareholders may choose to require the Company to purchase their equity interest. For certain entities, we may also have the right to require those shareholders to sell their equity interest to us. As these redeemable noncontrolling interests provide for redemption features not solely within our control, we classify the redeemable noncontrolling interests outside of permanent equity. The noncontrolling interest was initially recorded at fair value. In subsequent reporting periods, the values are adjusted to reflect the earnings, losses and distributions attributable to the noncontrolling interest. When a shareholder's right to require the Company to purchase its equity interest is exercisable, the redeemable noncontrolling interest is recorded at estimated redemption value. When the estimated redemption value for a redeemable noncontrolling interest exceeds its initial carrying value, an adjustment to increase or decrease the redeemable noncontrolling interest is recorded with an offsetting adjustment to Retained earnings or Additional paid-in capital in the absence of Retained earnings. When an adjustment is made to the carrying value of the redeemable noncontrolling interest, the calculation of Shareholders' net income per share will be adjusted if the redemption value exceeds fair value.&lt;/span&gt;&lt;/div&gt;</ci:RedeemableNoncontrollingInterestsPolicyPolicyTextBlock>
    <ci:AccountsPayableAccruedExpensesOtherLiabilitiesPolicyPolicyTextBlock contextRef="c-1" id="f-504">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued expenses and other liabilities (current) primarily includes financial and performance guarantee liabilities (see section G) and other liabilities arising from pharmacy contracts, management compensation, various insurance-related liabilities, including experience-rated refunds, reinsurance contracts and the risk adjustment and minimum medical loss ratio rebate accruals under The Patient Protection and Affordable Care Act (the "ACA"), and amounts due to financial institutions under the accounts receivable factoring facility (see Note 3). Other non-current liabilities primarily include uncertain tax positions (see Note 23), amounts held for self-funded clients to cover the administration and payment of claims that may emerge post contract termination, lease liabilities (see Note 21) and underfunded pension obligations (see Note 18).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company accrues for legal and regulatory matters when a loss contingency is both probable and estimable. The estimated loss is generally recorded in Selling, general and administrative expenses and represents the Company's best estimate of the loss contingency. If the loss estimate is a range, the Company accrues the minimum amount in the range if no amount is better than any other estimated amount in the range. Legal costs to defend the Company's litigation and arbitration matters are expensed as incurred in cases that the Company cannot reasonably estimate the ultimate cost to defend. If the Company can reasonably estimate the cost to defend, a liability &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;for these costs is accrued when the claim is reported. Litigation and legal or regulatory matters that the Company has identified with a reasonable possibility of material loss are described in Note 24.&lt;/span&gt;&lt;/div&gt;</ci:AccountsPayableAccruedExpensesOtherLiabilitiesPolicyPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-505">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company generally conducts its international business through foreign operating entities that maintain assets and liabilities in local currencies that are their functional currencies. The Company uses exchange rates as of the balance sheet date to translate assets and liabilities into U.S. dollars. Translation gains or losses on functional currencies, net of applicable taxes, are recorded in Accumulated other comprehensive loss. The Company uses average monthly exchange rates during the year to translate revenues and expenses into U.S. dollars.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="c-1" id="f-507">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Pharmacy revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Pharmacy revenues are primarily derived from providing pharmacy benefit management services to clients and customers. Pharmacy revenues are recognized when control of the promised goods or services is transferred to clients and customers, in an amount that reflects the consideration the Company expects to receive for those goods or services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company provides or makes available various services supporting benefit management and claims administration and is generally obligated to provide prescription drugs to clients' members using multiple distribution methods including retail networks, home delivery and specialty pharmacies. These goods and services are integrated into a single performance obligation to process claims, dispense prescription drugs and provide other services over the contract period (generally three years). This performance obligation is satisfied as the business stands ready to fulfill its obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Revenues for dispensing prescription drugs through retail pharmacies are reported gross and consist of the prescription price (ingredient cost and dispensing fee) contracted with clients, including the customer copayment and any associated fees for services, because the Company acts as the principal in these arrangements. When a prescription is presented to a retail network pharmacy, the Company is solely responsible for customer eligibility, drug utilization review, drug-to-drug interaction review, any required clinical intervention, plan provision information, payment to the pharmacy and client billing. These revenues are recognized based on the full prescription price when the pharmacy claim is processed and approved for payment. The Company also provides benefit design and formulary consultation services to clients and negotiates separate contractual relationships with clients and network pharmacies. These factors indicate that the Company has control over these transactions until the prescription is processed. Revenues are billed, due and recognized at contract rates either on a periodic basis or as services are provided (such as based on volume of claims processed). This recognition pattern aligns with the benefits from services provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Home delivery and specialty pharmacy revenues are due and recognized as each prescription is shipped, net of reserves for discounts and contractual allowances estimated based on historical experience. Any differences between estimates and actual collections are reflected in Pharmacy revenues when payments are received. Historically, adjustments to original estimates and returns have not been material. The Company has elected the practical expedient to account for shipping and handling as a fulfillment activity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We may also provide certain financial and performance guarantees, including a minimum level of discounts a client may receive, generic utilization rates and various service levels. Clients may be entitled to receive compensation if we fail to meet the guarantees. Actual performance is compared to the contractual guarantee for each measure throughout the period and the Company defers revenue for any estimated payouts within Accrued expenses and other liabilities (current). These estimates are adjusted and paid at the end of the annual guarantee period. Historically, adjustments to original estimates have not been material. The liability for these financial and performance guarantees was $1.6 billion as of December&#160;31, 2023 and $1.3 billion as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company administers programs through which we may receive rebates and other vendor consideration from pharmaceutical manufacturers. The amounts of such rebates or other vendor consideration shared with pharmacy benefit management services clients vary based on the contractual arrangement with the client and in some cases the type of consideration received from the pharmaceutical manufacturer. Rebates and other vendor consideration payable to pharmacy benefit management services clients are recorded as a reduction of Pharmacy revenues. Estimated amounts payable to clients are based on contractual sharing arrangements between the Company and the client and these amounts are adjusted when amounts are collected from pharmaceutical manufacturers in accordance with the contractual arrangement between the Company and the client. Historically, these adjustments have not been material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In retail, home delivery and specialty transactions, amounts may be collected from third-party payors. These are billed and collected in accordance with the Company's standard accounts receivable collection procedures. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other pharmacy service revenues are earned by distributing specialty pharmaceuticals and medical supplies to providers, clinics and hospitals. These revenues are billed, due and recognized at contracted rates as prescriptions and supplies are shipped and services are provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Pharmacy costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Pharmacy costs include the cost of prescriptions sold, network pharmacy claim costs and copayments. Also included are direct costs of dispensing prescriptions including supplies, shipping and handling and direct costs associated with clinical programs, such as drug utilization management and medication adherence counseling. Home delivery and specialty pharmacy costs are recognized when the drug is shipped and retail network costs are recognized when the drug is processed and approved for payment. Rebates and other vendor consideration received when providing pharmacy benefit management services are recorded as a reduction of pharmacy costs. Rebates are recognized as prescriptions are shipped or processed and approved for payment. Historically, the effect of adjustments resulting from the reconciliation of rebates recognized to the amounts billed and collected, net of contractual allowances, has not been material. The Company maintains reimbursement guarantees with certain retail network pharmacies. For each such guarantee, the Company records a pharmacy and other service costs payable or prepaid asset for applicable retail network claims based on our actual performance throughout the period against the contractual reimbursement rate. The Company's contracts with certain retail pharmacies give the Company the right to adjust reimbursement rates during the annual guarantee period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Incremental costs of obtaining service and pharmacy contracts for short-term arrangements are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;H.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:7.73pt;text-decoration:underline"&gt;Premiums and Related Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Premiums for short-duration group health, accident and life insurance and managed care coverages are recognized as revenue on a pro rata basis over the contract period. Benefits and expenses are recognized when incurred and, for our Cigna Healthcare business, are presented net of pharmaceutical manufacturer rebates. For experience-rated contracts, premium revenue includes an adjustment for experience-rated refunds based on contract terms and calculated using the customer's experience (including estimates of incurred but not reported claims).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Premiums received for the Company's Medicare Advantage plans, Medicare Part D plans and Individual and Family Plans from the Centers for Medicare and Medicaid Services ("CMS") and customers are recognized as revenue ratably over the contract period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;CMS provides risk-adjusted premium payments for Medicare Advantage plans and Medicare Part D plans based on our customer demographics and medical diagnoses, which may change from period to period based on the underlying health of our customers. The Company recognizes changes to risk-adjusted premiums as revenue when the amounts are determinable and collection is reasonably assured. Revenue adjustments are generally settled semi-annually with CMS. The final revenue adjustment is generally settled with CMS in the year following the contract year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Medicare Part D premiums include payments from CMS for risk-sharing adjustments that are estimated quarterly based on claim experience by comparing actual incurred prescription drug costs to the estimated costs submitted in the original contracts. These adjustments may result in more or less revenue from CMS. Final revenue adjustments generally occur in the year following the contract year. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The ACA prescribed a risk-adjustment program to mitigate the risk for participating health insurance companies selling individual coverage on the public exchanges. The risk-adjustment program reallocates funds from insurers with lower risk populations to insurers with higher risk populations based on the relative risk scores of participants. We estimate our receivable or payable based on the risk of our customers compared to the risk of other customers in the same state and market, considering data obtained from industry studies and the United States Department of Health and Human Services ("HHS"). Receivables or payables are recorded as adjustments to premium revenue based on our year-to-date experience when the amounts are reasonably estimable and collection is reasonably assured. Final revenue adjustments are determined by HHS in the year following the policy year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Premium revenue may also include an adjustment to reflect the estimated effect of rebates due to customers under medical loss ratio provisions of the ACA. These rebate liabilities are settled in the subsequent year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Premiums for long-duration insurance contracts, including individual life, accident and supplemental health insurance and annuity products, and excluding universal life and investment-related products, are recognized as revenue when due. Cigna Healthcare's long-duration premium revenues are associated with contracts that provide coverage greater than one year or are guaranteed to be renewed at the option of the policyholder beyond one year. Benefits and expenses are matched with premiums. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Revenue for universal life products is recognized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Investment income on assets supporting universal life products is recognized in Net investment income as earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Charges for mortality, administration and policy surrender are recognized in Premiums as earned. Administrative fees are considered earned when services are provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Benefits and expenses for universal life products consist of benefit claims in excess of policyholder account balances and income earned by policyholders. Expenses are recognized when claims are incurred and income is credited to policyholders in accordance with contract provisions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The unrecognized portion of premiums received is recorded as unearned premiums included in Insurance and contractholder liabilities (current and non-current) (see Note 10 to the Consolidated Financial Statements for further information).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;I.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:11.61pt;text-decoration:underline"&gt;Fees and Related Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The majority of the Company's service fees are derived from administrative services only ("ASO") arrangements, fee-for-service clinical solutions, Wholesale Marketplace Drug Formulary Management services, health benefit management services and administration of services to specialty pharmacy manufacturers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ASO arrangements allow plan sponsors to self-fund claims and assume the risk of medical or other benefit costs. Most of the Company's ASO arrangements are for medical and specialty solutions, including pharmacy benefits. Generally, the Company's ASO arrangements are short-term. Contract modifications typically occur on renewal and are prospective in nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In return for fees from these clients, the Company provides access to our participating provider networks and other services supporting benefit management, including claims administration, behavioral health services, disease management, utilization management and cost containment programs. In general, the Company considers these services to be a combined performance obligation to provide cost effective administration of plan benefits over the contract period. Fees are billed, due and recognized monthly at contracted rates based on current membership or utilization. This recognition pattern aligns with the benefits from services provided to clients. These revenues are reported in Fees and other revenues in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company may also provide performance guarantees that provide potential refunds to clients if certain service standards, clinical outcomes or financial metrics are not met. If these standards, outcomes and metrics are not met, the Company may be financially at risk up to a stated percentage of the contracted fee or a stated dollar amount. The Company defers revenue by recording a liability for estimated payouts associated with these guarantees within Accrued expenses and other liabilities. The amount of revenue deferred is estimated for each type of guarantee using either a most likely amount or expected value method depending on the nature of the guarantee and the information available to estimate refunds. Estimates are refined each reporting period as additional information on the Company's performance becomes available and upon final reconciliation and settlement following the guarantee period. Amounts accrued and paid for these performance guarantees during the reporting periods were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expenses associated with administrative programs and services are recognized as incurred in Selling, general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company also earns revenue, as part of its integrated pharmacy benefits performance obligation, by offering fee-for-service clinical solutions to our clients, such as drug utilization management and medication adherence counseling. These clinical programs help clients to drive better health outcomes at a lower cost by identifying and addressing potentially unsafe or wasteful prescribing, dispensing and utilization of prescription drugs and communicating with, or supporting communications with physicians, pharmacies and patients. Fees are billed, due and recognized at contracted rates either on a periodic basis or as services are provided. This recognition pattern aligns with the benefits from services provided. These revenues are reported in Fees and other revenues in the Consolidated Statements of Income. Direct costs associated with these programs are recognized in Pharmacy and other service costs, and other related expenses are recorded as incurred in Selling, general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company earns fees from our Wholesale Marketplace Drug Formulary Management services. These services include either our drug formulary administrative service arrangements or our formulary processing arrangements. Drug formulary administrative services may include formulary consultation, administration of rebate contracts, rebate submission, collection from drug manufacturers and the distribution of rebates to clients. Services may also include facilitating audits of data submissions and reporting of rebates to clients. Clients agree to pay administrative fees that are billed, due and recognized at contracted rates as services are performed. These revenues are reported gross in Fees and other revenues and associated costs are reported in Pharmacy and other service costs in the Consolidated Statements of Income. For certain other clients in our formulary processing arrangements, the Company does not control the right to retain rebates before they are transferred to the client for services performed. Clients agree to allow the Company to retain a portion of each rebate collected in exchange for formulary processing services provided. These drug formulary service and administrative fee revenues are reported net in Fees and other revenues in the Consolidated Statements of Income. Revenue is recognized as rebates are processed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company also earns fees by providing health benefit management solutions that drive cost reductions and improve quality outcomes. Clients are primarily sponsors of health benefit plans and fees may be stated as a per-member-per-month fee or as a per-claim fee. The Company considers the services to be a single performance obligation to stand ready to provide utilization management services over the contract period (generally three years). In certain arrangements, the Company assumes the financial obligation for third-party provider costs for medical services provided to the health plan's customers. Fees are recorded gross in Fees and other revenues in the Consolidated Statements of Income because the Company is acting as a principal in arranging for and controlling the services provided by third-party network providers. Contractual fees vary based on enrollment and provider costs and are billed, due &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;and recognized monthly. Direct costs associated with these programs are recognized in Pharmacy and other service costs, and other related expenses are recorded in Selling, general and administrative expenses as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Certain health benefit management contracts require the Company to share the results of medical cost experience that differ from specified targets. This variable consideration is estimated at contract inception and adjusted through the contract period. The estimated profits and costs are recognized net in Fees and other revenues.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company also earns other service fees related to administrating services to specialty pharmacy manufacturers that are recorded in Fees and other revenues in the Consolidated Statements of Income. These revenues are billed, due and recognized at contracted rates as services are provided.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c-1" id="f-506">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Pharmacy revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Pharmacy revenues are primarily derived from providing pharmacy benefit management services to clients and customers. Pharmacy revenues are recognized when control of the promised goods or services is transferred to clients and customers, in an amount that reflects the consideration the Company expects to receive for those goods or services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company provides or makes available various services supporting benefit management and claims administration and is generally obligated to provide prescription drugs to clients' members using multiple distribution methods including retail networks, home delivery and specialty pharmacies. These goods and services are integrated into a single performance obligation to process claims, dispense prescription drugs and provide other services over the contract period (generally three years). This performance obligation is satisfied as the business stands ready to fulfill its obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Revenues for dispensing prescription drugs through retail pharmacies are reported gross and consist of the prescription price (ingredient cost and dispensing fee) contracted with clients, including the customer copayment and any associated fees for services, because the Company acts as the principal in these arrangements. When a prescription is presented to a retail network pharmacy, the Company is solely responsible for customer eligibility, drug utilization review, drug-to-drug interaction review, any required clinical intervention, plan provision information, payment to the pharmacy and client billing. These revenues are recognized based on the full prescription price when the pharmacy claim is processed and approved for payment. The Company also provides benefit design and formulary consultation services to clients and negotiates separate contractual relationships with clients and network pharmacies. These factors indicate that the Company has control over these transactions until the prescription is processed. Revenues are billed, due and recognized at contract rates either on a periodic basis or as services are provided (such as based on volume of claims processed). This recognition pattern aligns with the benefits from services provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Home delivery and specialty pharmacy revenues are due and recognized as each prescription is shipped, net of reserves for discounts and contractual allowances estimated based on historical experience. Any differences between estimates and actual collections are reflected in Pharmacy revenues when payments are received. Historically, adjustments to original estimates and returns have not been material. The Company has elected the practical expedient to account for shipping and handling as a fulfillment activity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We may also provide certain financial and performance guarantees, including a minimum level of discounts a client may receive, generic utilization rates and various service levels. Clients may be entitled to receive compensation if we fail to meet the guarantees. Actual performance is compared to the contractual guarantee for each measure throughout the period and the Company defers revenue for any estimated payouts within Accrued expenses and other liabilities (current). These estimates are adjusted and paid at the end of the annual guarantee period. Historically, adjustments to original estimates have not been material. The liability for these financial and performance guarantees was $1.6 billion as of December&#160;31, 2023 and $1.3 billion as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company administers programs through which we may receive rebates and other vendor consideration from pharmaceutical manufacturers. The amounts of such rebates or other vendor consideration shared with pharmacy benefit management services clients vary based on the contractual arrangement with the client and in some cases the type of consideration received from the pharmaceutical manufacturer. Rebates and other vendor consideration payable to pharmacy benefit management services clients are recorded as a reduction of Pharmacy revenues. Estimated amounts payable to clients are based on contractual sharing arrangements between the Company and the client and these amounts are adjusted when amounts are collected from pharmaceutical manufacturers in accordance with the contractual arrangement between the Company and the client. Historically, these adjustments have not been material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In retail, home delivery and specialty transactions, amounts may be collected from third-party payors. These are billed and collected in accordance with the Company's standard accounts receivable collection procedures. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other pharmacy service revenues are earned by distributing specialty pharmaceuticals and medical supplies to providers, clinics and hospitals. These revenues are billed, due and recognized at contracted rates as prescriptions and supplies are shipped and services are provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Pharmacy costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Pharmacy costs include the cost of prescriptions sold, network pharmacy claim costs and copayments. Also included are direct costs of dispensing prescriptions including supplies, shipping and handling and direct costs associated with clinical programs, such as drug utilization management and medication adherence counseling. Home delivery and specialty pharmacy costs are recognized when the drug is shipped and retail network costs are recognized when the drug is processed and approved for payment. Rebates and other vendor consideration received when providing pharmacy benefit management services are recorded as a reduction of pharmacy costs. Rebates are recognized as prescriptions are shipped or processed and approved for payment. Historically, the effect of adjustments resulting from the reconciliation of rebates recognized to the amounts billed and collected, net of contractual allowances, has not been material. The Company maintains reimbursement guarantees with certain retail network pharmacies. For each such guarantee, the Company records a pharmacy and other service costs payable or prepaid asset for applicable retail network claims based on our actual performance throughout the period against the contractual reimbursement rate. The Company's contracts with certain retail pharmacies give the Company the right to adjust reimbursement rates during the annual guarantee period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Incremental costs of obtaining service and pharmacy contracts for short-term arrangements are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;H.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:7.73pt;text-decoration:underline"&gt;Premiums and Related Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Premiums for short-duration group health, accident and life insurance and managed care coverages are recognized as revenue on a pro rata basis over the contract period. Benefits and expenses are recognized when incurred and, for our Cigna Healthcare business, are presented net of pharmaceutical manufacturer rebates. For experience-rated contracts, premium revenue includes an adjustment for experience-rated refunds based on contract terms and calculated using the customer's experience (including estimates of incurred but not reported claims).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Premiums received for the Company's Medicare Advantage plans, Medicare Part D plans and Individual and Family Plans from the Centers for Medicare and Medicaid Services ("CMS") and customers are recognized as revenue ratably over the contract period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;CMS provides risk-adjusted premium payments for Medicare Advantage plans and Medicare Part D plans based on our customer demographics and medical diagnoses, which may change from period to period based on the underlying health of our customers. The Company recognizes changes to risk-adjusted premiums as revenue when the amounts are determinable and collection is reasonably assured. Revenue adjustments are generally settled semi-annually with CMS. The final revenue adjustment is generally settled with CMS in the year following the contract year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Medicare Part D premiums include payments from CMS for risk-sharing adjustments that are estimated quarterly based on claim experience by comparing actual incurred prescription drug costs to the estimated costs submitted in the original contracts. These adjustments may result in more or less revenue from CMS. Final revenue adjustments generally occur in the year following the contract year. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The ACA prescribed a risk-adjustment program to mitigate the risk for participating health insurance companies selling individual coverage on the public exchanges. The risk-adjustment program reallocates funds from insurers with lower risk populations to insurers with higher risk populations based on the relative risk scores of participants. We estimate our receivable or payable based on the risk of our customers compared to the risk of other customers in the same state and market, considering data obtained from industry studies and the United States Department of Health and Human Services ("HHS"). Receivables or payables are recorded as adjustments to premium revenue based on our year-to-date experience when the amounts are reasonably estimable and collection is reasonably assured. Final revenue adjustments are determined by HHS in the year following the policy year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Premium revenue may also include an adjustment to reflect the estimated effect of rebates due to customers under medical loss ratio provisions of the ACA. These rebate liabilities are settled in the subsequent year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Premiums for long-duration insurance contracts, including individual life, accident and supplemental health insurance and annuity products, and excluding universal life and investment-related products, are recognized as revenue when due. Cigna Healthcare's long-duration premium revenues are associated with contracts that provide coverage greater than one year or are guaranteed to be renewed at the option of the policyholder beyond one year. Benefits and expenses are matched with premiums. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Revenue for universal life products is recognized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Investment income on assets supporting universal life products is recognized in Net investment income as earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Charges for mortality, administration and policy surrender are recognized in Premiums as earned. Administrative fees are considered earned when services are provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Benefits and expenses for universal life products consist of benefit claims in excess of policyholder account balances and income earned by policyholders. Expenses are recognized when claims are incurred and income is credited to policyholders in accordance with contract provisions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The unrecognized portion of premiums received is recorded as unearned premiums included in Insurance and contractholder liabilities (current and non-current) (see Note 10 to the Consolidated Financial Statements for further information).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;I.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:11.61pt;text-decoration:underline"&gt;Fees and Related Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The majority of the Company's service fees are derived from administrative services only ("ASO") arrangements, fee-for-service clinical solutions, Wholesale Marketplace Drug Formulary Management services, health benefit management services and administration of services to specialty pharmacy manufacturers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ASO arrangements allow plan sponsors to self-fund claims and assume the risk of medical or other benefit costs. Most of the Company's ASO arrangements are for medical and specialty solutions, including pharmacy benefits. Generally, the Company's ASO arrangements are short-term. Contract modifications typically occur on renewal and are prospective in nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In return for fees from these clients, the Company provides access to our participating provider networks and other services supporting benefit management, including claims administration, behavioral health services, disease management, utilization management and cost containment programs. In general, the Company considers these services to be a combined performance obligation to provide cost effective administration of plan benefits over the contract period. Fees are billed, due and recognized monthly at contracted rates based on current membership or utilization. This recognition pattern aligns with the benefits from services provided to clients. These revenues are reported in Fees and other revenues in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company may also provide performance guarantees that provide potential refunds to clients if certain service standards, clinical outcomes or financial metrics are not met. If these standards, outcomes and metrics are not met, the Company may be financially at risk up to a stated percentage of the contracted fee or a stated dollar amount. The Company defers revenue by recording a liability for estimated payouts associated with these guarantees within Accrued expenses and other liabilities. The amount of revenue deferred is estimated for each type of guarantee using either a most likely amount or expected value method depending on the nature of the guarantee and the information available to estimate refunds. Estimates are refined each reporting period as additional information on the Company's performance becomes available and upon final reconciliation and settlement following the guarantee period. Amounts accrued and paid for these performance guarantees during the reporting periods were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expenses associated with administrative programs and services are recognized as incurred in Selling, general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company also earns revenue, as part of its integrated pharmacy benefits performance obligation, by offering fee-for-service clinical solutions to our clients, such as drug utilization management and medication adherence counseling. These clinical programs help clients to drive better health outcomes at a lower cost by identifying and addressing potentially unsafe or wasteful prescribing, dispensing and utilization of prescription drugs and communicating with, or supporting communications with physicians, pharmacies and patients. Fees are billed, due and recognized at contracted rates either on a periodic basis or as services are provided. This recognition pattern aligns with the benefits from services provided. These revenues are reported in Fees and other revenues in the Consolidated Statements of Income. Direct costs associated with these programs are recognized in Pharmacy and other service costs, and other related expenses are recorded as incurred in Selling, general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company earns fees from our Wholesale Marketplace Drug Formulary Management services. These services include either our drug formulary administrative service arrangements or our formulary processing arrangements. Drug formulary administrative services may include formulary consultation, administration of rebate contracts, rebate submission, collection from drug manufacturers and the distribution of rebates to clients. Services may also include facilitating audits of data submissions and reporting of rebates to clients. Clients agree to pay administrative fees that are billed, due and recognized at contracted rates as services are performed. These revenues are reported gross in Fees and other revenues and associated costs are reported in Pharmacy and other service costs in the Consolidated Statements of Income. For certain other clients in our formulary processing arrangements, the Company does not control the right to retain rebates before they are transferred to the client for services performed. Clients agree to allow the Company to retain a portion of each rebate collected in exchange for formulary processing services provided. These drug formulary service and administrative fee revenues are reported net in Fees and other revenues in the Consolidated Statements of Income. Revenue is recognized as rebates are processed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company also earns fees by providing health benefit management solutions that drive cost reductions and improve quality outcomes. Clients are primarily sponsors of health benefit plans and fees may be stated as a per-member-per-month fee or as a per-claim fee. The Company considers the services to be a single performance obligation to stand ready to provide utilization management services over the contract period (generally three years). In certain arrangements, the Company assumes the financial obligation for third-party provider costs for medical services provided to the health plan's customers. Fees are recorded gross in Fees and other revenues in the Consolidated Statements of Income because the Company is acting as a principal in arranging for and controlling the services provided by third-party network providers. Contractual fees vary based on enrollment and provider costs and are billed, due &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;and recognized monthly. Direct costs associated with these programs are recognized in Pharmacy and other service costs, and other related expenses are recorded in Selling, general and administrative expenses as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Certain health benefit management contracts require the Company to share the results of medical cost experience that differ from specified targets. This variable consideration is estimated at contract inception and adjusted through the contract period. The estimated profits and costs are recognized net in Fees and other revenues.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company also earns other service fees related to administrating services to specialty pharmacy manufacturers that are recorded in Fees and other revenues in the Consolidated Statements of Income. These revenues are billed, due and recognized at contracted rates as services are provided.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-78" decimals="-8" id="f-508" unitRef="usd">1600000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-79" decimals="-8" id="f-509" unitRef="usd">1300000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="c-1" id="f-516">&lt;div&gt;&lt;span id="i320b3e5344194d5b9823c6f2e7007e05_14"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 3 &#x2013; Accounts Receivable, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We bill pharmaceutical manufacturers based on management's interpretation of contractual terms and estimate a contractual allowance based on the best information available at the time a claim is processed. Contractual allowances for certain rebates receivable from pharmaceutical manufacturers are determined by reviewing payment experience and specific known items that could be adjusted under contract terms. The Company's estimation process for contractual allowances for pharmaceutical manufacturer receivables generally results in an allowance for balances outstanding greater than 90 days. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contractual allowances for certain receivables from third-party payors are based on their contractual terms and are estimated based on the Company's best information available at the time revenue is recognized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Discounts and claims adjustments issued to customers in the form of client credits and other non-credit adjustments are based on the current status of each customer's receivable balance, current economic and market conditions and a variety of other factors, including the length of time the receivables are past due, the financial health of customers and our past experience. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The allowance for expected credit losses for current accounts receivable is based primarily on past collections experience relative to the length of time receivables are past due; however, when available evidence reasonably supports an assumption that counterparty credit risk over the expected payment period will differ from current and historical payment collections, a forecasting adjustment is reflected in the allowance for expected credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Receivables and any associated allowance are written off only when all collection attempts have failed and such amounts are determined unrecoverable. We regularly review the adequacy of these allowances based on a variety of factors, including age of the outstanding receivable and collection history. When circumstances related to specific collection patterns change, estimates of the recoverability of receivables are adjusted.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's accounts receivable include amounts due from pharmaceutical manufacturers, clients, third-party payors and customers, and are presented net of allowances. These balances include:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt"&gt;Pharmaceutical manufacturers receivables - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;amounts due from pharmaceutical manufacturers. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt"&gt;Noninsurance customer receivables - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;amounts due from customers for noninsurance services, primarily pharmacy benefit management and ASO contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt"&gt;Insurance customer receivables - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;amounts due from customers under insurance and managed care contracts, primarily premiums receivable and amounts due from CMS.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt"&gt;Other receivables - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;all other accounts receivable not included in the categories above.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following amounts were included within Accounts receivable, net:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical manufacturers receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,169&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Noninsurance customer receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,044&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Insurance customer receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,359&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;272&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18,844&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net classified as assets of businesses held for sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17,722&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These receivables are reported net of our allowances of $3.7 billion as of December&#160;31, 2023 and $1.9 billion as of December&#160;31, 2022 as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Included in our Pharmaceutical manufacturers receivables are contractual allowances for certain rebates receivable with pharmaceutical manufacturers of $3.1 billion as of December&#160;31, 2023 and $1.3 billion as of December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Included in our Noninsurance customer receivables are contractual allowances from third-party payors of $386 million as of December&#160;31, 2023 and $336 million as of December&#160;31, 2022 based upon the contractual payment terms. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;The remaining allowances of $219 million as of December&#160;31, 2023 and $226 million as of December&#160;31, 2022 include discounts and claims adjustments issued to customers in the form of client credits, an allowance for current expected credit losses and other non-credit adjustments. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's allowance for current expected credit losses was $90 million as of December&#160;31, 2023 and $86 million as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounts Receivable Factoring Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2023, the Company entered into an uncommitted factoring facility (the "Facility") under which certain accounts receivable may be sold on a non-recourse basis to a financial institution. The Facility's total capacity is $1.0 billion with an initial term of two years, followed by automatic one year renewal terms unless terminated by either party. The transactions under the Facility are accounted for as a sale and recorded as a reduction to accounts receivable in the Consolidated Balance Sheets because control of, and risk related to, the accounts receivable are transferred to the financial institution. Although the sale is made without recourse, we provide collection services related to the transferred assets. Amounts associated with this Facility are reflected within Net cash provided by operating activities in the Consolidated Statements of Cash Flows. Factoring fees paid under this Facility are reflected in Interest expense and other in the Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;For the year ended December&#160;31, 2023, we sold $2.1 billion of accounts receivable under the Facility and factoring fees paid were not material. As of December&#160;31, 2023, all sold accounts receivable have been collected from manufacturers, $515 million of which have not been remitted to the financial institution. Such amounts are recorded within Accrued expenses and other liabilities in the Consolidated Balance Sheets.</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c-1" id="f-517">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We bill pharmaceutical manufacturers based on management's interpretation of contractual terms and estimate a contractual allowance based on the best information available at the time a claim is processed. Contractual allowances for certain rebates receivable from pharmaceutical manufacturers are determined by reviewing payment experience and specific known items that could be adjusted under contract terms. The Company's estimation process for contractual allowances for pharmaceutical manufacturer receivables generally results in an allowance for balances outstanding greater than 90 days. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contractual allowances for certain receivables from third-party payors are based on their contractual terms and are estimated based on the Company's best information available at the time revenue is recognized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Discounts and claims adjustments issued to customers in the form of client credits and other non-credit adjustments are based on the current status of each customer's receivable balance, current economic and market conditions and a variety of other factors, including the length of time the receivables are past due, the financial health of customers and our past experience. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The allowance for expected credit losses for current accounts receivable is based primarily on past collections experience relative to the length of time receivables are past due; however, when available evidence reasonably supports an assumption that counterparty credit risk over the expected payment period will differ from current and historical payment collections, a forecasting adjustment is reflected in the allowance for expected credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Receivables and any associated allowance are written off only when all collection attempts have failed and such amounts are determined unrecoverable. We regularly review the adequacy of these allowances based on a variety of factors, including age of the outstanding receivable and collection history. When circumstances related to specific collection patterns change, estimates of the recoverability of receivables are adjusted.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's accounts receivable include amounts due from pharmaceutical manufacturers, clients, third-party payors and customers, and are presented net of allowances. These balances include:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt"&gt;Pharmaceutical manufacturers receivables - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;amounts due from pharmaceutical manufacturers. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt"&gt;Noninsurance customer receivables - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;amounts due from customers for noninsurance services, primarily pharmacy benefit management and ASO contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt"&gt;Insurance customer receivables - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;amounts due from customers under insurance and managed care contracts, primarily premiums receivable and amounts due from CMS.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt"&gt;Other receivables - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;all other accounts receivable not included in the categories above.&lt;/span&gt;&lt;/div&gt;the Company entered into an uncommitted factoring facility (the "Facility") under which certain accounts receivable may be sold on a non-recourse basis to a financial institutionThe transactions under the Facility are accounted for as a sale and recorded as a reduction to accounts receivable in the Consolidated Balance Sheets because control of, and risk related to, the accounts receivable are transferred to the financial institutionAmounts associated with this Facility are reflected within Net cash provided by operating activities in the Consolidated Statements of Cash Flows. Factoring fees paid under this Facility are reflected in Interest expense and other in the Consolidated Statements of Income.As of December&#160;31, 2023, all sold accounts receivable have been collected from manufacturers, $515 million of which have not been remitted to the financial institution. Such amounts are recorded within Accrued expenses and other liabilities in the Consolidated Balance Sheets.</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="c-1" id="f-518">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following amounts were included within Accounts receivable, net:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical manufacturers receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,169&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Noninsurance customer receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,044&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Insurance customer receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,359&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;272&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18,844&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net classified as assets of businesses held for sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17,722&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <ci:PharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-519" unitRef="usd">8169000000</ci:PharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:PharmaceuticalManufacturerReceivable contextRef="c-13" decimals="-6" id="f-520" unitRef="usd">7108000000</ci:PharmaceuticalManufacturerReceivable>
    <ci:NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-521" unitRef="usd">8044000000</ci:NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivableBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable contextRef="c-13" decimals="-6" id="f-522" unitRef="usd">6899000000</ci:NoninsuranceCustomerReceivablesExcludingPharmaceuticalManufacturersReceivable>
    <ci:InsuranceCustomerReceivablesBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-523" unitRef="usd">2359000000</ci:InsuranceCustomerReceivablesBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:InsuranceCustomerReceivables contextRef="c-13" decimals="-6" id="f-524" unitRef="usd">2963000000</ci:InsuranceCustomerReceivables>
    <ci:AccountsAndOtherReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-525" unitRef="usd">272000000</ci:AccountsAndOtherReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="c-13" decimals="-6" id="f-526" unitRef="usd">248000000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <ci:ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-527" unitRef="usd">18844000000</ci:ReceivablesNetCurrentBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet contextRef="c-83" decimals="-6" id="f-528" unitRef="usd">1122000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:ReceivablesNetCurrent contextRef="c-12" decimals="-6" id="f-529" unitRef="usd">17722000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent contextRef="c-13" decimals="-6" id="f-530" unitRef="usd">17218000000</us-gaap:ReceivablesNetCurrent>
    <ci:AllowanceForReceivablesCurrent contextRef="c-12" decimals="-8" id="f-531" unitRef="usd">3700000000</ci:AllowanceForReceivablesCurrent>
    <ci:AllowanceForReceivablesCurrent contextRef="c-13" decimals="-8" id="f-532" unitRef="usd">1900000000</ci:AllowanceForReceivablesCurrent>
    <ci:ContractualAllowancePharmaceuticalManufacturersReceivables contextRef="c-12" decimals="-8" id="f-533" unitRef="usd">3100000000</ci:ContractualAllowancePharmaceuticalManufacturersReceivables>
    <ci:ContractualAllowancePharmaceuticalManufacturersReceivables contextRef="c-13" decimals="-6" id="f-534" unitRef="usd">1300000000</ci:ContractualAllowancePharmaceuticalManufacturersReceivables>
    <ci:ContractualAllowanceNoninsuranceCustomerReceivables contextRef="c-12" decimals="-6" id="f-535" unitRef="usd">386000000</ci:ContractualAllowanceNoninsuranceCustomerReceivables>
    <ci:ContractualAllowanceNoninsuranceCustomerReceivables contextRef="c-13" decimals="-6" id="f-536" unitRef="usd">336000000</ci:ContractualAllowanceNoninsuranceCustomerReceivables>
    <ci:AllowanceForReceivablesOther contextRef="c-12" decimals="-6" id="f-537" unitRef="usd">219000000</ci:AllowanceForReceivablesOther>
    <ci:AllowanceForReceivablesOther contextRef="c-13" decimals="-6" id="f-538" unitRef="usd">226000000</ci:AllowanceForReceivablesOther>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-12" decimals="-6" id="f-539" unitRef="usd">90000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-13" decimals="-6" id="f-540" unitRef="usd">86000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <ci:AccountsReceivableUncommittedFactoringFacilityTotalCapacity contextRef="c-84" decimals="-8" id="f-541" unitRef="usd">1000000000</ci:AccountsReceivableUncommittedFactoringFacilityTotalCapacity>
    <ci:AccountsReceivableUncommittedFactoringFacilityInitialTerm contextRef="c-85" id="f-542">P2Y</ci:AccountsReceivableUncommittedFactoringFacilityInitialTerm>
    <ci:AccountsReceivableUncommittedFactoringFacilityAutomaticRenewalTerm contextRef="c-85" id="f-543">P1Y</ci:AccountsReceivableUncommittedFactoringFacilityAutomaticRenewalTerm>
    <ci:AccountsReceivableUncommittedFactoringFacilityAmountSold contextRef="c-1" decimals="-8" id="f-544" unitRef="usd">2100000000</ci:AccountsReceivableUncommittedFactoringFacilityAmountSold>
    <ci:AccountsReceivableUncommittedFactoringFacilityAccountsReceivableReceivedButNotRemitted contextRef="c-12" decimals="-6" id="f-545" unitRef="usd">515000000</ci:AccountsReceivableUncommittedFactoringFacilityAccountsReceivableReceivedButNotRemitted>
    <us-gaap:SupplierFinanceProgramTextBlock contextRef="c-1" id="f-546">Note 4 &#x2013; Supplier Finance Program&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company facilitates a voluntary supplier finance program (the "Program") that provides suppliers the opportunity to sell their accounts receivable due from us (i.e., our payment obligations to the suppliers) to a financial institution, on a non-recourse basis, in order to be paid earlier than our payment terms require. The Cigna Group is not a party to the Program and agrees to commercial terms with its suppliers independently of their participation in the Program. Amounts due to suppliers that participate in the Program are generally paid within one month following the invoice date. A supplier's participation in the Program has no impact on the Company's payment terms and the Company has no economic interest in a supplier's decision to participate in the Program. The suppliers, at their sole discretion, determine which invoices, if any, to sell to the financial institution. No guarantees or pledged assets are provided by the Company or any of our subsidiaries under the Program. &lt;/span&gt;&lt;/div&gt;As of December&#160;31, 2023 and December&#160;31, 2022, $1.5&#160;billion and $1.3&#160;billion, respectively, of the Company's outstanding payment obligations were confirmed as valid within the Program by the financial institution and are reflected in &lt;span style="-sec-ix-hidden:f-550"&gt;&lt;span style="-sec-ix-hidden:f-551"&gt;Accounts payable&lt;/span&gt;&lt;/span&gt; in the Consolidated Balance Sheets. The amounts confirmed as valid for both periods are predominately associated with one supplier. As of December&#160;31, 2023, we have been informed by the financial institution that $298&#160;million of the Company's outstanding payment obligations were voluntarily elected by suppliers to be sold to the financial institution under the Program.</us-gaap:SupplierFinanceProgramTextBlock>
    <us-gaap:SupplierFinanceProgramPaymentTimingPeriod contextRef="c-12" id="f-547">P1M</us-gaap:SupplierFinanceProgramPaymentTimingPeriod>
    <us-gaap:SupplierFinanceProgramObligationCurrent contextRef="c-12" decimals="-8" id="f-548" unitRef="usd">1500000000</us-gaap:SupplierFinanceProgramObligationCurrent>
    <us-gaap:SupplierFinanceProgramObligationCurrent contextRef="c-13" decimals="-8" id="f-549" unitRef="usd">1300000000</us-gaap:SupplierFinanceProgramObligationCurrent>
    <ci:SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold contextRef="c-12" decimals="-6" id="f-552" unitRef="usd">298000000</ci:SupplierFinanceProgramOutstandingPaymentObligationCurrentVoluntarilyElectedToBeSold>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock contextRef="c-1" id="f-553">Note 5 &#x2013; Mergers, Acquisitions and Divestitures&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline"&gt;Investment in CarepathRx Health Systems Solutions&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2023, Evernorth Health, Inc. acquired a minority interest in CarepathRx Health Systems Solutions ("CHSS"), a provider of integrated hospital pharmacy solutions to support patients across their complete health care journey. This equity method investment is reported in Other assets and the Company's share of CHSS' net income or loss is reported in Fees and other revenues. The purchase price has been allocated to the acquired tangible and intangible assets, including customer relationships, trade names, internal-use software and goodwill. Amortization of the acquired intangibles is included in Fees and other revenues. The Company's share of CHSS' net loss and amortization of acquired intangibles were immaterial for the year ended December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company guaranteed $125&#160;million of CHSS' credit facilities through July 2026. The fair value of the guarantee is reflected in other liabilities and is not material. The acquisition also includes separate put and call options to increase our ownership, which &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;become exercisable annually beginning as early as April 2025. The net fair value of the options, determined using a Monte Carlo simulation, are not material and are included in Other non-current liabilities and Other assets, respectively.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt;text-decoration:underline"&gt;Divestiture of International Businesses&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2022, the Company completed the sale of its life, accident and supplemental benefits businesses in six countries (Hong Kong, Indonesia, New Zealand, South Korea, Taiwan and Thailand) (the "Chubb transaction") for approximately $5.4 billion in cash and recognized a gain of $1.7&#160;billion pre-tax ($1.4&#160;billion after-tax), which included recognition of previously unrealized capital losses on investments sold and translation loss on foreign currencies. In 2023, we recorded immaterial adjustments to the sales price reflecting resolution of certain contractual matters. In December 2022, the Company also divested its ownership interest in a joint venture in T&#xfc;rkiye. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline"&gt;Integration and Transaction-related Costs&lt;/span&gt;As part of our strategic plan, we incurred non-routine costs associated with the disposition and acquisition of certain businesses. In 2023, the Company incurred net costs related to the HCSC and Chubb transactions. In 2022 and 2021, the Company incurred costs related to the Chubb transaction, the sale of the Group Disability and Life business, the acquisition of MDLIVE and the terminated merger with Elevance Health, Inc. ("Elevance"), formerly known as Anthem, Inc. These costs were $45 million pre-tax ($35 million after-tax) for the year ended December&#160;31, 2023, compared with $135 million pre-tax ($103 million after-tax) for the year ended December&#160;31, 2022 and $169 million pre-tax ($71 million after-tax) for the year ended December&#160;31, 2021. These costs consisted primarily of certain projects to separate or integrate the Company's systems, products and services, fees for legal, advisory and other professional services and certain employment-related costs. After-tax costs for the year ended December 31, 2021 included a tax benefit from the resolution of a tax matter related to the sold Group Disability and Life business.</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:GuaranteeObligationsMaximumExposure contextRef="c-86" decimals="-6" id="f-554" unitRef="usd">125000000</us-gaap:GuaranteeObligationsMaximumExposure>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="c-87" decimals="-8" id="f-555" unitRef="usd">5400000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal contextRef="c-88" decimals="-8" id="f-556" unitRef="usd">1700000000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <ci:DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax contextRef="c-88" decimals="-8" id="f-557" unitRef="usd">1400000000</ci:DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax>
    <ci:TransactionRelatedCosts contextRef="c-1" decimals="-6" id="f-558" unitRef="usd">45000000</ci:TransactionRelatedCosts>
    <ci:TransactionRelatedCostsAfterTax contextRef="c-1" decimals="-6" id="f-559" unitRef="usd">35000000</ci:TransactionRelatedCostsAfterTax>
    <ci:TransactionRelatedCosts contextRef="c-7" decimals="-6" id="f-560" unitRef="usd">135000000</ci:TransactionRelatedCosts>
    <ci:TransactionRelatedCostsAfterTax contextRef="c-7" decimals="-6" id="f-561" unitRef="usd">103000000</ci:TransactionRelatedCostsAfterTax>
    <ci:TransactionRelatedCosts contextRef="c-8" decimals="-6" id="f-562" unitRef="usd">169000000</ci:TransactionRelatedCosts>
    <ci:TransactionRelatedCostsAfterTax contextRef="c-8" decimals="-6" id="f-563" unitRef="usd">71000000</ci:TransactionRelatedCostsAfterTax>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="c-1" id="f-564">&lt;div style="margin-top:10pt"&gt;&lt;span id="i4615696355794df3b07481211e495cbe_15"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Note 6 &#x2013; Assets and Liabilities of Businesses Held for Sale&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. The Company classifies assets and liabilities as held for sale ("disposal group") when management commits to a plan to sell the disposal group, the sale is probable within one year and the disposal group is available for immediate sale in its present condition. The Company considers various factors, particularly whether actions required to complete the plan indicate it is unlikely that significant changes to the plan will be made or the plan will be withdrawn. Assets held for sale are measured at the lower of carrying value or fair value less costs to sell. Any loss resulting from the measurement is recognized in the period the held-for-sale criteria are met. Conversely, gains are not recognized until the date of the sale. When the disposal group is classified as held for sale, depreciation and amortization for most long-lived assets ceases and the Company tests the assets for impairment. Deferred policy acquisition costs continue to be amortized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In January 2024, the Company entered into the HCSC transaction for a total purchase price of approximately $3.3 billion cash, subject to applicable regulatory approvals and other customary closing conditions. The transaction is expected to close in the first quarter of 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the fourth quarter of 2023, the Company determined that the Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare Supplement and CareAllies businesses met the criteria to be classified as held for sale and aggregated and classified the assets and liabilities as held for sale in our Consolidated Balance Sheet as of December 31, 2023. The Company measured the assets and liabilities held for sale at estimated fair value less costs to sell and recognized an estimated loss of $1.5 billion pre-tax ($1.4 billion after-tax) that was included within &lt;span style="-sec-ix-hidden:f-569"&gt;(Loss) gain on sale of businesses&lt;/span&gt; in the Consolidated Statements of Income for the year ended December 31, 2023. The estimated loss on sale represents primarily asset write-downs and estimated costs to sell.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The assets and liabilities of businesses held for sale were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:88.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;467&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,438&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,122&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets, including Goodwill &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,963&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets of businesses held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,990&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Insurance and contractholder liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,636&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;All other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,059&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities of businesses held for sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,695&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; Includes Goodwill of $396&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c-1" id="f-565">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. The Company classifies assets and liabilities as held for sale ("disposal group") when management commits to a plan to sell the disposal group, the sale is probable within one year and the disposal group is available for immediate sale in its present condition. The Company considers various factors, particularly whether actions required to complete the plan indicate it is unlikely that significant changes to the plan will be made or the plan will be withdrawn. Assets held for sale are measured at the lower of carrying value or fair value less costs to sell. Any loss resulting from the measurement is recognized in the period the held-for-sale criteria are met. Conversely, gains are not recognized until the date of the sale. When the disposal group is classified as held for sale, depreciation and amortization for most long-lived assets ceases and the Company tests the assets for impairment. Deferred policy acquisition costs continue to be amortized.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="c-75" decimals="-8" id="f-566" unitRef="usd">3300000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal contextRef="c-89" decimals="-8" id="f-567" unitRef="usd">-1500000000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <ci:DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax contextRef="c-89" decimals="-8" id="f-568" unitRef="usd">-1400000000</ci:DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="c-1" id="f-570">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The assets and liabilities of businesses held for sale were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:88.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;467&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,438&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,122&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets, including Goodwill &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,963&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets of businesses held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,990&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Insurance and contractholder liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,636&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;All other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,059&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities of businesses held for sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,695&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; Includes Goodwill of $396&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents contextRef="c-83" decimals="-6" id="f-571" unitRef="usd">467000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <ci:DisposalGroupIncludingDiscontinuedOperationInvestments contextRef="c-83" decimals="-6" id="f-572" unitRef="usd">1438000000</ci:DisposalGroupIncludingDiscontinuedOperationInvestments>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet contextRef="c-83" decimals="-6" id="f-573" unitRef="usd">1122000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <ci:DisposalGroupIncludingDiscontinuedOperationOtherAssetsGoodwill contextRef="c-83" decimals="-6" id="f-574" unitRef="usd">2963000000</ci:DisposalGroupIncludingDiscontinuedOperationOtherAssetsGoodwill>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="c-83" decimals="-6" id="f-575" unitRef="usd">5990000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <ci:DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities contextRef="c-83" decimals="-6" id="f-576" unitRef="usd">1636000000</ci:DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities>
    <ci:DisposalGroupIncludingDiscontinuedOperationLiabilitiesExcludingInsuranceAndContractholderLiabilities contextRef="c-83" decimals="-6" id="f-577" unitRef="usd">1059000000</ci:DisposalGroupIncludingDiscontinuedOperationLiabilitiesExcludingInsuranceAndContractholderLiabilities>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation contextRef="c-83" decimals="-6" id="f-578" unitRef="usd">2695000000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1 contextRef="c-83" decimals="-6" id="f-579" unitRef="usd">396000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-580">&lt;div style="margin-top:10pt"&gt;&lt;span id="id4b9b7f855c9494fb643b90b2afe1341_14"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 7 &#x2013; Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company computes basic earnings per share using the weighted-average number of unrestricted common and deferred shares outstanding. Diluted earnings per share also includes the dilutive effect of outstanding employee stock options and restricted stock using the treasury stock method and the effect of strategic performance shares.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Basic and diluted earnings per share were computed as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.241%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="51" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Shares in thousands, dollars in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of&lt;br/&gt;Dilution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of&lt;br/&gt;Dilution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of&lt;br/&gt;Dilution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shareholders' net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,164&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,164&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;293,892&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;293,892&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;309,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;309,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;337,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;337,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,990&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,990&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;293,892&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,990&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;296,882&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;309,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;313,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;337,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17.57&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(0.18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17.39&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amounts reflected above for the years ended December&#160;31, 2022 and 2021 have been restated to reflect the impact of adopting amended accounting guidance for long-duration insurance contracts (discussed in Note 2 to the Consolidated Financial Statements).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following outstanding employee stock options were not included in the computation of diluted earnings per share because their effect was anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Anti-dilutive options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-581">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company computes basic earnings per share using the weighted-average number of unrestricted common and deferred shares outstanding. Diluted earnings per share also includes the dilutive effect of outstanding employee stock options and restricted stock using the treasury stock method and the effect of strategic performance shares.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-582">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Basic and diluted earnings per share were computed as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.241%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="51" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Shares in thousands, dollars in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of&lt;br/&gt;Dilution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of&lt;br/&gt;Dilution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of&lt;br/&gt;Dilution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shareholders' net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,164&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,164&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;293,892&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;293,892&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;309,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;309,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;337,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;337,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,990&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,990&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;293,892&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,990&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;296,882&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;309,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;313,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;337,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17.57&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(0.18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17.39&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amounts reflected above for the years ended December&#160;31, 2022 and 2021 have been restated to reflect the impact of adopting amended accounting guidance for long-duration insurance contracts (discussed in Note 2 to the Consolidated Financial Statements).&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-1" decimals="-6" id="f-583" unitRef="usd">5164000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-1" decimals="-6" id="f-584" unitRef="usd">5164000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-7" decimals="-6" id="f-585" unitRef="usd">6704000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-7" decimals="-6" id="f-586" unitRef="usd">6704000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-8" decimals="-6" id="f-587" unitRef="usd">5370000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-8" decimals="-6" id="f-588" unitRef="usd">5370000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c-1" decimals="-3" id="f-589" unitRef="shares">293892000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c-1" decimals="-3" id="f-590" unitRef="shares">293892000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c-7" decimals="-3" id="f-591" unitRef="shares">309546000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c-7" decimals="-3" id="f-592" unitRef="shares">309546000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c-8" decimals="-3" id="f-593" unitRef="shares">337962000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c-8" decimals="-3" id="f-594" unitRef="shares">337962000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-1" decimals="-3" id="f-595" unitRef="shares">2990000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-1" decimals="-3" id="f-596" unitRef="shares">2990000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-7" decimals="-3" id="f-597" unitRef="shares">3519000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-7" decimals="-3" id="f-598" unitRef="shares">3519000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-8" decimals="-3" id="f-599" unitRef="shares">3004000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-8" decimals="-3" id="f-600" unitRef="shares">3004000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c-1" decimals="-3" id="f-601" unitRef="shares">293892000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-1" decimals="-3" id="f-602" unitRef="shares">2990000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-603" unitRef="shares">296882000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c-7" decimals="-3" id="f-604" unitRef="shares">309546000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-7" decimals="-3" id="f-605" unitRef="shares">3519000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="-3" id="f-606" unitRef="shares">313065000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c-8" decimals="-3" id="f-607" unitRef="shares">337962000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-8" decimals="-3" id="f-608" unitRef="shares">3004000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-8" decimals="-3" id="f-609" unitRef="shares">340966000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-610"
      unitRef="usdPerShare">17.57</us-gaap:EarningsPerShareBasic>
    <ci:EarningsPerShareEffectOfDilution
      contextRef="c-1"
      decimals="2"
      id="f-611"
      unitRef="usdPerShare">-0.18</ci:EarningsPerShareEffectOfDilution>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-612"
      unitRef="usdPerShare">17.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-613"
      unitRef="usdPerShare">21.66</us-gaap:EarningsPerShareBasic>
    <ci:EarningsPerShareEffectOfDilution
      contextRef="c-7"
      decimals="2"
      id="f-614"
      unitRef="usdPerShare">-0.25</ci:EarningsPerShareEffectOfDilution>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-615"
      unitRef="usdPerShare">21.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-8"
      decimals="2"
      id="f-616"
      unitRef="usdPerShare">15.89</us-gaap:EarningsPerShareBasic>
    <ci:EarningsPerShareEffectOfDilution
      contextRef="c-8"
      decimals="2"
      id="f-617"
      unitRef="usdPerShare">-0.14</ci:EarningsPerShareEffectOfDilution>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-8"
      decimals="2"
      id="f-618"
      unitRef="usdPerShare">15.75</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-619">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following outstanding employee stock options were not included in the computation of diluted earnings per share because their effect was anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Anti-dilutive options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-91" decimals="-5" id="f-620" unitRef="shares">900000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-92" decimals="-5" id="f-621" unitRef="shares">1000000.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-93" decimals="-5" id="f-622" unitRef="shares">1500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-623">&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span id="ic993c64b84024ee5a62a006b05ea76db_438"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 8 &#x2013; Debt&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The outstanding amounts of debt (net of issuance costs, discounts or premiums) and finance leases were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Short-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,237&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$17&#160;million, 8.300% Notes due January 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$63&#160;million, 7.650% Notes due March 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$700 million, Floating Rate Notes due July 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1,000 million, 3.000% Notes due July 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1,187 million, 3.750% Notes due July 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$500 million, 0.613% Notes due March 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1,000&#160;million, 3.500% Notes due June 2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;996&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, including finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;42&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total short-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,775&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$500 million, 0.613% Notes due March 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1,000&#160;million, 3.500% Notes due June 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$900&#160;million, 3.250% Notes due April 2025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;882&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$2,200&#160;million, 4.125% Notes due November 2025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,197&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1,500&#160;million, 4.500% Notes due February 2026&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,502&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$800 million, 1.250% Notes due March 2026 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;798&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$700 million, 5.685% Notes due March 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;698&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1,500&#160;million, 3.400% Notes due March 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,450&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$259&#160;million, 7.875% Debentures due May 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;259&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$600&#160;million, 3.050% Notes due October 2027 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;597&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$3,800&#160;million, 4.375% Notes due October 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,787&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1,500&#160;million, 2.400% Notes due March 2030 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,493&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1,500 million, 2.375% Notes due March 2031 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,397&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$45&#160;million, 8.080% Step Down Notes due January 2033 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$800 million, 5.400% Notes due March 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;794&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$190&#160;million, 6.150% Notes due November 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;190&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$2,200&#160;million, 4.800% Notes due August 2038 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,193&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$750&#160;million, 3.200% Notes due March 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;744&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$121&#160;million, 5.875% Notes due March 2041&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;119&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$448&#160;million, 6.125% Notes due November 2041&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;487&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$317&#160;million, 5.375% Notes due February 2042&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;315&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1,500&#160;million, 4.800% Notes due July 2046&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,467&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1,000&#160;million, 3.875% Notes due October 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;989&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$3,000&#160;million, 4.900% Notes due December 2048&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,970&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1,250&#160;million, 3.400% Notes due March 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,237&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1,500 million, 3.400% Notes due March 2051&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,479&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, including finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;66&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;28,155&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Included in the February 2024 debt tender offers discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;The Company has entered into interest rate swap contracts hedging a portion of these fixed-rate debt instruments. See Note 12 to the Consolidated Financial Statements for further information about the Company's interest rate risk management and these derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Interest rate step down to 8.080% effective January 15, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Short-term and Credit Facilities Debt&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Revolving Credit Agreements.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Our revolving credit agreements provide us with the ability to borrow amounts for general corporate purposes, including providing liquidity support if necessary under our commercial paper program discussed below. As of December&#160;31, 2023, there were no outstanding balances under these revolving credit agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In April 2023, The Cigna Group entered into the following revolving credit agreements (the "Credit Agreements"):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;a $4.0 billion five-year revolving credit and letter of credit agreement that will mature in April 2028 with an option to extend the maturity date for additional one-year periods, subject to consent of the banks. The Company can borrow up to $4.0 billion under the credit agreement for general corporate purposes, with up to $500 million available for issuance of letters of credit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;a $1.0 billion 364-day revolving credit agreement that will mature in April 2024. The Company can borrow up to $1.0 billion under the credit agreement for general corporate purposes. This agreement includes the option to "term out" any revolving loans that are outstanding at maturity by converting them into a term loan maturing on the one-year anniversary of conversion.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Each of the Credit Agreements include an option to increase commitments in an aggregate amount of up to $1.5 billion across both facilities for a maximum total commitment of $6.5 billion. The Credit Agreements allow for borrowings at either a base rate or an adjusted term Secured Overnight Funding Rate ("SOFR") plus, in each case, an applicable margin based on the Company's senior unsecured credit ratings.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Each of the two facilities is diversified among 21 large commercial banks, all of which had an A- equivalent or higher rating by at least one Nationally Recognized Statistical Rating Organization ("NRSRO") as of December&#160;31, 2023. Each facility also contains customary covenants and restrictions, including a financial covenant that the Company's leverage ratio, as defined in the Credit Agreements, may not exceed 60% subject to certain exceptions upon the consummation of an acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Credit Agreements replaced a prior $3.0 billion five-year revolving credit and letter of credit agreement maturing in April 2027; a $1.0 billion three-year revolving credit agreement maturing in April 2025; and a $1.0 billion 364-day revolving credit agreement maturing in April 2023. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Commercial Paper. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Under our commercial paper program, we may issue short-term, unsecured commercial paper notes privately placed on a discounted basis through certain broker-dealers at any time not to exceed an aggregate amount of $5.0 billion. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. The weighted average interest rate of our commercial paper was 5.63% at December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"&gt;Long-term debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Debt Issuance and Debt Tender Offers.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; On February 5, 2024, we issued $4.5 billion of new senior notes. The proceeds from this debt were used to pay the consideration for the cash tender offers as described below. We intend to use the remaining net proceeds to fund the repayment of our senior notes maturing in March 2024 and for general corporate purposes, which may include repayment of indebtedness and repurchases of shares of our common stock.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Concurrent with the debt issuance, we commenced tender offers to purchase for cash up to $2.25 billion in aggregate principal amount of outstanding notes, which included any and all of the $1.0 billion senior notes due June 2024. Following the early tender results, we increased the tender offers to up to $2.55 billion aggregate principal amount. On February 22, 2024, we purchased $1.8 billion principal amount of notes at early settlement of the tender offers. The tender offers will expire on March 5, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On March 7, 2023, the Company issued $1.5&#160;billion of new senior notes. The proceeds of this issuance were used for general corporate purposes, and included repayment of outstanding debt securities. Interest on this debt is paid semi-annually.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.486%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Proceeds&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$700 million &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 15, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.685%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$698 million&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$800 million &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 15, 2033&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.400%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$796 million&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; Redeemable at any time discounted at the U.S. Treasury rate plus 20 basis points. Redeemable at par on or after March 15, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; Redeemable at any time discounted at the U.S. Treasury rate plus 25 basis points. Redeemable at par on or after December 15, 2032.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Debt Maturities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Maturities of outstanding long-term debt as of December&#160;31, 2023 are as follows and exclude the impact of the 2024 debt issuance and debt tender offers described above:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:88.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.039%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Scheduled Maturities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,359&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Maturities after 2028&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16,122&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; Long-term debt maturity amounts include current maturities of long-term debt. Finance leases are excluded from this table. See Note 21 - Leases for finance lease maturity amounts.&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"&gt;Interest Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Interest expense on long-term and short-term debt was $1.4 billion in 2023 and $1.3 billion in both 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"&gt;Debt Covenants&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company was in compliance with its debt covenants as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <ci:ScheduleOfShortTermDebtLongTermDebtTableTextBlock contextRef="c-1" id="f-624">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The outstanding amounts of debt (net of issuance costs, discounts or premiums) and finance leases were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Short-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,237&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$17&#160;million, 8.300% Notes due January 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$63&#160;million, 7.650% Notes due March 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$700 million, Floating Rate Notes due July 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1,000 million, 3.000% Notes due July 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1,187 million, 3.750% Notes due July 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$500 million, 0.613% Notes due March 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1,000&#160;million, 3.500% Notes due June 2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;996&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, including finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;42&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total short-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,775&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$500 million, 0.613% Notes due March 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1,000&#160;million, 3.500% Notes due June 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$900&#160;million, 3.250% Notes due April 2025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;882&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$2,200&#160;million, 4.125% Notes due November 2025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,197&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1,500&#160;million, 4.500% Notes due February 2026&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,502&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$800 million, 1.250% Notes due March 2026 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;798&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$700 million, 5.685% Notes due March 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;698&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1,500&#160;million, 3.400% Notes due March 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,450&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$259&#160;million, 7.875% Debentures due May 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;259&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$600&#160;million, 3.050% Notes due October 2027 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;597&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$3,800&#160;million, 4.375% Notes due October 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,787&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1,500&#160;million, 2.400% Notes due March 2030 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,493&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1,500 million, 2.375% Notes due March 2031 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,397&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$45&#160;million, 8.080% Step Down Notes due January 2033 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$800 million, 5.400% Notes due March 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;794&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$190&#160;million, 6.150% Notes due November 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;190&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$2,200&#160;million, 4.800% Notes due August 2038 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,193&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$750&#160;million, 3.200% Notes due March 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;744&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$121&#160;million, 5.875% Notes due March 2041&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;119&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$448&#160;million, 6.125% Notes due November 2041&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;487&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$317&#160;million, 5.375% Notes due February 2042&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;315&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1,500&#160;million, 4.800% Notes due July 2046&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,467&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1,000&#160;million, 3.875% Notes due October 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;989&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$3,000&#160;million, 4.900% Notes due December 2048&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,970&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1,250&#160;million, 3.400% Notes due March 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,237&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1,500 million, 3.400% Notes due March 2051&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,479&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, including finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;66&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;28,155&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Included in the February 2024 debt tender offers discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;The Company has entered into interest rate swap contracts hedging a portion of these fixed-rate debt instruments. See Note 12 to the Consolidated Financial Statements for further information about the Company's interest rate risk management and these derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Interest rate step down to 8.080% effective January 15, 2023.&lt;/span&gt;&lt;/div&gt;</ci:ScheduleOfShortTermDebtLongTermDebtTableTextBlock>
    <us-gaap:CommercialPaper contextRef="c-12" decimals="-6" id="f-625" unitRef="usd">1237000000</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper contextRef="c-13" decimals="-6" id="f-626" unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-94" decimals="INF" id="f-627" unitRef="usd">17000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-94"
      decimals="INF"
      id="f-628"
      unitRef="number">0.08300</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtCurrent contextRef="c-94" decimals="-6" id="f-629" unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-95" decimals="-6" id="f-630" unitRef="usd">17000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-96" decimals="INF" id="f-631" unitRef="usd">63000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-96"
      decimals="INF"
      id="f-632"
      unitRef="number">0.07650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtCurrent contextRef="c-96" decimals="-6" id="f-633" unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-97" decimals="-6" id="f-634" unitRef="usd">63000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-98" decimals="INF" id="f-635" unitRef="usd">700000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebtCurrent contextRef="c-98" decimals="-6" id="f-636" unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-99" decimals="-6" id="f-637" unitRef="usd">700000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-100" decimals="INF" id="f-638" unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-100"
      decimals="INF"
      id="f-639"
      unitRef="number">0.03000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtCurrent contextRef="c-100" decimals="-6" id="f-640" unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-101" decimals="-6" id="f-641" unitRef="usd">994000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-102" decimals="INF" id="f-642" unitRef="usd">1187000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-102"
      decimals="INF"
      id="f-643"
      unitRef="number">0.03750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtCurrent contextRef="c-102" decimals="-6" id="f-644" unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-103" decimals="-6" id="f-645" unitRef="usd">1186000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-104" decimals="INF" id="f-646" unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-104"
      decimals="INF"
      id="f-647"
      unitRef="number">0.00613</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtCurrent contextRef="c-104" decimals="-6" id="f-648" unitRef="usd">500000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-105" decimals="-6" id="f-649" unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-106" decimals="INF" id="f-650" unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-106"
      decimals="INF"
      id="f-651"
      unitRef="number">0.03500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtCurrent contextRef="c-106" decimals="-6" id="f-652" unitRef="usd">996000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-107" decimals="-6" id="f-653" unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <ci:OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent contextRef="c-12" decimals="-6" id="f-654" unitRef="usd">42000000</ci:OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent>
    <ci:OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent contextRef="c-13" decimals="-6" id="f-655" unitRef="usd">33000000</ci:OtherShortTermDebtCurrentMaturitiesOfLongTermDebtAndLeaseObligationsCurrent>
    <us-gaap:DebtCurrent contextRef="c-12" decimals="-6" id="f-656" unitRef="usd">2775000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent contextRef="c-13" decimals="-6" id="f-657" unitRef="usd">2993000000</us-gaap:DebtCurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-104" decimals="INF" id="f-658" unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-104"
      decimals="INF"
      id="f-659"
      unitRef="number">0.00613</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-104" decimals="-6" id="f-660" unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-105" decimals="-6" id="f-661" unitRef="usd">499000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-106" decimals="INF" id="f-662" unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-106"
      decimals="INF"
      id="f-663"
      unitRef="number">0.03500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-106" decimals="-6" id="f-664" unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-107" decimals="-6" id="f-665" unitRef="usd">990000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-108" decimals="INF" id="f-666" unitRef="usd">900000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-108"
      decimals="INF"
      id="f-667"
      unitRef="number">0.03250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-108" decimals="-6" id="f-668" unitRef="usd">882000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-109" decimals="-6" id="f-669" unitRef="usd">872000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-110" decimals="INF" id="f-670" unitRef="usd">2200000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-110"
      decimals="INF"
      id="f-671"
      unitRef="number">0.04125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-110" decimals="-6" id="f-672" unitRef="usd">2197000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-111" decimals="-6" id="f-673" unitRef="usd">2195000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-112" decimals="INF" id="f-674" unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-112"
      decimals="INF"
      id="f-675"
      unitRef="number">0.04500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-112" decimals="-6" id="f-676" unitRef="usd">1502000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-113" decimals="-6" id="f-677" unitRef="usd">1503000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-114" decimals="INF" id="f-678" unitRef="usd">800000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-114"
      decimals="INF"
      id="f-679"
      unitRef="number">0.01250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-114" decimals="-6" id="f-680" unitRef="usd">798000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-115" decimals="-6" id="f-681" unitRef="usd">797000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-116" decimals="INF" id="f-682" unitRef="usd">700000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-116"
      decimals="INF"
      id="f-683"
      unitRef="number">0.05685</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-116" decimals="-6" id="f-684" unitRef="usd">698000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-117" decimals="-6" id="f-685" unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-118" decimals="INF" id="f-686" unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-118"
      decimals="INF"
      id="f-687"
      unitRef="number">0.03400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-118" decimals="-6" id="f-688" unitRef="usd">1450000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-119" decimals="-6" id="f-689" unitRef="usd">1436000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-120" decimals="INF" id="f-690" unitRef="usd">259000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-120"
      decimals="INF"
      id="f-691"
      unitRef="number">0.07875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-120" decimals="-6" id="f-692" unitRef="usd">259000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-121" decimals="-6" id="f-693" unitRef="usd">259000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-122" decimals="INF" id="f-694" unitRef="usd">600000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-122"
      decimals="INF"
      id="f-695"
      unitRef="number">0.03050</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-122" decimals="-6" id="f-696" unitRef="usd">597000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-123" decimals="-6" id="f-697" unitRef="usd">597000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-124" decimals="INF" id="f-698" unitRef="usd">3800000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-124"
      decimals="INF"
      id="f-699"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-124" decimals="-6" id="f-700" unitRef="usd">3787000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-125" decimals="-6" id="f-701" unitRef="usd">3785000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-126" decimals="INF" id="f-702" unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-126"
      decimals="INF"
      id="f-703"
      unitRef="number">0.02400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-126" decimals="-6" id="f-704" unitRef="usd">1493000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-127" decimals="-6" id="f-705" unitRef="usd">1492000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-128" decimals="INF" id="f-706" unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-128"
      decimals="INF"
      id="f-707"
      unitRef="number">0.02375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-128" decimals="-6" id="f-708" unitRef="usd">1397000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-129" decimals="-6" id="f-709" unitRef="usd">1380000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-130" decimals="INF" id="f-710" unitRef="usd">45000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-130"
      decimals="INF"
      id="f-711"
      unitRef="number">0.08080</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-130" decimals="-6" id="f-712" unitRef="usd">45000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-131" decimals="-6" id="f-713" unitRef="usd">45000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-132" decimals="INF" id="f-714" unitRef="usd">800000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-132"
      decimals="INF"
      id="f-715"
      unitRef="number">0.05400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-132" decimals="-6" id="f-716" unitRef="usd">794000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-133" decimals="-6" id="f-717" unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-134" decimals="INF" id="f-718" unitRef="usd">190000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-134"
      decimals="INF"
      id="f-719"
      unitRef="number">0.06150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-134" decimals="-6" id="f-720" unitRef="usd">190000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-135" decimals="-6" id="f-721" unitRef="usd">190000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-136" decimals="INF" id="f-722" unitRef="usd">2200000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-136"
      decimals="INF"
      id="f-723"
      unitRef="number">0.04800</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-136" decimals="-6" id="f-724" unitRef="usd">2193000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-137" decimals="-6" id="f-725" unitRef="usd">2192000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-138" decimals="INF" id="f-726" unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-138"
      decimals="INF"
      id="f-727"
      unitRef="number">0.03200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-138" decimals="-6" id="f-728" unitRef="usd">744000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-139" decimals="-6" id="f-729" unitRef="usd">743000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-140" decimals="INF" id="f-730" unitRef="usd">121000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-140"
      decimals="INF"
      id="f-731"
      unitRef="number">0.05875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-140" decimals="-6" id="f-732" unitRef="usd">119000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-141" decimals="-6" id="f-733" unitRef="usd">119000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-142" decimals="INF" id="f-734" unitRef="usd">448000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-142"
      decimals="INF"
      id="f-735"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-142" decimals="-6" id="f-736" unitRef="usd">487000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-143" decimals="-6" id="f-737" unitRef="usd">488000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-144" decimals="INF" id="f-738" unitRef="usd">317000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-144"
      decimals="INF"
      id="f-739"
      unitRef="number">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-144" decimals="-6" id="f-740" unitRef="usd">315000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-145" decimals="-6" id="f-741" unitRef="usd">315000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-146" decimals="INF" id="f-742" unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-146"
      decimals="INF"
      id="f-743"
      unitRef="number">0.04800</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-146" decimals="-6" id="f-744" unitRef="usd">1467000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-147" decimals="-6" id="f-745" unitRef="usd">1466000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-148" decimals="INF" id="f-746" unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-148"
      decimals="INF"
      id="f-747"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-148" decimals="-6" id="f-748" unitRef="usd">989000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-149" decimals="-6" id="f-749" unitRef="usd">989000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-150" decimals="INF" id="f-750" unitRef="usd">3000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-150"
      decimals="INF"
      id="f-751"
      unitRef="number">0.04900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-150" decimals="-6" id="f-752" unitRef="usd">2970000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-151" decimals="-6" id="f-753" unitRef="usd">2968000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-152" decimals="INF" id="f-754" unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-152"
      decimals="INF"
      id="f-755"
      unitRef="number">0.03400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-152" decimals="-6" id="f-756" unitRef="usd">1237000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-153" decimals="-6" id="f-757" unitRef="usd">1236000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-154" decimals="INF" id="f-758" unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-154"
      decimals="INF"
      id="f-759"
      unitRef="number">0.03400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-154" decimals="-6" id="f-760" unitRef="usd">1479000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-155" decimals="-6" id="f-761" unitRef="usd">1478000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLongTermDebtNoncurrent contextRef="c-12" decimals="-6" id="f-762" unitRef="usd">66000000</us-gaap:OtherLongTermDebtNoncurrent>
    <us-gaap:OtherLongTermDebtNoncurrent contextRef="c-13" decimals="-6" id="f-763" unitRef="usd">66000000</us-gaap:OtherLongTermDebtNoncurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c-12" decimals="-6" id="f-764" unitRef="usd">28155000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c-13" decimals="-6" id="f-765" unitRef="usd">28100000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-156"
      decimals="INF"
      id="f-766"
      unitRef="number">0.08080</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LineOfCredit contextRef="c-157" decimals="INF" id="f-767" unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-158" decimals="INF" id="f-768" unitRef="usd">4000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-159" id="f-769">P5Y</us-gaap:DebtInstrumentTerm>
    <ci:DebtInstrumentExtensionTerm contextRef="c-159" id="f-770">P1Y</ci:DebtInstrumentExtensionTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-158" decimals="INF" id="f-771" unitRef="usd">4000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-160" decimals="INF" id="f-772" unitRef="usd">500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-161" decimals="INF" id="f-773" unitRef="usd">1000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-162" id="f-774">P364D</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-161" decimals="INF" id="f-775" unitRef="usd">1000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <ci:LineOfCreditFacilityConversionToTermLoanTerm contextRef="c-162" id="f-776">P1Y</ci:LineOfCreditFacilityConversionToTermLoanTerm>
    <ci:LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity contextRef="c-163" decimals="INF" id="f-777" unitRef="usd">1500000000</ci:LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity>
    <ci:LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity contextRef="c-163" decimals="INF" id="f-778" unitRef="usd">6500000000</ci:LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity>
    <ci:NumberOfRevolvingCreditFacility
      contextRef="c-163"
      decimals="INF"
      id="f-779"
      unitRef="revolvingcreditfacility">2</ci:NumberOfRevolvingCreditFacility>
    <ci:NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement
      contextRef="c-163"
      decimals="INF"
      id="f-780"
      unitRef="position">21</ci:NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement>
    <ci:LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant
      contextRef="c-163"
      decimals="INF"
      id="f-781"
      unitRef="number">0.60</ci:LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-164" decimals="INF" id="f-782" unitRef="usd">3000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-165" id="f-783">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-166" decimals="INF" id="f-784" unitRef="usd">1000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-167" id="f-785">P3Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-168" decimals="INF" id="f-786" unitRef="usd">1000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-169" id="f-787">P364D</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-170" decimals="INF" id="f-788" unitRef="usd">5000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <srt:CommercialPaperAverageRatePaid contextRef="c-1" decimals="4" id="f-789" unitRef="number">0.0563</srt:CommercialPaperAverageRatePaid>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-171" decimals="-8" id="f-790" unitRef="usd">4500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount contextRef="c-172" decimals="-7" id="f-791" unitRef="usd">2250000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount contextRef="c-173" decimals="-8" id="f-792" unitRef="usd">1000000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount contextRef="c-174" decimals="-7" id="f-793" unitRef="usd">2550000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount contextRef="c-175" decimals="-8" id="f-794" unitRef="usd">1800000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <ci:ScheduleOfIssuancesOfLongTermDebtTableTextBlock contextRef="c-1" id="f-795">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On March 7, 2023, the Company issued $1.5&#160;billion of new senior notes. The proceeds of this issuance were used for general corporate purposes, and included repayment of outstanding debt securities. Interest on this debt is paid semi-annually.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.486%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Proceeds&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$700 million &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 15, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.685%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$698 million&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$800 million &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 15, 2033&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.400%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$796 million&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; Redeemable at any time discounted at the U.S. Treasury rate plus 20 basis points. Redeemable at par on or after March 15, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; Redeemable at any time discounted at the U.S. Treasury rate plus 25 basis points. Redeemable at par on or after December 15, 2032.&lt;/span&gt;&lt;/div&gt;</ci:ScheduleOfIssuancesOfLongTermDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-176" decimals="-8" id="f-796" unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-177" decimals="-6" id="f-797" unitRef="usd">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-177" decimals="5" id="f-798" unitRef="number">0.05685</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ci:ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees contextRef="c-178" decimals="-6" id="f-799" unitRef="usd">698000000</ci:ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-179" decimals="-6" id="f-800" unitRef="usd">800000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-179" decimals="5" id="f-801" unitRef="number">0.05400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ci:ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees contextRef="c-180" decimals="-6" id="f-802" unitRef="usd">796000000</ci:ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees>
    <ci:DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate contextRef="c-181" decimals="4" id="f-803" unitRef="number">0.0020</ci:DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate>
    <ci:DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate contextRef="c-182" decimals="4" id="f-804" unitRef="number">0.0025</ci:DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock contextRef="c-1" id="f-805">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Maturities of outstanding long-term debt as of December&#160;31, 2023 are as follows and exclude the impact of the 2024 debt issuance and debt tender offers described above:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:88.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.039%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Scheduled Maturities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,359&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Maturities after 2028&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16,122&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt; Long-term debt maturity amounts include current maturities of long-term debt. Finance leases are excluded from this table. See Note 21 - Leases for finance lease maturity amounts.</srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-12" decimals="-6" id="f-806" unitRef="usd">1500000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-12" decimals="-6" id="f-807" unitRef="usd">3100000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-12" decimals="-6" id="f-808" unitRef="usd">3000000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c-12" decimals="-6" id="f-809" unitRef="usd">2359000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="c-12" decimals="-6" id="f-810" unitRef="usd">3800000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive contextRef="c-12" decimals="-6" id="f-811" unitRef="usd">16122000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:InterestExpenseDebt contextRef="c-1" decimals="-6" id="f-812" unitRef="usd">1400000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-7" decimals="-8" id="f-813" unitRef="usd">1300000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-8" decimals="-8" id="f-814" unitRef="usd">1300000000</us-gaap:InterestExpenseDebt>
    <ci:ScheduleOfCommonStockByClassScheduleOfPreferredStockByClassTextBlock contextRef="c-1" id="f-815">&lt;div&gt;&lt;span id="i8317cb59d11e40858991b6bc9c38bb8b_16"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Note 9 &#x2013; Common and Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Cigna Group has a total of 25&#160;million shares of $1 par value preferred stock authorized for issuance. No shares of preferred stock were outstanding at December 31, 2023, 2022 or 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents the share activity of The Cigna Group:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Shares in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common: Par value $0.01; 600,000 shares authorized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding- January 1,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;298,676&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;322,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;354,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net issued for stock option exercises and other benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,619&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Repurchased common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(7,791)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(35,198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding- December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;292,504&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;322,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Treasury stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;107,390&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Issued- December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;399,894&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;397,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;394,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During 2023, 2022 and 2021, The Cigna Group declared quarterly cash dividends of $1.23, $1.12 and $1.00 per share of the Company's common stock, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table provides details of the Company's dividend payments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Record Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Payment Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Amount Paid&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt; (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 8, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 23, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$1.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$368&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 7, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 22, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$1.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$362&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 6, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 21, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$1.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$362&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 6, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 21, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$1.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$358&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 9, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 24, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$357&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 8, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 23, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$352&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 7, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 22, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$341&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 6, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 21, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$334&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 10, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 25, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$345&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 8, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 23, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$342&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 8, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 23, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$330&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 7, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 22, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$324&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On February&#160;2, 2024, the Board of Directors declared the first quarter cash dividend of $1.40 per share of The Cigna Group common stock to be paid on March&#160;21, 2024 to shareholders of record on March&#160;6, 2024. The Company currently intends to pay regular quarterly dividends, with future declarations subject to approval by its Board of Directors and the Board's determination that the declaration of dividends remains in the best interests of The Cigna Group and its shareholders. The decision of whether to pay future dividends and the amount of any such dividends will be based on the Company's financial position, results of operations, cash flows, capital requirements, the requirements of applicable law and any other factors the Board may deem relevant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accelerated Share Repurchase Agreements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In February 2024, as part of our existing share repurchase program, we entered into separate accelerated share repurchase agreements ("2024 ASR agreements") with Deutsche Bank AG and Bank of America, N.A. (collectively, the "2024 Counterparties") to repurchase $3.2 billion of common stock in aggregate. We remitted $3.2 billion to the 2024 Counterparties and received an initial delivery of approximately 7.6&#160;million shares of our common stock on February 15, 2024 representing $2.6 billion of the total remitted. The final number of shares to be received under the ASR agreements will be determined based on the daily volume-weighted average share price of our common stock over the term of the agreements, less a discount and subject to adjustments pursuant to the terms and conditions of the ASR agreements. We expect final settlement under the ASR agreements to occur in the second quarter of 2024. At final settlement, we may be entitled to receive additional shares of our common stock from the Counterparties or we may be required to make a payment. If we are obligated to make a payment, we may elect to satisfy such obligation in cash or shares of our common stock.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In June 2022, as part of our existing share repurchase program, we entered into separate accelerated share repurchase agreements ("2022 ASR agreements") with Mizuho Markets Americas LLC and Morgan Stanley &amp;amp; Co. LLC (collectively, the "2022 Counterparties") to repurchase $3.5 billion of common stock in aggregate. In July 2022, we remitted $3.5 billion to the 2022 Counterparties and received an initial delivery of 10.4&#160;million shares of our common stock representing $2.8 billion of the total remitted. Upon final settlement of the 2022 ASR agreements in November 2022, we received an additional 1.9 million shares of our common stock for no additional consideration as the value of this stock was held back by the 2022 Counterparties pending final settlement of the agreements. The total number of shares of our common stock repurchased under the 2022 ASR agreements was 12.3&#160;million based on an average daily volume-weighted average share price of our common stock over the term of the agreements, less a discount, of $285.10 per share.&lt;/span&gt;&lt;/div&gt;</ci:ScheduleOfCommonStockByClassScheduleOfPreferredStockByClassTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-12"
      decimals="INF"
      id="f-816"
      unitRef="shares">25000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-12"
      decimals="INF"
      id="f-817"
      unitRef="usdPerShare">1</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-13"
      decimals="INF"
      id="f-818"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-47"
      decimals="INF"
      id="f-819"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-12"
      decimals="INF"
      id="f-820"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ScheduleOfStockByClassTextBlock contextRef="c-1" id="f-821">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents the share activity of The Cigna Group:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Shares in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common: Par value $0.01; 600,000 shares authorized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding- January 1,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;298,676&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;322,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;354,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net issued for stock option exercises and other benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,619&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Repurchased common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(7,791)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(35,198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding- December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;292,504&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;322,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Treasury stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;107,390&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Issued- December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;399,894&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;397,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;394,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-12"
      decimals="INF"
      id="f-822"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-47"
      decimals="INF"
      id="f-823"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-13"
      decimals="INF"
      id="f-824"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-12"
      decimals="INF"
      id="f-825"
      unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-13"
      decimals="INF"
      id="f-826"
      unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-47"
      decimals="INF"
      id="f-827"
      unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-13" decimals="-3" id="f-828" unitRef="shares">298676000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-47" decimals="-3" id="f-829" unitRef="shares">322948000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-33" decimals="-3" id="f-830" unitRef="shares">354771000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan contextRef="c-1" decimals="-3" id="f-831" unitRef="shares">1619000</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan contextRef="c-7" decimals="-3" id="f-832" unitRef="shares">3173000</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan contextRef="c-8" decimals="-3" id="f-833" unitRef="shares">3375000</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockRepurchasedDuringPeriodShares contextRef="c-1" decimals="-3" id="f-834" unitRef="shares">7791000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares contextRef="c-7" decimals="-3" id="f-835" unitRef="shares">27445000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares contextRef="c-8" decimals="-3" id="f-836" unitRef="shares">35198000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-12" decimals="-3" id="f-837" unitRef="shares">292504000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-13" decimals="-3" id="f-838" unitRef="shares">298676000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-47" decimals="-3" id="f-839" unitRef="shares">322948000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TreasuryStockCommonShares contextRef="c-12" decimals="-3" id="f-840" unitRef="shares">107390000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares contextRef="c-13" decimals="-3" id="f-841" unitRef="shares">99143000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares contextRef="c-47" decimals="-3" id="f-842" unitRef="shares">71246000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:CommonStockSharesIssued contextRef="c-12" decimals="-3" id="f-843" unitRef="shares">399894000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-13" decimals="-3" id="f-844" unitRef="shares">397819000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-47" decimals="-3" id="f-845" unitRef="shares">394194000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-183"
      decimals="INF"
      id="f-846"
      unitRef="usdPerShare">1.23</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-184"
      decimals="INF"
      id="f-847"
      unitRef="usdPerShare">1.23</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-185"
      decimals="INF"
      id="f-848"
      unitRef="usdPerShare">1.23</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-186"
      decimals="INF"
      id="f-849"
      unitRef="usdPerShare">1.23</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-187"
      decimals="INF"
      id="f-850"
      unitRef="usdPerShare">1.12</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-188"
      decimals="INF"
      id="f-851"
      unitRef="usdPerShare">1.12</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-189"
      decimals="INF"
      id="f-852"
      unitRef="usdPerShare">1.12</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-190"
      decimals="INF"
      id="f-853"
      unitRef="usdPerShare">1.12</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-191"
      decimals="INF"
      id="f-854"
      unitRef="usdPerShare">1.00</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-192"
      decimals="INF"
      id="f-855"
      unitRef="usdPerShare">1.00</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-193"
      decimals="INF"
      id="f-856"
      unitRef="usdPerShare">1.00</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-194"
      decimals="INF"
      id="f-857"
      unitRef="usdPerShare">1.00</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsDeclaredTableTextBlock contextRef="c-1" id="f-858">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table provides details of the Company's dividend payments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Record Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Payment Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Amount Paid&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt; (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 8, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 23, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$1.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$368&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 7, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 22, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$1.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$362&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 6, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 21, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$1.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$362&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 6, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 21, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$1.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$358&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 9, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 24, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$357&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 8, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 23, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$352&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 7, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 22, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$341&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 6, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 21, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$334&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 10, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 25, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$345&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 8, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 23, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$342&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 8, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 23, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$330&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 7, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 22, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$1.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$324&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DividendsDeclaredTableTextBlock>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-195"
      decimals="INF"
      id="f-859"
      unitRef="usdPerShare">1.23</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-195" decimals="-6" id="f-860" unitRef="usd">368000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-196"
      decimals="INF"
      id="f-861"
      unitRef="usdPerShare">1.23</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-196" decimals="-6" id="f-862" unitRef="usd">362000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-197"
      decimals="INF"
      id="f-863"
      unitRef="usdPerShare">1.23</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-197" decimals="-6" id="f-864" unitRef="usd">362000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-198"
      decimals="INF"
      id="f-865"
      unitRef="usdPerShare">1.23</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-198" decimals="-6" id="f-866" unitRef="usd">358000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-199"
      decimals="INF"
      id="f-867"
      unitRef="usdPerShare">1.12</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-199" decimals="-6" id="f-868" unitRef="usd">357000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-200"
      decimals="INF"
      id="f-869"
      unitRef="usdPerShare">1.12</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-200" decimals="-6" id="f-870" unitRef="usd">352000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-201"
      decimals="INF"
      id="f-871"
      unitRef="usdPerShare">1.12</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-201" decimals="-6" id="f-872" unitRef="usd">341000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-202"
      decimals="INF"
      id="f-873"
      unitRef="usdPerShare">1.12</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-202" decimals="-6" id="f-874" unitRef="usd">334000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-203"
      decimals="INF"
      id="f-875"
      unitRef="usdPerShare">1.00</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-203" decimals="-6" id="f-876" unitRef="usd">345000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-204"
      decimals="INF"
      id="f-877"
      unitRef="usdPerShare">1.00</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-204" decimals="-6" id="f-878" unitRef="usd">342000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-205"
      decimals="INF"
      id="f-879"
      unitRef="usdPerShare">1.00</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-205" decimals="-6" id="f-880" unitRef="usd">330000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-206"
      decimals="INF"
      id="f-881"
      unitRef="usdPerShare">1.00</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-206" decimals="-6" id="f-882" unitRef="usd">324000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-207"
      decimals="INF"
      id="f-883"
      unitRef="usdPerShare">1.40</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-208" decimals="INF" id="f-884" unitRef="usd">3200000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt contextRef="c-208" decimals="-8" id="f-885" unitRef="usd">-3200000000</us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-209"
      decimals="-5"
      id="f-886"
      unitRef="shares">7600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-210" decimals="-8" id="f-887" unitRef="usd">2600000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-211" decimals="INF" id="f-888" unitRef="usd">3500000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt contextRef="c-212" decimals="-8" id="f-889" unitRef="usd">-3500000000</us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-213"
      decimals="-5"
      id="f-890"
      unitRef="shares">10400000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-214" decimals="-8" id="f-891" unitRef="usd">2800000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-215"
      decimals="-5"
      id="f-892"
      unitRef="shares">1900000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-216"
      decimals="-5"
      id="f-893"
      unitRef="shares">12300000</us-gaap:TreasuryStockSharesAcquired>
    <ci:AcceleratedShareRepurchasesVolumeWeightedAverageSharePriceLessDiscount
      contextRef="c-216"
      decimals="2"
      id="f-894"
      unitRef="usdPerShare">285.10</ci:AcceleratedShareRepurchasesVolumeWeightedAverageSharePriceLessDiscount>
    <us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock contextRef="c-1" id="f-895">Insurance and Contractholder Liabilities&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;A.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt;text-decoration:underline"&gt;Account Balances &#x2013; Insurance and Contractholder Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's insurance and contractholder liabilities were comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unpaid claims and claim expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cigna Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,017&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;75&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,092&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;99&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;154&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;253&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Future policy benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cigna Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;97&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;518&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;615&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;163&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,375&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,538&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractholder deposit funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cigna Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;133&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;145&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;362&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,178&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,540&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market risk benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;37&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;966&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,003&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unearned premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;846&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;868&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,633&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11,421&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18,054&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Insurance and contractholder liabilities classified as liabilities of businesses held for sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total insurance and contractholder liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,514&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,904&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16,418&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; Amounts classified as liabilities of businesses held for sale include $823&#160;million of Unpaid claims, $429&#160;million of Future policy benefits, $261&#160;million of Unearned premiums and $123&#160;million of Contractholder deposit funds as of December&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Insurance and contractholder liabilities expected to be paid within one year are classified as current. The Company adopted amended accounting guidance for long-duration insurance contracts on January 1, 2023, discussed further in Note 2 to the Consolidated Financial Statements, which resulted in restatement of prior period amounts. Additionally, see below updated accounting policies and incremental disclosures associated with future policy benefits (Note 10C), contractholder deposit funds (Note 10D), and market risk benefits (Note 10E).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy - Unearned Premium. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The unrecognized portion of premiums received is recorded as unearned premiums included in Insurance and contractholder liabilities (current and non-current). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company evaluates certain insurance contracts subject to premium deficiency testing and recognizes a premium deficiency loss and corresponding reserve when expected claims costs, claims adjustment expenses, maintenance costs, and unamortized acquisition costs exceed unearned premium. Anticipated investment income is considered in the calculation of premium deficiency. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt;text-decoration:underline"&gt;Unpaid Claims and Claim Expenses &#x2013; Cigna Healthcare&lt;/span&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;This liability reflects estimates of the ultimate cost of claims that have been incurred but not reported, expected development on reported claims, claims that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily comprised of accruals for incentives and other amounts payable to health care professionals and facilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company compares key assumptions used to establish the medical costs payable to actual experience for each reporting period. The unpaid claims liability is adjusted through current period Shareholders' net income when actual experience differs from these assumptions. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trend. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The liability is primarily calculated using "completion factors" developed by comparing the claim incurral date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1) electronic (auto-adjudication) versus manual &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;claim processing; 2) frequency and timeliness of provider claims submissions; 3) number of customers and 4) the mix of products. The Company uses historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company relies more heavily on medical cost trend analysis that reflects expected claim payment patterns and other relevant operational considerations for more recent months. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of health benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and deductibles, changes in provider practices and changes in consumer demographics and consumption behavior.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The total of incurred but not reported liabilities plus expected development on reported claims and reported claims in process was $4.8 billion at December&#160;31, 2023 and $3.9 billion at December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Activity, net of intercompany transactions, in the unpaid claims liability for the Cigna Healthcare segment was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,176&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Reinsurance and other amounts recoverable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;221&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,955&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Incurred costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35,953&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(279)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35,674&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Paid costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;31,322&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,451&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;34,773&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,856&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Add: Reinsurance and other amounts recoverable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;236&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,092&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; Includes $823&#160;million classified as liabilities of businesses held for sale as of December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Reinsurance and other amounts recoverable reflect amounts due from reinsurers and policyholders to cover incurred but not reported and pending claims of certain business for which the Company administers the plan benefits without any right of offset. See Note 11 to the Consolidated Financial Statements for additional information on reinsurance.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Variances in incurred costs related to prior years' unpaid claims and claim expenses that resulted from the differences between actual experience and the Company's key assumptions were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.883%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.889%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="24" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;% &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;% &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Actual completion factors&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical cost trend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;209&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total favorable variance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;279&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Percentage of current year incurred costs as reported for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Percentage of current year incurred costs as reported for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Favorable prior year development in both years reflects lower than expected utilization of medical services as compared to our assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table depicts the incurred and paid claims development and unpaid claims liability as of December&#160;31, 2023 (net of reinsurance) reported in the Cigna Healthcare segment. The information about incurred and paid claims development for the year ended December&#160;31, 2022 is presented as supplementary information and is unaudited.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Incurred Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Incurral Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;br/&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unpaid Claims &amp;amp; Claim Expenses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;30,050&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;209&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;34,878&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,498&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cumulative incurred costs for the periods presented&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;64,928&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative Costs Paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Incurral Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;br/&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29,841&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;30,380&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cumulative paid costs for the periods presented&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;60,221&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding liabilities for the periods presented, net of reinsurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,707&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-duration liabilities not included in development table above&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;149&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unpaid claims and claims expenses - Cigna Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,856&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reinsurance and other amounts recoverable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;236&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unpaid claims and claim expenses - Cigna Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,092&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Incurred claims do not typically remain outstanding for multiple years; more than 95% of health claims incurred in a year are paid by the end of the following year.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;There is no single or common claim frequency metric used in the health care industry. The Company believes a relevant metric for its health insurance business is the number of customers for whom an insured medical claim was paid. Customers for whom no insured medical claim was paid are excluded from the calculation. Claims that did not result in a liability are not included in the frequency metric. The claim frequency for 2023 and 2022 was approximately 5.5 million and 5.0&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline"&gt;Future Policy Benefits&lt;/span&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting Policy.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Future policy benefits represent the present value of estimated future obligations, estimated using actuarial methods, for long-duration insurance policies and annuity products currently in force, consisting primarily of reserves for annuity contracts, life insurance benefits, and certain supplemental health products that are guaranteed renewable beyond one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contracts are grouped at a level no higher than issue year, based on the original contract issue date, and at lower levels of disaggregation within each issue year for certain businesses to reflect factors including product type, plan type and currency. Management estimates these obligations based on assumptions for premiums, interest rates, mortality or morbidity, future claim adjudication expenses and surrenders. Mortality, morbidity and surrender assumptions are based on the Company's own experience and published actuarial tables, and are updated at least annually, to the extent changes in circumstances require. Interest rate assumptions are based on&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;market-level yields for low credit risk fixed income instruments ("upper-medium grade fixed income instrument"). For interest accretion purposes, interest rates are fixed at the year of the cohort's inception, however for purposes of liability measurement, are updated to the current rate quarterly, with all changes in the interest rate from inception to current period reported through Accumulated other comprehensive loss. For contracts issued domestically, we use observable inputs from a published spot rate curve for terms up to 30 years and extrapolate for longer terms using a constant forward rate approach. For contracts issued by foreign operating entities with functional currencies other than the U.S. dollar, we use observable inputs to approximate a risk free rate and add a credit spread adjustment to align with a low-credit risk fixed income instrument. For terms beyond the last observable risk free rates, which vary by international market, we extrapolate to the ultimate forward rate assuming a constant credit spread.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For the annuity business, the premium paying period is shorter than the benefit coverage period, and a deferred profit liability is reported in future policy benefits representing gross premium received in excess of net premiums. Deferred profit liability is amortized based on expected future benefit payments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2023, approximately 34% of the liability for future policy benefits, excluding amounts held for sale, was supported by assets in trust for the benefit of the ceding company under reinsurance agreements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Cigna Healthcare&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The weighted average interest rates applied and duration for future policy benefits in the Cigna Healthcare segment, consisting primarily of supplemental health products including individual Medicare supplement, limited benefit health products and individual private medical insurance, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest accretion rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.54&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current discount rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4.92&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average duration &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The net liability for future policy benefits for the segment's supplemental health products represents the present value of benefits expected to be paid to policyholders, net of the present value of expected net premiums, which is the portion of expected future gross premium expected to be collected from policyholders that is required to provide for all expected future benefits and expenses. The present values of expected net premiums and expected future policy benefits for the Cigna Healthcare segment are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Present value of expected net premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,557&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reversal of effect of beginning of period discount rate assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,537&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of assumption changes and actual variances from expected experience &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;314&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Issuances and lapses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,255&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net premiums collected&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest and other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;94&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance at original discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,387&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of end of period discount rate assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,537)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,233&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Present value of expected policy benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,945&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reversal of effect of discount rate assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,611&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(379)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of assumption changes and actual variances from expected experience &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;112&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Issuances and lapses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,309&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefit payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,401)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest and other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance at original discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,853&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of discount rate assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,633&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability for future policy benefits &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;215&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total liability for future policy benefits &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)(7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;615&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Includes the effect of actual variances from expectations, which (decreased)/increased the total liability for future policy benefits by $(12) million and $46 million, respectively, for the years ended December&#160;31, 2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Includes the foreign exchange rate impact of translating from transactional and functional currency to United States dollar and the impact of flooring the liability at zero. The flooring impact is calculated at the cohort level after discounting the reserves at the current discount rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;As of December&#160;31, 2023 and December&#160;31, 2022 undiscounted expected future gross premiums were $18.7 billion and $17.5 billion, respectively. As of December&#160;31, 2023 and December&#160;31, 2022 discounted expected future gross premiums were $13.5 billion and $12.2 billion, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;As of December&#160;31, 2023 and December&#160;31, 2022, undiscounted expected future policy benefits were $13.3 billion and $12.7 billion, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;The liability for future policyholder benefits includes immaterial businesses shown as reconciling items above, most of which are in run-off. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;$72 million and $155 million reported in Reinsurance recoverables in the Consolidated Balance Sheets as of December&#160;31, 2023 and December&#160;31, 2022, respectively, relate to the liability for future policy benefits. Additionally, $79 million of reinsurance recoverables are reported in assets of businesses held for sale in the Consolidated Balance Sheets as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Includes $429 million of future policy benefits classified as liabilities of businesses held for sale in the Consolidated Balance Sheets as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Other Operations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The weighted average interest rates applied and duration for future policy benefits in Other Operations, consisting of annuity and life insurance products, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest accretion rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5.64&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current discount rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4.87&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average duration &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Obligations for annuities represent discounted periodic benefits to be paid to an individual or groups of individuals over their remaining lives. Other Operations&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;'&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; traditional insurance contracts, which are in run-off, have no premium remaining to be collected; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;therefore, future policy benefit reserves represent the present value of expected future policy benefits, discounted using the current discount rate, and the remaining amortizable deferred profit liability.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Future policy benefits for Other Operations includes deferred profit liability of $384 million and $390&#160;million as of December&#160;31, 2023 and December&#160;31, 2022, respectively. Future policy benefits excluding deferred profit liability were $3.2&#160;billion as of both December&#160;31, 2023 and December&#160;31, 2022, and $4.3&#160;billion as of December&#160;31, 2021. These balances exclude amounts classified as liabilities of businesses held for sale of $3.8&#160;billion as of December&#160;31, 2021. The change in future policy benefits reserves year-to-date was primarily driven by changes in the current discount rate. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Undiscounted expected future policy benefits were $4.5&#160;billion as of December&#160;31, 2023 and $4.6&#160;billion as of December&#160;31, 2022. As of December&#160;31, 2023 and December&#160;31, 2022, $1.0&#160;billion and $1.1&#160;billion, respectively, of the future policy benefit reserve was recoverable through treaties with external reinsurers.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt;text-decoration:underline"&gt;Contractholder Deposit Funds&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting Policy. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Liabilities for contractholder deposit funds primarily include deposits received from customers for investment-related and universal life products as well as investment earnings on their fund balances in Other Operations. These liabilities are adjusted to reflect administrative charges and, for universal life fund balances, mortality charges. Interest credited on these funds is accrued ratably over the contract period. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contractholder deposit fund liabilities within Other Operations were $6.5 billion, $6.7 billion and $6.9 billion as of December&#160;31, 2023, December&#160;31, 2022 and December&#160;31, 2021, respectively. Approximately 39% of the balance is reinsured externally as of both December&#160;31, 2023 and December&#160;31, 2022. Activity in these liabilities is presented net of reinsurance in the Consolidated Statements of Cash Flows. The net year-to-date decrease in contractholder deposit fund liabilities generally relates to withdrawals and benefit payments from contractholder deposit funds, partially offset by deposits and interest credited to contractholder deposit funds.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2023, the weighted average crediting rate, net amount at risk and cash surrender value for contractholder deposit fund liabilities not effectively exited through reinsurance were 3.31%, $3.0 billion and $2.8 billion, respectively. The comparative amounts as of December&#160;31, 2022 were 3.08%, $3.0 billion and $2.4 billion, respectively. More than 99% of the $4.0 billion liability as of December&#160;31, 2023 and the $4.1 billion liability as of December&#160;31, 2022 not reinsured externally is for contracts with guaranteed interest rates of 3% - 4%, and approximately $1.2 billion represented contracts with policies at the guarantee. At both of these same period ends, $1.2 billion was 50-150 basis points ("bps") above the guarantee and the remaining $1.6 billion as of December&#160;31, 2023 and $1.7 billion as of December&#160;31, 2022 represented contracts above the guarantee that pay the policyholder based on the greater of a guaranteed minimum cash value or the actual cash value. More than 90% of these contracts have actual cash values of at least 110% of the guaranteed cash value.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt;text-decoration:underline"&gt;Market Risk Benefits&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Liabilities for market risk benefits consist of variable annuity reinsurance contracts (formerly referred to as GMDB and GMIB contracts) in Other Operations. These liabilities arise under annuities and riders to annuities written by ceding companies that guarantee the benefit received at death and, for a subset of policies, also provide contractholders the option, within 30 days of a policy anniversary after the appropriate waiting period, to elect minimum income payments. The Company's capital market risk exposure on variable annuity reinsurance contracts arises when the reinsured guaranteed minimum benefit exceeds the contractholder's account value in the related underlying mutual funds at the time the insurance benefit is payable under the respective contract. The Company receives and pays premium periodically based on the terms of the reinsurance agreements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting Policy.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Variable annuity reinsurance liabilities are measured as MRBs at fair value, net of nonperformance risk, with fluctuations in value gross of reinsurer nonperformance risk reported in benefit expenses, while fluctuations in the Company's own nonperformance risk (own credit risk) are reported in Accumulated other comprehensive loss. Nonperformance risk reflects risk that a party might default and therefore not fulfill its obligations (i.e. nonpayment risk). The nonperformance risk adjustment reflects a market participant's view of nonpayment risk by adding an additional spread to the discount rate in the calculation of both (a) the variable annuity reinsurance liabilities to be paid by the Company and (b) the variable annuity reinsurance assets to be paid by the reinsurers, after considering collateral. The Company classifies variable annuity assets and liabilities in Level 3 of the fair value hierarchy described in Note 13 to the Consolidated Financial Statements because assumptions related to future annuitant behavior are largely unobservable. As discussed further in Note 11 to the Consolidated Financial Statements, due to the reinsurance agreements covering these liabilities, the liabilities do not generally impact net income except for the change in nonperformance risk on the reinsurance recoverable, which is reported in benefit expenses and does not offset the nonperformance risk valuation on the liability. Variable annuity liabilities are established using capital market assumptions and assumptions related to future annuitant behavior (including mortality, lapse and annuity election rates). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Market risk benefits activity was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.877%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.911%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.912%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;1,268&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;1,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Balance, beginning of year, before the effect of nonperformance risk (own credit risk)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;1,379&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;1,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Changes due to expected run-off&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Changes due to capital markets versus expected&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;(254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Changes due to policyholder behavior versus expected&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Assumption changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Balance, end of period, before the effect of changes in nonperformance risk (own credit risk)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;1,085&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;1,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Nonperformance risk (own credit risk), end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;1,003&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;1,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Reinsured market risk benefit, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;1,081&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;1,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents the account value, net amount at risk, average attained age of contractholders (weighted by exposure) and the number of contractholders for guarantees assumed by the Company. The net amount at risk is the amount that the Company would have to pay to contractholders if all deaths or annuitizations occurred as of the earliest possible date in accordance with the insurance contract. As of December&#160;31, 2023, the account value increased primarily due to favorable equity market performance, which resulted in an decrease to the net amount at risk. The Company should be reimbursed in full for these payments unless the Berkshire reinsurance limit is exceeded.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Dollars in millions, excludes impact of reinsurance ceded)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Account value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,736&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net amount at risk&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,609&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Average attained age of contractholders (weighted by exposure)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;77.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74.7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Number of contractholders (estimated)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;140,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock>
    <us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense contextRef="c-1" id="f-896">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's insurance and contractholder liabilities were comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unpaid claims and claim expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cigna Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,017&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;75&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,092&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;99&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;154&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;253&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Future policy benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cigna Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;97&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;518&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;615&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;163&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,375&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,538&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractholder deposit funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cigna Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;133&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;145&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;362&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,178&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,540&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market risk benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;37&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;966&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,003&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unearned premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;846&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;868&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,633&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11,421&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18,054&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Insurance and contractholder liabilities classified as liabilities of businesses held for sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total insurance and contractholder liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,514&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,904&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16,418&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; Amounts classified as liabilities of businesses held for sale include $823&#160;million of Unpaid claims, $429&#160;million of Future policy benefits, $261&#160;million of Unearned premiums and $123&#160;million of Contractholder deposit funds as of December&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Activity, net of intercompany transactions, in the unpaid claims liability for the Cigna Healthcare segment was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,176&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Reinsurance and other amounts recoverable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;221&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,955&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Incurred costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35,953&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(279)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35,674&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Paid costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;31,322&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,451&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;34,773&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,856&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Add: Reinsurance and other amounts recoverable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;236&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,092&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; Includes $823&#160;million classified as liabilities of businesses held for sale as of December 31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <ci:LiabilityForClaimsAndClaimsAdjustmentExpenseCurrentIncludingDisposalGroups contextRef="c-217" decimals="-6" id="f-897" unitRef="usd">5017000000</ci:LiabilityForClaimsAndClaimsAdjustmentExpenseCurrentIncludingDisposalGroups>
    <ci:LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrentIncludingDisposalGroups contextRef="c-217" decimals="-6" id="f-898" unitRef="usd">75000000</ci:LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrentIncludingDisposalGroups>
    <ci:LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups contextRef="c-217" decimals="-6" id="f-899" unitRef="usd">5092000000</ci:LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups>
    <ci:LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent contextRef="c-218" decimals="-6" id="f-900" unitRef="usd">4117000000</ci:LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent>
    <ci:LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent contextRef="c-218" decimals="-6" id="f-901" unitRef="usd">59000000</ci:LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-218" decimals="-6" id="f-902" unitRef="usd">4176000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <ci:LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent contextRef="c-219" decimals="-6" id="f-903" unitRef="usd">99000000</ci:LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent>
    <ci:LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent contextRef="c-219" decimals="-6" id="f-904" unitRef="usd">154000000</ci:LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-219" decimals="-6" id="f-905" unitRef="usd">253000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <ci:LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent contextRef="c-220" decimals="-6" id="f-906" unitRef="usd">107000000</ci:LiabilityForClaimsAndClaimsAdjustmentExpenseCurrent>
    <ci:LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent contextRef="c-220" decimals="-6" id="f-907" unitRef="usd">177000000</ci:LiabilityForClaimsAndClaimsAdjustmentExpenseNoncurrent>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-220" decimals="-6" id="f-908" unitRef="usd">284000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <ci:LiabilityForFuturePolicyBenefitsCurrentIncludingDisposalGroups contextRef="c-217" decimals="-6" id="f-909" unitRef="usd">97000000</ci:LiabilityForFuturePolicyBenefitsCurrentIncludingDisposalGroups>
    <ci:LiabilityForFuturePolicyBenefitsNoncurrentIncludingDisposalGroups contextRef="c-217" decimals="-6" id="f-910" unitRef="usd">518000000</ci:LiabilityForFuturePolicyBenefitsNoncurrentIncludingDisposalGroups>
    <ci:LiabilityForFuturePolicyBenefitsIncludingDisposalGroups contextRef="c-217" decimals="-6" id="f-911" unitRef="usd">615000000</ci:LiabilityForFuturePolicyBenefitsIncludingDisposalGroups>
    <ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent contextRef="c-218" decimals="-6" id="f-912" unitRef="usd">43000000</ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent>
    <ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent contextRef="c-218" decimals="-6" id="f-913" unitRef="usd">544000000</ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent>
    <us-gaap:LiabilityForFuturePolicyBenefits contextRef="c-218" decimals="-6" id="f-914" unitRef="usd">587000000</us-gaap:LiabilityForFuturePolicyBenefits>
    <ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent contextRef="c-219" decimals="-6" id="f-915" unitRef="usd">163000000</ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent>
    <ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent contextRef="c-219" decimals="-6" id="f-916" unitRef="usd">3375000000</ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent>
    <us-gaap:LiabilityForFuturePolicyBenefits contextRef="c-219" decimals="-6" id="f-917" unitRef="usd">3538000000</us-gaap:LiabilityForFuturePolicyBenefits>
    <ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent contextRef="c-220" decimals="-6" id="f-918" unitRef="usd">150000000</ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceCurrent>
    <ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent contextRef="c-220" decimals="-6" id="f-919" unitRef="usd">3442000000</ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceNoncurrent>
    <us-gaap:LiabilityForFuturePolicyBenefits contextRef="c-220" decimals="-6" id="f-920" unitRef="usd">3592000000</us-gaap:LiabilityForFuturePolicyBenefits>
    <ci:PolicyholderContractDepositCurrentIncludingDisposalGroups contextRef="c-217" decimals="-6" id="f-921" unitRef="usd">12000000</ci:PolicyholderContractDepositCurrentIncludingDisposalGroups>
    <ci:PolicyholderContractDepositNoncurrentIncludingDisposalGroups contextRef="c-217" decimals="-6" id="f-922" unitRef="usd">133000000</ci:PolicyholderContractDepositNoncurrentIncludingDisposalGroups>
    <ci:PolicyholderContractDepositsIncludingDisposalGroups contextRef="c-217" decimals="-6" id="f-923" unitRef="usd">145000000</ci:PolicyholderContractDepositsIncludingDisposalGroups>
    <ci:PolicyholderContractDepositCurrent contextRef="c-218" decimals="-6" id="f-924" unitRef="usd">14000000</ci:PolicyholderContractDepositCurrent>
    <ci:PolicyholderContractDepositNoncurrent contextRef="c-218" decimals="-6" id="f-925" unitRef="usd">157000000</ci:PolicyholderContractDepositNoncurrent>
    <us-gaap:PolicyholderContractDeposits contextRef="c-218" decimals="-6" id="f-926" unitRef="usd">171000000</us-gaap:PolicyholderContractDeposits>
    <ci:PolicyholderContractDepositCurrent contextRef="c-219" decimals="-6" id="f-927" unitRef="usd">362000000</ci:PolicyholderContractDepositCurrent>
    <ci:PolicyholderContractDepositNoncurrent contextRef="c-219" decimals="-6" id="f-928" unitRef="usd">6178000000</ci:PolicyholderContractDepositNoncurrent>
    <us-gaap:PolicyholderContractDeposits contextRef="c-219" decimals="-6" id="f-929" unitRef="usd">6540000000</us-gaap:PolicyholderContractDeposits>
    <ci:PolicyholderContractDepositCurrent contextRef="c-220" decimals="-6" id="f-930" unitRef="usd">351000000</ci:PolicyholderContractDepositCurrent>
    <ci:PolicyholderContractDepositNoncurrent contextRef="c-220" decimals="-6" id="f-931" unitRef="usd">6358000000</ci:PolicyholderContractDepositNoncurrent>
    <us-gaap:PolicyholderContractDeposits contextRef="c-220" decimals="-6" id="f-932" unitRef="usd">6709000000</us-gaap:PolicyholderContractDeposits>
    <ci:MarketRiskBenefitLiabilityAmountCurrent contextRef="c-12" decimals="-6" id="f-933" unitRef="usd">37000000</ci:MarketRiskBenefitLiabilityAmountCurrent>
    <ci:MarketRiskBenefitLiabilityAmountNoncurrent contextRef="c-12" decimals="-6" id="f-934" unitRef="usd">966000000</ci:MarketRiskBenefitLiabilityAmountNoncurrent>
    <us-gaap:MarketRiskBenefitLiabilityAmount contextRef="c-12" decimals="-6" id="f-935" unitRef="usd">1003000000</us-gaap:MarketRiskBenefitLiabilityAmount>
    <ci:MarketRiskBenefitLiabilityAmountCurrent contextRef="c-13" decimals="-6" id="f-936" unitRef="usd">51000000</ci:MarketRiskBenefitLiabilityAmountCurrent>
    <ci:MarketRiskBenefitLiabilityAmountNoncurrent contextRef="c-13" decimals="-6" id="f-937" unitRef="usd">1217000000</ci:MarketRiskBenefitLiabilityAmountNoncurrent>
    <us-gaap:MarketRiskBenefitLiabilityAmount contextRef="c-13" decimals="-6" id="f-938" unitRef="usd">1268000000</us-gaap:MarketRiskBenefitLiabilityAmount>
    <ci:UnearnedPremiumsCurrentIncludingDisposalGroups contextRef="c-12" decimals="-6" id="f-939" unitRef="usd">846000000</ci:UnearnedPremiumsCurrentIncludingDisposalGroups>
    <ci:UnearnedPremiumsNoncurrentIncludingDisposalGroups contextRef="c-12" decimals="-6" id="f-940" unitRef="usd">22000000</ci:UnearnedPremiumsNoncurrentIncludingDisposalGroups>
    <ci:UnearnedPremiumsIncludingDisposalGroups contextRef="c-12" decimals="-6" id="f-941" unitRef="usd">868000000</ci:UnearnedPremiumsIncludingDisposalGroups>
    <ci:UnearnedPremiumsCurrent contextRef="c-13" decimals="-6" id="f-942" unitRef="usd">576000000</ci:UnearnedPremiumsCurrent>
    <ci:UnearnedPremiumsNoncurrent contextRef="c-13" decimals="-6" id="f-943" unitRef="usd">22000000</ci:UnearnedPremiumsNoncurrent>
    <us-gaap:UnearnedPremiums contextRef="c-13" decimals="-6" id="f-944" unitRef="usd">598000000</us-gaap:UnearnedPremiums>
    <ci:InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups contextRef="c-12" decimals="-6" id="f-945" unitRef="usd">6633000000</ci:InsuranceAndContractholderLiabilitiesCurrentIncludingDisposalGroups>
    <ci:InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups contextRef="c-12" decimals="-6" id="f-946" unitRef="usd">11421000000</ci:InsuranceAndContractholderLiabilitiesNoncurrentIncludingDisposalGroups>
    <ci:InsuranceAndContractholderLiabilitiesIncludingDisposalGroups contextRef="c-12" decimals="-6" id="f-947" unitRef="usd">18054000000</ci:InsuranceAndContractholderLiabilitiesIncludingDisposalGroups>
    <ci:DisposalGroupIncludingDiscontinuedOperationCurrentInsuranceAndContractholderLiabilities contextRef="c-83" decimals="-6" id="f-948" unitRef="usd">1119000000</ci:DisposalGroupIncludingDiscontinuedOperationCurrentInsuranceAndContractholderLiabilities>
    <ci:DisposalGroupIncludingDiscontinuedOperationNoncurrentInsuranceAndContractholderLiabilities contextRef="c-83" decimals="-6" id="f-949" unitRef="usd">517000000</ci:DisposalGroupIncludingDiscontinuedOperationNoncurrentInsuranceAndContractholderLiabilities>
    <ci:DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities contextRef="c-83" decimals="-6" id="f-950" unitRef="usd">1636000000</ci:DisposalGroupIncludingDiscontinuedOperationInsuranceAndContractholderLiabilities>
    <ci:InsuranceAndContractholderLiabilitiesCurrent contextRef="c-12" decimals="-6" id="f-951" unitRef="usd">5514000000</ci:InsuranceAndContractholderLiabilitiesCurrent>
    <ci:InsuranceAndContractholderLiabilitiesNoncurrent contextRef="c-12" decimals="-6" id="f-952" unitRef="usd">10904000000</ci:InsuranceAndContractholderLiabilitiesNoncurrent>
    <ci:InsuranceAndContractholderLiabilities contextRef="c-12" decimals="-6" id="f-953" unitRef="usd">16418000000</ci:InsuranceAndContractholderLiabilities>
    <ci:InsuranceAndContractholderLiabilitiesCurrent contextRef="c-13" decimals="-6" id="f-954" unitRef="usd">5409000000</ci:InsuranceAndContractholderLiabilitiesCurrent>
    <ci:InsuranceAndContractholderLiabilitiesNoncurrent contextRef="c-13" decimals="-6" id="f-955" unitRef="usd">11976000000</ci:InsuranceAndContractholderLiabilitiesNoncurrent>
    <ci:InsuranceAndContractholderLiabilities contextRef="c-13" decimals="-6" id="f-956" unitRef="usd">17385000000</ci:InsuranceAndContractholderLiabilities>
    <ci:LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups contextRef="c-83" decimals="-6" id="f-957" unitRef="usd">823000000</ci:LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups>
    <ci:LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups contextRef="c-83" decimals="-6" id="f-958" unitRef="usd">429000000</ci:LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups>
    <ci:UnearnedPremiumsAttributableToDisposalGroups contextRef="c-83" decimals="-6" id="f-959" unitRef="usd">261000000</ci:UnearnedPremiumsAttributableToDisposalGroups>
    <ci:PolicyholderContractDepositsAttributableToDisposalGroups contextRef="c-83" decimals="-6" id="f-960" unitRef="usd">123000000</ci:PolicyholderContractDepositsAttributableToDisposalGroups>
    <ci:InsuranceUnearnedPremiumsPolicyTextBlock contextRef="c-1" id="f-961">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy - Unearned Premium. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The unrecognized portion of premiums received is recorded as unearned premiums included in Insurance and contractholder liabilities (current and non-current). &lt;/span&gt;&lt;/div&gt;The Company evaluates certain insurance contracts subject to premium deficiency testing and recognizes a premium deficiency loss and corresponding reserve when expected claims costs, claims adjustment expenses, maintenance costs, and unamortized acquisition costs exceed unearned premium. Anticipated investment income is considered in the calculation of premium deficiency.</ci:InsuranceUnearnedPremiumsPolicyTextBlock>
    <us-gaap:UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy contextRef="c-1" id="f-962">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;This liability reflects estimates of the ultimate cost of claims that have been incurred but not reported, expected development on reported claims, claims that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily comprised of accruals for incentives and other amounts payable to health care professionals and facilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company compares key assumptions used to establish the medical costs payable to actual experience for each reporting period. The unpaid claims liability is adjusted through current period Shareholders' net income when actual experience differs from these assumptions. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trend. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The liability is primarily calculated using "completion factors" developed by comparing the claim incurral date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1) electronic (auto-adjudication) versus manual &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;claim processing; 2) frequency and timeliness of provider claims submissions; 3) number of customers and 4) the mix of products. The Company uses historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company relies more heavily on medical cost trend analysis that reflects expected claim payment patterns and other relevant operational considerations for more recent months. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of health benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and deductibles, changes in provider practices and changes in consumer demographics and consumption behavior.&lt;/span&gt;&lt;/div&gt;There is no single or common claim frequency metric used in the health care industry. The Company believes a relevant metric for its health insurance business is the number of customers for whom an insured medical claim was paid. Customers for whom no insured medical claim was paid are excluded from the calculation. Claims that did not result in a liability are not included in the frequency metric.</us-gaap:UnpaidPolicyClaimsAndClaimsAdjustmentExpensePolicy>
    <ci:LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses contextRef="c-217" decimals="-8" id="f-963" unitRef="usd">4800000000</ci:LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses>
    <ci:LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses contextRef="c-218" decimals="-8" id="f-964" unitRef="usd">3900000000</ci:LiabilityForClaimsAndClaimsAdjustmentExpenseExcludingPhysicianIncentivesAndOtherExpenses>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-218" decimals="-6" id="f-965" unitRef="usd">4176000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-221" decimals="-6" id="f-966" unitRef="usd">4261000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-222" decimals="-6" id="f-967" unitRef="usd">3695000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments contextRef="c-218" decimals="-6" id="f-968" unitRef="usd">221000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments contextRef="c-221" decimals="-6" id="f-969" unitRef="usd">261000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments contextRef="c-222" decimals="-6" id="f-970" unitRef="usd">237000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet contextRef="c-218" decimals="-6" id="f-971" unitRef="usd">3955000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet contextRef="c-221" decimals="-6" id="f-972" unitRef="usd">4000000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet contextRef="c-222" decimals="-6" id="f-973" unitRef="usd">3458000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense contextRef="c-223" decimals="-6" id="f-974" unitRef="usd">35953000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense contextRef="c-224" decimals="-6" id="f-975" unitRef="usd">31342000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense contextRef="c-225" decimals="-6" id="f-976" unitRef="usd">31755000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense contextRef="c-223" decimals="-6" id="f-977" unitRef="usd">-279000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense contextRef="c-224" decimals="-6" id="f-978" unitRef="usd">-259000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense contextRef="c-225" decimals="-6" id="f-979" unitRef="usd">-219000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1 contextRef="c-223" decimals="-6" id="f-980" unitRef="usd">35674000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1 contextRef="c-224" decimals="-6" id="f-981" unitRef="usd">31083000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1 contextRef="c-225" decimals="-6" id="f-982" unitRef="usd">31536000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1 contextRef="c-223" decimals="-6" id="f-983" unitRef="usd">31322000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1 contextRef="c-224" decimals="-6" id="f-984" unitRef="usd">27583000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1 contextRef="c-225" decimals="-6" id="f-985" unitRef="usd">27929000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1 contextRef="c-223" decimals="-6" id="f-986" unitRef="usd">3451000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1 contextRef="c-224" decimals="-6" id="f-987" unitRef="usd">3545000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1 contextRef="c-225" decimals="-6" id="f-988" unitRef="usd">3065000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense contextRef="c-223" decimals="-6" id="f-989" unitRef="usd">34773000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense contextRef="c-224" decimals="-6" id="f-990" unitRef="usd">31128000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense contextRef="c-225" decimals="-6" id="f-991" unitRef="usd">30994000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <ci:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups contextRef="c-217" decimals="-6" id="f-992" unitRef="usd">4856000000</ci:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet contextRef="c-218" decimals="-6" id="f-993" unitRef="usd">3955000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet contextRef="c-221" decimals="-6" id="f-994" unitRef="usd">4000000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet>
    <ci:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups contextRef="c-217" decimals="-6" id="f-995" unitRef="usd">236000000</ci:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments contextRef="c-218" decimals="-6" id="f-996" unitRef="usd">221000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments contextRef="c-221" decimals="-6" id="f-997" unitRef="usd">261000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <ci:LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups contextRef="c-217" decimals="-6" id="f-998" unitRef="usd">5092000000</ci:LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-218" decimals="-6" id="f-999" unitRef="usd">4176000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-221" decimals="-6" id="f-1000" unitRef="usd">4261000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <ci:LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups contextRef="c-83" decimals="-6" id="f-1001" unitRef="usd">823000000</ci:LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups>
    <us-gaap:ReinsuranceAccountingPolicy contextRef="c-1" id="f-1002">Reinsurance and other amounts recoverable reflect amounts due from reinsurers and policyholders to cover incurred but not reported and pending claims of certain business for which the Company administers the plan benefits without any right of offset. See Note 11 to the Consolidated Financial Statements for additional information on reinsurance&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's insurance subsidiaries enter into agreements with other insurance companies to limit losses from large exposures and to permit recovery of a portion of incurred losses. Reinsurance is ceded primarily in acquisition and disposition transactions when the underwriting company is not being acquired. Reinsurance does not relieve the originating insurer of liability. Therefore, reinsured liabilities must continue to be reported along with the related reinsurance recoverables. The Company regularly evaluates the financial condition of its reinsurers and monitors concentrations of its credit risk.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Reinsurance recoverables represent amounts due from reinsurers for both paid and unpaid claims of the Company's insurance businesses. The Company bears the risk of loss if its reinsurers and retrocessionaires do not meet or are unable to meet their reinsurance obligations to the Company. Most reinsurance recoverables are classified as non-current assets. The current portion of reinsurance recoverables is reported in Other current assets and consists primarily of recoverables on paid claims expected to be settled within one year. Reinsurance recoverables are presented net of allowances, consisting primarily of an allowance for expected credit losses which is recognized on reinsurance recoverable balances each period and adjusted through Medical costs and other benefit expenses. Estimates of the allowance for expected credit losses are based on internal and external data used to develop expected loss rates over the anticipated duration of the recoverable asset that vary by external credit rating and collateral level. &lt;/span&gt;&lt;/div&gt;The Company reviews its reinsurance arrangements and establishes reserves against the recoverables.&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Collateral levels are defined internally based on the fair value of the collateral relative to the carrying amount of the reinsurance recoverable, the frequency at which collateral is required to be replenished and the potential for volatility in the collateral's fair value.&lt;/span&gt;&lt;/div&gt;Variable annuity contracts are accounted for as assumed and ceded reinsurance and categorized as market risk benefits as discussed in Note 10 to the Consolidated Financial Statements.</us-gaap:ReinsuranceAccountingPolicy>
    <us-gaap:ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock contextRef="c-1" id="f-1003">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Variances in incurred costs related to prior years' unpaid claims and claim expenses that resulted from the differences between actual experience and the Company's key assumptions were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.883%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.889%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="24" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;% &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;% &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Actual completion factors&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical cost trend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;209&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total favorable variance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;279&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Percentage of current year incurred costs as reported for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Percentage of current year incurred costs as reported for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCausesOfIncreaseDecreaseInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseTextBlock>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense contextRef="c-226" decimals="-6" id="f-1004" unitRef="usd">-70000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage
      contextRef="c-226"
      decimals="3"
      id="f-1005"
      unitRef="number">0.002</ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense contextRef="c-227" decimals="-6" id="f-1006" unitRef="usd">-62000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage
      contextRef="c-227"
      decimals="3"
      id="f-1007"
      unitRef="number">0.002</ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense contextRef="c-228" decimals="-6" id="f-1008" unitRef="usd">-209000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage
      contextRef="c-228"
      decimals="3"
      id="f-1009"
      unitRef="number">0.007</ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense contextRef="c-229" decimals="-6" id="f-1010" unitRef="usd">-197000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage
      contextRef="c-229"
      decimals="3"
      id="f-1011"
      unitRef="number">0.006</ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense contextRef="c-223" decimals="-6" id="f-1012" unitRef="usd">-279000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage
      contextRef="c-223"
      decimals="3"
      id="f-1013"
      unitRef="number">0.009</ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense contextRef="c-224" decimals="-6" id="f-1014" unitRef="usd">-259000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage
      contextRef="c-224"
      decimals="3"
      id="f-1015"
      unitRef="number">0.008</ci:LiabilityForUnpaidMedicalClaimsAndClaimsAdjustmentExpenseIncurredClaimsPriorYearsPercentage>
    <us-gaap:ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock contextRef="c-1" id="f-1016">&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table depicts the incurred and paid claims development and unpaid claims liability as of December&#160;31, 2023 (net of reinsurance) reported in the Cigna Healthcare segment. The information about incurred and paid claims development for the year ended December&#160;31, 2022 is presented as supplementary information and is unaudited.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Incurred Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Incurral Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;br/&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unpaid Claims &amp;amp; Claim Expenses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;30,050&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;209&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;34,878&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,498&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cumulative incurred costs for the periods presented&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;64,928&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative Costs Paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Incurral Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;br/&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29,841&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;30,380&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cumulative paid costs for the periods presented&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;60,221&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding liabilities for the periods presented, net of reinsurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,707&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-duration liabilities not included in development table above&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;149&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unpaid claims and claims expenses - Cigna Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,856&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reinsurance and other amounts recoverable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;236&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unpaid claims and claim expenses - Cigna Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,092&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock>
    <ci:ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-230" decimals="-6" id="f-1017" unitRef="usd">30309000000</ci:ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-231" decimals="-6" id="f-1018" unitRef="usd">30050000000</ci:ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-231" decimals="-6" id="f-1019" unitRef="usd">209000000</ci:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-232" decimals="-6" id="f-1020" unitRef="usd">34878000000</ci:ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-232" decimals="-6" id="f-1021" unitRef="usd">4498000000</ci:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-217" decimals="-6" id="f-1022" unitRef="usd">64928000000</ci:ShortDurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-230" decimals="-6" id="f-1023" unitRef="usd">26687000000</ci:ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-231" decimals="-6" id="f-1024" unitRef="usd">29841000000</ci:ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-232" decimals="-6" id="f-1025" unitRef="usd">30380000000</ci:ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-217" decimals="-6" id="f-1026" unitRef="usd">60221000000</ci:ShortDurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNetBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-217" decimals="-6" id="f-1027" unitRef="usd">4707000000</ci:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseUsedInClaimsDevelopmentNetBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseLongDurationNetBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-217" decimals="-6" id="f-1028" unitRef="usd">149000000</ci:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseLongDurationNetBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups contextRef="c-217" decimals="-6" id="f-1029" unitRef="usd">4856000000</ci:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetIncludingDisposalGroups>
    <ci:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups contextRef="c-217" decimals="-6" id="f-1030" unitRef="usd">236000000</ci:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustmentsIncludingDisposalGroups>
    <ci:LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups contextRef="c-217" decimals="-6" id="f-1031" unitRef="usd">5092000000</ci:LiabilityForClaimsAndClaimsAdjustmentExpenseIncludingDisposalGroups>
    <us-gaap:ShortdurationInsuranceContractsHistoricalClaimsDurationYearOne
      contextRef="c-217"
      decimals="2"
      id="f-1032"
      unitRef="number">0.95</us-gaap:ShortdurationInsuranceContractsHistoricalClaimsDurationYearOne>
    <ci:ShortdurationInsuranceContractsNumberOfPaidClaims
      contextRef="c-223"
      decimals="-5"
      id="f-1033"
      unitRef="claim">5500000</ci:ShortdurationInsuranceContractsNumberOfPaidClaims>
    <ci:ShortdurationInsuranceContractsNumberOfPaidClaims
      contextRef="c-224"
      decimals="-5"
      id="f-1034"
      unitRef="claim">5000000</ci:ShortdurationInsuranceContractsNumberOfPaidClaims>
    <us-gaap:FuturePolicyBenefitsLiabilityPolicy contextRef="c-1" id="f-1035">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting Policy.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Future policy benefits represent the present value of estimated future obligations, estimated using actuarial methods, for long-duration insurance policies and annuity products currently in force, consisting primarily of reserves for annuity contracts, life insurance benefits, and certain supplemental health products that are guaranteed renewable beyond one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contracts are grouped at a level no higher than issue year, based on the original contract issue date, and at lower levels of disaggregation within each issue year for certain businesses to reflect factors including product type, plan type and currency. Management estimates these obligations based on assumptions for premiums, interest rates, mortality or morbidity, future claim adjudication expenses and surrenders. Mortality, morbidity and surrender assumptions are based on the Company's own experience and published actuarial tables, and are updated at least annually, to the extent changes in circumstances require. Interest rate assumptions are based on&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;market-level yields for low credit risk fixed income instruments ("upper-medium grade fixed income instrument"). For interest accretion purposes, interest rates are fixed at the year of the cohort's inception, however for purposes of liability measurement, are updated to the current rate quarterly, with all changes in the interest rate from inception to current period reported through Accumulated other comprehensive loss. For contracts issued domestically, we use observable inputs from a published spot rate curve for terms up to 30 years and extrapolate for longer terms using a constant forward rate approach. For contracts issued by foreign operating entities with functional currencies other than the U.S. dollar, we use observable inputs to approximate a risk free rate and add a credit spread adjustment to align with a low-credit risk fixed income instrument. For terms beyond the last observable risk free rates, which vary by international market, we extrapolate to the ultimate forward rate assuming a constant credit spread.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For the annuity business, the premium paying period is shorter than the benefit coverage period, and a deferred profit liability is reported in future policy benefits representing gross premium received in excess of net premiums. Deferred profit liability is amortized based on expected future benefit payments.&lt;/span&gt;&lt;/div&gt;</us-gaap:FuturePolicyBenefitsLiabilityPolicy>
    <ci:FuturePolicyBenefitsDomesticContractsObservableInputsFromPublishedSpotRateCurveMaximumTerm contextRef="c-1" id="f-1036">P30Y</ci:FuturePolicyBenefitsDomesticContractsObservableInputsFromPublishedSpotRateCurveMaximumTerm>
    <ci:LiabilityForFuturePolicyBenefitsPercentSupportedByAssetsHeldInTrust contextRef="c-12" decimals="2" id="f-1037" unitRef="number">0.34</ci:LiabilityForFuturePolicyBenefitsPercentSupportedByAssetsHeldInTrust>
    <us-gaap:LiabilityForFuturePolicyBenefitActivityTableTextBlock contextRef="c-1" id="f-1038">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The weighted average interest rates applied and duration for future policy benefits in the Cigna Healthcare segment, consisting primarily of supplemental health products including individual Medicare supplement, limited benefit health products and individual private medical insurance, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest accretion rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.54&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current discount rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4.92&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average duration &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The present values of expected net premiums and expected future policy benefits for the Cigna Healthcare segment are as follows: &lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Present value of expected net premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,557&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reversal of effect of beginning of period discount rate assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,537&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of assumption changes and actual variances from expected experience &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;314&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Issuances and lapses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,255&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net premiums collected&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest and other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;94&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance at original discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,387&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of end of period discount rate assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,537)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,233&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Present value of expected policy benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,945&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reversal of effect of discount rate assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,611&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(379)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of assumption changes and actual variances from expected experience &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;112&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Issuances and lapses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,309&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefit payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,401)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest and other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance at original discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,853&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of discount rate assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,633&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability for future policy benefits &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;215&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total liability for future policy benefits &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)(7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;615&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Includes the effect of actual variances from expectations, which (decreased)/increased the total liability for future policy benefits by $(12) million and $46 million, respectively, for the years ended December&#160;31, 2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Includes the foreign exchange rate impact of translating from transactional and functional currency to United States dollar and the impact of flooring the liability at zero. The flooring impact is calculated at the cohort level after discounting the reserves at the current discount rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;As of December&#160;31, 2023 and December&#160;31, 2022 undiscounted expected future gross premiums were $18.7 billion and $17.5 billion, respectively. As of December&#160;31, 2023 and December&#160;31, 2022 discounted expected future gross premiums were $13.5 billion and $12.2 billion, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;As of December&#160;31, 2023 and December&#160;31, 2022, undiscounted expected future policy benefits were $13.3 billion and $12.7 billion, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;The liability for future policyholder benefits includes immaterial businesses shown as reconciling items above, most of which are in run-off. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;$72 million and $155 million reported in Reinsurance recoverables in the Consolidated Balance Sheets as of December&#160;31, 2023 and December&#160;31, 2022, respectively, relate to the liability for future policy benefits. Additionally, $79 million of reinsurance recoverables are reported in assets of businesses held for sale in the Consolidated Balance Sheets as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Includes $429 million of future policy benefits classified as liabilities of businesses held for sale in the Consolidated Balance Sheets as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The weighted average interest rates applied and duration for future policy benefits in Other Operations, consisting of annuity and life insurance products, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest accretion rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5.64&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current discount rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4.87&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average duration &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LiabilityForFuturePolicyBenefitActivityTableTextBlock>
    <us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate
      contextRef="c-217"
      decimals="4"
      id="f-1039"
      unitRef="number">0.0254</us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate>
    <us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate
      contextRef="c-218"
      decimals="4"
      id="f-1040"
      unitRef="number">0.0258</us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate>
    <us-gaap:LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate
      contextRef="c-217"
      decimals="4"
      id="f-1041"
      unitRef="number">0.0492</us-gaap:LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate>
    <us-gaap:LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate
      contextRef="c-218"
      decimals="4"
      id="f-1042"
      unitRef="number">0.0557</us-gaap:LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate>
    <us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageDuration contextRef="c-217" id="f-1043">P7Y10M24D</us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageDuration>
    <us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageDuration contextRef="c-218" id="f-1044">P7Y8M12D</us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageDuration>
    <us-gaap:LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange contextRef="c-218" decimals="-6" id="f-1045" unitRef="usd">8557000000</us-gaap:LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange>
    <us-gaap:LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange contextRef="c-221" decimals="-6" id="f-1046" unitRef="usd">9314000000</us-gaap:LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange>
    <us-gaap:AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax contextRef="c-218" decimals="-6" id="f-1047" unitRef="usd">-1537000000</us-gaap:AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax>
    <us-gaap:AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax contextRef="c-221" decimals="-6" id="f-1048" unitRef="usd">367000000</us-gaap:AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax>
    <ci:LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience contextRef="c-218" decimals="-6" id="f-1049" unitRef="usd">314000000</ci:LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience>
    <ci:LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience contextRef="c-221" decimals="-6" id="f-1050" unitRef="usd">1286000000</ci:LiabilityForFuturePolicyBenefitExpectedNetPremiumCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience>
    <ci:LiabilityForFuturePolicyBenefitExpectedNetPremiumIssuanceAndDerecognition contextRef="c-223" decimals="-6" id="f-1051" unitRef="usd">1255000000</ci:LiabilityForFuturePolicyBenefitExpectedNetPremiumIssuanceAndDerecognition>
    <ci:LiabilityForFuturePolicyBenefitExpectedNetPremiumIssuanceAndDerecognition contextRef="c-224" decimals="-6" id="f-1052" unitRef="usd">1067000000</ci:LiabilityForFuturePolicyBenefitExpectedNetPremiumIssuanceAndDerecognition>
    <us-gaap:LiabilityForFuturePolicyBenefitExpectedNetPremiumNetPremiumCollected contextRef="c-223" decimals="-6" id="f-1053" unitRef="usd">1370000000</us-gaap:LiabilityForFuturePolicyBenefitExpectedNetPremiumNetPremiumCollected>
    <us-gaap:LiabilityForFuturePolicyBenefitExpectedNetPremiumNetPremiumCollected contextRef="c-224" decimals="-6" id="f-1054" unitRef="usd">1280000000</us-gaap:LiabilityForFuturePolicyBenefitExpectedNetPremiumNetPremiumCollected>
    <ci:LiabilityForFuturePolicyBenefitExpectedNetPremiumInterestIncomeAndOtherChanges contextRef="c-223" decimals="-6" id="f-1055" unitRef="usd">94000000</ci:LiabilityForFuturePolicyBenefitExpectedNetPremiumInterestIncomeAndOtherChanges>
    <ci:LiabilityForFuturePolicyBenefitExpectedNetPremiumInterestIncomeAndOtherChanges contextRef="c-224" decimals="-6" id="f-1056" unitRef="usd">74000000</ci:LiabilityForFuturePolicyBenefitExpectedNetPremiumInterestIncomeAndOtherChanges>
    <us-gaap:LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance contextRef="c-217" decimals="-6" id="f-1057" unitRef="usd">10387000000</us-gaap:LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance>
    <us-gaap:LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance contextRef="c-218" decimals="-6" id="f-1058" unitRef="usd">10094000000</us-gaap:LiabilityForFuturePolicyBenefitExpectedNetPremiumOriginalDiscountRateBeforeCashFlowAndReinsurance>
    <us-gaap:AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax contextRef="c-217" decimals="-6" id="f-1059" unitRef="usd">-1154000000</us-gaap:AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax>
    <us-gaap:AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax contextRef="c-218" decimals="-6" id="f-1060" unitRef="usd">-1537000000</us-gaap:AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax>
    <us-gaap:LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange contextRef="c-217" decimals="-6" id="f-1061" unitRef="usd">9233000000</us-gaap:LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange>
    <us-gaap:LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange contextRef="c-218" decimals="-6" id="f-1062" unitRef="usd">8557000000</us-gaap:LiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeReinsuranceAfterDiscountRateChange>
    <us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange contextRef="c-218" decimals="-6" id="f-1063" unitRef="usd">8945000000</us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange>
    <us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange contextRef="c-221" decimals="-6" id="f-1064" unitRef="usd">9794000000</us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange>
    <us-gaap:AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax contextRef="c-218" decimals="-6" id="f-1065" unitRef="usd">1611000000</us-gaap:AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax>
    <us-gaap:AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax contextRef="c-221" decimals="-6" id="f-1066" unitRef="usd">-379000000</us-gaap:AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax>
    <ci:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience contextRef="c-218" decimals="-6" id="f-1067" unitRef="usd">112000000</ci:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience>
    <ci:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience contextRef="c-221" decimals="-6" id="f-1068" unitRef="usd">1148000000</ci:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitCumulativeIncreaseDecreaseFromCashFlowChangeAndActualVarianceFromExpectedExperience>
    <ci:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitIssuanceAndDerecognition contextRef="c-223" decimals="-6" id="f-1069" unitRef="usd">1309000000</ci:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitIssuanceAndDerecognition>
    <ci:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitIssuanceAndDerecognition contextRef="c-224" decimals="-6" id="f-1070" unitRef="usd">1176000000</ci:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitIssuanceAndDerecognition>
    <us-gaap:LiabilityForFuturePolicyBenefitsPaymentForBenefits contextRef="c-223" decimals="-6" id="f-1071" unitRef="usd">1374000000</us-gaap:LiabilityForFuturePolicyBenefitsPaymentForBenefits>
    <us-gaap:LiabilityForFuturePolicyBenefitsPaymentForBenefits contextRef="c-224" decimals="-6" id="f-1072" unitRef="usd">1401000000</us-gaap:LiabilityForFuturePolicyBenefitsPaymentForBenefits>
    <ci:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitInterestExpenseAndOtherChanges contextRef="c-223" decimals="-6" id="f-1073" unitRef="usd">250000000</ci:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitInterestExpenseAndOtherChanges>
    <ci:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitInterestExpenseAndOtherChanges contextRef="c-224" decimals="-6" id="f-1074" unitRef="usd">218000000</ci:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitInterestExpenseAndOtherChanges>
    <us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance contextRef="c-217" decimals="-6" id="f-1075" unitRef="usd">10853000000</us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance>
    <us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance contextRef="c-218" decimals="-6" id="f-1076" unitRef="usd">10556000000</us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitOriginalDiscountRateBeforeCashFlowAndReinsurance>
    <us-gaap:AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax contextRef="c-217" decimals="-6" id="f-1077" unitRef="usd">1220000000</us-gaap:AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax>
    <us-gaap:AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax contextRef="c-218" decimals="-6" id="f-1078" unitRef="usd">1611000000</us-gaap:AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax>
    <us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange contextRef="c-217" decimals="-6" id="f-1079" unitRef="usd">9633000000</us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange>
    <us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange contextRef="c-218" decimals="-6" id="f-1080" unitRef="usd">8945000000</us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeReinsuranceAfterDiscountRateChange>
    <ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther contextRef="c-217" decimals="-6" id="f-1081" unitRef="usd">400000000</ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther>
    <ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther contextRef="c-218" decimals="-6" id="f-1082" unitRef="usd">388000000</ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceAndOther>
    <ci:LiabilityForFuturePolicyBenefitOther contextRef="c-217" decimals="-6" id="f-1083" unitRef="usd">215000000</ci:LiabilityForFuturePolicyBenefitOther>
    <ci:LiabilityForFuturePolicyBenefitOther contextRef="c-218" decimals="-6" id="f-1084" unitRef="usd">199000000</ci:LiabilityForFuturePolicyBenefitOther>
    <ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-217" decimals="-6" id="f-1085" unitRef="usd">615000000</ci:LiabilityForFuturePolicyBenefitBeforeReinsuranceBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:LiabilityForFuturePolicyBenefits contextRef="c-218" decimals="-6" id="f-1086" unitRef="usd">587000000</us-gaap:LiabilityForFuturePolicyBenefits>
    <ci:LiabilityForFuturePolicyBenefitsCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience contextRef="c-217" decimals="-6" id="f-1087" unitRef="usd">-12000000</ci:LiabilityForFuturePolicyBenefitsCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience>
    <ci:LiabilityForFuturePolicyBenefitsCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience contextRef="c-218" decimals="-6" id="f-1088" unitRef="usd">46000000</ci:LiabilityForFuturePolicyBenefitsCumulativeIncreaseDecreaseOfActualVarianceFromExpectedExperience>
    <us-gaap:LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumUndiscountedBeforeReinsurance contextRef="c-217" decimals="-8" id="f-1089" unitRef="usd">18700000000</us-gaap:LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumUndiscountedBeforeReinsurance>
    <us-gaap:LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumUndiscountedBeforeReinsurance contextRef="c-218" decimals="-8" id="f-1090" unitRef="usd">17500000000</us-gaap:LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumUndiscountedBeforeReinsurance>
    <us-gaap:LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumDiscountedBeforeReinsurance contextRef="c-217" decimals="-8" id="f-1091" unitRef="usd">13500000000</us-gaap:LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumDiscountedBeforeReinsurance>
    <us-gaap:LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumDiscountedBeforeReinsurance contextRef="c-218" decimals="-8" id="f-1092" unitRef="usd">12200000000</us-gaap:LiabilityForFuturePolicyBenefitExpectedFutureGrossPremiumDiscountedBeforeReinsurance>
    <us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance contextRef="c-217" decimals="-8" id="f-1093" unitRef="usd">13300000000</us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance>
    <us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance contextRef="c-218" decimals="-8" id="f-1094" unitRef="usd">12700000000</us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance>
    <us-gaap:LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance contextRef="c-217" decimals="-6" id="f-1095" unitRef="usd">72000000</us-gaap:LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance>
    <us-gaap:LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance contextRef="c-218" decimals="-6" id="f-1096" unitRef="usd">155000000</us-gaap:LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance>
    <ci:ReinsuranceRecoverablesLiabilityForFuturePolicyBenefitsAssetsHeldForSale contextRef="c-233" decimals="-6" id="f-1097" unitRef="usd">79000000</ci:ReinsuranceRecoverablesLiabilityForFuturePolicyBenefitsAssetsHeldForSale>
    <ci:LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups contextRef="c-83" decimals="-6" id="f-1098" unitRef="usd">429000000</ci:LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups>
    <us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate
      contextRef="c-219"
      decimals="4"
      id="f-1099"
      unitRef="number">0.0564</us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate>
    <us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate
      contextRef="c-220"
      decimals="4"
      id="f-1100"
      unitRef="number">0.0564</us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageInterestAccretionRate>
    <us-gaap:LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate
      contextRef="c-219"
      decimals="4"
      id="f-1101"
      unitRef="number">0.0487</us-gaap:LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate>
    <us-gaap:LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate
      contextRef="c-220"
      decimals="4"
      id="f-1102"
      unitRef="number">0.0519</us-gaap:LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate>
    <us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageDuration contextRef="c-219" id="f-1103">P11Y4M24D</us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageDuration>
    <us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageDuration contextRef="c-220" id="f-1104">P11Y6M</us-gaap:LiabilityForFuturePolicyBenefitWeightedAverageDuration>
    <ci:LiabilityForFuturePolicyBenefitsDeferredProfitLiability contextRef="c-219" decimals="-6" id="f-1105" unitRef="usd">384000000</ci:LiabilityForFuturePolicyBenefitsDeferredProfitLiability>
    <ci:LiabilityForFuturePolicyBenefitsDeferredProfitLiability contextRef="c-220" decimals="-6" id="f-1106" unitRef="usd">390000000</ci:LiabilityForFuturePolicyBenefitsDeferredProfitLiability>
    <ci:LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability contextRef="c-219" decimals="-8" id="f-1107" unitRef="usd">3200000000</ci:LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability>
    <ci:LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability contextRef="c-220" decimals="-8" id="f-1108" unitRef="usd">3200000000</ci:LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability>
    <ci:LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability contextRef="c-234" decimals="-8" id="f-1109" unitRef="usd">4300000000</ci:LiabilityForFuturePolicyBenefitExcludingDeferredProfitLiability>
    <ci:LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups contextRef="c-235" decimals="-8" id="f-1110" unitRef="usd">3800000000</ci:LiabilityForFuturePolicyBenefitsAttributableToDisposalGroups>
    <us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance contextRef="c-219" decimals="-8" id="f-1111" unitRef="usd">4500000000</us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance>
    <us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance contextRef="c-220" decimals="-8" id="f-1112" unitRef="usd">4600000000</us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitUndiscountedBeforeReinsurance>
    <us-gaap:LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance contextRef="c-219" decimals="-8" id="f-1113" unitRef="usd">1000000000</us-gaap:LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance>
    <us-gaap:LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance contextRef="c-220" decimals="-8" id="f-1114" unitRef="usd">1100000000</us-gaap:LiabilityForFuturePolicyBenefitReinsuranceRecoverableAfterAllowance>
    <ci:ContractholderDepositFundsPolicyPolicyTextBlock contextRef="c-1" id="f-1115">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting Policy. &lt;/span&gt;Liabilities for contractholder deposit funds primarily include deposits received from customers for investment-related and universal life products as well as investment earnings on their fund balances in Other Operations. These liabilities are adjusted to reflect administrative charges and, for universal life fund balances, mortality charges. Interest credited on these funds is accrued ratably over the contract period.</ci:ContractholderDepositFundsPolicyPolicyTextBlock>
    <us-gaap:PolicyholderContractDeposits contextRef="c-219" decimals="-8" id="f-1116" unitRef="usd">6500000000</us-gaap:PolicyholderContractDeposits>
    <us-gaap:PolicyholderContractDeposits contextRef="c-220" decimals="-8" id="f-1117" unitRef="usd">6700000000</us-gaap:PolicyholderContractDeposits>
    <us-gaap:PolicyholderContractDeposits contextRef="c-234" decimals="-8" id="f-1118" unitRef="usd">6900000000</us-gaap:PolicyholderContractDeposits>
    <ci:PolicyholderContractBalancePercentReinsuredExternally contextRef="c-12" decimals="2" id="f-1119" unitRef="number">0.39</ci:PolicyholderContractBalancePercentReinsuredExternally>
    <us-gaap:PolicyholderAccountBalanceWeightedAverageCreditingRate
      contextRef="c-219"
      decimals="4"
      id="f-1120"
      unitRef="number">0.0331</us-gaap:PolicyholderAccountBalanceWeightedAverageCreditingRate>
    <us-gaap:PolicyholderAccountBalanceNetAmountAtRisk contextRef="c-219" decimals="-8" id="f-1121" unitRef="usd">3000000000</us-gaap:PolicyholderAccountBalanceNetAmountAtRisk>
    <us-gaap:CashSurrenderValueDuePolicyholdersAmount contextRef="c-219" decimals="-8" id="f-1122" unitRef="usd">2800000000</us-gaap:CashSurrenderValueDuePolicyholdersAmount>
    <us-gaap:PolicyholderAccountBalanceWeightedAverageCreditingRate
      contextRef="c-220"
      decimals="4"
      id="f-1123"
      unitRef="number">0.0308</us-gaap:PolicyholderAccountBalanceWeightedAverageCreditingRate>
    <us-gaap:PolicyholderAccountBalanceNetAmountAtRisk contextRef="c-220" decimals="-8" id="f-1124" unitRef="usd">3000000000</us-gaap:PolicyholderAccountBalanceNetAmountAtRisk>
    <us-gaap:CashSurrenderValueDuePolicyholdersAmount contextRef="c-220" decimals="-8" id="f-1125" unitRef="usd">2400000000</us-gaap:CashSurrenderValueDuePolicyholdersAmount>
    <ci:PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage
      contextRef="c-236"
      decimals="2"
      id="f-1126"
      unitRef="number">0.99</ci:PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage>
    <ci:PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage
      contextRef="c-237"
      decimals="2"
      id="f-1127"
      unitRef="number">0.99</ci:PolicyholderAccountBalanceGuaranteedMinimumCreditingRatePercentage>
    <us-gaap:PolicyholderFunds contextRef="c-237" decimals="-8" id="f-1128" unitRef="usd">4000000000</us-gaap:PolicyholderFunds>
    <us-gaap:PolicyholderFunds contextRef="c-236" decimals="-8" id="f-1129" unitRef="usd">4100000000</us-gaap:PolicyholderFunds>
    <us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditRating
      contextRef="c-238"
      decimals="2"
      id="f-1130"
      unitRef="number">0.03</us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditRating>
    <us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditRating
      contextRef="c-239"
      decimals="2"
      id="f-1131"
      unitRef="number">0.03</us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditRating>
    <us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditRating
      contextRef="c-240"
      decimals="2"
      id="f-1132"
      unitRef="number">0.04</us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditRating>
    <us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditRating
      contextRef="c-241"
      decimals="2"
      id="f-1133"
      unitRef="number">0.04</us-gaap:PolicyholderAccountBalanceGuaranteedMinimumCreditRating>
    <us-gaap:PolicyholderFunds contextRef="c-242" decimals="-8" id="f-1134" unitRef="usd">1200000000</us-gaap:PolicyholderFunds>
    <us-gaap:PolicyholderFunds contextRef="c-243" decimals="-8" id="f-1135" unitRef="usd">1200000000</us-gaap:PolicyholderFunds>
    <us-gaap:PolicyholderFunds contextRef="c-244" decimals="-8" id="f-1136" unitRef="usd">1200000000</us-gaap:PolicyholderFunds>
    <us-gaap:PolicyholderFunds contextRef="c-245" decimals="-8" id="f-1137" unitRef="usd">1200000000</us-gaap:PolicyholderFunds>
    <us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate
      contextRef="c-246"
      decimals="3"
      id="f-1138"
      unitRef="number">0.0050</us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate>
    <us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate
      contextRef="c-247"
      decimals="3"
      id="f-1139"
      unitRef="number">0.0050</us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate>
    <us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate
      contextRef="c-248"
      decimals="3"
      id="f-1140"
      unitRef="number">0.0150</us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate>
    <us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate
      contextRef="c-249"
      decimals="3"
      id="f-1141"
      unitRef="number">0.0150</us-gaap:PolicyholderAccountBalanceAboveGuaranteedMinimumCreditingRate>
    <us-gaap:PolicyholderFunds contextRef="c-250" decimals="-8" id="f-1142" unitRef="usd">1600000000</us-gaap:PolicyholderFunds>
    <us-gaap:PolicyholderFunds contextRef="c-251" decimals="-8" id="f-1143" unitRef="usd">1700000000</us-gaap:PolicyholderFunds>
    <ci:PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue
      contextRef="c-250"
      decimals="2"
      id="f-1144"
      unitRef="number">0.90</ci:PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue>
    <ci:PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue
      contextRef="c-251"
      decimals="2"
      id="f-1145"
      unitRef="number">0.90</ci:PolicyholderAccountBalancePercentageWithCashValuesAtMoreThan110PercentOfGuaranteedCashValue>
    <ci:AnnuitizationElectionPeriod contextRef="c-1" id="f-1146">P30D</ci:AnnuitizationElectionPeriod>
    <us-gaap:MarketRiskBenefitPolicyTextBlock contextRef="c-1" id="f-1147">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting Policy.&lt;/span&gt; Variable annuity reinsurance liabilities are measured as MRBs at fair value, net of nonperformance risk, with fluctuations in value gross of reinsurer nonperformance risk reported in benefit expenses, while fluctuations in the Company's own nonperformance risk (own credit risk) are reported in Accumulated other comprehensive loss. Nonperformance risk reflects risk that a party might default and therefore not fulfill its obligations (i.e. nonpayment risk). The nonperformance risk adjustment reflects a market participant's view of nonpayment risk by adding an additional spread to the discount rate in the calculation of both (a) the variable annuity reinsurance liabilities to be paid by the Company and (b) the variable annuity reinsurance assets to be paid by the reinsurers, after considering collateral. The Company classifies variable annuity assets and liabilities in Level 3 of the fair value hierarchy described in Note 13 to the Consolidated Financial Statements because assumptions related to future annuitant behavior are largely unobservable. As discussed further in Note 11 to the Consolidated Financial Statements, due to the reinsurance agreements covering these liabilities, the liabilities do not generally impact net income except for the change in nonperformance risk on the reinsurance recoverable, which is reported in benefit expenses and does not offset the nonperformance risk valuation on the liability. Variable annuity liabilities are established using capital market assumptions and assumptions related to future annuitant behavior (including mortality, lapse and annuity election rates).</us-gaap:MarketRiskBenefitPolicyTextBlock>
    <us-gaap:MarketRiskBenefitActivityTableTextBlock contextRef="c-1" id="f-1148">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Market risk benefits activity was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.877%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.911%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.912%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;1,268&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;1,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Balance, beginning of year, before the effect of nonperformance risk (own credit risk)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;1,379&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;1,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Changes due to expected run-off&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Changes due to capital markets versus expected&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;(254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Changes due to policyholder behavior versus expected&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Assumption changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Balance, end of period, before the effect of changes in nonperformance risk (own credit risk)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;1,085&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;1,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Nonperformance risk (own credit risk), end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;(111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;1,003&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;1,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Reinsured market risk benefit, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;1,081&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;1,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.432%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Reinsurer &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Collateral and Other Terms&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;at December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Berkshire&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;873&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95% were secured by assets in a trust.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sun Life Assurance Company of Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;92&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liberty Re (Bermuda) Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;104&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100% were secured by assets in a trust.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SCOR SE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80% were secured by a letter of credit.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market risk benefits &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;All reinsurers are rated A- equivalent and higher by an NRSRO.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Includes IBNR and outstanding claims of $19 million. These amounts are excluded from market risk benefits at December&#160;31, 2023 in Note 10 and Note 11A to the Consolidated Financial Statements. At December&#160;31, 2022, IBNR and outstanding claims of $27 million offset by premium due of $3 million were excluded from the market risk benefits as restated due to the adoption of LDTI.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketRiskBenefitActivityTableTextBlock>
    <us-gaap:MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk contextRef="c-13" decimals="-6" id="f-1149" unitRef="usd">1268000000</us-gaap:MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk>
    <us-gaap:MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk contextRef="c-47" decimals="-6" id="f-1150" unitRef="usd">1824000000</us-gaap:MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk>
    <us-gaap:MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange contextRef="c-13" decimals="-6" id="f-1151" unitRef="usd">1379000000</us-gaap:MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange>
    <us-gaap:MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange contextRef="c-47" decimals="-6" id="f-1152" unitRef="usd">1949000000</us-gaap:MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange>
    <ci:MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff contextRef="c-1" decimals="-6" id="f-1153" unitRef="usd">-19000000</ci:MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff>
    <ci:MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff contextRef="c-7" decimals="-6" id="f-1154" unitRef="usd">-54000000</ci:MarketRiskBenefitIncreaseDecreaseDueToExpectedRunOff>
    <ci:MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange contextRef="c-1" decimals="-6" id="f-1155" unitRef="usd">-254000000</ci:MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange>
    <ci:MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange contextRef="c-7" decimals="-6" id="f-1156" unitRef="usd">-567000000</ci:MarketRiskBenefitIncreaseDecreaseFromInterestRateChangeAndEquityMarketChange>
    <us-gaap:MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected contextRef="c-1" decimals="-6" id="f-1157" unitRef="usd">-5000000</us-gaap:MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected>
    <us-gaap:MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected contextRef="c-7" decimals="-6" id="f-1158" unitRef="usd">-14000000</us-gaap:MarketRiskBenefitIncreaseDecreaseFromActualPolicyholderBehaviorDifferentFromExpected>
    <us-gaap:MarketRiskBenefitIncreaseDecreaseFromOtherAssumption contextRef="c-1" decimals="-6" id="f-1159" unitRef="usd">-16000000</us-gaap:MarketRiskBenefitIncreaseDecreaseFromOtherAssumption>
    <us-gaap:MarketRiskBenefitIncreaseDecreaseFromOtherAssumption contextRef="c-7" decimals="-6" id="f-1160" unitRef="usd">65000000</us-gaap:MarketRiskBenefitIncreaseDecreaseFromOtherAssumption>
    <us-gaap:MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange contextRef="c-12" decimals="-6" id="f-1161" unitRef="usd">1085000000</us-gaap:MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange>
    <us-gaap:MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange contextRef="c-13" decimals="-6" id="f-1162" unitRef="usd">1379000000</us-gaap:MarketRiskBenefitBeforeReinsuranceAndCumulativeIncreaseDecreaseFromInstrumentSpecificCreditRiskChange>
    <us-gaap:AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax contextRef="c-12" decimals="-6" id="f-1163" unitRef="usd">82000000</us-gaap:AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax>
    <us-gaap:AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax contextRef="c-13" decimals="-6" id="f-1164" unitRef="usd">111000000</us-gaap:AociMarketRiskBenefitInstrumentSpecificCreditRiskBeforeTax>
    <us-gaap:MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk contextRef="c-12" decimals="-6" id="f-1165" unitRef="usd">1003000000</us-gaap:MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk>
    <us-gaap:MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk contextRef="c-13" decimals="-6" id="f-1166" unitRef="usd">1268000000</us-gaap:MarketRiskBenefitAfterIncreaseDecreaseFromInstrumentSpecificCreditRisk>
    <us-gaap:MarketRiskBenefitReinsuranceRecoverableAfterAllowance contextRef="c-12" decimals="-6" id="f-1167" unitRef="usd">1081000000</us-gaap:MarketRiskBenefitReinsuranceRecoverableAfterAllowance>
    <us-gaap:MarketRiskBenefitReinsuranceRecoverableAfterAllowance contextRef="c-13" decimals="-6" id="f-1168" unitRef="usd">1374000000</us-gaap:MarketRiskBenefitReinsuranceRecoverableAfterAllowance>
    <us-gaap:ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock contextRef="c-1" id="f-1169">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents the account value, net amount at risk, average attained age of contractholders (weighted by exposure) and the number of contractholders for guarantees assumed by the Company. The net amount at risk is the amount that the Company would have to pay to contractholders if all deaths or annuitizations occurred as of the earliest possible date in accordance with the insurance contract. As of December&#160;31, 2023, the account value increased primarily due to favorable equity market performance, which resulted in an decrease to the net amount at risk. The Company should be reimbursed in full for these payments unless the Berkshire reinsurance limit is exceeded.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Dollars in millions, excludes impact of reinsurance ceded)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Account value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,736&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net amount at risk&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,609&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Average attained age of contractholders (weighted by exposure)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;77.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74.7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Number of contractholders (estimated)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;140,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetAmountOfRiskByProductAndGuaranteeTextBlock>
    <us-gaap:NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue contextRef="c-252" decimals="-6" id="f-1170" unitRef="usd">7736000000</us-gaap:NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue>
    <us-gaap:NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue contextRef="c-253" decimals="-6" id="f-1171" unitRef="usd">7436000000</us-gaap:NetAmountAtRiskByProductAndGuaranteeGeneralAccountValue>
    <us-gaap:NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk contextRef="c-252" decimals="-6" id="f-1172" unitRef="usd">1609000000</us-gaap:NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk>
    <us-gaap:NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk contextRef="c-253" decimals="-6" id="f-1173" unitRef="usd">2494000000</us-gaap:NetAmountAtRiskByProductAndGuaranteeNetAmountAtRisk>
    <us-gaap:NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1 contextRef="c-254" id="f-1174">P77Y3M18D</us-gaap:NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1>
    <us-gaap:NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1 contextRef="c-255" id="f-1175">P74Y8M12D</us-gaap:NetAmountAtRiskByProductAndGuaranteeWeightedAverageAttainedAge1>
    <ci:NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated
      contextRef="c-252"
      decimals="-4"
      id="f-1176"
      unitRef="position">140000</ci:NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated>
    <ci:NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated
      contextRef="c-253"
      decimals="-4"
      id="f-1177"
      unitRef="position">150000</ci:NetAmountAtRiskByProductAndGuaranteeNumberOfContractholdersEstimated>
    <us-gaap:ReinsuranceTextBlock contextRef="c-1" id="f-1178">&lt;div style="margin-bottom:10pt"&gt;&lt;span id="i06222830be1a4df2a23a97244932bcc5_626"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Note 11 &#x2013; Reinsurance&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's insurance subsidiaries enter into agreements with other insurance companies to limit losses from large exposures and to permit recovery of a portion of incurred losses. Reinsurance is ceded primarily in acquisition and disposition transactions when the underwriting company is not being acquired. Reinsurance does not relieve the originating insurer of liability. Therefore, reinsured liabilities must continue to be reported along with the related reinsurance recoverables. The Company regularly evaluates the financial condition of its reinsurers and monitors concentrations of its credit risk.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt;text-decoration:underline"&gt;Reinsurance Recoverables&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Reinsurance recoverables represent amounts due from reinsurers for both paid and unpaid claims of the Company's insurance businesses. The Company bears the risk of loss if its reinsurers and retrocessionaires do not meet or are unable to meet their reinsurance obligations to the Company. Most reinsurance recoverables are classified as non-current assets. The current portion of reinsurance recoverables is reported in Other current assets and consists primarily of recoverables on paid claims expected to be settled within one year. Reinsurance recoverables are presented net of allowances, consisting primarily of an allowance for expected credit losses which is recognized on reinsurance recoverable balances each period and adjusted through Medical costs and other benefit expenses. Estimates of the allowance for expected credit losses are based on internal and external data used to develop expected loss rates over the anticipated duration of the recoverable asset that vary by external credit rating and collateral level. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The majority of the Company's reinsurance recoverables resulted from acquisition and disposition transactions in which the underwriting company was not acquired. The Company reviews its reinsurance arrangements and establishes reserves against the recoverables.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's reinsurance recoverables as of December&#160;31, 2023 are presented at amount due by range of external credit rating and collateral level in the following table, with reinsurance recoverables that are market risk benefits separately presented at fair value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.237%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Fair value of collateral contractually required to meet or exceed carrying value of recoverable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Collateral provisions exist that may mitigate risk of credit loss &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;No collateral&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Ongoing Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;A- equivalent and higher current ratings &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;BBB- to BBB+ equivalent current credit ratings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;59&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;59&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Not rated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;151&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;182&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;338&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total recoverables related to ongoing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;151&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;331&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;487&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquisition, disposition or run-off activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BBB+ equivalent and higher current ratings &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lincoln National Life and Lincoln Life &amp;amp; Annuity of New York&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,656&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,656&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Empower Annuity Insurance Company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;130&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;130&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prudential Insurance Company of America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;341&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;341&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Life Insurance Company of North America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;356&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;356&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;166&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;14&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Not rated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total recoverables related to acquisition, disposition or run-off activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;507&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,038&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;148&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,693&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total reinsurance recoverables before market risk benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;658&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,043&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;479&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,180&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Allowance for uncollectible reinsurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market risk benefits &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,081&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total reinsurance recoverables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,226&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Certified by a NRSRO.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Includes collateral provisions requiring the reinsurer to fully collateralize its obligation if its external credit rating is downgraded to a specified level.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Prior to the adoption of LDTI, "acquisition, disposition or run-off activities" in the table above included Berkshire and certain Other recoverables that are related to the Company's variable annuity reinsurance products discussed in section B below. These amounts are now reported at fair market value as MRBs, as further discussed in Note 10 to the Consolidated Financial Statements. At December&#160;31, 2022, we reported $711 million of recoverables related to the GMDB variable annuity reinsurance product. The restated December&#160;31, 2022 variable annuity reinsurance recoverable balance is $1.4 billion, which also includes the GMIB variable annuity reinsurance product that was classified in Other assets prior to the adoption of LDTI.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Includes $183 million of current reinsurance recoverables that are reported in Other current assets and $208 million of reinsurance recoverables classified as assets of businesses held for sale.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Collateral levels are defined internally based on the fair value of the collateral relative to the carrying amount of the reinsurance recoverable, the frequency at which collateral is required to be replenished and the potential for volatility in the collateral's fair value.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline"&gt;Effective Exit of Variable Annuity Reinsurance Business&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company entered into an agreement with Berkshire to effectively exit the variable annuity reinsurance business via a reinsurance transaction in 2013. Variable annuity contracts are accounted for as assumed and ceded reinsurance and categorized as market risk benefits as discussed in Note 10 to the Consolidated Financial Statements. Berkshire reinsured 100% of the Company's future cash flows in this business, net of other reinsurance arrangements existing at that time. The reinsurance agreement is subject to an overall limit with approximately $3.1 billion remaining at December&#160;31, 2023. As a result of the reinsurance transaction, amounts payable are offset by a corresponding reinsurance recoverable, provided the increased recoverable remains within the overall Berkshire limit.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.432%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Reinsurer &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Collateral and Other Terms&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;at December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Berkshire&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;873&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95% were secured by assets in a trust.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sun Life Assurance Company of Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;92&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liberty Re (Bermuda) Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;104&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100% were secured by assets in a trust.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SCOR SE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80% were secured by a letter of credit.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market risk benefits &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;All reinsurers are rated A- equivalent and higher by an NRSRO.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Includes IBNR and outstanding claims of $19 million. These amounts are excluded from market risk benefits at December&#160;31, 2023 in Note 10 and Note 11A to the Consolidated Financial Statements. At December&#160;31, 2022, IBNR and outstanding claims of $27 million offset by premium due of $3 million were excluded from the market risk benefits as restated due to the adoption of LDTI.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The impact of nonperformance risk (i.e., the risk that a counterparty might default) on the variable annuity reinsurance asset was immaterial for the years ended 2023, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline"&gt;Effects of Reinsurance&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents direct, assumed and ceded earned premiums for both short-duration and long-duration insurance contracts. It also presents reinsurance recoveries that have been netted against Medical costs and other benefit expenses in the Company's Consolidated Statements of Income.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Short-duration contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Direct&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;42,266&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;303&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ceded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total short-duration contract premiums&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;42,292&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Long-duration contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Direct&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,084&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ceded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total long-duration contract premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,945&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total premiums&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;44,237&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total reinsurance recoveries&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;456&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;Total short-duration contracts written premiums were $41.1 billion, $35.0 billion and $35.6 billion for 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReinsuranceTextBlock>
    <us-gaap:ScheduleOfCededCreditRiskByReinsurerTextBlock contextRef="c-1" id="f-1179">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's reinsurance recoverables as of December&#160;31, 2023 are presented at amount due by range of external credit rating and collateral level in the following table, with reinsurance recoverables that are market risk benefits separately presented at fair value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.237%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Fair value of collateral contractually required to meet or exceed carrying value of recoverable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Collateral provisions exist that may mitigate risk of credit loss &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;No collateral&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Ongoing Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;A- equivalent and higher current ratings &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;BBB- to BBB+ equivalent current credit ratings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;59&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;59&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Not rated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;151&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;182&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;338&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total recoverables related to ongoing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;151&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;331&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;487&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquisition, disposition or run-off activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BBB+ equivalent and higher current ratings &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lincoln National Life and Lincoln Life &amp;amp; Annuity of New York&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,656&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,656&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Empower Annuity Insurance Company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;130&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;130&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prudential Insurance Company of America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;341&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;341&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Life Insurance Company of North America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;356&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;356&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;166&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;14&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Not rated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total recoverables related to acquisition, disposition or run-off activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;507&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,038&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;148&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,693&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total reinsurance recoverables before market risk benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;658&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,043&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;479&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,180&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Allowance for uncollectible reinsurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market risk benefits &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,081&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total reinsurance recoverables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,226&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Certified by a NRSRO.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Includes collateral provisions requiring the reinsurer to fully collateralize its obligation if its external credit rating is downgraded to a specified level.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Prior to the adoption of LDTI, "acquisition, disposition or run-off activities" in the table above included Berkshire and certain Other recoverables that are related to the Company's variable annuity reinsurance products discussed in section B below. These amounts are now reported at fair market value as MRBs, as further discussed in Note 10 to the Consolidated Financial Statements. At December&#160;31, 2022, we reported $711 million of recoverables related to the GMDB variable annuity reinsurance product. The restated December&#160;31, 2022 variable annuity reinsurance recoverable balance is $1.4 billion, which also includes the GMIB variable annuity reinsurance product that was classified in Other assets prior to the adoption of LDTI.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Includes $183 million of current reinsurance recoverables that are reported in Other current assets and $208 million of reinsurance recoverables classified as assets of businesses held for sale.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCededCreditRiskByReinsurerTextBlock>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-256" decimals="-6" id="f-1180" unitRef="usd">0</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-257" decimals="-6" id="f-1181" unitRef="usd">0</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-258" decimals="-6" id="f-1182" unitRef="usd">90000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-259" decimals="-6" id="f-1183" unitRef="usd">90000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-260" decimals="-6" id="f-1184" unitRef="usd">0</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-261" decimals="-6" id="f-1185" unitRef="usd">0</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-262" decimals="-6" id="f-1186" unitRef="usd">59000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-263" decimals="-6" id="f-1187" unitRef="usd">59000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-264" decimals="-6" id="f-1188" unitRef="usd">151000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-265" decimals="-6" id="f-1189" unitRef="usd">5000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-266" decimals="-6" id="f-1190" unitRef="usd">182000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-267" decimals="-6" id="f-1191" unitRef="usd">338000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-268" decimals="-6" id="f-1192" unitRef="usd">151000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-269" decimals="-6" id="f-1193" unitRef="usd">5000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-270" decimals="-6" id="f-1194" unitRef="usd">331000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-271" decimals="-6" id="f-1195" unitRef="usd">487000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-272" decimals="-6" id="f-1196" unitRef="usd">0</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-273" decimals="-6" id="f-1197" unitRef="usd">2656000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-274" decimals="-6" id="f-1198" unitRef="usd">0</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-275" decimals="-6" id="f-1199" unitRef="usd">2656000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-276" decimals="-6" id="f-1200" unitRef="usd">0</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-277" decimals="-6" id="f-1201" unitRef="usd">0</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-278" decimals="-6" id="f-1202" unitRef="usd">130000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-279" decimals="-6" id="f-1203" unitRef="usd">130000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-280" decimals="-6" id="f-1204" unitRef="usd">341000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-281" decimals="-6" id="f-1205" unitRef="usd">0</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-282" decimals="-6" id="f-1206" unitRef="usd">0</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-283" decimals="-6" id="f-1207" unitRef="usd">341000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-284" decimals="-6" id="f-1208" unitRef="usd">0</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-285" decimals="-6" id="f-1209" unitRef="usd">356000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-286" decimals="-6" id="f-1210" unitRef="usd">0</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-287" decimals="-6" id="f-1211" unitRef="usd">356000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-288" decimals="-6" id="f-1212" unitRef="usd">166000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-289" decimals="-6" id="f-1213" unitRef="usd">19000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-290" decimals="-6" id="f-1214" unitRef="usd">14000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-291" decimals="-6" id="f-1215" unitRef="usd">199000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-292" decimals="-6" id="f-1216" unitRef="usd">0</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-293" decimals="-6" id="f-1217" unitRef="usd">7000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-294" decimals="-6" id="f-1218" unitRef="usd">4000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-295" decimals="-6" id="f-1219" unitRef="usd">11000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-296" decimals="-6" id="f-1220" unitRef="usd">507000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-297" decimals="-6" id="f-1221" unitRef="usd">3038000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-298" decimals="-6" id="f-1222" unitRef="usd">148000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-299" decimals="-6" id="f-1223" unitRef="usd">3693000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-300" decimals="-6" id="f-1224" unitRef="usd">658000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-301" decimals="-6" id="f-1225" unitRef="usd">3043000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-302" decimals="-6" id="f-1226" unitRef="usd">479000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-1227" unitRef="usd">4180000000</ci:ReinsuranceRecoverablesGrossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:ReinsuranceRecoverableAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-1228" unitRef="usd">35000000</ci:ReinsuranceRecoverableAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:MarketRiskBenefitReinsuranceRecoverableAfterAllowance contextRef="c-303" decimals="-6" id="f-1229" unitRef="usd">1081000000</us-gaap:MarketRiskBenefitReinsuranceRecoverableAfterAllowance>
    <ci:ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-1230" unitRef="usd">5226000000</ci:ReinsuranceRecoverablesIncludingReinsurancePremiumPaidBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:MarketRiskBenefitReinsuranceRecoverableAfterAllowance contextRef="c-304" decimals="-6" id="f-1231" unitRef="usd">711000000</us-gaap:MarketRiskBenefitReinsuranceRecoverableAfterAllowance>
    <us-gaap:MarketRiskBenefitReinsuranceRecoverableAfterAllowance contextRef="c-305" decimals="-8" id="f-1232" unitRef="usd">1400000000</us-gaap:MarketRiskBenefitReinsuranceRecoverableAfterAllowance>
    <us-gaap:ReinsuranceRecoverables contextRef="c-306" decimals="-6" id="f-1233" unitRef="usd">183000000</us-gaap:ReinsuranceRecoverables>
    <ci:DisposalGroupIncludingDiscontinuedOperationReinsuranceRecoverablesIncludingReinsurancePremiumPaid contextRef="c-83" decimals="-6" id="f-1234" unitRef="usd">208000000</ci:DisposalGroupIncludingDiscontinuedOperationReinsuranceRecoverablesIncludingReinsurancePremiumPaid>
    <ci:CededReinsuranceAgreementReinsuredRiskPercentage
      contextRef="c-307"
      decimals="INF"
      id="f-1235"
      unitRef="number">1</ci:CededReinsuranceAgreementReinsuredRiskPercentage>
    <ci:CededReinsuranceAgreementCoverageLimitAmountRemaining contextRef="c-307" decimals="-8" id="f-1236" unitRef="usd">3100000000</ci:CededReinsuranceAgreementCoverageLimitAmountRemaining>
    <ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances contextRef="c-307" decimals="-6" id="f-1237" unitRef="usd">873000000</ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances>
    <ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances contextRef="c-308" decimals="-6" id="f-1238" unitRef="usd">1116000000</ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-309"
      decimals="INF"
      id="f-1239"
      unitRef="number">0.95</us-gaap:ConcentrationRiskPercentage1>
    <ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances contextRef="c-310" decimals="-6" id="f-1240" unitRef="usd">92000000</ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances>
    <ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances contextRef="c-311" decimals="-6" id="f-1241" unitRef="usd">115000000</ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances>
    <ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances contextRef="c-312" decimals="-6" id="f-1242" unitRef="usd">104000000</ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances>
    <ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances contextRef="c-313" decimals="-6" id="f-1243" unitRef="usd">128000000</ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-314"
      decimals="INF"
      id="f-1244"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances contextRef="c-315" decimals="-6" id="f-1245" unitRef="usd">31000000</ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances>
    <ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances contextRef="c-316" decimals="-6" id="f-1246" unitRef="usd">39000000</ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-317"
      decimals="INF"
      id="f-1247"
      unitRef="number">0.80</us-gaap:ConcentrationRiskPercentage1>
    <ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances contextRef="c-252" decimals="-6" id="f-1248" unitRef="usd">1100000000</ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances>
    <ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances contextRef="c-253" decimals="-6" id="f-1249" unitRef="usd">1398000000</ci:MarketRiskBenefitReinsuranceRecoverableAfterAllowanceAndRelatedBalances>
    <us-gaap:ReinsuranceReceivablesIncurredButNotReportedClaims contextRef="c-252" decimals="-6" id="f-1250" unitRef="usd">19000000</us-gaap:ReinsuranceReceivablesIncurredButNotReportedClaims>
    <us-gaap:ReinsuranceReceivablesIncurredButNotReportedClaims contextRef="c-253" decimals="-6" id="f-1251" unitRef="usd">27000000</us-gaap:ReinsuranceReceivablesIncurredButNotReportedClaims>
    <us-gaap:PremiumsReceivableAtCarryingValue contextRef="c-253" decimals="-6" id="f-1252" unitRef="usd">3000000</us-gaap:PremiumsReceivableAtCarryingValue>
    <us-gaap:EffectsOfReinsuranceTableTextBlock contextRef="c-1" id="f-1256">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents direct, assumed and ceded earned premiums for both short-duration and long-duration insurance contracts. It also presents reinsurance recoveries that have been netted against Medical costs and other benefit expenses in the Company's Consolidated Statements of Income.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Short-duration contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Direct&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;42,266&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;303&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ceded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total short-duration contract premiums&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;42,292&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Long-duration contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Direct&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,084&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ceded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total long-duration contract premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,945&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total premiums&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;44,237&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total reinsurance recoveries&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;456&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;Total short-duration contracts written premiums were $41.1 billion, $35.0 billion and $35.6 billion for 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:EffectsOfReinsuranceTableTextBlock>
    <us-gaap:DirectPremiumsEarned contextRef="c-319" decimals="-6" id="f-1257" unitRef="usd">42266000000</us-gaap:DirectPremiumsEarned>
    <us-gaap:DirectPremiumsEarned contextRef="c-320" decimals="-6" id="f-1258" unitRef="usd">36747000000</us-gaap:DirectPremiumsEarned>
    <us-gaap:DirectPremiumsEarned contextRef="c-321" decimals="-6" id="f-1259" unitRef="usd">36513000000</us-gaap:DirectPremiumsEarned>
    <us-gaap:AssumedPremiumsEarned contextRef="c-319" decimals="-6" id="f-1260" unitRef="usd">303000000</us-gaap:AssumedPremiumsEarned>
    <us-gaap:AssumedPremiumsEarned contextRef="c-320" decimals="-6" id="f-1261" unitRef="usd">416000000</us-gaap:AssumedPremiumsEarned>
    <us-gaap:AssumedPremiumsEarned contextRef="c-321" decimals="-6" id="f-1262" unitRef="usd">335000000</us-gaap:AssumedPremiumsEarned>
    <us-gaap:CededPremiumsEarned contextRef="c-319" decimals="-6" id="f-1263" unitRef="usd">277000000</us-gaap:CededPremiumsEarned>
    <us-gaap:CededPremiumsEarned contextRef="c-320" decimals="-6" id="f-1264" unitRef="usd">265000000</us-gaap:CededPremiumsEarned>
    <us-gaap:CededPremiumsEarned contextRef="c-321" decimals="-6" id="f-1265" unitRef="usd">148000000</us-gaap:CededPremiumsEarned>
    <us-gaap:PremiumsEarnedNet contextRef="c-319" decimals="-6" id="f-1266" unitRef="usd">42292000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-320" decimals="-6" id="f-1267" unitRef="usd">36898000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-321" decimals="-6" id="f-1268" unitRef="usd">36700000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:DirectPremiumsEarned contextRef="c-322" decimals="-6" id="f-1269" unitRef="usd">2084000000</us-gaap:DirectPremiumsEarned>
    <us-gaap:DirectPremiumsEarned contextRef="c-323" decimals="-6" id="f-1270" unitRef="usd">3219000000</us-gaap:DirectPremiumsEarned>
    <us-gaap:DirectPremiumsEarned contextRef="c-324" decimals="-6" id="f-1271" unitRef="usd">4753000000</us-gaap:DirectPremiumsEarned>
    <us-gaap:AssumedPremiumsEarned contextRef="c-322" decimals="-6" id="f-1272" unitRef="usd">72000000</us-gaap:AssumedPremiumsEarned>
    <us-gaap:AssumedPremiumsEarned contextRef="c-323" decimals="-6" id="f-1273" unitRef="usd">85000000</us-gaap:AssumedPremiumsEarned>
    <us-gaap:AssumedPremiumsEarned contextRef="c-324" decimals="-6" id="f-1274" unitRef="usd">99000000</us-gaap:AssumedPremiumsEarned>
    <us-gaap:CededPremiumsEarned contextRef="c-322" decimals="-6" id="f-1275" unitRef="usd">211000000</us-gaap:CededPremiumsEarned>
    <us-gaap:CededPremiumsEarned contextRef="c-323" decimals="-6" id="f-1276" unitRef="usd">286000000</us-gaap:CededPremiumsEarned>
    <us-gaap:CededPremiumsEarned contextRef="c-324" decimals="-6" id="f-1277" unitRef="usd">398000000</us-gaap:CededPremiumsEarned>
    <us-gaap:PremiumsEarnedNet contextRef="c-322" decimals="-6" id="f-1278" unitRef="usd">1945000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-323" decimals="-6" id="f-1279" unitRef="usd">3018000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-324" decimals="-6" id="f-1280" unitRef="usd">4454000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-1" decimals="-6" id="f-1281" unitRef="usd">44237000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-7" decimals="-6" id="f-1282" unitRef="usd">39916000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-8" decimals="-6" id="f-1283" unitRef="usd">41154000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded contextRef="c-1" decimals="-6" id="f-1284" unitRef="usd">456000000</us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded>
    <us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded contextRef="c-7" decimals="-6" id="f-1285" unitRef="usd">702000000</us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded>
    <us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded contextRef="c-8" decimals="-6" id="f-1286" unitRef="usd">552000000</us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded>
    <us-gaap:PremiumsWrittenNet contextRef="c-319" decimals="-8" id="f-1287" unitRef="usd">41100000000</us-gaap:PremiumsWrittenNet>
    <us-gaap:PremiumsWrittenNet contextRef="c-320" decimals="-8" id="f-1288" unitRef="usd">35000000000</us-gaap:PremiumsWrittenNet>
    <us-gaap:PremiumsWrittenNet contextRef="c-321" decimals="-8" id="f-1289" unitRef="usd">35600000000</us-gaap:PremiumsWrittenNet>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="c-1" id="f-1290">&lt;div&gt;&lt;span id="iba773ce036514c4ba5209af3290a59b4_16"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 12 &#x2013; Investments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Cigna Group's investment portfolio consists of a broad range of investments including debt securities, equity securities, commercial mortgage loans, policy loans, other long-term investments, short-term investments and derivative financial instruments. The sections below provide more detail regarding our investment balances and realized investment gains and losses. See Note 13 for information about the valuation of the Company's investment portfolio.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Debt securities, commercial mortgage loans, derivative financial instruments and short-term investments with contractual maturities during the next twelve months are classified on the balance sheet as current investments, unless they are held as statutory deposits or restricted for other purposes and then they are classified in Long-term investments. Equity securities may include funds that are used in our cash management strategy and are classified as current investments. All other investments are classified as Long-term investments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes the Company's investments by category and current or long-term classification:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.212%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;590&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,265&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,855&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,331&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,362&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial mortgage loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;182&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,351&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,533&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Policy loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,211&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,211&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,181&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,181&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,009&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;19,339&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;20,348&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments classified as assets of businesses held for sale &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,354)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,438)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments per Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;925&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17,985&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18,910&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; Investments related to the HCSC transaction that were held for sale as of December&#160;31, 2023. These investments were primarily comprised of debt securities and commercial mortgage loans, and to a lesser extent, other long term investments. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt;text-decoration:underline"&gt;Investment Portfolio&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Debt securities (including bonds, mortgage and other asset-backed securities and preferred stocks redeemable by the investor) are classified as available for sale and are carried at fair value with changes in fair value recorded either in Accumulated other comprehensive loss within Shareholders' equity or in credit loss expense based on fluctuations in the allowance for credit losses, as further discussed below. Prior to the adoption of LDTI on January 1, 2023, net unrealized appreciation on debt securities supporting the Company's run-off settlement annuity business was reported in Non-current insurance and contractholder liabilities rather than Accumulated other comprehensive loss. See Note 16 for impact to Accumulated other comprehensive loss. When the Company intends to sell or determines that it is more likely than not to be required to sell an impaired debt security, the excess of amortized cost over fair value is directly written down with a charge to Net realized investment (losses) gains. Certain asset-backed securities are considered variable interest entities. See Note 14 for additional information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company reviews declines in fair value from a debt security's amortized cost basis to determine whether a credit loss exists, and when appropriate, recognizes a credit loss allowance with a corresponding charge to credit loss expense, presented in Net realized investment (losses) gains in the Company's Consolidated Statements of Income. The allowance for credit loss represents the excess of amortized cost over the greater of its fair value or the net present value of the debt security's projected future cash flows (based on qualitative and quantitative factors, including the probability of default and the estimated timing and amount of recovery). Each period, the allowance for credit loss is adjusted as needed through credit loss expense.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company does not measure an allowance for credit losses for accrued interest receivables. When interest payments are delinquent based on contractual terms or when certain terms (interest rate or maturity date) of the investment have been restructured, accrued interest, reported in Other current assets, is written off through a charge to Net investment income and interest income is recognized on a cash basis.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The amortized cost and fair value by contractual maturity periods for debt securities were as follows as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;622&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;605&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,914&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,761&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,194&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,005&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,251&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,119&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;398&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;365&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,379&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,855&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Actual maturities of these securities could differ from their contractual maturities used in the table above because issuers may have the right to call or prepay obligations, with or without penalties.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Gross unrealized appreciation (depreciation) on debt securities by type of issuer is shown below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.046%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Allowance for Credit Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Appreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal government and agency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;251&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;267&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State and local government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;37&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;38&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;355&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;352&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,338&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;158&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,833&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset-backed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;398&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;365&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,379&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;195&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(686)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,855&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal government and agency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State and local government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(981)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset-backed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,059)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Review of declines in fair value. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Management reviews impaired debt securities to determine whether a credit loss allowance is needed based on criteria that include:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;severity of decline;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;financial health and specific prospects of the issuer; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;changes in the regulatory, economic or general market environment of the issuer's industry or geographic region.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The table below summarizes debt securities with a decline in fair value from amortized cost for which an allowance for credit losses has not been recorded, by investment grade and the length of time these securities have been in an unrealized loss position. Unrealized depreciation on these debt securities is primarily due to declines in fair value resulting from increasing interest rates since these securities were purchased. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.767%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of Issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of Issues&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;One year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investment grade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;330&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;338&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;142&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(594)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Below investment grade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;161&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;170&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;135&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;More than one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investment grade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,441&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,036&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(595)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,590&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Below investment grade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;701&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;775&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;486&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,633&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,319&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(686)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,353&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,059)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. Equity securities with a readily determinable fair value consist primarily of public equity investments in the health care sector and mutual funds that invest in fixed income debt securities while those without a readily determinable fair value consist of private equity investments. Changes in the fair values of equity securities that have a readily determinable fair value are reported in Net realized investment (losses) gains. Equity securities without a readily determinable fair value are carried at cost minus impairment, if any, plus or minus changes resulting from observable price changes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table provides the values of the Company's equity security investments. The amount of impairments or value changes resulting from observable price changes on equity securities with no readily determinable fair value still held was not material to the financial statements as of December&#160;31, 2023 or 2022.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.044%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;656&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;51&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities with no readily determinable fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,248&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,311&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,904&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,362&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2023, we became a minority owner in VillageMD by investing $2.7&#160;billion in VillageMD preferred equity. VillageMD is a provider of primary, multi-specialty and urgent care services that is majority-owned by Walgreens Boots Alliance, Inc. These securities are included in Equity securities with no readily determinable fair value in the above table. A compounding dividend of 5.5% accrues annually on $2.2&#160;billion of our cost basis in these shares. Consistent with our strategy to invest in targeted startup and growth-stage companies in the health care industry, approximately 95% of our investments in equity securities are in the health care sector.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Commercial Mortgage Loans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Commercial mortgage loans are carried at unpaid principal balances, net of an allowance for expected credit losses, and classified as either current or long-term investments based on their contractual maturities. Changes in the allowance for expected credit losses are recognized as credit loss expense and presented in Net realized investment (losses) gains in the Company's Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Each period, the Company establishes (or adjusts) its allowance for expected credit losses for commercial mortgage loans. The allowance for expected credit losses is based on a credit risk category that is assigned to each loan at origination using key credit quality indicators, including debt service coverage and loan-to-value ratios. Credit risk categories are updated as key credit quality indicators change. An expected loss rate, assigned based on the credit risk category, is applied to each loan's unpaid principal balance to develop the aggregate allowance for expected credit losses. Commercial mortgage loans are considered impaired and written off against the allowance when it is probable that the Company will not collect all amounts due per the terms of the promissory note. In the event of a foreclosure, the allowance for credit losses is based on the excess of the carrying value of the mortgage loan over the fair value of its underlying collateral.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Mortgage loans held by the Company are made exclusively to commercial borrowers and are diversified by property type, location and borrower. Loans are generally issued at fixed rates of interest and are secured by high quality, primarily completed and substantially leased operating properties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Credit quality&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; The Company regularly evaluates and monitors credit risk, beginning with the initial underwriting of a mortgage loan and continuing throughout the investment holding period. Mortgage origination professionals employ an internal credit quality rating system designed to evaluate the relative risk of the transaction at origination that is then updated each year as part of the annual portfolio loan review. The Company evaluates and monitors credit quality on a consistent and ongoing basis.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Quality ratings are based on our evaluation of a number of key inputs related to the loan, including real estate market-related factors such as rental rates and vacancies, and property-specific inputs such as growth rate assumptions and lease rollover statistics. However, the two most significant contributors to the credit quality rating are the debt service coverage and loan-to-value ratios. The debt service coverage ratio measures the amount of property cash flow available to meet annual interest and principal payments on debt, with a ratio below 1.0 indicating that there is not enough cash flow to cover the required loan payments. The loan-to-value ratio, commonly expressed as a percentage, compares the amount of the loan to the fair value of the underlying property collateralizing the loan.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes the credit risk profile of the Company's commercial mortgage loan portfolio:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.594%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.883%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.594%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.890%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Loan-to-Value Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average Debt Service Coverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average Loan-to-Value Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average Debt Service Coverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average Loan-to-Value Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Below 60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;802&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60% to 79%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;574&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.77&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.73&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80% to 100%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;157&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;0.65&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,533&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;64&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.89&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Policy Loans&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. Policy loans, primarily associated with our corporate-owned life insurance business, are carried at unpaid principal balances plus accumulated interest, the total of which approximates fair value. These loans are collateralized by life insurance policy cash values and therefore have minimal exposure to credit loss. Interest rates are reset annually based on a rolling average of benchmark interest rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Other Long-term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other long-term investments include investments in unconsolidated entities, including certain limited partnerships and limited liability companies holding real estate, securities or loans and health care-related investments. These investments are carried at cost plus the Company's ownership percentage of reporting income or loss, based on the financial statements of the underlying investments that are generally reported at fair value. Income or loss from these investments is reported on a one quarter lag due to the timing of when financial information is received from the general partner or manager of the investments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other long-term investments also include investment real estate carried at depreciated cost less any impairment write-downs to fair value when cash flows indicate that the carrying value may not be recoverable. Depreciation is generally recorded using the straight-line method based on the estimated useful life of each asset. Investment real estate as of December&#160;31, 2023 and 2022 is expected to be held longer than one year and may include real estate acquired through the foreclosure of commercial mortgage loans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additionally, foreign currency swaps carried at fair value and certain restricted deposits are reported in the table below as "Other." See discussion below for information on the Company's accounting policies for derivative financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other long-term investments and related commitments are diversified by issuer, property type and geographic regions. These investments are primarily unconsolidated variable interest entities (see Note 14 for additional information). The following table provides unfunded commitment and carrying value information for these investments. The Company expects to disburse approximately 25% of the committed amounts in 2024. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Our limited partnership investments are reduced as the Company receives cash distributions for returns on its investment that were previously recognized in Net investment income. The amount of these cash distributions was $253 million in 2023, $487 million in 2022 and $568 million in 2021. &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.237%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unfunded Commitments as of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value as of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Real estate investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;712&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,085&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;175&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,181&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,797&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Short-term Investments and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Security investments with maturities of greater than three months to one year from time of purchase are classified as short-term, available for sale and carried at fair value that approximates cost. Cash equivalents consist of short-term investments with maturities of three months or less from the time of purchase and are carried at cost that approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company uses derivative financial instruments to manage the characteristics of investment assets (such as duration, yield, currency and liquidity) to meet the varying demands of the related insurance and contractholder liabilities. The Company also uses derivative financial instruments to hedge the risk of changes in the net assets of certain of its foreign subsidiaries due to changes in foreign currency exchange rates and to hedge the interest rate risk of certain long-term debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Derivatives are recorded in our Consolidated Balance Sheets at fair value and are classified as current or non-current according to their contractual maturities. Further information on our policies for determining fair value are discussed in Note 13. The Company applies hedge accounting when derivatives are designated, qualified and highly effective as hedges. Under hedge accounting, the changes in fair value of the derivative and the hedged risk are generally recognized together and offset each other when reported in Shareholders' net income. Various qualitative or quantitative methods appropriate for each hedge are used to formally assess and document hedge effectiveness at inception and each period throughout the life of a hedge.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's derivative financial instruments are presented as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline"&gt;Fair value hedges of the foreign exchange-related changes in fair values of certain foreign-denominated bonds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;: Swap fair values are reported in Long-term investments or Other non-current liabilities. Offsetting changes in fair values attributable to the foreign exchange risk of the swap contracts and the hedged bonds are reported in Net realized investment (losses) gains. The portion of the swap contracts' changes in fair value excluded from the assessment of hedge effectiveness is recorded in Other comprehensive loss and recognized in Net investment income as swap coupon payments are accrued, offsetting the foreign-denominated coupons received on the designated bonds. Net cash flows are reported in Operating activities, while exchanges of notional principal amounts are reported in Investing activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline"&gt;Fair value hedges of the interest rate exposure on the Company's long-term debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;: Using fair value hedge accounting, the fair values of the swap contracts are reported in other assets or other liabilities. The critical terms of these swaps match those of the long-term debt being hedged. As a result, the carrying value of the hedged debt is adjusted to reflect changes in its fair value driven by the SOFR. The effects of those adjustments on interest expense are offset by the effects of corresponding changes in the swaps' fair value. The net impact from the hedge reported in Interest expense and other reflects interest expense on the hedged debt at the variable interest rate. Cash flows relating to these contracts are reported in Operating activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline"&gt;Net investment hedges of certain foreign subsidiaries that conduct their business principally in currencies other than the U.S. dollar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;: The fair values of the foreign currency swap and forward contracts are reported in other assets or other liabilities. The changes in fair values of these instruments are reported in Other comprehensive loss, specifically in translation of foreign currencies. The portion of the change in fair values relating to foreign exchange spot rates will be recognized in earnings upon deconsolidation of the hedged foreign subsidiaries. The remaining changes in fair value of these instruments are excluded from our effectiveness assessment and recognized in Interest expense and other over the term of the instrument. Cash flows relating to these contracts are reported in Investing activities. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The effects of derivative financial instruments used in our individual hedging strategies were not material to the Consolidated Financial Statements as of December&#160;31, 2023 and December&#160;31, 2022. The gross fair values of our derivative financial instruments are presented in Note 13 to the Consolidated Financial Statements. The following table summarizes the types and notional quantity of derivative instruments held by the Company: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Value as of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Purpose&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Type of Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;text-decoration:underline"&gt;Fair value hedge:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt; To hedge the foreign exchange-related changes in fair values of certain foreign-denominated bonds. The notional value of these derivatives matches the amortized cost of the hedged bonds. A majority of these instruments are denominated in Euros, with the remaining instruments denominated in British Pounds Sterling and Australian Dollars.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency swap contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,026&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Fair value hedge:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; To convert a portion of the interest rate exposure on the Company's long-term debt from fixed to variable rates. This more closely aligns the Company's interest expense with the interest income received on its cash equivalent and short-term investment balances. The variable rates are benchmarked to SOFR.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;text-decoration:underline"&gt;Net investment hedge:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt; To reduce the risk of changes in net assets due to changes in foreign currency spot exchange rates for certain foreign subsidiaries that conduct their business principally in currencies other than the U.S. Dollar. The notional value of hedging instruments matches the hedged amount of subsidiary net assets. Foreign currency swap contracts are denominated in Euros.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency swap contracts &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;415&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Concentration of Risk&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company did not have a concentration of investments in a single issuer or borrower exceeding 10% of shareholders' equity as of December&#160;31, 2023 or 2022.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline"&gt;Net Investment Income&lt;/span&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; When interest and principal payments on investments are current, the Company recognizes interest income when it is earned. The Company recognizes interest income on a cash basis when interest payments are delinquent based on contractual terms or when certain terms (interest rate or maturity date) of the investment have been restructured. For unconsolidated entities that are included in other long-term investments, investment income is generally recognized according to the Company's share of the reported income or loss on the underlying investments. Investment income attributed to the Company's separate accounts is excluded from our earnings because associated gains and losses generally accrue directly to separate account policyholders.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The components of Net investment income were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;123&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial mortgage loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;65&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Policy loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;123&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term investments and cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;339&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total investment income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,210&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less investment expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;44&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net investment income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,166&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt;text-decoration:underline"&gt;Realized Investment Gains and Losses&lt;/span&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Realized investment gains and losses are based on specifically identified assets and result from sales, investment asset write-downs, change in the fair value of certain derivatives and equity securities and changes in allowances for credit losses on debt securities and commercial mortgage loan investments. With the adoption of amended accounting guidance for long-duration insurance contracts on January 1, 2023 (discussed in Note 2 to the Consolidated Financial Statements), realized investment gains and losses no longer exclude amounts that were previously required to adjust future policy benefits for the run-off settlement annuity business. Prior period net realized investment losses have been updated to reflect the impact of adopting LDTI. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following realized gains and losses on investments exclude realized gains and losses attributed to the Company's separate accounts because those gains and losses generally accrue directly to separate account policyholders:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net realized investment (losses) gains, excluding credit loss expense and asset write-downs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(451)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Credit (loss) / recovery and other investment write-down (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net realized investment (losses) gains, before income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(487)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Net realized investment losses for the years ended December&#160;31, 2023 and December&#160;31, 2022 were primarily due to mark-to-market losses on a strategic health care equity securities investment.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c-1" id="f-1291">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Cigna Group's investment portfolio consists of a broad range of investments including debt securities, equity securities, commercial mortgage loans, policy loans, other long-term investments, short-term investments and derivative financial instruments. The sections below provide more detail regarding our investment balances and realized investment gains and losses. See Note 13 for information about the valuation of the Company's investment portfolio.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Debt securities, commercial mortgage loans, derivative financial instruments and short-term investments with contractual maturities during the next twelve months are classified on the balance sheet as current investments, unless they are held as statutory deposits or restricted for other purposes and then they are classified in Long-term investments. Equity securities may include funds that are used in our cash management strategy and are classified as current investments. All other investments are classified as Long-term investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Debt securities (including bonds, mortgage and other asset-backed securities and preferred stocks redeemable by the investor) are classified as available for sale and are carried at fair value with changes in fair value recorded either in Accumulated other comprehensive loss within Shareholders' equity or in credit loss expense based on fluctuations in the allowance for credit losses, as further discussed below. Prior to the adoption of LDTI on January 1, 2023, net unrealized appreciation on debt securities supporting the Company's run-off settlement annuity business was reported in Non-current insurance and contractholder liabilities rather than Accumulated other comprehensive loss. See Note 16 for impact to Accumulated other comprehensive loss. When the Company intends to sell or determines that it is more likely than not to be required to sell an impaired debt security, the excess of amortized cost over fair value is directly written down with a charge to Net realized investment (losses) gains. Certain asset-backed securities are considered variable interest entities. See Note 14 for additional information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company reviews declines in fair value from a debt security's amortized cost basis to determine whether a credit loss exists, and when appropriate, recognizes a credit loss allowance with a corresponding charge to credit loss expense, presented in Net realized investment (losses) gains in the Company's Consolidated Statements of Income. The allowance for credit loss represents the excess of amortized cost over the greater of its fair value or the net present value of the debt security's projected future cash flows (based on qualitative and quantitative factors, including the probability of default and the estimated timing and amount of recovery). Each period, the allowance for credit loss is adjusted as needed through credit loss expense.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company does not measure an allowance for credit losses for accrued interest receivables. When interest payments are delinquent based on contractual terms or when certain terms (interest rate or maturity date) of the investment have been restructured, accrued interest, reported in Other current assets, is written off through a charge to Net investment income and interest income is recognized on a cash basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Review of declines in fair value. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Management reviews impaired debt securities to determine whether a credit loss allowance is needed based on criteria that include:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;severity of decline;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;financial health and specific prospects of the issuer; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;changes in the regulatory, economic or general market environment of the issuer's industry or geographic region.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. Equity securities with a readily determinable fair value consist primarily of public equity investments in the health care sector and mutual funds that invest in fixed income debt securities while those without a readily determinable fair value consist of private equity investments. Changes in the fair values of equity securities that have a readily determinable fair value are reported in Net realized investment (losses) gains. Equity securities without a readily determinable fair value are carried at cost minus impairment, if any, plus or minus changes resulting from observable price changes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Commercial mortgage loans are carried at unpaid principal balances, net of an allowance for expected credit losses, and classified as either current or long-term investments based on their contractual maturities. Changes in the allowance for expected credit losses are recognized as credit loss expense and presented in Net realized investment (losses) gains in the Company's Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Each period, the Company establishes (or adjusts) its allowance for expected credit losses for commercial mortgage loans. The allowance for expected credit losses is based on a credit risk category that is assigned to each loan at origination using key credit quality indicators, including debt service coverage and loan-to-value ratios. Credit risk categories are updated as key credit quality indicators change. An expected loss rate, assigned based on the credit risk category, is applied to each loan's unpaid principal balance to develop the aggregate allowance for expected credit losses. Commercial mortgage loans are considered impaired and written off against the allowance when it is probable that the Company will not collect all amounts due per the terms of the promissory note. In the event of a foreclosure, the allowance for credit losses is based on the excess of the carrying value of the mortgage loan over the fair value of its underlying collateral.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Mortgage loans held by the Company are made exclusively to commercial borrowers and are diversified by property type, location and borrower. Loans are generally issued at fixed rates of interest and are secured by high quality, primarily completed and substantially leased operating properties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Credit quality&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; The Company regularly evaluates and monitors credit risk, beginning with the initial underwriting of a mortgage loan and continuing throughout the investment holding period. Mortgage origination professionals employ an internal credit quality rating system designed to evaluate the relative risk of the transaction at origination that is then updated each year as part of the annual portfolio loan review. The Company evaluates and monitors credit quality on a consistent and ongoing basis.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Quality ratings are based on our evaluation of a number of key inputs related to the loan, including real estate market-related factors such as rental rates and vacancies, and property-specific inputs such as growth rate assumptions and lease rollover statistics. However, the two most significant contributors to the credit quality rating are the debt service coverage and loan-to-value ratios. The debt service coverage ratio measures the amount of property cash flow available to meet annual interest and principal payments on debt, with a ratio below 1.0 indicating that there is not enough cash flow to cover the required loan payments. The loan-to-value ratio, commonly expressed as a percentage, compares the amount of the loan to the fair value of the underlying property collateralizing the loan.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. Policy loans, primarily associated with our corporate-owned life insurance business, are carried at unpaid principal balances plus accumulated interest, the total of which approximates fair value. These loans are collateralized by life insurance policy cash values and therefore have minimal exposure to credit loss. Interest rates are reset annually based on a rolling average of benchmark interest rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other long-term investments include investments in unconsolidated entities, including certain limited partnerships and limited liability companies holding real estate, securities or loans and health care-related investments. These investments are carried at cost plus the Company's ownership percentage of reporting income or loss, based on the financial statements of the underlying investments that are generally reported at fair value. Income or loss from these investments is reported on a one quarter lag due to the timing of when financial information is received from the general partner or manager of the investments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other long-term investments also include investment real estate carried at depreciated cost less any impairment write-downs to fair value when cash flows indicate that the carrying value may not be recoverable. Depreciation is generally recorded using the straight-line method based on the estimated useful life of each asset. Investment real estate as of December&#160;31, 2023 and 2022 is expected to be held longer than one year and may include real estate acquired through the foreclosure of commercial mortgage loans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additionally, foreign currency swaps carried at fair value and certain restricted deposits are reported in the table below as "Other." See discussion below for information on the Company's accounting policies for derivative financial instruments.&lt;/span&gt;&lt;/div&gt;Other long-term investments and related commitments are diversified by issuer, property type and geographic regions. These investments are primarily unconsolidated variable interest entities (see Note 14 for additional information).Our limited partnership investments are reduced as the Company receives cash distributions for returns on its investment that were previously recognized in Net investment income. &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Security investments with maturities of greater than three months to one year from time of purchase are classified as short-term, available for sale and carried at fair value that approximates cost. Cash equivalents consist of short-term investments with maturities of three months or less from the time of purchase and are carried at cost that approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; When interest and principal payments on investments are current, the Company recognizes interest income when it is earned. The Company recognizes interest income on a cash basis when interest payments are delinquent based on contractual terms or when certain terms (interest rate or maturity date) of the investment have been restructured. For unconsolidated entities that are included in other long-term investments, investment income is generally recognized according to the Company's share of the reported income or loss on the underlying investments. Investment income attributed to the Company's separate accounts is excluded from our earnings because associated gains and losses generally accrue directly to separate account policyholders.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy. &lt;/span&gt;Realized investment gains and losses are based on specifically identified assets and result from sales, investment asset write-downs, change in the fair value of certain derivatives and equity securities and changes in allowances for credit losses on debt securities and commercial mortgage loan investments. With the adoption of amended accounting guidance for long-duration insurance contracts on January 1, 2023 (discussed in Note 2 to the Consolidated Financial Statements), realized investment gains and losses no longer exclude amounts that were previously required to adjust future policy benefits for the run-off settlement annuity business. Prior period net realized investment losses have been updated to reflect the impact of adopting LDTI.</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock contextRef="c-1" id="f-1292">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes the Company's investments by category and current or long-term classification:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.212%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;590&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,265&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,855&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,331&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,362&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial mortgage loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;182&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,351&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,533&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Policy loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,211&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,211&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,181&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,181&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,009&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;19,339&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;20,348&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments classified as assets of businesses held for sale &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,354)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,438)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments per Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;925&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17,985&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18,910&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt; Investments related to the HCSC transaction that were held for sale as of December&#160;31, 2023. These investments were primarily comprised of debt securities and commercial mortgage loans, and to a lesser extent, other long term investments.</us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock>
    <ci:ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-325" decimals="-6" id="f-1293" unitRef="usd">590000000</ci:ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-325" decimals="-6" id="f-1294" unitRef="usd">9265000000</ci:LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-325" decimals="-6" id="f-1295" unitRef="usd">9855000000</ci:InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:ShortTermInvestments contextRef="c-326" decimals="-6" id="f-1296" unitRef="usd">654000000</us-gaap:ShortTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c-326" decimals="-6" id="f-1297" unitRef="usd">9218000000</us-gaap:LongTermInvestments>
    <us-gaap:Investments contextRef="c-326" decimals="-6" id="f-1298" unitRef="usd">9872000000</us-gaap:Investments>
    <ci:ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-327" decimals="-6" id="f-1299" unitRef="usd">31000000</ci:ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-327" decimals="-6" id="f-1300" unitRef="usd">3331000000</ci:LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-327" decimals="-6" id="f-1301" unitRef="usd">3362000000</ci:InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:ShortTermInvestments contextRef="c-328" decimals="-6" id="f-1302" unitRef="usd">45000000</us-gaap:ShortTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c-328" decimals="-6" id="f-1303" unitRef="usd">577000000</us-gaap:LongTermInvestments>
    <us-gaap:Investments contextRef="c-328" decimals="-6" id="f-1304" unitRef="usd">622000000</us-gaap:Investments>
    <ci:ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-329" decimals="-6" id="f-1305" unitRef="usd">182000000</ci:ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-329" decimals="-6" id="f-1306" unitRef="usd">1351000000</ci:LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-329" decimals="-6" id="f-1307" unitRef="usd">1533000000</ci:InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:ShortTermInvestments contextRef="c-330" decimals="-6" id="f-1308" unitRef="usd">67000000</us-gaap:ShortTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c-330" decimals="-6" id="f-1309" unitRef="usd">1547000000</us-gaap:LongTermInvestments>
    <us-gaap:Investments contextRef="c-330" decimals="-6" id="f-1310" unitRef="usd">1614000000</us-gaap:Investments>
    <ci:ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-331" decimals="-6" id="f-1311" unitRef="usd">0</ci:ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-331" decimals="-6" id="f-1312" unitRef="usd">1211000000</ci:LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-331" decimals="-6" id="f-1313" unitRef="usd">1211000000</ci:InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:ShortTermInvestments contextRef="c-332" decimals="-6" id="f-1314" unitRef="usd">0</us-gaap:ShortTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c-332" decimals="-6" id="f-1315" unitRef="usd">1218000000</us-gaap:LongTermInvestments>
    <us-gaap:Investments contextRef="c-332" decimals="-6" id="f-1316" unitRef="usd">1218000000</us-gaap:Investments>
    <ci:ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-333" decimals="-6" id="f-1317" unitRef="usd">0</ci:ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-333" decimals="-6" id="f-1318" unitRef="usd">4181000000</ci:LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-333" decimals="-6" id="f-1319" unitRef="usd">4181000000</ci:InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:ShortTermInvestments contextRef="c-334" decimals="-6" id="f-1320" unitRef="usd">0</us-gaap:ShortTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c-334" decimals="-6" id="f-1321" unitRef="usd">3728000000</us-gaap:LongTermInvestments>
    <us-gaap:Investments contextRef="c-334" decimals="-6" id="f-1322" unitRef="usd">3728000000</us-gaap:Investments>
    <ci:ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-335" decimals="-6" id="f-1323" unitRef="usd">206000000</ci:ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-335" decimals="-6" id="f-1324" unitRef="usd">0</ci:LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-335" decimals="-6" id="f-1325" unitRef="usd">206000000</ci:InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:ShortTermInvestments contextRef="c-336" decimals="-6" id="f-1326" unitRef="usd">139000000</us-gaap:ShortTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c-336" decimals="-6" id="f-1327" unitRef="usd">0</us-gaap:LongTermInvestments>
    <us-gaap:Investments contextRef="c-336" decimals="-6" id="f-1328" unitRef="usd">139000000</us-gaap:Investments>
    <ci:ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-1329" unitRef="usd">1009000000</ci:ShortTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-1330" unitRef="usd">19339000000</ci:LongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-1331" unitRef="usd">20348000000</ci:InvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent contextRef="c-83" decimals="-6" id="f-1332" unitRef="usd">84000000</ci:DisposalGroupIncludingDiscontinuedOperationCurrentInvestmentsCurrent>
    <ci:DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent contextRef="c-83" decimals="-6" id="f-1333" unitRef="usd">1354000000</ci:DisposalGroupIncludingDiscontinuedOperationNoncurrentInvestmentsCurrent>
    <ci:DisposalGroupIncludingDiscontinuedOperationInvestments contextRef="c-83" decimals="-6" id="f-1334" unitRef="usd">1438000000</ci:DisposalGroupIncludingDiscontinuedOperationInvestments>
    <us-gaap:ShortTermInvestments contextRef="c-12" decimals="-6" id="f-1335" unitRef="usd">925000000</us-gaap:ShortTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c-12" decimals="-6" id="f-1336" unitRef="usd">17985000000</us-gaap:LongTermInvestments>
    <us-gaap:Investments contextRef="c-12" decimals="-6" id="f-1337" unitRef="usd">18910000000</us-gaap:Investments>
    <us-gaap:ShortTermInvestments contextRef="c-13" decimals="-6" id="f-1338" unitRef="usd">905000000</us-gaap:ShortTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c-13" decimals="-6" id="f-1339" unitRef="usd">16288000000</us-gaap:LongTermInvestments>
    <us-gaap:Investments contextRef="c-13" decimals="-6" id="f-1340" unitRef="usd">17193000000</us-gaap:Investments>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="c-1" id="f-1341">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The amortized cost and fair value by contractual maturity periods for debt securities were as follows as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;622&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;605&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,914&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,761&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,194&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,005&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,251&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,119&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;398&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;365&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,379&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,855&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <ci:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-1342" unitRef="usd">622000000</ci:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-1343" unitRef="usd">605000000</ci:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOneBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-1344" unitRef="usd">3914000000</ci:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-1345" unitRef="usd">3761000000</ci:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFiveBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-1346" unitRef="usd">3194000000</ci:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-1347" unitRef="usd">3005000000</ci:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5Through10BeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-1348" unitRef="usd">2251000000</ci:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-1349" unitRef="usd">2119000000</ci:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear10BeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-1350" unitRef="usd">398000000</ci:DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-1351" unitRef="usd">365000000</ci:DebtSecuritiesAvailableForSaleMaturityWithoutSingleMaturityDateFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-1352" unitRef="usd">10379000000</ci:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-1353" unitRef="usd">9855000000</ci:DebtSecuritiesAvailableForSaleExcludingAccruedInterestBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock contextRef="c-1" id="f-1354">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Gross unrealized appreciation (depreciation) on debt securities by type of issuer is shown below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.046%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Allowance for Credit Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Appreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal government and agency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;251&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;267&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State and local government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;37&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;38&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;355&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;352&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,338&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;158&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,833&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset-backed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;398&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;365&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,379&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;195&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(686)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,855&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal government and agency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State and local government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(981)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset-backed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,059)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <ci:AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-337" decimals="-6" id="f-1355" unitRef="usd">251000000</ci:AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-337" decimals="-6" id="f-1356" unitRef="usd">0</ci:DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-337" decimals="-6" id="f-1357" unitRef="usd">24000000</ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-337" decimals="-6" id="f-1358" unitRef="usd">8000000</ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-337" decimals="-6" id="f-1359" unitRef="usd">267000000</ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-338" decimals="-6" id="f-1360" unitRef="usd">37000000</ci:AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-338" decimals="-6" id="f-1361" unitRef="usd">0</ci:DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-338" decimals="-6" id="f-1362" unitRef="usd">2000000</ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-338" decimals="-6" id="f-1363" unitRef="usd">1000000</ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-338" decimals="-6" id="f-1364" unitRef="usd">38000000</ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-339" decimals="-6" id="f-1365" unitRef="usd">355000000</ci:AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-339" decimals="-6" id="f-1366" unitRef="usd">0</ci:DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-339" decimals="-6" id="f-1367" unitRef="usd">10000000</ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-339" decimals="-6" id="f-1368" unitRef="usd">13000000</ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-339" decimals="-6" id="f-1369" unitRef="usd">352000000</ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-340" decimals="-6" id="f-1370" unitRef="usd">9338000000</ci:AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-340" decimals="-6" id="f-1371" unitRef="usd">33000000</ci:DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-340" decimals="-6" id="f-1372" unitRef="usd">158000000</ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-340" decimals="-6" id="f-1373" unitRef="usd">630000000</ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-340" decimals="-6" id="f-1374" unitRef="usd">8833000000</ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-341" decimals="-6" id="f-1375" unitRef="usd">398000000</ci:AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-341" decimals="-6" id="f-1376" unitRef="usd">0</ci:DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-341" decimals="-6" id="f-1377" unitRef="usd">1000000</ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-341" decimals="-6" id="f-1378" unitRef="usd">34000000</ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-341" decimals="-6" id="f-1379" unitRef="usd">365000000</ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-1380" unitRef="usd">10379000000</ci:AvailableForSaleDebtSecuritiesAmortizedCostBasisBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-1381" unitRef="usd">33000000</ci:DebtSecuritiesAvailableForSaleAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-1382" unitRef="usd">195000000</ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-1383" unitRef="usd">686000000</ci:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-1384" unitRef="usd">9855000000</ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss contextRef="c-342" decimals="-6" id="f-1385" unitRef="usd">292000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest contextRef="c-342" decimals="-6" id="f-1386" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-342" decimals="-6" id="f-1387" unitRef="usd">32000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-342" decimals="-6" id="f-1388" unitRef="usd">12000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-342" decimals="-6" id="f-1389" unitRef="usd">312000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss contextRef="c-343" decimals="-6" id="f-1390" unitRef="usd">43000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest contextRef="c-343" decimals="-6" id="f-1391" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-343" decimals="-6" id="f-1392" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-343" decimals="-6" id="f-1393" unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-343" decimals="-6" id="f-1394" unitRef="usd">41000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss contextRef="c-344" decimals="-6" id="f-1395" unitRef="usd">375000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest contextRef="c-344" decimals="-6" id="f-1396" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-344" decimals="-6" id="f-1397" unitRef="usd">11000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-344" decimals="-6" id="f-1398" unitRef="usd">21000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-344" decimals="-6" id="f-1399" unitRef="usd">365000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss contextRef="c-345" decimals="-6" id="f-1400" unitRef="usd">9742000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest contextRef="c-345" decimals="-6" id="f-1401" unitRef="usd">44000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-345" decimals="-6" id="f-1402" unitRef="usd">89000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-345" decimals="-6" id="f-1403" unitRef="usd">981000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-345" decimals="-6" id="f-1404" unitRef="usd">8806000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss contextRef="c-346" decimals="-6" id="f-1405" unitRef="usd">390000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest contextRef="c-346" decimals="-6" id="f-1406" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-346" decimals="-6" id="f-1407" unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-346" decimals="-6" id="f-1408" unitRef="usd">43000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-346" decimals="-6" id="f-1409" unitRef="usd">348000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss contextRef="c-13" decimals="-6" id="f-1410" unitRef="usd">10842000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest contextRef="c-13" decimals="-6" id="f-1411" unitRef="usd">44000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-13" decimals="-6" id="f-1412" unitRef="usd">133000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-13" decimals="-6" id="f-1413" unitRef="usd">1059000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-13" decimals="-6" id="f-1414" unitRef="usd">9872000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock contextRef="c-1" id="f-1415">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The table below summarizes debt securities with a decline in fair value from amortized cost for which an allowance for credit losses has not been recorded, by investment grade and the length of time these securities have been in an unrealized loss position. Unrealized depreciation on these debt securities is primarily due to declines in fair value resulting from increasing interest rates since these securities were purchased. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.767%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of Issues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of Issues&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;One year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investment grade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;330&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;338&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;142&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(594)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Below investment grade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;161&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;170&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;135&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;More than one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investment grade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,441&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,036&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(595)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,590&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Below investment grade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;701&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;775&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;486&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,633&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,319&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(686)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,353&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,059)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-347" decimals="-6" id="f-1416" unitRef="usd">330000000</ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-347" decimals="-6" id="f-1417" unitRef="usd">338000000</ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-347" decimals="-6" id="f-1418" unitRef="usd">8000000</ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureLessThan12MonthsNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale
      contextRef="c-347"
      decimals="INF"
      id="f-1419"
      unitRef="position">142</ci:AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureLessThan12MonthsNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-348" decimals="-6" id="f-1420" unitRef="usd">5533000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost contextRef="c-348" decimals="-6" id="f-1421" unitRef="usd">6127000000</ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-348" decimals="-6" id="f-1422" unitRef="usd">594000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="c-348"
      decimals="INF"
      id="f-1423"
      unitRef="position">1659</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-349" decimals="-6" id="f-1424" unitRef="usd">161000000</ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-349" decimals="-6" id="f-1425" unitRef="usd">170000000</ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-349" decimals="-6" id="f-1426" unitRef="usd">9000000</ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureLessThan12MonthsNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale
      contextRef="c-349"
      decimals="INF"
      id="f-1427"
      unitRef="position">135</ci:AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureLessThan12MonthsNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-350" decimals="-6" id="f-1428" unitRef="usd">887000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost contextRef="c-350" decimals="-6" id="f-1429" unitRef="usd">964000000</ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAmortizedCost>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-350" decimals="-6" id="f-1430" unitRef="usd">77000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="c-350"
      decimals="INF"
      id="f-1431"
      unitRef="position">1287</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-347" decimals="-6" id="f-1432" unitRef="usd">5441000000</ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-347" decimals="-6" id="f-1433" unitRef="usd">6036000000</ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-347" decimals="-6" id="f-1434" unitRef="usd">595000000</ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureTwelveMonthsOrLongerNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale
      contextRef="c-347"
      decimals="INF"
      id="f-1435"
      unitRef="position">1590</ci:AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureTwelveMonthsOrLongerNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-348" decimals="-6" id="f-1436" unitRef="usd">1151000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost contextRef="c-348" decimals="-6" id="f-1437" unitRef="usd">1487000000</ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-348" decimals="-6" id="f-1438" unitRef="usd">336000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="c-348"
      decimals="INF"
      id="f-1439"
      unitRef="position">462</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-349" decimals="-6" id="f-1440" unitRef="usd">701000000</ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValueBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-349" decimals="-6" id="f-1441" unitRef="usd">775000000</ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-349" decimals="-6" id="f-1442" unitRef="usd">74000000</ci:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureTwelveMonthsOrLongerNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale
      contextRef="c-349"
      decimals="INF"
      id="f-1443"
      unitRef="position">486</ci:AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureTwelveMonthsOrLongerNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-350" decimals="-6" id="f-1444" unitRef="usd">330000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost contextRef="c-350" decimals="-6" id="f-1445" unitRef="usd">382000000</ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAmortizedCost>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-350" decimals="-6" id="f-1446" unitRef="usd">52000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="c-350"
      decimals="INF"
      id="f-1447"
      unitRef="position">369</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <ci:DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-1448" unitRef="usd">6633000000</ci:DebtSecuritiesAvailableForSaleUnrealizedLossPositionBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-1449" unitRef="usd">7319000000</ci:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCostBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-1450" unitRef="usd">686000000</ci:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale
      contextRef="c-12"
      decimals="INF"
      id="f-1451"
      unitRef="position">2353</ci:AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-13" decimals="-6" id="f-1452" unitRef="usd">7901000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost contextRef="c-13" decimals="-6" id="f-1453" unitRef="usd">8960000000</ci:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAmortizedCost>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-13" decimals="-6" id="f-1454" unitRef="usd">1059000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="c-13"
      decimals="INF"
      id="f-1455"
      unitRef="position">3777</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <ci:EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock contextRef="c-1" id="f-1456">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table provides the values of the Company's equity security investments. The amount of impairments or value changes resulting from observable price changes on equity securities with no readily determinable fair value still held was not material to the financial statements as of December&#160;31, 2023 or 2022.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.044%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;656&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;51&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities with no readily determinable fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,248&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,311&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,904&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,362&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ci:EquitySecuritiesFVNIAndEquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock>
    <us-gaap:EquitySecuritiesFvNiCost contextRef="c-12" decimals="-6" id="f-1457" unitRef="usd">656000000</us-gaap:EquitySecuritiesFvNiCost>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-12" decimals="-6" id="f-1458" unitRef="usd">51000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCost contextRef="c-13" decimals="-6" id="f-1459" unitRef="usd">673000000</us-gaap:EquitySecuritiesFvNiCost>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-13" decimals="-6" id="f-1460" unitRef="usd">138000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <ci:EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost contextRef="c-12" decimals="-6" id="f-1461" unitRef="usd">3248000000</ci:EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-12" decimals="-6" id="f-1462" unitRef="usd">3311000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <ci:EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost contextRef="c-13" decimals="-6" id="f-1463" unitRef="usd">380000000</ci:EquitySecuritiesWithoutReadilyDeterminableFairValueAmortizedCost>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-13" decimals="-6" id="f-1464" unitRef="usd">484000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <ci:EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost contextRef="c-12" decimals="-6" id="f-1465" unitRef="usd">3904000000</ci:EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost>
    <ci:EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount contextRef="c-12" decimals="-6" id="f-1466" unitRef="usd">3362000000</ci:EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount>
    <ci:EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost contextRef="c-13" decimals="-6" id="f-1467" unitRef="usd">1053000000</ci:EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsAmortizedCost>
    <ci:EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount contextRef="c-13" decimals="-6" id="f-1468" unitRef="usd">622000000</ci:EquitySecuritiesFVNIAndWithoutReadilyDeterminableFairValueAndHybridInstrumentsCarryingAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-351" decimals="-8" id="f-1469" unitRef="usd">2700000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <ci:EquitySecuritiesDividend
      contextRef="c-351"
      decimals="3"
      id="f-1470"
      unitRef="number">0.055</ci:EquitySecuritiesDividend>
    <ci:EquitySecuritiesWithoutReadilyDeterminableFairValueValueOfSharesForAnnualDividendAccrual contextRef="c-351" decimals="-8" id="f-1471" unitRef="usd">2200000000</ci:EquitySecuritiesWithoutReadilyDeterminableFairValueValueOfSharesForAnnualDividendAccrual>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-352"
      decimals="2"
      id="f-1472"
      unitRef="number">0.95</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:FinancingReceivableCreditQualityIndicatorsTableTextBlock contextRef="c-1" id="f-1473">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes the credit risk profile of the Company's commercial mortgage loan portfolio:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.594%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.883%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.594%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.890%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Loan-to-Value Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average Debt Service Coverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average Loan-to-Value Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average Debt Service Coverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average Loan-to-Value Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Below 60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;802&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60% to 79%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;574&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.77&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.73&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80% to 100%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;157&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;0.65&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,533&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;64&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.89&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinancingReceivableCreditQualityIndicatorsTableTextBlock>
    <ci:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-353" decimals="-6" id="f-1474" unitRef="usd">802000000</ci:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale
      contextRef="c-354"
      decimals="2"
      id="f-1475"
      unitRef="number">2.13</ci:FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-355" decimals="-6" id="f-1476" unitRef="usd">901000000</us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio
      contextRef="c-356"
      decimals="2"
      id="f-1477"
      unitRef="number">2.12</ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio>
    <ci:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-357" decimals="-6" id="f-1478" unitRef="usd">574000000</ci:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale
      contextRef="c-358"
      decimals="2"
      id="f-1479"
      unitRef="number">1.77</ci:FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-359" decimals="-6" id="f-1480" unitRef="usd">564000000</us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio
      contextRef="c-360"
      decimals="2"
      id="f-1481"
      unitRef="number">1.73</ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio>
    <ci:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-361" decimals="-6" id="f-1482" unitRef="usd">157000000</ci:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale
      contextRef="c-362"
      decimals="2"
      id="f-1483"
      unitRef="number">0.65</ci:FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-363" decimals="-6" id="f-1484" unitRef="usd">149000000</us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio
      contextRef="c-364"
      decimals="2"
      id="f-1485"
      unitRef="number">1.17</ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio>
    <ci:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-365" decimals="-6" id="f-1486" unitRef="usd">1533000000</ci:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale
      contextRef="c-366"
      decimals="2"
      id="f-1487"
      unitRef="number">1.82</ci:FinancingReceivableCreditQualityDebtServiceCoverageRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:FinancingReceivableCreditQualityLoanToValueRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale
      contextRef="c-366"
      decimals="2"
      id="f-1488"
      unitRef="number">0.64</ci:FinancingReceivableCreditQualityLoanToValueRatioBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-367" decimals="-6" id="f-1489" unitRef="usd">1614000000</us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio
      contextRef="c-368"
      decimals="2"
      id="f-1490"
      unitRef="number">1.89</ci:FinancingReceivableCreditQualityDebtServiceCoverageRatio>
    <ci:FinancingReceivableCreditQualityLoanToValueRatio
      contextRef="c-368"
      decimals="2"
      id="f-1491"
      unitRef="number">0.60</ci:FinancingReceivableCreditQualityLoanToValueRatio>
    <ci:ScheduleOfOtherLongTermInvestmentsTableTextBlock contextRef="c-1" id="f-1492">The following table provides unfunded commitment and carrying value information for these investments. The Company expects to disburse approximately 25% of the committed amounts in 2024. &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Our limited partnership investments are reduced as the Company receives cash distributions for returns on its investment that were previously recognized in Net investment income. The amount of these cash distributions was $253 million in 2023, $487 million in 2022 and $568 million in 2021. &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.237%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unfunded Commitments as of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value as of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Real estate investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;712&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,085&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;175&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,181&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,797&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ci:ScheduleOfOtherLongTermInvestmentsTableTextBlock>
    <ci:UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear contextRef="c-12" decimals="2" id="f-1493" unitRef="number">0.25</ci:UnfundedCommitmentsPercentageExpectedToFundInNextFiscalYear>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions contextRef="c-1" decimals="-6" id="f-1494" unitRef="usd">253000000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions contextRef="c-7" decimals="-6" id="f-1495" unitRef="usd">487000000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions contextRef="c-8" decimals="-6" id="f-1496" unitRef="usd">568000000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:OtherLongTermInvestments contextRef="c-369" decimals="-6" id="f-1497" unitRef="usd">1606000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments contextRef="c-370" decimals="-6" id="f-1498" unitRef="usd">1319000000</us-gaap:OtherLongTermInvestments>
    <ci:CommitmentsToContributeAdditionalEquityAndCapital contextRef="c-369" decimals="-6" id="f-1499" unitRef="usd">712000000</ci:CommitmentsToContributeAdditionalEquityAndCapital>
    <us-gaap:OtherLongTermInvestments contextRef="c-371" decimals="-6" id="f-1500" unitRef="usd">2400000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments contextRef="c-372" decimals="-6" id="f-1501" unitRef="usd">2166000000</us-gaap:OtherLongTermInvestments>
    <ci:CommitmentsToContributeAdditionalEquityAndCapital contextRef="c-371" decimals="-6" id="f-1502" unitRef="usd">2085000000</ci:CommitmentsToContributeAdditionalEquityAndCapital>
    <ci:OtherLongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-373" decimals="-6" id="f-1503" unitRef="usd">175000000</ci:OtherLongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:OtherLongTermInvestments contextRef="c-374" decimals="-6" id="f-1504" unitRef="usd">243000000</us-gaap:OtherLongTermInvestments>
    <ci:CommitmentsToContributeAdditionalEquityAndCapital contextRef="c-373" decimals="-6" id="f-1505" unitRef="usd">0</ci:CommitmentsToContributeAdditionalEquityAndCapital>
    <ci:OtherLongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-1506" unitRef="usd">4181000000</ci:OtherLongTermInvestmentsBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:OtherLongTermInvestments contextRef="c-13" decimals="-6" id="f-1507" unitRef="usd">3728000000</us-gaap:OtherLongTermInvestments>
    <ci:CommitmentsToContributeAdditionalEquityAndCapital contextRef="c-12" decimals="-6" id="f-1508" unitRef="usd">2797000000</ci:CommitmentsToContributeAdditionalEquityAndCapital>
    <us-gaap:DerivativesPolicyTextBlock contextRef="c-1" id="f-1509">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company uses derivative financial instruments to manage the characteristics of investment assets (such as duration, yield, currency and liquidity) to meet the varying demands of the related insurance and contractholder liabilities. The Company also uses derivative financial instruments to hedge the risk of changes in the net assets of certain of its foreign subsidiaries due to changes in foreign currency exchange rates and to hedge the interest rate risk of certain long-term debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Derivatives are recorded in our Consolidated Balance Sheets at fair value and are classified as current or non-current according to their contractual maturities. Further information on our policies for determining fair value are discussed in Note 13. The Company applies hedge accounting when derivatives are designated, qualified and highly effective as hedges. Under hedge accounting, the changes in fair value of the derivative and the hedged risk are generally recognized together and offset each other when reported in Shareholders' net income. Various qualitative or quantitative methods appropriate for each hedge are used to formally assess and document hedge effectiveness at inception and each period throughout the life of a hedge.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's derivative financial instruments are presented as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline"&gt;Fair value hedges of the foreign exchange-related changes in fair values of certain foreign-denominated bonds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;: Swap fair values are reported in Long-term investments or Other non-current liabilities. Offsetting changes in fair values attributable to the foreign exchange risk of the swap contracts and the hedged bonds are reported in Net realized investment (losses) gains. The portion of the swap contracts' changes in fair value excluded from the assessment of hedge effectiveness is recorded in Other comprehensive loss and recognized in Net investment income as swap coupon payments are accrued, offsetting the foreign-denominated coupons received on the designated bonds. Net cash flows are reported in Operating activities, while exchanges of notional principal amounts are reported in Investing activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline"&gt;Fair value hedges of the interest rate exposure on the Company's long-term debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;: Using fair value hedge accounting, the fair values of the swap contracts are reported in other assets or other liabilities. The critical terms of these swaps match those of the long-term debt being hedged. As a result, the carrying value of the hedged debt is adjusted to reflect changes in its fair value driven by the SOFR. The effects of those adjustments on interest expense are offset by the effects of corresponding changes in the swaps' fair value. The net impact from the hedge reported in Interest expense and other reflects interest expense on the hedged debt at the variable interest rate. Cash flows relating to these contracts are reported in Operating activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;text-decoration:underline"&gt;Net investment hedges of certain foreign subsidiaries that conduct their business principally in currencies other than the U.S. dollar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;: The fair values of the foreign currency swap and forward contracts are reported in other assets or other liabilities. The changes in fair values of these instruments are reported in Other comprehensive loss, specifically in translation of foreign currencies. The portion of the change in fair values relating to foreign exchange spot rates will be recognized in earnings upon deconsolidation of the hedged foreign subsidiaries. The remaining changes in fair value of these instruments are excluded from our effectiveness assessment and recognized in Interest expense and other over the term of the instrument. Cash flows relating to these contracts are reported in Investing activities. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;text-decoration:underline"&gt;Fair value hedge:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt; To hedge the foreign exchange-related changes in fair values of certain foreign-denominated bonds. The notional value of these derivatives matches the amortized cost of the hedged bonds. A majority of these instruments are denominated in Euros, with the remaining instruments denominated in British Pounds Sterling and Australian Dollars.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Fair value hedge:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; To convert a portion of the interest rate exposure on the Company's long-term debt from fixed to variable rates. This more closely aligns the Company's interest expense with the interest income received on its cash equivalent and short-term investment balances. The variable rates are benchmarked to SOFR.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;text-decoration:underline"&gt;Net investment hedge:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt; To reduce the risk of changes in net assets due to changes in foreign currency spot exchange rates for certain foreign subsidiaries that conduct their business principally in currencies other than the U.S. Dollar. The notional value of hedging instruments matches the hedged amount of subsidiary net assets. Foreign currency swap contracts are denominated in Euros.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ScheduleOfDerivativeInstrumentsTextBlock contextRef="c-1" id="f-1510">The following table summarizes the types and notional quantity of derivative instruments held by the Company: &lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Value as of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Purpose&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Type of Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;text-decoration:underline"&gt;Fair value hedge:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt; To hedge the foreign exchange-related changes in fair values of certain foreign-denominated bonds. The notional value of these derivatives matches the amortized cost of the hedged bonds. A majority of these instruments are denominated in Euros, with the remaining instruments denominated in British Pounds Sterling and Australian Dollars.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency swap contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,026&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Fair value hedge:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; To convert a portion of the interest rate exposure on the Company's long-term debt from fixed to variable rates. This more closely aligns the Company's interest expense with the interest income received on its cash equivalent and short-term investment balances. The variable rates are benchmarked to SOFR.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;text-decoration:underline"&gt;Net investment hedge:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt; To reduce the risk of changes in net assets due to changes in foreign currency spot exchange rates for certain foreign subsidiaries that conduct their business principally in currencies other than the U.S. Dollar. The notional value of hedging instruments matches the hedged amount of subsidiary net assets. Foreign currency swap contracts are denominated in Euros.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency swap contracts &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;415&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
    <us-gaap:DerivativeNotionalAmount contextRef="c-375" decimals="-6" id="f-1511" unitRef="usd">1026000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-376" decimals="-6" id="f-1512" unitRef="usd">1083000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-377" decimals="-6" id="f-1513" unitRef="usd">1500000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-378" decimals="-6" id="f-1514" unitRef="usd">1500000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-379" decimals="-6" id="f-1515" unitRef="usd">415000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-380" decimals="-6" id="f-1516" unitRef="usd">460000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:InvestmentIncomeTextBlock contextRef="c-1" id="f-1523">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The components of Net investment income were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;123&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial mortgage loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;65&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Policy loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;123&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term investments and cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;339&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total investment income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,210&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less investment expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;44&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net investment income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,166&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentIncomeTextBlock>
    <ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue contextRef="c-381" decimals="-6" id="f-1524" unitRef="usd">500000000</ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue>
    <ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue contextRef="c-382" decimals="-6" id="f-1525" unitRef="usd">572000000</ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue>
    <ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue contextRef="c-383" decimals="-6" id="f-1526" unitRef="usd">689000000</ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue>
    <ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue contextRef="c-384" decimals="-6" id="f-1527" unitRef="usd">123000000</ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue>
    <ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue contextRef="c-385" decimals="-6" id="f-1528" unitRef="usd">14000000</ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue>
    <ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue contextRef="c-386" decimals="-6" id="f-1529" unitRef="usd">12000000</ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue>
    <ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue contextRef="c-387" decimals="-6" id="f-1530" unitRef="usd">65000000</ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue>
    <ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue contextRef="c-388" decimals="-6" id="f-1531" unitRef="usd">59000000</ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue>
    <ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue contextRef="c-389" decimals="-6" id="f-1532" unitRef="usd">60000000</ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue>
    <ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue contextRef="c-390" decimals="-6" id="f-1533" unitRef="usd">60000000</ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue>
    <ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue contextRef="c-391" decimals="-6" id="f-1534" unitRef="usd">59000000</ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue>
    <ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue contextRef="c-392" decimals="-6" id="f-1535" unitRef="usd">63000000</ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue>
    <ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue contextRef="c-393" decimals="-6" id="f-1536" unitRef="usd">123000000</ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue>
    <ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue contextRef="c-394" decimals="-6" id="f-1537" unitRef="usd">390000000</ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue>
    <ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue contextRef="c-395" decimals="-6" id="f-1538" unitRef="usd">758000000</ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue>
    <ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue contextRef="c-396" decimals="-6" id="f-1539" unitRef="usd">339000000</ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue>
    <ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue contextRef="c-397" decimals="-6" id="f-1540" unitRef="usd">115000000</ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue>
    <ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue contextRef="c-398" decimals="-6" id="f-1541" unitRef="usd">26000000</ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue>
    <ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue contextRef="c-1" decimals="-6" id="f-1542" unitRef="usd">1210000000</ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue>
    <ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue contextRef="c-7" decimals="-6" id="f-1543" unitRef="usd">1209000000</ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue>
    <ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue contextRef="c-8" decimals="-6" id="f-1544" unitRef="usd">1608000000</ci:InterestAndDividendIncomeOperatingAndOperatingLeasesIncomeStatementLeaseRevenue>
    <us-gaap:InvestmentIncomeInvestmentExpense contextRef="c-1" decimals="-6" id="f-1545" unitRef="usd">44000000</us-gaap:InvestmentIncomeInvestmentExpense>
    <us-gaap:InvestmentIncomeInvestmentExpense contextRef="c-7" decimals="-6" id="f-1546" unitRef="usd">54000000</us-gaap:InvestmentIncomeInvestmentExpense>
    <us-gaap:InvestmentIncomeInvestmentExpense contextRef="c-8" decimals="-6" id="f-1547" unitRef="usd">59000000</us-gaap:InvestmentIncomeInvestmentExpense>
    <us-gaap:NetInvestmentIncome contextRef="c-1" decimals="-6" id="f-1548" unitRef="usd">1166000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome contextRef="c-7" decimals="-6" id="f-1549" unitRef="usd">1155000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome contextRef="c-8" decimals="-6" id="f-1550" unitRef="usd">1549000000</us-gaap:NetInvestmentIncome>
    <us-gaap:RealizedGainLossOnInvestmentsTableTextBlock contextRef="c-1" id="f-1551">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following realized gains and losses on investments exclude realized gains and losses attributed to the Company's separate accounts because those gains and losses generally accrue directly to separate account policyholders:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net realized investment (losses) gains, excluding credit loss expense and asset write-downs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(451)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Credit (loss) / recovery and other investment write-down (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net realized investment (losses) gains, before income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(487)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RealizedGainLossOnInvestmentsTableTextBlock>
    <ci:RealizedInvestmentGainLossExcludingImpairments contextRef="c-1" decimals="-6" id="f-1552" unitRef="usd">-68000000</ci:RealizedInvestmentGainLossExcludingImpairments>
    <ci:RealizedInvestmentGainLossExcludingImpairments contextRef="c-7" decimals="-6" id="f-1553" unitRef="usd">-451000000</ci:RealizedInvestmentGainLossExcludingImpairments>
    <ci:RealizedInvestmentGainLossExcludingImpairments contextRef="c-8" decimals="-6" id="f-1554" unitRef="usd">196000000</ci:RealizedInvestmentGainLossExcludingImpairments>
    <ci:DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal contextRef="c-1" decimals="-6" id="f-1555" unitRef="usd">10000000</ci:DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal>
    <ci:DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal contextRef="c-7" decimals="-6" id="f-1556" unitRef="usd">36000000</ci:DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal>
    <ci:DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal contextRef="c-8" decimals="-6" id="f-1557" unitRef="usd">-2000000</ci:DebtSecuritiesAvailableForSaleAndCommercialMortgageLoansAllowanceForCreditLossExpenseRecoveryAndImpairmentsOnInvestmentsTotal>
    <ci:RealizedInvestmentGainLoss contextRef="c-1" decimals="-6" id="f-1558" unitRef="usd">-78000000</ci:RealizedInvestmentGainLoss>
    <ci:RealizedInvestmentGainLoss contextRef="c-7" decimals="-6" id="f-1559" unitRef="usd">-487000000</ci:RealizedInvestmentGainLoss>
    <ci:RealizedInvestmentGainLoss contextRef="c-8" decimals="-6" id="f-1560" unitRef="usd">198000000</ci:RealizedInvestmentGainLoss>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-1561">&lt;div style="margin-bottom:10pt"&gt;&lt;span id="i45a6e991e4ac4434bd4db2e67316940b_1591"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 13 &#x2013; Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company carries certain financial instruments at fair value in the financial statements including debt securities, certain equity securities, short-term investments and derivatives. Other financial instruments are measured at fair value only under certain conditions, such as when impaired or when there are observable price changes for equity securities with no readily determinable fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value is defined as the price at which an asset could be exchanged in an orderly transaction between market participants at the balance sheet date. A liability's fair value is defined as the amount that would be paid to transfer the liability to a market participant, not the amount that would be paid to settle the liability with the creditor.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's financial assets and liabilities carried at fair value have been classified based upon a hierarchy defined by GAAP. The hierarchy gives the highest ranking to fair values determined using unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest ranking to fair values determined using methodologies and models with unobservable inputs (Level 3). An asset's or a liability's classification is based on the lowest level of input that is significant to its measurement. For example, a financial asset or liability carried at fair value would be classified in Level 3 if unobservable inputs were significant to the instrument's fair value, even though the measurement may be derived using inputs that are both observable (Levels 1 and 2) and unobservable (Level 3).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company estimates fair values using prices from third parties or internal pricing methods. Fair value estimates received from third-party pricing services are based on reported trade activity and quoted market prices when available and other market information that a market participant would use to estimate fair value. The internal pricing methods are performed by the Company's investment professionals and generally involve using discounted cash flow analyses, incorporating current market inputs for similar financial instruments with comparable terms and credit quality as well as other qualitative factors. In instances where there is little or no market activity for the same or similar instruments, fair value is estimated using methods, models and assumptions that the Company believes a hypothetical market participant would use to determine a current transaction price. These valuation techniques involve some level of estimation and judgment that becomes significant with increasingly complex instruments or pricing models.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company is responsible for determining fair value and for assigning the appropriate level within the fair value hierarchy based on the significance of unobservable inputs. The Company reviews methodologies, processes and controls of third-party pricing services and compares prices on a test basis to those obtained from other external pricing sources or internal estimates. The Company performs ongoing analyses of both prices received from third-party pricing services and those developed internally to determine that they represent appropriate estimates of fair value. The controls executed by the Company include evaluating changes in prices and monitoring for potentially stale valuations. The Company also performs sample testing of sales values to confirm the accuracy of prior fair value estimates. The minimal exceptions identified during these processes indicate that adjustments to prices are infrequent and do not significantly impact valuations. An annual due-diligence review of the most significant pricing service is conducted to review their processes, methodologies and controls. This review includes a walk-through of inputs for a sample of securities held across various asset types to validate the documented pricing process.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline"&gt;Financial Assets and Financial Liabilities Carried at Fair Value&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table provides information about the Company's financial assets and liabilities carried at fair value. Further information regarding insurance assets and liabilities carried at fair value is provided in Note 10E to the Consolidated Financial Statements. Separate account assets are also recorded at fair value on the Company's Consolidated Balance Sheets and are reported separately in the Separate Accounts section below as gains and losses related to these assets generally accrue directly to contractholders:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.767%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financial assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal government and agency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;130&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;137&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;267&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State and local government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;38&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;38&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;352&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;352&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,432&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;401&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,833&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset-backed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;319&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;46&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;365&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;130&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,278&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;447&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,855&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;47&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;51&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;131&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;132&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financial liabilities at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Excludes certain equity securities that have no readily determinable fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Level 1 Financial Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Inputs for instruments classified in Level 1 include unadjusted quoted prices for identical assets in active markets accessible at the measurement date. Active markets provide pricing data for trades occurring at least weekly and include exchanges and dealer markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Assets in Level 1 include actively-traded U.S. government bonds and exchange-listed equity securities. A relatively small portion of the Company's investment assets are classified in this category given the narrow definition of Level 1 and the Company's investment asset strategy to maximize investment returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Level 2 Financial Assets and Financial Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Inputs for instruments classified in Level 2 include quoted prices for similar assets or liabilities in active markets, quoted prices from those willing to trade in markets that are not active or other inputs that are market observable or can be corroborated by market data for the term of the instrument. Such other inputs include market interest rates and volatilities, spreads and yield curves. An instrument is classified in Level 2 if the Company determines that unobservable inputs are insignificant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Debt and equity securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. Approximately 94% of the Company's investments in debt and equity securities are classified in Level 2 including most public and private corporate debt and equity securities, federal agency and municipal bonds, non-government mortgage-backed securities and preferred stocks. Third-party pricing services and internal methods often use recent trades of securities with similar features and characteristics because many debt securities do not trade daily. Pricing models are used to determine these prices when recent trades are not available. These models calculate fair values by discounting future cash flows at estimated market interest rates. Such market rates are derived by calculating the appropriate spreads over comparable U.S. Treasury securities based on the credit quality, industry and structure of the asset. Typical inputs and assumptions to pricing models include, but are not limited to, a combination of benchmark yields, reported trades, issuer spreads, liquidity, benchmark securities, bids, offers, reference data and industry and economic events. For mortgage-backed securities, inputs and assumptions may also include characteristics of the issuer, collateral attributes, prepayment speeds and credit rating. Nearly all of these instruments are valued using recent trades or pricing models. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Short-term investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; are carried at fair value that approximates cost. The Company compares market prices for these securities to recorded amounts on a regular basis to validate that current carrying amounts approximate exit prices. The short-term nature of the investments and corroboration of the reported amounts over the holding period support their classification in Level 2.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Derivative assets and liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; classified in Level 2 represent over-the-counter instruments such as foreign currency forward and swap contracts. Fair values for these instruments are determined using market observable inputs including forward currency and interest rate curves and widely published market observable indices. Credit risk related to the counterparty and the Company is considered when estimating the fair values of these derivatives. However, the Company is largely protected by collateral arrangements with counterparties and determined that no adjustments for credit risk were required as of December&#160;31, 2023 or December&#160;31, 2022. The nature and use of these derivative financial instruments are described in Note 12.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Level 3 Financial Assets and Financial Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Certain inputs for instruments classified in Level 3 are unobservable (supported by little or no market activity) and significant to their resulting fair value measurement. Unobservable inputs reflect the Company's best estimate of what hypothetical market participants would use to determine a transaction price for the asset or liability at the reporting date. Additionally, as discussed in Note 10E to the Consolidated Financial Statements, the Company classifies variable annuity assets and liabilities in Level 3 of the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company classifies certain newly-issued, privately-placed, complex or illiquid securities in Level 3. Approximately 5% of debt and equity securities are priced using significant unobservable inputs and classified in this category.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair values of mortgage and other asset-backed securities, as well as corporate and government debt securities, are primarily determined using pricing models that incorporate the specific characteristics of each asset and related assumptions including the investment type and structure, credit quality, industry and maturity date in comparison to current market indices, spreads and liquidity of assets with similar characteristics. Inputs and assumptions for pricing may also include characteristics of the issuer, collateral attributes and prepayment speeds for mortgage and other asset-backed securities. Recent trades in the subject security or similar securities are assessed when available, and the Company may also review published research in its evaluation, as well as the issuer's financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Quantitative Information about Unobservable Inputs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The significant unobservable input used to value our corporate and government debt securities and mortgage and other asset-backed securities is an adjustment for liquidity. This adjustment is needed to reflect current market conditions and issuer circumstances when there is limited trading activity for the security. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes the fair value and significant unobservable inputs that were developed directly by the Company and used in pricing these debt securities. The range and weighted average basis point amounts for liquidity reflect the Company's best estimates of the unobservable adjustments a market participant would make to calculate these fair values. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.094%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.101%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value as of&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Adjustment Range (Weighted Average by Quantity) as of&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Fair value in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Input December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;401&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liquidity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;70 - 1235 (310)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;bps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60 - 1060 (270)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;bps&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;46&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liquidity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;95 - 640 (310) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;bps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105 - 520 (310)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;bps&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Level 3 debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;447&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;An increase in liquidity spread adjustments would result in a lower fair value measurement, while a decrease would result in a higher fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes the changes in financial assets and financial liabilities classified in Level 3. Gains and losses reported in the table may include net changes in fair value that are attributable to both observable and unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Debt and Equity Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;447&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Losses) gains included in Shareholders' net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) included in Other comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Purchases, sales and settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total purchases, sales and settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Transfers into/(out of) Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Transfers into Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;95&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Transfers out of Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total transfers into/(out of) Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;36&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;447&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total losses included in Shareholders' net income attributable to instruments held at the reporting date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Change in unrealized gain or (loss) included in Other comprehensive loss for assets held at the end of the reporting period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total gains and losses included in Shareholders' net income in the tables above are reflected in the Consolidated Statements of Income as Net realized investment (losses) gains and Net investment income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Gains and losses included in Other comprehensive loss, net of tax in the tables above are reflected in Net unrealized appreciation (depreciation) on securities and derivatives in the Consolidated Statements of Comprehensive Income.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transfers into or out of the Level 3 category occur when unobservable inputs, such as the Company's best estimate of what a market participant would use to determine a current transaction price, become more or less significant to the fair value measurement. Market activity typically decreases during periods of economic uncertainty and this decrease in activity reduces the availability of market observable data. As a result, the level of unobservable judgment that must be applied to the pricing of certain instruments increases and is typically observed through the widening of liquidity spreads. Transfers between Level 2 and Level 3 during 2023 and 2022 primarily reflected changes in liquidity estimates for certain private placement issuers across several sectors. See discussion under Quantitative Information about Unobservable Inputs above for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Separate Accounts&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Separate account assets and liabilities are contractholder funds maintained in accounts with specific investment objectives. The assets of these accounts are legally segregated and are not subject to claims that arise out of any of the Company's other businesses. These separate account assets are carried at fair value with equal amounts recorded for related separate account liabilities. The investment income and fair value gains and losses of separate account assets generally accrue directly to the contractholders and, together with their deposits and withdrawals, are excluded from the Company's Consolidated Statements of Income and Cash Flows. Fees and charges earned for mortality risks, asset management or administrative services are reported in either Premiums or Fees and other revenues. Investments that are measured using the practical expedient of net asset value ("NAV") are excluded from the fair value hierarchy. The separate account activity for the year ended December&#160;31, 2023 and 2022 was primarily driven by changes in the market values of the underlying separate account investments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair values of Separate account assets were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.938%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Guaranteed separate accounts (See Note 24)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;226&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;352&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;578&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-guaranteed separate accounts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;158&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,797&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;217&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,172&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;384&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,149&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;217&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,750&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-guaranteed separate accounts priced at NAV as a practical expedient &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;680&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,430&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Non-guaranteed separate accounts include $4.0 billion as of December&#160;31, 2023 and December&#160;31, 2022 in assets supporting the Company's pension plans, including $0.2 billion classified in Level 3 as of December&#160;31, 2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Separate account assets classified as Level 1 primarily include exchange-listed equity securities. Level 2 assets primarily include:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;corporate and structured bonds valued using recent trades of similar securities or pricing models that discount future cash flows at estimated market interest rates as described above; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;actively-traded institutional and retail mutual fund investments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Separate account assets classified in Level 3 primarily support the Company's pension plans and include certain newly-issued, privately-placed, complex or illiquid securities that are priced using methods discussed above, as well as commercial mortgage loans. Activity, including transfers into and out of Level 3, was not material for the years ended December&#160;31, 2023 or 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Separate account investments in securities partnerships, real estate and hedge funds are generally valued based on the separate account's ownership share of the equity of the investee (NAV as a practical expedient), including changes in the fair values of its underlying investments. Substantially all of these assets support the Company's pension plans. The following table provides additional information on these investments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.316%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.322%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value as of&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unfunded Commitment as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Redemption Frequency&lt;br/&gt;(if currently eligible)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Redemption Notice&lt;br/&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;419&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;254&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Not applicable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Not applicable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Real estate funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;258&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Quarterly&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30 - 90 days&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Hedge funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Up to annually, varying by fund&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30 - 90 days&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;680&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;254&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2023, the Company does not have plans to sell any of these assets at less than fair value. These investments are structured to satisfy longer-term investment objectives. Securities partnerships are contractually non-redeemable and the underlying investment assets are expected to be liquidated by the fund managers within ten years after inception.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline"&gt;Assets and Liabilities Measured at Fair Value under Certain Conditions&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Some financial assets and liabilities are not carried at fair value, such as commercial mortgage loans that are carried at unpaid principal, investment real estate that is carried at depreciated cost and equity securities with no readily determinable fair value when there are no observable market transactions. However, these financial assets and liabilities may be measured using fair value under certain conditions, such as when investments become impaired and are written down to their fair value, or when there are observable price changes from orderly market transactions of equity securities that otherwise had no readily determinable fair value.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For the years ended December&#160;31, 2023 and 2022, realized investment gains and losses, including those from impairments recognized and observable price changes, were not material. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline"&gt;Fair Value Disclosures for Financial Instruments Not Carried at Fair Value&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table includes the Company's financial instruments not recorded at fair value but for which fair value disclosure is required. In addition to universal life products and finance leases, financial instruments that are carried in the Company's Consolidated Balance Sheets at amounts that approximate fair value are excluded from the following table:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.316%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.045%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification in Fair Value Hierarchy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial mortgage loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,430&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,533&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term debt, including current maturities, excluding finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;28,033&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29,585&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-1562">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company carries certain financial instruments at fair value in the financial statements including debt securities, certain equity securities, short-term investments and derivatives. Other financial instruments are measured at fair value only under certain conditions, such as when impaired or when there are observable price changes for equity securities with no readily determinable fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value is defined as the price at which an asset could be exchanged in an orderly transaction between market participants at the balance sheet date. A liability's fair value is defined as the amount that would be paid to transfer the liability to a market participant, not the amount that would be paid to settle the liability with the creditor.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's financial assets and liabilities carried at fair value have been classified based upon a hierarchy defined by GAAP. The hierarchy gives the highest ranking to fair values determined using unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest ranking to fair values determined using methodologies and models with unobservable inputs (Level 3). An asset's or a liability's classification is based on the lowest level of input that is significant to its measurement. For example, a financial asset or liability carried at fair value would be classified in Level 3 if unobservable inputs were significant to the instrument's fair value, even though the measurement may be derived using inputs that are both observable (Levels 1 and 2) and unobservable (Level 3).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company estimates fair values using prices from third parties or internal pricing methods. Fair value estimates received from third-party pricing services are based on reported trade activity and quoted market prices when available and other market information that a market participant would use to estimate fair value. The internal pricing methods are performed by the Company's investment professionals and generally involve using discounted cash flow analyses, incorporating current market inputs for similar financial instruments with comparable terms and credit quality as well as other qualitative factors. In instances where there is little or no market activity for the same or similar instruments, fair value is estimated using methods, models and assumptions that the Company believes a hypothetical market participant would use to determine a current transaction price. These valuation techniques involve some level of estimation and judgment that becomes significant with increasingly complex instruments or pricing models.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company is responsible for determining fair value and for assigning the appropriate level within the fair value hierarchy based on the significance of unobservable inputs. The Company reviews methodologies, processes and controls of third-party pricing services and compares prices on a test basis to those obtained from other external pricing sources or internal estimates. The Company performs ongoing analyses of both prices received from third-party pricing services and those developed internally to determine that they represent appropriate estimates of fair value. The controls executed by the Company include evaluating changes in prices and monitoring for potentially stale valuations. The Company also performs sample testing of sales values to confirm the accuracy of prior fair value estimates. The minimal exceptions identified during these processes indicate that adjustments to prices are infrequent and do not significantly impact valuations. An annual due-diligence review of the most significant pricing service is conducted to review their processes, methodologies and controls. This review includes a walk-through of inputs for a sample of securities held across various asset types to validate the documented pricing process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Level 1 Financial Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Inputs for instruments classified in Level 1 include unadjusted quoted prices for identical assets in active markets accessible at the measurement date. Active markets provide pricing data for trades occurring at least weekly and include exchanges and dealer markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Assets in Level 1 include actively-traded U.S. government bonds and exchange-listed equity securities. A relatively small portion of the Company's investment assets are classified in this category given the narrow definition of Level 1 and the Company's investment asset strategy to maximize investment returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Level 2 Financial Assets and Financial Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Inputs for instruments classified in Level 2 include quoted prices for similar assets or liabilities in active markets, quoted prices from those willing to trade in markets that are not active or other inputs that are market observable or can be corroborated by market data for the term of the instrument. Such other inputs include market interest rates and volatilities, spreads and yield curves. An instrument is classified in Level 2 if the Company determines that unobservable inputs are insignificant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Debt and equity securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. Approximately 94% of the Company's investments in debt and equity securities are classified in Level 2 including most public and private corporate debt and equity securities, federal agency and municipal bonds, non-government mortgage-backed securities and preferred stocks. Third-party pricing services and internal methods often use recent trades of securities with similar features and characteristics because many debt securities do not trade daily. Pricing models are used to determine these prices when recent trades are not available. These models calculate fair values by discounting future cash flows at estimated market interest rates. Such market rates are derived by calculating the appropriate spreads over comparable U.S. Treasury securities based on the credit quality, industry and structure of the asset. Typical inputs and assumptions to pricing models include, but are not limited to, a combination of benchmark yields, reported trades, issuer spreads, liquidity, benchmark securities, bids, offers, reference data and industry and economic events. For mortgage-backed securities, inputs and assumptions may also include characteristics of the issuer, collateral attributes, prepayment speeds and credit rating. Nearly all of these instruments are valued using recent trades or pricing models. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Short-term investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; are carried at fair value that approximates cost. The Company compares market prices for these securities to recorded amounts on a regular basis to validate that current carrying amounts approximate exit prices. The short-term nature of the investments and corroboration of the reported amounts over the holding period support their classification in Level 2.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Derivative assets and liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; classified in Level 2 represent over-the-counter instruments such as foreign currency forward and swap contracts. Fair values for these instruments are determined using market observable inputs including forward currency and interest rate curves and widely published market observable indices. Credit risk related to the counterparty and the Company is considered when estimating the fair values of these derivatives. However, the Company is largely protected by collateral arrangements with counterparties and determined that no adjustments for credit risk were required as of December&#160;31, 2023 or December&#160;31, 2022. The nature and use of these derivative financial instruments are described in Note 12.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Level 3 Financial Assets and Financial Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Certain inputs for instruments classified in Level 3 are unobservable (supported by little or no market activity) and significant to their resulting fair value measurement. Unobservable inputs reflect the Company's best estimate of what hypothetical market participants would use to determine a transaction price for the asset or liability at the reporting date. Additionally, as discussed in Note 10E to the Consolidated Financial Statements, the Company classifies variable annuity assets and liabilities in Level 3 of the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company classifies certain newly-issued, privately-placed, complex or illiquid securities in Level 3. Approximately 5% of debt and equity securities are priced using significant unobservable inputs and classified in this category.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair values of mortgage and other asset-backed securities, as well as corporate and government debt securities, are primarily determined using pricing models that incorporate the specific characteristics of each asset and related assumptions including the investment type and structure, credit quality, industry and maturity date in comparison to current market indices, spreads and liquidity of assets with similar characteristics. Inputs and assumptions for pricing may also include characteristics of the issuer, collateral attributes and prepayment speeds for mortgage and other asset-backed securities. Recent trades in the subject security or similar securities are assessed when available, and the Company may also review published research in its evaluation, as well as the issuer's financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Quantitative Information about Unobservable Inputs&lt;/span&gt;&lt;/div&gt;The significant unobservable input used to value our corporate and government debt securities and mortgage and other asset-backed securities is an adjustment for liquidity. This adjustment is needed to reflect current market conditions and issuer circumstances when there is limited trading activity for the security.&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total gains and losses included in Shareholders' net income in the tables above are reflected in the Consolidated Statements of Income as Net realized investment (losses) gains and Net investment income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Gains and losses included in Other comprehensive loss, net of tax in the tables above are reflected in Net unrealized appreciation (depreciation) on securities and derivatives in the Consolidated Statements of Comprehensive Income.&lt;/span&gt;&lt;/div&gt;Transfers into or out of the Level 3 category occur when unobservable inputs, such as the Company's best estimate of what a market participant would use to determine a current transaction price, become more or less significant to the fair value measurement. Market activity typically decreases during periods of economic uncertainty and this decrease in activity reduces the availability of market observable data. As a result, the level of unobservable judgment that must be applied to the pricing of certain instruments increases and is typically observed through the widening of liquidity spreads&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline"&gt;Assets and Liabilities Measured at Fair Value under Certain Conditions&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Some financial assets and liabilities are not carried at fair value, such as commercial mortgage loans that are carried at unpaid principal, investment real estate that is carried at depreciated cost and equity securities with no readily determinable fair value when there are no observable market transactions. However, these financial assets and liabilities may be measured using fair value under certain conditions, such as when investments become impaired and are written down to their fair value, or when there are observable price changes from orderly market transactions of equity securities that otherwise had no readily determinable fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="c-1" id="f-1563">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table provides information about the Company's financial assets and liabilities carried at fair value. Further information regarding insurance assets and liabilities carried at fair value is provided in Note 10E to the Consolidated Financial Statements. Separate account assets are also recorded at fair value on the Company's Consolidated Balance Sheets and are reported separately in the Separate Accounts section below as gains and losses related to these assets generally accrue directly to contractholders:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.767%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financial assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal government and agency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;130&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;137&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;267&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State and local government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;38&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;38&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;352&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;352&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,432&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;401&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,833&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset-backed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;319&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;46&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;365&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;130&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,278&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;447&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,855&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;47&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;51&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;206&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;131&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;132&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financial liabilities at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Excludes certain equity securities that have no readily determinable fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-399" decimals="-6" id="f-1564" unitRef="usd">130000000</ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-400" decimals="-6" id="f-1565" unitRef="usd">147000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-401" decimals="-6" id="f-1566" unitRef="usd">137000000</ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-402" decimals="-6" id="f-1567" unitRef="usd">165000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-403" decimals="-6" id="f-1568" unitRef="usd">0</ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-404" decimals="-6" id="f-1569" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-405" decimals="-6" id="f-1570" unitRef="usd">267000000</ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-406" decimals="-6" id="f-1571" unitRef="usd">312000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-407" decimals="-6" id="f-1572" unitRef="usd">0</ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-408" decimals="-6" id="f-1573" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-409" decimals="-6" id="f-1574" unitRef="usd">38000000</ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-410" decimals="-6" id="f-1575" unitRef="usd">41000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-411" decimals="-6" id="f-1576" unitRef="usd">0</ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-412" decimals="-6" id="f-1577" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-413" decimals="-6" id="f-1578" unitRef="usd">38000000</ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-414" decimals="-6" id="f-1579" unitRef="usd">41000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-415" decimals="-6" id="f-1580" unitRef="usd">0</ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-416" decimals="-6" id="f-1581" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-417" decimals="-6" id="f-1582" unitRef="usd">352000000</ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-418" decimals="-6" id="f-1583" unitRef="usd">365000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-419" decimals="-6" id="f-1584" unitRef="usd">0</ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-420" decimals="-6" id="f-1585" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-421" decimals="-6" id="f-1586" unitRef="usd">352000000</ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-422" decimals="-6" id="f-1587" unitRef="usd">365000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-423" decimals="-6" id="f-1588" unitRef="usd">0</ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-424" decimals="-6" id="f-1589" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-425" decimals="-6" id="f-1590" unitRef="usd">8432000000</ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-426" decimals="-6" id="f-1591" unitRef="usd">8394000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-427" decimals="-6" id="f-1592" unitRef="usd">401000000</ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-428" decimals="-6" id="f-1593" unitRef="usd">412000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-429" decimals="-6" id="f-1594" unitRef="usd">8833000000</ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-430" decimals="-6" id="f-1595" unitRef="usd">8806000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-431" decimals="-6" id="f-1596" unitRef="usd">0</ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-432" decimals="-6" id="f-1597" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-433" decimals="-6" id="f-1598" unitRef="usd">319000000</ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-434" decimals="-6" id="f-1599" unitRef="usd">313000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-435" decimals="-6" id="f-1600" unitRef="usd">46000000</ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-436" decimals="-6" id="f-1601" unitRef="usd">35000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-437" decimals="-6" id="f-1602" unitRef="usd">365000000</ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-438" decimals="-6" id="f-1603" unitRef="usd">348000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-439" decimals="-6" id="f-1604" unitRef="usd">130000000</ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-440" decimals="-6" id="f-1605" unitRef="usd">147000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-441" decimals="-6" id="f-1606" unitRef="usd">9278000000</ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-442" decimals="-6" id="f-1607" unitRef="usd">9278000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-443" decimals="-6" id="f-1608" unitRef="usd">447000000</ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-444" decimals="-6" id="f-1609" unitRef="usd">447000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-445" decimals="-6" id="f-1610" unitRef="usd">9855000000</ci:AvailableForSaleSecuritiesDebtSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-446" decimals="-6" id="f-1611" unitRef="usd">9872000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-439" decimals="-6" id="f-1612" unitRef="usd">4000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-440" decimals="-6" id="f-1613" unitRef="usd">6000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-441" decimals="-6" id="f-1614" unitRef="usd">47000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-442" decimals="-6" id="f-1615" unitRef="usd">132000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-443" decimals="-6" id="f-1616" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-444" decimals="-6" id="f-1617" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-445" decimals="-6" id="f-1618" unitRef="usd">51000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-446" decimals="-6" id="f-1619" unitRef="usd">138000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:OtherShortTermInvestments contextRef="c-439" decimals="-6" id="f-1620" unitRef="usd">0</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments contextRef="c-440" decimals="-6" id="f-1621" unitRef="usd">0</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments contextRef="c-441" decimals="-6" id="f-1622" unitRef="usd">206000000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments contextRef="c-442" decimals="-6" id="f-1623" unitRef="usd">139000000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments contextRef="c-443" decimals="-6" id="f-1624" unitRef="usd">0</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments contextRef="c-444" decimals="-6" id="f-1625" unitRef="usd">0</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments contextRef="c-445" decimals="-6" id="f-1626" unitRef="usd">206000000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments contextRef="c-446" decimals="-6" id="f-1627" unitRef="usd">139000000</us-gaap:OtherShortTermInvestments>
    <us-gaap:DerivativeAssets contextRef="c-447" decimals="-6" id="f-1628" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-448" decimals="-6" id="f-1629" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-449" decimals="-6" id="f-1630" unitRef="usd">131000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-450" decimals="-6" id="f-1631" unitRef="usd">230000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-451" decimals="-6" id="f-1632" unitRef="usd">1000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-452" decimals="-6" id="f-1633" unitRef="usd">1000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-453" decimals="-6" id="f-1634" unitRef="usd">132000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-454" decimals="-6" id="f-1635" unitRef="usd">231000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities contextRef="c-447" decimals="-6" id="f-1636" unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-448" decimals="-6" id="f-1637" unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-449" decimals="-6" id="f-1638" unitRef="usd">4000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-450" decimals="-6" id="f-1639" unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-451" decimals="-6" id="f-1640" unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-452" decimals="-6" id="f-1641" unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-453" decimals="-6" id="f-1642" unitRef="usd">4000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-454" decimals="-6" id="f-1643" unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <ci:DebtAndEquitySecuritiesClassifiedInLevel2PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-12" decimals="2" id="f-1644" unitRef="number">0.94</ci:DebtAndEquitySecuritiesClassifiedInLevel2PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities contextRef="c-455" decimals="INF" id="f-1645" unitRef="usd">0</us-gaap:DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities>
    <us-gaap:DerivativeCreditRiskValuationAdjustmentDerivativeAssets contextRef="c-455" decimals="INF" id="f-1646" unitRef="usd">0</us-gaap:DerivativeCreditRiskValuationAdjustmentDerivativeAssets>
    <us-gaap:DerivativeCreditRiskValuationAdjustmentDerivativeAssets contextRef="c-456" decimals="INF" id="f-1647" unitRef="usd">0</us-gaap:DerivativeCreditRiskValuationAdjustmentDerivativeAssets>
    <us-gaap:DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities contextRef="c-456" decimals="INF" id="f-1648" unitRef="usd">0</us-gaap:DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities>
    <ci:DebtAndEquitySecuritiesClassifiedInLevel3PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-12" decimals="2" id="f-1649" unitRef="number">0.05</ci:DebtAndEquitySecuritiesClassifiedInLevel3PercentageBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c-1" id="f-1650">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes the fair value and significant unobservable inputs that were developed directly by the Company and used in pricing these debt securities. The range and weighted average basis point amounts for liquidity reflect the Company's best estimates of the unobservable adjustments a market participant would make to calculate these fair values. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.094%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.101%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value as of&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Adjustment Range (Weighted Average by Quantity) as of&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Fair value in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Input December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;401&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liquidity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;70 - 1235 (310)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;bps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60 - 1060 (270)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;bps&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;46&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liquidity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;95 - 640 (310) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;bps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105 - 520 (310)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;bps&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Level 3 debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;447&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <ci:MarketableSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-457" decimals="-6" id="f-1651" unitRef="usd">401000000</ci:MarketableSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:MarketableSecurities contextRef="c-458" decimals="-6" id="f-1652" unitRef="usd">412000000</us-gaap:MarketableSecurities>
    <ci:DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput
      contextRef="c-459"
      decimals="4"
      id="f-1653"
      unitRef="number">0.0070</ci:DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput>
    <ci:DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput
      contextRef="c-460"
      decimals="4"
      id="f-1654"
      unitRef="number">0.1235</ci:DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput>
    <ci:DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput
      contextRef="c-461"
      decimals="4"
      id="f-1655"
      unitRef="number">0.0310</ci:DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput>
    <us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput
      contextRef="c-462"
      decimals="4"
      id="f-1656"
      unitRef="number">0.0060</us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput>
    <us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput
      contextRef="c-463"
      decimals="4"
      id="f-1657"
      unitRef="number">0.1060</us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput>
    <us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput
      contextRef="c-464"
      decimals="4"
      id="f-1658"
      unitRef="number">0.0270</us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput>
    <ci:MarketableSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-465" decimals="-6" id="f-1659" unitRef="usd">46000000</ci:MarketableSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:MarketableSecurities contextRef="c-466" decimals="-6" id="f-1660" unitRef="usd">35000000</us-gaap:MarketableSecurities>
    <ci:DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput
      contextRef="c-467"
      decimals="4"
      id="f-1661"
      unitRef="number">0.0095</ci:DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput>
    <ci:DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput
      contextRef="c-468"
      decimals="4"
      id="f-1662"
      unitRef="number">0.0640</ci:DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput>
    <ci:DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput
      contextRef="c-469"
      decimals="4"
      id="f-1663"
      unitRef="number">0.0310</ci:DebtSecuritiesAvailableForSaleIncludingDisposalGroupMeasurementInput>
    <us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput
      contextRef="c-470"
      decimals="4"
      id="f-1664"
      unitRef="number">0.0105</us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput>
    <us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput
      contextRef="c-471"
      decimals="4"
      id="f-1665"
      unitRef="number">0.0520</us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput>
    <us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput
      contextRef="c-472"
      decimals="4"
      id="f-1666"
      unitRef="number">0.0310</us-gaap:DebtSecuritiesAvailableForSaleMeasurementInput>
    <ci:MarketableSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-473" decimals="-6" id="f-1667" unitRef="usd">447000000</ci:MarketableSecuritiesBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:MarketableSecurities contextRef="c-474" decimals="-6" id="f-1668" unitRef="usd">447000000</us-gaap:MarketableSecurities>
    <ci:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock contextRef="c-1" id="f-1669">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes the changes in financial assets and financial liabilities classified in Level 3. Gains and losses reported in the table may include net changes in fair value that are attributable to both observable and unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Debt and Equity Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;447&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Losses) gains included in Shareholders' net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) included in Other comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Purchases, sales and settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total purchases, sales and settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Transfers into/(out of) Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Transfers into Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;95&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Transfers out of Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total transfers into/(out of) Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;36&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;447&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total losses included in Shareholders' net income attributable to instruments held at the reporting date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Change in unrealized gain or (loss) included in Other comprehensive loss for assets held at the end of the reporting period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ci:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-475" decimals="-6" id="f-1670" unitRef="usd">447000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <ci:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-476" decimals="-6" id="f-1671" unitRef="usd">796000000</ci:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 contextRef="c-477" decimals="-6" id="f-1672" unitRef="usd">-2000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 contextRef="c-478" decimals="-6" id="f-1673" unitRef="usd">11000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss contextRef="c-477" decimals="-6" id="f-1674" unitRef="usd">8000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss contextRef="c-478" decimals="-6" id="f-1675" unitRef="usd">-59000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases contextRef="c-477" decimals="-6" id="f-1676" unitRef="usd">10000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases contextRef="c-478" decimals="-6" id="f-1677" unitRef="usd">158000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements contextRef="c-477" decimals="-6" id="f-1678" unitRef="usd">52000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements contextRef="c-478" decimals="-6" id="f-1679" unitRef="usd">207000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements contextRef="c-477" decimals="-6" id="f-1680" unitRef="usd">-42000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements contextRef="c-478" decimals="-6" id="f-1681" unitRef="usd">-49000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3 contextRef="c-477" decimals="-6" id="f-1682" unitRef="usd">95000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3 contextRef="c-478" decimals="-6" id="f-1683" unitRef="usd">124000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3 contextRef="c-477" decimals="-6" id="f-1684" unitRef="usd">59000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3 contextRef="c-478" decimals="-6" id="f-1685" unitRef="usd">376000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet contextRef="c-477" decimals="-6" id="f-1686" unitRef="usd">36000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet contextRef="c-478" decimals="-6" id="f-1687" unitRef="usd">-252000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <ci:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-479" decimals="-6" id="f-1688" unitRef="usd">447000000</ci:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValueBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-475" decimals="-6" id="f-1689" unitRef="usd">447000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <ci:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAttributedToInstrumentsHeldIncludedInEarnings contextRef="c-477" decimals="-6" id="f-1690" unitRef="usd">-2000000</ci:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAttributedToInstrumentsHeldIncludedInEarnings>
    <ci:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAttributedToInstrumentsHeldIncludedInEarnings contextRef="c-478" decimals="-6" id="f-1691" unitRef="usd">-2000000</ci:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAttributedToInstrumentsHeldIncludedInEarnings>
    <ci:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss contextRef="c-1" decimals="-6" id="f-1692" unitRef="usd">3000000</ci:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss>
    <ci:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss contextRef="c-7" decimals="-6" id="f-1693" unitRef="usd">-60000000</ci:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:PolicyholderAccountsPolicy contextRef="c-1" id="f-1694">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Separate account assets and liabilities are contractholder funds maintained in accounts with specific investment objectives. The assets of these accounts are legally segregated and are not subject to claims that arise out of any of the Company's other businesses. These separate account assets are carried at fair value with equal amounts recorded for related separate account liabilities. The investment income and fair value gains and losses of separate account assets generally accrue directly to the contractholders and, together with their deposits and withdrawals, are excluded from the Company's Consolidated Statements of Income and Cash Flows. Fees and charges earned for mortality risks, asset management or administrative services are reported in either Premiums or Fees and other revenues. Investments that are measured using the practical expedient of net asset value ("NAV") are excluded from the fair value hierarchy. The separate account activity for the year ended December&#160;31, 2023 and 2022 was primarily driven by changes in the market values of the underlying separate account investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Separate account assets classified as Level 1 primarily include exchange-listed equity securities. Level 2 assets primarily include:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;corporate and structured bonds valued using recent trades of similar securities or pricing models that discount future cash flows at estimated market interest rates as described above; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;actively-traded institutional and retail mutual fund investments.&lt;/span&gt;&lt;/div&gt;Separate account assets classified in Level 3 primarily support the Company's pension plans and include certain newly-issued, privately-placed, complex or illiquid securities that are priced using methods discussed above, as well as commercial mortgage loans.Separate account investments in securities partnerships, real estate and hedge funds are generally valued based on the separate account's ownership share of the equity of the investee (NAV as a practical expedient), including changes in the fair values of its underlying investments</us-gaap:PolicyholderAccountsPolicy>
    <ci:FairValueOfSeparateAccountAssetsTableTextBlock contextRef="c-1" id="f-1695">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair values of Separate account assets were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.938%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Guaranteed separate accounts (See Note 24)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;226&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;352&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;578&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-guaranteed separate accounts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;158&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,797&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;217&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,172&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;384&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,149&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;217&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,750&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-guaranteed separate accounts priced at NAV as a practical expedient &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;680&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,430&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Non-guaranteed separate accounts include $4.0 billion as of December&#160;31, 2023 and December&#160;31, 2022 in assets supporting the Company's pension plans, including $0.2 billion classified in Level 3 as of December&#160;31, 2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</ci:FairValueOfSeparateAccountAssetsTableTextBlock>
    <ci:GuaranteedSeparateAccountAssets contextRef="c-480" decimals="-6" id="f-1696" unitRef="usd">226000000</ci:GuaranteedSeparateAccountAssets>
    <ci:GuaranteedSeparateAccountAssets contextRef="c-481" decimals="-6" id="f-1697" unitRef="usd">203000000</ci:GuaranteedSeparateAccountAssets>
    <ci:GuaranteedSeparateAccountAssets contextRef="c-482" decimals="-6" id="f-1698" unitRef="usd">352000000</ci:GuaranteedSeparateAccountAssets>
    <ci:GuaranteedSeparateAccountAssets contextRef="c-483" decimals="-6" id="f-1699" unitRef="usd">382000000</ci:GuaranteedSeparateAccountAssets>
    <ci:GuaranteedSeparateAccountAssets contextRef="c-484" decimals="-6" id="f-1700" unitRef="usd">0</ci:GuaranteedSeparateAccountAssets>
    <ci:GuaranteedSeparateAccountAssets contextRef="c-485" decimals="-6" id="f-1701" unitRef="usd">0</ci:GuaranteedSeparateAccountAssets>
    <ci:GuaranteedSeparateAccountAssets contextRef="c-12" decimals="-6" id="f-1702" unitRef="usd">578000000</ci:GuaranteedSeparateAccountAssets>
    <ci:GuaranteedSeparateAccountAssets contextRef="c-13" decimals="-6" id="f-1703" unitRef="usd">585000000</ci:GuaranteedSeparateAccountAssets>
    <ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy contextRef="c-480" decimals="-6" id="f-1704" unitRef="usd">158000000</ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy>
    <ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy contextRef="c-481" decimals="-6" id="f-1705" unitRef="usd">211000000</ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy>
    <ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy contextRef="c-482" decimals="-6" id="f-1706" unitRef="usd">5797000000</ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy>
    <ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy contextRef="c-483" decimals="-6" id="f-1707" unitRef="usd">5522000000</ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy>
    <ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy contextRef="c-484" decimals="-6" id="f-1708" unitRef="usd">217000000</ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy>
    <ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy contextRef="c-485" decimals="-6" id="f-1709" unitRef="usd">203000000</ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy>
    <ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy contextRef="c-12" decimals="-6" id="f-1710" unitRef="usd">6172000000</ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy>
    <ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy contextRef="c-13" decimals="-6" id="f-1711" unitRef="usd">5936000000</ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy>
    <ci:SeparateAccountAssetsClassifiedInFairValueHierarchy contextRef="c-480" decimals="-6" id="f-1712" unitRef="usd">384000000</ci:SeparateAccountAssetsClassifiedInFairValueHierarchy>
    <ci:SeparateAccountAssetsClassifiedInFairValueHierarchy contextRef="c-481" decimals="-6" id="f-1713" unitRef="usd">414000000</ci:SeparateAccountAssetsClassifiedInFairValueHierarchy>
    <ci:SeparateAccountAssetsClassifiedInFairValueHierarchy contextRef="c-482" decimals="-6" id="f-1714" unitRef="usd">6149000000</ci:SeparateAccountAssetsClassifiedInFairValueHierarchy>
    <ci:SeparateAccountAssetsClassifiedInFairValueHierarchy contextRef="c-483" decimals="-6" id="f-1715" unitRef="usd">5904000000</ci:SeparateAccountAssetsClassifiedInFairValueHierarchy>
    <ci:SeparateAccountAssetsClassifiedInFairValueHierarchy contextRef="c-484" decimals="-6" id="f-1716" unitRef="usd">217000000</ci:SeparateAccountAssetsClassifiedInFairValueHierarchy>
    <ci:SeparateAccountAssetsClassifiedInFairValueHierarchy contextRef="c-485" decimals="-6" id="f-1717" unitRef="usd">203000000</ci:SeparateAccountAssetsClassifiedInFairValueHierarchy>
    <ci:SeparateAccountAssetsClassifiedInFairValueHierarchy contextRef="c-12" decimals="-6" id="f-1718" unitRef="usd">6750000000</ci:SeparateAccountAssetsClassifiedInFairValueHierarchy>
    <ci:SeparateAccountAssetsClassifiedInFairValueHierarchy contextRef="c-13" decimals="-6" id="f-1719" unitRef="usd">6521000000</ci:SeparateAccountAssetsClassifiedInFairValueHierarchy>
    <ci:NonGuaranteedSeparateAccountAssetsPricedAtNetAssetValueAsAPracticalExpedient contextRef="c-12" decimals="-6" id="f-1720" unitRef="usd">680000000</ci:NonGuaranteedSeparateAccountAssetsPricedAtNetAssetValueAsAPracticalExpedient>
    <ci:NonGuaranteedSeparateAccountAssetsPricedAtNetAssetValueAsAPracticalExpedient contextRef="c-13" decimals="-6" id="f-1721" unitRef="usd">757000000</ci:NonGuaranteedSeparateAccountAssetsPricedAtNetAssetValueAsAPracticalExpedient>
    <us-gaap:SeparateAccountAssets contextRef="c-12" decimals="-6" id="f-1722" unitRef="usd">7430000000</us-gaap:SeparateAccountAssets>
    <us-gaap:SeparateAccountAssets contextRef="c-13" decimals="-6" id="f-1723" unitRef="usd">7278000000</us-gaap:SeparateAccountAssets>
    <ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy contextRef="c-486" decimals="-8" id="f-1724" unitRef="usd">4000000000</ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy>
    <ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy contextRef="c-487" decimals="-8" id="f-1725" unitRef="usd">4000000000</ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy>
    <ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy contextRef="c-488" decimals="-8" id="f-1726" unitRef="usd">200000000</ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy>
    <ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy contextRef="c-489" decimals="-8" id="f-1727" unitRef="usd">200000000</ci:NonGuaranteedSeparateAccountAssetsClassifiedInFairValueHierarchy>
    <us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTableTextBlock contextRef="c-1" id="f-1728">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Separate account investments in securities partnerships, real estate and hedge funds are generally valued based on the separate account's ownership share of the equity of the investee (NAV as a practical expedient), including changes in the fair values of its underlying investments. Substantially all of these assets support the Company's pension plans. The following table provides additional information on these investments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.316%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.322%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value as of&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unfunded Commitment as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Redemption Frequency&lt;br/&gt;(if currently eligible)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Redemption Notice&lt;br/&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;419&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;254&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Not applicable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Not applicable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Real estate funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;258&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Quarterly&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30 - 90 days&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Hedge funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Up to annually, varying by fund&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30 - 90 days&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;680&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;254&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTableTextBlock>
    <us-gaap:AlternativeInvestment contextRef="c-490" decimals="-6" id="f-1729" unitRef="usd">419000000</us-gaap:AlternativeInvestment>
    <us-gaap:AlternativeInvestment contextRef="c-491" decimals="-6" id="f-1730" unitRef="usd">451000000</us-gaap:AlternativeInvestment>
    <us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments contextRef="c-492" decimals="-6" id="f-1731" unitRef="usd">254000000</us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments>
    <us-gaap:AlternativeInvestment contextRef="c-493" decimals="-6" id="f-1732" unitRef="usd">258000000</us-gaap:AlternativeInvestment>
    <us-gaap:AlternativeInvestment contextRef="c-494" decimals="-6" id="f-1733" unitRef="usd">302000000</us-gaap:AlternativeInvestment>
    <us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments contextRef="c-495" decimals="-6" id="f-1734" unitRef="usd">0</us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments>
    <us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1 contextRef="c-496" id="f-1735">P30D</us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1>
    <us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1 contextRef="c-497" id="f-1736">P90D</us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1>
    <us-gaap:AlternativeInvestment contextRef="c-498" decimals="-6" id="f-1737" unitRef="usd">3000000</us-gaap:AlternativeInvestment>
    <us-gaap:AlternativeInvestment contextRef="c-499" decimals="-6" id="f-1738" unitRef="usd">4000000</us-gaap:AlternativeInvestment>
    <us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments contextRef="c-500" decimals="-6" id="f-1739" unitRef="usd">0</us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments>
    <us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1 contextRef="c-501" id="f-1740">P30D</us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1>
    <us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1 contextRef="c-502" id="f-1741">P90D</us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareInvestmentRedemptionNoticePeriod1>
    <us-gaap:AlternativeInvestment contextRef="c-503" decimals="-6" id="f-1742" unitRef="usd">680000000</us-gaap:AlternativeInvestment>
    <us-gaap:AlternativeInvestment contextRef="c-504" decimals="-6" id="f-1743" unitRef="usd">757000000</us-gaap:AlternativeInvestment>
    <us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments contextRef="c-505" decimals="-6" id="f-1744" unitRef="usd">254000000</us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments>
    <ci:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLiquidatingInvestmentPeriodFromInceptionSecuritiesPartnerships contextRef="c-506" id="f-1745">P10Y</ci:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLiquidatingInvestmentPeriodFromInceptionSecuritiesPartnerships>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock contextRef="c-1" id="f-1746">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table includes the Company's financial instruments not recorded at fair value but for which fair value disclosure is required. In addition to universal life products and finance leases, financial instruments that are carried in the Company's Consolidated Balance Sheets at amounts that approximate fair value are excluded from the following table:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.316%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.045%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification in Fair Value Hierarchy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial mortgage loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,430&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,533&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term debt, including current maturities, excluding finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;28,033&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29,585&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <ci:MortgageLoansOnRealEstateCommercialAndConsumerNetBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-507" decimals="-6" id="f-1747" unitRef="usd">1430000000</ci:MortgageLoansOnRealEstateCommercialAndConsumerNetBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <ci:MortgageLoansOnRealEstateCommercialAndConsumerNetBeforeReclassificationToDisposalGroupAssetsHeldForSale contextRef="c-508" decimals="-6" id="f-1748" unitRef="usd">1533000000</ci:MortgageLoansOnRealEstateCommercialAndConsumerNetBeforeReclassificationToDisposalGroupAssetsHeldForSale>
    <us-gaap:MortgageLoansOnRealEstateCommercialAndConsumerNet contextRef="c-509" decimals="-6" id="f-1749" unitRef="usd">1491000000</us-gaap:MortgageLoansOnRealEstateCommercialAndConsumerNet>
    <us-gaap:MortgageLoansOnRealEstateCommercialAndConsumerNet contextRef="c-510" decimals="-6" id="f-1750" unitRef="usd">1614000000</us-gaap:MortgageLoansOnRealEstateCommercialAndConsumerNet>
    <us-gaap:LongTermDebtFairValue contextRef="c-511" decimals="-6" id="f-1751" unitRef="usd">28033000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue contextRef="c-508" decimals="-6" id="f-1752" unitRef="usd">29585000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue contextRef="c-512" decimals="-6" id="f-1753" unitRef="usd">28653000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue contextRef="c-510" decimals="-6" id="f-1754" unitRef="usd">30994000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:VariableInterestEntityDisclosureTextBlock contextRef="c-1" id="f-1761">&lt;div&gt;&lt;span id="ie01e129ab42145fc8bf7e377e885a1a4_13"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 14 &#x2013; Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;When the Company becomes involved with a variable interest entity and when there is a change in the Company's involvement with an entity, the Company must determine if it is the primary beneficiary and must consolidate the entity. The Company is considered the primary beneficiary if it has the power to direct the entity's most significant economic activities and has the right to receive benefits or obligation to absorb losses that could be significant to the entity. The Company evaluates the following criteria:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;the structure and purpose of the entity;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;the risks and rewards created by and shared through the entity; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;the Company's ability to direct its activities, receive its benefits and absorb its losses relative to the other parties involved with the entity including its sponsors, equity holders, guarantors, creditors and servicers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company determined it was not a primary beneficiary in any material variable interest entity as of December&#160;31, 2023 or 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's involvement in variable interest entities for which it is not the primary beneficiary is described below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Securities limited partnerships and real estate limited partnerships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. The Company owns interests in securities limited partnerships and real estate limited partnerships that are defined as unconsolidated variable interest entities. These partnerships invest in the equity or mezzanine debt of privately-held companies and real estate properties. General partners unaffiliated with the Company control decisions that most significantly impact the partnership's operations and the limited partners do not have substantive kick-out or participating rights. The Company has invested in approximately 190 limited partnerships that have a carrying value of $2.9 billion as of December&#160;31, 2023 reported in other long-term investments. As of December&#160;31, 2023, we have commitments to contribute an additional $2.6 billion to these entities and the Company's maximum exposure to loss from these investments is $5.5 billion, calculated as the sum of our carrying value and the additional funding commitments. Our noncontrolling interest in each of these limited partnerships is generally less than 8% of the partnership ownership interests. See Note 12 for further information on the Company's accounting policy for other long-term investments. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has guaranteed debt payments to mortgage lenders for certain real estate limited partnerships should potential environmental obligations arise. No liability has been incurred related to these guarantees, and the Company's maximum exposure to these guarantees was approximately $488 million as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Other variable interest entities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. The Company is involved in other types of variable interest entities, including certain asset-backed and corporate securities, real estate joint ventures that develop properties for residential and commercial use, independent physician associations ("IPAs") that provide care management services and international health care joint ventures. As of December&#160;31, 2023, the Company's maximum exposure to loss is $0.5 billion from certain asset-backed and corporate securities and $0.9 billion from real estate joint ventures, which represents the sum of our carrying value and the additional funding commitments for these entities. The &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;carrying values and maximum exposures for the remaining unconsolidated variable interest entities were not material as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has not provided, and does not intend to provide, financial support to any of the variable interest entities in excess of its maximum exposure. We perform ongoing qualitative analyses of our involvement with these variable interest entities to determine if consolidation is required.&lt;/span&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <us-gaap:ConsolidationVariableInterestEntityPolicy contextRef="c-1" id="f-1762">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;When the Company becomes involved with a variable interest entity and when there is a change in the Company's involvement with an entity, the Company must determine if it is the primary beneficiary and must consolidate the entity. The Company is considered the primary beneficiary if it has the power to direct the entity's most significant economic activities and has the right to receive benefits or obligation to absorb losses that could be significant to the entity. The Company evaluates the following criteria:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;the structure and purpose of the entity;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;the risks and rewards created by and shared through the entity; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;the Company's ability to direct its activities, receive its benefits and absorb its losses relative to the other parties involved with the entity including its sponsors, equity holders, guarantors, creditors and servicers. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Securities limited partnerships and real estate limited partnerships&lt;/span&gt;. The Company owns interests in securities limited partnerships and real estate limited partnerships that are defined as unconsolidated variable interest entities. These partnerships invest in the equity or mezzanine debt of privately-held companies and real estate properties. General partners unaffiliated with the Company control decisions that most significantly impact the partnership's operations and the limited partners do not have substantive kick-out or participating rights. The Company has invested in approximately 190 limited partnerships that have a carrying value of $2.9 billion as of December&#160;31, 2023 reported in other long-term investments. We perform ongoing qualitative analyses of our involvement with these variable interest entities to determine if consolidation is required.</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <ci:VariableInterestEntitiesNumberOfEntities
      contextRef="c-515"
      decimals="0"
      id="f-1763"
      unitRef="entity">0</ci:VariableInterestEntitiesNumberOfEntities>
    <ci:VariableInterestEntitiesNumberOfEntities
      contextRef="c-516"
      decimals="0"
      id="f-1764"
      unitRef="entity">0</ci:VariableInterestEntitiesNumberOfEntities>
    <ci:VariableInterestEntitiesNumberOfEntities
      contextRef="c-517"
      decimals="0"
      id="f-1765"
      unitRef="limitedpartnership">190</ci:VariableInterestEntitiesNumberOfEntities>
    <us-gaap:NoncontrollingInterestInVariableInterestEntity contextRef="c-517" decimals="-8" id="f-1766" unitRef="usd">2900000000</us-gaap:NoncontrollingInterestInVariableInterestEntity>
    <us-gaap:OtherCommitment contextRef="c-518" decimals="-8" id="f-1767" unitRef="usd">2600000000</us-gaap:OtherCommitment>
    <us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount contextRef="c-517" decimals="-8" id="f-1768" unitRef="usd">5500000000</us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c-519"
      decimals="2"
      id="f-1769"
      unitRef="number">0.08</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:GuarantyLiabilities contextRef="c-520" decimals="-6" id="f-1770" unitRef="usd">0</us-gaap:GuarantyLiabilities>
    <us-gaap:GuaranteeObligationsMaximumExposure contextRef="c-520" decimals="-6" id="f-1771" unitRef="usd">488000000</us-gaap:GuaranteeObligationsMaximumExposure>
    <us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount contextRef="c-521" decimals="-8" id="f-1772" unitRef="usd">500000000</us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount>
    <us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount contextRef="c-520" decimals="-8" id="f-1773" unitRef="usd">900000000</us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock contextRef="c-1" id="f-1776">&lt;div style="margin-bottom:10pt"&gt;&lt;span id="ie9e3a7152b194e0d81f599bfea9605e2_2394"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Note 15 &#x2013; Collectively Significant Operating Unconsolidated Subsidiaries&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In addition to equity method investments, including certain limited partnerships and limited liability companies holding real estate, securities or loans (as disclosed in Note 12), we maintain a portfolio of operating joint ventures accounted for as equity method investments. Operating joint ventures accounted for under the equity method had a carrying value of $911 million as of December&#160;31, 2023 and $734 million as of December&#160;31, 2022, of which $214 million as of December&#160;31, 2023 and $602 million as of December&#160;31, 2022 related to our joint venture in China. Total Accumulated Other Comprehensive Income ("AOCI") includes losses of $510&#160;million as of December&#160;31, 2023 and $88&#160;million as of December&#160;31, 2022 related to the Company's share from unconsolidated entities reported on the equity method primarily driven by the requirement to update discount rate assumptions for certain long-duration liabilities following the adoption of LDTI (discussed in Note 2 to the Consolidated Financial Statements).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For the years ended December 31, 2023, 2022 and 2021, none of our unconsolidated subsidiary investments were individually significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We record in our Consolidated Statements of Income our proportionate share of net income or loss generated by equity method operating joint ventures within Fees and other revenues. In certain instances, income or loss is reported on a one month lag due to the timing of when financial information is received.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The below summarized results of operations and financial position of the operating joint venture investments accounted for under the equity method reflects the latest available financial information and does not represent the Company's proportionate share of the assets, liabilities or earnings of such entities. Prior period operating joint venture amounts have been retrospectively restated to reflect the adoption of amended accounting guidance for long-duration insurance contracts, as discussed in Note 2 to the Consolidated Financial Statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.431%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,962&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;98&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;26,681&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;25,534&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestments contextRef="c-523" decimals="-6" id="f-1777" unitRef="usd">911000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-524" decimals="-6" id="f-1778" unitRef="usd">734000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-525" decimals="-6" id="f-1779" unitRef="usd">214000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-526" decimals="-6" id="f-1780" unitRef="usd">602000000</us-gaap:EquityMethodInvestments>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-523" decimals="-6" id="f-1781" unitRef="usd">-510000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-524" decimals="-6" id="f-1782" unitRef="usd">-88000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:EquityMethodInvestmentsPolicy contextRef="c-1" id="f-1783">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We record in our Consolidated Statements of Income our proportionate share of net income or loss generated by equity method operating joint ventures within Fees and other revenues. In certain instances, income or loss is reported on a one month lag due to the timing of when financial information is received.&lt;/span&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:EquityMethodInvestmentsTextBlock contextRef="c-1" id="f-1784">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The below summarized results of operations and financial position of the operating joint venture investments accounted for under the equity method reflects the latest available financial information and does not represent the Company's proportionate share of the assets, liabilities or earnings of such entities. Prior period operating joint venture amounts have been retrospectively restated to reflect the adoption of amended accounting guidance for long-duration insurance contracts, as discussed in Note 2 to the Consolidated Financial Statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.431%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,962&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;98&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;26,681&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;25,534&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:Revenues contextRef="c-527" decimals="-6" id="f-1785" unitRef="usd">5962000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-528" decimals="-6" id="f-1786" unitRef="usd">4665000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-529" decimals="-6" id="f-1787" unitRef="usd">3750000000</us-gaap:Revenues>
    <us-gaap:ProfitLoss contextRef="c-527" decimals="-6" id="f-1788" unitRef="usd">98000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-528" decimals="-6" id="f-1789" unitRef="usd">-12000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-529" decimals="-6" id="f-1790" unitRef="usd">180000000</us-gaap:ProfitLoss>
    <us-gaap:Assets contextRef="c-530" decimals="-6" id="f-1791" unitRef="usd">26681000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-531" decimals="-6" id="f-1792" unitRef="usd">21026000000</us-gaap:Assets>
    <us-gaap:Liabilities contextRef="c-530" decimals="-6" id="f-1793" unitRef="usd">25534000000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-531" decimals="-6" id="f-1794" unitRef="usd">19462000000</us-gaap:Liabilities>
    <ci:AccumulatedOtherComprehensiveIncomeDisclosureTextBlock contextRef="c-1" id="f-1795">&lt;div style="margin-bottom:10pt"&gt;&lt;span id="i28e542229591430e91381eec66292ee8_1746"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 16 &#x2013; Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AOCI includes net unrealized (depreciation) appreciation on securities and derivatives, change in discount rate and instrument specific credit risk for certain long-duration insurance contractholder liabilities (Note 10 to the Consolidated Financial Statements), foreign currency translation and the net postretirement benefits liability adjustment. AOCI includes the Company's share from unconsolidated entities reported on the equity method. Generally, tax effects in AOCI are established at the currently enacted tax rate and reclassified to Shareholders' net income in the same period that the related pre-tax AOCI reclassifications are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Shareholders' other comprehensive (loss), net of tax, for the years ended 2023, 2022 and 2021, is primarily driven by the change in discount rates for certain long-duration liabilities, unrealized changes in the market values of securities and derivatives and changes in postretirement benefits liabilities, including the impacts from unconsolidated entities reported on the equity method.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Changes in the components of AOCI, including the restatement for amended accounting guidance for long-duration insurance contracts (discussed in Note 2 to the Consolidated Financial Statements), are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Securities and Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance, as previously disclosed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cumulative effect of accounting for Long-duration Insurance Contracts guidance (ASU 2018-12)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance, as retrospectively restated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized appreciation (depreciation) on securities and derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;620&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(335)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unrealized appreciation (depreciation) on securities and derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;474&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustment for losses included in Shareholders' net income ((Loss) gain on sale of businesses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustment for losses (gains) included in Shareholders' net income (Net realized investment (losses) gains)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;38&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustment for (gains) included in Shareholders' net income (Selling, general and administrative expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustment for tax (benefit) expense included in Shareholders' net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net losses (gains) reclassified from AOCI to Shareholders' net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;503&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,598)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;171&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net long-duration insurance and contractholder liabilities measurement adjustments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance, as previously disclosed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cumulative effect of accounting for Long-duration Insurance Contracts guidance (ASU 2018-12)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(832)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance, as retrospectively restated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(832)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current period change in discount rate for certain long-duration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(913)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;222&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period change in discount rate for certain long-duration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(691)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current period change in instrument-specific credit risk for market risk benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period change in instrument-specific credit risk for market risk benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive (loss) income, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(715)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(971)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Established upon the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Translation of foreign currencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance, as retrospectively restated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Translation of foreign currencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net translation of foreign currencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(310)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustment for losses included in Net income ((Loss) gain on sale of businesses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustment for tax expense included in Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net translation losses reclassified from AOCI to Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Translation of foreign currencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Net translation (loss) on foreign currencies attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shareholders' other comprehensive income (loss), net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Postretirement benefits liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(916)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,746)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustment for amortization of net prior actuarial losses and prior service costs (Interest expense and other)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;46&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustment for (gains) included in Shareholders' net income ((Loss) gain on sale of businesses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustment for settlement (Interest expense and other)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustment for tax (benefit) included in Shareholders' net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net adjustments reclassified from AOCI to Shareholders' net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Valuation update&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net change due to valuation update&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(916)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance, as previously disclosed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(861)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cumulative effect of accounting for Long-duration Insurance Contracts guidance (ASU 2018-12)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance, as retrospectively restated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,658)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,025)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shareholders' other comprehensive (loss), net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(590)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,864)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,658)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ci:AccumulatedOtherComprehensiveIncomeDisclosureTextBlock>
    <us-gaap:StockholdersEquityPolicyTextBlock contextRef="c-1" id="f-1796">Generally, tax effects in AOCI are established at the currently enacted tax rate and reclassified to Shareholders' net income in the same period that the related pre-tax AOCI reclassifications are recognized.</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="c-1" id="f-1797">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Changes in the components of AOCI, including the restatement for amended accounting guidance for long-duration insurance contracts (discussed in Note 2 to the Consolidated Financial Statements), are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Securities and Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance, as previously disclosed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cumulative effect of accounting for Long-duration Insurance Contracts guidance (ASU 2018-12)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance, as retrospectively restated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized appreciation (depreciation) on securities and derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;620&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(335)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unrealized appreciation (depreciation) on securities and derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;474&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustment for losses included in Shareholders' net income ((Loss) gain on sale of businesses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustment for losses (gains) included in Shareholders' net income (Net realized investment (losses) gains)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;38&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustment for (gains) included in Shareholders' net income (Selling, general and administrative expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustment for tax (benefit) expense included in Shareholders' net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net losses (gains) reclassified from AOCI to Shareholders' net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;503&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,598)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;171&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net long-duration insurance and contractholder liabilities measurement adjustments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance, as previously disclosed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cumulative effect of accounting for Long-duration Insurance Contracts guidance (ASU 2018-12)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(832)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance, as retrospectively restated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(832)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current period change in discount rate for certain long-duration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(913)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;222&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period change in discount rate for certain long-duration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(691)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current period change in instrument-specific credit risk for market risk benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period change in instrument-specific credit risk for market risk benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive (loss) income, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(715)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(971)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Established upon the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Translation of foreign currencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance, as retrospectively restated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Translation of foreign currencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net translation of foreign currencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(310)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustment for losses included in Net income ((Loss) gain on sale of businesses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustment for tax expense included in Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net translation losses reclassified from AOCI to Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Translation of foreign currencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Net translation (loss) on foreign currencies attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shareholders' other comprehensive income (loss), net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Postretirement benefits liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(916)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,746)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustment for amortization of net prior actuarial losses and prior service costs (Interest expense and other)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;46&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustment for (gains) included in Shareholders' net income ((Loss) gain on sale of businesses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustment for settlement (Interest expense and other)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustment for tax (benefit) included in Shareholders' net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net adjustments reclassified from AOCI to Shareholders' net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Valuation update&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net change due to valuation update&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(916)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.763%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance, as previously disclosed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(861)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cumulative effect of accounting for Long-duration Insurance Contracts guidance (ASU 2018-12)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance, as retrospectively restated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,658)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,025)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shareholders' other comprehensive (loss), net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(590)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,864)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,658)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-532" decimals="-6" id="f-1798" unitRef="usd">900000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-533" decimals="-6" id="f-1799" unitRef="usd">668000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-534" decimals="-6" id="f-1800" unitRef="usd">-332000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-535" decimals="-6" id="f-1801" unitRef="usd">1266000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-536" decimals="-6" id="f-1802" unitRef="usd">1568000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax contextRef="c-537" decimals="-6" id="f-1803" unitRef="usd">620000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax contextRef="c-538" decimals="-6" id="f-1804" unitRef="usd">-2274000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax contextRef="c-539" decimals="-6" id="f-1805" unitRef="usd">-335000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-537" decimals="-6" id="f-1806" unitRef="usd">146000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-538" decimals="-6" id="f-1807" unitRef="usd">-467000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-539" decimals="-6" id="f-1808" unitRef="usd">-52000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-537" decimals="-6" id="f-1809" unitRef="usd">474000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-538" decimals="-6" id="f-1810" unitRef="usd">-1807000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-539" decimals="-6" id="f-1811" unitRef="usd">-283000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="c-540" decimals="-6" id="f-1812" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="c-541" decimals="-6" id="f-1813" unitRef="usd">-172000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="c-542" decimals="-6" id="f-1814" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="c-543" decimals="-6" id="f-1815" unitRef="usd">-38000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="c-544" decimals="-6" id="f-1816" unitRef="usd">-47000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="c-545" decimals="-6" id="f-1817" unitRef="usd">24000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="c-546" decimals="-6" id="f-1818" unitRef="usd">1000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="c-547" decimals="-6" id="f-1819" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="c-548" decimals="-6" id="f-1820" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-537" decimals="-6" id="f-1821" unitRef="usd">-8000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-538" decimals="-6" id="f-1822" unitRef="usd">-10000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-539" decimals="-6" id="f-1823" unitRef="usd">5000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-537" decimals="-6" id="f-1824" unitRef="usd">-29000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-538" decimals="-6" id="f-1825" unitRef="usd">-209000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-539" decimals="-6" id="f-1826" unitRef="usd">19000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-537" decimals="-6" id="f-1827" unitRef="usd">503000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-538" decimals="-6" id="f-1828" unitRef="usd">-1598000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-539" decimals="-6" id="f-1829" unitRef="usd">-302000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-549" decimals="-6" id="f-1830" unitRef="usd">171000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-534" decimals="-6" id="f-1831" unitRef="usd">-332000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-535" decimals="-6" id="f-1832" unitRef="usd">1266000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-550" decimals="-6" id="f-1833" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-551" decimals="-6" id="f-1834" unitRef="usd">-832000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-552" decimals="-6" id="f-1835" unitRef="usd">-256000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-553" decimals="-6" id="f-1836" unitRef="usd">-765000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-554" decimals="-6" id="f-1837" unitRef="usd">-832000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax contextRef="c-555" decimals="-6" id="f-1838" unitRef="usd">-913000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax contextRef="c-556" decimals="-6" id="f-1839" unitRef="usd">642000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax contextRef="c-557" decimals="-6" id="f-1840" unitRef="usd">59000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-555" decimals="-6" id="f-1841" unitRef="usd">-222000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-556" decimals="-6" id="f-1842" unitRef="usd">122000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-557" decimals="-6" id="f-1843" unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-555" decimals="-6" id="f-1844" unitRef="usd">-691000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-556" decimals="-6" id="f-1845" unitRef="usd">520000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-557" decimals="-6" id="f-1846" unitRef="usd">56000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax contextRef="c-558" decimals="-6" id="f-1847" unitRef="usd">-29000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax contextRef="c-559" decimals="-6" id="f-1848" unitRef="usd">-14000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax contextRef="c-560" decimals="-6" id="f-1849" unitRef="usd">13000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-558" decimals="-6" id="f-1850" unitRef="usd">-5000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-559" decimals="-6" id="f-1851" unitRef="usd">-3000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-560" decimals="-6" id="f-1852" unitRef="usd">2000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-558" decimals="-6" id="f-1853" unitRef="usd">-24000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-559" decimals="-6" id="f-1854" unitRef="usd">-11000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-560" decimals="-6" id="f-1855" unitRef="usd">11000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-561" decimals="-6" id="f-1856" unitRef="usd">-715000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-562" decimals="-6" id="f-1857" unitRef="usd">509000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-563" decimals="-6" id="f-1858" unitRef="usd">67000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-564" decimals="-6" id="f-1859" unitRef="usd">-971000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-552" decimals="-6" id="f-1860" unitRef="usd">-256000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-553" decimals="-6" id="f-1861" unitRef="usd">-765000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-565" decimals="-6" id="f-1862" unitRef="usd">-154000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-566" decimals="-6" id="f-1863" unitRef="usd">-233000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-567" decimals="-6" id="f-1864" unitRef="usd">-15000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <ci:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity contextRef="c-568" decimals="-6" id="f-1865" unitRef="usd">0</ci:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity>
    <ci:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity contextRef="c-569" decimals="-6" id="f-1866" unitRef="usd">-277000000</ci:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity>
    <ci:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity contextRef="c-570" decimals="-6" id="f-1867" unitRef="usd">-213000000</ci:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTaxIncludingTemporaryEquity>
    <ci:OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity contextRef="c-568" decimals="-6" id="f-1868" unitRef="usd">-5000000</ci:OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity>
    <ci:OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity contextRef="c-569" decimals="-6" id="f-1869" unitRef="usd">33000000</ci:OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity>
    <ci:OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity contextRef="c-570" decimals="-6" id="f-1870" unitRef="usd">19000000</ci:OtherComprehensiveIncomeLossBeforeReclassificationsTaxIncludingTemporaryEquity>
    <ci:OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity contextRef="c-568" decimals="-6" id="f-1871" unitRef="usd">5000000</ci:OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity>
    <ci:OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity contextRef="c-569" decimals="-6" id="f-1872" unitRef="usd">-310000000</ci:OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity>
    <ci:OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity contextRef="c-570" decimals="-6" id="f-1873" unitRef="usd">-232000000</ci:OtherComprehensiveIncomeLossBeforeReclassificationsAfterTaxIncludingTemporaryEquity>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="c-568" decimals="-6" id="f-1874" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="c-569" decimals="-6" id="f-1875" unitRef="usd">-358000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="c-570" decimals="-6" id="f-1876" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-568" decimals="-6" id="f-1877" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-569" decimals="-6" id="f-1878" unitRef="usd">29000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-570" decimals="-6" id="f-1879" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-568" decimals="-6" id="f-1880" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-569" decimals="-6" id="f-1881" unitRef="usd">-387000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-570" decimals="-6" id="f-1882" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <ci:OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity contextRef="c-568" decimals="-6" id="f-1883" unitRef="usd">0</ci:OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity>
    <ci:OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity contextRef="c-569" decimals="-6" id="f-1884" unitRef="usd">81000000</ci:OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity>
    <ci:OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity contextRef="c-570" decimals="-6" id="f-1885" unitRef="usd">-213000000</ci:OtherComprehensiveIncomeLossBeforeTaxIncludingTemporaryEquity>
    <ci:OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity contextRef="c-568" decimals="-6" id="f-1886" unitRef="usd">-5000000</ci:OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity>
    <ci:OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity contextRef="c-569" decimals="-6" id="f-1887" unitRef="usd">4000000</ci:OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity>
    <ci:OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity contextRef="c-570" decimals="-6" id="f-1888" unitRef="usd">19000000</ci:OtherComprehensiveIncomeLossTaxIncludingTemporaryEquity>
    <ci:OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity contextRef="c-568" decimals="-6" id="f-1889" unitRef="usd">5000000</ci:OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity>
    <ci:OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity contextRef="c-569" decimals="-6" id="f-1890" unitRef="usd">77000000</ci:OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity>
    <ci:OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity contextRef="c-570" decimals="-6" id="f-1891" unitRef="usd">-232000000</ci:OtherComprehensiveIncomeLossNetOfTaxIncludingTemporaryEquity>
    <ci:TemporaryEquityOtherComprehensiveIncome contextRef="c-571" decimals="-6" id="f-1892" unitRef="usd">0</ci:TemporaryEquityOtherComprehensiveIncome>
    <ci:TemporaryEquityOtherComprehensiveIncome contextRef="c-572" decimals="-6" id="f-1893" unitRef="usd">-2000000</ci:TemporaryEquityOtherComprehensiveIncome>
    <ci:TemporaryEquityOtherComprehensiveIncome contextRef="c-573" decimals="-6" id="f-1894" unitRef="usd">-14000000</ci:TemporaryEquityOtherComprehensiveIncome>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-574" decimals="-6" id="f-1895" unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-575" decimals="-6" id="f-1896" unitRef="usd">79000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-576" decimals="-6" id="f-1897" unitRef="usd">-218000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-577" decimals="-6" id="f-1898" unitRef="usd">-149000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-565" decimals="-6" id="f-1899" unitRef="usd">-154000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-566" decimals="-6" id="f-1900" unitRef="usd">-233000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-578" decimals="-6" id="f-1901" unitRef="usd">-916000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-579" decimals="-6" id="f-1902" unitRef="usd">-1336000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-580" decimals="-6" id="f-1903" unitRef="usd">-1746000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="c-581" decimals="-6" id="f-1904" unitRef="usd">-46000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="c-582" decimals="-6" id="f-1905" unitRef="usd">-65000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="c-583" decimals="-6" id="f-1906" unitRef="usd">-85000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="c-584" decimals="-6" id="f-1907" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="c-585" decimals="-6" id="f-1908" unitRef="usd">1000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="c-586" decimals="-6" id="f-1909" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="c-587" decimals="-6" id="f-1910" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="c-588" decimals="-6" id="f-1911" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax contextRef="c-589" decimals="-6" id="f-1912" unitRef="usd">-4000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-590" decimals="-6" id="f-1913" unitRef="usd">-11000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-591" decimals="-6" id="f-1914" unitRef="usd">-16000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-592" decimals="-6" id="f-1915" unitRef="usd">-21000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-590" decimals="-6" id="f-1916" unitRef="usd">-35000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-591" decimals="-6" id="f-1917" unitRef="usd">-48000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-592" decimals="-6" id="f-1918" unitRef="usd">-68000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax contextRef="c-590" decimals="-6" id="f-1919" unitRef="usd">-46000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax contextRef="c-591" decimals="-6" id="f-1920" unitRef="usd">487000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax contextRef="c-592" decimals="-6" id="f-1921" unitRef="usd">448000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-590" decimals="-6" id="f-1922" unitRef="usd">-12000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-591" decimals="-6" id="f-1923" unitRef="usd">115000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-592" decimals="-6" id="f-1924" unitRef="usd">106000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-590" decimals="-6" id="f-1925" unitRef="usd">-34000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-591" decimals="-6" id="f-1926" unitRef="usd">372000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-592" decimals="-6" id="f-1927" unitRef="usd">342000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-590" decimals="-6" id="f-1928" unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-591" decimals="-6" id="f-1929" unitRef="usd">420000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-592" decimals="-6" id="f-1930" unitRef="usd">410000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-593" decimals="-6" id="f-1931" unitRef="usd">-915000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-578" decimals="-6" id="f-1932" unitRef="usd">-916000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-579" decimals="-6" id="f-1933" unitRef="usd">-1336000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-16" decimals="-6" id="f-1934" unitRef="usd">-861000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-22" decimals="-6" id="f-1935" unitRef="usd">-164000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-56" decimals="-6" id="f-1936" unitRef="usd">-1658000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-42" decimals="-6" id="f-1937" unitRef="usd">-1068000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-28" decimals="-6" id="f-1938" unitRef="usd">-1025000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-64" decimals="-6" id="f-1939" unitRef="usd">-206000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-51" decimals="-6" id="f-1940" unitRef="usd">-590000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-37" decimals="-6" id="f-1941" unitRef="usd">-43000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-69" decimals="-6" id="f-1942" unitRef="usd">-1864000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-56" decimals="-6" id="f-1943" unitRef="usd">-1658000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-42" decimals="-6" id="f-1944" unitRef="usd">-1068000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="c-1" id="f-1945">&lt;div style="margin-bottom:10pt"&gt;&lt;span id="ib4ae12875cf34f83a32bfa168076339d_4120"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Note 17 &#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Organizational Efficiency Plan&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the fourth quarter of 2023, the Company approved a strategic realignment to drive greater operating effectiveness and efficiency. This plan positions us to be more efficient and focused to deliver differentiated value and services to our clients and customers. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We recognized a charge in Selling, general and administrative expenses of $252 million, pre-tax ($193 million, after-tax). This charge included $232 million of accrued expenses primarily for severance costs related to headcount reductions, as well as, $20 million of one-time expenses related to abandonment of leased assets and impairment of property and equipment. We expect substantially all of the accrued liability to be paid by the end of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes a roll forward of the accrued liability recorded in Accrued expenses and other liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.789%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fourth quarter 2023 charge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;232&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023 payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;202&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringCharges contextRef="c-185" decimals="-6" id="f-1946" unitRef="usd">252000000</us-gaap:RestructuringCharges>
    <ci:RestructuringChargesNetOfTaxExpense contextRef="c-185" decimals="-6" id="f-1947" unitRef="usd">193000000</ci:RestructuringChargesNetOfTaxExpense>
    <us-gaap:SeveranceCosts1 contextRef="c-185" decimals="-6" id="f-1948" unitRef="usd">232000000</us-gaap:SeveranceCosts1>
    <us-gaap:BusinessExitCosts1 contextRef="c-185" decimals="-6" id="f-1949" unitRef="usd">20000000</us-gaap:BusinessExitCosts1>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="c-1" id="f-1950">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes a roll forward of the accrued liability recorded in Accrued expenses and other liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.789%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fourth quarter 2023 charge&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;232&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023 payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;202&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve contextRef="c-13" decimals="-6" id="f-1951" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:SeveranceCosts1 contextRef="c-185" decimals="-6" id="f-1952" unitRef="usd">232000000</us-gaap:SeveranceCosts1>
    <us-gaap:PaymentsForRestructuring contextRef="c-185" decimals="-6" id="f-1953" unitRef="usd">30000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve contextRef="c-12" decimals="-6" id="f-1954" unitRef="usd">202000000</us-gaap:RestructuringReserve>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="c-1" id="f-1955">&lt;div style="margin-bottom:10pt"&gt;&lt;span id="i99ce20099cc349af960781819814ec06_8144"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Note 18 &#x2013; Pension&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;A.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline"&gt;About Our Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company sponsors U.S. and non-U.S. defined benefit pension plans; future benefit accruals for the domestic plans are frozen.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; The Company measures the assets and liabilities of its domestic pension plans as of December 31. Benefit obligations are measured at the present value of estimated future payments based on actuarial assumptions. The Company uses the corridor method to account for changes in the benefit obligation when actual results differ from those assumed, or when assumptions change. These changes are called net unrecognized actuarial gains (losses). Under the corridor method, net unrecognized actuarial gains (losses) are initially recorded in Accumulated other comprehensive loss. When the unrecognized gain (loss) exceeds 10% of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;benefit obligation, that excess is amortized to expense over the expected remaining lives of plan participants. The net plan expense is reported in Interest expense and other in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For balance sheet purposes, we measure plan assets at fair value. When the actual return differs from the expected return, those differences are reflected in the net unrealized actuarial gain (loss) discussed above. However, to measure pension benefit costs, we use a market-related asset valuation that differs from the actual fair value for domestic pension plan assets invested in non-fixed income investments. The market-related value recognizes the difference between actual and expected long-term returns in the portfolio over five years, a method that reduces the short-term impact of market fluctuations on pension costs. The market-related asset value was approximately $4.0 billion, compared with a fair value of approximately $4.1 billion at December&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;B.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline"&gt;Funded Status and Amounts Included in Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes the projected benefit obligations and assets related to our U.S. and non-U.S. pension plans:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Change in benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefit obligation, January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,948&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;204&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Actuarial losses (gains), net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;93&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,094)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefits paid from plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(294)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(296)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefit obligation, December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,934&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Change in plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,186&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;246&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(366)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(294)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(296)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,138&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Funded status&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;204&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts presented in Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;204&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; 2023 losses reflect a decrease in the discount rate while 2022 gains reflect an increase in the discount rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:4.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We fund our qualified pension plans at least at the minimum amount required by the Employee Retirement Income Security Act of 1974 and the Pension Protection Act of 2006. The Company made immaterial contributions to the qualified pension plans in 2023. For 2024, contributions to the qualified pension plans are expected to be immaterial. Future years' contributions will ultimately be based on a wide range of factors including but not limited to asset returns, discount rates and funding targets. Non-qualified pension plans are generally funded on a pay-as-you-go basis as there are no plan assets for these plans.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Benefit payments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; The following benefit payments are expected to be paid in:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:88.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.040%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;319&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;316&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;317&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;314&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;311&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2029 - 2033&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,484&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amounts reflected in the pension assets/(liabilities) shown above that have not yet been reported in Net income and, therefore, have been included in Accumulated other comprehensive loss consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrecognized net (losses)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrecognized prior service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Postretirement benefits liability adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;C.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline"&gt;Cost of Our Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Net pension cost was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;204&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected long-term return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(272)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(269)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization of:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prior actuarial losses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;52&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlement loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net (benefit) cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;53&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;D.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline"&gt;Assumptions Used for Pension&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.883%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5.10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.43%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5.43%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.82%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expected long-term return on plan assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.75%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortality table for pension obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;White Collar mortality table with MP 2021 projection scale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;White Collar mortality table with MP 2021 projection scale&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company develops discount rates by applying actual annualized yields for high-quality bonds by duration to the expected pension plan liability cash flows. The bond yields represent a diverse mix of actively traded high quality fixed income securities that have an above average return at each duration as management believes this approach is representative of the yield achieved through plan asset investment strategy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The expected long-term return on plan assets was developed considering historical long-term actual returns, expected long-term market conditions, plan asset mix and management's plan asset investment strategy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;E.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline"&gt;Pension Plan Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2023, pension assets included $4.0 billion invested in the separate accounts of Connecticut General Life Insurance Company, a subsidiary of the Company, and an additional $0.1 billion invested in funds of unaffiliated investment managers.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair values of pension assets by category are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal government and agency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,780&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset-backed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;121&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fund investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;278&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,191&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International, including funds and pooled separate accounts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;419&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Real estate funds, including pooled separate accounts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;270&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial mortgage loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;46&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Guaranteed deposit account contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;48&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents and other current assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;131&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total pension assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,138&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; A pooled separate account has several participating benefit plans and each owns a share of the total pool of investments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's current target investment allocation percentages are 90% fixed income and 10% in other investments, including private equity (securities partnerships), public equity securities, and real estate, and are developed by management as guidelines, although the fair values of each asset category are expected to vary as a result of changes in market conditions. The Company will evaluate further allocation changes to equity securities, other investments and fixed income securities as funding levels change.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;See Note 13 for further details regarding how fair value is determined, including the level within the fair value hierarchy and the procedures we use to validate fair value measurements. The Company classifies substantially all debt securities in Level 2 for pension plan assets. These assets are valued using recent trades of similar securities or are fund investments priced using their daily net asset value that is the exit price. All domestic equity securities and international equity funds within pension assets are classified as Level 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Securities partnerships, real estate and hedge funds are valued using net asset value as a practical expedient and are excluded from the fair value hierarchy. See Note 13 for additional disclosures related to these assets invested in the separate accounts of the Company's subsidiary. Certain securities as described in Note 13, as well as commercial mortgage loans and guaranteed deposit account contracts, are classified in Level 3 because unobservable inputs used in their valuation are significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;F.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:9.4pt;text-decoration:underline"&gt;401(k) Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company sponsors a 401(k) plan. All employees are immediately eligible for the plan at hire and the Company matches a portion of employees' contributions to the plan. Participants in the plan may invest in various funds that invest in the Company's common stock, several diversified stock funds, a bond fund or stable value funds. The Company common stock fund under the plan constitutes an "employee stock ownership plan" as defined in the Internal Revenue Code. Dividends from the Company common stock fund are reinvested in a participant's stock fund account unless the participant elects to receive the dividends in cash.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company may elect to increase its matching contributions if the Company's annual performance meets certain targets. The Company's annual expense for the plan was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;296&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:PensionAndOtherPostretirementPlansPensionsPolicy contextRef="c-1" id="f-1956">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; The Company measures the assets and liabilities of its domestic pension plans as of December 31. Benefit obligations are measured at the present value of estimated future payments based on actuarial assumptions. The Company uses the corridor method to account for changes in the benefit obligation when actual results differ from those assumed, or when assumptions change. These changes are called net unrecognized actuarial gains (losses). Under the corridor method, net unrecognized actuarial gains (losses) are initially recorded in Accumulated other comprehensive loss. When the unrecognized gain (loss) exceeds 10% of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;benefit obligation, that excess is amortized to expense over the expected remaining lives of plan participants. The net plan expense is reported in Interest expense and other in the Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;For balance sheet purposes, we measure plan assets at fair value. When the actual return differs from the expected return, those differences are reflected in the net unrealized actuarial gain (loss) discussed above. However, to measure pension benefit costs, we use a market-related asset valuation that differs from the actual fair value for domestic pension plan assets invested in non-fixed income investments. The market-related value recognizes the difference between actual and expected long-term returns in the portfolio over five years, a method that reduces the short-term impact of market fluctuations on pension costs.&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company develops discount rates by applying actual annualized yields for high-quality bonds by duration to the expected pension plan liability cash flows. The bond yields represent a diverse mix of actively traded high quality fixed income securities that have an above average return at each duration as management believes this approach is representative of the yield achieved through plan asset investment strategy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The expected long-term return on plan assets was developed considering historical long-term actual returns, expected long-term market conditions, plan asset mix and management's plan asset investment strategy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;See Note 13 for further details regarding how fair value is determined, including the level within the fair value hierarchy and the procedures we use to validate fair value measurements. The Company classifies substantially all debt securities in Level 2 for pension plan assets. These assets are valued using recent trades of similar securities or are fund investments priced using their daily net asset value that is the exit price. All domestic equity securities and international equity funds within pension assets are classified as Level 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Securities partnerships, real estate and hedge funds are valued using net asset value as a practical expedient and are excluded from the fair value hierarchy. See Note 13 for additional disclosures related to these assets invested in the separate accounts of the Company's subsidiary. Certain securities as described in Note 13, as well as commercial mortgage loans and guaranteed deposit account contracts, are classified in Level 3 because unobservable inputs used in their valuation are significant.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementPlansPensionsPolicy>
    <ci:DefinedBenefitPlanMarketRelatedValueOfPensionPlanAssets contextRef="c-487" decimals="-8" id="f-1957" unitRef="usd">4000000000</ci:DefinedBenefitPlanMarketRelatedValueOfPensionPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-487" decimals="-8" id="f-1958" unitRef="usd">4100000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:ScheduleOfNetFundedStatusTableTextBlock contextRef="c-1" id="f-1959">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes the projected benefit obligations and assets related to our U.S. and non-U.S. pension plans:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Change in benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefit obligation, January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,948&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;204&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Actuarial losses (gains), net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;93&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,094)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefits paid from plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(294)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(296)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefit obligation, December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,934&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Change in plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,186&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;246&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(366)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(294)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(296)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,138&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Funded status&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;204&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts presented in Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;204&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; 2023 losses reflect a decrease in the discount rate while 2022 gains reflect an increase in the discount rate.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetFundedStatusTableTextBlock>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-486" decimals="-6" id="f-1960" unitRef="usd">3948000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-594" decimals="-6" id="f-1961" unitRef="usd">5223000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-595" decimals="-6" id="f-1962" unitRef="usd">1000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-596" decimals="-6" id="f-1963" unitRef="usd">2000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-595" decimals="-6" id="f-1964" unitRef="usd">204000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-596" decimals="-6" id="f-1965" unitRef="usd">140000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss contextRef="c-595" decimals="-6" id="f-1966" unitRef="usd">-93000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss contextRef="c-596" decimals="-6" id="f-1967" unitRef="usd">1094000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <ci:DefinedBenefitPlanBenefitsPaidFromPlanAssets contextRef="c-595" decimals="-6" id="f-1968" unitRef="usd">294000000</ci:DefinedBenefitPlanBenefitsPaidFromPlanAssets>
    <ci:DefinedBenefitPlanBenefitsPaidFromPlanAssets contextRef="c-596" decimals="-6" id="f-1969" unitRef="usd">296000000</ci:DefinedBenefitPlanBenefitsPaidFromPlanAssets>
    <ci:DefinedBenefitPlanBenefitsPaidOther contextRef="c-595" decimals="-6" id="f-1970" unitRef="usd">18000000</ci:DefinedBenefitPlanBenefitsPaidOther>
    <ci:DefinedBenefitPlanBenefitsPaidOther contextRef="c-596" decimals="-6" id="f-1971" unitRef="usd">27000000</ci:DefinedBenefitPlanBenefitsPaidOther>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-487" decimals="-6" id="f-1972" unitRef="usd">3934000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-486" decimals="-6" id="f-1973" unitRef="usd">3948000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-486" decimals="-6" id="f-1974" unitRef="usd">4186000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-594" decimals="-6" id="f-1975" unitRef="usd">4846000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets contextRef="c-595" decimals="-6" id="f-1976" unitRef="usd">246000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets contextRef="c-596" decimals="-6" id="f-1977" unitRef="usd">-366000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid contextRef="c-595" decimals="-6" id="f-1978" unitRef="usd">294000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid contextRef="c-596" decimals="-6" id="f-1979" unitRef="usd">296000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer contextRef="c-595" decimals="-6" id="f-1980" unitRef="usd">0</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer contextRef="c-596" decimals="-6" id="f-1981" unitRef="usd">2000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-487" decimals="-6" id="f-1982" unitRef="usd">4138000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-486" decimals="-6" id="f-1983" unitRef="usd">4186000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="c-487" decimals="-6" id="f-1984" unitRef="usd">204000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="c-486" decimals="-6" id="f-1985" unitRef="usd">238000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent contextRef="c-487" decimals="-6" id="f-1986" unitRef="usd">204000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent contextRef="c-486" decimals="-6" id="f-1987" unitRef="usd">238000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-597" decimals="INF" id="f-1988" unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock contextRef="c-1" id="f-1989">The following benefit payments are expected to be paid in:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:88.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.040%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;319&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;316&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;317&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;314&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;311&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2029 - 2033&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,484&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths contextRef="c-487" decimals="-6" id="f-1990" unitRef="usd">319000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo contextRef="c-487" decimals="-6" id="f-1991" unitRef="usd">316000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree contextRef="c-487" decimals="-6" id="f-1992" unitRef="usd">317000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour contextRef="c-487" decimals="-6" id="f-1993" unitRef="usd">314000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive contextRef="c-487" decimals="-6" id="f-1994" unitRef="usd">311000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter contextRef="c-487" decimals="-6" id="f-1995" unitRef="usd">1484000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock contextRef="c-1" id="f-1996">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amounts reflected in the pension assets/(liabilities) shown above that have not yet been reported in Net income and, therefore, have been included in Accumulated other comprehensive loss consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrecognized net (losses)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrecognized prior service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Postretirement benefits liability adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax contextRef="c-487" decimals="-6" id="f-1997" unitRef="usd">-1207000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax contextRef="c-486" decimals="-6" id="f-1998" unitRef="usd">-1208000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax contextRef="c-487" decimals="-6" id="f-1999" unitRef="usd">4000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax contextRef="c-486" decimals="-6" id="f-2000" unitRef="usd">5000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax contextRef="c-487" decimals="-6" id="f-2001" unitRef="usd">1211000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax contextRef="c-486" decimals="-6" id="f-2002" unitRef="usd">1213000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock contextRef="c-1" id="f-2003">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Net pension cost was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;204&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected long-term return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(272)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(269)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization of:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prior actuarial losses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;52&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlement loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net (benefit) cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;53&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-595" decimals="-6" id="f-2004" unitRef="usd">1000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-596" decimals="-6" id="f-2005" unitRef="usd">2000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost contextRef="c-598" decimals="-6" id="f-2006" unitRef="usd">2000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-595" decimals="-6" id="f-2007" unitRef="usd">204000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-596" decimals="-6" id="f-2008" unitRef="usd">140000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost contextRef="c-598" decimals="-6" id="f-2009" unitRef="usd">132000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets contextRef="c-595" decimals="-6" id="f-2010" unitRef="usd">204000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets contextRef="c-596" decimals="-6" id="f-2011" unitRef="usd">272000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets contextRef="c-598" decimals="-6" id="f-2012" unitRef="usd">269000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses contextRef="c-595" decimals="-6" id="f-2013" unitRef="usd">-52000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses contextRef="c-596" decimals="-6" id="f-2014" unitRef="usd">-89000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses contextRef="c-598" decimals="-6" id="f-2015" unitRef="usd">-78000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1 contextRef="c-595" decimals="-6" id="f-2016" unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1 contextRef="c-596" decimals="-6" id="f-2017" unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1 contextRef="c-598" decimals="-6" id="f-2018" unitRef="usd">-4000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c-595" decimals="-6" id="f-2019" unitRef="usd">53000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c-596" decimals="-6" id="f-2020" unitRef="usd">-41000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="c-598" decimals="-6" id="f-2021" unitRef="usd">-53000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock contextRef="c-1" id="f-2022">&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.883%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5.10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.43%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5.43%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.82%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expected long-term return on plan assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension benefit cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.75%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortality table for pension obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;White Collar mortality table with MP 2021 projection scale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;White Collar mortality table with MP 2021 projection scale&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="c-487"
      decimals="4"
      id="f-2023"
      unitRef="number">0.0510</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="c-486"
      decimals="4"
      id="f-2024"
      unitRef="number">0.0543</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="c-595"
      decimals="4"
      id="f-2025"
      unitRef="number">0.0543</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="c-596"
      decimals="4"
      id="f-2026"
      unitRef="number">0.0282</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="c-595"
      decimals="4"
      id="f-2027"
      unitRef="number">0.0650</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="c-596"
      decimals="4"
      id="f-2028"
      unitRef="number">0.0675</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <ci:DefinedBenefitPlanFairValueOfPlanAssetsInvestedInSeparateAccountsOfSubsidiaries contextRef="c-487" decimals="-8" id="f-2029" unitRef="usd">4000000000</ci:DefinedBenefitPlanFairValueOfPlanAssetsInvestedInSeparateAccountsOfSubsidiaries>
    <ci:DefinedBenefitPlanFairValueOfPlanAssetsInvestedInFundsOfferedByUnaffiliatedEntity contextRef="c-487" decimals="-8" id="f-2030" unitRef="usd">100000000</ci:DefinedBenefitPlanFairValueOfPlanAssetsInvestedInFundsOfferedByUnaffiliatedEntity>
    <us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock contextRef="c-1" id="f-2031">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair values of pension assets by category are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal government and agency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,780&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset-backed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;121&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fund investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;278&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,191&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International, including funds and pooled separate accounts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Securities partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;419&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Real estate funds, including pooled separate accounts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;270&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial mortgage loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;46&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Guaranteed deposit account contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;48&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents and other current assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;131&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total pension assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,138&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; A pooled separate account has several participating benefit plans and each owns a share of the total pool of investments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-599" decimals="-6" id="f-2032" unitRef="usd">12000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-600" decimals="-6" id="f-2033" unitRef="usd">11000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-601" decimals="-6" id="f-2034" unitRef="usd">2780000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-602" decimals="-6" id="f-2035" unitRef="usd">2349000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-603" decimals="-6" id="f-2036" unitRef="usd">121000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-604" decimals="-6" id="f-2037" unitRef="usd">109000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-605" decimals="-6" id="f-2038" unitRef="usd">278000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-606" decimals="-6" id="f-2039" unitRef="usd">478000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-607" decimals="-6" id="f-2040" unitRef="usd">3191000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-608" decimals="-6" id="f-2041" unitRef="usd">2947000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-609" decimals="-6" id="f-2042" unitRef="usd">27000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-610" decimals="-6" id="f-2043" unitRef="usd">89000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-611" decimals="-6" id="f-2044" unitRef="usd">6000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-612" decimals="-6" id="f-2045" unitRef="usd">35000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-613" decimals="-6" id="f-2046" unitRef="usd">33000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-614" decimals="-6" id="f-2047" unitRef="usd">124000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-615" decimals="-6" id="f-2048" unitRef="usd">419000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-616" decimals="-6" id="f-2049" unitRef="usd">452000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-617" decimals="-6" id="f-2050" unitRef="usd">270000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-618" decimals="-6" id="f-2051" unitRef="usd">315000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-619" decimals="-6" id="f-2052" unitRef="usd">46000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-620" decimals="-6" id="f-2053" unitRef="usd">63000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-621" decimals="-6" id="f-2054" unitRef="usd">48000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-622" decimals="-6" id="f-2055" unitRef="usd">50000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-623" decimals="-6" id="f-2056" unitRef="usd">131000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-624" decimals="-6" id="f-2057" unitRef="usd">235000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-487" decimals="-6" id="f-2058" unitRef="usd">4138000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-486" decimals="-6" id="f-2059" unitRef="usd">4186000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="c-607"
      decimals="INF"
      id="f-2060"
      unitRef="number">0.90</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="c-625"
      decimals="INF"
      id="f-2061"
      unitRef="number">0.10</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedContributionPlanDisclosuresTableTextBlock contextRef="c-1" id="f-2062">The Company's annual expense for the plan was as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;296&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DefinedContributionPlanDisclosuresTableTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-1" decimals="-6" id="f-2063" unitRef="usd">296000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-7" decimals="-6" id="f-2064" unitRef="usd">274000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-8" decimals="-6" id="f-2065" unitRef="usd">268000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-2068">&lt;div style="margin-bottom:10pt"&gt;&lt;span id="ia59fe69ab3a747a18a0ea7f12e4444a7_5726"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Note 19 &#x2013; Employee Incentive Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;A.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline"&gt;About Our Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The People Resources Committee (the "Committee") of the Board of Directors awards stock options, restricted stock grants, restricted stock units, deferred stock and strategic performance shares to certain employees. The Company issues original issue shares for these awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company records compensation expense for stock and option awards over their vesting periods primarily based on the estimated fair value at the grant date. Fair value is determined differently for each type of award as discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Shares of common stock available for award were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common shares available for award&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;14.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;B.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; The Company awards options to purchase The Cigna Group common stock at the market price of the stock on the grant date. Options vest over periods ranging from one year to three years and expire no later than 10 years from grant date. Fair value is estimated using the Black-Scholes option-pricing model by applying the assumptions presented below. That fair value is reduced by options expected to be forfeited during the vesting period. The Company estimates forfeitures at the grant date based on our experience and adjusts the expense to reflect actual forfeitures over the vesting period. The fair value of options, net of forfeitures, is recognized in Selling, general and administrative expenses on a straight-line basis over the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Black-Scholes option-pricing model assumptions and the resulting fair value of options are presented in the following table: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.955%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.883%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.744%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.749%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.58&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;30.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected option life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4.7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average fair value of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;79.66&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The dividend yield reflects expected future dividends. The Company intends to continue to pay dividends for the foreseeable future. The expected volatility reflects the past daily stock price volatility of The Cigna Group stock. The Company does not consider volatility implied in the market prices of traded options to be a good indicator of future volatility because remaining traded options will expire within one year. The risk-free interest rate is derived using the four-year U.S. Treasury bond yield rate as of the award date for the primary annual grant. Expected option life reflects the Company's historical experience.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table shows the status of, and changes in, common stock options:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Options in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding - January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,992&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;186.54&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;915&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;294.37&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;213.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,080)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;174.66&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,617)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,584)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired or canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(131)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;246.95&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(256)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;211.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding - December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,696&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;202.02&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;186.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options exercisable at year-end&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,616&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;179.28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;168.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Compensation expense of $67 million related to unvested stock options at December&#160;31, 2023 will be recognized over the next two years (weighted average period).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The table below summarizes information for stock options exercised:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intrinsic value of options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;126&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash received for options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;187&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax benefit from options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes information for outstanding common stock options:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;br/&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Number (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,696&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,616&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total intrinsic value (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;652&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;555&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;202.02&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;179.28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average remaining contractual life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4.7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;C.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline"&gt;Restricted Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company awards restricted stock (grants and units) to the Company's employees that vest over periods ranging from &lt;span style="-sec-ix-hidden:f-2151"&gt;one&lt;/span&gt; to three years. Recipients of restricted stock awards accumulate dividends during the vesting period, but generally forfeit their awards and accumulated dividends if their employment terminates before the vesting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Fair value of restricted stock awards is equal to the market price of The Cigna Group's common stock on the date of grant. This fair value is reduced by awards that are expected to forfeit. At the grant date, the Company estimates forfeitures based on experience and adjusts the expense to reflect actual forfeitures over the vesting period. This fair value, net of forfeitures, is recognized in Selling, general and administrative expenses over the vesting period on a straight-line basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table shows the status of, and changes in, restricted stock awards:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Awards in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Grants/Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Fair Value at Award Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Grants/Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Fair Value at Award Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Grants/Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Fair Value at Award Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding - January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,535&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;219.25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;186.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;294.60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;229.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;213.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(759)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;214.70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(714)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(866)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;184.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;256.24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(151)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding - December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,404&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;257.38&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;219.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of vested restricted stock at the vesting date was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of vested restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;220&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Approximately 8,900 employees held 1.4 million restricted stock awards at the end of 2023 with $196 million of related compensation expense to be recognized over the next two years (weighted average period).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;D.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline"&gt;Strategic Performance Shares ("SPS")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company awards SPSs to executives and certain other key employees generally with a performance period of three years. Half of these shares are subject to a market condition (total shareholder return relative to industry peer companies) and half are subject to a performance condition (cumulative adjusted net income). These targets are set by the Committee at the beginning of the performance period. Holders of these awards receive shares of The Cigna Group common stock at the end of the performance period ranging anywhere from 0 to 200% of the original awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Compensation expense for SPSs is recorded over the performance period. Fair value is determined at the grant date for "market condition" SPSs using a Monte Carlo simulation model and not subsequently adjusted regardless of the final outcome. Expense is initially accrued for "performance condition" SPSs based on the most likely outcome, but evaluated for adjustment each period for updates in the expected outcome. Expense is adjusted to the actual outcome (number of shares awarded times the share price at the grant date) at the end of the performance period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table shows the status of, and changes in, SPSs:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Awards in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Fair Value at Award Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Fair Value at Award Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Fair Value at Award Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding - January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;780&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;212.68&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;190.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;219&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;293.85&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;230.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;213.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;191.78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;183.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;196.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;237.50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;207.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding - December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;686&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;243.90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;212.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The weighted average fair value per share of SPSs for expense purposes, including the Monte Carlo factor, at the award date for the years ended December&#160;31, 2023, 2022 and 2021 was $329.11, $258.37 and $239.57, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of vested SPSs at the vesting date was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.212%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Shares in thousands; $ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares of The Cigna Group common stock distributed upon SPS vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;257&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;76&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Approximately 600 employees held 686,000 SPSs at the end of 2023 and $61&#160;million of related compensation expense is expected to be recognized over the next two years. The amount of expense for "performance condition" SPSs will vary based on actual performance in 2024 and 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;E.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline"&gt;Compensation Cost and Tax Effects of Share-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company records tax benefits in Shareholders' net income during the vesting period based on the amount of expense being recognized. The difference between tax benefits based on the expense and the actual tax benefit realized are also recorded in income tax expense when stock options are exercised, or when restricted stock and SPSs vest.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total compensation cost for shared-based awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;286&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax benefits recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;92&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-2069">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company records compensation expense for stock and option awards over their vesting periods primarily based on the estimated fair value at the grant date. Fair value is determined differently for each type of award as discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; The Company awards options to purchase The Cigna Group common stock at the market price of the stock on the grant date. Options vest over periods ranging from one year to three years and expire no later than 10 years from grant date. Fair value is estimated using the Black-Scholes option-pricing model by applying the assumptions presented below. That fair value is reduced by options expected to be forfeited during the vesting period. The Company estimates forfeitures at the grant date based on our experience and adjusts the expense to reflect actual forfeitures over the vesting period. The fair value of options, net of forfeitures, is recognized in Selling, general and administrative expenses on a straight-line basis over the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Fair value of restricted stock awards is equal to the market price of The Cigna Group's common stock on the date of grant. This fair value is reduced by awards that are expected to forfeit. At the grant date, the Company estimates forfeitures based on experience and adjusts the expense to reflect actual forfeitures over the vesting period. This fair value, net of forfeitures, is recognized in Selling, general and administrative expenses over the vesting period on a straight-line basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Compensation expense for SPSs is recorded over the performance period. Fair value is determined at the grant date for "market condition" SPSs using a Monte Carlo simulation model and not subsequently adjusted regardless of the final outcome. Expense is initially accrued for "performance condition" SPSs based on the most likely outcome, but evaluated for adjustment each period for updates in the expected outcome. Expense is adjusted to the actual outcome (number of shares awarded times the share price at the grant date) at the end of the performance period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="c-1" id="f-2070">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Shares of common stock available for award were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common shares available for award&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;14.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-12"
      decimals="-5"
      id="f-2071"
      unitRef="shares">14400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-13"
      decimals="-5"
      id="f-2072"
      unitRef="shares">16600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-47"
      decimals="-5"
      id="f-2073"
      unitRef="shares">19100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-628" id="f-2074">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-629" id="f-2075">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-629" id="f-2076">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-2077">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Black-Scholes option-pricing model assumptions and the resulting fair value of options are presented in the following table: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.955%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.883%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.744%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.749%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.58&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;30.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected option life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4.7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average fair value of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;79.66&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-630"
      decimals="4"
      id="f-2078"
      unitRef="number">0.0158</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-631"
      decimals="4"
      id="f-2079"
      unitRef="number">0.0198</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-632"
      decimals="4"
      id="f-2080"
      unitRef="number">0.0185</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-630"
      decimals="3"
      id="f-2081"
      unitRef="number">0.300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-631"
      decimals="3"
      id="f-2082"
      unitRef="number">0.300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-632"
      decimals="3"
      id="f-2083"
      unitRef="number">0.300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-630"
      decimals="3"
      id="f-2084"
      unitRef="number">0.036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-631"
      decimals="3"
      id="f-2085"
      unitRef="number">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-632"
      decimals="3"
      id="f-2086"
      unitRef="number">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-630" id="f-2087">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-631" id="f-2088">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-632" id="f-2089">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-630"
      decimals="2"
      id="f-2090"
      unitRef="usdPerShare">79.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-631"
      decimals="2"
      id="f-2091"
      unitRef="usdPerShare">50.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-632"
      decimals="2"
      id="f-2092"
      unitRef="usdPerShare">44.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <ci:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionReferenceTermOfTradedOptions contextRef="c-630" id="f-2093">P1Y</ci:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionReferenceTermOfTradedOptions>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="c-1" id="f-2094">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table shows the status of, and changes in, common stock options:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Options in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding - January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,992&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;186.54&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;915&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;294.37&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;213.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,080)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;174.66&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,617)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,584)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired or canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(131)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;246.95&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(256)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;211.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding - December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,696&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;202.02&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;186.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options exercisable at year-end&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,616&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;179.28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;168.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-633"
      decimals="-3"
      id="f-2095"
      unitRef="shares">6992000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-633"
      decimals="2"
      id="f-2096"
      unitRef="usdPerShare">186.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-634"
      decimals="-3"
      id="f-2097"
      unitRef="shares">8490000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-634"
      decimals="2"
      id="f-2098"
      unitRef="usdPerShare">169.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-635"
      decimals="-3"
      id="f-2099"
      unitRef="shares">9742000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-635"
      decimals="2"
      id="f-2100"
      unitRef="usdPerShare">152.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-630"
      decimals="-3"
      id="f-2101"
      unitRef="shares">915000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-630"
      decimals="2"
      id="f-2102"
      unitRef="usdPerShare">294.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-631"
      decimals="-3"
      id="f-2103"
      unitRef="shares">1375000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-631"
      decimals="2"
      id="f-2104"
      unitRef="usdPerShare">226.95</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-632"
      decimals="-3"
      id="f-2105"
      unitRef="shares">1524000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-632"
      decimals="2"
      id="f-2106"
      unitRef="usdPerShare">213.81</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-630"
      decimals="-3"
      id="f-2107"
      unitRef="shares">1080000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-630"
      decimals="2"
      id="f-2108"
      unitRef="usdPerShare">174.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-631"
      decimals="-3"
      id="f-2109"
      unitRef="shares">2617000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-631"
      decimals="2"
      id="f-2110"
      unitRef="usdPerShare">149.97</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-632"
      decimals="-3"
      id="f-2111"
      unitRef="shares">2584000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-632"
      decimals="2"
      id="f-2112"
      unitRef="usdPerShare">129.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c-630"
      decimals="-3"
      id="f-2113"
      unitRef="shares">131000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-630"
      decimals="2"
      id="f-2114"
      unitRef="usdPerShare">246.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c-631"
      decimals="-3"
      id="f-2115"
      unitRef="shares">256000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-631"
      decimals="2"
      id="f-2116"
      unitRef="usdPerShare">211.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c-632"
      decimals="-3"
      id="f-2117"
      unitRef="shares">192000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-632"
      decimals="2"
      id="f-2118"
      unitRef="usdPerShare">199.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-636"
      decimals="-3"
      id="f-2119"
      unitRef="shares">6696000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-636"
      decimals="2"
      id="f-2120"
      unitRef="usdPerShare">202.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-633"
      decimals="-3"
      id="f-2121"
      unitRef="shares">6992000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-633"
      decimals="2"
      id="f-2122"
      unitRef="usdPerShare">186.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-634"
      decimals="-3"
      id="f-2123"
      unitRef="shares">8490000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-634"
      decimals="2"
      id="f-2124"
      unitRef="usdPerShare">169.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-636"
      decimals="-3"
      id="f-2125"
      unitRef="shares">4616000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-636"
      decimals="2"
      id="f-2126"
      unitRef="usdPerShare">179.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-633"
      decimals="-3"
      id="f-2127"
      unitRef="shares">4410000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-633"
      decimals="2"
      id="f-2128"
      unitRef="usdPerShare">168.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-634"
      decimals="-3"
      id="f-2129"
      unitRef="shares">5612000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-634"
      decimals="2"
      id="f-2130"
      unitRef="usdPerShare">152.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-636" decimals="-6" id="f-2131" unitRef="usd">67000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-630" id="f-2132">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-2133">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The table below summarizes information for stock options exercised:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intrinsic value of options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;126&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash received for options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;187&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax benefit from options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes information for outstanding common stock options:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;br/&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Number (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,696&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,616&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total intrinsic value (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;652&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;555&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;202.02&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;179.28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average remaining contractual life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4.7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-630" decimals="-6" id="f-2134" unitRef="usd">126000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-631" decimals="-6" id="f-2135" unitRef="usd">313000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-632" decimals="-6" id="f-2136" unitRef="usd">268000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-630" decimals="-6" id="f-2137" unitRef="usd">187000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-631" decimals="-6" id="f-2138" unitRef="usd">389000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-632" decimals="-6" id="f-2139" unitRef="usd">326000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="c-630" decimals="-6" id="f-2140" unitRef="usd">17000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="c-631" decimals="-6" id="f-2141" unitRef="usd">47000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="c-632" decimals="-6" id="f-2142" unitRef="usd">50000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-636"
      decimals="-3"
      id="f-2143"
      unitRef="shares">6696000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-636"
      decimals="-3"
      id="f-2144"
      unitRef="shares">4616000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-636" decimals="-6" id="f-2145" unitRef="usd">652000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-636" decimals="-6" id="f-2146" unitRef="usd">555000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-636"
      decimals="2"
      id="f-2147"
      unitRef="usdPerShare">202.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-636"
      decimals="2"
      id="f-2148"
      unitRef="usdPerShare">179.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-630" id="f-2149">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-630" id="f-2150">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-638" id="f-2152">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="c-1" id="f-2153">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table shows the status of, and changes in, restricted stock awards:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Awards in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Grants/Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Fair Value at Award Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Grants/Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Fair Value at Award Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Grants/Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Fair Value at Award Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding - January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,535&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;219.25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;186.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;294.60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;229.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;213.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(759)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;214.70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(714)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(866)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;184.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;256.24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(151)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding - December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,404&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;257.38&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;219.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of vested restricted stock at the vesting date was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.494%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of vested restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;220&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-639"
      decimals="-3"
      id="f-2154"
      unitRef="shares">1535000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-639"
      decimals="2"
      id="f-2155"
      unitRef="usdPerShare">219.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-640"
      decimals="-3"
      id="f-2156"
      unitRef="shares">1524000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-640"
      decimals="2"
      id="f-2157"
      unitRef="usdPerShare">202.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-641"
      decimals="-3"
      id="f-2158"
      unitRef="shares">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-641"
      decimals="2"
      id="f-2159"
      unitRef="usdPerShare">186.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-642"
      decimals="-3"
      id="f-2160"
      unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-642"
      decimals="2"
      id="f-2161"
      unitRef="usdPerShare">294.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-643"
      decimals="-3"
      id="f-2162"
      unitRef="shares">876000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-643"
      decimals="2"
      id="f-2163"
      unitRef="usdPerShare">229.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-644"
      decimals="-3"
      id="f-2164"
      unitRef="shares">899000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-644"
      decimals="2"
      id="f-2165"
      unitRef="usdPerShare">213.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-642"
      decimals="-3"
      id="f-2166"
      unitRef="shares">759000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-642"
      decimals="2"
      id="f-2167"
      unitRef="usdPerShare">214.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-643"
      decimals="-3"
      id="f-2168"
      unitRef="shares">714000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-643"
      decimals="2"
      id="f-2169"
      unitRef="usdPerShare">197.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-644"
      decimals="-3"
      id="f-2170"
      unitRef="shares">866000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-644"
      decimals="2"
      id="f-2171"
      unitRef="usdPerShare">184.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-642"
      decimals="-3"
      id="f-2172"
      unitRef="shares">72000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-642"
      decimals="2"
      id="f-2173"
      unitRef="usdPerShare">256.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-643"
      decimals="-3"
      id="f-2174"
      unitRef="shares">151000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-643"
      decimals="2"
      id="f-2175"
      unitRef="usdPerShare">215.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-644"
      decimals="-3"
      id="f-2176"
      unitRef="shares">109000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-644"
      decimals="2"
      id="f-2177"
      unitRef="usdPerShare">197.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-645"
      decimals="-3"
      id="f-2178"
      unitRef="shares">1404000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-645"
      decimals="2"
      id="f-2179"
      unitRef="usdPerShare">257.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-639"
      decimals="-3"
      id="f-2180"
      unitRef="shares">1535000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-639"
      decimals="2"
      id="f-2181"
      unitRef="usdPerShare">219.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-640"
      decimals="-3"
      id="f-2182"
      unitRef="shares">1524000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-640"
      decimals="2"
      id="f-2183"
      unitRef="usdPerShare">202.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-642" decimals="-6" id="f-2184" unitRef="usd">220000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-643" decimals="-6" id="f-2185" unitRef="usd">167000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-644" decimals="-6" id="f-2186" unitRef="usd">183000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <ci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfEmployeesHolding
      contextRef="c-645"
      decimals="-2"
      id="f-2187"
      unitRef="employee">8900</ci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfEmployeesHolding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-645"
      decimals="-5"
      id="f-2188"
      unitRef="shares">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-645" decimals="-6" id="f-2189" unitRef="usd">196000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-642" id="f-2190">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <ci:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod contextRef="c-646" id="f-2191">P3Y</ci:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod>
    <ci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfOriginalGrantAwardedAtEndOfPerformancePeriod
      contextRef="c-647"
      decimals="INF"
      id="f-2192"
      unitRef="number">0</ci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfOriginalGrantAwardedAtEndOfPerformancePeriod>
    <ci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfOriginalGrantAwardedAtEndOfPerformancePeriod
      contextRef="c-648"
      decimals="INF"
      id="f-2193"
      unitRef="number">2</ci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfOriginalGrantAwardedAtEndOfPerformancePeriod>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock contextRef="c-1" id="f-2194">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table shows the status of, and changes in, SPSs:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Awards in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Fair Value at Award Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Fair Value at Award Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Fair Value at Award Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding - January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;780&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;212.68&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;190.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;219&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;293.85&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;230.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;213.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;191.78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;183.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;196.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;237.50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;207.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding - December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;686&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;243.90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;212.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of vested SPSs at the vesting date was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.212%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Shares in thousands; $ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares of The Cigna Group common stock distributed upon SPS vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;257&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;76&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-649"
      decimals="-3"
      id="f-2195"
      unitRef="shares">780000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-649"
      decimals="2"
      id="f-2196"
      unitRef="usdPerShare">212.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-650"
      decimals="-3"
      id="f-2197"
      unitRef="shares">860000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-650"
      decimals="2"
      id="f-2198"
      unitRef="usdPerShare">197.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-651"
      decimals="-3"
      id="f-2199"
      unitRef="shares">808000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-651"
      decimals="2"
      id="f-2200"
      unitRef="usdPerShare">190.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-646"
      decimals="-3"
      id="f-2201"
      unitRef="shares">219000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-646"
      decimals="2"
      id="f-2202"
      unitRef="usdPerShare">293.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-652"
      decimals="-3"
      id="f-2203"
      unitRef="shares">294000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-652"
      decimals="2"
      id="f-2204"
      unitRef="usdPerShare">230.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-653"
      decimals="-3"
      id="f-2205"
      unitRef="shares">331000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-653"
      decimals="2"
      id="f-2206"
      unitRef="usdPerShare">213.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-646"
      decimals="-3"
      id="f-2207"
      unitRef="shares">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-646"
      decimals="2"
      id="f-2208"
      unitRef="usdPerShare">191.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-652"
      decimals="-3"
      id="f-2209"
      unitRef="shares">261000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-652"
      decimals="2"
      id="f-2210"
      unitRef="usdPerShare">183.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-653"
      decimals="-3"
      id="f-2211"
      unitRef="shares">206000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-653"
      decimals="2"
      id="f-2212"
      unitRef="usdPerShare">196.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-646"
      decimals="-3"
      id="f-2213"
      unitRef="shares">63000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-646"
      decimals="2"
      id="f-2214"
      unitRef="usdPerShare">237.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-652"
      decimals="-3"
      id="f-2215"
      unitRef="shares">113000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-652"
      decimals="2"
      id="f-2216"
      unitRef="usdPerShare">207.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-653"
      decimals="-3"
      id="f-2217"
      unitRef="shares">73000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-653"
      decimals="2"
      id="f-2218"
      unitRef="usdPerShare">197.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-654"
      decimals="-3"
      id="f-2219"
      unitRef="shares">686000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-654"
      decimals="2"
      id="f-2220"
      unitRef="usdPerShare">243.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-649"
      decimals="-3"
      id="f-2221"
      unitRef="shares">780000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-649"
      decimals="2"
      id="f-2222"
      unitRef="usdPerShare">212.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-650"
      decimals="-3"
      id="f-2223"
      unitRef="shares">860000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-650"
      decimals="2"
      id="f-2224"
      unitRef="usdPerShare">197.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <ci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateFairValueIncludingMonteCarloFactor
      contextRef="c-646"
      decimals="2"
      id="f-2225"
      unitRef="usdPerShare">329.11</ci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateFairValueIncludingMonteCarloFactor>
    <ci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateFairValueIncludingMonteCarloFactor
      contextRef="c-652"
      decimals="2"
      id="f-2226"
      unitRef="usdPerShare">258.37</ci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateFairValueIncludingMonteCarloFactor>
    <ci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateFairValueIncludingMonteCarloFactor
      contextRef="c-653"
      decimals="2"
      id="f-2227"
      unitRef="usdPerShare">239.57</ci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateFairValueIncludingMonteCarloFactor>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-646"
      decimals="-3"
      id="f-2228"
      unitRef="shares">257000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-646" decimals="-6" id="f-2229" unitRef="usd">76000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-652"
      decimals="-3"
      id="f-2230"
      unitRef="shares">137000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-652" decimals="-6" id="f-2231" unitRef="usd">31000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-653"
      decimals="-3"
      id="f-2232"
      unitRef="shares">243000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-653" decimals="-6" id="f-2233" unitRef="usd">51000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <ci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfEmployeesHolding
      contextRef="c-654"
      decimals="-2"
      id="f-2234"
      unitRef="employee">600</ci:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfEmployeesHolding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-654"
      decimals="-3"
      id="f-2235"
      unitRef="shares">686000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-654" decimals="-6" id="f-2236" unitRef="usd">61000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-646" id="f-2237">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-2238">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline"&gt;Compensation Cost and Tax Effects of Share-based Compensation&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company records tax benefits in Shareholders' net income during the vesting period based on the amount of expense being recognized. The difference between tax benefits based on the expense and the actual tax benefit realized are also recorded in income tax expense when stock options are exercised, or when restricted stock and SPSs vest.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total compensation cost for shared-based awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;286&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax benefits recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;92&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-6" id="f-2239" unitRef="usd">286000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-7" decimals="-6" id="f-2240" unitRef="usd">264000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-8" decimals="-6" id="f-2241" unitRef="usd">268000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-1" decimals="-6" id="f-2242" unitRef="usd">92000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-7" decimals="-6" id="f-2243" unitRef="usd">80000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-8" decimals="-6" id="f-2244" unitRef="usd">73000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <ci:GoodwillOtherIntangiblesAndPropertyAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-2245">&lt;div style="margin-bottom:10pt"&gt;&lt;span id="id61656c4028645fb94828ae2f199db59_5551"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Note 20 &#x2013; Goodwill, Other Intangibles and Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;A.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Goodwill represents the excess of the cost of businesses acquired over the fair value of their net assets. The resulting goodwill is assigned to those reporting units expected to realize cash flows from the acquisition, based on those reporting units' relative fair values. The Company's reporting units are aligned with its operating segments as described in Note 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company conducts its annual quantitative evaluation for goodwill impairment during the third quarter at the reporting unit level and writes it down through Shareholders' net income if impaired. On a quarterly basis, the Company performs a qualitative impairment assessment to determine if events or changes in circumstances indicate that it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value. Fair value of a reporting unit is generally estimated based on discounted cash flow analysis and market approach models using assumptions that the Company believes a hypothetical market participant would use to determine a current transaction price. Following a change in reporting units or held for sale determination, goodwill is allocated using relative fair value. The significant assumptions and estimates used in determining fair value primarily include the discount rate and future cash flows. A discount rate is selected to correspond with each reporting unit's weighted average cost of capital, consistent with &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;that used for investment decisions considering the specific and detailed operating plans and strategies within each reporting unit. Projections of future cash flows differ by reporting unit and are consistent with our ongoing strategic projections. Future cash flows for Evernorth Health Services are primarily driven by the forecasted gross margins of the business, as well as operating expenses and long-term growth rates. Future cash flows for our other reporting units are primarily driven by forecasted revenues, benefit expenses, operating expenses and long-term growth rates.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Goodwill activity.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Goodwill activity was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.875%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Evernorth Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cigna Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2022 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill disposed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impact of foreign currency translation and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill transferred to assets of businesses held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,553)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,553)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impact of foreign currency translation and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill at December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35,130&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,129&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;44,259&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; Includes $234 million classified as assets of businesses held for sale, all reported within Other Operations.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;B.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline"&gt;Other Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; The Company's Other intangible assets primarily include purchased customer and producer relationships, trademarks and provider networks. The fair value of purchased customer relationships and the amortization method were determined as of the dates of purchase using an income approach that relies on projected future net cash flows including key assumptions for customer attrition and discount rates. The Company's definite-lived intangible assets are amortized on an accelerated or straight-line basis, reflecting their pattern of economic benefits, over periods from &lt;span style="-sec-ix-hidden:f-2278"&gt;three&lt;/span&gt; to 30 years. Management revises amortization periods if it believes there has been a change in the length of time that an intangible asset will continue to have value. Costs incurred to renew or extend the terms of these intangible assets are generally expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's amortized intangible assets are tested for impairment whenever events or changes in circumstances indicate that the &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;carrying amount may not be recoverable.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; If the total of the expected future undiscounted cash flows generated by the underlying asset group is less than the carrying amount of the asset group, the Company recognizes an impairment charge equal to the difference between the carrying value of the asset group and its estimated fair value. The Company's indefinite-lived intangible assets are reviewed for impairment at least annually by comparing their fair value with their carrying value. If the carrying value exceeds fair value, that excess is recognized as an impairment loss.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Components of other assets, including other intangibles.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Other intangible assets were comprised of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29,978&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,645&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;22,333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trade Name - Express Scripts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;317&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;110&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;207&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;38,695&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,755&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;30,940&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Value of business acquired ("VOBA" reported in Other assets)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;211&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;142&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;69&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;38,906&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,897&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;31,009&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trade Name - Express Scripts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Value of business acquired (reported in Other assets)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; Includes $69&#160;million of VOBA and $77&#160;million of Other intangible assets classified as assets of businesses held for sale.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has indefinite-lived intangible assets totaling $8.5 billion at December&#160;31, 2023 and December&#160;31, 2022, largely consisting of the Express Scripts trade name.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;C.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Property and equipment is carried at cost less accumulated depreciation. Cost includes interest, real estate taxes and other costs incurred during construction when applicable. Internal-use software that is acquired, developed or modified solely to meet the Company's internal needs, with no plan to market externally, is also included in this category. Costs directly related to acquiring, developing or modifying internal-use software are capitalized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company calculates depreciation and amortization principally using the straight-line method generally based on the estimated useful life of each asset as follows: buildings and improvements, 10 to 40 years; purchased and internally developed software, &lt;span style="-sec-ix-hidden:f-2323"&gt;three&lt;/span&gt; to five years; and furniture and equipment (including computer equipment), &lt;span style="-sec-ix-hidden:f-2325"&gt;three&lt;/span&gt; to 10 years. Improvements to leased facilities are depreciated over &lt;span style="-sec-ix-hidden:f-2327"&gt;the lesser of the remaining lease term or the estimated life of the improvement&lt;/span&gt;. The Company considers events and circumstances that would indicate the carrying value of property, equipment or capitalized software might not be recoverable. An impairment charge is recorded if the Company determines the carrying value of any of these assets is not recoverable. The Company also reviews and shortens the estimated useful lives of these assets, if necessary.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Components of property and equipment.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Property and equipment was comprised of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Internal-use software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,155&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,161&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,994&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,282&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,405&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;877&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total property and equipment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12,437&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,566&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,871&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Internal-use software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; Includes $176&#160;million of Property and equipment net carrying value classified as assets of businesses held for sale. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Components of depreciation and amortization.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Depreciation and amortization expense was comprised of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Internal-use software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,216&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;260&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Value of business acquired (reported in Other assets)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,552&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,035&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company estimates annual pre-tax amortization for intangible assets, including internal-use software, over the next five calendar years to be as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:88.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.040%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pre-tax Amortization&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,892&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,357&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,803&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,559&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,484&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ci:GoodwillOtherIntangiblesAndPropertyAndEquipmentDisclosureTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="c-1" id="f-2246">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Goodwill represents the excess of the cost of businesses acquired over the fair value of their net assets. The resulting goodwill is assigned to those reporting units expected to realize cash flows from the acquisition, based on those reporting units' relative fair values. The Company's reporting units are aligned with its operating segments as described in Note 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company conducts its annual quantitative evaluation for goodwill impairment during the third quarter at the reporting unit level and writes it down through Shareholders' net income if impaired. On a quarterly basis, the Company performs a qualitative impairment assessment to determine if events or changes in circumstances indicate that it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value. Fair value of a reporting unit is generally estimated based on discounted cash flow analysis and market approach models using assumptions that the Company believes a hypothetical market participant would use to determine a current transaction price. Following a change in reporting units or held for sale determination, goodwill is allocated using relative fair value. The significant assumptions and estimates used in determining fair value primarily include the discount rate and future cash flows. A discount rate is selected to correspond with each reporting unit's weighted average cost of capital, consistent with &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;that used for investment decisions considering the specific and detailed operating plans and strategies within each reporting unit. Projections of future cash flows differ by reporting unit and are consistent with our ongoing strategic projections. Future cash flows for Evernorth Health Services are primarily driven by the forecasted gross margins of the business, as well as operating expenses and long-term growth rates. Future cash flows for our other reporting units are primarily driven by forecasted revenues, benefit expenses, operating expenses and long-term growth rates.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="c-1" id="f-2247">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Goodwill activity.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Goodwill activity was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.875%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Evernorth Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cigna Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2022 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill disposed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impact of foreign currency translation and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill transferred to assets of businesses held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,553)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,553)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impact of foreign currency translation and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill at December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35,130&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,129&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;44,259&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; Includes $234 million classified as assets of businesses held for sale, all reported within Other Operations.&lt;/span&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <ci:GoodwillIncludingDisposalGroups contextRef="c-655" decimals="-6" id="f-2248" unitRef="usd">35128000000</ci:GoodwillIncludingDisposalGroups>
    <ci:GoodwillIncludingDisposalGroups contextRef="c-221" decimals="-6" id="f-2249" unitRef="usd">10683000000</ci:GoodwillIncludingDisposalGroups>
    <ci:GoodwillIncludingDisposalGroups contextRef="c-234" decimals="-6" id="f-2250" unitRef="usd">234000000</ci:GoodwillIncludingDisposalGroups>
    <ci:GoodwillIncludingDisposalGroups contextRef="c-47" decimals="-6" id="f-2251" unitRef="usd">46045000000</ci:GoodwillIncludingDisposalGroups>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit contextRef="c-656" decimals="-6" id="f-2252" unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit contextRef="c-224" decimals="-6" id="f-2253" unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit contextRef="c-657" decimals="-6" id="f-2254" unitRef="usd">234000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit contextRef="c-7" decimals="-6" id="f-2255" unitRef="usd">234000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-656" decimals="-6" id="f-2256" unitRef="usd">2000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-224" decimals="-6" id="f-2257" unitRef="usd">-2000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-657" decimals="-6" id="f-2258" unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-7" decimals="-6" id="f-2259" unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill contextRef="c-658" decimals="-6" id="f-2260" unitRef="usd">35130000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-218" decimals="-6" id="f-2261" unitRef="usd">10681000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-220" decimals="-6" id="f-2262" unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-13" decimals="-6" id="f-2263" unitRef="usd">45811000000</us-gaap:Goodwill>
    <ci:GoodwillTransfersToAssetsOfBusinessesHeldForSale contextRef="c-659" decimals="-6" id="f-2264" unitRef="usd">0</ci:GoodwillTransfersToAssetsOfBusinessesHeldForSale>
    <ci:GoodwillTransfersToAssetsOfBusinessesHeldForSale contextRef="c-223" decimals="-6" id="f-2265" unitRef="usd">1553000000</ci:GoodwillTransfersToAssetsOfBusinessesHeldForSale>
    <ci:GoodwillTransfersToAssetsOfBusinessesHeldForSale contextRef="c-660" decimals="-6" id="f-2266" unitRef="usd">0</ci:GoodwillTransfersToAssetsOfBusinessesHeldForSale>
    <ci:GoodwillTransfersToAssetsOfBusinessesHeldForSale contextRef="c-1" decimals="-6" id="f-2267" unitRef="usd">1553000000</ci:GoodwillTransfersToAssetsOfBusinessesHeldForSale>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-659" decimals="-6" id="f-2268" unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-223" decimals="-6" id="f-2269" unitRef="usd">1000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-660" decimals="-6" id="f-2270" unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-1" decimals="-6" id="f-2271" unitRef="usd">1000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill contextRef="c-661" decimals="-6" id="f-2272" unitRef="usd">35130000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-217" decimals="-6" id="f-2273" unitRef="usd">9129000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-219" decimals="-6" id="f-2274" unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-12" decimals="-6" id="f-2275" unitRef="usd">44259000000</us-gaap:Goodwill>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1 contextRef="c-662" decimals="-6" id="f-2276" unitRef="usd">234000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="c-1" id="f-2277">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; The Company's Other intangible assets primarily include purchased customer and producer relationships, trademarks and provider networks. The fair value of purchased customer relationships and the amortization method were determined as of the dates of purchase using an income approach that relies on projected future net cash flows including key assumptions for customer attrition and discount rates. The Company's definite-lived intangible assets are amortized on an accelerated or straight-line basis, reflecting their pattern of economic benefits, over periods from &lt;span style="-sec-ix-hidden:f-2278"&gt;three&lt;/span&gt; to 30 years. Management revises amortization periods if it believes there has been a change in the length of time that an intangible asset will continue to have value. Costs incurred to renew or extend the terms of these intangible assets are generally expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's amortized intangible assets are tested for impairment whenever events or changes in circumstances indicate that the &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;carrying amount may not be recoverable.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; If the total of the expected future undiscounted cash flows generated by the underlying asset group is less than the carrying amount of the asset group, the Company recognizes an impairment charge equal to the difference between the carrying value of the asset group and its estimated fair value. The Company's indefinite-lived intangible assets are reviewed for impairment at least annually by comparing their fair value with their carrying value. If the carrying value exceeds fair value, that excess is recognized as an impairment loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-664" id="f-2279">P30Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock contextRef="c-1" id="f-2281">Other intangible assets were comprised of the following:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29,978&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,645&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;22,333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trade Name - Express Scripts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;317&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;110&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;207&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;38,695&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,755&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;30,940&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Value of business acquired ("VOBA" reported in Other assets)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;211&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;142&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;69&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;38,906&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,897&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;31,009&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trade Name - Express Scripts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Value of business acquired (reported in Other assets)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; Includes $69&#160;million of VOBA and $77&#160;million of Other intangible assets classified as assets of businesses held for sale.&lt;/span&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c-1" id="f-2280">Other intangible assets were comprised of the following:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29,978&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,645&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;22,333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trade Name - Express Scripts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;317&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;110&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;207&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;38,695&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,755&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;30,940&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Value of business acquired ("VOBA" reported in Other assets)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;211&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;142&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;69&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;38,906&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,897&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;31,009&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trade Name - Express Scripts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Value of business acquired (reported in Other assets)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; Includes $69&#160;million of VOBA and $77&#160;million of Other intangible assets classified as assets of businesses held for sale.&lt;/span&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <ci:FiniteLivedIntangibleAssetsGrossIncludingDisposalGroupsHeldForSale contextRef="c-665" decimals="-6" id="f-2282" unitRef="usd">29978000000</ci:FiniteLivedIntangibleAssetsGrossIncludingDisposalGroupsHeldForSale>
    <ci:FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale contextRef="c-665" decimals="-6" id="f-2283" unitRef="usd">7645000000</ci:FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale>
    <ci:FiniteLivedIntangibleAssetsNetIncludingDisposalGroupsAssetsHeldForSale contextRef="c-665" decimals="-6" id="f-2284" unitRef="usd">22333000000</ci:FiniteLivedIntangibleAssetsNetIncludingDisposalGroupsAssetsHeldForSale>
    <ci:IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale contextRef="c-666" decimals="-6" id="f-2285" unitRef="usd">8400000000</ci:IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale>
    <ci:IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale contextRef="c-666" decimals="-6" id="f-2286" unitRef="usd">8400000000</ci:IndefiniteLivedIntangibleAssetsExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale>
    <ci:IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale contextRef="c-667" decimals="-6" id="f-2287" unitRef="usd">317000000</ci:IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale>
    <ci:FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale contextRef="c-667" decimals="-6" id="f-2288" unitRef="usd">110000000</ci:FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale>
    <ci:IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale contextRef="c-667" decimals="-6" id="f-2289" unitRef="usd">207000000</ci:IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale>
    <ci:IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-2290" unitRef="usd">38695000000</ci:IntangibleAssetsGrossExcludingGoodwillIncludingDisposalGroupsAssetsHeldForSale>
    <ci:FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-2291" unitRef="usd">7755000000</ci:FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingDisposalGroupsAssetsHeldForSale>
    <ci:IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-2292" unitRef="usd">30940000000</ci:IntangibleAssetsNetExcludingGoodwillIncludingDisposalsGroupsAssetsHeldForSale>
    <ci:FiniteLivedIntangibleAssetsGrossVOBAIncludingDisposalGroupsAssetHeldForSale contextRef="c-12" decimals="-6" id="f-2293" unitRef="usd">211000000</ci:FiniteLivedIntangibleAssetsGrossVOBAIncludingDisposalGroupsAssetHeldForSale>
    <ci:FiniteLivedIntangibleAssetsAccumulatedAmortizationVOBAIncludingDisposalGroupsAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-2294" unitRef="usd">142000000</ci:FiniteLivedIntangibleAssetsAccumulatedAmortizationVOBAIncludingDisposalGroupsAssetsHeldForSale>
    <ci:FiniteLivedIntangibleAssetsNetVOBAIncludingDisposalGroupsAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-2295" unitRef="usd">69000000</ci:FiniteLivedIntangibleAssetsNetVOBAIncludingDisposalGroupsAssetsHeldForSale>
    <ci:IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups contextRef="c-12" decimals="-6" id="f-2296" unitRef="usd">38906000000</ci:IntangibleAssetsGrossExcludingGoodwillIncludingVOBAIncludingDisposalGroups>
    <ci:FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVOBAIncludingDisposalGroups contextRef="c-12" decimals="-6" id="f-2297" unitRef="usd">7897000000</ci:FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVOBAIncludingDisposalGroups>
    <ci:IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups contextRef="c-12" decimals="-6" id="f-2298" unitRef="usd">31009000000</ci:IntangibleAssetsNetExcludingGoodwillIncludingVOBAIncludingDisposalGroups>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-668" decimals="-6" id="f-2299" unitRef="usd">29974000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-668" decimals="-6" id="f-2300" unitRef="usd">6099000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-668" decimals="-6" id="f-2301" unitRef="usd">23875000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-669" decimals="-6" id="f-2302" unitRef="usd">8400000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-669" decimals="-6" id="f-2303" unitRef="usd">8400000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c-670" decimals="-6" id="f-2304" unitRef="usd">348000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-670" decimals="-6" id="f-2305" unitRef="usd">131000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-670" decimals="-6" id="f-2306" unitRef="usd">217000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c-13" decimals="-6" id="f-2307" unitRef="usd">38722000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-13" decimals="-6" id="f-2308" unitRef="usd">6230000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-13" decimals="-6" id="f-2309" unitRef="usd">32492000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <ci:FiniteLivedIntangibleAssetsGrossVoba contextRef="c-13" decimals="-6" id="f-2310" unitRef="usd">210000000</ci:FiniteLivedIntangibleAssetsGrossVoba>
    <ci:FiniteLivedIntangibleAssetsAccumulatedAmortizationVoba contextRef="c-13" decimals="-6" id="f-2311" unitRef="usd">133000000</ci:FiniteLivedIntangibleAssetsAccumulatedAmortizationVoba>
    <ci:FiniteLivedIntangibleAssetsNetVoba contextRef="c-13" decimals="-6" id="f-2312" unitRef="usd">77000000</ci:FiniteLivedIntangibleAssetsNetVoba>
    <ci:IntangibleAssetsGrossExcludingGoodwillIncludingVoba contextRef="c-13" decimals="-6" id="f-2313" unitRef="usd">38932000000</ci:IntangibleAssetsGrossExcludingGoodwillIncludingVoba>
    <ci:FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVoba contextRef="c-13" decimals="-6" id="f-2314" unitRef="usd">6363000000</ci:FiniteLivedIntangibleAssetsAccumulatedAmortizationIncludingVoba>
    <ci:IntangibleAssetsNetExcludingGoodwillIncludingVoba contextRef="c-13" decimals="-6" id="f-2315" unitRef="usd">32569000000</ci:IntangibleAssetsNetExcludingGoodwillIncludingVoba>
    <ci:DisposalGroupIncludingDiscontinuedOperationValueOfBusinessAcquired contextRef="c-83" decimals="-6" id="f-2316" unitRef="usd">69000000</ci:DisposalGroupIncludingDiscontinuedOperationValueOfBusinessAcquired>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets contextRef="c-83" decimals="-6" id="f-2317" unitRef="usd">77000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-13" decimals="-8" id="f-2318" unitRef="usd">8500000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-12" decimals="-8" id="f-2319" unitRef="usd">8500000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-2320">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Property and equipment is carried at cost less accumulated depreciation. Cost includes interest, real estate taxes and other costs incurred during construction when applicable. Internal-use software that is acquired, developed or modified solely to meet the Company's internal needs, with no plan to market externally, is also included in this category. Costs directly related to acquiring, developing or modifying internal-use software are capitalized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company calculates depreciation and amortization principally using the straight-line method generally based on the estimated useful life of each asset as follows: buildings and improvements, 10 to 40 years; purchased and internally developed software, &lt;span style="-sec-ix-hidden:f-2323"&gt;three&lt;/span&gt; to five years; and furniture and equipment (including computer equipment), &lt;span style="-sec-ix-hidden:f-2325"&gt;three&lt;/span&gt; to 10 years. Improvements to leased facilities are depreciated over &lt;span style="-sec-ix-hidden:f-2327"&gt;the lesser of the remaining lease term or the estimated life of the improvement&lt;/span&gt;. The Company considers events and circumstances that would indicate the carrying value of property, equipment or capitalized software might not be recoverable. An impairment charge is recorded if the Company determines the carrying value of any of these assets is not recoverable. The Company also reviews and shortens the estimated useful lives of these assets, if necessary.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-671" id="f-2321">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-672" id="f-2322">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-674" id="f-2324">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-676" id="f-2326">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-2328">Property and equipment was comprised of the following:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Internal-use software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,155&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,161&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,994&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,282&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,405&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;877&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total property and equipment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12,437&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,566&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,871&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Internal-use software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt; Includes $176&#160;million of Property and equipment net carrying value classified as assets of businesses held for sale.</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <ci:PropertyPlantAndEquipmentGrossIncludingDisposalGroups contextRef="c-678" decimals="-6" id="f-2329" unitRef="usd">10155000000</ci:PropertyPlantAndEquipmentGrossIncludingDisposalGroups>
    <ci:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups contextRef="c-678" decimals="-6" id="f-2330" unitRef="usd">7161000000</ci:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups>
    <ci:PropertyPlantAndEquipmentNetIncludingDisposalGroups contextRef="c-678" decimals="-6" id="f-2331" unitRef="usd">2994000000</ci:PropertyPlantAndEquipmentNetIncludingDisposalGroups>
    <ci:PropertyPlantAndEquipmentGrossIncludingDisposalGroups contextRef="c-679" decimals="-6" id="f-2332" unitRef="usd">2282000000</ci:PropertyPlantAndEquipmentGrossIncludingDisposalGroups>
    <ci:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups contextRef="c-679" decimals="-6" id="f-2333" unitRef="usd">1405000000</ci:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups>
    <ci:PropertyPlantAndEquipmentNetIncludingDisposalGroups contextRef="c-679" decimals="-6" id="f-2334" unitRef="usd">877000000</ci:PropertyPlantAndEquipmentNetIncludingDisposalGroups>
    <ci:PropertyPlantAndEquipmentGrossIncludingDisposalGroups contextRef="c-12" decimals="-6" id="f-2335" unitRef="usd">12437000000</ci:PropertyPlantAndEquipmentGrossIncludingDisposalGroups>
    <ci:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups contextRef="c-12" decimals="-6" id="f-2336" unitRef="usd">8566000000</ci:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentIncludingDisposalGroups>
    <ci:PropertyPlantAndEquipmentNetIncludingDisposalGroups contextRef="c-12" decimals="-6" id="f-2337" unitRef="usd">3871000000</ci:PropertyPlantAndEquipmentNetIncludingDisposalGroups>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-680" decimals="-6" id="f-2338" unitRef="usd">8948000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-680" decimals="-6" id="f-2339" unitRef="usd">6100000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-680" decimals="-6" id="f-2340" unitRef="usd">2848000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-681" decimals="-6" id="f-2341" unitRef="usd">2256000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-681" decimals="-6" id="f-2342" unitRef="usd">1330000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-681" decimals="-6" id="f-2343" unitRef="usd">926000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-13" decimals="-6" id="f-2344" unitRef="usd">11204000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-13" decimals="-6" id="f-2345" unitRef="usd">7430000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-13" decimals="-6" id="f-2346" unitRef="usd">3774000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent contextRef="c-83" decimals="-6" id="f-2347" unitRef="usd">176000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent>
    <ci:ComponentsOfDepreciationAndAmortizationTableTextBlock contextRef="c-1" id="f-2348">Depreciation and amortization expense was comprised of the following:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Internal-use software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,216&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;260&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Value of business acquired (reported in Other assets)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,552&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,035&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ci:ComponentsOfDepreciationAndAmortizationTableTextBlock>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-682" decimals="-6" id="f-2349" unitRef="usd">1216000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-683" decimals="-6" id="f-2350" unitRef="usd">1068000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-684" decimals="-6" id="f-2351" unitRef="usd">1097000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-685" decimals="-6" id="f-2352" unitRef="usd">260000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-686" decimals="-6" id="f-2353" unitRef="usd">251000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-687" decimals="-6" id="f-2354" unitRef="usd">253000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-688" decimals="-6" id="f-2355" unitRef="usd">7000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-689" decimals="-6" id="f-2356" unitRef="usd">12000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-690" decimals="-6" id="f-2357" unitRef="usd">25000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-691" decimals="-6" id="f-2358" unitRef="usd">1552000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-692" decimals="-6" id="f-2359" unitRef="usd">1606000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-693" decimals="-6" id="f-2360" unitRef="usd">1548000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-6" id="f-2361" unitRef="usd">3035000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-7" decimals="-6" id="f-2362" unitRef="usd">2937000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-8" decimals="-6" id="f-2363" unitRef="usd">2923000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-2364">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company estimates annual pre-tax amortization for intangible assets, including internal-use software, over the next five calendar years to be as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:88.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.040%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pre-tax Amortization&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,892&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,357&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,803&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,559&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,484&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-12" decimals="-6" id="f-2365" unitRef="usd">2892000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-12" decimals="-6" id="f-2366" unitRef="usd">2357000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-12" decimals="-6" id="f-2367" unitRef="usd">1803000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-12" decimals="-6" id="f-2368" unitRef="usd">1559000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-12" decimals="-6" id="f-2369" unitRef="usd">1484000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:LesseeFinanceLeasesTextBlock contextRef="c-1" id="f-2371">&lt;div style="margin-top:10pt"&gt;&lt;span id="i5991b33a7b8f493f949a254d6e300e2d_1953"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 21 &#x2013; Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's leases are primarily for office space and certain computer and other equipment and have terms of up to 35 years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; The Company determines if an arrangement is a lease and its lease classification (operating or finance) at inception. Both operating and finance leases result in (1) a right-of-use ("ROU") asset that represents our right to use the underlying asset for the lease term and (2) a lease liability that represents our obligation to make lease payments arising from the lease. ROU assets and lease liabilities are reflected in the following lines in the Company's Consolidated Balance Sheets:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.431%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ROU Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Current Lease Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-Current Lease Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other liabilities (current)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other liabilities (non-current)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;These lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. Most of the Company's leases do not provide an implicit rate, so the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The ROU asset also includes any lease pre-payments made and excludes lease incentives for operating leases. The Company's expected life of a lease may consider options to extend or terminate a lease when it is reasonably certain that the Company will exercise that option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has lease agreements with lease and non-lease components that are accounted for as a single lease component. Operating lease ROU assets are amortized on a straight-line basis over the lease term, which is representative of the pattern in which benefit is expected to be derived from the right to use the underlying asset. Variable lease payments are expensed as incurred and represent amounts that are neither fixed in nature, such as maintenance and other services provided by the lessor, nor tied to an index or rate.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.432%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;115&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;38&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;198&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Supplemental cash flow information related to leases was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.931%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating cash outflows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;132&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating cash outflows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Financing cash outflows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ROU assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;103&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;48&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating and finance lease ROU assets and lease liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.319%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets in &lt;span style="-sec-ix-hidden:f-2410"&gt;&lt;span style="-sec-ix-hidden:f-2411"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;370&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-2414"&gt;&lt;span style="-sec-ix-hidden:f-2415"&gt;Accrued expenses and other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;105&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-2418"&gt;&lt;span style="-sec-ix-hidden:f-2419"&gt;Other non-current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;340&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;445&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;177&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-2428"&gt;&lt;span style="-sec-ix-hidden:f-2429"&gt;Property and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;104&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-2432"&gt;&lt;span style="-sec-ix-hidden:f-2433"&gt;Short-term debt&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;42&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-2436"&gt;&lt;span style="-sec-ix-hidden:f-2437"&gt;Long-term debt&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;66&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;108&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December 31, 2023, the weighted average remaining lease term was 6 years for operating leases and 3 years for finance leases, and the weighted average discount rate was 3.45% for operating leases and 4.29% for finance leases.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Maturities of lease liabilities are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;110&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;46&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;102&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;38&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;83&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;63&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;98&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;497&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;115&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;52&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;445&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;108&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-2370">&lt;div style="margin-top:10pt"&gt;&lt;span id="i5991b33a7b8f493f949a254d6e300e2d_1953"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note 21 &#x2013; Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's leases are primarily for office space and certain computer and other equipment and have terms of up to 35 years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; The Company determines if an arrangement is a lease and its lease classification (operating or finance) at inception. Both operating and finance leases result in (1) a right-of-use ("ROU") asset that represents our right to use the underlying asset for the lease term and (2) a lease liability that represents our obligation to make lease payments arising from the lease. ROU assets and lease liabilities are reflected in the following lines in the Company's Consolidated Balance Sheets:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.431%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ROU Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Current Lease Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-Current Lease Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other liabilities (current)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other liabilities (non-current)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;These lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. Most of the Company's leases do not provide an implicit rate, so the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The ROU asset also includes any lease pre-payments made and excludes lease incentives for operating leases. The Company's expected life of a lease may consider options to extend or terminate a lease when it is reasonably certain that the Company will exercise that option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has lease agreements with lease and non-lease components that are accounted for as a single lease component. Operating lease ROU assets are amortized on a straight-line basis over the lease term, which is representative of the pattern in which benefit is expected to be derived from the right to use the underlying asset. Variable lease payments are expensed as incurred and represent amounts that are neither fixed in nature, such as maintenance and other services provided by the lessor, nor tied to an index or rate.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.432%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;115&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;38&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;198&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Supplemental cash flow information related to leases was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.931%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating cash outflows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;132&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating cash outflows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Financing cash outflows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ROU assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;103&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;48&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating and finance lease ROU assets and lease liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.319%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets in &lt;span style="-sec-ix-hidden:f-2410"&gt;&lt;span style="-sec-ix-hidden:f-2411"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;370&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-2414"&gt;&lt;span style="-sec-ix-hidden:f-2415"&gt;Accrued expenses and other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;105&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-2418"&gt;&lt;span style="-sec-ix-hidden:f-2419"&gt;Other non-current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;340&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;445&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;177&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-2428"&gt;&lt;span style="-sec-ix-hidden:f-2429"&gt;Property and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;104&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-2432"&gt;&lt;span style="-sec-ix-hidden:f-2433"&gt;Short-term debt&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;42&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-2436"&gt;&lt;span style="-sec-ix-hidden:f-2437"&gt;Long-term debt&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;66&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;108&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December 31, 2023, the weighted average remaining lease term was 6 years for operating leases and 3 years for finance leases, and the weighted average discount rate was 3.45% for operating leases and 4.29% for finance leases.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Maturities of lease liabilities are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;110&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;46&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;102&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;38&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;83&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;63&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;98&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;497&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;115&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;52&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;445&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;108&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-664" id="f-2372">P35Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-2373">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy.&lt;/span&gt; The Company determines if an arrangement is a lease and its lease classification (operating or finance) at inception. Both operating and finance leases result in (1) a right-of-use ("ROU") asset that represents our right to use the underlying asset for the lease term and (2) a lease liability that represents our obligation to make lease payments arising from the lease.&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;These lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. Most of the Company's leases do not provide an implicit rate, so the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The ROU asset also includes any lease pre-payments made and excludes lease incentives for operating leases. The Company's expected life of a lease may consider options to extend or terminate a lease when it is reasonably certain that the Company will exercise that option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has lease agreements with lease and non-lease components that are accounted for as a single lease component. Operating lease ROU assets are amortized on a straight-line basis over the lease term, which is representative of the pattern in which benefit is expected to be derived from the right to use the underlying asset. Variable lease payments are expensed as incurred and represent amounts that are neither fixed in nature, such as maintenance and other services provided by the lessor, nor tied to an index or rate.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <ci:AssetsAndLiabilitiesLesseeTableTextBlock contextRef="c-1" id="f-2374">ROU assets and lease liabilities are reflected in the following lines in the Company's Consolidated Balance Sheets:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.431%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ROU Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Current Lease Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-Current Lease Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other liabilities (current)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other liabilities (non-current)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating and finance lease ROU assets and lease liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.319%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets in &lt;span style="-sec-ix-hidden:f-2410"&gt;&lt;span style="-sec-ix-hidden:f-2411"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;370&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-2414"&gt;&lt;span style="-sec-ix-hidden:f-2415"&gt;Accrued expenses and other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;105&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-2418"&gt;&lt;span style="-sec-ix-hidden:f-2419"&gt;Other non-current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;340&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;445&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;177&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-2428"&gt;&lt;span style="-sec-ix-hidden:f-2429"&gt;Property and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;104&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-2432"&gt;&lt;span style="-sec-ix-hidden:f-2433"&gt;Short-term debt&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;42&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-2436"&gt;&lt;span style="-sec-ix-hidden:f-2437"&gt;Long-term debt&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;66&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;108&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ci:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-2375">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.432%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;115&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;38&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;198&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-6" id="f-2376" unitRef="usd">115000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-7" decimals="-6" id="f-2377" unitRef="usd">124000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-8" decimals="-6" id="f-2378" unitRef="usd">170000000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-1" decimals="-6" id="f-2379" unitRef="usd">41000000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-7" decimals="-6" id="f-2380" unitRef="usd">33000000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-8" decimals="-6" id="f-2381" unitRef="usd">22000000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-1" decimals="-6" id="f-2382" unitRef="usd">4000000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-7" decimals="-6" id="f-2383" unitRef="usd">2000000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-8" decimals="-6" id="f-2384" unitRef="usd">2000000</us-gaap:FinanceLeaseInterestExpense>
    <ci:FinanceLeaseCost contextRef="c-1" decimals="-6" id="f-2385" unitRef="usd">45000000</ci:FinanceLeaseCost>
    <ci:FinanceLeaseCost contextRef="c-7" decimals="-6" id="f-2386" unitRef="usd">35000000</ci:FinanceLeaseCost>
    <ci:FinanceLeaseCost contextRef="c-8" decimals="-6" id="f-2387" unitRef="usd">24000000</ci:FinanceLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-6" id="f-2388" unitRef="usd">38000000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-7" decimals="-6" id="f-2389" unitRef="usd">41000000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-8" decimals="-6" id="f-2390" unitRef="usd">39000000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-6" id="f-2391" unitRef="usd">198000000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-7" decimals="-6" id="f-2392" unitRef="usd">200000000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-8" decimals="-6" id="f-2393" unitRef="usd">233000000</us-gaap:LeaseCost>
    <ci:CashFlowActivitiesLesseeTableTextBlock contextRef="c-1" id="f-2394">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Supplemental cash flow information related to leases was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.931%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating cash outflows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;132&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating cash outflows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Financing cash outflows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ROU assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;103&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;48&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ci:CashFlowActivitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-6" id="f-2395" unitRef="usd">132000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-7" decimals="-6" id="f-2396" unitRef="usd">148000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-8" decimals="-6" id="f-2397" unitRef="usd">167000000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-1" decimals="-6" id="f-2398" unitRef="usd">4000000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-7" decimals="-6" id="f-2399" unitRef="usd">2000000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-8" decimals="-6" id="f-2400" unitRef="usd">2000000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-1" decimals="-6" id="f-2401" unitRef="usd">39000000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-7" decimals="-6" id="f-2402" unitRef="usd">33000000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-8" decimals="-6" id="f-2403" unitRef="usd">22000000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-6" id="f-2404" unitRef="usd">103000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-7" decimals="-6" id="f-2405" unitRef="usd">43000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-8" decimals="-6" id="f-2406" unitRef="usd">122000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="c-1" decimals="-6" id="f-2407" unitRef="usd">48000000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="c-7" decimals="-6" id="f-2408" unitRef="usd">84000000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="c-8" decimals="-6" id="f-2409" unitRef="usd">20000000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-12" decimals="-6" id="f-2412" unitRef="usd">370000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-13" decimals="-6" id="f-2413" unitRef="usd">375000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-12" decimals="-6" id="f-2416" unitRef="usd">105000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-13" decimals="-6" id="f-2417" unitRef="usd">114000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-12" decimals="-6" id="f-2420" unitRef="usd">340000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-13" decimals="-6" id="f-2421" unitRef="usd">346000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c-12" decimals="-6" id="f-2422" unitRef="usd">445000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="c-13" decimals="-6" id="f-2423" unitRef="usd">460000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization contextRef="c-12" decimals="-6" id="f-2424" unitRef="usd">177000000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization contextRef="c-13" decimals="-6" id="f-2425" unitRef="usd">145000000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization contextRef="c-12" decimals="-6" id="f-2426" unitRef="usd">73000000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization contextRef="c-13" decimals="-6" id="f-2427" unitRef="usd">48000000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-12" decimals="-6" id="f-2430" unitRef="usd">104000000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-13" decimals="-6" id="f-2431" unitRef="usd">97000000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-12" decimals="-6" id="f-2434" unitRef="usd">42000000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-13" decimals="-6" id="f-2435" unitRef="usd">33000000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-12" decimals="-6" id="f-2438" unitRef="usd">66000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-13" decimals="-6" id="f-2439" unitRef="usd">66000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiability contextRef="c-12" decimals="-6" id="f-2440" unitRef="usd">108000000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability contextRef="c-13" decimals="-6" id="f-2441" unitRef="usd">99000000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-12" id="f-2442">P6Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-12" id="f-2443">P3Y</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-12" decimals="4" id="f-2444" unitRef="number">0.0345</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c-12" decimals="4" id="f-2445" unitRef="number">0.0429</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-2447">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Maturities of lease liabilities are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;110&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;46&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;102&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;38&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;83&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;63&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;98&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;497&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;115&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;52&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;445&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;108&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-2446">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Maturities of lease liabilities are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;110&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;46&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;102&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;38&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;83&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;63&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;98&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;497&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;115&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;52&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;445&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;108&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-12" decimals="-6" id="f-2448" unitRef="usd">110000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-12" decimals="-6" id="f-2449" unitRef="usd">46000000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-12" decimals="-6" id="f-2450" unitRef="usd">102000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo contextRef="c-12" decimals="-6" id="f-2451" unitRef="usd">38000000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-12" decimals="-6" id="f-2452" unitRef="usd">83000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree contextRef="c-12" decimals="-6" id="f-2453" unitRef="usd">19000000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-12" decimals="-6" id="f-2454" unitRef="usd">63000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour contextRef="c-12" decimals="-6" id="f-2455" unitRef="usd">6000000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-12" decimals="-6" id="f-2456" unitRef="usd">41000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive contextRef="c-12" decimals="-6" id="f-2457" unitRef="usd">6000000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-12" decimals="-6" id="f-2458" unitRef="usd">98000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-12" decimals="-6" id="f-2459" unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-12" decimals="-6" id="f-2460" unitRef="usd">497000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue contextRef="c-12" decimals="-6" id="f-2461" unitRef="usd">115000000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-12" decimals="-6" id="f-2462" unitRef="usd">52000000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount contextRef="c-12" decimals="-6" id="f-2463" unitRef="usd">7000000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-12" decimals="-6" id="f-2464" unitRef="usd">445000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability contextRef="c-12" decimals="-6" id="f-2465" unitRef="usd">108000000</us-gaap:FinanceLeaseLiability>
    <ci:StockholdersEquityAndDividendRestrictionsTextBlock contextRef="c-1" id="f-2466">&lt;div style="margin-bottom:10pt"&gt;&lt;span id="i3bcdef59d091463883ab932d4c87d696_1547"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Note 22 &#x2013; Shareholders' Equity and Dividend Restrictions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;State insurance departments and foreign jurisdictions that regulate certain of the Company's subsidiaries prescribe accounting practices (differing in some respects from GAAP) to determine statutory net income and surplus. The Company's life, accident and health insurance and Health Maintenance Organization ("HMO") subsidiaries are regulated by such statutory requirements. The statutory net income of the Company's life, accident and health insurance and HMO subsidiaries for the years ended, and their statutory surplus as of December 31 were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In billions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Surplus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;14.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's HMO and life, accident and health insurance subsidiaries are also subject to minimum statutory surplus requirements and may be required to maintain investments on deposit with state departments of insurance or other regulatory bodies. Additionally, these subsidiaries may be subject to regulatory restrictions on the amount of annual dividends or other distributions (such as loans or cash advances) that insurance companies may extend to their parent companies without prior approval. These amounts, including restricted GAAP net assets of the Company's subsidiaries, were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:88.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.040%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In billions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Minimum statutory surplus required by regulators &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments on deposit with regulatory bodies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Maximum dividend distributions permitted in 2024 without regulatory approval&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Maximum loans to the parent company permitted without regulatory approval&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted GAAP net assets of The Cigna Group's subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; Excludes amounts associated with foreign operated equity method joint ventures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Permitted practices used by the Company's insurance subsidiaries in 2023 that differed from prescribed regulatory accounting had an immaterial impact on statutory surplus.&lt;/span&gt;&lt;/div&gt;Undistributed earnings for equity method investments are $1.0 billion&#160;as of December&#160;31, 2023</ci:StockholdersEquityAndDividendRestrictionsTextBlock>
    <us-gaap:StatutoryAccountingPracticesDisclosureTextBlock contextRef="c-1" id="f-2467">The statutory net income of the Company's life, accident and health insurance and HMO subsidiaries for the years ended, and their statutory surplus as of December 31 were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In billions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Surplus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;14.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;These amounts, including restricted GAAP net assets of the Company's subsidiaries, were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:88.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.040%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In billions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Minimum statutory surplus required by regulators &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments on deposit with regulatory bodies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Maximum dividend distributions permitted in 2024 without regulatory approval&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Maximum loans to the parent company permitted without regulatory approval&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted GAAP net assets of The Cigna Group's subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; Excludes amounts associated with foreign operated equity method joint ventures.&lt;/span&gt;&lt;/div&gt;</us-gaap:StatutoryAccountingPracticesDisclosureTextBlock>
    <us-gaap:StatutoryAccountingPracticesStatutoryNetIncomeAmount contextRef="c-1" decimals="-8" id="f-2468" unitRef="usd">5300000000</us-gaap:StatutoryAccountingPracticesStatutoryNetIncomeAmount>
    <us-gaap:StatutoryAccountingPracticesStatutoryNetIncomeAmount contextRef="c-7" decimals="-8" id="f-2469" unitRef="usd">5700000000</us-gaap:StatutoryAccountingPracticesStatutoryNetIncomeAmount>
    <us-gaap:StatutoryAccountingPracticesStatutoryNetIncomeAmount contextRef="c-8" decimals="-8" id="f-2470" unitRef="usd">3400000000</us-gaap:StatutoryAccountingPracticesStatutoryNetIncomeAmount>
    <us-gaap:StatutoryCapitalAndSurplusApplyingNationalAssociationOfInsuranceCommissionersNAICPractices contextRef="c-12" decimals="-8" id="f-2471" unitRef="usd">14900000000</us-gaap:StatutoryCapitalAndSurplusApplyingNationalAssociationOfInsuranceCommissionersNAICPractices>
    <us-gaap:StatutoryCapitalAndSurplusApplyingNationalAssociationOfInsuranceCommissionersNAICPractices contextRef="c-13" decimals="-8" id="f-2472" unitRef="usd">16400000000</us-gaap:StatutoryCapitalAndSurplusApplyingNationalAssociationOfInsuranceCommissionersNAICPractices>
    <us-gaap:StatutoryCapitalAndSurplusApplyingNationalAssociationOfInsuranceCommissionersNAICPractices contextRef="c-47" decimals="-8" id="f-2473" unitRef="usd">13300000000</us-gaap:StatutoryCapitalAndSurplusApplyingNationalAssociationOfInsuranceCommissionersNAICPractices>
    <us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired contextRef="c-12" decimals="-8" id="f-2474" unitRef="usd">4800000000</us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired>
    <us-gaap:AssetsHeldByInsuranceRegulators contextRef="c-12" decimals="-8" id="f-2475" unitRef="usd">300000000</us-gaap:AssetsHeldByInsuranceRegulators>
    <us-gaap:StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments contextRef="c-12" decimals="-8" id="f-2476" unitRef="usd">2100000000</us-gaap:StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPayments>
    <ci:StatutoryAccountingPracticesAmountPermittedLendingAuthorityOfLifeInsuranceSubsidiaryToParent contextRef="c-12" decimals="-8" id="f-2477" unitRef="usd">1400000000</ci:StatutoryAccountingPracticesAmountPermittedLendingAuthorityOfLifeInsuranceSubsidiaryToParent>
    <us-gaap:AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries contextRef="c-12" decimals="-8" id="f-2478" unitRef="usd">12300000000</us-gaap:AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries>
    <us-gaap:RetainedEarningsUndistributedEarningsFromEquityMethodInvestees contextRef="c-12" decimals="-8" id="f-2479" unitRef="usd">1000000000</us-gaap:RetainedEarningsUndistributedEarningsFromEquityMethodInvestees>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-2480">&lt;div&gt;&lt;span id="if56053e95d5e46d0a8e1a2d4abbd865a_14"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Note 23 &#x2013; Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Deferred income taxes are reflected in the Consolidated Balance Sheets for differences between the financial and income tax reporting bases of the Company's underlying assets and liabilities, and are established based upon enacted tax rates and laws. Deferred income tax assets are recognized when available evidence indicates that realization is more likely than not and a valuation allowance is established to the extent this standard is not met. The deferred income tax provision generally represents the net change in deferred income tax assets and liabilities during the reporting period excluding adjustments to Accumulated other comprehensive income (loss) or amounts recorded in connection with a business combination. The current income tax provision generally represents estimated amounts due on income tax returns for the year reported to various jurisdictions plus the effect of any uncertain tax positions. The Company recognizes a liability for uncertain tax positions if management believes the probability that the positions will be sustained is 50% or less. For uncertain positions that management believes are more likely than not to be sustained, the Company recognizes a liability based upon management's estimate of the most likely settlement outcome with the taxing authority. The liabilities for uncertain tax positions are classified as current when the position is expected to be settled within 12 months or the statute of limitation expires within 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Income taxes attributable to the Company's foreign operations are generally provided using the respective foreign jurisdictions' tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;A.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline"&gt;Income Tax Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The components of income taxes were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Current taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,459&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;161&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;180&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total current taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deferred taxes (benefits)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. income tax benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(533)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign income (tax benefits) taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,046)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State income tax benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total deferred tax benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,659)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(472)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(216)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;141&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total income taxes were different from the amount computed using the nominal federal income tax rate for the following reasons:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.883%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.883%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.891%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="36" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax expense at nominal rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,158&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;21.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impact of sale of businesses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impact of businesses held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State income tax (benefit), net of federal income tax benefit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Swiss tax attributes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,674)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(30.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other foreign tax attributes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(153)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,290&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;141&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Consolidated pre-tax income from the Company's foreign operations was approximately 48% of the Company's pre-tax income in 2023, 46% in 2022 and 26% in 2021. The increase over 2022 is primarily driven by an increase to the Company's international pharmaceutical operations, partially offset by a reduction in earnings from the sold entities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Foreign Jurisdiction Tax Attributes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Impacting the effective tax rate for the year ended December&#160;31, 2023 was the recording of the Company's net deferred tax asset associated with foreign tax law changes and agreements in certain tax jurisdictions. The Company established deferred tax assets of approximately $1.8 billion associated with the foreign tax attributes and a related $772 million valuation allowance against these deferred tax assets based on projections of future earnings and requirements to utilize the assets within certain time periods. It is possible in future periods that the Company may revalue these net deferred tax assets due to modifications in certain assumptions such as forecasted future earnings. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Sale of Medicare Advantage and Related Businesses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. The Company recorded $584 million of deferred tax benefits and an equal amount of valuation allowance in connection with the HCSC transaction. The valuation allowance has been recorded due to the uncertainty relative to the recovery of the deferred tax benefits as the Company does not currently have capital gain capacity to offset these capital losses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;B.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline"&gt;Deferred Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred income tax assets and liabilities were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee and retiree benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;217&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other insurance and contractholder liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;353&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;200&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred loss - sale of business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;584&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;244&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Policy acquisition expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized depreciation on investments and foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;81&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign tax attributes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,827&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;242&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax assets before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,787&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Valuation allowance for deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,498)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,289&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;371&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Acquisition-related basis differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,105&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,476&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net deferred income tax liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,786)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Deferred tax liabilities, net in the Consolidated Balance Sheets as of December&#160;31, 2023, excludes $1,055&#160;million reported in Other assets and $69&#160;million reported in liabilities of businesses held for sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Management believes that future results will be sufficient to realize a majority of the Company's gross deferred tax assets. As of December&#160;31, 2023, we had approximately $218&#160;million in deferred tax assets ("DTAs") associated with unrealized investment losses that are partially recorded in Accumulated other comprehensive loss. We have determined that a valuation allowance against the DTAs is not currently required based on the Company's ability to carry back losses and our ability and intent to hold certain securities until recovery. We continue to monitor and evaluate the need for any valuation allowance in the future. As of December&#160;31, 2023, we had approximately $1.8 billion in DTAs associated with the foreign tax attributes as discussed above. We have determined that approximately $772 million valuation allowance against these DTAs is required based on the Company's taxable income projections and the requirement to utilize the assets within certain time periods. Additionally, the Company has $584 million of deferred tax assets and a full valuation allowance associated with the HCSC transaction, as discussed above. Valuation allowances are established against deferred tax assets when it is determined that it is more likely than not that the asset will not be recognized. Valuation allowances have been established against certain federal, state and foreign tax attributes. There are multiple expiration dates associated with these tax attributes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;C.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline"&gt;Uncertain Tax Positions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Reconciliations of unrecognized tax benefits were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at January 1,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,343&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Decrease) / Increase due to prior year positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Increase due to current year positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;107&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reduction related to settlements with taxing authorities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reduction related to lapse of applicable statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Substantially all unrecognized tax benefits would impact Shareholders' net income if recognized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company classifies net interest expense on uncertain tax positions as a component of income tax expense and in Other non-current liabilities in the Consolidated Balance Sheets. In addition to the amounts in the table above, the liability for net interest &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;expense on uncertain tax positions was approximately $220 million as of December&#160;31, 2023, $176 million as of December&#160;31, 2022 and $148 million as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;D.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline"&gt;Other Tax Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The statutes of limitations for The Cigna Group's consolidated federal income tax returns through 2016 have closed. However, The Cigna Group filed amended returns for both the 2015 and 2016 tax years, which are under review by the Internal Revenue Service ("IRS"). Additionally, the IRS is examining The Cigna Group's returns for 2017 and 2018. The statutes of limitations for Express Scripts' consolidated federal income tax returns through 2012 has closed. However, for 2010 through 2012 tax years, there remains a significant disputed matter. The IRS is also examining Express Scripts' consolidated federal income tax returns for 2013 through 2018. The Company has established adequate reserves for these matters.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company conducts business in a number of state and foreign jurisdictions and may be engaged in multiple audit proceedings at any given time. Generally, no further state or foreign audit activity is expected for tax years prior to 2014 for The Cigna Group's entities and 2010 for Express Scripts' entities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Pillar Two. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On December 15, 2022, the European Union ("EU") Member States formally adopted the EU's Pillar Two Directive, which generally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation and Development ("OECD") Pillar Two Framework that was supported by over 130 countries worldwide. The EU effective dates are January 1, 2024, and January 1, 2025, for different aspects of the directive. A significant number of other countries are also implementing similar legislation, and the OECD continues to release additional guidance on these rules. The Company is within the scope of the OECD Pillar Two model rules and continues to evaluate the potential impact on future periods of the Pillar Two Framework, pending legislative adoption by additional individual countries but expects the impact to not materially change its results from operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-2481">&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policy.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Deferred income taxes are reflected in the Consolidated Balance Sheets for differences between the financial and income tax reporting bases of the Company's underlying assets and liabilities, and are established based upon enacted tax rates and laws. Deferred income tax assets are recognized when available evidence indicates that realization is more likely than not and a valuation allowance is established to the extent this standard is not met. The deferred income tax provision generally represents the net change in deferred income tax assets and liabilities during the reporting period excluding adjustments to Accumulated other comprehensive income (loss) or amounts recorded in connection with a business combination. The current income tax provision generally represents estimated amounts due on income tax returns for the year reported to various jurisdictions plus the effect of any uncertain tax positions. The Company recognizes a liability for uncertain tax positions if management believes the probability that the positions will be sustained is 50% or less. For uncertain positions that management believes are more likely than not to be sustained, the Company recognizes a liability based upon management's estimate of the most likely settlement outcome with the taxing authority. The liabilities for uncertain tax positions are classified as current when the position is expected to be settled within 12 months or the statute of limitation expires within 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Income taxes attributable to the Company's foreign operations are generally provided using the respective foreign jurisdictions' tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Management believes that future results will be sufficient to realize a majority of the Company's gross deferred tax assets. As of December&#160;31, 2023, we had approximately $218&#160;million in deferred tax assets ("DTAs") associated with unrealized investment losses that are partially recorded in Accumulated other comprehensive loss. We have determined that a valuation allowance against the DTAs is not currently required based on the Company's ability to carry back losses and our ability and intent to hold certain securities until recovery. We continue to monitor and evaluate the need for any valuation allowance in the future. As of December&#160;31, 2023, we had approximately $1.8 billion in DTAs associated with the foreign tax attributes as discussed above. We have determined that approximately $772 million valuation allowance against these DTAs is required based on the Company's taxable income projections and the requirement to utilize the assets within certain time periods. Additionally, the Company has $584 million of deferred tax assets and a full valuation allowance associated with the HCSC transaction, as discussed above. Valuation allowances are established against deferred tax assets when it is determined that it is more likely than not that the asset will not be recognized. Valuation allowances have been established against certain federal, state and foreign tax attributes. There are multiple expiration dates associated with these tax attributes.&lt;/span&gt;&lt;/div&gt;The Company classifies net interest expense on uncertain tax positions as a component of income tax expense and in Other non-current liabilities in the Consolidated Balance Sheets.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-2482">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The components of income taxes were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Current taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,459&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;161&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;180&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total current taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deferred taxes (benefits)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. income tax benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(533)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign income (tax benefits) taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,046)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State income tax benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total deferred tax benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,659)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(472)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(216)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;141&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-2483" unitRef="usd">1459000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-7" decimals="-6" id="f-2484" unitRef="usd">1679000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-8" decimals="-6" id="f-2485" unitRef="usd">1267000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-2486" unitRef="usd">161000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-7" decimals="-6" id="f-2487" unitRef="usd">219000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-8" decimals="-6" id="f-2488" unitRef="usd">207000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-2489" unitRef="usd">180000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-7" decimals="-6" id="f-2490" unitRef="usd">189000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-8" decimals="-6" id="f-2491" unitRef="usd">112000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-2492" unitRef="usd">1800000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-7" decimals="-6" id="f-2493" unitRef="usd">2087000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-8" decimals="-6" id="f-2494" unitRef="usd">1586000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-2495" unitRef="usd">-533000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-7" decimals="-6" id="f-2496" unitRef="usd">-275000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-8" decimals="-6" id="f-2497" unitRef="usd">-163000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-2498" unitRef="usd">-1046000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-7" decimals="-6" id="f-2499" unitRef="usd">-28000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-8" decimals="-6" id="f-2500" unitRef="usd">69000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-2501" unitRef="usd">-80000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-7" decimals="-6" id="f-2502" unitRef="usd">-169000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-8" decimals="-6" id="f-2503" unitRef="usd">-122000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-2504" unitRef="usd">-1659000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-7" decimals="-6" id="f-2505" unitRef="usd">-472000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-8" decimals="-6" id="f-2506" unitRef="usd">-216000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-2507" unitRef="usd">141000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-7" decimals="-6" id="f-2508" unitRef="usd">1615000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-8" decimals="-6" id="f-2509" unitRef="usd">1370000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-2510">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total income taxes were different from the amount computed using the nominal federal income tax rate for the following reasons:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.883%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.883%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.891%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="36" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax expense at nominal rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,158&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;21.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impact of sale of businesses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impact of businesses held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State income tax (benefit), net of federal income tax benefit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Swiss tax attributes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,674)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(30.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other foreign tax attributes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(153)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,290&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;141&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="-6" id="f-2511" unitRef="usd">1158000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-1"
      decimals="INF"
      id="f-2512"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-7" decimals="-6" id="f-2513" unitRef="usd">1763000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-7"
      decimals="INF"
      id="f-2514"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-8" decimals="-6" id="f-2515" unitRef="usd">1426000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-8"
      decimals="INF"
      id="f-2516"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationDispositionOfBusiness contextRef="c-694" decimals="-6" id="f-2517" unitRef="usd">0</us-gaap:IncomeTaxReconciliationDispositionOfBusiness>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness
      contextRef="c-694"
      decimals="3"
      id="f-2518"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness>
    <us-gaap:IncomeTaxReconciliationDispositionOfBusiness contextRef="c-695" decimals="-6" id="f-2519" unitRef="usd">-37000000</us-gaap:IncomeTaxReconciliationDispositionOfBusiness>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness
      contextRef="c-695"
      decimals="3"
      id="f-2520"
      unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness>
    <us-gaap:IncomeTaxReconciliationDispositionOfBusiness contextRef="c-696" decimals="-6" id="f-2521" unitRef="usd">0</us-gaap:IncomeTaxReconciliationDispositionOfBusiness>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness
      contextRef="c-696"
      decimals="3"
      id="f-2522"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness>
    <us-gaap:IncomeTaxReconciliationDispositionOfBusiness contextRef="c-90" decimals="-6" id="f-2523" unitRef="usd">-213000000</us-gaap:IncomeTaxReconciliationDispositionOfBusiness>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness contextRef="c-90" decimals="3" id="f-2524" unitRef="number">-0.039</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness>
    <us-gaap:IncomeTaxReconciliationDispositionOfBusiness contextRef="c-697" decimals="-6" id="f-2525" unitRef="usd">0</us-gaap:IncomeTaxReconciliationDispositionOfBusiness>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness
      contextRef="c-697"
      decimals="3"
      id="f-2526"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness>
    <us-gaap:IncomeTaxReconciliationDispositionOfBusiness contextRef="c-698" decimals="-6" id="f-2527" unitRef="usd">0</us-gaap:IncomeTaxReconciliationDispositionOfBusiness>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness
      contextRef="c-698"
      decimals="3"
      id="f-2528"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness>
    <ci:IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings contextRef="c-1" decimals="-6" id="f-2529" unitRef="usd">173000000</ci:IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings>
    <ci:EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings contextRef="c-1" decimals="3" id="f-2530" unitRef="number">0.031</ci:EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings>
    <ci:IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings contextRef="c-7" decimals="-6" id="f-2531" unitRef="usd">96000000</ci:IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings>
    <ci:EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings contextRef="c-7" decimals="3" id="f-2532" unitRef="number">0.012</ci:EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings>
    <ci:IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings contextRef="c-8" decimals="-6" id="f-2533" unitRef="usd">33000000</ci:IncomeTaxReconciliationPermanentlyReinvestedForeignEarnings>
    <ci:EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings contextRef="c-8" decimals="3" id="f-2534" unitRef="number">0.005</ci:EffectiveIncomeTaxRateReconciliationPermanentlyReinvestedForeignEarnings>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="-6" id="f-2535" unitRef="usd">-39000000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-2536" unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-7" decimals="-6" id="f-2537" unitRef="usd">16000000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-7" decimals="3" id="f-2538" unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-8" decimals="-6" id="f-2539" unitRef="usd">-9000000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-8" decimals="3" id="f-2540" unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <ci:EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount contextRef="c-1" decimals="-6" id="f-2541" unitRef="usd">-1674000000</ci:EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount>
    <ci:EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent contextRef="c-1" decimals="3" id="f-2542" unitRef="number">-0.304</ci:EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent>
    <ci:EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount contextRef="c-7" decimals="-6" id="f-2543" unitRef="usd">0</ci:EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount>
    <ci:EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent contextRef="c-7" decimals="3" id="f-2544" unitRef="number">0</ci:EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent>
    <ci:EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount contextRef="c-8" decimals="-6" id="f-2545" unitRef="usd">0</ci:EffectiveIncomeTaxRateReconciliationSwissTaxAttributesAmount>
    <ci:EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent contextRef="c-8" decimals="3" id="f-2546" unitRef="number">0</ci:EffectiveIncomeTaxRateReconciliationSwissTaxAttributesPercent>
    <ci:EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount contextRef="c-1" decimals="-6" id="f-2547" unitRef="usd">-153000000</ci:EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount>
    <ci:EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent contextRef="c-1" decimals="3" id="f-2548" unitRef="number">-0.028</ci:EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent>
    <ci:EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount contextRef="c-7" decimals="-6" id="f-2549" unitRef="usd">0</ci:EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount>
    <ci:EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent contextRef="c-7" decimals="3" id="f-2550" unitRef="number">0</ci:EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent>
    <ci:EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount contextRef="c-8" decimals="-6" id="f-2551" unitRef="usd">0</ci:EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesAmount>
    <ci:EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent contextRef="c-8" decimals="3" id="f-2552" unitRef="number">0</ci:EffectiveIncomeTaxRateReconciliationOtherForeignTaxAttributesPercent>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="-6" id="f-2553" unitRef="usd">1290000000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="3" id="f-2554" unitRef="number">0.234</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-7" decimals="-6" id="f-2555" unitRef="usd">0</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-7" decimals="3" id="f-2556" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-8" decimals="-6" id="f-2557" unitRef="usd">0</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-8" decimals="3" id="f-2558" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c-1" decimals="-6" id="f-2559" unitRef="usd">-55000000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="c-1" decimals="3" id="f-2560" unitRef="number">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c-7" decimals="-6" id="f-2561" unitRef="usd">-31000000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="c-7" decimals="3" id="f-2562" unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c-8" decimals="-6" id="f-2563" unitRef="usd">-14000000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="c-8" decimals="3" id="f-2564" unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-2565" unitRef="usd">141000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-2566" unitRef="number">0.026</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-7" decimals="-6" id="f-2567" unitRef="usd">1615000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-7" decimals="3" id="f-2568" unitRef="number">0.192</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-8" decimals="-6" id="f-2569" unitRef="usd">1370000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-8" decimals="3" id="f-2570" unitRef="number">0.202</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-699"
      decimals="2"
      id="f-2571"
      unitRef="number">0.48</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-700"
      decimals="2"
      id="f-2572"
      unitRef="number">0.46</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-701"
      decimals="2"
      id="f-2573"
      unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
    <ci:DeferredTaxAssetsForeignTaxAttributes contextRef="c-12" decimals="-8" id="f-2574" unitRef="usd">1800000000</ci:DeferredTaxAssetsForeignTaxAttributes>
    <ci:DeferredTaxAssetsValuationAllowanceForeignTaxAttributes contextRef="c-12" decimals="-6" id="f-2575" unitRef="usd">772000000</ci:DeferredTaxAssetsValuationAllowanceForeignTaxAttributes>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="c-83" decimals="-6" id="f-2576" unitRef="usd">584000000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-83" decimals="-6" id="f-2577" unitRef="usd">584000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-2578">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred income tax assets and liabilities were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee and retiree benefit plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;217&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other insurance and contractholder liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;353&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;200&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred loss - sale of business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;584&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;244&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Policy acquisition expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized depreciation on investments and foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;81&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign tax attributes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,827&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;242&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax assets before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,787&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Valuation allowance for deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,498)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,289&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;371&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Acquisition-related basis differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,105&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,476&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net deferred income tax liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,786)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Deferred tax liabilities, net in the Consolidated Balance Sheets as of December&#160;31, 2023, excludes $1,055&#160;million reported in Other assets and $69&#160;million reported in liabilities of businesses held for sale.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <ci:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIncludingDisposalGroupsAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-2579" unitRef="usd">217000000</ci:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsIncludingDisposalGroupsAssetsHeldForSale>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c-13" decimals="-6" id="f-2580" unitRef="usd">189000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <ci:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilitiesIncludingDisposalGroupsAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-2581" unitRef="usd">353000000</ci:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilitiesIncludingDisposalGroupsAssetsHeldForSale>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities contextRef="c-13" decimals="-6" id="f-2582" unitRef="usd">278000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities>
    <ci:DeferredTaxAssetsOperatingLossCarryforwardsIncludingDisposalGroupsAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-2583" unitRef="usd">200000000</ci:DeferredTaxAssetsOperatingLossCarryforwardsIncludingDisposalGroupsAssetsHeldForSale>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-13" decimals="-6" id="f-2584" unitRef="usd">205000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="c-12" decimals="-6" id="f-2585" unitRef="usd">584000000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="c-13" decimals="-6" id="f-2586" unitRef="usd">0</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <ci:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOtherIncludingDisposalGroupsAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-2587" unitRef="usd">244000000</ci:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOtherIncludingDisposalGroupsAssetsHeldForSale>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther contextRef="c-13" decimals="-6" id="f-2588" unitRef="usd">265000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <ci:DeferredTaxAssetsPolicyAcquisitionExpensesIncludingDisposalGroupsAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-2589" unitRef="usd">39000000</ci:DeferredTaxAssetsPolicyAcquisitionExpensesIncludingDisposalGroupsAssetsHeldForSale>
    <ci:DeferredTaxAssetsPolicyAcquisitionExpenses contextRef="c-13" decimals="-6" id="f-2590" unitRef="usd">36000000</ci:DeferredTaxAssetsPolicyAcquisitionExpenses>
    <ci:DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTransactionIncludingDisposalGroupsAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-2591" unitRef="usd">81000000</ci:DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTransactionIncludingDisposalGroupsAssetsHeldForSale>
    <ci:DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTranslation contextRef="c-13" decimals="-6" id="f-2592" unitRef="usd">159000000</ci:DeferredTaxAssetsUnrealizedLossesOnInvestmentsAndForeignCurrencyTranslation>
    <ci:DeferredTaxAssetsForeignTaxAttributesIncludingDisposalGroupsAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-2593" unitRef="usd">1827000000</ci:DeferredTaxAssetsForeignTaxAttributesIncludingDisposalGroupsAssetsHeldForSale>
    <ci:DeferredTaxAssetsForeignTaxAttributes contextRef="c-13" decimals="-6" id="f-2594" unitRef="usd">0</ci:DeferredTaxAssetsForeignTaxAttributes>
    <ci:DeferredTaxAssetsOtherIncludingDisposalGroupsAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-2595" unitRef="usd">242000000</ci:DeferredTaxAssetsOtherIncludingDisposalGroupsAssetsHeldForSale>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-13" decimals="-6" id="f-2596" unitRef="usd">190000000</us-gaap:DeferredTaxAssetsOther>
    <ci:DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-2597" unitRef="usd">3787000000</ci:DeferredTaxAssetsGrossIncludingDisposalGroupsAssetsHeldForSale>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-13" decimals="-6" id="f-2598" unitRef="usd">1322000000</us-gaap:DeferredTaxAssetsGross>
    <ci:DeferredTaxAssetsValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-2599" unitRef="usd">1498000000</ci:DeferredTaxAssetsValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-13" decimals="-6" id="f-2600" unitRef="usd">208000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <ci:DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-2601" unitRef="usd">2289000000</ci:DeferredTaxAssetsNetOfValuationAllowanceIncludingDisposalGroupsAssetsHeldForSale>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-13" decimals="-6" id="f-2602" unitRef="usd">1114000000</us-gaap:DeferredTaxAssetsNet>
    <ci:DeferredTaxLiabilitiesPropertyPlantAndEquipmentIncludingDisposalGroupsAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-2603" unitRef="usd">371000000</ci:DeferredTaxLiabilitiesPropertyPlantAndEquipmentIncludingDisposalGroupsAssetsHeldForSale>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-13" decimals="-6" id="f-2604" unitRef="usd">512000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <ci:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIncludingDisposalGroupsAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-2605" unitRef="usd">8105000000</ci:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIncludingDisposalGroupsAssetsHeldForSale>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets contextRef="c-13" decimals="-6" id="f-2606" unitRef="usd">8347000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets>
    <ci:DeferredTaxLiabilitiesOtherIncludingDisposalGroupsAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-2607" unitRef="usd">0</ci:DeferredTaxLiabilitiesOtherIncludingDisposalGroupsAssetsHeldForSale>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-13" decimals="-6" id="f-2608" unitRef="usd">41000000</us-gaap:DeferredTaxLiabilitiesOther>
    <ci:DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale contextRef="c-12" decimals="-6" id="f-2609" unitRef="usd">8476000000</ci:DeferredTaxLiabilitiesGrossIncludingDisposalGroupsAssetsHeldForSale>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-13" decimals="-6" id="f-2610" unitRef="usd">8900000000</us-gaap:DeferredIncomeTaxLiabilities>
    <ci:DeferredTaxLiabilitiesNetIncludingDisposalGroup contextRef="c-12" decimals="-6" id="f-2611" unitRef="usd">6187000000</ci:DeferredTaxLiabilitiesNetIncludingDisposalGroup>
    <us-gaap:DeferredTaxLiabilities contextRef="c-13" decimals="-6" id="f-2612" unitRef="usd">7786000000</us-gaap:DeferredTaxLiabilities>
    <ci:DeferredTaxAssetsGrossInOtherAssetsNoncurrent contextRef="c-12" decimals="-6" id="f-2613" unitRef="usd">1055000000</ci:DeferredTaxAssetsGrossInOtherAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities contextRef="c-83" decimals="-6" id="f-2614" unitRef="usd">69000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities>
    <ci:DeferredTaxAssetsInvestmentsSubjectToFederalCapitalLossUtilizationRules contextRef="c-12" decimals="-6" id="f-2615" unitRef="usd">218000000</ci:DeferredTaxAssetsInvestmentsSubjectToFederalCapitalLossUtilizationRules>
    <ci:DeferredTaxAssetsForeignTaxAttributes contextRef="c-12" decimals="-8" id="f-2616" unitRef="usd">1800000000</ci:DeferredTaxAssetsForeignTaxAttributes>
    <ci:DeferredTaxAssetsValuationAllowanceForeignTaxAttributes contextRef="c-12" decimals="-6" id="f-2617" unitRef="usd">772000000</ci:DeferredTaxAssetsValuationAllowanceForeignTaxAttributes>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="c-83" decimals="-6" id="f-2618" unitRef="usd">584000000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-83" decimals="-6" id="f-2619" unitRef="usd">584000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c-1" id="f-2620">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Reconciliations of unrecognized tax benefits were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at January 1,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,343&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Decrease) / Increase due to prior year positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Increase due to current year positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;107&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reduction related to settlements with taxing authorities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reduction related to lapse of applicable statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-13" decimals="-6" id="f-2621" unitRef="usd">1343000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-47" decimals="-6" id="f-2622" unitRef="usd">1230000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-33" decimals="-6" id="f-2623" unitRef="usd">1210000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-6" id="f-2624" unitRef="usd">26000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-7" decimals="-6" id="f-2625" unitRef="usd">8000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-8" decimals="-6" id="f-2626" unitRef="usd">21000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-6" id="f-2627" unitRef="usd">107000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-7" decimals="-6" id="f-2628" unitRef="usd">137000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-8" decimals="-6" id="f-2629" unitRef="usd">31000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c-1" decimals="-6" id="f-2630" unitRef="usd">13000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c-7" decimals="-6" id="f-2631" unitRef="usd">4000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c-8" decimals="-6" id="f-2632" unitRef="usd">15000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-1" decimals="-6" id="f-2633" unitRef="usd">12000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-7" decimals="-6" id="f-2634" unitRef="usd">28000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-8" decimals="-6" id="f-2635" unitRef="usd">17000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-12" decimals="-6" id="f-2636" unitRef="usd">1399000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-13" decimals="-6" id="f-2637" unitRef="usd">1343000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-47" decimals="-6" id="f-2638" unitRef="usd">1230000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued contextRef="c-12" decimals="-6" id="f-2639" unitRef="usd">220000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued contextRef="c-13" decimals="-6" id="f-2640" unitRef="usd">176000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued contextRef="c-47" decimals="-6" id="f-2641" unitRef="usd">148000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-2642">&lt;div style="margin-bottom:10pt"&gt;&lt;span id="i27908228960e40488ce1e12ef7d7a82d_2913"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Note 24 &#x2013; Contingencies and Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company, through its subsidiaries, is contingently liable for various guarantees provided in the ordinary course of business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;A.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline"&gt;Financial Guarantees: Retiree and Life Insurance Benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company guarantees that separate account assets will be sufficient to pay certain life insurance or retiree benefits. For the majority of these benefits, the sponsoring employers are primarily responsible for ensuring that assets are sufficient to pay these benefits and are required to maintain assets that exceed a certain percentage of benefit obligations. If employers fail to do so, the Company or an affiliate of the buyer of the retirement benefits business has the right to redirect the management of the related assets to provide for benefit payments. As of December&#160;31, 2023, employers maintained assets that generally exceeded the benefit obligations under these arrangements of approximately $420 million. An additional liability is established if management believes that the Company will be required to make payments under the guarantees; there were no additional liabilities required for these guarantees, net of reinsurance, as of December&#160;31, 2023. Separate account assets supporting these guarantees are classified in Levels 1 and 2 of the GAAP fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company does not expect that these financial guarantees will have a material effect on the Company's consolidated results of operations, liquidity or financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;B.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline"&gt;Certain Other Guarantees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company had indemnification obligations as of December&#160;31, 2023 in connection with acquisition and disposition transactions. These indemnification obligations are triggered by the breach of representations or covenants provided by the Company, such as representations for the presentation of financial statements, filing of tax returns, compliance with laws or regulations or identification of outstanding litigation. These obligations are typically subject to various time limitations, defined by the contract or by operation of law, such as statutes of limitation. In some cases, the maximum potential amount due is subject to contractual limitations based on a stated dollar amount or a percentage of the transaction purchase price, while in other cases limitations are not specified or applicable. The Company does not believe that it is possible to determine the maximum potential amount due under these obligations because not all amounts due under these indemnification obligations are subject to limitation. There were no liabilities for these indemnification obligations as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;C.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline"&gt;Guaranty Fund Assessments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company operates in a regulatory environment that may require its participation in assessments under state insurance guaranty association laws. The Company's exposure to assessments for certain obligations of insolvent insurance companies to policyholders and claimants is based on its share of business written in the relevant jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;There were no material charges or credits resulting from existing or new guaranty fund assessments for the year ended December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline"&gt;Legal and Regulatory Matters&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company is routinely involved in numerous claims, lawsuits, regulatory inquiries and audits, government investigations, including under the federal False Claims Act and state false claims acts initiated by a government investigating body or by a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; relator's filing of a complaint under court seal, and other legal matters arising, for the most part, in the ordinary course of managing a global health company. Additionally, the Company has received and is cooperating with subpoenas or similar processes from various governmental agencies requesting information, all arising in the normal course of its business. Disputed tax matters arising from audits by the Internal Revenue Service or other state and foreign jurisdictions, including those resulting in litigation, are accounted for under GAAP guidance for uncertain tax positions, as described in Note 23.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Pending litigation and legal or regulatory matters that the Company has identified with a reasonably possible material loss and certain other material litigation matters are described below. For those matters that the Company has identified with a reasonably possible material loss, the Company provides disclosure in the aggregate of accruals and range of loss, or a statement that such information cannot be estimated. The Company's accrual for the matter discussed below under "Litigation Matters" is not material. Due to numerous uncertain factors presented in this case, it is not possible to estimate an aggregate range of loss (if any) for this matter at this time. In light of the uncertainties involved in this matter, there is no assurance that its ultimate resolution will not exceed the amount currently accrued by the Company. An adverse outcome in this matter could be material to the Company's results of operations, financial condition or liquidity for any particular period. The outcomes of lawsuits are inherently unpredictable and we may be unsuccessful in this ongoing litigation matter or any future claims or litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Litigation Matters&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Express Scripts Litigation with Elevance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. In March 2016, Elevance filed a lawsuit in the United States District Court for the Southern District of New York alleging various breach of contract claims against Express Scripts relating to the parties' rights and obligations under the periodic pricing review section of the pharmacy benefit management agreement between the parties including allegations that Express Scripts failed to negotiate new pricing concessions in good faith, as well as various alleged service issues. Elevance also requested that the court enter declaratory judgment that Express Scripts is required to provide Elevance competitive benchmark pricing, that Elevance can terminate the agreement and that Express Scripts is required to provide Elevance with post-termination services at competitive benchmark pricing for one year following any termination by Elevance. Elevance claimed it is entitled to $13 billion in additional pricing concessions over the remaining term of the agreement, as well as $1.8 billion for one year following any contract termination by Elevance and $150 million damages for service issues ("Elevance's Allegations"). On April 19, 2016, in response to Elevance's complaint, Express Scripts filed its answer denying Elevance's Allegations in their entirety and asserting affirmative defenses and counterclaims against Elevance. The court subsequently granted Elevance's motion to dismiss two of six counts of Express Scripts' amended counterclaims. Express Scripts filed its Motion for Summary Judgment on August 27, 2021. Elevance completed filing of its Response to Express Scripts' Motion for Summary Judgment on October 16, 2021. Express Scripts filed its Reply in Support of its Motion for Summary Judgment on November 19, 2021. On March 31, 2022, the court granted summary judgment in favor of Express Scripts on all of Elevance's pricing claims for damages totaling $14.8 billion and on most of Elevance's claims relating to service issues. Elevance's only remaining service claims relate to the review or processing of prior authorizations, with alleged damages over $100&#160;million. On November 1, 2023, the parties signed a settlement agreement pursuant to which Express Scripts agreed to resolve the service-related claims. The settlement agreement is not an admission of liability or fault by Express Scripts, the Company or its subsidiaries. Following the settlement, Elevance retains the right to appeal the pricing-related claims that were previously dismissed by the court and Express Scripts retains the ability to reassert its own pricing-related claims in the event any appeal by Elevance is successful. Elevance filed its Notice of Appeal of its pricing-related claims on December 12, 2023. Elevance&#x2019;s opening appellate brief is due March 25, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies contextRef="c-1" id="f-2643">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline"&gt;Financial Guarantees: Retiree and Life Insurance Benefits&lt;/span&gt;The Company guarantees that separate account assets will be sufficient to pay certain life insurance or retiree benefits. For the majority of these benefits, the sponsoring employers are primarily responsible for ensuring that assets are sufficient to pay these benefits and are required to maintain assets that exceed a certain percentage of benefit obligations. If employers fail to do so, the Company or an affiliate of the buyer of the retirement benefits business has the right to redirect the management of the related assets to provide for benefit payments.An additional liability is established if management believes that the Company will be required to make payments under the guarantees;Separate account assets supporting these guarantees are classified in Levels 1 and 2 of the GAAP fair value hierarchy.&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.84pt;text-decoration:underline"&gt;Certain Other Guarantees&lt;/span&gt;The Company had indemnification obligations as of December&#160;31, 2023 in connection with acquisition and disposition transactions. These indemnification obligations are triggered by the breach of representations or covenants provided by the Company, such as representations for the presentation of financial statements, filing of tax returns, compliance with laws or regulations or identification of outstanding litigation. These obligations are typically subject to various time limitations, defined by the contract or by operation of law, such as statutes of limitation. In some cases, the maximum potential amount due is subject to contractual limitations based on a stated dollar amount or a percentage of the transaction purchase price, while in other cases limitations are not specified or applicable. The Company does not believe that it is possible to determine the maximum potential amount due under these obligations because not all amounts due under these indemnification obligations are subject to limitation.&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:8.28pt;text-decoration:underline"&gt;Guaranty Fund Assessments&lt;/span&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company operates in a regulatory environment that may require its participation in assessments under state insurance guaranty association laws. The Company's exposure to assessments for certain obligations of insolvent insurance companies to policyholders and claimants is based on its share of business written in the relevant jurisdictions.&lt;/span&gt;&lt;/div&gt;</us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies>
    <us-gaap:GuaranteeObligationsLiquidationProceeds contextRef="c-702" decimals="-7" id="f-2644" unitRef="usd">420000000</us-gaap:GuaranteeObligationsLiquidationProceeds>
    <us-gaap:GuaranteeObligationsMaximumExposure contextRef="c-703" decimals="-7" id="f-2645" unitRef="usd">420000000</us-gaap:GuaranteeObligationsMaximumExposure>
    <us-gaap:GuaranteeObligationsCurrentCarryingValue contextRef="c-703" decimals="INF" id="f-2646" unitRef="usd">0</us-gaap:GuaranteeObligationsCurrentCarryingValue>
    <us-gaap:GuaranteeObligationsCurrentCarryingValue contextRef="c-704" decimals="INF" id="f-2647" unitRef="usd">0</us-gaap:GuaranteeObligationsCurrentCarryingValue>
    <us-gaap:LossContingencyDamagesSoughtValue contextRef="c-705" decimals="-9" id="f-2648" unitRef="usd">13000000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue contextRef="c-706" decimals="-8" id="f-2649" unitRef="usd">1800000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue contextRef="c-707" decimals="-6" id="f-2650" unitRef="usd">150000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyClaimsDismissedNumber
      contextRef="c-708"
      decimals="INF"
      id="f-2651"
      unitRef="claim">2</us-gaap:LossContingencyClaimsDismissedNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="c-709"
      decimals="INF"
      id="f-2652"
      unitRef="claim">6</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyDamagesSoughtValue contextRef="c-710" decimals="-8" id="f-2653" unitRef="usd">14800000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue contextRef="c-711" decimals="-6" id="f-2654" unitRef="usd">100000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-2657">&lt;div style="margin-bottom:10pt"&gt;&lt;span id="ia1cd7ace6b8e4804a5b34bf3f9213da6_446"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Note 25 &#x2013; Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;See Note 1 to the Consolidated Financial Statements for a description of our segments. A description of our basis for reporting segment operating results is outlined below. Intersegment revenues primarily reflect pharmacy and care services transactions between the Evernorth Health Services and Cigna Healthcare segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company uses "pre-tax adjusted income (loss) from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management believes these metrics best reflect the underlying results of business operations and permit analysis of trends in underlying revenue, expenses and profitability. We define pre-tax adjusted income from operations as income before income taxes excluding pre-tax income (loss) attributable to noncontrolling interests, net realized investment results, amortization of acquired intangible assets, and special items. The Cigna Group's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;that management believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future underlying performance of the business. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company does not report total assets by segment because this is not a metric used to allocate resources or evaluate segment performance.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents the special items charges (benefits) recorded by the Company, as well as the respective financial statement line items impacted: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.378%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="33" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pre-tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;After-tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pre-tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;After-tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pre-tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;After-tax&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss (gain) on sale of businesses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,499&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,429&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Charge for organizational efficiency plan&lt;br/&gt;&#160;(Selling, general and administrative expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;252&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;193&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Charges (benefits) associated with litigation matters&lt;br/&gt;&#160;(Selling, general and administrative expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;201&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;171&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Integration and transaction-related costs&lt;br/&gt;&#160;(Selling, general and administrative expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax (benefits), net&lt;br/&gt;&#160;(Income taxes, less amount attributable to noncontrolling interests)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,071)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Debt extinguishment costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total impact from special items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,997&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;757&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,533)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Effective January 1, 2023, we adopted amended accounting guidance for long-duration insurance contracts. See Note 2 to the Consolidated Financial Statements for further information. Prior period summarized segment information has been retrospectively adjusted to conform to this new basis of accounting. Summarized segment financial information was as follows:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.349%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Evernorth Health Services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cigna Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corporate and Eliminations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;147,588&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;46,219&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;291&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;194,099&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,670&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,332&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(10,002)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net investment income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;241&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;597&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;305&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,166&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;153,499&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;51,148&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;596&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(9,978)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;195,265&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Net realized investment results from certain equity method investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;57&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;57&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjusted revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;153,499&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;51,205&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;596&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(9,978)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;195,322&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,438&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;569&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,035&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,768&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,664&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;76&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,995)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,513&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pre-tax adjustments to reconcile to adjusted income from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Income) attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net realized investment losses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;133&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;135&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of acquired intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,774&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,819&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Special items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss on sale of businesses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,481&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,499&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Charge for organizational efficiency plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;252&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;252&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Charges associated with litigation matters&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;44&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;157&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;201&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Integration and transaction-related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pre-tax adjusted income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,442&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,478&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;96&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,318&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Evernorth Health Services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cigna Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corporate and Eliminations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues from external customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;179,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net investment income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Net realized investment results from certain equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjusted revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,595)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pre-tax adjustments to reconcile to adjusted income from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Income) attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net realized investment losses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of acquired intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Special items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Gain) on sale of businesses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Charge for organizational efficiency plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Benefits) associated with litigation matters&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Integration and transaction-related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pre-tax adjusted income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,466)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Includes the Company's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.046%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Evernorth Health Services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cigna Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corporate and Eliminations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;172,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,474)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net investment income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,475)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net realized investment results from certain equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjusted revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,475)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,790)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pre-tax adjustments to reconcile to adjusted income from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Income) attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net realized investment losses (gains) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of acquired intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Special items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Charge for organizational efficiency plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Benefits) associated with litigation matters&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Integration and transaction-related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Debt extinguishment costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pre-tax adjusted income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; Includes the Company's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span id="i447ccaf65a4944e2ab470d4dcddafa7a_953"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Revenue from external customers includes Pharmacy revenues, Premiums and Fees and other revenues. Prior period amounts have been retrospectively adjusted to reflect adoption of amended accounting guidance for long-duration insurance contracts (as discussed in Note 2 to the Consolidated Financial Statements) and to reflect the merger of the U.S. Commercial and U.S. Government operating segments into the U.S. Healthcare operating segment (as discussed in Note 1 to the Consolidated Financial Statements). The following table presents these revenues by product, premium and service type:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Products (Pharmacy revenues) (ASC 606)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Network revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;67,514&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Home delivery and specialty revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;65,732&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,047&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intercompany eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total pharmacy revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;137,243&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Insurance premiums (ASC 944)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cigna Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;U.S. Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employer insured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16,490&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,771&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stop loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,143&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Individual and Family Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,088&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,095&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;40,587&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,295&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Cigna Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;43,882&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Divested International businesses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;281&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intercompany eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;74&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;44,237&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Services (Fees) (ASC 606)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Evernorth Health Services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,866&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cigna Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,566&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;210&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intercompany eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,583)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,067)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total fees and other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12,619&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;194,099&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;179,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;172,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;U.S. and foreign revenues from external customers are shown below. The Company's foreign revenues are generated by its foreign operating entities. In the periods shown, no single foreign country contributed more than 2% of consolidated revenues from external customers.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;189,840&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;166,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign countries &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,259&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;194,099&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;179,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;172,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; The divested International businesses as described in Note 5 comprised of $1.6 billion and $3.2 billion in 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;Revenues from U.S. Federal Government agencies, under a number of contracts, were 15% of consolidated revenues in 2023 and 14% in both 2022 and 2021. These amounts were reported in the Evernorth Health Services and Cigna Healthcare segments.</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-2658">Intersegment revenues primarily reflect pharmacy and care services transactions between the Evernorth Health Services and Cigna Healthcare segments.&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company uses "pre-tax adjusted income (loss) from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management believes these metrics best reflect the underlying results of business operations and permit analysis of trends in underlying revenue, expenses and profitability. We define pre-tax adjusted income from operations as income before income taxes excluding pre-tax income (loss) attributable to noncontrolling interests, net realized investment results, amortization of acquired intangible assets, and special items. The Cigna Group's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;that management believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. &lt;/span&gt;&lt;/div&gt;The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future underlying performance of the business.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <ci:ScheduleOfSpecialItemsTableTextBlock contextRef="c-1" id="f-2659">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents the special items charges (benefits) recorded by the Company, as well as the respective financial statement line items impacted: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.378%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="33" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pre-tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;After-tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pre-tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;After-tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pre-tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;After-tax&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss (gain) on sale of businesses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,499&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,429&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Charge for organizational efficiency plan&lt;br/&gt;&#160;(Selling, general and administrative expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;252&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;193&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Charges (benefits) associated with litigation matters&lt;br/&gt;&#160;(Selling, general and administrative expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;201&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;171&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Integration and transaction-related costs&lt;br/&gt;&#160;(Selling, general and administrative expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax (benefits), net&lt;br/&gt;&#160;(Income taxes, less amount attributable to noncontrolling interests)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,071)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Debt extinguishment costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total impact from special items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,997&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;757&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,533)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ci:ScheduleOfSpecialItemsTableTextBlock>
    <ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes contextRef="c-1" decimals="-6" id="f-2660" unitRef="usd">-1499000000</ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes>
    <ci:SpecialItemGainLossOnSaleOfBusinessNetOfTax contextRef="c-1" decimals="-6" id="f-2661" unitRef="usd">-1429000000</ci:SpecialItemGainLossOnSaleOfBusinessNetOfTax>
    <ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes contextRef="c-7" decimals="-6" id="f-2662" unitRef="usd">1662000000</ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes>
    <ci:SpecialItemGainLossOnSaleOfBusinessNetOfTax contextRef="c-7" decimals="-6" id="f-2663" unitRef="usd">1332000000</ci:SpecialItemGainLossOnSaleOfBusinessNetOfTax>
    <ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes contextRef="c-8" decimals="-6" id="f-2664" unitRef="usd">0</ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes>
    <ci:SpecialItemGainLossOnSaleOfBusinessNetOfTax contextRef="c-8" decimals="-6" id="f-2665" unitRef="usd">0</ci:SpecialItemGainLossOnSaleOfBusinessNetOfTax>
    <us-gaap:RestructuringCharges contextRef="c-1" decimals="-6" id="f-2666" unitRef="usd">252000000</us-gaap:RestructuringCharges>
    <ci:RestructuringChargesNetOfTaxExpense contextRef="c-1" decimals="-6" id="f-2667" unitRef="usd">193000000</ci:RestructuringChargesNetOfTaxExpense>
    <us-gaap:RestructuringCharges contextRef="c-7" decimals="-6" id="f-2668" unitRef="usd">22000000</us-gaap:RestructuringCharges>
    <ci:RestructuringChargesNetOfTaxExpense contextRef="c-7" decimals="-6" id="f-2669" unitRef="usd">17000000</ci:RestructuringChargesNetOfTaxExpense>
    <us-gaap:RestructuringCharges contextRef="c-8" decimals="-6" id="f-2670" unitRef="usd">168000000</us-gaap:RestructuringCharges>
    <ci:RestructuringChargesNetOfTaxExpense contextRef="c-8" decimals="-6" id="f-2671" unitRef="usd">119000000</ci:RestructuringChargesNetOfTaxExpense>
    <ci:SpecialItemChargeBenefitBeforeTaxLitigation contextRef="c-1" decimals="-6" id="f-2672" unitRef="usd">201000000</ci:SpecialItemChargeBenefitBeforeTaxLitigation>
    <ci:SpecialItemChargeBenefitAfterTaxLitigation contextRef="c-1" decimals="-6" id="f-2673" unitRef="usd">171000000</ci:SpecialItemChargeBenefitAfterTaxLitigation>
    <ci:SpecialItemChargeBenefitBeforeTaxLitigation contextRef="c-7" decimals="-6" id="f-2674" unitRef="usd">-28000000</ci:SpecialItemChargeBenefitBeforeTaxLitigation>
    <ci:SpecialItemChargeBenefitAfterTaxLitigation contextRef="c-7" decimals="-6" id="f-2675" unitRef="usd">-20000000</ci:SpecialItemChargeBenefitAfterTaxLitigation>
    <ci:SpecialItemChargeBenefitBeforeTaxLitigation contextRef="c-8" decimals="-6" id="f-2676" unitRef="usd">-27000000</ci:SpecialItemChargeBenefitBeforeTaxLitigation>
    <ci:SpecialItemChargeBenefitAfterTaxLitigation contextRef="c-8" decimals="-6" id="f-2677" unitRef="usd">-21000000</ci:SpecialItemChargeBenefitAfterTaxLitigation>
    <ci:TransactionRelatedCosts contextRef="c-1" decimals="-6" id="f-2678" unitRef="usd">45000000</ci:TransactionRelatedCosts>
    <ci:TransactionRelatedCostsAfterTax contextRef="c-1" decimals="-6" id="f-2679" unitRef="usd">35000000</ci:TransactionRelatedCostsAfterTax>
    <ci:TransactionRelatedCosts contextRef="c-7" decimals="-6" id="f-2680" unitRef="usd">135000000</ci:TransactionRelatedCosts>
    <ci:TransactionRelatedCostsAfterTax contextRef="c-7" decimals="-6" id="f-2681" unitRef="usd">103000000</ci:TransactionRelatedCostsAfterTax>
    <ci:TransactionRelatedCosts contextRef="c-8" decimals="-6" id="f-2682" unitRef="usd">169000000</ci:TransactionRelatedCosts>
    <ci:TransactionRelatedCostsAfterTax contextRef="c-8" decimals="-6" id="f-2683" unitRef="usd">71000000</ci:TransactionRelatedCostsAfterTax>
    <ci:SpecialItemChargeBenefitTaxMatters contextRef="c-1" decimals="-6" id="f-2684" unitRef="usd">0</ci:SpecialItemChargeBenefitTaxMatters>
    <ci:SpecialItemChargeBenefitTaxMattersAfterTax contextRef="c-1" decimals="-6" id="f-2685" unitRef="usd">-1071000000</ci:SpecialItemChargeBenefitTaxMattersAfterTax>
    <ci:SpecialItemChargeBenefitTaxMatters contextRef="c-7" decimals="-6" id="f-2686" unitRef="usd">0</ci:SpecialItemChargeBenefitTaxMatters>
    <ci:SpecialItemChargeBenefitTaxMattersAfterTax contextRef="c-7" decimals="-6" id="f-2687" unitRef="usd">0</ci:SpecialItemChargeBenefitTaxMattersAfterTax>
    <ci:SpecialItemChargeBenefitTaxMatters contextRef="c-8" decimals="-6" id="f-2688" unitRef="usd">0</ci:SpecialItemChargeBenefitTaxMatters>
    <ci:SpecialItemChargeBenefitTaxMattersAfterTax contextRef="c-8" decimals="-6" id="f-2689" unitRef="usd">0</ci:SpecialItemChargeBenefitTaxMattersAfterTax>
    <ci:SpecialItemChargesDebtExtinguishmentCostsBeforeTax contextRef="c-1" decimals="-6" id="f-2690" unitRef="usd">0</ci:SpecialItemChargesDebtExtinguishmentCostsBeforeTax>
    <ci:SpecialItemChargesDebtExtinguishmentCostsNetOfTax contextRef="c-1" decimals="-6" id="f-2691" unitRef="usd">0</ci:SpecialItemChargesDebtExtinguishmentCostsNetOfTax>
    <ci:SpecialItemChargesDebtExtinguishmentCostsBeforeTax contextRef="c-7" decimals="-6" id="f-2692" unitRef="usd">0</ci:SpecialItemChargesDebtExtinguishmentCostsBeforeTax>
    <ci:SpecialItemChargesDebtExtinguishmentCostsNetOfTax contextRef="c-7" decimals="-6" id="f-2693" unitRef="usd">0</ci:SpecialItemChargesDebtExtinguishmentCostsNetOfTax>
    <ci:SpecialItemChargesDebtExtinguishmentCostsBeforeTax contextRef="c-8" decimals="-6" id="f-2694" unitRef="usd">141000000</ci:SpecialItemChargesDebtExtinguishmentCostsBeforeTax>
    <ci:SpecialItemChargesDebtExtinguishmentCostsNetOfTax contextRef="c-8" decimals="-6" id="f-2695" unitRef="usd">110000000</ci:SpecialItemChargesDebtExtinguishmentCostsNetOfTax>
    <ci:SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity contextRef="c-1" decimals="-6" id="f-2696" unitRef="usd">-1997000000</ci:SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity>
    <ci:SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity contextRef="c-1" decimals="-6" id="f-2697" unitRef="usd">-757000000</ci:SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity>
    <ci:SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity contextRef="c-7" decimals="-6" id="f-2698" unitRef="usd">1533000000</ci:SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity>
    <ci:SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity contextRef="c-7" decimals="-6" id="f-2699" unitRef="usd">1232000000</ci:SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity>
    <ci:SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity contextRef="c-8" decimals="-6" id="f-2700" unitRef="usd">-451000000</ci:SpecialItemGainOrLossBeforeTaxAttributableToReportngEntity>
    <ci:SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity contextRef="c-8" decimals="-6" id="f-2701" unitRef="usd">-279000000</ci:SpecialItemGainOrLossNetOfTaxAttributableToReportngEntity>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-2702">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Effective January 1, 2023, we adopted amended accounting guidance for long-duration insurance contracts. See Note 2 to the Consolidated Financial Statements for further information. Prior period summarized segment information has been retrospectively adjusted to conform to this new basis of accounting. Summarized segment financial information was as follows:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.349%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Evernorth Health Services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cigna Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corporate and Eliminations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;147,588&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;46,219&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;291&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;194,099&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,670&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,332&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(10,002)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net investment income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;241&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;597&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;305&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,166&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;153,499&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;51,148&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;596&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(9,978)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;195,265&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Net realized investment results from certain equity method investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;57&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;57&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjusted revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;153,499&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;51,205&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;596&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(9,978)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;195,322&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,438&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;569&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,035&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,768&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,664&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;76&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,995)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,513&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pre-tax adjustments to reconcile to adjusted income from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Income) attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net realized investment losses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;133&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;135&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of acquired intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,774&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,819&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Special items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss on sale of businesses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,481&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,499&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Charge for organizational efficiency plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;252&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;252&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Charges associated with litigation matters&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;44&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;157&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;201&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Integration and transaction-related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pre-tax adjusted income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,442&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,478&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;96&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,318&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Evernorth Health Services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cigna Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corporate and Eliminations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues from external customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;179,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net investment income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Net realized investment results from certain equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjusted revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,595)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pre-tax adjustments to reconcile to adjusted income from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Income) attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net realized investment losses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of acquired intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Special items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Gain) on sale of businesses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Charge for organizational efficiency plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Benefits) associated with litigation matters&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Integration and transaction-related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pre-tax adjusted income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,466)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Includes the Company's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.046%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Evernorth Health Services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cigna Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corporate and Eliminations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;172,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,474)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net investment income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,475)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net realized investment results from certain equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjusted revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,475)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,790)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pre-tax adjustments to reconcile to adjusted income from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Income) attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net realized investment losses (gains) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of acquired intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Special items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Charge for organizational efficiency plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Benefits) associated with litigation matters&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Integration and transaction-related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Debt extinguishment costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pre-tax adjusted income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt; Includes the Company's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting.</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <ci:NonInvestmentRevenue contextRef="c-659" decimals="-6" id="f-2703" unitRef="usd">147588000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-223" decimals="-6" id="f-2704" unitRef="usd">46219000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-660" decimals="-6" id="f-2705" unitRef="usd">291000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-714" decimals="-6" id="f-2706" unitRef="usd">1000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-1" decimals="-6" id="f-2707" unitRef="usd">194099000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-715" decimals="-6" id="f-2708" unitRef="usd">-5670000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-716" decimals="-6" id="f-2709" unitRef="usd">-4332000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-717" decimals="-6" id="f-2710" unitRef="usd">0</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-718" decimals="-6" id="f-2711" unitRef="usd">-10002000000</ci:NonInvestmentRevenue>
    <us-gaap:NetInvestmentIncome contextRef="c-719" decimals="-6" id="f-2712" unitRef="usd">241000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome contextRef="c-720" decimals="-6" id="f-2713" unitRef="usd">597000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome contextRef="c-721" decimals="-6" id="f-2714" unitRef="usd">305000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome contextRef="c-722" decimals="-6" id="f-2715" unitRef="usd">23000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome contextRef="c-1" decimals="-6" id="f-2716" unitRef="usd">1166000000</us-gaap:NetInvestmentIncome>
    <us-gaap:Revenues contextRef="c-719" decimals="-6" id="f-2717" unitRef="usd">153499000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-720" decimals="-6" id="f-2718" unitRef="usd">51148000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-721" decimals="-6" id="f-2719" unitRef="usd">596000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-722" decimals="-6" id="f-2720" unitRef="usd">-9978000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-1" decimals="-6" id="f-2721" unitRef="usd">195265000000</us-gaap:Revenues>
    <ci:RealizedInvestmentGainsLossesEquityMethodInvestments contextRef="c-719" decimals="-6" id="f-2722" unitRef="usd">0</ci:RealizedInvestmentGainsLossesEquityMethodInvestments>
    <ci:RealizedInvestmentGainsLossesEquityMethodInvestments contextRef="c-720" decimals="-6" id="f-2723" unitRef="usd">-57000000</ci:RealizedInvestmentGainsLossesEquityMethodInvestments>
    <ci:RealizedInvestmentGainsLossesEquityMethodInvestments contextRef="c-721" decimals="-6" id="f-2724" unitRef="usd">0</ci:RealizedInvestmentGainsLossesEquityMethodInvestments>
    <ci:RealizedInvestmentGainsLossesEquityMethodInvestments contextRef="c-722" decimals="-6" id="f-2725" unitRef="usd">0</ci:RealizedInvestmentGainsLossesEquityMethodInvestments>
    <ci:RealizedInvestmentGainsLossesEquityMethodInvestments contextRef="c-1" decimals="-6" id="f-2726" unitRef="usd">-57000000</ci:RealizedInvestmentGainsLossesEquityMethodInvestments>
    <ci:SegmentRevenues contextRef="c-719" decimals="-6" id="f-2727" unitRef="usd">153499000000</ci:SegmentRevenues>
    <ci:SegmentRevenues contextRef="c-720" decimals="-6" id="f-2728" unitRef="usd">51205000000</ci:SegmentRevenues>
    <ci:SegmentRevenues contextRef="c-721" decimals="-6" id="f-2729" unitRef="usd">596000000</ci:SegmentRevenues>
    <ci:SegmentRevenues contextRef="c-722" decimals="-6" id="f-2730" unitRef="usd">-9978000000</ci:SegmentRevenues>
    <ci:SegmentRevenues contextRef="c-1" decimals="-6" id="f-2731" unitRef="usd">195322000000</ci:SegmentRevenues>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-719" decimals="-6" id="f-2732" unitRef="usd">2438000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-720" decimals="-6" id="f-2733" unitRef="usd">569000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-721" decimals="-6" id="f-2734" unitRef="usd">3000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-722" decimals="-6" id="f-2735" unitRef="usd">25000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-6" id="f-2736" unitRef="usd">3035000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-719" decimals="-6" id="f-2737" unitRef="usd">4768000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-720" decimals="-6" id="f-2738" unitRef="usd">2664000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-721" decimals="-6" id="f-2739" unitRef="usd">76000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-722" decimals="-6" id="f-2740" unitRef="usd">-1995000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-2741" unitRef="usd">5513000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax contextRef="c-719" decimals="-6" id="f-2742" unitRef="usd">144000000</ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax>
    <ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax contextRef="c-720" decimals="-6" id="f-2743" unitRef="usd">2000000</ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax>
    <ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax contextRef="c-721" decimals="-6" id="f-2744" unitRef="usd">0</ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax>
    <ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax contextRef="c-714" decimals="-6" id="f-2745" unitRef="usd">0</ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax>
    <ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax contextRef="c-1" decimals="-6" id="f-2746" unitRef="usd">146000000</ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax>
    <ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries contextRef="c-719" decimals="-6" id="f-2747" unitRef="usd">0</ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries>
    <ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries contextRef="c-720" decimals="-6" id="f-2748" unitRef="usd">-133000000</ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries>
    <ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries contextRef="c-721" decimals="-6" id="f-2749" unitRef="usd">-2000000</ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries>
    <ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries contextRef="c-714" decimals="-6" id="f-2750" unitRef="usd">0</ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries>
    <ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries contextRef="c-1" decimals="-6" id="f-2751" unitRef="usd">-135000000</ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-719" decimals="-6" id="f-2752" unitRef="usd">1774000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-720" decimals="-6" id="f-2753" unitRef="usd">45000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-721" decimals="-6" id="f-2754" unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-714" decimals="-6" id="f-2755" unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-6" id="f-2756" unitRef="usd">1819000000</us-gaap:AmortizationOfIntangibleAssets>
    <ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes contextRef="c-719" decimals="-6" id="f-2757" unitRef="usd">0</ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes>
    <ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes contextRef="c-720" decimals="-6" id="f-2758" unitRef="usd">-1481000000</ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes>
    <ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes contextRef="c-721" decimals="-6" id="f-2759" unitRef="usd">-18000000</ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes>
    <ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes contextRef="c-714" decimals="-6" id="f-2760" unitRef="usd">0</ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes>
    <ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes contextRef="c-1" decimals="-6" id="f-2761" unitRef="usd">-1499000000</ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes>
    <us-gaap:RestructuringCharges contextRef="c-719" decimals="-6" id="f-2762" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-720" decimals="-6" id="f-2763" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-721" decimals="-6" id="f-2764" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-714" decimals="-6" id="f-2765" unitRef="usd">252000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-1" decimals="-6" id="f-2766" unitRef="usd">252000000</us-gaap:RestructuringCharges>
    <ci:SpecialItemChargeBenefitBeforeTaxLitigation contextRef="c-719" decimals="-6" id="f-2767" unitRef="usd">44000000</ci:SpecialItemChargeBenefitBeforeTaxLitigation>
    <ci:SpecialItemChargeBenefitBeforeTaxLitigation contextRef="c-720" decimals="-6" id="f-2768" unitRef="usd">157000000</ci:SpecialItemChargeBenefitBeforeTaxLitigation>
    <ci:SpecialItemChargeBenefitBeforeTaxLitigation contextRef="c-721" decimals="-6" id="f-2769" unitRef="usd">0</ci:SpecialItemChargeBenefitBeforeTaxLitigation>
    <ci:SpecialItemChargeBenefitBeforeTaxLitigation contextRef="c-714" decimals="-6" id="f-2770" unitRef="usd">0</ci:SpecialItemChargeBenefitBeforeTaxLitigation>
    <ci:SpecialItemChargeBenefitBeforeTaxLitigation contextRef="c-1" decimals="-6" id="f-2771" unitRef="usd">201000000</ci:SpecialItemChargeBenefitBeforeTaxLitigation>
    <ci:TransactionRelatedCosts contextRef="c-719" decimals="-6" id="f-2772" unitRef="usd">0</ci:TransactionRelatedCosts>
    <ci:TransactionRelatedCosts contextRef="c-720" decimals="-6" id="f-2773" unitRef="usd">0</ci:TransactionRelatedCosts>
    <ci:TransactionRelatedCosts contextRef="c-721" decimals="-6" id="f-2774" unitRef="usd">0</ci:TransactionRelatedCosts>
    <ci:TransactionRelatedCosts contextRef="c-714" decimals="-6" id="f-2775" unitRef="usd">45000000</ci:TransactionRelatedCosts>
    <ci:TransactionRelatedCosts contextRef="c-1" decimals="-6" id="f-2776" unitRef="usd">45000000</ci:TransactionRelatedCosts>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-719" decimals="-6" id="f-2777" unitRef="usd">6442000000</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-720" decimals="-6" id="f-2778" unitRef="usd">4478000000</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-721" decimals="-6" id="f-2779" unitRef="usd">96000000</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-722" decimals="-6" id="f-2780" unitRef="usd">-1698000000</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-2781" unitRef="usd">9318000000</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:NonInvestmentRevenue contextRef="c-656" decimals="-6" id="f-2782" unitRef="usd">135786000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-224" decimals="-6" id="f-2783" unitRef="usd">41738000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-657" decimals="-6" id="f-2784" unitRef="usd">1839000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-723" decimals="-6" id="f-2785" unitRef="usd">0</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-7" decimals="-6" id="f-2786" unitRef="usd">179363000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-724" decimals="-6" id="f-2787" unitRef="usd">-4463000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-725" decimals="-6" id="f-2788" unitRef="usd">-2535000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-726" decimals="-6" id="f-2789" unitRef="usd">0</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-727" decimals="-6" id="f-2790" unitRef="usd">-6998000000</ci:NonInvestmentRevenue>
    <us-gaap:NetInvestmentIncome contextRef="c-728" decimals="-6" id="f-2791" unitRef="usd">86000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome contextRef="c-729" decimals="-6" id="f-2792" unitRef="usd">638000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome contextRef="c-730" decimals="-6" id="f-2793" unitRef="usd">424000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome contextRef="c-731" decimals="-6" id="f-2794" unitRef="usd">7000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome contextRef="c-7" decimals="-6" id="f-2795" unitRef="usd">1155000000</us-gaap:NetInvestmentIncome>
    <us-gaap:Revenues contextRef="c-728" decimals="-6" id="f-2796" unitRef="usd">140335000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-729" decimals="-6" id="f-2797" unitRef="usd">44911000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-730" decimals="-6" id="f-2798" unitRef="usd">2263000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-731" decimals="-6" id="f-2799" unitRef="usd">-6991000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-7" decimals="-6" id="f-2800" unitRef="usd">180518000000</us-gaap:Revenues>
    <ci:RealizedInvestmentGainsLossesEquityMethodInvestments contextRef="c-728" decimals="-6" id="f-2801" unitRef="usd">0</ci:RealizedInvestmentGainsLossesEquityMethodInvestments>
    <ci:RealizedInvestmentGainsLossesEquityMethodInvestments contextRef="c-729" decimals="-6" id="f-2802" unitRef="usd">-126000000</ci:RealizedInvestmentGainsLossesEquityMethodInvestments>
    <ci:RealizedInvestmentGainsLossesEquityMethodInvestments contextRef="c-730" decimals="-6" id="f-2803" unitRef="usd">0</ci:RealizedInvestmentGainsLossesEquityMethodInvestments>
    <ci:RealizedInvestmentGainsLossesEquityMethodInvestments contextRef="c-731" decimals="-6" id="f-2804" unitRef="usd">0</ci:RealizedInvestmentGainsLossesEquityMethodInvestments>
    <ci:RealizedInvestmentGainsLossesEquityMethodInvestments contextRef="c-7" decimals="-6" id="f-2805" unitRef="usd">-126000000</ci:RealizedInvestmentGainsLossesEquityMethodInvestments>
    <ci:SegmentRevenues contextRef="c-728" decimals="-6" id="f-2806" unitRef="usd">140335000000</ci:SegmentRevenues>
    <ci:SegmentRevenues contextRef="c-729" decimals="-6" id="f-2807" unitRef="usd">45037000000</ci:SegmentRevenues>
    <ci:SegmentRevenues contextRef="c-730" decimals="-6" id="f-2808" unitRef="usd">2263000000</ci:SegmentRevenues>
    <ci:SegmentRevenues contextRef="c-731" decimals="-6" id="f-2809" unitRef="usd">-6991000000</ci:SegmentRevenues>
    <ci:SegmentRevenues contextRef="c-7" decimals="-6" id="f-2810" unitRef="usd">180644000000</ci:SegmentRevenues>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-728" decimals="-6" id="f-2811" unitRef="usd">2283000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-729" decimals="-6" id="f-2812" unitRef="usd">638000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-730" decimals="-6" id="f-2813" unitRef="usd">6000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-731" decimals="-6" id="f-2814" unitRef="usd">10000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-7" decimals="-6" id="f-2815" unitRef="usd">2937000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-728" decimals="-6" id="f-2816" unitRef="usd">4421000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-729" decimals="-6" id="f-2817" unitRef="usd">3470000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-730" decimals="-6" id="f-2818" unitRef="usd">2101000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-731" decimals="-6" id="f-2819" unitRef="usd">-1595000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-7" decimals="-6" id="f-2820" unitRef="usd">8397000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax contextRef="c-728" decimals="-6" id="f-2821" unitRef="usd">66000000</ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax>
    <ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax contextRef="c-729" decimals="-6" id="f-2822" unitRef="usd">4000000</ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax>
    <ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax contextRef="c-730" decimals="-6" id="f-2823" unitRef="usd">14000000</ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax>
    <ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax contextRef="c-723" decimals="-6" id="f-2824" unitRef="usd">0</ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax>
    <ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax contextRef="c-7" decimals="-6" id="f-2825" unitRef="usd">84000000</ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax>
    <ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries contextRef="c-728" decimals="-6" id="f-2826" unitRef="usd">0</ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries>
    <ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries contextRef="c-729" decimals="-6" id="f-2827" unitRef="usd">-530000000</ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries>
    <ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries contextRef="c-730" decimals="-6" id="f-2828" unitRef="usd">-83000000</ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries>
    <ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries contextRef="c-723" decimals="-6" id="f-2829" unitRef="usd">0</ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries>
    <ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries contextRef="c-7" decimals="-6" id="f-2830" unitRef="usd">-613000000</ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-728" decimals="-6" id="f-2831" unitRef="usd">1772000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-729" decimals="-6" id="f-2832" unitRef="usd">103000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-730" decimals="-6" id="f-2833" unitRef="usd">1000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-723" decimals="-6" id="f-2834" unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-7" decimals="-6" id="f-2835" unitRef="usd">1876000000</us-gaap:AmortizationOfIntangibleAssets>
    <ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes contextRef="c-728" decimals="-6" id="f-2836" unitRef="usd">0</ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes>
    <ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes contextRef="c-729" decimals="-6" id="f-2837" unitRef="usd">0</ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes>
    <ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes contextRef="c-730" decimals="-6" id="f-2838" unitRef="usd">1662000000</ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes>
    <ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes contextRef="c-723" decimals="-6" id="f-2839" unitRef="usd">0</ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes>
    <ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes contextRef="c-7" decimals="-6" id="f-2840" unitRef="usd">1662000000</ci:SpecialItemGainLossOnSaleOfBusinessBeforeTaxes>
    <us-gaap:RestructuringCharges contextRef="c-728" decimals="-6" id="f-2841" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-729" decimals="-6" id="f-2842" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-730" decimals="-6" id="f-2843" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-723" decimals="-6" id="f-2844" unitRef="usd">22000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-7" decimals="-6" id="f-2845" unitRef="usd">22000000</us-gaap:RestructuringCharges>
    <ci:SpecialItemChargeBenefitBeforeTaxLitigation contextRef="c-728" decimals="-6" id="f-2846" unitRef="usd">0</ci:SpecialItemChargeBenefitBeforeTaxLitigation>
    <ci:SpecialItemChargeBenefitBeforeTaxLitigation contextRef="c-729" decimals="-6" id="f-2847" unitRef="usd">0</ci:SpecialItemChargeBenefitBeforeTaxLitigation>
    <ci:SpecialItemChargeBenefitBeforeTaxLitigation contextRef="c-730" decimals="-6" id="f-2848" unitRef="usd">0</ci:SpecialItemChargeBenefitBeforeTaxLitigation>
    <ci:SpecialItemChargeBenefitBeforeTaxLitigation contextRef="c-723" decimals="-6" id="f-2849" unitRef="usd">-28000000</ci:SpecialItemChargeBenefitBeforeTaxLitigation>
    <ci:SpecialItemChargeBenefitBeforeTaxLitigation contextRef="c-7" decimals="-6" id="f-2850" unitRef="usd">-28000000</ci:SpecialItemChargeBenefitBeforeTaxLitigation>
    <ci:TransactionRelatedCosts contextRef="c-728" decimals="-6" id="f-2851" unitRef="usd">0</ci:TransactionRelatedCosts>
    <ci:TransactionRelatedCosts contextRef="c-729" decimals="-6" id="f-2852" unitRef="usd">0</ci:TransactionRelatedCosts>
    <ci:TransactionRelatedCosts contextRef="c-730" decimals="-6" id="f-2853" unitRef="usd">0</ci:TransactionRelatedCosts>
    <ci:TransactionRelatedCosts contextRef="c-723" decimals="-6" id="f-2854" unitRef="usd">135000000</ci:TransactionRelatedCosts>
    <ci:TransactionRelatedCosts contextRef="c-7" decimals="-6" id="f-2855" unitRef="usd">135000000</ci:TransactionRelatedCosts>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-728" decimals="-6" id="f-2856" unitRef="usd">6127000000</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-729" decimals="-6" id="f-2857" unitRef="usd">4099000000</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-730" decimals="-6" id="f-2858" unitRef="usd">509000000</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-731" decimals="-6" id="f-2859" unitRef="usd">-1466000000</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-7" decimals="-6" id="f-2860" unitRef="usd">9269000000</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:NonInvestmentRevenue contextRef="c-732" decimals="-6" id="f-2861" unitRef="usd">127692000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-225" decimals="-6" id="f-2862" unitRef="usd">41369000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-733" decimals="-6" id="f-2863" unitRef="usd">3459000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-734" decimals="-6" id="f-2864" unitRef="usd">0</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-8" decimals="-6" id="f-2865" unitRef="usd">172520000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-735" decimals="-6" id="f-2866" unitRef="usd">-4203000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-736" decimals="-6" id="f-2867" unitRef="usd">-2271000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-737" decimals="-6" id="f-2868" unitRef="usd">0</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-738" decimals="-6" id="f-2869" unitRef="usd">-6474000000</ci:NonInvestmentRevenue>
    <us-gaap:NetInvestmentIncome contextRef="c-739" decimals="-6" id="f-2870" unitRef="usd">17000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome contextRef="c-740" decimals="-6" id="f-2871" unitRef="usd">1003000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome contextRef="c-741" decimals="-6" id="f-2872" unitRef="usd">530000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome contextRef="c-742" decimals="-6" id="f-2873" unitRef="usd">-1000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome contextRef="c-8" decimals="-6" id="f-2874" unitRef="usd">1549000000</us-gaap:NetInvestmentIncome>
    <us-gaap:Revenues contextRef="c-739" decimals="-6" id="f-2875" unitRef="usd">131912000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-740" decimals="-6" id="f-2876" unitRef="usd">44643000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-741" decimals="-6" id="f-2877" unitRef="usd">3989000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-742" decimals="-6" id="f-2878" unitRef="usd">-6475000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-8" decimals="-6" id="f-2879" unitRef="usd">174069000000</us-gaap:Revenues>
    <ci:RealizedInvestmentGainsLossesEquityMethodInvestments contextRef="c-739" decimals="-6" id="f-2880" unitRef="usd">0</ci:RealizedInvestmentGainsLossesEquityMethodInvestments>
    <ci:RealizedInvestmentGainsLossesEquityMethodInvestments contextRef="c-740" decimals="-6" id="f-2881" unitRef="usd">0</ci:RealizedInvestmentGainsLossesEquityMethodInvestments>
    <ci:RealizedInvestmentGainsLossesEquityMethodInvestments contextRef="c-741" decimals="-6" id="f-2882" unitRef="usd">0</ci:RealizedInvestmentGainsLossesEquityMethodInvestments>
    <ci:RealizedInvestmentGainsLossesEquityMethodInvestments contextRef="c-742" decimals="-6" id="f-2883" unitRef="usd">0</ci:RealizedInvestmentGainsLossesEquityMethodInvestments>
    <ci:RealizedInvestmentGainsLossesEquityMethodInvestments contextRef="c-8" decimals="-6" id="f-2884" unitRef="usd">0</ci:RealizedInvestmentGainsLossesEquityMethodInvestments>
    <ci:SegmentRevenues contextRef="c-739" decimals="-6" id="f-2885" unitRef="usd">131912000000</ci:SegmentRevenues>
    <ci:SegmentRevenues contextRef="c-740" decimals="-6" id="f-2886" unitRef="usd">44643000000</ci:SegmentRevenues>
    <ci:SegmentRevenues contextRef="c-741" decimals="-6" id="f-2887" unitRef="usd">3989000000</ci:SegmentRevenues>
    <ci:SegmentRevenues contextRef="c-742" decimals="-6" id="f-2888" unitRef="usd">-6475000000</ci:SegmentRevenues>
    <ci:SegmentRevenues contextRef="c-8" decimals="-6" id="f-2889" unitRef="usd">174069000000</ci:SegmentRevenues>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-739" decimals="-6" id="f-2890" unitRef="usd">2316000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-740" decimals="-6" id="f-2891" unitRef="usd">551000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-741" decimals="-6" id="f-2892" unitRef="usd">52000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-742" decimals="-6" id="f-2893" unitRef="usd">4000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-8" decimals="-6" id="f-2894" unitRef="usd">2923000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-739" decimals="-6" id="f-2895" unitRef="usd">3908000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-740" decimals="-6" id="f-2896" unitRef="usd">3804000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-741" decimals="-6" id="f-2897" unitRef="usd">868000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-742" decimals="-6" id="f-2898" unitRef="usd">-1790000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-8" decimals="-6" id="f-2899" unitRef="usd">6790000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax contextRef="c-739" decimals="-6" id="f-2900" unitRef="usd">31000000</ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax>
    <ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax contextRef="c-740" decimals="-6" id="f-2901" unitRef="usd">3000000</ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax>
    <ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax contextRef="c-741" decimals="-6" id="f-2902" unitRef="usd">24000000</ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax>
    <ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax contextRef="c-734" decimals="-6" id="f-2903" unitRef="usd">0</ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax>
    <ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax contextRef="c-8" decimals="-6" id="f-2904" unitRef="usd">58000000</ci:IncomeLossAttributableToNoncontrollingInterestBeforeTax>
    <ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries contextRef="c-739" decimals="-6" id="f-2905" unitRef="usd">-4000000</ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries>
    <ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries contextRef="c-740" decimals="-6" id="f-2906" unitRef="usd">247000000</ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries>
    <ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries contextRef="c-741" decimals="-6" id="f-2907" unitRef="usd">-45000000</ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries>
    <ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries contextRef="c-734" decimals="-6" id="f-2908" unitRef="usd">0</ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries>
    <ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries contextRef="c-8" decimals="-6" id="f-2909" unitRef="usd">198000000</ci:RealizedInvestmentGainLossIncludingEquityMethodSubsidiaries>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-739" decimals="-6" id="f-2910" unitRef="usd">1937000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-740" decimals="-6" id="f-2911" unitRef="usd">47000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-741" decimals="-6" id="f-2912" unitRef="usd">14000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-734" decimals="-6" id="f-2913" unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-8" decimals="-6" id="f-2914" unitRef="usd">1998000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:RestructuringCharges contextRef="c-739" decimals="-6" id="f-2915" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-740" decimals="-6" id="f-2916" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-741" decimals="-6" id="f-2917" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-734" decimals="-6" id="f-2918" unitRef="usd">168000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-8" decimals="-6" id="f-2919" unitRef="usd">168000000</us-gaap:RestructuringCharges>
    <ci:SpecialItemChargeBenefitBeforeTaxLitigation contextRef="c-739" decimals="-6" id="f-2920" unitRef="usd">0</ci:SpecialItemChargeBenefitBeforeTaxLitigation>
    <ci:SpecialItemChargeBenefitBeforeTaxLitigation contextRef="c-740" decimals="-6" id="f-2921" unitRef="usd">0</ci:SpecialItemChargeBenefitBeforeTaxLitigation>
    <ci:SpecialItemChargeBenefitBeforeTaxLitigation contextRef="c-741" decimals="-6" id="f-2922" unitRef="usd">0</ci:SpecialItemChargeBenefitBeforeTaxLitigation>
    <ci:SpecialItemChargeBenefitBeforeTaxLitigation contextRef="c-734" decimals="-6" id="f-2923" unitRef="usd">-27000000</ci:SpecialItemChargeBenefitBeforeTaxLitigation>
    <ci:SpecialItemChargeBenefitBeforeTaxLitigation contextRef="c-8" decimals="-6" id="f-2924" unitRef="usd">-27000000</ci:SpecialItemChargeBenefitBeforeTaxLitigation>
    <ci:TransactionRelatedCosts contextRef="c-739" decimals="-6" id="f-2925" unitRef="usd">0</ci:TransactionRelatedCosts>
    <ci:TransactionRelatedCosts contextRef="c-740" decimals="-6" id="f-2926" unitRef="usd">0</ci:TransactionRelatedCosts>
    <ci:TransactionRelatedCosts contextRef="c-741" decimals="-6" id="f-2927" unitRef="usd">0</ci:TransactionRelatedCosts>
    <ci:TransactionRelatedCosts contextRef="c-734" decimals="-6" id="f-2928" unitRef="usd">169000000</ci:TransactionRelatedCosts>
    <ci:TransactionRelatedCosts contextRef="c-8" decimals="-6" id="f-2929" unitRef="usd">169000000</ci:TransactionRelatedCosts>
    <ci:SpecialItemChargesDebtExtinguishmentCostsBeforeTax contextRef="c-739" decimals="-6" id="f-2930" unitRef="usd">0</ci:SpecialItemChargesDebtExtinguishmentCostsBeforeTax>
    <ci:SpecialItemChargesDebtExtinguishmentCostsBeforeTax contextRef="c-740" decimals="-6" id="f-2931" unitRef="usd">0</ci:SpecialItemChargesDebtExtinguishmentCostsBeforeTax>
    <ci:SpecialItemChargesDebtExtinguishmentCostsBeforeTax contextRef="c-741" decimals="-6" id="f-2932" unitRef="usd">0</ci:SpecialItemChargesDebtExtinguishmentCostsBeforeTax>
    <ci:SpecialItemChargesDebtExtinguishmentCostsBeforeTax contextRef="c-734" decimals="-6" id="f-2933" unitRef="usd">141000000</ci:SpecialItemChargesDebtExtinguishmentCostsBeforeTax>
    <ci:SpecialItemChargesDebtExtinguishmentCostsBeforeTax contextRef="c-8" decimals="-6" id="f-2934" unitRef="usd">141000000</ci:SpecialItemChargesDebtExtinguishmentCostsBeforeTax>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-739" decimals="-6" id="f-2935" unitRef="usd">5818000000</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-740" decimals="-6" id="f-2936" unitRef="usd">3601000000</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-741" decimals="-6" id="f-2937" unitRef="usd">903000000</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-742" decimals="-6" id="f-2938" unitRef="usd">-1339000000</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-8" decimals="-6" id="f-2939" unitRef="usd">8983000000</ci:AdjustedIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock contextRef="c-1" id="f-2940">&lt;div&gt;&lt;span id="i447ccaf65a4944e2ab470d4dcddafa7a_953"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Revenue from external customers includes Pharmacy revenues, Premiums and Fees and other revenues. Prior period amounts have been retrospectively adjusted to reflect adoption of amended accounting guidance for long-duration insurance contracts (as discussed in Note 2 to the Consolidated Financial Statements) and to reflect the merger of the U.S. Commercial and U.S. Government operating segments into the U.S. Healthcare operating segment (as discussed in Note 1 to the Consolidated Financial Statements). The following table presents these revenues by product, premium and service type:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Products (Pharmacy revenues) (ASC 606)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Network revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;67,514&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Home delivery and specialty revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;65,732&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,047&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intercompany eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5,050)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total pharmacy revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;137,243&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Insurance premiums (ASC 944)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cigna Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;U.S. Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employer insured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16,490&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,771&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stop loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,143&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Individual and Family Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,088&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,095&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;40,587&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,295&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Cigna Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;43,882&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Divested International businesses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;281&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intercompany eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;74&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;44,237&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Services (Fees) (ASC 606)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Evernorth Health Services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,866&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cigna Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,566&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;210&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intercompany eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,583)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,067)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total fees and other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12,619&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;194,099&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;179,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;172,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-743" decimals="-6" id="f-2941" unitRef="usd">67514000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-744" decimals="-6" id="f-2942" unitRef="usd">64946000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-745" decimals="-6" id="f-2943" unitRef="usd">64992000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-746" decimals="-6" id="f-2944" unitRef="usd">65732000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-747" decimals="-6" id="f-2945" unitRef="usd">61283000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-748" decimals="-6" id="f-2946" unitRef="usd">54391000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-749" decimals="-6" id="f-2947" unitRef="usd">9047000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-750" decimals="-6" id="f-2948" unitRef="usd">6753000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-751" decimals="-6" id="f-2949" unitRef="usd">6428000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-752" decimals="-6" id="f-2950" unitRef="usd">-5050000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-753" decimals="-6" id="f-2951" unitRef="usd">-4416000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-754" decimals="-6" id="f-2952" unitRef="usd">-4398000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-4" decimals="-6" id="f-2953" unitRef="usd">137243000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-6" id="f-2954" unitRef="usd">128566000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-6" id="f-2955" unitRef="usd">121413000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:PremiumsEarnedNet contextRef="c-755" decimals="-6" id="f-2956" unitRef="usd">16490000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-756" decimals="-6" id="f-2957" unitRef="usd">15199000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-757" decimals="-6" id="f-2958" unitRef="usd">14315000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-758" decimals="-6" id="f-2959" unitRef="usd">8771000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-759" decimals="-6" id="f-2960" unitRef="usd">7896000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-760" decimals="-6" id="f-2961" unitRef="usd">8362000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-761" decimals="-6" id="f-2962" unitRef="usd">6143000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-762" decimals="-6" id="f-2963" unitRef="usd">5461000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-763" decimals="-6" id="f-2964" unitRef="usd">4868000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-764" decimals="-6" id="f-2965" unitRef="usd">5088000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-765" decimals="-6" id="f-2966" unitRef="usd">2636000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-766" decimals="-6" id="f-2967" unitRef="usd">2528000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-767" decimals="-6" id="f-2968" unitRef="usd">4095000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-768" decimals="-6" id="f-2969" unitRef="usd">3996000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-769" decimals="-6" id="f-2970" unitRef="usd">5076000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-770" decimals="-6" id="f-2971" unitRef="usd">40587000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-771" decimals="-6" id="f-2972" unitRef="usd">35188000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-772" decimals="-6" id="f-2973" unitRef="usd">35149000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-773" decimals="-6" id="f-2974" unitRef="usd">3295000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-774" decimals="-6" id="f-2975" unitRef="usd">2906000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-775" decimals="-6" id="f-2976" unitRef="usd">2588000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-720" decimals="-6" id="f-2977" unitRef="usd">43882000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-729" decimals="-6" id="f-2978" unitRef="usd">38094000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-740" decimals="-6" id="f-2979" unitRef="usd">37737000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-776" decimals="-6" id="f-2980" unitRef="usd">0</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-777" decimals="-6" id="f-2981" unitRef="usd">1596000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-778" decimals="-6" id="f-2982" unitRef="usd">3205000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-779" decimals="-6" id="f-2983" unitRef="usd">281000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-780" decimals="-6" id="f-2984" unitRef="usd">225000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-781" decimals="-6" id="f-2985" unitRef="usd">221000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-718" decimals="-6" id="f-2986" unitRef="usd">74000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-727" decimals="-6" id="f-2987" unitRef="usd">1000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-738" decimals="-6" id="f-2988" unitRef="usd">-9000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-1" decimals="-6" id="f-2989" unitRef="usd">44237000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-7" decimals="-6" id="f-2990" unitRef="usd">39916000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-8" decimals="-6" id="f-2991" unitRef="usd">41154000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-782" decimals="-6" id="f-2992" unitRef="usd">10866000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-783" decimals="-6" id="f-2993" unitRef="usd">7234000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-784" decimals="-6" id="f-2994" unitRef="usd">6070000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-785" decimals="-6" id="f-2995" unitRef="usd">6566000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-786" decimals="-6" id="f-2996" unitRef="usd">6053000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-787" decimals="-6" id="f-2997" unitRef="usd">5743000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-788" decimals="-6" id="f-2998" unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-789" decimals="-6" id="f-2999" unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-790" decimals="-6" id="f-3000" unitRef="usd">19000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-791" decimals="-6" id="f-3001" unitRef="usd">210000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-792" decimals="-6" id="f-3002" unitRef="usd">168000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-793" decimals="-6" id="f-3003" unitRef="usd">188000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-794" decimals="-6" id="f-3004" unitRef="usd">-5026000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-795" decimals="-6" id="f-3005" unitRef="usd">-2583000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-796" decimals="-6" id="f-3006" unitRef="usd">-2067000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="-6" id="f-3007" unitRef="usd">12619000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-6" id="f-3008" unitRef="usd">10881000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="-6" id="f-3009" unitRef="usd">9953000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ci:NonInvestmentRevenue contextRef="c-1" decimals="-6" id="f-3010" unitRef="usd">194099000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-7" decimals="-6" id="f-3011" unitRef="usd">179363000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-8" decimals="-6" id="f-3012" unitRef="usd">172520000000</ci:NonInvestmentRevenue>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock contextRef="c-1" id="f-3013">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;U.S. and foreign revenues from external customers are shown below. The Company's foreign revenues are generated by its foreign operating entities. In the periods shown, no single foreign country contributed more than 2% of consolidated revenues from external customers.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;189,840&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;166,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign countries &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,259&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;194,099&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;179,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;172,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; The divested International businesses as described in Note 5 comprised of $1.6 billion and $3.2 billion in 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-797"
      decimals="2"
      id="f-3014"
      unitRef="number">0.02</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-798"
      decimals="2"
      id="f-3015"
      unitRef="number">0.02</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-799"
      decimals="2"
      id="f-3016"
      unitRef="number">0.02</us-gaap:ConcentrationRiskPercentage1>
    <ci:NonInvestmentRevenue contextRef="c-800" decimals="-6" id="f-3017" unitRef="usd">189840000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-801" decimals="-6" id="f-3018" unitRef="usd">174540000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-802" decimals="-6" id="f-3019" unitRef="usd">166626000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-803" decimals="-6" id="f-3020" unitRef="usd">4259000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-804" decimals="-6" id="f-3021" unitRef="usd">4823000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-805" decimals="-6" id="f-3022" unitRef="usd">5894000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-1" decimals="-6" id="f-3023" unitRef="usd">194099000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-7" decimals="-6" id="f-3024" unitRef="usd">179363000000</ci:NonInvestmentRevenue>
    <ci:NonInvestmentRevenue contextRef="c-8" decimals="-6" id="f-3025" unitRef="usd">172520000000</ci:NonInvestmentRevenue>
    <ci:DisposalGroupIncludingDiscontinuedOperationsNonInvestmentRevenue contextRef="c-804" decimals="-8" id="f-3026" unitRef="usd">1600000000</ci:DisposalGroupIncludingDiscontinuedOperationsNonInvestmentRevenue>
    <ci:DisposalGroupIncludingDiscontinuedOperationsNonInvestmentRevenue contextRef="c-805" decimals="-8" id="f-3027" unitRef="usd">3200000000</ci:DisposalGroupIncludingDiscontinuedOperationsNonInvestmentRevenue>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-806"
      decimals="2"
      id="f-3028"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-807"
      decimals="2"
      id="f-3029"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-808"
      decimals="2"
      id="f-3030"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-185" id="f-3031">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-185" id="f-3032">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-185" id="f-3033">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-185" id="f-3034">false</ecd:Rule10b51ArrTrmntdFlag>
    <dei:AuditorFirmId contextRef="c-1" id="f-3035">238</dei:AuditorFirmId>
    <us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock contextRef="c-1" id="f-3036">&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span id="i04dc17a35c054b6d8e303f8417c40a64_204"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%"&gt;THE CIGNA GROUP AND SUBSIDIARIES&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%"&gt;SCHEDULE I&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%"&gt;CONDENSED FINANCIAL INFORMATION OF THE CIGNA GROUP&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%"&gt;(REGISTRANT)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%"&gt;STATEMENTS OF INCOME&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net investment income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intercompany interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;516&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;538&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;536&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest and other expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,215)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intercompany interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Debt extinguishment costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(914)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(881)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(878)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Loss of Parent Company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(722)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity in income of subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,886&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shareholders' net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,164&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shareholders' other comprehensive income (loss), net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unrealized appreciation (depreciation) on securities and derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;503&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,598)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net long-duration insurance and contractholder liabilities measurement adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(715)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net translation gains (losses) of foreign currencies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Postretirement benefits liability adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shareholders' other comprehensive loss, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(590)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shareholders' comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,958&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 1 to Schedule 1 for further information.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;See Notes to Financial Statements on the following pages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span id="i119a375e8e4342d49fe6b4b067c6a227_195"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%"&gt;THE CIGNA GROUP AND SUBSIDIARIES&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%"&gt;SCHEDULE I&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%"&gt;CONDENSED FINANCIAL INFORMATION OF THE CIGNA GROUP&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%"&gt;(REGISTRANT)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%"&gt;BALANCE SHEETS&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.041%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;303&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;309&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments in subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;69,703&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intercompany receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11,475&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;77&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;TOTAL ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;81,564&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,448&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,854&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,302&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;27,151&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intercompany payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,874&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;14&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;TOTAL LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35,341&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shareholders' Equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock (shares issued, 400 and 398; authorized, 600)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additional paid-in capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;30,669&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,864)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,658)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Retained earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41,652&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less treasury stock, at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(24,238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21,844)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;TOTAL SHAREHOLDERS' EQUITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;46,223&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;81,564&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 1 to Schedule 1 for further information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;See Notes to Financial Statements on the following pages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span id="i328d757352ff45b69e14fe0a6159da0e_253"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%"&gt;THE CIGNA GROUP AND SUBSIDIARIES&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%"&gt;SCHEDULE I&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%"&gt;CONDENSED FINANCIAL INFORMATION OF THE CIGNA GROUP&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%"&gt;(REGISTRANT)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%"&gt;STATEMENTS OF CASH FLOWS&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash Flows from Operating Activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shareholders' net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,164&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Adjustments to reconcile shareholders' net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;to net cash provided by operating activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity in income of subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5,886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Debt extinguishment costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividends received from subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,381&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;540&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;640&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;NET CASH PROVIDED BY OPERATING ACTIVITIES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,839&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash Flows from Investing Activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net change in amounts due from affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;622&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(901)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,007)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net proceeds from short-term investments sold (purchased)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;622&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(802)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash Flows from Financing Activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net change in amounts due to affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,473&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net change in commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,237&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,027)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments for debt extinguishment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Repayment of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2,822)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net proceeds on issuance of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,491&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Issuance of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;187&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common dividends paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,450)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Repurchase of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2,284)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,607)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax withholding on stock compensation and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;NET CASH USED IN FINANCING ACTIVITIES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2,278)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(740)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,849)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net increase (decrease) in cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;183&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;152&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash, end of year &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;335&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Noncash Investing and Financing Activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Net amounts due to/(from) affiliates settled through capital transactions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5,221)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 1 to Schedule 1 for further information.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; Includes restricted cash reported in Other non-current assets as of December&#160;31, 2023 and December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;See Notes to Financial Statements on the following pages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span id="i3e615b8bf0cc4c7e95f93f8da300a4b8_1153"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;THE CIGNA GROUP AND SUBSIDIARIES&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;SCHEDULE I&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;CONDENSED FINANCIAL INFORMATION OF THE CIGNA GROUP&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(REGISTRANT)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;NOTES TO CONDENSED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The accompanying condensed financial statements should be read in conjunction with the Consolidated Financial Statements and the accompanying notes thereto contained in this Annual Report on Form 10-K ("Form 10-K").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Note 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; - For purposes of these condensed financial statements, The Cigna Group's (the "Company") wholly-owned and majority-owned subsidiaries are recorded using the equity method of accounting. On January 1, 2023, The Cigna Group and its subsidiaries adopted Targeted Improvements to the Accounting for Long-Duration Contracts, Accounting Standards Update ("ASU") 2018-12 and related amendments. See Note 2 - Summary of significant accounting policies included in Part II, Item 8 of this Form 10-K for a description of the key provisions and impacts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Cigna Group, through its predecessor companies, was incorporated in Delaware in 1981. Cigna Corporation was renamed The Cigna Group in February 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Note 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; - See Note 8 &#x2013; Debt included in Part II, Item 8 of this Form 10-K for a description of the short-term and long-term debt obligations of The Cigna Group and its subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Short-term and Credit Facilities Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Revolving Credit Agreements.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Our revolving credit agreements provide us with the ability to borrow amounts for general corporate purposes, including for the purpose of providing liquidity support if necessary under our commercial paper program discussed below. As of December&#160;31, 2023, there were no outstanding balances under these revolving credit agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In April 2023, The Cigna Group entered into the following revolving credit agreements (the "Credit Agreements"):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;a $4.0 billion five-year revolving credit and letter of credit agreement that will mature in April 2028 with an option to extend the maturity date for additional one-year periods, subject to consent of the banks. The Company can borrow up to $4.0 billion under the credit agreement for general corporate purposes, with up to $500 million available for issuance of letters of credit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;a $1.0 billion 364-day revolving credit agreement that will mature in April 2024. The Company can borrow up to $1.0 billion under the credit agreement for general corporate purposes. This agreement includes the option to "term out" any revolving loans that are outstanding at maturity by converting them into a term loan maturing on the one-year anniversary of conversion.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Each of the Credit Agreements include an option to increase commitments in an aggregate amount of up to $1.5 billion across both facilities for a maximum total commitment of $6.5 billion. The Credit Agreements allow for borrowings at either a base rate or an adjusted term Secured Overnight Funding Rate ("SOFR") plus, in each case, an applicable margin based on the Company's senior unsecured credit ratings.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Each of the two facilities is diversified among 21 banks. Each facility also contains customary covenants and restrictions, including a financial covenant that the Company's leverage ratio, as defined in the Credit Agreements, may not exceed 60%, subject to certain exceptions upon the consummation of an acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Credit Agreements replaced a prior $3.0 billion five-year revolving credit and letter of credit agreement maturing on April 2027, a $1.0 billion three-year revolving credit agreement maturing on April 2025 and a $1.0 billion 364-day revolving credit agreement maturing in April 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Commercial Paper. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Under our commercial paper program, we may issue short-term, unsecured commercial paper notes privately placed on a discounted basis through certain broker-dealers at any time not to exceed an aggregate amount of $5.0 billion. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. The commercial paper program had approximately&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$1.2&#160;billion outstanding at December&#160;31, 2023 and an average interest rate of 5.63%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Long-Term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Debt Issuance and Debt Tender Offers. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On February 5, 2024, we issued $4.5 billion of new senior notes. The proceeds from this debt were used to pay the consideration for the cash tender offers as described below. We intend to use the remaining net proceeds to fund the repayment of our senior notes maturing in March 2024 and for general corporate purposes, which may include repayment of indebtedness and repurchases of shares of our common stock.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Concurrent with the debt issuance, The Company and its subsidiaries commenced tender offers to purchase for cash up to $2.25 billion in aggregate principal amount of outstanding notes, which included any and all of the $1.0 billion senior notes due June 2024. Following the early tender results, we increased the tender offers to up to $2.55 billion. On February 22, 2024, we purchased $1.8 billion principal amount of notes at early settlement of the tender offers. The tender offers will expire on March 5, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On March 7, 2023, the Company issued $1.5&#160;billion of new senior notes. The proceeds of this issuance were used for general &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;corporate purposes, and included repayment of outstanding debt securities. Interest on this debt is paid semi-annually.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.486%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Proceeds&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$700 million &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 15, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.685%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$698 million&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$800 million &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 15, 2033&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.400%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$796 million&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; Redeemable at any time discounted at the U.S. Treasury rate plus 20 basis points. Redeemable at par on or after March 15, 2024.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; Redeemable at any time discounted at the U.S. Treasury rate plus 25 basis points. Redeemable at par on or after December 15, 2032. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Debt Maturities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Maturities of the Company's long-term debt are as follows and exclude the impacts of the 2024 debt issuance and debt tender offers discussed above. &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:88.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.040%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,214&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,957&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,734&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,056&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Maturities after 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;15,091&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Debt Covenants. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company was in compliance with its debt covenants as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Note 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; - The Company's intercompany receivables consist primarily of net intercompany loan amounts due from Evernorth Health, Inc. of $8.5&#160;billion as of December&#160;31, 2023 and $8.3&#160;billion as of December&#160;31, 2022. Interest income on the loan receivable was accrued at an average rate of 5.21% in 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's intercompany payables primarily reflect intercompany balances related to cash pooling arrangements as well as net intercompany loan borrowing from three indirect wholly-owned subsidiaries as of December&#160;31, 2023. Interest expense on the loan payable was accrued at an average rate of 3.65% in 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Note 4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; - The Company guaranteed approximately $2.9 billion primarily related to intercompany indebtedness and financial obligations of certain direct and indirect wholly-owned subsidiaries. There were immaterial liabilities required for these guarantees as of December&#160;31, 2023. Effective January 2024, the amount of such guarantees increased to $6.4 billion.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Note 5&lt;/span&gt; - In February 2024, as part of our existing share repurchase program, we entered into separate ASR agreements ("2024 ASR agreements") with Deutsche Bank AG and Bank of America, N.A. (collectively, the "2024 Counterparties") to repurchase $3.2 billion of common stock in aggregate. We remitted $3.2 billion to the 2024 Counterparties and received an initial delivery of approximately 7.6&#160;million shares of our common stock on February 15, 2024 representing $2.6 billion of the total remitted. We expect final settlement under the 2024 ASR agreements to occur in the second quarter of 2024.</us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock>
    <us-gaap:NetInvestmentIncome contextRef="c-809" decimals="-6" id="f-3037" unitRef="usd">22000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome contextRef="c-810" decimals="-6" id="f-3038" unitRef="usd">5000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome contextRef="c-811" decimals="-6" id="f-3039" unitRef="usd">0</us-gaap:NetInvestmentIncome>
    <ci:IntercompanyInterestIncome contextRef="c-809" decimals="-6" id="f-3040" unitRef="usd">516000000</ci:IntercompanyInterestIncome>
    <ci:IntercompanyInterestIncome contextRef="c-810" decimals="-6" id="f-3041" unitRef="usd">478000000</ci:IntercompanyInterestIncome>
    <ci:IntercompanyInterestIncome contextRef="c-811" decimals="-6" id="f-3042" unitRef="usd">471000000</ci:IntercompanyInterestIncome>
    <us-gaap:Revenues contextRef="c-809" decimals="-6" id="f-3043" unitRef="usd">538000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-810" decimals="-6" id="f-3044" unitRef="usd">483000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-811" decimals="-6" id="f-3045" unitRef="usd">471000000</us-gaap:Revenues>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-809" decimals="-6" id="f-3046" unitRef="usd">2000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-810" decimals="-6" id="f-3047" unitRef="usd">2000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-811" decimals="-6" id="f-3048" unitRef="usd">8000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:BenefitsLossesAndExpenses contextRef="c-809" decimals="-6" id="f-3049" unitRef="usd">2000000</us-gaap:BenefitsLossesAndExpenses>
    <us-gaap:BenefitsLossesAndExpenses contextRef="c-810" decimals="-6" id="f-3050" unitRef="usd">2000000</us-gaap:BenefitsLossesAndExpenses>
    <us-gaap:BenefitsLossesAndExpenses contextRef="c-811" decimals="-6" id="f-3051" unitRef="usd">8000000</us-gaap:BenefitsLossesAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-809" decimals="-6" id="f-3052" unitRef="usd">536000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-810" decimals="-6" id="f-3053" unitRef="usd">481000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-811" decimals="-6" id="f-3054" unitRef="usd">463000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-809" decimals="-6" id="f-3055" unitRef="usd">-1332000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-810" decimals="-6" id="f-3056" unitRef="usd">-1215000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-811" decimals="-6" id="f-3057" unitRef="usd">-1197000000</us-gaap:OtherNonoperatingIncomeExpense>
    <ci:IntercompanyInterestExpense contextRef="c-809" decimals="-6" id="f-3058" unitRef="usd">118000000</ci:IntercompanyInterestExpense>
    <ci:IntercompanyInterestExpense contextRef="c-810" decimals="-6" id="f-3059" unitRef="usd">147000000</ci:IntercompanyInterestExpense>
    <ci:IntercompanyInterestExpense contextRef="c-811" decimals="-6" id="f-3060" unitRef="usd">13000000</ci:IntercompanyInterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-809" decimals="-6" id="f-3061" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-810" decimals="-6" id="f-3062" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-811" decimals="-6" id="f-3063" unitRef="usd">-131000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-809" decimals="-6" id="f-3064" unitRef="usd">-914000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-810" decimals="-6" id="f-3065" unitRef="usd">-881000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-811" decimals="-6" id="f-3066" unitRef="usd">-878000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-809" decimals="-6" id="f-3067" unitRef="usd">-192000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-810" decimals="-6" id="f-3068" unitRef="usd">-183000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-811" decimals="-6" id="f-3069" unitRef="usd">-180000000</us-gaap:IncomeTaxExpenseBenefit>
    <ci:LossOfParentCompany contextRef="c-809" decimals="-6" id="f-3070" unitRef="usd">-722000000</ci:LossOfParentCompany>
    <ci:LossOfParentCompany contextRef="c-810" decimals="-6" id="f-3071" unitRef="usd">-698000000</ci:LossOfParentCompany>
    <ci:LossOfParentCompany contextRef="c-811" decimals="-6" id="f-3072" unitRef="usd">-698000000</ci:LossOfParentCompany>
    <us-gaap:IncomeLossFromSubsidiariesNetOfTax contextRef="c-809" decimals="-6" id="f-3073" unitRef="usd">5886000000</us-gaap:IncomeLossFromSubsidiariesNetOfTax>
    <us-gaap:IncomeLossFromSubsidiariesNetOfTax contextRef="c-810" decimals="-6" id="f-3074" unitRef="usd">7402000000</us-gaap:IncomeLossFromSubsidiariesNetOfTax>
    <us-gaap:IncomeLossFromSubsidiariesNetOfTax contextRef="c-811" decimals="-6" id="f-3075" unitRef="usd">6068000000</us-gaap:IncomeLossFromSubsidiariesNetOfTax>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-809" decimals="-6" id="f-3076" unitRef="usd">5164000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-810" decimals="-6" id="f-3077" unitRef="usd">6704000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-811" decimals="-6" id="f-3078" unitRef="usd">5370000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-809" decimals="-6" id="f-3079" unitRef="usd">503000000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-810" decimals="-6" id="f-3080" unitRef="usd">-1598000000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-811" decimals="-6" id="f-3081" unitRef="usd">-302000000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <ci:OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent contextRef="c-809" decimals="-6" id="f-3082" unitRef="usd">-715000000</ci:OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent>
    <ci:OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent contextRef="c-810" decimals="-6" id="f-3083" unitRef="usd">509000000</ci:OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent>
    <ci:OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent contextRef="c-811" decimals="-6" id="f-3084" unitRef="usd">67000000</ci:OCILiabilityForFuturePolicyBenefitAndMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterReclassificationAdjustmentAndTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-809" decimals="-6" id="f-3085" unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-810" decimals="-6" id="f-3086" unitRef="usd">79000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-811" decimals="-6" id="f-3087" unitRef="usd">-218000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-809" decimals="-6" id="f-3088" unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-810" decimals="-6" id="f-3089" unitRef="usd">-420000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-811" decimals="-6" id="f-3090" unitRef="usd">-410000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-809" decimals="-6" id="f-3091" unitRef="usd">-206000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-810" decimals="-6" id="f-3092" unitRef="usd">-590000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-811" decimals="-6" id="f-3093" unitRef="usd">-43000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-809" decimals="-6" id="f-3094" unitRef="usd">4958000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-810" decimals="-6" id="f-3095" unitRef="usd">6114000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-811" decimals="-6" id="f-3096" unitRef="usd">5327000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-812" decimals="-6" id="f-3097" unitRef="usd">303000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-813" decimals="-6" id="f-3098" unitRef="usd">115000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherAssetsCurrent contextRef="c-812" decimals="-6" id="f-3099" unitRef="usd">6000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-813" decimals="-6" id="f-3100" unitRef="usd">6000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-812" decimals="-6" id="f-3101" unitRef="usd">309000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-813" decimals="-6" id="f-3102" unitRef="usd">121000000</us-gaap:AssetsCurrent>
    <us-gaap:InvestmentsAndOtherNoncurrentAssets contextRef="c-814" decimals="-6" id="f-3103" unitRef="usd">69703000000</us-gaap:InvestmentsAndOtherNoncurrentAssets>
    <us-gaap:InvestmentsAndOtherNoncurrentAssets contextRef="c-815" decimals="-6" id="f-3104" unitRef="usd">70679000000</us-gaap:InvestmentsAndOtherNoncurrentAssets>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-814" decimals="-6" id="f-3105" unitRef="usd">11475000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-815" decimals="-6" id="f-3106" unitRef="usd">10366000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-816" decimals="-6" id="f-3107" unitRef="usd">77000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-817" decimals="-6" id="f-3108" unitRef="usd">99000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-812" decimals="-6" id="f-3109" unitRef="usd">81564000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-813" decimals="-6" id="f-3110" unitRef="usd">81265000000</us-gaap:Assets>
    <us-gaap:DebtCurrent contextRef="c-812" decimals="-6" id="f-3111" unitRef="usd">2448000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent contextRef="c-813" decimals="-6" id="f-3112" unitRef="usd">2749000000</us-gaap:DebtCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-812" decimals="-6" id="f-3113" unitRef="usd">1854000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-813" decimals="-6" id="f-3114" unitRef="usd">1295000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-812" decimals="-6" id="f-3115" unitRef="usd">4302000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-813" decimals="-6" id="f-3116" unitRef="usd">4044000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c-812" decimals="-6" id="f-3117" unitRef="usd">27151000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c-813" decimals="-6" id="f-3118" unitRef="usd">26815000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-814" decimals="-6" id="f-3119" unitRef="usd">3874000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-815" decimals="-6" id="f-3120" unitRef="usd">5705000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-816" decimals="-6" id="f-3121" unitRef="usd">14000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-817" decimals="-6" id="f-3122" unitRef="usd">26000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-812" decimals="-6" id="f-3123" unitRef="usd">35341000000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-813" decimals="-6" id="f-3124" unitRef="usd">36590000000</us-gaap:Liabilities>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-812"
      decimals="-6"
      id="f-3125"
      unitRef="shares">400000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-813"
      decimals="-6"
      id="f-3126"
      unitRef="shares">398000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-812"
      decimals="INF"
      id="f-3127"
      unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-813"
      decimals="INF"
      id="f-3128"
      unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockValue contextRef="c-812" decimals="-6" id="f-3129" unitRef="usd">4000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-813" decimals="-6" id="f-3130" unitRef="usd">4000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-812" decimals="-6" id="f-3131" unitRef="usd">30669000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-813" decimals="-6" id="f-3132" unitRef="usd">30233000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-812" decimals="-6" id="f-3133" unitRef="usd">-1864000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-813" decimals="-6" id="f-3134" unitRef="usd">-1658000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-812" decimals="-6" id="f-3135" unitRef="usd">41652000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-813" decimals="-6" id="f-3136" unitRef="usd">37940000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockValue contextRef="c-812" decimals="-6" id="f-3137" unitRef="usd">24238000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue contextRef="c-813" decimals="-6" id="f-3138" unitRef="usd">21844000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity contextRef="c-812" decimals="-6" id="f-3139" unitRef="usd">46223000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-813" decimals="-6" id="f-3140" unitRef="usd">44675000000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-812" decimals="-6" id="f-3141" unitRef="usd">81564000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-813" decimals="-6" id="f-3142" unitRef="usd">81265000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-809" decimals="-6" id="f-3143" unitRef="usd">5164000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-810" decimals="-6" id="f-3144" unitRef="usd">6704000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-811" decimals="-6" id="f-3145" unitRef="usd">5370000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:IncomeLossFromSubsidiariesNetOfTax contextRef="c-809" decimals="-6" id="f-3146" unitRef="usd">5886000000</us-gaap:IncomeLossFromSubsidiariesNetOfTax>
    <us-gaap:IncomeLossFromSubsidiariesNetOfTax contextRef="c-810" decimals="-6" id="f-3147" unitRef="usd">7402000000</us-gaap:IncomeLossFromSubsidiariesNetOfTax>
    <us-gaap:IncomeLossFromSubsidiariesNetOfTax contextRef="c-811" decimals="-6" id="f-3148" unitRef="usd">6068000000</us-gaap:IncomeLossFromSubsidiariesNetOfTax>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-809" decimals="-6" id="f-3149" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-810" decimals="-6" id="f-3150" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-811" decimals="-6" id="f-3151" unitRef="usd">-131000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries contextRef="c-809" decimals="-6" id="f-3152" unitRef="usd">1381000000</us-gaap:CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries>
    <us-gaap:CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries contextRef="c-810" decimals="-6" id="f-3153" unitRef="usd">2056000000</us-gaap:CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries>
    <us-gaap:CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries contextRef="c-811" decimals="-6" id="f-3154" unitRef="usd">2726000000</us-gaap:CashDividendsPaidToParentCompanyByConsolidatedSubsidiaries>
    <ci:IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities contextRef="c-809" decimals="-6" id="f-3155" unitRef="usd">540000000</ci:IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities>
    <ci:IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities contextRef="c-810" decimals="-6" id="f-3156" unitRef="usd">5000000</ci:IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities>
    <ci:IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities contextRef="c-811" decimals="-6" id="f-3157" unitRef="usd">184000000</ci:IncreaseDecreaseInAccountsPayableAccruedAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-809" decimals="-6" id="f-3158" unitRef="usd">-640000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-810" decimals="-6" id="f-3159" unitRef="usd">-298000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-811" decimals="-6" id="f-3160" unitRef="usd">-439000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-809" decimals="-6" id="f-3161" unitRef="usd">1839000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-810" decimals="-6" id="f-3162" unitRef="usd">1661000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-811" decimals="-6" id="f-3163" unitRef="usd">2782000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <ci:IncreaseDecreaseInAmountsDueFromAffiliates contextRef="c-818" decimals="-6" id="f-3164" unitRef="usd">-622000000</ci:IncreaseDecreaseInAmountsDueFromAffiliates>
    <ci:IncreaseDecreaseInAmountsDueFromAffiliates contextRef="c-819" decimals="-6" id="f-3165" unitRef="usd">901000000</ci:IncreaseDecreaseInAmountsDueFromAffiliates>
    <ci:IncreaseDecreaseInAmountsDueFromAffiliates contextRef="c-820" decimals="-6" id="f-3166" unitRef="usd">1007000000</ci:IncreaseDecreaseInAmountsDueFromAffiliates>
    <us-gaap:PaymentsToAcquireOtherInvestments contextRef="c-809" decimals="-6" id="f-3167" unitRef="usd">0</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments contextRef="c-810" decimals="-6" id="f-3168" unitRef="usd">-99000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments contextRef="c-811" decimals="-6" id="f-3169" unitRef="usd">50000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-809" decimals="-6" id="f-3170" unitRef="usd">622000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-810" decimals="-6" id="f-3171" unitRef="usd">-802000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-811" decimals="-6" id="f-3172" unitRef="usd">-1057000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt contextRef="c-818" decimals="-6" id="f-3173" unitRef="usd">1473000000</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt contextRef="c-819" decimals="-6" id="f-3174" unitRef="usd">10392000000</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt contextRef="c-820" decimals="-6" id="f-3175" unitRef="usd">2062000000</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt contextRef="c-809" decimals="-6" id="f-3176" unitRef="usd">1237000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt contextRef="c-810" decimals="-6" id="f-3177" unitRef="usd">-2027000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt contextRef="c-811" decimals="-6" id="f-3178" unitRef="usd">997000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts contextRef="c-809" decimals="-6" id="f-3179" unitRef="usd">0</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts contextRef="c-810" decimals="-6" id="f-3180" unitRef="usd">0</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts contextRef="c-811" decimals="-6" id="f-3181" unitRef="usd">126000000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-809" decimals="-6" id="f-3182" unitRef="usd">2822000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-810" decimals="-6" id="f-3183" unitRef="usd">430000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-811" decimals="-6" id="f-3184" unitRef="usd">4199000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-809" decimals="-6" id="f-3185" unitRef="usd">1491000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-810" decimals="-6" id="f-3186" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-811" decimals="-6" id="f-3187" unitRef="usd">4260000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-809" decimals="-6" id="f-3188" unitRef="usd">187000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-810" decimals="-6" id="f-3189" unitRef="usd">389000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-811" decimals="-6" id="f-3190" unitRef="usd">326000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-809" decimals="-6" id="f-3191" unitRef="usd">1450000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-810" decimals="-6" id="f-3192" unitRef="usd">1384000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-811" decimals="-6" id="f-3193" unitRef="usd">1341000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-809" decimals="-6" id="f-3194" unitRef="usd">2284000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-810" decimals="-6" id="f-3195" unitRef="usd">7607000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-811" decimals="-6" id="f-3196" unitRef="usd">7742000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-809" decimals="-6" id="f-3197" unitRef="usd">110000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-810" decimals="-6" id="f-3198" unitRef="usd">73000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-811" decimals="-6" id="f-3199" unitRef="usd">86000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-809" decimals="-6" id="f-3200" unitRef="usd">-2278000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-810" decimals="-6" id="f-3201" unitRef="usd">-740000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-811" decimals="-6" id="f-3202" unitRef="usd">-5849000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-809" decimals="-6" id="f-3203" unitRef="usd">183000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-810" decimals="-6" id="f-3204" unitRef="usd">119000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-811" decimals="-6" id="f-3205" unitRef="usd">-4124000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-813" decimals="-6" id="f-3206" unitRef="usd">152000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-821" decimals="-6" id="f-3207" unitRef="usd">33000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-822" decimals="-6" id="f-3208" unitRef="usd">4157000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-812" decimals="-6" id="f-3209" unitRef="usd">335000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-813" decimals="-6" id="f-3210" unitRef="usd">152000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-821" decimals="-6" id="f-3211" unitRef="usd">33000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NotesReduction contextRef="c-818" decimals="-6" id="f-3212" unitRef="usd">5221000000</us-gaap:NotesReduction>
    <us-gaap:NotesReduction contextRef="c-819" decimals="-6" id="f-3213" unitRef="usd">5037000000</us-gaap:NotesReduction>
    <us-gaap:NotesReduction contextRef="c-820" decimals="-6" id="f-3214" unitRef="usd">8429000000</us-gaap:NotesReduction>
    <us-gaap:LineOfCredit contextRef="c-823" decimals="INF" id="f-3215" unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-824" decimals="INF" id="f-3216" unitRef="usd">4000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-825" id="f-3217">P5Y</us-gaap:DebtInstrumentTerm>
    <ci:DebtInstrumentExtensionTerm contextRef="c-825" id="f-3218">P1Y</ci:DebtInstrumentExtensionTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-824" decimals="INF" id="f-3219" unitRef="usd">4000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-826" decimals="INF" id="f-3220" unitRef="usd">500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-827" decimals="INF" id="f-3221" unitRef="usd">1000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-828" id="f-3222">P364D</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-827" decimals="INF" id="f-3223" unitRef="usd">1000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <ci:LineOfCreditFacilityConversionToTermLoanTerm contextRef="c-828" id="f-3224">P1Y</ci:LineOfCreditFacilityConversionToTermLoanTerm>
    <ci:LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity contextRef="c-829" decimals="INF" id="f-3225" unitRef="usd">1500000000</ci:LineOfCreditFacilityAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity>
    <ci:LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity contextRef="c-829" decimals="INF" id="f-3226" unitRef="usd">6500000000</ci:LineOfCreditFacilityMaximumBorrowingCapacityAndAccordionFeatureIncrementalIncreaseInMaximumBorrowingCapacity>
    <ci:NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement
      contextRef="c-829"
      decimals="INF"
      id="f-3227"
      unitRef="bank">21</ci:NumberOfBanksParticipatingInRevolvingCreditAndLetterOfCreditAgreement>
    <ci:LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant
      contextRef="c-829"
      decimals="INF"
      id="f-3228"
      unitRef="number">0.60</ci:LineOfCreditFacilityDebtToAdjustedCapitalRatioCovenant>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-830" decimals="INF" id="f-3229" unitRef="usd">3000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-831" id="f-3230">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-832" decimals="INF" id="f-3231" unitRef="usd">1000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-833" id="f-3232">P3Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-834" decimals="INF" id="f-3233" unitRef="usd">1000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-835" id="f-3234">P364D</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-836" decimals="INF" id="f-3235" unitRef="usd">5000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit contextRef="c-836" decimals="-8" id="f-3236" unitRef="usd">1200000000</us-gaap:LineOfCredit>
    <srt:CommercialPaperAverageRatePaid
      contextRef="c-809"
      decimals="4"
      id="f-3237"
      unitRef="number">0.0563</srt:CommercialPaperAverageRatePaid>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-171" decimals="-8" id="f-3238" unitRef="usd">4500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount contextRef="c-837" decimals="-7" id="f-3239" unitRef="usd">2250000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount contextRef="c-838" decimals="-8" id="f-3240" unitRef="usd">1000000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount contextRef="c-839" decimals="-7" id="f-3241" unitRef="usd">2550000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount contextRef="c-840" decimals="-8" id="f-3242" unitRef="usd">1800000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <ci:CondensedFinancialInformationOfParentCompanyOnlyScheduleOfIssuancesOfLongTermDebtTableTextBlock contextRef="c-1" id="f-3243">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On March 7, 2023, the Company issued $1.5&#160;billion of new senior notes. The proceeds of this issuance were used for general &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;corporate purposes, and included repayment of outstanding debt securities. Interest on this debt is paid semi-annually.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.486%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Proceeds&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$700 million &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 15, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.685%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$698 million&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$800 million &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 15, 2033&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.400%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$796 million&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; Redeemable at any time discounted at the U.S. Treasury rate plus 20 basis points. Redeemable at par on or after March 15, 2024.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt; Redeemable at any time discounted at the U.S. Treasury rate plus 25 basis points. Redeemable at par on or after December 15, 2032.</ci:CondensedFinancialInformationOfParentCompanyOnlyScheduleOfIssuancesOfLongTermDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-841" decimals="-8" id="f-3244" unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-842" decimals="-6" id="f-3245" unitRef="usd">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-842"
      decimals="5"
      id="f-3246"
      unitRef="number">0.05685</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ci:ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees contextRef="c-843" decimals="-6" id="f-3247" unitRef="usd">698000000</ci:ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-844" decimals="-6" id="f-3248" unitRef="usd">800000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-844"
      decimals="5"
      id="f-3249"
      unitRef="number">0.05400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ci:ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees contextRef="c-845" decimals="-6" id="f-3250" unitRef="usd">796000000</ci:ProceedsFromIssuanceOfLongTermDebtNetOfDiscountsAndUnderwritingFees>
    <ci:DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate
      contextRef="c-846"
      decimals="4"
      id="f-3251"
      unitRef="number">0.0020</ci:DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate>
    <ci:DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate
      contextRef="c-847"
      decimals="4"
      id="f-3252"
      unitRef="number">0.0025</ci:DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate>
    <ci:CondensedFinancialInformationOfParentCompanyOnlyScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="c-1" id="f-3253">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Maturities of the Company's long-term debt are as follows and exclude the impacts of the 2024 debt issuance and debt tender offers discussed above. &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:88.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.040%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,214&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,957&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,734&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,056&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Maturities after 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;15,091&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ci:CondensedFinancialInformationOfParentCompanyOnlyScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-812" decimals="-6" id="f-3254" unitRef="usd">1214000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-812" decimals="-6" id="f-3255" unitRef="usd">2957000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-812" decimals="-6" id="f-3256" unitRef="usd">2734000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c-812" decimals="-6" id="f-3257" unitRef="usd">2056000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="c-812" decimals="-6" id="f-3258" unitRef="usd">3800000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive contextRef="c-812" decimals="-6" id="f-3259" unitRef="usd">15091000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:OtherAssetsCurrent contextRef="c-848" decimals="-8" id="f-3260" unitRef="usd">8500000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-849" decimals="-8" id="f-3261" unitRef="usd">8300000000</us-gaap:OtherAssetsCurrent>
    <ci:IntercompanyReceivablesInterestRate
      contextRef="c-850"
      decimals="4"
      id="f-3262"
      unitRef="number">0.0521</ci:IntercompanyReceivablesInterestRate>
    <ci:AverageInterestRateOnIntercompanyLoan
      contextRef="c-851"
      decimals="4"
      id="f-3263"
      unitRef="number">0.0365</ci:AverageInterestRateOnIntercompanyLoan>
    <us-gaap:GuaranteeObligationsMaximumExposure contextRef="c-812" decimals="-8" id="f-3264" unitRef="usd">2900000000</us-gaap:GuaranteeObligationsMaximumExposure>
    <us-gaap:GuaranteeObligationsMaximumExposure contextRef="c-852" decimals="-8" id="f-3265" unitRef="usd">6400000000</us-gaap:GuaranteeObligationsMaximumExposure>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-853" decimals="-8" id="f-3266" unitRef="usd">3200000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt contextRef="c-853" decimals="-8" id="f-3267" unitRef="usd">-3200000000</us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-854"
      decimals="-5"
      id="f-3268"
      unitRef="shares">7600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-854" decimals="-8" id="f-3269" unitRef="usd">2600000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock contextRef="c-1" id="f-3270">THE CIGNA GROUP AND SUBSIDIARIES&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;SCHEDULE II&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;VALUATION AND QUALIFYING ACCOUNTS AND RESERVES&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.038%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.045%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Charged (Credited) to costs and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Charged (Credited) to other accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at end of year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investment asset valuation reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;44&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial mortgage loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;21&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;160&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;163&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax asset valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;208&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,286&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,498&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reinsurance recoverables &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investment asset valuation reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial mortgage loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax asset valuation allowance &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reinsurance recoverables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investment asset valuation reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial mortgage loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax asset valuation allowance &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reinsurance recoverables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e6e0ec;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:700;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt"&gt;Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts ("LDTI") in 2023. See Note 2 to the Consolidated Financial Statements included in Part II, Item 8 of this Form 10-K for further information.&lt;/span&gt;&lt;/div&gt;</srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-855" decimals="-6" id="f-3271" unitRef="usd">44000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-856" decimals="-6" id="f-3272" unitRef="usd">11000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="c-856" decimals="-6" id="f-3273" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-856" decimals="-6" id="f-3274" unitRef="usd">22000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-857" decimals="-6" id="f-3275" unitRef="usd">33000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-858" decimals="-6" id="f-3276" unitRef="usd">21000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-859" decimals="-6" id="f-3277" unitRef="usd">10000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="c-859" decimals="-6" id="f-3278" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-859" decimals="-6" id="f-3279" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-860" decimals="-6" id="f-3280" unitRef="usd">31000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-861" decimals="-6" id="f-3281" unitRef="usd">160000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-862" decimals="-6" id="f-3282" unitRef="usd">90000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="c-862" decimals="-6" id="f-3283" unitRef="usd">1000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-862" decimals="-6" id="f-3284" unitRef="usd">88000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-863" decimals="-6" id="f-3285" unitRef="usd">163000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-864" decimals="-6" id="f-3286" unitRef="usd">208000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-865" decimals="-6" id="f-3287" unitRef="usd">1286000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="c-865" decimals="-6" id="f-3288" unitRef="usd">4000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-865" decimals="-6" id="f-3289" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-866" decimals="-6" id="f-3290" unitRef="usd">1498000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-867" decimals="-6" id="f-3291" unitRef="usd">35000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-868" decimals="-6" id="f-3292" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="c-868" decimals="-6" id="f-3293" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-868" decimals="-6" id="f-3294" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-869" decimals="-6" id="f-3295" unitRef="usd">35000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-870" decimals="-6" id="f-3296" unitRef="usd">23000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-871" decimals="-6" id="f-3297" unitRef="usd">43000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="c-871" decimals="-6" id="f-3298" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-871" decimals="-6" id="f-3299" unitRef="usd">22000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-855" decimals="-6" id="f-3300" unitRef="usd">44000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-872" decimals="-6" id="f-3301" unitRef="usd">6000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-873" decimals="-6" id="f-3302" unitRef="usd">15000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="c-873" decimals="-6" id="f-3303" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-873" decimals="-6" id="f-3304" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-858" decimals="-6" id="f-3305" unitRef="usd">21000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-874" decimals="-6" id="f-3306" unitRef="usd">126000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-875" decimals="-6" id="f-3307" unitRef="usd">99000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="c-875" decimals="-6" id="f-3308" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-875" decimals="-6" id="f-3309" unitRef="usd">65000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-861" decimals="-6" id="f-3310" unitRef="usd">160000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-876" decimals="-6" id="f-3311" unitRef="usd">246000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-877" decimals="-6" id="f-3312" unitRef="usd">-13000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="c-877" decimals="-6" id="f-3313" unitRef="usd">-25000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-877" decimals="-6" id="f-3314" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-864" decimals="-6" id="f-3315" unitRef="usd">208000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-878" decimals="-6" id="f-3316" unitRef="usd">28000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-879" decimals="-6" id="f-3317" unitRef="usd">7000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="c-879" decimals="-6" id="f-3318" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-879" decimals="-6" id="f-3319" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-867" decimals="-6" id="f-3320" unitRef="usd">35000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-880" decimals="-6" id="f-3321" unitRef="usd">26000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-881" decimals="-6" id="f-3322" unitRef="usd">29000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="c-881" decimals="-6" id="f-3323" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-881" decimals="-6" id="f-3324" unitRef="usd">32000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-870" decimals="-6" id="f-3325" unitRef="usd">23000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-882" decimals="-6" id="f-3326" unitRef="usd">6000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-883" decimals="-6" id="f-3327" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="c-883" decimals="-6" id="f-3328" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-883" decimals="-6" id="f-3329" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-872" decimals="-6" id="f-3330" unitRef="usd">6000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-884" decimals="-6" id="f-3331" unitRef="usd">156000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-885" decimals="-6" id="f-3332" unitRef="usd">54000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="c-885" decimals="-6" id="f-3333" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-885" decimals="-6" id="f-3334" unitRef="usd">84000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-874" decimals="-6" id="f-3335" unitRef="usd">126000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-886" decimals="-6" id="f-3336" unitRef="usd">207000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-887" decimals="-6" id="f-3337" unitRef="usd">23000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="c-887" decimals="-6" id="f-3338" unitRef="usd">16000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-887" decimals="-6" id="f-3339" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-876" decimals="-6" id="f-3340" unitRef="usd">246000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-888" decimals="-6" id="f-3341" unitRef="usd">30000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-889" decimals="-6" id="f-3342" unitRef="usd">-2000000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="c-889" decimals="-6" id="f-3343" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-889" decimals="-6" id="f-3344" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-878" decimals="-6" id="f-3345" unitRef="usd">28000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#f-205"
          xlink:label="f-205"
          xlink:type="locator"/>
        <link:footnote id="fn-2" xlink:label="fn-2" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Par value per share, $0.01; shares issued, 400 million as of December&#160;31, 2023 and 398 million as of December&#160;31, 2022; authorized shares, 600 million.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-205"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnote id="fn-1" xlink:label="fn-1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-205"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-475"
          xlink:label="f-475"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-475"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnote id="fn-3" xlink:label="fn-3" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%;padding-left:2.94pt">Restricted cash and cash equivalents were reported in other long-term investments.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-475"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-476"
          xlink:label="f-476"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-476"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-476"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-481"
          xlink:label="f-481"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-481"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-481"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-482"
          xlink:label="f-482"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-482"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-482"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-457"
          xlink:label="f-457"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-433"
          xlink:label="f-433"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-418"
          xlink:label="f-418"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-440"
          xlink:label="f-440"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-355"
          xlink:label="f-355"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-120"
          xlink:label="f-120"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-127"
          xlink:label="f-127"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-133"
          xlink:label="f-133"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-96" xlink:label="f-96" xlink:type="locator"/>
        <link:loc xlink:href="#f-72" xlink:label="f-72" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-410"
          xlink:label="f-410"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-425"
          xlink:label="f-425"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-380"
          xlink:label="f-380"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-221"
          xlink:label="f-221"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-103"
          xlink:label="f-103"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-437"
          xlink:label="f-437"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-157"
          xlink:label="f-157"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-67" xlink:label="f-67" xlink:type="locator"/>
        <link:loc xlink:href="#f-90" xlink:label="f-90" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-406"
          xlink:label="f-406"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-183"
          xlink:label="f-183"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-48" xlink:label="f-48" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-368"
          xlink:label="f-368"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-487"
          xlink:label="f-487"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-79" xlink:label="f-79" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-219"
          xlink:label="f-219"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-97" xlink:label="f-97" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-132"
          xlink:label="f-132"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-124"
          xlink:label="f-124"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-39" xlink:label="f-39" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-126"
          xlink:label="f-126"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-379"
          xlink:label="f-379"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-415"
          xlink:label="f-415"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-106"
          xlink:label="f-106"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-397"
          xlink:label="f-397"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-191"
          xlink:label="f-191"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-112"
          xlink:label="f-112"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-195"
          xlink:label="f-195"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-419"
          xlink:label="f-419"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-452"
          xlink:label="f-452"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-114"
          xlink:label="f-114"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-389"
          xlink:label="f-389"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-466"
          xlink:label="f-466"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-358"
          xlink:label="f-358"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-439"
          xlink:label="f-439"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-395"
          xlink:label="f-395"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-43" xlink:label="f-43" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-458"
          xlink:label="f-458"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-82" xlink:label="f-82" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-175"
          xlink:label="f-175"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-371"
          xlink:label="f-371"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-217"
          xlink:label="f-217"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-91" xlink:label="f-91" xlink:type="locator"/>
        <link:loc xlink:href="#f-78" xlink:label="f-78" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-359"
          xlink:label="f-359"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-455"
          xlink:label="f-455"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-488"
          xlink:label="f-488"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-69" xlink:label="f-69" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-145"
          xlink:label="f-145"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-478"
          xlink:label="f-478"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-207"
          xlink:label="f-207"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-209"
          xlink:label="f-209"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-203"
          xlink:label="f-203"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-472"
          xlink:label="f-472"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-117"
          xlink:label="f-117"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-479"
          xlink:label="f-479"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-167"
          xlink:label="f-167"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-60" xlink:label="f-60" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-139"
          xlink:label="f-139"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-130"
          xlink:label="f-130"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-159"
          xlink:label="f-159"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-451"
          xlink:label="f-451"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-171"
          xlink:label="f-171"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-443"
          xlink:label="f-443"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-51" xlink:label="f-51" xlink:type="locator"/>
        <link:loc xlink:href="#f-81" xlink:label="f-81" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-141"
          xlink:label="f-141"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-102"
          xlink:label="f-102"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-409"
          xlink:label="f-409"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-416"
          xlink:label="f-416"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-149"
          xlink:label="f-149"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-428"
          xlink:label="f-428"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-121"
          xlink:label="f-121"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-108"
          xlink:label="f-108"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-52" xlink:label="f-52" xlink:type="locator"/>
        <link:loc xlink:href="#f-93" xlink:label="f-93" xlink:type="locator"/>
        <link:loc xlink:href="#f-49" xlink:label="f-49" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-193"
          xlink:label="f-193"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-449"
          xlink:label="f-449"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-153"
          xlink:label="f-153"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-385"
          xlink:label="f-385"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-129"
          xlink:label="f-129"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-189"
          xlink:label="f-189"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-185"
          xlink:label="f-185"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-386"
          xlink:label="f-386"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-115"
          xlink:label="f-115"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-99" xlink:label="f-99" xlink:type="locator"/>
        <link:loc xlink:href="#f-61" xlink:label="f-61" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-123"
          xlink:label="f-123"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-445"
          xlink:label="f-445"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-109"
          xlink:label="f-109"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-213"
          xlink:label="f-213"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-64" xlink:label="f-64" xlink:type="locator"/>
        <link:loc xlink:href="#f-54" xlink:label="f-54" xlink:type="locator"/>
        <link:loc xlink:href="#f-70" xlink:label="f-70" xlink:type="locator"/>
        <link:loc xlink:href="#f-66" xlink:label="f-66" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-427"
          xlink:label="f-427"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-485"
          xlink:label="f-485"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-173"
          xlink:label="f-173"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-463"
          xlink:label="f-463"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-87" xlink:label="f-87" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-404"
          xlink:label="f-404"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-446"
          xlink:label="f-446"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-57" xlink:label="f-57" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-181"
          xlink:label="f-181"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-370"
          xlink:label="f-370"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-422"
          xlink:label="f-422"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-373"
          xlink:label="f-373"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-55" xlink:label="f-55" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-470"
          xlink:label="f-470"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-392"
          xlink:label="f-392"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-85" xlink:label="f-85" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-151"
          xlink:label="f-151"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-407"
          xlink:label="f-407"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-367"
          xlink:label="f-367"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-197"
          xlink:label="f-197"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-187"
          xlink:label="f-187"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-434"
          xlink:label="f-434"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-460"
          xlink:label="f-460"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-365"
          xlink:label="f-365"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-143"
          xlink:label="f-143"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-473"
          xlink:label="f-473"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-177"
          xlink:label="f-177"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-362"
          xlink:label="f-362"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-412"
          xlink:label="f-412"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-163"
          xlink:label="f-163"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-63" xlink:label="f-63" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-211"
          xlink:label="f-211"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-94" xlink:label="f-94" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-391"
          xlink:label="f-391"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-430"
          xlink:label="f-430"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-413"
          xlink:label="f-413"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-467"
          xlink:label="f-467"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-179"
          xlink:label="f-179"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-42" xlink:label="f-42" xlink:type="locator"/>
        <link:loc xlink:href="#f-45" xlink:label="f-45" xlink:type="locator"/>
        <link:loc xlink:href="#f-84" xlink:label="f-84" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-100"
          xlink:label="f-100"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-118"
          xlink:label="f-118"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-40" xlink:label="f-40" xlink:type="locator"/>
        <link:loc xlink:href="#f-88" xlink:label="f-88" xlink:type="locator"/>
        <link:loc xlink:href="#f-73" xlink:label="f-73" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-356"
          xlink:label="f-356"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-165"
          xlink:label="f-165"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-484"
          xlink:label="f-484"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-155"
          xlink:label="f-155"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-161"
          xlink:label="f-161"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-388"
          xlink:label="f-388"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-448"
          xlink:label="f-448"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-424"
          xlink:label="f-424"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-376"
          xlink:label="f-376"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-454"
          xlink:label="f-454"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-136"
          xlink:label="f-136"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-111"
          xlink:label="f-111"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-382"
          xlink:label="f-382"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-169"
          xlink:label="f-169"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-76" xlink:label="f-76" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-464"
          xlink:label="f-464"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-383"
          xlink:label="f-383"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-377"
          xlink:label="f-377"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-469"
          xlink:label="f-469"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-436"
          xlink:label="f-436"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-394"
          xlink:label="f-394"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-201"
          xlink:label="f-201"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-461"
          xlink:label="f-461"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-199"
          xlink:label="f-199"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-135"
          xlink:label="f-135"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-364"
          xlink:label="f-364"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-374"
          xlink:label="f-374"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-400"
          xlink:label="f-400"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-147"
          xlink:label="f-147"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-138"
          xlink:label="f-138"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-401"
          xlink:label="f-401"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-46" xlink:label="f-46" xlink:type="locator"/>
        <link:loc
          xlink:href="#f-361"
          xlink:label="f-361"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-398"
          xlink:label="f-398"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-105"
          xlink:label="f-105"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-215"
          xlink:label="f-215"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-431"
          xlink:label="f-431"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-403"
          xlink:label="f-403"
          xlink:type="locator"/>
        <link:loc xlink:href="#f-58" xlink:label="f-58" xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-457"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-433"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-418"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-440"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-355"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-120"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-127"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-133"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-96"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-72"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-410"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-425"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-380"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-221"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-103"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-437"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-157"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-67"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-90"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-406"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-183"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-48"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-368"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-487"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-79"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-219"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-97"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-132"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-124"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-39"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-126"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-379"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-415"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-106"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-397"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-191"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-112"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-195"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-419"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-452"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-114"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-389"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-466"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-358"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-439"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-395"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-43"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-458"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-82"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-175"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-371"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-217"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-91"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-78"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-359"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-455"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-488"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-69"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-145"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-478"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-207"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-209"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-203"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-472"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-117"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-479"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-167"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-60"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-139"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-130"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-159"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-451"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-171"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-443"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-51"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-81"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-141"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-102"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-409"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-416"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-149"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-428"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-121"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-108"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-52"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-93"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-49"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-193"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-449"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-153"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-385"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-129"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-189"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-185"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-386"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-115"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-99"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-61"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-123"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-445"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-109"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-213"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-64"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-54"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-70"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-66"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-427"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-485"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-173"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-463"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-87"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-404"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-446"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-57"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-181"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-370"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-422"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-373"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-55"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-470"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-392"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-85"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-151"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-407"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-367"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-197"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-187"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-434"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-460"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-365"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-143"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-473"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-177"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-362"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-412"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-163"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-63"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-211"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-94"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-391"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-430"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-413"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-467"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-179"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-42"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-45"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-84"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-100"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-118"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-40"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-88"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-73"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-356"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-165"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-484"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-155"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-161"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-388"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-448"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-424"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-376"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-454"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-136"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-111"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-382"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-169"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-76"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-464"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-383"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-377"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-469"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-436"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-394"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-201"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-461"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-199"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-135"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-364"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-374"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-400"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-147"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-138"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-401"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-46"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-361"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-398"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-105"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-215"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-431"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-403"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-58"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-204"
          xlink:label="f-204"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-204"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-474"
          xlink:label="f-474"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-480"
          xlink:label="f-480"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-474"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-480"
          xlink:to="fn-3"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
